PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Koren, O; Rozner, E; Yosefia, S; Turgeman, Y				Koren, Ofir; Rozner, Ehud; Yosefia, Sawsan; Turgeman, Yoav			Therapeutic hypothermia after out of hospital cardiac arrest improve 1-year survival rate for selective patients	PLOS ONE			English	Article							CARDIOPULMONARY-RESUSCITATION; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; TASK-FORCE; REPERFUSION; COMMITTEE; EFFICACY; INJURY	Background Therapeutic Hypothermia (TH) is a standard of care after out-of-hospital cardiac arrest (OHCA). Previous reports failed to prove a significant benefit for survival or neurological outcomes. We examined whether the proper selection of patients would enhance treatment efficacy. Method We conducted a retrospective cohort study. Data was collected from January 2000 and August 2018. Patients were enrolled after OHCA and classified into two groups, patients treated with TH and patients who were not treated with TH. Results A total of 92 patients were included in the study. 57 (63%) patients were in the TH Group and 34 (37%) in the Non-TH group. There was no statistical difference in favorable neurological outcomes between the groups. Patients presenting with ventricular fibrillation had a higher 1-year survival rate from TH, while patients with asystole were found to benefit only if they were younger than 65 years (p < .007, p < .02, respectively). Conclusion Therapeutic Hypothermia patients failed to demonstrate a significant benefit in terms of improved neurological outcomes. Patients treated with TH following ventricular fibrillation experienced the most benefit in terms of 1-year survival, while patients who had suffered from asystole experienced a modest benefit only if they were younger than 65 years of age. Guidelines should address age and primary arrhythmia for proper treatment selection.	[Koren, Ofir; Rozner, Ehud; Turgeman, Yoav] Emek Med Ctr, Heart Inst, Afula, Israel; [Koren, Ofir; Turgeman, Yoav] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Haifa, Israel; [Yosefia, Sawsan] Emek Med Ctr, Internal Med C, Afula, Israel	Emek Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Emek Medical Center	Koren, O (corresponding author), Emek Med Ctr, Heart Inst, Afula, Israel.; Koren, O (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Haifa, Israel.	Ofirko1@clalit.org.il	Koren, Ofir/GYU-7333-2022; Koren, Ofir/AAZ-8573-2021	Koren, Ofir/0000-0002-8666-8276				Ajam K, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-38; BENSON D W, 1959, Anesth Analg, V38, P423; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bernard S, 2009, CRIT CARE MED, V37, pS227, DOI 10.1097/CCM.0b013e3181aa5d0c; Bhattacharjee S, 2016, J CLIN ANESTH, V33, P225, DOI 10.1016/j.jclinane.2016.03.001; Buxton AE, 2006, CIRCULATION, V114, P2534, DOI 10.1161/CIRCULATIONAHA.106.180199; Callaway CW, 2015, CIRCULATION, V132, pS84, DOI 10.1161/CIR.0000000000000273; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; D'Cruz BJ, 2002, J CEREBR BLOOD F MET, V22, P843, DOI 10.1097/00004647-200207000-00009; Dae MW, 2002, AM J PHYSIOL-HEART C, V282, pH1584, DOI 10.1152/ajpheart.00980.2001; Dunkley S, 2017, NURS CRIT CARE, V22, P150, DOI 10.1111/nicc.12242; European Heart Rhythm Association, 2006, J Am Coll Cardiol, V48, pe247, DOI 10.1016/j.jacc.2006.07.010; FELDMAN E, 1960, JAMA-J AM MED ASSOC, V173, P499, DOI 10.1001/jama.1960.03020230025006; Frohlich GM, 2013, CURR CARDIOL REV, V9, P316, DOI 10.2174/1573403X10666140214121152; Hicks SD, 2000, J CEREBR BLOOD F MET, V20, P520, DOI 10.1097/00004647-200003000-00011; Holzer M, 2005, CRIT CARE MED, V33, P414, DOI 10.1097/01.CCM.0000153410.87750.53; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hovdenes J, 2007, ACTA ANAESTH SCAND, V51, P137, DOI 10.1111/j.1399-6576.2006.01209.x; Jolly SS, 2011, HEART, V97, P197, DOI 10.1136/hrt.2010.195511; Lee JH, 2016, STROKE, V47, P1907, DOI 10.1161/STROKEAHA.116.013061; Merchant RM, 2009, CIRC-CARDIOVASC QUAL, V2, P421, DOI 10.1161/CIRCOUTCOMES.108.839605; Nielsen N, 2009, ACTA ANAESTH SCAND, V53, P926, DOI 10.1111/j.1399-6576.2009.02021.x; Nolan JP, 2003, CIRCULATION, V108, P118, DOI 10.1161/01.CIR.0000079019.02601.90; Sanders AB, 2006, CURRENT OPINION CRIT, V12; Shiozaki T, 2003, J NEUROSURG, V99, P47, DOI 10.3171/jns.2003.99.1.0047; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Soar J, 2015, RESUSCITATION, V95, P100, DOI 10.1016/j.resuscitation.2015.07.016; STEEN PA, 1980, ANESTHESIOLOGY, V52, P224, DOI 10.1097/00000542-198003000-00007; STERZ F, 1991, CRIT CARE MED, V19, P379, DOI 10.1097/00003246-199103000-00017; Walters JH, 2011, RESUSCITATION, V82, P508, DOI 10.1016/j.resuscitation.2011.01.021; WEINRAUCH V, 1992, STROKE, V23, P1454, DOI 10.1161/01.STR.23.10.1454; WILLIAMS GR, 1958, ANN SURG, V148, P462, DOI 10.1097/00000658-195809000-00014; Yang HJ, 2015, J KOREAN MED SCI, V30, P95, DOI 10.3346/jkms.2015.30.1.95	35	1	1	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2020	15	1							e0226956	10.1371/journal.pone.0226956	http://dx.doi.org/10.1371/journal.pone.0226956			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5BZ	31910226	gold, Green Published			2023-01-03	WOS:000534333800021
J	Fujii, Y; Matsumura, H; Yamazaki, S; Shirasu, A; Nakakura, H; Ogihara, T; Ashida, A				Fujii, Yuko; Matsumura, Hideki; Yamazaki, Satoshi; Shirasu, Akihiko; Nakakura, Hyogo; Ogihara, Tohru; Ashida, Akira			Efficacy of a mitochondrion-targeting agent for reducing the level of urinary protein in rats with puromycin aminonucleoside-induced minimal-change nephrotic syndrome	PLOS ONE			English	Article							PERMEABILITY TRANSITION; RADICAL SCAVENGER; OXIDATIVE STRESS; PODOCYTE INJURY; CYCLOSPORINE-A; MITO-TEMPO; DYSFUNCTION; SUPEROXIDE; INHIBITION; EDARAVONE	Background Oxidative stress is a major factor responsible for minimal-change nephrotic syndrome (MCNS), which occurs most commonly in children. However, the influence of oxidative stress localized to mitochondria remains unclear. We examined the effect of a mitochondrion-targeting antioxidant, MitoTEMPO, in rats with puromycin aminonucleoside (PAN)induced MCNS to clarify the degree to which mitochondrial oxidative stress affects MCNS. Materials and methods Thirty Wistar rats were divided into three groups: normal saline group (n = 7), PAN group (n = 12), and PAN + MitoTEMPO group (n = 11). Rats in the PAN and PAN + MitoTEMPO groups received PAN on day 1, and those in the PAN + MitoTEMPO group received MitoTEMPO on days 0 to 9. Whole-day urine samples were collected on days 3 and 9, and samples of glomeruli and blood were taken for measurement of lipid peroxidation products. We also estimated the mitochondrial damage score in podocytes in all 3 groups using electron microscopy. Results Urinary protein excretion on day 9 and the levels of lipid peroxidation products in urine, glomeruli, and blood were significantly lower in the PAN+MitoTEMPO group than in the PAN group (p = 0.0019, p = 0.011, p = 0.039, p = 0.030). The mitochondrial damage score in podocytes was significantly lower in the PAN+MitoTEMPO group than in the PAN group (p < 0.0001). Conclusions This mitochondrion-targeting agent was shown to reduce oxidative stress and mitochondrial damage in a MCNS model. A radical scavenger targeting mitochondria could be a promising drug for treatment of MCNS.	[Fujii, Yuko; Matsumura, Hideki; Yamazaki, Satoshi; Ogihara, Tohru; Ashida, Akira] Osaka Med Coll, Dept Pediat, Takatsuki, Osaka, Japan; [Shirasu, Akihiko] Hirakata City Hosp, Dept Pediat, Hirakata, Osaka, Japan; [Nakakura, Hyogo] Arisawa Gen Hosp, Dept Hemodialysis & Apheresis, Hirakata, Osaka, Japan	Osaka Medical College	Ashida, A (corresponding author), Osaka Med Coll, Dept Pediat, Takatsuki, Osaka, Japan.	ped006@osaka-med.ac.jp			Japan Society for the Promotion of Science (JSPS) KAKENHI [JP17K10161]	Japan Society for the Promotion of Science (JSPS) KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number JP17K10161. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ademowo OS, 2017, BIOGERONTOLOGY, V18, P859, DOI 10.1007/s10522-017-9710-z; Aon MA, 2006, BBA-MOL BASIS DIS, V1762, P232, DOI 10.1016/j.bbadis.2005.06.008; Che RC, 2015, PPAR RES, V2015, DOI 10.1155/2015/720383; Cui J, 2015, SCI REP-UK, V5, DOI 10.1038/srep11256; Czajka A, 2015, EBIOMEDICINE, V2, P499, DOI 10.1016/j.ebiom.2015.04.002; Dikalov S, 2011, FREE RADICAL BIO MED, V51, P1289, DOI 10.1016/j.freeradbiomed.2011.06.033; Dikalova AE, 2010, CIRC RES, V107, P106, DOI 10.1161/CIRCRESAHA.109.214601; Dong LF, 2014, PROG MOL BIOL TRANSL, V127, P211, DOI 10.1016/B978-0-12-394625-6.00008-8; Emma F, 2016, NAT REV NEPHROL, V12, P267, DOI 10.1038/nrneph.2015.214; Granata S, 2015, NUTR METAB, V12, DOI 10.1186/s12986-015-0044-z; Guan N, 2015, NEPHROL DIAL TRANSPL, V30, P957, DOI 10.1093/ndt/gfv015; Gunter TE, 2004, FEBS LETT, V567, P96, DOI 10.1016/j.febslet.2004.03.071; Gunter TE, 2009, BBA-BIOENERGETICS, V1787, P1291, DOI 10.1016/j.bbabio.2008.12.011; Gwinner W, 1997, J AM SOC NEPHROL, V8, P1722; Hasegawa M, 2009, BRAIN RES, V1283, P1, DOI 10.1016/j.brainres.2009.06.016; Holthofer H, 1999, FASEB J, V13, P523, DOI 10.1096/fasebj.13.3.523; Hotta O, 2001, KIDNEY INT, V59, P1236, DOI 10.1046/j.1523-1755.2001.0590041236.x; Rocha VCJ, 2016, CANCER CHEMOTH PHARM, V77, P659, DOI 10.1007/s00280-015-2949-7; Kezic A, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2950503; Lee SJ, 2011, AM J RESP CELL MOL, V45, P867, DOI 10.1165/rcmb.2010-0352OC; Li XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092003; Lin CH, 2012, KAOHSIUNG J MED SCI, V28, pS53, DOI 10.1016/j.kjms.2012.05.011; Matsumura H, 2006, CLIN NEPHROL, V66, P405; Nakakura H, 2004, PEDIATR NEPHROL, V19, P266, DOI 10.1007/s00467-003-1332-9; Ni R, 2016, FREE RADICAL BIO MED, V90, P12, DOI 10.1016/j.freeradbiomed.2015.11.013; Novak EA, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00062; Papazova DA, 2015, AM J PHYSIOL-RENAL, V308, pF22, DOI 10.1152/ajprenal.00278.2014; Patil NK, 2014, AM J PHYSIOL-RENAL, V306, pF734, DOI 10.1152/ajprenal.00643.2013; Picard M, 2013, AM J PHYSIOL-REG I, V304, pR393, DOI 10.1152/ajpregu.00584.2012; Picone P, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/780179; Qian T, 1997, AM J PHYSIOL-CELL PH, V273, pC1783, DOI 10.1152/ajpcell.1997.273.6.C1783; Sesso A, 2012, ANAT REC, V295, P1647, DOI 10.1002/ar.22553; Shen XJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep32087; Siemen D, 2013, IUBMB LIFE, V65, P255, DOI 10.1002/iub.1130; Sweetwyne MT, 2017, KIDNEY INT, V91, P1126, DOI 10.1016/j.kint.2016.10.036; SZABOLCS MJ, 1994, KIDNEY INT, V45, P1388, DOI 10.1038/ki.1994.181; Takayasu Y, 2007, J PHARMACOL SCI, V103, P434, DOI 10.1254/jphs.SC0070014; Vega-Warner V, 2004, KIDNEY INT, V66, P1881, DOI 10.1111/j.1523-1755.2004.00962.x; Zhang ZW, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6859523; Zhu CH, 2011, AM J PATHOL, V178, P2020, DOI 10.1016/j.ajpath.2011.01.029; Zorov DB, 2006, BBA-BIOENERGETICS, V1757, P509, DOI 10.1016/j.bbabio.2006.04.029	41	4	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2020	15	1							e0227414	10.1371/journal.pone.0227414	http://dx.doi.org/10.1371/journal.pone.0227414			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP4ZR	31905213	gold, Green Published			2023-01-03	WOS:000534327700021
J	Kubo, K; Wadasaki, K; Komichi, D; Sasaki, T; Yamada, H; Matsugu, Y; Itamoto, T; Doi, M; Shinozaki, K				Kubo, Katsumaro; Wadasaki, Koichi; Komichi, Daisuke; Sasaki, Tamito; Yamada, Hiroyasu; Matsugu, Yasuhiro; Itamoto, Toshiyuki; Doi, Mihoko; Shinozaki, Katsunori			A single institution experience of the treatment of pancreatic ductal carcinoma: The demand and the role of radiation therapy	PLOS ONE			English	Article							STEREOTACTIC BODY RADIOTHERAPY; LONG-TERM OUTCOMES; INDUCTION CHEMOTHERAPY; GEMCITABINE; CANCER; CHEMORADIATION; CHEMORADIOTHERAPY; OXALIPLATIN; FOLFIRINOX; SURVIVAL	We aimed to demonstrate a single institution experience of treatment of pancreatic ductal carcinoma and to identify the role of radiation therapy. We assessed all patients who were diagnosed with pancreatic ductal carcinoma from January 2011 to December 2017. A total of 342 patients were enrolled. Thirteen, 131, 36, and 162 patients had stage I, II, III, and IV disease, respectively (UICC TNM, 7th edition). Among the patients with stages I-III disease, 94 underwent surgery, and the median overall survival (OS) was 33 months. Of patients with stages I-III disease who were not suitable for surgery, 58 patients received chemotherapy, and the median OS was 12 months. Among them, 17 patients received chemoradiotherapy added on chemotherapy and their OS was significantly better than that of patients who received chemotherapy alone. Of patients with stage IV disease, 111 received chemotherapy, and the median OS was 6 months. This study evaluated the demand, role, and outcome of each treatment modality and demonstrated a single institution experience of treatment of pancreatic ductal carcinoma. The demand and role of radiation therapy remained small; however, radiation therapy might have some importance as a local treatment.	[Kubo, Katsumaro] Hiroshima High Precis Radiotherapy Canc Ctr, Dept Radiat Oncol, Hiroshima, Hiroshima, Japan; [Wadasaki, Koichi] Hiroshima Prefectural Hosp, Dept Radiat Oncol, Hiroshima, Hiroshima, Japan; [Komichi, Daisuke; Sasaki, Tamito; Yamada, Hiroyasu] Hiroshima Prefectural Hosp, Dept Gastroenterol, Hiroshima, Hiroshima, Japan; [Matsugu, Yasuhiro; Itamoto, Toshiyuki] Hiroshima Prefectural Hosp, Dept Surg, Hiroshima, Hiroshima, Japan; [Doi, Mihoko; Shinozaki, Katsunori] Hiroshima Prefectural Hosp, Dept Clin Oncol, Hiroshima, Hiroshima, Japan		Kubo, K (corresponding author), Hiroshima High Precis Radiotherapy Canc Ctr, Dept Radiat Oncol, Hiroshima, Hiroshima, Japan.	maro1987@hotmail.co.jp		/0000-0001-9021-3955; Kubo, Katsumaro/0000-0001-5601-8961				Abelson JA, 2012, INT J RADIAT ONCOL, V82, pE595, DOI 10.1016/j.ijrobp.2011.09.035; Arvold ND, 2012, CANCER-AM CANCER SOC, V118, P3026, DOI 10.1002/cncr.26633; Butturini G, 2008, ARCH SURG-CHICAGO, V143, P75, DOI 10.1001/archsurg.2007.17; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; de Geus SWL, 2017, CANCER-AM CANCER SOC, V123, P4158, DOI 10.1002/cncr.30856; Esnaola NF, 2014, INT J RADIAT ONCOL, V88, P837, DOI 10.1016/j.ijrobp.2013.12.030; Gourgou-Bourgade S, 2013, J CLIN ONCOL, V31, P23, DOI 10.1200/JCO.2012.44.4869; Huguet F, 2007, J CLIN ONCOL, V25, P326, DOI 10.1200/JCO.2006.07.5663; Jethwa K R, 2018, RADIAT ONCOL, V3, P314, DOI DOI 10.1016/j.adro.2018.04.003; Katz MHG, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3441-z; Katz MHG, 2016, JAMA SURG, V151, DOI 10.1001/jamasurg.2016.1137; Krishnan S, 2007, CANCER-AM CANCER SOC, V110, P47, DOI 10.1002/cncr.22735; Krishnan S, 2016, INT J RADIAT ONCOL, V94, P755, DOI 10.1016/j.ijrobp.2015.12.003; Leone F, 2013, CANCER-AM CANCER SOC, V119, P277, DOI 10.1002/cncr.27736; Mellon EA, 2015, ACTA ONCOL, V54, P979, DOI 10.3109/0284186X.2015.1004367; National Cancer Center Center for Cancer Control and Information Services, LAT CANC STAT 2017; National Comprehensive Cancer Network Inc, 2018, PANCR AD VERS 2; Palta M, PRINCIPLES PRACTICE, P1189; Sen N, 2014, CLIN ONCOL-UK, V26, P551, DOI 10.1016/j.clon.2014.06.003; Tabernero J, 2015, ONCOLOGIST, V20, P143, DOI 10.1634/theoncologist.2014-0394; Yamaguchi K, 2017, PANCREAS, V46, P595, DOI 10.1097/MPA.0000000000000816; Yovino S, 2011, INT J RADIAT ONCOL, V79, P158, DOI 10.1016/j.ijrobp.2009.10.043; Zhu XF, 2019, INT J RADIAT ONCOL, V104, P101, DOI 10.1016/j.ijrobp.2019.01.075	23	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2019	14	12							e0227305	10.1371/journal.pone.0227305	http://dx.doi.org/10.1371/journal.pone.0227305			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN8JV	31887205	Green Published, gold			2023-01-03	WOS:000515092200090
J	Alhakamy, NA; Fahmy, UA; Ahmed, OAA				Alhakamy, Nabil A.; Fahmy, Usama A.; Ahmed, Osama A. A.			Vitamin E TPGS based transferosomes augmented TAT as a promising delivery system for improved transdermal delivery of raloxifene	PLOS ONE			English	Article							BREAST-CANCER; POSTMENOPAUSAL WOMEN; P-GLYCOPROTEIN; IN-VITRO; VIVO; HYDROCHLORIDE; FORMULATION; SKIN; OPTIMIZATION; RISK	Raloxifene is commonly used for breast cancer protection. The low bioavailability of raloxifene (2%) is the result of its low solubility and intestinal glucuronidation. The nano-lipid carriers are characterized by small particle size, biocompatibility, and sustainable properties that improve cellular uptake of the loaded drug. The aim of this study was the improvement of raloxifene bioavailability by enhancing its solubility and cellular penetration through formulation of D-alpha-tocopheryl polyethylene glycol 1000 succinate based transferosomes and augmenting their effect with the cationic cell-penetrating peptide transactivator of transcription of the human immunodeficiency virus. Particle size, zeta potential, and transmission electron microscope investigation of the formed nanocarriers were carried out. Ex vivo raloxifene permeation through rat skin and cell viability studies was investigated. The results of D-alpha-tocopheryl polyethylene glycol 1000 succinate-transactivator of transcription of the human immunodeficiency virus transferosomes showed an average vesicle size of 96.05 nm with positively charged vesicles 39.4 mV of zeta potential value. The results revealed significant (p < 0.05) enhancement of raloxifene permeation from raloxifene transferosomes- loaded film when compared with raw raloxifene film. IC50 results showed significant improvement of formulated raloxifene cytotoxicity by 1.42-fold in comparison with raw raloxifene against MCF-7 cell lines. The developed raloxifene-transferosomes are considered promising nano-lipid carriers for the enhancement delivery of raloxifene.	[Alhakamy, Nabil A.; Fahmy, Usama A.; Ahmed, Osama A. A.] King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut, Jeddah, Saudi Arabia; [Ahmed, Osama A. A.] Menia Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Al Minya, Egypt	King Abdulaziz University; Egyptian Knowledge Bank (EKB); Minia University	Alhakamy, NA (corresponding author), King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut, Jeddah, Saudi Arabia.	nalhakamy@kau.edu.sa	Alhakamy, Nabil A/AAD-9804-2019; Fahmy, Usama Ahmed/AAR-3249-2020; Ahmed, Osama/AAH-3042-2019	Alhakamy, Nabil A/0000-0002-3826-1519; Fahmy, Usama Ahmed/0000-0002-6094-5570; Ahmed, Osama/0000-0002-3204-381X	Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah [D-013-166-1440]	Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah	This work was supported by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, under grant number (D-013-166-1440). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AHMED OAA, 2018, IJN, V14, P33, DOI DOI 10.2147/IJN.S187470; Ahmed OAA, 2018, INT J NANOMED, V13, P6325, DOI 10.2147/IJN.S181587; Ahmed OAA, 2018, DRUG DES DEV THER, V12, P2259, DOI 10.2147/DDDT.S171888; Ahmed OAA, 2014, TROP J PHARM RES, V13, P1207, DOI 10.4314/tjpr.v13i8.3; Ahmed OAA, 2014, EXPERT OPIN DRUG DEL, V11, P1005, DOI 10.1517/17425247.2014.906402; Ahmed TA, 2016, INT J PHARMACEUT, V500, P245, DOI 10.1016/j.ijpharm.2016.01.017; Alexander A, 2012, J CONTROL RELEASE, V164, P26, DOI 10.1016/j.jconrel.2012.09.017; Badr-Eldin SM, 2016, DRUG DES DEV THER, V10, P1323, DOI 10.2147/DDDT.S103122; Basavaiah K, 2008, ACTA PHARMACEUT, V58, P347, DOI 10.2478/v10007-008-0018-z; Benson Heather A E, 2006, Expert Opin Drug Deliv, V3, P727, DOI 10.1517/17425247.3.6.727; Chen J, 2013, EXPERT OPIN DRUG DEL, V10, P845, DOI 10.1517/17425247.2013.779252; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Desai P, 2010, MOL MEMBR BIOL, V27, P247, DOI 10.3109/09687688.2010.522203; Dintaman JM, 1999, PHARMACEUT RES, V16, P1550, DOI 10.1023/A:1015000503629; Dwivedi A, 2016, INT J PHARMACEUT, V503, P1, DOI 10.1016/j.ijpharm.2016.02.041; El-Say KM, 2015, PHARM DEV TECHNOL, V20, P919, DOI 10.3109/10837450.2014.938859; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Fahmy UA, 2016, EXPERT OPIN DRUG DEL, V13, P1653, DOI 10.1080/17425247.2016.1236788; Fahmy UA, 2015, DRUG DES DEV THER, V9, P6129, DOI 10.2147/DDDT.S94615; Fahmy UA, 2015, AAPS PHARMSCITECH, V16, P53, DOI 10.1208/s12249-014-0199-3; Goindi S, 2013, AAPS PHARMSCITECH, V14, P1284, DOI 10.1208/s12249-013-0017-3; Guo WP, 2010, INT CONF COMP SCI, P478, DOI 10.1109/ICCSIT.2010.5565042; Guo YY, 2013, EUR J PHARM SCI, V49, P175, DOI 10.1016/j.ejps.2013.02.006; Hartauer KJ, 2000, PHARM DEV TECHNOL, V5, P303, DOI 10.1081/PDT-100100545; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kim DE, 2015, MOL CELLS, V38, P138, DOI 10.14348/molcells.2015.2193; Lonn P, 2016, SCI REP-UK, V6, DOI 10.1038/srep32301; Mahmood S, 2018, INT J PHARMACEUT, V542, P36, DOI 10.1016/j.ijpharm.2018.02.044; Mahmood S, 2014, INT J NANOMED, V9, P4331, DOI 10.2147/IJN.S65408; Muchmore D B, 2000, Oncologist, V5, P388, DOI 10.1634/theoncologist.5-5-388; Nagai N, 2018, INT J NANOMED, V13, P5215, DOI 10.2147/IJN.S173216; Park D, 2018, BIOMACROMOLECULES, V19, P2682, DOI 10.1021/acs.biomac.8b00292; Pritchard T, 2016, J DRUG TARGET, V24, P441, DOI 10.3109/1061186X.2015.1086360; Seo JE, 2017, J EXPO SCI ENV EPID, V27, P320, DOI 10.1038/jes.2016.33; Skazik C, 2011, EXP DERMATOL, V20, P450, DOI 10.1111/j.1600-0625.2010.01237.x; Subedi RK, 2010, ARCH PHARM RES, V33, P339, DOI 10.1007/s12272-010-0301-7; Tahirov TH, 2010, NATURE, V465, P747, DOI 10.1038/nature09131; Thakkar HP, 2016, CURR DRUG DELIV, V13, P1111, DOI 10.2174/1567201813666160120151816; Vachon CM, 2015, BREAST CANCER RES TR, V149, P517, DOI 10.1007/s10549-014-3175-4; Wiedersberg S, 2014, J CONTROL RELEASE, V190, P150, DOI 10.1016/j.jconrel.2014.05.022; Zidan AS, 2016, DRUG DELIV, V23, P1536, DOI 10.3109/10717544.2014.980896	42	9	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2019	14	12							e0226639	10.1371/journal.pone.0226639	http://dx.doi.org/10.1371/journal.pone.0226639			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ4GI	31881053	gold, Green Published			2023-01-03	WOS:000512015900001
J	Vicini, FA; Cecchini, RS; White, JR; Arthur, DW; Julian, TB; Rabinovitch, RA; Kuske, RR; Ganz, PA; Parda, DS; Scheier, MF; Winter, KA; Paik, S; Kuerer, HM; Vallow, LA; Pierce, LJ; Mamounas, EP; McCormick, B; Costantino, JP; Bear, HD; Germain, I; Gustafson, G; Grossheim, L; Petersen, IA; Hudes, RS; Curran, WJ; Bryant, JL; Wolmark, N				Vicini, Frank A.; Cecchini, Reena S.; White, Julia R.; Arthur, Douglas W.; Julian, Thomas B.; Rabinovitch, Rachel A.; Kuske, Robert R.; Ganz, Patricia A.; Parda, David S.; Scheier, Michael F.; Winter, Kathryn A.; Paik, Soonmyung; Kuerer, Henry M.; Vallow, Laura A.; Pierce, Lori J.; Mamounas, Eleftherios P.; McCormick, Beryl; Costantino, Joseph P.; Bear, Harry D.; Germain, Isabelle; Gustafson, Gregory; Grossheim, Linda; Petersen, Ivy A.; Hudes, Richard S.; Curran, Walter J., Jr.; Bryant, John L.; Wolmark, Norman			Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial	LANCET			English	Article							FOLLOW-UP; RADIOTHERAPY; LUMPECTOMY; MASTECTOMY; SURVIVAL; TAMOXIFEN; OLDER	Background Whole-breast irradiation after breast-conserving surgery for patients with early-stage breast cancer decreases ipsilateral breast-tumour recurrence (IBTR), yielding comparable results to mastectomy. It is unknown whether accelerated partial breast irradiation (APBI) to only the tumour-bearing quadrant, which shortens treatment duration, is equally effective. In our trial, we investigated whether APBI provides equivalent local tumour control after lumpectomy compared with whole-breast irradiation. Methods We did this randomised, phase 3, equivalence trial (NSABP B-39/RTOG 0413) in 154 clinical centres in the USA, Canada, Ireland, and Israel. Adult women (>18 years) with early-stage (0, I, or II; no evidence of distant metastases, but up to three axillary nodes could be positive) breast cancer (tumour size <= 3 cm; including all histologies and multifocal breast cancers), who had had lumpectomy with negative (ie, no detectable cancer cells) surgical margins, were randomly assigned (1:1) using a biased-coin-based minimisation algorithm to receive either whole-breast irradiation (whole-breast irradiation group) or APBI (APBI group). Whole-breast irradiation was delivered in 25 daily fractions of 50 Gy over 5 weeks, with or without a supplemental boost to the tumour bed, and APBI was delivered as 34 Gy of brachytherapy or 38.5 Gy of external bream radiation therapy in 10 fractions, over 5 treatment days within an 8-day period. Randomisation was stratified by disease stage, menopausal status, hormone-receptor status, and intention to receive chemotherapy. Patients, investigators, and statisticians could not be masked to treatment allocation. The primary outcome of invasive and non-invasive IBTR as a first recurrence was analysed in the intentionto-treat population, excluding those patients who were lost to follow-up, with an equivalency test on the basis of a 50% margin increase in the hazard ratio (90% CI for the observed HR between 0.667 and 1.5 for equivalence) and a Cox proportional hazard model. Survival was assessed by intention to treat, and sensitivity analyses were done in the per-protocol population. This trial is registered with ClinicalTrials.gov, NCT00103181. Findings Between March 21, 2005, and April 16, 2013, 4216 women were enrolled. 2109 were assigned to the wholebreast irradiation group and 2107 were assigned to the APBI group. 70 patients from the whole-breast irradiation group and 14 from the APBI group withdrew consent or were lost to follow-up at this stage, so 2039 and 2093 patients respectively were available for survival analysis. Further, three and four patients respectively were lost to clinical follow-up (ie, survival status was assessed by phone but no physical examination was done), leaving 2036 patients in the whole-breast irradiation group and 2089 in the APBI group evaluable for the primary outcome. At a median follow-up of 10.2 years (IQR 7.5-11.5), 90 (4%) of 2089 women eligible for the primary outcome in the APBI group and 71 (3%) of 2036 women in the whole-breast irradiation group had an IBTR (HR 1.22, 90% CI 0.94-1.58). The 10-year cumulative incidence of IBTR was 4.6% (95% CI 3.7-5.7) in the APBI group versus 3.9% (3.1-5.0) in the whole-breast irradiation group. 44 (2%) of 2039 patients in the whole-breast irradiation group and 49 (2%) of 2093 patients in the APBI group died from recurring breast cancer. There were no treatment-related deaths. Second cancers and treatment-related toxicities were similar between the two groups. 2020 patients in the whole-breast irradiation group and 2089 in APBI group had available data on adverse events. The highest toxicity grade reported was: grade 1 in 845 (40%), grade 2 in 921 (44%), and grade 3 in 201 (10%) patients in the APBI group, compared with grade 1 in 626 (31%), grade 2 in 1193 (59%), and grade 3 in 143 (7%) in the whole-breast irradiation group. Interpretation APBI did not meet the criteria for equivalence to whole-breast irradiation in controlling IBTR for breast-conserving therapy. Our trial had broad eligibility criteria, leading to a large, heterogeneous pool of patients and sufficient power to detect treatment equivalence, but was not designed to test equivalence in patient subgroups or outcomes from different APBI techniques. For patients with early-stage breast cancer, our findings support wholebreast irradiation following lumpectomy; however, with an absolute difference of less than 1% in the 10-year cumulative incidence of IBTR, APBI might be an acceptable alternative for some women.	[Vicini, Frank A.; Cecchini, Reena S.; White, Julia R.; Arthur, Douglas W.; Julian, Thomas B.; Rabinovitch, Rachel A.; Kuske, Robert R.; Ganz, Patricia A.; Parda, David S.; Paik, Soonmyung; Kuerer, Henry M.; Mamounas, Eleftherios P.; McCormick, Beryl; Costantino, Joseph P.; Bear, Harry D.; Germain, Isabelle; Gustafson, Gregory; Grossheim, Linda; Petersen, Ivy A.; Curran, Walter J., Jr.; Bryant, John L.; Wolmark, Norman] NRG Oncol, Pittsburgh, PA USA; [Vicini, Frank A.] St Joseph Mercy Hosp Campus, Radiat Oncol Inst, Pontiac, MI USA; [Cecchini, Reena S.; Costantino, Joseph P.; Bryant, John L.; Wolmark, Norman] Univ Pittsburgh, Pittsburgh, PA USA; [White, Julia R.] Ohio State Univ, Comprehens Canc Ctr, Arthur G James Canc Hosp, Columbus, OH 43210 USA; [White, Julia R.] Richard J Solove Res Inst, Columbus, OH USA; [Arthur, Douglas W.; Bear, Harry D.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA; [Julian, Thomas B.; Parda, David S.; Wolmark, Norman] Allegheny Hlth Network, Inst Canc, Pittsburgh, PA USA; [Rabinovitch, Rachel A.] Univ Colorado, Ctr Canc, Aurora, CO USA; [Kuske, Robert R.] Arizona Breast Canc Specialists, Arizona Ctr Canc Care, Scottsdale, AZ USA; [Ganz, Patricia A.] Univ Calif Los Angeles, Los Angeles, CA USA; [Scheier, Michael F.] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA; [Winter, Kathryn A.] Amer Coll Radiol, NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA; [Paik, Soonmyung] Yonsei Univ, Coll Med, Seoul, South Korea; [Kuerer, Henry M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Vallow, Laura A.] Mayo Clin Florida, Jacksonville, FL USA; [Pierce, Lori J.] Hope Fdn Canc Res, Southwest Oncol Grp Canc Res Network, Portland, OR USA; [Pierce, Lori J.] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA; [Mamounas, Eleftherios P.] Orlando Hlth, UF Hlth Canc Ctr, Orlando, FL USA; [McCormick, Beryl] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Germain, Isabelle] Univ Laval, Ctr Hosp Univ Quebec, Pavillon Hotel Dieu Quebec, Quebec City, PQ, Canada; [Gustafson, Gregory] William Beaumont Hosp, Community Clin Oncol Program, Sterling Hts, MI USA; [Grossheim, Linda] Summit Canc Ctr, Post Falls, ID USA; [Petersen, Ivy A.] Mayo Clin, Rochester, MN USA; [Hudes, Richard S.] St Agnes Hosp, Baltimore, MD USA; [Hudes, Richard S.] Thomas Jefferson Univ, Baltimore, MD USA; [Curran, Walter J., Jr.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; Virginia Commonwealth University; University of Colorado System; University of Colorado Anschutz Medical Campus; Arizona Center Cancer Care; University of California System; University of California Los Angeles; Carnegie Mellon University; American College of Radiology; Yonsei University; Yonsei University Health System; University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic; University of Michigan System; University of Michigan; Memorial Sloan Kettering Cancer Center; Laval University; Beaumont Health; Mayo Clinic; Emory University	Vicini, FA (corresponding author), Michigan Healthcare Profess, 21st Century Oncol, Pontiac, MI 48341 USA.	frank.vicini@21co.com		Ganz, Patricia/0000-0002-1841-4143; Cecchini, Reena/0000-0002-9075-9357	NCI, Department of Health and Human Services, Public Health Service [U10-CA-180868, U10-CA-180822, UG1-CA-189867, U24-CA-19067]; NATIONAL CANCER INSTITUTE [U10CA180822, P30CA016058, U10CA180868, UG1CA189867] Funding Source: NIH RePORTER	NCI, Department of Health and Human Services, Public Health Service; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This trial was funded by the NCI, Department of Health and Human Services, Public Health Service Grants U10-CA-180868, U10-CA-180822, UG1-CA-189867, and U24-CA-19067.	Abe O, 2005, LANCET, V366, P2087; Bonin K, 2018, J CANCER EDUC, V33, P37, DOI 10.1007/s13187-016-1016-3; Coles CE, 2017, LANCET, V390, P1048, DOI 10.1016/S0140-6736(17)31145-5; Correa C, 2017, PRACT RADIAT ONCOL, V7, P73, DOI 10.1016/j.prro.2016.09.007; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; DeSantis CE, 2017, CA-CANCER J CLIN, V67, P439, DOI 10.3322/caac.21412; Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152; FISHER ER, 1992, SEMIN SURG ONCOL, V8, P161; HALL WH, 1991, JAMA-J AM MED ASSOC, V265, P391; Hoopes DJ, 2012, INT J RADIAT ONCOL, V82, P674, DOI 10.1016/j.ijrobp.2010.11.077; Hughes KS, 2013, J CLIN ONCOL, V31, P2382, DOI 10.1200/JCO.2012.45.2615; Kunkler IH, 2015, LANCET ONCOL, V16, P266, DOI 10.1016/S1470-2045(14)71221-5; Lam J, 2015, CLIN ONCOL-UK, V27, P465, DOI 10.1016/j.clon.2015.04.034; Livi L, 2015, EUR J CANCER, V51, P451, DOI 10.1016/j.ejca.2014.12.013; Nattinger AB, 2001, J NATL CANCER I, V93, P1344, DOI 10.1093/jnci/93.17.1344; Pan IW, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt340; Parekh A, 2018, BREAST CANCER RES TR, V172, P201, DOI 10.1007/s10549-018-4881-0; Rippy EE, 2014, BREAST, V23, P273, DOI 10.1016/j.breast.2013.12.009; Strnad V, 2016, LANCET, V387, P229, DOI 10.1016/S0140-6736(15)00471-7; van Maaren MC, 2016, LANCET ONCOL, V17, P1158, DOI 10.1016/S1470-2045(16)30067-5; Vicini FA, 2018, SAN ANT BREAST CANC; Whelan T, 2018, SAN ANT BREAST CANC; WHITE SJ, 1978, BRIT J CANCER, V37, P849, DOI 10.1038/bjc.1978.124	23	184	186	2	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 14	2019	394	10215					2155	2164		10.1016/S0140-6736(19)32514-0	http://dx.doi.org/10.1016/S0140-6736(19)32514-0			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV7MT	31813636	Green Accepted			2023-01-03	WOS:000502546300025
J	Oliveira, IDD; Colares, AV; Cardoso, FD; Tellis, CJM; Chagas, MDD; Behrens, MD; Calabrese, KD; Almeida-Souza, F; Abreu-Silva, AL				da Silva Oliveira, Iara dos Santos; Colares, Aracelio Viana; Cardoso, Flavia de Oliveira; Moragas Tellis, Carla Junqueira; dos Santos Chagas, Maria do Socorro; Behrens, Maria Dutra; Calabrese, Katie da Silva; Almeida-Souza, Fernando; Abreu-Silva, Ana Lucia			Vernonia polysphaera Baker: Anti-inflammatory activity in vivo and inhibitory effect in LPS-stimulated RAW 264.7 cells	PLOS ONE			English	Article							FACTOR-KAPPA-B; SESQUITERPENE LACTONES; CYCLOOXYGENASE-2 EXPRESSION; ARACHIDONIC-ACID; NITRIC-OXIDE; URSOLIC ACID; PART I; EXTRACT; ANTIOXIDANT; AMYGDALINA	Species of the Vernonia genius are widely distributed across the world. In traditional communities, they are commonly used in popular medicine for the treatment of inflammatory diseases. The objective of the present study was to evaluate the anti-inflammatory activity of Vernonia polysphaera Baker hydroalcoholic extract. A lambda-carrageenan-induced paw edema and peritonitis model was established in BALB/c mice. The in vitro activity of the extract was measured on LPS-stimulated RAW 264.7 cells. There was no toxic effect on mice or on the cells treated with the extract. Animals treated with V. polysphaera extract demonstrated inhibition of paw edema in comparison with the untreated animals at all the analyzed doses. In peritonitis, treatment with the extract at a dose of 500 mg/kg resulted in a lower total leukocyte count in the peritoneal fluid and blood and lower levels of IL-1 beta, IL-6, TNF-alpha and PGE-2 than the control group. Cells treated with 50 and 100 mu g/mL of the extract exhibited lower levels of nitrite and pro-inflammatory cytokine production and lower COX-2, NF-kappa B expression. The V. polysphaera extract demonstrated an anti-inflammatory effect, interfering with cell migration, reducing pro-inflammatory cytokine levels and COX-2 expression and consequent interference with PGE-2, as well as inhibiting NF-kappa B transcription.	[da Silva Oliveira, Iara dos Santos] Univ Fed Maranhao, Rede Nordeste Biotecnol, Sao Luis, Maranhao, Brazil; [Colares, Aracelio Viana] Ctr Univ Dr Leao Sampaio, Juazeiro Do Norte, Ceara, Brazil; [Cardoso, Flavia de Oliveira; Calabrese, Katie da Silva; Almeida-Souza, Fernando] Fundacao Oswaldo Cruz, Lab Imunomodulacao & Protozool, Rio De Janeiro, RJ, Brazil; [Moragas Tellis, Carla Junqueira; dos Santos Chagas, Maria do Socorro; Behrens, Maria Dutra] Fiocruz MS, Farmanguinhos, Dept Prod Nat, Rio De Janeiro, RJ, Brazil; [Almeida-Souza, Fernando; Abreu-Silva, Ana Lucia] Univ Estadual Maranhao, Posgrad Ciencia Anim, Sao Luis, Maranhao, Brazil	Universidade Federal do Maranhao; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Universidade Estadual do Maranhao	Almeida-Souza, F (corresponding author), Fundacao Oswaldo Cruz, Lab Imunomodulacao & Protozool, Rio De Janeiro, RJ, Brazil.; Almeida-Souza, F (corresponding author), Univ Estadual Maranhao, Posgrad Ciencia Anim, Sao Luis, Maranhao, Brazil.	femandoalsouza@gmail.com	Calabrese, Katia S/V-2631-2018; Colares, Aracelio/AAU-9457-2020; CARDOSO, FLÁVIA/AAZ-8666-2021; CARDOSO, FLÁVIA/AEX-9625-2022; Silva, Ana Lúcia Abreu/AAR-9739-2020; Almeida-Souza, Fernando/F-9809-2017	Almeida-Souza, Fernando/0000-0003-0047-6159; CARDOSO, FLAVIA/0000-0002-2026-1836	Coordination for the Improvement of Higher Education Personnel (the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) Brazil (CAPES) [001]; Research and Scientific and Technological Development Foundation of Maranhao (Fundacao de Amparo a Pesquisa e Desenvolvimento Cientifico e Tecnologico do Maranhao) [APP00844/09, Pronex-241709/2014]; National Scientific and Technological Development Council (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico) [407831/2012.6, 309885/2017-5]	Coordination for the Improvement of Higher Education Personnel (the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) Brazil (CAPES); Research and Scientific and Technological Development Foundation of Maranhao (Fundacao de Amparo a Pesquisa e Desenvolvimento Cientifico e Tecnologico do Maranhao); National Scientific and Technological Development Council (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico)	The present study was funded by the Coordination for the Improvement of Higher Education Personnel (the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) Brazil (CAPES) [Finance Code 001]; the Research and Scientific and Technological Development Foundation of Maranhao (Fundacao de Amparo a Pesquisa e Desenvolvimento Cientifico e Tecnologico do Maranhao) [grant numbers APP00844/09, Pronex-241709/2014 to A.L.A.S.]; the National Scientific and Technological Development Council (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico) [grant numbers 407831/2012.6 and 309885/2017-5 to A.L.A.S.]. Dr. Fernando Almeida-Souza are postdoctoral researcher fellows of CAPES. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to thank the Program for Technological Development in Health ToolsPDTIS-FIOCRUZ for the use of its facilities. The present study was funded by the Coordination for the Improvement of Higher Education Personnel (the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) Brazil (CAPES) [Finance Code 001]; the Research and Scientific and Technological Development Foundation of Maranhao (Fundacao de Amparo a Pesquisa e Desenvolvimento Cientifico e Tecnologico do Maranhao) [grant numbers APP00844/09, Pronex-241709/2014 to A.L.A.S]; the National Scientific and Technological Development Council (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico) [grant numbers 407831/2012.6 and 309885/2017-5 to A.L.A.S.]. Dr. Fernando Almeida-Souza are postdoctoral researcher fellows of CAPES. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abeysekera AM, 1999, FITOTERAPIA, V70, P317, DOI 10.1016/S0367-326X(99)00052-0; Autamashih M, 2011, J PHARM NEGAT RESULT, V2, P14, DOI 10.4103/0976-9234.82987; Barbastefano V, 2007, FITOTERAPIA, V78, P545, DOI 10.1016/j.fitote.2007.07.003; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; Calixto JB, 2003, PLANTA MED, V69, P973, DOI [10.1055/s-2003-45141, 10.1055/s-2004-815483]; Cespedes CL, 2010, B LATINOAM CARIBE PL, V9, P127; Cruvinel WD, 2010, REV BRAS REUMATOL, V50, P434, DOI 10.1590/S0482-50042010000400008; DAI Y, 1989, ACTA PHARMACOL SIN, V10, P381; Dominguez M, 2011, PHARM BIOL, V49, P118, DOI 10.3109/13880209.2010.503708; Franz J, 2017, BIOCHEM SOC T, V45, P999, DOI 10.1042/BST20170163; Fujiwara R. T., 2005, Polish Journal of Veterinary Sciences, V8, P17; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gresham Lecia J, 2008, Int J Environ Res Public Health, V5, P342; GUPTA MB, 1969, EUR J PHARMACOL, V6, P67, DOI 10.1016/0014-2999(69)90067-3; Heger K, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001762; Guerra ASHD, 2011, INT IMMUNOPHARMACOL, V11, P1816, DOI 10.1016/j.intimp.2011.07.010; Igual MO, 2013, BIOCHEM SYST ECOL, V51, P94, DOI 10.1016/j.bse.2013.08.018; Ikeda Y, 2001, LIFE SCI, V69, P2911, DOI 10.1016/S0024-3205(01)01374-1; Inngjerdingen KT, 2014, FITOTERAPIA, V95, P127, DOI 10.1016/j.fitote.2014.03.009; Kiplimo JJ, 2011, AFR J PHARM PHARMACO, V5, P1150; Kos O, 2006, PHYTOCHEMISTRY, V67, P62, DOI 10.1016/j.phytochem.2005.07.006; Kumar H, 2011, INT REV IMMUNOL, V30, P16, DOI 10.3109/08830185.2010.529976; Kumar PP, 2009, IMMUNOPHARM IMMUNOT, V31, P94, DOI 10.1080/08923970802438391; Le Bars D, 2001, PHARMACOL REV, V53, P597; Liang Qiao-Li, 2010, Chinese Journal of Natural Medicines, V8, P104, DOI 10.3724/SP.J.1009.2010.00104; Liao JC, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429320; Liu J, 2009, STEROIDS, V74, P51, DOI 10.1016/j.steroids.2008.09.005; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mueller M, 2010, FOOD CHEM, V122, P987, DOI 10.1016/j.foodchem.2010.03.041; Nergard CS, 2004, J ETHNOPHARMACOL, V91, P141, DOI 10.1016/j.jep.2003.12.007; Omoregie ES, 2016, AVICENNA J PHYTOMEDI, V6, P236; OMOREGIE ES, 2010, MALAR J S2, V9, pP30, DOI DOI 10.1186/1475-2875-9-S2-P30; Onasanwo SA, 2017, J INTERCULT ETHNOPHA, V6, P192, DOI 10.5455/jice.20170330010610; Park MH, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020015; Patel K, 2013, CHIN J INTEGR MED, V19, P792, DOI 10.1007/s11655-013-1595-3; Pei TL, 2016, J ETHNOPHARMACOL, V190, P272, DOI 10.1016/j.jep.2016.06.001; Pires BRB, 2018, GENES-BASEL, V9, DOI 10.3390/genes9010024; Pollo LAE, 2018, CHEM-BIOL INTERACT, V279, P95, DOI 10.1016/j.cbi.2017.11.003; Pradhan D, 2009, NATURAL PRODUCT RADI, V8; Pratheeshkumar P, 2011, IMMUNOPHARM IMMUNOT, V33, P73, DOI 10.3109/08923971003745977; Rajamurugan R, 2011, PHARM BIOL, V49, P1311, DOI 10.3109/13880209.2011.604334; Ribeiro RA, 2000, EUR J PHARMACOL, V387, P111, DOI 10.1016/S0014-2999(99)00790-6; Rodrigues KCM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17121929; Rodrigues VEG, 2001, CIENC AGROTEC, V25, P102; Salawu S. O., 2011, African Journal of Food Science, V5, P267; Sanchez T, 1999, BIOCHEM PHARMACOL, V58, P877, DOI 10.1016/S0006-2952(99)00169-0; Seo S, 2016, BIOL PHARM BULL, V39, P1830, DOI 10.1248/bpb.b16-00414; Sherwood Edward R, 2004, Best Pract Res Clin Anaesthesiol, V18, P385, DOI 10.1016/S1521-6896(03)00116-2; Sheu MJ, 2012, FOOD CHEM, V132, P1010, DOI 10.1016/j.foodchem.2011.09.140; Shim V, 2003, CANCER RES, V63, P2347; SIMON A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P68, DOI 10.1016/0005-2760(92)90157-Q; Sinisi A, 2015, J NAT PROD, V78, P1618, DOI 10.1021/acs.jnatprod.5b00179; Sonoshita M, 2002, CANCER RES, V62, P6846; Toyang NJ, 2013, J ETHNOPHARMACOL, V146, P681, DOI 10.1016/j.jep.2013.01.040; Ukwuani A. N., 2012, International Journal of Pharmaceutical Sciences and Drug Research, V4, P245; Valerio DAR, 2007, EUR J PHARMACOL, V562, P155, DOI 10.1016/j.ejphar.2007.01.029; Valverde A, 2005, ACTA HORTIC, P263, DOI 10.17660/ActaHortic.2005.693.32; Whittington RA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01464; Yang JH, 2013, FOOD CHEM TOXICOL, V59, P362, DOI 10.1016/j.fct.2013.05.049; YING QL, 1991, BIOCHEM J, V277, P521, DOI 10.1042/bj2770521; Youn UJ, 2012, BIOORG MED CHEM LETT, V22, P5559, DOI 10.1016/j.bmcl.2012.07.010	61	5	5	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2019	14	12							e0225275	10.1371/journal.pone.0225275	http://dx.doi.org/10.1371/journal.pone.0225275			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP1HF	31830043	Green Published, gold			2023-01-03	WOS:000534070200017
J	Boulet, SL; Chamberlain, AT; Biswas, HH; Jamieson, DJ				Boulet, Sheree L.; Chamberlain, Allison T.; Biswas, Hope H.; Jamieson, Denise J.			Trends in Infant Pertussis Hospitalizations in the United States, 2009-2017	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ADVISORY-COMMITTEE; DIPHTHERIA; TETANUS; RECOMMENDATIONS		[Boulet, Sheree L.; Biswas, Hope H.; Jamieson, Denise J.] Emory Univ, Sch Med, Dept Gynecol & Obstet, 69 Jesse Hill Jr Dr SE,Glenn Bldg,Fourth Floor, Atlanta, GA 30303 USA; [Chamberlain, Allison T.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA	Emory University; Emory University; Rollins School Public Health	Boulet, SL (corresponding author), Emory Univ, Sch Med, Dept Gynecol & Obstet, 69 Jesse Hill Jr Dr SE,Glenn Bldg,Fourth Floor, Atlanta, GA 30303 USA.	sboulet@emory.edu	Chamberlain, Allison T./AAA-3835-2019	Chamberlain, Allison T./0000-0001-6009-537X; Boulet, Sheree/0000-0002-7638-7374				Bozio C, 2017, OPEN FORUM INFECT DI, V4, pS5, DOI [10.1093/ofid/ofx162.010, DOI 10.1093/OFID/OFX162.010]; Centers for Disease Control and Prevention, 2017, PERT WHOOP COUGH SUR; Liang JL, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6702a1; Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131; Truven Health Analytics, 2017, TRUV HLTH MARKETSCAN; Winter K, 2017, CLIN INFECT DIS, V64, P9, DOI 10.1093/cid/ciw633	6	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	2019	322	21					2134	2136		10.1001/jama.2019.15577	http://dx.doi.org/10.1001/jama.2019.15577			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ6JE	31794618	Green Published, hybrid			2023-01-03	WOS:000505207400037
J	Galley, HF; Webster, NR				Galley, Helen F.; Webster, Nigel R.			Deep anaesthesia and poor outcomes: the jury isstill out	LANCET			English	Editorial Material							BISPECTRAL INDEX; POSTOPERATIVE MORTALITY; NEUROMUSCULAR BLOCK; DEPTH; METAANALYSIS		[Galley, Helen F.; Webster, Nigel R.] Univ Aberdeen, Inst Med Sci, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Galley, HF (corresponding author), Univ Aberdeen, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.	h.f.galley@abdn.ac.uk						Bruhn J, 2006, BRIT J ANAESTH, V97, P85, DOI 10.1093/bja/ael120; Dahaba AA, 2012, BRIT J ANAESTH, V108, P602, DOI 10.1093/bja/aer495; Hajat Z, 2017, ANAESTHESIA, V72, P38, DOI 10.1111/anae.13739; LEWIS SR, 2019, COCHRANE DB SYST REV, V9; Liu YH, 2019, J CLIN ANESTH, V56, P119, DOI 10.1016/j.jclinane.2019.01.046; Schuller PJ, 2015, BRIT J ANAESTH, V115, P95, DOI 10.1093/bja/aev072; Sessler DI, 2012, ANESTHESIOLOGY, V116, P1195, DOI 10.1097/ALN.0b013e31825683dc; Short TG, 2019, LANCET, DOI [10.1016/20.S0140-6736(19)32315-3, DOI 10.1016/20.S0140-6736(19)32315-3]; Sudhakaran R, 2018, INDIAN J ANAESTH, V62, P516, DOI 10.4103/ija.IJA_172_18; Zorrilla-Vaca A, 2017, CAN J ANESTH, V64, P597, DOI 10.1007/s12630-017-0872-6	10	2	2	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	2019	394	10212					1881	1882		10.1016/S0140-6736(19)32465-1	http://dx.doi.org/10.1016/S0140-6736(19)32465-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JQ3SI	31645289	Green Submitted			2023-01-03	WOS:000498868500005
J	Charles, A; Pozo-Rosich, P				Charles, Andrew; Pozo-Rosich, Patricia			Targeting calcitonin gene-related peptide: a new era in migraine therapy	LANCET			English	Review							RANDOMIZED CONTROLLED-TRIAL; RECEPTOR ANTAGONIST TELCAGEPANT; FREQUENCY EPISODIC MIGRAINE; DOUBLE-BLIND; PREVENTIVE TREATMENT; NEUROPEPTIDE CHANGES; RHESUS-MONKEY; EXERCISE TIME; NERVE-FIBERS; AMG 334	Migraine is one of the most prevalent and disabling diseases worldwide, but until recently, few migraine-specific therapies had been developed. Extensive basic and clinical scientific investigation has provided strong evidence that the neuropeptide calcitonin gene-related peptide (CGRP) has a key role in migraine. This evidence led to the development of small molecule CGRP receptor antagonists and monoclonal antibodies targeting either CGRP or its receptor. Clinical trials investigating these therapies have consistently shown statistically significant efficacy for either the acute or preventive treatment of migraine. No serious safety or tolerability issues have been identified in the trials of the monoclonal antibody therapies. Although the appropriate place of these new migraine-specific therapies relative to other available acute and preventive treatments remains to be determined, a growing body of evidence shows that therapeutic approaches targeting CGRP have the potential to transform the clinical management of migraine.	[Charles, Andrew] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Goldberg Migraine Program, Los Angeles, CA 90095 USA; [Pozo-Rosich, Patricia] Hosp Univ Vall dHebron, Dept Neurol, Headache Unit, Barcelona, Spain; [Pozo-Rosich, Patricia] Univ Autonoma Barcelona, Headache Res Grp, Vall dHebron Res Inst, Barcelona, Spain	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR)	Charles, A (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Goldberg Migraine Program, Los Angeles, CA 90095 USA.	acharles@ucla.edu			Eli Lilly; Novartis; Wendy and Leonard Goldberg Endowment; Meyer and Renee Luskin Chair in Migraine and Headache Studies at UCLA; Baldwin Foundation; Chiesi, Electrocore; Allergan; la Caixa Foundation; MINECO; AGAUR; Fundacio La Marato TV3, Instituto Investigacion Carlos III, Migraine Research Foundation, Mutual Medica	Eli Lilly(Eli Lilly); Novartis(Novartis); Wendy and Leonard Goldberg Endowment; Meyer and Renee Luskin Chair in Migraine and Headache Studies at UCLA; Baldwin Foundation; Chiesi, Electrocore(Chiesi Pharmaceuticals Inc); Allergan(AbbVieAllergan); la Caixa Foundation(La Caixa Foundation); MINECO(Spanish Government); AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); Fundacio La Marato TV3, Instituto Investigacion Carlos III, Migraine Research Foundation, Mutual Medica	AC has received compensation as a consultant for Alder, Amgen, Biohaven, Eli Lilly, eNeura, and Novartis. He receives grant support from the Wendy and Leonard Goldberg Endowment, the Arline and Seymour Kreshek fund, the Meyer and Renee Luskin Chair in Migraine and Headache Studies at UCLA, and the Baldwin Foundation. PP-R has received honoraria for participation in clinical trials and contribution to advisory boards or presentations from Allergan, Almirall, Amgen, Chiesi, Electrocore, Eli Lilly, Medscape, Novartis, and Teva. Financial support for research projects was provided by Allergan (outside of the submitted work). Headache research is supported by la Caixa Foundation, MINECO, AGAUR, Fundacio La Marato TV3, Instituto Investigacion Carlos III, Migraine Research Foundation, Mutual Medica, and PERIS.	Amin FM, 2013, LANCET NEUROL, V12, P454, DOI 10.1016/S1474-4422(13)70067-X; Ashina M, 2019, CEPHALALGIA, V39, P1455, DOI 10.1177/0333102419854082; Ashina M, 2018, CEPHALALGIA, V38, P1611, DOI 10.1177/0333102418788347; Ashina M, 2017, NEUROLOGY, V89, P1237, DOI 10.1212/WNL.0000000000004391; Behm MO, 2011, HEADACHE, V51, P954, DOI 10.1111/j.1526-4610.2011.01901.x; Bigal ME, 2015, LANCET NEUROL, V14, P1081, DOI 10.1016/S1474-4422(15)00249-5; Bigal ME, 2015, LANCET NEUROL, V14, P1091, DOI 10.1016/S1474-4422(15)00245-8; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; Buse DC, 2018, CEPHALALGIA, V38, P1622, DOI 10.1177/0333102418789072; Camporeale A, 2018, BMC NEUROL, V18, DOI 10.1186/s12883-018-1193-2; Campos CA, 2018, NATURE, V555, P617, DOI 10.1038/nature25511; Chaitman BR, 2012, CLIN PHARMACOL THER, V91, P459, DOI 10.1038/clpt.2011.246; Charles A, 2017, NEW ENGL J MED, V377, P1698; Charles A, 2013, LANCET NEUROL, V12, P419, DOI 10.1016/S1474-4422(13)70051-6; Cohen JM, 2017, HEADACHE, V57, P1375, DOI 10.1111/head.13156; Cohen-Barak O, 2018, CEPHALALGIA, V38, P1960, DOI 10.1177/0333102418771376; Connor KM, 2009, NEUROLOGY, V73, P970, DOI 10.1212/WNL.0b013e3181b87942; Croop R, 2019, LANCET, V394, P737, DOI 10.1016/S0140-6736(19)31606-X; de Hoon J, 2019, CEPHALALGIA, V39, P100, DOI 10.1177/0333102418776017; de Hoon J, 2018, CLIN PHARMACOL THER, V103, P815, DOI 10.1002/cpt.799; Depre C, 2018, HEADACHE, V58, P715, DOI 10.1111/head.13316; Detke HC, 2018, NEUROLOGY, V91, pE2211, DOI 10.1212/WNL.0000000000006640; Digre KB, 2019, HEADACHE, V59, P1, DOI 10.1111/head.13456; Dodick DW, 2019, CEPHALALGIA, V39, P1075, DOI 10.1177/0333102419858355; Dodick DW, 2018, JAMA-J AM MED ASSOC, V319, P1999, DOI 10.1001/jama.2018.4853; Dodick DW, 2018, CEPHALALGIA, V38, P1026, DOI 10.1177/0333102418759786; Dodick DW, 2014, LANCET NEUROL, V13, P885, DOI 10.1016/S1474-4422(14)70128-0; Edvinsson L, 2018, NAT REV NEUROL, V14, P338, DOI 10.1038/s41582-018-0003-1; Eftekhari S, 2016, J COMP NEUROL, V524, P90, DOI 10.1002/cne.23828; Eftekhari S, 2013, J PAIN, V14, P1289, DOI 10.1016/j.jpain.2013.03.010; FISHER LA, 1983, NATURE, V305, P534, DOI 10.1038/305534a0; Forderreuther S, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0951-2; Goadsby PJ, 2019, J NEUROL NEUROSUR PS, V90, P939, DOI 10.1136/jnnp-2018-320242; Goadsby PJ, 2019, CEPHALALGIA, V39, P817, DOI 10.1177/0333102419835459; Goadsby PJ, 2017, NEW ENGL J MED, V377, P2123, DOI 10.1056/NEJMoa1705848; GOADSBY PJ, 1993, ANN NEUROL, V33, P48, DOI 10.1002/ana.410330109; GOADSBY PJ, 1994, BRAIN, V117, P427, DOI 10.1093/brain/117.3.427; GOADSBY PJ, 1988, ANN NEUROL, V23, P193, DOI 10.1002/ana.410230214; Hansen JM, 2010, CEPHALALGIA, V30, P1179, DOI 10.1177/0333102410368444; Hepp Z, 2017, CEPHALALGIA, V37, P470, DOI 10.1177/0333102416678382; Hewitt DJ, 2011, CEPHALALGIA, V31, P712, DOI 10.1177/0333102411398399; Ho TW, 2016, CEPHALALGIA, V36, P148, DOI 10.1177/0333102415584308; Ho TW, 2014, NEUROLOGY, V83, P958, DOI 10.1212/WNL.0000000000000771; Ho TW, 2012, HEADACHE, V52, P224, DOI 10.1111/j.1526-4610.2011.02052.x; Ho TW, 2008, LANCET, V372, P2115, DOI 10.1016/S0140-6736(08)61626-8; Hostetler ED, 2013, J PHARMACOL EXP THER, V347, P478, DOI 10.1124/jpet.113.206458; Lassen LH, 2002, CEPHALALGIA, V22, P54, DOI 10.1046/j.1468-2982.2002.00310.x; LENZ HJ, 1985, GUT, V26, P550, DOI 10.1136/gut.26.6.550; Lipton RB, 2019, NEW ENGL J MED, V381, P142, DOI 10.1056/NEJMoa1811090; Lipton RB, 2019, NEUROLOGY, V92, pE2250, DOI 10.1212/WNL.0000000000007452; Marcus R, 2014, CEPHALALGIA, V34, P114, DOI 10.1177/0333102413500727; MCCULLOCH J, 1986, P NATL ACAD SCI USA, V83, P5731, DOI 10.1073/pnas.83.15.5731; Monteith D, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00740; Naot D, 2008, BONE, V43, P813, DOI 10.1016/j.bone.2008.07.003; Oakes TMM, 2018, CEPHALALGIA, V38, P1015, DOI 10.1177/0333102417747230; Olesen J, 2004, NEW ENGL J MED, V350, P1104, DOI 10.1056/NEJMoa030505; Paone DV, 2007, J MED CHEM, V50, P5564, DOI 10.1021/jm070668p; Rapoport A, 2006, HEADACHE, V46, P1151, DOI 10.1111/j.1526-4610.2006.00506.x; Reuter U, 2018, LANCET, V392, P2280, DOI 10.1016/S0140-6736(18)32534-0; Rosen N, 2018, HEADACHE, V58, P1347, DOI 10.1111/head.13427; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; Ruff DD, 2019, CEPHALALGIA, V39, P931, DOI 10.1177/0333102419847957; Sacco S, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-019-0972-5; Schulte LH, 2016, BRAIN, V139, P1987, DOI 10.1093/brain/aww097; Schwedt T, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0923-6; Serrano D, 2017, J HEADACHE PAIN, V18, DOI 10.1186/s10194-017-0787-1; Silberstein SD, 2019, HEADACHE, V59, P383, DOI 10.1111/head.13446; Silberstein SD, 2017, NEW ENGL J MED, V377, P2113, DOI 10.1056/NEJMoa1709038; Singh RBH, 2019, CEPHALALGIA, V39, P52, DOI 10.1177/0333102418772585; Skljarevski V, 2018, CEPHALALGIA, V38, P1442, DOI 10.1177/0333102418779543; Skljarevski V, 2018, JAMA NEUROL, V75, P187, DOI 10.1001/jamaneurol.2017.3859; Stauffer VL, 2018, JAMA NEUROL, V75, P1080, DOI 10.1001/jamaneurol.2018.1212; Stovner LJ, 2018, LANCET NEUROL, V17, P954, DOI [10.1016/S1474-4422(18)30322-3, 10.1016/S1474-4422(18)30499-X]; Sun H, 2016, LANCET NEUROL, V15, P382, DOI 10.1016/S1474-4422(16)00019-3; Tepper S, 2017, LANCET NEUROL, V16, P425, DOI 10.1016/S1474-4422(17)30083-2; Tepper SJ, 2019, NEUROLOGY, V92, pE2309, DOI 10.1212/WNL.0000000000007497; TIPPINS JR, 1984, NEUROPEPTIDES, V4, P425, DOI 10.1016/0143-4179(84)90118-5; Torres-Ferrus M, 2019, CURR OPIN NEUROL, V32, P395, DOI 10.1097/WCO.0000000000000689; UDDMAN R, 1985, NEUROSCI LETT, V62, P131, DOI 10.1016/0304-3940(85)90296-4; VanderPluym J, 2018, NEUROLOGY, V91, pE1152, DOI 10.1212/01.wnl.0000544321.19316.40; Vollesen ALH, 2018, JAMA NEUROL, V75, P1187, DOI 10.1001/jamaneurol.2018.1675; Voss T, 2016, CEPHALALGIA, V36, P887, DOI 10.1177/0333102416653233; Warfvinge K, 2019, CEPHALALGIA, V39, P342, DOI 10.1177/0333102417728873; ZAGAMI AS, 1990, NEUROPEPTIDES, V16, P69, DOI 10.1016/0143-4179(90)90114-E; Zhang YF, 2016, NAT MED, V22, P1160, DOI 10.1038/nm.4162	85	122	123	8	36	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 9	2019	394	10210					1765	1774		10.1016/S0140-6736(19)32504-8	http://dx.doi.org/10.1016/S0140-6736(19)32504-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN5DZ	31668411				2023-01-03	WOS:000496920300032
J	Eisenstein, M				Eisenstein, Michael			KEEPING TREATMENT OPTIONS OPEN	NATURE			English	Editorial Material							BRACHYTHERAPY; ASSOCIATION											Chen RC, 2017, JAMA-J AM MED ASSOC, V317, P1141, DOI 10.1001/jama.2017.1652; Claudio G., 2017, CAN J UROL, V24, P8728; Dutta SW, 2018, BRACHYTHERAPY, V17, P556, DOI 10.1016/j.brachy.2018.01.013; Laviana AA, 2016, CANCER-AM CANCER SOC, V122, P447, DOI 10.1002/cncr.29743; Morris WJ, 2017, INT J RADIAT ONCOL, V98, P275, DOI 10.1016/j.ijrobp.2016.11.026; Nabavizadeh N, 2016, INT J RADIAT ONCOL, V94, P228, DOI 10.1016/j.ijrobp.2015.10.014	6	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	2019	574	7780					S82	S83						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JI9UH	31666727				2023-01-03	WOS:000493807800010
J	Hill, J; Seguin, R; Phanga, T; Manda, A; Chikasema, M; Gopal, S; Smith, JS				Hill, Jacob; Seguin, Ryan; Phanga, Twambilile; Manda, Agness; Chikasema, Maria; Gopal, Satish; Smith, Jennifer S.			Facilitators and barriers to traditional medicine use among cancer patients in Malawi	PLOS ONE			English	Article							COMPLEMENTARY	Background Increasing access to conventional cancer treatment (CT) in low-income countries (LICs) is an important public health initiative to address the global burden of cancer. However, LICs have a high prevalence of use of traditional and complementary medicine (T&CM). It is important to consider the factors that influence a patient's choice to use T&CM, CT, or both for their cancer treatment. Methods We conducted focus groups among adult cancer patients in Lilongwe, Malawi to identify facilitators and barriers of T&CM use. Focus groups were recorded, transcribed, translated, and underwent thematic content analysis. Results Cultural norms, T&CM access, T&CM success, and CT failure were all identified as facilitators to T&CM use. CT success and T&CM failure were identified as barriers. Access and norms appear to determine initial treatment selection, while treatment outcomes dictate continued use of T&CM or CT. Conclusion This study identified a pragmatic and experience-based treatment selection process that aligns with the social cognitive theory of behavior and assists in comprehending the factors that influence T&CM use among cancer patients in a low resource setting.	[Hill, Jacob; Gopal, Satish; Smith, Jennifer S.] Univ N Carolina, Chapel Hill, NC 27515 USA; [Seguin, Ryan; Phanga, Twambilile; Manda, Agness; Chikasema, Maria; Gopal, Satish] Malawi Canc Consortium & Reg Ctr Res Excellence N, Lilongwe, Malawi; [Gopal, Satish] Univ Malawi, Coll Med, Blantyre, Malawi	University of North Carolina; University of North Carolina Chapel Hill; University of Malawi	Hill, J (corresponding author), Univ N Carolina, Chapel Hill, NC 27515 USA.	Jacob_hill@med.unc.edu			University of North Carolina, Chapel Hill, Lineberger Comprehensive Cancer Center Tier 1 Pilot Development Award; Research Fellowship in Complementary and Integrative Health from the National Center for Complementary and Integrative Health [5T32AT003378-12]; National Center for Complementary & Integrative Health [T32AT003378] Funding Source: NIH RePORTER	University of North Carolina, Chapel Hill, Lineberger Comprehensive Cancer Center Tier 1 Pilot Development Award; Research Fellowship in Complementary and Integrative Health from the National Center for Complementary and Integrative Health; National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was funded by University of North Carolina, Chapel Hill, Lineberger Comprehensive Cancer Center Tier 1 Pilot Development Award. Author JSS received this award. The funders did not play any role in study design, data collection and analysis, decision to publish, or in preparation of the manuscript (https://unclineberger.org/); and The Research Fellowship in Complementary and Integrative Health (5T32AT003378-12) from the National Center for Complementary and Integrative Health provides salary support for author JH. The funders did not play any role in study design, data collection and analysis, decision to publish, or in preparation of the manuscript (https://nccih.nih.gov/).	Bandura A., 1989, ANN CHILD DEV, V6; Bannerman R., 1993, TRADITIONAL MED HEAL; Block Keith I, 2002, Integr Cancer Ther, V1, P83, DOI 10.1177/1534735402001001007; Bodeker G, 2002, AM J PUBLIC HEALTH, V92, P1582, DOI 10.2105/AJPH.92.10.1582; Chibwana AI, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-219; Davis EL, 2012, ONCOLOGIST, V17, P1475, DOI 10.1634/theoncologist.2012-0223; De Boer C, 2014, INFECT AGENTS CANCER, V9, DOI 10.1186/1750-9378-9-17; Dunyo SK, T R SOC TROP MED HYG, V91, P446; Fisher E, 2017, J HEALTH CARE POOR U, V28, P1104, DOI 10.1353/hpu.2017.0100; Glanz K, HLTH BEHAV THEORY RE; Hill J, 2019, GLOB PUBLIC HEALTH, V14, P418, DOI 10.1080/17441692.2018.1534254; Hillenbrand E., 2006, NORD J AFR STUD, V15, P1; James PB, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000895; Letsyo E, 2017, J ETHNOPHARMACOL, V202, P154, DOI 10.1016/j.jep.2017.03.008; Ministry of Health, 2017, MAL HLTH SECT STRAT; Ministry of Health Malawi, 2012, HLTH SECT STRAT PLAN, P170; Moshabela M, 2017, SEX TRANSM INFECT, V93, DOI 10.1136/sextrans-2016-052974; Obrist M, 2014, BREAST, V23, P821, DOI 10.1016/j.breast.2014.08.014; Wang Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116897; WHO (World Health Organization), 2019, WHO GLOB REP TRAD CO; World Health Organization, 2002, WHO TRADITIONAL MED; World Health Organization, 2013, WHO TRAD MED STRAT 2	22	5	5	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2019	14	10							e0223853	10.1371/journal.pone.0223853	http://dx.doi.org/10.1371/journal.pone.0223853			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM9KZ	31634355	gold, Green Published			2023-01-03	WOS:000532568300017
J	Deconinck, L; Dinh, A; Nich, C; Tritz, T; Matt, M; Senard, O; Bessis, S; Bauer, T; Rottman, M; Salomon, J; Bouchand, F; Davido, B				Deconinck, Laurene; Dinh, Aurelien; Nich, Christophe; Tritz, Thomas; Matt, Morgan; Senard, Olivia; Bessis, Simon; Bauer, Thomas; Rottman, Martin; Salomon, Jerome; Bouchand, Frederique; Davido, Benjamin			Efficacy of cotrimoxazole (Sulfamethoxazole-Trimethoprim) as a salvage therapy for the treatment of bone and joint infections (BJIs)	PLOS ONE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; RISK-FACTORS; ANTIBIOTIC-TREATMENT; TREATMENT FAILURE; OSTEOMYELITIS; TRIMETHOPRIM/SULFAMETHOXAZOLE; COMBINATION; GUIDELINES; INVITRO; INVIVO	Introduction Cotrimoxazole (Sulfamethoxazole-Trimethoprim, SXT) has interesting characteristics for the treatment of bone and joint infection (BJI): a broad spectrum of activity with adequate bone diffusion and oral and intravenous formulations. However, its efficacy and safety in BJIs are poorly documented and its use remains limited. Methods We conducted a retrospective study in 2 reference centers for BJIs from 2013 to 2018 among patients treated with SXT for a BJI. Data were collected from patient's medical charts. Outcomes and adverse events were evaluated at day (D)7, D45 and D90. Results We analyzed 51 patients with a mean age of 60 20 (SD) years of which 76% presented with an orthopedic device infection (ODI). Gram-negative bacilli (GNB) were involved in 47% of BJIs (n = 24). Moreover, they were often polymicrobial infections (41%). Doses of SXT ranged from 800/160mg bid (61%; n = 31) to 800/160mg tid (39%; n = 20). Median SXT treatment duration was 45 days (IQR 40-45). SXT was part of a dual therapy in 84% of patients (n = 43), associated mainly with fluoroquinolones (n = 17) or rifampicin (n = 14). Outcome was favorable at D7 in 98% (n = 50), at D45 in 88.2% (n = 45) and at D90 in 78.4% (n = 40). The second agent combined with SXT was not an independent factor of favorable outcome (p = 0.97). Adverse events were reported in 8% (n = 4) of patients, with a median of 21 days (IQR 20-30) from SXT initiation and led to discontinuation (n = 3). Conclusion SXT appears to be effective for treatment of BJIs as a salvage therapy, even in GNB or poly microbial infection, including ODI. Further data are needed to confirm SXT efficacy as an alternative oral regimen in BJIs.	[Deconinck, Laurene; Dinh, Aurelien; Matt, Morgan; Senard, Olivia; Bessis, Simon; Salomon, Jerome; Davido, Benjamin] Ctr Hosp Univ Raymond Poincare, AP HP, Serv Malad Infect, Garches, France; [Nich, Christophe] Ctr Hosp Univ Raymond Poincare, AP HP, Serv Orthopedie, Garches, France; [Tritz, Thomas] Ctr Hosp Univ Ambroise Pare, Pharm Hosp, AP HP, Boulogne Billancourt, France; [Bauer, Thomas] Ctr Hosp Univ Ambroise Pare, AP HP, Serv Orthopedie, Boulogne Billancourt, France; [Rottman, Martin] Ctr Hosp Univ Raymond Poincare, AP HP, Lab Microbiol, Garches, France; [Bouchand, Frederique] Ctr Hosp Univ Raymond Poincare, Pharm Hosp, AP HP, Garches, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP	Davido, B (corresponding author), Ctr Hosp Univ Raymond Poincare, AP HP, Serv Malad Infect, Garches, France.	benjamin.davido@aphp.fr	Bessis, Simon/AAD-9786-2022; Rottman, Martin/I-3005-2012; Dinh, Aurélien/AAI-5355-2021; SALOMON, JEROME/AGY-7338-2022; Rottman, Martin/AAD-9075-2021	Rottman, Martin/0000-0001-5953-3344; 				BURMAN LG, 1986, SCAND J INFECT DIS, V18, P3, DOI 10.3109/00365548609032299; Campbell ML, 2012, ANN PHARMACOTHER, V46, P1587, DOI 10.1345/aph.1R211; Colodner R, 2004, EUR J CLIN MICROBIOL, V23, P163, DOI 10.1007/s10096-003-1084-2; CRAVEN JL, 1970, BRIT MED J, V3, P201, DOI 10.1136/bmj.3.5716.201; Darley ESR, 2004, J ANTIMICROB CHEMOTH, V53, P928, DOI 10.1093/jac/dkh191; El Haj C, 2018, INT J ANTIMICROB AG, V51, P854, DOI 10.1016/j.ijantimicag.2018.01.014; ELWELL LP, 1986, ANTIMICROB AGENTS CH, V29, P1092, DOI 10.1128/AAC.29.6.1092; Euba G, 2009, ANTIMICROB AGENTS CH, V53, P2672, DOI 10.1128/AAC.01504-08; Ferry T, 2010, EUR J CLIN MICROBIOL, V29, P171, DOI 10.1007/s10096-009-0837-y; Fica A, 2015, REV CHIL INFECTOL, V32, P609, DOI 10.4067/S0716-10182015000700001; Fraser TN, 2012, J ANTIMICROB CHEMOTH, V67, P1271, DOI 10.1093/jac/dks030; Gemmell CG, 2006, J ANTIMICROB CHEMOTH, V57, P589, DOI 10.1093/jac/dkl017; Gentry CA, 2013, ANN PHARMACOTHER, V47, P1618, DOI 10.1177/1060028013509973; GENTRY LO, 1991, ANTIMICROB AGENTS CH, V35, P538, DOI 10.1128/AAC.35.3.538; Grammatico-Guillon L, 2012, J HOSP INFECT, V82, P40, DOI 10.1016/j.jhin.2012.04.025; Harbarth S, 2015, J ANTIMICROB CHEMOTH, V70, P264, DOI 10.1093/jac/dku352; Ho JMW, 2011, CAN MED ASSOC J, V183, P1851, DOI 10.1503/cmaj.111152; Hsieh PH, 2009, CLIN INFECT DIS, V49, P1036, DOI 10.1086/605593; Kaka AS, 2006, J ANTIMICROB CHEMOTH, V58, P680, DOI 10.1093/jac/dkl283; Karamanis EM, 2008, SPINE, V33, pE297, DOI 10.1097/BRS.0b013e31816f6c22; Lazzarini L, 2005, INT J INFECT DIS, V9, P127, DOI 10.1016/j.ijid.2004.09.009; Lee CC, 2018, J AM COLL CARDIOL, V72, P1369, DOI 10.1016/j.jacc.2018.06.067; Liu C, 2011, CLIN INFECT DIS, V53, P319, DOI [10.1093/cid/ciq146, 10.1093/cid/cir353]; Messina AF, 2011, PEDIATR INFECT DIS J, V30, P1019, DOI 10.1097/INF.0b013e31822db658; Munckhof WJ, 2004, INT J ANTIMICROB AG, V24, P605, DOI 10.1016/j.ijantimicag.2004.08.009; Nguyen S, 2009, CLIN MICROBIOL INFEC, V15, P1163, DOI 10.1111/j.1469-0691.2009.02761.x; SAUX MC, 1982, PATHOL BIOL, V30, P385; Seng P, 2017, INT J ANTIMICROB AG, V49, P558, DOI 10.1016/j.ijantimicag.2017.03.004; Senneville E, 2011, CLIN INFECT DIS, V53, P334, DOI 10.1093/cid/cir402; Spellberg B, 2012, CLIN INFECT DIS, V54, P393, DOI 10.1093/cid/cir842; SPILF, 2009, REC PRAT CLIN INF OS; Stein A, 1998, ANTIMICROB AGENTS CH, V42, P3086, DOI 10.1128/AAC.42.12.3086; Stein GE, 2013, J ANTIMICROB CHEMOTH, V68, P2852, DOI 10.1093/jac/dkt267; Stengel D, 2001, Lancet Infect Dis, V1, P175, DOI 10.1016/S1473-3099(01)00094-9; Titecat M, 2013, ORTHOP TRAUMATOL-SUR, V99, P653, DOI 10.1016/j.otsr.2013.02.011; Tome AM, 2011, DRUG SAFETY, V34, P465, DOI 10.2165/11587280-000000000-00000; Tornero E, 2016, J ANTIMICROB CHEMOTH, V71, P1395, DOI 10.1093/jac/dkv481; Valour F, 2014, ANTIMICROB AGENTS CH, V58, P746, DOI 10.1128/AAC.02032-13; YELDANDI V, 1988, J ANTIMICROB CHEMOTH, V22, P873, DOI 10.1093/jac/22.6.873; Zimmerli W, 2004, NEW ENGL J MED, V351, P1645, DOI 10.1056/NEJMra040181	40	4	4	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2019	14	10							e0224106	10.1371/journal.pone.0224106	http://dx.doi.org/10.1371/journal.pone.0224106			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM9KP	31622440	gold, Green Published			2023-01-03	WOS:000532567300094
J	Ishida, JH; Wong, PO; Cohen, BE; Vali, M; Steigerwald, S; Keyhani, S				Ishida, Julie H.; Wong, Peggy O.; Cohen, Beth E.; Vali, Marzieh; Steigerwald, Stacey; Keyhani, Salomeh			Substitution of marijuana for opioids in a national survey of US adults	PLOS ONE			English	Article							CANNABIS USE; SUBSTANCES; ALCOHOL; DRUGS	Opioid prescriptions for chronic pain and subsequent opioid-related complications have risen dramatically in the US. Recent data suggest that medical marijuana laws have been associated with lower state-level opioid overdose mortality. In a national survey, we examined the prevalence of substitution of marijuana for opioids among US adults taking opioids for pain.Using GfK's KnowledgePanel, we conducted an Internet-based survey of a nationally representative sample of 16,280 adults in 2017 about individual perceptions and use of marijuana. We developed questions designed to assess the extent and reasons for substitution of marijuana for opioids. We examined opioid substitution among respondents with a history of ever using marijuana who used opioids in the past 12 months. There were 9,003 respondents, corresponding to a 55.3% response rate. The mean age was 48 years. Among the 5% (n = 486) who reported ever using marijuana and using opioids in the past year, 43% used opioids daily, and 23% reported current (past 30 day) marijuana use. Forty-one percent reported a decrease or cessation of opioid use due to marijuana use; 46% reported no change in opioid use; and 8% reported an increase in opioid use. We found that a substantial number of US adults reported that they substituted marijuana for opioids.	[Ishida, Julie H.] San Francisco VA Med Ctr, Dept Med, Div Nephrol, San Francisco, CA USA; [Wong, Peggy O.; Cohen, Beth E.; Vali, Marzieh; Steigerwald, Stacey; Keyhani, Salomeh] San Francisco VA Med Ctr, Dept Gen Internal Med, San Francisco, CA 94121 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Keyhani, S (corresponding author), San Francisco VA Med Ctr, Dept Gen Internal Med, San Francisco, CA 94121 USA.	Salomeh.Keyhani@ucsf.edu			National Heart, Lung, and Blood Institute [1R01HL130484]; National Institute of Diabetes and Digestive and Kidney Diseases [K23DK103963]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL130484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK103963] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the National Heart, Lung, and Blood Institute [grant number 1R01HL130484 (Dr. Keyhani)]; National Institute of Diabetes and Digestive and Kidney Diseases [grant number K23DK103963 (Dr. Ishida)].	Abraham A, 2018, J GEN INTERN MED, V33, P1438, DOI 10.1007/s11606-018-4492-9; [Anonymous], 2017, KNOWLEDGEPANEL; [Anonymous], 2018, STATE MED MARIJUANA; [Anonymous], 2018, 2017 NATL SURVEY DRU; Boehnke KF, 2016, J PAIN, V17, P739, DOI 10.1016/j.jpain.2016.03.002; Campbell G, 2018, LANCET PUBLIC HEALTH, V3, pE341, DOI 10.1016/S2468-2667(18)30110-5; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Fowler FJ, 2013, JAMA INTERN MED, V173, P1215, DOI 10.1001/jamainternmed.2013.6172; Han B, 2017, ANN INTERN MED, V167, P293, DOI 10.7326/M17-0865; Hanauer DA, 2014, JAMA INTERN MED, P7; Keyhani S, 2018, ANN INTERN MED, V169, P282, DOI 10.7326/M18-0810; Lucas P, 2017, INT J DRUG POLICY, V42, P30, DOI 10.1016/j.drugpo.2017.01.011; Lucas P, 2016, DRUG ALCOHOL REV, V35, P326, DOI 10.1111/dar.12323; Lucas P, 2013, ADDICT RES THEORY, V21, P435, DOI 10.3109/16066359.2012.733465; McAfee T, 2013, LANCET, V382, P2003, DOI 10.1016/S0140-6736(13)61686-4; Nugent SM, 2017, ANN INTERN MED, V167, P319, DOI 10.7326/M17-0155; Patel A, 2014, POSITION STATEMENT U; Powell D, 2018, J HEALTH ECON, V58, P29, DOI 10.1016/j.jhealeco.2017.12.007; Reiman A, 2007, J EVID-BASED INTEGR, V12, P31, DOI 10.1177/1533210107301834; Research A.A.F.P.O, 2016, STAND DEF FIN DISP C; Reuben DB, 2015, ANN INTERN MED, V162, P295, DOI 10.7326/M14-2775; Steigerwald S, 2018, ANN INTERN MED, V169, P890, DOI 10.7326/M18-1681; Tomlinson T, 2015, JAMA-J AM MED ASSOC, V313, P417, DOI 10.1001/jama.2014.16363; Vyas MB, 2018, NURS OUTLOOK, V66, P56, DOI 10.1016/j.outlook.2017.08.012	24	31	31	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2019	14	10							e0222577	10.1371/journal.pone.0222577	http://dx.doi.org/10.1371/journal.pone.0222577			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM7CZ	31584957	Green Published, gold			2023-01-03	WOS:000532407600009
J	Tlili, H; Hanen, N; Ben Arfa, A; Neffati, M; Boubakri, A; Buonocore, D; Dossena, M; Verri, M; Doria, E				Tlili, Hajer; Hanen, Najjaa; Ben Arfa, Abdelkerim; Neffati, Mohamed; Boubakri, Abdelbasset; Buonocore, Daniela; Dossena, Maurizia; Verri, Manuela; Doria, Enrico			Biochemical profile and in vitro biological activities of extracts from seven folk medicinal plants growing wild in southern Tunisia	PLOS ONE			English	Article							MARRUBIUM-VULGARE L.; ANTIOXIDANT ACTIVITY; THYMELAEA-HIRSUTA; INHIBITION; SAPONINS	Recently, much attention has been paid to the extracts obtained from plant species in order to analyse their biological activities. Due to the climate diversity in Tunisia, the traditional pharmacopoeia consists of a wide arsenal of medicinal plant species since long used in folk medicine, in foods as spices, and in aromatherapy. Although many of these species are nearly facing extinction, only a small proportion of them have been scientifically studied. Therefore, this study explores the biochemical properties of seven spontaneous plants, which were harvested in the arid Tunisian desert: Marrubium vulgare (L.), Rhus tripartita (Ucria) D.C., Thymelaea hirsute (L.) Endl., Plantago ovata (Forsk.), Herniaria fontanesii (J. Gay.), Ziziphus lotus (L.) and Hyoscyamus albus (L.). Extracts from these plants were found to contain different types of secondary metabolites (polyphenols, flavonoids, condensed tannins, crude saponins, carotenoids and alkaloids) that are involved in important biological activities. The biological activity of the extracts obtained from each Tunisian plant was assessed: first of all, leukaemia and colon cancer cell lines (K-562 and CaCo-2 respectively) were treated with different concentrations of extracts, and then the anti-proliferative activity was observed. The results showed, in particular, how the plant extract from Rhus tripartita significantly inhibits cell proliferation, especially on the K-562 tumour cell line. Subsequently, the anti-inflammatory activity was also assessed, and the results showed that Herniaria fontanesii and Marrubium vulgare possess the highest activity in the group of analysed plants. Finally, the greatest acetylcholinesterase inhibitory effect was exhibited by the extract obtained from Rhus tripartita. In conclusion, all the Tunisian plants we analysed were shown to contain a remarkable amount of different bio-active compounds, thus confirming their involvement in several biological activities. Rhus tripartita and Ziziphus lotus were shown to be particularly effective in anti-proliferative activity, while Herniaria fontanesii were shown to have the best anti-inflammatory activity.	[Tlili, Hajer; Hanen, Najjaa; Ben Arfa, Abdelkerim; Neffati, Mohamed; Boubakri, Abdelbasset] Inst Arid Reg IRA, Lab Pastoral Ecosyst & Valorisat Spontaneous Plan, Medenine, Tunisia; [Buonocore, Daniela; Dossena, Maurizia; Verri, Manuela; Doria, Enrico] Univ Pavia, Dept Biol & Biotechnol, Pavia, Italy	Institut des Regions Arides; University of Pavia	Doria, E (corresponding author), Univ Pavia, Dept Biol & Biotechnol, Pavia, Italy.	enrico.doria@unipv.it	Boubakri, Abdelbasset/AAY-8784-2020	Boubakri, Abdelbasset/0000-0001-8755-8362; Doria, Enrico/0000-0002-6805-0202; Verri, Manuela/0000-0003-3734-9540				Abdoul-Azize S, 2016, J NUTR METAB, V2016, DOI 10.1155/2016/2867470; Abdoul-Azize S, 2013, INT IMMUNOPHARMACOL, V15, P364, DOI 10.1016/j.intimp.2012.11.013; Adewusi EA, 2011, S AFR J BOT, V77, P638, DOI 10.1016/j.sajb.2010.12.009; Adzu B, 2003, ACTA TROP, V87, P245, DOI 10.1016/S0001-706X(03)00114-1; Akrout A, 2011, FOOD CHEM TOXICOL, V49, P342, DOI 10.1016/j.fct.2010.11.003; Ben Barka Z, 2016, BIOMED PHARMACOTHER, V83, P827, DOI 10.1016/j.biopha.2016.07.055; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Biradar S.R., 2013, AM J LIFE SCI, V1, P243, DOI [10.11648/j.ajls.20130106.1, DOI 10.11648/J.AJLS.20130106.1, 10.11648/j.ajls.20130106.11, DOI 10.11648/J.AJLS.20130106.11]; Borgi W, 2004, S AFRICAN J BOT, V74, P320; BORRIS RP, 1988, J ETHNOPHARMACOL, V24, P41, DOI 10.1016/0378-8741(88)90138-9; Chao HC, 2013, EXP DERMATOL, V22, P131, DOI 10.1111/exd.12089; Chatterjee P, 2012, J ADV PHARM TECHNOL, V3, P136, DOI 10.4103/2231-4040.97298; Chevallier A., 1996, ENCY MED PLANTS; CORDELL GA, 1995, PHYTOCHEMISTRY, V40, P1585, DOI 10.1016/0031-9422(95)00444-C; Cuenod A, 1954, FLORE ANAL SYNOPTIQU; Doit C, 1997, ANTIMICROB AGENTS CH, V41, P2050, DOI 10.1128/AAC.41.9.2050; El Amrani F, 2009, J MED PLANTS RES, V3, P625; El-Saltani Alghazeer Hussein, 2012, NATURAL SCI, V4, P324; El-Seedi HR, 2013, J ETHNOPHARMACOL, V145, P746, DOI 10.1016/j.jep.2012.12.007; Essawi T, 2000, J ETHNOPHARMACOL, V70, P343, DOI 10.1016/S0378-8741(99)00187-7; Essawy SS, 2014, SAUDI PHARM J, V22, P472, DOI 10.1016/j.jsps.2013.12.004; Fan FY, 2017, MOLECULES, V22, DOI 10.3390/molecules22030484; Fawole OA, 2010, J ETHNOPHARMACOL, V127, P235, DOI 10.1016/j.jep.2009.11.015; Garcia-Ayllon Maria-Salud, 2011, Front Mol Neurosci, V4, P22, DOI 10.3389/fnmol.2011.00022; Giancarlo S, 2006, NAT PROD RES, V20, P882, DOI 10.1080/14786410500520186; Haddadian K, 2014, INDIAN J TRADIT KNOW, V13, P681; Hajipoor K, 2015, IJBPAS, V4, P4016; Harrison A. P., 2006, American Journal of Pharmacology and Toxicology, V1, P26; Hernandez MF, 2010, FOOD CHEM, V120, P1076, DOI 10.1016/j.foodchem.2009.11.055; Itidel C, 2013, IND CROP PROD, V51, P171, DOI 10.1016/j.indcrop.2013.09.002; Kabbaj FZ, 2012, PHYTOPHARMACOLOGY, V2, P243; Kaur R., 2015, INT J PHARM BIOL SCI, V6, P826; Kawano M, 2007, EXP DERMATOL, V16, P977, DOI 10.1111/j.1600-0625.2007.00618.x; Khadri A, 2010, LWT-FOOD SCI TECHNOL, V43, P331, DOI 10.1016/j.lwt.2009.08.004; Kurilich AC, 1999, J AGR FOOD CHEM, V47, P1948, DOI 10.1021/jf981029d; Le Floc'h E., 1983, CONTRIBUTION ETUDE E; Le Houerou HN, 1969, ANN I NAT RECH AGR T, V42; Lodhi S, 2017, J INTERCULT ETHNOPHA, V6, P429, DOI 10.5455/jice.20170713060840; Loizzo MR, 2010, NUTR RES, V30, P823, DOI 10.1016/j.nutres.2010.09.016; Lola-Luz T, 2014, AGR FOOD SCI, V23, P28, DOI 10.23986/afsci.8832; Madland E., 2013, EXTRACTION ISOLATION; Mamta S, 2017, ASIAN J PHARM CLIN R, V10, P202; Marrif HI, 1995, J ETHNOPHARMACOL, V49, P51, DOI 10.1016/0378-8741(95)01302-4; Mbark AN, 2000, PHARMAZIE, V55, P690; Medoua GN, 2009, FOOD CHEM, V115, P260, DOI 10.1016/j.foodchem.2008.12.007; Mohammed I., 2015, J PHARMACOGN PHYTOCH, V4, P276; Moon JK, 2009, J AGR FOOD CHEM, V57, P1655, DOI 10.1021/jf803537k; Najjaa H, 2017, MED AROMATIC PLANTS, P3; Nargund L. V. G., 1993, Indian Journal of Experimental Biology, V31, P395; Ohtera A, 2013, BIOCHEM BIOPH RES CO, V440, P204, DOI 10.1016/j.bbrc.2013.09.003; Orhan IE, 2010, IND CROP PROD, V32, P566, DOI 10.1016/j.indcrop.2010.07.005; Ouelbani R, 2016, J ETHNOPHARMACOL, V194, P196, DOI 10.1016/j.jep.2016.08.016; Parveen M, 2014, NAT PROD RES, V28, P646, DOI 10.1080/14786419.2014.891201; Perk AA, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0124-6; Pourmorad F, 2006, AFR J BIOTECHNOL, V5, P1142; Renault JH, 1997, PHYTOCHEMISTRY, V44, P1321, DOI 10.1016/S0031-9422(96)00721-2; Rhiouani H, 2008, J ETHNOPHARMACOL, V118, P378, DOI 10.1016/j.jep.2008.05.009; Sakat S.S., 2010, INT J PHARM PHARM SC, V2, P82; Saso L, 2001, ARCH PHARM RES, V24, P150, DOI 10.1007/BF02976483; Schlemper V, 1996, PHYTOMEDICINE, V3, P211, DOI 10.1016/S0944-7113(96)80038-9; Souri E, 2008, DARU, V16, P83; Sung Bokyung, 2016, J Cancer Prev, V21, P216, DOI 10.15430/JCP.2016.21.4.216; Talukder P, 2016, J SCI FOOD AGR, V96, P232, DOI 10.1002/jsfa.7086; Trigui M, 2013, IND CROP PROD, V41, P150, DOI 10.1016/j.indcrop.2012.04.011; Wu T, 2013, FOOD CHEM, V138, P1333, DOI 10.1016/j.foodchem.2012.10.086; Zaabat N, 2011, FOOD CHEM TOXICOL, V49, P3328, DOI 10.1016/j.fct.2011.08.026; Ziyyat A, 1997, J ETHNOPHARMACOL, V58, P45, DOI 10.1016/S0378-8741(97)00077-9	67	14	15	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2019	14	9							e0213049	10.1371/journal.pone.0213049	http://dx.doi.org/10.1371/journal.pone.0213049			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM4PG	31527869	Green Submitted, Green Published, gold			2023-01-03	WOS:000532231400001
J	Saito, M; Tadaka, E; Arimoto, A				Saito, Midori; Tadaka, Etsuko; Arimoto, Azusa			Development of a family caregiver needs-assessment scale for end-of-life care for senility at home (FADE)	PLOS ONE			English	Article								Aim This study aimed to develop a "family caregiver needs-assessment scale for end-of-life care for senility at home" (FADE) and examine its reliability and validity. Method A draft item pool was developed based on a literature review, and simplified to 30 items in four domains. Next, the item pool was reviewed by four visiting nurses and four researchers and refined to 15 items. A cross-sectional study was then conducted using a self-reported questionnaire. Questionnaires were sent to 2703 visiting nurses. The survey questions included participants' basic demographic information, the importance of each item according to a modified scale, basic demographics for cases of death by senility at home, satisfaction with each item of the modified scale in an example case, and assessment of the case using the Japanese version of the Support Team Assessment Schedule (STAS-J). Internal consistency was assessed using Cronbach's alpha. Construct validity was confirmed using confirmatory factor analysis, and correlation between the new scale and the STAS-J was used to assess criterion-related validity. Results In total, 461 visiting nurses provided valid responses. The exploratory and confirmatory factor analyses identified 12 items from two factors: "Needs for adaptation to senility bereavement" and "Needs for essential skills in supporting a dignified death by senility." The final model showed appropriate index values: standardized root mean residual = 0.057, Tucker-Lewis index = 0.920, Akaike information criterion = 191.6, and Bayesian information criterion = 298.2. Cronbach's alpha for the entire scale was 0.908, and was above 0.840 for each factor. The correlation coefficient between STAS-J and the entire scale was 0.259-0.427 (p< 0.001). Conclusions The FADE scale showed acceptable internal consistency and concurrent validity. The scale can help clarify issues and desires that present themselves at home related to adaptation to senility bereavement and essential skills in supporting a dignified death by senility. Addressing these issues and desires is expected to reduce caregivers' anxiety and burden, and means the older adults under their care may be respected and enabled to live with dignity and peace.	[Saito, Midori] Kanagawa Ward Med Assoc, Visiting Nursing Stn, Yokohama, Kanagawa, Japan; [Tadaka, Etsuko; Arimoto, Azusa] Yokohama City Univ, Grad Sch Med, Dept Community Hlth Nursing, Yokohama, Kanagawa, Japan	Yokohama City University	Saito, M (corresponding author), Kanagawa Ward Med Assoc, Visiting Nursing Stn, Yokohama, Kanagawa, Japan.	verde0301@gmail.com		Arimoto, Azusa/0000-0002-8950-674X; Saito, Midori/0000-0002-5067-9010	Yuumi Memorial Foundation for Home Health Care	Yuumi Memorial Foundation for Home Health Care	This work is supported by the The Yuumi Memorial Foundation for Home Health Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert RH, 2017, AM FAM PHYSICIAN, V95, P356; Aoun S, 2015, PALLIATIVE MED, V29, P508, DOI 10.1177/0269216314566061; Aoun SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123012; Ewing G, 2013, PALLIATIVE MED, V27, P244, DOI 10.1177/0269216312440607; Higginson Irene J., 1993, Palliative Medicine, V7, P219, DOI 10.1177/026921639300700309; Hospice foundation, 2007, STAS J SCORING MANUA; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Ito Eriko, 2018, Nihon Ronen Igakkai Zasshi, V55, P81, DOI 10.3143/geriatrics.55.81; Japanese Nursing Association, VIS NURS ACT SURV RE; Karlsson C, 2011, NURS ETHICS, V18, P374, DOI 10.1177/0969733011398100; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; Marwit SJ, 2005, DEATH STUD, V29, P191, DOI 10.1080/07481180590916335; Matsumoto K, 2005, J ACAD HLTH SCI, V8, P154; Ministry of Health, 2016, MED FEE REV 2016; Ministry of Health, 2018, DEM SURV STAT; Ministry of Health, 2012, WHIT PAP ANN HLTH LA; Ministry of Health, 2017, REM STAND VIS NURS; Ministry of Health, 2010, SURV END OF LIF MED; Ministry of Health, 2016, DEM SURV STAT; Ministry of Health, 2015, CONSTR REG COMPR CAR; Miyashita Mitsunori, 2004, Palliat Support Care, V2, P379; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Perry L, 2011, DISABIL REHABIL, V33, P1890, DOI 10.3109/09638288.2011.553702; Petrini M, 2019, ANN I SUPER SANITA, V55, P41, DOI 10.4415/ANN_19_01_08; Riedel M, 2011, HANDBOOK OF SCHIZOPHRENIA SPRECTRUM DISORDERS, VOL III: THERAPEUTIC APPROACHES, COMORBIDITY, AND OUTCOMES, P93, DOI 10.1007/978-94-007-0834-1_5; Shimmura K, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019415; Stahl ST, 2017, CONT CLIN TRIAL COMM, V8, P99, DOI 10.1016/j.conctc.2017.09.002; Swinkels JC, 2019, GERONTOLOGIST, V59, P1103, DOI 10.1093/geront/gny132; United Nations Department of Economic and Social Affairs Population Division, WORLD POP PROSP 2017; Visser G, 2004, PALLIATIVE MED, V18, P468, DOI 10.1191/0269216304pm888oa; Weitzner MA, 1999, QUAL LIFE RES, V8, P55, DOI 10.1023/A:1026407010614; World Health Organization, 2022, ICD 11 MORTALITY MOR; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	33	0	0	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2019	14	9							e0222235	10.1371/journal.pone.0222235	http://dx.doi.org/10.1371/journal.pone.0222235			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM3YZ	31509587	Green Published, Green Submitted, gold			2023-01-03	WOS:000532188200045
J	Ahmed, R; Tariq, M; Hussain, M; Andleeb, A; Masoud, MS; Ali, I; Mraiche, F; Hasan, A				Ahmed, Rashid; Tariq, Muhammad; Hussain, Maria; Andleeb, Anisa; Masoud, Muhammad Shareef; Ali, Imran; Mraiche, Fatima; Hasan, Anwarul			Phenolic contents-based assessment of therapeutic potential of Syzygium cumini leaves extract	PLOS ONE			English	Article							ANTIOXIDANT ACTIVITY; BARK; CONSTITUENTS; PLANTS	Syzygium cumini (S. cumini) is an evergreen tropical plant that is well recognized for its therapeutic potential of common diseases. In this study, the therapeutic potential and biomedical application of S. cumini are assessed in vitro and in vivo to find its effectiveness for different complications. The methanolic crude extract of S. cumini leaves were screened for total phenolic and flavonoid content. In vitro, the DPPH scavenging assay, XTT assay, prothrombin and activated partial thromboplastin time were used to assess antioxidant, cytoprotective and thrombolytic activity of the S. cumini extract, respectively. The anti-inflammatory potential and the analgesic activity of the S. cumini extract were analyzed in rabbits by the Carrageenan induced paw edema method and the writhing method, respectively. Phytochemical analysis showed the presence of considerable amounts of total phenolic (369.75 +/- 17.9 mg GAE/g) and flavonoid (75.8 +/- 5.3 mgRE/g) content in the S. cumini extract. The DPPH assay demonstrated a higher antioxidant potential (IC-50 value of 133 mu g/ml), which was comparable to the IC-50 of ascorbic acid (122.4 mu g/ml). Moreover, the S. cumini extract showed a dose dependent cytoprotective effect against H2O2 treated bone marrow mesenchymal stem cells (BM-MSCs). S. cumini also possesses significant anticoagulant activity with a prothrombin time of 28.3 +/- 1.8 seconds vs 15.8 +/- 0.2 seconds of control, p<0.05. The leaf extract also demonstrated an analgesic effect in rabbits as indicated by the decrease in writhing (12.2 +/- 1.7 control vs. 3.7 +/- 0.6 treated) and anti-inflammatory activity in rabbits paw with a protection against inflammation of 64.1 +/- 2.4%. Our findings suggest that the methanolic extract of S. cumini leaves has antioxidant, cytoprotective, anticoagulant, analgesic and anti-inflammatory properties, and therefore, can be applied for treating cardiovascular diseases and cancers.	[Ahmed, Rashid; Tariq, Muhammad; Hussain, Maria; Andleeb, Anisa; Ali, Imran] Mirpur Univ Sci & Technol, Dept Biotechnol, Mirpur, Ajk, Pakistan; [Ahmed, Rashid; Hasan, Anwarul] Qatar Univ, Coll Engn, Dept Mech & Ind Engn, Doha, Qatar; [Ahmed, Rashid; Hasan, Anwarul] Qatar Univ, Biomed Res Ctr, Doha, Qatar; [Masoud, Muhammad Shareef] Govt Coll Univ, Dept Bioinformat & Biotechnol, Faisalabad, Pakistan; [Mraiche, Fatima] Qatar Univ, Coll Pharm, Doha, Qatar	Qatar University; Qatar University; Government College University Faisalabad; Qatar University	Tariq, M (corresponding author), Mirpur Univ Sci & Technol, Dept Biotechnol, Mirpur, Ajk, Pakistan.; Hasan, A (corresponding author), Qatar Univ, Coll Engn, Dept Mech & Ind Engn, Doha, Qatar.; Hasan, A (corresponding author), Qatar Univ, Biomed Res Ctr, Doha, Qatar.	tariq.awan@must.edu.pk; hassan.anwarul.mit@gmail.com	Tariq, Muhammad/ABC-2204-2020; Hasan, Anwarul/AAX-7440-2020; Masoud, Muhammad Shareef/F-7156-2010	Tariq, Muhammad/0000-0002-8239-9339; Hasan, Anwarul/0000-0001-8380-2233; Masoud, Muhammad Shareef/0000-0003-2395-7721; Ahmed, Rashid/0000-0002-6512-769X	Qatar National Research Foundation [NPRP10-0120-170211]; Qatar National Research Fund (Qatar Foundation) [NPRP10-0120-170211]; Qatar National Library	Qatar National Research Foundation(National Research Foundation of Korea); Qatar National Research Fund (Qatar Foundation)(Qatar Foundation (QF)Qatar National Research Fund (QNRF)); Qatar National Library(Qatar National Research Fund (QNRF))	Funded by Dr. Anwarul Hasan Grant Number: NPRP10-0120-170211. Qatar National Research Foundation. http://www.qnrf.org/en-us/Funding/Research-Programs/National-Priorities-Research-Program-NPRP.; This article was made possible by the NPRP10-0120-170211 grant funded by Qatar National Research Fund (a part of Qatar Foundation). The statements made here are solely responsibility of authors. The authors also thankfully acknowledge the Qatar National Library for providing the funding for the publication of this study, and Mirpur University of Science and Technology (MUST), Mirpur, AJK, Pakistan for providing their facilities needed for completion of the current study.	Aasim M, 2018, GLOBAL PERSPECTIVES, P165; Acosta-Estrada BA, 2014, FOOD CHEM, V152, P46, DOI 10.1016/j.foodchem.2013.11.093; Ahmed R, 2019, POLY LACTIC CO GLYCO, P2019; Ahmed R, 2018, INT J BIOL MACROMOL, V120, P385, DOI 10.1016/j.ijbiomac.2018.08.057; Ramirez-Cisneros MA, 2012, MOLECULES, V17, P861, DOI 10.3390/molecules17010861; Anhe GF, 2012, EUR J PHARMACOL, V689, P285, DOI 10.1016/j.ejphar.2012.06.007; Aqil F, 2012, NUTR CANCER, V64, P428, DOI 10.1080/01635581.2012.657766; Ayyanar Muniappan, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P240, DOI 10.1016/S2221-1691(12)60050-1; Baliga MS, 2011, FOOD RES INT, V44, P1776, DOI 10.1016/j.foodres.2011.02.007; BHATIA IS, 1975, PLANTA MED, V28, P346, DOI 10.1055/s-0028-1097868; Cai YZ, 2003, J AGR FOOD CHEM, V51, P2288, DOI 10.1021/jf030045u; Chagas VT, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00259; Djipa CD, 2000, J ETHNOPHARMACOL, V71, P307, DOI 10.1016/S0378-8741(99)00186-5; Hossain MS, 2018, J BASIC CLIN PHYSL P; Kaneria M, 2009, INDIAN J PHARM SCI, V71, P406, DOI 10.4103/0250-474X.57289; Mao WJ, 2009, INT J BIOL MACROMOL, V44, P70, DOI 10.1016/j.ijbiomac.2008.10.003; Masood N, 2019, INT J PHARMACEUT, V559, P23, DOI 10.1016/j.ijpharm.2019.01.019; Modi D. C., 2010, Journal of Pharmaceutical Education and Research, V1, P68; Mollika S., 2014, GLOBAL J PHARM, V8, P39, DOI DOI 10.5829/ID0SI.GJP.2014.8; Muruganandan S, 2001, FITOTERAPIA, V72, P369, DOI 10.1016/S0367-326X(00)00325-7; Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v; Parmar J, 2010, ASIAN PAC J CANCER P, V11, P261; Patel P. R., 2012, INT J CURR PHARM RES, V4, P36; Pugazhenthi G, 2008, INT J FOOD ENG, V4, DOI 10.2202/1556-3758.1385; Quettier-Deleu C, 2000, J ETHNOPHARMACOL, V72, P35, DOI 10.1016/S0378-8741(00)00196-3; Quintans JSS, 2014, PHARM BIOL, V52, P762, DOI 10.3109/13880209.2013.870582; Rastogi RP, 1990, DRUG RES PERSPECTIVE, V1, P10; Ruan ZP, 2008, MOLECULES, V13, P2545, DOI 10.3390/molecules13102545; Schmid-Schonbein GW, 2006, ANNU REV BIOMED ENG, V8, P93, DOI 10.1146/annurev.bioeng.8.061505.095708; Schulz M, 2016, FOOD RES INT, V89, P14, DOI 10.1016/j.foodres.2016.07.027; Shah M, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-2042-3; Sharma R, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-292; Singleton VL, 1999, METHOD ENZYMOL, V299, P152; Srivastava S, 2013, J SCI FOOD AGR, V93, P2084, DOI 10.1002/jsfa.6111; Swami SB, 2012, FOOD NUTR SCI, V3, P1100, DOI DOI 10.4236/FNS.2012.38146; Tariq M, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-115; Ugbabe GE, 2010, AFR J BIOTECHNOL, V9, P6943; Xie PY, 2017, FOOD FUNCT, V8, P2000, DOI 10.1039/c6fo01717g; Xie W, 2011, DIABETES OBES METAB, V13, P289, DOI 10.1111/j.1463-1326.2010.01336.x; You YL, 2007, MOLECULES, V12, P842, DOI 10.3390/12040842	40	10	10	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2019	14	8							e0221318	10.1371/journal.pone.0221318	http://dx.doi.org/10.1371/journal.pone.0221318			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW6AB	31465475	gold, Green Published, Green Submitted			2023-01-03	WOS:000485058200014
J	Eaton, M; Davies, AH; Devine, J; Zhao, X; Simmons, DG; Mariusdottir, E; Natale, DRC; Matyas, JR; Bering, EA; Workentine, ML; Hallgrimsson, B; Cross, JC				Eaton, Malcolm; Davies, Alastair H.; Devine, Jay; Zhao, Xiang; Simmons, David G.; Mariusdottir, Elin; Natale, David R. C.; Matyas, John R.; Bering, Elizabeth A.; Workentine, Matthew L.; Hallgrimsson, Benedikt; Cross, James C.			Complex patterns of cell growth in the placenta in normal pregnancy and as adaptations to maternal diet restriction	PLOS ONE			English	Article							FETAL-GROWTH; RESOURCE-ALLOCATION; TROPHOBLAST CELLS; GLYCOGEN CELLS; PROTEIN; MORPHOLOGY; PHENOTYPE; TRANSPORT; DIFFERENTIATION; EXPRESSION	The major milestones in mouse placental development are well described, but our understanding is limited to how the placenta can adapt to damage or changes in the environment. By using stereology and expression of cell cycle markers, we found that the placenta grows under normal conditions not just by hyperplasia of trophoblast cells but also through extensive polyploidy and cell hypertrophy. In response to feeding a low protein diet to mothers prior to and during pregnancy, to mimic chronic malnutrition, we found that this normal program was altered and that it was influenced by the sex of the conceptus. Male fetuses showed intrauterine growth restriction (IUGR) by embryonic day (E) 18.5, just before term, whereas female fetuses showed IUGR as early as E16.5. This difference was correlated with differences in the size of the labyrinth layer of the placenta, the site of nutrient and gas exchange. Functional changes were implied based on up-regulation of nutrient transporter genes. The junctional zone was also affected, with a reduction in both glycogen trophoblast and spongiotrophoblast cells. These changes were associated with increased expression of Phlda2 and reduced expression of Egfr. Polyploidy, which results from endoreduplication, is a normal feature of trophoblast giant cells (TGC) but also spongiotrophoblast cells. Ploidy was increased in sinusoidal-TGCs and spongiotrophoblast cells, but not parietal-TGCs, in low protein placentas. These results indicate that the placenta undergoes a range of changes in development and function in response to poor maternal diet, many of which we interpret are aimed at mitigating the impacts on fetal and maternal health.	[Eaton, Malcolm; Zhao, Xiang; Bering, Elizabeth A.; Cross, James C.] Univ Calgary, Cumming Sch Med, Dept Biochem & Mol Biol, Calgary, AB, Canada; [Davies, Alastair H.; Zhao, Xiang; Simmons, David G.; Mariusdottir, Elin; Natale, David R. C.; Matyas, John R.; Cross, James C.] Univ Calgary, Dept Comparat Biol & Expt Med, Fac Vet Med, Calgary, AB, Canada; [Devine, Jay; Hallgrimsson, Benedikt] Univ Calgary, Dept Anat & Cell Biol, Cumming Sch Med, Calgary, AB, Canada; [Workentine, Matthew L.] Univ Calgary, Fac Vet Med, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary	Cross, JC (corresponding author), Univ Calgary, Cumming Sch Med, Dept Biochem & Mol Biol, Calgary, AB, Canada.; Cross, JC (corresponding author), Univ Calgary, Dept Comparat Biol & Expt Med, Fac Vet Med, Calgary, AB, Canada.	jcross@ucalgary.ca	Simmons, David G/C-5983-2009; Cross, James/F-4814-2011	Simmons, David G/0000-0002-4115-9371; Cross, James/0000-0003-0956-9378	Canadian Institutes for Health Research [MOP-136900]; Alberta Innovates Health Solutions	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Alberta Innovates Health Solutions	The work was funded by grants from the Canadian Institutes for Health Research (to JCC, grant MOP-136900) and Alberta Innovates Health Solutions (to JCC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamson SL, 2002, DEV BIOL, V250, P358, DOI 10.1006/dbio.2002.0773; Barbeito-Andres J, 2019, J EXP BIOL, V222, DOI 10.1242/jeb.204651; Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235; Bouillot S, 2006, PLACENTA, V27, P882, DOI 10.1016/j.placenta.2005.09.009; Chen PY, 2013, PHYSIOL GENOMICS, V45, P565, DOI 10.1152/physiolgenomics.00034.2013; Coan PM, 2008, J PHYSIOL-LONDON, V586, P4567, DOI 10.1113/jphysiol.2008.156133; Coan PM, 2011, J PHYSIOL-LONDON, V589, P3659, DOI 10.1113/jphysiol.2011.208629; Coan PM, 2010, J PHYSIOL-LONDON, V588, P527, DOI 10.1113/jphysiol.2009.181214; Coan PM, 2006, DEV DYNAM, V235, P3280, DOI 10.1002/dvdy.20981; Coan PM, 2004, BIOL REPROD, V70, P1806, DOI 10.1095/biolreprod.103.024166; Coan PM, 2005, J ANAT, V207, P783, DOI 10.1111/j.1469-7580.2005.00488.x; Constancia M, 2002, NAT LETT, V417; Cross JC, 2016, REPROD FERT DEVELOP, V28, P75, DOI 10.1071/RD15342; Cross JC, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004330; Cuffe JSM, 2014, J PHYSIOL-LONDON, V592, P3127, DOI 10.1113/jphysiol.2014.272856; Dackor J, 2007, PLACENTA, V28, P1211, DOI 10.1016/j.placenta.2007.07.005; Endl E, 2000, EXP CELL RES, V257, P231, DOI 10.1006/excr.2000.4888; Eriksson JG, 2010, AM J HUM BIOL, V22, P330, DOI 10.1002/ajhb.20995; Fernandez-Twinn DS, 2003, BRIT J NUTR, V90, P815, DOI 10.1079/BJN2003967; Fowden AL, 2012, PLACENTA, V33, pE11, DOI 10.1016/j.placenta.2012.05.002; Fowden AL, 2009, J PHYSIOL-LONDON, V587, P3459, DOI 10.1113/jphysiol.2009.173013; Fox DT, 2013, DEVELOPMENT, V140, P3, DOI 10.1242/dev.080531; Gabory A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047986; Gaccioli F, 2013, J DEV ORIG HLTH DIS, V4, P101, DOI 10.1017/S2040174412000529; Gallou-Kabani C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014398; Gao Haijun, 2012, Front Biosci (Elite Ed), V4, P1434; Gasperowicz M, 2013, DEV BIOL, V382, P1, DOI 10.1016/j.ydbio.2013.08.005; Gonzalez PN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152227; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hannibal RL, 2016, CURR BIOL, V26, P230, DOI 10.1016/j.cub.2015.11.060; Hannibal RL, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004290; Hayakawa K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23832-2; Hendzel MJ, 1997, CHROMOSOMA, V106; Higgins JS, 2016, J PHYSIOL-LONDON, V594, P1341, DOI 10.1113/JP271057; Ishikawa H, 2003, BIOL REPROD, V69, P483, DOI 10.1095/biolreprod.102.012641; JOHANSSON S, 1993, ANAT EMBRYOL, V187, P409; Jones HN, 2007, PLACENTA, V28, P763, DOI 10.1016/j.placenta.2007.05.002; Langley-Evans SC, 1997, FETAL EXPOSURE LOW P, V127; MacAuley A, 1998, MOL BIOL CELL, V9, P795, DOI 10.1091/mbc.9.4.795; Mao J, 2010, P NATL ACAD SCI USA, V107, P5557, DOI 10.1073/pnas.1000440107; Mayhew TM, 2009, J ANAT, V215, P77, DOI 10.1111/j.1469-7580.2008.00994.x; Mayhew TM, 2001, PLACENTA, V22, P628, DOI 10.1053/plac.2001.0700; Morrison JL, 2008, CLIN EXP PHARMACOL P, V35, P730, DOI 10.1111/j.1440-1681.2008.04975.x; Outhwaite JE, 2015, PLACENTA, V36, P951, DOI 10.1016/j.placenta.2015.05.013; Pimentel H, 2017, NAT METHODS, V14, P687, DOI 10.1038/nmeth.4324; Prada JA, 1998, EUR J CLIN NUTR, V52, pS21; Rai A, 2015, DEV BIOL, V398, P110, DOI 10.1016/j.ydbio.2014.11.023; Rawn SM, 2008, ANNU REV CELL DEV BI, V24, P159, DOI 10.1146/annurev.cellbio.24.110707.175418; Rebelato HJ, 2013, J MOL HISTOL, V44, P629, DOI 10.1007/s10735-013-9522-7; Romo Agustin, 2009, Pediatr Endocrinol Rev, V6 Suppl 3, P332; Rosenfeld CS, 2015, ENDOCRINOLOGY, V156, P3422, DOI 10.1210/en.2015-1227; Sawa H, 1997, J HISTOCHEMISTRY CYT, V45; Schulz LC, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.103218; Sferruzzi-Perri AN, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00033; Sferruzzi-Perri AN, 2018, PLACENTA, V64, pS16, DOI 10.1016/j.placenta.2018.01.005; Sferruzzi-Perri AN, 2011, ENDOCRINOLOGY, V152; Sibley CP, 2004, P NATL ACAD SCI USA, V101, P8204, DOI 10.1073/pnas.0402508101; Simmons DG, 2007, DEV BIOL, V304, P567, DOI 10.1016/j.ydbio.2007.01.009; Simmons DG, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-352; Soares MJ, 2007, TRENDS ENDOCRIN MET, V18, P114, DOI 10.1016/j.tem.2007.02.005; Strakovsky RS, 2010, J NUTR, V140, P2116, DOI 10.3945/jn.110.127803; Tunster SJ, 2010, MOL CELL BIOL, V30, P295, DOI 10.1128/MCB.00662-09; Waddell BJ, 2000, BIOL REPROD, V63, P1913, DOI 10.1095/biolreprod63.6.1913; Warde-Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537; Watson ED, 2005, PHYSIOLOGY, V20, P180, DOI 10.1152/physiol.00001.2005; Watson ED, 2007, DEVELOPMENT, V134, P1809, DOI 10.1242/dev.02843; Yi L, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1419-z; Yu GC, 2016, MOL BIOSYST, V12, P477, DOI 10.1039/c5mb00663e; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zambrano E, 2006, J PHYSIOL-LONDON, V571, P221, DOI 10.1113/jphysiol.2005.100313; Zybina E V, 1975, CELL TISS RES, V60; Zybina EV, 2008, MICRON, V39, P593, DOI 10.1016/j.micron.2007.05.006	72	17	17	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2020	15	1							e0226735	10.1371/journal.pone.0226735	http://dx.doi.org/10.1371/journal.pone.0226735			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5ER	31917811	Green Published, gold			2023-01-03	WOS:000534341100009
J	Truse, R; Smyk, M; Schulz, J; Herminghaus, A; Weber, APM; Mettler-Altmann, T; Bauer, I; Picker, O; Vollmer, C				Truse, Richard; Smyk, Michael; Schulz, Jan; Herminghaus, Anna; Weber, Andreas P. M.; Mettler-Altmann, Tabea; Bauer, Inge; Picker, Olaf; Vollmer, Christian			Regional hypothermia improves gastric microcirculatory oxygenation during hemorrhage in dogs	PLOS ONE			English	Article							THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; TRAUMA PATIENTS; CARDIAC-ARREST; BLOOD-LOSS; ANESTHESIA; SHOCK; MECHANISMS; PREDICTOR	Mild systemic hypothermia increases gastric mucosal oxygenation (mu HbO(2)) during hemorrhagic shock in dogs. In the context of critical blood loss hypothermia might be fatal due to adverse side effects. Selective regional hypothermia might overcome these limitations. The aim of our study was to analyze the effects of regional gastric and oral mucosal hypothermia on mu HbO(2) and perfusion (mu flow). In a cross-over study six anesthetized dogs were subjected to local oral and gastric mucosal hypothermia (34 degrees C), or maintenance of local normothermia during normovolemia and hemorrhage (-20% blood volume). Macro- and microcirculatory variables were recorded continuously. During normovolemia, local hypothermia increased gastric microcirculatory flow (mu flow) without affecting oxygenation (mu HbO(2)) or oral microcirculation. During mild hemorrhagic shock gastric mu HbO(2) decreased from 72 +/- 2% to 38 +/- 3% in the normothermic group. This was attenuated by local hypothermia, where mu HbO(2) was reduced from 74 +/- 3% to 52 +/- 4%. Local perfusion, oral microcirculation and macrocirculatory variables were not affected. Selective local hypothermia improves gastric mu HbO(2) during hemorrhagic shock without relevant side effects. In contrast to systemic hypothermia, regional mucosal hypothermia did not affect perfusion and oxygen supply during hemorrhage. Thus, the increased mu HbO(2) during local hypothermia rather indicates reduced mucosal oxygen demand.	[Truse, Richard; Smyk, Michael; Schulz, Jan; Herminghaus, Anna; Bauer, Inge; Picker, Olaf; Vollmer, Christian] Duesseldorf Univ Hosp, Dept Anesthesiol, Dusseldorf, Germany; [Weber, Andreas P. M.; Mettler-Altmann, Tabea] Heinrich Heine Univ Duesseldorf, Inst Plant Biochem, Cluster Excellence Plant Sci CEPLAS, Dusseldorf, Germany; [Smyk, Michael] Duesseldorf Univ Hosp, Inst Diagnost & Intervent Radiol, Dusseldorf, Germany	Heinrich Heine University Dusseldorf; University of Cologne	Truse, R (corresponding author), Duesseldorf Univ Hosp, Dept Anesthesiol, Dusseldorf, Germany.	Richard.Truse@med.uni-duesseldorf.de		Truse, Richard/0000-0001-6650-5800	Heinrich-HeineUniversity [1229]	Heinrich-HeineUniversity	This work was supported by a grant of the Strategic Research Fund, Heinrich-HeineUniversity (No. 1229) to CV. We acknowledge support by the Heinrich-Heine-University Duesseldorf to cover the publication fee. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aykut G, 2015, INTENSIVE CARE MED E, V3; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bezemer R, 2012, CRIT CARE, V16, DOI 10.1186/cc11236; Brattstrom O, 2010, ACTA ANAESTH SCAND, V54, P1007, DOI 10.1111/j.1399-6576.2010.02266.x; Bro-Jeppesen J, 2014, RESUSCITATION, V85, P664, DOI 10.1016/j.resuscitation.2013.12.031; Carsetti A, 2015, INTENSIVE CARE MED E, V3; Clark DL, 2007, J CEREBR BLOOD F MET, V27, P115, DOI 10.1038/sj.jcbfm.9600327; De Backer D, 2007, CRIT CARE, V11, DOI 10.1186/cc6118; Deitch EA, 2006, FRONT BIOSCI-LANDMRK, V11, P520, DOI 10.2741/1816; Donnino MW, 2016, RESUSCITATION, V98, P97, DOI 10.1016/j.resuscitation.2015.09.396; Dyson DH, 2012, CAN VET J, V53, P63; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; FERRARA A, 1990, AM J SURG, V160, P515, DOI 10.1016/S0002-9610(05)81018-9; Fiehn Oliver, 2007, V358, P3, DOI 10.1007/978-1-59745-244-1_1; GUTIERREZ G, 1986, J APPL PHYSIOL, V60, P751, DOI 10.1152/jappl.1986.60.3.751; Haagsma JA, 2016, INJURY PREV, V22, P3, DOI 10.1136/injuryprev-2015-041616; Han YS, 2010, AM J PHYSIOL-HEART C, V298, pH890, DOI 10.1152/ajpheart.00805.2009; Holzer M, 2002, NEW ENGL J MED, V346, P549; Johansson T, 1999, ACTA ANAESTH SCAND, V43, P1005, DOI 10.1034/j.1399-6576.1999.431006.x; JURKOVICH GJ, 1987, J TRAUMA, V27, P1019, DOI 10.1097/00005373-198709000-00011; Kalia N, 2002, ANN SURG, V236, P67, DOI 10.1097/00000658-200207000-00011; Karnatovskaia LV, 2014, NEUROHOSPITALIST, V4, P153, DOI 10.1177/1941874413519802; Kim Jong-Heon, 2014, Exp Neurobiol, V23, P115, DOI 10.5607/en.2014.23.2.115; Koreny M, 2009, RESUSCITATION, V80, P56, DOI 10.1016/j.resuscitation.2008.08.019; Kortbeek JB, 2008, J TRAUMA, V64, P1638, DOI 10.1097/TA.0b013e3181744b03; Krug A, 2006, PHLEBOLOGIE, V35, P300; Lansink KWW, 2013, EUR J TRAUMA EMERG S, V39, P375, DOI 10.1007/s00068-013-0278-2; Leone BJ, 1998, J CARDIOTHOR VASC AN, V12, P393, DOI 10.1016/S1053-0770(98)90190-2; Ly HQ, 2005, AM HEART J, V150, DOI 10.1016/j.ahj.200502.049; MEDDINGS JB, 1993, GASTROENTEROLOGY, V104, P1619, DOI 10.1016/0016-5085(93)90637-R; Mustafa S, 2002, STROKE, V33, P256, DOI 10.1161/hs0102.101545; Patel JJ, 2016, CURR OPIN CRIT CARE, V22, P339, DOI 10.1097/MCC.0000000000000331; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Rajagopalan S, 2008, ANESTHESIOLOGY, V108, P71, DOI 10.1097/01.anes.0000296719.73450.52; SATO N, 1986, DIGEST DIS SCI, V31, pS35, DOI 10.1007/BF01309321; Schorghuber M, 2018, LANCET GASTROENTEROL, V3, P281, DOI 10.1016/S2468-1253(18)30036-0; SCHUMACKER PT, 1987, J APPL PHYSIOL, V63, P1246, DOI 10.1152/jappl.1987.63.3.1246; Schwartges I, 2010, SHOCK, V34, P636, DOI 10.1097/SHK.0b013e3181e68422; Schwartz DS, 2001, ANN THORAC SURG, V72, P804, DOI 10.1016/S0003-4975(01)02822-3; SHERIDAN WG, 1987, DIS COLON RECTUM, V30, P867, DOI 10.1007/BF02555426; STEEN PA, 1983, ANESTHESIOLOGY, V58, P527, DOI 10.1097/00000542-198306000-00009; SUTHERLAND LR, 1994, LANCET, V343, P998, DOI 10.1016/S0140-6736(94)90125-2; Truse R, 2017, J VASC RES, V54, P109, DOI 10.1159/000464262; Umehara S, 2006, ANESTH ANALG, V102, P38, DOI 10.1213/01.ane.0000183651.10514.9a; VandenBrande P, 1997, INT J MICROCIRC, V17, P55, DOI 10.1159/000179207; Venjakob AJ, 2013, J ORTHOP RES, V31, P1820, DOI 10.1002/jor.22417; Vollmer C, 2014, BRIT J ANAESTH, V113, P433, DOI 10.1093/bja/aet462; Vollmer C, 2016, AUTON NEUROSCI-BASIC, V195, P1, DOI 10.1016/j.autneu.2016.01.004; Vollmer C, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/589606; WANGENSTEEN SL, 1965, AM J MED, V38, P31, DOI 10.1016/0002-9343(65)90157-9; Xiong W, 2016, J SURG RES, V200, P250, DOI 10.1016/j.jss.2015.06.068	52	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2019	14	12							e0226146	10.1371/journal.pone.0226146	http://dx.doi.org/10.1371/journal.pone.0226146			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP0TY	31821374	Green Published, gold			2023-01-03	WOS:000534035700039
J	Dubo, S; Valenzuela, ED; Aquevedo, A; Jibaja, M; Berrutti, D; Labra, C; Lagos, R; Garcia, MF; Ramirez, V; Tobar, M; Picoita, F; Pelaez, C; Carpio, D; Alegria, L; Hidalgos, C; Godoy, K; Bruhn, A; Hernandez, G; Bakker, J; Castro, R				Dubo, Sebastian; Daniel Valenzuela, Emilio; Aquevedo, Andres; Jibaja, Manuel; Berrutti, Dolores; Labra, Christian; Lagos, Rossana; Fernanda Garcia, Maria; Ramirez, Vanessa; Tobar, Milton; Picoita, Fabricio; Pelaez, Cristian; Carpio, David; Alegria, Leyla; Hidalgos, Carolina; Godoy, Karen; Bruhn, Alejandro; Hernandez, Glenn; Bakker, Jan; Castro, Ricardo			Early rise in central venous pressure during a spontaneous breathing trial: A promising test to identify patients at high risk of weaning failure?	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; MECHANICAL VENTILATION; CRITICALLY-ILL; REINTUBATION; DYSFUNCTION	Background The spontaneous breathing trial (SBT) assesses the risk of weaning failure by evaluating some physiological responses to the massive venous return increase imposed by discontinuing positive pressure ventilation. This trial can be very demanding for some critically ill patients, inducing excessive physical and cardiovascular stress, including muscle fatigue, heart ischemia and eventually cardiac dysfunction. Extubation failure with emergency reintubation is a serious adverse consequence of a failed weaning process. Some data suggest that as many as 50% of patients that fail weaning do so because of cardiac dysfunction. Unfortunately, monitoring cardiovascular function at the time of the SBT is complex. The aim of our study was to explore if central venous pressure (CVP) changes were related to weaning failure after starting an SBT. We hypothesized that an early rise on CVP could signal a cardiac failure when handling a massive increase on venous return following a discontinuation of positive pressure ventilation. This CVP rise could identify a subset of patients at high risk for extubation failure. Methods Two-hundred and four mechanically ventilated patients in whom an SBT was decided were subjected to a monitoring protocol that included blinded assessment of CVP at baseline, and at 2 minutes after starting the trial (CVP-test). Weaning failure was defined as reintubation within 48-hours following extubation. Comparisons between two parametric or non-parametric variables were performed with student T test or Mann Whitney U test, respectively. A logistic multivariate regression was performed to determine the predictive value on extubation failure of usual clinical variables and CVP at 2-min after starting the SBT. Results One-hundred and sixty-five patients were extubated after the SBT, 11 of whom were reintubated within 48h. Absolute CVP values at 2-minutes, and the change from baseline (dCVP) were significantly higher in patients with extubation failure as compared to those successfully weaned. dCVP was an early predictor for reintubation (OR: 1.70 [1.31,2.19], p<0.001). Conclusions An early rise in CVP after starting an SBT was associated with an increased risk of extubation failure. This might represent a warning signal not captured by usual SBT monitoring and could have relevant clinical implications.	[Dubo, Sebastian] Univ Concepcion, Fac Med, Dept Kinesiol, Concepcion, Chile; [Dubo, Sebastian] Univ La Frontera, Programa Doctorado Ciencias Med, Temuco, Chile; [Daniel Valenzuela, Emilio; Labra, Christian; Lagos, Rossana; Carpio, David; Alegria, Leyla; Bruhn, Alejandro; Hernandez, Glenn; Bakker, Jan; Castro, Ricardo] Pontificia Univ Catolica Chile, Fac Med, Dept Med Intens, Santiago, Chile; [Aquevedo, Andres] Hosp Dr Sotero del Rio, Unidad Pacientes Crit, Santiago, Chile; [Jibaja, Manuel; Fernanda Garcia, Maria; Ramirez, Vanessa; Tobar, Milton; Picoita, Fabricio; Pelaez, Cristian] Hosp Eugenio Espejo, Unidad Cuidados Intens, Quito, Ecuador; [Jibaja, Manuel] Univ Int Ecuador, Escuela Med, Quito, Ecuador; [Berrutti, Dolores] Univ Republ Uruguay, Hosp Clin, Ctr Terapia Intens, Montevideo, Uruguay; [Carpio, David] Pontificia Univ Catolica Chile, Programa Doctorado Ciencias Med, Santiago, Chile; [Hidalgos, Carolina] Hosp Guillermo Grant Benavente, Unidad Cuidados Intens Cardioquirurg, Concepcion, Chile; [Godoy, Karen] Hosp Guillermo Grant Benavente, Unidad Cuidados Intens Neuroquirurg, Concepcion, Chile; [Bakker, Jan] Columbia Univ Coll Phys & Surg, Dept Pulm & Crit Care, 630 W 168th St, New York, NY 10032 USA; [Bakker, Jan] Erasmus MC Univ Med Ctr, Dept Intens Care Adults, Rotterdam, Netherlands; [Bakker, Jan] NYU, Med Ctr, Dept Pulm & Crit Care, New York, NY 10016 USA	Universidad de Concepcion; Universidad de La Frontera; Pontificia Universidad Catolica de Chile; Universidad de Chile; Universidad de la Republica, Uruguay; Pontificia Universidad Catolica de Chile; Columbia University; Erasmus University Rotterdam; Erasmus MC; New York University	Castro, R (corresponding author), Pontificia Univ Catolica Chile, Fac Med, Dept Med Intens, Santiago, Chile.	rcastro.med@gmail.com	alegria, leyla/HDM-9456-2022; Bakker, Jan/A-4011-2009	alegria, leyla/0000-0002-0930-4452; Bakker, Jan/0000-0003-2236-7391; Garcia Aguilera, Maria Fernanda/0000-0002-5375-3474; Dubo, Sebastian/0000-0002-3206-0433; Bruhn, Alejandro/0000-0001-8034-1937; Valenzuela Espinoza, Emilio Daniel/0000-0001-9758-3473	 [CONICYT-PFCHA/Doctorado Nacional/2018-21181376]		SD doctoral studies are supported by a grant from CONICYT-PFCHA/Doctorado Nacional/2018-21181376.	Amoroso P, 1989, LANCET, V334, P555, DOI [10.1016/S0140-6736(89)90670-3, DOI 10.1016/S0140-6736(89)90670-3]; Berlin DA, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0776-1; Boles JM, 2007, EUR RESPIR J, V29, P1033, DOI 10.1183/09031936.00010206; Cabello B, 2010, INTENS CARE MED, V36, P1171, DOI 10.1007/s00134-010-1870-0; Dasta JF, 2005, CRIT CARE MED, V33, P1266, DOI 10.1097/01.CCM.0000164543.14619.00; Dres M, 2015, INTENS CARE MED, V41, P487, DOI 10.1007/s00134-015-3653-0; Epstein SK, 1998, AM J RESP CRIT CARE, V158, P489, DOI 10.1164/ajrccm.158.2.9711045; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Fagon JY, 1996, J AM MED ASS; Frutos-Vivar F, 2011, J CRIT CARE, V26, P502, DOI 10.1016/j.jcrc.2010.12.015; Jaber S, 2018, CRIT CARE CRITICAL C, V22, P1; Jozwiak M, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.05.03; LEMAIRE F, 1988, ANESTHESIOLOGY, V69, P171, DOI 10.1097/00000542-198808000-00004; Liu JL, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1533-9; Magder S, 2018, J INTENSIVE CARE MED, V33, P430, DOI 10.1177/0885066616678578; Magder S, 2017, CHEST, V151, P908, DOI 10.1016/j.chest.2016.10.026; Fernandez MM, 2017, INTENS CARE MED, V43, P1660, DOI 10.1007/s00134-017-4911-0; McConville JF, 2012, NEW ENGL J MED, V367, P2233, DOI 10.1056/NEJMra1203367; Mehta S, 2000, CRIT CARE MED, V28, P1341, DOI 10.1097/00003246-200005000-00014; Monnet X, 2016, INTENS CARE MED, V42, P1935, DOI 10.1007/s00134-015-4134-1; Ouellette DR, 2017, CHEST, V151, P166, DOI 10.1016/j.chest.2016.10.036; Perren A, 2013, INTENS CARE MED, V39, P1885, DOI 10.1007/s00134-013-3014-9; Pinsky MR, 2000, INTENS CARE MED, V26, P1164, DOI 10.1007/s001340000619; Routsi C, 2010, CRIT CARE, V14, DOI 10.1186/cc9326; Selvan K, 2017, J INTENSIVE CARE MED, V32, P146, DOI 10.1177/0885066615612413; Sklar MC, 2017, AM J RESP CRIT CARE, V195, P1477, DOI 10.1164/rccm.201607-1338OC; Teboul JL, 2014, INTENS CARE MED, V40, P1069, DOI 10.1007/s00134-014-3334-4; Teboul JL, 2010, CRIT CARE, V14, DOI 10.1186/cc8852; Thille AW, 2013, AM J RESP CRIT CARE, V187, P1294, DOI 10.1164/rccm.201208-1523CI; Thille AW, 2013, CURR OPIN CRIT CARE, V19, P57, DOI 10.1097/MCC.0b013e32835c5095; Verscheure S, 2017, J CRIT CARE, V37, P65, DOI 10.1016/j.jcrc.2016.08.024; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]; WEIL MH, 1979, ANESTH ANALG, V58, P124	33	3	5	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2019	14	12							e0225181	10.1371/journal.pone.0225181	http://dx.doi.org/10.1371/journal.pone.0225181			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP0JY	31805071	Green Published			2023-01-03	WOS:000534009700018
J	Degenhardt, L; Grebely, J; Stone, J; Hickman, M; Vickerman, P; Marshall, BDL; Bruneau, J; Altice, FL; Henderson, G; Rahimi-Movaghar, A; Larney, S				Degenhardt, Louisa; Grebely, Jason; Stone, Jack; Hickman, Matthew; Vickerman, Peter; Marshall, Brandon D. L.; Bruneau, Julie; Altice, Frederick L.; Henderson, Graeme; Rahimi-Movaghar, Afarin; Larney, Sarah			Global patterns of opioid use and dependence: harms to populations, interventions, and future action	LANCET			English	Article							INJECTING DRUG-USERS; HEPATITIS-C VIRUS; SUBSTITUTION THERAPY; USE DISORDER; CHRONIC PAIN; HEROIN USE; METHADONE-MAINTENANCE; PSYCHOSOCIAL INTERVENTIONS; PRESCRIPTION OPIOIDS; HIV TRANSMISSION	We summarise the evidence for medicinal uses of opioids, harms related to the extramedical use of, and dependence on, these drugs, and a wide range of interventions used to address these harms. The Global Burden of Diseases, Injuries, and Risk Factors Study estimated that in 2017, 40.5 million people were dependent on opioids (95% uncertainty interval 34.3-47.9 million) and 109 500 people (105 800-113 600) died from opioid overdose. Opioid agonist treatment (OAT) can be highly effective in reducing illicit opioid use and improving multiple health and social outcomes-eg, by reducing overall mortality and key causes of death, including overdose, suicide, HIV, hepatitis C virus, and other injuries. Mathematical modelling suggests that scaling up the use of OAT and retaining people in treatment, including in prison, could avert a median of 7.7% of deaths in Kentucky, 10.7% in Kiev, and 25.9% in Tehran over 20 years (compared with no OAT), with the greater effects in Tehran and Kiev being due to reductions in HIV mortality, given the higher prevalence of HIV among people who inject drugs in those settings. Other interventions have varied evidence for effectiveness and patient acceptability, and typically affect a narrower set of outcomes than OAT does. Other effective interventions focus on preventing harm related to opioids. Despite strong evidence for the effectiveness of a range of interventions to improve the health and wellbeing of people who are dependent on opioids, coverage is low, even in high-income countries. Treatment quality might be less than desirable, and considerable harm might be caused to individuals, society, and the economy by the criminalisation of extramedical opioid use and dependence. Alternative policy frameworks are recommended that adopt an approach based on human rights and public health, do not make drug use a criminal behaviour, and seek to reduce drug-related harm at the population level.	[Degenhardt, Louisa; Larney, Sarah] Univ New South Wales Sydney, Natl Drug & Akohol Res Ctr, Sydney, NSW 2052, Australia; [Grebely, Jason] Univ New South Wales Sydney, Kirby Inst, Sydney, NSW, Australia; [Stone, Jack; Hickman, Matthew; Vickerman, Peter] Univ Bristol, Populat Hlth Sci, Bristol, Avon, England; [Henderson, Graeme] Univ Bristol, Bristol Neurosci, Bristol, Avon, England; [Marshall, Brandon D. L.] Brown Univ, Sch Publ Hlth, Providence, RI 02912 USA; [Bruneau, Julie] Ctr Hosp Univ Montreal, Res Ctr, Montreal, PQ, Canada; [Bruneau, Julie] Univ Montreal, Fac Med, Dept Family & Emergency Med, Succursale Ctr Ville, Montreal, PQ, Canada; [Altice, Frederick L.] Yale Univ, Sch Med, New Haven, CT USA; [Rahimi-Movaghar, Afarin] Univ Tehran Med Sci, Iranian Natl Ctr Addict Studies, Tehran, Iran	University of New South Wales Sydney; University of New South Wales Sydney; Kirby Institute; University of Bristol; University of Bristol; Brown University; Universite de Montreal; Universite de Montreal; Yale University; Tehran University of Medical Sciences	Degenhardt, L (corresponding author), Univ New South Wales Sydney, Natl Drug & Akohol Res Ctr, Sydney, NSW 2052, Australia.	l.degenhardt@unsw.edu.au	Hickman, Matthew/Y-2400-2019; Henderson, Graeme/AAC-5104-2022; Stone, Jack/AAS-5455-2021; Larney, Sarah/AAR-1372-2020; Stone, Jack/L-9149-2019	Hickman, Matthew/0000-0001-9864-459X; Larney, Sarah/0000-0002-5602-4963; Stone, Jack/0000-0002-4584-0068; Vickerman, Peter/0000-0002-8291-5890	Australian Government Department of Health under the Drug and Alcohol Program; National Health and Medical Research Council (NHMRC) fellowships; National Institutes of Health (NIH) grant from the National Institute on Drug Abuse (NIDA) [R01DA1104470]; NHMRC [APP1150078]; Australian Government Department of Health and Ageing; NIDA [R01DA033679, DP2-DA040236, RO1DA036975, K24 DA017072, R01 DA025943, R01 DA029910, R01 DA030768, R01 DA033679, R01 DA030762, R21 DA041953]; National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Evaluation of Interventions at University of Bristol, Bristol, UK; NIHR HPRU in Blood Borne and Sexually Transmitted Infections at University College London, London, UK; National Institute for Drug Abuse [R01 DA037773-01A1]; NIH grants from the National Institute of General Medical Sciences [P20GM125507]; European Monitoring Centre on Drugs and Drug Addiction; Australian National Drug and Alcohol Research Centre, University of New South Wales Sydney (Sydney, NSW, Australia); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM125507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA033679, R01DA036975, R01DA044170, R01DA029910, R21DA041953, R01DA037773] Funding Source: NIH RePORTER; MRC [MR/K006525/1, MR/K023233/1] Funding Source: UKRI	Australian Government Department of Health under the Drug and Alcohol Program; National Health and Medical Research Council (NHMRC) fellowships(National Health and Medical Research Council (NHMRC) of Australia); National Institutes of Health (NIH) grant from the National Institute on Drug Abuse (NIDA); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Australian Government Department of Health and Ageing(Australian GovernmentDepartment of Health & Ageing); NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Evaluation of Interventions at University of Bristol, Bristol, UK; NIHR HPRU in Blood Borne and Sexually Transmitted Infections at University College London, London, UK; National Institute for Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIH grants from the National Institute of General Medical Sciences(General Electric); European Monitoring Centre on Drugs and Drug Addiction; Australian National Drug and Alcohol Research Centre, University of New South Wales Sydney (Sydney, NSW, Australia); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The Australian National Drug and Alcohol Research Centre, University of New South Wales Sydney (Sydney, NSW, Australia), provided funding towards the costs of this Series paper. The Australian National Drug and Alcohol Research Centre is supported by funding from the Australian Government Department of Health under the Drug and Alcohol Program. LD and SL are supported by National Health and Medical Research Council (NHMRC) fellowships. SL and LD are supported by a National Institutes of Health (NIH) grant from the National Institute on Drug Abuse (NIDA; R01DA1104470). LD, JS, and MH acknowledge support from NHMRC (APP1150078). The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. JS and PV acknowledge support from NIDA (R01DA033679). JS, MH, and PV acknowledge support from National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Evaluation of Interventions at University of Bristol, Bristol, UK. MH is a NIHR senior investigator and acknowledges the NIHR School of Public Health Research and the NIHR Biomedical Research Centre in Bristol, UK. PV acknowledges support from the NIHR HPRU in Blood Borne and Sexually Transmitted Infections at University College London, London, UK and the National Institute for Drug Abuse (R01 DA037773-01A1). BDLM is supported by NIH grants from the National Institute of General Medical Sciences (P20GM125507) and NIDA (DP2-DA040236). GH is supported by NIDA (grant number RO1DA036975). FLA is supported on research related to this grant from NIDA (K24 DA017072, R01 DA025943, R01 DA029910, R01 DA030768, R01 DA033679, R01 DA030762, and R21 DA041953). The work informing this paper received support from the European Monitoring Centre on Drugs and Drug Addiction. We thank Lucy Thi Tran (University of New South Wales Sydney), Thomas Santo Jr (University of New South Wales Sydney), Harry Jin (Brown University School of Public Health, Providence, RI, USA), Behzad Hajarizadeh (University of New South Wales Sydney), and Samantha Colledge (University of New South Wales Sydney) for their assistance with some of the reviews summarised here; and Christinah Mukandavire (Imperial College London, London, UK) and Linda Gowing (University of Adelaide, Adelaide, SA, Australia) for provision of data from their reviews. We also thank Judy Chang (International Network of People Who Use Drugs, London, UK), Jude Byrne (Australian Injecting & Illicit Drug Users League, Turner, ACT, Australia), Emily Ebdon (Anglicare Tasmania), Binod Gurung (Sathi Samuha, Asian Network of People Who Use Drugs), Mick Mathews (International Network of People Who Use Drugs, London, UK), Penni Moore (Hepatitis SA and Drug and Alcohol Service SA), Martin McCusker (Lambeth Service User Council, London, UK), Eric Nsengiyumva (Burundi Association for People Who Use Drugs, Bujumbura, Burundi), Peter Parkes (Canberra Alliance for Harm Minimisation and Advocacy, Canberra, ACT, Australia), Bishnu Fueal Sharma (Tribhuwan University, Kirtipur, Nepal), Peter Sidaway (Northern Territory AIDS & Hepatitis Council, Darwin, NT, Australia), and Nandini Thapa (India Drug Users Forum). We also thank Pavlo Smyrnov (Alliance for Public Health, Kiev, Ukraine), and Maryam Alavi (University of New South Wales Sydney) who assisted with location of data to inform the mathematical modelling summarised here.	Alinejad S, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3757-1; Altice FL, 2010, LANCET, V376, P367, DOI 10.1016/S0140-6736(10)60829-X; Amato L, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003409.pub4; Amato L, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004147.pub4; Amin-Esmaeili M, 2016, ADDICTION, V111, P1836, DOI 10.1111/add.13453; [Anonymous], 2018, ASS PRESS; Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244; Aspinall EJ, 2014, INT J EPIDEMIOL, V43, P235, DOI 10.1093/ije/dyt243; Banerjee G, 2016, ADDICTION, V111, P2021, DOI 10.1111/add.13491; Berrettini W, 2017, DIALOGUES CLIN NEURO, V19, P229; Berterame S, 2016, LANCET, V387, P1644, DOI 10.1016/S0140-6736(16)00161-6; Campbell G, 2015, PAIN MED, V16, P1745, DOI 10.1111/pme.12773; Caudarella A, 2016, DRUG ALCOHOL DEPEN, V162, P51, DOI 10.1016/j.drugalcdep.2016.02.024; Caven M, 2019, INT J DRUG POLICY, V72, P169, DOI 10.1016/j.drugpo.2019.05.011; Cerda M, 2015, J PEDIATR-US, V167, P605, DOI 10.1016/j.jpeds.2015.04.071; Chen QS, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.7621; Chetty M, 2017, ADDICT SCI CLIN PRAC, V12, DOI 10.1186/s13722-017-0071-3; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Ciccarone D, 2019, INT J DRUG POLICY, V71, P183, DOI 10.1016/j.drugpo.2019.01.010; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Conroy E, 2009, CHILD ABUSE NEGLECT, V33, P343, DOI 10.1016/j.chiabu.2008.09.009; Copenhaver MM, 2006, J SUBST ABUSE TREAT, V31, P163, DOI 10.1016/j.jsat.2006.04.002; Cottler LB, 2014, LANCET GLOB HEALTH, V2, pE592, DOI 10.1016/S2214-109X(14)70290-6; Daniel JZ, 2009, DRUG ALCOHOL REV, V28, P142, DOI 10.1111/j.1465-3362.2008.00042.x; Darke S, 2000, ADDICTION, V95, P687, DOI 10.1046/j.1360-0443.2000.9556874.x; Darke S, 2003, J URBAN HEALTH, V80, P189, DOI 10.1093/jurban/jtg022; Day E, 2017, ADDICTION, V112, P1329, DOI 10.1111/add.13644; De Maeyer J, 2010, INT J DRUG POLICY, V21, P364, DOI 10.1016/j.drugpo.2010.01.010; DeBeck K, 2017, LANCET HIV, V4, pE357, DOI 10.1016/S2352-3018(17)30073-5; Degenhardt L, 2017, LANCET GLOB HEALTH, V5, pE1192, DOI 10.1016/S2214-109X(17)30375-3; Degenhardt L, 2014, ADDICTION, V109, P1306, DOI 10.1111/add.12536; Degenhardt L, 2009, DRUG ALCOHOL DEPEN, V105, P9, DOI 10.1016/j.drugalcdep.2009.05.021; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Ellerstrand J, 2018, 337 NDARC U NEW S WA; Ersche KD, 2007, NEUROPSYCHOL REV, V17, P317, DOI 10.1007/s11065-007-9033-y; European Monitoring Centre for Drugs and Drug Addiction, EUR DRUG REP 2018; Evoy KE, 2017, DRUGS, V77, P403, DOI 10.1007/s40265-017-0700-x; Faggiano F., 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002208, DOI 10.1002/14651858.CD002208]; Fareed A, 2017, J ADDICT DIS, V36, P105, DOI 10.1080/10550887.2017.1280898; Farrell M, 2019, LANCET, V394, P1652, DOI 10.1016/S0140-6736(19)32230-5; Feelemyer JP, 2014, DRUG ALCOHOL DEPEN, V134, P251, DOI 10.1016/j.drugalcdep.2013.10.011; FERGUSSON DM, 1994, J AM ACAD CHILD PSY, V33, P1122, DOI 10.1097/00004583-199410000-00008; Fink DS, 2018, ANN INTERN MED, V168, P783, DOI 10.7326/M17-3074; Ford JA, 2015, PREV SCI, V16, P633, DOI 10.1007/s11121-014-0514-y; Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243; Giannou FK, 2016, EXPERT REV PHARM OUT, V16, P489, DOI 10.1586/14737167.2016.1102635; Gilchrist G, 2017, AIDS BEHAV, V21, P1791, DOI 10.1007/s10461-017-1755-0; Gomes T, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002396; Gowing L, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004145.pub4; Grebely J, 2019, ADDICTION, V114, P150, DOI 10.1111/add.14393; Hall W, 2019, LANCET, V394, P1580, DOI 10.1016/S0140-6736(19)31789-1; Hayhurst KP, 2017, INT J DRUG POLICY, V39, P1, DOI 10.1016/j.drugpo.2016.08.015; Hedrich D, 2012, ADDICTION, V107, P501, DOI 10.1111/j.1360-0443.2011.03676.x; Hickman M, 2018, ADDICTION, V113, P1461, DOI 10.1111/add.14188; Hill R, 2018, BRIT J PHARMACOL, V175, P2492, DOI 10.1111/bph.14219; Hill R, 2016, NEUROPSYCHOPHARMACOL, V41, P762, DOI 10.1038/npp.2015.201; Hser YI, 2001, ARCH GEN PSYCHIAT, V58, P503, DOI 10.1001/archpsyc.58.5.503; Hulse GK, 1997, ADDICTION, V92, P1571; Humphreys K, 2014, ALCOHOL CLIN EXP RES, V38, P2688, DOI 10.1111/acer.12557; Jahagirdar D, 2017, NALTREXONE OPIOID US; James SL, 2018, LANCET, V392, P1789, DOI [10.1016/S0140-6736(18)32279-7, 10.1016/s0140-6736(18)32279-7]; Jarvis BP, 2018, ADDICTION, V113, P1188, DOI 10.1111/add.14180; Jones HE, 2010, NEW ENGL J MED, V363, P2320, DOI 10.1056/NEJMoa1005359; Jones JD, 2012, DRUG ALCOHOL DEPEN, V125, P8, DOI 10.1016/j.drugalcdep.2012.07.004; Katz C, 2013, DRUG ALCOHOL DEPEN, V132, P107, DOI 10.1016/j.drugalcdep.2013.01.010; Keegan J, 2010, J ADDICT DIS, V29, P175, DOI 10.1080/10550881003684723; Kertesz SG, 2019, ADDICTION, V114, P169, DOI 10.1111/add.14394; Kimber J, 2015, LANCET PSYCHIAT, V2, P901, DOI 10.1016/S2215-0366(15)00366-1; Kinlock TW, 2007, DRUG ALCOHOL DEPEN, V91, P220, DOI 10.1016/j.drugalcdep.2007.05.022; Kiunguyu K., 2018, THIS IS AFRICA; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Kourounis G, 2016, DRUG ALCOHOL DEPEN, V161, P1, DOI 10.1016/j.drugalcdep.2015.12.021; Krieger MS, 2018, INT J DRUG POLICY, V61, P52, DOI 10.1016/j.drugpo.2018.09.009; Kuyper L, 2011, ADDICT BEHAV, V36, P560, DOI 10.1016/j.addbeh.2011.01.022; Lake S, 2016, J ADDICT DIS, V35, P73, DOI 10.1080/10550887.2015.1127712; Langdon KJ, 2019, CURR OPIN PSYCHOL, V30, P17, DOI 10.1016/j.copsyc.2018.12.020; Larance B, 2011, DRUG ALCOHOL REV, V30, P236, DOI 10.1111/j.1465-3362.2010.00283.x; Larney S, JAMA PSYCHIAT; Larney S, 2017, LANCET GLOB HEALTH, V5, pE1208, DOI [10.1016/S2214-109X(17)30373-X, 10.1016/s2214-109x(17)30373-x]; Larney S, 2017, DRUG ALCOHOL DEPEN, V171, P39, DOI [10.1016/j.drugalcdep.2016.11.029, 10.1016/j.drugalcdep.2016.08.320]; Larney S, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004666; LaScala E, 2005, PREVENTING HARMFUL SUBSTANCE USE: THE EVIDENCE BASE FOR POLICY AND PRACTICE, P67, DOI 10.1002/9780470713624.ch6; Li W, 2013, BRAIN RES, V1531, P58, DOI 10.1016/j.brainres.2013.07.036; Loeber S, 2012, DRUG ALCOHOL DEPEN, V120, P81, DOI 10.1016/j.drugalcdep.2011.07.001; Low AJ, 2016, CLIN INFECT DIS, V63, P1094, DOI 10.1093/cid/ciw416; Lyndon A, 2017, ADDICTION, V112, P1580, DOI 10.1111/add.13843; LYNSKEY MT, 1995, J ABNORM CHILD PSYCH, V23, P281, DOI 10.1007/BF01447558; MacArthur GJ, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5945; MacArthur GJ, 2014, INT J DRUG POLICY, V25, P34, DOI 10.1016/j.drugpo.2013.07.001; Maglione MA, 2018, J SUBST ABUSE TREAT, V89, P28, DOI 10.1016/j.jsat.2018.03.001; Malivert M, 2012, EUR ADDICT RES, V18, P1, DOI 10.1159/000331007; Marsden J, 2017, ADDICTION, V112, P1408, DOI 10.1111/add.13779; Martins SS, 2017, JAMA PSYCHIAT, V74, P445, DOI 10.1001/jamapsychiatry.2017.0113; Martins SS, 2015, AM J PUBLIC HEALTH, V105, pE29, DOI 10.2105/AJPH.2015.302843; Mattick RP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub3; Mattick RP, 1996, LANCET, V347, P97, DOI 10.1016/S0140-6736(96)90215-9; McEachern J, 2019, INT J DRUG POLICY, V64, P30, DOI 10.1016/j.drugpo.2018.08.006; McGowan CR, 2018, INT J DRUG POLICY, V58, P31, DOI 10.1016/j.drugpo.2018.04.017; Merrall ELC, 2010, ADDICTION, V105, P1545, DOI 10.1111/j.1360-0443.2010.02990.x; Milloy MJ, 2009, ADDICTION, V104, P620, DOI 10.1111/j.1360-0443.2009.02541.x; Minozzi S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001333.pub4; Minozzi S, 2013, ADDICTION, V108, P688, DOI 10.1111/j.1360-0443.2012.04005.x; Mueller SR, 2015, SUBST ABUS, V36, P240, DOI 10.1080/08897077.2015.1010032; Murphy SM, 2019, ANN INTERN MED, V170, P90, DOI 10.7326/M18-0227; Neale J, 2018, DRUG ALCOHOL DEPEN, V189, P1, DOI 10.1016/j.drugalcdep.2018.03.057; NEEDLE RH, 1990, J MARRIAGE FAM, V52, P157, DOI 10.2307/352847; New England Comparative Effectiveness Public Advisory Council, 2017, AB DET FORM OP EFF V; Nielsen S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011117.pub2; Noble M, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006605.pub2; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Peacock A, 2019, LANCET, V394, P1668, DOI 10.1016/S0140-6736(19)32231-7; Perry AE, 2015, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD010862.PUB2; Platt L, 2018, ADDICTION, V113, P545, DOI 10.1111/add.14012; Platt L, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012021.pub2; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; Qiu YW, 2013, NEUROSCI LETT, V538, P43, DOI 10.1016/j.neulet.2013.01.019; Qiu YW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063212; Rahimi-Movaghar A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007775.pub2; Rajabi A, 2019, ADDICT BEHAV, V92, P225, DOI 10.1016/j.addbeh.2018.11.043; Reddon H, 2019, LANCET HIV, V6, pE128, DOI 10.1016/S2352-3018(18)30292-3; Rich JD, 2015, LANCET, V386, P350, DOI 10.1016/S0140-6736(14)62338-2; Rivera OJS, 2018, JAMA PSYCHIAT, V75, P863, DOI 10.1001/jamapsychiatry.2018.1214; ROBINS LN, 1974, AM J PUBLIC HEALTH, V64, P38, DOI 10.2105/AJPH.64.12_Suppl.38; Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Rutkow L, 2015, JAMA INTERN MED, V175, P1642, DOI 10.1001/jamainternmed.2015.3931; Saha TD, 2016, J CLIN PSYCHIAT, V77, P772, DOI 10.4088/JCP.15m10386; Samet JH, 2015, LANCET, V385, P1508, DOI 10.1016/S0140-6736(15)60750-4; Saucier R, 2018, DRUG SAFETY, V41, P981, DOI 10.1007/s40264-018-0653-3; Saulle R, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011983.pub2; Schlumberger MG, 1999, EUR J EPIDEMIOL, V15, P207, DOI 10.1023/A:1007578402083; Seltenhammer MH, 2013, ADDICTION, V108, P1287, DOI 10.1111/add.12106; Shahmanesh M, 2008, TROP MED INT HEALTH, V13, P659, DOI 10.1111/j.1365-3156.2008.02040.x; Singh D., 2018, INDIA TODAY; Smith LA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005338.pub2; Socias ME, 2016, ADDICTION, V111, P2079, DOI 10.1111/add.13479; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Spelman T, 2015, J EPIDEMIOL COMMUN H, V69, P745, DOI 10.1136/jech-2014-205224; Stenbacka M, 2007, DRUG ALCOHOL REV, V26, P55, DOI 10.1080/09595230601036994; Stone J, 2018, LANCET INFECT DIS, V18, P1397, DOI 10.1016/S1473-3099(18)30469-9; STRANG J, 2010, BMJ-BRIT MED J, V341, DOI DOI 10.1136/BMJ.C4851; STRANG J, 2014, BMJ-BRIT MED J, V349, DOI DOI 10.1136/BMJ.G6580; Substance Abuse and Mental Health Services Administration, 2014, REC NAT REG RES; Sweeting MJ, 2009, STAT METHODS MED RES, V18, P381, DOI 10.1177/0962280208094704; Tomko JR, 2018, PRIM CARE COMPANION, V20; Townsend L, 2007, CLIN CHILD FAM PSYCH, V10, P295, DOI 10.1007/s10567-007-0023-7; Tupper KW, 2018, DRUG ALCOHOL DEPEN, V190, P242, DOI 10.1016/j.drugalcdep.2018.06.020; Turner KME, 2011, ADDICTION, V106, P1978, DOI 10.1111/j.1360-0443.2011.03515.x; Voelker R, 2016, JAMA-J AM MED ASSOC, V316, P24, DOI 10.1001/jama.2016.8071; Volkow ND, 2018, LANCET, V391, P285, DOI 10.1016/S0140-6736(17)32893-3; Wegman MP, 2017, LANCET GLOB HEALTH, V5, pE198, DOI 10.1016/S2214-109X(16)30303-5; Werb D, 2016, INT J DRUG POLICY, V28, P1, DOI 10.1016/j.drugpo.2015.12.005; WHO, 2016, ICD 11 BET DRAFT; WHO Expert Committee on Drug Dependence, 2018, 41 ECDD M; Williams A, 2017, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20170313.059163/full, DOI 10.1377/HBLOG20170313.059163]; Williams AR, 2018, J SUBST ABUSE TREAT, V91, P57, DOI 10.1016/j.jsat.2018.06.001; Witkiewitz K, 2018, ALCOHOL CLIN EXP RES, V42, P478, DOI 10.1111/acer.13594; Wollman SC, 2015, AM J DRUG ALCOHOL AB, V41, P133, DOI 10.3109/00952990.2014.985829; World Health Organization, 2017, MOD LIST ESS MED, V20th; World Health Organization, 2009, GUID PSYCH ASS PHARM; Yazdy MM, 2015, J PEDIATR GENET, V4, P56, DOI 10.1055/s-0035-1556740; Yuan Y, 2009, BRAIN COGNITION, V71, P223, DOI 10.1016/j.bandc.2009.08.014; Zedler BK, 2016, ADDICTION, V111, P2115, DOI 10.1111/add.13462	163	238	239	5	41	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 26	2019	394	10208					1560	1579		10.1016/S0140-6736(19)32229-9	http://dx.doi.org/10.1016/S0140-6736(19)32229-9			20	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JI3WL	31657732	Green Submitted, Green Accepted			2023-01-03	WOS:000493399500027
J	Bello, JP; Garcia-Pena, C; Modrono, C; Hernandez-Martin, E; Perez-Martin, Y; Marcano, F; Gonzalez-Mora, JL				Plata Bello, Julio; Garcia-Pena, Carlos; Modrono, Cristian; Hernandez-Martin, Estefania; Perez-Martin, Yaiza; Marcano, Francisco; Luis Gonzalez-Mora, Jose			Visual inputs decrease brain activity in frontal areas during silent lipreading	PLOS ONE			English	Article							CORTICAL ORGANIZATION; NEURAL BASIS; SPEECH; PERCEPTION; LANGUAGE; FACES; FMRI	Aim The aim of the present work is to analyze the modulation of the brain activity within the areas involved in lipreading when an additional visual stimulus is included. Methods The experiment consisted of two fMRI runs (lipreading_only and lipreading+picture) where two conditions were considered in each one (oral speech sentences condition [OSS] and oral speech syllables condition [OSSY]). Results During lipreading-only, higher activity in the left middle temporal gyrus (MTG) was identified for OSS than OSSY; during lipreading+picture, apart from the left MTG, higher activity was also present in the supplementary motor area (SMA), the left precentral gyrus (PreCG) and the left inferior frontal gyrus (IFG). The comparison between these two runs revealed higher activity for lipreading-only in the SMA and the left IFG. Conclusion The presence of a visual reference during a lipreading task leads to a decrease in activity in frontal areas.	[Plata Bello, Julio; Garcia-Pena, Carlos; Modrono, Cristian; Hernandez-Martin, Estefania; Marcano, Francisco; Luis Gonzalez-Mora, Jose] Univ La Laguna, Fac Med, Dept Physiol, Santa Cruz de Tenerife, Spain; [Plata Bello, Julio] Hosp Univ Canarias, Dept Neurosurg, Santa Cruz de Tenerife, Spain; [Perez-Martin, Yaiza] Hosp Univ Canarias, Dept Neurol, Santa Cruz de Tenerife, Spain	Universidad de la Laguna; Universidad de la Laguna; Universidad de la Laguna	Bello, JP (corresponding author), Univ La Laguna, Fac Med, Dept Physiol, Santa Cruz de Tenerife, Spain.; Bello, JP (corresponding author), Hosp Univ Canarias, Dept Neurosurg, Santa Cruz de Tenerife, Spain.	jplatbel@ull.edu.es	Plata-Bello, Julio/AAB-1613-2019	Plata-Bello, Julio/0000-0002-2643-5470; Gonzalez-Mora, Jose Luis/0000-0001-8920-1375; Perez Martin, Maria Yaiza/0000-0002-4669-1906; Hernandez-Martin, Estefania/0000-0002-9745-3254				Bernstein LE, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00386; Bookheimer S, 2002, ANNU REV NEUROSCI, V25, P151, DOI 10.1146/annurev.neuro.25.112701.142946; Calvert GA, 2000, CURR BIOL, V10, P649, DOI 10.1016/S0960-9822(00)00513-3; Calvert GA, 2003, J COGNITIVE NEUROSCI, V15, P57, DOI 10.1162/089892903321107828; Campbell R, 2001, COGNITIVE BRAIN RES, V12, P233, DOI 10.1016/S0926-6410(01)00054-4; Cattaneo L, 2009, ARCH NEUROL-CHICAGO, V66, P557, DOI 10.1001/archneurol.2009.41; DODD B, 1977, PERCEPTION, V6, P31, DOI 10.1068/p060031; Duffau H, 2015, NAT REV NEUROL, V11, P255, DOI 10.1038/nrneurol.2015.51; Fridriksson J, 2008, NEUROIMAGE, V41, P605, DOI 10.1016/j.neuroimage.2008.02.046; Friederici AD, 2002, TRENDS COGN SCI, V6, P78, DOI 10.1016/S1364-6613(00)01839-8; Grant KW, 1998, J ACOUST SOC AM, V104, P2438, DOI 10.1121/1.423751; Grant KW, 2000, J ACOUST SOC AM, V108, P1197, DOI 10.1121/1.1288668; Hall DA, 2005, J COGNITIVE NEUROSCI, V17, P939, DOI 10.1162/0898929054021175; Hickok G, 2007, NAT REV NEUROSCI, V8, P393, DOI 10.1038/nrn2113; Hickok G, 2012, J COMMUN DISORD, V45, P393, DOI 10.1016/j.jcomdis.2012.06.004; Jeffers J., 1971, SPEECHREADING LIPREA; Kaplan E., 1983, BOSTON NAMING TEST; Kislyuk DS, 2008, J COGNITIVE NEUROSCI, V20, P2175, DOI 10.1162/jocn.2008.20152; LIBERMAN AM, 1985, COGNITION, V21, P1, DOI 10.1016/0010-0277(85)90021-6; MACLEOD A, 1987, British Journal of Audiology, V21, P131, DOI 10.3109/03005368709077786; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; MCGURK H, 1976, NATURE, V264, P746, DOI 10.1038/264746a0; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Paulesu E, 2003, J NEUROPHYSIOL, V90, P2005, DOI 10.1152/jn.00926.2002; Paulesu E, 1997, NEUROREPORT, V8, P2011, DOI 10.1097/00001756-199705260-00042; Bello JP, 2015, EUR J NEUROSCI, V41, P938, DOI 10.1111/ejn.12850; Poldrack RA, 1999, NEUROIMAGE, V10, P15, DOI 10.1006/nimg.1999.0441; Rijntjes Michel, 2012, Front Evol Neurosci, V4, P9, DOI 10.3389/fnevo.2012.00009; Rizzolatti G, 1998, TRENDS NEUROSCI, V21, P188, DOI 10.1016/S0166-2236(98)01260-0; Schroeder CE, 2008, TRENDS COGN SCI, V12, P106, DOI 10.1016/j.tics.2008.01.002; SUMMERFIELD Q, 1992, PHILOS T ROY SOC B, V335, P71, DOI 10.1098/rstb.1992.0009; Umarova RM, 2010, CEREB CORTEX, V20, P121, DOI 10.1093/cercor/bhp086	32	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2019	14	10							e0223782	10.1371/journal.pone.0223782	http://dx.doi.org/10.1371/journal.pone.0223782			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM7ZE	31600311	Green Published, gold			2023-01-03	WOS:000532467000126
J	Verkissen, MN; Hjermstad, MJ; Van Belle, S; Kaasa, S; Deliens, L; Pardon, K				Verkissen, Mariette N.; Hjermstad, Marianne J.; Van Belle, Simon; Kaasa, Stein; Deliens, Luc; Pardon, Koen			Quality of life and symptom intensity over time in people with cancer receiving palliative care: Results from the international European Palliative Care Cancer Symptom study	PLOS ONE			English	Article							PREVALENCE; EXPERIENCE; DISTRESS; FATIGUE; DISEASE	Background People with advanced cancer experience multiple symptoms during their illness trajectory, which can fluctuate in intensity. Aim To describe the course of self-reported quality of life, emotional functioning, physical functioning and symptom intensity over time in cancer patients receiving palliative care. Design Longitudinal study with monthly assessments, using the EORTC QLQ-C15-PAL. Data were analysed (1) prospectively, from baseline to >= 8-month follow-up; and (2) retrospectively, by taking death as index date and comparing results from three cross-sectional subsamples at different stages of illness (time to death >= 6, 5-3 and 2-0 months). Linear mixed models were calculated. Setting/participants A total of 1739 patients (mean age 66, 50% male) from 30 palliative care centers in 12 countries were included. Results In prospective analyses, quality of life, functioning and symptoms-except nausea/vomiting-remained generally stable over time. In retrospective analyses, patients 2-0 months before death reported significantly lower quality of life and physical functioning scores than those 5-3 months before death, who in turn scored lower than those >= 6 months before death, suggesting progressive decline. Emotional functioning remained initially unchanged, but decreased in the last months. Pain, fatigue and appetite loss showed a stable increase in intensity towards death. Dyspnea, insomnia and constipation increased from 5-3 to 2-0 months before death. Nausea/vomiting only increased when comparing those >= 6 months before death with those 2-0 months before death. Conclusion While the prospective approach showed predominantly stable patterns for quality of life, functioning and symptom severity throughout study duration, retrospective analyses indicated that deterioration was already apparent before the terminal phase and accelerated close to death. Our findings support the importance of early symptom identification and treatment in this population, and highlight the need for further studies to explore what characterizes those with either lower or higher symptom burden at different time points towards death.	[Verkissen, Mariette N.; Van Belle, Simon; Deliens, Luc; Pardon, Koen] Vrije Univ Brussel VUB, Dept Family Med & Chron Care, End Life Care Res Grp, Brussels, Belgium; [Verkissen, Mariette N.; Van Belle, Simon; Deliens, Luc; Pardon, Koen] Univ Ghent, Brussels, Belgium; [Hjermstad, Marianne J.] Univ Oslo, Oslo Univ Hosp, European Palliat Care Res Ctr PRC, Dept Oncol, Oslo, Norway; [Hjermstad, Marianne J.] Univ Oslo, Inst Clin Med, Oslo, Norway; [Van Belle, Simon] Ghent Univ Hosp, Dept Med Oncol, Ghent, Belgium; [Kaasa, Stein] Norwegian Univ Sci & Technol NTNU, Fac Med, European Palliat Care Res Ctr PRC, Dept Canc Res & Mol Med, Trondheim, Norway; [Kaasa, Stein] Trondheim Reg & Univ Hosp, St Olavs Hosp, Canc Clin, Trondheim, Norway; [Deliens, Luc] Univ Ghent, Dept Publ Hlth & Primary Care, Ghent, Belgium	Vrije Universiteit Brussel; Ghent University; University of Oslo; University of Oslo; Ghent University; Ghent University Hospital; Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Ghent University; Ghent University Hospital	Verkissen, MN (corresponding author), Vrije Univ Brussel VUB, Dept Family Med & Chron Care, End Life Care Res Grp, Brussels, Belgium.; Verkissen, MN (corresponding author), Univ Ghent, Brussels, Belgium.	mariette.verkissen@vub.be		Pardon, Koen/0000-0002-0571-709X	Norwegian University of Science and Technology (NTNU) [6070]; St. Olavs Hospital-Trondheim University Hospital [6070]; European Union's Seventh Framework Programme FP7/2007-2013 [602541]	Norwegian University of Science and Technology (NTNU); St. Olavs Hospital-Trondheim University Hospital; European Union's Seventh Framework Programme FP7/2007-2013	The European Palliative Care Cancer Symptom (EPCCS) study is a collaborative effort between the European Palliative Care Research Centre (PRC) and the European Association for Palliative Care -Research Network (EAPCS-RN). The study was partially funded by grant no. 6070 from the joint Research Council at Norwegian University of Science and Technology (NTNU) and St. Olavs Hospital-Trondheim University Hospital. The first author has received funding from the European Union's Seventh Framework Programme FP7/2007-2013 [grant no. 602541]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Ahmedzai SH, 2004, EUR J CANCER, V40, P2192, DOI 10.1016/j.ejca.2004.06.009; Barnes EA, 2002, INT J GYNECOL CANCER, V12, P424, DOI 10.1046/j.1525-1438.2002.t01-1-01147.x; Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644; Davis MP, 2004, J CLIN ONCOL, V22, P1510, DOI 10.1200/JCO.2004.03.103; Delgado-Guay MO, 2009, CANCER-AM CANCER SOC, V115, P437, DOI 10.1002/cncr.24017; Deshields T, 2014, SUPPORT CARE CANCER, V22, P1089, DOI 10.1007/s00520-013-2049-3; Deshields Teresa L, 2011, J Support Oncol, V9, P216, DOI 10.1016/j.suponc.2011.06.003; Elmqvist MA, 2009, SUPPORT CARE CANCER, V17, P191, DOI 10.1007/s00520-008-0477-2; Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056; Fayers P, 2001, EORTC QLQ C30 SCORIN, V3th; Giesinger JM, 2011, J PALLIAT MED, V14, P904, DOI 10.1089/jpm.2011.0086; Glare P, 2011, CLIN INTERV AGING, V6, P243, DOI 10.2147/CIA.S13109; Groenvold M, 2006, EUR J CANCER, V42, P55, DOI 10.1016/j.ejca.2005.06.022; Groenvold M, 2001, ADDENDUM EORTC QLQ C; Hagelin CL, 2006, SUPPORT CARE CANCER, V14, P320, DOI 10.1007/s00520-005-0886-4; Hjermstad MJ, 2018, BMJ SUPPORT PALLIAT, V8, P456, DOI 10.1136/bmjspcare-2015-000997; Hotopf M, 2002, PALLIATIVE MED, V16, P81, DOI 10.1191/02169216302pm507oa; Hwang SS, 2003, J PAIN SYMPTOM MANAG, V25, P225, DOI 10.1016/S0885-3924(02)00641-3; Jemal A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009584; Luckett T, 2009, PSYCHO-ONCOLOGY, V18, P1129, DOI 10.1002/pon.1545; Lynn J, 2003, RAND HLTH, P1; McCarter K, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008277; McCarthy EP, 2000, J AM GERIATR SOC, V48, pS110, DOI 10.1111/j.1532-5415.2000.tb03120.x; Mitchell AJ, 2011, LANCET ONCOL, V12, P160, DOI 10.1016/S1470-2045(11)70002-X; Nekolaichuk CL, 1999, PALLIATIVE MED, V13, P311, DOI 10.1191/026921699675854885; Raijmakers NJH, 2018, SUPPORT CARE CANCER, V26, P3397, DOI 10.1007/s00520-018-4181-6; Rome RB, 2011, OCHSNER J, V11, P348; Seow H, 2011, J CLIN ONCOL, V29, P1151, DOI 10.1200/JCO.2010.30.7173; Sigurdardottir Katrin Ruth, 2008, BMC Palliat Care, V7, P16, DOI 10.1186/1472-684X-7-16; Solano JP, 2006, J PAIN SYMPTOM MANAG, V31, P58, DOI 10.1016/j.jpainsymman.2005.06.007; Stromgren AS, 2006, J PAIN SYMPTOM MANAG, V31, P199, DOI 10.1016/j.jpainsymman.2005.07.007; Tanaka K, 2002, J PAIN SYMPTOM MANAG, V23, P417, DOI 10.1016/S0885-3924(02)00376-7; Tang ST, 2014, J PAIN SYMPTOM MANAG, V48, P863, DOI 10.1016/j.jpainsymman.2014.01.011; Teunissen SCCM, 2007, J PAIN SYMPTOM MANAG, V34, P94, DOI 10.1016/j.jpainsymman.2006.10.015; Tishelman C, 2007, J CLIN ONCOL, V25, P5381, DOI 10.1200/JCO.2006.08.7874	36	29	31	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2019	14	10							e0222988	10.1371/journal.pone.0222988	http://dx.doi.org/10.1371/journal.pone.0222988			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM7QS	31596849	Green Published, gold			2023-01-03	WOS:000532444100016
J	Cutler, DM				Cutler, David M.			Nursing Our Way to Better Health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									[Cutler, David M.] Harvard Univ, Appl Econ, Dept Econ, Cambridge, MA 02138 USA; [Cutler, David M.] Harvard Univ, Kennedy Sch Govt, Cambridge, MA 02138 USA	Harvard University; Harvard University	Cutler, DM (corresponding author), Harvard Univ, Appl Econ, Dept Econ, Cambridge, MA 02138 USA.; Cutler, DM (corresponding author), Harvard Univ, Kennedy Sch Govt, Cambridge, MA 02138 USA.	dcutler@fas.harvard.edu		Cutler, David/0000-0002-4949-8917					0	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	2019	322	11					1033	1034		10.1001/jama.2019.13834	http://dx.doi.org/10.1001/jama.2019.13834			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB8LM	31528996	Bronze			2023-01-03	WOS:000488821100003
J	Nogrady, B				Nogrady, Bianca			Operating without opioids	NATURE			English	Editorial Material							SURGERY											Alam A, 2012, ARCH INTERN MED, V172, P425, DOI 10.1001/archinternmed.2011.1827; Brat GA, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5790; Ladha KS, 2018, JAMA-J AM MED ASSOC, V320, P502, DOI 10.1001/jama.2018.6933; Lou I, 2017, ANN SURG ONCOL, V24, P1951, DOI 10.1245/s10434-017-5781-y; Mark J, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.5452; Roughead EE, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-023990; Trabulsi EJ, 2010, UROLOGY, V76, P1122, DOI 10.1016/j.urology.2010.03.052	7	0	0	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 12	2019	573	7773					S8	S9		10.1038/d41586-019-02685-3	http://dx.doi.org/10.1038/d41586-019-02685-3			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IX0XA	31511675	Bronze			2023-01-03	WOS:000485415400006
J	Winker, C; Rehbein, MA; Sabatinelli, D; Junghofer, M				Winker, Constantin; Rehbein, Maimu A.; Sabatinelli, Dean; Junghofer, Markus			Repeated noninvasive stimulation of the ventromedial prefrontal cortex reveals cumulative amplification of pleasant compared to unpleasant scene processing: A single subject pilot study	PLOS ONE			English	Article							SELECTIVE VISUAL-ATTENTION; BRAIN; PLEASURE	The ventromedial prefrontal cortex (vmPFC) is a major hub of the reward system and has been shown to activate specifically in response to pleasant / rewarding stimuli. Previous studies demonstrate enhanced pleasant cue reactivity after single applications of transcranial direct current stimulation (tDCS) to the vmPFC. Here we present a pilot case study in which we assess the cumulative impact of multiple consecutive vmPFC-tDCS sessions on the processing of visual emotional stimuli in an event-related MEG recording design. The results point to stable modulation of increased positivity biases (pleasant > unpleasant stimulus signal strength) after excitatory vmPFC stimulation and a reversed pattern (pleasant < unpleasant) after inhibitory stimulation across five consecutive tDCS sessions. Moreover, cumulative effects of these emotional bias modulations were observable for several sourcelocalized spatio-temporal clusters, suggesting an increase in modulatory efficiency by repeated tDCS sessions. This pilot study provides evidence for improvements in the effectiveness and utility of a novel tDCS paradigm in the context of emotional processing.	[Winker, Constantin; Rehbein, Maimu A.; Junghofer, Markus] Univ Munster, Inst Biomagnetism & Biosignalanal, Munster, Germany; [Winker, Constantin; Rehbein, Maimu A.; Junghofer, Markus] Univ Munster, Otto Creutzfeldt Ctr Cognit & Behav Neurosci, Munster, Germany; [Sabatinelli, Dean] Univ Georgia, Dept Psychol, Athens, GA 30602 USA; [Sabatinelli, Dean] Univ Georgia, BioImaging Res Ctr, Athens, GA 30602 USA	University of Munster; University of Munster; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Junghofer, M (corresponding author), Univ Munster, Inst Biomagnetism & Biosignalanal, Munster, Germany.; Junghofer, M (corresponding author), Univ Munster, Otto Creutzfeldt Ctr Cognit & Behav Neurosci, Munster, Germany.	markus.junghoefer@uni-muenster.de	Junghoefer, Markus/AAA-2892-2021	Junghoefer, Markus/0000-0002-8532-2986; sabatinelli, dean/0000-0001-7409-8504	Interdisciplinary Center for Clinical Research of the University of Muenster [Ju2/024/15]; Collaborative Research Center [SFB-TRR58/C08]	Interdisciplinary Center for Clinical Research of the University of Muenster; Collaborative Research Center	This work was funded by the Interdisciplinary Center for Clinical Research of the University of Muenster (Ju2/024/15) and the Collaborative Research Center (SFB-TRR58/C08). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abend R, 2019, NEUROMODULATION, V22, P884, DOI 10.1111/ner.12787; Alonzo A, 2012, BRAIN STIMUL, V5, P208, DOI 10.1016/j.brs.2011.04.006; Bikson M, 2016, BRAIN STIMUL, V9, P641, DOI 10.1016/j.brs.2016.06.004; Carlson JM, 2011, NEUROIMAGE, V57, P1608, DOI 10.1016/j.neuroimage.2011.05.037; Chib VS, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.44; Costa VD, 2010, HUM BRAIN MAPP, V31, P1446, DOI 10.1002/hbm.20948; Denny BT, 2014, EMOTION, V14, P425, DOI 10.1037/a0035276; Dittert N, 2018, FRONT BEHAV NEUROSCI, V12, DOI 10.3389/fnbeh.2018.00076; Greenberg T, 2013, DEPRESS ANXIETY, V30, P242, DOI 10.1002/da.22016; HAMALAINEN MS, 1994, MED BIOL ENG COMPUT, V32, P35, DOI 10.1007/BF02512476; Junghofer M, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00179; Junghofer M, 2017, CEREB CORTEX, V27, P3449, DOI 10.1093/cercor/bhx073; Keuper K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070788; Knutson B, 2003, NEUROIMAGE, V18, P263, DOI 10.1016/S1053-8119(02)00057-5; Laeger I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109949; Lefaucheur JP, 2017, CLIN NEUROPHYSIOL, V128, P56, DOI 10.1016/j.clinph.2016.10.087; Li FH, 2018, BIOL PSYCHOL, V136, P57, DOI 10.1016/j.biopsycho.2018.05.013; Maris E, 2007, J NEUROSCI METH, V164, P177, DOI 10.1016/j.jneumeth.2007.03.024; Milad MR, 2007, BIOL PSYCHIAT, V62, P446, DOI 10.1016/j.biopsych.2006.10.011; Milad MR, 2009, BIOL PSYCHIAT, V66, P1075, DOI 10.1016/j.biopsych.2009.06.026; Monte-Silva K, 2013, BRAIN STIMUL, V6, P424, DOI 10.1016/j.brs.2012.04.011; Monte-Silva K, 2010, J NEUROPHYSIOL, V103, P1735, DOI 10.1152/jn.00924.2009; Mungee A, 2014, NEUROREPORT, V25, P480, DOI 10.1097/WNR.0000000000000119; Perera T, 2016, BRAIN STIMUL, V9, P336, DOI 10.1016/j.brs.2016.03.010; Peyk P, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/861705; Pizzagalli D, 2001, AM J PSYCHIAT, V158, P405, DOI 10.1176/appi.ajp.158.3.405; Sabatinelli D, 2007, J NEUROPHYSIOL, V98, P1374, DOI 10.1152/jn.00230.2007; Sabatinelli D, 2007, CEREB CORTEX, V17, P1085, DOI 10.1093/cercor/bhl017; Sabatinelli D, 2015, BRAIN CONNECT, V5, P1, DOI 10.1089/brain.2013.0186; Schindler S, 2016, HUM BRAIN MAPP, V37, P3575, DOI 10.1002/hbm.23261; Schupp HT, 2006, PROG BRAIN RES, V156, P31, DOI 10.1016/S0079-6123(06)56002-9; Schupp HT, 2007, J NEUROSCI, V27, P1082, DOI 10.1523/JNEUROSCI.3223-06.2007; Steinberg C, 2012, J COGNITIVE NEUROSCI, V24, P17, DOI 10.1162/jocn_a_00067; van 't Wout M, 2016, BRAIN STIMUL, V9, P531, DOI 10.1016/j.brs.2016.03.004; Winker C, 2019, FRONT BEHAV NEUROSCI, V13, DOI 10.3389/fnbeh.2019.00083; Winker C, 2018, NEUROIMAGE, V175, P388, DOI 10.1016/j.neuroimage.2018.03.067	36	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2020	15	1							e0222057	10.1371/journal.pone.0222057	http://dx.doi.org/10.1371/journal.pone.0222057			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5QJ	31961881	gold, Green Published, Green Submitted			2023-01-03	WOS:000534372000003
J	Magwood, O; Salvalaggio, G; Beder, M; Kendall, C; Kpade, V; Daghmach, W; Habonimana, G; Marshall, Z; Snyder, E; O'Shea, T; Lennox, R; Hsu, H; Tugwell, P; Pottie, K				Magwood, Olivia; Salvalaggio, Ginetta; Beder, Michaels; Kendall, Claire; Kpade, Victoire; Daghmach, Wahab; Habonimana, Gilbert; Marshall, Zack; Snyder, Ellen; O'Shea, Tim; Lennox, Robin; Hsu, Helen; Tugwell, Peter; Pottie, Kevin			The effectiveness of substance use interventions for homeless and vulnerably housed persons: A systematic review of systematic reviews on supervised consumption facilities, managed alcohol programs, and pharmacological agents for opioid use disorder	PLOS ONE			English	Review							MEDICATION-ASSISTED TREATMENT; HIGH-INCOME COUNTRIES; MAINTENANCE TREATMENT; HARM REDUCTION; INTRAMUSCULAR NALOXONE; STRUCTURAL BARRIER; INJECTION SERVICES; DRUG-USE; HEALTH; PEOPLE	Background Substance use is disproportionately high among people who are homeless or vulnerably housed. We performed a systematic overview of reviews examining the effects of selected harm reduction and pharmacological interventions on the health and social well-being of people who use substances, with a focus on homeless populations. Methods and findings We searched MEDLINE, EMBASE, PsycINFO, Joanna Briggs Institute EBP, Cochrane Database of Systematic Reviews and DARE for systematic reviews from inception to August 2019. We conducted a grey literature search and hand searched reference lists. We selected reviews that synthesized evidence on supervised consumption facilities, managed alcohol programs and pharmacological interventions for opioid use disorders. We abstracted data specific to homeless or vulnerably housed populations. We assessed certainty of the evidence using the GRADE approach. Our search identified 483 citations and 30 systematic reviews met all inclusion criteria, capturing the results from 442 primary studies. This included three reviews on supervised consumption facilities, 24 on pharmacological interventions, and three on managed alcohol programs. Supervised consumption facilities decreased lethal overdoses and other high risk behaviours without any significant harm, and improved access to care. Pharmaceutical interventions reduced mortality, morbidity, and substance use, but the impact on retention in treatment, mental illness and access to care was variable. Managed alcohol programs reduced or stabilized alcohol consumption. Few studies on managed alcohol programs reported deaths. Conclusions Substance use is a common chronic condition impacting homeless populations. Supervised consumption facilities reduce overdose and improve access to care, while pharmacological interventions may play a role in reducing harms and addressing other morbidity. High quality evidence on managed alcohol programs is limited.	[Magwood, Olivia; Kendall, Claire; Kpade, Victoire; Daghmach, Wahab; Habonimana, Gilbert; Pottie, Kevin] Bruyere Res Inst, CT Lamont Primary Hlth Care Res Ctr, Ottawa, ON, Canada; [Salvalaggio, Ginetta] Univ Alberta, Dept Family Med, Edmonton, AB, Canada; [Beder, Michaels] Univ Toronto, St Michaels Hosp, Dept Psychiat, Toronto, ON, Canada; [Kendall, Claire; Pottie, Kevin] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada; [Kendall, Claire; Pottie, Kevin] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada; [Kpade, Victoire] McGill Univ, Dept Med, Montreal, PQ, Canada; [Marshall, Zack] McGill Univ, Sch Social Work, Montreal, PQ, Canada; [Snyder, Ellen] Univ Ottawa, Publ Hlth & Preventat Med Residency Program, Ottawa, ON, Canada; [O'Shea, Tim] McMaster Univ, Populat Hlth Res Inst, Dept Med, Hamilton, ON, Canada; [Lennox, Robin] McMaster Univ, Dept Family Med, Hamilton, ON, Canada; [Hsu, Helen; Tugwell, Peter] Univ Ottawa, Dept Med, Ottawa, ON, Canada	University of Ottawa; University of Alberta; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Ottawa; University of Ottawa; McGill University; McGill University; University of Ottawa; McMaster University; Population Health Research Institute; McMaster University; University of Ottawa	Pottie, K (corresponding author), Bruyere Res Inst, CT Lamont Primary Hlth Care Res Ctr, Ottawa, ON, Canada.; Pottie, K (corresponding author), Univ Ottawa, Dept Family Med, Ottawa, ON, Canada.; Pottie, K (corresponding author), Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada.	kpottie@uottawa.ca	Marshall, Zack/AAB-2866-2020; Pottie, Kevin/ABC-4385-2020; Tugwell, Peter/AFD-8076-2022	Marshall, Zack/0000-0003-2315-3512; Tugwell, Peter/0000-0001-5062-0556; Kendall, Claire/0000-0003-2686-1135; O'Shea, Tim/0000-0002-0793-6915; Magwood, Olivia/0000-0003-0262-5621; Habonimana, Gilbert/0000-0001-6167-0671	Inner City Health Associates, Toronto, Canada	Inner City Health Associates, Toronto, Canada	This systematic review was funded by Inner City Health Associates, Toronto, Canada. The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or the writing of the report. The corresponding author had full access to all of the data in the study and had final responsibility for the decision to submit for publication.	Aldridge RW, 2018, LANCET, V391, P241, DOI 10.1016/S0140-6736(17)31869-X; Andresen MA, 2010, INT J DRUG POLICY, V21, P70, DOI 10.1016/j.drugpo.2009.03.004; Baggett TP, 2013, JAMA INTERN MED, V173, P189, DOI 10.1001/jamainternmed.2013.1604; Bahji A, 2018, CAN J ADDICT, V9, P26, DOI 10.1097/CXA.0000000000000013; Bardwell G, 2017, INT J DRUG POLICY, V48, P27, DOI 10.1016/j.drugpo.2017.05.009; Bauer Leah K, 2016, J Health Care Poor Underserved, V27, P846, DOI 10.1353/hpu.2016.0075; Bayoumi AM, 2016, LANCET, V387, P1890, DOI 10.1016/S0140-6736(16)30308-7; Boucher LM, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0145-2; Bramley G., 2015, HARD EDGES MAPPING S; British Standards Institution Food Standards Agency & DEFRA, 2017, GUID CLIN MAN OP US, P1; Buccieri K., 2010, SOCIAL DEV ISSUES, V32, P1; Campbell DJT, 2015, BMC FAM PRACT, V16, DOI 10.1186/s12875-015-0361-3; Canadian Nurses Association, 2017, HARM RED ILL SUBST U; Canadian Observatory on Homelessness, 2012, CAN DEF HOM; Canavan R, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-222; Chimbar L, 2018, J ADDICT NURS, V29, P167, DOI 10.1097/JAN.0000000000000230; CLARK N, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002210; Coltman L, 2015, INTERSECT GLOB J SOC, V4; Committee ME, 2003, FIN REP EV SYDN MED; Dong KA, 2012, CAN J ADDICT, V3, P4; Drug Policy Alliance, 2018, SUP CONS SERV; Evans J, 2015, HEALTH PLACE, V33, P118, DOI 10.1016/j.healthplace.2015.02.011; Ezard N., 2015, FEASIBILITY MANAGED; Fairbairn N, 2019, CAN MED ASSOC J, V191, pE1049, DOI 10.1503/cmaj.190344; Fazel S, 2014, LANCET, V384, P1529, DOI 10.1016/S0140-6736(14)61132-6; Feng C, 2013, J ADOLESCENT HEALTH, V52, P499, DOI 10.1016/j.jadohealth.2012.07.011; Ferri M, 2006, J SUBST ABUSE TREAT, V30, P63, DOI 10.1016/j.jsat.2005.09.003; Frankish CJ, 2005, CAN J PUBLIC HEALTH, V96, pS23, DOI 10.1007/BF03403700; Government of Canada, 2008, VANC INSITE SERV OTH; Gowing L, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004145.pub4; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Haasen C, 2007, BRIT J PSYCHIAT, V191, P55, DOI 10.1192/bjp.bp.106.026112; Helm S, 2008, PAIN PHYSICIAN, V11, P225; Henwood BF, 2014, J BEHAV HEALTH SER R, V41, P80, DOI 10.1007/s11414-013-9318-2; Howie the Harp, 1990, PSYCHOSOC REHABIL, V13, P85, DOI [DOI 10.1037/H0099471, 10.1037/h0099471]; Hughes C., 2007, EFFECTS DECRIMINALIZ; Hwang SW, 2014, LANCET, V384, P1541, DOI 10.1016/S0140-6736(14)61133-8; Hwang SW, 2011, INT J PUBLIC HEALTH, V56, P609, DOI 10.1007/s00038-011-0283-3; Jackson LA, 2014, DRUG-EDUC PREV POLIC, V21, P244, DOI 10.3109/09687637.2013.870534; Johnson TP, 2007, AM J PREV MED, V32, pS211, DOI 10.1016/j.amepre.2007.02.015; Jones HE, 2012, ADDICTION, V107, P5, DOI 10.1111/j.1360-0443.2012.04035.x; Jozaghi E, 2013, SUBST ABUSE TREAT PR, V8, DOI 10.1186/1747-597X-8-25; Kaplan JL, 1999, ANN EMERG MED, V34, P42, DOI 10.1016/S0196-0644(99)70270-2; Karki Pramila, 2016, Evid Based Med Public Health, V2; Kelly AM, 2005, MED J AUSTRALIA, V182, P24, DOI 10.5694/j.1326-5377.2005.tb06550.x; Kennedy MC, 2017, CURR HIV-AIDS REP, V14, P161, DOI 10.1007/s11904-017-0363-y; Kerr D, 2009, ADDICTION, V104, P2067, DOI 10.1111/j.1360-0443.2009.02724.x; Kerr T, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0154-1; Khandor Erika, 2011, Open Med, V5, pe94; Khoury L, 2010, DEPRESS ANXIETY, V27, P1077, DOI 10.1002/da.20751; Kim HK, 2015, EXPERT OPIN DRUG SAF, V14, P1137, DOI 10.1517/14740338.2015.1037274; Kirchmayer U, 2002, ADDICTION, V97, P1241, DOI 10.1046/j.1360-0443.2002.00217.x; Klein A, 2015, DALHOUSIE LAW J, V38, P447; Klimas J, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025799; Kpade V, 2018, COCHRANE METHODS EQU; Krausz RM, 2013, SOC PSYCH PSYCH EPID, V48, P1235, DOI 10.1007/s00127-012-0649-8; Larney S, 2014, DRUG ALCOHOL REV, V33, P115, DOI 10.1111/dar.12095; Lobmaier P, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006140.pub2; Luchenski S, 2018, LANCET, V391, P266, DOI 10.1016/S0140-6736(17)31959-1; Lynn RR, 2018, THER ADV DRUG SAF, V9, P63, DOI 10.1177/2042098617744161; Maglione MA, 2018, J SUBST ABUSE TREAT, V89, P28, DOI 10.1016/j.jsat.2018.03.001; Magwood O, 2019, COCHRANE EQUITY METH; Marshall Z, 2015, DRUG ALCOHOL DEPEN, V151, P1, DOI 10.1016/j.drugalcdep.2015.03.002; Martins DC, 2008, PUBLIC HEALTH NURS, V25, P420, DOI 10.1111/j.1525-1446.2008.00726.x; Mattick RP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub3; Mattick RP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002209.pub2; McDonald R, 2016, ADDICTION, V111, P1177, DOI 10.1111/add.13326; McKnight I, 2007, AM J DRUG ALCOHOL AB, V33, P319, DOI 10.1080/00952990601175102; McNeil R, 2014, SOC SCI MED, V106, P151, DOI 10.1016/j.socscimed.2014.01.051; McVicar D, 2015, SOC SCI MED, V136, P89, DOI 10.1016/j.socscimed.2015.05.005; Meges D, 2014, ADAPTING YOUR PRACTI, DOI [10.1186/s13011-016-0052-7, DOI 10.1186/S13011-016-0052-7]; Mema SC, 2019, HARM REDUCT J, V16, DOI 10.1186/s12954-018-0273-3; Mericle AA, 2016, J DUAL DIAGN, V12, P150, DOI 10.1080/15504263.2016.1176408; Milby JB, 2008, J SUBST ABUSE TREAT, V34, P180, DOI 10.1016/j.jsat.2007.03.003; Millman M, 1993, ACCESS HLTH CARE AM; Milloy MJ, 2012, AIDS PATIENT CARE ST, V26, P60, DOI 10.1089/apc.2011.0169; Milloy MJ, 2009, ADDICTION, V104, P620, DOI 10.1111/j.1360-0443.2009.02541.x; Minozzi S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001333.pub4; Moberg J, 2018, HEALTH RES POLICY SY, V16, DOI 10.1186/s12961-018-0320-2; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Muckle W, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006747.pub2; Mueller SR, 2015, SUBST ABUS, V36, P240, DOI 10.1080/08897077.2015.1010032; Nielsen E, 2018, HARM REDUCTION INTER; Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4; Oviedo-Joekes E, 2009, NEW ENGL J MED, V361, P777, DOI 10.1056/NEJMoa0810635; Palepu A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075133; Palepu A, 2011, J URBAN HEALTH, V88, P545, DOI 10.1007/s11524-011-9562-9; Paquette K, 2016, J DUAL DIAGN, V12, P153, DOI 10.1080/15504263.2016.1175262; Patterson ML, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003442; Pauly BB, 2018, DRUG ALCOHOL REV, DOI [10.1016/j.jsat.2007.03.003, DOI 10.1016/J.JSAT.2007.03.003]; Pauly BB, 2016, HARM REDUCT J, V13, DOI 10.1186/s12954-016-0102-5; Pauly B, 2013, INT J DRUG POLICY, V24, P284, DOI 10.1016/j.drugpo.2013.03.008; Perry D, 2019, CAN FAM PHYSICIAN, V65, P117; Pettes T, 2010, J SUBST ABUSE TREAT, V39, P174, DOI 10.1016/j.jsat.2010.05.001; Pietrusza LM, 2018, J ADDICT NURS, V29, P188, DOI 10.1097/JAN.0000000000000235; Platt L, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012021.pub2; Pollock M., 2018, COCHRANE HDB SYSTEMA; Popay J, 2006, GUIDANCE CONDUCT NAR, DOI DOI 10.13140/2.1.1018.4643; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; Rhodes T, 2009, INT J DRUG POLICY, V20, P193, DOI 10.1016/j.drugpo.2008.10.003; Roozen HG, 2006, EUR NEUROPSYCHOPHARM, V16, P311, DOI 10.1016/j.euroneuro.2005.11.001; RUPREHT J, 1984, J TOXICOL-CLIN TOXIC, V21, P387, DOI 10.3109/15563658308990429; Rush B, 2019, J STUD ALCOHOL DRUGS, P9; Saulle R, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011983.pub2; Shannon K, 2008, INT J DRUG POLICY, V19, P140, DOI 10.1016/j.drugpo.2007.11.024; Shea BJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4008; Shoemaker E, ESTABLISHING NEED PO; Simoens S, 2005, BRIT J GEN PRACT, V55, P139; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Srivastava A, 2017, CAN FAM PHYSICIAN, V63, P200; Strang J, 2015, BRIT J PSYCHIAT, V207, P5, DOI 10.1192/bjp.bp.114.149195; Strike C, 2016, SUBST ABUSE TREAT PR, V11, DOI 10.1186/s13011-016-0052-7; Strike C, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0060-3; Strike C, 2014, ADDICTION, V109, P946, DOI 10.1111/add.12506; Thomas CP, 2014, PSYCHIAT SERV, V65, P158, DOI 10.1176/appi.ps.201300256; Tremblay J, 2019, J STUD ALCOHOL DRUGS, P64; Truong M, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-99; U.S. Department of Health and Human Services O of DP and HP, 2020, HLTH PEOPL 2020; Vakharia SP, 2017, CLIN SOC WORK J, V45, P65, DOI 10.1007/s10615-016-0584-3; van Boekel LC, 2013, DRUG ALCOHOL DEPEN, V131, P23, DOI 10.1016/j.drugalcdep.2013.02.018; Weinmann Stefan, 2004, Z Arztl Fortbild Qualitatssich, V98, P673; Wilder C, 2015, DRUG ALCOHOL DEPEN, V149, P225, DOI 10.1016/j.drugalcdep.2015.02.012	122	33	33	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2020	15	1							e0227298	10.1371/journal.pone.0227298	http://dx.doi.org/10.1371/journal.pone.0227298			31	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP5PQ	31945092	Green Published, gold, Green Submitted			2023-01-03	WOS:000534370100027
J	Truchetti, G; Otis, C; Brisville, AC; Beauchamp, G; Pang, D; Troncy, E				Truchetti, Geoffrey; Otis, Colombe; Brisville, Anne-Claire; Beauchamp, Guy; Pang, Daniel; Troncy, Eric			Management of veterinary anaesthesia in small animals: A survey of current practice in Quebec	PLOS ONE			English	Article							RISK-FACTORS; CONFIDENTIAL INQUIRY; POSTANESTHETIC HYPOTHERMIA; PAIN MANAGEMENT; PET OWNERS; DOGS; DEATH; COMPLICATIONS; GUIDELINES; MORTALITY	Objective To describe how small animal anaesthesia is performed in French-speaking Eastern Canada, and the variations between practices, in particular based on practice type, veterinarian gender and experience. Design Observational study, survey. Sample 156 respondents. Procedure A questionnaire was designed to assess current small animal anaesthesia practices in French-speaking Eastern Canada, mainly in the province of Quebec. The questionnaire was available through SurveyMonkey, and consisted of four parts: demographic information about the veterinarians surveyed, evaluation and management of anaesthetic risk, anaesthesia procedure, monitoring and safety. Gender, year of graduation, and type of practice were tested as potential risk factors. Chi-square exact test was used to study relations between each risk factor, and the effect of the selected risk factor on each response of the survey. For ordinal data, the Cochran-Mantel-Haenszel test was used to maximize power. Results Response rate over a period of 3 months was 20.85% (156 respondents). Overall, the way anaesthesia is performed by most respondents does not meet international guidelines, such as patient preparation and evaluation prior to anaesthesia, not using individualised protocols (for 41%), not obtaining intravenous access (12.4% use it for all their anaesthesia in cats, and 30.6% in dogs), lack of patient monitoring at certain intervals for 55% of the responses, and client prompted optional analgesia (for 29% of respondents). Some practices are more compliant than others. Among them, referral centres generally offer better care than general practices. Conclusions and clinical relevance The level of care in anaesthesia and analgesia in practices in French-speaking Eastern Canada is concerning, highlighting the need for more sustained continuing education.	[Truchetti, Geoffrey] Ctr Vet Rive Sud, Brossard, PQ, Canada; [Otis, Colombe; Beauchamp, Guy; Pang, Daniel; Troncy, Eric] Univ Montreal, Fac Vet Med, Grp Rech Pharmacol Anim Quebec GREPAQ, St Hyacinthe, PQ, Canada; [Brisville, Anne-Claire] Boehringer Ingelheim Anim Hlth, Bovine Unit, Burlington, ON, Canada	Universite de Montreal	Troncy, E (corresponding author), Univ Montreal, Fac Vet Med, Grp Rech Pharmacol Anim Quebec GREPAQ, St Hyacinthe, PQ, Canada.	eric.troncy@umontreal.ca	Troncy, Eric/J-6650-2013	Troncy, Eric/0000-0003-0209-5261; Pang, Daniel/0000-0002-6420-477X	Natural Sciences and Engineering Research Council (NSERC) of Canada [441651-2013, RDCPJ 491953-2016]; MITACS Canada Elevation postdoctoral scholarship [IT11643]	Natural Sciences and Engineering Research Council (NSERC) of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); MITACS Canada Elevation postdoctoral scholarship	There was not proprietary interest or funding directly provided for this project or to any of the authors. This work was indirectly supported (ET) by a Discovery grant (#441651-2013, supporting salaries) and a Collaborative Research and Development grant (#RDCPJ 491953-2016 supporting operations and salaries in partnership with ArthroLab Inc.) from the Natural Sciences and Engineering Research Council (NSERC) of Canada. CO is a recipient of a MITACS Canada Elevation postdoctoral scholarship (#IT11643). ACB received support in the form of salary from the Boehringer Ingelheim Animal Health, but she did participate in the survey outside of her regular tasks for the employer, which had in consequence no role in the present study. The authors got support from the company Dispomed Inc., i.e. to deliver the electronic survey to their clients, with the previous approval of the Ordre des me ' decins ve ' te ' rinaires du Que ' bec. The specific roles of all authors are articulated in the 'author contributions' section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American College of Veterinary Anesthesia and Analgesia, 2009, SMALL AN MON GUID; Association of American Veterinary Medical College, 2019, AAVMCS 2018 2019 ANN; Bednarski R, 2011, J AM ANIM HOSP ASSOC, V47, P377, DOI 10.5326/JAAHA-MS-5846; Bille C, 2012, VET ANAESTH ANALG, V39, P59, DOI 10.1111/j.1467-2995.2011.00686.x; Brodbelt DC, 2007, BRIT J ANAESTH, V99, P617, DOI 10.1093/bja/aem229; Brodbelt D.C., 2015, LUMB JONESVETERINARY, P11; Brodbelt DC, 2008, JAVMA-J AM VET MED A, V233, P1096, DOI 10.2460/javma.233.7.1096; Brodbelt DC, 2008, VET ANAESTH ANALG, V35, P365, DOI 10.1111/j.1467-2995.2008.00397.x; Brodbelt DC, 2006, VET REC, V158, P563, DOI 10.1136/vr.158.16.563; Carter JE, 2017, J AM ANIM HOSP ASSOC, V53, P206, DOI [10.5326/JAAHA-MS-6512, 10.5326/jaaha-ms-6512]; Clark WT, 2002, AUST VET J, V80, P37, DOI 10.1111/j.1751-0813.2002.tb12830.x; Clarke K. W., 1990, Journal of the Association of Veterinary Anaesthetists of Great Britain and Ireland, V17, P4; Duke-Novakovski T., 2016, BSAVA MANUAL CANINE; Dyson DH, 1998, J AM ANIM HOSP ASSOC, V34, P325, DOI 10.5326/15473317-34-4-325; Epstein M, 2015, J AM ANIM HOSP ASSOC, V51, P67, DOI 10.5326/JAAHA-MS-7331; Gaynor JS, 1999, J AM ANIM HOSP ASSOC, V35, P13, DOI 10.5326/15473317-35-1-13; Gil L, 2013, VET ANAESTH ANALG, V40, pE57, DOI 10.1111/vaa.12059; Hall LW, 2000, VET ANAESTHESIA; Hallqvist L, 2018, EUR J ANAESTH, V35, P273, DOI 10.1097/EJA.0000000000000735; Hallqvist L, 2016, EUR J ANAESTH, V33, P450, DOI 10.1097/EJA.0000000000000429; Hewson CJ, 2006, CAN VET J, V47, P453; Hosgood G, 2002, J VET EMERG CRIT CAR, V12, P9, DOI 10.1046/j.1534-6935.2002.00002.x; Hosgood G, 2007, J VET EMERG CRIT CAR, V8, P222, DOI DOI 10.1111/J.1476-4431.1998.TB00128.X; Iadarola MJ, 2018, PAIN, V159, P2105, DOI 10.1097/j.pain.0000000000001314; Joubert KE, 2007, J S AFR VET ASSOC, V78, P31; Mathews K, 2014, J SMALL ANIM PRACT, V55, pE10, DOI 10.1111/jsap.12200; Matthews NS, 2017, JAVMA-J AM VET MED A, V250, P655, DOI 10.2460/javma.250.6.655; Mckelvey D., 2003, VET ANAESTH ANALG; Oliver JAC, 2010, VET OPHTHALMOL, V13, P244, DOI 10.1111/j.1463-5224.2010.00793.x; Redondo JI, 2007, J VET MED A, V54, P470, DOI 10.1111/j.1439-0442.2007.00987.x; Redondo JI, 2012, VET REC, V171, P374, DOI 10.1136/vr.100476; Redondo JI, 2012, VET REC, V170, P206, DOI 10.1136/vr.100184; Robertson SA, 2018, J FELINE MED SURG, V20, P602, DOI [10.1177/1098612X18781391, 10.1177/1098612x18781391]; SAWYER DC, 1991, AM J VET RES, V52, P1826; SAWYER DC, 1987, J AM ANIM HOSP ASSOC, V23, P438; Seymour C, 2007, BSAVA MANUAL CANINE; Simon BT, 2018, VET SURG, V47, P277, DOI 10.1111/vsu.12753; Steagall PV, 2017, J SMALL ANIM PRACT, V58, P380, DOI 10.1111/jsap.12674; Wagner AE, 2003, J AM VET MED ASSOC, V223, P1426, DOI 10.2460/javma.2003.223.1426; Warne LN, 2018, AUST VET J, V96, P413, DOI 10.1111/avj.12762	40	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2020	15	1							e0227204	10.1371/journal.pone.0227204	http://dx.doi.org/10.1371/journal.pone.0227204			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5PQ	31945076	Green Published, gold			2023-01-03	WOS:000534370100024
J	Lahmann, AL; Bongiovanni, D; Berkefeld, A; Kettern, M; Martinez, L; Okrojek, R; Hoppmann, P; Laugwitz, KL; Mayr, P; Cassese, S; Byrne, R; Kutner, S; Xhepal, E; Schunkert, H; Kastrati, A; Joner, M				Lahmann, Anna Lena; Bongiovanni, Dario; Berkefeld, Anna; Kettern, Maximilian; Martinez, Lucas; Okrojek, Rainer; Hoppmann, Petra; Laugwitz, Karl-Ludwig; Mayr, Patrick; Cassese, Salvatore; Byrne, Robert; Kutner, Sebastian; Xhepal, Erion; Schunkert, Heribert; Kastrati, Adnan; Joner, Michael			Predicting factors for long-term survival in patients with out-of-hospital cardiac arrest - A propensity score-matched analysis	PLOS ONE			English	Article							CARDIOPULMONARY-RESUSCITATION; MYOCARDIAL-INFARCTION; COMATOSE SURVIVORS; OUTCOMES; CATHETERIZATION; CARE; ASSOCIATION; IMPACT; HEART; LIFE	Background Out-of-hospital cardiac arrest (OHCA) is one of the leading causes of death worldwide, with acute coronary syndromes accounting for most of the cases. While the benefit of early revascularization has been clearly demonstrated in patients with ST-segment-elevation myocardial infarction (STEMI), diagnostic pathways remain unclear in the absence of STEMI. We aimed to characterize OHCA patients presenting to 2 tertiary cardiology centers and identify predicting factors associated with survival. Methods We retrospectively analyzed 519 patients after OHCA from February 2003 to December 2017 at 2 centers in Munich, Germany. Patients undergoing immediate coronary angiography (CAG) were compared to those without. Multivariate regression analysis and inverse probability treatment weighting (IPTW) were performed to identify predictors for improved outcome in a matched population. Results Immediate CAG was performed in 385 (74.1%) patients after OHCA with presumed cardiac cause of arrest. As a result of multivariate analysis after propensity score matching, we found that immediate CAG, return of spontaneous circulation (ROSC) at admission, witnessed arrest and former smoking were associated with improved 30-days-survival [(OR, 0.46; 95% CI, 0.26-0.84), (OR, 0.21; 95% CI, 0.10-0.45), (OR, 0.50; 95% CI, 0.26-0.97), (OR, 0.43; 95% CI, 0.23-0.81)], and 1-year-survival [(OR, 0.39; 95% CI, 0.19-0.82), (OR, 0.29; 95% CI, 0.12-0.7), (OR, 0.43; 95% CI, 0.2-1.00), (OR, 0.3; 95% CI, 0.14-0.63)]. Conclusions In our study, immediate CAG, ROSC at admission, witnessed arrest and former smoking were independent predictors of survival in cardiac arrest survivors. Improvement in prehospital management including bystander CPR and best practice post-resuscitation care with optimized triage of patients to an early invasive strategy may help ameliorate overall outcome of this critically-ill patient population.	[Lahmann, Anna Lena; Kettern, Maximilian; Martinez, Lucas; Cassese, Salvatore; Byrne, Robert; Kutner, Sebastian; Xhepal, Erion; Schunkert, Heribert; Kastrati, Adnan; Joner, Michael] Tech Univ Munich, German Heart Ctr Munich, Dept Cardiol, Munich, Germany; [Bongiovanni, Dario; Berkefeld, Anna; Okrojek, Rainer; Hoppmann, Petra; Laugwitz, Karl-Ludwig] Tech Univ Munich, Dept Cardiol, Klinikum Rechts Isar, Munich, Germany; [Laugwitz, Karl-Ludwig; Schunkert, Heribert; Kastrati, Adnan; Joner, Michael] DZHK German Ctr Cardiovasc Res, Partner Site Munich Heart Alliance, Munich, Germany; [Mayr, Patrick] Tech Univ Munich, German Heart Ctr Munich, Dept Anesthesiol, Munich, Germany	German Heart Centre Munich; Technical University of Munich; Technical University of Munich; German Centre for Cardiovascular Research; Munich Heart Alliance; German Heart Centre Munich; Technical University of Munich	Lahmann, AL (corresponding author), Tech Univ Munich, German Heart Ctr Munich, Dept Cardiol, Munich, Germany.	annalena@lahmann.at	Mayr, N. Patrick/C-7389-2017; Bongiovanni, Dario/AAB-9161-2021; Joner, Michael/AAR-1229-2021; Xhepa, Erion/GQA-5562-2022; Xhepa, Erion/N-4435-2016	Mayr, N. Patrick/0000-0002-3549-3007; Bongiovanni, Dario/0000-0002-4162-1482; Xhepa, Erion/0000-0002-0728-2819				ABRAMSON NS, 1988, CRIT CARE MED, V16, P1053, DOI 10.1097/00003246-198810000-00019; Adrie C, 2006, EUR HEART J, V27, P2840, DOI 10.1093/eurheartj/ehl335; Anyfantakis ZA, 2009, AM HEART J, V157, P312, DOI 10.1016/j.ahj.2008.09.016; Atwood C, 2005, RESUSCITATION, V67, P75, DOI 10.1016/j.resuscitation.2005.03.021; Berdowski J, 2010, RESUSCITATION, V81, P1479, DOI 10.1016/j.resuscitation.2010.08.006; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Blom MT, 2014, CIRCULATION, V130, P1868, DOI 10.1161/CIRCULATIONAHA.114.010905; Bunch TJ, 2003, NEW ENGL J MED, V348, P2626, DOI 10.1056/NEJMoa023053; Camuglia AC, 2014, RESUSCITATION, V85, P1533, DOI 10.1016/j.resuscitation.2014.08.025; Dumas F, 2010, CIRC-CARDIOVASC INTE, V3, P200, DOI 10.1161/CIRCINTERVENTIONS.109.913665; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; GRUBB NR, 1995, LANCET, V346, P417, DOI 10.1016/S0140-6736(95)92784-0; Gupta T, 2014, AM J CARDIOL, V114, P169, DOI 10.1016/j.amjcard.2014.04.021; Hollenbeck RD, 2014, RESUSCITATION, V85, P88, DOI 10.1016/j.resuscitation.2013.07.027; Jacobs I, 2004, RESUSCITATION, V63, P233, DOI 10.1016/j.resuscitation.2004.09.008; Kern KB, 2015, JACC-CARDIOVASC INTE, V8, P1031, DOI 10.1016/j.jcin.2015.02.021; Kragholm K, 2017, NEW ENGL J MED, V376, P1737, DOI 10.1056/NEJMoa1601891; Rittenberger JC, 2011, RESUSCITATION, V82, P1036, DOI 10.1016/j.resuscitation.2011.03.034; Roberts Alexandra, 2014, Nat Rev Cardiol, V11, P374, DOI 10.1038/nrcardio.2014.73; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; Soholm H, 2015, CIRC-CARDIOVASC QUAL, V8, P268, DOI 10.1161/CIRCOUTCOMES.115.001767; Steg PG, 2012, EUR HEART J, V33, P2569, DOI 10.1093/eurheartj/ehs215; Stiell I, 2003, CIRCULATION, V108, P1939, DOI 10.1161/01.CIR.0000095028.95929.B0; Stiell IG, 2004, NEW ENGL J MED, V351, P647, DOI 10.1056/NEJMoa040325; Strote JA, 2012, AM J CARDIOL, V109, P451, DOI 10.1016/j.amjcard.2011.09.036; Wibrandt I, 2015, BMC EMERG MED, V15, DOI 10.1186/s12873-015-0028-3; Zanuttini D, 2012, AM J CARDIOL, V110, P1723, DOI 10.1016/j.amjcard.2012.08.006	27	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2020	15	1							e0218634	10.1371/journal.pone.0218634	http://dx.doi.org/10.1371/journal.pone.0218634			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5OV	31940337	Green Submitted, Green Published, gold			2023-01-03	WOS:000534368000001
J	Salam, T; Duhig, A; Patel, AA; Cameron, A; Voelker, J; Bookhart, B; Coleman, CI				Salam, Tabassum; Duhig, Amy; Patel, Aarti A.; Cameron, Ann; Voelker, Jennifer; Bookhart, Brahim; Coleman, Craig I.			Physicians' perspectives regarding non-medical switching of prescription medications: Results of an internet e-survey	PLOS ONE			English	Article							CARE	Background Physicians are in an ideal position to describe the impact of medication non-medical switching (switching commonly due to formulary changes by insurer for reasons unrelated to patient health) on their practice dynamics and patient care. We sought to examine physicians' openness to requests for non-medical switching and their experiences and opinions regarding the impact of non-medical switching on their practice, staff and patients. Methods An online survey of randomly-sampled physicians spending >= 10% of time providing patient care and having received >= 1 non-medical switch request during the prior 12-months. The impact of non-medical switching on clinical decision-making process; professional experience with clinical practice, patient-physician relationship, insurance process; and perceived impact on practice, staff and patients were assessed. Weighted percent responses were calculated. Results We sampled 1,010 physicians (response rate = 55.5%). Many responded being frequently not amenable (26.0%) or had reservations (41.8%) to non-medical switch requests; with > 50% indicating patient stability on current therapy and suboptimal alternatives as factors frequently influencing amenability. Physicians agreed non-medical switching can create ethical concerns (clinical judgement, autonomy, ability to treat per guidelines; 74.8%, 82.3%, 53.5%, respectively), while forcing them to take responsibility for insurers' decisions (81.1%) and diverting their clinical time (84.3%). Most indicated non-medical switching increased practice burden (administrative, non-billable interactions, additional staffing, non-office patient contact, calls to/from the pharmacy; 85.0%, 72.5%, 62.2%, 64.2%, 69.5%, respectively). Physicians felt insurer processes discouraged non-medical switch challenges (76.7%) and required inconvenient lengths-of-time (76.1%) speaking to insurer representatives without proper expertise (62.0%). They believed non-medical switching negatively impacted aspects of care (effectiveness, side-effects, medication adherence and abandonment, out-of-pocket costs, medication errors; 46.5%, 53.2%, 50.6%, 49.4%, 59.6%, 54.5%, respectively). Conclusions Physicians were frequently not amenable or had reservations regarding non-medical switching. They noted ethical concerns due to non-medical switching. Most felt non-medical switches burdened their practice and negatively impacted care.	[Salam, Tabassum] Amer Coll Physicians, Med Educ, Philadelphia, PA USA; [Duhig, Amy; Cameron, Ann] Xcenda, Consulting Serv, Palm Harbor, FL USA; [Patel, Aarti A.; Voelker, Jennifer; Bookhart, Brahim] Janssen Sci Affairs LLC, Titusville, NJ USA; [Coleman, Craig I.] Univ Connecticut, Sch Pharm, Storrs, CT 06269 USA; [Coleman, Craig I.] Hartford Hosp, Evidence Based Practice Ctr, Hartford, CT 06115 USA	American College of Physicians; AmerisourceBergen Corporation; Xcenda, LLC; Johnson & Johnson; Janssen Pharmaceuticals; University of Connecticut; Hartford Hospital	Coleman, CI (corresponding author), Univ Connecticut, Sch Pharm, Storrs, CT 06269 USA.; Coleman, CI (corresponding author), Hartford Hosp, Evidence Based Practice Ctr, Hartford, CT 06115 USA.	craig.coleman@hhchealth.org		Coleman, Craig/0000-0003-4868-7158	Janssen Scientific Affairs, Inc	Janssen Scientific Affairs, Inc	Financial support for this research was provided by Janssen Scientific Affairs, Inc, to Xcenda, a health economics consultancy providing services to the life science industry. In their role as coauthors, Drs Patel, Voelker and Mr. Bookhart of the funding body contributed to design and conduct of the study; management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	Allery LA, 2016, EDUC PRIM CARE, V27, P234, DOI 10.1080/14739879.2016.1175914; American Medical Association, H125991 AM MED ASS; American Medical Association, 2017, PRIOR AUTH UT MAN RE; [Anonymous], 2018, SPECIAL COMMISSION S; [Anonymous], 2018, CRIS HLTH CAR CALL A; [Anonymous], 2019, PROFESSIONALLY ACTIV; [Anonymous], 2017, RES REPORT; [Anonymous], PAT PAP; [Anonymous], 2018, PUTT PROF PAT PROV P; [Anonymous], NUMB PRACT PRIM CAR; Association AM, 2019, AMA PRIOR AUTH PA PH; Association of American Medical Colleges, 2018, 2018 PHYS SPEC DAT R; Bodenheimer T, 2014, ANN FAM MED, V12, P573, DOI 10.1370/afm.1713; Centers for Medicare and Medicaid Services, PAT PAP; Consumer Reports National Research Center, 2015, SURPRISE MEDICAL BIL; Dalen JE, 2017, AM J MED, V130, P766, DOI 10.1016/j.amjmed.2017.01.026; *DOCT PAT RIGHTS P, 2017, NOT WHAT DOCT ORD BA; Erickson SM, 2017, ANN INTERN MED, V166, P659, DOI 10.7326/M16-2697; Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34; Gray T, 2005, PHARMACOTHERAPY, V25, P1666, DOI 10.1592/phco.2005.25.11.1666; Han S, 2019, ANN INTERN MED, V170, P784, DOI 10.7326/M18-1422; HOLT D, 1979, J ROY STAT SOC A STA, V142, P33, DOI 10.2307/2344652; Nguyen E, 2016, CURR MED RES OPIN, V32, P1281, DOI 10.1185/03007995.2016.1170673; Nickel WK, 2018, ANN INTERN MED, V169, P796, DOI 10.7326/M18-0018; Phillips AW, 2016, MED TEACH, V38, P217, DOI 10.3109/0142159X.2015.1105945; Young A, 2017, J MED REGUL, V103, P7, DOI 10.30770/2572-1852-103.2.7	26	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 10	2020	15	1							e0225867	10.1371/journal.pone.0225867	http://dx.doi.org/10.1371/journal.pone.0225867			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5IB	31923201	gold, Green Published			2023-01-03	WOS:000534350000010
J	Vanstone, M; Neville, TH; Clarke, FJ; Swinton, M; Sadik, M; Takaoka, A; Smith, O; Baker, AJ; LeBlanc, A; Foster, D; Dhingra, V; Phung, P; Xu, XQ; Kao, YH; Heels-Ansdell, D; Tam, B; Toledo, F; Boyle, A; Cook, DJ				Vanstone, Meredith; Neville, Thanh H.; Clarke, France J.; Swinton, Marilyn; Sadik, Marina; Takaoka, Alyson; Smith, Orla; Baker, Andrew J.; LeBlanc, Allana; Foster, Denise; Dhingra, Vinay; Phung, Peter; Xu, Xueqing (Sherry); Kao, Yuhan; Heels-Ansdell, Diane; Tam, Benjamin; Toledo, Feli; Boyle, Anne; Cook, Deborah J.			Compassionate End-of-Life Care: Mixed-Methods Multisite Evaluation of the 3 Wishes Project	ANNALS OF INTERNAL MEDICINE			English	Article							FAMILY-MEMBERS; POSTTRAUMATIC STRESS; UNIT; BURNOUT; STAFF	Background: The 3 Wishes Project (3WP) is an end-of-life program that aims to honor the dignity of dying patients by creating meaningful patient- and family-centered memories while promoting humanistic interprofessional care. Objective: To determine whether this palliative intervention could be successfully implemented-defined as demonstrating value, transferability, affordability, and sustainability-beyond the intensive care unit in which it was created. Design: Mixed-methods formative program evaluation. (Clinical Trials.gov: NCT04147169) Setting: 4 North American intensive care units. Participants: Dying patients, their families, clinicians, hospital managers, and administrators. Intervention: Wishes from dying patients, family members, and clinicians were elicited and implemented. Measurements: Patient characteristics and processes of care; the number, type, and cost of each wish; and semistructured interviews and focus groups with family members, clinicians, and managers. Results: A total of 730 patients were enrolled, and 3407 wishes were elicited. Qualitative data were gathered from 75 family members, 72 clinicians, and 20 managers or hospital administrators. Value included intentional comforting of families as they honored the lives and legacies of their loved ones while inspiring compassionate clinical care. Factors promoting transferability included family appreciation and a collaborative intensive care unit culture committed to dignity-conserving end-of-life care. Staff participation evolved from passive support to professional agency. Program initiation required minimal investment for reusable materials; thereafter, the mean cost was $5.19 (SD, $17.14) per wish. Sustainability was demonstrated by the continuation of 3WP at each site after study completion. Limitation: This descriptive formative evaluation describes tertiary care center-specific experiences rather than aiming for generalizability to all jurisdictions. Conclusion: The 3WP is a transferrable, affordable, and sustainable program that provides value to dying patients, their families, clinicians, and institutions.	[Vanstone, Meredith; Clarke, France J.; Swinton, Marilyn; Sadik, Marina; Takaoka, Alyson; Heels-Ansdell, Diane] McMaster Univ, Room 2C11,1200 Main St West, Hamilton, ON L8N 3Z5, Canada; [Neville, Thanh H.; Phung, Peter; Xu, Xueqing (Sherry); Kao, Yuhan] Univ Calif Los Angeles, 43-229 Ctr Hlth Sci,BOX 951690, Los Angeles, CA 90095 USA; [Smith, Orla; Baker, Andrew J.] St Michaels Hosp, 4 Cardinal Carter North 30 Bond St, Toronto, ON M5B 1W8, Canada; [LeBlanc, Allana] Vancouver Coastal Hlth, Vancouver, BC, Canada; [Foster, Denise; Dhingra, Vinay] Univ British Columbia, Vancouver, BC, Canada; [Tam, Benjamin] Niagara Hlth, 1200 Fourth Ave, St Catharines, ON L2S 0A9, Canada; [Toledo, Feli] St Josephs Healthcare, Bishop Dowling Wing,Level 1,Room D-173, Hamilton, ON L8N 4A6, Canada; [Boyle, Anne; Cook, Deborah J.] McMaster Univ, St Josephs Healthcare, Hamilton, ON, Canada; [Vanstone, Meredith] McMaster Univ, 100 Main St West,DBHSC 5003E, Hamilton, ON L8P 1H6, Canada; [Clarke, France J.; Swinton, Marilyn; Takaoka, Alyson; Heels-Ansdell, Diane; Cook, Deborah J.] McMaster Univ, Med Ctr, 1280 Main St West,2C Area, Hamilton, ON L8S 4K1, Canada; [Sadik, Marina] McMaster Univ, DBHSC 5th Floor,100 Main St West, Hamilton, ON L8P 1H6, Canada; [Baker, Andrew J.] St Michaels Hosp, 300 Bond St, Toronto, ON M5B 1W8, Canada; [LeBlanc, Allana; Foster, Denise; Dhingra, Vinay] Jim Pattison Pavill,899 West 12th Ave, Vancouver, BC V5Z 1M9, Canada; [Phung, Peter; Xu, Xueqing (Sherry); Kao, Yuhan] Univ Calif Los Angeles, 757 Westwood Plaza, Los Angeles, CA 90095 USA; [Boyle, Anne] St Josephs Hosp, 50 Charlton Ave East,Fontbonne Bldg,8th Floor, Hamilton, ON L8N 4A6, Canada	McMaster University; University of California System; University of California Los Angeles; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Vancouver Coastal Health Research Institute; University of British Columbia; McMaster University; McMaster University; McMaster University; McMaster University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of California System; University of California Los Angeles; McGill University; McMaster University	Cook, DJ (corresponding author), McMaster Univ, Room 2C11,1200 Main St West, Hamilton, ON L8N 3Z5, Canada.; Cook, DJ (corresponding author), McMaster Univ, Med Ctr, 1280 Main St West,2C Area, Hamilton, ON L8S 4K1, Canada.	debcook@mcmaster.ca	neville, thanh/AAZ-9402-2020	neville, thanh/0000-0002-8506-7591	Greenwall Foundation; California State University Institute for Palliative Care	Greenwall Foundation; California State University Institute for Palliative Care	This study was funded by a grant from the Greenwall Foundation. The UCLA program was partially supported by the California State University Institute for Palliative Care and donations from philanthropists. The St. Joseph's Healthcare program was partially supported by donations from the ICU staff and the Canadian Institutes of Health Research.	3 Wishes Project Team, 2017, 3 WISH PROJ START GU; Albright K, 2013, ACAD PEDIATR, V13, P400, DOI 10.1016/j.acap.2013.06.010; Alonso-Ovies A, 2016, INTENS CARE MED, V42, P591, DOI 10.1007/s00134-015-4023-7; Anderson WG, 2008, J GEN INTERN MED, V23, P1871, DOI 10.1007/s11606-008-0770-2; Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; Birt L, 2016, QUAL HEALTH RES, V26, P1802, DOI 10.1177/1049732316654870; Centofanti J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010626; Cook D, 2015, ANN INTERN MED, V163, P271, DOI 10.7326/M15-0502; Davidson JE, 2012, CRIT CARE MED, V40, P618, DOI 10.1097/CCM.0b013e318236ebf9; Di Gangi S, 2013, J CRIT CARE, V28, P483, DOI 10.1016/j.jcrc.2012.11.001; Dzau VJ, 2018, NEW ENGL J MED, V378, P312, DOI 10.1056/NEJMp1715127; Elo S, 2008, J ADV NURS, V62, P107, DOI 10.1111/j.1365-2648.2007.04569.x; Flannery L, 2016, AUST CRIT CARE, V29, P97, DOI 10.1016/j.aucc.2015.07.004; Galvin IM, 2018, CAN J ANESTH, V65, P1348, DOI 10.1007/s12630-018-1227-7; Geller Gail, 2015, Narrat Inq Bioeth, V5, p27A, DOI 10.1353/nib.2015.0001; Hartog CS, 2018, CURR OPIN ANESTHESIO, V31, P195, DOI 10.1097/ACO.0000000000000557; Hayes H, 2011, J AM BOARD FAM MED, V24, P576, DOI 10.3122/jabfm.2011.05.110043; Neergaard MA, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-52; Neville TH, 2019, J PALLIAT MED, V22, P1561, DOI 10.1089/jpm.2019.0135; Pereira SM, 2011, NURS ETHICS, V18, P317, DOI 10.1177/0969733011398092; Perlo J, 2017, IHI FRAMEWORK IMPROV, P3; Riegel M, 2019, AUST CRIT CARE, V32, P442, DOI 10.1016/j.aucc.2018.12.002; Rushton CH, 2016, AACN ADV CRIT CARE, V27, P111, DOI 10.4037/aacnacc2016275; Sandelowski M, 2000, RES NURS HEALTH, V23, P334, DOI 10.1002/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G; Schwarzkopf D, 2015, J CRIT CARE, V30, P187, DOI 10.1016/j.jcrc.2014.09.015; Seaman JB, 2018, JAMA-J AM MED ASSOC, V320, P1981, DOI 10.1001/jama.2018.14285; Stetler CB, 2006, J GEN INTERN MED, V21, pS1, DOI [10.1007/s11606-006-0267-9, 10.1111/j.1525-1497.2006.00355.x]; Swinton M, 2017, AM J RESP CRIT CARE, V195, P198, DOI [10.1164/rccm.201606-110200, 10.1164/rccm.201606-1102OC]; Vanstone Meredith, 2016, BMJ Support Palliat Care, DOI 10.1136/bmjspcare-2016-001179	29	19	20	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 7	2020	172	1					1	+		10.7326/M19-2438	http://dx.doi.org/10.7326/M19-2438			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB7DC	31711111				2023-01-03	WOS:000506650200003
J	Elliott, L; Haddock, CK; Campos, S; Benoit, E				Elliott, Luther; Haddock, Christopher Keith; Campos, Stephanie; Benoit, Ellen			Polysubstance use patterns and novel synthetics: A cluster analysis from three US cities	PLOS ONE			English	Article							KHAT CATHA-EDULIS; BATH SALTS; PSYCHOACTIVE SUBSTANCES; GAMMA-HYDROXYBUTYRATE; DRUG-USERS; UNITED-STATES; COCAINE USE; ALCOHOL; PSYCHOSIS; ABUSE	The rapid emergence of novel psychoactive substances within the past decade has raised new concerns about the harms associated with unregulated drug use. Synthetic analogueschemically related to established psychoactive substances like cannabis sativa and catha edulis-in particular have proliferated rapidly, allowing little opportunity for scientific research or the establishment of informal guidelines for safe use among consumers. To explore how synthetic substance use relates to other forms of use, this paper presents an analysis of polysubstance use among a sample of 676 people who use illicit substances in the United States. Participants were sampled from three greater metropolitan areas (Houston/Galveston, Texas; New York City; and New Orleans, Louisiana). Study researchers used cluster-type analyses to develop dendrogram visualizations of the interrelationships between substance types. Results suggest a considerable variation in substance and polysubstance use patterns across states in the U.S. Polysubstance use clustered around well-observed combinations like MDMA/cannabis and cocaine/heroin. Synthetic cannabinoids and cathinones showed no strong clustering with other substances. High rates of binge drinking among users of other substances further support the importance of interventions sensitive to the clinical challenges of polysubstance use.	[Elliott, Luther] NYU, Coll Global Publ Hlth, Ctr Drug Use & HIV HCV Res, New York, NY 10003 USA; [Haddock, Christopher Keith] Natl Dev & Res Inst USA, Leawood, KS USA; [Campos, Stephanie] Columbia Univ, New York State Psychiat Inst, New York, NY USA; [Benoit, Ellen] North Jersey Community Res Initiat, Res Div, Newark, NJ USA	New York University; Columbia University; New York State Psychiatry Institute	Elliott, L (corresponding author), NYU, Coll Global Publ Hlth, Ctr Drug Use & HIV HCV Res, New York, NY 10003 USA.	Luther@NYU.edu		Elliott, Luther/0000-0001-5258-7438	National Institute on Drug Abuse (NIDA.gov) [R01DA035887]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA035887] Funding Source: NIH RePORTER	National Institute on Drug Abuse (NIDA.gov); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was funded solely by research grant R01DA035887 from the National Institute on Drug Abuse (NIDA.gov) awarded to principal investigator, EB. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams AJ, 2017, NEW ENGL J MED, V376, P235, DOI 10.1056/NEJMoa1610300; Al-Hebshi NN, 2005, ADDICT BIOL, V10, P299, DOI 10.1080/13556210500353020; Barrett SP, 2005, SUBST USE MISUSE, V40, P1525, DOI 10.1081/JA-200066866; Beckstead JW, 2002, WESTERN J NURS RES, V24, P307, DOI 10.1177/01939450222045923; Beitchman JH, 2001, AM J DRUG ALCOHOL AB, V27, P421, DOI 10.1081/ADA-100104510; Benjamin GA, 1990, INT J LAW PSYCHIAT; BRENNEISEN R, 1990, BRIT J CLIN PHARMACO, V30, P825, DOI 10.1111/j.1365-2125.1990.tb05447.x; Brew I, 2016, BRIT J GEN PRACT, V66, P125, DOI 10.3399/bjgp16X684253; Callaway JC, 1998, J PSYCHOACTIVE DRUGS, V30, P367; Cameron K, 2013, PSYCHOPHARMACOLOGY, V227, P493, DOI 10.1007/s00213-013-2967-2; Carbone PN, 2013, AM J FOREN MED PATH, V34, P26, DOI 10.1097/PAF.0b013e31827ab5da; Chavent M, 2012, J STAT SOFTWARD, V50, P1; Chin RL, 1998, ANN EMERG MED, V31, P716, DOI 10.1016/S0196-0644(98)70230-6; Connor JP, 2014, CURR OPIN PSYCHIATR, V27, P269, DOI 10.1097/YCO.0000000000000069; Connor Jason P, 2013, Front Psychiatry, V4, P79, DOI 10.3389/fpsyt.2013.00079; Conway KP, 2013, J ADOLESCENT HEALTH, V52, P716, DOI 10.1016/j.jadohealth.2012.12.006; Cooney R, 2018, LANCET US HLTH BLOG; Degenhardt L, 2005, SUBST USE MISUSE, V40, P1241, DOI 10.1081/JA-200066777; DOUGLASS FM, 1980, J ABNORM PSYCHOL, V89, P240; Dowling GP, 1990, ECSTASY CLIN PHARM N, P63; Dunlap E, 2012, INT J DRUG POLICY, V23, P473, DOI 10.1016/j.drugpo.2012.04.003; Elliott L, 2018, INT J DRUG POLICY, V51, P111, DOI 10.1016/j.drugpo.2017.10.007; Every-Palmer S, 2010, ADDICTION, V105, P1859, DOI 10.1111/j.1360-0443.2010.03119.x; Fan G, 2007, Curr Oncol, V14, P173, DOI 10.3747/co.2007.145; Galili T, 2018, PACKAGE DENDEXTEND C; Galloway GP, 1997, ADDICTION, V92, P89, DOI 10.1111/j.1360-0443.1997.tb03640.x; Gjersing L, 2016, DRUG ALCOHOL REV; Golub A, 2005, ADDICT RES THEORY, V13, P217, DOI 10.1080/16066350500053497; Golub A, 2001, AM J PUBLIC HEALTH, V91, P225, DOI 10.2105/AJPH.91.2.225; Grov C, 2009, SUBST USE MISUSE, V44, P848, DOI 10.1080/10826080802484702; Guenther UP, 2007, HUM MUTAT, V28, P808, DOI 10.1002/humu.20525; HEARN WL, 1991, J NEUROCHEM, V56, P698, DOI 10.1111/j.1471-4159.1991.tb08205.x; HEARN WL, 1991, PHARMACOL BIOCHEM BE, V39, P531, DOI 10.1016/0091-3057(91)90222-N; Iversen L, 2013, EUR J PHARMACOL, V700, P147, DOI 10.1016/j.ejphar.2012.12.006; Jones CM, 2014, MMWR-MORBID MORTAL W, V63, P881; Joseph AM, 2017, AM J DRUG ALCOHOL AB, V43, P117, DOI 10.1080/00952990.2016.1240799; KATZ JL, 1992, LIFE SCI, V50, P1351, DOI 10.1016/0024-3205(92)90286-X; Kau G, 2008, U PENN LAW REV, V156, P1077, DOI 10.2307/40041401; LUQMAN W, 1976, ANN INTERN MED, V85, P246, DOI 10.7326/0003-4819-85-2-246; Manning C., 2009, INTRO INFORM RETRIEV, P377; Mars SG, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0232-z; McCance-Katz EF, 1998, BIOL PSYCHIAT, V44, P250, DOI 10.1016/S0006-3223(97)00426-5; Medrano K., 2017, NEWSWEEK; Miotto K, 2001, AM J ADDICTION, V10, P232; Moss HB, 2014, DRUG ALCOHOL DEPEN, V136, P51, DOI 10.1016/j.drugalcdep.2013.12.011; National Institute on Drug Abuse, 2019, OP SUMM STAT; Newcomer SR, 2011, AM J MANAG CARE, V17, pE324; Occupati B, 2017, CLIN TOXICOLOGY; Palamar JJ, 2016, DRUG ALCOHOL DEPEN, V161, P200, DOI 10.1016/j.drugalcdep.2016.02.001; Parchman ML., 2007, APPL MULTIVAR RES, V12, P163, DOI [10.22329/amr.v12i3.658, DOI 10.22329/AMR.V12I3.658]; Patra J, 2009, ADDICT RES THEORY, V17, P168, DOI 10.1080/16066350802372827; Pedersen W, 1999, ADDICTION, V94, P1695, DOI 10.1046/j.1360-0443.1999.941116957.x; Peglow S, 2012, AM J ADDICTION, V21, P287, DOI 10.1111/j.1521-0391.2012.00222.x; Perrone D, 2016, WILEY HANDB CRIMINOL, P149; Perrone D, 2013, DRUG-EDUC PREV POLIC, V20, P216, DOI 10.3109/09687637.2012.749392; Prosser JM, 2012, J MED TOXICOL, V8, P33, DOI 10.1007/s13181-011-0193-z; Ramo DE, 2011, ADDICT BEHAV, V36, P1292, DOI 10.1016/j.addbeh.2011.08.003; Sacco L.N., 2011, SYNTHETIC DRUGS OVER; Schifano F, 2015, WORLD PSYCHIATRY, V14, P15, DOI 10.1002/wps.20174; Shaw SY, 2008, AM J PUBLIC HEALTH, V98, P1430, DOI 10.2105/AJPH.2007.120741; Sivagnanam K, 2013, AM J CASE REP, V14, P288, DOI 10.12659/AJCR.889381; SMILKSTEIN MJ, 1987, J TOXICOL-CLIN TOXIC, V25, P149, DOI 10.3109/15563658708992620; Substance Abuse and Mental Health Services Administration (SAMHSA), 2018, 2016 2017 NAT SURV D; Tait RJ, 2016, CLIN TOXICOL, V54, P1, DOI 10.3109/15563650.2015.1110590; Tourino C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009143; Tunnicliff G, 1997, J TOXICOL-CLIN TOXIC, V35, P581, DOI 10.3109/15563659709001236; van Amsterdam J, 2015, J PSYCHOPHARMACOL, V29, P254, DOI 10.1177/0269881114565142; WALSH DC, 1991, J STUD ALCOHOL, V52, P17, DOI 10.15288/jsa.1991.52.17; White JM, 1999, ADDICTION, V94, P961, DOI 10.1046/j.1360-0443.1999.9479612.x; Windsor Liliane Cambraia, 2012, J Ethn Subst Abuse, V11, P339, DOI 10.1080/15332640.2012.735176; Windsor LC, 2010, J BLACK STUD, V41, P21, DOI 10.1177/0021934708326875; Wood DM, 2012, QJM-INT J MED, V105, P959, DOI 10.1093/qjmed/hcs107; Yacoubian GS, 1998, J DRUG ISSUES, V28, P559, DOI 10.1177/002204269802800214; Zhang Z, 2017, ANN TRANSLATIONAL ME, V5	74	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2019	14	12							e0225273	10.1371/journal.pone.0225273	http://dx.doi.org/10.1371/journal.pone.0225273			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LO9UM	31794586	gold, Green Published			2023-01-03	WOS:000533969300014
J	Dalton, M; Holzman, E; Erwin, E; Michelen, S; Rositch, AF; Kumar, S; Vanderpuye, V; Yeates, K; Liebermann, EJ; Ginsburg, O				Dalton, Milena; Holzman, Emily; Erwin, Erica; Michelen, Sophia; Rositch, Anne F.; Kumar, Somesh; Vanderpuye, Verna; Yeates, Karen; Liebermann, Erica J.; Ginsburg, Ophira			Patient navigation services for cancer care in low-and middle-income countries: A scoping review	PLOS ONE			English	Review							BREAST-CANCER; RESEARCH-PROGRAM; FOLLOW-UP; HEALTH; POPULATION; DIAGNOSIS; IMPACT; ACCESS; NEED	Background Nearly 70% of all cancer deaths occur in low- and middle-income countries (LMICs) and many of these cancer deaths are preventable. In high-income countries (HICs), patient navigation strategies have been successfully implemented to facilitate the patient's journey at multiple points along the cancer care continuum. The purpose of this scoping review is to understand and describe the scope of patient navigation interventions and services employed in LMICs. Methods A systematic search of published articles was conducted including Medline, Biosis, Embase, Global Health, and Web of Science. Articles were examined for evidence of patient navigation interventions used in cancer care in LMICs. Evidence was synthesized by navigation service provided and by type of outcome. Results Fourteen studies reported on patient navigation interventions in cancer care in low-income and middle-income countries in Asia, South America, and Africa. Most studies reported on women's cancers and included navigation interventions at most points along the cancer care continuum i.e. awareness, education, screening participation, adherence to treatment and surveillance protocols. Conclusion Few studies report on cancer patient navigation in LMICs. With the use of an implementation science framework, patient navigation research can explore a broader range of outcomes to better evaluate its potential role in improving cancer control in LMICs.	[Dalton, Milena; Ginsburg, Ophira] NYU, Sch Med, Dept Populat Hlth, New York, NY 10003 USA; [Holzman, Emily; Yeates, Karen] NYU, Coll Global Publ Hlth, New York, NY USA; [Erwin, Erica] Better Outcomes Registry & Network BORN Ontario, Ottawa, ON, Canada; [Rositch, Anne F.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Kumar, Somesh] Jhpiego, Baltimore, MD USA; [Vanderpuye, Verna] Korle Bu Teaching Hosp, Accra, Ghana; [Liebermann, Erica J.] NYU, Rory Meyers Coll Nursing, New York, NY USA; [Ginsburg, Ophira] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY 10016 USA	New York University; New York University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Jhpiego; New York University; NYU Langone Medical Center	Ginsburg, O (corresponding author), NYU, Sch Med, Dept Populat Hlth, New York, NY 10003 USA.; Ginsburg, O (corresponding author), NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY 10016 USA.	Ophira.Ginsburg@nyulangone.org	Kumar, Somesh/AAK-1263-2020	Ginsburg, Ophira/0000-0002-1384-2675; Erwin, Erica/0000-0001-6261-4225				Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3; Alvarez E., 2017, PEDIAT BLOOD CANC, V64, P10; Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [DOI 10.1080/1364557032000119616, 10.1080/1364557032000119616]; Atun R, 2015, LANCET ONCOL, V16, P1153, DOI 10.1016/S1470-2045(15)00222-3; Battaglia TA, 2007, CANCER, V109, P359, DOI 10.1002/cncr.22354; Battaglia TA, 2012, CANCER EPIDEM BIOMAR, V21, P1645, DOI 10.1158/1055-9965.EPI-12-0532; Bray F, 2012, LANCET ONCOL, V13, P790, DOI 10.1016/S1470-2045(12)70211-5; Cazap E, 2016, J CLIN ONCOL, V34, P14, DOI 10.1200/JCO.2015.61.9189; Chavarri-Guerra Y, 2018, ONCOLOGIST; Chidyaonga-Maseko F, 2015, PAN AFR MED J, V21, DOI 10.11604/pamj.2015.21.231.6350; Chowdhury Touhidul Imran, 2015, Asian Pac J Cancer Prev, V16, P7853; Drake BF, 2015, J COMMUN HEALTH, V40, P1216, DOI 10.1007/s10900-015-0051-z; Ell K, 2007, PREV MED, V44, P26, DOI 10.1016/j.ypmed.2006.08.001; Ell K, 2009, CANCER-AM CANCER SOC, V115, P4606, DOI 10.1002/cncr.24500; Fillion Lise, 2006, Can Oncol Nurs J, V16, P11; Freeman Harold P, 2011, Cancer, V117, P3539, DOI 10.1002/cncr.26262; Freund KM, 2008, CANCER-AM CANCER SOC, V113, P3391, DOI 10.1002/cncr.23960; Ginsburg O, 2017, LANCET, V389, P847, DOI [10.1016/S0140-6736(16)31392-7, 10.1]; Ginsburg OM, 2014, ONCOLOGIST, V19, P177, DOI 10.1634/theoncologist.2013-0314; Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322; Jandorf L, 2005, J URBAN HEALTH, V82, P216, DOI 10.1093/jurban/jti046; Li XQ, 2016, IRAN J PUBLIC HEALTH, V45, P48; Lima TM, 2017, REV LATINO AM ENFERM, V25; Ma GX, 2012, CANCER EPIDEM BIOMAR, V21, P358, DOI 10.1158/1055-9965.EPI-11-0915; Martei YM, 2018, CLIN LAB MED, V38, P161, DOI 10.1016/j.cll.2017.10.013; Mishra GS, 2017, INDIAN J OTOLARYNGOL, V69, P488, DOI 10.1007/s12070-017-1231-1; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Nejad ZK, 2016, IRAN RED CRESCENT ME, V18, DOI 10.5812/ircmj.21627; Nyblade L, 2017, BMC WOMENS HEALTH, V17, DOI 10.1186/s12905-017-0407-x; Oluwole SF, 2003, J AM COLL SURGEONS, V196, P180, DOI 10.1016/S1072-7515(02)01765-9; Percac-Lima S, 2015, J WOMENS HEALTH, V24, P138, DOI 10.1089/jwh.2014.4954; Pesec M, 2015, FUTURE ONCOL, V11, P2235, DOI 10.2217/fon.15.142; Proctor E, 2011, ADM POLICY MENT HLTH, V38, P65, DOI 10.1007/s10488-010-0319-7; Randall TC, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00160; Riogi BW, 2017, S AFRICA J ONCOLOGY, V1; Sajjad S, 2016, EUR J ONCOL NURS, V21, P75, DOI 10.1016/j.ejon.2016.01.006; Steinberg ML, 2006, CANCER, V107, P2669, DOI 10.1002/cncr.22319; Sullivan R, 2015, LANCET ONCOL, V16, P1193, DOI 10.1016/S1470-2045(15)00223-5; Tegegne TK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203130; Tetteh DA, 2016, WOMENS HEALTH, V12, P147, DOI 10.2217/whe.15.76; The George Washington Cancer Institute Center for the Advancement of Cancer Survivorship Nativation and Policy, 2013, BEST PRACT PAT NAV C; Valaitis RK, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2046-1; VASCONCELOS CTM, 2017, REV LAT-AM ENFERM, V25, DOI DOI 10.1590/1518-8345.1337; Villarreal-Garza C, 2018, J GLOBAL ONCOLOGY S2, V4, p162s; Wells KJ, 2008, CANCER-AM CANCER SOC, V113, P1999, DOI 10.1002/cncr.23815; World Health Organization, 2018, DHAKA NONCOMMUNICABL; Yeoh ZY, 2018, J GLOB ONCOL, V4, DOI 10.1200/JGO.17.00229	47	34	34	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2019	14	10							e0223537	10.1371/journal.pone.0223537	http://dx.doi.org/10.1371/journal.pone.0223537			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM9KP	31622363	gold, Green Published			2023-01-03	WOS:000532567300024
J	McKinney, CM; Plange-Rhule, G; Ansong, D; Cunningham, ML; Agyeman, I; Coffey, PS				McKinney, Christy M.; Plange-Rhule, Gyikua; Ansong, Daniel; Cunningham, Michael L.; Agyeman, Irene; Coffey, Patricia S.			A randomized crossover trial comparing the Nifty cup to a medicine cup in preterm infants who have difficulty breastfeeding at Komfo Anokye Teaching Hospital (KATH) in Kumasi, Ghana	PLOS ONE			English	Article							NEWBORN; MOTHERS	Introduction Preterm infants make up the majority of the 9 million babies born in Africa and South Asia requiring supplemental feedings as they transition to exclusive breastfeeding. The World Health Organization recommends the use of a cup to feed newborns with breastfeeding difficulties in low-resource settings. We set out to evaluate the Nifty cup, a new feeding cup designed specifically for infants with breastfeeding difficulties. Materials and methods We conducted a randomized clinical trial in Ghana. We hypothesized infants would prefer the Nifty cup and that it would have less spillage as compared to a medicine cup. We enrolled mothers and preterm infants with breastfeeding difficulties indicated to cup feed at Komfo Anokye Teaching Hospital. Each mother-infant pair used the Nifty cup and a standard medicine cup; and two feeding assessments with each cup were conducted. We employed an intent-to-treat analysis comparing cup preference using a Wilcoxon signed rank test and spillage using generalized estimating equations. Results We enrolled 200 mothers and 237 infants. Many infants were very low birth weight (62%), less than two weeks old (62%), and multiple birth (29%). In response to separate questions about each cup, more mothers reported liking the Nifty cup a lot as compared to the medicine cup (85% versus 57%, p<0.001). When asked to choose between the two cups, more than 75% preferred the Nifty cup (p < 0.001). There was slightly less spillage with the Nifty cup (8.9%) versus the medicine cup (9.3%), which was not statistically significant (p = 0.35). Mothers reported greater confidence and ease of using the Nifty cup and greater use one-month post-discharge compared to the medicine cup (p-values <0.001). Nearly all mothers were breastfeeding and cup feeding their infants at study initiation and at one-month post-discharge. Discussion This is the first randomized clinical trial of cup feeding in sub-Saharan Africa. Mothers prefer the Nifty cup to a medicine cup for supplemental feeds to their preterm infant. The Nifty cup was used with greater ease and confidence. The Nifty cup can offer an improved feeding experience for the mother-infant pair.	[McKinney, Christy M.; Cunningham, Michael L.] Univ Washington, Sch Med, Dept Pediat, Div Craniofacial Med,Seattle Childrens Res Inst, Seattle, WA 98195 USA; [McKinney, Christy M.; Cunningham, Michael L.] Seattle Childrens Hosp, Craniofacial Ctr, Seattle, WA USA; [Plange-Rhule, Gyikua; Ansong, Daniel; Agyeman, Irene] Kwame Nkrumah Univ Sci & Technol, Komfo Anokye Teaching Hosp, Sch Med & Dent, Kumasi, Ghana; [Coffey, Patricia S.] PATH, Devices Tools Global Program, Seattle, WA 98121 USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; Seattle Children's Hospital; Kwame Nkrumah University Science & Technology	Coffey, PS (corresponding author), PATH, Devices Tools Global Program, Seattle, WA 98121 USA.	pcoffey@path.org		Coffey, Patricia/0000-0001-8961-0910	United States Agency for International Development (USAID); Government of Norway; Bill & Melinda Gates Foundation; Grand Challenges Canada; UK Department for International Development (DFID); Korea International Cooperation Agency (KOICA)	United States Agency for International Development (USAID)(United States Agency for International Development (USAID)CGIAR); Government of Norway; Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Grand Challenges Canada(CGIAR); UK Department for International Development (DFID); Korea International Cooperation Agency (KOICA)	This work was made possible through the generous support of the Saving Lives at Birth partners: The United States Agency for International Development (USAID), the Government of Norway, the Bill & Melinda Gates Foundation, Grand Challenges Canada, the UK Department for International Development (DFID), and the Korea International Cooperation Agency (KOICA). It was prepared by the authors and does not necessarily reflect the views of the Saving Lives at Birth partners.	Aloysius A, 2007, EARLY HUM DEV, V83, P619, DOI 10.1016/j.earlhumdev.2006.12.004; Becker GE, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006170.pub5; Boo NY, 2001, J HOSP INFECT, V49, P274, DOI 10.1053/jhin.2001.1117; Chan GJ, 2016, J GLOB HEALTH, V6, pe1; Conde-Agudelo A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002771.pub3; Dowling Donna A, 2002, J Hum Lact, V18, P13, DOI 10.1177/089033440201800103; DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5; GBD 2013 Mortality and Causes of Death Collaborators, 2015, LANCET, V385; Glass R P, 1994, J Hum Lact, V10, P185, DOI 10.1177/089033449401000316; Kuehl J, 1997, J PERINAT NEONAT NUR, V11, P56, DOI 10.1097/00005237-199709000-00007; Laerdal, 2016, NIFT FEED CUP US GUI; Lang S, 1994, Midwives Chron, V107, P171; Lawn JE, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-S1-S1; Lawn JE, 2010, INT J EPIDEMIOL, V39, P144, DOI 10.1093/ije/dyq031; Lozano R, 2011, LANCET, V378, P1139, DOI 10.1016/S0140-6736(11)61337-8; Malhotra N, 1999, EARLY HUM DEV, V54, P29, DOI 10.1016/S0378-3782(98)00082-6; March of Dimes, 2006, MARCH DIMES GLOBAL R; March of Dimes Save the Children WHO, 2012, BORN TOO SOON GLOBAL; Marinelli K A, 2001, J Perinatol, V21, P350, DOI 10.1038/sj.jp.7210539; McKinney CM, 2016, MATERN CHILD HLTH J, V20, P1620, DOI 10.1007/s10995-016-1961-9; Meier PP, 2007, J MIDWIFERY WOM HEAL, V52, P579, DOI 10.1016/j.jmwh.2007.08.003; Penny F, 2018, MATERN CHILD HLTH J, V22, P1568, DOI 10.1007/s10995-018-2632-9; Seidman G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125643; Thorley V, 1997, J Hum Lact, V13, P54, DOI 10.1177/089033449701300118; United Nations Children Fund, 2015, TRENDS EST MAT DEATH; United Nations Data United Nations Children Fund, 2018, ANN NUMB BIRTHS BIRT; Victora CG, 2016, LANCET, V387, P475, DOI 10.1016/S0140-6736(15)01024-7; WHO, 2018, GUIDELINES OPTIMAL F; WHO & UNICEF (World Health Organization & UNICEF), 1993, BREASTF COUNS TRAIN; World Health Organization, 2003, MAN NEWB PROBL GUID; Yilmaz G, 2014, J HUM LACT, V30, P174, DOI 10.1177/0890334413517940	31	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2019	14	10							e0223951	10.1371/journal.pone.0223951	http://dx.doi.org/10.1371/journal.pone.0223951			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM9KP	31622421	Green Published, gold			2023-01-03	WOS:000532567300075
J	Zhang, L; Hu, WS; Cai, ZY; Liu, JH; Wu, JM; Deng, YM; Yu, KP; Chen, XH; Zhu, L; Ma, JX; Qin, Y				Zhang, Lan; Hu, Weishu; Cai, Zhiyou; Liu, Jihong; Wu, Jianmei; Deng, Yangmin; Yu, Keping; Chen, Xiaohua; Zhu, Li; Ma, Jingxi; Qin, Yan			Early mobilization of critically ill patients in the intensive care unit: A systematic review and meta-analysis	PLOS ONE			English	Review							EARLY REHABILITATION THERAPY; ACUTE RESPIRATORY-FAILURE; ICU-ACQUIRED WEAKNESS; HANDGRIP STRENGTH; MECHANICAL VENTILATION; PHYSICAL-THERAPY; MUSCLE STRENGTH; EARLY EXERCISE; ADULT PATIENTS; MORTALITY	Background Physical therapy can prevent functional impairments and improve the quality of life of patients after hospital discharge. However, the effect of early mobilization on patients with a critical illness remains unclear. This study was performed to assess the evidence available regarding the effect of early mobilization on critically ill patients in the intensive care unit (ICU). Methods Electronic databases were searched from their inception to March 21, 2019. Randomized controlled trials (RCTs) comprising critically ill patients who received early mobilization were included. The methodological quality and risk of bias of each eligible trial were assessed using the Cochrane Collaboration tool. Data were extracted using a standard collection form each included study, and processed using the Mantel-Haenszel (M-H) or inverse-variance (I-V) test in the STATA v12.0 statistical software. Results A total of 1,898 records were screened. Twenty-three RCTs comprising 2,308 critically ill patients were ultimately included. Early mobilization decreased the incidence of ICU acquired weakness (ICU-AW) at hospital discharge (three studies, 190 patients, relative risk (RR): 0.60, 95% confidence interval (CI) [0.40, 0.90]; p=0.013, I-2 = 0.0%), increased the number of patients who were able to stand (one study, 50 patients, 90% vs. 62%, p=0.02), increased the number of ventilator-free days (six studies, 745 patients, standardized mean difference (SMD): 0.17, 95% CI [0.02, 0.31]; p=0.023, I-2=35.5%) during hospitalization, increased the distance the patient was able to walk unassisted (one study, 104 patients, 33.4 (0-91.4) meters vs. 0 (0-30.4) meters, p=0.004) at hospital discharge, and increased the discharged-to-home rate (seven studies, 793 patients, RR: 1.16, 95% CI [1.00, 1.34]; p =0.046). The mortality (28-day, ICU and hospital) and adverse event rates were moderately increased by early mobilization, but the differences were statistically non-significant. However, due to the substantial heterogeneity among the included studies, and the low quality of the evidence, the results of this study should be interpreted with caution. Publication bias was not identified. Conclusions Early mobilization appears to decrease the incidence of ICU-AW, improve the functional capacity, and increase the number of ventilator-free days and the discharged-to-home rate for patients with a critical illness in the ICU setting.	[Zhang, Lan; Liu, Jihong; Qin, Yan] Chongqing Med Univ, Affiliated Hosp 2, Dept Neurol, Chongqing, Peoples R China; [Zhang, Lan; Hu, Weishu; Cai, Zhiyou; Wu, Jianmei; Deng, Yangmin; Yu, Keping; Chen, Xiaohua; Zhu, Li; Ma, Jingxi] Chongqing Gen Hosp, Dept Neurol, Chongqing, Peoples R China	Chongqing Medical University	Qin, Y (corresponding author), Chongqing Med Univ, Affiliated Hosp 2, Dept Neurol, Chongqing, Peoples R China.	qinyan2015120@163.com		MA, JINGXI/0000-0001-9189-4684	Science and Technology Planning Project of Yuzhong District of Chongqing [20180136]	Science and Technology Planning Project of Yuzhong District of Chongqing	This work was supported by the Science and Technology Planning Project of Yuzhong District of Chongqing (grant number 20180136 to JM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adler Joseph, 2012, Cardiopulm Phys Ther J, V23, P5; Ahmed S, 2003, JAMA-J AM MED ASSOC, V289, P1634, DOI 10.1001/jama.289.13.1634-a; Ali NA, 2008, AM J RESP CRIT CARE, V178, P261, DOI 10.1164/rccm.200712-1829OC; Baldwin MR, 2014, J CRIT CARE, V29, P401, DOI 10.1016/j.jcrc.2013.12.019; Berry MJ, 2013, EXERC SPORT SCI REV, V41, P208, DOI 10.1097/JES.0b013e3182a4e67c; Brummel NE, 2014, INTENS CARE MED, V40, P370, DOI 10.1007/s00134-013-3136-0; Burtin C, 2009, CRIT CARE MED, V37, P2499, DOI 10.1097/CCM.0b013e3181a38937; Calvo-Ayala E, 2013, CHEST, V144, P1469, DOI 10.1378/chest.13-0779; Campellone JV, 1998, NEUROLOGY, V50, P46, DOI 10.1212/WNL.50.1.46; Castro-Avila AC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130722; Chang MY, 2011, RESP CARE, V56, P1533, DOI 10.4187/respcare.00938; Chiang LL, 2006, PHYS THER, V86, P1271, DOI 10.2522/ptj.20050036; Clarissa C, 2019, J INTENSIVE CARE, V7, DOI 10.1186/s40560-018-0355-z; Coutinho William Maia, 2016, Fisioter. Pesqui., V23, P278, DOI 10.1590/1809-2950/15549123032016; Dantas Camila Moura, 2012, Rev. bras. ter. intensiva, V24, P173, DOI 10.1590/S0103-507X2012000200013; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; de Jonghe Bernard, 2009, Crit Care Med, V37, pS309, DOI 10.1097/CCM.0b013e3181b6e64c; Denehy L, 2017, INTENS CARE MED, V43, P86, DOI 10.1007/s00134-016-4513-2; Denehy L, 2013, CRIT CARE, V17, DOI 10.1186/cc12835; Devlin JW, 2018, CRIT CARE MED, V46, P1532, DOI [10.1097/CCM.0000000000003299, 10.1097/CCM.0000000000003259]; Doiron KA, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010754.pub2; Dong ZH, 2014, WORLD J EMERG MED, V5, P48, DOI [10.5847/wjem.j.issn.1920-8642.2014.01.008, 10.5847/wjem.j.1920-8642.2014.01.008]; Dong ZH, 2016, INT HEART J, V57, P241, DOI 10.1536/ihj.15-316; Eggmann S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207428; Fan E, 2014, CRIT CARE MED, V42, P849, DOI 10.1097/CCM.0000000000000040; Farhan H, 2016, ANESTHESIOLOGY, V124, P207, DOI 10.1097/ALN.0000000000000874; Fossat G, 2018, JAMA-J AM MED ASSOC, V320, P368, DOI 10.1001/jama.2018.9592; Friedrich O, 2015, PHYSIOL REV, V95, P1025, DOI 10.1152/physrev.00028.2014; Gosselink R, 2008, INTENS CARE MED, V34, P1188, DOI 10.1007/s00134-008-1026-7; Hermans G, 2015, INTENS CARE MED, V41, P2138, DOI 10.1007/s00134-015-3979-7; Hermans G, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0993-7; Hickmann CE, 2018, CRIT CARE MED, V46, P1436, DOI 10.1097/CCM.0000000000003263; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hodgson CL, 2016, CRIT CARE MED, V44, P1145, DOI 10.1097/CCM.0000000000001643; Hodgson CL, 2013, CRIT CARE, V17, DOI 10.1186/cc11820; Jolley SE, 2016, CHEST, V150, P1129, DOI 10.1016/j.chest.2016.03.045; Kayambu G, 2015, INTENS CARE MED, V41, P865, DOI 10.1007/s00134-015-3763-8; Kayambu G, 2013, CRIT CARE MED, V41, P1543, DOI 10.1097/CCM.0b013e31827ca637; Kho ME, 2019, BMJ OPEN RESPIR RES, V6, DOI 10.1136/bmjresp-2018-000383; Laurent H, 2016, ANAESTH CRIT CARE PA, V35, P133, DOI 10.1016/j.accpm.2015.06.014; Li ZQ, 2013, ARCH PHYS MED REHAB, V94, P551, DOI 10.1016/j.apmr.2012.10.023; Ling CHY, 2010, CAN MED ASSOC J, V182, P429, DOI 10.1503/cmaj.091278; Machado AD, 2017, J BRAS PNEUMOL, V43, P134, DOI [10.1590/S1806-37562016000000170, 10.1590/s1806-37562016000000170]; Maffei P, 2017, ARCH PHYS MED REHAB, V98, P1518, DOI 10.1016/j.apmr.2017.01.028; McWilliams D, 2018, J CRIT CARE, V44, P407, DOI 10.1016/j.jcrc.2018.01.001; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Morris PE, 2016, JAMA-J AM MED ASSOC, V315, P2694, DOI 10.1001/jama.2016.7201; Moss M, 2016, AM J RESP CRIT CARE, V193, P1101, DOI 10.1164/rccm.201505-1039OC; Nava S, 1998, ARCH PHYS MED REHAB, V79, P849, DOI 10.1016/S0003-9993(98)90369-0; Norman K, 2014, EUR J CLIN NUTR, V68, P155, DOI 10.1038/ejcn.2013.261; Nydahl P, 2017, ANN AM THORAC SOC, V14, P766, DOI 10.1513/AnnalsATS.201611-843SR; Pena LL, 2003, CIRCULATION, V107, P1210, DOI 10.1161/01.CIR.0000055013.92097.40; Pinheiro Alessandra Rigo, 2012, Rev. bras. ter. intensiva, V24, P188, DOI 10.1590/S0103-507X2012000200016; Puthucheary ZA, 2013, JAMA-J AM MED ASSOC, V310, P1591, DOI 10.1001/jama.2013.278481; Santos PMR, 2017, PHYSIOTHERAPY, V103, P1, DOI 10.1016/j.physio.2016.08.003; Sarfati C, 2018, J CRIT CARE, V46, P37, DOI 10.1016/j.jcrc.2018.03.031; Schaller SJ, 2016, LANCET, V388, P1377, DOI 10.1016/S0140-6736(16)31637-3; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Taekema DG, 2010, AGE AGEING, V39, P331, DOI 10.1093/ageing/afq022; Verceles AC, 2018, J CRIT CARE, V47, P204, DOI 10.1016/j.jcrc.2018.07.006; Yosef-Brauner O, 2015, CLIN RESPIR J, V9, P1, DOI 10.1111/crj.12091; Zanotti E, 2003, CHEST, V124, P292, DOI 10.1378/chest.124.1.292; Zhang G., 2018, J EMERG CRIT CARE ME, V2, P9, DOI [10.21037/jeccm.2018.01.04, DOI 10.21037/JECCM.2018.01.04]	64	110	117	3	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2019	14	10							e0223185	10.1371/journal.pone.0223185	http://dx.doi.org/10.1371/journal.pone.0223185			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM6ZN	31581205	Green Published, gold			2023-01-03	WOS:000532398600040
J	Moroni, F; Dwyer, BJ; Graham, C; Pass, C; Bailey, L; Ritchie, L; Mitchell, D; Glover, A; Laurie, A; Doig, S; Hargreaves, E; Fraser, AR; Turner, ML; Campbell, JDM; McGowan, NWA; Barry, J; Moore, JK; Hayes, PC; Leeming, DJ; Nielsen, MJ; Musa, K; Fallowfield, JA; Forbes, SJ				Moroni, Francesca; Dwyer, Benjamin J.; Graham, Catriona; Pass, Chloe; Bailey, Laura; Ritchie, Lisa; Mitchell, Donna; Glover, Alison; Laurie, Audrey; Doig, Stuart; Hargreaves, Emily; Fraser, Alasdair R.; Turner, Marc L.; Campbell, John D. M.; McGowan, Neil W. A.; Barry, Jacqueline; Moore, Joanna K.; Hayes, Peter C.; Leeming, Diana J.; Nielsen, Mette J.; Musa, Kishwar; Fallowfield, Jonathan A.; Forbes, Stuart J.			Safety profile of autologous macrophage therapy for liver cirrhosis	NATURE MEDICINE			English	Article							FUNCTIONAL-CHARACTERIZATION; DUCTULAR REACTIONS; CELL THERAPY; DISEASE; INJURY; TRANSPLANTATION; DIAGNOSIS; MARKER	Therapies to reduce liver fibrosis and stimulate organ regeneration are urgently needed. We conducted a first-in-human, phase 1 dose-escalation trial of autologous macrophage therapy in nine adults with cirrhosis and a Model for End-Stage Liver Disease (MELD) score of 10-16 (ISRCTN 10368050). Groups of three participants received a single peripheral infusion of 10(7), 10(8) or up to 10(9) cells. Leukapheresis and macrophage infusion were well tolerated with no transfusion reactions, dose-limiting toxicities or macrophage activation syndrome. All participants were alive and transplant-free at one year, with only one clinical event recorded, the occurrence of minimal ascites. The primary outcomes of safety and feasibility were met. This study informs and provides a rationale for efficacy studies in cirrhosis and other fibrotic diseases.	[Moroni, Francesca; Dwyer, Benjamin J.; Moore, Joanna K.; Forbes, Stuart J.] Univ Edinburgh, MRC Ctr Regenerat Med, Edinburgh, Midlothian, Scotland; [Graham, Catriona] Univ Edinburgh, Edinburgh Clin Res Facil, Edinburgh, Midlothian, Scotland; [Pass, Chloe; Bailey, Laura; Ritchie, Lisa; Mitchell, Donna; Glover, Alison; Laurie, Audrey; Doig, Stuart; Hargreaves, Emily; Fraser, Alasdair R.; Turner, Marc L.; Campbell, John D. M.; McGowan, Neil W. A.] SNBTS, Tissues Cells & Adv Therapeut, Edinburgh, Midlothian, Scotland; [Barry, Jacqueline] Guys Hosp, Cell & Gene Therapy Catapult, 12th Floor Tower Wing, London, England; [Hayes, Peter C.; Fallowfield, Jonathan A.] Univ Edinburgh, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland; [Leeming, Diana J.; Nielsen, Mette J.; Musa, Kishwar] Nord Biosci, Fibrosis Biol & Biomarkers, Herlev, Denmark	University of Edinburgh; University of Edinburgh; Guy's & St Thomas' NHS Foundation Trust; University of Edinburgh; Nordic Bioscience	Forbes, SJ (corresponding author), Univ Edinburgh, MRC Ctr Regenerat Med, Edinburgh, Midlothian, Scotland.	stuart.forbes@ed.ac.uk		Dwyer, Benjamin/0000-0003-2527-5417; Fallowfield, Jonathan/0000-0002-5741-1471; Fraser, Alasdair/0000-0001-7822-650X	Medical Research Council UK grant (Biomedical Catalyst Major Awards Committee) [MR/M007588/1]; MRC [MR/M007588/1, G84/6205, MR/R015635/1, MC_PC_16043] Funding Source: UKRI	Medical Research Council UK grant (Biomedical Catalyst Major Awards Committee); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by a Medical Research Council UK grant (Biomedical Catalyst Major Awards Committee; reference MR/M007588/1) to S.J. Forbes. We thank Z.M. Younossi (Center for Outcomes Research in Liver Diseases, Washington, DC, USA) for academic use of the CLDQ instrument and L.J. Fallowfield (Sussex Health Outcomes Research & Education in Cancer (SHORE-C), University of Sussex, UK) for advice about health-related quality of life assessment.	Asrani SK, 2019, J HEPATOL, V70, P151, DOI 10.1016/j.jhep.2018.09.014; Barber K, 2011, TRANSPLANTATION, V92, P469, DOI 10.1097/TP.0b013e318225db4d; Bird TG, 2013, P NATL ACAD SCI USA, V110, P6542, DOI 10.1073/pnas.1302168110; Boulter L, 2012, NAT MED, V18, P572, DOI 10.1038/nm.2667; D'Amico G, 2006, J HEPATOL, V44, P217, DOI 10.1016/j.jhep.2005.10.013; Day J, 2019, J APPL LAB MED, V3, P815, DOI 10.1373/jalm.2018.027359; Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675; Fallowfield JA, 2007, J IMMUNOL, V178, P5288, DOI 10.4049/jimmunol.178.8.5288; Forbes SJ, 2015, J HEPATOL, V62, pS157, DOI 10.1016/j.jhep.2015.02.040; Foucher J, 2006, GUT, V55, P403, DOI 10.1136/gut.2005.069153; Fraser AR, 2017, CYTOTHERAPY, V19, P1113, DOI 10.1016/j.jcyt.2017.05.009; Friedrich-Rust M, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-103; Gouw ASH, 2011, HEPATOLOGY, V54, P1853, DOI 10.1002/hep.24613; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Huo TI, 2005, J HEPATOL, V42, P826, DOI 10.1016/j.jhep.2005.01.019; Hutchinson JA, 2011, J IMMUNOL, V187, P2072, DOI 10.4049/jimmunol.1100762; Karsdal MA, 2019, AM J PHYSIOL-GASTR L, V316, pG25, DOI 10.1152/ajpgi.00158.2018; Karsdal MA, 2013, ASSAY DRUG DEV TECHN, V11, P70, DOI 10.1089/adt.2012.474; Kullak-Ublick GA, 2017, GUT, V66, P1154, DOI 10.1136/gutjnl-2016-313369; Le Tourneau C, 2009, JNCI-J NATL CANCER I, V101, P708, DOI 10.1093/jnci/djp079; Leeming DJ, 2015, SCAND J GASTROENTERO, V50, P584, DOI 10.3109/00365521.2014.996590; Loria Anthony, 2013, Curr Gastroenterol Rep, V15, P301, DOI 10.1007/s11894-012-0301-5; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Moore JK, 2015, CYTOTHERAPY, V17, P1604, DOI 10.1016/j.jcyt.2015.07.016; Newsome PN, 2018, LANCET GASTROENTEROL, V3, P25, DOI 10.1016/S2468-1253(17)30326-6; Nielsen MJ, 2013, AM J TRANSL RES, V5, P303; Ramachandran P, 2012, P NATL ACAD SCI USA, V109, pE3186, DOI 10.1073/pnas.1119964109; Schuppan D, 2013, J CLIN INVEST, V123, P1887, DOI 10.1172/JCI66028; Sharkey J, 2017, CYTOTHERAPY, V19, P555, DOI 10.1016/j.jcyt.2017.01.003; Thomas JA, 2011, HEPATOLOGY, V53, P2003, DOI 10.1002/hep.24315; Tinegate H, 2012, BRIT J HAEMATOL, V159, P143, DOI 10.1111/bjh.12017; Veidal SS, 2010, LIVER INT, V30, P1293, DOI 10.1111/j.1478-3231.2010.02309.x; Younossi ZM, 1999, GUT, V45, P295, DOI 10.1136/gut.45.2.295; Younossi ZM, 2000, LIVER TRANSPLANT, V6, P779, DOI 10.1053/jlts.2000.18499	34	67	68	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2019	25	10					1560	+		10.1038/s41591-019-0599-8	http://dx.doi.org/10.1038/s41591-019-0599-8			16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	JC3GJ	31591593	Green Accepted			2023-01-03	WOS:000489166700025
J	Schwartz, KL; Chen, C; Langford, BJ; Brown, KA; Daneman, N; Johnstone, J; Wu, JHC; Leung, V; Garber, G				Schwartz, Kevin L.; Chen, Cynthia; Langford, Bradley J.; Brown, Kevin A.; Daneman, Nick; Johnstone, Jennie; Wu, Julie H. C.; Leung, Valerie; Garber, Gary			Validating a popular outpatient antibiotic database to reliably identify high prescribing physicians for patients 65 years of age and older	PLOS ONE			English	Article							UNITED-STATES; PROVIDER; CARE	Objective Many jurisdictions lack comprehensive population-based antibiotic use data and rely on third party companies, most commonly IQVIA. Our objective was to validate the accuracy of the IQVIA Xponent antibiotic database in identifying high prescribing physicians compared to the reference standard of a highly accurate population-wide database of outpatient antimicrobial dispensing for patients >= 65 years. Methods We conducted this study between 1 March 2016 and 28 February 2017 in Ontario, Canada. We evaluated the agreement and correlation between the databases using kappa statistics and Bland-Altman plots. We also assessed performance characteristics for Xponent to accurately identify high prescribing physicians with sensitivity, specificity, positive predictive value (PPV), and negative predictive value. Results We included 9,272 physicians. The Xponent database has a specificity of 92.4% (95%CI 92.0%-92.8%) and PPV of 77.2% (95%CI 76.0%-78.4%) for correctly identifying the top 25th percentile of physicians by antibiotic volume. In the sensitivity analysis, 94% of the top 25th percentile physicians in Xponent were within the top 40th percentile in the reference database. The mean number of antibiotic prescriptions per physician were similar with a relative difference of -0.4% and 2.7% for female and male patients, respectively. The error was greater in rural areas with a relative difference of -8.4% and -5.6% per physician for female and male patients, respectively. The weighted kappa for quartile agreement was 0.68 (95% CI 0.67-0.69). Conclusion We validated the IQVIA Xponent antibiotic database to identify high prescribing physicians for patients >= 65 years, and identified some important limitations. Collecting accurate population-based antibiotic use data will remain vital to global antimicrobial stewardship efforts.	[Schwartz, Kevin L.; Langford, Bradley J.; Brown, Kevin A.; Daneman, Nick; Johnstone, Jennie; Wu, Julie H. C.; Leung, Valerie; Garber, Gary] Publ Hlth Ontario, Toronto, ON, Canada; [Schwartz, Kevin L.; Chen, Cynthia; Brown, Kevin A.; Daneman, Nick] ICES, Toronto, ON, Canada; [Schwartz, Kevin L.; Brown, Kevin A.; Johnstone, Jennie] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Schwartz, Kevin L.] Unity Hlth Toronto, Toronto, ON, Canada; [Daneman, Nick] Sunnybrook Res Inst, Div Infect Dis, Toronto, ON, Canada; [Daneman, Nick] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Johnstone, Jennie] Sinai Hlth Syst, Toronto, ON, Canada; [Garber, Gary] Ottawa Res Inst, Ottawa, ON, Canada	University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Ottawa; Ottawa Hospital Research Institute	Schwartz, KL (corresponding author), Publ Hlth Ontario, Toronto, ON, Canada.; Schwartz, KL (corresponding author), ICES, Toronto, ON, Canada.; Schwartz, KL (corresponding author), Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.; Schwartz, KL (corresponding author), Unity Hlth Toronto, Toronto, ON, Canada.	Kevin.schwartz@oahpp.ca	Langford, Bradley/ABC-7937-2021	Langford, Bradley/0000-0001-5467-6776; Brown, Kevin Antoine/0000-0002-1483-2188	Public Health Ontario; ICES - Ontario Ministry of Health and Long-Term Care (MOHLTC)	Public Health Ontario; ICES - Ontario Ministry of Health and Long-Term Care (MOHLTC)(Ministry of Health and Long-Term Care, Ontario)	This research was supported by Public Health Ontario. This study was also supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred.	Adam HJ, 2009, INT J ANTIMICROB AG, V34, P82, DOI 10.1016/j.ijantimicag.2009.02.002; Bell BG, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-13; Benchimol EI, 2011, J CLIN EPIDEMIOL, V64, P821, DOI 10.1016/j.jclinepi.2010.10.006; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Boardman C, 2007, US patent, Patent No. [7,174,304, 7174304]; Costelloe C, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2096; Dalton B, 2013, IDWEEK 2013 2013 OCT; Dantes R, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv113; Fernandez-Lazaro CI, 2019, CLIN INFECT DIS, V69, P1467, DOI 10.1093/cid/ciy1130; Goossens H, 2007, CLIN INFECT DIS, V44, P1091, DOI 10.1086/512810; Government of Ontario, 2019, ONT DRUG BEN PROGR; Hicks LA, 2015, CLIN INFECT DIS, V60, P1308, DOI 10.1093/cid/civ076; Hicks LA, 2013, NEW ENGL J MED, V368, P1461, DOI 10.1056/NEJMc1212055; Hicks LA, 2011, CLIN INFECT DIS, V53, P631, DOI 10.1093/cid/cir443; Hong M., 2007, CAN J INFECT DIS MED, V18, P35; Hsia Y, 2019, LANCET INFECT DIS, V19, P67, DOI 10.1016/S1473-3099(18)30547-4; Kabbani S, 2018, J AM GERIATR SOC, V66, P1998, DOI 10.1111/jgs.15518; Karlowsky JA, 2009, INT J ANTIMICROB AG, V34, P375, DOI 10.1016/j.ijantimicag.2009.05.008; Klein EY, 2015, J ANTIMICROB CHEMOTH, V70, P1580, DOI 10.1093/jac/dku563; Kourlaba G, 2015, J ANTIMICROB CHEMOTH, V70, P2405, DOI 10.1093/jac/dkv091; LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786; Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67; Lin SJ, 2006, PHARMACOEPIDEM DR S, V15, P512, DOI 10.1002/pds.1149; O'Neill J., 2015, TACKLING DRUG RESIST; Public Health Agency of Canada, 2017, CAN COMMUN DIS REP, V43, P217; Public Health Agency of Canada, 2018, CAN ANT RES SURV SYS; Sanchez GV, 2016, MMWR RECOMM REP, V65, DOI 10.15585/mmwr.rr6506a1; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Schwartz KL, 2019, J ANTIMICROB CHEMOTH, V74, P2091, DOI 10.1093/jac/dkz033; Schwartz Kevin L, 2018, CMAJ Open, V6, pE445, DOI 10.9778/cmajo.20180017; Tan Charlie, 2017, CMAJ Open, V5, pE878, DOI 10.9778/cmajo.20170100; Tan C, 2016, J ANTIMICROB CHEMOTH, V71, P547, DOI 10.1093/jac/dkv373; Van Boeckel TP, 2014, LANCET INFECT DIS, V14, P742, DOI 10.1016/S1473-3099(14)70780-7; World Health Organization, 2015, GLOBAL ACTION PLAN A	34	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2019	14	9							e0223097	10.1371/journal.pone.0223097	http://dx.doi.org/10.1371/journal.pone.0223097			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM6FU	31557249	Green Published, gold			2023-01-03	WOS:000532345500065
J	Tichelman, E; Westerneng, M; Witteveen, AB; van Baar, AL; van der Horst, HE; de Jonge, A; Berger, MY; Schellevis, FG; Burger, H; Peters, LL				Tichelman, Elke; Westerneng, Myrte; Witteveen, Anke B.; van Baar, Anneloes L.; van der Horst, Henriette E.; de Jonge, Ank; Berger, Marjolein Y.; Schellevis, Francois G.; Burger, Huibert; Peters, Lilian L.			eCorrelates of prenatal and postnatal mother-to-infant bonding quality: A systematic review	PLOS ONE			English	Review							MATERNAL-FETAL ATTACHMENT; DEPRESSION; PREGNANCY; INTERVENTIONS; COHORT; ADOLESCENTS; EXPERIENCE; AGREEMENT; HEALTH; SCALES	Background Mother-to-infant bonding is defined as the emotional tie experienced by a mother towards her child, which is considered to be important for the socio-emotional development of the child. Numerous studies on the correlates of both prenatal and postnatal mother-to-infant bonding quality have been published over the last decades. An up-to-date systematic review of these correlates is lacking, however. Objective To systematically review correlates of prenatal and postnatal mother-to-infant bonding quality in the general population, in order to enable targeted interventions. Methods MEDLINE, Embase, CINAHL, and PsychINFO were searched through May 2018. Reference checks were performed. Case-control, cross-sectional or longitudinal cohort studies written in English, German, Swedish, Spanish, Norwegian, French or Dutch defining mother-to-infant bonding quality as stipulated in the protocol (PROSPERO CRD42016040183) were included. Two investigators independently reviewed abstracts, full-text articles and extracted data. Methodological quality was assessed using the National Institute of Health Quality Assessment Tool for Observational Cohort and Cross-sectional studies and was rated accordingly as poor, fair or good. Clinical and methodological heterogeneity were examined. Main results 131 studies were included. Quality was fair for 20 studies, and poor for 111 studies. Among 123 correlates identified, 3 were consistently associated with mother-to-infant bonding quality: 1) duration of gestation at assessment was positively associated with prenatal bonding quality, 2) depressive symptoms were negatively associated with postnatal mother-to-infant bonding quality, and 3) mother-to-infant bonding quality earlier in pregnancy or postpartum was positively associated with mother-to-infant bonding quality later in time. Conclusion Our review suggests that professionals involved in maternal health care should consider monitoring mother-to-infant bonding already during pregnancy. Future research should evaluate whether interventions aimed at depressive symptoms help to promote mother-to-infant bonding quality. More high-quality research on correlates for which inconsistent results were found is needed.	[Tichelman, Elke; Westerneng, Myrte; Witteveen, Anke B.; de Jonge, Ank; Peters, Lilian L.] Vrije Univ Amsterdam, Amsterdam UMC, Midwifery Sci, AVAG,Amsterdam Publ Hlth Res Inst, Amsterdam, Netherlands; [Tichelman, Elke; Berger, Marjolein Y.; Burger, Huibert; Peters, Lilian L.] Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice & Elderly Care Med, Groningen, Netherlands; [van Baar, Anneloes L.] Univ Utrecht, Child & Adolescent Studies, Utrecht, Netherlands; [van der Horst, Henriette E.; Schellevis, Francois G.] Vrije Univ Amsterdam, Amsterdam UMC, Dept Gen Practice & Elderly Care Med, Amsterdam Publ Hlth Res Inst, Amsterdam, Netherlands; [Schellevis, Francois G.] Netherlands Inst Hlth Serv Res, NIVEL, Utrecht, Netherlands	University of Amsterdam; Vrije Universiteit Amsterdam; University of Groningen; Utrecht University; University of Amsterdam; Vrije Universiteit Amsterdam; Netherlands Institute for Health Services Research	Tichelman, E (corresponding author), Vrije Univ Amsterdam, Amsterdam UMC, Midwifery Sci, AVAG,Amsterdam Publ Hlth Res Inst, Amsterdam, Netherlands.; Tichelman, E (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice & Elderly Care Med, Groningen, Netherlands.	e.tichelman@umcg.nl	de Jonge, Ank/F-6475-2013; Witteveen, Anke/ABG-2957-2020	Witteveen, Anke/0000-0002-9636-7522; Tichelman, Elke/0000-0002-4690-6188	Midwifery Academy Amsterdam Groningen; department of Midwifery Science	Midwifery Academy Amsterdam Groningen; department of Midwifery Science	This work was funded by the Midwifery Academy Amsterdam Groningen and the department of Midwifery Science which is located in Amsterdam (VU Medical Center Amsterdam) and Groningen (University Medical Center Groningen). The funding organizations had no role in study design, data collection, analysis, interpretation, in writing of the paper, or in the decision to submit the paper for publication.	Altman D.G., 1991, PRACTICAL STAT MED R; Barrett J, 2012, SOC NEUROSCI-UK, V7, P252, DOI 10.1080/17470919.2011.609907; Benoit Diane, 2004, Paediatr Child Health, V9, P541; Boekhorst MGBM, 2019, J AFFECT DISORDERS, V248, P139, DOI 10.1016/j.jad.2019.01.021; Bowlby J., 1969, ATTACHMENT LOSS, V1; Brennan K. A., 1998, SELF REPORT MEASUREM, P46; Brockington IF, 2006, ARCH WOMEN MENT HLTH, V9, P233, DOI 10.1007/s00737-006-0132-1; Cannella BL, 2005, J ADV NURS, V50, P60, DOI 10.1111/j.1365-2648.2004.03349.x; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; CRANLEY MS, 1981, NURS RES, V30, P281, DOI 10.1097/00006199-198109000-00008; Cunen NB, 2017, WOMEN BIRTH, V30, pE141, DOI 10.1016/j.wombi.2016.11.005; de Cock ESA, 2016, J FAM PSYCHOL, V30, P125, DOI 10.1037/fam0000138; Dennis CL, 2005, BMJ-BRIT MED J, V331, P15, DOI 10.1136/bmj.331.7507.15; Dudek J, 2018, CHILD DEV, P1; Evans J, 2001, BRIT MED J, V323, P257, DOI 10.1136/bmj.323.7307.257; Field T, 2010, INFANT BEHAV DEV, V33, P1, DOI 10.1016/j.infbeh.2009.10.005; Forray Ariadna, 2016, F1000Res, V5, DOI 10.12688/f1000research.7645.1; FULLER J R, 1990, Health Care for Women International, V11, P433; Hakanen H, 2019, J AFFECT DISORDERS, V257, P83, DOI 10.1016/j.jad.2019.06.048; Rodrigo MJ, 2011, DEV PSYCHOPATHOL, V23, P163, DOI 10.1017/S0954579410000714; Kinsey CB, 2014, MIDWIFERY, V30, pE188, DOI 10.1016/j.midw.2014.02.006; Kinsey CB, 2013, MIDWIFERY, V29, P1314, DOI 10.1016/j.midw.2012.12.019; Klaus M.H., 1996, BONDING BUILDING FDN; Klaus MH, 1976, MOTHER INFANT BONDIN; LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786; Laxton-Kane M, 2002, J REPROD INFANT PSYC, V20, P253, DOI 10.1080/0264683021000033174; Limlomwongse N, 2006, ARCH WOMEN MENT HLTH, V9, P131, DOI 10.1007/s00737-005-0115-7; Lindgren K, 2001, RES NURS HEALTH, V24, P203, DOI 10.1002/nur.1023; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Martin G, 2004, J NERV MENT DIS, V192, P650, DOI 10.1097/01.nmd.0000142028.10056.c6; Mason ZS, 2011, J REPROD INFANT PSYC, V29, P382, DOI 10.1080/02646838.2011.629994; McElwain NL, 2006, J FAM PSYCHOL, V20, P247, DOI 10.1037/0893-3200.20.2.247; Mercer RT, 2006, JOGNN-J OBST GYN NEO, V35, P568, DOI 10.1111/J.1552-6909.2006.00080.x; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Morrell CJ, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20370; National Heart Lung and Blood Institute, 2014, QUAL ASS TOOL OBS CO; Nunnally J. C., 1994, PSYCHOMETRIC THEORY, V3; OAKLEYBROWNE MA, 1995, J AFFECT DISORDERS, V34, P13, DOI 10.1016/0165-0327(94)00099-U; Ocaktan E, 2006, ANKARA U TIP FAKULTE, V59, P151; Olson CM, 2002, JAMA-J AM MED ASSOC, V287, P2825, DOI 10.1001/jama.287.21.2825; Parfitt Y, 2013, INFANT BEHAV DEV, V36, P599, DOI 10.1016/j.infbeh.2013.06.003; PARKER G, 1979, BRIT J MED PSYCHOL, V52, P1, DOI 10.1111/j.2044-8341.1979.tb02487.x; Rowe HJ, 2013, J PEDIATR ADOL GYNEC, V26, P327, DOI 10.1016/j.jpag.2013.06.009; Sato T, 1998, PSYCHOL MED, V28, P737, DOI 10.1017/S0033291797006430; Schmid B, 2011, J PSYCHIATR RES, V45, P1387, DOI 10.1016/j.jpsychires.2011.05.010; Siddiqui A, 2000, EARLY HUM DEV, V59, P13, DOI 10.1016/S0378-3782(00)00076-1; Slagt-Tichelman E, 2019, TIJDSCHR VERLOS, V3, P16; SPANIER GB, 1976, J MARRIAGE FAM, V38, P15, DOI 10.2307/350547; Spielberger C.D., 1970, MANUAL STATE TRAIT A, DOI 10.2307/1831273; Steiner B, 2014, J CRIM JUST, V42, P462, DOI 10.1016/j.jcrimjus.2014.08.001; Thoppil J, 2005, AM J OBSTET GYNECOL, V192, P1446, DOI 10.1016/j.ajog.2004.12.073; US Preventive Serv Task Force, 2009, ANN INTERN MED, V151, P784, DOI 10.7326/0003-4819-151-11-200912010-00006; Van den Bergh B, 2009, J REPROD INFANT PSYC, V27, P114, DOI 10.1080/02646830802007480; Yarcheski A, 2009, INT J NURS STUD, V46, P708, DOI 10.1016/j.ijnurstu.2008.10.013; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2; 2015, OBSTET GYNECOL, V125, P1268, DOI DOI 10.1097/01.AOG.0000465192.34779.	58	60	60	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2019	14	9							e0222998	10.1371/journal.pone.0222998	http://dx.doi.org/10.1371/journal.pone.0222998			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM5RZ	31550274	Green Published, gold			2023-01-03	WOS:000532307700040
J	Cooper, N; Ghanima, W				Cooper, Nichola; Ghanima, Waleed			Immune Thrombocytopenia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POPULATION-BASED COHORT; LONG-TERM TREATMENT; VENOUS THROMBOEMBOLISM; RECEPTOR-AGONISTS; ADULT PATIENTS; PURPURA; SPLENECTOMY; EFFICACY; SAFETY; ROMIPLOSTIM	Immune thrombocytopenia in patients who present with serious bleeding is treated with platelet transfusions, glucocorticoids, and intravenous immune globulin. In patients without serious bleeding, treatment decisions are guided by the platelet count and other factors. Commonly used agents include glucocorticoids, thrombopoietin-receptor agonists, and rituximab.	[Cooper, Nichola] Imperial Coll, Hammersmith Hosp, Dept Med, Du Cane Rd, London W12 0HS, England; [Ghanima, Waleed] Ostfold Hosp Trust, Dept Med, Kalnes, Norway; [Ghanima, Waleed] Ostfold Hosp Trust, Dept Hematol Oncol, Kalnes, Norway; [Ghanima, Waleed] Ostfold Hosp Trust, Dept Res, Kalnes, Norway; [Ghanima, Waleed] Oslo Univ Hosp, Dept Hematol, Oslo, Norway; [Ghanima, Waleed] Univ Oslo, Inst Clin Med, Oslo, Norway	Imperial College London; University of Oslo; University of Oslo	Cooper, N (corresponding author), Imperial Coll, Hammersmith Hosp, Dept Med, Du Cane Rd, London W12 0HS, England.	n.cooper@imperial.ac.uk						Adelborg K, 2019, J THROMB HAEMOST, V17, P912, DOI 10.1111/jth.14446; Arnold DM, 2007, ANN INTERN MED, V146, P25, DOI 10.7326/0003-4819-146-1-200701020-00006; Bao WL, 2010, BLOOD, V116, P4639, DOI 10.1182/blood-2010-04-281717; Boyle S, 2013, BLOOD, V121, P4782, DOI 10.1182/blood-2012-12-467068; Bussel J, 2018, AM J HEMATOL, V93, P921, DOI 10.1002/ajh.25125; Rocha AMC, 2011, HAEMATOL-HEMATOL J, V96, P1560, DOI 10.3324/haematol.2011.046417; Chaturvedi S, 2018, BLOOD, V131, P1172, DOI 10.1182/blood-2017-09-742353; Cheng G, 2011, LANCET, V377, P393, DOI 10.1016/S0140-6736(10)60959-2; Cheng YF, 2003, NEW ENGL J MED, V349, P831, DOI 10.1056/NEJMoa030254; Chugh S, 2015, LANCET HAEMATOL, V2, pE75, DOI 10.1016/S2352-3026(15)00003-4; Efficace F, 2016, AM J HEMATOL, V91, P995, DOI 10.1002/ajh.24463; Frederiksen H, 1999, BLOOD, V94, P909, DOI 10.1182/blood.V94.3.909.415k02_909_913; Frederiksen H, 2017, EUR J INTERN MED, V37, pE23, DOI 10.1016/j.ejim.2016.09.001; Ghanima W, 2019, HAEMATOLOGICA, V104, P1112, DOI 10.3324/haematol.2018.212845; Ghanima W, 2015, LANCET, V385, P1653, DOI 10.1016/S0140-6736(14)61495-1; Ghanima W, 2012, BLOOD, V120, P960, DOI 10.1182/blood-2011-12-309153; Godeau B, 2002, LANCET, V359, P23, DOI 10.1016/S0140-6736(02)07275-6; Gonzalez-Lopez TJ, 2015, AM J HEMATOL, V90, pE40, DOI 10.1002/ajh.23900; Jurczak W, 2018, BRIT J HAEMATOL, V183, P479, DOI 10.1111/bjh.15573; Khellaf M, 2005, HAEMATOLOGICA, V90, P829; Khellaf M, 2014, BLOOD, V124, P3228, DOI 10.1182/blood-2014-06-582346; Khellaf M, 2013, HAEMATOLOGICA, V98, P881, DOI 10.3324/haematol.2012.074633; Kojouri K, 2004, BLOOD, V104, P2623, DOI 10.1182/blood-2004-03-1168; Kuter DJ, 2008, LANCET, V371, P395, DOI 10.1016/S0140-6736(08)60203-2; Kuter DJ, 2013, BRIT J HAEMATOL, V161, P411, DOI 10.1111/bjh.12260; Lucchini E, 2019, HAEMATOLOGICA, V104, P1124, DOI 10.3324/haematol.2019.218883; Matzdorff A, 2018, ONCOL RES TREAT, V41, P1, DOI 10.1159/000492187; McMillan R, 2004, BLOOD, V103, P1364, DOI 10.1182/blood-2003-08-2672; Mithoowani S, 2016, LANCET HAEMATOL, V3, pE489, DOI 10.1016/S2352-3026(16)30109-0; Najaoui A, 2012, EUR J HAEMATOL, V88, P167, DOI 10.1111/j.1600-0609.2011.01718.x; Neunert C, 2011, BLOOD, V117, P4190, DOI 10.1182/blood-2010-08-302984; Neunert CE, 2018, HEMATOL-AM SOC HEMAT, P568, DOI 10.1182/asheducation-2018.1.568; Newland A, 2016, BRIT J HAEMATOL, V172, P262, DOI 10.1111/bjh.13827; Norgaard M, 2016, BRIT J HAEMATOL, V174, P639, DOI 10.1111/bjh.13787; Olsson B, 2003, NAT MED, V9, P1123, DOI 10.1038/nm921; Page LK, 2007, BRIT J HAEMATOL, V138, P245, DOI 10.1111/j.1365-2141.2007.06635.x; Park YH, 2016, ACTA HAEMATOL-BASEL, V135, P162, DOI 10.1159/000442703; Patel VL, 2012, BLOOD, V119, P5989, DOI 10.1182/blood-2011-11-393975; Piel-Julian ML, 2018, J THROMB HAEMOST, V16, P1830, DOI 10.1111/jth.14227; Provan D, 2010, BLOOD, V115, P168, DOI 10.1182/blood-2009-06-225565; Qu YK, 2014, INT SURG, V99, P286, DOI 10.9738/INTSURG-D-13-00175.1; Gonzalez-Porras JR, 2015, BRIT J HAEMATOL, V169, P111, DOI 10.1111/bjh.13266; Rodeghiero F, 2008, AM J HEMATOL, V83, P91, DOI 10.1002/ajh.21109; Rodeghiero F, 2016, AM J HEMATOL, V91, P39, DOI 10.1002/ajh.24234; Rodeghiero F, 2013, BLOOD, V121, P2596, DOI 10.1182/blood-2012-07-442392; Rodeghiero F, 2009, BLOOD, V113, P2386, DOI 10.1182/blood-2008-07-162503; Rorholt M, 2017, HAEMATOLOGICA, V102, P1333, DOI 10.3324/haematol.2016.157008; Sailer T, 2006, HAEMATOLOGICA, V91, P1041; Schoonen WM, 2009, BRIT J HAEMATOL, V145, P235, DOI 10.1111/j.1365-2141.2009.07615.x; Stasi R, 2008, BLOOD, V112, P1147, DOI 10.1182/blood-2007-12-129262; Thomsen RW, 2010, J THROMB HAEMOST, V8, P1413, DOI 10.1111/j.1538-7836.2010.03849.x; Wang L, 2016, SCI REP-UK, V6, DOI 10.1038/srep39003; Wong RSM, 2017, BLOOD, V130, P2527, DOI 10.1182/blood-2017-04-748707; Yong M, 2010, EUR J INTERN MED, V21, P12, DOI 10.1016/j.ejim.2009.10.003; Zufferey A, 2017, J CLIN MED, V6, DOI 10.3390/jcm6020016	55	142	152	11	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 5	2019	381	10					945	955		10.1056/NEJMcp1810479	http://dx.doi.org/10.1056/NEJMcp1810479			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IW9PR	31483965	Green Published			2023-01-03	WOS:000485326200009
J	Park, VY; Han, K; Kim, HJ; Lee, E; Youk, JH; Kim, EK; Moon, HJ; Yoon, JH; Kwak, JY				Park, Vivian Y.; Han, Kyunghwa; Kim, Hye Jung; Lee, Eunjung; Youk, Ji Hyun; Kim, Eun-Kyung; Moon, Hee Jung; Yoon, Jung Hyun; Kwak, Jin Young			Radiomics signature for prediction of lateral lymph node metastasis in conventional papillary thyroid carcinoma	PLOS ONE			English	Article							PREOPERATIVE DIAGNOSIS; PROGNOSTIC-FACTORS; TEXTURE ANALYSIS; NODULES; CANCER; ULTRASOUND; MALIGNANCY; GUIDELINES; BENIGN; KOREA	Purpose Preoperative neck ultrasound (US) for lateral cervical lymph nodes is recommended for all patients undergoing thyroidectomy for thyroid malignancy, but it is operator dependent. We aimed to develop a radiomics signature using US images of the primary tumor to preoperatively predict lateral lymph node metastasis (LNM) in patients with conventional papillary thyroid carcinoma (cPTC). Methods Four hundred consecutive cPTC patients from January 2004 to February 2006 were enrolled as the training cohort, and 368 consecutive cPTC patients from March 2006 to February 2007 served as the validation cohort. A radiomics signature, which consisted of 14 selected features, was generated by the least absolute shrinkage and selection operator (LASSO) regression model in the training cohort. The discriminating performance of the radiomics signature was assessed in the validation cohort with the area under the receiver operating characteristic curve (AUC). Results The radiomics signature was significantly associated with lateral cervical lymph node status (p < 0.001). The AUC of its performance in discriminating metastatic and non-metastatic lateral cervical lymph nodes was 0.710 (95% CI: 0.649-0.770) in the training cohort and was 0.621 (95% CI: 0.560-0.682) in the validation cohort. Conclusions The present study showed that US radiomic features of the primary tumor were associated with lateral cervical lymph node status. Although their discriminatory performance was slightly lower in the validation cohort, our study shows that US radiomic features of the primary tumor alone have the potential to predict lateral LNM.	[Park, Vivian Y.; Han, Kyunghwa; Kim, Eun-Kyung; Moon, Hee Jung; Yoon, Jung Hyun; Kwak, Jin Young] Yonsei Univ, Severance Hosp, Res Inst Radiol Sci, Dept Radiol,Coll Med, Seoul, South Korea; [Kim, Hye Jung] Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Radiol, Daegu, South Korea; [Lee, Eunjung] Yonsei Univ, Dept Computat Sci & Engn, Seoul, South Korea; [Youk, Ji Hyun] Yonsei Univ, Gangnam Severance Hosp, Res Inst Radiol Sci, Dept Radiol,Coll Med, Seoul, South Korea	Yonsei University; Yonsei University Health System; Kyungpook National University; Yonsei University; Yonsei University; Yonsei University Health System	Kwak, JY (corresponding author), Yonsei Univ, Severance Hosp, Res Inst Radiol Sci, Dept Radiol,Coll Med, Seoul, South Korea.	docjin@yuhs.ac	; Kim, Eun-Kyung/E-5211-2017	Moon, Hee Jung/0000-0002-5643-5885; Kim, Eun-Kyung/0000-0002-3368-5013; Yoon, Jung Hyun/0000-0002-2100-3513; Lee, Eunjung/0000-0001-9989-3555; Park, Vivian/0000-0002-5135-4058; Kwak, Jin Young/0000-0002-6212-1495	Basic Science Research Program through the National Research Foundation of Korea (NRF) by the Ministry of Education [2016R1D1A1B03930375]; National Research Foundation of Korea (NRF) - Korea government (MSIT) [2019R1A2C1002375]	Basic Science Research Program through the National Research Foundation of Korea (NRF) by the Ministry of Education; National Research Foundation of Korea (NRF) - Korea government (MSIT)	This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) by the Ministry of Education (2016R1D1A1B03930375) and by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2019R1A2C1002375). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn HS, 2016, THYROID, V26, P1535, DOI 10.1089/thy.2016.0075; Bhatia KSS, 2016, ULTRASOUND MED BIOL, V42, P1671, DOI 10.1016/j.ultrasmedbio.2016.01.013; Chen SJ, 2010, ULTRASOUND MED BIOL, V36, P2018, DOI 10.1016/j.ultrasmedbio.2010.08.019; Cho BY, 2013, THYROID, V23, P797, DOI 10.1089/thy.2012.0329; Cho E, 2018, AM J SURG, V216, P562, DOI 10.1016/j.amjsurg.2017.12.006; Gillies RJ, 2015, RADIOLOGY, DOI DOI 10.1148/RADIOL.2015151169; Grani G, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001129; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; Huang YQ, 2016, J CLIN ONCOL, V34, P2157, DOI 10.1200/JCO.2015.65.9128; Ito Y, 2005, WORLD J SURG, V29, P917, DOI 10.1007/s00268-005-7789-x; Kim H, 2017, THYROID, V27, P908, DOI 10.1089/thy.2016.0648; Kim SY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176103; Kim SY, 2015, AM J ROENTGENOL, V205, pW343, DOI 10.2214/AJR.14.13825; Kwak JY, 2009, ANN SURG ONCOL, V16, P1348, DOI 10.1245/s10434-009-0384-x; Lee JH, 2018, THYROID, V28, P1332, DOI 10.1089/thy.2018.0082; Lee SH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22981-8; Liang JY, 2018, THYROID, V28, P1024, DOI 10.1089/thy.2017.0525; Liu TT, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819831713; Liu TT, 2018, INT J COMPUT ASS RAD, V13, P1617, DOI 10.1007/s11548-018-1796-5; Londero SC, 2015, THYROID, V25, P78, DOI 10.1089/thy.2014.0294; Lundgren CI, 2006, CANCER, V106, P524, DOI 10.1002/cncr.21653; Moon HJ, 2012, ULTRASOUND MED BIOL, V38, P568, DOI 10.1016/j.ultrasmedbio.2012.01.002; Moon HJ, 2011, AM J ROENTGENOL, V197, pW324, DOI 10.2214/AJR.10.5576; Nam SJ, 2016, J ULTRAS MED, V35, P775, DOI 10.7863/ultra.15.05055; Park VY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004292; Qu JR, 2019, EUR RADIOL, V29, P906, DOI 10.1007/s00330-018-5583-z; Randolph GW, 2012, THYROID, V22, P1144, DOI 10.1089/thy.2012.0043; Suh CH, 2017, AM J NEURORADIOL, V38, P154, DOI 10.3174/ajnr.A4967; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Wu LM, 2012, EUR J RADIOL, V81, P1798, DOI 10.1016/j.ejrad.2011.04.028; Wu SX, 2017, CLIN CANCER RES, V23, P6904, DOI 10.1158/1078-0432.CCR-17-1510; Zhang B, 2017, CLIN CANCER RES, V23, P4259, DOI 10.1158/1078-0432.CCR-16-2910	32	18	20	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2020	15	1							e0227315	10.1371/journal.pone.0227315	http://dx.doi.org/10.1371/journal.pone.0227315			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5OV	31940386	Green Published, gold			2023-01-03	WOS:000534368000066
J	Cutler, DM				Cutler, David M.			Early Returns From the Era of Precision Medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item												dcutler@fas.harvard.edu		Cutler, David/0000-0002-4949-8917					0	14	14	1	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	2020	323	2					109	110		10.1001/jama.2019.20659	http://dx.doi.org/10.1001/jama.2019.20659			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF6MC	31935015	Bronze			2023-01-03	WOS:000509352900002
J	Wei, TT; Lin, YT; Tang, SP; Luo, CK; Tsai, CT; Shun, CT; Chen, CC				Wei, Tzu-Tang; Lin, Yi-Ting; Tang, Shao-Pu; Luo, Cong-Kai; Tsai, Chiou-Tsun; Shun, Chia-Tung; Chen, Ching-Chow			Metabolic targeting of HIF-1 alpha potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTORS; TUMOR HYPOXIA; HISTONE DEACETYLASE; DRUG-RESISTANCE; HIF-1; INFLAMMATION; CHEMORESISTANCE; ANGIOGENESIS; CHEMOTHERAPY; VASCULATURE	Drug resistance is a major problem limiting the efficacy of chemotherapy in cancer treatment, and the hypoxia-induced stabilization of HIF-1 alpha plays a role in this process. HIF-1 alpha overexpression has been observed in a variety of human cancers, including colorectal cancer (CRC). Therefore, targeting HIF-1 alpha is a promising strategy for overcoming chemoresistance to enhance the efficacy of chemotherapies in CRC. Here, we show that DNMT inhibitors can induce HIF-1 alpha degradation to overcome oxaliplatin resistance and enhance anti-CRC therapy. We found that a low-toxicity DNMT inhibitor, zebularine, could downregulate HIF-1 alpha expression and overcome hypoxia-induced oxaliplatin resistance in HCT116 cells and showed efficacy in HCT116 xenograft models and AOM/DSS-induced CRC mouse models. Zebularine could induce the degradation of HIF-1 alpha protein through hydroxylation. LC-MS analysis showed a decrease in succinate in various CRC cells under hypoxia and in colon tissues of AOM/DSS-induced CRC mice. The decrease was reversed by zebularine. Tumor angiogenesis was also reduced by zebularine. Furthermore, zebularine potentiated the anticancer effect of oxaliplatin in AOM/DSS-induced CRC models. This finding provides a new strategy in which an increase in HIF-1 alpha hydroxylation could overcome oxaliplatin resistance to enhance anti-CRC therapy.	[Wei, Tzu-Tang; Lin, Yi-Ting; Tang, Shao-Pu; Luo, Cong-Kai; Tsai, Chiou-Tsun; Chen, Ching-Chow] Natl Taiwan Univ, Dept Pharmacol, Coll Med, Taipei 100, Taiwan; [Wei, Tzu-Tang; Lin, Yi-Ting; Tang, Shao-Pu; Luo, Cong-Kai; Tsai, Chiou-Tsun; Shun, Chia-Tung; Chen, Ching-Chow] Natl Taiwan Univ, Grad Inst Forens Med, Coll Med, Taipei 100, Taiwan; [Shun, Chia-Tung] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 106, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital	Chen, CC (corresponding author), Natl Taiwan Univ, Dept Pharmacol, Coll Med, Taipei 100, Taiwan.; Chen, CC (corresponding author), Natl Taiwan Univ, Grad Inst Forens Med, Coll Med, Taipei 100, Taiwan.	chingchowchen@ntu.edu.tw	WEI, TZU-TANG/AAT-8447-2020; Tsai, Chiou-Tsun/AAO-6782-2021	SHUN, CHIA-TUNG/0000-0002-0468-4468	National Science Council of Taiwan; Institute of Biomedical Sciences, Academia Sinica [IBMS-CRC103-P02]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Institute of Biomedical Sciences, Academia Sinica(Academia Sinica - Taiwan)	This work was supported by a research grant from the National Science Council of Taiwan and the Institute of Biomedical Sciences, Academia Sinica (IBMS-CRC103-P02).	Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Berchner-Pfannschmidt U, 2008, J BIOL CHEM, V283, P31745, DOI 10.1074/jbc.M804390200; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005; Chan DA, 2009, CANCER CELL, V15, P527, DOI 10.1016/j.ccr.2009.04.010; Chen CC, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0248-3; Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023; Colgan SP, 2010, NAT REV GASTRO HEPAT, V7, P281, DOI 10.1038/nrgastro.2010.39; Fong GH, 2008, CELL DEATH DIFFER, V15, P635, DOI 10.1038/cdd.2008.10; Foxler DE, 2012, NAT CELL BIOL, V14, P201, DOI 10.1038/ncb2424; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kim MS, 2010, CANCER METAST REV, V29, P181, DOI 10.1007/s10555-010-9207-6; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Lee K, 2009, P NATL ACAD SCI USA, V106, P17910, DOI 10.1073/pnas.0909353106; Lendahl U, 2009, NAT REV GENET, V10, P821, DOI 10.1038/nrg2665; Liu LL, 2008, CANCER SCI, V99, P121, DOI 10.1111/j.1349-7006.2007.00643.x; Ma J, 2008, MOL CANCER THER, V7, P3670, DOI 10.1158/1535-7163.MCT-08-0715; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Meneses AM, 2016, HYPOXIA, V4, P53, DOI 10.2147/HP.S53576; Pientka FK, 2012, J CELL SCI, V125, P5168, DOI 10.1242/jcs.109041; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Rapisarda A, 2012, NAT REV CLIN ONCOL, V9, P378, DOI 10.1038/nrclinonc.2012.64; Remels AHV, 2015, ENDOCRINOLOGY, V156, P1770, DOI 10.1210/en.2014-1591; Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001; Samanta D, 2014, P NATL ACAD SCI USA, V111, pE5429, DOI 10.1073/pnas.1421438111; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Thienpont B, 2016, NATURE, V537, P63, DOI 10.1038/nature19081; Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135; Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057; Wei TT, 2016, EBIOMEDICINE, V10, P124, DOI 10.1016/j.ebiom.2016.07.019; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; Wilson TR, 2006, ANN ONCOL, V17, pX315, DOI 10.1093/annonc/mdl280; Yang PM, 2013, SCI REP-UK, V3, DOI 10.1038/srep03219; Zhong H, 1999, CANCER RES, V59, P5830	47	24	30	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					414	427		10.1038/s41388-019-0999-8	http://dx.doi.org/10.1038/s41388-019-0999-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477841				2023-01-03	WOS:000507766400012
J	Fan, R; Ma, PH; Zhou, D; Yuan, F; Cao, XL				Fan, Rui; Ma, Peihua; Zhou, Dan; Yuan, Fang; Cao, Xueli			The properties and formation mechanism of oat beta-glucan mixed gels with different molecular weight composition induced by high-pressure processing	PLOS ONE			English	Article							THERMAL GELLING PROPERTIES; RHEOLOGICAL PROPERTIES; HYDROSTATIC-PRESSURE; PROTEIN; ACTOMYOSIN; VISCOELASTICITY; MICROSTRUCTURE; SOLUBILITY; EXTRACTION	High pressure, an emerging nonthermal technology has been widely applied in food product modifications. The effects of oat beta-glucan concentration and pressure on the properties of mixed gels with the different ratios of varying molecular weight (MW) beta-gulcan induced by HPP were investigated. The results showed that the lowest beta-glucan concentration forming a gel was 15% at 200 MPa, while 8% beta-glucan was required to form a gel at 500 MPa. The gel intensity and textural properties increased with elevating beta-glucan total concentration and pressure. The characteristic compact and smooth mixed gel formed with 12% beta-glucan at a ratio of 50:50 at 400 MPa for 30 min. Under this optimal parameters, the mixed solution showed a relatively lower particle size and turbidity, and the hydrogen bonding and electrostatic interaction played the main role during the gel formation process by high pressure. In addition, the core molecular structure of beta-glucan was maintained in the mixed gel formed under the optimal parameters.	[Fan, Rui; Cao, Xueli] Beijing Technol & Business Univ, Beijing Adv Innovat Ctr Food Nutr & Human Hlth, Beijing, Peoples R China; [Fan, Rui] Peking Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Beijing, Peoples R China; [Ma, Peihua; Yuan, Fang] China Agr Univ, Coll Food Sci & Nutr Engn, Beijing, Peoples R China; [Zhou, Dan] Beijing Univ Chem Technol, Sch Life Sci & Technol, Beijing, Peoples R China	Beijing Technology & Business University; Peking University; China Agricultural University; Beijing University of Chemical Technology	Fan, R; Cao, XL (corresponding author), Beijing Technol & Business Univ, Beijing Adv Innovat Ctr Food Nutr & Human Hlth, Beijing, Peoples R China.; Fan, R (corresponding author), Peking Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Beijing, Peoples R China.	fanruirf@bjmu.edu.cn; caoxl@th.btbu.edu.cn	Ma, Peihua/ABD-5627-2021	Ma, Peihua/0000-0002-5041-0361; Fan, Rui/0000-0002-6895-763X	Beijing Advanced Innovation Center for Food Nutrition and Human Health [20161003]	Beijing Advanced Innovation Center for Food Nutrition and Human Health	This research was funded by the Beijing Advanced Innovation Center for Food Nutrition and Human Health(No.20161003), which funded the first author Dr. Fan to carried out this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agbenorhevi JK, 2011, INT J BIOL MACROMOL, V49, P369, DOI 10.1016/j.ijbiomac.2011.05.014; Ahmed J, 2016, LWT-FOOD SCI TECHNOL, V70, P63, DOI 10.1016/j.lwt.2016.02.027; [Anonymous], 2002, FED REGISTER, V73, P9938; Augusto PED, 2012, FOOD BIOPROCESS TECH, V5, P1715, DOI 10.1007/s11947-010-0472-8; BERNAL VM, 1987, J FOOD SCI, V52, P1121, DOI 10.1111/j.1365-2621.1987.tb14023.x; Bohm N, 1999, CARBOHYD RES, V315, P302, DOI 10.1016/S0008-6215(99)00036-1; Brummer Y, 2014, J AGR FOOD CHEM, V62, P3160, DOI 10.1021/jf405131d; Chen X, 2014, FOOD BIOPROCESS TECH, V7, P3608, DOI 10.1007/s11947-014-1368-9; Chen X, 2014, FOOD HYDROCOLLOID, V40, P262, DOI 10.1016/j.foodhyd.2014.03.018; Clark AH, 1987, FOOD POLYM GEL COLLO, V83, P322; Cleary LJ, 2007, FOOD CHEM, V102, P889, DOI 10.1016/j.foodchem.2006.06.027; DOUBLIER JL, 1995, CEREAL CHEM, V72, P335; Estrada A, 2013, MICROBIOL IMMUNOL, V41, P991, DOI DOI 10.1111/j.1348-0421.1997.tb01959.x; Haibo W, 2008, RHEOLOGICAL PROPERTI, P45; Hsu KC, 2007, FOOD CHEM, V103, P560, DOI 10.1016/j.foodchem.2006.09.001; Hussain PR, 2018, RADIAT PHYS CHEM, V144, P218, DOI 10.1016/j.radphyschem.2017.08.018; Hwang IW, 2018, APPL BIOL CHEM, V61, P235, DOI 10.1007/s13765-018-0350-z; Kayali H, 2005, NEUROSURG REV, V28, P298, DOI 10.1007/s10143-005-0389-2; Kim HS, 2011, CARBOHYD POLYM, V83, P755, DOI 10.1016/j.carbpol.2010.08.048; Kontogiorgos V, 2006, COLLOID SURFACE B, V49, P145, DOI 10.1016/j.colsurfb.2006.03.011; Lan-Pidhainy XM, 2007, CEREAL CHEM, V84, P512, DOI 10.1094/CCHEM-84-5-0512; Lazaridou A, 2003, FOOD HYDROCOLLOID, V17, P693, DOI 10.1016/S0268-005X(03)00036-5; Li XY, 2018, INNOV FOOD SCI EMERG, V47, P335, DOI 10.1016/j.ifset.2018.03.022; Limberger-Bayer VM, 2014, FOOD CHEM, V154, P84, DOI 10.1016/j.foodchem.2013.12.104; Liu R, 2011, MEAT SCI, V88, P234, DOI 10.1016/j.meatsci.2010.12.026; Lopez-Sanchez P, 2011, J SCI FOOD AGR, V91, P207, DOI 10.1002/jsfa.4168; Ma F, 2013, MEAT SCI, V95, P22, DOI 10.1016/j.meatsci.2013.04.025; Mensi A, 2013, FOOD CHEM, V139, P253, DOI 10.1016/j.foodchem.2013.02.004; Methacanon P, 2011, CARBOHYD POLYM, V86, P574, DOI 10.1016/j.carbpol.2011.04.075; Montero P, 2002, FOOD HYDROCOLLOID, V16, P197, DOI 10.1016/S0268-005X(01)00083-2; Morris ER, 2012, FOOD HYDROCOLLOID, V28, P373, DOI 10.1016/j.foodhyd.2012.01.004; Othman RA, 2011, NUTR REV, V69, P299, DOI 10.1111/j.1753-4887.2011.00401.x; Rabiey L, 2009, FOOD HYDROCOLLOID, V23, P973, DOI 10.1016/j.foodhyd.2008.07.009; Regand A, 2011, FOOD CHEM, V129, P297, DOI 10.1016/j.foodchem.2011.04.053; Samapark S, 2008, FOOD CHEM, V107, P984, DOI 10.1016/j.foodchem.2007.08.091; Tan J, 2015, J FOOD ENG, V166, P45, DOI 10.1016/j.jfoodeng.2015.05.025; TUANPHANXUAN, 2014, FOOD HYDROCOLLOID, V34, P227, DOI DOI 10.1016/J.FOODHYD.2012.09.008; Ueno S, 2018, HIGH PRESSURE RES, V25, P26; Wang YJ, 2005, CARBOHYD POLYM, V59, P93, DOI 10.1016/j.carbpol.2004.09.003; Wang Y, 2011, CARBOHYD POLYM, V86, P594, DOI 10.1016/j.carbpol.2011.04.078; WINTER HH, 1986, J RHEOL, V30, P367, DOI 10.1122/1.549853; Wolever TMS, 2010, P NUTR SOC, V69, pE461, DOI 10.1017/S0029665110003241; Wu XL, 2016, FOOD HYDROCOLLOID, V52, P942, DOI 10.1016/j.foodhyd.2015.09.012; Zhao YY, 2014, FOOD RES INT, V58, P98, DOI 10.1016/j.foodres.2014.01.024; Zhou YZ, 2014, J AGR FOOD CHEM, V62, P2655, DOI 10.1021/jf405381z	45	5	5	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2019	14	12							e0225208	10.1371/journal.pone.0225208	http://dx.doi.org/10.1371/journal.pone.0225208			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN8IR	31881549	Green Published, gold			2023-01-03	WOS:000515089200007
J	Al-Adwani, DG; Renno, WM; Orabi, KY				Al-Adwani, Dalal G.; Renno, Waleed M.; Orabi, Khaled Y.			Neurotherapeutic effects of Ginkgo biloba extract and its terpene trilactone, ginkgolide B, on sciatic crush injury model: A new evidence	PLOS ONE			English	Article							NERVE CRUSH; EGB 761; FUNCTIONAL RECOVERY; RAT MODEL; REGENERATION; INHIBITION; ACTIVATION; EXPRESSION; CELLS; PHARMACOKINETICS	Ginkgo biloba leaves extract (GBE) was subjected to neuroprotective-guided fractionation to produce eleven fractions with different polarities and constituents. The intermediate polar fraction was shown to be terpene trilactones-enriched fraction (TEGBE). Out of this fraction, pure ginkgolide B (G-B) was further purified and identified based on its spectral data. The effects of GBE and TEGBE were evaluated in comparison to that of G-B in the crush sciatic nerve injury rat model. To evaluate the neuroprotective effects, sixty Wistar male rats were randomly allocated into 6 groups: naive, sham, crush + normal saline, and three treatment groups; crush + GBE, crush + TEGBE, and crush + G-B. Treatments were given one hour following injury, and once daily for 14 days. Neurobehavioral tests, histomorphological examinations, and immunohistochemical analysis of the sciatic nerve and the spinal cord were performed at weeks 3 and 6 post-injury. GBE, TEGBE and G-B were shown to enhance the functional and sensory behavioral parameters and to protect the histological and the ultrastructural elements in the sciatic nerve. Additionally, all treatments prevented spinal cord neurons from further deterioration. It was shown that G-B has the most significant potential effects among all treatments with values that were nearly comparable to those of sham and naive groups.	[Al-Adwani, Dalal G.; Orabi, Khaled Y.] Kuwait Univ, Fac Pharm, Dept Pharmaceut Chem, Safat, Kuwait; [Renno, Waleed M.] Kuwait Univ, Fac Med, Dept Anat, Safat, Kuwait	Kuwait University; Kuwait University	Orabi, KY (corresponding author), Kuwait Univ, Fac Pharm, Dept Pharmaceut Chem, Safat, Kuwait.	kyorabi@hsc.edu.kw	Orabi, Khaled/ABC-6076-2020	Renno, Waleed/0000-0001-9024-9712; Orabi, Khaled/0000-0003-0262-4637	College of Graduate Studies; Research Sector, Kuwait University [YP03/15, GS01/01, GS01/03]	College of Graduate Studies; Research Sector, Kuwait University	This work was supported by: KYO, College of Graduate Studies, and Research Sector, Kuwait University, Kuwait (Grant Number YP03/15). Spectral analyses are supported by Research Sector, Kuwait University (Grant numbers GS01/01 and GS01/03).	Ao Q, 2006, SPINAL CORD, V44, P662, DOI 10.1038/sj.sc.3101900; Biber A, 2003, PHARMACOPSYCHIATRY, V36, pS32; BRAQUET P, 1987, Drugs of the Future, V12, P643; Chen L, 2008, ANAT REC, V291, P527, DOI 10.1002/ar.20692; Chen X, 2010, N AM J MED SCI, V2, P241, DOI 10.4297/najms.2010.2241; GARRISON CJ, 1991, BRAIN RES, V565, P1, DOI 10.1016/0006-8993(91)91729-K; Gu JH, 2012, EUR J PHARM SCI, V47, P652, DOI 10.1016/j.ejps.2012.07.016; Hsu SH, 2004, J BIOMATER APPL, V19, P163, DOI 10.1177/0885328204045580; Hussain ASM, 2018, NEUROPHARMACOLOGY, V128, P231, DOI 10.1016/j.neuropharm.2017.10.020; Jahanshahi M, 2012, ANAT CELL BIOL, V45, P92, DOI 10.5115/acb.2012.45.2.92; Jang CH, 2012, INT J PEDIATR OTORHI, V76, P1823, DOI 10.1016/j.ijporl.2012.09.009; Jaracz S, 2004, CHEM-EUR J, V10, P1507, DOI 10.1002/chem.200305473; Kang JW, 2010, PHYTOTHER RES, V24, pS77, DOI 10.1002/ptr.2913; Kiewert C, 2007, BRAIN RES, V1128, P70, DOI 10.1016/j.brainres.2006.10.042; Kim J, 2000, Environ Health Prev Med, V5, P53, DOI 10.1007/BF02932004; Kim JD, 2006, J NUTR BIOCHEM, V17, P165, DOI 10.1016/j.jnutbio.2005.06.006; Kim MS, 2004, PHYTOTHER RES, V18, P663, DOI 10.1002/ptr.1486; Kim YS, 2009, ANESTH ANALG, V108, P1958, DOI 10.1213/ane.0b013e31819f1972; Klein J, 1997, BRAIN RES, V755, P347, DOI 10.1016/S0006-8993(97)00239-4; Koltai M, 1994, Adv Pharmacol, V28, P81, DOI 10.1016/S1054-3589(08)60494-9; Li W, 2009, CHEM-BIOL INTERACT, V177, P121, DOI 10.1016/j.cbi.2008.10.048; Lin H, 2007, MICROSURG, V27, P673, DOI 10.1002/micr.20430; LOBSTEINGUTH A, 1983, J CHROMATOGR, V267, P431, DOI 10.1016/S0021-9673(01)90866-0; Ma K, 2009, EYE, V23, P1598, DOI 10.1038/eye.2008.286; Mizisin AP, 2017, NEUROPATHOLOGY; Nakanishi K, 2005, BIOORGAN MED CHEM, V13, P4987, DOI 10.1016/j.bmc.2005.06.014; Oliveira DR, 2009, BRAIN RES, V1269, P68, DOI 10.1016/j.brainres.2008.11.105; PANETTA T, 1987, BIOCHEM BIOPH RES CO, V149, P580, DOI 10.1016/0006-291X(87)90407-4; Park HJ, 2012, ANESTH ANALG, V115, P1228, DOI 10.1213/ANE.0b013e318262e170; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pezzuto JM, 1997, BIOCHEM PHARMACOL, V53, P121, DOI 10.1016/S0006-2952(96)00654-5; Rangel-Ordonez L, 2010, PLANTA MED, V76, P1683, DOI 10.1055/s-0030-1249962; Renno WM, 2017, J NEUROSURG-SPINE, V27, P593, DOI 10.3171/2016.10.SPINE16218; Renno WM, 2015, J NEUROTRAUM, V32, P170, DOI 10.1089/neu.2014.3491; Renno WM, 2013, NEUROCHEM INT, V62, P221, DOI 10.1016/j.neuint.2012.12.018; Renno WM, 2012, N-S ARCH PHARMACOL, V385, P807, DOI 10.1007/s00210-012-0758-7; Rocher MN, 2011, FITOTERAPIA, V82, P1075, DOI 10.1016/j.fitote.2011.07.001; Smith JV, 2003, J ALZHEIMERS DIS, V5, P287, DOI 10.3233/JAD-2003-5404; TANAKA K, 1992, EXP NEUROL, V118, P53, DOI 10.1016/0014-4886(92)90022-I; Taylor CA, 2008, AM J PHYS MED REHAB, V87, P381, DOI 10.1097/PHM.0b013e31815e6370; Teng BP, 2002, PCT International Patent Application, Patent No. 0283158; Ude C, 2013, CLIN PHARMACOKINET, V52, P727, DOI 10.1007/s40262-013-0074-5; van Beek TA, 2005, BIOORGAN MED CHEM, V13, P5001, DOI 10.1016/j.bmc.2005.05.056; van Beek TA, 2009, J CHROMATOGR A, V1216, P2002, DOI 10.1016/j.chroma.2009.01.013; Varejao ASP, 2004, J NEUROTRAUM, V21, P1652, DOI 10.1089/neu.2004.21.1652; WOOLF CJ, 1990, NEUROSCIENCE, V34, P465, DOI 10.1016/0306-4522(90)90155-W; Yan M, 2016, SPINAL CORD, V54, P259, DOI 10.1038/sc.2015.156; Zhang DY, 2011, J HUAZHONG U SCI-MED, V31, P789, DOI 10.1007/s11596-011-0678-7; Zhang F, 2000, CHIN J MICROSURG, V23, P279; Zhang Q, 2009, TOXICOL IN VITRO, V23, P797, DOI 10.1016/j.tiv.2009.04.007; Zhang YG, 2014, NEUROSCI LETT, V561, P198, DOI 10.1016/j.neulet.2013.12.068; Zhao L, 2011, BIOMED ENVIRON SCI, V24, P374, DOI 10.3967/0895-3988.2011.04.008; Zhao Z, 2011, J NEUROCHEM, V116, P1057, DOI 10.1111/j.1471-4159.2010.07160.x; Zheng J, 2016, GENET MOL RES, V15, P1; Zhu ZW, 2015, CELL MOL NEUROBIOL, V35, P273, DOI 10.1007/s10571-014-0122-1	55	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 26	2019	14	12							e0226626	10.1371/journal.pone.0226626	http://dx.doi.org/10.1371/journal.pone.0226626			31	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN8GX	31877172	Green Published, gold, Green Submitted			2023-01-03	WOS:000515084600030
J	Patel, DI; Abuchowski, K; Bedolla, R; Rivas, P; Musi, N; Reddick, R; Kumar, AP				Patel, Darpan I.; Abuchowski, Kira; Bedolla, Roble; Rivas, Paul; Musi, Nicolas; Reddick, Robert; Kumar, A. Pratap			Nexrutine and exercise similarly prevent high grade prostate tumors in transgenic mouse model	PLOS ONE			English	Article							AMURENSE BARK EXTRACT; QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; CANCER SURVIVORS; RESISTANCE EXERCISE; AEROBIC EXERCISE; SKELETAL-MUSCLE; RISK; CARCINOGENESIS; PROGRESSION	The purpose of this investigation was to compare the antitumorigenic effects of the natural product Nexrutine to voluntary wheel running (VWR) in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Forty-five, 10-week old TRAMP mice were randomized to either receive free access to the running wheel, Nexrutine pelleted into chow at 600 mg/kg or no treatment control. Mice were serially sacrificed at weeks 4, 8,12 and 20 weeks. Palpable tumors, body weight, food consumption and running wheel activity were monitored weekly. At necropsy, tumors and serum were harvested and stored for analysis. Serum was used to quantify circulating cytokines in 4 and 20 week time points. Nexrutine supplementation led to a 66% protection against high grade tumors. Exercise resulted in a 60% protection against high grade tumors. Both interventions reduced concentrations of IL-1 alpha. Exercise also significantly lowered concentrations of eotaxin, IL-5, IL-12(p40) and VEGF. While there were no significant differences at baseline, exercise mice had significantly lower IL-5 and VEGF compared to control at the 20 week time point. Nexrutine also significantly reduced circulating IL-9 concentrations. No significant differences were observed when compared to the control group. Immunohistochemistry of tumor sections showed significantly lower expression of pAkt in Nexrutine fed mice with no visible differences for NF kappa B. In conclusion, both Nexrutine and exercise suppressed tumor growth. Though similar outcomes were seen in this comparative effectiveness study, the mechanisms by which exercise and Nexrutine exert this benefit may focus on different pathways.	[Patel, Darpan I.; Abuchowski, Kira] UT Hlth San Antonio, Sch Nursing, San Antonio, TX 78229 USA; [Patel, Darpan I.; Kumar, A. Pratap] UT Hlth San Antonio, Mays Canc Ctr, San Antonio, TX 78229 USA; [Patel, Darpan I.; Musi, Nicolas] UT Hlth San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA; [Bedolla, Roble; Rivas, Paul; Kumar, A. Pratap] UT Hlth San Antonio, Dept Urol, Sch Med, San Antonio, TX 78229 USA; [Reddick, Robert] UT Hlth San Antonio, Dept Pathol, Sch Med, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Patel, DI (corresponding author), UT Hlth San Antonio, Sch Nursing, San Antonio, TX 78229 USA.; Patel, DI (corresponding author), UT Hlth San Antonio, Mays Canc Ctr, San Antonio, TX 78229 USA.; Patel, DI (corresponding author), UT Hlth San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.	pateld7@uthscsa.edu			UT Health San Antonio Cancer Center [P30 CA054174]; Department of Education [P031S150048]; Patient Centered Outcomes Research Institute [EAIN-6150]; NIH [R01-DK80157, R01-DK089229, U01 AR071150]; San Antonio Claude D. Pepper Older Americans Independence Center [P30 AG044271]; San Antonio Nathan Shock Center of Excellence on the Biology of Aging [P30 AG021890]; CTRC 40th Anniversary Distinguished Professor of Oncology Endowment; National Center for Complementary and Alternate Medicine [1R01 AT007448]; NATIONAL CANCER INSTITUTE [P30CA054174] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT007448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U01AR071150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG044271, T32AG021890] Funding Source: NIH RePORTER	UT Health San Antonio Cancer Center; Department of Education(US Department of Education); Patient Centered Outcomes Research Institute(Patient-Centered Outcomes Research Institute - PCORI); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); San Antonio Claude D. Pepper Older Americans Independence Center; San Antonio Nathan Shock Center of Excellence on the Biology of Aging; CTRC 40th Anniversary Distinguished Professor of Oncology Endowment; National Center for Complementary and Alternate Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Funding for this project was provided by the UT Health San Antonio Cancer Center (P30 CA054174) Population Science and Prevention pilot grant (DP; www.cancer.gov).DP is also supported by grants from the Department of Education (P031S150048; www.ed.gov), Patient Centered Outcomes Research Institute (EAIN-6150; www.pcori.org) and from the NIH (U01 AR071150; www.nih.gov).NM is supported by the San Antonio Claude D. Pepper Older Americans Independence Center (P30 AG044271; www.peppercenter.org), the San Antonio Nathan Shock Center of Excellence on the Biology of Aging (P30 AG021890; www.nia.nih.gov) and grants from the NIH (R01-DK80157 and R01-DK089229; www.nih.gov).APK is supported by the CTRC 40th Anniversary Distinguished Professor of Oncology Endowment and the National Center for Complementary and Alternate Medicine (1R01 AT007448; www.nccih.nih.gov).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal M, 2013, PROSTATE, V73, P573, DOI 10.1002/pros.22597; ANDRIANOPOULOS G, 1987, ANTICANCER RES, V7, P849; Antonelli JA, 2009, J UROLOGY, V182, P2226, DOI 10.1016/j.juro.2009.07.028; Barnard RJ, 2007, EUR J CANCER PREV, V16, P415, DOI 10.1097/01.cej.0000243851.66985.e4; Bellizzi KM, 2005, J CLIN ONCOL, V23, P8884, DOI 10.1200/JCO.2005.02.2343; Beydoun N, 2014, J MED IMAG RADIAT ON, V58, P369, DOI 10.1111/1754-9485.12115; Blackwell Debra L, 2018, Natl Health Stat Report, P1; Breuss JM, 2012, CELL ADHES MIGR, V6, P535, DOI 10.4161/cam.22243; Cohen L A, 1991, In Vivo, V5, P333; Coups EJ, 2005, PREV MED, V40, P702, DOI 10.1016/j.ypmed.2004.09.011; CRAVENGILES T, 1994, CANCER RES, V54, pS196; De Nunzio C, 2016, BJU INT, V117, pE29, DOI 10.1111/bju.13157; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Esser KA, 2009, PROSTATE, V69, P1372, DOI 10.1002/pros.20987; FONG Y, 1989, AM J PHYSIOL, V256, pR659, DOI 10.1152/ajpregu.1989.256.3.R659; Friedenreich CM, 2016, EUR UROL, V70, P576, DOI 10.1016/j.eururo.2015.12.032; Friedenreich CM, 2004, AM J EPIDEMIOL, V159, P740, DOI 10.1093/aje/kwh106; Galvao DA, 2006, MED SCI SPORT EXER, V38, P2045, DOI 10.1249/01.mss.0000233803.48691.8b; Galvao DA, 2010, J CLIN ONCOL, V28, P340, DOI 10.1200/JCO.2009.23.2488; Gao JC, 2009, CANCER SCI, V100, P389, DOI 10.1111/j.1349-7006.2008.01053.x; Garcia GE, 2006, NEOPLASIA, V8, P523, DOI 10.1593/neo.05745; Ghosh R, 2007, NEOPLASIA, V9, P893, DOI 10.1593/neo.07502; Ghosh R, 2010, ANTICANCER RES, V30, P857; Gingrich JR, 1999, PROSTATE CANCER P D, V2, P70, DOI 10.1038/sj.pcan.4500296; Glade MJ, 2008, NUTR PHYS ACTIVITY P; Goel HL, 2012, CELL ADHES MIGR, V6, P554, DOI 10.4161/cam.22419; Greiwe JS, 2001, FASEB J, V15, P475, DOI 10.1096/fj.00-0274com; Haas GP, 2008, CAN J UROL, V15, P3866; Hussain Suleman S, 2015, Curr Pharmacol Rep, V1, P365; Jagielska B, 2017, NOWOTWORY J ONCOLOGY, V67, P206; JAIN RK, 1988, CANCER RES, V48, P2641; Kenfield SA, 2011, J CLIN ONCOL, V29, P726, DOI 10.1200/JCO.2010.31.5226; Keogh JWL, 2010, NEW ZEAL MED J, V123, P20; Kumar AP, 2010, MINI-REV MED CHEM, V10, P388, DOI 10.2174/138955710791330936; Kumar AP, 2007, CLIN CANCER RES, V13, P2784, DOI 10.1158/1078-0432.CCR-06-2974; Kushi LH, 2012, CA-CANCER J CLIN, V62, P30, DOI 10.3322/caac.20140; Lee YM, 2010, INT IMMUNOL, V22, P805, DOI 10.1093/intimm/dxq431; Ma J, 2008, MOL CANCER THER, V7, P3670, DOI 10.1158/1535-7163.MCT-08-0715; McTiernan A, 2008, NAT REV CANCER, V8, P205, DOI 10.1038/nrc2325; Monga U, 2007, ARCH PHYS MED REHAB, V88, P1416, DOI 10.1016/j.apmr.2007.08.110; Norat T, 2014, CANCER TREAT RES, V159, P35, DOI 10.1007/978-3-642-38007-5_3; Perrot-Applanat M, 2012, CELL ADHES MIGR, V6, P547, DOI 10.4161/cam.23332; Richman EL, 2011, CANC RES; ROEBUCK BD, 1990, CANCER RES, V50, P6811; Sakamoto K, 2003, AM J PHYSIOL-ENDOC M, V285, pE1081, DOI 10.1152/ajpendo.00228.2003; Salcedo R, 2001, J IMMUNOL, V166, P7571, DOI 10.4049/jimmunol.166.12.7571; Segal RJ, 2003, J CLIN ONCOL, V21, P1653, DOI 10.1200/JCO.2003.09.534; Shephard RJ, 2017, SPORTS MED, V47, P1055, DOI 10.1007/s40279-016-0648-0; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Singh AA, 2013, CANCER-AM CANCER SOC, V119, P1338, DOI 10.1002/cncr.27791; Standard J, 2014, J NUTR BIOCHEM, V25, P1317, DOI 10.1016/j.jnutbio.2014.07.010; Swanson GP, 2015, PHYTOTHER RES, V29, P40, DOI 10.1002/ptr.5221; Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Wannamethee SG, 2001, BRIT J CANCER, V85, P1311, DOI 10.1054/bjoc.2001.2096; Wekesa A, 2015, PROSTATE CANCER P D, V18, P197, DOI 10.1038/pcan.2015.9; Windsor PM, 2004, CANCER, V101, P550, DOI 10.1002/cncr.20378; Winters-Stone KM, 2014, MED SCI SPORT EXER, V46, P1482, DOI 10.1249/MSS.0000000000000265; Yang M, 2015, CANCER PREV RES, V8, P545, DOI 10.1158/1940-6207.CAPR-14-0442; Zheng X, 2008, ONCOL REP, V19, P1583; Zheng X, 2012, NUTR CANCER, V64, P1029, DOI 10.1080/01635581.2012.716899; Zhu F, 2014, ONCOL REP, V31, P2049, DOI 10.3892/or.2014.3060	62	3	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2019	14	12							e0226187	10.1371/journal.pone.0226187	http://dx.doi.org/10.1371/journal.pone.0226187			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP3WL	31856170	gold, Green Published			2023-01-03	WOS:000534249400026
J	Chandra, J; Woo, WP; Dutton, JL; Xu, Y; Li, B; Kinrade, S; Druce, J; Finlayson, N; Griffin, P; Laing, KJ; Koelle, DM; Frazer, IH				Chandra, Janin; Woo, Wai-Ping; Dutton, Julie L.; Xu, Yan; Li, Bo; Kinrade, Sally; Druce, Julian; Finlayson, Neil; Griffin, Paul; Laing, Kerry J.; Koelle, David M.; Frazer, Ian H.			Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial	PLOS ONE			English	Article							GENITAL HERPES; THERAPEUTIC VACCINE; INFECTION; PROTECTS	Background Genital herpes simplex infection affects more than 500 million people worldwide. We have previously shown that COR-1, a therapeutic HSV-2 polynucleotide vaccine candidate, is safe and well tolerated in healthy subjects. Objective Here, we present a single center double-blind placebo-controlled, randomized phase I/IIa trial of COR-1 in HSV-2 positive subjects in which we assessed safety and tolerability as primary endpoints, and immunogenicity and therapeutic efficacy as exploratory endpoints. Methods Forty-four HSV-2+ subjects confirmed by positive serology or pathology, and positive qPCR during baseline shedding, with a recurrent genital HSV-2 history of at least 12 months including three to nine reported lesions in 12 months prior to screening, aged 18 to 50 years females and males with given written informed consent, were randomized into two groups. Three immunizations at 4-week intervals and one booster immunization at 6 months, each of 1 mg COR-1 DNA or placebo, were administered intradermally as two injections of 500 mu g each to either one forearm or both forearms. Results No serious adverse events, life-threatening events or deaths occurred throughout the study. As expected, HSV-2 infected subjects displayed gD2-specific antibody titers prior to immunization. COR-1 was associated with a reduction in viral shedding after booster administration compared with baseline. Conclusions This study confirms the previously demonstrated safety of COR-1 in humans and indicates a potential for use of COR-1 as a therapy to reduce viral shedding in HSV-2 infected subjects.	[Chandra, Janin; Woo, Wai-Ping; Dutton, Julie L.; Xu, Yan; Li, Bo; Finlayson, Neil; Frazer, Ian H.] Admedus Vaccines Pty Ltd, Translat Res Inst, Woolloongabba, Qld, Australia; [Chandra, Janin; Woo, Wai-Ping; Dutton, Julie L.; Xu, Yan; Li, Bo; Finlayson, Neil; Frazer, Ian H.] Univ Queensland, Diamantina Inst, Translat Res Inst, Woolloongabba, Qld, Australia; [Kinrade, Sally] Med Dev Ltd, Southbank, Vic, Australia; [Druce, Julian] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia; [Druce, Julian] Doherty Inst, Melbourne, Vic, Australia; [Griffin, Paul] Q Pharm Pty Ltd, Brisbane, Qld, Australia; [Griffin, Paul] Mater Hosp & Mater Med Res Inst, Dept Med & Infect Dis, Brisbane, Qld, Australia; [Griffin, Paul] Univ Queensland, Brisbane, Qld, Australia; [Griffin, Paul] QIMR Berghofer, Clin Trop Med Lab, Brisbane, Qld, Australia; [Laing, Kerry J.; Koelle, David M.] Univ Washington, Dept Med, Seattle, WA USA; [Koelle, David M.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Koelle, David M.] Fred Hutchinson Canc Res Inst, Vaccine & Infect Dis Div, Seattle, WA USA; [Koelle, David M.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Koelle, David M.] Benaroya Res Inst, Seattle, WA USA	University of Queensland; Victorian Infectious Diseases Reference Laboratory; Mater Research; University of Queensland; QIMR Berghofer Medical Research Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Benaroya Research Institute	Frazer, IH (corresponding author), Admedus Vaccines Pty Ltd, Translat Res Inst, Woolloongabba, Qld, Australia.; Frazer, IH (corresponding author), Univ Queensland, Diamantina Inst, Translat Res Inst, Woolloongabba, Qld, Australia.	i.frazer@uq.edu.au	Laing, Kerry J./C-2211-2008	Laing, Kerry J./0000-0001-9245-5325; Woo, Yvonne/0000-0002-1293-5124	Admedus Vaccines Pty Ltd.	Admedus Vaccines Pty Ltd.	This study was funded by Admedus Vaccines Pty Ltd. The funder provided support in the form of salaries for authors JC, WPW, YX, BL, NF, and paid consultancies for authors JLD and IHF. The funder had no role in data collection and preparation of the final clinical study report. For publication, employees of the funder played a role in re-analysis, decision to publish, and preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Agyemang E, 2018, J INFECT DIS, V218, P1691, DOI 10.1093/infdis/jiy372; Alvarez RD, 2016, GYNECOL ONCOL, V140, P245, DOI 10.1016/j.ygyno.2015.11.026; [Anonymous], 2016, THERAPEUTIC DNA VACC; Bernard MC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121518; Bernstein DI, 2017, J INFECT DIS, V215, P856, DOI 10.1093/infdis/jix004; Chandra J, 2017, J IMMUNOTHER, V40, P62, DOI 10.1097/CJI.0000000000000156; Corey L, 2004, NEW ENGL J MED, V350, P11, DOI 10.1056/NEJMoa035144; Desai DV, 2015, VIRAL IMMUNOL, V28, P546, DOI 10.1089/vim.2015.0012; Dutton JL, 2016, HUM VACC IMMUNOTHER, DOI [10.1080/21645515.2015.1137406, DOI 10.1080/21645515.2015.1137406]; Dutton JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076407; Flechtner JB, 2016, VACCINE, V34, P5314, DOI 10.1016/j.vaccine.2016.09.001; Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7; Freeman EE, 2009, VACCINE, V27, P940, DOI 10.1016/j.vaccine.2008.11.074; Gebhardt T, 2009, NAT IMMUNOL, V10, P524, DOI 10.1038/ni.1718; Jaishankar D, 2016, MICROB CELL, V3, P438, DOI 10.15698/mic2016.09.528; Johnston C, 2016, VACCINE, V34, P2948, DOI 10.1016/j.vaccine.2015.12.076; Johnston C, 2011, J CLIN INVEST, V121, P4600, DOI 10.1172/JCI57148; Kaufmann JK, 2016, CURR OPIN VIROL, V17, P80, DOI 10.1016/j.coviro.2016.01.021; Leggatt GR, 2014, VACCINES, V2, P537, DOI 10.3390/vaccines2030537; Rosales R, 2014, HUM GENE THER, V25, P1035, DOI 10.1089/hum.2014.024; Schiffer JT, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0160; Shin HN, 2012, NATURE, V491, P463, DOI 10.1038/nature11522; Tan DHS, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-502; Van Wagoner N, 2018, J INFECT DIS, V218, P1890, DOI 10.1093/infdis/jiy415; VanWagoner N KW, 2015, ID WEEK 2015; Villarreal DO, 2013, EXPERT REV VACCINES, V12, P537, DOI [10.1586/erv.13.33, 10.1586/ERV.13.33]	26	13	14	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2019	14	12							e0226320	10.1371/journal.pone.0226320	http://dx.doi.org/10.1371/journal.pone.0226320			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP3SK	31846475	Green Published, gold			2023-01-03	WOS:000534238700017
J	Ozyurt, MG; Haavik, H; Nedergaard, RW; Topkara, B; Senocak, BS; Goztepe, MB; Niazi, IK; Turker, KS				Ozyurt, Mustafa Gorkem; Haavik, Heidi; Nedergaard, Rasmus Wiberg; Topkara, Betilay; Senocak, Beatrice Selen; Goztepe, Mehmet Berke; Niazi, Imran Khan; Turker, Kemal Sitki			Transcranial magnetic stimulation induced early silent period and rebound activity reexamined	PLOS ONE			English	Article							BRAIN-STIMULATION; POSTSYNAPTIC POTENTIALS; CORTICAL INHIBITION; MOTOR UNITS; RESPONSES; EXCITABILITY; ELECTRODE; LOCATION; REFLEXES; SYSTEM	Despite being widely studied, the underlying mechanisms of transcranial magnetic brain stimulation (TMS) induced motor evoked potential (MEP), early cortical silent period (CSP) and rebound activity are not fully understood. Our aim is to better characterize these phenomena by combining various analysis tools on firing motor units. Responses of 29 tibialis anterior (TA) and 8 abductor pollicis brevis (APB) motor units to TMS pulses were studied using discharge rate and probability-based tools to illustrate the profile of the synaptic potentials as they develop on motoneurons in 24 healthy volunteers. According to probability based methods, TMS pulse produces a short-latency MEP which is immediately followed by CSP that terminates at rebound activity. Discharge rate analysis, however, revealed not three, but just two events with distinct time courses; a long-lasting excitatory period (71.2 +/- 9.0 ms for TA and 42.1 +/- 11.2 ms for APB) and a long-latency inhibitory period with duration of 57.9 +/- 9.5 ms for TA and 67.3 +/- 13.8 ms for APB. We propose that part of the CSP may relate to the falling phase of net excitatory postsynaptic potential induced by TMS. Rebound activity, on the other hand, may represent tendon organ inhibition induced by MEP activated soleus contraction and/or long-latency intracortical inhibition. Due to generation of field potentials when high intensity TMS is used, this study is limited to investigate the events evoked by low intensity TMS only and does not provide information about later parts of much longer CSPs induced by high intensity TMS. Adding discharge rate analysis contributes to obtain a more accurate picture about the characteristics of TMS-induced events. These results have implications for interpreting motor responses following TMS for diagnosis and overseeing recovery from various neurological conditions.	[Ozyurt, Mustafa Gorkem; Topkara, Betilay; Turker, Kemal Sitki] Koc Univ, Sch Med, Istanbul, Turkey; [Haavik, Heidi; Nedergaard, Rasmus Wiberg; Niazi, Imran Khan] New Zealand Coll Chiropract, Ctr Chiropract Res, Auckland, New Zealand; [Senocak, Beatrice Selen] Quinnipiac Univ, Frank H Netter MD Sch Med, North Haven, CT USA; [Goztepe, Mehmet Berke] Akdeniz Univ, Sch Med, Antalya, Turkey	Koc University; Quinnipiac University; Akdeniz University	Turker, KS (corresponding author), Koc Univ, Sch Med, Istanbul, Turkey.	kturker@ku.edu.tr	Niazi, Imran Khan/M-3346-2019; Haavik, Heidi/AAG-1084-2021	Niazi, Imran Khan/0000-0001-8752-7224; Haavik, Heidi/0000-0001-7182-2085; Ozyurt, M. Gorkem/0000-0003-2531-1174; TURKER, KEMAL SITKI/0000-0001-9962-075X; Nedergaard, Rasmus Bach/0000-0003-3271-1408; Topkara Arslan, Betilay/0000-0002-3509-9296; Goztepe, Mehmet Berke/0000-0002-1193-3696	Koc University School of Medicine; Scientific and Technological Research Council of Turkey (TUB?TAK) under "2211-A National Scholarship Programme for PhD Students"; Australian Spine Research Foundation (ASRF); Chiropractic Center of New Zealand	Koc University School of Medicine(Koc University); Scientific and Technological Research Council of Turkey (TUB?TAK) under "2211-A National Scholarship Programme for PhD Students"; Australian Spine Research Foundation (ASRF); Chiropractic Center of New Zealand	We would like to thank participants who attended this study. Also, we acknowledge the role of Chiropractic Center of New Zealand and Koc University School of Medicine for funding this study. We thank the Scientific and Technological Research Council of Turkey (TUB?TAK) for funding Mustafa GorkemOzyurt under "2211-A National Scholarship Programme for PhD Students". We also thank Australian Spine Research Foundation (ASRF) for partially funding the project.	Ahonen JP, 1998, ELECTROMYOGR MOTOR C, V109, P224, DOI 10.1016/S0924-980X(98)00014-9; BARKER AT, 1985, LANCET, V1, P1106; Bowery NG, 2006, CURR OPIN PHARMACOL, V6, P37, DOI 10.1016/j.coph.2005.10.002; BRASILNETO JP, 1995, ACTA NEUROL SCAND, V92, P383; Brinkworth RSA, 2003, J NEUROSCI METH, V122, P179, DOI 10.1016/S0165-0270(02)00321-7; Burne JA, 1996, BRAIN, V119, P1107, DOI 10.1093/brain/119.4.1107; CANTELLO R, 1992, NEUROLOGY, V42, P1951; Chen R, 1999, EXP BRAIN RES, V128, P539, DOI 10.1007/s002210050878; Devanne H, 1997, EXP BRAIN RES, V114, P329, DOI 10.1007/PL00005641; ELLAWAY PH, 1978, ELECTROEN CLIN NEURO, V45, P302, DOI 10.1016/0013-4694(78)90017-2; FUHR P, 1991, ELECTROEN CLIN NEURO, V81, P257, DOI 10.1016/0168-5597(91)90011-L; Guekht A, 2005, Electromyogr Clin Neurophysiol, V45, P291; Haavik H, 2018, J ELECTROMYOGR KINES, V42, P24, DOI 10.1016/j.jelekin.2018.06.010; HOMAN RW, 1987, ELECTROEN CLIN NEURO, V66, P376, DOI 10.1016/0013-4694(87)90206-9; INGHILLERI M, 1993, J PHYSIOL-LONDON, V466, P521; Julkunen P, 2009, NEUROIMAGE, V44, P790, DOI 10.1016/j.neuroimage.2008.09.040; Kernell D, 1983, Adv Neurol, V39, P213; Kimiskidis VK, 2006, EXP BRAIN RES, V173, P603, DOI 10.1007/s00221-006-0402-1; Kojima S, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-43; KUDINA LP, 1980, ELECTROEN CLIN NEURO, V50, P214, DOI 10.1016/0013-4694(80)90148-0; Lee JC, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00095; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; McNulty PA, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00518; MILES TS, 1989, EXP BRAIN RES, V77, P628; Moliadze V, 2003, J PHYSIOL-LONDON, V553, P665, DOI 10.1113/jphysiol.2003.050153; MOORE GP, 1970, BIOPHYS J, V10, P876, DOI 10.1016/S0006-3495(70)86341-X; Mueller JK, 2014, NAT NEUROSCI, V17, P1130, DOI 10.1038/nn.3751; Orth M, 2004, CLIN NEUROPHYSIOL, V115, P1076, DOI 10.1016/j.clinph.2003.12.025; Ozyurt MG, 2019, J PHYSIOL-LONDON, V597, P2185, DOI 10.1113/JP277129; Pearce SL, 2003, J PHYSIOL-LONDON, V549, P583, DOI 10.1113/jphysiol.2002.035352; Pierantozzi M, 2004, BRAIN RES, V1028, P1, DOI 10.1016/j.brainres.2004.06.009; POLSON MJR, 1982, MED BIOL ENG COMPUT, V20, P243, DOI 10.1007/BF02441362; Poston B, 2012, EUR J NEUROSCI, V36, P2964, DOI 10.1111/j.1460-9568.2012.08212.x; Powers RK, 2010, EXP BRAIN RES, V206, P427, DOI 10.1007/s00221-010-2423-z; Powers RK, 2010, CLIN NEUROPHYSIOL, V121, P1643, DOI 10.1016/j.clinph.2009.10.041; PRIORI A, 1994, BRAIN, V117, P317, DOI 10.1093/brain/117.2.317; ROICK H, 1993, EXP BRAIN RES, V94, P489, DOI 10.1007/BF00230207; Rossini P, 2015, CLIN NEUROPHYSIOL, V89; Saisanen L, 2008, J NEUROSCI METH, V169, P231, DOI 10.1016/j.jneumeth.2007.12.005; Schmied A, 2008, EXP BRAIN RES, V189, P229, DOI 10.1007/s00221-008-1420-y; Siebner HR, 1998, MUSCLE NERVE, V21, P1209, DOI 10.1002/(SICI)1097-4598(199809)21:9<1209::AID-MUS15>3.3.CO;2-O; Tataroglu C, 2004, SEIZURE-EUR J EPILEP, V13, P481, DOI 10.1016/j.seizure.2003.11.003; Taylor JL, 2000, J APPL PHYSIOL, V89, P305, DOI 10.1152/jappl.2000.89.1.305; Tergau F, 1999, EXP BRAIN RES, V124, P447, DOI 10.1007/s002210050640; Todd G, 2012, CLIN NEUROPHYSIOL, V123, P1002, DOI 10.1016/j.clinph.2011.09.019; Tucker KJ, 2005, J NEUROSCI METH, V149, P31, DOI 10.1016/j.jneumeth.2005.05.010; Turker KS, 1997, ARCH ORAL BIOL, V42, P121, DOI 10.1016/S0003-9969(96)00112-4; Turker KS, 2005, TRENDS NEUROSCI, V28, P379, DOI 10.1016/j.tins.2005.05.007; Turker KS, 2003, J PHYSIOL-LONDON, V551, P419, DOI 10.1113/jphysiol.2003.044982; TURKER KS, 1988, BRAIN RES BULL, V21, P139, DOI 10.1016/0361-9230(88)90130-X; TURKER KS, 1994, J NEUROSCI METH, V53, P225, DOI 10.1016/0165-0270(94)90181-3; van Kuijk AAA, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-1; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x; Wu L, 2002, CLIN NEUROPHYSIOL, V113, P1286, DOI 10.1016/S1388-2457(02)00160-8; Ziemann U, 2004, CLIN NEUROPHYSIOL, V115, P1717, DOI 10.1016/j.clinph.2004.03.006; Ziemann U, 2004, J NEUROSCI, V24, P1666, DOI 10.1523/JNEUROSCI.5016-03.2004	56	4	4	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2019	14	12							e0225535	10.1371/journal.pone.0225535	http://dx.doi.org/10.1371/journal.pone.0225535			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP0BN	31800618	Green Published, gold			2023-01-03	WOS:000533987600029
J	Jekarl, DW; Lee, S; Kwon, JH; Nam, SW; Kim, M; Kim, Y; Jang, JW				Jekarl, Dong Wook; Lee, Seungok; Kwon, Jung Hyun; Nam, Soon Woo; Kim, Myungshin; Kim, Yonggoo; Jang, Jeong Won			Complex interaction networks of cytokines after transarterial chemotherapy in patients with hepatocellular carcinoma	PLOS ONE			English	Article							BIOLOGY; PROTEIN	Treating hepatocellular carcinoma with transarterial chemoembolization (TACE) induces both local inflammation in the tumor microenvironment as well as systemic inflammation. We analyzed serum cytokine response to TACE to evaluate this. Serum samples obtained from 203 HCC patients treated with TACE were analyzed for inflammatory cytokines including interleukin (IL)-1 beta, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12, IL-13, IL-17, IL-22, TNF-alpha, IFN-gamma, and C-reactive protein (CRP) levels. Cytokine concentrations were measured at day 0 (D0, baseline, n = 203), day3 (D3, n = 156), day7 (D7, n = 147), and day 60 (D60, n = 115) after TACE. Network analysis of the cytokines was performed to understand their interactive relationship. After TACE, IL-1 beta,-6,-9,-12, and-22 increased by D60. IL-2,-5,-10,-17A and INF-. decreased by D60, and IL-4,-13 and TNF-alpha revealed stable concentration. D0 network revealed that IL-2,-4,-5, and-10 formed a module. D3 network had the highest clustering coefficient and average degree that revealed similar pattern as CRP. D7 network revealed that IL-6,-9 and CRP were isolated from the network. D60 network had the lower network heterogeneity and lower clustering coefficient, network diameter, shortest path and characteristic path length. Degree correlation revealed that assortative network turned to disassortative network by D60 indicating that the network gained scale free feature. D60 cytokine network retained inflammatory function and these parameters indicated that the systemic inflammation induced by TACE appeared to be attenuated by D60. IL-9 at D3 and D7 seemed to be related to anti-tumor effect and IL-6 at D7 and D60, and IL-22 at D60 was related to regenerative but not pro-or anti-inflammatory function. Median survival month of patient group with high and low values of cytokine with P-values were as follows: D0 CRP, 9.5 and 54.2 months (P< 0.0001); D0 IL-2, 39.9 and 56.1 months (P = 0.0084); D3 CRP, 31.3 and 55.1 months (P = 0.0056); D7 CRP, 28.7 and 50.7 months (P = 0.0065), respectively. TACE is associated with systemic inflammation which appears to peak at Day 3 and resolve by D60. Among the tested cytokines, IL-6 and IL-22 appear to play a regenerative role.	[Jekarl, Dong Wook; Kim, Myungshin; Kim, Yonggoo] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Lab Med, Seoul, South Korea; [Jekarl, Dong Wook; Lee, Seungok; Kim, Myungshin; Kim, Yonggoo] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Lab Dev & Evaluat Ctr, Seoul, South Korea; [Lee, Seungok] Catholic Univ Korea, Incheon St Marys Hosp, Coll Med, Dept Lab Med, Seoul, South Korea; [Kwon, Jung Hyun; Nam, Soon Woo] Catholic Univ Korea, Incheon St Marys Hosp, Coll Med, Dept Internal Med, Seoul, South Korea; [Jang, Jeong Won] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med, Seoul, South Korea	Catholic University of Korea; Seoul St. Mary's Hospital; Catholic University of Korea; Seoul St. Mary's Hospital; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Seoul St. Mary's Hospital	Jang, JW (corresponding author), Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med, Seoul, South Korea.	garden@catholic.ac.kr						Aino H, 2016, MOL CLIN ONCOL, V5, P83, DOI 10.3892/mco.2016.879; Assenov Y, 2008, BIOINFORMATICS, V24, P282, DOI 10.1093/bioinformatics/btm554; Barabasi A.-L, 2016, NETWORK SCI; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918; Boccaletti S, 2006, PHYS REP, V424, P175, DOI 10.1016/j.physrep.2005.10.009; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cheng J, 2016, ACTA PHYS SIN-CH ED, V65, DOI 10.7498/aps.65.060302; Csardi G., 2006, INTERJ COMPLEX SYST, V1695, P1; Doncheva NT, 2012, NAT PROTOC, V7, P670, DOI 10.1038/nprot.2012.004; Dudakov JA, 2015, ANNU REV IMMUNOL, V33, P747, DOI 10.1146/annurev-immunol-032414-112123; Estrada E., 2015, EVOLUTIONARY EQUATIO; Estrada E, 2010, PHYS REV E, V82, DOI 10.1103/PhysRevE.82.066102; Gaggianesi M, 2017, CANCER RES, V77, P3268, DOI 10.1158/0008-5472.CAN-16-3126; He CB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174769; Hernandez-Gea V, 2013, GASTROENTEROLOGY, V144, P512, DOI 10.1053/j.gastro.2013.01.002; Jacob R, 2017, ROY SOC OPEN SCI, V4, DOI 10.1098/rsos.160757; Jang JW, 2012, CYTOKINE, V60, P686, DOI 10.1016/j.cyto.2012.07.017; Jekarl DW, 2018, EUR CYTOKINE NETW, V29, P103, DOI 10.1684/ecn.2018.0414; Kim BH, 2018, CLIN MOL HEPATOL, V24, P1, DOI 10.3350/cmh.2017.0112; Kim MJ, 2013, CYTOKINE, V64, P516, DOI 10.1016/j.cyto.2013.07.021; Lee HL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40078-8; Liu C, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4121-3; Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.19, 10.1038/nrdp.2016.18]; Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Newman MEJ, 2006, P NATL ACAD SCI USA, V103, P8577, DOI 10.1073/pnas.0601602103; Pavlopoulos GA, 2011, BIODATA MIN, V4, DOI 10.1186/1756-0381-4-10; Ren XD, 2010, AM J PHYSIOL-GASTR L, V298, pG74, DOI 10.1152/ajpgi.00075.2009; Saito R, 2012, NAT METHODS, V9, P1069, DOI [10.1038/NMETH.2212, 10.1038/nmeth.2212]; Xu K, 2011, PROTEOMICS, V11, P1857, DOI 10.1002/pmic.201000684; Xue TC, 2015, TUMOR BIOL, V36, P8797, DOI 10.1007/s13277-015-3632-7; Zhang YF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005000; Zhu XW, 2007, GENE DEV, V21, P1010, DOI 10.1101/gad.1528707	35	11	11	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2019	14	11							e0224318	10.1371/journal.pone.0224318	http://dx.doi.org/10.1371/journal.pone.0224318			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO8PC	31751357	Green Published, Green Submitted, gold			2023-01-03	WOS:000533886900010
J	Keene, DJ; Alsousou, J; Harrison, P; Hulley, PA; Wagland, S; Parsons, SR; Thompson, J; O'Connor, HM; Schlussel, MM; Dutton, SJ; Lamb, SE; Willett, K; Handley, R; Lewis, K; Spoors, L; Zhang, YH; Mestre, M; Muller, D; Prasath, S; Austin, M; Bhatia, M; Attwal, M; Christie, C; Brear, T; Kelly, A; Beacham, K; Brown, S; Allen, J; Whitcher, A; James, K; Foster, E; Hepple, S; Barnfield, S; Coates, K; Halliday, R; Hooper, L; Hodgson, P; Hodgson, H; Cleary, C; Nott, C; Whiteman, J; Carmont, M; Tonics, L; Heidari, N; Kassam, J; Hilton, C; Ahmad, S; Young, S; Young, J; Clarkson, L; Turner, S; McGowan, K; Lowe, J; Stables, G; Bunworth, K; de Feyter, P; Ravindran, R; Vertue, M; Frostick, S; Maitland, K; Stokes-Denson, J; Watson, L; Scanlon, D; Walker, P; Carmichael, J; O'Sullivan, S; Butcher, D; Topliss, C; Hutchison, AM; Storton, S; Cook, A; Quinn, L; Mason, L; Earley, J; Ballal, M; Bradley-Potts, J; Williamson, G; McCormick, R; Davies, M; Walker, J; Badloe, J; Hughes, A; Grice, A; Dark, J; Barnes, S; Velpula, J; Amor, K; Brown, J; Solan, M				Keene, David J.; Alsousou, Joseph; Harrison, Paul; Hulley, Philippa Anne; Wagland, Susan; Parsons, Scott R.; Thompson, Jacqueline; O'Connor, Heather M.; Schlussel, Michael Maia; Dutton, Susan J.; Lamb, Sarah E.; Willett, Keith; Handley, Robert; Lewis, Kathryn; Spoors, Louise; Zhang, Yuhan; Mestre, Maria; Muller, Doreeen; Prasath, Sangeetha; Austin, Martin; Bhatia, Maneesh; Attwal, Manjit; Christie, Carla; Brear, Tracy; Kelly, Andrew; Beacham, Keira; Brown, Sarah; Allen, James; Whitcher, Alison; James, Kate; Foster, Eliza; Hepple, Steve; Barnfield, Steven; Coates, Katherine; Halliday, Ruth; Hooper, Lucille; Hodgson, Paul; Hodgson, Helen; Cleary, Cheryl; Nott, Claire; Whiteman, Jessica; Carmont, Michael; Tonics, Louise; Heidari, Nima; Kassam, Jamila; Hilton, Catherine; Ahmad, Shanaz; Young, Sophie; Young, Jonathan; Clarkson, Louise; Turner, Sylvia; McGowan, Kerri; Lowe, Janet; Stables, Gareth; Bunworth, Kerry; de Feyter, Pascal; Ravindran, Ranjith; Vertue, Mark; Frostick, Simon; Maitland, Kate; Stokes-Denson, Joanne; Watson, Lisa; Scanlon, Deborah; Walker, Philip; Carmichael, James; O'Sullivan, Susie; Butcher, Deborah; Topliss, Claire; Hutchison, Anne-Marie; Storton, Sharon; Cook, Amanda; Quinn, Leanne; Mason, Lyndon; Earley, Joanne; Ballal, Moez; Bradley-Potts, Joanne; Williamson, Georgina; McCormick, Richard; Davies, Mark; Walker, Julie; Badloe, Joanne; Hughes, Adrian; Grice, Anna; Dark, Jayne; Barnes, Simon; Velpula, Jagan; Amor, Kelly; Brown, Janet; Solan, Matthew		PATH-2 Trial Grp	Platelet rich plasma injection for acute Achilles tendon rupture: PATH-2 randomised, placebo controlled, superiority trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GROWTH-FACTOR; EPIDEMIOLOGY; METAANALYSIS; MANAGEMENT; SCALE	OBJECTIVE To determine whether an injection of platelet rich plasma improves outcomes after acute Achilles tendon rupture. DESIGN Randomised, placebo controlled, two arm, parallel group, participant and assessor masked, superiority trial. SETTING Secondary care trauma units across 19 hospitals in the United Kingdom's health service. PARTICIPANTS Recruitment commenced in July 2015 and follow-up was completed in March 2018. 230 adults aged 18 years and over were included, with acute Achilles tendon rupture presenting within 12 days of injury and managed with non-surgical treatment. Exclusions were injury at the insertion or musculotendinous junction, major leg injury or deformity, diabetes mellitus, platelet or haematological disorder, systemic corticosteroids, anticoagulation treatment, and other contraindicating conditions. INTERVENTIONS Participants were randomised 1:1 to platelet rich plasma (n=114) or placebo (dry needle; n=116) injection. All participants received standard rehabilitation care (ankle immobilisation followed by physiotherapy). MAIN OUTCOMES AND MEASURES Primary outcome was muscle tendon function at 24 weeks, measured objectively with the limb symmetry index (injured/uninjuredx100) in maximal work done during the heel rise endurance test (an instrumented measure of repeated single leg heel rises until fatigue). Secondary outcomes included patient reported function (Achilles tendon rupture score), quality of life (short form 12 version 2 (R)), pain (visual analogue scale), goal attainment (patient specific functional scale), and adverse events. A central laboratory analysed the quality and content of platelet rich plasma. Analyses were by modified intention to treat. RESULTS Participants were 46 years old on average, and 57 (25%) of 230 were female. At 24 weeks, 202 (88%) participants completed the heel rise endurance test and 216 (94%) the patient reported outcomes. The platelet rich plasma was of good quality, with expected growth factor content. No difference was detected in muscle tendon function between participants receiving platelet rich plasma injections and those receiving placebo injections (limb symmetry index, mean 34.7% (standard deviation 17.7%) v 38.5% (22.8%); adjusted mean difference -3.9% (95% confidence interval -10.5% to 2.7%)) or in any secondary outcomes or adverse event rates. Complier average causal effect analyses gave similar findings. CONCLUSIONS There is no evidence to indicate that injections of platelet rich plasma can improve objective muscle tendon function, patient reported function, or quality of life after acute Achilles tendon rupture compared with placebo, or that they offer any patient benefit.	[Keene, David J.; Wagland, Susan; Parsons, Scott R.; Thompson, Jacqueline; Lamb, Sarah E.; Willett, Keith] Univ Oxford, Kaoorie Res Ctr, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England; [Alsousou, Joseph] Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England; [Harrison, Paul] Univ Birmingham, Inst Inflammat & Ageing, Birmingham, W Midlands, England; [Hulley, Philippa Anne] Univ Oxford, Botnar Res Ctr, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England; [O'Connor, Heather M.; Schlussel, Michael Maia; Dutton, Susan J.; Lamb, Sarah E.] Univ Oxford, Ctr Stat Med, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford Clin Trials Res Unit, Oxford, England; [Handley, Robert; Lewis, Kathryn; Spoors, Louise; Zhang, Yuhan; Mestre, Maria; Muller, Doreeen; Prasath, Sangeetha; Austin, Martin] Oxford Univ Hosp NHS Trust, Oxford, England; [Bhatia, Maneesh; Attwal, Manjit; Christie, Carla; Brear, Tracy] Univ Hosp Leicester NHS Trust, Leicester, Leics, England; [Kelly, Andrew; Beacham, Keira; Brown, Sarah; Allen, James; Whitcher, Alison; James, Kate; Foster, Eliza] Taunton & Somerset NHS Fdn Trust, Taunton, Somerset, England; [Hepple, Steve; Barnfield, Steven; Coates, Katherine; Halliday, Ruth; Hooper, Lucille] North Bristol NHS Trust, Bristol, Avon, England; [Hodgson, Paul; Hodgson, Helen; Cleary, Cheryl; Nott, Claire; Whiteman, Jessica] Cardiff & Vale Univ Hlth Board, Cardiff, S Glam, Wales; [Carmont, Michael; Tonics, Louise] Shrewsbury & Telford Hosp NHS Trust, Shrewsbury, Salop, England; [Heidari, Nima; Kassam, Jamila; Hilton, Catherine; Ahmad, Shanaz; Young, Sophie] Barts Hlth NHS Trust, London, England; [Young, Jonathan; Clarkson, Louise; Turner, Sylvia; McGowan, Kerri; Lowe, Janet] Univ Hosp Coventry & Warwickshire NHS Trust, Coventry, W Midlands, England; [Stables, Gareth; Bunworth, Kerry; de Feyter, Pascal] Warrington & Halton Hosp NHS Fdn Trust, Warrington, Cheshire, England; [Ravindran, Ranjith; Vertue, Mark] Basildon & Thurrock Univ Hosp NHS Fdn Trust, Basildon, England; [Alsousou, Joseph; Frostick, Simon; Maitland, Kate; Stokes-Denson, Joanne; Watson, Lisa; Scanlon, Deborah; Walker, Philip] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Liverpool, Merseyside, England; [Carmichael, James; O'Sullivan, Susie; Butcher, Deborah] Peterborough & Stamford Hosp NHS Fdn Trust, Peterborough, Cambs, England; [Topliss, Claire; Hutchison, Anne-Marie; Storton, Sharon; Cook, Amanda; Quinn, Leanne] Abertawe Bro Morgannwg Univ Hlth Board, Port Talbot, Wales; [Alsousou, Joseph; Mason, Lyndon; Earley, Joanne] Univ Hosp Aintree NHS Fdn Trust, Liverpool, Merseyside, England; [Ballal, Moez; Bradley-Potts, Joanne; Williamson, Georgina; McCormick, Richard] Univ Hosp South Manchester NHS Fdn Trust, Manchester, Lancs, England; [Davies, Mark; Walker, Julie; Badloe, Joanne] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England; [Hughes, Adrian; Grice, Anna; Dark, Jayne] Royal Devon & Exeter NHS Fdn Trust, Exeter, Devon, England; [Barnes, Simon; Velpula, Jagan; Amor, Kelly; Brown, Janet] Mid Cheshire Hosp NHS Fdn Trust, Crewe, Cheshire, England; [Solan, Matthew] Royal Surrey Cty Hosp NHS Fdn Trust, Guildford, Surrey, England	University of Oxford; University of Liverpool; University of Birmingham; University of Oxford; University of Oxford; Oxford University Hospitals NHS Foundation Trust; University Hospitals of Leicester NHS Trust; University of Leicester; North Bristol NHS Trust; Barts Health NHS Trust; University of Warwick; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; Wythenshawe Hospital NHS Foundation Trust; University of Sheffield; University of Exeter; Royal Surrey County Hospital	Keene, DJ (corresponding author), John Radcliffe Hosp, Kadoorie Ctr Crit Care Res & Educ, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford OX3 9DU, England.	david.keene@ndorms.ox.ac.uk	Jacqueline, Thompson/GPT-2977-2022; Thompson, Jacqueline/AAO-4065-2021; Harrison, Paul/AAN-1916-2021; Mason, Lyndon/S-8392-2019; Hulley, Philippa A/A-8538-2011; Thompson, Jacqueline/I-5118-2019	Harrison, Paul/0000-0003-4610-8909; Hulley, Philippa A/0000-0002-4994-2264; Thompson, Jacqueline/0000-0002-9775-361X; Lamb, Sarah/0000-0003-4349-7195; Keene, David/0000-0001-7249-6496; Dutton, Susan/0000-0003-4573-5257	Medical Research Council (MRC) [12/206/30]; National Institute for Health Research (NIHR) [12/206/30]; NIHR Biomedical Research Centre, Oxford; NIHR [PDF-2016-09-056]; NIHR Collaboration for Leadership in Applied Health Research and Care Oxford at Oxford Health NHS Foundation Trust; University of Oxford; MRC [MC_PC_14143] Funding Source: UKRI	Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); NIHR Biomedical Research Centre, Oxford(National Institute for Health Research (NIHR)); NIHR(National Institute for Health Research (NIHR)); NIHR Collaboration for Leadership in Applied Health Research and Care Oxford at Oxford Health NHS Foundation Trust; University of Oxford; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The PATH-2 trial was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council (MRC) and National Institute for Health Research (NIHR) partnership (reference 12/206/30). The trial was supported by the NIHR Biomedical Research Centre, Oxford, and the NIHR Fellowship programme (DJK, PDF-2016-09-056). SEL receives funding from the NIHR Collaboration for Leadership in Applied Health Research and Care Oxford at Oxford Health NHS Foundation Trust. University of Birmingham staff were supported by the Scar Free Foundation and the NIHR Surgical Reconstruction and Microbiology Research Centre. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the MRC, NHS, NIHR, or Department of Health and Social Care. The sponsor (University of Oxford) and funders monitored the study but were not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	Alsousou J, 2013, PLATELETS, V24, P173, DOI 10.3109/09537104.2012.684730; Alsousou J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018135; [Anonymous], 2017, REUTERS; [Anonymous], 2013, CELL THER MED SYST A; Bang HJ, 2004, CONTROL CLIN TRIALS, V25, P143, DOI 10.1016/j.cct.2003.10.016; Brown S, 2005, STAT MED, V24, P3715, DOI 10.1002/sim.2391; Castillo TN, 2011, AM J SPORT MED, V39, P266, DOI 10.1177/0363546510387517; Chahla J, 2017, J BONE JOINT SURG AM, V99, P1769, DOI 10.2106/JBJS.16.01374; Chen X, 2018, AM J SPORT MED, V46, P2020, DOI 10.1177/0363546517743746; Clayton RAE, 2008, INJURY, V39, P1338, DOI 10.1016/j.injury.2008.06.021; Harm SK, 2015, TRANSFUSION, V55, P1596, DOI 10.1111/trf.13160; Harrison P, 2018, J THROMB HAEMOST, V16, P1895, DOI 10.1111/jth.14223; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Horn KK, 2012, J ORTHOP SPORT PHYS, V42, P30, DOI 10.2519/jospt.2012.3727; James KE, 1996, STAT MED, V15, P1421; Kearney RS, 2012, BRIT J SPORT MED, V46, P1102, DOI 10.1136/bjsports-2011-090497; Keene DJ, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i517; Khan RJK, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003674.pub4; Kushida S, 2014, J ARTIF ORGANS, V17, P186, DOI 10.1007/s10047-014-0761-5; Marques LF, 2015, PLATELETS, V26, P101, DOI 10.3109/09537104.2014.881991; Mattila VM, 2015, BRIT J SPORT MED, V49, P1084, DOI 10.1136/bjsports-2013-092756; Moraes VY, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010071.pub2; Nilsson-Helander K, 2007, AM J SPORT MED, V35, P421, DOI 10.1177/0363546506294856; Nilsson-Helander K, 2010, AM J SPORT MED, V38, P2186, DOI 10.1177/0363546510376052; Rachul C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182496; Schepull T, 2011, AM J SPORT MED, V39, P38, DOI 10.1177/0363546510383515; Schlussel MM, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2840-z; Schulz KF, 2010, J PHARMACOL PHARMACO, V1, P100, DOI [10.1016/j.jclinepi.2010.02.005, 10.4103/0976-500X.72352, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18]; Sheth U, 2017, BONE JOINT J, V99B, P78, DOI [10.1302/0301-620X.99B1.BJJ-2016-0434.R1, 10.1302/0301-620x.99b1.bjj-2016-0434.r1]; Silbernagel KG, 2010, KNEE SURG SPORT TR A, V18, P258, DOI 10.1007/s00167-009-0889-7; Stratford P., 1995, PHYSIOTHER CAN, V47, P258, DOI [10.3138/ptc.47.4.258, DOI 10.3138/PTC.47.4.258]; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Zellers JA, 2016, BRIT J SPORT MED, V50, P1325, DOI 10.1136/bjsports-2016-096106; Zhou YQ, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0172-4; Zou J, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/9364170	35	29	30	3	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	2019	367								l6132	10.1136/bmj.l6132	http://dx.doi.org/10.1136/bmj.l6132			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ3HV	31748208	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000498841000002
J	Packer, R; Ben Shlomo, Y; Whiting, P				Packer, Richard; Ben Shlomo, Yoav; Whiting, Penny			Can non-pharmacological interventions reduce hospital admissions in people with dementia? A systematic review	PLOS ONE			English	Review							CARE COORDINATION INTERVENTION; OLDER-ADULTS; COST-EFFECTIVENESS; MANAGEMENT INTERVENTION; OCCUPATIONAL-THERAPY; ALZHEIMERS-DISEASE; HOME; MIND; PARTNERS; OUTCOMES	Background People with dementia who are admitted to hospital have worse outcomes than those without dementia. Identifying interventions that could reduce the risk of hospitalisation in people with dementia has the potential to positively impact on lives of people with dementia. This review aimed to investigate whether there are non-pharmacological interventions that successfully reduce hospitalisation risk, length of stay and mortality in people with dementia. Methods 7 electronic databases and trial registries were searched from inception to October 2018. We included randomised controlled trials that evaluated non-pharmacological interventions in out of hospital settings and targeted people with any type of dementia. All stages of the review process were performed by two reviewers. Risk of bias was assessed using the Cochrane Risk of Bias tool. We grouped studies based on intervention: care management, counselling/self-help, enhanced GP services or memory clinics, and physiotherapy or occupational therapy. Data were pooled within intervention categories using random effects meta-analysis. Results There was no evidence that any of the intervention categories were associated with reduced hospital admission or mortality. There was very weak evidence to suggest that care management interventions (mean difference, MD, -0.16, 95% CI -0.32, 0.01), physiotherapy/occupational therapy (MD -0.16, 95% CI -0.36, 0.03) and enhanced GP/memory clinics (MD -0.14, 95% CI -0.31, 0.03) were associated with small reductions in hospital stay. There was no evidence for an effect of counselling/self-help interventions on length of hospital stay. Conclusions Current evidence from randomised trials suggests no clear benefit or harm associated with any of interventions on risks of hospitalisation, duration of hospitalisation or death. Further research with the primary aim to reduce hospitalisation in people with dementia is required.	[Packer, Richard] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England; [Ben Shlomo, Yoav; Whiting, Penny] Univ Hosp Bristol NHS Fdn Trust, Natl Inst Hlth Res Collaborat Leadership Appl Hlt, Bristol, Avon, England; [Ben Shlomo, Yoav; Whiting, Penny] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, England	University of Leicester; University of Bristol; University of Bristol	Whiting, P (corresponding author), Univ Hosp Bristol NHS Fdn Trust, Natl Inst Hlth Res Collaborat Leadership Appl Hlt, Bristol, Avon, England.; Whiting, P (corresponding author), Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, England.	penny.whiting@bristol.ac.uk	Ben-Shlomo, Yoav/ABD-2004-2021	Ben-Shlomo, Yoav/0000-0001-6648-3007; Whiting, Paul/0000-0002-4121-1379; Packer, Richard/0000-0003-2459-1020; Whiting, Penny/0000-0003-1138-5682	National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care West (NIHR CLAHRC West); MRC [MR/M02492X/1] Funding Source: UKRI	National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care West (NIHR CLAHRC West)(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This research was funded by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care West (NIHR CLAHRC West) to PW, https://clahrcwest.nihr.ac.uk/.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amjad H, 2018, HEALTH SERV RES, V53, P556, DOI 10.1111/1475-6773.12647; [Anonymous], 2006, EFFECTIVENESS COSTS; Bass David M, 2015, Alzheimers Dement (N Y), V1, P13, DOI 10.1016/j.trci.2015.03.003; Bass DM, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt242; Bass DM, 2013, J AM GERIATR SOC, V61, P1377, DOI 10.1111/jgs.12362; Bellantonio S, 2008, J AM GERIATR SOC, V56, P523, DOI 10.1111/j.1532-5415.2007.01591.x; Bentley Allison, 2014, Br J Community Nurs, V19, P342, DOI 10.12968/bjcn.2014.19.7.340; Bond M, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16210; Callahan CM, 2006, JAMA-J AM MED ASSOC, V295, P2148, DOI 10.1001/jama.295.18.2148; Cammisuli DM, 2016, EUR GERIATR MED, V7, P57, DOI 10.1016/j.eurger.2016.01.002; DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004; Donath C, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-314; Duru OK, 2009, AM J MANAG CARE, V15, P521; Eloniemi-Sulkava U, 2009, J AM GERIATR SOC, V57, P2200, DOI 10.1111/j.1532-5415.2009.02564.x; ENGEDAL K, 1989, Scandinavian Journal of Primary Health Care, V7, P161, DOI 10.3109/02813438909087234; Eska K, 2013, DEMENT GER COGN D EX, V3, P426, DOI 10.1159/000355079; Fogg C, 2018, INT J GERIATR PSYCH, V33, P1177, DOI 10.1002/gps.4919; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Graff MJL, 2008, BMJ-BRIT MED J, V336, P134, DOI 10.1136/bmj.39408.481898.BE; Graff MJL, 2006, BMJ-BRIT MED J, V333, P1196, DOI 10.1136/bmj.39001.688843.BE; Guijarro R, 2010, NEUROEPIDEMIOLOGY, V35, P101, DOI 10.1159/000311032; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Holle R, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-91; Kohler L, 2014, CURR ALZHEIMER RES, V11, P538, DOI 10.2174/1567205011666140618100727; Laakkonen ML, 2016, J AM GERIATR SOC, V64, P752, DOI 10.1111/jgs.14055; Laakkonen ML, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-133; LaMantia MA, 2016, ALZ DIS ASSOC DIS, V30, P35, DOI 10.1097/WAD.0000000000000118; Lehmann J, 2018, J ALZHEIMERS DIS, V64, P735, DOI 10.3233/JAD-171128; Lleo A, 2006, ANNU REV MED, V57, P513, DOI 10.1146/annurev.med.57.121304.131442; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Meeuwsen EJ, 2009, J NUTR HEALTH AGING, V13, P242, DOI 10.1007/s12603-009-0066-1; Meeuwsen E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079797; Meeuwsen EJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3086; Michalowsky B, 2016, ALZHEIMERS DEMENT, V12, pP255, DOI [10.1016/j.jalz.2016.06.457, DOI 10.1016/J.JALZ.2016.06.457]; Michalowsky B, 2018, EUR J HEALTH ECON, V19, P87, DOI 10.1007/s10198-017-0869-7; Mollers T, 2019, INT J GERIATR PSYCH, V34, P8, DOI 10.1002/gps.4993; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Morgan RO, 2015, J GEN INTERN MED, V30, P804, DOI 10.1007/s11606-015-3205-x; NICE, 2006, NICE CLIN GUID 42 DE; ONeill DJ, 2014, EUR GERIATR MED, V5, pS46, DOI [10.1016/S1878-7649(14)70087-7, DOI 10.1016/S1878-7649(14)70087-7]; Phelan EA, 2015, MED CARE, V53, P207, DOI 10.1097/MLR.0000000000000294; Phung KTT, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003584; Pitkala KH, 2013, JAMA INTERN MED, V173, P894, DOI 10.1001/jamainternmed.2013.359; Pitkala KH, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-92; Pitkala KHR, 2013, EUROPEAN GERIATRIC M, V4, pS8, DOI [10.1016/j.eurger.2013.07.012, DOI 10.1016/J.EURGER.2013.07.012]; Reilly S, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008345.pub2; Samus QM, 2014, AM J GERIAT PSYCHIAT, V22, P398, DOI 10.1016/j.jagp.2013.12.175; Schwarzkopf L, 2011, VALUE HEALTH, V14, P827, DOI 10.1016/j.jval.2011.04.005; Sogaard R, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004105; Tanner JA, 2015, AM J GERIAT PSYCHIAT, V23, P391, DOI 10.1016/j.jagp.2014.08.002; Thyrian JR, 2017, JAMA PSYCHIAT, V74, P996, DOI 10.1001/jamapsychiatry.2017.2124; Thyrian JR, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-56; Vickrey BG, 2006, ANN INTERN MED, V145, P713, DOI 10.7326/0003-4819-145-10-200611210-00004; Voigt-Radloff S, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000096; Voigt-Radloff Sebastian, 2009, BMC Geriatr, V9, P44, DOI 10.1186/1471-2318-9-44; Waldemar G, 2011, NEUROEPIDEMIOLOGY, V36, P52, DOI 10.1159/000322942; Waldorff FB, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4693; WHO, 2012, DEM PUBL HLTH PRIOR; Woods RT, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16480; Woods RT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152843; Woods RT, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-64; Xie J, 2008, BMJ-BRIT MED J, V336, P258, DOI 10.1136/bmj.39433.616678.25	63	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2019	14	10							e0223717	10.1371/journal.pone.0223717	http://dx.doi.org/10.1371/journal.pone.0223717			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM9KZ	31634375	Green Published, gold			2023-01-03	WOS:000532568300014
J	Malina, D				Malina, Debra			Preexisting Conditions	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TERM-CARE HOSPITALS; MEDICARE; LEVEL	Michelle has rheumatoid arthritis and shortness of breath, but the key preexisting condition that keeps her in a "long-term acute care hospital" for 25 days is a legislative carve-out for chronic care hospitals reimbursed on the basis of average per diem costs.	[Malina, Debra] Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA	Dartmouth College	Malina, D (corresponding author), Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA.							Ackerly DC, 2014, NEW ENGL J MED, V370, P689, DOI 10.1056/NEJMp1315350; Alexander JA, 2006, MILBANK Q, V84, P733, DOI 10.1111/j.1468-0009.2006.00466.x; [Anonymous], 2016, LONG TERM CARE HOSPI; Bryant DC, 1999, J GEN INTERN MED, V14, P182, DOI 10.1046/j.1525-1497.1999.00310.x; Einav L, 2018, NBER WORKING PAPER N; Institute of Medicine, 2013, VARIATION HLTH CARE; Kane RL, 2011, JAMA-J AM MED ASSOC, V305, P284, DOI 10.1001/jama.2010.2015; Kim YS, 2015, HEALTH AFFAIR, V34, P907, DOI 10.1377/hlthaff.2014.0778; KOSECOFF J, 1990, JAMA-J AM MED ASSOC, V264, P1980, DOI 10.1001/jama.264.15.1980; Liu K, 2001, HEALTH CARE FINANC R, V23, P1; Rosenthal E, 2017, AN AMERICAN SICKNESS; Sandy LG, 2019, JAMA-J AM MED ASSOC, V321, P933, DOI 10.1001/jama.2018.19357; Sharma G, 2009, JAMA-J AM MED ASSOC, V301, P1671, DOI 10.1001/jama.2009.517; Wachter RM, 2016, NEW ENGL J MED, V375, P1009, DOI 10.1056/NEJMp1607958	14	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	2019	381	16					1586	1589		10.1056/NEJMms1904668	http://dx.doi.org/10.1056/NEJMms1904668			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JF0NV	31618547				2023-01-03	WOS:000491085100014
J	Rinne, ST; Lindenauer, PK; Au, DH				Rinne, Seppo T.; Lindenauer, Peter K.; Au, David H.			Unexpected Harm From an Intensive COPD Intervention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MANAGEMENT		[Rinne, Seppo T.] Vet Affairs, Ctr Healthcare Org & Implementat Res, 200 Springs Rd, Bedford, MA 01730 USA; [Rinne, Seppo T.] Boston Univ, Sch Med, Pulm Ctr, Boston, MA 02118 USA; [Lindenauer, Peter K.] Univ Massachusetts, Med Sch Baystate, Inst Healthcare Delivery & Populat Sci, Dept Med, Springfield, MA USA; [Lindenauer, Peter K.] Univ Massachusetts, Med Sch, Dept Populat & Quantitat Hlth Sci, Worcester, MA USA; [Au, David H.] VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA USA; [Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA	Boston University; University of Massachusetts System; University of Massachusetts System; University of Massachusetts Worcester; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle	Rinne, ST (corresponding author), Vet Affairs, Ctr Healthcare Org & Implementat Res, 200 Springs Rd, Bedford, MA 01730 USA.	seppo@bu.edu		Rinne, Seppo/0000-0002-8662-1224	HSRD VA [IK2 HX002248] Funding Source: Medline	HSRD VA		Aboumatar H, 2019, JAMA-J AM MED ASSOC, V322, P1371, DOI 10.1001/jama.2019.11982; Aboumatar H, 2018, JAMA-J AM MED ASSOC, V320, P2335, DOI 10.1001/jama.2018.17933; Centers for Medicare and Medicaid Services (CMS) HHS, 2014, Fed Regist, V79, P49853; Cooke CR, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-37; Fan VS, 2012, ANN INTERN MED, V156, P673, DOI 10.7326/0003-4819-156-10-201205150-00003; Feemster LC, 2014, AM J RESP CRIT CARE, V189, P634, DOI 10.1164/rccm.201308-1541PP; Lenferink A, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011682.pub2; Prieto-Centurion Valentin, 2014, Ann Am Thorac Soc, V11, P417, DOI 10.1513/AnnalsATS.201308-254OC; Shah T, 2015, CHEST, V147, P1219, DOI 10.1378/chest.14-2181; Vogelmeier CF, 2017, AM J RESP CRIT CARE, V195, P557, DOI 10.1164/rccm.201701-0218PP; Wherry LR, 2016, ANN INTERN MED, V164, P795, DOI 10.7326/M15-2234; Zwerink M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002990.pub3	12	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2019	322	14					1357	1359		10.1001/jama.2019.12976	http://dx.doi.org/10.1001/jama.2019.12976			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE1GT	31593255	Bronze			2023-01-03	WOS:000490441900016
J	Elmer, J; Fogliato, R; Setia, N; Mui, W; Lynch, M; Hulsey, E; Nagin, D				Elmer, Jonathan; Fogliato, Riccardo; Setia, Nikita; Mui, Wilson; Lynch, Michael; Hulsey, Eric; Nagin, Daniel			Trajectories of prescription opioids filled over time	PLOS ONE			English	Article							UNITED-STATES; PRESCRIBING PATTERNS; IDENTIFY PATIENTS; RISK; OVERDOSES; ABUSE	We performed a retrospective cohort study that aimed to identify one or more groups that followed a pattern of chronic, high prescription use and quantify individuals' time-dependent probabilities of belonging to a high-utilizer group. We analyzed data from 52,456 adults age 18-45 who enrolled in Medicaid from 2009-2017 in Allegheny County, Pennsylvania who filled at least one prescription for an opioid analgesic. We used group-based trajectory modeling to identify groups of individuals with distinct patterns of prescription opioid use over time. We found the population to be comprised of three distinct trajectory groups. The first group comprised 83% of the population and filled few, if any, opioid prescriptions after their index prescription. The second group (12%) initially filled an average of one prescription per month, but declined over two years to near-zero. The third group (6%) demonstrated sustained high opioid prescriptions utilization. Using individual patients' posterior probability of membership in the high utilization group, which can be updated iteratively over time as new information become available, we defined a sensitive threshold predictive of sustained future opioid utilization. We conclude that individuals at risk of sustained opioid utilization can be identified early in their clinical course from limited observational data.	[Elmer, Jonathan] Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA 15260 USA; [Elmer, Jonathan] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Elmer, Jonathan] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; [Fogliato, Riccardo; Nagin, Daniel] Carnegie Mellon Univ, Dept Stat & Data Sci, Pittsburgh, PA 15213 USA; [Setia, Nikita; Mui, Wilson] Carnegie Mellon Univ, Heinz Coll, Pittsburgh, PA 15213 USA; [Lynch, Michael] Univ Pittsburgh, Sch Med, Dept Emergency Med, Div Med Toxicol, Pittsburgh, PA USA; [Hulsey, Eric] Allegheny Cty Dept Human Serv, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University; Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Elmer, J (corresponding author), Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA 15260 USA.; Elmer, J (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA.; Elmer, J (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.	elmerjp@upmc.edu			National Institutes of Health [5K23NS097629]; Deloitte Consulting, LLP; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS097629] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deloitte Consulting, LLP; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Research time is supported by the National Institutes of Health through grant 5K23NS097629 to JE. This work was supported by a grant by Deloitte Consulting, LLP, to Carnegie Mellon University (no grant number) to all. The funders played no role in the design of the study, or any aspects of the study conduct or decision to publish.	[Anonymous], 2017, PAIN MAN OP EP BAL S; Belgrade MJ, 2006, J PAIN, V7, P671, DOI 10.1016/j.jpain.2006.03.001; Blendon RJ, 2018, NEW ENGL J MED, V378, P407, DOI 10.1056/NEJMp1714529; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Butler SF, 2008, J PAIN, V9, P360, DOI 10.1016/j.jpain.2007.11.014; Compton PA, 2008, J PAIN SYMPTOM MANAG, V36, P383, DOI 10.1016/j.jpainsymman.2007.11.006; Han B, 2015, JAMA-J AM MED ASSOC, V314, P1468, DOI 10.1001/jama.2015.11859; Jones BL, 2007, SOCIOL METHOD RES, V35, P542, DOI 10.1177/0049124106292364; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; Kitzmiller EM, 2013, IDS CASE STUDY ALLEG; Klijn SL, 2017, STAT METHODS MED RES, V26, P2424, DOI 10.1177/0962280215598665; Miller M, 2015, JAMA INTERN MED, V175, P608, DOI 10.1001/jamainternmed.2014.8071; Nagin D., 2005, GROUP BASED MODELING, Vx; Nagin DS, 2010, ANNU REV CLIN PSYCHO, V6, P109, DOI 10.1146/annurev.clinpsy.121208.131413; Nagin DS, 2001, PSYCHOL METHODS, V6, P18, DOI 10.1037/1082-989X.6.1.18; Passik Steven D, 2005, J Opioid Manag, V1, P257; Paulozzi LJ, 2015, MMWR SURVEILL SUMM, V64, P1, DOI 10.15585/mmwr.ss6409a1; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Rice JB, 2012, PAIN MED, V13, P1162, DOI 10.1111/j.1526-4637.2012.01450.x; Ringwalt C, 2015, PAIN MED, V16, P633, DOI 10.1111/pme.12555; Scholl L, 2019, MMWR-MORBID MORTAL W, V67, P1419; Serdarevic M, 2017, CURR OPIN PSYCHIATR, V30, P238, DOI 10.1097/YCO.0000000000000337; Shah A, 2017, MMWR-MORBID MORTAL W, V66, P265, DOI 10.15585/mmwr.mm6610a1; Soelberg CD, 2017, ANESTH ANALG, V125, P1675, DOI 10.1213/ANE.0000000000002403; VanHouten JP, 2019, MMWR-MORBID MORTAL W, V68, P1, DOI 10.15585/mmwr.mm6801a1; Vivolo-Kantor AM, 2018, MMWR-MORBID MORTAL W, V67, P279, DOI 10.15585/mmwr.mm6709e1; White AG, 2009, AM J MANAG CARE, V15, P897	27	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2019	14	10							e0222677	10.1371/journal.pone.0222677	http://dx.doi.org/10.1371/journal.pone.0222677			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM7CZ	31584961	Green Published, gold			2023-01-03	WOS:000532407600010
J	Furfaro, LL; Chang, BJ; Kahler, CM; Payne, MS				Furfaro, Lucy L.; Chang, Barbara J.; Kahler, Charlene M.; Payne, Matthew S.			Genomic characterisation of perinatal Western Australian Streptococcus agalactiae isolates	PLOS ONE			English	Article							GROUP-B STREPTOCOCCUS; MULTIPLEX PCR ASSAY; SEROTYPE IV; ANTIBIOTIC-RESISTANCE; INVASIVE DISEASE; ANTIMICROBIAL SUSCEPTIBILITY; MOLECULAR CHARACTERIZATION; MATERNAL COLONIZATION; POPULATION-STRUCTURE; VIRULENCE FACTORS	As a leading cause of neonatal sepsis, Streptococcus agalactiae, commonly known as Group B Streptococcus, is a major neonatal pathogen. Current global screening practices employ risk- or culture-based protocols for detection of these organisms. In Western Australia (WA), universal culture-based screening is provided, with subsequent intrapartum antibiotic prophylaxis for all S. agalactiae-positive women during labour. Widespread antibiotic exposure is not ideal and this is one of the factors driving development of vaccines against S. agalactiae. Vaccine candidates have focused on the capsule, surface proteins and pilus types, however, capsule serotypes are known to vary geographically. The aim of this study was to use genome sequencing to gain an understanding of the circulating genotypes in WA, and to assess variations in the associated gene pools. We sequenced 141 antenatal carriage (vaginal/rectal) isolates and 10 neonatal invasive disease isolates from WA. Based on the global PubMLST database, the 151 strains were characterised into 30 sequence types, with clustering of these mainly into clonal complexes 1, 12, 17, 19 and 23. Of the genes encoding eleven surface proteins that were analysed, the most prevalent were fbp, lmb and scpB which were present in >= 98% of isolates. A cluster of non-haemolytic isolates, one of which was a neonatal invasive disease isolate, appeared to lack the entire cyl locus. Admixture analysis of population structure revealed evidence of genetic transfer among the WA isolates across structural groups. When compared against the PubMLST S. agalactiae data, WA isolates showed high levels of strain diversity with minimal apparent clustering. This is the first whole genome sequence study of WA S. agalactiae isolates and also represents the first addition of Australian isolate data to PubMLST. This report provides insight into the distribution and diversity of vaccine targets of S. agalactiae within Western Australia, indicating that the most appropriate capsular vaccine for this population would be the proposed pentavalent (Cps Ia, Ib, II, III and V) preparation, whilst vaccines targeting surface proteins should ideally utilise Fbp, Lmb and/or ScpB.	[Furfaro, Lucy L.; Payne, Matthew S.] Univ Western Australia, Sch Med, Div Obstet & Gynaecol, Perth, WA, Australia; [Chang, Barbara J.; Kahler, Charlene M.] Univ Western Australia, Marshall Ctr Infect Dis Res & Training, Sch Biomed Sci, Perth, WA, Australia	University of Western Australia; University of Western Australia	Furfaro, LL (corresponding author), Univ Western Australia, Sch Med, Div Obstet & Gynaecol, Perth, WA, Australia.	lucy.furfaro@uwa.edu.au	; Furfaro, Lucy/H-5569-2018	Chang, Barbara/0000-0002-6077-1646; Furfaro, Lucy/0000-0001-7652-0713	Wesfarmers Centre of Vaccines and Infectious Diseases; Australian Government; Women and Infants Research Foundation (WIRF); NHMRC [1144040]	Wesfarmers Centre of Vaccines and Infectious Diseases; Australian Government(Australian GovernmentCGIAR); Women and Infants Research Foundation (WIRF); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	This study was funded by a Wesfarmers Centre of Vaccines and Infectious Diseases Seed Funding Grant received by all authors. LLF is supported by the Australian Government Research Training Program Scholarship and the Professor Gordon King Postgraduate Scholarship provided by the Women and Infants Research Foundation (WIRF). MSP is supported by an NHMRC Project Grant [1144040]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bankevich A, 2012, J COMPUT BIOL, V19, P455, DOI 10.1089/cmb.2012.0021; Bellais S, 2012, J INFECT DIS, V206, P1745, DOI 10.1093/infdis/jis605; Bohnsack JF, 2008, J CLIN MICROBIOL, V46, P1285, DOI 10.1128/JCM.02105-07; Campisi E, 2016, SCI REP-UK, V6, DOI 10.1038/srep29799; Cheng L, 2013, MOL BIOL EVOL, V30, P1224, DOI 10.1093/molbev/mst028; Corander J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-539; Creti R, 2004, J CLIN MICROBIOL, V42, P1326, DOI 10.1128/JCM.42.3.1326-1329.2004; Da Cunha V, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5544; Dangor Z, 2015, EXPERT REV VACCINES, V14, P1651, DOI 10.1586/14760584.2015.1085307; Diedrick MJ, 2010, J CLIN MICROBIOL, V48, P3100, DOI 10.1128/JCM.00277-10; Dutra VG, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-323; Eskandarian N, 2015, EUR J CLIN MICROBIOL, V34, P579, DOI 10.1007/s10096-014-2265-x; Ferrieri P, 2013, EMERG INFECT DIS, V19, P551, DOI 10.3201/eid1904.121572; Flores AR, 2015, P NATL ACAD SCI USA, V112, P6431, DOI 10.1073/pnas.1504725112; Florindo C, 2014, EURO SURVEILL, V19; Furfaro LL, 2019, J MED MICROBIOLOGY; Furfaro LL, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00049-18; Furfaro LL, 2017, DIAGN MICR INFEC DIS, V89, P7, DOI 10.1016/j.diagmicrobio.2017.06.003; Gendrin C, 2017, J INFECT DIS; Gherardi G, 2007, J CLIN MICROBIOL, V45, P2909, DOI 10.1128/JCM.00999-07; Granlund M, 1998, J INFECT DIS, V177, P967, DOI 10.1086/515233; Gudjonsdottir MJ, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1266-4; Gurevich A, 2013, BIOINFORMATICS, V29, P1072, DOI 10.1093/bioinformatics/btt086; Heath PT, 2016, VACCINE, V34, P2876, DOI 10.1016/j.vaccine.2015.12.072; Herbert MA, 2004, CURR OPIN INFECT DIS, V17, P225, DOI 10.1097/00001432-200406000-00009; Hery-Arnaud G, 2007, APPL ENVIRON MICROB, V73, P4668, DOI 10.1128/AEM.02604-06; Inouye M, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0090-6; Jolley KA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-595; Jones N, 2003, J CLIN MICROBIOL, V41, P2530, DOI 10.1128/JCM.41.6.2530-2536.2003; Kapatai G, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3820-5; Ko DW, 2015, J PAEDIAT CHILD HLTH; Kong F, 2008, J CLIN MICROBIOL, V46, P2745, DOI 10.1128/JCM.00189-08; Kong FR, 2002, J CLIN MICROBIOL, V40, P620, DOI 10.1128/JCM.40.2.620-626.2002; Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]; Lachenauer CS, 1999, J INFECT DIS, V179, P1030, DOI 10.1086/314666; Larsson C, 2006, ARCH DIS CHILD-FETAL, V91, pF403, DOI 10.1136/adc.2005.090472; Lartigue MF, 2009, J CLIN MICROBIOL, V47, P2284, DOI 10.1128/JCM.00175-09; Lazzarin M, 2017, BMC MICROBIOL, V17, DOI 10.1186/s12866-017-1057-8; Le Doare K, 2013, VACCINE, V31, pD7, DOI 10.1016/j.vaccine.2013.01.009; Letunic I, 2016, NUCLEIC ACIDS RES, V44, pW242, DOI 10.1093/nar/gkw290; Lin SM, 2018, CLIN EXP VACCINE RES, V7, P76, DOI 10.7774/cevr.2018.7.1.76; Liu GYH, 2004, FRONT BIOSCI-LANDMRK, V9, P1794, DOI 10.2741/1296; Luan SL, 2005, J CLIN MICROBIOL, V43, P3727, DOI 10.1128/JCM.43.8.3727-3733.2005; Lyhs U, 2016, EMERG INFECT DIS, V22, P2097, DOI 10.3201/eid2212.151447; Madrid L, 2017, CLIN INFECT DIS, V65, pS160, DOI 10.1093/cid/cix656; Martins ER, 2010, J BACTERIOL, V192, P1361, DOI 10.1128/JB.01130-09; Meehan M, 2014, EUR J CLIN MICROBIOL, V33, P1155, DOI 10.1007/s10096-014-2055-5; Mehershahi KS, 2015, GENOME ANNOUNC, V3; MILLIGAN TW, 1978, INFECT IMMUN, V21, P738, DOI 10.1128/IAI.21.3.738-746.1978; Neemuchwala A, 2016, EMERG INFECT DIS, V22, P1941, DOI 10.3201//eid2211.152064; Rajagopal L, 2009, FUTURE MICROBIOL, V4, P201, DOI 10.2217/17460913.4.2.201; Rinaudo CD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009216; Rodriguez-Granger J, 2015, PATHOGENS DIS; Russell NJ, 2017, CLIN INFECT DIS, V65, pS100, DOI 10.1093/cid/cix658; Seale AC, 2016, NAT MICROBIOL, V1, DOI [10.1038/nmicrobiol.2016.67, 10.1038/NMICROBIOL.2016.67]; Sheen TR, 2011, J BACTERIOL, V193, P6834, DOI 10.1128/JB.00094-11; Singh P, 2012, J BACTERIOL, V194, P6005, DOI 10.1128/JB.01378-12; Six A, 2016, J CLIN MICROBIOL, V54, P75, DOI 10.1128/JCM.02177-15; Slotved HC, 2007, J CLIN MICROBIOL, V45, P2929, DOI 10.1128/JCM.00117-07; Springman AC, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-159; Suhaimi MES, 2017, J INFECT PUBLIC HEAL, V10, P14, DOI 10.1016/j.jiph.2016.01.009; Taylor K, 2006, THESIS; Teatero S, 2015, EMERG INFECT DIS, V21, P585, DOI 10.3201/eid2014.140759; Teatero S, 2014, J CLIN MICROBIOL, V52, P1441, DOI 10.1128/JCM.03554-13; van der Mee-Marquet N, 2008, J CLIN MICROBIOL, V46, P2906, DOI 10.1128/JCM.00421-08; Verani Jennifer R., 2010, Morbidity and Mortality Weekly Report, V59, P1; Yao KH, 2013, J CLIN MICROBIOL, V51, P503, DOI 10.1128/JCM.02417-12; Zeng XY, 2006, ANTIMICROB AGENTS CH, V50, P204, DOI 10.1128/AAC.50.1.204-209.2006; Zhao Z, 2008, CLIN MICROBIOL INFEC, V14, P260, DOI 10.1111/j.1469-0691.2007.01914.x	69	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2019	14	10							e0223256	10.1371/journal.pone.0223256	http://dx.doi.org/10.1371/journal.pone.0223256			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM6VM	31577825	Green Published, gold			2023-01-03	WOS:000532388000026
J	Bai, T; Li, JQ; Sinclair, A; Imren, S; Merriam, F; Sun, F; O'Kelly, MB; Nourigat, C; Jain, P; Delrow, JJ; Basom, RS; Hung, HC; Zhang, P; Li, BW; Heimfeld, S; Jiang, SY; Delaney, C				Bai, Tao; Li, Jianqiang; Sinclair, Andrew; Imren, Suzan; Merriam, Fabiola; Sun, Fang; O'Kelly, Mary Beth; Nourigat, Cynthia; Jain, Priyesh; Delrow, Jeffrey J.; Basom, Ryan S.; Hung, Hsiang-Chieh; Zhang, Peng; Li, Bowen; Heimfeld, Shelly; Jiang, Shaoyi; Delaney, Colleen			Expansion of primitive human hematopoietic stem cells by culture in a zwitterionic hydrogel	NATURE MEDICINE			English	Article							CORD-BLOOD TRANSPLANTATION; ACTIVATED PROTEIN-KINASE; SELF-RENEWAL; WNT; MAINTENANCE; HOMEOSTASIS; DERIVATIVES; POLYMERS; GLYCOL); NICHE	The ability to expand hematopoietic stem and progenitor cells (HSPCs) ex vivo is critical to fully realize the potential of HSPC-based therapies. In particular, the application of clinically effective therapies, such as cord blood transplantation, has been impeded because of limited HSPC availability. Here, using 3D culture of human HSPCs in a degradable zwitterionic hydrogel, we achieved substantial expansion of phenotypically primitive CD34(+) cord blood and bone-marrow-derived HSPCs. This culture system led to a 73-fold increase in long-term hematopoietic stem cell (LT-HSC) frequency, as demonstrated by limiting dilution assays, and the expanded HSPCs were capable of hematopoietic reconstitution for at least 24 weeks in immunocompromised mice. Both the zwitterionic characteristics of the hydrogel and the 3D format were important for HSPC self-renewal. Mechanistically, the impact of 3D zwitterionic hydrogel culture on mitigating HSPC differentiation and promoting self-renewal might result from an inhibition of excessive reactive oxygen species (ROS) production via suppression of O-2-related metabolism. HSPC expansion using zwitterionic hydrogels has the potential to facilitate the clinical application of hematopoietic-stem-cell therapies.	[Bai, Tao; Sinclair, Andrew; Sun, Fang; O'Kelly, Mary Beth; Jain, Priyesh; Hung, Hsiang-Chieh; Zhang, Peng; Jiang, Shaoyi] Univ Washington, Dept Chem Engn, Seattle, WA 98195 USA; [Li, Jianqiang; Imren, Suzan; Merriam, Fabiola; Nourigat, Cynthia; Heimfeld, Shelly; Delaney, Colleen] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA; [Delrow, Jeffrey J.; Basom, Ryan S.] Fred Hutchinson Canc Res Ctr, Genom & Bioinformat Shared Resources, 1124 Columbia St, Seattle, WA 98104 USA; [Li, Bowen; Jiang, Shaoyi] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Delaney, Colleen] Univ Washington, Dept Pediat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Jiang, SY (corresponding author), Univ Washington, Dept Chem Engn, Seattle, WA 98195 USA.; Delaney, C (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.; Jiang, SY (corresponding author), Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.; Delaney, C (corresponding author), Univ Washington, Dept Pediat, Seattle, WA 98195 USA.	sjiang@uw.edu; cdelaney@fredhutch.org	Li, Jing/GYU-5036-2022; LI, JIAN/GRY-2197-2022; Zhang, Peng/K-9566-2014; Li, Jin/GYQ-5363-2022; li, jian/GSE-0245-2022	Zhang, Peng/0000-0002-5409-7480; Delrow, Jeffrey/0000-0003-1020-3154; O'Kelly Boit, Mary/0000-0001-9990-6950	National Science Foundation [CBET-1264477, DMR 1307375]; Office of Naval Research [N00014-14-1-0090, N00014-15-1-2277]; University of Washington; NIDDK [DK 106829]; NIH/NCI Cancer Center Support Grant [P30 CA015704]; NATIONAL CANCER INSTITUTE [P30CA015704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U54DK106829] Funding Source: NIH RePORTER	National Science Foundation(National Science Foundation (NSF)); Office of Naval Research(Office of Naval Research); University of Washington(University of Washington); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIH/NCI Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	T.B., A.S., P.Z. and S.J. were supported by National Science Foundation (DMR 1307375). F.S., B.L. and S.J. were supported by National Science Foundation (CBET-1264477). P.J., H.-C.H. and S.J. were supported by the Office of Naval Research (N00014-14-1-0090 and N00014-15-1-2277). M.B.O. and S.J. were supported by the University of Washington. S.H. was supported by NIDDK grant (DK 106829). J.J.D. and R.S.B. were supported by NIH/NCI Cancer Center Support Grant (P30 CA015704). We thank D. Raftery and H. Gu from the Northwest Metabolomics Research Center (NW-MRC) for assisting with LC-MS assessment. We also thank all the mothers who donated their cord blood for research, without whom this work would not have been possible.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anderson SB, 2011, BIOMATERIALS, V32, P3564, DOI 10.1016/j.biomaterials.2011.01.064; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Ballen KK, 2013, BLOOD, V122, P491, DOI 10.1182/blood-2013-02-453175; Bigarella CL, 2014, DEVELOPMENT, V141, P4206, DOI 10.1242/dev.107086; Boitano AE, 2010, SCIENCE, V329, P1345, DOI 10.1126/science.1191536; BRETSCHER MS, 1975, NATURE, V258, P43, DOI 10.1038/258043a0; Carey AL, 2006, DIABETES, V55, P2688, DOI 10.2337/db05-1404; Csaszar E, 2012, CELL STEM CELL, V10, P218, DOI 10.1016/j.stem.2012.01.003; Cuchiara ML, 2016, BIOTECHNOL BIOENG, V113, P870, DOI 10.1002/bit.25848; Dahlberg A, 2011, BLOOD, V117, P6083, DOI 10.1182/blood-2011-01-283606; de Almeida MJ, 2017, CELL STEM CELL, V21, P725, DOI 10.1016/j.stem.2017.11.002; de Lima M, 2008, BONE MARROW TRANSPL, V41, P771, DOI 10.1038/sj.bmt.1705979; DeForest CA, 2011, NAT CHEM, V3, P925, DOI [10.1038/NCHEM.1174, 10.1038/nchem.1174]; DeForest CA, 2009, NAT MATER, V8, P659, DOI [10.1038/NMAT2473, 10.1038/nmat2473]; Delaney C, 2016, LANCET HAEMATOL, V3, pE330, DOI 10.1016/S2352-3026(16)30023-0; Delaney C, 2010, NAT MED, V16, P232, DOI 10.1038/nm.2080; Enver T, 2009, CELL STEM CELL, V4, P387, DOI 10.1016/j.stem.2009.04.011; Fares I, 2014, SCIENCE, V345, P1509, DOI 10.1126/science.1256337; Fleming HE, 2008, CELL STEM CELL, V2, P274, DOI 10.1016/j.stem.2008.01.003; Folmes CDL, 2012, CELL STEM CELL, V11, P596, DOI 10.1016/j.stem.2012.10.002; Gragert L, 2014, NEW ENGL J MED, V371, P339, DOI 10.1056/NEJMsa1311707; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Huang J, 2012, NAT MED, V18, P1778, DOI 10.1038/nm.2984; Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388; Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989; Ito K, 2014, NAT REV MOL CELL BIO, V15, P243, DOI 10.1038/nrm3772; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Jang YY, 2007, BLOOD, V110, P3056, DOI 10.1182/blood-2007-05-087759; Jiang SY, 2010, ADV MATER, V22, P920, DOI 10.1002/adma.200901407; KAPLAN SS, 1992, J BIOMED MATER RES, V26, P1039, DOI 10.1002/jbm.820260806; Keefe AJ, 2012, NAT CHEM, V4, P60, DOI 10.1038/nchem.1213; Liu WE, 2011, BIOMATERIALS, V32, P1796, DOI 10.1016/j.biomaterials.2010.11.029; Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044; Luo Y, 2014, TRANSPLANTATION, V97, P20, DOI 10.1097/TP.0b013e3182a7fcf8; Lutz JF, 2006, MACROMOLECULES, V39, P6376, DOI 10.1021/ma061557n; McGraw TE, 2010, NAT CHEM BIOL, V6, P176, DOI 10.1038/nchembio.324; Milano F, 2016, NEW ENGL J MED, V375, P944, DOI 10.1056/NEJMoa1602074; Murray LJ, 1999, EXP HEMATOL, V27, P1019, DOI 10.1016/S0301-472X(99)00031-4; Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397; Nishida M, 2005, J BIOL CHEM, V280, P18434, DOI 10.1074/jbc.M409710200; Pineault N, 2015, EXP HEMATOL, V43, P498, DOI 10.1016/j.exphem.2015.04.011; Ratajczak MZ, 2008, CURR OPIN HEMATOL, V15, P293, DOI 10.1097/MOH.0b013e328302c7ca; Rau A, 2013, BIOINFORMATICS, V29, P2146, DOI 10.1093/bioinformatics/btt350; Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Shen YI, 2014, BIOMATER SCI-UK, V2, P655, DOI 10.1039/c3bm60274e; Shin SY, 2004, CANCER LETT, V212, P225, DOI 10.1016/j.canlet.2004.03.003; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Wang Y, 2011, STEM CELLS DEV, V20, P1143, DOI 10.1089/scd.2010.0413; West JL, 1999, MACROMOLECULES, V32, P241, DOI 10.1021/ma981296k; Yoshida S, 2011, J BIOL CHEM, V286, P32651, DOI 10.1074/jbc.M111.238014; Young MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-2-r14; Yu L, 2015, J BIOMED MATER RES A, V103, P2987, DOI 10.1002/jbm.a.35432; Zhang L, 2013, NAT BIOTECHNOL, V31, P553, DOI 10.1038/nbt.2580; Zhang P, 2015, P NATL ACAD SCI USA, V112, P12046, DOI 10.1073/pnas.1512465112; Zhang Z, 2006, J PHYS CHEM B, V110, P10799, DOI 10.1021/jp057266i	60	109	111	17	212	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2019	25	10					1566	+		10.1038/s41591-019-0601-5	http://dx.doi.org/10.1038/s41591-019-0601-5			23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	JC3GJ	31591594				2023-01-03	WOS:000489166700026
J	Gough, N; Koffman, J; Ross, JR; Riley, J; Judson, I				Gough, Nicholas; Koffman, Jonathan; Ross, Joy R.; Riley, Julia; Judson, Ian			Does palliative chemotherapy really palliate and are we measuring it correctly? A mixed methods longitudinal study of health related quality of life in advanced soft tissue sarcoma	PLOS ONE			English	Article							CELL LUNG-CANCER; PROGNOSTIC-FACTORS; EUROPEAN-ORGANIZATION; 1ST-LINE TREATMENT; RANDOMIZED-TRIAL; SUPPORTIVE CARE; RESPONSE SHIFT; OPEN-LABEL; DOXORUBICIN; GEMCITABINE	Objective Soft tissue sarcoma (STS) is a rare cancer type that when locally advanced or metastatic, is predominantly treated with palliative chemotherapy with the aim of improving both quantity and quality of life. Given modest survival data after commencing first line chemotherapy, this study examines (i) what constitutes health related quality of life (HRQoL), (ii) whether the most commonly used HRQoL assessment tool measures this and (iii) to what extent HRQoL, and its components, change during and after treatment. Design Mixed-methods longitudinal study of 66 sarcoma patients living with STS (42 commencing chemotherapy, 24 under surveillance after completing chemotherapy) involving serial EORTC QLQ-C30 questionnaires and nested-qualitative semi-structured interviews with a sub-sample of participants. EORTC QLQ-C30 score change from baseline to primary evaluation point was examined using a paired t-test. Interviews were analysed using the framework approach before both datasets were integrated. Results Five main factors, including control of pain, were identified by study participants as important components of HRQoL; these are examined within the EORTC QLQ-C30. However, others e.g. independence loss and common causes of anxiety, are not. Whilst social and psychological domains are addressed by the EORTC QLQ-C30, the quantitative change over time did reflect qualitative descriptions of decline. The mean overall EORTC QLQ-C30 HRQoL score deteriorated from baseline (60.4) to the primary evaluation point (50.2) [change of -10.2, t-test: -2.70, p = 0.01] for those receiving chemotherapy; this was in concordance with patients' qualitative accounts. Baseline overall HRQoL scores were higher in the surveillance group suggesting a correlation with chemotherapy response and longer-term improvement in HRQoL. The evidence from both HRQoL scores and qualitative accounts indicated that the presence and control of physical symptoms were particularly important in maintaining HRQoL. Whilst fatigue deteriorated on chemotherapy (baseline 41.7 to 52.8; change of +11.1, t-test +2.51, p<0.05), pain (baseline 41.5 to 32.1; change -9.4, t-test -2.06 p<0.05) and sleep disturbance (43.1 to 28.5; change -14.6, t-test -3.05, p< 0.05) both improved. Conclusion A key finding was that the EORTC QLQ-C30 assesses some but not all of the patient-reported components of HRQoL in sarcoma patients highlighting the need for either STS specific modules within the EORTC QLQ-C30 or a completely new STS specific HRQoL tool. First line palliative chemotherapy improves specific symptoms known to be prevalent and to influence HRQoL in this patient group which in some patients may translate to sustained improvement in HRQoL: further exploration and validation of these findings in larger prospective studies are warranted.	[Gough, Nicholas] Guys & St Thomass Hosp NHS Fdn Trust, Palliat Care Dept, London, England; [Gough, Nicholas; Judson, Ian] Inst Canc Res, London, England; [Koffman, Jonathan] Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, London, England; [Ross, Joy R.; Riley, Julia] Royal Marsden NHS Fdn Trust, Royal Marsden & Royal Brompton Palliat Care Serv, London, England; [Ross, Joy R.; Riley, Julia] Imperial Coll, Natl Heart & Lung Inst, London, England; [Judson, Ian] Royal Marsden NHS Fdn Trust, Sarcoma Unit, London, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; King's College London; Royal Marsden NHS Foundation Trust; Imperial College London; Royal Marsden NHS Foundation Trust	Gough, N (corresponding author), Guys & St Thomass Hosp NHS Fdn Trust, Palliat Care Dept, London, England.; Gough, N (corresponding author), Inst Canc Res, London, England.	nicholas.gough@gstt.nhs.uk		Koffman, Jonathan/0000-0001-8513-5681; Gough, Nicholas/0000-0002-9251-3561	Sarcoma UK; NHS; Royal Marsden Palliative Care Research fund	Sarcoma UK; NHS; Royal Marsden Palliative Care Research fund	This research was funded jointly by a charitable grant from Sarcoma UK and by the Royal Marsden Palliative Care Research fund which is supported by charitable donations. The authors would like to acknowledge NHS funding to the Royal Marsden/ICR National Institute for Health Research (NIHR) Biomedical Research Centre, UK.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Aktas A, 2010, PALLIATIVE MED, V24, P373, DOI 10.1177/0269216310367842; Anderson H, 2000, BRIT J CANCER, V83, P447, DOI 10.1054/bjoc.2000.1307; [Anonymous], 2014, ANN ONCOL S3, V25; Armstrong Terri S, 2003, Oncol Nurs Forum, V30, P601, DOI 10.1188/03.ONF.601-606; Bando H, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.3_suppl.12; Basch E, 2012, J CLIN ONCOL, V30, P4249, DOI 10.1200/JCO.2012.42.5967; BENJAMIN RS, 1987, J CLIN ONCOL, V5, P833, DOI 10.1200/JCO.1987.5.6.833; CANNON S, 1989, SOCIOL HEALTH ILL, V11, P62, DOI 10.1111/1467-9566.ep10844052; Chang VT, 2000, CANCER, V89, P1162, DOI 10.1002/1097-0142(20000901)89:5<1162::AID-CNCR26>3.0.CO;2-Y; Clark MA, 2005, NEW ENGL J MED, V353, P701, DOI 10.1056/NEJMra041866; Coens C, 2015, CANCER; Coindre JM, 2001, CANCER-AM CANCER SOC, V91, P1914, DOI 10.1002/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3; Crino L, 1999, J CLIN ONCOL, V17, P3522, DOI 10.1200/JCO.1999.17.11.3522; Curt G A, 2000, Oncologist, V5, P353, DOI 10.1634/theoncologist.5-5-353; Delgado-Guay M, 2011, J PAIN SYMPTOM MANAG, V41, P819, DOI 10.1016/j.jpainsymman.2010.07.015; Etkind SN, 2015, J PAIN SYMPTOM MANAG, V49, P611, DOI 10.1016/j.jpainsymman.2014.07.010; Fayers PMaM D., 2007, QUALITY LIFE; Gough N, 2017, J PAIN SYMPTOM MANAG, V53, P588, DOI 10.1016/j.jpainsymman.2016.10.357; Gough Nicholas J., 2011, Sarcoma, V2011, P325189, DOI 10.1155/2011/325189; Greene J.C., 2007, MIXED METHODS SOCIAL; Grimer Robert, 2010, Sarcoma, V2010, P1, DOI 10.1155/2010/506182; Gronchi A, 2017, LANCET ONCOL, V18, P812, DOI 10.1016/S1470-2045(17)30334-0; GROND S, 1994, J PAIN SYMPTOM MANAG, V9, P372, DOI 10.1016/0885-3924(94)90174-0; Henderson M, 2005, J PAIN SYMPTOM MANAG, V29, P116, DOI 10.1016/j.jpainsymman.2004.12.001; Iop A, 2004, ANN ONCOL, V15, P712, DOI 10.1093/annonc/mdh102; Johnson RBAJO, 2007, DEFINITION MIXED MET, V1; Judson I, 2011, COMMUNICATION; Judson I, 2014, LANCET ONCOL, V15, P415, DOI 10.1016/S1470-2045(14)70063-4; Karavasilis V, 2008, CANCER-AM CANCER SOC, V112, P1585, DOI 10.1002/cncr.23332; Lowe M, 2011, LUNG CANCER, V74, P344, DOI 10.1016/j.lungcan.2011.03.011; Murray SA, 2006, LANCET, V368, P901, DOI 10.1016/S0140-6736(06)69350-1; Network NCI, 2013, BON SOFT TISS SARC U; O'Cathain A, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-85; Osoba David, 2011, Ther Adv Med Oncol, V3, P57, DOI 10.1177/1758834010395342; PETEET JR, 1992, RADIOLOGY, V182, P99, DOI 10.1148/radiology.182.1.1727318; Poveda A., 2005, Sarcoma, V9, P127, DOI 10.1080/13577140500287024; Preston NJ, 2013, PALLIATIVE MED, V27, P899, DOI 10.1177/0269216313486952; Quinten C, 2014, CANCER-AM CANCER SOC, V120, P302, DOI 10.1002/cncr.28382; Reichardt Peter, 2012, Sarcoma, V2012, P740279, DOI 10.1155/2012/740279; Ritchie J., 1994, ANAL QUALITATIVE DAT, P173, DOI [DOI 10.4324/9780203413081_CHAPTER_9, 10.4324/9780203413081_chapter_9]; Sandelowski M, 2001, RES NURS HEALTH, V24, P230, DOI 10.1002/nur.1025; Scott NW, 2008, EORTC QLQ C30 REFERE; Seddon B, 2017, LANCET ONCOL, V18, P1397, DOI 10.1016/S1470-2045(17)30622-8; Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095; Sinha S, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c7170; Sleijfer S, 2005, ONCOLOGIST, V10, P833, DOI 10.1634/theoncologist.10-10-833; Sleijfer SJ, 2012, YOU DECIDE WHETHER O; Sleijfer S, 2010, EUR J CANCER, V46, P72, DOI 10.1016/j.ejca.2009.09.022; Sprangers MAG, 1999, SOC SCI MED, V48, P1507, DOI 10.1016/S0277-9536(99)00045-3; Steinhauser KE, 2006, PALLIATIVE MED, V20, P745, DOI 10.1177/0269216306073112; Tap WD, 2016, LANCET, V388, P464, DOI 10.1016/S0140-6736(16)30587-6; Van Glabbeke M, 1999, J CLIN ONCOL, V17, P150, DOI 10.1200/JCO.1999.17.1.150; VANGLABBEKE M, 2002, EUR J CANCER, V38, P543, DOI DOI 10.1016/S0959-8049(01)00398-7; Velikova G, 2004, J CLIN ONCOL, V22, P714, DOI 10.1200/JCO.2004.06.078; WHO, 1948, PREAMBL CONST WHO AD; Winnette R, 2016, PATIENT EXPERIENCE S; Woll PJ, 2012, LANCET ONCOL, V13, P1045, DOI 10.1016/S1470-2045(12)70346-7; Younger E, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.11575	59	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2019	14	9							e0210731	10.1371/journal.pone.0210731	http://dx.doi.org/10.1371/journal.pone.0210731			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM6FU	31557183	gold, Green Published			2023-01-03	WOS:000532345500001
J	Kosilek, RP; Baumeister, SE; Ittermann, T; Grundling, M; Brunkhorst, FM; Felix, SB; Abel, P; Friesecke, S; Apfelbacher, C; Brandl, M; Schmidt, K; Hoffmann, W; Schmidt, CO; Chenot, JF; Volzke, H; Gensichen, JS				Kosilek, Robert P.; Baumeister, Sebastian E.; Ittermann, Till; Gruendling, Matthias; Brunkhorst, Frank M.; Felix, Stephan B.; Abel, Peter; Friesecke, Sigrun; Apfelbacher, Christian; Brandl, Magdalena; Schmidt, Konrad; Hoffmann, Wolfgang; Schmidt, Carsten O.; Chenot, Jean-Francois; Voelzke, Henry; Gensichen, Jochen S.			The association of intensive care with utilization and costs of outpatient healthcare services and quality of life	PLOS ONE			English	Article							RESOURCE UTILIZATION; SURVIVORS; OUTCOMES; UNIT; IMPACT; PHARMACISTS; ICU; POPULATION; MORTALITY; EUROQOL	Background Little is known about outpatient health services use following critical illness and intensive care. We examined the association of intensive care with outpatient consultations and quality of life in a population-based sample. Methods Cross-sectional analysis of data from 6,686 participants of the Study of Health in Pomerania (SHIP), which consists of two independent population-based cohorts. Statistical modeling was done using Poisson regression, negative binomial and generalized linear models for consultations, and a fractional response model for quality of life (EQ-5D-3L index value), with results expressed as prevalence ratios (PR) or percent change (PC). Entropy balancing was used to adjust for observed confounding. Results ICU treatment in the previous year was reported by 139 of 6,686 (2,1%) participants, and was associated with a higher probability (PR 1.05 [CI:1.03;1.07]), number (PC +58.0% [CI:22.8;103.2]) and costs (PC +64.1% [CI:32.0;103.9]) of annual outpatient consultations, as well as with a higher number of medications (PC +37.8% [CI:17.7;61.5]). Participants with ICU treatment were more likely to visit a specialist (PR 1.13 [CI:1.09; 1.16]), specifically internal medicine (PR 1.67 [CI:1.45;1.92]), surgery (PR 2.42 [CI:1.92;3.05]), psychiatry (PR 2.25 [CI:1.30;3.90]), and orthopedics (PR 1.54 [CI:1.11;2.14]). There was no significant effect regarding general practitioner consultations. ICU treatment was also associated with lower health-related quality of life (EQ-5D index value: PC -13.7% [CI:-27.0;-0.3]). Furthermore, quality of life was inversely associated with outpatient consultations in the previous month, more so for participants with ICU treatment. Conclusions Our findings suggest that ICU treatment is associated with an increased utilization of outpatient specialist services, higher medication intake, and impaired quality of life.	[Kosilek, Robert P.; Gensichen, Jochen S.] LMU Munchen, Inst Gen Practice & Family Med, Munich, Germany; [Baumeister, Sebastian E.] LMU Munchen, UNIKA T Augsburg, Chair Epidemiol, Augsburg, Germany; [Baumeister, Sebastian E.] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Independent Res Grp Clin Epidemiol, Munich, Germany; [Baumeister, Sebastian E.; Ittermann, Till; Hoffmann, Wolfgang; Schmidt, Carsten O.; Chenot, Jean-Francois; Voelzke, Henry] Univ Med Greifswald, Inst Community Med, Greifswald, Germany; [Gruendling, Matthias] Univ Med Greifswald, Dept Anesthesiol, Greifswald, Germany; [Brunkhorst, Frank M.] Jena Univ Hosp, Integrated Res & Treatment Ctr, Ctr Sepsis Control & Care CSCC, Jena, Germany; [Felix, Stephan B.; Abel, Peter; Friesecke, Sigrun] Univ Med Greifswald, Dept Internal Med B, Med Intens Care Unit, Greifswald, Germany; [Felix, Stephan B.; Voelzke, Henry] DZHK German Ctr Cardiovasc Res, Partner Site Greifswald, Greifswald, Germany; [Apfelbacher, Christian; Brandl, Magdalena] Univ Regensburg, Inst Epidemiol & Prevent Med, Med Sociol, Regensburg, Germany; [Apfelbacher, Christian] Nanyang Technol Univ Singapore, Lee Kong Chian Sch Med, Family Med & Primary Care, Singapore, Singapore; [Schmidt, Konrad] Charite Univ Med Berlin, Inst Gen Practice & Family Med, Berlin, Germany; [Schmidt, Konrad] Jena Univ Hosp, Inst Gen Practice & Family Med, Jena, Germany; [Voelzke, Henry] German Ctr Diabet Res, Site Greifswald, Greifswald, Germany	University of Munich; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Greifswald Medical School; Greifswald Medical School; Friedrich Schiller University of Jena; Greifswald Medical School; German Centre for Cardiovascular Research; University of Regensburg; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Friedrich Schiller University of Jena	Kosilek, RP (corresponding author), LMU Munchen, Inst Gen Practice & Family Med, Munich, Germany.	robert_philipp.kosilek@med.uni-muenchen.de	Baumeister, Sebastian-Edgar/P-7894-2019; Chenot, Jean-Francois/F-8241-2011; Schmidt, Konrad/V-5469-2017; Schmidt, Carsten Oliver/AAH-2778-2019	Baumeister, Sebastian-Edgar/0000-0002-9391-6602; Chenot, Jean-Francois/0000-0001-8877-2950; Schmidt, Konrad/0000-0001-5879-0664; Schmidt, Carsten Oliver/0000-0001-5266-9396	German Federal Ministry of Education and Research (BMBF) [01ZZ96030, 01ZZ0701]; DZHK (German Center for Cardiovascular Research)	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); DZHK (German Center for Cardiovascular Research)	The Study of Health in Pomerania (SHIP) is part of the Community Medicine Research net (CMR) (http://www.medizin.uni-greifswald.de/icm) of the University of Greifswald, funded by grants from the German Federal Ministry of Education and Research (BMBF grants 01ZZ96030 and 01ZZ0701). This study was further supported by the DZHK (German Center for Cardiovascular Research). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDERSEN R., 1968, Research Ser.; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; Angus DC, 2003, INTENS CARE MED, V29, P368, DOI 10.1007/s00134-002-1624-8; [Anonymous], 2012, BEVOLKERUNG ZUM STIC; [Anonymous], 2012, INTENSIVMEDIZINISCHE; Austin PC, 2015, STAT MED, V34, P3661, DOI 10.1002/sim.6607; Basu A, 2012, MED DECIS MAKING, V32, P56, DOI 10.1177/0272989X11416988; Baumeister SE, 2008, GASTROENTEROLOGY, V134, P85, DOI 10.1053/j.gastro.2007.10.024; Bell CM, 2011, JAMA-J AM MED ASSOC, V306, P840, DOI 10.1001/jama.2011.1206; Bock JO, 2015, GESUNDHEITSWESEN, V77, P53, DOI 10.1055/s-0034-1374621; Brandstetter S, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0544-5; Brilli RJ, 2001, CRIT CARE MED, V29, P2007, DOI 10.1097/00003246-200110000-00026; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Cheung AM, 2006, AM J RESP CRIT CARE, V174, P538, DOI 10.1164/rccm.200505-693OC; Cole SR, 2008, AM J EPIDEMIOL, V168, P656, DOI 10.1093/aje/kwn164; Cuthbertson BH, 2010, CRIT CARE, V14, DOI 10.1186/cc8848; Desai SV, 2011, CRIT CARE MED, V39, P371, DOI 10.1097/CCM.0b013e3181fd66e5; Dowdy DW, 2005, INTENS CARE MED, V31, P611, DOI 10.1007/s00134-005-2592-6; Esper AM, 2011, CRIT CARE MED, V39, P2728, DOI 10.1097/CCM.0b013e318236f27e; Garland A, 2015, ANN AM THORAC SOC, V12, P202, DOI 10.1513/AnnalsATS.201405-201CME; Gayat E, 2018, CRIT CARE, V22, DOI 10.1186/s13054-017-1922-8; Greenland S, 2004, AM J EPIDEMIOL, V160, P301, DOI 10.1093/aje/kwh221; Griffiths J, 2013, CRIT CARE, V17, DOI 10.1186/cc12745; Hainmueller J, 2013, J STAT SOFTW, V54; Held N, 2019, TURK THORAC J, V20, P147, DOI 10.5152/TurkThoracJ.2018.18172; Hill AD, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1248-y; Hua M, 2015, CRIT CARE MED, V43, P430, DOI 10.1097/CCM.0000000000000717; Jeitziner MM, 2015, J CLIN NURS, V24, P1347, DOI 10.1111/jocn.12749; Jensen JF, 2015, INTENS CARE MED, V41, P763, DOI 10.1007/s00134-015-3689-1; John U, 2001, SOZ PRAVENTIV MED, V46, P186, DOI 10.1007/BF01324255; Kane SL, 2003, INTENS CARE MED, V29, P691, DOI 10.1007/s00134-003-1705-3; Kawachi I, 1997, SOC SCI MED, V45, P1121, DOI 10.1016/S0277-9536(97)00044-0; Krauth C, 2005, GESUNDHEITSWESEN, V67, P736, DOI 10.1055/s-2005-858698; Linko R, 2010, CRIT CARE, V14, DOI 10.1186/cc8957; Lone NI, 2016, AM J RESP CRIT CARE, V194, P198, DOI 10.1164/rccm.201511-2234OC; MacLaren R, 2008, CRIT CARE MED, V36, P3184, DOI 10.1097/CCM.0b013e31818f2269; Manning WG, 2005, J HEALTH ECON, V24, P465, DOI 10.1016/j.jhealeco.2004.09.011; Ramos-Goni JM, 2011, STATA J, V11, P120, DOI 10.1177/1536867X1101100108; Marra A, 2018, CRIT CARE MED, V46, P1393, DOI 10.1097/CCM.0000000000003218; Marti J, 2016, J INTENSIVE CARE, V4, DOI 10.1186/s40560-016-0178-8; Morandi A, 2013, J AM GERIATR SOC, V61, P1128, DOI 10.1111/jgs.12329; Needham DM, 2012, CRIT CARE MED, V40, P502, DOI 10.1097/CCM.0b013e318232da75; Oeyen SG, 2010, CRIT CARE MED, V38, P2386, DOI 10.1097/CCM.0b013e3181f3dec5; Rattay P, 2013, BUNDESGESUNDHEITSBLA, V56, P832, DOI 10.1007/s00103-013-1665-x; Rawal G, 2017, J TRANSL INTERN MED, V5, P90, DOI 10.1515/jtim-2016-0016; Reijneveld SA, 2001, INT J EPIDEMIOL, V30, P1407, DOI 10.1093/ije/30.6.1407; Ritter PL, 2001, J CLIN EPIDEMIOL, V54, P136, DOI 10.1016/S0895-4356(00)00261-4; Ruhl AP, 2017, INTENS CARE MED, V43, P980, DOI 10.1007/s00134-017-4827-8; Ruhl AP, 2015, ANN AM THORAC SOC, V12, P392, DOI 10.1513/AnnalsATS.201409-422OC; Stollings JL, 2018, ANN PHARMACOTHER, V52, P713, DOI 10.1177/1060028018759343; Szakmany A, 2019, CRIT CARE MED, V47, P15, DOI 10.1097/CCM.0000000000003424; Unroe M, 2010, ANN INTERN MED, V153, P167, DOI 10.7326/0003-4819-153-3-201008030-00007; VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607; VanderWeele TJ, 2011, BIOMETRICS, V67, P1406, DOI 10.1111/j.1541-0420.2011.01619.x; Vijayaraghavan BKT, 2018, INTENS CARE MED, V44, P1542, DOI 10.1007/s00134-018-5117-9; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Volzke H, 2011, INT J EPIDEMIOL, V40, P294, DOI 10.1093/ije/dyp394; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Williams TA, 2010, ANAESTH INTENS CARE, V38, P732, DOI 10.1177/0310057X1003800417; Zhao QY, 2017, J CAUSAL INFERENCE, V5, DOI 10.1515/jci-2016-0010	61	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2019	14	9							e0222671	10.1371/journal.pone.0222671	http://dx.doi.org/10.1371/journal.pone.0222671			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM5OJ	31539397	Green Submitted, Green Published, gold			2023-01-03	WOS:000532297900024
J	Saerchen, E; Liedtke-Gruener, S; Kopp, M; Heisterkamp, A; Lubatschowski, H; Ripken, T				Saerchen, Emanuel; Liedtke-Gruener, Susann; Kopp, Maximilian; Heisterkamp, Alexander; Lubatschowski, Holger; Ripken, Tammo			Femtosecond laser induced step-like structures inside transparent hydrogel due to laser induced threshold reduction	PLOS ONE			English	Article							WAVE-GUIDES; HEAT ACCUMULATION; NANOSURGERY; FABRICATION; MECHANISMS; BREAKDOWN; CATARACT; POLYMERS; PATTERNS; WRITTEN	In the area of laser material processing, versatile applications for cutting glasses and transparent polymers exist. However, parasitic effects such as the creation of step-like structures appear when laser cutting inside a transparent material. To date, these structures were only described empirically. This work establishes the physical and chemical mechanisms behind the observed effects and describes the influence of process and material parameters onto the creation of step-like structures in hydrogel, Dihydroxyethylmethacrylat (HEMA). By focusing laser pulses in HEMA, reduced pulse separation distance below 50 nm and rise in pulse energy enhances the creation of unintended step-like structures. Spatial resolved Raman-spectroscopy was used to measure the laser induced chemical modification, which results into a reduced breakdown threshold. The reduction in threshold influences the position of optical breakdown for the succeeding laser pulses and consequently leads to the step-like structures. Additionally, the experimental findings were supplemented with numerical simulations of the influence of reduced damage threshold onto the position of optical breakdown. In summary, chemical material change was defined as cause of the step-like structures. Furthermore, the parameters to avoid these structures were identified.	[Saerchen, Emanuel; Kopp, Maximilian; Heisterkamp, Alexander; Ripken, Tammo] Laser Zentrum Hannover eV, Hannover, Germany; [Saerchen, Emanuel; Liedtke-Gruener, Susann; Lubatschowski, Holger] Rowiak GmbH, Hannover, Germany; [Heisterkamp, Alexander; Lubatschowski, Holger] Leibniz Univ Hannover, Inst Fuer Quantenopt, Hannover, Germany; [Liedtke-Gruener, Susann] Leibniz Inst Surface Engn IOM, Leipzig, Germany	Leibniz University Hannover	Ripken, T (corresponding author), Laser Zentrum Hannover eV, Hannover, Germany.	t.ripken@lzh.de		Ripken, Tammo/0000-0003-3512-9544	German Research Association DFG [RI2066/5-1]	German Research Association DFG(German Research Foundation (DFG))	TR received support from the German Research Association DFG (RI2066/5-1). ROWIAK GmbH provided support in the form of salaries for authors [ES, SLG, HL], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	[Anonymous], THESIS; Bellouard Y, 2011, OPT EXPRESS, V19, P6807, DOI 10.1364/OE.19.006807; Bellucci R, 2013, ESASO COURSE SER, V3, P38, DOI 10.1159/000350902; Close N, 2004, CELL BIOCHEM BIOPHYS, P9; Ding L, 2006, OPT EXPRESS, V14, P11901, DOI 10.1364/OE.14.011901; Donaldson KE, 2013, J CATARACT REFR SURG, V39, P1753, DOI 10.1016/j.jcrs.2013.09.002; Eaton SM, 2005, OPT EXPRESS, V13, P4708, DOI 10.1364/OPEX.13.004708; Farjo AA, 2013, OPHTHALMOLOGY, V120, pE5, DOI 10.1016/j.ophtha.2012.08.013; Ferrer A, 2011, J APPL PHYS, V109, DOI 10.1063/1.3572268; Ganin D, 2015, PHYSCS PROC, V73, P67, DOI 10.1016/j.phpro.2015.09.123; Gattass RR, 2006, THESIS; Giniunas L, 2014, 8 INT C PHOT TECHN L, P5; Hammer DX, 1997, APPL OPTICS, V36, P5630, DOI 10.1364/AO.36.005630; Hammer DX, 1994, P SOC PHOTO-OPT INS, V2134, P24; Heberle J, 2014, J LASER MICRO NANOEN, V9, P103, DOI 10.2961/jlmn.2014.02.0005; Hnatovskya C, 2005, J APPL PHYS, V98, P1; Kazansky PG, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2722240; KELDYSH LV, 1965, SOV PHYS JETP-USSR, V20, P1307; Kniggendorf AK, 2016, CHEMOSPHERE, V161, P112, DOI 10.1016/j.chemosphere.2016.06.096; Kniggendorf AK, 2014, BIOMED OPT EXPRESS, V5, P2054, DOI 10.1364/BOE.5.002054; Konig K, 1999, CELL MOL BIOL, V45, P195; Korte F, 2003, APPL PHYS A-MATER, V77, P229, DOI 10.1007/s00339-003-2110-z; Kruer W.L., 2003, PHYS LASER PLASMA IN; Lubatschowski H, 2013, KLIN MONATSBL AUGENH, V230, P1207, DOI 10.1055/s-0033-1351058; Lubatschowski H., 2007, OPT PHOTONIK, V2, P49; Lubatschowski H, 2008, J REFRACT SURG, V24, P102, DOI 10.3928/1081597X-20080101-18; Matsuo S, 2015, OPT EXPRESS, V23, P165, DOI 10.1364/OE.23.000165; Mauclair C, 2008, OPT EXPRESS, V16, P5481, DOI 10.1364/OE.16.005481; Mayer WJ, 2014, OPHTHALMOLOGE, V111, P69, DOI 10.1007/s00347-013-2975-y; Miese C, 2011, OPT EXPRESS, V19, P19542, DOI 10.1364/OE.19.019542; Musgraves JD, 2011, OPT MATER EXPRESS, V1, P921, DOI 10.1364/OME.1.000921; Oujja M, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3274127; Riau AK, 2014, INVEST OPHTH VIS SCI, V55, P3186, DOI 10.1167/iovs.14-14434; Richter S, 2013, OPT EXPRESS, V21, P15452, DOI 10.1364/OE.21.015452; Saliminia A, 2006, J APPL PHYS, V99, DOI 10.1063/1.2196237; Salomao MQ, 2010, J CATARACT REFR SURG, V36, P1024, DOI 10.1016/j.jcrs.2010.03.025; Schaffer C.B, 2001, INTERACTION FEMTOSEC; Schmidt U, 2005, MACROMOL SYMP, V230, P133, DOI 10.1002/masy.200551152; Schumacher S., 2009, THESIS; Seiler T, 2014, OPHTHALMOLOGE, V111, P539, DOI 10.1007/s00347-013-2993-9; Shah L, 2005, PROC SPIE, V5714, P253, DOI 10.1117/12.590850; Shaltev MV., 2009, THESIS; Tan DZ, 2016, PROG MATER SCI, V76, P154, DOI 10.1016/j.pmatsci.2015.09.002; Tel A, 2014, INT J THERM SCI, V85, P47, DOI 10.1016/j.ijthermalsci.2014.06.005; Terakawa M, 2010, APPL PHYS A-MATER, V100, P1041, DOI 10.1007/s00339-010-5942-3; Tinne N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114437; Toratani E, 2006, MICROELECTRON ENG, V83, P1782, DOI 10.1016/j.mee.2006.01.194; Vartapetov SK, 2015, QUANTUM ELECTRON+, V45, P725, DOI 10.1070/QE2015v045n08ABEH015515; Vitek DN, 2010, OPT EXPRESS, V18, P24673, DOI 10.1364/OE.18.024673; Vogel A, 2005, APPL PHYS B-LASERS O, V81, P1015, DOI 10.1007/s00340-005-2036-6; Vogel A, 1999, APPL PHYS B-LASERS O, V68, P271, DOI 10.1007/s003400050617; Xu L., 2013, SPECIES DIVERSITY FR; Xu LS, 2011, OPT MATER EXPRESS, V1, P1416, DOI 10.1364/OME.1.001416; Ya Cheng, 2003, RIKEN Review, P101	54	2	2	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2019	14	9							e0222293	10.1371/journal.pone.0222293	http://dx.doi.org/10.1371/journal.pone.0222293			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM4PG	31527880	Green Submitted, gold, Green Published			2023-01-03	WOS:000532231400015
J	Djima, MM; Ekouevi, DK; Gregoire, JP; Tchounga, B; Coffie, PA; Tran, VT; Toure, FY; Moisan, J				Djima, Mariam Mama; Ekouevi, Didier Koumavi; Gregoire, Jean-Pierre; Tchounga, Boris; Coffie, Patrick Ahuatchi; Viet-Thi Tran; Toure, Franck Y.; Moisan, Jocelyne			Use of non-HIV medication among people living with HIV and receiving antiretroviral treatment in Cote d'Ivoire, West Africa: A cross-sectional study	PLOS ONE			English	Article							DRUG-INTERACTIONS; INFECTED PATIENTS; PILL BURDEN; RISK; POLYPHARMACY; THERAPY; PREVALENCE; PREDICTORS; MORTALITY; MEDICINE	Background In Cote d'Ivoire, people living with HIV (PLHIV) have free access to antiretroviral therapy (ART) and cotrimoxazole. Yet, they may use other medications to treat non-HIV diseases. Scarce data are available regarding the use of non-HIV medications in Africa. This study describes the use of non-HIV medications and identifies the factors associated with their use by PLHIV on ART in Cote d'Ivoire. Methods A cross-sectional study was conducted in six HIV clinics in 2016. HIV-1-infected adults receiving ART for at least one year were eligible. A standardized questionnaire was used to collect demographics, HIV characteristics and medication use data. Associated factors were identified using a multivariate adjusted Poisson regression. Results A total of 1,458 participants (74% women) were enrolled. The median age was 44 years, and the median duration of ART was 81 months. A total of 696 (48%) participants reported having used at least one non-HIV medication. Among the 1,519 non-HIV medications used, 550 (36%) had not been prescribed and 397 (26%) were from the nervous system class. Individuals who were more likely to report the use of at least one non-HIV medication included those who had been treated in an Abidjan HIV clinic, had a high school education level, had a monthly income between 152 and 304 euros, had a poor perceived health status, had WHO advanced clinical stage, had used traditional medicine products and had not used cotrimoxazole. Conclusion Almost half PLHIV on ART reported using non-HIV medication. Further research is needed to assess whether the use of non-HIV medication is appropriate given about a third of those medications are not being prescribed.	[Djima, Mariam Mama; Ekouevi, Didier Koumavi; Tchounga, Boris; Coffie, Patrick Ahuatchi; Viet-Thi Tran; Toure, Franck Y.] CHU Treichville, PACCI, Abidjan, Cote Ivoire; [Djima, Mariam Mama] Inst Pasteur Cote dIvoire, Abidjan, Cote Ivoire; [Djima, Mariam Mama; Gregoire, Jean-Pierre; Moisan, Jocelyne] Univ Laval, Fac Pharm, Quebec City, PQ, Canada; [Ekouevi, Didier Koumavi] Univ Victor Segalen, Ctr Inserm 1219, ISPED, Bordeaux, France; [Ekouevi, Didier Koumavi] Univ Lome, Dept Sante Publ, Lome, Togo; [Gregoire, Jean-Pierre; Moisan, Jocelyne] Univ Laval, CHU Quebec, Ctr Rech, Axe Sante Populat & Prat Optimales Sante, Quebec City, PQ, Canada	Laval University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Laval University	Djima, MM (corresponding author), CHU Treichville, PACCI, Abidjan, Cote Ivoire.; Djima, MM (corresponding author), Inst Pasteur Cote dIvoire, Abidjan, Cote Ivoire.; Djima, MM (corresponding author), Univ Laval, Fac Pharm, Quebec City, PQ, Canada.	madjimar@gmail.com	Tran, Viet-Thi/F-1023-2018; Tran, Viet-Thi/Q-2789-2019	Tran, Viet-Thi/0000-0003-1863-6739; Tran, Viet-Thi/0000-0003-1863-6739; Tchounga, Boris Kevin/0000-0002-8747-9610; MAMA DJIMA, MARIAM/0000-0001-9099-9417; Gregoire, Jean-Pierre/0000-0002-1467-9750	French National Agency for Research on HIV and viral hepatitis (Agence Nationale de Recherche sur le Sida et les Hepatites Virales -ANRS) [12335]	French National Agency for Research on HIV and viral hepatitis (Agence Nationale de Recherche sur le Sida et les Hepatites Virales -ANRS)	This work was supported by the French National Agency for Research on HIV and viral hepatitis (Agence Nationale de Recherche sur le Sida et les Hepatites Virales -ANRS) [grant number 12335]. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrass CK, 2012, J AM GERIATR SOC, V60, P974, DOI 10.1111/j.1532-5415.2012.03948.x; Adams JL, 2012, INT J PSYCHIAT MED, V43, P105, DOI 10.2190/PM.43.2.a; Ajuoga E, 2008, RES SOC ADMIN PHARM, V4, P292, DOI 10.1016/j.sapharm.2007.08.001; Angwenyi V, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199977; [Anonymous], 2011, RAPPORT ANNUEL DACTI; Aziz MM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194240; Baker JV, 2008, AIDS, V22, P841, DOI 10.1097/QAD.0b013e3282f7cb76; Beauliere A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011213; Blot M, 2012, REV MAL RESPIR, V29, P785, DOI 10.1016/j.rmr.2011.10.974; Brown TT, 2017, INTERD T GERONT GERI, V42, P59, DOI 10.1159/000448544; Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7; Deeks SG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3172; Diouf A, 2017, REV EPIDEMIOL SANTE, V65, P295, DOI 10.1016/j.respe.2017.02.001; Eholie S P, 2009, Med Trop (Mars), V69, P520; Eholie SP, 2017, TROP MED INT HEALTH, V22, P1186, DOI 10.1111/tmi.12919; Ruiz ME, 2010, CURR DRUG SAF, V5, P315, DOI 10.2174/157488610792245966; Ford N, 2018, LANCET INFECT DIS, V18, pE76, DOI 10.1016/S1473-3099(17)30482-6; Furler MD, 2004, AIDS PATIENT CARE ST, V18, P568, DOI 10.1089/apc.2004.18.568; Furler MD, 2003, AIDS PATIENT CARE ST, V17, P155, DOI 10.1089/108729103321619764; Gimeno-Gracia M, 2015, HIV CLIN TRIALS, V16, P117, DOI 10.1179/1528433614Z.0000000012; Harris M, 2012, AIDS RES TREAT, V2012, DOI 10.1155/2012/595762; Harris TG, 2018, AIDS, V32, P1563, DOI 10.1097/QAD.0000000000001870; Holtzman C, 2013, J GEN INTERN MED, V28, P1302, DOI 10.1007/s11606-013-2449-6; International Diabetes Federation, 2013, IDF DIABETES ATLAS, V6th ed.; Justice AC, 2018, AIDS, V32, P739, DOI [10.1097/QAD.0000000000001756, 10.1097/qad.0000000000001756]; Justice Amy C, 2010, Curr HIV/AIDS Rep, V7, P69, DOI 10.1007/s11904-010-0041-9; Kamekis A, 2018, J CLIN PHARM THER, V43, P26, DOI 10.1111/jcpt.12601; Krentz HB, 2012, ANTIVIR THER, V17, P833, DOI 10.3851/IMP2076; Lamas CC, 2017, INFECTION, V45, P801, DOI 10.1007/s15010-017-1041-0; Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd; Marzolini C, 2011, J ANTIMICROB CHEMOTH, V66, P2107, DOI 10.1093/jac/dkr248; Marzolini C, 2010, ANTIVIR THER, V15, P413, DOI 10.3851/IMP1540; Moshabela M, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-182; Nombela N, 2006, JAIDS-J ACQ IMM DEF, V41, P225, DOI 10.1097/01.qai.0000179456.39185.9b; OMS, 2013, LIGN DIR COMB UT ANT; OMS, 2013, GLOB UPD HIV TREATM; Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16; PELTZER K, 2008, BMC PUBLIC HEALTH, V8, DOI DOI 10.1186/1471-2458-8-2551471-2458-8-255; Peltzer Karl, 2009, Afr J Tradit Complement Altern Med, V7, P125; Peters B S, 2011, Adv Dent Res, V23, P23, DOI 10.1177/0022034511399082; Radtke KK, 2018, JAIDS-J ACQ IMM DEF, V78, P202, DOI 10.1097/QAI.0000000000001658; Ranzani A, 2018, JAIDS-J ACQ IMM DEF, V78, P193, DOI 10.1097/QAI.0000000000001653; Sander LD, 2015, TROP MED INT HEALTH, V20, P391, DOI 10.1111/tmi.12443; Schmidt CO, 2008, INT J PUBLIC HEALTH, V53, P165, DOI 10.1007/s00038-008-7068-3; Seden K, 2013, J ANTIMICROB CHEMOTH, V68, P1, DOI 10.1093/jac/dks346; Tadesse BT, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2713-1; Tayebati SK, 2017, INT MARIT HEALTH, V68, P39, DOI 10.5603/IMH.2017.0007; The Joint United Nations Programme on HIV and AIDS, 2010, UNAIDS REP GLOB AIDS; Tseng A, 2013, ANN PHARMACOTHER, V47, P1429, DOI 10.1177/1060028013504075; WHO, 2002, STRAT LOMS MED TRAD; WHO UNAIDS UNICEF, 2012, GLOB HIV AIDS RESP E; Wilson M, 2010, ISSUES COMORBIDITY H; World Health Organization, 2001, Afr Health Sci, V1, P30; Zhou ST, 2014, AIDS PATIENT CARE ST, V28, P311, DOI 10.1089/apc.2014.0010	54	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2019	14	9							e0221335	10.1371/journal.pone.0221335	http://dx.doi.org/10.1371/journal.pone.0221335			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM4NC	31525222	Green Published, Green Submitted, gold			2023-01-03	WOS:000532225700011
J	John, GF; Hayworth, JS				John, Gerald F.; Hayworth, Joel S.			Enhanced effectiveness of oil dispersants in destabilizing water-in-oil emulsions	PLOS ONE			English	Article							CRUDE-OIL; CHEMICAL DESTABILIZATION	Oil impacting the northern Gulf of Mexico shoreline from the 2010 Deepwater Horizon accident was predominantly in the form of water-in-oil emulsions (WOE), a chemically weathered, highly viscous, neutrally buoyant material. Once formed, WOE are extremely difficult to destabilize. Commercially-available oil dispersants are largely ineffective de-emulsifiers as a result of the inability of dispersant surfactants to displace asphaltenes stabilizing the oil-water interface. This study investigated the effectiveness of the commercially-available dispersant Corexit 9500A, modified to enhance its polar fraction, in destabilizing WOE. Results suggest that Corexit modified to include between 20-60% fractional amount of either polar additive (1-octanol or hexylamine) will produce a modest increase in WOE instability, with a Corexit to hexylamine ratio of approximately 80/20 providing the most effective enhanced destabilization. Results support the hypothesis that modifying the fraction of polar constituents in commercial dispersants will increase asphaltene solubility, decrease oil-water interface stability, and enhance WOE instability.	[John, Gerald F.] Bryant Univ, Sci & Technol Dept, Smithfield, RI USA; [Hayworth, Joel S.] Auburn Univ, Civil Engn Dept, Auburn, AL 36849 USA	Bryant University; Auburn University System; Auburn University	Hayworth, JS (corresponding author), Auburn Univ, Civil Engn Dept, Auburn, AL 36849 USA.	jsh@auburn.edu			Bureau of Safety and Environmental Enforcement (BSEE), U.S. Department of Interior, Washington, D.C [M11PC00038]; U.S. Department of Interior, Bureau of Safety and Environmental Enforcement (BSEE)	Bureau of Safety and Environmental Enforcement (BSEE), U.S. Department of Interior, Washington, D.C; U.S. Department of Interior, Bureau of Safety and Environmental Enforcement (BSEE)	This study was funded by a grant to JSH from the Bureau of Safety and Environmental Enforcement (BSEE; https://www.bsee.gov/), U.S. Department of Interior, Washington, D.C., under Contract Number M11PC00038. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors thank the U.S. Department of Interior, Bureau of Safety and Environmental Enforcement (BSEE) for supporting this study. Thanks also to Pamela Turner, Assistant Research Engineer at the National Center for Asphalt Testing, Auburn, AL, USA for assistance measuring sample viscosity, and to Dr. Vanisree Mulabagal, Dr. T. Prabhakar Clement, and graduate students Jingyi Qui and Lan Liu for their assistance.	[Anonymous], 2012, D327912A ASTM INT, DOI 10.1520/D3279-12; [Anonymous], 2016, D400616A ASTM INT, DOI 10.1520/D4006-16; BOERSMA WH, 1990, AICHE J, V36, P321, DOI 10.1002/aic.690360302; Chandrasekar S, 2006, ICES J MAR SCI, V63, P1418, DOI 10.1016/j.icesjms.2006.04.019; Chanton J, 2014, ENVIRON SCI TECHNOL, V49, P8; Clayton J. R, 1993, OIL SPILL DISPERSANT; Council NR, 2005, OIL SPILL DISP EFF E; Daling PS, 1999, SPILL SCI TECHNOL B, V5, P63, DOI 10.1016/S1353-2561(98)00051-6; Djuve J, 2001, COLLOID POLYM SCI, V279, P232, DOI 10.1007/s003960000413; Fingas M, 2003, MAR POLLUT BULL, V47, P369, DOI 10.1016/S0025-326X(03)00212-1; Fingas M, 1994, ARCT MAR OILSP PROGR; Fingas M, 1996, P 19 ARCT MAR OILSP; Fingas MF, 2004, J HAZARD MATER, V107, P1, DOI 10.1016/j.jhazmat.2003.11.005; Fingas MF, 1993, P 16 ARCT MAR OIL SP; Hayworth JS, 2011, HYDROL EARTH SYST SC, V15, P3639, DOI 10.5194/hess-15-3639-2011; Hayworth JS, 2011, ENVIRON SCI TECHNOL, V45, P4201, DOI 10.1021/es201242k; Hayworth JS, 2012, MARINE POLLUTION B, V64, P10; Kaku VJ, 2006, J ENVIRON ENG, V132, P93, DOI 10.1061/(ASCE)0733-9372(2006)132:1(93); Kokal S, 2005, SPE PROD FACIL, V20, P5, DOI 10.2118/77497-PA; Lehr B., 2010, OIL BUDGET CALCULATO; Liu ZF, 2012, ENVIRON RES LETT, V7, DOI 10.1088/1748-9326/7/3/035302; McLean JD, 1998, STRUCTURE DYNAMICS A; McLean JD, 1997, J COLLOID INTERF SCI, V189, P12; McNutt MK, 2012, P NATL ACAD SCI USA, V109, P20260, DOI 10.1073/pnas.1112139108; Michel J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065087; OSAT-3, 2013, OSAT3; Pelz O., 2012, SELECTION SURROGATE; Sjoblom J, 2003, ADV COLLOID INTERFAC, V100, P399, DOI 10.1016/S0001-8686(02)00066-0; SJOBLOM J, 1990, COLLOID POLYM SCI, V268, P389, DOI 10.1007/BF01411682; SLRERL ALC Inc M, 2006, DISPERSANT EFFECTIVE; Valentine DL, 2014, P NATL ACAD SCI USA, V111, P5; Venosa AD, 2002, SPILL SCI TECHNOL B, V7, P299, DOI 10.1016/S1353-2561(02)00072-5; Venosa AD, 2013, MAR POLLUT BULL, V66, P73, DOI 10.1016/j.marpolbul.2012.11.009; WASAN DT, 1979, J RHEOL, V23, P181, DOI 10.1122/1.549524	34	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2019	14	9							e0222460	10.1371/journal.pone.0222460	http://dx.doi.org/10.1371/journal.pone.0222460			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM4NC	31525215	Green Published, Green Submitted, gold			2023-01-03	WOS:000532225700030
J	Visvanathan, A; Mead, G; Dennis, M; Whiteley, W; Doubal, F; Lawton, J				Visvanathan, Akila; Mead, Gillian; Dennis, Martin; Whiteley, William; Doubal, Fergus; Lawton, Julia			Maintaining hope after a disabling stroke: A longitudinal qualitative study of patients' experiences, views, information needs and approaches towards making treatment decisions	PLOS ONE			English	Article							INTERMITTENT PNEUMATIC COMPRESSION; DEEP-VEIN THROMBOSIS; ISCHEMIC-STROKE; OLDER-ADULTS; OF-LIFE; CLOTS 3; SUPPORT; TRIAL; POSTSTROKE; DEMENTIA	Background Some treatments after a disabling stroke increase the likelihood patients will survive longer but with significant disability. Patients and doctors should make collaborative decisions regarding these treatments. However, this can be challenging. To better understand treatment decision-making in acute disabling stroke, we explored the experiences, views and needs of stroke survivors in hospital and six months later. Methods Fifteen patients who had a disabling stroke were interviewed within a week of their diagnosis; eleven were re-interviewed six months later. Data were analysed thematically and longitudinally. Results Patients' functional abilities prior to their stroke and need for hope of functional recovery appeared to impact on their involvement in decision-making. In the early period post stroke, patients who were functionally independent pre- stroke described being emotionally devastated and ill-prepared for the consequences of stroke. They appeared unaware that treatments offered might extend their life but with significant disability and took all treatments in the hope of functional recovery. Those who were dependent pre-stroke appeared to be more stoic, had considered treatment implications and decided against such treatments. At follow-up, all patients had varying unmet psychological needs which appeared to contribute to poor quality of life. In the early period post stroke, patients looked for various ways to cultivate and maintain hope of functional recovery. While patients continued to look for hope at six months, they also reported wishing they had been given realistic information in the early period after stroke in order to prepare for the consequences. Conclusion Stroke survivors may benefit from psychological support. A collaborative approach towards treatment decision-making may not be realistic in all patients especially when they may be emotionally distressed and looking to maintain a positive outlook. Communication strategies to balance maintaining hope without providing false hope may be appropriate. Patients' information needs may need reassessed at different time points.	[Visvanathan, Akila; Mead, Gillian; Dennis, Martin; Whiteley, William; Doubal, Fergus] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [Lawton, Julia] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Visvanathan, A (corresponding author), Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland.	avisvana@exseed.ed.ac.uk		Whiteley, William/0000-0002-4816-8991	Chief Scientist Office [CAF/16/01]	Chief Scientist Office	This study was supported by Chief Scientist Office CAF/16/01 (https://www.cso.scot.nhs.uk/outputs/cso-funded-research/caf/) to AV. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamson J, 2004, THESIS, V13, P171; Albrecht GL, 1999, SOC SCI MED, V48, P977, DOI 10.1016/S0277-9536(98)00411-0; Andersen HE, 2002, CLIN REHABIL, V16, P593, DOI 10.1191/0269215502cr528oa; [Anonymous], 1999, EDITORIAL CHALLENGE, P747; Association Stroke, 2018, STAT NAT STROK STAT; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Bo K, 2005, 6 MONTH FUNCTIONAL R, P173; Campbell TC, 2010, CANCER J, V16, P461, DOI 10.1097/PPO.0b013e3181f30e07; Compare Angelo, 2011, Clin Pract Epidemiol Ment Health, V7, P148, DOI 10.2174/1745017901107010148; CORBIN J, 1990, Z SOZIOL, V19, P418, DOI 10.1007/BF00988593; Counsell C, 2002, STROKE, V33, P1041, DOI 10.1161/hs0402.105909; Davis Bonnie, 2005, Clin Nurs Res, V14, P253, DOI 10.1177/1054773805275520; Dennis M, 2006, HEALTH TECHNOL ASSES, V10, P1; Dennis M, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19760; Dennis M, 2013, LANCET, V382, P516, DOI 10.1016/S0140-6736(13)61050-8; Ditto PH, 1996, HEALTH PSYCHOL, V15, P332, DOI 10.1037/0278-6133.15.5.332; Ditto PH, 2003, HEALTH PSYCHOL, V22, P605, DOI 10.1037/0278-6133.22.6.605; Forster A, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001919.pub3; Frank C, 2017, CAN FAM PHYSICIAN, V63, P22; Fried TR, 2011, ARCH INTERN MED, V171, P75, DOI 10.1001/archinternmed.2010.318; Fried TR, 2006, PROSPECTIVE STUDY HL, P166; General Administration of Quality Supervision Inspection and Quarantine of the People's Republic of China, 2010, TECHNICAL GUIDELINES, P1; Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X; Guba E.G., 1989, 4 GENERATION EVALUAT; Harrison M, 2017, TOP STROKE REHABIL, V24, P119, DOI 10.1080/10749357.2016.1196908; Holloway RG, AHA ASA SCI STATEMEN; Improvement NHS, CANC PSYCH CAR STROK; Johnston B, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0250-1; Killen A, 2016, INT PSYCHOGERIATR, V28, P495, DOI 10.1017/S1041610215001362; Klein A, 2012, NEUROCRIT CARE, V16, P456, DOI 10.1007/s12028-012-9677-1; Kneebone II, 2016, STEPPED PSYCHOL CARE, P8288; Lawton J, 2003, SOCIOL HEALTH ILL, V25, P23; Lin J, 2018, J VIB ENG TECHNOL, V6, DOI 10.1007/s42417-018-0004-9; Mckinstry B, 2000, GEN PRACTICE, P867; Mead N, 2010, BRIT J PSYCHIAT, V196, P96, DOI 10.1192/bjp.bp.109.064089; Menard C, 2012, CURR OPIN ONCOL, V24, P381, DOI 10.1097/CCO.0b013e328354b2f6; Mistry A, 2010, JRSM Short Rep, V1, P30, DOI 10.1258/shorts.2010.010032; Newell SA, 2002, SYSTEMATIC REV PSYCH, V94; Party SW, 2016, NATL CLIN GUIDELINE; Points M., 2018, SCOTTISH STROKE IMPR; Power TE, 2011, PATIENT EDUC COUNS, V83, P163, DOI 10.1016/j.pec.2010.05.021; Quinn TJ, 2009, STROKE, V40, P3393, DOI [10.1161/STROKEAHA.109.557256, 10.1161/STROKEAHA.108.522516]; Reid J, 2013, PSYCHOL INTERVENTION, V8; Reuben DB., 2010, NIH PUBLIC ACCESS, V302, P2686; Rutten LJF, 2005, PATIENT EDUC COUNS, V57, P250, DOI 10.1016/j.pec.2004.06.006; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Sentinel Stroke National Audit Programme, 2021, SENTINEL STROKE NATL; Sorensen LV, 2008, AGING MENT HEALTH, V12, P444, DOI 10.1080/13607860802224342; Sprangers MAG, 1999, SOC SCI MED, V48, P1507, DOI 10.1016/S0277-9536(99)00045-3; Stroke I, 2011, NATL SENTINEL STROKE; Townsend N, 2012, CORONARY HEART DIS S, P107; Visvanathan A, 2015, PARENTERAL FLUID REG; Visvanathan A, 2017, INT J STROKE, V12, P920, DOI 10.1177/1747493017730746; von Sarnowski B, 2012, CLIN NEUROL NEUROSUR, V114, P627, DOI 10.1016/j.clineuro.2011.12.026; Weis J, 2003, SUPPORT CARE CANCER, V11, P763, DOI 10.1007/s00520-003-0536-7; Westendorp WF, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008530.pub2; Wilson T, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/s12911-017-0555-9; Wrobleski KK, 2005, EXP AGING RES, V31, P217, DOI 10.1080/03610730590915452; Zussman R, 1997, ANNU REV SOCIOL, V23, P171, DOI 10.1146/annurev.soc.23.1.171	59	15	16	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 13	2019	14	9							e0222500	10.1371/journal.pone.0222500	http://dx.doi.org/10.1371/journal.pone.0222500			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM4KS	31518369	gold, Green Published, Green Submitted			2023-01-03	WOS:000532219300022
J	Willyard, C				Willyard, Cassandra			Too little, too late	NATURE			English	Editorial Material																		Abouk R, 2019, JAMA INTERN MED, V179, P805, DOI 10.1001/jamainternmed.2019.0272; Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115; Cressman Alex M, 2017, CMAJ Open, V5, pE779, DOI 10.9778/cmajo.20170123; Goldman JE, 2019, HARM REDUCT J, V16, DOI 10.1186/s12954-018-0276-0; Green TC, 2018, JAMA PSYCHIAT, V75, P405, DOI 10.1001/jamapsychiatry.2017.4614; Karamouzian M, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0252-8; Puzantian T, 2018, JAMA-J AM MED ASSOC, V320, P1931, DOI 10.1001/jama.2018.12291	7	3	3	1	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 12	2019	573	7773					S17	S19		10.1038/d41586-019-02689-z	http://dx.doi.org/10.1038/d41586-019-02689-z			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IX0XA	31511670				2023-01-03	WOS:000485415400010
J	de Almeida, CDC; Silva, ACSE; Oliveira, JAD; Batista, ISF; Pereira, FH; Goncalves, JE; Nobre, V; Martins, MAP				Carneiro de Almeida, Claudmeire Dias; Simoes e Silva, Ana Cristina; de Queiroz Oliveira, Joao Antonio; Fonseca Batista, Isabela Soares; Pereira, Fernando Henrique; Goncalves, Jose Eduardo; Nobre, Vandack; Parreiras Martins, Maria Auxiliadora			Vancomycin-associated nephrotoxicity in noncritically ill patients admitted in a Brazilian public hospital: A prospective cohort study	PLOS ONE			English	Article							ACUTE KIDNEY INJURY; INFECTIOUS-DISEASES SOCIETY; PIPERACILLIN-TAZOBACTAM; TROUGH CONCENTRATIONS; PRACTICE GUIDELINES; RISK; RECOMMENDATIONS; COMBINATION; AMERICA; SAFETY	Introduction Vancomycin is widely used to treat infections caused by Gram positive bacteria, mostly methicillin-resistant strains. Despite its therapeutic effectiveness, vancomycin is a nephrotoxic drug that has been associated with the occurrence of acute kidney injury (AKI). In this study, we sought to evaluate the variability of serum trough concentrations of vancomycin and to determine the incidence and risk factors of vancomycin-associated nephrotoxicity (VAN) in non-critically ill patients. Methods This was a prospective cohort including Brazilian public hospital inpatients from April 2017 to June 2018. The participants received intravenous vancomycin therapy for at least 48 hours for any suspected or confirmed infection by Gram positive bacteria. Demographic, clinical and laboratory data were collected. Information on vancomycin therapy and concomitant use of other nephrotoxic drugs were also recorded. Patients were followed up until discontinuation of vancomycin treatment or death, whatever occurred first. The primary outcome was the occurrence of AKI. We performed a Poisson regression to determine risk factors for AKI. Results Overall, 98 participants were included in the study. Median age was 55.9 (interquartile range [IQR] 40.6-66.8) years and 58 (59.2%) were men. Most of them showed subtherapeutic (< 10mg/L) or supratherapeutic (> 20mg/L) trough levels of vancomycin; 42.9% and 15.3%, respectively. A total of 19 (19.4%) patients developed AKI. Poisson regression showed that male sex (odds ratio [OR] 2.90; confidence interval [CI] 95% 1.28-6.53; p = 0.011), concomitant use of piperacillin-tazobactam (OR 4.66; CI 95% 2.26-9.58; p <0.001) and vancomycin trough levels above 20mg/mL (OR 4.21; CI 95% 1.57-11.278; p = 0.004) were independently associated with AKI. Conclusions Our study showed that usual doses of vancomycin did not reach recommended therapeutic serum trough levels of vancomycin in non-critically ill patients. Besides that, nephrotoxicity was common in this population, being associated with male sex, concomitant use of piperacillin-tazobactam and supra-therapeutic trough serum levels of vancomycin.	[Carneiro de Almeida, Claudmeire Dias; Simoes e Silva, Ana Cristina; de Queiroz Oliveira, Joao Antonio; Fonseca Batista, Isabela Soares; Pereira, Fernando Henrique; Nobre, Vandack; Parreiras Martins, Maria Auxiliadora] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil; [Carneiro de Almeida, Claudmeire Dias; de Queiroz Oliveira, Joao Antonio; Nobre, Vandack; Parreiras Martins, Maria Auxiliadora] Univ Fed Minas Gerais, Hosp Clin, Belo Horizonte, MG, Brazil; [Carneiro de Almeida, Claudmeire Dias; Nobre, Vandack] Nucleo Interdisciplinar Invest Med Intens NIIMI, Belo Horizonte, MG, Brazil; [Goncalves, Jose Eduardo; Parreiras Martins, Maria Auxiliadora] Univ Fed Minas Gerais, Fac Farm, Belo Horizonte, MG, Brazil	Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais	Martins, MAP (corresponding author), Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil.; Martins, MAP (corresponding author), Univ Fed Minas Gerais, Hosp Clin, Belo Horizonte, MG, Brazil.; Martins, MAP (corresponding author), Univ Fed Minas Gerais, Fac Farm, Belo Horizonte, MG, Brazil.	auxiliadorapmartins@hotmail.com	Simões e Silva, Ana Cristina/A-4409-2013; Martins, Maria Auxiliadora P/I-6136-2018; Oliveira, Joao/L-9230-2018	Simões e Silva, Ana Cristina/0000-0001-9222-3882; Martins, Maria Auxiliadora P/0000-0002-5211-411X; Oliveira, Joao/0000-0003-3116-4713	Pro-Reitoria de Pesquisa da Universidade Federal de Minas Gerais (PRPq UFMG); Programa de Pos-Graduacao em Infectologia e Medicina Tropical da Universidade Federal de Minas Gerais; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Ni'vel Superior (CAPES); Fundacao de Amparo a Pesquisa de Minas Gerais (FAPEMIG)	Pro-Reitoria de Pesquisa da Universidade Federal de Minas Gerais (PRPq UFMG); Programa de Pos-Graduacao em Infectologia e Medicina Tropical da Universidade Federal de Minas Gerais; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Ni'vel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundacao de Amparo a Pesquisa de Minas Gerais (FAPEMIG)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG))	This study was supported by Pro-Reitoria de Pesquisa da Universidade Federal de Minas Gerais (PRPq UFMG). It was partially supported by the Programa de Pos-Graduacao em Infectologia e Medicina Tropical da Universidade Federal de Minas Gerais, by the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de Pessoal de Ni ' vel Superior (CAPES) and by the Fundacao de Amparo a Pesquisa de Minas Gerais (FAPEMIG). The funders had no participation in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Bakke V, 2017, ACTA ANAESTH SCAND, V61, P627, DOI 10.1111/aas.12897; Balci C, 2018, INT J ANTIMICROB AG, V52, P180, DOI 10.1016/j.ijantimicag.2018.03.024; Bicalho MD, 2015, INT J ENV RES PUB HE, V12, P11227, DOI 10.3390/ijerph120911227; Bosso JA, 2011, ANTIMICROB AGENTS CH, V55, P5475, DOI 10.1128/AAC.00168-11; Bruniera FR, 2015, EUR REV MED PHARMACO, V19, P694; Burgess LD, 2014, PHARMACOTHERAPY, V34, P670, DOI 10.1002/phar.1442; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chavanet P, 2013, MED MALADIES INFECT, V43, P451, DOI 10.1016/j.medmal.2013.09.011; Chuma M, 2018, THER DRUG MONIT, V40, P109, DOI 10.1097/FTD.0000000000000459; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Gomes DM, 2014, PHARMACOTHERAPY, V34, P662, DOI 10.1002/phar.1428; Hanrahan TP, 2014, CRIT CARE MED, V42, P2527, DOI 10.1097/CCM.0000000000000514; Hirano R, 2016, INFECT DRUG RESIST, V9, DOI 10.2147/IDR.S109485; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Liang XY, 2018, CLIN INFECT DIS, V67, pS249, DOI 10.1093/cid/ciy680; Liu C, 2011, CLIN INFECT DIS, V53, P319, DOI [10.1093/cid/ciq146, 10.1093/cid/cir353]; Lodise TP, 2008, ANTIMICROB AGENTS CH, V52, P1330, DOI 10.1128/AAC.01602-07; Lodise TP, 2009, CLIN INFECT DIS, V49, P507, DOI 10.1086/600884; Matsumoto K, 2013, J INFECT CHEMOTHER, V19, P365, DOI 10.1007/s10156-013-0599-4; Meaney CJ, 2014, PHARMACOTHERAPY, V34, P653, DOI 10.1002/phar.1423; Mullins BP, 2018, ANN PHARMACOTHER, V52, P639, DOI 10.1177/1060028018757497; Navalkele B, 2017, CLIN INFECT DIS, V64, P116, DOI 10.1093/cid/ciw709; O'Donnell JN, 2018, INT J ANTIMICROB AG, V51, P239, DOI 10.1016/j.ijantimicag.2017.08.012; Obara Vitor Yuzo, 2016, Rev. bras. ter. intensiva, V28, P380, DOI [10.5935/0103-507x.20160071, 10.5935/0103-507X.20160071]; Qian XD, 2017, INT J INFECT DIS, V60, P17, DOI [10.1016/j.ijid.2017.04.018, 10.10]; Rybak Michael, 2009, Am J Health Syst Pharm, V66, P82, DOI 10.2146/ajhp080434; Rybak MJ, 2009, PHARMACOTHERAPY, V29, P1275, DOI 10.1592/phco.29.11.1275; Tuon FF, 2018, INFECT DRUG RESIST, V11, P2393, DOI 10.2147/IDR.S184897; van Hal SJ, 2013, ANTIMICROB AGENTS CH, V57, P734, DOI 10.1128/AAC.01568-12; Ye ZK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099044; Zonozi R, 2019, MAYO CLIN PROC, V94, P17, DOI 10.1016/j.mayocp.2018.08.034	31	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 5	2019	14	9							e0222095	10.1371/journal.pone.0222095	http://dx.doi.org/10.1371/journal.pone.0222095			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM2LR	31487314	Green Published, gold, Green Submitted			2023-01-03	WOS:000532084200033
J	Oermann, MH; Krusmark, MA; Kardong-Edgren, S; Jastrzembski, TS; Gluck, KA				Oermann, Marilyn H.; Krusmark, Michael A.; Kardong-Edgren, Suzan; Jastrzembski, Tiffany S.; Gluck, Kevin A.			Training interval in cardiopulmonary resuscitation	PLOS ONE			English	Article							CARDIAC-ARREST; CPR; PSYCHOMOTOR; RETENTION; QUALITY; SKILLS	Aim Although evidence supports brief, frequent CPR training, optimal training intervals have not been established. The purpose of this study was to compare nursing students' CPR skills (compressions and ventilations) with 4 different spaced training intervals: daily, weekly, monthly, and quarterly, each for 4 times in a row. Methods Participants were nursing students (n = 475) in the first year of their prelicensure program in 10 schools of nursing across the United States. They were randomly assigned into the 4 training intervals in each of the schools. Students were trained in CPR on a Laerdal Resusci Anne adult manikin on the Resuscitation Quality Improvement (RQI) mobile simulation station. The outcome measures were quality of compressions and ventilations as measured by the RQI program. Results Although students were all certified in Basic Life Support prior to the study, they were not able to adequately perform compressions and ventilations at pretest. Overall compression scores improved from sessions 1 to 4 in all training intervals (all p < .001), but shorter intervals (daily training) resulted in larger increases in compression scores by session 4. There were similar findings for ventilation skills, but at session 4, both daily and weekly intervals led to better skill performance. Conclusion For students and other novices learning to perform CPR, the opportunity to train on consecutive days or weeks may be beneficial: if learners are aware of specific errors in performance, it may be easier for them to correct performance and refine skills when there is less time in between practice sessions.	[Oermann, Marilyn H.] Duke Univ, Sch Nursing, Durham, NC 27708 USA; [Krusmark, Michael A.] L3 Technol Air Force Res Lab, Wright Patterson AFB, OH USA; [Kardong-Edgren, Suzan] Ctr Med Simulat, Boston, MA USA; [Jastrzembski, Tiffany S.; Gluck, Kevin A.] Air Force Res Lab, Airman Syst Directorate, Human Performance Wing 711, Wright Patterson AFB, OH USA	Duke University; L3Harris Technologies; United States Department of Defense; United States Air Force; US Air Force Research Laboratory	Oermann, MH (corresponding author), Duke Univ, Sch Nursing, Durham, NC 27708 USA.	marilyn.oermann@duke.edu		Oermann, Marilyn/0000-0002-4534-8962; Kardong-Edgren, Suzan (Suzie)/0000-0002-5794-4075	National League for Nursing; Laerdal Medical Corporation; Air Force Research Laboratory	National League for Nursing; Laerdal Medical Corporation; Air Force Research Laboratory	Funding was provided to MHO by the National League for Nursing with funding it received from Laerdal Medical Corporation. Additional funding was provided by the Air Force Research Laboratory for the participation of MAK, TSJ, and KAG. Laerdal Medical Corporation supplied the RQI mobile simulation stations and program for the study at no cost to the schools of nursing that served as training sites. The National League for Nursing and Laerdal Medical Corporation were not involved in the collection, analysis, and interpretation of the data; in writing the manuscript; nor in the decision to submit the manuscript for publication. The investigators had sole responsibility for implementing the study, collecting and analyzing the data, and writing the manuscript. There were no restrictions by the National League for Nursing or Laerdal Medical Corporation on the statistical analysis or publication of the findings.	Anderson R, 2019, RESUSCITATION, V135, P153, DOI 10.1016/j.resuscitation.2018.10.033; Bhanji F, 2015, CIRCULATION, V132, pS561, DOI 10.1161/CIR.0000000000000268; Cheng A, 2018, CIRCULATION, V138, pE82, DOI 10.1161/CIR.0000000000000583; Christenson J, 2009, CIRCULATION, V120, P1241, DOI 10.1161/CIRCULATIONAHA.109.852202; Core TR, 2019, R LANG ENV STAT COMP; Cortegiani A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1740-z; Cortegiani A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169591; Dudzik LR, 2019, JT COMM J QUAL PATIE, V45, P789, DOI 10.1016/j.jcjq.2019.08.010; Gluck KA, 2008, P 30 ANN M COGN SCI; Greif R, 2015, RESUSCITATION, V95, P288, DOI 10.1016/j.resuscitation.2015.07.032; Harris J., 2009, P 9 INT C COGNITIVE; Kardong-Edgren S, 2019, J CONTIN EDUC NURS, V50, P257, DOI 10.3928/00220124-20190516-05; Kardong-Edgren S, 2012, J NURSES PROF DEV, V28, P9, DOI 10.1097/NND.0b013e318240a6ad; Kleinman ME, 2018, CIRCULATION, V137, pE802, DOI 10.1161/CIR.0000000000000561; Kyllonen P., 2000, TRAINING RETRAINING, P525; Laerdal, 2015, CPR SCOR EXPL; Larribau R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204169; Lin YQ, 2018, RESUSCITATION, V130, P6, DOI 10.1016/j.resuscitation.2018.06.025; Mancini ME, 2010, CIRCULATION, V122, P8539, DOI 10.1161/CIRCULATIONAHA.110.971143; Niles DE, 2017, SIMUL HEALTHC, V12, P213, DOI 10.1097/SIH.0000000000000228; Oermann MH, 2016, J CONTIN EDUC NURS, V47, P278, DOI 10.3928/00220124-20160518-10; Oermann MH, 2011, RESUSCITATION, V82, P447, DOI 10.1016/j.resuscitation.2010.11.022; Riggs M, 2019, RESUSCITATION, V138, P259, DOI 10.1016/j.resuscitation.2019.03.019; Saad R, 2019, SIMUL HEALTHC, V14, P351, DOI 10.1097/SIH.0000000000000383; Shute VJ, 2008, REV EDUC RES, V78, P153, DOI 10.3102/0034654307313795; Sutton RM, 2013, RESUSCITATION, V84, P1680, DOI 10.1016/j.resuscitation.2013.07.029; Sutton RM, 2011, PEDIATRICS, V128, pE145, DOI 10.1542/peds.2010-2105; Wolfe H, 2014, CRIT CARE MED, V42, P1688, DOI 10.1097/CCM.0000000000000327; Yeung J, 2009, RESUSCITATION, V80, P743, DOI 10.1016/j.resuscitation.2009.04.012	33	11	12	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2020	15	1							e0226736	10.1371/journal.pone.0226786	http://dx.doi.org/10.1371/journal.pone.0226786			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5PQ	31945074	Green Published, gold			2023-01-03	WOS:000534370100015
J	Hollenhorst, MI; Jurastow, I; Nandigama, R; Appenzeller, S; Li, L; Vogel, J; Wiederhold, S; Althaus, M; Empting, M; Altmuller, J; Hirsch, AKH; Flockerzi, V; Canning, BJ; Saliba, AE; Krasteva-Christ, G				Hollenhorst, Monika I.; Jurastow, Innokentij; Nandigama, Rajender; Appenzeller, Silke; Li, Lei; Vogel, Joerg; Wiederhold, Stephanie; Althaus, Mike; Empting, Martin; Altmueller, Janine; Hirsch, Anna K. H.; Flockerzi, Veit; Canning, Brendan J.; Saliba, Antoine-Emmanuel; Krasteva-Christ, Gabriela			Tracheal brush cells release acetylcholine in response to bitter tastants for paracrine and autocrine signaling	FASEB JOURNAL			English	Article						acetylcholine; brush cells; mucociliary clearance; single-cell RNA-seq; taste	CHOLINERGIC CHEMOSENSORY CELLS; TUFT CELLS; TASTE; RECEPTORS; MECHANISM; TRIGGERS; IMMUNITY; CILIA; MICE	For protection from inhaled pathogens many strategies have evolved in the airways such as mucociliary clearance and cough. We have previously shown that protective respiratory reflexes to locally released bacterial bitter "taste" substances are most probably initiated by tracheal brush cells (BC). Our single-cell RNA-seq analysis of murine BC revealed high expression levels of cholinergic and bitter taste signaling transcripts (Tas2r108, Gnat3, Trpm5). We directly demonstrate the secretion of acetylcholine (ACh) from BC upon stimulation with the Tas2R agonist denatonium. Inhibition of the taste transduction cascade abolished the increase in [Ca2+](i) in BC and subsequent ACh-release. ACh-release is regulated in an autocrine manner. While the muscarinic ACh-receptors M3R and M1R are activating, M2R is inhibitory. Paracrine effects of ACh released in response to denatonium included increased [Ca2+](i) in ciliated cells. Stimulation by denatonium or with Pseudomonas quinolone signaling molecules led to an increase in mucociliary clearance in explanted tracheae that was Trpm5- and M3R-mediated. We show that ACh-release from BC via the bitter taste cascade leads to immediate paracrine protective responses that can be boosted in an autocrine manner. This mechanism represents the initial step for the activation of innate immune responses against pathogens in the airways.	[Hollenhorst, Monika I.; Krasteva-Christ, Gabriela] Saarland Univ, Inst Anat & Cell Biol, Homburg, Germany; [Jurastow, Innokentij; Wiederhold, Stephanie] Justus Liebig Univ Giessen, Inst Anat & Cell Biol, Giessen, Germany; [Jurastow, Innokentij] Humboldt Univ, Univ Hosp Charite, Dept Anesthesiol & Intens Care Med CS, Berlin, Germany; [Nandigama, Rajender] Univ Wurzburg, Inst Anat & Cell Biol, Wurzburg, Germany; [Appenzeller, Silke] Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Li, Lei] Univ Wurzburg, Core Unit SysMed, Wurzburg, Germany; [Vogel, Joerg; Saliba, Antoine-Emmanuel] Helmholtz Ctr Infect Res HZI, Helmholtz Inst RNA Based Infect Res HIRI, Wurzburg, Germany; [Althaus, Mike] Newcastle Univ, Sch Nat & Environm Sci, Newcastle Upon Tyne, Tyne & Wear, England; [Empting, Martin; Hirsch, Anna K. H.] Helmholtz Ctr Infect Res HZI, Helmholtz Inst Pharmaceut Res Saarland HIPS, Dept Drug Design & Optimizat DDOP, Saarbrucken, Germany; [Empting, Martin; Hirsch, Anna K. H.] Saarland Univ, Dept Pharm, Saarbrucken, Germany; [Empting, Martin; Hirsch, Anna K. H.] German Ctr Infect Res DZIF, Saarbrucken, Germany; [Altmueller, Janine] Univ Cologne, Cologne Ctr Genom, Cologne, Germany; [Flockerzi, Veit] Saarland Univ, Inst Expt & Clin Pharmacol & Toxicol PZMS, Homburg, Germany; [Canning, Brendan J.] Johns Hopkins Univ, Sch Med, Dept Med, Div Allergy & Clin Immunol, Baltimore, MD 21205 USA	Universitatsklinikum des Saarlandes; Justus Liebig University Giessen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; University of Wurzburg; University of Wurzburg; Helmholtz Association; Helmholtz-Center for Infection Research; Newcastle University - UK; Helmholtz Association; Helmholtz-Center for Infection Research; Saarland University; German Center for Infection Research; University of Cologne; Universitatsklinikum des Saarlandes; Johns Hopkins University	Krasteva-Christ, G (corresponding author), Saarland Univ, Inst Anat & Cell Biol, UKS, Gebaude 61, D-66421 Homburg, Germany.	Gabriela.Krasteva-Christ@uks.eu	Saliba, Antoine-Emmanuel/AAC-1252-2022; Canning, Brendan/ABE-5261-2020; Vogel, Jörg/D-5574-2011; Krasteva-Christ, Gabriela/CAI-9036-2022; Canning, Brendan/AAM-9404-2021	Vogel, Jörg/0000-0003-2220-1404; Krasteva-Christ, Gabriela/0000-0002-0113-521X; Canning, Brendan/0000-0003-4197-5560; Appenzeller, Silke/0000-0002-5472-8692; Nandigama, Rajender/0000-0002-7344-4732; Altmuller, Janine/0000-0003-4372-1521; Empting, Martin/0000-0002-0503-5830; Althaus, Mike/0000-0002-3554-7538; Jurastow, Innokentij/0000-0002-5946-3363	German Research Society [DFG SFB TRR 152]; Helmholtz Association's Initiative and Networking Fund	German Research Society(German Research Foundation (DFG)); Helmholtz Association's Initiative and Networking Fund	German Research Society, Grant/Award Number: DFG SFB TRR 152; Helmholtz Association's Initiative and Networking Fund	Allegretta G, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00924; Bakshani CR, 2018, NPJ BIOFILMS MICROBI, V4, DOI 10.1038/s41522-018-0057-2; Bankova LG, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat9453; Carey RM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092017; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; Chilvers M A, 2000, Paediatr Respir Rev, V1, P27, DOI 10.1053/prrv.2000.0009; Dando R, 2012, J PHYSIOL-LONDON, V590, P3009, DOI 10.1113/jphysiol.2012.232009; Deckmann K, 2014, P NATL ACAD SCI USA, V111, P8287, DOI 10.1073/pnas.1402436111; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Droguett K, 2017, J PHYSIOL-LONDON, V595, P4755, DOI 10.1113/JP273996; Finger TE, 2003, P NATL ACAD SCI USA, V100, P8981, DOI 10.1073/pnas.1531172100; Finger TE, 2011, F1000 BIOL REP, V3, P1; Freund JR, 2018, J BIOL CHEM, V293, P9824, DOI 10.1074/jbc.RA117.001005; FRYER AD, 1993, LIFE SCI, V52, P529, DOI 10.1016/0024-3205(93)90311-P; Fu ZY, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00071; Gerbe F, 2016, NATURE, V529, P226, DOI 10.1038/nature16527; Hecker A, 2015, J IMMUNOL, V195, P2325, DOI 10.4049/jimmunol.1400974; Hollenhorst MI, 2012, BRIT J PHARMACOL, V166, P1388, DOI 10.1111/j.1476-5381.2012.01883.x; Howitt MR, 2016, SCIENCE, V351, P1329, DOI 10.1126/science.aaf1648; Kaske S, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-49; Kharchenko PV, 2014, NAT METHODS, V11, P740, DOI [10.1038/NMETH.2967, 10.1038/nmeth.2967]; Klein MK, 2009, EUR RESPIR J, V33, P1113, DOI 10.1183/09031936.00015108; Konig P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004938; Krasteva G, 2012, LIFE SCI, V91, P992, DOI 10.1016/j.lfs.2012.06.014; Krasteva G, 2011, P NATL ACAD SCI USA, V108, P9478, DOI 10.1073/pnas.1019418108; Krasteva-Christ G, 2015, INT IMMUNOPHARMACOL, V29, P158, DOI 10.1016/j.intimp.2015.05.028; Kummer W, 2008, HISTOCHEM CELL BIOL, V130, P219, DOI 10.1007/s00418-008-0455-2; Lee RJ, 2014, J CLIN INVEST, V124, P1393, DOI 10.1172/JCI72094; Lee RJ, 2012, J CLIN INVEST, V122, P4145, DOI 10.1172/JCI64240; Liu SY, 2017, FRONT PLANT SCI, V8, DOI 10.3389/fpls.2017.00739; Lossow K, 2016, J BIOL CHEM, V291, P15358, DOI 10.1074/jbc.M116.718544; LUCIANO L, 1968, Z ZELLFORSCH MIK ANA, V85, P350, DOI 10.1007/BF00328847; Martin M., 2011, EMBNET J, V17, P10, DOI 10.14806/ej.17.1.200; Montoro DT, 2018, NATURE, V560, P319, DOI 10.1038/s41586-018-0393-7; Nadjsombati MS, 2018, IMMUNITY, V49, P33, DOI 10.1016/j.immuni.2018.06.016; Ogura T, 2011, J NEUROPHYSIOL, V106, P1274, DOI 10.1152/jn.00186.2011; Plasschaert LW, 2018, NATURE, V560, P377, DOI 10.1038/s41586-018-0394-6; Richter K, 2016, SCI REP-UK, V6, DOI 10.1038/srep28660; Richter K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01604; Roper SD, 2017, NAT REV NEUROSCI, V18, P485, DOI 10.1038/nrn.2017.68; Runer T, 1998, OTOLARYNG HEAD NECK, V119, P278, DOI 10.1016/S0194-5998(98)70063-4; Saunders CJ, 2014, P NATL ACAD SCI USA, V111, P6075, DOI 10.1073/pnas.1402251111; Schmid A, 2011, BIOL CELL, V103, P159, DOI 10.1042/BC20100120; Schutz B, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00087; Shah AS, 2009, SCIENCE, V325, P1131, DOI 10.1126/science.1173869; Tallini YN, 2006, PHYSIOL GENOMICS, V27, P391, DOI 10.1152/physiolgenomics.00092.2006; Tizzano M, 2010, P NATL ACAD SCI USA, V107, P3210, DOI 10.1073/pnas.0911934107; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Xu HX, 2006, NAT NEUROSCI, V9, P628, DOI 10.1038/nn1692; Yamashita J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189340; Yan CH, 2017, AM J RHINOL ALLERGY, V31, P85, DOI 10.2500/ajra.2017.31.4424; You YJ, 2004, AM J PHYSIOL-LUNG C, V286, pL650, DOI 10.1152/ajplung.00170.2003	52	24	24	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2020	34	1					316	332		10.1096/fj.201901314RR	http://dx.doi.org/10.1096/fj.201901314RR			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KC6TY	31914675	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000507308900023
J	Timaner, M; Kotsofruk, R; Raviv, Z; Magidey, K; Shechter, D; Kan, T; Nevelsky, A; Daniel, S; de Vries, EGE; Zhang, TW; Kaidar-Person, O; Kerbel, RS; Shaked, Y				Timaner, Michael; Kotsofruk, Ruslana; Raviv, Ziv; Magidey, Ksenia; Shechter, Dvir; Kan, Tal; Nevelsky, Alexander; Daniel, Shahar; de Vries, Elisabeth G. E.; Zhang, Tongwu; Kaidar-Person, Orit; Kerbel, Robert S.; Shaked, Yuval			Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1	ONCOGENE			English	Article							CANCER-THERAPY; RADIOTHERAPY; CELLS; MECHANISMS; EXPRESSION; MEDIATORS; RESPONSES; ASSAY; MICROENVIRONMENT; MICROVESICLES	Radiotherapy induces immune-related responses in cancer patients by various mechanisms. Here, we investigate the immunomodulatory role of tumor-derived microparticles (TMPs)-extracellular vesicles shed from tumor cells-following radiotherapy. We demonstrate that breast carcinoma cells exposed to radiation shed TMPs containing elevated levels of immune-modulating proteins, one of which is programmed death-ligand 1 (PD-L1). These TMPs inhibit cytotoxic T lymphocyte (CTL) activity both in vitro and in vivo, and thus promote tumor growth. Evidently, adoptive transfer of CTLs pre-cultured with TMPs from irradiated breast carcinoma cells increases tumor growth rates in mice recipients in comparison with control mice receiving CTLs pre-cultured with TMPs from untreated tumor cells. In addition, blocking the PD-1-PD-L1 axis, either genetically or pharmacologically, partially alleviates TMP-mediated inhibition of CTL activity, suggesting that the immunomodulatory effects of TMPs in response to radiotherapy is mediated, in part, by PD-L1. Overall, our findings provide mechanistic insights into the tumor immune surveillance state in response to radiotherapy and suggest a therapeutic synergy between radiotherapy and immune checkpoint inhibitors.	[Timaner, Michael; Kotsofruk, Ruslana; Raviv, Ziv; Magidey, Ksenia; Shechter, Dvir; Kan, Tal; Shaked, Yuval] Technion, Cell Biol & Canc Sci, Rappaport Fac Med, Haifa, Israel; [Nevelsky, Alexander; Daniel, Shahar; Kaidar-Person, Orit] Rambam Hlth Care Campus, Radiat Oncol Unit, Oncol Inst, Haifa, Israel; [de Vries, Elisabeth G. E.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands; [Zhang, Tongwu] NCI, Div Canc Epidemiol & Genet, Integrat Tumor Epidemiol Branch, NIH, Bethesda, MD USA; [Kerbel, Robert S.] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; University of Groningen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Shaked, Y (corresponding author), Technion, Cell Biol & Canc Sci, Rappaport Fac Med, Haifa, Israel.	yshaked@tx.technion.ac.il		de Vries, Elisabeth/0000-0002-8949-7425; Zhang, Tongwu/0000-0003-2124-2706; Kaidar-Person, Orit/0000-0003-4023-1869	Israel Cancer Research Fund; European Research Council [771112]; Rappaport funds	Israel Cancer Research Fund; European Research Council(European Research Council (ERC)European Commission); Rappaport funds	This study was supported by grants from the Israel Cancer Research Fund supported the Buckstein Family to YS and RSK, the European Research Council (no. 771112) and Rappaport funds to YS.	Ahn GO, 2008, CANCER CELL, V13, P193, DOI 10.1016/j.ccr.2007.11.032; Al-Nedawi K, 2009, CELL CYCLE, V8, P2014, DOI 10.4161/cc.8.13.8988; Barcellos-Hoff MH, 2005, NAT REV CANCER, V5, P867, DOI 10.1038/nrc1735; Barcellos-Hoff MH, 2005, SEMIN CANCER BIOL, V15, P138, DOI 10.1016/j.semcancer.2004.08.010; Barker HE, 2015, NAT REV CANCER, V15, P409, DOI 10.1038/nrc3958; Chen G, 2018, NATURE, V560, P382, DOI 10.1038/s41586-018-0392-8; Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; Deng LF, 2014, J CLIN INVEST, V124, P687, DOI 10.1172/JCI67313; Dovedi SJ, 2014, CANCER RES, V74, P5458, DOI 10.1158/0008-5472.CAN-14-1258; EHLERS G, 1973, BRIT J RADIOL, V46, P220, DOI 10.1259/0007-1285-46-543-220; Formenti SC, 2009, LANCET ONCOL, V10, P718, DOI 10.1016/S1470-2045(09)70082-8; Fremder E, 2014, INT J CANCER, V135, P270, DOI 10.1002/ijc.28678; FU YX, 1990, CANCER RES, V50, P227; GENOVESI EV, 1984, CANCER RES, V44, P1489; Hutchinson Lisa, 2011, Nat Rev Clin Oncol, V8, P508, DOI 10.1038/nrclinonc.2011.112; Issman L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083680; Jaiswal R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061515; Kang J, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0156-7; Keklikoglou I, 2019, NAT CELL BIOL, V21, P190, DOI 10.1038/s41556-018-0256-3; Koller KM, 2017, CANCER BIOL THER, V18, P36, DOI 10.1080/15384047.2016.1264543; Lee TH, 2011, SEMIN IMMUNOPATHOL, V33, P455, DOI 10.1007/s00281-011-0250-3; Ma RH, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1118599; Makinde AY, 2016, SEMIN RADIAT ONCOL, V26, P254, DOI 10.1016/j.semradonc.2016.07.001; Matsumura S, 2008, J IMMUNOL, V181, P3099, DOI 10.4049/jimmunol.181.5.3099; Mege D, 2018, METHODS MOL BIOL, V1765, P271, DOI 10.1007/978-1-4939-7765-9_17; Mell LK, 2017, INT J RADIAT ONCOL, V97, P536, DOI 10.1016/j.ijrobp.2016.11.027; Meng YR, 2010, MOL THER, V18, P912, DOI 10.1038/mt.2010.18; Palayoor ST, 2014, MOL CANCER RES, V12, P1002, DOI 10.1158/1541-7786.MCR-13-0623; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Rak J, 2010, SEMIN THROMB HEMOST, V36, P888, DOI 10.1055/s-0030-1267043; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Reynders K, 2015, PROG TUMOR RES, V42, P67, DOI 10.1159/000437185; Ricklefs FL, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar2766; Rose B, 2017, PRACT RADIAT ONCOL, V7, pE291, DOI 10.1016/j.prro.2017.03.008; Russell JS, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00157; Shaked Y, 2016, NAT REV CLIN ONCOL, V13, P611, DOI 10.1038/nrclinonc.2016.57; Sharabi AB, 2015, LANCET ONCOL, V16, pE498, DOI 10.1016/S1470-2045(15)00007-8; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; STONE HB, 1979, JNCI-J NATL CANCER I, V63, P1229; Tang K, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2282; Timaner Michael, 2016, Curr Protoc Cell Biol, V70, DOI 10.1002/0471143030.cb1918s70; Timaner M, 2015, ONCOTARGET, V6, P27537, DOI 10.18632/oncotarget.4826; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tyanova S, 2018, METHODS MOL BIOL, V1711, P133, DOI 10.1007/978-1-4939-7493-1_7; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Voloshin T, 2014, CANCER MICROENVIRON, V7, P11, DOI 10.1007/s12307-014-0144-8; Wargo JA, 2015, SEMIN ONCOL, V42, P601, DOI 10.1053/j.seminoncol.2015.05.007; Wersall PJ, 2006, ACTA ONCOL, V45, P493, DOI 10.1080/02841860600604611; WINN HJ, 1961, J IMMUNOL, V86, P228; Wolford CC, 2013, J CLIN INVEST, V123, P2893, DOI 10.1172/JCI64410; Zhao LL, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0328-9	55	23	25	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					187	203		10.1038/s41388-019-0971-7	http://dx.doi.org/10.1038/s41388-019-0971-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31467431	Green Published, hybrid, Green Accepted			2023-01-03	WOS:000509849200013
J	Zhang, SS; Xu, XX; Xiang, WW; Zhang, HH; Lin, HL; Shen, LE; Lin, Q; Lin, F; Zhou, ZY				Zhang, Si-Si; Xu, Xin-Xin; Xiang, Wei-Wei; Zhang, Hui-Heng; Lin, Hui-Long; Shen, Lai-En; Lin, Qi; Lin, Feng; Zhou, Zhi-Yang			Using 17 beta-estradiol heparin-poloxamer thermosensitive hydrogel to enhance the endometrial regeneration and functional recovery of intrauterine adhesions in a rat model	FASEB JOURNAL			English	Article						17 beta-estradiol; apoptosis; heparin-poloxamer hydrogel; intrauterine adhesions; kisspeptin; regeneration	IN-VITRO; STEM/PROGENITOR CELLS; ASHERMANS-SYNDROME; STEM-CELLS; KISSPEPTIN; TRANSPLANTATION; IMPLANTATION; RECEPTIVITY; EXPRESSION; RECEPTORS	Mechanical damage or infection to the endometrium can lead to the formation of adhesions in the uterine cavity, which may result in reduced reproductive outcome and/or pregnancy complications. The prognosis of this disease is poor due to few effective treatments and the complex environment of endometrium. Heparin-Poloxamer Hydrogel (HP hydrogel) is a nontoxic and biodegradable biomaterial, which has been commonly used as a sustained-release delivery system. In this study, we applied a mini-endometrial curette to scrape the endometrium of rats to mimic the process of curettage in patients. After the establishment of IUA model in rats, we injected the thermo-sensitive hydrogel(E-2-HP hydrogel) into the injured uterine cavity and evaluated the therapeutic effect of E-2-HP hydrogel on the recovery of IUA. Our results showed that E-2-HP hydrogel can significantly facilitate the regeneration of injured endometrium along with inhibiting the cell apoptosis in IUA model. Furthermore, we revealed that E-2-HP hydrogel on the recovery of IUA was closely associated with the upregulation of kisspeptin through activating the ERK1/2 and MAPKs p38 pathways. In conclusion, E-2-HP hydrogel can effectively transfer E-2 into the injured endometrium and it can be considered as a promising therapeutic method for the women with intrauterine adhesions.	[Zhang, Si-Si; Lin, Hui-Long; Shen, Lai-En; Lin, Qi; Lin, Feng; Zhou, Zhi-Yang] Wenzhou Med Univ, Affiliated Hosp 1, Dept Gynaecol, Wenzhou 325035, Zhejiang, Peoples R China; [Xu, Xin-Xin] Zhejiang Univ, Womens Hosp, Sch Med, Dept Gynaecol, Hangzhou, Zhejiang, Peoples R China; [Xiang, Wei-Wei] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Neurol, Shanghai, Peoples R China; [Zhang, Hui-Heng] Wenzhou Med Univ, Sch Clin Med Sci 2, Wenzhou, Peoples R China; [Zhou, Zhi-Yang] Shanghai Jiao Tong Univ, Int Peace Maternal & Child Hlth Hosp, Sch Med, Shanghai, Peoples R China; [Zhou, Zhi-Yang] Shanghai Key Lab Embryo Original Dis, Shanghai, Peoples R China	Wenzhou Medical University; Zhejiang University; Shanghai Jiao Tong University; Wenzhou Medical University; Shanghai Jiao Tong University	Lin, F; Zhou, ZY (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Gynaecol, Wenzhou 325035, Zhejiang, Peoples R China.	23489067@qq.com; zhouzhiyang.19@hotmail.com			Zhejiang Provincal Administration of traditional Chinese Medicine [2016ZB079]; Medicine Grant from Wenzhou Bureau of Science and Technology [Y20180018]; National Natural Science Foundation of China [81803781]; Natural Science Foundation of Zhejiang Province, China [LQ18H280007]	Zhejiang Provincal Administration of traditional Chinese Medicine; Medicine Grant from Wenzhou Bureau of Science and Technology; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province, China(Natural Science Foundation of Zhejiang Province)	Zhejiang Provincal Administration of traditional Chinese Medicine, Grant/Award Number: 2016ZB079; Medicine Grant from Wenzhou Bureau of Science and Technology, Grant/Award Number: Y20180018; National Natural Science Foundation of China, Grant/Award Number: 81803781; Natural Science Foundation of Zhejiang Province, China, Grant/Award Number: LQ18H280007	Abomaray FM, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5184601; Aghajanova L, 2018, J ASSIST REPROD GEN, V35, P757, DOI 10.1007/s10815-018-1130-8; Cai HH, 2016, REPROD SCI, V23, P1208, DOI 10.1177/1933719116632923; Calder M, 2014, ENDOCRINOLOGY, V155, P3065, DOI 10.1210/en.2013-1916; Roman AC, 2012, FERTIL STERIL, V97, P1213, DOI 10.1016/j.fertnstert.2012.02.021; Clarkson J, 2013, FRONT NEUROENDOCRIN, V34, P120, DOI 10.1016/j.yfrne.2013.02.002; Ding LJ, 2014, BIOMATERIALS, V35, P4888, DOI 10.1016/j.biomaterials.2014.02.046; Evans-Hoeker EA, 2014, SEMIN REPROD MED, V32, P392, DOI 10.1055/s-0034-1376358; Fayazi M, 2015, REPROD BIOL ENDOCRIN, V13, DOI 10.1186/s12958-015-0105-1; Gargett CE, 2016, HUM REPROD UPDATE, V22, P137, DOI 10.1093/humupd/dmv051; Gilman AR, 2016, J OBSTET GYNAECOL CA, V38, P453, DOI 10.1016/j.jogc.2016.03.003; Jamil Z, 2017, REPROD BIOMED ONLINE, V34, P147, DOI 10.1016/j.rbmo.2016.11.004; Johary J, 2014, J MINIM INVAS GYN, V21, P44, DOI 10.1016/j.jmig.2013.07.018; Liu AZ, 2016, GYNECOL ENDOCRINOL, V32, P737, DOI 10.3109/09513590.2016.1160375; Miravet-Valenciano JA, 2015, CURR OPIN OBSTET GYN, V27, P187, DOI 10.1097/GCO.0000000000000173; Mittelman-Smith MA, 2015, ENDOCRINOLOGY, V156, P2162, DOI 10.1210/en.2014-1803; Quinn CE, 2009, HUM REPROD UPDATE, V15, P229, DOI 10.1093/humupd/dmn052; Salazar CA, 2017, CURR OPIN OBSTET GYN, V29, P249, DOI 10.1097/GCO.0000000000000378; Salma U, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/589296; Santamaria X, 2016, HUM REPROD, V31, P1087, DOI 10.1093/humrep/dew042; Sardo AD, 2016, EUR J OBSTET GYN R B, V203, P182, DOI 10.1016/j.ejogrb.2016.05.050; Tan JC, 2016, HUM REPROD, V31, P2723, DOI 10.1093/humrep/dew235; Taylor J, 2014, MOL REPROD DEV, V81, P42, DOI 10.1002/mrd.22279; Wahab F, 2016, NAT REV UROL, V13, P21, DOI 10.1038/nrurol.2015.277; Wei P, 2004, MOL REPROD DEV, V68, P456, DOI 10.1002/mrd.20104; Wiater J, 2018, REPROD DOMEST ANIM, V53, P333, DOI 10.1111/rda.13109; Xiao B, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801455; Xu HL, 2017, DRUG DELIV, V24, P867, DOI 10.1080/10717544.2017.1333173; Yoo MK, 2005, DRUG DEV IND PHARM, V31, P455, DOI 10.1080/03639040500214688; Zhang P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097647; Zhang S, 2018, REPROD DOMEST ANIM, V53, P143, DOI 10.1111/rda.13083; Zhang SS, 2017, INT J NANOMED, V12, P5643, DOI 10.2147/IJN.S137237; Zhang SW, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1155-7; Zhu XX, 2019, CURR STEM CELL RES T, V14, P293, DOI 10.2174/1574888X14666181205120110; Zhu Y, 2016, MED SCI MONITOR, V22, DOI 10.12659/MSM.896028	35	21	24	7	36	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2020	34	1					446	457		10.1096/fj.201901603RR	http://dx.doi.org/10.1096/fj.201901603RR			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KC6TY	31914682				2023-01-03	WOS:000507308900031
J	Ajisegiri, WS; Abubakar, AA; Gobir, AA; Balogun, MS; Sabitu, K				Ajisegiri, Whenayon Simeon; Abubakar, Aisha A.; Gobir, Abdulrazaq A.; Balogun, Muhammad Shakir; Sabitu, Kabiru			Palliative care for people living with HIV/AIDS: Factors influencing healthcare workers' knowledge, attitude and practice in public health facilities, Abuja, Nigeria	PLOS ONE			English	Article							NURSES	Background Physicians and nurses play vital roles in addressing palliative care (PC) needs of people living with HIV/AIDS (PLWHA). The healthcare workers' (HCWs) experiences determine the success of palliative care delivery. There is paucity of data on PC for PLWHA. For this reason, we assessed the knowledge, attitude and practice of PC for PLWHA and associated factors among health care professionals. Methods We conducted a cross-sectional descriptive study among HCWs in public health facilities in the Federal Capital Territory, Nigeria between February and May, 2017. Multistage sampling technique with proportionate-to-size allocation was used to determine facility sample size and HCWs per professional discipline. Data were collected with questionnaires adapted from Palliative Care Quiz for Nursing, Frommelt Attitude toward Care of the Dying and practical questions adapted from PC standard guidelines. Participants' knowledge, attitude and practice were assessed by awarding one (1) point for each correct answer; incorrect or "not sure" answers took a zero (0) score. Correct responses were summed up to get a total score for each participant. Descriptive statistics was done to describe frequencies and proportions displayed on tables. Linear regression was done to determine factors associated with HCW's knowledge, attitude and practice of PC for PLWHA Result With a 100% response rate, the mean age of the 348 participants was 37.5 years (SD: 8.9), 201 (57.8%) were female, 222 (63.8) were nurses and 230 (66.0%) had a work experience of 10 years or less. Majority of the participants, 310 (89.1%) agreed that palliative care focuses on the relief and prevention of suffering and 319 (91.7%) believe that PLWHA required palliative care. Misconceptions about palliative care include "palliative care is disease-oriented and not person oriented", 252 (72.6%) believed; "palliative care is concerned with prolongation of life", 279 (80.6%); and "use of placebos is appropriate in the treatment of some types of pain", 252 (72.6%). Among the participants, 52% disagreed that "palliative care should be given only for dying PLWHA" while only 18 (5.2%) were right on "family should be involved in the physical care of the dying PLWHA". Majority of the participants, 292 (84.1%) initiated palliative care discussion during patients' diagnosis while 290 (83.6%) informed terminally ill patients about their diagnosis. Regarding psychological issues, 22 (6.3%) participants hid the truth from the patients while 196 (56.3%) provided emotional support to the patients. Morphine 240 (69.0%) and Pentazocine 194 (55.7%) were the most commonly used drugs for treatment of severe pain by participants across all centres. Conclusion In-service training and undergraduate training on palliative care were associated with knowledge and practice of palliative care for people living with HIV/AIDS. We recommended continuous quality in-service training and education on palliative care for HCWs. While we ensure voluntariness of participation and other ethical principles, the high response rate could be as a result of more motivated health worker than the norm. The results are unlikely to be representative of doctors and nurses in primary health care centres.	[Ajisegiri, Whenayon Simeon; Balogun, Muhammad Shakir] NFELTP, Abuja, Federal Capital, Nigeria; [Ajisegiri, Whenayon Simeon; Abubakar, Aisha A.; Gobir, Abdulrazaq A.; Sabitu, Kabiru] Ahmadu Bello Univ, Dept Community Med, Zaria, Kaduna State, Nigeria; [Ajisegiri, Whenayon Simeon] Nigerian Field Epidemiol & Lab Training Programme, Abuja, Nigeria	Ahmadu Bello University	Ajisegiri, WS (corresponding author), NFELTP, Abuja, Federal Capital, Nigeria.; Ajisegiri, WS (corresponding author), Ahmadu Bello Univ, Dept Community Med, Zaria, Kaduna State, Nigeria.; Ajisegiri, WS (corresponding author), Nigerian Field Epidemiol & Lab Training Programme, Abuja, Nigeria.	doctorajisegiri@yahoo.com	Ajisegiri, Whenayon S/V-6028-2018; BALOGUN, MUHAMMAD/ABH-4227-2020	BALOGUN, MUHAMMAD/0000-0002-4846-9698; Ahmed Abubakar, Aisha/0000-0002-0112-9717; /0000-0002-8081-7058				Abu-Saad Huijer Huda, 2007, J Med Liban, V55, P121; Ali W.G.M., 2010, J MED BIOMEDICAL SCI, V1, P16; [Anonymous], 2000, UNAIDS TECHNICAL UPD; [Anonymous], 2006, NATL GUIDELINES HIVA, P1; Anstey S, 2016, BMJ SUPPORT PALLIAT, V6, P353, DOI 10.1136/bmjspcare-2015-000956; Anteneh S, 2016, ADV BIOL RES, V10, P110, DOI DOI 10.5829/IDOSI.ABR.2016.10.2.10397; Ayed A., 2015, NURSES KNOWLEDGE ATT; Bello OO, 2018, OPEN J OBSTET GYNECO, V8, P559; Commission N.P, 2017, NIG POP NOW 182 MILL; Das AG, 2015, INT J SCI RES, V4, P1790, DOI DOI 10.21275/V4I11.NOV151510; Fadare JO, 2014, INDIAN J PALLIAT CAR, V20, P1, DOI 10.4103/0973-1075.125547; Family Health International, 2009, PALL CAR STRAT HIV O; Gedamu, 2016, KNOWLEDGE ATTITUDE N; Green K, 2006, PALLIATIVE CARE VIET; Harding R, 2005, SEX TRANSM INFECT, V81, P5, DOI 10.1136/sti.2004.010132; Harding R, 2013, AIDS CARE, V25, P795, DOI 10.1080/09540121.2012.736608; Heath KV, 2003, CURR DRUG TARGETS, V4, P13, DOI 10.2174/1389450033347109; Jacquie P, 2005, PERSPECTIVE HOSPICE, P45; Kassa H, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-6; Khosla D, 2012, INDIAN J PALLIAT CAR, V18, P149, DOI 10.4103/0973-1075.105683; Lemeshow S., 1990, TITLE ADEQUACY SAMPL; Lorensen M, 2003, NURS ETHICS, V10, P175, DOI 10.1191/0969733003ne592oa; Meaza D, 2012, KNOWLEDGE ATTITUDE P, P1; Merlin J, 2018, PALLIATIVE CARE ISSU; Metropole C, 2011, FACTORS INFLUENCING; National Agency for the Control of AIDS, 2019, NIG HIV PREV RAT; National Agency for the Control of AIDS, 2015, HIV EP NIG NACA NIG; National Patient Safety Foundation, 2015, FREE HARM ACC PAT SA, P1; Onyeka TC, 2013, EUR J CANCER CARE, V22, P597, DOI 10.1111/ecc.12064; Onyeka TC, 2011, INDIAN J PALLIAT CAR, V17, P131, DOI 10.4103/0973-1075.84534; Oyebola F.O, 2017, J EMERGENCY INTERNAL, V1; Population Reference BBureau, 2015, WORLD POP DAT SHEET, P20; The Henry J. Kaiser Family Foundation, 2016, GLOB HLTH POL; World Health Organization, PALL CAR; Yang FM, 2017, PATIENT PREFER ADHER, V11, P853, DOI 10.2147/PPA.S132093; Youssef W, 2014, ADV LIFE SCI TECHNOL, V24, P100	36	1	1	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2019	14	12							e0207499	10.1371/journal.pone.0207499	http://dx.doi.org/10.1371/journal.pone.0207499			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN8LM	31891577	Green Submitted, Green Published, gold			2023-01-03	WOS:000515096600001
J	Dong, XL; Bond, AE; Yang, LJ				Dong, Xiuli; Bond, Ambrose E.; Yang, Liju			Essential oil-incorporated carbon nanotubes filters for bacterial removal and inactivation	PLOS ONE			English	Article							TEA TREE OIL; DISINFECTION BY-PRODUCTS; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; COATED FILTERS; MECHANISM; FILMS	In this study, essential oils (EO)-incorporated multi-walled carbon nanotubes (MWCNTs) filters were developed for achieving dual functions in effective removing bacteria from aqueous solutions and inactivating bacteria cells captured on the filters. Tea tree essential oil (TTO), lemon essential oil (LEO), and TTO-LEO-mixture were coated on MWCNTs filters with different MWCNTs loadings ranging from 3 mg to 6 mg. MWCNTs filters with 6.0 mg MWCNTs showed complete removal (100%) of E. coli cells from PBS buffer with 6.35 log10 decrease of cell numbers. TTO, LEO, and TTO/LEO Mix (1:1) coatings at the volume of 50 mu L on MWCNTs filters achieved bacterial removal rates of >98%, and highly effective inactivation efficiency. TTO coatings had the highest antimicrobial efficacies than LEO and Mix coatings, MWCNTs filters with 50 mu L TTO coating showed 100% inhibitory rate of the captured bacteria on the filter surfaces. Those captured but survived cells on filters with less TTO coating (20 mu L) significantly reduced their salt tolerances to 30 and 40 g/L NaCl in LB agar, and became less salt tolerance with longer incubation time on the filters. The developed TTO-MWCNTs filters had much higher antimicrobial efficacies than the filters with dual functions developed previously.	[Dong, Xiuli; Bond, Ambrose E.; Yang, Liju] North Carolina Cent Univ, Dept Pharmaceut Sci, Durham, NC 27707 USA; [Dong, Xiuli; Bond, Ambrose E.; Yang, Liju] North Carolina Cent Univ, BRITE, Durham, NC 27707 USA	University of North Carolina; North Carolina Central University; University of North Carolina; North Carolina Central University	Yang, LJ (corresponding author), North Carolina Cent Univ, Dept Pharmaceut Sci, Durham, NC 27707 USA.	lyang@nccu.edu		Yang, Liju/0000-0002-4776-7597	USDA grant [2014-67017-21706]	USDA grant(United States Department of Agriculture (USDA))	This research was supported by USDA grant #2014-67017-21706 to LY. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aidan A, 2007, J ENVIRON SCI HEAL A, V42, P895, DOI 10.1080/10934520701369941; Amin MS, 2014, SCI WORLD J, DOI 10.1155/2014/597180; Apul O, 2014, ABSTR PAP AM CHEM S, V248; Arweiler N B, 2000, Clin Oral Investig, V4, P70, DOI 10.1007/s007840050118; Bakkali F, 2008, FOOD CHEM TOXICOL, V46, P446, DOI 10.1016/j.fct.2007.09.106; Bove F, 2002, ENVIRON HEALTH PERSP, V110, P61, DOI 10.1289/ehp.02110s1161; Burt S, 2004, INT J FOOD MICROBIOL, V94, P223, DOI 10.1016/j.ijfoodmicro.2004.03.022; Carson CF, 2002, ANTIMICROB AGENTS CH, V46, P1914, DOI 10.1128/AAC.46.6.1914-1920.2002; Chen WS, 2019, ENVIRON SCI TECHNOL, V53, P7504, DOI 10.1021/acs.est.9b01678; Deng SG, 2008, IEEE SENS J, V8, P954, DOI 10.1109/JSEN.2008.923929; Dong XL, 2018, RSC ADV, V8, P8292, DOI [10.1039/C8RA00333E, 10.1039/c8ra00333e]; Dong XL, 2015, J BIOL ENG, V9, DOI 10.1186/s13036-015-0018-8; Fard AK, 2016, CHEMOSPHERE, V164, P142, DOI 10.1016/j.chemosphere.2016.08.099; Fisher LE, 2016, BIOINTERPHASES, V11, DOI 10.1116/1.4944062; Gupta S, 2016, J MATER CHEM A, V4, P1550, DOI 10.1039/c5ta08321d; Hans M, 2016, BIOINTERPHASES, V11, DOI 10.1116/1.4935853; Harkenthal M, 1999, PHARMAZIE, V54, P460; Hensher DA, 2015, APPLIED CHOICE ANALYSIS, 2ND EDITION, P1, DOI 10.1017/CBO9781316136232; Hrudey SE, 2009, WATER RES, V43, P2057, DOI 10.1016/j.watres.2009.02.011; Humblot V, 2009, BIOMATERIALS, V30, P3503, DOI 10.1016/j.biomaterials.2009.03.025; Huo ZY, 2018, J MATER CHEM A, V6, P18813, DOI 10.1039/c8ta06304d; Jin L, 2018, POLYM COMPOSITE, V39, pE271, DOI 10.1002/pc.24334; Kumar A, 2018, SURF COAT TECH, V349, P426, DOI 10.1016/j.surfcoat.2018.05.074; Kunicka-Styczynska A, 2009, J APPL MICROBIOL, V107, P1903, DOI 10.1111/j.1365-2672.2009.04372.x; Lee CJ, 2013, J FOOD DRUG ANAL, V21, P169, DOI 10.1016/j.jfda.2013.05.007; Lee J, 2016, SEP PURIF TECHNOL, V163, P109, DOI 10.1016/j.seppur.2016.02.032; Li WR, 2016, APPL MICROBIOL BIOT, V100, P8865, DOI 10.1007/s00253-016-7692-4; Miksusanti M, MODE ACTION TEMU KUN; Mohammadi A, 2015, POSTHARVEST BIOL TEC, V110, P203, DOI 10.1016/j.postharvbio.2015.08.019; Mulla M, 2017, FOOD CONTROL, V73, P663, DOI 10.1016/j.foodcont.2016.09.018; Nogueira JHC, 2010, INT J FOOD MICROBIOL, V137, P55, DOI 10.1016/j.ijfoodmicro.2009.10.017; Pandey PK, 2014, AMB EXPRESS, V4, DOI 10.1186/s13568-014-0051-x; Prabuseenivasan Seenivasan, 2006, BMC Complement Altern Med, V6, P39, DOI 10.1186/1472-6882-6-39; Predoi D, 2018, MATERIALS, V11, DOI 10.3390/ma11050652; Puskarova A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08673-9; Rasooli I, 2005, PHYTOCHEMISTRY, V66, P2851, DOI 10.1016/j.phytochem.2005.09.029; Renner LD, 2011, MRS BULL, V36, P347, DOI 10.1557/mrs.2011.65; Swami M, 2016, EUR TRANSP; Sweetman LJ, 2013, J NANOMATER, V2013, DOI 10.1155/2013/781212; Tao LH, 2005, TOXICOL SCI, V87, P344, DOI 10.1093/toxsci/kfi257; Thian ES, 2013, J MATER SCI-MATER M, V24, P437, DOI 10.1007/s10856-012-4817-x; Tighe S, 2013, TRANSL VIS SCI TECHN, V2, DOI 10.1167/tvst.2.7.2; Vecitis CD, 2011, ENVIRON SCI TECHNOL, V45, P3672, DOI 10.1021/es2000062; Villanueva CM, 2004, EPIDEMIOLOGY, V15, P357, DOI 10.1097/01.ede.0000121380.02594.fc; Walker T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15565-5; Wang HT, 2013, WATER RES, V47, P4198, DOI 10.1016/j.watres.2013.02.056; Xiang F, 2018, IND CROP PROD, V125, P582, DOI 10.1016/j.indcrop.2018.09.048; Xu JG, 1999, WORLD J GASTROENTERO, V5, P191; Yuan GF, 2016, FOOD RES INT, V89, P117, DOI 10.1016/j.foodres.2016.10.004	49	3	3	16	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2019	14	12							e0227220	10.1371/journal.pone.0227220	http://dx.doi.org/10.1371/journal.pone.0227220			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN8IR	31881054	gold, Green Published			2023-01-03	WOS:000515089200054
J	Hutchinson, RN				Hutchinson, Rebecca N.			Goals That Ricochet	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Hutchinson, Rebecca N.] Maine Med Ctr, Palliat Care Med, Portland, ME 04102 USA	Maine Medical Center	Hutchinson, RN (corresponding author), Maine Med Ctr, 22 Bramhall St, Portland, ME 04102 USA.	rhutchinso@mmc.org		Hutchinson, Rebecca/0000-0002-9121-6426					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	2019	322	24					2385	2386		10.1001/jama.2019.19557	http://dx.doi.org/10.1001/jama.2019.19557			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ6JW	31860050				2023-01-03	WOS:000505209400011
J	Huffman, MD; Salam, A; Patel, A				Huffman, Mark D.; Salam, Abdul; Patel, Anushka			Implementation Strategies for Cardiovascular Polypills	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HIGH-RISK; METAANALYSIS; PREVENTION; DISEASES		[Huffman, Mark D.] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, 680 N Lake Shore Dr,Ste 1400, Chicago, IL 60660 USA; [Huffman, Mark D.; Patel, Anushka] Univ New South Wales, George Inst Global Hlth, Sydney, NSW, Australia; [Salam, Abdul] Univ New South Wales, George Inst Global Hlth, Hyderabad, India	Northwestern University; Feinberg School of Medicine; George Institute for Global Health; University of New South Wales Sydney; University of Sydney	Huffman, MD (corresponding author), Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, 680 N Lake Shore Dr,Ste 1400, Chicago, IL 60660 USA.	m-huffman@northwestern.edu	Salam, Abdul/GWC-1029-2022	Patel, Anushka/0000-0003-3825-4092				Bahiru E, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009868.pub3; Ference BA, 2019, JAMA-J AM MED ASSOC, V322, P1381, DOI 10.1001/jama.2019.14120; Fulcher J, 2015, LANCET, V385, P1397, DOI 10.1016/S0140-6736(14)61368-4; Greenhalgh T, 2004, MILBANK Q, V82, P581, DOI 10.1111/j.0887-378X.2004.00325.x; McNeil JJ, 2018, NEW ENGL J MED, V379, P1499, DOI 10.1056/NEJMoa1800722; Munoz D, 2019, NEW ENGL J MED, V381, P1114, DOI 10.1056/NEJMoa1815359; Roshandel G, 2019, LANCET, V394, P672, DOI 10.1016/S0140-6736(19)31791-X; Sundstrom J, 2014, LANCET, V384, P591, DOI 10.1016/S0140-6736(14)61212-5; Webster R, 2016, INT J CARDIOL, V205, P147, DOI 10.1016/j.ijcard.2015.12.015; Yusuf S, 2012, CIRC-CARDIOVASC QUAL, V5, P463, DOI 10.1161/CIRCOUTCOMES.111.963637	10	6	6	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	2019	322	23					2279	2280		10.1001/jama.2019.18102	http://dx.doi.org/10.1001/jama.2019.18102			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ6JR	31764946				2023-01-03	WOS:000505208800010
J	Hall, KD				Hall, Kevin D.			Mystery or method? Evaluating claims of increased energy expenditure during a ketogenic diet	PLOS ONE			English	Article									[Hall, Kevin D.] NIDDK, Lab Biol Modeling, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hall, KD (corresponding author), NIDDK, Lab Biol Modeling, Bethesda, MD 20892 USA.	kevinh@niddk.nih.gov	Hall, Kevin/F-2383-2010	Hall, Kevin/0000-0003-4062-3133	Intramural Research Program of the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases	Intramural Research Program of the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the Intramural Research Program of the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Black AE, 2000, EUR J CLIN NUTR, V54, P386, DOI 10.1038/sj.ejcn.1600970; ELIA M, 1991, AM J PHYSIOL, V260, pE75, DOI 10.1152/ajpendo.1991.260.1.E75; Friedman MI, 2019, PLOS ONE; Hall KD, 2014, EFFECT EUCALORIC KET; Hall KD, 2019, INT J OBESITY, V43, P2350, DOI 10.1038/s41366-019-0456-3; Hall KD, 2019, AM J CLIN NUTR, V109, P1328, DOI 10.1093/ajcn/nqy390; Hall KD, 2016, AM J CLIN NUTR, V104, P1488, DOI 10.3945/ajcn.116.143628; Hall KD, 2016, AM J CLIN NUTR, V104, P324, DOI 10.3945/ajcn.116.133561; Ludwig DS, 2018, JAMA-J AM MED ASSOC, V320, P93, DOI 10.1001/jama.2018.5658; Ludwig DS, 2014, JAMA-J AM MED ASSOC, V311, P2167, DOI 10.1001/jama.2014.4133; Veldhorst MAB, 2009, AM J CLIN NUTR, V90, P519, DOI 10.3945/ajcn.2009.27834	11	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2019	14	12							e0225944	10.1371/journal.pone.0225944	http://dx.doi.org/10.1371/journal.pone.0225944			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP0PS	31815947	Green Published, gold			2023-01-03	WOS:000534024700012
J	Daniel, H; Bornstein, SS; Carney, JK; Cooney, TG; Engel, LS; Gantzer, HE; Henry, TL; Lenchus, JD; McCandless, BM; Southworth, MB; Syed, F; Quinton, J; Wallace, MA				Daniel, Hilary; Bornstein, Sue S.; Carney, Jan K.; Cooney, Thomas G.; Engel, Lee S.; Gantzer, Heather E.; Henry, Tracey L.; Lenchus, Joshua D.; McCandless, Bridget M.; Southworth, Molly B.; Syed, Fatima; Quinton, Jacob; Wallace, Mary Anderson		Amer Coll Phys	Policy Recommendations for Pharmacy Benefit Managers to Stem the Escalating Costs of Prescription Drugs: A Position Paper From the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Review								Recent discussions about the increasing prices of prescription drugs have focused on pharmacy benefit managers (PBMs), third-party intermediaries for various types of employers and government purchasers who negotiate drug prices in health plans and thus play a crucial role in determining the amount millions of Americans pay for medications. In this position paper, the American College of Physicians expands on its position paper from 2016 by offering additional recommendations to improve transparency in the PBM industry and highlighting the need for reliable, timely, and relevant information on prescription drug pricing for physicians and patients.	[Daniel, Hilary] Amer Coll Physicians, 25 Massachusetts Ave NW,Suite 700, Washington, DC 20001 USA; [Bornstein, Sue S.] Texas Med Home Initiat, Dallas, TX USA	American College of Physicians	Daniel, H (corresponding author), Amer Coll Physicians, 25 Massachusetts Ave NW,Suite 700, Washington, DC 20001 USA.	hdaniel@mail.acponline.org			ACP operating budget	ACP operating budget	Financial support for the development of this position paper came exclusively from the ACP operating budget.	Abelson R, 2018, NY TIMES; Andrus MR, 2015, J MANAG CARE SPEC PH, V21, P281, DOI 10.18553/jmcp.2015.21.4.281; Arrow KJ, 2017, 23257 NAT BUR EC RES; Bai G, 2018, ANN INTERN MED, V168, P436, DOI 10.7326/M17-2506; Berman A, 2017, CURBING UNFAIR DRUG; Dabora MC, 2017, JAMA-J AM MED ASSOC, V318, P21, DOI 10.1001/jama.2017.5607; Daniel H, 2016, ANN INTERN MED, V165, P50, DOI 10.7326/M15-2768; Department of Health and Human Services Office of Inspector General, 2011, CONC REB MED D; Hiltzik Michael, 2017, LOS ANGELES TIMES; Lee JL, 2013, HEALTH AFFAIR, V32, P1251, DOI 10.1377/hlthaff.2012.0902; Madara JL, 2018, COMMUNICATION   0807; Pharmaceutical Care Management Association, PBMS PROV CLIN VAL P; QuintilesIMS Institute, 2017, MED US SPEND US REV; Ramsey L., 2017, BUSINESS INSIDER; Rock TA, 2013, PEDIATRICS, V131, P1072, DOI 10.1542/peds.2012-1753; Rohr-Kirchgraber T., 2018, CNBC; Stebbins MR, 2013, J MANAGE CARE PHARM, V19, P534, DOI 10.18553/jmcp.2013.19.7.534; Tseng CW, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1752-4; US Department of Health & Human Services, 2018, AM PAT 1 TRUMP ADM B; Van Nuys K, 2018, OVERPAYING PRESCRIPT; Verma S, 2018, COMMUNICATION   0517; Visante, 2016, PHARM BEN MAN PBMS G; Visante, 2018, INCR COSTS ASS PROP	23	9	9	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 3	2019	171	11					823	+		10.7326/M19-0035	http://dx.doi.org/10.7326/M19-0035			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB3UY	31711103				2023-01-03	WOS:000506426000007
J	Wasir, R; Irawati, S; Makady, A; Postma, M; Goettsch, W; Feenstra, T; Buskens, E				Wasir, Riswandy; Irawati, Sylvi; Makady, Amr; Postma, Maarten; Goettsch, Wim; Feenstra, Talitha; Buskens, Erik			The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders	PLOS ONE			English	Article							HEALTH TECHNOLOGY-ASSESSMENT	Objectives This study aimed to identify the barriers and facilitators to improve the use of health technology assessment (HTA) for the selection of medicines listed in the e-Catalogue and the national formulary in Indonesia. Methods Semi-structured interviews were conducted to collect qualitative data. Purposive sampling was used to recruit the stakeholders consisting of policymakers, a pharmaceutical industry representative, healthcare providers, and patients. The data were analyzed using directed content analysis and following the COnsolidated criteria for REporting Qualitative studies (COREQ). Results The twenty-five participants interviewed agreed with the use of HTA for supporting the eCatalogue and the national formulary and perceived the advantages of HTA implementation outweighed the disadvantages. Barriers mentioned were a lack of capability of local human resources, financial incentives, a clear framework and insufficient data. Strategies suggested to overcome the barriers were establishing (inter)national networks to build up capacity, setting up departments of HTA in several universities in Indonesia, and introducing a clear HTA framework. Facilitators mentioned were the ambition to achieve universal health coverage, the presence of legal frameworks to implement HTA in the e-Catalogue and the national formulary, and the demands for appropriate medicine policies. Conclusions Several barriers are currently hampering broad implementation of HTA in medicine pricing and reimbursement policy in Indonesia. Solutions to these issues appear feasible and important facilitators exist.	[Wasir, Riswandy; Feenstra, Talitha; Buskens, Erik] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; [Wasir, Riswandy] Sekolah Tinggi Ilmu Farmasi Makassar, Makassar, Indonesia; [Wasir, Riswandy; Irawati, Sylvi; Postma, Maarten; Feenstra, Talitha] Univ Groningen, Fac Sci & Engn, Groningen Res Inst Pharm, Groningen, Netherlands; [Irawati, Sylvi] Univ Surabaya, Fac Pharm, Ctr Med Informat & Pharmaceut Care, Surabaya, Indonesia; [Irawati, Sylvi] Univ Surabaya, Fac Pharm, Dept Clin & Community Pharm, Surabaya, Indonesia; [Makady, Amr; Goettsch, Wim] Natl Hlth Care Inst, Diemen, Netherlands; [Makady, Amr; Goettsch, Wim] Univ Utrecht, Dept Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands; [Postma, Maarten] Univ Groningen, Dept Hlth Sci, Groningen, Netherlands; [Postma, Maarten] Univ Groningen, Fac Econ & Business, Dept Econ Econometr & Finance, Groningen, Netherlands; [Postma, Maarten] Univ Airlangga, Fac Med, Dept Pharmacol & Therapy, Surabaya, Indonesia; [Feenstra, Talitha] Dutch Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands; [Buskens, Erik] Univ Groningen, Fac Econ & Business, Dept Operat, Groningen, Netherlands	University of Groningen; University of Groningen; Universitas Surabaya (UBAYA); Universitas Surabaya (UBAYA); Utrecht University; University of Groningen; University of Groningen; Airlangga University; Netherlands National Institute for Public Health & the Environment; University of Groningen	Wasir, R (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands.; Wasir, R (corresponding author), Sekolah Tinggi Ilmu Farmasi Makassar, Makassar, Indonesia.; Wasir, R (corresponding author), Univ Groningen, Fac Sci & Engn, Groningen Res Inst Pharm, Groningen, Netherlands.	r.wasir@umcg.nl	Irawati, Sylvi/GLQ-9438-2022	buskens, erik/0000-0002-6463-1106; Wasir, Riswandy/0000-0001-6184-925X; Irawati, Sylvi/0000-0001-6278-9017; Postma, Maarten/0000-0002-6306-3653	DIKTI scholarship from the Ministry of Research, Technology and Higher Education; LPDP scholarship from the Ministry of Research, Technology and Higher Education; Ministry of Finance of the Republic Indonesia	DIKTI scholarship from the Ministry of Research, Technology and Higher Education(Ministry of Research and Technology of the Republic of Indonesia (RISTEK)); LPDP scholarship from the Ministry of Research, Technology and Higher Education; Ministry of Finance of the Republic Indonesia(Ministry of Research and Technology of the Republic of Indonesia (RISTEK))	This work was financially supported by DIKTI (to RW) and LPDP (to SI) scholarships from the Ministry of Research, Technology and Higher Education, and the Ministry of Finance of the Republic Indonesia, respectively. The DIKTI and LPDP had no direct role in research design, data collection, analysis and interpretation, or manuscript writing and publication.	Angelis A, 2018, EUR J HEALTH ECON, V19, P123, DOI 10.1007/s10198-017-0871-0; [Anonymous], 2013, MALAYSIA HEAL SYST R, V3, P103; Babar Z, 2017, PHARM POLICY COUNTRI; Babigumira JB, 2016, J PHARM HEALTH SERV, V7, P37, DOI 10.1111/jphs.12120; Bigdeli M, 2015, MED UNIVERSAL HLTH C, DOI [10.1186/s40545-015-0028-4, DOI 10.1186/S40545-015-0028-4]; Chalkidou K, 2013, LANCET, V382, pE48, DOI 10.1016/S0140-6736(13)62559-3; Dirjen Binfar dan Alkes Kemenkes RI, 2015, IMPL FORM NAS DAL PE; Hidayat B, 2015, OUT POCKET PAYMENTS; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Kalo Z, 2016, HEALTH ECON, V25, P179, DOI 10.1002/hec.3298; Kementrian Kesehatan R, 2013, PED PEN KAJ FARM; Kemetrian Kesehatan Republik Indonesia, 2015, PED PEN FORM NAS; Khan JAM, 2017, HEALTH POLICY PLANN, V32, P1102, DOI 10.1093/heapol/czx048; Kieny MP, 2017, B WORLD HEALTH ORGAN, V95, P537, DOI 10.2471/BLT.16.187476; Mundiharno TH, 2012, PETA JALAN MENUJU JA; Nguyen TA, 2017, PHARM POLICY COUNTRI, P75; Sachs JD, 2012, LANCET, V379, P2206, DOI 10.1016/S0140-6736(12)60685-0; Teerawattananon Y, 2009, INT J TECHNOL ASSESS, V25, P241, DOI 10.1017/S0266462309090709; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Wasir R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212328; WHO, GLOB HLTH EXP DAT; World Health Organization, 2015, TRACK UN HLTH COV 1; World Health Organization, 2019, HLTH TECHN ASS HTA W; World Health Organization, 2015, WHO GUID COUNTR PHAR; Yoongthong W, 2012, VALUE HEALTH, V15, pS126, DOI 10.1016/j.jval.2011.11.003	25	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2019	14	11							e0225626	10.1371/journal.pone.0225626	http://dx.doi.org/10.1371/journal.pone.0225626			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LO8SS	31774854	Green Published, Green Accepted, gold, Green Submitted			2023-01-03	WOS:000533896400044
J	Torres, D; Hou, XN; Bale, L; Heinzen, EP; Maurer, MJ; Zanfagnin, V; Oberg, AL; Conover, C; Weroha, SJ				Torres, Diogo; Hou, Xiaonan; Bale, Laurie; Heinzen, Ethan P.; Maurer, Matthew J.; Zanfagnin, Valentina; Oberg, Ann L.; Conover, Cheryl; Weroha, S. John			Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A	PLOS ONE			English	Article							GROWTH-FACTOR-I; FACTOR 1 RECEPTOR; MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY; PHASE-I; VIVO; INHIBITION; PACLITAXEL; PATHWAYS; EFFICACY	Objectives Inhibition of pregnancy-associated plasma protein-A (PAPP-A), an upstream activator of the insulin-like growth factor (IGF) pathway, is known to augment sensitivity to platinum-based chemotherapy. This study further tests the efficacy of PAPP-A inhibition with a monoclonal antibody inhibitor (mAb-PA) in ovarian cancer (OC) platinum-resistant patient-derived xenograft (PDX) models. Methods PAPP-A expression was quantitated in platinum-resistant PDX models by ELISA. A subset with High (n = 5) and Low (n = 2) expression were revived in female SCID/beige mice for studies with either saline, carboplatin/paclitaxel (CP) + mAb-PA, or CP + IgG2a. The primary endpoint was tumor area by ultrasound on day 28 relative to baseline. Conversion to platinum-sensitive was defined by average tumor regression below baseline. Statistical analyses included linear mixed effects modeling and Kaplan Meier curves. Response to therapy was correlated with changes in the ratio of phosphorylated/total AKT and ERK 1/2 using Wes analysis. Results The addition of mAb-PA to CP induced tumor regression below baseline in one High PAPP-A PDX model; another three models exhibited notable growth inhibition relative to CP + IgG2a. None of the Low PAPP-A PDX models regressed below baseline. The PDX model with the greatest magnitude of tumor regression from baseline after combination therapy was maintained on single agent mAb-PA or IgG2a, but no benefit was observed. Decreased phosphorylation of ERK1/2 correlated with conversion to platinum-sensitive. Conclusions The addition of mAb-PA to CP overcame platinum-resistance in one of five High PAPP-A PDX models; three other models demonstrated improved platinum-response. This supports further clinical development of this novel therapeutic.	[Torres, Diogo; Maurer, Matthew J.] Mayo Clin, Div Gynecol Surg, Dept Obstet & Gynecol, Rochester, MN USA; [Hou, Xiaonan; Zanfagnin, Valentina; Weroha, S. John] Mayo Clin, Div Med Oncol, Dept Oncol, Rochester, MN 55905 USA; [Bale, Laurie; Conover, Cheryl] Mayo Clin, Div Endocrinol, Rochester, MN USA; [Heinzen, Ethan P.; Oberg, Ann L.] Dept Hlth Sci Res, Div Biomed Stat & Informat, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Weroha, SJ (corresponding author), Mayo Clin, Div Med Oncol, Dept Oncol, Rochester, MN 55905 USA.	Weroha.Saravut@mayo.edu		Torres, Diogo/0000-0002-2096-0864	Minnesota Ovarian Cancer Alliance (MOCA); Mayo Clinic Ovarian SPORE [CA136393]; Fraternal Order of Eagles; Department of Obstetrics and Gynecology at Mayo Clinic	Minnesota Ovarian Cancer Alliance (MOCA); Mayo Clinic Ovarian SPORE; Fraternal Order of Eagles; Department of Obstetrics and Gynecology at Mayo Clinic	Minnesota Ovarian Cancer Alliance (MOCA) and Mayo Clinic Ovarian SPORE (CA136393) (SJW), Fraternal Order of Eagles, and the Department of Obstetrics and Gynecology at Mayo Clinic (DT).	Aletti GD, 2006, OBSTET GYNECOL, V107, P77, DOI 10.1097/01.AOG.0000192407.04428.bb; AlHilli MM, 2016, GYNECOL ONCOL, V143, P379, DOI 10.1016/j.ygyno.2016.08.328; Becker MA, 2015, MOL CANCER THER, V14, P973, DOI 10.1158/1535-7163.MCT-14-0880; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Beltran PJ, 2014, CLIN CANCER RES, V20, P2947, DOI 10.1158/1078-0432.CCR-13-3448; Boldt HB, 2011, ENDOCRINOLOGY, V152, P1470, DOI 10.1210/en.2010-1095; Butler KA, 2017, NEOPLASIA, V19, P628, DOI 10.1016/j.neo.2017.04.007; Conover CA, 2012, TRENDS ENDOCRIN MET, V23, P242, DOI 10.1016/j.tem.2012.02.008; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Glaser G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126867; Haluska P, 2014, CLIN CANCER RES, V20, P4747, DOI 10.1158/1078-0432.CCR-14-0114; HEITJAN DF, 1993, CANCER RES, V53, P6042; Iams WT, 2015, CLIN CANCER RES, V21, P4270, DOI 10.1158/1078-0432.CCR-14-2518; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Juergens H, 2011, J CLIN ONCOL, V29, P4534, DOI 10.1200/JCO.2010.33.0670; KALLI KR, 2003, FRONT BIOSCI, V8, pD71; Kehoe S, 2015, LANCET, V386, P2143, DOI 10.1016/S0140-6736(15)01052-1; King ER, 2011, GYNECOL ONCOL, V123, P13, DOI 10.1016/j.ygyno.2011.06.016; Konecny GE, 2014, ASCO M, V32, P5529, DOI DOI 10.1200/JC0.2014.32.15_SUPPL.5529; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; LITTELL RC, 2002, SAS SYSTEM MIXED MOD; Markman M, 2002, J CLIN ONCOL, V20, P2365, DOI 10.1200/JCO.2002.09.130; Meehan TF, 2017, CANCER RES, V77, pE62, DOI 10.1158/0008-5472.CAN-17-0582; Mikkelsen JH, 2008, J BIOL CHEM, V283, P16772, DOI 10.1074/jbc.M802429200; Mikkelsen JH, 2014, ONCOTARGET, V5, P1014, DOI 10.18632/oncotarget.1629; Oberg AL, TOPICS BIOSTATISTICS; Oberg Ann L., 2007, V404, P213, DOI 10.1007/978-1-59745-530-5_11; Olmos D, 2010, LANCET ONCOL, V11, P129, DOI 10.1016/S1470-2045(09)70354-7; Pappo AS, 2011, J CLIN ONCOL, V29, P4541, DOI 10.1200/JCO.2010.34.0000; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Puzanov I, 2015, CLIN CANCER RES, V21, P701, DOI 10.1158/1078-0432.CCR-14-0303; RESNICOFF M, 1993, LAB INVEST, V69, P756; Schoffski P, 2013, EUR J CANCER, V49, P3219, DOI 10.1016/j.ejca.2013.06.010; Staflin K, 2006, INT J GYNECOL CANCER, V16, P1557, DOI 10.1111/j.1525-1438.2006.00627.x; Wang Y, 2005, MOL CANCER THER, V4, P1214, DOI 10.1158/1535-7163.MCT-05-0048; Weroha SJ, 2014, CLIN CANCER RES, V20, P1288, DOI 10.1158/1078-0432.CCR-13-2611; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107	37	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2019	14	11							e0224564	10.1371/journal.pone.0224564	http://dx.doi.org/10.1371/journal.pone.0224564			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO8PC	31751381	Green Published, gold			2023-01-03	WOS:000533886900012
J	Helenius, K; Longford, N; Lehtonen, L; Modi, N; Gale, C; Babirecki, M; Kamalanathan, A; Wickham, T; Aucharaz, K; Gupta, A; Paul, N; Wong, LM; Mittal, A; Broggio, P; Surana, P; Singh, A; Seal, S; Hassan, A; Schwarz, K; Thomas, M; Foo, A; Anderson, J; Whincup, G; Brearey, S; Chang, J; Gad, K; Hasib, A; Garbash, M; Allwood, A; Adiotomre, P; Brooke, N; Deketelaere, A; Khader, KA; Shephard, R; Rekha, S; Abuzgia, B; Jain, M; Pirie, S; Surana, P; Zengeya, S; Watts, T; Balal, S; Seagrave, C; Bate, T; Dixon, H; Aladangady, N; Gaili, H; James, M; Lal, M; Ambadkar, P; Pandey, P; Hickey, A; Rhodes, S; Pai, V; Lama, M; Miall, L; Cusack, J; Kairamkonda, V; Grosdenier, M; Kollipara, L; Kefas, J; Yoxall, B; Birch, J; Whitehead, G; Krishnamurthy, R; Sashikumar, P; Misra, I; Pillay, T; Ali, I; Thiagarajan, P; Dyke, M; Selter, M; Kamath, P; Alsford, L; Spencer, V; Gupta, S; Nicholl, R; Wardle, S; Chakrabarti, S; Adams, E; McDevitt, K; Reddy, A; Gibson, D; Khashu, M; Reddy, C; Pearson, F; Amess, P; Deshpande, S; Sleight, E; Groves, C; Godambe, S; Bosman, D; Rewitzky, G; Banjoko, O; Kumar, N; Muogbo, D; Lopez, W; D'Amore, A; Mattara, S; Zipitis, C; De Halpert, P; Settle, P; Munyard, P; McIntyre, J; Bartle, D; Pain, K; Fedee, J; Maddock, N; Gupta, R; Moore, A; Godden, C; Amess, P; Jones, S; Fenton, A; Mahadevan, S; Brown, N; Mack, K; Adiotomre, P; Bolton, R; Khan, A; Mannix, P; Huddy, C; Yasin, S; Butterworth, S; Godambe, S; Nedungadi, S; Cairns, P; Reynolds, P; Brennan, N; Heal, C; Salgia, S; Abu-Harb, M; Birch, J; Knight, C; Clark, S; Theron, M; Murthy, V; Paul, S; Kisat, H; Kendall, G; Blake, K; Obi, O; Garbash, M; Kumar, H; Rawlingson, C; Webb, D; Bird, S; Narayanan, S; Eyre, E; Evans, I; Sanghavi, R; Sullivan, C; Garr, R; Leith, W; Vasu, V; Harry, L; Vamvakiti, K; Vemuri, G; Eaton, M; Samy, M				Helenius, Kjell; Longford, Nicholas; Lehtonen, Liisa; Modi, Neena; Gale, Chris; Babirecki, Matthew; Kamalanathan, Anand; Wickham, Tim; Aucharaz, Kavi; Gupta, Aashish; Paul, Nicola; Wong, Lai Men; Mittal, Anita; Broggio, Penny; Surana, Pinki; Singh, Anju; Seal, Sunita; Hassan, Ahmed; Schwarz, Karin; Thomas, Mark; Foo, Aiwyne; Anderson, Jo; Whincup, Graham; Brearey, Stephen; Chang, John; Gad, Khairy; Hasib, Abdul; Garbash, Mehdi; Allwood, Alex; Adiotomre, Pauline; Brooke, Nigel; Deketelaere, Abby; Khader, K. Abdul; Shephard, Ruth; Rekha, Sanghavi; Abuzgia, Belal; Jain, Mukta; Pirie, Simon; Surana, Pinki; Zengeya, Stanley; Watts, Timothy; Balal, Sobia; Seagrave, Cath; Bate, Tristan; Dixon, Hilary; Aladangady, Narendra; Gaili, Hassan; James, Matthew; Lal, Mithilesh; Ambadkar, Priyadarshan; Pandey, Poornima; Hickey, Ann; Rhodes, Simon; Pai, Vinay; Lama, Meera; Miall, Lawrence; Cusack, Jonathan; Kairamkonda, Venkatesh; Grosdenier, Michael; Kollipara, Lakshmi; Kefas, Jonathan; Yoxall, Bill; Birch, Jennifer; Whitehead, Gail; Krishnamurthy, Raghavendra; Sashikumar, Palaniappan; Misra, Indranil; Pillay, Tilly; Ali, Imdad; Thiagarajan, Prakash; Dyke, Mark; Selter, Michael; Kamath, Prakash; Alsford, Lesley; Spencer, Vivien; Gupta, Subodh; Nicholl, Richard; Wardle, Steven; Chakrabarti, Sandip; Adams, Eleri; McDevitt, Katharine; Reddy, Ajay; Gibson, David; Khashu, Minesh; Reddy, Chinnappa; Pearson, Freya; Amess, Philip; Deshpande, Sanjeev; Sleight, Elizabeth; Groves, Charlotte; Godambe, Sunit; Bosman, Dennis; Rewitzky, Glynis; Banjoko, Olutoyin; Kumar, Niraj; Muogbo, Dominic; Lopez, Wilson; D'Amore, Angela; Mattara, Shameel; Zipitis, Christos; De Halpert, Peter; Settle, Paul; Munyard, Paul; McIntyre, John; Bartle, David; Pain, Katie; Fedee, Joanne; Maddock, Natasha; Gupta, Richa; Moore, Alison; Godden, Charles; Amess, Philip; Jones, Stephen; Fenton, Alan; Mahadevan, Subramanian; Brown, Nick; Mack, Kirsten; Adiotomre, Pauline; Bolton, Rob; Khan, Arfa; Mannix, Paul; Huddy, Charlotte; Yasin, Salim; Butterworth, Sian; Godambe, Sunit; Nedungadi, Sajit; Cairns, Pamela; Reynolds, Peter; Brennan, Nick; Heal, Carrie; Salgia, Sanjay; Abu-Harb, Majd; Birch, Jacqeline; Knight, Chris; Clark, Simon; Theron, Marice; Murthy, Vadivelam; Paul, Siba; Kisat, Hamudi; Kendall, Giles; Blake, Kate; Obi, Ozioma; Garbash, Mehdi; Kumar, Hari; Rawlingson, Chris; Webb, Delyth; Bird, Sumedha; Narayanan, Sankara; Eyre, Elizabeth; Evans, Ian; Sanghavi, Rekha; Sullivan, Caroline; Garr, Ros; Leith, Wynne; Vasu, Vimal; Harry, Liza; Vamvakiti, Katia; Vemuri, Gopi; Eaton, Megan; Samy, Mahmoud		Neonatal Data Anal Unit	Association of early postnatal transfer and birth outside a tertiary hospital with mortality and severe brain injury in extremely preterm infants: observational cohort study with propensity score matching	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEURODEVELOPMENTAL OUTCOMES; NEONATAL TRANSPORT; WEIGHT INFANTS; IN-UTERO; CARE; MORBIDITY; LEVEL; HEMORRHAGE; REGIONALIZATION; DELIVERY	OBJECTIVE To determine if postnatal transfer or birth in a non-tertiary hospital is associated with adverse outcomes. DESIGN Observational cohort study with propensity score matching. SETTING National health service neonatal care in England; population data held in the National Neonatal Research Database. PARTICIPANTS Extremely preterm infants born at less than 28 gestational weeks between 2008 and 2015 (n=17 577) grouped based on birth hospital and transfer within 48 hours of birth: upward transfer (non-tertiary to tertiary hospital, n=2158), non-tertiary care (born in non-tertiary hospital; not transferred, n=2668), and controls (born in tertiary hospital; not transferred, n=10 866). Infants were matched on propensity scores and predefined background variables to form subgroups with near identical distributions of confounders. Infants transferred between tertiary hospitals (horizontal transfer) were separately matched to controls in a 1:5 ratio. MAIN OUTCOME MEASURES Death, severe brain injury, and survival without severe brain injury. RESULTS 2181 infants, 727 from each group (upward transfer, non-tertiary care, and control) were well matched. Compared with controls, infants in the upward transfer group had no significant difference in the odds of death before discharge (odds ratio 1.22, 95% confidence interval 0.92 to 1.61) but significantly higher odds of severe brain injury (2.32, 1.78 to 3.06; number needed to treat (NNT) 8) and significantly lower odds of survival without severe brain injury (0.60, 0.47 to 0.76; NNT 9). Compared with controls, infants in the non-tertiary care group had significantly higher odds of death (1.34, 1.02 to 1.77; NNT 20) but no significant difference in the odds of severe brain injury (0.95, 0.70 to 1.30) or survival without severe brain injury (0.82, 0.64 to 1.05). Compared with infants in the upward transfer group, infants in the non-tertiary care group had no significant difference in death before discharge (1.10, 0.84 to 1.44) but significantly lower odds of severe brain injury (0.41, 0.31 to 0.53; NNT 8) and significantly higher odds of survival without severe brain injury (1.37, 1.09 to 1.73; NNT 14). No significant differences were found in outcomes between the horizontal transfer group (n=305) and controls (n=1525). CONCLUSIONS In extremely preterm infants, birth in a non-tertiary hospital and transfer within 48 hours are associated with poor outcomes when compared with birth in a tertiary setting. We recommend perinatal services promote pathways that facilitate delivery of extremely preterm infants in tertiary hospitals in preference to postnatal transfer.	[Helenius, Kjell; Lehtonen, Liisa] Turku Univ Hosp, Dept Paediat & Adolescent Med, Turku, Finland; [Helenius, Kjell; Lehtonen, Liisa] Univ Turku, Dept Clin Med, Turku, Finland; [Helenius, Kjell; Longford, Nicholas; Modi, Neena; Gale, Chris] Imperial Coll London, Dept Med, Sect Neonatal Med, Chelsea & Westminster campus, London SW10 9NH, England; Airedale Dist Gen Hosp, Keighley, England; [Babirecki, Matthew] Arrowe Pk Hosp, Upton, NY USA; [Kamalanathan, Anand] Barnet Hosp, Barnet, England; [Wickham, Tim] Barnsley Dist Gen Hosp, Barnsley, England; [Aucharaz, Kavi] Basildon Hosp, Basildon, England; [Gupta, Aashish] Basingstoke & North Hampshire Hosp, Basingstoke, Hants, England; [Paul, Nicola] Bassetlaw Dist Gen Hosp, Worksop, England; [Wong, Lai Men] Bedford Hosp, Bedford, England; [Mittal, Anita] Birmingham City Hosp, Birmingham, W Midlands, England; [Broggio, Penny] Birmingham Heartlands Hosp, Birmingham, W Midlands, England; [Surana, Pinki] Birmingham Womens Hosp, Birmingham, W Midlands, England; [Singh, Anju] Bradford Royal Infirm, Bradford, W Yorkshire, England; [Seal, Sunita] Broomfield Hosp, Chelmsford, Essex, England; [Hassan, Ahmed] Calderdale Royal Hosp, Halifax, NS, Canada; [Schwarz, Karin] Chelsea & Westminster Hosp, London, England; [Thomas, Mark] Chesterfield & North Derbyshire Royal Hosp, Chesterfield, England; [Foo, Aiwyne] Colchester Gen Hosp, Colchester, Essex, England; [Anderson, Jo] Conquest Hosp, St Leonards On Sea, England; [Whincup, Graham] Countess Chester Hosp, Chester, Cheshire, England; [Brearey, Stephen] Croydon Univ Hosp, Thorton Heath, England; [Chang, John] Cumberland Infirm, Carlisle, England; [Gad, Khairy] Darent Valley Hosp, Dartford, England; [Hasib, Abdul] Darlington Mem Hosp, Darlington, Durham, England; [Garbash, Mehdi] Derriford Hosp, Plymouth, Devon, England; [Allwood, Alex] Diana Princess Wales Hosp, Grimsby, England; [Adiotomre, Pauline] Doncaster Royal Infirm, Doncaster, England; [Brooke, Nigel] Dorset Cty Hosp, Dorchester, England; [Deketelaere, Abby] East Surrey Hosp, Redhill, Surrey, England; [Khader, K. Abdul] Epsom Gen Hosp, Epsom, Surrey, England; [Shephard, Ruth] Frimley Pk Hosp, Camberley, England; [Rekha, Sanghavi] Furness Gen Hosp, Barrow In Furness, England; [Abuzgia, Belal] George Eliot Hosp, Nuneaton, England; [Jain, Mukta] Gloucester Royal Hosp, Gloucester, England; [Pirie, Simon] Good Hope Hosp, Sutton Coldfield, England; [Surana, Pinki] Great Western Hosp, Swindon, Wilts, England; [Zengeya, Stanley] Guys & St Thomas Hosp, London, England; [Watts, Timothy] Harrogate Dist Hosp, Harrogate, England; [Balal, Sobia] Hereford Cty Hosp, Hereford, England; [Seagrave, Cath] Hillingdon Hosp, Uxbridge, Middx, England; [Bate, Tristan] Hinchingbrooke Hosp, Huntington, England; [Dixon, Hilary] Homerton Hosp, London, England; [Aladangady, Narendra] Hull Royal Infirm, Kingston Upon Hull, N Humberside, England; [Gaili, Hassan] Ipswich Hosp, Ipswich, Suffolk, England; [James, Matthew] James Cook Univ Hosp, Middlesbrough, England; [Lal, Mithilesh] James Paget Hosp, Gorleston, England; [Ambadkar, Priyadarshan] Kettering & Dist Gen Hosp, Kettering, England; [Pandey, Poornima] Kings Coll Hosp London, Camberwell, England; [Hickey, Ann] Kings Mill Hosp, Sutton In Ashfield, England; [Rhodes, Simon] Kingston Hosp, Kingston Upon Thames, Surrey, England; [Pai, Vinay] Lancashire Women & Newborn Ctr, Burnley, Lancs, England; [Lama, Meera] Leeds Neonatal Serv, Leeds, W Yorkshire, England; [Miall, Lawrence] Leicester Gen Hosp, Leicester, Leics, England; [Cusack, Jonathan] Leicester Royal Infirm, Leicester, Leics, England; [Kairamkonda, Venkatesh] Leighton Hosp, Crewe, England; [Grosdenier, Michael] Lincoln Cty Hosp, Lincoln, England; [Kollipara, Lakshmi] Lister Hosp, Stevenage, Herts, England; [Kefas, Jonathan] Liverpool Womens Hosp, Liverpool, Merseyside, England; [Yoxall, Bill] Luton & Dunstable Hosp, Luton, Beds, England; [Birch, Jennifer] Macclesfield Hosp, Macclesfield, Cheshire, England; [Whitehead, Gail] Manor Hosp, Walsall, W Midlands, England; [Krishnamurthy, Raghavendra] Medway Maritime Hosp, Gillingham, England; [Sashikumar, Palaniappan] Milton Keynes Dist Gen Hosp, Milton Keynes, Bucks, England; [Misra, Indranil] New Cross Hosp, Wolwerhampton, England; [Pillay, Tilly] Newham Dist Gen Hosp, Plaistow, England; [Ali, Imdad] Nobles Isle Man Hosp, Douglas, Man, England; [Thiagarajan, Prakash] Norfolk & Norwich Univ Hosp, Norwich, Norfolk, England; [Dyke, Mark] North Devon Dist Hosp, Barnstaple, England; [Selter, Michael] North Manchester Gen Hosp, Manchester, Lancs, England; [Kamath, Prakash] North Middlesex Univ Hosp, Edmonton, AB, Canada; [Alsford, Lesley] North Tyneside Gen Hosp, Cramlington, England; [Spencer, Vivien] Northampton Gen Hosp, Northampton, England; [Gupta, Subodh] Northwick Pk Hosp & Clin Res Ctr, Harrow, Middx, England; [Nicholl, Richard] Nottingham City Hosp, Nottingham, England; [Wardle, Steven] Nottingham Univ Hosp QMC, Nottingham, England; [Wardle, Steven] Ormskirk Dist Gen Hosp, Ormskirk, England; [Chakrabarti, Sandip] Oxford Univ Hosp, John Radcliffe Hosp, Oxford, England; [Adams, Eleri] Peterborough City Hosp, Peterborough, Cambs, England; [McDevitt, Katharine] Pilgrim Hosp, Boston, MA USA; [Reddy, Ajay] Pinderfields Gen Hosp, Pontefract Gen Infirm, Pontefract, England; [Gibson, David] Poole Gen Hosp, Poole, Dorset, England; [Khashu, Minesh] Princess Alexandra Hosp, Harlow, Essex, England; [Reddy, Chinnappa] Princess Anne Hosp, Southampton, Hants, England; [Pearson, Freya] Princess Royal Hosp, Haywards Heath, England; [Amess, Philip] Princess Royal Hosp, Shrewsbury, Salop, England; [Deshpande, Sanjeev] Princess Royal Univ Hosp, Orpington, England; [Sleight, Elizabeth] Queen Alexandra Hosp, Portsmouth, Hants, England; [Groves, Charlotte] Queen Charlottes Hosp, East Acton, England; [Godambe, Sunit] Queen Elizabeth Hosp, Gateshead, England; [Bosman, Dennis] Queen Elizabeth Hosp, Kings Lynn, England; [Rewitzky, Glynis] Queen Elizabeth Hosp, Woolwich, England; [Banjoko, Olutoyin] Queen Elizabeth Queen Mother Hosp, Margate, England; [Kumar, Niraj] Queens Hosp, Burton Upon Trent, England; [Muogbo, Dominic] Queens Hosp, Romford, Essex, England; [Lopez, Wilson] Rosie Matern Hosp, Cambridge, England; [D'Amore, Angela] Rotherham Dist Gen Hosp, Rotherham, S Yorkshire, England; [Mattara, Shameel] Royal Albert Edward Infirm, Wigan, England; [Zipitis, Christos] Royal Berkshire Hosp, Reading, Berks, England; [De Halpert, Peter] Royal Bolton Hosp, Bolton, England; [Settle, Paul] Royal Cornwall Hosp, Truro, England; [Munyard, Paul] Royal Derby Hosp, Derby, England; [McIntyre, John] Royal Devon & Exeter Hosp, Exeter, Devon, England; [Bartle, David] Royal Hampshire Cty Hosp, Winchester, Hants, England; [Pain, Katie] Royal Lancaster Infirm, Lancaster, England; [Fedee, Joanne] Royal Oldham Hosp, Oldham, England; [Maddock, Natasha] Royal Preston Hosp, Preston, Lancs, England; [Gupta, Richa] Royal Stoke Univ Hosp, Stoke On Trent, Staffs, England; [Moore, Alison] Royal Surrey Cty Hosp, Guildford, Surrey, England; [Godden, Charles] Royal Sussex Cty Hosp, Brighton, E Sussex, England; [Amess, Philip] Royal United Hosp, Bath, Avon, England; [Jones, Stephen] Royal Victoria Infirm, Newcastle Upon Tyne, Tyne & Wear, England; [Fenton, Alan] Russells Hall Hosp, Dudley, England; [Mahadevan, Subramanian] Salisbury Dist Hosp, Salisbury, Wilts, England; [Brown, Nick] Scarborough Gen Hosp, Scarborough, England; [Mack, Kirsten] Scunthorpe Gen Hosp, Scunthorpe, England; [Adiotomre, Pauline] South Tyneside Dist Hosp, South Shields, England; [Bolton, Rob] Southend Hosp, Southend On Sea, England; [Khan, Arfa] Southmead Hosp, Bristol, Avon, England; [Mannix, Paul] St George Hosp, Tooting, England; [Huddy, Charlotte] St Helier Hosp, Carshalton, Surrey, England; [Yasin, Salim] St Marys Hosp, Newport, Wight, England; [Butterworth, Sian] St Marys Hosp, London, England; [Godambe, Sunit] St Marys Hosp, Manchester, Lancs, England; [Nedungadi, Sajit] St Michaels Hosp, Bristol, Avon, England; [Cairns, Pamela] St Peters Hosp, Chertsey, England; [Reynolds, Peter] St Richards Hosp, Chichester, England; [Brennan, Nick] Stepping Hill Hosp, Stockport, Lancs, England; [Heal, Carrie] Stoke Mandeville Hosp, Aylesbury, Bucks, England; [Salgia, Sanjay] Sunderland Royal Hosp, Sunderland, England; [Abu-Harb, Majd] Tameside Gen Hosp, Ashton Under Lyne, England; [Birch, Jacqeline] Taunton & Somerset Hosp, Taunton, Somerset, England; [Knight, Chris] Jessop Wing, Sheffield, S Yorkshire, England; [Clark, Simon] Royal Free Hosp, London, England; [Theron, Marice] Royal London Hosp Constance Green, London, England; [Murthy, Vadivelam] Torbay Hosp, Torquay, England; [Paul, Siba] Tunbridge Wells Hosp, Pembury, England; [Kisat, Hamudi] Univ Coll Hosp, London, England; [Kendall, Giles] Univ Hosp Coventry, Coventry, W Midlands, England; [Blake, Kate] Univ Hosp Lewisham, Lewisham, England; [Obi, Ozioma] Univ Hosp North Durham, Durham, England; [Garbash, Mehdi] Univ Hosp North Tees, Stockton On Tees, England; [Kumar, Hari] Victoria Hosp, Blackpool, England; [Rawlingson, Chris] Warrington Hosp, Warrington, Cheshire, England; [Webb, Delyth] Warwick Hosp, Warwick, England; [Bird, Sumedha] Watford Dist Gen Hosp, Watford, England; [Narayanan, Sankara] West Cumberland Hosp, Whitehaven, England; West Middlesex Univ Hosp, Isleworth, England; [Eyre, Elizabeth] West Suffolk Hosp, Bury St Edmunds, Suffolk, England; [Evans, Ian] Wexham Pk Hosp, Slough, Berks, England; [Sanghavi, Rekha] Whipps Cross Univ Hosp, Leytonstone, England; [Sullivan, Caroline] Whiston Hosp, Prescot, England; [Garr, Ros] Whittington Hosp, London, England; [Leith, Wynne] William Harvey Hosp, Ashford, Kent, England; [Vasu, Vimal] Worcestershire Royal Hosp, Worcester, England; [Harry, Liza] Worthing Dist Hosp, Worthing, England; [Vamvakiti, Katia] Wythenshawe Hosp, Wythenshawe, England; [Vemuri, Gopi] Yeovil Dist Hosp, Yeovil, England; [Eaton, Megan] York Dist Gen Hosp, York, N Yorkshire, England	University of Turku; University of Turku; Imperial College London; Heart of England NHS Foundation Trust; University of Birmingham; Birmingham Women's Hospital; Bradford Royal Infirmary; Mid Essex Hospital Services NHS Trust; Broomfield Hospital; Imperial College London; Croydon University Hospital; Derriford Hospital; East Surrey Hospital; Heart of England NHS Foundation Trust; Good Hope Hospital; Guy's & St Thomas' NHS Foundation Trust; University of Hull; Ipswich Hospital NHS Trust; Ipswich Hospital; James Cook University Hospital; King's College Hospital NHS Foundation Trust; King's College Hospital; University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Leicester; Lister Hospital; University of Liverpool; Medway Maritime Hospital; New Cross Hospital; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital; Imperial College London; Nottingham University Hospital NHS Trust; Nottingham City Hospital; Nottingham University Hospital NHS Trust; University of Oxford; Pinderfields Hospital; Poole Hospital; Princess Alexandra Hospital NHS Trust; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; Royal Berkshire Hospital; Royal Bolton Hospital; Royal Cornwall Hospital; University of Nottingham; University of Exeter; Royal Preston Hospital; Royal Stoke University Hospital; Royal Surrey County Hospital; University of Brighton; Newcastle University - UK; Russells Hall Hospital; Salisbury District Hospital; Southmead Hospital; St Georges University London; St Helier Hospital; Imperial College London; University of Manchester; Sunderland Royal Hospital; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; University of Warwick; University Hospital of North Tees; Watford General Hospital; Whiston Hospital; University of London; University College London; Wythenshawe Hospital NHS Foundation Trust	Gale, C (corresponding author), Imperial Coll London, Dept Med, Sect Neonatal Med, Chelsea & Westminster campus, London SW10 9NH, England.	christopher.gale@imperial.ac.uk	Khashu, Minesh/GLT-6749-2022; Helenius, Kjell/AAL-7825-2021; Khashu, Minesh/GRF-0302-2022; Gale, Chris/F-1833-2010	Khashu, Minesh/0000-0003-2673-5948; Helenius, Kjell/0000-0002-6296-6797; Lehtonen, Liisa/0000-0001-8925-2594; Longford, Nicholas/0000-0003-4129-9726; Gale, Chris/0000-0003-0707-876X	UK Medical Research Council [MR/N008405/1]; Foundation of Neonatal Research of southwest Finland; MRC [MR/N008405/1] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Foundation of Neonatal Research of southwest Finland; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	CG was funded by the UK Medical Research Council (grant No MR/N008405/1) and KH by the Foundation of Neonatal Research of southwest Finland. The funding bodies played no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. All researchers are independent from funders.	[Anonymous], 2017, SAFER MATERNITY CARE; Battersby C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201815; Battersby C, 2017, LANCET GASTROENTEROL, V2, P43, DOI 10.1016/S2468-1253(16)30117-0; Binder S, 2011, PEDIATRICS, V127, P487, DOI 10.1542/peds.2010-1064; Blaxter L, 2017, P I MECH ENG H, V231, P99, DOI 10.1177/0954411916680235; Bliss, 2015, BLISS BAB REP 2015; BOWMAN E, 1988, BRIT MED J, V297, P1098, DOI 10.1136/bmj.297.6656.1098; Brookhart MA, 2006, AM J EPIDEMIOL, V163, P1149, DOI 10.1093/aje/kwj149; Cole TJ, 2011, ANN HUM BIOL, V38, P7, DOI 10.3109/03014460.2011.544139; Costeloe KL, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7976; Gale C, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2105; Gale C, 2012, EARLY HUM DEV, V88, P147, DOI 10.1016/j.earlhumdev.2011.07.016; Gale C, 2018, ARCH DIS CHILD-FETAL, V103, pF301, DOI 10.1136/archdischild-2017-313707; HARDING JE, 1993, J PAEDIATR CHILD H, V29, P146; Hauspy J, 2001, EARLY HUM DEV, V63, P1, DOI 10.1016/S0378-3782(00)00128-6; Helenius K, 2016, J PEDIATR-US, V169, P81, DOI 10.1016/j.jpeds.2015.10.062; Imbens GW, 2015, CAUSAL INFERENCE FOR STATISTICS, SOCIAL, AND BIOMEDICAL SCIENCES: AN INTRODUCTION, P1, DOI 10.1017/CBO9781139025751; Johansson S, 2004, PEDIATRICS, V113, P1230, DOI 10.1542/peds.113.5.1230; KOLLEE LAA, 1988, OBSTET GYNECOL, V72, P729; LAMONT RF, 1983, J PERINAT MED, V11, P200, DOI 10.1515/jpme.1983.11.4.200; Lasswell SM, 2010, JAMA-J AM MED ASSOC, V304, P992, DOI 10.1001/jama.2010.1226; Lehtonen L, 2011, ANN MED, V43, pS47, DOI 10.3109/07853890.2011.586359; Longford NT., 2018, STAT T, V19, P87, DOI [10.21307/stattrans-2018-006, DOI 10.21307/STATTRANS-2018-006]; Longhini F, 2015, PEDIATR CRIT CARE ME, V16, P733, DOI 10.1097/PCC.0000000000000482; Lorch SA, 2012, PEDIATRICS, V130, P270, DOI 10.1542/peds.2011-2820; LUBCHENCO LO, 1989, AM J OBSTET GYNECOL, V160, P539, DOI 10.1016/S0002-9378(89)80022-5; Lui K, 2006, PEDIATRICS, V118, P2076, DOI 10.1542/peds.2006-1540; Marlow N, 2014, ARCH DIS CHILD-FETAL, V99, pF181, DOI 10.1136/archdischild-2013-305555; Martin Joyce A, 2015, Natl Vital Stat Rep, V64, P1; McCaffrey DF, 2013, STAT MED, V32, P3388, DOI 10.1002/sim.5753; McNamara P J, 2005, J Perinatol, V25, P309, DOI 10.1038/sj.jp.7211263; Ministry for Social Affairs and Health. Finland, SOS JA TERV YHT PAIV; Mohamed MA, 2010, ARCH DIS CHILD-FETAL, V95, pF403, DOI 10.1136/adc.2010.183236; Mukerji A, 2015, PEDIATRICS, V136, P1132, DOI 10.1542/peds.2015-0944; Palmer Kristine G, 2005, J Perinatol, V25, P270, DOI 10.1038/sj.jp.7211239; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Papile LA, 2012, PEDIATRICS, V130, P587, DOI 10.1542/peds.2012-1999; Pappas A, 2014, JAMA PEDIATR, V168, P137, DOI 10.1001/jamapediatrics.2013.4248; Phibbs CS, 2007, NEW ENGL J MED, V356, P2165, DOI 10.1056/NEJMsa065029; Rautava L, 2007, PEDIATRICS, V119, pE257, DOI 10.1542/peds.2006-1964; Roberts D, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub3; RUBIN DB, 1980, J AM STAT ASSOC, V75, P591, DOI 10.2307/2287653; Serenius F, 2016, JAMA PEDIATR, V170, P954, DOI 10.1001/jamapediatrics.2016.1210; Shlossman PA, 1997, AM J PERINAT, V14, P449, DOI 10.1055/s-2007-994178; Stoll BJ, 2015, JAMA-J AM MED ASSOC, V314, P1039, DOI 10.1001/jama.2015.10244; Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313; Watson A, 2013, J PERINATOL, V33, P366, DOI 10.1038/jp.2012.126; Watson SI, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004856	48	49	49	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 16	2019	367								l5678	10.1136/bmj.l5678	http://dx.doi.org/10.1136/bmj.l5678			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG4QI	31619384	Green Published, hybrid			2023-01-03	WOS:000492058700004
J	Sayon-Orea, C; Razquin, C; Bullo, M; Corella, D; Fito, M; Romaguera, D; Vioque, J; Alonso-Gomez, AM; Warnberg, J; Martinez, JA; Serra-Majem, L; Estruch, R; Tinahones, FJ; Lapetra, J; Pinto, X; Tur, JA; Lopez-Miranda, J; Bueno-Cavanillas, A; Delgado-Rodriguez, M; Matia-Martin, P; Daimiel, L; Sanchez, VM; Vidal, J; Vazquez, C; Ros, E; Ruiz-Canela, M; Sorli, JV; Castaner, O; Fiol, M; Navarrete-Munoz, EM; Aros, F; Gomez-Gracia, E; Zulet, MA; Sanchez-Villegas, A; Casas, R; Bernal-Lopez, R; Santos-Lozano, JM; Corbella, E; Bouzas, C; Garcia-Arellano, A; Basora, J; Asensio, EM; Schroder, H; Monino, M; de la Hera, MG; Tojal-Sierra, L; Toledo, E; Diaz-Lopez, A; Goday, A; Salas-Salvado, J; Martinez-Gonzalez, MA				Sayon-Orea, Carmen; Razquin, Cristina; Bullo, Monica; Corella, Dolores; Fito, Montserrat; Romaguera, Dora; Vioque, Jesus; Alonso-Gomez, Angel M.; Warnberg, Julia; Alfredo Martinez, J.; Serra-Majem, Luis; Estruch, Ramon; Tinahones, Francisco J.; Lapetra, Jose; Pinto, Xavier; Tur, Josep A.; Lopez-Miranda, Jose; Bueno-Cavanillas, Aurora; Delgado-Rodriguez, Miguel; Matia-Martin, Pilar; Daimiel, Lidia; Martin Sanchez, Vicente; Vidal, Josep; Vazquez, Clotilde; Ros, Emilio; Ruiz-Canela, Miguel; Sorli, Jose V.; Castaner, Olga; Fiol, Miquel; Navarrete-Munoz, Eva M.; Aros, Fernando; Gomez-Gracia, Enrique; Angeles Zulet, M.; Sanchez-Villegas, Almudena; Casas, Rosa; Bernal-Lopez, Rosa; Santos-Lozano, Jose M.; Corbella, Emili; Bouzas, Cristina; Garcia-Arellano, Ana; Basora, Josep; Asensio, Eva M.; Schroder, Helmut; Monino, Manuel; Garcia de la Hera, Manoli; Tojal-Sierra, Lucas; Toledo, Estefania; Diaz-Lopez, Andres; Goday, Albert; Salas-Salvado, Jordi; Martinez-Gonzalez, Miguel A.			Effect of a Nutritional and Behavioral Intervention on Energy-Reduced Mediterranean Diet Adherence Among Patients With Metabolic Syndrome: Interim Analysis of the PREDIMED-Plus Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WEIGHT-LOSS; METAANALYSIS; DISEASE; HEALTH; CHOLESTEROL; MEN	Key PointsQuestionWhat is the effect of a nutritional and behavioral intervention focused on encouraging an energy-reduced Mediterranean diet and physical activity on the dietary pattern of participants after 12 months? FindingsIn this preliminary analysis of an ongoing randomized clinical trial involving 6874 participants, an intervention focused on encouraging an energy-reduced Mediterranean diet and promoting physical activity, compared with advice to follow an energy-unrestricted Mediterranean diet, resulted in a significant increase in a measure of diet adherence, the 17-item energy-reduced Mediterranean diet score, at 12 months (4.7 points vs 2.5 points; score range, 0-17; minimal clinically important difference, 1 point). MeaningA nutritional and behavioral intervention focused on encouraging an energy-reduced Mediterranean diet and physical activity led to a significant improvement in a measure of diet adherence at 12 months. Further evaluation of the effects on long-term cardiovascular and other health outcomes is needed. ImportanceHigh-quality dietary patterns may help prevent chronic disease, but limited data exist from randomized trials about the effects of nutritional and behavioral interventions on dietary changes. ObjectiveTo assess the effect of a nutritional and physical activity education program on dietary quality. Design, Setting, and ParticipantsPreliminary exploratory interim analysis of an ongoing randomized trial. In 23 research centers in Spain, 6874 men and women aged 55 to 75 years with metabolic syndrome and no cardiovascular disease were enrolled in the trial between September 2013 and December 2016, with final data collection in March 2019. InterventionsParticipants were randomized to an intervention group that encouraged an energy-reduced Mediterranean diet, promoted physical activity, and provided behavioral support (n=3406) or to a control group that encouraged an energy-unrestricted Mediterranean diet (n=3468). All participants received allotments of extra-virgin olive oil (1 L/mo) and nuts (125 g/mo) for free. Main Outcomes and MeasuresThe primary outcome was 12-month change in adherence based on the energy-reduced Mediterranean diet (er-MedDiet) score (range, 0-17; higher scores indicate greater adherence; minimal clinically important difference, 1 point). ResultsAmong 6874 randomized participants (mean [SD] age, 65.0 [4.9] years; 3406 [52%] men), 6583 (96%) completed the 12-month follow-up and were included in the main analysis. The mean (SD) er-MedDiet score was 8.5 (2.6) at baseline and 13.2 (2.7) at 12 months in the intervention group (increase, 4.7 [95% CI, 4.6-4.8]) and 8.6 (2.7) at baseline and 11.1 (2.8) at 12 months in the control group (increase, 2.5 [95% CI, 2.3-2.6]) (between-group difference, 2.2 [95% CI, 2.1-2.4]; P<.001). Conclusions and RelevanceIn this preliminary analysis of an ongoing trial, an intervention that encouraged an energy-reduced Mediterranean diet and physical activity, compared with advice to follow an energy-unrestricted Mediterranean diet, resulted in a significantly greater increase in diet adherence after 12 months. Further evaluation of long-term cardiovascular effects is needed. Trial Registrationisrctn.com Identifier: ISRCTN89898870 This preliminary exploratory analysis of the ongoing PREDIMED-Plus randomized trial reports dietary adherence among Spanish community-dwelling participants with metabolic syndrome randomized to an energy-reduced Mediterranean diet, physical activity, and behavioral support vs an energy-unrestricted Mediterranean diet alone.	[Sayon-Orea, Carmen; Razquin, Cristina; Bullo, Monica; Corella, Dolores; Fito, Montserrat; Romaguera, Dora; Vioque, Jesus; Alonso-Gomez, Angel M.; Warnberg, Julia; Alfredo Martinez, J.; Serra-Majem, Luis; Estruch, Ramon; Tinahones, Francisco J.; Lapetra, Jose; Pinto, Xavier; Tur, Josep A.; Lopez-Miranda, Jose; Bueno-Cavanillas, Aurora; Delgado-Rodriguez, Miguel; Matia-Martin, Pilar; Daimiel, Lidia; Martin Sanchez, Vicente; Vidal, Josep; Vazquez, Clotilde; Ros, Emilio; Ruiz-Canela, Miguel; Sorli, Jose V.; Castaner, Olga; Fiol, Miquel; Navarrete-Munoz, Eva M.; Aros, Fernando; Gomez-Gracia, Enrique; Angeles Zulet, M.; Sanchez-Villegas, Almudena; Casas, Rosa; Bernal-Lopez, Rosa; Santos-Lozano, Jose M.; Corbella, Emili; Bouzas, Cristina; Garcia-Arellano, Ana; Basora, Josep; Asensio, Eva M.; Schroder, Helmut; Monino, Manuel; Garcia de la Hera, Manoli; Tojal-Sierra, Lucas; Toledo, Estefania; Diaz-Lopez, Andres; Goday, Albert; Salas-Salvado, Jordi; Martinez-Gonzalez, Miguel A.] Inst Salud Carlos III, Ctr Invest Biomed Red CIBER, Madrid, Spain	CIBER - Centro de Investigacion Biomedica en Red; Instituto de Salud Carlos III	Martinez-Gonzalez, MA (corresponding author), Univ Navarra, Dept Prevent Med & Publ Hlth, C Irunlarrea 1, Navarra 31080, Spain.; Salas-Salvado, J (corresponding author), Univ Rovira & Virgili, Fac Med & Hlth Sci, Human Nutr Unit, C St Llorenc 21, Tarragona 43201, Spain.	jordi.salas@urv.cat; mamartinez@unav.es	Razquin, Cristina/H-2366-2017; Moñino, Manuel/AAD-3308-2020; Tur, Josep/AAE-5748-2020; Sanchez-Villegas, Almudena/T-6733-2019; Pintó, Xavier/AGI-4297-2022; Ruiz-Canela, Miguel/I-7738-2016; Martinez-Gonzalez, Miguel A./AAE-7669-2019; Toledo, Estefania/H-6211-2014; Salas-Salvado, Jordi/C-7229-2017; Estruch, Ramon/AAZ-3723-2020; Navarrete-Muñoz, Eva Maria/F-1666-2011; Schroder, Helmut/G-2586-2015; Warnberg, Julia/G-1390-2011; Fiol, Miguel/F-6793-2016; Corbella, Emili/AGI-4105-2022; Tinahones, Francisco José/AAB-2882-2020; Salas-Huetos, Albert/A-8509-2011; Martin, Vicente/GRE-8306-2022; Bulló, Mònica/F-2925-2016; Casas, Rosa/ABD-1915-2020; Romaguera, Dora/ABE-7004-2020; vioque, jesus/A-1066-2008; Martin, Vicente/ABF-2276-2021; Martin, Vicente/A-1597-2008; Romaguera, Dora/AAB-2852-2020; Bueno Cavanillas, Aurora/O-1513-2015; Daimiel-Ruiz, Lidia Angeles/M-7779-2014; Sayon-Orea, Carmen/A-9828-2017	Razquin, Cristina/0000-0003-3480-2645; Moñino, Manuel/0000-0003-1230-8013; Tur, Josep/0000-0002-6940-0761; Sanchez-Villegas, Almudena/0000-0001-7733-9238; Pintó, Xavier/0000-0002-2216-2444; Ruiz-Canela, Miguel/0000-0002-7684-2787; Toledo, Estefania/0000-0002-6263-4434; Salas-Salvado, Jordi/0000-0003-2700-7459; Schroder, Helmut/0000-0003-2231-5081; Warnberg, Julia/0000-0002-8408-316X; Fiol, Miguel/0000-0002-5370-1391; Corbella, Emili/0000-0001-8818-1907; Salas-Huetos, Albert/0000-0001-5914-6862; Martin, Vicente/0000-0003-0552-2804; Bulló, Mònica/0000-0002-0218-7046; Casas, Rosa/0000-0002-0211-9166; Romaguera, Dora/0000-0002-5762-8558; vioque, jesus/0000-0002-2284-148X; Martin, Vicente/0000-0003-0552-2804; GARCIA ARELLANO, ANA/0000-0003-1491-9627; Bueno Cavanillas, Aurora/0000-0002-0649-3016; Vidal, Josep/0000-0002-4564-4518; Daimiel-Ruiz, Lidia Angeles/0000-0001-9898-6629; Bouzas Velasco, Cristina/0000-0002-1407-8461; Castaner Nino, Olga/0000-0003-3169-997X; Compan Gabucio, Laura M/0000-0001-5324-1535; Tinahones, Francisco J/0000-0001-6871-4403; Domenech, Monica/0000-0001-5447-6686; Sayon-Orea, Carmen/0000-0002-4137-3263; Basora, Josep/0000-0003-0278-1149; Garcia de la Hera, Manuela/0000-0001-5742-2704; Tojal Sierra, Lucas/0000-0001-5338-9601; Sorli, Jose V/0000-0002-0130-2006	European Research Council [340918]; CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn); Instituto de Salud Carlos III (ISCIII) through the Fondo de Investigacion para la Salud (FIS) - European Regional Development Fund [PI13/00673, PI13/00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/00728, PI13/01090, PI13/01056, PI14/01722, PI14/00636, PI14/00618, PI14/00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI14/00972, PI14/00728, PI14/01471, PI16/00473, PI16/00662, PI16/01873, PI16/01094, PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120, PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827, PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926, PI19/00957, PI19/00386, PI19/00309, PI19/01032, PI19/00576, PI19/00017, PI19/01226, PI19/00781, PI19/01560, PI19/01332]; Especial Action Project "Implementacion y evaluacion de una intervencion intensivasobre la actividad fisica Cohorte PREDIMED-Plus"; Recercaixa [2013ACUP00194]; SEMERGEN grant; International Nut and Dried Fruit Council-FESNAD [201302]; AstraZeneca; Consejeria de Salud de la Junta de Andalucia [PI0458/2013, PS0358/2016, PI0137/2018]; Generalitat Valenciana [PROMETEO/2017/017]; Balearic Islands Gov [35/2011]	European Research Council(European Research Council (ERC)European Commission); CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn); Instituto de Salud Carlos III (ISCIII) through the Fondo de Investigacion para la Salud (FIS) - European Regional Development Fund; Especial Action Project "Implementacion y evaluacion de una intervencion intensivasobre la actividad fisica Cohorte PREDIMED-Plus"; Recercaixa(La Caixa Foundation); SEMERGEN grant; International Nut and Dried Fruit Council-FESNAD; AstraZeneca(AstraZeneca); Consejeria de Salud de la Junta de Andalucia(Junta de Andalucia); Generalitat Valenciana(Center for Forestry Research & Experimentation (CIEF)European Commission); Balearic Islands Gov	This work was supported by the European Research Council (Advanced Research grant 2014-2019; agreement #340918; granted to Dr Martinez-Gonzalez); the official Spanish institutions for funding scientific biomedical research, CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn) and Instituto de Salud Carlos III (ISCIII) through the Fondo de Investigacion para la Salud (FIS), which is cofunded by the European Regional Development Fund (coordinated FIS projects led by Drs Salas-Salvado and Vidal, including the following projects: PI13/00673, PI13/00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/00728, PI13/01090, PI13/01056, PI14/01722, PI14/00636, PI14/00618, PI14/00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI14/00972, PI14/00728, PI14/01471, PI16/00473, PI16/00662, PI16/01873, PI16/01094, PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120, PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827, PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926, PI19/00957, PI19/00386, PI19/00309, PI19/01032, PI19/00576, PI19/00017, PI19/01226, PI19/00781, PI19/01560, PI19/01332) and the Especial Action Project "Implementacion y evaluacion de una intervencion intensivasobre la actividad fisica Cohorte PREDIMED-Plus" (Dr Salas-Salvado); the Recercaixa (grant number 2013ACUP00194) (Dr Salas-Salvado); the SEMERGEN grant; International Nut and Dried Fruit Council-FESNAD (Long-term effects of an energy-restricted Mediterranean diet on mortality and cardiovascular disease 2014 -2015; No. 201302) (Dr Martinez-Gonzalez); the AstraZeneca Young Investigators Award in Category of Obesity and T2D 2017 (Dr Romaguera); grants from the Consejeria de Salud de la Junta de Andalucia (PI0458/2013; PS0358/2016; PI0137/2018), the PROMETEO/2017/017 grant from the Generalitat Valenciana, the SEMERGEN grant; grant of support to research groups 35/2011 (Balearic Islands Gov; FEDER funds) (Drs Tur and Bouzas).	Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5; Diaz-Lopez A, 2015, DIABETES CARE, V38, P2134, DOI 10.2337/dc15-1117; Esposito K, 2011, METAB SYNDR RELAT D, V9, P1, DOI 10.1089/met.2010.0031; Estruch R, 2018, NEW ENGL J MED, V378, DOI [10.1056/NEJMoa1800389, 10.1056/nejmoa1800389]; Ezzati M, 2017, LANCET, V390, P2627, DOI 10.1016/S0140-6736(17)32129-3; Feldman AL, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4081-6; Fernandez-Ballarth JD, 2010, BRIT J NUTR, V103, P1808, DOI 10.1017/S0007114509993837; Fung TT, 2018, AM J CLIN NUTR, V107, P120, DOI 10.1093/ajcn/nqx015; Gonzalez-Muniesa P, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.34; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; Maillot M, 2011, AM J CLIN NUTR, V94, P1127, DOI 10.3945/ajcn.111.016501; Martinez-Gonzalez MA, 2005, PUBLIC HEALTH NUTR, V8, P920, DOI 10.1079/PHN2005745; Martinez-Gonzalez MA, 2019, CIRC RES, V124, P779, DOI 10.1161/CIRCRESAHA.118.313348; Martinez-Gonzalez MA, 2019, INT J EPIDEMIOL, V48, P387, DOI 10.1093/ije/dyy225; Martinez-Gonzalez MA, 2013, NEW ENGL J MED, V369, P2357, DOI 10.1056/NEJMc1312802; Molina L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168148; Moreiras O., 2007, TABLA COMPOSICION AL, P37; Narayan KMV, 2019, ANN INTERN MED, V170, P330, DOI 10.7326/M18-3653; Nordestgaard BG, 2014, LANCET, V384, P626, DOI 10.1016/S0140-6736(14)61177-6; Rosato V, 2019, EUR J NUTR, V58, P173, DOI 10.1007/s00394-017-1582-0; Ruiz-Canela M, 2014, JAMA-J AM MED ASSOC, V311, P415, DOI 10.1001/jama.2013.280618; Salas-Salvado J, 2019, DIABETES CARE, V42, P777, DOI 10.2337/dc18-0836; Salas-Salvado J, 2014, ANN INTERN MED, V160, P1, DOI 10.7326/M13-1725; Sanchez-Tainta A, 2016, EUR J NUTR, V55, P93, DOI 10.1007/s00394-014-0828-3; Schliemann D, 2019, PUBLIC HEALTH NUTR, V22, P942, DOI 10.1017/S1368980018003750; Schroder H, 2011, J NUTR, V141, P1140, DOI 10.3945/jn.110.135566; Schwingshackl L, 2014, NUTR METAB CARDIOVAS, V24, P929, DOI 10.1016/j.numecd.2014.03.003; Sokka T, 2008, CLIN EXP RHEUMATOL, V26, pS35, DOI 10.1161/CIRCULATIONAHA.109.192644; Spahn JM, 2010, J AM DIET ASSOC, V110, P879, DOI 10.1016/j.jada.2010.03.021; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Verheijden MW, 2004, J NUTR EDUC BEHAV, V36, P228, DOI 10.1016/S1499-4046(06)60385-0; Willett W., 2013, MONOGRAPHS EPIDEMIOL, V3rd; Williamson DA, 2015, OBESITY, V23, P2319, DOI 10.1002/oby.21358; Xie XF, 2016, LANCET, V387, P435, DOI 10.1016/S0140-6736(15)00805-3	34	54	53	6	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2019	322	15					1486	1499		10.1001/jama.2019.14630	http://dx.doi.org/10.1001/jama.2019.14630			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JI4ST	31613346	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000493458400018
J	Oh, ES; Needham, DM; Nikooie, R; Wilson, LM; Zhang, A; Robinson, KA; Neufeld, KJ				Oh, Esther S.; Needham, Dale M.; Nikooie, Roozbeh; Wilson, Lisa M.; Zhang, Allen; Robinson, Karen A.; Neufeld, Karin J.			Antipsychotics for Preventing Delirium in Hospitalized Adults A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							ELDER LIFE PROGRAM; POSTOPERATIVE DELIRIUM; HALOPERIDOL PROPHYLAXIS; DOUBLE-BLIND; SUBSYNDROMAL DELIRIUM; OLDER; PLACEBO; METAANALYSIS; SURGERY; RISK	Background: Delirium is an acute disorder marked by impairments in attention and cognition, caused by an underlying medical problem. Antipsychotics are used to prevent delirium, but their benefits and harms are unclear. Purpose: To conduct a systematic review evaluating the benefits and harms of antipsychotics for prevention of delirium in adults. Data Sources: PubMed, Embase, CENTRAL, CINAHL, and PsycINFO from inception through July 2019, without restrictions based on study setting, language of publication, or length of follow-up. Study Selection: Randomized, controlled trials (RCTs) that compared an antipsychotic with placebo or another antipsychotic, and prospective observational studies with a comparison group. Data Extraction: One reviewer extracted data and graded the strength of the evidence, and a second reviewer confirmed the data. Two reviewers independently assessed the risk of bias. Data Synthesis: A total of 14 RCTs were included. There were no differences in delirium incidence or duration, hospital length of stay (high strength of evidence [SOE]), and mortality between haloperidol and placebo used for delirium prevention. Little to no evidence was found to determine the effect of haloperidol on cognitive function, delirium severity (insufficient SOE), inappropriate continuation, and sedation (insufficient SOE). There is limited evidence that second-generation antipsychotics may lower delirium incidence in the postoperative setting. There is little evidence that short-term use of antipsychotics was associated with neurologic harms. In some of the trials, potentially harmful cardiac effects occurred more frequently with antipsychotic use. Limitations: There was significant heterogeneity in antipsychotic dosing, route of antipsychotic administration, assessment of outcomes, and adverse events. There were insufficient or no data available to draw conclusions for many of the outcomes. Conclusion: Current evidence does not support routine use of haloperidol or second-generation antipsychotics for prevention of delirium. There is limited evidence that second-generation antipsychotics may lower the incidence of delirium in postoperative patients, but more research is needed. Future trials should use standardized outcome measures. Primary Funding Source: Agency for Healthcare Research and Quality. (PROSPERO: CRD42018109552)	[Oh, Esther S.; Needham, Dale M.; Nikooie, Roozbeh; Robinson, Karen A.; Neufeld, Karin J.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Wilson, Lisa M.; Zhang, Allen] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Neufeld, Karin J.] Johns Hopkins Bayview Med Ctr, Dept Psychiat, A4 Ctr Suite 457,4940 Eastern Ave, Baltimore, MD 21224 USA; [Oh, Esther S.] Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Mason F Lord Bldg Ctr Tower,5200 Eastern Ave, Baltimore, MD 21224 USA; [Robinson, Karen A.] Johns Hopkins Univ, Sch Med, Dept Med, 1830 East Monument St,Room 8068, Baltimore, MD 21287 USA; [Needham, Dale M.; Nikooie, Roozbeh] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, 1830 East Monument St,Fifth Floor, Baltimore, MD 21287 USA; [Wilson, Lisa M.; Zhang, Allen] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 North Broadway,Sixth Floor, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Neufeld, KJ (corresponding author), Johns Hopkins Bayview Med Ctr, Dept Psychiat, A4 Ctr Suite 457,4940 Eastern Ave, Baltimore, MD 21224 USA.	LisaWilson@jhmi.edu; kneufel2@jhmi.edu			Agency for Healthcare Research and Quality [PROSPERO: CRD42018109552]	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Agency for Healthcare Research and Quality. (PROSPERO: CRD42018109552)	Abdelgalel EF, 2016, EGYPT J ANAESTH, V32, P473, DOI 10.1016/j.egja.2016.05.008; Al-Qadheeb NS, 2016, CRIT CARE MED, V44, P583, DOI 10.1097/CCM.0000000000001411; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU; [Anonymous], 2015, J AM COLL SURGEONS, V220, P136, DOI 10.1016/j.jamcollsurg.2014.10.019; [Anonymous], 2014, AHRQ PUBLICATION, V10(12)-EHC063-EF; [Anonymous], 2018, MOB NETW PUBL; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bellelli G, 2014, J AM GERIATR SOC, V62, P1335, DOI 10.1111/jgs.12885; Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528; Chen CCH, 2017, JAMA SURG, V152, P827, DOI 10.1001/jamasurg.2017.1083; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Devlin JW, 2018, CRIT CARE MED, V46, pE825, DOI 10.1097/CCM.0000000000003299; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fick DM, 2017, J AM GERIATR SOC, V65, P2158, DOI 10.1111/jgs.14942; Fukata S, 2014, SURG TODAY, V44, P2305, DOI 10.1007/s00595-014-0859-7; Girard TD, 2010, CRIT CARE MED, V38, P428, DOI 10.1097/CCM.0b013e3181c58715; Gross AL, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0552-4; Hakim SM, 2012, ANESTHESIOLOGY, V116, P987, DOI 10.1097/ALN.0b013e31825153cc; Hardy RJ, 1996, STAT MED, V15, P619, DOI 10.1002/(SICI)1097-0258(19960330)15:6<619::AID-SIM188>3.0.CO;2-A; Herling SF, 2018, COCHRANE DB SYST REV, DOI [10.1002/14651858.C.D009783.pub2, 10.1002/14651858.CD009783.pub2]; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Hshieh TT, 2018, PSYCHIAT CLIN N AM, V41, P1, DOI 10.1016/j.psc.2017.10.001; Hshieh TT, 2017, ANN SURG, V265, P647, DOI 10.1097/SLA.0000000000001952; Inouye SK, 2016, ALZHEIMERS DEMENT, V12, P766, DOI 10.1016/j.jalz.2016.03.005; Inouye SK, 2015, J AM GERIATR SOC, V63, P142, DOI 10.1111/jgs.13281; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; Jones RN, 2019, JAMA INTERN MED, V179, P231, DOI 10.1001/jamainternmed.2018.6975; Kalisvaart KJ, 2005, J AM GERIATR SOC, V53, P1658, DOI 10.1111/j.1532-5415.2005.53503.x; Kaneko Tetsuya, 1999, Yonago Acta Medica, V42, P179; Khan BA, 2018, J AM GERIATR SOC, V66, P2289, DOI 10.1111/jgs.15640; Larsen KA, 2010, PSYCHOSOMATICS, V51, P409, DOI 10.1176/appi.psy.51.5.409; Leslie DL, 2008, ARCH INTERN MED, V168, P27, DOI 10.1001/archinternmed.2007.4; Marcantonio ER, 2001, J AM GERIATR SOC, V49, P516, DOI 10.1046/j.1532-5415.2001.49108.x; Network for Investigation of Delirium: Unifying Scientists (NIDUS), 2018, DEL RES CAT; Neufeld KJ, 2016, J AM GERIATR SOC, V64, P705, DOI 10.1111/jgs.14076; Neufeld KJ, 2019, ANTIPSYCHOTICS FOR T; Nikooie R, 2019, ANN INTERN MED, V171, P485, DOI 10.7326/M19-1860; Oh ES, 2017, JAMA-J AM MED ASSOC, V318, P1161, DOI 10.1001/jama.2017.12067; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; Page VJ, 2013, LANCET RESP MED, V1, P515, DOI 10.1016/S2213-2600(13)70166-8; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Prakanrattana U, 2007, ANAESTH INTENS CARE, V35, P714, DOI 10.1177/0310057X0703500509; Rover C, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0091-1; Rose L, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016371; Rubin FH, 2006, J AM GERIATR SOC, V54, P969, DOI 10.1111/j.1532-5415.2006.00744.x; Saczynski JS, 2012, NEW ENGL J MED, V367, P30, DOI 10.1056/NEJMoa1112923; Santos Eduardo, 2017, JBI Database System Rev Implement Rep, V15, P1440, DOI 10.11124/JBISRIR-2017-003391; Schrijver EJM, 2018, AGE AGEING, V47, P48, DOI 10.1093/ageing/afx124; Scottish Intercollegiate Guidelines Network (SIGN), 2019, SIGN PUBL, V157; Siddiqi N, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005563.pub3; Sieber F, 2019, BRIT J ANAESTH, V122, P480, DOI 10.1016/j.bja.2018.12.021; Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761; U.S. Food and Drug Administration, 2014, PUBLIC HLTH ADVISORY; van den Boogaard M, 2018, JAMA-J AM MED ASSOC, V319, P680, DOI 10.1001/jama.2018.0160; Wang W, 2012, CRIT CARE MED, V40, P731, DOI 10.1097/CCM.0b013e3182376e4f; Witlox J, 2010, JAMA-J AM MED ASSOC, V304, P443, DOI 10.1001/jama.2010.1013; Zayed Y, 2019, J CRIT CARE, V50, P280, DOI 10.1016/j.jcrc.2019.01.009	57	44	46	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	2019	171	7					474	+		10.7326/M19-1859	http://dx.doi.org/10.7326/M19-1859			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JB4LK	31476766				2023-01-03	WOS:000488527900005
J	Tekelab, T; Chojenta, C; Smith, R; Loxton, D				Tekelab, Tesfalidet; Chojenta, Catherine; Smith, Roger; Loxton, Deborah			The impact of antenatal care on neonatal mortality in sub-Saharan Africa: A systematic review and meta-analysis	PLOS ONE			English	Review							PRENATAL-CARE; CHILD-MORTALITY; NATIONAL CAUSES; NEWBORN BABIES; SCALE-UP; HEALTH; INTERVENTIONS; STRATEGIES; COST; STILLBIRTHS	Background Newborns are at greatest risk of dying at and shortly after the time of birth. Newborn mortality remains an urgent concern and is an important indicator of child health, development and well-being. Studies examining the effectiveness of antenatal care on maternal and newborn health outcomes have provided conflicting results. The aim of this review and meta-analysis was to determine the pooled effect of antenatal care on neonatal mortality in sub-Saharan Africa. Methods We searched PubMed, Medline, EMBASE, CINAHL and Google Scholar from September to November 2016 and then updated our search on April 13, 2019. Two independent reviewers extracted data from eligible studies. The quality of each included study was assessed using the Risk of Bias Assessment tool for Non-Randomized Studies (RoBANS). The results were reported based on risk ratio (RR) with 95% confidence intervals (CI) using a random-effects model. Results Eight hundred and ninety eight studies were initially identified. During screening, 23 studies were found to be relevant for data extraction. Of these, only twelve studies fulfilled the inclusion criteria and were included in the analysis. In five of the twelve studies included in the analysis, antenatal care service utilization had a significant association with neonatal mortality. The pooled risk ratio by the random-effects model was 0.61 (95% CI: 0.43, 0.86) for neonates born to women who received at least one antenatal care visit by a skilled provider as compared to neonates born to women who did not receive antenatal care. Conclusion This review indicates that utilization of at least one antenatal care visit by a skilled provider during pregnancy reduces the risk of neonatal mortality by 39% in sub-Saharan African countries. Thus, in order to accelerate progress towards the reduction of newborn deaths, all pregnant women should receive antenatal care during pregnancy.	[Tekelab, Tesfalidet; Chojenta, Catherine; Loxton, Deborah] Univ Newcastle, Fac Hlth & Med, Res Ctr Generat Hlth & Ageing, Newcastle, NSW, Australia; [Tekelab, Tesfalidet] Wollega Univ, Coll Med & Hlth Sci, Nekemte, Oromia, Ethiopia; [Smith, Roger] Univ Newcastle, Hunter Med Res Inst, Mothers & Babies Res Ctr, Newcastle, NSW, Australia	University of Newcastle; Hunter Medical Research Institute; University of Newcastle	Tekelab, T (corresponding author), Univ Newcastle, Fac Hlth & Med, Res Ctr Generat Hlth & Ageing, Newcastle, NSW, Australia.; Tekelab, T (corresponding author), Wollega Univ, Coll Med & Hlth Sci, Nekemte, Oromia, Ethiopia.	ttesfalove@gmail.com	Chojenta, Catherine L/B-2521-2008	Chojenta, Catherine L/0000-0002-2541-4491; Loxton, Deborah/0000-0002-4745-8612; Smith, Roger/0000-0003-4720-0280; Beyene, Dr Tesfalidet/0000-0003-0774-7708				Adam T, 2005, BMJ-BRIT MED J, V331, P1107, DOI 10.1136/bmj.331.7525.1107; [Anonymous], 2009, WOM HLTH TOD EV TOM; Arunda M, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1328796; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bhutta ZA, 2014, LANCET, V384, P347, DOI 10.1016/S0140-6736(14)60792-3; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; BUEKENS P, 1995, INT J GYNECOL OBSTET, V48, P91, DOI 10.1016/0020-7292(94)02265-8; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Carroli G, 2001, LANCET, V357, P1565, DOI 10.1016/S0140-6736(00)04723-1; Central Statistical Agency (CSA) [Ethiopia] and ICF International, 2016, ETH DEM HLTH SURV 20; Chinkhumba J, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1014; Coimbra LC, 2007, BRAZ J MED BIOL RES, V40, P1195, DOI 10.1590/S0100-879X2006005000116; Darmstadt GL, 2008, HEALTH POLICY PLANN, V23, P101, DOI 10.1093/heapol/czn001; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Debelew GT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107184; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Diallo AH, 2011, J PERINATOL, V31, P656, DOI 10.1038/jp.2011.6; Diallo AH, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-45; Dickson KE, 2014, LANCET, V384, P438, DOI 10.1016/S0140-6736(14)60582-1; Doku DT, 2017, INT J EPIDEMIOL, V46, P1668, DOI 10.1093/ije/dyx125; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Engmann C, 2012, TROP MED INT HEALTH, V17, P272, DOI 10.1111/j.1365-3156.2011.02931.x; Engmann C, 2009, INT J GYNECOL OBSTET, V105, P112, DOI 10.1016/j.ijgo.2008.12.012; Ezeh OK, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-521; Farah AE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203314; Graft-Johnson J, 2006, CONTINUUM CARE MATER; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hollenweger J, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S4-S7; Ibrahim J, 2012, J TROP PEDIATRICS, V58, P184, DOI 10.1093/tropej/fmr067; Kidus F, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2243-5; Kim SY, 2013, J CLIN EPIDEMIOL, V66, P408, DOI 10.1016/j.jclinepi.2012.09.016; KOLOLA T, 2016, PLOS ONE, V11, DOI DOI 10.1371/JOURNAL.PONE.0164472; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Lawn JE, 2010, SEMIN PERINATOL, V34, P371, DOI 10.1053/j.semperi.2010.09.011; Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6; Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1; Makate M, 2017, HEALTH POLICY PLANN, V32, P395, DOI 10.1093/heapol/czw154; Mbuagbaw L, 2015, HLTH SYSTEM COMMUNIT; McCurdy RJ, 2011, ACTA OBSTET GYN SCAN, V90, P779, DOI 10.1111/j.1600-0412.2011.01133.x; Moher D, 2015, STATEMENT SYST REV, V4, DOI [10.1186/2046-4053-4-1, DOI 10.1186/2046-4053-4-1, 10.1186/s13643-015-0163-7, DOI 10.14306/RENHYD.20.2.223]; Nankabirwa V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019674; National Population Commission (NPC) [Nigeria] and ICF Macro, 2009, NIG DEM HLTH SURV 20; Oduro AR, 2012, INT J EPIDEMIOL, V41, P968, DOI 10.1093/ije/dys111; Orsido TT, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2227-5; Pandey PK, 2013, INDIAN J OPHTHALMOL, V61, DOI 10.4103/0301-4738.107212; Raven JH, 2012, MIDWIFERY, V28, pE676, DOI 10.1016/j.midw.2011.09.003; Roper MH, 2007, LANCET, V370, P1947, DOI 10.1016/S0140-6736(07)61261-6; Shah D, 2000, INT J GYNECOL OBSTET, V71, P209, DOI 10.1016/S0020-7292(00)00215-0; Titaley CR, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001399; Tura G, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-18; UN, 2019, IMPROVING SUSTAINABL; UN DoEaSA Population Division Population Division, 2015, 241 UN DOEASA ESAPWP; UNICEF, 2017, EST DEV UN INT GROUP; UNICEF, 2014, COMM CHILD SURV PROM; UNICEF, 2016, GLOB DAT 2016 BAS MU; Unicef, 2015, PROGR REP 2015; Welaga P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058924; WHO, 2016, WHO TECH REP SER, V997, P1; WHO, 2006, WHO NEON PER MORT CO; WHO, 2014, EV NEWB ACT PLAN END; World Health Organization, TRENDS MAT MORT 1990; You D, 2015, LEVELS TRENDS CHILD	62	43	43	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 13	2019	14	9							e0222566	10.1371/journal.pone.0222566	http://dx.doi.org/10.1371/journal.pone.0222566			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM4KS	31518365	Green Published, gold, Green Submitted			2023-01-03	WOS:000532219300027
J	Vogt, H; Green, S; Ekstrom, CT; Brodersen, J				Vogt, Henrik; Green, Sara; Ekstrom, Claus Thorn; Brodersen, John			How precision medicine and screening with big data could increase overdiagnosis	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HEALTH RESEARCH; WELLNESS; EVENTS		[Vogt, Henrik] Univ Oslo, Ctr Med Eth, Oslo, Norway; [Vogt, Henrik] Univ Oslo, Hybrid Technol Hub, Oslo, Norway; [Vogt, Henrik] Norwegian Univ Sci & Technol, Gen Practice Res Unit, Trondheim, Norway; [Green, Sara] Univ Copenhagen, Dept Sci Educ, Copenhagen, Denmark; [Green, Sara] Univ Copenhagen, Ctr Med Sci & Technol Studies, Copenhagen, Denmark; [Ekstrom, Claus Thorn] Univ Copenhagen, Dept Publ Hlth, Biostat, Copenhagen, Denmark; [Brodersen, John] Univ Copenhagen, Ctr Res & Educ Gen Practice, Copenhagen, Denmark; [Brodersen, John] Primary Hlth Care Res Unit, Copenhagen, Region Zealand, Denmark	University of Oslo; University of Oslo; Norwegian University of Science & Technology (NTNU); University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen	Vogt, H (corresponding author), Univ Oslo, Ctr Med Eth, Oslo, Norway.; Vogt, H (corresponding author), Univ Oslo, Hybrid Technol Hub, Oslo, Norway.; Vogt, H (corresponding author), Norwegian Univ Sci & Technol, Gen Practice Res Unit, Trondheim, Norway.	henrik.vogt@medisin.uio.no		Ekstrom, Claus Thorn/0000-0003-1191-373X; Brodersen, John Brandt/0000-0001-9369-3376; Green, Sara/0000-0001-7011-7202				Alyass A, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0108-y; Brodersen J, 2018, BMJ EVID-BASED MED, V23, P1, DOI 10.1136/ebmed-2017-110886; Diamandis EP, 2015, BMC MED, V13, DOI 10.1186/s12916-014-0239-6; Few S., 2018, BIG DATA BIG DUPE LI, P96; FIRTH WJ, 1991, BRIT MED J, V303, P1565, DOI 10.1136/bmj.303.6817.1565; Fortmann-Roe S, 2012, UNDERSTANDING BIAS V; Hofmann B, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3314; Johansson M, 2016, BMJ-BRIT MED J, V353, pi2230; Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z; Koshy AN, 2018, INT J CARDIOL, V266, P124, DOI 10.1016/j.ijcard.2018.02.073; Mega JL, 2015, LANCET, V385, P2264, DOI 10.1016/S0140-6736(14)61730-X; National Institutes of Health, 2018, NAT I HLTH COR PROT; Nebert DW, 2012, SCIENCE, V337, P910, DOI 10.1126/science.337.6097.910-a; Pathirana T, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3879; Perkins BA, 2018, P NATL ACAD SCI USA, V115, P3686, DOI 10.1073/pnas.1706096114; Price ND, 2017, NAT BIOTECHNOL, V35, P747, DOI 10.1038/nbt.3870; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; Rose SMSF, 2019, NAT MED, V25, P792, DOI 10.1038/s41591-019-0414-6; Sharon T, 2016, PERS MED, V13, P563, DOI 10.2217/pme-2016-0057; Shendure J, 2019, CELL, V177, P45, DOI 10.1016/j.cell.2019.02.003; Smith GD, 2011, INT J EPIDEMIOL, V40, P537, DOI 10.1093/ije/dyr117; Topol EJ., 2015, PATIENT WILL SEE YOU; Torkamani A, 2017, CELL, V170, P828, DOI 10.1016/j.cell.2017.08.007; Vogt H, 2018, NAT BIOTECHNOL, V36, P678, DOI 10.1038/nbt.4210; Vogt H, 2016, MED HEALTH CARE PHIL, V19, P307, DOI 10.1007/s11019-016-9683-8; Waldo AL, 2017, CIRCULATION, V136, P1795, DOI 10.1161/CIRCULATIONAHA.117.030705; Welch H, 2011, OVERDIAGNOSED MAKING; Weng SF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174944; Wilson JMG, 1968, PRINCIPLES PRACTICE; Xu S, 2019, NATURE, V571, P319, DOI 10.1038/d41586-019-02143-0	30	15	16	2	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 13	2019	366								l5270	10.1136/bmj.l5270	http://dx.doi.org/10.1136/bmj.l5270			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IY8MX	31519649	Green Published			2023-01-03	WOS:000486649800002
J	Beato, M; Bigby, AEJ; De Keijzer, KL; Nakamura, FY; Coratella, G; McErlain-Naylor, SA				Beato, Marco; Bigby, Alexander E. J.; De Keijzer, Kevin L.; Nakamura, Fabio Y.; Coratella, Giuseppe; McErlain-Naylor, Stuart A.			Post-activation potentiation effect of eccentric overload and traditional weightlifting exercise on jumping and sprinting performance in male athletes	PLOS ONE			English	Article							POSTACTIVATION POTENTIATION; SOCCER PLAYERS; MAXIMAL POWER; RELIABILITY; PROTOCOLS; DIRECTION; MUSCLE; SPEED; SQUAT	The aim of this study was to evaluate the post-activation potentiation (PAP) effects following eccentric overload (EOL) and traditional weightlifting (TW) exercise on standing long jump (SLJ), countermovement jump (CMJ), and 5 m sprint acceleration performance. Ten male athletes were involved in a randomized, crossover study. The subjects performed 3 sets of 6 repetitions of EOL or TW half squat exercise followed by SLJ, CMJ, and 5 m sprint tests at 1 min, 3 min and 7 min, in separate sessions using a randomized order. Bayes factor (BF10) was reported to show the strength of the evidence. Differences were found using EOL for SLJ distance at 3 min (BF10 = 7.24, +8%), and 7 min (BF10 = 19.5, +7%), for CMJ at 3 min (BF10 = 3.25, +9%), and 7 min (BF10 = 4.12, +10.5%). Differences were found using TW exercise for SLJ at 3 min (BF10 = 3.88, +9%), and 7 min (BF10 = 12.4, +9%), CMJ at 3 min (BF10 = 7.42, +9.5%), and 7 min (BF10 = 12.4, +12%). No meaningful differences were found between EOL and TW exercises for SLJ (BF10 = 0.33), CMJ (BF10 = 0.27), and 5 m sprint (BF10 = 0.22). In conclusion, EOL and TW exercises acutely increase SLJ and CMJ, but not 5 m sprint performance. The PAP time window was found between 3 min and 7 min using both protocols. This study did not find differences between EOL and TW exercises, and so both methodologies can be used to stimulate a PAP response.	[Beato, Marco; Bigby, Alexander E. J.; De Keijzer, Kevin L.; McErlain-Naylor, Stuart A.] Univ Suffolk, Sch Hlth & Sports Sci, Ipswich, Suffolk, England; [Nakamura, Fabio Y.] Univ Fed Paraiba, Associate Grad Program Phys Educ UPE, Joao Pessoa, Paraiba, Brazil; [Nakamura, Fabio Y.] James Cook Univ, Coll Healthcare Sci, Townsville, Qld, Australia; [Coratella, Giuseppe] Univ Milan, Dept Biomed Sci Hlth, Milan, Italy	Universidade Federal da Paraiba; James Cook University; University of Milan	Beato, M (corresponding author), Univ Suffolk, Sch Hlth & Sports Sci, Ipswich, Suffolk, England.	M.Beato@uos.ac.uk	de Keijzer, Kevin/ABE-9091-2021; McErlain-Naylor, Stuart A./AAS-9715-2020	McErlain-Naylor, Stuart A./0000-0002-9745-138X; Beato, Marco/0000-0001-5373-2211; CORATELLA, GIUSEPPE/0000-0001-7523-9102				Atkinson G, 1998, SPORTS MED, V26, P217, DOI 10.2165/00007256-199826040-00002; Baudry S, 2007, J APPL PHYSIOL, V102, P1394, DOI 10.1152/japplphysiol.01254.2006; Bauer P, 2019, J STRENGTH COND RES, V33, P995, DOI 10.1519/JSC.0000000000002422; Beato M, 2019, J HUM KINET, V69, DOI [10.2478/hukin-2018-0050, DOI 10.2478/HUKIN-2018-0050]; Beato M, 2021, J STRENGTH COND RES, V35, P2616, DOI 10.1519/JSC.0000000000003214; Beato M, 2021, J STRENGTH COND RES, V35, P1825, DOI 10.1519/JSC.0000000000003005; Beato M, 2018, J STRENGTH COND RES, V32, P289, DOI 10.1519/JSC.0000000000002371; Bevan HR, 2010, J STRENGTH COND RES, V24, P701, DOI 10.1519/JSC.0b013e3181c7b68a; Bianchi M, 2019, J SPORT MED PHYS FIT, V59, P910, DOI 10.23736/S0022-4707.18.08804-7; Bishop D, 2003, SPORTS MED, V33, P439, DOI 10.2165/00007256-200333060-00005; Coratella G, 2018, J STRENGTH COND RES, V32, P921, DOI 10.1519/JSC.0000000000002463; Cormie P, 2011, SPORTS MED, V41, P125, DOI 10.2165/11538500-000000000-00000; Cuenca-Fernandez F, 2015, J STRENGTH COND RES, V29, P647, DOI 10.1519/JSC.0000000000000696; de Hoyo M, 2015, INT J SPORTS MED, V36, P308, DOI 10.1055/s-0034-1395521; Dello Iacono A, 2018, J SPORT SCI, V36, P2375, DOI 10.1080/02640414.2018.1458400; Dello Iacono A, 2018, J SPORT SCI, V36, P1269, DOI 10.1080/02640414.2017.1374657; Dello Iacono A, 2016, J STRENGTH COND RES, V30, P3122, DOI 10.1519/JSC.0000000000001393; Docherty D, 2007, INT J SPORT PHYSIOL, V2, P439, DOI 10.1123/ijspp.2.4.439; Enright K, 2018, SCI MED FOOTBALL, V2, P177, DOI 10.1080/24733938.2017.1411603; Golas A, 2017, J STRENGTH COND RES, V31, P3010, DOI 10.1519/JSC.0000000000001917; Golas A, 2016, J HUM KINET, V52, P95, DOI 10.1515/hukin-2015-0197; Gonzalo-Skok O, 2017, INT J SPORT PHYSIOL, V12, P951, DOI 10.1123/ijspp.2016-0251; Lee M.D., 2013, BAYESIAN COGNITIVE M; Markovic G, 2004, J STRENGTH COND RES, V18, P551, DOI 10.1519/00124278-200408000-00028; Mola JN, 2014, J STRENGTH COND RES, V28, P1529, DOI 10.1519/JSC.0000000000000313; Robbins DW, 2005, J STRENGTH COND RES, V19, P898; Sainani KL, 2018, MED SCI SPORT EXER, V50, P2611, DOI 10.1249/MSS.0000000000001737; Sale DG, 2002, EXERC SPORT SCI REV, V30, P138, DOI 10.1097/00003677-200207000-00008; Scott SL, 2004, J STRENGTH COND RES, V18, P201; Seitz LB, 2016, SPORTS MED, V46, P231, DOI 10.1007/s40279-015-0415-7; Suchomel TJ, 2016, SPORTS MED, V46, P1419, DOI 10.1007/s40279-016-0486-0; Tillin NA, 2009, SPORTS MED, V39, P147, DOI 10.2165/00007256-200939020-00004; Tous-Fajardo J, 2016, INT J SPORT PHYSIOL, V11, P66, DOI 10.1123/ijspp.2015-0010; VANDOORN J, 2019, JASP GUIDELINES COND; Vicens-Bordas J, 2018, J SCI MED SPORT, V21, P2, DOI 10.1016/j.jsams.2017.09.001; Westfall PH, 1997, BIOMETRIKA, V84, P419, DOI 10.1093/biomet/84.2.419	37	24	25	4	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2019	14	9							e0222466	10.1371/journal.pone.0222466	http://dx.doi.org/10.1371/journal.pone.0222466			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM4IG	31513671	Green Submitted, gold, Green Accepted, Green Published			2023-01-03	WOS:000532212700084
J	Feinberg, J				Feinberg, Judith			Tackle the epidemic, not the opioids	NATURE			English	Editorial Material									[Feinberg, Judith] West Virginia Univ, Behav Med Psychiat & Infect Dis, Morgantown, WV 26506 USA	West Virginia University	Feinberg, J (corresponding author), West Virginia Univ, Behav Med Psychiat & Infect Dis, Morgantown, WV 26506 USA.	judith.feinberg@hsc.wvu.edu		feinberg, judith/0000-0003-4206-7214	NIGMS NIH HHS [U54 GM104942] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))			0	7	7	1	4	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 12	2019	573	7773					165	165		10.1038/d41586-019-02671-9	http://dx.doi.org/10.1038/d41586-019-02671-9			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IX0XA	31501585	Bronze, Green Accepted			2023-01-03	WOS:000485415400021
J	Onwuneme, G				Onwuneme, Gloria			Meet the occupational therapist: Niamh O'Flaherty	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Onwuneme, Gloria] United Lincolnshire Hosp NHS Trust, Lincoln, England		Onwuneme, G (corresponding author), United Lincolnshire Hosp NHS Trust, Lincoln, England.	gn.onwuneme@yahoo.com							0	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	2019	366								l4890	10.1136/bmj.l4890	http://dx.doi.org/10.1136/bmj.l4890			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IX1DI	31477577				2023-01-03	WOS:000485431800002
J	Valente, JDS; Fiedler, RA; Heidemann, MS; Molento, CFM				Soares Valente, Julia de Paula; Fiedler, Rodrigo Alonso; Heidemann, Marina Sucha; Maiolino Molento, Carla Forte			First glimpse on attitudes of highly educated consumers towards cell-based meat and related issues in Brazil	PLOS ONE			English	Article							CULTURED MEAT; ANIMAL-WELFARE; STEM-CELLS; CHALLENGES; CONSUMPTION; ACCEPTANCE	Our aim was to study Brazilian consumer attitudes towards cell-based meat and related issues. From 408 respondents from Curitiba and 218 from Joinville, the majority was women with higher level of education; 65.2% and 70.2% frequently consumed meat and 50.7% and 50.9% would not stop eating meat; 81.6% and 82.6% had little or no knowledge about cell-based meat. After watching an explanatory video, 41.9% and 34.4% stated they would eat cell-based meat without restrictions; 24.5% and 23.9% stated they would try depending on conditionals. Overall, 63.6% declared they would eat cell-based meat; among vegetarians and vegans, 24% and 8% stated they would eat cell-based meat, with additional 25.0% and 27.0% stating "it depends"; thus, the major public for cell-based meat seems to be meat eaters. Animal welfare was the principal reason for considering not eating meat and a major benefit of cell-based meat. In conclusion, the majority of respondents would not stop eating meat; additionally, they would eat cell-based meat.	[Soares Valente, Julia de Paula; Fiedler, Rodrigo Alonso; Heidemann, Marina Sucha; Maiolino Molento, Carla Forte] Univ Fed Parana, Anim Welf Lab, Curitiba, Parana, Brazil	Universidade Federal do Parana	Molento, CFM (corresponding author), Univ Fed Parana, Anim Welf Lab, Curitiba, Parana, Brazil.	carlamolento@ufpr.br	de Paula Soares Valente, Julia/AAO-7098-2021; VALENTE, JÚLIA/AAH-7114-2020	Molento, Carla Forte Maiolino/0000-0003-1408-7891	CAPES (Coordination for the Improvement of Higher Education Personnel) [025/2014]	CAPES (Coordination for the Improvement of Higher Education Personnel)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	Grant number 025/2014, CAPES (Coordination for the Improvement of Higher Education Personnel), awarded to C. F. M. M. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors gladly acknowledge all anonymous respondents involved in this study and the assistance provided by Juliana da Costa Cidral in inviting respondents in Joinville. Also, we are thankful for the financial support granted by CAPES (Coordination for the Improvement of Higher Education Personnel), grant number 025/2014, awarded to CFMM.	[Anonymous], 2018, BRAZ LIV PROD ANN AN; Bar-On YM, 2018, P NATL ACAD SCI USA, V115, P6506, DOI 10.1073/pnas.1711842115; Bekker GA, 2017, APPETITE, V108, P245, DOI 10.1016/j.appet.2016.10.002; Bryant C, 2019, FRONT NUTR, V6, DOI 10.3389/fnut.2019.00103; Datar I, 2010, INNOV FOOD SCI EMERG, V11, P13, DOI 10.1016/j.ifset.2009.10.007; Day L, 2013, TRENDS FOOD SCI TECH, V32, P25, DOI 10.1016/j.tifs.2013.05.005; De Backer CJS, 2015, MEAT SCI, V99, P68, DOI 10.1016/j.meatsci.2014.08.011; Gasteratos K. S., 2018, CONSUMER INTEREST CL; GOODMAN LA, 1961, ANN MATH STAT, V32, P148, DOI 10.1214/aoms/1177705148; Graca J, 2015, APPETITE, V90, P80, DOI 10.1016/j.appet.2015.02.037; Grandin T, 2014, MEAT SCI, V98, P461, DOI 10.1016/j.meatsci.2014.05.011; Hartmann C, 2017, TRENDS FOOD SCI TECH, V61, P11, DOI 10.1016/j.tifs.2016.12.006; Hoek AC, 2011, APPETITE, V56, P662, DOI 10.1016/j.appet.2011.02.001; Hoek AC, 2011, FOOD QUAL PREFER, V22, P371, DOI 10.1016/j.foodqual.2011.01.008; Ingvar Ekesbo, 2018, FARM ANIMAL BEHAV CH; Instituto Brasileiro de Geografia e Estatistica, 2017, PROD AGR MUN; Instituto Brasileiro de Geografia e Estatistica-IBGE, 2010, CENS DEM; Instituto Brasileiro de Opiniao Publica e Estatistica, 2018, 14 POP SE DECL VEG; Instituto Brasileiro de Publica e Estatistica, 2012, DIA MUND VEG 8 POP B; Kadim IT, 2015, J INTEGR AGR, V14, P222, DOI 10.1016/S2095-3119(14)60881-9; Laestadius LI, 2015, PUBLIC HEALTH NUTR, V18, P2457, DOI 10.1017/S1368980015000622; Lynch J, 2019, FRONTIERS SUSTAINABL, V3; Malhotra Naresh K, 2008, PESQUISA MARKETING O; Mancini MC, 2019, MEAT SCI, V150, P101, DOI 10.1016/j.meatsci.2018.12.014; Maria Schlindwein Madalena, 2006, REV ECON SOCIOL RURA, V44, P549, DOI [10.1590/S0103-20032006000300009, DOI 10.1590/S0103-20032006000300009]; Mattick CS, 2015, ENVIRON SCI TECHNOL, V49, P11941, DOI 10.1021/acs.est.5b01614; Parker HW, 2019, NUTR REV, V77, P144, DOI 10.1093/nutrit/nuy067; Paul Shapiro, 2018, CLEAN MEAT; Post MJ, 2012, MEAT SCI, V92, P297, DOI 10.1016/j.meatsci.2012.04.008; Robinson TP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096084; Ruby MB, 2011, APPETITE, V56, P447, DOI 10.1016/j.appet.2011.01.018; Santos G., 2017, TRANSFORMING PATRIAR; Schosler H, 2015, APPETITE, V89, P152, DOI 10.1016/j.appet.2015.02.013; Siegrist M, 2017, APPETITE, V113, P320, DOI 10.1016/j.appet.2017.03.019; Stephens N, 2018, TRENDS FOOD SCI TECH, V78, P155, DOI 10.1016/j.tifs.2018.04.010; Tuomisto HL, 2011, ENVIRON SCI TECHNOL, V45, P6117, DOI 10.1021/es200130u; Verbeke W, 2015, J INTEGR AGR, V14, P285, DOI 10.1016/S2095-3119(14)60884-4; Verbeke W, 2015, MEAT SCI, V102, P49, DOI 10.1016/j.meatsci.2014.11.013; Wilks M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171904	39	30	30	2	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2019	14	8							e0221129	10.1371/journal.pone.0221129	http://dx.doi.org/10.1371/journal.pone.0221129			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW6BO	31469862	Green Submitted, Green Published, gold			2023-01-03	WOS:000485062200011
J	Oz, E				Oz, Emel			Effects of smoke flavoring using different wood chips and barbecuing on the formation of polycyclic aromatic hydrocarbons and heterocyclic aromatic amines in salmon fillets	PLOS ONE			English	Article							COOKING METHODS; MODEL SYSTEMS; COOKED FOODS; MEAT; FISH; RISKS; PAHS; ANTIOXIDANTS; CHEMISTRY; RESIDUES	Herein, the concentrations of food toxicants, polycyclic aromatic hydrocarbons (PAHs) and heterocyclic aromatic amines (HAAs), in salmon fillets smoke flavored with different smoking wood chips (oak, apple, bourbon soaked oak, cherry and hickory) and barbecuing were determined. Benzo[a]anthracene (up to 0.24 ng/g) and chrysene (0.22 ng/g) were determined in the raw salmon fillets. While Sigma PAH8 (benzo[a]anthracene, chrysene, benzo[b] fluoranthene, benzo[k]fluoranthene, benzo[a]pyrene, dibenzo[a,h]anthracene, benzo[g,h,i] perylene, indeno[1,2,3-cd]pyrene) in the raw samples ranged between 0.44 and 0.46 ng/g, smoke flavoring increased the amount of Sigma PAH8 and the amount varied between 0.47 and 0.73 ng/g. Salmon smoked flavored with bourbon soaked oak, cherry and hickory wood chips and barbecued showed significantly (P < 0.05) lower contents of Sigma PAH4 (benzo[a] anthracene, chrysene, benzo[b]fluoranthene, benzo[a]pyrene) and Sigma PAH8 compared to non-smoke flavored barbecued samples. Additionally, smoke flavoring with apple, bourbon soaked oak, and cherry wood chips significantly (P < 0.05) reduced the total HAA contents in barbecued salmon. A remarkable result was that the bourbon-soaked oak and cherry wood chips had inhibitory effects on both PAH and HAA contents. In sum, barbecued non-smoke flavored and smoke flavored salmon with different wood chips could be considered safe from the perspective of the detected amounts of PAHs and HAAs in salmon fillets.	[Oz, Emel] Ataturk Univ, Fac Agr, Dept Food Engn, Erzurum, Turkey	Ataturk University	Oz, E (corresponding author), Ataturk Univ, Fac Agr, Dept Food Engn, Erzurum, Turkey.	emel.oz@atauni.edu.tr		Oz, Emel/0000-0003-3766-2713				Britt C, 1998, J AGR FOOD CHEM, V46, P4891, DOI 10.1021/jf980233y; Chiu CP, 1998, J FOOD PROTECT, V61, P712, DOI 10.4315/0362-028X-61.6.712; Costa M, 2009, J AGR FOOD CHEM, V57, P3173, DOI 10.1021/jf8035808; Duedahl-Olesen L, 2015, FOOD CONTROL, V57, P169, DOI 10.1016/j.foodcont.2015.04.012; Farhadian A, 2011, FOOD CHEM, V124, P141, DOI 10.1016/j.foodchem.2010.05.116; Forsberg ND, 2012, J AGR FOOD CHEM, V60, P6899, DOI 10.1021/jf300978m; GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010, IARC Monogr Eval Carcinog Risks Hum, V92, P1; Iwasaki M, 2010, J FOOD COMPOS ANAL, V23, P61, DOI 10.1016/j.jfca.2009.07.004; Janoszka B, 2011, FOOD CHEM, V126, P1344, DOI 10.1016/j.foodchem.2010.11.097; Kjallstrand J, 2001, FOOD CHEM, V74, P85, DOI 10.1016/S0308-8146(01)00102-9; Malarut JA, 2018, FOOD CONTROL, V85, P98, DOI 10.1016/j.foodcont.2017.09.020; Messner C, 2004, J CHROMATOGR B, V802, P19, DOI 10.1016/j.jchromb.2003.11.015; Moazzen M, 2013, TALANTA, V115, P957, DOI 10.1016/j.talanta.2013.07.005; Murkovic M, 2004, EUR J LIPID SCI TECH, V106, P777, DOI 10.1002/ejlt.200400993; NAGAO M, 1977, CANCER LETT, V2, P221, DOI 10.1016/S0304-3835(77)80025-6; Oz E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221680; Oz F, 2010, LWT-FOOD SCI TECHNOL, V43, P1345, DOI 10.1016/j.lwt.2010.04.014; Oz F, 2016, FOOD CONTROL, V67, P216, DOI 10.1016/j.foodcont.2016.03.013; Oz F, 2016, FOOD CHEM, V203, P59, DOI 10.1016/j.foodchem.2016.02.041; Oz F, 2011, J FOOD PROCESS PRES, V35, P739, DOI 10.1111/j.1745-4549.2011.00524.x; Pais P, 1999, J AGR FOOD CHEM, V47, P1098, DOI 10.1021/jf980644e; Phillips DH, 1999, MUTAT RES-GEN TOX EN, V443, P139, DOI 10.1016/S1383-5742(99)00016-2; Pohlmann M, 2013, FOOD CONTROL, V34, P347, DOI 10.1016/j.foodcont.2013.05.005; Puangsombat K, 2012, MEAT SCI, V90, P739, DOI 10.1016/j.meatsci.2011.11.005; Remy CC, 2016, J ETHNOBIOL, V36, P312, DOI 10.2993/0278-0771-36.2.312; Rose M, 2015, FOOD CHEM TOXICOL, V78, P1, DOI 10.1016/j.fct.2014.12.018; Sidhu KS, 2003, REGUL TOXICOL PHARM, V38, P336, DOI 10.1016/j.yrtph.2003.07.002; Skog K, 2002, FOOD CHEM TOXICOL, V40, P1197, DOI 10.1016/S0278-6915(02)00052-2; Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1; Stolyhwo A, 2005, FOOD CHEM, V91, P303, DOI 10.1016/j.foodchem.2004.06.012; Storelli MM, 2003, J FOOD PROTECT, V66, P1095, DOI 10.4315/0362-028X-66.6.1095; Stumpe-Viksna I, 2008, FOOD CHEM, V110, P794, DOI 10.1016/j.foodchem.2008.03.004; Sun YQ, 2019, TRENDS FOOD SCI TECH, V83, P86, DOI 10.1016/j.tifs.2018.11.015; Toth L., 1984, Advances in Food Research, V29, P87; Rahman UU, 2014, LWT-FOOD SCI TECHNOL, V59, P229, DOI 10.1016/j.lwt.2014.06.005; Viegas O, 2012, FOOD CHEM TOXICOL, V50, P2128, DOI 10.1016/j.fct.2012.03.051; Visciano P, 2006, J FOOD PROTECT, V69, P1134, DOI 10.4315/0362-028X-69.5.1134; Visciano P, 2009, INT J FOOD SCI TECH, V44, P2028, DOI 10.1111/j.1365-2621.2009.02026.x; Vitaglione P, 2004, J CHROMATOGR B, V802, P189, DOI 10.1016/j.jchromb.2003.09.029; WEISBURGER JH, 1994, CANCER LETT, V83, P143, DOI 10.1016/0304-3835(94)90311-5; Zachara A, 2017, FOOD CONTROL, V80, P45, DOI 10.1016/j.foodcont.2017.04.024	42	17	19	6	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2020	15	1							e0227508	10.1371/journal.pone.0227508	http://dx.doi.org/10.1371/journal.pone.0227508			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ7KG	31935242	gold, Green Published			2023-01-03	WOS:000530339100001
J	Silverstein, M; Hsu, HE; Bell, A				Silverstein, Michael; Hsu, Heather E.; Bell, Alastair			Addressing Social Determinants to Improve Population Health The Balance Between Clinical Care and Public Health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Silverstein, Michael; Hsu, Heather E.; Bell, Alastair] Boston Med Ctr, One Boston Med Ctr Pl, Boston, MA 02118 USA; [Silverstein, Michael; Hsu, Heather E.] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA	Boston Medical Center; Boston University	Silverstein, M (corresponding author), Boston Med Ctr, One Boston Med Ctr Pl, Boston, MA 02118 USA.	Michael.Silverstein@bmc.org		Hsu, Heather/0000-0002-5863-1804				Braveman P, 2011, ANNU REV PUBL HEALTH, V32, P381, DOI 10.1146/annurev-publhealth-031210-101218; Curry SJ, 2019, JAMA-J AM MED ASSOC, V321, P1502, DOI 10.1001/jama.2019.3326; Daniel H, 2018, ANN INTERN MED, V168, P577, DOI 10.7326/M17-2441; Davidson KW, 2019, JAMA-J AM MED ASSOC, V322, P1037, DOI 10.1001/jama.2019.10915; Kindig D, 2003, AM J PUBLIC HEALTH, V93, P380, DOI 10.2105/AJPH.93.3.380; National Academies of Science Engineering and Medicine, 2019, INT SOC CAR DEL HLTH; Siu AL, 2016, JAMA-J AM MED ASSOC, V315, P380, DOI 10.1001/jama.2015.18392; US Department of Health and Human Services, VIOL PSYCH HARM TRAU; Wilper AP, 2009, HEALTH AFFAIR, V28, pW1151, DOI 10.1377/hlthaff.28.6.w1151; ZORITCH B, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000564	10	23	23	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	2019	322	24					2379	2380		10.1001/jama.2019.18055	http://dx.doi.org/10.1001/jama.2019.18055			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JZ6JW	31790542				2023-01-03	WOS:000505209400008
J	Olfson, M; Rossen, LM; Wall, MM; Houry, D; Blanco, C				Olfson, Mark; Rossen, Lauren M.; Wall, Melanie M.; Houry, Debra; Blanco, Carlos			Trends in Intentional and Unintentional Opioid Overdose Deaths in the United States, 2000-2017	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							SUICIDE		[Olfson, Mark; Wall, Melanie M.] Columbia Univ, Dept Psychiat, Vagelos Coll Phys & Surg, New York, NY 10032 USA; [Rossen, Lauren M.] Natl Ctr Hlth Stat, Div Res & Methodol, Hyattsville, MD 20782 USA; [Houry, Debra] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; [Blanco, Carlos] NIDA, Bethesda, MD 20892 USA	Columbia University; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Olfson, M (corresponding author), Columbia Univ, Vagelos Coll Phys & Surg, 1051 Riverside Dr, New York, NY 10032 USA.	mo49@cumc.columbia.edu	Olfson, Mark/AAA-8547-2021; Wall, Melanie/AAE-7828-2019					Bohnert ASB, 2013, INJURY PREV, V19, P326, DOI 10.1136/injuryprev-2012-040631; Donaldson AE, 2006, INJURY PREV, V12, P338, DOI 10.1136/ip.2005.011171; Olfson M, 2018, JAMA PSYCHIAT, V75, P820, DOI 10.1001/jamapsychiatry.2018.1471; Oquendo MA, 2018, NEW ENGL J MED, V378, P1567, DOI 10.1056/NEJMp1801417; Spencer MR, 2019, NATL VITAL STAT REPO, V68	5	42	42	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	2019	322	23					2340	2342		10.1001/jama.2019.16566	http://dx.doi.org/10.1001/jama.2019.16566			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ6JR	31846008	Green Published, Bronze			2023-01-03	WOS:000505208800024
J	Kuo, TJ; Wu, PC; Tang, PL; Yin, CH; Chu, CH; Hung, YM				Kuo, Tsu Jen; Wu, Pei Chen; Tang, Pei Ling; Yin, Chun-Hao; Chu, Chi Hsiang; Hung, Yao-Min			Effects of continuity of care on the postradiotherapy survival of working-age patients with oral cavity cancer: A nationwide population-based cohort study in Taiwan	PLOS ONE			English	Article							TYPE-2 DIABETES-MELLITUS; SOCIOECONOMIC-STATUS; DENTAL MANAGEMENT; NECK-CANCER; RISK; HEAD; SMOKING; EXPERIENCES; CARCINOMA; ONCOLOGY	Objectives Cancer of the oral cavity, a well-known global health concern, remains one of most common causes of cancer mortality. Continuity of care (COC), a measurement of the extent to which an individual patient receives care from a given provider over a specified period of time, can help cancer survivors process their experiences of dealing with the illness and recuperation; however, limited research has focused on the survival rate of working-age patients with oral cancer. Methods A total of 14,240 working-age patients (20 < age <= 65 years) with oral cavity cancer treated with radiotherapy (RT) during 2000-2013 were included in this study from a registry of patients with catastrophic illnesses maintained by the Taiwan National Health Insurance Research Database. We evaluated the effects of the Continuity of Care Index (COCI) proposed by Bice and Boxerman, sociodemographic factors, and comorbidities on the survival rate. This study categorized COC into three groups-low (COCI < 0.23), intermediate (COCI = 0.23-0.37), and high (COCI >= 0.38)-according to the distribution of scores in our sample. A multivariate Cox proportional hazards regression model was used to determine the demographic factors and comorbidities associated with the survival rate. Results Among all the relevant variables, low COCI, male sex, low socioeconomic status, no receipt, and a history of diabetes increased the risk of mortality. Pre-RT dental evaluation and management was significantly associated with reduced post-RT mortality (adjusted hazard ratio [aHR] = 0.767, 95% confidence interval [CI] = 0.729-0.806, p < 0.001). Compared with patients with a high COCI, those with a low COCI exhibited an increased risk of mortality (aHR = 1.170, 95% CI = 1.093-1.252, p < 0.001). The mortality risk in the intermediate COC group was significantly higher than that in the high COC group (aHR = 1.194, 95% CI = 1.127-1.266, p < 0.001). To balance the distribution of the potential risk factors, propensity-score matching was used for the high COC (COCI > 0.38) and non-high COC (COCI <= 0.38) groups. After propensity-score matching, the mortality risk in the low and intermediate COC groups was also found to be significantly higher than that in the high COC group (aHR = 1.178, 95% CI = 1.074-1.292, p < 0.001 and aHR = 1.189, 95% CI = 1.107-1.277, p = 0.001, respectively). Conclusions In Taiwan, COC and prior dental treatment before RT significantly affected the survival rate of working-age patients with oral cancer. This result merits policymakers' attention.	[Kuo, Tsu Jen] Kaohsiung Vet Gen Hosp, Dept Stomatol, Kaohsiung, Taiwan; [Kuo, Tsu Jen] Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources, Kaohsiung, Taiwan; [Kuo, Tsu Jen] Shu Zen Jr Coll Med & Management, Dept Dent Technol, Kaohsiung, Taiwan; [Wu, Pei Chen] Tzu Chi Univ, Dept Mol Biol & Human Genet, Hualien, Taiwan; [Tang, Pei Ling; Yin, Chun-Hao] Kaohsiung Vet Gen Hosp, Res Ctr Med Informat, Kaohsiung, Taiwan; [Tang, Pei Ling] Meiho Univ, Dept Nursing, Pingtung, Taiwan; [Tang, Pei Ling] Kaohsiung Med Univ, Coll Nursing, Kaohsiung, Taiwan; [Chu, Chi Hsiang] Kaohsiung Chang Gung Mem Hosp, Clin Trial Ctr, Kaohsiung, Taiwan; [Chu, Chi Hsiang] Natl Univ Kaohsiung, Inst Stat, Kaohsiung, Taiwan; [Hung, Yao-Min] Kaohsiung Municipal United Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Hung, Yao-Min] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan; [Hung, Yao-Min] Yuhing Jr Coll Hlth Care & Management, Kaohsiung, Taiwan	Kaohsiung Veterans General Hospital; National Sun Yat Sen University; Tzu Chi University; Kaohsiung Veterans General Hospital; Kaohsiung Medical University; Chang Gung Memorial Hospital; National University Kaohsiung; National Yang Ming Chiao Tung University	Chu, CH (corresponding author), Kaohsiung Chang Gung Mem Hosp, Clin Trial Ctr, Kaohsiung, Taiwan.; Chu, CH (corresponding author), Natl Univ Kaohsiung, Inst Stat, Kaohsiung, Taiwan.; Hung, YM (corresponding author), Kaohsiung Municipal United Hosp, Dept Internal Med, Kaohsiung, Taiwan.; Hung, YM (corresponding author), Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.; Hung, YM (corresponding author), Yuhing Jr Coll Hlth Care & Management, Kaohsiung, Taiwan.	loveweib@gmail.com; ymhung1@gmail.com	Chu, Chi-Hsiang/AAS-6012-2020	Chu, Chi-Hsiang/0000-0002-7883-377X	Kaohsiung Veterans General Hospital [VGHKS104-133]; Taiwan Health Promotion Administration	Kaohsiung Veterans General Hospital; Taiwan Health Promotion Administration	This study was supported by grants (VGHKS104-133) from Kaohsiung Veterans General Hospital and the Taiwan Health Promotion Administration to PLT. The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amjad H, 2016, JAMA INTERN MED, V176, P1371, DOI 10.1001/jamainternmed.2016.3553; Aubin M, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007672.pub2; Beacher NG, 2018, BRIT DENT J, V225, P855, DOI 10.1038/sj.bdj.2018.932; BICE TW, 1977, MED CARE, V15, P347, DOI 10.1097/00005650-197704000-00010; Alvarez PB, 2018, INDIAN J CANCER, V55, P251, DOI 10.4103/ijc.IJC_20_18; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chang CC, 2017, ONCOTARGET, V8, P98865, DOI 10.18632/oncotarget.22010; Chang PY, 2018, THER CLIN RISK MANAG, V14, P511, DOI 10.2147/TCRM.S150638; Chen CC, 2013, TAIWAN J PUBLIC HLTH, V32, P116; Chen CC, 2011, AM J MANAG CARE, V17, P420; Chen PH, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3904098; Chen Tzeng-Ji, 2007, J Chin Med Assoc, V70, P110; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Cheng SH, 2014, MED CARE, V52, P149, DOI 10.1097/MLR.0000000000000042; Chiang CJ, 2010, JPN J CLIN ONCOL, V40, P897, DOI 10.1093/jjco/hyq057; Cohen Castel O, 2019, SUPPORTIVE CARE CANC; Easley J, 2016, CAN FAM PHYSICIAN, V62, P821; Frenkel M, 2016, SUPPORT CARE CANCER, V24, P4249, DOI 10.1007/s00520-016-3255-6; Gong YH, 2015, ORAL ONCOL, V51, P332, DOI 10.1016/j.oraloncology.2015.01.003; Guo Y, 2015, CANCER MED-US, V4, P1612, DOI 10.1002/cam4.509; Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219; Hansen RP, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-100; Hsing AW, 2015, JAMA INTERN MED, V175, P1527, DOI 10.1001/jamainternmed.2015.3540; Huang CC, 2015, ORAL ONCOL, V51, P349, DOI 10.1016/j.oraloncology.2015.01.001; Huang WY, 2015, CLIN OTOLARYNGOL, V40, P327, DOI 10.1111/coa.12371; Husain A, 2013, SUPPORT CARE CANCER, V21, P1351, DOI 10.1007/s00520-012-1673-7; Hussey PS, 2014, JAMA INTERN MED, V174, P742, DOI 10.1001/jamainternmed.2014.245; Jee SH, 2006, MED CARE RES REV, V63, P158, DOI 10.1177/1077558705285294; Kao YH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004948; KO YC, 1992, J ORAL PATHOL MED, V21, P261, DOI 10.1111/j.1600-0714.1992.tb01007.x; KO YC, 1995, J ORAL PATHOL MED, V24, P450, DOI 10.1111/j.1600-0714.1995.tb01132.x; Kobleder A, 2017, J CLIN NURS, V26, P4890, DOI 10.1111/jocn.13966; Kreppel M, 2016, ORAL ONCOL, V60, P68, DOI 10.1016/j.oraloncology.2016.07.004; Kuo TJ, 2016, ORAL ONCOL, V62, P136, DOI 10.1016/j.oraloncology.2016.10.015; Lai YC, 2018, PEERJ, V6, DOI 10.7717/peerj.5591; Lalla R, 2017, ORAL DIS, V23, P1134, DOI 10.1111/odi.12710; Lee CC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126482; Lee CC, 2012, ORAL ONCOL, V48, P253, DOI 10.1016/j.oraloncology.2011.10.002; Lee KD, 2017, ONCOTARGET, V8, P44567, DOI 10.18632/oncotarget.17818; Liang SY, 2019, EUR J CANCER CARE, V28, DOI 10.1111/ecc.12891; Lin HH, 2014, PANCREAS, V43, P1117, DOI 10.1097/MPA.0000000000000209; Marcazzan S, 2018, ORAL ONCOL, V76, P1, DOI 10.1016/j.oraloncology.2017.11.014; Margalit DN, 2015, J ONCOL PRACT, V11, P151, DOI 10.1200/JOP.2014.000414; Noto H, 2013, J DIABETES INVEST, V4, P225, DOI 10.1111/jdi.12068; Osazuwa-Peters N, 2016, J CANCER RES CLIN, V142, P521, DOI 10.1007/s00432-015-2061-8; Pan CS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203410; Rivera C, 2015, INT J CLIN EXP PATHO, V8, P11884; Rogers S, 2014, J PUBLIC HEALTH-UK, V36, P658, DOI 10.1093/pubmed/fdt127; Saultz John W, 2003, Ann Fam Med, V1, P134, DOI 10.1370/afm.23; Schweyen R, 2017, CLIN ORAL INVEST, V21, P1123, DOI 10.1007/s00784-016-1874-4; Su CC, 2010, ORAL ONCOL, V46, P586, DOI 10.1016/j.oraloncology.2010.05.001; Tsai WC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175148; Tu HP, 2017, JOINT BONE SPINE, V84, P189, DOI 10.1016/j.jbspin.2016.02.024; Waring E, 2019, SUPPORTIVE CARE CANC; Warnakulasuriya S, 2009, ORAL ONCOL, V45, P309, DOI 10.1016/j.oraloncology.2008.06.002	55	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2019	14	12							e0225635	10.1371/journal.pone.0225635	http://dx.doi.org/10.1371/journal.pone.0225635			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP3RM	31841525	gold, Green Published			2023-01-03	WOS:000534236300012
J	[Anonymous]				[Anonymous]			Diet and Intestinal Bacteria (Reprinted from JAMA, vol 73, pg 1844, 1919)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint																		Mendel LB, 1919, AM J MED SCI, V158, P297; Porter L, 1919, AM J DIS CHILD, V18, P254; Torrey JC, 1919, J MED RES, V39, P415; 1919, JAMA, V73, P1844	4	0	0	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	2019	322	22					2252	2252		10.1001/jama.2018.15638	http://dx.doi.org/10.1001/jama.2018.15638			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ6JI	31821422				2023-01-03	WOS:000505207800026
J	Leventhal, AM; Miech, R; Barrington-Trimis, J; Johnston, LD; O'Malley, PM; Patrick, ME				Leventhal, Adam M.; Miech, Richard; Barrington-Trimis, Jessica; Johnston, Lloyd D.; O'Malley, Patrick M.; Patrick, Megan E.			Flavors of e-Cigarettes Used by Youths in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Leventhal, Adam M.; Barrington-Trimis, Jessica] Univ Southern Calif, Inst Addict Sci, 2250 Alcazar St,CSC 271, Los Angeles, CA 90033 USA; [Miech, Richard; Johnston, Lloyd D.; O'Malley, Patrick M.] Univ Michigan, Survey Res Ctr, Ann Arbor, MI 48109 USA; [Patrick, Megan E.] Univ Minnesota, Inst Translat Res Childrens Mental Hlth, Minneapolis, MN USA	University of Southern California; University of Michigan System; University of Michigan; University of Minnesota System; University of Minnesota Twin Cities	Leventhal, AM (corresponding author), Univ Southern Calif, Inst Addict Sci, 2250 Alcazar St,CSC 271, Los Angeles, CA 90033 USA.	adam.leventhal@usc.edu	Barrington-Trimis, Jessica/ABE-7311-2020		National Cancer Institute [U54CA180905]; US Food and Drug Administration (FDA) Center for Tobacco Products (CTP) [U54CA180905]; National Institute on Drug Abuse (NIDA) [K24048160]; NIDA [3R01DA001411-44S1]; FDA CTP [3R01DA001411-44S1]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA001411] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); US Food and Drug Administration (FDA) Center for Tobacco Products (CTP); National Institute on Drug Abuse (NIDA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); FDA CTP; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Research reported in this publication was supported by the National Cancer Institute and the US Food and Drug Administration (FDA) Center for Tobacco Products (CTP) under award U54CA180905 (Dr Leventhal), the National Institute on Drug Abuse (NIDA) under award K24048160 (Dr Leventhal), and the NIDA and FDA CTP under award 3R01DA001411-44S1 (Dr Miech).	Kaplan S, NY TIMES; Miech RA, 2019, MONITORING FUTURE NA, V1; Public. Health Law Center, US SAL RESTR FLAV TO; Schneller LM, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16162991; US Food and Drug Administration, FDA ISS PROP RUL PRE; US Food and Drug Administration, FDA ISS PROP PREM TO; Wells Fargo Securities, 2018, NIELS TOB ALL CHANN	7	68	67	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	2019	322	21					2132	2134		10.1001/jama.2019.17968	http://dx.doi.org/10.1001/jama.2019.17968			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ6JE	31688891	Bronze, Green Published			2023-01-03	WOS:000505207400036
J	Ajah, LO; Onu, FA; Ogbuinya, OC; Ajah, MI; Ozumba, BC; Agbata, AT; Onoh, RC; Ekwedigwe, KC				Ajah, Leonard O.; Onu, Fidelis A.; Ogbuinya, Oliver C.; Ajah, Monique, I; Ozumba, Benjamin C.; Agbata, Anthony T.; Onoh, Robinson C.; Ekwedigwe, Kenneth C.			Choice of birth place among antenatal clinic attendees in rural mission hospitals in Ebonyi State, South-East Nigeria	PLOS ONE			English	Article							CARE	Background Low utilization of health facilities for delivery by pregnant women poses a public health challenge in Nigeria. Aim To determine the factors that influence the choice of birth place among antenatal clinic attendees. Methodology This was a cross-sectional study of the eligible antenatal clinic attendees recruited at Mater Misericordiae Hospital, Afikpo and Saint Vincent Hospital, Ndubia in Ebonyi State from February 1, 2016 to June 30, 2016. Analysis was done using EPI Info 7.21 software (CDC Atlanta Georgia). Results A total of 397(99.3%) completely filled questionnaires were collated and analysed. Approximately 71% of the health facilities closest to the respondents had maternity services. It took at least 1 hour for 80.9% of the respondents to access health facilities with maternity services. Most (60.2%) of the respondents had at least one antenatal clinic attendance and majority of them did so at public hospitals. Approximately 43.8% of the respondents were delivered by the skilled birth attendants. The respondents' age and the couple's educational level, history of antenatal clinic attendance, distance of the health facility and availability of transport fare had a significant effect on delivery by skilled birth attendants. The common determinants of birth place were nearness of the health facilities, familiarity of healthcare providers, improved services, sudden labour onset and cost. Also 61.7% of the respondents chose to deliver in public health facilities due to favourable reasons but this could be hampered by the rudeness of some healthcare providers at such facilities. A significant proportion of private health facilities had unskilled manpower and shortage of drugs. Conclusion A greater proportion of women will prefer to deliver in health facilities. However there are barriers to utilization of these facilities hence the need to address such barriers.	[Ajah, Leonard O.; Ozumba, Benjamin C.] Univ Nigeria, Fac Med Sci, Dept Obstet & Gynaecol, Ituku Ozalla Campus, Enugu, Nigeria; [Ajah, Leonard O.; Onu, Fidelis A.; Ogbuinya, Oliver C.; Agbata, Anthony T.; Onoh, Robinson C.; Ekwedigwe, Kenneth C.] Fed Teaching Hosp, Dept Obstet & Gynaecol, Abakaliki, Nigeria; [Ajah, Monique, I] Univ Nigeria, Inst Maternal & Childhlth, Ituku Ozalla Campus, Enugu, Nigeria	University of Nigeria; University of Nigeria	Ajah, LO (corresponding author), Univ Nigeria, Fac Med Sci, Dept Obstet & Gynaecol, Ituku Ozalla Campus, Enugu, Nigeria.; Ajah, LO (corresponding author), Fed Teaching Hosp, Dept Obstet & Gynaecol, Abakaliki, Nigeria.	leonard.ajah@unn.edu.ng						Abouzahr C, MATERNAL MORTALITY 2; Adam YM, 2002, NIGER J OBSTET GYNEA, V22, P600; Alastair A, 2005, HLTH POPUL PLANNING, V20, P76; Ambreen N, 2013, ISRA MED J, V5; Anthony Kkonde, 2010, FACTORS INFLUENCE PR; Bhatia J, 2004, HEALTH POLICY PLANN, V19, P402, DOI 10.1093/heapol/czh055; Charan Jaykaran, 2013, Indian J Psychol Med, V35, P121, DOI 10.4103/0253-7176.116232; Department of Health Service (DOHS), 200910 DOHS MOHP; Dickson Kwamena Sekyi, 2017, ADV PUBLIC HLTH, V2017, P1, DOI 10.1155/2017/9102808; Gabrysch S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000394; Idowu A, 2017, ETHIOP J HEALTH SCI, V27, P291, DOI 10.4314/ejhs.v27i3.11; Kimani H, 2015, PUBLIC HLTH RES, V5, P1, DOI DOI 10.5923/J.PHR.20150501.01; Kyei NNA, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-151; Lwelamira J, 2012, ASIAN J MED SCI, V4, P105; National Population Commission (NPC) [Nigeria] and ICF International, 2014, NIG DEM HLTH SURV 20; Pardeshi GS, 2011, J HEALTH POPUL NUTR, V29, P71; Ramesh KD, 2013, INT J MATERNAL CHILD, P30; Ravi RP., 2014, AM J PUBLIC HLTH RES, V2, P75, DOI [DOI 10.12691/AJPHR-2-3-2, 10.12691/ajphr-2-3-2]; Russell S, 2005, SOC SCI MED, V61, P1396, DOI 10.1016/j.socscimed.2004.11.077; Seljeskog Line, 2006, Afr J Reprod Health, V10, P66; United Nations, 2018, PROGR INF SUST DEV G, V3; WHO Reproductive Health Library, 2018, WHO REC RESP MAT CAR; WHO (World Health Organization), 2015, TRENDS MATERNAL MORT	23	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2019	14	11							e0211306	10.1371/journal.pone.0211306	http://dx.doi.org/10.1371/journal.pone.0211306			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN1BP	31689292	Green Published, Green Submitted, gold			2023-01-03	WOS:000532680100001
J	Arce, DY; Bellavia, A; Cantonwine, DE; Napoli, OJ; Meeker, JD; James-Todd, T; McElrath, TF; Tsen, LC				Arce, Dominique Y.; Bellavia, Andrea; Cantonwine, David E.; Napoli, Olivia J.; Meeker, John D.; James-Todd, Tamarra; McElrath, Thomas F.; Tsen, Lawrence C.			Average and time-specific maternal prenatal inflammatory biomarkers and the risk of labor epidural associated fever	PLOS ONE			English	Article							INTRAPARTUM FEVER; CYTOKINES; INTERLEUKIN-6; TEMPERATURE; CHORIOAMNIONITIS; ENCEPHALOPATHY; IL-1-BETA; ANALGESIA; PREGNANCY; ALPHA	Background The use of labor epidural analgesia has been associated with intrapartum fever, known as labor epidural associated fever (LEAF). LEAF is most commonly non-infectious in origin and associated with elevated inflammatory cytokines. Methods The LIFECODES pregnancy cohort was designed to prospectively collect data to evaluate the association of maternal inflammatory biomarkers with preterm birth in women who delivered between 2007 and 2008 at Brigham and Women's Hospital. Our secondary analysis of the data from the cohort identified 182 women for whom inflammatory biomarkers (i.e. interleukin-10, interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha and C-reactive protein) collected longitudinally over four prenatal visits was available. Maternal temperature and other clinical variables were abstracted from medical records. The primary outcome, the presence of LEAF, was defined as oral temperature >= 38 degrees C (>= 100.4 degrees F) after epidural analgesia initiation. Multivariable logistic regression estimated the association between inflammatory biomarker concentrations and the odds of developing an intrapartum fever after adjusting for a number of potential confounders. Results Women who developed LEAF were more likely to have a longer duration of epidural analgesia, whereas women who did not develop LEAF were more likely to have induced labor and positive or unknown Group B Streptococcus colonization status. However, no differences were seen by nulliparity, mode of delivery, white blood cell count at admission, baseline temperature, length of rupture of membranes and number of cervical exams performed during labor. Unadjusted and multivariable logistic regression models did not provide evidence for or exclude an association between individual maternal inflammatory biomarkers and the odds of developing LEAF, regardless of visit time-period. Conclusion The predictive value of maternal inflammatory biomarkers measured during early- and midpregnancy for the risk of developing LEAF cannot be excluded.	[Arce, Dominique Y.; Tsen, Lawrence C.] Harvard Med Sch, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Div Obstetr Anesthesia, Boston, MA 02115 USA; [Bellavia, Andrea; James-Todd, Tamarra] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Cantonwine, David E.; McElrath, Thomas F.] Harvard Med Sch, Dept Obstet & Gynecol, Div Maternal Fetal Med, Brigham & Womens Hosp, Boston, MA 02115 USA; [Napoli, Olivia J.] Lake Erie Coll Osteopath Med, Erie, PA USA; [Meeker, John D.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Michigan System; University of Michigan	Arce, DY (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Div Obstetr Anesthesia, Boston, MA 02115 USA.	DArce@bwh.harvard.edu	Bellavia, Andrea/ABE-8431-2020	Meeker, John/0000-0001-8357-5085	Harvard Anesthesia Departments National Institutes of Health T32 training grant [5T32GM007592-40]; National Institute of Environmental Health Sciences by the National Institutes of Health [R01ESO18872]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007592] Funding Source: NIH RePORTER	Harvard Anesthesia Departments National Institutes of Health T32 training grant; National Institute of Environmental Health Sciences by the National Institutes of Health; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported by the Harvard Anesthesia Departments National Institutes of Health T32 training grant (https://www.nigms.nih.gov/training/instpostdoc/pages/PostdocInst-Anesthesiology.aspx) (5T32GM007592-40) (DYA). This research was also supported by the National Institute of Environmental Health Sciences by the National Institutes of Health (https://www.niehs.nih.gov) (R01ESO18872) (JDM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbassi-Ghanavati M, 2009, OBSTET GYNECOL, V114, P1326, DOI 10.1097/AOG.0b013e3181c2bde8; American College of Obstetricians and Gynecologists, 2017, OBSTET GYNECOL, V130, pe95, DOI [10.1097/AOG.0000000000002236, DOI 10.1097/AOG.000, DOI 10.1097/AOG.0000000000002236]; Bergeron J, 2016, PLACENTA, V47, P116, DOI 10.1016/j.placenta.2016.09.016; Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200; Blume HK, 2008, DEV MED CHILD NEUROL, V50, P19, DOI 10.1111/j.1469-8749.2007.02007.x; Brennan FM, 2008, EUR J IMMUNOL, V38, P1106, DOI 10.1002/eji.200737821; Butwick AJ, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.6567; Cahill AG, 2012, OBSTET GYNECOL, V119, P1096, DOI 10.1097/AOG.0b013e318256ce3f; Cartmell T, 2000, J PHYSIOL-LONDON, V526, P653, DOI 10.1111/j.1469-7793.2000.00653.x; Chai Z, 1996, J EXP MED, V183, P311, DOI 10.1084/jem.183.1.311; Christian LM, 2014, CYTOKINE, V70, P134, DOI 10.1016/j.cyto.2014.06.018; Christian LM, 2014, AM J OBSTET GYNECOL, V211, P275, DOI 10.1016/j.ajog.2014.06.042; Clodi M, 2008, AM J PHYSIOL-ENDOC M, V295, pE686, DOI 10.1152/ajpendo.90263.2008; Curtin WM, 2015, J PERINATOL, V35, P396, DOI 10.1038/jp.2014.235; del Arroyo AG, 2019, BRIT J ANAESTH, V122, P92, DOI 10.1016/j.bja.2018.09.024; Dinarello CA, 2011, EUR J IMMUNOL, V41, P1203, DOI 10.1002/eji.201141550; Ferguson KK, 2014, AM J REPROD IMMUNOL, V72, P326, DOI 10.1111/aji.12265; Ferguson KK, 2014, JAMA PEDIATR, V168, P61, DOI 10.1001/jamapediatrics.2013.3699; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Goetzl L, 2002, AM J OBSTET GYNECOL, V187, P834, DOI 10.1067/mob.2002.127135; Goetzl Laura, 2004, J Perinatol, V24, P471, DOI 10.1038/sj.jp.7211128; Greenwell EA, 2012, PEDIATRICS, V129, pE447, DOI 10.1542/peds.2010-2301; Grether JK, 1997, JAMA-J AM MED ASSOC, V278, P207, DOI 10.1001/jama.278.3.207; Impey L, 2001, BRIT J OBSTET GYNAEC, V108, P594, DOI 10.1111/j.1471-0528.2001.00145.x; Keelan JA, 2003, PLACENTA, V24, pS33, DOI 10.1053/plac.2002.0948; LEMAY L G, 1990, Cytokine, V2, P199, DOI 10.1016/1043-4666(90)90016-M; Lieberman E, 1997, PEDIATRICS, V99, P415, DOI 10.1542/peds.99.3.415; Maayan-Metzger A, 2006, FETAL PEDIATR PATHOL, V25, P169, DOI 10.1080/15513810600908461; Marrie RA, 2009, J CLIN EPIDEMIOL, V62, P511, DOI 10.1016/j.jclinepi.2008.05.015; Ouyang WJ, 2011, ANNU REV IMMUNOL, V29, P71, DOI 10.1146/annurev-immunol-031210-101312; Riley LE, 2011, OBSTET GYNECOL, V117, P588, DOI 10.1097/AOG.0b013e31820b0503; Segal S., 2010, ANESTHESIA ANALGESIA, V111; Segal S, 2017, ANESTH ANALG, V125, P2134, DOI 10.1213/ANE.0000000000002479; Sharma SK, 2014, ANESTHESIA ANALGESIA, V118, P2054; Sun X, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201808868; Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295; Wang JP, 1997, NEUROIMMUNOMODULAT, V4, P230, DOI 10.1159/000097341; Wang LZ, 2011, INT J GYNECOL OBSTET, V113, P40, DOI 10.1016/j.ijgo.2010.10.026; Zaretsky MV, 2004, OBSTET GYNECOL, V103, P546, DOI 10.1097/01.AOG.0000114980.40445.83; ZHENG H, 1995, IMMUNITY, V3, P9, DOI 10.1016/1074-7613(95)90154-X	40	2	3	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2019	14	11							e0222958	10.1371/journal.pone.0222958	http://dx.doi.org/10.1371/journal.pone.0222958			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN1BP	31689293	Green Published, gold			2023-01-03	WOS:000532680100005
J	Yang, G; Anderson, DW; Baier, F; Dohmen, E; Hong, N; Carr, PD; Kamerlin, SCL; Jackson, CJ; Bornberg-Bauer, E; Tokuriki, N				Yang, Gloria; Anderson, Dave W.; Baier, Florian; Dohmen, Elias; Hong, Nansook; Carr, Paul D.; Kamerlin, Shina Caroline Lynn; Jackson, Colin J.; Bornberg-Bauer, Erich; Tokuriki, Nobuhiko			Higher-order epistasis shapes the fitness landscape of a xenobiotic-degrading enzyme	NATURE CHEMICAL BIOLOGY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; PHYLOGENETIC ANALYSIS; METHYL PARATHION; EVOLUTION; SPECIFICITY; PHOSPHOTRIESTERASE; DEGRADATION; REFINEMENT; MUTATIONS; PATHWAYS	Characterizing the adaptive landscapes that encompass the emergence of novel enzyme functions can provide molecular insights into both enzymatic and evolutionary mechanisms. Here, we combine ancestral protein reconstruction with biochemical, structural and mutational analyses to characterize the functional evolution of methyl-parathion hydrolase (MPH), an organophosphate-degrading enzyme. We identify five mutations that are necessary and sufficient for the evolution of MPH from an ancestral dihydrocoumarin hydrolase. In-depth analyses of the adaptive landscapes encompassing this evolutionary transition revealed that the mutations form a complex interaction network, defined in part by higher-order epistasis, that constrained the adaptive pathways available. By also characterizing the adaptive landscapes in terms of their functional activities towards three additional organophosphate substrates, we reveal that subtle differences in the polarity of the substrate substituents drastically alter the network of epistatic interactions. Our work suggests that the mutations function collectively to enable substrate recognition via subtle structural repositioning.	[Yang, Gloria; Anderson, Dave W.; Baier, Florian; Tokuriki, Nobuhiko] Univ British Columbia, Michael Smith Labs, Vancouver, BC, Canada; [Anderson, Dave W.] Univ Calgary, Biochem & Mol Biol, Calgary, AB, Canada; [Dohmen, Elias; Bornberg-Bauer, Erich] Westfalische Wilhelms Univ, Inst Evolut & Biodivers, Evolutionary Bioinformat, Munster, Germany; [Hong, Nansook; Carr, Paul D.; Jackson, Colin J.] Australian Natl Univ, Res Sch Chem, Canberra, ACT, Australia; [Kamerlin, Shina Caroline Lynn] Uppsala Univ, Dept Chem BMC, Sci Life Lab, Uppsala, Sweden	University of British Columbia; University of Calgary; University of Munster; Australian National University; Uppsala University	Tokuriki, N (corresponding author), Univ British Columbia, Michael Smith Labs, Vancouver, BC, Canada.	tokuriki@msl.ubc.ca	Bornberg-Bauer, Erich/A-1563-2013; Dohmen, Elias/V-6713-2019	Bornberg-Bauer, Erich/0000-0002-1826-3576; Dohmen, Elias/0000-0002-7203-2314; Jackson, Colin/0000-0001-6150-3822	Human Frontier Science Program (HFSP) [RGP0006/2013]; Natural Sciences and Engineering Research Council of Canada (NSERC) [RGPIN 418262-12, RGPIN 2017-04909]; Knut and Alice Wallenberg Foundation (Wallenberg Academy Fellowships) [2013.0124, 2018.0140]; Swedish National Infrastructure for Computing (SNIC); NSERC; MSFHR	Human Frontier Science Program (HFSP)(Human Frontier Science Program); Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Knut and Alice Wallenberg Foundation (Wallenberg Academy Fellowships); Swedish National Infrastructure for Computing (SNIC); NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); MSFHR(Michael Smith Foundation for Health Research)	We thank A. Pabis for performing computational analysis and providing revision and comments on the manuscript. N.T. and E.B.-B. thank the Human Frontier Science Program (HFSP) for support via research grant RGP0006/2013. N.T. acknowledges support by the Natural Sciences and Engineering Research Council of Canada (NSERC) via discovery grants RGPIN 418262-12 and RGPIN 2017-04909. N.T. is a CIHR new investigator and a Michael Smith Foundation of Health Research (MSFHR) career investigator. S.C.L.K. thanks the Knut and Alice Wallenberg Foundation (Wallenberg Academy Fellowships 2013.0124 and 2018.0140) and the Swedish National Infrastructure for Computing (SNIC). D.W.A. thanks NSERC and the MSFHR for post-doctoral support.	Abascal F, 2005, BIOINFORMATICS, V21, P2104, DOI 10.1093/bioinformatics/bti263; Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308; Afriat-Jurnou L, 2012, BIOCHEMISTRY-US, V51, P6047, DOI 10.1021/bi300694t; Anderson DW, 2015, ELIFE, V4, DOI 10.7554/eLife.07864; Baier F, 2014, J MOL BIOL, V426, P2442, DOI 10.1016/j.jmb.2014.04.013; Bas DC, 2008, PROTEINS, V73, P765, DOI 10.1002/prot.22102; Boucher JI, 2014, ELIFE, V3, DOI 10.7554/eLife.02304; Bridgham JT, 2006, SCIENCE, V312, P97, DOI 10.1126/science.1123348; Campbell E, 2016, NAT CHEM BIOL, V12, P944, DOI [10.1038/nchembio.2175, 10.1038/NCHEMBIO.2175]; Canale AS, 2018, CURR OPIN STRUC BIOL, V48, P141, DOI 10.1016/j.sbi.2018.01.001; Clifton BE, 2018, NAT CHEM BIOL, V14, P542, DOI 10.1038/s41589-018-0043-2; Copley SD, 2000, TRENDS BIOCHEM SCI, V25, P261, DOI 10.1016/S0968-0004(00)01562-0; Crawford RL, 2007, BIODEGRADATION, V18, P525, DOI 10.1007/s10532-006-9090-6; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o; Fu LM, 2012, BIOINFORMATICS, V28, P3150, DOI 10.1093/bioinformatics/bts565; Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864; Hochberg GKA, 2017, ANNU REV BIOPHYS, V46, P247, DOI 10.1146/annurev-biophys-070816-033631; Hong SB, 1996, BIOCHEMISTRY-US, V35, P10904, DOI 10.1021/bi960663m; INGLES DW, 1967, BIOCHEM J, V104, P369, DOI 10.1042/bj1040369; Jackson CJ, 2005, ORG BIOMOL CHEM, V3, P4343, DOI 10.1039/b512399b; Jackson CJ, 2008, J MOL BIOL, V375, P1189, DOI 10.1016/j.jmb.2007.10.061; Jimenez-Oses G, 2014, NAT CHEM BIOL, V10, P431, DOI 10.1038/nchembio.1503; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P133, DOI 10.1107/S0907444909047374; Kaltenbach M, 2018, NAT CHEM BIOL, V14, P548, DOI 10.1038/s41589-018-0042-3; Kaltenbach M, 2014, J EXP ZOOL PART B, V322, P468, DOI 10.1002/jez.b.22562; Khersonsky O, 2005, BIOCHEMISTRY-US, V44, P6371, DOI 10.1021/bi047440d; Kratzer JT, 2014, P NATL ACAD SCI USA, V111, P3763, DOI 10.1073/pnas.1320393111; Le SQ, 2008, MOL BIOL EVOL, V25, P1307, DOI 10.1093/molbev/msn067; Liu H, 2005, BIOCHEM BIOPH RES CO, V334, P1107, DOI 10.1016/j.bbrc.2005.07.006; Lobkovsky Alexander E., 2012, Frontiers in Genetics, V3, P246, DOI 10.3389/fgene.2012.00246; Lozovsky ER, 2009, P NATL ACAD SCI USA, V106, P12025, DOI 10.1073/pnas.0905922106; Lunzer M, 2005, SCIENCE, V310, P499, DOI 10.1126/science.1115649; Luo XJ, 2014, BIOTECHNOL BIOENG, V111, P1920, DOI 10.1002/bit.25272; Malla RK, 2011, ORG LETT, V13, P3094, DOI 10.1021/ol200991x; McKeown AN, 2014, CELL, V159, P58, DOI 10.1016/j.cell.2014.09.003; Meini MR, 2015, MOL BIOL EVOL, V32, P1774, DOI 10.1093/molbev/msv059; Miton CM, 2018, P NATL ACAD SCI USA, V115, pE7293, DOI 10.1073/pnas.1607817115; Miton CM, 2016, PROTEIN SCI, V25, P1260, DOI 10.1002/pro.2876; Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314; O'Maille PE, 2008, NAT CHEM BIOL, V4, P617, DOI 10.1038/nchembio.113; Nguyen PC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11843-4; Purg M, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2016.0150; Russell RJ, 2011, EVOL APPL, V4, P225, DOI 10.1111/j.1752-4571.2010.00175.x; Sailer ZR, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005541; Sambrook J., 2001, MOL CLONING LAB MANU, V3; Schrodinger, 2018, REL 2018 3 MAESTR; Siddiq MA, 2017, CURR OPIN STRUC BIOL, V47, P113, DOI 10.1016/j.sbi.2017.07.003; Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033; Starr TN, 2017, NATURE, V549, P409, DOI 10.1038/nature23902; Stormo GD, 2011, GENETICS, V187, P1219, DOI 10.1534/genetics.110.126052; Sun L, 2004, ACTA CRYSTALLOGR D, V60, P954, DOI 10.1107/S0907444904005669; Sunden F, 2015, ELIFE, V4, DOI 10.7554/eLife.06181; Tokuriki N, 2009, SCIENCE, V324, P203, DOI 10.1126/science.1169375; Tufts DM, 2015, MOL BIOL EVOL, V32, P287, DOI 10.1093/molbev/msu311; Wallace IM, 2006, NUCLEIC ACIDS RES, V34, P1692, DOI 10.1093/nar/gkl091; Weinreich DM, 2018, J STAT PHYS, V172, P208, DOI 10.1007/s10955-018-1975-3; Weinreich DM, 2006, SCIENCE, V312, P111, DOI 10.1126/science.1123539; Yang ZH, 2007, MOL BIOL EVOL, V24, P1586, DOI 10.1093/molbev/msm088	60	36	38	3	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	NOV	2019	15	11					1120	+		10.1038/s41589-019-0386-3	http://dx.doi.org/10.1038/s41589-019-0386-3			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG3RE	31636435				2023-01-03	WOS:000491990800019
J	Degenhardt, L; Wolfe, D; Hall, W; Hickman, M; Chang, J; Bruneau, J; Farrell, M; Griffiths, P				Degenhardt, Louisa; Wolfe, Daniel; Hall, Wayne; Hickman, Matthew; Chang, Judy; Bruneau, Julie; Farrell, Michael; Griffiths, Paul			Strategies to reduce drug-related harm: responding to the evidence base	LANCET			English	Editorial Material							INDIVIDUALS; OFFENDERS; STIGMA		[Degenhardt, Louisa; Farrell, Michael] UNSW Sydney, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia; [Wolfe, Daniel] Open Soc Fdn, Publ Hlth Program, Int Harm Reduct Dev, New York, NY USA; [Hall, Wayne] Univ Queensland, Ctr Youth Subst Abuse Res, Brisbane, Qld, Australia; [Hall, Wayne] Kings Coll London, Natl Addict Ctr, London, England; [Hickman, Matthew] Univ Bristol, Populat Hlth Sci, Bristol, Avon, England; [Chang, Judy] Int Network People Who Use Drugs, London, England; [Bruneau, Julie] Ctr Hosp Univ Montreal, Res Ctr, Montreal, PQ, Canada; [Bruneau, Julie] Univ Montreal, Dept Family & Emergency Med, Fac Med, Montreal, PQ, Canada; [Griffiths, Paul] European Monitoring Ctr Drugs & Drug Addict, Lisbon, Portugal	University of New South Wales Sydney; University of Queensland; University of London; King's College London; University of Bristol; Universite de Montreal; Universite de Montreal	Degenhardt, L (corresponding author), UNSW Sydney, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia.	l.degenhardt@unsw.edu.au	Hall, Wayne D/A-3283-2008; Hickman, Matthew/Y-2400-2019	Hall, Wayne D/0000-0003-1984-0096; Hickman, Matthew/0000-0001-9864-459X	Indivior; Mundipharma; Seqirus; Gilead Sciences; Dutch Government; Robert Carr Fund; ViiV Healthcare; Global Fund to Fight AIDS, Tuberculosis and Malaria; Open Society Foundations; Australian Government Department of Health under the Drug and Alcohol Program; NHMRC Fellowships; National Institute of Health (NIH) grants National Institute on Drug Abuse (NIDA) [R01DA1104470]; NIHR Health Protection Research Unit (HPRU) in Evaluation of Interventions at the University of Bristol; European Monitoring Centre for Drugs and Drug Addiction; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA044170] Funding Source: NIH RePORTER	Indivior; Mundipharma; Seqirus; Gilead Sciences(Gilead Sciences); Dutch Government; Robert Carr Fund; ViiV Healthcare; Global Fund to Fight AIDS, Tuberculosis and Malaria; Open Society Foundations; Australian Government Department of Health under the Drug and Alcohol Program; NHMRC Fellowships(National Health and Medical Research Council (NHMRC) of Australia); National Institute of Health (NIH) grants National Institute on Drug Abuse (NIDA); NIHR Health Protection Research Unit (HPRU) in Evaluation of Interventions at the University of Bristol; European Monitoring Centre for Drugs and Drug Addiction; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	LD and MF have received investigator-initiated, untied educational grants for studies of opioid medications in Australia from Indivior, Mundipharma, and Seqirus. MH reports unrestricted honoraria for speaking at expert meetings from Gilead, AbbVie, and MSD. JB has received research support from Gilead Sciences and consulting fees from AbbVie, Gilead Sciences, and Merck/MSD, in relation to hepatitis C virus treatment for people who use drugs. The International Network of People Who Use Drugs INPUD is a not for profit organisation that receives funds directly from the Dutch Government and the Robert Carr Fund to which governments contribute and receives a grant from ViiV Healthcare for HIV and human rights activities, and also receives money through the Global Fund to Fight AIDS, Tuberculosis and Malaria, which receives development aid from various governments. DW has received support from the Open Society Foundations. The National Drug and Alcohol Research Centre, UNSW Sydney, is supported by funding from the Australian Government Department of Health under the Drug and Alcohol Program. LD is supported by NHMRC Fellowships and by National Institute of Health (NIH) grants National Institute on Drug Abuse (NIDA) (R01DA1104470). MH acknowledges support from NIHR Health Protection Research Unit (HPRU) in Evaluation of Interventions at the University of Bristol. MH is an NIHR senior investigator and acknowledges NIHR School of Public Health Research. The work informing this paper received support from the European Monitoring Centre for Drugs and Drug Addiction. We declare no other competing interests.	Crapanzano KA, 2019, SUBST ABUSE REHABIL, V10, P1, DOI 10.2147/SAR.S183252; Degenhardt L, 2019, LANCET, V394, P1560, DOI 10.1016/S0140-6736(19)32229-9; Degenhardt L, 2018, LANCET PSYCHIAT, V5, P987, DOI 10.1016/S2215-0366(18)30337-7; Farrell M, 2019, LANCET, V394, P1652, DOI 10.1016/S0140-6736(19)32230-5; Hajarizadeh B, 2018, LANCET GASTROENTEROL, V3, P754, DOI 10.1016/S2468-1253(18)30304-2; Hall W, 2019, LANCET, V394, P1580, DOI 10.1016/S0140-6736(19)31789-1; Hammarlund R, 2018, SUBST ABUSE REHABIL, V9, P115, DOI 10.2147/SAR.S183256; Hayhurst KP, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19060; MacKenzie DL, 2015, J EXP CRIMINOL, V11, P565, DOI 10.1007/s11292-015-9244-9; Maulik PK, 2019, BRIT J PSYCHIAT, V214, P90, DOI 10.1192/bjp.2018.190; Peacock A, 2019, LANCET, V394, P1668, DOI 10.1016/S0140-6736(19)32231-7; Vuong T, 2018, J SUBST ABUSE TREAT, V87, P9, DOI 10.1016/j.jsat.2018.01.011; Wegman MP, 2017, LANCET GLOB HEALTH, V5, pE198, DOI 10.1016/S2214-109X(16)30303-5	13	14	14	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 26	2019	394	10208					1490	1493		10.1016/S0140-6736(19)32232-9	http://dx.doi.org/10.1016/S0140-6736(19)32232-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JI3WL	31657727				2023-01-03	WOS:000493399500009
J	Calcagni, N; Gana, K; Quintard, B				Calcagni, Nicolas; Gana, Kamel; Quintard, Bruno			A systematic review of complementary and alternative medicine in oncology: Psychological and physical effects of manipulative and body-based practices	PLOS ONE			English	Review							RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; BREAST-CANCER; AROMATHERAPY MASSAGE; SUPPORTIVE CARE; DELIVERED REFLEXOLOGY; SYMPTOM-MANAGEMENT; CLINICAL-TRIAL; PAIN; ACUPRESSURE	Background Complementary and Alternative Medicines (CAM) are widely used by cancer patients, despite limited evidence of efficacy. Manipulative and body-based practices are some of the most commonly used CAM. This systematic review evaluates their benefits in oncology. Method A systematic literature review was carried out with no restriction of language, time, cancer location or type. PubMed, CENTRAL, PsycArticle, Psychlnfo, Psychology and Behavioral Sciences Collection and SOCindex were queried. Inclusion criteria were adult cancer patients and randomized controlled trials (RCT) assessing manipulative and body-based complementary practices on psychological and symptom outcomes. Effect size was calculated when applicable. Results Of 1624 articles retrieved, 41 articles were included: massage (24), reflexology (11), acu-pressure (6). Overall, 25 studies showed positive and significant effects on symptom outcomes (versus 9 that did not), especially pain and fatigue. Mixed outcomes were found for quality of life (8 papers finding a significant effect vs. 10 which did not) and mood (14 papers vs. 13). In most studies, there was a high risk of bias with a mean Jadad score of 2, making interpretation of results difficult. Conclusion These results seem to indicate that manipulative CAM may be effective on symptom management in cancer. However, more robust methodologies are needed. The methodological requirements of randomized controlled trials are challenging, and more informative results may be provided by more pragmatic study design.	[Calcagni, Nicolas; Quintard, Bruno] INSERM, UMR 1219, Team Handicap Act Cognit Hlth HACH, Lab EA 4136, Bordeaux, France; [Calcagni, Nicolas; Gana, Kamel; Quintard, Bruno] Univ Bordeaux, Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux	Calcagni, N (corresponding author), INSERM, UMR 1219, Team Handicap Act Cognit Hlth HACH, Lab EA 4136, Bordeaux, France.; Calcagni, N (corresponding author), Univ Bordeaux, Bordeaux, France.	nicolas.calcagni@u-bordeaux.fr		Calcagni, Nicolas/0000-0003-3235-7066	French 'Site de Recherche Integree sur le Cancer Bordeaux Recherche Integree en Oncologie' (SIRIC -BRIO)	French 'Site de Recherche Integree sur le Cancer Bordeaux Recherche Integree en Oncologie' (SIRIC -BRIO)	This research was funded by the French `Site de Recherche Integree sur le Cancer Bordeaux Recherche Integree en Oncologie' (SIRIC -BRIO, https://siric-brio.com), which brings together multidisciplinary research teams working in synergy to produce new knowledge for the benefit of patients. NC received the funding.; This research was funded by the French `Site de Recherche Integree sur le Cancer-Bordeaux Recherche Integree en Oncologie' (SIRIC-BRIO), which brings together multidisciplinary research teams working in synergy to produce new knowledge for the benefit of patients.	ALCANTARA J, 2012, CLIN CHIROPR, V15, P23; [Anonymous], 2018, COMPL ALT INT HLTH W; Avci HS, 2016, HOLIST NURS PRACT, V30, P257, DOI 10.1097/HNP.0000000000000161; Ayik C, 2018, COMPLEMENT THER MED, V36, P93, DOI 10.1016/j.ctim.2017.12.002; Barnes Patricia M., 2008, NATL HLTH STAT REPOR, V12, P1, DOI DOI 10.1037/E623942009-001; Beikmoradi A, 2015, IRAN RED CRESCENT ME, V17, DOI 10.5812/ircmj.25919; Berger VW, 2006, J RHEUMATOL, V33, P1710; Billhult A, 2008, AUTON NEUROSCI-BASIC, V140, P88, DOI 10.1016/j.autneu.2008.03.006; Billhult A, 2007, J ALTERN COMPLEM MED, V13, P53, DOI 10.1089/acm.2006.6049; Bishop FL, 2010, PEDIATRICS, V125, P768, DOI 10.1542/peds.2009-1775; Buchanan DR, 2005, J CLIN ONCOL, V23, P6682, DOI 10.1200/JCO.2005.10.728; Buzyn A., 2014, TRIBUNES SANTE, V43, P53; Campeau Marie-Pierre, 2007, J Soc Integr Oncol, V5, P133, DOI 10.2310/7200.2007.018; Clark HD, 1999, CONTROL CLIN TRIALS, V20, P448, DOI 10.1016/S0197-2456(99)00026-4; Cumming G, 2017, INTRO NEW STAT ESTIM; Darabpour S, 2016, IRAN RED CRESCENT ME, V18, DOI 10.5812/ircmj.25461; Donoyama N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196638; Efficace F, 2006, J CLIN EPIDEMIOL, V59; Ernst E, 2011, MATURITAS, V68, P116, DOI 10.1016/j.maturitas.2010.10.011; Ernst E, 2009, SUPPORT CARE CANCER, V17, P333, DOI 10.1007/s00520-008-0569-z; Fernandez-Lao C, 2012, EUR J CANCER CARE, V21, P233, DOI 10.1111/j.1365-2354.2011.01306.x; Giordano J, 2002, J ALTERN COMPLEM MED, V8, P897, DOI 10.1089/10755530260511892; Harrison S, 2017, RES SYNTH METHODS, V8, P281, DOI 10.1002/jrsm.1239; Haute Autorite de Sante, 2011, DEV PRESCR THER NONM; Hernandez-Reif M, 2004, J PSYCHOSOM RES, V57, P45, DOI 10.1016/S0022-3999(03)00500-2; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hodgson H, 2000, Nurs Stand, V14, P33; Hsiung WT, 2015, COMPLEMENT THER MED, V23, P339, DOI 10.1016/j.ctim.2015.03.010; Jackson C, 2015, HOLIST NURS PRACT, V29, P178, DOI 10.1097/HNP.0000000000000088; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jane SW, 2011, PAIN, V152, P2432, DOI 10.1016/j.pain.2011.06.021; Johnson SB, 2018, JAMA ONCOL, V4, P1375, DOI 10.1001/jamaoncol.2018.2487; Kashani Fahimeh, 2014, Iran J Nurs Midwifery Res, V19, P113; Kim JI, 2010, INTEGR CANCER THER, V9, P326, DOI 10.1177/1534735410387423; Kinkead B, 2017, CANCER, V124, P546; Kotronoulas G, 2017, EUR J ONCOL NURS, V29, P60, DOI 10.1016/j.ejon.2017.05.004; Krohn M, 2011, SUPPORT CARE CANCER, V19, P1303, DOI 10.1007/s00520-010-0946-2; Kurt S, 2018, EUR J ONCOL NURS, V32, P12, DOI 10.1016/j.ejon.2017.11.001; Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003; Lai T K T, 2011, Complement Ther Clin Pract, V17, P37, DOI 10.1016/j.ctcp.2010.02.004; Ling WM, 2014, ONCOL NURS FORUM, V41, P581, DOI 10.1188/14.ONF.581-592; Listing M, 2010, ARCH WOMEN MENT HLTH, V13, P165, DOI 10.1007/s00737-009-0143-9; Listing M, 2009, PSYCHO-ONCOLOGY, V18, P1290, DOI 10.1002/pon.1508; Loquai C, 2017, EUR J CANCER, V71, P70, DOI 10.1016/j.ejca.2016.10.029; Massingill Jeanne, 2018, Int J Ther Massage Bodywork, V11, P4; McVicar A, 2016, J ALTERN COMPLEM MED, V22, P739, DOI 10.1089/acm.2016.0015; Miladinia M, 2017, CANCER NURS, V40, P31, DOI 10.1097/NCC.0000000000000353; Moher D, 2015, SYSTEMATIC REV, V4; Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110; Ozdelikara A, 2017, COMPLEMENT THER CLIN, V29, P122, DOI 10.1016/j.ctcp.2017.09.004; Pan YQ, 2014, INT J CLIN ONCOL, V19, P829, DOI 10.1007/s10147-013-0635-5; Price David, 2014, Ann Am Thorac Soc, V11 Suppl 2, pS92, DOI 10.1513/AnnalsATS.201308-276RM; Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505; Rizi MS, 2017, COMPLEMENT THER CLIN, V29, P136, DOI 10.1016/j.ctcp.2017.09.002; Robinson N, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-88; Ross CSK, 2002, PALLIATIVE MED, V16, P544, DOI 10.1191/0269216302pm597xx; Sagar S. M., 2007, CURRENT ONCOLOGY, V45; Scott E, 2019, CANC NURS PRACT, DOI [10.7748/cnp.2019.e1566, DOI 10.7748/CNP.2019.E1566]; Sharif Nia H, 2017, INT J NURS PRACT, V23; Sharp DM, 2010, EUR J CANCER, V46, P312, DOI 10.1016/j.ejca.2009.10.006; Sikorskii A, 2009, NURS RES, V58, P444, DOI 10.1097/NNR.0b013e3181bf15fe; Simon L, 2007, B CANCER, V94, P483; Smith JD, 2012, PSYCHOL METHODS, V17, P510, DOI 10.1037/a0029312; Soden K, 2004, PALLIATIVE MED, V18, P87, DOI 10.1191/0269216304pm874oa; Stephenson N, 2003, APPL NURS RES, V16, P284, DOI 10.1016/j.apnr.2003.08.003; Stephenson NLN, 2007, ONCOL NURS FORUM, V34, P127, DOI 10.1188/07.ONF.127-132; Sterne JAC, BMJ; Toth M, 2013, J ALTERN COMPLEM MED, V19, P650, DOI 10.1089/acm.2012.0466; Trager S., 2016, PLACE THERAPIES COMP, V125, P11; Tsay SL, 2008, CANCER NURS, V31, P109, DOI 10.1097/01.NCC.0000305694.74754.7b; Uysal N, 2017, INT J NURS PRACT, V23, DOI 10.1111/ijn.12532; Valentine JC, 2015, INT ENCY SOCIAL BEHA, P906; Wang T, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0346-9; Weinrich S P, 1990, Appl Nurs Res, V3, P140, DOI 10.1016/S0897-1897(05)80135-1; Wilcock A, 2004, PALLIATIVE MED, V18, P287, DOI 10.1191/0269216304pm895oa; Wilkie D J, 2000, Hosp J, V15, P31; Wilkinson S, 2008, J ADV NURS, V63, P430, DOI 10.1111/j.1365-2648.2008.04712.x; Wilkinson SM, 2007, J CLIN ONCOL, V25, P532, DOI 10.1200/JCO.2006.08.9987; Wilson D., 2018, EFF SIZ CALC; Wyatt G, 2017, J PAIN SYMPTOM MANAG, V54, P670, DOI 10.1016/j.jpainsymman.2017.07.037; Wyatt G, 2012, ONCOL NURS FORUM, V39, P568, DOI 10.1188/12.ONF.568-577; Zhang B, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007750	82	8	8	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2019	14	10							e0223564	10.1371/journal.pone.0223564	http://dx.doi.org/10.1371/journal.pone.0223564			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM9KP	31622362	gold, Green Published			2023-01-03	WOS:000532567300028
J	Maina, M; Tosas-Auguet, O; McKnight, J; Zosi, M; Kimemia, G; Mwaniki, P; Schultsz, C; English, M				Maina, Michuki; Tosas-Auguet, Olga; McKnight, Jacob; Zosi, Mathias; Kimemia, Grace; Mwaniki, Paul; Schultsz, Constance; English, Mike			Evaluating the foundations that help avert antimicrobial resistance: Performance of essential water sanitation and hygiene functions in hospitals and requirements for action in Kenya	PLOS ONE			English	Article								Background Water Sanitation and Hygiene (WASH) in healthcare facilities is critical in the provision of safe and quality care. Poor WASH increases hospital-associated infections and contributes to the rise of antimicrobial resistance (AMR). It is therefore essential for governments and hospital managers to know the state of WASH in these facilities to set priorities and allocate resources. Methods Using a recently developed survey tool and scoring approach, we assessed WASH across four domains in 14 public hospitals in Kenya (65 indicators) with specific assessments of individual wards (34 indicators). Aggregate scores were generated for whole facilities and individual wards and used to illustrate performance variation and link findings to specific levels of health system accountability. To help interpret and contextualise these scores, we used data from key informant interviews with hospital managers and health workers. Results Aggregate hospital performance ranged between 47 and 71% with five of the 14 hospitals scoring below 60%. A total of 116 wards were assessed within these facilities. Linked to specific domains, ward scores varied within and across hospitals and ranged between 20% and 80%. At ward level, some critical indicators, which affect AMR like proper waste segregation and hand hygiene compliance activities had pooled aggregate scores of 45 and 35% respectively. From 31 interviews conducted, the main themes that explained this heterogenous performance across facilities and wards included differences in the built environment, resource availability, leadership and the degree to which local managers used innovative approaches to cope with shortages. Conclusion Significant differences and challenges exist in the state of WASH within and across hospitals. Whereas the senior hospital management can make some improvements, input and support from the national and regional governments are essential to improve WASH as a basic foundation for averting nosocomial infections and the spread of AMR as part of safe, quality hospital care in Kenya.	[Maina, Michuki; Zosi, Mathias; Kimemia, Grace; Mwaniki, Paul; English, Mike] KEMRI Wellcome Trust Res Programme, Hlth Serv Res Grp, Nairobi, Kenya; [Maina, Michuki; Schultsz, Constance] Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands; [Tosas-Auguet, Olga; McKnight, Jacob; English, Mike] Univ Oxford, Nuffield Dept Med, Oxford, England; [Schultsz, Constance] Amsterdam Inst Global Hlth & Dev Amsterdam, Amsterdam, Netherlands	University of Amsterdam; University of Oxford	Maina, M (corresponding author), KEMRI Wellcome Trust Res Programme, Hlth Serv Res Grp, Nairobi, Kenya.; Maina, M (corresponding author), Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands.	mmaina@kemri-wellcome.org	Maina, Michuki/AAD-4712-2022	English, Michael/0000-0002-7427-0826; Mwaniki, Paul/0000-0003-0359-8426; Maina, Jackson/0000-0001-6874-8929; Kimemia, Grace/0000-0003-0080-6322	Economic and Social Research Council ESRCS [ES/P004938/1]; Wellcome Trust [207522, 107769]; African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) [DEL-15-003]; New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); UK government; ESRC [ES/P004938/1] Funding Source: UKRI	Economic and Social Research Council ESRCS; Wellcome Trust(Wellcome TrustEuropean Commission); African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA); New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); UK government; ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	MM, GK, JM, MZ and OT were supported by funds through a grant from the Economic and Social Research Council ESRCS (ES/P004938/1) awarded to ME. A Senior Research Fellowship awarded to ME by The Wellcome Trust (#207522, https://doi.org/10.35802/207522) supported PM. MM received additional support from a grant to the Initiative to Develop African Research Leaders (IDeAL) through the DELTAS Africa Initiative (DEL-15-003), an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (#107769, https://doi.org/10.35802/107769) and the UK government.	Adams J., 2008, ESSENTIAL ENV HLTH S; Amirabadi Zadeh Hassan, 2015, Glob J Health Sci, V8, P199, DOI 10.5539/gjhs.v8n3p199; [Anonymous], R LANG ENV STAT COMP; Barasa E, 2018, HEALTH SYST REFORM, V4, P346, DOI 10.1080/23288604.2018.1513267; Desa U.N., 2016, TRANSF OUR WORLD 203; English M, 2017, HEALTH RES POLICY SY, V15, DOI 10.1186/s12961-017-0172-1; Health Improvement Scotland, 2021, SAFE MANAGEMENT WAST; Ichoho JW, 2013, IMPLEMENTATION UNPUB; Kolmos Hans Jorn, 2012, INFECT CONTROL UPDAT; Maina M, 2019, EXTENDING USE WHO WA; Ministry of Health Kenya, 2017, NAT COUNT HLTH BUDG; QSR International Pty Ltd, 2018, NVIVO QUAL DAT AN SO; Weber N, 2019, J WATER SANIT HYG DE, V9, P380, DOI 10.2166/washdev.2019.090; Weber N, 2018, HEALTH SECUR, V16, pS54, DOI 10.1089/hs.2018.0042; WHO and Unicef, 2019, WATER SANITATION HYG; WHO/UNICEF, 2019, WASH HLTH CAR FAC GL; World Health Organisation, 2016, GLOB STRAT BURD DIS; World Health Organization, 2016, GUID COR COMP INF PR; World Health Organization UNICEF, 2017, WAT SAN HLTH FAC IMP	19	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2019	14	10							e0222922	10.1371/journal.pone.0222922	http://dx.doi.org/10.1371/journal.pone.0222922			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM7QS	31596861	Green Published, gold			2023-01-03	WOS:000532444100014
J	Aboumatar, H; Naqibuddin, M; Chung, SN; Chaudhry, H; Kim, SW; Saunders, J; Bone, L; Gurses, AP; Knowlton, A; Pronovost, P; Putcha, N; Rand, C; Roter, D; Sylvester, C; Thompson, C; Wolff, JL; Hibbard, J; Wise, RA				Aboumatar, Hanan; Naqibuddin, Mohammad; Chung, Suna; Chaudhry, Hina; Kim, Samuel W.; Saunders, Jamia; Bone, Lee; Gurses, Ayse P.; Knowlton, Amy; Pronovost, Peter; Putcha, Nirupama; Rand, Cynthia; Roter, Debra; Sylvester, Carol; Thompson, Carol; Wolff, Jennifer L.; Hibbard, Judith; Wise, Robert A.			Effect of a Hospital-Initiated Program Combining Transitional Care and Long-term Self-management Support on Outcomes of Patients Hospitalized With Chronic Obstructive Pulmonary Disease A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; COPD; INTERVENTIONS; REHOSPITALIZATION; EXACERBATION	IMPORTANCE Patients hospitalized for chronic obstructive pulmonary disease (COPD) exacerbations have high rehospitalization rates and reduced quality of life. OBJECTIVE To evaluate whether a hospital-initiated program that combined transition and long-term self-management support for patients hospitalized due to COPD and their family caregivers can improve outcomes. DESIGN, SETTING, AND PARTICIPANTS Single-site randomized clinical trial conducted in Baltimore, Maryland, with 240 participants. Participants were patients hospitalized due to COPD, randomized to intervention or usual care, and followed up for 6 months after hospital discharge. Enrollment occurred from March 2015 to May 2016; follow-up ended in December 2016. INTERVENTIONS The intervention (n = 120) involved a comprehensive 3-month program to help patients and their family caregivers with long-term self-management of COPD. It was delivered by nurses with special training on supporting patients with COPD using standardized tools. Usual care (n = 120) included transition support for 30 days after discharge to ensure adherence to discharge plan and connection to outpatient care. MAIN OUTCOMES AND MEASURES The primary outcome was number of COPD-related acute care events (hospitalizations and emergency department visits) per participant at 6 months. The co-primary outcome was change in participants' health-related quality of life measured by the St George's Respiratory Questionnaire (SGRQ) at 6 months after discharge (score, 0 [best] to 100 [worst]; 4-point difference is clinically meaningful). RESULTS Among 240 patients who were randomized (mean [SD] age, 64.9 [9.8] years; 61.7% women), 203 (85%) completed the study. The mean (SD) baseline SGRQ score was 62.3 (18.8) in the intervention group and 63.6 (17.4) in the usual care group. The mean number of COPD-related acute care events per participant at 6 months was 1.40 (95% CI, 1.01-1.79) in the intervention group vs 0.72 (95% CI, 0.45-0.97) in the usual care group (difference, 0.68 [95% CI, 0.22-1.15]; P = .004). The mean change in participants' SGRQ total score at 6 months was 2.81 in the intervention group and -2.69 in the usual care group (adjusted difference, 5.18 [95% CI, -2.15 to 12.51]; P = .11). During the study period, there were 15 deaths (intervention: 8; usual care: 7) and 339 hospitalizations (intervention: 202; usual care: 137). CONCLUSIONS AND RELEVANCE In a single-site randomized clinical trial of patients hospitalized due to COPD, a 3-month program that combined transition and long-term self-management support resulted in significantly greater COPD-related hospitalizations and emergency department visits, without improvement in quality of life. Further research is needed to determine reasons for this unanticipated finding.	[Aboumatar, Hanan; Naqibuddin, Mohammad; Chung, Suna; Chaudhry, Hina; Kim, Samuel W.; Saunders, Jamia; Gurses, Ayse P.; Pronovost, Peter] Johns Hopkins Sch Med, Armstrong Inst Patient Safety & Qual, 750 E Pratt St,15th Floor, Baltimore, MD 21202 USA; [Aboumatar, Hanan] Johns Hopkins Sch Med, Dept Med, Div Gen Internal Med, Baltimore, MD USA; [Aboumatar, Hanan; Bone, Lee; Knowlton, Amy; Roter, Debra] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA; [Aboumatar, Hanan; Bone, Lee; Roter, Debra] Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA; [Aboumatar, Hanan; Pronovost, Peter; Wolff, Jennifer L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [Gurses, Ayse P.; Pronovost, Peter] Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD USA; [Gurses, Ayse P.] Johns Hopkins Sch Med, Div Hlth Sci Informat, Baltimore, MD USA; [Gurses, Ayse P.] Johns Hopkins Univ, Whiting Sch Engn, Malone Ctr Engn Healthcare, Baltimore, MD USA; [Putcha, Nirupama; Rand, Cynthia; Wise, Robert A.] Johns Hopkins Sch Med, Pulm & Crit Care Med, Baltimore, MD USA; [Sylvester, Carol] Johns Hopkins Bayview Med Ctr, Baltimore, MD 21224 USA; [Thompson, Carol] Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Biostatist Ctr, Baltimore, MD USA; [Hibbard, Judith] Univ Oregon, Hlth Policy Res Grp, Eugene, OR USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Oregon	Aboumatar, H (corresponding author), Johns Hopkins Sch Med, Armstrong Inst Patient Safety & Qual, 750 E Pratt St,15th Floor, Baltimore, MD 21202 USA.	habouma1@jhmi.edu			PCORI [IHS 1304-7118]	PCORI(Patient-Centered Outcomes Research Institute - PCORI)	Funding was provided by PCORI (Award IHS 1304-7118).	Aboumatar H, 2017, CONTEMP CLIN TRIALS, V62, P159, DOI 10.1016/j.cct.2017.08.018; Bahadori Katayoon, 2007, Int J Chron Obstruct Pulmon Dis, V2, P241; Bourbeau J, 2003, ARCH INTERN MED, V163, P585, DOI 10.1001/archinte.163.5.585; Calverley Peter M A, 2005, COPD, V2, P143; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P421; Chapman KR, 2013, COPD, V10, P243, DOI 10.3109/15412555.2012.733463; Fan VS, 2012, ANN INTERN MED, V156, P673, DOI 10.7326/0003-4819-156-10-201205150-00003; Ford ES, 2013, CHEST, V144, P284, DOI 10.1378/chest.13-0809; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Hibbard JH, 2005, HEALTH SERV RES, V40, P1918, DOI 10.1111/j.1475-6773.2005.00438.x; Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883; Jones PW, 2014, AM J RESP CRIT CARE, V189, P250, DOI 10.1164/rccm.201310-1863PP; JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6; Jones PW, 2002, EUR RESPIR J, V19, P398, DOI 10.1183/09031936.02.00063702; Kumbhare SD, 2016, CHRON OBSTR PULM DIS, V3, P539, DOI 10.15326/jcopdf.3.2.2015.0155; McGhan R, 2007, CHEST, V132, P1748, DOI 10.1378/chest.06-3018; Naylor MD, 2011, HEALTH AFFAIR, V30, P746, DOI 10.1377/hlthaff.2011.0041; Newham JJ, 2017, INT J CHRONIC OBSTR, V12, P1705, DOI 10.2147/COPD.S133317; Ospina MB, 2017, THORAX, V72, P31, DOI 10.1136/thoraxjnl-2016-208820; Pedersen Preben Ulrich, 2017, JBI Database System Rev Implement Rep, V15, P2060, DOI 10.11124/JBISRIR-2016-003045; Pinkhasov RM, 2010, INT J CLIN PRACT, V64, P475, DOI 10.1111/j.1742-1241.2009.02290.x; Prieto-Centurion Valentin, 2014, Ann Am Thorac Soc, V11, P417, DOI 10.1513/AnnalsATS.201308-254OC; Rice KL, 2010, AM J RESP CRIT CARE, V182, P890, DOI 10.1164/rccm.200910-1579OC; Shah T, 2016, CHEST, V150, P916, DOI 10.1016/j.chest.2016.05.002; Varadhan R, 2014, J BIOPHARM STAT, V24, P154, DOI 10.1080/10543406.2013.856023; Vegda K, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-217; Zwerink M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002990.pub3	27	54	55	0	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2019	322	14					1371	1380		10.1001/jama.2019.11982	http://dx.doi.org/10.1001/jama.2019.11982			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE1GT	31593271	Bronze, Green Published			2023-01-03	WOS:000490441900018
J	Munoz, D; Uzoije, P; Reynolds, C; Miller, R; Walkley, D; Pappalardo, S; Tousey, P; Munro, H; Gonzales, H; Song, W; White, C; Blot, WJ; Wang, TJ				Munoz, Daniel; Uzoije, Prince; Reynolds, Cassandra; Miller, Roslynn; Walkley, David; Pappalardo, Susan; Tousey, Phyllis; Munro, Heather; Gonzales, Holly; Song, Wenliang; White, Charles; Blot, William J.; Wang, Thomas J.			Polypill for Cardiovascular Disease Prevention in an Underserved Population	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ASSOCIATION TASK-FORCE; BLOOD-PRESSURE; AMERICAN-COLLEGE; RANDOMIZED-TRIAL; UNITED-STATES; RISK-FACTORS; HYPERTENSION; HEART; PREVALENCE; CARE	Participants in an underserved minority population in the United States were randomly assigned to receive a polypill that included low doses of atorvastatin, amlodipine, losartan, and hydrochlorothiazide or to receive usual care. At 12 months, systolic blood pressure and LDL cholesterol levels were significantly lower in the polypill group. Background Persons with low socioeconomic status and nonwhite persons in the United States have high rates of cardiovascular disease. The use of combination pills (also called "polypills") containing low doses of medications with proven benefits for the prevention of cardiovascular disease may be beneficial in such persons. However, few data are available regarding the use of polypill therapy in underserved communities in the United States, in which adherence to guideline-based care is generally low. Methods We conducted a randomized, controlled trial involving adults without cardiovascular disease. Participants were assigned to the polypill group or the usual-care group at a federally qualified community health center in Alabama. Components of the polypill were atorvastatin (at a dose of 10 mg), amlodipine (2.5 mg), losartan (25 mg), and hydrochlorothiazide (12.5 mg). The two primary outcomes were the changes from baseline in systolic blood pressure and low-density lipoprotein (LDL) cholesterol level at 12 months. Results The trial enrolled 303 adults, of whom 96% were black. Three quarters of the participants had an annual income below $15,000. The mean estimated 10-year cardiovascular risk was 12.7%, the baseline blood pressure was 140/83 mm Hg, and the baseline LDL cholesterol level was 113 mg per deciliter. The monthly cost of the polypill was $26. At 12 months, adherence to the polypill regimen, as assessed on the basis of pill counts, was 86%. The mean systolic blood pressure decreased by 9 mm Hg in the polypill group, as compared with 2 mm Hg in the usual-care group (difference, -7 mm Hg; 95% confidence interval [CI], -12 to -2; P=0.003). The mean LDL cholesterol level decreased by 15 mg per deciliter in the polypill group, as compared with 4 mg per deciliter in the usual-care group (difference, -11 mg per deciliter; 95% CI, -18 to -5; P<0.001). Conclusions A polypill-based strategy led to greater reductions in systolic blood pressure and LDL cholesterol level than were observed with usual care in a socioeconomically vulnerable minority population. (Funded by the American Heart Association Strategically Focused Prevention Research Network and the National Institutes of Health; ClinicalTrials.gov number, .)	[Munoz, Daniel; Reynolds, Cassandra; Wang, Thomas J.] Vanderbilt Univ, Med Ctr, Vanderbilt Translat & Clin Cardiovasc Res Ctr, Nashville, TN USA; [Munoz, Daniel; Reynolds, Cassandra; Gonzales, Holly; Song, Wenliang; Wang, Thomas J.] Vanderbilt Univ, Med Ctr, Div Cardiovasc Med, Nashville, TN USA; [Walkley, David; Pappalardo, Susan; Tousey, Phyllis; Munro, Heather; Blot, William J.] Vanderbilt Univ, Med Ctr, Dept Med, Div Epidemiol, Nashville, TN USA; [Walkley, David; Pappalardo, Susan; Tousey, Phyllis; Munro, Heather; Blot, William J.] Vanderbilt Univ, Med Ctr, Vanderbilt Inst Clin & Translat Res, Nashville, TN USA; [Uzoije, Prince; Miller, Roslynn; White, Charles] Franklin Primary Hlth Ctr, Mobile, AL USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Wang, TJ (corresponding author), Vanderbilt Univ, Vanderbilt Translat & Clin Cardiovasc Res Ctr, Div Cardiovasc Med, Med Ctr, 2220 Pierce Ave,PRB 383, Nashville, TN 37232 USA.	thomas.j.wang@vumc.org; thomas.j.wang@vumc.org		Wang, Thomas/0000-0003-4063-6508; Song, Wenliang/0000-0002-1866-0635	American Heart Association Strategically Focused Prevention Research Network; National Institutes of Health; NATIONAL CANCER INSTITUTE [U01CA202979] Funding Source: NIH RePORTER	American Heart Association Strategically Focused Prevention Research Network; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by the American Heart Association Strategically Focused Prevention Research Network and the National Institutes of Health; ClinicalTrials.gov number, NCT02278471.	Agodoa L, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5680; Ahluwalia JS, 1997, J GEN INTERN MED, V12, P7, DOI 10.1046/j.1525-1497.1997.12107.x; American College of Cardiology, 2016, ASCVD RISK EST PLUS; [Anonymous], 2016, JAMA-J AM MED ASSOC, V316, P1997, DOI DOI 10.1001/jama.2016.15450; Chow CK, 2017, LANCET, V389, P1035, DOI 10.1016/S0140-6736(17)30260-X; Ettehad D, 2016, LANCET, V387, P957, DOI 10.1016/S0140-6736(15)01225-8; Goff DC, 2014, CIRCULATION, V129, pS49, DOI 10.1161/01.cir.0000437741.48606.98; Hajjar I, 2003, JAMA-J AM MED ASSOC, V290, P199, DOI 10.1001/jama.290.2.199; Hill MN, 1999, AM J HYPERTENS, V12, P951, DOI 10.1016/S0895-7061(99)00121-1; Khot UN, 2003, JAMA-J AM MED ASSOC, V290, P898, DOI 10.1001/jama.290.7.898; Khoury MJ, 2016, JAMA-J AM MED ASSOC, V316, P1357, DOI 10.1001/jama.2016.12260; Kotchen JM, 1998, AM J PUBLIC HEALTH, V88, P1696, DOI 10.2105/AJPH.88.11.1696; Law MR, 2003, BRIT MED J, V326, P1427, DOI 10.1136/bmj.326.7404.1427; Mensah GA, 2018, CIRC RES, V122, P213, DOI 10.1161/CIRCRESAHA.117.312243; Mihaylova B, 2012, LANCET, V380, P581, DOI 10.1016/S0140-6736(12)60367-5; Patel A, 2015, EUR J PREV CARDIOL, V22, P920, DOI 10.1177/2047487314530382; Pencina MJ, 2014, NEW ENGL J MED, V370, P1422, DOI 10.1056/NEJMoa1315665; Psaty BM, 2018, JAMA-J AM MED ASSOC, V320, P751, DOI 10.1001/jama.2018.8377; Rodgers A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019857; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Roth GA, 2017, J AM COLL CARDIOL, V70, P1, DOI 10.1016/j.jacc.2017.04.052; Roth GA, 2017, JAMA-J AM MED ASSOC, V317, P1976, DOI 10.1001/jama.2017.4150; Sampson UKA, 2014, CIRC-CARDIOVASC QUAL, V7, P33, DOI 10.1161/CIRCOUTCOMES.113.000155; Selak V, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3318; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; Signorello LB, 2010, J HEALTH CARE POOR U, V21, P26, DOI 10.1353/hpu.0.0245; Silverman MG, 2016, JAMA-J AM MED ASSOC, V316, P1289, DOI 10.1001/jama.2016.13985; Soliman EZ, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-3; Stone NJ, 2014, CIRCULATION, V129, pS1, DOI 10.1161/01.cir.0000437738.63853.7a; Sundstrom J, 2015, ANN INTERN MED, V162, P184, DOI 10.7326/M14-0773; Taylor HA, 2009, AM J MED, V122, P454, DOI 10.1016/j.amjmed.2008.09.049; Wald DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041297; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Wang TJ, 2006, NEW ENGL J MED, V355, P2631, DOI 10.1056/NEJMoa055373; Webster R, 2018, JAMA-J AM MED ASSOC, V320, P566, DOI 10.1001/jama.2018.10359; Whelton PK, 2018, CIRCULATION, V138, pE484, DOI 10.1161/CIR.0000000000000596; Yusuf S, 2009, LANCET, V373, P1341, DOI 10.1016/S0140-6736(09)60611-5; Yusuf S, 2016, NEW ENGL J MED, V374, P2032, DOI 10.1056/NEJMoa1600177; Zanchetti A, 2015, CIRC RES, V116, P1058, DOI 10.1161/CIRCRESAHA.116.303641	39	77	79	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 19	2019	381	12					1114	1123		10.1056/NEJMoa1815359	http://dx.doi.org/10.1056/NEJMoa1815359			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IZ4PY	31532959	Green Accepted, Bronze			2023-01-03	WOS:000487066900006
J	Doughty, H; Verissimo, D; Tan, RCQ; Lee, JSH; Carrasco, LR; Oliver, K; Milner-Gulland, EJ				Doughty, Hunter; Verissimo, Diogo; Tan, Regina Chun Qi; Lee, Janice Ser Huay; Carrasco, L. Roman; Oliver, Kathryn; Milner-Gulland, E. J.			Saiga horn user characteristics, motivations, and purchasing behaviour in Singapore	PLOS ONE			English	Article							WILDLIFE TRADE; CONSUMPTION; CHILDHOOD; ATTITUDES; MEDICINE	Unsustainable wildlife trade is a pervasive issue affecting wildlife globally. To address this issue, a plethora of demand reduction efforts have been carried out. These necessitate consumer research which provides crucial knowledge for designing and evaluating targeted interventions. We implemented a rigorous consumer survey on saiga (Saiga tatarica) horn use in Singapore, where usage is legal and widely sold. Saiga are Critically Endangered antelopes from Central Asia with horns (often marketed as ling yang) used in traditional Chinese medicine (TCM). Few past studies have assessed saiga horn consumers. This work is the most extensive consumer research to date specifically characterising saiga horn consumers and usage. We conducted 2294 in-person surveys on saiga horn use with Chinese Singaporeans, employing neutral questioning approaches. We found 19% of individuals reported saiga horn as a product they choose most often for themselves and/or others when treating fever and/or heatiness (a TCM state of illness), indicating a minimum estimate of high-frequency usage, not including possible low-frequency users. Overall saiga users were most characterised as middle-aged Buddhists and Taoists. However, saiga users were found in a range of demographic groups. Women preferred saiga shavings (the more traditional form), while men preferred saiga cooling water (the more modern form). About 53% of individuals who used saiga horn themselves also bought it for someone else. Buyers for others were most likely to be female middle-aged Buddhists or Taoists. Key motivating reasons for usage were "it works" and "someone recommended it to me." The top two reported recommenders were family and TCM shopkeepers. Saiga users were more likely than nonsaiga users to perceive saiga as a common species in the wild. This research holds significance for interventions targeting saiga horn consumption within Singapore and throughout Asia, by identifying potential target audiences, product types, non-desirable alternatives, and motivations for use.	[Doughty, Hunter; Verissimo, Diogo; Milner-Gulland, E. J.] Univ Oxford, Dept Zool, Oxford, England; [Verissimo, Diogo] San Diego Zoo, Inst Conservat Res, Escondido, CA USA; [Lee, Janice Ser Huay] Nanyang Technol Univ Singapore, Asian Sch Environm, Singapore, Singapore; [Carrasco, L. Roman] Natl Univ Singapore, Dept Biol Sci, Singapore, Singapore; [Oliver, Kathryn] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, London, England	University of Oxford; Zoological Society of San Diego; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore; University of London; London School of Hygiene & Tropical Medicine	Doughty, H (corresponding author), Univ Oxford, Dept Zool, Oxford, England.	hunter.doughty@zoo.ox.ac.uk	Carrasco, Luis R/H-8017-2012; Oliver, Kathryn/I-9905-2019	Carrasco, Luis R/0000-0002-2894-1473; Oliver, Kathryn/0000-0002-4326-5258; Doughty, Hunter/0000-0001-5203-5115	Oxford University through the Oxford Martin Programme on Illegal Wildlife Trade	Oxford University through the Oxford Martin Programme on Illegal Wildlife Trade	This research was funded by Oxford University through the Oxford Martin Programme on Illegal Wildlife Trade (grant held by EJMG). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barton K., 2016, MUMIN MULTIMODEL INF; Brooks E, 2010, BIOL CONSERV, V143, DOI [10.1016/j.biocon.2010.07.028, DOI 10.1016/J.BIOCON.2010.07.028]; Brown TJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009828; Challender DWS, 2014, CONSERV LETT, V7, P484, DOI 10.1111/conl.12082; Chang L, 2014, J WOMEN AGING, V26, P257, DOI 10.1080/08952841.2014.888881; Christy B., 2014, NATL GEOGRAPHIC ONLI; CITES Seventieth meeting of the Standing Committee, 2018, CITES 17 M STAND COM; Convention on the Conservation of Migratory Species of Wild Animals (CMS), 2005, MEM UND CONS REST SU; Cooke L, 2007, J HUM NUTR DIET, V20, P294, DOI 10.1111/j.1365-277X.2007.00804.x; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Dutton AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021243; Fox J, 2002, COX PROPORTIONAL HAZ; Frost J., 2017, NONPARAMETRIC TESTS; Greenfield S, 2019, SOC MARK Q, V25, P40, DOI 10.1177/1524500418813543; Haenlein C, 2016, WHITEHALL PAPERS NAT; IUCN SSC Antelope Specialist Group, 2018, IUCN RED LIST THREAT, DOI [10.2305/IUCN.UK.2018-2.RLTS.T19832A50194357.en, DOI 10.2305/IUCN.UK.2018-2.RLTS.T19832A50194357.EN]; John FAVS, 2014, J APPL ECOL, V51, P1479, DOI 10.1111/1365-2664.12352; Kabilsingh C, 2004, EARLY BUDDHIST VIEWS, P130; Kaptchuk T.J., 2000, CHINESE MED WEB HAS; Kim DA, 2015, LANCET, V386, P145, DOI 10.1016/S0140-6736(15)60095-2; Kock RA, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aao2314; Kuhl A, 2009, BIOL CONSERV, V142, P1442, DOI 10.1016/j.biocon.2009.02.009; Lam J., 2012, THESIS; Li J, 2014, CONSERV BIOL, V28, P87, DOI 10.1111/cobi.12135; Lim MK, 2005, COMPLEMENT THER MED, V13, P16, DOI 10.1016/j.ctim.2004.11.002; Loh CH, 2009, SINGAP MED J, V50, P1162; Lokker N, 2009, PEDIATRICS, V123, P1464, DOI 10.1542/peds.2008-0854; Milner-Gulland EJ, 2001, ORYX, V35, P340, DOI 10.1017/S0030605300032105; Moorhouse TP, 2019, J SUSTAIN TOUR, V27, P12, DOI 10.1080/09669582.2018.1533019; Olmedo A., 2017, CONSERV LETT, V11, P1, DOI DOI 10.1111/C0NL.12365; Orleans CT., 2008, THEORY REASONED ACTI, V4th, P68; Rittersmith A., 2009, JASO ONLINE, V1; Roberton S, 2014, NATL GEOGRAPHIC BLOG; Rosen GE, 2010, ECOHEALTH, V7, P24, DOI 10.1007/s10393-010-0317-y; Ryan SM, 2010, AUST NZ J PSYCHIAT, V44, P774, DOI 10.1080/00048674.2010.501759; Schneider J.L., 2008, J CONTEMP CRIM JUST, V24, P274, DOI [10.1177/1043986208318226, DOI 10.1177/1043986208318226]; Singapore Department of Statistics, 2017, YB STAT SING; Singh AS, 2008, OBES REV, V9, P474, DOI 10.1111/j.1467-789X.2008.00475.x; 't Sas-Rolfes M, 2019, ANNU REV ENV RESOUR, V44, P201, DOI 10.1146/annurev-environ-101718-033253; Taher A, 2012, INT J PHARM HEALTHC, V6, P140, DOI 10.1108/17506121211243068; Tan J, 2011, J RETAILING CONSUMER, V18; Theng M, 2018, ORYX, V52, P736, DOI 10.1017/S0030605317001624; Trim K, 2012, OBSTET GYNECOL INT, V2012, DOI 10.1155/2012/921236; Truong VD, 2016, CONSUMP MARK CULT, V19, P353, DOI 10.1080/10253866.2015.1108915; URA, 2014, URB RED AUTH MAST PL; Verissimo D, 2019, CONSERV BIOL, V33, P623, DOI 10.1111/cobi.13227; Von Meibom S., 2010, SAIGA ANTELOPE TRADE; Xia Y, 2006, ASIA PAC J MARKET LO, V18, P201, DOI 10.1108/13555850610675661; Zhang L, 2008, BIODIVERS CONSERV, V17, P1493, DOI 10.1007/s10531-008-9358-8	49	24	24	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2019	14	9							e0222038	10.1371/journal.pone.0222038	http://dx.doi.org/10.1371/journal.pone.0222038			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM3TE	31504051	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000532172700017
J	Dingley, J; Okano, S; Lee-Kelland, R; Scull-Brown, E; Thoresen, M; Chakkarapani, E				Dingley, John; Okano, Satomi; Lee-Kelland, Richard; Scull-Brown, Emma; Thoresen, Marianne; Chakkarapani, Ela			Closed circuit xenon delivery for 72h in neonatal piglets following hypoxic insult using an ambient pressure automated control system: Development, technical evaluation and pulmonary effects	PLOS ONE			English	Article							COMPUTER-CONTROLLED INFUSION; THERAPEUTIC HYPOTHERMIA; CARDIAC-ARREST; INHALED XENON; DELAYED XENON; NEUROPROTECTION; ANESTHESIA; PROTECTS; INJURY; FEASIBILITY	Background Therapeutic hypothermia (TH) for 72h is the standard treatment following neonatal encephalopathy (NE). However, one-third do not benefit and adjunctive therapies are urgently needed. Xenon enhances neuroprotection with TH when administered at 50% concentration within 5hours of hypoxia in experimental studies. Delayed initiation (similar to 10 hours of age) of 30% xenon for 24 hours during TH did not improve early adverse biomarkers in a clinical trial of Xenon+TH vs TH. After hypoxia-ischemia, excitotoxic injury via N-methyl-D-aspartate receptor overactivation lasts days. Since xenon partially inhibits this receptor, we hypothesised that giving 50% xenon throughout the entire 72h TH and rewarming periods would enhance neuroprotection. Xenon costs $30/litre, so a closed-circuit breathing system is desirable with automated fresh gas delivery. Methods Seven mechanically ventilated newborn pigs were randomized to receive 50% inhaled xenon for 72h during hypothermia (rectal-temperature 35 degrees C) and subsequent rewarming following a global hypoxic-ischemic insult (XeHT, N = 4) or under normothermia for 72h (rectal-temperature 38.5 degrees C) following sham insult (XeNT, N = 3). An automated fresh gas delivery system injected oxygen/air/xenon boluses into a closed-circuit based on measured Results and discussion Median (IQR) xenon consumption was 0.31 L/h (0.18, 0.50) and 0.34L/h (0.32, 0.49) for hypothermic and normothermic groups respectively, 0.34L/h (0.25, 0.53) overall. 92% of 9626 xenon and 69% of 9635 oxygen measurements were within 20% variation from targets. For xenon concentration, the median absolute performance errors for the XeHT and XeNT groups were 6.14% and 3.84% respectively and 4.31% overall. For oxygen these values were 13.42%, 15.05% and 12.4% respectively. There were no adverse pulmonary pathophysiology findings. Clinical problems over the total period included three related to sensors, seven breathing system leaks, ten partial and one complete tracheal tube occlusion episodes. Conclusion The automated controller functioned as intended maintaining an inhaled xenon concentration close to the 50% target for 72-78h at a xenon cost of $11.1/h.	[Dingley, John] ABM Univ Hlth Board, Dept Anaesthet, Swansea, W Glam, Wales; [Dingley, John] Swansea Univ, Coll Med, Swansea, W Glam, Wales; [Okano, Satomi; Lee-Kelland, Richard; Scull-Brown, Emma; Thoresen, Marianne; Chakkarapani, Ela] Univ Bristol, Bristol Med Sch, Translat Hlth Sci, Bristol, Avon, England; [Thoresen, Marianne] Univ Oslo, Inst Basic Med Sci, Dept Physiol, Oslo, Norway	Swansea University; University of Bristol; University of Oslo	Dingley, J (corresponding author), ABM Univ Hlth Board, Dept Anaesthet, Swansea, W Glam, Wales.; Dingley, J (corresponding author), Swansea Univ, Coll Med, Swansea, W Glam, Wales.	j.dingley@swan.ac.uk		Chakkarapani, Elavazhagan/0000-0003-3380-047X	Wellcome Trust TRACK award [WT14]; ROSETREES TRUST [A1017]; SPARKS [18BTL01]	Wellcome Trust TRACK award; ROSETREES TRUST(Rosetrees Trust); SPARKS	This work was supported by the Wellcome Trust TRACK award WT14, (https://wellcome.ac.uk/) and ROSETREES TRUST, A1017 (https://rosetreestrust.co.uk) to EC. MT received a grant from SPARKS 18BTL01 that supported the staff salaries for the project (https://www.sparks.org.uk/).The sponsors or funders did not play any role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.; We thank Dr Xun Liu PhD, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol BS28EG, United Kingdom for assisting with the experiments and Dr Silvia Planas MD, Consultant Pathologist, North Bristol Hospital NHS Trust, Bristol, United Kingdom, for blind scoring of the lung sections into 4 categories.	Arola O, 2017, J AM COLL CARDIOL, V70, P2652, DOI 10.1016/j.jacc.2017.09.1088; Azzopardi D, 2016, LANCET NEUROL, V15, P145, DOI 10.1016/S1474-4422(15)00347-6; Bantel C, 2009, ANESTHESIOLOGY, V110, P986, DOI 10.1097/ALN.0b013e31819dadc7; Baumert JH, 2007, ANESTH ANALG, V105, P1200, DOI 10.1213/01.ane.0000284697.73471.9c; Campos-Pires R, 2019, BRIT J ANAESTH, V123, P60, DOI 10.1016/j.bja.2019.02.032; Campos-Pires R, 2018, J NEUROTRAUM, V35, P1037, DOI 10.1089/neu.2017.5360; Chakkarapani E., 2015, ANIMAL MODELS DEVELO; Chakkarapani E, 2009, ANESTH ANALG, V109, P451, DOI 10.1213/ane.0b013e3181aa9550; Chakkarapani E, 2010, ANN NEUROL, V68, P330, DOI 10.1002/ana.22016; Dickinson R, 2007, ANESTHESIOLOGY, V107, P756, DOI 10.1097/01.anes.0000287061.77674.71; Dingley J, 2015, ANESTH ANALG, V120, P1331, DOI 10.1213/ANE.0000000000000693; Dingley J, 2014, PEDIATRICS, V133, P809, DOI 10.1542/peds.2013-0787; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; Fries M, 2012, CRIT CARE MED, V40, P1297, DOI 10.1097/CCM.0b013e31823c8ce7; Goto T, 1998, BRIT J ANAESTH, V80, P255, DOI 10.1093/bja/80.2.255; Gruss M, 2004, MOL PHARMACOL, V65, P443, DOI 10.1124/mol.65.2.443; Hagberg H, 2016, NEUROBIOL DIS, V92, P102, DOI 10.1016/j.nbd.2015.09.011; Hobbs C, 2008, STROKE, V39, P1307, DOI 10.1161/STROKEAHA.107.499822; Jia P, 2015, CRIT CARE MED, V43, pE250, DOI 10.1097/CCM.0000000000001001; Jia P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064329; Kee WDN, 2007, ANAESTHESIA, V62, P1251, DOI 10.1111/j.1365-2044.2007.05257.x; Laitio R, 2016, JAMA-J AM MED ASSOC, V315, P1120, DOI 10.1001/jama.2016.1933; Li Q, 2013, HEART LUNG CIRC, V22, P276, DOI 10.1016/j.hlc.2012.10.016; Liu X, 2017, EPILEPSIA, V58, P1902, DOI 10.1111/epi.13914; Liu X, 2015, PEDIATR RES, V77, P779, DOI 10.1038/pr.2015.49; Miao YF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18914-6; National Institute for Health and Care Excellence, 2010, THER HYP INTR TEMP M; Peng T, 2013, CNS NEUROSCI THER; PIETRA GG, 1989, CIRCULATION, V80, P1198, DOI 10.1161/01.CIR.80.5.1198; Preckel B, 2006, ANESTHESIOLOGY, V105, P187, DOI 10.1097/00000542-200607000-00029; Rawat S, 2010, ANESTH ANALG, V110, P101, DOI 10.1213/ANE.0b013e3181be0e17; Sheng SP, 2012, ANESTHESIOLOGY, V117, P1262, DOI 10.1097/ALN.0b013e3182746b81; Thoresen M, 1996, PEDIATR RES, V40, P738, DOI 10.1203/00006450-199611000-00014; Thoresen M, 2015, COOL XENON STUDY; Thoresen M, 2009, J CEREBR BLOOD F MET, V29, P707, DOI 10.1038/jcbfm.2008.163; VARVEL JR, 1992, J PHARMACOKINET BIOP, V20, P63, DOI 10.1007/BF01143186; Veldeman M, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00511; Zhao HL, 2014, KIDNEY INT, V85, P112, DOI 10.1038/ki.2013.334	38	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2020	15	1							e0224447	10.1371/journal.pone.0224447	http://dx.doi.org/10.1371/journal.pone.0224447			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5QJ	31961878	Green Published, gold			2023-01-03	WOS:000534372000004
J	Li, Z; Jiang, YY; Guengerich, FP; Ma, L; Li, SY; Zhang, W				Li, Zhong; Jiang, Yuanyuan; Guengerich, F. Peter; Ma, Li; Li, Shengying; Zhang, Wei			Engineering cytochrome P450 enzyme systems for biomedical and biotechnological applications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review						cytochrome P450; enzyme mechanism; protein engineering; metabolic engineering; substrate specificity; directed evolution; electron source engineering; ferredoxin; light activation; redox partner proteins; substrate engineering	SELF-SUFFICIENT CYTOCHROME-P450; FATTY-ACID HYDROXYLATION; DRIVEN DRUG-METABOLISM; ELECTRON-TRANSFER; CRYSTAL-STRUCTURE; P450 ENZYMES; ESCHERICHIA-COLI; STRUCTURAL BASIS; MECHANISTIC INSIGHTS; DIRECTED EVOLUTION	Cytochrome P450 enzymes (P450s) are broadly distributed among living organisms and play crucial roles in natural product biosynthesis, degradation of xenobiotics, steroid biosynthesis, and drug metabolism. P450s are considered as the most versatile biocatalysts in nature because of the vast variety of substrate structures and the types of reactions they catalyze. In particular, P450s can catalyze regio- and stereoselective oxidations of nonactivated C?H bonds in complex organic molecules under mild conditions, making P450s useful biocatalysts in the production of commodity pharmaceuticals, fine or bulk chemicals, bioremediation agents, flavors, and fragrances. Major efforts have been made in engineering improved P450 systems that overcome the inherent limitations of the native enzymes. In this review, we focus on recent progress of different strategies, including protein engineering, redox-partner engineering, substrate engineering, electron source engineering, and P450-mediated metabolic engineering, in efforts to more efficiently produce pharmaceuticals and other chemicals. We also discuss future opportunities for engineering and applications of the P450 systems.	[Li, Zhong; Jiang, Yuanyuan] Chinese Acad Sci, Shandong Prov Key Lab Synthet Biol, Qingdao 266101, Shandong, Peoples R China; [Li, Zhong; Jiang, Yuanyuan] Chinese Acad Sci, CAS Key Lab Biofuels, Qingdao Inst Bioenergy & Bioproc Technol, Qingdao 266101, Shandong, Peoples R China; [Li, Zhong; Jiang, Yuanyuan; Ma, Li; Li, Shengying; Zhang, Wei] Shandong Univ, State Key Lab Microbial Technol, Qingdao 266237, Shandong, Peoples R China; [Li, Zhong; Jiang, Yuanyuan] Univ Chinese Acad Sci, Beijing 100049, Peoples R China; [Guengerich, F. Peter] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; [Li, Shengying; Zhang, Wei] Qingdao Natl Lab Marine Sci & Technol, Lab Marine Biol & Biotechnol, Qingdao 266237, Shandong, Peoples R China	Chinese Academy of Sciences; Chinese Academy of Sciences; Qingdao Institute of Bioenergy & Bioprocess Technology, CAS; Shandong University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Vanderbilt University; Qingdao National Laboratory for Marine Science & Technology	Zhang, W (corresponding author), Shandong Univ, State Key Lab Microbial Technol, Qingdao 266237, Shandong, Peoples R China.; Zhang, W (corresponding author), Qingdao Natl Lab Marine Sci & Technol, Lab Marine Biol & Biotechnol, Qingdao 266237, Shandong, Peoples R China.	zhang_wei@sdu.edu.cn	jiang, anyi/GPT-0379-2022	Zhang, Wei/0000-0001-9459-680X	National Key R&D Program of China [2019YFA0905400-04]; National Natural Science Foundation of China [31570030, 31600045, 31872729]; National Institutes of Health [R01 GM118122]; Qilu Youth Scholar Startup Funding of Shandong University; State Key Laboratory of Bio-organic and Natural Products Chemistry, CAS [SKLBNPC18242]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Qilu Youth Scholar Startup Funding of Shandong University; State Key Laboratory of Bio-organic and Natural Products Chemistry, CAS(Chinese Academy of Sciences)	This work was supported by National Key R&D Program of China Grant 2019YFA0905400-04 (to W. Z.), National Natural Science Foundation of China Grants 31570030 (to W. Z.), 31600045 (to L. M.), and 31872729 (to S. L.); National Institutes of Health Grant R01 GM118122 (to F. P. G.); a Qilu Youth Scholar Startup Funding of Shandong University grant (to W. Z.); and the State Key Laboratory of Bio-organic and Natural Products Chemistry, CAS, Grant SKLBNPC18242 (to W. Z.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Anzai Y, 2008, CHEM BIOL, V15, P950, DOI 10.1016/j.chembiol.2008.07.014; Arnold FH, 1998, ACCOUNTS CHEM RES, V31, P125, DOI 10.1021/ar960017f; Ba L, 2013, BIOTECHNOL BIOENG, V110, P2815, DOI 10.1002/bit.24960; Ban JG, 2014, J IND MICROBIOL BIOT, V41, P879, DOI 10.1007/s10295-014-1432-5; Barriuso J, 2011, J AM CHEM SOC, V133, P8078, DOI 10.1021/ja201138v; Bate N, 1999, J IND MICROBIOL BIOT, V23, P118, DOI 10.1038/sj.jim.2900707; Bell SG, 2012, CHEM COMMUN, V48, P11692, DOI 10.1039/c2cc35968e; Belsare KD, 2017, PROTEIN ENG DES SEL, V30, P119, DOI 10.1093/protein/gzw072; Bernhardt R, 2014, APPL MICROBIOL BIOT, V98, P6185, DOI 10.1007/s00253-014-5767-7; Biggs BW, 2016, P NATL ACAD SCI USA, V113, P3209, DOI 10.1073/pnas.1515826113; Bistolas N, 2005, BIOSENS BIOELECTRON, V20, P2408, DOI 10.1016/j.bios.2004.11.023; Chen J, 2019, ACS CATAL, V9, P7350, DOI 10.1021/acscatal.9b02507; Chun YJ, 2007, J BIOL CHEM, V282, P17486, DOI 10.1074/jbc.M700863200; Ciaramella A, 2017, REND LINCEI-SCI FIS, V28, P169, DOI 10.1007/s12210-016-0581-z; Cong ZQ, 2015, ACS CATAL, V5, P150, DOI 10.1021/cs501592f; Coon MJ, 2005, ANNU REV PHARMACOL, V45, P1, DOI 10.1146/annurev.pharmtox.45.120403.100030; Dalber A, 2005, J INORG BIOCHEM, V99, P185, DOI 10.1016/j.jinorgbio.2004.09.018; Di Nardo G, 2012, INT J MOL SCI, V13, P15901, DOI 10.3390/ijms131215901; Ding Y, 2008, J AM CHEM SOC, V130, P5492, DOI 10.1021/ja710520q; Dodhia VR, 2006, J BIOL INORG CHEM, V11, P903, DOI 10.1007/s00775-006-0144-3; Du L, 2017, P NATL ACAD SCI USA, V114, pE5129, DOI 10.1073/pnas.1702317114; Du L, 2016, J BIOL CHEM, V291, P6583, DOI 10.1074/jbc.M115.695320; Ewen KM, 2011, BBA-PROTEINS PROTEOM, V1814, P111, DOI 10.1016/j.bbapap.2010.06.003; Fairhead M, 2005, J BIOL INORG CHEM, V10, P842, DOI 10.1007/s00775-005-0033-1; Fujii T, 2009, BIOSCI BIOTECH BIOCH, V73, P805, DOI 10.1271/bbb.80627; Fujii Y, 2011, BIOCHEM BIOPH RES CO, V404, P511, DOI 10.1016/j.bbrc.2010.12.013; Fujii Y, 2009, BIOCHEM BIOPH RES CO, V385, P170, DOI 10.1016/j.bbrc.2009.05.033; Galanie S, 2015, SCIENCE, V349, P1095, DOI 10.1126/science.aac9373; Gandomkar S, 2018, ANGEW CHEM INT EDIT, V57, P427, DOI 10.1002/anie.201710227; Girhard M, 2013, BIOTECHNOL APPL BIOC, V60, P111, DOI 10.1002/bab.1063; Guengerich FP, 2018, ACS CATAL, V8, P10964, DOI 10.1021/acscatal.8b03401; Guengerich FP, 2013, J BIOL CHEM, V288, P17065, DOI 10.1074/jbc.R113.462275; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; Gumulya Y, 2018, NAT CATAL, V1, P878, DOI 10.1038/s41929-018-0159-5; Guo J, 2013, P NATL ACAD SCI USA, V110, P12108, DOI 10.1073/pnas.1218061110; Hannemann F, 2007, BBA-GEN SUBJECTS, V1770, P330, DOI 10.1016/j.bbagen.2006.07.017; Hayashi K, 2008, BIOCHEMISTRY-US, V47, P11964, DOI 10.1021/bi801222d; Hayashi K, 2010, FEBS J, V277, P3999, DOI 10.1111/j.1742-4658.2010.07791.x; HOSOBUCHI M, 1993, BIOTECHNOL BIOENG, V42, P815, DOI 10.1002/bit.260420705; Hsu PY, 1999, J BIOL CHEM, V274, P762, DOI 10.1074/jbc.274.2.762; Huang XN, 2019, ACS SYNTH BIOL, V8, P818, DOI 10.1021/acssynbio.8b00489; Ito S, 1999, ACTA CRYSTALLOGR D, V55, P1209, DOI 10.1107/S0907444999003716; Janocha S, 2016, CHEMBIOCHEM, V17, P852, DOI 10.1002/cbic.201500524; Jensen K, 2011, ACS CHEM BIOL, V6, P533, DOI 10.1021/cb100393j; Jiang YY, 2018, CHINESE J ORG CHEM, V38, P2307, DOI 10.6023/cjoc201805055; Johannes TW, 2007, BIOTECHNOL BIOENG, V96, P18, DOI 10.1002/bit.21168; Karasawa M, 2018, ANGEW CHEM INT EDIT, V57, P12264, DOI 10.1002/anie.201804924; Kawakami N, 2011, ANGEW CHEM INT EDIT, V50, P5315, DOI 10.1002/anie.201007975; KAWAUCHI H, 1994, BBA-GENE STRUCT EXPR, V1219, P179, DOI 10.1016/0167-4781(94)90266-6; Kern F, 2015, SCI REP-UK, V5, DOI 10.1038/srep14881; Khatri Y, 2010, CHEM BIOL, V17, P1295, DOI 10.1016/j.chembiol.2010.10.010; KIDO T, 1979, J BIOL CHEM, V254, P1806; Kille S, 2011, NAT CHEM, V3, P738, DOI [10.1038/NCHEM.1113, 10.1038/nchem.1113]; KLINGENBERG M, 1958, ARCH BIOCHEM BIOPHYS, V75, P376, DOI 10.1016/0003-9861(58)90436-3; Krishnan S, 2011, J PHYS CHEM B, V115, P8371, DOI 10.1021/jp201235m; Krishnan S, 2011, J AM CHEM SOC, V133, P1459, DOI 10.1021/ja108637s; Krishnan S, 2009, J AM CHEM SOC, V131, P16215, DOI 10.1021/ja9065317; Kulig JK, 2015, BIOORGAN MED CHEM, V23, P5603, DOI 10.1016/j.bmc.2015.07.025; Kumar S, 2003, J BIOL CHEM, V278, P17178, DOI 10.1074/jbc.M212515200; Lee DS, 2003, J BIOL CHEM, V278, P9761, DOI 10.1074/jbc.M211575200; Lee MJ, 2013, APPL ENVIRON MICROB, V79, P2253, DOI 10.1128/AEM.03722-12; Lewis JC, 2009, P NATL ACAD SCI USA, V106, P16550, DOI 10.1073/pnas.0908954106; Li QL, 2018, ORG LETT, V20, P4854, DOI 10.1021/acs.orglett.8b01997; Li SY, 2007, J AM CHEM SOC, V129, P12940, DOI 10.1021/ja075842d; Li SY, 2009, P NATL ACAD SCI USA, V106, P18463, DOI 10.1073/pnas.0907203106; Liu WF, 2007, BIOTECHNOL ADV, V25, P369, DOI 10.1016/j.biotechadv.2007.03.002; Liu Y, 2014, BIOTECHNOL BIOFUELS, V7, DOI 10.1186/1754-6834-7-28; Lowell AN, 2017, J AM CHEM SOC, V139, P7913, DOI 10.1021/jacs.7b02875; Lu C, 2018, ACS CATAL, V8, P5794, DOI 10.1021/acscatal.8b01313; Lu JS, 2015, ELECTROCHIM ACTA, V165, P36, DOI 10.1016/j.electacta.2015.02.183; Lu JS, 2014, CHEM COMMUN, V50, P13896, DOI 10.1039/c4cc06200k; Lu Y, 2007, J IND MICROBIOL BIOT, V34, P247, DOI 10.1007/s10295-006-0193-1; Ma L, 2015, APPL ENVIRON MICROB, V81, P6268, DOI 10.1128/AEM.01353-15; Ma NN, 2018, ANGEW CHEM INT EDIT, V57, P7628, DOI 10.1002/anie.201801592; Mak LH, 2010, ANAL CHEM, V82, P5357, DOI 10.1021/ac101072h; Matthews S, 2017, J BIOL CHEM, V292, P5128, DOI 10.1074/jbc.M116.762336; McLean KJ, 2015, ADV EXP MED BIOL, V851, P299, DOI 10.1007/978-3-319-16009-2_11; McLean KJ, 2015, P NATL ACAD SCI USA, V112, P2847, DOI 10.1073/pnas.1419028112; Meinhold P, 2006, ADV SYNTH CATAL, V348, P763, DOI 10.1002/adsc.200505465; Mellor SB, 2017, PHOTOSYNTH RES, V134, P329, DOI 10.1007/s11120-017-0364-0; Mellor SB, 2016, ACS CHEM BIOL, V11, P1862, DOI 10.1021/acschembio.6b00190; Menard A, 2012, CHEMBIOCHEM, V13, P2527, DOI 10.1002/cbic.201200524; Meunier B, 2004, CHEM REV, V104, P3947, DOI 10.1021/cr020443g; Mie Y, 2009, J AM CHEM SOC, V131, P6646, DOI 10.1021/ja809364r; Minas W, 1998, BIOTECHNOL PROGR, V14, P561, DOI 10.1021/bp980055t; Muhammed MT, 2019, CHEM BIOL DRUG DES, V93, P12, DOI 10.1111/cbdd.13388; Muller A, 1998, STRUCTURE, V6, P269, DOI 10.1016/S0969-2126(98)00031-8; Munro AW, 2007, BBA-GEN SUBJECTS, V1770, P345, DOI 10.1016/j.bbagen.2006.08.018; Nakamura K, 2001, ARCH BIOCHEM BIOPHYS, V395, P25, DOI 10.1006/abbi.2001.2569; Narayan ARH, 2015, NAT CHEM, V7, P653, DOI [10.1038/NCHEM.2285, 10.1038/nchem.2285]; Negretti S, 2014, J AM CHEM SOC, V136, P4901, DOI 10.1021/ja5016052; Nelson DR, 2018, BBA-PROTEINS PROTEOM, V1866, P141, DOI 10.1016/j.bbapap.2017.05.003; Nerimetla R, 2017, ACS CATAL, V7, P3446, DOI 10.1021/acscatal.6b03588; Nerimetla R, 2015, CHEM COMMUN, V51, P11681, DOI 10.1039/c5cc03364k; Tran NH, 2012, J INORG BIOCHEM, V115, P50, DOI 10.1016/j.jinorgbio.2012.05.012; Nielsen AZ, 2013, ACS SYNTH BIOL, V2, P308, DOI 10.1021/sb300128r; Otey CR, 2006, BIOTECHNOL BIOENG, V93, P494, DOI 10.1002/bit.20744; Paddon CJ, 2013, NATURE, V496, P528, DOI 10.1038/nature12051; Parikh A, 1997, NAT BIOTECHNOL, V15, P784, DOI 10.1038/nbt0897-784; Parikh A, 1999, BIOCHEMISTRY-US, V38, P5283, DOI 10.1021/bi990142+; Park JH, 2015, ANGEW CHEM INT EDIT, V54, P969, DOI 10.1002/anie.201410059; Podust LM, 2012, NAT PROD REP, V29, P1251, DOI 10.1039/c2np20020a; Polic V, 2017, ADV SYNTH CATAL, V359, P3983, DOI 10.1002/adsc.201700637; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; Qi FF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04772-x; Lam Q, 2016, BBA-BIOENERGETICS, V1857, P589, DOI 10.1016/j.bbabio.2015.09.004; Ro DK, 2006, NATURE, V440, P940, DOI 10.1038/nature04640; Roberts GA, 2003, J BIOL CHEM, V278, P48914, DOI 10.1074/jbc.M309630200; Robin A, 2011, BEILSTEIN J ORG CHEM, V7, P1494, DOI 10.3762/bjoc.7.173; Robin A, 2009, CHEM COMMUN, P2478, DOI 10.1039/b901716j; Rudolf JD, 2017, NAT PROD REP, V34, P1141, DOI 10.1039/c7np00034k; Sabbadin F, 2010, CHEMBIOCHEM, V11, P987, DOI 10.1002/cbic.201000104; Sadeghi SJ, 2013, BIOTECHNOL APPL BIOC, V60, P102, DOI 10.1002/bab.1086; Sadeghi SJ, 2011, BBA-PROTEINS PROTEOM, V1814, P237, DOI 10.1016/j.bbapap.2010.07.010; Sakaki T, 2012, BIOL PHARM BULL, V35, P844, DOI 10.1248/bpb.35.844; Sandberg M, 2002, BRIT J CLIN PHARMACO, V54, P423, DOI 10.1046/j.1365-2125.2002.01660.x; Sawayama AM, 2009, CHEM-EUR J, V15, P11723, DOI 10.1002/chem.200900643; Schmitz LM, 2019, BIOTECHNOL BIOENG, V116, P3469, DOI 10.1002/bit.27156; Schuckel J, 2012, CHEMBIOCHEM, V13, P2758, DOI 10.1002/cbic.201200572; Schwede T, 2013, STRUCTURE, V21, P1531, DOI 10.1016/j.str.2013.08.007; Sevrioukova IF, 2011, ARCH BIOCHEM BIOPHYS, V507, P66, DOI 10.1016/j.abb.2010.08.022; Shalan H, 2018, BBA-PROTEINS PROTEOM, V1866, P80, DOI 10.1016/j.bbapap.2017.06.002; SHEPHARD EA, 1983, BIOCHEM J, V211, P333, DOI 10.1042/bj2110333; Sherman DH, 2006, J BIOL CHEM, V281, P26289, DOI 10.1074/jbc.M605478200; Shoji O., 2007, ANGEW CHEM, V119, P3730, DOI DOI 10.1002/ANGE.200700068; Shoji O, 2017, ANGEW CHEM INT EDIT, V56, P10324, DOI 10.1002/anie.201703461; Shoji O, 2017, CHEM LETT, V46, P278, DOI 10.1246/cl.160963; Shoji O, 2015, ISR J CHEM, V55, P32, DOI 10.1002/ijch.201400096; Shoji O, 2014, J BIOL INORG CHEM, V19, P529, DOI 10.1007/s00775-014-1106-9; Shumyantseva VV, 2005, J INORG BIOCHEM, V99, P1051, DOI 10.1016/j.jinorgbio.2005.01.014; Sowden RJ, 2005, ORG BIOMOL CHEM, V3, P57, DOI 10.1039/b413068e; Strushkevich N, 2011, P NATL ACAD SCI USA, V108, P10139, DOI 10.1073/pnas.1019441108; Sugimoto H, 2008, BIOCHEMISTRY-US, V47, P4017, DOI 10.1021/bi7023767; Sulistyaningdyah WT, 2005, APPL MICROBIOL BIOT, V67, P556, DOI 10.1007/s00253-004-1761-9; Sun CL, 2019, ORG LETT, V21, P1453, DOI 10.1021/acs.orglett.9b00208; Sun Y, 2017, J IND MICROBIOL BIOT, V44, P161, DOI 10.1007/s10295-016-1875-y; SUZUKI K, 1993, BIOCHIM BIOPHYS ACTA, V1203, P215, DOI 10.1016/0167-4838(93)90086-7; Szczebara FM, 2003, NAT BIOTECHNOL, V21, P143, DOI 10.1038/nbt775; Tanaka Y, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0432; Taylor M, 2000, BIOCHEM BIOPH RES CO, V279, P708, DOI 10.1006/bbrc.2000.4002; Tosstorff A, 2014, J MOL CATAL B-ENZYM, V108, P51, DOI 10.1016/j.molcatb.2014.06.011; Tripathi S, 2013, SCIENCE, V340, P1227, DOI 10.1126/science.1235797; Turner NJ, 2009, NAT CHEM BIOL, V5, P568, DOI 10.1038/nchembio.203; UHLMANN H, 1994, J BIOL CHEM, V269, P22557; Urlacher VB, 2004, APPL MICROBIOL BIOT, V64, P317, DOI 10.1007/s00253-003-1514-1; Urlacher VB, 2019, TRENDS BIOTECHNOL, V37, P882, DOI 10.1016/j.tibtech.2019.01.001; Urlacher VB, 2012, TRENDS BIOTECHNOL, V30, P26, DOI 10.1016/j.tibtech.2011.06.012; Walgama C, 2015, ANAL CHEM, V87, P4712, DOI 10.1021/ac5044362; Wasalathanthri DP, 2012, ELECTROANAL, V24, P2049, DOI 10.1002/elan.201200373; Wei YF, 2018, CURR OPIN CHEM BIOL, V43, P1, DOI 10.1016/j.cbpa.2017.08.006; Whitehouse CJC, 2012, CHEM SOC REV, V41, P1218, DOI 10.1039/c1cs15192d; Williams PA, 2000, MOL CELL, V5, P121, DOI 10.1016/S1097-2765(00)80408-6; Wlodarczyk A, 2016, METAB ENG, V33, P1, DOI 10.1016/j.ymben.2015.10.009; Wong TS, 2004, BIOTECHNOL BIOENG, V85, P351, DOI 10.1002/bit.10896; Woodley JM, 2013, CURR OPIN CHEM BIOL, V17, P310, DOI 10.1016/j.cbpa.2013.03.017; Xu JK, 2019, CHEM-EUR J, V25, P6853, DOI 10.1002/chem.201806383; Xu LH, 2018, SYN SYST BIOTECHNO, V3, P283, DOI 10.1016/j.synbio.2018.10.001; Yasuda K, 2018, BBA-PROTEINS PROTEOM, V1866, P23, DOI 10.1016/j.bbapap.2017.05.014; Yasutake Y, 2010, J BIOL CHEM, V285, P31193, DOI 10.1074/jbc.M110.147009; Yu D, 2019, J AM CHEM SOC, V141, P5655, DOI 10.1021/jacs.9b01939; Zachos L, 2015, CHEM COMMUN, V51, P1918, DOI 10.1039/c4cc07276f; Zhang JD, 2011, J IND MICROBIOL BIOT, V38, P633, DOI 10.1007/s10295-010-0809-3; Zhang W, 2018, ACS CATAL, V8, P9992, DOI 10.1021/acscatal.8b02913; Zhang W, 2014, J AM CHEM SOC, V136, P3640, DOI 10.1021/ja4130302; Zhang XW, 2017, NAT PROD REP, V34, P1061, DOI 10.1039/c7np00028f; Zhao FL, 2016, BIOTECHNOL BIOENG, V113, P1787, DOI 10.1002/bit.25934; Zilly FE, 2009, CHEM COMMUN, P7152, DOI 10.1039/b913863c; Zuo R, 2016, BIOTECHNOL J, V11, P624, DOI 10.1002/biot.201500416	168	91	100	80	330	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	2020	295	3					833	849		10.1074/jbc.REV119.008758	http://dx.doi.org/10.1074/jbc.REV119.008758			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE2IW	31811088	Green Published, hybrid			2023-01-03	WOS:000508382900014
J	Fujishima, MAT; Sa, DMC; Lima, CMD; Bittencourt, JPAHM; Pereira, WLA; Muribeca, ADB; Silva, CYYE; da Silva, MN; de Sousa, FFO; dos Santos, CBR; da Silva, JO				Teles Fujishima, Mayara Amoras; Cunha Sa, Dayse Maria; de Sousa Lima, Carolina Miranda; Bittencourt, Jose Prime Adolfo H. M.; Assuncao Pereira, Washington Luiz; Barbosa Muribeca, Abraao de Jesus; Yoshioka e Silva, Consuelo Yumiko; da Silva, Milton Nascimento; Oliveira de Sousa, Francisco Fabio; dos Santos, Cleydson B. R.; da Silva, Jocivania Oliveira			Chemical profiling of Curatella americana Linn leaves by UPLC-HRMS and its wound healing activity in mice	PLOS ONE			English	Article							MEDICINAL-PLANTS; HUMAN SKIN; IN-VITRO; INFLAMMATION; EXTRACTS; ANTIOXIDANTS; MECHANISMS; QUERCETIN; CHEMISTRY; CATECHIN	Based on ethnopharmacological studies, a lot of plants, as well as its compounds, have been investigated for the potential use as wound healing agents. In Brazil, Curatella americana is traditionally used by local people to treat wounds, ulcers and inflammations. However, to the best of our knowledge, its traditional use in the treatment of wounds has not been validated by a scientific study. Here, some compounds, many of them flavonoids, were identified in the hydroethanolic extract from the leaves of C. americana (HECA) by LC-HRMS and LC-MS/MS. Besides that, solutions containing different concentrations of HECA and a gel produced with this extract were evaluated for its antimicrobial, coagulant and wound healing activities on an excision mouse wound model as well as its acute dermal safety. A total of thirteen compounds were identified in HECA, mainly quercetin, kaempferol and glucoside derivatives of both, besides catechin and epicatechin known as wound healing agents. The group treated with 1% of HECA exhibited highest wound healing activity and best rate of wound contraction confirmed by histopathology results. The present study provides scientific evidence of, this extract (HECA) possess remarkable wound healing activity, thereby, supporting the traditional use.	[Teles Fujishima, Mayara Amoras; Cunha Sa, Dayse Maria; de Sousa Lima, Carolina Miranda; Bittencourt, Jose Prime Adolfo H. M.; Oliveira de Sousa, Francisco Fabio; dos Santos, Cleydson B. R.; da Silva, Jocivania Oliveira] Univ Fed Amapa, Postgrad Program Pharmaceut Innovat, Macapa, AP, Brazil; [Teles Fujishima, Mayara Amoras; Cunha Sa, Dayse Maria; de Sousa Lima, Carolina Miranda; da Silva, Jocivania Oliveira] Univ Fed Amapa, Dept Biol & Hlth Sci, Lab Toxicol, Macapa, AP, Brazil; [Teles Fujishima, Mayara Amoras; Bittencourt, Jose Prime Adolfo H. M.; dos Santos, Cleydson B. R.] Univ Fed Amapa, Dept Biol & Hlth Sci, Lab Modeling & Computat Chem, Macapa, AP, Brazil; [Assuncao Pereira, Washington Luiz] Fed Rural Univ Amazonia, Inst Anim Prod, Lab Anim Pathol, Belem, Para, Brazil; [Barbosa Muribeca, Abraao de Jesus; Yoshioka e Silva, Consuelo Yumiko; da Silva, Milton Nascimento] Fed Univ Para, Dept Chem, Lab Liquid Chromatog, Belem, Para, Brazil	Fundacao Universidade Federal do Amapa; Fundacao Universidade Federal do Amapa; Fundacao Universidade Federal do Amapa; Universidade Federal Rural da Amazonia (UFRA); Universidade Federal do Para	Fujishima, MAT (corresponding author), Univ Fed Amapa, Postgrad Program Pharmaceut Innovat, Macapa, AP, Brazil.; Fujishima, MAT (corresponding author), Univ Fed Amapa, Dept Biol & Hlth Sci, Lab Toxicol, Macapa, AP, Brazil.; Fujishima, MAT (corresponding author), Univ Fed Amapa, Dept Biol & Hlth Sci, Lab Modeling & Computat Chem, Macapa, AP, Brazil.	mayarafuji@hotmail.com	PEREIRA, WASHINGTON/AAG-9373-2021; de Sousa, Francisco Fábio Oliveira/O-7585-2019; Dos Santos, Cleydson Breno Rodrigues/G-5744-2015	de Sousa, Francisco Fábio Oliveira/0000-0002-7366-1622; Dos Santos, Cleydson Breno Rodrigues/0000-0001-9878-6256	Postgraduate Program of Pharmaceutical Innovation	Postgraduate Program of Pharmaceutical Innovation	This study was supported by the Postgraduate Program of Pharmaceutical Innovation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agyare C, 2016, J ETHNOPHARMACOL, V177, P85, DOI 10.1016/j.jep.2015.11.008; Ahmed OM, 2018, BIOMED PHARMACOTHER, V101, P58, DOI 10.1016/j.biopha.2018.02.040; Alexandre-Moreira MS, 1999, J ETHNOPHARMACOL, V67, P171, DOI 10.1016/S0378-8741(99)00009-4; Barros ASA, 2017, BIOMED PHARMACOTHER, V96, P182, DOI 10.1016/j.biopha.2017.09.142; Amaral DD, 2016, BRAZ J BIOSC, V14, P257; Anchisi C, 2001, FARMACO, V56, P427, DOI 10.1016/S0014-827X(01)01055-2; [Anonymous], 2004, COSM PROD STAB GUID, V1; [Anonymous], 2010, BRAZ PHARM, V1, P546; [Anonymous], 2012, NAT FORM BRAZ PHARM; Baillon H, 1871, NATURAL HIST PLANTS, P1827; Barbosa Reinaldo Imbrozio, 2005, Acta Bot. Bras., V19, P323, DOI 10.1590/S0102-33062005000200015; Cabral MS, 2015, THESIS; Canuto J. Z., 2011, FILOGEOGRAFIA CURATE; Corrêa Nágila Maluf, 2005, Rev. Bras. Cienc. Farm., V41, P73, DOI 10.1590/S1516-93322005000100008; Costa ES, 2008, PHYTOTHER RES, V22, P705, DOI 10.1002/ptr.2397; de Medeiros PM, 2013, J ETHNOPHARMACOL, V150, P729, DOI 10.1016/j.jep.2013.09.026; de Toledo CEM, 2011, J ETHNOPHARMACOL, V133, P420, DOI 10.1016/j.jep.2010.10.021; ELAZIZI MM, 1980, J PHARM SCI, V69, P360, DOI 10.1002/jps.2600690333; Fernandez ML, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926-013-0396-1; FORM DM, 1983, P SOC EXP BIOL MED, V172, P214; Futagami A, 2002, LAB INVEST, V82, P1503, DOI 10.1097/01.LAB.0000035024.75914.39; Ghosh PK, 2013, J PHARM PHARM SCI, V16, P760, DOI 10.18433/J3831V; Gomathi K, 2003, BIOMATERIALS, V24, P2767, DOI 10.1016/S0142-9612(03)00059-0; Guerrero MF, 2002, J ETHNOPHARMACOL, V80, P37, DOI 10.1016/S0378-8741(01)00420-2; GURNI AA, 1981, BIOCHEM SYST ECOL, V9, P109, DOI 10.1016/0305-1978(81)90028-4; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; Heim KE, 2002, J NUTR BIOCHEM, V13, P572, DOI 10.1016/S0955-2863(02)00208-5; Hiruma-Lima CA, 2009, J ETHNOPHARMACOL, V121, P425, DOI 10.1016/j.jep.2008.10.017; Iwasaki Y, 2004, J GASTROENTEROL, V39, P831, DOI 10.1007/s00535-004-1399-5; Jeong WS, 2004, PHARM BIOL, V42, P84, DOI 10.3109/13880200490893500; Kant V, 2014, ACTA HISTOCHEM, V116, P5, DOI 10.1016/j.acthis.2013.04.010; Kim HP, 2004, J PHARMACOL SCI, V96, P229, DOI 10.1254/jphs.CRJ04003X; KING D J, 1989, Reviews on Environmental Health, V8, P3; Kumara B, 2007, J ETHNOPHARMACOL, V114, P103, DOI 10.1016/j.jep.2007.08.010; Parente LML, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/375671; Leonardi GR, 2002, BRAS DERMATOL, V77, P563, DOI DOI 10.1590/S0365-05962002000500006; Lima C.C., 2014, J PHARMACOGNOSY PHYT, V3, P181; Lobmann R, 2005, DIABETES CARE, V28, P461, DOI 10.2337/diacare.28.2.461; Lopes TRM, 2014, BIOL, DOI [10.3109/13880209.2014.948634, DOI 10.3109/13880209.2014.948634]; Mandelbaum Samuel Henrique, 2003, An. Bras. Dermatol., V78, P393, DOI 10.1590/S0365-05962003000400002; Mercer PF, 2013, BBA-MOL BASIS DIS, V1832, P1018, DOI 10.1016/j.bbadis.2012.12.013; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Moura LD, 2014, MAR DRUGS, V12, P2471, DOI 10.3390/md12052471; Mulisa E, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0878-y; NCCLS, 2006, METH DIL ANT SUSC TE; Negrao R, 2013, J NUTR BIOCHEM, V24, P435, DOI 10.1016/j.jnutbio.2011.12.011; OECD, 2017, OECD GUIDELINES TEST, DOI [10.1787/9789264070585-en, DOI 10.1787/9789264070585-EN]; Lopes RHO, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9681425; Ousey K, 2016, J WOUND CARE, V25, P122, DOI 10.12968/jowc.2016.25.3.122; Pamplona S, 2015, MOLECULES, V20, P18777, DOI 10.3390/molecules201018777; Panchatcharam M, 2006, MOL CELL BIOCHEM, V290, P87, DOI 10.1007/s11010-006-9170-2; Ratter J. A., 2003, Edinburgh Journal of Botany, V60, P57, DOI 10.1017/S0960428603000064; Rhodes LE, 2013, BRIT J NUTR, V110, P891, DOI 10.1017/S0007114512006071; Rodriguez M, 2014, MOL PHARMACOL, V85, P187, DOI 10.1124/mol.113.089573; Sen CK, 2009, WOUND REPAIR REGEN, V17, P763, DOI 10.1111/j.1524-475X.2009.00543.x; Shrivastava R, 2011, DIABETES RES CLIN PR, V92, P92, DOI 10.1016/j.diabres.2010.12.021; Singer AJ, 2008, NEW ENGL J MED, V359, P1037, DOI 10.1056/NEJMra0707253; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Singleton VL, 1999, METHOD ENZYMOL, V299, P152; Souza CD, 2006, ACTA BOT BRAS, V20, P135, DOI DOI 10.1590/S0102-33062006000100013; Stadelmann WK, 1998, AM J SURG, V176, p26S, DOI 10.1016/S0002-9610(98)00183-4; Suriyamoorthy S, 2012, REV BRAS FARMACOGN, V22, P1338, DOI 10.1590/S0102-695X2012005000121; Swamy HMK, 2007, J ETHNOPHARMACOL, V109, P529, DOI 10.1016/j.jep.2006.09.003; Talekar YP, 2017, J AYURVEDA INTEGR ME, V8, P73, DOI 10.1016/j.jaim.2016.11.007; Fujishima MAT, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11030072; Tsuruya M, 2014, APPL BIOCHEM BIOTECH, V174, P2223, DOI 10.1007/s12010-014-1124-7; Tulio AZ, 2014, FOOD CHEM, V157, P540, DOI 10.1016/j.foodchem.2014.02.047; Vila Verde GM, 2003, VER BRAS FARMACOG, V13, P64, DOI [10.1590/S0102-695X200300024, DOI 10.1590/S0102-695X200300024]; Villarroel Daniel, 2010, Ecología en Bolivia, V45, P116; World Health Organization (WHO), 2007, WHO GUID ASS QUAL HE; Yoon JJ, 2010, BIOCHEM BIOPH RES CO, V391, P96, DOI 10.1016/j.bbrc.2009.11.009; Zielins ER, 2015, EXPERT OPIN EMERG DR, V20, P235, DOI 10.1517/14728214.2015.1018176	72	3	3	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2020	15	1							e0225514	10.1371/journal.pone.0225514	http://dx.doi.org/10.1371/journal.pone.0225514			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5IZ	31929529	Green Published, gold			2023-01-03	WOS:000534352500004
J	Tian, R; Guo, YD; Ye, PP; Zhang, CX; Luo, Y				Tian, Ru; Guo, Yidan; Ye, Pengpeng; Zhang, Chunxia; Luo, Yang			The validation of the Beijing version of the Montreal Cognitive Assessment in Chinese patients undergoing hemodialysis	PLOS ONE			English	Article							MENTAL-STATE-EXAMINATION; RISK-FACTORS; SCREENING INSTRUMENT; PARKINSONS-DISEASE; CUTOFF SCORES; MOCA TEST; IMPAIRMENT; PERFORMANCE; PEOPLE; MEMORY	Objective Cognitive impairment is common among hemodialysis patient, but still lack adequate screening in clinical settings. The Montreal Cognitive Assessment (MoCA) is reportedly to be a sensitive screening tool for cognitive impairment, but its clinical value in patients undergoing hemodialysis is not well established. We aimed to validate the utility of the Beijing version of the MoCA (MoCA-BJ) for detecting cognitive impairment in comparison to a detailed neuropsychological battery as the gold standard. Methods We assessed 613 patients undergoing hemodialysis using the MoCA-BJ, the Mini-Mental State Examination (MMSE), and a comprehensive neuropsychological battery. Cognitive dysfunction was defined by the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V). Spearman's correlation and linear regression were used to estimate the performance of the MoCA-BJ and MMSE in predicting cognitive impairment. A receiver operating characteristic (ROC) curve analysis was used to evaluate the utility of various cutoffs of the MoCA-BJ and MMSE for predicting cognitive impairment. Results Cognitive impairment was diagnosed in 80.91% (496/613), 75.69% (464/613), and 61.34% (376 /613) of the patients using the DSM-V, MoCA-BJ, and MMSE, respectively. Spearman's rank correlation analysis indicated that the MoCA-BJ was significantly correlated with the neuropsychological battery (r(s) = 0.639, p < 0.001), whereas the MMSE had a weaker correlation with the battery. The area under the ROC curve for cognitive impairment diagnosis using the MoCA-BJ was 0.891 (95% confidence interval: 0.859-0.924) while using the MMSE was 0.823 (95% confidence interval: 0.786-0.860). The optimal MoCA-BJ cutoff score in discriminating patients with and without cognitive impairment was 24 points with a sensitivity of 0.877 and specificity of 0.752. Conclusion The MoCA-BJ offers good sensitivity and specificity levels in detecting cognitive impairment in hemodialysis patients. These findings support the utility of the MoCA-BJ as a screening tool for cognitive impairment in Chinese patients undergoing hemodialysis.	[Tian, Ru; Guo, Yidan; Zhang, Chunxia; Luo, Yang] Capital Med Univ, Beijing Shijitan Hosp, Div Nephrol, Beijing, Peoples R China; [Ye, Pengpeng] Chinese Ctr Dis Control & Prevent, Div Injury Prevent, Beijing, Peoples R China; [Ye, Pengpeng] Chinese Ctr Dis Control & Prevent, Mental Hlth Natl Ctr Chron & Noncommunicable Dis, Beijing, Peoples R China	Capital Medical University; Chinese Center for Disease Control & Prevention; Chinese Center for Disease Control & Prevention	Luo, Y (corresponding author), Capital Med Univ, Beijing Shijitan Hosp, Div Nephrol, Beijing, Peoples R China.	luoyang96@163.com	Luo, Yang/AAJ-3150-2021	Luo, Yang/0000-0002-1458-5519; Ye, Pengpeng/0000-0002-2924-1436	Beijing Municipal Science & Technology Commission [Z161100002616005]	Beijing Municipal Science & Technology Commission(Beijing Municipal Science & Technology Commission)	This project is supported by a grant from the Beijing Municipal Science & Technology Commission, NO. Z161100002616005 (https://mis.kw.beijing.gov.cn/out/typt/staticHTML/homePage.html) to YL. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bosco A, 2017, AGING CLIN EXP RES, V29, P1113, DOI 10.1007/s40520-017-0727-6; Chen X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132361; Ciesielska N, 2016, PSYCHIATR POL, V50, P1039, DOI 10.12740/PP/45368; Coen RF, 2011, INT J GERIATR PSYCH, V26, P107, DOI 10.1002/gps.2471; Costa AS, 2014, AM J KIDNEY DIS, V64, P434, DOI 10.1053/j.ajkd.2014.02.012; DAI XY, 1990, INT J NEUROSCI, V55, P107, DOI 10.3109/00207459008985956; Damian AM, 2011, DEMENT GERIATR COGN, V31, P126, DOI 10.1159/000323867; Drew DA, 2017, AM J KIDNEY DIS, V69, P780, DOI 10.1053/j.ajkd.2016.11.015; EADIE K, 1995, J CLIN EXP NEUROPSYC, V17, P731, DOI 10.1080/01688639508405163; Eggers B, 2003, J NEUROL, V250, P576, DOI 10.1007/s00415-003-1039-7; First MB, 2013, J NERV MENT DIS, V201, P727, DOI 10.1097/NMD.0b013e3182a2168a; Guo QH, 2009, ALZ DIS ASSOC DIS, V23, P253, DOI 10.1097/WAD.0b013e3181999e92; Hermann DM, 2014, J NEURAL TRANSM, V121, P627, DOI 10.1007/s00702-014-1160-z; Huang L, 2018, NEUROPSYCH DIS TREAT, V14, P2133, DOI 10.2147/NDT.S174293; Iyasere O, 2017, CLIN KIDNEY J, V10, P89, DOI 10.1093/ckj/sfw128; Kopecek M, 2017, APPL NEUROPSYCH-ADUL, V24, P23, DOI 10.1080/23279095.2015.1065261; Lee SH, 2018, RENAL FAILURE, V40, P323, DOI 10.1080/0886022X.2018.1455589; Li G, 2018, J CLIN SLEEP MED, V14, P785, DOI 10.5664/jcsm.7106; Lifshitz M, 2012, J GERIATR PSYCH NEUR, V25, P155, DOI 10.1177/0891988712457047; Lin KN, 2002, DEMENT GERIATR COGN, V14, P176, DOI 10.1159/000066024; Liu YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056002; Lu J, 2011, J GERIATR PSYCH NEUR, V24, P184, DOI 10.1177/0891988711422528; Luis CA, 2009, INT J GERIATR PSYCH, V24, P197, DOI 10.1002/gps.2101; Mok EHL, 2004, DEMENT GERIATR COGN, V18, P120, DOI 10.1159/000079190; Naganuma T, 2015, CONTRIB NEPHROL, V185, P138, DOI 10.1159/000380978; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nazem S, 2009, J AM GERIATR SOC, V57, P304, DOI 10.1111/j.1532-5415.2008.02096.x; Nie K, 2012, J CLIN NEUROSCI, V19, P1497, DOI 10.1016/j.jocn.2011.11.039; Sarnak MJ, 2013, NEUROLOGY, V80, P471, DOI 10.1212/WNL.0b013e31827f0f7f; Seidel UK, 2014, KIDNEY INT, V85, P693, DOI 10.1038/ki.2013.366; Siciliano M, 2019, NEUROL SCI, V40, P691, DOI 10.1007/s10072-019-3700-7; Sorensen EP, 2012, AM J KIDNEY DIS, V60, P417, DOI 10.1053/j.ajkd.2011.12.029; Tholen S, 2014, DEMENT GERIATR COGN, V38, P31, DOI 10.1159/000357803; Tiffin-Richards FE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106700; Yang Z, 2016, AM J ALZHEIMERS DIS, V31, P650, DOI 10.1177/1533317516662336; Yu J, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-156; Zhang YH, 2018, AM J KIDNEY DIS, V72, P691, DOI 10.1053/j.ajkd.2018.04.020; Zheng K, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0777-1; Zhou AH, 2009, INT J GERIATR PSYCH, V24, P1352, DOI 10.1002/gps.2265	39	11	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2020	15	1							e0227073	10.1371/journal.pone.0227073	http://dx.doi.org/10.1371/journal.pone.0227073			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP5ER	31917792	Green Published, gold			2023-01-03	WOS:000534341100014
J	O'Brien, KM; Tworoger, SS; Harris, HR; Anderson, GL; Weinberg, CR; Trabert, B; Kaunitz, AM; D'Aloisio, AA; Sandler, DP; Wentzensen, N				O'Brien, Katie M.; Tworoger, Shelley S.; Harris, Holly R.; Anderson, Garnet L.; Weinberg, Clarice R.; Trabert, Britton; Kaunitz, Andrew M.; D'Aloisio, Aimee A.; Sandler, Dale P.; Wentzensen, Nicolas			Association of Powder Use in the Genital Area With Risk of Ovarian Cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TALC USE; BODY POWDER; DISEASE; ORIGIN	Question Is use of powder in the genital area associated with the risk of developing ovarian cancer? Findings In this analysis that pooled data from 4 cohorts with a total of 252745 women, the hazard ratio for the association between self-reported ever use vs never use of powder in the genital area and incident ovarian cancer was 1.08 (95% CI, 0.99-1.17). Meaning Among women from 4 prospective cohorts, there was not a statistically significant association between use of powder in the genital area and ovarian cancer, but the study may have been underpowered to identify a small increase in risk. This cohort study uses pooled data from 4 cohorts to estimate associations between perineal use of body powder and ovarian cancer in US women. Importance The relationship between use of powder in the genital area and ovarian cancer is not established. Positive associations reported in case-control studies have not been confirmed in cohort studies. Objective To estimate the association between use of powder in the genital area and ovarian cancer using prospective observational data. Design, Setting, and Participants Data were pooled from 4 large, US-based cohorts: Nurses' Health Study (enrollment 1976; follow-up 1982-2016; n = 81869), Nurses' Health Study II (enrollment 1989; follow-up 2013-2017; n = 61261), Sister Study (enrollment 2003-2009; follow-up 2003-2017; n = 40647), and Women's Health Initiative Observational Study (enrollment 1993-1998; follow-up 1993-2017; n = 73267). Exposures Ever, long-term (>= 20 years), and frequent (>= 1/week) use of powder in the genital area. Main Outcomes and Measures The primary analysis examined the association between ever use of powder in the genital area and self-reported incident ovarian cancer. Covariate-adjusted hazard ratios (HRs) and 95% CIs were estimated using Cox proportional hazards models. Results The pooled sample included 252745 women (median age at baseline, 57 years) with 38% self-reporting use of powder in the genital area. Ten percent reported long-term use, and 22% reported frequent use. During a median of 11.2 years of follow-up (3.8 million person-years at risk), 2168 women developed ovarian cancer (58 cases/100000 person-years). Ovarian cancer incidence was 61 cases/100000 person-years among ever users and 55 cases/100000 person-years among never users (estimated risk difference at age 70 years, 0.09% [95% CI, -0.02% to 0.19%]; estimated HR, 1.08 [95% CI, 0.99 to 1.17]). The estimated HR for frequent vs never use was 1.09 (95% CI, 0.97 to 1.23) and for long-term vs never use, the HR was 1.01 (95% CI, 0.82 to 1.25). Subgroup analyses were conducted for 10 variables; the tests for heterogeneity were not statistically significant for any of these comparisons. While the estimated HR for the association between ever use of powder in the genital area and ovarian cancer risk among women with a patent reproductive tract was 1.13 (95% CI, 1.01 to 1.26), the P value for interaction comparing women with vs without patent reproductive tracts was .15. Conclusions and Relevance In this analysis of pooled data from women in 4 US cohorts, there was not a statistically significant association between use of powder in the genital area and incident ovarian cancer. However, the study may have been underpowered to identify a small increase in risk.	[O'Brien, Katie M.; Sandler, Dale P.] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA; [Tworoger, Shelley S.] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL USA; [Tworoger, Shelley S.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Harris, Holly R.] Fred Hutchinson Canc Res Ctr, Program Epidemiol, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA; [Harris, Holly R.] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98195 USA; [Anderson, Garnet L.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA; [Weinberg, Clarice R.] NIEHS, Biostat & Computat Biol Branch, POB 12233, Res Triangle Pk, NC 27709 USA; [Trabert, Britton] NCI, Metab Epidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD USA; [Kaunitz, Andrew M.] Univ Florida, Coll Med, Dept Obstet & Gynecol, Jacksonville, FL USA; [D'Aloisio, Aimee A.] Social & Sci Syst Inc, Durham, NC USA; [Wentzensen, Nicolas] NCI, Clin Genet Branch, Div Canc Epidemiol & Genet, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); H Lee Moffitt Cancer Center & Research Institute; Harvard University; Harvard T.H. Chan School of Public Health; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University System of Florida; University of Florida; Social & Scientific Systems; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	O'Brien, KM (corresponding author), NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA.	obrienkm2@niehs.nih.gov	Kaunitz, Andrew/AAL-8448-2020; Harris, Holly/AAK-6844-2020; Trabert, Britton/F-8051-2015; O'Brien, Katie/G-8579-2014	Harris, Holly/0000-0002-2572-6727; Trabert, Britton/0000-0002-1539-6090; O'Brien, Katie/0000-0002-1931-1349; Weinberg, Clarice/0000-0002-7713-8556; Sandler, Dale/0000-0002-6776-0018	Intramural Research Program of NIH, National Institute of Environmental Health Sciences [Z01-ES044005]; Intramural Research Program of the National Cancer Institute; US Department of Defense OCRP [W81XWH-12-1-0561]; NIH [UM1 CA186107, P01 CA87969, UM1 CA176726, R01 CA67262, K22 CA193860]; NHLBI, NIH/US Department of Health and Human Services [HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, HHSN268201600004C]; National Institute of Environmental Health Sciences (Sister Study [SIS]); National Institute of Environmental Health Sciences; Social and Scientific Systems (Durham, North Carolina)	Intramural Research Program of NIH, National Institute of Environmental Health Sciences; Intramural Research Program of the National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); US Department of Defense OCRP(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI, NIH/US Department of Health and Human Services; National Institute of Environmental Health Sciences (Sister Study [SIS]); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Social and Scientific Systems (Durham, North Carolina)	This work was supported by the Intramural Research Program of NIH, National Institute of Environmental Health Sciences (Z01-ES044005 to Dr Sandler); the Intramural Research Program of the National Cancer Institute; US Department of Defense OCRP (W81XWH-12-1-0561); NIH (UM1 CA186107, P01 CA87969, UM1 CA176726, and R01 CA67262 [Nurses' Health Study {NHS} and Nurses' Health Study II {NHSII}]); NHLBI, NIH/US Department of Health and Human Services (HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C [Women's Health Initiative Observational Study {WHI-OS}]); and the National Institute of Environmental Health Sciences (Sister Study [SIS]). Dr Harris is supported by an NIH grant (K22 CA193860). Statistical analysis services fromWestat (Durham, North Carolina) were provided through a support contract from the National Institute of Environmental Health Sciences with Social and Scientific Systems (Durham, North Carolina).	Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Bao Y, 2016, AM J PUBLIC HEALTH, V106, P1573, DOI 10.2105/AJPH.2016.303338; Breslow NE, 1972, J R STAT SOC B, V34, P216, DOI DOI 10.1111/J.2517-6161.1972.TB00900.X; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Erickson BK, 2013, AM J OBSTET GYNECOL, V209, P409, DOI 10.1016/j.ajog.2013.04.019; Fiume MM, 2015, INT J TOXICOL, V34, p66S, DOI 10.1177/1091581815586797; Gertig DM, 2000, J NATL CANCER I, V92, P249, DOI 10.1093/jnci/92.3.249; Gonzalez NL, 2016, EPIDEMIOLOGY, V27, P797, DOI 10.1097/EDE.0000000000000528; Greenland S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008; HENDERSON WJ, 1971, J OBSTET GYN BR COMM, V78, P266; Houghton SC, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju208; Hsu T, 2018, NY TIMES; Hsu Tiffany, 2017, NY TIMES; International Agency for Research on Cancer, 2012, IARC MON ARS MET F C, V100C; McGinley L, 2017, WASHINGTON POST; National Cancer Institute Surveillance Epidemiology and End Results Program, CANC STAT FACTS OV C; Ness RB, 1999, JNCI-J NATL CANCER I, V91, P1459, DOI 10.1093/jnci/91.17.1459; Penninkilampi R, 2018, EPIDEMIOLOGY, V29, P41, DOI [10.1097/EDE.0000000000000745, 10.1097/ede.0000000000000745]; Peres LC, 2019, JNCI-J NATL CANCER I, V111, P60, DOI 10.1093/jnci/djy071; Rabin RC, 2018, NY TIMES; Rasmussen CB, 2017, CANCER EPIDEM BIOMAR, V26, P104, DOI 10.1158/1055-9965.EPI-16-0459; Sandler DP, 2017, ENVIRON HEALTH PERSP, V125, DOI 10.1289/EHP1923; Schildkraut JM, 2016, CANCER EPIDEM BIOMAR, V25, P1411, DOI 10.1158/1055-9965.EPI-15-1281; Terry KL, 2013, CANCER PREV RES, V6, P811, DOI 10.1158/1940-6207.CAPR-13-0037; Trabert B, 2019, JNCI-J NATL CANCER I, V111, P137, DOI 10.1093/jnci/djy100; Trabert B, 2019, JNCI-J NATL CANCER I, V111, P129, DOI 10.1093/jnci/djy084; Trabert B, 2016, CANCER EPIDEM BIOMAR, V25, P1369, DOI 10.1158/1055-9965.EPI-16-0476; Wentzensen N, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju260; World Health Organization International Agency for Research on Cancer, 2010, IARC MON EV CARC RIS, V93; Xue XN, 2013, CANCER EPIDEM BIOMAR, V22, P275, DOI 10.1158/1055-9965.EPI-12-1050; ZAZENSKI R, 1995, REGUL TOXICOL PHARM, V21, P218, DOI 10.1006/rtph.1995.1032	31	29	32	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	2020	323	1					49	59		10.1001/jama.2019.20079	http://dx.doi.org/10.1001/jama.2019.20079			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB9WM	31910280	Bronze, Green Published, Green Accepted			2023-01-03	WOS:000506838300015
J	Chow, LQM				Chow, Laura Q. M.			Head and Neck Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; TRANSORAL LASER MICROSURGERY; PHASE-III TRIAL; INDUCTION CHEMOTHERAPY; HUMAN-PAPILLOMAVIRUS; RADIATION-THERAPY; OPEN-LABEL; CONCURRENT CHEMORADIOTHERAPY; CONCOMITANT CHEMOTHERAPY	Most head and neck cancers (73% in the United States) are now related to human papillomavirus infection rather than tobacco and alcohol. Primary cancers are largely squamous-cell cancers, but combined treatment is resulting in long-term survival for most patients.	[Chow, Laura Q. M.] Univ Washington, Dept Med, Div Med Oncol, Thorac Head & Neck Malignancies,Seattle Canc Care, Seattle, WA USA; [Chow, Laura Q. M.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA	Seattle Cancer Care Alliance; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Chow, LQM (corresponding author), Univ Texas Austin, Dell Med Sch, 1701 Trinity St,Stop Z1100, Austin, TX 78712 USA.	laura.chow@austin.utexas.edu						Adelstein D, 2017, J NATL COMPR CANC NE, V15, P761, DOI 10.6004/jnccn.2017.0101; Adelstein DJ, 2003, J CLIN ONCOL, V21, P92, DOI 10.1200/JCO.2003.01.008; Adoga AA, 2009, HEAD NECK ONCOL, V1, DOI 10.1186/1758-3284-1-9; Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388; Ang KK, 2014, J CLIN ONCOL, V32, P2940, DOI 10.1200/JCO.2013.53.5633; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; [Anonymous], 2019, FDA APPR PEMBR 1 LIN; Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X; Bauml J, 2017, J CLIN ONCOL, V35, P1542, DOI 10.1200/JCO.2016.70.1524; Bauml JM, 2019, JNCI-J NATL CANCER I, V111, P490, DOI 10.1093/jnci/djy133; Bernier J, 2005, HEAD NECK-J SCI SPEC, V27, P843, DOI 10.1002/hed.20279; Bernier J, 2004, NEW ENGL J MED, V350, P1945, DOI 10.1056/NEJMoa032641; Blanchard P, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw376.2; Blanchard P, 2018, SEMIN RADIAT ONCOL, V28, P53, DOI 10.1016/j.semradonc.2017.08.004; Blanchard P, 2013, J CLIN ONCOL, V31, P2854, DOI 10.1200/JCO.2012.47.7802; Blanchard P, 2011, RADIOTHER ONCOL, V100, P33, DOI 10.1016/j.radonc.2011.05.036; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Bourhis J, 2012, LANCET ONCOL, V13, P145, DOI 10.1016/S1470-2045(11)70346-1; Braakhuis BJM, 2012, ANN ONCOL, V23, P173, DOI 10.1093/annonc/mds299; Brana I, 2012, ANN ONCOL, V23, P178, DOI 10.1093/annonc/mds322; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burtness B, 2019, LANCET, V394, P1915, DOI 10.1016/S0140-6736(19)32591-7; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Cheraghlou S, 2018, CANCER-AM CANCER SOC, V124, P717, DOI 10.1002/cncr.31104; Cohen EEW, 2004, HEMATOL ONCOL CLIN N, V18, P81, DOI 10.1016/S0889-8588(03)00148-5; Cohen EEW, 2019, LANCET, V393, P156, DOI 10.1016/S0140-6736(18)31999-8; Cooper JS, 2012, INT J RADIAT ONCOL, V84, P1198, DOI 10.1016/j.ijrobp.2012.05.008; Cooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646; D'Cruz AK, 2015, NEW ENGL J MED, V373, P521, DOI 10.1056/NEJMoa1506007; D'Souza G, 2017, JAMA ONCOL, V3, P169, DOI 10.1001/jamaoncol.2016.3067; Eskander A, 2014, LARYNGOSCOPE, V124, P2081, DOI 10.1002/lary.24704; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Ferris RL, 2018, ORAL ONCOL, V81, P45, DOI 10.1016/j.oraloncology.2018.04.008; Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688; Forastiere AA, 2013, J CLIN ONCOL, V31, P845, DOI 10.1200/JCO.2012.43.6097; Gillison ML, 2019, LANCET, V393, P40, DOI 10.1016/S0140-6736(18)32779-X; Gillison ML, 2015, J CLIN ONCOL, V33, P3235, DOI 10.1200/JCO.2015.61.6995; Guan J, 2016, ONCOTARGET, V7, P7110, DOI 10.18632/oncotarget.6858; Gupta T, 2018, OBSTET GYNECOL, V13, pe0200137; Haddad RI, 2018, ANN ONCOL, V29, P1130, DOI 10.1093/annonc/mdy102; Haddad R, 2013, LANCET ONCOL, V14, P257, DOI 10.1016/S1470-2045(13)70011-1; Haughey BH, 2011, HEAD NECK-J SCI SPEC, V33, P1683, DOI 10.1002/hed.21669; Hitt R, 2005, J CLIN ONCOL, V23, P8636, DOI 10.1200/JCO.2004.00.1990; Lacas B, 2017, LANCET ONCOL, V18, P1221, DOI 10.1016/S1470-2045(17)30458-8; Larkins E, 2017, ONCOLOGIST, V22, P873, DOI 10.1634/theoncologist.2016-0496; LEEMANS CR, 1990, LARYNGOSCOPE, V100, P1194; Lefebvre J-L, 2005, ANN ONCOL S6, V16, pvi7; Lorch JH, 2008, HEMATOL ONCOL CLIN N, V22, P1155, DOI 10.1016/j.hoc.2008.08.004; Lydiatt WM, 2017, CA-CANCER J CLIN, V67, P122, DOI 10.3322/caac.21389; Marur S, 2017, J CLIN ONCOL, V35, P490, DOI 10.1200/JCO.2016.68.3300; Mehanna H, 2019, LANCET, V393, P51, DOI 10.1016/S0140-6736(18)32752-1; Mehra R, 2018, BRIT J CANCER, V119, P153, DOI 10.1038/s41416-018-0131-9; Moore EJ, 2013, INT J RADIAT ONCOL, V85, P1163, DOI 10.1016/j.ijrobp.2012.08.033; Moore EJ, 2012, CLIN ANAT, V25, P135, DOI 10.1002/ca.22008; Mourad M, 2017, J ORAL MAXIL SURG, V75, P2562, DOI 10.1016/j.joms.2017.05.008; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; Nguyen-Tan PF, 2014, J CLIN ONCOL, V32, P3858, DOI 10.1200/JCO.2014.55.3925; Noronha V, 2018, J CLIN ONCOL, V36, P1064, DOI 10.1200/JCO.2017.74.9457; O'Sullivan B, 2016, LANCET ONCOL, V17, P440, DOI 10.1016/S1470-2045(15)00560-4; Pfister DG, 2014, J NATL COMPR CANC NE, V12, P1454, DOI 10.6004/jnccn.2014.0142; Pignon JP, 2009, RADIOTHER ONCOL, V92, P4, DOI 10.1016/j.radonc.2009.04.014; Porceddu SV, 2017, ORAL ONCOL, V66, P81, DOI 10.1016/j.oraloncology.2017.01.002; Posner MR, 2007, NEW ENGL J MED, V357, P1705, DOI 10.1056/NEJMoa070956; Seiwert TY, 2019, ANN ONCOL, V30, P297, DOI 10.1093/annonc/mdy522; Seiwert TY, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-LB-339; Seiwert TY, 2016, LANCET ONCOL, V17, P956, DOI 10.1016/S1470-2045(16)30066-3; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tandon S, 2008, HEAD NECK-J SCI SPEC, V30, P1246, DOI 10.1002/hed.20849; Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656; Vermorken JB, 2008, CANCER-AM CANCER SOC, V112, P2710, DOI 10.1002/cncr.23442; Vokes EE, 2015, BETON- STAHLBETONBAU, V107, pdjv344; Weiss BG, 2017, HEAD NECK-J SCI SPEC, V39, P1631, DOI 10.1002/hed.24814; Worden Francis P, 2008, J Natl Compr Canc Netw, V6, P707	73	553	565	28	129	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 2	2020	382	1					60	72		10.1056/NEJMra1715715	http://dx.doi.org/10.1056/NEJMra1715715			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA2CZ	31893516				2023-01-03	WOS:000505606700010
J	Goswami, S; Walle, T; Cornish, AE; Basu, S; Anandhan, S; Fernandez, I; Vence, L; Blando, J; Zhao, H; Yadav, SS; Ott, M; Kong, LY; Heimberger, AB; de Groot, J; Sepesi, B; Overman, M; Kopetz, S; Allison, JP; Pe'er, D; Sharma, P				Goswami, Sangeeta; Walle, Thomas; Cornish, Andrew E.; Basu, Sreyashi; Anandhan, Swetha; Fernandez, Irina; Vence, Luis; Blando, Jorge; Zhao, Hao; Yadav, Shalini Singh; Ott, Martina; Kong, Ling Y.; Heimberger, Amy B.; de Groot, John; Sepesi, Boris; Overman, Michael; Kopetz, Scott; Allison, James P.; Pe'er, Dana; Sharma, Padmanee			Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma	NATURE MEDICINE			English	Article							NIVOLUMAB; CANCER; CELLS; VISUALIZATION; ANTI-CTLA-4; MULTICENTER; IPILIMUMAB; DOCETAXEL; CARCINOMA; THERAPY	Immune checkpoint therapy with anti-CTLA-4 and anti-PD-1/PD-L1 has revolutionized the treatment of many solid tumors. However, the clinical efficacy of immune checkpoint therapy is limited to a subset of patients with specific tumor types(1,2). Multiple clinical trials with combinatorial immune checkpoint strategies are ongoing; however, the mechanistic rationale for tumor-specific targeting of immune checkpoints is elusive. To garner an insight into tumor-specific immunomodulatory targets, we analyzed 94 patients representing five different cancer types, including those that respond relatively well to immune checkpoint therapy and those that do not, such as glioblastoma multiforme, prostate cancer and colorectal cancer. Through mass cytometry and single-cell RNA sequencing, we identified a unique population of CD73(hi) macrophages in glioblastoma multiforme that persists after anti-PD-1 treatment. To test if targeting CD73 would be important for a successful combination strategy in glioblastoma multiforme, we performed reverse translational studies using CD73(-/-) mice. We found that the absence of CD73 improved survival in a murine model of glioblastoma multiforme treated with anti-CTLA-4 and anti-PD-1. Our data identified CD73 as a specific immunotherapeutic target to improve antitumor immune responses to immune checkpoint therapy in glioblastoma multiforme and demonstrate that comprehensive human and reverse translational studies can be used for rational design of combinatorial immune checkpoint strategies. Analysis of a mass cytometry dataset for different human solid tumors coupled with murine reverse translational experiments suggests that targeting CD73 could enhance the efficacy of checkpoint inhibitor therapy in glioblastoma.	[Goswami, Sangeeta; Anandhan, Swetha; Sharma, Padmanee] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Walle, Thomas] Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany; [Walle, Thomas] German Canc Res Ctr, Clin Cooperat Unit Mol Radiooncol, Heidelberg, Germany; [Cornish, Andrew E.; Pe'er, Dana] Sloan Kettering Inst, Computat & Syst Biol Program, New York, NY USA; [Cornish, Andrew E.] NYU, Sch Med, Dept Med, New York, NY USA; [Basu, Sreyashi; Fernandez, Irina; Vence, Luis; Blando, Jorge; Zhao, Hao; Yadav, Shalini Singh; Allison, James P.; Sharma, Padmanee] Univ Texas MD Anderson Canc Ctr, Immunotherapy Platform, Houston, TX 77030 USA; [Ott, Martina; Kong, Ling Y.; Heimberger, Amy B.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; [de Groot, John] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; [Sepesi, Boris] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; [Overman, Michael; Kopetz, Scott] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; [Allison, James P.; Sharma, Padmanee] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Memorial Sloan Kettering Cancer Center; New York University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Sharma, P (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.; Sharma, P (corresponding author), Univ Texas MD Anderson Canc Ctr, Immunotherapy Platform, Houston, TX 77030 USA.; Sharma, P (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA.	padsharma@mdanderson.org	Kopetz, Scott/AAC-1387-2019; Walle, Thomas/AHB-1054-2022	Kopetz, Scott/0000-0001-9647-3416; Walle, Thomas/0000-0003-4835-955X; Anandhan, Swetha/0000-0001-9187-7921; Goswami, Sangeeta/0000-0001-9201-4503	National Institutes of Health/National Cancer Institute [CA1208113, P30CA016672]	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the entire Immunotherapy Platform team at the MD Anderson Cancer Center for assistance in obtaining patient samples and processing them for CyTOF, immunofluorescence and gene expression analysis. We thank F. Gherardini at The Parker Institute for Cancer Immunotherapy for his expert advice with normalization of CyTOF data and J. Zhang and S. Meena Natarajan for technical assistance with the murine experiments. This work was supported by philanthropic contributions to the University of Texas MD Anderson Cancer Center Glioblastoma Moon Shot and Lung Cancer Moon Shot Program and by the National Institutes of Health/National Cancer Institute (award no. CA1208113 to A.B.H. and no. P30CA016672 to B.S.) and used the Tissue Biospecimen and Pathology Resource. P.S. is a member of the Parker Institute for Cancer Immunotherapy and the codirector of the Parker Institute for Cancer Immunotherapy at the MD Anderson Cancer Center.	Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Andrews LP, 2017, IMMUNOL REV, V276, P80, DOI 10.1111/imr.12519; Antonio L, 2017, DRUG DISCOV TODAY, V22, P1686, DOI 10.1016/j.drudis.2017.06.005; Antonioli L, 2013, TRENDS MOL MED, V19, P355, DOI 10.1016/j.molmed.2013.03.005; Azambuja JH, 2020, MOL NEUROBIOL, V57, P635, DOI 10.1007/s12035-019-01730-6; Azambuja JH, 2019, MOL NEUROBIOL, V56, P3260, DOI 10.1007/s12035-018-1240-4; Azizi E, 2018, CELL, V174, P1293, DOI 10.1016/j.cell.2018.05.060; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Cannarile MA, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0257-y; Chang AL, 2016, CANCER RES, V76, P5671, DOI 10.1158/0008-5472.CAN-16-0144; Chen ZH, 2017, CANCER RES, V77, P2266, DOI 10.1158/0008-5472.CAN-16-2310; Chevrier S, 2017, CELL, V169, P736, DOI 10.1016/j.cell.2017.04.016; Chew V, 2017, P NATL ACAD SCI USA, V114, pE5900, DOI 10.1073/pnas.1706559114; Cloughesy TF, 2019, NAT MED, V25, P477, DOI 10.1038/s41591-018-0337-7; Finck R, 2013, CYTOM PART A, V83A, P483, DOI 10.1002/cyto.a.22271; Gao JJ, 2016, CELL, V167, P397, DOI 10.1016/j.cell.2016.08.069; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Pham K, 2012, J NEUROIMMUNOL, V246, P10, DOI 10.1016/j.jneuroim.2012.02.009; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Lavin Y, 2017, CELL, V169, P750, DOI 10.1016/j.cell.2017.04.014; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Levine JH, 2015, CELL, V162, P184, DOI 10.1016/j.cell.2015.05.047; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Muller S, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1362-4; Papadopoulos KP, 2017, CLIN CANCER RES, V23, P5703, DOI 10.1158/1078-0432.CCR-16-3261; Perrot I, 2019, CELL REP, V27, P2411, DOI 10.1016/j.celrep.2019.04.091; Pfannenstiel LW, 2019, CANCER IMMUNOL RES, V7, P510, DOI 10.1158/2326-6066.CIR-18-0054; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Saito T, 2016, NAT MED, V22, P679, DOI 10.1038/nm.4086; Schalper KA, 2019, NAT MED, V25, P470, DOI 10.1038/s41591-018-0339-5; Sharma P, 2017, LANCET ONCOL, V18, P312, DOI 10.1016/S1470-2045(17)30065-7; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Stack EC, 2014, METHODS, V70, P46, DOI 10.1016/j.ymeth.2014.08.016; Stagg J, 2011, CANCER RES, V71, P2892, DOI 10.1158/0008-5472.CAN-10-4246; Takenaka MC, 2019, NAT NEUROSCI, V22, P729, DOI 10.1038/s41593-019-0370-y; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; van Dijk D, 2018, CELL, V174, P716, DOI 10.1016/j.cell.2018.05.061; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Wang Y, 2016, ONCOL REP, V36, P3522, DOI 10.3892/or.2016.5171; Wei J, 2016, NEURO-ONCOLOGY, V18, P639, DOI 10.1093/neuonc/nov292; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; Yan A, 2019, J NEUROSCI, V39, P4387, DOI 10.1523/JNEUROSCI.1118-18.2019; Zunder ER, 2015, NAT PROTOC, V10, P316, DOI 10.1038/nprot.2015.020	45	150	152	12	81	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2020	26	1					39	+		10.1038/s41591-019-0694-x	http://dx.doi.org/10.1038/s41591-019-0694-x			22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	KG3GZ	31873309	Green Accepted			2023-01-03	WOS:000509831900024
J	Coleman, RL; Fleming, GF; Brady, MF; Swisher, EM; Steffensen, KD; Friedlander, M; Okamoto, A; Moore, KN; Ben-Baruch, NE; Werner, TL; Cloven, NG; Oaknin, A; DiSilvestro, PA; Morgan, MA; Nam, JH; Leath, CA; Nicum, S; Hagemann, AR; Littell, RD; Cella, D; Baron-Hay, S; Garcia-Donas, J; Mizuno, M; Bell-McGuinn, K; Sullivan, DM; Bach, BA; Bhattacharya, S; Ratajczak, CK; Ansell, PJ; Dinh, MH; Aghajanian, C; Bookman, MA				Coleman, R. L.; Fleming, G. F.; Brady, M. F.; Swisher, E. M.; Steffensen, K. D.; Friedlander, M.; Okamoto, A.; Moore, K. N.; Ben-Baruch, N. Efrat; Werner, T. L.; Cloven, N. G.; Oaknin, A.; DiSilvestro, P. A.; Morgan, M. A.; Nam, J. -H.; Leath, C. A., III; Nicum, S.; Hagemann, A. R.; Littell, R. D.; Cella, D.; Baron-Hay, S.; Garcia-Donas, J.; Mizuno, M.; Bell-McGuinn, K.; Sullivan, D. M.; Bach, B. A.; Bhattacharya, S.; Ratajczak, C. K.; Ansell, P. J.; Dinh, M. H.; Aghajanian, C.; Bookman, M. A.			Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMARY PERITONEAL CANCER; PARP INHIBITOR VELIPARIB; EPITHELIAL OVARIAN; OPEN-LABEL; FALLOPIAN-TUBE; DOUBLE-BLIND; PRIMARY SURGERY; PLATINUM; OLAPARIB; PHASE-2	BACKGROUND Data are limited regarding the use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors, such as veliparib, in combination with chemotherapy followed by maintenance as initial treatment in patients with high-grade serous ovarian carcinoma. METHODS In an international, phase 3, placebo-controlled trial, we assessed the efficacy of veliparib added to first-line induction chemotherapy with carboplatin and paclitaxel and continued as maintenance monotherapy in patients with previously untreated stage III or IV high-grade serous ovarian carcinoma. Patients were randomly assigned in a 1:1:1 ratio to receive chemotherapy plus placebo followed by placebo maintenance (control), chemotherapy plus veliparib followed by placebo maintenance (veliparib combination only), or chemotherapy plus veliparib followed by veliparib maintenance (veliparib throughout). Cytoreductive surgery could be performed before initiation or after 3 cycles of trial treatment. Combination chemotherapy was 6 cycles, and maintenance therapy was 30 additional cycles. The primary end point was investigator-assessed progression-free survival in the veliparib-throughout group as compared with the control group, analyzed sequentially in the BRCA-mutation cohort, the cohort with homologous-recombination deficiency (HRD) (which included the BRCA-mutation cohort), and the intention-to-treat population. RESULTS A total of 1140 patients underwent randomization. In the BRCA-mutation cohort, the median progression-free survival was 34.7 months in the veliparib-throughout group and 22.0 months in the control group (hazard ratio for progression or death, 0.44; 95% confidence interval [CI], 0.28 to 0.68; P<0.001); in the HRD cohort, it was 31.9 months and 20.5 months, respectively (hazard ratio, 0.57; 95 CI, 0.43 to 0.76; P<0.001); and in the intention-to-treat population, it was 23.5 months and 17.3 months (hazard ratio, 0.68; 95% CI, 0.56 to 0.83; P<0.001). Veliparib led to a higher incidence of anemia and thrombocytopenia when combined with chemotherapy as well as of nausea and fatigue overall. CONCLUSIONS Across all trial populations, a regimen of carboplatin, paclitaxel, and veliparib induction therapy followed by veliparib maintenance therapy led to significantly longer progression-free survival than carboplatin plus paclitaxel induction therapy alone. The independent value of adding veliparib during induction therapy without veliparib maintenance was less clear.	[Coleman, R. L.] Univ Texas MD Anderson Canc Ctr, 1155 Pressler Dr, Houston, TX 77030 USA; [Fleming, G. F.] Univ Chicago Med, Chicago, IL USA; [Cella, D.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Sullivan, D. M.; Bach, B. A.; Bhattacharya, S.; Ratajczak, C. K.; Ansell, P. J.; Dinh, M. H.] AbbVie, N Chicago, IL 60064 USA; [Brady, M. F.] Roswell Pk Canc Inst, NRG Oncol Stat & Data Ctr, Buffalo, NY USA; [Bell-McGuinn, K.; Aghajanian, C.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Swisher, E. M.] Univ Washington, Seattle, WA 98195 USA; [Swisher, E. M.] Seattle Canc Care Alliance, Seattle, WA USA; [Steffensen, K. D.] Lillebaelt Univ Hosp Southern Denmark, Vejle, Denmark; [Steffensen, K. D.] Univ Southern Denmark, Vejle, Denmark; [Friedlander, M.] Univ New South Wales, Prince Wales Clin Sch, Sydney, NSW, Australia; [Friedlander, M.] Royal Hosp Women, Sydney, NSW, Australia; [Baron-Hay, S.] Northern Canc Inst, Sydney, NSW, Australia; [Okamoto, A.] Jikei Univ, Sch Med, Tokyo, Japan; [Mizuno, M.] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan; [Moore, K. N.] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA; [Ben-Baruch, N. Efrat] Kaplan Med Ctr, Rehovot, Israel; [Werner, T. L.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Cloven, N. G.] US Oncol Res Network, Texas Oncol, Ft Worth, TX USA; [Oaknin, A.] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain; [DiSilvestro, P. A.] Women & Infants Hosp Rhode Isl, Providence, RI USA; [Morgan, M. A.] Penn Med, Philadelphia, PA USA; [Nam, J. -H.] Asan Med Ctr, Seoul, South Korea; [Leath, C. A., III] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA; [Nicum, S.] Oxford Univ Hosp, Oxford, England; [Hagemann, A. R.] Washington Univ, Sch Med, St Louis, MO 14263 USA; [Littell, R. D.; Bookman, M. A.] Kaiser Permanente Northern Calif, San Francisco, CA USA; [Garcia-Donas, J.] HM Hosp, Ctr Integral Oncol HM Clara Campal, Madrid, Spain	University of Texas System; UTMD Anderson Cancer Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; AbbVie; Roswell Park Cancer Institute; Memorial Sloan Kettering Cancer Center; University of Washington; University of Washington Seattle; Seattle Cancer Care Alliance; University of Southern Denmark; Lillebaelt Hospital; University of Southern Denmark; University of New South Wales Sydney; Jikei University; Aichi Cancer Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Hebrew University of Jerusalem; Kaplan Medical Center; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Texas Oncology; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Women & Infants Hospital Rhode Island; University of Pennsylvania; Pennsylvania Medicine; University of Alabama System; University of Alabama Birmingham; Washington University (WUSTL); Kaiser Permanente	Coleman, RL (corresponding author), Univ Texas MD Anderson Canc Ctr, 1155 Pressler Dr, Houston, TX 77030 USA.	rcoleman@mdanderson.org		Dahl Steffensen, Karina/0000-0002-9217-3907; OAKNIN, ANA/0000-0002-3592-7194; Bhattacharya, Sudipta/0000-0002-2155-9773	AbbVie; NATIONAL CANCER INSTITUTE [P30CA016672, UG1CA233193] Funding Source: NIH RePORTER	AbbVie(AbbVie); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by AbbVie; VELIA/GOG-3005 ClinicalTrials.gov number, NCT02470585.	Armstrong DK, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.5523; Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985; Bogliolo S, 2016, EXPERT OPIN INV DRUG, V25, P367, DOI 10.1517/13543784.2016.1146677; Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390; Coleman RL, 2017, LANCET, V390, P1949, DOI 10.1016/S0140-6736(17)32440-6; Coleman RL, 2015, GYNECOL ONCOL, V137, P386, DOI 10.1016/j.ygyno.2015.03.042; Donawho CK, 2007, CLIN CANCER RES, V13, P2728, DOI 10.1158/1078-0432.CCR-06-3039; du Bois A, 2016, LANCET ONCOL, V17, P78, DOI 10.1016/S1470-2045(15)00366-6; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fagotti A, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.5516; Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5; Gonzalez-Martin A, 2016, J CLIN ONCOL S, V34, P15; Gray HJ, 2018, GYNECOL ONCOL, V148, P507, DOI 10.1016/j.ygyno.2017.12.029; Hodgson DR, 2018, BRIT J CANCER, V119, P1401, DOI 10.1038/s41416-018-0274-8; Jensen SE, 2011, GYNECOL ONCOL, V120, P214, DOI 10.1016/j.ygyno.2010.09.025; Katsumata N, 2013, LANCET ONCOL, V14, P1020, DOI 10.1016/S1470-2045(13)70363-2; Kehoe S, 2015, LANCET, V386, P249, DOI 10.1016/S0140-6736(14)62223-6; Kohn EC, 2017, CLIN CANCER RES, V23, P7155, DOI 10.1158/1078-0432.CCR-17-2186; Konstantinopoulos PA, 2015, CANCER DISCOV, V5, P1137, DOI 10.1158/2159-8290.CD-15-0714; Ledermann J, 2014, LANCET ONCOL, V15, P852, DOI 10.1016/S1470-2045(14)70228-1; Ledermann J, 2012, NEW ENGL J MED, V366, P1382, DOI 10.1056/NEJMoa1105535; Ledermann JA, 2016, EUR J CANCER, V60, P49, DOI 10.1016/j.ejca.2016.03.005; Lee JM, 2017, ONCOTARGET, V8, P79175, DOI 10.18632/oncotarget.16577; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310; Moore K, 2018, NEW ENGL J MED, V379, P2495, DOI 10.1056/NEJMoa1810858; Mukhopadhyay A, 2012, CANCER RES, V72, P5675, DOI 10.1158/0008-5472.CAN-12-0324; National Comprehensive Cancer Network, 2019, NCCN CLIN PRACT GUID; Oza AM, 2015, LANCET ONCOL, V16, P87, DOI 10.1016/S1470-2045(14)71135-0; Pennington KP, 2014, CLIN CANCER RES, V20, P764, DOI 10.1158/1078-0432.CCR-13-2287; Perren TJ, 2011, NEW ENGL J MED, V365, P2484, DOI 10.1056/NEJMoa1103799; Prat J, 2014, INT J GYNECOL OBSTET, V124, P1, DOI 10.1016/j.ijgo.2013.10.001; Pujade-Lauraine E, 2017, LANCET ONCOL, V18, P1274, DOI 10.1016/S1470-2045(17)30469-2; Ray-Coquard I, 2016, J CLIN ONCOL S, V34, P15; Steffensen KD, 2017, INT J GYNECOL CANCER, V27, P1842, DOI 10.1097/IGC.0000000000001089; Stronach EA, 2018, MOL CANCER RES, V16, P1103, DOI 10.1158/1541-7786.MCR-18-0034; Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/S1470-2045(16)30559-9, 10.1016/s1470-2045(16)30559-9]; Telli ML, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.519; Trigg A, 2019, VALUE HEALTH, V22, pS110, DOI 10.1016/j.jval.2019.04.403; van der Biessen DAJ, 2018, INVEST NEW DRUG, V36, P828, DOI 10.1007/s10637-017-0551-z; Vergote I, 2010, NEW ENGL J MED, V363, P943, DOI 10.1056/NEJMoa0908806	41	409	417	6	76	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 19	2019	381	25					2403	2415		10.1056/NEJMoa1909707	http://dx.doi.org/10.1056/NEJMoa1909707			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ6OG	31562800	Green Published, Green Accepted			2023-01-03	WOS:000505222400005
J	Dias, CCQ; Madruga, MS; Pintado, MME; Almeida, GHO; Alves, APV; Dantas, FA; Bezerra, JKG; de Melo, MFFT; Viera, VB; Soares, JKB				Dias, Celina C. Q.; Madruga, Marta S.; Pintado, Maria Manuela E.; Oliveira Almeida, Gabriel Henrique; Vilar Alves, Ana Paula; Dantas, Francileide Amaro; Galvao Bezerra, Jessyka Kallyne; Frazao Tavares de Melo, Marilia Ferreira; Viera, Vanessa Bordin; Soares, Juliana Kessia B.			Cashew nuts (Anacardium occidentale L.) decrease visceral fat, yet augment glucose in dyslipidemic rats	PLOS ONE			English	Article							DIET-INDUCED OBESITY; INFLAMMATORY MARKERS; HEALTH-BENEFITS; ADIPOSE-TISSUE; SERUM-LIPIDS; CONSUMPTION; ANTIOXIDANT; FIBER; LIVER; ALMONDS	The objective of this study was to evaluate the biological effects of roasted Cashew nuts consumption on biochemical and murinometric parameters in dyslipidemic rats receiving lipid supplementation. Young male rats were randomly assigned to three experimental groups (n = 10). The Control group (CONT) was treated with water, the Dyslipidemic group (DL) received a high fat content emulsion throughout the experiment, and the Dyslipidemic Cashew Nuts group (DLCN) received the same high fat content emulsion throughout the experiment, yet was treated with Cashew nuts. Body parameters, biochemical, hepatic and fecal fatty acid profiles were all evaluated. The levels of total cholesterol and triglycerides were higher in the DL and DLCN groups as compared to the control group. DLCN and CONT presented no difference in HDL levels. DLCN presented higher glycemia levels than the other groups. There was reduction of body fat in DLCN as compared to other groups, but with higher accumulations of liver fat. DLCN presented a reduction in saturated hepatic fatty acids of 20.8%, and an increase of 177% in relation to CONT; there was also a 21% in increase DL for omega 9 fatty acids in comparison to CONT. As for fecal fatty acids, there was a lower concentration of polysaturates in DLCN as compared to the other groups. The data showed that the consumption of Cashew nuts by the dyslipidemic animals treated with a hyperlipidic diet induced greater accumulations of liver fat and worsened glycemic levels, despite having reduced visceral fats and increased fecal fat excretion.	[Dias, Celina C. Q.; Madruga, Marta S.] Univ Fed Paraiba, Ctr Technol, DEA Dept Food Engn, Joao Pessoa, Paraiba, Brazil; [Pintado, Maria Manuela E.] Univ Catolica Portuguese, CBQF, Lab Associado, Escola Super Biotecnol, Porto, Portugal; [Oliveira Almeida, Gabriel Henrique] Univ Fed Paraiba, Dept Anim Sci, Areia, Paraiba, Brazil; [Vilar Alves, Ana Paula; Dantas, Francileide Amaro; Galvao Bezerra, Jessyka Kallyne; Frazao Tavares de Melo, Marilia Ferreira; Viera, Vanessa Bordin; Soares, Juliana Kessia B.] Univ Fed Campina Grande, Ctr Educ & Hlth, Dept Nutr, Cuite, Paraiba, Brazil	Universidade Federal da Paraiba; Universidade Catolica Portuguesa; Universidade Federal da Paraiba; Universidade Federal de Campina Grande	Dias, CCQ (corresponding author), Univ Fed Paraiba, Ctr Technol, DEA Dept Food Engn, Joao Pessoa, Paraiba, Brazil.	celinadias_cel@hotmail.com	Pintado, Maria Manuela/AAW-6709-2021; Pintado, Maria Manuela/ABE-2085-2021	Pintado, Maria Manuela/0000-0002-0760-3184; de Castro Querino Dias, Celina/0000-0002-6576-5683	Coordination for the Improvement of Higher Education Personnel - CAPES, Brazil; FCT [UID/Multi/50016/2013]	Coordination for the Improvement of Higher Education Personnel - CAPES, Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	This research was supported by the grants from the Coordination for the Improvement of Higher Education Personnel - CAPES, Brazil to CCQD.; We would like to thank the scientific collaboration of CBQF under the FCT project UID/Multi/50016/2013 and the Fuel and Materials Laboratory of UFPB.	Agila A, 2011, J FOOD SCI, V76, pC768, DOI 10.1111/j.1750-3841.2011.02180.x; Andrade TDAD, 2011, FOOD CHEM, V126, P1044, DOI 10.1016/j.foodchem.2010.11.122; Albert CM, 2002, ARCH INTERN MED, V162, P1382, DOI 10.1001/archinte.162.12.1382; Alexiadou K, 2011, EUR J INTERN MED, V22, P141, DOI 10.1016/j.ejim.2010.11.008; Almeida-Suhett CP, 2017, PHYSIOL BEHAV, V169, P130, DOI 10.1016/j.physbeh.2016.11.016; AOAC, 1997, OFFICIAL METHODS ANA, V2, P1; Baptista A, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3753562; Barbosa VM, 2014, IND CROP PROD, V55, P280, DOI 10.1016/j.indcrop.2014.02.021; Belchior T, 2015, MOL NUTR FOOD RES, V59, P957, DOI 10.1002/mnfr.201400914; Bhaskaran S, 2017, FREE RADICAL BIO MED, V108, P704, DOI 10.1016/j.freeradbiomed.2017.04.028; Brennan AM, 2010, OBESITY, V18, P1176, DOI 10.1038/oby.2009.409; Brockman DA, 2014, J NUTR, V144, P1415, DOI 10.3945/jn.114.191577; Cardoso BR, 2017, FOOD RES INT, V100, P9, DOI 10.1016/j.foodres.2017.08.036; Casas-Agustench P, 2011, NUTR METAB CARDIOVAS, V21, P126, DOI 10.1016/j.numecd.2009.08.005; Chang SM, 2017, J MICROBIOL BIOTECHN, V27, P856, DOI 10.4014/jmb.1610.10058; Cinti S, 2005, PROSTAG LEUKOTR ESS, V73, P9, DOI 10.1016/j.plefa.2005.04.010; Damavandi RD, 2013, J RES MED SCI, V18, P314; Esmaillzadeh A, 2006, AM J CLIN NUTR, V83, P36; Fabbrini E, 2010, HEPATOLOGY, V51, P679, DOI 10.1002/hep.23280; Faludi AA, 2017, ARQUIVOS BRASILEIRO, V109; FOLCH J, 1957, J BIOL CHEM, V226, P497; de Melo MFFT, 2017, INT J DEV NEUROSCI, V61, P58, DOI 10.1016/j.ijdevneu.2017.06.006; Grosso G, 2016, MATURITAS, V84, P11, DOI 10.1016/j.maturitas.2015.10.014; Guo XF, 2018, PROSTAG LEUKOTR ESS, V136, P47, DOI 10.1016/j.plefa.2017.09.011; Hartman L, 1973, Lab Pract, V22, P475; International Nut and Dried Fruit Council Foundation (INC), NUTS DRIED FRUITS ST; Jaiswal Y S, 2017, J Tradit Complement Med, V7, P421, DOI 10.1016/j.jtcme.2016.11.007; Jia Z, 1999, FOOD CHEM, V64, P555, DOI 10.1016/S0308-8146(98)00102-2; Jiang R, 2006, AM J EPIDEMIOL, V163, P222, DOI 10.1093/aje/kwj033; Kahn HS, 2003, AM J CLIN NUTR, V78, P928, DOI 10.1093/ajcn/78.5.928; Kahn SE, 2014, LANCET, V383, P1068, DOI 10.1016/S0140-6736(13)62154-6; Kozimor A, 2013, APPETITE, V69, P39, DOI 10.1016/j.appet.2013.05.006; Kristensen M, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-8; Lee J, 2017, TOXICOL LETT, V277, P92, DOI 10.1016/j.toxlet.2017.06.005; Lee YJ, 2014, NUTR RES, V34, P814, DOI 10.1016/j.nutres.2014.08.011; Liu M, 2002, J AGR FOOD CHEM, V50, P2926, DOI 10.1021/jf0111209; Lovejoy JC, 2002, AM J CLIN NUTR, V76, P1000, DOI 10.1093/ajcn/76.5.1000; Ma YY, 2010, DIABETES CARE, V33, P227, DOI 10.2337/dc09-1156; Maljaars J, 2009, AM J CLIN NUTR, V89, P1019, DOI 10.3945/ajcn.2008.27335; Gomez-Caravaca AM, 2010, J CHROMATOGR A, V1217, P7411, DOI 10.1016/j.chroma.2010.09.054; Martínez Aguilar Yordan, 2012, Rev Cubana Plant Med, V17, P320; McRae MP, 2017, J CHIROPR MED, V16, P289, DOI 10.1016/j.jcm.2017.05.005; Meireles BRLA, 2017, THESIS; Neyrinck AM, 2009, INT IMMUNOPHARMACOL, V9, P767, DOI 10.1016/j.intimp.2009.02.015; Carvalho ALN, 2011, J ETHNOPHARMACOL, V135, P730, DOI 10.1016/j.jep.2011.04.002; Novelli ELB, 2007, LAB ANIM-UK, V41, P111, DOI 10.1258/002367707779399518; Picklo MJ, 2017, PROSTAG LEUKOTR ESS, V119, P25, DOI 10.1016/j.plefa.2017.03.001; Poudyal H, 2013, J NUTR BIOCHEM, V24, P1381, DOI 10.1016/j.jnutbio.2012.11.006; PROSKY L, 1988, J ASSOC OFF ANA CHEM, V71, P1017; Rao TP, 2016, PHYSIOL BEHAV, V164, P277, DOI 10.1016/j.physbeh.2016.06.014; Rosqvist F, 2014, DIABETES, V63, P2356, DOI 10.2337/db13-1622; Sabate J, 2003, AM J CLIN NUTR, V77, P1379, DOI 10.1093/ajcn/77.6.1379; Sajilata MG, 2006, RADIAT PHYS CHEM, V75, P297, DOI 10.1016/j.radphyschem.2005.07.004; Sauder K., 2013, FASEB J, V27, P368, DOI DOI 10.1096/FJ.12-213728; Schutte AE, 2006, AM J HYPERTENS, V19, P629, DOI 10.1016/j.amjhyper.2005.12.014; Slavin JL, 2005, NUTRITION, V21, P411, DOI 10.1016/j.nut.2004.08.018; Tan SY, 2013, EUR J CLIN NUTR, V67, P1205, DOI 10.1038/ejcn.2013.184; Trox J, 2011, FOOD CHEM, V128, P1094, DOI 10.1016/j.foodchem.2011.04.018; Trox J, 2010, J AGR FOOD CHEM, V58, P5341, DOI 10.1021/jf904580k; Vadivel V, 2012, NUTRITION, V28, P1089, DOI 10.1016/j.nut.2012.01.004; Vaidya HB, 2017, NUTR RES, V46, P31, DOI 10.1016/j.nutres.2017.07.004; Wong ND, 2014, NAT REV CARDIOL, V11, P276, DOI 10.1038/nrcardio.2014.26; Xu DY, 2012, LIFE SCI, V90, P30, DOI 10.1016/j.lfs.2011.10.010; Yang J, 2009, LWT-FOOD SCI TECHNOL, V42, P1, DOI 10.1016/j.lwt.2008.07.007; Yang MY, 2015, J AGR FOOD CHEM, V63, P4587, DOI 10.1021/acs.jafc.5b00346	65	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2019	14	12							e0225736	10.1371/journal.pone.0225736	http://dx.doi.org/10.1371/journal.pone.0225736			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP1HF	31830056	Green Published, gold			2023-01-03	WOS:000534070200024
J	Charles, O; Onakpoya, I; Benipal, S; Woods, H; Bali, A; Aronson, JK; Heneghan, C; Persaud, N				Charles, Onella; Onakpoya, Igho; Benipal, Simran; Woods, Hannah; Bali, Anjli; Aronson, Jeffrey K.; Heneghan, Carl; Persaud, Nav			Withdrawn medicines included in the essential medicines lists of 136 countries	PLOS ONE			English	Article							HEALTH; ROFECOXIB	Background Essential medicines lists and related policies are intended to meet the priority health needs of populations and their implementation is associated with more appropriate use of medicines. The World Health Organization (WHO) recommends that countries carefully select the medicines to be included in their national essential medicines lists. Lists that are used to prioritize access to important treatments should not include medicines that have been withdrawn elsewhere because of an unfavourable benefit-to-harm balance; however, countries still list and use medicines that have been withdrawn worldwide. The objective of this study was to determine whether the national essential medicines lists of 137 countries include medicines that have been withdrawn in other countries. Methods and findings We performed an audit of national essential medicines lists for medicines that had been withdrawn. Medicines withdrawn from worldwide markets between 1953 and 2014 were identified using a systematic review of published literature and regulatory documents. The reviewers used sources including the WHO's database of drugs, PubMed, and the websites of regulatory agencies to obtain information regarding adverse effects associated with the medicines, the year of first withdrawal, markets of withdrawal, and the level of evidence supporting each withdrawal. We recorded the number of countries with a withdrawn medicine included in their national medicines list, the number of withdrawn medicines included in each nation's list, and the number of national essential medicines including each withdrawn medicine. 97 medicines were withdrawn in at least one country but still included in one more national essential medicines list. Of 137 countries with a national essential medicines list, 136 lists included at least one withdrawn medicine, with 54% of the lists containing 5 or fewer withdrawn medicines, and 27% including 10 or more withdrawn medicines. 11 medicines were withdrawn worldwide but still included on at least one national essential medicines list. Countries with longer essential medicines lists had more withdrawn medicines included in their lists. Conclusions This study found that withdrawn medicines are included in all but one national essential medicines list, representing a need for more stringent processes for selecting and removing medicines on these lists. Countries may wish to apply special scrutiny to medicines withdrawn in other nations when selecting medicines to include on their lists.	[Charles, Onella; Benipal, Simran; Woods, Hannah; Bali, Anjli; Persaud, Nav] St Michaels Hosp, MAP Ctr Urban Hlth Solut, Toronto, ON, Canada; [Onakpoya, Igho; Aronson, Jeffrey K.; Heneghan, Carl] Univ Oxford, Ctr Evidence Based Med, Nuffield Dept Primary Care Hlth Sci, Oxford, England; [Persaud, Nav] St Michaels Hosp, Dept Family & Community Med, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Oxford; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Persaud, N (corresponding author), St Michaels Hosp, MAP Ctr Urban Hlth Solut, Toronto, ON, Canada.; Persaud, N (corresponding author), St Michaels Hosp, Dept Family & Community Med, Toronto, ON, Canada.	nav_persaud@utoronto.ca		heneghan, carl/0000-0002-1009-1992; Charles, Onella/0000-0002-1781-3994; Aronson, Jeffrey/0000-0003-1139-655X; Bali, Anjli/0000-0002-0595-639X	Canadian Institutes of Health Research; Ontario SPOR (Strategy for Patient Oriented Research) Support Unit	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario SPOR (Strategy for Patient Oriented Research) Support Unit	This work is supported by the Canadian Institutes of Health Research and Ontario SPOR (Strategy for Patient Oriented Research) Support Unit. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2018, ESS MED SEL NAT MED; Aronson JK, 2005, DRUG SAFETY, V28, P851, DOI 10.2165/00002018-200528100-00003; Centre for Evidence-Based Medicine, 2016, OCEBM LEV EV CTR EV; Den Norske Legeforening, DICL 2006; Friedman MA, 1999, JAMA-J AM MED ASSOC, V281, P1728, DOI 10.1001/jama.281.18.1728; Holloway KA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152020; Holloway KA, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001724; Juni P, 2004, LANCET, V364, P2021, DOI 10.1016/S0140-6736(04)17514-4; Lee KH, 2015, J KOREAN MED SCI, V30, P1567, DOI 10.3346/jkms.2015.30.11.1567; Mahmic-Kaknjo M, 2018, J CLIN EPIDEMIOL, V98, P41, DOI 10.1016/j.jclinepi.2018.02.006; Nations United, 2008, PHARM EC SOCIAL AFFA; Nations United, 2005, PHARM EC SOCIAL AFFA, P1; Onakpoya IJ, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0553-2; Onakpoya IJ, 2015, BMC MED, V13, DOI 10.1186/s12916-014-0262-7; Persaud N, 2019, B WHO; Persaud N, 2017, CAN FAM PHYSICIAN, V63, P266; Sibbald B, 2004, CAN MED ASSOC J, V171, P1027, DOI 10.1503/cmaj.1041606; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286; Vaithianathan R, 2009, DRUG SAFETY, V32, P335, DOI 10.2165/00002018-200932040-00007; Wertheimer, 2012, INNOV PHARM, V3, P1; WHO Collaborating Centre for Drug Statistics Methodology, 2018, ATC DDD IND 2018 NOR; Wirtz VJ, 2017, LANCET, V389, P403, DOI 10.1016/S0140-6736(16)31599-9; Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037	24	4	5	3	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2019	14	12							e0225429	10.1371/journal.pone.0225429	http://dx.doi.org/10.1371/journal.pone.0225429			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO9FT	31791048	Green Published, gold			2023-01-03	WOS:000533930800034
J	Ianiro, G; Murri, R; Sciume, GD; Impagnatiello, M; Masucci, L; Ford, AC; Law, GR; Tilg, H; Sanguinetti, M; Cauda, R; Gasbarrini, A; Fantoni, M; Cammarota, G				Ianiro, Gianluca; Murri, Rita; Sciume, Giusi Desire; Impagnatiello, Michele; Masucci, Luca; Ford, Alexander C.; Law, Graham R.; Tilg, Herbert; Sanguinetti, Maurizio; Cauda, Roberto; Gasbarrini, Antonio; Fantoni, Massimo; Cammarota, Giovanni			Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent Clostridioides difficile Infection Treated With Fecal Microbiota Transplantation or Antibiotics A Prospective Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							VANCOMYCIN-RESISTANT ENTEROCOCCI; CLINICAL-PRACTICE GUIDELINES; CARE-ASSOCIATED INFECTION; DISEASES SOCIETY; TOXIN-A; COLONIZATION; BURDEN; GUT; PREVENTION; EFFICACY	Background: Clostridioides difficile infection (CDI) is a risk factor for bloodstream infection (BSI). Fecal microbiota transplantation (FMT) is more effective than antibiotics in treating recurrent CDI, but its efficacy in preventing CDI-related BSI is uncertain. Objective: To assess incidence of primary BSI in patients with recurrent CDI treated with FMT versus antibiotics. Design: Prospective cohort study. Patients treated with FMT and those treated with antibiotics were matched on propensity score. Setting: Single academic medical center. Patients: 290 inpatients with recurrent CDI (57 patients per treatment in matched cohort). Intervention: FMT or antibiotics. Measurements: The primary outcome was primary BSI within 90 days. Secondary outcomes were length of hospitalization and overall survival (OS) at 90 days. Results: Of the 290 patients, 109 were treated with FMT and 181 received antibiotics. Five patients in the FMT group and 40 in the antibiotic group developed BSI. Because of differences in the patients treated with FMT versus antibiotics in many baseline characteristics, including number of recurrences and CDI severity, comparative analyses were limited to the matched cohort. Risk for BSI was 23 percentage points (95% CI, 10 to 35 percentage points) lower in the FMT group; the FMT group also had 14 fewer days of hospitalization (CI, 9 to 20 fewer days) and a 32-percentage point increase in OS (CI, 16 to 47 percentage points) compared with the antibiotic group. Limitation: Nonrandomized study with potential for unmeasured or residual confounding; limited generalizability of the propensity score-matched cohort. Conclusion: In a propensity score-matched cohort, patients with recurrent CDI treated with FMT were less likely to develop primary BSI. Primary Funding Source: None.	[Ianiro, Gianluca; Murri, Rita; Sciume, Giusi Desire; Impagnatiello, Michele; Masucci, Luca; Sanguinetti, Maurizio; Cauda, Roberto; Gasbarrini, Antonio; Fantoni, Massimo; Cammarota, Giovanni] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCCS, Largo A Gemelli 8, I-00168 Rome, Italy; [Ford, Alexander C.] Univ Leeds, Leeds, W Yorkshire, England; [Ford, Alexander C.] St James Univ Hosp, Bexley Wing, Leeds LS9 7TF, W Yorkshire, England; [Law, Graham R.] Univ Lincoln, Sarah Swift Bldg, Lincoln LN6 7TS, England; [Tilg, Herbert] Med Univ Innsbruck, Innsbruck, Austria; [Tilg, Herbert] Dept Internal Med I Gastroenterol Hepatol Metab &, Anichstr 35, A-6020 Innsbruck, Austria	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Leeds; Saint James's University Hospital; University of Lincoln; Medical University of Innsbruck	Ianiro, G (corresponding author), Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCCS, Digest Dis Ctr, Largo A Gemelli 8, I-00168 Rome, Italy.	gianluca.ianiro@hotmail.it	Sanguinetti, Maurizio/A-1453-2019; Fantoni, Massimo/AAB-7371-2022; Cammarota, Giovanni/AAD-1732-2022; Ford, Alexander/K-5491-2012; Ianiro, Gianluca/K-5578-2016; Sciumè, Giusi Desirè/AAC-3727-2022	Sanguinetti, Maurizio/0000-0002-9780-7059; Cammarota, Giovanni/0000-0002-3626-6148; Ford, Alexander/0000-0001-6371-4359; Ianiro, Gianluca/0000-0002-8318-0515; michele, impagnatiello/0000-0003-4833-0941; Gasbarrini, Antonio/0000-0003-4863-6924; Sciume, Giusi Desire/0000-0003-4525-4779; Masucci, Luca/0000-0002-8358-6726; FANTONI, Massimo/0000-0001-6913-8460; Murri, Rita/0000-0001-9468-5458				Agrawal M, 2016, J CLIN GASTROENTEROL, V50, P403, DOI 10.1097/MCG.0000000000000410; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Bilinski J, 2017, CLIN INFECT DIS, V65, P364, DOI 10.1093/cid/cix252; Brain D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190093; Cammarota G, 2015, ALIMENT PHARM THER, V41, P835, DOI 10.1111/apt.13144; Cammarota G, 2017, GUT, V66, P569, DOI 10.1136/gutjnl-2016-313017; Cammarota G, 2015, ANN INTERN MED, V163, P487, DOI 10.7326/L15-5139; Cassini A, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002150; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cohen J., 2013, STAT POWER ANAL BEHA; Debast SB, 2014, CLIN MICROBIOL INFEC, V20, P1, DOI 10.1111/1469-0691.12418; Donskey CJ, 2000, NEW ENGL J MED, V343, P1925, DOI 10.1056/NEJM200012283432604; Dubberke ER, 2012, CLIN INFECT DIS, V55, pS88, DOI 10.1093/cid/cis335; Edlund C, 1997, CLIN INFECT DIS, V25, P729, DOI 10.1086/513755; Falcone M, 2016, ANTIMICROB AGENTS CH, V60, P252, DOI 10.1128/AAC.01927-15; Fischer M, 2015, ALIMENT PHARM THER, V42, P470, DOI 10.1111/apt.13290; Fischer M, 2017, GUT MICROBES, V8, P289, DOI 10.1080/19490976.2016.1273998; HECHT G, 1988, J CLIN INVEST, V82, P1516, DOI 10.1172/JCI113760; HEYMAN M, 1989, GUT, V30, P1087, DOI 10.1136/gut.30.8.1087; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Hvas CL, 2019, GASTROENTEROLOGY, V156, P1324, DOI 10.1053/j.gastro.2018.12.019; Ianiro G, 2018, ALIMENT PHARM THER, V48, P152, DOI 10.1111/apt.14816; Ianiro G, 2017, CLIN MICROBIOL INFEC, V23, DOI 10.1016/j.cmi.2016.12.025; Ianiro G, 2018, UNITED EUR GASTROENT, V6, P1232, DOI 10.1177/2050640618780762; Jakobsson HE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009836; Kelly CP, 2012, CLIN MICROBIOL INFEC, V18, P21, DOI 10.1111/1469-0691.12046; Lagier JC, 2015, EUR J CLIN MICROBIOL, V34, P1597, DOI 10.1007/s10096-015-2394-x; Lessa FC, 2015, NEW ENGL J MED, V372, P2369, DOI [10.1056/NEJMc1505190, 10.1056/NEJMoa1408913]; Louie TJ, 2009, ANTIMICROB AGENTS CH, V53, P261, DOI 10.1128/AAC.01443-07; Ma GK, 2017, ANN INTERN MED, V167, P152, DOI [10.7326/M16-2733, 10.7326/m16-2733]; McDonald LC, 2018, CLIN INFECT DIS, V66, pE1, DOI [10.1093/cid/cix1085, 10.1093/cid/ciy149]; Miller BA, 2011, INFECT CONT HOSP EP, V32, P387, DOI 10.1086/659156; Nerandzic MM, 2012, CLIN INFECT DIS, V55, pS121, DOI 10.1093/cid/cis440; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Olsen MA, 2015, CLIN MICROBIOL INFEC, V21, P164, DOI 10.1016/j.cmi.2014.08.017; Pappas PG, 2009, CLIN INFECT DIS, V48, P503, DOI 10.1086/596757; Pultz NJ, 2005, ANTIMICROB AGENTS CH, V49, P438, DOI 10.1128/AAC.49.1.438-440.2005; Raponi G, 2014, CLIN INFECT DIS, V59, P1648, DOI 10.1093/cid/ciu637; Ramirez ER, 2018, ADV EXP MED BIOL, V1050, P1, DOI 10.1007/978-3-319-72799-8_1; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Russo A, 2015, CLIN MICROBIOL INFEC, V21, DOI 10.1016/j.cmi.2014.12.024; Surawicz CM, 2013, AM J GASTROENTEROL, V108, P478, DOI 10.1038/ajg.2013.4; Tiru B, 2015, PHARMACOECONOMICS, V33, P925, DOI 10.1007/s40273-015-0282-y; TRIADAFILOPOULOS G, 1987, GASTROENTEROLOGY, V93, P273, DOI 10.1016/0016-5085(87)91014-6; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; van Schaik W, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0087	46	54	58	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 19	2019	171	10					695	+		10.7326/M18-3635	http://dx.doi.org/10.7326/M18-3635			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN5DU	31683278	Green Accepted			2023-01-03	WOS:000496919800014
J	Charpak, N; Ruiz-Pelaez, JG				Charpak, Nathalie; Ruiz-Pelaez, Juan G.			Improving survival of infants with low birthweight cared for outside hospitals	LANCET			English	Editorial Material							KANGAROO MOTHER CARE; CONTROLLED-TRIAL		[Charpak, Nathalie] Javeriana Univ, San Ignacio Teaching Hosp, Bogota 110231, Colombia; [Charpak, Nathalie] Kangaroo Fdn Bogota, Bogota, Colombia; [Ruiz-Pelaez, Juan G.] Florida Int Univ, Dept Med & Populat Hlth Sci Res, Herbert Wertheim Coll Med, Miami, FL 33199 USA	Pontificia Universidad Javeriana; State University System of Florida; Florida International University	Charpak, N (corresponding author), Javeriana Univ, San Ignacio Teaching Hosp, Bogota 110231, Colombia.; Charpak, N (corresponding author), Kangaroo Fdn Bogota, Bogota, Colombia.	ncharpak@gmail.com						Boundy EO, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2238; Chan GJ, 2016, J GLOB HEALTH, V6, DOI 10.7189/jogh.06.010701; Charpak N, 1997, PEDIATRICS, V100, P682, DOI 10.1542/peds.100.4.682; Charpak N, 2001, PEDIATRICS, V108, P1072, DOI 10.1542/peds.108.5.1072; Charpak N, 2011, CURR WOMENS HEALTH R, V7, P232, DOI 10.2174/157340411796355180; Conde-Agudelo A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002771.pub2; Ruiz JG, 2017, J CLIN EPIDEMIOL, V86, P91, DOI 10.1016/j.jclinepi.2016.10.007; Lawn JE, 2010, INT J EPIDEMIOL, V39, P144, DOI 10.1093/ije/dyq031; Mazumder S, 2019, LANCET, V394, P1724, DOI 10.1016/S0140-6736(19)32223-8; Moxon SG, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/1471-2393-15-S2-S8; Rey E, 1983, CAHIERS NOUVEAU NE, V6, P197; World Health Organization, 2015, WHO RECOMMENDATIONS	12	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 9	2019	394	10210					1688	1690		10.1016/S0140-6736(19)32257-3	http://dx.doi.org/10.1016/S0140-6736(19)32257-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JN5DZ	31590990				2023-01-03	WOS:000496920300006
J	Lugo, VM; Garmendia, O; Suarez-Giron, M; Torres, M; Vazquez-Polo, FJ; Negrin, MA; Moraleda, A; Roman, M; Puig, M; Ruiz, C; Egea, C; Masa, JF; Farre, R; Montserrat, JM				Lugo, Vera M.; Garmendia, Onintza; Suarez-Giron, Monique; Torres, Marta; Vazquez-Polo, Francisco J.; Negrin, Miguel A.; Moraleda, Anabel; Roman, Mariana; Puig, Marta; Ruiz, Concepcion; Egea, Carlos; Masa, Juan F.; Farre, Ramon; Montserrat, Josep M.			Comprehensive management of obstructive sleep apnea by telemedicine: Clinical improvement and cost-effectiveness of a Virtual Sleep Unit. A randomized controlled trial	PLOS ONE			English	Article							QUALITY-OF-LIFE; DAYTIME SLEEPINESS; MOBILE HEALTH; CARE; STRATEGY; SAVINGS; IMPACT; ADULTS; CPAP; OSA	Introduction Obstructive sleep apnea (OSA) is a prevalent disease associated with significant morbidity and high healthcare costs. Information and communication technology could offer cost-effective management options. Objectives To evaluate an out-of-hospital Virtual Sleep Unit (VSU) based on telemedicine to manage all patients with suspected OSA, including those with and without continuous positive airway pressure (CPAP) therapy. Methods This was an open randomized controlled trial. Patients with suspected OSA were randomized to hospital routine (HR) or VSU groups to compare the clinical improvement and cost-effectiveness in a non-inferiority analysis. Improvement was assessed by changes in the Quebec Sleep Questionnaire (QSQ), EuroQol (EQ-5D and EQ-VAS), and Epworth Sleepiness Scale (ESS). The follow-up was 3 months. Cost-effectiveness was assessed by a Bayesian analysis based on quality-adjusted life-years (QALYs). Results The HR group (n: 92; 78% OSA, 57% CPAP) compared with the VSU group (n: 94; 83% OSA, 43% CPAP) showed: CPAP compliance was similar in both groups, the QSQ social interactions domain improved significantly more in the HR group whereas the EQ-VAS improved more in the VSU group. Total and OSA-related costs were lower in the VSU group than the HR. The Bayesian cost-effectiveness analysis showed that VSU was cost-effective for a wide range of willingness to pay for QALYs. Conclusions The VSU offered a cost-effective means of improving QALYs than HR. However, the assessment of its clinical improvement was influenced by the choice of the questionnaire; hence, additional measurements of clinical improvement are needed. Our findings indicate that VSU could help with the management of many patients, irrespective of CPAP use.	[Lugo, Vera M.; Garmendia, Onintza; Suarez-Giron, Monique; Torres, Marta; Moraleda, Anabel; Roman, Mariana; Puig, Marta; Ruiz, Concepcion; Montserrat, Josep M.] Hosp Clin Barcelona, Resp Dept, Sleep Unit, Barcelona, Spain; [Garmendia, Onintza; Suarez-Giron, Monique; Torres, Marta; Egea, Carlos; Masa, Juan F.; Farre, Ramon; Montserrat, Josep M.] Ctr Invest Biomed Red CIBER Enfermedades Resp, Madrid, Spain; [Torres, Marta; Farre, Ramon] Univ Barcelona, Sch Med & Hlth Sci, Biophys & Bioengn Dept, Barcelona, Spain; [Torres, Marta; Farre, Ramon; Montserrat, Josep M.] Inst Invest Biomed Pi i Sunyer IDIBAPS, Barcelona, Spain; [Vazquez-Polo, Francisco J.; Negrin, Miguel A.] Las Palmas De Gran Canaria Univ, Quantitat Methods Dept, Las Palmas Gran Canaria, Spain; [Vazquez-Polo, Francisco J.; Negrin, Miguel A.] Las Palmas De Gran Canaria Univ, TiDES Inst, Las Palmas Gran Canaria, Spain; [Egea, Carlos] Alava Univ Hosp, Resp Dept, Sleep Unit, Vitoria, Spain; [Masa, Juan F.] San Pedro de Alcantara Hosp, Resp Unit, Caceres, Caceres, Spain; [Masa, Juan F.] Inst Univ Invest Biosanitaria Extremadura, Caceres, Spain; [Montserrat, Josep M.] Univ Barcelona, Sch Med & Hlth Sci, Med Dept, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Universidad de Las Palmas de Gran Canaria; Universidad de Las Palmas de Gran Canaria; University Hospital of Araba; University of Barcelona	Montserrat, JM (corresponding author), Ctr Invest Biomed Red CIBER Enfermedades Resp, Madrid, Spain.; Montserrat, JM (corresponding author), Univ Barcelona, Sch Med & Hlth Sci, Med Dept, Barcelona, Spain.	jmmontserrat@ub.edu	Farre, Ramon/L-2664-2017; Vazquez-Polo, Francisco-Jose/C-9730-2009	Farre, Ramon/0000-0002-9084-7824; Egea, Carlos/0000-0002-7618-7444; Vazquez-Polo, Francisco-Jose/0000-0002-0632-6138	Spanish Ministry of Economy and Competitiveness [PI14/00416, PI17/01068]; Catalan Society of Pneumology (SOCAP)	Spanish Ministry of Economy and Competitiveness(Spanish Government); Catalan Society of Pneumology (SOCAP)	The Spanish Ministry of Economy and Competitiveness (PI14/00416 and PI17/01068, http://www.isciii.es) and the Catalan Society of Pneumology (SOCAP, www.socapnet.org) funded this study. JMM received the funds. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. It has also been included in the manuscript.; The authors would thank Mr Hermes Carretero and Mr Andreu Vilalta for implementing the Sleep Virtual Unit custom website, Mr Albert Gabarru ' s for his statistical assistance, Mr Ricardo Pereira for implementing the on-line database, and Ms Gemma Guerrero for recruiting patients.	Abma IL, 2016, SLEEP MED REV, V28, P18, DOI 10.1016/j.smrv.2015.07.006; [Anonymous], 2015, SPAN WAG STRUCT SURV; [Anonymous], 1998, ICH HARMONIZED TRIPA; Anttalainen U, 2016, SLEEP BREATH, V20, P1209, DOI 10.1007/s11325-016-1337-9; Badia X, 1999, MED CLIN-BARCELONA, V112, P79; Campos-Rodriguez F, 2016, AM J RESP CRIT CARE, V194, P1286, DOI 10.1164/rccm.201602-0265OC; Chai-Coetzer CL, 2013, JAMA-J AM MED ASSOC, V309, P997, DOI 10.1001/jama.2013.1823; Chervin RD, 1997, SLEEP, V20, P284, DOI 10.1093/sleep/20.4.284; DeMolles DA, 2004, MED CARE, V42, P764, DOI 10.1097/01.mlr.0000132353.99209.fe; Dullet NW, 2017, VALUE HEALTH, V20, P542, DOI 10.1016/j.jval.2017.01.014; Farre R, 2018, AM J RESP CRIT CARE, V197, P12, DOI 10.1164/rccm.201709-1791ED; Fields BG, 2016, SLEEP, V39, P501, DOI 10.5665/sleep.5514; Guerrero A, 2014, SLEEP, V37, P1363, DOI 10.5665/sleep.3932; Heatley EM, 2013, SLEEP MED REV, V17, P349, DOI 10.1016/j.smrv.2012.09.004; Hwang D, 2018, AM J RESP CRIT CARE, V197, P117, DOI 10.1164/rccm.201703-0582OC; Hwang D, 2016, SLEEP MED CLIN, V11, P161, DOI 10.1016/j.jsmc.2016.01.008; Isetta V, 2015, ERS MONOGR, P280; Isetta V, 2015, THORAX, V70, P1054, DOI 10.1136/thoraxjnl-2015-207032; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kuna ST, 2010, RESP CARE, V55, P1196; Lacasse Y, 2004, THORAX, V59, P494, DOI 10.1136/thx.2003.011205; Levy P., 2015, NAT REV DIS PRIMERS; Liddy C, 2017, INT J CIRCUMPOL HEAL, V76, P1, DOI 10.1080/22423982.2017.1323493; Lim DC, 2017, ANNU REV MED, V68, P99, DOI 10.1146/annurev-med-042915-102623; Lugo V, 2017, EXPERT REV RESP MED, V11, P699, DOI 10.1080/17476348.2017.1343147; Masa JF, 2011, SLEEP BREATH, V15, P549, DOI 10.1007/s11325-010-0399-3; Montserrat JM, 2019, ARCH BRONCONEUMOL, V55, P122, DOI 10.1016/j.arbres.2018.05.012; O'Hagan A, 2001, STAT MED, V20, P733, DOI 10.1002/sim.861; Parikh R, 2011, TELEMED E-HEALTH, V17, P609, DOI 10.1089/tmj.2011.0025; Pepin JL, 2017, RESPIROLOGY, V22, P1508, DOI 10.1111/resp.13183; Richardson G, 2004, HEALTH ECON, V13, P1203, DOI 10.1002/hec.901; Spiegelhalter D., 2007, MESQUITE MODULAR SYS; Stepnowsky CJ, 2007, J MED INTERNET RES, V9, DOI 10.2196/jmir.9.2.e14; Thaker DA, 2013, MED J AUSTRALIA, V199, P414, DOI 10.5694/mja12.11781; Turino C, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01128-2016; Villanueva JA, 2017, SMART HOMECARE TECHN, V4, P1, DOI 10.2147/SHTT.S108048; Walter RJ, 2017, SLEEP MED, V38, P73, DOI 10.1016/j.sleep.2017.07.020; Wilson SR, 2012, ARCH INTERN MED, V172, P779, DOI 10.1001/archinternmed.2012.685	38	18	18	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2019	14	10							e0224069	10.1371/journal.pone.0224069	http://dx.doi.org/10.1371/journal.pone.0224069			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN0JK	31647838	Green Published, gold			2023-01-03	WOS:000532631800044
J	Harries, L				Harries, Lorna			Eclipsed by CRISPR	NATURE			English	Editorial Material									[Harries, Lorna] Univ Exeter, Mol Genet, Exeter, Devon, England	University of Exeter	Harries, L (corresponding author), Univ Exeter, Mol Genet, Exeter, Devon, England.	l.w.harries@exeter.ac.uk							0	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	2019	574	7778					S15	S15		10.1038/d41586-019-03074-6	http://dx.doi.org/10.1038/d41586-019-03074-6			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JE9DI	31619802				2023-01-03	WOS:000490988300022
J	Heras-Palou, C				Heras-Palou, Carlos			Patisiran's path to approval	NATURE			English	Editorial Material									[Heras-Palou, Carlos] Univ Hosp Derby & Burton NHS Fdn Trust, Derby, England		Heras-Palou, C (corresponding author), Univ Hosp Derby & Burton NHS Fdn Trust, Derby, England.	carlos.heraspalou2@gmail.com							0	9	9	3	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	2019	574	7778					S7	S7		10.1038/d41586-019-03070-w	http://dx.doi.org/10.1038/d41586-019-03070-w			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JE9DI	31619801				2023-01-03	WOS:000490988300018
J	Ballo, O; Stratmann, J; Serve, H; Steffen, B; Finkelmeier, F; Brandts, C				Ballo, Olivier; Stratmann, Jan; Serve, Hubert; Steffen, Bjoern; Finkelmeier, Fabian; Brandts, Christian			Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy	PLOS ONE			English	Article							ACUTE MYELOID-LEUKEMIA; COMPLETE REMISSION; ELDERLY-PATIENTS; GENE-MUTATIONS; ACHIEVEMENT; EXPRESSION; MORPHOLOGY	Introduction Vacuolization is a frequently found morphological feature in acute myeloid leukemia (AML) blasts. Subcellular origin and biological function as well as prognostic impact are currently unknown. The aim of this study was to evaluate whether vacuolization correlates with clinically relevant AML features. Materials & methods Bone marrow smears of patients diagnosed with AML at the University Hospital Frankfurt between January 2011 and August 2013 were analyzed for blast vacuolization and correlated with clinically relevant AML features. Patients undergoing standard induction chemotherapy were further analyzed for molecular and cytogenetic features as well as treatment response and survival. Results 14 of 100 patients diagnosed with AML receiving standard induction chemotherapy had evidence of blast vacuolization. Positivity for vacuolization correlated with a CD15 positive immunophenotype and with a higher incidence of high-risk AML according to the European LeukemiaNet risk stratification. AML patients with blast vacuolization had a poor blast clearance after standard induction chemotherapy and poor survival. Discussion In conclusion, our findings demonstrate that vacuolization can easily be determined in myeloid leukemia blasts and may be a useful biomarker to predict AML risk groups as well as early treatment response rates and survival.	[Ballo, Olivier; Stratmann, Jan; Serve, Hubert; Steffen, Bjoern; Brandts, Christian] Goethe Univ, Dept Med Hematol Oncol, Frankfurt, Germany; [Serve, Hubert; Brandts, Christian] German Canc Consortium DKTK, Heidelberg, Germany; [Serve, Hubert; Brandts, Christian] German Canc Res Ctr, Heidelberg, Germany; [Finkelmeier, Fabian] Goethe Univ, Dept Med Gastroenterol Hepatol & Endocrinol, Frankfurt, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Goethe University Frankfurt	Ballo, O; Brandts, C (corresponding author), Goethe Univ, Dept Med Hematol Oncol, Frankfurt, Germany.; Brandts, C (corresponding author), German Canc Consortium DKTK, Heidelberg, Germany.; Brandts, C (corresponding author), German Canc Res Ctr, Heidelberg, Germany.	oliver.ballo@kgu.de; christian.brandts@kgu.de						BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; CAMPOS L, 1989, BRIT J HAEMATOL, V72, P161, DOI 10.1111/j.1365-2141.1989.tb07677.x; Chen WN, 2006, BLOOD, V108, P1783, DOI 10.1182/blood-2006-03-014340; Chen YJ, 2016, ONCOTARGETS THER, V9, P4453, DOI 10.2147/OTT.S105664; Chisini M, 2017, HEMATOL ONCOL, V35, P804, DOI 10.1002/hon.2331; Dang H, 2013, HUM PATHOL, V44, P55, DOI 10.1016/j.humpath.2012.04.008; Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358; FENAUX P, 1993, BLOOD, V82, P3241; Fernandez HF, 2009, NEW ENGL J MED, V361, P1249, DOI 10.1056/NEJMoa0904544; Gervais C, 2008, LEUKEMIA, V22, P1567, DOI 10.1038/leu.2008.128; HIDDEMANN W, 1987, BLOOD, V69, P744; Hoelzer D, 2016, ANN ONCOL, V27, pv69, DOI 10.1093/annonc/mdw025; Hoelzer D, 2014, BLOOD, V124, P3870, DOI 10.1182/blood-2014-03-563627; Huang LS, 2017, LEUKEMIA RES, V53, P20, DOI 10.1016/j.leukres.2016.11.016; Kern W, 2003, BLOOD, V101, P64, DOI 10.1182/blood-2002-02-0532; KERR MA, 1992, HISTOCHEM J, V24, P811, DOI 10.1007/BF01046353; Kroschinsky FP, 2008, HAEMATOLOGICA, V93, P283, DOI 10.3324/haematol.11669; Krug U, 2011, DTSCH ARZTEBL INT, V108, P863, DOI 10.3238/arztebl.2011.0863; Kussick SJ, 2004, LEUKEMIA, V18, P1591, DOI 10.1038/sj.leu.2403458; LARSON RA, 1986, BLOOD, V68, P1242; Pang C, 2015, J AM MED INFORM ASSN, V22, P65, DOI 10.1136/amiajnl-2013-002577; Pappenheim A., 1912, FOLIA HAEMATOL, P339; Tang GL, 2015, HUM PATHOL, V46, P65, DOI 10.1016/j.humpath.2014.09.008; Tien HF, 1995, CANCER GENET CYTOGEN, V84, P60, DOI 10.1016/0165-4608(95)00084-4; Virchow R., 1845, WEISSES BLUT FRORIEP, P151	25	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2019	14	9							e0223013	10.1371/journal.pone.0223013	http://dx.doi.org/10.1371/journal.pone.0223013			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM6MW	31568521	gold, Green Published			2023-01-03	WOS:000532364900019
J	Sagara, H; Sekiryu, T; Imaizumi, K; Shintake, H; Sugiyama, U; Maehara, H				Sagara, Hideto; Sekiryu, Tetsuju; Imaizumi, Kimihiro; Shintake, Hiroaki; Sugiyama, Urara; Maehara, Hiroki			Impact of tear metrics on the reliability of perimetry in patients with dry eye	PLOS ONE			English	Article							FALSE-NEGATIVE RESPONSES; OPEN-ANGLE GLAUCOMA; FIELD; INDICATORS; THRESHOLD; FREQUENCY; BLINKING; FATIGUE; QUALITY	Background The application of artificial tears before performing perimetry can improve the reliability and results of perimetry in patients with glaucoma and dry eye (DE). However, the effects of ocular surface and tear film conditions on perimetry measurements and reliability have not been fully characterized. Methods This prospective, cross-sectional, multicenter study investigated tear metrics in perimetry and assessed the relationships that existed among ocular surface condition, tear condition, and perimetry reliability. Forty-three eyes (43 patients) with DE disease according to the 2016 Japanese diagnostic criteria of DE and 43 eyes (43 subjects) of age- and visual field mean deviation-matched normal control subjects were studied. Perimetry was performed using the Humphrey Field Analyzer (30-2 SITA-Standard). Schirmer's test, strip meniscometry value, blink rate, tear film break-up time (TFBUT), fluorescein staining of ocular surface, and Dry Eye-related Quality of Life Score (DEQS) were measured. Blink rate was remeasured during perimetry. TFBUT and fluorescein staining were re-evaluated after perimetry. Perimetry reliability was evaluated with fixation loss, false-positive, and false-negative rates. Results Blink rate during perimetry was significantly lower for both patients with DE and normal controls (both P<0.001). TFBUT after perimetry was significantly higher than before perimetry in patients with DE (P<0.001). Fluorescein staining of ocular surface was significantly increased in patients with DE and normal control subjects (P=0.002 and P<0.001, respectively). Spearman correlation analysis revealed that blink rate during perimetry was negatively correlated with fixation-loss rate (r=-0.393, P=0.009) in patients with DE. Conclusions Performing perimetry was associated with a significant change in tear condition and ocular surface condition in both patients with DE and normal control subjects. The changes in tear condition and ocular surface condition may impact the reliability of perimetry in patients with DE.	[Sagara, Hideto] Marui Eye Clin, Minamisoma City, Fukushima, Japan; [Sagara, Hideto; Sekiryu, Tetsuju; Imaizumi, Kimihiro; Shintake, Hiroaki; Sugiyama, Urara; Maehara, Hiroki] Fukushima Med Univ, Dept Ophthalmol, Sch Med, Minamisoma City, Fukushima, Japan	Fukushima Medical University	Sagara, H (corresponding author), Marui Eye Clin, Minamisoma City, Fukushima, Japan.; Sagara, H (corresponding author), Fukushima Med Univ, Dept Ophthalmol, Sch Med, Minamisoma City, Fukushima, Japan.	hide1234@ruby.ocn.ne.jp		Sekiryu, Tetsuju/0000-0001-8042-2729				Anderson D. R., 1999, AUTOMATED STATIC PER, P80; Arai T, 2018, BRIT J OPHTHALMOL, V102, P525, DOI 10.1136/bjophthalmol-2017-310309; Bengtsson B, 2000, INVEST OPHTH VIS SCI, V41, P2201; Bron AJ, 2003, CORNEA, V22, P640, DOI 10.1097/00003226-200310000-00008; Bron AJ, 2007, OCUL SURF, V5, P108; Carl Zeiss Meditec, 2017, HUMPHR FIELD AN 2 I; Dogru M, 2006, INVEST OPHTH VIS SCI, V47, P1895, DOI 10.1167/iovs.05-0802; HOLLAND MK, 1972, PSYCHOL REP, V31, P119, DOI 10.2466/pr0.1972.31.1.119; Horikoshi N, 2001, JPN J OPHTHALMOL, V45, P503, DOI 10.1016/S0021-5155(01)00371-9; Ibrahim OMA, 2011, INVEST OPHTH VIS SCI, V52, P2194, DOI 10.1167/iovs.10-5986; Ishikawa S, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012969; Johnson CA, 2014, J GLAUCOMA, V23, P288, DOI 10.1097/IJG.0b013e31829463ab; Kastelan S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/696328; Kocabeyoglu S, 2013, CAN J OPHTHALMOL, V48, P110, DOI 10.1016/j.jcjo.2012.11.001; Kunimatsu, 2000, Jpn J Ophthalmol, V44, P190, DOI 10.1016/S0021-5155(99)00209-9; Lal SKL, 2002, PSYCHOPHYSIOLOGY, V39, P313, DOI 10.1017/S0048577201393095; Matsumoto C, 2003, JPN J OPHTHALMOL, V47, P22, DOI 10.1016/S0021-5155(02)00663-9; Milla E, 2012, BRIT J OPHTHALMOL, V96, P826, DOI 10.1136/bjophthalmol-2011-301015; Ohtsuki Masanori, 2001, Nippon Ganka Gakkai Zasshi, V105, P149; Pavlidis M, 2005, GRAEF ARCH CLIN EXP, V243, P228, DOI 10.1007/s00417-004-1033-5; RIEGER G, 1992, BRIT J OPHTHALMOL, V76, P157, DOI 10.1136/bjo.76.3.157; Sakane Y, 2013, JAMA OPHTHALMOL, V131, P1331, DOI 10.1001/jamaophthalmol.2013.4503; Schein OD, 1997, AM J OPHTHALMOL, V124, P723, DOI 10.1016/S0002-9394(14)71688-5; Schein OD, 1999, ARCH INTERN MED, V159, P1359, DOI 10.1001/archinte.159.12.1359; Schleicher R, 2008, ERGONOMICS, V51, P982, DOI 10.1080/00140130701817062; TSUBOTA K, 1995, ARCH OPHTHALMOL-CHIC, V113, P155, DOI 10.1001/archopht.1995.01100020037025; Tsubota K, 2017, OCUL SURF, V15, P65, DOI 10.1016/j.jtos.2016.09.003; Uchida H, 1996, JPN J OPHTHALMOL, V40, P548; Van Orden KF, 2000, BIOL PSYCHOL, V52, P221, DOI 10.1016/S0301-0511(99)00043-5; Wang JH, 2008, AM J OPHTHALMOL, V145, P795, DOI 10.1016/j.ajo.2007.12.035; Wang YF, 2011, INVEST OPHTH VIS SCI, V52, P4546, DOI 10.1167/iovs.10-6553; Yamazaki Y, 2002, JPN J OPHTHALMOL, V46, P89, DOI 10.1016/S0021-5155(01)00461-0; Yenice O, 2007, EYE, V21, P214, DOI 10.1038/sj.eye.6702252	33	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2019	14	9							e0222467	10.1371/journal.pone.0222467	http://dx.doi.org/10.1371/journal.pone.0222467			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM4PG	31527920	gold, Green Submitted, Green Published			2023-01-03	WOS:000532231400023
J	Luster, J; Turner, AN; Henry, JP; Gallo, MF				Luster, Jamie; Turner, Abigail Norris; Henry, John P., Jr.; Gallo, Maria F.			Association between pubic hair grooming and prevalent sexually transmitted infection among female university students	PLOS ONE			English	Article							REMOVAL; INJURIES; WOMEN	Recent findings have suggested an association between pubic hair grooming and self-reported history of sexually transmitted infection (STI), specifically gonococcal infection (GC), chlamydial infection (CT), or human immunodeficiency virus (HIV). We evaluated the association between self-reported extreme grooming and laboratory-confirmed prevalence of GC/CT. Between April 2017 and April 2018, we enrolled English-speaking, adult, female students at a large, Midwestern university who presented on-campus for STI testing. Participants completed a questionnaire on demographics and sexual and grooming behaviors, which was linked to their GC/CT test results based on nucleic acid amplification testing. We defined extreme grooming as removal of all pubic hair either at least weekly in the past 12 months or. 6 times in the past 30 days. We used two separate logistic regression models to determine whether odds of GC/CT varied by extreme groomer status for either time interval. In the study sample of 214 women, prevalence of GC/CT was 9.8%. Nearly all participants (98.1%) reported ever grooming; 53.6% were extreme groomers in the past year and 18% in the past month. Extreme grooming was not associated with prevalent GC/CT in the past year (odds ratio [OR] = 0.8; 95% confidence interval [CI]: 0.3-1.9; adjusted OR = 0.7; 95% CI: 0.3-2.0) or in the past month (OR = 0.5; 95% CI: 0.1-2.0; aOR = 0.4; 95% CI: 0.1-1.9). Pubic hair grooming was common among female university students attending for STI testing. Findings do not support pubic hair grooming as an STI risk factor in this population.	[Luster, Jamie; Gallo, Maria F.] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA; [Turner, Abigail Norris] Coll Med, Div Infect Dis, Columbus, OH USA; [Henry, John P., Jr.] Columbus Publ Hlth, Clin Hlth Div, Columbus, OH USA	University System of Ohio; Ohio State University	Gallo, MF (corresponding author), Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA.	gallo.86@osu.edu	Norris Turner, Abigail/GYD-4753-2022	Gallo, Maria/0000-0002-9411-4767	National Center for Advancing Translational Sciences [UL1TR001070]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001070] Funding Source: NIH RePORTER	National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	The study received REDCap support from the Award Number UL1TR001070 from the National Center for Advancing Translational Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.	Barton J., 2016, SEXUALLY TRANSMITTED; Butler SM, 2015, J SEX MED, V12, P48, DOI 10.1111/jsm.12763; Centers for Disease Control and Prevention, 2018, SEX TRANSM DIS SURV; DeMaria AL, 2016, SEX HEALTH, V13, P248, DOI 10.1071/SH15034; Desruelles F, 2013, SEX TRANSM INFECT, V89, P216, DOI 10.1136/sextrans-2012-050982; Frisse AC, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2016.12.005; Gaither TW, 2015, J SEX MED, V12, P631, DOI 10.1111/jsm.12780; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Mojola SA, 2012, PERSPECT SEX REPRO H, V44, P125, DOI 10.1363/4412512; Osterberg EC, 2017, SEX TRANSM INFECT, V93, DOI 10.1136/sextrans-2016-052687; Rowen TS, 2016, JAMA DERMATOL, V152, P1106, DOI 10.1001/jamadermatol.2016.2154; Schmidtberger L, 2014, JAMA DERMATOL, V150, P122, DOI 10.1001/jamadermatol.2013.8364; Torrone E, 2014, MMWR-MORBID MORTAL W, V63, P834; Truesdale MD, 2017, JAMA DERMATOL, V153, P1114, DOI 10.1001/jamadermatol.2017.2815	14	4	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2019	14	9							e0221303	10.1371/journal.pone.0221303	http://dx.doi.org/10.1371/journal.pone.0221303			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IY3SM	31483828	Green Published, gold, Green Submitted			2023-01-03	WOS:000486313000029
J	Cha, KC; Kim, HI; Kim, YW; Ahn, GJ; Kim, YS; Kim, SJ; Lee, JH; Hwang, SO				Cha, Kyoung-Chul; Kim, Hyung Il; Kim, Yong Won; Ahn, Gyo Jin; Kim, Yoon Seob; Kim, Sun Ju; Lee, Jun Hyuk; Hwang, Sung Oh			Comparison of hemodynamic effects and resuscitation outcomes between automatic simultaneous sterno-thoracic cardiopulmonary resuscitation device and LUCAS in a swine model of cardiac arrest	PLOS ONE			English	Article							MECHANICAL CHEST COMPRESSION; ASSOCIATION GUIDELINES UPDATE; SHORT-TERM SURVIVAL; LIFE-SUPPORT; BLOOD-FLOW; QUALITY	Introduction Mechanical cardiopulmonary resuscitation (CPR) devices are widely used to rescue patients from cardiac arrest. This study aimed to compare hemodynamic effects and resuscitation outcomes between a motor-driven, automatic simultaneous sterno-thoracic cardiopulmonary resuscitation device and the Lund University cardiac arrest system (LUCAS). Material and methods After 2 minutes of electrically induced ventricular fibrillation (VF), Yorkshire pigs (weight 35-60 kg) received CPR with an automatic simultaneous sterno-thoracic CPR device (X-CPR group, n = 13) or the Lund University cardiac arrest system (LUCAS group, n = 12). Basic life support for 6 minutes and advanced cardiovascular life support for 12 minutes, including defibrillation and epinephrine administration, were provided. Hemodynamic parameters and resuscitation outcomes, including return of spontaneous circulation (ROSC), 24-hour survival, and cerebral performance category (CPC) at 24 hours, were evaluated. Results Hemodynamic parameters, including aortic pressures, coronary perfusion pressure, carotid blood flow, and end-tidal carbon dioxide pressure were not significantly different between the two groups. Resuscitation outcomes were also not significantly different between the groups (X-CPR vs. LUCAS; rate of ROSC: 31% vs 25%, p = 1.000; 24-hour survival rate: 31% vs 17%, p = 0.645; neurological outcome with CPC. 2: 31% vs 17%, p = 0.645). Also no significant difference in incidence complications associated with resuscitation was found between the groups. Conclusions CPR with a motor-driven X-CPR and CPR with the LUCAS produced similar hemodynamic effects and resuscitation outcomes in a swine model of cardiac arrest.	[Cha, Kyoung-Chul; Ahn, Gyo Jin; Kim, Yoon Seob; Kim, Sun Ju; Hwang, Sung Oh] Yonsei Univ, Wonju Coll Med, Dept Emergency Med, Wonju, South Korea; [Kim, Hyung Il] Dankook Univ, Coll Med, Dept Emergency Med, Cheonan, South Korea; [Kim, Yong Won] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Emergency Med, Ulsan, South Korea; [Lee, Jun Hyuk] Yonsei Univ, Wonju Coll Med, Dept Biostat, Wonju, South Korea	Yonsei University; Dankook University; University of Ulsan; Ulsan University Hospital; Yonsei University	Hwang, SO (corresponding author), Yonsei Univ, Wonju Coll Med, Dept Emergency Med, Wonju, South Korea.	shwang@yonsei.ac.kr	Kim, Yong Won/AAA-2134-2022; Hwang, Sung Oh/AAO-5838-2021	Kim, Yong Won/0000-0003-0108-8932; Kim, Hyung-il/0000-0002-2843-5597; Kim, Yoon-Seop/0000-0001-5929-4291; Hwang, Sung Oh/0000-0003-4585-3181; KIM, SUN JU/0000-0002-8169-5750; Lee, Jun Hyeok/0000-0002-7745-3599	Korea Evaluation Institute of Industrial Technology, South Korea government [10045801]	Korea Evaluation Institute of Industrial Technology, South Korea government	This research was supported by the Korea Evaluation Institute of Industrial Technology, South Korea government, 10045801 to Dr. Sung Oh Hwang. The sponsor had no play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Axelsson C, 2009, RESUSCITATION, V80, P1099, DOI 10.1016/j.resuscitation.2009.08.006; Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558; BERG RA, 1994, CRIT CARE MED, V22, P282, DOI 10.1097/00003246-199402000-00020; Bonnes JL, 2016, ANN EMERG MED, V67, P349, DOI 10.1016/j.annemergmed.2015.09.023; Brooks SC, 2015, CIRCULATION, V132, pS436, DOI 10.1161/CIR.0000000000000260; Christenson J, 2009, CIRCULATION, V120, P1241, DOI 10.1161/CIRCULATIONAHA.109.852202; Duchateau FX, 2010, INTENS CARE MED, V36, P1256, DOI 10.1007/s00134-010-1784-x; Friess SH, 2013, CRIT CARE MED, V41, P2698, DOI 10.1097/CCM.0b013e318298ad6b; HIGHTOWER D, 1995, ANN EMERG MED, V26, P300, DOI 10.1016/S0196-0644(95)70076-5; Hwang SO, 2002, RESUSCITATION, V53, P209, DOI 10.1016/S0300-9572(02)00011-4; Hwang SO, 2001, RESUSCITATION, V48, P293, DOI 10.1016/S0300-9572(00)00250-1; Idris AH, 2012, CIRCULATION, V125, P3004, DOI 10.1161/CIRCULATIONAHA.111.059535; Kashiura M, 2017, BMC ANESTHESIOL, V17, DOI 10.1186/s12871-017-0351-1; Koster RW, 2017, EUR HEART J, V38, P3006, DOI 10.1093/eurheartj/ehx318; Larsen AI, 2010, RESUSCITATION, V81, P493, DOI 10.1016/j.resuscitation.2010.02.002; Lautz AJ, 2019, CRIT CARE MED, V47, pE241, DOI 10.1097/CCM.0000000000003620; Lee DK, 2018, J EMERG MED, V55, P226, DOI 10.1016/j.jemermed.2018.04.060; Lee MJ, 2016, CLIN EXP EMERG MED, V3, pS17, DOI 10.15441/ceem.16.134; Nolan JP, 2014, CURR OPIN CRIT CARE, V20, P227, DOI 10.1097/MCC.0000000000000083; Perkins GD, 2015, LANCET, V385, P947, DOI 10.1016/S0140-6736(14)61886-9; Perkins GD, 2005, RESUSCITATION, V64, P103, DOI 10.1016/j.resuscitation.2004.08.011; Rehatscatschek G, 2016, MINERVA ANESTESIOL, V82, P429; Rubertsson S, 2005, RESUSCITATION, V65, P357, DOI 10.1016/j.resuscitation.2004.12.006; Rubertsson S, 2014, JAMA-J AM MED ASSOC, V311, P53, DOI 10.1001/jama.2013.282538; Russi CS, 2016, WEST J EMERG MED, V17, P634, DOI 10.5811/westjem.2016.6.29949; Soar J, 2015, RESUSCITATION, V95, P100, DOI 10.1016/j.resuscitation.2015.07.016; Steen S, 2002, RESUSCITATION, V55, P285, DOI 10.1016/S0300-9572(02)00271-X; Wagner H, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0198-3; Wang PL, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007260.pub4; William P, 2016, CIRC J, V80, P1292, DOI 10.1253/circj.CJ-16-0330	32	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2019	14	8							e0221965	10.1371/journal.pone.0221965	http://dx.doi.org/10.1371/journal.pone.0221965			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW6BO	31469891	Green Submitted, gold, Green Published			2023-01-03	WOS:000485062200043
J	Modi, S; Saura, C; Yamashita, T; Park, YH; Kim, SB; Tamura, K; Andre, F; Iwata, H; Ito, Y; Tsurutani, J; Sohn, J; Denduluri, N; Perrin, C; Aogi, K; Tokunaga, E; Im, SA; Lee, KS; Hurvitz, SA; Cortes, J; Lee, CL; Chen, SQ; Zhang, L; Shahidi, J; Yver, A; Krop, I				Modi, Shanu; Saura, Cristina; Yamashita, Toshinari; Park, Yeon Hee; Kim, Sung-Bae; Tamura, Kenji; Andre, Fabrice; Iwata, Hiroji; Ito, Yoshinori; Tsurutani, Junji; Sohn, Joohyuk; Denduluri, Neelima; Perrin, Christophe; Aogi, Kenjiro; Tokunaga, Eriko; Im, Seock-Ah; Lee, Keun Seok; Hurvitz, Sara A.; Cortes, Javier; Lee, Caleb; Chen, Shuquan; Zhang, Lin; Shahidi, Javad; Yver, Antoine; Krop, Ian		DESTINY-Breast01 Investigators	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTIBODY-DRUG CONJUGATE; EMTANSINE; DS-8201A; TUMORS; RESISTANCE; SURVIVAL	In this single-group, phase 2 study, the use of trastuzumab deruxtecan resulted in a response in 60% of women with HER2-positive advanced breast cancer who had received a median of six previous lines of therapy. The drug was associated with myelosuppression and gastrointestinal toxicity; interstitial lung disease was reported in 13.6% of the patients. Background Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation. Methods In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety. Results Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%). Conclusions Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, .)	[Modi, Shanu] Mem Sloan Kettering Canc Ctr, 300 E 66th St, New York, NY 10065 USA; [Saura, Cristina; Cortes, Javier] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain; [Cortes, Javier] IOB Inst Oncol, Quiron Grp, Barcelona, Spain; [Cortes, Javier] IOB Inst Oncol, Quiron Grp, Madrid, Spain; [Yamashita, Toshinari] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan; [Tamura, Kenji] Natl Canc Ctr, Tokyo, Japan; [Ito, Yoshinori] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan; [Tsurutani, Junji] Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan; [Iwata, Hiroji] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan; [Tsurutani, Junji] Kindai Univ, Fac Med, Osaka, Japan; [Aogi, Kenjiro] Shikoku Canc Ctr, Matsuyama, Ehime, Japan; [Tokunaga, Eriko] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan; [Park, Yeon Hee] Samsung Med Ctr, Seoul, South Korea; [Kim, Sung-Bae] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea; [Sohn, Joohyuk] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea; [Im, Seock-Ah] Seoul Natl Univ, Seoul Natl Univ Hosp, Canc Res Inst, Coll Med, Seoul, South Korea; [Lee, Keun Seok] Natl Canc Ctr, Goyang Si, Gyeonggi, South Korea; [Andre, Fabrice] Univ Paris Sud, Inst Gustave Roussy, Villejuif, France; [Perrin, Christophe] Ctr Eugene Marquis, Rennes, France; [Denduluri, Neelima] Virginia Canc Specialists, US Oncol Network, Arlington, VA USA; [Hurvitz, Sara A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA; [Lee, Caleb; Chen, Shuquan; Zhang, Lin; Shahidi, Javad; Yver, Antoine] Daiichi Sankyo, Basking Ridge, NJ USA; [Krop, Ian] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA	Memorial Sloan Kettering Cancer Center; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Kanagawa Prefectural Cancer Center; National Cancer Center - Japan; Japanese Foundation for Cancer Research; Showa University; Aichi Cancer Center; Kindai University (Kinki University); Kyushu Cancer Center; Sungkyunkwan University (SKKU); Samsung Medical Center; University of Ulsan; Yonsei University; Yonsei University Health System; Seoul National University (SNU); Seoul National University Hospital; National Cancer Center - Korea (NCC); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Centre Eugene Marquis; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Daiichi Sankyo Company Limited; Harvard University; Dana-Farber Cancer Institute	Modi, S (corresponding author), Mem Sloan Kettering Canc Ctr, 300 E 66th St, New York, NY 10065 USA.; Krop, I (corresponding author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.	modis@mskcc.org; ikrop@partners.org	ANDRE, Fabrice/AAL-2683-2020; Yamashita, Toshinari/GZN-0536-2022	ANDRE, Fabrice/0000-0001-5795-8357; Fukui, Jami/0000-0002-0248-266X; Gonzalez Farre, Xavier/0000-0002-5797-7037; Yamashita, Toshinari/0000-0002-6479-1660; Sohn, Joohyuk/0000-0002-2303-2764; Teixeira, Luis/0000-0003-1049-9661; Saura, Cristina/0000-0001-8296-5065	Daiichi Sankyo; AstraZeneca	Daiichi Sankyo(Daiichi Sankyo Company Limited); AstraZeneca(AstraZeneca)	Supported by Daiichi Sankyo and AstraZeneca.	Aggarwal N, 2014, PROTEOM CLIN APPL, V8, P427, DOI 10.1002/prca.201300105; [Anonymous], 2010, HERCEPTIN SUMMARY PR; [Anonymous], 2016, KADC INJ FIU FULL PR; [Anonymous], 2013, PERJETA SUMMARY PROD; [Anonymous], 2017, PERJ INJ FIU FULL PR; [Anonymous], [No title captured]; [Anonymous], 2017, HERC INJ FIU FULL PR; [Anonymous], [No title captured]; Barok M, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3621; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; Dimopoulou I, 2006, ANN ONCOL, V17, P372, DOI 10.1093/annonc/mdj057; Doi T, 2017, LANCET ONCOL, V18, P1512, DOI 10.1016/S1470-2045(17)30604-6; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Gonzalez-Angulo AM, 2009, J CLIN ONCOL, V27, P5700, DOI 10.1200/JCO.2009.23.2025; Krop IE, 2014, LANCET ONCOL, V15, P689, DOI 10.1016/S1470-2045(14)70178-0; Lin L, 2019, AM J CLIN PATHOL, V152, P479, DOI [10.1093/AJCP/AQZ061, 10.1093/ajcp/aqz061]; Loganzo F, 2015, MOL CANCER THER, V14, P952, DOI 10.1158/1535-7163.MCT-14-0862; Marcoux J, 2015, PROTEIN SCI, V24, P1210, DOI 10.1002/pro.2666; Modi S, 2017, 2017 SAN ANT BREAST; Nakada T, 2019, CHEM PHARM BULL, V67, P173, DOI 10.1248/cpb.c18-00744; National Comprehensive Cancer Network, 2019, BREAST CANC VERS 2; Ogitani Y, 2016, CLIN CANCER RES, V22, P5097, DOI 10.1158/1078-0432.CCR-15-2822; Ogitani Y, 2016, CANCER SCI, V107, P1039, DOI 10.1111/cas.12966; Onitilo AA, 2009, CLIN MED RES, V7, P4, DOI 10.3121/cmr.2009.825; Powell CA, 2018, 2018 SAN ANT BREAST; Rios-Luci C, 2017, CANCER RES, V77, P4639, DOI 10.1158/0008-5472.CAN-16-3127; RUGO HS, 2019, J CLIN ONCOL S, V37; SAURA C, 2019, J CLIN ONCOL S, V37; Shitara K, 2019, LANCET ONCOL, V20, P827, DOI 10.1016/S1470-2045(19)30088-9; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sung M, 2018, MOL CANCER THER, V17, P243, DOI 10.1158/1535-7163.MCT-17-0403; Swain SM, 2015, NEW ENGL J MED, V372, P724, DOI 10.1056/NEJMoa1413513; Swain SM, 2019, J CLIN ONCOL S, V15, P1020; Tamura K, 2019, LANCET ONCOL, V20, P816, DOI 10.1016/S1470-2045(19)30097-X; Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124; 2014, REG ANESTH PAIN MED, V9, pE1121	36	640	658	36	164	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 13	2020	382	7					610	621		10.1056/NEJMoa1914510	http://dx.doi.org/10.1056/NEJMoa1914510			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KO2MG	31825192	Bronze, Green Accepted			2023-01-03	WOS:000515383300006
J	Fishbane, S; Jamal, A; Munera, C; Wen, W; Menzaghi, F				Fishbane, Steven; Jamal, Aamir; Munera, Catherine; Wen, Warren; Menzaghi, Frederique		KALM-1 Trial Investigators	A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UREMIC PRURITUS; DIALYSIS OUTCOMES; PRACTICE PATTERNS; RATING-SCALE; ITCH; PAIN; CR845	Background Difelikefalin is a peripherally restricted and selective agonist of kappa opioid receptors that are considered to be important in modulating pruritus in conditions such as chronic kidney disease. Methods In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned patients undergoing hemodialysis who had moderate-to-severe pruritus to receive either intravenous difelikefalin (at a dose of 0.5 mu g per kilogram of body weight) or placebo three times per week for 12 weeks. The primary outcome was the percentage of patients with an improvement (decrease) of at least 3 points from baseline at week 12 in the weekly mean score on the 24-hour Worst Itching Intensity Numerical Rating Scale (WI-NRS; scores range from 0 to 10, with higher scores indicating greater itch intensity). The secondary outcomes included the change from baseline in itch-related quality-of-life measures, the percentage of patients with an improvement of at least 4 points in the WI-NRS score at week 12, and safety. Results A total of 378 patients underwent randomization. A total of 82 of 158 patients (51.9%) in the difelikefalin group had a decrease of at least 3 points in the WI-NRS score (primary outcome), as compared with 51 of 165 (30.9%) in the placebo group. The imputed percentage of patients with a decrease of at least 3 points in the WI-NRS score was 49.1% in the difelikefalin group, as compared with 27.9% in the placebo group (P<0.001). Difelikefalin also resulted in a significant improvement from baseline to week 12 in itch-related quality of life as measured by the 5-D itch scale and the Skindex-10 scale. The imputed percentage of patients with a decrease of at least 4 points in the WI-NRS score at week 12 was significantly greater in the difelikefalin group than in the placebo group (37.1% [observed data: 64 of 158 patients] vs. 17.9% [observed data: 35 of 165 patients], P<0.001). Diarrhea, dizziness, and vomiting were more common in the difelikefalin group than in the placebo group. Conclusions Patients treated with difelikefalin had a significant reduction in itch intensity and improved itch-related quality of life as compared with those who received placebo. (Funded by Cara Therapeutics; KALM-1 ClinicalTrials.gov number, NCT03422653.)	[Fishbane, Steven] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Med, 100 Community Dr,2nd Fl, Great Neck, NY 11021 USA; [Jamal, Aamir] North Amer Res Inst, San Dimas, CA USA; [Munera, Catherine; Wen, Warren; Menzaghi, Frederique] Cara Therapeut, Stamford, CT USA		Fishbane, S (corresponding author), Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Med, 100 Community Dr,2nd Fl, Great Neck, NY 11021 USA.	sfishbane@northwell.edu			Cara Therapeutics	Cara Therapeutics	Funded by Cara Therapeutics; KALM-1 ClinicalTrials.gov number, NCT03422653.	Albert-Vartanian A, 2016, J CLIN PHARM THER, V41, P371, DOI 10.1111/jcpt.12404; Aresi G, 2019, J PAIN SYMPTOM MANAG, V58, P578, DOI 10.1016/j.jpainsymman.2019.06.010; Bigliardi PL, 2014, ITCH MECH TREATMENT; Butelman ER, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00190; Chavkin C, 2011, NEUROPSYCHOPHARMACOL, V36, P369, DOI 10.1038/npp.2010.137; Cowan A, 2015, HANDB EXP PHARMACOL, V226, P291, DOI 10.1007/978-3-662-44605-8_16; Cui L, 1999, BIOMETRICS, V55, P853, DOI 10.1111/j.0006-341X.1999.00853.x; Elman S, 2010, BRIT J DERMATOL, V162, P587, DOI 10.1111/j.1365-2133.2009.09586.x; Gardell LR, 2008, 12 WORLD C PAIN GLAS; GOSSOP M, 1990, ADDICT BEHAV, V15, P487, DOI 10.1016/0306-4603(90)90036-W; HANDELSMAN L, 1987, AM J DRUG ALCOHOL AB, V13, P293, DOI 10.3109/00952998709001515; Hayani K, 2016, ACTA DERM-VENEREOL, V96, P361, DOI 10.2340/00015555-2280; Kimata N, 2014, HEMODIAL INT, V18, P657, DOI 10.1111/hdi.12158; Kimball AB, 2016, BRIT J DERMATOL, V175, P157, DOI 10.1111/bjd.14464; Kimmel M, 2006, NEPHROL DIAL TRANSPL, V21, P749, DOI 10.1093/ndt/gfi204; Kuypers DRJ, 2009, NAT CLIN PRACT NEPHR, V5, P157, DOI 10.1038/ncpneph1040; Lawrence J, 2003, BIOMETRICAL J, V45, P143, DOI 10.1002/bimj.200390001; Mathur VS, 2010, CLIN J AM SOC NEPHRO, V5, P1410, DOI 10.2215/CJN.00100110; Menzaghi F, 2015, J PAIN, V16, pS81, DOI 10.1016/j.jpain.2015.01.341; Menzaghi F, 2016, PAIN WEEK 2016 LAS V; Menzaghi F, 2018, 27 ANN C EUR AC DERM; Mettang T, 2002, NEPHROL DIAL TRANSPL, V17, P1558, DOI 10.1093/ndt/17.9.1558; Mettang T, 2015, KIDNEY INT, V87, P685, DOI 10.1038/ki.2013.454; Narita I, 2006, KIDNEY INT, V69, P1626, DOI 10.1038/sj.ki.5000251; Phan NQ, 2012, ACTA DERM-VENEREOL, V92, P502, DOI 10.2340/00015555-1246; O'Connor SJ, 2010, INT ASS STUD PAIN MO; Pisoni RL, 2006, NEPHROL DIAL TRANSPL, V21, P3495, DOI 10.1093/ndt/gfl461; Rayner HC, 2017, CLIN J AM SOC NEPHRO, V12, P2000, DOI 10.2215/CJN.03280317; Roth BL, 2002, P NATL ACAD SCI USA, V99, P11934, DOI 10.1073/pnas.182234399; Shirazian S, 2017, INT J NEPHROL RENOV, V10, P11, DOI 10.2147/IJNRD.S108045; Spencer RH, 2010, INT ASS STUD PAIN MO; Tey HL, 2011, BRIT J DERMATOL, V165, P5, DOI 10.1111/j.1365-2133.2011.10217.x; Webster L, 2015, J PAIN, V16, pS81, DOI 10.1016/j.jpain.2015.01.340; Yosipovitch G, 2003, LANCET, V361, P690, DOI 10.1016/S0140-6736(03)12570-6	34	104	111	7	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 16	2020	382	3					222	232		10.1056/NEJMoa1912770	http://dx.doi.org/10.1056/NEJMoa1912770			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD1HI	31702883	Bronze			2023-01-03	WOS:000507622100006
J	Robert, P; Vergara, C; Silva-Weiss, A; Osorio, FA; Santander, R; Saenz, C; Gimenez, B				Robert, Paz; Vergara, Cristina; Silva-Weiss, Andrea; Osorio, Fernando A.; Santander, Rocio; Saenz, Carmen; Gimenez, Begona			Influence of gelation on the retention of purple cactus pear extract in microencapsulated double emulsions	PLOS ONE			English	Article							N-3 FATTY-ACIDS; PERFORMANCE LIQUID-CHROMATOGRAPHY; GELLED DOUBLE EMULSIONS; IN-WATER EMULSIONS; DELIVERY-SYSTEM; HYDROXYTYROSOL; STABILITY; BETALAIN; BETANIN; ENCAPSULATION	A purple cactus pear (Opuntia ficus-indica) extract (CP) was encapsulated in double emulsions (DE) gelled with gelatin (DE-CP-G) and with gelatin and transglutaminase (DE-CP-GT), as well as in a DE with a liquid external aqueous phase (DE-CP), in order to study the retention of betanin as colorant agent. Both gelled DEs showed a predominantly elastic behavior,in contrast with DE-CP. The degradation rate constant of betanin was significantly higher in DE-CP-GT (90.2 x 10(-3) days(-1)) than in DE-CP-G (11.0 x 10(-3) days-(1)) and DE-CP (14.6 x 10(-3) days(-1)) during cold-storage (4 degrees C). A shift towards yellow color was found in all the systems during cold-storage (4 degrees C) and after thermal treatment (70 degrees C/30 min), especially in DE-CP-GT, denoting a higher degradation of betanin. Betalamic acid, cyclo-Dopa 5-O-beta-glucoside, 17-decarboxy-betanin and neobetanin were identified by UHPLC-MS/MS as degradation products of betanin.	[Robert, Paz] Univ Chile, Fac Ciencias Quim & Farmaceut, Dept Ciencia Alimentos & Tecnol Quim, Santiago, Chile; [Vergara, Cristina] Inst Invest Agr, INIA La Platina, Santiago, Chile; [Silva-Weiss, Andrea; Osorio, Fernando A.; Gimenez, Begona] Univ Santiago Chile, Fac Tecnol, Dept Ciencia & Tecnol Alimentos, Santiago, Chile; [Santander, Rocio] Univ Santiago Chile, Fac Quim & Biol, Dept Ciencias Ambiente, Santiago, Chile; [Saenz, Carmen] Univ Chile, Fac Ciencias Agron, Dept Agroind & Enol, Santiago, Chile	Universidad de Chile; Universidad de Santiago de Chile; Universidad de Santiago de Chile; Universidad de Chile	Gimenez, B (corresponding author), Univ Santiago Chile, Fac Tecnol, Dept Ciencia & Tecnol Alimentos, Santiago, Chile.	bego.gimenez@usach.cl	Santander, Rocio/K-7645-2013; Osorio, Fernando Alberto/AAY-7304-2021; Vergara, Cristina/AAT-9575-2021; Silva-Weiss, Andrea/AAL-3271-2021; Robert, Paz/G-8198-2014	Osorio, Fernando Alberto/0000-0001-7206-0924; Silva-Weiss, Andrea/0000-0001-7541-9947; 	FONDECYT [1150835]	FONDECYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT)	This work was supported by FONDECYT 1150835 (Conicyt -Chile).	Andrade J, 2018, FOOD RES INT, V105, P41, DOI 10.1016/j.foodres.2017.10.070; [Anonymous], 2016, FOOD EMULSIONS PRINC; Bou R, 2014, LWT-FOOD SCI TECHNOL, V59, P621, DOI 10.1016/j.lwt.2014.06.044; Bou R, 2014, INNOV FOOD SCI EMERG, V23, P1, DOI 10.1016/j.ifset.2014.04.001; Cai YZ, 1998, J AGR FOOD CHEM, V46, P4491, DOI 10.1021/jf980457g; Cofrades S, 2013, FOOD CHEM, V141, P338, DOI 10.1016/j.foodchem.2013.02.097; Cofrades S, 2017, J FOOD SCI TECH MYS, V54, P1785, DOI 10.1007/s13197-017-2604-x; Dickinson E, 2011, FOOD BIOPHYS, V6, P1, DOI 10.1007/s11483-010-9188-6; Ding SK, 2019, J CONTROL RELEASE, V295, P31, DOI 10.1016/j.jconrel.2018.12.037; Eisinaite V, 2017, J FOOD ENG, V213, P54, DOI 10.1016/j.jfoodeng.2017.05.022; Esatbeyoglu T, 2015, MOL NUTR FOOD RES, V59, P36, DOI 10.1002/mnfr.201400484; Pagano APE, 2018, FOOD RES INT, V109, P489, DOI 10.1016/j.foodres.2018.04.053; Esteves LC, 2018, PHOTOCHEM PHOTOBIOL, V94, P853, DOI 10.1111/php.12897; Fernandez-Lopez JA, 2001, J CHROMATOGR A, V913, P415, DOI 10.1016/S0021-9673(00)01224-3; Flaiz L, 2016, FOOD CHEM, V213, P49, DOI 10.1016/j.foodchem.2016.06.005; FORNI E, 1992, J CHROMATOGR, V593, P177, DOI 10.1016/0021-9673(92)80284-2; Freire M, 2017, J FOOD SCI TECH MYS, V54, P3959, DOI 10.1007/s13197-017-2860-9; Freire M, 2017, FOOD RES INT, V100, P298, DOI 10.1016/j.foodres.2017.08.047; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Herbach KA, 2006, J AGR FOOD CHEM, V54, P390, DOI 10.1021/jf051854b; Herbach KM, 2006, J FOOD SCI, V71, pR41, DOI 10.1111/j.1750-3841.2006.00022.x; Herbach KM, 2004, EUR FOOD RES TECHNOL, V219, P377, DOI 10.1007/s00217-004-0948-8; Herbach KM, 2004, J FOOD SCI, V69, pC491, DOI 10.1111/j.1365-2621.2004.tb10994.x; Jimenez-Colmenero F, 2015, TRENDS FOOD SCI TECH, V44, P177, DOI 10.1016/j.tifs.2015.04.011; Jimenez-Colmenero F, 2013, FOOD RES INT, V52, P64, DOI 10.1016/j.foodres.2013.02.040; Kaimainen M, 2015, LWT-FOOD SCI TECHNOL, V60, P899, DOI 10.1016/j.lwt.2014.10.016; Khan MI, 2016, FOOD CHEM, V197, P1280, DOI 10.1016/j.foodchem.2015.11.043; Kukizaki M, 2007, COLLOID SURFACE A, V293, P87, DOI 10.1016/j.colsurfa.2006.07.011; Lamba H, 2015, FOOD BIOPROCESS TECH, V8, P709, DOI 10.1007/s11947-014-1468-6; Ma LL, 2017, J AGR FOOD CHEM, V65, P9735, DOI 10.1021/acs.jafc.7b04042; Mao LK, 2015, FOOD ENG REV, V7, P439, DOI 10.1007/s12393-015-9108-0; Matos M, 2018, J FOOD ENG, V226, P73, DOI 10.1016/j.jfoodeng.2018.01.007; McClements DJ, 2009, CRIT REV FOOD SCI, V49, P577, DOI 10.1080/10408390902841529; Ninfali P, 2013, FITOTERAPIA, V89, P188, DOI 10.1016/j.fitote.2013.06.004; Pigment Guneser O., 2016, FOOD CHEM, V196, P220, DOI [10.1016/j.foodchem.2015.09.033, DOI 10.1016/J.FOODCHEM.2015.09.033]; ROSSMURPHY SB, 1995, J TEXTURE STUD, V26, P391, DOI 10.1111/j.1745-4603.1995.tb00979.x; Saenz C, 2009, FOOD CHEM, V114, P616, DOI 10.1016/j.foodchem.2008.09.095; Silva W, 2018, FOOD CHEM, V253, P71, DOI 10.1016/j.foodchem.2018.01.128; Stintzing FC, 2005, J AGR FOOD CHEM, V53, P442, DOI 10.1021/jf048751y; Surh J, 2007, J AGR FOOD CHEM, V55, P175, DOI 10.1021/jf061637q; Vergara C, 2014, FOOD CHEM, V157, P246, DOI 10.1016/j.foodchem.2014.02.037; Weiss J, 2005, FOOD HYDROCOLLOID, V19, P605, DOI 10.1016/j.foohyd.2004.10.023; Yang M, 2013, FOOD RES INT, V52, P409, DOI 10.1016/j.foodres.2011.11.012	43	3	3	3	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2020	15	1							e0227866	10.1371/journal.pone.0227866	http://dx.doi.org/10.1371/journal.pone.0227866			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5PQ	31945132	Green Published, gold			2023-01-03	WOS:000534370100068
J	Hamdi, M; Abdel-Bar, HM; Elmowafy, E; Al-Jamal, KT; Awad, GAS				Hamdi, Mohamed; Abdel-Bar, Hend Mohamed; Elmowafy, Enas; Al-Jamal, Khuloud T.; Awad, Gehanne A. S.			An integrated vitamin E-coated polymer hybrid nanoplatform: A lucrative option for an enhanced in vitro macrophage retention for an anti-hepatitis B therapeutic prospect	PLOS ONE			English	Article							SOLID LIPID NANOPARTICLES; CELLULAR UPTAKE; PARTICLE-SIZE; PLGA NANOPARTICLES; FORMULATION DESIGN; DELIVERY PLATFORM; ALPHA-TOCOPHEROL; ORAL DELIVERY; DRUG-RELEASE; OPTIMIZATION	A platform capable of specifically delivering an antiviral drug to the liver infected with hepatitis B is a major concern in hepatology. Vaccination has had a major effect on decreasing the emerging numbers of new cases of infection. However, the total elimination of the hepatitis B virus from the body requires prolonged therapy. In this work, we aimed to target the liver macrophages with lipid polymer hybrid nanoparticles (LPH), combining the merit of polymeric nanoparticles and lipid vesicles. The hydrophilic antiviral drug, entecavir (E), loaded LPH nanoparticles were optimized and physicochemically characterized. A modulated lipidic corona, as well as, an additional coat with vitamin E were used to extend the drug release enhance the macrophage uptake. The selected vitamin E coated LPH nanoparticles enriched with lecithin-glyceryl monostearate lipid shell exhibited high entrapment for E (80.47%), a size. 200 nm for liver passive targeting, extended release over one week, proven serum stability, retained stability after refrigeration storage for 6 months. Upon macrophage uptake in vitro assessment, the presented formulation displayed promising traits, enhancing the cellular retention in J774 macrophages cells. In vivo and antiviral activity futuristic studies would help in the potential application of the ELPH in hepatitis B control.	[Hamdi, Mohamed; Abdel-Bar, Hend Mohamed] Univ Sadat City, Dept Pharmaceut, Fac Pharm, Sadat City, Egypt; [Elmowafy, Enas; Awad, Gehanne A. S.] Ain Shams Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Sadat City, Egypt; [Al-Jamal, Khuloud T.] Kings Coll London, Fac Life Sci & Med, Inst Pharmaceut Sci, London, England	Egyptian Knowledge Bank (EKB); University of Sadat City; Egyptian Knowledge Bank (EKB); Ain Shams University; University of London; King's College London	Abdel-Bar, HM (corresponding author), Univ Sadat City, Dept Pharmaceut, Fac Pharm, Sadat City, Egypt.	hend.abdelbar@fop.usc.edu.eg	Elmowafy, Enas/AAJ-4255-2021; Abdel-Bar, Hend Mohamed/H-5871-2017; Abdel-Bar, Hend Mohamed/ABG-6088-2021; Amira, Mohamed/AAT-9940-2021; Al-Jamal, Khuloud/ABD-5668-2021	Abdel-Bar, Hend Mohamed/0000-0001-5833-9267; Abdel-Bar, Hend Mohamed/0000-0001-5833-9267; Amira, Mohamed/0000-0002-3616-8636; AL-JAMAL, KHULOUD/0000-0001-5165-2699; Awad, Gehanne A/0000-0003-0357-3114				Abdel-Bar HM, 2017, BIOMED PHARMACOTHER, V93, P561, DOI 10.1016/j.biopha.2017.06.093; Aeschimann W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05148-9; Ali MH, 2010, J PHARM PHARMACOL, V62, P1646, DOI 10.1111/j.2042-7158.2010.01090.x; Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037; Ana R, 2019, INT J PHARMACEUT, V554, P352, DOI 10.1016/j.ijpharm.2018.11.028; Asthana S, 2015, EUR J PHARM BIOPHARM, V89, P62, DOI 10.1016/j.ejpb.2014.11.019; Boltjes A, 2014, J HEPATOL, V61, P660, DOI 10.1016/j.jhep.2014.04.026; Bongiorno D, 2006, INT J PHARMACEUT, V312, P96, DOI 10.1016/j.ijpharm.2006.01.017; Bose RJC, 2017, DRUG DISCOV TODAY, V22, P1258, DOI 10.1016/j.drudis.2017.05.015; Briuglia ML, 2015, DRUG DELIV TRANSL RE, V5, P231, DOI 10.1007/s13346-015-0220-8; Chan JM, 2009, BIOMATERIALS, V30, P1627, DOI 10.1016/j.biomaterials.2008.12.013; Chaudhary Z, 2018, INT J POLYM MATER PO, V67, P86, DOI 10.1080/00914037.2017.1300900; Chen LC, 2016, SCI REP-UK, V6, DOI 10.1038/srep37122; Chen RE, 2015, DRUG DELIV, V22, P666, DOI 10.3109/10717544.2014.882446; Chen WL, 2017, MOL PHARMACEUT, V14, P459, DOI 10.1021/acs.molpharmaceut.6b00896; D'Addio SM, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0128; Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043; Das S, 2011, COLLOID SURFACE B, V88, P483, DOI 10.1016/j.colsurfb.2011.07.036; Date T, 2018, J CONTROL RELEASE, V271, P60, DOI 10.1016/j.jconrel.2017.12.016; Dehaini D, 2016, NANOSCALE, V8, P14411, DOI 10.1039/c6nr04091h; Devrim B, 2016, DRUG DEV IND PHARM, V42, P1865, DOI 10.1080/03639045.2016.1180392; Dizaj SM, 2015, J DRUG DELIV SCI TEC, V29, P125, DOI 10.1016/j.jddst.2015.06.015; Dobrovoiskaia MA, 2008, NANO LETT, V8, P2180, DOI 10.1021/nl0805615; Dora CP, 2010, ACTA POL PHARM, V67, P283; Duan R, 2017, COLLOID SURFACE B, V159, P880, DOI 10.1016/j.colsurfb.2017.08.042; El-Gogary RI, 2014, ACS NANO, V8, P1384, DOI 10.1021/nn405155b; Emami J, 2014, RES PHARM SCI, V9, P301; Faure-Dupuy S, 2018, LIVER INT, V38, P1718, DOI 10.1111/liv.13884; Gajra B, 2016, DRUG DEV IND PHARM, V42, P747, DOI 10.3109/03639045.2015.1093496; Gardouh AR, 2013, BRIT J PHARM RES, V3, P326, DOI 10.9734/BJPR/2013/2770; Hadinoto K, 2013, EUR J PHARM BIOPHARM, V85, P427, DOI 10.1016/j.ejpb.2013.07.002; Hallan SS, 2016, ARTIF CELL NANOMED B, V44, P334, DOI 10.3109/21691401.2014.951721; He SS, 2018, MOL PHARMACEUT, V15, P3953, DOI 10.1021/acs.molpharmaceut.8b00408; Ho MJ, 2018, INT J PHARMACEUT, V543, P52, DOI 10.1016/j.ijpharm.2018.03.042; Hodgins NO, 2017, J CONTROL RELEASE, V256, P141, DOI 10.1016/j.jconrel.2017.04.025; Hu Y, 2015, ACTA BIOMATER, V28, P149, DOI 10.1016/j.actbio.2015.09.032; Huo ZJ, 2015, CANCER SCI, V106, P1429, DOI 10.1111/cas.12737; Hussain T, 2013, ACTA POL PHARM, V70, P749; Ishak RAH, 2017, DRUG DELIV, V24, DOI 10.1080/10717544.2017.1410263; Jin X, 2013, DRUG DEV IND PHARM, V39, P1421, DOI 10.3109/03639045.2012.719234; Joshi SA, 2010, EUR J PHARM BIOPHARM, V76, P189, DOI 10.1016/j.ejpb.2010.07.007; Ju C, 2016, CELL MOL IMMUNOL, V13, P316, DOI 10.1038/cmi.2015.104; Jung HJ, 2018, MOLECULES, V23, DOI 10.3390/molecules23040731; Kashif PM, 2017, AAPS PHARMSCITECH, V18, P1810, DOI 10.1208/s12249-016-0653-5; Klippstein R, 2015, SMALL, V11, P4704, DOI 10.1002/smll.201403799; Konjufca VK, 2004, POULTRY SCI, V83, P1530, DOI 10.1093/ps/83.9.1530; Krishnamachari Y, 2007, INT J PHARM, V338, P238, DOI 10.1016/j.ijpharm.2007.02.015; Kulkarni SA, 2013, PHARM RES-DORDR, V30, P2512, DOI 10.1007/s11095-012-0958-3; Kumar R., 2013, DRUG INVENT TODAY, V5, P246; Lalani J, 2015, AAPS PHARMSCITECH, V16, P413, DOI 10.1208/s12249-014-0235-3; Leng DL, 2018, INT J PHARMACEUT, V548, P740, DOI 10.1016/j.ijpharm.2017.08.094; Lewis ED, 2019, IUBMB LIFE, V71, P487, DOI 10.1002/iub.1976; Li AM, 2019, INT J NANOMED, V14, P913, DOI 10.2147/IJN.S190164; Li LJ, 2010, NANO TODAY, V5, P296, DOI 10.1016/j.nantod.2010.06.007; Liang J, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0391-9; Lim JL, 2015, INT J PHARMACEUT, V490, P265, DOI 10.1016/j.ijpharm.2015.05.049; Maboos M, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-018-0783-8; Magarkar A, 2014, SCI REP-UK, V4, DOI 10.1038/srep05005; Mandal B, 2016, EUR J PHARM SCI, V81, P162, DOI 10.1016/j.ejps.2015.10.021; Massella D, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10101092; Meng R, 2016, J HUAZHONG U SCI-MED, V36, P14, DOI 10.1007/s11596-016-1535-5; Morales-Cruz Moraima, 2012, Results Pharma Sci, V2, P79; Moran-Valero MI, 2017, COLLOID SURFACE B, V151, P68, DOI 10.1016/j.colsurfb.2016.12.015; Mukherjee A, 2019, INT J NANOMED, V14, P1937, DOI 10.2147/IJN.S198353; Mustafa S, 2017, J DRUG DELIV, V2017, DOI 10.1155/2017/1253294; Nam HY, 2009, J CONTROL RELEASE, V135, P259, DOI 10.1016/j.jconrel.2009.01.018; Nishina K, 2008, MOL THER, V16, P734, DOI 10.1038/mt.2008.14; PAGANO RE, 1972, J MEMBRANE BIOL, V10, P11, DOI 10.1007/BF01867845; Pooja D, 2014, COLLOID SURFACE B, V121, P461, DOI 10.1016/j.colsurfb.2014.06.059; Rigotti A, 2007, MOL ASPECTS MED, V28, P423, DOI 10.1016/j.mam.2007.01.002; Salatin S, 2017, RES PHARM SCI, V12, P1, DOI 10.4103/1735-5362.199041; Sato Y, 2012, J CONTROL RELEASE, V163, P267, DOI 10.1016/j.jconrel.2012.09.009; Sengel-Turk CT, 2017, J DRUG DELIV SCI TEC, V39, P16, DOI 10.1016/j.jddst.2017.02.012; Shah B, 2015, EUR J PHARM SCI, V78, P54, DOI 10.1016/j.ejps.2015.07.002; Shah VP, 1998, PHARMACEUT RES, V15, P889, DOI 10.1023/A:1011976615750; Shao XR, 2015, CELL PROLIFERAT, V48, P465, DOI 10.1111/cpr.12192; Silva EJ, 2018, CURR DRUG DELIV, V15, P979, DOI 10.2174/1567201815666171215110026; Singh L, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050267; Singh L, 2017, THER ADV INFECT DIS, V4, P105, DOI 10.1177/2049936117713593; Sylvester B, 2018, DRUG DEV IND PHARM, V44, P385, DOI 10.1080/03639045.2017.1395457; Tahir N, 2017, INT J PHARMACEUT, V533, P156, DOI 10.1016/j.ijpharm.2017.09.061; Tamilselvan N, 2015, J YOUNG PHARM, V7, P28, DOI 10.5530/jyp.2015.1.6; Thanki K, 2017, EUR J PHARM BIOPHARM, V120, P22, DOI 10.1016/j.ejpb.2017.07.014; Traber MG, 2007, ANNU REV NUTR, V27, P347, DOI 10.1146/annurev.nutr.27.061406.093819; Uppulurj KB, 2015, BIOMEDICAL PHARM J, V6, P355; Wang AZ, 2010, NANOMEDICINE-UK, V5, P361, DOI 10.2217/NNM.10.6; Win KY, 2005, BIOMATERIALS, V26, P2713, DOI 10.1016/j.biomaterials.2004.07.050; Wu XN, 2019, INFECT DRUG RESIST, V12, P745, DOI 10.2147/IDR.S185120; Yanasarn N, 2009, INT J PHARMACEUT, V379, P174, DOI 10.1016/j.ijpharm.2009.06.004; Yokosuka O, 2010, J HEPATOL, V52, P791, DOI 10.1016/j.jhep.2009.12.036; Zhang CY, 2019, INT J PHARMACEUT, V560, P27, DOI 10.1016/j.ijpharm.2019.01.052; Zhang L, 2010, NANO LIFE, V1, P163, DOI 10.1142/S179398441000016X; Zhao PQ, 2012, EUR J PHARM BIOPHARM, V81, P248, DOI 10.1016/j.ejpb.2012.03.004; Zhao X, 2015, BIOMATERIALS, V46, P13, DOI 10.1016/j.biomaterials.2014.12.028; Zingg JM, 2007, MOL ASPECTS MED, V28, P400, DOI 10.1016/j.mam.2007.05.004; Zoubari G, 2017, EUR J PHARM BIOPHARM, V110, P39, DOI 10.1016/j.ejpb.2016.10.021; Zoutendijk R, 2011, HEPATOLOGY, V54, P443, DOI 10.1002/hep.24406	97	14	14	3	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 10	2020	15	1							e0227231	10.1371/journal.pone.0227231	http://dx.doi.org/10.1371/journal.pone.0227231			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5IB	31923260	Green Published, gold			2023-01-03	WOS:000534350000058
J	Gebremichael, TG; Welesamuel, TG				Gebremichael, Tsgehana Gebregyorgis; Welesamuel, Tsehaynesh Gidey			Adherence to iron-folic acid supplement and associated factors among antenatal care attending pregnant mothers in governmental health institutions of Adwa town, Tigray, Ethiopia: Cross-sectional study	PLOS ONE			English	Article							MATERNAL ANEMIA; NUTRITION; BIRTH	Background Iron-folic acid supplementation during pregnancy is among the very effective interventions to prevent iron deficiency anemia, low birth weight, and prematurity. There is a need of having recent studies on adherence to the supplement that consider the very recent interventions targeted to scale up the use of iron-folic acid (IFA) supplement. Therefore we sought to assess adherence to IFA supplement and its associated factors among antenatal care attending pregnant mothers in governmental health institutions of Adwa town. Methods Institution-based cross-sectional study was conducted among 629 antenatal care attending pregnant mothers. Systematic random sampling method was used to select the study subjects. Data were collected through face-to-face interview and chart-review. Bivariable and multivariable binary logistic regression was computed. Variables with P-value < 0.05 were considered statistically significant at 95% confidence interval (CI). Result Only 40.9% (95%CI: 37.0%-44.7%) of participants were adherent (took four or more tablets per week). Women in the age group of 25-29 years [AOR: 2.22(1.21-4.07)] had increased odds of adherence as compared to those in the age group >= 35 years. Women who received nutrition counseling [AOR: 4.12(2.12-8.03)] and partner support [AOR: 2.23 (1.42-3.49)] had increased odds of adherence as compared to those who didn't receive nutrition counseling and partner support respectively. Similarly, women who had satisfactory knowledge on IFA supplement (AOR: 2.16(1.37-3.40)) had increased odds of adherence as compared to those who didn't have satisfactory knowledge on IFA supplement. Conclusion Adherence to the supplement was low. Efforts shall be done to improve awareness of pregnant mothers about IFA supplement through targeted nutrition counseling that includes the engagement of a partner.	[Gebremichael, Tsgehana Gebregyorgis] Axum Univ, Specialized & Compress Hosp, Dept Human Nutr, Axum, Ethiopia; [Welesamuel, Tsehaynesh Gidey] Axum Univ, Specialized & Compress Hosp, Dept Publ Hlth, Axum, Ethiopia		Gebremichael, TG (corresponding author), Axum Univ, Specialized & Compress Hosp, Dept Human Nutr, Axum, Ethiopia.	hanagmichael@gmail.com			Axum University, Axum, Ethiopia	Axum University, Axum, Ethiopia	This study was funded by Axum University, Axum, Ethiopia.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2016, ETHIOPIA NATL NUTR P; [Anonymous], 2014, 2025 ANAEMIA POLICY; Arega Sadore A, 2015, J ENV PUBLIC HLTH, V2015; Birhanu Tesfaye Molla, 2018, BMC Res Notes, V11, P345, DOI 10.1186/s13104-018-3433-3; Central statistical agency, ETH DEM HLTH SURV 20; Christian P, 2015, SEMIN PERINATOL, V39, P361, DOI 10.1053/j.semperi.2015.06.009; Ethiopian Public Health Institute (EPHI), 2016, ETH NAT MICR SURV RE, P9; Federal Ministry of Health of Ethiopia, 2016, NAT GUID CONTR PREV; Gebre A, 2015, INT J NUTR FOOD SCI, V4, P161, DOI [10.11648/j.ijnfs.20150402.16, DOI 10.11648/J.IJNFS.20150402.16]; Gebreamlak B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169415; Getachew M, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1716-2; Imdad A, 2012, PAEDIATR PERINAT EP, V26, P168, DOI 10.1111/j.1365-3016.2012.01312.x; Jasti S, 2005, J NUTR, V135, P1093, DOI 10.1093/jn/135.5.1093; Kamau MW, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5437-2; Marti-carvaja A.L, 2002, PREVALENCE ANEMIA PR; McLean E, 2009, PUBLIC HEALTH NUTR, V12, P444, DOI 10.1017/S1368980008002401; Mithra P, 2013, Afr Health Sci, V13, P880, DOI 10.4314/ahs.v13i4.3; Rahman MM, 2016, AM J CLIN NUTR, V103, P495, DOI 10.3945/ajcn.115.107896; Shewasinad S, 2017, J PREGNANCY CHILD HL, DOI [10.4172/2376-127X.1000301, DOI 10.4172/2376-127X.1000301]; Taye B, 2015, J ENV PUBLIC HLTH, V20, P1; Tegegne M., 2017, GLOBAL J MED RES; Tetanus WMIA, 2006, INT MAN PREGN CHILDB; Villalpando S, 2008, FOOD NUTR BULL, V29, pS112, DOI 10.1177/15648265080292S115; World Health Organization, 2013, ESS NUTR ACT IMPR MA	24	14	14	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2020	15	1							e0227090	10.1371/journal.pone.0227090	http://dx.doi.org/10.1371/journal.pone.0227090			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5BZ	31910215	Green Published, gold			2023-01-03	WOS:000534333800026
J	Ray-Coquard, I; Pautier, P; Pignata, S; Perol, D; Gonzalez-Martin, A; Berger, R; Fujiwara, K; Vergote, I; Colombo, N; Maenpaa, J; Selle, F; Sehouli, J; Lorusso, D; Alia, EMG; Reinthaller, A; Nagao, S; Lefeuvre-Plesse, C; Canzler, U; Scambia, G; Lortholary, A; Marme, F; Combe, P; de Gregorio, N; Rodrigues, M; Buderath, P; Dubot, C; Burges, A; You, B; Pujade-Lauraine, E; Harter, P				Ray-Coquard, I.; Pautier, P.; Pignata, S.; Perol, D.; Gonzalez-Martin, A.; Berger, R.; Fujiwara, K.; Vergote, I.; Colombo, N.; Maenpaa, J.; Selle, F.; Sehouli, J.; Lorusso, D.; Alia, E. M. Guerra; Reinthaller, A.; Nagao, S.; Lefeuvre-Plesse, C.; Canzler, U.; Scambia, G.; Lortholary, A.; Marme, F.; Combe, P.; de Gregorio, N.; Rodrigues, M.; Buderath, P.; Dubot, C.; Burges, A.; You, B.; Pujade-Lauraine, E.; Harter, P.		PAOLA-Investigators	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRIAL GROUPS REQUIREMENTS; DOUBLE-BLIND; EUROPEAN NETWORK; ACADEMIC GROUPS; THERAPY; CARCINOMA; SURVIVAL; OUTCOMES; WOMEN	BACKGROUND Olaparib has shown significant clinical benefit as maintenance therapy in women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of combining maintenance olaparib and bevacizumab in patients regardless of BRCA mutation status is unknown. METHODS We conducted a randomized, double-blind, international phase 3 trial. Eligible patients had newly diagnosed, advanced, high-grade ovarian cancer and were having a response after first-line platinum-taxane chemotherapy plus bevacizumab. Patients were eligible regardless of surgical outcome or BRCA mutation status. Patients were randomly assigned in a 2:1 ratio to receive olaparib tablets (300 mg twice daily) or placebo for up to 24 months; all the patients received bevacizumab at a dose of 15 mg per kilogram of body weight every 3 weeks for up to 15 months in total. The primary end point was the time from randomization until investigator-assessed disease progression or death. RESULTS Of the 806 patients who underwent randomization, 537 were assigned to receive olaparib and 269 to receive placebo. After a median follow-up of 22.9 months, the median progression-free survival was 22.1 months with olaparib plus bevacizumab and 16.6 months with placebo plus bevacizumab (hazard ratio for disease progression or death, 0.59; 95% confidence interval [CI], 0.49 to 0.72; P<0.001). The hazard ratio (olaparib group vs. placebo group) for disease progression or death was 0.33 (95% CI, 0.25 to 0.45) in patients with tumors positive for homologous-recombination deficiency (HRD), including tumors that had BRCA mutations (median progression-free survival, 37.2 vs. 17.7 months), and 0.43 (95% CI, 0.28 to 0.66) in patients with HRD-positive tumors that did not have BRCA mutations (median progression-free survival, 28.1 vs. 16.6 months). Adverse events were consistent with the established safety profiles of olaparib and bevacizumab. CONCLUSIONS In patients with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, the addition of maintenance olaparib provided a significant progression-free survival benefit, which was substantial in patients with HRD-positive tumors, including those without a BRCA mutation.	[Ray-Coquard, I.; Perol, D.] Ctr Leon Berard, 28 Prom Lea & Napoleon Bullukian, F-69008 Lyon, France; [Ray-Coquard, I.] Univ Claude Bernard Lyon 1, Lyon, France; [You, B.] Ctr Hosp Lyon Sud, Lyon, France; [Ray-Coquard, I.; Pautier, P.; Selle, F.; Lefeuvre-Plesse, C.; Lortholary, A.; Combe, P.; Rodrigues, M.; Dubot, C.; You, B.; Pujade-Lauraine, E.] GINECO, Paris, France; [Selle, F.] Grp Hosp Diaconesses Croix St Simon, Paris, France; [Combe, P.] Hop Europeen Georges Pompidou, Paris, France; [Rodrigues, M.] Hop Claudius Regaud, Inst Curie, Paris, France; [Pujade-Lauraine, E.] Assoc Rech Canc Gynecol ARCAGY, Paris, France; [Pautier, P.] Gustave Roussy, Villejuif, France; [Lefeuvre-Plesse, C.] Ctr Eugene Marquis, Rennes, France; [Lortholary, A.] Hop Prive Confluent, Ctr Catherine Sienne, Nantes, France; [Dubot, C.] Hop Rene Huguenin, Inst Curie, St Cloud, France; [Pignata, S.] Ist Nazl Tumori IRCCS Fdn G Pascale, Dept Urol & Gynecol, Naples, Italy; [Pignata, S.] Multictr Italian Trials Ovarian Canc & Gynecol Ma, Naples, Italy; [Colombo, N.] Univ Milano Bicocca, Milan, Italy; [Colombo, N.] European Inst Oncol IRCCS, Milan, Italy; [Colombo, N.] Mario Negri Gynecol Oncol Grp MANGO, Milan, Italy; [Lorusso, D.] Fdn IRCCS Ist Nazl Tumori, Milan, Italy; [Lorusso, D.] MITO, Milan, Italy; [Scambia, G.] Univ Cattolica, Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy; [Scambia, G.] MITO, Rome, Italy; [Gonzalez-Martin, A.] MD Anderson Canc Ctr Madrid, Madrid, Spain; [Gonzalez-Martin, A.; Alia, E. M. Guerra] GEICO, Madrid, Spain; [Alia, E. M. Guerra] Hosp Univ Ramon y Cajal, Madrid, Spain; [Berger, R.] Med Univ Innsbruck, Univ Clin Gynecol & Obstet, Innsbruck, Austria; [Berger, R.; Reinthaller, A.] Arbeitsgemeinschaft Gynakol Onkol Study Grp AGO A, Innsbruck, Austria; [Reinthaller, A.] Med Univ Vienna, Vienna, Austria; [Fujiwara, K.] Saitama Med Univ, Int Med Ctr, Hidaka, Japan; [Fujiwara, K.; Nagao, S.] GOTIC, Moroyama, Saitama, Japan; [Nagao, S.] Hyogo Canc Ctr, Akashi, Hyogo, Japan; [Vergote, I.] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium; [Vergote, I.] Belgium & Luxembourg Gynecol Oncol Grp BGOG, Leuven, Belgium; [Maenpaa, J.] Tampere Univ, Tampere, Finland; [Maenpaa, J.] Univ Hosp, Tampere, Finland; [Maenpaa, J.] NSGO, Copenhagen, Denmark; [Sehouli, J.] Charite Med Univ Berlin, Campus Virchow Klinikum, Berlin, Germany; [Sehouli, J.; Canzler, U.; de Gregorio, N.; Buderath, P.; Burges, A.; Harter, P.] German Soc Gynecol Oncol AGO, Essen, Germany; [Buderath, P.] Univ Klinikum Essen, Essen, Germany; [Harter, P.] Kliniken Essen Mitte, Essen, Germany; [Canzler, U.] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Dresden, Germany; [Marme, F.] Univ Klinikum Heidelberg, Heidelberg, Germany; [de Gregorio, N.] Univ Klinikum Ulm, Ulm, Germany; [Burges, A.] Klinikum Univ Munchen, Munich, Germany	UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut Claudius Regaud; UNICANCER; Gustave Roussy; UNICANCER; Centre Eugene Marquis; Rene Huguenin Hospital; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; IRCCS Fondazione Pascale; University of Milano-Bicocca; IRCCS European Institute of Oncology (IEO); Fondazione IRCCS Istituto Nazionale Tumori Milan; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Texas System; UTMD Anderson Cancer Center; Hospital Universitario Ramon y Cajal; Medical University of Innsbruck; Medical University of Vienna; Saitama Medical University; Hyogo Cancer Center; KU Leuven; University Hospital Leuven; Tampere University; Tampere University; Tampere University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Duisburg Essen; Kliniken Essen-Mitte; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Ruprecht Karls University Heidelberg; Ulm University; University of Munich	Ray-Coquard, I (corresponding author), Ctr Leon Berard, 28 Prom Lea & Napoleon Bullukian, F-69008 Lyon, France.	isabelle.ray-coquard@lyon.unicancer.fr	Rodrigues, Manuel/C-8506-2018; de+Gregorio, Nikolaus/AAL-4158-2020; d, p/GWC-4283-2022; Martín, Antonio González/AAC-5935-2020; Lorusso, Domenica/K-6523-2016; Hietanen, Sakari/N-6849-2016	Rodrigues, Manuel/0000-0002-5443-0802; de+Gregorio, Nikolaus/0000-0002-0037-127X; Martín, Antonio González/0000-0001-8376-9576; pignata, sandro/0000-0002-8836-2633; Bauerschlag, Dirk O./0000-0001-8157-6121; Schnelzer, Andreas/0000-0002-5410-3561; Luis, Manso/0000-0002-1683-550X; Hanker, Lars/0000-0001-6697-018X; Lorusso, Domenica/0000-0003-0981-0598; D'Hondt, Veronique/0000-0001-5238-4032; Ruhwedel, Wencke/0000-0001-6265-0496; Hietanen, Sakari/0000-0003-4734-4743	ARCAGY Research; PAOLA-1	ARCAGY Research; PAOLA-1	Funded by ARCAGY Research and others; PAOLA-1 ClinicalTrials.gov number, NCT02477644.	Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390; Chan N, 2010, CANCER RES, V70, P8045, DOI 10.1158/0008-5472.CAN-10-2352; Cnaan A, 1997, STAT MED, V16, P2349, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E; Cocks K, 2012, EUR J CANCER, V48, P1713, DOI 10.1016/j.ejca.2012.02.059; Coleman RL, 2017, LANCET, V390, P1949, DOI 10.1016/S0140-6736(17)32440-6; Colombo N, 2019, ANN ONCOL, V30, P672, DOI 10.1093/annonc/mdz062; du Bois A, 2015, INT J GYNECOL CANCER, V25, P1328, DOI 10.1097/IGC.0000000000000478; Herzog TJ, 2014, GYNECOL ONCOL, V132, P8, DOI 10.1016/j.ygyno.2013.11.008; Karam A, 2017, ANN ONCOL, V28, P711, DOI 10.1093/annonc/mdx011; Ledermann JA, 2013, ANN ONCOL, V24, P24, DOI 10.1093/annonc/mdt333; Ledermann J, 2014, LANCET ONCOL, V15, P852, DOI 10.1016/S1470-2045(14)70228-1; Ledermann JA, 2016, LANCET ONCOL, V17, P1579, DOI 10.1016/S1470-2045(16)30376-X; Liu JF, 2019, ANN ONCOL, V30, P551, DOI 10.1093/annonc/mdz018; Liu JF, 2014, LANCET ONCOL, V15, P1207, DOI 10.1016/S1470-2045(14)70391-2; Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310; MIRZA MR, 2019, J CLIN ONCOL S, V37; Moore K, 2018, NEW ENGL J MED, V379, P2495, DOI 10.1056/NEJMoa1810858; Norquist BM, 2018, CLIN CANCER RES, V24, P777, DOI 10.1158/1078-0432.CCR-17-1327; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Oza AM, 2015, LANCET ONCOL, V16, P928, DOI 10.1016/S1470-2045(15)00086-8; Perren TJ, 2011, NEW ENGL J MED, V365, P2484, DOI 10.1056/NEJMoa1103799; Pujade-Lauraine E, 2017, LANCET ONCOL, V18, P1274, DOI 10.1016/S1470-2045(17)30469-2; Tewari KS, 2019, J CLIN ONCOL, V37, P2317, DOI 10.1200/JCO.19.01009; Vergote I, 2010, INT J GYNECOL CANCER, V20, P476, DOI 10.1111/IGC.0b013e3181d3caa8	25	657	681	11	68	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 19	2019	381	25					2416	2428		10.1056/NEJMoa1911361	http://dx.doi.org/10.1056/NEJMoa1911361			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ6OG	31851799	Bronze, Green Published			2023-01-03	WOS:000505222400006
J	Sijpkens, MK; Lagendijk, J; van Minde, MRC; de Kroon, MLA; Bertens, LCM; Rosman, AN; Steegers, EAP				Sijpkens, Meertien K.; Lagendijk, Jacqueline; van Minde, Minke R. C.; de Kroon, Marlou L. A.; Bertens, Loes C. M.; Rosman, Ageeth N.; Steegers, Eric A. P.			Integrating interconception care in preventive child health care services: The Healthy Pregnancy 4 All program	PLOS ONE			English	Article							PRECONCEPTION CARE; EUROPEAN COUNTRIES; RISK-ASSESSMENT; INTERVENTION; BEHAVIORS; INTENTION; OUTCOMES; VISITS	Background Most parents with young children pay routine visits to Well-Baby Clinics, or so-called Preventive Child Health Care (PCHC) services. This offers a unique opportunity to promote and deliver interconception care. This study aimed to integrate such care and perform an implementation evaluation. Methods In seven Dutch municipalities, PCHC professionals were instructed to discuss the possibility of an interconception care consultation during each routine six-months well-baby visit. The primary outcome of this study was coverage of the intervention, quantified as the proportion of visits during which women were informed about interconception care. Secondary outcomes included adoption, fidelity, feasibility, appropriateness, acceptability and effectiveness of the intervention, studied by surveying PCHC professionals and women considering becoming pregnant. Results The possibility of interconception care was discussed during 29% (n = 1,849) of all visits, and 60% of the PCHC physicians adopted the promotion of interconception care by regularly informing women. About half of the PCHC professionals and most women judged integration of interconception care in PCHC appropriate and acceptable. Estimated feasibility was poor, since 13% of the professionals judged future integration in daily practice as probable. The uptake of interconception care consultations was low (n = 4 consultations). Conclusions Promotion of interconception care was achieved in approximately one-third of the routine PCHC consultations and appeared promising with regards to adoption, appropriateness and acceptability. However, concerns on feasibility and uptake of interconception care consultations in daily practice remain. Suggestions for improvement may include further integration of interconception care health promotion in routine PCHC consultations, while allocating sufficient resources.	[Sijpkens, Meertien K.; Lagendijk, Jacqueline; van Minde, Minke R. C.; de Kroon, Marlou L. A.; Bertens, Loes C. M.; Rosman, Ageeth N.; Steegers, Eric A. P.] Erasmus MC, Dept Obstet & Gynaecol, Div Obstet & Prenatal Med, Univ Med Ctr Rotterdam, Rotterdam, Netherlands; [van Minde, Minke R. C.; de Kroon, Marlou L. A.] Erasmus MC, Dept Publ Hlth, Univ Med Ctr Rotterdam, Rotterdam, Netherlands; [de Kroon, Marlou L. A.] Univ Med Ctr Groningen, Dept Hlth Sci, Groningen, Netherlands; [Rosman, Ageeth N.] Rotterdam Univ Appl Sci, Dept Hlth Care Studies, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Groningen	Sijpkens, MK (corresponding author), Erasmus MC, Dept Obstet & Gynaecol, Div Obstet & Prenatal Med, Univ Med Ctr Rotterdam, Rotterdam, Netherlands.	m.sijpkens@erasmusmc.nl	Bertens, Loes CM/AAV-4664-2020; de Kroon, Marlou MLA/M-4040-2014	Bertens, Loes CM/0000-0003-0897-0709; de Kroon, Marlou/0000-0003-1730-4994; van Minde, Minke/0000-0003-3316-336X; Lagendijk, Jacqueline/0000-0002-7178-8910	Dutch Ministry of Health, Welfare and Sport, The Hague [323911]	Dutch Ministry of Health, Welfare and Sport, The Hague	The Healthy Pregnancy 4 All study is funded by the Dutch Ministry of Health, Welfare and Sport, The Hague (grant number 323911). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen D, 2017, MATERN CHILD HLTH J, V21, P387, DOI 10.1007/s10995-017-2283-2; Atrash HK, 2006, MATERN CHILD HLTH J, V10, pS3, DOI 10.1007/s10995-006-0100-4; Bloomfield J, 2013, J MIDWIFERY WOM HEAL, V58, P683, DOI 10.1111/jmwh.12132; Burgess CK, 2017, FAM PRACT; Chilukuri N, 2018, J PEDIATR-US, V192, P247, DOI 10.1016/j.jpeds.2017.09.020; Chuang CH, 2011, PREV MED, V53, P85, DOI 10.1016/j.ypmed.2011.04.009; Chuang CH, 2010, MATERN CHILD HLTH J, V14, P501, DOI 10.1007/s10995-009-0453-6; de Smit DJ, 2015, PUBLIC HEALTH NUTR, V18, P1119, DOI 10.1017/S1368980014000986; DeCesare JZ, 2015, OBSTET GYNECOL SURV, V70, P465, DOI 10.1097/OGX.0000000000000196; Denktas S, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-253; Deville WLJM, 2012, HERIJKING STEDELIJKE; Fleuren M, 2014, INT J QUAL HLTH CARE; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Health Council of the Netherlands, 2007, USITC PUBL, V2007; Jack BW, 2008, AM J OBSTET GYNECOL, V199, pS266, DOI 10.1016/j.ajog.2008.07.067; Jambroes M, 2015, HEALTH POLICY, V119, P1557, DOI 10.1016/j.healthpol.2015.08.002; Kuo AA, 2006, PEDIATRICS, V118, P1692, DOI 10.1542/peds.2006-0620; Mook-Kanamori DO, 2010, JAMA-J AM MED ASSOC, V303, P527, DOI 10.1001/jama.2010.78; Neta G, 2015, AM J PUBLIC HEALTH, V105, P49, DOI 10.2105/AJPH.2014.302206; Okah FA, 2014, AM J HEALTH BEHAV, V38, P316, DOI 10.5993/AJHB.38.2.17; Peters DH, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6753; Poels M, 2016, OBSTET GYNECOL SURV, V71, P603, DOI 10.1097/OGX.0000000000000360; Proctor E, 2011, ADM POLICY MENT HLTH, V38, P65, DOI 10.1007/s10488-010-0319-7; Robbins CL, 2014, MMWR SURVEILL SUMM, V63, P1; Rosener SE, 2016, ANN FAM MED, V14, P350, DOI 10.1370/afm.1933; Sanchez A, 2017, BMC FAM PRACT, V18, DOI 10.1186/s12875-017-0585-5; Shawe J, 2015, EUR J CONTRACEP REPR, V20, P77, DOI 10.3109/13625187.2014.990088; Sijpkens MK, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-3882-y; Sijpkens MK, 2016, MATERN CHILD HLTH J, V20, pS117, DOI 10.1007/s10995-016-2046-5; Srinivasan S, 2018, J AM BOARD FAM MED, V31, P201, DOI 10.3122/jabfm.2018.02.170227; Steegers-Theunissen RPM, 2013, HUM REPROD UPDATE, V19, P640, DOI 10.1093/humupd/dmt041; Stephenson J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103085; Temel S, 2015, J COMMUN GENET, V6, P107, DOI 10.1007/s12687-014-0204-2; Toivonen KI, 2017, PREV MED, V96, P1, DOI 10.1016/j.ypmed.2016.11.022; van Voorst S, 2016, EUR J CONTRACEP REPR, V21, P251, DOI 10.3109/13625187.2016.1154524; Van Voorst SF, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006284; van Voorst SF, 2017, HLTH EXPECT; Vink-van Os LCA, 2015, PUBLIC HEALTH GENOM, V18, P204, DOI 10.1159/000381449; Waelput AJM, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1425-2; Wieske RCN, 2012, INT J PUBLIC HEALTH, V57, P637, DOI 10.1007/s00038-011-0305-1	40	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2019	14	11							e0224427	10.1371/journal.pone.0224427	http://dx.doi.org/10.1371/journal.pone.0224427			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LN1FJ	31693703	Green Published, gold			2023-01-03	WOS:000532690100025
J	Hovinga, JAK; George, JN				Hovinga, Johanna A. Kremer; George, James N.			Hereditary Thrombotic Thrombocytopenic Purpura	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							VON-WILLEBRAND-FACTOR; FACTOR-CLEAVING PROTEASE; UPSHAW-SCHULMAN SYNDROME; FACTOR-VIII; ADAMTS13 DEFICIENCY; PLASMA; PREGNANCY; TTP; POLYMORPHISMS; PURIFICATION	Hereditary thrombotic thrombocytopenic purpura is an autosomal recessive disorder caused by the absence of a functional protease (ADAMTS13) that processes von Willebrand factor multimers into smaller fragments. The multimers bind to platelets and initiate abnormal clotting, thrombosis, and hemolysis.	[Hovinga, Johanna A. Kremer] Univ Bern, Dept Hematol, Bern, Switzerland; [Hovinga, Johanna A. Kremer] Univ Bern, Bern Univ Hosp, Inselspital, Cent Hematol Lab, Bern, Switzerland; [Hovinga, Johanna A. Kremer] Univ Bern, Dept Biomed Res, Bern, Switzerland; [George, James N.] Univ Oklahoma, Coll Med, Hudson Coll Publ Hlth, Dept Biostat & Epidemiol,Dept Med,Hlth Sci Ctr, Oklahoma City, OK 73190 USA	University of Bern; University of Bern; University Hospital of Bern; University of Bern; University of Oklahoma System; University of Oklahoma Health Sciences Center	George, JN (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Hudson Coll Publ Hlth, Dept Biostat & Epidemiol, 801 NE 13th St, Oklahoma City, OK 73104 USA.	jamesgeorge@ouhsc.edu	Hovinga, Johanna A Kremer/M-3482-2013	Hovinga, Johanna A Kremer/0000-0002-1300-7135				ABILDGAARD C F, 1967, Seminars in Hematology, V4, P424; Akiyama M, 2008, J THROMB HAEMOST, V6, P1830, DOI 10.1111/j.1538-7836.2008.03109.x; Alwan F, 2019, BLOOD, V133, P1644, DOI 10.1182/blood-2018-11-884700; AMOROSI EL, 1966, MEDICINE, V45, P139, DOI 10.1097/00005792-196603000-00003; Benhamou Y, 2015, J THROMB HAEMOST, V13, P293, DOI 10.1111/jth.12790; BYRNES JJ, 1977, NEW ENGL J MED, V297, P1386, DOI 10.1056/NEJM197712222972507; Camilleri RS, 2008, J THROMB HAEMOST, V6, P331, DOI 10.1111/j.1538-7836.2007.02846.x; Chen JM, 2018, BLOOD, V132, P141, DOI 10.1182/blood-2018-02-769000; Drury-Stewart DN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112935; FUCHS WE, 1976, JAMA-J AM MED ASSOC, V235, P2126, DOI 10.1001/jama.235.19.2126; Fujikawa K, 2001, BLOOD, V98, P1662, DOI 10.1182/blood.V98.6.1662; Fujimura Y, 2011, J THROMB HAEMOST, V9, P283, DOI 10.1111/j.1538-7836.2011.04341.x; Fujimura Y, 2009, BRIT J HAEMATOL, V144, P742, DOI 10.1111/j.1365-2141.2008.07515.x; Furlan M, 1999, THROMB HAEMOSTASIS, V81, P8; Furlan M, 1997, BLOOD, V89, P3097, DOI 10.1182/blood.V89.9.3097; Furlan M, 1998, NEW ENGL J MED, V339, P1578, DOI 10.1056/NEJM199811263392202; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Gerritsen HE, 2001, BLOOD, V98, P1654, DOI 10.1182/blood.V98.6.1654; Hager HB, 2018, BLOOD, V131, P1627, DOI 10.1182/blood-2018-01-827063; Hovinga JAK, 2018, J THROMB HAEMOST, V16, P618, DOI 10.1111/jth.13956; Hovinga JAK, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.20; Jain A, 2018, J PEDIAT, V200; Jin SY, 2013, BLOOD, V121, P3825, DOI 10.1182/blood-2013-02-486779; Joly BS, 2018, THROMB HAEMOSTASIS, V118, P1902, DOI 10.1055/s-0038-1673686; Joly BS, 2017, BLOOD, V129, P2836, DOI 10.1182/blood-2016-10-709857; Kates Erica Hyman, 2007, Pediatr Rev, V28, P33, DOI 10.1542/pir.28-1-33; Katneni UK, 2019, J THROMB HAEMOST, V17, P429, DOI 10.1111/jth.14374; Kokame K, 2002, P NATL ACAD SCI USA, V99, P11902, DOI 10.1073/pnas.172277399; Kovarova P, 2019, J CLIN APHERESIS, V34, P13, DOI 10.1002/jca.21664; Laje P, 2009, BLOOD, V113, P2172, DOI 10.1182/blood-2008-08-173021; Leebeek FWG, 2016, NEW ENGL J MED, V375, P2067, DOI 10.1056/NEJMra1601561; Lenting PJ, 2015, BLOOD, V125, P2019, DOI 10.1182/blood-2014-06-528406; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; LIAN ECY, 1979, BLOOD, V53, P333; Lotta LA, 2010, HUM MUTAT, V31, P11, DOI 10.1002/humu.21143; Mannucci PM, 2012, BLOOD, V119, P4108, DOI 10.1182/blood-2012-01-394411; MOAKE JL, 1982, NEW ENGL J MED, V307, P1432, DOI 10.1056/NEJM198212023072306; Moatti-Cohen M, 2012, BLOOD, V119, P5888, DOI 10.1182/blood-2012-02-408914; Moschcowitz E., 1924, P NY PATHOL SOC, V24, P21; Naik S, 2013, J PEDIAT HEMATOL ONC, V35, P551, DOI 10.1097/MPH.0b013e3182755c38; Page EE, 2017, BLOOD ADV, V1, P590, DOI 10.1182/bloodadvances.2017005124; Plaimauer B, 2006, BLOOD, V107, P118, DOI 10.1182/blood-2005-06-2482; Raval JS, 2015, AM J HEMATOL, V90, pE22, DOI 10.1002/ajh.23851; Reese JA, 2013, PEDIATR BLOOD CANCER, V60, P1676, DOI 10.1002/pbc.24612; Sadler JE, 2017, BLOOD, V130, P1181, DOI 10.1182/blood-2017-04-636431; Schneppenheim R, 2006, THROMB HAEMOSTASIS, V96, P3, DOI 10.1160/TH05-12-0817; SCHULMAN I, 1960, BLOOD, V16, P943, DOI 10.1182/blood.V16.1.943.943; Scully M, 2006, BRIT J HAEMATOL, V135, P101, DOI 10.1111/j.1365-2141.2006.06264.x; Scully M, 2017, BLOOD, V130, P2055, DOI 10.1182/blood-2017-06-788026; Scully M, 2014, BLOOD, V124, P211, DOI 10.1182/blood-2014-02-553131; SINGER K, 1947, BLOOD, V2, P542, DOI 10.1182/blood.V2.6.542.542; Sonneveld MAH, 2015, BLOOD, V126, P2739, DOI [10.1182/blood-2015-05-643338, 10.1182/blood-2015-05643338]; South K, 2018, J THROMB HAEMOST, V16, P6, DOI 10.1111/jth.13898; Studt JD, 2005, BLOOD, V105, P542, DOI 10.1182/blood-2004-06-2096; Sundd P, 2019, ANNU REV PATHOL-MECH, V14, P263, DOI 10.1146/annurev-pathmechdis-012418-012838; Taylor A, 2019, J THROMB HAEMOST, V17, P88, DOI 10.1111/jth.14345; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; Turner NA, 2009, BLOOD, V114, P5102, DOI 10.1182/blood-2009-07-231597; UPSHAW JD, 1978, NEW ENGL J MED, V298, P1350, DOI 10.1056/NEJM197806152982407; van Dorland HA, 2019, HAEMATOLOGICA, V104, P2107, DOI 10.3324/haematol.2019.216796; Veyradier A, 2006, J THROMB HAEMOST, V4, P700, DOI 10.1111/j.1538-7836.2005.01768.x; von Krogh AS, 2016, J THROMB HAEMOST, V14, P73, DOI 10.1111/jth.13186; von Krogh AS, 2014, THROMB HAEMOSTASIS, V111, P1180, DOI 10.1160/TH13-08-0713; WALLACE DC, 1975, AM J MED, V58, P724, DOI 10.1016/0002-9343(75)90510-0; WEINSTEIN MJ, 1989, BRIT J HAEMATOL, V72, P68, DOI 10.1111/j.1365-2141.1989.tb07654.x; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200; Zheng Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8858; Zhou WH, 2005, LAB INVEST, V85, P780, DOI 10.1038/labinvest.3700275	69	52	52	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	2019	381	17					1653	1662		10.1056/NEJMra1813013	http://dx.doi.org/10.1056/NEJMra1813013			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK2QT	31644845				2023-01-03	WOS:000494692200009
J	Ookawara, S; Kaku, Y; Ito, K; Kizukuri, K; Namikawa, A; Nakahara, S; Horiuchi, Y; Inose, N; Miyahara, M; Shiina, M; Minato, S; Shindo, M; Miyazawa, H; Hirai, K; Hoshino, T; Murakoshi, M; Tabei, K; Morishita, Y				Ookawara, Susumu; Kaku, Yoshio; Ito, Kiyonori; Kizukuri, Kanako; Namikawa, Aiko; Nakahara, Shinobu; Horiuchi, Yuko; Inose, Nagisa; Miyahara, Mayako; Shiina, Michiko; Minato, Saori; Shindo, Mitsutoshi; Miyazawa, Haruhisa; Hirai, Keiji; Hoshino, Taro; Murakoshi, Miho; Tabei, Kaoru; Morishita, Yoshiyuki			Effects of dietary intake and nutritional status on cerebral oxygenation in patients with chronic kidney disease not undergoing dialysis: A cross-sectional study	PLOS ONE			English	Article							ENDOTHELIAL-CELLS; RENAL-FUNCTION; GHRELIN; SATURATION; HEMODIALYSIS; TRANSFUSION; METABOLISM; PRESSURE; HORMONE; INFANTS	Background Dietary management is highly important for the maintenance of renal function in patients with chronic kidney disease (CKD). Cerebral oxygen saturation (rSO(2)) was reportedly associated with the estimated glomerular filtration rate (eGFR) and cognitive function. However, data concerning the association between cerebral rSO(2) and dietary intake of CKD patients is limited. Methods This was a single-center observational study. We recruited 67 CKD patients not undergoing dialysis. Cerebral rSO(2) was monitored using the INVOS 5100c oxygen saturation monitor. Energy intake was evaluated by dietitians based on 3-day meal records. Daily protein and salt intakes were calculated from 24-h urine collection. Results Multivariable regression analysis showed that cerebral rSO(2) was independently associated with energy intake (standardized coefficient: 0.370) and serum albumin concentration (standardized coefficient: 0.236) in Model 1 using parameters with p < 0.10 in simple linear regression analysis (body mass index, Hb level, serum albumin concentration, salt and energy intake) and confounding factors (eGFR, serum sodium concentration, protein intake), and the energy/salt index (standardized coefficient: 0.343) and Hb level (standardized coefficient: 0.284) in Model 2 using energy/protein index as indicated by energy intake/protein intake and energy/salt index by energy intake/salt intake in place of salt, protein and energy intake. Conclusions Cerebral rSO(2) is affected by energy intake, energy/salt index, serum albumin concentration and Hb level. Sufficient energy intake and adequate salt restriction is important to prevent deterioration of cerebral oxygenation, which might contribute to the maintenance of cognitive function in addition to the prevention of renal dysfunction in CKD patients.	[Ookawara, Susumu; Kaku, Yoshio; Ito, Kiyonori; Minato, Saori; Shindo, Mitsutoshi; Miyazawa, Haruhisa; Hirai, Keiji; Hoshino, Taro; Morishita, Yoshiyuki] Jichi Med Univ, Saitama Med Ctr, Dept Integrated Med 1, Div Nephrol, Saitama, Japan; [Ookawara, Susumu; Kizukuri, Kanako; Namikawa, Aiko; Nakahara, Shinobu; Horiuchi, Yuko; Inose, Nagisa; Miyahara, Mayako; Shiina, Michiko; Murakoshi, Miho] Jichi Med Univ, Saitama Med Ctr, Dept Nutr, Saitama, Japan; [Tabei, Kaoru] Minami Uonuma City Hosp, Dept Internal Med, Niigata, Japan	Jichi Medical University; Jichi Medical University	Ookawara, S (corresponding author), Jichi Med Univ, Saitama Med Ctr, Dept Integrated Med 1, Div Nephrol, Saitama, Japan.; Ookawara, S (corresponding author), Jichi Med Univ, Saitama Med Ctr, Dept Nutr, Saitama, Japan.	su-ooka@hb.tp1.jp			Japanese Association of Dialysis Physicians [20179]; Kidney Foundation, Japan [JKFB 17-4]	Japanese Association of Dialysis Physicians; Kidney Foundation, Japan(Kidney Foundation, Japan)	This work was supported by a grant from the Japanese Association of Dialysis Physicians (http://www.touseki-ikai.or.jp/) (JADP Grant 20179) and a grant from The Kidney Foundation, Japan (JKFB 17-4) (http://www.jinzouzaidan.or.jp/) to SO. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2010, EV BAS NUTR PRACT GU; Ashby DR, 2009, KIDNEY INT, V76, P199, DOI 10.1038/ki.2009.114; Cheung WW, 2010, INT J PEPT, DOI [10.1038/ki.2009.114, DOI 10.1038/KI.2009.114]; Dhabangi A, 2016, JAMA PEDIATR, V170, P995, DOI 10.1001/jamapediatrics.2016.1254; Duenhas MR, 2003, EUR J CLIN NUTR, V57, P1473, DOI 10.1038/sj.ejcn.1601713; Faraco G, 2018, NAT NEUROSCI, V21, P240, DOI 10.1038/s41593-017-0059-z; Ferrari M, 2004, CAN J APPL PHYSIOL, V29, P463, DOI 10.1139/h04-031; Fouque D, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001892.pub3; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; Gualillo O, 2003, FEBS LETT, V552, P105, DOI 10.1016/S0014-5793(03)00965-7; Gupta RK, 2013, CLIN J AM SOC NEPHRO, V8, P1098, DOI 10.2215/CJN.09170912; Heye AK, 2016, J CEREBR BLOOD F MET, V36, P264, DOI 10.1038/jcbfm.2015.64; HONGO K, 1995, NEUROL RES, V17, P89, DOI 10.1080/01616412.1995.11740293; Hoshino T, 2014, NEPHRON CLIN PRACT, V126, P57, DOI 10.1159/000358432; Huang MC, 2008, J RENAL NUTR, V18, P187, DOI 10.1053/j.jrn.2007.08.003; Hyttel-Sorensen S, 2011, BIOMED OPT EXPRESS, V2, P3047, DOI 10.1364/BOE.2.003047; Ito K, 2017, NEPHRON EXTRA, V7, P42, DOI 10.1159/000471812; Ito K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117474; Japanese Society of Nephrology, 2012, CLIN PRACT GUID DIAG; Konturek SJ, 2004, J PHYSIOL PHARMACOL, V55, P137; Kopple JD, 2001, AM J KIDNEY DIS, V37, pS66, DOI 10.1053/ajkd.2001.20748; Kovarova L, 2018, NEPHRON, V139, P113, DOI 10.1159/000487092; Lemmers PMA, 2008, PEDIATRICS, V121, P142, DOI 10.1542/peds.2007-0925; Levin A, 2013, KIDNEY INT SUPPL, V3, P5, DOI 10.1038/kisup.2012.77; Lin JL, 2010, CLIN J AM SOC NEPHRO, V5, P836, DOI 10.2215/CJN.08001109; MARONI BJ, 1985, KIDNEY INT, V27, P58, DOI 10.1038/ki.1985.10; Maslehaty Homajoun, 2012, ISRN Neurol, V2012, P907187, DOI 10.5402/2012/907187; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Meier U, 2004, CLIN CHEM, V50, P1511, DOI 10.1373/clinchem.2004.032482; Miyazawa H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199366; Neunhoeffer F, 2018, PEDIATR CRIT CARE ME, V19, P318, DOI 10.1097/PCC.0000000000001483; Ookawara S, 2014, THER APHER DIAL, V18, P202, DOI 10.1111/1744-9987.12070; Prohovnik I, 2007, J CEREBR BLOOD F MET, V27, P1861, DOI 10.1038/sj.jcbfm.9600478; Resource council, 2012, STAND TABL FOOD COMP, V5th; Robertson L, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002181.pub2; Schmitz J, 2014, PHYSIOL MEAS, V35, P1349, DOI 10.1088/0967-3334/35/7/1349; Slagman MCJ, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4366; Strazzullo P, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4567; Swift PA, 2005, HYPERTENSION, V46, P308, DOI 10.1161/01.HYP.0000172662.12480.7f; Tesauro M, 2010, CURR DIABETES REV, V6, P228, DOI 10.2174/157339910791658871; Tobias JD, 2006, EXPERT REV MED DEVIC, V3, P235, DOI 10.1586/17434440.3.2.235; Torella F, 2003, J SURG RES, V110, P217, DOI 10.1016/S0022-4804(03)00037-4; van Hoften JCR, 2010, ARCH DIS CHILD-FETAL, V95, pF352, DOI 10.1136/adc.2009.163592; Vegter S, 2012, J AM SOC NEPHROL, V23, P165, DOI 10.1681/ASN.2011040430; Virdis A, 2016, CURR PHARM DESIGN, V22, P52, DOI 10.2174/1381612822666151119144458; Wang YB, 2011, CELL BIOL INT, V35, P135, DOI 10.1042/CBI20100139; Wynne K, 2005, J AM SOC NEPHROL, V16, P2111, DOI 10.1681/ASN.2005010039; Yuruk K, 2012, TRANSFUSION, V52, P641, DOI 10.1111/j.1537-2995.2011.03312.x; Zhao H, 2007, BIOCHEM BIOPH RES CO, V362, P677, DOI 10.1016/j.bbrc.2007.08.021	49	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2019	14	10							e0223605	10.1371/journal.pone.0223605	http://dx.doi.org/10.1371/journal.pone.0223605			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM7ZE	31600287	Green Published, gold			2023-01-03	WOS:000532467000092
J	Christenson, A; Johansson, E; Reynisdottir, S; Torgerson, J; Hemmingsson, E				Christenson, Anne; Johansson, Eva; Reynisdottir, Signy; Torgerson, Jarl; Hemmingsson, Erik			"...or else I close my ears" How women with obesity want to be approached and treated regarding gestational weight management: A qualitative interview study	PLOS ONE			English	Article							MATERNAL OBESITY; FOCUS GROUPS; INDIVIDUAL INTERVIEWS; GAIN; CARE; PREGNANCY; OUTCOMES; INTERVENTIONS; PERSPECTIVES; METAANALYSIS	Introduction The importance of helping pregnant women maintain a healthy lifestyle and prevent excessive gestational weight gain is well recognized, but pregnant women do not always perceive communication about body weight as respectful or helpful. Furthermore, fear of inducing shame or guilt can prohibit some midwives from talking about body weight, especially if the woman has obesity. We aimed to explore what women of reproductive age with obesity regard to be the most important and relevant aspects when discussing gestational weight management. Methods Qualitative interview study using focus groups and individual semi-structured interviews with 17 women of reproductive age (19-39 y) with obesity. Thematic analysis was used to analyze the data. Results We identified three themes: 1) Importance of obtaining vital medical information; 2) A wish to feel understood and treated with respect; 3) Midwives' approach is crucial in sensitive key situations, which include bringing up the subject of body weight, weighing, providing weightrelated information, coaching lifestyle modification, dealing with emotional reactions and ending a conversation. Conclusions A majority of the interviewed women wished to receive information about risks about obesity and gestational weight gain, and recommendations on weight management. However, the risk of midwives offending someone by raising the topic may be increased if the pregnant woman believe that gestational weight gain is uncontrollable by the individual. Also, several situations during maternity care meetings can be stigmatizing and make women less receptive to advice or support. Women suggest that a good working alliance is likely to be achieved if midwives have knowledge about the causes of obesity, take interest in the patients' background, have a non-judgmental approach and refrain from giving unsolicited advice.	[Christenson, Anne; Reynisdottir, Signy] Acad Specialist Ctr, Stockholm Hlth Serv, Obes Ctr, Stockholm, Sweden; [Christenson, Anne] Karolinska Inst, Dept Med, Stockholm, Sweden; [Johansson, Eva] Karolinska Inst, Dept Publ Hlth Sci IHCAR, Stockholm, Sweden; [Torgerson, Jarl] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Mol & Clin Med, Gothenburg, Sweden; [Hemmingsson, Erik] Swedish Sch Sports & Hlth Sci, Astrand Lab Work Physiol, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; University of Gothenburg; Swedish School of Sport & Health Sciences	Christenson, A (corresponding author), Acad Specialist Ctr, Stockholm Hlth Serv, Obes Ctr, Stockholm, Sweden.; Christenson, A (corresponding author), Karolinska Inst, Dept Med, Stockholm, Sweden.	anne.christenson@ki.es						Allen-Walker V, 2017, MIDWIFERY, V49, P95, DOI 10.1016/j.midw.2016.12.006; Barter C., 2000, INT J SOC RES METHOD, V3, P307, DOI [DOI 10.1080/13645570050178594, 10.1080/13645570050178594]; Beckman M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181715; Bjermo H, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1624-6; Blomberg M, 2011, OBSTET GYNECOL, V117, P1065, DOI 10.1097/AOG.0b013e318214f1d1; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Brownfoot FC, 2016, BJOG-INT J OBSTET GY, V123, P254, DOI 10.1111/1471-0528.13735; Bye A, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1745-x; CATALANO PM, 2017, BMJ-BRIT MED J, V356, DOI DOI 10.1136/BMJ.J1; Christensen AP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166167; Christenson A, 2018, MIDWIFERY, V63, P1, DOI 10.1016/j.midw.2018.04.020; Das UN, 2010, NUTRITION, V26, P459, DOI 10.1016/j.nut.2009.09.020; DEJONG W, 1980, J HEALTH SOC BEHAV, V21, P75, DOI 10.2307/2136696; Dencker A, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0969-x; Denison FC, 2019, BJOG-INT J OBSTET GY, V126, pE62, DOI 10.1111/1471-0528.15386; Deputy NP, 2018, MMWR-MORBID MORTAL W, V66, P1402, DOI 10.15585/mmwr.mm665152a3; Devlieger R, 2016, EUR J OBSTET GYN R B, V201, P203, DOI 10.1016/j.ejogrb.2016.04.005; DiCicco-Bloom B, 2006, MED EDUC, V40, P314, DOI 10.1111/j.1365-2929.2006.02418.x; Farpour-Lambert NJ, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00546; Fieril KP, 2017, MIDWIFERY, V44, P1, DOI 10.1016/j.midw.2016.10.011; Forsberg L, 2012, CLIN ACQUISITION RET; Foster H.J., 2014, BR J MIDWIFERY, V22, P254, DOI [DOI 10.12968/BJOM.2014.22.4.254, DOI 10.12968/BJ0M.2014.22.4.254]; Gresham E, 2016, PUBLIC HEALTH NUTR, V19, P2975, DOI 10.1017/S1368980016001245; Guest G, 2017, INT J SOC RES METHOD, V20, P693, DOI 10.1080/13645579.2017.1281601; Haby K, 2015, MIDWIFERY, V31, P685, DOI 10.1016/j.midw.2015.03.014; Hansson LM, 2014, BODY IMAGE, V11, P43, DOI 10.1016/j.bodyim.2013.10.004; Heslehurst N, 2013, MIDWIFERY, V29, P736, DOI 10.1016/j.midw.2012.07.007; Hill B, 2013, OBES REV, V14, P435, DOI 10.1111/obr.12022; Holton S, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1538-7; Jelsma JGM, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1471-9; Jones C, 2017, MIDWIFERY, V53, P87, DOI 10.1016/j.midw.2017.07.011; Kapadia MZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132650; Kaplowitz MD, 2000, QUAL QUANT, V34, P419, DOI 10.1023/A:1004844425448; Knight-Agarwal CR, 2016, WOMEN BIRTH, V29, P189, DOI 10.1016/j.wombi.2015.10.008; Lambert SD, 2008, J ADV NURS, V62, P228, DOI 10.1111/j.1365-2648.2007.04559.x; Lavender T, 2016, HEALTH EXPECT, V19, P222, DOI 10.1111/hex.12339; Lindhardt CL, 2014, ACTA OBSTET GYN SCAN, V93, P698, DOI 10.1111/aogs.12401; Lindhardt CL, 2015, MIDWIFERY, V31, P678, DOI 10.1016/j.midw.2015.03.010; Lindholm ES, 2010, ACTA OBSTET GYN SCAN, V89, P840, DOI 10.3109/00016340903428370; Lindsay AC, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14111412; Linne Y, 2004, OBES RES, V12, P1166, DOI 10.1038/oby.2004.146; Lundahl B, 2013, PATIENT EDUC COUNS, V93, P157, DOI 10.1016/j.pec.2013.07.012; Malta MB, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0957-1; Malterud K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; Malterud K, 2016, QUAL HEALTH RES, V26, P1753, DOI 10.1177/1049732315617444; McDonald SD, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.05.039; McDowell M, 2019, J MIDWIFERY WOM HEAL, V64, P46, DOI 10.1111/jmwh.12927; Mirijello A, 2015, J AFFECT DISORDERS, V179, P95, DOI 10.1016/j.jad.2015.03.030; Nilses C, 2017, SEX REPROD HEALTHC, V11, P47, DOI 10.1016/j.srhc.2016.08.004; Nyman VMK, 2010, MIDWIFERY, V26, P424, DOI 10.1016/j.midw.2008.10.008; Olander EK, 2016, NURS EDUC TODAY, V42, P59, DOI 10.1016/j.nedt.2016.04.009; Oliver I, 2012, IEEE IC COMP COM NET; Organization WH, 2018, OBESITY OVERWEIGHT D; Patton MQ., 2015, QUALITATIVE RES EVAL, V4th, DOI [10.1016/j.ymeth.2015.04.005, DOI 10.1016/J.YMETH.2015.04.005]; Puhl RM, 2018, PEDIATR OBES, V13, P533, DOI 10.1111/ijpo.12275; Robillard PY, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e00615; Rohatgi KW, 2017, PEERJ, V5, DOI 10.7717/peerj.4091; Rosenthal M, 2016, CURR PHARM TEACH LEA, V8, P509, DOI 10.1016/j.cptl.2016.03.021; Ruifrok AE, 2014, AM J PERINAT, V31, P353, DOI 10.1055/s-0033-1352484; Santos S, 2019, BJOG-INT J OBSTET GY, V126, P984, DOI 10.1111/1471-0528.15661; Schoenberg N.E., 2000, INT J SOC RES METHOD, V3, P63, DOI [DOI 10.1080/136455700294932, 10.1080/136455700294932]; Shub Alexis, 2013, BMC Res Notes, V6, P278, DOI 10.1186/1756-0500-6-278; Sogg S, 2018, SURG OBES RELAT DIS, V14, P682, DOI 10.1016/j.soard.2018.01.013; The national board of health and welfare, 2016, SWED PREGN DAT BAS; Universal health coverage and universal access, 2013, B WHO; Vieten C, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1757-6; Wahedi M, 2016, BR J MIDWIFERY, V24, P724, DOI DOI 10.12968/BJ0M.2016.24.10.724; Yang ZJ, 2019, AUST NZ J OBSTET GYN, V59, P367, DOI 10.1111/ajo.12866	68	8	8	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2019	14	9							e0222543	10.1371/journal.pone.0222543	http://dx.doi.org/10.1371/journal.pone.0222543			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM5BF	31536545	Green Published, gold, Green Submitted			2023-01-03	WOS:000532262800053
J	Ganho-Avila, A; Goncalves, OF; Guiomar, R; Boggio, PS; Asthana, MK; Krypotos, AM; Almeida, J				Ganho-Avila, Ana; Goncalves, Oscar F.; Guiomar, Raquel; Boggio, Paulo Sergio; Asthana, Manish Kumar; Krypotos, Angelos-Miltiadis; Almeida, Jorge			The effect of cathodal tDCS on fear extinction: A cross-measures study	PLOS ONE			English	Article							DIRECT-CURRENT STIMULATION; PREFRONTAL CORTEX; ANXIETY DISORDER; PANIC DISORDER; RECONSOLIDATION; MECHANISMS; AVOIDANCE; HUMANS; ACQUISITION; RESPONSES	Background Extinction-based procedures are often used to inhibit maladaptive fear responses. However, because extinction procedures show efficacy limitations, transcranial direct current stimulation (tDCS) has been suggested as a promising add-on enhancer. Objective In this study, we tested how cathodal tDCS over the right dorsolateral prefrontal cortex affects extinction and tried to unveil the processes at play that boost the effectiveness of extinction procedures and its translational potential to the treatment of anxiety disorders. Methods We implemented a fear conditioning paradigm whereby 41 healthy women (mean age = 20.51 +/- 5.0) were assigned to either cathodal tDCS (n = 27) or sham tDCS (n = 16). Fear responses were measured with self-reports, autonomic responses, and implicit avoidance tendencies. Results Cathodal tDCS shows no statistically significant effect in extinction, according to selfreports, and seems to even negatively affect fear conditioned skin conductance responses. However, one to three months after the tDCS session and extinction, we found a group difference in the action tendencies towards the neutral stimuli (F (1, 41) = 12.04, p =.001,.p2 =.227), with the cathodal tDCS group (as opposed to the sham group) showing a safety learning (a positive bias towards the CS-), with a moderate effect size. This suggests that cathodal tDCS may foster stimuli discrimination, leading to a decreased generalization effect. Discussion Cathodal tDCS may have enhanced long-term distinctiveness between threatening cues and perceptively similar neutral cues through a disambiguation process of the value of the neutral stimuli-a therapeutic target in anxiety disorders. Future studies should confirm these results and extend the study of cathodal tDCS effect on short term avoidance tendencies.	[Ganho-Avila, Ana; Guiomar, Raquel; Almeida, Jorge] Univ Coimbra, Cognit & Behav Ctr Res & Intervent, Fac Psychol & Educ Sci, Proact Lab, Coimbra, Portugal; [Ganho-Avila, Ana; Goncalves, Oscar F.] Univ Minho, Sch Psychol, Neuropsychophysiol Lab, CiPsi, Braga, Portugal; [Goncalves, Oscar F.] Harvard Med Sch, Spaulding Rehabil Hosp, Spaulding Neuromodulat Ctr, Boston, MA 02115 USA; [Boggio, Paulo Sergio; Asthana, Manish Kumar] Univ Prebiteriana Mackenzie, Ctr Hlth & Biol Sci, Social & Cognit Neurosci Lab, Sao Paulo, Brazil; [Boggio, Paulo Sergio; Asthana, Manish Kumar] Univ Prebiteriana Mackenzie, Ctr Hlth & Biol Sci, Dev Disorders Program, Sao Paulo, Brazil; [Asthana, Manish Kumar] Indian Inst Technol, Dept Humanities & Social Sci, Roorkee, Uttar Pradesh, India; [Krypotos, Angelos-Miltiadis] Univ Utrecht, Dept Clin Psychol, Utrecht, Netherlands	Universidade de Coimbra; Universidade do Minho; Harvard University; Harvard Medical School; Spaulding Rehabilitation Hospital; Universidade Presbiteriana Mackenzie; Universidade Presbiteriana Mackenzie; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Roorkee; Utrecht University	Ganho-Avila, A (corresponding author), Univ Coimbra, Cognit & Behav Ctr Res & Intervent, Fac Psychol & Educ Sci, Proact Lab, Coimbra, Portugal.; Ganho-Avila, A (corresponding author), Univ Minho, Sch Psychol, Neuropsychophysiol Lab, CiPsi, Braga, Portugal.	ganhoavila@fpce.uc.pt	Guiomar, Raquel/ABH-9355-2022; Asthana, Manish/AAE-8450-2019; Boggio, Paulo S/K-6272-2012; Ganho-Ávila, Ana/AGU-8094-2022; Krypotos, Angelos-Miltiadis/ABD-1739-2020; Gonçalves, Óscar F./G-5278-2010	Guiomar, Raquel/0000-0001-9611-1167; Asthana, Manish/0000-0002-0270-8913; Boggio, Paulo S/0000-0002-6109-0447; Ganho-Ávila, Ana/0000-0001-5355-6166; Krypotos, Angelos-Miltiadis/0000-0001-9704-6520; Gonçalves, Óscar F./0000-0003-2735-9155; Almeida, Jorge/0000-0002-6302-7564	Foundation for Science and Technology, Portugal [SFRH/BD/80945/2011, PTDC/MHC-PAP/5618/2014, POCI-01-0145FEDER-016836, POCI-01-0145-FEDER-016836, PTDC/MHC-PCN/3575/2012, PTDC/MHC-PCN/0522/2014, PTDC/MHC-PCN/6805/2014]; Programa COMPETE [SFRH/BD/80945/2011, PTDC/MHC-PAP/5618/2014, POCI-01-0145FEDER-016836, POCI-01-0145-FEDER-016836, PTDC/MHC-PCN/3575/2012, PTDC/MHC-PCN/0522/2014, PTDC/MHC-PCN/6805/2014]; Portuguese Foundation for Science and Technology; Portuguese Ministry of Education and Science; FEDER through COMPETE2020 under the PT2020 Partnership Agreement [UID/PSI/01662/2013, POCI-01-0145-FEDER007653]; Proaction Laboratory;  [POCI-01-0145-FEDER016836]	Foundation for Science and Technology, Portugal(Portuguese Foundation for Science and Technology); Programa COMPETE; Portuguese Foundation for Science and Technology(Portuguese Foundation for Science and Technology); Portuguese Ministry of Education and Science(Portuguese Foundation for Science and Technology); FEDER through COMPETE2020 under the PT2020 Partnership Agreement; Proaction Laboratory; 	AGA is supported by the Foundation for Science and Technology, Portugal and Programa COMPETE [grants numbers SFRH/BD/80945/2011, PTDC/MHC-PAP/5618/2014 (POCI-01-0145FEDER-016836); http://www.poci-compete2020.pt/].JA is supported by the Foundation for Science and Technology, Portugal and Programa COMPETE [grants numbers PTDC/MHC-PAP/5618/2014 (POCI-01-0145-FEDER-016836), PTDC/MHC-PCN/3575/2012, PTDC/MHC-PCN/0522/2014, PTDC/MHC-PCN/6805/2014; https://www.fct.pt/index.phtml.en].The Cognitive and Behavioral Center for Research and Intervention of the Faculty of Psychology and Educational Sciences of the University of Coimbra is supported by the Portuguese Foundation for Science and Technology and the Portuguese Ministry of Education and Science through national funds and co-financed by FEDER through COMPETE2020 under the PT2020 Partnership Agreement [UID/PSI/01662/2013; https://www.portugal2020.pt].The Psychology Research Centre of the University of Minho is supported by the Portuguese Foundation for Science and Technology and the Portuguese Ministry of Education and Science through national funds and co-financed by FEDER through COMPETE2020 under the PT2020 Partnership Agreement (POCI-01-0145-FEDER007653). The Proaction Laboratory and the PTDC/MHC-PAP/5618/2014 (POCI-01-0145-FEDER016836) directly supported this research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abend R, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.197; Adhikari A, 2015, NATURE, V527, P179, DOI 10.1038/nature15698; Ahs F, 2015, NEUROIMAGE, V122, P262, DOI 10.1016/j.neuroimage.2015.07.051; Alberini CM, 2013, CURR BIOL, V23, pR746, DOI 10.1016/j.cub.2013.06.046; Almeida J, 2017, CORTEX, V94, P176, DOI 10.1016/j.cortex.2017.07.001; Ardolino G, 2005, J PHYSIOL-LONDON, V568, P653, DOI 10.1113/jphysiol.2005.088310; Asthana Manish, 2013, Front Psychiatry, V4, P107, DOI 10.3389/fpsyt.2013.00107; Bell CC., 1994, JAMA-J AM MED ASSOC, V272, P828, DOI DOI 10.1001/JAMA.1994.03520100096046; BINDMAN LJ, 1962, NATURE, V196, P584, DOI 10.1038/196584a0; Boddez Y, 2013, J BEHAV THER EXP PSY, V44, P201, DOI 10.1016/j.jbtep.2012.08.003; Boucsein W, 2012, PSYCHOPHYSIOLOGY, V49, P1017, DOI 10.1111/j.1469-8986.2012.01384.x; Boucsein W, 2012, ELECTRODERMAL ACTIVITY, SECOND EDITION, P1, DOI 10.1007/978-1-4614-1126-0; BROWN TA, 1995, J CONSULT CLIN PSYCH, V63, P408, DOI 10.1037/0022-006X.63.3.408; Brunoni AR, 2012, BRAIN STIMUL, V5, P175, DOI 10.1016/j.brs.2011.03.002; Canavarro C, 2007, AVALIACAO PSICOLOGIC, P305; Dittert N, 2018, FRONT BEHAV NEUROSCI, V12, DOI 10.3389/fnbeh.2018.00076; Dunsmoor JE, 2015, BIOL PSYCHIAT, V78, P203, DOI 10.1016/j.biopsych.2014.12.008; Dymond S, 2015, BEHAV THER, V46, P561, DOI 10.1016/j.beth.2014.10.001; Feeser M, 2014, BRAIN STIMUL, V7, P105, DOI 10.1016/j.brs.2013.08.006; Frijda NH, 2010, BIOL PSYCHOL, V84, P570, DOI 10.1016/j.biopsycho.2010.01.005; Ganho-Avila A, 2019, MEAS EVAL COUNS DEV, V52, P223, DOI 10.1080/07481756.2019.1594916; Golkar A, 2017, BEHAV RES THER, V92, P87, DOI 10.1016/j.brat.2017.02.004; Heeren A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124182; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; Ironside M, 2016, BIOL PSYCHIAT, V79, P823, DOI 10.1016/j.biopsych.2015.06.012; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; KELLER MB, 1994, J NERV MENT DIS, V182, P290, DOI 10.1097/00005053-199405000-00007; Kindt M, 2009, NAT NEUROSCI, V12, P256, DOI 10.1038/nn.2271; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Krause MR, 2017, CURR BIOL, V27, P3086, DOI 10.1016/j.cub.2017.09.020; Kronberg G, 2017, BRAIN STIMUL, V10, P51, DOI 10.1016/j.brs.2016.10.001; Krypotos AM, 2014, CLIN PSYCHOL SCI, V2, P336, DOI 10.1177/2167702613503139; Krypotos AM, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00189; Lang P. J., INT AFFECTIVE DIGITI; Lang P. J., 1980, TECHNOLOGY MENTAL HL, P119; Lang PJ, 2010, BIOL PSYCHOL, V84, P437, DOI 10.1016/j.biopsycho.2009.10.007; Lebron-Milad K, 2012, BIOL MOOD ANXIETY DI, V2, DOI [10.1186/2045-5380-2-7, 10.1186/2045-5380-2-3]; Lefaucheur JP, 2017, CLIN NEUROPHYSIOL, V128, P56, DOI 10.1016/j.clinph.2016.10.087; Lonsdorf TB, 2019, BIOL PSYCHIAT, V85, P1074, DOI 10.1016/j.biopsych.2019.02.011; Lonsdorf TB, 2017, NEUROSCI BIOBEHAV R, V77, P247, DOI 10.1016/j.neubiorev.2017.02.026; Luyten L, 2017, NEUROBIOL LEARN MEM, V144, P208, DOI 10.1016/j.nlm.2017.07.014; Marquez-Ruiz J, 2012, P NATL ACAD SCI USA, V109, P6710, DOI 10.1073/pnas.1121147109; Mauss I, 2009, COGNITION EMOTION, V23, P209, DOI 10.1080/02699930802204677; Milad MR, 2007, BIOL PSYCHIAT, V62, P446, DOI 10.1016/j.biopsych.2006.10.011; Monfils MH, 2009, SCIENCE, V324, P951, DOI 10.1126/science.1167975; Moors A, 2006, PSYCHOL BULL, V132, P297, DOI 10.1037/0033-2909.132.2.297; Morriss J, 2015, BIOL MOOD ANXIETY DI, V5, DOI 10.1186/s13587-015-0019-8; Mungee A, 2016, BRAIN SCI, V6, DOI 10.3390/brainsci6040055; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Ochsner KN, 2002, J COGNITIVE NEUROSCI, V14, P1215, DOI 10.1162/089892902760807212; Phelps EA, 2004, NEURON, V43, P897, DOI 10.1016/j.neuron.2004.08.042; Rinck M, 2007, J BEHAV THER EXP PSY, V38, P105, DOI 10.1016/j.jbtep.2006.10.001; Rusticus SA, 2015, PRACTICAL ASSESSMENT, V19; Schiller D, 2013, P NATL ACAD SCI USA, V110, P20040, DOI 10.1073/pnas.1320322110; Schroyens N, 2017, FRONT BEHAV NEUROSCI, V11, DOI [10.3309/fnbeh.2017.00065, 10.3389/fnbeh.2017.00065]; Shiozawa P, 2014, J DEPRESSION ANXIETY, P1; Shiozawa P, 2014, BIOL PSYCHIAT, V75, pE17, DOI 10.1016/j.biopsych.2013.07.014; SOLOMON RL, 1953, J ABNORM SOC PSYCH, V48, P291, DOI 10.1037/h0058943; Spielberger C. D., 1989, STATE TRAIT ANXIETY; Thair H, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00641; van 't Wout M, 2016, BRAIN STIMUL, V9, P531, DOI 10.1016/j.brs.2016.03.004; Vervliet B, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00351; Vidal-Gonzalez I, 2006, LEARN MEMORY, V13, P728, DOI 10.1101/lm.306106; Voroslakos M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02928-3; Zaghi S, 2010, NEUROSCIENTIST, V16, P285, DOI 10.1177/1073858409336227; Zheng X, 2011, NEUROIMAGE, V58, P26, DOI 10.1016/j.neuroimage.2011.06.018	66	12	12	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2019	14	9							e0221282	10.1371/journal.pone.0221282	http://dx.doi.org/10.1371/journal.pone.0221282			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM4SI	31532768	Green Published, gold, Green Submitted			2023-01-03	WOS:000532239600006
J	Izquierdo, AG; Carreira, MC; Amil, M; Mosteiro, CS; Garcia-Caballero, T; Fernandez-Quintela, A; Portillo, MP; Casanueva, FF; Crujeiras, AB				Izquierdo, Andrea G.; Carreira, Marcos C.; Amil, Maria; Mosteiro, Carlos S.; Garcia-Caballero, Tomas; Fernandez-Quintela, Alfredo; Portillo, Maria P.; Casanueva, Felipe F.; Crujeiras, Ana B.			An energy restriction-based weight loss intervention is able to reverse the effects of obesity on the expression of liver tumor-promoting genes	FASEB JOURNAL			English	Article						adipose tissue dysfunction; carcinogenesis; inflammation; NAFLD; NASH; oxidative stress	INFLAMMATION-RELATED GENES; OXIDATIVE STRESS; ADIPOSE-TISSUE; MONONUCLEAR-CELLS; SECRETED FACTORS; FATTY LIVER; CANCER; OVERWEIGHT; SURVIVIN; DISEASE	The epidemiological evidence regarding the association of obesity with liver disease and possibly hepatocellular carcinoma highlights the need for investigations of whether obesity itself could induce the differential expression of genes commonly associated with the initial phase of liver tumorigenesis, and whether such phenomenon could be reversed after a weight loss intervention. In this study, obese Zucker rats were found to have dysregulated cell proliferation, antioxidative defenses, and tumor suppressor gene expression in association with liver dysfunction parameters, as well as oxidative stress and inflammation. Importantly, after a 4-week weight loss protocol of energy restriction and/or exercise, this effect on the liver carcinogenesis-related genes was reversed concomitantly with reductions in the fat mass, hepatic lipid content, oxidative stress, and inflammation. The findings indicate that the oxidative stress and inflammation associated with excess adiposity promote dysregulation of the genes involved in liver tumorigenesis. This is clinically relevant because these effects were detectable in the liver without evidence of a tumoral mass and were reversed after weight loss. Consequently, this study reveals the susceptibility of obese individuals to the initiation of a hepatocarcinogenic process, and how this can be prevented by achieving a healthy body weight.	[Izquierdo, Andrea G.; Crujeiras, Ana B.] Complejo Hospitalario Universitario Santiago Comp, Lab Epign Endocrinol, Instituto Investigac Sanitaria Santiago Compostel, IDIS,CHUS,SERGAS,Nutr, Santiago De Compostela, Spain; [Izquierdo, Andrea G.; Carreira, Marcos C.; Amil, Maria; Fernandez-Quintela, Alfredo; Portillo, Maria P.; Casanueva, Felipe F.; Crujeiras, Ana B.] CIBER Fisiopatol Obes Nutr, CIBERobn, Madrid, Spain; [Carreira, Marcos C.; Amil, Maria; Mosteiro, Carlos S.; Casanueva, Felipe F.] Santiago Compostela Univ, Complejo Hospitalario Universitario Santiago Comp, Lab Mol, Instituto Investigac Sanitaria Santiago Compostel, Santiago De Compostela, Spain; [Garcia-Caballero, Tomas] Univ Santiago Compostela, Sch Med, Dept Morphol Sciences, Santiago De Compostela, Spain; [Fernandez-Quintela, Alfredo; Portillo, Maria P.] Univ Basque Country, Lucio Lascaray Res Inst,Hlth Res Inst BIOARABA, Dept Nutr,UPV,EHU,Nutr,Obes Grp,Food Sci, Vitoria, Spain; Epign Unit, E-15706 Santiago De Compostela, Spain	Complexo Hospitalario Universitario de Santiago de Compostela; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Universidade de Santiago de Compostela; Bioaraba Health Research Institute; University of Basque Country	Crujeiras, AB (corresponding author), Complejo Hospitalario Universitario Santiago Comp, Lab Epign Endocrinol, Instituto Investigac Sanitaria Santiago Compostel, IDIS,CHUS,SERGAS,Nutr, Santiago De Compostela, Spain.	anabelencrujeiras@hotmail.com	Portillo, Maria Puy/ABH-2374-2020; Crujeiras, Ana/ABA-8866-2021; Izquierdo, Andrea G/ABB-9559-2020	Portillo, Maria Puy/0000-0003-0210-6549; Crujeiras, Ana/0000-0003-4392-0301; Izquierdo, Andrea G/0000-0002-0846-8834; Garcia-Caballero, Tomas/0000-0002-7938-1437; PORTILLO BAQUEDANO, MARIA PUY/0000-0003-2290-592X; Fernandez-Quintela, Alfredo/0000-0003-2709-4118				Abraham PE, 2016, NAT PLANTS, V2, DOI [10.1038/nplants.2016.178, 10.1038/NPLANTS.2016.178]; Altieri DC, 2008, ONCOGENE, V27, P6276, DOI 10.1038/onc.2008.303; Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Beltran-Ramirez O, 2010, TRANSL ONCOL, V3, P142, DOI 10.1593/tlo.09298; Bergstrom A, 2001, INT J CANCER, V91, P421, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1053&gt;3.0.CO;2-T; Boutari C, 2018, METABOLISM, V81, pA3, DOI 10.1016/j.metabol.2017.12.015; Bultman SJ, 2018, TRENDS ENDOCRIN MET, V29, P529, DOI 10.1016/j.tem.2018.05.004; Cabia B, 2016, OBES REV, V17, P361, DOI 10.1111/obr.12377; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408; Carmiel-Haggai M, 2004, FASEB J, V18, P136, DOI 10.1096/fj.04-2291fje; Casanueva FF, 2010, CLIN ENDOCRINOL, V73, P35, DOI 10.1111/j.1365-2265.2009.03727.x; Clement K, 2004, FASEB J, V18, P1657, DOI 10.1096/fj.04-2204com; Crujeiras AB, 2008, EUR J CLIN INVEST, V38, P672, DOI 10.1111/j.1365-2362.2008.01998.x; Crujeiras AB, 2017, INT J OBESITY, V41, P1570, DOI 10.1038/ijo.2017.138; Crujeiras AB, 2016, INT J OBESITY, V40, P514, DOI 10.1038/ijo.2015.208; Crujeiras AB, 2016, INT J OBESITY, V40, P403, DOI 10.1038/ijo.2015.206; Crujeiras AB, 2009, EUR J NUTR, V48, P341, DOI 10.1007/s00394-009-0019-9; Crujeiras AB, 2008, OMICS, V12, P251, DOI 10.1089/omi.2008.0001; Ezzati M, 2017, LANCET, V390, P2627, DOI 10.1016/S0140-6736(17)32129-3; Fang J, 2009, ADV DRUG DELIVER REV, V61, P290, DOI 10.1016/j.addr.2009.02.005; Fukuda S, 2006, MOL CANCER THER, V5, P1087, DOI 10.1158/1535-7163.MCT-05-0375; Gan L, 2018, BBA-REV CANCER, V1869, P97, DOI 10.1016/j.bbcan.2017.12.006; Garces-Rimon M, 2018, NUTRIENTS, V10, DOI 10.3390/nu10040441; Gomez-Arbelaez D, 2017, J CLIN ENDOCR METAB, V102, P488, DOI 10.1210/jc.2016-2385; Gomez-Zorita S, 2012, BRIT J NUTR, V107, P202, DOI 10.1017/S0007114511002753; Halliwell B., 2007, FREE RADICALS BIOL M; Horvath S, 2014, P NATL ACAD SCI USA, V111, P15538, DOI 10.1073/pnas.1412759111; Khandekar MJ, 2011, NAT REV CANCER, V11, P886, DOI 10.1038/nrc3174; Krstic J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030921; Kundu JK, 2012, FREE RADICAL BIO MED, V52, P2013, DOI 10.1016/j.freeradbiomed.2012.02.035; Li RF, 2018, CELL REP, V22, P624, DOI 10.1016/j.celrep.2017.12.071; Li Y, 2011, FASEB J, V25, P1664, DOI 10.1096/fj.10-173492; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marengo A, 2016, ANNU REV MED, V67, P103, DOI 10.1146/annurev-med-090514-013832; Marrero JA, 2002, HEPATOLOGY, V36, P1349, DOI 10.1053/jhep.2002.36939; Mi CJ, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414-431X20198009, 10.1590/1414-431x20198009]; Morgan MM, 2019, FASEB J, V33, P8623, DOI 10.1096/fj.201802347RRR; O'Sullivan J, 2018, NAT REV GASTRO HEPAT, V15, P699, DOI 10.1038/s41575-018-0069-7; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Purushotham A, 2009, CELL METAB, V9, P327, DOI 10.1016/j.cmet.2009.02.006; Said A, 2017, WORLD J CLIN ONCOL, V8, P429, DOI 10.5306/wjco.v8.i6.429; Sanchez-Perez Y, 2005, CANCER LETT, V217, P25, DOI 10.1016/j.canlet.2004.07.019; Stauffer JK, 2012, HEPATOLOGY, V56, P1567, DOI 10.1002/hep.25674; Sun BC, 2012, J HEPATOL, V56, P704, DOI 10.1016/j.jhep.2011.09.020; Upadhyay J, 2018, MED CLIN N AM, V102, P13, DOI 10.1016/j.mcna.2017.08.004; Vincent HK, 2007, DIABETES OBES METAB, V9, P813, DOI 10.1111/j.1463-1326.2007.00692.x; Vincent HK, 2006, INT J OBESITY, V30, P400, DOI 10.1038/sj.ijo.0803177	48	9	9	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2020	34	2					2312	2325		10.1096/fj.201901147RR	http://dx.doi.org/10.1096/fj.201901147RR			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KN2HU	31908001	Bronze			2023-01-03	WOS:000514663600027
J	Khera, R; Wang, YF; Bernheim, SM; Lin, ZQ; Krumholz, HM				Khera, Rohan; Wang, Yongfei; Bernheim, Susannah M.; Lin, Zhenqiu; Krumholz, Harlan M.			Post-discharge acute care and outcomes following readmission reduction initiatives: national retrospective cohort study of Medicare beneficiaries in the United States	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROFILING HOSPITAL PERFORMANCE; 30-DAY MORTALITY-RATES; PROGRAM; ASSOCIATION	OBJECTIVES To determine whether patients discharged after hospital admissions for conditions covered by national readmission programs who received care in emergency departments or observation units but were not readmitted within 30 days had an increased risk of death and to evaluate temporal trends in post-discharge acute care utilization in inpatient units, emergency departments, and observation units for these patients. DESIGN Retrospective cohort study. SETTING Medicare claims data for 2008-16 in the United States. PARTICIPANTS Patients aged 65 or older admitted to hospital with heart failure, acute myocardial infarction, or pneumonia-conditions included in the US Hospital Readmissions Reduction Program. MAIN OUTCOME MEASURES Post-discharge 30 day mortality according to patients 30 day acute care utilization; acute care utilization in inpatient and observation units and the emergency department during the 30 day and 31-90 day post-discharge period. RESULTS 3 772 924 hospital admissions for heart failure, 1 570 113 for acute myocardial infarction, and 3 131 162 for pneumonia occurred. The overall post-discharge 30 day mortality was 8.7% for heart failure, 7.3% for acute myocardial infarction, and 8.4% for pneumonia. Risk adjusted mortality increased annually by 0.05% (95% confidence interval 0.02% to 0.08%) for heart failure, decreased by 0.06% (-0.09% to -0.04%) for acute myocardial infarction, and did not significantly change for pneumonia. Specifically, mortality increased for patients with heart failure who did not utilize any post-discharge acute care, increasing at a rate of 0.08% (0.05% to 0.12%) per year, exceeding the overall absolute annual increase in post-discharge mortality in heart failure, without an increase in mortality in observation units or the emergency department. Concurrent with a reduction in 30 day readmission rates, stays for observation and visits to the emergency department increased across all three conditions during and beyond the 30 day post-discharge period. Overall 30 day post-acute care utilization did not change significantly. CONCLUSIONS The only condition with increasing mortality through the study period was heart failure; the increase preceded the policy and was not present among patients who received emergency department or observation unit care without admission to hospital. During this period, the overall acute care utilization in the 30 days after discharge significantly decreased for heart failure and pneumonia, but not for acute myocardial infarction.	[Khera, Rohan] Univ Texas Southwestern Med Ctr Dallas, Div Cardiol, Dallas, TX 75219 USA; [Wang, Yongfei; Lin, Zhenqiu; Krumholz, Harlan M.] Yale Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT USA; [Wang, Yongfei; Lin, Zhenqiu; Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT USA; [Bernheim, Susannah M.] Yale Sch Med, Dept Internal Med, Sect Gen Med, New Haven, CT USA; [Bernheim, Susannah M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, Qual Measurement Programs, New Haven, CT USA; [Krumholz, Harlan M.] Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; Yale University; Yale University; Yale University; Yale University; Yale University	Khera, R (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Div Cardiol, Dallas, TX 75219 USA.	rohankhera@outlook.com	Khera, Rohan/AAQ-6838-2021; , Harlan/AAI-2875-2020	Khera, Rohan/0000-0001-9467-6199; Krumholz, Harlan/0000-0003-2046-127X	National Center for Advancing Translational Sciences [UL1TR001105]; National Institutes of Health	National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	RK is supported by the National Center for Advancing Translational Sciences (UL1TR001105) of the National Institutes of Health. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.	Centers for Medicare and Medicaid Services, MEAS METH AMI HF EXC; Centers for Medicare and Medicaid Services, 2017, OUTC MEAS; Chatterjee P, 2018, JAMA CARDIOL, V3, P336, DOI 10.1001/jamacardio.2018.0218; Desai NR, 2016, JAMA-J AM MED ASSOC, V316, P2647, DOI 10.1001/jama.2016.18533; Dharmarajan K, 2017, JAMA-J AM MED ASSOC, V318, P270, DOI 10.1001/jama.2017.8444; Dharmarajan K, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j2616; Fonarow GC, 2018, JAMA-J AM MED ASSOC, V320, P2539, DOI 10.1001/jama.2018.19325; Gupta A, 2018, JAMA CARDIOL, V3, P44, DOI 10.1001/jamacardio.2017.4265; Harrison Jeffrey P, 2013, J Health Care Finance, V39, P1; Huckfeldt P, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0634; Huckfeldt P, 2018, J AM COLL CARDIOL, V72, P2539, DOI 10.1016/j.jacc.2018.08.2174; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Khera R, 2019, 19010074 MEDRXIV, DOI [10.1101/19010074, DOI 10.1101/19010074]; Khera R, 2019, J AM COLL CARDIOL, V74, P219, DOI 10.1016/j.jacc.2019.04.060; Khera R, 2018, CIRC-CARDIOVASC QUAL, V11, DOI 10.1161/CIRCOUTCOMES.118.005083; Khera R, 2018, JAMA CARDIOL, V3, P729, DOI 10.1001/jamacardio.2018.1813; Khera R, 2018, JACC-HEART FAIL, V6, P610, DOI 10.1016/j.jchf.2018.02.011; Khera R, 2018, JAMA-J AM MED ASSOC, V320, P133, DOI 10.1001/jama.2018.6823; Krumholz HM, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.1938; Krumholz HM, 2018, JAMA CARDIOL, V3, P265, DOI 10.1001/jamacardio.2017.5321; Krumholz HM, 2011, CIRC-CARDIOVASC QUAL, V4, P243, DOI 10.1161/CIRCOUTCOMES.110.957498; Krumholz HM, 2006, CIRCULATION, V113, P1683, DOI 10.1161/CIRCULATIONAHA.105.611186; Krumholz HM, 2006, CIRCULATION, V113, P1693, DOI 10.1161/CIRCULATIONAHA.105.611194; Lindenauer PK, 2011, J HOSP MED, V6, P142, DOI 10.1002/jhm.890; McIlvennan CK, 2015, CIRCULATION, V131, P1796, DOI 10.1161/CIRCULATIONAHA.114.010270; Medicare Payment Advisory Commission, 2018, MAND REP EFF HOSP RE; Medicare Payment Advisory Commission, 2019, UPD MEDPAC EC MED HO; Ody C, 2019, HEALTH AFFAIR, V38, P36, DOI 10.1377/hlthaff.2018.05178; Sandhu AT, 2019, AM HEART J, V209, P63, DOI 10.1016/j.ahj.2018.12.002; Tsugawa Y, 2019, JAMA INTERN MED, V179, P1287, DOI 10.1001/jamainternmed.2019.1005; Wadhera RK, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4563; Wadhera RK, 2019, NEW ENGL J MED, V380, P2289, DOI 10.1056/NEJMp1901225; Wadhera RK, 2018, JAMA-J AM MED ASSOC, V320, P2542, DOI 10.1001/jama.2018.19232; Wasfy JH, 2017, ANN INTERN MED, V166, P324, DOI 10.7326/M16-0185; Yale New Haven Health Services Corporation/Center for Outcomes Research & Evaluation (YNHHSC/CORE), 2017, QUALITYNET ARCH RES; Zar J. H., 2010, BIOSTAT ANAL; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	37	19	19	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 15	2020	368								l6831	10.1136/bmj.l6831	http://dx.doi.org/10.1136/bmj.l6831			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF9PC	31941686	Green Published, hybrid			2023-01-03	WOS:000509573400003
J	Fenaux, P; Platzbecker, U; Mufti, GJ; Garcia-Manero, G; Buckstein, R; Santini, V; Diez-Campelo, M; Finelli, C; Cazzola, M; Ilhan, O; Sekeres, MA; Falantes, JF; Arrizabalaga, B; Salvi, F; Giai, V; Vyas, P; Bowen, D; Selleslag, D; DeZern, AE; Jurcic, JG; Germing, U; Gotze, KS; Quesnel, B; Beyne-Rauzy, O; Cluzeau, T; Voso, MT; Mazure, D; Vellenga, E; Greenberg, PL; Hellstrom-Lindberg, E; Zeidan, AM; Ades, L; Verma, A; Savona, MR; Laadem, A; Benzohra, A; Zhang, JN; Rampersad, A; Dunshee, DR; Linde, PG; Sherman, ML; Komrokji, RS; List, AF				Fenaux, Pierre; Platzbecker, Uwe; Mufti, Ghulam J.; Garcia-Manero, Guillermo; Buckstein, Rena; Santini, Valeria; Diez-Campelo, Maria; Finelli, Carlo; Cazzola, Mario; Ilhan, Osman; Sekeres, Mikkael A.; Falantes, Jose F.; Arrizabalaga, Beatriz; Salvi, Flavia; Giai, Valentina; Vyas, Paresh; Bowen, David; Selleslag, Dominik; DeZern, Amy E.; Jurcic, Joseph G.; Germing, Ulrich; Goetze, Katharina S.; Quesnel, Bruno; Beyne-Rauzy, Odile; Cluzeau, Thomas; Voso, Maria-Teresa; Mazure, Dominiek; Vellenga, Edo; Greenberg, Peter L.; Hellstrom-Lindberg, Eva; Zeidan, Amer M.; Ades, Lionel; Verma, Amit; Savona, Michael R.; Laadem, Abderrahmane; Benzohra, Aziz; Zhang, Jennie; Rampersad, Anita; Dunshee, Diana R.; Linde, Peter G.; Sherman, Matthew L.; Komrokji, Rami S.; List, Alan F.			Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNATIONAL WORKING GROUP; PROGNOSTIC SCORING SYSTEM; WORLD-HEALTH-ORGANIZATION; MYELOID NEOPLASMS; RESPONSE CRITERIA; 5Q DELETION; ERYTHROPOIESIS; ANEMIA; BETA; LENALIDOMIDE	Background Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth factor beta superfamily ligands to reduce SMAD2 and SMAD3 signaling, showed promising results in a phase 2 study. Methods In a double-blind, placebo-controlled, phase 3 trial, we randomly assigned patients with very-low-risk, low-risk, or intermediate-risk myelodysplastic syndromes (defined according to the Revised International Prognostic Scoring System) with ring sideroblasts who had been receiving regular red-cell transfusions to receive either luspatercept (at a dose of 1.0 up to 1.75 mg per kilogram of body weight) or placebo, administered subcutaneously every 3 weeks. The primary end point was transfusion independence for 8 weeks or longer during weeks 1 through 24, and the key secondary end point was transfusion independence for 12 weeks or longer, assessed during both weeks 1 through 24 and weeks 1 through 48. Results Of the 229 patients enrolled, 153 were randomly assigned to receive luspatercept and 76 to receive placebo; the baseline characteristics of the patients were balanced. Transfusion independence for 8 weeks or longer was observed in 38% of the patients in the luspatercept group, as compared with 13% of those in the placebo group (P<0.001). A higher percentage of patients in the luspatercept group than in the placebo group met the key secondary end point (28% vs. 8% for weeks 1 through 24, and 33% vs. 12% for weeks 1 through 48; P<0.001 for both comparisons). The most common luspatercept-associated adverse events (of any grade) included fatigue, diarrhea, asthenia, nausea, and dizziness. The incidence of adverse events decreased over time. Conclusions Luspatercept reduced the severity of anemia in patients with lower-risk myelodysplastic syndromes with ring sideroblasts who had been receiving regular red-cell transfusions and who had disease that was refractory to or unlikely to respond to erythropoiesis-stimulating agents or who had discontinued such agents owing to an adverse event. (Funded by Celgene and Acceleron Pharma; MEDALIST ClinicalTrials.gov number, NCT02631070; EudraCT number, 2015-003454-41.)	[Fenaux, Pierre; Ades, Lionel] Hop St Louis, AP HP, Serv Hematol Seniors, Paris, France; [Fenaux, Pierre; Ades, Lionel] Univ Paris 07, Paris, France; [Quesnel, Bruno] Ctr Hosp Univ CHU Lille, Hop Huriez, Serv Malad Sang, Lille, France; [Beyne-Rauzy, Odile] CHU Toulouse, Inst Univ Canc Toulouse, Dept Internal Med, Toulouse, France; [Cluzeau, Thomas] Univ Cote Azur, CHU Nice, Dept Hematol Clin, Nice, France; [Platzbecker, Uwe] Leipzig Univ Hosp, Med Clin & Policlin 1, Hematol & Cellular Therapy, Johannisallee 32 A, D-04103 Leipzig, Germany; [Germing, Ulrich] Univ Klin Dusseldorf, Klin Hamatol Onkol & Klin Immunol, Dusseldorf, Germany; [Goetze, Katharina S.] Tech Univ Munich, Klin & Poliklin Innere Med 3, Munich, Germany; [Mufti, Ghulam J.] Kings Coll London, Dept Haematooncol, London, England; [Vyas, Paresh] Univ Oxford, John Radcliffe Hosp, Radcliffe Dept Med, Oxford, England; [Bowen, David] Leeds Teaching Hosp NHS Trust, Dept Haematol, Leeds, W Yorkshire, England; [Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Buckstein, Rena] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada; [Santini, Valeria] Univ Florence, Azienda Osped Univ Careggi, MDS Unit, Florence, Italy; [Finelli, Carlo] S Orsola Malpighi Univ Hosp, Dept Hematol & Oncol, Bologna, Italy; [Cazzola, Mario] Univ Pavia, Fdn IRCCS Policlin S Matteo, Pavia, Italy; [Salvi, Flavia; Giai, Valentina] St Antonio & Biagio & Cesare Arrigo Hosp, Hematol Unit, Alessandria, Italy; [Voso, Maria-Teresa] Univ Roma Tor Vergata, Dipartimento Biomed & Prevenz, Rome, Italy; [Diez-Campelo, Maria] Univ Hosp Salamanca, Inst Biomed Res Salamanca, Dept Hematol, Salamanca, Spain; [Falantes, Jose F.] Hosp Univ Virgen del Rocio, Unidad Hematol, Seville, Spain; [Arrizabalaga, Beatriz] Hosp Univ Cruces, Dept Hematol, Vizcaya, Spain; [Ilhan, Osman] Ankara Univ, Sch Med, Dept Hematol Sci, Ankara, Turkey; [Sekeres, Mikkael A.] Cleveland Clin, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA; [Selleslag, Dominik] Algemeen Ziekenhuis St Jan, Dept Hematol, Brugge, Belgium; [Mazure, Dominiek] Univ Ziekenhuis Gent, Ghent, Belgium; [DeZern, Amy E.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA; [Jurcic, Joseph G.] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, Div Hematol Oncol, New York, NY USA; [Verma, Amit] Albert Einstein Coll Med, New York, NY USA; [Vellenga, Edo] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands; [Greenberg, Peter L.] Stanford Univ, Ctr Canc, Stanford, CA 94305 USA; [Hellstrom-Lindberg, Eva] Karolinska Inst, Dept Med, Ctr Hematol & Regenerat Med, Stockholm, Sweden; [Zeidan, Amer M.] Yale Univ, Yale Sch Med, Dept Internal Med, New Haven, CT USA; [Savona, Michael R.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA; [Laadem, Abderrahmane; Zhang, Jennie; Rampersad, Anita; Dunshee, Diana R.] Celgene, Summit, NJ USA; [Benzohra, Aziz] Celgene Int, Boudry, Switzerland; [Linde, Peter G.; Sherman, Matthew L.] Acceleron Pharma, Cambridge, MA USA; [Komrokji, Rami S.; List, Alan F.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; CHU Lille; CHU de Toulouse; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; Leipzig University; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Technical University of Munich; University of London; King's College London; University of Oxford; University of Leeds; University of Texas System; UTMD Anderson Cancer Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Florence; Azienda Ospedaliero Universitaria Careggi; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Fondazione San Matteo; University of Pavia; Azienda Ospedaliera SS Antonio Biagio Cesare Arrigo; University of Rome Tor Vergata; Virgen del Rocio University Hospital; Hospital Universitario Cruces; Ankara University; Cleveland Clinic Foundation; Ghent University; Ghent University Hospital; Johns Hopkins University; Johns Hopkins Medicine; Columbia University; Yeshiva University; University of Groningen; Stanford University; Karolinska Institutet; Yale University; Vanderbilt University; Bristol-Myers Squibb; Celgene Corporation; Acceleron Pharma; H Lee Moffitt Cancer Center & Research Institute	Fenaux, P (corresponding author), Hop St Louis, 1 Ave Claude Vellefaux, F-75475 Paris, France.; Platzbecker, U (corresponding author), Leipzig Univ Hosp, Med Clin & Policlin 1, Hematol & Cellular Therapy, Johannisallee 32 A, D-04103 Leipzig, Germany.	pierre.fenaux@aphp.fr; uwe.platzbecker@medizin.uni-leipzig.de	ilhan, osman/ABC-8182-2021; SANTINI, VALERIA/AAL-3135-2020; Vyas, Paresh/B-5708-2009; Cazzola, Mario/AAQ-8854-2021; Cluzeau, Thomas/AAI-1296-2020; Quesnel, Bruno/D-5533-2018; Germing, Ulrich/AAX-1036-2021; Voso, Maria Teresa/F-1172-2014; Beyne-Rauzy, Odile/AAN-1873-2020	SANTINI, VALERIA/0000-0002-5439-2172; Vyas, Paresh/0000-0003-3931-0914; Cazzola, Mario/0000-0001-6984-8817; Quesnel, Bruno/0000-0002-6563-2709; Voso, Maria Teresa/0000-0002-6164-4761; Beyne-Rauzy, Odile/0000-0003-0321-6029; komrokji, rami/0000-0002-1876-5269; Diez Campelo, Maria/0000-0002-1467-6779	Medical Research Council [MC_U137961146, G1000729, MC_UU_12009/11, MC_UU_00016/11, MR/L008963/1] Funding Source: Medline; MRC [MC_UU_00016/11, MC_UU_12009/11, MR/L008963/1, G1000729, MC_U137961146] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ades L, 2014, LANCET, V383, P2239, DOI 10.1016/S0140-6736(13)61901-7; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Bataller A, 2019, LEUKEMIA, V33, P1076, DOI 10.1038/s41375-019-0420-1; Camaschella C, 2019, BLOOD, V134, P500, DOI 10.1182/blood.2019001983; Cheson BD, 2000, BLOOD, V96, P3671; Cheson BD, 2006, BLOOD, V108, P419, DOI 10.1182/blood-2005-10-4149; Fenaux P, 2019, BLOOD, V133, P790, DOI 10.1182/blood-2018-11-876888; Fenaux P, 2018, LEUKEMIA, V32, P2648, DOI 10.1038/s41375-018-0118-9; Fenaux P, 2013, BLOOD, V121, P4280, DOI 10.1182/blood-2013-02-453068; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Greenberg PL, 2012, BLOOD, V120, P2454, DOI 10.1182/blood-2012-03-420489; Guerra A, 2019, BLOOD, V134, P568, DOI 10.1182/blood.2019001057; HELLSTROMLINDBERG E, 1995, BRIT J HAEMATOL, V89, P67, DOI 10.1111/j.1365-2141.1995.tb08909.x; HIWASE DK, 2013, BLOOD, V122; Kelaidi C, 2013, LEUKEMIA, V27, P1283, DOI 10.1038/leu.2013.16; Malcovati L, 2005, J CLIN ONCOL, V23, P7594, DOI 10.1200/JCO.2005.01.7038; Malcovati L, 2007, J CLIN ONCOL, V25, P3503, DOI 10.1200/JCO.2006.08.5696; Malcovati L, 2006, HAEMATOLOGICA, V91, P1588; Malcovati L, 2013, BLOOD, V122, P2943, DOI 10.1182/blood-2013-03-492884; Malcovati L, 2009, CLIN LYMPHOMA MYELOM, V9, pS305, DOI 10.3816/CLM.2009.s.029; Oliva EN, 2011, AM J BLOOD RES, V1, P160; Park S, 2008, BLOOD, V111, P574, DOI 10.1182/blood-2007-06-096370; Park S, 2017, J CLIN ONCOL, V35, P1591, DOI 10.1200/JCO.2016.71.3271; Platzbecker U, 2019, BLOOD, V133, P1020, DOI 10.1182/blood-2018-06-857102; Platzbecker U, 2019, BLOOD, V133, P1096, DOI 10.1182/blood-2018-10-844696; Platzbecker U, 2017, LANCET ONCOL, V18, P1338, DOI 10.1016/S1470-2045(17)30615-0; Santini V, 2016, J CLIN ONCOL, V34, P2988, DOI 10.1200/JCO.2015.66.0118; Santini V, 2013, BLOOD, V122, P2286, DOI 10.1182/blood-2013-07-512442; Stauder R, 2018, BLOOD, V131, P505, DOI 10.1182/blood-2017-07-746446; Suragani RNVS, 2014, BLOOD, V123, P3864, DOI 10.1182/blood-2013-06-511238; Suragani RNVS, 2014, NAT MED, V20, P408, DOI 10.1038/nm.3512; Talati C, 2017, SEMIN HEMATOL, V54, P159, DOI 10.1053/j.seminhematol.2017.06.003; Tehranchi R, 2005, BLOOD, V106, P247, DOI 10.1182/blood-2004-12-4649; Tehranchi R, 2003, BLOOD, V101, P1080, DOI 10.1182/blood-2002-06-1774; Thepot S, 2016, HAEMATOLOGICA, V101, P918, DOI 10.3324/haematol.2015.140988; Tobiasson M, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.8; Toma A, 2016, LEUKEMIA, V30, P897, DOI 10.1038/leu.2015.296; Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262; Zhou L, 2008, BLOOD, V112, P3434, DOI 10.1182/blood-2008-02-139824	39	199	212	6	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 9	2020	382	2					140	151		10.1056/NEJMoa1908892	http://dx.doi.org/10.1056/NEJMoa1908892			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB6CS	31914241	Bronze, Green Published			2023-01-03	WOS:000506581500012
J	Maeda, S; Yamaguchi, M; Maeda, K; Kobayashi, N; Izumi, N; Nagai, M; Obayashi, T; Ohashi, W; Katsuno, T; Nobata, H; Ito, Y				Maeda, Sayaka; Yamaguchi, Makoto; Maeda, Kunihiro; Kobayashi, Naoto; Izumi, Naoki; Nagai, Masaaki; Obayashi, Takaaki; Ohashi, Wataru; Katsuno, Takayuki; Nobata, Hironobu; Ito, Yasuhiko			Proton pump inhibitor use increases the risk of peritonitis in peritoneal dialysis patients	PLOS ONE			English	Article							BACTERIAL OVERGROWTH; ACID SUPPRESSANTS; GUT MICROBIOTA; ASSOCIATION; PHARMACOKINETICS; COLONOSCOPY; INFECTION	Peritonitis is a major and the most significant complication of peritoneal dialysis (PD). Although some predictors of peritonitis in PD patients are known, the association between proton pump inhibitor (PPI) use and peritonitis has not been characterized. Here, we examined whether PPI use is a risk factor for the development of peritonitis, based on a single-center retrospective analysis of 230 consecutive Japanese PD patients at Narita Memorial Hospital. We assessed the association between PPI use and subsequent first episode of peritonitis using multivariate Cox proportional hazards models, following adjustment for clinically relevant factors. The median follow-up period was 36 months (interquartile range, 19-57 months). In total, 86 patients (37.4%) developed peritonitis. Analysis with multivariate Cox proportional hazards models revealed the following significant predictors of peritonitis: PPI use (adjusted hazard ratio [HR] = 1.72, 95% confidence interval [CI]: 1.11-2.66; P = 0.016) and low serum albumin level (per g/dl adjusted HR = 0.59, 95% CI: 0.39-0.90; P = 0.014). Thus, PPI use was independently associated with PD-related peritonitis. The results suggest that nephrology physicians should exercise caution when prescribing PPIs for PD patients.	[Maeda, Sayaka; Maeda, Kunihiro; Kobayashi, Naoto; Izumi, Naoki; Nagai, Masaaki; Obayashi, Takaaki] Narita Mem Hosp, Dept Nephrol, Toyohashi, Aichi, Japan; [Yamaguchi, Makoto; Katsuno, Takayuki; Nobata, Hironobu; Ito, Yasuhiko] Aichi Med Univ, Dept Nephrol & Rheumatol, Nagakute, Aichi, Japan; [Ohashi, Wataru] Aichi Med Univ, Clin Res Ctr, Div Biostat, Nagakute, Aichi, Japan	Aichi Medical University; Aichi Medical University	Ito, Y (corresponding author), Aichi Med Univ, Dept Nephrol & Rheumatol, Nagakute, Aichi, Japan.	yasuito@aichi-med-u.ac.jp						Brooks AW, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2006842; Chang CS, 1998, HEPATOLOGY, V28, P1187, DOI 10.1002/hep.510280504; Chang SS, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000944; Chen L, 2016, SCI REP-UK, V6, DOI 10.1038/srep23075; Cho Y, 2014, AM J KIDNEY DIS, V64, P278, DOI 10.1053/j.ajkd.2014.02.025; Ciz M, 2013, BRIT J PHARMACOL, V170, P17, DOI 10.1111/bph.12107; Deshpande A, 2012, CLIN GASTROENTEROL H, V10, P225, DOI 10.1016/j.cgh.2011.09.030; Frei R, 2013, J ALLERGY CLIN IMMUN, V132, P194, DOI 10.1016/j.jaci.2013.01.013; Imhann F, 2016, GUT, V65, P740, DOI 10.1136/gutjnl-2015-310376; Jump RLP, 2007, ANTIMICROB AGENTS CH, V51, P2883, DOI 10.1128/AAC.01443-06; Keane WF, 1996, PERITON DIALYSIS INT, V16, P557; Keane WF, 1999, J CLIN PHARMACOL, V39, P927, DOI 10.1177/00912709922008542; Kwon JE, 2014, WORLD J GASTROENTERO, V20, P8187, DOI 10.3748/wjg.v20.i25.8187; Li PKT, 2016, PERITON DIALYSIS INT, V36, P481, DOI 10.3747/pdi.2016.00078; Machuca Eduardo, 2005, Adv Perit Dial, V21, P60; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Min YW, 2014, ALIMENT PHARM THER, V40, P695, DOI 10.1111/apt.12875; Perez-Fontan M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148806; Poortvliet W, 2010, NETH J MED, V68, P377; Prasad N, 2007, PERITON DIALYSIS INT, V27, P42; SICA DA, 1987, EUR J CLIN PHARMACOL, V32, P587, DOI 10.1007/BF02455993; Takagi T, 2018, J CLIN BIOCHEM NUTR, V62, P100, DOI 10.3164/jcbn.17-78; Takahashi Y, 2006, J GASTROEN HEPATOL, V21, P1664, DOI 10.1111/j.1440-1746.2006.04270.x; Thorens J, 1996, GUT, V39, P54, DOI 10.1136/gut.39.1.54; Troidle L, 2003, AM J KIDNEY DIS, V42, P350, DOI 10.1016/S0272-6386(03)00661-9; van Diepen ATN, 2012, CLIN J AM SOC NEPHRO, V7, P1266, DOI 10.2215/CJN.00980112; Voinescu CG, 2002, INT J ARTIF ORGANS, V25, P249, DOI 10.1177/039139880202500402; Wang Q, 2003, AM J KIDNEY DIS, V41, P664, DOI 10.1053/ajkd.2003.50128; Yip T, 2007, PERITON DIALYSIS INT, V27, P560; Zhong HJ, 2019, J CLIN PHARM THER, V44, P209, DOI 10.1111/jcpt.12769	30	8	8	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2019	14	11							e0224859	10.1371/journal.pone.0224859	http://dx.doi.org/10.1371/journal.pone.0224859			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN1GV	31697753	Green Published, gold			2023-01-03	WOS:000532694400071
J	Freire, JMO; Chaves, HV; Teixeira, AH; de Sousa, LHT; Pinto, IR; Costa, JJD; de Souse, NA; Pereira, KMA; Girao, VCC; Ferreira, VCS; dos Santos, JED; Lima, MAS; Pimenta, ATA; Montenegro, RD; de Moraes, MEA; Pinto, VDT; Filho, GC; Bezerra, MM				Freire, Jordania M. O.; Chaves, Helliada, V; Teixeira, Alrieta H.; de Sousa, Luzia Herminia T.; Pinto, Isabela Ribeiro; Costa, Jose Jackson do N.; de Souse, Nayara Alves; Pereira, Karuza Maria A.; Girao, Virginia C. C.; Ferreira, Vanessa C. S.; de Avila dos Santos, Joao Evangelista; Lima, Mary Anne S.; Pimenta, Antonia T. A.; Montenegro, Raquel de C.; de Moraes, Maria Elisabete A.; Pinto, Vicente de P. T.; Filho, Gerardo C.; Bezerra, Mirna M.			Protective effect of Platymiscium floribundum Vog. in tree extract on periodontitis inflammation in rats	PLOS ONE			English	Article							BONE LOSS; AGGRESSIVE PERIODONTITIS; SUPEROXIDE-DISMUTASE; NITRIC-OXIDE; CYCLOOXYGENASE-2; INHIBITION; FLAVONOIDS; BIOMARKERS; IL-1-BETA; INDUCTION	Periodontitis is an immuno-inflammatory disease, which can lead to tooth loss. This study aimed to investigate the efficacy of Platymiscium floribundum Vog., a Brazilian tree which has been used in folk medicine as an anti-inflammatory agent, in a pre-clinical trial of periodontitis in rats. Periodontitis was induced by placing a sterilized nylon (3.0) thread ligature around the cervix of the second left upper molar of the rats, which received (per os) P. floribundum extract (0.1, 1 or 10 mg/kg) or vehicle 1h before periodontitis-challenge and once daily during 11 days. Treatment with P. floribundum (10mg/kg) decreased alveolar bone loss, MPO activity nitrite/nitrate levels, oxidative stress, TNF-alpha, IL1-beta, IL-8/CINC-1, and PGE2 gingival levels, and transcription of TNF-alpha, IL1-beta, COX-2, iNOS, RANK, and RANKL genes, while elevated both BALP serum levels and IL-10 gingival levels. The animals did not show signs of toxicity throughout the experimental course. These findings show that P. floribundum has anti-inflammatory and anti-resorptive properties in a pre-clinical trial of periodontitis, representing an interesting biotechnological tool.	[Freire, Jordania M. O.; Chaves, Helliada, V; de Sousa, Luzia Herminia T.; Pinto, Isabela Ribeiro] Univ Fed Ceara, Northeast Biotechnol Network PhD Program, Sobral, Ceara, Brazil; [Teixeira, Alrieta H.] Univ Fed Ceara, Sch Dent, Sobral, Ceara, Brazil; [Costa, Jose Jackson do N.] Univ CenterINTA UNINTA, Sch Med, Sobral, Ceara, Brazil; [de Souse, Nayara Alves; Pinto, Vicente de P. T.; Filho, Gerardo C.; Bezerra, Mirna M.] Univ Fed Ceara, Sch Med, Sobral, Ceara, Brazil; [Pereira, Karuza Maria A.; Girao, Virginia C. C.] Univ Fed Ceara, Sch Med, Dept Morphol, Fortaleza, Ceara, Brazil; [Ferreira, Vanessa C. S.] Univ Fed Ceara, Sch Med, Dept Morphol, Postgrad Program Morphofunct Sci, Fortaleza, Ceara, Brazil; [de Avila dos Santos, Joao Evangelista; Lima, Mary Anne S.; Pimenta, Antonia T. A.] Univ Fed Ceara, Dept Organ & Inorgan Chem, Fortaleza, Ceara, Brazil; [Montenegro, Raquel de C.; de Moraes, Maria Elisabete A.; Bezerra, Mirna M.] Univ Fed Ceara, Drug Res & Dev Ctr NPDM, Fortaleza, Ceara, Brazil	Universidade Federal do Ceara; Universidade Federal do Ceara; Universidade Federal do Ceara; Universidade Federal do Ceara; Universidade Federal do Ceara; Universidade Federal do Ceara; Universidade Federal do Ceara	Bezerra, MM (corresponding author), Univ Fed Ceara, Sch Med, Sobral, Ceara, Brazil.; Bezerra, MM (corresponding author), Univ Fed Ceara, Drug Res & Dev Ctr NPDM, Fortaleza, Ceara, Brazil.	mirna@ufc.br	Ferreira, Virginia Clara Teixeira/I-3612-2016	Ferreira, Virginia Clara Teixeira/0000-0002-4648-3461; Marques, Jordania/0000-0002-3412-8964; Costa, Vanessa/0000-0002-6699-5384; Avila dos Santos, Joao Evangelista/0000-0001-9447-5418; Teixeira, Alrieta/0000-0002-4142-4059; Torres Avila Pimenta, Antonia/0000-0002-1191-0363; de sousa, vanessa/0000-0001-8899-043X	Brazilian grants from Conselho Nacional de Pesquisa (CNPq) [471974/2013-7]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Capes) and Fundacao Cearense de Apoio ao Desenvolvimento Cienti'fico e Tecnolo gico (Funcap) (Capes/Funcap grant) [AE1-0052-000180100/2011]; Instituto de Biomedicina do Semi-A' rido Brasileiro (INCT-IBISAB)	Brazilian grants from Conselho Nacional de Pesquisa (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Capes) and Fundacao Cearense de Apoio ao Desenvolvimento Cienti'fico e Tecnolo gico (Funcap) (Capes/Funcap grant)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Instituto de Biomedicina do Semi-A' rido Brasileiro (INCT-IBISAB)	This work was supported by Brazilian grants from Conselho Nacional de Pesquisa (CNPq) (grant #471974/2013-7), Coordenacao de Aperfeicoamento de Pessoal de Ni ' vel Superior (Capes) and Fundacao Cearense de Apoio ao Desenvolvimento Cienti ' fico e Tecnolo ' gico (Funcap) (Capes/Funcap grant #AE1-0052-000180100/2011), and Instituto de Biomedicina do Semi-A ' rido Brasileiro (INCT-IBISAB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexandre JTM, 2018, CLIN ORAL INVEST, V22, P2175, DOI 10.1007/s00784-017-2308-7; Azoubel MCF, 2008, J PERIODONTOL, V79, P1719, DOI [10.1902/jop.2008.080019, 10.1902/jop.2008.080019 ]; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Belibasakis GN, 2012, J CLIN PERIODONTOL, V39, P239, DOI 10.1111/j.1600-051X.2011.01810.x; Bezerra MM, 2000, J PERIODONTOL, V71, P1009, DOI 10.1902/jop.2000.71.6.1009; BRADLEY PP, 1982, BLOOD, V60, P618; Buommino E, 2014, MINI-REV MED CHEM, V14, P1169; Cardoso-Lopes EM, 2008, REV BRAS FARMACOGN, V18, P655, DOI 10.1590/S0102-695X2008000500002; Chang PC, 2017, J PERIODONTOL, V88, P190, DOI 10.1902/jop.2016.160189; DING AH, 1988, J IMMUNOL, V141, P2407; Falcao MJC, 2005, J NAT PROD, V68, P423, DOI 10.1021/np049854d; Ribeiro DDF, 2018, BIOMED PHARMACOTHER, V98, P863, DOI 10.1016/j.biopha.2018.01.011; Hajishengallis G, 2014, MOL ORAL MICROBIOL, V29, P248, DOI 10.1111/omi.12065; Kuhr A, 2004, J PERIODONTAL RES, V39, P101, DOI 10.1111/j.1600-0765.2004.00710.x; La VD, 2011, J PERIODONTOL, V82, P122, DOI 10.1902/jop.2010.100342; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MAEHLY AC, 1954, METHOD BIOCHEM ANAL, V1, P357; Martins CS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153716; Messier C, 2012, ORAL DIS, V18, P32, DOI 10.1111/j.1601-0825.2011.01842.x; Militao GCG, 2006, LIFE SCI, V78, P2409, DOI 10.1016/j.lfs.2005.09.044; Palm F, 2014, INNATE IMMUN-LONDON, V20, P511, DOI 10.1177/1753425913501214; Sanchez GA, 2013, J CLIN PERIODONTOL, V40, P1112, DOI 10.1111/jcpe.12164; Sukhtankar L, 2013, DIS MARKERS, V34, P305, DOI [10.3233/DMA-130978, 10.1155/2013/269027]; Sundar NM, 2013, J CLIN DIAGN RES, V7, P1223, DOI 10.7860/JCDR/2013/5386.3068; Teixeira AH, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00988; Trindade F, 2014, PROTEOM CLIN APPL, V8, P748, DOI 10.1002/prca.201400028; Uslu MO, 2018, J APPL ORAL SCI, V26, DOI 10.1590/1678-7757-2017-0266; Val D.R., 2014, EUR J PAIN, V18, P1280; van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365-2567.2001.01261.x; Varela-Lopez A, 2015, ANTIOXIDANTS-BASEL, V4, P447, DOI 10.3390/antiox4030447; Veloso PA, 2012, J BRAZIL CHEM SOC, V23, P1239, DOI 10.1590/S0103-50532012000700007; WHITBY LG, 1975, CLIN CHIM ACTA, V59, P361, DOI 10.1016/0009-8981(75)90012-1; Whyte MP, 2010, ANN NY ACAD SCI, V1192, P190, DOI 10.1111/j.1749-6632.2010.05387.x	33	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2019	14	11							e0223800	10.1371/journal.pone.0223800	http://dx.doi.org/10.1371/journal.pone.0223800			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN1AJ	31682614	Green Published, gold			2023-01-03	WOS:000532676800006
J	Eisenstein, M				Eisenstein, Michael			Prostate cancer: A declining art	NATURE			English	Editorial Material																			0	12	12	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	2019	574	7780					S81	S81						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JI9UH	31666726				2023-01-03	WOS:000493807800009
J	Jiao, XF; Lin, XM; Ni, XF; Li, HL; Zhang, C; Yang, CS; Song, HX; Yi, QS; Zhang, LL				Jiao, Xue-feng; Lin, Xue-mei; Ni, Xiao-feng; Li, Hai-long; Zhang, Chuan; Yang, Chun-song; Song, Hao-xin; Yi, Qiu-sha; Zhang, Ling-li			Volatile anesthetics versus total intravenous anesthesia in patients undergoing coronary artery bypass grafting: An updated meta-analysis and trial sequential analysis of randomized controlled trials	PLOS ONE			English	Article							CARDIAC-SURGERY; MYOCARDIAL PROTECTION; COMPLICATIONS; SEVOFLURANE; DESFLURANE; MORTALITY; QUALITY	Background The benefits of volatile anesthetics in coronary artery bypass grafting (CABG) patients remain controversial. We aimed to conduct an updated meta-analysis to assess whether the use of volatile anesthetics during CABG could reduce mortality and other outcomes. Methods We searched eight databases from inception to June 2019 and included randomized controlled trials (RCTs) comparing the effects of volatile anesthetics versus total intravenous anesthesia (TIVA) in CABG patients. The primary outcomes were operative mortality and one-year mortality. The secondary outcomes included the length of stay in the intensive care unit (ICU) and hospital and postoperative safety outcomes (myocardial infarction, heart failure, arrhythmia, stroke, delirium, postoperative cognitive impairment, acute kidney injury, and the use of intra-aortic balloon pump (IABP) or other mechanical circulatory support). Trial sequential analysis (TSA) was performed to control for random errors. Results A total of 89 RCTs comprising 14,387 patients were included. There were no significant differences between the volatile anesthetics and TIVA groups in operative mortality (relative risk (RR) = 0.92, 95% confidence interval (CI): 0.68-1.24, p = 0.59, I-2 = 0%), one-year mortality (RR = 0.64, 95% CI: 0.32-1.26, p = 0.19, I-2 = 51%), or any of the postoperative safety outcomes. The lengths of stay in the ICU and hospital were shorter in the volatile anesthetics group than in the TIVA group. TSA revealed that the results for operative mortality, one-year mortality, length of stay in the ICU, heart failure, stroke, and the use of IABP were inconclusive. Conclusions Conventional meta-analysis suggests that the use of volatile anesthetics during CABG is not associated with reduced risk of mortality or other postoperative safety outcomes when compared with TIVA. TSA shows that the current evidence is insufficient and inconclusive. Thus, future large RCTs are required to clarify this issue.	[Jiao, Xue-feng; Ni, Xiao-feng; Li, Hai-long; Zhang, Chuan; Yang, Chun-song; Song, Hao-xin; Yi, Qiu-sha; Zhang, Ling-li] Sichuan Univ, West China Univ Hosp 2, Dept Pharm, Chengdu, Sichuan, Peoples R China; [Jiao, Xue-feng; Ni, Xiao-feng; Li, Hai-long; Zhang, Chuan; Yang, Chun-song; Song, Hao-xin; Yi, Qiu-sha; Zhang, Ling-li] Sichuan Univ, West China Univ Hosp 2, Evidence Based Pharm Ctr, Chengdu, Sichuan, Peoples R China; [Jiao, Xue-feng; Lin, Xue-mei; Ni, Xiao-feng; Li, Hai-long; Zhang, Chuan; Yang, Chun-song; Song, Hao-xin; Yi, Qiu-sha; Zhang, Ling-li] Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Child, Minist Educ, Chengdu, Sichuan, Peoples R China; [Jiao, Xue-feng; Ni, Xiao-feng; Yi, Qiu-sha] Sichuan Univ, West China Sch Med, Chengdu, Sichuan, Peoples R China; [Lin, Xue-mei] Sichuan Univ, West China Univ Hosp 2, Dept Anesthesiol, Chengdu, Sichuan, Peoples R China	Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University	Zhang, LL (corresponding author), Sichuan Univ, West China Univ Hosp 2, Dept Pharm, Chengdu, Sichuan, Peoples R China.; Zhang, LL (corresponding author), Sichuan Univ, West China Univ Hosp 2, Evidence Based Pharm Ctr, Chengdu, Sichuan, Peoples R China.; Zhang, LL (corresponding author), Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Child, Minist Educ, Chengdu, Sichuan, Peoples R China.	zhanglingli@scu.edu.cn			Natural Science Foundation of China [81373381]; National Science and Technology Major Project: Construction of pediatric new drug clinical evaluation technology platform [2017ZX09304029]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Project: Construction of pediatric new drug clinical evaluation technology platform	This study was supported by Natural Science Foundation of China: Evidence based establishment of evaluation index system for pediatric rational drug use in China (No. 81373381), and National Science and Technology Major Project: Construction of pediatric new drug clinical evaluation technology platform (No. 2017ZX09304029) to LZ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank Group of People with Highest Risk of Drug Exposure of International Network for the Rational Use of Drugs, China and Evidence-based Pharmacy Committee of Chinese Pharmaceutical Association for helping to coordinate the authors to review earlier manuscript drafts and provide valuable comments.	Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; Barbato E, 2016, NEW ENGL J MED, V375, DOI 10.1056/NEJMc1608042; Benjamin EJ, 2017, CIRCULATION, V135, pE146, DOI 10.1161/CIR.0000000000000485; Cai JR, 2014, J THORAC CARDIOV SUR, V148, P3127, DOI 10.1016/j.jtcvs.2014.07.085; Delamothe T, 2004, BMJ-BRIT MED J, V328, P1, DOI 10.1136/bmj.328.7430.1; El Dib R, 2017, J CLIN ANESTH, V40, P127, DOI 10.1016/j.jclinane.2017.05.010; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hillis LD, 2011, J AM COLL CARDIOL, V58, pE123, DOI 10.1016/j.jacc.2011.08.009; Hofland J, 2017, ANESTHESIOLOGY, V127, P918, DOI 10.1097/ALN.0000000000001873; Landoni G, 2013, BRIT J ANAESTH, V111, P886, DOI 10.1093/bja/aet231; Landoni G, 2007, J CARDIOTHOR VASC AN, V21, P502, DOI 10.1053/j.jvca.2007.02.013; Landoni G, 2019, NEW ENGL J MED, V380, P1214, DOI 10.1056/NEJMoa1816476; Likhvantsev VV, 2016, J CARDIOTHOR VASC AN, V30, P1221, DOI 10.1053/j.jvca.2016.02.030; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Meco M, 2007, EUR J CARDIO-THORAC, V32, P319, DOI 10.1016/j.ejcts.2007.05.005; Moazzami K, 2017, J CARDIOTHOR VASC AN, V31, P19, DOI 10.1053/j.jvca.2016.08.008; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Overman DM, 2013, WORLD J PEDIATR CONG, V4, P10, DOI 10.1177/2150135112461924; Pagel PS, 2018, J CARDIOTHOR VASC AN, V32, P1112, DOI 10.1053/j.jvca.2017.12.029; Pagel PS, 2013, J CARDIOTHOR VASC AN, V27, P972, DOI 10.1053/j.jvca.2012.10.011; Sousa-Uva M, 2018, EUR J CARDIO-THORAC, V53, P5, DOI 10.1093/ejcts/ezx314; Symons JA, 2006, BRIT J ANAESTH, V97, P127, DOI 10.1093/bja/ael149; Uhlig C, 2016, ANESTHESIOLOGY, V124, P1230, DOI 10.1097/ALN.0000000000001120; Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135; Warltier DC, 2000, ANESTHESIOLOGY, V92, P253, DOI 10.1097/00000542-200001000-00038; Wetterslev J, USER MANUAL TRIAL SE; Yu CH, 2006, CAN J ANAESTH, V53, P906, DOI 10.1007/BF03022834; Zangrillo A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134264	29	19	23	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2019	14	10							e0224562	10.1371/journal.pone.0224562	http://dx.doi.org/10.1371/journal.pone.0224562			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN0RS	31661512	Green Published, gold			2023-01-03	WOS:000532653400041
J	Chen, CC; Wang, YL; Chang, CP				Chen, Chi-Chun; Wang, Yu-Lin; Chang, Ching-Ping			Remarkable cell recovery from cerebral ischemia in rats using an adaptive escalator-based rehabilitation mechanism	PLOS ONE			English	Article							ARTERY OCCLUSION; EXERCISE; STROKE; BRAIN; MICROCONTROLLER; VOLUNTARY; SYSTEM	Currently, many ischemic stroke patients worldwide suffer from physical and mental impairments, and thus have a low quality of life. However, although rehabilitation is acknowledged as an effective way to recover patients' health, there does not exist yet an adaptive training platform for animal tests so far. For this sake, this paper aims to develop an adaptive escalator (AE) for rehabilitation of rats with cerebral ischemia. Rats were observed to climb upward spontaneously, and a motor-driven escalator, equipped with a position detection feature and an acceleration/deceleration mechanism, was constructed accordingly as an adaptive training platform. The rehabilitation performance was subsequently rated using an incline test, a rotarod test, the infarction volume, the lesion volume, the number of MAP2 positive cells and the level of cortisol. This paper is presented in 3 parts as follows. Part 1 refers to the escalator mechanism design, part 2 describes the adaptive ladder-climbing rehabilitation mechanism, and part 3 discusses the validation of an ischemic stroke model. As it turned out, a rehabilitated group using this training platform, designated as the AE group, significantly outperformed a control counterpart in terms of a rotarod test. After the sacrifice of the rats, the AE group gave an average infarction volume of (34.36 +/- 3.8)%, while the control group gave (66.41 +/- 3.1)%, validating the outperformance of the escalator-based rehabilitation platform in a sense. An obvious difference between the presented training platform and conventional counterparts is the platform mechanism, and for the first time in the literature rats can be well and voluntarily rehabilitated at full capacity using an adaptive escalator. Taking into account the physical diversity among rats, the training strength provided was made adaptive as a reliable way to eliminate workout or secondary injury. Accordingly, more convincing arguments can be made using this mental stress-free training platform.	[Chen, Chi-Chun] Natl Chin Yi Univ Technol, Dept Elect Engn, Taichung, Taiwan; [Wang, Yu-Lin] Natl Cheng Kung Univ, Dept Biomed Engn, Tainan, Taiwan; [Wang, Yu-Lin] Southern Taiwan Univ Sci & Technol, Ctr Gen Educ, Tainan, Taiwan; [Wang, Yu-Lin] Chi Mei Med Ctr, Dept Phys Med & Rehabil, Tainan, Taiwan; [Chang, Ching-Ping] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan	National Chin-Yi University of Technology; National Cheng Kung University; Southern Taiwan University of Science & Technology; Chi Mei Hospital; Chi Mei Hospital	Chen, CC (corresponding author), Natl Chin Yi Univ Technol, Dept Elect Engn, Taichung, Taiwan.	chichun@ncut.edu.tw		Chen, Chi-Chun/0000-0002-8353-5603; Chang, Ching-Ping/0000-0003-0890-9414	Ministry of Science and Technology, Taiwan [MOST 106-2221-E-167-004 -MY3]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by the Ministry of Science and Technology, Taiwan, under grant number MOST 106-2221-E-167-004 -MY3 to C-CC.	Brown DA, 2007, J APPL PHYSIOL, V103, P1979, DOI 10.1152/japplphysiol.00706.2007; Chang MW, 2008, J NEUROSCI METH, V168, P186, DOI 10.1016/j.jneumeth.2007.09.013; Chen CC, 2014, BRAZ J MED BIOL RES, V47, P858, DOI 10.1590/1414-431X20143754; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Dawson DA, 1996, J CEREBR BLOOD F MET, V16, P170, DOI 10.1097/00004647-199601000-00020; Ding Y, 2004, NEUROSCIENCE, V124, P583, DOI 10.1016/j.neuroscience.2003.12.029; Docherty D, 2000, SPORTS MED, V30, P385, DOI 10.2165/00007256-200030060-00001; Dominici N, 2012, NAT MED, V18, P1142, DOI 10.1038/nm.2845; Fantegrossi WE, 2013, J NEUROSCI METH, V212, P338, DOI 10.1016/j.jneumeth.2012.10.020; Frasier CR, 2011, J APPL PHYSIOL, V111, P905, DOI 10.1152/japplphysiol.00004.2011; Hatem SM, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00442; Hayes K, 2008, ACTA NEUROPATHOL, V115, P289, DOI 10.1007/s00401-008-0340-z; Jung S, 2015, J PHYSIOL SCI, V65, P515, DOI 10.1007/s12576-015-0388-1; Ke Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016643; Kennard JA, 2012, PHYSIOL BEHAV, V106, P423, DOI 10.1016/j.physbeh.2012.02.023; Leasure JL, 2008, NEUROSCIENCE, V156, P456, DOI 10.1016/j.neuroscience.2008.07.041; Lee MY, 2013, NEUROSCI LETT, V533, P7, DOI 10.1016/j.neulet.2012.11.041; Lin W, 2017, CELL TRANSPLANT, V26, P1798, DOI 10.1177/0963689717728936; Livingston-Thomas J, 2016, NEUROTHERAPEUTICS, V13, P395, DOI 10.1007/s13311-016-0423-9; Lohse K, 2016, ARCH PHYS MED REHAB, V97, P1423, DOI 10.1016/j.apmr.2016.03.021; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Moraska A, 2000, AM J PHYSIOL-REG I, V279, pR1321, DOI 10.1152/ajpregu.2000.279.4.R1321; Neves RVP, 2016, ARQ BRAS CARDIOL, V106, P201, DOI 10.5935/abc.20160019; Peng CW, 2011, J MED BIOL ENG, V31, P1, DOI 10.5405/jmbe.718; Pin-Barre C, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/608581; Pin-Barre C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089953; Ploughman M, 2005, NEUROSCIENCE, V136, P991, DOI 10.1016/j.neuroscience.2005.08.037; Ploughman M, 2007, BRAIN RES, V1150, P207, DOI 10.1016/j.brainres.2007.02.065; Schaaf MJM, 1998, BRAIN RES, V813, P112, DOI 10.1016/S0006-8993(98)01010-5; Smith HK, 2015, J NEUROSCI METH, V249, P99, DOI 10.1016/j.jneumeth.2015.04.008; Soya H, 2007, BIOCHEM BIOPH RES CO, V358, P961, DOI 10.1016/j.bbrc.2007.04.173; Stoller O, 2015, J NEUROL PHYS THER, V39, P156, DOI 10.1097/NPT.0000000000000095; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tang L, 2016, CALCIFIED TISSUE INT, V98, P85, DOI 10.1007/s00223-015-0063-9; Udoekwere UI, 2016, J NEUROSCI, V36, P8341, DOI 10.1523/JNEUROSCI.2435-14.2016; Vilela TC, 2018, EXP GERONTOL, V106, P21, DOI 10.1016/j.exger.2018.02.014; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Wang RY, 2001, BRAIN RES, V922, P140, DOI 10.1016/S0006-8993(01)03154-7; Waters RP, 2008, PHYSIOL BEHAV, V93, P1044, DOI 10.1016/j.physbeh.2008.01.013; Yang YR, 2003, CAN J NEUROL SCI, V30, P252, DOI 10.1017/S0317167100002687; Zhao S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25475-9; Zheng HQ, 2014, INT J MOL SCI, V15, P10974, DOI 10.3390/ijms150610974; Zhu J, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008389; Zille M, 2012, J CEREBR BLOOD F MET, V32, P213, DOI 10.1038/jcbfm.2011.150	44	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2019	14	10							e0223820	10.1371/journal.pone.0223820	http://dx.doi.org/10.1371/journal.pone.0223820			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD9CM	31603928	Green Published, gold			2023-01-03	WOS:000508159300001
J	Swider, K; Babel, P; Wronka, E; van Rijn, CM; Oosterman, JM				Swider, Karolina; Babel, Przemyslaw; Wronka, Eligiusz; van Rijn, Clementina M.; Oosterman, Joukje M.			Placebo analgesia induced by verbal suggestion in the context of experimentally induced fear and anxiety	PLOS ONE			English	Article							MOVEMENT-RELATED PAIN; NOCEBO HYPERALGESIA; INDUCED EXPECTATIONS; RESPONSE EXPECTANCY; BACK-PAIN; FMRI; ACQUISITION; MECHANISMS; EXPERIENCE; AVOIDANCE	The role of state anxiety and state fear in placebo effects is still to be determined. We aimed to investigate the effect of fear of movement-related pain (FMRP) and contextual pain related anxiety (CPRA) on the magnitude of placebo analgesia induced by verbal suggestion. Fifty-six female participants completed a modified voluntary joystick movement paradigm (VJMP) where half participated in a predictable pain condition (PC), in which one of the joystick movements is always followed by pain and the other movement is never followed by pain, and half in an unpredictable pain condition (UC), in which pain was delivered unpredictably. By varying the level of pain predictability, FMRP and CPRA were induced in PC and UC respectively. Colour stimuli were presented at the beginning of each trail. Half of the participants were verbally informed that the green or red colour indicated less painful stimuli (experimental groups), the other half did not receive any suggestion (control groups). We measured self-reported pain intensity, expectancy of pain intensity (PC only), pain related fear and anxiety (eyeblink startle response and self-ratings) and avoidance behaviour (movement-onset latency and duration). The results indicate that the placebo effect was successfully induced in both experimental conditions. In the PC, the placebo effect was predicted by expectancy. Despite the fact that FMRP and CPRA were successfully induced, no difference was found in the magnitude of the placebo effect between PC and UC. Concluding, we did not find a divergent effect of fear and anxiety on placebo analgesia.	[Swider, Karolina; van Rijn, Clementina M.; Oosterman, Joukje M.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands; [Swider, Karolina; Babel, Przemyslaw] Jagiellonian Univ, Pain Res Grp, Inst Psychol, Krakow, Poland; [Wronka, Eligiusz] Jagiellonian Univ, Inst Psychol, Krakow, Poland	Radboud University Nijmegen; Jagiellonian University; Jagiellonian University	Swider, K (corresponding author), Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands.; Swider, K (corresponding author), Jagiellonian Univ, Pain Res Grp, Inst Psychol, Krakow, Poland.	swider.karolina.joanna@gmail.com	van Rijn, Clementina/D-5828-2012; Oosterman, Joukje/D-6125-2012	Oosterman, Joukje/0000-0003-0549-8832	National Science Centre in Poland (Narodowe Centrum Nauki - NCN) [2013/09/N/HS6/02947]; Radboud Fellowship Programme, Donders Centre for Cognition, Radboud University, Nijmegen, The Netherlands	National Science Centre in Poland (Narodowe Centrum Nauki - NCN); Radboud Fellowship Programme, Donders Centre for Cognition, Radboud University, Nijmegen, The Netherlands(Netherlands Government)	This work is the result of research project no. 2013/09/N/HS6/02947, funded by the National Science Centre in Poland (Narodowe Centrum Nauki - NCN) and Radboud Fellowship Programme, Donders Centre for Cognition, Radboud University, Nijmegen, The Netherlands. The funder had no role in the study design, data collection nor analysis, decision to publish, or preparation of the manuscript	Amanzio M, 1999, J NEUROSCI, V19, P484, DOI 10.1523/JNEUROSCI.19-01-00484.1999; Anxiety Rachman S., 2004, ANXIETY, P1; Aslaksen PM, 2008, PSYCHOSOM MED, V70, P811, DOI 10.1097/PSY.0b013e31818105ed; Babel P, 2008, STUD PSYCHOL, V46, P13; Babel P, 2018, PAIN MED, V19, P1156, DOI 10.1093/pm/pnx177; Babel P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181856; Blumenthal TD, 2005, PSYCHOPHYSIOLOGY, V42, P1, DOI 10.1111/j.1469-8986.2005.00271.x; Buchel C, 2014, NEURON, V81, P1223, DOI 10.1016/j.neuron.2014.02.042; Buer N, 2002, PAIN, V99, P485, DOI 10.1016/S0304-3959(02)00265-8; Colagiuri B, 2015, J PAIN, V16, P995, DOI 10.1016/j.jpain.2015.06.012; Colloca L, 2011, PHILOS T R SOC B, V366, P1859, DOI 10.1098/rstb.2010.0398; Colloca L, 2009, PAIN, V144, P28, DOI 10.1016/j.pain.2009.01.033; Crombez G, 1999, PAIN, V80, P329, DOI 10.1016/S0304-3959(98)00229-2; deJong PJ, 1996, INT J BEHAV MED, V3, P14, DOI 10.1207/s15327558ijbm0301_2; Eippert F, 2009, NEURON, V63, P533, DOI 10.1016/j.neuron.2009.07.014; Evans FJ, 1977, PSYCHIAT AREAS PROMI, P249; Freeman S, 2015, NEUROIMAGE, V112, P197, DOI 10.1016/j.neuroimage.2015.03.015; Grillon C, 2008, PSYCHOPHARMACOLOGY, V199, P421, DOI 10.1007/s00213-007-1019-1; Helsen K, 2011, J PAIN, V12, P1230, DOI 10.1016/j.jpain.2011.07.002; Hubbard CS, 2011, PAIN, V152, P1632, DOI 10.1016/j.pain.2011.03.001; Kirsch I, 1997, APPL PREV PSYCHOL, V6, P69, DOI 10.1016/S0962-1849(05)80012-5; KIRSCH I, 1985, AM PSYCHOL, V40, P1189, DOI 10.1037/0003-066X.40.11.1189; Kirsch Irving, 2014, Psychol Conscious (Wash D C), V1, P51; Lachaud CM, 2011, APPL PSYCHOLINGUIST, V32, P389, DOI 10.1017/S0142716410000457; Lyby PS, 2012, PAIN, V153, P1114, DOI 10.1016/j.pain.2012.02.042; McCracken LM, 2007, PAIN, V130, P119, DOI 10.1016/j.pain.2006.11.016; MCGLASHA.TH, 1969, PSYCHOSOM MED, V31, P227, DOI 10.1097/00006842-196905000-00003; Meulders A, 2014, J PAIN, V15, P632, DOI 10.1016/j.jpain.2014.02.009; Meulders A, 2013, J PAIN, V14, P412, DOI 10.1016/j.jpain.2012.12.014; Meulders A, 2012, PAIN, V153, P1504, DOI 10.1016/j.pain.2012.04.013; Meulders A, 2012, PAIN, V153, P1030, DOI 10.1016/j.pain.2012.02.005; Meulders A, 2011, PAIN, V152, P2460, DOI 10.1016/j.pain.2011.05.015; Miller FG, 2010, PERSPECT BIOL MED, V53, P509, DOI 10.1353/pbm.2010.0004; Montgomery GH, 1997, PAIN, V72, P107, DOI 10.1016/S0304-3959(97)00016-X; Oka S, 2010, J PAIN, V11, P239, DOI 10.1016/j.jpain.2009.07.009; Olsson A, 2007, NAT NEUROSCI, V10, P1095, DOI 10.1038/nn1968; Perusini JN, 2015, LEARN MEMORY, V22, P417, DOI 10.1101/lm.039180.115; Petrovic P, 2005, NEURON, V46, P957, DOI 10.1016/j.neuron.2005.05.023; Piedimonte A, 2017, EUR J PAIN, V21, P874, DOI 10.1002/ejp.990; Price DD, 1999, PAIN, V83, P147, DOI 10.1016/S0304-3959(99)00081-0; Rhudy JL, 2000, PAIN, V84, P65, DOI 10.1016/S0304-3959(99)00183-9; Schmid J, 2015, NEUROIMAGE, V120, P114, DOI 10.1016/j.neuroimage.2015.06.060; Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34; Scott DJ, 2007, NEURON, V55, P325, DOI 10.1016/j.neuron.2007.06.028; Spielberger CD, 1988, HDB ANXIETY, P31; Stewart-Williams S, 2004, PSYCHOL BULL, V130, P324, DOI 10.1037/0033-2909.130.2.324; Swider K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158363; Swider K, 2013, PAIN, V154, P1312, DOI 10.1016/j.pain.2013.04.001; Sylvers P, 2011, CLIN PSYCHOL REV, V31, P122, DOI 10.1016/j.cpr.2010.08.004; Tracey I, 2010, NAT MED, V16, P1277, DOI 10.1038/nm.2229; Vase L, 2005, PAIN, V115, P338, DOI 10.1016/j.pain.2005.03.014; Vase L, 2003, PAIN, V105, P17, DOI 10.1016/S0304-3959(03)00073-3; VOUDOURIS NJ, 1985, J PERS SOC PSYCHOL, V48, P47, DOI 10.1037/0022-3514.48.1.47; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Wager TD, 2013, NEW ENGL J MED, V368, P1388, DOI 10.1056/NEJMoa1204471; Walker DL, 2003, EUR J PHARMACOL, V463, P199, DOI 10.1016/S0014-2999(03)01282-2	56	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2019	14	9							e0222805	10.1371/journal.pone.0222805	http://dx.doi.org/10.1371/journal.pone.0222805			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM5RZ	31550290	Green Published, gold			2023-01-03	WOS:000532307700025
J	Kaszeta, D				Kaszeta, Dan			Restrict use of riot-control chemicals	NATURE			English	Editorial Material							CS		[Kaszeta, Dan] Strongpoint Secur London, London, England		Kaszeta, D (corresponding author), Strongpoint Secur London, London, England.	director@strongpointsecurity.co.uk						Clarot F, 2003, FORENSIC SCI INT, V137, P45, DOI 10.1016/S0379-0738(03)00282-2; JONES GRN, 1972, NATURE, V235, P257, DOI 10.1038/235257a0; Kluchinsky TA, 2001, J MICROCOLUMN SEP, V13, P186, DOI 10.1002/mcs.1040; MacIntosh AR, 2019, APPL ERGON, V75, P178, DOI 10.1016/j.apergo.2018.10.004; National Research Council, 2014, AC EXP GUID LEV SEL, V16; [No title captured]; [No title captured]	7	2	2	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 5	2019	573	7772					27	29		10.1038/d41586-019-02594-5	http://dx.doi.org/10.1038/d41586-019-02594-5			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IV0KI	31481785				2023-01-03	WOS:000483967700019
J	Freedberg, M; Reeves, JA; Hussain, SJ; Zaghloul, KA; Wassermann, EM				Freedberg, Michael; Reeves, Jack A.; Hussain, Sara J.; Zaghloul, Kareem A.; Wassermann, Eric M.			Identifying site- and stimulation-specific TMS-evoked EEG potentials using a quantitative cosine similarity metric	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; CORTICAL EFFECTIVE CONNECTIVITY; INDEPENDENT COMPONENT ANALYSIS; CORTEX; OSCILLATIONS; EXCITABILITY; RELIABILITY; PERFORMANCE; INHIBITION; BREAKDOWN	The ability to interpret transcranial magnetic stimulation (TMS)-evoked electroencephalography (EEG) potentials (TEPs) is limited by artifacts, such as auditory evoked responses produced by discharge of the TMS coil. TEPs generated from direct cortical stimulation should vary in their topographical activity pattern according to stimulation site and differ from responses to sham stimulation. Responses that do not show these effects are likely to be artifactual. In 20 healthy volunteers, we delivered active and sham TMS to the right prefrontal, left primary motor, and left posterior parietal cortex and compared the waveform similarity of TEPs between stimulation sites and active and sham TMS using a cosine similarity-based analysis method. We identified epochs after the stimulus when the spatial pattern of TMS-evoked activation showed greater than random similarity between stimulation sites and sham vs. active TMS, indicating the presence of a dominant artifact. To do this, we binarized the derivatives of the TEPs recorded from 30 EEG channels and calculated cosine similarity between conditions at each time point with millisecond resolution. Only TEP components occurring before approximately 80 ms differed across stimulation sites and between active and sham, indicating site and condition-specific responses. We therefore conclude that, in the absence of noise masking or other measures to decrease neural artifact, TEP components before about 80 ms can be safely interpreted as stimulation location-specific responses to TMS, but components beyond this latency should be interpreted with caution due to high similarity in their topographical activity pattern.	[Freedberg, Michael; Reeves, Jack A.; Wassermann, Eric M.] NINDS, Behav Neurol Unit, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Freedberg, Michael] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD 20817 USA; [Hussain, Sara J.] NINDS, Human Cort Physiol & Neurorehabil Sect, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Zaghloul, Kareem A.] NINDS, Funct & Restorat Neurosurg Unit, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Freedberg, M (corresponding author), NINDS, Behav Neurol Unit, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.; Freedberg, M (corresponding author), Henry M Jackson Fdn Adv Mil Med, Bethesda, MD 20817 USA.	michael.freedberg@nih.gov	Zaghloul, Kareem/AAV-4208-2020	Freedberg, Michael/0000-0003-3738-8259				Belardinelli P, 2019, BRAIN STIMUL, V12, P787, DOI 10.1016/j.brs.2019.01.010; Bortoletto M, 2015, NEUROSCI BIOBEHAV R, V49, P114, DOI 10.1016/j.neubiorev.2014.12.014; Brockhardt, 2011, TMS MOTOR THRESHOLD; Bruckmann S, 2012, BRAIN, V135, P2215, DOI 10.1093/brain/aws071; Conde V, 2019, NEUROIMAGE, V185, P300, DOI 10.1016/j.neuroimage.2018.10.052; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Darmani G, 2016, J NEUROSCI, V36, P12312, DOI 10.1523/JNEUROSCI.1689-16.2016; Du XM, 2017, EXP BRAIN RES, V235, P69, DOI 10.1007/s00221-016-4773-7; Ferrarelli F, 2010, P NATL ACAD SCI USA, V107, P2681, DOI 10.1073/pnas.0913008107; Ferreri F, 2016, HUM BRAIN MAPP, V37, P2083, DOI 10.1002/hbm.23158; Foxe JJ, 2002, J NEUROPHYSIOL, V88, P540, DOI 10.1152/jn.2002.88.1.540; Frantseva M, 2014, CEREB CORTEX, V24, P211, DOI 10.1093/cercor/bhs304; Furnham A, 2002, ERGONOMICS, V45, P203, DOI 10.1080/00140130210121932; Garcia JO, 2011, J NEUROPHYSIOL, V106, P1734, DOI 10.1152/jn.00739.2010; Hallgren Kevin A, 2012, Tutor Quant Methods Psychol, V8, P23; Harquel S, 2016, NEUROIMAGE, V135, P115, DOI 10.1016/j.neuroimage.2016.05.009; Herring JD, 2015, J NEUROSCI, V35, P14435, DOI 10.1523/JNEUROSCI.1833-15.2015; Herweg NA, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01639; HJORTH B, 1975, ELECTROEN CLIN NEURO, V39, P526, DOI 10.1016/0013-4694(75)90056-5; Hyvarinen A, 2000, NEURAL NETWORKS, V13, P411, DOI 10.1016/S0893-6080(00)00026-5; Kerwin LJ, 2018, BRAIN STIMUL, V11, P536, DOI 10.1016/j.brs.2017.12.010; Koch G, 2013, J NEUROSCI, V33, P9725, DOI 10.1523/JNEUROSCI.4988-12.2013; Lioumis P, 2009, HUM BRAIN MAPP, V30, P1387, DOI 10.1002/hbm.20608; Maris E, 2007, J NEUROSCI METH, V164, P177, DOI 10.1016/j.jneumeth.2007.03.024; Massimini M, 2005, SCIENCE, V309, P2228, DOI 10.1126/science.1117256; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Michel CM, 2004, CLIN NEUROPHYSIOL, V115, P2195, DOI 10.1016/j.clinph.2004.06.001; MILLS KR, 1992, ELECTROEN CLIN NEURO, V85, P17, DOI 10.1016/0168-5597(92)90096-T; Molholm S, 2002, COGNITIVE BRAIN RES, V14, P115, DOI 10.1016/S0926-6410(02)00066-6; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; Nikouline V, 1999, CLIN NEUROPHYSIOL, V110, P1325, DOI 10.1016/S1388-2457(99)00070-X; Poldrack RA, 2001, NATURE, V414, P546, DOI 10.1038/35107080; Rogasch NC, 2017, NEUROIMAGE, V147, P934, DOI 10.1016/j.neuroimage.2016.10.031; Rogasch NC, 2015, CORTEX, V64, P68, DOI 10.1016/j.cortex.2014.10.003; Rogasch NC, 2014, NEUROIMAGE, V101, P425, DOI 10.1016/j.neuroimage.2014.07.037; Rosanova M, 2009, J NEUROSCI, V29, P7679, DOI 10.1523/JNEUROSCI.0445-09.2009; SALTON G, 1975, COMMUN ACM, V18, P613, DOI 10.1145/361219.361220; Siebner HR, 2019, BRAIN STIMUL, V12, P1051, DOI 10.1016/j.brs.2019.03.076; Soderlund GBW, 2016, FRONT PSYCHOL, V7, DOI [10.3389/FPSYG.2016.00007, DOI 10.3389/FPSYG.2016.00007]; Spiegler A, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0068-16.2016; Stam C. J., 2006, NONLINEAR BRAIN DYNA; ter Braack EM, 2015, BRAIN TOPOGR, V28, P520, DOI 10.1007/s10548-013-0312-z; Yaffe RB, 2014, P NATL ACAD SCI USA, V111, P18727, DOI 10.1073/pnas.1417017112	43	16	16	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2020	15	1							e0216185	10.1371/journal.pone.0216185	http://dx.doi.org/10.1371/journal.pone.0216185			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5IZ	31929531	Green Published, Green Submitted, gold			2023-01-03	WOS:000534352500001
J	Finkelstein, A; Zhou, A; Taubman, S; Doyle, J				Finkelstein, Amy; Zhou, Annetta; Taubman, Sarah; Doyle, Joseph			Health Care Hotspotting - A Randomized, Controlled Trial	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSITIONS INTERVENTION; HIGH-NEED; PROGRAM	Background There is widespread interest in programs aiming to reduce spending and improve health care quality among "superutilizers," patients with very high use of health care services. The "hotspotting" program created by the Camden Coalition of Healthcare Providers (hereafter, the Coalition) has received national attention as a promising superutilizer intervention and has been expanded to cities around the country. In the months after hospital discharge, a team of nurses, social workers, and community health workers visits enrolled patients to coordinate outpatient care and link them with social services. Methods We randomly assigned 800 hospitalized patients with medically and socially complex conditions, all with at least one additional hospitalization in the preceding 6 months, to the Coalition's care-transition program or to usual care. The primary outcome was hospital readmission within 180 days after discharge. Results The 180-day readmission rate was 62.3% in the intervention group and 61.7% in the control group. The adjusted between-group difference was not significant (0.82 percentage points; 95% confidence interval, -5.97 to 7.61). In contrast, a comparison of the intervention-group admissions during the 6 months before and after enrollment misleadingly suggested a 38-percentage-point decline in admissions related to the intervention because the comparison did not account for the similar decline in the control group. Conclusions In this randomized, controlled trial involving patients with very high use of health care services, readmission rates were not lower among patients randomly assigned to the Coalition's program than among those who received usual care. (Funded by the National Institute on Aging and others; ClinicalTrials.gov number, ; American Economic Association registry number, AEARCTR-0000329.)	[Finkelstein, Amy; Doyle, Joseph] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Zhou, Annetta; Taubman, Sarah] Natl Bur Econ Res, Cambridge, MA 02138 USA	Massachusetts Institute of Technology (MIT); National Bureau of Economic Research	Finkelstein, A (corresponding author), MIT, Dept Econ, 50 Mem Dr, Cambridge, MA 02142 USA.	afink@mit.edu			National Institute on Aging of the National Institutes of Health [R01AGO49897]; Sloan School of Management of the Massachusetts Institute of Technology	National Institute on Aging of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Sloan School of Management of the Massachusetts Institute of Technology	Supported by the National Institute on Aging of the National Institutes of Health under award number R01AGO49897; the Health Care Delivery Initiative of. 1 -PAL North America; and the Sloan School of Management of the Massachusetts Institute of Technology.	Allen Arthur, 2017, POLITICO; Anderson GF, 2015, AM J MANAG CARE, V21, pE597; [Anonymous], HLTH CAR INN AW CAL; [Anonymous], 2014, LIF LOURD CEL 5 YEAR; [Anonymous], 2012, EXPANDING HOT SPOTTI; [Anonymous], 2016, INSIDE COOPER   0717; [Anonymous], HLTH CAR INN AW NEW; [Anonymous], CARE COORD CONS; [Anonymous], CARE COORD; Blumenthal SJ, 2016, HUFFINGTON POST; Boerner H., 2017, WASHINGTON MONTHLY; Boodman SG, 2013, WASHINGTON POST; Cardiovascular Disease and Risk Management, 2019, DIABETES CARE, V2, pS103, DOI 10.2337/dc19-S010; Cohen GA, 2014, LECTURES ON THE HISTORY OF MORAL AND POLITICAL PHILOSOPHY, P120; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Crippen D, 2013, HLTH AFFAIRS BLOG; Figueroa JF, 2019, HEALTH AFFAIR, V38, P107, DOI 10.1377/hlthaff.2018.05160; Figueroa JF, 2018, ANN INTERN MED, V169, P528, DOI 10.7326/M18-0085; Gawande A. A., 2011, PERSONAL BEST; Gilman B, 2014, EVALUATION HLTH CARE; Gorenstein D., 2013, MARKETPLACE      SUM; Green SR, 2010, HOPE NEW JERSEYS CIT, V7, p1d; Grinberg Charlotte, 2016, Popul Health Manag, V19, P248, DOI 10.1089/pop.2015.0097; Holahan J, 2011, POTENTIAL SAVINGS EN; Hong C.S., 2014, CARING HIGH NEED HIG; Johnson TL, 2015, HEALTH AFFAIR, V34, P1312, DOI 10.1377/hlthaff.2014.1186; Joynt KE, 2013, JAMA-J AM MED ASSOC, V309, P2572, DOI 10.1001/jama.2013.7103; Kangovi S, 2018, JAMA INTERN MED, V178, P1635, DOI 10.1001/jamainternmed.2018.4630; Katz MH, 2017, JAMA INTERN MED, V177, P162, DOI 10.1001/jamainternmed.2016.8433; Leiby Richard., 2013, WASHINGTON POST; Lynch CS, 2016, J GEN INTERN MED, V31, P797, DOI 10.1007/s11606-016-3598-1; Mann C., 2013, TARGETING MEDICAID S; Milstein A, 2009, HLTH AFFAIRS BLOG; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; Naylor MD, 2011, HEALTH AFFAIR, V30, P746, DOI 10.1377/hlthaff.2011.0041; Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Noonan K, 2019, CAMDEN COALITION HOT; Parry Carla, 2009, Home Health Care Serv Q, V28, P84, DOI 10.1080/01621420903155924; Peikes D, 2009, JAMA-J AM MED ASSOC, V301, P603, DOI 10.1001/jama.2009.126; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Sevak Purvi, 2018, Am J Manag Care, V24, pe365; US Census Bureau, 2017, AM COMMUNITY SURVEY; Vaida B, 2017, HEALTH AFFAIR, V36, P394, DOI 10.1377/hlthaff.2017.0112; WEINTRAUB K, 2017, ATLANTIC; White IR, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d40; Zulman DM, 2017, JAMA INTERN MED, V177, P166, DOI 10.1001/jamainternmed.2016.8021	47	153	151	2	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 9	2020	382	2					152	162		10.1056/NEJMsa1906848	http://dx.doi.org/10.1056/NEJMsa1906848			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KB6CS	31914242	Bronze, Green Published, Green Accepted			2023-01-03	WOS:000506581500013
J	Barroso, J; Wakaizumi, K; Reckziegel, D; Pinto-Ramos, J; Schnitzer, T; Galhardo, V; Apkarian, AV				Barroso, Joana; Wakaizumi, Kenta; Reckziegel, Diane; Pinto-Ramos, Joao; Schnitzer, Thomas; Galhardo, Vasco; Apkarian, A. Vania			Prognostics for pain in osteoarthritis: Do clinical measures predict pain after total joint replacement?	PLOS ONE			English	Article							POSTOPERATIVE PAIN; KNEE ARTHROPLASTY; TOTAL HIP; RADIOGRAPHIC SEVERITY; QUESTIONNAIRE; VALIDITY; OUTCOMES; UPDATE; IMPACT; TESTS	A significant proportion of osteoarthritis (OA) patients continue to experience moderate to severe pain after total joint replacement (TJR). Preoperative factors related to pain persistence are mainly studied using individual predictor variables and distinct pain outcomes, thus leading to a lack of consensus regarding the influence of preoperative parameters on post-TJR pain. In this prospective observational study, we evaluated knee and hip OA patients before, 3 and 6 months post-TJR searching for clinical predictors of pain persistence. We assessed multiple measures of quality, mood, affect, health and quality of life, together with radiographic evaluation and performance-based tasks, modeling four distinct pain outcomes. Multivariate regression models and network analysis were applied to pain related biopsychosocial measures and their changes with surgery. A total of 106 patients completed the study. Pre-surgical pain levels were not related to post-surgical residual pain. Although distinct pain scales were associated with different aspects of post-surgical pain, multi-factorial models did not reliably predict post-surgical pain in knee OA (across four distinct pain scales) and did not generalize to hip OA. However, network analysis showed significant changes in biopsychosocial-defined OA personality post-surgery, in both groups. Our results show that although tested clinical and biopsychosocial variables reorganize after TJR in OA, their presurgical values are not predictive of post-surgery pain. Derivation of prognostic markers for pain persistence after TJR will require more comprehensive understanding of underlying mechanisms.	[Barroso, Joana; Galhardo, Vasco] Univ Porto, Dept Biomed, Fac Med, Porto, Portugal; [Barroso, Joana; Galhardo, Vasco] Univ Porto, Inst Invest & Inovacao Saude I3S, Porto, Portugal; [Barroso, Joana; Wakaizumi, Kenta; Schnitzer, Thomas; Apkarian, A. Vania] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Barroso, Joana; Reckziegel, Diane; Apkarian, A. Vania] Northwestern Univ, Dept Physiol, Feinberg Sch Med, Chicago, IL 60611 USA; [Wakaizumi, Kenta] Shirley Ryan Abil Lab, Chicago, IL USA; [Pinto-Ramos, Joao] Ctr Hosp & Univ Sao Joao, Dept Med Fis & Reabilitacao, Porto, Portugal; [Schnitzer, Thomas] Northwestern Univ, Dept Rheumatol, Feinberg Sch Med, Chicago, IL 60611 USA	Universidade do Porto; Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Apkarian, AV (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA.; Apkarian, AV (corresponding author), Northwestern Univ, Dept Physiol, Feinberg Sch Med, Chicago, IL 60611 USA.	a-apkarian@northwestern.edu	Wakaizumi, Kenta/AAM-5030-2021; Ramos, João/GSM-7241-2022	Wakaizumi, Kenta/0000-0003-4884-6251; Apkarian, A. Vania/0000-0002-9788-7458; Monteiro, Joana/0000-0002-7826-5354	CCDRN [Norte-08-5369-FSE-000026]; OARSI Collaborative Scholarship 2018; Luso-American Development Foundation R&D@PhD scholarship grant	CCDRN; OARSI Collaborative Scholarship 2018; Luso-American Development Foundation R&D@PhD scholarship grant	J.B. was funded through CCDRN [Norte-08-5369-FSE-000026], OARSI Collaborative Scholarship 2018 and Luso-American Development Foundation R&D@PhD scholarship grant. This research did not receive other specific funding from agencies in the public or commercial sectors.	Azevedo LF, 2007, DOR, V15, P6; Bachmeier CJM, 2001, OSTEOARTHR CARTILAGE, V9, P137, DOI 10.1053/joca.2000.0369; Baert IAC, 2016, OSTEOARTHR CARTILAGE, V24, P213, DOI 10.1016/j.joca.2015.09.002; Baliki MN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106133; Baliki MN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026010; BALKE B, 1963, Rep Civ Aeromed Res Inst US, P1; Beswick AD, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000435; Bouhassira D, 2005, PAIN, V114, P29, DOI 10.1016/j.pain.2004.12.010; BYRNE M, 1982, PAIN, V13, P193, DOI 10.1016/0304-3959(82)90029-X; Creamer P, 1999, J RHEUMATOL, V26, P1785; Dabare C, 2017, INT J RHEUM DIS, V20, P1350, DOI 10.1111/1756-185X.13083; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; Dobson F, 2013, OSTEOARTHR CARTILAGE, V21, P1042, DOI 10.1016/j.joca.2013.05.002; Erlenwein J, 2017, J PAIN RES, V10, P2183, DOI 10.2147/JPR.S137892; Ferreira P L, 2000, Acta Med Port, V13, P55; Finan PH, 2013, ARTHRITIS RHEUM-US, V65, P363, DOI 10.1002/art.34646; Forsythe ME, 2008, PAIN RES MANAG, V13, P335, DOI 10.1155/2008/730951; Goncalves RS, 2009, OSTEOARTHR CARTILAGE, V17, P1156, DOI 10.1016/j.joca.2009.01.009; Harden RN, 2005, J PAIN, V6, P364, DOI 10.1016/j.jpain.2005.01.350; Harmelink KEM, 2017, J ARTHROPLASTY, V32, P3840, DOI 10.1016/j.arth.2017.07.011; Hochman JR, 2011, OSTEOARTHR CARTILAGE, V19, P647, DOI 10.1016/j.joca.2011.03.007; Keller S, 2004, CLIN J PAIN, V20, P309, DOI 10.1097/00002508-200409000-00005; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Kennedy DM, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-3; Kim DH, 2018, J ARTHROPLASTY, V33, P3372, DOI 10.1016/j.arth.2018.07.028; Leung YY, 2019, OSTEOARTHR CARTILAGE, V27, P49, DOI 10.1016/j.joca.2018.09.003; Lewis GN, 2015, BRIT J ANAESTH, V114, P551, DOI 10.1093/bja/aeu441; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Neogi T, 2013, OSTEOARTHR CARTILAGE, V21, P1145, DOI 10.1016/j.joca.2013.03.018; Nilsdotter AK, 2003, BMC MUSCULOSKEL DIS, V4, DOI 10.1186/1471-2474-4-10; Pais-Ribeiro J, 2007, Psychol Health Med, V12, P225, DOI 10.1080/13548500500524088; Petersen KK, 2016, PAIN, V157, P1400, DOI 10.1097/j.pain.0000000000000531; Petersen KK, 2015, PAIN, V156, P55, DOI 10.1016/j.pain.0000000000000022; Pinto PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073917; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; REJESKI WJ, 1995, OSTEOARTHR CARTILAGE, V3, P157, DOI 10.1016/S1063-4584(05)80050-0; Roos Ewa M, 2003, Health Qual Life Outcomes, V1, P64, DOI 10.1186/1477-7525-1-64; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Singh JA, 2008, CLIN ORTHOP RELAT R, V466, P2717, DOI 10.1007/s11999-008-0399-9; Sullivan M, 2011, PAIN, V152, P2287, DOI 10.1016/j.pain.2011.06.014; Sullivan MJL, 1995, PSYCHOL ASSESSMENT, V7, P524, DOI 10.1037/1040-3590.7.4.524; Valdes AM, 2012, SEMIN ARTHRITIS RHEU, V41, P568, DOI 10.1016/j.semarthrit.2011.07.002; Vissers MM, 2012, SEMIN ARTHRITIS RHEU, V41, P576, DOI 10.1016/j.semarthrit.2011.07.003; Werner MU, 2014, BRIT J ANAESTH, V113, P1, DOI 10.1093/bja/aeu012; Wylde V, 2012, MUSCULOSKELET CARE, V10, P110, DOI 10.1002/msc.1008; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zuo XN, 2019, NAT HUM BEHAV, V3, P768, DOI 10.1038/s41562-019-0655-x	48	9	11	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2020	15	1							e0222370	10.1371/journal.pone.0222370	http://dx.doi.org/10.1371/journal.pone.0222370			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5DK	31914126	Green Published, Green Submitted, gold			2023-01-03	WOS:000534337700004
J	Sall, J; Eapen, BC; Tran, JE; Bowles, AO; Bursaw, A; Rodgers, ME				Sall, James; Eapen, Blessen C.; Tran, Johanna Elizabeth; Bowles, Amy O.; Bursaw, Andrew; Rodgers, M. Eric			The Management of Stroke Rehabilitation: A Synopsis of the 2019 US Department of Veterans Affairs and US Department of Defense Clinical Practice Guideline	ANNALS OF INTERNAL MEDICINE			English	Article							NEUROMUSCULAR ELECTRICAL-STIMULATION; UPPER-EXTREMITY; CONTROLLED-TRIAL; DEPRESSION; THERAPY; RECOMMENDATIONS; METAANALYSIS; EFFICACY; OUTCOMES	Description: In June 2019, the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) approved an update of the joint clinical practice guideline for rehabilitation after stroke. This synopsis summarizes the key recommendations from this guideline. Methods: In February 2018, the VA/DoD Evidence-Based Practice Work Group convened a joint VA/DoD guideline development effort that included clinical stakeholders and stroke survivors and conformed to the National Academy of Medicine (formerly the Institute of Medicine) tenets for trustworthy clinical practice guidelines. The guideline panel identified key questions, systematically searched and evaluated the literature, and developed 2 algorithms and 42 key recommendations using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Stroke survivors and their family members were invited to share their perspectives to further inform guideline development. Recommendations: The guideline recommendations provide evidence-based guidance for the rehabilitation care of patients after stroke. The recommendations are applicable to health care providers in both primary care and rehabilitation. Key features of the guideline are recommendations in 6 areas: timing and approach; motor therapy; dysphagia; cognitive, speech, and sensory therapy; mental health therapy; and other functions, such as returning to work and driving.	[Sall, James; Tran, Johanna Elizabeth; Rodgers, M. Eric] Dept Vet Affairs, 811 Vermont Ave NW, Los Angeles, CA 20420 USA; [Eapen, Blessen C.] VA Greater Los Angeles Hlth Care Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA; [Bowles, Amy O.] Brooke Army Med Ctr, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA; [Bursaw, Andrew] US Air Force Acad, Gen & Vasc Neurol, LtCol US Air Force Med Corps, Colorado Springs, CO USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; San Antonio Military Medical Center; United States Department of Defense; United States Army; United States Department of Defense; United States Air Force; United States Air Force Academy	Sall, J (corresponding author), Dept Vet Affairs, 811 Vermont Ave NW, Los Angeles, CA 20420 USA.			Tran, Johanna/0000-0001-6231-5620	Department of Veterans Affairs	Department of Veterans Affairs(US Department of Veterans Affairs)	By the Department of Veterans Affairs.	Aben L, 2014, NEUROREHAB NEURAL RE, V28, P199, DOI 10.1177/1545968313478487; Agency for Healthcare Research and Quality, 2012, AHRQ PUBLICATION, V12-EC017; Ambrosini E, 2011, STROKE, V42, P1068, DOI 10.1161/STROKEAHA.110.599068; Andrews J, 2013, J CLIN EPIDEMIOL, V66, P719, DOI 10.1016/j.jclinepi.2012.03.013; Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003; Asadollahi M, 2018, CLIN REHABIL, V32, P1069, DOI 10.1177/0269215518777791; Ayerbe L, 2013, BRIT J PSYCHIAT, V202, P14, DOI 10.1192/bjp.bp.111.107664; Beis JM, 1999, ARCH PHYS MED REHAB, V80, P71, DOI 10.1016/S0003-9993(99)90310-6; Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558; Breitenstein C, 2017, LANCET, V389, P1528, DOI 10.1016/S0140-6736(17)30067-3; CIFU DX, 1999, ARCH PHYS MED REHAB, V80, pS3; D'Anci KE, 2019, ANN INTERN MED, V171, P906, DOI 10.7326/M19-2414; das Nair R, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002293.pub3; Delamothe T, 2004, BMJ-BRIT MED J, V328, P1, DOI 10.1136/bmj.328.7430.1; Deng Linghui, 2018, Oncotarget, V9, P23718, DOI 10.18632/oncotarget.23891; Dennis M, 2019, LANCET, V393, P265, DOI 10.1016/S0140-6736(18)32823-X; FRENCH K, 2016, COCHRANE DB SYST REV, V11, DOI DOI 10.1371/JOURNAL.PONE.0169332; Gao J, 2017, CLIN REHABIL, V31, P71, DOI 10.1177/0269215515626232; Godecke E, 2012, INT J STROKE, V7, P635, DOI 10.1111/j.1747-4949.2011.00631.x; Gu SC, 2018, J STROKE CEREBROVASC, V27, P1178, DOI 10.1016/j.jstrokecerebrovasdis.2017.11.031; Hackett ML, 2014, INT J STROKE, V9, P1017, DOI 10.1111/ijs.12357; Hong ZQ, 2018, ARCH PHYS MED REHAB, V99, P1011, DOI 10.1016/j.apmr.2017.12.019; Hsu SS, 2010, STROKE, V41, P821, DOI 10.1161/STROKEAHA.109.574160; Institute of Medicine, 2011, CLIN PRACTICE GUIDEL; Knutson JS, 2016, STROKE, V47, P2596, DOI 10.1161/STROKEAHA.116.013791; Langhorne P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub3; Lin ZL, 2011, J REHABIL MED, V43, P506, DOI 10.2340/16501977-0807; Machner B, 2014, STROKE, V45, P2465, DOI 10.1161/STROKEAHA.114.006059; Masiero S, 2014, NEUROREHAB NEURAL RE, V28, P377, DOI 10.1177/1545968313513073; Maulden SA, 2005, ARCH PHYS MED REHAB, V86, pS34, DOI 10.1016/j.apmr.2005.08.119; Mehrholz J, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006876.pub3, 10.1002/14651858.CD006876.pub4]; Ng, 2016, HONG KONG MED J, V22, P33; Norouzi-Gheidari N, 2012, J REHABIL RES DEV, V49, P479, DOI 10.1682/JRRD.2010.10.0210; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; Pan XN, 2018, BRIT J PSYCHOL, V109, P395, DOI 10.1111/bjop.12290; Peng YH, 2015, J STROKE CEREBROVASC, V24, P1793, DOI 10.1016/j.jstrokecerebrovasdis.2015.04.009; Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158; Qian QY, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00447; Reinkensmeyer David J, 2012, Am J Phys Med Rehabil, V91, pS232, DOI 10.1097/PHM.0b013e31826bce79; SAUNDERS TJ, 2016, COCHRANE DB SYST REV, V3, DOI DOI 10.1098/RSOS.150710; Smith EE, 2011, STROKE, V42, P3110, DOI 10.1161/STROKEAHA.111.613208; Synhaeve NE, 2014, STROKE, V45, P1157, DOI 10.1161/STROKEAHA.113.004411; Tan ZM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/545408; VA Quality Enhancement Research Initiative (QUERI), 2014, STROKE; Wang SB, 2018, J AFFECT DISORDERS, V235, P589, DOI 10.1016/j.jad.2018.04.011; Winstein CJ, 2016, STROKE, V47, pE98, DOI 10.1161/STR.0000000000000098	46	10	12	1	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 17	2019	171	12					916	+		10.7326/M19-1695	http://dx.doi.org/10.7326/M19-1695			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB3WA	31739317				2023-01-03	WOS:000506428800018
J	Lawyer, GR; Jackson, M; Prinz, M; Lamb, T; Wang, Q; Muthumalage, T; Rahman, I				Lawyer, Gina R.; Jackson, Monica; Prinz, Melanie; Lamb, Thomas; Wang, Qixin; Muthumalage, Thivanka; Rahman, Irfan			Classification of flavors in cigarillos and little cigars and their variable cellular and acellular oxidative and cytotoxic responses	PLOS ONE			English	Article							TOBACCO PRODUCTS; E-CIGARETTES; CHEMICALS; MAINSTREAM; HOMEOSTASIS; MECHANISMS; STRESS; DAMAGE; CANDY	Flavored tobacco products are increasing in popularity but remain unregulated, with the exception of the ban on flavored conventional cigarettes. Lack of regulation of cigarillos and little cigars allows vendors to have their own version of popular flavors, each with different chemical components. A new classification system was created for flavored cigars in order to easily communicate our results with the scientific community. To understand the physicochemical characteristics of flavored little cigars and cigarillo smoke, size distribution and concentration of particulate matter in smoke were determined. Acellular reactive oxygen species generation was measured as an indirect measurement of the potential to cause oxidative stress in cells. In addition, cigarillo smoke extract treatment on bronchial epithelial (Beas-2b) cells were assessed to determine the flavor-induced cellular toxicity. Flavored cigars/cigarillos showed significant variability in the tested parameters between flavors as well as brands of the same flavor, but most of the cigars showed higher potential of generating oxidative stress, than research grade cigarettes. Flavored cigars produced maximum particle concentrations at 1.0 mu m and 4.0 mu m compared with 3R4F reference research cigarettes. A differential cytotoxic response was observed with cigarillo smoke extract treatments, with "fruits/ candy" and "drinks" being the most toxic, but were not more cytotoxic than smoke from cigarettes. These cigarillos with flavors must be well characterized for toxicity in order to prevent adverse effects caused by exposure to flavor chemicals. Our study provides insight into understanding the potential health effects of flavor-infused cigars/cigarillos and the need for the regulation of those flavoring chemicals in these products. Future research is directed to determine the flavoring toxicity of little cigars and cigarillos in vivo studies.	[Lawyer, Gina R.; Jackson, Monica; Prinz, Melanie; Lamb, Thomas; Wang, Qixin; Muthumalage, Thivanka; Rahman, Irfan] Univ Rochester, Med Ctr, Sch Med & Dent, Dept Environm Med, Rochester, NY 14642 USA	University of Rochester	Rahman, I (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Environm Med, Rochester, NY 14642 USA.	Irfan_rahman@urmc.rochester.edu	Wang, Qixin/W-2259-2019	Wang, Qixin/0000-0001-9051-8388	National Institutes of Health (NIH) [NIH 1R01HL135613, NIH 1R01HL085613]; Food and Drug Administration (FDA) Center for Tobacco Products (CTP); National Cancer Institute of the National Institutes of Health (NIH); Food and Drug Administration (FDA) Center for Tobacco Products [U54CA228110]; NATIONAL CANCER INSTITUTE [U54CA228110] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL135613, R01HL085613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007026] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food and Drug Administration (FDA) Center for Tobacco Products (CTP)(United States Department of Health & Human Services); National Cancer Institute of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Food and Drug Administration (FDA) Center for Tobacco Products; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported in part by a National Institutes of Health (NIH) Grants, NIH 1R01HL135613, NIH 1R01HL085613, and the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). Also in part was supported by the National Cancer Institute of the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) Center for Tobacco Products under Award Number U54CA228110. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen JG, 2016, ENVIRON HEALTH PERSP, V124, P733, DOI 10.1289/ehp.1510185; Baker F, 2000, JAMA-J AM MED ASSOC, V284, P735, DOI 10.1001/jama.284.6.735; Brown JE, 2014, NEW ENGL J MED, V370, P2250, DOI 10.1056/NEJMc1403015; Chang CM, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1617-5; Chen ZH, 2015, ENVIRON HEALTH PREV, V20, P318, DOI 10.1007/s12199-015-0469-z; Courtemanche CJ, 2017, AM J PREV MED, V52, pE139, DOI 10.1016/j.amepre.2016.11.019; DeVito EE, 2018, CURR NEUROPHARMACOL, V16, P438, DOI 10.2174/1570159X15666171016164430; Dickinson DM, 2016, NICOTINE TOB RES, V18, P850, DOI 10.1093/ntr/ntv285; Erythropel HC, 2018, JAMA-J AM MED ASSOC, V320, P1380, DOI 10.1001/jama.2018.11187; Gerharz J, 2018, J AIR WASTE MANAGE, V68, P608, DOI 10.1080/10962247.2017.1417184; Gerloff Janice, 2017, Appl In Vitro Toxicol, V3, P28, DOI 10.1089/aivt.2016.0030; Ghio AJ, 2008, AM J RESP CRIT CARE, V178, P1130, DOI 10.1164/rccm.200802-334OC; Ghosh A, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.19; Ghosh A, 2017, SCI REP-UK, V7, DOI 10.1038/srep46239; Hamad Samera H, 2017, Tob Regul Sci, V3, P459, DOI 10.18001/TRS.3.4.7; Huang MF, 2005, INDOOR AIR, V15, P135, DOI 10.1111/j.1600-0668.2005.00330.x; Kaur G, 2018, TOXICOL LETT, V288, P143, DOI 10.1016/j.toxlet.2018.02.025; Klager S, 2017, ENVIRON SCI TECHNOL, V51, P10806, DOI 10.1021/acs.est.7b02205; Korfei M, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0870-4; Kostygina G, 2016, TOB CONTROL, V25, P66, DOI 10.1136/tobaccocontrol-2014-051830; Krusemann EJZ, 2018, TOB CONTROL, V27, P105, DOI 10.1136/tobaccocontrol-2016-052961; Li X, 2014, J ENVIRON SCI, V26, P827, DOI 10.1016/S1001-0742(13)60472-6; Muthumalage T, 2018, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.01130; NAKAYAMA T, 1989, FREE RADICAL BIO MED, V7, P9, DOI 10.1016/0891-5849(89)90094-4; O'Connor RJ, 2012, TOB CONTROL, V21, P181, DOI 10.1136/tobaccocontrol-2011-050281; Odani S, 2020, NICOTINE TOB RES, V22, P1004, DOI 10.1093/ntr/ntz092; Park HS, 2009, RESPIROLOGY, V14, P27, DOI 10.1111/j.1440-1843.2008.01447.x; Pham-Huy Lien Ai, 2008, Int J Biomed Sci, V4, P89; Pickworth WB, 2018, CHEM RES TOXICOL, V31, P251, DOI 10.1021/acs.chemrestox.7b00312; Protano C, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15102172; Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008; Rosanna D, 2012, CURR PHARM DESIGN, V18, P3889, DOI 10.2174/138161212802083716; Sundar IK, 2013, ANTIOXID REDOX SIGN, V18, P1956, DOI 10.1089/ars.2012.4863; Talhout R, 2011, INT J ENV RES PUB HE, V8, P613, DOI 10.3390/ijerph8020613; Tierney PA, 2016, TOB CONTROL, V25, pE10, DOI 10.1136/tobaccocontrol-2014-052175; Valavanidis A, 2009, INT J ENV RES PUB HE, V6, P445, DOI 10.3390/ijerph6020445; Wackowski OA, 2016, HEALTH EDUC BEHAV, V43, P328, DOI 10.1177/1090198115599988; Wang HB, 2016, INHAL TOXICOL, V28, P89, DOI 10.3109/08958378.2016.1140851; Zhao JY, 2018, J HAZARD MATER, V344, P549, DOI 10.1016/j.jhazmat.2017.10.057	39	7	7	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2019	14	12							e0226066	10.1371/journal.pone.0226066	http://dx.doi.org/10.1371/journal.pone.0226066			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP1GO	31825984	gold, Green Published			2023-01-03	WOS:000534068500040
J	McCann, ME; Soriano, SG				McCann, Mary Ellen; Soriano, Sulpicio G.			Does general anesthesia affect neurodevelopment in infants and children?	BMJ-BRITISH MEDICAL JOURNAL			English	Review							AWAKE-REGIONAL ANESTHESIA; SEVOFLURANE ANESTHESIA; EMERGENCE DELIRIUM; YOUNG-CHILDREN; ACADEMIC-PERFORMANCE; BEHAVIORAL OUTCOMES; CARDIAC-SURGERY; EARLY EXPOSURE; RECOVERY CHARACTERISTICS; NEUROCOGNITIVE OUTCOMES	General anesthesia has been unequivocally linked to abnormal development of the central nervous system, leading to neurocognitive impairments in laboratory models. In vitro and in vivo studies have consistently shown that exposure to GABA agonists (eg, volatile anesthetics, midazolam, and propofol) or NMDA antagonists (eg, ketamine, isoflurane, and nitrous oxide) produces dose dependent and developmental age dependent effects on various neuronal transmission systems. Exposure to these drugs increases neuronal cell death in juvenile animals including rats, mice, and non-human primates. The possibility of anesthetic induced neurotoxicity occurring in children has led to concerns about the safety of pediatric anesthesia. A spectrum of behavioral changes has been documented after general anesthetic exposure in young children, including emergence delirium, which may be evidence of toxicity. Most clinical studies are retrospective; specifics about medications or monitoring are unavailable and many of the outcomes may not be sensitive to detect small neurocognitive deficits. Some of these retrospective studies have shown an association between anesthesia exposure at a young age and neurocognitive deficits, but others have not. Practitioners and families should be reassured that although general anesthetics have the potential to induce neurotoxicity, very little clinical evidence exists to support this.	[McCann, Mary Ellen; Soriano, Sulpicio G.] Harvard Med Sch, Dept Anesthesia, Boston, MA 02115 USA; [McCann, Mary Ellen; Soriano, Sulpicio G.] Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Soriano, SG (corresponding author), Harvard Med Sch, Dept Anesthesia, Boston, MA 02115 USA.; Soriano, SG (corresponding author), Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, Boston, MA 02115 USA.	Sulpicio.Soriano@childrens.harvard.edu	Soriano, Sulpicio/K-3501-2019					Alvarado MC, 2017, BRIT J ANAESTH, V119, P517, DOI 10.1093/bja/aew473; Andropoulos DB, 2014, PEDIATR ANESTH, V24, P266, DOI 10.1111/pan.12350; [Anonymous], 2007, TOXICOLOGICAL PRINCI; Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Aouad MT, 2007, ANESTHESIOLOGY, V107, P733, DOI 10.1097/01.anes.0000287009.46896.a7; Banerjee P, 2019, JAMA ONCOL, V5, P1456, DOI 10.1001/jamaoncol.2019.1094; Bartels DD, 2018, PEDIATR ANESTH, V28, P520, DOI 10.1111/pan.13391; Bartels M, 2009, TWIN RES HUM GENET, V12, P246, DOI 10.1375/twin.12.3.246; Block RI, 2012, ANESTHESIOLOGY, V117, P494, DOI 10.1097/ALN.0b013e3182644684; Bong CL, 2013, ANESTH ANALG, V117, P1419, DOI 10.1213/ANE.0b013e318299a7c2; Boscolo A, 2013, ANESTHESIOLOGY, V118, P1086, DOI 10.1097/ALN.0b013e318289bc9b; Briner A, 2010, ANESTHESIOLOGY, V112, P546, DOI 10.1097/ALN.0b013e3181cd7942; Buss RR, 2006, ANNU REV NEUROSCI, V29, P1, DOI 10.1146/annurev.neuro.29.051605.112800; Card E, 2015, BRIT J ANAESTH, V115, P411, DOI 10.1093/bja/aeu442; Chan MH, 2012, SCHIZOPHR RES, V136, P96, DOI 10.1016/j.schres.2012.01.024; Clausen NG, 2018, BRIT J ANAESTH, V120, P1255, DOI 10.1016/j.bja.2017.11.107; Clausen NG, 2017, CLEFT PALATE-CRAN J, V54, P371, DOI 10.1597/15-185; Cohen IT, 2002, ANESTH ANALG, V94, P1178, DOI 10.1097/00000539-200205000-00023; Cravero J, 2000, PAEDIATR ANAESTH, V10, P419, DOI 10.1046/j.1460-9592.2000.00560.x; Davidson AJ, 2016, LANCET, V387, P239, DOI 10.1016/S0140-6736(15)00608-X; De Roo M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007043; DiMaggio C, 2009, J NEUROSURG ANESTH, V21, P286, DOI 10.1097/ANA.0b013e3181a71f11; DiNardo JA, 2011, PEDIATR ANESTH, V21, P781, DOI 10.1111/j.1460-9592.2010.03429.x; Doyle LW, 1996, J PAEDIATR CHILD H, V32, P167; Dzhala VI, 2005, NAT MED, V11, P1205, DOI 10.1038/nm1301; Edwards DA, 2010, ANESTHESIOLOGY, V112, P567, DOI 10.1097/ALN.0b013e3181cf9138; Fineberg SJ, 2013, SPINE, V38, P1790, DOI 10.1097/BRS.0b013e3182a0d507; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Flick RP, 2011, PEDIATRICS, V128, pE1053, DOI 10.1542/peds.2011-0351; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Gaynor JW, 2015, PEDIATRICS, V135, P816, DOI 10.1542/peds.2014-3825; Glatz P, 2017, JAMA PEDIATR, V171, DOI 10.1001/jamapediatrics.2016.3470; Graham MR, 2016, ANESTHESIOLOGY, V125, P667, DOI 10.1097/ALN.0000000000001245; Guerra GG, 2011, PEDIATR ANESTH, V21, P932, DOI 10.1111/j.1460-9592.2011.03581.x; Habre W, 2017, LANCET RESP MED, V5, P412, DOI 10.1016/S2213-2600(17)30116-9; Hammon K, 1985, Anesth Prog, V32, P107; Hansen TG, 2017, PEDIATR ANESTH, V27, P558, DOI 10.1111/pan.13160; Hansen TG, 2013, PEDIATR ANESTH, V23, P883, DOI 10.1111/pan.12225; Hansen TG, 2011, ANESTHESIOLOGY, V114, P1076, DOI 10.1097/ALN.0b013e31820e77a0; Hedrick HL, 2004, J PEDIATR SURG, V39, P319, DOI 10.1016/j.jpedsurg.2003.11.006; Hensch TK, 2005, NAT REV NEUROSCI, V6, P877, DOI 10.1038/nrn1787; HOLZGRAFE RE, 1973, ANESTH ANALG, V52, P921; Homsy J, 2015, SCIENCE, V350, P1262, DOI 10.1126/science.aac9396; Hu DQ, 2017, ANESTHESIOLOGY, V127, P227, DOI 10.1097/ALN.0000000000001735; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ing C, 2017, BRIT J ANAESTH, V119, P532, DOI 10.1093/bja/aew413; Ing C, 2017, ANESTH ANALG, V125, P1988, DOI 10.1213/ANE.0000000000002423; Ing C, 2012, PEDIATRICS, V130, pE476, DOI 10.1542/peds.2011-3822; Ing CH, 2014, J NEUROSURG ANESTH, V26, P377, DOI 10.1097/ANA.0000000000000121; Ing CH, 2014, ANESTHESIOLOGY, V120, P1319, DOI 10.1097/ALN.0000000000000248; Jacob Z, 2012, ANESTHESIOLOGY, V117, P1062, DOI 10.1097/ALN.0b013e31826be417; Jevtovic-Todorovic V, 2018, ANESTHESIOLOGY, V128, P832, DOI 10.1097/ALN.0000000000002047; Ju LS, 2018, BRIT J ANAESTH, V121, P406, DOI 10.1016/j.bja.2018.04.034; Kabra NS, 2007, J PEDIATR-US, V150, P229, DOI 10.1016/j.jpeds.2006.11.039; Kalisvaart KJ, 2006, J AM GERIATR SOC, V54, P817, DOI 10.1111/j.1532-5415.2006.00704.x; Kanaya A, 2014, J ANESTH, V28, P4, DOI 10.1007/s00540-013-1656-y; Ko WR, 2014, PEDIATR ANESTH, V24, P741, DOI 10.1111/pan.12371; KONGSRUD F, 1982, ACTA ANAESTH SCAND, V26, P620, DOI 10.1111/j.1399-6576.1982.tb01827.x; Lee JR, 2017, BRIT J ANAESTH, V119, P492, DOI 10.1093/bja/aex219; Leighton C, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00106; Lepouse C, 2006, BRIT J ANAESTH, V96, P747, DOI 10.1093/bja/ael094; Lerman J, 1996, ANESTHESIOLOGY, V84, P1332, DOI 10.1097/00000542-199606000-00009; Li YJ, 2007, NEUROPHARMACOLOGY, V53, P942, DOI 10.1016/j.neuropharm.2007.09.005; Lin EP, 2017, NEUROTOXICOL TERATOL, V60, P117, DOI 10.1016/j.ntt.2016.10.008; Liu JR, 2016, ANESTH ANALG, V123, P1008, DOI 10.1213/ANE.0000000000001527; Martin JC, 2014, ANESTHESIOLOGY, V121, P740, DOI 10.1097/ALN.0000000000000376; Mayberry RI, 2002, NATURE, V417, P38, DOI 10.1038/417038a; McCann ME, 2012, BRIT J ANAESTH, V109, pI60, DOI 10.1093/bja/aes424; McCann ME, 2019, LANCET, V393, P664, DOI 10.1016/S0140-6736(18)32485-1; Mutch WAC, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00177; Newton LE, 2016, J PEDIATR SURG, V51, P743, DOI 10.1016/j.jpedsurg.2016.02.015; O'Leary JD, 2016, ANESTHESIOLOGY, V125, P272, DOI 10.1097/ALN.0000000000001200; Olbrecht VA, 2018, ANESTHESIOLOGY, V128, P85, DOI 10.1097/ALN.0000000000001920; Paule MG, 2011, NEUROTOXICOL TERATOL, V33, P220, DOI 10.1016/j.ntt.2011.01.001; Paule MG, 1999, NEUROTOXICOL TERATOL, V21, P223, DOI 10.1016/S0892-0362(98)00045-2; Penzes P, 2011, NAT NEUROSCI, V14, P285, DOI 10.1038/nn.2741; Perera FP, 2006, ENVIRON HEALTH PERSP, V114, P1287, DOI 10.1289/ehp.9084; Perez-Zoghbi JF, 2017, BRIT J ANAESTH, V119, P506, DOI 10.1093/bja/aex222; Raper J, 2015, ANESTHESIOLOGY, V123, P1084, DOI 10.1097/ALN.0000000000000851; Richardson GA, 2008, NEUROTOXICOL TERATOL, V30, P96, DOI 10.1016/j.ntt.2007.12.006; Sanders RD, 2009, ANESTHESIOLOGY, V110, P1077, DOI 10.1097/ALN.0b013e31819daedd; Scheiman MM, 2005, ARCH OPHTHALMOL-CHIC, V123, P437; Shen X, 2013, ANESTHESIOLOGY, V118, P502, DOI 10.1097/ALN.0b013e3182834d77; Shih J, 2012, ANESTHESIOLOGY, V116, P586, DOI 10.1097/ALN.0b013e318247564d; Shukry M, 2005, PEDIATR ANESTH, V15, P1098, DOI 10.1111/j.1460-9592.2005.01660.x; Slikker W, 2007, J APPL TOXICOL, V27, P201, DOI 10.1002/jat.1207; Soriano SG, 2017, BRIT J ANAESTH, V119, P443, DOI 10.1093/bja/aex238; Stolwijk LJ, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-1728; Sun LS, 2016, JAMA-J AM MED ASSOC, V315, P2312, DOI 10.1001/jama.2016.6967; Sury MRJ, 1996, ANAESTHESIA, V51, P543, DOI 10.1111/j.1365-2044.1996.tb12560.x; Tellez-Rojo MM, 2006, PEDIATRICS, V118, pE323, DOI 10.1542/peds.2005-3123; Vacas S, 2013, BRIT MED BULL, V106, P161, DOI 10.1093/bmb/ldt006; Valley RD, 1999, ANESTH ANALG, V88, P742, DOI 10.1097/00000539-199904000-00010; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Vutskits L, 2005, ANESTHESIOLOGY, V102, P970, DOI 10.1097/00000542-200505000-00016; Vutskits L, 2019, ANESTHESIOLOGY, V131, P762, DOI 10.1097/ALN.0000000000002863; Vutskits L, 2016, NAT REV NEUROSCI, V17, P705, DOI 10.1038/nrn.2016.128; Vutskits L, 2012, ANESTH ANALG, V115, P1174, DOI 10.1213/ANE.0b013e31826a1178; Warner DO, 2018, ANESTHESIOLOGY, V129, P89, DOI 10.1097/ALN.0000000000002232; Warner DO, 2019, BRIT J ANAESTH, V122, P470, DOI 10.1016/j.bja.2018.12.020; Welborn LG, 1996, ANESTH ANALG, V83, P917, DOI 10.1097/00000539-199611000-00005; Wilder RT, 2009, ANESTHESIOLOGY, V110, P796, DOI 10.1097/01.anes.0000344728.34332.5d; Williams RK, 2014, ANESTH ANALG, V119, P651, DOI 10.1213/ANE.0000000000000288; Wong AME, 2008, CAN J OPHTHALMOL, V43, P643, DOI 10.3129/i08-115; Yahalom B, 2011, ANESTHESIOLOGY, V114, P1325, DOI 10.1097/ALN.0b013e31821b5729; Zaccariello MJ, 2019, BRIT J ANAESTH, V122, P671, DOI 10.1016/j.bja.2019.01.022; Zhang LL, 2006, J NEUROPHYSIOL, V95, P2404, DOI 10.1152/jn.00578.2005	107	65	69	4	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 9	2019	367								l6459	10.1136/bmj.l6459	http://dx.doi.org/10.1136/bmj.l6459			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW1FS	31818811				2023-01-03	WOS:000502804800002
J	Guyot, M; Simon, T; Ceppo, F; Panzolini, C; Guyon, A; Lavergne, J; Murris, E; Daoudlarian, D; Brusini, R; Zarif, H; Abelanet, S; Hugues-Ascery, S; Divoux, JL; Lewis, SJ; Sridhar, A; Glaichenhaus, N; Blancou, P				Guyot, Melanie; Simon, Thomas; Ceppo, Franck; Panzolini, Clara; Guyon, Alice; Lavergne, Julien; Murris, Emilie; Daoudlarian, Douglas; Brusini, Romain; Zarif, Hadi; Abelanet, Sophie; Hugues-Ascery, Sandrine; Divoux, Jean-Louis; Lewis, Stephen J.; Sridhar, Arun; Glaichenhaus, Nicolas; Blancou, Philippe			Pancreatic nerve electrostimulation inhibits recent-onset autoimmune diabetes	NATURE BIOTECHNOLOGY			English	Article							CROSS-PRESENTATION; T-CELLS; STIMULATION; ANTIGENS; DISEASE	Vagus nerve stimulation can ameliorate autoimmune diseases such as rheumatoid arthritis by modulation of the immune system. Its efficacy for the treatment of type 1 diabetes has not been explored, in part because the nerves projecting to the pancreatic lymph nodes (pLNs) in mice are unmapped. Here, we map the nerve projecting to the pancreas and pLNs in mice and use a minimally invasive surgical procedure to implant micro-cuff electrodes onto the nerve. Pancreatic nerve electrical stimulation (PNES) resulted in beta-adrenergic receptor-mediated-accumulation of B and T cells in pLNs and reduced production of pro-inflammatory cytokines following lipopolysaccharide stimulation. Autoreactive T cells showed reduced proliferation in pLNs of mice receiving PNES as compared to sham controls. In a spontaneous mouse model of autoimmune diabetes, PNES inhibited disease progression in diabetic mice.	[Guyot, Melanie; Simon, Thomas; Ceppo, Franck; Panzolini, Clara; Guyon, Alice; Lavergne, Julien; Murris, Emilie; Daoudlarian, Douglas; Brusini, Romain; Zarif, Hadi; Abelanet, Sophie; Glaichenhaus, Nicolas; Blancou, Philippe] Univ Cote Azur, CNRS, Inst Pharmacol Mol & Cellulaire, Valbonne, France; [Hugues-Ascery, Sandrine] E PHY SCIENCE, Valbonne, France; [Divoux, Jean-Louis] AXONIC, Vallauris, France; [Lewis, Stephen J.] Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; [Lewis, Stephen J.] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Sridhar, Arun] Galvani Bioelect, Stevenage, Herts, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Case Western Reserve University; Case Western Reserve University	Blancou, P (corresponding author), Univ Cote Azur, CNRS, Inst Pharmacol Mol & Cellulaire, Valbonne, France.	blancou@ipmc.cnrs.fr	Simon, Thomas/N-8879-2019; Blancou, Philippe/M-4149-2018	Simon, Thomas/0000-0001-9699-959X; /0000-0002-5854-9253; Glaichenhaus, Nicolas/0000-0002-8997-0470; Blancou, Philippe/0000-0003-0305-8622; Sridhar, Arun/0000-0002-8682-6545	LABEX SIGNALIFE [ANR-11-LABX-0028-01]	LABEX SIGNALIFE	This work was funded by a collaborative research grant from GlaxoSmithKline Bioelectronics R&D to P.B. This work was also supported by the LABEX SIGNALIFE (no. ANR-11-LABX-0028-01) and the FHU Oncoage.	Amrani A, 1999, J CLIN INVEST, V103, P1201, DOI 10.1172/JCI6266; Bonaz B, 2016, NEUROGASTROENT MOTIL, V28, P948, DOI 10.1111/nmo.12792; Chen YL, 2017, CYTOKINE, V94, P14, DOI 10.1016/j.cyto.2017.01.002; CHRISTIANSON SW, 1993, DIABETES, V42, P44, DOI 10.2337/diabetes.42.1.44; Coppieters K, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00283; DUCLAUX R, 1976, J PHYSIOL-LONDON, V260, P487, DOI 10.1113/jphysiol.1976.sp011527; Faustman DL, 2018, DIABETES-METAB RES, V34, DOI 10.1002/dmrr.2941; Herold KC, 2013, LANCET DIABETES ENDO, V1, P261, DOI 10.1016/S2213-8587(13)70123-2; Herve J, 2013, J IMMUNOL, V190, P3163, DOI 10.4049/jimmunol.1201391; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Koopman FA, 2016, P NATL ACAD SCI USA, V113, P8284, DOI 10.1073/pnas.1605635113; Kurts C, 1998, J EXP MED, V188, P415, DOI 10.1084/jem.188.2.415; Kurts C, 1998, J EXP MED, V188, P409, DOI 10.1084/jem.188.2.409; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Mandrup-Poulsen Thomas, 2012, Rev Diabet Stud, V9, P338, DOI 10.1900/RDS.2012.9.338; Nakai A, 2014, J EXP MED, V211, P2583, DOI 10.1084/jem.20141132; Padro CJ, 2014, SEMIN IMMUNOL, V26, P357, DOI 10.1016/j.smim.2014.01.003; Savitt JM, 2005, J NEUROSCI, V25, P6721, DOI 10.1523/JNEUROSCI.0760-05.2005	18	13	14	4	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2019	37	12					1446	+		10.1038/s41587-019-0295-8	http://dx.doi.org/10.1038/s41587-019-0295-8			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	JT1HK	31712773	Green Submitted			2023-01-03	WOS:000500748900018
J	Wei, YG; Wang, Y; Di, Q; Choirat, C; Wang, Y; Koutrakis, P; Zanobetti, A; Dominici, F; Schwartz, JD				Wei, Yaguang; Wang, Yan; Di, Qian; Choirat, Christine; Wang, Yun; Koutrakis, Petros; Zanobetti, Antonella; Dominici, Francesca; Schwartz, Joel D.			Short term exposure to fine particulate matter and hospital admission risks and costs in the Medicare population: time stratified, case crossover study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FIRED POWER-PLANT; AIR-POLLUTION; CARDIOVASCULAR-DISEASE; PM2.5; IMPACT; MORTALITY; CARE; QUALITY	OBJECTIVE To assess risks and costs of hospital admission associated with short term exposure to fine particulate matter with diameter less than 2.5 mu m (PM2.5) for 214 mutually exclusive disease groups. DESIGN Time stratified, case crossover analyses with conditional logistic regressions adjusted for nonlinear confounding effects of meteorological variables. SETTING Medicare inpatient hospital claims in the United States, 2000-12 (n=95 277 169). PARTICIPANTS All Medicare fee-for-service beneficiaries aged 65 or older admitted to hospital. MAIN OUTCOME MEASURES Risk of hospital admission, number of admissions, days in hospital, inpatient and post-acute care costs, and value of statistical life (that is, the economic value used to measure the cost of avoiding a death) due to the lives lost at discharge for 214 disease groups. RESULTS Positive associations between short term exposure to PM2.5 and risk of hospital admission were found for several prevalent but rarely studied diseases, such as septicemia, fluid and electrolyte disorders, and acute and unspecified renal failure. Positive associations were also found between risk of hospital admission and cardiovascular and respiratory diseases, Parkinson's disease, diabetes, phlebitis, thrombophlebitis, and thromboembolism, confirming previously published results. These associations remained consistent when restricted to days with a daily PM2.5 concentration below the WHO air quality guideline for the 24 hour average exposure to PM2.5. For the rarely studied diseases, each 1 mu g/m(3) increase in short term PM2.5 was associated with an annual increase of 2050 hospital admissions (95% confidence interval 1914 to 2187 admissions), 12 216 days in hospital (11 358 to 13 075), US$31m (24m pound, (sic)28m; $29m to $34m) in inpatient and post-acute care costs, and $2.5bn ($2.0bn to $2.9bn) in value of statistical life. For diseases with a previously known association, each 1 mu g/m(3) increase in short term exposure to PM2.5 was associated with an annual increase of 3642 hospital admissions (3434 to 3851), 20 098 days in hospital (18 950 to 21 247), $69m ($65m to $73m) in inpatient and post-acute care costs, and $4.1bn ($3.5bn to $4.7bn) in value of statistical life. CONCLUSIONS New causes and previously identified causes of hospital admission associated with short term exposure to PM2.5 were found. These associations remained even at a daily PM2.5 concentration below the WHO 24 hour guideline. Substantial economic costs were linked to a small increase in short term PM2.5.	[Wei, Yaguang; Wang, Yan; Koutrakis, Petros; Zanobetti, Antonella; Schwartz, Joel D.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Wang, Yan; Wang, Yun; Dominici, Francesca] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Di, Qian] Tsinghua Univ, Sch Med, Res Ctr Publ Hlth, Beijing, Peoples R China; [Choirat, Christine] Swiss Fed Inst Technol, Swiss Data Sci Ctr, Zurich, Switzerland; [Choirat, Christine] EPFL, Zurich, Switzerland	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Tsinghua University; Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Dominici, F (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.	fdominic@hsph.harvard.edu	Wei, Yaguang/AFN-8388-2022	Dominici, Francesca/0000-0002-9382-0141; Choirat, Christine/0000-0002-3745-9718	National Institute of Health (NIH) [P30 ES000002, R01 ES024332-01A1, R01 ES026217, R01 ES028033, R21 ES024012]; NIH/National Cancer Institute (NCI) [R35 CA197449]; Health Effects Institute (HEI) [4953-RFA14-3/16-4]; United States Environmental Protection Agency (US EPA) [RD-83587201-0, RD-83479801]; US EPA [CR-83467701]; NATIONAL CANCER INSTITUTE [R35CA197449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002, R01ES024332, R01ES028033, R01ES026217] Funding Source: NIH RePORTER	National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)National Research Council of Science & Technology (NST), Republic of Korea); Health Effects Institute (HEI); United States Environmental Protection Agency (US EPA)(United States Environmental Protection Agency); US EPA(United States Environmental Protection Agency); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This study was supported by National Institute of Health (NIH) grants P30 ES000002, R01 ES024332-01A1, R01 ES026217, R01 ES028033, and R21 ES024012; NIH/National Cancer Institute (NCI) grant R35 CA197449; Health Effects Institute (HEI) grant 4953-RFA14-3/16-4; and United States Environmental Protection Agency (US EPA) grants RD-83587201-0 and RD-83479801. The contents of this publication are solely the responsibility of the grantee and do not necessarily represent the official views of the US EPA. Further, the US EPA does not endorse the purchase of any commercial products or services mentioned in the publication. Research described in this article was conducted under contract to the HEI, an organization jointly funded by the US EPA (Assistance Award No CR-83467701) and certain motor vehicle and engine manufacturers. The contents of this article do not necessarily reflect the views of HEI, or its sponsors, nor do they necessarily reflect the views and policies of the US EPA or motor vehicle and engine manufacturers.	Alshekhlee A, 2011, J STROKE CEREBROVASC, V20, P196, DOI 10.1016/j.jstrokecerebrovasdis.2009.11.019; [Anonymous], 2006, AIR QUAL GUID WHO; Bell ML, 2014, ENVIRON HEALTH PERSP, V122, P138, DOI 10.1289/ehp.1306656; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bobb JF, 2014, JAMA-J AM MED ASSOC, V312, P2659, DOI 10.1001/jama.2014.15715; Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8; Centers for Medicare and Medicaid Services, 2018, MED FEE FOR SERV PRO; Chandra A, 2013, HEALTH AFFAIR, V32, P864, DOI 10.1377/hlthaff.2012.1262; Di Q, 2017, JAMA-J AM MED ASSOC, V318, P2446, DOI 10.1001/jama.2017.17923; Di Q, 2017, NEW ENGL J MED, V376, P2513, DOI 10.1056/NEJMoa1702747; Di Q, 2016, ENVIRON SCI TECHNOL, V50, P4712, DOI 10.1021/acs.est.5b06121; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Feng SL, 2016, ECOTOX ENVIRON SAFE, V128, P67, DOI 10.1016/j.ecoenv.2016.01.030; Hart JE, 2011, AM J RESP CRIT CARE, V183, P73, DOI 10.1164/rccm.200912-1903OC; Jaffe DA, 2009, ATMOS CHEM PHYS, V9, P7997, DOI 10.5194/acp-9-7997-2009; James SL, 2018, LANCET, V392, P1789, DOI [10.1016/S0140-6736(18)32279-7, 10.1016/s0140-6736(18)32279-7]; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Kloog I, 2015, J THROMB HAEMOST, V13, P768, DOI 10.1111/jth.12873; Kloog I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088578; Kloog I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034664; Levy D, 2001, EPIDEMIOLOGY, V12, P186, DOI 10.1097/00001648-200103000-00010; Lipsitch M, 2010, EPIDEMIOLOGY, V21, P383, DOI 10.1097/EDE.0b013e3181d61eeb; Medicare Payment Advisory Commission, 2018, REP C MED PAYM POL; Navidi W, 1998, BIOMETRICS, V54, P596, DOI 10.2307/3109766; Papanicolas I, 2018, JAMA-J AM MED ASSOC, V319, P1024, DOI 10.1001/jama.2018.1150; Puett RC, 2009, ENVIRON HEALTH PERSP, V117, P1697, DOI 10.1289/ehp.0900572; Radley DC, 2008, J CLIN EPIDEMIOL, V61, P580, DOI 10.1016/j.jclinepi.2007.08.001; Russell MC, 2017, J AIR WASTE MANAGE, V67, P3, DOI 10.1080/10962247.2016.1170738; Symons JM, 2006, AM J EPIDEMIOL, V164, P421, DOI 10.1093/aje/kwj206; Talbott EO, 2014, ENVIRON RES, V134, P455, DOI 10.1016/j.envres.2014.06.018; US Bureau of Labor Statistics, 2018, CPI ALL URB CONS MED; US Environmental Protection Agency, 2018, MORT RISK VAL; Wellenius GA, 2012, ARCH INTERN MED, V172, P229, DOI 10.1001/archinternmed.2011.732; Wood S, 2017, GEN ADDITIVE MODELS, V2, DOI 10.1201/9781315370279; World Health Organization, 2016, WHO EXP CONS AV EV F; Wu X, 2019, ANN APPL STAT, V13, P520, DOI 10.1214/18-AOAS1206; Xing YF, 2016, J THORAC DIS, V8, pE69, DOI 10.3978/j.issn.2072-1439.2016.01.19; Zanobetti A, 2014, ENVIRON HEALTH-GLOB, V13, DOI 10.1186/1476-069X-13-38; Zanobetti A, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-58	39	93	95	4	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	2019	367								l6258	10.1136/bmj.l6258	http://dx.doi.org/10.1136/bmj.l6258			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU3QJ	31776122	Green Published, hybrid			2023-01-03	WOS:000501592300002
J	Sammer, M; Zahnbrecher, E; Dobiasch, S; Girst, S; Greubel, C; Ilicic, K; Reindl, J; Schwarz, B; Siebenwirth, C; Walsh, DWM; Combs, SE; Dollinger, G; Schmid, TE				Sammer, Matthias; Zahnbrecher, Esther; Dobiasch, Sophie; Girst, Stefanie; Greubel, Christoph; Ilicic, Katarina; Reindl, Judith; Schwarz, Benjamin; Siebenwirth, Christian; Walsh, Dietrich W. M.; Combs, Stephanie E.; Dollinger, Gunther; Schmid, Thomas E.			Proton pencil minibeam irradiation of an in-vivo mouse ear model spares healthy tissue dependent on beam size	PLOS ONE			English	Article							RADIATION-THERAPY; RADIOTHERAPY; OPTIMIZATION; SKIN	Proton radiotherapy using minibeams of sub-millimeter dimensions reduces side effects in comparison to conventional proton therapy due to spatial fractionation. Since the proton minibeams widen with depth, the homogeneous irradiation of a tumor can be ensured by adjusting the beam distances to tumor size and depth to maintain tumor control as in conventional proton therapy. The inherent advantages of protons in comparison to photons like a limited range that prevents a dosage of distal tissues are maintained by proton minibeams and can even be exploited for interlacing from different beam directions. A first animal study was conducted to systematically investigate and quantify the tissue-sparing effects of proton pencil minibeams as a function of beam size and dose distributions, using beam widths between s = 95, 199, 306, 411, 561 and 883 mu m (standard deviation) at a defined center-to-center beam distance (ctc) of 1.8 mm. The average dose of 60 Gy was distributed in 4x4 minibeams using 20 MeV protons (LET similar to 2.7 keV/mu m). The induced radiation toxicities were measured by visible skin reactions and ear swelling for 90 days after irradiation. The largest applied beam size to ctc ratio (s/ctc = 0.49) is similar to a homogeneous irradiation and leads to a significant 3-fold ear thickness increase compared to the control group. Erythema and desquamation was also increased significantly 3-4 weeks after irradiation. With decreasing beam sizes and thus decreasing s/ctc, the maximum skin reactions are strongly reduced until no ear swelling or other visible skin reactions should occur for s/ctc < 0.032 (extrapolated from data). These results demonstrate that proton pencil minibeam radiotherapy has better tissue-sparing for smaller s/ctc, corresponding to larger peak-to-valley dose ratios PVDR, with the best effect for s/ctc < 0.032. However, even quite large s/ctc (e.g. s/ctc = 0.23 or 0.31, i.e. PVDR = 10 or 2.7) show less acute side effects than a homogeneous dose distribution. This suggests that proton minibeam therapy spares healthy tissue not only in the skin but even for dose distributions appearing in deeper layers close to the tumor enhancing its benefits for clinical proton therapy.	[Sammer, Matthias; Girst, Stefanie; Greubel, Christoph; Reindl, Judith; Schwarz, Benjamin; Siebenwirth, Christian; Walsh, Dietrich W. M.; Dollinger, Gunther] Univ Bundeswehr Munchen, Inst Angew Phys & Messtech LRT2, Neubiberg, Germany; [Zahnbrecher, Esther; Dobiasch, Sophie; Ilicic, Katarina; Siebenwirth, Christian; Walsh, Dietrich W. M.; Combs, Stephanie E.; Schmid, Thomas E.] Tech Univ Munich, Dept Radiat Oncol, Klinikum Rechts Isar, Munich, Germany; [Zahnbrecher, Esther; Dobiasch, Sophie; Ilicic, Katarina; Combs, Stephanie E.; Schmid, Thomas E.] Helmholtz Zentrum Munchen HMGU, Dept Radiat Sci DRS, Inst Radiat Med IRM, Oberschleissheim, Germany; [Dobiasch, Sophie; Ilicic, Katarina; Combs, Stephanie E.] Deutsch Konsortium Translat Krebsforsch DKTK, Partner Site Munich, Heidelberg, Germany; [Siebenwirth, Christian] Univ Ulm, Bundeswehr Inst Radiobiol, Munich, Germany	Bundeswehr University Munich; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Ulm University	Sammer, M (corresponding author), Univ Bundeswehr Munchen, Inst Angew Phys & Messtech LRT2, Neubiberg, Germany.	matthias.sammer@unibw.de		Walsh, Dietrich/0000-0003-2067-1883; Reindl, Judith/0000-0002-3238-8586	project 'LET-Verbund' of the German Federal Ministry of Education and Research [02NUK031A]; DFG-Cluster of Excellence 'Munich-Centre for Advanced Photonics'; Maier Leibnitz Laboratory Munich	project 'LET-Verbund' of the German Federal Ministry of Education and Research; DFG-Cluster of Excellence 'Munich-Centre for Advanced Photonics'(German Research Foundation (DFG)); Maier Leibnitz Laboratory Munich	Supported by the project 'LET-Verbund' (funding no. 02NUK031A; GD) of the German Federal Ministry of Education and Research, by the DFG-Cluster of Excellence 'Munich-Centre for Advanced Photonics' and by the Maier Leibnitz Laboratory Munich. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brauer-Krisch E, 2003, MED PHYS, V30, P583, DOI 10.1118/1.1562169; Deasy JO, 2003, MED PHYS, V30, P979, DOI 10.1118/1.1568978; Dilmanian FA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00269; Dilmanian FA, 2012, INT J RADIAT ONCOL, V84, P514, DOI 10.1016/j.ijrobp.2011.12.025; Dombrowsky AC, 2019, CANCERS, V11, DOI 10.3390/cancers11050727; Girst S, 2016, INT J RADIAT ONCOL, V95, P234, DOI 10.1016/j.ijrobp.2015.10.020; Greubel C, 2008, RADIAT ENVIRON BIOPH, V47, P415, DOI 10.1007/s00411-008-0181-0; Greubel C, 2011, RADIAT ENVIRON BIOPH, V50, P339, DOI 10.1007/s00411-011-0365-x; Hauptner A, 2004, RADIAT ENVIRON BIOPH, V42, P237, DOI 10.1007/s00411-003-0222-7; Liao WP, 2017, RADIAT RES, V187, P454, DOI 10.1667/RR007CC.1; Paganetti H, 2002, INT J RADIAT ONCOL, V53, P407, DOI 10.1016/S0360-3016(02)02754-2; PARKINSON EK, 1986, BRIT J CANCER, V53, P81; Prezado Y, 2013, MED PHYS, V40, DOI 10.1118/1.4791648; Prezado Y, 2009, MED PHYS, V36, P4897, DOI 10.1118/1.3232000; Prezado Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34796-8; Prezado Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14786-y; Prezado Y, 2012, J SYNCHROTRON RADIAT, V19, P60, DOI 10.1107/S0909049511047042; Sammer M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221454; Sammer M, 2017, MED PHYS, V44, P6096, DOI 10.1002/mp.12566; Schell S, 2010, MED PHYS, V37, P5330, DOI 10.1118/1.3491406; Zlobinskaya O, 2013, RADIAT ENVIRON BIOPH, V52, P123, DOI 10.1007/s00411-012-0450-9	21	14	14	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 25	2019	14	11							e0224873	10.1371/journal.pone.0224873	http://dx.doi.org/10.1371/journal.pone.0224873			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO8QR	31765436	Green Published, gold			2023-01-03	WOS:000533891000010
J	Sessler, DI; Pei, LJ; Huang, YG; Fleischmann, E; Marhofer, P; Kurz, A; Mayers, DB; Meyer-Treschan, TA; Grady, M; Tan, EY; Ayad, S; Mascha, EJ; Buggy, DJ				Sessler, Daniel I.; Pei, Lijian; Huang, Yuguang; Fleischmann, Edith; Marhofer, Peter; Kurz, Andrea; Mayers, Douglas B.; Meyer-Treschan, Tanja A.; Grady, Martin; Tan, Ern Yu; Ayad, Sabry; Mascha, Edward J.; Buggy, Donal J.		Breast Canc Recurrence	Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial	LANCET			English	Article							PERSISTENT PAIN; PARAVERTEBRAL BLOCK; ANALGESIA REDUCE; TERM SURVIVAL; FOLLOW-UP; SURGERY; METAANALYSIS; CHOICE; RATES; SERUM	Background Three perioperative factors impair host defence against recurrence during cancer surgery: the surgical stress response, use of volatile anaesthetic, and opioids for analgesia. All factors are ameliorated by regional anaesthesia-analgesia. We tested the primary hypothesis that breast cancer recurrence after potentially curative surgery is lower with regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol than with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia. A second hypothesis was that regional anaesthesia-analgesia reduces persistent incisional pain. Methods We did a randomised controlled trial at 13 hospitals in Argentina, Austria, China, Germany, Ireland, New Zealand, Singapore, and the USA. Women (age <85 years) having potentially curative primary breast cancer resections were randomised by computer to either regional anaesthesia-analgesia (paravertebral blocks and propofol) or general anaesthesia (sevoflurane) and opioid analgesia. The primary outcome was local or metastatic breast cancer recurrence. The secondary outcome was incisional pain at 6 months and 12 months. Primary analyses were done under intention-to-treat principles. This trial is registered with ClinicalTrials.gov, NCT00418457. The study was stopped after a preplanned futility boundary was crossed. Findings Between Jan 30, 2007, and Jan 18, 2018, 2132 women were enrolled to the study, of whom 24 were excluded before surgery. 1043 were assigned to regional anaesthesia-analgesia and 1065 were allocated to general anaesthesia. Baseline characteristics were well balanced between study groups. Median follow-up was 36 (IQR 24-49) months. Among women assigned regional anaesthesia-analgesia, 102 (10%) recurrences were reported, compared with 111 (10%) recurrences among those allocated general anaesthesia (hazard ratio 0 center dot 97, 95% CI 0 center dot 74-1 center dot 28; p=0 center dot 84). Incisional pain was reported by 442 (52%) of 856 patients assigned to regional anaesthesia-analgesia and 456 (52%) of 872 patients allocated to general anaesthesia at 6 months, and by 239 (28%) of 854 patients and 232 (27%) of 852 patients, respectively, at 12 months (overall interim-adjusted odds ratio 1 center dot 00, 95% CI 0 center dot 85-1 center dot 17; p=0 center dot 99). Neuropathic breast pain did not differ by anaesthetic technique and was reported by 87 (10%) of 859 patients assigned to regional anaesthesia-analgesia and 89 (10%) of 870 patients allocated to general anaesthesia at 6 months, and by 57 (7%) of 857 patients and 57 (7%) of 854 patients, respectively, at 12 months. Interpretation In our study population, regional anaesthesia-analgesia (paravertebral block and propofol) did not reduce breast cancer recurrence after potentially curative surgery compared with volatile anaesthesia (sevoflurane) and opioids. The frequency and severity of persistent incisional breast pain was unaffected by anaesthetic technique. Clinicians can use regional or general anaesthesia with respect to breast cancer recurrence and persistent incisional pain.	[Sessler, Daniel I.; Kurz, Andrea; Mayers, Douglas B.; Grady, Martin; Ayad, Sabry; Mascha, Edward J.] Cleveland Clin, Inst Anesthesiol, Dept Outcomes Res, Cleveland, OH 44195 USA; [Kurz, Andrea] Cleveland Clin, Inst Anesthesiol, Dept Gen Anesthesiol, Cleveland, OH 44195 USA; [Mayers, Douglas B.; Grady, Martin; Ayad, Sabry] Cleveland Clin, Inst Anesthesiol, Dept Reg Anesthesiol, Cleveland, OH 44195 USA; [Mascha, Edward J.] Cleveland Clin, Inst Anesthesiol, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA; [Sessler, Daniel I.; Kurz, Andrea; Mayers, Douglas B.; Grady, Martin; Ayad, Sabry; Mascha, Edward J.] Cleveland Clin, Lerner Res Inst, Dept Outcomes Res, Cleveland, OH 44106 USA; [Kurz, Andrea] Cleveland Clin, Lerner Res Inst, Dept Gen Anesthesiol, Cleveland, OH 44106 USA; [Mayers, Douglas B.; Grady, Martin; Ayad, Sabry] Cleveland Clin, Lerner Res Inst, Dept Reg Anesthesiol, Cleveland, OH 44106 USA; [Mascha, Edward J.] Cleveland Clin, Lerner Res Inst, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA; [Pei, Lijian; Huang, Yuguang] Peking Union Med Coll Hosp, Dept Anesthesiol, Beijing, Peoples R China; [Fleischmann, Edith; Marhofer, Peter] Med Univ Vienna, Dept Anaesthesia Gen Intens Care & Pain Managemen, Vienna, Austria; [Meyer-Treschan, Tanja A.] Univ Dusseldorf, Dept Anesthesiol, Dusseldorf, Germany; [Tan, Ern Yu] Tan Tock Seng Hosp, Singapore, Singapore; [Buggy, Donal J.] Univ Coll Dublin, Mater Univ Hosp, Sch Med, Dublin, Ireland	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Medical University of Vienna; Heinrich Heine University Dusseldorf; Tan Tock Seng Hospital; Mater Misericordiae University Hospital; University College Dublin	Sessler, DI (corresponding author), Cleveland Clin, Inst Anesthesiol, Dept Outcomes Res, Cleveland, OH 44195 USA.; Huang, YG (corresponding author), Peking Union Med Coll Hosp, Dept Anesthesiol, Beijing, Peoples R China.	ds@or.org; garybeijing@163.com	Meyer-Treschan, Tanja A./S-6624-2017; ayad, sabry/ABA-8262-2020	Meyer-Treschan, Tanja A./0000-0001-9363-1028; Keane, Helen/0000-0002-6042-306X; lijian, Pei/0000-0001-7174-9105; Kurz, Andrea/0000-0001-5887-3099; AYAD, SABRY/0000-0002-6728-9297; Buggy, Donal/0000-0003-3922-4397	Sisk Healthcare Foundation (Ireland); Eccles Breast Cancer Research Fund; British Journal of Anaesthesia International; College of Anaesthetists of Ireland; Peking Union Medical College Hospital; Science Fund for Junior Faculty 2016; Central Bank of Austria; National Healthcare Group	Sisk Healthcare Foundation (Ireland); Eccles Breast Cancer Research Fund; British Journal of Anaesthesia International; College of Anaesthetists of Ireland; Peking Union Medical College Hospital; Science Fund for Junior Faculty 2016; Central Bank of Austria; National Healthcare Group	Sisk Healthcare Foundation (Ireland), Eccles Breast Cancer Research Fund, British Journal of Anaesthesia International, College of Anaesthetists of Ireland, Peking Union Medical College Hospital, Science Fund for Junior Faculty 2016, Central Bank of Austria, and National Healthcare Group.	Andersen KG, 2015, PAIN, V156, P2413, DOI 10.1097/j.pain.0000000000000298; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Binczak M, 2013, Ann Fr Anesth Reanim, V32, pe81, DOI 10.1016/j.annfar.2013.02.027; Buckley A, 2014, BRIT J ANAESTH, V113, P56, DOI 10.1093/bja/aeu200; Christopherson R, 2008, ANESTH ANALG, V107, P325, DOI 10.1213/ane.0b013e3181770f55; Connolly C, 2016, CURR OPIN ANESTHESIO, V29, P468, DOI 10.1097/ACO.0000000000000360; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; Duff S, 2016, INT ANESTHESIOL CLIN, V54, P48, DOI 10.1097/AIA.0000000000000120; Eden P, 2004, EUR J CANCER, V40, P1837, DOI 10.1016/j.ejca.2004.02.025; Eochagain AN, 2018, ANAESTHESIA, V73, P603, DOI 10.1111/anae.14207; Gartner R, 2009, JAMA-J AM MED ASSOC, V302, P1985, DOI 10.1001/jama.2009.1568; Heesen M, 2016, ANAESTHESIA, V71, P1471, DOI 10.1111/anae.13649; Hiller JG, 2018, NAT REV CLIN ONCOL, V15, P205, DOI 10.1038/nrclinonc.2017.194; Holly E, 2017, J PUBLIC HLTH RES, V6, P867; Ilfeld BM, 2015, ANN SURG ONCOL, V22, P2017, DOI 10.1245/s10434-014-4248-7; Iwasaki M, 2016, ONCOTARGET, V7, P26042, DOI 10.18632/oncotarget.8304; Jaura AI, 2014, BRIT J ANAESTH, V113, P63, DOI 10.1093/bja/aet581; Karmakar MK, 2017, ANTICANCER RES, V37, P5813, DOI 10.21873/anticanres.12024; Krause SJ, 2003, CLIN J PAIN, V19, P306, DOI 10.1097/00002508-200309000-00004; Markovic-Bozic J, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0182-5; Mcdowell I., 2006, MEASURING HLTH GUIDE, V3, P37, DOI [DOI 10.1093/ACPROF:OSO/9780195165678.001.0001, 10.1093/acprof:oso/9780195165678.001.0001]; Myles PS, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1491; Pei LJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142249; Saphner T, 1996, J CLIN ONCOL, V14, P2738, DOI 10.1200/JCO.1996.14.10.2738; Sessler DI, 2008, CONTEMP CLIN TRIALS, V29, P517, DOI 10.1016/j.cct.2008.01.002; Sessler DI, 2008, EUR J CANCER PREV, V17, P269, DOI 10.1097/CEJ.0b013e3282f0c005; Tsui BCH, 2010, CAN J ANAESTH, V57, P107, DOI 10.1007/s12630-009-9214-7; Wall T, 2019, BRIT J ANAESTH, V123, P135, DOI 10.1016/j.bja.2019.04.062; Wang L, 2016, CAN MED ASSOC J, V188, pE352, DOI 10.1503/cmaj.151276; Weng ML, 2016, ONCOTARGET, V7, P15262, DOI 10.18632/oncotarget.7683; Wigmore TJ, 2016, ANESTHESIOLOGY, V124, P69, DOI 10.1097/ALN.0000000000000936; Wu J, 2015, CAN J ANESTH, V62, P241, DOI 10.1007/s12630-014-0285-8	32	166	173	7	40	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	2019	394	10211					1807	1815		10.1016/S0140-6736(19)32313-X	http://dx.doi.org/10.1016/S0140-6736(19)32313-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN5EG	31645288				2023-01-03	WOS:000496921000027
J	Dugdale, CM; Phillips, TK; Myer, L; Hyle, EP; Brittain, K; Freedberg, KA; Cunnama, L; Walensky, RP; Zerbe, A; Weinstein, MC; Abrams, EJ; Ciaranello, AL				Dugdale, Caitlin M.; Phillips, Tamsin K.; Myer, Landon; Hyle, Emily P.; Brittain, Kirsty; Freedberg, Kenneth A.; Cunnama, Lucy; Walensky, Rochelle P.; Zerbe, Allison; Weinstein, Milton C.; Abrams, Elaine J.; Ciaranello, Andrea L.		MCH-ART Trial Team	Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa	PLOS ONE			English	Article							MOTHER-TO-CHILD; SINGLE-DOSE NEVIRAPINE; DAR-ES-SALAAM; HIV-1 TRANSMISSION; CAPE-TOWN; FOLLOW-UP; PREGNANCY; EFFICACY; PREVENTION; ZIDOVUDINE	Background Poor engagement in postpartum maternal HIV care is a challenge worldwide and contributes to adverse maternal outcomes and vertical transmission. Our objective was to project the clinical and economic impact of integrated postpartum maternal antiretroviral therapy (ART) and pediatric care in South Africa. Methods Using the CEPAC computer simulation models, parameterized with data from the Maternal and Child Health-Antiretroviral Therapy (MCH-ART) randomized controlled trial, we evaluated the cost-effectiveness of integrated postpartum care for women initiating ART in pregnancy and their children. We compared two strategies: 1) standard of care (SOC) referral to local clinics after delivery for separate standard ART services for women and pediatric care for infants, and 2) the MCH-ART intervention (MCH-ART) of co-located maternal/pediatric care integrated in Maternal and Child Health (MCH) services throughout breastfeeding. Trial-derived inputs included: 12-month maternal retention in care and virologic suppression (SOC: 49%, MCH-ART: 67%), breastfeeding duration (SOC: 6 months, MCH-ART: 8 months), and postpartum healthcare costs for mother-infant pairs (SOC: $50, MCH-ART: $69). Outcomes included pediatric HIV infections, maternal and infant life expectancy (LE), lifetime HIV-related per-person costs, and incremental cost-effectiveness ratios (ICERs; ICER <US$903/YLS considered "cost-effective"). Results Compared to SOC, MCH-ART increased maternal LE (SOC: 25.26 years, MCH-ART: 26.20 years) and lifetime costs (SOC: $9,912, MCH-ART: $10,207; discounted). Projected pediatric outcomes for all HIV-exposed children were similar between arms, although undiscounted LE for HIV-infected children was shorter in SOC (SOC: 23.13 years, MCH-ART: 23.40 years). Combining discounted maternal and pediatric outcomes, the ICER was $599/ YLS. Conclusion Co-located maternal HIV and pediatric care, integrated in MCH services throughout breastfeeding, is a cost-effective strategy to improve maternal and pediatric outcomes and should be implemented in South Africa.	[Dugdale, Caitlin M.; Hyle, Emily P.; Freedberg, Kenneth A.; Walensky, Rochelle P.; Ciaranello, Andrea L.] Massachusetts Gen Hosp, Dept Med, Med Practice Evaluat Ctr, Boston, MA 02114 USA; [Dugdale, Caitlin M.; Hyle, Emily P.; Freedberg, Kenneth A.; Walensky, Rochelle P.; Ciaranello, Andrea L.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA; [Dugdale, Caitlin M.; Hyle, Emily P.; Freedberg, Kenneth A.; Walensky, Rochelle P.; Ciaranello, Andrea L.] Harvard Med Sch, Boston, MA 02115 USA; [Phillips, Tamsin K.; Myer, Landon; Brittain, Kirsty] Univ Cape Town, Sch Publ Hlth & Family Med, Div Epidemiol & Biostat, Cape Town, South Africa; [Phillips, Tamsin K.; Myer, Landon; Brittain, Kirsty] Univ Cape Town, Sch Publ Hlth & Family Med, Ctr Infect Dis Epidemiol & Res, Cape Town, South Africa; [Freedberg, Kenneth A.; Walensky, Rochelle P.; Ciaranello, Andrea L.] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA; [Freedberg, Kenneth A.; Weinstein, Milton C.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA; [Cunnama, Lucy] Univ Cape Town, Sch Publ Hlth & Family Med, Hlth Econ Unit, Cape Town, South Africa; [Zerbe, Allison; Abrams, Elaine J.] Columbia Univ, ICAP Columbia, New York, NY USA; [Zerbe, Allison; Abrams, Elaine J.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA; [Abrams, Elaine J.] Columbia Univ, Coll Phys & Surg, New York, NY USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Cape Town; University of Cape Town; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; University of Cape Town; Columbia University; Columbia University; Columbia University	Dugdale, CM (corresponding author), Massachusetts Gen Hosp, Dept Med, Med Practice Evaluat Ctr, Boston, MA 02114 USA.; Dugdale, CM (corresponding author), Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA.; Dugdale, CM (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	cdugdale@mgh.harvard.edu	Cunnama, Lucy/AAQ-6468-2021; , Andrea/ABB-3330-2021; Cunnama, Lucy/AAK-3159-2021	, Andrea/0000-0002-4268-3263; Cunnama, Lucy/0000-0003-2134-4905; Dugdale, Caitlin/0000-0002-6604-6111; Phillips, Tamsin/0000-0003-4554-2922	President's Emergency Plan for AIDS Relief (PEPFAR) through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [R01 HD074558]; Elizabeth Glaser Pediatric AIDS Foundation; National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Disease [NIAID] [T32 AI007433, R01 AI058736, R37 AI09326]; NICHD [R01 HD079214]; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT.) Group; National Heart, Lung, and Blood Institute [K01 HL123349]; Steve and Deborah Gorlin Massachusetts General Hospital (MGH) Research Scholars Award; Harvard University Center for AIDS Research (CFAR), an NIH [P30 AI060354]; NIAID; NCI; NICHD; NIDCR; NHLBI; NIDA; NIMH; NIA; NIDDK; NIGMS; NIMHD; FIC; OAR; Department of Health and Human Services [HHSN275201300003C]; NIAID of the NIH [UM1 AI068632, UM1 AI068616]; National Institute of Mental Health (NIHM); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD079214] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL123349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058736, UM1AI068616, R37AI093269, T32AI007433, P30AI060354, UM1AI068632, R37AI058736] Funding Source: NIH RePORTER	President's Emergency Plan for AIDS Relief (PEPFAR) through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Elizabeth Glaser Pediatric AIDS Foundation; National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Disease [NIAID]; NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT.) Group; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Steve and Deborah Gorlin Massachusetts General Hospital (MGH) Research Scholars Award; Harvard University Center for AIDS Research (CFAR), an NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMHD; FIC; OAR; Department of Health and Human Services; NIAID of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Mental Health (NIHM); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The MCH-ART trial was supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD; R01 HD074558). Additional funding comes from the Elizabeth Glaser Pediatric AIDS Foundation. This work was supported by the National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Disease [NIAID; T32 AI007433 (CMD), R01 AI058736 (KAF, RPW), R37 AI093269 (RPW)], NICHD [R01 HD079214 (ALC)], the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT.) Group (CMD, ALC, RPW, KAF), the National Heart, Lung, and Blood Institute [K01 HL123349 (EPH)], and the Steve and Deborah Gorlin Massachusetts General Hospital (MGH) Research Scholars Award (RPW). This research was funded in part by a 2017 developmental grant from the Harvard University Center for AIDS Research (CFAR), an NIH funded program (P30 AI060354: CMD) which is supported by the following NIH co-funding and participating Institutes and Centers: NIAID, NCI, NICHD, NIDCR, NHLBI, NIDA, NIMH, NIA, NIDDK, NIGMS, NIMHD, FIC, and OAR. This project has been funded in whole or in part with federal funds from NICHD, NIH, and the Department of Health and Human Services, under Contract No. HHSN275201300003C. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the MGH Research Scholars Award.. Overall support for IMPAACT was provided by NIAID of the NIH under Award Numbers UM1 AI068632 (IMPAACT LOC), UM1 AI068616 (IMPAACT SDMC), with co-funding from NICHD and the National Institute of Mental Health (NIHM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aliyu MH, 2016, LANCET HIV, V3, pE202, DOI 10.1016/S2352-3018(16)00018-7; Andrews JR, 2012, AIDS, V26, P987, DOI 10.1097/QAD.0b013e3283522d47; [Anonymous], 2016, GUID UPD HIV INF FEE, DOI [DOI 10.1103/PHYSREVA.63.023818, 10.1103/PhysRevA.63.023818]; Arikawa S, 2018, CLIN INFECT DIS, V66, P1668, DOI 10.1093/cid/cix1102; Briggs AH, 2012, MED DECIS MAKING, V32, P722, DOI 10.1177/0272989X12458348; Chammartin F, 2018, CLIN INFECT DIS, V67, P1643, DOI 10.1093/cid/ciy347; Chapman RH, 2004, HEALTH ECON, V13, P429, DOI 10.1002/hec.853; Chetty T, 2018, TROP MED INT HEALTH, V23, P79, DOI 10.1111/tmi.13001; Chigwedere P, 2008, AIDS RES HUM RETROV, V24, P827, DOI 10.1089/aid.2007.0291; Ciaranello AL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083389; Cleary S, 2005, HLTH SYSTEMS TRUST S; Cohan D, 2015, AIDS, V29, P183, DOI 10.1097/QAD.0000000000000531; Dabis F, 2005, AIDS, V19, P309; Dunning L, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002446; Fawzi W, 2002, JAIDS-J ACQ IMM DEF, V31, P331, DOI 10.1097/00126334-200211010-00010; Flynn PM, 2018, JAIDS-J ACQ IMM DEF, V77, P383, DOI 10.1097/QAI.0000000000001612; Francke JA, 2016, J INFECT DIS, V214, P1319, DOI 10.1093/infdis/jiw379; Goga AE, 2016, HIGHEST RISK MOTHER; Grimsrud AT, 2013, J CLIN EPIDEMIOL, V66, P1006, DOI 10.1016/j.jclinepi.2013.03.013; Guillaine Neza, 2017, Int J MCH AIDS, V6, P36, DOI 10.21106/ijma.186; Haas AD, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25084; Haas AD, 2016, LANCET HIV, V3, pE175, DOI 10.1016/S2352-3018(16)00008-4; Iliff PJ, 2005, AIDS, V19, P699, DOI 10.1097/01.aids.0000166093.16446.c9; International Monetary Fund, WORLD EC OUTLOOK DAT; Kalk E, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25212; Kilewo C, 2008, JAIDS-J ACQ IMM DEF, V48, P315, DOI 10.1097/QAI.0b013e31816e395c; Kiragu K, 2017, JAIDS-J ACQ IMM DEF, V75, pS36, DOI [10.1097/qai.0000000000001323, 10.1097/QAI.0000000000001323]; Knettel BA, 2018, JAIDS-J ACQ IMM DEF, V77, P427, DOI 10.1097/QAI.0000000000001616; Kuhn L, 2008, NEW ENGL J MED, V359, P130, DOI 10.1056/NEJMoa073788; Leroy V, 2002, AIDS, V16, P631, DOI 10.1097/00002030-200203080-00016; Mandelbrot L, 2015, CLIN INFECT DIS, V61, P1715, DOI 10.1093/cid/civ578; Marseille E, 2015, B WORLD HEALTH ORGAN, V93, P118, DOI 10.2471/BLT.14.138206; Massachusetts General Hospital Medical Practice Evaluation Center, COST EFF PREV AIDS C; Meda N, 2011, LANCET INFECT DIS, V11, P171, DOI 10.1016/S1473-3099(10)70288-7; Meyer-Rath G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186496; Myer L, 2017, HIV MED, V18, P80, DOI 10.1111/hiv.12397; Myer L, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002547; Ngoma MS, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.19352; Oanda, HIST EXCH RAT PER AV; Onoya D, 2017, AIDS, V31, P1593, DOI 10.1097/QAD.0000000000001517; Peltier CA, 2009, AIDS, V23, P2415, DOI 10.1097/QAD.0b013e32832ec20d; Perry MEO, 2016, HIV MED, V17, P28, DOI 10.1111/hiv.12277; Phillips T, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19242; Robinson LA, 2017, HEALTH POLICY PLANN, V32, P141, DOI 10.1093/heapol/czw096; Saba J, 2002, LANCET, V359, P1178; Sanders GD, 2016, JAMA-J AM MED ASSOC, V316, P1093, DOI 10.1001/jama.2016.12195; Shapiro RL, 2010, NEW ENGL J MED, V362, P2282, DOI 10.1056/NEJMoa0907736; South Africa Department of Health, 2015, NAT CONS GUID PREV M; Stewart RD, 2014, AM J OBSTET GYNECOL, V211, DOI 10.1016/j.ajog.2014.04.020; Thior I, 2006, JAMA-J AM MED ASSOC, V296, P794, DOI 10.1001/jama.296.7.794; Thomas TK, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001015; Walensky RP, 2013, NEW ENGL J MED, V369, P1715, DOI 10.1056/NEJMsa1214720; Winestone LE, 2012, GLOB PUBLIC HEALTH, V7, P149, DOI 10.1080/17441692.2011.621964; Woods B, 2015, COUNTRY LEVEL COST E; Zulliger R, 2014, AIDS BEHAV, V18, P697, DOI 10.1007/s10461-013-0641-7	55	7	7	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2019	14	11							e0225104	10.1371/journal.pone.0225104	http://dx.doi.org/10.1371/journal.pone.0225104			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LN2YM	31730630	Green Published, gold			2023-01-03	WOS:000532809500023
J	Jiao, SP; Subudhi, SK; Aparicio, A; Ge, ZQ; Guan, BX; Miura, Y; Sharma, P				Jiao, Shiping; Subudhi, Sumit K.; Aparicio, Ana; Ge, Zhongqi; Guan, Baoxiang; Miura, Yuji; Sharma, Padmanee			Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy	CELL			English	Article							IFN-GAMMA; TGF-BETA; COMBINED NIVOLUMAB; CELLS; CANCER; IPILIMUMAB; TH17; MEMORY; EFFECTOR; DIFFERENTIATION	Immune checkpoint therapy (ICT) shows encouraging results in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC) but still elicits a sub-optimal response among those with bone metastases. Analysis of patients' bone marrow samples revealed increased T(h)17 instead of T(h)1 subsets after ICT. To further evaluate the different tumor microenvironments, we injected mice with prostate tumor cells either subcutaneously or intraosseously. ICT in the subcutaneous CRPC model significantly increases intra-tumoral T(h)1 subsets and improves survival. However, ICT fails to elicit an anti-tumor response in the bone CRPC model despite an increase in the intra-tumoral CD4 T cells, which are polarized to T(h)17 rather than T(h)1 lineage. Mechanistically, tumors in the bone promote osteoclast-mediated bone resorption that releases TGF-8, which restrains T(h)1 lineage development. Blocking TGF-beta along with ICT increases T(h)1 subsets and promotes clonal expansion of CD8 T cells and subsequent regression of bone CRPC and improves survival.	[Jiao, Shiping; Subudhi, Sumit K.; Aparicio, Ana; Guan, Baoxiang; Miura, Yuji; Sharma, Padmanee] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Ge, Zhongqi; Sharma, Padmanee] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Jiao, Shiping; Sharma, Padmanee] Univ Texas MD Anderson Canc Ctr UTHlth, Grad Sch Biomed Sci, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Sharma, P (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.; Sharma, P (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA.; Sharma, P (corresponding author), Univ Texas MD Anderson Canc Ctr UTHlth, Grad Sch Biomed Sci, Houston, TX 77030 USA.	padsharma@mdanderson.org	Miura, Y/AFL-6835-2022	Jiao, Shiping/0000-0001-6546-9369				Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Asadzadeh Z, 2017, CELL IMMUNOL, V322, P15, DOI 10.1016/j.cellimm.2017.10.015; Bailey SR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00276; Beer TM, 2017, J CLIN ONCOL, V35, P40, DOI 10.1200/JCO.2016.69.1584; Berish RB, 2018, NAT REV UROL, V15, P403, DOI 10.1038/s41585-018-0020-2; Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018; Bronkhorst IHG, 2012, INVEST OPHTH VIS SCI, V53, P5370, DOI 10.1167/iovs.11-9280; Chen H, 2009, P NATL ACAD SCI USA, V106, P2729, DOI 10.1073/pnas.0813175106; CHIU CP, 1988, P NATL ACAD SCI USA, V85, P7099, DOI 10.1073/pnas.85.19.7099; Doering TA, 2012, IMMUNITY, V37, P1130, DOI 10.1016/j.immuni.2012.08.021; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Fu S, 2004, AM J TRANSPLANT, V4, P1614, DOI 10.1111/j.1600-6143.2004.00566.x; Fuchs CS, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2018.0013; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gao JJ, 2017, NAT MED, V23, P551, DOI 10.1038/nm.4308; Halabi S, 2016, J CLIN ONCOL, V34, P1652, DOI 10.1200/JCO.2015.65.7270; He SB, 2011, INT J MOL SCI, V12, P7424, DOI 10.3390/ijms12117424; Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/S1470-2045(16)30624-6, 10.1016/s1470-2045(16)30624-6]; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Intlekofer AM, 2005, NAT IMMUNOL, V6, P1236, DOI 10.1038/ni1268; ISHIMI Y, 1990, J IMMUNOL, V145, P3297; Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441; Kurachi M, 2011, J EXP MED, V208, P1605, DOI 10.1084/jem.20102101; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Liakou CI, 2008, P NATL ACAD SCI USA, V105, P14987, DOI 10.1073/pnas.0806075105; Lin JT, 2005, J IMMUNOL, V174, P5950, DOI 10.4049/jimmunol.174.10.5950; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Marcais A, 2006, J IMMUNOL, V177, P4451, DOI 10.4049/jimmunol.177.7.4451; Martin F, 2012, TRENDS MOL MED, V18, P742, DOI 10.1016/j.molmed.2012.09.007; Milner JJ, 2017, NATURE, V552, P253, DOI 10.1038/nature24993; Noack M, 2014, AUTOIMMUN REV, V13, P668, DOI 10.1016/j.autrev.2013.12.004; Nowicka Malgorzata, 2017, F1000Res, V6, P748, DOI 10.12688/f1000research.11622.3; Ogasawara H, 1996, J CELL PHYSIOL, V169, P209, DOI 10.1002/(SICI)1097-4652(199610)169:1<209::AID-JCP21>3.3.CO;2-Y; Park IK, 2005, J IMMUNOL, V175, P5666, DOI 10.4049/jimmunol.175.9.5666; Patel MR, 2018, LANCET ONCOL, V19, P51, DOI 10.1016/S1470-2045(17)30900-2; Punt S, 2016, CANCER IMMUNOL IMMUN, V65, P393, DOI 10.1007/s00262-016-1805-x; Qiu XJ, 2017, NAT METHODS, V14, P309, DOI [10.1038/NMETH.4150, 10.1038/nmeth.4150]; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8; Scheper W, 2019, NAT MED, V25, P89, DOI 10.1038/s41591-018-0266-5; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; SHARMA P, 2019, J CLIN ONCOL S, V37; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Simoni Y, 2018, NATURE, V557, P575, DOI 10.1038/s41586-018-0130-2; Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Zhang JP, 2009, J HEPATOL, V50, P980, DOI 10.1016/j.jhep.2008.12.033; Zou WP, 2010, NAT REV IMMUNOL, V10, P248, DOI 10.1038/nri2742	55	162	173	8	46	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 14	2019	179	5					1177	+		10.1016/j.cell.2019.10.029	http://dx.doi.org/10.1016/j.cell.2019.10.029			27	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN5BQ	31730856	Bronze			2023-01-03	WOS:000496914200014
J	Brunelli, DT; Finardi, EAR; Bonfante, ILP; Gaspari, AF; Sardeli, AV; Souza, TMF; Chacon-Mikahil, MPT; Cavaglieri, CR				Brunelli, Diego T.; Finardi, Enrico A. R.; Bonfante, Ivan L. P.; Gaspari, Arthur F.; Sardeli, Amanda, V; Souza, Thiago M. F.; Chacon-Mikahil, Mara P. T.; Cavaglieri, Claudia R.			Acute low- compared to high-load resistance training to failure results in greater energy expenditure during exercise in healthy young men	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; STRENGTH; RELIABILITY; METABOLISM; VALIDITY; WORK	The objective of the present study was to verify the energy expenditure (EE), energy system contributions and autonomic control during and after an acute low-load or high-load resistance training (RT) protocol to momentary failure (MF) in young adults. Eleven young men (22 +/- 3 yrs, 71.8 +/- 7.7 kg; 1.75 +/- 0.06 m) underwent a randomized crossover design of three knee extension acute protocols: a low-load RT [30% of their maximal strength (1RM); RT30] or a high-load RT (80% of 1RM; RT80) protocol, with all sets being performed to MF; or a control session (Control) without exercise. Participants were measured for EE, energy system contributions, and cardiac autonomic control before, during, and after each exercise session. Exercise EE was significantly higher for RT30 as compared to RT80. Furthermore, post measurements of blood lactate levels and the anaerobic lactic system contribution were significantly greater for RT30 as compared to RT80. In addition, parasympathetic restoration was lower for RT30 as compared to RT80. In conclusion, a low-load (30% 1RM) RT session produced higher EE during exercise than a high-load (80% 1RM) RT session to MF, and may be a good option for fitness professionals, exercise physiologists, and practitioners when choosing the optimal RT protocol that provides more EE, especially for those who want or need to lose weight.	[Brunelli, Diego T.; Finardi, Enrico A. R.; Bonfante, Ivan L. P.; Gaspari, Arthur F.; Sardeli, Amanda, V; Souza, Thiago M. F.; Chacon-Mikahil, Mara P. T.; Cavaglieri, Claudia R.] Univ Campinas UNICAMP, Exercise Physiol Lab FISEX, Fac Phys Educ, Campinas, SP, Brazil; [Sardeli, Amanda, V; Chacon-Mikahil, Mara P. T.; Cavaglieri, Claudia R.] Univ Campinas UNICAMP, Fac Med Sci, Grad Program Gerontol, Campinas, SP, Brazil	Universidade Estadual de Campinas; Universidade Estadual de Campinas	Brunelli, DT (corresponding author), Univ Campinas UNICAMP, Exercise Physiol Lab FISEX, Fac Phys Educ, Campinas, SP, Brazil.	diegotbrunelli@gmail.com	Sardeli, Amanda V/Q-3096-2016; Bonfante, Ivan Luiz Padilha/AAN-3544-2020; Cavaglieri, Cláudia Regina/C-4291-2012; Souza, Thiago Moreno L./G-2900-2012	Sardeli, Amanda V/0000-0003-0575-7996; Cavaglieri, Cláudia Regina/0000-0002-7795-6575; Souza, Thiago Moreno L./0000-0003-2212-3899; Chacon-Mikahil, Mara Patricia Traina/0000-0002-6109-5141; Brunelli, Diego/0000-0001-8538-7096; Bonfante, Ivan/0000-0001-6278-4611	National Council for Scientific and Technological Development [CNPq] [123216/2015-0]	National Council for Scientific and Technological Development [CNPq](Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by the Scientific initiation scholarship supported by the National Council for Scientific and Technological Development [CNPq; process no 123216/2015-0 scientific initiation scholarship to E.A.R.F. -http://www.cnpq.br).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	Amann M, 2010, J APPL PHYSIOL, V109, P966, DOI 10.1152/japplphysiol.00462.2010; Artioli GG, 2012, JOVE-J VIS EXP, V20; Bertuzzi R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145733; BORG G, 1962, ACTA PHYSIOL SCAND, V55, P353, DOI 10.1111/j.1748-1716.1962.tb02449.x; Borsheim E, 1998, ACTA PHYSIOL SCAND, V162, P313, DOI 10.1046/j.1365-201X.1998.0321e.x; Borsheim E, 2003, SPORTS MED, V33, P1037; Brown LE, 2001, J EXERC PHYSL ONLINE, V4, P1; Burd NA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012033; Camm AJ, 1996, EUR HEART J, V17, P354; Catai AM, 2019, BRAZ J PHYS THER; di Prampero PE, 1999, RESP PHYSIOL, V118, P103, DOI 10.1016/S0034-5687(99)00083-3; Donnelly JE, 2009, MED SCI SPORT EXER, V41, P459, DOI 10.1249/MSS.0b013e3181949333; Fisher JP, 2015, COMPR PHYSIOL, V5, P475, DOI 10.1002/cphy.c140022; Florindo AAL, 2003, REV BRAS MED ESPORTE, V9, P8; Gastin P. B., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P91; Haseler LJ, 1999, J APPL PHYSIOL, V86, P2013, DOI 10.1152/jappl.1999.86.6.2013; Hunter RP, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9010010; Jenkins NDM, 2016, J STRENGTH COND RES, V30, P2174, DOI 10.1519/JSC.0000000000001308; Kelleher AR, 2010, J STRENGTH COND RES, V24, P1043, DOI 10.1519/JSC.0b013e3181d3e993; Margaria R, 1933, AM J PHYSIOL, V106, P689, DOI 10.1152/ajplegacy.1933.106.3.689; Marx JO, 2001, MED SCI SPORT EXER, V33, P635, DOI 10.1097/00005768-200104000-00019; Mookerjee S, 2016, J STRENGTH COND RES, V30, P1447, DOI 10.1519/JSC.0000000000001230; Morton RW, 2016, J APPL PHYSIOL, V121, P129, DOI 10.1152/japplphysiol.00154.2016; Niskanen JP, 2004, COMPUT METH PROG BIO, V76, P73, DOI 10.1016/j.cmpb.2004.03.004; Nunan D, 2009, MED SCI SPORT EXER, V41, P243, DOI 10.1249/MSS.0b013e318184a4b1; Paoli A, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-237; Pizza FX, 2001, CAN J APPL PHYSIOL, V26, P245, DOI 10.1139/h01-015; Prestes J, 2009, J STRENGTH COND RES, V23, P266, DOI 10.1519/JSC.0b013e3181874bf3; Sardeli AV, 2017, INT J SPORTS MED, V38, P928, DOI 10.1055/s-0043-115737; Scott CB, 2011, J STRENGTH COND RES, V25, P903, DOI 10.1519/JSC.0b013e3181c6a128; Shaffer F, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00258; Steele J, 2017, MUSCLE NERVE, V56, P368, DOI 10.1002/mus.25557; Strasser B, 2012, OBES REV, V13, P578, DOI 10.1111/j.1467-789X.2012.00988.x; Thompson PD, 2007, CIRCULATION, V115, P2358, DOI 10.1161/CIRCULATIONAHA.107.181485; Thornton MK, 2002, MED SCI SPORT EXER, V34, P715, DOI 10.1249/00005768-200204000-00024	35	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2019	14	11							e0224801	10.1371/journal.pone.0224801	http://dx.doi.org/10.1371/journal.pone.0224801			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN1IV	31710635	gold, Green Published			2023-01-03	WOS:000532699900021
J	Perry, BL; Yang, KC; Kaminski, P; Odabas, M; Park, J; Martel, M; Oser, CB; Freeman, PR; Ahn, YY; Talbert, J				Perry, Brea L.; Yang, Kai Cheng; Kaminski, Patrick; Odabas, Meltem; Park, Jaehyuk; Martel, Michelle; Oser, Carrie B.; Freeman, Patricia R.; Ahn, Yong-Yeol; Talbert, Jeffery			Co-prescription network reveals social dynamics of opioid doctor shopping	PLOS ONE			English	Article							DRUG-MONITORING PROGRAMS; HEROIN USE; UNITED-STATES; SHOPPERS; IMPACT	This paper examines network prominence in a co-prescription network as an indicator of opioid doctor shopping (i.e., fraudulent solicitation of opioids from multiple prescribers). Using longitudinal data from a large commercially insured population, we construct a network where a tie between patients is weighted by the number of shared opioid prescribers. Given prior research suggesting that doctor shopping may be a social process, we hypothesize that active doctor shoppers will occupy central structural positions in this network. We show that network prominence, operationalized using PageRank, is associated with more opioid prescriptions, higher predicted risk for dangerous morphine dosage, opioid overdose, and opioid use disorder, controlling for number of prescribers and other variables. Moreover, as a patient's prominence increases over time, so does their risk for these outcomes, compared to their own average level of risk. Results highlight the importance of co-prescription networks in characterizing high-risk social dynamics.	[Perry, Brea L.; Ahn, Yong-Yeol] Indiana Univ, Network Sci Inst, 1001 45-46 Bypass, Bloomington, IN 47408 USA; [Perry, Brea L.; Kaminski, Patrick; Odabas, Meltem] Indiana Univ, Dept Sociol, Bloomington, IN 47408 USA; [Yang, Kai Cheng; Kaminski, Patrick; Park, Jaehyuk; Ahn, Yong-Yeol] Indiana Univ, Sch Informat Comp & Engn, Bloomington, IN USA; [Martel, Michelle] Univ Kentucky, Dept Psychol, Lexington, KY 40506 USA; [Oser, Carrie B.] Univ Kentucky, Dept Sociol, Lexington, KY USA; [Freeman, Patricia R.; Talbert, Jeffery] Univ Kentucky, Dept Pharm Practice & Sci, Lexington, KY USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; University of Kentucky; University of Kentucky; University of Kentucky	Perry, BL (corresponding author), Indiana Univ, Network Sci Inst, 1001 45-46 Bypass, Bloomington, IN 47408 USA.; Perry, BL (corresponding author), Indiana Univ, Dept Sociol, Bloomington, IN 47408 USA.	blperry@indiana.edu	Yang, Kai-Cheng/HGT-9880-2022; Ahn, Yong-Yeol/C-6334-2011; Odabas, Meltem/AAG-8715-2021; Yang, Kai-Cheng/ABI-7165-2020	Yang, Kai-Cheng/0000-0003-4627-9273; Ahn, Yong-Yeol/0000-0002-4352-4301; Odabas, Meltem/0000-0001-6123-0676; Talbert, Jeffery/0000-0002-4304-5167; Perry, Brea/0000-0001-7869-7168; Kaminski, Patrick/0000-0002-2009-9170	National Institute on Drug Abuse [R01 DA039928]; Indiana University Addictions Grand Challenge Grant; University of Kentucky Interdisciplinary Research Collaborations Seed Grant; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA039928] Funding Source: NIH RePORTER	National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Indiana University Addictions Grand Challenge Grant; University of Kentucky Interdisciplinary Research Collaborations Seed Grant; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This research was funded by a grant from the National Institute on Drug Abuse (R01 DA039928) to the first author, BLP. Information about NIDA can be found at https://www.drugabuse.gov/.Funding was also provided by an Indiana University Addictions Grand Challenge Grant, and a University of Kentucky Interdisciplinary Research Collaborations Seed Grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This research was funded by the National Institute on Drug Abuse (R01 DA039928), an Indiana University Addictions Grand Challenge Grant, and a University of Kentucky Interdisciplinary Research Collaborations Seed Grant. We would like to thank the information technology team at the Indiana University Network Science Institute for their technical support.	Ahmad F.B., 2018, PROVISIONAL DRUG OVE; Ali MM, 2017, ADDICT BEHAV, V69, P65, DOI 10.1016/j.addbeh.2017.01.011; Alpert A, 2018, AM ECON J-ECON POLIC, V10, P1, DOI 10.1257/pol.20170082; Appalachian Regional Commission, 2018, APP REG 2018; Ayres I, 2018, J LAW MED ETHICS, V46, P387, DOI 10.1177/1073110518782948; Brin S, 1998, COMPUT NETWORKS ISDN, V30, P107, DOI 10.1016/S0169-7552(98)00110-X; Centers for Disease Control and Prevention, 2017, 1 CTR DIS CONTR PREV; Cepeda MS, 2015, AM J DRUG ALCOHOL AB, V41, P226, DOI 10.3109/00952990.2014.945591; Cepeda MS, 2013, J PAIN, V14, P1158, DOI 10.1016/j.jpain.2013.04.014; Cicero TJ, 2014, JAMA PSYCHIAT, V71, P821, DOI 10.1001/jamapsychiatry.2014.366; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Dasgupta N, 2018, AM J PUBLIC HEALTH, V108, P182, DOI 10.2105/AJPH.2017.304187; Deng HB, 2009, KDD-09: 15TH ACM SIGKDD CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P239; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Finley EP, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2354-5; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Harp JP, 2015, DRUG ALCOHOL DEPEN, V100, pe135; Hoffman L, 2015, MULTIVAR APPL SER, P1; Inciardi JA, 2007, PAIN MED, V8, P171, DOI 10.1111/j.1526-4637.2006.00255.x; Jalal H, 2018, SCIENCE, V361, P1218, DOI 10.1126/science.aau1184; Jena Anupam B, 2014, BMJ, V348, pg1393, DOI 10.1136/bmj.g1393; Keyes KM, 2014, AM J PUBLIC HEALTH, V104, pE52, DOI 10.2105/AJPH.2013.301709; Lowder EM, 2018, AM J PUBLIC HEALTH, V108, P1682, DOI 10.2105/AJPH.2018.304683; Martin T, 2014, PHYS REV E, V90, DOI 10.1103/PhysRevE.90.052808; Martins SS, 2017, JAMA PSYCHIAT, V74, P445, DOI 10.1001/jamapsychiatry.2017.0113; Martyres RF, 2004, MED J AUSTRALIA, V180, P211, DOI 10.5694/j.1326-5377.2004.tb05887.x; McCarty D, 2018, ANNU REV PUBL HEALTH, V39, P525, DOI [10.1146/annurev-publhealth-040617-013526, 10.1146/annurev-publhealth0040617-013526]; Ong MS, 2016, J GEN INTERN MED, V31, P164, DOI 10.1007/s11606-015-3470-8; Pauly NJ, 2018, DRUG ALCOHOL DEPEN, V184, P26, DOI 10.1016/j.drugalcdep.2017.12.002; Peirce GL, 2012, MED CARE, V50, P494, DOI 10.1097/MLR.0b013e31824ebd81; Reifler LM, 2012, PAIN MED, V13, P434, DOI 10.1111/j.1526-4637.2012.01327.x; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Ruhm CJ, 2018, ADDICTION, V113, P1339, DOI 10.1111/add.14144; SAMHSA Administration, 2014, METH ASS MORT REP AN; Simeone R, 2017, SUBST ABUS-RES TREAT, V11, DOI 10.1177/1178221817696077; Slavova S, 2015, PUBLIC HEALTH REP, V130, P339, DOI 10.1177/003335491513000411; Williams J, 2002, APPALACHIA HIST; Wilsey BL, 2011, PHARMACOEPIDEM DR S, V20, P1262, DOI 10.1002/pds.2129; Wood EF, 2017, INT J DRUG POLICY, V41, P132, DOI 10.1016/j.drugpo.2016.12.010; Worley J, 2014, WESTERN J NURS RES, V36, P456, DOI 10.1177/0193945913509692; Worley J, 2012, RES THEOR NURS PRACT, V26, P262, DOI 10.1891/1541-6577.26.4.262	41	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 25	2019	14	10							e0223849	10.1371/journal.pone.0223849	http://dx.doi.org/10.1371/journal.pone.0223849			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LN0LX	31652266	Green Published, gold, Green Submitted			2023-01-03	WOS:000532638300011
J	Rawal, S; Srighanthan, J; Vasantharoopan, A; Hu, HX; Tomlinson, G; Cheung, AM				Rawal, Shail; Srighanthan, Jeevitha; Vasantharoopan, Arthi; Hu, Hanxian; Tomlinson, George; Cheung, Angela M.			Association Between Limited English Proficiency and Revisits and Readmissions After Hospitalization for Patients With Acute and Chronic Conditions in Toronto, Ontario, Canada	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							LANGUAGE BARRIERS; CARE	This study discusses observed associations between limited English proficiency, revisits, and readmissions to 2 Toronto hospitals.	[Rawal, Shail; Tomlinson, George; Cheung, Angela M.] Univ Toronto, Dept Med, 190 Elizabeth St,R Fraser Elliot Bldg,3-805, Toronto, ON M5G 2C4, Canada; [Srighanthan, Jeevitha; Hu, Hanxian] Univ Hlth Network, Toronto Gen Res Inst, Toronto, ON, Canada; [Vasantharoopan, Arthi] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of London; London School of Hygiene & Tropical Medicine	Rawal, S (corresponding author), Univ Toronto, Dept Med, 190 Elizabeth St,R Fraser Elliot Bldg,3-805, Toronto, ON M5G 2C4, Canada.	shail.rawal@uhn.ca	Tomlinson, George/L-5432-2016	Tomlinson, George/0000-0002-9328-6399; Cheung, Angela M./0000-0001-8332-0744	HoPingKong Centre for Excellence in Education and Practice; Canada Research Chair award	HoPingKong Centre for Excellence in Education and Practice; Canada Research Chair award(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs)	Dr Rawal was supported by a fellowship from the HoPingKong Centre for Excellence in Education and Practice and Dr Cheung by a Tier 1 Canada Research Chair award.	Divi C, 2007, INT J QUAL HEALTH C, V19, P60, DOI 10.1093/intqhc/mzl069; Graham CL, 2009, GERONTOLOGIST, V49, P23, DOI 10.1093/geront/gnp005; Grubbs V, 2008, J GEN INTERN MED, V23, P190, DOI 10.1007/s11606-007-0459-y; Karliner LS, 2012, MED CARE, V50, P283, DOI 10.1097/MLR.0b013e318249c949; Karliner LS, 2010, J HOSP MED, V5, P276, DOI 10.1002/jhm.658; Wilson E, 2005, J GEN INTERN MED, V20, P800, DOI 10.1111/j.1525-1497.2005.0174.x	6	28	28	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	2019	322	16					1605	1607		10.1001/jama.2019.13066	http://dx.doi.org/10.1001/jama.2019.13066			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ0VU	31638666	Bronze, Green Published			2023-01-03	WOS:000498673500021
J	Pulopulos, MM; De Witte, S; Vanderhasselt, MA; De Raedt, R; Schiettecatte, J; Anckaert, E; Salvador, A; Baeken, C				Pulopulos, Matias M.; De Witte, Sara; Vanderhasselt, Marie-Anne; De Raedt, Rudi; Schiettecatte, Johan; Anckaert, Ellen; Salvador, Alicia; Baeken, Chris			The influence of personality on the effect of iTBS after being stressed on cortisol secretion	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; HF-RTMS SESSION; PITUITARY-ADRENAL AXIS; UNDER-THE-CURVE; SALIVARY CORTISOL; PSYCHOSOCIAL STRESS; PREFRONTAL CORTEX; MAJOR DEPRESSION; SEX-DIFFERENCES; 5-FACTOR MODEL	Over the last years, individualization of repetitive Transcranial Magnetic Stimulation (rTMS) parameters has been a focus of attention in the field of non-invasive stimulation. It has been proposed that in stress-related disorders personality characteristics may influence the clinical outcome of rTMS. However, the underlying physiological mechanisms as to how personality may affect the rTMS response to stress remains to be clarified. In this sham-controlled crossover study, after being stressed by the Trier Social Stress Test, 38 healthy females received two sessions of intermittent theta burst stimulation (iTBS) applied to the left dorsolateral prefrontal cortex. To take possible personality influences into account, they also completed the Temperament and Character Inventory. Mood and salivary cortisol were assessed throughout the experimental protocol. Overall, two iTBS sessions did not significantly alter mood or influenced cortisol secretion. When taking into account personality features, higher scores on the character dimension Cooperativeness was related to decreased cortisol output, only when active iTBS was administered after the social stressor. In line with other studies, personality features such as the character dimension Cooperativeness may be of particular interest to explain individual neurobiological responses to neurostimulation.	[Pulopulos, Matias M.; De Raedt, Rudi] Univ Ghent, Dept Expt Clin & Hlth Psychol, Ghent, Belgium; [De Witte, Sara; Vanderhasselt, Marie-Anne; Baeken, Chris] Univ Ghent, Dept Head & Skin, Ghent, Belgium; [De Witte, Sara; Vanderhasselt, Marie-Anne; Baeken, Chris] Univ Ghent, Ghent Expt Psychiat GHEP Lab, Ghent, Belgium; [Schiettecatte, Johan; Anckaert, Ellen] Univ Hosp UZBrussel, Lab Hormonol & Tumor Markers, Brussels, Belgium; [Salvador, Alicia] Univ Valencia, Dept Psychobiol, Lab Social Cognit Neurosci, Valencia, Spain; [Salvador, Alicia] Univ Valencia, IDOCAL, Valencia, Spain; [Baeken, Chris] Univ Hosp UZBrussel, Dept Psychiat, Brussels, Belgium; [Baeken, Chris] Eindhoven Univ Technol, Dept Elect Engn, Eindhoven, Netherlands	Ghent University; Ghent University; Ghent University; University of Valencia; University of Valencia; Eindhoven University of Technology	Pulopulos, MM (corresponding author), Univ Ghent, Dept Expt Clin & Hlth Psychol, Ghent, Belgium.	matias.pulopulos@ugent.be	De Raedt, Rudi/A-3269-2012; De Raedt, Rudi/AAL-4093-2021; Pulopulos, Matias M./M-1573-2014; Baeken, Chris/D-6790-2013	De Raedt, Rudi/0000-0001-6781-4808; De Raedt, Rudi/0000-0001-6781-4808; Pulopulos, Matias M./0000-0002-7048-3795; Schiettecatte, Johan/0000-0001-7491-5914; Vanderhasselt, Marie-Anne/0000-0002-4045-1055; De Witte, Sara/0000-0001-9808-6516	Ghent University [BOF16/GOA/017, BOFSTA2017002501]; Applied Biomedical (TBM) grant of the agency for Innovation through Science and Technology (IWT), part of the Research Foundation -Flanders (FWO) [B/14730/01]; Fonds Wetenschappelijk Onderzoek (FWO) Rode Neuzen [G0F4617N]; Research Foundation Flanders [FWO18/PDO/174]	Ghent University(Ghent University); Applied Biomedical (TBM) grant of the agency for Innovation through Science and Technology (IWT), part of the Research Foundation -Flanders (FWO); Fonds Wetenschappelijk Onderzoek (FWO) Rode Neuzen; Research Foundation Flanders(FWO)	This study was supported by Grant BOF16/GOA/017 for a Concerted Research Action of Ghent University and by an Applied Biomedical (TBM) grant of the agency for Innovation through Science and Technology (IWT), part of the Research Foundation -Flanders (FWO), awarded to the PrevenD project (B/14730/01), a grant of het Fonds Wetenschappelijk Onderzoek (FWO) Rode Neuzen G0F4617N, and a grant for research at Ghent University (BOFSTA2017002501, awarded to MAV). MMP is a postdoctoral research fellow, supported by the Research Foundation Flanders (FWO18/PDO/174). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen AP, 2017, NEUROBIOL STRESS, V6, P113, DOI 10.1016/j.ynstr.2016.11.001; Baeken C, 2014, NEUROPSYCHOLOGIA, V57, P112, DOI 10.1016/j.neuropsychologia.2014.02.019; Baeken C, 2011, PSYCHONEUROENDOCRINO, V36, P60, DOI 10.1016/j.psyneuen.2010.06.006; Baeken C, 2010, BEHAV BRAIN RES, V214, P450, DOI 10.1016/j.bbr.2010.06.029; Baeken C, 2009, J AFFECT DISORDERS, V113, P100, DOI 10.1016/j.jad.2008.05.008; Baeken C, 2014, PSYCHIAT RES, V220, P269, DOI 10.1016/j.psychres.2014.07.084; Baeken C, 2014, WORLD J BIOL PSYCHIA, V15, P286, DOI 10.3109/15622975.2013.872295; Baeken Chris, 2011, Dialogues Clin Neurosci, V13, P139; Baeken C, 2009, WORLD J BIOL PSYCHIA, V10, P586, DOI 10.1080/15622970701560351; Bakker N, 2015, BRAIN STIMUL, V8, P208, DOI 10.1016/j.brs.2014.11.002; Barden N, 2004, J PSYCHIATR NEUROSCI, V29, P185; Barrash J, 2000, DEV NEUROPSYCHOL, V18, P355, DOI 10.1207/S1532694205Barrash; Bayon C, 1996, J PSYCHIAT RES, V30, P341, DOI 10.1016/0022-3956(96)00024-6; Beck A.T., 1996, BECK DEPRESSION INVE, DOI DOI 10.1037/T00742-000; Berlim MT, 2013, NEUROSCI LETT, V534, P306, DOI 10.1016/j.neulet.2012.12.029; Blumberger DM, 2018, LANCET, V391, P1683, DOI 10.1016/S0140-6736(18)30295-2; Brunoni AR, 2017, JAMA PSYCHIAT, V74, P143, DOI 10.1001/jamapsychiatry.2016.3644; Buck R, 1999, PSYCHOL REV, V106, P301, DOI 10.1037/0033-295X.106.2.301; CLONINGER CR, 1987, ARCH GEN PSYCHIAT, V44, P573; Cloninger CR, 1998, J AFFECT DISORDERS, V51, P21, DOI 10.1016/S0165-0327(98)00153-0; Cloninger RC., 1994, TEMPERAMENT CHARACTE; Connaughton A, 2014, FRONT MED, V1, DOI 10.3389/fmed.2014.00022; De Fruyt F, 2000, PERS INDIV DIFFER, V29, P441, DOI 10.1016/S0191-8869(99)00204-4; de la Rie SM, 1998, J PERS DISORD, V12, P362, DOI 10.1521/pedi.1998.12.4.362; De Raedt R, 2015, FROM SYMPTOM TO SYNAPSE: A NEUROCOGNITIVE PERSPECTIVE ON CLINICAL PSYCHOLOGY, P247; Drysdale AT, 2017, NAT MED, V23, P28, DOI 10.1038/nm.4246; Duprat R, 2016, J AFFECT DISORDERS, V200, P6, DOI 10.1016/j.jad.2016.04.015; Fekedulegn DB, 2007, PSYCHOSOM MED, V69, P651, DOI 10.1097/PSY.0b013e31814c405c; Goodman WK, 2017, PSYCHONEUROENDOCRINO, V80, P26, DOI 10.1016/j.psyneuen.2017.02.030; Gusnard DA, 2003, P NATL ACAD SCI USA, V100, P3479, DOI 10.1073/pnas.0538050100; Herman JP, 2005, PROG NEURO-PSYCHOPH, V29, P1201, DOI 10.1016/j.pnpbp.2005.08.006; Hermans EJ, 2014, TRENDS NEUROSCI, V37, P304, DOI 10.1016/j.tins.2014.03.006; Hori H, 2013, J AFFECT DISORDERS, V147, P128, DOI 10.1016/j.jad.2012.10.022; Horia H, 2010, J PSYCHIATR RES, V44, P865, DOI 10.1016/j.jpsychires.2010.02.007; Huber TJ, 2003, PSYCHIAT RES, V120, P103, DOI 10.1016/S0165-1781(03)00170-7; Keck ME, 2003, SUPPL CLIN NEUROPHYS, V56, P100; Keck ME, 2001, PEPTIDES, V22, P835, DOI 10.1016/S0196-9781(01)00398-9; KIRSCHBAUM C, 1992, PSYCHOSOM MED, V54, P648, DOI 10.1097/00006842-199211000-00004; KIRSCHBAUM C, 1993, NEUROPSYCHOBIOLOGY, V28, P76, DOI 10.1159/000119004; Kudielka BM, 2004, PSYCHONEUROENDOCRINO, V29, P83, DOI 10.1016/S0306-4530(02)00146-4; Kudielka BM, 2009, PSYCHONEUROENDOCRINO, V34, P2, DOI 10.1016/j.psyneuen.2008.10.004; Lecrubier Y, 1997, EUR PSYCHIAT, V12, P224, DOI 10.1016/S0924-9338(97)83296-8; Lefaucheur JP, 2014, CLIN NEUROPHYSIOL, V125, P2150, DOI 10.1016/j.clinph.2014.05.021; Liu JJW, 2017, PSYCHONEUROENDOCRINO, V82, P26, DOI 10.1016/j.psyneuen.2017.04.007; MCCORMACK HM, 1988, PSYCHOL MED, V18, P1007, DOI 10.1017/S0033291700009934; MCCRAE RR, 1987, J PERS SOC PSYCHOL, V52, P81, DOI 10.1037/0022-3514.52.1.81; McGirr A, 2014, NEUROSCI LETT, V563, P144, DOI 10.1016/j.neulet.2014.01.037; Padberg F, 2017, EUR ARCH PSY CLIN N, V267, pS109, DOI 10.1007/s00406-017-0853-3; Pridmore S, 1999, PSYCHIAT CLIN NEUROS, V53, P33; Pruessner JC, 2003, PSYCHONEUROENDOCRINO, V28, P916, DOI 10.1016/S0306-4530(02)00108-7; Pulopulos MM, 2018, PSICOTHEMA, V30, P171, DOI 10.7334/psicothema2017.200; Remue J, 2016, NEUROPSYCHOLOGY, V30, P756, DOI 10.1037/neu0000255; Remue J, 2016, NEUROPSYCHOLOGIA, V85, P184, DOI 10.1016/j.neuropsychologia.2016.03.012; Schulze L, 2018, BRAIN STIMUL, V11, P327, DOI 10.1016/j.brs.2017.11.002; Schutter DJLG, 2009, PSYCHOL MED, V39, P65, DOI 10.1017/S0033291708003462; Schutter DJLG, 2010, PSYCHONEUROENDOCRINO, V35, P171, DOI 10.1016/j.psyneuen.2009.04.009; Siddiqi SH, 2016, J PSYCHIATR PRACT, V22, P193, DOI 10.1097/PRA.0000000000000150; Singh A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42067-3; Stephens MAC, 2016, PSYCHONEUROENDOCRINO, V66, P47, DOI 10.1016/j.psyneuen.2015.12.021; SVRAKIC DM, 1993, ARCH GEN PSYCHIAT, V50, P991; Van der Does A.J.W, 2002, MANUAL DUTCH VERSION; Van Schuerbeek P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153865; Van Schuerbeek P, 2014, BEHAV BRAIN FUNCT, V10, DOI 10.1186/1744-9081-10-18; Van Schuerbeek P, 2011, BRAIN RES, V1371, P32, DOI 10.1016/j.brainres.2010.11.073; Xin YY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17053-2; Zafar N, 2008, CLIN NEUROPHYSIOL, V119, P1393, DOI 10.1016/j.clinph.2008.02.006; Zorn JV, 2017, PSYCHONEUROENDOCRINO, V77, P25, DOI 10.1016/j.psyneuen.2016.11.036	67	9	9	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2019	14	10							e0223927	10.1371/journal.pone.0223927	http://dx.doi.org/10.1371/journal.pone.0223927			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KX0DI	31618272	Green Published, gold			2023-01-03	WOS:000521553400001
J	Palekar, RS; Rolfes, MA; Arriola, CS; Acosta, BO; Guidos, PA; Vargas, XB; Bancej, C; Ramirez, JB; Baumeister, E; Bruno, A; Cabello, MA; Chen, JF; Couto, P; De Paula, FJ; Fasce, R; de Almeida, WF; Solorzano, VEF; Ramirez, CF; Goni, N; de Molto, YI; Lara, J; Malo, DC; Osis, JLM; Mejia, H; Castillo, LM; Mustaquim, D; Nwosu, A; Ojeda, J; Samoya, AP; Pulido, PA; Hernandez, HMR; Lopez, RR; Rodriguez, A; Saboui, M; Bolanos, HS; Santoro, A; Silvera, JE; Sosa, P; Sotomayor, V; Suarez, L; Von Horoch, M; Azziz-Baumgartner, E				Palekar, Rakhee S.; Rolfes, Melissa A.; Arriola, C. Sofia; Acosta, Belsy O.; Guidos, Patricia Alberto; Badilla Vargas, Xiomara; Bancej, Christina; Barbosa Ramirez, Juliana; Baumeister, Elsa; Bruno, Alfredo; Cabello, Maria Agueda; Chen, Jufu; Couto, Paula; De Paula Junior, Francisco J.; Fasce, Rodrigo; de Almeida, Walquiria Ferreira; Fiesta Solorzano, Victor E.; Ramirez, Carlos Flores; Goni, Natalia; de Molto, Yadira Isaza; Lara, Jenny; Malo, Diana C.; Medina Osis, Jose L.; Mejia, Homer; Castillo, Lourdes Moreno; Mustaquim, Desiree; Nwosu, Andrea; Ojeda, Jenny; Paredes Samoya, Antonio; Pulido, Paola A.; Hernandez, Hector M. Ramos; Lopez, Rudvelinda Rivera; Rodriguez, Angel; Saboui, Myriam; Salazar Bolanos, Hilda; Santoro, Adrian; Eduardo Silvera, Jose; Sosa, Paulina; Sotomayor, Viviana; Suarez, Lourdes; Von Horoch, Marta; Azziz-Baumgartner, Eduardo			Burden of influenza-associated respiratory hospitalizations in the Americas, 2010-2015	PLOS ONE			English	Article							SEASONAL INFLUENZA; HEALTH-CARE; EXCESS PNEUMONIA; UNITED-STATES; SURVEILLANCE; DEATHS; VIRUS; ILLNESS; MORTALITY; CHILDREN	Background Despite having influenza vaccination policies and programs, countries in the Americas underutilize seasonal influenza vaccine, in part because of insufficient evidence about severe influenza burden. We aimed to estimate the annual burden of influenza-associated respiratory hospitalizations in the Americas. Methods Thirty-five countries in the Americas with national influenza surveillance were invited to provide monthly laboratory data and hospital discharges for respiratory illness (International Classification of Diseases 10th edition J codes 0-99) during 2010-2015. In three age-strata (< 5, 5-64, and >= 65 years), we estimated the influenza-associated hospitalizations rate by multiplying the monthly number of respiratory hospitalizations by the monthly proportion of influenza-positive samples and dividing by the census population. We used random effects meta-analyses to pool age-group specific rates and extrapolated to countries that did not contribute data, using pooled rates stratified by age group and country characteristics found to be associated with rates. Results Sixteen of 35 countries (46%) contributed primary data to the analyses, representing 79% of the America's population. The average pooled rate of influenza-associated respiratory hospitalization was 90/100,000 population (95% confidence interval 61-132) among children aged < 5 years, 21/100,000 population (13-32) among persons aged 5-64 years, and 141/100,000 population (95-211) among persons aged.65 years. We estimated the average annual number of influenza-associated respiratory hospitalizations in the Americas to be 772,000 (95% credible interval 716,000-829,000). Conclusions Influenza-associated respiratory hospitalizations impose a heavy burden on health systems in the Americas. Countries in the Americas should use this information to justify investments in seasonal influenza vaccination-especially among young children and the elderly.	[Palekar, Rakhee S.; Couto, Paula; Rodriguez, Angel; Sosa, Paulina] Pan Amer Hlth Org, WHO, Washington, DC 20037 USA; [Rolfes, Melissa A.; Arriola, C. Sofia; Chen, Jufu; Mustaquim, Desiree; Azziz-Baumgartner, Eduardo] Ctr Dis Control & Prevent, Atlanta, GA USA; [Acosta, Belsy O.] Pedro Kouri Inst Trop Med, Dept Virol, Havana, Cuba; [Guidos, Patricia Alberto; Hernandez, Hector M. Ramos] Minist Hlth, San Salvador, El Salvador; [Badilla Vargas, Xiomara] Costa Rican Dept Social Secur, San Jose, Costa Rica; [Bancej, Christina; Nwosu, Andrea; Saboui, Myriam] Publ Hlth Agcy Canada, Ottawa, ON, Canada; [Barbosa Ramirez, Juliana; Malo, Diana C.; Pulido, Paola A.] Natl Inst Hlth, Bogota, Colombia; [Baumeister, Elsa] Natl Reference Lab Viral Resp Infect, Buenos Aires, DF, Argentina; [Baumeister, Elsa] Natl Influenza Ctr, Buenos Aires, DF, Argentina; [Bruno, Alfredo] Natl Inst Publ Hlth Res, Guayaquil, Ecuador; [Cabello, Maria Agueda; Von Horoch, Marta] Minist Publ Hlth & Social Welf, Asuncion, Paraguay; [Chen, Jufu] Battelle Mem Inst, Atlanta, GA USA; [De Paula Junior, Francisco J.; de Almeida, Walquiria Ferreira] Minist Hlth, Brasilia, DF, Brazil; [Fasce, Rodrigo] Inst Publ Hlth, Santiago, Chile; [Fiesta Solorzano, Victor E.; Medina Osis, Jose L.] Natl Ctr Epidemiol Prevent & Control Dis, Lima, Peru; [Ramirez, Carlos Flores] Directorate Hlth Serv, Guatemala City, Guatemala; [Goni, Natalia] Dept Publ Hlth Labs, Montevideo, Uruguay; [de Molto, Yadira Isaza; Castillo, Lourdes Moreno] Minist Hlth, Panama City, Panama; [Lara, Jenny] Costa Rican Inst Res & Educ Nutr & Hlth, Cartago, Costa Rica; [Mejia, Homer; Lopez, Rudvelinda Rivera] Hlth Secretariat, Tegucigalpa, Honduras; [Ojeda, Jenny] Minist Hlth, Quito, Ecuador; [Paredes Samoya, Antonio] Minist Publ Hlth, Guatemala City, Guatemala; [Salazar Bolanos, Hilda] Minist Hlth, San Jose, Costa Rica; [Santoro, Adrian] Directorate Stat & Hlth Informat, Buenos Aires, DF, Argentina; [Eduardo Silvera, Jose] Minist Hlth, Montevideo, Uruguay; [Sotomayor, Viviana] Minist Hlth Santiago, Santiago, Chile; [Suarez, Lourdes] Minist Publ Hlth Cuba, Havana, Cuba	Pan American Health Organization; World Health Organization; Centers for Disease Control & Prevention - USA; Public Health Agency of Canada; Ministerio de Salud de la Republica de Panama	Palekar, RS (corresponding author), Pan Amer Hlth Org, WHO, Washington, DC 20037 USA.	rpalekar@gmail.com	BRUNO, ALFREDO/AAW-8354-2020; Fiestas, Victor/J-6894-2019; Couto, Paula/X-2212-2018	BRUNO, ALFREDO/0000-0002-9678-4203; Fiestas, Victor/0000-0002-5554-3542; Couto, Paula/0000-0003-1900-2543; Rolfes, Melissa/0000-0002-0483-9941; de Paula Junior, Francisco Jose/0000-0002-7302-0614; Palekar, Rakhee/0000-0001-5216-3117; Medina Osis, Jose Lionel/0000-0002-6929-6714	World Health Organization [001] Funding Source: Medline	World Health Organization(World Health Organization)		Azziz-Baumgartner E, 2013, INFLUENZA OTHER RESP, V7, P686, DOI 10.1111/irv.12022; Azziz-Baumgartner E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047540; Bhat-Schelbert K, 2012, VACCINE, V30, P2448, DOI 10.1016/j.vaccine.2012.01.049; Biggerstaff M, 2014, J INFECT DIS, V210, P535, DOI 10.1093/infdis/jiu224; Cheng PY, 2015, INFLUENZA OTHER RESP, V9, P13, DOI 10.1111/irv.12317; Cheng W, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14020217; Clara W, 2012, B WORLD HEALTH ORGAN, V90, P756, DOI 10.2471/BLT.11.098202; Dawood FS, 2012, LANCET INFECT DIS, V12, P687, DOI 10.1016/S1473-3099(12)70121-4; Dawood FS, 2010, J PEDIATR-US, V157, P808, DOI 10.1016/j.jpeds.2010.05.012; Descalzo MA, 2016, INFLUENZA OTHER RESP, V10, P340, DOI 10.1111/irv.12385; Deutscher M, 2012, J EPIDEMIOL GLOB HEA, V2, P73, DOI 10.1016/j.jegh.2012.03.001; Emukule GO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105543; Finelli L, 2011, J INFECT DIS, V203, P1701, DOI 10.1093/infdis/jir175; Fischer WA, 2014, GLOB HEART, V9, P325, DOI 10.1016/j.gheart.2014.08.004; Flood EM, 2010, CLIN THER, V32, P1448, DOI 10.1016/j.clinthera.2010.06.020; Grijalva CG, 2007, EPIDEMIOL INFECT, V135, P951, DOI 10.1017/S095026880600762X; Saborio GG, 2014, EMERG INFECT DIS, V20, P878, DOI 10.3201/eid2005.131775; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Kuypers J, 2006, J CLIN MICROBIOL, V44, P2382, DOI 10.1128/JCM.00216-06; Lafond KE, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001977; Lindblade KA, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-885; Lutwama JJ, 2012, J INFECT DIS, V206, pS87, DOI 10.1093/infdis/jis578; Marcone DN, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1213-4; MCBEAN AM, 1993, ARCH INTERN MED, V153, P2105, DOI 10.1001/archinte.153.18.2105; Nyamusore J, 2018, INFLUENZA OTHER RESP, V12, P38, DOI 10.1111/irv.12494; Palekar R, 2017, INFLUENZA OTHER RESP; Pan American Health Organisation, 2015, HLTH SIT AM BAS IND; Pan American Health Organization, 2016, IMM AM 2016 SUMM 201; Pan American Health Organization, INFL OTH RESP VIR SU; Pan American Health Organization, 2017, SEV AC RESP INF NETW; Qasmieh S, 2016, WHO INFLUENZA TRANSM; Rabarison JH, 2019, INFLUENZA OTHER RESP, V13, P138, DOI 10.1111/irv.12557; Reed C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118369; Rodrigues E, 2018, INFLUENZA OTHER RESP, V12, P153, DOI 10.1111/irv.12501; Rolfes MA, 2018, INFLUENZA OTHER RESP, V12, P132, DOI 10.1111/irv.12486; Ropero-Alvarez AM, 2016, HUM VACC IMMUNOTHER, V12, P2206, DOI 10.1080/21645515.2016.1157240; Savy V, 2013, INFLUENZA OTHER RESP, V7, P1017, DOI 10.1111/irv.12036; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; SERFLING RE, 1963, PUBLIC HEALTH REP, V78, P494, DOI 10.2307/4591848; Sotomayor V, 2018, INFLUENZA OTHER RESP, V12, P138, DOI 10.1111/irv.12502; Tallo VL, 2014, INFLUENZA OTHER RESP, V8, P159, DOI 10.1111/irv.12223; Thind A, 2003, SOC SCI MED, V56, P1173, DOI 10.1016/S0277-9536(02)00116-8; Thommes EW, 2017, HUM VACC IMMUNOTHER, V13, P867, DOI 10.1080/21645515.2016.1251537; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Tinoco YO, 2017, CLIN INFECT DIS, V65, P1532, DOI 10.1093/cid/cix565; Verani JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083600; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; WHO/FluNet, 2021, INFL LAB SURV INF GU; Wong CM, 2006, PLOS MED, V3, P485, DOI 10.1371/journal.pmed.0030121; World Health Organization, 2015, MAN EST DIS BURD ASS; Zhou H, 2012, CLIN INFECT DIS, V54, P1427, DOI 10.1093/cid/cis211	51	21	21	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2019	14	9							e0221479	10.1371/journal.pone.0221479	http://dx.doi.org/10.1371/journal.pone.0221479			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM2ZH	31490961	Green Submitted, Green Published, gold			2023-01-03	WOS:000532119700025
J	Hugues, A; Di Marco, J; Ribault, S; Ardaillon, H; Janiaud, P; Xue, Y; Zhu, J; Pires, J; Khademi, H; Rubio, L; Bernal, PH; Bahar, Y; Charvat, H; Szulc, P; Ciumas, C; Won, H; Cucherat, M; Bonan, I; Gueyffier, F; Rode, G				Hugues, Aurelien; Di Marco, Julie; Ribault, Shams; Ardaillon, Hugo; Janiaud, Perrine; Xue, Yufeng; Zhu, Jin; Pires, Jennifer; Khademi, Hooman; Rubio, Laura; Bernal, Paloma Hernandez; Bahar, Yeliz; Charvat, Hadrien; Szulc, Pawel; Ciumas, Carolina; Won, Heiwon; Cucherat, Michel; Bonan, Isabelle; Gueyffier, Francois; Rode, Gilles			Limited evidence of physical therapy on balance after stroke: A systematic review and meta-analysis	PLOS ONE			English	Review							COMMUNITY AMBULATION; PUBLICATION BIAS; POSTURAL SWAY; FILL METHOD; REHABILITATION; RECOVERY; PEOPLE; STANCE; FALLS; GAIT	Background Stroke results in balance disorders and these directly affect autonomy and quality of life. The purpose of this systematic review and meta-analysis was to determine the efficacy of physical therapy (PT) on balance and postural control after stroke. Methods We included all randomized controlled trials assessing the efficacy of PT on balance and postural control in adult patients after stroke without language restriction. Medline, Embase/Scopus, Cochrane Central Register of Controlled Trials, PEDro, Pascal, and Francis databases were searched until January 2019. Primary outcomes were balance (Berg Balance scale and Postural Assessment Scale for Stroke) and postural control with postural deviation or stability measurement in sitting or standing static evaluation. A pair of independent reviewers selected studies, extracted data, and assessed risk of bias. Meta-analyses with subgroups (categories of PT, time post-stroke, and lesion location) and meta-regression (duration of PT) were conducted. Results A total of 145 studies (n = 5912) were selected from the 13,123 records identified. For balance, evidence was found in favor of the efficacy of functional task-training alone (standardized mean difference 0.39, 95% confidence interval [0.09; 0.68], heterogeneity I-2 = 63%) or associated with musculoskeletal intervention and/or cardiopulmonary intervention (0.37, [0.19; 0.55], I-2 = 48%), electrostimulation (0.91, [0.49; 1.34], I-2 = 52%) immediately after intervention, compared to sham treatment or usual care (ST/UC). For postural deviation eyes open, assistive devices were more effective than no treatment (-0.21, [-0.37; -0.05], I-2 = 0%) immediately after intervention; for postural stability eyes open, functional task-training and sensory interventions were more effective than ST/UC (0.97, [0.35; 1.59], I-2 = 65% and 0.80, [0.46; 1.13], I-2 = 37% respectively) immediately after intervention. Conclusions Functional task-training associated with musculoskeletal intervention and/or cardiopulmonary intervention and sensory interventions seem to be immediately effective in improving balance and postural stability, respectively. The heterogeneity of PT and the weak methodological quality of studies limited the interpretation and the confidence in findings.	[Hugues, Aurelien; Ribault, Shams; Ardaillon, Hugo; Rode, Gilles] Hosp Civils Lyon, Hop Henry Gabrielle, Serv Med Phys & Readaptat, St Genis Laval, France; [Hugues, Aurelien; Ribault, Shams; Ardaillon, Hugo; Rode, Gilles] Hosp Civils Lyon, Hop Henry Gabrielle, Plate Forme Mouvement & Handicap, St Genis Laval, France; [Hugues, Aurelien; Rode, Gilles] Univ Lyon 1, Univ Lyon, CNRS,Equipe ImpAct, UMR 5292,INSERM,UMR S 1028,Ctr Rech Neurosci Lyon, Bron, France; [Di Marco, Julie] Univ Paris 05, AP HP, Paris, France; [Janiaud, Perrine; Cucherat, Michel; Gueyffier, Francois] Univ Lyon 1, Univ Lyon, CNRS Lyon, UMR 5558, Lyon, France; [Xue, Yufeng] Univ St Etienne, Univ Claude Bernard Lyon 1, Univ Lyon, HESPER,EA 7425, St Etienne, France; [Zhu, Jin] Univ Jiaotong Shanghai, Dept Pharmacol, Shanghai, Peoples R China; [Pires, Jennifer] Rovisco Pais Rehabil Ctr, Tocha, Portugal; [Pires, Jennifer] Univ Porto, Med Fac, Oporto, Portugal; [Khademi, Hooman] WHO, Int Agcy Res Canc, Lyon, France; [Rubio, Laura] Ctr Lescer, Madrid, Spain; [Bernal, Paloma Hernandez] Rehaklin Zihlschlach, Neurol Rehabil Zentrum, Zihlschlacht, Switzerland; [Bahar, Yeliz] Hitit Univ, Erol Olcok Training & Res Hosp, Corum, Turkey; [Charvat, Hadrien] Natl Canc, Ctr Publ Hlth Sci, Div Prevent, Tokyo, Japan; [Szulc, Pawel] Univ Lyon 1, Univ Lyon, Hop Edouard Herriot, INSERM,UMR 1033, Lyon, France; [Ciumas, Carolina] Univ Lyon1, Univ Lyon, CNRS,Ctr Rech Neurosci Lyon, UMR5292,INSERM,U1028,Translat & Integrat Grp Epil, Lyon, France; [Ciumas, Carolina] Univ Lyon 1, Univ Lyon, Inst Epilepsies, Lyon, France; [Ciumas, Carolina] CHU Vaudois, Dept Clin Neurosci, Lausanne, Switzerland; [Won, Heiwon] Univ Grenoble Alpes, UMR Litt & Arts 5316, Grenoble, France; [Won, Heiwon] Kyung Hee Univ, Seoul, South Korea; [Cucherat, Michel; Gueyffier, Francois] Hosp Civils Lyon, Serv Hosp Univ Pharmacotoxicol, Grp Hosp Est, Bron, France; [Bonan, Isabelle] CHU Rennes, Serv Med Phys & Readaptat, Rennes, France; [Bonan, Isabelle] Univ Rennes 1, INSERM, Unite U746, Equipe VisAGeS, Rennes, France	CHU Lyon; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Jean Monnet; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Universite Jean Monnet; Universidade do Porto; World Health Organization; International Agency for Research on Cancer (IARC); Hitit University; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Humanities & Social Sciences (INSHS); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Kyung Hee University; Assistance Publique Hopitaux Paris (APHP); CHU Lyon; CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes	Hugues, A (corresponding author), Hosp Civils Lyon, Hop Henry Gabrielle, Serv Med Phys & Readaptat, St Genis Laval, France.; Hugues, A (corresponding author), Hosp Civils Lyon, Hop Henry Gabrielle, Plate Forme Mouvement & Handicap, St Genis Laval, France.; Hugues, A (corresponding author), Univ Lyon 1, Univ Lyon, CNRS,Equipe ImpAct, UMR 5292,INSERM,UMR S 1028,Ctr Rech Neurosci Lyon, Bron, France.	huguesaurelien@gmail.com	Charvat, Hadrien/AAJ-1910-2021; Ozdemir, Yeliz Bahar/AAT-3595-2020; Khademi, Hooman/AAZ-8798-2020	Ozdemir, Yeliz Bahar/0000-0003-2253-3767; Pires, Jennifer/0000-0001-5141-5853; Hugues, Aurelien/0000-0001-9190-2867; Szulc, Pawel/0000-0003-4168-6697; Rubio, Laura/0000-0001-9458-4358; ARDAILLON, Hugo/0000-0002-4113-2427				AMBLARD B, 1985, EXP BRAIN RES, V61, P21; Armijo-Olivo S, 2017, AM J PHYS MED REHAB, V96, P34, DOI 10.1097/PHM.0000000000000521; Armijo-Olivo S, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008562; Bonan IV, 2004, ARCH PHYS MED REHAB, V85, P268, DOI 10.1016/j.apmr.2003.06.017; Bramer WM, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0644-y; Brazzelli M, 2011, COCHRANE DB SYST REV, V11; Dechartres A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2304; Dickstein R, 2000, ARCH PHYS MED REHAB, V81, P364, DOI 10.1053/apmr.2000.0810364; DIFABIO RP, 1990, ARCH PHYS MED REHAB, V71, P365; Durcan S, 2016, DISABIL REHABIL, V38, P245, DOI 10.3109/09638288.2015.1035460; Dworzynski K, 2015, CLIN MED, V15, P461, DOI 10.7861/clinmedicine.15-5-461; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; English C, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007513.pub3; Feigin VL, 2017, CIRC RES, V120, P439, DOI 10.1161/CIRCRESAHA.116.308413; Fulk GD, 2010, ARCH PHYS MED REHAB, V91, P1582, DOI 10.1016/j.apmr.2010.07.005; Furnari A, 2014, BRAIN INJURY, V28, P1109, DOI 10.3109/02699052.2014.910700; Geneva World Health Organization, 2016, GLOB HLTH EST 2015 B; Genthon N, 2008, STROKE, V39, P1793, DOI 10.1161/STROKEAHA.107.497701; Geurts ACH, 2005, GAIT POSTURE, V22, P267, DOI 10.1016/j.gaitpost.2004.10.002; Hatano S., EXPERIENCE MULTICENT, P13; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Hugues A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013348; Iatridou G, 2017, CLIN REHABIL; Ishii F, 2010, CLIN NEUROL NEUROSUR, V112, P406, DOI 10.1016/j.clineuro.2010.02.006; Jin ZC, 2015, STAT MED, V34, P343, DOI 10.1002/sim.6342; Kwong PW, 2017, CLIN REHABIL; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Laver KE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008349.pub2, 10.1002/14651858.CD008349.pub3, 10.1002/14651858.CD008349.pub4]; Lawrence M, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011483.pub2; Lee KB, 2015, TOP STROKE REHABIL, V22, P63, DOI 10.1179/1074935714Z.0000000001; Li RQ, 2017, COMPLEMENT THER CLIN, V28, P75, DOI 10.1016/j.ctcp.2017.05.009; Louie DR, 2018, J REHABIL MED, V50, P37, DOI 10.2340/16501977-2280; Lu J, 2015, TOP STROKE REHABIL, V22, P161, DOI 10.1179/1074935714Z.0000000005; Mavridis D, 2014, EVID-BASED MENT HEAL, V17, P30, DOI 10.1136/eb-2013-101699; Mehrholz J, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008186.pub2; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Mueller KF, 2016, J CLIN EPIDEMIOL, V80, P25, DOI 10.1016/j.jclinepi.2016.04.015; National Institute for Health and Care Excellence, 2013, STROK REH AD; Peters JL, 2007, STAT MED, V26, P4544, DOI 10.1002/sim.2889; Pollock A, 2014, PHYS REHABILITATION; Rode G, 1997, SCAND J REHABIL MED, V29, P11; Rode G, 1998, SCAND J REHABIL MED, V30, P9; SACKLEY C M, 1990, Physiotherapy Theory and Practice, V6, P179, DOI 10.3109/09593989009048293; Schmid AA, 2013, TOP STROKE REHABIL, V20, P340, DOI 10.1310/tsr2004-340; Schmid AA, 2012, ARCH PHYS MED REHAB, V93, P1101, DOI 10.1016/j.apmr.2012.01.020; Thilarajah S, 2018, ARCH PHYS MED REHAB, V99, P1876, DOI 10.1016/j.apmr.2017.09.117; Thomas A., 1940, EQUILIBRE EQUILIBRAT; Tyson SF, 2006, PHYS THER, V86, P30, DOI 10.1093/ptj/86.1.30; van de Port IG, 2008, J REHABIL MED, V40, P23, DOI 10.2340/16501977-0114; van der Kooi E, 2017, ARCH PHYS MED REHAB, V98, P2393, DOI 10.1016/j.apmr.2017.05.003; van Duijnhoven HJR, 2016, STROKE, V47, P2603, DOI 10.1161/STROKEAHA.116.013839; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Vloothuis JDM, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011058.pub2; Walker MF, 2017, INT J STROKE, V12, P472, DOI 10.1177/1747493017711815; Winstein CJ, 2016, STROKE, V47, pE98, DOI 10.1161/STR.0000000000000098; Wist S, 2016, ANN PHYS REHABIL MED, V59, P114, DOI 10.1016/j.rehab.2016.02.001; World Confederation for Physical Therapy, POL STAT DESCR PHYS; Xu TM, 2018, ARCH PHYS MED REHAB, V99, P563, DOI 10.1016/j.apmr.2017.06.032	58	16	17	3	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2019	14	8							e0221700	10.1371/journal.pone.0221700	http://dx.doi.org/10.1371/journal.pone.0221700			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW6AB	31465462	Green Published, Green Submitted, gold			2023-01-03	WOS:000485058200037
J	Helmink, BA; Reddy, SM; Gao, JJ; Zhang, SJ; Basar, R; Thakur, R; Yizhak, K; Sade-Feldman, M; Blando, J; Han, GC; Gopalakrishnan, V; Xi, YX; Zhao, H; Amaria, RN; Tawbi, HA; Cogdill, AP; Liu, WB; LeBleu, VS; Kugeratski, FG; Patel, S; Davies, MA; Hwu, P; Lee, JE; Gershenwald, JE; Lucci, A; Arora, R; Woodman, S; Keung, EZ; Gaudreau, PO; Reuben, A; Spencer, CN; Burton, EM; Haydu, LE; Lazar, AJ; Zapassodi, R; Hudgens, CW; Ledesma, DA; Ong, S; Bailey, M; Warren, S; Rao, D; Krijgsman, O; Rozeman, EA; Peeper, D; Blank, CU; Schumacher, TN; Butterfield, LH; Zelazowska, MA; McBride, KM; Kalluri, R; Allison, J; Petitprez, F; Fridman, WH; Sautes-Fridman, C; Hacohen, N; Rezvani, K; Sharma, P; Tetzlaff, MT; Wang, LH; Wargo, JA				Helmink, Beth A.; Reddy, Sangeetha M.; Gao, Jianjun; Zhang, Shaojun; Basar, Rafet; Thakur, Rohit; Yizhak, Keren; Sade-Feldman, Moshe; Blando, Jorge; Han, Guangchun; Gopalakrishnan, Vancheswaran; Xi, Yuanxin; Zhao, Hao; Amaria, Rodabe N.; Tawbi, Hussein A.; Cogdill, Alex P.; Liu, Wenbin; LeBleu, Valerie S.; Kugeratski, Fernanda G.; Patel, Sapna; Davies, Michael A.; Hwu, Patrick; Lee, Jeffrey E.; Gershenwald, Jeffrey E.; Lucci, Anthony; Arora, Reetakshi; Woodman, Scott; Keung, Emily Z.; Gaudreau, Pierre-Olivier; Reuben, Alexandre; Spencer, Christine N.; Burton, Elizabeth M.; Haydu, Lauren E.; Lazar, Alexander J.; Zapassodi, Roberta; Hudgens, Courtney W.; Ledesma, Deborah A.; Ong, SuFey; Bailey, Michael; Warren, Sarah; Rao, Disha; Krijgsman, Oscar; Rozeman, Elisa A.; Peeper, Daniel; Blank, Christian U.; Schumacher, Ton N.; Butterfield, Lisa H.; Zelazowska, Monika A.; McBride, Kevin M.; Kalluri, Raghu; Allison, James; Petitprez, Florent; Fridman, Wolf Herman; Sautes-Fridman, Catherine; Hacohen, Nir; Rezvani, Katayoun; Sharma, Padmanee; Tetzlaff, Michael T.; Wang, Linghua; Wargo, Jennifer A.			B cells and tertiary lymphoid structures promote immunotherapy response	NATURE			English	Article							IMMUNE CONTEXTURE; DENDRITIC CELLS; MELANOMA; CANCER; LYMPHOCYTES; BIOMARKERS; CYTOSCAPE; DENSITY	Multiomic profiling of several cohorts of patients treated with immune checkpoint blockade highlights the presence and potential role of B cells and tertiary lymphoid structures in promoting therapy response. Treatment with immune checkpoint blockade (ICB) has revolutionized cancer therapy. Until now, predictive biomarkers(1-10) and strategies to augment clinical response have largely focused on the T cell compartment. However, other immune subsets may also contribute to anti-tumour immunity(11-15), although these have been less well-studied in ICB treatment(16). A previously conducted neoadjuvant ICB trial in patients with melanoma showed via targeted expression profiling(17) that B cell signatures were enriched in the tumours of patients who respond to treatment versus non-responding patients. To build on this, here we performed bulk RNA sequencing and found that B cell markers were the most differentially expressed genes in the tumours of responders versus non-responders. Our findings were corroborated using a computational method (MCP-counter(18)) to estimate the immune and stromal composition in this and two other ICB-treated cohorts (patients with melanoma and renal cell carcinoma). Histological evaluation highlighted the localization of B cells within tertiary lymphoid structures. We assessed the potential functional contributions of B cells via bulk and single-cell RNA sequencing, which demonstrate clonal expansion and unique functional states of B cells in responders. Mass cytometry showed that switched memory B cells were enriched in the tumours of responders. Together, these data provide insights into the potential role of B cells and tertiary lymphoid structures in the response to ICB treatment, with implications for the development of biomarkers and therapeutic targets.	[Helmink, Beth A.; Thakur, Rohit; Gopalakrishnan, Vancheswaran; Cogdill, Alex P.; Lee, Jeffrey E.; Gershenwald, Jeffrey E.; Lucci, Anthony; Keung, Emily Z.; Gaudreau, Pierre-Olivier; Burton, Elizabeth M.; Haydu, Lauren E.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Reddy, Sangeetha M.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Gao, Jianjun] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Cancers, Houston, TX 77030 USA; [Zhang, Shaojun; Han, Guangchun; Arora, Reetakshi; Lazar, Alexander J.; Wang, Linghua; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Basar, Rafet; Rezvani, Katayoun] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA; [Yizhak, Keren; Sade-Feldman, Moshe; Hacohen, Nir] Massachusetts Gen Hosp, Dept Med, Ctr Canc, Boston, MA 02114 USA; [Sade-Feldman, Moshe; Hacohen, Nir] MIT, Broad Inst, Boston, MA USA; [Blando, Jorge; Zhao, Hao; Liu, Wenbin; Allison, James; Sharma, Padmanee] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Xi, Yuanxin] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Amaria, Rodabe N.; Tawbi, Hussein A.; Patel, Sapna; Davies, Michael A.; Hwu, Patrick; Woodman, Scott] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA; [LeBleu, Valerie S.; Kalluri, Raghu] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Reuben, Alexandre] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Spencer, Christine N.] Parker Inst Canc Immunotherapy, San Francisco, CA USA; [Reuben, Alexandre; Hudgens, Courtney W.; Ledesma, Deborah A.; Tetzlaff, Michael T.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Reuben, Alexandre; Tetzlaff, Michael T.] Univ Texas MD Anderson Canc Ctr, Dept Translat & Mol Pathol, Houston, TX 77030 USA; [Zapassodi, Roberta] Mem Sloan Kettering Canc Ctr, Immunol Program, Sloan Kettering Inst, 1275 York Ave, New York, NY 10021 USA; [Ong, SuFey; Bailey, Michael; Warren, Sarah] Nanostring Technol, Seattle, WA USA; [Rao, Disha; Krijgsman, Oscar; Rozeman, Elisa A.; Peeper, Daniel; Blank, Christian U.; Schumacher, Ton N.] Netherlands Canc Inst, Div Mol Oncol & Immunol, Amsterdam, Netherlands; [Butterfield, Lisa H.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA; [Butterfield, Lisa H.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; [Butterfield, Lisa H.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; [Butterfield, Lisa H.] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA USA; [Butterfield, Lisa H.] Univ Pittsburgh, Dept Clin & Translat Sci, Pittsburgh, PA USA; [Zelazowska, Monika A.; McBride, Kevin M.] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Houston, TX 77030 USA; [Petitprez, Florent; Fridman, Wolf Herman; Sautes-Fridman, Catherine] INSERM, Cordeliers Res Ctr, Team Canc, Immune Control & Escape, Paris, France; [Petitprez, Florent; Fridman, Wolf Herman; Sautes-Fridman, Catherine] Univ Paris Descartes Paris 5, Ctr Rech Cordeliers, Sorbonne Paris Cite, Paris, France; [Petitprez, Florent] Ligue Natl Canc, Programme Cartes Identite Tumeurs, Paris, France	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Netherlands Cancer Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; UTMD Anderson Cancer Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Helmink, BA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.	bhelmink@mdanderson.org; jwargo@mdanderson.org	Reddy, Sangeetha/GNZ-8658-2022; Kugeratski, Fernanda/ABA-9800-2020; Han, Guangchun/AAU-8230-2021; Gershenwald, Jeff/AAX-4367-2020; Butterfield, Lisa H./W-1564-2019; Davies, Michael/GWV-2527-2022; Burton, Elizabeth/AAB-9393-2021; Kugeratski, Fernanda G/S-5926-2018; Schumacher, Ton/Y-2432-2019; Petitprez, Florent/AAD-5296-2020; Kalluri, Raghu/E-2677-2015	Kugeratski, Fernanda/0000-0001-9731-1275; Gershenwald, Jeff/0000-0003-4519-5369; Butterfield, Lisa H./0000-0002-3439-9844; Burton, Elizabeth/0000-0002-3424-4922; Kugeratski, Fernanda G/0000-0001-9731-1275; Schumacher, Ton/0000-0003-0517-8804; Petitprez, Florent/0000-0002-5117-6466; Zhang, Shaojun/0000-0001-5760-5797; Cogdill, Alexandria/0000-0001-8917-9462; Kalluri, Raghu/0000-0002-2190-547X; Wang, Linghua/0000-0001-9380-0266; Lucci, Anthony/0000-0003-4039-174X; fridman, wolf herman/0000-0002-1332-0973; Zelazowska, Monika/0000-0002-7373-7631; sautes-fridman, catherine/0000-0003-1735-8722; Helmink, Beth/0000-0002-8206-0351; Rao, Disha/0000-0002-9024-4759	MD Anderson Melanoma Moon Shot Program; Parker Institute for Cancer Immunotherapy; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; AIM at Melanoma Foundation; Office of the Assistant Secretary for Defense for Health Affairs [W81XWH-16-1-0120, W81XWH-16-1-0121]; Cancer Prevention Research Institute of Texas [RR190020]; MD Anderson Cancer Center support grant [P30 CA016672]; CPRIT Research Training Program [RP170067]; United States Department of State's Bureau of Educational and Cultural Affairs; National Institutes of Health [T32 CA009599, T32 CA 009666, CA 009599]; Odyssey Program at the MD Anderson Cancer Center; Theodore N. Law Endowment for Scientific Achievement; Cancer Prevention and Research Institute of Texas; National Cancer Institute [CA213233, P01CA117969, CA195733]; CPRIT [RP190507]; CCSG grant [NIGH P30CA016672];  [CA016672]	MD Anderson Melanoma Moon Shot Program; Parker Institute for Cancer Immunotherapy; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; AIM at Melanoma Foundation; Office of the Assistant Secretary for Defense for Health Affairs; Cancer Prevention Research Institute of Texas; MD Anderson Cancer Center support grant; CPRIT Research Training Program; United States Department of State's Bureau of Educational and Cultural Affairs; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Odyssey Program at the MD Anderson Cancer Center; Theodore N. Law Endowment for Scientific Achievement; Cancer Prevention and Research Institute of Texas; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CPRIT; CCSG grant; 	The correlative research was funded by philanthropic support from the MD Anderson Melanoma Moon Shot Program, the Parker Institute for Cancer Immunotherapy, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, and the AIM at Melanoma Foundation. It was supported by The Immunotherapy Platform and the Core grant CA016672 (SMF) to support the Sequencing and Microarray Facility at UT-MDACC as well as the the Office of the Assistant Secretary for Defense for Health Affairs grant (W81XWH-16-1-0120 and W81XWH-16-1-0121). S.M.R. received support from National Institutes of Health T32 CA 009666 and Cancer Prevention Research Institute of Texas RR190020. B.A.H. received support from National Institutes of Health T32 CA 009599 and the MD Anderson Cancer Center support grant P30 CA016672. A.P.C. is supported by the CPRIT Research Training Program (RP170067) and the United States Department of State's Bureau of Educational and Cultural Affairs. E.Z.K. is supported by National Institutes of Health grant T32 CA009599. F.G.K. is supported with funding from the Odyssey Program at the MD Anderson Cancer Center with support from the Theodore N. Law Endowment for Scientific Achievement. Research in the Kalluri laboratory is supported by the Cancer Prevention and Research Institute of Texas and National Cancer Institute grants CA213233, P01CA117969, and CA195733. K.M.M. and M.A.Z. are supported by CPRIT RP190507. The High Resolution Electron Microscopy Facility at UT-MDASS is supported by CCSG grant NIGH P30CA016672. We thank to O. Contrares for technical support on the multiplex immunofluorescence and for M. Andrews for technical support on RNA-seq library preparation and K. McAndrews, D. P. Dowlatshahi, L. Snowden, J. Leveille and S. Yang for support with analyses of exosomes.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Amaria RN, 2018, NAT MED, V24, P1649, DOI 10.1038/s41591-018-0197-1; Amaria RN, 2018, LANCET ONCOL, V19, P181, DOI 10.1016/S1470-2045(18)30015-9; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Avram G, 2013, HISTOPATHOLOGY, V63, P852, DOI 10.1111/his.12235; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Blank CU, 2018, NAT MED, V24, P1655, DOI 10.1038/s41591-018-0198-0; Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Chiaruttini G, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1294296; Cipponi A, 2012, CANCER RES, V72, P3997, DOI 10.1158/0008-5472.CAN-12-1377; Colbeck EJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01830; Cottrell TR, 2018, CANCER J, V24, P41, DOI 10.1097/PPO.0000000000000301; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; DeLuca DS, 2012, BIOINFORMATICS, V28, P1530, DOI 10.1093/bioinformatics/bts196; Dieu-Nosjean MC, 2014, TRENDS IMMUNOL, V35, P571, DOI 10.1016/j.it.2014.09.006; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Erdag G, 2012, CANCER RES, V72, P1070, DOI 10.1158/0008-5472.CAN-11-3218; Fridman WH, 2017, NAT REV CLIN ONCOL, V14, P717, DOI 10.1038/nrclinonc.2017.101; Garg K, 2016, HUM PATHOL, V54, P157, DOI 10.1016/j.humpath.2016.03.022; Germain C, 2014, AM J RESP CRIT CARE, V189, P832, DOI 10.1164/rccm.201309-1611OC; Goc J, 2014, CANCER RES, V74, P705, DOI 10.1158/0008-5472.CAN-13-1342; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Griss J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12160-2; Hiraoka N, 2015, BRIT J CANCER, V112, P1782, DOI 10.1038/bjc.2015.145; Hu XH, 2019, NAT GENET, V51, P560, DOI 10.1038/s41588-018-0339-x; Iglesia MD, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw144; Jacquelot N, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00608-2; Ladanyi A, 2007, CANCER IMMUNOL IMMUN, V56, P1459, DOI 10.1007/s00262-007-0286-3; Ladanyi A, 2011, CANCER IMMUNOL IMMUN, V60, P1729, DOI 10.1007/s00262-011-1071-x; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Love Michael I, 2015, F1000Res, V4, P1070, DOI 10.12688/f1000research.7035.1; Martinet L, 2012, ONCOIMMUNOLOGY, V1, P829, DOI 10.4161/onci.20492; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Messina JL, 2012, SCI REP-UK, V2, DOI 10.1038/srep00765; Nazarov VI, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0613-1; Petitprez F, 2020, NATURE, V577, P556, DOI 10.1038/s41586-019-1906-8; Pimenta EM, 2014, CANCERS, V6, P969, DOI 10.3390/cancers6020969; Posch F, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1378844; Reddy SM, 2019, CANCER IMMUNOL RES, V7, P1025, DOI 10.1158/2326-6066.CIR-18-0619; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Ruddle NH, 2014, J CLIN INVEST, V124, P953, DOI 10.1172/JCI71611; Sade-Feldman M, 2018, CELL, V175, P998, DOI 10.1016/j.cell.2018.10.038; Sarvaria A, 2017, CELL MOL IMMUNOL, V14, P662, DOI 10.1038/cmi.2017.35; Sautes-Fridman C, 2019, NAT REV CANCER, V19, P307, DOI 10.1038/s41568-019-0144-6; Selitsky SR, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0647-5; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Silina K, 2018, CANCER RES, V78, P1308, DOI 10.1158/0008-5472.CAN-17-1987; Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675; Song IH, 2017, CANCER RES TREAT, V49, P399, DOI 10.4143/crt.2016.215; Subudhi SK, 2016, P NATL ACAD SCI USA, V113, P11919, DOI 10.1073/pnas.1611421113; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Tsou PL, 2016, CANCER RES, V76, P5597, DOI 10.1158/0008-5472.CAN-16-0431; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Wu Guanming, 2014, F1000Res, V3, P146, DOI 10.12688/f1000research.4431.1; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Yoav Benjamini, 2001, Behavioural Brain Research, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Yuen GJ, 2016, TRENDS CANCER, V2, P747, DOI 10.1016/j.trecan.2016.10.010	60	798	816	40	316	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN	2020	577	7791					549	+		10.1038/s41586-019-1922-8	http://dx.doi.org/10.1038/s41586-019-1922-8		JAN 2020	28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF4FM	31942075	Green Submitted, Green Accepted			2023-01-03	WOS:000508287700003
J	Grailey, KE; Murray, EJ; Billings, J; Brett, SJ				Grailey, K. E.; Murray, E. J.; Billings, J.; Brett, S. J.			How do critical care staff respond to organisational challenge? A qualitative exploration into personality types and cognitive processing in critical care	PLOS ONE			English	Article								Critical care staff are frequently required to respond to stressful scenarios. The way staff counter organisational challenge may be influenced by their underlying personality type, preferred style of cognitive processing and previous clinical experience. Our objective was to explore the personality types of a sample of critical care workers, and the potential relationship of this with cognitive processing. This was achieved through a qualitative interview study in which participants were presented with difficult but realistic scenarios pertaining to staffing. Data on individual's personality were captured using the '16 Personality Factor' assessment, a tool that produces scores for 16 different elements of an individual's personality. The existence of perfectionist and pragmatic cognitive processing styles were identified as one theme emerging from a prior analysis of these interview transcripts. We aimed to validate this, explore our ability to categorise individuals into groups based upon their cognitive processing. We identified that some individuals strongly tended to either a perfectionist or pragmatic style of cognitive processing for the majority of their decisions; however most adapted their style of processing according to the nature of the decision. Overall participants generally demonstrated average scores for all 16 personality factors tested. However, we observed that some factors tended to higher scores than others, indicating a pattern within the personalities of our sample cohort. Whilst a small sample size, our data suggests that individuals working within the same critical care environment may have clear differences in their approach to problem solving as a consequence of both their personality type and preferred style of cognitive processing. Thus there may be individuals within this environment who would benefit from increased support to minimise their risk of cognitive dissonance and stress in times of challenge.	[Grailey, K. E.; Brett, S. J.] Imperial Coll London, Dept Surg & Canc, London, England; [Murray, E. J.] Univ Oxford, Said Business Sch, Oxford, England; [Billings, J.] UCL, London, England	Imperial College London; University of Oxford; University of London; University College London	Grailey, KE (corresponding author), Imperial Coll London, Dept Surg & Canc, London, England.	k.grailey18@imperial.ac.uk	Billings, Jo/ABA-4690-2020	Billings, Jo/0000-0003-1238-2440; Grailey, Kate/0000-0002-4104-8444	BUPA Cromwell Hospital; Health Foundation; National Institute for Health Research Comprehensive Biomedical Research Centre based at Imperial College Healthcare NHS Trust; Imperial College London; National Institute for Health Research (NIHR), Imperial Biomedical Research Centre (BRC)	BUPA Cromwell Hospital; Health Foundation; National Institute for Health Research Comprehensive Biomedical Research Centre based at Imperial College Healthcare NHS Trust; Imperial College London(General Electric); National Institute for Health Research (NIHR), Imperial Biomedical Research Centre (BRC)	KG received an unrestricted educational grant from BUPA Cromwell Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study analyses data originally collected in a previous qualitative study by the authors (EM, SJB). EM's institution received funding from The Health Foundation. SJB's institution received funding from The Health Foundation. In addition, he received general support for research from the National Institute for Health Research Comprehensive Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of this manuscript.; This work was originally supported by the Health Foundation. In addition, the work was supported by the National Institute for Health Research (NIHR), Imperial Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the NIHR, the UK Department of Health or the UK National Health Service.	[Anonymous], 2016, 16PF COMPR INS REP; Cattell H. E. P., 2008, SAGE HDB PERSONALITY, V2, P135, DOI [10.4135/9781849200479.n7, DOI 10.4135/9781849200479.N7]; Cattell R, 1980, HDB 16 PERSONALITY F; Chuang CH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005629; D'Lima DM, 2018, CRIT CARE MED, V46, P60, DOI 10.1097/CCM.0000000000002773; Epp Kirstin, 2012, Dynamics, V23, P25; Flett GL, 2002, PERFECTIONISM THEORY, DOI [DOI 10.1037/10458-001, DOI 10.1037/10458-002]; GERBING DW, 1991, MULTIVAR BEHAV RES, V26, P271, DOI 10.1207/s15327906mbr2602_5; Khatibi M, J ED MANAGE STUD, V6, P13; Kluger MT, 1999, ANAESTH INTENS CARE, V27, P282, DOI 10.1177/0310057X9902700310; Meit SS, 2005, PSYCHOL REP, V96, P1029; Oxford Dictionaries | English, 2018, DEFINITION REASONING; Rieke, 1994, 16PF TECHNICAL MANUA; Russell MT, 2002, 16PF ADM MANUAL; Stoeber J, 2010, J PERS ASSESS, V92, P577, DOI 10.1080/00223891.2010.513306; Wilhite A, 2016, COMPUTING EC FINANCE, V103; Zhang L, 2013, CONTEMP NURSE, V43, P219, DOI 10.5172/conu.2013.43.2.219	17	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2020	15	1							e0226800	10.1371/journal.pone.0226800	http://dx.doi.org/10.1371/journal.pone.0226800			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5DK	31914163	Green Published, gold, Green Submitted			2023-01-03	WOS:000534337700017
J	Swift, SL; Glymour, MM; Elfassy, T; Lewis, C; Kiefe, CI; Sidney, S; Calonico, S; Feaster, D; Bailey, Z; Al Hazzouri, AZ				Swift, Samuel L.; Glymour, M. Maria; Elfassy, Tali; Lewis, Cora; Kiefe, Catarina I.; Sidney, Stephen; Calonico, Sebastian; Feaster, Daniel; Bailey, Zinzi; Al Hazzouri, Adina Zeki			Racial discrimination in medical care settings and opioid pain reliever misuse in a US cohort: 1992 to 2015	PLOS ONE			English	Article							SELF-REPORTED EXPERIENCES; SUBSTANCE USE DISORDERS; PERCEIVED DISCRIMINATION; MEDIATION ANALYSIS; AFRICAN-AMERICANS; HEALTH; BLACK; CRISIS; TRENDS; CARDIA	Background In the United States whites are more likely to misuse opioid pain relievers (OPRs) than blacks, and blacks are less likely to be prescribed OPRs than whites. Our objective is to determine whether racial discrimination in medical settings is protective for blacks against OPR misuse, thus mediating the black-white disparities in OPR misuse. Methods We used data from 3528 black and white adults in the Coronary Artery Risk Development in Young Adults (CARDIA) study, an ongoing multi-site cohort. We employ causal mediation methods, with race (black vs white) as the exposure, lifetime discrimination in medical settings prior to year 2000 as the mediator, and OPR misuse after 2000 as the outcome. Results We found black participants were more likely to report discrimination in a medical setting (20.3% vs 0.9%) and less likely to report OPR misuse (5.8% vs 8.0%, OR = 0.71, 95% CI = 0.55, 0.93, adjusted for covariates). Our mediation models suggest that when everyone is not discriminated against, the disparity is wider with black persons having even lower odds of reporting OPR misuse (OR = 0.63, 95% CI = 0.45, 0.89) compared to their white counterparts, suggesting racial discrimination in medical settings is a risk factor for OPR misuse rather than protective. Conclusions These results suggest that racial discrimination in a medical setting is a risk factor for OPR misuse rather than being protective, and thus could not explain the seen black-white disparity in OPR misuse.	[Swift, Samuel L.] Univ New Mexico, Sch Med, Ctr Hlth Equ Kidney Dis, Albuquerque, NM 87131 USA; [Glymour, M. Maria] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA; [Elfassy, Tali] Univ Miami, Div Epidemiol, Dept Publ Hlth Sci, Miami, FL USA; [Lewis, Cora] Univ Alabama, Dept Med, Div Preventat Med, Tuscaloosa, AL USA; [Kiefe, Catarina I.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Boston, MA 02125 USA; [Sidney, Stephen] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA; [Calonico, Sebastian] Columbia Univ, Dept Hlth Policy & Management, New York, NY USA; [Feaster, Daniel] Univ Miami, Div Biostat, Dept Publ Hlth Sci, Miami, FL USA; [Bailey, Zinzi] Univ Miami, Jay Weiss Inst Hlth Equ, Sylvester Comprehens Canc Ctr, Miami, FL USA; [Al Hazzouri, Adina Zeki] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA	University of New Mexico; University of California System; University of California San Francisco; University of Miami; University of Alabama System; University of Alabama Tuscaloosa; University of Massachusetts System; University of Massachusetts Boston; Kaiser Permanente; Columbia University; University of Miami; University of Miami; Columbia University	Swift, SL (corresponding author), Univ New Mexico, Sch Med, Ctr Hlth Equ Kidney Dis, Albuquerque, NM 87131 USA.	samswift@salud.unm.edu	s, s/HIK-1178-2022; s, s/HHD-0404-2022; s, s/GYR-2278-2022	Swift, Samuel/0000-0001-5858-8247	National Heart, Lung, and Blood Institute [HHSN268201300025C, HHSN268201300026C, HHSN268201300027C, HHSN268201300028C, HHSN268201300029C, HHSN268200900041C]; Intramural Research Program of the National Institute on Aging; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR002737] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural Research Program of the National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	The Coronary Artery Risk Development in Young Adults Study (CARDIA) is supported by contracts HHSN268201300025C, HHSN268201300026C, HHSN268201300027C, HHSN268201300028C, HHSN268201300029C, and HHSN268200900041C from the National Heart, Lung, and Blood Institute and the Intramural Research Program of the National Institute on Aging.	Alexander MJ, 2018, EPIDEMIOLOGY, V29, P707, DOI [10.1097/EDE.0000000000000858, 10.1097/ede.0000000000000858]; [Anonymous], 2002, SAS SOFTW VERS 9 4; Borrell LN, 2007, AM J EPIDEMIOL, V166, P1068, DOI 10.1093/aje/kwm180; Case A, 2015, P NATL ACAD SCI USA, V112, P15078, DOI 10.1073/pnas.1518393112; Centers for Disease Control and Prevention NCfHS, 2017, UND CAUS DEATH 1999; Chavez LJ, 2015, AM J PREV MED, V48, P42, DOI 10.1016/j.amepre.2014.08.013; Clark TT, 2015, ADDICT BEHAV, V40, P119, DOI 10.1016/j.addbeh.2014.08.006; Cunningham TJ, 2013, J BIOSOC SCI, V45, P267, DOI 10.1017/S0021932012000429; FRIEDMAN GD, 1988, J CLIN EPIDEMIOL, V41, P1105, DOI 10.1016/0895-4356(88)90080-7; Hausmann LRM, 2008, J GEN INTERN MED, V23, P1679, DOI 10.1007/s11606-008-0730-x; James K, 2018, J LAW MED ETHICS, V46, P404, DOI 10.1177/1073110518782949; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Krieger N, 2005, SOC SCI MED, V61, P1576, DOI 10.1016/j.socscimed.2005.03.006; Krieger N, 2010, AM J PUBLIC HEALTH, V100, pS132, DOI 10.2105/AJPH.2009.181628; Landrine H., 1996, J BLACK PSYCHOL, V22, P144, DOI DOI 10.1177/00957984960222002; Lyapustina T, 2017, PAIN PRACT, V17, P1097, DOI 10.1111/papr.12568; Martin JK, 2003, J HEALTH SOC BEHAV, V44, P408, DOI 10.2307/1519787; McCabe SE, 2010, AM J PUBLIC HEALTH, V100, P1946, DOI 10.2105/AJPH.2009.163147; McLaughlin KA, 2010, AM J PUBLIC HEALTH, V100, P1477, DOI 10.2105/AJPH.2009.181586; Mossey JM, 2011, CLIN ORTHOP RELAT R, V469, P1859, DOI 10.1007/s11999-011-1770-9; Mouton CP, 2010, J HEALTH CARE POOR U, V21, P287, DOI 10.1353/hpu.0.0273; Mustillo S, 2004, AM J PUBLIC HEALTH, V94, P2125, DOI 10.2105/AJPH.94.12.2125; Nandi A, 2012, EPIDEMIOLOGY, V23, P223, DOI 10.1097/EDE.0b013e31824570bd; Nelson A, 2002, J NATL MED ASSOC, V94, P666; (NIDA) NIoDA, 2016, MIS PRESCR DRUGS; Pascoe EA, 2009, PSYCHOL BULL, V135, P531, DOI 10.1037/a0016059; Pletcher MJ, 2008, JAMA-J AM MED ASSOC, V299, P70, DOI 10.1001/jama.2007.64; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Shiels MS, 2018, ANN INTERN MED, V168, P453, DOI 10.7326/M17-1812; Unick GJ, 2017, INT J DRUG POLICY, V46, P112, DOI 10.1016/j.drugpo.2017.06.003; Valeri L, 2013, PSYCHOL METHODS, V18, P137, DOI 10.1037/a0031034; VanderWeele TJ, 2010, AM J EPIDEMIOL, V172, P1339, DOI 10.1093/aje/kwq332; Womack VY, 2014, AM J HEALTH BEHAV, V38, P641, DOI 10.5993/AJHB.38.5.1	35	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2019	14	12							e0226490	10.1371/journal.pone.0226490	http://dx.doi.org/10.1371/journal.pone.0226490			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP3ZM	31860661	Green Published, gold			2023-01-03	WOS:000534257500017
J	Thirugnanasambandam, N; Contreras-Castro, FG; Hallett, M				Thirugnanasambandam, Nivethida; Contreras-Castro, Felix G.; Hallett, Mark			Dual-hemispheric transcranial direct current stimulation (tDCS) over primary motor cortex does not affect movement selection	PLOS ONE			English	Article							MAGNETIC STIMULATION; HANDEDNESS; PHYSIOLOGY	Volition and sense of agency are two primary components of a voluntary or internally generated movement. It has been shown that movement selection cannot be altered without interfering with the sense of volition using single pulse transcranial magnetic stimulation over the primary motor cortex. In the current study, we aimed at examining whether modulating the cortical excitability of the final effector in the voluntary motor pathway-the primary motor cortex, using transcranial direct current stimulation (tDCS) would alter movement selection. Our hypothesis was that anodal tDCS would increase motor cortical excitability and thereby decrease the threshold for movement execution, which could favor selection of the contralateral hand. We recruited 13 healthy adults to perform a movement selection task involving free-choice and externally-cued trials while applying real/sham tDCS in a C3-C4 dual-hemispheric electrode montage. Contrary to our hypothesis, we did not observe any effect of tDCS on movement selection either at the individual or group level. However, our data confirms the strong preference of right-handed individuals for the dominant right hand. We also found higher reaction time for internally generated movement compared to externally triggered movement. We therefore conclude that movement selection cannot be influenced at the level of primary motor cortex and that brain areas upstream of the primary motor cortex in the voluntary motor pathway may be possible targets for influencing movement selection.	[Thirugnanasambandam, Nivethida; Contreras-Castro, Felix G.; Hallett, Mark] NINDS, Human Motor Control Sect, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Contreras-Castro, Felix G.] Amherst Coll, Amherst, MA 01002 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Amherst College	Hallett, M (corresponding author), NINDS, Human Motor Control Sect, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.	hallettm@ninds.nih.gov		Contreras-Castro, Felix/0000-0001-7798-603X; Thirugnanasambandam, Nivethida/0000-0002-4834-3016	NINDS Intramural Program [Z01 NS002669]	NINDS Intramural Program	This work was supported by the NINDS Intramural Program (Z01 NS002669). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AMMON K, 1990, J NEUROL NEUROSUR PS, V53, P705, DOI 10.1136/jnnp.53.8.705; BRASILNETO JP, 1992, J NEUROL NEUROSUR PS, V55, P964, DOI 10.1136/jnnp.55.10.964; Brass M, 2008, NEUROSCIENTIST, V14, P319, DOI 10.1177/1073858408317417; Fried I, 2017, J NEUROSCI, V37, P10842, DOI 10.1523/JNEUROSCI.2584-17.2017; Gonzalez CLR, 2006, J NEUROPHYSIOL, V95, P3496, DOI 10.1152/jn.01187.2005; Gonzalez CLR, 2007, EXP BRAIN RES, V182, P275, DOI 10.1007/s00221-007-1090-1; Hallett M, 2007, CLIN NEUROPHYSIOL, V118, P1179, DOI 10.1016/j.clinph.2007.03.019; Hallett M, 2016, ANN NEUROL, V80, P5, DOI 10.1002/ana.24657; Kranick SM, 2013, EXP BRAIN RES, V229, P313, DOI 10.1007/s00221-013-3399-2; Lewis PA, 2003, CURR OPIN NEUROBIOL, V13, P250, DOI 10.1016/S0959-4388(03)00036-9; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Seghezzi S, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.00804; Sohn YH, 2003, J NEUROL NEUROSUR PS, V74, P985, DOI 10.1136/jnnp.74.7.985; Vines BW, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-103; Woods AJ, 2016, CLIN NEUROPHYSIOL, V127, P1031, DOI 10.1016/j.clinph.2015.11.012	16	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2019	14	12							e0226103	10.1371/journal.pone.0226103	http://dx.doi.org/10.1371/journal.pone.0226103			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP1HF	31830094	gold, Green Published			2023-01-03	WOS:000534070200047
J	Brady, WJ; Mattu, A; Slovis, CM				Brady, William J.; Mattu, Amal; Slovis, Corey M.			Lay Responder Care for an Adult with Out-of-Hospital Cardiac Arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ONLY CARDIOPULMONARY-RESUSCITATION; BASIC LIFE-SUPPORT; EMERGENCY CARDIOVASCULAR CARE; PUBLIC-ACCESS DEFIBRILLATION; HEART-ASSOCIATION GUIDELINES; AUTOMATED EXTERNAL DEFIBRILLATORS; VENTRICULAR-FIBRILLATION; REGIONAL-VARIATION; SURVIVAL; BYSTANDER		[Brady, William J.] Univ Virginia Hlth Syst, Dept Emergency Med, Albemarle Cty Fire Rescue, Charlottesville, VA USA; [Mattu, Amal] Univ Maryland, Sch Med, Dept Emergency Med, Baltimore, MD 21201 USA; [Slovis, Corey M.] Vanderbilt Univ, Med Ctr, Dept Emergency Med, Nashville, TN USA; [Slovis, Corey M.] Metro Nashville Fire Dept, Nashville, TN USA; [Slovis, Corey M.] Nashville Int Airport Dept Publ Safety, Nashville, TN USA	University of Virginia; University System of Maryland; University of Maryland Baltimore; Vanderbilt University	Brady, WJ (corresponding author), Univ Virginia Hlth Syst, Dept Emergency Med, POB 800699, Charlottesville, VA 22908 USA.	wjbrady@virginia.edu						Agerskov M, 2015, RESUSCITATION, V96, P53, DOI 10.1016/j.resuscitation.2015.07.021; Anderson ML, 2014, JAMA INTERN MED, V174, P194, DOI 10.1001/jamainternmed.2013.11320; Andre Anthony D, 2004, Prehosp Emerg Care, V8, P284, DOI 10.1016/j.prehos.2004.02.004; Atwood C, 2005, RESUSCITATION, V67, P75, DOI 10.1016/j.resuscitation.2005.03.021; Baekgaard JS, 2017, CIRCULATION, V136, P954, DOI 10.1161/CIRCULATIONAHA.117.029067; Bardy GH, 2008, NEW ENGL J MED, V358, P1793, DOI 10.1056/NEJMoa0801651; Beck B, 2018, RESUSCITATION, V126, P49, DOI 10.1016/j.resuscitation.2018.02.029; Becker TK, 2019, EMERG MED J, V36, P660, DOI 10.1136/emermed-2018-208234; Berdowski J, 2010, RESUSCITATION, V81, P1479, DOI 10.1016/j.resuscitation.2010.08.006; Bobrow BJ, 2011, CIRC-CARDIOVASC QUAL, V4, P220, DOI 10.1161/CIRCOUTCOMES.110.959353; Bobrow BJ, 2010, JAMA-J AM MED ASSOC, V304, P1447, DOI 10.1001/jama.2010.1392; Bobrow BJ, 2008, CIRCULATION, V118, P2550, DOI 10.1161/CIRCULATIONAHA.108.799940; Bodtker H, 2018, RESUSCITATION, V127, pE12, DOI 10.1016/j.resuscitation.2018.04.002; Bottiger BW, 2018, RESUSCITATION, V128, P188, DOI 10.1016/j.resuscitation.2018.04.015; Boutilier JJ, 2017, CIRCULATION, V135, P2454, DOI 10.1161/CIRCULATIONAHA.116.026318; Brinkrolf P, 2018, RESUSCITATION, V127, P114, DOI 10.1016/j.resuscitation.2018.04.017; Bunch TJ, 2004, HEART RHYTHM, V1, P255, DOI 10.1016/j.hrthm.2004.04.017; Case R, 2018, RESUSCITATION, V129, P43, DOI 10.1016/j.resuscitation.2018.06.001; Chang MP, 2017, RESUSCITATION, V116, P22, DOI 10.1016/j.resuscitation.2017.04.028; Cheng A, 2018, CIRCULATION, V138, pE82, DOI 10.1161/CIR.0000000000000583; Claesson A, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0313-5; Deakin CD, 2018, RESUSCITATION, V126, P80, DOI 10.1016/j.resuscitation.2018.02.012; Dowie R, 2003, RESUSCITATION, V56, P173, DOI 10.1016/S0300-9572(02)00343-X; Ewy GA, 2013, J AM COLL CARDIOL, V61, P113, DOI 10.1016/j.jacc.2012.06.064; Field JM, 2010, CIRCULATION, V122, pS640, DOI 10.1161/CIRCULATIONAHA.110.970889; Fredman D, 2016, RESUSCITATION, V107, P129, DOI 10.1016/j.resuscitation.2016.06.022; Gardett I, 2019, PREHOSP EMERG CARE, V23, P683, DOI 10.1080/10903127.2018.1559565; Gilmore CM, 2006, AM J CARDIOL, V98, P497, DOI 10.1016/j.amjcard.2006.02.055; Girotra S, 2016, CIRCULATION, V133, P2159, DOI 10.1161/CIRCULATIONAHA.115.018175; Grasner JT, 2016, RESUSCITATION, V105, P188, DOI 10.1016/j.resuscitation.2016.06.004; Graham RM, 2015, STRATEGIES IMPROVE C; Hallstrom AP, 2004, NEW ENGL J MED, V351, P637; Hansen CM, 2015, JAMA-J AM MED ASSOC, V314, P255, DOI 10.1001/jama.2015.7938; Hansen CM, 2013, CIRCULATION, V128, P2224, DOI 10.1161/CIRCULATIONAHA.113.003066; Hawkes C, 2017, RESUSCITATION, V110, P133, DOI 10.1016/j.resuscitation.2016.10.030; Heard DG, 2019, ANN EMERG MED, V73, P599, DOI 10.1016/j.annemergmed.2018.09.026; Herlitz J, 2000, EUR HEART J, V21, P1251, DOI 10.1053/euhj.2000.2150; Holmberg MJ, 2017, RESUSCITATION, V120, P77, DOI 10.1016/j.resuscitation.2017.09.003; Hupfl M, 2010, LANCET, V376, P1552, DOI 10.1016/S0140-6736(10)61454-7; Iwami T, 2015, CIRCULATION, V132, P415, DOI 10.1161/CIRCULATIONAHA.114.014905; Kragholm K, 2017, NEW ENGL J MED, V376, P1737, DOI 10.1056/NEJMoa1601891; Kronick SL, 2015, CIRCULATION, V132, pS397, DOI 10.1161/CIR.0000000000000258; Lee SY, 2019, RESUSCITATION, V138, P198, DOI 10.1016/j.resuscitation.2019.01.045; Link MS, 2010, CIRCULATION, V122, pS706, DOI 10.1161/CIRCULATIONAHA.110.970954; Luo SY, 2017, RESUSCITATION, V121, P1, DOI 10.1016/j.resuscitation.2017.09.014; Moller TP, 2016, RESUSCITATION, V109, P1, DOI 10.1016/j.resuscitation.2016.09.012; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Nakahara S, 2015, JAMA-J AM MED ASSOC, V314, P247, DOI 10.1001/jama.2015.8068; Nehme Z, 2019, RESUSCITATION, V143, P85, DOI 10.1016/j.resuscitation.2019.08.018; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Nishi T, 2015, AM J EMERG MED, V33, P43, DOI 10.1016/j.ajem.2014.10.018; Nordberg P, 2009, RESUSCITATION, V80, P329, DOI 10.1016/j.resuscitation.2008.11.013; Ong MEH, 2015, RESUSCITATION, V96, P100, DOI 10.1016/j.resuscitation.2015.07.026; Panchal AR, 2013, RESUSCITATION, V84, P435, DOI 10.1016/j.resuscitation.2012.07.038; Pijls RWM, 2016, RESUSCITATION, V105, P182, DOI 10.1016/j.resuscitation.2016.06.006; Polentini MS, 2006, PREHOSP EMERG CARE, V10, P52, DOI 10.1080/10903120500366961; Pollack RA, 2018, CIRCULATION, V137, P2104, DOI 10.1161/CIRCULATIONAHA.117.030700; Pulver A, 2016, PREHOSP EMERG CARE, V20, P378, DOI 10.3109/10903127.2015.1115932; Rajan S, 2016, CIRCULATION, V134, P2095, DOI 10.1161/CIRCULATIONAHA.116.024400; Rea TD, 2004, RESUSCITATION, V63, P17, DOI 10.1016/j.resuscitation.2004.03.025; Rea TD, 2010, ANN EMERG MED, V55, P249, DOI 10.1016/j.annemergmed.2009.09.018; Ringh M, 2015, NEW ENGL J MED, V372, P2316, DOI 10.1056/NEJMoa1406038; Riou M, 2018, RESUSCITATION, V133, P95, DOI 10.1016/j.resuscitation.2018.10.011; Riva G, 2019, CIRCULATION, V139, P2600, DOI 10.1161/CIRCULATIONAHA.118.038179; Riyapan S, 2016, AM J EMERG MED, V34, P590, DOI 10.1016/j.ajem.2015.12.015; Ro YS, 2017, ANN EMERG MED, V69, P52, DOI 10.1016/j.annemergmed.2016.07.028; Rumsfeld JS, 2016, CIRCULATION, V134, pE87, DOI 10.1161/CIR.0000000000000428; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; Sayre MR, 2008, CIRCULATION, V117, P2162, DOI 10.1161/CIRCULATIONAHA.107.189380; Semeraro F, 2017, RESUSCITATION, V116, P27, DOI 10.1016/j.resuscitation.2017.04.038; Sondergaard KB, 2018, RESUSCITATION, V124, P138, DOI 10.1016/j.resuscitation.2017.11.067; Song JT, 2018, SCAND J TRAUMA RESUS, V26, DOI 10.1186/s13049-018-0552-8; Sun CLF, 2016, J AM COLL CARDIOL, V68, P836, DOI 10.1016/j.jacc.2016.03.609; Travers AH, 2015, CIRCULATION, V132, pS51, DOI 10.1161/CIR.0000000000000272; Viereck S, 2017, RESUSCITATION, V115, P141, DOI 10.1016/j.resuscitation.2017.04.006; Viereck S, 2017, SCAND J TRAUMA RESUS, V25, DOI 10.1186/s13049-017-0350-8; Virkkunen I, 2006, J INTERN MED, V260, P39, DOI 10.1111/j.1365-2796.2006.01664.x; Weisfeldt ML, 2010, J AM COLL CARDIOL, V55, P1712, DOI 10.1016/j.jacc.2009.11.077; Wu ZX, 2018, RESUSCITATION, V122, P135, DOI 10.1016/j.resuscitation.2017.07.016; Zive D, 2011, RESUSCITATION, V82, P277, DOI 10.1016/j.resuscitation.2010.10.022	82	19	20	2	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 5	2019	381	23					2242	2251		10.1056/NEJMra1802529	http://dx.doi.org/10.1056/NEJMra1802529			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ6NK	31800989				2023-01-03	WOS:000505219800009
J	Lucas, PJ; Uddin, MR; Khisa, N; Akter, SMS; Unicomb, L; Nahar, P; Islam, MA; Nizame, FA; Rousham, EK				Lucas, Patricia Jane; Uddin, Mohammad Rofi; Khisa, Nirnita; Akter, S. M. Salim; Unicomb, Leanne; Nahar, Papreen; Islam, Mohammad Aminul; Nizame, Fosiul Alam; Rousham, Emily K.			Pathways to antibiotics in Bangladesh: A qualitative study investigating how and when households access medicine including antibiotics for humans or animals when they are ill	PLOS ONE			English	Article							RISK-FACTORS; HEALTH; CHILDREN; ILLNESS; DHAKA; POOR	Background To understand how to reduce antibiotic use, greater knowledge is needed about the complexities of access in countries with loose regulation or enforcement. This study aimed to explore how households in Bangladesh were accessing antimicrobials for themselves and their domestic animals. Methods In-depth interviews were conducted with 48 households in one urban and one rural area. Households were purposively sampled from two lower income strata, prioritising those with under 5-year olds, older adults, household animals and minority groups. Households where someone was currently ill with a suspected infection (13 households) were invited for a follow-up interview. Framework analysis was used to explore access to healthcare and medicines. Findings People accessed medicines for themselves through five pathways: drugs shops, private clinics, government/charitable hospitals, community/family planning clinics, and specialised/private hospitals. Drug shops provided direct access to medicines for common, less serious and acute illnesses. For persistent or serious illnesses, the healthcare pathway may include contacts with several of these settings, but often relied on medicines provided by drug shops. In the 13 households with an unwell family member, most received at least one course of antibiotics for this illness. Multiple and incomplete dosing were common even when prescribed by a qualified doctor. Antibiotics were identified by their high cost compared to other medicines. Cost was a reported barrier to purchasing full courses of antibiotics. Few households in the urban area kept household animals. In this rural area, government animal health workers provided most care for large household animals (cows), but drug shops were also important. Conclusions In Bangladesh, unregulated drug shops provide an essential route to medicines including those prescribed in the formal sector. Wherever licensed suppliers are scarce and expensive, regulations which prohibit this supply risk removing access entirely for many people.	[Lucas, Patricia Jane] Univ Bristol, Sch Policy Studies, Bristol, Avon, England; [Uddin, Mohammad Rofi; Khisa, Nirnita; Akter, S. M. Salim; Unicomb, Leanne; Islam, Mohammad Aminul; Nizame, Fosiul Alam] Int Ctr Diarrhoea Dis Res, Icddr B, Dhaka, Bangladesh; [Nahar, Papreen] Univ Sussex, Brighton & Sussex Med Sch, Brighton, E Sussex, England; [Islam, Mohammad Aminul] Washington State Univ, Paul G Allen Sch Global Anim Hlth, Pullman, WA 99164 USA; [Rousham, Emily K.] Loughborough Univ, Sch Sport Exercise & Hlth Sci, Ctr Global Hlth & Human Dev, Loughborough, Leics, England; [Khisa, Nirnita] Univ Technol Sydney, Fac Hlth, Sydney, NSW, Australia	University of Bristol; International Centre for Diarrhoeal Disease Research (ICDDR); University of Brighton; University of Sussex; Washington State University; Loughborough University; University of Technology Sydney	Lucas, PJ (corresponding author), Univ Bristol, Sch Policy Studies, Bristol, Avon, England.	Patricia.lucas@bristol.ac.uk	Unicomb, Leanne Elizabeth/AAW-4900-2021	Unicomb, Leanne Elizabeth/0000-0002-7757-5641; Nahar, Papreen/0000-0002-5817-8093; Lucas, Patricia Jane/0000-0002-0469-8085; Rousham, Emily/0000-0001-5654-9279	Antimicrobial Resistance Cross-Council Initiative; Department of Health; UK Department of Environment Food and Rural Affairs; Global Challenges Research Fund (Economic and Social Research Council) [ES/P004563/1]; ESRC [ES/P004563/1] Funding Source: UKRI	Antimicrobial Resistance Cross-Council Initiative; Department of Health; UK Department of Environment Food and Rural Affairs(Department for Environment, Food & Rural Affairs (DEFRA)); Global Challenges Research Fund (Economic and Social Research Council); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	This work was supported by the Antimicrobial Resistance Cross-Council Initiative supported by the seven UK research councils in partnership with the Department of Health, the UK Department of Environment Food and Rural Affairs and the Global Challenges Research Fund (Economic and Social Research Council grant ES/P004563/1 awarded to Dr Emily Rousham). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams AM, 2015, HEALTH POLICY PLANN, V30, pi32, DOI 10.1093/heapol/czu094; Ahmed S, 2018, AM J TROP MED HYG, V98, P1571, DOI 10.4269/ajtmh.17-0988; Ahmed Syed Masud, 2017, J Pharm Policy Pract, V10, P21, DOI 10.1186/s40545-017-0108-8; Ahmed SM, 2013, LANCET, V382, P1746, DOI 10.1016/S0140-6736(13)62147-9; Bangladesh Bureau of Statistics, 2011, REPORT 2008 09 HOUSE; Bloom G, 2015, 16 STEPS CTR I DEV; Charani E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209847; Chowdhury F, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3486-y; Chowdhury F, 2017, PATIENT PREFER ADHER, V11, P479, DOI 10.2147/PPA.S121800; Correspondent Staff, 2019, DAILY STAR; Directorate General of Drug Administration, 2016, STAND EST OP MOD PHA; Directorate General of Drug Administration, 2018, LIST MOD PHARM; Dyar OJ, 2017, CLIN MICROBIOL INFEC, V23, P793, DOI 10.1016/j.cmi.2017.08.026; Faiz M. A., 2011, Regional Health Forum, V15, P1; Founou RC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189621; Harris AR, 2016, ENVIRON SCI TECHNOL, V50, P4642, DOI 10.1021/acs.est.5b06282; Holmes AH, 2016, LANCET, V387, P176, DOI 10.1016/S0140-6736(15)00473-0; Laxminarayan R, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001974; Laxminarayan R, 2013, LANCET INFECT DIS, V13, P1057, DOI 10.1016/S1473-3099(13)70318-9; Le Doare K, 2015, BRIT J CLIN PHARMACO, V79, P446, DOI 10.1111/bcp.12320; Mahmood SS, 2010, BMC INT HEALTH HUM R, V10, DOI 10.1186/1472-698X-10-18; Miller R, 2016, HEALTH POLICY PLANN, V31, P940, DOI 10.1093/heapol/czw007; Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9; Nahar P, 2017, SOCIOL HEALTH ILL, V39, P614, DOI 10.1111/1467-9566.12521; Roess AA, 2015, ZOONOSES PUBLIC HLTH, V62, P569, DOI 10.1111/zph.12186; Rousham EK, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028215; Rousham EK, 2018, P ROY SOC B-BIOL SCI, V285, DOI 10.1098/rspb.2018.0332; Rutta E., 2014, MED HLTH SYSTEMS ADV; Saha S, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2072-z; SIAPS, 2015, BAS STUD PRIV DRUG S; Sirinavin Sayomporn, 2004, Semin Pediatr Infect Dis, V15, P94, DOI 10.1053/j.spid.2004.01.012; Spencer L., 2014, QUALITATIVE RES PRAC, V2, P269; Sultana J., 2018, BANGLADESH PHARM J, V21, P47, DOI [10.3329/bpj.v21i1.37906, DOI 10.3329/BPJ.V21I1.37906]; Wardrop NA, 2018, INT J HYG ENVIR HEAL, V221, P33, DOI 10.1016/j.ijheh.2017.09.014; WHO, 2001, WHO GLOB STRAT CONT; WHO, ANT US UND; World Health Organisation, 2015, GLOB ACT PLAN AMR; World Health Organization Food and Agriculture Organization of the United Nations Health WOfA, 2016, ANT RES MAN DEV NAT	38	17	17	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 22	2019	14	11							e0225270	10.1371/journal.pone.0225270	http://dx.doi.org/10.1371/journal.pone.0225270			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO8QA	31756224	Green Published, Green Accepted, gold			2023-01-03	WOS:000533889300015
J	Bang, SP; Yeon, CY; Adhikari, N; Neupane, S; Kim, H; Lee, DC; Son, MJ; Lee, HG; Kim, JY; Jun, JH				Bang, Seung Pil; Yeon, Chang Yeor; Adhikari, Nirpesh; Neupane, Sanjiv; Kim, Harim; Lee, Dong Cheol; Son, Myeong Jin; Lee, Hyun Gyo; Kim, Jae-Young; Jun, Jong Hwa			Cyclosporine A eyedrops with self-nanoemulsifying drug delivery systems have improved physicochemical properties and efficacy against dry eye disease in a murine dry eye model	PLOS ONE			English	Article							NF-KAPPA-B; INFLAMMATORY CYTOKINES; SQUAMOUS METAPLASIA; OPHTHALMIC EMULSION; SIGNALING PATHWAYS; T-CELLS; ACTIVATION; EXPRESSION; SJOGRENS; TEAR	Purpose We aimed to compare the physicochemical properties and in vivo efficacy of commercially available nanoemulsion cyclosporine A (CsA) eyedrops in benzalkonium chloride (BAC)induced dry eye disease (DED). Methods Particle size analysis was performed on conventional 0.05% CsA (Restasis, C-CsA) and two new types of 0.05% CsA eyedrops based on a self-nanoemulsifying drug delivery system (SNEDDS, SNEDDS-N and -T). Turbidometry, pH measurements and instability indices of each CsA solution were measured. DED was induced with BAC, and animals were treated with vehicle or CsA preparations. Tear volume and fluorescein staining scores were evaluated on days 7 and 14. Eyes were enucleated and subjected to IHC, TUNEL staining, periodic acid-Schiff (PAS) staining, real-time PCR and western blotting. Results Both SNEDDSs had lower and more uniform particle size distribution than C-CsA, and a similar optical density to phosphate-buffered saline and stable pH, in contrast to the high turbidity and unstable pH of C-CsA. Aqueous tear volume and fluorescein staining scores were improved in C-CsA- and SNEDDS-treated mice. Numbers of PAS-positive goblet cells and levels of inflammatory mediators were decreased by both C-CsA and SNEDDS, although SNEDDS resolved inflammation more effectively than C-CsA. Conclusions Cyclosporine A eyedrops with SNEDDS have improved physicochemical properties and treatment efficacy in BAC-induced DED.	[Bang, Seung Pil; Kim, Harim; Lee, Dong Cheol; Son, Myeong Jin; Lee, Hyun Gyo; Jun, Jong Hwa] Keimyung Univ, Dept Ophthalmol, Dongsan Med Ctr, Sch Med, Daegu, South Korea; [Bang, Seung Pil] Univ Rochester, Dept Biomed Engn, Rochester, NY USA; [Yeon, Chang Yeor; Adhikari, Nirpesh; Neupane, Sanjiv; Kim, Jae-Young] Kyungpook Natl Univ, Sch Dent, Dept Biochem, IHBR, Daegu, South Korea	Keimyung University; University of Rochester; Kyungpook National University	Jun, JH (corresponding author), Keimyung Univ, Dept Ophthalmol, Dongsan Med Ctr, Sch Med, Daegu, South Korea.	junjonghwa@gmail.com		ADHIKARI, NIRPESH/0000-0002-8922-2114; Neupane, Sanjiv/0000-0003-2051-9865; Bang, Seung Pil/0000-0002-7521-544X	National Research Foundation of Korea (NRF) - Korea Government (MSIP) [2014R1A5A2010008, NRF-2018R1D1A1B07045362]	National Research Foundation of Korea (NRF) - Korea Government (MSIP)	This work was supported by the National Research Foundation of Korea (NRF) Grant funded by the Korea Government (MSIP) (No.2014R1A5A2010008) and NRF-2018R1D1A1B07045362. This funding body had no role in the design of the study, in the collection, analysis and interpretation of data, or in the preparation of the manuscript.	Agarwal P, 2016, DRUG DISCOV TODAY, V21, P977, DOI 10.1016/j.drudis.2016.04.002; Anton N, 2011, PHARM RES-DORDR, V28, P978, DOI 10.1007/s11095-010-0309-1; Barbosa FL, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050978; Barnadas-Rodriguez R, 2001, INT J PHARMACEUT, V213, P175, DOI 10.1016/S0378-5173(00)00661-X; Bron AJ, 2017, OCUL SURF, V15, P438, DOI 10.1016/j.jtos.2017.05.011; Chen M, 2010, EXP EYE RES, V90, P437, DOI 10.1016/j.exer.2009.12.004; Chen MK, 2011, INT IMMUNOPHARMACOL, V11, P549, DOI 10.1016/j.intimp.2010.11.025; Chen YT, 2009, MOL VIS, V15, P563; Coursey TG, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.24; Craig JP, 2017, OCUL SURF, V15, P276, DOI 10.1016/j.jtos.2017.05.008; Dogru M, 2006, INVEST OPHTH VIS SCI, V47, P1895, DOI 10.1167/iovs.05-0802; Einhorn-Stoll U, 2002, NAHRUNG, V46, P294, DOI [10.1002/1521-3803(20020701)46:4<294::AID-FOOD294>3.0.CO;2-2, 10.1002/1521-3803(20020701)46:4&lt;294::AID-FOOD294&gt;3.0.CO;2-2]; Farkouh A, 2016, CLIN OPHTHALMOL, V10, P2433, DOI 10.2147/OPTH.S118409; Galooyak SS, 2015, J FOOD SCI TECH MYS, V52, P2558, DOI 10.1007/s13197-014-1363-1; Gao JP, 2013, INVEST OPHTH VIS SCI, V54, P4717, DOI 10.1167/iovs.13-11681; Kim H, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01820; Kunert KS, 2000, ARCH OPHTHALMOL-CHIC, V118, P1489; Lallemand F, 2003, EUR J PHARM BIOPHARM, V56, P307, DOI 10.1016/S0939-6411(03)00138-3; Lallemand F, 2017, EUR J PHARM BIOPHARM, V117, P14, DOI 10.1016/j.ejpb.2017.03.006; Lee SY, 2013, AM J OPHTHALMOL, V156, P247, DOI 10.1016/j.ajo.2013.04.003; Li S, 2008, INVEST OPHTH VIS SCI, V49, P34, DOI 10.1167/iovs.07-0685; Lin ZR, 2011, MOL VIS, V17, P257; Liu XF, 2015, EXP CELL RES, V331, P223, DOI 10.1016/j.yexcr.2014.08.040; Liu Y, 2008, INVEST OPHTH VIS SCI, V49, P3336, DOI 10.1167/iovs.07-0972; Luo LH, 2004, INVEST OPHTH VIS SCI, V45, P4293, DOI 10.1167/iovs.03-1145; Mah F, 2012, CLIN OPHTHALMOL, V6, P1971, DOI 10.2147/OPTH.S30261; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; MEHTA RC, 1992, AM J HOSP PHARM, V49, P2749, DOI 10.1093/ajhp/49.11.2749; Murube J, 2003, EUR J OPHTHALMOL, V13, P115, DOI 10.1177/112067210301300201; Niederkorn JY, 2006, J IMMUNOL, V176, P3950, DOI 10.4049/jimmunol.176.7.3950; Orita T, 2010, INVEST OPHTH VIS SCI, V51, P5556, DOI 10.1167/iovs.09-4909; Pflugfelder SC, 2008, CORNEA, V27, P64, DOI 10.1097/ICO.0b013e318158f6dc; Pflugfelder SC, 2015, INVEST OPHTH VIS SCI, V56, P7545, DOI 10.1167/iovs.15-17627; POWER WJ, 1993, CORNEA, V12, P507, DOI 10.1097/00003226-199311000-00008; Rao SN, 2011, J OCUL PHARMACOL TH, V27, P603, DOI 10.1089/jop.2011.0073; Rehman FU, 2017, EXPERT OPIN DRUG DEL, V14, P1325, DOI 10.1080/17425247.2016.1218462; Saheki A, 2012, INT J PHARMACEUT, V422, P489, DOI 10.1016/j.ijpharm.2011.10.060; Sall K, 2000, OPHTHALMOLOGY, V107, P631, DOI 10.1016/S0161-6420(99)00176-1; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Seo MJ, 2010, CURR EYE RES, V35, P165, DOI 10.3109/02713680903453494; Shahba AAW, 2012, AAPS PHARMSCITECH, V13, P967, DOI 10.1208/s12249-012-9821-4; Shetty R, 2015, INVEST OPHTH VIS SCI, V56, P738, DOI 10.1167/iovs.14-14831; Stern ME, 2002, INVEST OPHTH VIS SCI, V43, P2609; Tadros T, 2004, ADV COLLOID INTERFAC, V108, P303, DOI 10.1016/j.cis.2003.10.023; Tang SY, 2013, ULTRASON SONOCHEM, V20, P485, DOI 10.1016/j.ultsonch.2012.04.005; Turner K, 2000, CORNEA, V19, P492, DOI 10.1097/00003226-200007000-00018; Utine CA, 2010, OCUL IMMUNOL INFLAMM, V18, P352, DOI 10.3109/09273948.2010.498657; Wan KH, 2015, OCUL SURF, V13, P213, DOI 10.1016/j.jtos.2014.12.006; Wang Z, 2011, MOL VIS, V17, P3137; Wu H, 2011, MOL VIS, V17, P3364; Xiao XY, 2012, INVEST OPHTH VIS SCI, V53, P191, DOI 10.1167/iovs.11-8553; Xie YF, 2014, J INFLAMM-LOND, V11, DOI 10.1186/s12950-014-0038-z; Zhang WW, 2018, MOL MED REP, V17, P1913, DOI 10.3892/mmr.2017.8073; Zhang XB, 2011, AM J PATHOL, V179, P1807, DOI 10.1016/j.ajpath.2011.06.030; Zhang Z, 2014, INVEST OPHTH VIS SCI, V55, P2963, DOI 10.1167/iovs.13-13577; Zhu SP, 2017, EXP EYE RES, V164, P109, DOI 10.1016/j.exer.2017.07.017	56	10	11	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2019	14	11							e0224805	10.1371/journal.pone.0224805	http://dx.doi.org/10.1371/journal.pone.0224805			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN3EY	31738791	Green Published, gold			2023-01-03	WOS:000532826300022
J	Conti, RM				Conti, Rena M.			Financial Toxicity of Prescription Drugs	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Conti, Rena M.] Boston Univ, Questrom Sch Business, 595 Commonwealth Ave, Boston, MA 02215 USA	Boston University	Conti, RM (corresponding author), Boston Univ, Questrom Sch Business, 595 Commonwealth Ave, Boston, MA 02215 USA.	rconti@bu.edu						Arora S, 2017, AM J MANAG CARE, V23, P410; Center for Medicare and Medicaid Services, 2019, NADAC NAT AV DRUG AC; Everlance, 2019, 2019 GAS PRIC PER ST; Luo J, 2019, ANN INTERN MED, V171, P605, DOI 10.7326/M18-1138; Zhang YT, 2012, NEW ENGL J MED, V367, P1724, DOI 10.1056/NEJMsa1203980; Zhang YT, 2010, NEW ENGL J MED, V363, P405, DOI 10.1056/NEJMp1004872	6	0	0	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 5	2019	171	9					665	666		10.7326/M19-2899	http://dx.doi.org/10.7326/M19-2899			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK6WN	31569210				2023-01-03	WOS:000494983000011
J	Reidy, W; Nuwagaba-Biribonwoha, H; Shongwe, S; Sahabo, R; Hartsough, K; Wu, YF; Gachuhi, A; Mthethwa-Hleta, S; Abrams, EJ				Reidy, William; Nuwagaba-Biribonwoha, Harriet; Shongwe, Siphesihle; Sahabo, Ruben; Hartsough, Kieran; Wu, Yingfeng; Gachuhi, Averie; Mthethwa-Hleta, Simangele; Abrams, Elaine J.			Engagement in care among women and their infants lost to follow-up under Option B plus in eSwatini	PLOS ONE			English	Article							HIV-INFECTED PATIENTS; BREAST-FEEDING WOMEN; ANTIRETROVIRAL THERAPY; RETENTION; MORTALITY; PROGRAMS; LILONGWE; OUTCOMES	Background Universal antiretroviral treatment (ART) for pregnant women with HIV, Option B+, has been adopted widely for prevention of mother-to-child HIV transmission (PMTCT). Some evidence shows high loss to follow-up (LTF) under this model. However, gaps in data systems limit this evidence. We collected additional information for women and infants LTF from Option B+ in Eswatini to assess more accurate outcomes. Methods LTF at 6-months postpartum was assessed using facility data. Additional data was gathered from: 1) the national ART database and paper records; 2) patient tracing; and 3) interviews and abstraction from patient-held records. Engagement in care was defined as any clinic visit within 91 days before or after 6-months postpartum or completion of a documented transfer; or, for those traced but not completing study interviews, visits at 6-months postpartum or later (for infants), or visits within 3-months of tracing (for women). Multivariable log linear models were used to identify correlates of engagement. Results One-hundred-ninety-four (44.7%) of 434 LTF women had outcomes ascertained, including 122 (62.9%) women engaged in care. Among 510 LTF infants, 265 (52.0%) had ascertained outcomes, including 143 (54.0%) engaged in care, 47 (17.7%) pregnancy losses, and 18 (6.8%) deaths. Seventy-two of 189 live infants (38.1%) with ascertained outcomes had a 6-week early infant diagnostic (EID) test. Among women with ascertained outcomes, gestational age of 20+ weeks (vs. fewer than 20 weeks, aRR 0.80; 95% CI 0.68-0.94) and age 25-29 years (vs. 15-24 years, aRR 0.81; 95% CI 0.67-0.97), were associated with lower engagement; initiating ART after first ANC visit was associated with higher engagement (vs. at first ANC visit, aRR 1.12; 95% CI 1.04-1.21). Among infants with ascertained outcomes, mother not initiating ART was associated with lower engagement (vs. ART at first ANC visit, aRR 0.71; 95% Cl 0.54-0.91). Conclusion Substantial numbers of women and infants classified as LTF under Option B+ were engaged in care, though a suboptimal level of 6-week EID testing was observed. These findings highlight a need to improve coverage of routine EID testing, and improve data systems to better capture PMTCT patient outcomes.	[Reidy, William; Nuwagaba-Biribonwoha, Harriet; Shongwe, Siphesihle; Sahabo, Ruben; Hartsough, Kieran; Wu, Yingfeng; Gachuhi, Averie; Abrams, Elaine J.] Columbia Univ, Mailman Sch Publ Hlth, ICAP Columbia, New York, NY 10027 USA; [Reidy, William; Nuwagaba-Biribonwoha, Harriet; Abrams, Elaine J.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA; [Mthethwa-Hleta, Simangele] Minist Hlth, Mbabane, Eswatini; [Abrams, Elaine J.] Columbia Univ, Dept Pediat, Vagelos Coll Phys & Surg, New York, NY 10027 USA	Columbia University; Columbia University; Columbia University	Reidy, W (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, ICAP Columbia, New York, NY 10027 USA.; Reidy, W (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA.	wr2205@columbia.edu		Reidy, William/0000-0001-5701-038X	United States National Institutes of Health [1R21AI120690-01]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI120690] Funding Source: NIH RePORTER	United States National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was funded by the United States National Institutes of Health, grant number 1R21AI120690-01 (WR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The opinions expressed in this paper are those of the authors and do not necessarily represent those of the United States Government.	Abrams EJ, 2019, AIDS, V33, P45, DOI 10.1097/QAD.0000000000002027; Ahmed S, 2013, CURR OPIN HIV AIDS, V8, P474, DOI 10.1097/COH.0b013e328363a8f2; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P1; Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790; Clouse K, 2017, JAIDS-J ACQ IMM DEF, V74, P383, DOI 10.1097/qai.0000000000001284; Essajee S, 2017, JAIDS-J ACQ IMM DEF, V75, pS51, DOI [10.1097/qai.0000000000001319, 10.1097/QAI.0000000000001319]; Eswatini G, 2019, SWAZILAND HIV INCIDE; Geng EH, 2010, TROP MED INT HEALTH, V15, P63, DOI 10.1111/j.1365-3156.2010.02507.x; Gugsa S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179838; Haas AD, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21947; Hauser BM, 2018, INT J STD AIDS, V29, P185, DOI 10.1177/0956462417721658; Innes S, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.18914; Joint United Nations Programme on HIV/AIDS (UNAIDS), JOINT UN PROGR HIV A; Kieffer MP, 2014, JAIDS-J ACQ IMM DEF, V67, pS188, DOI 10.1097/QAI.0000000000000372; Kiwanuka G, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3450-9; Knettel BA, 2018, JAIDS-J ACQ IMM DEF, V77, P427, DOI 10.1097/QAI.0000000000001616; Low-Beer D, 2017, AIDS BEHAV, V21, pS15, DOI 10.1007/s10461-017-1754-1; Ministry of Health, 2019, UPHIA UG POP HIV IMP; Ministry of Health M, 2018, MAL POP BAS HIV IMP; Ministry of Health S, 2015, ANN HIV PROGR REP; Nkambule R., 2002, 9 INT AIDS SOC C HIV, V34, P7389, DOI [10.1016/j.biomaterials.2013.06.009, DOI 10.1016/J.BIOMATERIALS.2013.06.009]; Phillips T, 2015, JAIDS-J ACQ IMM DEF, V70, pE102, DOI 10.1097/QAI.0000000000000771; Phillips TK, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25114; Reidy W, 2018, C RETR OPP INF CROI; Reidy W, 2016, CLIN INFECT DIS, V63, P426, DOI 10.1093/cid/ciw302; Shaffer N, 2014, AIDS, V28, P599, DOI 10.1097/QAD.0000000000000144; Silvestre E., 2017, IMPLEMENTING SWAZILA; Sullivan TR, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0414-5; Tenthani L, 2014, AIDS, V28, P589, DOI 10.1097/QAD.0000000000000143; Tweya H, 2014, TROP MED INT HEALTH, V19, P1360, DOI 10.1111/tmi.12369; UNAIDS, 2018, UNAIDS DAT 2018; Whiteside A, 2003, WHAT IS DRIVING HIV; Wilkinson LS, 2015, TROP MED INT HEALTH, V20, P365, DOI 10.1111/tmi.12434; Woelk G, 2015, SECONDARY ANAL RETEN; World Health Organization, 2012, 3 INT PAT MON SYST H; Zurcher K, 2017, TROP MED INT HEALTH, V22, P375, DOI 10.1111/tmi.12843	36	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2019	14	10							e0222959	10.1371/journal.pone.0222959	http://dx.doi.org/10.1371/journal.pone.0222959			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN0VZ	31665137	Green Published, gold			2023-01-03	WOS:000532664700005
J	Garcia, A; Boffi, SM; Gayet-Ageron, A; Vernaz, N				Garcia, Amandine; Boffi, Sascha Moore; Gayet-Ageron, Angele; Vernaz, Nathalie			Access to unauthorized hepatitis C generics: Perception and knowledge of physicians, pharmacists, patients and non-healthcare professionals	PLOS ONE			English	Article							BIOEQUIVALENCE; FLEXIBILITIES; MEDICINES; TABLETS	Objectives Hepatitis C virus (HCV) causes both acute and chronic infection, which can potentially develop into cirrhosis and liver cancer. Healthcare systems are struggling to finance costly direct-acting antiviral agents through public funding for uninsured patients, despite the unprecedented high cure rates of these agents. Vulnerable populations are at higher risk of HCV infection. The personal importation scheme is based on the legal right to import any unauthorized generics for personal use. This study was designed to assess the knowledge and perceptions of stakeholders on unauthorized generics. Methods We conducted an anonymous online survey based on the fictitious situation of a patient diagnosed with HCV who lacked mandatory health insurance and personal financial resources. Results We obtained a sample of 781 respondents: 445 physicians, 77 pharmacists, 51 patients and 207 non-healthcare professionals. We found that only 36% and 58% of respondents believe that the quality and efficacy, respectively, of unauthorized generics are equivalent to their corresponding brand. An overwhelming majority (98%) favoured quality control upon arrival, and 31% felt they could recognize fraudulent websites. A total of 79% expressed support for financial assistance for vulnerable patients, and support among physicians was 83%. Conclusions Overall, the limited knowledge of the efficacy and quality of unauthorized generics, despite evidence in peer-reviewed literature, contrasts with the overwhelmingly positive attitudes toward financial assistance for personal import. This finding emphasizes the need for clearer information on imported generics and the potential safety provided by buyers' club schemes to complete the WHO agenda of eradicating viral hepatitis by 2030 within otherwise excluded vulnerable populations.	[Garcia, Amandine] Univ Geneva, Fac Med, Geneva, Switzerland; [Boffi, Sascha Moore] Grp Sida Geneve, Geneva, Switzerland; [Gayet-Ageron, Angele] Geneva Univ Hosp, Div Clin Epidemiol, Med Directorate, Geneva, Switzerland; [Vernaz, Nathalie] Univ Geneva, Geneva Univ Hosp, Finance Directorate, Med Directorate, Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva	Vernaz, N (corresponding author), Univ Geneva, Geneva Univ Hosp, Finance Directorate, Med Directorate, Geneva, Switzerland.	nathalie.vernaz@hcuge.ch		Vernaz, Nathalie/0000-0002-1371-5510; Gayet-Ageron, Angele/0000-0002-6164-9693				Abozeid M, 2018, INT J INFECT DIS, V75, P109, DOI 10.1016/j.ijid.2018.07.025; Assefa Y, 2018, INT J INFECT DIS, V70, P65, DOI 10.1016/j.ijid.2018.03.004; Beck EJ, 2019, GLOBAL HEALTH ACTION, V12, DOI 10.1080/16549716.2019.1586317; Bendas ER, 2018, CLIN DRUG INVEST, V38, P439, DOI 10.1007/s40261-018-0622-8; Chachad S, 2009, ARZNEIMITTELFORSCH, V59, P263, DOI 10.1055/s-0031-1296395; Chahal HS, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000651; Chahal HS, 2017, J INT AIDS SOC, V20, DOI 10.1002/jia2.25019; Chen ML, 2018, EUR J PHARM SCI, V111, P153, DOI 10.1016/j.ejps.2017.09.047; COMPARIS, COMM SES MED INT ATT; Dunne S, 2013, BMC PHARMACOL TOXICO, V14, DOI 10.1186/2050-6511-14-1; Federation romande des consommateurs, ACH LIGN MED MEF VOU; Fraeyman J, 2015, J MANAG CARE SPEC PH, V21, P288, DOI 10.18553/jmcp.2015.21.4.288; Freeman JAD, 2016, LIVER INT, V36, P929, DOI 10.1111/liv.13157; Gangadhar B N, 2018, Indian J Med Ethics, V3, P84, DOI 10.20529/IJME.2018.006; Godman B, 2012, GABI J, V1, P22; Godman B, 2010, PHARMACEUTICALS, V3, P2470, DOI 10.3390/ph3082470; Hamilton WL, 2016, HEALTH POLICY PLANN, V31, P1448, DOI 10.1093/heapol/czw062; Hill A, 2018, J VIRUS ERAD, V4, P128; IRACM, FALS INT; Jacomet C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117214; Kesselheim AS, 2017, PHARMACOEPIDEM DR S, V26, P694, DOI 10.1002/pds.4205; Liu CH, 2018, ALIMENT PHARM THER, V47, P1690, DOI 10.1111/apt.14647; Liu CH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32060-7; Love J, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d1694; Mylan Pharma GmbH, LAUNCH 1 GEN; Negro F, 2014, DIGEST LIVER DIS, V46, pS158, DOI 10.1016/j.dld.2014.09.023; Nicol D, 2013, B WORLD HEALTH ORGAN, V91, P533, DOI 10.2471/BLT.12.115865; OFSP, MED HEP C FORT RED P; Pala KC, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3445-6; Petersen A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184165; Premkumar M, 2017, J CLIN EXP HEPATOL, V7, P253, DOI 10.1016/j.jceh.2017.08.003; Ravinetto Raffaella, 2016, J Pharm Policy Pract, V9, P36; Rhumorbarbe D., ACHETER MED INTERNET; Riner B, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2682-5; Swissmedic, ACT PANGEA 11 SUISS; Swissmedic, GUID MED INT; t Hoen EFM, PRACTICAL APPL FLEXI; 't Hoen EFM, 2018, B WORLD HEALTH ORGAN, V96, P185, DOI 10.2471/BLT.17.199364; Tang L, 2018, Interdiscip Perspect Infect Dis, V2018, P9124604, DOI 10.1155/2018/9124604; Velasquez G., 2018, USE TRIPS FLEXIBILIT, P54; Vernaz N, 2018, SWISS MED WEEKLY, V148; Vernaz N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157098; Wang X, 2019, INT J STD AIDS; Waning B, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-35; WHO, COMB HEP B C 2030; World Health Organization, PREQ MED WHO; World Health Organization, 2016, GLOB HLTH SECT STRAT; World Health Organization, GLOB HEP REP; WTO, INT PROP TRIPS 2	49	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2019	14	10							e0223649	10.1371/journal.pone.0223649	http://dx.doi.org/10.1371/journal.pone.0223649			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM7ZE	31600328	Green Published, gold			2023-01-03	WOS:000532467000106
J	Burki, T				Burki, Talha			Brexit and medicine shortages in the UK	LANCET			English	Editorial Material																			0	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 5	2019	394	10205					1218	1218		10.1016/S0140-6736(19)32264-0	http://dx.doi.org/10.1016/S0140-6736(19)32264-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JB8XK	31591974				2023-01-03	WOS:000488862500011
J	Hediger, K; Petignat, M; Marti, R; Hund-Georgiadis, M				Hediger, Karin; Petignat, Milena; Marti, Rahel; Hund-Georgiadis, Margret			Animal-assisted therapy for patients in a minimally conscious state: A randomized two treatment multi-period crossover trial	PLOS ONE			English	Article							HEART-RATE-VARIABILITY; PET THERAPY; DISORDERS; STRESS	Objective To investigate if animal-assisted therapy (AAT) leads to higher consciousness in patients in a minimally conscious state during a therapy session, measured via behavioral reactions, heart rate and heart rate variability. Methods In a randomized two treatment multi-period crossover trial, 10 patients in a minimally conscious state participated in eight AAT sessions and eight paralleled conventional therapy sessions, leading to 78 AAT and 73 analyzed control sessions. Patients' responses during sessions were assessed via behavioral video coding and the Basler Vegetative State Assessment (BAVESTA), heart rate and heart rate variability (SDNN, RMSSD, HF and LF). Data were analyzed with generalized linear mixed models. Results Patients showed more eye movements (IRR = 1.31, 95% CI: 1.23 to 1.40, p<0.001) and active movements per tactile input during AAT compared to control sessions (IRR = 1.13, 95% CI: 1.02 to 1.25, p = 0.018). No difference was found for positive emotions. With BAVESTA, patients' overall behavioral reactions were rated higher during AAT (b = 0.11, 95% CI: 0.01 to 0.22, p = 0.038). AAT led to significantly higher LF (b = 5.82, 95% CI: 0.55 to 11.08, p= 0.031) and lower HF (b =-5.80, 95% CI:-11.06 to-0.57, p = 0.030), while heart rate, SDNN, RMSSD did not differ. Conclusions Patients in a minimally conscious state showed more behavioral reactions and increased physiological arousal during AAT compared to control sessions. This might indicate increased consciousness during therapeutic sessions in the presence of an animal.	[Hediger, Karin; Petignat, Milena; Marti, Rahel] Univ Basel, Dept Psychol, Div Clin Psychol & Psychotherapy, Basel, Switzerland; [Hediger, Karin; Petignat, Milena; Marti, Rahel; Hund-Georgiadis, Margret] Clin Neurorehabil & Paraplegiol, REHAB Basel, Basel, Switzerland; [Hediger, Karin] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Human & Anim Hlth Unit, Basel, Switzerland; [Hediger, Karin] Inst Interdisciplinary Res Human Anim Relationshi, Basel, Switzerland	University of Basel; University of Basel; Swiss Tropical & Public Health Institute	Hediger, K (corresponding author), Univ Basel, Dept Psychol, Div Clin Psychol & Psychotherapy, Basel, Switzerland.; Hediger, K (corresponding author), Clin Neurorehabil & Paraplegiol, REHAB Basel, Basel, Switzerland.; Hediger, K (corresponding author), Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Human & Anim Hlth Unit, Basel, Switzerland.; Hediger, K (corresponding author), Inst Interdisciplinary Res Human Anim Relationshi, Basel, Switzerland.	karin.hediger@unibas.ch	Marti, Rahel/AAE-7247-2019; Hediger, Karin/R-5445-2016	Marti, Rahel/0000-0002-9072-8905; Hediger, Karin/0000-0002-7202-4816	Ambizione grant from the Swiss National Science Foundation [PZ00P1_174082]; Forderverein pro REHAB Basel	Ambizione grant from the Swiss National Science Foundation; Forderverein pro REHAB Basel	Karin Hediger received support from an Ambizione grant from the Swiss National Science Foundation (grant PZ00P1_174082) and the Forderverein pro REHAB Basel. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Affolter F., 2000, NONVERBAL PERCEPTUAL; Bardl S, 2013, REHABILITATION, V52, P399, DOI 10.1055/s-0033-1334915; Borgi M, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00298; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Camm AJ, 1996, EUR HEART J, V17, P354; Covelli V, 2016, ACTA NEUROL SCAND, V134, P352, DOI 10.1111/ane.12550; Eapen BC, 2017, PHYS MED REH CLIN N, V28, P245, DOI 10.1016/j.pmr.2016.12.003; Ein N, 2018, STRESS HEALTH, V34, P477, DOI 10.1002/smi.2812; Fingelkurts AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025967; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Giacino JT, 1993, ARCH PHYS MED REHAB, V74, P662; Hjortskov N, 2004, EUR J APPL PHYSIOL, V92, P84, DOI 10.1007/s00421-004-1055-z; Huber M, 2014, INT J HLTH CARE PROF, V1, P50; IAHAIO, 2014, IAHAIO WHIT PAP; Jones MG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210761; Kaminski M, 2002, CHILD HEALTH CARE, V31, P321, DOI 10.1207/S15326888CHC3104_5; Kim HG, 2018, PSYCHIAT INVEST, V15, P235, DOI 10.30773/pi.2017.08.17; Kreibig SD, 2010, BIOL PSYCHOL, V84, P394, DOI 10.1016/j.biopsycho.2010.03.010; La Gattuta E, 2018, NEUROL SCI, V39, P641, DOI 10.1007/s10072-017-3235-8; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Motooka M, 2006, MED J AUSTRALIA, V184, P60, DOI 10.5694/j.1326-5377.2006.tb00116.x; Perrin F, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01102; Pisa FE, 2014, J HEAD TRAUMA REHAB, V29, pE23, DOI 10.1097/HTR.0b013e3182a4469f; Pistarini C, 2018, NEUROPSYCHOL REHABIL, V28, P1319, DOI 10.1080/09602011.2018.1500920; Schretzmayer L, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00090; Silva K, 2018, J ALTERN COMPLEM MED, V24, P238, DOI 10.1089/acm.2017.0254; Sun YX, 2018, BMC NEUROL, V18, DOI 10.1186/s12883-018-1040-5; Thomas BL, 2019, NEUROPSYCHOBIOLOGY, V78, P14, DOI 10.1159/000495519; Zupan M, 2016, PHYSIOL BEHAV, V155, P102, DOI 10.1016/j.physbeh.2015.11.027	30	8	9	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2019	14	10							e0222846	10.1371/journal.pone.0222846	http://dx.doi.org/10.1371/journal.pone.0222846			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM6RH	31574106	Green Accepted, Green Published, gold			2023-01-03	WOS:000532376700016
J	Miao, L; Li, LX; Huang, YX; Delcassian, D; Chahal, J; Han, JS; Shi, YH; Sadtler, K; Gao, WT; Lin, JQ; Doloff, JC; Langer, R; Anderson, DG				Miao, Lei; Li, Linxian; Huang, Yuxuan; Delcassian, Derfogail; Chahal, Jasdave; Han, Jinsong; Shi, Yunhua; Sadtler, Kaitlyn; Gao, Wenting; Lin, Jiaqi; Doloff, Joshua C.; Langer, Robert; Anderson, Daniel G.			Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation	NATURE BIOTECHNOLOGY			English	Article							MULTICOMPONENT REACTIONS; IN-VIVO; SIRNA DELIVERY; RIG-I; NANOPARTICLES; POTENT; ANTIGEN; OPTIMIZATION; RECOGNITION; CHEMISTRY	Therapeutic messenger RNA vaccines enable delivery of whole antigens, which can be advantageous over peptide vaccines. However, optimal efficacy requires both intracellular delivery, to allow antigen translation, and appropriate immune activation. Here, we developed a combinatorial library of ionizable lipid-like materials to identify mRNA delivery vehicles that facilitate mRNA delivery in vivo and provide potent and specific immune activation. Using a three-dimensional multi-component reaction system, we synthesized and evaluated the vaccine potential of over 1,000 lipid formulations. The top candidate formulations induced a robust immune response, and were able to inhibit tumor growth and prolong survival in melanoma and human papillomavirus E7 in vivo tumor models. The top-performing lipids share a common structure: an unsaturated lipid tail, a dihydroimidazole linker and cyclic amine head groups. These formulations induce antigen-presenting cell maturation via the intracellular stimulator of interferon genes (STING) pathway, rather than through Toll-like receptors, and result in limited systemic cytokine expression and enhanced anti-tumor efficacy.	[Miao, Lei; Li, Linxian; Huang, Yuxuan; Delcassian, Derfogail; Chahal, Jasdave; Shi, Yunhua; Sadtler, Kaitlyn; Gao, Wenting; Lin, Jiaqi; Doloff, Joshua C.; Langer, Robert; Anderson, Daniel G.] MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Miao, Lei; Li, Linxian; Shi, Yunhua; Doloff, Joshua C.; Langer, Robert; Anderson, Daniel G.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA; [Li, Linxian; Han, Jinsong] Karolinska Inst, Ming Wai Lau Ctr Reparat Med, Hong Kong, Peoples R China; [Delcassian, Derfogail; Sadtler, Kaitlyn; Doloff, Joshua C.; Langer, Robert; Anderson, Daniel G.] Boston Childrens Hosp, Dept Anesthesiol, Boston, MA 02115 USA; [Delcassian, Derfogail] Univ Nottingham, Div Regenerat Med & Cellular Therapy, Nottingham, England; [Langer, Robert; Anderson, Daniel G.] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Langer, Robert; Anderson, Daniel G.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Doloff, Joshua C.] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Translat Tissue Engn Ctr,Wilmer Eye Inst, Baltimore, MD 21205 USA; [Doloff, Joshua C.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Translat Tissue Engn Ctr,Dept Mat Sci Engn, Baltimore, MD 21205 USA; [Doloff, Joshua C.] Johns Hopkins Univ, Sch Med, Inst NanoBioTechnol, Baltimore, MD USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital; University of Nottingham; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Anderson, DG (corresponding author), MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Anderson, DG (corresponding author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.; Anderson, DG (corresponding author), Boston Childrens Hosp, Dept Anesthesiol, Boston, MA 02115 USA.; Anderson, DG (corresponding author), MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Anderson, DG (corresponding author), MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.	dgander@mit.edu	Han, Jinsong/B-3793-2017; Miao, Lei/H-2700-2017; Delcassian, Derfogail/P-3415-2014	Han, Jinsong/0000-0003-1832-2641; Miao, Lei/0000-0003-4235-2680; Delcassian, Derfogail/0000-0002-8030-7672; Li, Linxian/0000-0002-3451-577X	Translate Bio (Lexington, MA); Juvenile Diabetes Research Foundation [17-2007-1063, 3-PDF-2015-91-A-N]; Cancer Center Support (core) from the National Institutes of Health [P30-CA14051]; Misrock postdoctoral fellowship; EPSRC E-TERM Fellowship [EP/I017801/1]; Marie Sklodowska Curie Fellowship [IF/798348]; Ruth L. Kirschstein NRSA Postdoctoral Fellowship from the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health [1F32EB025688-01A1]; Ming Wai Lau Centre for Reparative Medicine, Karolinska Institutet; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [F32EB025688] Funding Source: NIH RePORTER	Translate Bio (Lexington, MA); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); Cancer Center Support (core) from the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Misrock postdoctoral fellowship; EPSRC E-TERM Fellowship(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Marie Sklodowska Curie Fellowship; Ruth L. Kirschstein NRSA Postdoctoral Fellowship from the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health; Ming Wai Lau Centre for Reparative Medicine, Karolinska Institutet; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This work was supported by Translate Bio (Lexington, MA) and the Juvenile Diabetes Research Foundation (grant nos. 17-2007-1063 and 3-PDF-2015-91-A-N). This work is supported in part by the Cancer Center Support (core) (grant no. P30-CA14051) from the National Institutes of Health. D.G.A. is a consultant for Translate Bio. L.M. was supported by a Misrock postdoctoral fellowship. D.D. was supported by an EPSRC E-TERM Fellowship (EP/I017801/1) and a Marie Sklodowska Curie Fellowship (IF/798348). K.S. was supported by the Ruth L. Kirschstein NRSA Postdoctoral Fellowship (no. 1F32EB025688-01A1) from the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health. L.L. and J.H. were supported by a Ming Wai Lau grant from the Ming Wai Lau Centre for Reparative Medicine, Karolinska Institutet. The authors would like to acknowledge the use of resources at the W. M. Keck Biological Imaging Facility (Whitehead Institute) and at the Microscopy, Histology, Animal Imaging & Preclinical Testing and Flow Cytometry Core Facilities (Swanson Biotechnology Center, David H. Koch Institute for Integrative Cancer Research at MIT), and acknowledge Wuxi Further Pharmaceutical Co., Ltd for synthesizing and providing lipid materials.	Akinc A, 2008, NAT BIOTECHNOL, V26, P561, DOI 10.1038/nbt1402; Aviles E, 2015, BIOORG MED CHEM LETT, V25, P5339, DOI 10.1016/j.bmcl.2015.09.033; Barbalat R, 2011, ANNU REV IMMUNOL, V29, P185, DOI 10.1146/annurev-immunol-031210-101340; Barber GN, 2015, NAT REV IMMUNOL, V15, P760, DOI 10.1038/nri3921; Belliveau NM, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.28; Bloom MB, 1997, J EXP MED, V185, P453, DOI 10.1084/jem.185.3.453; Broos Katrijn, 2016, Mol Ther Nucleic Acids, V5, pe326, DOI 10.1038/mtna.2016.38; Caucheteux SM, 2016, J INVEST DERMATOL, V136, P2127, DOI 10.1016/j.jid.2016.07.020; Chahal JS, 2016, P NATL ACAD SCI USA, V113, pE4133, DOI 10.1073/pnas.1600299113; Cheng N, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120638; Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031; Deering RP, 2014, EXPERT OPIN DRUG DEL, V11, P885, DOI 10.1517/17425247.2014.901308; Demaria O, 2015, P NATL ACAD SCI USA, V112, P15408, DOI 10.1073/pnas.1512832112; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Fenton OS, 2016, ADV MATER, V28, P2939, DOI 10.1002/adma.201505822; Fotin-Mleczek M, 2012, J GENE MED, V14, P428, DOI 10.1002/jgm.2605; Fu J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4306; Gilleron J, 2013, NAT BIOTECHNOL, V31, P638, DOI 10.1038/nbt.2612; Gu B, 2015, INT J PHARMACEUT, V491, P208, DOI 10.1016/j.ijpharm.2015.06.006; Heyes J, 2005, J CONTROL RELEASE, V107, P276, DOI 10.1016/j.jconrel.2005.06.014; Holm CK, 2012, NAT IMMUNOL, V13, P737, DOI 10.1038/ni.2350; Hulme C, 2003, CURR MED CHEM, V10, P51, DOI 10.2174/0929867033368600; Iribarren K, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1088631; Iurescia S, 2018, RECENT PAT ANTI-CANC, V13, P2, DOI 10.2174/1574892812666171030163804; Jayaraman M, 2012, ANGEW CHEM INT EDIT, V51, P8529, DOI 10.1002/anie.201203263; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Kauffman KJ, 2016, J CONTROL RELEASE, V240, P227, DOI 10.1016/j.jconrel.2015.12.032; Kauffman KJ, 2015, NANO LETT, V15, P7300, DOI 10.1021/acs.nanolett.5b02497; Kazmaier U, 2005, ORG BIOMOL CHEM, V3, P3184, DOI 10.1039/b507028g; Koopmanschap G, 2014, BEILSTEIN J ORG CHEM, V10, P544, DOI 10.3762/bjoc.10.50; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Kuai R, 2017, NAT MATER, V16, P489, DOI [10.1038/NMAT4822, 10.1038/nmat4822]; Li K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020404; Luo M, 2017, NAT NANOTECHNOL, V12, P648, DOI [10.1038/NNANO.2017.52, 10.1038/nnano.2017.52]; Ma DY, 2009, SEMIN IMMUNOL, V21, P265, DOI 10.1016/j.smim.2009.05.010; Maruggi G, 2017, VACCINE, V35, P361, DOI 10.1016/j.vaccine.2016.11.040; Oberli MA, 2017, NANO LETT, V17, P1326, DOI 10.1021/acs.nanolett.6b03329; Ohkuri T, 2017, CANCER IMMUNOL IMMUN, V66, P705, DOI 10.1007/s00262-017-1975-1; Pan SC, 2008, ANGEW CHEM INT EDIT, V47, P3622, DOI 10.1002/anie.200800494; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pollard C, 2013, MOL THER, V21, P251, DOI 10.1038/mt.2012.202; Rao Ravella Sreenivas, 2008, Biotechnology Journal, V3, P510, DOI 10.1002/biot.200700201; Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017; Sahay G, 2013, NAT BIOTECHNOL, V31, P653, DOI 10.1038/nbt.2614; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Schlee M, 2009, IMMUNITY, V31, P25, DOI 10.1016/j.immuni.2009.05.008; Semple SC, 2010, NAT BIOTECHNOL, V28, P172, DOI 10.1038/nbt.1602; Tanaka Y, 2007, ORG LETT, V9, P4407, DOI 10.1021/ol701570c; Uchida S, 2018, BIOMATERIALS, V150, P162, DOI 10.1016/j.biomaterials.2017.09.033; Ugi I, 2003, MOLECULES, V8, P53, DOI 10.3390/80100053; Van Lint S, 2012, CANCER RES, V72, P1661, DOI 10.1158/0008-5472.CAN-11-2957; WADA J, 1973, J MED CHEM, V16, P930, DOI 10.1021/jm00266a013; Walseng E, 2010, J BIOL CHEM, V285, P41749, DOI 10.1074/jbc.M110.157586; Wang J, 2016, J INVEST DERMATOL, V136, P2183, DOI 10.1016/j.jid.2016.05.105; Whitehead KA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5277; Whitehead KA, 2012, ACS NANO, V6, P6922, DOI 10.1021/nn301922x; Wilson DR, 2018, NANOMED-NANOTECHNOL, V14, P237, DOI 10.1016/j.nano.2017.10.013; Zevini A, 2017, TRENDS IMMUNOL, V38, P194, DOI 10.1016/j.it.2016.12.004	58	212	222	68	442	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2019	37	10					1174	+		10.1038/s41587-019-0247-3	http://dx.doi.org/10.1038/s41587-019-0247-3			14	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	JI2ST	31570898				2023-01-03	WOS:000493315800019
J	Magaziner, J; Mangione, KK; Orwig, D; Baumgarten, M; Magder, L; Terrin, M; Fortinsky, RH; Gruber-Baldini, AL; Beamer, BA; Tosteson, ANA; Kenny, AM; Shardell, M; Binder, EF; Koval, K; Resnick, B; Miller, R; Forman, S; McBride, R; Craik, RL				Magaziner, Jay; Mangione, Kathleen K.; Orwig, Denise; Baumgarten, Mona; Magder, Laurence; Terrin, Michael; Fortinsky, Richard H.; Gruber-Baldini, Ann L.; Beamer, Brock A.; Tosteson, Anna N. A.; Kenny, Anne M.; Shardell, Michelle; Binder, Ellen F.; Koval, Kenneth; Resnick, Barbara; Miller, Ram; Forman, Sandra; McBride, Ruth; Craik, Rebecca L.			Effect of a Multicomponent Home-Based Physical Therapy Intervention on Ambulation After Hip Fracture in Older Adults: The CAP Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINI NUTRITIONAL ASSESSMENT; PERFORMANCE-MEASURES; SAMPLE-SIZE; PROGRAM; REHABILITATION; RECOVERY; IDENTIFICATION; NONADHERENCE; VALIDATION; VELOCITY	ImportanceDisability persists after hip fracture in older persons. Current rehabilitation may not be sufficient to restore ability to walk in the community. ObjectiveTo compare a multicomponent home-based physical therapy intervention (training) with an active control on ability to walk in the community. Design, Setting, and ParticipantsParallel, 2-group randomized clinical trial conducted at 3 US clinical centers (Arcadia University, University of Connecticut Health Center, and University of Maryland, Baltimore). Randomization began on September 16, 2013, and ended on June 20, 2017; follow-up ended on October 17, 2017. Patients aged 60 years and older were enrolled after nonpathologic, minimal trauma hip fracture, if they were living in the community and walking without human assistance before the fracture, were assessed within 26 weeks of hospitalization, and were not able to walk during daily activities at the time of enrollment. A total of 210 participants were randomized and reassessed 16 and 40 weeks later. InterventionsThe training intervention (active treatment) (n=105) included aerobic, strength, balance, and functional training. The active control group (n=105) received transcutaneous electrical nerve stimulation and active range-of-motion exercises. Both groups received 2 to 3 home visits from a physical therapist weekly for 16 weeks; nutritional counseling; and daily vitamin D (2000 IU), calcium (600 mg), and multivitamins. Main Outcomes and MeasuresThe primary outcome (community ambulation) was defined as walking 300 m or more in 6 minutes at 16 weeks after randomization. The study was designed to test a 1-sided hypothesis of superiority of training compared with active control. ResultsAmong 210 randomized participants (mean age, 80.8 years; 161 women [76.7%]), 197 (93.8%) completed the trial (187 [89.0%] by completing the 6-minute walk test at 16 weeks and 10 [4.8%] by adjudication of the primary outcome). Among these, 22 of 96 training participants (22.9%) and 18 of 101 active control participants (17.8%) (difference, 5.1% [1-sided 97.5% CI, -infinity to 16.3%]; 1-sided P=.19) became community ambulators. Seventeen training participants (16.2%) and 15 control participants (14.3%) had 1 or more reportable adverse events during the intervention period. The most common reportable adverse events reported were falls (training: 6 [5.7%], control: 4 [3.8%]), femur/hip fracture (2 in each group), pneumonia (training: 2, control: 0), urinary tract infection (training: 2, control: 0), dehydration (training: 0, control: 2), and dyspnea (training: 0, control: 2). Conclusions and RelevanceAmong older adults with a hip fracture, a multicomponent home-based physical therapy intervention compared with an active control that included transcutaneous electrical nerve stimulation and active range-of-motion exercises did not result in a statistically significant improvement in the ability to walk 300 m or more in 6 minutes after 16 weeks.	[Magaziner, Jay; Orwig, Denise; Baumgarten, Mona; Magder, Laurence; Terrin, Michael; Gruber-Baldini, Ann L.; Shardell, Michelle; Forman, Sandra] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, 660 W Redwood St,Ste 200, Baltimore, MD 21201 USA; [Mangione, Kathleen K.; Craik, Rebecca L.] Arcadia Univ, Coll Hlth Sci, Dept Phys Therapy, Glenside, PA USA; [Fortinsky, Richard H.] UConn Hlth, UConn Ctr Aging, Farmington, CT USA; [Beamer, Brock A.] Baltimore Vet Affairs Med Ctr, GRECC, Baltimore, MD USA; [Beamer, Brock A.] Univ Maryland, Sch Med, Div Gerontol & Geriatr Med, Baltimore, MD 21201 USA; [Tosteson, Anna N. A.] Geisel Sch Med Dartmouth, Dept Med, Hanover, NH USA; [Tosteson, Anna N. A.] Geisel Sch Med Dartmouth, Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA; [Kenny, Anne M.] UConn Hlth, Dept Med, Farmington, CT USA; [Shardell, Michelle] NIA, NIH, Baltimore, MD 21224 USA; [Binder, Ellen F.] Washington Univ, Sch Med, Div Geriatr & Nutr Sci, St Louis, MO USA; [Koval, Kenneth] Orlando Reg Med Ctr Inc, Dept Orthopaed Surg, Orlando, FL USA; [Resnick, Barbara] Univ Maryland, Sch Nursing, Baltimore, MD 21201 USA; [Miller, Ram] Novartis Inst BioMed Res, Cambridge, MA USA; [McBride, Ruth] Axio Res LLC, Seattle, WA USA	University System of Maryland; University of Maryland Baltimore; University of Connecticut; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center; University System of Maryland; University of Maryland Baltimore; Dartmouth College; Dartmouth College; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Washington University (WUSTL); Orlando Regional Medical Center; University System of Maryland; University of Maryland Baltimore; Novartis	Magaziner, J (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, 660 W Redwood St,Ste 200, Baltimore, MD 21201 USA.			Mangione, Kathleen/0000-0003-1214-4426	Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Aging at the National Institutes of Health [R01 AG035009, R21 HD043269, R37 AG09901, T32 AG00262, P30 AG028747]; University of Maryland, Baltimore, Institute for Clinical and Translational Research; VA Maryland Health Care System; Baltimore VA Medical Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG035009, R37AG009901, P30AG028747, T32AG000262, R01AG048069] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute on Aging at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); University of Maryland, Baltimore, Institute for Clinical and Translational Research; VA Maryland Health Care System; Baltimore VA Medical Center(US Department of Veterans Affairs); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute on Aging at the National Institutes of Health (R01 AG035009, R21 HD043269, R37 AG09901, T32 AG00262, and P30 AG028747). We also acknowledge support from the University of Maryland, Baltimore, Institute for Clinical and Translational Research. This material is the result of work supported with resources and the use of facilities at the VA Maryland Health Care System and Baltimore VA Medical Center.	Alley DE, 2011, J AM GERIATR SOC, V59, P1650, DOI 10.1111/j.1532-5415.2011.03560.x; [Anonymous], 2016, PACKAGE GSDESIGN GRO; Picorelli AMA, 2014, J PHYSIOTHER, V60, P151, DOI 10.1016/j.jphys.2014.06.012; Babatunde F, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2311-3; Binder EF, 2004, JAMA-J AM MED ASSOC, V292, P837, DOI 10.1001/jama.292.7.837; BORG GAV, 1973, MED SCI SPORT EXER, V5, P90; Brown CA, 2012, J ORTHOP TRAUMA, V26, P117, DOI 10.1097/BOT.0b013e318219c61a; Brown M, 2000, J GERONTOL A-BIOL, V55, pM350, DOI 10.1093/gerona/55.6.M350; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Dyer SM, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0332-0; Fay MP, 2007, BIOMETRICS, V63, P465, DOI 10.1111/j.1541-0420.2006.00703.x; Freedman VA, 2011, J GERONTOL A-BIOL, V66, P1013, DOI 10.1093/gerona/glr087; Guigoz Y, 1996, NUTR REV, V54, pS59; Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; Handoll HHG, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001704.pub3; Hauer K, 2002, AGE AGEING, V31, P49, DOI 10.1093/ageing/31.1.49; HWANG IK, 1990, STAT MED, V9, P1439, DOI 10.1002/sim.4780091207; Jones TG, 2002, ARCH CLIN NEUROPSYCH, V17, P171, DOI 10.1016/S0887-6177(00)00108-6; Kaiser MJ, 2009, J NUTR HEALTH AGING, V13, P782, DOI 10.1007/s12603-009-0214-7; Langlois JA, 1997, AM J PUBLIC HEALTH, V87, P393, DOI 10.2105/AJPH.87.3.393; Latham NK, 2014, JAMA-J AM MED ASSOC, V311, P700, DOI 10.1001/jama.2014.469; Lavin KM, 2019, PHYSIOLOGY, V34, P112, DOI 10.1152/physiol.00044.2018; Lee KB, 2015, TOP STROKE REHABIL, V22, P63, DOI 10.1179/1074935714Z.0000000001; Lewinsohn PM, 1997, PSYCHOL AGING, V12, P277, DOI 10.1037/0882-7974.12.2.277; Magaziner J, 2000, J GERONTOL A-BIOL, V55, pM498, DOI 10.1093/gerona/55.9.M498; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Orwig D, 2017, J Physiother, V63, P45, DOI 10.1016/j.jphys.2016.10.001; Osho O, 2018, J AGING PHYS ACTIV, V26, P304, DOI 10.1123/japa.2016-0326; Palombaro KM, 2006, PHYS THER, V86, P809, DOI 10.1093/ptj/86.6.809; Perera S, 2006, J AM GERIATR SOC, V54, P743, DOI 10.1111/j.1532-5415.2006.00701.x; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Resnick B, 2007, ANN BEHAV MED, V34, P67, DOI 10.1007/BF02879922; ROBINETT CS, 1988, PHYS THER, V68, P1371, DOI 10.1093/ptj/68.9.1371; Salpakoski A, 2014, J AM MED DIR ASSOC, V15, P361, DOI 10.1016/j.jamda.2013.12.083; Sayers SP, 2005, J AM GERIATR SOC, V53, P467, DOI 10.1111/j.1532-5415.2005.53166.x; Shardell MD, 2009, BIOMETRICS, V65, P635, DOI 10.1111/j.1541-0420.2008.01114.x; Stevens JA, 2013, OSTEOPOROSIS INT, V24, P2725, DOI 10.1007/s00198-013-2375-9; Tombaugh TN, 1996, PSYCHOL ASSESSMENT, V8, P48, DOI 10.1037/1040-3590.8.1.48; WINTER DA, 1995, GAIT ANAL THEORY APP, P252	40	35	36	1	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	2019	322	10					946	956		10.1001/jama.2019.12964	http://dx.doi.org/10.1001/jama.2019.12964			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IY6YZ	31503309	Green Published, Bronze			2023-01-03	WOS:000486543500016
J	Matsuda, Y; Inoue, Y; Hiratsuka, M; Kawakatsu, S; Arai, T; Matsueda, K; Saiura, A; Takazawa, Y				Matsuda, Yoko; Inoue, Yosuke; Hiratsuka, Makiko; Kawakatsu, Shoji; Arai, Tomio; Matsueda, Kiyoshi; Saiura, Akio; Takazawa, Yutaka			Encapsulating fibrosis following neoadjuvant chemotherapy is correlated with outcomes in patients with pancreatic cancer	PLOS ONE			English	Article							PLUS NAB-PACLITAXEL; PREOPERATIVE THERAPY; GEMCITABINE; ADENOCARCINOMA; SURVIVAL; PANCREATICODUODENECTOMY; CHEMORADIATION; RECURRENCE; SPECIMENS; IMPACT	Pathological assessments of the treatment effect are critical for predicting patient outcomes after surgery. This study included 82 localized pancreatic cancer, 40 of whom were treated with neoadjuvant therapy (NAT) using four courses of gemcitabine plus nab-paclitaxel (GnP) followed by pancreatectomy (GnP group). The remaining 42 patients were treated with upfront pancreatectomy (UP) followed by adjuvant chemotherapy (UP group). We reviewed clinicopathological data of these patients to assess differences between the GnP and UP groups and further evaluate the prognostic impact of residual tumors after GnP treatment. Adjuvant treatment (S1, GnP or gemcitabine) was administered for 36 patients in the GnP group and 33 patients in the UP group. Compared to the UP group, the GnP group showed lower serum CA19-9 levels, microscopic tumor volume, and tumor-stroma ratio and decreased number of lymph node metastasis and vascular invasion. Higher incidence of encapsulating fibrosis was observed in the GnP group than in the UP group. Relative to the UP group (69%), a higher R0 rate was observed in the GnP group (85%). As for prognosis, encapsulating fibrosis was correlated with the overall survival of patients in the GnP group. However, overall survival did not show any correlation with other clinicopathological factors, including tumor reduction ratio (determined by computed tomography) and tumor regression grade (determined following criteria of Evans' grading system or those of the College of American Pathologists). In conclusion, the present study revealed that GnP-induced encapsulating fibrosis could predict patients' outcome. Nevertheless, large cohort studies are warranted to further evaluate the prognostic value of fibrosis, possibly with the help of imaging and biomarkers.	[Matsuda, Yoko] Kagawa Univ, Fac Med, Dept Pathol & Host Def, Oncol Pathol, Takamatsu, Kagawa, Japan; [Matsuda, Yoko; Arai, Tomio] Tokyo Metropolitan Geriatr Hosp, Dept Pathol, Tokyo, Japan; [Inoue, Yosuke; Kawakatsu, Shoji; Saiura, Akio] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Digest & HBP Surg, Tokyo, Japan; [Hiratsuka, Makiko; Matsueda, Kiyoshi] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Radiol, Tokyo, Japan; [Takazawa, Yutaka] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Pathol, Tokyo, Japan	Kagawa University; Tokyo Metropolitan Institute of Gerontology; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research	Matsuda, Y (corresponding author), Kagawa Univ, Fac Med, Dept Pathol & Host Def, Oncol Pathol, Takamatsu, Kagawa, Japan.; Matsuda, Y (corresponding author), Tokyo Metropolitan Geriatr Hosp, Dept Pathol, Tokyo, Japan.	youkoh@med.kagawa-u.ac.jp		Matsuda, Yoko/0000-0002-3235-655X	Japan Society for the Promotion of Science [16KT0125]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported in part by a grant-in-aid from the Japan Society for the Promotion of Science (C, No. 16KT0125) to Y. Matsuda.	Ahrendt S. A., 2002, ONCOLOGY WILLISTON P, V16, P34; Ahrendt S. A., 2002, ONCOLOGY WILLISTON P, V16, P40; Ahrendt S. A., 2002, ONCOLOGY WILLISTON P, V16, P36; Ahrendt S. A., 2002, ONCOLOGY WILLISTON P, V16, P43; Ahrendt SA, 2002, ONCOLOGY-NY, V16, P725; Akita H, 2009, ONCOGENE, V28, P2903, DOI 10.1038/onc.2009.158; Alvarez R, 2013, BRIT J CANCER, V109, P926, DOI 10.1038/bjc.2013.415; [Anonymous], 2017, CLASS PANC CARC; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Chatterjee D, 2012, CANCER-AM CANCER SOC, V118, P3182, DOI 10.1002/cncr.26651; Chatterjee D, 2012, AM J SURG PATHOL, V36, P409, DOI 10.1097/PAS.0b013e31824104c5; Chun YS, 2011, ANN SURG ONCOL, V18, P3601, DOI 10.1245/s10434-011-2086-4; Conroy T, 2018, NEW ENGL J MED, V379, P2395, DOI 10.1056/NEJMoa1809775; Estrella JS, 2012, CANCER-AM CANCER SOC, V118, P268, DOI 10.1002/cncr.26243; EVANS DB, 1992, ARCH SURG-CHICAGO, V127, P1335; Heinhuis KM, 2019, ANN ONCOL, V30, P219, DOI 10.1093/annonc/mdy551; Ikeda R, 2010, EXP THER MED, V1, P853, DOI 10.3892/etm.2010.130; Katz MHG, 2012, CANCER-AM CANCER SOC, V118, P5749, DOI 10.1002/cncr.27636; Kawada N, 2016, WORLD J GASTROENTERO, V22, P3712, DOI 10.3748/wjg.v22.i14.3712; Langer R, 2018, VIRCHOWS ARCH, V472, P175, DOI 10.1007/s00428-017-2232-x; Marechal R, 2012, GASTROENTEROLOGY, V143, P664, DOI 10.1053/j.gastro.2012.06.006; Miyashita T, 2018, ANTICANCER RES, V38, P337, DOI 10.21873/anticanres.12227; Motoi F, 2013, ANN SURG ONCOL, V20, P3794, DOI 10.1245/s10434-013-3129-9; Murata Y, 2012, PANCREAS, V41, P130, DOI 10.1097/MPA.0b013e3182236442; Neoptolemos JP, 2010, JAMA-J AM MED ASSOC, V304, P1073, DOI 10.1001/jama.2010.1275; Papavasiliou P, 2014, HPB, V16, P34, DOI 10.1111/hpb.12058; Provenzano E, 2015, MODERN PATHOL, V28, P1185, DOI 10.1038/modpathol.2015.74; Tajima H, 2012, EXP THER MED, V3, P787, DOI 10.3892/etm.2012.482; Tempero MA, 2014, J NATL COMPR CANC NE, V12, P1083, DOI 10.6004/jnccn.2014.0106; Ueno H, 2015, ANN SURG ONCOL, V22, P1504, DOI 10.1245/s10434-014-4149-9; van Hell AJ, 2017, CELL SIGNAL, V34, P86, DOI 10.1016/j.cellsig.2017.02.021; Verbeke C, 2018, PANCREATOLOGY, V18, P467, DOI 10.1016/j.pan.2018.04.010; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Von Hoff DD, 2011, J CLIN ONCOL, V29, P4548, DOI 10.1200/JCO.2011.36.5742; Zhao QF, 2012, INT CONF AWARE SCI, P29	35	10	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2019	14	9							e0222155	10.1371/journal.pone.0222155	http://dx.doi.org/10.1371/journal.pone.0222155			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM2ZH	31491010	gold, Green Published, Green Submitted			2023-01-03	WOS:000532119700079
J	Selekman, RE; Gaither, TW; Kornberg, Z; Liaw, A; Copp, HL				Selekman, Rachel E.; Gaither, Thomas W.; Kornberg, Zachary; Liaw, Aron; Copp, Hillary L.			Unwanted Medication Disposal: Audit of California Pharmacy Advice	ANNALS OF INTERNAL MEDICINE			English	Letter									[Selekman, Rachel E.] Childrens Natl Hosp, Washington, DC 20010 USA; [Gaither, Thomas W.; Kornberg, Zachary; Liaw, Aron; Copp, Hillary L.] Univ Calif San Francisco, San Francisco, CA 94143 USA	Children's National Health System; University of California System; University of California San Francisco	Selekman, RE (corresponding author), Childrens Natl Hosp, Washington, DC 20010 USA.							Kinrys G, 2018, J INT MED RES, V46, P927, DOI 10.1177/0300060517738681; Ruhoy IS, 2008, ENVIRON INT, V34, P1157, DOI 10.1016/j.envint.2008.05.002; Tong AYC, 2011, ENVIRON INT, V37, P292, DOI 10.1016/j.envint.2010.10.002; US Food and Drug Administration, DISP UN MED; WWAMI Rural Health Research Center, RUR URB COMM AR COD	5	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 5	2020	172	9					632	+		10.7326/M19-2409	http://dx.doi.org/10.7326/M19-2409			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK7EH	31887740				2023-01-03	WOS:000531024900020
J	Localio, AR; Mulrow, CD; Griswold, ME				Localio, A. Russell; Mulrow, Cynthia D.; Griswold, Michael E.			Advancing Personalized Medicine Through Prediction	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Localio, A. Russell] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Griswold, Michael E.] Univ Mississippi, Med Ctr, 2500 North State St, Jackson, MS 39216 USA; [Localio, A. Russell] Univ Penn, Dept Biostat Epidemiol & Informat, 617 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Mississippi; University of Mississippi Medical Center; University of Pennsylvania	Localio, AR (corresponding author), Univ Penn, Dept Biostat Epidemiol & Informat, 617 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	rlocalio@pennmedicine.upenn.edu						Janes H, 2011, ANN INTERN MED, V154, P253, DOI 10.7326/0003-4819-154-4-201102150-00006; Kent DM, 2020, ANN INTERN MED, V172, pW1, DOI 10.7326/M18-3668; Kent DM, 2020, ANN INTERN MED, V172, P35, DOI 10.7326/M18-3667; Laine C, 2007, ANN INTERN MED, V146, P450, DOI 10.7326/0003-4819-146-6-200703200-00154; Lanza ST, 2013, PREV SCI, V14, P157, DOI 10.1007/s11121-011-0201-1; Raji OY, 2012, ANN INTERN MED, V157, P242, DOI 10.7326/0003-4819-157-4-201208210-00004; Schwartz LM, 2006, BMJ-BRIT MED J, V333, P1248, DOI 10.1136/bmj.38985.564317.7C; Senn S, 2018, NATURE, V563, P619, DOI 10.1038/d41586-018-07535-2; VanderWeele TJ, 2007, EPIDEMIOLOGY, V18, P561, DOI 10.1097/EDE.0b013e318127181b; Vickers AJ, 2006, MED DECIS MAKING, V26, P565, DOI 10.1177/0272989X06295361	10	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 7	2020	172	1					63	+		10.7326/M19-3010	http://dx.doi.org/10.7326/M19-3010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB7DC	31711098				2023-01-03	WOS:000506650200012
J	Lejri, I; Grimm, A; Eckert, A				Lejri, Imane; Grimm, Amandine; Eckert, Anne			Ginkgo biloba extract increases neurite outgrowth and activates the Akt/mTOR pathway	PLOS ONE			English	Article							EGB 761(R); PHOSPHORYLATION; NEUROGENESIS; BETA; DIFFERENTIATION; MECHANISMS; FLAVONOIDS; NEURONS; EGB-761; CELLS	Background Standardized Ginkgo biloba extract (GBE) has demonstrated efficacy in the cognitive functional neuropsychiatric symptoms of patients with Alzheimer's disease (AD). With regard to its underlying molecular mode of action, first evidence was provided that GBE was able to modulate neuronal outgrowth in vitro, but the mechanisms underlying GBE effects on neuroplasticity remain unclear. Methodology/Principal findings In this study, we investigated the effect of GBE on neurite outgrowth using SH-SY5Y neuroblastoma cells in a 2D and 3D surface culture. The effects of the GBE LI1370 on neuroplasticity and neurite outgrowth were compared to those of nerve growth factor (NGF, 50 ng/ml) which was used as a positive control. We evaluated several parameters of neurite outgrowth such as the neurite number, total neurite length and extend of branching. Our findings showed that GBE (10 and 100 mu g/ml) significantly increased neurite outgrowth in the 2D as well as 3D culture model after 3 days of treatment with a comparable effect than that NGF. The use of the 3D cell culture allowed us to better reproduce the in vivo neuronal microenvironment for the evaluation the neurite formation after GBE treatment. In addition, we assessed the effects of GBE on the Akt/mTOR pathway, which is known to promote neuroplasticity induced by nerve growth factors. We showed that GBE treatment induced an increase of phosphorylated IGF1R (Tyr1135/Tyr1136), Akt (Ser473), TSC2 (Ser939), mTOR (Ser2448), PTEN (Ser380) and GSK3 beta (Ser9). Conclusion Together, these findings indicate that GBE promotes neurite growth and activates the PI3K/Akt/mTOR pathway suggesting that this plant extract supports neuronal plasticity.	[Lejri, Imane; Grimm, Amandine; Eckert, Anne] Univ Basel, Transfac Res Platform Mol & Cognit Neurosci, Neurobiol Lab Brain Aging & Mental Hlth, Basel, Switzerland; [Lejri, Imane; Grimm, Amandine; Eckert, Anne] Univ Basel, Psychiat Univ Clin, Basel, Switzerland	University of Basel; University of Basel	Eckert, A (corresponding author), Univ Basel, Transfac Res Platform Mol & Cognit Neurosci, Neurobiol Lab Brain Aging & Mental Hlth, Basel, Switzerland.; Eckert, A (corresponding author), Univ Basel, Psychiat Univ Clin, Basel, Switzerland.	anne.eckert@upk.ch	Grimm, Amandine/ABE-5634-2020	Grimm, Amandine/0000-0003-3323-1756; Eckert, Anne/0000-0002-9341-3669	Vifor Pharma Switzerland; Swiss National Science Foundation (SNF) [31003A_149728]; Synapsis Foundation - Alzheimer Research Switzerland ARS; Transfaculty Research Platform, Molecular & Cognitive Neuroscience, University of Basel	Vifor Pharma Switzerland; Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF)); Synapsis Foundation - Alzheimer Research Switzerland ARS; Transfaculty Research Platform, Molecular & Cognitive Neuroscience, University of Basel	This study was partly supported by a principal investigator (AE) - initiated research grant supported by Vifor Pharma Switzerland, withregard to consumables and materials as well as GBE supply. Remaining funding was provided by grants from the Swiss National Science Foundation (SNF #31003A_149728, to AE) and Synapsis Foundation - Alzheimer Research Switzerland ARS to AG, and funding from the Transfaculty Research Platform, Molecular & Cognitive Neuroscience, University of Basel. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Kader R, 2007, PHARMACOL RES, V56, P493, DOI 10.1016/j.phrs.2007.09.011; Cheng AW, 2010, ASN NEURO, V2, P243, DOI 10.1042/AN20100019; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Cunha C, 2010, FRONT MOL NEUROSCI, V3, DOI 10.3389/neuro.02.001.2010; Eckert A, 2012, INT PSYCHOGERIATR, V24, pS18, DOI 10.1017/S1041610212000531; FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEFTI F, 1986, J NEUROSCI, V6, P2155; Hou Y, 2010, NEUROPHARMACOLOGY, V58, P911, DOI 10.1016/j.neuropharm.2009.11.002; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Lejri I, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9695412; Li WQ, 2006, J BIOL CHEM, V281, P23785, DOI 10.1074/jbc.M605269200; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mattson MP, 2007, NEUROCHEM RES, V32, P707, DOI 10.1007/s11064-006-9170-3; Muller WE, 2019, WORLD J BIOL PSYCHIA, V20, P173, DOI 10.1080/15622975.2017.1308552; Muller WE, 2012, INT PSYCHOGERIATR, V24, pS21, DOI 10.1017/S1041610212000592; Nada SE, 2014, MOL NEUROBIOL, V49, P945, DOI 10.1007/s12035-013-8572-x; Nada SE, 2012, NEUROBIOL DIS, V46, P180, DOI 10.1016/j.nbd.2012.01.006; Oudit GY, 2009, CARDIOVASC RES, V82, P250, DOI 10.1093/cvr/cvp014; Park KK, 2010, EXP NEUROL, V223, P45, DOI 10.1016/j.expneurol.2009.12.032; Rendeiro C, 2015, NEUROCHEM INT, V89, P126, DOI 10.1016/j.neuint.2015.08.002; Rhein V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012359; Rhein V, 2009, P NATL ACAD SCI USA, V106, P20057, DOI 10.1073/pnas.0905529106; Rossner S, 1998, PROG NEUROBIOL, V56, P541, DOI 10.1016/S0301-0082(98)00044-6; Sagara Y, 2004, J NEUROCHEM, V90, P1144, DOI 10.1111/j.1471-4159.2004.02563.x; Tchantchou F, 2007, FASEB J, V21, P2400, DOI 10.1096/fj.06-7649com; Tchantchou F, 2009, J ALZHEIMERS DIS, V18, P787, DOI 10.3233/JAD-2009-1189; Wang CP, 2015, CELL MOL NEUROBIOL, V35, P861, DOI 10.1007/s10571-015-0180-z; Wyatt LA, 2014, J COMP NEUROL, V522, P2741, DOI 10.1002/cne.23580; Xu SSD, 2013, ADV FUZZY SYST, V2013, DOI 10.1155/2013/504728; Xu SL, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/278273; Xu Y, 2007, EUR J NEUROSCI, V26, P2931, DOI 10.1111/j.1460-9568.2007.05905.x; Yu T, 2018, BIOMED PHARMACOTHER, V107, P329, DOI 10.1016/j.biopha.2018.08.012; Zeng K, 2018, CURR ALZHEIMER RES, V15, P89, DOI 10.2174/1567205014666170829102135; Zuo W, 2017, AGING DIS, V8, P812, DOI 10.14336/AD.2017.0615	35	7	7	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2019	14	12							e0225761	10.1371/journal.pone.0225761	http://dx.doi.org/10.1371/journal.pone.0225761			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO9FT	31790465	gold, Green Published			2023-01-03	WOS:000533930800064
J	Molmy, P; Vangrunderbeeck, N; Nigeon, O; Lemyze, M; Thevenin, D; Mallat, J				Molmy, Perrine; Vangrunderbeeck, Nicolas; Nigeon, Olivier; Lemyze, Malcolm; Thevenin, Didier; Mallat, Jihad			Patients with limitation or withdrawal of life supporting care admitted in a medico-surgical intermediate care unit: Prevalence, description and outcome over a six-month period	PLOS ONE			English	Article							HIGH-DEPENDENCY CARE; INTENSIVE-CARE; OF-LIFE; NONINVASIVE VENTILATION; SUSTAINING TREATMENT; HOSPITAL MORTALITY; DECISION-MAKING; END; IMPACT; ICU	Purpose There have been few studies on the limitation of Life Supporting Care (LSC) and Withdrawal of LSC in Intermediate Care Units (IMCUs). We report the prevalence of LSC limited patients in a medico-surgical IMCU over a six-month period, examining the description, outcomes, and patterns of LSC Limitations and Withdrawal of LSC. Methods Single center, retrospective observational study in an IMCU of a 500-bed general hospital. Results Our study of 404 patients, reported 79 (19.5%, 95%CI: [16.0-23.7]%) being admitted with LSC limitations in the IMCU. This group of LSC limited patients presented with higher chronic and acute severity scores. The most common admission diagnosis of LSC limited patients was acute respiratory failure (51%). Non-invasive ventilation (NIV) was frequently used within this population (39%). Hospital mortality for LSC limited patients was high (53%) and associated with age (OR = 1.07, 95%CI: [1.01-1.13)]), SOFA score (OR 1.29, 95%CI: [1.01-1.64]), and hypoxemic respiratory failure (OR 7.2, 95%CI: [1.27-40.9]). Withdrawal of LSC occurred in 19.5% of cases, often accompanied with terminal sedation with or without NIV removal (43.8%). Conclusions Patients with limitation of LSC are frequently admitted into IMCU. Hospital mortality rate was high and associated with age, acute organ failures, and hypoxemic respiratory failure. Life support withdrawal includes palliative sedation with or without NIV discontinuation.	[Molmy, Perrine; Vangrunderbeeck, Nicolas; Nigeon, Olivier; Mallat, Jihad] Ctr Hosp Lens, Intermediate Care Unit, Lens, France; [Molmy, Perrine; Lemyze, Malcolm; Thevenin, Didier; Mallat, Jihad] Ctr Hosp Lens, Intens Care Unit, Lens, France; [Vangrunderbeeck, Nicolas] Ctr Hosp Lens, Resp & Infect Dis Unit, Lens, France; [Mallat, Jihad] Cleveland Clin Abu Dhabi, Dept Crit Care Med, Crit Care Inst, Abu Dhabi, U Arab Emirates	Cleveland Clinic Foundation	Vangrunderbeeck, N; Mallat, J (corresponding author), Ctr Hosp Lens, Intermediate Care Unit, Lens, France.; Mallat, J (corresponding author), Ctr Hosp Lens, Intens Care Unit, Lens, France.; Vangrunderbeeck, N (corresponding author), Ctr Hosp Lens, Resp & Infect Dis Unit, Lens, France.; Mallat, J (corresponding author), Cleveland Clin Abu Dhabi, Dept Crit Care Med, Crit Care Inst, Abu Dhabi, U Arab Emirates.	nicovgdb9@orange.fr; mallatjihad@gmail.com		Mallat, Jihad/0000-0001-6372-7360				Alegre F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130989; Angus DC, 2004, CRIT CARE MED, V32, P638, DOI 10.1097/01.CCM.0000114816.62331.08; Azoulay E, 2013, INTENS CARE MED, V39, P292, DOI 10.1007/s00134-012-2746-2; Azoulay E, 2011, INTENS CARE MED, V37, P1250, DOI 10.1007/s00134-011-2263-8; Azoulay E, 2009, INTENS CARE MED, V35, P623, DOI 10.1007/s00134-008-1310-6; Binney ZO, 2014, CRIT CARE MED, V42, P1074, DOI 10.1097/CCM.0000000000000120; Capuzzo M, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0551-8; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Christensen Steffen, 2011, Clin Epidemiol, V3, P203, DOI 10.2147/CLEP.S20247; Demoule A, 2016, INTENS CARE MED, V42, P82, DOI 10.1007/s00134-015-4087-4; Downar J, 2015, CRIT CARE MED, V43, P270, DOI 10.1097/CCM.0000000000000704; Ferrand E, 2001, LANCET, V357, P9, DOI 10.1016/S0140-6736(00)03564-9; Ferrante LE, 2015, JAMA INTERN MED, V175, P523, DOI 10.1001/jamainternmed.2014.7889; Hager DN, 2018, J CRIT CARE, V46, P94, DOI 10.1016/j.jcrc.2018.05.009; Heyland D, 2015, CRIT CARE MED, V43, P1352, DOI 10.1097/CCM.0000000000001024; Hillman KM, 2015, INTENS CARE MED, V41, P1700, DOI 10.1007/s00134-015-3712-6; Hosmer DW, APPL LOGISTIC REGRES, P91, DOI [10.1164/rccm.201506-1252OC, DOI 10.1164/RCCM.201506-1252OC]; Kahn JM, 2010, INTENS CARE MED, V36, P8, DOI 10.1007/s00134-009-1672-4; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; lapichino G, 2010, INTENS CARE MED, V36, P1772; Lautrette A, 2015, INTENS CARE MED, V41, P1763, DOI 10.1007/s00134-015-3944-5; Lemyze M, 2013, INTENS CARE MED, V39, P983, DOI 10.1007/s00134-013-2859-2; Martinez-Urbistondo D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139702; Montuclard L, 2000, CRIT CARE MED, V28, P3389, DOI 10.1097/00003246-200010000-00002; Nava S, 2007, EUR RESPIR J, V30, P156, DOI 10.1183/09031936.00128306; Nava S, 2009, LANCET, V374, P250, DOI 10.1016/S0140-6736(09)60496-7; Niederman MS, 2010, CRIT CARE MED, V38, pS518, DOI 10.1097/CCM.0b013e3181f1cba5; Piers RD, 2014, CHEST, V146, P267, DOI 10.1378/chest.14-0256; Prin M, 2015, INTENS CARE MED, V41, P1903, DOI 10.1007/s00134-015-4011-y; Prin M, 2014, AM J RESP CRIT CARE, V190, P1210, DOI 10.1164/rccm.201406-1117PP; Quill CM, 2014, CHEST, V146, P573, DOI 10.1378/chest.13-2529; Robert R, 2015, ANN INTENSIVE CARE, V5, DOI 10.1186/s13613-015-0099-z; Rosenthal GE, 1998, ARCH INTERN MED, V158, P1144, DOI 10.1001/archinte.158.10.1144; Rubio O, 2013, MED INTENSIVA, V37, P333, DOI 10.1016/j.medin.2012.06.002; Schettino G, 2005, CRIT CARE MED, V33, P1976, DOI 10.1097/01.CCM.0000178176.51024.82; Sjoding MW, 2016, AM J RESP CRIT CARE, V193, P163, DOI 10.1164/rccm.201506-1252OC; Societe de reanimation de langue francaise, REANIMATION, DOI [10.1097/00003246-198108000-00008, DOI 10.1097/00003246-198108000-00008]; Sprung CL, 2012, CRIT CARE MED, V40, P132, DOI 10.1097/CCM.0b013e318232d6b0; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; Vincent JL, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0813-0; Wunsch H, 2015, AM J RESP CRIT CARE, V191, P186, DOI 10.1164/rccm.201408-1525OC	41	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 22	2019	14	11							e0225303	10.1371/journal.pone.0225303	http://dx.doi.org/10.1371/journal.pone.0225303			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO8QA	31756229	Green Published, gold			2023-01-03	WOS:000533889300017
J	Saliba-Gustafsson, EA; Roing, M; Borg, MA; Rosales-Klintz, S; Lundborg, CS				Saliba-Gustafsson, Erika A.; Roing, Marta; Borg, Michael A.; Rosales-Klintz, Senia; Lundborg, Cecilia Stalsby			General practitioners' perceptions of delayed antibiotic prescription for respiratory tract infections: A phenomenographic study	PLOS ONE			English	Article							RANDOMIZED CONTROLLED TRIAL; PRESCRIBING STRATEGIES; PRIMARY-CARE; PHYSICIANS; CHILDREN; RESISTANCE; EUROPE	Background Antibiotic use is a major driver of antibiotic resistance. Although delayed antibiotic prescription is a recommended strategy to reduce antibiotic use, practices vary; it appears less commonly used in southern European countries where antibiotic consumption is highest. Despite these variations, few qualitative studies have explored general practitioners' perceptions of delayed antibiotic prescription. We therefore aimed to explore and describe the perceptions of delayed antibiotic prescription for respiratory tract infections among general practitioners in Malta. Methods This qualitative phenomenographic study was conducted in Malta. A semi-structured interview guide was developed in English, pilot tested and revised accordingly. Interview topics included views on antibiotic resistance, antibiotic use and delayed antibiotic prescription for respiratory tract infections, and barriers and facilitators to antibiotic prescription. Individual, face-to-face interviews were held in 2014 with a quota sample of 20 general practitioners and transcribed verbatim. Data were subsequently analysed using a phenomenographic approach. Findings General practitioners perceived delayed antibiotic prescription in five qualitatively different ways: (A) "The Service Provider"-maintaining a good general practitioner-patient relationship to retain patients and avoid doctor-shopping, (B) "The Uncertainty Avoider"-reaching a compromise and providing treatment just in case, (C) "The Comforter"-providing the patient comfort and reassurance, (D) "The Conscientious Practitioner"-empowering and educating patients, and limiting antibiotic use, and (E) "The Holder of Professional Power"-retaining general practitioner responsibility by employing a wait-and-see approach. Although general practitioners were largely positive towards delayed antibiotic prescription, not all supported the strategy; some preferred a wait-and-see approach with follow-up. Many delayed antibiotic prescription users selectively practiced delayed prescription with patients they trusted or who they believed had a certain level of knowledge and understanding. They also preferred a patient-led approach with a one to three day delay; post-dating delayed antibiotic prescriptions was uncommon. Conclusions In this study we have shown that general practitioners hold varying perceptions about delayed antibiotic prescription and that there is variation in the way delayed antibiotic prescription is employed in Malta. Whilst delayed antibiotic prescription is utilised in Malta, not all general practitioners support the strategy, and motivations and practices differ. In high consumption settings, formal and standardised implementation of delayed antibiotic prescription could help curb antibiotic overuse. Diagnosis-specific delayed antibiotic prescription recommendations should also be incorporated into guidelines. Finally, further investigation into patients' and pharmacists' views on delayed antibiotic prescription is required.	[Saliba-Gustafsson, Erika A.; Rosales-Klintz, Senia; Lundborg, Cecilia Stalsby] Karolinska Inst, Dept Global Publ Hlth Hlth Syst & Policy Improvin, Stockholm, Sweden; [Roing, Marta] Uppsala Univ, Dept Publ Hlth & Caring Sci, Hlth Serv Res, Uppsala, Sweden; [Borg, Michael A.] Mater Dei Hosp, Dept Infect Prevent & Control, Msida, Malta; [Borg, Michael A.] Univ Malta, Fac Med & Surg, Msida, Malta; [Rosales-Klintz, Senia] European Ctr Dis Prevent & Control, Unit Surveillance & Response Support, Solna, Sweden	Karolinska Institutet; Uppsala University; University of Malta; European Centre for Disease Prevention & Control	Saliba-Gustafsson, EA (corresponding author), Karolinska Inst, Dept Global Publ Hlth Hlth Syst & Policy Improvin, Stockholm, Sweden.	erika.saliba@gmail.com	Gustafsson, Erika Saliba/AAR-7256-2021	Rosales Klintz, Senia/0000-0002-2897-6123; Saliba-Gustafsson, Erika A/0000-0003-1587-9591; Stalsby Lundborg, Cecilia/0000-0001-6525-1861	Karolinska Institutet [3-1233/2013]	Karolinska Institutet(Karolinska Institutet)	This work was supported by Karolinska Institutet funding for doctoral education (KIDfunding 3-1233/2013). It was also supported by funding available to CSL at Karolinska Institutet. This study received no other specific grant from any public, commercial or not-for-profit funding agencies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2018, TNS OP SOC SPEC EUR; Arroll B, 2003, BRIT J GEN PRACT, V53, P871; Arroll B, 2002, J FAM PRACTICE, V51, P954; Azzopardi-Muscat N, 2017, HEALT SYST TRANSIT, V19, P1; Bjorkman I, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2008.029199; Bjorkman I, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-1; Bjornsdottir I, 2002, Eur J Gen Pract, V8, P18, DOI DOI 10.3109/13814780209160824; Borg MA, 2002, INT J ANTIMICROB AG, V20, P253, DOI 10.1016/S0924-8579(02)00194-2; Borg MA, 2012, J ANTIMICROB CHEMOTH, V67, P763, DOI 10.1093/jac/dkr541; Butler CC, 1998, BMJ-BRIT MED J, V317, P637, DOI 10.1136/bmj.317.7159.637; Cals JWL, 2010, ANN FAM MED, V8, P124, DOI 10.1370/afm.1090; Cassini A, 2019, LANCET INFECT DIS, V19, P56, DOI 10.1016/S1473-3099(18)30605-4; Cates C, 1999, BRIT MED J, V318, P715, DOI 10.1136/bmj.318.7185.715; Costelloe C, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2096; Dahlgren L.O., 1991, RES SOC ADMIN PHARM, V8, P150, DOI DOI 10.1080/17482620601068105; Abad MD, 2016, JAMA INTERN MED, V176, P21, DOI 10.1001/jamainternmed.2015.7088; Deschepper R, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-123; Dowell J, 2001, BRIT J GEN PRACT, V51, P200; Dyar OJ, 2016, EXPERT REV ANTI-INFE, V14, P403, DOI 10.1586/14787210.2016.1151353; European Centre for Disease Prevention and Control, 2017, SUMM LAT DAT ANT CON; European Centre for Disease Prevention and Control European Medicines Agency, 2009, BACT CHALL TIM REACT; European Commission, 2017, EUR 1 HLTH ACT PLAN; Francis NA, 2012, BRIT J GEN PRACT, V62, DOI [10.3399/bjgp12X653561, 10.3399/bjgp12X654614]; Gaygisiz U, 2017, J INFECT PUBLIC HEAL, V10, P755, DOI 10.1016/j.jiph.2016.11.011; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Hofstede G., 2010, CULTURES ORG SOFTWAR, Vthird; Hoye S, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-34; Hoye S, 2010, BRIT J GEN PRACT, V60, P907, DOI 10.3399/bjgp10X544087; Kumar S, 2003, BMJ-BRIT MED J, V326, P138, DOI 10.1136/bmj.326.7381.138; Little P, 2001, BMJ-BRIT MED J, V322, P336, DOI 10.1136/bmj.322.7282.336; Little P, 2005, JAMA-J AM MED ASSOC, V293, P3029, DOI 10.1001/jama.293.24.3029; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Little P, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1606; Llor C, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X572436; Lum EPM, 2018, INFECT DIS HEALTH, V23, P74, DOI 10.1016/j.idh.2017.12.002; Lundborg CS, 1999, SCAND J PRIM HEALTH, V17, P226; Mack N., 2005, QUALITATIVE RES METH; Marton F., 1986, J THOUGHT, V21, P28, DOI DOI 10.2307/42589189; Marton F., 2013, LEARNING AWARENESS; McDermott L, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016903; National Institute for Health and Care Excellence, 2008, RESP TRACT INF SELF; Peters S, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X593866; Petursson P, 2005, SCAND J PRIM HEALTH, V23, P120, DOI 10.1080/02813430510018491; PricewaterhouseCoopers, 2012, HEALTHC DEL MALT; Raft CF, 2017, EUR J GEN PRACT, V23, P191, DOI 10.1080/13814788.2017.1347628; Rahmner PB, 2010, ANN FAM MED, V8, P40, DOI 10.1370/afm.1074; Roing M, 2006, SUPPORT CARE CANCER, V14, P1046, DOI 10.1007/s00520-006-0043-8; Roing M, 2018, QUAL HEALTH RES, V28, P273, DOI 10.1177/1049732317719433; Ryves R, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011882; Saliba-Gustafsson EA, 2019, J ANTIMICROB CHEMOTH, V74, P1116, DOI 10.1093/jac/dky544; Saliba-Gustafsson EA, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017992; Sharland M, 2005, BMJ-BRIT MED J, V331, P328, DOI 10.1136/bmj.38503.706887.AE1; Spurling GKP, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004417.pub4; Touboul-Lundgren P, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2254-8; World Health Organization, 2015, GLOB ACT PLAN AN RES; Yates C., 2012, LIB INFORM RES, V36, P96, DOI DOI 10.29173/lirg496; [No title captured], DOI DOI 10.1136/BMJ.I3410	57	11	11	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 22	2019	14	11							e0225506	10.1371/journal.pone.0225506	http://dx.doi.org/10.1371/journal.pone.0225506			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO8QA	31756197	Green Published, gold			2023-01-03	WOS:000533889300034
J	Gudeta, TA; Regassa, TM; Belay, AS				Gudeta, Tesfaye Abera; Regassa, Tilahun Mekonnen; Belay, Alemayehu Sayih			Magnitude and factors associated with anemia among pregnant women attending antenatal care in Bench Maji, Keffa and Sheka zones of public hospitals, Southwest, Ethiopia, 2018: A cross-sectional study	PLOS ONE			English	Article							LOW-BIRTH-WEIGHT; LOW-INCOME; PREVALENCE	Background Anemia during pregnancy is a common public health problem globally and it defined as the hemoglobin concentration of less than 11 g/dl. Anemia during pregnancy has maternal and perinatal diverse consequences and it increase the risk of maternal and perinatal mortality. The aim of this study is to assess magnitude and factors associated with anemia among pregnant women attending antenatal care in Bench Maji, Keffa and Sheka zones of public hospitals, South west, Ethiopia, 2018. Methods A cross-sectional study was employed on 1871 pregnant mothers from selected hospitals. All third trimester pregnant women attending antenatal care at Mizan-Tepi University Teaching Hospital, Tepi, Gebretsadik Shawo and Wacha public hospitals were included in the study. Data was entered to Epidata version 3.1 and exported to SPSS version 21 for analysis. Logistic regression analysis was carried out to identify independently associate factors at confidence interval of 95% and significance level of P-value <0.05. Result The magnitude of anemia in this study from the total study participant was 356 (19.0%). Among anemic pregnant women, 330 (92.7%), 21(5.9%) and 5(1.4%) were mild anemia, moderate anemia and severe anemia respectively. Age group 20-24 [AOR 6.28(2.40-16.42)], 25-29 [AOR = 6.38 (2.71-15.01)], 30-34 [AOR = 5.13 (2.27-11.58) and age >= 35 years [AOR = 2.53 (1.07-5.98)], educational status (read and write) [AOR 2.06, 95% CI (1.12-3.80)], gestational age(term)[AOR 1.94, 95% CI (1.27-2.96)], Caffeine (coffee and tea) and alcohol use occasionally [AOR 2.01, 95% CI (1.14-3.55)] and [AOR 2.59, 95% CI (1.49-4.52)] respectively, nutritional status (under nutrition) [AOR 3.00, 95% CI (2.22-3.97)] and family size (>6) [AOR 2.66, 95% CI (1.49-4.77)] were factors associated with anemia. Conclusion The magnitude of anemia found to be high. Age, educational status of the mother, gestational age, caffeine and alcohol use, Nutritional status and family size were factors significantly associated with anemia. To prevent adverse outcome of anemia, health care providers should work on these factors.	[Gudeta, Tesfaye Abera; Belay, Alemayehu Sayih] Mizan Tepi Univ, Coll Hlth Sci, Dept Nursing, Maternal Hlth Unit, Mizan Aman, Ethiopia; [Regassa, Tilahun Mekonnen] Mizan Tepi Univ, Dept Nursing, Adult Hlth Unit, Coll Hlth Sci, Mizan Aman, Ethiopia		Gudeta, TA (corresponding author), Mizan Tepi Univ, Coll Hlth Sci, Dept Nursing, Maternal Hlth Unit, Mizan Aman, Ethiopia.	tesfeabera2013@gmail.com	Belay, Alemayehu Sayih/AAT-1788-2021	Belay, Alemayehu Sayih/0000-0001-7039-6600	Mizan-Tepi University	Mizan-Tepi University	The budget of this study was funded by Mizan-Tepi University.	Abel G, J NUTR METABOLISM, V2015, DOI [10.1155/2015/165430, DOI 10.1155/2015/165430]; Abriha Abrehet, 2014, BMC Res Notes, V7, P888, DOI 10.1186/1756-0500-7-888; Acheampong K., 2018, GHANA INT J HLTH SCI, V8, P186; Adam I, 2016, ANEMIA PREGNANCY; Aghajanian Paola, 2007, CURRENT DIAGNOSIS TR; Akhtar M, 2012, SEVERE ANAEMIA LATE, V2012; Alene KA, 2014, ANEMIA, V2014, DOI 10.1155/2014/561567; [Anonymous], 2008, WORLDWIDE PREVALENCE; Argaw B, 2015, J COMMUNITY MED HLTH, V5, P2161, DOI DOI 10.4172/2161-0711.1000353; Baig-Ansari N, 2008, FOOD NUTR BULL, V29, P132, DOI 10.1177/156482650802900207; Balarajan Y, 2011, LANCET, V378, P2123, DOI 10.1016/S0140-6736(10)62304-5; Bereka S., 2017, J PREG CHILD HLTH, V4, P2, DOI [10.4172/2376-127X.1000337, DOI 10.4172/2376-127X.1000337]; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; CSA I, 2012, ETH DEM HLTH SURV 20, P430; CSA ICF, 2016, ETH DEM HLTH SURV; Ebrahim Mohammed, 2018, CENTRAL AFRICAN J PU, V4, P149, DOI [10.11648/j.cajph.20180405.14, DOI 10.11648/J.CAJPH.20180405.14]; Esmat Barooti, 2010, J Reprod Infertil, V11, P17; Haidar J, 2010, J HEALTH POPUL NUTR, V28, P359; Karaoglu L, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-329; Kefiyalew Filagot, 2014, BMC Res Notes, V7, P771, DOI 10.1186/1756-0500-7-771; Kenea A, 2018, ANEMIA, V2018, DOI 10.1155/2018/9201383; Lebso M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188783; Lee AI, 2011, HEMATOL ONCOL CLIN N, V25, P241, DOI 10.1016/j.hoc.2011.02.001; Levy A, 2005, EUR J OBSTET GYN R B, V122, P182, DOI 10.1016/j.ejogrb.2005.02.015; McClure EM, 2013, INT J GYNECOL OBSTET, V121, P103, DOI 10.1016/j.ijgo.2012.12.014; Mihiretie H., 2015, J MEDICAL MICROBIOLO, V4, P1, DOI DOI 10.4172/21610703.1000197; Negwo DT, 2018, J WOMENS HLTH CARE, V7, P443, DOI [10.4172/2167-0420.1000443, DOI 10.4172/2167-0420.1000443]; Organization WH, GLOB PREV AN 2011 GL; Rosas JP, 2009, COCHRANE DB SYST REV, V4; Salhan S, 2012, ANEMIA, V2012, DOI 10.1155/2012/608658; Shridevi, 2018, INT J REPROD CONTRAC, V7, P2612; Sifakis S, 2000, ANN NY ACAD SCI, V900, P125, DOI 10.1111/j.1749-6632.2000.tb06223.x; Soh KL., 2015, J BIOSCI MED, V3, P6, DOI [10.4236/jbm.2015.33002, DOI 10.4236/JBM.2015.33002]; Targets WGN, 2014, 2025 AN POL BRIEF; Viveki R. G., 2012, Al Ameen Journal of Medical Sciences, V5, P216; WHO, 2015, GLOB PREV AN 2011; Zekarias B., 2017, HLTH SCI J, V11, P529, DOI [DOI 10.21767/1791-809X.1000529, 10.21767/1791-809X.1000529]	37	10	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2019	14	11							e0225148	10.1371/journal.pone.0225148	http://dx.doi.org/10.1371/journal.pone.0225148			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO8PC	31751368	gold, Green Published			2023-01-03	WOS:000533886900032
J	Madden, M; Morris, S; Stewart, D; Atkin, K; Gough, B; McCambridge, J				Madden, Mary; Morris, Stephanie; Stewart, Duncan; Atkin, Karl; Gough, Brendan; McCambridge, Jim			Conceptualising alcohol consumption in relation to long-term health conditions: Exploring risk in interviewee accounts of drinking and taking medications	PLOS ONE			English	Article							LAY EPIDEMIOLOGY; MEDICINES; ADHERENCE; BURDEN; CARE	Background Alcohol use is a major contributor to the burden of disease, including long-term non-communicable diseases. Alcohol can also interact with and counter the effects of medications. This study addresses how people with long term conditions, who take multiple medications, experience and understand their alcohol use. The study objective is to explore how people conceptualise the risks posed to their own health from their concurrent alcohol and medicines use. Methods and findings Semi-structured interviews were conducted with a sample of 24 people in the North of England taking medication for long term conditions who drank alcohol twice a week or more often. Transcripts were analysed using a modified framework method with a constructionist thematic analysis. Alcohol was consumed recreationally and to aid with symptoms of sleeplessness, stress and pain. Interviewees were concerned about the felt effects of concurrent alcohol and medicines use and sought ways to minimise the negative effects. Interviewees associated their own drinking with short-term reward, pleasure and relief. Risky drinking was located elsewhere, in the drinking of others. People made experiential, embodied sense of health harms and did not seem aware of, or convinced by, (or in some cases appeared resigned to) future harms to their own health from alcohol use. The study has limitations common to exploratory qualitative studies. Conclusions Health risk communication should be better informed about how people with long-term health conditions perceive health outcomes over time, and how they adopt experience-based safety strategies in contexts in which alcohol consumption is heavily promoted and weakly regulated, whilst medicines adherence is expected. Supporting people to make active and informed connections between medicines, alcohol and potential personal health harms requires more than a one-way style of risk communication if it is to be perceived as opening up rather than restricting choice.	[Madden, Mary; Morris, Stephanie; Stewart, Duncan; Atkin, Karl; McCambridge, Jim] Univ York, Dept Hlth Sci, Seebohm Rowntree Bldg, York, N Yorkshire, England; [Gough, Brendan] Leeds Beckett Univ, Sch Social Sci, Leeds, W Yorkshire, England	University of York - UK; Leeds Beckett University	Madden, M (corresponding author), Univ York, Dept Hlth Sci, Seebohm Rowntree Bldg, York, N Yorkshire, England.	mary.madden@york.ac.uk	Stewart, Duncan/GZL-1637-2022	Stewart, Duncan/0000-0001-7355-4280; Madden, Mary/0000-0001-5749-2665; Morris, Steph/0000-0002-9005-4680; McCambridge, Jim/0000-0002-5461-7001	National Institute for Health Research (NIHR) [RP-PG-0216-20002]	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR))	This research was funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research (RP-PG-0216-20002). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Thanks to the interviewees and the patient and public involvement group who advised on the study. This research was funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research (RP-PG-0216-20002).	Ahmed H, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3996; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Bradley KA, 1998, ALCOHOL CLIN EXP RES, V22, P1842, DOI 10.1111/j.1530-0277.1998.tb03991.x; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Britten N., 2008, MEDICINES SOC PATIEN; Bryson CL, 2008, J GEN INTERN MED, V23, P346; Bush J, 2009, RES SOC ADMIN PHARM, V5, P305, DOI 10.1016/j.sapharm.2009.01.003; DAVISON C, 1991, SOCIOL HEALTH ILL, V13, P1, DOI 10.1111/1467-9566.ep11340301; Department for Communities and Local Government, 2015, ENGLISH INDICES DEPR; Edwards G, 2000, WORLDS FAVOURITE DRU; Ewbank L, 2018, RISING COST MEDICINE; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Griswold MG, 2018, LANCET, V392, P1015, DOI [10.1016/s0140-6736(18)31310-2, 10.1016/S0140-6736(18)31310-2, 10.1136/bmj.l94]; Grodensky CA, 2012, J STUD ALCOHOL DRUGS, V73, P899, DOI 10.15288/jsad.2012.73.899; Haighton C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205956; Holton AE, 2017, BMC GERIATR, P17; Holton AE, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017453; Hui M, 2017, RHEUMATOLOGY, V56, P1056, DOI 10.1093/rheumatology/kex150; Khadjesari Z, 2019, J PUBLIC HEALTH-UK, V41, pE185, DOI 10.1093/pubmed/fdy067; Kypri K, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3944; Ling J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-892; Lovatt M, 2015, ADDICTION, V110, P1912, DOI 10.1111/add.13072; Madden M, 2019, RES SOCIAL ADM PHARM; Mahler C, 2010, J EVAL CLIN PRACT, V16, P574, DOI 10.1111/j.1365-2753.2009.01169.x; Moriarty HJ, 2012, FAM PRACT, V29, P213, DOI 10.1093/fampra/cmr082; Morris S, 2019, DRUG ALCOHOL REV, V38, P561, DOI 10.1111/dar.12960; Muhlack E, 2018, BMC PUBLIC HEALTH, P18; Payne, 2013, POLYPHARMACY MED OPT; Pound P, 2005, SOC SCI MED, V61, P133, DOI 10.1016/j.socscimed.2004.11.063; PSNC, 2018, NEW MED SERV NMS PHA; PSNC, MURS BAS 2018; Public Health England, 2019, DEP WITHDR ASS SOM P; Quirk A, 2016, DRUG ALCOHOL DEPEN, V161, P36, DOI 10.1016/j.drugalcdep.2016.01.023; Rapley T, 2006, SOC SCI MED, V63, P2418, DOI 10.1016/j.socscimed.2006.05.025; Rathbone AP, 2017, RES SOC ADMIN PHARM, V13, P403, DOI 10.1016/j.sapharm.2016.06.004; Rehm J, 2017, ADDICTION, V112, P968, DOI 10.1111/add.13757; Rehm J, 2009, LANCET, V373, P2223, DOI 10.1016/S0140-6736(09)60746-7; Scambler G, 2010, NEW DIRECTIONS SOCIO; Stein Michael D, 2005, Subst Abus, V26, P1, DOI 10.1300/J465v26n01_01; Teuscher U, 2011, PSYCHOL REC, V61, P613, DOI 10.1007/BF03395780; The National Institute for Health and Care Excellence (NICE), 2010, ALC US DIS PREV; UK Department of Health, 2016, UK CHIEF MED OFF LOW; Webster A, 2009, SCI CULT-UK, V18, P233, DOI 10.1080/09505430902885631; Wilson GB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071792; World Health Organization, 2012, WHOEMPMAR20123	45	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2019	14	11							e0224706	10.1371/journal.pone.0224706	http://dx.doi.org/10.1371/journal.pone.0224706			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LN1GV	31697723	Green Published, Green Accepted, gold			2023-01-03	WOS:000532694400045
J	Paraje, G; Araya, D; Drope, J				Paraje, Guillermo; Araya, Daniel; Drope, Jeffrey			The association between flavor capsule cigarette use and sociodemographic variables: Evidence from Chile	PLOS ONE			English	Article							MENTHOL CIGARETTES; TOBACCO; PERCEPTIONS; BEHAVIOR; MARKET	Purpose The objective of this article is to examine the factors associated with smoking of flavor capsule cigarettes in Chile, where the popularity of these products has increased dramatically, a trend increasingly observed across the world. Methods A representative poll of 851 smokers in Metropolitan Santiago de Chile, which comprises 40% of the country's total population, was implemented in mid-2017. Smokers were given a questionnaire that collected socio-demographic information and information on smoking patterns. Four discrete-choice models were estimated on the decision to smoke flavor capsule cigarettes to better understand the statistical relationships between traits of smokers and the consumption of flavor capsule cigarettes. Results The results of these models show that each year less in a smoker's age increases the likelihood of preferring flavor capsule cigarettes by, on average, between 0.8 and 0.9 percentage points. If the smoker is a woman, the likelihood of preferring flavor capsule cigarettes increases between 13.4 and 13.5 percentage points. Results also reveal a positive relationship between the price paid and the consumption of flavor capsule cigarettes, indicating that these cigarettes tend to be more expensive. There is no statistical relationship between participation in the labor market and smoking these products. Conclusions Chile has the world's highest prevalence of flavor capsule cigarette smoking, which is concentrated among young people (25 years and younger) and females. No relationship between socioeconomic status and use of these products is found, though there are indications that such relationship may exist, as they were at the time of study 14% more expensive, on average, than conventional non-flavored cigarettes. As in most countries, the tobacco industry appears to be deliberately promoting these products with the goal of halting or slowing the decline in cigarette consumption in Chile. Thus, to reduce cigarette consumption (especially among youth), restricting or forbidding cigarette flavorings of all types, including flavor capsules, would be an effective strategy.	[Paraje, Guillermo; Araya, Daniel] Univ Adolfo Ibanez, Escuela Negocios, Santiago, Chile; [Paraje, Guillermo; Drope, Jeffrey] Amer Canc Soc, Econ & Hlth Policy Res, Atlanta, GA 30329 USA; [Drope, Jeffrey] Marquette Univ, Dept Polit Sci, Atlanta, GA USA	Universidad Adolfo Ibanez; American Cancer Society	Paraje, G (corresponding author), Univ Adolfo Ibanez, Escuela Negocios, Santiago, Chile.; Paraje, G (corresponding author), Amer Canc Soc, Econ & Hlth Policy Res, Atlanta, GA 30329 USA.	guillermo.paraje@uai.cl		Paraje, Guillermo/0000-0002-7863-907X; Araya, Daniel/0000-0002-3459-1422	American Cancer Society; Global Tobacco Control Leadership Program of the Bloomberg School of Public Health of the Johns Hopkins University; International Development Research Centre grant [108442-001]; Canada's International Development Research Centre [108442-001]; Global Tobacco Control Leadership Program of the Bloomberg School of Public Health of Johns Hopkins University	American Cancer Society(American Cancer Society); Global Tobacco Control Leadership Program of the Bloomberg School of Public Health of the Johns Hopkins University; International Development Research Centre grant; Canada's International Development Research Centre; Global Tobacco Control Leadership Program of the Bloomberg School of Public Health of Johns Hopkins University	This work was carried out with the aid of a grant from the American Cancer Society, and a grant from the Global Tobacco Control Leadership Program of the Bloomberg School of Public Health of the Johns Hopkins University and International Development Research Centre grant 108442-001. ACS, as an independent research institution publishes widely in the field of global health, and its research is funded by small, individual donors. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was carried out with the aid of a grant from the American Cancer Society, a grant from the Global Tobacco Control Leadership Program of the Bloomberg School of Public Health of Johns Hopkins University and from Canada's International Development Research Centre (grant 108442-001 to Guillermo Paraje and Daniel Araya). ACS, as an independent research institution publishes widely in the field of global health, and its research is funded largely by small, individual donors. It has a strict policy of no donations from the tobacco industry and/or its proxies.	Anderson SJ, 2011, TOB CONTROL, V20, pII49, DOI 10.1136/tc.2010.041947; Anderson SJ, 2011, TOB CONTROL, V20, pII20, DOI 10.1136/tc.2010.041939; [Anonymous], 2017, LA TERCERA      0201; Camara de Diputados de Chile, 2015, SES 49; Cancian N, 2018, FOLHA SAO PAULO; Consejo Nacional para el Control de Estupefacientes, 2007, SEPT EST NAC DROG PO; Euromonitor International, 2019, PASSP DAT 2019; Feigl AB, 2015, B WORLD HEALTH ORGAN, V93, P468, DOI 10.2471/BLT.14.146092; Gray A, 2018, FINANCIAL TIMES; Guindon GE, 2019, JAMA PEDIAT, pE1; Huang LL, 2017, TOB CONTROL, V26, P709, DOI 10.1136/tobaccocontrol-2016-053196; Huang LL, 2015, TOB CONTROL, V24, P28, DOI [10.1136/tobaccocontrol-2014-052064, 10.1136/tobaccocontrol-2013-051475]; International Euromonitor, 2017, CIG CHIL; Kabbani N, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00095; Klausner K, 2011, TOB CONTROL, V20, pII12, DOI 10.1136/tc.2010.041954; Lencucha R, 2016, SOC SCI MED, V164, P100, DOI 10.1016/j.socscimed.2016.07.026; Maldonado N, 2018, TOBACCO CONTROL; Minister of Justice of Canada, 2018, TOB VAP PROD ACT; Moodie C, 2018, TOBACCO CONTROL; Moodie C, 2018, NICOTINE TOBACCO RES; Mostrador El, 2017, EL MOSTRADOR    0619; Observatorio Chileno de Drogas, 2016, 11 EST NAC DROG POBL; Observatorio Chileno de Drogas, 2015, 11 NAC DROGS POBL GE; Observatorio Chileno de Drogas, 2017, 12 EST NAC DROG POBL; Observatorio Chileno de Drogas, 2018, 12 EST NAC DROG POBL; Observatorio de Comercio Ilicito Camara Nacional de Comercio, 2018, INF IND 2018; Paraje G., 2018, NICOTINE TOBACCO RES; Paraje G, 2018, TOBACCO CONTROL; Paraje G, 2019, CONFRONTING ILLICIT; PARAJE GUILLERMO, 2010, RAE, V25, P193; Roman J, 2018, PAUTA           0626; Said J., 2019, EL LIBERO       0516; Scollo M, 2018, TOB CONTROL, V27, P580, DOI 10.1136/tobaccocontrol-2017-053912; Secretaria de Planificacion de Transporte, 2015, ENC OR DEST 2012; Thrasher JF, 2017, TOB CONTROL, V26, P468, DOI 10.1136/tobaccocontrol-2016-053030; Tobacco Control Legal Consortium, OTH COUNTR REG FLAV; Wertz MS, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001145; WHO Framework Convention on Tobacco Control, 2012, BRAZ FLAV CIG BANN 2; World Health Organization, 2018, WHONMHPND181; World Health Organization, 2010, PART GUID IMPL ART 9	40	15	15	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2019	14	10							e0224217	10.1371/journal.pone.0224217	http://dx.doi.org/10.1371/journal.pone.0224217			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM9XB	31644598	Green Published, gold			2023-01-03	WOS:000532599700054
J	Restar, AJ; Santamaria, EK; Adia, A; Nazareno, J; Chan, R; Lurie, M; Sandfort, T; Hernandez, L; Cu-Uvin, S; Operario, D				Restar, Arjee J.; Santamaria, E. Karina; Adia, Alexander; Nazareno, Jennifer; Chan, Randolph; Lurie, Mark; Sandfort, Theo; Hernandez, Laufred; Cu-Uvin, Susan; Operario, Don			Gender affirmative HIV care framework: Decisions on feminizing hormone therapy (FHT) and antiretroviral therapy (ART) among transgender women	PLOS ONE			English	Article							FACIAL FEMINIZATION SURGERY; HEALTH-CARE; MENTAL-HEALTH; BARRIERS; FACILITATORS; PREVENTION; ENGAGEMENT; QUALITY; YOUTH; LIMA	Background Integration of feminizing hormone therapy (FHT) and antiretroviral therapy (ART) is critical in providing gender-affirming HIV care for transgender (trans) women living with HIV. However, interpersonal communications with HIV providers who are not competent with FHT may complicate this integration. Methods We conducted semi-structured interviews with trans women (n = 9) who self-reported as HIV-positive and their HIV providers (n = 15) from community-based venues (e.g., clinics) in Manila, Philippines. Results We identified five key themes from our qualitative data: (1) provider's concerns; (2) patient's goals; (3) affirmative vs. non-affirmative provider rhetoric; (4) alignment vs. misalignment of provider rhetoric to patient goals; and (5) FHT and ART-related decisions. Based on these themes, we describe a gender-affirmative HIV care framework to understand FHT-ART decisions among trans women living with HIV. Based on our data, this framework shows that provider-patient communications regarding ART and FHT consists primarily of provider concerns and patient goals regarding FHT. These communications can take on a gender-affirmative or non-affirmative style of rhetoric that either aligns or misaligns with patient goals and may lead to differences in FHT and ART-related decisions among trans women living with HIV. Conclusion There exist mixed regimens and beliefs about taking FHT and ART among this sample of trans women. While trans participants' main source of health information is their HIV provider, providers are likely to communicate non-affirmative rhetoric that negatively impacts trans women's decision to take FHT and ART. Research is needed to elucidate co-prescriptions of gender-affirmative services with HIV care among this group in the Philippines.	[Restar, Arjee J.; Santamaria, E. Karina; Adia, Alexander; Nazareno, Jennifer; Lurie, Mark; Cu-Uvin, Susan; Operario, Don] Brown Univ, Dept Behav & Social Sci, Sch Publ Hlth, Providence, RI 02912 USA; [Restar, Arjee J.; Adia, Alexander; Nazareno, Jennifer; Cu-Uvin, Susan; Operario, Don] Brown Univ, Sch Publ Hlth, Philippine Hlth Initiat Res Serv & Training, Providence, RI 02912 USA; [Restar, Arjee J.] AmfAR, Washington, DC 20005 USA; [Chan, Randolph] Educ Univ Hong Kong, Dept Special Educ & Counselling, Tai Po, Hong Kong, Peoples R China; [Sandfort, Theo] New York State Psychiat Inst & Hosp, Div Gender Sexual & Hlth, Dept Psychiat, HIV Ctr Clin & Behav Studies, New York, NY 10032 USA; [Sandfort, Theo] Columbia Univ, New York, NY USA; [Hernandez, Laufred] Univ Philippines Manila, Dept Behav Sci, Manila, Philippines; [Cu-Uvin, Susan] Providence Boston Ctr AIDS Res, Providence, RI USA; [Cu-Uvin, Susan] Miriam Hosp, Dept Med, Providence, RI 02906 USA	Brown University; Brown University; Education University of Hong Kong (EdUHK); New York State Psychiatry Institute; Columbia University; University of the Philippines System; University of the Philippines Manila; Lifespan Health Rhode Island; Miriam Hospital	Restar, AJ (corresponding author), Brown Univ, Dept Behav & Social Sci, Sch Publ Hlth, Providence, RI 02912 USA.; Restar, AJ (corresponding author), Brown Univ, Sch Publ Hlth, Philippine Hlth Initiat Res Serv & Training, Providence, RI 02912 USA.; Restar, AJ (corresponding author), AmfAR, Washington, DC 20005 USA.	Arjee_Restar@brown.edu	Sandfort, Theo/D-1796-2011; Chan, Randolph C. H./AAQ-5462-2021	Sandfort, Theo/0000-0002-4986-1739; Chan, Randolph C. H./0000-0002-4604-5154; Restar, Arjee/0000-0003-2992-8198; Adia, Alexander/0000-0002-8879-8269	National Institute of Health-Fogarty International Center [D43TW010565]; Providence/Boston Center for AIDS Research [P30AI042853]; National Institute On Drug Abuse [R36DA048682]; NIH-National Institute on Minority Health and Health Disparities at Brown University's Global Health Initiative [5T37MD008655]; Robert Wood Johnson Foundation Health Policy Research Scholars; National Institutes of Health [R25GM083270, R25MH83620, T32DA013911]; NIMH Center [P30-MH43520]; FOGARTY INTERNATIONAL CENTER [D43TW010565] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI042853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM083270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R25MH083620, P30MH043520, R25MH067127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R36DA048682, T32DA013911] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [T37MD008655] Funding Source: NIH RePORTER	National Institute of Health-Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Providence/Boston Center for AIDS Research; National Institute On Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIH-National Institute on Minority Health and Health Disparities at Brown University's Global Health Initiative; Robert Wood Johnson Foundation Health Policy Research Scholars(Robert Wood Johnson Foundation (RWJF)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIMH Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This research was supported by the National Institute of Health-Fogarty International Center (D43TW010565), Providence/Boston Center for AIDS Research (P30AI042853), National Institute On Drug Abuse (R36DA048682), and the NIH-National Institute on Minority Health and Health Disparities (5T37MD008655) at Brown University's Global Health Initiative. Ms. Restar is a recipient of the Robert Wood Johnson Foundation Health Policy Research Scholars and a Public Policy Fellow at amFAR, the Foundation for AIDS Research. E. Karina Santamaria's effort was supported by several training grants from the National Institutes of Health (R25GM083270, PI: Campbell, A.G.; R25MH83620, PI: Nunn, A.; T32DA013911, PI: Flanigan, T.P.). Dr. Sandfort's contribution is supported by NIMH Center under Grant P30-MH43520 (P.I.: Robert Remien, PhD). The views and opinions expressed in this article are solely those of the authors and do not necessarily represent the official views of the sponsors. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altman K, 2012, INT J ORAL MAX SURG, V41, P885, DOI 10.1016/j.ijom.2012.04.024; [Anonymous], 2018, HIV AIDS ART REG PHI; Asuncion I, 2017, STATE PHILIPPINE HIV; Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8; Bauer GR, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1867-2; Bauer GR, 2009, J ASSOC NURSE AIDS C, V20, P348, DOI 10.1016/j.jana.2009.07.004; BIERNACKI P, 1981, SOCIOL METHOD RES, V10, P141, DOI 10.1177/004912418101000205; Bradford J, 2013, AM J PUBLIC HEALTH, V103, P1820, DOI 10.2105/AJPH.2012.300796; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Brentano F., 2012, PSYCHOL EMPIRICAL ST; Carmel TC, 2016, PSYCHIAT ANN, V46, P346, DOI 10.3928/00485713-20160419-02; da Silva DC, 2016, J SEX MED, V13, P988, DOI 10.1016/j.jsxm.2016.03.370; Day HR, 1972, P ANN CONV AM PSYCH; Dedoose, 2015, WEB APPL MANAGING AN; DiMatteo MR, 2000, ARCH INTERN MED, V160, P2101, DOI 10.1001/archinte.160.14.2101; Dowshen Nadia, 2017, Transgend Health, V2, P81, DOI 10.1089/trgh.2016.0046; Dubov A, 2018, AM J BIOETHICS, V18, P3, DOI 10.1080/15265161.2018.1531159; Edwards A. L., 1957, SOCIAL DESIRABILITY; Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243; Gonzalez A.B., 1998, J MULTILING MULTICUL, V5, P487, DOI DOI 10.1080/01434639808666365; Grossman AH, 2006, J HOMOSEXUAL, V51, P111, DOI 10.1300/J082v51n01_06; Jin H, 2019, AIDS CARE, V31, P125, DOI 10.1080/09540121.2018.1539213; Lombardi EL, 2000, J SUBST ABUSE TREAT, V19, P291, DOI 10.1016/S0740-5472(00)00114-8; Newfield E, 2006, QUAL LIFE RES, V15, P1447, DOI 10.1007/s11136-006-0002-3; Nuttbrock L, 2009, JAIDS-J ACQ IMM DEF, V52, P417, DOI 10.1097/QAI.0b013e3181ab6ed8; Ogden J, 2006, HEALTH POLICY PLANN, V21, P333, DOI 10.1093/heapol/czl025; Patton MQ, 1999, HEALTH SERV RES, V34, P1189; Philippines Department of Health, 2016, HIV AIDS ART REG PHI; Philippines Department of Health, 2017, 2015 INT HIV BEHAV S; Philippines Department of Health, 2017, HIV AIDS ART REG PHI; Poteat T, 2013, SOC SCI MED, V84, P22, DOI 10.1016/j.socscimed.2013.02.019; Radix A, 2016, J INT AIDS SOC, V19, P44, DOI 10.7448/IAS.19.3.20810; Reisner SL, 2017, AIDS BEHAV, V21, P3299, DOI 10.1007/s10461-017-1768-8; Reisner SL, 2016, JAIDS-J ACQ IMM DEF, V72, pS235, DOI 10.1097/QAI.0000000000001088; Reisner SL, 2015, J URBAN HEALTH, V92, P584, DOI 10.1007/s11524-015-9947-2; Reisner SL, 2015, J ADOLESCENT HEALTH, V56, P274, DOI 10.1016/j.jadohealth.2014.10.264; Restar A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207663; Rich KM, 2018, LGBT HEALTH, V5, P477, DOI 10.1089/lgbt.2017.0186; Richman WL, 1999, J APPL PSYCHOL, V84, P754, DOI 10.1037/0021-9010.84.5.754; Saunders B, 2018, QUAL QUANT, V52, P1893, DOI 10.1007/s11135-017-0574-8; Sevelius JM, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.7.21105; Sevelius JM, 2016, GLOB PUBLIC HEALTH, V11, P1060, DOI 10.1080/17441692.2016.1154085; Sevelius JM, 2014, AIDS CARE, V26, P976, DOI 10.1080/09540121.2014.896451; Sevelius JM, 2014, ANN BEHAV MED, V47, P5, DOI 10.1007/s12160-013-9565-8; Sevelius JM, 2013, SEX ROLES, V68, P675, DOI 10.1007/s11199-012-0216-5; Sevelius JM, 2010, J ASSOC NURSE AIDS C, V21, P256, DOI 10.1016/j.jana.2010.01.005; Stewart M, 2000, J FAM PRACTICE, V49, P796; Stieglitz KA, 2010, J ASSOC NURSE AIDS C, V21, P192, DOI 10.1016/j.jana.2009.08.004; STRAUSS JS, 1963, JAMA-J AM MED ASSOC, V186, P759, DOI 10.1001/jama.1963.03710080031006; Tawasil JR., 2012, HIVAIDS ED HLTH PROF; Thomas DD, 2015, ENDOCR PRACT, V21, P1134, DOI 10.4158/EP15777.OR; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; UNAIDS, 2014, 90 90 90 AMBITIOUS T; Fontanari AMV, 2019, SOC SCI MED, V230, P280, DOI 10.1016/j.socscimed.2019.03.016; Vance SR, 2015, J ADOLESCENT HEALTH, V56, P251, DOI 10.1016/j.jadohealth.2014.11.002; White Hughto Jaclyn M, 2016, Transgend Health, V1, P21; World Health Organization, 2016, COUNTR PROF HIV PHIL; World Health Organization, 2015, TRANSG PEOPL HIV; World Health Organization, 2015, EXT REV NAT HLTH SEC; Wylie K, 2016, LANCET, V388, P401, DOI 10.1016/S0140-6736(16)00682-6	60	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2019	14	10							e0224133	10.1371/journal.pone.0224133	http://dx.doi.org/10.1371/journal.pone.0224133			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM9KZ	31634378	Green Submitted, gold, Green Published			2023-01-03	WOS:000532568300027
J	Zhang, HW; Chen, J; Liu, TT; Dang, J; Li, G				Zhang, Hongwei; Chen, Jun; Liu, Tingting; Dang, Jun; Li, Guang			First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis	PLOS ONE			English	Article							II RANDOMIZED-TRIAL; OPEN-LABEL; PHASE-III; CARBOPLATIN-PACLITAXEL; SURVIVAL-DATA; ERLOTINIB; CHEMOTHERAPY; GEFITINIB; ADENOCARCINOMA; AFATINIB	Background It remains unknown which is the optimal first-line treatment regimen for patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). We performed a network meta-analysis to address this important issue. Methods PubMed, Embase, Cochrane Library, Web of Science and major international scientific meetings were searched for relevant randomized controlled trials (RCTs). Progression-free survival (PFS) data was the primary outcome of interest, and overall survival (OS) and serious adverse events (SAEs) were the secondary outcomes of interests, reported as hazard ratio (HR) or odds ratio (OR) and 95% confidence intervals (CIs). Results 25 RCTs with a total of 5005 patients randomized to receive seven treatments were included in the meta-analysis. Third-generation tyrosine kinase inhibitor (TKI) (osimertinib) and first-generation TKIs (F-TKIs) in combination with chemotherapy (F-TKIs+CT) were more effective than F-TKIs alone in terms of PFS (HR = 0.46, 95% CI: 0.22-0.93; P = 0.031 and HR = 0.62, 95% CI: 0.39-0.98; P = 0.041) and OS (HR = 0.63, 95% CI: 0.43-0.91; P = 0.014 and HR = 0.73, 95% CI: 0.57-0.92; P = 0.008). Second-generation TKIs (S-TKIs) showed significant OS advantage over F-TKIs (HR = 0.83, 95% CI: 0.70-0.99; P = 0.04). Based on treatment ranking in terms of PFS and OS, osimertinib had the highest probability of being the most effective treatment (89% and 86%) and with the best tolerability. F-TKIs+CT was ranked the second-most effective regimen, but with relatively high risk of SAEs. Conclusions Osimertinib seemed to be the most preferable first-line treatment in advanced EGFR-mutated NSCLC. However, limitations of the study including a single RCT investigating osimertinib and immature OS data need to be considered.	[Zhang, Hongwei; Dang, Jun; Li, Guang] China Med Univ, Hosp 1, Dept Radiat Oncol, Shenyang, Peoples R China; [Chen, Jun] Shenyang Chest Hosp, Dept Radiat Oncol, Shenyang, Peoples R China; [Liu, Tingting] Anshan Canc Hosp, Dept Radiat Oncol, Anshan, Peoples R China	China Medical University	Dang, J (corresponding author), China Med Univ, Hosp 1, Dept Radiat Oncol, Shenyang, Peoples R China.	dangjunsy@163.com	liu, ting/GZM-3326-2022	Dang, Jun/0000-0002-1408-4749				Batson S, 2017, ONCOTARGETS THER, V10, P2473, DOI 10.2147/OTT.S134382; Brooks SP, 1998, J COMPUT GRAPH STAT, V7, P434, DOI 10.2307/1390675; Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654; Chen YM, 2012, J THORAC ONCOL, V7, P412, DOI 10.1097/JTO.0b013e31823a39e8; Cheng Y, 2016, J CLIN ONCOL, V34, P3258, DOI 10.1200/JCO.2016.66.9218; de Marinis F, 2018, ESMO OPEN, V3, DOI 10.1136/esmoopen-2017-000298; Fukuoka M, 2011, J CLIN ONCOL, V29, P2866, DOI 10.1200/JCO.2010.33.4235; Furuya N, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.9006; Gridelli C, 2012, J CLIN ONCOL, V30, P3002, DOI 10.1200/JCO.2011.41.2056; Han JY, 2012, J CLIN ONCOL, V30, P1122, DOI 10.1200/JCO.2011.36.8456; Herbst RS, 2005, J CLIN ONCOL, V23, P5892, DOI 10.1200/JCO.2005.02.840; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hirsch FR, 2011, J CLIN ONCOL, V29, P3567, DOI 10.1200/JCO.2010.34.4929; Inoue A, 2013, ANN ONCOL, V24, P54, DOI 10.1093/annonc/mds214; Janne PA, 2012, J CLIN ONCOL, V30, P2063, DOI 10.1200/JCO.2011.40.1315; Leighl NB, 2017, CLIN LUNG CANCER, V18, P34, DOI 10.1016/j.cllc.2016.07.007; Lin JZ, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011569; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Mitsudomi T, 2012, J CLIN ONCOLOGY S1, V30; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Mok TS, 2018, J CLIN ONCOL, V36, P2244, DOI 10.1200/JCO.2018.78.7994; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Nakamura A, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.9005; National Comprehensive Cancer Network (NCCN), 2018, NCCN CLIN PRACT GUID; Neupane B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115065; Park K, 2016, LANCET ONCOL, V17, P577, DOI 10.1016/S1470-2045(16)30033-X; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Paz-Ares L, 2017, ANN ONCOL, V28, P270, DOI 10.1093/annonc/mdw611; Planchard D, 2019, CLIN CANCER RES, V25, P2058, DOI 10.1158/1078-0432.CCR-18-3325; Reck M, 2017, NEW ENGL J MED, V377, P849, DOI 10.1056/NEJMra1703413; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Rubin D. B., 1992, STAT SCI, V7, P457, DOI DOI 10.1111/j.1469-8137.2011.03796.x; Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806; Seto T, 2014, LANCET ONCOL, V15, P1236, DOI 10.1016/S1470-2045(14)70381-X; Shi YK, 2017, ANN ONCOL, V28, P2443, DOI 10.1093/annonc/mdx359; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; van Valkenhoef G, 2016, RES SYNTH METHODS, V7, P80, DOI 10.1002/jrsm.1167; Wu YL, 2015, ANN ONCOL, V26, P1883, DOI 10.1093/annonc/mdv270; Wu YL, 2017, LANCET ONCOL, V18, P1454, DOI 10.1016/S1470-2045(17)30608-3; Wu YL, 2014, LANCET ONCOL, V15, P213, DOI 10.1016/S1470-2045(13)70604-1; Wu YL, 2013, LANCET ONCOL, V14, P777, DOI 10.1016/S1470-2045(13)70254-7; Yamamoto N, 2018, P AM SOC CLIN ON S15, V36, P9007, DOI DOI 10.1200/JCO.2018.36.15_suppl.9007; Yang JCH, 2015, LANCET ONCOL, V16, P141, DOI 10.1016/S1470-2045(14)71173-8; Yu H, 2014, CANCER BIOL THER, V15, P832, DOI 10.4161/cbt.28874; Zhou C, 2015, ANN ONCOL, V26, P1877, DOI 10.1093/annonc/mdv276; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X	48	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2019	14	10							e0223530	10.1371/journal.pone.0223530	http://dx.doi.org/10.1371/journal.pone.0223530			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW4XI	31581247	gold, Green Published			2023-01-03	WOS:000521168900001
J	Caarls, PJ; van Schijndel, MA; van den Berk, G; Boenink, AD; Boerman, D; Lijmer, JG; Honig, A; Terra, M; Thijs, A; Verwey, B; van Waarde, JA; van Wijngaarden, J; van Busschbach, JJ				Caarls, P. J.; van Schijndel, M. A.; van den Berk, G.; Boenink, A. D.; Boerman, D.; Lijmer, J. G.; Honig, A.; Terra, M.; Thijs, A.; Verwey, B.; van Waarde, J. A.; van Wijngaarden, J.; van Busschbach, J. J.		MPU Study Grp	Factors influencing the admission decision for Medical Psychiatry Units: A concept mapping approach	PLOS ONE			English	Article							MENTAL-HEALTH; CARE; EVOLUTION; QUALITY; MODELS	Objective Medical Psychiatry Units (MPUs), also known as Complexity Intervention Units (CIUs), provide care for complex patients suffering from both psychiatric and physical disorders. Because there is no consensus on the indications for admission to an MPU, daily practice and effectiveness research are hampered. This study therefore used a concept mapping approach to investigate which organizational and medical factors determine the decision to admit a patient to an MPU. Methods The first step of the concept mapping approach was to create a list of factors determining MPU admission from literature. Secondly, clinical experts sorted and ranked these factors. The sorted and ranked data were then analyzed, and a draft conceptual framework was created. A final conceptual MPU admission framework was then drawn during an expert consensus meeting and recommendations for implementation were suggested. Results Thirteen clinical experts defined 90 factors from literature, which were sorted and ranked by 40 experts from 21 Dutch hospitals. This concept mapping approach resulted in a five-cluster solution for an MPU admission framework based on: 1. Staff competencies and organizational pre-requisites; 2. Patient context; 3. Patient characteristics; 4. Medical needs and capabilities; and 5. Psychiatric symptoms and behavioral problems. Furthermore, three inclusion and two exclusion criteria were formulated to help the clinicians decide whether or not to admit patients to an MPU. These criteria can be implemented in daily practice. Conclusion Implementing the five criteria derived from this conceptual framework will help make the admission decision for complex patients with psychiatric and physical disorders to an MPU more correct, consistent, and transparent.	[Caarls, P. J.; van Schijndel, M. A.; van Busschbach, J. J.] Univ Med Ctr, Erasmus Med Ctr, Rotterdam, Netherlands; [van Schijndel, M. A.; Boerman, D.; Verwey, B.; van Waarde, J. A.] Rijnstate Hosp, Arnhem, Netherlands; [van den Berk, G.; Lijmer, J. G.; Honig, A.] Onze Lieve Vrouw Hosp, Amsterdam, Netherlands; [Boenink, A. D.; Honig, A.; Terra, M.; Thijs, A.] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [van Wijngaarden, J.] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Rijnstate Hospital; Onze Lieve Vrouwe Gasthuis Hospital; University of Amsterdam; Erasmus University Rotterdam	Caarls, PJ (corresponding author), Univ Med Ctr, Erasmus Med Ctr, Rotterdam, Netherlands.	p.caarls@erasmusmc.nl		Boenink, Annette/0000-0001-9791-8800				Alberque C, 2009, PSYCHOSOMATICS, V50, P354, DOI 10.1176/appi.psy.50.4.354; Beckers T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199668; BRUNS W, 1990, GEN HOSP PSYCHIAT, V12, P137, DOI 10.1016/0163-8343(90)90071-J; BUCKLEY P, 1994, PSYCHOSOMATICS, V35, P515, DOI 10.1016/S0033-3182(94)71719-9; Chiu A, 2009, ARCH GERONTOL GERIAT, V49, P233, DOI 10.1016/j.archger.2008.08.008; Eytan A, 2004, EUR PSYCHIAT, V19, P499, DOI 10.1016/j.eurpsy.2004.09.004; Faught DD, 2013, NURS EDUC, V38, P122, DOI 10.1097/NNE.0b013e31828dc27b; FAVA GA, 1985, PSYCHOTHER PSYCHOSOM, V43, P194, DOI 10.1159/000287879; GERTLER R, 1995, GEN HOSP PSYCHIAT, V17, P26, DOI 10.1016/0163-8343(94)00063-J; Guthrie E, 2016, BJPSYCH BULL, V40, P175, DOI 10.1192/pb.bp.115.051771; Johnsen JA, 2000, EVAL PROGRAM PLANN, V23, P67, DOI 10.1016/S0149-7189(99)00038-5; KATHOL RG, 1994, GEN HOSP PSYCHIAT, V16, P1, DOI 10.1016/0163-8343(94)90080-9; Kathol RG, 1999, INT CONGR SER, V1174, P13; KATHOL RG, 1992, PSYCHOSOMATICS, V33, P376, DOI 10.1016/S0033-3182(92)71942-2; Kathol RG, 2010, J PSYCHOSOM RES, V68, P293, DOI 10.1016/j.jpsychores.2009.06.012; Kathol RG, 2009, PSYCHOSOMATICS, V50, P93, DOI 10.1176/appi.psy.50.2.93; Kishi Y, 1999, PSYCHOSOMATICS, V40, P345, DOI 10.1016/S0033-3182(99)71230-2; Leue C, 2010, J PSYCHOSOM RES, V68, P295, DOI 10.1016/j.jpsychores.2009.04.010; Marra D, 2003, REV MED INTERNE, V24, P279, DOI 10.1016/S0248-8663(03)00051-1; Regan Judy, 2005, Tenn Med, V98, P448; STOUDEMIRE A, 1987, HOSP COMMUNITY PSYCH, V38, P815; TROCHIM WMK, 1989, EVAL PROGRAM PLANN, V12, P1, DOI 10.1016/0149-7189(89)90016-5; van Manen JG, 2012, J PERS DISORD, V26, P481, DOI 10.1521/pedi.2012.26.4.481; Van Schijndel M., 2018, P SOC COMPUTATION LI, P1, DOI [10.1159/000485001, DOI 10.1159/000485001]; van Schijndel MA, 2017, NED TIJDSCHR GENEES, V161; van Schijndel MA, 2019, PSYCHOTHER PSYCHOSOM, V88, P127, DOI 10.1159/000493689; van Schijndel MA, 2018, GEN HOSP PSYCHIAT, V55, P27, DOI 10.1016/j.genhosppsych.2018.09.009; van Waarde J A, 2004, Ned Tijdschr Geneeskd, V148, P209; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; Wulsin LR, 2006, MED CLIN N AM, V90, P647, DOI 10.1016/j.mcna.2006.05.005	30	5	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2019	14	9							e0221807	10.1371/journal.pone.0221807	http://dx.doi.org/10.1371/journal.pone.0221807			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM4PG	31527872	Green Submitted, gold, Green Published			2023-01-03	WOS:000532231400007
J	Singh, DR; Harvey, CM; Bohara, P; Nath, D; Singh, S; Szabo, S; Karki, K				Singh, Devendra Raj; Harvey, Chloe M.; Bohara, Pushpalata; Nath, Dhirendra; Singh, Sunita; Szabo, Sylvia; Karki, Kshitij			Factors associated with newborn care knowledge and practices in the upper Himalayas	PLOS ONE			English	Article							NEONATAL-MORTALITY; NEPAL; MOTHERS; PERCEPTIONS; SURVIVAL; DISTRICT; SAFETY; HOME	Background Globally, neonatal deaths remain a major public health challenge and account for the majority of deaths occurring among children under five years of age. Despite Nepal's significant achievements in meeting the maternal and child health targets of the Millennium Development Goals, an estimated 23,000 Nepalese children under five years die every year, with three out of five babies dying within the first 28 days of life. This study therefore aimed to examine the level of knowledge and practices of newborn care among Nepalese mothers in the upper Himalayas and the factors associated with these. Materials and methods A community based cross-sectional study was conducted among 302 randomly selected mothers with children under two years of age in Tripurasundari Municipality of Dolpa district, an upper Himalayan region of Nepal. Mothers were interviewed using semi-structured questionnaires. Mean score for knowledge and Bloom's criteria for practice were considered to categorize newborn care knowledge and practices. Multivariate logistic regression was used to identify factors associated with the newborn care knowledge and practices. Results In this study, 147 (48.7%) of the mothers were found to have inadequate knowledge of newborn care, while 102 (33.8%) mothers had reported unsatisfactory newborn care practices. Mothers with at least secondary level of formal education were more likely to possess adequate newborn care knowledge compared to mothers who never attended school (AOR 4.93 at 95% CI 1.82-13.33). Mothers whose first pregnancy occurred between the ages of 20-24 years (AOR 3.89 at 95% CI 1.81-8.37) were also more likely to possess adequate newborn care knowledge, compared to mothers with a younger age at first pregnancy. Furthermore, mothers who had completed at least four ANC visits (AOR 2.89 at 95% CI 1.04-7.96), mothers who had completed three PNC visits (AOR 2.79 at 95% CI 1.16-6.72) and mothers who reported that their nearest health facility was less than one hour (30-59 minutes) walking distance (AOR 3.66 at 95% CI 1.43-9.33) had higher odds of having adequate newborn care knowledge. Similarly, mothers whose household monthly income was more than $100 (AOR 4.17 at 95% CI 1.75-9.69), mothers who had completed three PNC visits (AOR 3.27 at 95% CI 1.16-9.20) and mothers with adequate newborn care knowledge (AOR 15.35 at 95% CI 5.82-40.47) were found to be more likely to practice a satisfactory level of newborn care practices in adjusted analysis. Conclusion The study revealed high prevalence of inadequate newborn care and knowledge amongst mothers in upper Himalayan dwellings. Approximately one third of all interviewed mothers practiced suboptimal newborn care. The results indicate an urgent need to increase awareness of neonatal services available to mothers and to prioritize investments by local governments in neonatal health services, in order to improve accessibility and quality of care for mothers and newborns.	[Singh, Devendra Raj; Bohara, Pushpalata; Karki, Kshitij] Purbanchal Univ, Asian Coll Adv Studies, Dept Publ Hlth, Lalitpur, Nepal; [Singh, Devendra Raj; Nath, Dhirendra] Southeast Asia Dev Act Network SADAN, Res & Innovat Sect, Lalitpur, Nepal; [Harvey, Chloe M.; Szabo, Sylvia] Univ Southampton, Dept Social Stat & Demog, Southampton, Hants, England; [Singh, Sunita] Minist Hlth & Populat, Sukraraj Trop & Infect Dis Hosp, Kathmandu, Nepal; [Szabo, Sylvia] Asian Inst Technol, Dept Dev & Sustainabil, Pathum Thani, Thailand; [Karki, Kshitij] Grp Tech Assistance, Program & Res Dept, Lalitpur, Nepal	University of Southampton; Asian Institute of Technology	Singh, DR (corresponding author), Purbanchal Univ, Asian Coll Adv Studies, Dept Publ Hlth, Lalitpur, Nepal.; Singh, DR (corresponding author), Southeast Asia Dev Act Network SADAN, Res & Innovat Sect, Lalitpur, Nepal.	dsingh3797@gmail.com	Nath, Dhirendra/X-7398-2018; Karki, Kshitij/ABE-7737-2020; Singh, Devendra Raj/R-2197-2019	Nath, Dhirendra/0000-0001-5481-4550; Singh, Devendra Raj/0000-0003-1450-9476; Harvey, Chloe Mercedes/0000-0002-3732-2973; Karki, Kshitij/0000-0002-6039-8909				Abdullahi A, 2016, INT J GEN MED, V9, P79, DOI 10.2147/IJGM.S98436; Acharya LB, 2000, HEALTH POLICY PLANN, V15, P223, DOI 10.1093/heapol/15.2.223; Al-Ayed IH, 2010, J FAM COMMUNITY MED, V17, P22, DOI 10.4103/1319-1683.68785; Bennett J, 1999, INT J EPIDEMIOL, V28, P1172, DOI 10.1093/ije/28.6.1172; Berhe M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175902; Berhea TA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202542; Beun MH, 2003, J HEALTH POPUL NUTR, V21, P367; Bhattarai B, 2008, MARRIAGE FAM REV, V44, P318, DOI 10.1080/01494920802255943; Bloom Benjamin, 1956, HDB 1 COGNITIVE DOMA; Central Bureau of Statistics, 2014, NAT POP HOUS CENS 20; Dhakal Sulochana, 2007, BMC Pregnancy Childbirth, V7, P19, DOI 10.1186/1471-2393-7-19; Family Health Division, 2009, AAM SUR PROGR POL GU; Glenton C, 2010, SOC SCI MED, V70, P1920, DOI 10.1016/j.socscimed.2010.02.034; Gul S, 2014, INT J HEALTH SCI-IJH, V8, P167, DOI 10.12816/0006083; Kaphle S, 2013, MIDWIFERY, V29, P1173, DOI 10.1016/j.midw.2013.06.002; Kibaru Elizabeth Gathoni, 2016, BMC Res Notes, V9, P481; Lamichhane R, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-016-3922-z; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6; Mehata S, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1532-0; Ministry of Health and Population; New ERA; and ICF, 2011, NEP DEM HLTH SURV 20, DOI [10.1007/978-94-6091-391-4_15, DOI 10.1007/978-94-6091-391-4_15]; Ministry of Health-MOH/Nepal New ERA/Nepal ICF., 2017, NEP DEM HLTH SURV 20; Misgna HG, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0931-y; MoHP[Nepal], 2016, NEP EV NEWB ACT PLAN; Mullany LC, 2005, J TROP PEDIATRICS, V51, P82, DOI 10.1093/tropej/fmh083; Mullany LC, 2006, LANCET, V367, P910, DOI 10.1016/S0140-6736(06)68381-5; National Planning Commission, 2016, NEP MILL DEV GOALS F; Neupane S, 2014, J EPIDEMIOL GLOB HEA, V4, P213, DOI 10.1016/j.jegh.2014.02.001; Paudel D, 2011, TRENDS DETERMINANTS; Shah R, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0454-y; Sharma SR, 2014, BMC PUBLIC HEALTH, V14, P1, DOI [10.1186/1471-2458-14-1, DOI 10.1186/1471-2458-14-1]; Sreeramareddy Chandrashekhar T, 2006, BMC Pregnancy Childbirth, V6, P27, DOI 10.1186/1471-2393-6-27; UNICEF, 2016, STATE WORLDS CHILDRE; United Nations, 2016, SUST DEV GOALS REP; United Nations Children's Fund; National Planning Commission, 2015, MON SIT CHILDR WOM N; V. D. of Health, 2017, ANN SCH SELF REP IMM; WHO, 2017, WHO REC NEWB HLTH; World Health Organization, 2006, NEON PER MORT COUNTR; World Health Organization, 2018, WORLD HLTH STAT MON	39	7	7	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2019	14	9							e0222582	10.1371/journal.pone.0222582	http://dx.doi.org/10.1371/journal.pone.0222582			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM4NC	31525242	Green Submitted, Green Published, gold			2023-01-03	WOS:000532225700039
J	Hossain, Z; Akter, R; Sultana, N; Kabir, E				Hossain, Zakir; Akter, Rozina; Sultana, Nasrin; Kabir, Enamul			Modelling zero-truncated overdispersed antenatal health care count data of women in Bangladesh	PLOS ONE			English	Article							SERVICES; TESTS	Overdispersion in count data analysis is very common in many practical fields of health sciences. Ignorance of the presence of overdispersion in such data analysis may cause misleading inferences and thus lead to incorrect interpretations of the results. Researchers should account for the consequences of overdispersion and need to select the correct choice of models for the analysis of such data. In this paper, Generalized Linear Models (GLMs) are applied in modelling and analysis of antenatal care (ANC) count data extracted from the Bangladesh Demographic and Health Survey (BDHS) 2014. Pearson chi-square and different score tests are used to investigate the effect of overdispersion in the analysis. Overdispersion is found to be significant in the antenatal health care count data and so appropriate modelling is used to produce valid inferences for the regression parameters. The zero-truncated negative binomial regression (0-NBR) is found to be the best choice for analysing such data while excluding zero counts. Study findings reveal that place of residence, order of birth, exposure to mass media, wealth index and education of mother have significant impacts on the ANC status of women during pregnancy in Bangladesh.	[Hossain, Zakir; Akter, Rozina] Univ Dhaka, Dept Stat, Dhaka, Bangladesh; [Sultana, Nasrin] Univ Kansas, Med Ctr, Dept Biostat & Data Sci, Kansas City, MO USA; [Kabir, Enamul] Univ Southern Queensland, Sch Sci, Toowoomba, Qld, Australia	University of Dhaka; University of Kansas; University of Southern Queensland	Hossain, Z (corresponding author), Univ Dhaka, Dept Stat, Dhaka, Bangladesh.	zakir.hossain@du.ac.bd		Kabir, Enamul/0000-0002-6157-2753; Hossain, Zakir/0000-0003-4128-3097	National Science and Technology (NST) Fellowship, Ministry of Science and Technology, Government of Bangladesh; National Science and Technology (NST), Ministry of Science and Technology, Government of Bangladesh	National Science and Technology (NST) Fellowship, Ministry of Science and Technology, Government of Bangladesh; National Science and Technology (NST), Ministry of Science and Technology, Government of Bangladesh	RA was funded by the National Science and Technology (NST) Fellowship, Ministry of Science and Technology, Government of Bangladesh under the supervision of ZH.; The authors would like to acknowledge DHS (Demographic and Health Surveys) who made their data available for free and National Science and Technology (NST), Ministry of Science and Technology, Government of Bangladesh for funding this work. We would like to express our gratitude to Department of Statistics, University of Dhaka, Bangladesh and Faculty of Health, Engineering and Sciences (HES) of University of Southern Queensland, Australia for the technical support.	Akaike H, 1998, 2 INT S INFORM THEOR, P199, DOI 10.1007/978-1-4612-1694-0; [Anonymous], 2007, STAND MAT NEON CAR; Becker S, 1993, Health Transit Rev, V3, P77; BMMS. Bangladesh Maternal Mortality and Health Care Survey, 2016, PRELIMINARY REPORT; CAMERON AC, 1990, J ECONOMETRICS, V46, P347, DOI 10.1016/0304-4076(90)90014-K; Chakraborty N, 2003, HEALTH PROMOT INT, V18, P327, DOI 10.1093/heapro/dag414; Chowdhury Rafiqul Islam, 2007, World Health Popul, V9, P9; DEAN C, 1989, J AM STAT ASSOC, V84, P467, DOI 10.2307/2289931; Dobson AJ, 2008, INTRO GEN LINEAR MOD; Hilbe J.M., 2011, NEGATIVE BINOMIAL RE; Islam M, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2392-6; Jayaraman A., 2008, DHS WORKING PAPERS, V59; Kiser H, 2018, HEALTH INF SCI SYST, V7, DOI 10.1007/s13755-018-0064-y; Latif AHMM, 2008, AUST J STAT, V37, P175; McCullagh P., 1989, GEN LINEAR MODELS; Mohammad K.A., 2018, BANGLADESH J SCI RES, V30, P23, DOI [10.3329/BJSR.V30I1-2.36117, DOI 10.3329/BJSR.V30I1-2.36117]; Mustafizur Rahman K.M., 2009, RES J APPL SCI, V4, P113; National Institute of Population Research and Training (NIPORT) and ICF. 2019, BANGL DEM HLTH SURV; Navaneetham K, 2002, SOC SCI MED, V55, P1849, DOI 10.1016/S0277-9536(01)00313-6; Nisar N, 2003, J Pak Med Assoc, V53, P47; Pandit R D, 1992, Asia Oceania J Obstet Gynaecol, V18, P1; Stroup WW., 2012, GEN LINEAR MIXED MOD; Titaley CR, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-61; WHO, 2019, MAT MORT; WHO, 2018, WHO SUST DEV GOALS S; Winkelmann R, 2008, ECONOMETRIC ANAL COU; Yebyo H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124718	27	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2020	15	1							e0227824	10.1371/journal.pone.0227824	http://dx.doi.org/10.1371/journal.pone.0227824			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP5JP	31935274	Green Accepted, Green Published, gold			2023-01-03	WOS:000534354100058
J	Tukayo, BLA; Sunderland, B; Parsons, R; Czarniak, P				Tukayo, Brechkerts Lieske Angruni; Sunderland, Bruce; Parsons, Richard; Czarniak, Petra			High prevalence of off-label and unlicensed paediatric prescribing in a hospital in Indonesia during the period Aug.-Oct. 2014	PLOS ONE			English	Article							ADVERSE DRUG-REACTIONS; INTENSIVE-CARE UNITS; CHILDREN; MEDICINES	Background Data on off-label and unlicensed prescribing in children in Indonesia is limited. The aims of this study were to determine the prevalence of off-label and unlicensed prescribing for paediatric patients in a public hospital, Indonesia. Method A retrospective cross-sectional study of 200 randomly selected paediatric patients admitted to hospital between August and October 2014, collected patient details and all drugs prescribed. Licensed drugs were classified as off-label if there was a non-compliance with the Product Information for age, weight, indication, dose, frequency and route of administration, if there was a contraindication, special precautions or not recommended for children. Unlicensed drugs were those not approved for use in Indonesia. The main outcome was the prevalence of off-label or unlicensed prescribing to infants, children and adolescents and the impact of age group on off-label prescribing. Results A total of 200 patients received 1961 medicines of which 1807/1961 (92.1%) were licensed and 154/1961 (7.9%) were unlicensed. There were 1403/1961 (71.5%) drugs prescribed off-label. More than half of the total drugs (n = 1066; 54.4%) were administered parenterally. Every patient was prescribed at least one off-label drug. Indication (n = 810; 34.6%) was the most common reason for off-label prescribing. Ranitidine was the most frequent drug prescribed off label. Darplex (R) (dihydroartemisinin and piperaquine), although manufactured in Indonesia, was unlicensed. There was a significant difference between age group and offlabel prescribing in that children were prescribed significantly less off-label drugs (p< 0.0003). Conclusion This study revealed a high prevalence of off-label and unlicensed drug use in paediatric patients in this hospital, exposing them to drug treatments or regimens that had not been approved by regulatory authorities. The high incidence of invasive parenteral prescribing is of concern for paediatric patients. Incentives are needed to encourage specific drug evaluation in paediatric populations.	[Tukayo, Brechkerts Lieske Angruni; Sunderland, Bruce; Czarniak, Petra] Curtin Univ, Sch Pharm & Biomed Sci, Bentley, WA, Australia; [Tukayo, Brechkerts Lieske Angruni] Indonesian Minist Hlth, Hlth Polytech Jayapura, Jakarta, Indonesia; [Parsons, Richard] Curtin Univ, Sch Occupat Therapy Social Work & Speech Pathol, Bentley, WA, Australia	Curtin University; Ministry of Health - Indonesia; Curtin University	Czarniak, P (corresponding author), Curtin Univ, Sch Pharm & Biomed Sci, Bentley, WA, Australia.	P.Czarniak@curtin.edu.au		Tukayo, Brechkerts Lieske Angruni/0000-0003-3720-9329				Allegaert K, 2014, PEDIATR ANESTH, V24, P30, DOI 10.1111/pan.12176; [Anonymous], 2015, MIMS IND PET KONS 14; [Anonymous], 2017, REV LAWS REGULATIONS; [Anonymous], 2017, STATE PAEDIAT MED EU; [Anonymous], 2015, MONTHL IND MED SPEC; Balan S, 2018, WORLD J PEDIATR, V14, P528, DOI 10.1007/s12519-018-0186-y; Ballard CDJ, 2013, J PAEDIATR CHILD H, V49, P38, DOI 10.1111/jpc.12065; Bavdekar SB, 2009, INDIAN J PEDIATR, V76, P1113, DOI 10.1007/s12098-009-0238-3; Bonati M, 2017, ARCH DIS CHILD, V102, P53, DOI 10.1136/archdischild-2016-311527; Carnovale C, 2013, EUR J PEDIATR, V172, P1679, DOI 10.1007/s00431-013-2111-7; Contopoulos-Ioannidis DG, 2010, J PEDIATR-US, V157, P322, DOI 10.1016/j.jpeds.2010.02.011; Corny Jennifer, 2015, J Pediatr Pharmacol Ther, V20, P316, DOI 10.5863/1551-6776-20.4.316; Czarniak P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120630; Delmas S, UNLICENSED OFF LABEL; Ferreira LD, 2012, REV ASSOC MED BRAS, V58, P82; Hill P, 2005, ARCH DIS CHILD, V90, pI17, DOI 10.1136/adc.2004.058867; Hsien L, 2008, PHARM WORLD SCI, V30, P497, DOI 10.1007/s11096-008-9193-8; Ivanovska V, 2014, PEDIATRICS, V134, P361, DOI 10.1542/peds.2013-3225; Jonville-Bera AP, 2005, EUR J CLIN PHARMACOL, V61, P231, DOI 10.1007/s00228-004-0881-6; Khdour MR, 2011, INT J CLIN PHARM-NET, V33, P650, DOI 10.1007/s11096-011-9520-3; Knellwolf AL, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-12; Laforgia N, 2014, PEDIATR INT, V56, P57, DOI 10.1111/ped.12190; Landwehr C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210237; Lathyris D, 2014, PEDIATRICS, V133, pE666, DOI 10.1542/peds.2013-3128; Lee JL, 2013, INT J CLIN PHARM-NET, V35, P1025, DOI 10.1007/s11096-013-9846-0; Li YB, 2012, HEALTH AFFAIR, V31, P1075, DOI 10.1377/hlthaff.2010.0965; Lindell-Osuagwu L, 2014, J CLIN PHARM THER, V39, P144, DOI 10.1111/jcpt.12119; Magalhaes J, 2015, EUR J CLIN PHARMACOL, V71, P1, DOI 10.1007/s00228-014-1768-9; Rahajeng Bangunawati, 2018, INT J PHARM PHARM SC, V10, P119, DOI [10.22159/ijpps.2018v10i5.25388, DOI 10.22159/IJPPS.2018V10I5.25388]; Ramadaniati HU, 2017, ASIAN J PHARM CLIN R, V10, P355; Sabtu N, 2015, BRIT MED BULL, V116, P105, DOI 10.1093/bmb/ldv041; Slaneva J., 2012, EUR PHARM J, V59, P48; The Head of Drug and Food Controller Agency, REG HEAD DRUG FOOD C; The National Agency of Drug and Food Control, 2015, INDONESIA; Wallerstedt SM, 2011, DRUG SAFETY, V34, P669, DOI 10.2165/11591730-000000000-00000; WHO Collaborating Centre for Drug Statistics Methodology, 2015, ATC DDD IND 2015; World Health Organisation, 2002, SAF APPR US INJ WORL; Yamashiro Y, 2012, J PEDIATR GASTR NUTR, V55, P506, DOI 10.1097/MPG.0b013e318272af1f	38	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2020	15	1							e0227687	10.1371/journal.pone.0227687	http://dx.doi.org/10.1371/journal.pone.0227687			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5JP	31935254	Green Published, gold			2023-01-03	WOS:000534354100044
J	Kovacevic, S; Ivanov, M; Miloradovic, Z; Brkic, P; Vajic, UJ; Zivotic, M; Mihailovic-Stanojevic, N; Jovovic, D; Karanovic, D; Jeremic, R; Nesovic-Ostojic, J				Kovacevic, Sanjin; Ivanov, Milan; Miloradovic, Zoran; Brkic, Predrag; Vajic, Una Jovana; Zivotic, Maja; Mihailovic-Stanojevic, Nevena; Jovovic, Djurdjica; Karanovic, Danijela; Jeremic, Rada; Nesovic-Ostojic, Jelena			Hyperbaric oxygen preconditioning and the role of NADPH oxidase inhibition in postischemic acute kidney injury induced in spontaneously hypertensive rats	PLOS ONE			English	Article							RENAL ISCHEMIA-REPERFUSION; BLOOD-PRESSURE; OXIDATIVE STRESS; APOCYNIN; EXPRESSION; ACTIVATION; TOLERANCE; CATALASE; BALANCE; TISSUES	Renal ischemia/reperfusion injury is a common cause of acute kidney injury (AKI) and hypertension might contribute to the increased incidence of AKI. The purpose of this study was to investigate the effects of single and combined hyperbaric oxygen (HBO) preconditioning and NADPH oxidase inhibition on oxidative stress, kidney function and structure in spontaneously hypertensive rats (SHR) after renal ischemia reperfusion injury. HBO preconditioning was performed by exposing to pure oxygen (2.026 bar) twice a day for two consecutive days for 60 minutes, and 24h before AKI induction. For AKI induction, the right kidney was removed and ischemia was performed by clamping the left renal artery for 45 minutes. NADPH oxidase inhibition was induced by apocynin (40 mg/kg b.m., intravenously) 5 minutes before reperfusion. AKI significantly increased renal vascular resistance and reduced renal blood flow, which were significantly improved after apocynin treatment. Also, HBO preconditioning, with or without apocynin treatment showed improvement on renal hemodynamics. AKI significantly increased plasma creatinine, urea, phosphate levels and lipid peroxidation in plasma. Remarkable improvement, with decrease in creatinine, urea and phosphate levels was observed in all treated groups. HBO preconditioning, solitary or with apocynin treatment decreased lipid peroxidation in plasma caused by AKI induction. Also, combined with apocynin, it increased catalase activity and solitary, glutathione reductase enzyme activity in erythrocytes. While AKI induction significantly increased plasma KIM- 1 levels, HBO preconditioning, solitary or with apocynin decreased its levels. Considering renal morphology, significant morphological alterations present after AKI induction were significantly improved in all treated groups with reduced tubular dilatation, tubular necrosis in the cortico-medullary zone and PAS positive cast formation. Our results reveal that NADPH oxidase inhibition and hyperbaric oxygen preconditioning, with or without NADPH oxidase inhibition may have beneficial effects, but their protective role should be evaluated in further studies.	[Kovacevic, Sanjin; Nesovic-Ostojic, Jelena] Univ Belgrade, Fac Med, Dept Pathophysiol, Belgrade, Serbia; [Ivanov, Milan; Miloradovic, Zoran; Vajic, Una Jovana; Mihailovic-Stanojevic, Nevena; Jovovic, Djurdjica; Karanovic, Danijela] Univ Belgrade, Inst Med Res, Dept Cardiovasc Physiol, Belgrade, Serbia; [Brkic, Predrag; Jeremic, Rada] Univ Belgrade, Fac Med, Dept Med Physiol, Belgrade, Serbia; [Zivotic, Maja] Univ Belgrade, Fac Med, Dept Pathol, Belgrade, Serbia	University of Belgrade; University of Belgrade; University of Belgrade; University of Belgrade	Kovacevic, S; Nesovic-Ostojic, J (corresponding author), Univ Belgrade, Fac Med, Dept Pathophysiol, Belgrade, Serbia.	sanjin.kovacevic@med.bg.ac.rs; jelena.nesovic-ostojic@med.bg.ac.rs	Karanovic, Danijela/GVT-7443-2022; Kovacevic, Sanjin/S-9564-2019; Ivanov, Milan/ABD-4357-2021	Kovacevic, Sanjin/0000-0001-5905-7173; Karanovic, Danijela/0000-0001-5746-746X; Brkic, Predrag/0000-0001-7541-4986; Mihailovic-Stanojevic, Nevena/0000-0001-5356-8706; Ivanov, Milan/0000-0001-8683-5751	Ministry of Education, Science and Technological Development, Republic of Serbia [175096]	Ministry of Education, Science and Technological Development, Republic of Serbia	This work was carried out with funding from Ministry of Education, Science and Technological Development, Republic of Serbia, Grant number 175096. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study was supported by grant 175096 from the Ministry of Education and Science of Republic of Serbia. Also, authors would like to thank Center for Hyperbaric Medicine, Belgrade, Serbia for their continuous support.	Abdelrahman RS, 2018, HUM EXP TOXICOL, V37, P27, DOI 10.1177/0960327116689716; Altintas R, 2013, J ENDOUROL, V27, P617, DOI 10.1089/end.2012.0556; Baumer AT, 2007, CLIN EXP HYPERTENS, V29, P287, DOI 10.1080/10641960701500398; Bonventre JV, 2011, J CLIN INVEST, V121, P4210, DOI 10.1172/JCI45161; BOWMER CJ, 1983, BRIT J PHARMACOL, V79, P471, DOI 10.1111/j.1476-5381.1983.tb11020.x; Brkic Predrag, 2007, Srp Arh Celok Lek, V135 11-12, P669; Calvert JW, 2007, NEUROL RES, V29, P132, DOI 10.1179/016164107X174156; Cartin-Ceba R, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/691013; Choi HM, 2015, KIDNEY RES CLIN PRAC, V34, P13, DOI 10.1016/j.krcp.2014.11.002; Coca SG, 2009, AM J KIDNEY DIS, V53, P961, DOI 10.1053/j.ajkd.2008.11.034; Drenjancevic I, 2013, UNDERSEA HYPERBAR M, V40, P319; He XZ, 2011, J SURG RES, V170, pE271, DOI 10.1016/j.jss.2011.06.008; Hentia C, 2018, BRAIN BEHAV, V8, DOI 10.1002/brb3.959; Heumuller S, 2008, HYPERTENSION, V51, P211, DOI 10.1161/HYPERTENSIONAHA.107.100214; Ivanov M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096353; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; Kim CH, 2001, PFLUG ARCH EUR J PHY, V442, P519, DOI 10.1007/s004240100571; Kim SY, 2012, IMMUNOL CELL BIOL, V90, P441, DOI 10.1038/icb.2011.60; Kinsey GR, 2012, CRIT CARE, V16, DOI 10.1186/cc11228; Klemetti E, 2005, LAB ANIM-UK, V39, P116, DOI 10.1258/0023677052886529; Labrouche S, 1999, THROMB RES, V96, P309, DOI 10.1016/S0049-3848(99)00107-3; Lavrnja I, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/498405; Li JS, 2008, BRAIN RES, V1210, P223, DOI 10.1016/j.brainres.2008.03.007; Li L, 2007, J IMMUNOL, V178, P5899, DOI 10.4049/jimmunol.178.9.5899; Li ZM, 2015, TOXICOL REP, V2, P1111, DOI 10.1016/j.toxrep.2015.07.019; Liano F, 1996, KIDNEY INT, V50, P811, DOI 10.1038/ki.1996.380; Mas-Font S, 2017, MED INTENSIVA, V41, P116, DOI 10.1016/j.medin.2016.12.004; Meng XM, 2018, LAB INVEST, V98, P63, DOI 10.1038/labinvest.2017.120; Mihaljevic Z, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/7406027; Miloradovic Z, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/512619; Mohamed NSE, 2011, LIFE SCI J, V8, P204; MORENO S, 1995, J HISTOCHEM CYTOCHEM, V43, P1253, DOI 10.1177/43.12.8537642; Parabucki AB, 2012, CROAT MED J, V53, P586, DOI 10.3325/cmj.2012.53.586; Paravicini TM, 2008, DIABETES CARE, V31, pS170, DOI 10.2337/dc08-s247; Park YM, 2004, BIOCHEM BIOPH RES CO, V313, P812, DOI 10.1016/j.bbrc.2003.11.173; Rabb Hamid, 1996, Frontiers in Bioscience (online), V1, pE9; Ratliff BB, 2016, ANTIOXID REDOX SIGN, V25, P119, DOI 10.1089/ars.2016.6665; Rubinger Dvora, 2005, Nephron Physiology, V100, P1; Rubinstein I, 2009, NEPHROL DIAL TRANSPL, V24, P428, DOI 10.1093/ndt/gfn511; Rybka J, 2011, CARDIOVASC TOXICOL, V11, P1, DOI 10.1007/s12012-010-9096-5; Sabbisetti VS, 2014, J AM SOC NEPHROL, V25, P2177, DOI 10.1681/ASN.2013070758; Schluter T, 2008, CARDIOVASC RES, V80, P271, DOI 10.1093/cvr/cvn185; SIMONS JM, 1990, FREE RADICAL BIO MED, V8, P251, DOI 10.1016/0891-5849(90)90070-Y; Stefanska J, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/106507; Sureda A, 2009, MED SCI SPORT EXER, V41, P1271, DOI 10.1249/MSS.0b013e3181951069; Tadagavadi RK, 2010, J AM SOC NEPHROL, V21, P53, DOI 10.1681/ASN.2009040407; Tajra LCF, 1999, J SURG RES, V87, P32, DOI 10.1006/jsre.1999.5724; Tian N, 2007, AM J PHYSIOL-HEART C, V293, pH3388, DOI 10.1152/ajpheart.00981.2007; TOKUDA Y, 1993, NEUROCHEM INT, V23, P107, DOI 10.1016/0197-0186(93)90087-L; Vajic UJ, 2018, PHYTOMEDICINE, V46, P39, DOI 10.1016/j.phymed.2018.04.037; Virdis A, 2016, VASC PHARMACOL, V87, P1, DOI 10.1016/j.vph.2016.08.006; Weaver L.K., 2014, HYPERBARIC OXYGEN TH; Welch WJ, 2001, KIDNEY INT, V59, P230, DOI 10.1046/j.1523-1755.2001.00483.x	53	7	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2020	15	1							e0226974	10.1371/journal.pone.0226974	http://dx.doi.org/10.1371/journal.pone.0226974			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5DK	31914135	Green Published, Green Submitted, gold			2023-01-03	WOS:000534337700023
J	Bhatnagar, R; Piotrowska, HEG; Laskawiec-Szkonter, M; Kahan, BC; Luengo-Fernandez, R; Pepperell, JCT; Evison, MD; Holme, J; Al-Aloul, M; Psallidas, I; Lim, WS; Blyth, KG; Roberts, ME; Cox, G; Downer, NJ; Herre, J; Sivasothy, P; Menzies, D; Munavvar, M; Kyi, MM; Ahmed, L; West, AG; Harrison, RN; Prudon, B; Hettiarachchi, G; Chakrabarti, B; Kavidasan, A; Sutton, BP; Zahan-Evans, NJ; Quaddy, JL; Edey, AJ; Clive, AO; Walker, SP; Little, MHR; Mei, XW; Harvey, JE; Hooper, CE; Davies, HE; Slade, M; Sivier, M; Miller, RF; Rahman, NM; Maskell, NA				Bhatnagar, Rahul; Piotrowska, Hania E. G.; Laskawiec-Szkonter, Magda; Kahan, Brennan C.; Luengo-Fernandez, Ramon; Pepperell, Justin C. T.; Evison, Matthew D.; Holme, Jayne; Al-Aloul, Mohamed; Psallidas, Ioannis; Lim, Wei Shen; Blyth, Kevin G.; Roberts, Mark E.; Cox, Giles; Downer, Nicola J.; Herre, Jurgen; Sivasothy, Pasupathy; Menzies, Daniel; Munavvar, Mohammed; Kyi, Moe M.; Ahmed, Liju; West, Alex G.; Harrison, Richard N.; Prudon, Benjamin; Hettiarachchi, Gihan; Chakrabarti, Biswajit; Kavidasan, Ajikumar; Sutton, Benjamin P.; Zahan-Evans, Natalie J.; Quaddy, Jack L.; Edey, Anthony J.; Clive, Amelia O.; Walker, Steven P.; Little, Matthew H. R.; Mei, Xue W.; Harvey, John E.; Hooper, Clare E.; Davies, Helen E.; Slade, Mark; Sivier, Merle; Miller, Robert F.; Rahman, Najib M.; Maskell, Nick A.			Effect of Thoracoscopic Talc Poudrage vs Talc Slurry via Chest Tube on Pleurodesis Failure Rate Among Patients With Malignant Pleural Effusions A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Winter Meeting of the British-Thoracic-Society	DEC 04-06, 2019	London, ENGLAND	British Thorac Soc			1ST CHOICE MANAGEMENT; CATHETER; HEALTH	Objective To test the hypothesis that administration of talc poudrage during thoracoscopy with local anesthesia is more effective than talc slurry delivered via chest tube in successfully inducing pleurodesis. Design, Setting, and Participants Open-label, randomized clinical trial conducted at 17 UK hospitals. A total of 330 participants were enrolled from August 2012 to April 2018 and followed up until October 2018. Patients were eligible if they were older than 18 years, had a confirmed diagnosis of MPE, and could undergo thoracoscopy with local anesthesia. Patients were excluded if they required a thoracoscopy for diagnostic purposes or had evidence of nonexpandable lung. Interventions Patients randomized to the talc poudrage group (n = 166) received 4 g of talc poudrage during thoracoscopy while under moderate sedation, while patients randomized to the control group (n = 164) underwent bedside chest tube insertion with local anesthesia followed by administration of 4 g of sterile talc slurry. Main Outcomes and Measures The primary outcome was pleurodesis failure up to 90 days after randomization. Secondary outcomes included pleurodesis failure at 30 and 180 days; time to pleurodesis failure; number of nights spent in the hospital over 90 days; patient-reported thoracic pain and dyspnea at 7, 30, 90, and 180 days; health-related quality of life at 30, 90, and 180 days; all-cause mortality; and percentage of opacification on chest radiograph at drain removal and at 30, 90, and 180 days. Results Among 330 patients who were randomized (mean age, 68 years; 181 [55%] women), 320 (97%) were included in the primary outcome analysis. At 90 days, the pleurodesis failure rate was 36 of 161 patients (22%) in the talc poudrage group and 38 of 159 (24%) in the talc slurry group (adjusted odds ratio, 0.91 [95% CI, 0.54-1.55]; P = .74; difference, -1.8% [95% CI, -10.7% to 7.2%]). No statistically significant differences were noted in any of the 24 prespecified secondary outcomes. Conclusions and Relevance Among patients with malignant pleural effusion, thoracoscopic talc poudrage, compared with talc slurry delivered via chest tube, resulted in no significant difference in the rate of pleurodesis failure at 90 days. However, the study may have been underpowered to detect small but potentially important differences. Question Is thoracoscopy with local anesthesia and administration of talc poudrage more effective than chest tube placement with local anesthesia and administration of talc slurry at inducing pleurodesis in individuals with malignant pleural effusion? Findings In this randomized clinical trial that included 330 patients, thoracoscopic talc poudrage, compared with chest tube insertion and talc slurry, resulted in no significant difference in the rate of pleurodesis failure at 90 days (22% vs 24%). Meaning Among patients with malignant pleural effusion, there was no significant difference in the rate of pleurodesis failure between the use of talc poudrage and talc slurry; however, the study may have been underpowered to detect small but potentially important differences.	[Bhatnagar, Rahul; Zahan-Evans, Natalie J.; Clive, Amelia O.; Walker, Steven P.; Maskell, Nick A.] Univ Bristol, Acad Resp Unit, Bristol, Avon, England; [Bhatnagar, Rahul; Zahan-Evans, Natalie J.; Edey, Anthony J.; Clive, Amelia O.; Walker, Steven P.; Harvey, John E.; Maskell, Nick A.] North Bristol NHS Trust, North Bristol Lung Ctr, Bristol, Avon, England; [Piotrowska, Hania E. G.; Laskawiec-Szkonter, Magda; Quaddy, Jack L.; Rahman, Najib M.] Univ Oxford, Nuffield Dept Expt Med, Oxford Resp Trials Unit, Oxford, England; [Kahan, Brennan C.] Queen Mary Univ London, Pragmat Clin Trials Unit, London, England; [Luengo-Fernandez, Ramon; Little, Matthew H. R.; Mei, Xue W.] Univ Oxford, Nuffield Dept Populat Hlth, Hlth Econ Res Ctr, Oxford, England; [Pepperell, Justin C. T.] Taunton & Somerset NHS Fdn Trust, Somerset Lung Ctr Musgrove Pk Hosp, Taunton, Somerset, England; [Evison, Matthew D.; Holme, Jayne; Al-Aloul, Mohamed] Manchester Univ NHS Fdn Trust, North West Lung Ctr, Manchester, Lancs, England; [Psallidas, Ioannis] UCL, Lungs Living Res Ctr, London, England; [Lim, Wei Shen] Nottingham Univ Hosp NHS Trust, Resp Med, Nottingham, England; [Lim, Wei Shen] Univ Nottingham, Nottingham, England; [Blyth, Kevin G.] Queen Elizabeth Univ Hosp, Glasgow Pleural Dis Unit, Glasgow, Lanark, Scotland; [Blyth, Kevin G.] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland; [Roberts, Mark E.; Cox, Giles; Downer, Nicola J.] Sherwood Forest Hosp Trust, Resp Dept, Glasgow, Lanark, Scotland; [Herre, Jurgen; Sivasothy, Pasupathy] Univ Hosp NHS Fdn Trust, Cambridge, England; [Menzies, Daniel] Glan Clwyd Gen Hosp, North Wales, Wales; [Munavvar, Mohammed] Lancashire Teaching Hosp NHS Fdn Trust, Preston, Lancs, England; [Kyi, Moe M.] Doncaster & Bassetlaw Teaching Hosp NHS Fdn Trust, Resp Dept, Doncaster, England; [Ahmed, Liju; West, Alex G.] Guys & St Thomas NHS Trust, Resp Dept, London, England; [Harrison, Richard N.; Prudon, Benjamin] North Tees & Hartlepool NHS Fdn, Resp Med, Stoke On Tees, Staffs, England; [Hettiarachchi, Gihan] Medway NHS Fdn Trust, Gillingham, England; [Chakrabarti, Biswajit] Aintree Univ Hosp NHS Fdn Trust, Liverpool, Merseyside, England; [Kavidasan, Ajikumar] Milton Keynes Univ Hosp, Milton Keynes, Bucks, England; [Kavidasan, Ajikumar] Croydon Univ Hosp, Croydon, England; [Sutton, Benjamin P.] Birmingham NHS Fdn Trust, Birmingham, W Midlands, England; [Hooper, Clare E.] Worcester Acute Hosp NHS Trust, Worcester, England; [Davies, Helen E.] Cardiff & Vale Univ Hlth Board, Cardiff, Wales; [Slade, Mark] Gloucestershire Hosp NHS Fdn Trust, Dept Resp Med, Cheltenham, Glos, England; [Miller, Robert F.] UCL, Inst Global Hlth, London, England	University of Bristol; North Bristol NHS Trust; University of Oxford; University of London; Queen Mary University London; University of Oxford; University of London; University College London; Nottingham University Hospital NHS Trust; University of Nottingham; Queen Elizabeth University Hospital (QEUH); University of Glasgow; Guy's & St Thomas' NHS Foundation Trust; Aintree University Hospitals NHS Foundation Trust; Croydon University Hospital; Gloucestershire Hospitals NHS Foundation Trust; University of London; University College London	Bhatnagar, R (corresponding author), Univ Bristol, Acad Resp Unit, Southmead Hosp, Learning & Res Bldg, Bristol BS10 5NB, Avon, England.	rahul.bhatnagar@bristol.ac.uk	; Ahmed, Liju/I-6286-2018	Bhatnagar, Rahul/0000-0003-3906-1997; Miller, Robert/0000-0003-2067-4291; Davies, Helen/0000-0001-6102-256X; Ahmed, Liju/0000-0001-7722-8829; maskell, nick/0000-0002-1276-6500; Mei, Xue/0000-0002-6279-4884; Rahman, Najib M/0000-0003-1195-1680	United Kingdom National Institute for Health Research; North Bristol National Health Service (NHS) Trust; MRC [G0600475] Funding Source: UKRI	United Kingdom National Institute for Health Research(National Institute for Health Research (NIHR)); North Bristol National Health Service (NHS) Trust; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Funding to conduct the study was awarded to the University of Bristol, to which Dr Bhatnagar, DrWalker, Dr Clive, Ms Zahan-Evans and Dr Maskell were affiliated, and to the University of Oxford, to which Ms Laskawiec-Szkonter, Ms Piotrowska, Dr Little, Ms Mei, Dr Luengo-Fernandez, Mr Quaddy, and Dr Rahman were affiliated. The study was funded by the United Kingdom National Institute for Health Research and sponsored by North Bristol National Health Service (NHS) Trust.	Altman DG, 2005, BRIT MED J, V330, P843, DOI 10.1136/bmj.330.7495.843; Bhatnagar R, 2018, NEW ENGL J MED, V378, P1313, DOI 10.1056/NEJMoa1716883; Bhatnagar R, 2014, RESPIRATION, V88, P74, DOI 10.1159/000360769; Bibby AC, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00349-2018; Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; Clive AO, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010529.pub2; Clive AO, 2014, THORAX, V69, P1098, DOI 10.1136/thoraxjnl-2014-205285; Davies HE, 2012, JAMA-J AM MED ASSOC, V307, P2383, DOI 10.1001/jama.2012.5535; de Fonseka D, 2018, RESPIRATION, V96, P560, DOI 10.1159/000491674; Dipper A, 2019, CURR OPIN PULM MED, V25, P380, DOI 10.1097/MCP.0000000000000587; Dresler CM, 2005, CHEST, V127, P909, DOI 10.1378/chest.127.3.909; Feller-Kopman DJ, 2018, AM J RESP CRIT CARE, V198, P839, DOI 10.1164/rccm.201807-1415ST; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Janssen JP, 2007, LANCET, V369, P1535, DOI 10.1016/S0140-6736(07)60708-9; Jenkinson C, 1999, J EPIDEMIOL COMMUN H, V53, P46, DOI 10.1136/jech.53.1.46; Kahan BC, 2012, STAT MED, V31, P328, DOI 10.1002/sim.4431; Kharroubi SA, 2007, J HEALTH ECON, V26, P597, DOI 10.1016/j.jhealeco.2006.09.002; Lee P, 2012, CHEST, V142, P15, DOI 10.1378/chest.12-1085; Light RW, 2012, CHEST, V142, P17, DOI 10.1378/chest.12-1087; Maskell NA, 2004, AM J RESP CRIT CARE, V170, P377, DOI 10.1164/rccm.200311-1579OC; Mishra EK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123798; Morris TP, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-11; Muruganandan S, 2018, LANCET RESP MED, V6, P671, DOI 10.1016/S2213-2600(18)30288-1; Psallidas I, 2018, LANCET ONCOL, V19, P930, DOI 10.1016/S1470-2045(18)30294-8; Rahman NM, 2011, NEW ENGL J MED, V365, P518, DOI 10.1056/NEJMoa1012740; Rahman Najib M, 2010, Thorax, V65 Suppl 2, pii54, DOI 10.1136/thx.2010.137018; Roberts ME, 2010, THORAX, V65, P32, DOI 10.1136/thx.2010.136994; Terra RM, 2009, CHEST, V136, P361, DOI 10.1378/chest.08-2448; Thomas R, 2017, JAMA-J AM MED ASSOC, V318, P1903, DOI 10.1001/jama.2017.17426; van Hout B, 2012, VALUE HEALTH, V15, P708, DOI 10.1016/j.jval.2012.02.008; Wahidi MM, 2017, AM J RESP CRIT CARE, V195, P1050, DOI 10.1164/rccm.201607-1404OC; White IR, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d40; Yim APC, 1996, ANN THORAC SURG, V62, P1655, DOI 10.1016/S0003-4975(96)00808-9	33	32	35	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	2020	323	1					60	69		10.1001/jama.2019.19997	http://dx.doi.org/10.1001/jama.2019.19997			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	KB9WM	31804680	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000506838300016
J	Nwaroh, C; Giuffre, A; Cole, L; Bell, T; Carlson, HL; MacMaster, FP; Kirton, A; Harris, AD				Nwaroh, Chidera; Giuffre, Adrianna; Cole, Lauran; Bell, Tiffany; Carlson, Helen L.; MacMaster, Frank P.; Kirton, Adam; Harris, Ashley D.			Effects of Transcranial Direct Current Stimulation on GABA and Glx in Children: A pilot study	PLOS ONE			English	Article							NONINVASIVE CORTICAL STIMULATION; PRIMARY MOTOR CORTEX; BRAIN-STIMULATION; SENSORIMOTOR CORTEX; SKILL ACQUISITION; PERINATAL STROKE; HD-TDCS; SPECTROSCOPY; EXCITABILITY; MODULATION	Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that safely modulates brain excitability and has therapeutic potential for many conditions. Several studies have shown that anodal tDCS of the primary motor cortex (M1) facilitates motor learning and plasticity, but there is little information about the underlying mechanisms. Using magnetic resonance spectroscopy (MRS), it has been shown that tDCS can affect local levels of gamma-aminobutyric acid (GABA) and Glx (a measure of glutamate and glutamine combined) in adults, both of which are known to be associated with skill acquisition and plasticity; however this has yet to be studied in children and adolescents. This study examined GABA and Glx in response to conventional anodal tDCS (a-tDCS) and high definition tDCS (HD-tDCS) targeting the M1 in a pediatric population. Twenty-four typically developing, right-handed children ages 12-18 years participated in five consecutive days of tDCS intervention (sham, a-tDCS or HD-tDCS) targeting the right M1 while training in a fine motor task (Purdue Pegboard Task) with their left hand. Glx and GABA were measured before and after the protocol (at day 5 and 6 weeks) using a PRESS and GABA-edited MEGA-PRESS MRS sequence in the sensorimotor cortices. Glx measured in the left sensorimotor cortex was higher in the HD-tDCS group compared to a-tDCS and sham at 6 weeks (p = 0.001). No changes in GABA were observed in either sensorimotor cortex at any time. These results suggest that neither a-tDCS or HD-tDCS locally affect GABA and Glx in the developing brain and therefore it may demonstrate different responses in adults.	[Nwaroh, Chidera; Bell, Tiffany; Harris, Ashley D.] Univ Calgary, Dept Radiol, Calgary, AB, Canada; [Nwaroh, Chidera; Giuffre, Adrianna; Cole, Lauran; Bell, Tiffany; Carlson, Helen L.; MacMaster, Frank P.; Kirton, Adam; Harris, Ashley D.] Alberta Childrens Hosp ACHRI, Calgary, AB, Canada; [Nwaroh, Chidera; Giuffre, Adrianna; Cole, Lauran; Bell, Tiffany; Carlson, Helen L.; MacMaster, Frank P.; Kirton, Adam; Harris, Ashley D.] Hotchkiss Brain Inst, Calgary, AB, Canada; [Nwaroh, Chidera; Bell, Tiffany; MacMaster, Frank P.; Harris, Ashley D.] Child & Adolescent Imaging Res CAIR Program, Calgary, AB, Canada; [Giuffre, Adrianna; Cole, Lauran] Univ Calgary, Dept Neurosci, Calgary, AB, Canada; [Giuffre, Adrianna; Cole, Lauran; Kirton, Adam] Univ Calgary, Dept Pediat, Calgary, AB, Canada; [Carlson, Helen L.; MacMaster, Frank P.; Kirton, Adam] Univ Calgary, Dept Psychiat, Calgary, AB, Canada; [MacMaster, Frank P.] Univ Calgary, Mathison Ctr Mental Hlth Res & Educ, Calgary, AB, Canada; [MacMaster, Frank P.] Addict & Mental Hlth Strateg Clin Network, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Calgary	Harris, AD (corresponding author), Univ Calgary, Dept Radiol, Calgary, AB, Canada.; Harris, AD (corresponding author), Alberta Childrens Hosp ACHRI, Calgary, AB, Canada.; Harris, AD (corresponding author), Hotchkiss Brain Inst, Calgary, AB, Canada.; Harris, AD (corresponding author), Child & Adolescent Imaging Res CAIR Program, Calgary, AB, Canada.	ashley.harris2@ucalgary.ca	Bell, Tiffany/AAB-4896-2019	Bell, Tiffany/0000-0002-9591-706X; Giuffre, Dr. Adrianna/0000-0001-9632-0612; MacMaster, Frank/0000-0002-7159-7583	Behaviour and the Developing Brain Theme of the Alberta Children's Hospital Research Institute the Hotchkiss Brain Institute, University of Calgary; Canadian Institute of Health Research	Behaviour and the Developing Brain Theme of the Alberta Children's Hospital Research Institute the Hotchkiss Brain Institute, University of Calgary; Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR))	Funding for this project was received from the Behaviour and the Developing Brain Theme of the Alberta Children's Hospital Research Institute the Hotchkiss Brain Institute, University of Calgary and the Canadian Institute of Health Research.	Ambrus GG, BRAIN STIMUL; Anguera JA, 2007, BRAIN RES, V1185, P136, DOI 10.1016/j.brainres.2007.09.088; Antal A, 2003, EXP BRAIN RES, V150, P375, DOI 10.1007/s00221-003-1459-8; Antal A, 2008, CEREB CORTEX, V18, P2701, DOI 10.1093/cercor/bhn032; Auvichayapat P, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00366; Bachtiar V, 2015, ELIFE, V4, DOI 10.7554/eLife.08789; Bikson M, 2016, BRAIN STIMUL, V9, P641, DOI 10.1016/j.brs.2016.06.004; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Boggio PS, 2006, NEUROSCI LETT, V404, P232, DOI 10.1016/j.neulet.2006.05.051; Boissy P, 1997, ARCH PHYS MED REHAB, V78, P1117, DOI 10.1016/S0003-9993(97)90138-6; Borckardt JJ, 2012, J PAIN, V13, P112, DOI 10.1016/j.jpain.2011.07.001; Caparelli-Daquer EM, 2017, PILOT STUDY EFFECTS, V20, P48, DOI [10.1007/s00221-005-2334-6, DOI 10.1007/S00221-005-2334-6]; Carlson HL, 2018, BRAIN STIMUL, V11, P94, DOI 10.1016/j.brs.2017.09.007; Ciechanski P, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00268; Ciechanski P, 2017, J NEUROPHYSIOL, V118, P140, DOI 10.1152/jn.00076.2017; Ciechanski P, 2017, CEREB CORTEX, V27, P2758, DOI 10.1093/cercor/bhw114; Clark VP, 2011, NEUROSCI LETT, V500, P67, DOI 10.1016/j.neulet.2011.05.244; Cole L, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00787; Datta A, 2010, NIH PUBLIC ACCESS, V2, P201, DOI DOI 10.1016/j.brs.2009.03.005.Gyri; Davis NJ, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00600; Dmochowski JP, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046011; Dwyer GE, 2019, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.01145; Edden RAE, 2014, J MAGN RESON IMAGING, V40, P1445, DOI 10.1002/jmri.24478; Floyer-Lea A, 2006, J NEUROPHYSIOL, V95, P1639, DOI 10.1152/jn.00346.2005; Foerster BR, 2015, ARTHRITIS RHEUMATOL, V67, P576, DOI 10.1002/art.38945; Fregni F, 2006, BIPOLAR DISORD, V8, P203, DOI 10.1111/j.1399-5618.2006.00291.x; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2006, MOVEMENT DISORD, V21, P1693, DOI 10.1002/mds.21012; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; Froc DJ, 2000, J NEUROSCI, V20, P438, DOI 10.1523/JNEUROSCI.20-01-00438.2000; Gasparovic C, 2006, MAGN RESON MED, V55, P1219, DOI 10.1002/mrm.20901; Hameed MQ, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0719-0; Harris AD, 2019, BRAIN STIMUL; Harris AD, 2019, NEUROBIOL AGING, V79, P75, DOI 10.1016/j.neurobiolaging.2019.03.011; Harris AD, 2017, MAGN RESON MED, V77, P1377, DOI 10.1002/mrm.26619; Harris AD, 2015, J MAGN RESON IMAGING, V42, P1431, DOI 10.1002/jmri.24903; Hone-Blanchet A, 2016, BIOL PSYCHIAT, V80, P432, DOI 10.1016/j.biopsych.2015.11.008; Hunter MA, 2015, BRAIN RES, V1594, P92, DOI 10.1016/j.brainres.2014.09.066; Kadosh KC, 2015, HUM BRAIN MAPP, V36, P4334, DOI 10.1002/hbm.22921; Kessler SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076112; Kim S, 2014, NEUROIMAGE, V99, P237, DOI 10.1016/j.neuroimage.2014.05.070; Kirton A, 2017, NEUROLOGY, V88, P259, DOI 10.1212/WNL.0000000000003518; Kirton A, 2013, PEDIATR NEUROL, V48, P81, DOI 10.1016/j.pediatrneurol.2012.08.001; Kirton A, 2010, CLIN NEUROPHYSIOL, V121, P1922, DOI 10.1016/j.clinph.2010.04.021; Kolasinski J, 2019, J PHYSIOL-LONDON, V597, P271, DOI 10.1113/JP276626; Krause B, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00602; Kuo HI, 2013, BRAIN STIMUL, V6, P644, DOI 10.1016/j.brs.2012.09.010; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Lee M, 2010, J PHYSIOL-LONDON, V588, P201, DOI 10.1113/jphysiol.2009.183855; Luscher C, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a005710; Mullins PG, 2014, NEUROIMAGE, V86, P43, DOI 10.1016/j.neuroimage.2012.12.004; Near J, 2015, MAGN RESON MED, V73, P44, DOI 10.1002/mrm.25094; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2003, J COGNITIVE NEUROSCI, V15, P619, DOI 10.1162/089892903321662994; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Oldfield RC, 1971, NEUROPSYCHOLOGIA; Patel HJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39262-7; Prichard G, 2014, BRAIN STIMUL, V7, P532, DOI 10.1016/j.brs.2014.04.005; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Rajapakse T, 2013, TRANSL NEUROSCI, V4, P217, DOI 10.2478/s13380-013-0116-3; Reis J, 2011, CURR OPIN NEUROL, V24, P590, DOI 10.1097/WCO.0b013e32834c3db0; Reis J, 2009, P NATL ACAD SCI USA, V106, P1590, DOI 10.1073/pnas.0805413106; Richardson J, 2015, NEUROREHABILITATION, V36, P115, DOI 10.3233/NRE-141199; Ryan K, 2018, PLOS ONE, V13, P1; Schambra HM, 2011, J NEUROPHYSIOL, V106, P652, DOI 10.1152/jn.00210.2011; Stagg CJ, 2011, CURR BIOL, V21, P480, DOI 10.1016/j.cub.2011.01.069; Stagg CJ, 2009, J NEUROSCI, V29, P5202, DOI 10.1523/JNEUROSCI.4432-08.2009; Tiffin J, 1948, J APPL PSYCHOL, V32, P234, DOI 10.1037/h0061266; Turrigiano GG, 2000, CURR OPIN NEUROBIOL, V10, P358, DOI 10.1016/S0959-4388(00)00091-X; Villamar MF, 2013, JOVE-J VIS EXP, DOI 10.3791/50309; Vines BW, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-103; Woods AJ, 2016, CLIN NEUROPHYSIOL, V127, P1031, DOI 10.1016/j.clinph.2015.11.012; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141; Zhao HC, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00685	75	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2020	15	1							e0222620	10.1371/journal.pone.0222620	http://dx.doi.org/10.1371/journal.pone.0222620			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5BZ	31910218	Green Published, Green Submitted, gold			2023-01-03	WOS:000534333800004
J	Cai, J; Shao, X; Yan, ZD; Liu, XY; Yang, YQ; Luo, EP; Jing, D				Cai, Jing; Shao, Xi; Yan, Zedong; Liu, Xiyu; Yang, Yongqing; Luo, Erping; Jing, Da			Differential skeletal response in adult and aged rats to independent and combinatorial stimulation with pulsed electromagnetic fields and mechanical vibration	FASEB JOURNAL			English	Article						age-related osteopenia; osteoporosis; bone anabolism; bone quality; canonical Wnt signaling; pulsed electromagnetic fields; whole-body vibration	WHOLE-BODY VIBRATION; PROMOTING BONE-FORMATION; LOW-MAGNITUDE; THERAPY; OSTEOPOROSIS; FRACTURE; STRENGTH; WOMEN; ACTIVATION; PREVENTION	Pulsed electromagnetic fields (PEMFs) and whole-body vibration (WBV) are proved to partially preserve bone mass/strength in hindlimb-unloaded and ovariectomized animals. However, the potential age-dependent skeletal response to either PEMF or WBV has not been fully investigated. Moreover, whether the coupled "mechano-electro-magnetic" signals can induce greater osteogenic potential than single stimulation remains unknown. Herein, 5-month-old or 20-month-old rats were assigned to the Control, PEMF, WBV, and PEMF + WBV groups. After 8-week treatment, single PEMF/WBV enhanced bone mass, strength, and anabolism in 5-month-old rats, but not in 20-month-old rats. PEMF + WBV induced greater increase of bone quantity, quality, and anabolism than single PEMF/WBV in young adult rats. PEMF + WBV also inhibited bone loss in elderly rats by primarily improving osteoblast and osteocyte activity, but had no effects on bone resorption. PEMF + WBV upregulated the expression of various canonical Wnt ligands and downstream molecules (p-GSK-3 beta and beta-catenin), but had no impacts on noncanonical Wnt5a expression in aged skeleton, revealing the potential involvement of canonical Wnt signaling in bone anabolism of PEMF + WBV. This study not only reveals much weaker responsiveness of aged skeleton to single PEMF/WBV relative to young adult skeleton, but also presents a novel noninvasive approach based on combinatorial treatment with PEMF + WBV for improving bone health and preserving bone quantity/quality (especially for age-related osteoporosis) with stronger anabolic effects.	[Cai, Jing] Shaanxi Univ Chinese Med, Coll Basic Med, Xianyang, Peoples R China; [Cai, Jing; Shao, Xi; Yan, Zedong; Liu, Xiyu; Yang, Yongqing; Luo, Erping; Jing, Da] Fourth Mil Med Univ, Dept Biomed Engn, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China	Shaanxi University of Chinese Medicine; Air Force Military Medical University	Jing, D (corresponding author), Fourth Mil Med Univ, Dept Biomed Engn, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.	jingdaasq@126.com			National Natural Science Foundation of China [31500760, 51777211, 11972366, 51907111]; Young Talent Supporting Project in Military Technology of China [17-JCJQ-QT-038]; Shaanxi Provincial Natural Science Foundation of China [2018JQ8056]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Young Talent Supporting Project in Military Technology of China; Shaanxi Provincial Natural Science Foundation of China	National Natural Science Foundation of China, Grant/Award Number: 31500760, 51777211, 11972366 and 51907111; Young Talent Supporting Project in Military Technology of China, Grant/Award Number: 17-JCJQ-QT-038; Shaanxi Provincial Natural Science Foundation of China, Grant/Award Number: 2018JQ8056	ANDERSON JC, 1970, NATURE, V227, P491, DOI 10.1038/227491a0; Assiotis A, 2012, J ORTHOP SURG RES, V7, DOI 10.1186/1749-799X-7-24; Bala Y, 2012, J BONE MINER RES, V27, P825, DOI 10.1002/jbmr.1501; Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074; BASSETT CAL, 1974, SCIENCE, V184, P575; Benhaj K, 2006, ONCOL REP, V15, P701; Blume SW, 2011, OSTEOPOROSIS INT, V22, P1835, DOI 10.1007/s00198-010-1419-7; Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320; Cai J, 2018, OSTEOPOROSIS INT, V29, P1177, DOI 10.1007/s00198-018-4392-1; Catalano A, 2018, BONE, V116, P42, DOI 10.1016/j.bone.2018.07.010; Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140-6736(98)09075-8; Chan ME, 2013, CURR OSTEOPOROS REP, V11, P36, DOI 10.1007/s11914-012-0132-1; Chan ME, 2012, FASEB J, V26, P4855, DOI 10.1096/fj.12-209841; Clarke BL, 1996, J CLIN ENDOCR METAB, V81, P2264, DOI 10.1210/jc.81.6.2264; De Laet CEDH, 2000, BEST PRACT RES CL EN, V14, P171, DOI 10.1053/beem.2000.0067; Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905; Ferguson VL, 2003, BONE, V33, P387, DOI 10.1016/S8756-3282(03)00199-6; Gabel L, 2017, J BONE MINER RES, V32, P1525, DOI 10.1002/jbmr.3115; Ganesan K, 2009, INDIAN J EXP BIOL, V47, P939; Gao JZ, 2016, ANN BIOMED ENG, V44, P2489, DOI 10.1007/s10439-015-1532-z; Gilsanz V, 2006, J BONE MINER RES, V21, P1464, DOI 10.1359/JBMR.060612; Grace KLR, 1998, ORTHOPEDICS, V21, P297; Gruntmanis U, 2007, AM J MED SCI, V333, P85, DOI 10.1097/00000441-200702000-00004; Holguin N, 2016, J BONE MINER RES, V31, P2215, DOI 10.1002/jbmr.2900; Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564; Jing D, 2011, OSTEOPOROSIS INT, V22, P1885, DOI 10.1007/s00198-010-1447-3; Jing D, 2018, BONE, V106, P11, DOI 10.1016/j.bone.2017.10.001; Jing D, 2016, J BONE MINER RES, V31, P1713, DOI 10.1002/jbmr.2837; Jing D, 2014, J BONE MINER RES, V29, P2250, DOI 10.1002/jbmr.2260; Jing D, 2014, FASEB J, V28, P1582, DOI 10.1096/fj.13-237578; Jing D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079377; Jing D, 2010, BONE, V46, P487, DOI 10.1016/j.bone.2009.09.021; Khosla S, 2008, ENDOCR REV, V29, P441, DOI 10.1210/er.2008-0002; Kiel DP, 2015, J BONE MINER RES, V30, P1319, DOI 10.1002/jbmr.2448; Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551; Lambert Jessica K, 2011, Curr Osteoporos Rep, V9, P229, DOI 10.1007/s11914-011-0066-z; Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182; Lynch MA, 2010, J ORTHOP RES, V28, P241, DOI 10.1002/jor.20965; Mahavni V, 2001, CURR OPIN ONCOL, V13, P384, DOI 10.1097/00001622-200109000-00012; Manolagas SC, 2010, TRENDS ENDOCRIN MET, V21, P369, DOI 10.1016/j.tem.2010.01.010; Meakin LB, 2014, J BONE MINER RES, V29, P1859, DOI 10.1002/jbmr.2222; Musette P, 2010, OSTEOPOROSIS INT, V21, P723, DOI 10.1007/s00198-009-1097-5; Olivares-Navarrete R, 2011, ACTA BIOMATER, V7, P2740, DOI 10.1016/j.actbio.2011.02.030; OLIVER WC, 1992, J MATER RES, V7, P1564, DOI 10.1557/JMR.1992.1564; Razi H, 2015, J BONE MINER RES, V30, P1864, DOI 10.1002/jbmr.2528; Rizzoli R, 2011, CALCIFIED TISSUE INT, V89, P91, DOI 10.1007/s00223-011-9499-8; Rubin C, 2001, FASEB J, V15, P2225, DOI 10.1096/fj.01-0166com; Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122; Rubin C, 2004, J BONE MINER RES, V19, P343, DOI 10.1359/JBMR.0301251; Sanudo B, 2017, MENOPAUSE, V24, P1208, DOI 10.1097/GME.0000000000000872; Sehmisch S, 2009, OSTEOPOROSIS INT, V20, P1999, DOI 10.1007/s00198-009-0892-3; Shen WW, 2010, BIOELECTROMAGNETICS, V31, P113, DOI 10.1002/bem.20535; Sherk VD, 2013, J CLIN DENSITOM, V16, P104, DOI 10.1016/j.jocd.2012.07.009; Sinder BP, 2013, J BONE MINER RES, V28, P73, DOI 10.1002/jbmr.1717; Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003; Vanleene M, 2013, BONE, V53, P507, DOI 10.1016/j.bone.2013.01.023; Verschueren SMP, 2004, J BONE MINER RES, V19, P352, DOI 10.1359/JBMR.0301245; Wang P, 2019, J CELL PHYSIOL, V234, P10588, DOI 10.1002/jcp.27734; Wang T, 2019, OSTEOPOROSIS INT, V30, P267, DOI 10.1007/s00198-018-04822-6; Zhai MM, 2016, BIOELECTROMAGNETICS, V37, P152, DOI 10.1002/bem.21961; Zhu SY, 2017, BIOELECTROMAGNETICS, V38, P406, DOI 10.1002/bem.22065	61	8	8	2	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2020	34	2					3037	3050		10.1096/fj.201902779R	http://dx.doi.org/10.1096/fj.201902779R		DEC 2019	14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KN2HU	31908035	Bronze			2023-01-03	WOS:000504854800001
J	Ahmed, MAA; Al-Nafeesah, A; Al-Wutayd, O; Mahgoub, HM; Adam, I				Ahmed, Mohammed Ahmed A.; Al-Nafeesah, Abdullah; Al-Wutayd, Osama; Mahgoub, Hyder M.; Adam, Ishag			Severe childhood anemia and emergency blood transfusion in Gadarif Hospital, eastern Sudan	PLOS ONE			English	Article							CHILDREN	Background Anemia is a major cause of global morbidity and mortality, particularly among children. Management of anemia depends on causes and severity of anemia. However blood transfusion is a lifesaving intervention in severe and life-threatening anemia. There are no published data on blood transfusion for anemia in Sudan. Methods A descriptive study was conducted in Gadarif Hospital in eastern Sudan during 1 August, 2017 to 31 March, 2018. Consecutive children who presented at the emergency room with an indication for blood transfusion were enrolled in the study. A detailed history was gathered from all patients. Physical examinations, including vital signs, were performed. The World Health Organization guidelines for blood transfusion were followed. Results During the study period, a total of 1800 children were admitted to the emergency pediatric ward in Gadarif Hospital and were assessed for anemia, 513 (28.5%) were anemic and 141 (7.8%) had severe anemia. Three hundred anemic children received blood transfusion. The median (interquartile) of the age of the 300 children who received blood transfusion was 4.2 4.2(2.0-9.0) years. A total of 148 (49.3%) of the children were boys and 151 (50.3%) were younger than 5 years. The diagnoses associated with the order for blood transfusion were sickle cell disease (129, 43.0%), active bleeding (58, 19.3%), malaria (50, 16.7%), visceral leishmaniasis (25, 8.3%), severe acute malnutrition (16, 5.30%), snake bite (11, 3.7%), sepsis (5, 1.7%), and others. Two hundred eighty-five (95.0%) children improved, nine children were discharged against medical advice, and six (2.0%) children died. Conclusion There is a high burden of anemia in eastern Sudan. Sickle cell disease, malaria, and visceral leishmaniasis are the main causes of anemia in this region. Further research on blood transfusion is needed.	[Ahmed, Mohammed Ahmed A.] Gadarif Univ, Fac Med, Gadarif, Sudan; [Al-Nafeesah, Abdullah] Qassim Univ, Unaizah Coll Med, Dept Paediat, Unaizah, Saudi Arabia; [Al-Wutayd, Osama] Qassim Univ, Unaizah Coll Med, Dept Family & Community Med, Unaizah, Saudi Arabia; [Mahgoub, Hyder M.] New Halfa Hosp, New Halfa, Sudan; [Adam, Ishag] Qassim Univ, Unaizah Coll Med, Dept Obstet & Gynecol, Unaizah, Saudi Arabia	Qassim University; Qassim University; Qassim University	Adam, I (corresponding author), Qassim Univ, Unaizah Coll Med, Dept Obstet & Gynecol, Unaizah, Saudi Arabia.	ishagadam@hotmail.com	Al-Wutayd, Osama/AAU-7492-2020	Al-Wutayd, Osama/0000-0001-6029-9663; Adam, Ishag/0000-0001-5031-7741				Ahmed MAA, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3875-2; Badawi MM, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1060-1; Calis JCJ, 2016, MALAWI MED J, V28, P99; Daak AA, 2016, TROP MED INT HEALTH, V21, P642, DOI 10.1111/tmi.12689; Eltayeb MSE, 2016, PAN AFR MED J, V24, DOI 10.11604/pamj.2016.24.244.8355; Emmanuel JC., 2001, CLIN US BLOOD HDB; English M, 2002, LANCET, V359, P494, DOI 10.1016/S0140-6736(02)07666-3; Giha HA, 2009, EUR J CLIN MICROBIOL, V28, P661, DOI 10.1007/s10096-008-0665-5; Hashim Hasan Awadalla, 2017, Sudan J Paediatr, V17, P35, DOI 10.24911/SJP.2017.2.4; Himeidan YE, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-109; HOLZER BR, 1993, ACTA TROP, V55, P47, DOI 10.1016/0001-706X(93)90047-F; Kahama AI, 1999, AM J TROP MED HYG, V61, P215, DOI 10.4269/ajtmh.1999.61.215; Kassebaum NJ, 2014, BLOOD, V123, P615, DOI 10.1182/blood-2013-06-508325; Kiguli S, 2015, BMC MED, V13, DOI 10.1186/s12916-014-0246-7; Mahgoub HM, 2010, J HELMINTHOL, V84, P132, DOI 10.1017/S0022149X09990368; Mahgoub H, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-154; Maitland K, 2019, NEW ENGL J MED, V381, P407, DOI 10.1056/NEJMoa1900105; Malamba S, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-143; Manning L, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001972; McLean E, 2009, PUBLIC HEALTH NUTR, V12, P444, DOI 10.1017/S1368980008002401; Muoneke VU, 2012, INDIAN PEDIATR, V49, P119, DOI 10.1007/s13312-012-0026-4; Nabwera HM, 2016, TRANSFUSION, V56, P2732, DOI 10.1111/trf.13774; Opoka RO, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3382-5; Orish VN, 2016, AM J TROP MED HYG, V94, P691, DOI 10.4269/ajtmh.15-0310; Qureshi B, 2006, J R SOC PROMO HEALTH, V126, P285, DOI 10.1177/1466424006070493; Sabahelzain MM, 2014, PAN AFR MED J, V18, DOI 10.11604/pamj.2014.18.13.3280; Shari Catherine R, 2017, BMC Hematol, V17, P19, DOI 10.1186/s12878-017-0091-y; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; TEESDALE CH, 1976, B WORLD HEALTH ORGAN, V54, P703; Thomas J, 2017, AM J TROP MED HYG, V96, P511, DOI 10.4269/ajtmh.16-0735; WHO, 2018, HAEM CONC DIAGN AN A; World Health Organization, 2017, GLOB HLTH OBS GHO DA; World Health Organization, SICKLE CELL DIS; World HO (WHO), 2017, WHO POCK BOOK HOSP C; 2009, WHO CHILD GROWTH STA, V958, P1	35	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2019	14	12							e0225731	10.1371/journal.pone.0225731	http://dx.doi.org/10.1371/journal.pone.0225731			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO9UM	31794569	Green Published, gold			2023-01-03	WOS:000533969300024
J	Hellmann, MD; Paz-Ares, L; Caro, RB; Zurawski, B; Kim, SW; Costa, EC; Park, K; Alexandru, A; Lupinacci, L; Jimenez, ED; Sakai, H; Albert, I; Vergnenegre, A; Peters, S; Syrigos, K; Barlesi, F; Reck, M; Borghaei, H; Brahmer, JR; O'Byrne, KJ; Geese, WJ; Bhagavatheeswaran, P; Rabindran, SK; Kasinathan, RS; Nathan, FE; Ramalingam, SS				Hellmann, M. D.; Paz-Ares, L.; Bernabe Caro, R.; Zurawski, B.; Kim, S. -W.; Carcereny Costa, E.; Park, K.; Alexandru, A.; Lupinacci, L.; de la Mora Jimenez, E.; Sakai, H.; Albert, I.; Vergnenegre, A.; Peters, S.; Syrigos, K.; Barlesi, F.; Reck, M.; Borghaei, H.; Brahmer, J. R.; O'Byrne, K. J.; Geese, W. J.; Bhagavatheeswaran, P.; Rabindran, S. K.; Kasinathan, R. S.; Nathan, F. E.; Ramalingam, S. S.			Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONOTHERAPY	BACKGROUND In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC. METHODS In this open-label, phase 3 trial, we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The patients who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy alone. All the patients had received no previous chemotherapy. The primary end point reported here was overall survival with nivolumab plus ipilimumab as compared with chemotherapy in patients with a PD-L1 expression level of 1% or more. RESULTS Among the patients with a PD-L1 expression level of 1% or more, the median duration of overall survival was 17.1 months (95% confidence interval [CI], 15.0 to 20.1) with nivolumab plus ipilimumab and 14.9 months (95% CI, 12.7 to 16.7) with chemotherapy (P=0.007), with 2-year overall survival rates of 40.0% and 32.8%, respectively. The median duration of response was 23.2 months with nivolumab plus ipilimumab and 6.2 months with chemotherapy. The overall survival benefit was also observed in patients with a PD-L1 expression level of less than 1%, with a median duration of 17.2 months (95% CI, 12.8 to 22.0) with nivolumab plus ipilimumab and 12.2 months (95% CI, 9.2 to 14.3) with chemotherapy. Among all the patients in the trial, the median duration of overall survival was 17.1 months (95% CI, 15.2 to 19.9) with nivolumab plus ipilimumab and 13.9 months (95% CI, 12.2 to 15.1) with chemotherapy. The percentage of patients with grade 3 or 4 treatment-related adverse events in the overall population was 32.8% with nivolumab plus ipilimumab and 36.0% with chemotherapy. CONCLUSIONS First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up.	[Hellmann, M. D.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Paz-Ares, L.] Univ Complutense, Ctr Nacl Invest Oncol, Hosp Univ Doce Octubre, Madrid, Spain; [Paz-Ares, L.] Ctr Invest Biomed Red Canc, Madrid, Spain; [Bernabe Caro, R.] Hosp Univ Virgen Del Rocio, Seville, Spain; [Carcereny Costa, E.] Germans Trias & Pujol Hosp, Catalan Inst Oncol, Badalona, Spain; [Zurawski, B.] Ambulatorium Chemioterapii, Bydgoszcz, Poland; [Kim, S. -W.] Asan Med Ctr, Seoul, South Korea; [Park, K.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea; [Alexandru, A.] Inst Oncol Prof Dr Alexandru Trestioreanu, Bucharest, Romania; [Lupinacci, L.] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina; [de la Mora Jimenez, E.] Inst Jalisciense Cancerol, Guadalajara, Jalisco, Mexico; [Sakai, H.] Saitama Canc Ctr, Saitama, Japan; [Albert, I.] Matrai Gyogyint, Matrahaza, Hungary; [Vergnenegre, A.] Limoges Univ Hosp, Limoges, France; [Barlesi, F.] Aix Marseille Univ, AP HM, INSERM, Natl Ctr Sci Res,Ctr Rech Cancerol Marseillen, Marseille, France; [Peters, S.] Lausanne Univ, CHU Vaudois, Lausanne, Switzerland; [Syrigos, K.] Univ Athens, Sotiria Gen Hosp, Athens, Greece; [Reck, M.] German Ctr Lung Res, Airway Res Ctr North, Lung Clin Grosshansdorf, Grosshansdorf, Germany; [Borghaei, H.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Brahmer, J. R.] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA; [O'Byrne, K. J.] Princess Alexandra Hosp, Brisbane, Qld, Australia; [Geese, W. J.; Bhagavatheeswaran, P.; Rabindran, S. K.; Kasinathan, R. S.; Nathan, F. E.] Bristol Myers Squibb, Princeton, NJ USA; [Ramalingam, S. S.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA	Memorial Sloan Kettering Cancer Center; Complutense University of Madrid; Hospital Universitario 12 de Octubre; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Virgen del Rocio University Hospital; Catalan Institute of Oncology; Sungkyunkwan University (SKKU); Samsung Medical Center; Institute of Oncology "Prof. Dr. Al Trestioreanu"; Hospital Italiano de Buenos Aires; University of Buenos Aires; CHU Limoges; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Fox Chase Cancer Center; Johns Hopkins University; Johns Hopkins Medicine; Bristol-Myers Squibb; Emory University	Hellmann, MD (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Thorac Oncol Serv, 885 2nd Ave, New York, NY 10017 USA.	hellmanm@mskcc.org	Ramalingam, Suresh/AAV-7478-2020; Gales, Laurentia/AAF-7655-2019; Reck, Martin/ABF-5721-2020	Gales, Laurentia/0000-0002-0414-1607; Reck, Martin/0000-0002-5348-4462; Sakai, Hiroshi/0000-0002-3185-0804; O'Byrne, Kenneth/0000-0002-6754-5633; Bernabe, Reyes/0000-0003-0312-9195	Bristol-Myers Squibb; Ono Pharmaceutical	Bristol-Myers Squibb(Bristol-Myers Squibb); Ono Pharmaceutical	Supported by Bristol-Myers Squibb and Ono Pharmaceutical.	[Anonymous], 2019, TEC AT PRESCR INF; [Anonymous], 2019, KEYTR PEMBR PRESCR I; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Dako, 2016, PD L1 IHC 28 8 PHARM; Devarakonda S, 2018, J CLIN ONCOL, V36, P2995, DOI 10.1200/JCO.2018.78.1963; Foundation Medicine, 2017, FDN ON CDX; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Gide TN, 2019, CANCER CELL, V35, P238, DOI 10.1016/j.ccell.2019.01.003; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/S1470-2045(16)30624-6, 10.1016/s1470-2045(16)30624-6]; Kowanetz M, 2017, J THORAC ONCOL, V12, pS321, DOI 10.1016/j.jtho.2016.11.343; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140-6736(18)32409-7; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Ready N, 2019, J CLIN ONCOL, V37, P992, DOI 10.1200/JCO.18.01042; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rizvi H, 2018, J CLIN ONCOL, V36, P633, DOI 10.1200/JCO.2017.75.3384; Rizvi NA, 2019, J CLIN ONCOL, V37; Sade-Feldman M, 2018, CELL, V175, P998, DOI 10.1016/j.cell.2018.10.038; Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Spitzer MH, 2017, CELL, V168, P487, DOI 10.1016/j.cell.2016.12.022; Sun JX, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1005965; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; Yost KE, 2019, NAT MED, V25, P1251, DOI 10.1038/s41591-019-0522-3	28	1148	1179	14	107	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 21	2019	381	21					2020	2031		10.1056/NEJMoa1910231	http://dx.doi.org/10.1056/NEJMoa1910231			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ6NB	31562796	Bronze			2023-01-03	WOS:000505218800006
J	van Vugt, VA; van der Wouden, JC; Essery, R; Yardley, L; Twisk, JWR; van der Horst, HE; Maarsingh, OR				van Vugt, Vincent A.; van der Wouden, Johannes C.; Essery, Rosie; Yardley, Lucy; Twisk, Jos W. R.; van der Horst, Henriette E.; Maarsingh, Otto R.			Internet based vestibular rehabilitation with and without physiotherapy support for adults aged 50 and older with a chronic vestibular syndrome in general practice: three armed randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIZZY PATIENTS; INTERNATIONAL CLASSIFICATION; PRIMARY-CARE; DIZZINESS; SYMPTOMS; VERTIGO; MANAGEMENT; THERAPY; DEPRESSION; ANXIETY	OBJECTIVE To investigate the clinical effectiveness and safety of stand alone and blended internet based vestibular rehabilitation (VR) in the management of chronic vestibular syndromes in general practice. DESIGN Pragmatic, three armed, parallel group, individually randomised controlled trial. SETTING 59 general practices in the Netherlands. PARTICIPANTS 322 adults aged 50 and older with a chronic vestibular syndrome. INTERVENTIONS Stand alone VR comprising a six week, internet based intervention with weekly online sessions and daily exercises (10-20 minutes a day). In the blended VR group, the same internet based intervention was supplemented by face-to-face physiotherapy support (home visits in weeks 1 and 3). Participants in the usual care group received standard care from a general practitioner, without any restrictions. MAIN OUTCOME MEASURES The primary outcome was vestibular symptoms after six months as measured by the vertigo symptom scale-short form (VSS-SF range 0-60, clinically relevant difference >= 3 points). Secondary outcomes were dizziness related impairment, anxiety, depressive symptoms, subjective improvement of vestibular symptoms after three and six months, and adverse events. RESULTS In the intention-to-treat analysis, participants in the stand alone and blended VR groups had lower VSS-SF scores at six months than participants in the usual care group (adjusted mean difference -4.1 points, 95% confidence interval -5.8 to -2.5; and -3.5 points, -5.1 to -1.9, respectively). Similar differences in VSS-SF scores were seen at three months follow-up. Participants in the stand alone and blended VR groups also experienced less dizziness related impairment, less anxiety, and more subjective improvement of vestibular symptoms at three and six months. No serious adverse events related to online VR occurred during the trial. CONCLUSION Stand alone and blended internet based VR are clinically effective and safe interventions to treat adults aged 50 and older with a chronic vestibular syndrome. Online VR is an easily accessible form of treatment, with the potential to improve care for an undertreated group of patients in general practice.	[van Vugt, Vincent A.; van der Wouden, Johannes C.; van der Horst, Henriette E.; Maarsingh, Otto R.] Vrije Univ Amsterdam, Amsterdam UMC, Amsterdam Publ Hlth, Dept Gen Practice & Elderly Care Med, Boelelaan 1117, Amsterdam, Netherlands; [Essery, Rosie; Yardley, Lucy] Univ Southampton, Dept Psychol, Southampton, Hants, England; [Twisk, Jos W. R.] Vrije Univ Amsterdam, Amsterdam UMC, Amsterdam Publ Hlth, Dept Epidemiol & Biostat, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; University of Southampton; University of Amsterdam; Vrije Universiteit Amsterdam	van Vugt, VA (corresponding author), Vrije Univ Amsterdam, Amsterdam UMC, Amsterdam Publ Hlth, Dept Gen Practice & Elderly Care Med, Boelelaan 1117, Amsterdam, Netherlands.	v.vanvugt@amsterdamumc.nl	van der Wouden, Johannes C/O-5109-2019; Maarsingh, Otto/AAD-1553-2022	van der Wouden, Johannes C/0000-0001-6639-6050; Essery, Rosie/0000-0002-2702-6951; Maarsingh, Otto/0000-0002-3747-9217; Yardley, Lucy/0000-0002-3853-883X	Netherlands Organisation for Health Research and Development (ZonMw) [839110015]	Netherlands Organisation for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development)	This study was funded by the Netherlands Organisation for Health Research and Development (ZonMw) (programme Quality in health care; grant No 839110015). The sponsors did not participate in the study design; data collection, analysis, and interpretation; or the preparation or submission of this report.	Andersson G, 2016, ANNU REV CLIN PSYCHO, V12, P157, DOI 10.1146/annurev-clinpsy-021815-093006; [Anonymous], 2017, SUMM DUTCH COLL GEN; [Anonymous], 2011, NAT I HLTH CAR EXC N; Bhattacharyya N, 2017, OTOLARYNG HEAD NECK, V156, pS1, DOI 10.1177/0194599816689667; Bigelow RT, 2016, J NEUROL NEUROSUR PS, V87, P367, DOI 10.1136/jnnp-2015-310319; Bisdorff A, 2016, HAND CLINIC, V137, P83, DOI 10.1016/B978-0-444-63437-5.00006-6; Bisdorff A, 2009, J VESTIBUL RES-EQUIL, V19, P1, DOI 10.3233/VES-2009-0343; Bisdorff AR, 2015, NEUROL CLIN, V33, P541, DOI 10.1016/j.ncl.2015.04.010; Bosner S, 2018, BMC FAM PRACT, V19, DOI 10.1186/s12875-017-0695-0; Boutron I, 2017, ANN INTERN MED, V167, P40, DOI 10.7326/M17-0046; Brandt T, 2000, J NEUROL, V247, P491, DOI 10.1007/s004150070146; de Moraes SA, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-4; Dros J, 2012, J AM GERIATR SOC, V60, P2263, DOI 10.1111/jgs.12031; Dunlap PM, 2019, CURR OPIN NEUROL, V32, P137, DOI 10.1097/WCO.0000000000000632; Essery R, 2017, PSYCHOL HEALTH, V32, P1327, DOI 10.1080/08870446.2017.1310861; Essery R, 2015, AM J AUDIOL, V24, P276, DOI 10.1044/2015_AJA-14-0081; Fong E, 2015, ARCH PHYS MED REHAB, V96, P357, DOI 10.1016/j.apmr.2014.09.017; Gassmann KG, 2009, J NUTR HEALTH AGING, V13, P278, DOI 10.1007/s12603-009-0073-2; Geraghty AWA, 2017, ANN FAM MED, V15, P209, DOI 10.1370/afm.2070; Geraghty AWA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005871; Hall CD, 2016, J NEUROL PHYS THER, V40, P124, DOI 10.1097/NPT.0000000000000120; Hanley K, 2002, BRIT J GEN PRACT, V52, P809; Heber E, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.5774; Herdman SJ, 2012, NEUROREHAB NEURAL RE, V26, P151, DOI 10.1177/1545968311407514; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Jayarajan V, 2003, J LARYNGOL OTOL, V117, P599, DOI 10.1258/002221503768199915; Jonsson R, 2004, J VESTIBUL RES-EQUIL, V14, P47; Kirby S, 2014, DISABIL REHABIL, V36, P1924, DOI 10.3109/09638288.2013.876106; Kloek C, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.8108; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lacour M, 2016, J NEUROL, V263, pS54, DOI 10.1007/s00415-015-7903-4; Lacour M, 2015, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00285; Maarsingh OR, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-133; Maarsingh OR, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-2; MacDowell SG, 2017, J VESTIBUL RES-EQUIL, V27, P295, DOI 10.3233/VES-170627; McDonnell MN, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005397.pub4; Meli A, 2007, J PSYCHOSOM RES, V63, P185, DOI 10.1016/j.jpsychores.2007.02.007; Moller UO, 2013, ARCH GERONTOL GERIAT, V56, P160, DOI 10.1016/j.archger.2012.08.013; Neuhauser HK, 2016, HAND CLINIC, V137, P67, DOI 10.1016/B978-0-444-63437-5.00005-4; Neuhauser HK, 2009, SEMIN NEUROL, V29, P473, DOI 10.1055/s-0029-1241043; Olthuis JV, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011565.pub2; Porciuncula F, 2012, J VESTIBUL RES-EQUIL, V22, P283, DOI 10.3233/VES-120464; Richards D, 2012, CLIN PSYCHOL REV, V32, P329, DOI 10.1016/j.cpr.2012.02.004; Sloane P D, 1994, J Am Board Fam Pract, V7, P1; Sloane PD, 2001, ANN INTERN MED, V134, P823, DOI 10.7326/0003-4819-134-9_Part_2-200105011-00005; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Stam H, 2018, ANN FAM MED, V16, P428, DOI 10.1370/afm.2289; Stam H, 2016, SCAND J PRIM HEALTH, V34, P165, DOI 10.3109/02813432.2016.1160634; Strupp M, 1998, NEUROLOGY, V51, P838, DOI 10.1212/WNL.51.3.838; Tehrani ASS, 2013, ACAD EMERG MED, V20, P689, DOI 10.1111/acem.12168; Tinetti ME, 2000, ANN INTERN MED, V132, P337, DOI 10.7326/0003-4819-132-5-200003070-00002; Twisk J, 2018, CONT CLIN TRIAL COMM, V10, P80, DOI 10.1016/j.conctc.2018.03.008; Twisk J, 2013, J CLIN EPIDEMIOL, V66, P1022, DOI 10.1016/j.jclinepi.2013.03.017; van Ballegooijen W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100674; van der Vaart R, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0355-z; van Vugt VA, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3727; Vugt VA, 2017, SCAND J PRIM HEALTH, V35, P19, DOI 10.1080/02813432.2017.1288683; van Vugt VA, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015479; Walker A, 2018, DISABIL REHABIL, V40, P829, DOI 10.1080/09638288.2016.1277393; Wilhelmsen K, 2009, BMC EAR NOSE THROAT, V9, DOI 10.1186/1472-6815-9-2; Wilhelmsen K, 2008, BMC EAR NOSE THROAT, V8, DOI 10.1186/1472-6815-8-2; Wilhelmsen M, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-296; YARDLEY L, 1992, J PSYCHOSOM RES, V36, P731, DOI 10.1016/0022-3999(92)90131-K; Yardley L, 2004, ANN INTERN MED, V141, P598, DOI 10.7326/0003-4819-141-8-200410190-00007; Yardley L, 1998, BRIT J GEN PRACT, V48, P1136; Yardley L, 2006, PSYCHOSOM MED, V68, P762, DOI 10.1097/01.psy.0000232269.17906.92; Yardley L, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4055; Yardley L, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2237; Zwarenstein M, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2390	70	27	28	3	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	2019	367								l5922	10.1136/bmj.l5922	http://dx.doi.org/10.1136/bmj.l5922			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JP3PI	31690561	Green Accepted, Green Published, hybrid			2023-01-03	WOS:000498179100002
J	Drew, L				Drew, Liam			A tale of two drugs	NATURE			English	Editorial Material																		Aartsma-Rus A, 2002, NEUROMUSCULAR DISORD, V12, pS71, DOI 10.1016/S0960-8966(02)00086-X	1	2	2	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	2019	574	7778					S16	S18		10.1038/d41586-019-03075-5	http://dx.doi.org/10.1038/d41586-019-03075-5			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JE9DI	31619800				2023-01-03	WOS:000490988300023
J	Wang, C; Vegna, S; Jin, HJ; Benedict, B; Lieftink, C; Ramirez, C; de Oliveira, RL; Morris, B; Gadiot, J; Wang, W; du Chatinier, A; Wang, LQ; Gao, DM; Evers, B; Jin, GZ; Xue, Z; Schepers, A; Jochems, F; Sanchez, AM; Mainardi, S; te Riele, H; Beijersbergen, RL; Qin, WX; Akkari, L; Bernards, R				Wang, Cun; Vegna, Serena; Jin, Haojie; Benedict, Bente; Lieftink, Cor; Ramirez, Christel; de Oliveira, Rodrigo Leite; Morris, Ben; Gadiot, Jules; Wang, Wei; du Chatinier, Aimee; Wang, Liqin; Gao, Dongmei; Evers, Bastiaan; Jin, Guangzhi; Xue, Zheng; Schepers, Arnout; Jochems, Fleur; Sanchez, Antonio Mulero; Mainardi, Sara; te Riele, Hein; Beijersbergen, Roderick L.; Qin, Wenxin; Akkari, Leila; Bernards, Rene			Inducing and exploiting vulnerabilities for the treatment of liver cancer	NATURE			English	Article							SENESCENCE; DISTINCT; KINASE; TARGET	Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies(1,2); broad-spectrum kinase inhibitors such as sorafenib provide only a modest benefit to patients with hepatocellular carcinoma(3). The induction of senescence may represent a strategy for the treatment of cancer, especially when combined with a second drug that selectively eliminates senescent cancer cells (senolysis)(4,5). Here, using a kinome-focused genetic screen, we show that pharmacological inhibition of the DNA-replication kinase CDC7 induces senescence selectively in liver cancer cells with mutations in TP53. A follow-up chemical screen identified the antidepressant sertraline as an agent that kills hepatocellular carcinoma cells that have been rendered senescent by inhibition of CDC7. Sertraline suppressed mTOR signalling, and selective drugs that target this pathway were highly effective in causing the apoptotic cell death of hepatocellular carcinoma cells treated with a CDC7 inhibitor. The feedback reactivation of mTOR signalling after its inhibition(6) is blocked in cells that have been treated with a CDC7 inhibitor, which leads to the sustained inhibition of mTOR and cell death. Using multiple in vivo mouse models of liver cancer, we show that treatment with combined inhibition of of CDC7 and mTOR results in a marked reduction of tumour growth. Our data indicate that exploiting an induced vulnerability could be an effective treatment for liver cancer.	[Wang, Cun; Jin, Haojie; Qin, Wenxin] Shanghai Jiao Tong Univ, Renji Hosp, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst,Sch Med, Shanghai, Peoples R China; [Wang, Cun; Jin, Haojie; Lieftink, Cor; de Oliveira, Rodrigo Leite; Morris, Ben; du Chatinier, Aimee; Wang, Liqin; Evers, Bastiaan; Xue, Zheng; Schepers, Arnout; Jochems, Fleur; Sanchez, Antonio Mulero; Mainardi, Sara; Beijersbergen, Roderick L.; Bernards, Rene] Netherlands Canc Inst, Div Mol Carcinogenesis, Oncode Inst, Amsterdam, Netherlands; [Vegna, Serena; Benedict, Bente; Ramirez, Christel; Gadiot, Jules; te Riele, Hein; Akkari, Leila] Netherlands Canc Inst, Div Tumour Biol & Immunol, Oncode Inst, Amsterdam, Netherlands; [Wang, Wei] Netherlands Canc Inst, Div Cell Biol, Amsterdam, Netherlands; [Gao, Dongmei] Fudan Univ, Zhongshan Hosp, Key Lab Carcinogenesis & Canc Invas, Liver Canc Inst,Minist Educ, Shanghai, Peoples R China; [Jin, Guangzhi] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Pathol, Shanghai, Peoples R China	Shanghai Jiao Tong University; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Fudan University; Naval Medical University	Qin, WX (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst,Sch Med, Shanghai, Peoples R China.; Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Oncode Inst, Amsterdam, Netherlands.; Akkari, L (corresponding author), Netherlands Canc Inst, Div Tumour Biol & Immunol, Oncode Inst, Amsterdam, Netherlands.	wxqin@sjtu.edu.cn; l.akkari@nki.nl; r.bernards@nki.nl		Wang, Wei/0000-0003-4869-6716; Mulero Sanchez, Antonio/0000-0003-1668-7022; Wang, Liqin/0000-0002-9881-6432; Benedict, Bente/0000-0002-7503-8527; Akkari, Leila/0000-0001-5479-641X	European Research Council (ERC) [787925]; Dutch Cancer Society through the Oncode Institute [KWF 12049/2018-2, 6702/2014]; Center for Cancer Genomics (CGC); National Basic Research Program of China (973 Program) [2015CB553905]; National Key Sci-Tech Special Projects of Infectious Diseases of China [2018ZX10732202-002-003]; National Natural Science Foundation of China [81920108025, 81421001, 81672933, 81874229]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20181703]; Shanghai Municipal Commission of Health and Family Planning [2017YQ064, 2018YQ20]; Shanghai Rising-Star Program [18QA1403900]	European Research Council (ERC)(European Research Council (ERC)); Dutch Cancer Society through the Oncode Institute; Center for Cancer Genomics (CGC); National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Key Sci-Tech Special Projects of Infectious Diseases of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; Shanghai Municipal Commission of Health and Family Planning; Shanghai Rising-Star Program	We thank L. Zender, R. Smits, X. Qiao and L. Li for the kind gift of cell lines. This work was funded by grants from the European Research Council (ERC 787925 to R.B.), the Dutch Cancer Society (KWF 12049/2018-2 to L.A., 6702/2014 to B.B. and H.t.R) through the Oncode Institute and the Center for Cancer Genomics (CGC: http://cancergenomics.nl), the National Basic Research Program of China (973 Program: 2015CB553905), the National Key Sci-Tech Special Projects of Infectious Diseases of China (2018ZX10732202-002-003), the National Natural Science Foundation of China (81920108025, 81421001, 81672933, and 81874229), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20181703), Shanghai Municipal Commission of Health and Family Planning (2017YQ064 and 2018YQ20) and Shanghai Rising-Star Program (18QA1403900). We thank the facilities of Netherlands Cancer Institute: Animal Laboratory, Mouse Clinic Imaging Unit, Experimental Animal Pathology, Flow Cytometry, Sequencing and BioImaging.	Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010; Dauch D, 2016, NAT MED, V22, P744, DOI 10.1038/nm.4107; Eggert T, 2016, CANCER CELL, V30, P533, DOI 10.1016/j.ccell.2016.09.003; Evers B, 2016, NAT BIOTECHNOL, V34, P631, DOI 10.1038/nbt.3536; Faget DV, 2019, NAT REV CANCER, V19, P439, DOI 10.1038/s41568-019-0156-2; Flynn MJ, 2019, HEPATOLOGY, V69, P2258, DOI 10.1002/hep.30337; Fortanet JG, 2016, J MED CHEM, V59, P7773, DOI 10.1021/acs.jmedchem.6b00680; Fridman AL, 2008, ONCOGENE, V27, P5975, DOI 10.1038/onc.2008.213; Georgilis A, 2018, CANCER CELL, V34, P85, DOI 10.1016/j.ccell.2018.06.007; Keng VW, 2009, NAT BIOTECHNOL, V27, P264, DOI 10.1038/nbt.1526; Koelzer VH, 2018, HISTOPATHOLOGY, V73, P397, DOI 10.1111/his.13528; Koltun ES, 2012, BIOORG MED CHEM LETT, V22, P3727, DOI 10.1016/j.bmcl.2012.04.024; Lin CJ, 2010, CANCER RES, V70, P3199, DOI 10.1158/0008-5472.CAN-09-4072; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.19, 10.1038/nrdp.2016.18]; Milanovic M, 2018, NATURE, V553, P96, DOI 10.1038/nature25167; Montagnoli A, 2010, CLIN CANCER RES, V16, P4503, DOI 10.1158/1078-0432.CCR-10-0185; Ogrodnik M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15691; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085; Sieben CJ, 2018, TRENDS CELL BIOL, V28, P723, DOI 10.1016/j.tcb.2018.04.006; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Wang C, 2018, CELL RES, V28, P690, DOI 10.1038/s41422-018-0020-z; Wang LQ, 2017, CELL REP, V21, P773, DOI 10.1016/j.celrep.2017.09.085; Zucman-Rossi J, 2015, GASTROENTEROLOGY, V149, P1226, DOI 10.1053/j.gastro.2015.05.061	28	153	158	14	138	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 10	2019	574	7777					268	+		10.1038/s41586-019-1607-3	http://dx.doi.org/10.1038/s41586-019-1607-3			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD2DB	31578521	Green Accepted			2023-01-03	WOS:000489784200052
J	Li, MD; Hung, A; Lenon, GB; Yang, AWH				Li, Mingdi; Hung, Andrew; Lenon, George Binh; Yang, Angela Wei Hong			Chinese herbal formulae for the treatment of menopausal hot flushes: A systematic review and meta-analysis	PLOS ONE			English	Review							PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; ER-XIAN DECOCTION; POSTMENOPAUSAL WOMEN; DOUBLE-BLIND; HORMONE-THERAPY; MEDICINAL HERBS; POSITION STATEMENT; VASOMOTOR SYMPTOMS; CLINICAL-TRIAL	Objectives This systematic review aimed to evaluate the therapeutic effects and safety of Chinese herbal medicine (CHM) formulae for managing menopausal hot flushes (MHF). Methods Seven English and Chinese databases were searched for studies from respective inceptions to February 2019. Randomized controlled trials investigating the clinical effects and safety of CHM formulae on MHF were considered for inclusion. The outcomes of subjective feelings (MHF and quality of life), objective changes (hormones and peripheral blood flow) and safety were analyzed. The most frequently prescribed formulae and herbs were summarized. Results Nineteen randomized clinical trials involving 2469 patients were included. When compared to menopausal hormone therapy, CHM had similar effects to menopausal hormone therapy on total effectiveness rate (OR 1.41, 95% CI 0.84 to 2.35) and total Kupperman index (KI) score (SMD -0.13, 95% CI -0.61 to 0.36), and could significantly reduce vasomotor symptom score (MD -0.43, 95% CI -0.55 to -0.31) and upper-body peripheral blood flow (MD -3.56, 95% CI -5.14 to -1.98 under the jaw, MD -7.10, 95% CI -11.01 to -3.19 in the fingertip). When compared to placebo, CHM could reduce MHF severity (MD -0.70, 95% CI-1.00 to -0.40) and improve total KI score (MD -12.61, 95% CI -15.21 to -10.01). However, no statistically significant changes to hormone levels were detected. Most commonly seen adverse events were mild gastrointestinal tract reactions. The most popularly studied formula was Kun Tai capsule and the most frequently prescribed herb was Bai shao (Paeoniae Radix Alba, Paeonia lactiflora Pall.). More than 50% included studies had low risks of bias in the domains of selection, performance, attrition and reporting. Conclusions This review indicated that CHM formulae were safe to be applied in MHF females and able to improve MHF-related symptom scores as well as the peripheral blood flow. Further studies should focus on specific formulae.	[Li, Mingdi; Lenon, George Binh; Yang, Angela Wei Hong] RMIT Univ, Sch Hlth & Biomed Sci, Bundoora, Vic, Australia; [Hung, Andrew] RMIT Univ, Sch Sci, Melbourne, Vic, Australia	Royal Melbourne Institute of Technology (RMIT); Royal Melbourne Institute of Technology (RMIT)	Yang, AWH (corresponding author), RMIT Univ, Sch Hlth & Biomed Sci, Bundoora, Vic, Australia.	angela.yang@rmit.edu.au		Yang, Angela/0000-0001-9345-4607; Hung, Andrew/0000-0003-3569-2951; Li, Mingdi/0000-0002-5329-4562				Avis NE, 2009, MENOPAUSE, V16, P860, DOI 10.1097/gme.0b013e3181a3cdaf; Azizi H, 2011, ALTERN THER HEALTH M, V17, P48; Bair YA, 2008, MENOPAUSE, V15, P32, DOI 10.1097/gme.0b013e31813429d6; Berek J. S., 2012, BEREK NOVAKS GYNECOL; Carpenter J, 2015, MENOPAUSE, V22, P1155, DOI 10.1097/GME.0000000000000546; Chen HY, 2008, AM J CHINESE MED, V36, P233, DOI 10.1142/S0192415X08005746; Chen HL, 2014, CHINA PHARM, V23, P108; Chen JT, 2003, MATURITAS, V45, P199, DOI 10.1016/S0378-5122(03)00128-2; Cochrane Collaboration, 2014, REV MAN REVMAN VERS; Davis SR, 2001, MED J AUSTRALIA, V174, P68, DOI 10.5694/j.1326-5377.2001.tb143156.x; Fragkos Konstantinos C, 2014, Int Sch Res Notices, V2014, P825383, DOI 10.1155/2014/825383; Fu LH, 2015, WORLD J INTEGRATED T, P89; Fu SF, 2016, MENOPAUSE, V23, P311, DOI 10.1097/GME.0000000000000534; Grady Deborah, 2005, Am J Med, V118 Suppl 12B, P163, DOI 10.1016/j.amjmed.2005.09.051; Grady D, 2009, MENOPAUSE, V16, P458, DOI 10.1097/gme.0b013e31818e64dd; Haines CJ, 2008, CLIMACTERIC, V11, P244, DOI 10.1080/13697130802073029; Hao Qingxiu, 2009, Zhongguo Zhong Yao Za Zhi, V34, P620; Holm ACES, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/579321; Hunter MS, 2012, BJOG-INT J OBSTET GY, V119, P40, DOI 10.1111/j.1471-0528.2011.03166.x; HUNTER MS, 1995, BRIT J CLIN PSYCHOL, V34, P589, DOI 10.1111/j.2044-8260.1995.tb01493.x; Lee SH, 2004, J NUTR BIOCHEM, V15, P452, DOI 10.1016/j.jnutbio.2004.01.007; Li HY, 2018, HEBEI MED J, V40, P3610; Li YQ, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/1327251; Liu XY., 2008, GUIDING J TRADITIONA, V14, P47; [栾燕秋 Luan Yanqiu], 2004, [中国临床药理学杂志, The Chinese Journal of Clinical Pharmacology], V20, P452; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; National Guideline Clearinghouse, 2015, MEN DIAGN MAN; Nedeljkovic M, 2014, MENOPAUSE, V21, P15, DOI [10.1097/GME.0b013e31829374e8, 10.1097/gme.0b013e31829374e8]; Pinkerton JV, 2017, MENOPAUSE, V24, P728, DOI 10.1097/GME.0000000000000921; Plotnikoff GA, 2011, MENOPAUSE, V18, P886, DOI 10.1097/gme.0b013e31821643d9; Scheid V, 2010, MATURITAS, V66, P111, DOI 10.1016/j.maturitas.2009.11.020; Shams T, 2014, J GEN INTERN MED, V29, P204, DOI 10.1007/s11606-013-2535-9; Smith RL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155079; Sturdee DW, 2017, CLIMACTERIC, V20, P296, DOI 10.1080/13697137.2017.1306507; Sun AJ, 2018, CHIN J INTEGR MED, V24, P487, DOI 10.1007/s11655-016-2266-y; Suurmond R, 2017, RES SYNTH METHODS, V8, P537, DOI 10.1002/jrsm.1260; Ushiroyama T, 2005, AM J CHINESE MED, V33, P259, DOI 10.1142/S0192415X05002813; van der Sluijs CP, 2009, MENOPAUSE, V16, P336, DOI 10.1097/gme.0b013e3181883dc1; Xia Y, 2012, MENOPAUSE, V19, P234, DOI 10.1097/gme.0b013e3182273177; Xu H, 2012, J ETHNOPHARMACOL, V143, P109, DOI 10.1016/j.jep.2012.06.009; Xu LW, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/568106; Zhao Pi-Wen, 2007, Zhongguo Zhong Yao Za Zhi, V32, P436; Zhong LLD, 2013, MENOPAUSE, V20, P767, DOI [10.1097/gme.0b013e31827cd3dd, 10.1097/GME.0b013e31827cd3dd]; Zhou J, 2007, EXPLORE-NY, V3, P478, DOI 10.1016/j.explore.2007.06.002; Zhou YJ, 2016, JIANGXI MED J, V51, P170	46	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2019	14	9							e0222383	10.1371/journal.pone.0222383	http://dx.doi.org/10.1371/journal.pone.0222383			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM5BF	31536531	Green Published, Green Submitted, gold			2023-01-03	WOS:000532262800040
J	Shen, SP; Liu, YF; Qiu, H; Tsai, KY; Wu, HC; Liang, WM; Shu, M; Chou, FHC				Shen, Shih-Pei; Liu, Yanfang; Qiu, Hong; Tsai, Kuan-Yi; Wu, Hung-Chi; Liang, Wen-Miin; Shu, Meng; Chou, Frank Huang-Chih			The risk of bone fracture after long-term risperidone exposure is not increased compared to other atypical antipsychotics: A retrospective cohort study	PLOS ONE			English	Article							HIP FRACTURE; PROLACTIN LEVELS; MINERAL DENSITY; SERUM PROLACTIN; BREAST-CANCER; SCHIZOPHRENIA	Objective Antipsychotic agents can increase circulating serum prolactin levels, potentially leading to osteoporosis and increased risk of bone fracture. The risk appears to be lower for atypical antipsychotics. We investigated whether risperidone was associated with an increased fracture risk by estimating the incidence of hip/femur and non-hip/femur fractures in users of risperidone, other atypical, and typical antipsychotics. Methods This retrospective cohort study with a nested case-control study used claims data from the Taiwan National Healthcare Insurance database. All new users of antipsychotics between 2000-2012 were included. Incident fractures were identified using ICD-9 codes from inpatient records. Cox proportional hazards models compared fracture incidence among exposure groups. Conditional logistic regression models compared antipsychotic exposure among fracture cases versus matched controls. Results 340,948 patients were included in the analysis. There were 2832 hip/femur fractures and 2693 non-hip/femur fractures: Hip/femur fracture incidence 636.8/100,000 person-years (Risperidone), 885.7/100,000 person-years (Other Atypical), 519.4/100,000 person-years (Typical). The adjusted hazard ratio of hip/femur fracture was 0.92 (95%CI 0.84-1.01) comparing Other Atypical with Risperidone, and 1.00 (95%CI 0.89-1.11) comparing Typical with Risperidone. The adjusted hazard ratio of non-hip/femur fracture was 1.08 (95%CI 0.981.20) for Other Atypical versus Risperidone, and 1.10 (95%CI 0.99-1.22) for Typical versus Risperidone. The adjusted odds ratio for hip/femur fractures was 0.92 (95% CI 0.83-1.01) in cases and controls exposed to other atypical antipsychotics compared with risperidone for 1 year prior to fracture date, 0.97 (95% CI 0.87-1.07) during 1-3 years, and 0.92 (95% CI 0.81-1.06) during 3-5 years prior to fracture date. The adjusted odds ratio for non-hip/femur fractures were 1.11 (95% CI 0.99-1.24), 1.02 (95% CI 0.0.91-1.14), and 0.95 (95% CI 0.82-1.09), respectively. Conclusion There was no increased risk of bone fracture in long-term users of risperidone compared to users of other atypical antipsychotics.	[Shen, Shih-Pei] China Med Univ, Dept Publ Hlth, Taichung, Taiwan; [Liu, Yanfang; Qiu, Hong] Janssen Res & Dev LLC, Global Epidemiol, Titusville, NJ USA; [Tsai, Kuan-Yi; Wu, Hung-Chi; Chou, Frank Huang-Chih] Kai Syuan Psychiat Hosp, Dept Community Psychiat, Kaohsiung, Taiwan; [Liang, Wen-Miin] China Med Univ, Dept Hlth Serv Adm, Taichung, Taiwan; [Shu, Meng] Janssen China R&D Ctr, Shanghai, Peoples R China	China Medical University Taiwan; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; China Medical University Taiwan	Chou, FHC (corresponding author), Kai Syuan Psychiat Hosp, Dept Community Psychiat, Kaohsiung, Taiwan.	f50911.tw@yahoo.com.tw	liu, yan/HGV-1365-2022; liu, yan/HCI-5542-2022		Janssen Research & Development, LLC (Titusville, New Jersey, United States); Janssen Research and Development	Janssen Research & Development, LLC (Titusville, New Jersey, United States); Janssen Research and Development	The study was sponsored by Janssen Research & Development, LLC (Titusville, New Jersey, United States), which manufactures and markets risperidone. The funder provided support in the form of salaries for authors YL, HQ and SM. The sponsor planned the study, developed the protocol and reviewed the manuscript. The creation of the data sets and analysis were conducted independently by the Kaohsiung Municipal KaiSyuan Psychiatric Hospital and National Health Research Institute under contracts with Janssen Research &and Development. Prof Chou, Dr. Wu, Dr.Tsai, Ms. Shen were involved in the study design and methods, statistical analysis and interpretation of the results. The data analysis was conducted under the supervision of the Janssen Epidemiology team. Both Kaohsiung Municipal Kai-Syuan Psychiatric Hospital and National Health Research Institute had completed control over the data.	Abraham G, 2003, AM J PSYCHIAT, V160, P1618, DOI 10.1176/appi.ajp.160.9.1618; Bolton JM, 2008, J CLIN PSYCHOPHARM, V28, P384, DOI 10.1097/JCP.0b013e31817d5943; Bostwick JR, 2009, PHARMACOTHERAPY, V29, P64, DOI 10.1592/phco.29.1.64; Bushe Chris, 2008, J Psychopharmacol, V22, P46, DOI 10.1177/0269881107088435; Chou FHC, 2013, J PSYCHIATR RES, V47, P460, DOI 10.1016/j.jpsychires.2012.12.007; David SR, 2000, CLIN THER, V22, P1085, DOI 10.1016/S0149-2918(00)80086-7; De Hert M, 2016, EXPERT OPIN DRUG SAF, V15, P809, DOI 10.1517/14740338.2016.1167873; Ernst D, NEW WARNING ADDED AN; Guo ZC, 1998, AM J EPIDEMIOL, V148, P887; Halbreich U, 2003, PSYCHONEUROENDOCRINO, V28, P53, DOI 10.1016/S0306-4530(02)00112-9; Howard L, 2007, BRIT J PSYCHIAT, V190, P129, DOI 10.1192/bjp.bp.106.023671; Hugenholtz GWK, 2005, BONE, V37, P864, DOI 10.1016/j.bone.2005.07.005; Jacqmin-Gadda H, 1998, EPIDEMIOLOGY, V9, P417, DOI 10.1097/00001648-199807000-00012; Kishimoto T, 2008, J CLIN PSYCHIAT, V69, P385, DOI 10.4088/JCP.v69n0307; Lai SW, 2013, LIBYAN J MED, V8, DOI 10.3402/ljm.v8i0.20911; Lean M, 2004, INT CLIN PSYCHOPHARM, V19, P31, DOI 10.1097/00004850-200401000-00006; Montero-Odasso M, 2018, J AM GERIATR SOC, V66, P367, DOI 10.1111/jgs.15219; Nurminen J, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-396; O'Keane Veronica, 2008, J Psychopharmacol, V22, P70, DOI 10.1177/0269881107088439; Oderda LH, 2012, ANN PHARMACOTHER, V46, P917, DOI 10.1345/aph.1Q589; Okita K, 2014, SCHIZOPHR RES, V157, P137, DOI 10.1016/j.schres.2014.05.009; Papola D, 2018, INT CLIN PSYCHOPHARM, V33, P181, DOI 10.1097/YIC.0000000000000221; Partti K, 2010, PSYCHOSOM MED, V72, P933, DOI 10.1097/PSY.0b013e3181f7abd3; Rahman T, 2014, AM J PSYCHIAT, V171, P616, DOI 10.1176/appi.ajp.2013.13050650; Reutfors J, 2017, SCHIZOPHR RES, V182, P98, DOI 10.1016/j.schres.2016.10.035; Sorensen HJ, 2013, EUR NEUROPSYCHOPHARM, V23, P872, DOI 10.1016/j.euroneuro.2013.04.002; Tamiya H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129366; Thiese MS, 2014, BIOCHEM MEDICA, V24, P199, DOI 10.11613/BM.2014.022; Tsai KY, 2014, SCHIZOPHR RES, V159, P322, DOI 10.1016/j.schres.2014.09.032; Vestergaard P, 2006, OSTEOPOROSIS INT, V17, P807, DOI 10.1007/s00198-005-0065-y; Walter S, 2009, EUR J EPIDEMIOL, V24, P733, DOI 10.1007/s10654-009-9411-2; Wu CS, 2015, J CLIN PSYCHIAT, V76, P1216, DOI 10.4088/JCP.14m09098; Wu HS, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/167138	33	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 5	2019	14	9							e0221948	10.1371/journal.pone.0221948	http://dx.doi.org/10.1371/journal.pone.0221948			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM2LR	31487309	gold, Green Published, Green Submitted			2023-01-03	WOS:000532084200027
J	Murthy, RK; Loi, S; Okines, A; Paplomata, E; Hamilton, E; Hurvitz, SA; Lin, NU; Borges, V; Abramson, V; Anders, C; Bedard, PL; Oliveira, M; Jakobsen, E; Bachelot, T; Shachar, SS; Muller, V; Braga, S; Duhoux, FP; Greil, R; Cameron, D; Carey, LA; Curigliano, G; Gelmon, K; Hortobagyi, G; Krop, I; Loibl, S; Pegram, M; Slamon, D; Palanca-Wessels, MC; Walker, L; Feng, W; Winer, EP				Murthy, R. K.; Loi, S.; Okines, A.; Paplomata, E.; Hamilton, E.; Hurvitz, S. A.; Lin, N. U.; Borges, V.; Abramson, V.; Anders, C.; Bedard, P. L.; Oliveira, M.; Jakobsen, E.; Bachelot, T.; Shachar, S. S.; Mueller, V.; Braga, S.; Duhoux, F. P.; Greil, R.; Cameron, D.; Carey, L. A.; Curigliano, G.; Gelmon, K.; Hortobagyi, G.; Krop, I.; Loibl, S.; Pegram, M.; Slamon, D.; Palanca-Wessels, M. C.; Walker, L.; Feng, W.; Winer, E. P.			Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LAPATINIB PLUS CAPECITABINE; NERVOUS-SYSTEM METASTASES; BRAIN METASTASES; SOLID TUMORS; PHASE-II; PERTUZUMAB; DOCETAXEL; SURVIVAL; TRIAL	(N Engl J Med ;:-). In the Safety subsection of Results (page 8 in the version published online on December 11, 2019), the paragraph beginning "Elevations in the ALT and AST levels" should have ended, "A single patient in the tucatinib-combination group met Hy's law criteria on the basis of ALT, 152 U per liter (4.8 times the upper limit of normal [ULN]); AST, 128 U per liter (3.6xULN); total bilirubin, 2.6 mg per deciliter (2.2xULN); and alkaline phosphatase (ALP), 165 U per liter (1.4xULN). This patient had an adaptive response, with recovery of laboratory values to baseline after dose modification of both tucatinib and . . .	[Murthy, R. K.; Hortobagyi, G.] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 1354, Houston, TX 77030 USA; [Loi, S.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Okines, A.] Royal Marsden NHS Fdn Trust, London, England; [Cameron, D.] Edinburgh Canc Res Ctr, Edinburgh, Midlothian, Scotland; [Paplomata, E.] Winship Canc Inst, Atlanta, GA USA; [Hamilton, E.] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA; [Abramson, V.] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Hurvitz, S. A.; Slamon, D.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Med Ctr, Los Angeles, CA 90024 USA; [Pegram, M.] Stanford Comprehens Canc Inst, Palo Alto, CA USA; [Lin, N. U.; Krop, I.; Winer, E. P.] Dana Farber Canc Inst, 4500 Brookline Ave, Boston, MA 02215 USA; [Borges, V.] Univ Colorado, Ctr Canc, Aurora, CO USA; [Anders, C.] Duke Canc Inst, Durham, NC USA; [Carey, L. A.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA; [Bedard, P. L.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Gelmon, K.] British Columbia Canc, Vancouver, BC, Canada; [Oliveira, M.] Hosp Univ Vall Hebron, Barcelona, Spain; [Jakobsen, E.] Sygehus Lillebaelt Vejle Sygehus, Vejle, Denmark; [Bachelot, T.] Ctr Leon Berard, Lyon, France; [Shachar, S. S.] Rambam Hlth Care Campus, Haifa, Israel; [Mueller, V.] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany; [Loibl, S.] German Breast Grp, Neu Isenburg, Germany; [Braga, S.] Hosp Cuf Descobertas R Mario Botas, Lisbon, Portugal; [Duhoux, F. P.] Clin Univ St Luc, Brussels, Belgium; [Greil, R.] Paracelsus Med Univ Salzburg, Med Dept 3, Salzburg Canc Res Inst, Ctr Clin Canc & Immunol Trials, Salzburg, Austria; [Greil, R.] Canc Cluster Salzburg, Salzburg, Austria; [Curigliano, G.] Univ Milan, IRCCS, Ist Europeo Oncol, Milan, Italy; [Palanca-Wessels, M. C.; Walker, L.; Feng, W.] Seattle Genet, Bothell, WA USA	University of Texas System; UTMD Anderson Cancer Center; Peter Maccallum Cancer Center; Royal Marsden NHS Foundation Trust; University of Edinburgh; Sarah Cannon Research Institute; Tennessee Oncology; Vanderbilt University; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Harvard University; Dana-Farber Cancer Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Hospital Universitari Vall d'Hebron; UNICANCER; Centre Leon Berard; Rambam Health Care Campus; University of Hamburg; University Medical Center Hamburg-Eppendorf; German Breast Group; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Paracelsus Private Medical University; IRCCS European Institute of Oncology (IEO); University of Milan; Seattle Genetics	Murthy, RK (corresponding author), Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 1354, Houston, TX 77030 USA.; Winer, EP (corresponding author), Dana Farber Canc Inst, 4500 Brookline Ave, Boston, MA 02215 USA.	rmurthy1@mdanderson.org; eric_winer@dfci.harvard.edu	Curigliano, Giuseppe/D-3371-2018; Oliveira, Mafalda/I-1695-2015	Curigliano, Giuseppe/0000-0003-1781-2518; Bedard, Philippe/0000-0002-6771-2999; Oliveira, Mafalda/0000-0001-9152-8799	Seattle Genetics	Seattle Genetics	Supported by Seattle Genetics.	Bachelot T, 2013, LANCET ONCOL, V14, P64, DOI 10.1016/S1470-2045(12)70432-1; Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Bendell JC, 2003, CANCER-AM CANCER SOC, V97, P2972, DOI 10.1002/cncr.11436; Brufsky AM, 2011, CLIN CANCER RES, V17, P4834, DOI 10.1158/1078-0432.CCR-10-2962; Cardoso F, 2018, ANN ONCOL, V29, P1634, DOI 10.1093/annonc/mdy192; Cronin KA, 2010, CANCER INVEST, V28, P963, DOI 10.3109/07357907.2010.496759; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Freedman RA, 2019, J CLIN ONCOL, V37, P1081, DOI 10.1200/JCO.18.01511; Giordano SH, 2018, J ONCOL PRACT, V14, P501, DOI 10.1200/JOP.18.00290; Krop IE, 2015, ANN ONCOL, V26, P113, DOI 10.1093/annonc/mdu486; Leyland-Jones B, 2009, J CLIN ONCOL, V27, P5278, DOI 10.1200/JCO.2008.19.8481; Lin N, 2017, J CLIN ONCOL, V35, P3760, DOI DOI 10.1200/JCO.2017.74.0761; Lin NU, 2009, CLIN CANCER RES, V15, P1452, DOI 10.1158/1078-0432.CCR-08-1080; Moulder SL, 2017, CLIN CANCER RES, V23, P3529, DOI 10.1158/1078-0432.CCR-16-1496; Murthy R, 2018, LANCET ONCOL, V19, P880, DOI 10.1016/S1470-2045(18)30256-0; National Comprehensive Cancer Network (NCCN), 2018, CLIN PRACT GUID ONC; NCCN, 2019, CLIN PRACT GUID ONC; Olson EM, 2013, BREAST, V22, P525, DOI 10.1016/j.breast.2012.12.006; Owens Marilyn A, 2004, Clin Breast Cancer, V5, P63, DOI 10.3816/CBC.2004.n.011; Pestalozzi BC, 2013, LANCET ONCOL, V14, P244, DOI 10.1016/S1470-2045(13)70017-2; Pheneger T, 2009, CANCER RES, V69; Pivot X, 2015, J CLIN ONCOL, V33, P1564, DOI 10.1200/JCO.2014.57.1794; Rosenberger W.F., 2016, RANDOMIZATION CLIN T, V2nd ed; RUGO HS, 2019, J CLIN ONCOL S, V37; SAURA C, 2019, J CLIN ONCOL S, V37; Sutherland S, 2010, BRIT J CANCER, V102, P995, DOI 10.1038/sj.bjc.6605586; Swain SM, 2013, LANCET ONCOL, V14, P461, DOI 10.1016/S1470-2045(13)70130-X; Ye YN, 2013, STAT MED, V32, P1112, DOI 10.1002/sim.5700	28	496	507	10	109	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 13	2020	382	7					597	609		10.1056/NEJMoa1914609	http://dx.doi.org/10.1056/NEJMoa1914609			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KO2MG	31825569	Green Published			2023-01-03	WOS:000515383300005
J	Zafalon, RVA; Risolia, LW; Vendramini, THA; Rodrigues, RBA; Pedrinelli, V; Teixeira, FA; Rentas, MF; Perini, MP; Alvarenga, IC; Brunetto, MA				Amorim Zafalon, Rafael Vessecchi; Risolia, Larissa Wunsche; Annibale Vendramini, Thiago Henrique; Ayres Rodrigues, Roberta Bueno; Pedrinelli, Vivian; Teixeira, Fabio Alves; Rentas, Mariana Fragoso; Perini, Mariana Pamplona; Alvarenga, Isabella Corsato; Brunetto, Marcio Antonio			Nutritional inadequacies in commercial vegan foods for dogs and cats	PLOS ONE			English	Article							MESSENGER-RNA EXPRESSION; BONE-MINERAL DENSITY; TAURINE DEFICIENCY; DILATED CARDIOMYOPATHY; SECONDARY HYPERPARATHYROIDISM; PLASMA TAURINE; IN-VITRO; NUTRIENT DIGESTIBILITY; RETINAL DEGENERATION; VEGETARIAN DIETS	The objective of this study was to evaluate the macronutrients composition, fatty acid and amino acid profiles, and essential minerals content of all vegan foods for dogs and cats available in the Brazilian market, and to compare results with FEDIAF (2019) and AAFCO (2019) recommendations. Four vegan pet foods were assessed (three for dogs and one for cats). The comparisons were made in a descriptive manner. All foods met the minimum recommendations for macronutrients. Arachidonic acid was not reported in any food label. Regarding the FEDIAF recommendations, one food for dogs had low calcium, another had low potassium and a third had low sodium. The cat food presented potassium content lower than recommended. The Ca:P ratio did not meet the minimum recommendation of FEDIAF (2019) and AAFCO (2019) in any of the dog's foods analyzed, and the cat food also did not present the minimum recommendation based on FEDIAF (2019). Copper concentrations exceeded the legal limit in all foods. Zinc concentrations exceeded this limit in two foods (one for dogs and one for cats) and iron levels exceeded the legal limit in one dog food. One of the dog foods did not meet the minimum recommendation for methionine and the cat food did not meet the minimum recommendation for arginine. In addition, when the amount of nutrients consumed by animals with low energy requirements was simulated, in addition to the same non-conformities described above, it was observed that the cat food does not meet the minimum recommended of protein and taurine in unit/Kg(0.67). It was concluded that all foods analyzed had one or more nutrients below the recommended levels and some presented zinc and copper excess, therefore, these foods should not be recommended for dogs and cats, because dietary deficiencies found may lead to health risks for dogs and cats. Furthermore, manufacturers should review their formulations to ensure the nutritional adequacy of these foods.	[Amorim Zafalon, Rafael Vessecchi; Risolia, Larissa Wunsche; Annibale Vendramini, Thiago Henrique; Ayres Rodrigues, Roberta Bueno; Pedrinelli, Vivian; Teixeira, Fabio Alves; Rentas, Mariana Fragoso; Perini, Mariana Pamplona; Brunetto, Marcio Antonio] Univ Sao Paulo, Sch Vet Med & Anim Sci, Pirassununga, SP, Brazil; [Alvarenga, Isabella Corsato] Kansas State Univ, Dept Grain Sci & Ind, Manhattan, KS 66506 USA	Universidade de Sao Paulo; Kansas State University	Brunetto, MA (corresponding author), Univ Sao Paulo, Sch Vet Med & Anim Sci, Pirassununga, SP, Brazil.	mabrunetto@usp.br	Brunetto, Marcio/AAQ-9767-2021; Pedrinelli, Vivian/AFG-3190-2022; Pedrinelli, Vivian/AAH-4103-2019; Pedrinelli, Vivian/AAF-1350-2022	Pedrinelli, Vivian/0000-0001-5954-4086; Pedrinelli, Vivian/0000-0001-5954-4086; Alves Teixeira, Fabio/0000-0001-6198-9367; Fragoso Rentas, Mariana/0000-0001-9423-9976; Brunetto, Marcio/0000-0003-3240-0343; , Mariana Pamplona Perini/0000-0001-6071-8565; Vendramini, Thiago/0000-0003-4457-8392				AOAC, 2006, OFFICIAL METHODS ANA; Association of American Feed Control Officials, 2019, 2019 OFF PUBL; BACKUS RC, 1995, J NUTR, V125, P2650; Backus RC, 2003, J AM VET MED ASSOC, V223, P1130, DOI 10.2460/javma.2003.223.1130; BARNETT KC, 1980, J SMALL ANIM PRACT, V21, P521, DOI 10.1111/j.1748-5827.1980.tb01354.x; Bednar GE, 2000, ARCH ANIM NUTR, V53, P127, DOI 10.1080/17450390009381942; Belanger MC, 2005, J AM ANIM HOSP ASSOC, V41, P284, DOI 10.5326/0410284; Chiu JF, 1997, CALCIFIED TISSUE INT, V60, P245, DOI 10.1007/PL00005812; COOK SD, 1983, CLIN ORTHOP RELAT R, P105; Craig WJ, 2009, AM J CLIN NUTR, V89, pS1627, DOI 10.3945/ajcn.2009.26736N; CZARNECKI GL, 1984, J NUTR, V114, P581, DOI 10.1093/jn/114.3.581; Davey GK, 2003, PUBLIC HEALTH NUTR, V6, P259, DOI 10.1079/PHN2002430; de Fomel-Thibaud P, 2007, J AM ANIM HOSP ASSOC, V43, P52, DOI 10.5326/0430052; Dirksen K, 2017, VET CLIN N AM-SMALL, V47, P631, DOI 10.1016/j.cvsm.2016.11.011; Dodd SAS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210806; Fascetti AJ, 2003, J AM VET MED ASSOC, V223, P1137, DOI 10.2460/javma.2003.223.1137; FEDIAF, 2019, NUTR GUID COMPL COMP; Freeman LM, 2018, JAVMA-J AM VET MED A, V253, P1390, DOI 10.2460/javma.253.11.1390; Funaba M, 2002, AM J VET RES, V63, P1247, DOI 10.2460/ajvr.2002.63.1247; Galvao JFD, 2013, J VET EMERG CRIT CAR, V23, P134, DOI 10.1111/vec.12036; Gray CM, 2004, JAVMA-J AM VET MED A, V225, P1670, DOI 10.2460/javma.2004.225.1670; Hayes K C, 1988, Nutr Res Rev, V1, P99, DOI 10.1079/NRR19880009; HAYES KC, 1975, SCIENCE, V188, P949, DOI 10.1126/science.1138364; HAYES KC, 1982, CAN VET J, V23, P2; HICKMAN MA, 1992, J NUTR, V122, P1019, DOI 10.1093/jn/122.4.1019; Hill RC, 2001, J ANIM SCI, V79, P2162; IMAKI H, 1986, DEV NEUROSCI-BASEL, V8, P160, DOI 10.1159/000112251; International Organization for Standardization (ISO), 1978, 5509 ISO; JACOBSON SG, 1987, EXP EYE RES, V45, P481, DOI 10.1016/S0014-4835(87)80059-3; Jaffey J, 2017, J VET INTERN MED, V31, P775; Jaffey JA, 2018, VET J, V236, P31, DOI 10.1016/j.tvjl.2018.04.010; Kanakubo K, 2015, JAVMA-J AM VET MED A, V247, P385, DOI 10.2460/javma.247.4.385; KAWAGUCHI K, 1993, JPN J VET RES, V41, P89; Kienzle E., 2001, COMPENDIUM, V23, P81; KIM SW, 1995, J NUTR, V125, P2831; KIRK CA, 2000, SMALL ANIMAL CLIN NU, P291; Kittleson MD, 1997, J VET INTERN MED, V11, P204, DOI 10.1111/j.1939-1676.1997.tb00092.x; Ko Kwang Suk, 2016, Journal of Animal Science and Technology, V58, P29, DOI 10.1186/s40781-016-0112-6; KRAMER GA, 1995, J VET INTERN MED, V9, P253, DOI 10.1111/j.1939-1676.1995.tb01076.x; Kunakornsawat S, 2004, J STEROID BIOCHEM, V89-90, P409, DOI 10.1016/j.jsbmb.2004.03.009; Kunakornsawat S, 2001, ANTICANCER RES, V21, P3355; Lau EMC, 1998, EUR J CLIN NUTR, V52, P60, DOI 10.1038/sj.ejcn.1600516; Laws EJ, 2018, J SMALL ANIM PRACT, V59, P222, DOI 10.1111/jsap.12791; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Loureiro BA, 2018, P 22 C EUR SOC VET C, P123; MACDONALD ML, 1984, AM J VET RES, V45, P1310; Malone EK, 2010, VET COMP ONCOL, V8, P209, DOI 10.1111/j.1476-5829.2010.00223.x; Montaser A., 1998, INDUCTIVELY COUPLED; MORRIS JG, 1978, SCIENCE, V199, P431, DOI 10.1126/science.619464; MORRIS JG, 1985, J NUTR, V115, P524, DOI 10.1093/jn/115.4.524; Morris JG, 2002, J ANIM PHYSIOL AN N, V86, P229, DOI 10.1046/j.1439-0396.2002.00379.x; Morris JG, 1994, VET CLIN NUTR, V1, P118; Morris JH, 1992, METABOLIC BASIS TAUR, P33; Motlagh BM, 2015, IRAN J BASIC MED SCI, V18, P672; NAP RC, 1994, VET QUART, V16, P50, DOI 10.1080/01652176.1994.9694417; National Research Council, 2006, NUTR REQ DOGS CATS; NEIRINCK K, 1991, J NUTR, V121, pS64, DOI 10.1093/jn/121.suppl_11.S64; NOVOTNY MJ, 1994, CAN J VET RES, V58, P6; Parker VJ, 2017, JAVMA-J AM VET MED A, V250, P1259, DOI 10.2460/javma.250.11.1259; Pawlosky RJ, 1996, J NUTR, V126, pS1081, DOI 10.1093/jn/126.suppl_4.1081S; Pedrinelli V., 2018, ESVCN P 2018, P236; Pion PD, 1998, VET CLIN N AM-SMALL, V28, P1495, DOI 10.1016/S0195-5616(98)50134-9; Pludowski P, 2013, AUTOIMMUN REV, V12, P976, DOI 10.1016/j.autrev.2013.02.004; Rassnick KM, 2008, CANCER CHEMOTH PHARM, V62, P881, DOI 10.1007/s00280-008-0678-x; RENTSCHLER LA, 1986, COMP BIOCHEM PHYS B, V84, P319, DOI 10.1016/0305-0491(86)90084-2; RIVERS JPW, 1975, NATURE, V258, P171, DOI 10.1038/258171a0; Rodriguez-Cortes A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03662-4; ROGERS QR, 1985, J NUTR, V115, P146, DOI 10.1093/jn/115.1.146; Schaffer S, 2016, AMINO ACIDS, V48, P549, DOI 10.1007/s00726-015-2110-2; Schaffer SW, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-S1-S2; Spitze AR, 2003, J ANIM PHYSIOL AN N, V87, P251, DOI 10.1046/j.1439-0396.2003.00434.x; STURMAN JA, 1992, J NUTR, V122, P82, DOI 10.1093/jn/122.1.82; SVANBERG G, 1973, SCAND J DENT RES, V81, P155; Tomsa C, 1999, J SMALL ANIM PRACT, V40, P533, DOI 10.1111/j.1748-5827.1999.tb03015.x; Wakefield LA, 2006, JAVMA-J AM VET MED A, V229, P70, DOI 10.2460/javma.229.1.70; Williams RD, 1935, J BIOL CHEM, V108, P653	76	19	19	15	71	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2020	15	1							e0227046	10.1371/journal.pone.0227046	http://dx.doi.org/10.1371/journal.pone.0227046			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5PU	31951617	gold, Green Published			2023-01-03	WOS:000534370500008
J	Petitprez, F; de Reynies, A; Keung, EZ; Chen, TWW; Sun, CM; Calderaro, J; Jeng, YM; Hsiao, LP; Lacroix, L; Bougouin, A; Moreira, M; Lacroix, G; Natario, I; Adam, J; Lucchesi, C; Laizet, Y; Toulmonde, M; Burgess, MA; Bolejack, V; Reinke, D; Wani, KM; Wang, WL; Lazar, AJ; Roland, CL; Wargo, JA; Italiano, A; Sautes-Fridman, C; Tawbi, HA; Fridman, WH				Petitprez, Florent; de Reynies, Aurelien; Keung, Emily Z.; Chen, Tom Wei-Wu; Sun, Cheng-Ming; Calderaro, Julien; Jeng, Yung-Ming; Hsiao, Li-Ping; Lacroix, Laetitia; Bougouein, Antoine; Moreira, Marco; Lacroix, Guillaume; Natario, Ivo; Adam, Julien; Lucchesi, Carlo; Laizet, Yec'han; Toulmonde, Maud; Burgess, Melissa A.; Bolejack, Vanessa; Reinke, Denise; Wani, Khalid M.; Wang, Wei-Lien; Lazar, Alexander J.; Roland, Christina L.; Wargo, Jennifer A.; Italiano, Antoine; Sautes-Fridman, Catherine; Tawbi, Hussein A.; Fridman, Wolf H.			B cells are associated with survival and immunotherapy response in sarcoma	NATURE			English	Article							TERTIARY LYMPHOID STRUCTURES; SOFT-TISSUE SARCOMA; TUMOR-INFILTRATING LYMPHOCYTES; CHROMOSOME INSTABILITY; OPEN-LABEL; T-CELLS; EXPRESSION; CHECKPOINTS; PROGNOSIS; CARCINOMA	Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50 histological subtypes(1,2). The clinical presentation of patients with different subtypes is often atypical, and responses to therapies such as immune checkpoint blockade vary widely(3,4). To explain this clinical variability, here we study gene expression profiles in 608 tumours across subtypes of soft-tissue sarcoma. We establish an immune-based classification on the basis of the composition of the tumour microenvironment and identify five distinct phenotypes: immune-low (A and B), immune-high (D and E), and highly vascularized (C) groups. In situ analysis of an independent validation cohort shows that class E was characterized by the presence of tertiary lymphoid structures that contain T cells and follicular dendritic cells and are particularly rich in B cells. B cells are the strongest prognostic factor even in the context of high or low CD8(+) T cells and cytotoxic contents. The class-E group demonstrated improved survival and a high response rate to PD1 blockade with pembrolizumab in a phase 2 clinical trial. Together, this work confirms the immune subtypes in patients with soft-tissue sarcoma, and unravels the potential of B-cell-rich tertiary lymphoid structures to guide clinical decision-making and treatments, which could have broader applications in other diseases. Immune profiling of the tumour microenvironment of soft-tissue sarcoma identifies a group of patients with high levels of B-cell infiltration and tertiary lymphoid structures that have improved survival and a high response rate to immune checkpoint blockade therapy.	[Petitprez, Florent; Sun, Cheng-Ming; Calderaro, Julien; Lacroix, Laetitia; Bougouein, Antoine; Moreira, Marco; Lacroix, Guillaume; Natario, Ivo; Sautes-Fridman, Catherine; Fridman, Wolf H.] Univ Paris 05, INSERM, Ctr Rech Cordeliers, Team Canc Immune Control & Escape, Paris, France; [Petitprez, Florent; Sun, Cheng-Ming; Lacroix, Laetitia; Bougouein, Antoine; Moreira, Marco; Lacroix, Guillaume; Natario, Ivo] Univ Paris, Ctr Rech Cordeliers, Sorbonne Paris Cite, Paris, France; [Petitprez, Florent; Sun, Cheng-Ming; Lacroix, Laetitia; Bougouein, Antoine; Moreira, Marco; Lacroix, Guillaume; Natario, Ivo] Sorbonne Univ, Ctr Rech Cordeliers, Paris, France; [Petitprez, Florent; de Reynies, Aurelien] Ligue Natl Canc, Programme Cartes Ident Tumeurs, Paris, France; [Keung, Emily Z.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Chen, Tom Wei-Wu] Natl Taiwan Univ, Grad Inst Oncol, Coll Med, Taipei, Taiwan; [Chen, Tom Wei-Wu] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan; [Chen, Tom Wei-Wu] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan; [Chen, Tom Wei-Wu] Natl Taiwan Univ, Ctr Genom & Precis Med, Taipei, Taiwan; [Calderaro, Julien] Grp Hosp Henri Mondor, AP HP, Dept Pathol, Creteil, France; [Calderaro, Julien] Inst Mondor Rech Biomed, Creteil, France; [Jeng, Yung-Ming] Natl Taiwan Univ, Dept Pathol, Taipei, Taiwan; [Adam, Julien] Gustave Roussy, Dept Biol & Pathol, Villejuif, France; [Lucchesi, Carlo; Laizet, Yec'han; Toulmonde, Maud] Inst Bergonie, Bordeaux, France; [Lucchesi, Carlo; Laizet, Yec'han] Inst Bergonie, Bioinformat Unit, Bordeaux, France; [Toulmonde, Maud] Inst Bergonie, Dept Oncol, Bordeaux, France; [Burgess, Melissa A.] Univ Pittsburgh, Div Hematol Oncol, Dept Med, Pittsburgh, PA USA; [Bolejack, Vanessa] Canc Res & Biostat, Seattle, WA USA; [Reinke, Denise] Sarcoma Alliance Res Collaborat, Ann Arbor, MI USA; [Wani, Khalid M.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Lazar, Alexander J.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Italiano, Antoine] Univ Bordeaux, Bordeaux, France; [Tawbi, Hussein A.] Univ Texas MD Anderson Canc Ctr, Dept Med Oncol, Houston, TX 77030 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; University of Texas System; UTMD Anderson Cancer Center; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); National Taiwan University; UNICANCER; Gustave Roussy; UNICANCER; Institut Bergonie; UNICANCER; Institut Bergonie; UNICANCER; Institut Bergonie; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Cancer Research & Biostatistics; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; UDICE-French Research Universities; Universite de Bordeaux; University of Texas System; UTMD Anderson Cancer Center	Fridman, WH (corresponding author), Univ Paris 05, INSERM, Ctr Rech Cordeliers, Team Canc Immune Control & Escape, Paris, France.; Tawbi, HA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Med Oncol, Houston, TX 77030 USA.	htawbi@mdanderson.org; herve.fridman@crc.jussieu.fr	Sun, Cheng-Ming/G-6505-2018; Petitprez, Florent/AAD-5296-2020	Sun, Cheng-Ming/0000-0002-2392-7701; Petitprez, Florent/0000-0002-5117-6466; Lucchesi, Carlo/0000-0001-6657-2341; fridman, wolf herman/0000-0002-1332-0973; Moreira, Marco/0000-0002-9933-7767; Chen, Tom Wei-Wu/0000-0003-4112-4029; sautes-fridman, catherine/0000-0003-1735-8722	Institut National de la Sante et de la Recherche Medicale; Universite de Paris; Programme Cartes d'Identite des Tumeurs (CIT) from the Ligue Nationale Contre le Cancer; Institut National du Cancer (HTE-INSERM plan cancer) [C16082DS]; Association pour la Recherche sur le Cancer (ARC); Cancer Research for Personalized Medecine programme [CARPEM T8]; French Sarcoma Group; European Connective Tissue Cancer Network (CONTICANET) [FP6-018806]; 'FONCER contre le cancer' programme; Labex Immuno-Oncology [LAXE62_9UMRS972 FRIDMAN]; National Institutes of Health [T32CA0095999]; Moon Shot program at MD Anderson Cancer Center; Ministry of Education, Taiwan [NTU-107L9014]; Ministry of Science and Technology, Taiwan [MOST 107-3017-F-002 -002-]; National Taiwan University [S-01, S-03]; Merck, Inc.; SARC; Sarcoma Foundation of America; QuadW Foundation; CARPEM doctorate fellowship; Paul Calabresi Clinical Oncology Award [K12 CA088084]; Sorbonne University	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Universite de Paris; Programme Cartes d'Identite des Tumeurs (CIT) from the Ligue Nationale Contre le Cancer; Institut National du Cancer (HTE-INSERM plan cancer); Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Cancer Research for Personalized Medecine programme; French Sarcoma Group; European Connective Tissue Cancer Network (CONTICANET); 'FONCER contre le cancer' programme; Labex Immuno-Oncology; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Moon Shot program at MD Anderson Cancer Center; Ministry of Education, Taiwan(Ministry of Education, Taiwan); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); National Taiwan University(National Taiwan University); Merck, Inc.(Merck & Company); SARC; Sarcoma Foundation of America; QuadW Foundation; CARPEM doctorate fellowship; Paul Calabresi Clinical Oncology Award; Sorbonne University	This work was supported by the Institut National de la Sante et de la Recherche Medicale, the Universite de Paris, Sorbonne University, the Programme Cartes d'Identite des Tumeurs (CIT) from the Ligue Nationale Contre le Cancer, grants from Institut National du Cancer (HTE-INSERM plan cancer, C16082DS), Association pour la Recherche sur le Cancer (ARC), Cancer Research for Personalized Medecine programme (CARPEM T8), French Sarcoma Group, the European Connective Tissue Cancer Network (CONTICANET, FP6-018806), 'FONCER contre le cancer' programme, Labex Immuno-Oncology (LAXE62_9UMRS972 FRIDMAN), the National Institutes of Health (E.Z.K. is supported by T32CA0095999) and the Moon Shot program at MD Anderson Cancer Center. Grants from the Ministry of Education (NTU-107L9014) and Ministry of Science and Technology (MOST 107-3017-F-002 -002-), Taiwan and from the National Taiwan University (YongLin Chair Grant S-01 and S-03) also supported this study. SARC028 was jointly funded by Merck, Inc., SARC, Sarcoma Foundation of America, and the QuadW Foundation. F.P. supported by CARPEM doctorate fellowship. C.L.R. is recipient of the Paul Calabresi Clinical Oncology Award (K12 CA088084). The slides stained for immunofluorescence were scanned and analysed at the Centre d'Histologie, d'Imagerie et de Cytometrie (CHIC), Centre de Recherche des Cordeliers UMRS1138 (Paris, France). CHIC is a member of the Sorbonne University Flow Cytometry Network (RECYF). We thank C. Klein, K. Garbin and E. Devevre for their support with the imaging. The Nanostring analysis of the NTUH core cohort was performed by the Plateforme Genomique of the Institut Curie (Paris, France). We thank D. Gentien and E. Henry for their support. We acknowledge the help of H. Yan and B. Singh.	Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Beck AH, 2010, ONCOGENE, V29, P845, DOI 10.1038/onc.2009.381; Bertucci F, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1278100; Beuselinck B, 2015, CLIN CANCER RES, V21, P1329, DOI 10.1158/1078-0432.CCR-14-1128; BURGESS MA, 2019, J CLIN ONCOL S, V37, DOI DOI 10.1200/JCO.2019.37.7_suppl.393; Chibon F, 2010, NAT MED, V16, P781, DOI 10.1038/nm.2174; Coppola D, 2011, AM J PATHOL, V179, P37, DOI 10.1016/j.ajpath.2011.03.007; D'Angelo SP, 2018, LANCET ONCOL, V19, P416, DOI 10.1016/S1470-2045(18)30006-8; D'Angelo SP, 2015, HUM PATHOL, V46, P357, DOI 10.1016/j.humpath.2014.11.001; Dieu-Nosjean MC, 2014, TRENDS IMMUNOL, V35, P571, DOI 10.1016/j.it.2014.09.006; Dorfman DM, 2006, AM J SURG PATHOL, V30, P802, DOI 10.1097/01.pas.0000209855.28282.ce; Fletcher CDM, 2013, WHO CLASSIFICATION T; Gibault L, 2011, J PATHOL, V223, P64, DOI 10.1002/path.2787; Giraldo NA, 2015, CLIN CANCER RES, V21, P3031, DOI 10.1158/1078-0432.CCR-14-2926; Gobble RM, 2011, CANCER RES, V71, P2697, DOI 10.1158/0008-5472.CAN-10-3588; Gu-Trantien C, 2013, J CLIN INVEST, V123, P2873, DOI 10.1172/JCI67428; Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168; Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8; Hennequin A, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1054598; Honda Y, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1253657; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kim J, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0074458, 10.1371/journal.pone.0051986, 10.1371/journal.pone.0060505, 10.1371/journal.pone.0069961]; Kroeger DR, 2016, CLIN CANCER RES, V22, P3005, DOI 10.1158/1078-0432.CCR-15-2762; Lagarde P, 2013, J CLIN ONCOL, V31, P608, DOI 10.1200/JCO.2012.46.0147; Lagarde P, 2012, CLIN CANCER RES, V18, P826, DOI 10.1158/1078-0432.CCR-11-1610; Lazar AJ, 2017, CELL, V171, P950, DOI 10.1016/j.cell.2017.10.014; McCall MN, 2010, BIOSTATISTICS, V11, P242, DOI 10.1093/biostatistics/kxp059; Montfort A, 2017, CLIN CANCER RES, V23, P250, DOI 10.1158/1078-0432.CCR-16-0081; Nielsen JS, 2012, CLIN CANCER RES, V18, P3281, DOI 10.1158/1078-0432.CCR-12-0234; Paydas S, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0807-z; Petitprez F, 2018, CANCER IMMUNOL IMMUN, V67, P981, DOI 10.1007/s00262-017-2058-z; Pollack SM, 2017, CANCER-AM CANCER SOC, V123, P3291, DOI 10.1002/cncr.30726; Posch F, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1378844; Sautes-Fridman C, 2019, NAT REV CANCER, V19, P307, DOI 10.1038/s41568-019-0144-6; Silina K, 2018, CANCER RES, V78, P1308, DOI 10.1158/0008-5472.CAN-17-1987; Sorbye SW, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-5; Sorbye SW, 2012, ONCOIMMUNOLOGY, V1, P75, DOI 10.4161/onci.1.1.17825; Tawbi HA, 2017, LANCET ONCOL, V18, P1493, DOI 10.1016/S1470-2045(17)30624-1; Wouters MCA, 2018, CLIN CANCER RES, V24, P6125, DOI 10.1158/1078-0432.CCR-18-1481	40	675	685	17	141	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN	2020	577	7791					556	+		10.1038/s41586-019-1906-8	http://dx.doi.org/10.1038/s41586-019-1906-8		JAN 2020	24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF4FM	31942077	Green Submitted, hybrid			2023-01-03	WOS:000508287700001
J	Ytterberg, C; Kristensen, HK; Tistad, M; von Koch, L				Ytterberg, Charlotte; Kristensen, Hanne Kaae; Tistad, Malin; von Koch, Lena			Factors related to met needs for rehabilitation 6 years after stroke	PLOS ONE			English	Article							SHARED DECISION-MAKING; TERM UNMET NEEDS; LIFE SATISFACTION; CARE; IMPACT; SELF; SURVIVORS; CONSEQUENCES; EXPERIENCES; DEMANDS	Introduction Research on stroke rehabilitation mainly concerns the first year of recovery, and there is a lack of knowledge regarding long-term rehabilitation needs and associated factors. Aim The aim was to explore the perceived needs for rehabilitation services of people six years after stroke and factors associated with having rehabilitation services needs met. Methods The study was a 6-year follow up of a prospective study on the rehabilitation process after stroke. Data on perceived needs for rehabilitation, personal factors, disease specific factors, and patient-reported disability were collected through face-to-face interviews in the participants' homes. Logistic regression models were created to explore associations between having rehabilitation services needs met in 11 problem areas (dependent variable) and the independent variables: involvement in decisions regarding care and treatment, sex, age, sense of coherence, self-defined level of private financing, stroke severity, frequency of social everyday activities, perceived impact of stroke, and life satisfaction. Results The 121 participants had a mean age of 63 years at stroke onset and 58% were men. In all problem areas the majority (53-88%) reported having needs met at six years after stroke, however 47% reported unmet needs regarding fatigue and 45% regarding mobility. A lower perceived impact on participation was found to be associated with having rehabilitation services needs met in seven problem areas: mobility, falls, pain, fatigue, concentration, memory, and sight. The strongest association for having needs met was found for the independent variable, involvement in care and treatment, within the three problem areas mobility, falls, and speaking. Conclusion In a long-term perspective, there were several modifiable factors associated with having rehabilitation services needs met. The most prominent were perceived involvement in care and treatment, and perceived participation. These factors had a stronger association with having rehabilitation services needs met than disease specific factors six years after stroke.	[Ytterberg, Charlotte; Tistad, Malin; von Koch, Lena] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Huddinge, Sweden; [Ytterberg, Charlotte; von Koch, Lena] Karolinska Univ Hosp, Huddinge, Sweden; [Ytterberg, Charlotte; Kristensen, Hanne Kaae] Univ Southern Denmark, Inst Clin Res, Res Unit Rehabil, Odense, Denmark; [Kristensen, Hanne Kaae] Univ Coll Lillebaelt, Hlth Sci Res Ctr, Odense, Denmark; [Tistad, Malin] Dalarna Univ, Sch Educ Hlth & Social Studies, Falun, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of Southern Denmark; Dalarna University	Ytterberg, C (corresponding author), Karolinska Inst, Dept Neurobiol Care Sci & Soc, Huddinge, Sweden.; Ytterberg, C (corresponding author), Karolinska Univ Hosp, Huddinge, Sweden.; Ytterberg, C (corresponding author), Univ Southern Denmark, Inst Clin Res, Res Unit Rehabil, Odense, Denmark.	charlotte.ytterberg@ki.se	von Koch, Lena/P-2310-2018	von Koch, Lena/0000-0002-8560-3016; Kristensen, Hanne Kaae/0000-0002-9596-5571; Ytterberg, Charlotte/0000-0003-3704-8887	Swedish Research Council [20073087, 2013-2806]; Stockholms Lans Landsting [2006-0700]; Swedish Stroke Association; Promobilia Foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); Stockholms Lans Landsting; Swedish Stroke Association; Promobilia Foundation	LvK: Swedish Research Council 20073087 and 2013-2806 http://www.vr.se/, Stockholms Lans Landsting 2006-0700 https://www.sll.se/.CY: Swedish Stroke Association www.strokeforbundet.se/and the Promobilia Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali L., 2017, J CLIN NURS; Andrew NE, 2014, INT J STROKE, V9, P106, DOI 10.1111/ijs.12325; ANTONOVSKY A, 1993, SOC SCI MED, V36, P725, DOI 10.1016/0277-9536(93)90033-Z; Armstrong MJ, 2017, STROKE VASC NEUROL, V2, P84, DOI 10.1136/svn-2017-000081; Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI 10.1161/CIR.0000000000000659; Blomgren C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216822; Brown M, 2014, DISABIL REHABIL, V36, P1020, DOI 10.3109/09638288.2013.825653; Burton CR, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-63; de Port IGLV, 2007, DISABIL REHABIL, V29, P1841, DOI 10.1080/09638280601129157; Dean SG, 2012, INTERPROFESSIONAL RE, P45; Duncan PW, 1999, STROKE, V30, P2131, DOI 10.1161/01.STR.30.10.2131; Dworzynski K, 2015, CLIN MED, V15, P461, DOI 10.7861/clinmedicine.15-5-461; Ekman I, 2011, EUR J CARDIOVASC NUR, V10, P248, DOI 10.1016/j.ejcnurse.2011.06.008; Elf M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161942; Elwyn G, 2012, J GEN INTERN MED, V27, P1361, DOI 10.1007/s11606-012-2077-6; Erikson A, 2016, J REHABIL MED, V48, P847, DOI 10.2340/16501977-2161; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; Govan L, 2009, STROKE, V40, P3396, DOI 10.1161/STROKEAHA.109.557645; Jaracz K, 2014, NEUROL NEUROCHIR POL, V48, P280, DOI 10.1016/j.pjnns.2014.07.004; Kersten P, 2002, DISABIL REHABIL, V24, P860, DOI 10.1080/09638280210142167; Kristensen HK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157149; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Levack WMM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009727.pub2; Lindsay P, 2014, INT J STROKE, V9, P4, DOI 10.1111/ijs.12371; Lund A, 2018, SCAND J OCCUP THER, V25, P127, DOI 10.1080/11038128.2017.1341958; MAHONEY F I, 1965, Md State Med J, V14, P61; McKevitt C, 2011, STROKE, V42, P1398, DOI 10.1161/STROKEAHA.110.598839; Norlander A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149395; Northcott S, 2016, CLIN REHABIL, V30, P811, DOI 10.1177/0269215515602136; Olaiya MT, 2017, NEUROLOGY, V89, P68, DOI 10.1212/WNL.0000000000004063; Pallesen H, 2019, REHABIL RES PRACT, V2019, DOI 10.1155/2019/1726964; Parsons JGM, 2018, DISABIL REHABIL, V40, P309, DOI 10.1080/09638288.2016.1253115; Plant SE, 2016, CLIN REHABIL, V30, P921, DOI 10.1177/0269215516655856; Pollock A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001920.pub3; Pound P, 1999, STROKE, V30, P49, DOI 10.1161/01.STR.30.1.49; Regan EW, 2019, DISABIL HLTH J; Reimer WJMSO, 1999, QUAL HEALTH CARE, V8, P30, DOI 10.1136/qshc.8.1.30; Rose A, 2017, PATIENT EDUC COUNS, V100, P65, DOI 10.1016/j.pec.2016.07.030; Satink T, 2013, ARCH PHYS MED REHAB, V94, P1171, DOI 10.1016/j.apmr.2013.01.011; Sennfalt S, 2019, STROKE, V50, P53, DOI 10.1161/STROKEAHA.118.022913; Shay LA, 2015, MED DECIS MAKING, V35, P114, DOI 10.1177/0272989X14551638; Singam A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144344; Slomic M, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1808-5; Stacey D, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001431.pub5; Susanne P, 2012, J NEUROL SCI, V321, P29, DOI 10.1016/j.jns.2012.07.024; Tistad M, 2013, HEALTH EXPECT, V16, pE24, DOI 10.1111/hex.12095; Tistad M, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-40; Tistad M, 2012, J NEUROL SCI, V313, P160, DOI 10.1016/j.jns.2011.08.038; Ullberg T, 2016, STROKE, V47, P539, DOI 10.1161/STROKEAHA.115.011670; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Verberne DPJ, 2018, NEUROREHAB NEURAL RE, V32, P821, DOI 10.1177/1545968318796341; VIITANEN M, 1988, SCAND J REHABIL MED, V20, P17; Wade D T, 1985, Int Rehabil Med, V7, P176; Wade D, 2016, CLIN REHABIL, V30, P109, DOI 10.1177/0269215515601177; Wolf A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016491; Woodman P, 2014, DISABIL REHABIL, V36, P2031, DOI 10.3109/09638288.2014.887796; World Health Organization, WHO FRAM INT PEOPL C; Wu SM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007030.pub3; Ytterberg C, 2017, J REHABIL MED, V49, P637, DOI 10.2340/16501977-2258	59	5	5	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2020	15	1							e0227867	10.1371/journal.pone.0227867	http://dx.doi.org/10.1371/journal.pone.0227867			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP5OV	31940423	gold, Green Published			2023-01-03	WOS:000534368000105
J	Dong, TT; Guo, M; Zhang, PY; Sun, GG; Chen, B				Dong, Tingting; Guo, Man; Zhang, Peiyue; Sun, Guogang; Chen, Bo			The effects of low-carbohydrate diets on cardiovascular risk factors: A meta-analysis	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; LOW-FAT DIETS; WEIGHT-LOSS; MEDITERRANEAN DIET; OVERWEIGHT; CHOLESTEROL; PREVENTION; EFFICACY; PROTEIN; TRIALS	Background Low-carbohydrate diets are associated with cardiovascular risk factors; however, the results of different studies are inconsistent. Purpose The aim of this meta-analysis was to assess the relationship between low-carbohydrate diets and cardiovascular risk factors. Method Four electronic databases (PubMed, Embase, Medline, and the Cochrane Library) were searched from their inception to November 2018. We collected data from 12 randomized trials on low-carbohydrate diets including total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, and blood pressure levels, as well as weight as the endpoints. The average difference (MD) was used as the index to measure the effect of a low-carbohydrate diet on cardiovascular risk factors with a fixed-effects model or random-effects model. The analysis was further stratified by factors that might affect the results of the intervention. Results From 1292 studies identified in the initial search results, 12 randomized studies were included in the final analysis, which showed that a low-carbohydrate diet was associated with a decrease in triglyceride levels of -0.15mmol/l (95% confidence interval -0.23 to -0.07). Low-carbohydrate diet interventions lasting less than 6 months were associated with a decrease of -0.23mmol/l (95% confidence interval -0.32 to -0.15), while those lasting 12-23 months were associated with a decrease of -0.17mmol/l (95% confidence interval -0.32 to -0.01). The change in the body weight in the observation groups was -1.58kg (95% confidence interval -1.58 to -0.75); with for less than 6 months of intervention,this change was -1.14 kg (95% confidence interval -1.65 to -0.63),and with for 6-11 months of intervention, this change was -1.73kg (95% confidence interval -2.7 to -0.76). The change in the systolic blood pressure of the observation group was -1.41mmHg (95% confidence interval-2.26 to -0.56); the change in diastolic blood pressure was -1.71mmHg (95% confidence interval-2.36 to -1.06); the change in plasma HDL-C levels was 0.1mmHg (95% confidence interval 0.08 to 0.12); and the change in serum total cholesterol was 0.13mmol/l (95% confidence interval 0.08 to 0.19). The plasma LDL-C level increased by 0.11mmol/l (95% confidence interval 0.02 to 0.19), and the fasting blood glucose level changed 0.03mmol/l (95% confidence interval -0.05 to 0.12),which was not significant. Conclusions This meta-analysis confirms that low-carbohydrate diets have a beneficial effect on cardiovascular risk factors but that the long-term effects on cardiovascular risk factors require further research.	[Dong, Tingting; Zhang, Peiyue; Sun, Guogang; Chen, Bo] Southwest Med Univ, Human Anat Histol & Embryol, Luzhou, Peoples R China; [Guo, Man] Southwest Med Univ, Affiliated Hosp, Dept Diabet & Endocrinol, Luzhou, Peoples R China	Southwest Medical University; Southwest Medical University	Chen, B (corresponding author), Southwest Med Univ, Human Anat Histol & Embryol, Luzhou, Peoples R China.	tingtingdoris@163.com			Department of Science and Technology of Sichuan Province-Luzhou city-Luzhou Medical College joint fund [14JC0175]	Department of Science and Technology of Sichuan Province-Luzhou city-Luzhou Medical College joint fund	The work was supported by the Department of Science and Technology of Sichuan Province-Luzhou city-Luzhou Medical College joint fund (14JC0175).	Afilalo J, 2007, HEART, V93, P914, DOI 10.1136/hrt.2006.112508; Appel LJ, 2005, JAMA-J AM MED ASSOC, V294, P2455, DOI 10.1001/jama.294.19.2455; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Barclay AW, 2008, AM J CLIN NUTR, V87, P627, DOI 10.1093/ajcn/87.3.627; Bazzano LA, 2014, ANN INTERN MED, V161, P309, DOI 10.7326/M14-0180; Blaak EE, 2012, OBES REV, V13, P923, DOI 10.1111/j.1467-789X.2012.01011.x; Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480; Bueno NB, 2013, BRIT J NUTR, V110, P1178, DOI 10.1017/S0007114513000548; Chen Z, 2008, 3 NATL RETROSPECTIVE; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; Dehghan M, 2017, LANCET, V390, P2050, DOI [10.1016/s0140-6736(17)32252-3, 10.1016/S0140-6736(17)32252-3]; Elhayany A, 2010, DIABETES OBES METAB, V12, P204, DOI 10.1111/j.1463-1326.2009.01151.x; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Foster GD, 2010, ANN INTERN MED, V153, P147, DOI 10.7326/0003-4819-153-3-201008030-00005; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; Gardner CD, 2007, JAMA-J AM MED ASSOC, V297, P969, DOI 10.1001/jama.297.9.969; Gjuladin-Hellon T, 2019, NUTR REV, V77, P161, DOI 10.1093/nutrit/nuy049; Goff DC, 2006, CIRCULATION, V113, P647, DOI 10.1161/CIRCULATIONAHA.105.552737; Goldstein JL, 2015, CELL, V161, P161, DOI 10.1016/j.cell.2015.01.036; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Hu T, 2012, AM J EPIDEMIOL, V176, pS44, DOI 10.1093/aje/kws264; Kastorini CM, 2011, J AM COLL CARDIOL, V57, P1299, DOI 10.1016/j.jacc.2010.09.073; Krauss RM, 2004, ENDOCRIN METAB CLIN, V33, P405, DOI 10.1016/j.ecl.2004.03.016; Krauss RM, 2006, AM J CLIN NUTR, V83, P1025, DOI 10.1093/ajcn/83.5.1025; KrisEtherton PM, 1997, AM J CLIN NUTR, V65, P560, DOI 10.1093/ajcn/65.2.560; Lagiou P, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4026; Lean MEJ, 1997, EUR J CLIN NUTR, V51, P243, DOI 10.1038/sj.ejcn.1600391; Lim SS, 2010, NUTR METAB CARDIOVAS, V20, P599, DOI 10.1016/j.numecd.2009.05.003; Liu X, 2013, BRIT J NUTR, V110, P1444, DOI 10.1017/S0007114513000640; Meisinger C, 2005, CIRCULATION, V112, P651, DOI 10.1161/CIRCULATIONAHA.104.529297; Morgan LM, 2009, PUBLIC HEALTH NUTR, V12, P799, DOI 10.1017/S1368980008003236; Naude CE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100652; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Rader DJ, 2014, LANCET, V384, P618, DOI 10.1016/S0140-6736(14)61217-4; Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Santos FL, 2012, OBES REV, V13, P1048, DOI 10.1111/j.1467-789X.2012.01021.x; Schwingshackl L, 2013, J ACAD NUTR DIET, V113, P1640, DOI 10.1016/j.jand.2013.07.010; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; Tay J, 2018, DIABETES OBES METAB, V20, P858, DOI 10.1111/dom.13164; Tay J, 2015, AM J CLIN NUTR, V102, P780, DOI 10.3945/ajcn.115.112581; Thongtang N, 2017, J LIPID RES, V58, P1315, DOI 10.1194/jlr.M073882; World Health Organization, CARD DIS CVDS; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	44	30	30	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2020	15	1							e0225348	10.1371/journal.pone.0225348	http://dx.doi.org/10.1371/journal.pone.0225348			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5JP	31935216	gold, Green Published			2023-01-03	WOS:000534354100006
J	Chiavari-Frederico, MO; Barbosa, LN; dos Santos, IC; da Silva, GR; de Castro, AF; Bortolucci, WD; Barboza, LN; Campos, CFDA; Goncalves, JE; Menetrier, JV; Jacomassi, E; Gazim, ZC; Wietzikoski, S; Livero, FAD; Lovato, ECW				Chiavari-Frederico, Marcela Oliveira; Barbosa, Lidiane Nunes; dos Santos, Isabela Carvalho; da Silva, Gustavo Ratti; de Castro, Alanna Fernandes; Bortolucci, Wanessa de Campos; Barboza, Lorena Neris; de Araujo Almeida Campos, Caio Franco; Eduardo Goncalves, Jose; Menetrier, Jacqueline Vergutz; Jacomassi, Ezilda; Gazim, Zilda Cristiani; Wietzikoski, Samantha; dos Reis Livero, Francislaine Aparecida; Wietzikoski Lovato, Evellyn Claudia			Antimicrobial activity of Asteraceae species against bacterial pathogens isolated from postmenopausal women	PLOS ONE			English	Article							URINARY-TRACT-INFECTIONS; ANTIBACTERIAL ACTIVITY; CHEMICAL-COMPOSITION; ESCHERICHIA-COLI; PLANT-EXTRACTS; L.; EPIDEMIOLOGY; MENOPAUSE; PRODUCTS; HEALTH	Purpose Investigation of the antibacterial action of aqueous extracts of Bidens sulphurea, Bidens pilosa, and Tanacetum vulgare, species of Asteraceae family that are popularly used for the treatment of genito-urinary infection. Methods The minimum inhibitory concentration (MIC) and minimal bacterial concentration (MBC) of the extracts against standard strains of Staphylococcus aureus (ATCC25923), Enterococcus faecalis (ATCC29212), Escherichia coli (ATCC25922), and Pseudomonas aeruginosa (ATCC27853) and against bacteria that were isolated from cultures of vaginal secretions and urine from menopausal women with a diagnosis of recurrent urinary tract infections (rUTI) were determined by broth microdilution. Results The MIC values of the three extracts against Gram-positive and Gram-negative standard bacterial strains ranged from 7.81 to 125.00 mg ml(-1), and the MBC values ranged from 7.81 to 500.00 mg ml(-1). However, B. sulphurea was more efficient. In the urine samples, the three extracts inhibited the growth of coagulase-negative Staphylococcus spp., and the B. pilosa was the most active extract against E. coli compared with the other ones. For the vaginal secretion samples, no significant differences in the inhibition of coagulase-positive Staphylococcus spp. and P. mirabilis were found among the extracts. T. vulgare and B. sulphurea were more effective in inhibiting coagulase-negative Staphylococcus spp. compared with B. pilosa. E. coli was more susceptible to the B. sulphurea extract compared with the B. pilosa and T. vulgare extracts. Conclusion The present results suggested the potential medicinal use of Asteraceae species, especially B. sulphurea, as therapeutic agents against rUTI-related bacteria.	[Chiavari-Frederico, Marcela Oliveira; de Castro, Alanna Fernandes; Barboza, Lorena Neris; Wietzikoski, Samantha; Wietzikoski Lovato, Evellyn Claudia] Univ Paranaense, Lab Preclin Res Nat Prod, Umuarama, PR, Brazil; [Chiavari-Frederico, Marcela Oliveira; Menetrier, Jacqueline Vergutz; Jacomassi, Ezilda; dos Reis Livero, Francislaine Aparecida; Wietzikoski Lovato, Evellyn Claudia] Univ Paranaense, Med Plants & Phytotherap Basic Attent, Umuarama, PR, Brazil; [Barbosa, Lidiane Nunes; dos Santos, Isabela Carvalho; da Silva, Gustavo Ratti] Univ Paranaense, Lab Prevent Vet Med & Publ Hlth, Umuarama, PR, Brazil; [Barbosa, Lidiane Nunes; dos Reis Livero, Francislaine Aparecida] Univ Paranaense, Anim Sci Emphasis Bioact Prod, Umuarama, PR, Brazil; [Bortolucci, Wanessa de Campos; Gazim, Zilda Cristiani] Univ Paranaense, Biotechnol Appl Agr, Chem Lab Nat Prod, Umuarama, PR, Brazil; [de Araujo Almeida Campos, Caio Franco; Eduardo Goncalves, Jose] Univ Ctr Maringa, Clean Technol, Maringa, PR, Brazil; [Eduardo Goncalves, Jose] Univ Ctr Maringa, Technol & Food Safety & Cesumar Inst Sci Technol, Maringa, PR, Brazil	Universidade Paranaense; Universidade Paranaense; Universidade Paranaense; Universidade Paranaense; Universidade Paranaense	Lovato, ECW (corresponding author), Univ Paranaense, Lab Preclin Res Nat Prod, Umuarama, PR, Brazil.; Lovato, ECW (corresponding author), Univ Paranaense, Med Plants & Phytotherap Basic Attent, Umuarama, PR, Brazil.	evellyn@prof.unipar.br	de Campos Bortolucci, Wanessa/AAK-9897-2020; Santos, Isabela Carvalho/GLQ-6273-2022; Wietzikoski, E.C./N-8166-2015; Barbosa, Lidiane Nunes/AFO-3012-2022; Goncalves, Jose Eduardo/Y-1015-2018	de Campos Bortolucci, Wanessa/0000-0002-7233-8313; Goncalves, Jose Eduardo/0000-0002-2505-0536; Gazim, Zilda Cristiani/0000-0003-0392-5976; Carvalho Dos Santos, Isabela/0000-0002-7971-5126	Universidade Paranaense; Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention; Graduate Program in Animal Science with Emphasis on Bioactive Products; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [800435/2018-4]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [PNPD20132409-40028011002P4]; Fundacao Araucaria (FUNDACAO ARAUCARIA) [47661.491.48325.12122016]	Universidade Paranaense; Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention; Graduate Program in Animal Science with Emphasis on Bioactive Products; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundacao Araucaria (FUNDACAO ARAUCARIA)(Fundacao Araucaria de Apoio ao Desenvolvimento Cientifico e Tecnologico do Estado do Parana FA)	The authors are grateful to Universidade Paranaense, Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention, and Graduate Program in Animal Science with Emphasis on Bioactive Products for financial support. This work was supported by grants from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; no. 800435/2018-4), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES; no. PNPD20132409-40028011002P4) and Fundacao Araucaria (FUNDACAO ARAUCARIA; no. 47661.491.48325.12122016).	Adams R.P., 2012, IDENTIFICATION ESSEN; Alaagib R.M.O., 2015, TPI, V4, P73; [Anonymous], 2012, SCI SECURE J BIOTECH; Baranauskiene R, 2014, IND CROP PROD, V60, P113, DOI 10.1016/j.indcrop.2014.05.047; Bartolome AP, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/340215; Bessada SMP, 2015, IND CROP PROD, V76, P604, DOI 10.1016/j.indcrop.2015.07.073; Blake J, 2006, BEST PRACT RES CL OB, V20, P799, DOI 10.1016/j.bpobgyn.2006.07.001; Borges C.C., 2013, Rev. bras. plantas med., V15, P34, DOI 10.1590/S1516-05722013000100004; Caretto M, 2017, MATURITAS, V99, P43, DOI 10.1016/j.maturitas.2017.02.004; Chattopadhyay D, 2002, J ETHNOPHARMACOL, V82, P229, DOI 10.1016/S0378-8741(02)00165-4; Choi K, 2016, INT J VET HLTH SCI R, V4, P88, DOI [10.19070/2332-2748-1600022, DOI 10.19070/2332-2748-1600022]; CLSI, 2015, PERFORMANCE STANDARD; Costa LC., 2010, REV BRAS ANAL CLIN, V42, P175; da Silva BP, 2017, J AGR FOOD CHEM, V65, P5161, DOI 10.1021/acs.jafc.7b01922; de Souza GC, 2004, J ETHNOPHARMACOL, V90, P135, DOI 10.1016/j.jep.2003.09.039; Deba F, 2007, WEED BIOL MANAG, V7, P77, DOI 10.1111/j.1445-6664.2007.00239.x; Dias H. J., 2017, INT J COMPLEM ALT ME, V6, P188; Oliveira SGD, 2012, J ETHNOPHARMACOL, V140, P428, DOI 10.1016/j.jep.2012.01.054; Duarte MCT, 2005, J ETHNOPHARMACOL, V97, P305, DOI 10.1016/j.jep.2004.11.016; Flores-Mireles AL, 2015, NAT REV MICROBIOL, V13, P269, DOI 10.1038/nrmicro3432; Foxman B, 2010, NAT REV UROL, V7, P653, DOI 10.1038/nrurol.2010.190; Hemaiswarya S, 2008, PHYTOMEDICINE, V15, P639, DOI 10.1016/j.phymed.2008.06.008; Hernandez MM, 1999, J ETHNOPHARMACOL, V67, P37, DOI 10.1016/S0378-8741(99)00041-0; Jhang JF, 2017, TZU CHI MED J, V29, P131, DOI 10.4103/tcmj.tcmj_53_17; Kannan RRR, 2012, FOOD CHEM, V135, P2470, DOI 10.1016/j.foodchem.2012.07.070; Knight JA, 2000, ANN CLIN LAB SCI, V30, P145; Kohanski MA, 2010, NAT REV MICROBIOL, V8, P423, DOI 10.1038/nrmicro2333; Koneman EK, 2008, DIAGNOSTICO MICROBIO; Kostakioti M, 2012, VIRULENCE, V3, P592, DOI 10.4161/viru.22364; KRUMPERMAN PH, 1983, APPL ENVIRON MICROB, V46, P165, DOI 10.1128/AEM.46.1.165-170.1983; Martino MDV, 2002, J BRAS NEFROL, V24, P71; Mazili P. M. L., 2011, Revista Brasileira de Medicina, V68, P74; Medeiros S, 2017, ELLIPSIS, V2, P7; Miah, 2012, INT CURRENT PHARM J, V1, DOI [https://doi.org/10.3329/icpj.v1i6.10534, DOI 10.3329/ICPJ.V1I6.10534]; Moore KN, 2002, J CLIN NURS, V11, P568, DOI 10.1046/j.1365-2702.2002.00629.x; Neilson JP, 2008, OBSTET GYNECOL, V112, P689, DOI 10.1097/AOG.0b013e318185f7a5; Oliveira DF, 2007, FITOTERAPIA, V78, P142, DOI 10.1016/j.fitote.2006.09.027; Persu C, 2011, J Med Life, V4, P75; Raskin I, 2002, TRENDS BIOTECHNOL, V20, P522, DOI 10.1016/S0167-7799(02)02080-2; Raz R, 2011, KOREAN J UROL, V52, P801, DOI 10.4111/kju.2011.52.12.801; Rosselli S, 2012, MOLECULES, V17, P8186, DOI 10.3390/molecules17078186; Silva DR, 2009, MOLECULES, V14, P1171, DOI 10.3390/molecules14031171; Sribalan R, 2016, SAUDI PHARM J, V24, P658, DOI 10.1016/j.jsps.2015.05.003; Sridevi VK, 2012, NAT PROD RES, V26, P1135, DOI 10.1080/14786419.2011.560849; Thomas-White K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03968-5; Tsuchiya H, 1996, J ETHNOPHARMACOL, V50, P27, DOI 10.1016/0378-8741(96)85514-0; Xie G, 2007, INT IMMUNOPHARMACOL, V7, P1639, DOI 10.1016/j.intimp.2007.08.013; Zeeuwen PLJM, 2013, CURR OPIN ALLERGY CL, V13, P514, DOI 10.1097/ACI.0b013e328364ebeb	48	8	8	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2020	15	1							e0227023	10.1371/journal.pone.0227023	http://dx.doi.org/10.1371/journal.pone.0227023			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP4ZR	31905207	gold, Green Published			2023-01-03	WOS:000534327700014
J	Kiavue, N; Cabel, L; Melaabi, S; Bataillon, G; Callens, C; Lerebours, F; Pierga, JY; Bidard, FC				Kiavue, Nicolas; Cabel, Luc; Melaabi, Samia; Bataillon, Guillaume; Callens, Celine; Lerebours, Florence; Pierga, Jean-Yves; Bidard, Francois-Clement			ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics	ONCOGENE			English	Review							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; CELL LUNG-CANCER; GENOMIC CHARACTERIZATION; BREAST; ACTIVATION; DOMAIN; TUMOR; HER3; LANDSCAPE	HER3, a member of the EGFR family of receptor tyrosine kinases coded by the ERBB3 gene, plays an important role in cancer, despite its lack of intrinsic kinase activity. As with genes coding for potential heterodimeric partners of HER3, EGFR, and HER2, oncogenic mutations of ERBB3 have been explored by several studies. In this review, we discuss the evidence presenting ERBB3 somatic mutations as potential tumoral drivers. We then show that ERBB3 mutations are not uncommon in many cancer types. Finally, we present the recent results of several studies evaluating different therapeutic approaches for treating patients with oncogenic ERBB3 mutations.	[Kiavue, Nicolas; Cabel, Luc; Melaabi, Samia; Bataillon, Guillaume; Callens, Celine; Lerebours, Florence; Pierga, Jean-Yves; Bidard, Francois-Clement] PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France; [Cabel, Luc; Bidard, Francois-Clement] Versailles St Quentin en Yvelines Univ, Paris Saclay Univ, Paris, France; [Pierga, Jean-Yves] Paris Descartes Univ, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite	Bidard, FC (corresponding author), PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France.; Bidard, FC (corresponding author), Versailles St Quentin en Yvelines Univ, Paris Saclay Univ, Paris, France.	francois-clement.bidard@curie.fr						Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Bidard FC, 2015, ANN ONCOL, V26, P1704, DOI 10.1093/annonc/mdv217; Bose R, 2009, EXP CELL RES, V315, P649, DOI 10.1016/j.yexcr.2008.07.031; Brand TM, 2018, CANCER RES, V78, P2383, DOI 10.1158/0008-5472.CAN-17-1672; Braunstein EM, 2016, LEUKEMIA, V30, P2242, DOI 10.1038/leu.2016.173; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Burk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386; Burstein HJ, 2010, J CLIN ONCOL, V28, P1301, DOI 10.1200/JCO.2009.25.8707; Cabel L, 2018, JCO PRECIS ONCOL, V2, P1, DOI 10.1200/PO.17.00243; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chae J, 2018, BMB REP, V51, P584, DOI 10.5483/BMBRep.2018.51.11.091; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chang MT, 2018, CANCER DISCOV, V8, P174, DOI 10.1158/2159-8290.CD-17-0321; Chang MT, 2016, NAT BIOTECHNOL, V34, P155, DOI 10.1038/nbt.3391; Chiou VL, 2015, J CLIN ONCOL, V33, P3541, DOI 10.1200/JCO.2015.61.6870; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Choudhury NJ, 2016, J CLIN ONCOL, V34, P2165, DOI 10.1200/JCO.2015.66.3047; Collier TS, 2013, J BIOL CHEM, V288, P25254, DOI 10.1074/jbc.M113.474882; Connell CM, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2017-000279; DeMatteo RP, 2009, LANCET, V373, P1097, DOI 10.1016/S0140-6736(09)60500-6; Deniziaut G, 2016, ONCOTARGET, V7, P73337, DOI 10.18632/oncotarget.11819; Desmedt C, 2016, J CLIN ONCOL, V34, P1872, DOI 10.1200/JCO.2015.64.0334; Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Frazier NM, 2019, ONCOGENE, V38, P1936, DOI 10.1038/s41388-018-0537-0; Gaborit N, 2016, HUM VACC IMMUNOTHER, V12, P576, DOI 10.1080/21645515.2015.1102809; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Hanninen UA, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007200; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Hutcheson IR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2848; Hyman DM, 2018, NATURE, V554, P189, DOI 10.1038/nature25475; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Jaiswal BS, 2013, CANCER CELL, V23, P603, DOI 10.1016/j.ccr.2013.04.012; Jeong EG, 2006, INT J CANCER, V119, P2986, DOI 10.1002/ijc.22257; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Kennedy SP, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00088; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Kumar A, 2008, J CLIN ONCOL, V26, P1742, DOI 10.1200/JCO.2007.12.1178; Li M, 2018, GUT; Li ML, 2014, NAT GENET, V46, P872, DOI 10.1038/ng.3030; Littlefield P, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005786; Loree JM, 2018, JNCI-J NATL CANCER I, V110, P1409, DOI 10.1093/jnci/djy067; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Migden MR, 2018, NEW ENGL J MED, V379, P341, DOI 10.1056/NEJMoa1805131; Milewska M, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758834017746040; Mishra R, 2018, ONCOTARGET, V9; Mishra R, 2018, ONCOL REV, V12, P45, DOI 10.4081/oncol.2018.355; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Narayan M, 2009, CANCER RES, V69, P2191, DOI 10.1158/0008-5472.CAN-08-1056; Narkis G, 2007, AM J HUM GENET, V81, P589, DOI 10.1086/520770; Petrelli F, 2017, BREAST CANCER RES TR, V166, P339, DOI 10.1007/s10549-017-4419-x; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Ross JS, 2018, CANCER-AM CANCER SOC, V124, P1358, DOI 10.1002/cncr.31125; Schrock AB, 2017, JAMA ONCOL, V3, P1546, DOI 10.1001/jamaoncol.2017.1051; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Sithanandam G, 2008, CANCER GENE THER, V15, P413, DOI 10.1038/cgt.2008.15; Skoulidis F, 2015, CANCER DISCOV, V5, P860, DOI 10.1158/2159-8290.CD-14-1236; Steinkamp MP, 2014, MOL CELL BIOL, V34, P965, DOI 10.1128/MCB.01605-13; Strickley JD, 2018, EXP HEMATOL ONCOL, V7, DOI 10.1186/s40164-018-0111-z; Tamura S, 2018, BLADDER CANCER, V4, P77, DOI 10.3233/BLC-170144; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Umelo I, 2016, ONCOTARGET, V7, P3068, DOI 10.18632/oncotarget.6585; Verlingue L, 2018, EUR J CANCER, V92, P1, DOI 10.1016/j.ejca.2017.12.020; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Wang ZX, 2017, METHODS MOL BIOL, V1652, P3, DOI 10.1007/978-1-4939-7219-7_1; Watson P, 2005, FAM CANCER, V4, P245, DOI 10.1007/s10689-004-7994-z; Yin MX, 2015, ACTA BIOCH BIOPH SIN, V47, P39, DOI 10.1093/abbs/gmu111; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	81	47	50	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					487	502		10.1038/s41388-019-1001-5	http://dx.doi.org/10.1038/s41388-019-1001-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31519989				2023-01-03	WOS:000509718300001
J	Weinreich, UM				Weinreich, Ulla Moller			Domiciliary high-flow treatment in patients with COPD and chronic hypoxic failure: In whom can we reduce exacerbations and hospitalizations?	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; OXYGEN-THERAPY	Introduction Domiciliary High-flow, humidified, nasal cannula (HFNC) is a possible add-on in patients with chronic respiratory diseases. This post-hoc study investigates benefit of HFNC in subgroups of advanced COPD patients with chronic hypoxic failure on reduction of exacerbations and hospitalizations. Methods One hundred patients were randomized to HFNC in a previous trial. Subgroups with 0-1 (N = 32) respectively two or more (2+) (N = 68) exacerbations 12 months pre-study were investigated. Changes in number of exacerbations and hospitalizations pre- and in study were analyzed, corrected for HFNC days with HFNC. Results Patients were comparable at baseline. Exacerbations increased in subgroup 0-1 (p = 0.01) and decreased in subgroup 2+ (p = 0.03). Correcting for HFNC days no correlation was seen in subgroup 0-1 (p = 0.08), but in subgroup 2+ (p<0.001). Number of hospitalizations increased in subgroup 0-1 (p = 0.01) with no change in days of hospitalization (p = 0.08). Number and days of hospitalization decreased in subgroup 2+ (p = 0.002 resp. 0.025). Correcting for HFNC days no correlation was found in number or days of hospitalization in subgroup 0-1 (p = 0.48 and p = 0.65). Positive correlation was found in subgroup 2+ (both p<0.001). Conclusion In patients with advanced COPD, chronic hypoxic failure and two or more exacerbations per year, HFNC significantly reduced exacerbations and hospitalizations.	[Weinreich, Ulla Moller] Aalborg Univ, Dept Resp Dis, Aalborg Univ Hosp, Aalborg, Denmark; [Weinreich, Ulla Moller] Aalborg Univ, Clin Inst, Aalborg, Denmark	Aalborg University; Aalborg University Hospital; Aalborg University	Weinreich, UM (corresponding author), Aalborg Univ, Dept Resp Dis, Aalborg Univ Hosp, Aalborg, Denmark.; Weinreich, UM (corresponding author), Aalborg Univ, Clin Inst, Aalborg, Denmark.	ulw@rn.dk	Weinreich, Ulla M/L-9069-2013	Weinreich, Ulla M/0000-0003-1975-3654				[Anonymous], 2013, GLOB STRAT DIAGN MAN; Burge S, 2003, EUR RESPIR J, V21, p46S, DOI 10.1183/09031936.03.00078002; Chatila W, 2004, CHEST, V126, P1108, DOI 10.1378/chest.126.4.1108; Fraser JF, 2016, THORAX, V71, P759, DOI 10.1136/thoraxjnl-2015-207962; Gerald Lynn B, 2002, J Cardiopulm Rehabil, V22, P234, DOI 10.1097/00008483-200207000-00004; Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2017, GOLD 2017 GLOB STRAT; Halpin DMG, 2017, INT J CHRONIC OBSTR, V12, P2891, DOI 10.2147/COPD.S139470; Hardinge M, 2015, THORAX, V70, P1, DOI 10.1136/thoraxjnl-2015-206865; Hill Nicholas S, 2017, Tanaffos, V16, pS12; Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883; Katajisto M, 2017, INT J CHRONIC OBSTR, V12, P2763, DOI 10.2147/COPD.S144571; Mannino DM, 2006, EUR RESPIR J, V27, P627, DOI 10.1183/09031936.06.00024605; Muellerova H, 2015, CHEST, V147, P999, DOI 10.1378/chest.14-0655; Murphy PB, 2017, JAMA-J AM MED ASSOC, V317, P2177, DOI 10.1001/jama.2017.4451; Nilius G, 2013, ADV EXP MED BIOL, V755, P27, DOI 10.1007/978-94-007-4546-9_4; Rea H, 2010, RESP MED, V104, P525, DOI 10.1016/j.rmed.2009.12.016; Storgaard LH, 2018, INT J CHRONIC OBSTR, P1195; Storgaard LH, 2018, INT J CHRON OBS PULM; Storgaard LH, 2017, J SLEEP RES, V28; Vestbo J, 2015, EUR RESPIR J, V1, P1, DOI [10.1183/23120541.00011-2015, DOI 10.1183/23120541.00011-2015]; Viniol C, 2018, EUR RESPIR REV, V27, DOI 10.1183/16000617.0103-2017; Weinreich UM, 2019, MINIMAL DATA SET DOM, DOI [10.5278/ebe30ad7-292e-4217-9182-9cc4509723e2, DOI 10.5278/EBE30AD7-292E-4217-9182-9CC4509723E2]	22	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2019	14	12							e0227221	10.1371/journal.pone.0227221	http://dx.doi.org/10.1371/journal.pone.0227221			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN8JV	31887206	gold, Green Published			2023-01-03	WOS:000515092200085
J	D'Anci, KE; Uhl, S; Oristaglio, J; Sullivan, N; Tsou, AY				D'Anci, Kristen E.; Uhl, Stacey; Oristaglio, Jeffrey; Sullivan, Nancy; Tsou, Amy Y.			Treatments for Poststroke Motor Deficits and Mood Disorders: A Systematic Review for the 2019 US Department of Veterans Affairs and US Department of Defense Guidelines for Stroke Rehabilitation	ANNALS OF INTERNAL MEDICINE			English	Review							TRANSCRANIAL MAGNETIC STIMULATION; NEUROMUSCULAR ELECTRICAL-STIMULATION; UPPER-EXTREMITY; RANDOMIZED-TRIAL; SUBACUTE STROKE; DOUBLE-BLIND; RECOVERY; DEPRESSION; THERAPY; INTERVENTION	Background: Early rehabilitation after stroke is essential to help reduce disability. Purpose: To summarize evidence on the benefits and harms of nonpharmacologic and pharmacologic treatments for motor deficits and mood disorders in adults who have had stroke. Data Sources: English-language searches of multiple electronic databases from April 2009 through July 2018; targeted searches to December 2018 for studies of selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors. Study Selection: 19 systematic reviews and 37 randomized controlled trials addressing therapies for motor deficits or mood disorders in adults with stroke. Data Extraction: One investigator abstracted the data, and quality and GRADE assessment were checked by a second investigator. Data Synthesis: Most interventions (for example, SSRIs, mental practice, mirror therapy) did not improve motor function. High-quality evidence did not support use of fluoxetine to improve motor function. Moderate-quality evidence supported use of cardiorespiratory training to improve maximum walking speed and repetitive task training or transcranial direct current stimulation to improve activities of daily living (ADLs). Low-quality evidence supported use of robotic arm training to improve ADLs. Low-quality evidence indicated that antidepressants may reduce depression, whereas the frequency and severity of antidepressant-related adverse effects was unclear. Low-quality evidence suggested that cognitive behavioral therapy and exercise, including mind-body exercise, may reduce symptoms of depression and anxiety. Limitation: Studies were of poor quality, interventions and comparators were heterogeneous, and evidence on harms was scarce. Conclusion: Cardiorespiratory training, repetitive task training, and transcranial direct current stimulation may improve ADLs in adults with stroke. Cognitive behavioral therapy, exercise, and SSRIs may reduce symptoms of poststroke depression, but use of SSRIs to prevent depression or improve motor function was not supported.	[D'Anci, Kristen E.; Uhl, Stacey; Oristaglio, Jeffrey; Sullivan, Nancy; Tsou, Amy Y.] ECRI Inst, Plymouth Meeting, PA USA; [D'Anci, Kristen E.; Uhl, Stacey; Oristaglio, Jeffrey; Sullivan, Nancy; Tsou, Amy Y.] ECRI Inst, Ctr Clin Evidence & Guidelines, 5200 Butler Pike, Plymouth Meeting, PA 19462 USA		D'Anci, KE (corresponding author), ECRI Inst, Ctr Clin Evidence & Guidelines, 5200 Butler Pike, Plymouth Meeting, PA 19462 USA.	kdanci@ecri.org		Tsou, Amy/0000-0002-5544-3090	U.S. Department of Veterans Affairs, Veterans Health Administration	U.S. Department of Veterans Affairs, Veterans Health Administration(US Department of Veterans Affairs)	U.S. Department of Veterans Affairs, Veterans Health Administration.	Ada L, 2010, J PHYSIOTHER, V56, P153, DOI 10.1016/S1836-9553(10)70020-5; Agency for Healthcare Research and Quality, 2014, USITC PUBL, V10; Aidar FJ, 2018, J SPORT MED PHYS FIT, V58, P1171, DOI 10.23736/S0022-4707.17.07284-X; Ambrosini E, 2011, STROKE, V42, P1068, DOI 10.1161/STROKEAHA.110.599068; Arya KN, 2019, NEUROPSYCHOL REHABIL, V29, P1193, DOI 10.1080/09602011.2017.1377087; Ballard M, 2017, RES SYNTH METHODS, V8, P92, DOI 10.1002/jrsm.1229; Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558; Braun SM, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2010.07.009; Brunner I, 2017, NEUROLOGY, V89, P2413, DOI 10.1212/WNL.0000000000004744; Chun HYY, 2018, J PSYCHOSOM RES, V104, P65, DOI 10.1016/j.jpsychores.2017.11.010; Cockayne NL, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0762-6; Corbetta D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004433.pub3; Deng Linghui, 2018, Oncotarget, V9, P23718, DOI 10.18632/oncotarget.23891; Dennis M, 2019, LANCET, V393, P265, DOI 10.1016/S0140-6736(18)32823-X; Du J, 2016, EUR J NEUROL, V23, P1666, DOI 10.1111/ene.13105; Elsner B, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009645.pub3; Eng JJ, 2014, CLIN REHABIL, V28, P731, DOI 10.1177/0269215514523631; Etoom M, 2016, INT J REHABIL RES, V39, P197, DOI 10.1097/MRR.0000000000000169; Fang Yihong, 2017, Int J Health Sci (Qassim), V11, P53; Feng RF, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013453; FRENCH K, 2016, COCHRANE DB SYST REV, V11, DOI DOI 10.1371/JOURNAL.PONE.0169332; Ganann R, 2010, IMPLEMENT SCI, V5, P10, DOI 10.1186/1748-5908-5-56; Gao J, 2017, CLIN REHABIL, V31, P71, DOI 10.1177/0269215515626232; Gu SC, 2018, J STROKE CEREBROVASC, V27, P1178, DOI 10.1016/j.jstrokecerebrovasdis.2017.11.031; Guan YZ, 2017, CNS NEUROSCI THER, V23, P940, DOI 10.1111/cns.12762; Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069; Hong ZQ, 2018, ARCH PHYS MED REHAB, V99, P1011, DOI 10.1016/j.apmr.2017.12.019; Hsu SS, 2010, STROKE, V41, P821, DOI 10.1161/STROKEAHA.109.574160; Hu ZY, 2017, IRAN J PUBLIC HEALTH, V46, P180; Huang YZ, 2018, AM J PHYS MED REHAB, V97, P339, DOI 10.1097/PHM.0000000000000850; Khedr EM, 2009, EUR J NEUROL, V16, P1323, DOI 10.1111/j.1468-1331.2009.02746.x; Kim JS, 2017, LANCET PSYCHIAT, V4, P33, DOI 10.1016/S2215-0366(16)30417-5; Kim JS, 2016, J STROKE, V18, P244, DOI 10.5853/jos.2016.01144; Knutson JS, 2016, STROKE, V47, P2596, DOI 10.1161/STROKEAHA.116.013791; Koh CL, 2017, ARCH PHYS MED REHAB, V98, P2477, DOI 10.1016/j.apmr.2017.05.025; Lee HC, 2017, GAMES HEALTH J, V6, P303, DOI 10.1089/g4h.2016.0109; Lin ZL, 2011, J REHABIL MED, V43, P506, DOI 10.2340/16501977-0807; Love MF, 2019, STROKE, V50, P434, DOI 10.1161/STROKEAHA.118.021150; Masiero S, 2014, NEUROREHAB NEURAL RE, V28, P377, DOI 10.1177/1545968313513073; Mehrholz J, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002840.pub4; Mehrholz J, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006185.pub3; Mehrholz J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006876.pub4; Michielsen ME, 2011, NEUROREHAB NEURAL RE, V25, P223, DOI 10.1177/1545968310385127; Mitchell PH, 2009, STROKE, V40, P3073, DOI 10.1161/STROKEAHA.109.549808; Ng S S M, 2016, Hong Kong Med J, V22 Suppl 2, pS33; Norouzi-Gheidari N, 2012, J REHABIL RES DEV, V49, P479, DOI 10.1682/JRRD.2010.10.0210; Peng YH, 2015, J STROKE CEREBROVASC, V24, P1793, DOI 10.1016/j.jstrokecerebrovasdis.2015.04.009; Pogrebnoy D, 2020, ARCH PHYS MED REHAB, V101, P154, DOI 10.1016/j.apmr.2019.06.015; Pomeroy VM, 2016, NEUROREHAB NEURAL RE, V30, P40, DOI 10.1177/1545968315583724; Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158; Prenton S, 2016, J REHABIL MED, V48, P646, DOI 10.2340/16501977-2136; Qian QY, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00447; Regan EW, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012761; Reinkensmeyer David J, 2012, Am J Phys Med Rehabil, V91, pS232, DOI 10.1097/PHM.0b013e31826bce79; Ballester BR, 2017, JMIR SERIOUS GAMES, V5, DOI 10.2196/games.6773; Sall J, 2019, ANN INTERN MED, V171, P916, DOI 10.7326/M19-1695; Salter KL, 2013, J STROKE CEREBROVASC, V22, P1243, DOI 10.1016/j.jstrokecerebrovasdis.2012.03.013; SAUNDERS TJ, 2016, COCHRANE DB SYST REV, V3, DOI DOI 10.1098/RSOS.150710; Schunemann H., 2013, GRADE HDB; Seniow J, 2012, NEUROREHAB NEURAL RE, V26, P1072, DOI 10.1177/1545968312445635; Smith EE, 2011, STROKE, V42, P3110, DOI 10.1161/STROKEAHA.111.613208; Synhaeve NE, 2014, STROKE, V45, P1157, DOI 10.1161/STROKEAHA.113.004411; Tan ZM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/545408; Timmermans AAA, 2013, J AM MED DIR ASSOC, V14, P204, DOI 10.1016/j.jamda.2012.10.010; U.S. Department of Veterans Affairs, 2019, VA DOD CLIN PRACT GU; U.S. Preventive Services Task Force, 2019, METH PROC; Wang SB, 2018, J AFFECT DISORDERS, V235, P589, DOI 10.1016/j.jad.2018.04.011; Wichowicz HM, 2017, BRAIN INJURY, V31, P1507, DOI 10.1080/02699052.2017.1341997; Wilkinson IA, 2015, DISABIL REHABIL-ASSI, V10, P468, DOI 10.3109/17483107.2014.917125; Woon FL, 2010, PROG NEURO-PSYCHOPH, V34, P1181, DOI 10.1016/j.pnpbp.2010.06.016; Yadav RK, 2016, J CLIN DIAGN RES, V10, pYC1, DOI 10.7860/JCDR/2016/23468.8899; Zhang LS, 2013, EUR NEUROL, V69, P336, DOI 10.1159/000345374; Zhang Y, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15122791	73	13	15	3	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 17	2019	171	12					906	+		10.7326/M19-2414	http://dx.doi.org/10.7326/M19-2414			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KB3WA	31739315				2023-01-03	WOS:000506428800017
J	Robinson, A; McIntosh, J; Peberdy, H; Wishart, D; Brown, G; Pope, H; Kumar, S				Robinson, Aleisha; McIntosh, Jenna; Peberdy, Hamish; Wishart, David; Brown, Georgia; Pope, Henry; Kumar, Saravana			The effectiveness of physiotherapy interventions on pain and quality of life in adults with persistent post-surgical pain compared to usual care: A systematic review	PLOS ONE			English	Review							RISK-FACTORS; SURGERY; EXERCISE; MANAGEMENT; REHABILITATION; THORACOTOMY; PREDICTORS; DEPRESSION; DISORDERS; THERAPY	Background Persistent post-surgical pain (PPSP) is a common condition following surgery, resulting in persistent pain and reduced quality of life (QoL). While pharmacological management is common, its effectiveness remains equivocal. This systematic review investigated the effectiveness of physiotherapy management in adults with PPSP in comparison to usual care. Methods A systematic search of six electronic databases was conducted. Studies of human adults (> 18 years) with PPSP localised or directly referred from the surgical site, pain persisting for at least two months post-surgery and with physiotherapy as the intervention were included. This review was conducted and reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The McMaster critical review form for quantitative studies was utilised to assess the methodological quality. A descriptive synthesis was undertaken due to the heterogeneity of the included studies. Results Of the 1395 articles that were screened, eight studies met the inclusion criteria. A diverse range of physiotherapy interventions were utilised, and effectiveness was measured through diverse outcomes and measures. Summarised findings from the heterogenous evidence base indicated that physiotherapy interventions for PPSP has a positive impact across a range of outcomes, including pain, quality of life (QoL), physical function and depression. While these are encouraging findings, the current evidence base lacks uniformity with regards to participant characteristics, time periods since diagnosis, interventions delivered, and its parameters, and outcomes measured. Conclusion Due to ongoing challenges in the management of PPSP, alternate treatment strategies such as physiotherapy are being trialled. Despite a number of methodological constraints, current evidence indicates that physiotherapy could play a role in the management of PPSP.	[Robinson, Aleisha; McIntosh, Jenna; Peberdy, Hamish; Wishart, David; Brown, Georgia; Pope, Henry; Kumar, Saravana] Univ South Australia, Adelaide, SA, Australia	University of South Australia	Kumar, S (corresponding author), Univ South Australia, Adelaide, SA, Australia.	saravana.kumar@unisa.edu.au	Kumar, Saravana/B-8876-2009	Kumar, Saravana/0000-0002-4003-4411; Robinson, Aleisha/0000-0002-3486-9818; Wishart, David/0000-0003-3736-8792				Albayrak I, 2017, J KNEE SURG, V30, P134, DOI 10.1055/s-0036-1583268; Andersen KG, 2011, J PAIN, V12, P725, DOI 10.1016/j.jpain.2010.12.005; Andreae MH, 2013, BRIT J ANAESTH, V111, P711, DOI 10.1093/bja/aet213; Atalay OT, 2015, J PHYS THER SCI, V27, P865, DOI 10.1589/jpts.27.865; Bailey JC, 2018, PAIN MED, V19, P385, DOI 10.1093/pm/pnx060; Bize R, 2007, PREV MED, V45, P401, DOI 10.1016/j.ypmed.2007.07.017; Bjersa K, 2013, INT J OSTEOPATH MED, V16, P68, DOI 10.1016/j.ijosm.2012.10.003; Chaparro LE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008307.pub2; Chou CH, 2012, ARCH PHYS MED REHAB, V93, P237, DOI 10.1016/j.apmr.2011.08.042; Chukhraev N, 2017, J PHYS ED SPORT, V17, P414; Cooney GM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub6; Correll Darin, 2017, F1000Res, V6, P1054, DOI 10.12688/f1000research.11101.1; Dars S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193060; Geiss A, 2005, PAIN, V114, P104, DOI 10.1016/j.pain.2004.12.007; Ginnerup-Nielsen E, 2016, BRIT J SPORT MED, V50, P965, DOI 10.1136/bjsports-2015-095741; Graziottin A, 2014, GYNECOL ENDOCRINOL, V30, P472, DOI 10.3109/09513590.2014.911280; Guastella V, 2011, PAIN, V152, P74, DOI 10.1016/j.pain.2010.09.004; Guertin JR, 2018, J PAIN RES, V11, P2741, DOI 10.2147/JPR.S175090; Hakeem A, 2011, WORLD J GASTRO SURG, V3, P73, DOI 10.4240/wjgs.v3.i6.73; Hillier S, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-23; Hinrichs-Rocker A, 2009, EUR J PAIN, V13, P719, DOI 10.1016/j.ejpain.2008.07.015; Hodgson CL, 2017, J PHYSIOTHER, V63, P4, DOI 10.1016/j.jphys.2016.10.011; Honerlaw KR, 2016, GYNECOL ONCOL, V140, P301, DOI 10.1016/j.ygyno.2015.09.005; Humble SR, 2015, EUR J PAIN, V19, P451, DOI 10.1002/ejp.567; Jayakody K, 2014, BRIT J SPORT MED, V48, P187, DOI 10.1136/bjsports-2012-091287; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Kumar S, 2010, ADV MED EDUC PRACT, V1, P1; Lavand'homme P, 2017, CHRONIC POSTSURGICAL; Law M., 2007, CRITICAL REV FORM QU; Ministry of health social services and equality galician agency for health technology assessment (avalia-t) (ES), CLIN PRACT GUID MAN; Mortimer R, 2014, J MULTIDISCIP HEALTH, V7, P93, DOI 10.2147/JMDH.S55345; National Health and Medical Research Council (NHMRC), 2009, NHMRC ADD LEV EV GRA; Neil Michael Je, 2009, Rev Pain, V3, P6, DOI 10.1177/204946370900300203; Nunez-Cortes R, 2017, J ORTHOP SPORT PHYS, V47, P209, DOI 10.2519/jospt.2017.7089; Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860; Pons Tracey, 2011, Physiotherapy Theory and Practice, V27, P238, DOI 10.3109/09593985.2010.483268; Powell R, 2012, EUR J PAIN, V16, P600, DOI 10.1016/j.ejpain.2011.08.010; Pyszora A, 2017, SUPPORT CARE CANCER, V25, P2899, DOI 10.1007/s00520-017-3742-4; Smart KM, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010853.pub2; Thapa P, 2018, KOREAN J PAIN, V31, P155, DOI 10.3344/kjp.2018.31.3.155; van Haren IEPM, 2013, PHYS THER, V93, P514, DOI 10.2522/ptj.20120181; Vas L, 2014, PAIN MED, V15, P1781, DOI 10.1111/pme.12508; Wang L, 2016, CAN MED ASSOC J, V188, pE352, DOI 10.1503/cmaj.151276; Wang MJ, 2015, PAK J MED SCI, V31, P833, DOI [10.12669/pjms.314.7555, DOI 10.12669/PJMS.314.7555]; Werner MU, 2014, BRIT J ANAESTH, V113, P1, DOI 10.1093/bja/aeu012; Wong YY, 2015, J ORTHOP SPORT PHYS, V45, P1006, DOI 10.2519/jospt.2015.5766; Wylde V, 2017, BRIT J SURG, V104, P1293, DOI 10.1002/bjs.10601	47	4	4	3	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2019	14	12							e0226227	10.1371/journal.pone.0226227	http://dx.doi.org/10.1371/journal.pone.0226227			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP3QF	31834898	Green Published, Green Accepted, gold			2023-01-03	WOS:000534232900022
J	Ueda, R; Nakao, M; Maruyama, Y; Nakashima, A; Yamamoto, I; Matsuo, N; Tanno, Y; Ohkido, I; Ikeda, M; Yamamoto, H; Yokoyama, K; Yokoo, T				Ueda, Risa; Nakao, Masatsugu; Maruyama, Yukio; Nakashima, Akio; Yamamoto, Izumi; Matsuo, Nanae; Tanno, Yudo; Ohkido, Ichiro; Ikeda, Masato; Yamamoto, Hiroyasu; Yokoyama, Keitaro; Yokoo, Takashi			Effect of diabetes on incidence of peritoneal dialysis-associated peritonitis	PLOS ONE			English	Article							SINGLE-CENTER; RISK-FACTORS; MELLITUS; PREDICTORS; OUTCOMES	Background Several reports on patients with diabetes mellitus (DM) treated by peritoneal dialysis (PD) have shown a higher risk of PD-associated peritonitis compared to non-DM (NDM) patients. The aim of this study was to investigate the incidence of PD-associated peritonitis in DM patients. Methods We divided all patients who received PD at a single center between January 1980 and December 2012 into three groups according to era: Period 1 (n = 43, 1980-1993); Period 2 (n = 123, 1994-2004); and Period 3 (n = 207, 2005-2012). We investigated incidences of PD-associated peritonitis between patients with and without DM. Results In Periods 1 and 2, incidence of PD-associated peritonitis was higher in the DM group than in the NDM group (P<0.05). However, no difference according to presence of DM was seen in Period 3. Multivariate Cox regression analysis revealed DM as a risk factor for incidence of PD-associated peritonitis in Periods 1 and 2, but not in Period 3 (hazard ratio [HR], 2.49; 95% confidence interval [CI], 1.15 to 5.23; HR, 2.36; 95%CI, 1.13 to 4.58; and HR, 0.82; 95%CI, 0.41 to 1.54, respectively). Furthermore, the peritonitis-free period was significantly shorter in the DM group than in the DM group in Periods 1 and 2, whereas no significant difference was seen in Period 3 (P<0.01, P<0.01 and P = 0.55, respectively). Moreover, a significant interaction was seen between diabetes and study period, and became less pronounced during Period 3 (P<0.01). Conclusions The increased risk of peritonitis in diabetics reported in previous periods has not been evident in recent years.	[Ueda, Risa; Nakao, Masatsugu; Maruyama, Yukio; Nakashima, Akio; Yamamoto, Izumi; Matsuo, Nanae; Tanno, Yudo; Ohkido, Ichiro; Ikeda, Masato; Yamamoto, Hiroyasu; Yokoyama, Keitaro; Yokoo, Takashi] Jikei Univ, Sch Med, Dept Internal Med, Div Nephrol & Hypertens, Tokyo, Japan	Jikei University	Nakao, M (corresponding author), Jikei Univ, Sch Med, Dept Internal Med, Div Nephrol & Hypertens, Tokyo, Japan.	2013nakaomasatsugu@gmail.com	Ikeda, Masato/AHD-4141-2022	Ikeda, Masato/0000-0003-3583-5975; shang tian, li sha/0000-0002-1592-1748	Baxter International Inc.; Terumo Corporation; Baxter International Inc. [16CECPDAP0002]	Baxter International Inc.; Terumo Corporation; Baxter International Inc.	YM has received scholarship funds from Baxter International Inc. and Terumo Corporation. MI has received scholarship funds from Baxter International Inc. and Terumo Corporation. YT has received research grants from Baxter International Inc. (grant number 16CECPDAP0002). The specific roles of these authors are articulated in the 'author contributions' section. The funders had no direct involvement in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or the preparation, review, or approval of the manuscript.	Chow KM, 2005, PERITON DIALYSIS INT, V25, P374; Daly C, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003078.pub2; Govindarajulu S, 2010, PERITON DIALYSIS INT, V30, P311, DOI 10.3747/pdi.2008.00258; Han SH, 2007, NEPHROL DIAL TRANSPL, V22, P2653, DOI 10.1093/ndt/gfm242; Hiramatsu T, 2015, THER APHER DIAL, V19, P598, DOI 10.1111/1744-9987.12319; Ito H, 2013, DIABETES THER, V4, P321, DOI 10.1007/s13300-013-0029-8; Johnson DW, 2012, PERITON DIALYSIS INT, V32, P497, DOI 10.3747/pdi.2012.00052; Joshi N, 1999, NEW ENGL J MED, V341, P1906, DOI 10.1056/NEJM199912163412507; Kitterer D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135969; Kramer A, 2018, CLIN KIDNEY J, V11, P108, DOI 10.1093/ckj/sfx149; Lee MJ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003118; Li PKT, 2016, PERITON DIALYSIS INT, V36, P481, DOI 10.3747/pdi.2016.00078; Martin LC, 2011, CLIN J AM SOC NEPHRO, V6, P1944, DOI 10.2215/CJN.11431210; Masakane I., 2018, RENAL REPLACE THER, V4, DOI [10.1186/s41100-018-0149-8, DOI 10.1186/S41100-018-0149-8]; Masakane I, 2015, THER APHER DIAL, V19, P540, DOI 10.1111/1744-9987.12378; Nadeau-Fredette AC, 2016, PERITON DIALYSIS INT, V36, P509, DOI 10.3747/pdi.2015.00146; Nakao M, 2017, NEPHROLOGY, V22, P907, DOI 10.1111/nep.12911; Nakao M, 2016, THER APHER DIAL, V20, P60, DOI 10.1111/1744-9987.12372; Nessim SJ, 2009, CLIN J AM SOC NEPHRO, V4, P1195, DOI 10.2215/CJN.00910209; Nishina M, 2014, CLIN EXP NEPHROL, V18, P649, DOI 10.1007/s10157-013-0872-y; O'Shea S, 2009, BMC NEPHROL, V10, DOI 10.1186/1471-2369-10-19; Oo TN, 2005, AM J KIDNEY DIS, V45, P372, DOI 10.1053/j.ajkd.2004.10.008; Ozener C, 2014, RENAL FAILURE, V36, P149, DOI 10.3109/0886022X.2013.843275; Park SH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004543; Rodriguez-Carmona A, 2014, PERITON DIALYSIS INT, V34, P618, DOI 10.3747/pdi.2012.00185; Saran R, 2018, AM J KIDNEY DIS, V71, pS1, DOI 10.1053/j.ajkd.2018.01.002; Shah BR, 2003, DIABETES CARE, V26, P510, DOI 10.2337/diacare.26.2.510; Shukla A, 2006, NEPHROL DIAL TRANSPL, V21, P3545, DOI 10.1093/ndt/gfl407; Srivastava S, 2011, KIDNEY INT, V80, P986, DOI 10.1038/ki.2011.244; Tsai CC, 2013, SURG INFECT, V14, P540, DOI 10.1089/sur.2012.195; Wang Q, 2003, AM J KIDNEY DIS, V41, P664, DOI 10.1053/ajkd.2003.50128	31	5	8	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2019	14	12							e0225316	10.1371/journal.pone.0225316	http://dx.doi.org/10.1371/journal.pone.0225316			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP1HF	31830041	Green Published, gold			2023-01-03	WOS:000534070200020
J	de Prada, VG; Ortega, JF; Morales-Palomo, F; Ramirez-Jimenez, M; Moreno-Cabanas, A; Mora-Rodriguez, R				Guio de Prada, Valle; Fernando Ortega, Juan; Morales-Palomo, Felix; Ramirez-Jimenez, Miguel; Moreno-Cabanas, Alfonso; Mora-Rodriguez, Ricardo			Women with metabolic syndrome show similar health benefits from high-intensity interval training than men	PLOS ONE			English	Article							UPTAKE EFFICIENCY SLOPE; TESTING DATA ASSESSMENT; MAXIMAL FAT OXIDATION; OXYGEN-UPTAKE; CARDIORESPIRATORY FITNESS; CLINICAL RECOMMENDATIONS; PHYSICAL-ACTIVITY; SKELETAL-MUSCLE; HEART-FAILURE; EXERCISE	High-intensity interval training (HIIT), is effective to improve cardiorespiratory fitness (CRF) and metabolic syndrome (MetS) components in adults. However, it is unclear if CRF and MetS components respond similarly in men and women after HIIT. For 16 weeks, 63 women (53 +/- 7 years) and 56 men (55 +/- 8 years) with MetS underwent a three day/week HIIT program. Bodyweight and composition, VO2MAX, surrogate parameters of CRF (Ventilatory threshold (VT), oxygen uptake efficiency slope (OUES) and VE/VCO2 slope), maximal rate of fat oxidation (MFO), and MetS components were assessed before and after training. All reported variables were analyzed by split-plot ANOVA looking for time by sex interactions. Before training men had higher absolute values of VO2MAX (58.6%), and MFO (24.6%), while lower body fat mass (10.5%) than women (all P<0.05). After normalization by fat-free mass (FFM), VO2MAX remained 16.6% higher in men (P<0.05), whereas differences in MFO disappeared (P = 0.292). After intervention VO2MAX (P<0.001), VO2 at VT (P<0.001), OUES (P<0.001), and VE/VCO2 slope (P<0.001) increased without differences by sex (P>0.05). After training MetS Z-score (P<0.001) improved without differences between men and women (P>0.05). From the MetS components, only blood pressure (P<0.001) and waist circumference (P<0.001) improved across time, without differences by sex. In both, women and men, changes in OUES (r = 0.685 and r = 0.445, respectively), and VO2 at VT (r = 0.378, and r = 0.445, respectively), correlated with VO2MAX. While only bodyweight changes correlated with MetS Z-score changes (r = 0.372, and = 0.300, respectively). Despite baseline differences, 16-weeks of HIIT similarly improved MetS, cardiorespiratory and metabolic fitness in women and men with MetS. This suggests that there are no restrictions due to sex on the benefits derived from an intense exercise program in the health of MetS participants.	[Guio de Prada, Valle] Diputacion Toledo, Sports Med Ctr, Toledo, Spain; [Guio de Prada, Valle; Fernando Ortega, Juan; Morales-Palomo, Felix; Ramirez-Jimenez, Miguel; Moreno-Cabanas, Alfonso; Mora-Rodriguez, Ricardo] Univ Castilla La Mancha, Exercise Physiol Lab, Toledo, Spain	Universidad de Castilla-La Mancha	Mora-Rodriguez, R (corresponding author), Univ Castilla La Mancha, Exercise Physiol Lab, Toledo, Spain.	ricardo.mora@uclm.es	Moreno-Cabañas, Alfonso/AAN-9353-2021; Morales Palomo, Felix/ABW-4574-2022; Mora-Rodriguez, Ricardo/AAC-9096-2022; Morales Palomo, Felix/AAH-1607-2019	Moreno-Cabañas, Alfonso/0000-0002-5117-425X; Morales Palomo, Felix/0000-0001-8881-8592; Morales Palomo, Felix/0000-0001-8881-8592; Ramirez-Jimenez, Miguel/0000-0002-3085-4061; Mora-Rodriguez, Ricardo/0000-0001-9252-4933; Guio de Prada, Maria/0000-0003-4350-5562	Spanish Government (Ministerio de Economia y Competitividad) [DEP-2017-83244-R]	Spanish Government (Ministerio de Economia y Competitividad)	Spanish Government (Ministerio de Economia y Competitividad, DEP-2017-83244-R). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644; Anaya SA, 2009, MED SCI SPORT EXER, V41, P971, DOI 10.1249/MSS.0b013e3181930009; Arena R, 2001, J Cardiopulm Rehabil, V21, P130, DOI 10.1097/00008483-200105000-00002; Arena R, 2009, CIRC-HEART FAIL, V2, P113, DOI 10.1161/CIRCHEARTFAILURE.108.834168; Astorino TA, 2018, EUR J APPL PHYSIOL, V118, P1811, DOI 10.1007/s00421-018-3910-3; Astorino TA, 2017, EUR J APPL PHYSIOL, V117, P745, DOI 10.1007/s00421-017-3535-y; Astorino TA, 2011, EUR J APPL PHYSIOL, V111, P1279, DOI 10.1007/s00421-010-1741-y; ASTRAND I, 1960, Acta Physiol Scand Suppl, V49, P1; Baba R, 1996, J AM COLL CARDIOL, V28, P1567, DOI 10.1016/S0735-1097(96)00412-3; Brage S, 2004, DIABETES CARE, V27, P2141, DOI 10.2337/diacare.27.9.2141; Dalleck LC, 2012, RES SPORTS MED, V20, P118, DOI 10.1080/15438627.2012.660825; Dandanell S, 2017, APPL PHYSIOL NUTR ME, V42, P405, DOI 10.1139/apnm-2016-0518; Franks PW, 2004, DIABETES CARE, V27, P1187, DOI 10.2337/diacare.27.5.1187; FRAYN KN, 1983, J APPL PHYSIOL, V55, P628, DOI 10.1152/jappl.1983.55.2.628; Gademan MGJ, 2008, EUR J CARDIOV PREV R, V15, P140, DOI 10.1097/HJR.0b013e3282ef19986; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Guazzi M, 2016, CIRCULATION, V133, pE694, DOI 10.1161/CIR.0000000000000406; Guazzi M, 2012, CIRCULATION, V126, P2261, DOI 10.1161/CIR.0b013e31826fb946; de Prada VG, 2019, EUR J SPORT SCI, V19, P549, DOI 10.1080/17461391.2018.1540659; HANSEN JE, 1984, AM REV RESPIR DIS, V129, pS49, DOI 10.1164/arrd.1984.129.2P2.S49; Hassinen M, 2008, DIABETES CARE, V31, P1242, DOI 10.2337/dc07-2298; Haufe S, 2010, HORM METAB RES, V42, P215, DOI 10.1055/s-0029-1242745; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; Holloszy JO, 2011, COMPR PHYSIOL, V1, P921, DOI 10.1002/cphy.c100052; HOSSACK KF, 1982, J APPL PHYSIOL, V53, P799, DOI 10.1152/jappl.1982.53.4.799; Howden EJ, 2015, J APPL PHYSIOL, V119, P37, DOI 10.1152/japplphysiol.00092.2015; Jeukendrup AE, 2005, INT J SPORTS MED, V26, pS28, DOI 10.1055/s-2004-830512; Katzmarzyk PT, 2003, MED SCI SPORT EXER, V35, P1703, DOI 10.1249/01.MSS.0000089337.73244.9B; Keller-Ross ML, 2018, IJC HEART VASC, V21, P107, DOI 10.1016/j.ijcha.2018.10.009; Kelley DE, 1999, AM J PHYSIOL-ENDOC M, V277, pE1130; Kemps HMC, 2010, EUR J APPL PHYSIOL, V108, P469, DOI 10.1007/s00421-009-1230-3; Lakens D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00863; Lakka TA, 2003, MED SCI SPORT EXER, V35, P1279, DOI 10.1249/01.MSS.0000079076.74931.9A; Lepretre PM, 2009, INT J CLIN PRACT, V63, P1472, DOI 10.1111/j.1742-1241.2009.02120.x; MARTIN WH, 1991, CIRCULATION, V84, P654, DOI 10.1161/01.CIR.84.2.654; MARTIN WH, 1993, AM J PHYSIOL, V265, pE708, DOI 10.1152/ajpendo.1993.265.5.E708; Maunder E, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00599; McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054; Metcalfe RS, 2016, APPL PHYSIOL NUTR ME, V41, P1117, DOI 10.1139/apnm-2016-0253; Meyer T, 2005, INT J SPORTS MED, V26, pS38, DOI 10.1055/s-2004-830514; Mora-Rodriguez R, 2020, DIABETES METAB, V46, P210, DOI 10.1016/j.diabet.2019.05.004; Mora-Rodriguez R, 2016, INT J SPORTS MED, V37, P274, DOI 10.1055/s-0035-1564259; Mora-Rodriguez R, 2014, NUTR METAB CARDIOVAS, V24, P792, DOI 10.1016/j.numecd.2014.01.011; Morita N, 2013, CIRC J, V77, P646, DOI 10.1253/circj.CJ-12-0607; Mozumdar A, 2011, DIABETES CARE, V34, P216, DOI 10.2337/dc10-0879; OGAWA T, 1992, CIRCULATION, V86, P494, DOI 10.1161/01.CIR.86.2.494; Okura T, 2007, OBESITY, V15, P2478, DOI 10.1038/oby.2007.294; Onofre T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172894; Poggio R, 2010, AM HEART J, V160, P1004, DOI 10.1016/j.ahj.2010.08.037; Poole DC, 2017, J APPL PHYSIOL, V122, P997, DOI 10.1152/japplphysiol.01063.2016; San-Millan I, 2018, SPORTS MED, V48, P467, DOI 10.1007/s40279-017-0751-x; Skinner JS, 2001, J APPL PHYSIOL, V90, P1770, DOI 10.1152/jappl.2001.90.5.1770; SPINA RJ, 1992, J APPL PHYSIOL, V72, P2458, DOI 10.1152/jappl.1992.72.6.2458; SUE DY, 1988, CHEST, V94, P931, DOI 10.1378/chest.94.5.931; Sun XG, 2002, AM J RESP CRIT CARE, V166, P1443, DOI 10.1164/rccm.2202033; Tarnopolsky MA, 2000, CAN J APPL PHYSIOL, V25, P312, DOI 10.1139/h00-024; Taylor KL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125166; Van Laethem C, 2007, EUR J HEART FAIL, V9, P625, DOI 10.1016/j.ejheart.2007.01.007; Venables MC, 2005, J APPL PHYSIOL, V98, P160, DOI 10.1152/japplphysiol.00662.2003; Wang CH, 2010, ANN NY ACAD SCI, V1201, P157, DOI 10.1111/j.1749-6632.2010.05625.x; Woo JS, 2006, J AM COLL CARDIOL, V47, P1049, DOI 10.1016/j.jacc.2005.09.066; Wu YT, 2014, CURR PHARM DESIGN, V20, P5510, DOI 10.2174/1381612820666140306103401	62	3	3	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2019	14	12							e0225893	10.1371/journal.pone.0225893	http://dx.doi.org/10.1371/journal.pone.0225893			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP0TY	31821339	Green Published, gold, Green Submitted			2023-01-03	WOS:000534035700024
J	Buijze, GA; De Jong, HMY; Kox, M; van de Sande, MG; Van Schaardenburg, D; Van Vugt, RM; Popa, CD; Pickkers, P; Baeten, DLP				Buijze, G. A.; De Jong, H. M. Y.; Kox, M.; van de Sande, M. G.; Van Schaardenburg, D.; Van Vugt, R. M.; Popa, C. D.; Pickkers, P.; Baeten, D. L. P.			An add-on training program involving breathing exercises, cold exposure, and meditation attenuates inflammation and disease activity in axial spondyloarthritis - A proof of concept trial	PLOS ONE			English	Article							INNATE IMMUNE-RESPONSE; NERVOUS-SYSTEM	Objectives The primary objective of this trial was to assess safety and anti-inflammatory effects of an add-on training program involving breathing exercises, cold exposure, and meditation in patients with axial spondyloarthritis Methods This study was an open-label, randomised, one-way crossover clinical proof-of-concept trial. Twenty-four patients with moderately active axial spondyloarthritis(ASDAS > 2.1) and hs-CRP >= 5mg/L were included and randomised to an intervention (n = 13) and control group (n = 11) group that additionally received the intervention after the control period. The intervention period lasted for 8 weeks. The primary endpoint was safety, secondary endpoints were change in hs-CRP, serum calprotectin levels and ESR over the 8-week period. Exploratory endpoints included disease activity measured by ASDAS-CRP and BASDAI, quality of life (SF-36, EQ-5D, EQ-5D VAS), and hospital anxiety and depression (HADS). Results We found no significant differences in adverse events between groups, with one serious adverse event occurring 8 weeks after end of the intervention and judged 'unrelated'. During the 8-week intervention period, there was a significant decline of ESR from (median [interquartile range] to 16 [9-26.5] to 9 [5-23] mm/hr, p = 0.040, whereas no effect was found in the control group (from 14 [8.3-27.3] to 16 [5-37] m/hr, p = 0.406). ASDAS-CRP declined from 3.1 [2.5-3.6] to 2.3 [1.9-3.2] in the intervention group (p = 0.044). A similar trend was observed for serum calprotectin (p = 0.064 in the intervention group versus p = 0.182 in the control group), but not for hs-CRP. Conclusions This proof-of-concept study in axial spondyloarthritis met its primary endpoint with no safety signals during the intervention. There was a significant decrease in ESR levels and ASDASCRP upon the add-on training program in the intervention group. These findings warrant full-scale randomised controlled trials of this novel therapeutic approach in patients with inflammatory conditions.	[Buijze, G. A.] Univ Amsterdam, Dept Orthopaed Surg, Amsterdam UMC, Amsterdam, Netherlands; [De Jong, H. M. Y.; van de Sande, M. G.; Van Schaardenburg, D.; Baeten, D. L. P.] Univ Amsterdam, Amsterdam Rheumatol & Immunol Ctr, Dept Rheumatol & Clin Immunol, Amsterdam UMC, Amsterdam, Netherlands; [Kox, M.; Pickkers, P.] RadboudUMC Nijmegen, Dept Intens Care Med, Nijmegen Inst Infect, Nijmegen, Netherlands; [Van Schaardenburg, D.] Amsterdam Rheumatol & Immunol Ctr, Reade, Amsterdam, Netherlands; [Van Vugt, R. M.] Vrije Univ Amsterdam, Dept Rheumatol & Clin Immunol, Amsterdam UMC, Amsterdam, Netherlands; [Popa, C. D.] Sint Maartenskliniek, Dept Rheumatol, Nijmegen, Netherlands; [Popa, C. D.] RadboudUMC Nijmegen, Dept Rheumatol, Nijmegen, Netherlands	University of Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Sint Maartens Clinic	Buijze, GA (corresponding author), Univ Amsterdam, Dept Orthopaed Surg, Amsterdam UMC, Amsterdam, Netherlands.	g.a.buijze@amc.uva.nl						Ambarus C, 2012, CURR OPIN RHEUMATOL, V24, P351, DOI 10.1097/BOR.0b013e3283534df4; Dougados M, 2011, LANCET, V377, P2127, DOI 10.1016/S0140-6736(11)60071-8; GARRETT S, 1994, J RHEUMATOL, V21, P2286; Kox M, 2014, P NATL ACAD SCI USA, V111, P7379, DOI 10.1073/pnas.1322174111; Kox M, 2012, PSYCHOSOM MED, V74, P489, DOI 10.1097/PSY.0b013e3182583c6d; Lukas C, 2009, ANN RHEUM DIS, V68, P18, DOI 10.1136/ard.2008.094870; Rudwaleit M, 2009, ANN RHEUM DIS, V68, P777, DOI 10.1136/ard.2009.108233; Turina MC, 2014, CALPROTECTIN S100A8, P1; van Teeseling MCF, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01264; Ware JE, 2012, CONCEPTUAL FRAMEWORK, V30, P473; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	12	11	11	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2019	14	12							e0225749	10.1371/journal.pone.0225749	http://dx.doi.org/10.1371/journal.pone.0225749			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO9FT	31790484	Green Submitted, Green Published, gold			2023-01-03	WOS:000533930800063
J	Wales, J				Wales, Joshua			Last Song - Sharing Humanity while Maintaining Boundaries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SELF-DISCLOSURE	When his home palliative care patient asks him to sing for her, the physician hesitates. Boundary crossings create uncertainty and risk shifting the focus from the patient to the physician. Yet patients want physicians who aren't robots, who are friendly and relatable.	[Wales, Joshua] Univ Toronto, Temmy Latner Ctr Palliat Care, Toronto, ON, Canada	University of Toronto	Wales, J (corresponding author), Univ Toronto, Temmy Latner Ctr Palliat Care, Toronto, ON, Canada.							Chen JA, 2018, ACAD MED, V93, P1624, DOI 10.1097/ACM.0000000000002305; Curran KA, 2014, NEW ENGL J MED, V371, P8, DOI 10.1056/NEJMp1404119; Lussier MT, 2007, CAN FAM PHYSICIAN, V53, P421; McDaniel SH, 2007, ARCH INTERN MED, V167, P1321, DOI 10.1001/archinte.167.12.1321	4	1	1	2	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 14	2019	381	20					1894	1895		10.1056/NEJMp1907600	http://dx.doi.org/10.1056/NEJMp1907600			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JO6FL	31722149				2023-01-03	WOS:000497673000004
J	Lentz, TA; Harman, JS; Marlow, NM; Beneciuk, JM; Fillingim, RB; George, SZ				Lentz, Trevor A.; Harman, Jeffrey S.; Marlow, Nicole M.; Beneciuk, Jason M.; Fillingim, Roger B.; George, Steven Z.			Factors associated with persistently high-cost health care utilization for musculoskeletal pain	PLOS ONE			English	Article							LOW-BACK-PAIN; SUPER-UTILIZERS; OLDER-ADULTS; POPULATION; EXPENDITURES; COMORBIDITY; OUTCOMES; OSTEOARTHRITIS; DEPRESSION; MANAGEMENT	Background Musculoskeletal pain conditions incur high costs and produce significant personal and public health consequences, including disability and opioid-related mortality. Persistence of high-cost health care utilization for musculoskeletal pain may help identify system inefficiencies that could limit value of care. The objective of this study was to identify factors associated with persistent high-cost utilization among individuals seeking health care for musculoskeletal pain. Methods This was a retrospective cohort study of Medical Expenditure Panel Survey data (2008-2013) that included a non-institutionalized, population-based sample of individuals seeking health care for a musculoskeletal pain condition (n = 12,985). Expenditures associated with musculoskeletal pain conditions over two consecutive years were analyzed from prescribed medicine, office-based medical provider visits, outpatient department visits, emergency room visits, inpatient hospital stays, and home health visits. Persistent high-cost utilization was defined as being in the top 15th percentile for annual musculoskeletal pain-related expenditures over 2 consecutive years. We used multinomial regression to determine which modifiable and non-modifiable sociodemographic, health, and pain-related variables were associated with persistent high-cost utilization. Results Approximately 35% of direct costs for musculoskeletal pain were concentrated among the 4% defined as persistent high-cost utilizers. Non-modifiable variables associated with expenditure group classification included age, race, poverty level, geographic region, insurance status, diagnosis type and total number of musculoskeletal pain diagnoses. Modifiable variables associated with increased risk of high expenditure classification were higher number of missed work days, greater pain interference, and higher use of prescription medication for pain, while higher self-reported physical and mental health were associated with lower risk of high expenditure classification. Conclusions Health care delivery models that prospectively identify these potentially modifiable factors may improve the costs and value of care for individuals with musculoskeletal pain prone to risk for high-cost care episodes.	[Lentz, Trevor A.; George, Steven Z.] Duke Univ, Duke Clin Res Inst, Durham, NC 27708 USA; [Lentz, Trevor A.; George, Steven Z.] Duke Univ, Dept Orthopaed Surg, Durham, NC 27708 USA; [Harman, Jeffrey S.] Florida State Univ, Dept Behav Sci & Social Med, Tallahassee, FL 32306 USA; [Marlow, Nicole M.] Univ Florida, Dept Hlth Serv Res Management & Policy, Gainesville, FL USA; [Beneciuk, Jason M.] Univ Florida, Brooks Rehabil, Dept Phys Therapy, Coll Publ Hlth & Hlth Profess Res Collaborat, Gainesville, FL USA; [Fillingim, Roger B.] Univ Florida, Pain Res & Intervent Ctr Excellence, Gainesville, FL USA	Duke University; Duke University; State University System of Florida; Florida State University; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Lentz, TA (corresponding author), Duke Univ, Duke Clin Res Inst, Durham, NC 27708 USA.; Lentz, TA (corresponding author), Duke Univ, Dept Orthopaed Surg, Durham, NC 27708 USA.	trevor.lentz@duke.edu		George, Steven/0000-0003-4988-9421	Foundation for Physical Therapy Promotion of Doctoral Studies I II Awards; National Institutes of Health (NIH) Rehabilitation Research Career Development Program [K12-HD055929]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD055929] Funding Source: NIH RePORTER	Foundation for Physical Therapy Promotion of Doctoral Studies I II Awards; National Institutes of Health (NIH) Rehabilitation Research Career Development Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by the Foundation for Physical Therapy (https://foundation4pt.org) Promotion of Doctoral Studies I & II Awards to TAL; and the National Institutes of Health (NIH) Rehabilitation Research Career Development Program (https://www.nichd.nih.gov) K12-HD055929 to JMB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; [Anonymous], 2019, MMWR Morb Mortal Wkly Rep, V68, P409, DOI 10.15585/mmwr.mm6817a7; [Anonymous], 2000, SAS SYSTEM REGRESSIO; Bair MJ, 2003, ARCH INTERN MED, V163, P2433, DOI 10.1001/archinte.163.20.2433; Blackwell DL, 2014, VITAL HLTH STAT, V10, P1; Briggs AM, 2016, GERONTOLOGIST, V56, pS243, DOI 10.1093/geront/gnw002; Cahana A, 2013, PAIN MED, V14, P36, DOI 10.1111/pme.12013; Charlson M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112479; Chechulin Yuriy, 2014, Healthc Policy, V9, P68; Cohen J., 1997, SAMPLE DESIGN MED EX; Cohen S, 2009, TESTING SURVEY ATTRI; Colla CH, 2018, HEALTH SERV RES, V53, P730, DOI 10.1111/1475-6773.12665; Coughlan D, 2014, VALUE HEALTH, V17, P90, DOI 10.1016/j.jval.2013.10.004; Cross MJ, 2006, RHEUMATOLOGY, V45, P92, DOI 10.1093/rheumatology/kei114; Cullen KL, 2018, J OCCUP REHABIL, V28, P1, DOI 10.1007/s10926-016-9690-x; de Oliveira C, 2016, HEALTH AFFAIR, V35, P36, DOI 10.1377/hlthaff.2015.0278; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Elliott MN, 2008, HEALTH SERV RES, V43, P833, DOI 10.1111/j.1475-6773.2007.00820.x; Emeche U, 2015, ANN FAM MED, V13, P6, DOI 10.1370/afm.1746; Figueroa JF, 2018, ANN INTERN MED, V169, P528, DOI 10.7326/M18-0085; Franche RL, 2005, J OCCUP REHABIL, V15, P607, DOI 10.1007/s10926-005-8038-8; Fujii T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193208; Garfinkel S A, 1988, Health Care Financ Rev, V9, P41; Gaskin DJ, 2012, J PAIN, V13, P715, DOI 10.1016/j.jpain.2012.03.009; Gatchel RJ, 2018, J PAIN, V19, P837, DOI 10.1016/j.jpain.2018.02.015; Guilcher SJT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149179; Gurung T, 2015, PHYSIOTHERAPY, V101, P243, DOI 10.1016/j.physio.2015.01.006; Harris LJ, 2016, J EMERG MED, V50, pE203, DOI 10.1016/j.jemermed.2015.09.002; Hart DL, 2011, PHYS THER, V91, P1812, DOI 10.2522/ptj.20100377; Heslop L, 2005, HEALTH SERV MANAG RE, V18, P232, DOI 10.1258/095148405774518633; HORNERJOHNSON W, 1999, HLTH SERV RES, V0049, P01980, DOI DOI 10.1111/1475-6773.12195; Karjalainen K, 2003, SPINE, V28, P2634, DOI 10.1097/01.BRS.0000099097.61495.2E; Kelsall HL, 2014, PAIN, V155, P685, DOI 10.1016/j.pain.2013.12.025; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Leininger LJ, 2015, MED CARE, V53, P729, DOI 10.1097/MLR.0000000000000391; Lentz TA, 2017, PHYS THER, V97, P354, DOI 10.2522/ptj.20160167; Luo XM, 2004, SPINE, V29, P79, DOI 10.1097/01.BRS.0000105527.13866.0F; Maeng DD, 2015, PAIN RES MANAG, V20, P234, DOI 10.1155/2015/862702; Martin BI, 2008, JAMA-J AM MED ASSOC, V299, P656, DOI 10.1001/jama.299.6.656; Merkesdal S, 2005, INT J REHABIL RES, V28, P119, DOI 10.1097/00004356-200506000-00004; Mitchell EM, 2001, CONCENTRATION HLTH E; Nyman JA, 2004, HEALTH AFFAIR, V23, P194, DOI 10.1377/hlthaff.23.5.194; Otani Koichiro, 2009, Health Mark Q, V26, P198, DOI 10.1080/07359680903263599; Prochaska JJ, 2012, INT J METH PSYCH RES, V21, P88, DOI 10.1002/mpr.1349; Ritzwoller DP, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-72; Rosella LC, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0532-2; Roydhouse JK, 2018, HEALTH SERV RES, V53, P3809, DOI 10.1111/1475-6773.12980; Roydhouse JK, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-017-0823-5; Rundell SD, 2017, ARCH PHYS MED REHAB, V98, P43, DOI 10.1016/j.apmr.2016.06.022; Sennehed CP, 2018, PAIN, V159, P1456, DOI 10.1097/j.pain.0000000000001216; Thomas E, 2004, PAIN, V110, P361, DOI 10.1016/j.pain.2004.04.017; Thorn BE, 2018, ANN INTERN MED, V168, P471, DOI 10.7326/M17-0972; Traeger AC, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002019; *US BUR LAB STAT, BLS MEAS PRIC CHANG; Von Korff M, 2016, J PAIN, V17, P1068, DOI 10.1016/j.jpain.2016.06.009; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003	58	20	20	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2019	14	11							e0225125	10.1371/journal.pone.0225125	http://dx.doi.org/10.1371/journal.pone.0225125			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LN1IV	31710655	Green Published, gold			2023-01-03	WOS:000532699900041
J	Droit-Volet, S; Chaulet, M; Dutheil, F; Dambrun, M				Droit-Volet, Sylvie; Chaulet, Magali; Dutheil, Frederic; Dambrun, Michael			Mindfulness meditation, time judgment and time experience: Importance of the time scale considered (seconds or minutes)	PLOS ONE			English	Article							STRESS REDUCTION; SELF; PERCEPTION; DURATION; PASSAGE; NETWORK	This manuscript presents two studies on the effect of mindfulness meditation on duration judgment and its relationship to the subjective experience of time when the interval durations are on the second or the minute time scale. After the first 15 minutes of a 30-min meditation or control exercise, meditation-trained participants judged interval durations of 15 to 50 s or 2 to 6 min, during which they performed either a mindfulness meditation exercise or a control exercise. The participants' scores on the self-reported scales indicated the effectiveness of the meditation exercise, as it increased the level of present-moment awareness and happiness and decreased that of anxiety. The results showed an underestimation of time for the short interval durations and an overestimation of time for the long intervals, although the participants always reported that time passed faster with meditation than with the control exercise. Further statistical analyses revealed that the focus on the present-moment significantly mediated the exercise effect on the time estimates for long durations. The inversion in time estimates between the two time scales is explained in terms of the different mechanisms underlying the judgment of short and long durations, i.e., the cognitive mechanisms of attention and memory, respectively.	[Droit-Volet, Sylvie; Chaulet, Magali; Dambrun, Michael] Univ Clermont Auvergne, CNRS, Lapsco, UMR 6024, Clermont Ferrand, France; [Dutheil, Frederic] Univ Clermont Auvergne, CHU Clermont Ferrand, Prevent & Occupat Med,WittyFit, CNRS,Lapsco,UMR 6024,Physiol & Psychosocial Stres, Clermont Ferrand, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite Clermont Auvergne (UCA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite Clermont Auvergne (UCA); CHU Clermont Ferrand	Droit-Volet, S (corresponding author), Univ Clermont Auvergne, CNRS, Lapsco, UMR 6024, Clermont Ferrand, France.	Sylvie.droit-volet@uca.fr		Droit-Volet, Sylvie/0000-0002-1523-952X; DAMBRUN, Michael/0000-0003-1418-7294				Ainsworth B, 2013, PSYCHIAT RES, V210, P1226, DOI 10.1016/j.psychres.2013.09.002; [Anonymous], 2019, JAM PROJ; Berkovich-Ohana A, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00912; Berkovich-Ohana A, 2012, CLIN NEUROPHYSIOL, V123, P700, DOI 10.1016/j.clinph.2011.07.048; BLOCK RA, 1978, J EXP PSYCHOL-HUM L, V4, P656, DOI 10.1037/0278-7393.4.6.656; Block RA., 1989, TIME HUMAN COGNITION, P333, DOI [10.1016/S0166-4115(08)61046-8, DOI 10.1016/S0166-4115(08)61046-8, 10.1016/S0166-4115(08)61046-8.]; Brown S. W, 2010, ATTENTION TIME, P107, DOI DOI 10.1093/ACPROF:0S0/9780199563456.003.0008; Chen KW, 2012, DEPRESS ANXIETY, V29, P545, DOI 10.1002/da.21964; Dambrun M, MINDFULNESS; Dambrun M, 2017, PEERJ, V5, DOI 10.7717/peerj.3306; Dambrun M, 2016, CONSCIOUS COGN, V46, P89, DOI 10.1016/j.concog.2016.09.013; Dambrun M, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00016; Droit-Volet S, 2015, CONSCIOUS COGN, V31, P86, DOI 10.1016/j.concog.2014.10.007; Droit-Volet S, 2019, PSYCH J, V8, P51, DOI 10.1002/pchj.270; Droit-Volet S, 2018, CURR DIR PSYCHOL SCI, V27, P422, DOI 10.1177/0963721418779978; Droit-Volet S, 2018, MINDFULNESS, V9, P1557, DOI 10.1007/s12671-018-0903-6; Droit-Volet S, 2018, PLOS ONE, V13, DOI [10.1371/journal.pone.0195357, 10.1371/journal.pone.0195397]; Droit-Volet S, 2017, MINDFULNESS, V8, P266, DOI 10.1007/s12671-016-0597-6; Droit-Volet S, 2017, ACTA PSYCHOL, V173, P116, DOI 10.1016/j.actpsy.2016.12.010; Droit-Volet S, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00176; Fabio RA, 2018, COGN PROCESS, V19, P73, DOI 10.1007/s10339-017-0844-3; Farb NAS, 2010, EMOTION, V10, P25, DOI 10.1037/a0017151; Glisksohn J, 2017, FRONT HUM NEUROSCI, V11, P497, DOI [10.3389/fnhum.2017.00497, DOI 10.3389/FNHUM.2017.00497]; Hayes A.F., 2018, INTRO MEDIATION MODE; Holzel BK, 2011, PERSPECT PSYCHOL SCI, V6, P537, DOI 10.1177/1745691611419671; Jackson J.L., 1985, TIME MIND BEHAV, P169; Jha AP, 2007, COGN AFFECT BEHAV NE, V7, P109, DOI 10.3758/CABN.7.2.109; KABATZINN J, 1992, AM J PSYCHIAT, V149, P936; Khoury B, 2015, J PSYCHOSOM RES, V78, P519, DOI 10.1016/j.jpsychores.2015.03.009; Kramer RSS, 2013, CONSCIOUS COGN, V22, P846, DOI 10.1016/j.concog.2013.05.008; Krull JL, 2001, MULTIVAR BEHAV RES, V36, P249, DOI 10.1207/S15327906MBR3602_06; Lupianez J., 2010, ATTENTION TIME, P17; Malinowski P, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00008; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; Moore A, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00018; Moore A, 2009, CONSCIOUS COGN, V18, P176, DOI 10.1016/j.concog.2008.12.008; Nair AK, 2017, CONSCIOUS COGN, V53, P176, DOI 10.1016/j.concog.2017.06.002; Ornstein RE., 1969, EXPERIENCE TIME; Otten S, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01215; Poynter D., 1989, TIME HUMAN COGNITION, P305; Prevert Jacques, 1949, PAROLES; Raffone A, 2017, MINDFULNESS, V8, P1, DOI 10.1007/s12671-016-0654-1; Rahl HA, 2017, EMOTION, V17, P224, DOI 10.1037/emo0000250; Rattat AC, 2012, BEHAV RES METHODS, V44, P67, DOI 10.3758/s13428-011-0135-3; Schotz E, 2016, PERS INDIV DIFFER, V93, P16, DOI 10.1016/j.paid.2015.10.023; Schumer MC, 2018, J CONSULT CLIN PSYCH, V86, P569, DOI 10.1037/ccp0000324; Shapiro SL, 2008, J CLIN PSYCHOL, V64, P840, DOI 10.1002/jclp.20491; Sucala M., 2013, TRANSYLVANIAN J PSYC, V14, P243; Tang YY, 2015, NAT REV NEUROSCI, V16, P213, DOI 10.1038/nrn3916; THOMAS EAC, 1975, PERCEPT PSYCHOPHYS, V17, P363, DOI 10.3758/BF03199347; Thones S., 2016, PSYCHOL CONSCIOUS, V3, P316, DOI [10.1037/cns0000088, DOI 10.1037/CNS0000088, https://doi.org/10.1037/cns0000088]; Van Dam NT, 2014, MINDFULNESS, V5, P574, DOI 10.1007/s12671-013-0229-3; Wearden JH, 2015, CONSCIOUS COGN, V38, P165, DOI 10.1016/j.concog.2015.06.005; Weiner L, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00786; Wittmann M., 2018, ALTERED STATES CONSC; Wittmann M, 2015, CONSCIOUS COGN, V38, P172, DOI 10.1016/j.concog.2015.06.008; Wittmann M, 2014, PERS INDIV DIFFER, V64, P41, DOI 10.1016/j.paid.2014.02.011; Zakay D., 1994, TIME DYNAMIC CONTROL, P167; Zakay D., 1989, TIME HUMAN COGNITION, P365, DOI [10.1016/S0166-4115(08)61047-X, DOI 10.1016/S0166-4115(08)61047-X]; Zeidan F, 2010, CONSCIOUS COGN, V19, P597, DOI 10.1016/j.concog.2010.03.014	60	4	4	2	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2019	14	10							e0223567	10.1371/journal.pone.0223567	http://dx.doi.org/10.1371/journal.pone.0223567			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM9KT	31626645	Green Published, gold			2023-01-03	WOS:000532567700013
J	Walker, AJ; Pretis, F; Powell-Smith, A; Ben Goldacre				Walker, Alex J.; Pretis, Felix; Powell-Smith, Anna; Ben Goldacre			Variation in responsiveness to warranted behaviour change among NHS clinicians: novel implementation of change detection methods in longitudinal prescribing data	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DRUGS	OBJECTIVES To determine how clinicians vary in their response to new guidance on existing or new interventions, by measuring the timing and magnitude of change at healthcare institutions. DESIGN Automated change detection in longitudinal prescribing data. SETTING Prescribing data in English primary care. PARTICIPANTS English general practices. MAIN OUTCOME MEASURES In each practice the following were measured: the timing of the largest changes, steepness of the change slope (change in proportion per month), and magnitude of the change for two example time series (expiry of the Cerazette patent in 2012, leading to cheaper generic desogestrel alternatives becoming available; and a change in antibiotic prescribing guidelines after 2014, favouring nitrofurantoin over trimethoprim for uncomplicated urinary tract infection (UTI)). RESULTS Substantial heterogeneity was found between institutions in both timing and steepness of change. The range of time delay before a change was implemented was large (interquartile range 2-14 months (median 8) for Cerazette, and 5-29 months (18) for UTI). Substantial heterogeneity was also seen in slope following a detected change (interquartile range 2-28% absolute reduction per month (median 9%) for Cerazette, and 1-8% (2%) for UTI). When changes were implemented, the magnitude of change showed substantially less heterogeneity (interquartile range 44-85% (median 66%) for Cerazette and 28-47% (38%) for UTI). CONCLUSIONS Substantial variation was observed in the speed with which individual NHS general practices responded to warranted changes in clinical practice. Changes in prescribing behaviour were detected automatically and robustly. Detection of structural breaks using indicator saturation methods opens up new opportunities to improve patient care through audit and feedback by moving away from cross sectional analyses, and automatically identifying institutions that respond rapidly, or slowly, to warranted changes in clinical practice.	[Walker, Alex J.; Powell-Smith, Anna; Ben Goldacre] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Radcliffe Observ Quarter, DataLab, Oxford OX2 6GG, England; [Pretis, Felix] Univ Victoria, Dept Econ, Victoria, BC, Canada; [Pretis, Felix] Univ Oxford, Oxford Martin Sch, Inst New Econ Thinking, Oxford, England	University of Oxford; University of Victoria; University of Oxford	Ben Goldacre (corresponding author), Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Radcliffe Observ Quarter, DataLab, Oxford OX2 6GG, England.	ben.goldacre@phc.ox.ac.uk		Goldacre, Ben/0000-0002-5127-4728	Health Foundation [7599]; National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford; NIHR School of Primary Care Research grant [327]; Robertson Foundation	Health Foundation; National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford(National Institute for Health Research (NIHR)); NIHR School of Primary Care Research grant; Robertson Foundation	No specific funding was sought for this analysis. Work on OpenPrescribing is supported by the Health Foundation (reference 7599); the National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford; and by an NIHR School of Primary Care Research grant (reference 327). FP is supported by a grant from the Robertson Foundation. Funders had no role in the study design, collection, analysis, and interpretation of the data; in the writing of the report; and in the decision to submit the article for publication.	Berwick DM, 2003, JAMA-J AM MED ASSOC, V289, P1969, DOI 10.1001/jama.289.15.1969; Castle JL, 2015, ECONOMETRICS, V3, P240, DOI 10.3390/econometrics3020240; Coleman J. S., 1966, MED INNOVATION DIFFU; Croker R, 2019, J ANTIMICROB CHEMOTH, V74, P1125, DOI 10.1093/jac/dky509; Curtis HJ, 2019, LANCET PSYCHIAT, V6, P140, DOI 10.1016/S2215-0366(18)30471-1; Curtis HJ, 2019, J ANTIMICROB CHEMOTH, V74, P242, DOI 10.1093/jac/dky377; Curtis HJ, 2018, DIABETES OBES METAB, V20, P2159, DOI 10.1111/dom.13346; Curtis HJ, 2018, BRIT J CANCER, V118, P1268, DOI 10.1038/s41416-018-0065-2; Curtis HJ, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019921; Doornik JA, 2018, EMPIRICAL ECONOMETRI, VI; Eccles M, 2005, J CLIN EPIDEMIOL, V58, P107, DOI 10.1016/j.jclinepi.2004.09.002; Ivers N, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000259.pub3; Jones MI, 2001, BMJ-BRIT MED J, V323, P378, DOI 10.1136/bmj.323.7309.378; NHS Digital, 2017, NUMB PAT REG GP PRAC; Pretis F, 2018, J STAT SOFTW, V86, DOI 10.18637/jss.v086.i03; Pretis F, 2016, J ECON SURV, V30, P403, DOI 10.1111/joes.12148; Pretis F, 2015, CLIMATIC CHANGE, V131, P705, DOI 10.1007/s10584-015-1391-5; Prosser H, 2003, FAM PRACT, V20, P583, DOI 10.1093/fampra/cmg516; Prosser H, 2003, FAM PRACT, V20, P61, DOI 10.1093/fampra/20.1.61; Rogers EM, 2010, DIFFUSION INNOVATION; Ryan B, 1950, RES B INT COMM NW AT, V29, P1; Steffensen FH, 1999, FAM PRACT, V16, P407, DOI 10.1093/fampra/16.4.407; TERASVIRTA T, 1994, J AM STAT ASSOC, V89, P208, DOI 10.2307/2291217; Walker AJ, 2019, J ANTIMICROB CHEMOTH, V74, P1133, DOI 10.1093/jac/dky528; Walker AJ, 2019, J ROY SOC MED, V112, P4, DOI 10.1177/0141076818808429; Walker AJ, 2018, J ROY SOC MED, V111, P203, DOI 10.1177/0141076818769408; Walker AJ, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021312; Wennberg JE, 2010, TRACKING MED RES QUE; Wise J, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c6809	29	17	17	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 2	2019	367								l5205	10.1136/bmj.l5205	http://dx.doi.org/10.1136/bmj.l5205			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD1ZH	31578187	hybrid, Green Published			2023-01-03	WOS:000489774400001
J	James, PB; Wardle, J; Steel, A; Adams, J				James, Peter Bai; Wardle, Jon; Steel, Amie; Adams, Jon			Pattern of health care utilization and traditional and complementary medicine use among Ebola survivors in Sierra Leone	PLOS ONE			English	Article							ALTERNATIVE MEDICINE; HERBAL MEDICINE; SEEKING; HIV	Background It is well established that Ebola Survivors experience a myriad of physical and psychological sequelae. However, little is known about how they seek care to address their health needs. Our study determines the current healthcare seeking behaviour among Ebola survivors and determines the prevalence, pattern of use and correlates of traditional and complementary medicine (T&CM) use among Ebola survivors in Sierra Leone. Methods We conducted a nationwide questionnaire survey among a cross-sectional sample of Ebola Survivors in Sierra Leone between January and August 2018. We employed descriptive statistics, chi-square test, Fisher exact two-tailed test and backward stepwise binary regression analysis for data analysis. A p-value less than 0.05 was considered statistically significant. Results Ebola Survivors who participated in our study (n = 358), visited a healthcare provider (n = 308, 86.0%), self-medicated with conventional medicines (n = 255, 71.2%) and visited a private pharmacy outlet (n = 141, 39.4%). Survivors also self-medicated with T&CM products (n = 107, 29.9%), concurrently self-medicated with conventional and T&CM products (n = 62, 17.3%), and visited a T&CM practitioner (n = 41, 11.5%). Almost half of (n = 163, 45.5%) Ebola survivors reported using T&CM treatments for post ebola related symptoms and non-Ebola related symptoms since their discharge from an Ebola treatment centre. Ebola survivors who considered their health to be fair or poor (AOR = 4.08; 95%CI: 2.22-7.50; p<0.01), presented with arthralgia (AOR = 2.52; 95%CI: 1.11-5.69, p = 0.026) and were discharged three years or less (AOR = 3.14; 95%CI: 1.13-8.73, p = 0.028) were more likely to use T&CM. Family (n = 101,62.0%) and friends (n = 38,23.3%) were the common sources of T&CM information. Abdominal pain (n = 49, 30.1%) followed by joint pain (n = 46, 28.2%) and back pain (n = 43, 26.4%) were the most cited post-Ebola indications for T&CM use. More than three-quarters of T&CM users (n = 135, 82.8%) failed to disclose their use of T&CM to their healthcare providers. Conclusion Ebola survivors in Sierra Leone employ a myriad of healthcare options including T&CM in addressing their healthcare needs. Researchers, health policy makers and healthcare providers should be aware of the substantial role of T&CM in the health seeking of survivors, and this topic that should be factored into future research, policy formulation and implementation as well as routine practice regarding Ebola survivors.	[James, Peter Bai; Wardle, Jon; Steel, Amie; Adams, Jon] Univ Technol Sydney, Fac Hlth, Australian Res Ctr Inw Complementary & Integrat M, Sydney, NSW, Australia; [James, Peter Bai] Univ Sierra Leone, Coll Med & Allied Hlth Sci, Fac Pharmaceut Sci, Freetown, Sierra Leone	University of Technology Sydney	James, PB (corresponding author), Univ Technol Sydney, Fac Hlth, Australian Res Ctr Inw Complementary & Integrat M, Sydney, NSW, Australia.; James, PB (corresponding author), Univ Sierra Leone, Coll Med & Allied Hlth Sci, Fac Pharmaceut Sci, Freetown, Sierra Leone.	Peter.B.James@students.uts.edu.au	James, Peter Bai/P-8492-2015	James, Peter Bai/0000-0002-6373-5704; Steel, Amie/0000-0001-6643-9444; Wardle, Jonathan/0000-0001-8813-3542	Faculty of Health, University of Technology Sydney	Faculty of Health, University of Technology Sydney	This research received support from the Faculty of Health, University of Technology Sydney.	Artus M, 2007, BMC FAM PRACT, V8, DOI 10.1186/1471-2296-8-26; Auerbach BJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041737; Bakshi SS, 2013, ACTA TROP, V127, P46, DOI 10.1016/j.actatropica.2013.03.010; Corp N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200879; De Roo A, 1998, TROPICAL MED INT HLT, V3; de St Maurice A, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy239; Deng Yichu, 2016, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V28, P106, DOI 10.3760/cma.j.issn.2095-4352.2016.02.005; Diaz T, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-157; Donnelly J, 2011, LANCET, V377, P1393, DOI 10.1016/S0140-6736(11)60559-X; Draucker CB, 2009, ARCH PSYCHIAT NURS, V23, P343, DOI 10.1016/j.apnu.2008.10.008; Etard JF, 2017, LANCET INFECT DIS, V17, P545, DOI 10.1016/S1473-3099(16)30516-3; Falci L, 2016, PREV CHRONIC DIS, V13, DOI 10.5888/pcd13.150501; Foley H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38279-8; Government of Sierra Leone Ministry of Health and Sanitation, 2016, ANN HLTH SECT PERF R; Hsu CH, 2008, EVID-BASED COMPL ALT, V5, P355, DOI 10.1093/ecam/nem035; James PB, 2019, TROP MED INT HEALTH, V24, P671, DOI 10.1111/tmi.13226; James PB, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2479-7; James PB, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000895; James PB, 2018, WOMEN BIRTH, V31, pE302, DOI 10.1016/j.wombi.2017.12.006; James PB, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/9493807; James PB, 2018, COMPLEMENT THER CLIN, V31, P7, DOI 10.1016/j.ctcp.2018.01.001; James PB, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1102-4; Lee LS, 2006, CLIN INFECT DIS, V43, P1052, DOI 10.1086/507894; Lorenc A, 2013, AIDS PATIENT CARE ST, V27, P503, DOI 10.1089/apc.2013.0175; Lotsch F, 2017, TRAVEL MED INFECT DI, V18, P18, DOI 10.1016/j.tmaid.2017.05.001; Manguvo A, 2015, PAN AFR MED J, V22, DOI 10.11694/pamj.supp.2015.22.1.6190; Mbizo J, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2342-2; Mills A, 2014, NEW ENGL J MED, V370, P552, DOI 10.1056/NEJMra1110897; Ministry of Health and Sanitation, 2017, NATL HLTH SECT STRAT; Morens DM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003467; Naidoo P, 2014, S AFR FAM PRACT, V56, P223, DOI 10.1080/20786190.2014.953884; National Malaria Control Programme (NMCP) [Sierra Leone] SSL University of Sierra Leone Catholic Relief Services and ICF, SIERR LEON MAL IND S; Nlooto M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170983; Peltzer K, 2010, AFRICAN J TRADITIONA, V7; Peltzer K, 2018, CHIN J INTEGR MED, V24, P584, DOI 10.1007/s11655-016-2748-y; Ranasinghe S, 2015, J ETHNOPHARMACOL, V166, P200, DOI 10.1016/j.jep.2015.03.028; Scott JT, 2016, EMERG INFECT DIS, V22, P641, DOI 10.3201/eid2204.151302; Statistics Sierra Leone, 2017, SIERR LEON 2015 POP; Stawicki SP, 2017, J GLOB INFECT DIS, V9, P41, DOI 10.4103/jgid.jgid_20_17; Tiffany A, 2016, CLIN INFECT DIS, V62, P1360, DOI 10.1093/cid/ciw158; Ukwaja KN, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-25; Vetter Pauline, 2016, Lancet Infect Dis, V16, pe82, DOI 10.1016/S1473-3099(16)00077-3; Wardle JL, 2014, EUR J INTEGR MED, V6, P409, DOI 10.1016/j.eujim.2014.01.001; Warren N, 2013, HEALTH-LONDON, V17, P323, DOI 10.1177/1363459312460699; WHO, 2017, SIERR LEON TRAD HEAL; WHO, 2016, GEOGR DISTR NEW TOT; Wilson HW, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1909410; World Health Organisation, 2016, EB SIT REP 30 MARCH; World Health Organization, 2016, CLIN CAR SURV EB VIR; World Health Organization, 2017, TOP 10 CAUS DEATH LE; World Health Organization, 2013, WHO TRAD MED STRAT 2; World Health Organization, 2007, WORLD HLTH REP 2007; World Health Organization, 2004, SARS CLIN TRIALS TRE	53	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 27	2019	14	9							e0223068	10.1371/journal.pone.0223068	http://dx.doi.org/10.1371/journal.pone.0223068			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM6IT	31560708	Green Published, gold			2023-01-03	WOS:000532353700034
J	Fink, DL; Collins, S; Barret, R; Pollara, G; Marks, M; Logan, S				Fink, Doug L.; Collins, Steven; Barret, Ronnie; Pollara, Gabriele; Marks, Michael; Logan, Sarah			Shortening duration of ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections: A retrospective study	PLOS ONE			English	Article							SPECTRUM-BETA-LACTAMASE; ACUTE PYELONEPHRITIS; ESCHERICHIA-COLI; METAANALYSIS; BACTEREMIA; IMPACT	Background The incidence of multi-drug resistant ESBL-associated urinary tract infections (UTIs) is increasing globally. Patients with abnormal renal tract anatomy and other co-morbidities are at increased risk of complicated UTI and ESBL-associated infections. The duration and safety of OPAT for this cohort of patients is unknown. Objectives This study aims to provide an evidence base to support decision-making regarding duration of antibiotic treatment for complicated UTIs. Methods We retrospectively reviewed all patients receiving ertapenem with or without adjunctive fosfomycin for complicated UTIs in the OPAT service of our tertiary infectious diseases hospital. All data had been collected prospectively as part of routine clinical care. Our primary outcomes were microbiological and clinical cure of UTI. Results We identified 33 treatment episodes of ertapenem use for UTIs. 76% episodes related to pyelonephritis or urosepsis diagnoses. Renal tract abnormalities or prior urological surgery were present in 45% of patients. The median duration of appropriate parenteral antibiotic therapy in our study was 6 days. Clinical cure was achieved with short-course parenteral treatment alone in 81% of patients and this increased to 96% when adjunctive fosfomycin was used. There was a single treatment failure resulting in hospital admission. Conclusions Short duration ertapenem via OPAT with or without adjunctive fosfomycin is safe and effective for the treatment of complicated UTIs. Further studies are required to inform optimal treatment strategies and publication of guidelines in this field.	[Fink, Doug L.; Pollara, Gabriele] Univ Coll London Hosp, Dept Microbiol, London, England; [Fink, Doug L.; Pollara, Gabriele] UCL, Div Infect & Immun, London, England; [Collins, Steven; Barret, Ronnie; Marks, Michael; Logan, Sarah] Univ Coll London Hosp, Hosp Trop Dis, London, England; [Marks, Michael] Univ Coll London Hosp NHS Trust, London Sch Hyg & Trop Med Hosp Trop Dis, Fac Infect & Trop Dis, Clin Res Dept, London, England	University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London	Marks, M (corresponding author), Univ Coll London Hosp, Hosp Trop Dis, London, England.; Marks, M (corresponding author), Univ Coll London Hosp NHS Trust, London Sch Hyg & Trop Med Hosp Trop Dis, Fac Infect & Trop Dis, Clin Res Dept, London, England.	michael.marks@lshtm.ac.uk		Logan, Sarah/0000-0001-8527-450X; Marks, Michael/0000-0002-7585-4743	Wellcome Trust [WT102807, WT205236, WT101766]; NIHR Biomedical Research Centre	Wellcome Trust(Wellcome TrustEuropean Commission); NIHR Biomedical Research Centre(National Institute for Health Research (NIHR))	MM (WT102807), DF (WT205236) and GP (WT101766) are supported by the Wellcome Trust. All authors are supported by NIHR Biomedical Research Centre funding to UCLH and UCL. The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chapman ALN, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1585; Eliakim-Raz N, 2013, J ANTIMICROB CHEMOTH, V68, P2183, DOI 10.1093/jac/dkt177; EUA, UROLOGICAL INFECT; Kyriakidou KG, 2008, CLIN THER, V30, P1859, DOI 10.1016/j.clinthera.2008.10.007; Lee S, 2014, MICROB DRUG RESIST, V20, P39, DOI 10.1089/mdr.2013.0075; Marks M, 2015, J INFECTION, V71, P402, DOI 10.1016/j.jinf.2015.04.007; Matthews PC, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1888-1; NICE, MULT RES UR TRACT IN; Park SH, 2015, ANTIMICROB AGENTS CH, V59, P1962, DOI 10.1128/AAC.04821-14; Qureshi ZA, 2014, ANTIMICROB AGENTS CH, V58, P3437, DOI 10.1128/AAC.02721-14; Rosso-Fernandez C, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007363; Sawyer RG, 2015, NEW ENGL J MED, V372, P1996, DOI 10.1056/NEJMoa1411162; Schwaber MJ, 2007, J ANTIMICROB CHEMOTH, V60, P913, DOI 10.1093/jac/dkm318; Senol S, 2010, J CHEMOTHERAPY, V22, P355, DOI 10.1179/joc.2010.22.5.355; Teillant A, 2015, LANCET INFECT DIS, V15, P1429, DOI 10.1016/S1473-3099(15)00270-4; Toner L, 2016, WORLD J UROL, V34, P1031, DOI 10.1007/s00345-015-1718-x; Trad MA, 2017, J CHEMOTHERAPY, V29, P25, DOI 10.1080/1120009X.2016.1158937; Underwood J, 2019, J ANTIMICROB CHEMOTH, V74, P787, DOI 10.1093/jac/dky474; Vardakas KZ, 2012, J ANTIMICROB CHEMOTH, V67, P2793, DOI 10.1093/jac/dks301; Yilmaz E, 2008, J CHEMOTHERAPY, V20, P581, DOI 10.1179/joc.2008.20.5.581	20	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2019	14	9							e0223130	10.1371/journal.pone.0223130	http://dx.doi.org/10.1371/journal.pone.0223130			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM6FU	31557236	Green Published, Green Accepted, gold			2023-01-03	WOS:000532345500077
J	Bagegni, NA; Tao, Y; Ademuyiwa, FO				Bagegni, Nusayba A.; Tao, Yu; Ademuyiwa, Foluso O.			Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database	PLOS ONE			English	Article							PREOPERATIVE CHEMOTHERAPY; SURVIVAL; PATTERNS; THERAPY; DISEASE	Purpose Triple negative breast cancer (TNBC) patients frequently receive neoadjuvant chemotherapy (NAC). Only 50% will achieve pathological complete response (pCR). In this retrospective study, we evaluated TNBC outcomes with NAC vs. AC. Methods Patients with stages II and III TNBC treated with NAC or AC between 2010 and 2013 were identified from the National Cancer Database. Baseline characteristics were compared with chi(2) and two sample t tests. Kaplan-Meier survival analyses were computed in patients treated with NAC or AC, and log-rank tests used to examine differences. Unadjusted analyses of trends in proportions over time were performed using Cochran-Armitage tests. Logbinomial models were applied to estimate relative risks of non-pCR following NAC. Results Of 19,151 patients, 5,621 (29.4%) received NAC, 13,530 (70.6%) received AC. NAC treated patients had worse OS compared to AC treated patients (73.4% vs. 76.8%; p<0.0001). pCR rate following NAC was 47.4%, and was associated with improved 5 year OS compared to non-pCR (86.2% vs. 62.3%; p<0.0001). In patients who received NAC, age, black race, clinical stage, diagnosis year, and Charlson-Deyo comorbidity score predicted non-pCR status. Use of NAC increased over the study period from 2010 to 2013 (27.8% - 31.2%; p = 0.0002). Conclusions NAC may be inferior to AC in TNBC, likely related to the high frequency of non-pCR following NAC. It is unclear if removing the primary tumor prior to chemotherapy will have a beneficial biologic impact on therapeutic efficacy. These data should be considered hypothesis-generating as it is possible that the findings are due to selection bias, as physicians may use NAC for TNBC patients with more advanced local disease. Although, NAC still has a role in TNBC, developing biomarkers to identify patients likely to achieve pCR and benefit from NAC is an urgent need.	[Bagegni, Nusayba A.; Tao, Yu; Ademuyiwa, Foluso O.] Washington Univ, Sch Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Ademuyiwa, FO (corresponding author), Washington Univ, Sch Med, St Louis, MO 63110 USA.	bisiademuyiwa@wustl.edu		Bagegni, Nusayba/0000-0001-9322-2451; ADEMUYIWA, FOLUSO/0000-0002-6766-2258				Alberro JA, 2018, LANCET ONCOL, V19, P27, DOI 10.1016/S1470-2045(17)30777-5; Caramelo O, 2019, HERED CANCER CLIN PR, V17, DOI 10.1186/s13053-019-0111-y; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Chen VE, 2017, ADV RADIAT ONCOL, V2, P105, DOI 10.1016/j.adro.2017.01.012; Clifton K, 2018, BREAST CANCER RES TR, V170, P101, DOI 10.1007/s10549-018-4727-9; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Daly B, 2017, JAMA ONCOL, V3, P928, DOI 10.1001/jamaoncol.2016.6380; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Fisher B, 1997, J CLIN ONCOL, V15, P2483, DOI 10.1200/JCO.1997.15.7.2483; Fisher CS, 2012, ANN SURG ONCOL, V19, P253, DOI 10.1245/s10434-011-1877-y; Kennedy CR, 2010, J SURG RES, V163, P52, DOI 10.1016/j.jss.2010.04.015; Kern P, 2015, ANTICANCER RES, V35, P5479; Kuroi K, 2015, BREAST CANCER-TOKYO, V22, P486, DOI 10.1007/s12282-013-0511-1; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Litton JK, 2018, NEW ENGL J MED, V379, P753, DOI 10.1056/NEJMoa1802905; Masuda H, 2013, CLIN CANCER RES, V19, P5533, DOI 10.1158/1078-0432.CCR-13-0799; Masuda N, 2017, NEW ENGL J MED, V376, P2147, DOI 10.1056/NEJMoa1612645; Mauriac L, 1999, ANN ONCOL, V10, P47, DOI 10.1023/A:1008337009350; Mougalian SS, 2015, CANCER-AM CANCER SOC, V121, P2544, DOI 10.1002/cncr.29348; Murphy BL, 2018, ANN SURG ONCOL, V25, P2241, DOI 10.1245/s10434-018-6531-5; National Cancer Institute Surveillance E and End Results (SEER), CANC STAT FACTS FEM; Network NCC, NCCN CLIN PRACT GUID; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Plasilova ML, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004614; Puig CA, 2017, ANN SURG ONCOL, V24, P1242, DOI 10.1245/s10434-016-5733-y; Robson M, 2017, NEW ENGL J MED, V377, P523, DOI 10.1056/NEJMoa1706450; Sikov WM, 2016, SAN ANT BREAST CANC; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Symmans WF, 2017, J CLIN ONCOL, V35, P1049, DOI 10.1200/JCO.2015.63.1010; van der Hage JA, 2001, J CLIN ONCOL, V19, P4224, DOI 10.1200/JCO.2001.19.22.4224; von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595	33	25	25	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2019	14	9							e0222358	10.1371/journal.pone.0222358	http://dx.doi.org/10.1371/journal.pone.0222358			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM5BF	31536530	gold, Green Published, Green Submitted			2023-01-03	WOS:000532262800039
J	Vallabhajosyula, S; Dunlay, SM; Barsness, GW; Vallabhajosyula, S; Vallabhajosyula, S; Sundaragiri, PR; Gersh, BJ; Jaffe, AS; Kashani, K				Vallabhajosyula, Saraschandra; Dunlay, Shannon M.; Barsness, Gregory W.; Vallabhajosyula, Saarwaani; Vallabhajosyula, Shashaank; Sundaragiri, Pranathi R.; Gersh, Bernard J.; Jaffe, Allan S.; Kashani, Kianoush			Temporal trends, predictors, and outcomes of acute kidney injury and hemodialysis use in acute myocardial infarction-related cardiogenic shock	PLOS ONE			English	Article							DIALYSIS; RISK	Background There are limited data on acute kidney injury (AKI) complicating acute myocardial infarction with cardiogenic shock (AMI-CS). This study sought to evaluate 15-year national prevalence, temporal trends and outcomes of AKI with no need for hemodialysis (AKI-ND) and requiring hemodialysis (AKI-D) following AMI-CS. Methods This was a retrospective cohort study from 2000-2014 from the National Inpatient Sample (20% stratified sample of all community hospitals in the United States). Adult patients (>18 years) admitted with a primary diagnosis of AMI and secondary diagnosis of CS were included. The primary outcome was in-hospital mortality in cohorts with no AKI, AKI-ND, and AKI-D. Secondary outcomes included predictors, resource utilization and disposition. Results During this 15-year period, 440,257 admissions for AMI-CS were included, with AKI in 155,610 (35.3%) and hemodialysis use in 14,950 (3.4%). Older age, black race, non-private insurance, higher comorbidity, organ failure, and use of cardiac and non-cardiac organ support were associated with the AKI development and hemodialysis use. There was a 2.6-fold higher adjusted risk of developing AKI in 2014 compared to 2000. Presence of AKI-ND and AKI-D was associated with a 1.3 and 1.7-fold higher adjusted risk of mortality. Compared to the cohort without AKI, AKI-ND and AKI-D were associated with longer length of stay (9 +/- 10,12 +/- 13, and 18 +/- 19 days respectively; p<0.001) and higher hospitalization costs ($101,859 +/- 116,204, $159,804 +/- 190,766, and $265,875 +/- 254,919 respectively; p<0.001). Conclusion AKI-ND and AKI-D are associated with higher in-hospital mortality and resource utilization in AMI-CS.	[Vallabhajosyula, Saraschandra; Dunlay, Shannon M.; Barsness, Gregory W.; Vallabhajosyula, Saarwaani; Gersh, Bernard J.; Jaffe, Allan S.] Mayo Clin, Dept Cardiovasc Med, Rochester, MN 55905 USA; [Vallabhajosyula, Saraschandra; Vallabhajosyula, Shashaank; Kashani, Kianoush] Mayo Clin, Div Pulm & Crit Care Med, Dept Med, Rochester, MN 55905 USA; [Dunlay, Shannon M.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA; [Sundaragiri, Pranathi R.] Mayo Clin, Dept Med, Div Hosp Internal Med, Rochester, MN USA; [Kashani, Kianoush] Mayo Clin, Div Nephrol & Hypertens, Dept Med, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Vallabhajosyula, S (corresponding author), Mayo Clin, Dept Cardiovasc Med, Rochester, MN 55905 USA.; Vallabhajosyula, S (corresponding author), Mayo Clin, Div Pulm & Crit Care Med, Dept Med, Rochester, MN 55905 USA.	Vallabhajosyula.Saraschandra@mayo.edu	Vallabhajosyula, Saraschandra/I-9707-2019	Vallabhajosyula, Saraschandra/0000-0002-1631-8238	Clinical and Translational Science Award (CTSA) from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1 TR000135]	Clinical and Translational Science Award (CTSA) from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Dr. Saraschandra Vallabhajosyula is supported by the Clinical and Translational Science Award (CTSA) Grant Number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH.	Adegbala O, 2019, AM J CARDIOL, V123, P1816, DOI 10.1016/j.amjcard.2019.02.038; Adler C, 2013, RESUSCITATION, V84, P194, DOI 10.1016/j.resuscitation.2012.06.013; Ahmed A, 2015, J CRIT CARE, V30, P988, DOI 10.1016/j.jcrc.2015.05.007; Amin AP, 2012, ARCH INTERN MED, V172, P246, DOI 10.1001/archinternmed.2011.1202; Chan L, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.004509; Correa A, 2018, J CARD FAIL, V24, P442, DOI 10.1016/j.cardfail.2018.05.001; Dasta JF, 2019, J PHARM PRACT, V32, P292, DOI 10.1177/0897190019852556; Hsu RK, 2016, CLIN J AM SOC NEPHRO, V11, P14, DOI 10.2215/CJN.04520415; Jentzer JC, 2018, CHEST, V154, P416, DOI 10.1016/j.chest.2017.12.021; Jentzer JC, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008169; Kane-Gill SL, 2015, AM J KIDNEY DIS, V65, P860, DOI 10.1053/j.ajkd.2014.10.018; Kashani K, 2019, CLIN J AM SOC NEPHRO, V14, P941, DOI 10.2215/CJN.01250119; Ko DT, 2008, J AM COLL CARDIOL, V51, P716, DOI 10.1016/j.jacc.2007.10.039; Kotecha A, 2018, J CRIT CARE, V43, P122, DOI 10.1016/j.jcrc.2017.08.044; Lauridsen MD, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1170-8; Lim HS, 2018, SHOCK, V50, P167, DOI 10.1097/SHK.0000000000001052; Moman RN, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-018-0468-5; Ostermann M, 2019, CHEST, V156, P594, DOI 10.1016/j.chest.2019.04.004; Ronco C, 2008, J AM COLL CARDIOL, V52, P1527, DOI 10.1016/j.jacc.2008.07.051; Ronco C, 2017, NEPHROL DIAL TRANSPL, V32, P408, DOI 10.1093/ndt/gfx016; Sakhuja A, 2019, MAYO CLIN PROC, V94, P1509, DOI 10.1016/j.mayocp.2019.01.040; Sakhuja A, 2015, AM J RESP CRIT CARE, V192, P951, DOI 10.1164/rccm.201502-0329OC; Siew ED, 2015, KIDNEY INT, V87, P46, DOI 10.1038/ki.2014.293; Sinha SS, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.117.003616; Tumlin JA, 2018, CRIT CARE MED, V46, P949, DOI 10.1097/CCM.0000000000003092; Vallabhajosyula S, 2019, AGING-US, V11, P4774, DOI 10.18632/aging.102104; Vallabhajosyula S, 2019, IJC HEART VASC, V24, DOI 10.1016/j.ijcha.2019.100414; Vallabhajosyula S, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0571-2; Vallabhajosyula S, 2020, ASAIO J, V66, P497, DOI 10.1097/MAT.0000000000001039; Vallabhajosyula S, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.011954; Vallabhajosyula S, 2019, ESC HEART FAIL, V6, P874, DOI 10.1002/ehf2.12482; Vallabhajosyula S, 2019, AM J CARDIOL, V124, P491, DOI 10.1016/j.amjcard.2019.05.038; Vallabhajosyula S, 2019, JACC-HEART FAIL, V7, P469, DOI 10.1016/j.jchf.2018.12.007; Vallabhajosyula S, 2019, J AM COLL CARDIOL, V73, P1781, DOI 10.1016/j.jacc.2019.01.053; Vallabhajosyula S, 2019, INT J CARDIOL, V285, P6, DOI 10.1016/j.ijcard.2019.03.008; Vallabhajosyula S, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.010193; Vallabhajosyula S, 2019, AM J CARDIOL, V123, P489, DOI 10.1016/j.amjcard.2018.10.029; Vallabhajosyula S, 2018, CIRC-CARDIOVASC INTE, V11, DOI 10.1161/CIRCINTERVENTIONS.118.006930; Vallabhajosyula S, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009608; Vallabhajosyula S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190965; Vallabhajosyula S, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.11.36; Waikar SS, 2006, J AM SOC NEPHROL, V17, P1688, DOI 10.1681/ASN.2006010073	42	38	38	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2019	14	9							e0222894	10.1371/journal.pone.0222894	http://dx.doi.org/10.1371/journal.pone.0222894			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM4SI	31532793	Green Published, Green Submitted, gold			2023-01-03	WOS:000532239600038
J	Wang, YN; Lu, YX; Liu, J; Jin, Y; Bi, HC; Zhao, Q; Liu, ZX; Li, YQ; Hu, JJ; Sheng, H; Jiang, YM; Zhang, C; Tian, F; Chen, Y; Pan, ZZ; Chen, G; Zeng, ZL; Liu, KY; Ogasawara, M; Yun, JP; Ju, HQ; Feng, JX; Xie, D; Gao, S; Jia, WH; Kopetz, S; Xu, RH; Wang, F				Wang, Ying-Nan; Lu, Yun-Xin; Liu, Jie; Jin, Ying; Bi, Hui-Chang; Zhao, Qi; Liu, Ze-Xian; Li, Ying-Qin; Hu, Jia-Jia; Sheng, Hui; Jiang, Yi-Ming; Zhang, Chao; Tian, Feng; Chen, Yang; Pan, Zhi-Zhong; Chen, Gong; Zeng, Zhao-Lei; Liu, Kai-Yan; Ogasawara, Marcia; Yun, Jin-Ping; Ju, Huai-Qiang; Feng, Jian-Xiong; Xie, Dan; Gao, Song; Jia, Wei-Hua; Kopetz, Scott; Xu, Rui-Hua; Wang, Feng			AMPK alpha 1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; NEGATIVE REGULATOR; COLON-CANCER; AMPK; GROWTH; EXPRESSION; NUTRIENT; RECEPTOR; GENE	Patients with stage II or III colorectal cancer (CRC) exhibit various clinical outcomes after radical treatments. The 5-year survival rate was between 50 and 87%. However, the underlying mechanisms of the variation remain unclear. Here we show that AMPK alpha 1 is overexpressed in CRC patient specimens and the high expression is correlated with poor patient survival. We further reveal a previously unrecognized function of AMPK alpha 1, which maintains high level of reduced glutathione to keep reduction-oxidation reaction (redox) homeostasis under stress conditions, thus promoting CRC cell survival under metabolic stress in vitro and enhancing tumorigenesis in vivo. Mechanistically, AMPK alpha 1 regulate the glutathione reductase (GSR) phosphorylation possibly through residue Thr507 which enhances its activity. Suppression of AMPK alpha 1 by using nano-sized polymeric vector induces a favorable therapeutic effect, especially when in combination with oxaliplatin. Our study uncovers a novel function of AMPK alpha 1 in redox regulation and identifies a promising therapeutic strategy for treatment of CRC.	[Wang, Ying-Nan; Lu, Yun-Xin; Jin, Ying; Zhao, Qi; Liu, Ze-Xian; Hu, Jia-Jia; Sheng, Hui; Zhang, Chao; Chen, Yang; Zeng, Zhao-Lei; Liu, Kai-Yan; Yun, Jin-Ping; Ju, Huai-Qiang; Feng, Jian-Xiong; Xie, Dan; Gao, Song; Jia, Wei-Hua; Xu, Rui-Hua; Wang, Feng] Sun Yat Sen Univ, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Wang, Ying-Nan; Lu, Yun-Xin; Jin, Ying; Zhao, Qi; Liu, Ze-Xian; Hu, Jia-Jia; Sheng, Hui; Zhang, Chao; Chen, Yang; Pan, Zhi-Zhong; Chen, Gong; Zeng, Zhao-Lei; Liu, Kai-Yan; Yun, Jin-Ping; Ju, Huai-Qiang; Feng, Jian-Xiong; Xie, Dan; Gao, Song; Jia, Wei-Hua; Xu, Rui-Hua; Wang, Feng] Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [Liu, Jie; Li, Ying-Qin] Sun Yat Sen Univ, Sch Engn, Dept Biomed Engn, Guangzhou 510006, Guangdong, Peoples R China; [Jin, Ying; Xu, Rui-Hua; Wang, Feng] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Bi, Hui-Chang; Jiang, Yi-Ming] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China; [Tian, Feng; Kopetz, Scott] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; [Pan, Zhi-Zhong; Chen, Gong] Sun Yat Sen Univ, Canc Ctr, Dept Colorectal Surg, Guangzhou 510060, Guangdong, Peoples R China; [Ogasawara, Marcia] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center	Xu, RH; Wang, F (corresponding author), Sun Yat Sen Univ, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.; Xu, RH; Wang, F (corresponding author), Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China.; Xu, RH; Wang, F (corresponding author), Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.; Kopetz, S (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.	skopetz@mdanderson.org; xurh@sysucc.org.cn; wangfeng@sysucc.org.cn	xu, rui/GRX-5734-2022; Chen, Yang/L-7304-2018; Chen, Yang/AFL-4729-2022; Xu, Rui-Hua/AAW-4766-2021; Kopetz, Scott/AAC-1387-2019; Liu, Zexian/D-1153-2011	Chen, Yang/0000-0001-7661-5923; Xu, Rui-Hua/0000-0001-9771-8534; Kopetz, Scott/0000-0001-9647-3416; Liu, Zexian/0000-0001-9698-0610; Gao, Song/0000-0001-7427-6681	National Key Research and Development Program of China [2017YFC1308900, 2018YFC1313300]; Natural Science Foundation of Guangdong Province [2014A030312015, 2017A030313485]; National Natural Science Foundation of China [81872011, 81572392]; Science and Technology Program of Guangdong [2019B020227002]; Science and Technology Program of Guangzhou [201904020046, 201803040019, 201704020228]; Guangzhou Health and Medical Collaborative Innovation Project [201704020220]; Sun Yat-sen University Clinical Research 5010 Program [2018014]	National Key Research and Development Program of China; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Program of Guangdong; Science and Technology Program of Guangzhou; Guangzhou Health and Medical Collaborative Innovation Project; Sun Yat-sen University Clinical Research 5010 Program	This study was supported, in part, by the National Key Research and Development Program of China (2017YFC1308900, 2018YFC1313300), Natural Science Foundation of Guangdong Province (2014A030312015, 2017A030313485); National Natural Science Foundation of China (81872011, 81572392); Science and Technology Program of Guangdong (2019B020227002), Science and Technology Program of Guangzhou (201904020046, 201803040019, 201704020228), Guangzhou Health and Medical Collaborative Innovation Project (201704020220), and the Sun Yat-sen University Clinical Research 5010 Program (2018014). FW is the Young Physician Scientist Program of Sun Yat-sen University Cancer Center.	[Anonymous], 2013, Cancer Discov, V3, pOF15, DOI 10.1158/2159-8290.CD-RW2013-018; Bhandaru M, 2014, J INVEST DERMATOL, V134, P1763, DOI 10.1038/jid.2014.26; Bi HC, 2014, CARCINOGENESIS, V35, P2264, DOI 10.1093/carcin/bgu174; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Chen DL, 2014, HEPATOLOGY, V60, P598, DOI 10.1002/hep.27118; Chen WQ, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0042-6; Chiu YC, 2009, CARCINOGENESIS, V30, P1651, DOI 10.1093/carcin/bgp156; Faubert B, 2015, CANCER LETT, V356, P165, DOI 10.1016/j.canlet.2014.01.018; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Fu X, 2013, MOL CELL BIOL, V33, P4517, DOI 10.1128/MCB.01078-13; Goh V, 2012, J NUCL MED, V53, P687, DOI 10.2967/jnumed.111.098525; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hari DM, 2013, J AM COLL SURGEONS, V217, P181, DOI 10.1016/j.jamcollsurg.2013.04.018; Hoffman NJ, 2015, CELL METAB, V22, P922, DOI 10.1016/j.cmet.2015.09.001; Huang FY, 2006, GYNECOL ONCOL, V103, P219, DOI 10.1016/j.ygyno.2006.02.028; Jeon SM, 2015, ARCH PHARM RES, V38, P346, DOI 10.1007/s12272-015-0549-z; Jeon Sang-Min, 2012, Cell Logist, V2, P197; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Ju HQ, 2016, J PINEAL RES, V60, P27, DOI 10.1111/jpi.12285; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Lee YC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078709; Li M, 2005, WORLD J GASTROENTERO, V11, P4685, DOI 10.3748/wjg.v11.i30.4685; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; Lu SC, 2009, MOL ASPECTS MED, V30, P42, DOI 10.1016/j.mam.2008.05.005; Ma MZ, 2015, CANCER LETT, V368, P88, DOI 10.1016/j.canlet.2015.07.031; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; O'Connell JB, 2004, JNCI-J NATL CANCER I, V96, P1420, DOI 10.1093/jnci/djh275; Phoenix Kathryn N, 2012, Genes Cancer, V3, P51, DOI 10.1177/1947601912452883; Saito Y, 2015, CELL STEM CELL, V17, P585, DOI 10.1016/j.stem.2015.08.019; Santoro V, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv394; Schreuders EH, 2015, GUT, V64, P1637, DOI 10.1136/gutjnl-2014-309086; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2015, CELL STEM CELL, V17, P503, DOI 10.1016/j.stem.2015.10.007; Sung JJY, 2015, GUT, V64, P121, DOI 10.1136/gutjnl-2013-306503; Svensson RU, 2012, NATURE, V485, P590, DOI 10.1038/485590a; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Yu K, 2019, NUCLEIC ACIDS RES, V47, pD451, DOI 10.1093/nar/gky1052; Yuan SQ, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0174-2; Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004; Zeng ZL, 2014, CLIN CANCER RES, V20, P1042, DOI 10.1158/1078-0432.CCR-13-0171; Zhao G, 2013, MOL CANCER THER, V12, P83, DOI 10.1158/1535-7163.MCT-12-0534-T; Zhou Q, 2015, CHIN J CANCER, V34, P1, DOI 10.1186/s40880-015-0026-6	43	10	10	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					637	650		10.1038/s41388-019-1004-2	http://dx.doi.org/10.1038/s41388-019-1004-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31530934	Green Published, hybrid			2023-01-03	WOS:000509718300011
J	Whelan, TJ; Julian, JA; Berrang, TS; Kim, DH; Germain, I; Nichol, AM; Akra, M; Lavertu, S; Germain, F; Fyles, A; Trotter, T; Perera, FE; Balkwill, S; Chafe, S; McGowan, T; Muanza, T; Beckham, WA; Chua, BH; Gu, CS; Levine, MN; Olivotto, IA				Whelan, Timothy J.; Julian, Jim A.; Berrang, Tanya S.; Kim, Do-Hoon; Germain, Isabelle; Nichol, Alan M.; Akra, Mohamed; Lavertu, Sophie; Germain, Francois; Fyles, Anthony; Trotter, Theresa; Perera, Francisco E.; Balkwill, Susan; Chafe, Susan; McGowan, Thomas; Muanza, Thierry; Beckham, Wayne A.; Chua, Boon H.; Gu, Chu Shu; Levine, Mark N.; Olivotto, Ivo A.		RAPID Trial Investigators	External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial	LANCET			English	Article							INTRAOPERATIVE RADIOTHERAPY; LUMPECTOMY; SURVIVAL; THERAPY; PHASE-3	Background Whole breast irradiation delivered once per day over 3-5 weeks after breast conserving surgery reduces local recurrence with good cosmetic results. Accelerated partial breast irradiation (APBI) delivered over 1 week to the tumour bed was developed to provide a more convenient treatment. In this trial, we investigated if external beam APBI was non-inferior to whole breast irradiation. Methods We did this multicentre, randomised, non-inferiority trial in 33 cancer centres in Canada, Australia and New Zealand. Women aged 40 years or older with ductal carcinoma in situ or node-negative breast cancer treated by breast conserving surgery were randomly assigned (1:1) to receive either external beam APBI (38.5 Gy in ten fractions delivered twice per day over 5-8 days) or whole breast irradiation (42.5 Gy in 16 fractions once per day over 21 days, or 50 Gy in 25 fractions once per day over 35 days). Patients and clinicans were not masked to treatment assignment. The primary outcome was ipsilateral breast tumour recurrence (IBTR), analysed by intention to treat. The trial was designed on the basis of an expected 5 year IBTR rate of 1.5% in the whole breast irradiation group with 85% power to exclude a 1.5% increase in the APBI group; non-inferiority was shown if the upper limit of the two-sided 90% CI for the IBTR hazard ratio (HR) was less than 2.02. This trial is registered with ClinicalTrials.gov, NCT00282035. Findings Between Feb 7, 2006, and July 15, 2011, we enrolled 2135 women. 1070 were randomly assigned to receive APBI and 1065 were assigned to receive whole breast irradiation. Six patients in the APBI group withdrew before treatment, four more did not receive radiotherapy, and 16 patients received whole breast irradiation. In the whole breast irradiation group, 16 patients withdrew, and two more did not receive radiotherapy. In the APBI group, a further 14 patients were lost to follow-up and nine patients withdrew during the follow-up period. In the whole breast irradiation group, 20 patients were lost to follow-up and 35 withdrew during follow-up. Median follow-up was 8.6 years (IQR 7.3-9.9). The 8-year cumulative rates of IBTR were 3.0% (95% CI 1.9-4.0) in the APBI group and 2.8% (1.8-3.9) in the whole breast irradiation group. The HR for APBI versus whole breast radiation was 1.27 (90% CI 0.84-1.91). Acute radiation toxicity (grade >= 2, within 3 months of radiotherapy start) occurred less frequently in patients treated with APBI (300 [28%] of 1070 patients) than whole breast irradiation (484 [45%] of 1065 patients, p<0.0001). Late radiation toxicity (grade >= 2, later than 3 months) was more common in patients treated with APBI (346 [32%] of 1070 patients) than whole breast irradiation (142 [13%] of 1065 patients; p<0.0001). Adverse cosmesis (defined as fair or poor) was more common in patients treated with APBI than in those treated by whole breast irradiation at 3 years (absolute difference, 11.3%, 95% CI 7.5-15.0), 5 years (16.5%, 12.5-20.4), and 7 years (17.7%, 12.9-22.3). Interpretation External beam APBI was non-inferior to whole breast irradiation in preventing IBTR. Although less acute toxicity was observed, the regimen used was associated with an increase in moderate late toxicity and adverse cosmesis, which might be related to the twice per day treatment. Other approaches, such as treatment once per day, might not adversely affect cosmesis and should be studied.	[Whelan, Timothy J.; Julian, Jim A.; Kim, Do-Hoon; Gu, Chu Shu; Levine, Mark N.] McMaster Univ, Dept Oncol, Hamilton, ON, Canada; [Whelan, Timothy J.; Julian, Jim A.; Kim, Do-Hoon; Gu, Chu Shu; Levine, Mark N.] Juravinski Canc Ctr, Hamilton, ON L8V 5C2, Canada; [Berrang, Tanya S.] Univ British Columbia, BC Canc Victoria, Radiat Therapy Program, Vancouver, BC, Canada; [Germain, Isabelle] Univ Laval, CHU Quebec, Dept Radiat Oncol, Quebec City, PQ, Canada; [Nichol, Alan M.; Germain, Francois] Univ British Columbia, Div Radiat Oncol, Vancouver, BC, Canada; [Nichol, Alan M.] BC Canc Vancouver, Vancouver, BC, Canada; [Akra, Mohamed] Univ Manitoba, Dept Radiat Oncol, Winnipeg, MB, Canada; [Lavertu, Sophie] Ctr Hosp Univ Montreal, Dept Radiat Oncol, Montreal, PQ, Canada; [Germain, Francois] BC Canc Kelowna, Kelowna, BC, Canada; [Fyles, Anthony] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada; [Fyles, Anthony] Princess Margaret Canc Ctr, Radiat Med Program, Toronto, ON, Canada; [Trotter, Theresa; Olivotto, Ivo A.] Univ Calgary, Calgary, AB, Canada; [Perera, Francisco E.] Western Univ, Dept Oncol, London, ON, Canada; [Perera, Francisco E.] London Reg Canc Program, London, ON, Canada; [Balkwill, Susan] BC Canc, Surrey, BC, Canada; [Chafe, Susan] Univ Alberta, Dept Oncol, Div Radiat Oncol, Edmonton, AB, Canada; [Chafe, Susan] Cross Canc Inst, Edmonton, AB, Canada; [McGowan, Thomas] Trillium Hlth Partners Credit Valley Hosp, Mississauga, ON, Canada; [Muanza, Thierry] McGill Univ, Dept Oncol, Montreal, PQ, Canada; [Muanza, Thierry] Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ, Canada; [Beckham, Wayne A.] Univ Victoria, Dept Phys & Astron, Victoria, BC, Canada; [Beckham, Wayne A.] BC Canc, Victoria, BC, Canada; [Chua, Boon H.] Univ New South Wales, Sydney, NSW, Australia; [Chua, Boon H.] Prince Wales Hosp, Sydney, NSW, Australia	McMaster University; McMaster University; University of British Columbia; Laval University; University of British Columbia; University of Manitoba; Universite de Montreal; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Calgary; Western University (University of Western Ontario); Western University (University of Western Ontario); University of Alberta; University of Alberta; University of Toronto; Trillium Health Partners; Credit Valley Hospital; McGill University; McGill University; University of Victoria; University of New South Wales Sydney	Whelan, TJ (corresponding author), Juravinski Canc Ctr, Hamilton, ON L8V 5C2, Canada.	twhelan@hhsc.ca; mlevine@mcmaster.ca	Nichol, Alan McVey/AAB-3551-2020; Whelan, Timothy/D-3185-2017; Sussman, Jonathan/AAQ-1588-2021	Nichol, Alan McVey/0000-0002-4146-881X; Whelan, Timothy/0000-0001-9844-2023; Lavertu, Sophie/0000-0001-6788-8292; , Nadeem/0000-0003-3821-4357; Nashd, Maged/0000-0001-6145-3888; Sussman, Jonathan/0000-0002-7702-8816; Holloway, Courtney Jean/0000-0003-3661-1957; Goldenberg, Benjamin/0000-0001-9393-6438; Huang, Fleur/0000-0001-7487-9642; Morgan, Scott/0000-0002-6568-3346; Hijal, Tarek/0000-0002-9341-1735; Chung, Caroline/0000-0002-9662-1519	Canadian Institutes for Health Research; Canadian Breast Cancer Research Alliance	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Research Alliance	Canadian Institutes for Health Research and Canadian Breast Cancer Research Alliance.	AARONSON NK, 1988, EUR J SURG ONCOL, V14, P133; Bentzen SM, 2010, INT J RADIAT ONCOL, V77, P969, DOI 10.1016/j.ijrobp.2010.01.059; Berrang TS, 2011, INT J RADIAT ONCOL, V81, P1220, DOI 10.1016/j.ijrobp.2010.07.2003; Clark RM, 1996, J NATL CANCER I, V88, P1659, DOI 10.1093/jnci/88.22.1659; Coles CE, 2017, LANCET, V390, P1048, DOI 10.1016/S0140-6736(17)31145-5; Correa C, 2017, PRACT RADIAT ONCOL, V7, P73, DOI 10.1016/j.prro.2016.09.007; Early Breast Canc Trialists Collab, 2011, LANCET, V378, P1707, DOI 10.1016/S0140-6736(11)61629-2; Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152; Formenti SC, 2012, INT J RADIAT ONCOL, V84, P606, DOI 10.1016/j.ijrobp.2012.01.039; FOWLER JF, 1989, BRIT J RADIOL, V62, P679, DOI 10.1259/0007-1285-62-740-679; Grendarova P, 2019, PRACT RADIAT ONCOL, V9, pE457, DOI 10.1016/j.prro.2019.04.002; Hoekstra N, 2018, RADIOTHER ONCOL, V128, P428, DOI 10.1016/j.radonc.2018.05.032; Liljegren G, 1999, J CLIN ONCOL, V17, P2326, DOI 10.1200/JCO.1999.17.8.2326; Livi L, 2015, EUR J CANCER, V51, P451, DOI 10.1016/j.ejca.2014.12.013; Mitchell T, 2011, MED DOSIM, V36, P10, DOI 10.1016/j.meddos.2009.10.003; Mouw KW, 2012, ONCOLOGY-NY, V26, P820; Olivotto IA, 2013, J CLIN ONCOL, V31, P4038, DOI 10.1200/JCO.2013.50.5511; Peterson D, 2015, INT J RADIAT ONCOL, V91, P968, DOI 10.1016/j.ijrobp.2014.12.040; Salvadori B, 1999, BRIT J SURG, V86, P84, DOI 10.1046/j.1365-2168.1999.00961.x; Smith BD, 2018, PRACT RADIAT ONCOL, V8, P145, DOI 10.1016/j.prro.2018.01.012; Smith BD, 2009, INT J RADIAT ONCOL, V74, P987, DOI 10.1016/j.ijrobp.2009.02.031; Strnad V, 2016, LANCET, V387, P229, DOI 10.1016/S0140-6736(15)00471-7; Vaidya JS, 2014, LANCET, V383, P603, DOI 10.1016/S0140-6736(13)61950-9; Veronesi U, 2001, ANN ONCOL, V12, P997, DOI 10.1023/A:1011136326943; VERONESI U, 1993, NEW ENGL J MED, V328, P1587, DOI 10.1056/NEJM199306033282202; Veronesi U, 2013, LANCET ONCOL, V14, P1269, DOI 10.1016/S1470-2045(13)70497-2; Vicini F, 2019, SAN ANTONIO BREAST C, V79, P4; Whelan TJ, 2010, NEW ENGL J MED, V362, P513, DOI 10.1056/NEJMoa0906260; Yarnold J, 2011, INT J RADIAT ONCOL, V79, P1, DOI 10.1016/j.ijrobp.2010.08.035	29	162	163	1	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 14	2019	394	10215					2165	2172		10.1016/S0140-6736(19)32515-2	http://dx.doi.org/10.1016/S0140-6736(19)32515-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV7MT	31813635				2023-01-03	WOS:000502546300026
J	Kaiser, AH; Hehman, L; Forsberg, BC; Simangolwa, WM; Sundewall, J				Kaiser, Andrea Hannah; Hehman, Lindsey; Forsberg, Birger Carl; Simangolwa, Warren Mukelabai; Sundewall, Jesper			Availability, prices and affordability of essential medicines for treatment of diabetes and hypertension in private pharmacies in Zambia	PLOS ONE			English	Article							ACCESS; INSULIN; CARE	Objectives To explore availability, prices and affordability of essential medicines for diabetes and hypertension treatment in private pharmacies in three provinces of Zambia. Methods A cross-sectional survey was conducted in 99 pharmacies across three Zambian provinces. Methods were based on a standardized methodology by the World Health Organization and Health Action International. Availability was analysed as mean availability per pharmacy and individual medicine. Median prices were compared to international reference prices and differences in price between medicine forms (original brand or generic product) were computed. Affordability was assessed as number of days' salaries required to purchase a standard treatment course using the absolute poverty line and mean per capita provincial household income as standard. An analysis identifying medicines considered both available and affordable was conducted. Results Two antidiabetics and nine antihypertensives had high-level availability (>= 80%) in all provinces; availability levels for the remaining surveyed antidiabetics and antihypertensives were largely found below 50%. Availability further varied markedly across medicines and medicine forms. Prices for most medicines were higher than international reference prices and great price variations were found between pharmacies, medicines and medicine forms. Compared to original brand products, purchase of generics was associated with price savings for patients between 21.54% and 96.47%. No medicine was affordable against the absolute poverty line and only between four and eleven using mean per capita provincial incomes. Seven generics in Copperbelt/Lusaka and two in Central province were highly available and affordable. Conclusions The study showed that the majority of surveyed antidiabetic and antihypertensive medicines was inadequately available (<80%). In addition, most prices were higher than their international reference prices and that treatment with these medicines was largely unaffordable against the set affordability thresholds. Underlying reasons for the findings should be explored as a basis for targeted policy initiatives.	[Kaiser, Andrea Hannah] Karolinska Inst, Stockholm, Sweden; [Hehman, Lindsey; Simangolwa, Warren Mukelabai] Clinton Hlth Access Initiat Inc CHAI, Lusaka, Zambia; [Forsberg, Birger Carl] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden; [Sundewall, Jesper] Univ Kwazulu Natal, HEARD, Durban, South Africa; [Sundewall, Jesper] Lund Univ, Div Social Med & Global Hlth, Lund, Sweden	Karolinska Institutet; Karolinska Institutet; University of Kwazulu Natal; Lund University	Forsberg, BC (corresponding author), Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden.	birger.forsberg@ki.se		Kaiser, Andrea Hannah/0000-0001-9595-8059; Sundewall, Jesper/0000-0001-5357-5754	Clinton Health Access Initiative (CHAI)	Clinton Health Access Initiative (CHAI)	AHK received funding from the Clinton Health Access Initiative (CHAI, https://clintonhealthaccess.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aantjes CJ, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-295; [Anonymous], 2011, PRIORITIZED RES AGEN; [Anonymous], 2016, DIABETES CARE S1, V39, pS1, DOI 10.2337/dc16-S001; [Anonymous], 2017, COMMUN MATH STAT, V5, P1, DOI DOI 10.1007/S40304-017-0103-Z; Bank of Zambia, 2019, MARK RAT DAIL ZMW US; Beran D, 2005, DIABETES CARE, V28, P2136, DOI 10.2337/diacare.28.9.2136; Beran D, 2016, LANCET DIABETES ENDO, V4, P275, DOI 10.1016/S2213-8587(15)00521-5; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Center for Global Development, 2019, TACKL TRIPL TRANS GL; Dabare PRL, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-817; Ewen M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171284; Freedom to Create, 2016, POL REP HEALTHC FIN; Gelders S, 2005, PRICE AVAILABILITY A; Gong SW, 2018, HEALTH POLICY PLANN, V33, P937, DOI 10.1093/heapol/czy076; Government of Zambia, 2012, NAT HLTH POL NAT HLT; Health Action International, 2016, ADDR CHALL CONSTR IN; Health Action International, 2010, LIF SAV INS LARG UN; Hogerzeil HV, 2013, LANCET, V381, P680, DOI 10.1016/S0140-6736(12)62128-X; Indonesia T., 2021, TELKOM CSS 2021 2025; International Diabetes Federation, 2012, GLOB GUID TYP 2 DIAB; International Insulin Foundation Diabetes Association of Zambia, 2004, FIN REP INT INS FDN; International Trade Administration, 2019, ZAMB COUNT COMM GUID; Jingi AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111812; Johnston A, 2011, BRIT J CLIN PHARMACO, V72, P727, DOI 10.1111/j.1365-2125.2011.03987.x; Kalungia CA., 2017, MED J ZAMBIA, V44, P140; Kibirige D, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0651-6; Li ZJ, 2019, TROP MED INT HEALTH, V24, P43, DOI 10.1111/tmi.13167; Liu CX, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2553-0; Management Sciences for Health, 2016, INT MED PROD PRIC GU; Masiye F, 2016, INT J HEALTH POLICY, V5, P693, DOI 10.15171/ijhpm.2016.65; MEASURE Evaluation USAID, 2001, MEASURE EV MAN SER, V3; Medical Stores Limited. Medical Stores Limited, 2017, WHAT WE DO; Ministry of Health, 2015, ZAMB HOUS HLTH EXP U; Ministry of Health (MOH), 2017, ZAMB NAT HLTH STRAT; National Institutes of Health State-of-the-Science Conference statement, 2007, AM J CLIN NUTR, V85, p257S; Niens LM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000333; Novo Nordisk, 2019, ACC INS COMM; Republic of Zambia. Central Statistical Office, 2015, MONTHLY, V148; Republic of Zambia. Central Statistical Office, 2018, MONTHLY, V186; Republic of Zambia. Central Statistical Office, 2015, 2015 LIV COND MON SU; Republic of Zambia. Ministry of Health, 2017, ZAMB NAT FORM 2017; Republic of Zambia. Ministry of Health, 2017, ZAMB ESS MED LIST ZE; Republic of Zambia. Ministry of Health and Ministry of Community Development Mother and Child Health, 2015, MIDT REV IMPL PERF R; Roger L, 2017, EXCHANGE RATE INFLAT; Rotenstein LS., 2012, CLIN DIABETES, V30, P138, DOI DOI 10.2337/DIACLIN.30.4.138; Tieu C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195012; Topp SM, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0783-3; Trapsida J, 2012, PREVENTING CONTROLLI; van Mourik MSM, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-25; Volman B, 2008, DIRECT COSTS AVAILAB; Weber MA, 2014, J CLIN HYPERTENS, V16, P14, DOI 10.1111/jch.12237; WHO, 2017, WHO GLOB SURV MON SY; WHO Collaborating Centre for Drug Statistics Methodology, 2018, DDD DEF GEN CONS; Wilkins Alasdair R, 2014, J Diabetes Sci Technol, V8, P23; World Health Organization, 2016, MED TRANSP ALL META; World Health Organization, 2013, WHODCOWHD20132; World Health Organization, 2019, NONC DIS MENT HLTH T; World Health Organization, 2015, WHO GLOBAL ACTION PL; World Health Organization, 2016, GLOB REP PSOR; World Health Organization, 2017, ESS MED SEL WHO MOD; World Health Organization Health Action International., 2008, MEAS MED PRIC AFF AV; World Health Organization The Global Fund, 2011, PHARM SECT COUNTR PR; Yadav P., 2007, ANAL PUBLIC PRIVATE; Yang H, 2010, HEALTH POLICY PLANN, V25, P219, DOI 10.1093/heapol/czp056; Zambia Medicines Regulatory Authority, 2018, 2018 REG MARK AUTH M; Zambia Medicines Regulatory Authority, 2017, MED ALL SUBST CERT R; Zambia Revenue Authority, 2017, VAL ADD TAX GUID	67	11	11	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2019	14	12							e0226169	10.1371/journal.pone.0226169	http://dx.doi.org/10.1371/journal.pone.0226169			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX6TX	31834889	gold, Green Published			2023-01-03	WOS:000503865900001
J	Wang, MM; Wen, JQ; Guo, YX; Shen, YL; An, XZ; Hu, YN; Xiao, JW				Wang, Mingmin; Wen, Jinquan; Guo, Yuxia; Shen, Yali; An, Xizhou; Hu, Yanni; Xiao, Jianwen			Clinical characterization and prognosis of T cell acute lymphoblastic leukemia with high CRLF2 gene expression in children	PLOS ONE			English	Article							RECEPTOR	It has been reported that overexpression of the CRLF2 gene is associated with poor outcomes in pediatric B cell acute lymphoblastic leukemia (B-ALL), but the incidence rates, clinical characteristics and outcomes of CRLF2 gene overexpression in pediatric T cell ALL (T-ALL) have not been systematically analyzed. In this study, CRLF2 mRNA expression levels and clinical and laboratory parameters in 63 pediatric T-ALL patients were detected at the Children's Hospital of Chongqing Medical University and Children's Hospital of Xianyang between February 2015 and June 2018. The patients were treated according to the modified St. Jude TXV ALL protocol, and early treatment responses (bone marrow smear and MRD level) and prognoses in the enrolled patients were assessed. CRLF2 overexpression was detected in 21/63 (33.33%) patients. Statistical differences were not found for clinical or laboratory parameters (including sex, age, initial WBC count, incidence mediastinal involvement, abnormal karyotype and fusion genes) between patients with high CRLF2 expression and patients with low expression of CRLF2 (P>0.05). One patient died of tumor lysis syndrome and renal failure, and the treatment response was monitored on day 19 (TP1) of remission in 62 patients. One patient quit treatment because of family decisions, and 61 patients underwent treatment response evaluation on day 46 (TP2) of remission. Significant differences were not found between patients with high CRLF2 expression and patients with low CRLF2 expression in terms of the treatment responses at TP1 or TP2 (P>0.05). Following October 2018, 12 patients among the 61 evaluable patients relapsed (relapse rate: 19.67%), 3 patients died from chemotherapy, and the treatment-related mortality (TRM) rate was 4.92%. Secondary tumors occurred in 1 patient. The 3-year prospective EFS rate was 54.1 +/- 11.2% and 77.7 +/- 6.6% for the 61 evaluable patients and 58 patients without TRM. Patients with low CRLF2 expression had longer EFS durations than patients with high CRLF2 expression (61 evaluable patients: 35.91 +/- 2.38 months vs 23.43 +/- 2.57 months; 58 patients without TRM: 37.86 +/- 2.08 months vs 24.55 +/- 2.43 months, P<0.05). CRLF2 expression levels were also monitored in 13 patients at TP1 and TP2, and the MRD level did not vary with the CRLF2 expression level. Our data suggest that clinical features, laboratory findings and treatment responses in the pediatric T-ALL population do not vary based on the overexpression of CRLF2 but that CRLF2 overexpression can contribute to a high risk of relapse in pediatric T-ALL. Thus, CRLF2 expression levels should not be used as biomarkers for monitoring MRD.	[Wang, Mingmin; Guo, Yuxia; Shen, Yali; An, Xizhou; Hu, Yanni; Xiao, Jianwen] Chongqing Med Univ, Childrens Hosp, Dept Hematol, Chongqing, Peoples R China; [Wang, Mingmin; Guo, Yuxia; An, Xizhou; Hu, Yanni; Xiao, Jianwen] Minist Educ, Key Lab Child Dev & Disorders, Chongqing, Peoples R China; [Wang, Mingmin; Shen, Yali; Xiao, Jianwen] Chongqing Key Lab Pediat, Chongqing, Peoples R China; [Wen, Jinquan] Childrens Hosp Xianyang, Dept Hematol, Xian, Peoples R China; [Guo, Yuxia; Shen, Yali; Hu, Yanni] China Int Sci & Technol Cooperat Ctr Child Dev &, Chongqing, Peoples R China	Chongqing Medical University	Xiao, JW (corresponding author), Chongqing Med Univ, Childrens Hosp, Dept Hematol, Chongqing, Peoples R China.; Xiao, JW (corresponding author), Minist Educ, Key Lab Child Dev & Disorders, Chongqing, Peoples R China.; Xiao, JW (corresponding author), Chongqing Key Lab Pediat, Chongqing, Peoples R China.	tomahawk6502@sohu.com	An, Xizhou/GLS-7753-2022	XIAO, Jianwen/0000-0002-8322-9286	Natural Scientific Foundation Commission of China PR [81700158]; Chongqing Science and Technology Development Foundation [cstc2018jsyj-jsyjX0015]	Natural Scientific Foundation Commission of China PR; Chongqing Science and Technology Development Foundation	This study was supported by the Natural Scientific Foundation Commission of China PR (Project No. 81700158 Dr. Xizhou AN) and Chongqing Science and Technology Development Foundation cstc2018jsyj-jsyjX0015 Dr. Jianwen XIAO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barba P, 2019, EUR J HAEMATOL, V102, P79, DOI 10.1111/ejh.13178; Chiaretti S, 2016, LEUKEMIA RES, V41, P36, DOI 10.1016/j.leukres.2015.11.018; Francis OL, 2016, HAEMATOLOGICA, V101, P417, DOI 10.3324/haematol.2015.125336; Goldberg JM, 2003, J CLIN ONCOL, V21, P3616, DOI 10.1200/JCO.2003.10.116; Hanada I, 2014, GENE CHROMOSOME CANC, V53, P902, DOI 10.1002/gcc.22201; Kim B, 2016, INT J LAB HEMATOL, V38, P444, DOI 10.1111/ijlh.12521; Lin SC, 2016, EUR J CLIN INVEST, V46, P511, DOI 10.1111/eci.12623; Marjerrison S, 2013, CANCER-AM CANCER SOC, V119, P1277, DOI 10.1002/cncr.27846; Pallisgaard N, 1998, BLOOD, V92, P574, DOI 10.1182/blood.V92.2.574; Palmi C, 2016, ONCOTARGET, V7, P59260, DOI 10.18632/oncotarget.10610; Pui CH, 2017, LEUKEMIA, V31, P333, DOI 10.1038/leu.2016.234; Sayed DM, 2018, CLIN LYMPHOMA MYELOM, V17, P443; Shago M, 2017, METHODS MOL BIOL, V1541, P257, DOI 10.1007/978-1-4939-6703-2_21; Tamaki K, 2018, CANCER SCI, V109, P2286, DOI 10.1111/cas.13641; Tatsuno K, 2015, J INVEST DERMATOL, V135, P3017, DOI 10.1038/jid.2015.318; Yamashita Y, 2013, PEDIATR BLOOD CANCER, V60, P1587, DOI 10.1002/pbc.24571; Yeh TC, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27496	17	2	3	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2019	14	12							e0224652	10.1371/journal.pone.0224652	http://dx.doi.org/10.1371/journal.pone.0224652			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP1HF	31830053	Green Published, gold			2023-01-03	WOS:000534070200011
J	Rosenthal, LM; Leithner, C; Tong, G; Streitberger, KJ; Krech, J; Storm, C; Schmitt, KRL				Rosenthal, Lisa-Maria; Leithner, Christoph; Tong, Giang; Streitberger, Kaspar Josche; Krech, Jana; Storm, Christian; Schmitt, Katharina Rose Luise			RBM3 and CIRP expressions in targeted temperature management treated cardiac arrest patients-A prospective single center study	PLOS ONE			English	Article							RNA-BINDING PROTEIN; REGULATED EXPRESSION; HYPOTHERMIA; RESUSCITATION; STRESS; INJURY; CELLS; CARE; APOPTOSIS; ISCHEMIA	Background Management of cardiac arrest patients includes active body temperature control and strict prevention of fever to avoid further neurological damage. Cold-shock proteins RNA-binding motif 3 (RBM3) and cold inducible RNA-binding protein (CIRP) expressions are induced in vitro in response to hypothermia and play a key role in hypothermia-induced neuroprotection. Objective To measure gene expressions of RBM3, CIRP, and inflammatory biomarkers in whole blood samples from targeted temperature management (TTM)-treated post-cardiac arrest patients for the potential application as clinical biomarkers for the efficacy of TTM treatment. Methods A prospective single center trial with the inclusion of 22 cardiac arrest patients who were treated with TTM (33 degrees C for 24 hours) after ROSC was performed. RBM3, CIRP, interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1), and inducible nitric oxide synthase (iNOS) mRNA expressions were quantified by RT-qPCR. Serum RBM3 protein concentration was quantified using an enzyme-linked immunosorbent assay (ELISA). Results RBM3 mRNA expression was significantly induced in post-cardiac arrest patients in response to TTM. RBM3 mRNA was increased 2.2-fold compared to before TTM. A similar expression kinetic of 1.4-fold increase was observed for CIRP mRNA, but did not reached significancy. Serum RBM3 protein was not increased in response to TTM. IL-6 and MCP-1 expression peaked after ROSC and then significantly decreased. iNOS expression was significantly increased 24h after return of spontaneous circulation (ROSC) and TTM. Conclusions RBM3 is temperature regulated in patients treated with TTM after CA and ROSC. RBM3 is a possible biomarker candidate to ensure the efficacy of TTM treatment in post-cardiac arrest patients and its pharmacological induction could be a potential future intervention strategy that warrants further research.	[Rosenthal, Lisa-Maria; Tong, Giang; Krech, Jana; Schmitt, Katharina Rose Luise] Deutsch Herzzentrum Berlin, Dept Congenital Heart Dis Pediat Cardiol, Berlin, Germany; [Rosenthal, Lisa-Maria; Streitberger, Kaspar Josche] Berlin Inst Hlth, Berlin, Germany; [Leithner, Christoph; Streitberger, Kaspar Josche] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany; [Storm, Christian] Charite Univ Med Berlin, Dept Internal Med Nephrol & Intens Care Charite, Berlin, Germany; [Schmitt, Katharina Rose Luise] Charite Univ Med Berlin, Dept Pediat Cardiol, Berlin, Germany; [Schmitt, Katharina Rose Luise] DHZK German Ctr Cardiovasc Res, Berlin, Germany	German Heart Center Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Centre for Cardiovascular Research	Schmitt, KRL (corresponding author), Deutsch Herzzentrum Berlin, Dept Congenital Heart Dis Pediat Cardiol, Berlin, Germany.; Schmitt, KRL (corresponding author), Charite Univ Med Berlin, Dept Pediat Cardiol, Berlin, Germany.; Schmitt, KRL (corresponding author), DHZK German Ctr Cardiovasc Res, Berlin, Germany.	kschmitt@dhzb.de	Tong, Giang/AAY-9865-2021; Rosenthal, Lisa-Maria/AFS-1484-2022; Schmitt, Katharina Rose Luise/AEU-1004-2022	Tong, Giang/0000-0002-3470-9750; Schmitt, Katharina/0000-0003-0860-1137; Lucht, Jana/0000-0001-8687-8313; Rosenthal, Lisa-Maria/0000-0003-4083-1186; Leithner, Christoph/0000-0002-8277-846X	Charite-Universitatsmedizin Berlin; Berlin Institute of Health	Charite-Universitatsmedizin Berlin; Berlin Institute of Health	Dr. Lisa-Maria Rosenthal is participant in the Berlin Institute of Health Charite Junior Clinician Scientist Program funded by the Charite-Universitatsmedizin Berlin and the Berlin Institute of Health. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams JA, 2007, RESUSCITATION, V74, P516, DOI 10.1016/j.resuscitation.2007.02.009; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bro-Jeppesen J, 2017, RESUSCITATION, V121, P179, DOI 10.1016/j.resuscitation.2017.09.019; Chip S, 2011, NEUROBIOL DIS, V43, P388, DOI 10.1016/j.nbd.2011.04.010; Cui ZM, 2014, J MOL NEUROSCI, V54, P252, DOI 10.1007/s12031-014-0282-y; Danno S, 1997, BIOCHEM BIOPH RES CO, V236, P804, DOI 10.1006/bbrc.1997.7059; Efendijev I, 2018, RESUSCITATION, V131, P128, DOI 10.1016/j.resuscitation.2018.06.028; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jackson TC, 2015, NEUROSCIENCE, V305, P268, DOI 10.1016/j.neuroscience.2015.08.012; Kern KB, 2008, RESUSCITATION, V77, P401, DOI 10.1016/j.resuscitation.2008.01.026; Lebsack TW, 2010, J CELL BIOCHEM, V110, P372, DOI 10.1002/jcb.22547; Lemiale V, 2013, INTENS CARE MED, V39, P1972, DOI 10.1007/s00134-013-3043-4; Li SC, 2012, BRAIN RES, V1441, P47, DOI 10.1016/j.brainres.2011.12.053; Liu JL, 2015, BRAIN RES, V1597, P189, DOI 10.1016/j.brainres.2014.11.061; Matsumoto H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32275-8; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nishiyama H, 1997, J CELL BIOL, V137, P899, DOI 10.1083/jcb.137.4.899; Nolan JP, 2015, RESUSCITATION, V95, P202, DOI 10.1016/j.resuscitation.2015.07.018; Nolan JP, 2008, RESUSCITATION, V79, P350, DOI 10.1016/j.resuscitation.2008.09.017; Peretti D, 2015, NATURE, V518, P236, DOI 10.1038/nature14142; Pilotte J, 2009, BRAIN RES, V1258, P12, DOI 10.1016/j.brainres.2008.12.050; Qiang XL, 2013, NAT MED, V19, P1489, DOI 10.1038/nm.3368; Rosenthal LM, 2017, HYPOXIA, V5, P33, DOI 10.2147/HP.S132462; Saito K, 2010, BRAIN RES, V1358, P20, DOI 10.1016/j.brainres.2010.08.048; Schmitt Katharina Rose Luise, 2014, Mol Cell Pediatr, V1, P7, DOI 10.1186/s40348-014-0007-x; Shi H, 2017, MOD J LANG TEACH MET, V7, P162; Streitberger KJ, 2017, CRIT CARE MED, V45, P1145, DOI 10.1097/CCM.0000000000002335; Tong G, 2013, BRAIN RES, V1504, P74, DOI 10.1016/j.brainres.2013.01.041; Wellmann S, 2004, J CELL SCI, V117, P1785, DOI 10.1242/jcs.01026; Wellmann S, 2010, PEDIATR RES, V67, P35, DOI 10.1203/PDR.0b013e3181c13326; Xue JH, 1999, FREE RADICAL BIO MED, V27, P1238, DOI 10.1016/S0891-5849(99)00158-6; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Zhou M, 2014, BBA-GEN SUBJECTS, V1840, P2253, DOI 10.1016/j.bbagen.2014.02.027; Zhou YY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137721; Zhu XZ, 2016, CELL MOL LIFE SCI, V73, P3839, DOI 10.1007/s00018-016-2253-7; Zhu XZ, 2016, FASEB J, V30, P624, DOI 10.1096/fj.15-274639	36	5	6	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2019	14	12							e0226005	10.1371/journal.pone.0226005	http://dx.doi.org/10.1371/journal.pone.0226005			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP0TY	31821351	Green Published, gold			2023-01-03	WOS:000534035700030
J	Abbing, A; de Sonneville, L; Baars, E; Bourne, D; Swaab, H				Abbing, Annemarie; de Sonneville, Leo; Baars, Erik; Bourne, Danielle; Swaab, Hanna			Anxiety reduction through art therapy in women. Exploring stress regulation and executive functioning as underlying neurocognitive mechanisms	PLOS ONE			English	Article							HEART-RATE-VARIABILITY; COGNITIVE-BEHAVIORAL THERAPY; POWER SPECTRUM ANALYSIS; SELF-REPORT ASSESSMENT; EMOTION REGULATION; SOCIAL ANXIETY; DISORDERS; WORRY; METAANALYSIS; INHIBITION	Objectives To explore possible working mechanisms of anxiety reduction in women with anxiety disorders, treated with art therapy (AT). Methods A RCT comparing AT versus waiting list (WL) condition on aspects of self-regulation. Stress regulation (heart rate and heart rate variability) and executive functioning (daily behavioural and cognitive performance aspects of executive functioning (EF)) were evaluated in a prepost design. Participants were women, aged 18-65 years with moderate to severe anxiety symptoms. Results Effectiveness of AT compared to WL was demonstrated in a higher resting HRV post treatment, improvements in aspects of self-reported daily EF (emotion control, working memory, plan/organize and task monitor), but not in cognitive performance of EF, stress responsiveness and down regulation of stress. The decrease in anxiety level was associated with improvements in self-reported daily EF. Conclusions AT improves resting HRV and aspects of EF, the latter was associated with art therapyrelated anxiety reduction.	[Abbing, Annemarie; Baars, Erik] Univ Appl Sci Leiden, Fac Hlth, Leiden, Netherlands; [Abbing, Annemarie; de Sonneville, Leo; Swaab, Hanna] Leiden Univ, Fac Social Sci, Clin Neurodev Sci, Leiden, Netherlands; [de Sonneville, Leo; Swaab, Hanna] Leiden Inst Brain & Cognit, Leiden, Netherlands; [Bourne, Danielle] Univ Med Ctr Utrecht, Dept Psychiat, Utrecht, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Utrecht University; Utrecht University Medical Center	Abbing, A (corresponding author), Univ Appl Sci Leiden, Fac Hlth, Leiden, Netherlands.; Abbing, A (corresponding author), Leiden Univ, Fac Social Sci, Clin Neurodev Sci, Leiden, Netherlands.	abbing.a@hsleiden.nl		Swaab, Hanna/0000-0003-3697-060X; Abbing, Annemarie/0000-0002-8096-3530; Baars, Erik/0000-0003-4428-5135	Iona Foundation; Stichting AG Phoenix; Dutch association of anthroposophic art therapy (NVKToag)	Iona Foundation; Stichting AG Phoenix; Dutch association of anthroposophic art therapy (NVKToag)	This study was co-funded by the Iona Foundation (www.iona.nl), Stichting AG Phoenix and the Dutch association of anthroposophic art therapy (NVKToag). These organisations had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbing A, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.01203; AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, P189; Anxiety and Depression Association of America (ADAA), 2018, AADA FACTS STAT; Appelhans BM, 2006, ANXIETY STRESS COPIN, V19, P93, DOI 10.1080/10652460600774448; Asay TP, 1999, HEART AND SOUL OF CHANGE, P23, DOI 10.1037/11132-001; Beck AT, 2014, ANNU REV CLIN PSYCHO, V10, P1, DOI 10.1146/annurev-clinpsy-032813-153734; Bolwerk A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101035; Borenstein M., 2009, HDB RES SYNTHESIS ME, V2, P221, DOI DOI 10.7758/9781610441384; Brosschot JF, 2007, INT J PSYCHOPHYSIOL, V63, P39, DOI 10.1016/j.ijpsycho.2006.07.016; Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822; Cacioppo JT, 2007, HANDBOOK OF PSYCHOPHYSIOLOGY, 3RD EDITION, P1, DOI 10.2277/ 0521844711; Camm AJ, 1996, EUR HEART J, V17, P354; Chalmers JA, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00080; Cisler JM, 2010, J PSYCHOPATHOL BEHAV, V32, P68, DOI 10.1007/s10862-009-9161-1; CLARK LA, 1991, J ABNORM PSYCHOL, V100, P316, DOI 10.1037/0021-843X.100.3.316; Cohen H, 2000, PSYCHIAT RES, V96, P1, DOI 10.1016/S0165-1781(00)00195-5; De Sonneville L. M. J., 2014, HDB AMSTERDAM NEUROP, DOI [10.1016/0005-7967(92)90036-g, DOI 10.1016/0005-7967(92)90036-G]; De Sonneville LMJ, 2002, NEUROPSYCHOLOGIA, V40, P1751, DOI 10.1016/S0028-3932(02)00041-6; de Sonneville LMJ, 1999, COMP PSYCH, V6, P187; Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824; Egger N, 2015, J AFFECT DISORDERS, V180, P21, DOI 10.1016/j.jad.2015.03.037; Fisher AJ, 2013, BIOL PSYCHOL, V93, P65, DOI 10.1016/j.biopsycho.2013.01.012; Friedman BH, 1998, BIOL PSYCHOL, V47, P243, DOI 10.1016/S0301-0511(97)00027-6; Gladstone GL, 2005, DEPRESS ANXIETY, V22, P103, DOI 10.1002/da.20082; Haeyen S, 2018, J PERS DISORD, V32, P527, DOI 10.1521/pedi_2017_31_312; Haeyen S, 2018, ART PSYCHOTHER, V58, P11, DOI 10.1016/j.aip.2017.12.009; Hallion LS, 2017, COGNITIVE THER RES, V41, P610, DOI 10.1007/s10608-017-9832-2; Hassink-Franke L, 2012, HUISARTS WET, V55, P68; Hofmann SG, 2008, J CLIN PSYCHIAT, V69, P621, DOI 10.4088/jcp.v69n0415; Huijbregts SCJ, 2011, PSYCHONEUROENDOCRINO, V36, P913, DOI 10.1016/j.psyneuen.2010.12.008; Huizinga M, 2010, J COGN DEV, V11, P408, DOI 10.1080/15248371003700031; IBM Corp, IBM SPSS STAT WIND V; Kaimal G, 2016, ART THER, V33, P74, DOI 10.1080/07421656.2016.1166832; Kazdin A., 2000, DIRECTIONS RES PRACT; KIRSCHBAUM C, 1993, NEUROPSYCHOBIOLOGY, V28, P76, DOI 10.1159/000119004; Konrad K, 2004, J AM ACAD CHILD PSY, V43, P191, DOI 10.1097/00004583-200402000-00015; LEHRER PM, 1982, BEHAV ASSESS, V4, P167; Levine JC, 2016, J AFFECT DISORDERS, V205, P207, DOI 10.1016/j.jad.2016.07.019; Lezak M., 2012, NEUROPSYCHOLOGICAL A; Mennin DS, 2008, DEPRESS ANXIETY, V25, P289, DOI 10.1002/da.20493; Miu AC, 2009, AUTON NEUROSCI-BASIC, V145, P99, DOI 10.1016/j.autneu.2008.11.010; Miyake A, 2012, CURR DIR PSYCHOL SCI, V21, P8, DOI 10.1177/0963721411429458; Nickel P, 2003, HUM FACTORS, V45, P575, DOI 10.1518/hfes.45.4.575.27094; Nunan D, 2010, PACE, V33, P1407, DOI 10.1111/j.1540-8159.2010.02841.x; Pittig A, 2013, INT J PSYCHOPHYSIOL, V87, P19, DOI 10.1016/j.ijpsycho.2012.10.012; Porges SW, 2007, BIOL PSYCHOL, V74, P116, DOI 10.1016/j.biopsycho.2006.06.009; Rosellini Anthony J, 2015, J Exp Psychopathol, Va2, P110, DOI 10.5127/pr.036014; Roth R.M., 2005, BRIEF BEHAV RATING I; Rowbotham I, 2009, NEUROPSYCHOLOGY, V23, P50, DOI 10.1037/a0013927; Sandmire DA, 2012, ART THER, V29, P68, DOI 10.1080/07421656.2012.683748; SCHOLING A, 1992, BEHAV RES THER, V30, P521, DOI 10.1016/0005-7967(92)90036-G; Segerstorm SC, 2016, HANDBOOK OF SELF-REGULATION, 3 EDITION, P131; Segerstrom SC, 2007, PSYCHOL SCI, V18, P275, DOI 10.1111/j.1467-9280.2007.01888.x; Sharp PB, 2015, INT J PSYCHOPHYSIOL, V98, P365, DOI 10.1016/j.ijpsycho.2015.07.001; Sjak-Shie E., 2017, PHYSIODATA TOOLBOX V; Smits JAJ, 2012, J CONSULT CLIN PSYCH, V80, P624, DOI 10.1037/a0028957; Suveg C, 2010, J ANXIETY DISORD, V24, P924, DOI 10.1016/j.janxdis.2010.06.018; TAYLOR SE, 1994, PSYCHOL BULL, V116, P21, DOI 10.1037/0033-2909.116.1.21; Terluin B, 1996, HUISARTS WET, V39, P538; Thayer JF, 2012, NEUROSCI BIOBEHAV R, V36, P747, DOI 10.1016/j.neubiorev.2011.11.009; Van Hooren S., 2018, COMMUNICATION; Williams B, 2017, TRANSFUS MED REV, V31, P11, DOI 10.1016/j.tmrv.2016.08.005; Williams DP, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00261	64	2	3	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2019	14	12							e0225200	10.1371/journal.pone.0225200	http://dx.doi.org/10.1371/journal.pone.0225200			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LO9UM	31794566	Green Published, gold			2023-01-03	WOS:000533969300013
J	Manning , KE; Beresford-Webb, JA; Aman, LCS; Ring, HA; Watson, PC; Porges, SW; Oliver, C; Jennings, SR; Holland, AJ				Manning, Katherine E.; Beresford-Webb, Jessica A.; Aman, Lucie C. S.; Ring, Howard A.; Watson, Peter C.; Porges, Stephen W.; Oliver, Chris; Jennings, Sally R.; Holland, Anthony J.			Transcutaneous vagus nerve stimulation (t-VNS): A novel effective treatment for temper outbursts in adults with Prader-Willi Syndrome indicated by results from a non-blind study	PLOS ONE			English	Article							QUALITY-OF-LIFE; BEHAVIOR; DELETION; INDIVIDUALS; DISORDERS; EPILEPSY; CHILDREN; ANXIETY; PEOPLE; THREAT	Temper outbursts are a severe problem for people with Prader-Willi Syndrome (PWS). Previous reports indicate that vagus nerve stimulation (VNS) may reduce maladaptive behaviour in neurodevelopmental disorders, including PWS. We systematically investigated the effectiveness of transcutaneous VNS (t-VNS) in PWS. Using a non-blind single case repeat measures modified ABA design, with participants as their own controls, t-VNS was evaluated in five individuals with PWS [three males; age 22-41 (M = 26.8)]. After a baseline phase, participants received four-hours of t-VNS daily for 12 months, followed by one month of daily t-VNS for two-hours. The primary outcome measure was the mean number of behavioural outbursts per day. Secondary outcomes included findings from behavioural questionnaires and both qualitative and goal attainment interviews. Four of the five participants who completed the study exhibited a statistically significant reduction in number and severity of temper outbursts after approximately nine months of daily four-hour t-VNS. Subsequent two-hour daily t-VNS was associated with increased outbursts for all participants, two reaching significance. Questionnaire and interview data supported these findings, the latter indicating potential mechanisms of action. No serious safety issues were reported. t-VNS is an effective, novel and safe intervention for chronic temper outbursts in PWS. We propose these changes are mediated through vagal projections and their effects both centrally and on the functioning of the parasympathetic nervous system. These findings challenge our present biopsychosocial understanding of such behaviours suggesting that there is a single major mechanism that is modifiable using t-VNS. This intervention is potentially generalizable across other clinical groups. Future research should address the lack of a sham condition in this study along with the prevalence of high drop out rates, and the potential effects of different stimulation intensities, frequencies and pulse widths.	[Manning, Katherine E.; Beresford-Webb, Jessica A.; Aman, Lucie C. S.; Ring, Howard A.; Jennings, Sally R.; Holland, Anthony J.] Univ Cambridge, Dept Psychiat, Cambridge, Cambs, England; [Manning, Katherine E.] Univ Essex, Sch Hlth & Social Care, Colchester, Essex, England; [Manning, Katherine E.] Essex Partnership Univ NHS Fdn Trust, Wickford, Essex, England; [Watson, Peter C.] Univ Cambridge, MRC, Cognit & Brain Sci Unit, Cambridge, Cambs, England; [Porges, Stephen W.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27515 USA; [Oliver, Chris] Univ Birmingham, Sch Psychol, Birmingham, W Midlands, England	University of Cambridge; University of Essex; University of Cambridge; University of North Carolina; University of North Carolina Chapel Hill; University of Birmingham	Beresford-Webb, JA (corresponding author), Univ Cambridge, Dept Psychiat, Cambridge, Cambs, England.	jb2192@medschl.cam.ac.uk	Oliver, Christopher/A-7519-2008	Oliver, Christopher/0000-0001-5217-6209; Beresford-Webb, Jessica/0000-0001-5068-5675	Foundation for Prader-Willi Research (FPWR); UK PWSA; Sam's Foundation; Health Foundation; NIHR CLAHRC for the East of England; MRC [MC_UU_00005/14, MC_U105579212] Funding Source: UKRI	Foundation for Prader-Willi Research (FPWR); UK PWSA; Sam's Foundation; Health Foundation; NIHR CLAHRC for the East of England; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The Foundation for Prader-Willi Research (FPWR) funded this study, with additional support from the UK PWSA and Sam's Foundation; https://www.fpwr.org/, https://www.pwsa.co.uk/. The Health Foundation and NIHR CLAHRC for the East of England also supported AJH; https://www.health.org.uk/, http://www.clahrc-eoe.nihr.ac.uk/.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AMAN MG, 1985, AM J MENT DEF, V89, P485; Bar-Haim Y, 2007, PSYCHOL BULL, V133, P1, DOI 10.1037/0033-2909.133.1.1; BENMENACHEM E, 1995, EPILEPSY RES, V20, P221, DOI 10.1016/0920-1211(94)00083-9; Bittel Douglas C., 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405009531; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Capone F, 2015, J NEURAL TRANSM, V122, P679, DOI 10.1007/s00702-014-1299-7; Cassidy SB, 1997, AM J MED GENET, V68, P433; Cummins RA, 2005, PERSONAL WELLBEING I; Dugard P., 2001, SINGLE CASE SMALL N; DYKENS EM, 1992, J AM ACAD CHILD PSY, V31, P1125, DOI 10.1097/00004583-199211000-00022; Ellrich J, 2011, EUR NEUROL REV, V6, P254, DOI DOI 10.17925/ENR.2011.06.04.254; Galli R, 2003, EPILEPSY BEHAV, V4, P185, DOI 10.1016/S1525-5050(03)00003-9; Holland AJ, 2003, PSYCHOL MED, V33, P141, DOI 10.1017/S0033291702006736; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Hull MM, 2015, CHILD NERV SYST, V31, P1377, DOI 10.1007/s00381-015-2720-8; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; Kossoff EH, 2004, EPILEPSY BEHAV, V5, P256, DOI 10.1016/j.yebeh.2003.12.008; Manning KE, 2016, J INTELL DISABIL RES, V60, P149, DOI 10.1111/jir.12203; Mazaheri MM, 2013, J INTELL DISABIL RES, V57, P861, DOI 10.1111/j.1365-2788.2012.01634.x; Murphy JV, 2000, PEDIATR NEUROL, V23, P167, DOI 10.1016/S0887-8994(00)00170-3; Murray BJ, 2001, NEUROLOGY, V57, P1523, DOI 10.1212/WNL.57.8.1523; Oliver C, 2003, J APPL RES INTELLECT, V16, P53, DOI 10.1046/j.1468-3148.2003.00145.x; Porges SW, 2011, INFANT CHILD DEV, V20, P106, DOI 10.1002/icd.688; Rice LJ, 2016, AM J MED GENET B, V171, P1041, DOI 10.1002/ajmg.b.32472; Robinson OJ, 2011, COGN AFFECT BEHAV NE, V11, P217, DOI 10.3758/s13415-011-0030-5; Rojahn J, 2001, J AUTISM DEV DISORD, V31, P577, DOI 10.1023/A:1013299028321; Turner-Stokes L, 2009, CLIN REHABIL, V23, P362, DOI 10.1177/0269215508101742; Usami K, 2013, BRAIN STIMUL, V6, P615, DOI 10.1016/j.brs.2012.09.007; Van Leusden JWR, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00102; Warwick TC, 2007, EPILEPSY BEHAV, V10, P344, DOI 10.1016/j.yebeh.2007.01.001; Whittington JE, 2001, J MED GENET, V38, P792, DOI 10.1136/jmg.38.11.792; Woodcock K, 2009, J INTELL DISABIL RES, V53, P265, DOI 10.1111/j.1365-2788.2008.01122.x; Woodcock KA, 2011, J INTELL DISABIL RES, V55, P152, DOI 10.1111/j.1365-2788.2010.01368.x; Woodcock KA, 2010, BRAIN RES, V1363, P128, DOI 10.1016/j.brainres.2010.09.093; Woodcock KA, 2009, COGN NEUROPSYCHOL, V26, P172, DOI 10.1080/02643290802685921	35	9	9	4	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2019	14	12							e0223750	10.1371/journal.pone.0223750	http://dx.doi.org/10.1371/journal.pone.0223750			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LO9UM	31794560	Green Published, gold			2023-01-03	WOS:000533969300006
J	Waldman, E				Waldman, Elisha			Two Rooms	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								In this narrative medicine essay a pediatric palliative care physician reflects on the contrast between his healthy children and the dying patients he cares for and expresses his struggle to bridge the gap between being fully present for his patients' families through their grieving and the deep gratitude he feels that his family is healthy and not forced to confront the same loss and grief.	[Waldman, Elisha] Ann & Robert H Lurie Childrens Hosp Chicago, Div Palliat Care, 225 E Chicago Ave,Box 16, Chicago, IL 60611 USA	Ann & Robert H. Lurie Children's Hospital of Chicago	Waldman, E (corresponding author), Ann & Robert H Lurie Childrens Hosp Chicago, Div Palliat Care, 225 E Chicago Ave,Box 16, Chicago, IL 60611 USA.	edwaldman@luriechildrens.org							0	0	0	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	2019	322	20					1955	1956		10.1001/jama.2019.17601	http://dx.doi.org/10.1001/jama.2019.17601			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV7XA	31769829				2023-01-03	WOS:000502573000008
J	Giordano, A; Liu, YY; Armeson, K; Park, Y; Ridinger, M; Erlander, M; Reuben, J; Britten, C; Kappler, C; Yeh, E; Ethier, S				Giordano, Antonio; Liu, Yueying; Armeson, Kent; Park, Yeonhee; Ridinger, Maya; Erlander, Mark; Reuben, James; Britten, Carolyn; Kappler, Christiana; Yeh, Elizabeth; Ethier, Stephen			Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer	PLOS ONE			English	Article							PHASE-II TRIAL; VOLASERTIB BI 6727; DOSE-ESCALATION; CELL-LINES; OPEN-LABEL; EXPERIMENTAL-DESIGN; ANTITUMOR-ACTIVITY; OVARIAN-CANCER; CHEMOTHERAPY; COMBINATION	Within triple negative breast cancer, several molecular subtypes have been identified, underlying the heterogeneity of such an aggressive disease. The basal-like subtype is characterized by mutations in the TP53 gene, and is associated with a low pathologic complete response rate following neoadjuvant chemotherapy. In a genome-scale short hairpin RNA (shRNA) screen of breast cancer cells, polo-like kinase 1 (Plk1) was a frequent and strong hit in the basal breast cancer cell lines indicating its importance for growth and survival of these breast cancer cells. Plk1 regulates progression of cells through the G2-M phase of the cell cycle. We assessed the activity of two ATP-competitive Plk1 inhibitors, GSK461364 and onvansertib, alone and with a taxane in a set of triple negative breast cancer cell lines and in vivo. GSK461364 showed synergism with docetaxel in SUM149 (Combination Index 0.70) and SUM159 (CI, 0.62). GSK461364 in combination with docetaxel decreased the clonogenic potential (interaction test for SUM149 and SUM159, p<0.001 and p = 0.01, respectively) and the tumorsphere formation of SUM149 and SUM159 (interaction test, p = 0.01 and p<0.001). In the SUM159 xenograft model, onvansertib plus paclitaxel significantly decreased tumor volume compared to single agent paclitaxel (p<0.0001). Inhibition of Plk1 in combination with taxanes shows promising results in a subset of triple negative breast cancer intrinsically resistant to chemotherapy. Onvansertib showed significant tumor volume shrinkage when combined with paclitaxel in vivo and should be considered in clinical trials for the treatment of triple negative cancers.	[Giordano, Antonio; Liu, Yueying; Britten, Carolyn] Med Univ South Carolina, Dept Med, Div Hematol & Oncol, Charleston, SC 29425 USA; [Armeson, Kent; Park, Yeonhee] Med Univ South Carolina, Hollings Canc Ctr, Dept Publ Hlth Sci, Charleston, SC 29425 USA; [Ridinger, Maya; Erlander, Mark] Trovagene Oncol, San Diego, CA USA; [Reuben, James] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Kappler, Christiana; Ethier, Stephen] Med Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Yeh, Elizabeth] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA	Medical University of South Carolina; Medical University of South Carolina; University of Texas System; UTMD Anderson Cancer Center; Medical University of South Carolina; Indiana University System; Indiana University Bloomington	Giordano, A (corresponding author), Med Univ South Carolina, Dept Med, Div Hematol & Oncol, Charleston, SC 29425 USA.	giordana@musc.edu	Park, Yeonhee/ABE-8543-2020	Giordano, Antonio/0000-0002-7760-9717	Paul Calabresi K12 funding, Hollings Cancer Center, Medical University of South Carolina [K12 CA157688]; Cell Evaluation & Therapy Shared Resource, Hollings Cancer Center, Medical University of South Carolina [P30 CA138313]; Genomics Shared Resource, Hollings Cancer Center, Medical University of South Carolina; Biostatistics Shared Resource, Hollings Cancer Center, Medical University of South Carolina [P30 CA138313]; NATIONAL CANCER INSTITUTE [K12CA157688, P30CA138313] Funding Source: NIH RePORTER	Paul Calabresi K12 funding, Hollings Cancer Center, Medical University of South Carolina; Cell Evaluation & Therapy Shared Resource, Hollings Cancer Center, Medical University of South Carolina; Genomics Shared Resource, Hollings Cancer Center, Medical University of South Carolina; Biostatistics Shared Resource, Hollings Cancer Center, Medical University of South Carolina; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	AG work was supported in part by the Paul Calabresi K12 funding, Hollings Cancer Center, Medical University of South Carolina (K12 CA157688); this work was supported in part by the Cell Evaluation & Therapy Shared Resource, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313); SE was supported in part by the Genomics Shared Resource, Hollings Cancer Center, Medical University of South Carolina; KA was supported in part by the Biostatistics Shared Resource, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313).	Archambault V, 2017, CELL CYCLE, V16, P1220, DOI 10.1080/15384101.2017.1325043; Awad MM, 2017, LUNG CANCER, V104, P126, DOI 10.1016/j.lungcan.2016.12.019; Awada A, 2015, INVEST NEW DRUG, V33, P611, DOI 10.1007/s10637-015-0223-9; Balic M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-358; Beria I, 2011, BIOORG MED CHEM LETT, V21, P2969, DOI 10.1016/j.bmcl.2011.03.054; Burstein MD, 2015, CLIN CANCER RES, V21, P1688, DOI 10.1158/1078-0432.CCR-14-0432; Casolaro A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058424; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; de Braud F, 2015, ANN ONCOL, V26, P2341, DOI 10.1093/annonc/mdv354; Degenhardt Y, 2010, MOL CANCER THER, V9, P2079, DOI 10.1158/1535-7163.MCT-10-0095; Dibb M, 2012, BRIT J CANCER, V107, P1766, DOI 10.1038/bjc.2012.424; Ellis PM, 2015, CLIN LUNG CANCER, V16, P457, DOI 10.1016/j.cllc.2015.05.010; Ellis PM, 2013, CLIN LUNG CANCER, V14, P19, DOI 10.1016/j.cllc.2012.04.003; Ethier S., 2018, SUMLINEKNOWLEDGEBASE; Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007; Frost A, 2012, CURR ONCOL, V19, pE28, DOI 10.3747/co.19.866; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Gilmartin AG, 2009, CANCER RES, V69, P6969, DOI 10.1158/0008-5472.CAN-09-0945; Gutteridge REA, 2016, MOL CANCER THER, V15, P1427, DOI 10.1158/1535-7163.MCT-15-0897; Hartsink-Segers SA, 2013, HAEMATOLOGICA, V98, P1539, DOI 10.3324/haematol.2013.084434; Hofheinz RD, 2010, CLIN CANCER RES, V16, P4666, DOI 10.1158/1078-0432.CCR-10-0318; Hollestelle A, 2010, BREAST CANCER RES TR, V121, P53, DOI 10.1007/s10549-009-0460-8; Hugle M, 2015, CELL DEATH DIFFER, V22, P1946, DOI 10.1038/cdd.2015.59; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kappler CS, 2015, MOL ONCOL, V9, P527, DOI 10.1016/j.molonc.2014.10.006; Korangath P, 2015, CLIN CANCER RES, V21, P3263, DOI 10.1158/1078-0432.CCR-14-1200; Lacerda L, 2014, STEM CELL TRANSL MED, V3, P849, DOI 10.5966/sctm.2013-0204; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Lin CC, 2014, BRIT J CANCER, V110, P2434, DOI 10.1038/bjc.2014.195; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Machiels JP, 2015, CANCER CHEMOTH PHARM, V76, P843, DOI 10.1007/s00280-015-2860-2; Maire V, 2013, CANCER RES, V73, P813, DOI 10.1158/0008-5472.CAN-12-2633; Masuda H, 2013, CLIN CANCER RES, V19, P5533, DOI 10.1158/1078-0432.CCR-13-0799; McKenzie L, 2010, CELL CYCLE, V9, P4200, DOI 10.4161/cc.9.20.13532; Mross K, 2012, BRIT J CANCER, V107, P280, DOI 10.1038/bjc.2012.257; Mross K, 2008, J CLIN ONCOL, V26, P5511, DOI 10.1200/JCO.2008.16.1547; Mukhopadhyay NK, 2017, SCI REP-UK, V7, DOI 10.1038/srep46017; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nokihara H, 2016, INVEST NEW DRUG, V34, P66, DOI 10.1007/s10637-015-0300-0; Oliver PG, 2012, BREAST CANCER RES TR, V133, P417, DOI 10.1007/s10549-011-1755-0; Olmos D, 2011, CLIN CANCER RES, V17, P3420, DOI 10.1158/1078-0432.CCR-10-2946; Park Jung-Eun, 2017, F1000Res, V6, P1024, DOI 10.12688/f1000research.11398.1; Perez EA, 2001, J CLIN ONCOL, V19, P4216, DOI 10.1200/JCO.2001.19.22.4216; Posch C, 2015, J INVEST DERMATOL, V135, P2475, DOI 10.1038/jid.2015.198; Prat A, 2013, BREAST CANCER RES TR, V142, P237, DOI 10.1007/s10549-013-2743-3; Pujade-Lauraine E, 2016, J CLIN ONCOL, V34, P706, DOI 10.1200/JCO.2015.62.1474; Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39; Schoffski P, 2012, EUR J CANCER, V48, P179, DOI 10.1016/j.ejca.2011.11.001; Schoffski P, 2010, EUR J CANCER, V46, P2206, DOI 10.1016/j.ejca.2010.03.039; Sebastian M, 2010, J THORAC ONCOL, V5, P1060, DOI 10.1097/JTO.0b013e3181d95dd4; Sero V, 2014, INVEST NEW DRUG, V32, P1167, DOI 10.1007/s10637-014-0158-6; Sharma P, 2018, CLIN CANCER RES, V24, P5820, DOI 10.1158/1078-0432.CCR-18-0585; Stadler WM, 2014, CANCER-AM CANCER SOC, V120, P976, DOI 10.1002/cncr.28519; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Streicher KL, 2007, MOL CANCER RES, V5, P847, DOI 10.1158/1541-7786.MCR-06-0427; TAIT L, 1990, CANCER RES, V50, P6087; Tan J, 2013, CANCER DISCOV, V3, P1156, DOI 10.1158/2159-8290.CD-12-0595; Team RC., 2013, R LANG ENV STAT COMP; Valsasina B, 2012, MOL CANCER THER, V11, P1006, DOI 10.1158/1535-7163.MCT-11-0765; Weiss GJ, 2018, INVEST NEW DRUG, V36, P85, DOI 10.1007/s10637-017-0491-7; Weiss LM, 2016, INT J CANCER, V138, P497, DOI 10.1002/ijc.29725; Yang AM, 2017, CANCER RES, V77, P6641, DOI 10.1158/0008-5472.CAN-16-3452; Zhang N, 2016, AM J CANCER RES, V6, P97; Zhang Z, 2016, ONCOL LETT, V11, P2685, DOI 10.3892/ol.2016.4228; Zitouni S, 2014, NAT REV MOL CELL BIO, V15, P433, DOI 10.1038/nrm3819	69	21	21	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2019	14	11							e0224420	10.1371/journal.pone.0224420	http://dx.doi.org/10.1371/journal.pone.0224420			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO8PC	31751384	Green Published, gold			2023-01-03	WOS:000533886900011
J	Goupil, B; Balusson, F; Naudet, F; Esvan, M; Bastian, B; Chapron, A; Frouard, P				Goupil, Bruno; Balusson, Frederic; Naudet, Florian; Esvan, Maxime; Bastian, Benjamin; Chapron, Anthony; Frouard, Pierre			Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databases	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INDUSTRY PAYMENTS; PHYSICIANS; DISCLOSURE	OBJECTIVE To evaluate the association between gifts from pharmaceutical companies to French general practitioners (GPs) and their drug prescribing patterns. DESIGN Retrospective study using data from two French databases (National Health Data System, managed by the French National Health Insurance system, and Transparency in Healthcare). SETTING Primary care, France. PARTICIPANTS 41 257 GPs who in 2016 worked exclusively in the private sector and had at least five registered patients. The GPs were divided into six groups according to the monetary value of the received gifts reported by pharmaceutical, medical device, and other health related companies in the Transparency in Healthcare database. MAIN OUTCOME MEASURES The main outcome measures were the amount reimbursed by the French National Health Insurance for drug prescriptions per visit (to the practice or at home) and 11 drug prescription efficiency indicators used by the National Health Insurance to calculate the performance related financial incentives of the doctors. Doctor and patient characteristics were used as adjustment variables. The significance threshold was 0.001 for statistical analyses. RESULTS The amount reimbursed by the National Health Insurance for drug prescriptions per visit was lower in the GP group with no gifts reported in the Transparency in Healthcare database in 2016 and since its launch in 2013 (no gift group) compared with the GP groups with at least one gift in 2016 (-(sic)5.33 (99.9% confidence interval -(sic)6.99 to -(sic)3.66) compared with the GP group with gifts valued at (sic)1000 or more reported in 2016) (P<0.001). The no gift group also more frequently prescribed generic antibiotics (2.17%, 1.47% to 2.88% compared with the >=(sic)1000 group), antihypertensives (4.24%, 3.72% to 4.77% compared with the =(sic)1000 group), and statins (12.14%, 11.03% to 13.26% compared with the >=(sic)1000 group) than GPs with at least one gift between 2013 and 2016 (P<0.001). The no gift group also prescribed fewer benzodiazepines for more than 12 weeks (-0.68%, -1.13% to -0.23% compared with the (sic)240-(sic)999 group) and vasodilators (-0.15%, -0.28% to -0.03% compared with the >=(sic)1000 group) than GPs with gifts valued at (sic)240 or more reported in 2016, and more angiotensin converting enzyme (ACE) inhibitors compared with all ACE and sartan prescriptions (1.67%, 0.62% to 2.71%) compared with GPs with gifts valued at (sic)1000 or more reported in 2016 (P<0.001). Differences were not significant for the prescription of aspirin and generic antidepressants and generic proton pump inhibitors. CONCLUSION The findings suggest that French GPs who do not receive gifts from pharmaceutical companies have better drug prescription efficiency indicators and less costly drug prescriptions than GPs who receive gifts. This observational study is susceptible to residual confounding and therefore no causal relation can be concluded.	[Goupil, Bruno; Bastian, Benjamin; Chapron, Anthony; Frouard, Pierre] Univ Rennes 1, Dept Gen Med, Rennes, France; [Balusson, Frederic] Univ Rennes, Rennes Univ Hosp, REPERES, EA Pharmacoepidemiol & Hlth Serv Res 7449, Rennes, France; [Naudet, Florian; Esvan, Maxime; Bastian, Benjamin; Chapron, Anthony] Univ Rennes, CHU Rennes, INSERM, Ctr Invest Clin Rennes,CIC 1414, F-35000 Rennes, France; [Naudet, Florian] Rennes Univ Hosp, Dept Adult Psychiat, Rennes, France	Universite de Rennes; CHU Rennes; Universite de Rennes; CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; CHU Rennes; Universite de Rennes	Frouard, P (corresponding author), Univ Rennes 1, Dept Gen Med, Rennes, France.	pierre.frouard@gmail.com	Naudet, Florian/H-5644-2019	Naudet, Florian/0000-0003-3760-3801; Bastian, Benjamin/0000-0002-8549-2264				[Anonymous], 2015, Prescrire Int, V24, P279; Assurance Maladie, 2017, ASSURANCE MALADIE, P29; Bezin J, 2017, PHARMACOEPIDEM DR S, V26, P954, DOI 10.1002/pds.4233; Brax H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175493; Chapman S, 2004, REGULATING PHARM EUR, P144; Darmon D, 2015, SANTE PUBLIQUE, V27, P353, DOI 10.3917/spub.153.0353; DeJong C, 2016, JAMA INTERN MED, V176, P1114, DOI 10.1001/jamainternmed.2016.2765; European Observatory on Health Systems and Policies Series, 2014, EUROPEAN OBSERVATORY; Fabbri A, 2018, INT J HEALTH POLICY, V7, P504, DOI 10.15171/ijhpm.2018.20; Fickweiler F, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016408; Grande D, 2009, ARCH INTERN MED, V169, P887, DOI 10.1001/archinternmed.2009.64; Hadland SE, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.6007; Hauray B, 2018, REV FRANCAISE ADM PU, P49, DOI DOI 10.3917/RFAP.165.0049]; Health Action International, 2016, FACT FICT WHAT HEALT; Ioannidis JPA, 2019, ANN INTERN MED, V170, P108, DOI 10.7326/M18-2159; Lo B, 2017, JAMA-J AM MED ASSOC, V317, P1719, DOI 10.1001/jama.2017.1872; Mejia J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12317-z; Ministere de l'economie, 2017, 199 MIN EC; Perlis RH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155474; Qian JJ, 2017, PHARMACOEPIDEM DR S, V26, P819, DOI 10.1002/pds.4224; Quotidien du Medecin, 2012, QUOTIDIEN MED; Rhee TG, 2019, JAMA INT MED; Sah S, 2013, J LAW MED ETHICS, V41, P665, DOI 10.1111/jlme.12076; Scailteux LM, 2019, THERAPIE, V74, P215, DOI 10.1016/j.therap.2018.09.072; Sharma M, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3043-8; Spurling GK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000352; Walker AJ, 2019, J MED INTERNET RES, V21, DOI 10.2196/10929; Wilson M, 2014, J ROY SOC MED, V107, P216, DOI 10.1177/0141076814532744; World Health Organization Health Action International, 2009, UND RESP PHARM PROM; Yeh JS, 2016, JAMA INTERN MED, V176, P763, DOI 10.1001/jamainternmed.2016.1709	30	26	26	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 6	2019	367								l6015	10.1136/bmj.l6015	http://dx.doi.org/10.1136/bmj.l6015			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP3PQ	31690553	Green Published, hybrid			2023-01-03	WOS:000498179900002
J	Bouton, TC; de Vos, M; Ragan, EJ; White, LF; Van Zyl, L; Theron, D; Horsburgh, CR; Warren, RM; Jacobson, KR				Bouton, Tara C.; de Vos, Margaretha; Ragan, Elizabeth J.; White, Laura F.; Van Zyl, Leonie; Theron, Danie; Horsburgh, C. Robert; Warren, Robin M.; Jacobson, Karen R.			Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis	PLOS ONE			English	Article							MDR-TB; PREVALENCE; OUTCOMES	South Africa led the world with guidelines on bedaquiline (BDQ) use as a single drug substitution to manage rifampin resistant tuberculosis regimen toxicity. We examined reasons for giving BDQ in a retrospective cohort: >75% of patients were switched to BDQ for toxicity (ototoxicity or renal dysfunction) rather than drug resistance.	[Bouton, Tara C.] Brown Univ, Div Infect Dis, Alpert Sch Med, Providence, RI 02912 USA; [de Vos, Margaretha; Warren, Robin M.] South Africa Med Res Council TB Res, Natl Res Fdn, Dept Sci & Technol, Ctr Excellence Biomed TB Res, Cape Town, South Africa; [de Vos, Margaretha; Warren, Robin M.] Stellenbosch Univ, Fac Med & Hlth Sci, Div Mol Biol & Human Genet, Cape Town, South Africa; [Ragan, Elizabeth J.; Jacobson, Karen R.] Boston Univ, Sch Med, Sect Infect Dis, Boston, MA 02118 USA; [White, Laura F.; Horsburgh, C. Robert] Boston Univ, Dept Biostat, Sch Publ Hlth, Boston, MA 02215 USA; [Van Zyl, Leonie; Theron, Danie] Brewelskloof Hosp, Worcester, South Africa; [Horsburgh, C. Robert] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Horsburgh, C. Robert] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA; [Horsburgh, C. Robert] Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA 02215 USA	Brown University; National Research Foundation - South Africa; Stellenbosch University; Boston University; Boston University; Boston University; Boston University; Boston University	Bouton, TC (corresponding author), Brown Univ, Div Infect Dis, Alpert Sch Med, Providence, RI 02912 USA.; Jacobson, KR (corresponding author), Boston Univ, Sch Med, Sect Infect Dis, Boston, MA 02118 USA.	Tara.Bouton@lifespan.org; kjacobso@bu.edu	Jacobson, Karen/AAX-9461-2021	de Vos, Margaretha/0000-0003-3059-2986; Bouton, Tara/0000-0002-1521-148X; Jacobson, Karen/0000-0003-4239-3685; Warren, Robin/0000-0001-5741-7358; Ragan, Elizabeth/0000-0001-6062-0058	National Institutes of Health [T32, DA013911]; Burroughs Wellcome Fund/American Society for Tropical Medicine and Hygiene Postdoctoral Fellowship in Tropical Infectious Diseases; Brown University School of Public Health Nora Kahn Piore Award; Brown University School of Public Health Clinical and Translational Science Institute [1UL1TR001430]; TORCH through the Flemish Fund for Scientific Research [FWO G0F8316N]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI042853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA013911] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund/American Society for Tropical Medicine and Hygiene Postdoctoral Fellowship in Tropical Infectious Diseases; Brown University School of Public Health Nora Kahn Piore Award; Brown University School of Public Health Clinical and Translational Science Institute; TORCH through the Flemish Fund for Scientific Research; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	TCB is supported by the National Institutes of Health [grant number T32, DA013911] and the Burroughs Wellcome Fund/American Society for Tropical Medicine and Hygiene Postdoctoral Fellowship in Tropical Infectious Diseases. Additional support for this project was provided by a Brown University School of Public Health Nora Kahn Piore Award and and Clinical and Translational Science Institute grant support [grant number 1UL1TR001430]. MDV is supported by TORCH funding through the Flemish Fund for Scientific Research [grant number FWO G0F8316N]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad N, 2018, LANCET, V392, P821, DOI 10.1016/S0140-6736(18)31644-1; Cegielski JP, 2016, CLIN INFECT DIS, V62, P418, DOI 10.1093/cid/civ910; Department of Health Republic of South Africa, 2015, INTR NEW DRUGS DRUG; Dheda K, 2018, RESPIROLOGY, V23, P36, DOI 10.1111/resp.13143; Guglielmetti L, 2017, INT J TUBERC LUNG D, V21, P167, DOI 10.5588/ijtld.16.0493; Murray CJL, 2014, LANCET, V384, P1005, DOI 10.1016/S0140-6736(14)60844-8; Schnippel K, 2017, J ANTIMICROB CHEMOTH, V72, P1871, DOI 10.1093/jac/dkx107; Nguyen TVA, 2018, CLIN INFECT DIS, V66, P1625, DOI 10.1093/cid/cix992; Villellas C, 2017, J ANTIMICROB CHEMOTH, V72, P684, DOI 10.1093/jac/dkw502; Whitfield MG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133869; Zhao Y, 2018, CLIN INFECT DIS	11	1	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2019	14	10							e0223308	10.1371/journal.pone.0223308	http://dx.doi.org/10.1371/journal.pone.0223308			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM9KP	31622366	Green Published, gold			2023-01-03	WOS:000532567300020
J	Grupp, C; Troche-Polzien, I; Stock, J; Bramlage, C; Muller, GA; Koziolek, M				Grupp, Clemens; Troche-Polzien, Ilka; Stock, Johanna; Bramlage, Carsten; Mueller, Gerhard A.; Koziolek, Michael			Thrombophilic risk factors in hemodialysis: Association with early vascular access occlusion and patient survival in long-term follow-up	PLOS ONE			English	Article							FACTOR-V G1691A; METHYLENETETRAHYDROFOLATE-REDUCTASE C677T; CHRONIC KIDNEY-DISEASE; ANTICARDIOLIPIN ANTIBODIES; HYPERCOAGULABLE STATES; ARTERIOVENOUS-FISTULA; PROTHROMBIN G20210A; THROMBOSIS; DIALYSIS; HOMOCYSTEINE	Objective Thrombophilic risk factors (TRFs) occur rather frequently in hemodialysis (HD) patients. However, little is known about their significance in HD patients, besides their potential impact on arteriovenous (AV) access failure, with varying results. We examined the effects of a wide variety of TRFs on both early AV fistula occlusion and survival among HD patients in long-term follow-up. Methods In this single-center, observational study, 70 consecutive HD patients from our dialysis center were examined with respect to shunt occlusion within the first 2 years after fistula creation and patient survival in a long-term follow-up (at least 16 years). We examined the presence of factor V, prothrombin, and MTHFR mutations using real-time fluorescence polymerase chain reaction. Furthermore, antithrombin (AT), protein C, protein S, and antiphospholipid antibodies (APL-Abs) were assessed. Results Among the 70 patients, 32 had MTHFR mutations, 10 had heterozygous factor V Leiden mutations, 4 had prothrombin mutations, 4 had protein S deficiency, 2 had protein C deficiency, 9 had AT deficiency, and 14 had APL-Abs. 40 patients had shunt occlusion. TRFs were associated with a significantly increased risk for shunt thrombosis (P<0.02). Kaplan-Meier analysis with a log-rank test revealed significantly shorter survival in HD patients with TRFs (P<0.02). Cox regression analysis showed that the presence of TRFs (P<0.05; hazard ratio, 1.94; 95% CI: 1.07-3.56), but not early shunt occlusion, was associated with short patient survival. Conclusions TRFs in hemodialysis patients have a strong impact on patient survival and early AV fistula failure; however, patient survival is not significantly affected by early shunt occlusion.	[Grupp, Clemens; Troche-Polzien, Ilka; Stock, Johanna; Bramlage, Carsten; Mueller, Gerhard A.; Koziolek, Michael] Georg August Univ, Dept Nephrol & Rheumatol, Gottingen, Germany; [Grupp, Clemens] Acad Teaching Hosp Bamberg, Dept Nephrol Hypertens & Rheumatol, Bamberg, Germany	University of Gottingen	Grupp, C (corresponding author), Georg August Univ, Dept Nephrol & Rheumatol, Gottingen, Germany.; Grupp, C (corresponding author), Acad Teaching Hosp Bamberg, Dept Nephrol Hypertens & Rheumatol, Bamberg, Germany.	cgrupp@gwdg.de						Adler S, 2001, CLIN NEPHROL, V56, P428; Allon M, 2002, KIDNEY INT, V62, P1109, DOI 10.1111/j.1523-1755.2002.kid551.x; Almasri J, 2016, J VASC SURG, V64, P236, DOI 10.1016/j.jvs.2016.01.053; Ambuhl PM, 1997, NEPHROL DIAL TRANSPL, V12, P2355, DOI 10.1093/ndt/12.11.2355; Biuckians A, 2008, J VASC SURG, V47, P415, DOI 10.1016/j.jvs.2007.10.041; Bremer C, 1997, NEPHROL DIAL TRANSPL, V12, P1775, DOI 10.1093/ndt/12.8.1775; BRUNET P, 1995, KIDNEY INT, V48, P794, DOI 10.1038/ki.1995.352; Chen TY, 2018, CARDIOVASC INTER RAD, V41, P1683, DOI 10.1007/s00270-018-2046-5; Chuang FR, 2005, RENAL FAILURE, V27, P25, DOI 10.1081/JDI-200042815; Dixon BS, 2002, AM J KIDNEY DIS, V39, P92, DOI 10.1053/ajkd.2002.29886; Feldman HI, 1996, J AM SOC NEPHROL, V7, P523; Fodinger M, 2000, J NEPHROL, V13, P20; Fodinger M, 1996, NEPHROL DIAL TRANSPL, V11, P668, DOI 10.1093/oxfordjournals.ndt.a027357; Fukasawa M, 2003, AM J KIDNEY DIS, V41, P637, DOI 10.1053/ajkd.2003.50125; Ghisdal L, 2011, NEPHROL DIAL TRANSPL, V26, P2700, DOI 10.1093/ndt/gfq791; Hessner MJ, 1999, THROMB HAEMOSTASIS, V81, P733; Hojs R, 2002, RENAL FAILURE, V24, P215, DOI 10.1081/JDI-120004098; Huisman M V, 1999, Curr Opin Hematol, V6, P291, DOI 10.1097/00062752-199909000-00004; Khan S, 2006, THROMB J, V4, DOI 10.1186/1477-9560-4-15; Klamroth R, 2013, VASA, V42, P32, DOI 10.1024/0301-1526/a000245; Knoll GA, 2005, J AM SOC NEPHROL, V16, P1108, DOI 10.1681/ASN.2004110999; Lee HA, 1999, AM J KIDNEY DIS, V34, P259, DOI 10.1016/S0272-6386(99)70353-7; LeSar CJ, 1999, J AM COLL SURGEONS, V189, P73, DOI 10.1016/S1072-7515(99)00086-1; Middeldorp S, 2007, SEMIN THROMB HEMOST, V33, P563, DOI 10.1055/s-2007-985752; Nakashima MO, 2014, BLOOD RES, V49, P85, DOI 10.5045/br.2014.49.2.85; Osinbowale O, 2010, POSTGRAD MED, V122, P54, DOI 10.3810/pgm.2010.03.2122; Palmer SC, 2012, ANN INTERN MED, V156, P445, DOI 10.7326/0003-4819-156-6-201203200-00007; Palomo I, 2002, NEPHRON, V92, P957, DOI 10.1159/000065580; PRAKASH R, 1995, AM J KIDNEY DIS, V26, P347, DOI 10.1016/0272-6386(95)90656-8; Puskar D, 2002, CROAT MED J, V43, P306; Reitsma PH, 2015, HAMOSTASEOLOGIE, V35, P47, DOI 10.5482/HAMO-14-11-0062; Rodriguez JA, 2001, NEFROLOGIA, V21, P260; Salmela B, 2013, CLIN J AM SOC NEPHRO, V8, P962, DOI 10.2215/CJN.03860412; Seligsohn U, 2001, NEW ENGL J MED, V344, P1222, DOI 10.1056/NEJM200104193441607; Tanner NC, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002786.pub3; Tonelli M, 2011, AM J TRANSPLANT, V11, P2093, DOI 10.1111/j.1600-6143.2011.03686.x; Valeri A, 1999, CLIN NEPHROL, V51, P116; von Ahsen N, 1999, CLIN CHEM, V45, P694; von Ahsen N, 2000, CLIN BIOCHEM, V33, P535, DOI 10.1016/S0009-9120(00)00161-2; Wald DS, 2002, BMJ-BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202	40	4	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2019	14	9							e0222102	10.1371/journal.pone.0222102	http://dx.doi.org/10.1371/journal.pone.0222102			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM5OJ	31539375	Green Published, Green Submitted, gold			2023-01-03	WOS:000532297900006
J	Pugh, MJ; Swan, AA; Amuan, ME; Eapen, BC; Jaramillo, CA; Delgado, R; Tate, DF; Yaffe, K; Wang, CP				Pugh, Mary Jo; Swan, Alicia A.; Amuan, Megan E.; Eapen, Blessen C.; Jaramillo, Carlos A.; Delgado, Roxana; Tate, David F.; Yaffe, Kristine; Wang, Chen-Pin			Deployment, suicide, and overdose among comorbidity phenotypes following mild traumatic brain injury: A retrospective cohort study from the Chronic Effects of Neurotrauma Consortium	PLOS ONE			English	Article							POLYTRAUMA-CLINICAL-TRIAD; MISERABLE MINORITY; RISK-FACTORS; CHRONIC PAIN; VETERANS; AFGHANISTAN; IRAQ; ASSOCIATION; DISABILITY; SEVERITY	Mild traumatic brain injury in the Veteran population is frequently comorbid with pain, posttraumatic stress disorder, and/or depression. However, not everyone exposed to mild traumatic brain injury experiences these comorbidities and it is unclear what factors contribute to this variability. The objective of this study was to identify comorbidity phenotypes among Post-9/11 deployed Veterans with no or mild traumatic brain injury and examine the association of comorbidity phenotypes with adverse outcomes. We found that Veterans with mild traumatic brain injury (n = 93,003) and no brain injury (n = 434,378) were mean age of 32.0 (SD 9.21) on entering Department of Veterans Health Administration care, were predominantly Caucasian non-Hispanic (64.69%), and served in the Army (61.31%). Latent class analysis revealed five phenotypes in each subcohort; Moderately Healthy and Mental Health phenotypes were common to both. The Healthy phenotype was found only in no brain injury. Unique phenotypes in mild traumatic brain injury included Moderately Healthy+Decline, Polytrauma, and Polytrauma+Improvement. There was substantial variation in adverse outcomes. The Polytrauma+Improvement phenotype had the lowest likelihood of adverse outcomes. There were no differences between Moderately Healthy+Decline and Polytrauma phenotypes. Phenotypes of comorbidity vary significantly by traumatic brain injury status including divergence in phenotypes (and outcomes) over time in the mild traumatic brain injury subcohort. Understanding risk factors for the divergence between Polytrauma vs. Polytrauma+Improvement and Moderately Healthy vs. Moderately Healthy+Decline, will improve our ability to proactively mitigate risk, better understand the early patterns of comorbidity that are associated with neurodegenerative sequelae following mild traumatic brain injury, and plan more patient-centered care.	[Pugh, Mary Jo; Amuan, Megan E.] VA Salt Lake City Hlth Care Syst, Informat Decis Enhancement & Analyt Sci Ctr, Salt Lake City, UT 84148 USA; [Pugh, Mary Jo] Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT 84132 USA; [Swan, Alicia A.] Univ Texas San Antonio, Dept Psychol, San Antonio, TX USA; [Eapen, Blessen C.] VA Greater Los Angeles Hlth Care Syst, Dept Phys Med & Rehabil, Los Angeles, CA USA; [Eapen, Blessen C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; [Jaramillo, Carlos A.; Delgado, Roxana] South Texas Vet Hlth Care Syst, Polytrauma Rehabil Ctr, San Antonio, TX USA; [Tate, David F.] Univ Missouri, Missouri Inst Mental Hlth, St Louis, MO 63121 USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat Neurol & Epidemiol, San Francisco, CA 94143 USA; [Wang, Chen-Pin] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA	US Department of Veterans Affairs; Utah System of Higher Education; University of Utah; University of Texas System; University of Texas at San Antonio (UTSA); US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Missouri System; University of Missouri Saint Louis; University of California System; University of California San Francisco; University of Texas System; University of Texas Health San Antonio	Pugh, MJ (corresponding author), VA Salt Lake City Hlth Care Syst, Informat Decis Enhancement & Analyt Sci Ctr, Salt Lake City, UT 84148 USA.; Pugh, MJ (corresponding author), Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT 84132 USA.	MaryJo.Pugh@hsc.utah.edu	Swan, Alicia A/O-3536-2018; Delgado, Roxana/CAF-1964-2022; Tate, David/G-5166-2011	Swan, Alicia A/0000-0003-2412-0499; Delgado, Roxana/0000-0002-8922-4857; Pugh, Mary Jo/0000-0003-4196-7763; Tate, David/0000-0003-0213-1920	U.S. Department of Veterans Affairs funds [I01CX001246]; U.S. Department of Defense [W81XWH-13-2-0095-04]; Veterans Affairs [I01CX001135] Funding Source: NIH RePORTER	U.S. Department of Veterans Affairs funds; U.S. Department of Defense(United States Department of Defense); Veterans Affairs(US Department of Veterans Affairs)	This study was supported by U.S. Department of Veterans Affairs funds, I01CX001246, https://www.research.va.gov, to MJP; and U.S. Department of Defense W81XWH-13-2-0095-04, http://cdmrp.army.mil, to KY. The sponsors played no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.	Amick MM, 2018, J HEAD TRAUMA REHAB, V33, pE30, DOI 10.1097/HTR.0000000000000308; Bosco MA, 2013, HEADACHE J HEAD FACE; Brickell TA, 2014, MIL MED, V179, P827, DOI 10.7205/MILMED-D-13-00506; Collett GA., 2016, DRUGS-REAL WOR OUTC, V3, P45; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Edens EL, 2011, AM J ADDICTION, V20, P412, DOI 10.1111/j.1521-0391.2011.00166.x; Helmick KM, 2015, BRAIN IMAGING BEHAV, V9, P358, DOI 10.1007/s11682-015-9399-z; Jaramillo CA, 2015, BRAIN IMAGING BEHAV, V9, P445, DOI 10.1007/s11682-015-9402-8; Johnson DC, 2014, AM J PSYCHIAT, V171, P844, DOI 10.1176/appi.ajp.2014.13040502; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lippa SM, 2015, J TRAUMA STRESS, V28, P25, DOI 10.1002/jts.21979; Military Health System, 2016, SURV CAS DEF 13 0 NE; North CS, 2004, AM J PUBLIC HEALTH, V94, P103, DOI 10.2105/AJPH.94.1.103; Peixoto C, 2018, J PAIN RES, V11, P1927, DOI 10.2147/JPR.S165077; Peterson R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132664; Pugh MJ, 2018, ARCH PHYS MED REHAB, V99, pS40, DOI 10.1016/j.apmr.2017.05.021; Pugh MJ, 2016, BRAIN INJURY, V30, P1481, DOI 10.1080/02699052.2016.1219055; Pugh MJV, 2014, MED CARE, V52, P172, DOI 10.1097/MLR.0000000000000059; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Swan AA, 2018, BRAIN INJURY, V32, P1197, DOI 10.1080/02699052.2018.1495340; Tanielian T., 2017, IMPROVING SUPPORT AM, DOI 10.7249/RR1873; The Management of Concussion-mild Traumatic Brain Injury Working Group, VA DOD CLIN PRACT GU; Wang C-P, 2012, RESIDUAL DIAGNOSTICS; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	26	13	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2019	14	9							e0222674	10.1371/journal.pone.0222674	http://dx.doi.org/10.1371/journal.pone.0222674			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM5OJ	31539410	Green Published, Green Submitted, gold			2023-01-03	WOS:000532297900025
J	Lundqvist, M; Alwin, J; Levin, LA				Lundqvist, Martina; Alwin, Jenny; Levin, Lars-Ake			Certified service dogs - A cost-effectiveness analysis appraisal	PLOS ONE			English	Article								Introduction Individuals with functional impairments or chronic diseases are often in need of assistance in their daily lives. For these individuals it is essential to find novel, cost-effective solutions to meet their needs. Service dogs are dogs that are specially trained to assist individuals with functional impairments and may be able to improve these individuals' quality of life at a reasonable cost, i.e. be cost effective. Cost-effectiveness analyses are used to illustrate the cost of an intervention in relation to its effects and provide important input to decision-makers when setting priorities. Aim The aim of this study is to assess the cost effectiveness of a certified physical service dog and a diabetes alert dog compared to a regular companion dog. Method Costs, life years and quality-adjusted life years were estimated over a 10-year time horizon using a decision-analytic model built upon evidence from the"service and hearing dog project". The primary outcome was the incremental cost-effectiveness ratio expressed as cost per gained quality-adjusted life year. The analysis was conducted from a societal perspective. Costs and effects were discounted with 3% per annum and reported in USD. Results Compared to a regular companion dog, a physical service dog is cost saving [-6,000 USD] and gives the dog owner more quality-adjusted life years [0.28]. The diabetes alert dog is also cost effective in comparison with a regular companion dog [-4,500 USD, 0.06 QALYs]. Conclusion This study indicates that a certified service dog is cost saving in comparison with a regular companion dog for individuals with functional impairments or chronic diseases. The uncertainty of the analysis implies that further studies are needed in order to confirm these results. Nevertheless, physical service dogs and diabetes alert dogs show potential to be a valuable support and decision analytic models are useful tools to provide this information.	[Lundqvist, Martina; Alwin, Jenny; Levin, Lars-Ake] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden	Linkoping University	Lundqvist, M (corresponding author), Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden.	martina.lundqvist@liu.se		Lundqvist, Martina/0000-0001-9291-6232	Region Ostergotland; Jimmy Dahlstens foundation	Region Ostergotland; Jimmy Dahlstens foundation	This study was funded by Region Ostergotland and Jimmy Dahlstens foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to thank the National Board of Health and Welfare, the Swedish Institute of Assistive Technology, the Swedish Association of Service Dogs (SAF) and the Swedish Kennel Club (SKK) for being involved in the planning and execution of this study. The author would also like to thank Mattias Aronsson for methodological assistance.	Assistance Dogs International, TYP ASS DOGS; Claxton K, 2005, HEALTH ECON, V14, P339, DOI 10.1002/hec.985; Corp IBM, IBM SPSS WIND VERS 2; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Egenvall A, 2005, ACTA VET SCAND, V46, P121, DOI 10.1186/1751-0147-46-121; Fenwick E, 2004, HEALTH ECON, V13, P405, DOI 10.1002/hec.903; JOHANNESSON M, 1991, HEALTH POLICY, V18, P141, DOI 10.1016/0168-8510(91)90095-F; Lundqvist M, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3014-0; McPhail SM, 2016, RISK MANAG HEALTHC P, V9, P143, DOI 10.2147/RMHP.S97248; Ramsey S, 2005, VALUE HEALTH, V8, P521, DOI 10.1111/j.1524-4733.2005.00045.x; Swedish Statistics (SCB), AV MONTHL SAL GEND Y; Swedish Statistics (SCB), LIF TABL 2010 2014 D; The Swedish Association of Service Dogs, SERV SIGN HUNDSF ASS; The Swedish Kennel Club, ASS SOM HJALPM	14	5	5	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2019	14	9							e0219911	10.1371/journal.pone.0219911	http://dx.doi.org/10.1371/journal.pone.0219911			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM4IG	31513601	Green Published, gold, Green Submitted			2023-01-03	WOS:000532212700011
J	Joly, JH; Delfarah, A; Phung, PS; Parrish, S; Graham, NA				Joly, James H.; Delfarah, Alireza; Phung, Philip S.; Parrish, Sydney; Graham, Nicholas A.			A synthetic lethal drug combination mimics glucose deprivation-induced cancer cell death in the presence of glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						glucose metabolism; cancer biology; redox regulation; Warburg effect; metabolomics; L-cystine; NADPH; SLC7A11	OXIDATIVE STRESS; GLUTAMINE-METABOLISM; INDUCED CYTOTOXICITY; XCT ANTIPORTER; H2O2 MEDIATE; TUMOR-CELLS; DEPENDENCY; SULFOXIMINE; ACTIVATION; INHIBITION	Metabolic reprogramming in cancer cells can increase their dependence on metabolic substrates such as glucose. As such, the vulnerability of cancer cells to glucose deprivation creates an attractive opportunity for therapeutic intervention. Because it is not possible to starve tumors of glucose in vivo, here we sought to identify the mechanisms in glucose deprivation-induced cancer cell death and then designed inhibitor combinations to mimic glucose deprivation-induced cell death. Using metabolomic profiling, we found that cells undergoing glucose deprivation-induced cell death exhibited dramatic accumulation of intracellular L-cysteine and its oxidized dimer, L-cystine, and depletion of the antioxidant GSH. Building on this observation, we show that glucose deprivation-induced cell death is driven not by the lack of glucose, but rather by L-cystine import. Following glucose deprivation, the import of L-cystine and its subsequent reduction to L-cysteine depleted both NADPH and GSH pools, thereby allowing toxic accumulation of reactive oxygen species. Consistent with this model, we found that the glutamate/cystine antiporter (xCT) is required for increased sensitivity to glucose deprivation. We searched for glycolytic enzymes whose expression is essential for the survival of cancer cells with high xCT expression and identified glucose transporter type 1 (GLUT1). Testing a drug combination that co-targeted GLUT1 and GSH synthesis, we found that this combination induces synthetic lethal cell death in high xCT-expressing cell lines susceptible to glucose deprivation. These results indicate that co-targeting GLUT1 and GSH synthesis may offer a potential therapeutic approach for targeting tumors dependent on glucose for survival.	[Joly, James H.; Delfarah, Alireza; Phung, Philip S.; Parrish, Sydney; Graham, Nicholas A.] Univ Southern Calif, Mork Family Dept Chem Engn & Mat Sci, Los Angeles, CA 90089 USA; [Graham, Nicholas A.] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Graham, NA (corresponding author), Univ Southern Calif, 3710 McClintock Ave,RTH 509, Los Angeles, CA 90089 USA.	nagraham@usc.edu	Graham, Nicholas/GYD-5066-2022; Graham, Nicholas A./X-2738-2019; Delfarah, Alireza/AAN-2110-2020	Graham, Nicholas/0000-0002-6811-1941; Graham, Nicholas A./0000-0002-6811-1941; Joly, James/0000-0003-3780-9412; Delfarah, Alireza/0000-0002-3192-5941	American Cancer Society [IRG-16-181-57]; Rose Hills Foundation; USC Provost's Office; Viterbi School of Engineering	American Cancer Society(American Cancer Society); Rose Hills Foundation; USC Provost's Office; Viterbi School of Engineering	This work supported by American Cancer Society Grant IRG-16-181-57, the Rose Hills Foundation, the USC Provost's Office, and the Viterbi School of Engineering. The authors declare that they have no conflicts of interest with the contents of this article.	Adams DJ, 2014, ACS CHEM BIOL, V9, P2247, DOI 10.1021/cb500347p; Ahmad IM, 2005, J BIOL CHEM, V280, P4254, DOI 10.1074/jbc.M411662200; Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71; Andringa KK, 2006, CANCER RES, V66, P1605, DOI 10.1158/0008-5472.CAN-05-3462; Arensman MD, 2019, P NATL ACAD SCI USA, V116, P9533, DOI 10.1073/pnas.1814932116; ARRICK BA, 1982, J BIOL CHEM, V257, P1231; Aykin-Burns N, 2009, BIOCHEM J, V418, P29, DOI 10.1042/BJ20081258; Bailey HH, 1998, CHEM-BIOL INTERACT, V112, P239, DOI 10.1016/S0009-2797(97)00164-6; Cairns RA, 2016, NAT REV CANCER, V16, P613, DOI 10.1038/nrc.2016.100; Chan DA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002394; Chavez A, 2015, NAT METHODS, V12, P326, DOI [10.1038/NMETH.3312, 10.1038/nmeth.3312]; Choo AY, 2010, MOL CELL, V38, P487, DOI 10.1016/j.molcel.2010.05.007; Cramer SL, 2017, NAT MED, V23, P120, DOI 10.1038/nm.4232; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Delfarah A, 2019, J BIOL CHEM, V294, P10564, DOI 10.1074/jbc.RA118.005806; Dey P, 2017, NATURE, V542, P119, DOI 10.1038/nature21052; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236; Fath MA, 2009, CANCER BIOL THER, V8, P1228, DOI 10.4161/cbt.8.13.8631; Franklin CC, 2009, MOL ASPECTS MED, V30, P86, DOI 10.1016/j.mam.2008.08.009; Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145; Ganapathy-Kanniappan S, 2012, ONCOTARGET, V3, P940, DOI 10.18632/oncotarget.623; Goji T, 2017, J BIOL CHEM, V292, P19721, DOI 10.1074/jbc.M117.814392; Graham NA, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.20; GRUETTER R, 1992, P NATL ACAD SCI USA, V89, P1109, DOI 10.1073/pnas.89.3.1109; Halliwell B, 2003, FEBS LETT, V540, P3, DOI 10.1016/S0014-5793(03)00235-7; Hamanaka RB, 2012, J EXP MED, V209, P211, DOI 10.1084/jem.20120162; HAWKINS RA, 1992, J NUCL MED, V33, P339; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; HIRONO I, 1961, GANN, V52, P39; Ho SM, 2017, STEM CELL REP, V9, P615, DOI 10.1016/j.stemcr.2017.06.012; HUANG CS, 1993, J BIOL CHEM, V268, P19675; Jae HJ, 2009, KOREAN J RADIOL, V10, P596, DOI 10.3348/kjr.2009.10.6.596; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Koppula P, 2017, J BIOL CHEM, V292, P14240, DOI 10.1074/jbc.M117.798405; Krejsa CM, 2010, J BIOL CHEM, V285, P16116, DOI 10.1074/jbc.M110.116210; Kryukov GV, 2016, SCIENCE, V351, P1214, DOI 10.1126/science.aad5214; Labak CM, 2016, AM J CANCER RES, V6, P1599; Lee HY, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aam7893; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Leonard PG, 2016, NAT CHEM BIOL, V12, P1053, DOI [10.1038/NCHEMBIO.2195, 10.1038/nchembio.2195]; Lu WY, 2018, ANTIOXID REDOX SIGN, V28, P167, DOI 10.1089/ars.2017.7014; Marjon K, 2016, CELL REP, V15, P574, DOI 10.1016/j.celrep.2016.03.043; Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60; Mavrakis KJ, 2016, SCIENCE, V351, P1208, DOI 10.1126/science.aad5944; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Miwa H, 2013, ONCOL REP, V29, P2053, DOI 10.3892/or.2013.2299; Muir A, 2017, ELIFE, V6, DOI 10.7554/eLife.27713; Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024; O'Neil NJ, 2017, NAT REV GENET, V18, P613, DOI 10.1038/nrg.2017.47; Ottestad-Hansen S, 2018, GLIA, V66, P951, DOI 10.1002/glia.23294; Pader I, 2014, P NATL ACAD SCI USA, V111, P6964, DOI 10.1073/pnas.1317320111; Priebe A, 2011, GYNECOL ONCOL, V122, P389, DOI 10.1016/j.ygyno.2011.04.024; Qi LS, 2013, CELL, V152, P1173, DOI 10.1016/j.cell.2013.02.022; Quan Michelle, 2017, React Oxyg Species (Apex), V3, P47, DOI 10.20455/ros.2017.801; Robert SM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8103; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Shin CS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15074; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Villablanca JG, 2016, PEDIATR BLOOD CANCER, V63, P1349, DOI 10.1002/pbc.25994; White CC, 2003, ANAL BIOCHEM, V318, P175, DOI 10.1016/S0003-2697(03)00143-X; Winterbourn CC, 2008, FREE RADICAL BIO MED, V45, P549, DOI 10.1016/j.freeradbiomed.2008.05.004; Xiao G, 2018, CELL, V173, P470, DOI 10.1016/j.cell.2018.02.048; Yoshikawa M, 2013, CANCER RES, V73, P1855, DOI 10.1158/0008-5472.CAN-12-3609-T; Yuan M, 2012, NAT PROTOC, V7, P872, DOI 10.1038/nprot.2012.024	67	19	19	4	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	2020	295	5					1350	1365		10.1074/jbc.RA119.011471	http://dx.doi.org/10.1074/jbc.RA119.011471			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM0QP	31914417	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000513822300015
J	Yan, LD; Hanvoravongchai, P; Aekplakorn, W; Chariyalertsak, S; Kessomboon, P; Assanangkornchai, S; Taneepanichskul, S; Neelapaichit, N; Stokes, AC				Yan, Lily D.; Hanvoravongchai, Piya; Aekplakorn, Wichai; Chariyalertsak, Suwat; Kessomboon, Pattapong; Assanangkornchai, Sawitri; Taneepanichskul, Surasak; Neelapaichit, Nareemarn; Stokes, Andrew C.			Universal coverage but unmet need: National and regional estimates of attrition across the diabetes care continuum in Thailand	PLOS ONE			English	Article							UNITED-STATES; TRENDS; PREVALENCE; CASCADE; GLUCOSE	Background Diabetes is a growing challenge in Thailand. Data to assess health system response to diabetes is scarce. We assessed what factors influence diabetes care cascade retention, under universal health coverage. Methods We conducted a cross-sectional analysis of the 2014 Thai National Health Examination Survey. Diabetes was defined as fasting plasma glucose >= 126mg/dL or on treatment. National and regional care cascades were constructed across screening, diagnosis, treatment, and control. Unmet need was defined as the total loss across cascade levels. Logistic regression was used to examine the demographic and healthcare factors associated with cascade attrition. Findings We included 15,663 individuals. Among Thai adults aged 20+ with diabetes, 67.0% (95% CI 60.9% to 73.1%) were screened, 34.0% (95% CI 30.6% to 37.2%) were diagnosed, 33.3% (95% CI 29.9% to 36.7%) were treated, and 26.0% (95% CI 22.9% to 29.1%) were controlled. Total unmet need was 74.0% (95% CI 70.9% to 77.1%), with regional variation ranging from 58.4% (95% CI 45.0% to 71.8%) in South to 78.0% (95% CI 73.0% to 83.0%) in Northeast. Multivariable models indicated older age (OR 1.76), males (OR 0.65), and a higher density of medical staff (OR 2.40) and health centers (OR 1.58) were significantly associated with being diagnosed among people with diabetes. Older age (OR 1.80) and higher geographical density of medical staff (OR 1.82) and health centers (OR 1.56) were significantly associated with being controlled. Conclusions Substantial attrition in the diabetes care continuum was observed at diabetes screening and diagnosis, related to both individual and health system factors. Even with universal health insurance, Thailand still needs effective behavioral and structural interventions, especially in primary health care settings, to address unmet need in diabetes care for its population.	[Yan, Lily D.] Boston Med Ctr, Internal Med, Boston, MA USA; [Hanvoravongchai, Piya] Chulalongkorn Univ, Fac Med, Bangkok, Thailand; [Aekplakorn, Wichai] Mahidol Univ, Fac Med, Dept Community Med, Ramathibodi Hosp, Bangkok, Thailand; [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand; [Chariyalertsak, Suwat] Chiang Mai Univ, Fac Publ Hlth, Chiang Mai, Thailand; [Kessomboon, Pattapong] Khon Kaen Univ, Med, Khon Kaen, Thailand; [Assanangkornchai, Sawitri] Prince Songkla Univ, Epidemiol Unit, Hat Yai, Thailand; [Taneepanichskul, Surasak] Chulalongkorn Univ, Coll Publ Hlth Sci, Bangkok, Thailand; [Neelapaichit, Nareemarn] Mahidol Univ, Ramathibodi Hosp, Ramathibodi Sch Nursing, Fac Med, Bangkok, Thailand; [Neelapaichit, Nareemarn] Chiang Mai Univ, Thailand Res Inst Hlth Sci, Chiang Mai, Thailand; [Stokes, Andrew C.] Boston Univ, Sch Publ Hlth, Global Hlth, Boston, MA 02118 USA	Boston Medical Center; Chulalongkorn University; Mahidol University; Chiang Mai University; Chiang Mai University; Khon Kaen University; Prince of Songkla University; Chulalongkorn University; Mahidol University; Chiang Mai University; Boston University	Stokes, AC (corresponding author), Boston Univ, Sch Publ Hlth, Global Hlth, Boston, MA 02118 USA.	acstokes@bu.edu	Yan, Lily/AAR-6163-2021; Aekplakorn, Wichai/AAK-6867-2021	Yan, Lily/0000-0001-6363-7920; Kessomboon, Pattapong/0000-0003-2118-5676; Aekplakorn, Wichai/0000-0002-3292-510X				Aekplakorn W, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/1654530; Aekplakorn W, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/396505; Ali MK, 2014, ANN INTERN MED, V161, P681, DOI 10.7326/M14-0019; [Anonymous], 2017, BURDEN DIS INJURIES; Anutrakulchai S, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1792-9; Aungkulanon S, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0479-5; Bauldry S, 2018, STATA J, V18, P924, DOI 10.1177/1536867X1801800410; Berry KM, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2017-000348; Bureau of Policy, 2014, REPPUBL HLTH RES; Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X; Evans T. G., 2012, INDEPENDENT ASSESSME, V10, P2001; Geiss LS, 2014, JAMA-J AM MED ASSOC, V312, P1218, DOI 10.1001/jama.2014.11494; Giordano TP, 2015, JAMA INTERN MED, V175, P596, DOI 10.1001/jamainternmed.2014.8199; Hirunrassamee S, 2009, INT J HEALTH CARE FI, V9, P153, DOI 10.1007/s10754-009-9062-6; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Institute for Health Metrics and Evaluation, 2016, THAIL COUNTR PROF; Kruk ME, 2018, LANCET GLOB HEALTH, V6, pE1196, DOI 10.1016/S2214-109X(18)30386-3; Manne-Goehler J, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002751; MCLEROY KR, 1988, HEALTH EDUC QUART, V15, P351, DOI 10.1177/109019818801500401; Nishtar S, 2018, LANCET, V392, P245, DOI 10.1016/S0140-6736(18)31258-3; Perlman DC, 2017, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00296; Sowattanangoon N, 2009, DIABETES RES CLIN PR, V84, P245, DOI 10.1016/j.diabres.2009.02.011; Stokes A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184264; Tangcharoensathien V, 2018, LANCET, V391, P1205, DOI 10.1016/S0140-6736(18)30198-3; Tangcharoensathien V, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001726; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4; Wanwong Y., 2017, J HLTH SYST RES, V11, P182; Zhou B, 2016, LANCET, V387, P1513, DOI 10.1016/S0140-6736(16)00618-8	30	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2020	15	1							e0226286	10.1371/journal.pone.0226286	http://dx.doi.org/10.1371/journal.pone.0226286			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5OV	31940366	gold, Green Published			2023-01-03	WOS:000534368000026
J	Kouyoumdjian, FG; Lee, JY; Orkin, AM; Cheng, SY; Fung, K; O'Shea, T; Guyatt, G				Kouyoumdjian, Fiona G.; Lee, Ji Yun; Orkin, Aaron M.; Cheng, Stephanie Y.; Fung, Kinwah; O'Shea, Tim; Guyatt, Gordon			Thirty-day readmission after medical-surgical hospitalization for people who experience imprisonment in Ontario, Canada: A retrospective cohort study	PLOS ONE			English	Article							PRIMARY-CARE; HIGH-RISK; HEALTH; INCARCERATION; PHYSICIANS; RELEASE; ACCESS; ADULTS; WOMEN	We aimed to compare 30-day readmission after medical-surgical hospitalization for people who experience imprisonment and matched people in the general population in Ontario, Canada. We used linked population-based correctional and health administrative data. Of people released from Ontario prisons in 2010, we identified those with at least one medical or surgical hospitalization between 2005 and 2015 while they were in prison or within 6 months after release. For those with multiple eligible hospitalizations, we randomly selected one hospitalization. We stratified people by whether they were in prison or recently released from prison at the time of hospital discharge. We matched each person with a person in the general population based on age, sex, hospitalization case mix group, and hospital discharge year. Our primary outcome was 30-day hospital readmission. We included 262 hospitalizations for people in prison and 1,268 hospitalizations for people recently released from prison. Readmission rates were 7.7% (95%CI 4.4-10.9) for people in prison and 6.9% (95% CI 5.5-8.3) for people recently released from prison. Compared with matched people in the general population, the unadjusted HR was 0.72 (95%CI 0.41-1.27) for people in prison and 0.78 (95%CI 0.60-1.02) for people recently released from prison. Adjusted for baseline morbidity and social status, hospitalization characteristics, and post-discharge health care use, the HR for 30-day readmission was 0.74 (95%CI 0.40-1.37) for people in prison and 0.48 (95%CI 0.36-0.63) for people recently released from prison. In conclusion, people recently released from prison had relatively low rates of readmission. Research is needed to elucidate reasons for lower readmission to ensure care quality and access.	[Kouyoumdjian, Fiona G.] McMaster Univ, Dept Family Med, Hamilton, ON, Canada; [Kouyoumdjian, Fiona G.; Cheng, Stephanie Y.; Fung, Kinwah] ICES, Toronto, ON, Canada; [Kouyoumdjian, Fiona G.] St Michaels Hosp, Ctr Urban Hlth Solut, Toronto, ON, Canada; [Lee, Ji Yun] McMaster Univ, Fac Hlth Sci, Hamilton, ON, Canada; [Orkin, Aaron M.] St Josephs Hlth Ctr, Unity Hlth, Dept Emergency Med, Toronto, ON, Canada; [Orkin, Aaron M.] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Orkin, Aaron M.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [O'Shea, Tim; Guyatt, Gordon] McMaster Univ, Dept Med, Fac Med, Hamilton, ON, Canada	McMaster University; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; McMaster University; University of Toronto; University Toronto Affiliates; Saint Joseph's Health Centre, Toronto; Western University (University of Western Ontario); University of Toronto; University of Toronto; McMaster University	Kouyoumdjian, FG (corresponding author), McMaster Univ, Dept Family Med, Hamilton, ON, Canada.; Kouyoumdjian, FG (corresponding author), ICES, Toronto, ON, Canada.; Kouyoumdjian, FG (corresponding author), St Michaels Hosp, Ctr Urban Hlth Solut, Toronto, ON, Canada.	kouyouf@mcmaster.ca	Orkin, Aaron/K-2500-2014	Orkin, Aaron/0000-0002-1111-8720; Kouyoumdjian, Fiona/0000-0002-6869-7516; O'Shea, Tim/0000-0002-0793-6915	Physicians' Services Incorporated Foundation [15-22]	Physicians' Services Incorporated Foundation	FK received funding from Physicians' Services Incorporated Foundation (15-22).	Austin PC, 2011, MED CARE, V49, P932, DOI 10.1097/MLR.0b013e318215d5e2; Austin PC, 2009, COMMUN STAT-SIMUL C, V38, P1228, DOI 10.1080/03610910902859574; Axon RN, 2011, JAMA-J AM MED ASSOC, V305, P504, DOI 10.1001/jama.2011.72; Baillargeon J, 2010, AM J COMMUN PSYCHOL, V46, P361, DOI 10.1007/s10464-010-9345-6; Balogh R, 2018, PSYCHIAT SERV, V69, P353, DOI 10.1176/appi.ps.201600534; Bergseth KJ, 2011, WOMEN CRIM JUSTICE, V21, P100, DOI 10.1080/08974454.2011.558799; Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115; Canadian Institutes of Health Research NSaERCoC Social Sciences and Humanities Research Council of Canada, 2014, SOC SCI HUM RES COUN; Colbert AM, 2016, J FORENSIC NURS, V12, P19, DOI 10.1097/JFN.0000000000000102; Fahmy N, 2018, ANN FAM MED, V16, P549, DOI 10.1370/afm.2314; Fazel S, 2011, LANCET, V377, P956, DOI 10.1016/S0140-6736(10)61053-7; Frank Joseph W, 2014, Health Justice, V2, P6; Friedman B, 2004, MED CARE RES REV, V61, P225, DOI 10.1177/1077558704263799; Government of Ontario, 2017, APPL OHIP GET HLTH C; Graffam Joe, 2004, J OFFENDER REHABIL, V40, P147, DOI DOI 10.1300/J076V40N01_08; Green Samantha, 2016, BMC Res Notes, V9, P131, DOI 10.1186/s13104-016-1935-4; Howell BA, 2016, J GEN INTERN MED, V31, P1496, DOI 10.1007/s11606-016-3857-1; Hu C, 2019, ACHIEVING CONTINUITY; Institute for Clinical Evaluative Sciences, 2018, MENT HLTH ADD SYST P; Jha AK, 2018, JAMA NETWORK OPEN, V1; Joynt KE, 2012, NEW ENGL J MED, V366, P1366, DOI 10.1056/NEJMp1201598; Kangovi S, 2011, JAMA-J AM MED ASSOC, V306, P1796, DOI 10.1001/jama.2011.1562; Kinner SA, 2014, AM J PUBLIC HEALTH, V104, P1352, DOI 10.2105/AJPH.2014.301883; Kouyoumdjian F, 2016, CAN FAM PHYSICIAN, V62, P215; Kouyoumdjian FG, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201592; Kouyoumdjian Fiona G, 2016, CMAJ Open, V4, pE153, DOI 10.9778/cmajo.20150098; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Pager D, 2003, AM J SOCIOL, V108, P937, DOI 10.1086/374403; PINK GH, 1994, CAN MED ASSOC J, V150, P1255; Ramaswamy M, 2015, AM J HEALTH BEHAV, V39, P221, DOI 10.5993/AJHB.39.2.9; Saab D, 2016, J GEN INTERN MED, V31, P1011, DOI 10.1007/s11606-016-3680-8; The Johns Hopkins University, J HOPK ACG SYST 2018; Ti LP, 2015, AM J PUBLIC HEALTH, V105, pE53, DOI 10.2105/AJPH.2015.302885; Turney K, 2013, AM SOCIOL REV, V78, P949, DOI 10.1177/0003122413505589; Urach C, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-1128-7; van Walraven C, 2011, CAN MED ASSOC J, V183, pE391, DOI 10.1503/cmaj.101860; Wang EA, 2013, JAMA INTERN MED, V173, P1621, DOI 10.1001/jamainternmed.2013.9008	37	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 10	2020	15	1							e0227588	10.1371/journal.pone.0227588	http://dx.doi.org/10.1371/journal.pone.0227588			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP5IB	31923231	Green Published, gold			2023-01-03	WOS:000534350000097
J	de Wit, R; de Bono, J; Sternberg, CN; Fizazi, K; Tombal, B; Wulfing, C; Kramer, G; Eymard, JC; Bamias, A; Carles, J; Iacovelli, R; Melichar, B; Sverrisdottir, A; Theodore, C; Feyerabend, S; Helissey, C; Ozatilgan, A; Geffriaud-Ricouard, C; Castellano, D; de Wit, R; de Bono, J; Sternberg, CN; Fizazi, K; Tombal, B; Wulfing, C; Kramer, G; Eymard, JC; Bamias, A; Carles, J; Iacovelli, R; Melichar, B; Sverrisdottir, A; Theodore, C; Feyerabend, S; Helissey, C; Ozatilgan, A; Geffriaud-Ricouard, C; Castellano, D				de Wit, Ronald; de Bono, Johann; Sternberg, Cora N.; Fizazi, Karim; Tombal, Bertrand; Wuelfing, Christian; Kramer, Gero; Eymard, Jean-Christophe; Bamias, Aristotelis; Carles, Joan; Iacovelli, Roberto; Melichar, Bohuslav; Sverrisdottir, Asgerdur; Theodore, Christine; Feyerabend, Susan; Helissey, Carole; Ozatilgan, Ayse; Geffriaud-Ricouard, Christine; Castellano, Daniel; de Wit, Ronald; de Bono, Johann; Sternberg, Cora N.; Fizazi, Karim; Tombal, Bertrand; Wulfing, Christian; Kramer, Gero; Eymard, Jean-Christophe; Bamias, Aristotelis; Carles, Joan; Iacovelli, Roberto; Melichar, Bohuslav; Sverrisdottir, Asgerour; Theodore, Christine; Feyerabend, Susan; Helissey, Carole; Ozatilgan, Ayse; Geffriaud-Ricouard, Christine; Castellano, Daniel		CARD Investigators	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOCETAXEL TREATMENT; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; OPEN-LABEL; PHASE-III; PREDNISONE; THERAPY; MEN; CHEMOTHERAPY; MITOXANTRONE	A randomized trial involving patients with metastatic prostate cancer whose disease progressed after receipt of docetaxel and hormonal therapy showed that cabazitaxel was superior to an androgen-signaling-targeted agent in extending imaging-based progression-free survival, overall survival, and PSA response. Background The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear. Methods We randomly assigned, in a 1:1 ratio, patients who had previously received docetaxel and an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide) to receive cabazitaxel (at a dose of 25 mg per square meter of body-surface area intravenously every 3 weeks, plus prednisone daily and granulocyte colony-stimulating factor) or the other androgen-signaling-targeted inhibitor (either 1000 mg of abiraterone plus prednisone daily or 160 mg of enzalutamide daily). The primary end point was imaging-based progression-free survival. Secondary end points of survival, response, and safety were assessed. Results A total of 255 patients underwent randomization. After a median follow-up of 9.2 months, imaging-based progression or death was reported in 95 of 129 patients (73.6%) in the cabazitaxel group, as compared with 101 of 126 patients (80.2%) in the group that received an androgen-signaling-targeted inhibitor (hazard ratio, 0.54; 95% confidence interval [CI], 0.40 to 0.73; P<0.001). The median imaging-based progression-free survival was 8.0 months with cabazitaxel and 3.7 months with the androgen-signaling-targeted inhibitor. The median overall survival was 13.6 months with cabazitaxel and 11.0 months with the androgen-signaling-targeted inhibitor (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.89; P=0.008). The median progression-free survival was 4.4 months with cabazitaxel and 2.7 months with an androgen-signaling-targeted inhibitor (hazard ratio for progression or death, 0.52; 95% CI, 0.40 to 0.68; P<0.001), a prostate-specific antigen response occurred in 35.7% and 13.5% of the patients, respectively (P<0.001), and tumor response was noted in 36.5% and 11.5% (P=0.004). Adverse events of grade 3 or higher occurred in 56.3% of patients receiving cabazitaxel and in 52.4% of those receiving an androgen-signaling-targeted inhibitor. No new safety signals were observed. Conclusions Cabazitaxel significantly improved a number of clinical outcomes, as compared with the androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who had been previously treated with docetaxel and the alternative androgen-signaling-targeted agent (abiraterone or enzalutamide). (Funded by Sanofi; CARD ClinicalTrials.gov number, .)	[de Wit, Ronald] Erasmus MC, Rotterdam, Netherlands; [de Bono, Johann] Inst Canc Res, London, England; [de Bono, Johann] Royal Marsden Hosp, London, England; [Sternberg, Cora N.] Weill Cornell Med, Englander Inst Precis Med, New York, NY USA; [Fizazi, Karim] Inst Gustave Roussy, Villejuif, France; [Fizazi, Karim] Univ Paris Sud, Villejuif, France; [Eymard, Jean-Christophe] Jean Godinot Inst, Reims, France; [Eymard, Jean-Christophe] Reims Champagne Ardenne Univ, Reims, France; [Theodore, Christine] Foch Hosp, Suresnes, France; [Helissey, Carole] Hop Instruct Armees Begin, St Mande, France; [Geffriaud-Ricouard, Christine] Sanofi, Europe Med Oncol, Paris, France; [Tombal, Bertrand] Catholic Univ Louvain, Inst Rech Clin, Louvain, Belgium; [Wuelfing, Christian] Asklepios Klin Altona, Asklepios Tumorzentrum Hamburg, Dept Urol, Hamburg, Germany; [Feyerabend, Susan] Studien Praxis Urol, Nurtingen, Germany; [Kramer, Gero] Med Univ Vienna, Vienna, Austria; [Bamias, Aristotelis] Natl & Kapodistrian Univ Athens, Alexandra Hosp, Athens, AL USA; [Carles, Joan] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain; [Iacovelli, Roberto] Azienda Ospedaliera Univ Integrata, Verona, Italy; [Iacovelli, Roberto] Fdn Policlinico Agostino Gemelli IRCCS, Rome, Italy; [Melichar, Bohuslav] Palacky Univ, Sch Med, Olomouc, Czech Republic; [Melichar, Bohuslav] Teaching Hosp, Olomouc, Czech Republic; [Sverrisdottir, Asgerdur] Landspitali Univ Hosp, Reykjavik, Iceland; [Ozatilgan, Ayse] Sanofi, Global Med Oncol, Cambridge, MA USA; [Castellano, Daniel] 12 Octubre Univ Hosp, Madrid, Spain	Erasmus University Rotterdam; Erasmus MC; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Cornell University; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Institut Jean Godinot; Universite de Reims Champagne-Ardenne; Hospital Foch; Sanofi-Aventis; Sanofi France; Universite Catholique Louvain; Asklepios Klinik Altona; Medical University of Vienna; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; Palacky University Olomouc; University Hospital Olomouc; Landspitali National University Hospital; Sanofi-Aventis; Hospital Universitario 12 de Octubre		r.dewit@erasmusmc.nl	Gravis, Gwenaelle/CAG-3019-2022; Helissey, Carole/ABA-5343-2021; Iacovelli, Roberto/AAB-9850-2019; FACCHINI, GAETANO/P-4491-2015	Gravis, Gwenaelle/0000-0002-3127-1554; Iacovelli, Roberto/0000-0002-1750-2117; de Bono, Johann S/0000-0002-2034-595X; MAHAMMEDI, Hakim/0000-0002-7596-2357; McDermott, Ray/0000-0002-8952-4315; OUDARD, Stephane/0000-0003-0893-285X; DURAN, IGNACIO/0000-0001-8571-7163; Westgeest, Hans/0000-0002-5735-3638; FACCHINI, GAETANO/0000-0002-7430-001X	Sanofi	Sanofi	Supported by Sanofi.	Al Nakouzi N, 2015, EUR UROL, V68, P228, DOI 10.1016/j.eururo.2014.04.015; Antonarakis ES, 2015, JAMA ONCOL, V1, P582, DOI 10.1001/jamaoncol.2015.1341; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Atkinson TM, 2010, PAIN MED, V11, P337, DOI 10.1111/j.1526-4637.2009.00774.x; Attard G, 2018, J CLIN ONCOL, V36, P2639, DOI 10.1200/JCO.2018.77.9827; Azarenko O, 2014, MOL CANCER THER, V13, P2092, DOI 10.1158/1535-7163.MCT-14-0265; Beer TM, 2017, LANCET ONCOL, V18, P1532, DOI 10.1016/S1470-2045(17)30605-8; Chi KN, 2019, NEW ENGL J MED, V381, P13, DOI 10.1056/NEJMoa1903307; Conteduca V, 2019, EUR J CANCER, V116, P158, DOI 10.1016/j.ejca.2019.05.007; Davis ID, 2019, NEW ENGL J MED, V381, P121, DOI 10.1056/NEJMoa1903835; de Bono JS, 2017, EUR UROL, V71, P656, DOI 10.1016/j.eururo.2016.06.033; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; de Morree E, 2016, PROSTATE, V76, P927, DOI 10.1002/pros.23182; Delanoy N, 2018, EUR UROL ONCOL, V1, P467, DOI 10.1016/j.euo.2018.05.009; Eisenberger M, 2017, J CLIN ONCOL, V35, P3198, DOI 10.1200/JCO.2016.72.1076; Fitzpatrick JM, 2014, EUR UROL, V65, P1198, DOI 10.1016/j.eururo.2013.07.022; Fizazi K, 2019, NEW ENGL J MED, V380, P1235, DOI 10.1056/NEJMoa1815671; Fizazi K, 2017, NEW ENGL J MED, V377, P352, DOI 10.1056/NEJMoa1704174; Heidenreich A, 2014, EUR J CANCER, V50, P1090, DOI 10.1016/j.ejca.2014.01.006; Hussain M, 2018, NEW ENGL J MED, V378, P2465, DOI 10.1056/NEJMoa1800536; James ND, 2017, NEW ENGL J MED, V377, P338, DOI 10.1056/NEJMoa1702900; James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Loriot Y, 2013, ANN ONCOL, V24, P1807, DOI 10.1093/annonc/mdt136; Maines F, 2015, CRIT REV ONCOL HEMAT, V96, P498, DOI 10.1016/j.critrevonc.2015.07.013; Malvezzi M, 2019, ANN ONCOL, V30, P781, DOI 10.1093/annonc/mdz051; Maughan BL, 2017, PROSTATE, V77, P33, DOI 10.1002/pros.23246; Mezynski J, 2012, ANN ONCOL, V23, P2943, DOI 10.1093/annonc/mds119; Miyake H, 2017, CLIN GENITOURIN CANC, V15, pE591, DOI 10.1016/j.clgc.2016.12.015; Morris MJ, 2015, J CLIN ONCOL, V33, P1356, DOI 10.1200/JCO.2014.55.3875; Oh WK, 2018, UROL ONCOL-SEMIN ORI, V36, DOI 10.1016/j.urolonc.2018.08.002; Oudard S, 2017, J CLIN ONCOL, V35, P3189, DOI 10.1200/JCO.2016.72.1068; Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755; Rescigno P, 2018, EUR UROL ONCOL, V1, P71, DOI 10.1016/j.euo.2018.02.006; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith MR, 2018, NEW ENGL J MED, V378, P1408, DOI 10.1056/NEJMoa1715546; Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Terada N, 2017, INT J UROL, V24, P441, DOI 10.1111/iju.13346; van Soest RJ, 2015, EUR J CANCER, V51, P2562, DOI 10.1016/j.ejca.2015.07.037; van Soest RJ, 2015, EUR UROL, V67, P981, DOI 10.1016/j.eururo.2014.11.033	44	271	273	3	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 26	2019	381	26					2506	2518		10.1056/NEJMoa1911206	http://dx.doi.org/10.1056/NEJMoa1911206			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA1LR	31566937	Green Published, Bronze			2023-01-03	WOS:000505560800006
J	Wilensky, G				Wilensky, Gail			Health Care Legislation, the 2020 Election, and Beyond	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									[Wilensky, Gail] Project HOPE, Bethesda, MD 20814 USA		Wilensky, G (corresponding author), Project HOPE, Bethesda, MD 20814 USA.	gwilensky@projecthope.org							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	2019	322	24					2372	2373		10.1001/jama.2019.20085	http://dx.doi.org/10.1001/jama.2019.20085			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ6JW	31860033	Bronze			2023-01-03	WOS:000505209400003
J	Russell, C; Neufeld, M; Sabioni, P; Varatharajan, T; Ali, F; Miles, S; Henderson, J; Fischer, B; Rehm, J				Russell, Cayley; Neufeld, Maria; Sabioni, Pamela; Varatharajan, Thepikaa; Ali, Farihah; Miles, Sarah; Henderson, Joanna; Fischer, Benedikt; Rehm, Juergen			Assessing service and treatment needs and barriers of youth who use illicit and non-medical prescription drugs in Northern Ontario, Canada	PLOS ONE			English	Article							MENTAL-HEALTH; PARTICIPATORY RESEARCH; SUBSTANCE USE; INTERVENTION; ALCOHOL; STIGMA; ACCESS; CARE	Background Illicit drug use rates are high among Canadian youth, and are particularly pronounced in Northern Ontario. The availability and accessibility of effective substance use-related treatments and services are required to address this problem, especially among rural and remote Northern communities. In order to assess specific service and treatment needs, as well as barriers and deterrents to accessing and utilizing services and treatments for youth who use illicit drugs in Northern Ontario, we conducted the present study. Methods This study utilized a mixed-methods design and incorporated a community-based participatory research approach. Questionnaires were administered in conjunction with audio-recorded semi-structured interviews and/or focus groups with youth (aged 14-25) who live in Northern Ontario and use illicit drugs. Interviews with 'key informants' who work with the youth in each community were also conducted. Between August and December 2017, the research team traveled to Northern Ontario communities and carried out data collection procedures. Results A total of 102 youth and 35 key informants from eleven different Northern Ontario communities were interviewed. The most commonly used drugs were prescription opioids, cocaine and crack-cocaine. Most participants experienced problems related to their drug use, and reported 'fair' mental and physical health status. Qualitative analyses highlighted an overall lack of services; barriers to accessing treatment and services included lack of motivation, stigmatization, long wait-lists and transportation/mobility issues. Articulated needs revolved around the necessity of harm reduction-based services, low-threshold programs, specialized programming, and peer-based counselling. Conclusions Although each community varied in terms of drug use behaviors and available services, an overall need for youth-specific, low-threshold services was identified. Information gathered from this study can be used to help inform rural and remote communities towards improving treatment and service system performance and provision.	[Russell, Cayley; Neufeld, Maria; Sabioni, Pamela; Varatharajan, Thepikaa; Ali, Farihah; Fischer, Benedikt; Rehm, Juergen] Ctr Addict & Mental Hlth CAMH, Inst Mental Hlth Policy Res, Toronto, ON, Canada; [Neufeld, Maria; Rehm, Juergen] Tech Univ Dresden, Inst Klin Psychol & Psychotherapie, Dresden, Germany; [Sabioni, Pamela] Ctr Addict & Mental Hlth CAMH, Translat Addict Res Lab, Toronto, ON, Canada; [Miles, Sarah] Toronto Gen Hosp, Dept Anesthesia & Pain Management, Toronto, ON, Canada; [Henderson, Joanna; Fischer, Benedikt; Rehm, Juergen] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Henderson, Joanna] Margaret & Wallace McCain Ctr Child Youth & Famil, Ctr Addict & Mental Hlth, Toronto, ON, Canada; [Fischer, Benedikt] Simon Fraser Univ, Fac Hlth Sci, Ctr Appl Res Mental Hlth & Addict CARMHA, Vancouver, BC, Canada; [Fischer, Benedikt] Univ Auckland, Fac Med & Hlth Sci, Auckland, New Zealand; [Fischer, Benedikt] Fed Univ Sao Paulo UNIFESP, Dept Psychiat, Sao Paulo, Brazil; [Rehm, Juergen] Univ Toronto, Inst Med Sci IMS, Toronto, ON, Canada; [Rehm, Juergen] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Rehm, Juergen] IM Sechenov First Moscow State Med Univ, Dept Int Hlth Projects, Inst Leadership & Hlth Management, Moscow, Russia	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; Technische Universitat Dresden; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; Simon Fraser University; University of Auckland; Universidade Federal de Sao Paulo (UNIFESP); University of Toronto; University of Toronto; Sechenov First Moscow State Medical University	Neufeld, M (corresponding author), Ctr Addict & Mental Hlth CAMH, Inst Mental Hlth Policy Res, Toronto, ON, Canada.; Neufeld, M (corresponding author), Tech Univ Dresden, Inst Klin Psychol & Psychotherapie, Dresden, Germany.	neufeld.maria@gmail.com	Neufeld, Maria/AAF-1416-2021	Fischer, B/0000-0002-2186-4030; Henderson, Joanna/0000-0002-9387-5193; Miles, Sarah/0000-0002-9728-7428; Neufeld, Maria/0000-0001-6364-3765	Canadian Institutes of Health Research (CIHR) [SMN-139150]; Open Access Publication Funds of the SLUB/TU (Sachsische Landesbibliothek -Staats-und Universitatsbibliothek and Technische Universitat) Dresden, Germany	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Open Access Publication Funds of the SLUB/TU (Sachsische Landesbibliothek -Staats-und Universitatsbibliothek and Technische Universitat) Dresden, Germany	BF, JR, PS, JH, SM, MN, CR, TV, and FA acknowledge funding from Canadian Institutes of Health Research (CIHR) for the Ontario CRISM Node Team (grant #SMN-139150). The authors acknowledge support by the Open Access Publication Funds of the SLUB/TU (Sachsische Landesbibliothek -Staats-und Universitatsbibliothek and Technische Universitat) Dresden, Germany. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adlaf EM, 2009, ADDICT BEHAV, V34, P360, DOI 10.1016/j.addbeh.2008.11.012; Amartey A., 2017, MENTAL HLTH CHILDREN; Anderson TJ, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1053-3; [Anonymous], 2019, WORLD DRUG REP 2018; Barton J, 2016, CAN J FAM YOUTH, V8, P1; Battjes RJ, 2003, J SUBST ABUSE TREAT, V24, P221, DOI 10.1016/S0740-5472(03)00022-9; Berryman A., 2016, MERITS SUPERVISED IN; Boak A.H., 2017, DRUG USE ONTARIO STU; Borders TF, 2015, J RURAL HEALTH, V31, P98, DOI 10.1111/jrh.12092; Brownlie EB., 2017, CAN J COMMUN MENT HL, V36, P133, DOI [10.7870/cjcmh-2017-018, DOI 10.7870/CJCMH-2017-018]; Brundisini F, 2013, Ont Health Technol Assess Ser, V13, P1; Calloway M, 1999, J RURAL HEALTH, V15, P296, DOI 10.1111/j.1748-0361.1999.tb00751.x; Canadian Centre for Substance Abuse (CCSA), 2007, DRUG PREV STRAT CAN; Canadian Centre on Substance Abuse (CCSA), 2007, SUBST AB CAN YOUTH F; Canadian Centre on Substance Abuse (CCSA), 2011, CROSS CAN REP STUD A; Chaim G, 2014, YOUTH SYSTEM SERVICE, P12; Chiefs of Ontario, 2009, ONT REG 1 NAT ADD SE; Corrigan P, 2004, AM PSYCHOL, V59, P614, DOI 10.1037/0003-066X.59.7.614; Creswell J, 2017, RES DESIGN QUALITATI; Degenhardt L, 2016, LANCET PSYCHIAT, V3, P251, DOI 10.1016/S2215-0366(15)00508-8; Diaczuk D., TB NEWSWATCH; DiClemente CC, 2004, AM J ADDICTION, V13, P103, DOI 10.1080/10550490490435777; Durbin J, 2010, IMPACT STUDY FINAL R; Erskine HE, 2015, PSYCHOL MED, V45, P1551, DOI 10.1017/S0033291714002888; Gale F., 2007, MENTAL HLTH INTERVEN, P58; Gibbs G., 2002, QUALITATIVE DATA ANA; Gomes T, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3207; GraphPad Prism, 2017, 7 02 GRAPHPAD SOFTW; Gulliver A, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-113; Hall WD, 2016, LANCET PSYCHIAT, V3, P265, DOI 10.1016/S2215-0366(16)00013-4; Halsall Tanya, 2019, Healthc Manage Forum, V32, P51, DOI 10.1177/0840470418808815; Health Canada, 2019, CAN TOB ALC DRUGS SU; Henderson J., 2013, NATL YOUTH SCREENING; Holkup PA, 2004, ADV NURS SCI, V27, P162, DOI 10.1097/00012272-200407000-00002; Hsia R, 2011, ARCH SURG-CHICAGO, V146, P46, DOI 10.1001/archsurg.2010.299; Ialomiteanu AR, 2018, CAMH MONITOR E REPOR; Islam MM, 2013, INT J DRUG POLICY, V24, P220, DOI 10.1016/j.drugpo.2013.03.005; Israel BA, 2019, URBAN HLTH, DOI [10.1093/oso/9780190915858.003.0029, DOI 10.1093/OSO/9780190915858.003.0029]; Israel BA, 2010, AM J PUBLIC HEALTH, V100, P2094, DOI 10.2105/AJPH.2009.170506; Kurdyak P, 2018, CAN FAM PHYSICIAN, V64, pE95; Luce J, 2011, CROSS CANADA SCAN ME; Mental Health and Addictions Leadership Advisory Council, 2015, BETT MENT HLTH MEANS; Mitra S, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6606-7; Motulsky H., 1999, ANAL DATA GRAPHPAD P; North East Local Health Integration Network (LHIN), 2018, 2016 2017 ANN REP; North West Local Health Integration Network (LHIN), 2017, 2015 2016 N W LOC HL; O'Connor PJ, 2014, J ADV NURS, V70, P2577, DOI 10.1111/jan.12423; Perlmutter Alexander S, 2018, Curr Addict Rep, V5, P120, DOI 10.1007/s40429-018-0194-y; Peterson PL, 2006, PSYCHOL ADDICT BEHAV, V20, P254, DOI 10.1037/0893-164X.20.3.254; Province of British Columbia, 2017, WILDF SEAS SUMM 2017; Public Health Ontario, 2011, OP MINDS HLTH MIND O; QSR International Pty Ltd, 2018, NVIVO VERS 12; Rost K, 2002, MED CARE RES REV, V59, P231, DOI 10.1177/1077558702059003001; Rourke, 2017, ONTARIO INTEGRATED S; Rowan M, 2014, SUBST ABUSE TREAT PR, V9, DOI 10.1186/1747-597X-9-34; Rush B, 2016, N E LOCAL HLTH INTEG; Russell C, 2016, RURAL REMOTE HEALTH, V16; Rutherford K., CBC NEWS; Ryan-Nicholls KD, 2007, J PSYCHOSOC NURS MEN, V45, P37, DOI 10.3928/02793695-20071201-08; Satcher D., 2005, METHODS COMMUNITY BA; Sawula E, 2018, OPIOID USE IMPACTS T; Schroder R, 2009, DRUG ALCOHOL REV, V28, P663, DOI 10.1111/j.1465-3362.2009.00076.x; Sibley LM, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-20; Smalley KB, 2010, J CLIN PSYCHOL, V66, P479, DOI 10.1002/jclp.20688; Strasser R, 2003, FAM PRACT, V20, P457, DOI 10.1093/fampra/cmg422; Varatharajan T, 2018, F1000RESEARCH, P7; Wallerstein NB, 2006, HEALTH PROMOT PRACT, V7, P312, DOI 10.1177/1524839906289376; Weaver KE, 2013, CANCER-AM CANCER SOC, V119, P1050, DOI 10.1002/cncr.27840; Winters KC, 2011, CURR PSYCHIAT REP, V13, P416, DOI 10.1007/s11920-011-0214-2; Wisdom JP, 2011, ADDICT RES THEORY, V19, P179, DOI 10.3109/16066359.2010.530711; Wong S, 2009, RURAL REMOTE HEALTH, V9; Yap MBH, 2011, SOC PSYCH PSYCH EPID, V46, P1257, DOI 10.1007/s00127-010-0300-5; Youth Wellness Hubs Ontario, 2017, YOUTH WELLN HUBS ONT	73	13	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2019	14	12							e0225548	10.1371/journal.pone.0225548	http://dx.doi.org/10.1371/journal.pone.0225548			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP0JY	31805082	Green Published, gold			2023-01-03	WOS:000534009700029
J	Chen, C; Liu, XJ; Wang, XF; Li, W; Qu, WX; Dong, LL; Li, XY; Rui, ZQ; Yang, XQ				Chen, Cai; Liu, Xuejian; Wang, Xianfeng; Li, Wei; Qu, Wenxiu; Dong, Leilei; Li, Xiyuan; Rui, Zhiqing; Yang, Xueqing			Risk of temperature, humidity and concentrations of air pollutants on the hospitalization of AECOPD	PLOS ONE			English	Article							PARTICULATE MATTER; RESPIRATORY-DISEASE; ACUTE EXACERBATION; PULMONARY; COPD; INFLAMMATION; POLLUTION; IMPACT; CHINA	Aim To investigate the effect of temperature, humidity and the concentration of ambient air pollution on the hospitalization of AECOPD. Method Hospitalization record was obtained from Shenyang Medical Insurance Bureau, concluding patient's age, gender, income hospital time, outcome hospital; Generalized additive model was used to analyze the relationship between temperature, humidity, the concentration of ambient air pollution and the hospitalization of AECOPD. Result The effect of ozone on admission rate in male group was higher than that in female group. Ambient air pollution had a weak influence on age <= 50 group. It was found that the optimal lag day for daily relative 40 humidity to age <= 50 group, 50<age <= 60, 60<age <= 70 group and age> 70 group was on lag5, lag4, lag4 and lag5, respectively. Conclusion Air pollution, relative humidity and temperature can increase the risk of admission for acute exacerbation of COPD, and in this process there was a lag effect.	[Chen, Cai; Li, Wei; Dong, Leilei; Li, Xiyuan] Shandong Univ, Sch Control Sci & Engn, Biomed Engn Inst, Jinan, Peoples R China; [Liu, Xuejian; Qu, Wenxiu] China Med Univ, Shengjing Hosp, Gen Internal Med 1, Shenyang, Liaoning, Peoples R China; [Wang, Xianfeng] Dept Ecol & Environm Peoples Republ Shandong, Jinan, Peoples R China; [Rui, Zhiqing] Chinese Acad Sci, Inst Software, Beijing, Peoples R China; [Yang, Xueqing] Helmholz Ctr Environm Res UFZ, Dept Bioenergy, Leipzig, Germany	Shandong University; China Medical University; Chinese Academy of Sciences; Institute of Software, CAS; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ)	Li, W (corresponding author), Shandong Univ, Sch Control Sci & Engn, Biomed Engn Inst, Jinan, Peoples R China.; Qu, WX (corresponding author), China Med Univ, Shengjing Hosp, Gen Internal Med 1, Shenyang, Liaoning, Peoples R China.	cindy@sdu.edu.cn; quwx@sj-hospital.org		Yang, Xueqing/0000-0002-5816-8477	National Natural Science Foundation [21728701]; Ministry of Education postdoctoral fund [2015M572044]; Shandong Province Science and Technology Development Project [GG201709260070]; Shenyang Science and Technology Bureau Project [F15-199-1-44]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Ministry of Education postdoctoral fund; Shandong Province Science and Technology Development Project; Shenyang Science and Technology Bureau Project	This study was supported by the National Natural Science Foundation 21728701, Ministry of Education postdoctoral fund 2015M572044, and Shandong Province Science and Technology Development Project GG201709260070 to WL. This study was also supported by the Shenyang Science and Technology Bureau Project F15-199-1-44 to WQ.	Almagro P, 2015, INT J CHRONIC OBSTR, V10, P899, DOI 10.2147/COPD.S75710; Barbone F, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16061057; Chen C, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015634; Choi J, 2018, INT J CHRONIC OBSTR, V13, P1053, DOI 10.2147/COPD.S156617; Dehghan A, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0613-9; Gruzieva O, 2019, ENVIRON HEALTH PERSP, V127, DOI 10.1289/EHP4522; Han M, 2017, ENVIRON SCI POLLUT R, V24, P27843, DOI 10.1007/s11356-017-0402-7; Ho SC, 2019, SCI TOTAL ENVIRON, V677, P524, DOI 10.1016/j.scitotenv.2019.04.358; Jin YF, 2017, ENVIRON TOXICOL, V32, P1121, DOI 10.1002/tox.22308; Jo EJ, 2017, RESP MED, V124, P79, DOI 10.1016/j.rmed.2017.02.010; Ma YX, 2018, ENVIRON SCI POLLUT R, V25, P17942, DOI 10.1007/s11356-018-2013-3; Mu Z, 2017, INT J BIOMETEOROL, V61, P1919, DOI 10.1007/s00484-017-1379-0; Phosri A, 2019, SCI TOTAL ENVIRON, V651, P1144, DOI 10.1016/j.scitotenv.2018.09.183; Rocks N, 2019, THORAX, V74, P768, DOI 10.1136/thoraxjnl-2018-211990; Sun SZ, 2018, THORAX, V73, P951, DOI 10.1136/thoraxjnl-2017-211333; Sun XL, 2017, TOXICOL LETT, V278, P1, DOI 10.1016/j.toxlet.2017.07.853; Tasci SS, 2018, EMERG MED INT, V2018, DOI 10.1155/2018/4183203; Tian YH, 2018, ENVIRON HEALTH-GLOB, V17, DOI 10.1186/s12940-018-0369-y; Tseng CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057066; Vepkhvadze N, 2017, Georgian Med News, P1114; Waterston A, 2018, BIOPHYS J, V114, p334A; Wigenstam E, 2016, TOXICOLOGY, V368, P28, DOI 10.1016/j.tox.2016.08.018; Xie JG, 2019, INT J BIOMETEOROL, V63, P315, DOI 10.1007/s00484-018-01665-y; Zhu BF, 2018, INT J CHRONIC OBSTR, V13, P1353, DOI 10.2147/COPD.S161555	24	13	15	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 26	2019	14	11							e0225307	10.1371/journal.pone.0225307	http://dx.doi.org/10.1371/journal.pone.0225307			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO8RE	31770406	Green Published, gold			2023-01-03	WOS:000533892300014
J	Bernstein, JJJ; Holt, GB; Bernstein, J				Bernstein, John J. J.; Holt, Gerhard B.; Bernstein, Joseph			Price dispersion of generic medications	PLOS ONE			English	Article								Generic pharmaceuticals should have very little price dispersion. Economics' Law of One Price suggests that identical goods, in the absence of trade frictions and under conditions of free competition and price flexibility, should sell for the same price, and the FDA ensures that generics are identical. In this study, we examine whether generic pharmaceuticals indeed have the low price dispersion that theory predicts, and if not, whether the dispersion seen for pharmaceuticals used to treat neuropsychiatric conditions is substantially higher than that of other drugs. Such a difference may offer an explanation for the price dispersion seen: namely, a strategy that takes advantage of buyers' cognitive constraints and impaired ability to comparison shop. We thus assembled a list of generic pharmaceuticals and their prices using www.GoodRx.com, based on a convenience sample of the 5 most popular drugs for 10 common medical conditions listed there. Three neuropsychiatric diagnoses were used: Alzheimer's disease, depression and schizophrenia. Seven other diagnoses served as controls: asthma; diabetes mellitus-type II; high cholesterol; hypertension; osteoarthritis; osteoporosis; and urinary tract infection. For each drug, we identified the highest and lowest prices and calculated the mean, median and coefficient of variation (CV). We further calculated the ratios of the highest price to the median price and of the highest to lowest price. We found that the mean price CV was 43%. For neuropsychiatric drugs and controls, it was 61% and 35%, respectively. The mean high-to-median ratio was3.7 for neuropsychiatric drugs and 1.9 for controls. The mean high-to-low ratio was 5.9 for neuropsychiatric drugs and 2.8 for controls. In short, generic medications have high price dispersion, despite public availability of prices. Although our study did not examine why this price dispersion is present, the especially large high-to-low price ratio for neuropsychiatric medications suggests a strategy that exploits vulnerable patients.	[Bernstein, John J. J.] Haverford High Sch, Haverford, PA USA; [Bernstein, Joseph] Univ Penn, Philadelphia, PA 19104 USA	University of Pennsylvania	Bernstein, J (corresponding author), Univ Penn, Philadelphia, PA 19104 USA.	Joseph.Bernstein@uphs.upenn.edu						Dobkin HE, 2017, J AM ACAD DERMATOL, V77, P1181, DOI 10.1016/j.jaad.2017.07.017; Ellison G, 2009, ECONOMETRICA, V77, P427, DOI 10.3982/ECTA5708; Miller D., 2019, CLIN PSYCHIAT NEWS; Scholten P, EC INTERNET E COMMER, P63; Sorensen AT, 2000, J POLIT ECON, V108, P833, DOI 10.1086/316103	5	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2019	14	11							e0225280	10.1371/journal.pone.0225280	http://dx.doi.org/10.1371/journal.pone.0225280			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LN3EY	31738807	gold, Green Published			2023-01-03	WOS:000532826300044
J	Salim, H; Lee, PY; Sazlina, SG; Ching, SM; Mawardi, M; Shamsuddin, NH; Ali, H; Adibah, HI; Tan, NC				Salim, Hani; Lee, Ping Yein; Sazlina, Shariff Ghazali; Ching, Siew Mooi; Mawardi, Maliza; Shamsuddin, Nurainul Hana; Ali, Hanifatiyah; Adibah, Hanim Ismail; Tan, Ngiap Chuan			The self-care profiles and its determinants among adults with hypertension in primary health care clinics in Selangor, Malaysia	PLOS ONE			English	Article							AFRICAN-AMERICAN; CHRONIC DISEASE; BLOOD-PRESSURE; MANAGEMENT; INTERVENTIONS; TOOL	Introduction Self-care has been shown to improve clinical outcome of hypertension. Gauging the level of self-care among patients with hypertension enables the design of their personalized care plans. This study aimed to determine the self-care profiles and its determinants among patients with hypertension in the Malaysian primary care setting. Methods This was a cross sectional study conducted between 1 October 2016-30 April 2017 in three primary care clinics in the state of Selangor, Malaysia. All adults aged 18 years and above with hypertension for at least 6 months were recruited with a systematic random sampling of 1:2 ratio. The participants were assisted in the administration of the structured questionnaire, which included socio-demographic information, medical information and the Hypertension Self-Care Profile (HTN SCP) tool. Statistical analysis was done using SPSS version 20.0. Multiple linear regression was performed to determine the determinants for self-care. Results The mean age of the participants was 59.5 (SD10.2) years old. There were more women (52.5%) and most were Malays (44.0%) follow by Chinese (34%) and Indians (21%). Majority (84.2%) had secondary or primary school level of education. A third (30.7%) had a family history of hypertension. The mean total HTN-SCP score was 124.2 (SD 22.8) out of 180. The significant determinants that influenced the HTN-SCP scores included being men (B4.5, P-value0.008), Chinese ethnicity (B-14.7, P-value<0.001), primary level education/no formal school education level (B-15.7, P-value<0.001), secondary level education (B-9.2, P-value<0.001) and family history of hypertension (B 4.4, P-value 0.014). Conclusions The overall hypertension self-care profile among patients in this multi-ethnic country was moderate. Being men, Chinese, lower education level and without family history of hypertension were associated with lower hypertension self-care profile score. Healthcare intervention programmes to address self-care should target this group of patients.	[Salim, Hani; Lee, Ping Yein; Sazlina, Shariff Ghazali; Ching, Siew Mooi; Mawardi, Maliza; Shamsuddin, Nurainul Hana; Ali, Hanifatiyah; Adibah, Hanim Ismail] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Family Med, Serdang, Selangor, Malaysia; [Tan, Ngiap Chuan] SingHlth Polyclin, Jalan Bukit Merah Connect One, Singapore, Singapore; [Tan, Ngiap Chuan] SingHlth Duke NUS Family Med Acad Clin Programme, Jalan Bukit Merah Connect One, Singapore, Singapore	Universiti Putra Malaysia	Lee, PY (corresponding author), Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Family Med, Serdang, Selangor, Malaysia.	yein@upm.edu.my	MEDIC, NURAINUL HANA BINTI SHAMSUDDIN //AAY-6897-2021; Lee, Ping Yein/C-1923-2012; Ismail, Adibah Hanim/B-8293-2019; Ching, Siew Mooi/I-5817-2013	MEDIC, NURAINUL HANA BINTI SHAMSUDDIN //0000-0001-8326-0024; Lee, Ping Yein/0000-0002-0912-6043; Ismail, Adibah Hanim/0000-0002-6904-375X; Ching, Siew Mooi/0000-0002-4425-7989	Malaysian Hypertension Society [MSH RG/2017/HSS]	Malaysian Hypertension Society	Funding of this work was supported by the Malaysian Hypertension Society research Grant No.: MSH RG/2017/HSS. All authors are investigators under this research grant. The funder was not involve in the study design, data collection, analysis, preparation of manuscript or decision to publish this manuscript.	Andrulis DP, 2007, AM J HEALTH BEHAV, V31, pS122; Azar Tol, 2012, J EDU HLTH PROMOT, V1, P19; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Bosch-Capblanch X, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004808.pub3; Britt E, 2004, PATIENT EDUC COUNS, V53, P147, DOI 10.1016/S0738-3991(03)00141-1; Chodosh J, 2005, ANN INTERN MED, V143, P427, DOI 10.7326/0003-4819-143-6-200509200-00007; Choong Y O, 2015, E P INT C SOC SCI RE; Dickinson HO, 2006, J HYPERTENS, V24, P215, DOI 10.1097/01.hjh.0000199800.72563.26; Ebrahim S., 1998, HLTH TECHNOL ASSESS, V2; Fan AZ, 2010, PREV MED, V50, P138, DOI 10.1016/j.ypmed.2009.12.007; Glynn LG, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005182.pub4; Hamilton DF, 2015, BONE JOINT RES, V4, P152, DOI 10.1302/2046-3758.49.2000571; Han HR, 2014, J CARDIOVASC NURS, V29, pE11, DOI 10.1097/JCN.0b013e3182a3fd46; Han HR, 2014, J CARDIOVASC NURS, V29, P55, DOI 10.1097/JCN.0b013e3182775fd1; Hu H, 2013, INT J ANTENN PROPAG, V2013, DOI 10.1155/2013/416096; Institute for Public Health, 2015, NAT HLTH MORB SURV N, V2, P17; Koh YLE, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002955; Lemeshow S., 1990, TITLE ADEQUACY SAMPL; Lin PH, 2007, J AM DIET ASSOC, V107, P1541, DOI 10.1016/j.jada.2007.06.019; Malaysia MoH, 2015, CLIN PRACTICE GUIDEL, V5th; McLean G, 2016, J HYPERTENS, V34, P600, DOI 10.1097/HJH.0000000000000859; Ministry of Health Malaysia, 2015, NAT HLTH MORB SURV 2; Ministry of Health Malaysia, 2004, CLIN PRACT GUID MAN; Ministry of Health Malaysia, 2013, CLIN PRACTICE GUIDEL; Neminqani D.M., 2013, INT J SCI RES, V12, P1705; Ngoh SHA, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008568; Orem DE, 1985, CONCEPTS PRACTICE, V3; Resnick B, 2009, J CARDIOVASC NURS, V24, P352, DOI 10.1097/JCN.0b013e3181ac0301; Schroeder K, 2004, ARCH INTERN MED, V164, P722, DOI 10.1001/archinte.164.7.722; Seow KC, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016152; Tahereh Etesamifard, 2014, J BIOL TODAYS WORLD, V3, P275; Tan AKG, 2011, METAB SYNDR RELAT D, V9, P441, DOI 10.1089/met.2011.0031; Taylor SJ., 2014, HEALTH SERV DELIVERY, DOI [10.3310/hsdr02530, DOI 10.3310/HSDR02530]; Verberk WJ, 2011, BLOOD PRESS MONIT, V16, P149, DOI 10.1097/MBP.0b013e328346e092; Warren-Findlow J, 2012, J COMMUN HEALTH, V37, P15, DOI 10.1007/s10900-011-9410-6; WHO, 2013, WHO GLOB BRIEF HYP; WHO, MENS HLTH GAP MEN MU; Zinat Motlagh Sayed Fazel, 2016, IRAN RED CRESCENT ME, V18	38	7	7	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2019	14	11							e0224649	10.1371/journal.pone.0224649	http://dx.doi.org/10.1371/journal.pone.0224649			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN1FJ	31693677	Green Published, gold			2023-01-03	WOS:000532690100033
J	Aljunid, SM; Aung, YN; Ismail, A; Rashid, SAZA; Nur, AM; Cheah, J; Matzen, P				Aljunid, Syed Mohamed; Aung, Yin Nwe; Ismail, Aniza; Rashid, Siti Athirah Zafirah Abdul; Nur, Amrizal M.; Cheah, Julius; Matzen, Priya			Economic burden of hypoglycemia for type II diabetes mellitus patients in Malaysia	PLOS ONE			English	Article							MANAGEMENT; AWARENESS; COST	This study mainly aims to identify the direct cost and economic burden of hypoglycemia for patients with type II diabetes mellitus in Malaysia. A cross-sectional study explored the cost incurred for hypoglycemia among patients admitted to University Kebangsaan Malaysia Medical Centre (UKMMC). The study covered patients aged 20-79 years hospitalized with a primary diagnosis of ICD-10 hypoglycemia and discharged between January 2010 and September 2015 according to the casemix database. A costing analysis was done through a step-down approach from the perspective of health providers. Cost data were collected for three levels of cost centers with the help of a hospital-costing template. The costing data from UKMMC were used to estimate the national burden of hypoglycemia among type II diabetics for the whole country. Of 244 diabetes patients admitted primarily for hypoglycemia to UKMMC, 52% were female and 88% were over 50 years old. The cost increased with severity. Managing a hypoglycemic case requires five days (median) of inpatient stay on average, with a range of 2-26 days, and costs RM 8,949 (USD 2,289). Of the total cost, 30% related to ward (final cost center), 16% to ICU, and 15% to pharmacy (secondary-level cost center) services. Considering that 3.2% of all admissions were hypoglycemia related, the total annual cost of hypoglycemia care for adult diabetics in Malaysia is estimated at RM 117.4 (USD 30.0) million, which translates to 0.5% of the Ministry of Health budget. Hypoglycemia imposes a substantial economic impact even without the direct and indirect cost incurred by patients and other cost of complications. Diabetic management needs to include proper diabetic care and health education to reduce episodes of hypoglycemia.	[Aljunid, Syed Mohamed; Aung, Yin Nwe; Ismail, Aniza; Rashid, Siti Athirah Zafirah Abdul; Nur, Amrizal M.] Univ Kebangsaan Malaysia, Fac Med, Int Ctr Casemix & Clin Coding, Kuala Lumpur, Malaysia; [Aljunid, Syed Mohamed; Nur, Amrizal M.] Kuwait Univ, Fac Publ Hlth, Dept Hlth Policy & Management, Hawalli, Kuwait; [Aung, Yin Nwe] UCSI Univ, Fac Med & Hlth Sci, Dept Pathol & Community Med, Kuala Lumpur, Malaysia; [Cheah, Julius; Matzen, Priya] Novo Nordisk Pharma Malaysia Sdn Bhd, Market Access & Publ Affairs, Kuala Lumpur, Malaysia; [Cheah, Julius] Monash Univ Malaysia, Jeffrey Cheah Sch Med & Hlth Sci, Global Publ Hlth, Kuala Lumpur, Malaysia; [Matzen, Priya] Univ Southampton, Fac Med, Human Dev & Hlth, Southampton, Hants, England	Universiti Kebangsaan Malaysia; Kuwait University; UCSI University; Novo Nordisk; Monash University; Monash University Sunway; University of Southampton	Aljunid, SM (corresponding author), Univ Kebangsaan Malaysia, Fac Med, Int Ctr Casemix & Clin Coding, Kuala Lumpur, Malaysia.; Aljunid, SM (corresponding author), Kuwait Univ, Fac Publ Hlth, Dept Hlth Policy & Management, Hawalli, Kuwait.	saljunid@gmail.com	Aung, Yin Nwe/H-1051-2017; Aung, Yin Nwe/AAD-4187-2019; Aljunid, Syed/J-6009-2014; Ismail, Aniza/AAA-9721-2020	Aung, Yin Nwe/0000-0003-3093-8019; Aljunid, Syed/0000-0002-0380-1335; Ismail, Aniza/0000-0002-5846-4460; MN, Amrizal/0000-0001-7170-0918	Novo Nordisk Pharma (Malaysia) Sdn Bhd [FF-2016-147]; Novo Nordisk Pharma (Malaysia) Sdn Bhd	Novo Nordisk Pharma (Malaysia) Sdn Bhd; Novo Nordisk Pharma (Malaysia) Sdn Bhd	The research project is funded by Novo Nordisk Pharma (Malaysia) Sdn Bhd grant FF-2016-147 to SMA. The funder had no role in the study design, data collection, analysis, decision to publish or preparation of the manuscript.; We would like to acknowledge the financial support we received from Novo Nordisk Pharma (Malaysia) Sdn Bhd to undertake this study. We would also like to extend our gratitude to the Research and Ethics Committee of National University of Malaysia for providing ethical approval to conduct this research. We would also like to acknowledge Dr Letchuman Ramanathan (Hospital Raja Permaisuri Bainun), Prof Dr Nor Azmi Kamaruddin (Universiti Kebangsaan Malaysia), and Dr Zanariah Hussein (Hospital Putrajaya) for their valuable inputs on the estimated prevalence of hospital-admitted hypoglycemia in Malaysia.	Amiel SA, 2008, DIABETIC MED, V25, P245, DOI 10.1111/j.1464-5491.2007.02341.x; [Anonymous], 2015, IDF DIABETES ATLAS; Basevi V, 2011, DIABETES CARE, V34, P1887, DOI 10.2337/dc11-s011; Bloomfield HE., 2012, PREDICTORS CONSEQUEN; Brackenridge A, 2006, EMERG MED J, V23, P183, DOI 10.1136/emj.2005.026252; Crver PE, 2003, GLUCOSE HOMEOSTATIS; Cryer PE, 2004, NEW ENGL J MED, V350, P2272, DOI 10.1056/NEJMra031354; FRIER BM, 1993, BAILLIERE CLIN ENDOC, V7, P757, DOI 10.1016/S0950-351X(05)80218-6; Holstein A, 2002, DIABETES CARE, V25, P2109, DOI 10.2337/diacare.25.11.2109; Holstein A, 2012, DIABETES CARE, V35, P972, DOI 10.2337/dc11-1470; Hussein Z, 2017, DIABETES RES CLIN PR, V133, P40, DOI 10.1016/j.diabres.2017.08.007; Institute for Public Health Ministry of Health Malaysia, 2015, NAT HLTH MORB SURV N; Jonsson L, 2006, VALUE HEALTH, V9, P193, DOI 10.1111/j.1524-4733.2006.00100.x; Jorgensen HV, 2003, DIABETES CARE, V26, P1106, DOI 10.2337/diacare.26.4.1106; Kim G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151282; Leese GP, 2003, DIABETES CARE, V26, P1176, DOI 10.2337/diacare.26.4.1176; Mafauzy BM, 2006, J MED MALAYSIA, V61, P2; McCrimmon RJ, 2010, DIABETES, V59, P2333, DOI 10.2337/db10-0103; McEwan P, 2015, BMJ OPEN DIAB RES CA, V3, DOI 10.1136/bmjdrc-2014-000057; Miller CD, 2001, ARCH INTERN MED, V161, P1653, DOI 10.1001/archinte.161.13.1653; Ministry of Health Malaysia, 2014, MIN HLTH MAL ANN REP; Ministry of Health Malaysia, 2015, NAT HLTH MORB SURV; Moisan J, 2013, CAN J DIABETES, V37, P143, DOI 10.1016/j.jcjd.2013.02.039; OECD, 2014, HLTH GLANC AS PAC 20; PRAMMING S, 1991, DIABETIC MED, V8, P217, DOI 10.1111/j.1464-5491.1991.tb01575.x; Riewpaiboon Arthorn, 2011, Int J Pharm Pract, V19, P342, DOI 10.1111/j.2042-7174.2011.00131.x; Shafiee G, 2012, J DIABETES METAB DIS, V11, DOI 10.1186/2251-6581-11-17; Shepard DS, 2000, ANAL HOSP COST MANUA; Sircar M, 2016, CAN J DIABETES, V40, P66, DOI 10.1016/j.jcjd.2015.10.004	29	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 25	2019	14	10							e0211248	10.1371/journal.pone.0211248	http://dx.doi.org/10.1371/journal.pone.0211248			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN0LX	31652253	Green Published, gold			2023-01-03	WOS:000532638300001
J	Mathais, Q; Montcriol, A; Cotte, J; Gil, C; Contargyris, C; Lacroix, G; Prunet, B; Bordes, J; Meaudre, E				Mathais, Quentin; Montcriol, Ambroise; Cotte, Jean; Gil, Celine; Contargyris, Claire; Lacroix, Guillaume; Prunet, Bertrand; Bordes, Julien; Meaudre, Eric			Anesthesia during deployment of a military forward surgical unit in low income countries: A register study of 1547 anesthesia cases	PLOS ONE			English	Article							RESOURCE-LIMITED SETTINGS; US-MARINE-CORPS; REGIONAL ANESTHESIA; HUMANITARIAN; CARE; OPERATION; CASUALTIES; LESSONS; TEAM; AFGHANISTAN	Background Military anesthesia meets unique logistical, technical, tactical, and human constraints, but to date limited data have been published on anesthesia management during military operations. Objective This study aimed to describe and analyze French anesthetic activity in a deployed military setting. Methods Between October 2015 and February 2018, all patients managed by Sainte-Anne Military Hospital anesthesiologists deployed in mission were included. Anesthesia management was described and compared with the same surgical procedures in France performed by the same anesthesia team (hernia repair, lower and upper limb surgeries). Demographics, type of surgical procedure, and surgical activity were also described. The primary endpoint was to describe anesthesia management during the deployment of forward surgical teams (FST). The secondary endpoint was to compare anesthesia modalities during FST deployment with those usually used in a military teaching hospital. Results During the study period, 1547 instances of anesthesia were performed by 11 anesthesiologists during 20 missions, totaling 1237 days of deployment in nine different theaters. The majority consisted of regional anesthesia, alone (43.5%) or associated with general anesthesia (21%). Compared with France, there was a statistically significant increase in the use of regional anesthesia in hernia repair, lower and upper limb surgeries during deployment. The majority of patients were civilians as part of medical support to populations. Conclusion In the context of an austere environment, the use of regional anesthesia techniques pre-dominated when possible. These results show that the training of military anesthetists must be complete, including anesthesia, intensive care, pediatrics, and regional anesthesia.	[Mathais, Quentin; Montcriol, Ambroise; Cotte, Jean; Gil, Celine; Contargyris, Claire; Lacroix, Guillaume; Bordes, Julien; Meaudre, Eric] Mil Hosp St Anne, Dept Anesthesiol & Intens Care, Toulon, France; [Prunet, Bertrand] Serv Med Brigade Sapeurs Pompiers Paris, Paris, France; [Prunet, Bertrand; Bordes, Julien; Meaudre, Eric] Ecole Val De Grace, French Mil Hlth Serv Acad Unit, Paris, France		Mathais, Q (corresponding author), Mil Hosp St Anne, Dept Anesthesiol & Intens Care, Toulon, France.	quentin.mathais@orange.fr						Agazio J, 2010, INT J NURS PRACT, V16, P166, DOI 10.1111/j.1440-172X.2010.01826.x; Ariyo P, 2016, ANESTHESIOLOGY, V124, P561, DOI 10.1097/ALN.0000000000000985; Bansal T, 2013, JIMSA, V26, P127; Barbier O, 2017, MIL MED, V182, pE1756, DOI 10.7205/MILMED-D-16-00121; Bilski TR, 2003, J TRAUMA, V54, P814, DOI 10.1097/01.TA.0000046627.87250.1D; Bonnet S, 2015, MIL MED, V180, P1075, DOI 10.7205/MILMED-D-14-00688; Bourgouin S, 2017, HERNIA, V21, P749, DOI 10.1007/s10029-017-1631-x; Brethauer SA, 2008, ARCH SURG-CHICAGO, V143, P564, DOI 10.1001/archsurg.143.6.564; Buckenmaier CC, 2003, REGION ANESTH PAIN M, V28, P321, DOI 10.1016/S1098-7339(03)00198-6; Chambers LW, 2006, J TRAUMA, V60, P1155, DOI 10.1097/01.ta.0000220340.91356.7e; Chambers LW, 2005, ARCH SURG-CHICAGO, V140, P26, DOI 10.1001/archsurg.140.1.26; Chmatal P, 2005, MIL MED, V170, P473, DOI 10.7205/MILMED.170.6.473; Cozowicz C, 2016, REGION ANESTH PAIN M, V41, P43, DOI 10.1097/AAP.0000000000000342; d'Aranda Erwan, 2016, J Spec Oper Med, V16, P30, DOI 10.55460/CD5C-3NPJ; De Oliveira GS, 2014, ANESTH ANALG, V118, P454, DOI 10.1213/ANE.0000000000000066; Debas HT, 2015, ESSENTIAL SURG, V1; Donat N, 2017, ANESTH REANIM, V3, P440, DOI 10.1016/j.anrea.2017.06.006; Drifmeyer J, 2004, MIL MED, V169, P23, DOI 10.7205/MILMED.169.1.23; Forrester JD, 2017, SURGERY, V162, P366, DOI 10.1016/j.surg.2017.03.001; French Military Doctrine:, 2014, MED SUPP OP DIA 4 0; French Military Doctrine, 2009, MED AID POP DIA3 10; Gordon S, 2014, SOC SCI MED, V120, P421, DOI 10.1016/j.socscimed.2014.04.025; Gyedu A, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-016-0308-4; Jenkins CL, 2006, MIL MED, V171, P762, DOI 10.7205/MILMED.171.8.762; Kelly J, 2015, J ROY ARMY MED CORPS, V161, P10, DOI 10.1136/jramc-2015-000545; Koscielniak-Nielsen ZJ, 2008, ACTA ANAESTH SCAND, V52, P727, DOI 10.1111/j.1399-6576.2008.01666.x; Lagrew J, 2012, MIL MED, V177, P939, DOI 10.7205/MILMED-D-12-00044; Le TD, 2018, JAMA SURG, V153, P800, DOI 10.1001/jamasurg.2018.1166; Malgras B, 2015, MIL MED, V180, P533, DOI 10.7205/MILMED-D-14-00212; Mercer SJ, 2010, BRIT J ANAESTH, V105, P9, DOI 10.1093/bja/aeq110; Mock CN, 2015, LANCET, V385, P2209, DOI 10.1016/S0140-6736(15)60091-5; Moss NE, 2002, SOC SCI MED, V54, P649, DOI 10.1016/S0277-9536(01)00115-0; NATO, 1997, NATO LOG HDB; Raju M S V K, 2014, Ind Psychiatry J, V23, P149, DOI 10.4103/0972-6748.151693; Ramasamy A, 2009, INJURY, V40, P493, DOI 10.1016/j.injury.2008.03.028; Reade MC, 2000, MED J AUSTRALIA, V173, P586, DOI 10.5694/j.1326-5377.2000.tb139350.x; Tobin J, 2005, J MED ETHICS, V31, P571, DOI 10.1136/jme.2004.008839; Trelles M, 2016, SURGERY, V160, P1414, DOI 10.1016/j.surg.2016.05.024; VLASSOFF C, 1994, SOC SCI MED, V39, P1249, DOI 10.1016/0277-9536(94)90357-3; Walker KJ, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006459.pub2; White RL, 2007, ANESTHESIOLOGY, V107, P1003, DOI 10.1097/01.anes.0000290605.55736.e1; Wilder A, 2010, DISASTERS, V34, pS406, DOI 10.1111/j.1467-7717.2010.01209.x; Wilensky Robert J., 2004, MILITARY MED WIN HEA; Woll M, 2013, MIL MED, V178, P385, DOI 10.7205/MILMED-D-12-00411; Wong EG, 2014, SURGERY, V156, P642, DOI 10.1016/j.surg.2014.02.002; World Health Organization, 2013, WHO MOD LIST ESS MED	46	5	5	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2019	14	10							e0223497	10.1371/journal.pone.0223497	http://dx.doi.org/10.1371/journal.pone.0223497			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM7CZ	31584991	gold, Green Published			2023-01-03	WOS:000532407600042
J	Fahey, CA; Chevrier, J; Crause, M; Obida, M; Bornman, R; Eskenazi, B				Fahey, Carolyn A.; Chevrier, Jonathan; Crause, Madelein; Obida, Muvhulawa; Bornman, Riana; Eskenazi, Brenda			Seasonality of antenatal care attendance, maternal dietary intake, and fetal growth in the VHEMBE birth cohort, South Africa	PLOS ONE			English	Article							MULTIPLE IMPUTATION; WEIGHT-GAIN; RESTRICTION; WOMEN	Background Seasonality of food availability, physical activity, and infections commonly occurs within rural communities in low and middle-income countries with distinct rainy seasons. To better understand the implications of these regularly occurring environmental stressors for maternal and child health, this study examined seasonal variation in nutrition and health care access of pregnant women and infants in rural South Africa. Methods We analyzed data from the Venda Health Examination of Mothers, Babies and their Environment (VHEMBE) birth cohort study of 752 mother-infant pairs recruited at delivery from August 2012 to December 2013 in the Vhembe District of Limpopo Province, the northernmost region of South Africa. We used truncated Fourier series regression to assess seasonality of antenatal care (ANC) attendance, dietary intake, and birth size. We additionally regressed ANC attendance on daily rainfall values. Models included adjustment for sociodemographic characteristics. Results Maternal ANC attendance, dietary composition, and infant birth size exhibited significant seasonal variation in both unadjusted and adjusted analyses. Adequate frequency of ANC attendance during pregnancy (>= 4 visits) was highest among women delivering during the gardening season and lowest during the lean (rainy) season. High rainfall during the third trimester was also negatively associated with adequate ANC attendance (adjusted OR = 0.59, 95% CI: 0.40, 0.86). Carbohydrate intake declined during the harvest season and increased during the vegetable gardening and lean seasons, while fat intake followed the opposite trend. Infant birth weight, length, and head circumference z-scores peaked following the gardening season and were lowest after the harvest season. Maternal protein intake and ANC <= 12 weeks did not significantly vary by season or rainfall. Conclusions Seasonal patterns were apparent in ANC utilization, dietary intake, and fetal growth in rural South Africa. Interventions to promote maternal and child health in similar settings should consider seasonal factors.	[Fahey, Carolyn A.; Eskenazi, Brenda] Univ Calif Berkeley, Sch Publ Hlth, Ctr Environm Res & Childrens Hlth CERCH, Berkeley, CA 94720 USA; [Chevrier, Jonathan] McGill Univ, Fac Med, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Crause, Madelein; Obida, Muvhulawa; Bornman, Riana] Univ Pretoria, Univ Pretoria Inst Sustainable Malaria Control UP, Sch Hlth Syst & Publ Hlth, Pretoria, South Africa	University of California System; University of California Berkeley; McGill University; University of Pretoria	Fahey, CA; Eskenazi, B (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Ctr Environm Res & Childrens Hlth CERCH, Berkeley, CA 94720 USA.	cfahey@berkeley.edu; eskenazi@berkeley.edu		Fahey, Carolyn A./0000-0001-9865-2397	U.S. National Institute of Environmental Health Sciences (NIEHS) [R01ES020360-01]; Canada Research Chairs program (CRC)	U.S. National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Canada Research Chairs program (CRC)(Canada Research ChairsAustralian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme)	Funding for the VHEMBE study was provided by the U.S. National Institute of Environmental Health Sciences (NIEHS: https://www.niehs.nih.gov/index.cfm) (B. Eskenazi, Award ID: R01ES020360-01) and the Canada Research Chairs program (CRC: http://www.chairschaires.gc.ca/home-accueil-eng.aspx) (J. Chevrier). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABRAMS B, 1995, OBSTET GYNECOL, V86, P163, DOI 10.1016/0029-7844(95)00118-B; [Anonymous], 2004, 40 FAO UN; [Anonymous], 2008, ANT CAR COV LEAST ON; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786, DOI 10.1136/bmj.315.7111.786; Chodick G, 2009, HUM BIOL, V81, P463, DOI 10.3378/027.081.0405; Cox NJ, 2006, STATA J, V6, P561, DOI 10.1177/1536867X0600600408; Currie J, 2013, P NATL ACAD SCI USA, V110, P13228, DOI 10.1073/pnas.1307582110; Darrow LA, 2009, EPIDEMIOLOGY, V20, P699, DOI 10.1097/EDE.0b013e3181a66e96; De Cock N, 2013, FOOD SECUR, V5, P269, DOI 10.1007/s12571-013-0247-y; Ebonwu J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191903; Famine Early Warning Systems Network, SO AFR SEAS CAL TYP; Ferro-Luzzi A, 1993, NUTR SEASONALITY DIM; Finlayson K, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001373; Fulford AJC, 2006, PAEDIATR PERINAT EP, V20, P251, DOI 10.1111/j.1365-3016.2006.00714.x; Funk C, 2015, SCI DATA, V2, DOI 10.1038/sdata.2015.66; Glassman A, 2013, J HEALTH POPUL NUTR, V31, P48; Haddad DN, 2016, INT J GYNECOL OBSTET, V132, P64, DOI 10.1016/j.ijgo.2015.06.041; Haklay M, 2008, IEEE PERVAS COMPUT, V7, P12, DOI 10.1109/MPRV.2008.80; Hasan SMT, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212116; Hughes MM, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-310; Kotir Julius H., 2011, Environment Development and Sustainability, V13, P587, DOI 10.1007/s10668-010-9278-0; Lincetto O, 2006, ANTENATAL CARE OPPOR; MacIntyre UE, 2001, PUBLIC HEALTH NUTR, V4, P53, DOI 10.1079/PHN200040; Matsuoka S, 2010, HEALTH POLICY, V95, P255, DOI 10.1016/j.healthpol.2009.12.011; Myer L, 2003, J MIDWIFERY WOM HEAL, V48, P268, DOI 10.1016/S1526-9523(02)00421-X; National Department of Health and ICF, 2019, S AFR DEM HLTH SURV; Pell C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053747; Rao S, 2009, INT J EPIDEMIOL, V38, P1094, DOI 10.1093/ije/dyp223; Rayco-Solon P, 2005, AM J CLIN NUTR, V81, P134; Reason CJC, 2005, INT J CLIMATOL, V25, P1835, DOI 10.1002/joc.1228; Royston P, 2011, J STAT SOFTW, V45, P1, DOI 10.18637/jss.v045.i04; Seaman SR, 2013, STAT METHODS MED RES, V22, P278, DOI 10.1177/0962280210395740; Seaman SR, 2012, BIOMETRICS, V68, P129, DOI 10.1111/j.1541-0420.2011.01666.x; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; Simkhada B, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-34; Strauss RS, 1999, J NUTR, V129, P988, DOI 10.1093/jn/129.5.988; Titaley CR, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-61; Toe LC, 2015, J NUTR, V145, P634, DOI 10.3945/jn.114.203448; Vaitla B, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000101; World Health Organization, 2002, ANT CAR RAND TRIAL M; World Health Organization, 2011, WHO ANTHR VERS 3 2 2; World Health Organization, 2015, WORLD HLTH STAT 2015	43	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2019	14	9							e0222888	10.1371/journal.pone.0222888	http://dx.doi.org/10.1371/journal.pone.0222888			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM5WE	31553767	gold, Green Published			2023-01-03	WOS:000532319200040
J	Chang, TE; Park, S; Yang, QH; Loustalot, F; Butler, J; Ritchey, MD				Chang, Tiffany E.; Park, Soyoun; Yang, Quanhe; Loustalot, Fleetwood; Butler, Javed; Ritchey, Matthew D.			Association between long-term adherence to class-I recommended medications and risk for potentially preventable heart failure hospitalizations among younger adults	PLOS ONE			English	Article							HYDRALAZINE-ISOSORBIDE DINITRATE; CLINICAL EFFECTIVENESS; MEDICARE; IMPACT; MANAGEMENT; BENEFICIARIES; NONADHERENCE; OUTCOMES; THERAPY; COPAYMENT	Background Five guideline-recommended medication categories are available to treat patients who have heart failure (HF) with reduced ejection fraction. However, adherence to these medications is often suboptimal, which places patients at increased risk for poor health outcomes, including hospitalization. We aimed to examine the association between adherence to these medications and potentially preventable HF hospitalizations among younger insured adults with newly diagnosed HF. Methods and results Using the 2008-2012 IBM MarketScan Commercial database, we followed 26,439 individuals aged 18-64 years with newly diagnosed HF and calculated their adherence (using the proportion of days covered (PDC) algorithm) to the five guideline-recommended medication categories: angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers; beta blockers; aldosterone receptor antagonists; hydralazine; and isosorbide dinitrate. We determined the association between PDC and long-term preventable HF hospitalizations (observation years 3-5) as defined by the United States (U.S.) Agency for Healthcare Research and Quality. Overall, 49.0% of enrollees had good adherence (PDC.80%), which was more common among enrollees who were older, male, residing in higher income counties, initially diagnosed with HF in an outpatient setting, and who filled prescriptions for fewer medication categories assessed. Adherence differed by medication category and was lowest for isosorbide dinitrate (PDC = 60.7%). In total, 7.6% of enrollees had preventable HF hospitalizations. Good adherers, compared to poor adherers (PDC< 40%), were 15% less likely to have a preventable hospitalization (HR 0.85, 95% confidence interval, 0.75-0.96). Conclusion We found that approximately half of insured U.S. adults aged 18-64 years with newly diagnosed HF had good adherence to their HF medications. Patients with good adherence, compared to those with poor adherence, were less likely to have a potentially preventable HF hospitalization 3-5 years after their initial diagnosis. Because HF is a chronic condition that requires long-term management, future studies may want to assess the effectiveness of interventions in sustaining adherence.	[Chang, Tiffany E.; Park, Soyoun; Yang, Quanhe; Loustalot, Fleetwood; Ritchey, Matthew D.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA; [Chang, Tiffany E.] IHRC Inc, Atlanta, GA USA; [Butler, Javed] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA	Centers for Disease Control & Prevention - USA; University of Mississippi; University of Mississippi Medical Center	Ritchey, MD (corresponding author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.	mritchey@cdc.gov		Park, Soyoun/0000-0003-1862-6370	NIGMS NIH HHS [U54 GM115428] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agency for Healthcare Research and Quality, GUID PREV QUAL IND H; Agency for Healthcare Research & Quality, PREV QUAL IND TECHN; Aguilar KM, 2015, J MANAG CARE SPEC PH, V21, P670, DOI 10.18553/jmcp.2015.21.8.670; Ambardekar AV, 2009, AM HEART J, V158, P644, DOI 10.1016/j.ahj.2009.07.034; Andersson C, 2014, HEART FAIL CLIN, V10, P377, DOI 10.1016/j.hfc.2014.04.003; Bagchi AD, 2007, CLIN THER, V29, P1771, DOI 10.1016/j.clinthera.2007.08.015; Bansilal S, 2016, J AM COLL CARDIOL, V68, P789, DOI 10.1016/j.jacc.2016.06.005; Bellera CA, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-20; Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI 10.1161/CIR.0000000000000659; Chang LL, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007998; Choudhry NK, 2011, ARCH INTERN MED, V171, P814, DOI 10.1001/archinternmed.2010.495; Choudhry NK, 2009, AM J MANAG CARE, V15, P457; Cole JA, 2006, PHARMACOTHERAPY, V26, P1157, DOI 10.1592/phco.26.8.1157; Cox ZL, 2017, CLIN CARDIOL, V40, P620, DOI 10.1002/clc.22711; Fitzgerald AA, 2011, J CARD FAIL, V17, P664, DOI 10.1016/j.cardfail.2011.04.011; Gourzoulidis G, 2017, HEALTH POLICY, V121, P363, DOI 10.1016/j.healthpol.2017.02.008; Hansen LG, 2011, WHITE PAPER HLTH RES; Heidenreich PA, 2013, CIRC-HEART FAIL, V6, P606, DOI 10.1161/HHF.0b013e318291329a; Heldenbrand S, 2016, J AM PHARM ASSOC, V56, P293, DOI 10.1016/j.japh.2015.12.014; Hincapie AL, 2015, J MANAG CARE SPEC PH, V21, P391, DOI 10.18553/jmcp.2015.21.5.391; Hood SR, 2018, PHARMACOTHERAPY, V38, P539, DOI 10.1002/phar.2107; IMS Health, 2008, UN SYST CLASS USC; Khazanie P, 2016, CIRC-HEART FAIL, V9, P1, DOI 10.1161/CIRCHEARTFAILURE.115.002444; Kronish IM, 2013, PROG CARDIOVASC DIS, V55, P590, DOI 10.1016/j.pcad.2013.02.001; Kuhle J, PQA MEASURES USED CM; Lloyd JT, 2019, MED CARE, V57, P218, DOI 10.1097/MLR.0000000000001067; Lopert R, 2012, AM J MANAG CARE, V18, P556; Mockler M, 2009, AM J CARDIOL, V103, P834, DOI 10.1016/j.amjcard.2008.11.058; Murray MD, 2007, ANN INTERN MED, V146, P714, DOI 10.7326/0003-4819-146-10-200705150-00005; Nair KV, 2011, PATIENT PREFER ADHER, V5, P195, DOI 10.2147/PPA.S18481; National Quality Forum, 2010, NAT VOL CONS STAND M; Nau DP, PROPORTION DAYS COVE; Riegel B, 2014, PATIENT PREFER ADHER, V8, P1, DOI 10.2147/PPA.S54520; Ruppar TM, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002606; Shah KS, 2017, J AM COLL CARDIOL, V70, P2476, DOI 10.1016/j.jacc.2017.08.074; Sherman BW, 2009, AM J MANAG CARE, V15, pE53; Shimp LA, 2012, J AM PHARM ASSOC, V52, P768, DOI 10.1331/JAPhA.2012.11186; Sueta CA, 2015, AM J CARDIOL, V116, P413, DOI 10.1016/j.amjcard.2015.04.058; Svensson S, 2000, INT J CARDIOL, V76, P157, DOI 10.1016/S0167-5273(00)00374-0; Tang J, 2008, STROKE, V39, P1938, DOI 10.1161/STROKEAHA.107.504688; US Food and Drug Administration, NAT DRUG COD DIR; USDHHS HRSA, AR HLTH RES FIL AHRF; Will JC, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110260; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019; Yang QH, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006056; Zhang YT, 2014, J GEN INTERN MED, V29, P602, DOI 10.1007/s11606-013-2692-x; Ziaeian B, 2017, JACC-HEART FAIL, V5, P632, DOI 10.1016/j.jchf.2017.04.008; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	48	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2019	14	9							e0222868	10.1371/journal.pone.0222868	http://dx.doi.org/10.1371/journal.pone.0222868			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM5QI	31545830	Green Published, gold			2023-01-03	WOS:000532303200039
J	Bergot, E; De Leotoing, L; Bendjenana, H; Tournier, C; Vainchtock, A; Nachbaur, G; Humbert, M				Bergot, Emmanuel; De Leotoing, Lucie; Bendjenana, Hakim; Tournier, Charlene; Vainchtock, Alexandre; Nachbaur, Gaelle; Humbert, Marc			Hospital burden of pulmonary arterial hypertension in France	PLOS ONE			English	Article							ECONOMIC BURDEN; COSTS; CARE; EPIDEMIOLOGY; GUIDELINES; DIAGNOSIS; OUTCOMES; US	Background & aims Pulmonary arterial hypertension is a severe disease associated with frequent hospitalisations. This retrospective analysis of the French medical information PMSI-MSO database aimed to describe incident cases of patients with pulmonary arterial hypertension hospitalised in France in 2013 and to document associated hospitalisation costs from the national health insurance perspective. Methods Cases of pulmonary arterial hypertension were identified using a diagnostic algorithm. All cases hospitalised in 2013 with no hospitalisation the previous two years were retained. All hospital stays during the year following the index hospitalisation were extracted, and classified as incident stays, monitoring stays or stays due to disease worsening. Costs were attributed from French national tariffs. Results 384 patients in France were hospitalised with incident pulmonary arterial hypertension in 2013. Over the following twelve months, patients made 1,271 stays related to pulmonary arterial hypertension (415 incident stays, 604 monitoring stays and 252 worsening stays). Mean age was 59.6 years and 241 (62.8%) patients were women. Liver disease and connective tissue diseases were documented in 62 patients (16.1%) each. Thirty-one patients (8.1%) died during hospitalisation and four (1.0%) received a lung/heart-lung transplantation. The total annual cost of these hospitalisations was (sic) 3,640,382. (sic) 2,985,936 was attributable to standard tariffs (82.0%), (sic) 463,325 to additional ICU stays (12.7%) and (sic) 191,118 to expensive drugs (5.2%). The mean cost/stay was (sic) 2,864, ranging from (sic) 1,282 for monitoring stays to (sic) 7,285 for worsening stays. Conclusions Although pulmonary arterial hypertension is rare, it carries a high economic burden.	[Bergot, Emmanuel] CHU Caen, Serv Pneumol & Oncol Thorac, Caen, France; [Bergot, Emmanuel] Unicaen, UFR Sante, Caen, France; [De Leotoing, Lucie; Tournier, Charlene; Vainchtock, Alexandre] HEVA, Lyon, France; [Bendjenana, Hakim; Nachbaur, Gaelle] GlaxoSmithKline, Rueil Malmaison, France; [Humbert, Marc] Univ Paris Sud, Univ Paris Saclay, Fac Med, Le Kremlin Bicetre, France; [Humbert, Marc] Hop Bicetre, AP HP, Serv Pneumol, Le Kremlin Bicetre, France; [Humbert, Marc] INSERM, UMR S 999, Le Kremlin Bicetre, France	CHU de Caen NORMANDIE; Universite de Caen Normandie; Universite de Caen Normandie; GlaxoSmithKline; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Bergot, E (corresponding author), CHU Caen, Serv Pneumol & Oncol Thorac, Caen, France.; Bergot, E (corresponding author), Unicaen, UFR Sante, Caen, France.	bergot.e@gmail.com	Humbert, Marc/AAC-8459-2019; Humbert, Marc/ABD-5112-2021	Humbert, Marc/0000-0003-0703-2892; 	GlaxoSmithKline	GlaxoSmithKline(GlaxoSmithKline)	This study was initiated and funded by GlaxoSmithKline. The sponsor delegated management of the study and data analysis to HEVA (Lyon, France). Representatives of the funders (listed as authors of the study) were involved in study design, the decision to publish, and reviewed the final manuscript before submission. They had no role in data collection or analysis.; The writing and preparation of this manuscript was funded by GlaxoSmithKline. Initial data analyses were undertaken by CT, who is employee of HEVA (Lyon, France) and received funding from GlaxoSmithKline. Editorial support in drafting this manuscript was provided by Adam Doble of Foxymed (Paris, France), and was funded by GlaxoSmithKline. All authors had complete access to the data that supports this publication and have contributed to a draft and approved the manuscript for publication. The corresponding author had the final responsibility to submit for publication.	Angalakuditi Mallik, 2010, J Med Econ, V13, P393, DOI 10.3111/13696998.2010.496694; Bezin J, 2017, PHARMACOEPIDEM DR S, V26, P954, DOI 10.1002/pds.4233; Bouee S, 2013, VALUE HEALTH, V16, pA521, DOI 10.1016/j.jval.2013.08.1256; Burke JP, 2015, AM J MANAG CARE, V21, pS47; Chevalier P, 2014, VALUE HEALTH, V17, pA593, DOI 10.1016/j.jval.2014.08.2037; Escribano-Subias P, 2016, INT J CARDIOL, V203, P938, DOI 10.1016/j.ijcard.2015.11.039; Farber HW, 2015, CHEST, V148, P1043, DOI 10.1378/chest.15-0300; Galie N, 2009, EUR RESPIR J, V34, P1219, DOI 10.1183/09031936.00139009; Galie N, 2016, REV ESP CARDIOL, V69, P177, DOI 10.1016/j.rec.2016.01.002; Gu SY, 2016, PHARMACOECONOMICS, V34, P533, DOI 10.1007/s40273-015-0361-0; Heresi GA, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0399-1; Hoeper MM, 2016, LANCET RESP MED, V4, P306, DOI 10.1016/S2213-2600(15)00543-3; Hoeper MM, 2016, INT J CARDIOL, V203, P612, DOI 10.1016/j.ijcard.2015.11.001; Hoeper MM, 2014, EUR RESPIR REV, V23, P450, DOI 10.1183/09059180.00007814; Hoeper MM, 2013, INT J CARDIOL, V168, P871, DOI 10.1016/j.ijcard.2012.10.026; Humbert M, 2006, AM J RESP CRIT CARE, V173, P1023, DOI 10.1164/rccm.200510-1668OC; Johnson Samuel, 2013, J Med Econ, V16, P1414, DOI 10.3111/13696998.2013.849713; Kirson NY, 2011, APPL HEALTH ECON HEA, V9, P293, DOI 10.2165/11592430-000000000-00000; Ling Y, 2012, AM J RESP CRIT CARE, V186, P790, DOI 10.1164/rccm.201203-0383OC; Maladie Assurance, 2018, PROP ASS MAL 2019; McGoon MD, 2012, EUR RESPIR REV, V21, P8, DOI 10.1183/09059180.00008211; McGoon MD, 2013, J AM COLL CARDIOL, V62, pD51, DOI 10.1016/j.jacc.2013.10.023; Molinari N, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0469-6; Montani D, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-97; Murali S, 2006, CURR OPIN CRIT CARE, V12, P228, DOI 10.1097/01.ccx.0000224867.78581.0c; Provencher S, 2005, CHEST, V128, p622S, DOI 10.1378/chest.128.6_suppl.622S; Said Qayyim, 2012, J Med Econ, V15, P500, DOI 10.3111/13696998.2012.665109; Scan Sante, 2017, PLATEFORME RESTITUTI; Sikirica M, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0676-0; Wilkens H, 2010, RESP MED, V104, P902, DOI 10.1016/j.rmed.2010.01.002; World Health Organization, 2010, INT CLASS DIS	31	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2019	14	9							e0221211	10.1371/journal.pone.0221211	http://dx.doi.org/10.1371/journal.pone.0221211			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM5BF	31536491	Green Published, gold, Green Submitted			2023-01-03	WOS:000532262800015
J	Mendlowitz, AB; Shanbour, A; Downar, J; Vila-Rodriguez, F; Daskalakis, ZJ; Isaranuwatchai, W; Blumberger, DM				Mendlowitz, Andrew B.; Shanbour, Alaa; Downar, Jonathan; Vila-Rodriguez, Fidel; Daskalakis, Zafiris J.; Isaranuwatchai, Wanrudee; Blumberger, Daniel M.			Implementation of intermittent theta burst stimulation compared to conventional repetitive transcranial magnetic stimulation in patients with treatment resistant depression: A cost analysis	PLOS ONE			English	Article							MAJOR DEPRESSION; ELECTROCONVULSIVE-THERAPY; PREFRONTAL CORTEX; RTMS; MANAGEMENT; SAFETY; EFFICACY; NETWORK; MOOD	Background Repetitive transcranial magnetic stimulation (rTMS) is an evidence-based treatment for depression that is increasingly implemented in healthcare systems across the world. A new form of rTMS called intermittent theta burst stimulation (iTBS) can be delivered in 3 min and has demonstrated comparable effectiveness to the conventional 37.5 min 10Hz rTMS protocol in patients with depression. Objectives To compare the direct treatment costs per course and per remission for iTBS compared to 10Hz rTMS treatment in depression. Methods We conducted a cost analysis from a healthcare system perspective using patient-level data from a large randomized non-inferiority trial (THREE-D). Depressed adults 18 to 65 received either 10Hz rTMS or iTBS treatment. Treatment costs were calculated using direct healthcare costs associated with equipment, coils, physician assessments and technician time over the course of treatment. Cost per remission was estimated using the proportion of patients achieving remission following treatment. Deterministic sensitivity analyses and non-parametric bootstrapping was used to estimate uncertainty. Results From a healthcare system perspective, the average cost per patient was USD$1,108 (SD 166) for a course of iTBS and $1,844 (SD 304) for 10Hz rTMS, with an incremental net savings of $735 (95% CI 688 to 783). The average cost per remission was $3,695 (SD 552) for iTBS and $6,146 (SD 1,015) for 10Hz rTMS, with an average incremental net savings of $2,451 (95% CI 2,293 to 2,610). Conclusions The shorter session durations and treatment capacity increase associated with 3 min iTBS translate into significant cost-savings per patient and per remission when compared to 10Hz rTMS.	[Mendlowitz, Andrew B.; Daskalakis, Zafiris J.; Blumberger, Daniel M.] Ctr Addict & Mental Hlth, Temerty Ctr Therapeut Brain Intervent, Toronto, ON, Canada; [Mendlowitz, Andrew B.; Isaranuwatchai, Wanrudee] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Mendlowitz, Andrew B.] Toronto Hlth Econ & Technol Assessment Collaborat, Toronto, ON, Canada; [Shanbour, Alaa; Downar, Jonathan; Daskalakis, Zafiris J.; Blumberger, Daniel M.] Univ Toronto, Fac Med, Dept Psychiat & Inst Med Sci, Toronto, ON, Canada; [Downar, Jonathan] Univ Hlth Network, MRI Guided rTMS Clin, Toronto, ON, Canada; [Downar, Jonathan] Univ Hlth Network, Krembil Res Inst, Toronto, ON, Canada; [Vila-Rodriguez, Fidel] Univ British Columbia Hosp, Noninvas Neurostimulat Therapies NINET Lab, Vancouver, BC, Canada; [Vila-Rodriguez, Fidel] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Isaranuwatchai, Wanrudee] St Michaels Hosp, Ctr Excellence Econ Anal Res, Li Ka Shing Knowledge Inst, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Krembil Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of British Columbia; University of British Columbia; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Blumberger, DM (corresponding author), Ctr Addict & Mental Hlth, Temerty Ctr Therapeut Brain Intervent, Toronto, ON, Canada.; Blumberger, DM (corresponding author), Univ Toronto, Fac Med, Dept Psychiat & Inst Med Sci, Toronto, ON, Canada.	daniel.blumberger@camh.ca	Downar, Jonathan/I-9002-2016	Downar, Jonathan/0000-0002-5140-174X; Vila-Rodriguez, Fidel/0000-0002-8273-8820; Mendlowitz, Andrew/0000-0002-0178-5087	Canadian Institutes of Health Research (CIHR) [MOP-136801]; Temerty Family Foundation; Campbell Family Mental Health Research Institute at the Centre for Addiction and Mental Health; Grant Family Foundation; Tina Buchan and the Buchan Family Fund through the University Health Network	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Temerty Family Foundation; Campbell Family Mental Health Research Institute at the Centre for Addiction and Mental Health; Grant Family Foundation; Tina Buchan and the Buchan Family Fund through the University Health Network	The THREE-D trial was funded by the Canadian Institutes of Health Research (CIHR) (grant number MOP-136801) and supported by the Temerty Family Foundation, Grant Family Foundation and Campbell Family Mental Health Research Institute at the Centre for Addiction and Mental Health and Tina Buchan and the Buchan Family Fund through the University Health Network. Magventure provided in-kind equipment support in the form of two coils and two high performance coolers at each site. Magventure had no role in the study design, data analysis, interpretation, or preparation of this manuscript. None of the investigators receive any financial compensation or hold any interest in Magventure. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bakker N, 2015, BRAIN STIMUL, V8, P208, DOI 10.1016/j.brs.2014.11.002; Baldwin RC, 1997, J AFFECT DISORDERS, V46, P163, DOI 10.1016/S0165-0327(97)00143-2; Blumberger DM, 2018, LANCET, V391, P1683, DOI 10.1016/S0140-6736(18)30295-2; Brooks M., 2018, MEDSCAPE MED NEWS; Brunoni AR, 2017, JAMA PSYCHIAT, V74, P143, DOI 10.1001/jamapsychiatry.2016.3644; Canadian Agency for Drugs and Technology in Health, 2016, ENV SCAN; Di Lazzaro V, 2011, J NEUROPHYSIOL, V105, P2150, DOI 10.1152/jn.00781.2010; Downar J, 2016, CAN MED ASSOC J, V188, P1175, DOI 10.1503/cmaj.151316; Duprat R, 2016, J AFFECT DISORDERS, V200, P6, DOI 10.1016/j.jad.2016.04.015; Friedrich M J, 2017, JAMA, V317, P1517, DOI 10.1001/jama.2017.3826; Gaynes BN, 2014, J CLIN PSYCHIAT, V75, P477, DOI 10.4088/JCP.13r08815; George MS, 2013, CURR OPIN PSYCHIATR, V26, P13, DOI 10.1097/YCO.0b013e32835ab46d; George MS, 2010, ARCH GEN PSYCHIAT, V67, P507, DOI 10.1001/archgenpsychiatry.2010.46; GEORGE MS, 1995, NEUROREPORT, V6, P1853, DOI 10.1097/00001756-199510020-00008; Getty SS, 2017, MENT ILLN, V9, P63, DOI 10.4081/mi.2017.7181; Glick H.A., 2014, EC EVALUATION CLIN T; Health Quality Ontario, 2016, Ont Health Technol Assess Ser, V16, P1; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Li CT, 2014, BRAIN, V137, P2088, DOI 10.1093/brain/awu109; Lisanby SH, 2007, NEW ENGL J MED, V357, P1939, DOI 10.1056/NEJMct075234; Malhi GS, 2005, ACTA PSYCHIAT SCAND, V112, P302, DOI 10.1111/j.1600-0447.2005.00602.x; McClintock SM, 2018, J CLIN PSYCHIAT, V79; Milev RV, 2016, CAN J PSYCHIAT, V61, P561, DOI 10.1177/0706743716660033; National Institute for Health and Care Excellence, 2015, REP TRANSCR MAG STIM; Nemeroff CB, 2007, J CLIN PSYCHIAT, V68, P17; O'Reardon JP, 2007, BIOL PSYCHIAT, V62, P1208, DOI 10.1016/j.biopsych.2007.01.018; Oberman L, 2011, J CLIN NEUROPHYSIOL, V28, P67, DOI 10.1097/WNP.0b013e318205135f; Olchanski N, 2013, CLIN THER, V35, P512, DOI 10.1016/j.clinthera.2012.09.001; PascualLeone A, 1996, LANCET, V348, P233, DOI 10.1016/S0140-6736(96)01219-6; Plewnia C, 2014, J AFFECT DISORDERS, V156, P219, DOI 10.1016/j.jad.2013.12.025; Rizvi SJ, 2014, CAN J PSYCHIAT, V59, P349, DOI 10.1177/070674371405900702; Rush AJ, 2006, AM J PSYCHIAT, V163, P1905, DOI 10.1176/appi.ajp.163.11.1905; Rush AJ, 2006, NEUROPSYCHOPHARMACOL, V31, P1841, DOI 10.1038/sj.npp.1301131; Souery D, 1999, EUR NEUROPSYCHOPHARM, V9, P83, DOI 10.1016/S0924-977X(98)00004-2; U.S. Centers for Medicare and Medicaid Services, 2018, PHYS FEE SCHED SEARC; Vallejo-Torres L, 2015, PSYCHOL MED, V45, P1459, DOI 10.1017/S0033291714002554; WHO, 2011, GLOBAL BURDEN MENTAL	37	11	12	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2019	14	9							e0222546	10.1371/journal.pone.0222546	http://dx.doi.org/10.1371/journal.pone.0222546			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM4IG	31513675	Green Published, gold, Green Submitted			2023-01-03	WOS:000532212700090
J	Chen, JC; Luu, AR; Wise, N; De Angelis, R; Agrawal, V; Mangini, L; Vincelette, J; Handyside, B; Sterling, H; Lo, MJ; Wong, H; Galicia, N; Pacheco, G; Van Vleet, J; Giaramita, A; Fong, S; Roy, SM; Hague, C; Lawrence, R; Bullens, S; Christianson, TM; d'Azzo, A; Crawford, BE; Bunting, S; LeBowitz, JH; Yogalingam, G				Chen, Joseph C.; Luu, Amanda R.; Wise, Nathan; De Angelis, Rolando; Agrawal, Vishal; Mangini, Linley; Vincelette, Jon; Handyside, Britta; Sterling, Harry; Lo, Melanie J.; Wong, Hio; Galicia, Nicole; Pacheco, Glenn; Van Vleet, Jeremy; Giaramita, Alexander; Fong, Sylvia; Roy, Sushmita M.; Hague, Chuck; Lawrence, Roger; Bullens, Sherry; Christianson, Terri M.; d'Azzo, Alessandra; Crawford, Brett E.; Bunting, Stuart; LeBowitz, Jonathan H.; Yogalingam, Gouri			Intracerebroventricular enzyme replacement therapy with beta-galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						lysosomal storage disease; gene therapy; unfolded protein response (UPR); toxicity; biophysics; beta-galactosidase; cation-independent mannose-6-phosphate receptor; enzyme replacement therapy (ERT); lysosome; neurodegeneration; endoplasmic reticulum stress; safety; GM1 gangliosidosis	ER STRESS; BMN 250; ACCUMULATION; DISEASE; PROTEIN; ASSOCIATION; ATTENUATION; JUVENILE; INSULIN; COMPLEX	Autosomal recessive mutations in the galactosidase beta 1 (GLB1) gene cause lysosomal beta-gal deficiency, resulting in accumulation of galactose-containing substrates and onset of the progressive and fatal neurodegenerative lysosomal storage disease, GM1 gangliosidosis. Here, an enzyme replacement therapy (ERT) approach in fibroblasts from GM1 gangliosidosis patients with recombinant human beta-gal (rh beta-gal) produced in Chinese hamster ovary cells enabled direct and precise rh beta-gal delivery to acidified lysosomes. A single, low dose (3 nm) of rh beta-gal was sufficient for normalizing beta-gal activity and mediating substrate clearance for several weeks. We found that rh beta-gal uptake by the fibroblasts is dose-dependent and saturable and can be competitively inhibited by mannose 6-phosphate, suggesting cation-independent, mannose 6-phosphate receptor-mediated endocytosis from the cell surface. A single intracerebroventricularly (ICV) administered dose of rh beta-gal (100 mu g) resulted in broad bilateral biodistribution of rh beta-gal to critical regions of pathology in a mouse model of GM1 gangliosidosis. Weekly ICV dosing of rh beta-gal for 8 weeks substantially reduced brain levels of ganglioside and oligosaccharide substrates and reversed well-established secondary neuropathology. Of note, unlike with the ERT approach, chronic lentivirus-mediated GLB1 overexpression in the GM1 gangliosidosis patient fibroblasts caused accumulation of a prelysosomal pool of beta-gal, resulting in activation of the unfolded protein response and endoplasmic reticulum stress. This outcome was unsurprising in light of ourin vitrobiophysical findings for rh beta-gal, which include pH-dependent and concentration-dependent stability and dynamic self-association. Collectively, our results highlight that ICV-ERT is an effective therapeutic intervention for managing GM1 gangliosidosis potentially more safely than with gene therapy approaches.	[Chen, Joseph C.; Luu, Amanda R.; Wise, Nathan; Agrawal, Vishal; Mangini, Linley; Vincelette, Jon; Handyside, Britta; Lo, Melanie J.; Wong, Hio; Galicia, Nicole; Pacheco, Glenn; Van Vleet, Jeremy; Giaramita, Alexander; Fong, Sylvia; Lawrence, Roger; Bullens, Sherry; Christianson, Terri M.; Crawford, Brett E.; Bunting, Stuart; LeBowitz, Jonathan H.; Yogalingam, Gouri] BioMarin Pharmaceut Inc, Res, Novato, CA 94949 USA; [De Angelis, Rolando; Sterling, Harry; Roy, Sushmita M.; Hague, Chuck] BioMarin Pharmaceut Inc, Proc Sci, Novato, CA 94949 USA; [d'Azzo, Alessandra] St Jude Childrens Res Hosp, Dept Genet, 332 N Lauderdale St, Memphis, TN 38105 USA	BioMarin Pharmaceutical Inc.; BioMarin Pharmaceutical Inc.; St Jude Children's Research Hospital	Yogalingam, G (corresponding author), BioMarin Pharmaceut Inc, 105 Digital Dr, Novato, CA 94949 USA.	gyogalingam@bmrn.com		Fong, Sylvia/0000-0002-3818-4146; Mangini, Linley/0000-0001-8691-7562				Aoyagi-Scharber M, 2017, MOL THER-METH CLIN D, V6, P43, DOI 10.1016/j.omtm.2017.05.009; Baek RC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013468; Bonten EJ, 2014, CELL MOL LIFE SCI, V71, P2017, DOI 10.1007/s00018-013-1538-3; Bonten EJ, 2009, J BIOL CHEM, V284, P28430, DOI 10.1074/jbc.M109.031419; Brinker T, 2014, FLUIDS BARRIERS CNS, V11, DOI 10.1186/2045-8118-11-10; Brunetti-Pierri N, 2008, MOL GENET METAB, V94, P391, DOI 10.1016/j.ymgme.2008.04.012; Caciotti A, 2011, BBA-MOL BASIS DIS, V1812, P782, DOI 10.1016/j.bbadis.2011.03.018; Casado M, 2014, ANAL BIOANAL CHEM, V406, P4337, DOI 10.1007/s00216-014-7832-6; d'Azzo A, 2006, CELL DEATH DIFFER, V13, P404, DOI 10.1038/sj.cdd.4401834; Ellinwood NM, 2018, MOL GENET METAB, V123, pS42, DOI 10.1016/j.ymgme.2017.12.091; Escher C, 2012, PROTEOMICS, V12, P1111, DOI 10.1002/pmic.201100463; Hahn CN, 1997, HUM MOL GENET, V6, P205, DOI 10.1093/hmg/6.2.205; HELMERHORST E, 1987, DIABETES, V36, P261, DOI 10.2337/diabetes.36.3.261; Jeyakumar M, 2003, BRAIN, V126, P974, DOI 10.1093/brain/awg089; Kan S, 2014, P NATL ACAD SCI USA, V111, P14870, DOI 10.1073/pnas.1416660111; Kannebley JS, 2015, JIMD REP, V24, P115, DOI 10.1007/8904_2015_451; KOBAYASHI T, 1986, BIOCHIM BIOPHYS ACTA, V875, P115; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Lawrence R, 2019, MOL GENET METAB REP, V21, DOI 10.1016/j.ymgmr.2019.100524; Luu AR, 2020, J BIOL CHEM, V295, P13556, DOI 10.1074/jbc.RA119.010794; Martin DR, 2008, MOL GENET METAB, V94, P212, DOI 10.1016/j.ymgme.2008.02.004; McCurdy VJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007733; Nestrasil I, 2018, MOL GENET METAB, V123, P97, DOI 10.1016/j.ymgme.2017.12.432; Ohto U, 2012, J BIOL CHEM, V287, P1801, DOI 10.1074/jbc.M111.293795; Piraud M, 2017, RAPID COMMUN MASS SP, V31, P951, DOI 10.1002/rcm.7860; Poswar F, 2017, EXPERT OPIN INV DRUG, V26, P1331, DOI 10.1080/13543784.2017.1397130; Pshezhetsky AV, 1996, J BIOL CHEM, V271, P28359, DOI 10.1074/jbc.271.45.28359; Reiter L, 2011, NAT METHODS, V8, P430, DOI [10.1038/nmeth.1584, 10.1038/NMETH.1584]; Sano R, 2009, MOL CELL, V36, P500, DOI 10.1016/j.molcel.2009.10.021; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Sperb F, 2013, GENE, V512, P113, DOI 10.1016/j.gene.2012.09.106; Takaura N, 2003, GENE THER, V10, P1487, DOI 10.1038/sj.gt.3302033; Tessitore A, 2004, MOL CELL, V15, P753, DOI 10.1016/j.molcel.2004.08.029; Utz JRJ, 2017, MOL GENET METAB, V121, P170, DOI 10.1016/j.ymgme.2017.04.011; van der Spoel A, 2000, J BIOL CHEM, V275, P10035, DOI 10.1074/jbc.275.14.10035; Vistica J, 2004, ANAL BIOCHEM, V326, P234, DOI 10.1016/j.ab.2003.12.014; Yogalingam G, 2008, DEV CELL, V15, P74, DOI 10.1016/j.devcel.2008.05.005; Yogalingam G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0207836; ZHANG SQ, 1994, BIOCHEM J, V304, P281, DOI 10.1042/bj3040281; ZHOU XY, 1995, GENE DEV, V9, P2623, DOI 10.1101/gad.9.21.2623	40	18	18	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	2020	295	39					13532	13555		10.1074/jbc.RA119.009811	http://dx.doi.org/10.1074/jbc.RA119.009811			24	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY3VI	31481471	hybrid, Green Published			2023-01-03	WOS:000576321100010
J	Kam, A; Loo, S; Fan, JS; Sze, SK; Yang, DW; Tam, JP				Kam, Antony; Loo, Shining; Fan, Jing-Song; Sze, Siu Kwan; Yang, Daiwen; Tam, James P.			Roseltide rT7 is a disulfide-rich, anionic, and cell-penetrating peptide that inhibits proteasomal degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						proteasome; cell-penetrating peptide (CPP); peptides; peptide chemical synthesis; enzyme inhibitor; protease inhibitor; structure-function; natural product; drug discovery; drug action; cystine-knot peptide; Hibiscus sabdariffa; plant peptide; proteasome inhibitor; roseltide rT7	NF-KAPPA-B; CRYSTAL-STRUCTURE; 20S PROTEASOME; KNOT; SYSTEM; ACTIVATION; EXPRESSION; PROTEIN; ICAM-1; EPOXOMICIN	Disulfide-rich plant peptides with molecular masses of 2?6 kDa represent an expanding class of peptidyl-type natural products with diverse functions. They are structurally compact, hyperstable, and underexplored as cell-penetrating agents that inhibit intracellular functions. Here, we report the discovery of an anionic, 34-residue peptide, the disulfide-rich roseltide rT7 from Hibiscus sabdariffa (of the Malvaceae family) that penetrates cells and inhibits their proteasomal activities. Combined proteomics and NMR spectroscopy revealed that roseltide rT7 is a cystine-knotted, six-cysteine hevein-like cysteine-rich peptide. A pair-wise comparison indicated that roseltide rT7 is >100-fold more stable against protease degradation than its S-alkylated analog. Confocal microscopy studies and cell-based assays disclosed that after roseltide rT7 penetrates cells, it causes accumulation of ubiquitinated proteins, inhibits human 20S proteasomes, reduces tumor necrosis factor-induced I?B? degradation, and decreases expression levels of intercellular adhesion molecule-1. Structure-activity studies revealed that roseltide rT7 uses a canonical substrate-binding mechanism for proteasomal inhibition enabled by an IIML motif embedded in its proline-rich and exceptionally long intercysteine loop 4. Taken together, our results provide mechanistic insights into a novel disulfide-rich, anionic, and cell-penetrating peptide, representing a potential lead for further development as a proteasomal inhibitor in anti-cancer or anti-inflammatory therapies.	[Kam, Antony; Loo, Shining; Sze, Siu Kwan; Tam, James P.] Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore; [Fan, Jing-Song; Yang, Daiwen] Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore	Tam, JP (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	JPTam@ntu.edu.sg	Sze, Siu Kwan/AAO-3342-2020; Tam, James P/A-2176-2011; yang, daiwen/H-8408-2012; LOO, Shining/AAT-2864-2021	Sze, Siu Kwan/0000-0002-5652-1687; Tam, James P/0000-0003-4433-198X; yang, daiwen/0000-0002-6804-0071; LOO, Shining/0000-0002-2220-8297; Kam, Antony/0000-0003-2155-6887	Nanyang Technological University Internal Funding-Synzymes and Natural Products (SYNC); AcRF Tier 3 funding [MOE2016-T3-1-003]	Nanyang Technological University Internal Funding-Synzymes and Natural Products (SYNC)(Nanyang Technological University); AcRF Tier 3 funding	This work was supported in part by Nanyang Technological University Internal Funding-Synzymes and Natural Products (SYNC) and AcRF Tier 3 funding Grant MOE2016-T3-1-003. The authors declare that they have no conflicts of interest with the contents of this article.	Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; Bard JAM, 2018, ANNU REV BIOCHEM, V87, P697, DOI 10.1146/annurev-biochem-062917-011931; Basit A, 2006, AM J PHYSIOL-LUNG C, V291, pL200, DOI 10.1152/ajplung.00346.2005; Bax M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060581; Beck P, 2012, BIOL CHEM, V393, P1101, DOI 10.1515/hsz-2012-0212; Blackburn C, 2010, BIOCHEM J, V430, P461, DOI 10.1042/BJ20100383; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Budenholzer L, 2017, J MOL BIOL, V429, P3500, DOI 10.1016/j.jmb.2017.05.027; Bundy RE, 2005, ANTIOXID REDOX SIGN, V7, P14, DOI 10.1089/ars.2005.7.14; Cascales L, 2011, J BIOL CHEM, V286, P36932, DOI 10.1074/jbc.M111.264424; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Daly NL, 2011, CURR OPIN CHEM BIOL, V15, P362, DOI 10.1016/j.cbpa.2011.02.008; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Elliott PJ, 2003, J MOL MED, V81, P235, DOI 10.1007/s00109-003-0422-2; Gao XX, 2016, SCI REP-UK, V6, DOI 10.1038/srep35179; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; Grawert MA, 2012, CHEM COMMUN, V48, P1364, DOI 10.1039/c1cc15273d; Greenwood KP, 2007, INT J BIOCHEM CELL B, V39, P2252, DOI 10.1016/j.biocel.2007.06.016; Groll M, 2006, STRUCTURE, V14, P451, DOI 10.1016/j.str.2005.11.019; Groll M, 2000, J AM CHEM SOC, V122, P1237, DOI 10.1021/ja993588m; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Groll M, 2002, CHEM BIOL, V9, P655, DOI 10.1016/S1074-5521(02)00144-8; Groll M, 2004, BBA-MOL CELL RES, V1695, P33, DOI 10.1016/j.bbamcr.2004.09.025; Gunasekera S, 2008, J MED CHEM, V51, P7697, DOI 10.1021/jm800704e; HANADA M, 1992, J ANTIBIOT, V45, P1746, DOI 10.7164/antibiotics.45.1746; Henriques ST, 2010, DRUG DISCOV TODAY, V15, P57, DOI 10.1016/j.drudis.2009.10.007; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; Holden NS, 2004, EUR J BIOCHEM, V271, P785, DOI 10.1111/j.1432-1033.2004.03982.x; Huber EM, 2015, J AM CHEM SOC, V137, P7835, DOI 10.1021/jacs.5b03688; Huma Habib, 2007, Biotechnology and Molecular Biology Reviews, V2, P068; Iyer S, 2011, FEBS J, V278, P4304, DOI 10.1111/j.1742-4658.2011.08350.x; Jha D, 2011, BIOCONJUGATE CHEM, V22, P319, DOI 10.1021/bc100045s; Ji YB, 2013, J AM CHEM SOC, V135, P11623, DOI 10.1021/ja405108p; Kam A, 2019, J BIOL CHEM, V294, P4000, DOI 10.1074/jbc.RA118.006693; Kam A, 2014, INT J CARDIOL, V171, P231, DOI 10.1016/j.ijcard.2013.12.020; Kim KB, 1999, BIOORG MED CHEM LETT, V9, P3335, DOI 10.1016/S0960-894X(99)00612-5; Kloetzel PM, 2004, CURR OPIN IMMUNOL, V16, P76, DOI 10.1016/j.coi.2003.11.004; Konno S, 2002, AM J RESP CELL MOL, V26, P594, DOI 10.1165/ajrcmb.26.5.4438; Kwon YT, 2017, TRENDS BIOCHEM SCI, V42, P873, DOI 10.1016/j.tibs.2017.09.002; Lee W, 2015, BIOINFORMATICS, V31, P1325, DOI 10.1093/bioinformatics/btu830; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loo SN, 2017, FRONT PLANT SCI, V8, DOI 10.3389/fpls.2017.02162; Loo SN, 2016, SCI REP-UK, V6, DOI 10.1038/srep39401; Mae M, 2006, CURR OPIN PHARMACOL, V6, P509, DOI 10.1016/j.coph.2006.04.004; Makarov SS, 2000, MOL MED TODAY, V6, P441, DOI 10.1016/S1357-4310(00)01814-1; Melikov K, 2005, CELL MOL LIFE SCI, V62, P2739, DOI 10.1007/s00018-005-5293-y; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Molesini B, 2017, BRIT J CLIN PHARMACO, V83, P63, DOI 10.1111/bcp.12932; Moore SJ, 2012, METHOD ENZYMOL, V503, P223, DOI 10.1016/B978-0-12-396962-0.00009-4; Northfield SE, 2014, EUR J MED CHEM, V77, P248, DOI 10.1016/j.ejmech.2014.03.011; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Pai P. P., 2017, TOXINS DRUG DISCOVER; Peraro L, 2018, ANGEW CHEM INT EDIT, V57, P11868, DOI 10.1002/anie.201801361; Pereira AR, 2012, CHEMBIOCHEM, V13, P810, DOI 10.1002/cbic.201200007; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Nguyen QT, 2015, J BIOL CHEM, V290, P31138, DOI 10.1074/jbc.M115.654855; Riaz G, 2018, BIOMED PHARMACOTHER, V102, P575, DOI 10.1016/j.biopha.2018.03.023; Richardson Paul G, 2003, Cancer Control, V10, P361; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; Sadler K, 2002, BIOCHEMISTRY-US, V41, P14150, DOI 10.1021/bi026661l; Silverman AP, 2011, J MOL RECOGNIT, V24, P127, DOI 10.1002/jmr.1036; Splith K, 2011, EUR BIOPHYS J BIOPHY, V40, P387, DOI 10.1007/s00249-011-0682-7; Tam JP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33894-x; Varshavsky A, 2017, ANNU REV BIOCHEM, V86, P123, DOI 10.1146/annurev-biochem-061516-044859; Winter MB, 2017, ELIFE, V6, DOI 10.7554/eLife.27364; Wong CTT, 2012, ANGEW CHEM INT EDIT, V51, P5620, DOI 10.1002/anie.201200984; Yabe K, 2009, J BIOCHEM, V145, P217, DOI 10.1093/jb/mvn160; Zhou ZG, 2007, CELL SIGNAL, V19, P1238, DOI 10.1016/j.cellsig.2006.12.013	72	8	8	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2019	294	51					19604	19615		10.1074/jbc.RA119.010796	http://dx.doi.org/10.1074/jbc.RA119.010796			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY0CP	31727740	hybrid, Green Published			2023-01-03	WOS:000504093200013
J	Lascarrou, JB; Merdji, H; Le Gouge, A; Colin, G; Grillet, G; Girardie, P; Coupez, E; Dequin, PF; Cariou, A; Boulain, T; Brule, N; Frat, JP; Asfar, P; Pichon, N; Landais, M; Plantefeve, G; Quenot, JP; Chakarian, JC; Sirodot, M; Legriel, S; Letheulle, J; Thevenin, D; Desachy, A; Delahaye, A; Botoc, V; Vimeux, S; Martino, F; Giraudeau, B; Reignier, J				Lascarrou, J. -B.; Merdji, H.; Le Gouge, A.; Colin, G.; Grillet, G.; Girardie, P.; Coupez, E.; Dequin, P. -F.; Cariou, A.; Boulain, T.; Brule, N.; Frat, J. -P.; Asfar, P.; Pichon, N.; Landais, M.; Plantefeve, G.; Quenot, J. -P.; Chakarian, J. -C.; Sirodot, M.; Legriel, S.; Letheulle, J.; Thevenin, D.; Desachy, A.; Delahaye, A.; Botoc, V.; Vimeux, S.; Martino, F.; Giraudeau, B.; Reignier, J.		CRICS-TRIGGERSEP Grp	Targeted Temperature Management for Cardiac Arrest with Nonshockable Rhythm	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MILD THERAPEUTIC HYPOTHERMIA; CARDIOPULMONARY-RESUSCITATION; TIME; ASSOCIATION; GUIDELINES; CARE; INTERVENTION; HYPERTHERMIA; 33-DEGREES-C; SURVIVAL	BACKGROUND Moderate therapeutic hypothermia is currently recommended to improve neurologic outcomes in adults with persistent coma after resuscitated out-of-hospital cardiac arrest. However, the effectiveness of moderate therapeutic hypothermia in patients with nonshockable rhythms (asystole or pulseless electrical activity) is debated. METHODS We performed an open-label, randomized, controlled trial comparing moderate therapeutic hypothermia (33 degrees C during the first 24 hours) with targeted normothermia (37 degrees C) in patients with coma who had been admitted to the intensive care unit (ICU) after resuscitation from cardiac arrest with nonshockable rhythm. The primary outcome was survival with a favorable neurologic outcome, assessed on day 90 after randomization with the use of the Cerebral Performance Category (CPC) scale (which ranges from 1 to 5, with higher scores indicating greater disability). We defined a favorable neurologic outcome as a CPC score of 1 or 2. Outcome assessment was blinded. Mortality and safety were also assessed. RESULTS From January 2014 through January 2018, a total of 584 patients from 25 ICUs underwent randomization, and 581 were included in the analysis (3 patients withdrew consent). On day 90, a total of 29 of 284 patients (10.2%) in the hypothermia group were alive with a CPC score of 1 or 2, as compared with 17 of 297 (5.7%) in the normothermia group (difference, 4.5 percentage points; 95% confidence interval [CI], 0.1 to 8.9; P = 0.04). Mortality at 90 days did not differ significantly between the hypothermia group and the normothermia group (81.3% and 83.2%, respectively; difference, -1.9 percentage points; 95% CI, -8.0 to 4.3). The incidence of prespecified adverse events did not differ significantly between groups. CONCLUSIONS Among patients with coma who had been resuscitated from cardiac arrest with nonshockable rhythm, moderate therapeutic hypothermia at 33 degrees C for 24 hours led to a higher percentage of patients who survived with a favorable neurologic outcome at day 90 than was observed with targeted normothermia.	[Lascarrou, J. -B.; Brule, N.; Reignier, J.] Univ Hosp Ctr, Med Intens Reanimat, Nantes, France; [Lascarrou, J. -B.; Cariou, A.] Paris Cardiovasc Res Ctr, INSERM, Unite 970, Paris, France; [Cariou, A.] Cochin Univ Hosp Ctr, Med Intens Care Unit, Paris, France; [Lascarrou, J. -B.; Cariou, A.; Pichon, N.; Legriel, S.] AfterROSC Network, Paris, France; [Merdji, H.] Univ Strasbourg, Fac Med, Strasbourg, France; [Merdji, H.] Hop Univ Strasbourg, Nouvel Hop Civil, Serv Med Intens Reanimat, Strasbourg, France; [Merdji, H.] Univ Strasbourg, Federat Med Translat Strasbourg, INSERM, Regenerat Nano Med,UMR 1260, Strasbourg, France; [Le Gouge, A.; Giraudeau, B.] CHRU Tours, INSERM, Ctr Invest Clin CIC 1415, Tours, France; [Dequin, P. -F.] Univ Hosp Ctr, Med Intens Care Unit, Tours, France; [Dequin, P. -F.] Tours Univ, Ctr Etud Pathol Resp, INSERM, UMR 1100, Tours, France; [Giraudeau, B.] Univ Tours, Tours, France; [Colin, G.] Dist Hosp Ctr, Med Surg Intens Care Unit, La Roche Sur Yon, France; [Grillet, G.] South Brittany Gen Hosp Ctr, Med Intens Care Unit, Lorient, France; [Girardie, P.] CHU Lille, Med Intens Reanimat, Lille, France; [Girardie, P.] Univ Lille, Fac Med, Lille, France; [Coupez, E.] Univ Hosp Ctr, Med Intens Care Unit, Clermont Ferrand, France; [Boulain, T.] Reg Hosp Ctr, Med Intens Care Unit, Orleans, France; [Frat, J. -P.] Univ Hosp Ctr, INSERM, CIC 1402, Med Intens Care Unit,Equipe ALIVE, Poitiers, France; [Frat, J. -P.] Univ Poitiers, Fac Med & Pharm Poitiers, Poitiers, France; [Asfar, P.] Univ Hosp Ctr, Med Intens Care Unit, Angers, France; [Pichon, N.] Univ Hosp Ctr, Serv Reanimat Polyvalente, Limoges, France; [Pichon, N.] Univ Hosp Ctr, CIC 1435, Limoges, France; [Landais, M.] Gen Hosp Ctr, Med Surg Intens Care Unit, Le Mans, France; [Plantefeve, G.] Gen Hosp Ctr, Med Surg Intens Care Unit, Argenteuil, France; [Quenot, J. -P.] Univ Hosp Ctr, Med Intens Care Unit, Dijon, France; [Chakarian, J. -C.] Gen Hosp Ctr, Med Surg Intens Care Unit, Roanne, France; [Sirodot, M.] Gen Hosp Ctr, Med Surg Intens Care Unit, Annecy, France; [Legriel, S.] Versailles Hosp, Med Surg Intens Care Unit, Versailles, France; [Letheulle, J.] Gen Hosp Ctr, Med Surg Intens Care Unit, St Brieuc, France; [Thevenin, D.] Gen Hosp Ctr, Med Surg Intens Care Unit, Lens, France; [Desachy, A.] Gen Hosp Ctr, Med Surg Intens Care Unit, Angouleme, France; [Delahaye, A.] Gen Hosp Ctr, Med Surg Intens Care Unit, Rodez, France; [Botoc, V.] Gen Hosp Ctr, Med Surg Intens Care Unit, St Malo, France; [Vimeux, S.] Gen Hosp Ctr, Med Surg Intens Care Unit, Montauban, France; [Martino, F.] Univ Hosp Ctr, Med Intens Care Unit, Point A Pitre, France	Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; CHD Vendee; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; Universite de Lille; CHU Clermont Ferrand; Centre Hospitalier Regional d'Orleans; CHU Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers; Universite de Poitiers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU Limoges; CHU Limoges; Centre Hospitalier Le Mans; CHU Dijon Bourgogne; Centre Hospitalier Annecy Genevois; Centre Hospitalier de Versailles	Lascarrou, JB (corresponding author), CHU Nantes, Serv Med Intens Reanimat, 30 Blvd Jean Monnet, F-44093 Nantes 1, France.	jeanbaptiste.lascarrou@chu-nantes.fr	Giraudeau, Bruno/L-9003-2015; François, Bruno/O-8404-2016; Boulain, Thierry/M-3309-2019; merdji, hamid/GXF-7656-2022; Colin, Gwenhael/AAL-1780-2021; Chiche, Jean-Daniel/P-5220-2017	Giraudeau, Bruno/0000-0003-3031-8258; François, Bruno/0000-0002-2531-1652; Boulain, Thierry/0000-0003-4664-3661; merdji, hamid/0000-0002-4670-1596; Colin, Gwenhael/0000-0001-7607-9913; Chiche, Jean-Daniel/0000-0002-6433-6254; QUENOT, Jean-Pierre/0000-0003-2351-682X; Troche, Gilles/0000-0002-8150-6630; KAMEL, Toufik/0000-0001-6788-2544	French Ministry of Health; nonprofit health care institution Centre Hospitalier Departemental Vendee; Laerdal Foundation	French Ministry of Health; nonprofit health care institution Centre Hospitalier Departemental Vendee; Laerdal Foundation	Supported by independent research grants from the French Ministry of Health, the nonprofit health care institution Centre Hospitalier Departemental Vendee, and the Laerdal Foundation.	[Anonymous], 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-018-0474-7; Argaud L, 2016, JAMA CARDIOL, V1, P557, DOI 10.1001/jamacardio.2016.1701; Becker LB, 2011, CIRCULATION, V124, P2158, DOI 10.1161/CIR.0b013e3182340239; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bougouin W, 2014, INTENS CARE MED, V40, P846, DOI 10.1007/s00134-014-3252-5; Bradley SM, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.4511; Chan PS, 2016, JAMA-J AM MED ASSOC, V316, P1375, DOI 10.1001/jama.2016.14380; Dankiewicz J, 2016, RESUSCITATION, V99, P44, DOI 10.1016/j.resuscitation.2015.10.013; Dumas F, 2011, CIRCULATION, V123, P877, DOI 10.1161/CIRCULATIONAHA.110.987347; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Fayol P., 2004, Annales de Readaptation et de Medecine Physique, V47, P142, DOI 10.1016/j.annrmp.2004.01.004; Frydlandad M, 2015, RESUSCITATION, V89, P142, DOI 10.1016/j.resuscitation.2014.12.033; Harrington D, 2019, NEW ENGL J MED, V381, P285, DOI 10.1056/NEJMe1906559; Hassager C, 2018, LANCET, V391, P989, DOI 10.1016/S0140-6736(18)30315-5; Hasselqvist-Ax I, 2015, NEW ENGL J MED, V372, P2307, DOI 10.1056/NEJMoa1405796; Holzer M, 2002, NEW ENGL J MED, V346, P549; Isaacs E, 2000, ANN EMERG MED, V35, P147, DOI 10.1016/S0196-0644(00)70134-X; JENNETT B, 1975, LANCET, V1, P480; Khera R, 2018, CIRC-CARDIOVASC QUAL, V11, DOI 10.1161/CIRCOUTCOMES.118.004829; Kirkegaard H, 2017, JAMA-J AM MED ASSOC, V318, P341, DOI 10.1001/jama.2017.8978; Lascarrou J, 2012, REANIMATION, V21, pS193; Lascarrou JB, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0103-5; Lascarrou JB, 2014, RESUSCITATION, V85, P1257, DOI 10.1016/j.resuscitation.2014.05.017; Mader TJ, 2014, THER HYPOTHERMIA TEM, V4, P21, DOI 10.1089/ther.2013.0018; Makker P, 2017, THER HYPOTHERMIA TEM, V7, P206, DOI 10.1089/ther.2017.0009; Maupain C, 2016, EUR HEART J, V37, P3222, DOI 10.1093/eurheartj/ehv556; Mongardon N, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-45; Myat A, 2018, LANCET, V391, P970, DOI 10.1016/S0140-6736(18)30472-0; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nolan JP, 2015, RESUSCITATION, V95, P202, DOI 10.1016/j.resuscitation.2015.07.018; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Perkins GD, 2018, NEW ENGL J MED, V379, P711, DOI 10.1056/NEJMoa1806842; Perman SM, 2015, CIRCULATION, V132, P2146, DOI 10.1161/CIRCULATIONAHA.115.016317; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Robert R, 2017, INTENS CARE MED, V43, P1793, DOI 10.1007/s00134-017-4891-0; Testori C, 2012, RESUSCITATION, V83, P596, DOI 10.1016/j.resuscitation.2011.11.019; Testori C, 2011, RESUSCITATION, V82, P1162, DOI 10.1016/j.resuscitation.2011.05.022; Vaahersalo J, 2013, INTENS CARE MED, V39, P826, DOI 10.1007/s00134-013-2868-1; Wissenberg M, 2013, JAMA-J AM MED ASSOC, V310, P1377, DOI 10.1001/jama.2013.278483; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007	40	271	280	1	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 12	2019	381	24					2327	2337		10.1056/NEJMoa1906661	http://dx.doi.org/10.1056/NEJMoa1906661			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ6NZ	31577396	Bronze			2023-01-03	WOS:000505221600007
J	St James, ML; Kosanovich, DL; Snyder, LB; Zhao, QQ; Jones, BG; Johnson, RA				St James, Mariko L.; Kosanovich, DeAnna L.; Snyder, Lindsey B.; Zhao, Qianqian; Jones, Brian G.; Johnson, Rebecca A.			Effects of acupuncture at Pericardium-6 and Stomach-36 on nausea, sedation and gastrointestinal motility in healthy dogs administered intravenous lidocaine infusions	PLOS ONE			English	Article							IMPREGNATED POLYETHYLENE SPHERES; MINIMUM ALVEOLAR CONCENTRATION; CONSTANT RATE INFUSION; POSTOPERATIVE ILEUS; SYSTEMIC LIDOCAINE; RECTAL DISTENSION; HYDROMORPHONE; MAROPITANT; MECHANISMS; PREVENTION	The objectives of this study were to assess gastrointestinal transit times, sedation, and signs of nausea associated with intravenous lidocaine infusions in dogs following targeted acupuncture at Pericardium-6 (PC6) and Stomach-36 (ST36). In a randomized, blind cross-over design, 6 healthy, adult Beagles were fed thirty 1.5 mm barium-impregnated polyethylene spheres (BIPS), then were subject to 30 minutes of: 1) no acupuncture, 2) bilateral targeted acupuncture at PC6 and ST36, or 3) bilateral non-target acupuncture at Lung-5 (LU5) and Bladder-55 (BL55). Lidocaine was immediately administered at 1 mg/kg intravenously followed by 50 mu g/kg/min. BIPS were tracked radiographically; sedation and nausea were scored at baseline (Time 0) and for 11 hours during lidocaine infusions. Transit times and sedation and nausea scores were analyzed with a linear mixed-effects model; the number of BIPS at defined time points was analyzed with a piecewise linear mixed-effects model. All P values were two-sided and P < 0.05 was considered significant. Sedation and nausea scores did not differ between treatments at any time point (all P > 0.05). However, nausea scores in all groups were significantly greater at Times 5 through 7 and at Time 11 compared to Time 0 whereas sedation scores in all groups were significantly greater at Times 2 through 11 compared to Time 0 (all P < 0.05). The number of BIPs found out of the stomach, the number found in the large intestine, gastric emptying and gastrointestinal transit times did not differ between treatments (all P > 0.05). Acupuncture at PC6 and ST36 did not alleviate nausea and sedation associated with lidocaine infusions in clinically normal animals or affect gastric emptying and gastrointestinal transit.	[St James, Mariko L.; Kosanovich, DeAnna L.; Snyder, Lindsey B.; Johnson, Rebecca A.] Univ Wisconsin, Dept Surg Sci, Madison, WI 53706 USA; [Zhao, Qianqian] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; [Jones, Brian G.] Antech Imaging Serv, Fountain Valley, CA USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Johnson, RA (corresponding author), Univ Wisconsin, Dept Surg Sci, Madison, WI 53706 USA.	Rebecca.johnson@wisc.edu			University of Wisconsin's Companion Animal Fund [233 AAD 2554]; Boehringer Ingelheim Veterinary Research Scholars Program	University of Wisconsin's Companion Animal Fund; Boehringer Ingelheim Veterinary Research Scholars Program(Boehringer Ingelheim)	Supported in part by a University of Wisconsin's Companion Animal Fund (233 AAD 2554; RAJ) and the Boehringer Ingelheim Veterinary Research Scholars Program (DLK). Antech Imaging Services provided support in the form of a salary for BGJ. Barium-impregnated spheres were provided by Medical I.D. Systems, Inc, Grand Rapids, MI. No sponsors or funders played any role in the study design, data collection or analysis, decision to publish or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	Acar HV, 2016, COMPLEMENT THER MED, V29, P48, DOI 10.1016/j.ctim.2016.09.013; AlSadi M, 1997, ANAESTHESIA, V52, P658, DOI 10.1111/j.1365-2044.1997.143-az0147.x; CHEONG KB, 2013, PLOS ONE, V8, DOI DOI 10.1371/JOURNAL.PONE.0083474; Chrisman C, 2007, XIES VET ACUPUNCTURE, P134; Cook VL, 2008, JAVMA-J AM VET MED A, V232, P1144, DOI 10.2460/javma.232.8.1144; Doherty TJ, 2009, VET CLIN N AM-EQUINE, V25, P351, DOI 10.1016/j.cveq.2009.04.011; Gilbert RT, 2017, J PERIANESTH NURS, V32, P445, DOI 10.1016/j.jopan.2015.08.014; Gouveia F, 2016, J ACUPUNCT MERIDIAN, V9, P325, DOI 10.1016/j.jams.2016.09.005; Alves IPG, 2014, ACTA CIR BRAS, V29, P245, DOI 10.1590/S0102-86502014000400005; Haker E, 2000, J AUTONOM NERV SYST, V79, P52, DOI 10.1016/S0165-1838(99)00090-9; Hofmeister EH, 2010, JAVMA-J AM VET MED A, V237, P1155, DOI 10.2460/javma.237.10.1155; Jin HF, 2015, AM J PHYSIOL-GASTR L, V309, pG368, DOI 10.1152/ajpgi.00467.2014; Johnson RA, 2017, AM J VET RES, V78, P550, DOI 10.2460/ajvr.78.5.550; Kotani N, 2001, ANESTHESIOLOGY, V95, P349, DOI 10.1097/00000542-200108000-00015; Kraus BLH, 2017, VET MED-RES REP, V8, P41, DOI 10.2147/VMRR.S126469; Kraus BLH, 2014, JAVMA-J AM VET MED A, V244, P1164, DOI 10.2460/javma.244.10.1164; Lamont LA, 2008, VET CLIN N AM-SMALL, V38, P1187, DOI 10.1016/j.cvsm.2008.06.002; Lee A, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003281.pub4; Li H, 2015, WORLD J GASTROENTERO, V21, P8304, DOI 10.3748/wjg.v21.i27.8304; Li JY, 2018, INT J SURG, V50, P137, DOI 10.1016/j.ijsu.2018.01.001; Li QQ, 2013, EVID-BASED COMPL ALT; Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107; Liu JS, 2012, AM J PHYSIOL-REG I, V303, pR209, DOI 10.1152/ajpregu.00301.2010; Lorenzutti AM, 2017, CAN VET J, V58, P35; Lu Z, 2015, BRIT J ANAESTH, V115, P183, DOI 10.1093/bja/aev227; MacDougall LM, 2009, VET ANAESTH ANALG, V36, P512, DOI 10.1111/j.1467-2995.2009.00480.x; Malone E, 2006, VET SURG, V35, P60, DOI 10.1111/j.1532-950X.2005.00113.x; Matic Z, 2020, VOJNOSANIT PREGL, V77, P79, DOI 10.2298/VSP170818016M; Matsubara LM, 2009, VET ANAESTH ANALG, V36, P407, DOI 10.1111/j.1467-2995.2009.00471.x; Mittleman E, 2000, J AM VET MED ASSOC, V217, P1201, DOI 10.2460/javma.2000.217.1201; Nelson OL, 2001, J AM ANIM HOSP ASSOC, V37, P444, DOI 10.5326/15473317-37-5-444; Ortega M, 2011, CAN VET J, V52, P856; Ouyang H, 2002, AM J PHYSIOL-GASTR L, V282, pG390, DOI 10.1152/ajpgi.00272.2001; Radkey DI, 2019, J SMALL ANIM PRACT, V60, P38, DOI 10.1111/jsap.12935; Robertson ID, 2000, VET CLIN N AM-SMALL, V30, P449, DOI 10.1016/S0195-5616(00)50030-8; Scallan EM, 2016, VET ANAESTH ANALG, V43, P495, DOI 10.1111/vaa.12347; Sikander A, 2009, CLIN CHIM ACTA, V403, P47, DOI 10.1016/j.cca.2009.01.028; Smith LJ, 2004, VET ANAESTH ANALG, V31, P53, DOI 10.1111/j.1467-2995.2004.00142.x; Torfs S, 2009, J VET INTERN MED, V23, P606, DOI 10.1111/j.1939-1676.2009.0311.x; Tsai TY, 2013, VET ANAESTH ANALG, V40, P615, DOI 10.1111/vaa.12064; Valverde A, 2004, VET ANAESTH ANALG, V31, P264, DOI 10.1111/j.1467-2995.2004.00165.x; Wagner MC, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1027-2; White A, 2001, Acupunct Med, V19, P84; Xu J, 2008, NEUROGASTROENT MOTIL, V20, P236, DOI 10.1111/j.1365-2982.2007.00995.x; Yu XY, 2009, DIGEST DIS SCI, V54, P922, DOI 10.1007/s10620-008-0470-0; Zhang B, 2018, AM J GASTROENTEROL, V113, P1026, DOI 10.1038/s41395-018-0156-y	46	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2019	14	12							e0226065	10.1371/journal.pone.0226065	http://dx.doi.org/10.1371/journal.pone.0226065			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP0JY	31805134	Green Published, gold			2023-01-03	WOS:000534009700094
J	Nakamura, S; Igaki, H; Ito, M; Okamoto, H; Nishioka, S; Iijima, K; Nakayama, H; Takemori, M; Imamichi, S; Kashihara, T; Takahashi, K; Inaba, K; Okuma, K; Murakami, N; Abe, Y; Nakayama, Y; Masutani, M; Nishio, T; Itami, J				Nakamura, Satoshi; Igaki, Hiroshi; Ito, Masashi; Okamoto, Hiroyuki; Nishioka, Shie; Iijima, Kotaro; Nakayama, Hiroki; Takemori, Mihiro; Imamichi, Shoji; Kashihara, Tairo; Takahashi, Kana; Inaba, Koji; Okuma, Kae; Murakami, Naoya; Abe, Yoshihisa; Nakayama, Yuko; Masutani, Mitsuko; Nishio, Teiji; Itami, Jun			Characterization of the relationship between neutron production and thermal load on a target material in an accelerator-based boron neutron capture therapy system employing a solid-state Li target	PLOS ONE			English	Article							NEAR-THRESHOLD; RECURRENT HEAD; BNCT; BEAM; ENERGY; IRRADIATION; THICKNESS; DESIGN; LI-7(P	An accelerator-based boron neutron capture therapy (BNCT) system that employs a solid-state Li target can achieve sufficient neutron flux derived from the Li-7(p,n) reaction. However, neutron production is complicated by the large thermal load expected on the target. The relationship between neutron production and thermal load was examined under various conditions. A target structure for neutron production consists of a Li target and a target basement. Four proton beam profiles were examined to vary the local thermal load on the target structure while maintaining a constant total thermal load. The efficiency of neutron production was evaluated with respect to the total number of protons delivered to the target structure. The target structure was also evaluated by observing its surface after certain numbers of protons were delivered. The yield of the sputtering effect was calculated via a Monte Carlo simulation to investigate whether it caused complications in neutron production. The efficiency of neutron production and the amount of damage done depended on the proton profile. A more focused proton profile resulted in greater damage. The efficiency decreased as the total number of protons delivered to the target structure increased, and the rate of decrease depended on the proton profile. The sputtering effect was not sufficiently large to be a main factor in the reduction in neutron production. The proton beam profile on the target structure was found to be important to the stable operation of the system with a solid-state Li target. The main factor in the rate of reduction in neutron production was found to be the local thermal load induced by proton irradiation of the target.	[Nakamura, Satoshi; Okamoto, Hiroyuki; Nishioka, Shie; Iijima, Kotaro; Nakayama, Hiroki; Takemori, Mihiro; Itami, Jun] Natl Canc Ctr, Dept Med Phys, Chuo Ku, Tokyo, Japan; [Nakamura, Satoshi; Igaki, Hiroshi; Okamoto, Hiroyuki; Nishioka, Shie; Imamichi, Shoji; Abe, Yoshihisa; Masutani, Mitsuko; Itami, Jun] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Chuo Ku, Tokyo, Japan; [Igaki, Hiroshi; Kashihara, Tairo; Takahashi, Kana; Inaba, Koji; Okuma, Kae; Murakami, Naoya; Nakayama, Yuko; Itami, Jun] Natl Canc Ctr, Dept Radiat Oncol, Chuo Ku, Tokyo, Japan; [Ito, Masashi] Natl Ctr Global Hlth & Med, Dept Radiol, Shinjuku Ku, Tokyo, Japan; [Nakayama, Hiroki; Takemori, Mihiro] Grad Sch Human Hlth Sci, Dept Radiol Sci, Arakawa Ku, Tokyo, Japan; [Imamichi, Shoji; Masutani, Mitsuko] Natl Canc Ctr, Div Cellular Signaling, Lab Collaborat Res, Res Inst,Chuo Ku, Tokyo, Japan; [Abe, Yoshihisa] Natl Canc Ctr, Dept Radiol Technol, Chuo Ku, Tokyo, Japan; [Masutani, Mitsuko] Nagasaki Univ, Ctr Bioinformat & Mol Med, Dept Frontier Life Sci, Grad Sch Biomed Sci, Nagasaki, Japan; [Nishio, Teiji] Tokyo Womens Med Univ, Grad Sch Med, Dept Med Phys, Shinjuku Ku, Tokyo, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Center for Global Health & Medicine - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Nagasaki University; Tokyo Women's Medical University	Igaki, H (corresponding author), Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Chuo Ku, Tokyo, Japan.; Igaki, H (corresponding author), Natl Canc Ctr, Dept Radiat Oncol, Chuo Ku, Tokyo, Japan.	hirigaki@ncc.go.jp	Igaki, Hiroshi/GOH-1916-2022; Murakami, Naoya/J-7671-2019; Itami, Jun/AAB-1380-2022	Igaki, Hiroshi/0000-0001-7817-624X; Murakami, Naoya/0000-0003-0660-9987; 	JSPS [16K10410, 19K17218, 15H04912, 26860410]; National Cancer Center Research and Development Fund [29-A-8, 26-A-18, 23-A-46]	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); National Cancer Center Research and Development Fund(National Cancer Center - Japan)	This work was supported by a JSPS Grant-in-Aid for Young Scientists (Grant Number 19K17218), and JSPS Grant-in-Aid for Young Scientists (B) (Grant Number 26860410), partially supported by a JSPS Grant-in-Aid for Scientific Research (B) (Grant Number 15H0491215H04912), by a JSPS Grant-in-Aid for Scientific Research (C) (Grant Number 16K10410), and by the National Cancer Center Research and Development Fund (29-A-8), (26-A-18), and (23-A-46). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agostinelli S, 2003, NUCL INSTRUM METH A, V506, P250, DOI 10.1016/S0168-9002(03)01368-8; Aihara T, 2014, APPL RADIAT ISOTOPES, V88, P12, DOI 10.1016/j.apradiso.2014.04.007; ALLEN DA, 1995, PHYS MED BIOL, V40, P807, DOI 10.1088/0031-9155/40/5/007; Astrelin VT, 2010, J NUCL MATER, V396, P43, DOI 10.1016/j.jnucmat.2009.10.051; Chiappiniello A, 2018, CURR RADIOPHARM, V11, P92, DOI 10.2174/1874471011666180412170219; Dahl K, 2017, J LABELLED COMPD RAD, V60, P624, DOI 10.1002/jlcr.3561; Hirota Y, 2014, J RADIAT RES, V55, P75, DOI 10.1093/jrr/rrt095; Inoue R, 2014, APPL RADIAT ISOTOPES, V88, P225, DOI 10.1016/j.apradiso.2013.12.017; Kamada S, 2014, APPL RADIAT ISOTOPES, V88, P195, DOI 10.1016/j.apradiso.2014.03.015; Kato I, 2004, APPL RADIAT ISOTOPES, V61, P1069, DOI 10.1016/j.apradiso.2004.05.059; Kobayashi T, 2007, PHYS MED BIOL, V52, P645, DOI 10.1088/0031-9155/52/3/008; Kudriavtsev Y, 2005, APPL SURF SCI, V239, P273, DOI 10.1016/j.apsusc.2004.06.014; Kumada H, 2014, APPL RADIAT ISOTOPES, V88, P211, DOI 10.1016/j.apradiso.2014.02.018; Lee CL, 1999, NUCL INSTRUM METH B, V152, P1, DOI 10.1016/S0168-583X(99)00026-9; Lee CL, 2000, MED PHYS, V27, P192, DOI 10.1118/1.598884; Loeffler MJ, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3079612; Masunaga S, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-128; Minsky DM, 2011, APPL RADIAT ISOTOPES, V69, P1668, DOI 10.1016/j.apradiso.2011.02.047; Nakai K, 2011, APPL RADIAT ISOTOPES, V69, P1790, DOI 10.1016/j.apradiso.2011.03.049; Nakamura S, 2017, P JPN B, V93, P1; Nakamura S, 2019, PHYS MEDICA, V58, P121, DOI 10.1016/j.ejmp.2019.02.010; Nakamura S, 2017, APPL RADIAT ISOTOPES, V125, P80, DOI 10.1016/j.apradiso.2017.03.027; Nakamura S, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2329-7; NICKLES RJ, 1980, NUCL INSTRUM METHODS, V177, P593, DOI 10.1016/0029-554X(80)90077-4; Randers-Pehrson G, 1998, MED PHYS, V25, P894, DOI 10.1118/1.598266; Sun T, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-195; Suzuki M, 2000, JPN J CANCER RES, V91, P1058, DOI 10.1111/j.1349-7006.2000.tb00885.x; Takada M, 2012, NUCL INSTRUM METH A, V689, P22, DOI 10.1016/j.nima.2012.06.019; Tanaka H, 2011, APPL RADIAT ISOTOPES, V69, P1642, DOI 10.1016/j.apradiso.2011.03.020	29	7	7	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 22	2019	14	11							e0225587	10.1371/journal.pone.0225587	http://dx.doi.org/10.1371/journal.pone.0225587			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO8QA	31756237	Green Published, gold			2023-01-03	WOS:000533889300043
J	Bello, AK; Levin, A; Lunney, M; Osman, MA; Ye, F; Ashuntantang, GE; Bellorin-Font, E; Gharbi, MB; Davison, SN; Ghnaimat, M; Harden, P; Htay, H; Jha, V; Kalantar-Zadeh, K; Kerr, PG; Klarenbach, S; Kovesdy, CP; Luyckx, VA; Neuen, BL; O'Donoghue, D; Ossareh, S; Perl, J; Rashid, HU; Rondeau, E; See, E; Saad, S; Sola, L; Tchokhonelidze, I; Tesar, V; Tungsanga, K; Kazancioglu, RT; Wang, AYM; Wiebe, N; Yang, CW; Zemchenkov, A; Zhao, MH; Jager, KJ; Caskey, F; Perkovic, V; Jindal, KK; Okpechi, IG; Tonelli, M; Feehally, J; Harris, DC; Johnson, DW				Bello, Aminu K.; Levin, Adeera; Lunney, Meaghan; Osman, Mohamed A.; Ye, Feng; Ashuntantang, Gloria E.; Bellorin-Font, Ezequiel; Gharbi, Mohammed Benghanem; Davison, Sara N.; Ghnaimat, Mohammad; Harden, Paul; Htay, Htay; Jha, Vivekanand; Kalantar-Zadeh, Kamyar; Kerr, Peter G.; Klarenbach, Scott; Kovesdy, Csaba P.; Luyckx, Valerie A.; Neuen, Brendon L.; O'Donoghue, Donal; Ossareh, Shahrzad; Perl, Jeffrey; Rashid, Harun Ur; Rondeau, Eric; See, Emily; Saad, Syed; Sola, Laura; Tchokhonelidze, Irma; Tesar, Vladimir; Tungsanga, Kriang; Kazancioglu, Rumeyza Turan; Wang, Angela Yee-Moon; Wiebe, Natasha; Yang, Chih-Wei; Zemchenkov, Alexander; Zhao, Ming-hui; Jager, Kitty J.; Caskey, Fergus; Perkovic, Vlado; Jindal, Kailash K.; Okpechi, Ikechi G.; Tonelli, Marcello; Feehally, John; Harris, David C.; Johnson, David W.			Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIALYSIS OUTCOMES; GLOBAL HEALTH; DISPARITIES; ACCESS; HEMODIALYSIS	OBJECTIVE To determine the global capacity (availability, accessibility, quality, and affordability) to deliver kidney replacement therapy (dialysis and transplantation) and conservative kidney management. DESIGN International cross sectional survey. SETTING International Society of Nephrology (ISN) survey of 182 countries from July to September 2018. PARTICIPANTS Key stakeholders identified by ISN's national and regional leaders. MAIN OUTCOME MEASURES Markers of national capacity to deliver core components of kidney replacement therapy and conservative kidney management. RESULTS Responses were received from 160 (87.9%) of 182 countries, comprising 97.8% (7338.5 million of 7501.3 million) of the world's population. A wide variation was found in capacity and structures for kidney replacement therapy and conservative kidney management-namely, funding mechanisms, health workforce, service delivery, and available technologies. Information on the prevalence of treated end stage kidney disease was available in 91 (42%) of 218 countries worldwide. Estimates varied more than 800-fold from 4 to 3392 per million population. Rwanda was the only low income country to report data on the prevalence of treated disease; 5 (<10%) of 53 African countries reported these data. Of 159 countries, 102 (64%) provided public funding for kidney replacement therapy. Sixty eight (43%) of 159 countries charged no fees at the point of care delivery and 34 (21%) made some charge. Haemodialysis was reported as available in 156 (100%) of 156 countries, peritoneal dialysis in 119 (76%) of 156 countries, and kidney transplantation in 114 (74%) of 155 countries. Dialysis and kidney transplantation were available to more than 50% of patients in only 108 (70%) and 45 (29%) of 154 countries that offered these services, respectively. Conservative kidney management was available in 124 (81%) of 154 countries. Worldwide, the median number of nephrologists was 9.96 per million population, which varied with income level. CONCLUSIONS These comprehensive data show the capacity of countries (including low income countries) to provide optimal care for patients with end stage kidney disease. They demonstrate substantial variability in the burden of such disease and capacity for kidney replacement therapy and conservative kidney management, which have implications for policy.	[Bello, Aminu K.; Ye, Feng; Davison, Sara N.; Klarenbach, Scott; Saad, Syed; Wiebe, Natasha; Jindal, Kailash K.] Univ Alberta, Dept Med, Div Nephrol & Immunol, Edmonton, AB T6B 2B7, Canada; [Levin, Adeera] Univ British Columbia, Div Nephrol, Dept Med, Vancouver, BC, Canada; [Lunney, Meaghan] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Osman, Mohamed A.] Univ Ottawa, Ottawa, ON, Canada; [Ashuntantang, Gloria E.] Univ Yaounde, Yaounde Gen Hosp, Fac Med & Biomed Sci, Yaounde, Cameroon; [Bellorin-Font, Ezequiel] St Louis Univ, Dept Med, Div Nephol & Hypertens, St Louis, MO 63103 USA; [Gharbi, Mohammed Benghanem] Univ Hassan II Casablanca, Fac Med & Pharm Casablanca, Urinary Tract Dis Dept, Casablanca, Morocco; [Ghnaimat, Mohammad] Specialty Hosp, Nephrol Div, Dept Internal Med, Amman, Jordan; [Harden, Paul] Oxford Univ Hosp NHS Fdn Trust, Oxford Kidney Unit, Oxford, England; [Htay, Htay] Singapore Gen Hosp, Dept Renal Med, Singapore, Singapore; [Jha, Vivekanand] UNSW, George Inst Global Hlth, New Delhi, India; [Jha, Vivekanand] Univ Oxford, Nuffield Dept Clin Med, Oxford, England; [Jha, Vivekanand] MAHE, Manipal, Karnataka, India; [Kalantar-Zadeh, Kamyar] Univ Calif Irvine, Med Ctr, Div Nephrol & Hypertens, Orange, CA USA; [Kalantar-Zadeh, Kamyar] Univ Calif Los Angeles, Fielding Sch Publ Hlth Irvine & Los Angeles, Los Angeles, CA USA; [Kerr, Peter G.] Monash Hlth, Monash Med Ctr, Dept Nephrol, Clayton, Vic, Australia; [Kerr, Peter G.] Monash Univ, Dept Med, Clayton, Vic, Australia; [Kovesdy, Csaba P.] Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA; [Kovesdy, Csaba P.] Memphis VA Med Ctr, Memphis, TN USA; [Luyckx, Valerie A.] Univ Zurich, Inst Biomed Eth & Hist Med, Zurich, Switzerland; [Luyckx, Valerie A.] Harvard Med Sch, Brigham & Womens Hosp, Renal Div, Boston, MA 02115 USA; [Neuen, Brendon L.] George Inst Global Hlth, Newtown, NSW, Australia; [O'Donoghue, Donal] Salford Royal NHS Fdn Trust, Salford, Lancs, England; [O'Donoghue, Donal] Univ Manchester, Manchester, Lancs, England; [Ossareh, Shahrzad] Iran Univ Med Sci, Hasheminejad Kidney Ctr, Dept Med, Div Nephrol, Tehran, Iran; [Perl, Jeffrey] St Michaels Hosp, Div Nephrol, Toronto, ON, Canada; [Perl, Jeffrey] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON, Canada; [Perl, Jeffrey] Univ Toronto, Dept Med, Div Nephrol, Toronto, ON, Canada; [Rashid, Harun Ur] Kidney Fdn Hosp & Res Inst, Dept Nephrol, Dhaka, Bangladesh; [Rondeau, Eric] Hop Tenon, AP HP, Intens Care Nephrol & Transplantat Dept, Paris, France; [Rondeau, Eric] Sorbonne Univ, Paris, France; [See, Emily] Austin Hlth, Dept Intens Care, Austin, Vic, Australia; [See, Emily] Univ Melbourne, Sch Med, Melbourne, Vic, Australia; [Sola, Laura] CASMU IAMPP, Dialysis Unit, Montevideo, Uruguay; [Tchokhonelidze, Irma; Wang, Angela Yee-Moon] Tbilisi State Med Univ, Nephrol Dev Clin Ctr, Tbilisi, Georgia; [Tesar, Vladimir] Charles Univ Prague, Gen Univ Hosp, Dept Nephrol, Prague, Czech Republic; [Tungsanga, Kriang] Chulalongkorn Univ, King Chulalongkorn Mem Hosp, Fac Med, Dept Med, Bangkok, Thailand; [Tungsanga, Kriang] Bhumirajanagarindra Kidney Inst, Bangkok, Thailand; [Kazancioglu, Rumeyza Turan] Bezmialem Vakif Univ, Div Nephrol, Istanbul, Turkey; Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China; [Yang, Chih-Wei] Chang Gung Mem Hosp, Dept Nephrol, Kidney Res Ctr, Linkou, Taiwan; [Yang, Chih-Wei] Chang Gung Univ, Coll Med, Taoyuan, Taiwan; [Zemchenkov, Alexander] North Western State Med Univ, Dept Internal Dis & Nephrol, St Petersburg, Russia; [Zemchenkov, Alexander] Pavlov First St Petersburg State Med Univ, Dept Nephrol & Dialysis, St Petersburg, Russia; [Zhao, Ming-hui] Peking Univ, Hosp 1, Dept Med, Renal Div, Beijing, Peoples R China; [Zhao, Ming-hui] Minist Hlth China, Key Lab Renal Dis, Beijing, Peoples R China; [Zhao, Ming-hui] Minist Educ China, Key Lab Chron Kidney Dis Prevent & Treatment, Beijing, Peoples R China; [Zhao, Ming-hui] Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China; [Jager, Kitty J.] Univ Amsterdam, Amsterdam Publ Hlth Res Inst, Acad Med Ctr, ERA EDTA Registry,Dept Med Informat, Amsterdam, Netherlands; [Caskey, Fergus] Univ Bristol, Populat Hlth Sci, Bristol, Avon, England; [Caskey, Fergus] North Bristol NHS Trust, Southmead Hosp, Richard Bright Renal Unit, Bristol, Avon, England; [Perkovic, Vlado] Univ New South Wales Sydney, George Inst Global Hlth, Sydney, NSW, Australia; [Okpechi, Ikechi G.] Univ Cape Town, Div Nephrol & Hypertens, Cape Town, South Africa; [Okpechi, Ikechi G.] Univ Cape Town, Kidney & Hypertens Res Unit, Cape Town, South Africa; [Tonelli, Marcello] Univ Calgary, Dept Med, Calgary, AB, Canada; [Tonelli, Marcello] Univ Calgary, Pan Amer Hlth Org, World Hlth Org Collaborating Ctr Prevent & Contro, Calgary, AB, Canada; [Feehally, John] Univ Leicester, Leicester, Leics, England; [Harris, David C.] Univ Sydney, Westmead Inst Med Res, Ctr Transplantat & Renal Res, Sydney, NSW, Australia; [Johnson, David W.] Univ Queensland, Ctr Kidney Dis Res, Brisbane, Qld, Australia; [Johnson, David W.] Translat Res Inst, Brisbane, Qld, Australia; [Johnson, David W.] Princess Alexandra Hosp, Metro South & Ipswich Nephrol & Transplant Serv, Brisbane, Qld, Australia	University of Alberta; University of British Columbia; University of Calgary; University of Ottawa; University of Yaounde I; Saint Louis University; Hassan II University of Casablanca; Oxford University Hospitals NHS Foundation Trust; Singapore General Hospital; University of Oxford; Manipal Academy of Higher Education (MAHE); University of California System; University of California Irvine; University of California System; University of California Los Angeles; Monash University; Monash University; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Zurich; Harvard University; Brigham & Women's Hospital; Harvard Medical School; George Institute for Global Health; University of Sydney; Salford Royal NHS Foundation Trust; University of Manchester; Iran University of Medical Sciences; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Tbilisi State Medical University; Charles University Prague; General University Hospital Prague; Chulalongkorn University; Bezmialem Vakif University; University of Hong Kong; Chang Gung Memorial Hospital; Chang Gung University; North-Western State Medical University named after I.I. Mechnikov; Pavlov First Saint Petersburg State Medical University; Peking University; Ministry of Education, China; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Bristol; North Bristol NHS Trust; Southmead Hospital; George Institute for Global Health; University of New South Wales Sydney; University of Sydney; University of Cape Town; University of Cape Town; University of Calgary; Pan American Health Organization; University of Calgary; University of Leicester; University of Sydney; Westmead Institute for Medical Research; University of Queensland	Bello, AK (corresponding author), Univ Alberta, Dept Med, Div Nephrol & Immunol, Edmonton, AB T6B 2B7, Canada.	aminu1@ualberta.ca	Tesar, Vladimir/O-2312-2017; Luyckx, Valerie/J-9747-2019; Perkovic, Vlado/AAY-1933-2021; Kalantar-Zadeh, Kamyar/Q-4734-2018; Kazancıoğlu, Rümeyza/AAH-7666-2019; Tonelli, Marcello/B-3028-2009; Neuen, Brendon/GLN-5967-2022; Htay, Htay/AAU-8471-2021; Zemchenkov, Alexander Yu/L-9987-2014; Johnson, David/F-2897-2011	Tesar, Vladimir/0000-0001-6982-0689; Luyckx, Valerie/0000-0001-7066-8135; Kalantar-Zadeh, Kamyar/0000-0002-8666-0725; Kazancıoğlu, Rümeyza/0000-0003-1217-588X; Tonelli, Marcello/0000-0002-0846-3187; Htay, Htay/0000-0001-6597-7267; Zemchenkov, Alexander Yu/0000-0002-4590-3380; Neuen, Brendon/0000-0001-9276-8380; Wang, Angela Yee-Moon/0000-0003-2508-7117; Jager, Kitty/0000-0003-0444-8569; Bello, Aminu K/0000-0002-6905-5937; Jha, Vivekanand/0000-0002-8015-9470; Caskey, Fergus/0000-0002-5199-3925; Johnson, David/0000-0001-5491-3460	International Society of Nephrology [RES0033080]	International Society of Nephrology	This work was supported by the International Society of Nephrology (grant RES0033080 to the University of Alberta). The International Society of Nephrology provided administrative support for the design and implementation of the study and data collection activities. The authors were responsible for data management, analysis, and interpretation, as well as manuscript preparation, review, and approval, and the decision to submit the manuscript for publication. The International Society of Nephrology has no role in the analysis, interpretation of data, writing of the manuscript, decision to submit the article for publication.	Annual USRDS, 2018, ANN USRDS; Bello AK, 2017, KIDNEY INT SUPPL, V7, P145, DOI 10.1016/j.kisu.2017.08.001; Bello AK, 2017, JAMA-J AM MED ASSOC, V317, P1864, DOI 10.1001/jama.2017.4046; Bhutta ZA, 2012, JAMA-J AM MED ASSOC, V307, P2035, DOI 10.1001/jama.2012.4659; Coresh J, 2015, LANCET, V385, P1926, DOI 10.1016/S0140-6736(14)61890-0; Crews DC, 2019, KIDNEY INT, V95, P242, DOI 10.1016/j.kint.2018.11.007; Davison SN, 2015, KIDNEY INT, V88, P447, DOI 10.1038/ki.2015.110; Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34; Fuller DS, 2016, J AM SOC NEPHROL, V27, P2205, DOI 10.1681/ASN.2015060673; Gansevoort RT, 2013, LANCET, V382, P339, DOI 10.1016/S0140-6736(13)60595-4; Gostin LO, 2015, JAMA-J AM MED ASSOC, V314, P2621, DOI 10.1001/jama.2015.16281; Gostin LO, 2012, JAMA-J AM MED ASSOC, V307, P2087, DOI 10.1001/jama.2012.4395; Gupta V, 2018, NEW ENGL J MED, V379, P1891, DOI 10.1056/NEJMp1809808; Harris DCH, 2019, KIDNEY INT, V95, pS1, DOI 10.1016/j.kint.2018.12.005; Harrison TG, 2019, AM J KIDNEY DIS, V73, P174, DOI 10.1053/j.ajkd.2018.08.014; Jay CL, 2018, JAMA-J AM MED ASSOC, V319, P24, DOI 10.1001/jama.2017.19617; Jha V, 2017, LANCET, V389, P1851, DOI 10.1016/S0140-6736(16)32408-4; Klarenbach SW, 2014, NAT REV NEPHROL, V10, P644, DOI 10.1038/nrneph.2014.145; Leowski J, 2009, HEALTH POLICY, V92, P43, DOI 10.1016/j.healthpol.2009.02.003; Levey AS, 2012, LANCET, V379, P165, DOI 10.1016/S0140-6736(11)60178-5; Levin Adeera, 2017, Lancet, V390, P1888, DOI 10.1016/S0140-6736(17)30788-2; Liu FX, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0028-2; Liyanage T, 2015, LANCET, V385, P1975, DOI 10.1016/S0140-6736(14)61601-9; Mandayam S, 2017, JAMA-J AM MED ASSOC, V317, P1838, DOI 10.1001/jama.2017.2825; McDermott I, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027622; Moran AE, 2014, GLOB HEART, V9, P3, DOI 10.1016/j.gheart.2014.03.1220; Pisoni RL, 2018, AM J KIDNEY DIS, V71, P469, DOI 10.1053/j.ajkd.2017.09.012; Purnell TS, 2018, JAMA-J AM MED ASSOC, V319, P49, DOI 10.1001/jama.2017.19152; Shah KK, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027776; Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9; The George Institute, AFF DIAL PROJ; Thomas B, 2017, J AM SOC NEPHROL, V28, P2167, DOI 10.1681/ASN.2016050562; Thomas B, 2015, J AM SOC NEPHROL, V26, P2621, DOI 10.1681/ASN.2014101017; Weldring T, 2013, HEALTH SERV INSIGHTS, V6, P61, DOI 10.4137/HSI.S11093; WHO, 2018, 13TH GENERAL PROGRAM; Winkelmayer WC, 2002, MED DECIS MAKING, V22, P417, DOI 10.1177/027298902236927; World Health Organization, 2015, ASS NAT CAP PREV CON; World Health Organization, 2012, GLOBAL OBSERVATORY O; World Health Organization, 2010, MONITORING BUILDING; Xie Y, 2018, KIDNEY INT, V94, P567, DOI 10.1016/j.kint.2018.04.011	40	84	85	1	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 31	2019	367								l5873	10.1136/bmj.l5873	http://dx.doi.org/10.1136/bmj.l5873			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM3YA	31672760	Green Published, Green Accepted, Green Submitted, hybrid			2023-01-03	WOS:000496152800001
J	Amati, M; Grignoli, N; Rubinelli, S; Amann, J; Zanini, C				Amati, Mirjam; Grignoli, Nicola; Rubinelli, Sara; Amann, Julia; Zanini, Claudia			The role of hope for health professionals in rehabilitation: A qualitative study on unfavorable prognosis communication	PLOS ONE			English	Article							BREAKING-BAD-NEWS; PATIENT-CENTERED CARE; OF-LIFE; CHRONIC DISEASE; CANCER CARE; UNCERTAINTY; OUTCOMES; DISABILITY; MANAGEMENT; DELIVERY	Background The communication of prognosis represents an ethical and clinical challenge in medical practice due to the inherent uncertain character of prognostic projections. The literature has stressed that the mode of communicating prognoses has an impact on patients' hope, which is considered to play a major role in adapting to illness and disability. In light of this, this study aims to explore health professionals' (HPs) perceptions of the role of hope in rehabilitation and to examine if and how they use strategies to maintain hope when discussing prognostic information with patients. Methods Eleven qualitative semi-structured interviews with a purposive sample of HPs were conducted at two rehabilitation clinics in the Canton of Ticino, Switzerland. The interviews were analyzed using thematic analysis. Results The HPs perceive hope in rehabilitation as a double-edged sword. Three main strategies were identified to maintain hope while avoiding false hope: 1) giving space for self-evaluation; 2) tailoring the communication of prognostic information; and 3) supporting the patient in dealing with the prognosis. These strategies are particularly suitable when HPs consider that patients might not be ready to accept the prognosis, due to their expectations for recovery. Conclusions The strategies identified here support a person-centered approach to the communication of prognosis and are in line with existing protocols for the communication of unfavorable medical information. The findings emphasize the need for strengthening communication and inter-professional collaboration skills of rehabilitation HPs.	[Amati, Mirjam; Rubinelli, Sara; Amann, Julia; Zanini, Claudia] Univ Lucerne, Dept Hlth Sci & Med, Lucerne Nottwil, Switzerland; [Amati, Mirjam; Rubinelli, Sara; Amann, Julia; Zanini, Claudia] Swiss Parapleg Res, Lucerne Nottwil, Switzerland; [Grignoli, Nicola] Sasso Corbaro Med Humanities Fdn, Bellinzona, Switzerland; [Grignoli, Nicola] Ente Osped Cantonale, Rehabil Clin, Novaggio, Switzerland; [Grignoli, Nicola] Org Sociopsichiatr Cantonale, Psychiat Consultat Liaison Serv, Mendrisio, Switzerland; [Rubinelli, Sara; Amann, Julia; Zanini, Claudia] Swiss Parapleg Res, Nottwil, Switzerland	Swiss Paraplegic Research; Swiss Paraplegic Research	Grignoli, N (corresponding author), Sasso Corbaro Med Humanities Fdn, Bellinzona, Switzerland.; Grignoli, N (corresponding author), Ente Osped Cantonale, Rehabil Clin, Novaggio, Switzerland.; Grignoli, N (corresponding author), Org Sociopsichiatr Cantonale, Psychiat Consultat Liaison Serv, Mendrisio, Switzerland.	nicola.grignoli@eoc.ch	Grignoli, Nicola/I-3819-2019	Grignoli, Nicola/0000-0001-6028-2159	Scientific Research Advisory Board of the Ente Ospedaliero cantonale (ABREOC); Scientific Research Advisory Board of Ente Ospedaliero Cantonale; Sasso Corbaro Medical Humanities Foundation	Scientific Research Advisory Board of the Ente Ospedaliero cantonale (ABREOC); Scientific Research Advisory Board of Ente Ospedaliero Cantonale; Sasso Corbaro Medical Humanities Foundation	This work received a grant from the Scientific Research Advisory Board of the Ente Ospedaliero cantonale (ABREOC) and perceived a salary from the Sasso Corbaro Medical Humanities Foundation for this study to NG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors are grateful to all participants in this study for sharing their experience and to the two clinics involved for their helpfulness and openness. M. Amati carried out this study in partial fulfilment for the requirements for the degree of Master of Arts in Health Sciences, Department of Health Sciences and Health Policy, University of Lucerne, Switzerland. This work was supported by the Scientific Research Advisory Board of Ente Ospedaliero Cantonale and by the Sasso Corbaro Medical Humanities Foundation. The authors thank Giovanni Rabito, Head of quality service and patients' safety REHA TICINO, for providing the data concerning the population of patients admitted to the two rehabilitation clinics. The authors thank John Hodgson for proofreading this article.	Abbaszadeh A, 2014, J MED ETHICS HIST ME, V7, P1; [Anonymous], 2019, WMA DECL HELS ETH PR; ANQ, 2005, PIAN MIS NAZ RIAB MO; Aslakson RA, 2012, J PALLIAT MED, V15, P910, DOI 10.1089/jpm.2011.0481; Aslakson RA, 2010, CRIT CARE, V14, DOI 10.1186/cc9346; Baile W F, 2000, Oncologist, V5, P302, DOI 10.1634/theoncologist.5-4-302; Baile WF, 1999, CANCER-AM CANCER SOC, V86, P887, DOI 10.1002/(SICI)1097-0142(19990901)86:5<887::AID-CNCR27>3.0.CO;2-X; Berger R, 2000, SMITH COLL STUD SOC, V70, P307, DOI 10.1080/00377310009517594; Bhise V, 2018, INT J QUAL HEALTH C, V30, P2, DOI 10.1093/intqhc/mzx170; BOCCOLINI F, 1953, Rev Paul Med, V42, P364; Boonstra AM, 2015, DISABIL REHABIL, V37, P1242, DOI 10.3109/09638288.2014.961657; Braun V., 2013, SUCCESSFUL QUALITATI; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Buckman R., 1992, BREAK BAD NEWS GUIDE; CALMAN KC, 1984, J MED ETHICS, V10, P124, DOI 10.1136/jme.10.3.124; Carod-Artal FJ, 2009, CEREBROVASC DIS, V27, P204, DOI 10.1159/000200461; Carr AJ, 2001, BMJ-BRIT MED J, V322, P1240, DOI 10.1136/bmj.322.7296.1240; Creswell JW, 2000, THEOR PRACT, V39, P124, DOI 10.1207/s15430421tip3903_2; Entwistle VA, 2013, AM J BIOETHICS, V13, P29, DOI 10.1080/15265161.2013.802060; Fallowfield L, 2004, LANCET, V363, P312, DOI 10.1016/S0140-6736(03)15392-5; FALLOWFIELD L, 1993, LANCET, V341, P476, DOI 10.1016/0140-6736(93)90219-7; Foronda C, 2016, NURSE EDUC PRACT, V19, P36, DOI 10.1016/j.nepr.2016.04.005; Goodman SN, 1999, ANN INTERN MED, V130, P604, DOI 10.7326/0003-4819-130-7-199904060-00022; Graz B, 2005, SPINE, V30, P1448, DOI 10.1097/01.brs.0000166508.88846.b3; Guest G, 2011, APPL THEMATIC ANAL, DOI [10.4135/9781483384436, DOI 10.4135/9781483384436]; Hagerty RG, 2005, ANN ONCOL, V16, P1005, DOI 10.1093/annonc/mdi211; Hancock K, 2007, PALLIATIVE MED, V21, P507, DOI 10.1177/0269216307080823; Houghton Catherine E, 2010, Nurse Res, V18, P15; Hudon C, 2012, PATIENT EDUC COUNS, V88, P170, DOI 10.1016/j.pec.2012.01.009; Ignacio JJ, 2013, INT J NURS PRACT, V19, P56, DOI 10.1111/ijn.12017; International Council of Nurses (ICN), 2012, ICN COD ETH NURS; Johnson R., 1997, EDUCATION, V118, P282, DOI DOI 10.1016/J.CEDPSYCH.2016.09.005; Johnson Ros, 2004, Physiother Res Int, V9, P121, DOI 10.1002/pri.312; Koch T, 2001, J MED ETHICS, V27, P370, DOI 10.1136/jme.27.6.370; Korner M, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0888-y; Kortte KB, 2012, REHABIL PSYCHOL, V57, P248, DOI 10.1037/a0029004; Lally J, 2014, ACAD PSYCHIATR, V38, P339, DOI 10.1007/s40596-014-0100-4; Lazarus R, 1999, SOC RES, V66; Leventhal N, 1975, Am Arch Rehabil Ther, V23, P26; LINN BS, 1968, J AM GERIATR SOC, V16, P622, DOI 10.1111/j.1532-5415.1968.tb02103.x; Meyer T, 2011, J REHABIL MED, V43, P765, DOI 10.2340/16501977-0865; Mudge S, 2014, DISABIL REHABIL, V36, P457, DOI 10.3109/09638288.2013.797515; Newman AR, 2016, CANCER NURS, V39, pE48, DOI 10.1097/NCC.0000000000000365; Olsman E, 2016, MED HEALTH CARE PHIL, V19, P11, DOI 10.1007/s11019-015-9642-9; Orb A, 2001, J NURS SCHOLARSHIP, V33, P93, DOI 10.1111/j.1547-5069.2001.00093.x; Patrick L, 2001, J AM GERIATR SOC, V49, P1471, DOI 10.1046/j.1532-5415.2001.4911239.x; Patton MQ, 1999, HEALTH SERV RES, V34, P1189; Phillips BN, 2016, DISABIL REHABIL, V38, P1672, DOI 10.3109/09638288.2015.1107639; Rabow MW, 1999, WESTERN J MED, V171, P260; Rathert C, 2013, MED CARE RES REV, V70, P351, DOI 10.1177/1077558712465774; Roth M, 2007, PSYCHOSOC MED; Sarafis P, 2013, GLOB J HLTH SCI, V6, P128, DOI DOI 10.5539/GJHS.V6N2P128; Saunders B, 2018, QUAL QUANT, V52, P1893, DOI 10.1007/s11135-017-0574-8; Schiavon CC, 2017, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.02022; Seifart C, 2014, ANN ONCOL, V25, P707, DOI 10.1093/annonc/mdt582; Shaw J, 2012, PATIENT EDUC COUNS, V87, P186, DOI 10.1016/j.pec.2011.08.005; Smith AK, 2013, NEW ENGL J MED, V368, P2448, DOI 10.1056/NEJMp1303295; Snyder CR, 2006, REHABIL PSYCHOL, V51, P89, DOI 10.1037/0090-5550.51.2.89; Snyder CR, 2017, OXFORD HDB HOPE; Soundy A, 2014, INT J THER REHABIL, V21, P257, DOI 10.12968/ijtr.2014.21.6.257; Swiss Federal Office of Statistics, 2018, PERS ACT OCC 15 ANS; Thorne SE, 2008, PATIENT EDUC COUNS, V71, P34, DOI 10.1016/j.pec.2007.11.010; Vandekieft GK, 2001, AM FAM PHYSICIAN, V64, P1975; Watkins DC, 2012, HEALTH PROMOT PRACT, V13, P153, DOI 10.1177/1524839912437370; Wiles R, 2004, SOC SCI MED, V59, P1263, DOI 10.1016/j.socscimed.2003.12.022	65	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2019	14	10							e0224394	10.1371/journal.pone.0224394	http://dx.doi.org/10.1371/journal.pone.0224394			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LN0RS	31661529	gold, Green Published			2023-01-03	WOS:000532653400024
J	Cook, R; Davidson, P; Martin, R				Cook, Rob; Davidson, Peter; Martin, Rosie		NIHR Dissemination Ctr	Cardiac rehabilitation for heart failure can improve quality of life and fitness	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Cook, Rob; Martin, Rosie] Bazian, Economist Intelligence Unit Healthcare, London, England; [Davidson, Peter] Univ Southampton, Wessex Inst, Southampton, Hants, England	University of Southampton	Cook, R (corresponding author), Bazian, Economist Intelligence Unit Healthcare, London, England.	rob.cook@bazian.com						British Heart Foundation, 2019, CARDIAC REHABILITATI; British Heart Foundation, 2018, NAT AUD CARD REH NAC; Long L, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003331.pub5; National Institute for Health and Care Excellence, 2013, MYOC INF CARD REH PR; National Institute for Health and Care Excellence, 2018, CHRON HEART FAIL AD	5	3	3	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	2019	367								l5456	10.1136/bmj.l5456	http://dx.doi.org/10.1136/bmj.l5456			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD1ZC	31575520				2023-01-03	WOS:000489773900003
J	Sawyers, CL				Sawyers, Charles L.			Herceptin: A First Assault on Oncogenes that Launched a Revolution	CELL			English	Editorial Material							GROWTH-FACTOR-RECEPTOR; PLUS ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; BREAST-CANCER; TRASTUZUMAB; GENE; AMPLIFICATION; EXPRESSION; SURVIVAL	This year's Lasker Clinical Research Award honors H. Michael Shepard, Dennis J. Slamon, and Axel Ullrich for their invention of Herceptin, the first monoclonal antibody that blocks a cancer-causing protein, and for its development as a life-saving therapy for women with breast cancer.	[Sawyers, Charles L.] Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Human Oncol & Pathogenesis Program, New York, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Sawyers, CL (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Human Oncol & Pathogenesis Program, New York, NY 10021 USA.	sawyersc@mskcc.org						Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Doi T, 2017, LANCET ONCOL, V18, P1512, DOI 10.1016/S1470-2045(17)30604-6; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Perez EA, 2014, J CLIN ONCOL, V32, P3744, DOI 10.1200/JCO.2014.55.5730; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124	18	12	14	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	2019	179	1					8	12		10.1016/j.cell.2019.08.027	http://dx.doi.org/10.1016/j.cell.2019.08.027			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	IY8BG	31519311	Bronze			2023-01-03	WOS:000486618500003
J	Wolkart, G; Kollau, A; Stessel, H; Russwurm, M; Koesling, D; Schrammel, A; Schmidt, K; Mayer, B				Woelkart, Gerald; Kollau, Alexander; Stessel, Heike; Russwurm, Michael; Koesling, Doris; Schrammel, Astrid; Schmidt, Kurt; Mayer, Bernd			Effects of flavoring compounds used in electronic cigarette refill liquids on endothelial and vascular function	PLOS ONE			English	Article							ESSENTIAL OIL; CINNAMALDEHYDE; CALCIUM; EUGENOL; TOBACCO; ARTERIES; SMOKING; 4,5-DIAMINOFLUORESCEIN; INVOLVEMENT; DYSFUNCTION	Electronic cigarette refill liquids are commercially provided with a wide variety of flavoring agents. A recent study suggested that several common flavors may scavenge nitric oxide (NO) and cause endothelial dysfunction. It was the aim of the present study to investigate the effects of these flavors on NO/cyclic GMP-mediated signaling and vascular relaxation. We tested the flavoring agents for effects on Ca2+-induced cGMP accumulation and NO synthase activation in cultured endothelial cells. NO scavenging was studied with NO-activated soluble guanylate cyclase and as NO release from a NO donor, measured with a NO electrode. Blood vessel function was studied with precontracted rat aortic rings in the absence and presence of acetylcholine or a NO donor. Cinnamaldehyde inhibited Ca2+-stimulated endothelial cGMP accumulation and NO synthase activation at >= 0.3 mM. Cinnamaldehyde and diacetyl inhibited NO-activated soluble guanylate cyclase with IC50 values of 0.56 (0.54-0.58) and 0.29 (0.24-0.36) mM, respectively, and caused moderate NO scavenging at 1 mM that was not mediated by superoxide anions. The other compounds did not scavenge NO at 1 mM. None of the flavorings interfered with acetylcholine-induced vascular relaxation, but they caused relaxation of pre-contracted aortas. The most potent compounds were eugenol and cinnamaldehyde with EC50 values of similar to 0.5 mM. Since the flavors did not affect endothelium-dependent vascular relaxation, NO scavenging by cinnamaldehyde and diacetyl does not result in impaired blood vessel function. Although not studied in vivo, the low potency of the compounds renders it unlikely that the observed effects are relevant to humans inhaling flavored vapor from electronic cigarettes.	[Woelkart, Gerald; Kollau, Alexander; Stessel, Heike; Schrammel, Astrid; Schmidt, Kurt; Mayer, Bernd] Karl Franzens Univ Graz, Dept Pharmacol & Toxicol, Inst Pharmaceut Sci, Graz, Austria; [Russwurm, Michael; Koesling, Doris] Ruhr Univ Bochum, Dept Pharmacol & Toxicol, Bochum, Germany	University of Graz; Ruhr University Bochum	Mayer, B (corresponding author), Karl Franzens Univ Graz, Dept Pharmacol & Toxicol, Inst Pharmaceut Sci, Graz, Austria.	mayer@uni-graz.at		Woelkart, Gerald/0000-0003-2552-1999; Mayer, Bernd/0000-0002-2921-3494; Kollau, Alexander/0000-0002-3326-0517	Austrian Science Fund (FWF) [P24946]	Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	This work was supported by the Austrian Science Fund (FWF) grant [P24946] to BM. website: https://www.fwf.ac.at/en/.The FWF had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Balcerczyk A, 2005, FREE RADICAL BIO MED, V39, P327, DOI 10.1016/j.freeradbiomed.2005.03.017; Barboza JN, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3957262; Behar RZ, 2016, TOB CONTROL, V25, pii94, DOI 10.1136/tobaccocontrol-2016-053224; Boulanger CM, 2018, ARTERIOSCL THROM VAS, V38, pE198, DOI 10.1161/ATVBAHA.118.312054; Brass DM, 2017, TOXICOLOGY, V388, P15, DOI 10.1016/j.tox.2017.02.011; Broillet MC, 2001, FEBS LETT, V491, P227, DOI 10.1016/S0014-5793(01)02206-2; Carnevale R, 2016, CHEST, V150, P606, DOI 10.1016/j.chest.2016.04.012; Cheang WS, 2013, EUR J PHARMACOL, V702, P79, DOI 10.1016/j.ejphar.2013.01.028; Damiani CEN, 2003, VASC PHARMACOL, V40, P59, DOI 10.1016/S1537-1891(02)00311-7; Dorri M, 2018, DRUG CHEM TOXICOL, V41, P338, DOI 10.1080/01480545.2017.1417995; Etter JF, 2015, DRUG ALCOHOL DEPEN, V147, P68, DOI 10.1016/j.drugalcdep.2014.12.007; Fagerstrom K, 2012, NICOTINE TOB RES, V14, P75, DOI 10.1093/ntr/ntr137; Farsalinos K, 2019, INTERN EMERG MED, V14, P835, DOI 10.1007/s11739-018-02023-x; Farsalinos KE, 2015, ADDICTION, V110, P1352, DOI 10.1111/add.12942; Farsalinos KE, 2014, THER ADV DRUG SAF, V5, P67, DOI 10.1177/2042098614524430; Farsalinos KE, 2013, INT J ENV RES PUB HE, V10, P5146, DOI 10.3390/ijerph10105146; Fetterman JL, 2018, ARTERIOSCL THROM VAS, V38, P1607, DOI 10.1161/ATVBAHA.118.311156; Friedman M, 2000, J AGR FOOD CHEM, V48, P5702, DOI 10.1021/jf000585g; Hajek P, 2019, NEW ENGL J MED, V380, P629, DOI 10.1056/NEJMoa1808779; Interaminense LFL, 2007, FUND CLIN PHARMACOL, V21, P497, DOI 10.1111/j.1472-8206.2007.00514.x; Johnson CD, 2009, AM J PHYSIOL-HEART C, V296, pH1868, DOI 10.1152/ajpheart.01112.2008; Johnson L., 2018, NICOTINE TOB RES; Jourd'Heuil D, 2002, FREE RADICAL BIO MED, V33, P676, DOI 10.1016/S0891-5849(02)00955-3; Kalkhoran S, 2016, LANCET RESP MED, V4, P116, DOI 10.1016/S2213-2600(15)00521-4; Kapelewski Christine H, 2011, Curr Drug Abuse Rev, V4, P110; Lahlou S, 2004, J CARDIOVASC PHARM, V43, P250, DOI 10.1097/00005344-200402000-00013; LeBouf RF, 2018, ANAL BIOANAL CHEM, V410, P5951, DOI 10.1007/s00216-018-1215-3; Lee CE, 2018, INT C SYNTH MODEL AN, P273; Martuzevicius D, 2018, NICOTINE TOB RES; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; Mills EJ, 2014, CIRCULATION, V129, P28, DOI 10.1161/CIRCULATIONAHA.113.003961; Momtaz S, 2018, PHARMACOL RES, V130, P241, DOI 10.1016/j.phrs.2017.12.011; O'Connell G, 2015, INT J ENV RES PUB HE, V12, P4889, DOI 10.3390/ijerph120504889; Omaiye EE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39550-2; Peixoto-Neves D, 2015, BRIT J PHARMACOL, V172, P3484, DOI 10.1111/bph.13156; Polosa R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14043-2; Polosa R, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0481-x; Polosa R, 2016, DISCOV MED, V21, P99; Pozsgai G, 2010, CARDIOVASC RES, V87, P760, DOI 10.1093/cvr/cvq118; Putzhammer R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157337; Raffai G, 2015, J PHARMACOL EXP THER, V352, P14, DOI 10.1124/jpet.114.217935; Raffai G, 2014, INT J NANOMED, V9, P2557, DOI 10.2147/IJN.S56578; Russell C, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0238-6; Russwurm M, 2005, METHOD ENZYMOL, V396, P492, DOI 10.1016/S0076-6879(05)96041-2; Schmidt K, 1999, EUR J BIOCHEM, V259, P25, DOI 10.1046/j.1432-1327.1999.00003.x; SCHMIDT K, 1989, EUR J PHARMACOL, V170, P157, DOI 10.1016/0014-2999(89)90536-0; Schneller LM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202744; Schweitzer KS, 2015, AM J PHYSIOL-LUNG C, V309, pL175, DOI 10.1152/ajplung.00411.2014; Silva DF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143171; Simmons VN, 2016, ADDICT RES THEORY, V24, P313, DOI 10.3109/16066359.2016.1139700; Soares PMG, 2007, LIFE SCI, V81, P1085, DOI 10.1016/j.lfs.2007.08.027; Sun L, 2017, J ETHNOPHARMACOL, V206, P107, DOI 10.1016/j.jep.2017.05.023; van Drooge BL, 2019, ENVIRON SCI POLLUT R, V26, P4654, DOI 10.1007/s11356-018-3975-x; Vanhoutte PM, 2009, ACTA PHYSIOL, V196, P193, DOI 10.1111/j.1748-1716.2009.01964.x; Vasconcelos NG, 2018, MICROB PATHOGENESIS, V120, P198, DOI 10.1016/j.micpath.2018.04.036; Walele T, 2018, REGUL TOXICOL PHARM, V92, P226, DOI 10.1016/j.yrtph.2017.12.010; Wang F, 2015, CELL PHYSIOL BIOCHEM, V36, P315, DOI 10.1159/000374074; Wei BN, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15020201; Wolkart G, 2017, BRIT J PHARMACOL, V174, P3640, DOI 10.1111/bph.13967; YUAN JH, 1992, FOOD CHEM TOXICOL, V30, P997, DOI 10.1016/0278-6915(92)90109-X; Zhao H, 2014, J PHARMACEUT BIOMED, V89, P150, DOI 10.1016/j.jpba.2013.10.044	61	10	10	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2019	14	9							e0222152	10.1371/journal.pone.0222152	http://dx.doi.org/10.1371/journal.pone.0222152			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM3GL	31498828	gold, Green Published, Green Submitted			2023-01-03	WOS:000532138700036
J	Zhang, BB; Kan, LD; Dong, AQ; Zhang, JQ; Bai, ZF; Xie, Y; Liu, QH; Peng, YZ				Zhang, Bingbing; Kan, Laidi; Dong, Anqin; Zhang, Jiaqi; Bai, Zhongfei; Xie, Yi; Liu, Qianhao; Peng, Yuzhong			The effects of action observation training on improving upper limb motor functions in people with stroke: A systematic review and meta-analysis	PLOS ONE			English	Review							ACTION OBSERVATION THERAPY; MIRROR NEURONS; RECOVERY; REHABILITATION; IMPACT; NEUROREHABILITATION; DEXTERITY	Background and objective Action observation training (AOT) has been used as a new intervention for improving upper limb motor functions in people with stroke. This systematic review and meta-analysis aims to investigate the effects of AOT on improving upper limb motor functions in people with stroke. Methods We searched ten electronic databases to identify randomized controlled trials (RCTs) about the effects of AOT on upper limb motor functions in stroke survivors. Methodological quality of included studies was assessed by the Risk of Bias Tool in the Cochrane Handbook for Systematic Reviews of Interventions. A random-effects meta-analysis was performed by pooling the standardized mean difference (SMD) of upper limb motor outcomes. Results Seven studies of 276 participants with stroke were included. Meta-analysis showed a significant effect favoring AOT on improving upper limb motor functions in patients with stroke [SMD = 0.35, 95% confidence interval [CI], 0.10 to 0.61, I-2 = 10.14%, p = 0.007]. Conclusions AOT appears to be an effective intervention for improving the upper limb motor functions in people after stroke. Further studies need to investigate the neural mechanism underlying the effects of AOT.	[Zhang, Bingbing; Kan, Laidi; Dong, Anqin; Liu, Qianhao; Peng, Yuzhong] Zhengzhou Univ, Affiliated Hosp 5, Dept Rehabil Med, Zhengzhou, Henan, Peoples R China; [Zhang, Bingbing] Hong Kong Polytech Univ, Dept Biomed Engn, Hong Kong, Peoples R China; [Zhang, Jiaqi; Bai, Zhongfei] Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Peoples R China; [Bai, Zhongfei] Shanghai Yangzhi Rehabil Hosp, Shanghai Sunshine Rehabil Ctr, Dept Occupat Therapy, Shanghai, Peoples R China; [Xie, Yi] Zhengzhou Univ, Affiliated Hosp 5, Dept Rehabil Engn, Zhengzhou, Henan, Peoples R China	Zhengzhou University; Hong Kong Polytechnic University; Hong Kong Polytechnic University; Zhengzhou University	Dong, AQ (corresponding author), Zhengzhou Univ, Affiliated Hosp 5, Dept Rehabil Med, Zhengzhou, Henan, Peoples R China.	vicky.dong@hotmail.com	ZHANG, Jack Jiaqi/GNP-0712-2022	ZHANG, Jack Jiaqi/0000-0002-4656-1909; Dong, Vicky/0000-0003-1084-6184; Bai, Zhongfei/0000-0001-9800-7080; Kan, Laidi/0000-0003-0894-0243				Bahr F, 2018, NEURAL PLAST, V2018, DOI 10.1155/2018/8369262; Borenstein M, 2017, RES SYNTH METHODS, V8, P5, DOI 10.1002/jrsm.1230; Borenstein M, 2013, PREV SCI, V14, P134, DOI 10.1007/s11121-013-0377-7; Broeks JG, 1999, DISABIL REHABIL, V21, P357; Brunner IC, 2014, NEUROREHAB NEURAL RE, V28, P874, DOI 10.1177/1545968314527350; Cameirao MS, 2012, STROKE, V43, P2720, DOI 10.1161/STROKEAHA.112.653196; Carvalho Diana, 2013, Int Arch Med, V6, P41, DOI 10.1186/1755-7682-6-41; Chhatbar PY, 2016, BRAIN STIMUL, V9, P16, DOI 10.1016/j.brs.2015.09.002; Corbetta D, 2015, COCHRANE DATABASE SY, V2015; Cowles T, 2013, NEUROREHAB NEURAL RE, V27, P173, DOI 10.1177/1545968312452470; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ertelt D, 2007, NEUROIMAGE, V36, pT164, DOI 10.1016/j.neuroimage.2007.03.043; Fabbri-Destro M, 2008, PHYSIOLOGY, V23, P171, DOI 10.1152/physiol.00004.2008; Favre I, 2014, STROKE, V45, P1077, DOI 10.1161/STROKEAHA.113.003168; Franceschini M, 2012, NEUROREHAB NEURAL RE, V26, P456, DOI 10.1177/1545968311427406; Fritz CO, 2012, J EXP PSYCHOL GEN, V141, P2, DOI 10.1037/a0024338; Fu JM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008080; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Kim E, 2015, J PHYS THER SCI, V27, P2867, DOI 10.1589/jpts.27.2867; Koski L, 2002, CEREB CORTEX, V12, P847, DOI 10.1093/cercor/12.8.847; Kuk EJ, 2016, TOP STROKE REHABIL, V23, P318, DOI 10.1080/10749357.2016.1157972; Kwakkel G, 2003, STROKE, V34, P2181, DOI 10.1161/01.STR.0000087172.16305.CD; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Liew SL, 2012, OTJR-OCCUP PART HEAL, V32, P79, DOI 10.3928/15394492-20111209-01; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Mendis S, 2013, INT J STROKE, V8, P3, DOI 10.1111/j.1747-4949.2012.00969.x; Nilsen DM, 2015, AM J OCCUP THER, V69, P31, DOI 10.5014/ajot.2015.011965; Sarasso Elisabetta, 2015, Arch Physiother, V5, P14, DOI 10.1186/s40945-015-0013-x; Small SL, 2013, NAT REV NEUROL, V9, P698, DOI 10.1038/nrneurol.2013.222; Takeuchi N, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/128641; Yuan TF, 2015, CNS NEUROL DISORD-DR, V14, P1267, DOI 10.2174/1871527315666151111130956; Zhu MH, 2015, Int J Nurs Sci, V2, P279, DOI 10.1016/j.ijnss.2015.08.006; 김창현, 2016, [Journal of the Korean Society of Physical Medicine, 대한물리의학회지], V11, P133, DOI 10.13066/kspm.2016.11.1.133	33	13	14	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2019	14	8							e0221166	10.1371/journal.pone.0221166	http://dx.doi.org/10.1371/journal.pone.0221166			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW6BO	31469840	gold, Green Published, Green Submitted			2023-01-03	WOS:000485062200012
J	de Azevedo, LFC; Ferreira, TAA; Melo, KM; Dias, CLP; Bastos, CEMC; Santos, SF; Santos, AD; Nagamachi, CY; Pieczarka, JC				Calandrini de Azevedo, Luana Franca; Alves Ferreira, Tassia Alana; Melo, Karina Motta; Porfirio Dias, Clara Louise; Matos Carvalho Bastos, Carlos Eduardo; Santos, Seidel Ferreira; Santos, Alberdan da Silva; Nagamachi, Cleusa Yoshiko; Pieczarka, Julio Cesar			Aqueous ethanol extract of Libidibia ferrea (Mart. Ex Tul) LP Queiroz (juca) exhibits antioxidant and migration-inhibiting activity in human gastric adenocarcinoma (ACP02) cells	PLOS ONE			English	Article							PHENOLIC-COMPOUNDS; DNA-DAMAGE; IN-VITRO; ASSAY; LINE	Libidibia ferrea (juca) is a plant belonging to the Fabaceae (Leguminosae) family, whose antioxidant activity has been widely described in the literature. We evaluated this parameter of Aqueous ethanol extract (AE), ethyl acetate (ACO), chloroform (CLO) and hexane (HEX) extracts of L. ferrea. We then tested the most active extract for its toxicity and ability to inhibit migratory activity in the ACP02 gastric adenocarcinoma cell line in vitro. The AE and ACO extracts both had antioxidant activity, the AE extract showing greater potential. This may reflect that both extracts contained phenolic compounds. Although AE extract showed no cytotoxic, mutagenic or genotoxic effect, it altered cell morphology and migration activity. Analysis of apoptosis/necrosis indicated that this parameter does not appear to account for the apparent ability of AE to inhibit cancer cell migration. We speculate that the morphological changes in AE-treated cells could be due to cytoskeleton alterations related to the presence of myo-inositol in AE extract. Together, our results demonstrate this extract of L. ferrea can act as an exogenous antioxidant and might prove useful in efforts to fight secondary tumors.	[Calandrini de Azevedo, Luana Franca; Alves Ferreira, Tassia Alana; Melo, Karina Motta; Porfirio Dias, Clara Louise; Matos Carvalho Bastos, Carlos Eduardo; Nagamachi, Cleusa Yoshiko; Pieczarka, Julio Cesar] Univ Fed Para, Ctr Estudos Avancados Biodiversidade, Inst Ciencias Biol, Lab Citogenet, Belem, Para, Brazil; [Santos, Seidel Ferreira; Santos, Alberdan da Silva] Univ Fed Para, Lab Invest Sistemat Biotecnol & Biodiversidade Mo, Belem, Para, Brazil	Universidade Federal do Para; Universidade Federal do Para	Pieczarka, JC (corresponding author), Univ Fed Para, Ctr Estudos Avancados Biodiversidade, Inst Ciencias Biol, Lab Citogenet, Belem, Para, Brazil.	juliopieczarka@gmail.com	Nagamachi, Cleusa/AAV-8985-2021; Pieczarka, Julio C/E-7585-2016	Pieczarka, Julio C/0000-0003-2951-8877; Ferreira, Tassia/0000-0002-1096-0262	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior [047/2012]; Banco Nacional de Desenvolvimento Economico e Social [2.318.697.0001]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES; Edital Pro-Amazonia Biodiversidade e Sustentabilidade) [047/2012]; Banco Nacional de Desenvolvimento Economico e Social-BNDES [2.318.697.0001]; CAPES	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Banco Nacional de Desenvolvimento Economico e Social; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES; Edital Pro-Amazonia Biodiversidade e Sustentabilidade)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Banco Nacional de Desenvolvimento Economico e Social-BNDES; CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	JCP received the grant 047/2012 from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (https://www.capes.gov.br) and 2.318.697.0001 from Banco Nacional de Desenvolvimento Economico e Social (http://www.bndes.gov.br).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study was funded by Coordenacao de Aperfeicoamento de Pessoal de Ni ' vel Superior (CAPES; Edital Pro-Amazonia Biodiversidade e Sustentabilidade 047/2012) and Banco Nacional de Desenvolvimento Economico e Social-BNDES (Operation 2.318.697.0001) in projects coordinated by Julio Cesar Pieczarka. This study is part of the mastership dissertation of Luana Franca Calandrini de Azevedo in the post-graduation program in Genetics and Molecular Biology of the Universidade Federal do Para ' (scholarship granted by CAPES).	Alberts B, 2014, MOL BIOL CELL, DOI DOI 10.1201/9780203833445; Alizadeh AM, 2014, TUMOR BIOL, V35, P8483, DOI 10.1007/s13277-014-2421-z; Andrighetti-Frohner CR, 2006, MUTAT RES-GEN TOX EN, V603, P97, DOI 10.1016/j.mrgentox.2005.11.001; [Anonymous], 2016, IN VITR MAMM CELL MI, DOI DOI 10.1787/9789264264861-EN; Ayres M., 2007, BIOESTAT 50 APLICACO; Barroso GM, 1999, FRUTOS SEMENTES MORF, DOI DOI 10.17801/0101-3122/RBS.V21N2P64-69; Broinizi PRB, 2007, CIENCIA TECNOL ALIME, V27, P902, DOI 10.1590/S0101-20612007000400035; BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25; BURK RR, 1973, P NATL ACAD SCI USA, V70, P369, DOI 10.1073/pnas.70.2.369; Carvalho A.C.B., 2011, THESIS; Chappill J. A, 1995, ADV LEGUME SYSTEMATI, V7; COLLINS AR, 1995, MUTAT RES-DNA REPAIR, V336, P69, DOI 10.1016/0921-8777(94)00043-6; Cunha A. P., 2012, PLANTAS E PRODUTOS V; De Albuquerque UP, 2007, J ETHNOPHARMACOL, V114, P325, DOI 10.1016/j.jep.2007.08.017; de Almeida MV, 2003, QUIM NOVA, V26, P105, DOI 10.1590/S0100-40422003000100018; DeguYspari CH., 2004, VISAO ACAD, V5, P33, DOI [10.5380/acd.v5i1.540, DOI 10.5380/ACD.V5I1.540]; EASTMOND DA, 1989, ENVIRON MOL MUTAGEN, V13, P34, DOI 10.1002/em.2850130104; Elias ST, 2014, THESIS; GRIN-USDA ARS National Genetic Resources Program, 2017, NAT GEN RES PROGR; Guerra A.C.V.A, 2017, THESIS; Harvey AL, 1998, TOXICON, V36, P1635, DOI 10.1016/S0041-0101(98)00156-1; Huang DJ, 2002, J AGR FOOD CHEM, V50, P4437, DOI 10.1021/jf0201529; Krug M.S, 2013, THESIS; Leal MF, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/631268; Lewis G.P., 1987, LEGUMES BAHIA; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lotfi CFP, 1996, MUTAT RES-FUND MOL M, V349, P77, DOI 10.1016/0027-5107(95)00160-3; Maryas J, 2014, PROTEOMICS, V14, P426, DOI 10.1002/pmic.201300264; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Moco S, 2007, TRAC-TREND ANAL CHEM, V26, P855, DOI 10.1016/j.trac.2007.08.003; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; da Silva LCN, 2011, FOOD CHEM TOXICOL, V49, P2222, DOI 10.1016/j.fct.2011.06.019; Oliveira A.F., 2010, Rev. bras. plantas med., V12, P302, DOI 10.1590/S1516-05722010000300007; Ou BX, 2001, J AGR FOOD CHEM, V49, P4619, DOI 10.1021/jf010586o; Port's PD, 2013, FOOD RES INT, V53, P875, DOI 10.1016/j.foodres.2013.02.010; Ramos J., 2012, THESIS U ZARAGOZA; Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3; Reisa A, 2017, THESIS; Sampaio FC, 2009, J ETHNOPHARMACOL, V124, P289, DOI 10.1016/j.jep.2009.04.034; Schummer C, 2009, TALANTA, V77, P1473, DOI 10.1016/j.talanta.2008.09.043; Silva EM, 2007, FOOD CHEM, V101, P1012, DOI 10.1016/j.foodchem.2006.02.055; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Souza T. M., 2007, Revista de Ciencias Farmaceuticas Basica e Aplicada, V28, P221; Sperotto RA, 2014, PROTOCOLOS METODOS A; Valente T.O.N, 2014, THESIS; Yunes RA, 2001, QUIM NOVA, V24, P147, DOI 10.1590/S0100-40422001000100025	46	6	6	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2020	15	1							e0226979	10.1371/journal.pone.0226979	http://dx.doi.org/10.1371/journal.pone.0226979			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5PU	31952077	Green Published, gold			2023-01-03	WOS:000534370500007
J	Good, SS; Moussa, A; Zhou, XJ; Pietropaolo, K; Sommadossi, JP				Good, Steven S.; Moussa, Adel; Zhou, Xiao-Jian; Pietropaolo, Keith; Sommadossi, Jean-Pierre			Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus	PLOS ONE			English	Article							METABOLIC-ACTIVATION; POLYMERASE; INHIBITOR; INDUCTION	Despite the availability of highly effective direct-acting antiviral (DAA) regimens for the treatment of hepatitis C virus (HCV) infections, sustained viral response (SVR) rates remain suboptimal for difficult-to-treat patient populations such as those with HCV genotype 3, cirrhosis or prior treatment experience, warranting development of more potent HCV replication antivirals. AT-527 is the hemi-sulfate salt of AT-511, a novel phosphoramidate prodrug of 2'-fluoro-2'-C-methylguanosine-5'-monophosphate that has potent in vitro activity against HCV. The EC50 of AT-511, determined using HCV laboratory strains and clinical isolates with genotypes 1-5, ranged from 5-28 nM. The active 5'-triphosphate metabolite, AT-9010, specifically inhibited the HCV RNA-dependent RNA polymerase. AT-511 did not inhibit the replication of other selected RNA or DNA viruses in vitro. AT-511 was approximately 10-fold more active than sofosbuvir (SOF) against a panel of laboratory strains and clinical isolates of HCV genotypes 1-5 and remained fully active against S282T resistance-associated variants, with up to 58-fold more potency than SOF. In vitro, AT-511 did not inhibit human DNA polymerases or elicit cytotoxicity or mitochondrial toxicity at concentrations up to 100 mu M. Unlike the other potent guanosine analogs PSI-938 and PSI-661, no mutagenic O6 -alkylguanine bases were formed when incubated with cytochrome P450 (CYP) 3A4, and AT-511 had IC50 values >= 25 mu M against a panel of CYP enzymes. In hepatocytes from multiple species, the active triphosphate was the predominant metabolite produced from the prodrug, with a half-life of 10 h in human hepatocytes. When given orally to rats and monkeys, AT527 preferentially delivered high levels of AT-9010 in the liver in vivo. These favorable preclinical attributes support the ongoing clinical development of AT-527 and suggest that, when used in combination with an HCV DAA from a different class, AT-527 may increase SVR rates, especially for difficult-to-treat patient populations, and could potentially shorten treatment duration for all patients.	[Good, Steven S.; Moussa, Adel; Zhou, Xiao-Jian; Pietropaolo, Keith; Sommadossi, Jean-Pierre] Atea Pharmaceut Inc, Boston, MA 02110 USA		Good, SS (corresponding author), Atea Pharmaceut Inc, Boston, MA 02110 USA.	good.steven@ateapharma.com		Good, Steven/0000-0003-1476-9892				AASLD-IDSA, REC TEST MAN TREAT H; Ahmad T, 2015, HEPATOLOGY, V62, P409, DOI 10.1002/hep.27488; Arnold JJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003030; Bahar FG, 2012, J PHARM SCI-US, V101, P3979, DOI 10.1002/jps.23258; Berry Loren M, 2009, Drug Metab Lett, V3, P70; Bonatti S, 2000, MUTAGENESIS, V15, P361, DOI 10.1093/mutage/15.4.361; BONATTI S, 1986, MUTAGENESIS, V1, P99, DOI 10.1093/mutage/1.2.99; Chang W, 2011, ACS MED CHEM LETT, V2, P130, DOI 10.1021/ml100209f; Feld JJ, 2017, LIVER INT, V37, P5, DOI 10.1111/liv.13212; Feng Joy Y., 2018, Antiviral Chemistry & Chemotherapy, V26, p2040206618758524, DOI 10.1177/2040206618758524; Feng JY, 2016, ANTIMICROB AGENTS CH, V60, P806, DOI 10.1128/AAC.01922-15; Furman PA, 2011, ANTIVIR RES, V91, P120, DOI 10.1016/j.antiviral.2011.05.003; Hosein S, HCV TREATMENT ADV LI; Lalezari J, 2013, ONCE DAILY SOFOSBUVI, DOI [10.1053/j.gastro.2013.11.007, DOI 10.1053/J.GASTRO.2013.11.007]; Migliaccio G, 2003, J BIOL CHEM, V278, P49164, DOI 10.1074/jbc.M305041200; Murakami E, 2011, J MED CHEM, V54, P5902, DOI 10.1021/jm200650j; Murakami E, 2010, J BIOL CHEM, V285, P34337, DOI 10.1074/jbc.M110.161802; Niu CR, 2012, ANTIMICROB AGENTS CH, V56, P3767, DOI 10.1128/AAC.00530-12; SIMILI M, 1995, MUTAGENESIS, V10, P105, DOI 10.1093/mutage/10.2.105; Walsky R, 2004, DRUG METAB DISPOS, V32; World Health Organization, 2019, HEP C FACT SHEET	21	21	22	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2020	15	1							e0227104	10.1371/journal.pone.0227104	http://dx.doi.org/10.1371/journal.pone.0227104			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5DK	31914458	Green Published, gold			2023-01-03	WOS:000534337700028
J	El-Bassel, N; Marotta, PL; Goddard-Eckrich, D; Chang, M; Hunt, T; Wu, E; Gilbert, L				El-Bassel, Nabila; Marotta, Phillip L.; Goddard-Eckrich, Dawn; Chang, Mingway; Hunt, Tim; Wu, Ewin; Gilbert, Louisa			Drug overdose among women in intimate relationships: The role of partner violence, adversity and relationship dependencies	PLOS ONE			English	Article							SUBSTANCE USE; GENDER-DIFFERENCES; RECEIVING CARE; INJECT DRUGS; HIV RISK; ABUSE; PEOPLE; TRAUMA; ASSOCIATIONS; EXPERIENCES	Background This study examines the relationship between experiencing intimate partner violence (IPV), exposure to prior childhood adversity, lifetime adverse experiences, drug-related relationship dependencies with intimate partners and overdose, hospitalization for drug use, friends and family members who overdosed and witnessing overdose. Methodology This paper included a sample of 201 women who use drugs in heterosexual relationships with criminal justice-involved men in New York City. We included measures of experiencing overdose, hospitalization for drug use, witnessing overdose, and having friends and family who overdosed. Intimate partner violence consisted of either 1) none/verbal only, 2) moderate and 3) severe abuse. Dichotomous indicators of drug-related relationship dependencies included financial support, drug procurement, splitting and pooling drugs. A scale measured cumulative exposure to childhood adversity and lifetime exposures to adverse events. This paper hypothesized that experiencing moderate and severe IPV, drug-related dependencies and exposure to prior childhood and lifetime adversity would be associated with a greater risk of experiencing overdose, hospitalization for drug use, witnessing overdose and having friends and family members who overdosed. Generalized linear modeling with robust variance estimated relative risk ratios that accounted for potential bias in confidence intervals and adjusted for race, ethnicity, education and marital status. Results We found experiencing moderate or severe IPV was associated with ever being hospitalized for drug use and having a family member who experienced overdose. Experiencing moderate IPV was associated with increased risk of witnessing overdose, Partner drug dependencies were associated with overdose, ever being hospitalized for drug use, witnessing overdose, and having a family member or friend who experienced overdose. Childhood and lifetime adversity exposures were significantly associated with increased risk of overdose, ever being hospitalized for drug use, ever witnessing overdose and having a friend and family member who overdosed. Conclusion Findings underscore the intersection of experiencing IPV and drug-related relationship dependencies, childhood adversity and lifetime adversity in shaping experiences of and witnessing overdose among women who use drugs. They highlight the urgent need to address IPV, adversity experiences and drug-related relationship dependencies in overdose prevention for women who use drugs.	[El-Bassel, Nabila; Goddard-Eckrich, Dawn; Chang, Mingway; Hunt, Tim; Wu, Ewin; Gilbert, Louisa] Columbia Univ, Sch Social Work, New York, NY USA; [Marotta, Phillip L.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA	Columbia University; Yale University	Marotta, PL (corresponding author), Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA.	phillip.marotta@yale.edu	Goddard-eckrich, Dawn/GNM-6708-2022	Goddard-Eckrich, Dawn/0000-0002-3456-2322	National Institute on Drug Abuse [R01 DA033168, T32 DA019426, F31 DA044794]; NATIONAL INSTITUTE ON DRUG ABUSE [F31DA044794, T32DA019426, R01DA033168] Funding Source: NIH RePORTER	National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	National Institute on Drug Abuse R01 DA033168 to NE, National Institute on Drug Abuse T32 DA019426 to PM, and National Institute on Drug Abuse F31 DA044794 to PM supported this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agresti A, 2011, CATEGORICAL DATA ANA, P206; AMARO H, 1990, AM J PUBLIC HEALTH, V80, P575, DOI 10.2105/AJPH.80.5.575; [Anonymous], 2019, STATACORP REFERENCE; Blankenship KM, 2006, J URBAN HEALTH, V83, P59, DOI 10.1007/s11524-005-9007-4; Burke JG, 2005, VIOLENCE AGAINST WOM, V11, P1140, DOI 10.1177/1077801205276943; Caldwell JE, 2012, PSYCHOL VIOLENCE, V2, P42, DOI 10.1037/a0026296; Carbone-Lopez K, 2006, PUBLIC HEALTH REP, V121, P382, DOI 10.1177/003335490612100406; Centers for Disease Control and Prevention (CDC), 2017, AN NAT VIT STAT SYAT; Cramer D., 2003, ADV QUANTITATIVE DAT; Cummings P, 2009, STATA J, V9, P175, DOI 10.1177/1536867X0900900201; Cunradi CB, 2002, ALCOHOL CLIN EXP RES, V26, P493, DOI 10.1111/j.1530-0277.2002.tb02566.x; Davidson PJ, 2002, ADDICTION, V97, P1511, DOI 10.1046/j.1360-0443.2002.00210.x; Dobson A. J, 2008, INTRO GEN LLINEAR MO; El-Bassel N, 2003, WOMEN HEALTH ISS, V13, P16, DOI 10.1016/S1049-3867(02)00142-1; El-Bassel N, 2004, AIDS BEHAV, V8, P429, DOI 10.1007/s10461-004-7327-0; El-Bassel N, 2005, AM J PUBLIC HEALTH, V95, P465, DOI 10.2105/AJPH.2003.023200; El-Bassel N, 2007, EMERG MED J, V24, P255, DOI 10.1136/emj.2006.041541; El-Bassel N, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.1139; El-Bassel N, 2015, JAIDS-J ACQ IMM DEF, V69, pS182, DOI 10.1097/QAI.0000000000000628; El-Bassel N, 2014, CURR HIV-AIDS REP, V11, P45, DOI 10.1007/s11904-013-0192-6; Finkelhor D, 2015, CHILD ABUSE NEGLECT, V48, P13, DOI 10.1016/j.chiabu.2015.07.011; Gilbert L, 2015, JAIDS-J ACQ IMM DEF, V69, pS118, DOI 10.1097/QAI.0000000000000626; Golinelli D, 2009, J BEHAV HEALTH SER R, V36, P199, DOI 10.1007/s11414-008-9114-6; Goodman LA, 1998, J TRAUMA STRESS, V11, P521, DOI 10.1023/A:1024456713321; Hammersley R, 2016, ADDICT RES THEORY, V24, P135, DOI 10.3109/16066359.2015.1093120; Hankin A, 2010, WEST J EMERG MED, V11, P252; Jiwatram-Negron T, 2015, WOMEN HEALTH ISS, V25, P420, DOI 10.1016/j.whi.2015.04.007; Kim D, 2009, AM J PUBLIC HEALTH, V99, P402, DOI 10.2105/AJPH.2008.136937; Lake S, 2015, ADDICT BEHAV, V43, P83, DOI 10.1016/j.addbeh.2014.12.014; Lumley T, 2006, RELATIVE RISK REGRES; Mack KA, 2013, MMWR-MORBID MORTAL W, V62, P537; Marsh JC, 2018, J SUBST ABUSE TREAT, V87, P79, DOI 10.1016/j.jsat.2018.01.001; Martin SL, 2003, AM J DRUG ALCOHOL AB, V29, P599, DOI 10.1081/ADA-120023461; Martins SS, 2015, AM J PUBLIC HEALTH, V105, pE29, DOI 10.2105/AJPH.2015.302843; McCullagh P., 2019, LONDON GEN LINEAR MO, V2nd; Merritt MHB, 2006, PEDIATRICS, V117, pE278, DOI 10.1154/peds.2005-1473; NELDER JA, 1972, J R STAT SOC SER A-G, V135, P370, DOI 10.2307/2344614; Office on Women''s Health, 2017, FIN REP OP US MIS OV; Papp J, 2017, ANN EMERG MED, V70, pS170, DOI 10.1016/j.annemergmed.2017.07.315; Randhawa G, 2018, J TRAUMA STRESS, V31, P383, DOI 10.1002/jts.22286; Rhodes T, 2005, BMJ-BRIT MED J, V331, P220, DOI 10.1136/bmj.331.7510.220; Rhodes T., 2002, INT J DRUG POLICY, V13, P85, DOI [10.1016/S0955-3959(02)00007-5, DOI 10.1016/S0955-3959(02)00007-5]; Roberts A., 2010, WOMEN WHO INJECT DRU; Sacks JY, 2008, J SUBST ABUSE TREAT, V34, P90, DOI 10.1016/j.jsat.2007.01.010; Salomon A, 2002, VIOLENCE AGAINST WOM, V8, P785, DOI 10.1177/107780102400388489; Simmons J, 2006, SUBST ABUSE TREAT PR, V1, DOI 10.1186/1747-597X-1-7; Smith PH, 2012, PSYCHOL ADDICT BEHAV, V26, P236, DOI 10.1037/a0024855; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Spencer Merianne R, 2019, Natl Vital Stat Rep, V68, P1; Straus MA, 1996, J FAM ISSUES, V17, P283, DOI 10.1177/019251396017003001; Testa M, 2003, ADDICT BEHAV, V28, P1649, DOI 10.1016/j.addbeh.2003.08.040; Tracy M, 2005, DRUG ALCOHOL DEPEN, V79, P181, DOI 10.1016/j.drugalcdep.2005.01.010; van Dam D, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-172; VanHouten JP, 2019, MMWR-MORBID MORTAL W, V68, P1, DOI 10.15585/mmwr.mm6801a1; Wilcoxon F., 1970, SELECTED TABLES MATH, V1, P171, DOI DOI 10.1007/SPRINGERREFERENCE_205698	55	11	11	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2019	14	12							e0225854	10.1371/journal.pone.0225854	http://dx.doi.org/10.1371/journal.pone.0225854			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KN8IR	31881035	Green Published, gold			2023-01-03	WOS:000515089200010
J	Nkoke, C; Jingi, AM; Makoge, C; Teuwafeu, D; Nkouonlack, C; Dzudie, A				Nkoke, Clovis; Jingi, Ahmadou Musa; Makoge, Christelle; Teuwafeu, Denis; Nkouonlack, Cyrille; Dzudie, Anastase			Epidemiology of cardiovascular diseases related admissions in a referral hospital in the South West region of Cameroon: A cross-sectional study in sub-Saharan Africa	PLOS ONE			English	Article							MORTALITY; BURDEN; WOMEN; RISK	Background Sub-Saharan Africa (SSA) is experiencing an epidemic of cardiovascular diseases (CVD) as a result of a rapid epidemiological transition. Little is known about the admission for CVD and outcome in rural and semi-urban settings in Cameroon in this era of epidemiological transition. The aim of this study was to determine the frequency and the pattern of CVD admissions in the South West region of Cameroon. Methods This retrospective descriptive study included all adult patients admitted for CVD in the medical unit of the Buea Regional Hospital between Jan 2016 and December 2017. Results Out of the 3140 patients admitted, 499(15.9%) had CVD. There were 304(60.9%) females. The mean age was 58.7 +/- 16.2 years. There was no age difference between men and women (59.7 years vs 58.1 years, p = 0.29). The most commonly affected age group was those aged 50-59 years (22%). Heart failure (38.5%), stroke (33.3%) and uncontrolled hypertension (22.4%) were the most prevalent CVDs. The length of hospital stay ranged from 1 to 37 days with a median length of hospital stay of 7 days. In-hospital case fatality was 78(15.8%). Mortality was higher in women compared to men (9% vs 7%, p = 0.43). The case fatality for stroke was higher compared to case fatality for heart failure (21.7% vs 16.7%, p = 0.23). Conclusion CVDs are a common cause of hospital admission in this semi-urban setting, dominated by heart failure. Women were disproportionately affected and it was associated with high mortality. Prevention, early detection and management of risk factors for cardiovascular disease are imperative given the growing burden of CVD in SSA to reduce CVD morbidity and mortality.	[Nkoke, Clovis; Teuwafeu, Denis; Nkouonlack, Cyrille] Buea Reg Hosp, Buea, Cameroon; [Nkoke, Clovis; Jingi, Ahmadou Musa; Dzudie, Anastase] Clin Res Educ Networking & Consultancy, Douala, Cameroon; [Jingi, Ahmadou Musa; Makoge, Christelle; Dzudie, Anastase] Univ Yaounde, Fac Med & Biomed Sci, Yaounde, Cameroon; [Teuwafeu, Denis] Univ Buea, Fac Hlth Sci, Buea, Cameroon; [Dzudie, Anastase] Douala Gen Hosp, Douala, Cameroon	University of Yaounde I	Nkoke, C (corresponding author), Buea Reg Hosp, Buea, Cameroon.; Nkoke, C (corresponding author), Clin Res Educ Networking & Consultancy, Douala, Cameroon.	cnkoke@yahoo.com	Teuwafeu, Denis Georges/AFT-3798-2022	DZUDIE, Anastase/0000-0003-4038-4128				Amendezo E, 2008, ANN TROP MED PUBLIC, V1, P9, DOI 10.4103/1755-6783.43071; Ansa VO, 2008, NIGER J CLIN PRACT, V11, P22; Appiah LT, 2017, CLIN CARDIOL, V40, P783, DOI 10.1002/clc.22753; Damasceno A, 2007, J AM COLL CARDIOL, V50, P1688, DOI 10.1016/j.jacc.2007.07.030; Damasceno A, 2012, ARCH INTERN MED, V172, P1386, DOI 10.1001/archinternmed.2012.3310; Dzudie A, 2019, EUR HEART J SUPPL, V21, pD31, DOI 10.1093/eurheartj/suz081; Fezeu L, 2006, INT J EPIDEMIOL, V35, P105, DOI 10.1093/ije/dyi214; Fleg JL, 2011, NAT REV CARDIOL, V8, P13, DOI 10.1038/nrcardio.2010.162; Hamid S, 2019, AGING MALE, V22, P169, DOI 10.1080/13685538.2019.1582621; Huxley R, 2006, BMJ-BRIT MED J, V332, P73, DOI 10.1136/bmj.38678.389583.7C; Kariuki JK, 2015, CARDIOL RES PRACT, V2015, DOI 10.1155/2015/921021; Kip KE, 2004, CIRCULATION, V109, P706, DOI 10.1161/01.CIR.0000115514.44135.A8; Lekoubou A, 2015, J NEUROL SCI, V350, P24, DOI 10.1016/j.jns.2015.02.002; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mayosi BM, 2009, LANCET, V374, P934, DOI 10.1016/S0140-6736(09)61087-4; Menanga A, 2016, CARDIOVASC DIAGN THE, V6, P439, DOI 10.21037/cdt.2016.04.03; Mocumbi AO, 2012, CARDIOVASC DIAGN THE, V2, P74, DOI 10.3978/j.issn.2223-3652.2012.01.03; Mosca, 2011, CIRCULATION, V123, pE624, DOI 10.1161/CIR.0b013e318222b330; Njim T, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4037-x; Nkoke C, 2019, J XIANGYA MED, V4, P1, DOI [10.21037/jxym.2019.02.01, DOI 10.21037/JXYM.2019.02.01]; Okunola OO, 2011, J DENT MED MED SCI, V1; Osuji CU, 2014, PAN AFR MED J, V17, DOI 10.11604/pamj.2014.17.116.1837; Pancha M. O., 2015, HLTH SCI DIS, V16, P1; Ukpabi OJ, 2017, ANN AFR MED, V16, P70, DOI 10.4103/aam.aam_30_16; World Health Organization, 2018, GLOB HLTH EST DEATH; Yach D, 2004, JAMA-J AM MED ASSOC, V291, P2616, DOI 10.1001/jama.291.21.2616	26	2	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2019	14	12							e0226644	10.1371/journal.pone.0226644	http://dx.doi.org/10.1371/journal.pone.0226644			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP3WL	31856221	Green Published, gold			2023-01-03	WOS:000534249400054
J	Shoemaker, EA; Dale, K; Cohn, DA; Kelly, MP; Zoerhoff, KL; Batcho, WE; Bougouma, C; Nko'Ayissi, GB; Meite, A; Marfo, B; Goepogui, A; Telfort, MA; Sianipar, LR; Traore, M; Rimal, P; Alfari, DA; Anyaike, C; Badiane, FN; Kargbo-Labour, I; Mwingira, UJ; Awoussi, MS; Stelmach, RD; Smith, CL; Arney, J; Faramand, TH; Stukel, DM; Pou, B; Rotondo, LA; Kraemer, JD; Baker, MC				Shoemaker, Erica A.; Dale, Kelly; Cohn, Daniel A.; Kelly, Maureen P.; Zoerhoff, Kathryn L.; Batcho, Wilfrid E.; Bougouma, Clarisse; Nko'Ayissi, Georges B.; Meite, Aboulaye; Marfo, Benjamin; Goepogui, Andre; Telfort, Marc-Aurele; Sianipar, Lita Renata; Traore, Mahamadou; Rimal, Pradip; Alfari, Djibo Aichatou; Anyaike, Chukwuma; Badiane, Fatou N.; Kargbo-Labour, Ibrahim; Mwingira, Upendo J.; Awoussi, Marcel S.; Stelmach, Rachel D.; Smith, Carly L.; Arney, Jennifer; Faramand, Taroub Harb; Stukel, Diana M.; Pou, Bolivar; Rotondo, Lisa A.; Kraemer, John D.; Baker, Margaret C.			Gender and neglected tropical disease front-line workers: Data from 16 countries	PLOS ONE			English	Article							PERFORMANCE	Background Delivery of preventive chemotherapy (PC) through mass drug administration (MDA) is used to control or eliminate five of the most common neglected tropical diseases (NTDs). The success of an MDA campaign relies on the ability of drug distributors and their supervisors -the NTD front-line workers-to reach populations at risk of NTDs. In the past, our understanding of the demographics of these workers has been limited, but with increased access to sex-disaggregated data, we begin to explore the implications of gender and sex for the success of NTD front-line workers. Methodology/Principal findings We reviewed data collected by USAID-supported NTD projects from national NTD programs from fiscal years (FY) 2012-2017 to assess availability of sex-disaggregated data on the workforce. What we found was sex-disaggregated data on 2,984,908 trainees trained with financial support from the project. We then analyzed the percentage of males and females trained by job category, country, and fiscal year. During FY12, 59% of these data were disaggregated by sex, which increased to nearly 100% by FY15 and was sustained through FY17. In FY17, 43% of trainees were female, with just four countries reporting more females than males trained as drug distributors and three countries reporting more females than males trained as trainers/supervisors. Except for two countries, there were no clear trends over time in changes to the percent of females trained. Conclusions/Significance There has been a rapid increase in availability of sex-disaggregated data, but little increase in recruitment of female workers in countries included in this study. Women continue to be under-represented in the NTD workforce, and while there are often valid reasons for this distribution, we need to test this norm and better understand gender dynamics within NTD programs to increase equity.	[Shoemaker, Erica A.; Kelly, Maureen P.; Zoerhoff, Kathryn L.; Stelmach, Rachel D.; Rotondo, Lisa A.; Kraemer, John D.; Baker, Margaret C.] RTI Int, Washington, DC 20005 USA; [Dale, Kelly; Faramand, Taroub Harb] WI HER, Vienna, VA USA; [Cohn, Daniel A.; Arney, Jennifer; Stukel, Diana M.; Pou, Bolivar] FHI 360, Washington, DC USA; [Batcho, Wilfrid E.] Minist Hlth, Natl Communicable Dis Control Program, Cotonou, Benin; [Bougouma, Clarisse] Minist Hlth, Natl Neglected Trop Dis Control Program, Dis Control Directorate, Ouagadougou, Burkina Faso; [Nko'Ayissi, Georges B.] Minist Publ Hlth, Malaria & Neglected Trop Dis Subdept, Yaounde, Cameroon; [Meite, Aboulaye] Minist Hlth & Publ Hyg, Natl Control Program Prevent Chemotherapy Neglect, Abidjan, Cote Ivoire; [Marfo, Benjamin] Ghana Hlth Serv, Natl Neglected Trop Dis Program, Accra, Ghana; [Goepogui, Andre] Minist Hlth, Natl Onchocerciasis & Blindness & Neglected Trop, Natl Prevent & Community Hlth Directorate, Conakry, Guinea; [Telfort, Marc-Aurele] Minist Publ Hlth & Populat, Natl Malaria Control Program, Port Au Prince, Haiti; [Sianipar, Lita Renata] Minist Hlth, Subdirectorate Filariasis & Helminthiasis Control, Directorate Vector Borne Dis Control, Directorate Gen Communicable Dis & Environm Hlth, Jakarta, Indonesia; [Traore, Mahamadou] Minist Hlth & Publ Hyg, Natl Schistosomiasis & Soil Transmitted Helminths, Bamako, Mali; [Rimal, Pradip] Minist Hlth, Epidemiol & Dis Control Div, Dept Hlth Serv, Kathmandu, Nepal; [Alfari, Djibo Aichatou] Minist Publ Hlth, NTD Control Program, Directorate Protect Publ Hlth, Niamey, Niger; [Anyaike, Chukwuma] Fed Minist Hlth, Dept Publ Hlth, Neglected Trop Dis Div, Abuja, Nigeria; [Badiane, Fatou N.] Minist Hlth & Social Work, NTD Control Program, Dis Control Directorate, Dakar, Senegal; [Kargbo-Labour, Ibrahim] Minist Hlth & Sanitat, Neglected Trop Dis Programme, Dis Prevent & Control Directorate, Freetown, Sierra Leone; [Mwingira, Upendo J.] Minist Hlth, Neglected Trop Dis Control Programme, Dar Es Salaam, Tanzania; [Mwingira, Upendo J.] Natl Inst Med Res, Dar Es Salaam, Tanzania; [Awoussi, Marcel S.] Minist Hlth & Social Welf, Natl Neglected Trop Dis Control Program, Gen Directorate Hlth, Lome, Togo; [Smith, Carly L.] US Agcy Int Dev, Off Infect Dis, Washington, DC 20523 USA; [Kraemer, John D.] Georgetown Univ, Dept Hlth Syst Adm, Washington, DC USA	Research Triangle Institute; Ghana Health Service; Ministry of Health - Indonesia; Ministry of Health & Sanitation Sierra Leone; National Institute of Medical Research; United States Agency for International Development (USAID); Georgetown University	Shoemaker, EA (corresponding author), RTI Int, Washington, DC 20005 USA.	eshoemaker@rti.org		Shoemaker, Erica/0000-0002-9799-6021; mwingira, upendo/0000-0001-6852-6402; Rotondo, Lisa/0000-0003-3404-3343; Cohn, Daniel/0000-0001-7014-0031; Stelmach, Rachel/0000-0002-4903-4995; Baker, Margaret/0000-0002-4537-3914	US Agency for International Development (USAID) under the ENVISION project [AID-OAA-A-11-00048, 7200AA18CA00040]; End Neglected Tropical Diseases in Africa (END in Africa) project [AID-OAA-A-1000050, 7200AA18CA00011]	US Agency for International Development (USAID) under the ENVISION project(United States Agency for International Development (USAID)); End Neglected Tropical Diseases in Africa (END in Africa) project	This publication was made possible thanks to funding from the US Agency for International Development (USAID) under the ENVISION project and the Act to End NTDs | East program led by RTI International under cooperative agreements No. AID-OAA-A-11-00048 and No. 7200AA18CA00040, and by the End Neglected Tropical Diseases in Africa (END in Africa) project and Act to End NTDs vertical bar West program led by FHI 360 under cooperative agreements No. AID-OAA-A-1000050 and No. 7200AA18CA00011. The contents are the responsibility of the authors and do not necessary reflect the views of USAID or the United States government. Other than the personal contributions of CLS, who provided input while employed by USAID (and therefore listed as a coauthor on this article), the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. JDK receives partial salary support from RTI International as a visiting scholar in RTI's international development group.	Baker M, 2016, ASTMH C 2016; Brooker S, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000291; Chami GF, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1303-z; Cohn DA, 2019, GENDER EQUITY MASS D; Gouvras A, 2017, NEGLECTED TROPICAL D; Guerra-Silveira F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062390; Huang YX, 2005, ACTA TROP, V96, P223, DOI 10.1016/j.actatropica.2005.07.015; International Labour Office, 2018, GLOB WAG REP 2018 19; Isaacs D, 2018, J PAEDIATR CHILD H, V54; Jenson A, 2014, INT J QUAL HEALTH C, V26, P524, DOI 10.1093/intqhc/mzu067; Katabarwa MN, 2002, HEALTH SOC CARE COMM, V10, P382, DOI 10.1046/j.1365-2524.2002.00378.x; Kiliminjaro Centre for Community Ophthalmology The Elfenworks Foundation. The Carter Center, 2009, WOM TRACH ACH GEND E; Langer A, 2015, LANCET, V386, P1165, DOI 10.1016/S0140-6736(15)60497-4; McCollum R, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3043-8; Prasad S, 2015, OCCUPTATIONAL MED HL, V3; Rilkoff H, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002312; Seto EYW, 2012, GEOSPATIAL HEALTH, V7, P1; Steege R, SOCIAL SCI MED, V209, P1; USAID, 2012, GEND EQ FEM EMP POL; Vouking MZ, 2015, PAN AFR MED J, V20, DOI 10.11604/pamj.2015.20.188.3337; WHO, 2006, PREV CHEM HUM HELM; WHO, 2019, DEL WOM LED MEN GEND; World Health Organization, 2018, WHO GUID HLTH POL SY, DOI DOI 1157598/RETRIEVE; World Health Organization, 2019, UPD GLOB STAT IMPL P	24	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2019	14	12							e0224925	10.1371/journal.pone.0224925	http://dx.doi.org/10.1371/journal.pone.0224925			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP3WL	31856174	gold, Green Published			2023-01-03	WOS:000534249400008
J	Misaki, T; Fukunaga, A; Shimizu, Y; Ishikawa, A; Nakano, K				Misaki, Taro; Fukunaga, Akiko; Shimizu, Yoshitaka; Ishikawa, Akira; Nakano, Kazuhiko			Possible link between dental diseases and arteriosclerosis in patients on hemodialysis	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; STREPTOCOCCUS-MUTANS; PULSE PRESSURE; HEALTH; MORTALITY; RISK	Background Patients on hemodialysis must undergo this procedure at a hospital three times weekly and might be unable to visit a dentist. In addition, dentists might hesitate to provide oral care because such patients tend to bleed because they are medicated with anticoagulants, are susceptible to bacterial infections, and might have unusual drug reactions. We postulated that patients on hemodialysis have worse oral status than healthy people, which in turn might predispose such patients to systemic complications. Methods We compared the status of dental caries and periodontal diseases among 80 patients on hemodialysis and 76 healthy individuals (controls) using the decayed, missing, or filled teeth (DMFT) index, total number of C4 teeth (destruction of the entire tooth crown), and periodontal pocket depth. Clinical data were analyzed after all patients on hemodialysis and controls provided written, informed consent to participate in the study. Results Total number of C4 teeth (p = 0.021), missing teeth (MT) index (p = 0.0302), and DMFT index score >= 24 (p = 0.017) were significantly higher in patients on hemodialysis than controls. Pulse pressure (p = 0.0042) and the prevalence of a history of heart disease such as angina pectoris and acute myocardial infarction (p = 0.029) were higher in patients on hemodialysis with higher (>= 24) than lower (< 24) DMFT index scores. Periodontal pocket depth was not significantly different between these two groups. Conclusion Worse status of dental caries is possibly associated with arteriosclerosis among patients on hemodialysis.	[Misaki, Taro; Shimizu, Yoshitaka] Seirei Hamamatsu Gen Hosp, Div Nephrol, Hamamatsu, Shizuoka, Japan; [Misaki, Taro] Seirei Christopher Univ, Fac Nursing, Dept Nursing, Hamamatsu, Shizuoka, Japan; [Fukunaga, Akiko] Seirei Hamamatsu Gen Hosp, Div Dent, Hamamatsu, Shizuoka, Japan; [Ishikawa, Akira] Ai Dent Clin, Hamamatsu, Shizuoka, Japan; [Nakano, Kazuhiko] Osaka Univ, Grad Sch Dent, Div Oral Infect & Dis Control, Dept Pediat Dent, Suita, Osaka, Japan	Osaka University	Misaki, T (corresponding author), Seirei Hamamatsu Gen Hosp, Div Nephrol, Hamamatsu, Shizuoka, Japan.; Misaki, T (corresponding author), Seirei Christopher Univ, Fac Nursing, Dept Nursing, Hamamatsu, Shizuoka, Japan.	misakitar@sis.seirei.or.jp	Misaki, Taro/HHY-7358-2022		JSPS KAKENHI [JP19K10098, JP18H03010]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by JSPS KAKENHI (nos. JP19K10098 and JP18H03010).	[Anonymous], 2016, REP MIN HLTH, P13; Blacher J, 2000, ARCH INTERN MED, V160, P1085, DOI 10.1001/archinte.160.8.1085; Blinkhorn A S, 1996, Int Dent J, V46, P119; Borawski J, 2007, NEPHROL DIAL TRANSPL, V22, P457, DOI 10.1093/ndt/gfl676; Bossola M, 2012, NAT REV NEPHROL, V8, P176, DOI 10.1038/nrneph.2011.218; Chae CU, 1999, JAMA-J AM MED ASSOC, V281, P634, DOI 10.1001/jama.281.7.634; Chambrone L, 2013, J CLIN PERIODONTOL, V40, P443, DOI 10.1111/jcpe.12067; Chertow GM, 2016, J AM SOC NEPHROL, V27, P3129, DOI 10.1681/ASN.2015111232; Covic A, 2018, LANCET DIABETES ENDO, V6, P319, DOI 10.1016/S2213-8587(17)30310-8; Dhaun N, 2014, KIDNEY INT, V85, P1039, DOI 10.1038/ki.2013.512; Kanda E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214524; Masakane I, 2015, THER APHER DIAL, V19, P540, DOI 10.1111/1744-9987.12378; Misaki T, 2016, SCI REP-UK, V6, DOI 10.1038/srep36455; Montebugnoli L, 2005, J CLIN PERIODONTOL, V32, P188, DOI 10.1111/j.1600-051X.2005.00641.x; Montebugnoli L, 2004, J CLIN PERIODONTOL, V31, P25, DOI 10.1111/j.0303-6979.2004.00432.x; Nakano K, 2006, J CLIN MICROBIOL, V44, P3313, DOI 10.1128/JCM.00377-06; Palmer SC, 2015, AM J KIDNEY DIS, V66, P666, DOI 10.1053/j.ajkd.2015.04.051; Ruospo M, 2014, NEPHROL DIAL TRANSPL, V29, P364, DOI 10.1093/ndt/gft401; Tonelli M, 2006, J AM SOC NEPHROL, V17, P2034, DOI 10.1681/ASN.2005101085; Wakasugi M, 2016, NEPHROL DIAL TRANSPL, V31, P1501, DOI 10.1093/ndt/gfw249; Yue Q, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204674	21	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2019	14	12							e0225038	10.1371/journal.pone.0225038	http://dx.doi.org/10.1371/journal.pone.0225038			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP3QF	31834880	Green Published, gold			2023-01-03	WOS:000534232900005
J	Jakes, AD; Oakeshott, P; Bick, D				Jakes, Adam D.; Oakeshott, Pippa; Bick, Debra			The maternal six week postnatal check	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Jakes, Adam D.] Guys & St Thomas Hosp NHS Trust, London, England; [Oakeshott, Pippa] St Georges Univ London, Populat Hlth Res Inst, London, England; [Bick, Debra] Univ Warwick, Warwick Med Sch, Warwick Clin Trials Unit, Coventry, W Midlands, England	St Georges University London; University of Warwick	Jakes, AD (corresponding author), Guys & St Thomas Hosp NHS Trust, London, England.	a.jakes@nhs.net		Oakeshott, Pippa/0000-0003-2568-8211				Bellamy L, 2009, LANCET, V373, P1773, DOI 10.1016/S0140-6736(09)60731-5; Brown S, 2015, BJOG-INT J OBSTET GY, V122, P954, DOI 10.1111/1471-0528.12963; Faculty of Sexual & Reproductive Healthcare (FSRH), 2017, CONTR PREGN; Heinemann K, 2015, CONTRACEPTION, V91, P274, DOI 10.1016/j.contraception.2015.01.007; IOM (Institute of Medicine), 2001, DIETARY REFERENCE IN, DOI DOI 10.17226/10026; Jones I, 2014, BMJ-BRIT MED J, V349, pg4500; Kamel H, 2014, NEW ENGL J MED, V370, P1307, DOI 10.1056/NEJMoa1311485; McDonald EA, 2013, BJOG-INT J OBSTET GY, V120, P823, DOI 10.1111/1471-0528.12166; National Institute for Health and Care Excellence, 2018, ANT POSTN MENT HLTH; National Institute for Health and Care Excellence, 2015, POSTN CAR 8 WEEKS BI; National Institute for Health and Clinical Excellence (NICE), 2010, HLTH CLIN EXC REC WE; NICE, 2015, DIAB PREGN MAN PREC; Pavord S, 2012, BRIT J HAEMATOL, V156, P588, DOI 10.1111/j.1365-2141.2011.09012.x; Pena-Rosas JP, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009997.pub2; Public Health England, 2013, IMMUNISATION INFECT; Public Health England, 2016, NHS CERV SCREEN PROG; Shorey S, 2018, J PSYCHIATR RES, V104, P235, DOI 10.1016/j.jpsychires.2018.08.001; The National Institute for Health and Care Excellence, 2019, 133 NICE	18	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 2	2019	367								l6482	10.1136/bmj.l6482	http://dx.doi.org/10.1136/bmj.l6482			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU3QW	31791954	Green Accepted			2023-01-03	WOS:000501593700002
J	Williams, SA; Kivimaki, M; Langenberg, C; Hingorani, AD; Casas, JP; Bouchard, C; Jonasson, C; Sarzynski, MA; Shipley, MJ; Alexander, L; Ash, J; Bauer, T; Chadwick, J; Datta, G; DeLisle, RK; Hagar, Y; Hinterberg, M; Ostroff, R; Weiss, S; Ganz, P; Wareham, NJ				Williams, Stephen A.; Kivimaki, Mika; Langenberg, Claudia; Hingorani, Aroon D.; Casas, J. P.; Bouchard, Claude; Jonasson, Christian; Sarzynski, Mark A.; Shipley, Martin J.; Alexander, Leigh; Ash, Jessica; Bauer, Tim; Chadwick, Jessica; Datta, Gargi; DeLisle, Robert Kirk; Hagar, Yolanda; Hinterberg, Michael; Ostroff, Rachel; Weiss, Sophie; Ganz, Peter; Wareham, Nicholas J.			Plasma protein patterns as comprehensive indicators of health	NATURE MEDICINE			English	Article							PREVENTION; SELECTION; CARE	Proteins are effector molecules that mediate the functions of genes(1,2) and modulate comorbidities(3-10), behaviors and drug treatments(11.) They represent an enormous potential resource for personalized, systemic and data-driven diagnosis, prevention, monitoring and treatment. However, the concept of using plasma proteins for individualized health assessment across many health conditions simultaneously has not been tested. Here, we show that plasma protein expression patterns strongly encode for multiple different health states, future disease risks and lifestyle behaviors. We developed and validated protein-phenotype models for 11 different health indicators: liver fat, kidney filtration, percentage body fat, visceral fat mass, lean body mass, cardiopulmonary fitness, physical activity, alcohol consumption, cigarette smoking, diabetes risk and primary cardiovascular event risk. The analyses were prospectively planned, documented and executed at scale on archived samples and clinical data, with a total of similar to 85 million protein measurements in 16,894 participants. Our proof-of-concept study demonstrates that protein expression patterns reliably encode for many different health issues, and that large-scale protein scanning(12-16) coupled with machine learning is viable for the development and future simultaneous delivery of multiple measures of health. We anticipate that, with further validation and the addition of more protein-phenotype models, this approach could enable a single-source, individualized so-called liquid health check.	[Williams, Stephen A.; Alexander, Leigh; Ash, Jessica; Bauer, Tim; Chadwick, Jessica; Datta, Gargi; DeLisle, Robert Kirk; Hagar, Yolanda; Hinterberg, Michael; Ostroff, Rachel; Weiss, Sophie] SomaLogic Inc, Boulder, CO 80301 USA; [Kivimaki, Mika; Shipley, Martin J.] UCL, Dept Epidemiol & Publ Hlth, London, England; [Langenberg, Claudia; Wareham, Nicholas J.] Univ Cambridge, MRC Epidemiol Unit, Cambridge, England; [Hingorani, Aroon D.] UCL, Inst Cardiovasc Sci, London, England; [Hingorani, Aroon D.] UCL, British Heart Fdn Res Accelerator, London, England; [Hingorani, Aroon D.] Hlth Data Res UK, London, England; [Casas, J. P.] Vet Affairs Boston Healthcare Syst, Massachusetts Vet Epidemiol & Res Informat Ctr, Boston, MA USA; [Bouchard, Claude] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; [Jonasson, Christian] NTNU Norwegian Univ Sci & Technol, Fac Med & Hlth Sci, HUNT Res Ctr, Trondheim, Norway; [Jonasson, Christian] NTNU Norwegian Univ Sci & Technol, Fac Med & Hlth Sci, KG Jebsen Ctr Genet Epidemiol, Trondheim, Norway; [Sarzynski, Mark A.] Univ South Carolina, Dept Exercise Sci, Arnold Sch Publ Hlth, Columbia, SC 29208 USA; [Ganz, Peter] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Ctr Excellence Vasc Res, Div Cardiol, San Francisco, CA 94143 USA	University of London; University College London; University of Cambridge; University of London; University College London; University of London; University College London; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); University of South Carolina System; University of South Carolina Columbia; University of California System; University of California San Francisco	Williams, SA (corresponding author), SomaLogic Inc, Boulder, CO 80301 USA.	swilliams@somalogic.com	Bouchard, Claude/AAE-2035-2019; Sarzynski, Mark/A-9798-2014; Langenberg, Claudia/ABG-9067-2021; Bouchard, Claude/A-7637-2009; Kivimaki, Mika/B-3607-2012; Datta, Gargi/I-4104-2019	Langenberg, Claudia/0000-0002-5017-7344; Bouchard, Claude/0000-0002-0048-491X; Kivimaki, Mika/0000-0002-4699-5627; Datta, Gargi/0000-0002-1314-7824; Jonasson, Christian/0000-0002-7694-6025; Williams, Stephen/0000-0002-8661-4315; Hingorani, Aroon/0000-0001-8365-0081; Ganz, Peter/0000-0002-0437-8882	UK Medical Research Council UK [MR/R024227/1]; US National Institutes on Aging (NIH) [US R01AG056477, R01AG062553]; British Heart Foundation [RG/16/11/32334]; National Institute for Health Research University College London Hospitals Biomedical Research Centre; UCL BHF Research Accelerator [AA/18/6/34223]; UK Medical Research Council [MC_UU_12015/1]; Norwegian Ministry of Health; Norwegian University of Science and Technology; Norwegian Research Council; Central Norway Regional Health Authority; Nord-Trondelag County Council; Norwegian Institute of Public Health; US National Heart, Lung and Blood Institute grants (NIH/NHLBI) [R01HL146462, HL45670]; SomaLogic, Inc.; MRC [MR/S011676/1, MR/R024227/1, MC_UU_12015/1] Funding Source: UKRI; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL146462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG056477] Funding Source: NIH RePORTER	UK Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); US National Institutes on Aging (NIH); British Heart Foundation(British Heart Foundation); National Institute for Health Research University College London Hospitals Biomedical Research Centre(General Electric); UCL BHF Research Accelerator; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Norwegian Ministry of Health; Norwegian University of Science and Technology; Norwegian Research Council(Research Council of NorwayEuropean Commission); Central Norway Regional Health Authority; Nord-Trondelag County Council; Norwegian Institute of Public Health; US National Heart, Lung and Blood Institute grants (NIH/NHLBI); SomaLogic, Inc.; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The Whitehall II study is supported by the UK Medical Research Council UK (no. MR/R024227/1, to M.K.), the US National Institutes on Aging (NIH, nos. US R01AG056477, R01AG062553) to M.K. and the British Heart Foundation (no. RG/16/11/32334) to M.J.S. A.D.H. is a NIHR Senior Investigator and was also supported, in part, by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and the UCL BHF Research Accelerator (AA/18/6/34223). FENLAND (the Fenland study, no. 10.22025/2017.10.101.00001) is funded by UK Medical Research Council (no. MC_UU_12015/1), and N.W. is a NIHR senior investigator. We also thank the Fenland Study Investigators, Fenland Study Co-ordination team and the Epidemiology Field, Data and Laboratory teams. HUNT3 is funded by the Norwegian Ministry of Health, Norwegian University of Science and Technology and Norwegian Research Council, Central Norway Regional Health Authority, the Nord-Trondelag County Council and the Norwegian Institute of Public Health. The HERITAGE Family study was funded by the US National Heart, Lung and Blood Institute grants (NIH/NHLBI, no. R01HL146462 to M.A.S.) and no. HL45670 (HERITAGE, to C.B.). All authors are grateful to all volunteers/participants in all of the cohorts, and to the general practitioners, other physicans and practice staff for assistance with recruitment. SomaScan assays and the Covance study were funded by SomaLogic, Inc. The authors also thank A. Lowell (leader of the SomaLogic assay team), D. Perry for the bioinformatics of quality control, J. Williams for the agreements with the study institutions and J. Zach for clinical data organization and management.	Barry E, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6538; Brody E, 2012, J MOL BIOL, V422, P595, DOI 10.1016/j.jmb.2012.06.021; Candia J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14755-5; Christensson A, 2018, PROTEOM CLIN APPL, V12, DOI 10.1002/prca.201700067; de Silva CGD, 2019, INT J OBESITY, V43, P2225, DOI 10.1038/s41366-018-0257-0; Dimitrov DV, 2016, HEALTHC INFORM RES, V22, P156, DOI 10.4258/hir.2016.22.3.156; Emilsson V, 2018, SCIENCE, V361, P769, DOI 10.1126/science.aaq1327; Ezkurdia I, 2014, HUM MOL GENET, V23, P5866, DOI 10.1093/hmg/ddu309; Fielding Cory M, 2014, Curr Hepatol Rep, V13, P151; Flores M, 2013, PERS MED, V10, P565, DOI 10.2217/pme.13.57; Forouzanfar MH, 2015, LANCET, V386, P2287, DOI 10.1016/S0140-6736(15)00128-2; Ganna A, 2012, AM J EPIDEMIOL, V175, P715, DOI 10.1093/aje/kwr374; Ganz P, 2016, JAMA-J AM MED ASSOC, V315, P2532, DOI 10.1001/jama.2016.5951; Gold L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015004; Han ZJ, 2018, DIAGNOSTICS, V8, DOI 10.3390/diagnostics8040071; Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7; Hobbs FDR, 2010, QJM-INT J MED, V103, P727, DOI 10.1093/qjmed/hcq122; Kim CH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26640-w; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Lin HS, 2008, SCIENCE, V320, P807, DOI 10.1126/science.1154370; Maruthappu M, 2016, LANCET DIABETES ENDO, V4, P299, DOI 10.1016/S2213-8587(16)00073-5; Menni C, 2015, J GERONTOL A-BIOL, V70, P809, DOI 10.1093/gerona/glu121; Middleton KR, 2013, AM J LIFESTYLE MED, V7, P395, DOI 10.1177/1559827613488867; Musich S, 2016, POPUL HEALTH MANAG, V19, P389, DOI 10.1089/pop.2015.0171; O'Dwyer DN, 2017, SCI REP-UK, V7, DOI 10.1038/srep46560; Ostroff RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046091; Ostroff Rachel M, 2010, PLoS One, V5, pe15003, DOI 10.1371/journal.pone.0015003; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Robson J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-008840; Rohloff JC, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.49; Ross R, 2016, CIRCULATION, V134, pE653, DOI 10.1161/CIR.0000000000000461; Shuster A, 2012, BRIT J RADIOL, V85, P1, DOI 10.1259/bjr/38447238; Sun BB, 2018, NATURE, V558, P73, DOI 10.1038/s41586-018-0175-2; Tasaki S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05044-4; Thrush AB, 2018, INT J OBESITY, V42, P353, DOI 10.1038/ijo.2017.286; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Usher-Smith JA, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i3139; Williams SA, 2018, CIRCULATION, V137, P999, DOI 10.1161/CIRCULATIONAHA.117.028213; Wood GC, 2017, SCI REP-UK, V7, DOI 10.1038/srep43238; Yki-Jarvinen H, 2014, LANCET DIABETES ENDO, V2, P901, DOI 10.1016/S2213-8587(14)70032-4; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	41	117	117	7	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2019	25	12					1851	+		10.1038/s41591-019-0665-2	http://dx.doi.org/10.1038/s41591-019-0665-2			17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	JT2KO	31792462	Green Accepted, Green Submitted			2023-01-03	WOS:000500824900028
J	Tayyar, Y; Shiels, R; Bulmer, AC; Lam, AK; Clarke, D; Idris, A; McMillan, NA				Tayyar, Yaman; Shiels, Ryan; Bulmer, Andrew C.; Lam, Alfred K.; Clarke, Daniel; Idris, Adi; McMillan, Nigel A.			Development of an intravaginal ring for the topical delivery of Aurora kinase A inhibitor, MLN8237	PLOS ONE			English	Article							HIV MICROBICIDE TMC120; VAGINAL RINGS; NONOXYNOL-9; PAPILLOMAVIRUS; RELEASE	Human papilloma virus (HPV) is the main culprit in cervical cancers. Although the HPV vaccine is now available, the slow and gradual process for HPV cancers to form means little will change, even for vaccinated individuals. This warrants the development of new therapeutic strategies in both the newly diagnosed and recurrent patients. We have previously shown that Alisertib (MLN8237), an Aurora A kinase inhibitor, potently and selectively kills HPVpositive cervical cancer cells. However, Alisertib is known for its unfavorable side effects when administered systemically. A targeted delivery approach is therefore warranted. The topical delivery of drugs to the cervix for the treatment of cervical cancer is an underexplored area of research that has the potential to significantly improve therapeutic outcome. Here, we design a novel topical drug delivery system for localized delivery in the vaginal tract using intravaginal silicone rings loaded with Alisertib. We assessed the suitability of the drug for the application and delivery method and develop a high-performance liquid chromatography method, then show that the vaginal rings were effective at releasing Alisertib over an extended period of time. Furthermore, we showed that Alisertib-loaded vaginal rings did not induce overt inflammation in the mouse vaginal tract. Our work has major translational implications for the future development of vaginal ring devices for the topical treatment of cervical cancer.	[Tayyar, Yaman; Shiels, Ryan; Bulmer, Andrew C.; Clarke, Daniel; Idris, Adi; McMillan, Nigel A.] Griffith Univ, Sch Med Sci, Southport, Qld, Australia; [Tayyar, Yaman; Lam, Alfred K.; Idris, Adi; McMillan, Nigel A.] Griffith Univ, Menzies Hlth Inst Queensland, Southport, Qld, Australia	Griffith University; Griffith University	Idris, A (corresponding author), Griffith Univ, Sch Med Sci, Southport, Qld, Australia.; Idris, A (corresponding author), Griffith Univ, Menzies Hlth Inst Queensland, Southport, Qld, Australia.	a.idris@griffith.edu.au	Lam, Alfred/C-1652-2008; McMillan, Nigel/AAQ-5416-2021; Idris, Adi/N-3500-2016; Tayyar, Yaman/E-3896-2016	Lam, Alfred/0000-0003-2771-564X; Idris, Adi/0000-0002-0562-1549; Tayyar, Yaman/0000-0003-4385-0569; McMillan, Nigel/0000-0002-9471-1406	National Health and Medical Research Council [APP1104186]	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the National Health and Medical Research Council (APP1104186). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2016, CANC CERVIX UTERI IN; Bell SEJ, 2007, J PHARM PHARMACOL, V59, P203, DOI 10.1211/jpp.59.2.0007; Dang TTN, 2014, POLYM MATRIX DEVICES; Fetherston SM, 2013, EUR J PHARM SCI, V48, P406, DOI 10.1016/j.ejps.2012.12.002; Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055; Gabrielli B, 2015, MOL CANCER THER, V14, P2753, DOI 10.1158/1535-7163.MCT-15-0506; Malcolm K, 2003, J CONTROL RELEASE, V91, P355, DOI 10.1016/S0168-3659(03)00260-8; Malcolm RK, 2016, ADV DRUG DELIVER REV, V103, P33, DOI 10.1016/j.addr.2016.01.015; Malcolm RK, 2010, ANTIVIR RES, V88, pS30, DOI 10.1016/j.antiviral.2010.09.003; Malcolm RK, 2005, J ANTIMICROB CHEMOTH, V56, P954, DOI 10.1093/jac/dki326; Martin D, 2017, MOL CANCER THER, V16, P1934, DOI 10.1158/1535-7163.MCT-17-0159; Morrow RJ, 2011, EUR J PHARM BIOPHARM, V77, P3, DOI 10.1016/j.ejpb.2010.10.010; Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4; Pecorelli S, 2003, CANCER J, V9, P390, DOI 10.1097/00130404-200309000-00009; RADOMSKY ML, 1992, BIOL REPROD, V47, P133, DOI 10.1095/biolreprod47.1.133; Seiden MV, 2012, HARRISONS PRINCIPLES; Stafford MK, 1998, J ACQ IMMUN DEF SYND, V17, P327, DOI 10.1097/00042560-199804010-00006; Tayyar Y, 2017, CRIT REV ONCOL HEMAT, V119, P59, DOI 10.1016/j.critrevonc.2017.09.006; Van Damme L, 2002, LANCET, V360, P971, DOI 10.1016/S0140-6736(02)11079-8; Woolfson AD, 2006, INT J PHARMACEUT, V325, P82, DOI 10.1016/j.ijpharm.2006.06.026; Wyatt TL, 1998, J CONTROL RELEASE, V50, P93, DOI 10.1016/S0168-3659(97)00114-4; Yugaw T, 2013, MOL CELL BIOL, V33, P4434, DOI 10.1128/MCB.00577-13; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	23	2	2	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2019	14	11							e0225774	10.1371/journal.pone.0225774	http://dx.doi.org/10.1371/journal.pone.0225774			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO8SS	31774882	Green Published, gold			2023-01-03	WOS:000533896400061
J	Watkins, JA; Ross, JDC; Thandi, S; Brittain, C; Kai, J; Griffiths, F				Watkins, Jocelyn Anstey; Ross, Jonathan D. C.; Thandi, Sukhwinder; Brittain, Clare; Kai, Joe; Griffiths, Frances			Acceptability of and treatment preferences for recurrent bacterial vaginosis-Topical lactic acid gel or oral metronidazole antibiotic: Qualitative findings from the VITA trial	PLOS ONE			English	Article							ADHERENCE; SAFETY	Background Bacterial vaginosis (BV) is associated with an elevated vaginal pH and the presence of abnormal offensive discharge. It is common, often recurrent, and the most effective treatment regimen is unknown. 'Metronidazole Versus lactic acId for Treating bacterial vAginosis' (VITA) is a UK-based randomised controlled trial assessing clinical and cost-effectiveness of topical lactic acid gel compared to oral metronidazole antibiotic for treating second and subsequent BV episodes. Few BV trials report on women's preferences for treatment in the context of their own experiences. Method This qualitative study investigated the acceptability and tolerability of the two treatments. During the trial, semi-structured telephone interviews were undertaken between January-May 2018. A total of 33 women diagnosed with BV were consecutively sampled then interviewed from six sites across England. Thematic analysis was guided by the acceptability of health interventions framework. Potential causes of BV and its impact on women's lives were explored in addition to women's treatment preference and perceived treatment effectiveness. Results Although women felt antibiotics treat BV effectively, and were associated with longer time periods between episodes, they generally preferred using the lactic acid gel because of ease of use, once daily application and less side-effects. Women would recommend the lactic acid gel to others for mild cases of BV but to take antibiotics when more severe. The risk of antibiotic drug resistance was a common concern. Self-help medicating or self-decision to not treat was also evident due to prior experience of poor outcomes from treatment. Triggers of BV were attributed to personal hygiene habits-soaps used to wash the vagina and sexual practices such as unprotected sex. Conclusion Acceptability and preference for topical lactic acid gel or oral metronidazole tablets in the treatment of recurrent BV was affected by personal choice relating to affective attitude, burden, ethicality, intervention coherence, opportunity costs, and self-efficacy. These differed depending on ease of use, tolerability and past experiences, but not necessarily based on perceived drug effectiveness. Knowledge of a patient preference for topical lactic acid gel therapy despite lower perceived effectiveness may be useful for clinicians when making treatment decisions.	[Watkins, Jocelyn Anstey; Griffiths, Frances] Univ Warwick, Warwick Med Sch, Coventry, W Midlands, England; [Ross, Jonathan D. C.] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, England; [Thandi, Sukhwinder; Brittain, Clare] Univ Nottingham, Nottingham Clin Trials Unit, Nottingham, England; [Kai, Joe] Univ Nottingham, Div Primary Care, Nottingham, England; [Griffiths, Frances] Univ Witwatersrand, Ctr Hlth Policy, Johannesburg, South Africa	University of Warwick; University of Birmingham; University of Nottingham; University of Nottingham; University of Witwatersrand	Watkins, JA (corresponding author), Univ Warwick, Warwick Med Sch, Coventry, W Midlands, England.	j.watkins.1@warwick.ac.uk		Kai, Joe/0000-0001-9040-9384; Brittain, Clare/0000-0002-2950-0733; Anstey Watkins, Jocelyn/0000-0003-4984-1057; Ross, Jonathan/0000-0002-4193-6919; Griffiths, Frances/0000-0002-4173-1438	National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme (U.K.) [15/110/02]	National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme (U.K.)(National Institute for Health Research (NIHR))	This trial is funded by The National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme (U.K.), Grant holder: Professor Jonathan D. C. Ross, Bio link: https://www.fundingawards.nihr.ac.uk/award/15/110/02.Grant number: 15/110/02, Funder website: https://www.nihr.ac.uk/explore-nihr/funding-programmes/health-technologyassessment.htm.The funders provided an external review of the study proposal but had no role in the protocol design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adolfsson A., 2017, ADV SEX MED, V7, P1, DOI [10.4236/asm.2017.71001, DOI 10.4236/ASM.2017.71001]; Armitage C, 2017, WOMEN'S HEALTH IN PRIMARY CARE, P37; Barbosa CD, 2012, PATIENT PREFER ADHER, V6, P39, DOI 10.2147/PPA.S24752; Bilardi JE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173637; Bilardi JE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074378; Bradshaw CS, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1027-4; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Coggins C, 2000, SEX TRANSM INFECT, V76, P480, DOI 10.1136/sti.76.6.480; Devaux S, 2012, J EUR ACAD DERMATOL, V26, P61, DOI 10.1111/j.1468-3083.2012.04525.x; Forsum U, 2005, APMIS, V113, P81, DOI 10.1111/j.1600-0463.2005.apm1130201.x; Hay S.P.P., 2012, UK NATL GUIDELINE MA; Hemmerling A, 2010, SEX TRANSM DIS, V37, P745, DOI 10.1097/OLQ.0b013e3181e50026; Hull CE, 2016, CLIN REVS, V44; ISRCTN, 2019, BMC SPRINGER NATURE, DOI [10.1186/ISRCTN14161293, DOI 10.1186/ISRCTN14161293]; KAZDIN AE, 1980, J APPL BEHAV ANAL, V13, P259, DOI 10.1901/jaba.1980.13-259; Lindsay Armstrong-Buisseret CB, 2019, TRIALS; Ma LY, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-019301; Machado D, 2016, BACTERIAL VAGINOSIS; McGowan I, 2011, AIDS, V25, P1057, DOI 10.1097/QAD.0b013e328346bd3e; MILTENBERGER RG, 1990, TOP EARLY CHILD SPEC, V10, P24, DOI 10.1177/027112149001000304; Mogha KV, 2017, REV MED MICROBIOL, V28, P19, DOI 10.1097/MRM.0000000000000090; NICE, 2012, UK NATL GUID MAN BAC; O'Brien BC, 2014, ACAD MED, V89, P1245, DOI 10.1097/ACM.0000000000000388; O'Brien RF, 2005, CURR OPIN PEDIATR, V17, P473, DOI 10.1097/01.mop.0000170516.35272.45; Payne SC, 2010, J AM ACAD NURSE PRAC, V22, P101, DOI 10.1111/j.1745-7599.2009.00474.x; Sekhon M, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2031-8; Turovskiy Y, 2011, J APPL MICROBIOL, V110, P1105, DOI 10.1111/j.1365-2672.2011.04977.x; Wilson J, 2004, SEX TRANSM INFECT, V80, P8, DOI 10.1136/sti.2002.002733	28	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2019	14	11							e0224964	10.1371/journal.pone.0224964	http://dx.doi.org/10.1371/journal.pone.0224964			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN2YM	31730666	Green Published, gold			2023-01-03	WOS:000532809500016
J	Bauknight, DK; Osinski, V; Dasa, SSK; Nguyen, AT; Marshall, MA; Hartman, J; Harms, M; O'Mahony, G; Boucher, J; Klibanov, AL; McNamara, CA; Kelly, KA				Bauknight, Dustin K.; Osinski, Victoria; Dasa, Siva Sai Krishna; Nguyen, Anh T.; Marshall, Melissa A.; Hartman, Julia; Harms, Matthew; O'Mahony, Gavin; Boucher, Jeremie; Klibanov, Alexander L.; McNamara, Coleen A.; Kelly, Kimberly A.			Importance of thorough tissue and cellular level characterization of targeted drugs in the evaluation of pharmacodynamic effects	PLOS ONE			English	Article							RECEPTOR-ALPHA/GAMMA AGONIST; INSULIN-RESISTANCE; ENDOTHELIAL-CELLS; ADIPOSE-TISSUE; B-LYMPHOCYTES; PPAR-ALPHA; TESAGLITAZAR; MACROPHAGES; PROHIBITIN; LIPOSOMES	Targeted nanoparticle delivery is a promising strategy for increasing efficacy and limiting side effects of therapeutics. When designing a targeted liposomal formulation, the in vivo biodistribution of the particles must be characterized to determine the value of the targeting approach. Peroxisome proliferator-activated receptor (PPAR) agonists effectively treat metabolic syndrome by decreasing dyslipidemia and insulin resistance but side effects have limited their use, making them a class of compounds that could benefit from targeted liposomal delivery. The adipose targeting sequence peptide (ATS) could fit this role, as it has been shown to bind to adipose tissue endothelium and induce weight loss when delivered conjugated to a pro-apoptotic peptide. To date, however, a full assessment of ATS in vivo biodistribution has not been reported, leaving important unanswered questions regarding the exact mechanisms whereby ATS targeting enhances therapeutic efficacy. We designed this study to evaluate the biodistribution of ATS-conjugated liposomes loaded with the PPAR alpha/gamma dual agonist tesaglitazar in leptin-deficient ob/ob mice. The ATS-liposome biodistribution in adipose tissue and other organs was examined at the cellular and tissue level using microscopy, flow cytometry, and fluorescent molecular tomography. Changes in metabolic parameters and gene expression were measured by target and off-target tissue responses to the treatment. Unexpectedly, ATS targeting did not increase liposomal uptake in adipose relative to other tissues, but did increase uptake in the kidneys. Targeting also did not significantly alter metabolic parameters. Analysis of the liposome cellular distribution in the stromal vascular fraction with flow cytometry revealed high uptake by multiple cell types. Our findings highlight the need for thorough study of in vivo biodistribution when evaluating a targeted therapy.	[Bauknight, Dustin K.; Dasa, Siva Sai Krishna; Hartman, Julia; Klibanov, Alexander L.; Kelly, Kimberly A.] Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22903 USA; [Bauknight, Dustin K.; Dasa, Siva Sai Krishna; Kelly, Kimberly A.] Univ Virginia, Canc Ctr, Charlottesville, VA 22903 USA; [Osinski, Victoria; Nguyen, Anh T.; Marshall, Melissa A.; Hartman, Julia; Klibanov, Alexander L.; McNamara, Coleen A.] Univ Virginia, Robert M Berne Cardiovasc Res Ctr, Charlottesville, VA USA; [Osinski, Victoria] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; [Harms, Matthew; O'Mahony, Gavin; Boucher, Jeremie] AstraZeneca, BioPharmaceut R&D, Res & Early Dev Cardiovasc Renal & Metab CVRM, Gothenburg, Sweden; [Boucher, Jeremie] Univ Gothenburg, Lundberg Lab Diabet Res, Gothenburg, Sweden; [Boucher, Jeremie] Univ Gothenburg, Wallenberg Ctr Mol & Translat Med, Gothenburg, Sweden; [Klibanov, Alexander L.; McNamara, Coleen A.] Univ Virginia, Dept Med, Div Cardiovasc Med, Charlottesville, VA USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia; AstraZeneca; University of Gothenburg; University of Gothenburg; University of Virginia	Kelly, KA (corresponding author), Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22903 USA.; Kelly, KA (corresponding author), Univ Virginia, Canc Ctr, Charlottesville, VA 22903 USA.	kak3x@virginia.edu	Osinski, Victoria/AGX-7982-2022; Nguyen, Anh/GQQ-3393-2022; Osinski, Victoria/AAU-5839-2020	Osinski, Victoria/0000-0002-8969-8454	AstraZeneca/UVA Strategic Alliance; NATIONAL CANCER INSTITUTE [R01CA168712, P30CA008748] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055798] Funding Source: NIH RePORTER	AstraZeneca/UVA Strategic Alliance(AstraZeneca); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was funded by the AstraZeneca/UVA Strategic Alliance to CAM, KAK & ALK. Authors HM, GO, and JB are employees of AstraZeneca. The funder provided support in the form of salaries for authors HM, GO, and JB but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section. Competing interests:	Ande SR, 2016, TRENDS ENDOCRIN MET, V27, P531, DOI 10.1016/j.tem.2016.05.003; Bailey Clifford J, 2007, Diab Vasc Dis Res, V4, P161; Barenholz Y, 2012, J CONTROL RELEASE, V160, P117, DOI 10.1016/j.jconrel.2012.03.020; Barnhart KF, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002621; Bays Harold, 2007, Diab Vasc Dis Res, V4, P181; Beech JR, 2013, CURR PHARM DESIGN, V19, P6560; Bu L, 2013, AAPS J, V15, P1001, DOI 10.1208/s12248-013-9501-7; Bulbake U, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9020012; Church CD, 2014, METHOD ENZYMOL, V537, P31, DOI 10.1016/B978-0-12-411619-1.00003-3; Dasa SSK, 2017, NANOMED-NANOTECHNOL, V13, P2565, DOI 10.1016/j.nano.2017.07.005; Dasa SSK, 2015, J CONTROL RELEASE, V220, P556, DOI 10.1016/j.jconrel.2015.06.017; Fagerberg B, 2005, DIABETOLOGIA, V48, P1716, DOI 10.1007/s00125-005-1846-8; Feng B, 2011, PLOS ONE, V6, P1, DOI DOI 10.1371/J0URNAL.P0NE.0024358; Glassman PM, 2019, J PHARMACOL EXP THER, V370, P570, DOI 10.1124/jpet.119.257113; Goldstein BJ, 2006, CURR MED RES OPIN, V22, P2575, DOI 10.1185/030079906X154169; Grygiel-Gorniak B, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-17; Hamren B, 2012, J CLIN PHARMACOL, V52, P1317, DOI 10.1177/0091270011416937; Heilbronn LK, 2008, CURR PHARM DESIGN, V14, P1225, DOI 10.2174/138161208784246153; Hossen MN, 2012, J CONTROL RELEASE, V163, P101, DOI 10.1016/j.jconrel.2012.09.002; Hossen MN, 2010, J CONTROL RELEASE, V147, P261, DOI 10.1016/j.jconrel.2010.07.100; Kajimoto K, 2010, J IMMUNOL METHODS, V357, P43, DOI 10.1016/j.jim.2010.03.011; Kim DH, 2010, DIABETES, V59, P907, DOI 10.2337/db09-1141; Kiss-Toth E, 2008, PPAR RES, V2008, DOI 10.1155/2008/183108; Kolonin MG, 2004, NAT MED, V10, P625, DOI 10.1038/nm1048; Kulkarni JA, 2019, NANOSCALE, V11, P9023, DOI 10.1039/c9nr02004g; Ljung B, 2002, J LIPID RES, V43, P1855, DOI 10.1194/jlr.M200127-JLR200; McDonnell ME, 2012, OBESITY, V20, P1372, DOI 10.1038/oby.2012.54; Murakami K, 2007, EUR J PHARMACOL, V561, P206, DOI 10.1016/j.ejphar.2006.12.037; Oakes ND, 2005, AM J PHYSIOL-REG I, V289, pR938, DOI 10.1152/ajpregu.00252.2005; Osman C, 2009, J CELL SCI, V122, P3823, DOI 10.1242/jcs.037655; Pang C, 2008, AM J PHYSIOL-ENDOC M, V295, pE313, DOI 10.1152/ajpendo.90296.2008; Penas F, 2015, BBA-MOL BASIS DIS, V1852, P893, DOI 10.1016/j.bbadis.2014.12.019; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; Rakhshandehroo M, 2010, PPAR RES, V2010, DOI 10.1155/2010/612089; Ramakrishnan VM, 2018, TISSUE ENG PART B-RE, V24, P289, DOI [10.1089/ten.teb.2017.0061, 10.1089/ten.TEB.2017.0061]; Rizos CV, 2009, EXPERT OPIN DRUG SAF, V8, P15, DOI [10.1517/14740330802597821 , 10.1517/14740330802597821]; Ruan XZ, 2008, AM J PHYSIOL-RENAL, V294, pF1032, DOI 10.1152/ajprenal.00152.2007; Salameh A, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86351; Schleicher M, 2008, J CELL BIOL, V180, P101, DOI 10.1083/jcb.200706072; Schuster H, 2008, ATHEROSCLEROSIS, V197, P355, DOI 10.1016/j.atherosclerosis.2007.05.029; Sharma A, 2004, P NATL ACAD SCI USA, V101, P17492, DOI 10.1073/pnas.0407536101; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; Sugii S, 2009, P NATL ACAD SCI USA, V106, P22504, DOI 10.1073/pnas.0912487106; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; Tonstad S, 2007, METABOLISM, V56, P1285, DOI 10.1016/j.metabol.2007.05.003; Wang FF, 2013, P NATL ACAD SCI USA, V110, P18656, DOI 10.1073/pnas.1314863110; Wang YJ, 2014, BBA-MOL CELL RES, V1843, P1393, DOI 10.1016/j.bbamcr.2014.04.005; Wang YX, 2010, CELL RES, V20, P124, DOI 10.1038/cr.2010.13; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Won YW, 2014, NAT MATER, V13, P1157, DOI [10.1038/NMAT4092, 10.1038/nmat4092]; Working P. K., 1994, Journal of Liposome Research, V4, P667, DOI 10.3109/08982109409037065; Xue Y, 2016, P NATL ACAD SCI USA, V113, P5552, DOI 10.1073/pnas.1603840113; Zhang HJ, 2016, ONCOTARGETS THER, V9, P3001, DOI 10.2147/OTT.S105587	54	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2019	14	11							e0224917	10.1371/journal.pone.0224917	http://dx.doi.org/10.1371/journal.pone.0224917			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN2HK	31725756	Green Published, gold			2023-01-03	WOS:000532764500034
J	van Mourik, N; Metske, HA; Hofstra, JJ; Binnekade, JM; Geerts, BF; Schultz, MJ; Vlaar, APJ				van Mourik, Niels; Metske, Hennie A.; Hofstra, Jorrit J.; Binnekade, Jan M.; Geerts, Bart F.; Schultz, Marcus J.; Vlaar, Alexander P. J.			Cumulative fluid balance predicts mortality and increases time on mechanical ventilation in ARDS patients: An observational cohort study	PLOS ONE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; CRITICALLY-ILL; MANAGEMENT; OUTCOMES	Introduction Acute respiratory distress syndrome (ARDS) is characterized by acute, diffuse, inflammatory lung injury leading to increased pulmonary vascular permeability, pulmonary oedema and loss of aerated tissue. Previous literature showed that restrictive fluid therapy in ARDS shortens time on mechanical ventilation and length of ICU-stay. However, the effect of intravenous fluid use on mortality remains uncertain. We investigated the relationship between cumulative fluid balance (FB), time on mechanical ventilation and mortality in ARDS patients. Materials and methods Retrospective observational study. Patients were divided in four cohorts based on cumulative FB on day 7 of ICU-admission: <= 0 L (Group I); 0-3.5 L (Group II); 3.5-8 L (Group III) and >= 8 L (Group IV). In addition, we used cumulative FB on day 7 as continuum as a predictor of mortality. Primary outcomes were 28-day mortality and ventilator-free days. Secondary outcomes were 90-day mortality and ICU length of stay. Results Six hundred ARDS patients were included, of whom 156 (26%) died within 28 days. Patients with a higher cumulative FB on day 7 had a longer length of ICU-stay and fewer ventilatorfree days on day 28. Furthermore, after adjusting for severity of illness, a higher cumulative FB was associated with 28-day mortality (Group II, adjusted OR (aOR) 2.1 [1.0-4.6], p = 0.045; Group III, aOR 3.3 [1.7-7.2], p = 0.001; Group IV, aOR 7.9 [4.0-16.8], p<0.001). Using restricted cubic splines, a non-linear dose-response relationship between cumulative FB and probability of death at day 28 was found; where a more positive FB predicted mortality and a negative FB showed a trend towards survival. Conclusions A higher cumulative fluid balance is independently associated with increased risk of death, longer time on mechanical ventilation and longer length of ICU-stay in patients with ARDS. This underlines the importance of implementing restrictive fluid therapy in ARDS patients.	[van Mourik, Niels; Metske, Hennie A.; Geerts, Bart F.] Univ Amsterdam, Amsterdam UMC, Dept Anaesthesiol, Locat AMC, Amsterdam, Netherlands; [van Mourik, Niels; Hofstra, Jorrit J.; Binnekade, Jan M.; Schultz, Marcus J.; Vlaar, Alexander P. J.] Univ Amsterdam, Dept Intens Care Med, Amsterdam UMC, Locat AMC, Amsterdam, Netherlands	University of Amsterdam; University of Amsterdam	Vlaar, APJ (corresponding author), Univ Amsterdam, Dept Intens Care Med, Amsterdam UMC, Locat AMC, Amsterdam, Netherlands.	a.p.vlaar@amc.uva.nl	Schultz, Marcus/AAB-6379-2021	Schultz, Marcus/0000-0003-3969-7792; Vlaar, Alexander/0000-0002-3453-7186				Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Boyd JH, 2011, CRIT CARE MED, V39, P259, DOI 10.1097/CCM.0b013e3181feeb15; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Carrasco Loza R, 2015, Open Respir Med J, V9, P112, DOI 10.2174/1874306401509010112; Godin M, 2013, NEPHRON CLIN PRACT, V123, P238, DOI 10.1159/000354713; Grams ME, 2011, CLIN J AM SOC NEPHRO, V6, P966, DOI 10.2215/CJN.08781010; Koonrangsesomboon W, 2015, INDIAN J CRIT CARE M, V19, P708, DOI 10.4103/0972-5229.171356; Lee J, 2015, J INTERN MED, V277, P468, DOI 10.1111/joim.12274; Maca J, 2017, RESP CARE, V62, P113, DOI 10.4187/respcare.04716; Malbrain MLNG, 2014, ANAESTH INTENSIVE TH, V46, P361, DOI 10.5603/AIT.2014.0060; Micek ST, 2013, CRIT CARE, V17, DOI 10.1186/cc13072; Mikkelsen ME, 2012, AM J RESP CRIT CARE, V185, P1307, DOI 10.1164/rccm.201111-2025OC; Murphy CV, 2009, CHEST, V136, P102, DOI 10.1378/chest.08-2706; Nagl C, 2006, IEEE INT ENTERP DIST, P35; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Roch A, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-16; Sakr Y, 2005, CHEST, V128, P3098, DOI 10.1378/chest.128.5.3098; Shaver CM, 2014, CLIN CHEST MED, V35, P639, DOI 10.1016/j.ccm.2014.08.004; Silversides JA, 2018, CRIT CARE MED, V46, P1600, DOI 10.1097/CCM.0000000000003276; Uhlig C, 2014, CRIT CARE, V18, DOI 10.1186/cc13187; Vlaar APJ, 2010, CRIT CARE MED, V38, P771, DOI 10.1097/CCM.0b013e3181cc4d4b; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; Zhang ZH, 2015, PEERJ, V3, DOI 10.7717/peerj.752	23	34	34	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2019	14	10							e0224563	10.1371/journal.pone.0224563	http://dx.doi.org/10.1371/journal.pone.0224563			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN0VZ	31665179	Green Published, gold			2023-01-03	WOS:000532664700039
J	Larkin, J; Chiarion-Sileni, V; Gonzalez, R; Grob, JJ; Rutkowski, P; Lao, CD; Cowey, CL; Schadendorf, D; Wagstaff, J; Dummer, R; Ferrucci, PF; Smylie, M; Hogg, D; Hill, A; Marquez-Rodas, I; Haanen, J; Guidoboni, M; Maio, M; Schoffski, P; Carlino, MS; Lebbe, C; McArthur, G; Ascierto, PA; Daniels, GA; Long, GV; Bastholt, L; Rizzo, JI; Balogh, A; Moshyk, A; Hodi, FS; Wolchok, JD				Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J-J; Rutkowski, P.; Lao, C. D.; Cowey, C. L.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; Ferrucci, P. F.; Smylie, M.; Hogg, D.; Hill, A.; Marquez-Rodas, I.; Haanen, J.; Guidoboni, M.; Maio, M.; Schoffski, P.; Carlino, M. S.; Lebbe, C.; McArthur, G.; Ascierto, P. A.; Daniels, G. A.; Long, G. V.; Bastholt, L.; Rizzo, J. I.; Balogh, A.; Moshyk, A.; Hodi, F. S.; Wolchok, J. D.			Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial. Methods We randomly assigned patients with previously untreated advanced melanoma to receive one of the following regimens: nivolumab (at a dose of 1 mg per kilogram of body weight) plus ipilimumab (3 mg per kilogram) every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram every 2 weeks); nivolumab (3 mg per kilogram every 2 weeks) plus ipilimumab-matched placebo; or ipilimumab (3 mg per kilogram every 3 weeks for four doses) plus nivolumab-matched placebo. The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group, as compared with the ipilimumab group. Results At a minimum follow-up of 60 months, the median overall survival was more than 60.0 months (median not reached) in the nivolumab-plus-ipilimumab group and 36.9 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.52; hazard ratio for death with nivolumab vs. ipilimumab, 0.63). Overall survival at 5 years was 52% in the nivolumab-plus-ipilimumab group and 44% in the nivolumab group, as compared with 26% in the ipilimumab group. No sustained deterioration of health-related quality of life was observed during or after treatment with nivolumab plus ipilimumab or with nivolumab alone. No new late toxic effects were noted. Conclusions Among patients with advanced melanoma, sustained long-term overall survival at 5 years was observed in a greater percentage of patients who received nivolumab plus ipilimumab or nivolumab alone than in those who received ipilimumab alone, with no apparent loss of quality of life in the patients who received regimens containing nivolumab.	[Larkin, J.] Royal Marsden NHS Fdn Trust, 203 Fulham Rd, London SW3 6JJ, England; [Wagstaff, J.] Swansea Univ, Coll Med, Swansea, W Glam, Wales; [Chiarion-Sileni, V.] IRCCS, Oncol Inst Veneto, Padua, Italy; [Ferrucci, P. F.] IRCCS, European Inst Oncol, Milan, Italy; [Ascierto, P. A.] Ist Nazl Tumori IRCCS Fdn Pascale, Naples, Italy; [Guidoboni, M.] IRCCS Ist Sci Romagnolo Studio Cura Tumori, Immunotherapy & Somat Cell Therapy Unit, Meldola, Italy; [Maio, M.] Univ Hosp, Ctr Immunooncol Med Oncol & Immunotherapy, Siena, Italy; [Gonzalez, R.] Univ Colorado, Canc Ctr, Aurora, CO USA; [Grob, J-J] Aix Marseille Univ, Hop Timone, AP HM, Marseille, France; [Lebbe, C.] Univ Paris, AP HP, INSERM, Dermatol,Unite 976, Paris, France; [Lebbe, C.] St Louis Hosp, Ctr Invest Clin, Paris, France; [Rutkowski, P.] Maria Sklodowska Curie Inst, Oncol Ctr, Warsaw, Poland; [Lao, C. D.] Univ Michigan, Ann Arbor, MI 48109 USA; [Cowey, C. L.] Baylor Charles A Sammons Canc Ctr, Texas Oncol, Dallas, TX USA; [Schadendorf, D.] Univ Essen Gesamthsch, Dept Dermatol, Essen, Germany; [Schadendorf, D.] German Canc Consortium, Heidelberg, Germany; [Dummer, R.] Univ Spital, Zurich, Switzerland; [Smylie, M.] Cross Canc Inst, Edmonton, AB, Canada; [Hogg, D.] Princess Margaret Canc Ctr, Toronto, ON, Canada; [Hill, A.] Tasman Oncol Res, Southport, Qld, Australia; [Carlino, M. S.; Long, G. V.] Univ Sydney, Melanoma Inst Australia, Crown Princess Mary Canc Ctr, Sydney, NSW, Australia; [Long, G. V.] Royal North Shore & Mater Hosp, Sydney, NSW, Australia; [McArthur, G.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Marquez-Rodas, I.] Gen Univ Hosp Gregorio Maranon, Madrid, Spain; [Marquez-Rodas, I.] Ctr Invest Biomed Red Oncol, Madrid, Spain; [Haanen, J.] Netherlands Canc Inst, Amsterdam, Netherlands; [Schoffski, P.] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven Canc Inst, Leuven, Belgium; [Daniels, G. A.] Univ Calif San Diego, Hlth La Jolla Moores, La Jolla, CA 92093 USA; [Bastholt, L.] Odense Univ Hosp, Dept Oncol, Odense, Denmark; [Rizzo, J. I.; Balogh, A.; Moshyk, A.] Bristol Myers Squibb, Princeton, NJ USA; [Hodi, F. S.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Wolchok, J. D.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Wolchok, J. D.] Weill Cornell Med Coll, New York, NY USA	Royal Marsden NHS Foundation Trust; Swansea University; IRCCS Istituto Oncologico Veneto (IOV); IRCCS European Institute of Oncology (IEO); IRCCS Fondazione Pascale; IRCCS Meldola (IRST); University of Siena; University Hospital of Siena; University of Colorado System; University of Colorado Anschutz Medical Campus; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Maria Sklodowska-Curie National Research Institute of Oncology; University of Michigan System; University of Michigan; Baylor University Medical Center; Texas Oncology; Texas Oncology-Baylor Charles A Sammons Cancer Center; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); University of Alberta; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Melanoma Institute Australia; University of Sydney; Royal North Shore Hospital; Peter Maccallum Cancer Center; General University Gregorio Maranon Hospital; Netherlands Cancer Institute; KU Leuven; University Hospital Leuven; University of California System; University of California San Diego; University of Southern Denmark; Odense University Hospital; Bristol-Myers Squibb; Harvard University; Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer Center; Cornell University	Larkin, J (corresponding author), Royal Marsden NHS Fdn Trust, 203 Fulham Rd, London SW3 6JJ, England.	james.larkin@rmh.nhs.uk	sileni, vanna chiarion/B-9042-2018; Carlino, Matteo/GRS-7198-2022; Rutkowski, Piotr/B-3907-2013; Ascierto, Paolo A/J-9106-2016; Haanen, John/AAD-8534-2022; Schadendorf, Dirk/AAE-8206-2019; Ferrucci, Pier Francesco/AAQ-9002-2020; Marquez-Rodas, Ivan/ABD-5532-2021; Haanen, John/AAD-8578-2022; Long, Georgina/C-1771-2013	sileni, vanna chiarion/0000-0001-9191-9124; Rutkowski, Piotr/0000-0002-8920-5429; Ascierto, Paolo A/0000-0002-8322-475X; Haanen, John/0000-0001-5884-7704; Marquez-Rodas, Ivan/0000-0002-2476-668X; Schadendorf, Dirk/0000-0003-3524-7858; Guidoboni, Massimo/0000-0001-7703-790X; Bastholt, Lars/0000-0001-5478-9826; Ferrucci, Pier Francesco/0000-0001-6255-5851; Larkin, James/0000-0001-5569-9523; Melucci, Maria Teresa/0000-0002-1677-3345; Carlino, Matteo/0000-0002-7861-4104; Long, Georgina/0000-0001-8894-3545	Bristol-Myers Squibb [P30CA008748]; National Cancer Institute; National Institute for Health Research Royal Marsden-Institute of Cancer Research Biomedical Research Centre	Bristol-Myers Squibb(Bristol-Myers Squibb); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute for Health Research Royal Marsden-Institute of Cancer Research Biomedical Research Centre	Supported by Bristol-Myers Squibb, a grant (P30CA008748, to Dr. Wolchok) from the National Cancer Institute, and a grant (to Dr. Larkin) from the National Institute for Health Research Royal Marsden-Institute of Cancer Research Biomedical Research Centre.	Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Hodi FS, 2018, LANCET ONCOL, V19, P1480, DOI 10.1016/S1470-2045(18)30700-9; Khair DO, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00453; Lebbe C, 2019, J CLIN ONCOL, V37, P867, DOI 10.1200/JCO.18.01998; Long GV, 2018, LANCET ONCOL, V19, P672, DOI 10.1016/S1470-2045(18)30139-6; Pickard AS, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-70; Regan MM, 2019, J CLIN ONCOL; Robert C, 2019, NEW ENGL J MED, V381, P626, DOI 10.1056/NEJMoa1904059; Schadendorf D, 2019, AM SOC CLIN ONC ASCO, P9551; Tarhini A, 2019, IMMUNOTHERAPY-UK, V11, P283, DOI 10.2217/imt-2018-0168; Tarhini A, 2018, IMMUNOTHERAPY-UK, V10, P1241, DOI 10.2217/imt-2018-0085; Tawbi HA, 2018, NEW ENGL J MED, V379, P722, DOI 10.1056/NEJMoa1805453; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684	14	1490	1517	7	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	2019	381	16					1535	1546		10.1056/NEJMoa1910836	http://dx.doi.org/10.1056/NEJMoa1910836			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF0NV	31562797	Green Published, Bronze			2023-01-03	WOS:000491085100007
J	Wogayehu, B; Chisha, Y; Tekabe, B; Adinew, A; Asefaw, M				Wogayehu, Biruk; Chisha, Yilma; Tekabe, Be'emnetu; Adinew, Ayalew; Asefaw, Mulugeta			A cross sectional comparison of drug use indicators using WHO methodology in primary level hospitals participating in an Auditable Pharmaceutical Transactions and Services program versus non-APTS primary hospitals in Southern Ethiopia	PLOS ONE			English	Article							HEALTH-CARE CENTERS; PATIENT-CARE; FACILITIES	Introduction Ethiopian pharmaceutical sector has been facing inaccessibility and unaffordability to key essential medicines due to medicines diversion from the public to private health care facilities, lack of transparency, poor inventory management, and poor dispensing workflow. In an effort to improve the pharmaceutical sector, the government of Ethiopia in 2011 introduced Auditable Pharmaceutical Transactions and Services program. This study intended to compare drug use indicators in auditable and non-auditable primary level hospitals. Methods A cross-sectional comparative study was conducted between January 2018 and December 2018 at primary level hospitals in southern Ethiopia: one with Auditable Pharmaceutical Transactions and Services (APTS) program; another without APTS (Non-APTS). WHO drug use indicators in auditable primary hospitals (n = 10) and similar non-auditable primary hospitals (n = 10) were compared. The prescribing indicators and average cost of medicines were evaluated retrospectively using 1000 prescriptions from each group. Patient care indicators were evaluated prospectively by interviewing and observing 1000 patients from each group. Patient satisfaction was assessed by interviewing 1000 patients from each group. Health care facilities were evaluated through observation. We performed descriptive analysis, t-test, logistic regression, Mann-Whitney U test and linear regression using SPSS version 20.0. Results The mean consultation time in auditable and non-auditable hospitals was found to be 6.5 minutes and 3.46 minutes, respectively. The average dispensing time in auditable and non-auditable hospitals was found to be 6.6 minutes and 1.02 minutes, respectively. The proportion of drugs actually dispensed was 97.59% in APTS facilities and 76.44% in the non-audit able facilities with the lowest value seen in a non-auditable facility (51.65%). The average number of drugs per prescription was 2.32 (+/- 1.26) and 2.84 (+/- 1.17) in auditable and non-auditable facilities, respectively. The level of patient satisfaction on the convenience of pharmacy location, information on contraindications, availability of drugs and amount of time for counseling was significantly higher in the auditable facilities than the non-auditable facilities (p<0.001). Conclusions This study revealed that patient care indicator values, the level of patient satisfaction on the pharmacy services and health facility indicator values were significantly better in APTS than Non-APTS primary level hospitals. Most of prescribing indicators and labeling practices were not met WHO stated standard in both auditable and non-auditable facilities. This indicates that the auditable program should include additional strategies to reverse the existing irrational prescribing and inadequate labeling practices.	[Wogayehu, Biruk] Arbaminch Coll Hlth Sci, Dept Pharm, Arbaminch, Ethiopia; [Chisha, Yilma; Tekabe, Be'emnetu] Arbaminch Univ, Dept Publ Hlth, Arbaminch, Ethiopia; [Adinew, Ayalew] Fed Minist Hlth, Pharm Serv, Addis Ababa, Ethiopia; [Asefaw, Mulugeta] Reg Hlth Bur, Pharm Serv, Hawassa, Ethiopia	Arba Minch University; Federal Ministry of Health - Ethiopia (FMOH)	Wogayehu, B (corresponding author), Arbaminch Coll Hlth Sci, Dept Pharm, Arbaminch, Ethiopia.	biruk900zelalem@gmail.com	Wogayehu, Biruk/AAW-3176-2021; Chisha, Yilma/GOH-2697-2022	Wogayehu, Biruk/0000-0001-7199-9235; 				Adinew A, 2012, AUDITABLE PHARM T SE; Akl OA, 2014, J TAIBAH UNIV MED SC, V9, P54, DOI 10.1016/j.jtumed.2013.06.002; Aljasmi F, 2018, DRUG HEALTHC PATIENT, V10, P1, DOI 10.2147/DHPS.S147994; [Anonymous], 2005, IRRATIONAL DRUG USE; [Anonymous], 2013, ANTIMICROBIAL RESI S, V2, pO30; Anson A, 2012, GLOBALIZATION HEALTH, V8, DOI 10.1186/1744-8603-8-22; Antonia Efrauzina Campeto Lopes ADAT, 1996, INRUD NEWS, V6, P17; Atif M, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1932-2; Awad A, 2010, EUR J CLIN PHARMACOL, V66, P1247, DOI 10.1007/s00228-010-0872-8; Ayalew MB, 2017, J RES PHARM PRACT, V6, P21, DOI 10.4103/2279-042X.200995; Bilal AI, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1414-6; Bimo D., 1992, INRUD NEWS, V3, P9; Birna Abdosh, 2006, Ethiopian Journal of Health Development, V20, P199; Bogale T, 2005, J HLTH POPULATION NU, V15, P229; Boonstra E, 2002, TROP MED INT HEALTH, V7, P178, DOI 10.1046/j.1365-3156.2002.00842.x; Bosu W, 1999, W AFR J MED, V19, P298; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; de Valk BO H, 1994, INRUD NEWS, V4, P20; El Mahalli A. A., 2012, Eastern Mediterranean Health Journal, V18, P1086; Eva Ombaka, 1995, INRUD NEWS, V5, P20; Federal Democratic Republic of Ethiopia /Central Statistical Agency (FDRE/CSA), 2013, POP PROJ ETH ALL REG; Federal Ministry of Health, 2016, AUD PHARM T SERV APT; Federal Ministry of Health of Ethiopia and World Health Organization, 2003, ASS PHARM SECT ETH; Federal Ministry of Health of Ethiopia plan and program directorate, 1997, HSDPI1997982002 FED; Folkedal SF G, 1994, INRUD NEWS, V4, P21; Gelders S., 1992, WORLD HLTH ORG DRUG; Guan A, 2007, CHINA PHARM, V25, P39; GUYON AB, 1994, B WORLD HEALTH ORGAN, V72, P265; HOGERZEIL HV, 1993, LANCET, V342, P1408, DOI 10.1016/0140-6736(93)92760-Q; Holloway KA, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001724; Janelle Plummer, 2012, DIAGNOSING CORRUPTIO; Kalungia C.A, 2016, J PREVENTIVE REHABIL, V1, P16, DOI [10.21617/jprm.2016.0101.3, DOI 10.21617/JPRM.2016.0101.3]; Kefale AT, 2016, INTEGR PHARM RES PRA, V5, P85, DOI 10.2147/IPRP.S118657; Khuluza F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175399; Kumari R, 2008, INDIAN J PHARMACOL, V40, P243, DOI 10.4103/0253-7613.45148; Lima MG, 2017, REVSAUDE PUBLICA, V51; Ndukwe HC., 2013, W AFRICAN J PHARM, V24, P88; Nsimba Stephen Elias Damson, 2006, Southeast Asian Journal of Tropical Medicine and Public Health, V37, P206; Otoom S, 2002, East Mediterr Health J, V8, P544; Russell S., 2002, TOO POOR BE SICK COP; Shiferaw G, 2010, ETHIOP PHARM J, V28, P55; Surur AS, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0900-6; Syhakhang L, 2008, HLTH SOCIAL PROTECTI, P519; Tadeg H, 2014, AUDITABLE PHARM T SE; Teferi G, 2016, OUTCOMES AUDITABLE P; Tomson G, 1992, INRUD NEWS, V3, P3; United Nations (UN), 2008, MILL DEV GOAL 8 DEL; Wang J-p, 2008, CHINA PHARM, V35, P38; WHO, 2004, WORLD HLTH SIT; WHO, 1993, WHODAP9311993; WHO Health Action International, 2008, MEAS MED PRIC AV AFF, V2nd; Wiffen P., 2002, BANDOLIER EXTRA; World Health Organization, 2002, ANTITB OTHER MED PRE	53	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 7	2019	14	10							e0223523	10.1371/journal.pone.0223523	http://dx.doi.org/10.1371/journal.pone.0223523			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM7KN	31589641	Green Published, gold			2023-01-03	WOS:000532427300026
J	Lai, A; Ho, L; Evashwick-Rogler, TW; Watanabe, H; Salandra, J; Winkelstein, BA; Laudier, D; Hecht, AC; Pasinetti, GM; Iatridis, JC				Lai, Alon; Ho, Lap; Evashwick-Rogler, Thomas W.; Watanabe, Hironobu; Salandra, Jonathan; Winkelstein, Beth A.; Laudier, Damien; Hecht, Andrew C.; Pasinetti, Giulio M.; Iatridis, James C.			Dietary polyphenols as a safe and novel intervention for modulating pain associated with intervertebral disc degeneration in an in-vivo rat model	PLOS ONE			English	Article							ISSLS PRIZE WINNER; LOW-BACK-PAIN; NEUROPATHIC PAIN; NEEDLE PUNCTURE; MECHANICAL ALLODYNIA; SENSORY INNERVATION; DORSAL PORTION; ORAL TOXICITY; NERVE INJURY; MOUSE MODEL	Developing effective therapies for back pain associated with intervertebral disc (IVD) degeneration is a research priority since it is a major socioeconomic burden and current conservative and surgical treatments have limited success. Polyphenols are naturally occurring compounds in plant-derived foods and beverages, and evidence suggests dietary supplementation with select polyphenol preparations can modulate diverse neurological and painful disorders. This study tested whether supplementation with a select standardized Bioactive-Dietary-Polyphenol-Preparation (BDPP) may alleviate pain symptoms associated with IVD degeneration. Painful IVD degeneration was surgically induced in skeletally-mature rats by intradiscal saline injection into three consecutive lumbar IVDs. Injured rats were given normal or BDPP-supplemented drinking water. In-vivo hindpaw mechanical allodynia and IVD height were assessed weekly for 6 weeks following injury. Spinal column, dorsal-root-ganglion (DRG) and serum were collected at 1 and 6 weeks post-operative (post-op) for analyses of IVD-related mechanical and biological pathogenic processes. Dietary BDPP significantly alleviated the typical behavioral sensitivity associated with surgical procedures and IVD degeneration, but did not modulate IVD degeneration nor changes of pro-inflammatory cytokine levels in IVD. Gene expression analyses suggested BDPP might have an immunomodulatory effect in attenuating the expression of pro-inflammatory cytokines in DRGs. This study supports the idea that dietary supplementation with BDPP has potential to alleviate IVD degeneration-related pain, and further investigations are warranted to identify the mechanisms of action of dietary BDPP.	[Lai, Alon; Evashwick-Rogler, Thomas W.; Laudier, Damien; Hecht, Andrew C.; Iatridis, James C.] Icahn Sch Med Mt Sinai, Leni & Peter W May Dept Orthopaed, New York, NY 10029 USA; [Ho, Lap; Pasinetti, Giulio M.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Ho, Lap; Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA; [Watanabe, Hironobu] Keiyu Orthoped Hosp, Tatebayashi, Japan; [Salandra, Jonathan] Philadelphia Coll Osteopath Med, Philadelphia, PA USA; [Winkelstein, Beth A.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; University of Pennsylvania	Iatridis, JC (corresponding author), Icahn Sch Med Mt Sinai, Leni & Peter W May Dept Orthopaed, New York, NY 10029 USA.	james.iatridis@mssm.edu		Lai, Alon/0000-0002-0163-4588; Pasinetti, Giulio/0000-0002-1524-5196; Iatridis, James/0000-0002-2186-0590	NIAMS/NIH [R01AR064157, R01AR057397]; NCCIH/DODS [P50 AT008661-01]; Senior VA Career Scientist Award; National Center for Complementary & Integrative Health [P50AT008661] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR064157, R01AR057397] Funding Source: NIH RePORTER	NIAMS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCCIH/DODS; Senior VA Career Scientist Award; National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by NIAMS/NIH grant numbers R01AR064157 & R01AR057397 (JCI) and NCCIH/DODS grant number P50 AT008661-01 (GMP). GMP holds a Senior VA Career Scientist Award. We acknowledge that the contents of this study do not represent the views of the NCCIH, the ODS, the NIH, the U.S. Department of Veterans Affairs, or the United States Government.	Adams MA, 2006, SPINE, V31, P2151, DOI 10.1097/01.brs.0000231761.73859.2c; Al-Amin H, 2011, EXP NEUROL, V228, P30, DOI 10.1016/j.expneurol.2010.11.005; Apkarian AV, 2006, NEUROSCI LETT, V407, P176, DOI 10.1016/j.neulet.2006.08.034; Assas BM, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00023; Aziz MH, 2005, PHOTOCHEM PHOTOBIOL, V81, P25, DOI 10.1562/2004-08-13-RA-274.1; Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028; Blom SM, 2014, J NEUROSCI, V34, P5754, DOI 10.1523/JNEUROSCI.3667-13.2014; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; Brox JI, 2010, ANN RHEUM DIS, V69, P1643, DOI 10.1136/ard.2009.108902; Buckley CT, 2018, JOR SPINE, V1, DOI 10.1002/jsp2.1029; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chen TY, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201700111; Covey WC, 2000, BRAIN RES, V859, P113, DOI 10.1016/S0006-8993(00)01965-X; Dong L, 2012, BRAIN RES, V1461, P51, DOI 10.1016/j.brainres.2012.04.026; Elliott DM, 2008, SPINE, V33, P588, DOI 10.1097/BRS.0b013e318166e0a2; Elmali N, 2005, INFLAMM RES, V54, P158, DOI 10.1007/s00011-004-1341-6; Evashwick-Rogler TW, 2018, JOR SPINE, V1, DOI 10.1002/jsp2.1014; Ferruzzi MG, 2009, J ALZHEIMERS DIS, V18, P113, DOI 10.3233/JAD-2009-1135; Foster NE, 2018, LANCET, V391, P2368, DOI 10.1016/S0140-6736(18)30489-6; Freemont AJ, 1997, LANCET, V350, P178, DOI 10.1016/S0140-6736(97)02135-1; Frolinger T, 2018, BIOL OPEN, V7, DOI 10.1242/bio.035196; Frolinger T, 2018, FASEB J, V32, P5390, DOI 10.1096/fj.201800030R; Frye CA, 2001, COGN AFFECT BEHAV NE, V1, P371, DOI 10.3758/CABN.1.4.371; Gordon FT, 1996, HORM BEHAV, V30, P244, DOI 10.1006/hbeh.1996.0029; Hadipour-Jahromy M, 2010, PHYTOTHER RES, V24, P182, DOI 10.1002/ptr.2880; Hall H, 2008, BMJ CLIN EVID 2008; Han B, 2008, SPINE, V33, P1925, DOI 10.1097/BRS.0b013e31817c64a9; Hartvigsen J, 2018, LANCET, V391, P2356, DOI 10.1016/S0140-6736(18)30480-X; Ho L, 2013, FASEB J, V27, P769, DOI 10.1096/fj.12-212118; Hsieh AH, 2009, SPINE, V34, P998, DOI 10.1097/BRS.0b013e31819c09c4; Ignatowski TA, 2005, NEUROPHARMACOLOGY, V48, P448, DOI 10.1016/j.neuropharm.2004.11.001; Ignatowski TA, 1999, BRAIN RES, V841, P70, DOI 10.1016/S0006-8993(99)01782-5; Janle EM, 2010, J MED FOOD, V13, P926, DOI 10.1089/jmf.2009.0157; Jaumard NV, 2015, SPINE, V40, pE1084, DOI 10.1097/BRS.0000000000001021; Johnson WD, 2011, FOOD CHEM TOXICOL, V49, P3319, DOI 10.1016/j.fct.2011.08.023; Kim JS, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3485; Krikorian R, 2012, J AGR FOOD CHEM, V60, P5736, DOI 10.1021/jf300277g; Krupkova O, 2014, EUR CELLS MATER, V28, P372, DOI 10.22203/eCM.v028a26; Kundu JK, 2006, BIOCHEM PHARMACOL, V72, P1506, DOI 10.1016/j.bcp.2006.08.005; LaCroix-Fralish ML, 2005, SPINE, V30, P1821, DOI 10.1097/01.brs.0000174122.63291.38; Lai A, 2007, MED ENG PHYS, V29, P814, DOI 10.1016/j.medengphy.2006.08.013; Lai A, 2016, SPINE J, V16, P420, DOI 10.1016/j.spinee.2015.11.019; Lai A, 2015, J ORTHOP RES, V33, P755, DOI 10.1002/jor.22833; Lee M, 2009, ANESTH ANALG, V109, P1287, DOI 10.1213/ane.0b013e3181b31f39; Li CL, 2016, CELL RES, V26, P967, DOI 10.1038/cr.2016.90; Livshits G, 2011, ANN RHEUM DIS, V70, P1740, DOI 10.1136/ard.2010.137836; Luchtmann M, 2015, NEURAL REGEN RES, V10, P1234, DOI 10.4103/1673-5374.162754; Luchtmann M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090816; Masuda K, 2005, SPINE, V30, P5, DOI 10.1097/01.brs.0000148152.04401.20; Michalek AJ, 2010, EUR SPINE J, V19, P2110, DOI 10.1007/s00586-010-1473-z; Miyagi M, 2012, SPINE, V37, P1810, DOI 10.1097/BRS.0b013e31824ffac6; Miyagi M, 2011, SPINE, V36, P2260, DOI 10.1097/BRS.0b013e31820e68c7; Mogil JS, 2010, PROG BRAIN RES, V186, P141, DOI 10.1016/B978-0-444-53630-3.00009-9; Mosley GE, 2019, SPINE, V44, P1257, DOI 10.1097/BRS.0000000000003055; Mosley GE, 2017, ANN NY ACAD SCI, V1409, P51, DOI 10.1111/nyas.13429; Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703; National Research Council Committee on Pesticides in the Diets of Infants and Children, 1993, PEST DIETINF CHILD; Ohtori S, 1999, SPINE, V24, P2295, DOI 10.1097/00007632-199911150-00002; Ohtori S, 2001, SPINE, V26, P946, DOI 10.1097/00007632-200104150-00020; PRICE J, 1985, J NEUROSCI, V5, P2051; Rusanescu G, 2017, J CELL MOL MED, V21, P299, DOI 10.1111/jcmm.12965; Rutges JPHJ, 2013, OSTEOARTHR CARTILAGE, V21, P2039, DOI 10.1016/j.joca.2013.10.001; Shakibaei M, 2008, BIOCHEM PHARMACOL, V76, P1426, DOI 10.1016/j.bcp.2008.05.029; Singh BN, 2011, BIOCHEM PHARMACOL, V82, P1807, DOI 10.1016/j.bcp.2011.07.093; Sivaprakasapillai B, 2009, METABOLISM, V58, P1743, DOI 10.1016/j.metabol.2009.05.030; Sorge RE, 2017, J NEUROSCI RES, V95, P1271, DOI 10.1002/jnr.23841; Ulrich JA, 2007, SPINE, V32, P2812, DOI 10.1097/BRS.0b013e31815b9850; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Wang J, 2008, J NEUROSCI, V28, P6388, DOI 10.1523/JNEUROSCI.0364-08.2008; Wang J, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00042; Wang J, 2013, MOL NUTR FOOD RES, V57, P2091, DOI 10.1002/mnfr.201300230; Wang J, 2010, J ALZHEIMERS DIS, V22, P653, DOI 10.3233/JAD-2010-101074; Wang X, 2009, DETC 2008: PROCEEDINGS OF THE ASME INTERNATIONAL DESIGN ENGINEERING TECHNICAL CONFERENCES AND COMPUTERS AND INFORMATIONAL IN ENGINEERING CONFERENCE, VOL 3, PTS A AND B, P1541; Weisshaar CL, 2010, J NEUROTRAUM, V27, P2261, DOI 10.1089/neu.2010.1460; Wren AF, 2002, J AGR FOOD CHEM, V50, P2180, DOI 10.1021/jf011066w; Wuertz K, 2011, SPINE, V36, pE1373, DOI 10.1097/BRS.0b013e318221e655; Xia EQ, 2010, INT J MOL SCI, V11, P622, DOI 10.3390/ijms11020622; Xu YP, 2011, J AGR FOOD CHEM, V59, P10586, DOI 10.1021/jf202438d; Xu ZZ, 2015, NAT MED, V21, P1326, DOI 10.1038/nm.3978; Zhao W, 2015, NEUROCHEM INT, V89, P191, DOI 10.1016/j.neuint.2015.07.023	80	7	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2019	14	10							e0223435	10.1371/journal.pone.0223435	http://dx.doi.org/10.1371/journal.pone.0223435			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM6VM	31577822	Green Published, gold			2023-01-03	WOS:000532388000036
J	Sun, CY; Sung, JM; Wang, JD; Li, CY; Kuo, YT; Lee, CC; Wu, JL; Chang, YT				Sun, Chien-Yao; Sung, Junne-Ming; Wang, Jung-Der; Li, Chung-Yi; Kuo, Yi-Ting; Lee, Chia-Chun; Wu, Jia-Ling; Chang, Yu-Tzu			A comparison of the risk of congestive heart failure-related hospitalizations in patients receiving hemodialysis and peritoneal dialysis - A retrospective propensity score-matched study	PLOS ONE			English	Article							CARDIOVASCULAR-DISEASE; P-CRESOL; DEATH; ASSOCIATION; MORTALITY; THERAPY	Introduction Congestive heart failure (CHF) is associated with high mortality and a heavy financial and healthcare burden in the dialysis population. Determining which dialysis modality is associated with a higher risk of developing CHF might facilitate clinical decision making and surveillance programs in the dialysis population. Methods Using the Taiwan National Health Insurance Database, we recruited all incident dialysis patients during the period from January 1, 1998 to December 31, 2010. The propensity score matching method was applied to establish the matched hemodialysis (HD) and peritoneal dialysis (PD) cohort. Incidence rates and cumulative incidence rates of CHF-related hospitalization were first compared for the HD and PD patients. Multivariable subdistribution hazards models were then constructed to control for potential confounders. Results Among a total of 65,899 enrolled dialysis patients, 4,754 matched pairs of HD and PD patients were identified. The incidence rates of CHF in the matched HD and PD patients were 25.98 and 19.71 per 1000 patient-years, respectively (P = 0.001). The cumulative incidence rate of CHF was also higher in the matched HD patients (0.16, 95% confidence interval (CI)(0.12-0.21)] than in the corresponding PD patients (0.09, 95% CI [0.08-0.11]) (P<0.0001). HD was consistently associated with an increased subdistribution hazard ratio (HR) of CHF compared with PD in the matched cohort (HR: 1.45, 95% CI [1.23-1.7]). Similar phenomenons were observed in either the subgroup analysis stratified by selected confounders or in the HD and PD group without matching. Conclusions HD is associated with a higher risk of developing CHF-related hospitalization than PD. The surveillance program for CHF should differ in patients receiving different dialysis modalities.	[Sun, Chien-Yao; Sung, Junne-Ming; Wang, Jung-Der; Kuo, Yi-Ting; Lee, Chia-Chun; Wu, Jia-Ling; Chang, Yu-Tzu] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med, Tainan, Taiwan; [Wang, Jung-Der; Li, Chung-Yi] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan, Taiwan; [Wang, Jung-Der] Natl Cheng Kung Univ Hosp, Dept Environm & Occupat Hlth, Tainan, Taiwan	National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital	Chang, YT (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med, Tainan, Taiwan.	kangxiemperor@gmail.com	Chang, Yu-Tzu/AAE-6781-2022; sun, chienyao/ADD-3507-2022; LI, CHUNG-YI/ABI-1419-2020	sun, chienyao/0000-0001-6236-6022; LI, CHUNG-YI/0000-0002-0321-8908; Chang, Yu-Tzu/0000-0003-1449-9431	National ChengKung University Hospital, Tainan, Taiwan, ROC [NCKUH-10702005, NCKUH-10802052]	National ChengKung University Hospital, Tainan, Taiwan, ROC	Our research was partly supported by the grants of NCKUH-10702005 and NCKUH-10802052 to Chang YT from the National ChengKung University Hospital, Tainan, Taiwan, ROC (http://crc.hosp.ncku.edu.tw).None of the funding sources had any role in the study design, analysis, and interpretation of the data, the preparation, review, or approval of the manuscript.	Barrett BJ, 1997, AM J KIDNEY DIS, V29, P214, DOI 10.1016/S0272-6386(97)90032-9; Berry SD, 2010, J AM GERIATR SOC, V58, P783, DOI 10.1111/j.1532-5415.2010.02767.x; Bolton K, 2005, AM J KIDNEY DIS, V45, pS7, DOI 10.1053/j.ajkd.2005.01.016; Brookhart MA, 2006, AM J EPIDEMIOL, V163, P1149, DOI 10.1093/aje/kwj149; Cao XS, 2015, CLIN J AM SOC NEPHRO, V10, P111, DOI 10.2215/CJN.04730514; Chang YT, 2016, SCI REP-UK, V6, DOI 10.1038/srep30266; Chang YT, 2014, DIABETES CARE, V37, P277, DOI 10.2337/dc13-0781; Chawla LS, 2014, J AM COLL CARDIOL, V63, P1246, DOI 10.1016/j.jacc.2014.01.020; Cheng CL, 2015, INT J CARDIOL, V201, P96, DOI 10.1016/j.ijcard.2015.07.075; Dasselaar JJ, 2009, NEPHROL DIAL TRANSPL, V24, P604, DOI 10.1093/ndt/gfn501; Evenepoel P, 2006, KIDNEY INT, V70, P794, DOI 10.1038/sj.ki.5001640; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Foley RN, 1998, J AM SOC NEPHROL, V9, P267; Foley RN, 2003, SEMIN DIALYSIS, V16, P111, DOI 10.1046/j.1525-139X.2003.160271.x; Green JB, 2015, NEW ENGL J MED, V373, P232, DOI 10.1056/NEJMoa1501352; HARNETT JD, 1995, KIDNEY INT, V47, P884, DOI 10.1038/ki.1995.132; Hiramatsu Takeyuki, 2007, Adv Perit Dial, V23, P62; Johnson DW, 2009, CLIN J AM SOC NEPHRO, V4, P1620, DOI 10.2215/CJN.01750309; Kontodimopoulos N, 2008, HEALTH POLICY, V86, P85, DOI 10.1016/j.healthpol.2007.10.002; Lekawanvijit S, 2015, J RENAL NUTR, V25, P149, DOI 10.1053/j.jrn.2014.10.009; Locatelli F, 2001, J AM SOC NEPHROL, V12, P2411, DOI 10.1681/ASN.V12112411; McIntyre CW, 2008, CLIN J AM SOC NEPHRO, V3, P19, DOI 10.2215/CJN.03170707; Meijers BKI, 2008, KIDNEY INT, V73, P1174, DOI 10.1038/ki.2008.31; Ministry of Health and Welfare R.O.C. (Taiwan), 2017, 2015 TAIW HLTH WELF; Puttagunta H, 2015, PERITON DIALYSIS INT, V35, P645, DOI 10.3747/pdi.2014.00340; Ranasinghe P, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-42; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; SCHURIG R, 1979, ARTIF ORGANS, V3, P215; Scirica BM, 2013, NEW ENGL J MED, V369, P1317, DOI 10.1056/NEJMoa1307684; Sniderman AD, 2010, CLIN J AM SOC NEPHRO, V5, P335, DOI 10.2215/CJN.06300909; Su VYF, 2019, AGING-US, V11, P3650, DOI 10.18632/aging.102004; Taiwan Society of Nephrology, 2015, 2015 ANN REP KIDN DI; Trespalacios FC, 2003, AM J KIDNEY DIS, V41, P1267, DOI 10.1016/S0272-6386(03)00359-7; United States Renal Data System, END STAG REN DIS ESR, V2; VINSON JM, 1990, J AM GERIATR SOC, V38, P1290, DOI 10.1111/j.1532-5415.1990.tb03450.x; Wang IK, 2016, INT J CARDIOL, V218, P219, DOI 10.1016/j.ijcard.2016.05.036; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019	38	7	8	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2019	14	10							e0223336	10.1371/journal.pone.0223336	http://dx.doi.org/10.1371/journal.pone.0223336			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM6RH	31574134	Green Published, gold			2023-01-03	WOS:000532376700043
J	Ezzat, MI; Okba, MM; Ahmed, SH; El-Banna, HA; Prince, A; Mohamed, SO; Ezzat, SM				Ezzat, Marwa, I; Okba, Mona M.; Ahmed, Sherif H.; El-Banna, Hossny A.; Prince, Abdelbary; Mohamed, Shanaz O.; Ezzat, Shahira M.			In-depth hepatoprotective mechanistic study of Phyllanthus niruri: In vitro and in vivo studies and its chemical characterization	PLOS ONE			English	Article							TETRACHLORIDE-INDUCED HEPATOTOXICITY; INDUCED LIVER-DAMAGE; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; CARBON-TETRACHLORIDE; OXIDATIVE STRESS; TIME-COURSE; ANTIOXIDANT ACTIVITY; HEPATIC-INJURY; KUPFFER CELLS	Phyllanthus niruri L. is a widespread tropical plant which is used in Ayurvedic system for liver and kidney ailments. The present study aims at specifying the most active hepatoprotective extract of P. niruriand applying a bio-guided protocol to identify the active compounds responsible for this effect. P. niruri aerial parts were extracted separately with water, 50%, 70% and 80% ethanol. The cytoprotective activity of the extracts was evaluated against CCl4-induced hepatotoxicity in clone-9 and Hepg2 cells. Bioassay-guided fractionation of the aqueous extract (AE) was accomplished for the isolation of the active compounds. Antioxidant activity was assessed using DPPH (1, 1-diphenyl-2-picrylhydrazyl) radical scavenging method and ferric reducing antioxidant power (FRAP). The in vivo hepatoprotective activity of AE was evaluated in CCl4-induced hepatotoxicity in rats at different doses after determination of its LD50. Pretreatment of clone-9 and Hepg2 with different concentrations of AE (1, 0.1, 0.01 mg/ml) had significantly reduced the levels of alanine amino-transferase (ALT) and aspartate aminotransferase (AST) against CCl4 injures, and restored the activity of the natural antioxidants; glutathione (GSH) and superoxide dismutase (SOD) towards normalization. Fractionation of AE gave four fractions (I-IV). Fractions I, II, and IV showed a significant in vitro hepatoprotective activity. Purification of I, II and IV yielded seven compounds; corilagin C1, isocorilagin C2, brevifolin C3, quercetin C4, kaempferol rhamnoside C5, gallic acid C6, and brevifolin carboxylic acid C7. Compounds C1, C2, C5, and C7 showed the highest (p< 0.001) hepatoprotective potency, while C3, C4, and C6 exhibited a moderate (p< 0.001) activity. The AE exhibited strong antioxidant DPPH (IC50 11.6 +/- 2 mu g/ml) and FRAP (79.352 +/- 2.88 mM Ferrous equivalents) activity. In vivo administration of AE in rats (25, 50, 100 and 200 mg/kg) caused normalization of AST, ALT, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), total cholesterol (TC), triglycyrides (TG), total bilirubin (TB), glucose, total proteins (TP), urea and creatinine levels which were elevated by CCl4. AE also decreased TNF-alpha, NF-kappa B, IL-6, IL-8, IL-10 and COX-2 expression, and significantly antagonizes the effect of CCl4 on the antioxidant enzymes SOD, catalase (CAT), glutathione reductase (GR), and glutathione peroxidase (GSP). The histopathological study also supported the hepatoprotective effect of AE. P. niruri isolates exhibited a potent hepatoprotective activity against CCl4-induced hepatotoxicity in clone-9 and Hepg2 cell lines through reduction of lipid peroxidation and maintaining glutathione in its reduced form. This is attributable to their phenolic nature and hence antioxidative potential.	[Ezzat, Marwa, I; Okba, Mona M.; Ezzat, Shahira M.] Cairo Univ, Fac Pharm, Pharmacognosy Dept, Kasr El Ainy St, Cairo, Egypt; [Ahmed, Sherif H.] Cairo Univ, Fac Agr, Dept Biochem, Giza, Egypt; [El-Banna, Hossny A.] Cairo Univ, Fac Vet Med, Dept Pharmacol, Giza, Egypt; [Prince, Abdelbary] Cairo Univ, Fac Vet Med, Dept Biochem, Giza, Egypt; [Mohamed, Shanaz O.] Univ Sains Malaysia, Sch Pharmaceut Sci, George Town, Malaysia; [Ezzat, Shahira M.] October Univ Modern Sci & Arts MSA, Dept Pharmacognosy, Fac Pharm, Giza, Egypt	Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Cairo University; Universiti Sains Malaysia; Egyptian Knowledge Bank (EKB); Modern Sciences & Arts University (MSA)	Ezzat, MI (corresponding author), Cairo Univ, Fac Pharm, Pharmacognosy Dept, Kasr El Ainy St, Cairo, Egypt.	marwa.ezzat@pharma.cu.edu.eg	Ezzat, Shahira/AAJ-3122-2021	Ezzat, Shahira/0000-0003-2232-7357; El Banna, Hossny/0000-0003-4476-7775; Ezzat, Marwa I./0000-0002-7776-0265; Prince, Abdelbary/0000-0002-6155-8871	Ministry of Agriculture Malaysia initiative under the New Key Economic Areas Entry Point Project on High Value Herbals	Ministry of Agriculture Malaysia initiative under the New Key Economic Areas Entry Point Project on High Value Herbals	The authors received no specific funding for this work. Natural Wellness Biotech organization only provided support in the form of research materials but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This research was made possible as part of Ministry of Agriculture Malaysia initiative under the New Key Economic Areas Entry Point Project on High Value Herbals awarded to Natural Wellness Biotech (M) Sdn Bhd. The authors express their gratitude and appreciation for the trust and opportunity given. The authors extend their gratitude to Cairo University staff for their collaboration and excellent teamwork.	Al-Shabanah OA, 1999, LIFE SCI, V66, P265; Amacher DE, 1998, REGUL TOXICOL PHARM, V27, P119, DOI 10.1006/rtph.1998.1201; ANIYA Y, 1993, BIOCHEM PHARMACOL, V45, P37; Asha VV, 2004, J ETHNOPHARMACOL, V92, P67, DOI 10.1016/j.jep.2004.02.005; Bagalkotkar G, 2006, J PHARM PHARMACOL, V58, P1559, DOI 10.1211/jpp.58.12.0001; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; BEYER W, 1991, PROG NUCLEIC ACID RE, V40, P221; Bhattacharjee R, 2007, FOOD CHEM TOXICOL, V45, P817, DOI 10.1016/j.fct.2006.10.029; Bilal C, 2016, HEALING IN UROLOGY C; Breikaa RM, 2013, BIOSCI BIOTECH BIOCH, V77, P909, DOI 10.1271/bbb.120675; Calixto JB, 1998, MED RES REV, V18, P225, DOI 10.1002/(SICI)1098-1128(199807)18:4&lt;225::AID-MED2&gt;3.0.CO;2-X; CHAMULITRAT W, 1994, MOL PHARMACOL, V46, P391; Clemens MG, 1999, HEPATOLOGY, V30, P1, DOI 10.1002/hep.510300148; COLTEN HR, 1992, J APPL PHYSIOL, V72, P1; de Abajo FJ, 2004, BRIT J CLIN PHARMACO, V58, P71, DOI 10.1111/j.1365-2125.2004.02133.x; DeCicco LA, 1998, TOXICOL LETT, V98, P115, DOI 10.1016/S0378-4274(98)00110-6; Deepak HB, 2012, PHARMACOGN MAG, V8, P116, DOI 10.4103/0973-1296.96553; DISIMPLICIO P, 1983, TOXICOL LETT, V18, P285, DOI 10.1016/0378-4274(83)90108-X; EDWARDS MJ, 1993, TOXICOL APPL PHARM, V119, P275, DOI 10.1006/taap.1993.1069; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fang YZ, 2002, NUTRITION, V18, P872, DOI 10.1016/S0899-9007(02)00916-4; FRIDOVICH I, 1993, FREE RADICAL BIO MED, V15, P472, DOI 10.1016/0891-5849(93)90188-Z; Gardner CR, 1998, HEPATOLOGY, V27, P748, DOI 10.1002/hep.510270316; Gulati Raj Kumari, 1995, Indian Journal of Experimental Biology, V33, P261; Habib-Ur-Rehman, 2007, NAT PROD RES, V21, P775, DOI 10.1080/14786410601124664; Harish R, 2006, FOOD CHEM, V95, P180, DOI 10.1016/j.foodchem.2004.11.049; Hoek JB, 2002, ALCOHOL, V27, P63, DOI 10.1016/S0741-8329(02)00215-X; HORN HJ, 1956, BIOMETRICS, V12, P311, DOI 10.2307/3001470; Hsu CT, 1998, J AUTONOM NERV SYST, V70, P79, DOI 10.1016/S0165-1838(98)00035-6; Hu KQ, 2003, PROSTAG LEUKOTR ESS, V69, P329, DOI 10.1016/j.plefa.2003.07.001; ISHIYAMA H, 1995, EUR J PHARM-ENVIRON, V292, P135, DOI 10.1016/0926-6917(95)90005-5; Ismail Nagwa A, 2010, Saudi J Gastroenterol, V16, P90, DOI 10.4103/1319-3767.61234; Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166; Jain Nilesh Kumar, 2011, Zhong Xi Yi Jie He Xue Bao, V9, P49, DOI 10.3736/jcim20110109; Janakat S, 2002, J PHARMACOL TOXICOL, V48, P41, DOI 10.1016/S1056-8719(03)00019-4; Kalekar SA, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-257; Khanna AK, 2002, J ETHNOPHARMACOL, V82, P19, DOI 10.1016/S0378-8741(02)00136-8; Khatoon S, 2006, J ETHNOPHARMACOL, V104, P79, DOI 10.1016/j.jep.2005.08.048; Kinoshita S, 2007, PHYTOMEDICINE, V14, P755, DOI 10.1016/j.phymed.2006.12.012; Krithika R, 2009, CHEM-BIOL INTERACT, V181, P351, DOI 10.1016/j.cbi.2009.06.014; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Lee NYS, 2016, J PHARM PHARMACOL, V68, P953, DOI 10.1111/jphp.12565; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; Lykkesfeldt J, 2007, CLIN CHIM ACTA, V380, P50, DOI 10.1016/j.cca.2007.01.028; Manjrekar AP, 2008, INDIAN J EXP BIOL, V46, P514; Mates JM, 1999, CLIN BIOCHEM, V32, P595, DOI 10.1016/S0009-9120(99)00075-2; McGregor D, 1996, MUTAT RES-REV GENET, V366, P181; MEHENDALE HM, 1994, FASEB J, V8, P1285, DOI 10.1096/fasebj.8.15.8001741; Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319; Morio LA, 2001, TOXICOL APPL PHARM, V172, P44, DOI 10.1006/taap.2000.9133; Murugaiyah V, 2009, J ETHNOPHARMACOL, V124, P233, DOI 10.1016/j.jep.2009.04.026; NAWWAR MAM, 1994, PHYTOCHEMISTRY, V36, P793, DOI 10.1016/S0031-9422(00)89820-9; Orhan DD, 2007, J ETHNOPHARMACOL, V112, P145, DOI 10.1016/j.jep.2007.02.013; Pareek A, 2013, J ETHNOPHARMACOL, V150, P973, DOI 10.1016/j.jep.2013.09.048; Popovic M, 2008, MOLECULES, V13, P2249, DOI 10.3390/molecules13092249; Pramyothin P, 2007, J ETHNOPHARMACOL, V114, P169, DOI 10.1016/j.jep.2007.07.037; Ramkumar KM, 2003, NUTRITION, V19, P358, DOI 10.1016/S0899-9007(02)00961-9; Rasool MK, 2010, J PHARM PHARMACOL, V62, P638, DOI 10.1211/jpp.62.05.0012; RECKNAGEL RO, 1989, PHARMACOL THERAPEUT, V43, P139, DOI 10.1016/0163-7258(89)90050-8; REES KR, 1960, J PATHOL BACTERIOL, V80, P297, DOI 10.1002/path.1700800213; Rhiouani H, 1999, THERAPIE, V54, P735; ROCKEY DC, 1997, AM J PHYSL 1, V273, pG12, DOI DOI 10.1152/AJPGI.1997.273.1.G124; Sabir SM, 2008, FOOD CHEM, V111, P845, DOI 10.1016/j.foodchem.2008.04.060; Saemann MD, 2010, EUR J CLIN INVEST, V40, P1131, DOI 10.1111/j.1365-2362.2010.02361.x; SHIMADA K, 1992, J AGR FOOD CHEM, V40, P945, DOI 10.1021/jf00018a005; SMEJKALOVA J, 1985, PHYSIOL BOHEMOSLOV, V34, P494; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smyth R, 2009, INT J EXP PATHOL, V90, P500, DOI 10.1111/j.1365-2613.2009.00666.x; Sprenger RF, 2016, ORG BIOMOL CHEM, V14, P3369, DOI 10.1039/c6ob00049e; Sturgill MG, 1997, CLIN CHEM, V43, P1512; SYAMASUNDAR KV, 1985, J ETHNOPHARMACOL, V14, P41, DOI 10.1016/0378-8741(85)90026-1; Tatiya AU, 2012, PHARMACOGN RES, V4, P50, DOI 10.4103/0974-8490.91040; Tewari D, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00519; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; Vos TA, 1999, HEPATOLOGY, V29, P421, DOI 10.1002/hep.510290231; Zhang Lan-zhen, 2000, Zhongguo Zhongyao Zazhi, V25, P615; Zhu RZ, 2012, HEPATOL RES, V42, P741, DOI 10.1111/j.1872-034X.2012.00996.x; Zhu W, 2000, FREE RADICAL BIO MED, V29, P870, DOI 10.1016/S0891-5849(00)00396-8	78	18	20	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2020	15	1							e0226185	10.1371/journal.pone.0226185	http://dx.doi.org/10.1371/journal.pone.0226185			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5OV	31940365	Green Published, gold			2023-01-03	WOS:000534368000021
J	Schmidt, EKA; Torres-Espin, A; Raposo, PJF; Madsen, KL; Kigerl, KA; Popovich, PG; Fenrich, KK; Fouad, K				Schmidt, Emma K. A.; Torres-Espin, Abel; Raposo, Pamela J. F.; Madsen, Karen L.; Kigerl, Kristina A.; Popovich, Phillip G.; Fenrich, Keith K.; Fouad, Karim			Fecal transplant prevents gut dysbiosis and anxiety-like behaviour after spinal cord injury in rats	PLOS ONE			English	Article							ELEVATED PLUS-MAZE; ONE-TRIAL TOLERANCE; CLOSTRIDIUM-DIFFICILE INFECTION; BACTERIAL TRANSLOCATION; IMMUNE SUPPRESSION; OPEN-FIELD; MICROBIOTA; DEPRESSION; INFLAMMATION; SYSTEM	Secondary manifestations of spinal cord injury beyond motor and sensory dysfunction can negatively affect a person's quality of life. Spinal cord injury is associated with an increased incidence of depression and anxiety; however, the mechanisms of this relationship are currently not well understood. Human and animal studies suggest that changes in the composition of the intestinal microbiota (dysbiosis) are associated with mood disorders. The objective of the current study is to establish a model of anxiety following a cervical contusion spinal cord injury in rats and to determine whether the microbiota play a role in the observed behavioural changes. We found that spinal cord injury caused dysbiosis and increased symptoms of anxiety-like behaviour. Treatment with a fecal transplant prevented both spinal cord injury-induced dysbiosis as well as the development of anxiety-like behaviour. These results indicate that an incomplete unilateral cervical spinal cord injury can cause affective disorders and intestinal dysbiosis, and that both can be prevented by treatment with fecal transplant therapy.	[Schmidt, Emma K. A.; Fenrich, Keith K.; Fouad, Karim] Univ Alberta, Neurosci & Mental Hlth Inst, Edmonton, AB, Canada; [Torres-Espin, Abel; Raposo, Pamela J. F.; Fenrich, Keith K.; Fouad, Karim] Univ Alberta, Fac Rehabil Med, Edmonton, AB, Canada; [Torres-Espin, Abel; Raposo, Pamela J. F.; Fouad, Karim] Univ Alberta, Dept Phys Therapy, Edmonton, AB, Canada; [Madsen, Karen L.] Univ Alberta, Fac Med & Dent, Div Gastroenterol, Edmonton, AB, Canada; [Kigerl, Kristina A.; Popovich, Phillip G.] Ohio State Univ, Belford Ctr Spinal Cord Injury, Ctr Brain & Spinal Cord Repair, Dept Neurosci,Wexner Med Ctr, Columbus, OH 43210 USA	University of Alberta; University of Alberta; University of Alberta; University of Alberta; University System of Ohio; Ohio State University	Fouad, K (corresponding author), Univ Alberta, Neurosci & Mental Hlth Inst, Edmonton, AB, Canada.; Fouad, K (corresponding author), Univ Alberta, Fac Rehabil Med, Edmonton, AB, Canada.; Fouad, K (corresponding author), Univ Alberta, Dept Phys Therapy, Edmonton, AB, Canada.	karim.fouad@ualberta.ca	Torres-Espin, Abel/ABD-1354-2020; Torres Espin, Abel/HGA-5068-2022; Madsen, Karen L/H-5898-2011; Fenrich, Keith/AAG-2780-2020	Torres-Espin, Abel/0000-0002-9787-8738; Fenrich, Keith/0000-0003-4360-064X; Doolin, Emma/0000-0001-9803-6391	Craig Neilsen Foundation [NPRG 542589]; Canadian Institutes of Health Research [MOP 119281]	Craig Neilsen Foundation; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by Craig Neilsen Foundation (NPRG 542589), https://chnfoundation.org/, to KF; and Canadian Institutes of Health Research (MOP 119281), http://www.cihr-irsc.gc.ca.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alam R, 2017, AM J MED GENET B, V174, P651, DOI 10.1002/ajmg.b.32567; Albrechet-Souza L, 2009, NEUROSCIENCE, V164, P387, DOI 10.1016/j.neuroscience.2009.08.038; BERG RD, 1992, J MED, V23, P217; Bertoglio LJ, 2002, PHARMACOL BIOCHEM BE, V73, P963, DOI 10.1016/S0091-3057(02)00958-9; Bik EM, 2014, GENOME BIOL, V15, DOI 10.1186/gb4182; Bourin M, 2003, EUR J PHARMACOL, V463, P55, DOI 10.1016/S0014-2999(03)01274-3; Carabotti M, 2015, ANN GASTROENTEROL, V28, P203; Carola V, 2002, BEHAV BRAIN RES, V134, P49, DOI 10.1016/S0166-4328(01)00452-1; Chapman BC, 2016, J TRAUMA ACUTE CARE, V81, P756, DOI 10.1097/TA.0000000000001195; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Desbonnet L, 2010, NEUROSCIENCE, V170, P1179, DOI 10.1016/j.neuroscience.2010.08.005; DEVIVO MJ, 1991, PARAPLEGIA, V29, P620, DOI 10.1038/sc.1991.91; Santo CCD, 2019, BRAIN BEHAV IMMUN, V78, P91, DOI 10.1016/j.bbi.2019.01.012; Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; FILE SE, 1990, PSYCHOPHARMACOLOGY, V102, P98, DOI 10.1007/BF02245751; FILE SE, 1990, PSYCHOPHARMACOLOGY, V100, P281, DOI 10.1007/BF02244419; Foster JA, 2013, TRENDS NEUROSCI, V36, P305, DOI 10.1016/j.tins.2013.01.005; Frenois F, 2007, PSYCHONEUROENDOCRINO, V32, P516, DOI 10.1016/j.psyneuen.2007.03.005; Fung TC, 2017, NAT NEUROSCI, V20, P145, DOI 10.1038/nn.4476; Galley JD, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-189; Geissler S.A., 2013, J SPINE, DOI [10.4172/2165-7939.S4-001, DOI 10.4172/2165-7939.S4-001]; Gungor B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145878; Guo SH, 2013, AM J PATHOL, V182, P375, DOI 10.1016/j.ajpath.2012.10.014; Hawrelak Jason A, 2004, Altern Med Rev, V9, P180; Huang RX, 2016, NUTRIENTS, V8, DOI 10.3390/nu8080483; Kassam Z, 2013, AM J GASTROENTEROL, V108, P500, DOI 10.1038/ajg.2013.59; Kennedy P, 2000, ARCH PHYS MED REHAB, V81, P932, DOI 10.1053/apmr.2000.5580; Kigerl KA, 2016, J EXP MED, V213, P2603, DOI 10.1084/jem.20151345; Kohler O, 2014, JAMA PSYCHIAT, V71, P1381, DOI 10.1001/jamapsychiatry.2014.1611; Krassioukov A, 2009, RESP PHYSIOL NEUROBI, V169, P157, DOI 10.1016/j.resp.2009.08.003; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Lim SW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169623; Liu JW, 2004, SPINE, V29, P164, DOI 10.1097/01.BRS.0000107234.74249.CD; Lucin KM, 2007, EXP NEUROL, V207, P75, DOI 10.1016/j.expneurol.2007.05.019; Luedtke K, 2014, J NEUROTRAUM, V31, P1107, DOI 10.1089/neu.2013.3204; Lynch AC, 2000, SPINAL CORD, V38, P717, DOI 10.1038/sj.sc.3101058; Maldonado-Bouchard S, 2016, BRAIN BEHAV IMMUN, V51, P176, DOI 10.1016/j.bbi.2015.08.009; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029; Naseribafrouei A, 2014, NEUROGASTROENT MOTIL, V26, P1155, DOI 10.1111/nmo.12378; Neufeld KM, 2011, NEUROGASTROENT MOTIL, V23, DOI 10.1111/j.1365-2982.2010.01620.x; O'Connor G, 2018, J NEUROTRAUM, V35, P2159, DOI 10.1089/neu.2017.5349; O'Donovan A, 2010, BRAIN BEHAV IMMUN, V24, P1074, DOI 10.1016/j.bbi.2010.03.003; ODWYER ST, 1988, ARCH SURG-CHICAGO, V123, P1459; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Peruga I, 2011, BEHAV BRAIN RES, V220, P20, DOI 10.1016/j.bbr.2011.01.018; Phipson B, 2016, ANN APPL STAT, V10, P946, DOI 10.1214/16-AOAS920; Pop M, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-6-r76; Popovich P, 2009, NAT MED, V15, P736, DOI 10.1038/nm0709-736; Post MWM, 2012, SPINAL CORD, V50, P382, DOI 10.1038/sc.2011.182; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; R Core Team, R LANG ENV STAT COMP; R Studio Team, 2015, RSTUDIO INT DEV R; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; RODGERS RJ, 1993, PSYCHOPHARMACOLOGY, V113, P237, DOI 10.1007/BF02245704; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Schwab JM, 2014, EXP NEUROL, V258, P121, DOI 10.1016/j.expneurol.2014.04.023; Singh V, 2016, J NEUROSCI, V36, P7428, DOI 10.1523/JNEUROSCI.1114-16.2016; Slattery DA, 2012, NAT PROTOC, V7, P1009, DOI 10.1038/nprot.2012.044; Smith PA, 2015, NATURE, V526, P312, DOI 10.1038/526312a; STERU L, 1985, PSYCHOPHARMACOLOGY, V85, P367, DOI 10.1007/BF00428203; Sudo N, 2004, J PHYSIOL-LONDON, V558, P263, DOI 10.1113/jphysiol.2004.063388; Valles-Colomer M, 2019, NAT MICROBIOL, V4, P623, DOI 10.1038/s41564-018-0337-x; WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358; Yirmiya R, 1996, BRAIN RES, V711, P163, DOI 10.1016/0006-8993(95)01415-2; Zhang Y, 2013, J NEUROSCI, V33, P12970, DOI 10.1523/JNEUROSCI.1974-13.2013; Zhou H, 2015, PHARMACOL BIOCHEM BE, V135, P40, DOI 10.1016/j.pbb.2015.05.009; Zorrilla EP, 2001, BRAIN BEHAV IMMUN, V15, P199, DOI 10.1006/brbi.2000.0597	70	39	42	7	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2020	15	1							e0226128	10.1371/journal.pone.0226128	http://dx.doi.org/10.1371/journal.pone.0226128			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5OV	31940312	Green Published, gold, Green Submitted			2023-01-03	WOS:000534368000019
J	Wadley, L; Backwell, L; d'Errico, F; Sievers, C				Wadley, Lyn; Backwell, Lucinda; d'Errico, Francesco; Sievers, Christine			Cooked starchy rhizomes in Africa 170 thousand years ago	SCIENCE			English	Article							ISOTOPIC EVIDENCE; CALCIUM-OXALATE; EARLY HOMINID; BORDER CAVE; PLANT FOODS; DIET; STORAGE; BEHAVIOR; ANATOMY	Plant carbohydrates were undoubtedly consumed in antiquity, yet starchy geophytes were seldom preserved archaeologically. We report evidence for geophyte exploitation by early humans from at least 170,000 years ago. Charred rhizomes from Border Cave, South Africa, were identified to the genus Hypoxis L. by comparing the morphology and anatomy of ancient and modern rhizomes. Hypoxis angustifolia Lam., the likely taxon, proliferates in relatively well-watered areas of sub-Saharan Africa and in Yemen, Arabia. In those areas and possibly farther north during moist periods, Hypoxis rhizomes would have provided reliable and familiar carbohydrate sources for mobile groups.	[Wadley, Lyn; Backwell, Lucinda] Univ Witwatersrand, Evolutionary Studies Inst, Johannesburg, South Africa; [Backwell, Lucinda] Consejo Nacl Invest Cient & Tecn, ISES, San Miguel De Tucuman, Tucuman, Argentina; [d'Errico, Francesco] Univ Bordeaux, CNRS, PACEA, UMR 5199, Batiment B2,Allee Geoffroy St Hilaire,CS 50023, F-33615 Pessac, France; [d'Errico, Francesco] Univ Bergen, SFF Ctr Early Sapiens Behav SapienCE, Oysteinsgate 3,Postboks 7805, N-5020 Bergen, Norway; [Sievers, Christine] Univ Witwatersrand, Sch Geog Archaeol & Environm Studies, Johannesburg, South Africa	University of Witwatersrand; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; University of Bergen; University of Witwatersrand	Wadley, L (corresponding author), Univ Witwatersrand, Evolutionary Studies Inst, Johannesburg, South Africa.	lyn.wadley@wits.ac.za	Wadley, Lyn/AAC-6577-2022	Backwell, Lucinda/0000-0001-5816-3353; Wadley, Lyn/0000-0003-0053-0813; Sievers, Christine/0000-0001-5704-6913	National Geographic Society [NGS-54810R-19]; Centre of Excellence [OP2015/04LB]; Research Council of Norway Centres of Excellence, SFF Centre for Early Sapiens Behavior (SapienCE) [262618]	National Geographic Society(National Geographic Society); Centre of Excellence; Research Council of Norway Centres of Excellence, SFF Centre for Early Sapiens Behavior (SapienCE)	L.B. received funding from the National Geographic Society (NGS-54810R-19) and Centre of Excellence (OP2015/04LB). The Research Council of Norway Centres of Excellence, SFF Centre for Early Sapiens Behavior (SapienCE) (262618) partly funded F.D.	[Anonymous], 2019, WORLD CHECKL SEL PLA; Backwell LR, 2018, J FIELD ARCHAEOL, V43, P417, DOI 10.1080/00934690.2018.1504544; Bayley A. D., 1989, THESIS; Beaumont PB, 1978, THESIS; Bews JW, 1930, ANN BOT-LONDON, V44, P689, DOI 10.1093/oxfordjournals.aob.a090243; Brooks AS, 2018, SCIENCE, V360, P90, DOI 10.1126/science.aao2646; Butterworth PJ., 2016, WILD HARVEST PLANTS, P31, DOI [10.2307/j.ctvh1dmjj.7, DOI 10.2307/J.CTVH1DMJJ.7]; Carretero LG, 2017, VEG HIST ARCHAEOBOT, V26, P415, DOI 10.1007/s00334-017-0602-6; CHEADLE VI, 1968, PHYTOMORPHOLOGY, V18, P412; Cholewa E, 2004, J EXP BOT, V55, P731, DOI 10.1093/jxb/erh054; Crowther A., 2012, NEW DIRECTIONS ARCHA; d'Errico F, 2012, P NATL ACAD SCI USA, V109, P13214, DOI 10.1073/pnas.1204213109; Dahlgren RM., 1982, MONOCOTYLEDONS COMP; de Menezes NL, 2012, PLANT ECOL DIVERS, V5, P153, DOI 10.1080/17550874.2011.604925; Deacon HJ., 1976, S AFRICAN ARCHAEOLOG, V1; Dominy NJ, 2008, EVOL BIOL, V35, P159, DOI 10.1007/s11692-008-9026-7; Ekeke C., 2018, Journal of Applied Sciences & Environmental Management, V22, P7, DOI 10.4314/jasem.v22i1.2; Grun R, 2003, J HUM EVOL, V45, P155, DOI 10.1016/S0047-2484(03)00102-7; Hardy K, 2015, Q REV BIOL, V90, P251, DOI 10.1086/682587; Hather J, 1993, OXBOW MONOGRAPH, V1; Hather J. G., 2000, ARCHAEOLOGICAL PAREN; HATHER JG, 1991, J ARCHAEOL SCI, V18, P661, DOI 10.1016/0305-4403(91)90028-N; Henry AG, 2014, J HUM EVOL, V69, P44, DOI 10.1016/j.jhevol.2013.12.014; Hillman G, 2014, PUBL INST ARCHAEOL, V61, P37; Inchley CE, 2016, SCI REP-UK, V6, DOI 10.1038/srep37198; Jones M, 2009, VERTEBR PALEOBIOL PA, P171, DOI 10.1007/978-1-4020-9699-0_12; Kauff F, 2000, PLANT SYST EVOL, V223, P139, DOI 10.1007/BF00985275; Larbey C, 2019, J HUM EVOL, V131, P210, DOI 10.1016/j.jhevol.2019.03.015; Lee-Thorp J, 2012, P NATL ACAD SCI USA, V109, P20369, DOI 10.1073/pnas.1204209109; Melamed Y, 2016, P NATL ACAD SCI USA, V113, P14674, DOI 10.1073/pnas.1607872113; Millard AR, 2006, QUAT GEOCHRONOL, V1, P159, DOI 10.1016/j.quageo.2006.03.002; Munro S. L., 2000, THESIS; Muthukumar T., 2018, Lankesteriana, V18, P13, DOI 10.15517/lank.v18i1.32701; Peters CR, 2005, J HUM EVOL, V48, P219, DOI 10.1016/j.jhevol.2004.11.003; Pooley E, 1998, FIELD GUIDE WILD FLO; Prychid CJ, 2008, ANN BOT-LONDON, V101, P983, DOI 10.1093/aob/mcn022; Prychid CJ, 1999, ANN BOT-LONDON, V84, P725, DOI 10.1006/anbo.1999.0975; Prychid CJ, 2003, ANN BOT-LONDON, V92, P571, DOI 10.1093/aob/mcg172; Raven P.H., 1986, BIOL PLANTS; Rodrigues AC, 2009, ACTA BOT BRAS, V23, P889, DOI 10.1590/S0102-33062009000300030; RUDALL P, 1995, IAWA J, V16, P261, DOI 10.1163/22941932-90001409; RUDALL P, 1984, BOT GAZ, V145, P524, DOI 10.1086/337488; RUDALL P, 1994, BOT J LINN SOC, V114, P1, DOI 10.1111/j.1095-8339.1994.tb01920.x; Silberbauer GeorgeB., 1981, HUNTER HABITAT CENTR; Singels E, 2016, J HUM EVOL, V101, P79, DOI 10.1016/j.jhevol.2016.09.008; Singh Y., 2000, THESIS; SPETH JD, 1983, J ANTHROPOL ARCHAEOL, V2, P1, DOI 10.1016/0278-4165(83)90006-5; Sponheimer M, 1999, SCIENCE, V283, P368, DOI 10.1126/science.283.5400.368; THOMPSON M F, 1976, Bothalia, V12, P111; Wadley L, 1987, CAMBRIDGE MONOGRAPHS, V25; Wandsnider L, 1997, J ANTHROPOL ARCHAEOL, V16, P1, DOI 10.1006/jaar.1997.0303; Webb MA, 1999, PLANT CELL, V11, P751, DOI 10.1105/tpc.11.4.751; Weyrich LS, 2017, NATURE, V544, P357, DOI 10.1038/nature21674; Wiland-Szymanska J., 2009, Biodiversity: Research and Conservation, V14, P1, DOI 10.2478/v10119-009-0011-5; Wiland-Szymanska J, 2002, NOVON, V12, P142, DOI 10.2307/3393254; Wollstonecroft MM, 2008, VEG HIST ARCHAEOBOT, V17, pS19, DOI 10.1007/s00334-008-0162-x; Wrangham R, 2017, CURR ANTHROPOL, V58, pS303, DOI 10.1086/692113	57	42	42	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 3	2020	367	6473					87	+		10.1126/science.aaz5926	http://dx.doi.org/10.1126/science.aaz5926			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KB7QZ	31896717				2023-01-03	WOS:000506686400040
J	Hofstoetter, US; Freundl, B; Binder, H; Minassian, K				Hofstoetter, Ursula S.; Freundl, Brigitta; Binder, Heinrich; Minassian, Karen			Recovery cycles of posterior root-muscle reflexes evoked by transcutaneous spinal cord stimulation and of the H reflex in individuals with intact and injured spinal cord	PLOS ONE			English	Article							POST-ACTIVATION DEPRESSION; EPIDURAL ELECTRICAL-STIMULATION; LOW-FREQUENCY DEPRESSION; PRESYNAPTIC INHIBITION; IA AFFERENTS; LEG MUSCLES; HOMOSYNAPTIC DEPRESSION; MOTOR-NEURONS; SOLEUS MUSCLE; LUMBAR CORD	Posterior root-muscle (PRM) reflexes are short-latency spinal reflexes evoked by epidural or transcutaneous spinal cord stimulation (SCS) in clinical and physiological studies. PRM reflexes share key physiological characteristics with the H reflex elicited by electrical stimulation of large-diameter muscle spindle afferents in the tibial nerve. Here, we compared the H reflex and the PRM reflex of soleus in response to transcutaneous stimulation by studying their recovery cycles in ten neurologically intact volunteers and ten individuals with traumatic, chronic spinal cord injury (SCI). The recovery cycles of the reflexes, i.e., the time course of their excitability changes, were assessed by paired pulses with conditioning-test intervals of 20-5000 ms. Between the subject groups, no statistical difference was found for the recovery cycles of the H reflexes, yet those of the PRM reflexes differed significantly, with a striking suppression in the intact group. When comparing the reflex types, they did not differ in the SCI group, while the PRM reflexes were more strongly depressed in the intact group for durations characteristic for presynaptic inhibition. These differences may arise from the concomitant stimulation of several posterior roots containing afferent fibers of various lower extremity nerves by transcutaneous SCS, producing multi-source heteronymous presynaptic inhibition, and the collective dysfunction of inhibitory mechanisms after SCI contributing to spasticity. PRM-reflex recovery cycles additionally obtained for bilateral rectus femoris, biceps femoris, tibialis anterior, and soleus all demonstrated a stronger suppression in the intact group. Within both subject groups, the thigh muscles showed a stronger recovery than the lower leg muscles, which may reflect a characteristic difference in motor control of diverse muscles. Based on the substantial difference between intact and SCI individuals, PRM-reflex depression tested with paired pulses could become a sensitive measure for spasticity and motor recovery.	[Hofstoetter, Ursula S.; Minassian, Karen] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria; [Freundl, Brigitta; Binder, Heinrich] Otto Wagner Hosp, Neurol Ctr, Maria Theresien Schloessel, Vienna, Austria	Medical University of Vienna	Hofstoetter, US (corresponding author), Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.	ursula.hofstoetter@meduniwien.ac.at		Minassian, Karen/0000-0003-4197-6141; Hofstoetter, Ursula S./0000-0002-3156-6483				Andrews JC, 2015, J NEUROPHYSIOL, V114, P485, DOI 10.1152/jn.01007.2014; Andrews JC, 2015, NEUROSCI LETT, V589, P144, DOI 10.1016/j.neulet.2015.01.041; Angeli CA, 2018, NEW ENGL J MED, V379, P1244, DOI 10.1056/NEJMoa1803588; BAUMGARTNER MG, 1984, ARZNEIMITTEL-FORSCH, V34-1, P724; BERGMANS J, 1978, EXP NEUROL, V60, P380, DOI 10.1016/0014-4886(78)90091-2; BESWICK FB, 1957, J PHYSIOL-LONDON, V135, P400, DOI 10.1113/jphysiol.1957.sp005719; BIANCONI R, 1964, ACTA PHYSIOL SCAND, V61, P331; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BUN H, 1987, ARZNEIMITTEL-FORSCH, V37-1, P199; BURKE D, 1984, J NEUROPHYSIOL, V52, P435, DOI 10.1152/jn.1984.52.3.435; BURKE D, 1983, J PHYSIOL-LONDON, V339, P535, DOI 10.1113/jphysiol.1983.sp014732; CALANCIE B, 1993, ELECTROEN CLIN NEURO, V89, P177, DOI 10.1016/0168-5597(93)90131-8; Calvert JS, 2019, J NEUROTRAUM, V36, P1451, DOI 10.1089/neu.2018.5921; Capogrosso M, 2013, J NEUROSCI, V33, P19326, DOI 10.1523/JNEUROSCI.1688-13.2013; Cisi RRL, 2007, P ANN INT IEEE EMBS, P2713, DOI 10.1109/IEMBS.2007.4352889; Courtine GG, 2007, J PHYSIOL-LONDON, V582, P1125, DOI 10.1113/jphysiol.2007.128447; CRONE C, 1989, EXP BRAIN RES, V78, P28, DOI 10.1007/bf00230683; Danner SM, 2011, ARTIF ORGANS, V35, P257, DOI 10.1111/j.1525-1594.2011.01213.x; DELWAIDE PJ, 1994, NEUROLOGY, V44, P21; DELWAIDE PJ, 1976, J NEUROL NEUROSUR PS, V39, P545, DOI 10.1136/jnnp.39.6.545; DIAMANTOPOULOS E, 1967, J NEUROL NEUROSUR PS, V30, P427, DOI 10.1136/jnnp.30.5.427; Dy CJ, 2010, J NEUROPHYSIOL, V103, P2808, DOI 10.1152/jn.00316.2009; ECCLES JC, 1954, J PHYSIOL-LONDON, V126, P524, DOI 10.1113/jphysiol.1954.sp005226; ECCLES JC, 1962, J PHYSIOL-LONDON, V161, P282, DOI 10.1113/jphysiol.1962.sp006886; Elbasiouny SM, 2010, NEUROREHAB NEURAL RE, V24, P23, DOI 10.1177/1545968309343213; Estes SP, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00017; FAIST M, 1994, BRAIN, V117, P1449, DOI 10.1093/brain/117.6.1449; Formento E, 2018, NAT NEUROSCI, V21, P1728, DOI 10.1038/s41593-018-0262-6; Gad P, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00333; Gill ML, 2018, NAT MED, V24, P1677, DOI 10.1038/s41591-018-0175-7; Grey MJ, 2008, EXP BRAIN RES, V185, P189, DOI 10.1007/s00221-007-1142-6; Hoffman P., 1910, ARCH F PHYSL, V1, P223; Hoffmann P, 1918, Z BIOL-MUNICH, V68, P351; Hoffmann P, 1924, Z BIOL-MUNICH, V81, P37; Hofstoetter US, 2008, ARTIF ORGANS, V32, P644, DOI 10.1111/j.1525-1594.2008.00616.x; Hofstoetter US, 2020, J NEUROTRAUM, V37, P481, DOI 10.1089/neu.2019.6588; Hofstoetter US, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192013; Hofstoetter US, 2015, ARTIF ORGANS, V39, pE176, DOI 10.1111/aor.12615; Hofstoetter US, 2014, J SPINAL CORD MED, V37, P202, DOI 10.1179/2045772313Y.0000000149; HULME A, 1985, EUR J CLIN PHARMACOL, V29, P467, DOI 10.1007/BF00613463; HULTBORN H, 1987, J PHYSIOL-LONDON, V389, P729, DOI 10.1113/jphysiol.1987.sp016680; Hultborn H, 1996, EXP BRAIN RES, V108, P450; ILES JF, 1987, J PHYSIOL-LONDON, V385, P69, DOI 10.1113/jphysiol.1987.sp016484; ISHIKAWA K, 1966, EXP NEUROL, V15, P140, DOI 10.1016/0014-4886(66)90039-2; Kagamihara Y, 1998, MUSCLE NERVE, V21, P352, DOI 10.1002/(SICI)1097-4598(199803)21:3<352::AID-MUS9>3.0.CO;2-9; Katz R, 1999, J PHYSIOLOGY-PARIS, V93, P379, DOI 10.1016/S0928-4257(00)80065-0; Kiernan MC, 1996, BRAIN, V119, P1099, DOI 10.1093/brain/119.4.1099; Kirshblum S, 2014, PHYS MED REH CLIN N, V25, P505, DOI 10.1016/j.pmr.2014.04.001; Kitano K, 2009, J NEUROSCI METH, V180, P111, DOI 10.1016/j.jneumeth.2009.03.006; Knikou M, 2008, J NEUROSCI METH, V171, P1, DOI 10.1016/j.jneumeth.2008.02.012; Kohn AF, 1997, EXP BRAIN RES, V116, P375, DOI 10.1007/PL00005765; Kohn AF, 1995, C P IEEE ENG MED BIO, V1995, P1233; KUNO M, 1964, J PHYSIOL-LONDON, V175, P100, DOI 10.1113/jphysiol.1964.sp007505; Ladenbauer J, 2010, IEEE T NEUR SYS REH, V18, P637, DOI 10.1109/TNSRE.2010.2054112; Lamy JC, 2005, EXP BRAIN RES, V166, P248, DOI 10.1007/s00221-005-2360-4; Lang J, 1983, Morphol Med, V3, P27; MAGLADERY JW, 1951, B JOHNS HOPKINS HOSP, V88, P520; MAGLADERY JW, 1950, B JOHNS HOPKINS HOSP, V86, P265; MAGLADERY JW, 1951, B JOHNS HOPKINS HOSP, V88, P499; Malangat G, 2008, EXPERT OPIN PHARMACO, V9, P2209, DOI [10.1517/14656560802252595, 10.1517/14656566.9.12.2209 ]; MAO CC, 1984, EXP BRAIN RES, V56, P341; MATHIAS C J, 1989, Journal of Rehabilitation Research and Development, V26, P9; MEUNIER S, 1990, J PHYSIOL-LONDON, V423, P661, DOI 10.1113/jphysiol.1990.sp018046; MEUNIER S, 1993, EXP BRAIN RES, V96, P534; Milosevic M, 2019, EXP BRAIN RES, V237, P467, DOI 10.1007/s00221-018-5437-6; Minassian K, 2007, HUM MOVEMENT SCI, V26, P275, DOI 10.1016/j.humov.2007.01.005; Minassian K, 2004, SPINAL CORD, V42, P401, DOI 10.1038/sj.sc.3101615; Minassian K., 2011, RESTORATIVE NEUROLOG, P226; Minassian K, 2009, NEUROSCIENCE M PLANN; Minassian K, 2007, MUSCLE NERVE, V35, P327, DOI 10.1002/mus.20700; Minassian K, 2017, NEUROSCIENTIST, V23, P649, DOI 10.1177/1073858417699790; Minassian K, 2016, NEUROREHAB NEURAL RE, V30, P233, DOI 10.1177/1545968315591706; MIZUNO Y, 1971, J NEUROPHYSIOL, V34, P1010, DOI 10.1152/jn.1971.34.6.1010; MORIN C, 1984, NEUROSCI LETT, V44, P137, DOI 10.1016/0304-3940(84)90071-5; Morita H, 2001, BRAIN, V124, P826, DOI 10.1093/brain/124.4.826; MORITA H, 1993, MUSCLE NERVE, V16, P648, DOI 10.1002/mus.880160611; Murg M, 2000, SPINAL CORD, V38, P394, DOI 10.1038/sj.sc.3101038; Nakazawa K, 2006, ARCH PHYS MED REHAB, V87, P71, DOI 10.1016/j.apmr.2005.08.122; NIELSEN J, 1993, EXP BRAIN RES, V97, P173; NIELSEN J, 1994, J PHYSIOL-LONDON, V477, P47, DOI 10.1113/jphysiol.1994.sp020170; NIELSEN J, 1995, BRAIN, V118, P995, DOI 10.1093/brain/118.4.995; Nielsen J., 2018, NEUROLOGICAL REHABIL, P25; OLSEN PZ, 1967, J NEUROL NEUROSUR PS, V30, P325, DOI 10.1136/jnnp.30.4.325; Paillard J, 1955, ETUDE NEUROPHYSIOLOG; Pierrot-Deseilligny E, 2000, NEUROPHYSIOL CLIN, V30, P67, DOI 10.1016/S0987-7053(00)00062-9; PierrotDeseilligny E, 2012, CIRCUITRY OF THE HUMAN SPINAL CORD: SPINAL AND CORTICOSPINAL MECHANISMS OF MOVEMENT, P1, DOI 10.1017/CBO9781139026727; Rattay F, 2000, SPINAL CORD, V38, P473, DOI 10.1038/sj.sc.3101039; Saito A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214818; Sayenko DG, 2019, J NEUROTRAUM, V36, P1435, DOI 10.1089/neu.2018.5956; Sayenko DG, 2014, J NEUROPHYSIOL, V111, P1088, DOI 10.1152/jn.00489.2013; SCHENCK E, 1951, PFLUG ARCH GES PHYS, V253, P286, DOI 10.1007/BF00363395; SCHIEPPATI M, 1987, PROG NEUROBIOL, V28, P345, DOI 10.1016/0301-0082(87)90007-4; Schindler-Ivens S, 2000, EXP BRAIN RES, V133, P233, DOI 10.1007/s002210000377; Shellenberger MK, 1999, DRUG METAB DISPOS, V27, P201; SHIMAMURA M, 1964, JPN J PHYSIOL, V14, P411; TABORIKOVA H, 1969, BRAIN, V92, P203, DOI 10.1093/brain/92.1.203; TABORKOVA HELENA, 1966, BRAIN RES, V2, P192, DOI 10.1016/0006-8993(66)90026-6; TSE FLS, 1987, FUNDAM CLIN PHARM, V1, P479, DOI 10.1111/j.1472-8206.1987.tb00581.x; Wagner FB, 2018, NATURE, V563, P65, DOI 10.1038/s41586-018-0649-2; Zhu Y, 1998, ELECTROMYOGR MOTOR C, V109, P10, DOI 10.1016/S0924-980X(97)00058-1	100	22	24	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 26	2019	14	12							e0227057	10.1371/journal.pone.0227057	http://dx.doi.org/10.1371/journal.pone.0227057			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN8GX	31877192	Green Published, gold			2023-01-03	WOS:000515084600056
J	Ray, MJ; Tallman, GB; Bearden, DT; Elman, MR; McGregor, JC				Ray, Michael J.; Tallman, Gregory B.; Bearden, David T.; Elman, Miriam R.; McGregor, Jessina C.			Antibiotic prescribing without documented indication in ambulatory care clinics: national cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY-TRACT INFECTIONS; BEHAVIORAL INTERVENTIONS; UNITED-STATES; ADULTS; TRENDS; HOSPITALS; PROVIDER; PATIENT; COLDS	OBJECTIVES To identify the frequency with which antibiotics are prescribed in the absence of a documented indication in the ambulatory care setting, to quantify the potential effect on assessments of appropriateness of antibiotics, and to understand patient, provider, and visit level characteristics associated with antibiotic prescribing without a documented indication. DESIGN Cross sectional study. SETTING 2015 National Ambulatory Medical Care Survey. PARTICIPANTS 28 332 sample visits representing 990.9 million ambulatory care visits nationwide. MAIN OUTCOME MEASURES Overall antibiotic prescribing and whether each antibiotic prescription was accompanied by appropriate, inappropriate, or no documented indication as identified through ICD-9-CM (international classification of diseases, 9th revision, clinical modification) codes. Survey weighted multivariable logistic regression was used to evaluate potential risk factors for receipt of an antibiotic prescription without a documented indication. RESULTS Antibiotics were prescribed during 13.2% (95% confidence interval 11.6% to 13.7%) of the estimated 990.8 million ambulatory care visits in 2015. According to the criteria, 57% (52% to 62%) of the 130.5 million prescriptions were for appropriate indications, 25% (21% to 29%) were inappropriate, and 18% (15% to 22%) had no documented indication. This corresponds to an estimated 24 million prescriptions without a documented indication. Being an adult male, spending more time with the provider, and seeing a non-primary care specialist were significantly positively associated with antibiotic prescribing without an indication. Sulfonamides and urinary anti-infective agents were the antibiotic classes most likely to be prescribed without documentation. CONCLUSIONS This nationally representative study of ambulatory visits identified a large number of prescriptions for antibiotics without a documented indication. Antibiotic prescribing in the absence of a documented indication may severely bias national estimates of appropriate antibiotic use in this setting. This study identified a wide range of factors associated with antibiotic prescribing without a documented indication, which may be useful in directing initiatives aimed at supporting better documentation.	[Ray, Michael J.; Elman, Miriam R.] Portland State Univ, Oregon Hlth & Sci Univ, Sch Publ, Portland, OR 97239 USA; [Ray, Michael J.; Bearden, David T.; McGregor, Jessina C.] Oregon State Univ, Coll Pharm, Portland, OR 97201 USA; [Tallman, Gregory B.] Pacific Univ, Sch Pharm, Hillsboro, OR 97123 USA	Oregon Health & Science University; Portland State University; Oregon State University	Ray, MJ (corresponding author), Portland State Univ, Oregon Hlth & Sci Univ, Sch Publ, Portland, OR 97239 USA.; Ray, MJ (corresponding author), Oregon State Univ, Coll Pharm, Portland, OR 97201 USA.	raymi@ohsu.edu	McGregor, Jessina C/A-7625-2008	Ray, Michael/0000-0001-7670-9639; McGregor, Jessina/0000-0002-6093-5444				Baggs J, 2016, JAMA INTERN MED, V176, P1639, DOI 10.1001/jamainternmed.2016.5651; Barlam TF, 2016, CLIN INFECT DIS, V62, pE51, DOI 10.1093/cid/ciw118; Cantrell R, 2002, CLIN THER, V24, P170, DOI 10.1016/S0149-2918(02)85013-5; Centers for Disease Control and Prevention, 2017, OUTP ANT PRESCR US 2; Centers for Disease Control and Prevention, 2015, NAMCS MICR FIL DOC S; Chua KP, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.k5092; Dobson EL, 2017, J AM PHARM ASSOC, V57, P464, DOI 10.1016/j.japh.2017.03.014; Duffy E, 2018, J CLIN PHARM THER, V43, P59, DOI 10.1111/jcpt.12610; Fleming-Dutra KE, 2016, JAMA-J AM MED ASSOC, V315, P1864, DOI 10.1001/jama.2016.4151; Fleming-Dutra KE, 2019, OPEN FORUM INFECT S2, V6, pS32; Gonzales R, 2001, CLIN INFECT DIS, V33, P757, DOI 10.1086/322627; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; Grigoryan L, 2019, ANN INTERN MED, V171, P257, DOI 10.7326/M19-0505; Havers FP, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0243; Hawker JI, 2014, J ANTIMICROB CHEMOTH, V69, P3423, DOI 10.1093/jac/dku291; Hicks LA, 2015, CLIN INFECT DIS, V60, P1308, DOI 10.1093/cid/civ076; Linder JA, 2017, JAMA-J AM MED ASSOC, V318, P1391, DOI 10.1001/jama.2017.11152; Magill SS, 2014, JAMA-J AM MED ASSOC, V312, P1438, DOI 10.1001/jama.2014.12923; Martinez KA, 2019, ANN INTERN MED, V170, P275, DOI 10.7326/M18-2042; McGregor JC, IDWEEK; Meeker D, 2016, JAMA-J AM MED ASSOC, V315, P562, DOI 10.1001/jama.2016.0275; Palms DL, 2018, JAMA INTERN MED, V178, P1267, DOI 10.1001/jamainternmed.2018.1632; Ray MJ, 2018, INFECT CONT HOSP EP, V39, P377, DOI 10.1017/ice.2018.23; Sanchez GV, 2016, MMWR RECOMM REP, V65, DOI 10.15585/mmwr.rr6506a1; Schmidt ML, 2018, INFECT CONT HOSP EP, V39, P307, DOI 10.1017/ice.2017.263; Shapiro DJ, 2014, J ANTIMICROB CHEMOTH, V69, P234, DOI 10.1093/jac/dkt301; Steinman MA, 2003, ANN INTERN MED, V138, P525, DOI 10.7326/0003-4819-138-7-200304010-00008; Suda KJ, 2014, ANTIMICROB AGENTS CH, V58, P2763, DOI 10.1128/AAC.02239-13; Suda KJ, 2013, J ANTIMICROB CHEMOTH, V68, P715, DOI 10.1093/jac/dks445	29	35	37	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	2019	367								l6461	10.1136/bmj.l6461	http://dx.doi.org/10.1136/bmj.l6461			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW1GC	31826860	hybrid, Green Published			2023-01-03	WOS:000502805800002
J	Daniel, H; Bornstein, SS; Carney, JK; Cooney, TG; Engel, LS; Gantzer, HE; Henry, TL; Lenchus, JD; McCandless, BM; Southworth, MB; Syed, F; Quinton, J; Wallace, MA				Daniel, Hilary; Bornstein, Sue S.; Carney, Jan K.; Cooney, Thomas G.; Engel, Lee S.; Gantzer, Heather E.; Henry, Tracey L.; Lenchus, Joshua D.; McCandless, Bridget M.; Southworth, Molly B.; Syed, Fatima; Quinton, Jacob; Wallace, Mary Anderson			Policy Recommendations for Public Health Plans to Stem the Escalating Costs of Prescription Drugs: A Position Paper From the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Review								The increasing price of prescription drugs is an ongoing concern for Medicare and Medicaid, particularly for patients with chronic health conditions who are using multiple medications and patients in these programs taking high-priced brand-name specialty drugs. Shifts in benefit design, including higher deductibles and a movement away from copayments to coinsurance, have increased patient out-of-pocket costs and put pressure on program budgets. In this paper, the American College of Physicians expands on its position paper from 2016 and offers additional recommendations to decrease out-of-pocket costs for patients, enhance the government's purchasing power, and address existing policies that add costs to the health care system.	[Daniel, Hilary] Amer Coll Physicians, 25 Massachusetts Ave NW,Suite 700, Washington, DC 20001 USA; [Bornstein, Sue S.] Texas Med Home Initiat, Dallas, TX USA	American College of Physicians	Daniel, H (corresponding author), Amer Coll Physicians, 25 Massachusetts Ave NW,Suite 700, Washington, DC 20001 USA.	hdaniel@mail.acponline.org			ACP operating budget	ACP operating budget	Financial support for the development of this position paper came exclusively from the ACP operating budget.	Aitken M, 2016, HEALTH AFFAIR, V35, P1595, DOI 10.1377/hlthaff.2015.1636; [Anonymous], 2018, SPECIALTY PHARM 1231; [Anonymous], 2018, PRESCR DRUG PRIC HLT; Centers for Medicare & Medicaid Services, 2018, MED DRUG COV MED A; Centers for Medicare & Medicaid Services, 2018, MEDICAID DRUG REBATE; Centers for Medicare & Medicaid Services, 2019, MED PRESCR DRUGS; Centers for Medicare & Medicaid Services, 2017, 2018 RES COST SHAR L; Centers for Medicare & Medicaid Services, 2015, DOES ENR GEN TIER D; Cubanski J., 2019, WHATS LATEST MEDICAR; Cubanski J, 2017, NO LIMIT MEDICARE D; Daniel H, 2016, ANN INTERN MED, V165, P50, DOI 10.7326/M15-2768; Gagnon MA, 2015, POLICY BRIEF; Government Accountability Office, 2014, PRESCR DRUGS COMP DO; Hatch O, 2018, COMMUNICATION   0322; Kaiser Family Foundation, 2017, MED D; Kaiser Family Foundation, 2019, 10 ESS FACTS MED PRE; Kirchhoff SM, 2018, FREQUENTLY ASKED QUE; Kirzinger A, 2017, KAISER HLTH TRACKING; Marrufo GM, 2010, ESTIMATING EFFECTS D; McLean R, 2016, COMMUNICATION   0509; Medicare Payment Advisory Commission, 2017, PUBL M TRANSCR 2 MAR; Medicare Payment Advisory Committee, 2014, REP C MED PAYM POL; Medicare Payment Advisory Committee, 2017, HLTH CAR SPEND MED P; Miller DP, 2019, AM J HEALTH ECON, V5, P191, DOI 10.1162/ajhe_a_00119; Mulcahy Andrew W, 2018, Rand Health Q, V7, P3; National Academies of Sciences Engineering and Medicine, 2018, MAKING MED AFFORDABL, DOI [10.17226/24946, DOI 10.17226/24946]; National Academy for State Health Policy, 2019, UPD WHATS NEWS STAT; Newman T., 2018, FACTS MEDICARE SPEND; Office of Management and Budget, 2019, BUDG US GOV FASC YEA; Orszag PR, 2007, COMMUNICATION   0410; Outterson K, 2009, HEALTH AFFAIR, V28, pW832, DOI 10.1377/hlthaff.28.5.w832; Papanicolas I, 2018, JAMA-J AM MED ASSOC, V319, P1024, DOI 10.1001/jama.2018.1150; Raymond N., 2008, REUTERS; Sarnak Dana O, 2017, Issue Brief (Commonw Fund), V2017, P1; Schoen Cathy, 2017, Issue Brief (Commonw Fund), V11, P1; Schondelmeyer SW, 2017, TRENDS RETAIL PRICES; Shih C, 2016, HLTH AFFAIRS BLOG; Siegel JF, 2017, BIOLOGICS BLOG  1218; Spiro T., 2015, ENOUGH IS ENOUGH TIM; Trish E, 2016, HEALTH AFFAIR, V35, P1564, DOI 10.1377/hlthaff.2016.0418; U.S. Department of Health and Human Services, 2017, OEI031700100 US DEP; U.S. Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation, 2018, SAV AV FULL GEN SU D; U.S. Department of Health and Human Services Office of the Inspector General, 2015, MED REB BRAND NAM DR; US Department of Health & Human Services, 2018, AM PAT 1 TRUMP ADM B; White House Council of Economic Advisers, 2018, REF BIOPH PRIC HOM A; Young K, 2018, SNAPSHOTS RECENT STA	46	6	6	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 3	2019	171	11					825	+		10.7326/M19-0013	http://dx.doi.org/10.7326/M19-0013			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KB3UY	31711137				2023-01-03	WOS:000506426000008
J	Dunn, LK; Taylor, DG; Smith, SJ; Skojec, AJ; Wang, TR; Chung, J; Hanak, MF; Lacomis, CD; Palmer, JD; Ruminski, C; Fang, SH; Tsang, S; Spangler, SN; Durieux, ME; Naik, BI				Dunn, Lauren K.; Taylor, Davis G.; Smith, Samantha J.; Skojec, Alexander J.; Wang, Tony R.; Chung, Joyce; Hanak, Mark F.; Lacomis, Christopher D.; Palmer, Justin D.; Ruminski, Caroline; Fang, Shenghao; Tsang, Siny; Spangler, Sarah N.; Durieux, Marcel E.; Naik, Bhiken, I			Persistent post-discharge opioid prescribing after traumatic brain injury requiring intensive care unit admission: A cross-sectional study with longitudinal outcome	PLOS ONE			English	Article							PRESSURE	Traumatic brain injury (TBI) is associated with increased risk for psychological and substance use disorders. The study aim is to determine incidence and risk factors for persistent opioid prescription after hospitalization for TBI. Electronic medical records of patients age. 18 admitted to a neuroscience intensive care unit between January 2013 and February 2017 for an intracranial injury were retrospectively reviewed. Primary outcome was opioid use through 12 months post-hospital discharge. A total of 298 patients with complete data were included in the analysis. The prevalence of opioid use among preadmission opioid users was 48 (87%), 36 (69%) and 22 (56%) at 1, 6 and 12-months post-discharge, respectively. In the opioid naive group, 69 (41%), 24 (23%) and 17 (19%) were prescribed opioids at 1, 6 and 12 months, respectively. Preadmission opioid use (OR 324.8, 95% CI 23.116907.5, p = 0.0004) and higher opioid requirements during hospitalization (OR 4.5, 95% CI 1.8-16.3, p = 0.006) were independently associated with an increased risk of being prescribed opioids 12 months post-discharge. These factors may be used to identify and target at-risk patients for intervention.	[Dunn, Lauren K.; Smith, Samantha J.; Skojec, Alexander J.; Chung, Joyce; Hanak, Mark F.; Lacomis, Christopher D.; Palmer, Justin D.; Ruminski, Caroline; Fang, Shenghao; Spangler, Sarah N.; Durieux, Marcel E.; Naik, Bhiken, I] Univ Virginia Hlth Syst, Dept Anesthesiol, Charlottesville, VA 22903 USA; [Taylor, Davis G.; Wang, Tony R.; Durieux, Marcel E.; Naik, Bhiken, I] Univ Virginia Hlth Syst, Dept Neurol Surg, Charlottesville, VA USA; [Tsang, Siny] Washington State Univ, Nutr & Exercise Physiol, Spokane, WA USA	University of Virginia; University of Virginia; Washington State University	Dunn, LK (corresponding author), Univ Virginia Hlth Syst, Dept Anesthesiol, Charlottesville, VA 22903 USA.	lak3r@virginia.edu		Skojec, Alexander/0000-0002-9400-9916; Tsang, Siny/0000-0001-5076-5587				Alnemari AM, 2017, WORLD NEUROSURG, V106, P509, DOI 10.1016/j.wneu.2017.07.009; Brummett CM, 2017, JAMA SURG, V152, DOI 10.1001/jamasurg.2017.0504; Camps AS, 2000, CRIT CARE MED, V28, P3612, DOI 10.1097/00003246-200011000-00009; Colton K, 2016, J INTENSIVE CARE MED, V31, P263, DOI 10.1177/0885066614555692; Devlin JW, 2018, CRIT CARE MED, V46, P1532, DOI [10.1097/CCM.0000000000003299, 10.1097/CCM.0000000000003259]; Dunn LK, 2018, ANESTH ANALG; Harbaugh CM, 2018, JAMA-J AM MED ASSOC, V320, P504, DOI 10.1001/jama.2018.9023; Hudson TJ, 2018, PAIN MED, V19, P774, DOI 10.1093/pm/pnx208; James SL, 2019, LANCET NEUROL, V18, P56, DOI 10.1016/S1474-4422(18)30415-0; Oddo M, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1294-5; Portenoy R. K., 2017, CANC PAIN MANAGEMENT; Shehabi Y, 2019, NEW ENGL J MED, V380, P2506, DOI 10.1056/NEJMoa1904710; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; Sun YX, 2012, DIS COLON RECTUM, V55, P1183, DOI 10.1097/DCR.0b013e318259bcd8; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Team RDC, 2015, R LANG ENV STAT COMP; van der Naalt J, 2017, LANCET NEUROL, V16, P532, DOI 10.1016/S1474-4422(17)30117-5; Vaughn MG, 2019, PSYCHIAT QUART, V90, P151, DOI 10.1007/s11126-018-9617-0; Wang HT, 2018, CRIT CARE MED, V46, P1934, DOI 10.1097/CCM.0000000000003401; Wiener J, 2019, BRAIN INJURY, V33, P559, DOI 10.1080/02699052.2019.1574328; Zhao HY, 2019, J CRIT CARE, V54, P136, DOI 10.1016/j.jcrc.2019.08.022	21	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2019	14	11							e0225787	10.1371/journal.pone.0225787	http://dx.doi.org/10.1371/journal.pone.0225787			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO8SS	31774864	Green Published, gold			2023-01-03	WOS:000533896400063
J	de Souza, W; de Abreu, LC; da Silva, LG; Bezerra, IMP				de Souza, Wesley; de Abreu, Luiz Carlos; da Silva, Leonardo Gomes; Pinheiro Bezerra, Italla Maria			Incidence of chronic kidney disease hospitalisations and mortality in Espirito Santo between 1996 to 2017	PLOS ONE			English	Article								Introduction Chronic kidney disease (CKD) has a set of clinical and laboratory abnormalities where renal function loss is noted. The high prevalence of comorbidity of people living with CKD, its economic impact and its prognosis have made it a public health problem, justifying the need to implement preventive measures. Objective To analyse the mortality and incidence of hospital admissions for CKD. Methods Ecological study with a time series design using secondary microdata of deaths and hospital admissions from patients with CKD from 1996 to 2017 in the State of Espi ' rito Santo, Brazil. Results The average mortality rate of CKD during the studied years was 2.92 per 100,000 inhabitants per year. During this period global mortality was a stationary phenomenon. In women, the trend of mortality from 2005 on increased 7,87% per year. Between 2008 and 2017, the average incidence hospital admissions due to CKD per year was 45.76 per 100,000 inhabitants. It was observed that the overall hospital admission increased by the equivalent of 6.23% per year. More than a half of mortality and hospitalisations correspond to male patients over 50 years of age. In terms of mortality, 32.99% corresponded to Caucasian patients, while 35.13% of hospitalisations were mixed race. Conclusion We found that age and gender are factors associated with deaths and hospitalisations for chronic kidney disease. While hospitalisation increases 6.23% per year, global mortality remains stationary. However, from 2005 onwards a trend towards increasing of 7.87%/ annual in mortality was observed in women.	[de Souza, Wesley; de Abreu, Luiz Carlos; Pinheiro Bezerra, Italla Maria] Escola Super Ciencias Santa Casa Misericordia Vit, Programa Mestrado Polit Publ & Desenvolvimento Lo, Vitoria, ES, Brazil; [de Abreu, Luiz Carlos; da Silva, Leonardo Gomes; Pinheiro Bezerra, Italla Maria] Escola Super Ciencias Santa Casa Misericordia Vit, Lab Escrita Cient, Vitoria, ES, Brazil; [de Abreu, Luiz Carlos; Pinheiro Bezerra, Italla Maria] Ctr Univ Sande ABC CUSABC, Lab Delineamento Estudos & Escrita Cient, Santo Andre, SP, Brazil; [de Abreu, Luiz Carlos] Univ Limerick, Grad Entry Med Sch, Limerick, Ireland; [Pinheiro Bezerra, Italla Maria] Univ Fed Acre, Bolsista Capes Brasil, Programa Mestrado Ciencias Saude Amazonia, Rio Branco, Acre, Brazil	Escola Superior de Ciencias da Santa Casa de Misericordia de Vitoria; Escola Superior de Ciencias da Santa Casa de Misericordia de Vitoria; University of Limerick; Universidade Federal do Acre (UFAC)	de Abreu, LC (corresponding author), Escola Super Ciencias Santa Casa Misericordia Vit, Programa Mestrado Polit Publ & Desenvolvimento Lo, Vitoria, ES, Brazil.; de Abreu, LC (corresponding author), Escola Super Ciencias Santa Casa Misericordia Vit, Lab Escrita Cient, Vitoria, ES, Brazil.; de Abreu, LC (corresponding author), Ctr Univ Sande ABC CUSABC, Lab Delineamento Estudos & Escrita Cient, Santo Andre, SP, Brazil.; de Abreu, LC (corresponding author), Univ Limerick, Grad Entry Med Sch, Limerick, Ireland.	luiz.abreu@emescam.br	de Abreu, Luiz Carlos/AAL-8219-2021	de Abreu, Luiz Carlos/0000-0002-7618-2109; Gomes da Silva, Leonardo/0000-0002-1820-8075				Abreu LC, 2017, J HUM GROWTH DEV, V27, P258, DOI DOI 10.7322/jhgd.141485; Ahmad OB, 2001, AGE STANDARDIZATION, V31, DOI [10.1161/HYPERTENSIONAHA.114.04394, DOI 10.1161/HYPERTENSIONAHA.114.04394]; Antunes JLF, 2015, EPIDEMIOL E SERVICOS, DOI [10.5123/S1679-49742915000390024, DOI 10.5123/S1679-49742915000390024]; Bernardi Cesarino C, 2013, ACTA PAUL ENFERM; Brasil M da S, 2014, DIRETRIZES CLIN CUID, DOI [10.1007/s13398-014-0173-7.2, DOI 10.1007/S13398-014-0173-7.2]; de Vries EF, 2016, NEPHRON, V133, P89, DOI 10.1159/000446548; Garcia-Garcia G, 2015, AM J NEPHROL, V41, P116, DOI 10.1159/000369843; Goes EF, 2013, SAUDE DEBATE, DOI [10.1590/S0103-11042013000400004, DOI 10.1590/S0103-11042013000400004]; Gouveia Denise Sbrissia e Silva, 2017, Braz. J. Nephrol., V39, P162, DOI 10.5935/0101-2800.20170019; Green JA, 2015, ADV CHRONIC KIDNEY D, V22, P24, DOI 10.1053/j.ackd.2014.07.004; Hemke AC, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-258; Herrera-Anazco Percy, 2015, J Bras Nefrol, V37, P192, DOI 10.5935/0101-2800.20150031; Hill NR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158765; Jain P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100831; James MT, 2010, LANCET, V375, P1296, DOI 10.1016/S0140-6736(09)62004-3; Jha V, 2013, LANCET, DOI [10.1016/S0140-673(13)60687-X, DOI 10.1016/S0140-673(13)60687-X]; Kao CC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177759; Kihal-Talantikite W, 2015, CLIN KIDNEY J, V8, P7, DOI 10.1093/ckj/sfu131; Magalhães Fernanda Guilhermino, 2015, Rev. bras. geriatr. gerontol., V18, P679, DOI 10.1590/1809-9823.2015.14132; Magalhaes LP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0167895; Maria I, 2017, J HUM GROWTH DEV J H, DOI [10.7322/j.hgd.123189, DOI 10.7322/J.HGD.123189]; Marinovich S, 2012, NEFROLOGIA, V32, P79, DOI 10.3265/Nefrologia.pre2011.Nov.11110; Domingos MAM, 2017, SAO PAULO MED J, V135, P133, DOI 10.1590/1516-3180.2016.0272261116; Narres M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147329; Obrador GT, 2014, EPIDEMIOL CHRON, V7, P2014; Pinheiro Rejane Sobrino, 2002, Ciênc. saúde coletiva, V7, P687; Registro Brasileiro de Transplantes, 2018, DIM TRANSPL BRAS CAD; Goncalves GMR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203992; Scialla JJ, 2012, KIDNEY INT, V82, P106, DOI 10.1038/ki.2012.82; Sesso R, 2008, NEFROLOGIA; Shen YJ, 2017, ENDOCRINE, V55, P75, DOI 10.1007/s12020-016-1014-6; Silva JRM, 2017, THESIS; Sociedade Brasileira de Nefrologia (SBN), 2017, CENS 2016; Terra FS, 2007, THESIS; Tonelli M, 2014, KIDNEY INT, V85, P1269, DOI 10.1038/ki.2012.488; Wei XJ, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3610-z; World Health Organization, 2003, GLOBAL BURDEN DIS ST; Zetola VH, 2001, ARQ NEUROPSIQUIATR	38	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2019	14	11							e0224889	10.1371/journal.pone.0224889	http://dx.doi.org/10.1371/journal.pone.0224889			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN1GV	31697772	Green Published, gold			2023-01-03	WOS:000532694400077
J	Ades, V; Goddard, B; Ayala, SP; Greene, JA				Ades, Veronica; Goddard, Brian; Ayala, Savannah Pearson; Greene, Judy A.			CLINICAL UPDATE Caring for long term health needs in women with a history of sexual trauma	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							POSTTRAUMATIC-STRESS-DISORDER; CARE UTILIZATION; INFORMED CARE; ABUSE; VIOLENCE; REVICTIMIZATION; SURVIVORS; PTSD; EXPERIENCES; EXPOSURE		[Ades, Veronica] NYU, Sch Med, Dept Obstet & Gynecol, New York, NY 10003 USA; [Goddard, Brian; Ayala, Savannah Pearson] NYU, Sch Med, New York, NY USA; [Greene, Judy A.] NYU, Sch Med, Dept Psychiat, New York, NY USA	New York University; New York University; New York University	Ades, V (corresponding author), NYU, Sch Med, Dept Obstet & Gynecol, New York, NY 10003 USA.	Veronica.Ades@nyumc.org	Goddard, Brian/GQB-1679-2022	Ades, Veronica/0000-0002-9163-7511				Ades V, 2019, OBSTET GYNECOL, V133, P803, DOI 10.1097/AOG.0000000000003186; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; Amos T, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006239.pub2; [Anonymous], 2019, Obstet Gynecol, V133, pe296, DOI 10.1097/AOG.0000000000003178; Badura AS, 1997, OBSTET GYNECOL, V90, P405, DOI 10.1016/S0029-7844(97)00287-1; Bibbins-Domingo K, 2017, JAMA-J AM MED ASSOC, V317, P947, DOI [10.1001/jama.2016.12819, 10.1001/jama.2017.0807]; Breslau N, 2009, TRAUMA VIOLENCE ABUS, V10, P198, DOI 10.1177/1524838009334448; Campbell R, 2006, RES NURS HEALTH, V29, P399, DOI 10.1002/nur.20155; Cardena E, 2000, J TRAUMA STRESS, V13, P719, DOI 10.1023/A:1007822603186; Chen LP, 2010, MAYO CLIN PROC, V85, P618, DOI 10.4065/mcp.2009.0583; Classen CC, 2005, TRAUMA VIOLENCE ABUS, V6, P103, DOI 10.1177/1524838005275087; Cohen JA, 2015, CHILD ADOL PSYCH CL, V24, P557, DOI 10.1016/j.chc.2015.02.005; Dayton L, 2016, CURR PROB PEDIATR AD, V46, P391, DOI 10.1016/j.cppeds.2016.11.004; Dworkin ER, 2018, TRAUMA VIOLENCE ABUS, V25; Elliott DM, 2004, J TRAUMA STRESS, V17, P203, DOI 10.1023/B:JOTS.0000029263.11104.23; Farley M, 2001, WOMEN HEALTH, V34, P15, DOI 10.1300/J013v34n02_02; Farley MS, 2002, J FAM PRACTICE, V51, P827; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1002/jts.2490060405; Frans O, 2005, ACTA PSYCHIAT SCAND, V111, P291, DOI 10.1111/j.1600-0447.2004.00463.x; Ginzburg Karni, 2006, J Trauma Dissociation, V7, P7, DOI 10.1300/J229v07n02_02; Havig K, 2008, TRAUMA VIOLENCE ABUS, V9, P19, DOI 10.1177/1524838007309805; Hilden M, 2003, ACTA OBSTET GYN SCAN, V82, P1030; Ingemann-Hansen O, 2013, BEST PRACT RES CL OB, V27, P91, DOI 10.1016/j.bpobgyn.2012.08.014; Kenagy GP, 2005, HEALTH SOC WORK, V30, P19, DOI 10.1093/hsw/30.1.19; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Krug EG, 2002, LANCET, V360, P1083, DOI 10.1016/S0140-6736(02)11133-0; Lanthier S, 2018, TRAUMA VIOLENCE ABUS, V19, P251, DOI 10.1177/1524838016659484; Leeners B, 2007, PSYCHOSOMATICS, V48, P385, DOI 10.1176/appi.psy.48.5.385; Letourneau EJ, 1999, WOMEN HEALTH ISS, V9, P115, DOI 10.1016/S1049-3867(98)00031-0; Linden JA, 2011, NEW ENGL J MED, V365, P834, DOI 10.1056/NEJMcp1102869; Mark H, 2008, J PSYCHOSOM OBST GYN, V29, P164, DOI 10.1080/01674820701832770; Mazza D, 1996, MED J AUSTRALIA, V164, P14, DOI 10.5694/j.1326-5377.1996.tb94101.x; McGregor K, 2010, J CHILD SEX ABUS, V19, P239, DOI 10.1080/10538711003789015; Messman-Moore TL, 2003, CLIN PSYCHOL REV, V23, P537, DOI 10.1016/S0272-7358(02)00203-9; Mittendorfer-Rutz E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099869; Raja S, 2015, FAM COMMUNITY HEALTH, V38, P216, DOI 10.1097/FCH.0000000000000071; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; Roberts NP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006869.pub2; Roberts NP, 2009, AM J PSYCHIAT, V166, P293, DOI 10.1176/appi.ajp.2008.08040590; Roodman AA, 2001, CLIN PSYCHOL REV, V21, P183, DOI 10.1016/S0272-7358(99)00045-8; Rose S. C., 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000560; Sanchez NF, 2009, AM J PUBLIC HEALTH, V99, P713, DOI 10.2105/AJPH.2007.132035; Shalev A, 2017, NEW ENGL J MED, V376, P2459, DOI 10.1056/NEJMra1612499; Slade M, 2007, DM-DIS MON, V53, P536, DOI 10.1016/j.disamonth.2007.10.001; Stotzer RL, 2009, AGGRESS VIOLENT BEH, V14, P170, DOI 10.1016/j.avb.2009.01.006; Substance Abuse and Mental Health Services Administration, 2014, HHS PUBL; Suris A, 2004, PSYCHOSOM MED, V66, P749, DOI 10.1097/01.psy.0000138117.58559.7b; Thielke S, 2007, PRIMARY CARE, V34, P571, DOI 10.1016/j.pop.2007.05.007; Ullman SE, 2005, CHILD ABUSE NEGLECT, V29, P767, DOI 10.1016/j.chiabu.2005.01.005; Walker J, 2005, ARCH SEX BEHAV, V34, P69, DOI 10.1007/s10508-005-1001-0; Walsh K, 2012, CLIN PSYCHOL-SCI PR, V19, P260, DOI 10.1111/cpsp.12004; Walters M. L., 2011, NATL INTIMATE PARTNE; Weitlauf JC, 2008, OBSTET GYNECOL, V112, P1343, DOI 10.1097/AOG.0b013e31818e4678; World Health Organization, 2003, GUID MED LEG CAR VIC; World Health Organization, 1999, REP CONS CHILD AB PR	56	5	5	2	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 22	2019	367								l5825	10.1136/bmj.l5825	http://dx.doi.org/10.1136/bmj.l5825			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JI4NQ	31640984				2023-01-03	WOS:000493444800002
J	Rippe, W; Dittberner, A; Boeger, D; Buentzel, J; Hoffmann, K; Kaftan, H; Mueller, A; Radtke, G; Guntinas-Lichius, O				Rippe, Wido; Dittberner, Andreas; Boeger, Daniel; Buentzel, Jens; Hoffmann, Kerstin; Kaftan, Holger; Mueller, Andreas; Radtke, Gerald; Guntinas-Lichius, Orlando			30-day unplanned readmission rate in otolaryngology patients: A population-based study in Thuringia, Germany	PLOS ONE			English	Article							NECK-CANCER; HOSPITAL READMISSION; RISK-FACTORS; INPATIENT TREATMENT; HEAD; ASSOCIATION; PROGRAM	Purpose Analyze associations between patients' characteristics and treatment factors with 30-day unplanned readmissions in hospitalized otolaryngology patients in the German Diagnosis Related Group (D-DRG) system. Methods A retrospective cohort study was performed on 15.271 otolaryngology admissions of 12.859 patients in 2015 in Thuringia, Germany. The medical records of the 1173 cases (7.6%) with readmission within 30-days were analyzed in detail. Results The 30-day readmission was planned in 747 cases (4.9%) and was unplanned in 422 cases (2.8%). The median interval between primary and next inpatient treatment was 11 days. The principal diagnosis was the same as during the primary index treatment in 72% of the cases. The most frequent reasons for readmission were: Need for non-surgical therapy (31.2%), need for further surgery (26.3%), post-surgical complaints (16.9%), and recurrence of primary complaints (10.7%). The multivariate analysis revealed that discharge due to patient's request against medical advice was a strong independent factor with high risk for unplanned readmission (Odds Ratio [OR] = 9.62]; confidence interval [CI] = 2.69-34.48). Surgery at index admission (OR = 3.33; CI = 1.86-5.96) was the second important independent risk factor for unplanned readmission. Unplanned readmission had more frequently a non-surgical treatment at readmission than a surgical treatment (OR = 3.92; CI = 2.24-6.84) and needed more frequently further diagnostics (OR = 2.34; CI = 1.34-4.11). The following index International Classification of Diseases (ICD) categories had the highest risk for unplanned readmission: Injury, poisoning and certain other consequences of external causes, ICD: S00-T98 (OR = 66.67; CI = 15.87-333.33), symptoms, signs, abnormal findings, ill-defined causes, not otherwise classified, ICD: R00-R99 (OR = 62.5; CI = 11.76333.33), blood forming organ diseases, ICD: D50-D90 (OR = 21.276; CI = 3.508-125), and eye/ ear diseases, ICD: H00-H95 (OR = 12.66; CI = 4.29-37.03). Conclusions The causes of unplanned 30-day readmission in German otolaryngology inpatients are multifactorial. Specific patient and treatment characteristics were identified to be targeted with health care interventions to decrease unplanned readmissions.	[Rippe, Wido; Dittberner, Andreas; Guntinas-Lichius, Orlando] Jena Univ Hosp, Dept Otorhinolaryngol, Jena, Germany; [Boeger, Daniel] SRH Zentralklinikum, Dept Otorhinolaryngol, Suhl, Germany; [Buentzel, Jens] Sudharz Krankenhaus gGmbH, Dept Otorhinolaryngol, Nordhausen, Germany; [Hoffmann, Kerstin] Sophien Hufeland Klinikum, Dept Otorhinolaryngol, Weimar, Germany; [Kaftan, Holger] HELIOS Klin, Dept Otorhinolaryngol, Erfurt, Germany; [Mueller, Andreas] SRH Wald Klinikum, Dept Otorhinolaryngol, Gera, Germany; [Radtke, Gerald] Ilm Kreis Kliniken, Dept Otorhinolaryngol, Arnstadt, Germany	Friedrich Schiller University of Jena; Helios Kliniken	Guntinas-Lichius, O (corresponding author), Jena Univ Hosp, Dept Otorhinolaryngol, Jena, Germany.	orlando.guntinas@med.uni-jena.de	Mueller, Andreas H./ABF-6570-2020; Guntinas-Lichius, Orlando/L-1871-2016; Müller, Andreas H./F-5101-2013	Guntinas-Lichius, Orlando/0000-0001-9671-0784; Müller, Andreas H./0000-0002-9820-5527				Addison A, 2017, RHINOLOGY, V55, P99, DOI [10.4193/Rhino16.259, 10.4193/Rhin16.259]; [Anonymous], DIAGNOSIS RELATED GR; Bur AM, 2016, JAMA OTOLARYNGOL, V142, P1184, DOI 10.1001/jamaoto.2016.2807; Busato A, 2010, HEALTH RES POLICY SY, V8, DOI 10.1186/1478-4505-8-31; Desai NR, 2016, JAMA-J AM MED ASSOC, V316, P2647, DOI 10.1001/jama.2016.18533; Dziegielewski PT, 2016, HEAD NECK-J SCI SPEC, V38, pE502, DOI 10.1002/hed.24030; Ferrandino R, 2018, LARYNGOSCOPE, V128, P1842, DOI 10.1002/lary.27012; Ghiam MK, 2018, OTOLARYNG HEAD NECK, V159, P149, DOI 10.1177/0194599818776633; Goel AN, 2019, LARYNGOSCOPE, V129, P910, DOI 10.1002/lary.27461; Gollnitz I, 2016, CANCER MED-US, V5, P3260, DOI 10.1002/cam4.882; Graboyes EM, 2017, JAMA OTOLARYNGOL, V143, P1200, DOI 10.1001/jamaoto.2017.1460; Graboyes EM, 2017, LARYNGOSCOPE, V127, P868, DOI 10.1002/lary.26301; Graboyes EM, 2013, OTOLARYNG HEAD NECK, V149, P562, DOI 10.1177/0194599813500023; Hendricks BL, 2016, OTOLARYNG HEAD NECK, V154, P359, DOI 10.1177/0194599815617130; Hernandez-Meza G, 2019, JAMA OTOLARYNGOL, V145, P328, DOI 10.1001/jamaoto.2018.4504; Heuschkel A, 2018, EUR ARCH OTO-RHINO-L, V275, P699, DOI 10.1007/s00405-018-4870-2; Hopfe M, 2018, HEALTH SERV INSIGHTS, V11, DOI 10.1177/1178632918796776; Horwitz LI, 2015, BMJ-BRIT MED J, V350, DOI [10.1136/BMJ.h447, 10.1136/bmj.h447]; Jha AK, 2009, NEW ENGL J MED, V361, P2637, DOI 10.1056/NEJMsa0904859; Kakarmath S, 2018, JMIR RES PROTOC, V7, DOI 10.2196/resprot.9466; Kwok CS, 2019, AM J CARDIOL, V124, P736, DOI 10.1016/j.amjcard.2019.05.053; Lee HY, 2019, INT J QUAL HEALTH C, V31, P768, DOI 10.1093/intqhc/mzz044; Li LDT, 2013, J AM GERIATR SOC, V61, P1175, DOI 10.1111/jgs.12307; Paul G, 2019, INDIAN J CRIT CARE M, V23, P143, DOI 10.5005/jp-journals-10071-23138; Plumbaum K, 2017, CLIN OTOLARYNGOL, V42, P1267, DOI 10.1111/coa.12862; Renner V, 2017, OTOL NEUROTOL, V38, pE460, DOI 10.1097/MAO.0000000000001568; Sacks GD, 2014, JAMA SURG, V149, P759, DOI 10.1001/jamasurg.2014.18; Wu V, 2018, J OTOLARYNGOL-HEAD N, V47, DOI 10.1186/s40463-018-0283-x	28	3	3	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2019	14	10							e0224146	10.1371/journal.pone.0224146	http://dx.doi.org/10.1371/journal.pone.0224146			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM9KP	31622434	Green Published, gold			2023-01-03	WOS:000532567300101
J	Dorling, J; Abbott, J; Berrington, J; Bosiak, B; Bowler, U; Boyle, E; Embleton, N; Hewer, O; Johnson, S; Juszczak, E; Leaf, A; Linsell, L; McCormick, K; McGuire, W; Omar, O; Partlett, C; Patel, M; Roberts, T; Stenson, B; Townend, J				Dorling, Jon; Abbott, Jane; Berrington, Janet; Bosiak, Beth; Bowler, Ursula; Boyle, Elaine; Embleton, Nicholas; Hewer, Oliver; Johnson, Samantha; Juszczak, Edmund; Leaf, Alison; Linsell, Louise; McCormick, Kenny; McGuire, William; Omar, Omar; Partlett, Christopher; Patel, Mehali; Roberts, Tracy; Stenson, Ben; Townend, John		SIFT Investigators Grp	Controlled Trial of Two Incremental Milk-Feeding Rates in Preterm Infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; NECROTIZING ENTEROCOLITIS; SLOW; BIRTH; ADVANCEMENT; OUTCOMES	Background Observational data have shown that slow advancement of enteral feeding volumes in preterm infants is associated with a reduced risk of necrotizing enterocolitis but an increased risk of late-onset sepsis. However, data from randomized trials are limited. Methods We randomly assigned very preterm or very-low-birth-weight infants to daily milk increments of 30 ml per kilogram of body weight (faster increment) or 18 ml per kilogram (slower increment) until reaching full feeding volumes. The primary outcome was survival without moderate or severe neurodevelopmental disability at 24 months. Secondary outcomes included components of the primary outcome, confirmed or suspected late-onset sepsis, necrotizing enterocolitis, and cerebral palsy. Results Among 2804 infants who underwent randomization, the primary outcome could be assessed in 1224 (87.4%) assigned to the faster increment and 1246 (88.7%) assigned to the slower increment. Survival without moderate or severe neurodevelopmental disability at 24 months occurred in 802 of 1224 infants (65.5%) assigned to the faster increment and 848 of 1246 (68.1%) assigned to the slower increment (adjusted risk ratio, 0.96; 95% confidence interval [CI], 0.92 to 1.01; P=0.16). Late-onset sepsis occurred in 414 of 1389 infants (29.8%) in the faster-increment group and 434 of 1397 (31.1%) in the slower-increment group (adjusted risk ratio, 0.96; 95% CI, 0.86 to 1.07). Necrotizing enterocolitis occurred in 70 of 1394 infants (5.0%) in the faster-increment group and 78 of 1399 (5.6%) in the slower-increment group (adjusted risk ratio, 0.88; 95% CI, 0.68 to 1.16). Conclusions There was no significant difference in survival without moderate or severe neurodevelopmental disability at 24 months in very preterm or very-low-birth-weight infants with a strategy of advancing milk feeding volumes in daily increments of 30 ml per kilogram as compared with 18 ml per kilogram. (Funded by the Health Technology Assessment Programme of the National Institute for Health Research; SIFT Current Controlled Trials number, ISRCTN76463425.) In this randomized trial involving very preterm or very-low-birth-weight infants, there was no significant difference in survival without moderate or severe neurodevelopmental disability at 24 months with a strategy of advancing milk feeding volumes in daily increments of 30 ml per kilogram of body weight as compared with 18 ml per kilogram.	[Dorling, Jon] Dalhousie Univ, Div Neonatal Perinatal Med, Halifax, NS, Canada; [Abbott, Jane; Patel, Mehali] Bliss, London, England; [Bosiak, Beth; Bowler, Ursula; Hewer, Oliver; Juszczak, Edmund; Linsell, Louise; Omar, Omar; Partlett, Christopher; Townend, John] Univ Oxford, Nuffield Dept Populat Hlth, Natl Perinatal Epidemiol Unit, Clin Trials Unit, Oxford, England; [McCormick, Kenny] John Radcliffe Hosp, Oxford, England; [Berrington, Janet; Embleton, Nicholas] Royal Victoria Infirm, Newcastle Neonatal Serv, Newcastle Upon Tyne, Tyne & Wear, England; [Boyle, Elaine; Johnson, Samantha] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England; [Leaf, Alison] Southampton Biomed Res Ctr, Natl Inst Hlth Res, Dept Child Hlth, Southampton, Hants, England; [McGuire, William] Univ York, Ctr Reviews & Disseminat, York, N Yorkshire, England; [Roberts, Tracy] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham, W Midlands, England; [Stenson, Ben] Royal Infirm Edinburgh NHS Trust, Simpson Ctr Reprod Hlth, Edinburgh, Midlothian, Scotland	Dalhousie University; University of Oxford; University of Oxford; Newcastle University - UK; University of Leicester; University of York - UK; University of Birmingham; Royal Infirmary of Edinburgh; University of Edinburgh	Dorling, J (corresponding author), Div Neonatal Perinatal Med, 5850-5980 Univ Ave, Halifax, NS B3K 6R8, Canada.	jon.dorling@iwk.nshealth.ca	Roberts, Tracy/AAO-4610-2021; Peters, Mark/AAD-7518-2019; Dorling, Jon/B-7409-2015; Embleton, Nicholas/D-4905-2011; Boyle, Elaine/I-6298-2018	Roberts, Tracy/0000-0002-0624-0537; Peters, Mark/0000-0003-3653-4808; Dorling, Jon/0000-0002-1691-3221; Townend, Jonathan/0000-0002-5881-5806; Embleton, Nicholas/0000-0003-3750-5566; Boyle, Elaine/0000-0002-5038-3148; Partlett, Christopher/0000-0001-5139-3412; Johnson, Samantha/0000-0001-8963-7881; Hewer, Oliver/0000-0002-6251-7174; Berrington, Janet/0000-0002-6185-2843	Health Technology Assessment Programme of the National Institute for Health Research	Health Technology Assessment Programme of the National Institute for Health Research	Supported by the Health Technology Assessment Programme of the National Institute for Health Research.	Abbott J, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0794-z; Berrington JE, 2012, J PEDIAT, V160; British Association of Perinatal Medicine, 2008, REP BAPM RCPCH WORK; BROWN EG, 1978, JAMA-J AM MED ASSOC, V240, P2452, DOI 10.1001/jama.240.22.2452; Caple J, 2004, PEDIATRICS, V114, P1597, DOI 10.1542/peds.2004-1232; Henderson G, 2009, ARCH DIS CHILD-FETAL, V94, pF120, DOI 10.1136/adc.2007.119560; Holman RC, 2006, PAEDIATR PERINAT EP, V20, P498, DOI 10.1111/j.1365-3016.2006.00756.x; Jain S, 2016, J MATERN-FETAL NEO M, V29, P2828, DOI 10.3109/14767058.2015.1105954; Johnson S, 2008, DEV MED CHILD NEUROL, V50, P58, DOI 10.1111/j.1469-8749.2007.02010.x; Johnson S, 2015, ARCH DIS CHILD-FETAL, V100, pF301, DOI 10.1136/archdischild-2014-307684; Johnson S, 2010, J AM ACAD CHILD PSY, V49, P453, DOI 10.1016/j.jaac.2010.02.002; Kamoji VM, 2008, ACTA PAEDIATR, V97, P327, DOI 10.1111/j.1651-2227.2008.00671.x; Karagol BS, 2013, JPEN-PARENTER ENTER, V37, P223, DOI 10.1177/0148607112449482; Krishnamurthy S, 2010, ACTA PAEDIATR, V99, P42, DOI 10.1111/j.1651-2227.2009.01519.x; LUCAS A, 1990, LANCET, V336, P1519, DOI 10.1016/0140-6736(90)93304-8; Mangham LJ, 2009, PEDIATRICS, V123, pE312, DOI 10.1542/peds.2008-1827; MCKEOWN RE, 1992, J PEDIATR-US, V121, P764, DOI 10.1016/S0022-3476(05)81913-4; Modi M, 2015, ANN M PED AC SOC SAN; Moore T, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7961; Morgan J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001241.pub6; Neu J, 2011, NEW ENGL J MED, V364, P255, DOI 10.1056/NEJMra1005408; Raban S, 2016, PAEDIATR INT CHILD H, V36, P288, DOI 10.1179/2046905515Y.0000000056; Rayyis SF, 1999, J PEDIATR-US, V134, P293, DOI 10.1016/S0022-3476(99)70452-X; Salhotra A, 2004, Indian Pediatr, V41, P435; Schlapbach LJ, 2011, PEDIATRICS, V128, pE348, DOI 10.1542/peds.2010-3338; Vermont Oxford Network, 2011, VERM OXF NETW DAT DA	26	61	64	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 10	2019	381	15					1434	1443		10.1056/NEJMoa1816654	http://dx.doi.org/10.1056/NEJMoa1816654			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC9YG	31597020	Green Published, Green Submitted, Green Accepted, Bronze			2023-01-03	WOS:000489631900008
J	Polito, A; Combescure, C; Levy-Jamet, Y; Rimensberger, P				Polito, Angelo; Combescure, Christophe; Levy-Jamet, Yann; Rimensberger, Peter		Swiss Soc Intensive Care Med	Long-stay patients in pediatric intensive care unit: Diagnostic-specific definition and predictors	PLOS ONE			English	Article							CRITICAL ILLNESS; PALLIATIVE CARE; CHILDREN; QUALITY	Aims To stipulate a new definition for long-stay patients (LSPs) in pediatric intensive care unit (PICU). We defined LSPs as the 10% of patients with the longest PICU length-of-stay (LOS) for each age and diagnostic group. To assess whether the thresholds (days of PICU stay) for the definition of LSPs in PICU significantly differ among diagnostic and age categories. To determine whether independent associations exist between patients' characteristics at admission and LSPs diagnosis in pre-specified diagnostic and age groups. Methods This was a multicenter retrospective cohort study including all PICUs in Switzerland. Multivariable regression analysis was used to seek for association between patients' variables at admission and LSPs Results We included 22,284 patients with a median (IQR) age of 12 (1-84) months. Significantly different thresholds across diagnostic and age subgroups are identified. Readmission to PICU, higher PIM2 and NEMS (a score used to quantify nursing workload at intensive care unit level) at admission were associated with higher likelihood of becoming LSPs. Conclusions Our results showed a significantly different definitions of LSPs for specific diagnoses and age categories. Readmission to PICU and higher acuity at admission are associated with longer PICU length-of-stay in the majority of diagnostic groups. A more personalized definition of LSPs in children based on actual patients' characteristics should probably be used in an effort to optimize care and reduce costs.	[Polito, Angelo; Levy-Jamet, Yann; Rimensberger, Peter] Univ Hosp Geneva, Dept Pediat, Pediat & Neonatal Intens Care Unit, Geneva, Switzerland; [Combescure, Christophe] Univ Geneva, Fac Med, Div Clin Epidemiol, Geneva, Switzerland; [Combescure, Christophe] Geneva Univ Hosp, Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva	Polito, A (corresponding author), Univ Hosp Geneva, Dept Pediat, Pediat & Neonatal Intens Care Unit, Geneva, Switzerland.	angelo.polito@hcuge.ch		Rimensberger, Peter/0000-0002-9760-9220; Polito, Angelo/0000-0003-4686-726X				Bagshaw SM, 2018, INTENS CARE MED, V44, P2134, DOI 10.1007/s00134-018-5440-1; Boss R, 2014, PEDIATR CRIT CARE ME, V15, P762, DOI 10.1097/PCC.0000000000000209; Briassoulis G, 2005, J CRIT CARE, V20, P139, DOI 10.1016/j.jcrc.2005.04.003; Chen F, 2016, ARCH DIS CHILD-FETAL, V101, pF377, DOI 10.1136/archdischild-2015-308579; Fraser LK, 2018, ARCH DIS CHILD, V103, P540, DOI 10.1136/archdischild-2017-312638; Iapichino G, 2001, INTENS CARE MED, V27, P131, DOI 10.1007/s001340000776; Iwashyna TJ, 2016, LANCET RESP MED, V4, P566, DOI 10.1016/S2213-2600(16)30098-4; Kahn JM, 2015, LANCET RESP MED, V3, P501, DOI 10.1016/S2213-2600(15)00205-2; Marcin JP, 2001, CRIT CARE MED, V29, P652, DOI 10.1097/00003246-200103000-00035; Namachivayam P, 2012, PEDIATR CRIT CARE ME, V13, P520, DOI 10.1097/PCC.0b013e31824fb989; Nelson JE, 2005, J CRIT CARE, V20, P79, DOI 10.1016/j.jcrc.2004.11.003; Nelson JE, 2007, ARCH INTERN MED, V167, P2509, DOI 10.1001/archinte.167.22.2509; Nelson JE, 2012, RESP CARE, V57, P1004, DOI 10.4187/respcare.01624; Nelson JE, 2010, AM J RESP CRIT CARE, V182, P446, DOI 10.1164/rccm.201002-0210CI; Pagowska-Klimek I, 2011, EUR J CARDIO-THORAC, V40, P179, DOI 10.1016/j.ejcts.2010.11.038; PON S, 1993, J PEDIATR-US, V123, P355, DOI 10.1016/S0022-3476(05)81732-9; Shapiro Miriam C, 2017, Hosp Pediatr, V7, P236, DOI 10.1542/hpeds.2016-0107; Simon TD, 2014, PEDIATRICS, V133, pE1647, DOI 10.1542/peds.2013-3875; Slater A, 2003, INTENS CARE MED, V29, P278, DOI 10.1007/s00134-002-1601-2; Slater A, 2003, INTENS CARE MED, V29, P271, DOI 10.1007/s00134-002-1600-3; Weissman C, 2000, INTENS CARE MED, V26, P1319, DOI 10.1007/s001340000612	21	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2019	14	10							e0223369	10.1371/journal.pone.0223369	http://dx.doi.org/10.1371/journal.pone.0223369			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM6VM	31577836	Green Published, gold			2023-01-03	WOS:000532388000033
J	Aboy, M; Liddell, K; Crespo, C; Cohen, IG; Liddicoat, J; Gerke, S; Minssen, T				Aboy, Mateo; Liddell, Kathleen; Crespo, Cristina; Cohen, I. Glenn; Liddicoat, Johnathon; Gerke, Sara; Minssen, Timo			How does emerging patent case law in the US and Europe affect precision medicine?	NATURE BIOTECHNOLOGY			English	Editorial Material							MYRIAD; IMPACT		[Aboy, Mateo; Liddell, Kathleen; Crespo, Cristina; Liddicoat, Johnathon] Univ Cambridge, Fac Law, Ctr Law Med & Life Sci LML, Cambridge, England; [Cohen, I. Glenn; Gerke, Sara] Harvard Univ, Petrie Flom Ctr Hlth Law Policy Biotechnol & Bioe, Harvard Law Sch, Cambridge, MA 02138 USA; [Minssen, Timo] Univ Copenhagen, Ctr Adv Studies Biomed Innovat Law CeBIL, Copenhagen, Denmark	University of Cambridge; Harvard University; University of Copenhagen	Aboy, M (corresponding author), Univ Cambridge, Fac Law, Ctr Law Med & Life Sci LML, Cambridge, England.	ma608@cam.ac.uk	Gerke, Sara/AAN-5448-2021; Liddicoat, Johnathon/J-7156-2014	Gerke, Sara/0000-0002-5718-3982; Aboy, Mateo/0000-0002-5168-4321; Minssen, Timo/0000-0002-3286-4888; Liddicoat, Johnathon/0000-0001-7370-3936				Aboy M, 2019, NAT BIOTECHNOL, V37, P513, DOI 10.1038/s41587-019-0111-5; Aboy M, 2018, NAT BIOTECHNOL, V36, P1146, DOI 10.1038/nbt.4308; Aboy M, 2017, NAT BIOTECHNOL, V35, P820, DOI 10.1038/nbt.3953; Aboy M, 2016, NAT BIOTECHNOL, V34, P1119, DOI 10.1038/nbt.3719; [Anonymous], 2018, EPO GUIDELINES G 7 5; [Anonymous], 2018, EPO GUIDELINES G 2 4; [Anonymous], 2018, EPO GUIDELINES G 2 2; [Anonymous], 2016, G MASON LAW REV; [Anonymous], 2018, EPO GUIDELINES G 2 5; [Anonymous], 2018, EPO GUIDELINES EXA G; [Anonymous], 2018, EPO GUIDELINES G 2 3; BIS Research, 2019, GLOB PREC MED MARK A; Breastcancer.org, ONC DX TEST; Cole P, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a020891; FDA-NIH Biomarker Working Group, 2016, BEST BIOM ENDPOINTS; Fox JL, 2012, NAT BIOTECHNOL, V30, P373, DOI 10.1038/nbt0512-373; Gold R. E., 2013, SCI TRANSL MED, V5, P192; Hogarth S., 2016, PERSONALIZED MED TYP; Horak FB, 2013, MOVEMENT DISORD, V28, P1544, DOI 10.1002/mds.25684; Ioannidis JPA, 2017, CLIN CHEM, V63, P963, DOI 10.1373/clinchem.2016.254649; Malecek M.J., 2016, PETITION WRIT CERTIO; Matthijs G, 2013, NAT BIOTECHNOL, V31, P704, DOI 10.1038/nbt.2644; Minssen T., 2018, BIG DATA HLTH LAW BI; Minssen T., 2017, RES HDB INTELLECTUAL, P26; Minssen T, 2016, J LAW BIOSCI, V3, P365, DOI 10.1093/jlb/lsw019; Nicholson W., 2015, HARV JL TECH, V28, P419; Norton ME, 2015, NEW ENGL J MED, V372, P1589, DOI 10.1056/NEJMoa1407349; Schwartz Robert M., 2015, INTELL PROP Q, V3, P189; Sherkow JS, 2015, ANNU REV GENET, V49, P161, DOI 10.1146/annurev-genet-112414-054731; U.S. Patent and Trademark Office, 2019, **DROPPED REF**, V84, P50	30	11	11	2	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2019	37	10					1118	1126		10.1038/s41587-019-0276-y	http://dx.doi.org/10.1038/s41587-019-0276-y			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	JI2ST	31578504	Bronze			2023-01-03	WOS:000493315800010
J	Peng, MJ; Wang, ZH; Peng, S; Zhang, ML; Duan, YH; Li, FN; Shi, SY; Yang, QL; Zhang, CW				Peng, Mijun; Wang, Zhihong; Peng, Sheng; Zhang, Minglong; Duan, Yehui; Li, Fengna; Shi, Shuyun; Yang, Qiuling; Zhang, Changwei			Dietary supplementation with the extract from Eucommia ulmoides leaves changed epithelial restitution and gut microbial community and composition of weanling piglets	PLOS ONE			English	Article							GROWTH-PERFORMANCE; EXPRESSION; POWDER; OLIV.; ALTERNATIVES; RESISTANCE; MUSCLE; SERUM; ALTER; PH	This study was conducted to compare the effects of Eucommia ulmoides leaves (EL) in different forms (EL extract, fermented EL, and EL powder) with antibiotics on growth performance, intestinal morphology, and the microbiota composition and diversity of weanling piglets. Compared to the control group, the antibiotics and EL extract significantly increased the average daily gain and decreased the feed: gain ratio as well as the diarrhea rate (P < 0.05). The EL extract significantly decreased the crypt depth and increased the ratio of villus height to crypt depth (P < 0.05), while the fermented EL group did the opposite (P < 0.05). The crypt depth in the antibiotics group was of similar value to the EL extract group, and was lower than the fermented EL and EL powder groups (P < 0.05). Compared to the control and antibiotics groups, the jejunul claudin-3 mRNA expression and the concentrations of total VFA, Chao 1, and ACE were significantly augmented in the EL extract group of piglets (P < 0.05). The EL extract groups also showed elevated Shannon (P < 0.05) and Simpson (P = 0.07) values relative to the control and antibiotics groups. At the phylum level, the EL extract group exhibited a reduced abundance of Bacteroidetes and an enhanced abundance of Firmicutes. At the genus level, the abundance of Prevotella was augmented in the EL extract group. Moreover, compared with the antibiotic group, the acetate concentration was enhanced in the EL extract and fermented EL groups. Overall, dietary supplementation with the EL extract, but not the fermented EL or EL powder, improved growth performance, jejunul morphology and function, as well as changed colonic microbial composition and diversity, which might be an alternative to confer protection against weanling stress in weanling piglets.	[Peng, Mijun; Wang, Zhihong; Zhang, Minglong; Yang, Qiuling] Guangdong Inst Anal, Guangdong Prov Publ Lab Anal & Testing Technol, Guangzhou, Peoples R China; [Peng, Sheng] Jishou Univ, Natl & Local United Engn Lab Integrat Utilizat Te, Zhangjiajie, Peoples R China; [Duan, Yehui; Li, Fengna] Chinese Acad Sci, Key Lab Agroecol Proc Subtrop Reg,Sci Observing &, Inst Subtrop Agr,Minist Agr,Hunan Prov Engn Res C, Natl Engn Lab Pollut Control & Waste Utilizat Liv, Changsha, Peoples R China; [Li, Fengna] Hunan Collaborat Innovat Ctr Utilizat Bot Funct I, Hunan Coinnovat Ctr Anim Prod Safety, CICAPS, Changsha, Hunan, Peoples R China; [Shi, Shuyun] Cent South Univ, Coll Chem & Chem Engineer, Changsha, Hunan, Peoples R China; [Zhang, Changwei] CAF, Inst Chem Ind Forest Prod, Nanjing, Peoples R China	Guangdong Academy of Sciences; Institute of Analysis, Guangdong Academy of Sciences; Jishou University; Chinese Academy of Sciences; Institute of Subtropical Agriculture, CAS; Ministry of Agriculture & Rural Affairs; Central South University; Chinese Academy of Forestry; Institute of Chemical Industry of Forest Products, CAF	Peng, MJ (corresponding author), Guangdong Inst Anal, Guangdong Prov Publ Lab Anal & Testing Technol, Guangzhou, Peoples R China.	pengmj163@163.com			GDAS' Project of Science and Technology Development [2019GDASYL-0502003, 2019GDASYL-0103024]; National Natural Science Foundation of China [31660181]; Educational Commission of Hunan Province of China [16A175]; National & local United Engineering Laboratory of Integrative Utilization Technology of Eucommia ulmoides [NLE201602, NLE201704]	GDAS' Project of Science and Technology Development; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Educational Commission of Hunan Province of China; National & local United Engineering Laboratory of Integrative Utilization Technology of Eucommia ulmoides	This study was financially supported by the GDAS' Project of Science and Technology Development (2019GDASYL-0502003, 2019GDASYL-0103024) and the Project supported by the National Natural Science Foundation of China (31660181) and the Educational Commission of Hunan Province of China (16A175) and the National & local United Engineering Laboratory of Integrative Utilization Technology of Eucommia ulmoides (NLE201602 and NLE201704).	Abreu AC, 2012, NAT PROD REP, V29, P1007, DOI 10.1039/c2np20035j; Canh TT, 1998, J ANIM SCI, V76, P1887; CASPARY WF, 1992, AM J CLIN NUTR, V55, P299, DOI 10.1093/ajcn/55.1.299s; Chen YuMin, 2015, Chinese Journal of Animal Nutrition, V27, P2224; Cheng GY, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00217; Dai XP, 2013, FOOD CHEM, V139, P563, DOI 10.1016/j.foodchem.2013.02.006; Duan YH, 2018, NUTRITION, V54, P173, DOI 10.1016/j.nut.2018.03.057; Duan YH, 2015, ANIM NUTR, V1, P30, DOI 10.1016/j.aninu.2015.02.005; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Feng HB, 2016, CARBOHYD POLYM, V136, P803, DOI 10.1016/j.carbpol.2015.09.079; Guo FC, 2003, WORLD POULTRY SCI J, V59, P427, DOI 10.1079/WPS20030026; Hamer HM, 2008, ALIMENT PHARM THER, V27, P104, DOI 10.1111/j.1365-2036.2007.03562.x; Hashemi S. R., 2008, IJP - International Journal of Pharmacology, V4, P352; Hashemi SR, 2011, VET RES COMMUN, V35, P169, DOI 10.1007/s11259-010-9458-2; Hong YH, 2005, ENDOCRINOLOGY, V146, P5092, DOI 10.1210/en.2005-0545; Hu CH, 2013, J ANIM SCI, V91, P1094, DOI 10.2527/jas.2012-5796; Jia Z, 1999, FOOD CHEM, V64, P555, DOI 10.1016/S0308-8146(98)00102-2; Kong XF, 2007, LIVEST SCI, V108, P272, DOI 10.1016/j.livsci.2007.01.079; Kong XF, 2016, SCI REP-UK, V6, DOI 10.1038/srep37224; Lange K, 2016, DIGEST DIS, V34, P260, DOI 10.1159/000443360; [李凤龙 Li Fenglong], 2016, [西北农业学报, Acat Agriculturae Boreali-Occidentalis Sinica], V25, P1137; LIN J, 2014, FRONT MICROBIOL, V5, DOI DOI 10.3389/FMICB.2014.00033; Liu SJ, 2018, J SCI FOOD AGR, V98, P5816, DOI 10.1002/jsfa.9131; Long CM, 2016, ANIM NUTR, V2, P271, DOI 10.1016/j.aninu.2016.08.006; Luo XB, 2004, J LIQ CHROMATOGR R T, V27, P63, DOI 10.1081/JLC-120027086; Macfarlane S, 2003, P NUTR SOC, V62, P67, DOI 10.1079/PNS2002207; Moller FM, 1998, APMIS, V106, P606, DOI 10.1111/j.1699-0463.1998.tb01391.x; Myer PR, 2015, J ANIM SCI, V93, P5327, DOI 10.2527/jas.2015-9415; Myer PR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129174; National Research Council (NRC), 2012, NUTR REQ SWIN, DOI DOI 10.17226/13298; Pie S, 2004, J NUTR, V134, P641, DOI 10.1093/jn/134.3.641; SALYERS AA, 1984, ANNU REV MICROBIOL, V38, P293, DOI 10.1146/annurev.mi.38.100184.001453; Savoia D, 2012, FUTURE MICROBIOL, V7, P979, DOI [10.2217/FMB.12.68, 10.2217/fmb.12.68]; Shi SY, 2019, FOOD CHEM, V288, P215, DOI 10.1016/j.foodchem.2019.03.013; Shi Ying, 2008, Journal of Zhejiang University (Agriculture and Life Sciences), V34, P200; Shin NR, 2015, TRENDS BIOTECHNOL, V33, P496, DOI 10.1016/j.tibtech.2015.06.011; Stanton TB, 2013, TRENDS MICROBIOL, V21, P111, DOI 10.1016/j.tim.2012.11.002; Sun DL, 2013, APPL ENVIRON MICROB, V79, P5962, DOI 10.1128/AEM.01282-13; Thibault R, 2010, INFLAMM BOWEL DIS, V16, P684, DOI 10.1002/ibd.21108; Walker AW, 2005, APPL ENVIRON MICROB, V71, P3692, DOI 10.1128/AEM.71.7.3692-3700.2005; Wang J, 2015, J ANIM SCI, V93, P1679, DOI 10.2527/jas.2014-8230; Wang ZY, 2017, LIVEST SCI, V206, P1, DOI 10.1016/j.livsci.2017.09.026; Wu SG, 2013, WORLD J MICROB BIOT, V29, P1585, DOI 10.1007/s11274-013-1322-4; Yen GC, 2000, J AGR FOOD CHEM, V48, P3431, DOI 10.1021/jf000150t; Zhang Q, 2013, MOLECULES, V18, P1857, DOI 10.3390/molecules18021857; ZHOU YS, 2015, PLOS ONE, V10, DOI DOI 10.1371/JOURNAL.PONE.0138277; Zhu MO, 2018, J AGR FOOD CHEM, V66, P5433, DOI 10.1021/acs.jafc.8b01312	47	11	13	5	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2019	14	9							e0223002	10.1371/journal.pone.0223002	http://dx.doi.org/10.1371/journal.pone.0223002			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM6FU	31557247	Green Published, gold			2023-01-03	WOS:000532345500058
J	Guirro, M; Costa, A; Gual-Grau, A; Herrero, P; Torrell, H; Canela, N; Arola, L				Guirro, Maria; Costa, Andrea; Gual-Grau, Andreu; Herrero, Pol; Torrell, Helena; Canela, Nuria; Arola, Lluis			Effects from diet-induced gut microbiota dysbiosis and obesity can be ameliorated by fecal microbiota transplantation: A multiomics approach	PLOS ONE			English	Article							HIGH-FAT; MODULATION; COMMUNITY	Obesity and its comorbidities are currently considered an epidemic, and the involved pathophysiology is well studied. Hypercaloric diets are tightly related to the obesity etiology and also cause alterations in gut microbiota functionality. Diet and antibiotics are known to play crucial roles in changes in the microbiota ecosystem and the disruption of its balance; therefore, the manipulation of gut microbiota may represent an accurate strategy to understand its relationship with obesity caused by diet. Fecal microbiota transplantation, during which fecal microbiota from a healthy donor is transplanted to an obese subject, has aroused interest as an effective approach for the treatment of obesity. To determine its success, a multiomics approach was used that combined metagenomics and metaproteomics to study microbiota composition and function. To do this, a study was performed in rats that evaluated the effect of a hypercaloric diet on the gut microbiota, and this was combined with antibiotic treatment to deplete the microbiota before fecal microbiota transplantation to verify its effects on gut microbiota-host homeostasis. Our results showed that a high-fat diet induces changes in microbiota biodiversity and alters its function in the host. Moreover, we found that antibiotics depleted the microbiota enough to reduce its bacterial content. Finally, we assessed the use of fecal microbiota transplantation as a complementary obesity therapy, and we found that it reversed the effects of antibiotics and reestablished the microbiota balance, which restored normal functioning and alleviated microbiota disruption. This new approach could be implemented to support the dietary and healthy habits recommended as a first option to maintain the homeostasis of the microbiota.	[Guirro, Maria; Gual-Grau, Andreu; Arola, Lluis] Univ Rovira & Virgili, Biochem & Biotechnol Dept, Nutrigen Res Grp, Tarragona, Spain; [Guirro, Maria; Costa, Andrea; Herrero, Pol; Torrell, Helena; Canela, Nuria] Univ Rovira & Virgili, Unique Sci & Tech Infrastruct ICTS, EURECAT, Ctr Tecnol Catalunya,Ctr Omic Sci COS,Joint Unit, Reus, Spain; [Arola, Lluis] Ctr Tecnol Catalunya, Biotechnol Area, Eurecat, Reus, Spain	Universitat Rovira i Virgili; Universitat Rovira i Virgili	Canela, N (corresponding author), Univ Rovira & Virgili, Unique Sci & Tech Infrastruct ICTS, EURECAT, Ctr Tecnol Catalunya,Ctr Omic Sci COS,Joint Unit, Reus, Spain.	nuria.canela@eurecat.org	Arola, Lluís/C-6074-2011; Canela, Nuria/I-5401-2015; Torrell Galceran, Helena/R-7895-2017; Herrero, Pol/I-1912-2015	Arola, Lluís/0000-0003-2767-1974; Canela, Nuria/0000-0003-0261-2396; Costa Lopez, Andrea/0000-0002-8393-4639; Torrell Galceran, Helena/0000-0001-5487-4289; Herrero, Pol/0000-0002-8746-7214; Guirro, Maria/0000-0002-3330-0312; Gual-Grau, Andreu/0000-0002-8901-3582				Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Behr C, 2017, ARCH TOXICOL, V91, P3439, DOI 10.1007/s00204-017-1949-2; Boi SK, 2016, OBESITY, V24, P2140, DOI 10.1002/oby.21620; Buettner R, 2007, OBESITY, V15, P798, DOI 10.1038/oby.2007.608; Cani PD, 2011, PHARMACOL THERAPEUT, V130, P202, DOI 10.1016/j.pharmthera.2011.01.012; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Daniel H, 2014, ISME J, V8, P295, DOI 10.1038/ismej.2013.155; del Bas JM, 2018, INT J OBESITY, V42, P746, DOI 10.1038/ijo.2017.284; Frohlich EE, 2016, BRAIN BEHAV IMMUN, V56, P140, DOI 10.1016/j.bbi.2016.02.020; Grasa L, 2015, MICROB ECOL, V70, P835, DOI 10.1007/s00248-015-0613-8; Guirro M, 2019, J PROTEOME RES; Guirro M, 2018, ELECTROPHORESIS, V39, P1692, DOI 10.1002/elps.201700476; Ha M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139774; Heinritz SN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154329; Hernandez-Jarguin A, 2018, TICKS TICK-BORNE DIS, V9, P1241, DOI 10.1016/j.ttbdis.2018.04.020; Heymsfield SB, 2017, NEW ENGL J MED, V376, P254, DOI 10.1056/NEJMra1514009; Hoban AE, 2016, NEUROSCIENCE, V339, P463, DOI 10.1016/j.neuroscience.2016.10.003; Janssen AWF, 2015, FASEB J, V29, P3111, DOI 10.1096/fj.14-269514; Lai ZL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33893-y; Lamendella R, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-103; Le Bastard Q, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24342-x; Lee P, 2019, DIABETES OBES METAB, V21, P479, DOI 10.1111/dom.13561; Lee S, 2018, J NUTR, V148, P209, DOI 10.1093/jn/nxx027; Matsunaga N, 2018, ANAEROBE, V51, P124, DOI 10.1016/j.anaerobe.2018.05.001; Nilsson C, 2012, ACTA PHARMACOL SIN, V33, P173, DOI 10.1038/aps.2011.203; Oberbach A, 2017, J PROTEOME RES, V16, P1593, DOI 10.1021/acs.jproteome.6b00973; Ottman N, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00104; Reikvam DH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017996; Schreiber W, 1999, MICROBIOL-SGM, V145, P1839, DOI 10.1099/13500872-145-8-1839; Schuijt TJ, 2016, GUT, V65, P575, DOI 10.1136/gutjnl-2015-309728; Shen J, 2013, MOL ASPECTS MED, V34, P39, DOI 10.1016/j.mam.2012.11.001; Sun WJ, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8308671; Tanca A, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00391; Tulstrup MVL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144854; Verdu EF, 2006, GUT, V55, P182, DOI 10.1136/gut.2005.066100; Villamil SI, 2018, NUTR RES, V50, P25, DOI 10.1016/j.nutres.2017.11.008; Wang S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31353-1; Wei FW, 2019, SCI CHINA LIFE SCI, V62, P168, DOI 10.1007/s11427-018-9423-3; Xiao MM, 2017, APPL MICROBIOL BIOT, V101, P3077, DOI 10.1007/s00253-017-8215-7; Zhang YC, 2014, TOXICOL APPL PHARM, V277, P138, DOI 10.1016/j.taap.2014.03.009; Zhao L, 2017, FOOD FUNCT, V8, P4644, DOI [10.1039/c7fo01383c, 10.1039/C7FO01383C]; ZHOU D, 2017, SCI REP, V7, DOI DOI 10.1038/S41598-016-0028-X	42	35	37	6	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2019	14	9							e0218143	10.1371/journal.pone.0218143	http://dx.doi.org/10.1371/journal.pone.0218143			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM5QI	31545802	Green Published, gold			2023-01-03	WOS:000532303200007
J	Kurokawa, H; Ito, H; Terasaki, M; Matano, D; Taninaka, A; Shigekawa, H; Matsui, H				Kurokawa, Hiromi; Ito, Hiromu; Terasaki, Masahiko; Matano, Daisuke; Taninaka, Atsushi; Shigekawa, Hidemi; Matsui, Hirofumi			Nitric oxide regulates the expression of heme carrier protein-1 via hypoxia inducible factor-1 alpha stabilization	PLOS ONE			English	Article							TUMOR-GROWTH; HIF-1-ALPHA; THERAPY; ACID	Photodynamic therapy (PDT) is a cancer therapy that capitalizes on cancer-specific porphyrin accumulation. We have investigated this phenomenon to propose the following three conclusions: 1) the mechanism underlying this phenomenon is closely related to both nitric oxide (NO) and heme carrier protein-1 (HCP-1), 2) NO inactivates ferrochelatase, and thus, the intracellular porphyrin levels in the cells are increased by the administration of an NO donor after 5-aminolevulinic acid treatment, 3) HCP-1 transports not only heme but also other porphyrins. Since NO stabilizes hypoxia-inducible factor (HIF)-1 alpha, resulting in the upregulation of heme biosynthesis, HCP-1 expression can be increased by HIF-1 alpha stabilization. In this study, we determined whether NO regulates HCP-1 expression by stabilizing HIF-1 alpha expression. For this purpose, rat gastric cancer cell line RGK36 was treated with Larginine or N6-(1-iminoethyl)-L-lysine (L-NIL). L-arginine treatment increased the intracellular NO concentration, and both HCP-1 and HIF-1 alpha expression, while L-NIL treatment decreased them. Cytotoxicity of PDT was enhanced by L-arginine, following intracellular hemato-porphyrin dihydrochloride (HpD) accumulation. Both Cytotoxicity of PDT and HpD accumulation were decreased by L-NIL. The HCP-1 and HIF-1 alpha expression, intracellular HpD accumulation and PDT cytotoxicity were decreased by 2-methoxyestradiol, which is a HIF-1 alpha inhibitor. Moreover, these phenomena were not increased by a combination of both L-arginine and 2-Me. Thus, HCP-1 can be a downstream target of HIF-1 alpha. These effects were also induced in the human gastric cancer cell line MKN45. Taken together, we conclude that HCP-1 expression is regulated by NO via HIF-1 alpha stabilization.	[Kurokawa, Hiromi; Matsui, Hirofumi] Univ Tsukuba, Fac Med, Tsukuba, Ibaraki, Japan; [Ito, Hiromu] Kagoshima Univ, Grad Sch Med & Dent Sci, Kagoshima, Japan; [Terasaki, Masahiko; Matano, Daisuke] Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki, Japan; [Taninaka, Atsushi; Shigekawa, Hidemi] Univ Tsukuba, Fac Pure & Appl Sci, Tsukuba, Ibaraki, Japan	University of Tsukuba; Kagoshima University; University of Tsukuba; University of Tsukuba	Matsui, H (corresponding author), Univ Tsukuba, Fac Med, Tsukuba, Ibaraki, Japan.	hmatsui@md.tsukuba.ac.jp	kurokawa, hiromi/B-4340-2017					Andrews NC, 2005, NEW ENGL J MED, V353, P2508, DOI 10.1056/NEJMcibr053987; Brune B, 2007, CARDIOVASC RES, V75, P275, DOI 10.1016/j.cardiores.2007.03.005; Fukumura D, 1997, AM J PATHOL, V150, P713; Hiyama K, 2013, J PORPHYR PHTHALOCYA, V17, P36, DOI 10.1142/S1088424612501192; Ito H, 2014, J CLIN BIOCHEM NUTR, V55, P67, DOI 10.3164/jcbn.14-27; Jadeski LC, 2000, INT J CANCER, V86, P30, DOI 10.1002/(SICI)1097-0215(20000401)86:1<30::AID-IJC5>3.0.CO;2-I; Jazwa A, 2015, VASC PHARMACOL, V71, P127, DOI 10.1016/j.vph.2015.02.011; Jedrych E, 2011, BIOMICROFLUIDICS, V5, DOI 10.1063/1.3658842; Kiziltepe T, 2007, BLOOD, V110, P709, DOI 10.1182/blood-2006-10-052845; Kwiatkowski S, 2018, BIOMED PHARMACOTHER, V106, P1098, DOI 10.1016/j.biopha.2018.07.049; Lee JB, 2008, BRIT J DERMATOL, V159, P61, DOI 10.1111/j.1365-2133.2008.08611.x; Lee JY, 2017, ANN GERIATR MED RES, V21, P95, DOI 10.4235/agmr.2017.21.3.95; Lin CZ, 2004, J ORTHOP RES, V22, P1175, DOI 10.1016/j.orthres.2004.03.002; Liu YYL, 2004, LIFE SCI, V75, P2035, DOI 10.1016/j.lfs.2004.03.027; Luo DD, 2017, ADV SCI, V4, DOI 10.1002/advs.201600106; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Malik Rajvir, 2010, Indian J Dent Res, V21, P285, DOI 10.4103/0970-9290.66659; Matsui H, 2008, J JAPAN SOC LASER SU, V29, P153; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; Nishiwaki Y., 2015, NIPPON LASER IGAKKAI, V36, P138; Park YK, 2008, MOL PHARMACOL, V74, P236, DOI 10.1124/mol.108.045278; Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478; Rajesh S, 2011, J Indian Soc Periodontol, V15, P323, DOI 10.4103/0972-124X.92563; Sandau KB, 2001, BLOOD, V97, P1009, DOI 10.1182/blood.V97.4.1009; Shayeghi M, 2005, CELL, V122, P789, DOI 10.1016/j.cell.2005.06.025; Shimokawa O, 2008, IN VITRO CELL DEV-AN, V44, P26, DOI 10.1007/s11626-007-9067-8; Shupik MA, 2011, BIOCHEMISTRY-MOSCOW+, V76, P1197, DOI 10.1134/S0006297911110010; Vannini F, 2015, REDOX BIOL, V6, P334, DOI 10.1016/j.redox.2015.08.009; Yamamoto F, 2007, BIOCHEM BIOPH RES CO, V353, P541, DOI 10.1016/j.bbrc.2006.12.007	30	2	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2019	14	9							e0222074	10.1371/journal.pone.0222074	http://dx.doi.org/10.1371/journal.pone.0222074			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM4IG	31513628	Green Published, gold, Green Submitted			2023-01-03	WOS:000532212700030
J	McBain, RK; Dick, A; Sorbero, M; Stein, BD				McBain, Ryan K.; Dick, Andrew; Sorbero, Mark; Stein, Bradley D.			Growth and Distribution of Buprenorphine-Waivered Providers in the United States, 2007-2017	ANNALS OF INTERNAL MEDICINE			English	Letter									[McBain, Ryan K.; Dick, Andrew] RAND Corp, Boston, MA 02116 USA; [Sorbero, Mark; Stein, Bradley D.] RAND Corp, Pittsburgh, PA USA	RAND Corporation; RAND Corporation	McBain, RK (corresponding author), RAND Corp, Boston, MA 02116 USA.	rmcbain@rand.org			National Institute on Drug Abuse [5R01DA045800-02, 5P50DA046351-02]	National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This study was supported by grants 5R01DA045800-02 and 5P50DA046351-02 from the National Institute on Drug Abuse, which had no role in the study's design, conduct, or reporting, apart from general oversight in accordance with National Institutes of Health guidelines.	Jones CM, 2019, ADDICTION, V114, P471, DOI 10.1111/add.14436; Kaiser Family Foundation, 2019, PROF ACT PHYS; Palombi LC, 2018, ANN EPIDEMIOL, V28, P641, DOI 10.1016/j.annepidem.2018.05.008; Substance Abuse and Mental Health Association, 2019, PRACT PROGR DAT; Substance Abuse and Mental Health Services Administration (SAMHSA) HHS, 2016, Fed Regist, V81, P66191	5	27	27	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 7	2020	172	7					504	+		10.7326/M19-2403	http://dx.doi.org/10.7326/M19-2403			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA6DM	31905379	Green Accepted			2023-01-03	WOS:000524036500014
J	Young, PJ; Bagshaw, SM; Forbes, AB; Nichol, AD; Wright, SE; Bailey, M; Bellomo, R; Beasley, R; Brickell, K; Eastwood, GM; Gattas, DJ; van Haren, F; Litton, E; Mackle, DM; McArthur, CJ; McGuinness, SP; Mouncey, PR; Navarra, L; Opgenorth, D; Pilcher, D; Saxena, MK; Webb, SA; Wiley, D; Rowan, KM				Young, Paul J.; Bagshaw, Sean M.; Forbes, Andrew B.; Nichol, Alistair D.; Wright, Stephen E.; Bailey, Michael; Bellomo, Rinaldo; Beasley, Richard; Brickell, Kathy; Eastwood, Glenn M.; Gattas, David J.; Van Haren, Frank; Litton, Edward; Mackle, Diane M.; McArthur, Colin J.; McGuinness, Shay P.; Mouncey, Paul R.; Navarra, Leanlove; Opgenorth, Dawn; Pilcher, David; Saxena, Manoj K.; Webb, Steve A.; Wiley, Daisy; Rowan, Kathryn M.		Australian New Zealand Intensive; Alberta Hlth Serv Critical Care; Irish Critical Care Trials Grp	Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation The PEPTIC Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE; PANTOPRAZOLE; ANTAGONISTS	Importance Proton pump inhibitors (PPIs) or histamine-2 receptor blockers (H(2)RBs) are often prescribed for patients as stress ulcer prophylaxis drugs in the intensive care unit (ICU). The comparative effect of these drugs on mortality is unknown. Objective To compare in-hospital mortality rates using PPIs vs H(2)RBs for stress ulcer prophylaxis. Design, Setting, and Participants Cluster crossover randomized clinical trial conducted at 50 ICUs in 5 countries between August 2016 and January 2019. Patients requiring invasive mechanical ventilation within 24 hours of ICU admission were followed up for 90 days at the hospital. Interventions Two stress ulcer prophylaxis strategies were compared (preferential use with PPIs vs preferential use with H(2)RBs). Each ICU used each strategy sequentially for 6 months in random order; 25 ICUs were randomized to the sequence with use of PPIs and then use of H(2)RBs and 25 ICUs were randomized to the sequence with use of H(2)RBs and then use of PPIs (13436 patients randomized by site to PPIs and 13392 randomized by site to H(2)RBs). Main Outcomes and Measures The primary outcome was all-cause mortality within 90 days during index hospitalization. Secondary outcomes were clinically important upper gastrointestinal bleeding, Clostridioides difficile infection, and ICU and hospital lengths of stay. Results Among 26 982 patients who were randomized, 154 opted out, and 26 828 were analyzed (mean [SD] age, 58 [17.0] years; 9691 [36.1%] were women). There were 26 771 patients (99.2%) included in the mortality analysis; 2459 of 13415 patients (18.3%) in the PPI group died at the hospital by day 90 and 2333 of 13 356 patients (17.5%) in the H2RB group died at the hospital by day 90 (risk ratio, 1.05 [95% CI, 1.00 to 1.10]; absolute risk difference, 0.93 percentage points [95% CI, -0.01 to 1.88] percentage points; P = .054). An estimated 4.1% of patients randomized by ICU site to PPIs actually received H(2)RBs and an estimated 20.1% of patients randomized by ICU site to H(2)RBs actually received PPIs. Clinically important upper gastrointestinal bleeding occurred in 1.3% of the PPI group and 1.8% of the H2RB group (risk ratio, 0.73 [95% CI, 0.57 to 0.92]; absolute risk difference, -0.51 percentage points [95% CI, -0.90 to -0.12 percentage points]; P = .009). Rates of Clostridioides difficile infection and ICU and hospital lengths of stay were not significantly different by treatment group. One adverse event (an allergic reaction) was reported in 1 patient in the PPI group. Conclusions and Relevance Among ICU patients requiring mechanical ventilation, a strategy of stress ulcer prophylaxis with use of proton pump inhibitors vs histamine-2 receptor blockers resulted in hospital mortality rates of 18.3% vs 17.5%, respectively, a difference that did not reach the significance threshold. However, study interpretation may be limited by crossover in the use of the assigned medication.	[Young, Paul J.; Beasley, Richard; Mackle, Diane M.; McArthur, Colin J.; McGuinness, Shay P.; Navarra, Leanlove] Med Res Inst New Zealand, Wellington, New Zealand; [Young, Paul J.] Wellington Hosp, Intens Care Unit, Private Bag 7902, Wellington, New Zealand; [Bagshaw, Sean M.; Opgenorth, Dawn] Univ Alberta Hosp, Dept Crit Care Med, Edmonton, AB, Canada; [Forbes, Andrew B.] Monash Univ, Biostat Unit, Melbourne, Vic, Australia; [Nichol, Alistair D.; Pilcher, David] Alfred Hosp, Intens Care Unit, Melbourne, Vic, Australia; [Nichol, Alistair D.; Bailey, Michael; Bellomo, Rinaldo; Pilcher, David] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [Nichol, Alistair D.; Brickell, Kathy] Univ Coll Dublin, St Vincents Hosp, Clin Res Ctr, Dublin, Ireland; [Wright, Stephen E.] Freeman Rd Hosp, Intens Care Unit, Newcastle Upon Tyne, Tyne & Wear, England; [Bailey, Michael; Bellomo, Rinaldo] Univ Melbourne, Melbourne, Vic, Australia; [Bellomo, Rinaldo; Eastwood, Glenn M.] Austin Hosp, Intens Care Unit, Heidelberg, Vic, Australia; [Gattas, David J.] Royal Prince Alfred Hosp, Intens Care Unit, Camperdown, NSW, Australia; [Gattas, David J.; Saxena, Manoj K.] Univ New South Wales, George Inst Global Hlth, Sydney, NSW, Australia; [Van Haren, Frank] Canberra Hosp, Intens Care Unit, Canberra, ACT, Australia; [Litton, Edward] Fiona Stanley Hosp, Intens Care Unit, Murdoch, WA, Australia; [McArthur, Colin J.] Auckland City Hosp, Dept Crit Care Med, Auckland, New Zealand; [McGuinness, Shay P.] Auckland City Hosp, Cardiothorac & Vasc Intens Care Unit, Auckland, New Zealand; [Mouncey, Paul R.; Wiley, Daisy; Rowan, Kathryn M.] Intens Care Natl Audit & Res Ctr, London, England; [Pilcher, David] Australian & New Zealand Intens Care Soc, Ctr Outcome & Resource Evaluat, Camberwell, Australia; [Saxena, Manoj K.] Bankstown Hosp, Intens Care Unit, Bankstown, Australia; [Webb, Steve A.] Royal Perth Hosp, Intens Care Unit, Perth, WA, Australia; [Young, Paul J.] Med Res Inst New Zealand, Wellington, New Zealand; [Young, Paul J.] Wellington Hosp, Wellington, New Zealand; [Bagshaw, Sean M.] Univ Alberta Hosp, Edmonton, AB, Canada; [Nichol, Alistair D.] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [Nichol, Alistair D.] Alfred Hosp, Melbourne, Vic, Australia; [Nichol, Alistair D.] St Vincents Hosp, Dublin, Ireland; [Wright, Stephen E.] Dorset Cty Hosp, Dorchester, England; [Bellomo, Rinaldo] Austin Hosp, Heidelberg, Vic, Australia; [Bellomo, Rinaldo] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [Bellomo, Rinaldo] Univ Melbourne, Melbourne, Vic, Australia; [Beasley, Richard] Med Res Inst New Zealand, Wellington, New Zealand; [Brickell, Kathy] St Vincents Hosp, Dublin, Ireland; [Bellomo, Rinaldo; Eastwood, Glenn M.] Austin Hosp, Heidelberg, Vic, Australia; [Gattas, David J.] Royal Prince Alfred Hosp, Sydney, NSW, Australia; [Van Haren, Frank] Canberra Hosp, Canberra, ACT, Australia; [Litton, Edward] Fiona Stanley Hosp, Perth, WA, Australia; [Mackle, Diane M.; McArthur, Colin J.; McGuinness, Shay P.; Navarra, Leanlove] Med Res Inst New Zealand, Wellington, New Zealand; [McArthur, Colin J.; McGuinness, Shay P.] Auckland City Hosp, Auckland, New Zealand; [Mouncey, Paul R.] Intens Care Audit & Res Ctr, London, England; [Opgenorth, Dawn] Univ Alberta Hosp, Edmonton, AB, Canada; [Pilcher, David] Monash Univ, Alfred Hosp, Australian & New Zealand Intens Care Soc Ctr Outc, Melbourne, Vic, Australia; [Pilcher, David] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [Saxena, Manoj K.] Univ New South Wales, Bankstown Hosp, Intens Care Unit, Sydney, NSW, Australia; [Saxena, Manoj K.] Univ New South Wales, George Inst Global Hlth, Sydney, NSW, Australia; [Webb, Steve A.] Royal Perth Hosp, Perth, WA, Australia; [Wiley, Daisy] Intens Care Audit & Res Ctr, London, England; [Rowan, Kathryn M.] Intens Care Audit & Res Ctr, London, England	Medical Research Institute Of New Zealand; University of Alberta; Monash University; Florey Institute of Neuroscience & Mental Health; Monash University; University College Dublin; Newcastle Freeman Hospital; Newcastle University - UK; University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Sydney; George Institute for Global Health; University of New South Wales Sydney; University of Sydney; Australian National University; Canberra Hospital; Auckland City Hospital; Auckland City Hospital; Intensive Care National Audit & Research Centre; Royal Perth Hospital; University of Western Australia; Medical Research Institute Of New Zealand; University of Alberta; Monash University; Florey Institute of Neuroscience & Mental Health; University College Dublin; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Monash University; University of Melbourne; Medical Research Institute Of New Zealand; University College Dublin; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Sydney; Australian National University; Canberra Hospital; Medical Research Institute Of New Zealand; Auckland City Hospital; University of Alberta; Florey Institute of Neuroscience & Mental Health; Monash University; Monash University; University of New South Wales Sydney; George Institute for Global Health; University of New South Wales Sydney; University of Sydney; Royal Perth Hospital; University of Western Australia	Young, PJ (corresponding author), Wellington Hosp, Intens Care Unit, Private Bag 7902, Wellington, New Zealand.		Gattas, David/AAN-9668-2020; Bailey, Michael J/A-4499-2012; litton, edward/C-5384-2017	Gattas, David/0000-0002-9282-7093; Bailey, Michael J/0000-0002-5551-1401; Rowan, Kathryn/0000-0001-8217-5602; Young, Paul/0000-0002-3428-3083; McGuinness, Shay/0000-0003-0620-4787; Nichol, Alistair/0000-0002-4689-1238; Mouncey, Paul/0000-0002-8510-8517; litton, edward/0000-0002-5125-6829; Saxena, Manoj/0000-0002-0385-6731	Health Research Council of New Zealand; Canadian Institutes of Health Research; Australian and New Zealand Intensive Care Foundation; Health Research Board of Ireland; UK National Institute for Health Research Critical Care Clinical Research Networks; UK Critical Care Research Group	Health Research Council of New Zealand(Health Research Council of New Zealand); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Australian and New Zealand Intensive Care Foundation; Health Research Board of Ireland; UK National Institute for Health Research Critical Care Clinical Research Networks; UK Critical Care Research Group	Funded by the Health Research Council of New Zealand, the Canadian Institutes of Health Research, the Australian and New Zealand Intensive Care Foundation, and the Health Research Board of Ireland. The PEPTIC trial was supported by the UK National Institute for Health Research Critical Care Clinical Research Networks and the UK Critical Care Research Group.	Alhazzani W, 2013, CRIT CARE MED, V41, P693, DOI 10.1097/CCM.0b013e3182758734; AYBAY C, 1995, GEN PHARMACOL-VASC S, V26, P1413, DOI 10.1016/0306-3623(94)00301-3; Barbateskovic M, 2019, INTENS CARE MED, V45, P143, DOI 10.1007/s00134-019-05526-z; Bateman BT, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5416; Begg MD, 2003, STAT MED, V22, P2591, DOI 10.1002/sim.1524; Capodicasa E, 1999, IMMUNOPHARM IMMUNOT, V21, P357, DOI 10.3109/08923979909052768; Eastwood GM, 2014, CRIT CARE RESUSC, V16, P170; Forbes AB, 2015, CLIN TRIALS, V12, P34, DOI 10.1177/1740774514559610; Kedika RR, 2009, DIGEST DIS SCI, V54, P2312, DOI 10.1007/s10620-009-0951-9; Krag M, 2018, NEW ENGL J MED, V379, P2199, DOI 10.1056/NEJMoa1714919; Krag M, 2015, INTENS CARE MED, V41, P833, DOI 10.1007/s00134-015-3725-1; Litton E, 2014, CRIT CARE RESUSC, V16, P158; Localio AR, 2007, J CLIN EPIDEMIOL, V60, P874, DOI 10.1016/j.jclinepi.2006.12.001; MacLaren R, 2014, JAMA INTERN MED, V174, P564, DOI 10.1001/jamainternmed.2013.14673; Marker S, 2019, INTENS CARE MED, V45, P609, DOI 10.1007/s00134-019-05589-y; Miano TA, 2009, CHEST, V136, P440, DOI 10.1378/chest.08-1634; PEPTIC Investigators, STAT AN PLAN PEPTIC; US Centers for Disease Control and Prevention, DEV ASS MOD VENT ASS; Vincent JL, 2014, LANCET RESP MED, V2, P380, DOI 10.1016/S2213-2600(14)70061-X; Young PJ, 2018, CRIT CARE RESUSC, V20, P182	20	76	82	3	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	2020	323	7					616	626		10.1001/jama.2019.22190	http://dx.doi.org/10.1001/jama.2019.22190			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR0OF	31950977	Green Published, Bronze			2023-01-03	WOS:000517319500016
J	Liu, YY; Wang, CR; Li, JS; Li, TT; Zhang, Y; Liang, YX; Mei, YX				Liu, Yangyang; Wang, Chaorui; Li, Jinshan; Li, Tiantian; Zhang, Yong; Liang, Yunxiang; Mei, Yuxia			Phellinus linteus polysaccharide extract improves insulin resistance by regulating gut microbiota composition	FASEB JOURNAL			English	Article						gut microbiota; insulin signaling; inflammation; Phellinus linteus polysaccharide; short-chain fatty acids	CHAIN FATTY-ACIDS; DIETARY FIBER; AGARICUS-BISPORUS; OBESITY; STREPTOZOTOCIN; METABOLISM; FERMENTATION; DYSFUNCTION; INDIVIDUALS; METAGENOME	The hypoglycemic effect of Phellinus linteus polysaccharide extract (PLPE) has been documented in several previous studies, but the functional interactions among PLPE, gut microbiota, and the hypoglycemic effect remain unclear. We examined the regulatory effect of PLPE on gut microbiota, and the molecular mechanism underlying improvement of insulin resistance, using a type 2 diabetic rat model. Here, 24 male Sprague-Dawley rats were randomly divided into four groups that were subjected to intervention of saline (normal and model control group), metformin (120 mg/kg.bw), and PLPE (600 mg/kg.bw) by oral administration. After 8 weeks of treatment, PLPE increased levels of short-chain fatty acids (SCFAs) by enhancing abundance of SCFA-producing bacteria. SCFAs maintained intestinal barrier function and reduced lipopolysaccharides content in blood, thereby helping to reduce systemic inflammation and reverse insulin resistance. Our findings suggest that PLPE (in which polysaccharides are the major component) has potential application as a prebiotic for regulating gut microbiota composition in diabetic patients.	[Liu, Yangyang; Wang, Chaorui; Li, Jinshan; Li, Tiantian; Zhang, Yong; Liang, Yunxiang; Mei, Yuxia] Huazhong Agr Univ, Coll Life Sci & Technol, State Key Lab Agr Microbiol, Wuhan 430070, Hubei, Peoples R China; [Mei, Yuxia] Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	Huazhong Agricultural University; University of California System; University of California Davis	Mei, YX (corresponding author), Huazhong Agr Univ, Coll Life Sci & Technol, State Key Lab Agr Microbiol, Wuhan 430070, Hubei, Peoples R China.	mei@mail.hzau.edu.cn	Li, Jinshan/AAQ-9461-2020	Li, Jinshan/0000-0003-3109-5092	State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University; Fundamental Research Funds for the Central Universities of China [2662019PY066, 2662016PY132]; China Scholarship Council [201706765055]	State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University; Fundamental Research Funds for the Central Universities of China(Fundamental Research Funds for the Central Universities); China Scholarship Council(China Scholarship Council)	This study was supported by funds from the State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Fundamental Research Funds for the Central Universities of China (grant No. 2662019PY066, No. 2662016PY132), and a special grant from China Scholarship Council (No. 201706765055). The authors are grateful to Dr. S. Anderson for English editing of the manuscript.	Canfora EE, 2015, NAT REV ENDOCRINOL, V11, P577, DOI 10.1038/nrendo.2015.128; Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Chang CJ, 2015, NAT COMMUN, V6, DOI [10.1038/ncomms8489, 10.1038/ncomms8216]; Chen H, 2016, FITOTERAPIA, V113, P6, DOI 10.1016/j.fitote.2016.06.009; Cho NH, 2018, DIABETES RES CLIN PR, V138, P271, DOI 10.1016/j.diabres.2018.02.023; de Assis AM, 2009, EXP BIOL MED, V234, P1296, DOI 10.3181/0904-RM-126; De Vadder F, 2014, CELL, V156, P84, DOI 10.1016/j.cell.2013.12.016; Desai MS, 2016, CELL, V167, P1339, DOI 10.1016/j.cell.2016.10.043; Ding QA, 2017, FOOD HYDROCOLLOID, V63, P646, DOI 10.1016/j.foodhyd.2016.10.018; Duan YH, 2019, FASEB J, V33, P10019, DOI 10.1096/fj.201900665RR; Duncan SH, 2016, ENVIRON MICROBIOL, V18, P2214, DOI 10.1111/1462-2920.13158; Everard A, 2013, P NATL ACAD SCI USA, V110, P9066, DOI 10.1073/pnas.1219451110; Feng H, 2018, CARBOHYD POLYM, V200, P144, DOI 10.1016/j.carbpol.2018.07.086; Forslund K, 2015, NATURE, V528, P262, DOI 10.1038/nature15766; Hanley AJG, 2002, DIABETES CARE, V25, P1177, DOI 10.2337/diacare.25.7.1177; Hehemann JH, 2019, ISME J, V13, P1883, DOI 10.1038/s41396-019-0406-z; Hu T, 2018, CARBOHYD POLYM, V200, P487, DOI 10.1016/j.carbpol.2018.08.021; Hwang HJ, 2008, KOREAN J CHEM ENG, V25, P308, DOI 10.1007/s11814-008-0054-x; Jakobsdottir G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080476; Jayachandran M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091934; Karlsson FH, 2013, NATURE, V498, P99, DOI 10.1038/nature12198; Kieler IN, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41195-0; Koh A, 2016, CELL, V165, P1332, DOI 10.1016/j.cell.2016.05.041; Kovatcheva-Datchary P, 2015, CELL METAB, V22, P971, DOI 10.1016/j.cmet.2015.10.001; Liu YY, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020296; Makki K, 2018, CELL HOST MICROBE, V23, P705, DOI 10.1016/j.chom.2018.05.012; Martel J, 2017, NAT REV ENDOCRINOL, V13, P149, DOI 10.1038/nrendo.2016.142; Martens EC, 2018, NAT REV MICROBIOL, V16, P457, DOI 10.1038/s41579-018-0036-x; Mei YX, 2015, CARBOHYD POLYM, V124, P90, DOI 10.1016/j.carbpol.2015.02.009; Musso G, 2011, ANNU REV MED, V62, P361, DOI 10.1146/annurev-med-012510-175505; Ng SF, 2010, NATURE, V467, P963, DOI 10.1038/nature09491; Palacio J C, 1990, Nutr Clin Pract, V5, P99, DOI 10.1177/011542659000500399; Puddu Alessandra, 2014, Mediators Inflamm, V2014, P162021, DOI 10.1155/2014/162021; Qin JJ, 2012, NATURE, V490, P55, DOI 10.1038/nature11450; Ravachol J, 2016, SCI REP-UK, V6, DOI 10.1038/srep22770; Scott TA, 2017, CELL, V169, P442, DOI 10.1016/j.cell.2017.03.040; Singh A, 2019, FASEB J, V33, P6748, DOI 10.1096/fj.201801627RRR; Solano-Aguilar GI, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111721; Sonnenburg ED, 2014, CELL METAB, V20, P779, DOI 10.1016/j.cmet.2014.07.003; Tian Y, 2018, J FUNCT FOODS, V45, P223, DOI 10.1016/j.jff.2018.04.008; Uyanoglu M, 2014, INT J FOOD SCI NUTR, V65, P482, DOI 10.3109/09637486.2013.869796; Vanegas SM, 2017, AM J CLIN NUTR, V105, P635, DOI 10.3945/ajcn.116.146928; Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031; Wan Y, 2019, GUT, V68, P1417, DOI 10.1136/gutjnl-2018-317609; Wu H, 2017, NAT MED, V23, P850, DOI 10.1038/nm.4345; Wu TR, 2019, GUT, V68, P248, DOI 10.1136/gutjnl-2017-315458; Yang Q, 2018, NAT REV MOL CELL BIO, V19, P654, DOI 10.1038/s41580-018-0044-8; Yang WY, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0205784; You YM, 2015, FOOD FUNCT, V6, P3144, DOI 10.1039/c5fo00432b; Zhang BW, 2018, J FUNCT FOODS, V46, P256, DOI 10.1016/j.jff.2018.04.070; Zhao C, 2014, J FOOD SCI, V79, pH1002, DOI 10.1111/1750-3841.12464; Zhao GH, 2006, BIOMED CHROMATOGR, V20, P674, DOI 10.1002/bmc.580; Zhao LP, 2018, SCIENCE, V359, P1151, DOI 10.1126/science.aao5774; Zhou D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01751-y	55	34	37	4	71	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2020	34	1					1065	1078		10.1096/fj.201901943RR	http://dx.doi.org/10.1096/fj.201901943RR			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KC6TY	31914668				2023-01-03	WOS:000507308900072
J	Gonsalves, L; Wyss, K; Gichangi, P; Say, L; Hilber, AM				Gonsalves, Lianne; Wyss, Kaspar; Gichangi, Peter; Say, Lale; Hilber, Adriane Martin			Regulating pharmacists as contraception providers: A qualitative study from Coastal Kenya on injectable contraception provision to youth	PLOS ONE			English	Article							COUNTRIES	Introduction Young people worldwide are often reticent to access family planning services from public health facilities: instead, they choose to get contraception from private, retail pharmacies. In Kenya, certain contraceptives are available in pharmacies: these include injectables, which can be dispensed but not administered, according national guidelines. However, Kenya struggles with enforcement of its pharmacy regulations and addressing illegal activity. Therefore, in this qualitative study, we assessed private pharmacies as an existing source of injectable contraception for young Kenyans (age 18-24), and investigated the perceived quality of service provision. Methods This study used: focus group discussions (6) with young community members; in-depth interviews (18) with youth who had purchased contraception from pharmacies; key informant interviews with pharmacy personnel and pharmacy stakeholders (25); and a mystery shopper (visiting 45 pharmacies). Results The study found that for injectable contraception, private pharmacies had expanded to service provision, and pharmacy personnel's roles had transcended formal or informal training previously received-young people could both purchase and be injected in many pharmacies. Pharmacies were perceived to lack consistent quality or strong regulation, resulting in young clients, pharmacy personnel, and regulators being concerned about illegal activity. Participants' suggestions to improve pharmacy service quality and regulation compliance focused on empowering consumers to demand quality service; strengthening regulatory mechanisms; expanding training opportunities to personnel in private pharmacies; and establishing a quality-based 'brand' for pharmacies. Discussion Kenya's recent commitments to universal health coverage and interest in revising pharmacy policy provide an opportunity to improve pharmacy quality. Multi-pronged initiatives with both public and private partners are needed to improve pharmacy practice, update and enforce regulations, and educate the public. Additionally, the advent of self-administrable injectables present a new possible role for pharmacies, and could offer young clients a clean, discreet place to self-inject, with pharmacy personnel serving as educators and dispensers.	[Gonsalves, Lianne; Say, Lale] World Hlth Org, Special Programme Res Dev & Res Training Human Re, Dept Reprod Hlth & Res Including UNDP, UNFPA,UNICEF,WHO,World Bank, Geneva, Switzerland; [Gonsalves, Lianne; Wyss, Kaspar; Hilber, Adriane Martin] Swiss Trop & Publ Hlth Inst Swiss TPH, Basel, Switzerland; [Gonsalves, Lianne; Wyss, Kaspar; Hilber, Adriane Martin] Univ Basel, Basel, Switzerland; [Gichangi, Peter] Int Ctr Reprod Hlth Kenya, Mombasa, Kenya; [Gichangi, Peter] Univ Nairobi, Dept Human Anat, Nairobi, Kenya; [Gichangi, Peter] Univ Ghent, Ghent, Belgium	The World Bank; United Nations Population Fund; World Health Organization; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; University of Nairobi; Ghent University	Gonsalves, L (corresponding author), World Hlth Org, Special Programme Res Dev & Res Training Human Re, Dept Reprod Hlth & Res Including UNDP, UNFPA,UNICEF,WHO,World Bank, Geneva, Switzerland.; Gonsalves, L (corresponding author), Swiss Trop & Publ Hlth Inst Swiss TPH, Basel, Switzerland.; Gonsalves, L (corresponding author), Univ Basel, Basel, Switzerland.	gonsalvesl@who.int	, lalesay/AAG-1912-2021	Wyss, Kaspar/0000-0003-0156-5989; Gonsalves, Lianne/0000-0003-2409-5043	UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP)	UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP)	This study was partially supported by the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP). The funders had no role in study design, data collection and analysis, decision to public or preparation of the manuscript.	[Anonymous], 2018, THE STAR; Aywak D, 2017, CAN J HOSP PHARM, V70, P456; Centers for Disease Control and Prevention, 2016, US MED EL CRIT US ME; Chin-Quee DS, 2006, STUD FAMILY PLANN, V37, P99, DOI 10.1111/j.1728-4465.2006.00089.x; Corroon M, 2016, GLOB HEALTH-SCI PRAC, V4, P594, DOI 10.9745/GHSP-D-16-00197; Drug Shops and Pharmacies, 2013, SOURC FAM PLANN COMM; Embrey M, 2018, GLOBAL HLTH IMPACT B; Gonsalves L, 2017, CONTRACEPTION, V95, P339, DOI 10.1016/j.contraception.2016.12.002; Hermansyah A, 2016, HEALTH SOC CARE COMM, V24, pE11, DOI 10.1111/hsc.12289; High-Impact Practices in Family Planning (HIPs), 2015, AD FRIENDL CONTR SER; International Consortium for Emergency Contraception, 2018, EC STAT AV COUNTR NO; Janowitz B, 2012, STUD FAMILY PLANN, V43, P57, DOI 10.1111/j.1728-4465.2012.00302.x; Kennedy CE, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2018-001350; Kenya National Bureau of Statistics Ministry of Health National AIDS Control Council Kenya Medical Research Institute, 2015, KEN DEM HLTH SURV 20; Mayora C, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3343-z; Miller R, 2016, HEALTH POLICY PLANN, V31, P940, DOI 10.1093/heapol/czw007; Ministry of Health, 2010, NAT FAM PLANN GUID S; Ministry of Health Kenya, 2015, NATL ADOLESCENT SEXU; Ministry of Health/Kenya Pharmacy and Poisons Board, 2013, GUID IMPL CONT PROF; Ministry of Medical Services/Kenya MoPHaSK, 2013, CPD PROGR PHARM PROF; Ministry of Planning and National Development/Kenya MoHK, 2003, AD REPR HLTH DEV POL; Monja B, 2018, STAR; OCs OTC Working Group, 2018, GLOB OR CONTR AV; Ostola J, 2015, PRIVATE SECTOR DISTR; Otieno J, 2018, MED FAULT PUSH AMEND; Pande S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010398; Rutta Edmund, 2015, J Pharm Policy Pract, V8, P23, DOI 10.1186/s40545-015-0044-4; SHOPS Plus, 2019, SOURC FAM PLANN NEP; Smith F, 2009, PHARM WORLD SCI, V31, P351, DOI 10.1007/s11096-009-9294-z; Smith F, 2009, TROP MED INT HEALTH, V14, P362, DOI 10.1111/j.1365-3156.2009.02232.x; Sunday F., 2019, FACT CHECKER PHARM R; Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program, 2015, BAS STUD PRIV DRUG S; Thiong'o J., 2019, MED HAVE SPECIAL COD; Wafula FN, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-223; World Health Organization, 2017, TASK SHAR IMPR ACC F	35	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2019	14	12							e0226133	10.1371/journal.pone.0226133	http://dx.doi.org/10.1371/journal.pone.0226133			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP3WL	31856196	Green Accepted, gold, Green Published			2023-01-03	WOS:000534249400024
J	Attal, M; Richardson, PG; Rajkumar, SV; San-Miguel, J; Beksac, M; Spicka, I; Leleu, X; Schjesvold, F; Moreau, P; Dimopoulos, MA; Huang, JSY; Minarik, J; Cavo, M; Prince, HM; Mace, S; Corzo, KP; Campana, F; Le-Guennec, S; Dubin, F; Anderson, KC				Attal, Michel; Richardson, Paul G.; Rajkumar, S. Vincent; San-Miguel, Jesus; Beksac, Meral; Spicka, Ivan; Leleu, Xavier; Schjesvold, Fredrik; Moreau, Philippe; Dimopoulos, Meletios A.; Huang, Jeffrey Shang-Yi; Minarik, Jiri; Cavo, Michele; Prince, H. Miles; Mace, Sandrine; Corzo, Kathryn P.; Campana, Frank; Le-Guennec, Solenn; Dubin, Franck; Anderson, Kenneth C.		ICARIA-MM Study Grp	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study	LANCET			English	Article							DARATUMUMAB; BORTEZOMIB; SAR650984	Background Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous phase 1b study, around 65% of patients with relapsed and refractory multiple myeloma achieved an overall response with a combination of isatuximab with pomalidomide and low-dose dexamethasone. The aim of this study was to determine the progression-free survival benefit of isatuximab plus pomalidomide and dexamethasone compared with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma. Methods We did a randomised, multicentre, open-label, phase 3 study at 102 hospitals in 24 countries in Europe, North America, and the Asia-Pacific regions. Eligible participants were adult patients with relapsed and refractory multiple myeloma who had received at least two previous lines of treatment, including lenalidomide and a proteasome inhibitor. Patients were excluded if they were refractory to previous treatment with an anti-CD38 monoclonal antibody. We randomly assigned patients (1:1) to either isatuximab 10 mg/kg plus pomalidomide 4 mg plus dexamethasone 40 mg (20 mg for patients aged >= 75 years), or pomalidomide 4 mg plus dexamethasone 40 mg. Randomisation was done using interactive response technology and stratified according to the number of previous lines of treatment (2-3 vs >3) and age (< 75 years vs >= 75 years). Treatments were assigned based on a permuted blocked randomisation scheme with a block size of four. The isatuximab-pomalidomide-dexamethasone group received isatuximab intravenously on days 1, 8, 15, and 22 in the first 28-day cycle, then on days 1 and 15 in subsequent cycles. Both groups received oral pomalidomide on days 1 to 21 in each cycle, and oral or intravenous dexamethasone on days 1, 8, 15, and 22 of each cycle. Treatment continued until disease progression, unacceptable toxicity, or consent withdrawal. Dose reductions for adverse reactions were permitted for pomalidomide and dexamethasone, but not for isatuximab. The primary endpoint was progression-free survival, determined by an independent response committee and assessed in the intention-to-treat population. Safety was assessed in all participants who received at least one dose of study drug. This study is registered at ClinicalTrials.gov, number NCT02990338. Findings Between Jan 10, 2017, and Feb 2, 2018, we randomly assigned 307 patients to treatment: 154 to isatuximab-pomalidomide-dexamethasone, and 153 to pomalidomide-dexamethasone. At a median follow-up of 11.6 months (IQR 10.1-13.9), median progression-free survival was 11.5 months (95% CI 8.9-13.9) in the isatuximab-pomalidomide-dexamethasone group versus 6.5 months (4.5-8.3) in the pomalidomide-dexamethasone group; hazard ratio 0.596, 95% CI 0.44-0.81; p=0.001 by stratified log-rank test. The most frequent treatment-emergent adverse events (any grade; isatuximab-pomalidomide-dexamethasone vs pomalidomide-dexamethasone) were infusion reactions (56 [38%] vs 0), upper respiratory tract infections (43 [28%] vs 26 [17%]), and diarrhoea (39 [26%] vs 29 [20%]). Adverse events with a fatal outcome were reported in 12 patients (8%) in the isatuximab-pomalidomide-dexamethasone group and 14 (9%) in the pomalidomide-dexamethasone group. Deaths due to treatment-related adverse events were reported for one patient (<1%) in the isatuximab-pomalidomide-dexamethasone group (sepsis) and two (1%) in the pomalidomide-dexamethasone group (pneumonia and urinary tract infection). Interpretation The addition of isatuximab to pomalidomide-dexamethasone significantly improves progression-free survival in patients with relapsed and refractory multiple myeloma. Isatuximab is an important new treatment option for the management of relapsed and refractory myeloma, particularly for patients who become refractory to lenalidomide and a proteasome inhibitor.Copyright (C) 2019 Elsevier Ltd. All rights reserved.	[Attal, Michel] Inst Univ Canc Toulouse Oncopole, Toulouse, France; [Richardson, Paul G.; Anderson, Kenneth C.] Harvard Med Sch, Jerome Lipper Multiple Myeloma Ctr, Dana Farber Canc Inst, Boston, MA 02215 USA; [Rajkumar, S. Vincent] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA; [San-Miguel, Jesus] Clin Univ Navarra, Clin & Translat Med, Pamplona, Spain; [San-Miguel, Jesus] CIBER ONC, IDISNA, CIMA, Pamplona, Spain; [Beksac, Meral] Ankara Univ, Dept Hematol, Ankara, Turkey; [Spicka, Ivan] Charles Univ Prague, Dept Med 1, Dept Hematol, Fac Med 1, Prague, Czech Republic; [Spicka, Ivan] Gen Hosp Prague, Prague, Czech Republic; [Leleu, Xavier] CHU Mil Poitiers, Dept Haematol, Poitiers, France; [Schjesvold, Fredrik] Oslo Univ Hosp, Oslo Myeloma Ctr, Oslo, Norway; [Schjesvold, Fredrik] Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Oslo, Norway; [Moreau, Philippe] CHU Nantes, Dept Hematol, Nantes, France; [Dimopoulos, Meletios A.] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Athens, Greece; [Huang, Jeffrey Shang-Yi] Natl Taiwan Univ Hosp, Dept Hematol, Taipei, Taiwan; [Minarik, Jiri] Palacky Univ, Dept Hematooncol, Fac Med & Dent, Olomouc, Czech Republic; [Minarik, Jiri] Univ Hosp Olomouc, Olomouc, Czech Republic; [Cavo, Michele] Univ Bologna, Seragnoli Inst Hematol, Dept Expt Diagnost & Specialty Med, Bologna, Italy; [Prince, H. Miles] Univ Melbourne, Epworth Healthcare, Canc Immunol & Mol Oncol, Melbourne, Vic, Australia; [Mace, Sandrine; Le-Guennec, Solenn; Dubin, Franck] Sanofi Res & Dev, Vitry Sur Seine, France; [Corzo, Kathryn P.; Campana, Frank] Sanofi Genzyme Oncol, Cambridge, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Mayo Clinic; University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Ankara University; Charles University Prague; General University Hospital Prague; CHU Poitiers; Universite de Poitiers; University of Oslo; University of Oslo; Nantes Universite; CHU de Nantes; National & Kapodistrian University of Athens; National Taiwan University; National Taiwan University Hospital; Palacky University Olomouc; University Hospital Olomouc; University of Bologna; University of Melbourne; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Genzyme Corporation	Richardson, PG (corresponding author), Harvard Med Sch, Jerome Lipper Multiple Myeloma Ctr, Dana Farber Canc Inst, Boston, MA 02215 USA.; Attal, M (corresponding author), 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France.	attal.michel@iuct-oncopole.fr; paul_richardson@dfci.harvard.edu	Rajkumar, S. Vincent/AAV-1834-2021; Zambello, Renato/AAB-5280-2022; ALEGRE, ADRIAN/AAE-4268-2021; LEMOLI, ROBERTO/AAC-2370-2022; Minarik, Jiri/GWR-0249-2022; Symeonidis, Argiris/K-2287-2019; CAVO, MICHELE/AAK-8274-2020; San-Miguel, Jesús F./V-8977-2018; Maisnar, Vladimir/Q-8579-2017	Rajkumar, S. Vincent/0000-0002-5862-1833; Zambello, Renato/0000-0002-8799-5324; ALEGRE, ADRIAN/0000-0002-2423-822X; LEMOLI, ROBERTO/0000-0001-9000-562X; Minarik, Jiri/0000-0003-0513-326X; Symeonidis, Argiris/0000-0002-3685-3473; CAVO, MICHELE/0000-0003-4514-3227; San-Miguel, Jesús F./0000-0002-9183-4857; Ocio, Enrique M./0000-0002-5765-0085; Arat, Mutlu/0000-0003-2039-8557; moreau, philippe/0000-0003-1780-8746; Maisnar, Vladimir/0000-0003-1738-4920; Gonzalez, Marta Sonia/0000-0001-5494-9009; Walter-Croneck, Adam/0000-0003-0908-0396; Perrot, Aurore/0000-0003-0131-8689	Sanofi	Sanofi	Sanofi.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Abramson HN, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123924; Atanackovic D, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1217374; CAI T, 2013, CLIN LYMPH MYELOMA L, V13, pP288; CHARI A, 2018, J CLIN ONCOL S15, V36; Chari A, 2017, BLOOD, V130, P974, DOI 10.1182/blood-2017-05-785246; Deckert J, 2014, CLIN CANCER RES, V20, P4574, DOI 10.1158/1078-0432.CCR-14-0695; Dimopoulos MA, 2016, NEW ENGL J MED, V375, P1319, DOI 10.1056/NEJMoa1607751; Dimopoulos MA, 2018, BLOOD, V132, DOI 10.1182/blood-2018-155; Dimopoulos MA, 2018, NEW ENGL J MED, V379, P1811, DOI 10.1056/NEJMoa1805762; Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284; Fayers PM, 2001, EUR J CANCER, V37, P1331, DOI 10.1016/S0959-8049(01)00127-7; Jiang H, 2016, LEUKEMIA, V30, P399, DOI 10.1038/leu.2015.240; Kumar SK, 2012, LEUKEMIA, V26, P149, DOI 10.1038/leu.2011.196; Lin P, 2004, AM J CLIN PATHOL, V121, P482, DOI 10.1039/74R4TB90BUWH27JX; Martin T, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-019-0198-4; Martin T, 2017, BLOOD, V129, P3294, DOI 10.1182/blood-2016-09-740787; Mikhael J, 2019, BLOOD, V134, P123, DOI 10.1182/blood-2019-02-895193; Moreau P, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-019-0200-1; Moreno L, 2019, CLIN CANCER RES, V25, P3176, DOI 10.1158/1078-0432.CCR-18-1597; Palumbo A, 2016, NEW ENGL J MED, V375, P754, DOI 10.1056/NEJMoa1606038; Rajkumar SV, 2009, CURR PROB CANCER, V33, P7, DOI 10.1016/j.currproblcancer.2009.01.001; Richardson PG, 2019, LANCET ONCOL, V20, P781, DOI 10.1016/S1470-2045(19)30152-4; Richardson PG, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0141-0; Richardson PG, 2018, FUTURE ONCOL, V14, P1035, DOI 10.2217/fon-2017-0616; Richardson PG, 2014, BLOOD, V123, P1826, DOI 10.1182/blood-2013-11-538835; Richter JR, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.8005; Miguel JS, 2013, LANCET ONCOL, V14, P1055, DOI 10.1016/S1470-2045(13)70380-2; Stead ML, 1999, BRIT J HAEMATOL, V104, P605, DOI 10.1046/j.1365-2141.1999.01206.x; Usmani S, 2019, PRELIMINARY DATA PHA; van de Donk NWCJ, 2016, IMMUNOL REV, V270, P95, DOI 10.1111/imr.12389; Varga C, 2018, BRIT J HAEMATOL, V181, P433, DOI 10.1111/bjh.15116	32	156	160	1	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 7	2019	394	10214					2096	2107		10.1016/S0140-6736(19)32556-5	http://dx.doi.org/10.1016/S0140-6736(19)32556-5			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT4HF	31735560				2023-01-03	WOS:000500951600028
J	Hoskin, PJ; Hopkins, K; Misra, V; Holt, T; McMenemin, R; Dubois, D; McKinna, F; Foran, B; Madhavan, K; MacGregor, C; Bates, A; O'Rourke, N; Lester, JF; Sevitt, T; Roos, D; Dixit, S; Brown, G; Arnott, S; Thomas, SS; Forsyth, S; Beare, S; Reczko, K; Hackshaw, A; Lopes, A				Hoskin, Peter J.; Hopkins, Kirsten; Misra, Vivek; Holt, Tanya; McMenemin, Rhona; Dubois, Danny; McKinna, Fiona; Foran, Bernadette; Madhavan, Krishnaswamy; MacGregor, Carol; Bates, Andrew; O'Rourke, Noelle; Lester, Jason F.; Sevitt, Tim; Roos, Daniel; Dixit, Sanjay; Brown, Gillian; Arnott, Seonaid; Thomas, Sharon Shibu; Forsyth, Sharon; Beare, Sandy; Reczko, Krystyna; Hackshaw, Allan; Lopes, Andre			Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer The SCORAD Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORD COMPRESSION; BONE METASTASES; EUROPEAN COUNTRIES; RADIATION-THERAPY; MANAGEMENT; UPDATE; CARE	IMPORTANCE Malignant spinal canal compression, a major complication of metastatic cancer, is managed with radiotherapy to maintain mobility and relieve pain, although there is no standard radiotherapy regimen. OBJECTIVE To evaluate whether single-fraction radiotherapy is noninferior to 5 fractions of radiotherapy. DESIGN, SETTING, AND PARTICIPANTS Multicenter noninferiority randomized clinical trial conducted in 42 UK and 5 Australian radiotherapy centers. Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area. Patients were recruited between February 2008 and April 2016, with final follow-up in September 2017. INTERVENTIONS Patients were randomized to receive external beam single-fraction 8-Gy radiotherapy (n = 345) or 20 Gy of radiotherapy in 5 fractions over 5 consecutive days (n = 341). MAIN OUTCOMES AND MEASURES The primary end point was ambulatory status at week 8, based on a 4-point scale and classified as grade 1 (ambulatory without the use of aids and grade 5 of 5 muscle power) or grade 2 (ambulatory using aids or grade 4 of 5 muscle power). The noninferiority margin for the difference in ambulatory status was -11%. Secondary end points included ambulatory status at weeks 1, 4, and 12 and overall survival. RESULTS Among 686 randomized patients (median [interquartile range] age, 70 [64-77] years; 503 (73%) men; 44% had prostate cancer, 19% had lung cancer, and 12% had breast cancer), 342 (49.8%) were analyzed for the primary end point (255 patients died before the 8-week assessment). Ambulatory status grade 1 or 2 at week 8 was achieved by 115 of 166 (69.3%) patients in the single-fraction group vs 128 of 176 (72.7%) in the multifraction group (difference, -3.5%[1-sided 95% CI, -11.5% to infinity]; P value for noninferiority = .06). The difference in ambulatory status grade 1 or 2 in the single-fraction vs multifraction group was -0.4%(63.9% vs 64.3%; [1-sided 95% CI, -6.9 to infinity]; P value for noninferiority = .004) at week 1, -0.7%(66.8% vs 67.6%; [1-sided 95% CI, -8.1 to infinity]; P value for noninferiority = .01) at week 4, and 4.1% (71.8% vs 67.7%; [1-sided 95% CI, -4.6 to infinity]; P value for noninferiority = .002) at week 12. Overall survival rates at 12 weeks were 50% in the single-fraction group vs 55% in the multifraction group (stratified hazard ratio, 1.02 [95% CI, 0.74-1.41]). Of the 11 other secondary end points that were analyzed, the between-group differences were not statistically significant or did not meet noninferiority criterion. CONCLUSIONS AND RELEVANCE Among patients with malignant metastatic solid tumors and spinal canal compression, a single radiotherapy dose, compared with a multifraction dose delivered over 5 days, did not meet the criterion for noninferiority for the primary outcome (ambulatory at 8 weeks). However, the extent to which the lower bound of the CI overlapped with the noninferiority margin should be considered when interpreting the clinical importance of this finding.	[Hoskin, Peter J.] Mt Vernon Canc Ctr, Rickmansworth Rd, Northwood HA6 2RN, Middx, England; [Hoskin, Peter J.] Univ Manchester, Manchester, Lancs, England; [Hopkins, Kirsten] Bristol Ctr Haematol & Oncol Bristol, Bristol, Avon, England; [Misra, Vivek] Christie Hosp, Manchester, Lancs, England; [Holt, Tanya] Univ Queensland, Princess Alexandra Hosp, Brisbane, Qld, Australia; [McMenemin, Rhona] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England; [Dubois, Danny] Queen Alexandra Hosp, Portsmouth, Hants, England; [McKinna, Fiona] Royal Sussex Cty Hosp, Brighton, E Sussex, England; [Foran, Bernadette; Brown, Gillian] Weston Pk Hosp, Sheffield, S Yorkshire, England; [Madhavan, Krishnaswamy; Thomas, Sharon Shibu] Southend Univ Hosp, Southend On Sea, England; [MacGregor, Carol; Arnott, Seonaid] Raigmore Hosp, Inverness, Scotland; [Bates, Andrew] Southampton Gen Hosp, Southampton, Hants, England; [O'Rourke, Noelle] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland; [Lester, Jason F.] Velindre Canc Ctr, Cardiff, S Glam, Wales; [Sevitt, Tim] Kent Oncol Ctr, Maidstone, Kent, England; [Roos, Daniel] Royal Adelaide Hosp, Adelaide, SA, Australia; [Roos, Daniel] Univ Adelaide, Adelaide, SA, Australia; [Dixit, Sanjay] Castle Hill Hosp, Kingston Upon Hull, N Humberside, England; [Forsyth, Sharon; Beare, Sandy; Reczko, Krystyna; Hackshaw, Allan; Lopes, Andre] CRUK & UCL Canc Trials Ctr, London, England	Mount Vernon Cancer Centre; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; University of Queensland; Newcastle Freeman Hospital; Newcastle University - UK; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; University of Brighton; Weston Park Hospital; University of Southampton; Beatson Oncology Centre; Velindre Cancer Centre; Royal Adelaide Hospital; University of Adelaide; University of Hull; University of London; University College London	Hoskin, PJ (corresponding author), Mt Vernon Canc Ctr, Rickmansworth Rd, Northwood HA6 2RN, Middx, England.	peterhoskin@nhs.net		Lopes, Andre/0000-0002-1405-7337; Bates, Andrew/0000-0002-4346-2788; Hoskin, Peter/0000-0001-8323-9567	University College London [UCL/09/0199]; CRUK Project Grants [C2422/7932, C2422/A11408, CRUK/06/034]; Cancer Council Queensland for Australian Site Data Management; UK National Institute of Health Research	University College London(General Electric); CRUK Project Grants; Cancer Council Queensland for Australian Site Data Management; UK National Institute of Health Research(National Institute for Health Research (NIHR))	The trial was sponsored by University College London (UCL/09/0199) and coordinated by the Cancer Research UK and UCL Cancer Trials Centre. The trial was funded by CRUK Project Grants C2422/7932 and C2422/A11408 (funder reference CRUK/06/034) and by the Cancer Council Queensland for Australian Site Data Management. UK trial centers were supported by the UK National Institute of Health Research.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Abu-Hegazy M, 2011, CHIN GER J CLIN ONCO, V10, P535, DOI [10.1007/s10330-011-0832-5, DOI 10.1007/S10330-011-0832-5]; [Anonymous], 1976, 45 MED RES COUNC; [Anonymous], 2008, MET SPIN CORD COMPR; Bekelman JE, 2013, JAMA-J AM MED ASSOC, V310, P1501, DOI 10.1001/jama.2013.277081; Borras JM, 2015, VALUE HEALTH, V18, pA481, DOI 10.1016/j.jval.2015.09.1311; Borras JM, 2015, RADIOTHER ONCOL, V116, P38, DOI 10.1016/j.radonc.2015.04.018; Chow E, 2012, CLIN ONCOL-UK, V24, P112, DOI 10.1016/j.clon.2011.11.004; Chow E, 2007, J CLIN ONCOL, V25, P1423, DOI 10.1200/JCO.2006.09.5281; Cocks K, 2011, J CLIN ONCOL, V29, P89, DOI 10.1200/JCO.2010.28.0107; Hartsell WF, 2005, JNCI-J NATL CANCER I, V97, P798, DOI 10.1093/jnci/dji139; Lee KA, 2018, ACTA ONCOL, V57, P965, DOI 10.1080/0284186X.2018.1433320; Lievens Y, 2014, RADIOTHER ONCOL, V112, P178, DOI 10.1016/j.radonc.2014.08.034; Lin CC, 2016, INT J RADIAT ONCOL, V94, P719, DOI 10.1016/j.ijrobp.2015.12.012; Loblaw DA, 2012, INT J RADIAT ONCOL, V84, P312, DOI 10.1016/j.ijrobp.2012.01.014; Loblaw DA, 1998, J CLIN ONCOL, V16, P1613, DOI 10.1200/JCO.1998.16.4.1613; Loblaw DA, 2005, J CLIN ONCOL, V23, P2028, DOI 10.1200/JCO.2005.00.067; Lutz S, 2017, PRACT RADIAT ONCOL, V7, P4, DOI 10.1016/j.prro.2016.08.001; Maranzano E, 2005, J CLIN ONCOL, V23, P3358, DOI 10.1200/JCO.2005.08.193; Maranzano E, 2009, RADIOTHER ONCOL, V93, P174, DOI 10.1016/j.radonc.2009.05.012; McDonald R, 2017, JAMA ONCOL, V3, P953, DOI 10.1001/jamaoncol.2016.6770; National Comprehensive Cancer Network (NCCN) guidelines in oncology, 2018, AD CANC PAIN VERS 1; National Institute for Health and Care Excellence, 2008, METASTATIC SPINAL CO; Oxford Cancer Intelligence Unit National Cancer Intelligence Network, TRAV TIM DIST RAD CT; Qu S, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001843; Rades D, 2018, ANTICANCER RES, V38, P1009, DOI 10.21873/anticanres.12316; Rades D, 2016, J CLIN ONCOL, V34, P597, DOI 10.1200/JCO.2015.64.0862; Raghunathan T.E., 2001, SURV METHODOL, V27, P85; Ryu S, 2015, J RADIOSURGERY SBRT, V3, P237; Schmidt Meic H, 2005, J Natl Compr Canc Netw, V3, P711; StataCorp, 2017, STAT 15 MULT IMP MAN; Thirion P, 2014, INT J RADIAT ONCOL, V90, P1263, DOI 10.1016/j.ijrobp.2014.10.036; van der Linden YM, 2006, RADIOTHER ONCOL, V78, P245, DOI 10.1016/j.radonc.2006.02.007	33	43	43	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	2019	322	21					2084	2094		10.1001/jama.2019.17913	http://dx.doi.org/10.1001/jama.2019.17913			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ6JE	31794625	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000505207400029
J	Mugglin, C; Haas, AD; van Oosterhout, JJ; Msukwa, M; Tenthani, L; Estill, J; Egger, M; Keiser, O				Mugglin, Catrina; Haas, Andreas D.; van Oosterhout, Joep J.; Msukwa, Malango; Tenthani, Lyson; Estill, Janne; Egger, Matthias; Keiser, Olivia			Long-term retention on antiretroviral therapy among infants, children, adolescents and adults in Malawi: A cohort study	PLOS ONE			English	Article							HIV-INFECTED PATIENTS; FOLLOW-UP; TREATMENT PROGRAMS; DRUG-RESISTANCE; PATIENTS LOST; RISK-FACTORS; CARE; ADHERENCE; INTERVENTIONS; INITIATION	Objectives We examine long-term retention of adults, adolescents and children on antiretroviral therapy under different HIV treatment guidelines in Malawi. Design Prospective cohort study. Setting and participants Adults and children starting ART between 2005 and 2015 in 21 health facilities in southern Malawi. Methods We used survival analysis to assess retention at clinic level, Cox regression to examine risk factors for loss to follow up, and competing risk analysis to assess long-term outcomes of people on antiretroviral therapy (ART). Results We included 132,274 individuals in our analysis, totalling 270,256 person years of follow up (PYFU; median per patient 1.3, interquartile range (IQR) 0.26-3.1), 62% were female and the median age was 32 years. Retention on ART was lower in the first year on ART compared to subsequent years for all guideline periods and age groups. Infants (0-3 years), adolescents and young adults (15-24 years) were at highest risk of LTFU. Comparing the different calendar periods of ART initiation we found that retention improved initially, but remained stable thereafter. Conclusion Even though the number of patients and the burden on health care system increased substantially during the study period of rapid ART expansion, retention on ART improved in the early years of ART provision, but gains in retention were not maintained over 5 years on ART. Reducing high attrition in the first year of ART should remain a priority for ART programs, and so should addressing poor retention among adolescents, young adults and men.	[Mugglin, Catrina; Haas, Andreas D.; Tenthani, Lyson; Estill, Janne; Egger, Matthias; Keiser, Olivia] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland; [van Oosterhout, Joep J.] Dignitas Int, Zomba, Malawi; [van Oosterhout, Joep J.] Univ Malawi, Coll Med, Dept Med, Blantyre, Malawi; [Msukwa, Malango] Baobab Hlth Trust, Lilongwe, Malawi; [Msukwa, Malango; Estill, Janne; Keiser, Olivia] Univ Geneva, Inst Global Hlth, Geneva, Switzerland; [Tenthani, Lyson] I TECH Malawi, Lilongwe, Malawi	University of Bern; University of Malawi; University of Geneva	Mugglin, C (corresponding author), Univ Bern, Inst Social & Prevent Med, Bern, Switzerland.	catrina.mugglin@ispm.unibe.ch	Haas, Andreas D./AAR-3187-2020	Haas, Andreas D./0000-0002-4849-181X; Mugglin, Catrina/0000-0001-7966-3939; Egger, Matthias/0000-0001-7462-5132	Bill and Melinda Gates Foundation [OPP1090200]; National Institute of Allergy And Infectious Diseases of the National Institutes of Health [U01AI069924]; Schweizerische Akademie der Medizinischen Wissenschaften (SAMW); Swiss National Science Foundation (SNF) [163878]; SNF Early Postdoc.Mobility Fellowship [P2BEP3_178602]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI069924] Funding Source: NIH RePORTER	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); National Institute of Allergy And Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Schweizerische Akademie der Medizinischen Wissenschaften (SAMW); Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF)); SNF Early Postdoc.Mobility Fellowship; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The study was funded by the Bill and Melinda Gates Foundation (OPP1090200), and the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under Award Number U01AI069924. CM was supported by a MD-PhD fellowship from Schweizerische Akademie der Medizinischen Wissenschaften (SAMW). OK was supported by a professorship grant from the Swiss National Science Foundation (SNF) (163878) and AH was partly supported by a SNF Early Postdoc.Mobility Fellowship (P2BEP3_178602). These funding organizations did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of author's salaries and research material. We would like to thank all the participants of the study, and the staff who collected the data. The study was funded by the Bill and Melinda Gates Foundation (OPP1090200), and the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under Award Number U01AI069924. CM was supported by a MD-PhD fellowship from Schweizerische Akademie der Medizinischen Wissenschaften (SAMW). OK was supported by professorship grant from the Swiss National Science Foundation (SNF)(163878) and AH was partly supported by a SNF Early Postdoc.Mobility Fellowship (P2BEP3_178602). These funding organizations did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of author's salaries and research material.	Adejumo OA, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20049; Attia S, 2009, AIDS, V23, P1397, DOI 10.1097/QAD.0b013e32832b7dca; Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790; Bucciardini R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136117; Douglas GP, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000319; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Fox MP, 2016, LANCET HIV, V3, pE554, DOI 10.1016/S2352-3018(16)30149-7; Fox MP, 2015, JAIDS-J ACQ IMM DEF, V69, P98, DOI 10.1097/QAI.0000000000000553; Fox MP, 2015, AIDS, V29, P493, DOI 10.1097/QAD.0000000000000559; Geng EH, 2016, CLIN INFECT DIS, V62, P935, DOI 10.1093/cid/civ1004; GRIMSRUD A, 2015, J INT AIDS SOC, V18, DOI DOI 10.7448/IAS.18.1; Grimsrud A, 2016, J EPIDEMIOL COMMUN H, V70, P549, DOI 10.1136/jech-2015-206629; Grimsrud AT, 2013, J CLIN EPIDEMIOL, V66, P1006, DOI 10.1016/j.jclinepi.2013.03.013; Gwynn RC, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0898-9; Haas AD, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25084; Haas AD, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21947; Haas AD, 2016, LANCET HIV, V3, pE175, DOI 10.1016/S2352-3018(16)00008-4; Harries AD, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3620-x; Harrigan PR, 2005, J INFECT DIS, V191, P339, DOI 10.1086/427192; Johnson LF, 2014, AM J EPIDEMIOL, V180, P1208, DOI 10.1093/aje/kwu295; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2014, 90 90 90 AMB TREATM, V40; Koole O, 2014, TROP MED INT HEALTH, V19, P1397, DOI 10.1111/tmi.12386; Koole Olivier, 2014, J Acquir Immune Defic Syndr, V67, pe27, DOI 10.1097/QAI.0000000000000252; Kranzer K, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21737; Lall P, 2015, J INT AIDS SOC, V18, P41, DOI 10.7448/IAS.18.2.19393; MacPherson P, 2015, TROP MED INT HEALTH, V20, P1015, DOI 10.1111/tmi.12517; Matyanga CMJ, 2016, PUBLIC HEALTH ACTION, V6, P97, DOI 10.5588/pha.15.0077; Meresse M, 2014, HIV MED, V15, P478, DOI 10.1111/hiv.12140; Mills EJ, 2014, LANCET HIV, V1, pE104, DOI 10.1016/S2352-3018(14)00003-4; Nachega JB, 2007, ANN INTERN MED, V146, P564, DOI 10.7326/0003-4819-146-8-200704170-00007; Nachega JB, 2016, PATIENT PREFER ADHER, V10, P683, DOI 10.2147/PPA.S100002; Okoboi S, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.5.20841; Rosen S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001056; Tenthani L, 2014, AIDS, V28, P589, DOI 10.1097/QAD.0000000000000143; Tiruneh YM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156619; Tweya H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075761; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013; Weigel R, 2012, AIDS, V26, P365, DOI 10.1097/QAD.0b013e32834ed814; Weigel R, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-31; Yehia BR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129376; Yehia BR, 2014, JAIDS-J ACQ IMM DEF, V65, P333, DOI 10.1097/QAI.0000000000000023; Zurcher K, 2017, TROP MED INT HEALTH, V22, P375, DOI 10.1111/tmi.12843	42	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2019	14	11							e0224837	10.1371/journal.pone.0224837	http://dx.doi.org/10.1371/journal.pone.0224837			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN2HK	31725750	Green Published, gold, Green Submitted			2023-01-03	WOS:000532764500032
J	Appleby, E; Gill, ST; Hayes, LK; Walker, TL; Walsh, M; Kumar, S				Appleby, Emma; Gill, Sophie Taylor; Hayes, Lucinda Kate; Walker, Tessa Lauren; Walsh, Matt; Kumar, Saravana			Effectiveness of telerehabilitation in the management of adults with stroke: A systematic review	PLOS ONE			English	Review							PHYSICAL FUNCTION; VIRTUAL-REALITY; OLDER-ADULTS; BALANCE; CARE; SATISFACTION; PROGRAM; REHABILITATION; TELEMEDICINE; RECOVERY	Background Stroke is a leading cause of mortality and morbidity and access to timely rehabilitation can reduce morbidity and help patients to return to normal life. Telerehabilitation can deliver rehabilitation services with the use of technology to increase patient options, deliver services more efficiently and overcome geographical barriers to healthcare access. Despite its popularity, there is conflicting evidence for its effectiveness. Therefore, the aim of this systematic review was to update the current evidence base on the effectiveness of telerehabilitation for stroke. Methods A systematic search of databases (Medline Ovid; Embase; Emcare; Scopus; The Cochrane Library; PEDro; OTSeeker) was conducted in April 2018 (updated in October 2018). This review was conducted and reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and methodology registered with PROSPERO (CRD42018090445). A modified McMaster critical appraisal tool for quantitative studies was used to assess the methodological quality of the included studies. Given the heterogeneity of the included studies, a descriptive synthesis was conducted. Results Out of 1868 studies, 13 randomised controlled trials met the inclusion criteria. A diverse range of interventions were delivered through a variety of telerehabilitation systems and the effectiveness measured through a myriad of outcome measures. Summarised findings from the heterogeneous evidence base indicate that telerehabilitation may have a positive impact on a range of primary and secondary outcomes. However, despite these positive findings, the current evidence lacks clarity and uniformity in terms of intervention parameters and measurement of outcomes, which limits broader application of these results. Discussion Telerehabilitation, as an alternate form of rehabilitation for people with stroke, shows potential. However, due to methodological and practical concerns, an unequivocal recommendation cannot be made. Findings from this review may inform future policies and practices regarding the use of telerehabilitation for stroke patients.	[Appleby, Emma; Gill, Sophie Taylor; Hayes, Lucinda Kate; Walker, Tessa Lauren; Walsh, Matt; Kumar, Saravana] Univ South Australia, Adelaide, SA, Australia	University of South Australia	Kumar, S (corresponding author), Univ South Australia, Adelaide, SA, Australia.	saravana.kumar@unisa.edu.au	Kumar, Saravana/B-8876-2009	Kumar, Saravana/0000-0002-4003-4411				An MJ, 2011, J NEUROSCI NURS, V43, P298, DOI 10.1097/JNN.0b013e318234ea24; Australian Institute of Health and Welfare, 2019, AUSTR HLTH 2018; Australian Institute of Health and Welfare, 2016, AUSTR HLTH 2016 AUST, V15; Carey JR, 2007, NEUROREHAB NEURAL RE, V21, P216, DOI 10.1177/1545968306292381; Chen J, 2017, AM J PHYS MED REHAB, V96, P152, DOI 10.1097/PHM.0000000000000559; Chen J, 2015, J STROKE CEREBROVASC, V24, P2660, DOI 10.1016/j.jstrokecerebrovasdis.2015.09.014; Chumbler NR, 2015, J TELEMED TELECARE, V21, P139, DOI 10.1177/1357633X15571995; Chumbler NR, 2012, STROKE, V43, P2168, DOI 10.1161/STROKEAHA.111.646943; Coleman K, 2009, NHMRC ADD LEV EV GRA; Deng HQ, 2012, PHYS THER, V92, P197, DOI 10.2522/ptj.20110018; Department of Health, 2015, TEL; Dodakian L, 2017, NEUROREHAB NEURAL RE, V31, P923, DOI 10.1177/1545968317733818; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Elion O, 2013, 2013 INT C VIRT REH; Forducey PG, 2012, PSYCHOL SERV, V9, P144, DOI 10.1037/a0028112; Hillier S, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-23; Huijgen BCH, 2008, J TELEMED TELECARE, V14, P249, DOI 10.1258/jtt.2008.080104; Julien M, 2017, PHYS OCCUP THER GERI, V35, P109, DOI 10.1080/02703181.2017.1356897; Khan F, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009509.pub3; Krpic A, 2013, INT J REHABIL RES, V36, P162, DOI 10.1097/MRR.0b013e32835dd63b; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Laver KE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010255.pub2; Law M., 2007, CRITICAL REV FORM QU; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lin KH, 2014, SENSORS-BASEL, V14, P12451, DOI 10.3390/s140712451; Llorens R, 2015, ARCH PHYS MED REHAB, V96, P418, DOI 10.1016/j.apmr.2014.10.019; Luker JA, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-161; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Piron L, 2008, J TELEMED TELECARE, V14, P257, DOI 10.1258/jtt.2008.080304; Piron L, 2009, J REHABIL MED, V41, P1016, DOI 10.2340/16501977-0459; Pollock A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001920.pub3; Schwamm LH, 2009, STROKE, V40, P2616, DOI 10.1161/STROKEAHA.109.192360; Stroke Foundation, 2018, POSTC UNT STROK AUST; Stroke Foundation, 2018, CLIN GUID STROK MAN; Stroke Foundation, 2018, NAT STROK AUD AC SER; Vahlberg B, 2017, DISABIL REHABIL, V39, P1207, DOI 10.1080/09638288.2016.1191551; van Duijnhoven HJR, 2016, STROKE, V47, P2603, DOI 10.1161/STROKEAHA.116.013839	37	46	48	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2019	14	11							e0225150	10.1371/journal.pone.0225150	http://dx.doi.org/10.1371/journal.pone.0225150			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN1MV	31714924	Green Accepted, gold, Green Published			2023-01-03	WOS:000532710400032
J	Pilaquinga, F; Morejon, B; Ganchala, D; Morey, J; Pina, N; Debut, A; Neira, M				Pilaquinga, Fernanda; Morejon, Bianca; Ganchala, Danny; Morey, Jeroni; Pina, Neus; Debut, Alexis; Neira, Marco			Green synthesis of silver nanoparticles using Solanum mammosum L. (Solanaceae) fruit extract and their larvicidal activity against Aedes aegypti L. (Diptera: Culicidae)	PLOS ONE			English	Article							INSECTICIDE RESISTANCE; MOSQUITOS; PESTICIDES; TOXICITY; EFFICACY; PLANT	The family of mosquitoes (Diptera: Culicidae) contains several species of major public health relevance due to their role as vectors of human disease. One of these species, Aedes aegypti, is responsible for the transmission of some of the most important vector-borne viruses affecting humankind, including dengue fever, chikungunya and Zika. Traditionally, control of Ae. aegypti and other arthropod species has relied on the use of a relatively small diversity of chemical insecticides. However, widespread and intensive use of these substances has caused significant adverse environmental effects and has contributed to the appearance of pesticide-resistant populations in an increasing number of locations around the world, thereby dramatically reducing their efficiency. Therefore, it becomes urgent to develop novel alternative tools for vector control. In that context, our study aimed at evaluating the insecticidal activity against Ae. aegypti of aqueous extracts obtained from the fruits of Solanum mammosum L., as well as silver nanoparticles synthesized using aqueous extracts from this plant species (SmAgNPs). To perform the test, third instar Ae. aegypti larvae were exposed to increasing concentrations of plant extract and SmAgNPs for 24 h. Our results suggest that both the aqueous extract and SmAgNPs were toxic to the larvae, with SmAgNPs displaying a much higher level of toxicity than the extract alone, as reflected in their LC50 values (0.06 ppm vs 1631.27 ppm, respectively). These results suggest that both S. mammosum extracts and SmAgNPs exhibit noteworthy larvicidal activity, and should be further explored as potential source of alternative tools in the fight against insect vectors of human disease.	[Pilaquinga, Fernanda; Morey, Jeroni; Pina, Neus] Univ Balearic Isl, Dept Chem, Palma De Mallorca, Balearic Island, Spain; [Pilaquinga, Fernanda; Ganchala, Danny] Pontificia Univ Catolica Ecuador, Dept Exact & Nat Sci, Lab Nanotechnol, Quito, Ecuador; [Morejon, Bianca; Neira, Marco] Pontificia Univ Catolica Ecuador, Ctr Res Hlth Latin Amer, Dept Exact & Nat Sci, Quito, Ecuador; [Debut, Alexis] Univ Fuerzas Armadas ESPE, Ctr Nanociencia & Nanotecnol, Sangolqui, Ecuador	Universitat de les Illes Balears; Pontificia Universidad Catolica del Ecuador; Pontificia Universidad Catolica del Ecuador; Escuela Politecnica Superior del Ejercito	Neira, M (corresponding author), Pontificia Univ Catolica Ecuador, Ctr Res Hlth Latin Amer, Dept Exact & Nat Sci, Quito, Ecuador.	mvneira@puce.edu.ec	Debut, Alexis/H-8424-2019; Morey, Jeroni/K-5426-2014; Piña, M Nieves/L-1190-2014	Debut, Alexis/0000-0002-8269-7619; Morey, Jeroni/0000-0002-9483-5433; Piña, M Nieves/0000-0002-3363-0004; Ganchala Vega, Danny/0000-0002-9386-4822; Pilaquinga, Fernanda/0000-0002-0841-6313; Morejon, Bianca/0000-0001-5142-8996; Neira, Marco/0000-0001-8068-5772	Pontificia Universidad Catolica del Ecuador [N13409, O13083]	Pontificia Universidad Catolica del Ecuador	This study was performed in part with funds from the following sources: MN received grant N13409 from Pontificia Universidad Catolica del Ecuador (website: www.puce.edu.ec).FP received grant O13083 from Pontificia Universidad Catolica del Ecuador (website: www.puce.edu.ec).All bioassays were performed using the infrastructure available at the Center for Research on Health in Latin America, Pontificia Universidad Cato ' lica del Ecuador. Nanoparticle characterization was performed with technical support provided by Universidad de las Islas Baleares Chemistry Department (Organic Chemistry Area) and ESPE's Laboratory for Nanomaterial Characterization. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	Aguirre A., 2016, THESIS; Aguirre-Obando OA, 2015, ZOOLOGIA-CURITIBA, V32, P14, DOI 10.1590/S1984-46702015000100003; Beltran DB, 2015, B MALARIOL SALUD AMB, V55, P173; Benelli G, 2016, PARASITOL RES, V115, P23, DOI 10.1007/s00436-015-4800-9; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Bisset J, 2006, J MED ENTOMOL, V43, P1185, DOI 10.1603/0022-2585(2006)43[1185:SOIAAA]2.0.CO;2; Borase H., 2013, J NANOMED BIOTHERAP, V3, P1, DOI [10.4172/2155-983X.1000111, DOI 10.4172/2155-983X.1000111]; Carvalho DO, 2014, JOVE-J VIS EXP, DOI 10.3791/3579; CDC, 2017, INT MOSQ MAN; CHOWANSKI S, 2016, TOXINS, V8, DOI DOI 10.3390/TOXINS5010060; Chowdhury N, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-10; Cook G, 2008, MANSONS TROPICAL DIS; De la Torre L., 2008, ENCICLOPEDIA PLANTAS; Desneux N, 2007, ANNU REV ENTOMOL, V52, P81, DOI 10.1146/annurev.ento.52.110405.091440; FINNEY D J, 1971, P333; Frierson J. Gordon, 2010, Yale Journal of Biology and Medicine, V83, P77; Garcia GD, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006227; Goindin D, 2017, INFECT DIS POVERTY, V6, DOI 10.1186/s40249-017-0254-x; Govindarajan M, 2016, RES VET SCI, V107, P95, DOI 10.1016/j.rvsc.2016.05.017; Gubler DJ, 2011, ASIA PACIFIC J MOL B, V19, P111; HAYA K, 1989, ENVIRON TOXICOL CHEM, V8, P381, DOI 10.1002/etc.5620080504; Jerzykiewicz Jolanta, 2007, Postepy Biochem, V53, P280; Jorgensen P.M., 1999, MONOGRAPHS SYSTEMATI, V75, P1; Kumar B, 2015, COGENT CHEM, V1, DOI 10.1080/23312009.2015.1120982; Kumar B, 2016, BIONANOSCIENCE, V6, P15, DOI 10.1007/s12668-016-0193-1; Kumar PM, 2012, PARASITOL RES, V110, P2541, DOI 10.1007/s00436-011-2797-2; Manjarres-Suarez Alejandra, 2013, Rev. costarric. salud pública, V22, P68; Margni M, 2002, AGR ECOSYST ENVIRON, V93, P379, DOI 10.1016/S0167-8809(01)00336-X; MILLER RH, 1969, BOT GAZ, V130, P230, DOI 10.1086/336496; Mondal NK, 2015, IJSR PUB, V3, P47; Morejon B, 2018, J NANOTECHNOL, V2018, DOI 10.1155/2018/6917938; Muktar Y, 2016, J TROP DIS, V4, DOI [10.4172/2329-891X.1000101, DOI 10.4172/2329-891X.1000101]; Murugan K, 2015, PARASITOL RES, V114, P4645, DOI 10.1007/s00436-015-4710-x; Patil CD, 2011, PARASITOL RES, V108, P1253, DOI 10.1007/s00436-010-2174-6; Pradeep T., 2003, TXB NANOSCIENCE NANO; Premalatha S, 2013, ASIAN PAC J TROP MED, V6, P854, DOI 10.1016/S1995-7645(13)60152-2; R Core Team, 2021, R LANG ENV STAT COMP; Raghavendra K, 2009, INDIAN J MED RES, V130, P74; Ramesh S, 2016, BIOMATER SCI-UK, V4, P1713, DOI 10.1039/c6bm00688d; Rawani A, 2013, ACTA TROP, V128, P613, DOI 10.1016/j.actatropica.2013.09.007; Roghelia V, 2017, RES REV J HLTH PROFE, V7, P30; Siegwart M, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.00381; Vizuete KS, 2017, GREEN PROCESS SYNTH, V6, P23, DOI 10.1515/gps-2016-0015; Sorescu A A, 2016, 4 INT VIRT C ADV SCI, V1, P188, DOI [10.18638/scieconf.2016.4.1.386, DOI 10.18638/SCIECONF.2016.4.1.386]; Spring P, 2016, 5 INT C INN RES ENG; Subramaniam J, 2015, ENVIRON SCI POLLUT R, V22, P20067, DOI 10.1007/s11356-015-5253-5; Thiyagarajan P., 2014, ACTA BIOL INDICA, V3, P527; VENABLES WN, 2002, MODERN APPL STAT S; Wu YL, 2016, INT J MOL SCI, V17, DOI [10.3390/ijms17020153, 10.3390/ijms17091534]; Yufera E., 1995, QUIMICA ORGANICA BAS	50	25	28	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2019	14	10							e0224109	10.1371/journal.pone.0224109	http://dx.doi.org/10.1371/journal.pone.0224109			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN0YA	31671165	gold, Green Published			2023-01-03	WOS:000532670600024
J	Kumar, S; Wong, PS; Hasan, SS; Kairuz, T				Kumar, Suresh; Wong, Pei Se; Hasan, Syed Shahzad; Kairuz, Therese			The relationship between sleep quality, inappropriate medication use and frailty among older adults in aged care homes in Malaysia	PLOS ONE			English	Article							DRUG BURDEN INDEX; OF-LIFE; PEOPLE; RESIDENTS; CRITERIA; DISTURBANCES; FALLS; RISK	Poor sleep quality is prevalent among older adults and is compounded by frailty and polypharmacy. This descriptive, cross-sectional study examines the associations between sleep quality, inappropriate medication use and frailty. The study was conducted among 151 residents of 11 aged care homes in three states in Malaysia; convenience sampling was used. Subjective sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), and Groningen Frailty Indicator (GFI) was used to assess frailty. Medication appropriateness was assessed using Drug burden Index (DBI), Potentially Inappropriate Medications (PIMs) and Potentially Inappropriate Prescriptions (PIPs). Most of the subjects (approximately 95%) reported poor sleep quality, as measured by a cut-off of global PSQI score of >= 5. With a second cut-off at 10, just over half (56%) reported moderately poor sleep quality followed by 39% who had very poor sleep quality. Most (90%) denied taking medication to improve their sleep during the previous month. There was no statistically significant association between medication inappropriateness (PIMs, PIPs, DBI) and global PSQI score. However, the average number of PIM was associated significantly with sleep efficiency (a measure of the actual 'sleep to total time spent in bed) (p = 0.037). The average number of PIP was associated with subjective sleep quality (p = 0.045) and the use of sleep medications (p = 0.001), and inversely associated with sleep disturbance (0.049). Furthermore, frailty correlated significantly with poor overall sleep quality (p = 0.032). Findings support the need for medication review to identify and reduce PIMs and optimise prescriptions to improve sleep quality and hence, related health outcomes among residents of aged care homes.	[Kumar, Suresh; Wong, Pei Se] Int Med Univ, Dept Pharm Practice, Kuala Lumpur, Malaysia; [Hasan, Syed Shahzad] Univ Huddersfield, Dept Pharm, Huddersfield, W Yorkshire, England; [Hasan, Syed Shahzad; Kairuz, Therese] Univ Newcastle, Sch Biol Sci & Pharm, Newcastle, NSW, Australia	International Medical University Malaysia; University of Huddersfield; University of Newcastle	Hasan, SS (corresponding author), Univ Huddersfield, Dept Pharm, Huddersfield, W Yorkshire, England.; Hasan, SS (corresponding author), Univ Newcastle, Sch Biol Sci & Pharm, Newcastle, NSW, Australia.	s.hasan@hud.ac.uk	R, Suresh Kumar B/I-2946-2018; Hasan, Syed Shahzad/V-9082-2018	R, Suresh Kumar B/0000-0002-2806-1986; Hasan, Syed Shahzad/0000-0002-4058-2215; Wong, Pei Se/0000-0002-3958-0001	International Medical University	International Medical University	We wish to express our gratitude to the International Medical University for supporting our study and to all aged care homes and residents for their generous participation.	Azri MA, 2016, PROCD SOC BEHV, V234, P74, DOI 10.1016/j.sbspro.2016.10.221; Backhaus J, 2002, J PSYCHOSOM RES, V53, P737, DOI 10.1016/S0022-3999(02)00330-6; Becker NB, 2017, PSYCHOL HEALTH MED, V22, P889, DOI 10.1080/13548506.2016.1274042; Bosboom PR, 2012, DEMENT GER COGN D EX, V2, P361, DOI 10.1159/000342172; Bourgeois J, 2014, DRUG AGING, V31, P677, DOI 10.1007/s40266-014-0203-3; Bourgeois J, 2013, SLEEP MED, V14, P614, DOI 10.1016/j.sleep.2013.03.012; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Byerly MJ, 2001, DRUG AGING, V18, P45, DOI 10.2165/00002512-200118010-00004; Carlson LE, 2005, INT J BEHAV MED, V12, P278, DOI 10.1207/s15327558ijbm1204_9; Carpenter JS, 1998, J PSYCHOSOM RES, V45, P5, DOI 10.1016/S0022-3999(97)00298-5; Chapman JB, 2006, PAIN MED, V7, P105, DOI 10.1111/j.1526-4637.2006.00110.x; Miguel MDC, 2010, EUR GERIATR MED, V1, P9, DOI 10.1016/j.eurger.2009.12.002; Draugalis JR, 2009, AM J PHARM EDUC, V73, DOI 10.5688/aj7308142; Grandner Michael A, 2006, Sleep Biol Rhythms, V4, P129, DOI 10.1111/j.1479-8425.2006.00207.x; Hagg M, 2014, SCAND J CARING SCI, V28, P842, DOI 10.1111/scs.12119; HANLON JT, 1992, J CLIN EPIDEMIOL, V45, P1045, DOI 10.1016/0895-4356(92)90144-C; Hasan SS, 2017, NEUROEPIDEMIOLOGY, V49, P82, DOI 10.1159/000480433; Hasan SS, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007929; Hilmer SN, 2007, ARCH INTERN MED, V167, P781, DOI 10.1001/archinte.167.8.781; Hosseini Habibollah, 2011, Iran J Nurs Midwifery Res, V16, P55; Kwon AM, 2016, ASIA-PAC J PUBLIC HE, V28, P271, DOI 10.1177/1010539516628638; Llorca PM, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1213-6; Lo CMH, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-72; Luo J, 2013, PLOS ONE, V8; Lwanga S.K., 1991, SAMPLE SIZE DETERMIN; Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2; Maust DT, 2015, JAMA PSYCHIAT, V72, P438, DOI 10.1001/jamapsychiatry.2014.3018; Neikrug AB, 2010, J NUTR HEALTH AGING, V14, P207, DOI 10.1007/s12603-010-0051-8; Ng BJ, 2018, DRUGS AGING; O'Mahony D, 2010, EUR GERIATR MED, V1, P45, DOI 10.1016/j.eurger.2010.01.007; O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145; Peters LL, 2012, J AM MED DIR ASSOC, V13, P546, DOI 10.1016/j.jamda.2012.04.007; Radcliff S, 2015, J AM GERIATR SOC, V63, P2227, DOI 10.1111/jgs.13702; Rashid Abdul, 2012, Iran J Nurs Midwifery Res, V17, P512; Schuurmans H, 2004, J GERONTOL A-BIOL, V59, P962; Sterke CS, 2012, J CLIN PHARMACOL, V52, P947, DOI 10.1177/0091270011405665; Tel H, 2013, NEUROL PSYCHIAT BR, V19, P48, DOI DOI 10.1016/J.NPBR.2012.10.002; Tsai YF, 2008, J CLIN NURS, V17, P1219, DOI 10.1111/j.1365-2702.2007.02020.x; Westbury JL, 2018, MED J AUSTRALIA, V208, P398, DOI 10.5694/mja17.00857; Wilson NM, 2011, J AM GERIATR SOC, V59, P875, DOI 10.1111/j.1532-5415.2011.03386.x; Wu CY, 2012, J CHIN MED ASSOC, V75, P75, DOI 10.1016/j.jcma.2011.12.011	41	10	11	3	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2019	14	10							e0224122	10.1371/journal.pone.0224122	http://dx.doi.org/10.1371/journal.pone.0224122			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM9KP	31622445	gold, Green Published			2023-01-03	WOS:000532567300098
J	Kim, RY; Kwon, S; Ra, H				Kim, Rae Young; Kwon, Soonil; Ra, Ho			Gravity influences bevacizumab distribution in an undisturbed balanced salt solution in vitro	PLOS ONE			English	Article							INTRAVITREAL BEVACIZUMAB; VITRECTOMY; PHARMACOKINETICS	Purpose The effects of gravity on bevacizumab or the recommended head position after intraocular bevacizumab injection have not been reported. To evaluate the effect of gravity on bevacizumab in vitro, we added bevacizumab to the upper part of a test tube filled with balanced salt solution (BSS) and examined its distribution over time. Materials and methods Sixty-four test tubes were divided equally into two groups; group 1 (32, collected from upper part of the tube) and group 2 (32, collected from lower part of the tube). Each test tube was filled with 5 mL BSS before bevacizumab (1.25 mg/0.05 mL) was added, and then stored at 36 degrees C. Bevacizumab concentration in 8 test tubes from each group was measured at 12, 24, 48, and 168 h using an enzyme-linked immunosorbent analysis (ELISA) kit. Mann-Whitney and Jonckheere-Terpstra tests were used for statistical analysis. Results Bevacizumab concentration was significantly higher in Group 2 than in Group 1 at 12, 24, 48, and 168 h (12, 24, 48, and 168 h; P < 0.01 each; Mann-Whitney test). The mean change in bevacizumab concentration over time tended to increase in Group 1 (P < 0.01; Jonckheere-Terpstra test), but tended to decrease in Group 2 (P < 0.01; Jonckheere-Terpstra test). Conclusions The significant differences in concentration between the upper and lower parts even after a considerable amount of storage time showed that bevacizumab did not dissolve immediately and diffused evenly throughout the solution. It appeared that more bevacizumab settled in the lower part of the tube than in the upper part because of gravitational force. However, the concentration difference between the upper and lower parts decreased as bevacizumab gradually diffused over time, indicating that the difference in concentration due to gravity was more significant at the beginning of bevacizumab injection.	[Kim, Rae Young; Ra, Ho] Catholic Univ Korea, Coll Med, Dept Ophthalmol & Visual Sci, Seoul, South Korea; [Kwon, Soonil] Hallym Univ, Dept Ophthalmol, Sacred Heart Hosp, Anyang, South Korea	Catholic University of Korea; Hallym University	Ra, H (corresponding author), Catholic Univ Korea, Coll Med, Dept Ophthalmol & Visual Sci, Seoul, South Korea.; Kwon, S (corresponding author), Hallym Univ, Dept Ophthalmol, Sacred Heart Hosp, Anyang, South Korea.	magicham@hallym.or.kr; raho@catholic.ac.kr		Ra, Ho/0000-0001-9671-2210; Kwon, Soonil/0000-0003-1543-981X				Ahn J, 2013, J OCUL PHARMACOL TH, V29, P612, DOI 10.1089/jop.2013.0009; Cheema RA, 2010, RETINA-J RET VIT DIS, V30, P1646, DOI 10.1097/IAE.0b013e3181d6def0; Christoforidis JB, 2013, RETINA-J RET VIT DIS, V33, P946, DOI 10.1097/IAE.0b013e3182753b12; Ferenchak K, 2014, RETINA-J RET VIT DIS, V34, P1177, DOI 10.1097/IAE.0000000000000058; Jaissle GB, 2007, OPHTHAL SURG LAS IM, V38, P238, DOI 10.3928/15428877-20070501-10; Jooybar E, 2014, MATH BIOSCI, V255, P11, DOI 10.1016/j.mbs.2014.06.008; LIM JI, 1994, ARCH OPHTHALMOL-CHIC, V112, P1363, DOI 10.1001/archopht.1994.01090220113032; Moss SE, 1998, OPHTHALMOLOGY, V105, P998, DOI 10.1016/S0161-6420(98)96025-0; Smiddy WE, 1999, SURV OPHTHALMOL, V43, P491, DOI 10.1016/S0039-6257(99)00036-3; Xu Y, 2012, INVEST OPHTH VIS SCI, V53, P5221, DOI 10.1167/iovs.12-9702	10	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2019	14	10							e0223418	10.1371/journal.pone.0223418	http://dx.doi.org/10.1371/journal.pone.0223418			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM7CZ	31584989	Green Published, gold			2023-01-03	WOS:000532407600031
J	Csenkey, A; Jozsa, G; Gede, N; Pakai, E; Tinusz, B; Rumbus, Z; Lukacs, A; Gyongyi, Z; Hamar, P; Sepp, R; Romanovsky, AA; Hegyi, P; Vajda, P; Garami, A				Csenkey, Alexandra; Jozsa, Gergo; Gede, Noemi; Pakai, Eszter; Tinusz, Benedek; Rumbus, Zoltan; Lukacs, Anita; Gyongyi, Zoltan; Hamar, Peter; Sepp, Robert; Romanovsky, Andrej A.; Hegyi, Peter; Vajda, Peter; Garami, Andras			Systemic antibiotic prophylaxis does not affect infectious complications in pediatric burn injury: A meta-analysis	PLOS ONE			English	Article							RISK-FACTORS; EPIDEMIOLOGY; MANAGEMENT; CHILDREN; PREVENTION; GUIDELINES; CARE	In pediatric burns the use of systemic antibiotic prophylaxis is a standard procedure in some burn centers, though its beneficial effect on the infectious complications is debated. The present meta-analysis aimed at determining whether systemic antibiotic prophylaxis prevents infectious complications in pediatric patients with burn injuries. We searched the PubMed, EMBASE, and Cochrane Library databases from inception to August 2019. We included 6 studies, in which event rates of infectious complications were reported in children with burn injuries receiving or not receiving systemic antibiotic prophylaxis. We found that the overall odds ratio (OR) of developing an infection (including local and systemic) was not different between the groups (OR = 1.35; 95% CI, 0.44, 4.18). The chances for systemic infectious complications alone were also not different between antibiotic-treated and non-treated patients (OR = 0.74; 95% CI, 0.38, 1.45). Based on the age, affected total body surface area, and country income level, we did not find any subgroup that benefited from the prophylaxis. Our findings provide quantitative evidence for the inefficacy of systemic antibiotic prophylaxis in preventing infections in pediatric burns. To validate our conclusion, multinational, randomized trials in a diverse population of children with burn injuries are warranted.	[Csenkey, Alexandra; Jozsa, Gergo; Pakai, Eszter; Rumbus, Zoltan; Garami, Andras] Univ Pecs, Med Sch, Inst Translat Med, Dept Thermophysiol, Pecs, Hungary; [Csenkey, Alexandra; Jozsa, Gergo; Vajda, Peter] Univ Pecs, Dept Paediat, Surg Div, Pecs, Hungary; [Gede, Noemi; Tinusz, Benedek; Hamar, Peter; Hegyi, Peter] Univ Pecs, Med Sch, Inst Translat Med, Pecs, Hungary; [Lukacs, Anita] Univ Szeged, Fac Med, Dept Publ Hlth, Szeged, Hungary; [Gyongyi, Zoltan] Univ Pecs, Med Sch, Dept Publ Hlth Med, Pecs, Hungary; [Sepp, Robert] Univ Szeged, Dept Internal Med 2, Szeged, Hungary; [Sepp, Robert] Univ Szeged, Cardiol Ctr, Szeged, Hungary; [Romanovsky, Andrej A.] St Josephs Hosp, Thermoregulat & Syst Inflammat Lab, Trauma Res, FeverLab, Phoenix, AZ USA	University of Pecs; University of Pecs; University of Pecs; Szeged University; University of Pecs; Szeged University; Szeged University; St. Joseph's Hospital and Medical Center	Garami, A (corresponding author), Univ Pecs, Med Sch, Inst Translat Med, Dept Thermophysiol, Pecs, Hungary.	andras.garami@aok.pte.hu	Garami, Andras/AAF-8588-2020; Gyöngyi, Zoltán/B-6433-2014; VAJDA, Peter/K-4603-2013	Garami, Andras/0000-0003-2493-0571; Gyöngyi, Zoltán/0000-0001-9330-9119; VAJDA, Peter/0000-0002-4835-6458; Romanovsky, Andrej/0000-0003-3772-8575; Lukacs, Anita/0000-0002-0746-8920	National Research, Development and Innovation Office [FK 124483]; Medical School, University of Pecs [KA-2019-27]; Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary [20765-3/2018/FEKUTSTRAT]; GINOP STAY ALIVE [2.3.2-15-2016-00048]; EFOP LIVE LONGER [3.6.2-16-2017-00006]; Janos Bolyai Scholarship of the Hungarian Academy of Sciences	National Research, Development and Innovation Office(National Research, Development & Innovation Office (NRDIO) - Hungary); Medical School, University of Pecs; Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary; GINOP STAY ALIVE; EFOP LIVE LONGER; Janos Bolyai Scholarship of the Hungarian Academy of Sciences(Hungarian Academy of Sciences)	This work was supported by the National Research, Development and Innovation Office (FK 124483 to AG), the Medical School, University of Pecs (KA-2019-27 to AG), the Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary (20765-3/2018/FEKUTSTRAT to PH and AG), GINOP STAY ALIVE (2.3.2-15-2016-00048 to PH), and EFOP LIVE LONGER (3.6.2-16-2017-00006 to PH). AG acknowledges the Janos Bolyai Scholarship of the Hungarian Academy of Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahuja RB, 2016, BURNS, V42, P953, DOI 10.1016/j.burns.2016.05.013; Avni T, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c241; Barajas-Nava LA, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008738.pub2; Brusselaers N, 2010, CRIT CARE, V14, DOI 10.1186/cc9300; Celko AM, 2009, B WORLD HEALTH ORGAN, V87, P374, DOI 10.2471/BLT.08.059535; Chahed Jamila, 2014, Afr J Paediatr Surg, V11, P323, DOI 10.4103/0189-6725.143141; Church D, 2006, CLIN MICROBIOL REV, V19, P403, DOI 10.1128/CMR.19.2.403-434.2006; Davies A, 2017, BURNS, V43, P215, DOI 10.1016/j.burns.2016.07.032; Ergun O, 2004, EUR J PEDIATR SURG, V14, P422, DOI 10.1055/s-2004-821065; Geyik MF, 2003, AM J INFECT CONTROL, V31, P342, DOI 10.1016/S0196-6553(02)48226-0; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hyder AA, 2009, B WORLD HEALTH ORGAN, V87, P345, DOI 10.2471/BLT.08.055798; Jamshidi R, 2013, PEDIATR REV, V34, P395, DOI 10.1542/pir.34-9-395; Krishnamoorthy Vijay, 2012, Int J Crit Illn Inj Sci, V2, P128, DOI 10.4103/2229-5151.100889; Laitakari E, 2015, J PEDIATR SURG, V50, P608, DOI 10.1016/j.jpedsurg.2014.05.034; Lee F, 2009, J TROP PEDIATRICS, V55, P73, DOI 10.1093/tropej/fmp017; Lymperopoulos NS, 2015, J BURN CARE RES, V36, P565, DOI 10.1097/BCR.0000000000000210; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Mulgrew S, 2014, ANN PLAS SURG, V72, P34, DOI 10.1097/SAP.0b013e31829be8be; Natterer J, 2009, SWISS MED WKLY, V139, P535, DOI smw-12605; Olah E, 2018, J NEUROTRAUM, V35, P2407, DOI 10.1089/neu.2018.5649; PAPINI RPG, 1995, BRIT J SURG, V82, P505, DOI 10.1002/bjs.1800820423; Park JO, 2009, BURNS, V35, P482, DOI 10.1016/j.burns.2008.10.007; Peck MD, 2011, BURNS, V37, P1087, DOI 10.1016/j.burns.2011.06.005; Rashid A, 2005, BURNS, V31, P981, DOI 10.1016/j.burns.2005.06.017; Rawlins JM, 2007, PEDIATR EMERG CARE, V23, P289, DOI 10.1097/01.pec.0000248698.42175.2b; Rodgers GL, 2000, PEDIATR INFECT DIS J, V19, P990, DOI 10.1097/00006454-200010000-00010; Rumbus Z, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170152; Sengoelge Mathilde, 2017, Prev Med Rep, V6, P115, DOI 10.1016/j.pmedr.2017.02.024; Sheridan RL, 2001, J TRAUMA, V51, P352, DOI 10.1097/00005373-200108000-00022; Smolle C, 2017, BURNS, V43, P249, DOI 10.1016/j.burns.2016.08.013; Rosanova MT, 2013, ARCH ARGENT PEDIATR, V111, P303, DOI [10.5546/aap.2013.303, 10.5546/aap.2013.eng.303]; Thorpe KE, 2018, HEALTH AFFAIR, V37, P662, DOI 10.1377/hlthaff.2017.1153; Turner RM, 2012, INT J EPIDEMIOL, V41, P818, DOI 10.1093/ije/dys041; Vloemans AFPM, 2011, BURNS, V37, P1161, DOI 10.1016/j.burns.2011.05.001; Wells G.A., 2000, NEWCASTLE OTTAWA SCA; Williams FN, 2009, CRIT CARE, V13, DOI 10.1186/cc8170	39	10	10	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2019	14	9							e0223063	10.1371/journal.pone.0223063	http://dx.doi.org/10.1371/journal.pone.0223063			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM5WE	31553768	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000532319200053
J	Beaglehole, R; Bates, C; Youdan, B; Bonita, R				Beaglehole, Robert; Bates, Clive; Youdan, Ben; Bonita, Ruth			Nicotine without smoke: fighting the tobacco epidemic with harm reduction	LANCET			English	Editorial Material									[Beaglehole, Robert; Bonita, Ruth] Univ Auckland, Auckland 0624, New Zealand; [Bates, Clive] Counterfactual Consulting Ltd, London, England; [Youdan, Ben] ASH NZ, Heart Fdn, Auckland, New Zealand	University of Auckland	Beaglehole, R (corresponding author), Univ Auckland, Auckland 0624, New Zealand.	r.beaglehole@auckland.ac.nz		Bates, Clive/0000-0002-4106-7119				Abrams DB, 2018, COMMUNICATION   1001; [Anonymous], 2019, REPORT COMMISSIONED; ASH, 2019, FACT SHEET US E CIG; ASH New Zealand, 2018 ASH YEAR 10 SNA; E-cigarette Intelligence, 2019, KEY GLOB CIG MARK DA; European Commission, 2017, EUR SPEC SURV 458 AT; Gentzke AS, 2019, MMWR-MORBID MORTAL W, V68, P157, DOI 10.15585/mmwr.mm6806e1; Ghebreyesus TA, 2019, LANCET, V394, P548, DOI 10.1016/S0140-6736(19)31730-1; Hajek P, 2019, NEW ENGL J MED, V380, P629, DOI 10.1056/NEJMoa1808779; Hammond D, 2019, BMJ-BRIT MED J, V365, P1212; Hartmann-Boyce J, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub5; Jackson SE, 2019, ADDICTION, V114, P1627, DOI 10.1111/add.14656; Japan Tobacco, JAP DOM CIG SAL RES; Kozlowski Lynn T, 2017, Drug Alcohol Depend, V174, P209, DOI 10.1016/j.drugalcdep.2017.01.001; National Academies of Sciences Engineering and Medicine, 2018, PUBL HLTH CONS E CIG; Notley C, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0237-7; Polosa R, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0187-5; RUSSELL MAH, 1976, BRIT MED J, V1, P1430, DOI 10.1136/bmj.1.6023.1430; Schluger N., 2018, TOBACCO ATLAS; Tobacco Advisory Group of the Royal College of Physicians, 2016, NIC SMOK TOB HARM RE; US Food and Drug Administration, 2019, PREM TOB PROD MARK O; World Health Organization, 2019, WHO REP GLOB TOB EP; Zhu SH, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3262	23	29	29	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	2019	394	10200					718	720		10.1016/S0140-6736(19)31884-7	http://dx.doi.org/10.1016/S0140-6736(19)31884-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IT6UW	31478489				2023-01-03	WOS:000483011400012
J	Alam, MM; Sanchez-Azqueta, A; Janha, O; Flannery, EL; Mahindra, A; Mapesa, K; Char, AB; Sriranganadane, D; Brancucci, NMB; Antonova-Koch, Y; Crouch, K; Simwela, NV; Millar, SB; Akinwale, J; Mitcheson, D; Solyakov, L; Dudek, K; Jones, C; Zapatero, C; Doerig, C; Nwakanma, DC; Vazquez, MJ; Colmenarejo, G; Lafuente-Monasterio, MJ; Leon, ML; Godoi, PHC; Elkins, JM; Waters, AP; Jamieson, AG; Alvaro, EF; Ranford-Cartwright, LC; Marti, M; Winzeler, EA; Gamo, FJ; Tobin, AB				Alam, Mahmood M.; Sanchez-Azqueta, Ana; Janha, Omar; Flannery, Erika L.; Mahindra, Amit; Mapesa, Kopano; Char, Aditya B.; Sriranganadane, Dev; Brancucci, Nicolas M. B.; Antonova-Koch, Yevgeniya; Crouch, Kathryn; Simwela, Nelson Victor; Millar, Scott B.; Akinwale, Jude; Mitcheson, Deborah; Solyakov, Lev; Dudek, Kate; Jones, Carolyn; Zapatero, Cleofe; Doerig, Christian; Nwakanma, Davis C.; Jesus Vazquez, Maria; Colmenarejo, Gonzalo; Jose Lafuente-Monasterio, Maria; Luisa Leon, Maria; Godoi, Paulo H. C.; Elkins, Jon M.; Waters, Andrew P.; Jamieson, Andrew G.; Fernandez Alvaro, Elena; Ranford-Cartwright, Lisa C.; Marti, Matthias; Winzeler, Elizabeth A.; Javier Gamo, Francisco; Tobin, Andrew B.			Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target	SCIENCE			English	Article							PLASMODIUM-FALCIPARUM MALARIA; PRP4 KINASE; TRI-SNRNP; PARASITE; RESISTANCE; REVEALS; DEUBIQUITINASE; ARTEMISININ; PIPERAQUINE; INHIBITORS	The requirement for next-generation antimalarials to be both curative and transmission-blocking necessitates the identification of previously undiscovered druggable molecular pathways. We identified a selective inhibitor of the Plasmodium falciparum protein kinase PfCLK3, which we used in combination with chemogenetics to validate PfCLK3 as a drug target acting at multiple parasite life stages. Consistent with a role for PfCLK3 in RNA splicing, inhibition resulted in the down-regulation of more than 400 essential parasite genes. Inhibition of PfCLK3 mediated rapid killing of asexual liver-and blood-stage P. falciparum and blockade of gametocyte development, thereby preventing transmission, and also showed parasiticidal activity against P. berghei and P. knowlesi. Hence, our data establish PfCLK3 as a target for drugs, with the potential to offer a cure-to be prophylactic and transmission blocking in malaria.	[Alam, Mahmood M.; Crouch, Kathryn; Simwela, Nelson Victor; Millar, Scott B.; Waters, Andrew P.; Marti, Matthias] Univ Glasgow, Wellcome Ctr Integrat Parasitol, Glasgow G12 8QQ, Lanark, Scotland; [Sanchez-Azqueta, Ana; Janha, Omar; Tobin, Andrew B.] Univ Glasgow, Ctr Translat Pharmacol, Inst Mol Cell & Syst Biol, Glasgow G12 8QQ, Lanark, Scotland; [Flannery, Erika L.] Novartis Inst Biomed Res, Emeryville, CA 94608 USA; [Mahindra, Amit; Mapesa, Kopano; Jamieson, Andrew G.] Univ Glasgow, Sch Chem, Glasgow G12 8QQ, Lanark, Scotland; [Char, Aditya B.; Ranford-Cartwright, Lisa C.] Univ Glasgow, Coll Med Vet & Life Sci, Inst Biodivers Anim Hlth & Comparat Med, Glasgow G12 8QQ, Lanark, Scotland; [Sriranganadane, Dev; Godoi, Paulo H. C.] Univ Estadual Campinas, Struct Genom Consortium, BR-13083886 Campinas, SP, Brazil; [Brancucci, Nicolas M. B.] Swiss Trop & Publ Hlth Inst, Dept Med Parasitol & Infect Biol, CH-4051 Basel, Switzerland; [Antonova-Koch, Yevgeniya; Winzeler, Elizabeth A.] Univ Calif San Diego, Sch Med, Skaggs Sch Pharmaceut Sci, UC Hlth Sci Ctr Immunol Infect & Inflammat, La Jolla, CA 92093 USA; [Akinwale, Jude; Solyakov, Lev; Dudek, Kate; Jones, Carolyn] Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; [Mitcheson, Deborah] Univ Leicester, Dept Mol Cell Biol, Leicester LE1 9HN, Leics, England; [Zapatero, Cleofe; Jesus Vazquez, Maria; Jose Lafuente-Monasterio, Maria; Luisa Leon, Maria; Fernandez Alvaro, Elena; Javier Gamo, Francisco] GlaxoSmithKline, Dis Dev World, Madrid 28760, Spain; [Doerig, Christian] RMIT Univ, Sch Hlth & Biomed Sci, Biomed Sci Cluster, Melbourne, Vic 3000, Australia; [Nwakanma, Davis C.] MRC Unit Gambia, Banjul, Gambia; [Colmenarejo, Gonzalo] IMDEA Food Inst, Biostat & Bioinformat Unit, Madrid 28049, Spain; [Elkins, Jon M.] Univ Oxford, Nuffield Dept Clin Med, Struct Genom Consortium, Oxford OX3 7DQ, England	University of Glasgow; University of Glasgow; Novartis; University of Glasgow; University of Glasgow; Universidade Estadual de Campinas; University of Basel; Swiss Tropical & Public Health Institute; University of California System; University of California San Diego; University of Leicester; University of Leicester; GlaxoSmithKline; Royal Melbourne Institute of Technology (RMIT); University of London; London School of Hygiene & Tropical Medicine; University of Oxford	Tobin, AB (corresponding author), Univ Glasgow, Ctr Translat Pharmacol, Inst Mol Cell & Syst Biol, Glasgow G12 8QQ, Lanark, Scotland.	andrew.tobin@glasgow.ac.uk	Alam, Mahmood/GQQ-9664-2022; Sriranganadane, Dev/M-6249-2015; Millar, Scott/GPX-7987-2022; Colmenarejo, Gonzalo/Q-6535-2018; Simwela, Nelson/AAF-3013-2021; Crouch, Kathryn/HDO-6240-2022; Winzeler, Elizabeth/AAP-6752-2020; Godoi, Paulo HC/B-9847-2012; Ranford-Cartwright, Lisa/H-4701-2013	Sriranganadane, Dev/0000-0003-1818-1420; Colmenarejo, Gonzalo/0000-0002-8249-4547; Simwela, Nelson/0000-0002-4734-0518; Crouch, Kathryn/0000-0001-9310-4762; Winzeler, Elizabeth/0000-0002-4049-2113; Godoi, Paulo HC/0000-0003-1859-3513; Janha, Dr Omar/0000-0002-9121-2396; Brancucci, Nicolas/0000-0003-0655-3266; Millar, Scott/0000-0003-1718-1947; MAHINDRA, AMIT/0000-0001-5439-2466; Ranford-Cartwright, Lisa/0000-0003-1992-3940; Char, Aditya/0000-0002-9910-1244; Antonova-Koch, Yevgeniya/0000-0003-2862-0407	MRC Toxicology Unit program; MRC Developmental Gap Fund; Lord Kelvin Adam Smith Fellowship; GSK Open Lab Foundation Award; MRC Toxicology Unit; MRC Unit the Gambia PhD program; Wellcome Centre for Integrative Parasitology Core [WT104111AIA]; NIH [5R01AI090141, R01AI103058]; Bill & Melinda Gates Foundation [OPP1086217, OPP1141300]; Medicines for Malaria Venture (MMV); WT award [172862-01]; Royal Society; AbbVie; Bayer Pharma AG; Canada Foundation for Innovation; Eshelman Institute for Innovation; Genome Canada; Innovative Medicines Initiative (European Union [EU]/European Federation of Pharmaceutical Industries and Associations [EFPIA]) (ULTRA-DD grant) [115766]; Janssen; Merck Company; Merck KGaA; Novartis Pharma AG; Ontario Ministry of Economic Development and Innovation; Pfizer; Sao Paulo Research Foundation (FAPESP) [2013/50724-5]; Takeda; Wellcome Trust [106169/ZZ14/Z]; Tres Cantos Lab Foundation [TC125]; Scottish Funding Council Global Challenges Research Fund; Boehringer Ingelheim; Daphne Jackson Fellowship; EPSRC [1954365] Funding Source: UKRI; MRC [MC_PC_14117] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI103058, R01AI090141] Funding Source: NIH RePORTER	MRC Toxicology Unit program; MRC Developmental Gap Fund; Lord Kelvin Adam Smith Fellowship; GSK Open Lab Foundation Award; MRC Toxicology Unit(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC Unit the Gambia PhD program; Wellcome Centre for Integrative Parasitology Core; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Medicines for Malaria Venture (MMV); WT award; Royal Society(Royal Society of London); AbbVie(AbbVie); Bayer Pharma AG; Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Eshelman Institute for Innovation; Genome Canada(Genome Canada); Innovative Medicines Initiative (European Union [EU]/European Federation of Pharmaceutical Industries and Associations [EFPIA]) (ULTRA-DD grant); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Merck Company(Merck & Company); Merck KGaA; Novartis Pharma AG; Ontario Ministry of Economic Development and Innovation; Pfizer(Pfizer); Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Takeda(Takeda Pharmaceutical Company Ltd); Wellcome Trust(Wellcome Trust); Tres Cantos Lab Foundation; Scottish Funding Council Global Challenges Research Fund; Boehringer Ingelheim(Boehringer Ingelheim); Daphne Jackson Fellowship; EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by an MRC Toxicology Unit program grant (A.B.T., M.M.A.), MRC Developmental Gap Fund (A.S.-A.), Lord Kelvin Adam Smith Fellowship (M.M.A.), GSK Open Lab Foundation Award (A. S.-A.), joint MRC Toxicology Unit and MRC Unit the Gambia PhD program (O.J.), and Daphne Jackson Fellowship (D.M.). A.P.W., M.M., M.M. A., K.C., N.V.S., and S.B.M. are supported by Wellcome Centre for Integrative Parasitology Core support award WT104111AIA. E.A.W. is supported by grants from the NIH (5R01AI090141 and R01AI103058) and by grants from the Bill & Melinda Gates Foundation (OPP1086217, OPP1141300) as well as by Medicines for Malaria Venture (MMV). Drug WR99210 for selection of transgenic parasites was a gift from Jacobus Pharmaceuticals. M. M. is supported through WT award 172862-01 and a Wolfson Merit award from the Royal Society. The Structural Genomics Consortium (SGC) is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, the Canada Foundation for Innovation, the Eshelman Institute for Innovation, Genome Canada, the Innovative Medicines Initiative (European Union [EU]/European Federation of Pharmaceutical Industries and Associations [EFPIA]) (ULTRA-DD grant no. 115766), Janssen, Merck & Company, Merck KGaA, Novartis Pharma AG, the Ontario Ministry of Economic Development and Innovation, Pfizer, the Sao Paulo Research Foundation (FAPESP number 2013/50724-5), Takeda, and the Wellcome Trust (106169/ZZ14/Z). E.F.A. was supported by the Tres Cantos Lab Foundation (grant TC125). A.B.C. was supported by a Scottish Funding Council Global Challenges Research Fund award to L.C.R.-C.	Agarwal S, 2011, J CELL BIOCHEM, V112, P1295, DOI 10.1002/jcb.23034; Alam MM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8285; Amaratunga C, 2016, LANCET INFECT DIS, V16, P357, DOI 10.1016/S1473-3099(15)00487-9; [Anonymous], 2017, R LANG ENV STAT COMP; Ariey F, 2014, NATURE, V505, P50, DOI 10.1038/nature12876; Axel R, 2005, ANGEW CHEM INT EDIT, V44, P6110, DOI 10.1002/anie.200501726; Bates D, 2013, J STAT SOFTW, V52, P1, DOI 10.18637/jss.v052.i05; Brancucci NMB, 2017, CELL, V171, P1532, DOI 10.1016/j.cell.2017.10.020; Brancucci NMB, 2015, NAT PROTOC, V10, P1131, DOI 10.1038/nprot.2015.072; Burnham KP, 2011, BEHAV ECOL SOCIOBIOL, V65, P23, DOI 10.1007/s00265-010-1029-6; Burrows JN, 2017, MALARIA J, V16, DOI 10.1186/s12936-016-1675-x; Bushell E, 2017, CELL, V170, P260, DOI 10.1016/j.cell.2017.06.030; Carter R, 1993, Methods Mol Biol, V21, P67; Collins CR, 2013, MOL MICROBIOL, V88, P687, DOI 10.1111/mmi.12206; Doerig C, 2008, TRENDS PARASITOL, V24, P570, DOI 10.1016/j.pt.2008.08.007; Doerig C, 2015, NAT REV MICROBIOL, V13, P160, DOI 10.1038/nrmicro3402; Doerig C, 2010, BBA-PROTEINS PROTEOM, V1804, P604, DOI 10.1016/j.bbapap.2009.10.009; Dranchak P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057888; Fidock DA, 2004, NAT REV DRUG DISCOV, V3, P509, DOI 10.1038/nrd1416; Fraile JM, 2017, J BIOL CHEM, V292, P4164, DOI 10.1074/jbc.M116.762757; Gamo FJ, 2010, NATURE, V465, P305, DOI 10.1038/nature09107; Gao Q, 2013, J BIOL CHEM, V288, P30125, DOI 10.1074/jbc.M113.473348; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Goodyer ID, 1997, EXP PARASITOL, V86, P158, DOI 10.1006/expr.1997.4156; Gross S, 2015, J CLIN INVEST, V125, P1780, DOI 10.1172/JCI76094; Guiguemde WA, 2010, NATURE, V465, P311, DOI 10.1038/nature09099; Hadjivassiliou H, 2014, RNA, V20, P656, DOI 10.1261/rna.042838.113; Hui R, 2015, TRENDS PHARMACOL SCI, V36, P452, DOI 10.1016/j.tips.2015.04.011; Johnson LN, 2009, Q REV BIOPHYS, V42, P1, DOI 10.1017/S0033583508004745; Kafsack BFC, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-187; Kern S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105732; Lasonder E, 2012, MICROBES INFECT, V14, P811, DOI 10.1016/j.micinf.2012.04.008; Leang R, 2015, ANTIMICROB AGENTS CH, V59, P4719, DOI 10.1128/AAC.00835-15; Lourido S, 2010, NATURE, V465, P359, DOI 10.1038/nature09022; Lucet IS, 2012, FUTURE MED CHEM, V4, P2295, DOI [10.4155/FMC.12.183, 10.4155/fmc.12.183]; Makarova OV, 2001, EMBO J, V20, P2553, DOI 10.1093/emboj/20.10.2553; McNamara CW, 2013, NATURE, V504, P248, DOI 10.1038/nature12782; Nakagawa S, 2017, J R SOC INTERFACE, V14, DOI 10.1098/rsif.2017.0213; Plouffe D, 2008, P NATL ACAD SCI USA, V105, P9059, DOI 10.1073/pnas.0802982105; Roskoski R, 2015, PHARMACOL RES, V100, P1, DOI 10.1016/j.phrs.2015.07.010; Rottmann M, 2010, SCIENCE, V329, P1175, DOI 10.1126/science.1193225; Sanz LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030949; Schneider M, 2010, NAT STRUCT MOL BIOL, V17, P216, DOI 10.1038/nsmb.1718; Solyakov L, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1558; Spangenberg T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062906; Straimer J, 2015, SCIENCE, V347, P428, DOI 10.1126/science.1260867; Swann J, 2016, ACS INFECT DIS, V2, P281, DOI 10.1021/acsinfecdis.5b00143; Talevich E, 2011, BMC EVOL BIOL, V11, DOI 10.1186/1471-2148-11-321; Tewari R, 2010, CELL HOST MICROBE, V8, P377, DOI 10.1016/j.chom.2010.09.006; Zhang M, 2018, SCIENCE, V360, P506, DOI 10.1126/science.aap7847; Zhou ZH, 2013, CHROMOSOMA, V122, P191, DOI 10.1007/s00412-013-0407-z	51	35	35	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 30	2019	365	6456					884	+	eaau1682	10.1126/science.aau1682	http://dx.doi.org/10.1126/science.aau1682			57	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IV0NL	31467193	Green Accepted, Green Submitted			2023-01-03	WOS:000483975800038
J	Tesfaye, BT; Gudina, EK; Bosho, DD; Mega, TA				Tesfaye, Behailu Terefe; Gudina, Esayas Kebede; Bosho, Dula Dessalegn; Mega, Teshale Ayele			Short-term clinical outcomes of patients admitted with chronic liver disease to selected teaching hospitals in Ethiopia	PLOS ONE			English	Article							HEPATIC-ENCEPHALOPATHY; DECOMPENSATED CIRRHOSIS; RISK-FACTORS; BURDEN; MORTALITY; COMPLICATIONS; FAILURE; ASCITES	Background Chronic liver disease (CLD) is a progressive destruction of liver tissue with subsequent necrosis that persists for at least 6 months. In Ethiopia, despite the high burden report, data on CLD is limited. The objective of this study was to assess short-term clinical outcomes in patients admitted with chronic liver disease to three tertiary teaching hospitals in Ethiopia and to identify predictors of mortality. Methods A cohort of 109 patients admitted with CLD to three tertiary teaching hospitals in Ethiopia, were prospectively followed from the time of admission to 30-days of hospital discharge. The study was conducted from April 1, 2018, to October 5, 2018. Kaplan-Maier curve was used to estimate survival and cox-regression analysis to identify predictors of mortality. Result A total of 109 patients (80% male) diagnosed with CLD were included. Median age of the participants was 38(IQR, 30-48). The overall median length of hospital stay was 7(IQR, 4-11) days. Of the total, 39(35.8%) patients were HBsAg positive, and 12(11%) patients were anti-HCV positive. The 30-day mortality was 38(34.9%), and most of the deaths, 31 (81.6%) occurred before hospital discharge. Hepatic encephalopathy at admission; being with unidentified risk factor/etiologies of CLD and total bilirubin level were independent predictors of in-hospital mortality. Patients with hepatic encephalopathy at admission had approximately 11 times increased risk of death as compared to patients without hepatic encephalopathy at admission. Similarly, the hazard of mortality was 5.8 times higher in those patients with unidentified risk factor/etiology as compared to others. The risk of dying had also increased with an increase in bilirubin (1.188[95% CI, 1.0719-1.316]) level. Conclusion Approximately one-quarter of patients with CLD died during their hospital stay, and the risk of death continued after hospital discharge. Hepatic encephalopathy at admission, unidentified risk factor/etiology and increased level of total bilirubin are poor prognostic factors. Given that more than one third the patients had HBV-infection, access to antiviral drugs could help improve the prognosis of patients with end-stage liver disease in Ethiopia, as well as prevent the progression of the disease if initiated earlier.	[Tesfaye, Behailu Terefe; Bosho, Dula Dessalegn; Mega, Teshale Ayele] Jimma Univ, Sch Pharm, Dept Clin Pharm, Jimma, Ethiopia; [Gudina, Esayas Kebede] Jimma Univ, Sch Med, Dept Internal Med, Jimma, Ethiopia	Jimma University; Jimma University	Tesfaye, BT (corresponding author), Jimma Univ, Sch Pharm, Dept Clin Pharm, Jimma, Ethiopia.	terefebh@gmail.com	Gudina, Esayas Kebede/AAX-2374-2020; MEGA, TESHALE AYELE/AAE-6330-2022; Tesfaye, Behailu Terefe/AAL-6003-2020	Gudina, Esayas Kebede/0000-0002-6264-9695; Tesfaye, Behailu Terefe/0000-0002-4512-2111				Adhanom M, 2017, ETHIOPIAN MED J, V55, P267; Ashenafi W, 2017, POPUL HEALTH METR, V15, P1; Bajaj JS, 2017, CLIN GASTROENTEROL H, V15, P565, DOI 10.1016/j.cgh.2016.09.157; Charif I., 2014, OPEN J GASTROENTEROL, V4, P141, DOI DOI 10.4236/OJGAS.2014.43021; Cordoba J, 2014, J HEPATOL, V60, P275, DOI 10.1016/j.jhep.2013.10.004; Ethiopian data portal, 2017, WORLD GDP CAP RANK 2; Fagan KJ, 2014, INTERN MED J, V44, P865, DOI 10.1111/imj.12491; Federal Democratic Republic of Ethiopia, 2009, HLTH DEV, P2; Garcia-Tsao G, 2010, HEPATOLOGY, V51, P1445, DOI 10.1002/hep.23478; Giannousis IP, 2010, EUR J GASTROEN HEPAT, V22, P172, DOI 10.1097/MEG.0b013e328331115b; Heidelbaugh JJ, 2006, AM FAM PHYSICIAN, V74, P767; Hsiang JC, 2014, INTERN MED J, P160; Institute for Health Metrics and Evaluation (IHME), 2018, GBD COMP DAT VIS; Jimma university HMIS, 2017, HOSP PROF; Kasper D, 2015, HARRISONS PRINCIPLES, P2031; Kim Bong Sik Matthew, 2014, World J Gastrointest Pathophysiol, V5, P467, DOI 10.4291/wjgp.v5.i4.467; Kooffreh-Ada M., 2015, IOSR J MED DENT SCI, V14, P6; Levesque E, 2012, J HEPATOL, V56, P95, DOI 10.1016/j.jhep.2011.06.024; Magnus S, 2018, BMC GASTROENTEROL BM, V18, P1; Moriwaki H, 2010, J GASTROEN HEPATOL, V25, P858, DOI 10.1111/j.1440-1746.2010.06242.x; Mukherjee PS, 2017, PLOS ONE, V10, P1; Murphy S, 2017, DEATHS FINAL DATA 20; NICE, 2017, LIV DIS QUAL STAND, P1; Nusrat S, 2014, WORLD J GASTROENTERO, V20, P5442, DOI 10.3748/wjg.v20.i18.5442; Review World Population, 2018, ETH POP 2018; Samonakis DN, 2014, WORLD J HEPATOL, V6, P504, DOI 10.4254/wjh.v6.i7.504; St Paul's Millennium Medical College, WHO WE AR; Tanaka A, 2015, HEPATOL RES, V45, P994, DOI [10.1111/hepr.12442, DOI 10.1111/HEPR.12442]; Topdagi O, 2014, EURASIAN J MED, V46, P110, DOI 10.5152/eajm.2014.25; TSEGA E, 1992, ETHIOPIAN MED J, V30, P1; Udompap P, 2015, CLIN GASTROENTEROL H, V13, P2031, DOI 10.1016/j.cgh.2015.08.015; UNDP, 2018, HUMAN DEV INDICES IN; Vicco MH, 2015, REV ASSOC MED BRAS, V61, P35, DOI 10.1590/1806-9282.61.01.035; Wang FS, 2014, HEPATOLOGY, V60, P2099, DOI 10.1002/hep.27406; Warren A, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0257-6; Weldearegawi B, 2013, HEALTH POLICY PLANN, V28, P891, DOI 10.1093/heapol/czs135; World Health Organization, 2016, GLOB HLTH SECT STRAT; World Health Organization, 2017, GLOB ACT PLAN PUBL H; Zubieta-Rodriguez R., 2017, INTEGR MED RES, V82, P203, DOI [10.1016/j.rgmxen.2016.10.005, DOI 10.1016/J.RGMXEN.2016.10.005]	39	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2019	14	8							e0221806	10.1371/journal.pone.0221806	http://dx.doi.org/10.1371/journal.pone.0221806			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW6BO	31469861	Green Submitted, gold, Green Published			2023-01-03	WOS:000485062200030
J	Mackle, D; Bellomo, MNR; Bailey, M; Beasley, R; Deane, A; Eastwood, G; Finfer, S; Freebairn, R; King, V; Linke, N; Litton, E; McArthur, C; McGuinness, S; Panwar, R; Young, P				Mackle, Diane; Bellomo, M. N. Rinaldo; Bailey, Michael; Beasley, Richard; Deane, Adam; Eastwood, Glenn; Finfer, Simon; Freebairn, Ross; King, Victoria; Linke, Natalie; Litton, Edward; McArthur, Colin; McGuinness, Shay; Panwar, Rakshit; Young, Paul		ICU-ROX Investigators; Australian New Zealand Intens C	Conservative Oxygen Therapy during Mechanical Ventilation in the ICU	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTENSIVE-CARE-UNIT; ARTERIAL HYPEROXIA; CARDIAC-ARREST; METAANALYSIS; ASSOCIATION; MULTICENTER; MORTALITY; TARGETS; ILL	Background Patients who are undergoing mechanical ventilation in the intensive care unit (ICU) often receive a high fraction of inspired oxygen (Fio(2)) and have a high arterial oxygen tension. The conservative use of oxygen may reduce oxygen exposure, diminish lung and systemic oxidative injury, and thereby increase the number of ventilator-free days (days alive and free from mechanical ventilation). Methods We randomly assigned 1000 adult patients who were anticipated to require mechanical ventilation beyond the day after recruitment in the ICU to receive conservative or usual oxygen therapy. In the two groups, the default lower limit for oxygen saturation as measured by pulse oximetry (Spo(2)) was 90%. In the conservative-oxygen group, the upper limit of the Spo(2) alarm was set to sound when the level reached 97%, and the Fio(2) was decreased to 0.21 if the Spo(2) was above the acceptable lower limit. In the usual-oxygen group, there were no specific measures limiting the Fio(2) or the Spo(2). The primary outcome was the number of ventilator-free days from randomization until day 28. Results The number of ventilator-free days did not differ significantly between the conservative-oxygen group and the usual-oxygen group, with a median duration of 21.3 days (interquartile range, 0 to 26.3) and 22.1 days (interquartile range, 0 to 26.2), respectively, for an absolute difference of -0.3 days (95% confidence interval [CI], -2.1 to 1.6; P=0.80). The conservative-oxygen group spent more time in the ICU with an Fio(2) of 0.21 than the usual-oxygen group, with a median duration of 29 hours (interquartile range, 5 to 78) and 1 hour (interquartile range, 0 to 17), respectively (absolute difference, 28 hours; 95% CI, 22 to 34); the conservative-oxygen group spent less time with an Spo(2) exceeding 96%, with a duration of 27 hours (interquartile range, 11 to 63.5) and 49 hours (interquartile range, 22 to 112), respectively (absolute difference, 22 hours; 95% CI, 14 to 30). At 180 days, mortality was 35.7% in the conservative-oxygen group and 34.5% in the usual-oxygen group, for an unadjusted odds ratio of 1.05 (95% CI, 0.81 to 1.37). Conclusions In adults undergoing mechanical ventilation in the ICU, the use of conservative oxygen therapy, as compared with usual oxygen therapy, did not significantly affect the number of ventilator-free days. (Funded by the Health Research Council of New Zealand; ICU-ROX Australian and New Zealand Clinical Trials Registry number, ACTRN12615000957594.)	[Mackle, Diane; Beasley, Richard; Freebairn, Ross; McArthur, Colin; McGuinness, Shay; Young, Paul] Med Res Inst New Zealand, Wellington, New Zealand; [Young, Paul] Wellington Hosp, Intens Care Unit, Wellington, New Zealand; [Freebairn, Ross] Hawkes Bay Hosp, Intens Care Unit, Hastings, New Zealand; [McArthur, Colin] Auckland City Hosp, Dept Crit Care Med, Auckland, New Zealand; [McGuinness, Shay] Auckland City Hosp, Cardiothorac & Vasc Intens Care Unit, Auckland, New Zealand; [Bellomo, M. N. Rinaldo; Bailey, Michael; King, Victoria; Linke, Natalie] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [Bellomo, M. N. Rinaldo; Eastwood, Glenn] Austin Hosp, Intens Care Unit, Heidelberg, Vic, Australia; [Bellomo, M. N. Rinaldo; Bailey, Michael; Deane, Adam] Univ Melbourne, Parkville, Vic, Australia; [Deane, Adam] Royal Melbourne Hosp, Intens Care Unit, Parkville, Vic, Australia; [Finfer, Simon] George Inst Global Hlth, Div Crit Care & Trauma, Sydney, NSW, Australia; [Finfer, Simon] Royal North Shore Hosp, Malcolm Fisher Dept Intens Care Med, St Leonards, NSW, Australia; [Litton, Edward] Fiona Stanley Hosp, Intens Care Unit, Murdoch, WA, Australia; [Panwar, Rakshit] John Hunter Hosp, Intens Care Unit, New Lambton Hts, NSW, Australia; [Panwar, Rakshit] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia	Medical Research Institute Of New Zealand; Auckland City Hospital; Auckland City Hospital; Monash University; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Royal Melbourne Hospital; George Institute for Global Health; University of Sydney; Royal North Shore Hospital; John Hunter Hospital; University of Newcastle	Young, P (corresponding author), Wellington Reg Hosp, Intens Care Unit, Private Bag 7902, Wellington, New Zealand.	paulyoung@ccdhb.org.nz	Bailey, Michael J/A-4499-2012; Deane, Adam/AAF-7370-2020; litton, edward/C-5384-2017	Bailey, Michael J/0000-0002-5551-1401; Deane, Adam/0000-0002-7620-5577; Panwar, Rakshit/0000-0001-9090-8829; Wigmore, Geoffrey/0000-0003-0989-5640; Grieve, Richard/0000-0001-8899-1301; litton, edward/0000-0002-5125-6829; McGuinness, Shay/0000-0003-0620-4787; Young, Paul/0000-0002-3428-3083; Raith, Eamon/0000-0001-7060-2283; Freebairn, Ross/0000-0002-1967-8183; Finfer, Simon/0000-0002-2785-5864; Linke, Natalie/0000-0002-4727-547X	Health Research Council of New Zealand	Health Research Council of New Zealand(Health Research Council of New Zealand)	Supported by the Health Research Council of New Zealand.	Asfar P, 2017, LANCET RESP MED, V5, P180, DOI 10.1016/S2213-2600(17)30046-2; Badia X, 2001, INTENS CARE MED, V27, P1901, DOI 10.1007/s00134-001-1137-x; Chu DK, 2018, LANCET, V391, P1693, DOI 10.1016/S0140-6736(18)30479-3; Davydow Dimitry S, 2013, Ann Am Thorac Soc, V10, P450, DOI 10.1513/AnnalsATS.201303-060OC; Ferguson ND, 2016, JAMA-J AM MED ASSOC, V316, P1553, DOI 10.1001/jama.2016.13800; Girardis M, 2016, JAMA-J AM MED ASSOC, V316, P1583, DOI 10.1001/jama.2016.11993; Helmerhorst HJF, 2017, CRIT CARE MED, V45, P187, DOI 10.1097/CCM.0000000000002084; Helmerhorst HJF, 2015, CRIT CARE MED, V43, P1508, DOI 10.1097/CCM.0000000000000998; Helmerhorst HJF, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/s13613-014-0023-y; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Hodgson CL, 2016, CRIT CARE MED, V44, P1145, DOI 10.1097/CCM.0000000000001643; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOENKER R., 1993, J R STAT SOC C-APPL, V43, P410, DOI DOI 10.2307/2986030; Lehmann E.L., 2006, NONPARAMETRICS STAT; Mackle DM, 2018, CRIT CARE RESUSC, V20, P22; Panwar R, 2013, ANAESTH INTENS CARE, V41, P505, DOI 10.1177/0310057X1304100412; Panwar R, 2016, AM J RESP CRIT CARE, V193, P43, DOI 10.1164/rccm.201505-1019OC; Pilcher J, 2012, RESUSCITATION, V83, P417, DOI 10.1016/j.resuscitation.2011.12.021; Ridgeon E, 2016, CRIT CARE RESUSC, V18, P50; Roberts BW, 2018, CIRCULATION, V137, P2114, DOI 10.1161/CIRCULATIONAHA.117.032054; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Suzuki S, 2014, CRIT CARE MED, V42, P1414, DOI 10.1097/CCM.0000000000000219; Weir J, 2012, J NEUROTRAUM, V29, P53, DOI 10.1089/neu.2011.2137; Young PJ, 2017, CRIT CARE RESUSC, V19, P344; Young PJ, 2015, CRIT CARE RESUSC, V17, P202	26	187	189	4	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 12	2020	382	11					989	998		10.1056/NEJMoa1903297	http://dx.doi.org/10.1056/NEJMoa1903297			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU7TA	31613432	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000519914300005
J	Thomsen, MK; Skouboe, MK; Boularan, C; Vernejoul, F; Lioux, T; Leknes, SL; Berthelsen, MF; Riedel, M; Cai, HQ; Joseph, JV; Perouzel, E; Tiraby, M; Vendelbo, MH; Paludan, SR				Thomsen, Martin K.; Skouboe, Morten K.; Boularan, Cedric; Vernejoul, Fabienne; Lioux, Thierry; Leknes, Siv L.; Berthelsen, Martin F.; Riedel, Maria; Cai, Huiqiang; Joseph, Justin, V; Perouzel, Eric; Tiraby, Michele; Vendelbo, Mikkel H.; Paludan, Soren R.			The cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma	ONCOGENE			English	Article							INTERFERON-ALPHA; CANCER; DNA; ACTIVATION; INFLAMMATION; IMMUNITY; CELLS; HEPATOCYTES; CONTRIBUTES; REGRESSION	Hepatocellular carcinoma (HCC) is the most common primary liver cancer, and the incidence of HCC is increasing. Recently, cancer immunotherapy has emerged as an efficient treatment against some cancers. Here we have used a mouse model of mutagen-induced HCC to explore the therapeutic usefulness of targeting the DNA-activated STING pathway in HCC. STING-deficient mice exhibited unaltered initial development of HCC, but had higher number of large tumors at late stages of disease. In the liver of STING-deficient HCC mice, we observed reduced levels of phospho-STAT1, autophagy, and cleaved caspase3. These responses were activated in the liver by treatment with a cyclic dinucleotide (CDN) STING agonist. Importantly, CDN treatment of mice after HCC development efficiently reduced tumor size. Initiation of CDN treatment at an even later stage of disease to allow HCC detection by MR scanning revealed that the majority of tumors regressed in response to CDN, but new tumors were also detected, which were unresponsive to CDN treatment. Overall, the modulation of the STING pathway affects the development of HCC, and holds promise for a use as a treatment of this disease, most likely in combination with other immunomodulatory treatments such as PD1 inhibitors or with standard of care.	[Thomsen, Martin K.; Skouboe, Morten K.; Vendelbo, Mikkel H.; Paludan, Soren R.] Univ Aarhus, Dept Biomed, Hoegh Guldberg Gade 10, Aarhus C, Denmark; [Thomsen, Martin K.; Leknes, Siv L.; Berthelsen, Martin F.; Riedel, Maria; Cai, Huiqiang; Joseph, Justin, V] Univ Aarhus, Dept Clin Med, Palle Juul Jensens Blvd 82, DK-8200 Aarhus N, Denmark; [Boularan, Cedric; Vernejoul, Fabienne; Lioux, Thierry; Perouzel, Eric; Tiraby, Michele] InvivoGen, Toulouse, France; [Vendelbo, Mikkel H.] Aarhus Univ Hosp, Dept Nucl Med, Aarhus, Denmark; [Vendelbo, Mikkel H.] Aarhus Univ Hosp, PET Ctr, Aarhus, Denmark	Aarhus University; Aarhus University; Aarhus University; Aarhus University	Thomsen, MK; Paludan, SR (corresponding author), Univ Aarhus, Dept Biomed, Hoegh Guldberg Gade 10, Aarhus C, Denmark.; Thomsen, MK (corresponding author), Univ Aarhus, Dept Clin Med, Palle Juul Jensens Blvd 82, DK-8200 Aarhus N, Denmark.	mkt@clin.au.dk; srp@biomed.au.dk	Thomsen, Martin/AAU-5014-2021	Thomsen, Martin/0000-0002-5055-7531; Riedel, Maria/0000-0002-6545-0243; Skouboe, Morten Kelder/0000-0001-9358-5500; Vendelbo, Mikkel Holm/0000-0003-0431-2522	Danish Medical Research Council [12-124330, DFF-6110-00068]; Lundbeck Foundation [R198-2015-171]; InvivoGen; Danish Cancer Society [R146-A9394-16-S2, R204-A12490]; Ministry of health [4-1612-236/7]; AUFF NOVA [E-2o15-FLS-9-8]	Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Lundbeck Foundation(Lundbeckfonden); InvivoGen; Danish Cancer Society(Danish Cancer Society); Ministry of health; AUFF NOVA	We thank Mette Simonsen for assistant with scanning, Latifa Bakiri for thoroughly reading and comments on the manuscript, and Kirsten S Petersen for technical assistance. This work was funded by the Danish Medical Research Council (grants nos: 12-124330 and DFF-6110-00068), the Lundbeck Foundation (grant no R198-2015-171), and an unrestricted research grant from InvivoGen (all to SRP). MKT was funded by a fellowship sponsored by InvivoGen, Danish Cancer Society (R146-A9394-16-S2 and R204-A12490), Ministry of health (4-1612-236/7), and AUFF NOVA (E-2o15-FLS-9-8).	Ahn J, 2015, ONCOGENE, V34, P5302, DOI 10.1038/onc.2014.457; Ahn J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4723; Ariff B, 2009, WORLD J GASTROENTERO, V15, P1289, DOI 10.3748/wjg.15.1289; Bakiri L, 2013, MOL ONCOL, V7, P206, DOI 10.1016/j.molonc.2013.01.005; Chen DS, 2018, P NATL ACAD SCI USA, V115, P3930, DOI 10.1073/pnas.1717190115; Cheon H, 2014, SEMIN ONCOL, V41, P156, DOI 10.1053/j.seminoncol.2014.02.002; Corrales L, 2015, CLIN CANCER RES, V21, P4774, DOI 10.1158/1078-0432.CCR-15-1362; Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031; Diner EJ, 2013, CELL REP, V3, P1355, DOI 10.1016/j.celrep.2013.05.009; Gao P, 2014, CELL REP, V8, P1668, DOI 10.1016/j.celrep.2014.08.010; Gulen MF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00573-w; Haanen JBAG, 2015, PROG TUMOR RES, V42, P55, DOI 10.1159/000437178; Hou J, 2014, CANCER CELL, V25, P49, DOI 10.1016/j.ccr.2013.11.011; Iurescia S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00711; Jessy Thomas, 2011, J Nat Sci Biol Med, V2, P43, DOI 10.4103/0976-9668.82318; Larkin B, 2017, J IMMUNOL, V199, P397, DOI 10.4049/jimmunol.1601999; Lau L, 2015, SCIENCE, V350, P568, DOI 10.1126/science.aab3291; Li K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020404; Li T, 2018, J EXP MED, V215, P1287, DOI 10.1084/jem.20180139; Lucas ED, 2018, J IMMUNOL, V45, P520; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Muhlbauer M, 2006, J HEPATOL, V45, P520, DOI 10.1016/j.jhep.2006.05.007; Ohkuri T, 2014, CANCER IMMUNOL RES, V2, P1199, DOI 10.1158/2326-6066.CIR-14-0099; Paludan SR, 2019, NAT REV IMMUNOL, V19, P141, DOI 10.1038/s41577-018-0117-0; Paludan SR, 2015, MICROBIOL MOL BIOL R, V79, P225, DOI 10.1128/MMBR.00061-14; Parker BS, 2016, NAT REV CANCER, V16, P131, DOI 10.1038/nrc.2016.14; Prabakaran T, 2018, EMBO J, V37, DOI 10.15252/embj.201797858; Rasmussen SB, 2011, J IMMUNOL, V187, P5268, DOI 10.4049/jimmunol.1100949; Sakamaki A, 2017, WORLD J GASTROENTERO, V23, P3797, DOI 10.3748/wjg.v23.i21.3797; Schlageter M, 2014, WORLD J GASTROENTERO, V20, P15955, DOI 10.3748/wjg.v20.i43.15955; Schoggins JW, 2014, NATURE, V505, P691, DOI 10.1038/nature12862; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Skouboe MK, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006976; Sokolowska O, 2018, ARCH IMMUNOL THER EX, V66, P125, DOI 10.1007/s00005-017-0481-7; Sze A, 2013, CELL HOST MICROBE, V14, P422, DOI 10.1016/j.chom.2013.09.009; Takahashi A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03555-8; Thomsen MK, 2016, HEPATOLOGY, V64, P746, DOI 10.1002/hep.28685; vanRooijen N, 1996, J IMMUNOL METHODS, V193, P93, DOI 10.1016/0022-1759(96)00056-7; Wang H, 2017, P NATL ACAD SCI USA, V114, P1637, DOI 10.1073/pnas.1621363114; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Yeung JT, 2013, CLIN CANCER RES, V19, P1816, DOI 10.1158/1078-0432.CCR-12-2861; Young A, 2018, CANCER IMMUNOL RES, V6, P1445, DOI 10.1158/2326-6066.CIR-18-0487; Yu YS, 2019, J CLIN INVEST, V129, P546, DOI 10.1172/JCI121842; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zhang CX, 2019, CELL DEATH DIFFER, V26, P2314, DOI 10.1038/s41418-019-0302-0; Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051; Zhu QF, 2014, J IMMUNOL, V193, P4779, DOI 10.4049/jimmunol.1402051	47	27	27	3	31	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1652	1664		10.1038/s41388-019-1108-8	http://dx.doi.org/10.1038/s41388-019-1108-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740782				2023-01-03	WOS:000514923000003
J	Lanza, E; Muglia, R; Bolengo, I; Poretti, D; D'Antuono, F; Ceriani, R; Torzilli, G; Pedicini, V				Lanza, Ezio; Muglia, Riccardo; Bolengo, Isabella; Poretti, Dario; D'Antuono, Felice; Ceriani, Roberto; Torzilli, Guido; Pedicini, Vittorio			Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization	PLOS ONE			English	Article							TRANSCATHETER ARTERIAL EMBOLIZATION; SYMPTOMATIC TREATMENT; CONTROLLED-TRIAL; CHEMOEMBOLIZATION; CYANOACRYLATE; THERAPY; MANAGEMENT; ABLATION; LIPIODOL	Locoregional therapies for hepatocellular carcinoma (HCC) include endovascular treatments such as chemoembolization (TACE) and bland embolization (TAE). TACE is the most adopted technique, despite a lack of definitive evidence of superiority over TAE, which is less costly and better tolerated due to the absence of chemotherapy. However, few studies have reported data on TAE monotherapy for unresectable HCC. We report our results in a cohort of 230 patients with unresectable HCC treated with TAE (TAE with 40-100 micron microparticles, TAE with microparticles plus n-butyl-2-cyanoacrylate, TAE with Lipiodol) over the course of seven years. Thirty-seven patients (14%) were down-staged during observation and also received a percutaneous ablation. We observed 1-, 2-, 3-, 4- and 5year rates of 84,8%, 58,7%, 38,3%, 28,3%, and 18,7%. Patients who also received percutaneous treatment performed best. Our results broaden the body of evidence for the use of TAE in advanced HCC.	[Lanza, Ezio; Poretti, Dario; D'Antuono, Felice; Pedicini, Vittorio] Humanitas Clin & Res Hosp IRCCS, Dept Diagnost & Intervent Radiol, Milan, Italy; [Muglia, Riccardo; Bolengo, Isabella] Humanitas Univ, Training Sch Radiol, Milan, Italy; [Ceriani, Roberto] Humanitas Clin & Res Hosp IRCCS, Dept Internal Med Hepatol, Milan, Italy; [Torzilli, Guido] Humanitas Clin & Res Hosp IRCCS, Dept Surg Hepatobiliary & Gen Surg, Milan, Italy	Humanitas University	Lanza, E (corresponding author), Humanitas Clin & Res Hosp IRCCS, Dept Diagnost & Intervent Radiol, Milan, Italy.	eziolanza@gmail.com	Lanza, Ezio/AAO-8516-2020; D'Antuono, Felice/AAV-2822-2020	Lanza, Ezio/0000-0003-1889-8798; D'Antuono, Felice/0000-0002-9973-0593; Ceriani, Roberto/0000-0003-4838-7366; pedicini, vittorio/0000-0001-7830-6307				Berghammer P, 1998, CARDIOVASC INTER RAD, V21, P214, DOI 10.1007/s002709900247; Bonomo G, 2010, CARDIOVASC INTER RAD, V33, P552, DOI 10.1007/s00270-009-9752-y; Bouvier A, 2011, EUR RADIOL, V21, P1719, DOI 10.1007/s00330-011-2118-2; Bruix J, 1998, HEPATOLOGY, V27, P1578, DOI 10.1002/hep.510270617; Burroughs A, 2004, LANCET ONCOL, V5, P409, DOI 10.1016/S1470-2045(04)01508-6; CHANG JM, 1994, CANCER, V74, P2449, DOI 10.1002/1097-0142(19941101)74:9<2449::AID-CNCR2820740910>3.0.CO;2-4; Chevallier P, 2015, DIAGN INTERV IMAG, V96, P637, DOI 10.1016/j.diii.2015.04.006; Colombo GL, 2015, THER CLIN RISK MANAG, V11, P1603, DOI 10.2147/TCRM.S88208; European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019; Facciorusso A, 2017, UNITED EUR GASTROENT, V5, P511, DOI 10.1177/2050640616673516; Gbolahan OB, 2017, J GASTROINTEST ONCOL, V8, P215, DOI 10.21037/jgo.2017.03.13; Idee JM, 2013, CRIT REV ONCOL HEMAT, V88, P530, DOI 10.1016/j.critrevonc.2013.07.003; Katsanos K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184597; KAWAI S, 1992, CANCER CHEMOTH PHARM, V31, pS1, DOI 10.1007/BF00687096; Kudo M, 2017, LIVER CANCER, V6, P16, DOI 10.1159/000449343; Lanza E, 2018, J ARTHROPLASTY, V33, P2273, DOI 10.1016/j.arth.2018.02.005; Lanza E, 2017, NUCL MED COMMUN, V38, P826, DOI 10.1097/MNM.0000000000000719; Lanza E, 2017, LIVER CANCER, V6, P27, DOI 10.1159/000449347; Lanza E, 2014, J VASC INTERV RADIOL, V25, P1482, DOI 10.1016/j.jvir.2014.05.018; LIN DY, 1988, GASTROENTEROLOGY, V94, P453, DOI 10.1016/0016-5085(88)90436-2; Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Loewe C, 2002, J VASC INTERV RADIOL, V13, P61, DOI 10.1016/S1051-0443(07)60010-4; Malagari K, 2010, CARDIOVASC INTER RAD, V33, P541, DOI 10.1007/s00270-009-9750-0; Marelli L, 2007, CARDIOVASC INTER RAD, V30, P6, DOI 10.1007/s00270-006-0062-3; Meyer T, 2013, BRIT J CANCER, V108, P1252, DOI 10.1038/bjc.2013.85; Monsignore LM, 2015, CLINICS, V70, P781, DOI 10.6061/clinics/2015(12)04; Oliveri RS, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004787.pub2; Pedicini V, 2017, J VASC INTERV RADIOL, V28, P1444, DOI 10.1016/j.jvir.2017.06.020; Prajapati HJ, 2014, AM J ROENTGENOL, V203, pW706, DOI 10.2214/AJR.13.12308; Wang Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201525; Wang YXJ, 2015, CHINESE J CANCER RES, V27, P96, DOI 10.3978/j.issn.1000-9604.2015.03.03; Young S, 2019, EUR RADIOL, V29, P3287, DOI 10.1007/s00330-018-5782-7; Young S, 2018, J CLIN TRANSL HEPATO, V6, P189, DOI 10.14218/JCTH.2017.00059; Yu SCH, 2014, RADIOLOGY, V270, P607, DOI 10.1148/radiol.13130498	35	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2020	15	1							e0227711	10.1371/journal.pone.0227711	http://dx.doi.org/10.1371/journal.pone.0227711			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5JP	31935255	Green Published, gold			2023-01-03	WOS:000534354100045
J	de Rezende, ACP; Weltman, E; Chen, MJ; Helito, JK; de Carvalho, IT; Sakuraba, RK; Silva, NS; Cappellano, AM; Hamerschlak, N				Pires de Rezende, Ana Carolina; Weltman, Eduardo; Chen, Michael Jenwei; Helito, Juliana Karassawa; de Carvalho, Icaro Thiago; Sakuraba, Roberto Kenji; Silva, Nasjla Saba; Cappellano, Andrea Maria; Hamerschlak, Nelson			Intensity-modulated ventricular irradiation for intracranial germ-cell tumors: Survival analysis and impact of salvage re-irradiation	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; PHOTON RADIATION-THERAPY; WHOLE-BRAIN IRRADIATION; CRANIOSPINAL IRRADIATION; CHEMOTHERAPY; GERMINOMA; RADIOTHERAPY; CHILDHOOD; OUTCOMES; PROTON	Background and purpose The roles of surgery, chemotherapy, and parameters of radiation therapy for treating very rare central nervous system germ cell tumors (CNS-GCT) are still under discussion. We aimed to evaluate the survival and recurrence patterns of patients with CNS-GCT treated with chemotherapy followed by whole ventricle irradiation with intensity-modulated radiation therapy. Materials and methods We reviewed the clinical outcomes of 20 consecutive patients with CNS-GCT treated with chemotherapy and intensity-modulated radiation therapy from 2004 to 2014 in two partner institutions. Results Twenty children with a median age of 12 years were included (16 males). Sixteen tumors were pure germinomas, and 4 were non-germinomatous germ cell tumors (NGGCT). All patients were treated with intensity-modulated radiation therapy guided by daily images, and 70% with volumetric intensity-modulated arc radiotherapy additionally. The median dose for the whole-ventricle was 25.2 Gy (range: 18-30.6 Gy) and 36 Gy (range: 30-54 Gy) for the tumor bed boost. The median post-radiation therapy follow-up was 57.5 months. There were 3 recurrences (2 NGGCT and 1 germinoma that recurred as a NGGCT), with 1 death from the disease and the other 2 cases each successfully rescued with chemotherapy and craniospinal irradiation. The overall survival at 5 years was 95% and disease-free survival was 85%. Conclusions The results of this study suggest that the combined use of chemotherapy followed by whole ventricle irradiation with intensity-modulated radiation therapy is effective for CNS-GCTs, especially pure germinomas. Even being rescued with craniospinal irradiation, the NGGCT cases have markedly worse prognoses and should be more rigorously selected for localized treatment.	[Pires de Rezende, Ana Carolina; Weltman, Eduardo; Helito, Juliana Karassawa; de Carvalho, Icaro Thiago; Sakuraba, Roberto Kenji] Hosp Israelita Albert Einstein, Dept Radiat Oncol, Sao Paulo, Brazil; [Weltman, Eduardo] Univ Sao Paulo, Dept Radiat Oncol, Fac Med, Sao Paulo, Brazil; [Chen, Michael Jenwei] Univ Fed Sao Paulo, Dept Radiat Oncol, Inst Oncol Pediat, Grp Apoio Adolescente & Crianca Canc GRAACC, Sao Paulo, Brazil; [Silva, Nasjla Saba; Cappellano, Andrea Maria] Univ Fed Sao Paulo, Dept Pediat Oncol, Inst Oncol Pediat, Grp Apoio Adolescente & Crianca Canc GRAACC, Sao Paulo, Brazil; [Hamerschlak, Nelson] Hosp Israelita Albert Einstein, Dept Hematol & Clin Oncol, Sao Paulo, Brazil	Hospital Israelita Albert Einstein; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP); Hospital Israelita Albert Einstein	de Rezende, ACP (corresponding author), Hosp Israelita Albert Einstein, Dept Radiat Oncol, Sao Paulo, Brazil.	ana.rezende@einstein.br	de Carvalho, Icaro Thiago/AAY-4278-2020; Cappellano, Andrea M/AAF-4229-2021; Chen, Michael/W-1705-2018; Hamerschlak, Nelson/M-8060-2015	de Carvalho, Icaro Thiago/0000-0003-0607-7589; Chen, Michael/0000-0001-7897-7733; Hamerschlak, Nelson/0000-0002-5140-5310; Weltman, Eduardo/0000-0002-7964-2051	Instituto Israelita de Responsabilidade Social	Instituto Israelita de Responsabilidade Social	This study was partially supported by the Instituto Israelita de Responsabilidade Social (the foundation that supports research and other projects conducted in Hospital Israelita Albert Einstein, https://www.einstein.br/sobre-einstein).This entity took no part in the study design, data collection, or interpretation of results. There is no "grant protocol number" for this support.	Al-Naeeb AB, 2018, CLIN ONCOL-UK, V30, P204, DOI 10.1016/j.clon.2018.01.009; Bishop AJ, 2014, INT J RADIAT ONCOL, V90, P354, DOI 10.1016/j.ijrobp.2014.05.051; Cahlon O, 2014, INT J RADIAT ONCOL, V90, pS723, DOI 10.1016/j.ijrobp.2014.05.2111; Calaminus G, 2017, NEURO-ONCOLOGY, V19, P1661, DOI 10.1093/neuonc/nox122; Calaminus G, 2013, NEURO-ONCOLOGY, V15, P788, DOI 10.1093/neuonc/not019; Calaminus G, 2011, PEDIATR BLOOD CANCER, V57, P743; Cappellano AM, 2012, NEUROONCOL S1, V14, pi49; Chen MJ, 2010, INT J RADIAT ONCOL, V76, P608, DOI 10.1016/j.ijrobp.2009.06.028; Cheng S, 2016, J NEURO-ONCOL, V127, P173, DOI 10.1007/s11060-015-2029-1; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; da Silva NS, 2010, PEDIATR BLOOD CANCER, V54, P377, DOI 10.1002/pbc.22381; De B, 2017, J NEURO-ONCOL, V134, P349, DOI 10.1007/s11060-017-2532-7; Echevarria ME, 2008, ONCOLOGIST, V13, P690, DOI 10.1634/theoncologist.2008-0037; EMAMI B, 1991, INT J RADIAT ONCOL, V21, P109, DOI 10.1016/0360-3016(91)90171-Y; Eom KY, 2008, INT J RADIAT ONCOL, V71, P667, DOI 10.1016/j.ijrobp.2008.01.061; Hill JM, 1998, CANCER-AM CANCER SOC, V82, P208; Hu YW, 2012, INT J RADIAT ONCOL, V84, P639, DOI 10.1016/j.ijrobp.2011.12.052; Kahalley LS, 2016, J CLIN ONCOL, V34, P1043, DOI 10.1200/JCO.2015.62.1383; Kenjo M, 2015, JPN J RADIOL, V33, P336, DOI 10.1007/s11604-015-0424-3; Khatua S, 2010, PEDIATR BLOOD CANCER, V55, P42, DOI 10.1002/pbc.22468; Kim JY, 2015, J KOREAN NEUROSURG S, V57, P315, DOI 10.3340/jkns.2015.57.5.315; Ladra MM, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.27046; Lawrence YR, 2010, INT J RADIAT ONCOL, V76, pS20, DOI 10.1016/j.ijrobp.2009.02.091; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Matsutani M, 1997, J NEUROSURG, V86, P446, DOI 10.3171/jns.1997.86.3.0446; Matsutani M, 2001, J NEURO-ONCOL, V54, P311, DOI 10.1023/A:1012743707883; Matsutani M, 2013, TREATMENT INTRACRANI, P8; Merchant TE, 2006, INT J RADIAT ONCOL, V65, P210, DOI 10.1016/j.ijrobp.2005.10.038; Mulhern RK, 1998, J CLIN ONCOL, V16, P1723, DOI 10.1200/JCO.1998.16.5.1723; Murray MJ, 2015, LANCET ONCOL, V16, pE470, DOI 10.1016/S1470-2045(15)00244-2; O'Neil S, 2011, PEDIATR BLOOD CANCER, V57, P669, DOI 10.1002/pbc.23146; Ogino H, 2005, INT J RADIAT ONCOL, V62, P803, DOI 10.1016/j.ijrobp.2004.10.026; Paganetti H, 2015, INT J RADIAT ONCOL, V91, P892, DOI 10.1016/j.ijrobp.2014.11.021; Pirzkall A, 2000, INT J RADIAT ONCOL, V48, P1371, DOI 10.1016/S0360-3016(00)00772-0; Poynter JN, 2013, CANCER RES, V73, DOI 10.1158/1538-7445.AM2013-2291; Rickert CH, 2001, CHILD NERV SYST, V17, P503, DOI 10.1007/s003810100496; Robertson PL, 2014, J NEURO-ONCOL, V118, P93, DOI 10.1007/s11060-013-1306-0; Rogers SJ, 2005, LANCET ONCOL, V6, P509, DOI 10.1016/S1470-2045(05)70245-X; Rosemberg S, 2005, CHILD NERV SYST, V21, P940, DOI 10.1007/s00381-005-1181-x; Shim KW, 2013, CHILD NERV SYST, V29, P239, DOI 10.1007/s00381-012-1902-x; SILBER JH, 1992, J CLIN ONCOL, V10, P1390, DOI 10.1200/JCO.1992.10.9.1390; St Clair WH, 2004, INT J RADIAT ONCOL, V58, P727, DOI 10.1016/S0360-3016(03)01574-8; Yang JC, 2016, PEDIATR BLOOD CANCER, V63, P646, DOI 10.1002/pbc.25867; Yock TI, 2016, LANCET ONCOL, V17, P287, DOI 10.1016/S1470-2045(15)00167-9	44	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2019	14	12							e0226350	10.1371/journal.pone.0226350	http://dx.doi.org/10.1371/journal.pone.0226350			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP3ZM	31860688	Green Published, gold			2023-01-03	WOS:000534257500015
J	Clamp, AR; James, EC; McNeish, IA; Dean, A; Kim, JW; O'Donnell, DM; Hook, J; Coyle, C; Blagden, S; Brenton, JD; Naik, R; Perren, T; Sundar, S; Cook, AD; Gopalakrishnan, GS; Gabra, H; Lord, R; Dark, G; Earl, HM; Hall, M; Banerjee, S; Glasspool, RM; Jones, R; Williams, S; Swart, AM; Stenning, S; Parmar, M; Kaplan, R; Ledermann, JA				Clamp, Andrew R.; James, Elizabeth C.; McNeish, Iain A.; Dean, Andrew; Kim, Jae-Weon; O'Donnell, Dearbhaile M.; Hook, Jane; Coyle, Christopher; Blagden, Sarah; Brenton, James D.; Naik, Raj; Perren, Tim; Sundar, Sudha; Cook, Adrian D.; Gopalakrishnan, Gosala S.; Gabra, Hani; Lord, Rosemary; Dark, Graham; Earl, Helena M.; Hall, Marcia; Banerjee, Susana; Glasspool, Rosalind M.; Jones, Rachel; Williams, Sarah; Swart, Ann Marie; Stenning, Sally; Parmar, Mahesh; Kaplan, Richard; Ledermann, Jonathan A.			Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial	LANCET			English	Article							SINGLE-AGENT PACLITAXEL; EVERY 3 WEEKS; CLINICAL-TRIALS; PRIMARY SURGERY; OPEN-LABEL; CANCER; CARBOPLATIN; MULTICENTER; CONSENSUS	Background Carboplatin and paclitaxel administered every 3 weeks is standard-of-care first-line chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a significant improvement in progression-free and overall survival with dose-dense weekly paclitaxel and 3-weekly carboplatin. In this study, we aimed to compare efficacy and safety of two dose-dense weekly regimens to standard 3-weekly chemotherapy in a predominantly European population with epithelial ovarian cancer. Methods In this phase 3 trial, women with newly diagnosed International Federation of Gynecology and Obstetrics stage IC-IV epithelial ovarian cancer were randomly assigned to group 1 (carboplatin area under the curve [AUC]5 or AUC6 and 175 mg/m(2) paclitaxel every 3 weeks), group 2 (carboplatin AUC5 or AUC6 every 3 weeks and 80 mg/m(2) paclitaxel weekly), or group 3 (carboplatin AUC2 and 80 mg/m(2) paclitaxel weekly). Written informed consent was provided by all women who entered the trial. The protocol had the appropriate national research ethics committee approval for the countries where the study was conducted. Patients entered the trial after immediate primary surgery, or before neoadjuvant chemotherapy with subsequent planned delayed primary surgery. The trial coprimary outcomes were progression-free survival and overall survival. Data analyses were done on an intention-to-treat basis, and were powered to detect a hazard ratio of 0 .75 in progression-free survival. The main comparisons were between the control group (group 1) and each of the weekly research groups (groups 2 and 3). Findings Between June 6, 2011, and Nov 28, 2014, 1566 women were randomly assigned to treatment. 72% (365), completed six protocol-defined treatment cycles in group 1, 60% (305) in group 2, and 63% (322) in group 3, although 90% (454), 89% (454), and 85% (437) completed six platinum-based chemotherapy cycles, respectively. Paclitaxel dose intensification was achieved with weekly treatment (median total paclitaxel dose 1010 mg/m(2) in group 1; 1233 mg/m(2) in group 2; 1274 mg/m(2) in group 3). By February, 2017, 1018 (65%) patients had experienced disease progression. No significant progression-free survival increase was observed with either weekly regimen (restricted mean survival time 24.4 months [97.5% CI 23.0-26.0] in group 1, 24.9 months [24.0-25.9] in group 2, 25.3 months [23.9-26.9] in group 3; median progression-free survival 17.7 months [IQR 10.6-not reached] in group 1, 20.8 months [11.9-59.0] in group 2, 21.0 months [12.0-54.0] in group 3; log-rank p=0.35 for group 2 vs group 1; group 3 vs 1 p=0.51). Although grade 3 or 4 toxic effects increased with weekly treatment, these effects were predominantly uncomplicated. Febrile neutropenia and sensory neuropathy incidences were similar across groups. Interpretation Weekly dose-dense chemotherapy can be delivered successfully as first-line treatment for epithelial ovarian cancer but does not significantly improve progression-free survival compared with standard 3-weekly chemotherapy in predominantly European populations. Copyright (C) 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.	[Clamp, Andrew R.] Christie Natl Hlth Serv Fdn Trust, Dept Med Oncol, Manchester, Lancs, England; [Clamp, Andrew R.] Univ Manchester, Manchester, Lancs, England; [James, Elizabeth C.; Cook, Adrian D.; Gopalakrishnan, Gosala S.; Stenning, Sally; Parmar, Mahesh; Kaplan, Richard] UCL, Clin Trials Unit, MRC, Inst Clin Trials & Methodol, London WC1V6LJ, England; [McNeish, Iain A.; Gabra, Hani] Imperial Coll London, Dept Surg & Canc, London, England; [Dean, Andrew] St John God Hosp, Dept Oncol, Subiaco, WA, Australia; [Kim, Jae-Weon] Seoul Natl Univ, Dept Obstet & Gynaecol, Seoul, South Korea; [O'Donnell, Dearbhaile M.] Canc Trials Ireland, Dublin, Ireland; [Hook, Jane; Perren, Tim] St James Univ Hosp, Leeds, W Yorkshire, England; [Coyle, Christopher] Portsmouth Hosp Natl Hlth ServiceTrust, Queen Alexandra Hosp, Portsmouth, Hants, England; [Blagden, Sarah] Univ Oxford, Churchill Hosp, Oxford, England; [Brenton, James D.] Canc Res UK Cambridge Inst, Li Ka Shing Ctr, Cambridge, England; [Naik, Raj] Queen Elizabeth Hosp, Gynaecol Oncol Ctr, Gateshead, England; [Sundar, Sudha] Univ Birmingham, Inst Canc & Genom, Birmingham, W Midlands, England; [Gabra, Hani] AstraZeneca, Early Clin Dev, Cambridge, England; [Lord, Rosemary] Clatterbridge Canc Ctr, Dept Oncol, Wirral, Merseyside, England; [Dark, Graham] Freeman Rd Hosp, Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England; [Earl, Helena M.] Addenbrookes Hosp, Dept Med Oncol, Cambridge, England; [Hall, Marcia] Mt Vernon Canc Ctr, Dept Med Oncol, Northwood, Middx, England; [Banerjee, Susana] Royal Marsden Natl Hlth Serv Fdn Trust, Gynaecol Unit, London, England; [Banerjee, Susana] Inst Canc Res, London, England; [Glasspool, Rosalind M.] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland; [Jones, Rachel] Velindre Canc Ctr, Cardiff, S Glam, Wales; [Williams, Sarah] Birmingham City Hosp, Birmingham, W Midlands, England; [Swart, Ann Marie] Univ East Anglia, Norwich Med Sch, Norwich, Norfolk, England; [Ledermann, Jonathan A.] UCL, Inst Canc, London, England; [Ledermann, Jonathan A.] Univ Coll London Hosp, London, England	Christie NHS Foundation Trust; University of Manchester; Medical Research Council Clinical Trials Unit; University of London; University College London; Imperial College London; St John of God Health Care; Seoul National University (SNU); Saint James's University Hospital; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; University of Oxford; Cancer Research UK; CRUK Cambridge Institute; University of Birmingham; AstraZeneca; Clatterbridge Cancer Centre; Newcastle Freeman Hospital; Newcastle University - UK; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Mount Vernon Cancer Centre; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Beatson Oncology Centre; Velindre Cancer Centre; University of East Anglia; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London	James, EC (corresponding author), UCL, Clin Trials Unit, MRC, Inst Clin Trials & Methodol, London WC1V6LJ, England.	e.james@ucl.ac.uk	Brenton, James D/B-3174-2008; Perren, Timothy/D-5387-2013	Brenton, James D/0000-0002-5738-6683; Earl, Helena/0000-0003-1549-8094; Perren, Timothy/0000-0001-8472-8856; Swart, Ann Marie/0000-0002-9359-6995; James, Elizabeth/0000-0002-0490-7211; Hall, marcia/0000-0003-0039-5041; McNeish, Iain/0000-0002-9387-7586; Kaplan, Richard S./0000-0002-0189-8348; Gabra, Hani/0000-0002-3322-4399; Banerjee, Susana/0000-0002-8840-7934; Sundar, Sudha/0000-0002-5843-3015	Cancer Research UK; Medical Research Council; Health Research Board in Ireland; Irish Cancer Society; Cancer Australia; MRC [MC_UU_12023/28, MC_U122861379, MC_UU_12023/9] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Health Research Board in Ireland; Irish Cancer Society; Cancer Australia; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Cancer Research UK, Medical Research Council, Health Research Board in Ireland, Irish Cancer Society, Cancer Australia.	Bookman MA, 2017, ANN ONCOL, V28, P30, DOI 10.1093/annonc/mdx449; CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748; CHAN JD, 2016, NEW ENGL J MED, V12, DOI DOI 10.1371/JOURNAL.PPAT.1005651; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Gandara DR, 2009, J CLIN ONCOL, V27, P3540, DOI 10.1200/JCO.2008.20.8793; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; JELLIFFE RW, 1973, ANN INTERN MED, V79, P604, DOI 10.7326/0003-4819-79-4-604; Kamat AA, 2007, CANCER RES, V67, P281, DOI 10.1158/0008-5472.CAN-06-3282; Katsumata N, 2013, LANCET ONCOL, V12; Katsumata N, 2009, LANCET, V374, P1331, DOI 10.1016/S0140-6736(09)61157-0; Kehoe S, 2015, LANCET, V386, P249, DOI 10.1016/S0140-6736(14)62223-6; Klauber N, 1997, CANCER RES, V57, P81; Komatsu M, 2015, CLIN CANCER RES, V21, P4337, DOI 10.1158/1078-0432.CCR-15-0133; Markman M, 2002, J CLIN ONCOL, V20, P2365, DOI 10.1200/JCO.2002.09.130; Marx GM, 2004, ANN ONCOL, V15, P291, DOI 10.1093/annonc/mdh079; Mauri D, 2010, CANCER TREAT REV, V36, P69, DOI 10.1016/j.ctrv.2009.10.006; McNeish IA, 2014, ANN ONCOL, V25, P1988, DOI 10.1093/annonc/mdu363; Pignata S, 2008, CRIT REV ONCOL HEMAT, V66, P229, DOI 10.1016/j.critrevonc.2007.12.005; Pignata S, 2014, LANCET ONCOL, V15, P396, DOI 10.1016/S1470-2045(14)70049-X; Rosenberg P, 2002, ACTA ONCOL, V41, P418, DOI 10.1080/028418602320404998; Safra T, 2009, GYNECOL ONCOL, V114, P215, DOI 10.1016/j.ygyno.2009.04.008; Sparano JA, 2008, NEW ENGL J MED, V358, P1663, DOI 10.1056/NEJMoa0707056; Stuart GCE, 2011, INT J GYNECOL CANCER, V21, P750, DOI 10.1097/IGC.0b013e31821b2568; Vergote I, 2000, J NATL CANCER I, V92, P1534, DOI 10.1093/jnci/92.18.1534; Vergote I, 2018, LANCET ONCOL, V19, P1680, DOI 10.1016/S1470-2045(18)30566-7; Vergote I, 2010, NEW ENGL J MED, V363, P943, DOI 10.1056/NEJMoa0908806	27	93	102	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 7	2019	394	10214					2084	2095		10.1016/S0140-6736(19)32259-7	http://dx.doi.org/10.1016/S0140-6736(19)32259-7			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT4HF	31791688	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000500951600027
J	Soto, AP				Presa Soto, Alejandro			Surface nanopatterning with polymer brushes	SCIENCE			English	Editorial Material							MICELLES		[Presa Soto, Alejandro] Univ Oviedo, Dept Organ & Inorgan Chem, Sch Chem, E-33006 Oviedo, Spain	University of Oviedo	Soto, AP (corresponding author), Univ Oviedo, Dept Organ & Inorgan Chem, Sch Chem, E-33006 Oviedo, Spain.	presaalejandro@uniovi.es	Soto, Alejandro Presa/I-1440-2012; Presa Soto, Alejandro/N-1831-2015	Presa Soto, Alejandro/0000-0003-3565-4672				Cai JD, 2019, SCIENCE, V366, P1095, DOI 10.1126/science.aax9075; Feng C, 2018, ACCOUNTS CHEM RES, V51, P2314, DOI 10.1021/acs.accounts.8b00307; Jia L, 2015, ACS NANO, V9, P10673, DOI 10.1021/acsnano.5b01176; Jia L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4882; Mai YY, 2012, CHEM SOC REV, V41, P5969, DOI 10.1039/c2cs35115c; Qiu HB, 2016, SCIENCE, V352, P697, DOI 10.1126/science.aad9521; Qiu HB, 2015, SCIENCE, V347, P1329, DOI 10.1126/science.1261816; Rupar PA, 2012, SCIENCE, V337, P559, DOI 10.1126/science.1221206; Wang XS, 2007, SCIENCE, V317, P644, DOI 10.1126/science.1141382	9	2	2	2	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	2019	366	6469					1078	1079		10.1126/science.aay8350	http://dx.doi.org/10.1126/science.aay8350			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JS0YA	31780547				2023-01-03	WOS:000500039200026
J	Dignam, C; Thomas, J; Brown, M; Thompson, CH				Dignam, Colette; Thomas, Josephine; Brown, Margaret; Thompson, Campbell H.			The impact of language on the interpretation of resuscitation clinical care plans by doctors. A mixed methods study	PLOS ONE			English	Article							ORDERS	Introduction Resuscitation clinical care plans (resuscitation plans) are gradually replacing 'Not for Cardiopulmonary Resuscitation' orders in the hospital setting. The 7-Step Pathway Resuscitation Plan and Alert form (7-Step form) is one example of a resuscitation plan. Treatment recommendations in resuscitation plans currently lack standardised language, creating potential for misinterpretation and patient harm. Aims To explore how terminology used in resuscitation plans is interpreted and applied by clinicians. Method A mixed methods study surveyed 50 general medical doctors, who were required to interpret and apply a 7-Step form in three case vignettes and define seven key terms. Statistical analysis on multiple choice and thematic analysis on free-text responses was performed. Results Terminology was inconsistently interpreted and inconsistently applied, resulting in clinically significant differences in treatment choices. Three key themes influenced the application of a resuscitation plan: in-depth discussion, precise documentation and personal experience of the bedside deciding doctor. Discussion This study highlights persistent communication deficiencies in resuscitation plan documentation and how this may adversely affect patient care; findings unlikely to be unique to Australia or South Australia. Conclusion Removing ambiguity by standardising and defining the terminology in resuscitation plans will improve bedside decision-making, while also supporting the rights of the patient to receive appropriate and desired care.	[Dignam, Colette; Thompson, Campbell H.] Univ Adelaide, Fac Hlth & Med Sci, Div Med, Adelaide, SA, Australia; [Dignam, Colette; Thompson, Campbell H.] Royal Adelaide Hosp, Div Med, Adelaide, SA, Australia; [Thomas, Josephine] Univ Adelaide, Fac Hlth & Med Sci, Adelaide Med Sch, Adelaide, SA, Australia; [Brown, Margaret] Univ South Australia, Sch Psychol Social Work & Social Policy, Div Educ Arts & Social Sci, Adelaide, SA, Australia	University of Adelaide; Royal Adelaide Hospital; University of Adelaide; University of South Australia	Dignam, C (corresponding author), Univ Adelaide, Fac Hlth & Med Sci, Div Med, Adelaide, SA, Australia.; Dignam, C (corresponding author), Royal Adelaide Hosp, Div Med, Adelaide, SA, Australia.	colette.dignam@sa.gov.au	Thompson, Campbell/E-2885-2010	Thompson, Campbell/0000-0002-5164-3327; Thomas, Josephine/0000-0001-8124-5920; Brown, Margaret/0000-0001-8127-8669; Dignam, Colette/0000-0003-3319-1037				Akhunbay-Fudge CY, 2014, BMJ QUAL IMPROV REP, P3; Beach MC, 2002, J AM GERIATR SOC, V50, P2057, DOI 10.1046/j.1532-5415.2002.50620.x; Braun V, 2014, INT J QUAL STUD HEAL, V9, DOI 10.3402/qhw.v9.26152; Citko J, 2011, J PALLIAT MED, V14, P241, DOI 10.1089/jpm.2010.9730; Dignam C, 2019, AUSTRALAS J AGEING, V38, P28, DOI 10.1111/ajag.12587; Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34; Fadel Michael G, 2018, BMJ Open Qual, V7, pe000268, DOI 10.1136/bmjoq-2017-000268; Fritz Z, 2017, BMJ, V356, P1; Fritz Z, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j2213; Health SA, 2014, RES PLAN 7 STEP PATH; Hui D, 2013, SUPPORT CARE CANCER, V21, P659, DOI 10.1007/s00520-012-1564-y; Patient Care Quality Office, MED ORD SCOP TREATM; Schmidt TA, 2014, RESUSCITATION, V85, P480, DOI 10.1016/j.resuscitation.2013.11.027; Shermon E., 2017, BMJ OPEN QUAL, V6, DOI [10.1136/bmjoq-2017-000011, DOI 10.1136/BMJOQ-2017-000011]; The Australian Commission on Safety and Quality in Health Care, 2015, NATL CONS STAT ESS E; The National POLST Paradigm, NAT POLST FORM PORT; Zanartu C, 2013, AM J HOSP PALLIAT ME, V30, P35, DOI 10.1177/1049909112440740	17	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 25	2019	14	11							e0225338	10.1371/journal.pone.0225338	http://dx.doi.org/10.1371/journal.pone.0225338			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO8QR	31765418	Green Published, gold, Green Accepted			2023-01-03	WOS:000533891000022
J	Hollern, DP; Xu, N; Thennavan, A; Glodowski, C; Garcia-Recio, S; Mott, KR; He, XP; Garay, JP; Carey-Ewend, K; Marron, D; Ford, J; Liu, SY; Vick, SC; Martin, M; Parker, JS; Vincent, BG; Serody, JS; Perou, CM				Hollern, Daniel P.; Xu, Nuo; Thennavan, Aatish; Glodowski, Cherise; Garcia-Recio, Susana; Mott, Kevin R.; He, Xiaping; Garay, Joseph P.; Carey-Ewend, Kelly; Marron, David; Ford, John; Liu, Siyao; Vick, Sarah C.; Martin, Miguel; Parker, Joel S.; Vincent, Benjamin G.; Serody, Jonathan S.; Perou, Charles M.			B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer	CELL			English	Article							PD-1 BLOCKADE; RNA-SEQ; EXPRESSION; INSIGHTS; TUMORS; CHEMOTHERAPY; LYMPHOCYTES; LANDSCAPE; ANTIBODY; SUBSETS	This study identifies mechanisms mediating responses to immune checkpoint inhibitors using mouse models of triple-negative breast cancer. By creating new mammary tumor models, we find that tumor mutation burden and specific immune cells are associated with response. Further, we developed a rich resource of single-cell RNA-seq and bulk mRNA-seq data of immunotherapy-treated and non-treated tumors from sensitive and resistant murine models. Using this, we uncover that immune checkpoint therapy induces T follicular helper cell activation of B cells to facilitate the anti-tumor response in these models. We also show that B cell activation of T cells and the generation of antibody are key to immunotherapy response and propose a new biomarker for immune checkpoint therapy. In total, this work presents resources of new preclinical models of breast cancer with large mRNA-seq and single-cell RNA-seq datasets annotated for sensitivity to therapy and uncovers new components of response to immune checkpoint inhibitors.	[Hollern, Daniel P.; Thennavan, Aatish; Glodowski, Cherise; Garcia-Recio, Susana; Mott, Kevin R.; He, Xiaping; Garay, Joseph P.; Carey-Ewend, Kelly; Marron, David; Ford, John; Liu, Siyao; Parker, Joel S.; Vincent, Benjamin G.; Serody, Jonathan S.; Perou, Charles M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Hollern, Daniel P.; Thennavan, Aatish; Garcia-Recio, Susana; Mott, Kevin R.; He, Xiaping; Garay, Joseph P.; Carey-Ewend, Kelly; Marron, David; Ford, John; Liu, Siyao; Parker, Joel S.; Perou, Charles M.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; [Xu, Nuo; Vick, Sarah C.; Vincent, Benjamin G.; Serody, Jonathan S.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; [Vincent, Benjamin G.; Serody, Jonathan S.] Univ N Carolina, Dept Hematol Oncol, Dept Med, Chapel Hill, NC 27599 USA; [Vincent, Benjamin G.] Univ N Carolina, Curriculum Bioinformat & Computat Biol, Chapel Hill, NC 27599 USA; [Thennavan, Aatish] Univ N Carolina, Oral & Craniofacial Biomed Program, Sch Dent, Chapel Hill, NC 27515 USA; [Glodowski, Cherise] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; [Martin, Miguel] Univ Complutense, Inst Invest Sanitaria Gregorio Maranon, CIBERONC, Madrid, Spain	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Complutense University of Madrid	Perou, CM (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.; Perou, CM (corresponding author), Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.	cperou@med.unc.edu	Recio, Susana Garcia/M-4723-2019; Parker, Joel/AAG-1108-2019; , Animal Studies Core/AAF-4432-2022; , Pathology Services Core/CEZ-2246-2022; Martin, Miguel/AAJ-9242-2020; Perou, Charles M/H-9934-2014; , Animal Studies Core/ADK-4234-2022	Recio, Susana Garcia/0000-0003-3820-1679; Martin, Miguel/0000-0001-9237-3231; Perou, Charles M/0000-0001-9827-2247; Xu, Nuo/0000-0001-6920-6048; Carey-Ewend, Kelly/0000-0002-3200-1644	NCI F32 Ruth L. Kirschstein National Research Service Award individual postdoctoral fellowship (Parent F32) [CA210427]; NCI Breast SPORE program [P50-CA58223, RO1-CA148761, RO1-CA195740]; Breast Cancer Research Foundation; Susan G. Komen [SAC-160074]; Susan G. Komen Career Catalyst research grant; Susan G. Komen postdoctoral fellowship [PDF17479425]; Corsorcio Centro de Investigacion Biomedica en Red, thematic area for cancer (CIBERONC), Instituto de Salud Carlos III, Spain; NATIONAL CANCER INSTITUTE [R01CA195740, R01CA148761, P50CA058223] Funding Source: NIH RePORTER	NCI F32 Ruth L. Kirschstein National Research Service Award individual postdoctoral fellowship (Parent F32); NCI Breast SPORE program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; Susan G. Komen(Susan G. Komen Breast Cancer Foundation); Susan G. Komen Career Catalyst research grant(Susan G. Komen Breast Cancer Foundation); Susan G. Komen postdoctoral fellowship(Susan G. Komen Breast Cancer Foundation); Corsorcio Centro de Investigacion Biomedica en Red, thematic area for cancer (CIBERONC), Instituto de Salud Carlos III, Spain; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to the UNC Mouse Phase One Unit, Lineberger Comprehensive Cancer Center Immune Monitoring and Genomics Facility (IMGF); Janet Dow and the UNC Flow Cytometry Core Facility; Dr. Nana Feinberg, Yongjuan Xia, and Dr. Dawud Hilliard from UNC Translational Pathology and Histopathology labs; and the UNC Animal Studies Core for technical support and assistance. We thank Dr. Eran Andrechek for providing MMTV-PyMT tumors for RNA-sequencing. This work was supported by the following grants: NCI F32 Ruth L. Kirschstein National Research Service Award individual postdoctoral fellowship (Parent F32) CA210427 (to D.P.H.); NCI Breast SPORE program (P50-CA58223), RO1-CA148761, RO1-CA195740, the Breast Cancer Research Foundation, and Susan G. Komen SAC-160074 (to C.M.P.); Susan G. Komen Career Catalyst research grant (to B.G.V.); Susan G. Komen postdoctoral fellowship (PDF17479425) (to S.G.-R.); Corsorcio Centro de Investigacion Biomedica en Red, thematic area for cancer (CIBERONC), Instituto de Salud Carlos III, Spain (to M.M.).	An YJ, 2018, CELL REP, V25, P702, DOI 10.1016/j.celrep.2018.09.056; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Bischof J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161569; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Budczies J, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1526613; Bullard JH, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-94; Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Echavarria I., 2018, PATHOLOGICAL RESPONS; Eksteen B, 2006, J IMMUNOL, V177, P593, DOI 10.4049/jimmunol.177.1.593; Esserman LJ, 2012, BREAST CANCER RES TR, V132, P1049, DOI 10.1007/s10549-011-1895-2; Fan C, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-3; Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Hollern DP, 2019, BREAST CANCER RES TR, V174, P143, DOI 10.1007/s10549-018-5061-y; Hong S, 2018, IMMUNITY, V49, P695, DOI 10.1016/j.immuni.2018.08.012; Huang H., 2015, PACKAGE SIGCLUST; Hundal J, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0264-5; Iglesia MD, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw144; Iglesia MD, 2014, CLIN CANCER RES, V20, P3818, DOI 10.1158/1078-0432.CCR-13-3368; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; King C, 2009, NAT REV IMMUNOL, V9, P757, DOI 10.1038/nri2644; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kooreman NG, 2018, CELL STEM CELL, V22, P501, DOI 10.1016/j.stem.2018.01.016; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Li H., 2013, ARXIV PREPRINT; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Magurran AE, 2013, MEASURING BIOL DIVER; Miller L.D., 2016, IMMUNOGENIC SUBTYPES; Miyake T, 2012, CANCER SCI, V103, P913, DOI 10.1111/j.1349-7006.2012.02231.x; Morganella S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11383; Nelson BH, 2010, J IMMUNOL, V185, P4977, DOI 10.4049/jimmunol.1001323; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Nolan E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4922; Nzula S, 2003, CANCER RES, V63, P3275; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Patro R., 2015, BIORXIV, V9; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Pauken KE, 2016, SCIENCE, V354, P1160, DOI 10.1126/science.aaf2807; Peggs KS, 2009, J EXP MED, V206, P1717, DOI 10.1084/jem.20082492; Pfefferle AD, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.037192; Pfefferle AD, 2016, DIS MODEL MECH, V9, P749, DOI 10.1242/dmm.025239; Pfefferle AD, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r125; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Sade-Feldman M, 2018, CELL, V175, P998, DOI 10.1016/j.cell.2018.10.038; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Selitsky SR, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0647-5; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shen M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00470; Smid M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12910; Tanioka M., 2018, CLIN CANC RES OFFICI; Taylor NA, 2017, J CLIN INVEST, V127, P3478, DOI 10.1172/JCI90499; Thibult ML, 2013, INT IMMUNOL, V25, P129, DOI 10.1093/intimm/dxs098; Tischler G, 2014, SOURCE CODE BIOL MED, V9, DOI 10.1186/1751-0473-9-13; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tsavaris N, 2002, BRIT J CANCER, V87, P21, DOI 10.1038/sj.bjc.6600347; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Turner LH, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006684; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Vogelzang A, 2008, IMMUNITY, V29, P127, DOI 10.1016/j.immuni.2008.06.001; Waisman A, 2007, J EXP MED, V204, P747, DOI 10.1084/jem.20062024; Wang SX, 2018, ONCOGENE, V37, P3924, DOI 10.1038/s41388-018-0245-9; Wang XY, 2021, ENVIRON TECHNOL, V42, P2021, DOI 10.1080/09593330.2019.1687588; Wein L, 2018, BRIT J CANCER, V119, P4, DOI 10.1038/s41416-018-0126-6; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Zhang XX, 2019, NUCLEIC ACIDS RES, V47, pD721, DOI 10.1093/nar/gky900	76	175	178	12	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 14	2019	179	5					1191	+		10.1016/j.cell.2019.10.028	http://dx.doi.org/10.1016/j.cell.2019.10.028			37	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN5BQ	31730857	Green Accepted, Green Published, Bronze			2023-01-03	WOS:000496914200015
J	Prinja, S; Jagnoor, J; Sharma, D; Aggarwal, S; Katoch, S; Lakshmi, PVM; Ivers, R				Prinja, Shankar; Jagnoor, Jagnoor; Sharma, Deepshikha; Aggarwal, Sameer; Katoch, Swati; Lakshmi, P. V. M.; Ivers, Rebecca			Out-of-pocket expenditure and catastrophic health expenditure for hospitalization due to injuries in public sector hospitals in North India	PLOS ONE			English	Article							GLOBAL BURDEN; SYSTEMATIC ANALYSIS; LIFE EXPECTANCY; ECONOMIC BURDEN; TRAUMA CARE; COST; INSURANCE; DISEASE; STATE	Background Injuries are a major public health problem, resulting in high health care demand and economic burden. They result in loss of disability adjusted life years (DALYs) and high out-of-pocket expenditure. However, there is little evidence on the economic burden of injuries in India. We undertook this study to report out-of-pocket expenditure and the prevalence of catastrophic health expenditure for injuries related hospitalizations in public sector hospitals in North India. Further, we also evaluate the determinants of catastrophic health expenditure. Methods and analysis A prospective observational study was conducted. Participants were recruited from three hospitals for all injury cases. Data were collected via face-to-face baseline interviews and follow-up interviews over the phone at 1, 2, 4 and 12 months post-injury. Prevalence of catastrophic health expenditure (more than 30% of consumption expenditure) and impoverishment (International dollar 1.90) were estimated. Results Road traffic injuries (57%) were the leading cause of injury. Direct out-of-pocket expenditure for hospitalizations was INR 16,768 (USD 263) while indirect productivity loss was INR 8,164 (USD 128). The prevalence of catastrophic expenditure was 22.2% with 12.2% slipping below poverty line. Prevalence of catastrophic health expenditure and impoverishment was higher and significantly associated with poorest quintile, tertiary care hospital and increased duration of hospitalization (p < 0.001). Conclusion The economic impact of injuries is notably high both in terms of out-of-pocket expenditure and productivity loss. A high proportion of households experienced catastrophic expenditure and impoverishment following an injury, highlighting need for programs to prevent injuries.	[Prinja, Shankar; Sharma, Deepshikha; Aggarwal, Sameer; Katoch, Swati; Lakshmi, P. V. M.] Post Grad Inst Med Educ & Res, Chandigarh, India; [Jagnoor, Jagnoor] George Inst Global Hlth, New Delhi, India; [Jagnoor, Jagnoor; Ivers, Rebecca] Univ Sydney, George Inst Global Hlth, Sydney, NSW, Australia	Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; George Institute for Global Health; University of Sydney	Prinja, S (corresponding author), Post Grad Inst Med Educ & Res, Chandigarh, India.	shankarprinja@gmail.com		jagnoor, Jagnoor/0000-0002-5276-9095; Ivers, Rebecca/0000-0003-3448-662X	Road Traffic Injury Resource Network	Road Traffic Injury Resource Network	The study was funded by the Road Traffic Injury Resource Network. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to acknowledge The Road Traffic Injury Resource Network for providing the funding for undertaking this study.	Aeron-Thomas A, 2004, PPR010 TRANSP RES LA; Alvarez-Hernandez E, 2012, REUMATOL CLIN, V8, P168, DOI [10.1016/j.reumae.2012.06.018, 10.1016/j.reuma.2012.05.002]; [Anonymous], 2014, 71 SOC CONS SURV; Banerjee A, 2013, ACM IEEE INT CONF CY, P71, DOI 10.1109/ICCPS.2013.6604001; Brinda EM, 2015, J EPIDEMIOL COMMUN H, V69, P489, DOI 10.1136/jech-2014-204960; Chandran A, 2010, EPIDEMIOL REV, V32, P110, DOI 10.1093/epirev/mxq009; Chatterjee P, 2018, LANCET, V392, P997, DOI 10.1016/S0140-6736(18)32284-0; Dror DM, 2008, INDIAN J MED RES, V127, P347; Engelgau M, 2012, EC IMPACT NONCOMMUNI; Gopalakrishnan S, 2012, J Family Med Prim Care, V1, P144, DOI 10.4103/2249-4863.104987; Greene W. H., 2003, ECONOMETRIC ANAL; Gururaj G, 2008, NATL MED J INDIA, V21, P14; Nguyen H, 2013, INJURY, V44, P684, DOI 10.1016/j.injury.2012.05.006; Nguyen H, 2013, INJURY PREV, V19, P79, DOI 10.1136/injuryprev-2011-040293; Heeley E, 2009, STROKE, V40, P2149, DOI 10.1161/STROKEAHA.108.540054; Huffman MD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020821; Jagnoor J, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008884; Jan S, 2016, B WORLD HEALTH ORGAN, V94, P193, DOI 10.2471/BLT.15.158303; Joshipura MK, 2008, WORLD J SURG, V32, P1613, DOI 10.1007/s00268-008-9634-5; Kassebaum NJ, 2016, LANCET, V388, P1603, DOI 10.1016/S0140-6736(16)31470-2; KOOPMANSCHAP MA, 1995, J HEALTH ECON, V14, P171, DOI 10.1016/0167-6296(94)00044-5; Kumar GA, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-285; Mohan Dinesh, 2004, ROAD AHEAD TRAFFIC I; NSSO, 2001, CONC DEF US NSS; OECD, 1982, OECD LIST SOC IND; OECD [Organisation for Economic Co-operation and Development], 2001, MEAS PROD OECD MAN M; Papola T. S., 2017, ILO ASIA PACIFIC WOR, V178; Prinja S, 2016, FINAL REPORT 2016 EV; Prinja S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170996; Prinja S, 2015, LANCET, V385, P57, DOI 10.1016/S0140-6736(15)60852-2; Prinja S, 2012, INDIAN J MED RES, V136, P421; Reddy G M M, 2009, Indian J Med Sci, V63, P549; Rice D P, 1985, Health Care Financ Rev, V7, P61; Rocha-Garcia A, 2003, SALUD PUBLICA MEXICO, V45, P285, DOI 10.1590/S0036-36342003000400007; Scott K., LIVING STANDARDS MEA; Sharma D, 2017, INDIAN J MED RES, V146, P759, DOI 10.4103/ijmr.IJMR_2003_15; Van Beeck EF, 2007, J TRAUMA, V62, P534, DOI 10.1097/TA.0b013e31802e70c7; Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; Wesson HKH, 2014, HEALTH POLICY PLANN, V29, P795, DOI 10.1093/heapol/czt064; World Health Organization, 2014, INJ VIOL FACTS; World Health Organization, 2018, NONCOMMUNICABLE DIS	42	13	13	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2019	14	11							e0224721	10.1371/journal.pone.0224721	http://dx.doi.org/10.1371/journal.pone.0224721			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LN1GV	31697781	Green Published, gold			2023-01-03	WOS:000532694400050
J	Sampson, EL; Stringer, A; La Frenais, F; Higgins, S; Doyle, MJ; Laybourne, A; Livingston, G; Leavey, G				Sampson, Elizabeth L.; Stringer, Aisling; La Frenais, Francesca; Higgins, Shanlee; Doyle, Mary-Jo; Laybourne, Anne; Livingston, Gill; Leavey, Gerard			Agitation near the end of life with dementia: An ethnographic study of care	PLOS ONE			English	Article							HOSPITAL WARDS; PEOPLE; PREVALENCE; EXPERIENCE; RESIDENTS; VIOLENCE; HOMES; OLDER	Background and objectives Agitation is common in people living with dementia especially at the end of life. We examined how staff interpreted agitation behavior in people with dementia nearing end of life, how this may influence their responses and its impact on the quality of care. Research design Ethnographic study. Structured and semi-structured non-participant observations (referred to subsequently in this paper as "structured observations") of people living with dementia nearing the end of life in hospital and care homes (south-east England) and in-depth interviews with staff, conducted August 2015-March 2017. Methods Three data sources: 1) detailed field notes, 2) observations using a structured tool and checklist for behaviors classed as agitation and staff and institutional responses, 3) staff semi-structured qualitative interviews. We calculated the time participants were agitated and described staff responses. Data sources were analyzed separately, developed continuously and relationally during the study and synthesized where appropriate. Results We identified two main 'ideal types' of staff explanatory models for agitation: In the first, staff attribute agitated behaviors to the person's "moral judgement", making them prone to rejecting or punitive responses. In the second staff adopt a more "needs-based" approach in which agitation behaviors are regarded as meaningful and managed with proactive and investigative approaches. These different approaches appear to have significant consequences for the timing, frequency and quality of staff response. While these models may overlap they tend to reflect distinct organizational resources and values. Conclusions Care worker knowledge about agitation is not enough, and staff need organizational support to care better for people living with dementia towards end of life. Positional theory may help to explain much of the cultural-structural context that produces staff disengagement from people with dementia, offering insights on how agitation behavior is reframed by some staff as dangerous. Such behavior may be associated with low-resource institutions with minimal staff training where the personhood of staff may be neglected.	[Sampson, Elizabeth L.] UCL, Div Psychiat, Marie Curie Palliat Care Res Unit, London, England; [Stringer, Aisling; La Frenais, Francesca; Laybourne, Anne; Livingston, Gill] UCL, Dept Old Age Psychiat, Div Psychiat, London, England; [Higgins, Shanlee; Doyle, Mary-Jo] Camden & Islington NHS Fdn Trust, London, England; [Leavey, Gerard] Ulster Univ, Bamford Ctr Mental Hlth & Wellbeing, Sch Psychol, Coleraine, Londonderry, North Ireland	University of London; University College London; University of London; University College London; Ulster University	Sampson, EL (corresponding author), UCL, Div Psychiat, Marie Curie Palliat Care Res Unit, London, England.	e.sampson@ucl.ac.uk	Higgins, Shanlee/GQB-4926-2022; Sampson, Elizabeth L/B-8647-2009; Leavey, Gerard/AAU-2912-2020	Sampson, Elizabeth L/0000-0001-8929-7362; Leavey, Gerard/0000-0001-8411-8919; Livingston, Gill/0000-0001-6741-5516	UK Economic and Social Research Council; National Institute of Health Research [NIHR/ESRC ES/L001780/1]; UCLH NIHR Biomedical Research Centre; Marie Curie core grant [MCCC-FCO-16-U]; ESRC [ES/L001780/1] Funding Source: UKRI	UK Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); National Institute of Health Research(National Institute for Health Research (NIHR)); UCLH NIHR Biomedical Research Centre; Marie Curie core grant; ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	This study was funded by a grant from the UK Economic and Social Research Council and the National Institute of Health Research Grant number NIHR/ESRC ES/L001780/1. ELS and GL are supported by the UCLH NIHR Biomedical Research Centre. ELS is supported by Marie Curie core grant funding [MCCC-FCO-16-U]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Algase DL, 1996, AM J ALZHEIMERS DIS, V11; Boddington P, 2018, BIOETHICS, V32, P251, DOI 10.1111/bioe.12446; Brodaty H, 2003, J ADV NURS, V44, P583, DOI 10.1046/j.0309-2402.2003.02848.x; Clissett P, 2013, INT J NURS STUD, V50, P1495, DOI 10.1016/j.ijnurstu.2013.03.001; COHENMANSFIELD J, 1989, J GERONTOL, V44, pM77, DOI 10.1093/geronj/44.3.M77; Cummings J, 2015, INT PSYCHOGERIATR, V27, P7, DOI 10.1017/S1041610214001963; Di Giulio P, 2008, J PALLIAT MED, V11, P1023, DOI 10.1089/jpm.2008.0020; Digby R, 2017, J CLIN NURS, V26, P1152, DOI 10.1111/jocn.13429; Folkman S., 1984, STRESS APPRAISAL COP; Fossey J, 2014, INT J GERIATR PSYCH, V29, P797, DOI 10.1002/gps.4072; Harre R., 2003, SELF OTHERS POSITION; Harre R, 2008, SELF CARE DEPENDENT, V16, P4; Harre R, 2009, THEOR PSYCHOL, V19, P5, DOI 10.1177/0959354308101417; Huynh T, 2008, J ADV NURS, V64, P195, DOI 10.1111/j.1365-2648.2008.04780.x; Kadri A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200031; Kitwood T, 1997, AGING MENT HEALTH, V1, P13, DOI 10.1080/13607869757344; Kleinman A., 1980, PATIENTS HEALERS CON; Kovach CR, 2005, J NURS SCHOLARSHIP, V37, P134, DOI 10.1111/j.1547-5069.2005.00025_1.x; Levin E., 1989, NOTICEABLE PROBLEMS; Livingston G, 2017, BJPSYCH OPEN, V3, P171, DOI 10.1192/bjpo.bp.117.005181; Miles M.B., 1994, QUALITATIVE DATA ANA; Mitchell SL, 2009, NEW ENGL J MED, V361, P1529, DOI 10.1056/NEJMoa0902234; Moyle W, 2008, INT J OLDER PEOPLE N, V3, P121, DOI 10.1111/j.1748-3743.2008.00114.x; Mulhall A, 2003, J ADV NURS, V41, P306, DOI 10.1046/j.1365-2648.2003.02514.x; PAVEZA GJ, 1992, GERONTOLOGIST, V32, P493, DOI 10.1093/geront/32.4.493; PILLEMER K, 1989, GERONTOLOGIST, V29, P314, DOI 10.1093/geront/29.3.314; Porock D, 2015, AGEING SOC, V35, P37, DOI 10.1017/S0144686X13000561; Rapaport P, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022260; REISBERG B, 1988, PSYCHOPHARMACOL BULL, V24, P653; Sabat SR, 2008, PEACE PSYCHOL BOOK S, P81, DOI 10.1007/978-0-387-72112-5_5; Sampson EL, 2018, PALLIATIVE MED, V32, P668, DOI 10.1177/0269216317726443; Sampson EL, 2015, PAIN, V156, P675, DOI 10.1097/j.pain.0000000000000095; Sleeman KE, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-59; StataCorp, 2015, STAT STAT SOFTW REL; Stevens M, 2013, BRIT J SOCIOL, V64, P267, DOI 10.1111/1468-4446.12017; Wharton TC, 2014, J GERONTOL SOC WORK, V57, P460, DOI 10.1080/01634372.2014.882466	36	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2019	14	10							e0224043	10.1371/journal.pone.0224043	http://dx.doi.org/10.1371/journal.pone.0224043			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM9XB	31644549	Green Published, gold			2023-01-03	WOS:000532599700041
J	Choonoo, G; Blucher, AS; Higgins, S; Boardman, M; Jeng, S; Zheng, C; Jacobs, J; Anderson, A; Chamberlin, S; Evans, N; Vigoda, M; Cordier, B; Tyner, JW; Kulesz-Martin, M; McWeeney, SK; Laderas, T				Choonoo, Gabrielle; Blucher, Aurora S.; Higgins, Samuel; Boardman, Mitzi; Jeng, Sophia; Zheng, Christina; Jacobs, James; Anderson, Ashley; Chamberlin, Steven; Evans, Nathaniel; Vigoda, Myles; Cordier, Benjamin; Tyner, Jeffrey W.; Kulesz-Martin, Molly; McWeeney, Shannon K.; Laderas, Ted			Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma	PLOS ONE			English	Article							HUMAN-PAPILLOMAVIRUS; SYNTHETIC LETHALITY; CANCER; GENOME; RISK; COMBINATION; EXPRESSION; LANDSCAPE; MUTATION; THERAPY	Head and neck squamous cell carcinoma (HNSCC) remains a morbid disease with poor prognosis and treatment that typically leaves patients with permanent damage to critical functions such as eating and talking. Currently only three targeted therapies are FDA approved for use in HNSCC, two of which are recently approved immunotherapies. In this work, we identify biological pathways involved with this disease that could potentially be targeted by current FDA approved cancer drugs and thereby expand the pool of potential therapies for use in HNSCC treatment. We analyzed 508 HNSCC patients with sequencing information from the Genomic Data Commons (GDC) database and assessed which biological pathways were significantly enriched for somatic mutations or copy number alterations. We then further classified pathways as either "light" or "dark" to the current reach of FDA-approved cancer drugs using the Cancer Targetome, a compendium of drug-target information. Light pathways are statistically enriched with somatic mutations (or copy number alterations) and contain one or more targets of current FDA-approved cancer drugs, while dark pathways are enriched with somatic mutations (or copy number alterations) but not currently targeted by FDA-approved cancer drugs. Our analyses indicated that approximately 35-38% of disease-specific pathways are in scope for repurposing of current cancer drugs. We further assess light and dark pathways for subgroups of patient tumor samples according to HPV status. The framework of light and dark pathways for HNSCC-enriched biological pathways allows us to better prioritize targeted therapies for further research in HNSCC based on the HNSCC genetic landscape and FDA-approved cancer drug information. We also highlight the importance in the identification of sub-pathways where targeting and cross targeting of other pathways may be most beneficial to predict positive or negative synergy with potential clinical significance. This framework is ideal for precision drug panel development, as well as identification of highly aberrant, untargeted candidates for future drug development.	[Choonoo, Gabrielle; Blucher, Aurora S.; Jeng, Sophia; Zheng, Christina; Jacobs, James; Tyner, Jeffrey W.; McWeeney, Shannon K.; Laderas, Ted] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA; [Choonoo, Gabrielle; Higgins, Samuel; Boardman, Mitzi; Zheng, Christina; Jacobs, James; Chamberlin, Steven; Evans, Nathaniel; Cordier, Benjamin; McWeeney, Shannon K.; Laderas, Ted] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Div Bioinformat & Computat Biol, Portland, OR 97201 USA; [Blucher, Aurora S.; Vigoda, Myles; Tyner, Jeffrey W.; Kulesz-Martin, Molly] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA; [Jeng, Sophia; McWeeney, Shannon K.] Oregon Hlth & Sci Univ, Oregon Clin & Translat Res Inst, Portland, OR 97201 USA; [Jacobs, James] OHSU Doernbecher Childrens Hosp, Pediat Hematol & Oncol, Portland, OR USA; [Anderson, Ashley; Vigoda, Myles; Kulesz-Martin, Molly] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA; [Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA; [Choonoo, Gabrielle] Regeneron Pharmaceut, Tarrytown, NY USA; [Higgins, Samuel] Roche Sequencing Solut, Santa Clara, CA USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Regeneron	Blucher, AS (corresponding author), Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.; Blucher, AS (corresponding author), Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA.	blucher@ohsu.edu		Anderson, Ashley/0000-0002-7522-846X; Cordier, Benjamin/0000-0001-5122-7879; Blucher, Aurora/0000-0001-6460-010X	National Cancer Institute [1R01CA192405]; National Library of Medicine Informatics Training Grant [T15LM007088]; Knight Cancer Institute [P30 CA069533]; National Center for Advancing Translational Sciences [5UL1TR000128]; NATIONAL CANCER INSTITUTE [P30CA069533, R01CA192405] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007088] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Library of Medicine Informatics Training Grant; Knight Cancer Institute; National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	This work was supported by the National Cancer Institute 1R01CA192405 (MKM, SKM), National Library of Medicine Informatics Training Grant T15LM007088 (ASB, MB, SC, BC), Knight Cancer Institute P30 CA069533 and the National Center for Advancing Translational Sciences 5UL1TR000128 (SKM). Samuel Higgins is now employed by Roche Sequencing Solutions and Gabrielle Choonoo is now employed by Regeneron Pharmaceuticals. Their contributions to this paper as outlined in the author contributions section were made while they were employed by Oregon Health & Science University, and as such their current employers did not play a role in the study design, data collection and analysis, decision to publish, or preparation of this manuscript.	American Cancer Society, 2018, CANC FACTS FIG 2018; Benjamini Y, 2001, ANN STAT, V29, P1165; Blucher Aurora S, 2019, F1000Res, V8, P908, DOI 10.12688/f1000research.19592.1; Blucher AS, 2017, TRENDS PHARMACOL SCI, V38, P1085, DOI 10.1016/j.tips.2017.08.006; Brand TM, 2018, CANCER RES, V78, P2383, DOI 10.1158/0008-5472.CAN-17-1672; Chen JJ, 2013, ONCOTARGET, V4, P206, DOI 10.18632/oncotarget.813; Chin D, 2004, BRIT J PLAST SURG, V57, P595, DOI 10.1016/j.bjps.2004.06.010; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Eckhardt M, 2018, CANCER DISCOV, V8, P1474, DOI 10.1158/2159-8290.CD-17-1018; Economopoulou P, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000122; Ferrari E, 2010, EUR J CANCER, V46, P2889, DOI 10.1016/j.ejca.2010.07.031; Fukusumi T, 2018, J DENT RES, V97, P645, DOI 10.1177/0022034518760297; Furquim CP, 2018, CRIT REV ONCOL HEMAT, V125, P35, DOI 10.1016/j.critrevonc.2018.02.013; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gillison ML, 2008, JNCI-J NATL CANCER I, V100, P407, DOI 10.1093/jnci/djn025; Gillison ML, 2019, GENOME RES, V29, P1, DOI 10.1101/gr.241141.118; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Gross AM, 2014, NAT GENET, V46, P939, DOI 10.1038/ng.3051; Grossman RL, 2016, NEW ENGL J MED, V375, P1109, DOI 10.1056/NEJMp1607591; Hedberg ML, 2019, J EXP MED, V216, P419, DOI 10.1084/jem.20181936; Higgins S., 2016, DRUG SENSITIVITIES C, DOI [10.6083/m48k7732, DOI 10.6083/M48K7732]; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Jung AC, 2013, CLIN CANCER RES, V19, P4174, DOI 10.1158/1078-0432.CCR-12-3690; Jung M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020273; Khatri P, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002375; Kurtz SE, 2017, P NATL ACAD SCI USA, V114, pE7554, DOI 10.1073/pnas.1703094114; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lehtonen S, 2004, AM J PATHOL, V165, P923, DOI 10.1016/S0002-9440(10)63354-8; Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; McLornan DP, 2014, NEW ENGL J MED, V371, P1725, DOI 10.1056/NEJMra1407390; Moskovitz J, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912-018-0654-5; Murphy BA, 2007, CRIT REV ONCOL HEMAT, V62, P251, DOI 10.1016/j.critrevonc.2006.07.005; National Cancer Institute (NCI), 2019, TARG CANC THER; Nulton TJ, 2017, ONCOTARGET, V8, P17684, DOI 10.18632/oncotarget.15179; Nyman PE, 2018, CLIN CANCER RES, V24, P6308, DOI 10.1158/1078-0432.CCR-17-3535; Palmer AC, 2017, CELL, V171, P1678, DOI 10.1016/j.cell.2017.11.009; Parfenov M, 2014, P NATL ACAD SCI USA, V111, P15544, DOI 10.1073/pnas.1416074111; Perdomo S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191701; Scheckenbach K, 2012, KLIN PADIATR, V224, P132, DOI 10.1055/s-0032-1308989; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Siu LL, 2019, JAMA ONCOL, V5, P195, DOI 10.1001/jamaoncol.2018.4628; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taberna M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00383; Teng MS, 2005, ARCH OTOLARYNGOL, V131, P407, DOI 10.1001/archotol.131.5.407; Union for International Cancer Control, 2014, LOC ADV SQUAM CELL C; Velleuer Eunike, 2014, Mol Cell Pediatr, V1, P9, DOI 10.1186/s40348-014-0009-8; Worsham MJ, 2011, EXPERT REV ANTICANC, V11, P1321, DOI [10.1586/era.11.135, 10.1586/ERA.11.135]; Wu Guanming, 2014, F1000Res, V3, P146, DOI 10.12688/f1000research.4431.1; Zhou LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051545	50	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2019	14	10							e0223639	10.1371/journal.pone.0223639	http://dx.doi.org/10.1371/journal.pone.0223639			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM7QS	31596908	gold, Green Published			2023-01-03	WOS:000532444100053
J	Abu, HO; Lapane, KL; Waring, ME; Ulbricht, CM; Devereaux, RS; McManus, DD; Allison, JJ; Kiefe, CI; Goldberg, RJ				Abu, Hawa O.; Lapane, Kate L.; Waring, Molly E.; Ulbricht, Christine M.; Devereaux, Randolph S.; McManus, David D.; Allison, Jeroan J.; Kiefe, Catarina, I; Goldberg, Robert J.			Religious practices and long-term survival after hospital discharge for an acute coronary syndrome	PLOS ONE			English	Article							ALL-CAUSE MORTALITY; RISK-FACTORS; SHORT-FORM; HEALTH; PRAYER; SPIRITUALITY; PREDICTORS; ATTENDANCE; OUTCOMES; ASSOCIATION	Background Prior studies of healthy populations have found religious practices to be associated with survival. However, no contemporary studies have examined whether religiosity influences survival among patients discharged from the hospital after an acute coronary syndrome (ACS). The present study examined the relationship between religious practices and 2-year all-cause mortality among hospital survivors of an ACS. Methods Patients hospitalized for an ACS were recruited from 6 medical centers in Massachusetts and Georgia between 2011 and 2013. Study participants self-reported three items assessing religiosity: strength/comfort from religion, petition prayers for health, and awareness of intercessory prayers by others. All cause-mortality within 2-years of hospital discharge was ascertained by review of medical records at participating study hospitals and from death certificates. Cox proportional hazards models were used to estimate the multivariable adjusted risk of 2-year all-cause mortality. Results Participants (n = 2,068) were on average 61 years old, 34% were women, and 81% were non-Hispanic White. Approximately 85% derived strength/comfort from religion, 61% prayed for their health, and 89% were aware of intercessions. Overall, 6% died within 2 years post-discharge. After adjusting for sociodemographic variables (age, sex, and race/ethnicity), petition prayers were associated with an increased risk of 2-year all-cause mortality (HR: 1.64; 95% CI: 1.01-2.66). With further adjustment for several clinical and psychosocial measures, this association was no longer statistically significant. Strength and comfort from religion and intercessory prayers were not significantly associated with mortality. Conclusions Most ACS survivors acknowledge deriving strength and comfort from religion, praying for their health, and intercessions made by others for their health. Although the reported religious practices were not associated with post-discharge survival after multivariable adjustment, acknowledging that patients utilize their religious beliefs and practices as strategies to improve their health would ensure a more holistic approach to patient management and promote cultural competence in healthcare.	[Abu, Hawa O.; Lapane, Kate L.; Ulbricht, Christine M.; Allison, Jeroan J.; Kiefe, Catarina, I; Goldberg, Robert J.] Univ Massachusetts, Sch Med, Dept Populat & Quantitat Hlth Sci, Worcester, MA 01655 USA; [Waring, Molly E.] Univ Connecticut, Dept Allied Hlth Sci, Storrs, CT USA; [Devereaux, Randolph S.] Mercer Univ, Sch Med, Dept Community Med, Macon, GA 31207 USA; [McManus, David D.] Univ Massachusetts, Sch Med, Dept Med, Div Cardiovasc Med, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Connecticut; Mercer University; University of Massachusetts System; University of Massachusetts Worcester	Abu, HO (corresponding author), Univ Massachusetts, Sch Med, Dept Populat & Quantitat Hlth Sci, Worcester, MA 01655 USA.	Hawa.Abu@umassmed.edu		Abu, Hawa/0000-0002-9359-7373	National Institutes of Health [U01HL105268]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Grant support: Transitions, Risks, and Actions in Coronary Events: Center for Outcomes Research and Education (TRACE-CORE) was supported by National Institutes of Health (U01HL105268). The funding source had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abu HO, 2019, COMMUNITY ENGAGEMENT, DOI [10.13028/vb4f-cr19, DOI 10.13028/VB4F-CR19]; Ai A. L., 2000, INT J PSYCHOL RELIG, V10, P205, DOI DOI 10.1207/S15327582IJPR1004_01; Anderson JL, 2013, CIRCULATION, V127, pE663, DOI 10.1161/CIR.0b013e31828478ac; Andrade Chittaranjan, 2009, Indian J Psychiatry, V51, P247, DOI 10.4103/0019-5545.58288; Barnes Patricia M, 2004, Adv Data, P1; BEARON LB, 1990, GERONTOLOGIST, V30, P249, DOI 10.1093/geront/30.2.249; Bernardi L, 2001, BRIT MED J, V323, P1446, DOI 10.1136/bmj.323.7327.1446; Berntson GG, 2008, ANN BEHAV MED, V35, P198, DOI 10.1007/s12160-008-9027-x; Blumenthal JA, 2007, PSYCHOSOM MED, V69, P501, DOI 10.1097/PSY.0b013e3180cab76c; Boersma E, 2000, CIRCULATION, V101, P2557, DOI 10.1161/01.CIR.101.22.2557; COHEN Y, 1988, J CHEM SOC PERK T 2, P31, DOI 10.1039/p29880000031; Debnam KJ, 2012, AM J HEALTH BEHAV, V36, P360, DOI 10.5993/AJHB.36.3.7; Eagle KA, 2004, JAMA-J AM MED ASSOC, V291, P2727, DOI 10.1001/jama.291.22.2727; Ferrucci I, 1998, AGING CLIN EXP RES, V10, P332; Fosarelli P, 2011, LINACRE Q, V78, P125, DOI 10.1179/002436311803888384; Fox KAA, 2006, BMJ-BRIT MED J, V333, P1091, DOI 10.1136/bmj.38985.646481.55; Gall TL, 2005, CAN PSYCHOL, V46, P88, DOI 10.1037/h0087008; Goldberg RJ, 2015, AM J MED, V128, P1087, DOI 10.1016/j.amjmed.2015.05.002; Gupta R, 1997, J CLIN EPIDEMIOL, V50, P203, DOI 10.1016/S0895-4356(96)00281-8; Hibbard JH, 2005, HEALTH SERV RES, V40, P1918, DOI 10.1111/j.1475-6773.2005.00438.x; Kalamazoo MI, 1999, MULTIDIMENSIONAL MEA; Koenig Harold G, 2012, ISRN Psychiatry, V2012, P278730, DOI 10.5402/2012/278730; Kolansky Daniel M, 2009, Am J Manag Care, V15, pS36; Krause N, 2005, INT J PSYCHOL RELIG, V15, P73, DOI [DOI 10.1207/s15327582ijpr1501_6, 10.1207/]; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Krucoff MW, 2005, LANCET, V366, P211, DOI 10.1016/S0140-6736(05)66910-3; Li SS, 2016, JAMA INTERN MED, V176, P777, DOI 10.1001/jamainternmed.2016.1615; Manson JE, 2002, NEW ENGL J MED, V347, P716, DOI 10.1056/NEJMoa021067; OXMAN TE, 1995, PSYCHOSOM MED, V57, P5, DOI 10.1097/00006842-199501000-00002; Park CL, 2007, J BEHAV MED, V30, P319, DOI 10.1007/s10865-007-9111-x; Paxton AE, 2011, AM J PREV MED, V40, P67, DOI 10.1016/j.amepre.2010.10.009; Pocock S, 2015, EUR HEART J-ACUTE CA, V4, P509, DOI 10.1177/2048872614554198; Powers BJ, 2010, JAMA-J AM MED ASSOC, V304, P76, DOI 10.1001/jama.2010.896; Ross LE, 2008, J ALTERN COMPLEM MED, V14, P931, DOI 10.1089/acm.2007.0788; Schnall E, 2010, PSYCHOL HEALTH, V25, P249, DOI 10.1080/08870440802311322; SPERTUS JA, 1995, J AM COLL CARDIOL, V25, P333, DOI 10.1016/0735-1097(94)00397-9; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Strawbridge WJ, 1997, AM J PUBLIC HEALTH, V87, P957, DOI 10.2105/AJPH.87.6.957; Trevino KM, 2014, J RELIG HEALTH, V53, P1907, DOI 10.1007/s10943-014-9897-0; VanderWeele TJ, 2017, AM J EPIDEMIOL, V185, P515, DOI 10.1093/aje/kww179; Walter S, 2009, EUR J EPIDEMIOL, V24, P733, DOI 10.1007/s10654-009-9411-2; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Waring ME, 2012, CIRC-CARDIOVASC QUAL, V5, pE44, DOI 10.1161/CIRCOUTCOMES.112.965418; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487	44	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2019	14	10							e0223442	10.1371/journal.pone.0223442	http://dx.doi.org/10.1371/journal.pone.0223442			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM7CZ	31584980	Green Published, gold			2023-01-03	WOS:000532407600034
J	Genberg, BL; Hogan, JW; Xu, YZ; Nyambura, M; Tarus, C; Rotich, E; Kafu, C; Wachira, J; Goodrich, S; Braitstein, P				Genberg, Becky L.; Hogan, Joseph W.; Xu, Yizhen; Nyambura, Monicah; Tarus, Caren; Rotich, Elyne; Kafu, Catherine; Wachira, Juddy; Goodrich, Suzanne; Braitstein, Paula			Population-based estimates of engagement in HIV care and mortality using double-sampling methods following home-based counseling and testing in western Kenya	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; LINKAGE; PROGRAM	Introduction Data on engagement in HIV care from population-based samples in sub-Saharan Africa are limited. The objective of this study was to use double-sampling methods to estimate linkage to HIV care, ART initiation, and mortality among all adults diagnosed with HIV by a comprehensive home-based counseling and testing (HBCT) program in western Kenya. Methods HBCT was conducted door-to-door from December 2009 to April 2011 in three sub-counties of western Kenya by AMPATH (Academic Model Providing Access to Healthcare). For those identified as HIV-positive, data were merged with electronic medical records to determine engagement with HIV care. A randomly-drawn follow-up sample of 120 adults identified via HBCT who had not linked to care as of June 2015 in Bunyala sub-county were visited by trained fieldworkers to ascertain HIV care engagement and vital status. Double-sampled data were used to generate, via multinomial regression, predicted probabilities of engagement in care and mortality among those whose status could not be ascertained by matching with the electronic medical records in the three catchments. Results Incorporating information from the double-sampling yielded estimates of prospective linkage to HIV care that ranged from 40-45%. Mortality estimates of those who did not engage in care following HBCT ranged from 12-16%. Among those who linked to care following HBCT, between 72-81% initiated ART. Discussion In settings without universal national identifiers, rates of linkage to care from community-based programs may be subject to substantial underestimation. Follow-up samples of those with missing information can be used to partially correct this bias, as has been demonstrated previously for mortality among those who were lost-to-care programs. There is a need for harmonized data systems across health systems and programs.	[Genberg, Becky L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Genberg, Becky L.] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA; [Hogan, Joseph W.; Xu, Yizhen] Brown Univ, Sch Publ Hlth, Dept Biostat, Providence, RI 02912 USA; [Hogan, Joseph W.; Nyambura, Monicah; Tarus, Caren; Rotich, Elyne; Kafu, Catherine; Wachira, Juddy; Braitstein, Paula] Acad Model Providing Access Healthcare AMPATH, Eldoret, Kenya; [Wachira, Juddy; Braitstein, Paula] Moi Univ, Sch Med, Coll Hlth Sci, Eldoret, Kenya; [Goodrich, Suzanne] Indiana Univ, Sch Med, Div Infect Dis, Indianapolis, IN USA; [Braitstein, Paula] Univ Toronto, Dalla Lana Sch Publ Hlth, Off Global Publ Hlth Educ & Training, Epidemiol Div, Toronto, ON, Canada	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Brown University; Brown University; Moi University; Indiana University System; Indiana University-Purdue University Indianapolis; University of Toronto	Braitstein, P (corresponding author), Acad Model Providing Access Healthcare AMPATH, Eldoret, Kenya.; Braitstein, P (corresponding author), Moi Univ, Sch Med, Coll Hlth Sci, Eldoret, Kenya.; Braitstein, P (corresponding author), Univ Toronto, Dalla Lana Sch Publ Hlth, Off Global Publ Hlth Educ & Training, Epidemiol Div, Toronto, ON, Canada.	pbraitstein@gmail.com		Genberg, Becky/0000-0002-9450-5311; Kafu, Catherine/0000-0003-4890-4458; Braitstein, Paula/0000-0003-0541-2955	National Institute of Allergy And Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD); National Institute On Drug Abuse (NIDA); National Cancer Institute (NCI); National Institute of Mental Health (NIMH); National Institutes of Health [U01AI069911]; NIMH [K01MH099966]; NIAD [R01AI108441]; Providence-Boston CFAR [P30AI042853]; Regenstrief Institute; President's Emergency Plan for AIDS Relief (PEPFAR) through USAID [AID-623-A-12-0001]; United States Agency for International Development (USAID); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI069911, P30AI042853, R01AI108441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K01MH099966] Funding Source: NIH RePORTER	National Institute of Allergy And Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute On Drug Abuse (NIDA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIAD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Providence-Boston CFAR; Regenstrief Institute; President's Emergency Plan for AIDS Relief (PEPFAR) through USAID(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); United States Agency for International Development (USAID)(United States Agency for International Development (USAID)CGIAR); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Research reported in this publication was supported by the National Institute of Allergy And Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), National Institute On Drug Abuse (NIDA), National Cancer Institute (NCI), and the National Institute of Mental Health (NIMH), in accordance with the regulatory requirements of the National Institutes of Health under award number U01AI069911 East Africa IeDEA Consortium (PB). Additional support was provided by NIMH (K01MH099966; BLG), NIAD (R01AI108441; JWH), Providence-Boston CFAR (P30AI042853; JWH) and the Regenstrief Institute (PB). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through USAID under the terms of cooperative agreement no. AID-623-A-12-0001. It is made possible through joint support of the United States Agency for International Development (USAID). The contents of this journal article are the sole responsibility of AMPATH and do not necessarily reflect the views of USAID or the United States Government.	Bassett IV, 2014, HIV MED, V15, P367, DOI 10.1111/hiv.12115; Einterz RM, 2007, ACAD MED, V82, P812, DOI 10.1097/ACM.0b013e3180cc29f1; Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243; Genberg BL, 2015, LANCET HIV, V2, pE20, DOI 10.1016/S2352-3018(14)00034-4; Geng EH, 2015, LANCET HIV, V2, pE107, DOI 10.1016/S2352-3018(15)00002-8; Haber N, 2017, LANCET HIV, V4, pE223, DOI 10.1016/S2352-3018(16)30224-7; Inui TS, 2007, J GEN INTERN MED, V22, P1745, DOI 10.1007/s11606-007-0437-4; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2017, END AIDS PROGR 90 90; Kilmarx PH, 2013, CURR OPIN HIV AIDS, V8, P59, DOI 10.1097/COH.0b013e32835b806e; Kimaiyo S, 2010, East Afr Med J, V87, P100; Layer EH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104961; Mugglin C, 2012, TROP MED INT HEALTH, V17, P1509, DOI 10.1111/j.1365-3156.2012.03089.x; Rachlis B, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3462-6; Rachlis B, 2015, JAIDS-J ACQ IMM DEF, V68, pE46, DOI 10.1097/QAI.0000000000000492; Rosen S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001056; Ruzagira E, 2017, TROP MED INT HEALTH, V22, P807, DOI 10.1111/tmi.12888; Sayers A, 2016, INT J EPIDEMIOL, V45, P954, DOI 10.1093/ije/dyv322; UNAIDS, 2014, 90 90 90 AMB TREATM; Wachira J, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0646-6	19	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2019	14	10							e0223187	10.1371/journal.pone.0223187	http://dx.doi.org/10.1371/journal.pone.0223187			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM6VM	31577834	Green Published, gold			2023-01-03	WOS:000532388000024
J	Edwards, PJ; Stechman, MJ; Green, JT				Edwards, Peter J.; Stechman, Michael J.; Green, John T.			How to pass the emergency OSCE station	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Edwards, Peter J.] Univ Bristol Sch Med, Bristol, Avon, England; [Stechman, Michael J.; Green, John T.] Cardiff & Vale Univ Hlth Board, Cardiff, S Glam, Wales; [Stechman, Michael J.; Green, John T.] Cardiff Univ, Sch Med, Cardiff, S Glam, Wales	University of Bristol; Cardiff University	Edwards, PJ (corresponding author), Univ Bristol Sch Med, Bristol, Avon, England.	peter.edwards@bristol.ac.uk		Edwards, Peter/0000-0001-6999-753X				Arunakirinathan M, 2014, SUCCESSFULLY APPLY A; Blackburn JR, 2015, STUDENT BMJ, V23, ph1367, DOI [10.1136/sbmj.h1367, DOI 10.1136/SBMJ.H1367]; Daniels R, 2011, EMERG MED J, V28, P507, DOI 10.1136/emj.2010.095067; General Medical Council, 2015, OUTC GRAD TOM DOCT; General Medical Council, 2018, OUTC GRAD GMC 2018; Heinke W, 2013, BMC MED EDUC, V13, DOI 10.1186/1472-6920-13-138; Interview Skills Consulting Ltd, 2019, STRUCT CT ST INT 201; Mansbridge C., 2014, ACUTE PRESENTATION A; Marcus A, 2013, STUDENT BMJ, V21, P871, DOI [10.1136/sbmj.f871, DOI 10.1136/SBMJ.F871]; MERTEN H, 2017, BMJ-BRIT MED J, V359, P93308, DOI DOI 10.1136/BMJ.J4328; National Institute for Health and Care Excellence, 2012, VEN THROMB DIS DIAGN, V144; Nolan J, 2016, ADV LIFE SUPPORT; Resuscitation Council (UK), ABCDE APPR; Royal College of Physicians, 2017, NAT EARL WARN SCOR N; T Dornan, 2009, DEPTH INVESTIGATION	15	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	2019	367								l2414	10.1136/sbmj.l2414	http://dx.doi.org/10.1136/sbmj.l2414			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD1ZC	31575527	Green Submitted			2023-01-03	WOS:000489773900001
J	Oud, L				Oud, Lavi			In-hospital cardiopulmonary resuscitation of patients with cirrhosis: A population-based analysis	PLOS ONE			English	Article							UNITED-STATES; MORTALITY; EPIDEMIOLOGY; OUTCOMES; LIVER; SURVIVAL; DISEASES; BURDEN; TRENDS; DEATH	Objective To examine the epidemiology and outcomes of in-hospital cardiopulmonary resuscitation (CPR) among patients with cirrhosis. Methods We used the Texas Inpatient Public Use Data File to identify hospitalizations aged. 18 years with and without cirrhosis during 2009-2014 and those in each group who have undergone in-hospital CPR. Short-term survival (defined as absence of hospital mortality or discharge to hospice) following in-hospital CPR was examined. Multivariate logistic regression modeling was used to assess the prognostic impact of cirrhosis following in-hospital CPR and predictors of short-term survival among cirrhosis hospitalizations. Results In-hospital CPR was reported in 2,511 and 51,969 hospitalizations with and without cirrhosis, respectively. The rate of in-hospital CPR (per 1,000 hospitalizations) was 7.6 and 4.0 among hospitalizations with and without cirrhosis, respectively. The corresponding rate of in-hospital CPR among decedents was 10.7% and 13.4%, respectively. Short-term survival following in-hospital CPR among hospitalizations with and without cirrhosis was 14.9% and 27.3%, respectively, and remained unchanged over time on adjusted analyses among the former (p = 0.1753), while increasing among the latter (p = 0.0404). Cirrhosis was associated with lower odds of short-term survival following in-hospital CPR (adjusted odds ratio [aOR] 0.55 [95% CI: 0.49-0.62]). Lack of health insurance (vs. Medicare) (aOR] 0.47 [95% CI: 0.34-0.67]) and sepsis ([aOR] 0.67 [95% CI: 0.53-85]) were associated with lower odds of short-term survival following in-hospital CPR among cirrhosis hospitalizations. Conclusions The rate of in-hospital CPR was nearly 2-fold higher among hospitalizations with cirrhosis than among those without it, though it was used more selectively among the former. Short-term survival following in-hospital CPR remained markedly lower among cirrhosis hospitalizations, while progressively improving among those without cirrhosis. Strategies to increase access to health insurance and improve early identification and control of infection should be explored in future preventive and interventional efforts.	[Oud, Lavi] Texas Tech Univ, Dept Internal Med, Div Pulm & Crit Care Med, Hlth Sci Ctr Permian Basin, Odessa, TX 79763 USA	Texas Tech University System; Texas Tech University	Oud, L (corresponding author), Texas Tech Univ, Dept Internal Med, Div Pulm & Crit Care Med, Hlth Sci Ctr Permian Basin, Odessa, TX 79763 USA.	lavi.oud@ttuhsc.edu		Oud, Lavi/0000-0002-9003-6845				Ahmad S, 2013, GASTROENTEROLOGY, V144, pS1000; Chung CP, 2010, PHARMACOEPIDEM DR S, V19, P563, DOI 10.1002/pds.1888; de Vos R, 1999, ARCH INTERN MED, V159, P845, DOI 10.1001/archinte.159.8.845; Everhart JE, 2009, GASTROENTEROLOGY, V136, P1134, DOI 10.1053/j.gastro.2009.02.038; Girotra S, 2012, NEW ENGL J MED, V367, P1912, DOI 10.1056/NEJMoa1109148; Hennessy S, 2010, PHARMACOEPIDEM DR S, V19, P555, DOI 10.1002/pds.1869; Kazaure HS, 2013, RESUSCITATION, V84, P1255, DOI 10.1016/j.resuscitation.2013.02.021; Khera R, 2017, JAMA CARDIOL, V2, P1275, DOI 10.1001/jamacardio.2017.2904; Kramer JR, 2008, ALIMENT PHARM THERAP, V27, P274, DOI 10.1111/j.1365-2036.2007.03572.x; Lyon SM, 2011, AM J RESP CRIT CARE, V184, P809, DOI 10.1164/rccm.201101-0089OC; Majumdar A, 2017, J HEPATOL, V67, P1185, DOI 10.1016/j.jhep.2017.07.024; Mallikethi-Reddy S, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.116.003194; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Oud L, 2015, CRIT CARE RES PRACT, V2015, DOI 10.1155/2015/618067; Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433; Reinders ME, 2017, CLIN GASTROENTEROL H, V15, P1808, DOI 10.1016/j.cgh.2017.05.044; Roedl K, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0322-1; Scaglione S, 2015, J CLIN GASTROENTEROL, V49, P690, DOI 10.1097/MCG.0000000000000208; Schmidt ML, 2015, GASTROENTEROLOGY, V148, P967, DOI 10.1053/j.gastro.2015.01.032; Shaheen NJ, 2006, AM J GASTROENTEROL, V101, P2128, DOI 10.1111/j.1572-0241.2006.00723.x; Shahreyar Muhammad, 2017, JACC Clin Electrophysiol, V3, P174, DOI 10.1016/j.jacep.2016.08.011; Singal AK, 2014, ALIMENT PHARM THER, V40, P105, DOI 10.1111/apt.12797; Stapleton RD, 2014, CHEST, V146, P1214, DOI 10.1378/chest.13-2110; Zoch TW, 2000, ARCH INTERN MED, V160, P1969, DOI 10.1001/archinte.160.13.1969	24	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2019	14	9							e0222873	10.1371/journal.pone.0222873	http://dx.doi.org/10.1371/journal.pone.0222873			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM6MW	31568520	gold, Green Published			2023-01-03	WOS:000532364900012
J	Knikou, M; Murray, LM				Knikou, Maria; Murray, Lynda M.			Repeated transspinal stimulation decreases soleus H-reflex excitability and restores spinal inhibition in human spinal cord injury	PLOS ONE			English	Article							POST-ACTIVATION DEPRESSION; INDUCED MUSCLE-CONTRACTION; EPIDURAL STIMULATION; FLEXION REFLEX; MOTOR; MOTONEURONS; MODULATION; LOCOMOTION; SPASTICITY; AFFERENTS	Transcutaneous spinal cord or transspinal stimulation over the thoracolumbar enlargement, the spinal location of motoneurons innervating leg muscles, modulates neural circuits engaged in the control of movement. The extent to which daily sessions (e.g. repeated) of transspinal stimulation affects soleus H-reflex excitability in individuals with chronic spinal cord injury (SCI) remains largely unknown. In this study, we established the effects of repeated cathodal transspinal stimulation on soleus H-reflex excitability and spinal inhibition in individuals with and without chronic SCI. Ten SCI and 10 healthy control subjects received monophasic transspinal stimuli of 1-ms duration at 0.2 Hz at subthreshold and suprathreshold intensities of the right soleus transspinal evoked potential (TEP). SCI subjects received an average of 16 stimulation sessions, while healthy control subjects received an average of 10 stimulation sessions. Before and one or two days post intervention, we used the soleus H reflex to assess changes in motoneuron recruitment, homosynaptic depression following single tibial nerve stimuli delivered at 0.1, 0.125, 0.2, 0.33 and 1.0 Hz, and postactivation depression following paired tibial nerve stimuli at the interstimulus intervals of 60, 100, 300, and 500 ms. Soleus H-reflex excitability was decreased in both legs in motor incomplete and complete SCI but not in healthy control subjects. Soleus H-reflex homosynaptic and postactivation depression was present in motor incomplete and complete SCI but was of lesser strength to that observed in healthy control subjects. Repeated transspinal stimulation increased homosynaptic depression in all SCI subjects and remained unaltered in healthy controls. Postactivation depression remained unaltered in all subject groups. Lastly, transspinal stimulation decreased the severity of spasms and ankle clonus. The results indicate decreased reflex hyperexcitability and recovery of spinal inhibitory control in the injured human spinal cord with repeated transspinal stimulation. Transspinal stimulation is a noninvasive neuromodulation method for restoring spinally-mediated afferent reflex actions after SCI in humans.	[Knikou, Maria; Murray, Lynda M.] CUNY Coll Staten Isl, Dept Phys Therapy, Klab4Recovery Res Lab, Staten Isl, NY 10301 USA; [Knikou, Maria] CUNY, Grad Ctr, PhD Program Biol, New York, NY 10021 USA; [Knikou, Maria] CUNY, Grad Ctr, Collaborat Neurosci Program, New York, NY 10021 USA	City University of New York (CUNY) System; College of Staten Island (CUNY); City University of New York (CUNY) System; City University of New York (CUNY) System	Knikou, M (corresponding author), CUNY Coll Staten Isl, Dept Phys Therapy, Klab4Recovery Res Lab, Staten Isl, NY 10301 USA.; Knikou, M (corresponding author), CUNY, Grad Ctr, PhD Program Biol, New York, NY 10021 USA.; Knikou, M (corresponding author), CUNY, Grad Ctr, Collaborat Neurosci Program, New York, NY 10021 USA.	Maria.Knikou@csi.cuny.edu	, Lynda/E-3207-2015	, Lynda/0000-0001-7467-5607; Knikou, Maria/0000-0002-6277-236X	Craig H. Neilsen Foundation [339705]; Spinal Cord Injury Research Board of the New York State Department of Health [C32248GG]	Craig H. Neilsen Foundation; Spinal Cord Injury Research Board of the New York State Department of Health	This research was supported by grants from the Craig H. Neilsen Foundation [Grant No. 339705], and by the Spinal Cord Injury Research Board of the New York State Department of Health [Contract No. C32248GG], both awarded to Maria Knikou. The funder(s) had no role in the design and conduct of the study, collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	Adams MM, 2007, ARCH PHYS MED REHAB, V88, P1185, DOI 10.1016/j.apmr.2007.06.012; Aymard C, 2000, BRAIN, V123, P1688, DOI 10.1093/brain/123.8.1688; BERGMANS J, 1969, ARCH INT PHYS BIOCH, V77, P354; CHOFFLON M, 1982, J PHYSIOL-LONDON, V323, P393, DOI 10.1113/jphysiol.1982.sp014079; Christiansen L, 2018, NEUROTHERAPEUTICS, V15, P618, DOI 10.1007/s13311-018-0639-y; Cote MP, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00784; Cote MP, 2014, J NEUROSCI, V34, P8976, DOI 10.1523/JNEUROSCI.0678-14.2014; Cote MP, 2011, J NEUROTRAUM, V28, P299, DOI 10.1089/neu.2010.1594; CRONE C, 1989, EXP BRAIN RES, V78, P28, DOI 10.1007/bf00230683; D'Amico JM, 2013, J NEUROPHYSIOL, V109, P1473, DOI 10.1152/jn.00821.2012; Dimitrijevic MR, 1998, ANN NY ACAD SCI, V860, P360, DOI 10.1111/j.1749-6632.1998.tb09062.x; ECCLES JC, 1967, EXP BRAIN RES, V3, P58; ECCLES JC, 1951, J NEUROPHYSIOL, V14, P353, DOI 10.1152/jn.1951.14.5.353; Eccles JC, 1941, J PHYSIOL-LONDON, V100, P318, DOI 10.1113/jphysiol.1941.sp003945; ElBasiouny SM, 2010, CLIN NEUROPHYSIOL, V121, P1669, DOI 10.1016/j.clinph.2009.12.041; ElBasiouny SM, 2007, J APPL PHYSIOL, V103, P1824, DOI 10.1152/japplphysiol.00362.2007; ElBasiouny SM, 2007, J APPL PHYSIOL, V103, P276, DOI 10.1152/japplphysiol.01222.2006; Frischknecht R, 2009, NAT NEUROSCI, V12, P897, DOI 10.1038/nn.2338; Grey MJ, 2008, EXP BRAIN RES, V185, P189, DOI 10.1007/s00221-007-1142-6; Harkema S, 2011, LANCET, V377, P1938, DOI 10.1016/S0140-6736(11)60547-3; Hofstoetter US, 2017, CURR PHARM DESIGN, V23, P1805, DOI 10.2174/1381612822666161214144655; Hofstoetter US, 2015, ARTIF ORGANS, V39, pE176, DOI 10.1111/aor.12615; Hofstoetter US, 2014, J SPINAL CORD MED, V37, P202, DOI 10.1179/2045772313Y.0000000149; Hultborn H, 1996, EXP BRAIN RES, V108, P450; HUNTER JP, 1994, J PHYSIOL-LONDON, V474, P407, DOI 10.1113/jphysiol.1994.sp020032; KATZ R, 1977, J NEUROL NEUROSUR PS, V40, P575, DOI 10.1136/jnnp.40.6.575; Kim H, 2017, J APPL PHYSIOL, V123, P1166, DOI 10.1152/japplphysiol.00034.2017; Klimstra M, 2008, EXP BRAIN RES, V186, P93, DOI 10.1007/s00221-007-1207-6; Knikou M, 2007, SPINAL CORD, V45, P69, DOI 10.1038/sj.sc.3101917; Knikou M, 2005, SPINAL CORD, V43, P640, DOI 10.1038/sj.sc.3101772; Knikou M, 2002, MUSCLE NERVE, V26, P374, DOI 10.1002/mus.10206; Knikou M, 2008, J NEUROSCI METH, V171, P1, DOI 10.1016/j.jneumeth.2008.02.012; Knikou M, 2007, EXP NEUROL, V204, P171, DOI 10.1016/j.expneurol.2006.10.006; Knikou M, 2018, J ELECTROMYOGR KINES, V43, P174, DOI 10.1016/j.jelekin.2018.10.005; Knikou M, 2015, J NEUROPHYSIOL, V114, P1486, DOI 10.1152/jn.00449.2015; Knikou M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102313; Knikou M, 2014, J NEUROPHYSIOL, V111, P2264, DOI 10.1152/jn.00871.2013; Knikou M, 2013, BIOELECTROMAGNETICS, V34, P630, DOI 10.1002/bem.21808; Knikou M, 2013, EXP BRAIN RES, V228, P279, DOI 10.1007/s00221-013-3560-y; Knikou M, 2010, CLIN NEUROPHYSIOL, V121, P1655, DOI 10.1016/j.clinph.2010.01.039; Lamy JC, 2005, EXP BRAIN RES, V166, P248, DOI 10.1007/s00221-005-2360-4; Lin SH, 2019, J NEUROPHYSIOL, V121, P1352, DOI 10.1152/jn.00776.2018; Minassian K, 2004, SPINAL CORD, V42, P401, DOI 10.1038/sj.sc.3101615; Murray LM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213696; Murray LM, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00050; Norton JA, 2008, BRAIN, V131, P1478, DOI 10.1093/brain/awn050; Savic G, 2007, SPINAL CORD, V45, P444, DOI 10.1038/sj.sc.3102044; Sayenko DG, 2015, J APPL PHYSIOL, V118, P1364, DOI 10.1152/japplphysiol.01128.2014; Schindler-Ivens S, 2000, EXP BRAIN RES, V133, P233, DOI 10.1007/s002210000377; Smith AC, 2015, EXP BRAIN RES, V233, P89, DOI 10.1007/s00221-014-4094-7; TABORIKOVA H, 1969, BRAIN, V92, P203, DOI 10.1093/brain/92.1.203; Thompson AK, 2013, J NEUROSCI, V33, P2365, DOI 10.1523/JNEUROSCI.3968-12.2013; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; Tsentsevitsky A, 2017, J NEUROSCI RES, V95, P1391, DOI 10.1002/jnr.23977; Wang Y, 2006, EUR J NEUROSCI, V23, P141, DOI 10.1111/j.1460-9568.2005.04547.x; Wang Y, 2009, NEUROSCI LETT, V452, P124, DOI 10.1016/j.neulet.2009.01.054	56	13	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2019	14	9							e0223135	10.1371/journal.pone.0223135	http://dx.doi.org/10.1371/journal.pone.0223135			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM6FU	31557238	Green Published, gold			2023-01-03	WOS:000532345500079
J	Morita, T; Ando, M; Ohtsu, Y				Morita, Tomohiro; Ando, Michihito; Ohtsu, Yui			Mass evacuation and increases in long-term care benefits: Lessons from the Fukushima nuclear disaster	PLOS ONE			English	Article							EAST JAPAN EARTHQUAKE; FUNCTIONAL DISABILITY; EXCESS MORTALITY; OLDER-PEOPLE; HEALTH; IMPACT; PREVALENCE; TSUNAMI	Background Though mass evacuation may increase the need for long-term care (LTC) services, how the need for LTC services increases and how the public LTC system affects it is not well understood. We evaluated changes in public LTC benefits for the people living in the mandatory evacuation areas established after the 2011 Fukushima nuclear disaster and examined the roles of the universal LTC insurance system in Japan. Methods In order to evaluate the effect of the mandatory evacuation on LTC benefits, we examined the trends of LTC benefits in the Fukushima evacuation group and the nationwide non-evacuation group. We first decomposed per-elderly-individual benefits at the municipality level into the LTC certification rate and per-certified-individual benefits, and then implemented difference-in-differences analysis using these variables as outcomes. Results Per-elderly-individual benefits significantly increased from 2012 onward in the evacuation group, and this was explained by an increase in the certification rate rather than in per-certified-individual benefits. Increases in per-elderly-individual benefits and the certification rate in the post-disaster period were observed in all but the highest care level, and the corresponding outcomes for the highest care level decreased immediately after the disaster. We also found that the increase in the certification rate had been mostly realized by an increase in the number of certified individuals. Conclusions The increase in LTC benefits can be associated with the impact of the increase in the number of people newly certified to receive LTC benefits after the mandatory evacuation. In order to cope with the increase in utilization of long-term care and associated costs after disasters in aging societies, both formal long-term care services and social support for informal care for evacuees should be considered important.	[Morita, Tomohiro] Soma Cent Hosp, Internal Med, Soma, Fukushima, Japan; [Ando, Michihito] Rikkyo Univ, Dept Econ, Toshima Ku, Tokyo, Japan; [Ohtsu, Yui] Saitama Univ, Grad Sch Humanities & Social Sci, Sakura Ku, Saitama, Japan	Rikkyo University; Saitama University	Morita, T (corresponding author), Soma Cent Hosp, Internal Med, Soma, Fukushima, Japan.	t.morita526@gmail.com	Ando, Michihito/AAD-2335-2021	Morita, Tomohiro/0000-0002-8621-4602; Ando, Michihito/0000-0002-5294-2994	Rikkyo University Special Fund for Research [15FK-1]; Rikkyo University; Health and Labour Sciences Research Grants [H30-Tokei-Ippan-005]; Ministry of Welfare, Labour and Welfare	Rikkyo University Special Fund for Research; Rikkyo University(Rikkyo University); Health and Labour Sciences Research Grants(Ministry of Health, Labour and Welfare, Japan); Ministry of Welfare, Labour and Welfare	This research was funded by Rikkyo University Special Fund for Research (Grant number 15FK-1) funded by Rikkyo University (M.A. and Y.O.). Health and Labour Sciences Research Grants (Grant Number H30-Tokei-Ippan-005) funded by Ministry of Welfare, Labour and Welfare (M.A.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	COTTON J, 1988, REV ECON STAT, V70, P236, DOI 10.2307/1928307; Council NR Grid I, 2016, GLOBAL REPORT INTERN; Dobkin C, 2018, AM ECON REV, V108, P308, DOI 10.1257/aer.20161038; Fernandez Lauren S, 2002, Prehosp Disaster Med, V17, P67; Finkelstein A, 2007, Q J ECON, V122, P1, DOI 10.1162/qjec.122.1.1; Hasegawa J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122631; Matsuyama Y, 2018, TOHOKU J EXP MED, V244, P163, DOI 10.1620/tjem.244.163; Ministry of Internal Affairs and Communications, PORT SIT OFF STAT JA; Morita T, 2017, J EPIDEMIOL COMMUN H, V71, P974, DOI 10.1136/jech-2016-208652; Morita T, 2016, J EPIDEMIOL COMMUN H, V70, P738, DOI 10.1136/jech-2015-206983; OECD, 2012, JAP APOS S COMP SYST; Solon G, 2015, J HUM RESOUR, V50, P301, DOI 10.3368/jhr.50.2.301; Tomata Y, 2015, SOC SCI MED, V147, P296, DOI 10.1016/j.socscimed.2015.11.016; Tomata Y, 2014, J EPIDEMIOL COMMUN H, V68, P530, DOI 10.1136/jech-2013-203541; Tsutsui T, 2007, J AM GERIATR SOC, V55, P1458, DOI 10.1111/j.1532-5415.2007.01281.x; Uchimura M, 2014, J EPIDEMIOL COMMUN H, V68, P874, DOI 10.1136/jech-2014-204063; Yasumura S, 2013, PUBLIC HEALTH, V127, P186, DOI 10.1016/j.puhe.2012.10.019	17	4	4	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2019	14	9							e0218835	10.1371/journal.pone.0218835	http://dx.doi.org/10.1371/journal.pone.0218835			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM5WE	31553728	Green Published, Green Submitted, gold			2023-01-03	WOS:000532319200002
J	Mulrooney, DA; Hyun, G; Ness, KK; Ehrhardt, MJ; Yasui, Y; Duprez, D; Howell, RM; Leisenring, WM; Constine, LS; Tonorezos, E; Gibson, TM; Robison, LL; Oeffinger, KC; Hudson, MM; Armstrong, GT				Mulrooney, Daniel A.; Hyun, Geehong; Ness, Kirsten K.; Ehrhardt, Matthew J.; Yasui, Yutaka; Duprez, Daniel; Howell, Rebecca M.; Leisenring, Wendy M.; Constine, Louis S.; Tonorezos, Emily; Gibson, Todd M.; Robison, Leslie L.; Oeffinger, Kevin C.; Hudson, Melissa M.; Armstrong, Gregory T.			Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HIGH-RISK NEUROBLASTOMA; OUTCOMES; CHILDREN; CHEMOTHERAPY; RADIOTHERAPY; MORTALITY; THERAPY; DISEASE	OBJECTIVE To investigate the impact of modifications to contemporary cancer protocols, which minimize exposures to cardiotoxic treatments and preserve long term health, on serious cardiac outcomes among adult survivors of childhood cancer. DESIGN Retrospective cohort study. SETTING 27 institutions participating in the Childhood Cancer Survivor Study. PARTICIPANTS 23?462 five year survivors (6193 (26.4%) treated in the 1970s, 9363 (39.9%) treated in the 1980s, and 7906 (33.6%) treated in the 1990s) of leukemia, brain cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, renal tumors, neuroblastoma, soft tissue sarcomas, and bone sarcomas diagnosed prior to age 21 years between 1 January 1970 and 31 December 1999. Median age at diagnosis was 6.1 years (range 0-20.9) and 27.7 years (8.2-58.3) at last follow-up. A comparison group of 5057 siblings of cancer survivors were also included. MAIN OUTCOME MEASURES Cumulative incidence and 95% confidence intervals of reported heart failure, coronary artery disease, valvular heart disease, pericardial disease, and arrhythmias by treatment decade. Events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events. Multivariable subdistribution hazard models were used to estimate hazard ratios by decade, and mediation analysis examined risks with and without exposure to cardiotoxic treatments. RESULTS The 20 year cumulative incidence of heart failure (0.69% for those treated in the 1970s, 0.74% for those treated in the 1980s, 0.54% for those treated in the 1990s) and coronary artery disease (0.38%, 0.24%, 0.19%, respectively), decreased in more recent eras (P<0.01), though not for valvular disease (0.06%, 0.06%, 0.05%), pericardial disease (0.04%, 0.02%, 0.03%), or arrhythmias (0.08%, 0.09%, 0.13%). Compared with survivors with a diagnosis in the 1970s, the risk of heart failure, coronary artery disease, and valvular heart disease decreased in the 1980s and 1990s but only significantly for coronary artery disease (hazard ratio 0.65, 95% confidence interval 0.45 to 0.92 and 0.53, 0.36 to 0.77, respectively). The overall risk of coronary artery disease was attenuated by adjustment for cardiac radiation (0.90, 0.78 to 1.05), particularly among survivors of Hodgkin lymphoma (unadjusted for radiation: 0.77, 0.66 to 0.89; adjusted for radiation: 0.87, 0.69 to 1.10). CONCLUSIONS Historical reductions in exposure to cardiac radiation have been associated with a reduced risk of coronary artery disease among adult survivors of childhood cancer. Additional follow-up is needed to investigate risk reductions for other cardiac outcomes.	[Mulrooney, Daniel A.; Ehrhardt, Matthew J.; Hudson, Melissa M.] St Jude Childrens Res Hosp, Dept Oncol, Div Canc Survivorship, MS 735,262 Danny Thomas Pl, Memphis, TN 38105 USA; [Mulrooney, Daniel A.; Hyun, Geehong; Ness, Kirsten K.; Ehrhardt, Matthew J.; Yasui, Yutaka; Gibson, Todd M.; Robison, Leslie L.; Hudson, Melissa M.; Armstrong, Gregory T.] St Jude Childrens Res Hosp, Dept Epidemiol & Canc Control, 332 N Lauderdale St, Memphis, TN 38105 USA; [Duprez, Daniel] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA; [Howell, Rebecca M.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA; [Leisenring, Wendy M.] Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA; [Constine, Louis S.] Univ Rochester, Med Ctr, James P Wilmot Canc Inst, Dept Radiat Oncol, Rochester, NY 14642 USA; [Constine, Louis S.] Univ Rochester, Med Ctr, James P Wilmot Canc Inst, Dept Pediat, Rochester, NY 14642 USA; [Tonorezos, Emily] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA; [Oeffinger, Kevin C.] Duke Univ, Dept Med, Durham, NC USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Minnesota System; University of Minnesota Twin Cities; University of Texas System; UTMD Anderson Cancer Center; Fred Hutchinson Cancer Center; University of Rochester; University of Rochester; Memorial Sloan Kettering Cancer Center; Duke University	Mulrooney, DA (corresponding author), St Jude Childrens Res Hosp, Dept Oncol, Div Canc Survivorship, MS 735,262 Danny Thomas Pl, Memphis, TN 38105 USA.; Mulrooney, DA (corresponding author), St Jude Childrens Res Hosp, Dept Epidemiol & Canc Control, 332 N Lauderdale St, Memphis, TN 38105 USA.	daniel.mulrooney@stjude.org	Armstrong, Gregory/N-8096-2018; Ness, Kirsten K/N-2550-2018; Gibson, Todd/N-6999-2018	Ness, Kirsten K/0000-0002-2084-1507; Leisenring, Wendy/0000-0001-7405-0906; Gibson, Todd/0000-0002-8718-699X	National Cancer Institute [CA55727]; Cancer Center Support (CORE) grant [CA21765]; American Lebanese Syrian Associated Charities (ALSAC), Memphis, TN	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center Support (CORE) grant; American Lebanese Syrian Associated Charities (ALSAC), Memphis, TN(American Lebanese Syrian Associated Charities (ALSAC))	The Childhood Cancer Survivor Study is supported by the National Cancer Institute grant CA55727 (to GTA, principal investigator), the Cancer Center Support (CORE) grant (CA21765) to St Jude Children's Research Hospital (to CW Roberts, principal investigator) and the American Lebanese Syrian Associated Charities (ALSAC), Memphis, TN. The funders of the study had no role in the study design; data collection, analysis, or interpretation; or in writing of the report; and in the decision to submit the article for publication. All authors had independence from funders and full access to the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and accuracy of the data analysis.	Armstrong GT, 2016, NEW ENGL J MED, V374, P833, DOI 10.1056/NEJMoa1510795; Armstrong GT, 2013, J CLIN ONCOL, V31, P3673, DOI 10.1200/JCO.2013.49.3205; Bhakta N, 2017, LANCET, V390, P2569, DOI 10.1016/S0140-6736(17)31610-0; Bhatia S, 1996, NEW ENGL J MED, V334, P745, DOI 10.1056/NEJM199603213341201; Feijen EAM, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.009122; Feijen EAM, 2015, J CLIN ONCOL, V33, P3774, DOI 10.1200/JCO.2015.61.5187; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Gibson TM, 2018, LANCET ONCOL, V19, P1590, DOI 10.1016/S1470-2045(18)30537-0; Gibson TM, 2017, CANCER EPIDEM BIOMAR, V26, P1705, DOI 10.1158/1055-9965.EPI-17-0510; Green DM, 2013, PEDIATR BLOOD CANCER, V60, P1083, DOI 10.1002/pbc.24487; HANCOCK SL, 1993, J CLIN ONCOL, V11, P1208, DOI 10.1200/JCO.1993.11.7.1208; HENSON KE, MORTALITY, P200, DOI DOI 10.1161/CIRCULATIONAHA.116.022514; Hudson MM, 2013, JAMA-J AM MED ASSOC, V309, P2371, DOI 10.1001/jama.2013.6296; Hudson MM, 2012, PEDIATR BLOOD CANCER, V58, P334, DOI 10.1002/pbc.23385; Jones LW, 2014, J CLIN ONCOL, V32, P3643, DOI 10.1200/JCO.2014.56.7511; Matthay KK, 2009, J CLIN ONCOL, V27, P1007, DOI 10.1200/JCO.2007.13.8925; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Metzger ML, 2012, JAMA-J AM MED ASSOC, V307, P2609, DOI 10.1001/jama.2012.5847; Mulrooney DA, 2016, ANN INTERN MED, V164, P93, DOI 10.7326/M15-0424; Mulrooney DA, 2014, CANCER-AM CANCER SOC, V120, P3536, DOI 10.1002/cncr.28925; Mulrooney DA, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4606; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Reulen RC, 2010, JAMA-J AM MED ASSOC, V304, P172, DOI 10.1001/jama.2010.923; Robison LL, 2009, J CLIN ONCOL, V27, P2308, DOI 10.1200/JCO.2009.22.3339; Robison LL, 2002, MED PEDIATR ONCOL, V38, P229, DOI 10.1002/mpo.1316; Stovall M, 2006, RADIAT RES, V166, P141, DOI 10.1667/RR3525.1; TOYEARS O, 2016, YOUNG, V134, P1519, DOI DOI 10.1001/JAMA.2012.5847; TOYEARS O, YOUNG, P39; van der Pal HJ, 2012, J CLIN ONCOL, V30, P1429, DOI 10.1200/JCO.2010.33.4730; Yu AL, 2010, NEW ENGL J MED, V363, P1324, DOI 10.1056/NEJMoa0911123	30	45	45	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 15	2020	368								l6794	10.1136/bmj.l6794	http://dx.doi.org/10.1136/bmj.l6794			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF9PC	31941657	hybrid, Green Published			2023-01-03	WOS:000509573400002
J	Tolles, J; Waterman, G; Coffey, CE; Sandoval, R; Fleischman, RJ; Hess, M; Sarff, L; Lewis, RJ; Spellberg, B				Tolles, Juliana; Waterman, Gabriel; Coffey, Charles E., Jr.; Sandoval, Rebecca; Fleischman, Ross J.; Hess, Mailee; Sarff, Laura; Lewis, Roger J.; Spellberg, Brad		BRAVE Study Grp	A randomized trial of a behavioral intervention to decrease hospital length of stay by decreasing bedrest	PLOS ONE			English	Article							FUNCTIONAL DECLINE; EARLY MOBILIZATION; LOW MOBILITY; DISCHARGE; PROTOCOL; IMPACT	Background Approximately half of hospitalized patients suffer functional decline due to spending the vast majority of their time in bed. Previous studies of early mobilization have demonstrated improvement in outcomes, but the interventions studied have been resource-intensive. We aimed to decrease the time hospital inpatients spend in bed through a pragmatic mobilization protocol. Methods This prospective, non-blinded, controlled clinical trial assigned inpatients to the study wards per routine clinical care in an urban teaching hospital. All subjects on intervention wards were provided with a behavioral intervention, consisting of educational handouts, by the nursing staff. Half of the intervention wards were supplied with recliner chairs in which subjects could sit. The primary outcome was hospital length of stay. The secondary outcome was the '6-Clicks' functional score. Results During a 6-month study period, 6082 patient encounters were included. The median length of stay was 84 hours (IQR 44-175 hours) in the control group, 80 hours (IQR 44-155 hours) in the group who received the behavioral intervention alone, and 88 hours (IQR 44-185 hours) in the group that received both the behavioral intervention and the recliner chair. In the multivariate analysis, neither the behavioral intervention nor the provision of a recliner chair was associated with a significant decrease in length of stay or increase in functional status as measured by the '6-Clicks' functional score. Conclusion The program of educational handouts and provision of recliner chairs to discourage bed rest did not increase functional status or decrease length of stay for inpatients in a major urban academic center. Education and physical resources must be supplemented by other active interventions to reduce time spent in bed, functional decline, and length of stay.	[Tolles, Juliana; Fleischman, Ross J.; Lewis, Roger J.] Harbor UCLA Med Ctr, Dept Emergency Med, Torrance, CA 90509 USA; [Tolles, Juliana; Fleischman, Ross J.; Hess, Mailee; Lewis, Roger J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Waterman, Gabriel] CareMore Hlth, Pico Rivera, CA USA; [Coffey, Charles E., Jr.; Sarff, Laura; Spellberg, Brad] Los Angeles Cty Univ Southern Calif USC, Med Ctr, Los Angeles, CA USA; [Coffey, Charles E., Jr.; Sandoval, Rebecca; Spellberg, Brad] USC, Keck Sch Med, Dept Med, Los Angeles, CA USA; [Hess, Mailee] Harbor UCLA Med Ctr, Dept Med, Torrance, CA 90509 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California; University of Southern California Keck Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Tolles, J (corresponding author), Harbor UCLA Med Ctr, Dept Emergency Med, Torrance, CA 90509 USA.; Tolles, J (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.	jtolles@emedharbor.edu		Sarff, John/0000-0001-8883-6678	Los Angeles County University of Southern California Medical Center - LAC+USC Medical Center	Los Angeles County University of Southern California Medical Center - LAC+USC Medical Center	Los Angeles County University of Southern California Medical Center, which provided funding for the study as a quality improvement project were involved in the study design and data collection. Funders were not involved in data analysis, the decision to publish, or the preparation of the manuscript.; This was a quality improvement improvement activity funded by LAC+USC Medical Center.	Brown CJ, 2004, J AM GERIATR SOC, V52, P1263, DOI 10.1111/j.1532-5415.2004.52354.x; Brown CJ, 2009, J AM GERIATR SOC, V57, P1660, DOI 10.1111/j.1532-5415.2009.02393.x; Chuang KH, 2003, J AM GERIATR SOC, V51, P1729, DOI 10.1046/j.1532-5415.2003.51556.x; Convertino VA, 1997, MED SCI SPORT EXER, V29, P191, DOI 10.1097/00005768-199702000-00005; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; Graf C, 2006, AM J NURS, V106, P58, DOI 10.1097/00000446-200601000-00032; HIRSCH CH, 1990, J AM GERIATR SOC, V38, P1296, DOI 10.1111/j.1532-5415.1990.tb03451.x; Hoyer EH, 2015, AM J PHYS MED REHAB, V94, P304, DOI 10.1097/PHM.0000000000000185; Jette DU, 2014, PHYS THER, V94, P1252, DOI 10.2522/ptj.20130359; Jette DU, 2014, PHYS THER, V94, P379, DOI 10.2522/ptj.20130199; Jette DU, 2014, PHYS THER; King Barbara Doherty, 2006, Medsurg Nurs, V15, P265; Mundy LM, 2003, CHEST, V124, P883, DOI 10.1378/chest.124.3.883; Padula CA, 2009, J NURS CARE QUAL, V24, P325, DOI 10.1097/NCQ.0b013e3181a4f79b; Pashikanti L, 2012, CLIN NURSE SPEC, V26, P87, DOI 10.1097/NUR.0b013e31824590e6; Sands LP, 2003, J GERONTOL A-BIOL, V58, P37; Suesada MM, 2007, AM J PHYS MED REHAB, V86, P455, DOI 10.1097/PHM.0b013e31805b7566	17	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 10	2020	15	1							e0226332	10.1371/journal.pone.0226332	http://dx.doi.org/10.1371/journal.pone.0226332			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP5IB	31923203	Green Published, gold			2023-01-03	WOS:000534350000015
J	Burris, S; Anderson, ED; Davis, CS; Beletsky, L				Burris, Scott; Anderson, Evan D.; Davis, Corey S.; Beletsky, Leo			Toward Healthy Drug Policy in the United States - The Case of Safehouse	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Burris, Scott] Temple Univ, Beasley Sch Law, Ctr Publ Hlth Law Res, Philadelphia, PA 19122 USA; [Anderson, Evan D.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; [Anderson, Evan D.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Davis, Corey S.] Network Publ Hlth Law, Los Angeles, CA USA; [Beletsky, Leo] Northeastern Univ, Bouve Coll Hlth Sci, Sch Law, Boston, MA 02115 USA; [Beletsky, Leo] Northeastern Univ, Hlth Justice Act Lab, Boston, MA 02115 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Northeastern University; Northeastern University	Burris, S (corresponding author), Temple Univ, Beasley Sch Law, Ctr Publ Hlth Law Res, Philadelphia, PA 19122 USA.		Burris, Scott/HJA-8301-2022	Burris, Scott/0000-0002-6013-5842; Davis, Corey/0000-0002-6278-5013				Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; National Institute on Drug Abuse, 2015, NAT TRENDS; Office of National Drug Control Policy, 2015, NAT DRUG CONTR STRAT; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; Wood EF, 2017, INT J DRUG POLICY, V41, P132, DOI 10.1016/j.drugpo.2016.12.010	5	6	6	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 2	2020	382	1					4	5		10.1056/NEJMp1913448	http://dx.doi.org/10.1056/NEJMp1913448			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KA2CZ	31800980	Bronze, Green Published			2023-01-03	WOS:000505606700003
J	Hishida, M; Shafi, T; Appel, LJ; Maruyama, S; Inaguma, D; Matsushita, K				Hishida, Manabu; Shafi, Tariq; Appel, Lawrence J.; Maruyama, Shoichi; Inaguma, Daijo; Matsushita, Kunihiro			Lower levels of proteinuria are associated with elevated mortality in incident dialysis patients	PLOS ONE			English	Article							GLOMERULAR-FILTRATION-RATE; KIDNEY-DISEASE MEASURES; STAGE RENAL-DISEASE; ALL-CAUSE; COLLABORATIVE METAANALYSIS; CARDIOVASCULAR MORTALITY; MICROALBUMINURIA; POPULATION; HYPERTENSION; INDIVIDUALS	Introduction Proteinuria is a potent predictor of adverse events in general, although a few large studies have reported a J-shaped association between proteinuria and mortality in individuals with glomerular filtration rate < 30 ml/min/1.73m(2). However, this association has not been specifically evaluated among incident dialysis patients. Methods Among 1,380 Japanese patients who initiated dialysis, we quantified the association of pre-dialysis dipstick proteinuria (negative/trace, 1+, 2+, and >= 3+) with mortality using Cox models adjusting for potential confounders, such as age, gender, clinical history of hypertension, diabetes, and cardiovascular disease. Results Mean age of study participants was 67.4 (SD 13.0) years, and 67.6% were men. The most common dipstick proteinuria category was >= 3+ (55.4%), followed by 2+ (31.2%), 1+ (9.9%), and negative or trace (3.5%). Patients with lower proteinuria level were older than those with higher proteinuria. Lower proteinuria was significantly associated with a higher risk of all-cause mortality, even after accounting for potential confounders (p for trend <0.001). In those with negative/trace dipstick proteinuria compared to those with dipstick proteinuria >= 3+, the adjusted hazard ratio was 2.60 [95% CI: 1.62-4.17] in the fully adjusted model. Similar findings were observed when analyses were restricted to patients older than 70 years, and when cardiovascular mortality and non-cardiovascular mortality were analyzed separately. Conclusions In incident dialysis patients, pre-dialysis proteinuria was inversely associated with mortality risk. Although future studies are needed to identify mechanisms, our findings suggest the need to carefully interpret proteinuria in patients with incident dialysis.	[Hishida, Manabu; Appel, Lawrence J.; Matsushita, Kunihiro] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Hishida, Manabu; Maruyama, Shoichi] Nagoya Univ, Grad Sch Med, Dept Nephrol, Nagoya, Aichi, Japan; [Shafi, Tariq; Appel, Lawrence J.; Matsushita, Kunihiro] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Inaguma, Daijo] Fujita Hlth Univ Hosp, Dept Nephrol, Toyoake, Aichi, Japan; [Shafi, Tariq] Univ Mississippi, Med Ctr, Div Nephrol, Jackson, MS 39216 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Nagoya University; Johns Hopkins University; Fujita Health University; University of Mississippi; University of Mississippi Medical Center	Inaguma, D (corresponding author), Fujita Hlth Univ Hosp, Dept Nephrol, Toyoake, Aichi, Japan.	daijo@fujita-hu.ac.jp	Matsushita, Kunihiro/AAJ-5817-2020; Appel, Larry/GLT-2608-2022	Matsushita, Kunihiro/0000-0002-7179-718X; Hishida, Manabu/0000-0002-6068-8228	Aichi Kidney Foundation	Aichi Kidney Foundation	Manabu Hishida reports grants from the Kaikoukai Healthcare Group. The Aichi Kidney Foundation partially provided funding for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2013, Kidney Int Suppl (2011), V3, P19; [Anonymous], TRAJ CAUS DEATH CRUD; Astor BC, 2011, KIDNEY INT, V79, P1331, DOI 10.1038/ki.2010.550; Fox CS, 2012, LANCET, V380, P1662, DOI 10.1016/S0140-6736(12)61350-6; Hishida M, 2016, CLIN EXP NEPHROL, V20, P795, DOI 10.1007/s10157-015-1206-z; Inaguma D, 2017, CLIN EXP NEPHROL, V21, P159, DOI 10.1007/s10157-016-1262-z; Ishay A, 2006, DIABETIC MED, V23, P185, DOI 10.1111/j.1464-5491.2005.01758.x; Kalantar-Zadeh K, 2005, HYPERTENSION, V45, P811, DOI 10.1161/01.HYP.0000154895.18269.67; Klausen K, 2004, CIRCULATION, V110, P32, DOI 10.1161/01.CIR.0000133312.96477.48; Kovesdy CP, 2013, J AM COLL CARDIOL, V61, P1626, DOI 10.1016/j.jacc.2012.11.071; Mahmoodi BK, 2012, LANCET, V380, P1649, DOI 10.1016/S0140-6736(12)61272-0; MAHONEY F I, 1965, Md State Med J, V14, P61; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Matsushita K, 2015, LANCET DIABETES ENDO, V3, P514, DOI 10.1016/S2213-8587(15)00040-6; Matsushita K, 2010, LANCET, V375, P2073, DOI 10.1016/S0140-6736(10)60674-5; Miller WG, 2009, CLIN CHEM, V55, P24, DOI 10.1373/clinchem.2008.106567; Port FK, 1999, AM J KIDNEY DIS, V33, P507, DOI 10.1016/S0272-6386(99)70188-5; Romundstad S, 2003, AM J KIDNEY DIS, V42, P466, DOI 10.1016/S0272-6386(03)00742-X; Ronald A, 2001, INT J ANTIMICROB AG, V17, P287, DOI 10.1016/S0924-8579(00)00356-3; Tanaka A, 2016, NEPHRON, V132, P86, DOI 10.1159/000443314; Whelton P. K., 2017, J AM COLL CARDIOLOGY; Yuyun MF, 2004, INT J EPIDEMIOL, V33, P189, DOI 10.1093/ije/dyh008	22	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2019	14	12							e0226866	10.1371/journal.pone.0226866	http://dx.doi.org/10.1371/journal.pone.0226866			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN8GE	31869391	Green Published, gold			2023-01-03	WOS:000515082600058
J	Jud, P; Hafner, F; Brodmann, M				Jud, Philipp; Hafner, Franz; Brodmann, Marianne			Frostbite of the hands after paragliding: a chilling experience	LANCET			English	Editorial Material									[Jud, Philipp; Hafner, Franz; Brodmann, Marianne] Med Univ Graz, Dept Internal Med, Div Angiol, A-8036 Graz, Austria	Medical University of Graz	Jud, P (corresponding author), Med Univ Graz, Dept Internal Med, Div Angiol, A-8036 Graz, Austria.	philipp.jud@medunigraz.at							0	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	2019	394	10216					2282	2282						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JX5QC	31868633				2023-01-03	WOS:000503788300031
J	Smink, W; Sools, AM; van der Zwaan, JM; Wiegersma, S; Veldkamp, BP; Westerhof, GJ				Smink, Wouter; Sools, Anneke M.; van der Zwaan, Janneke M.; Wiegersma, Sytske; Veldkamp, Bernard P.; Westerhof, Gerben J.			Towards text mining therapeutic change: A systematic review of text-based methods for Therapeutic Change Process Research	PLOS ONE			English	Review							NATURAL-LANGUAGE USE; PSYCHOTHERAPY-RESEARCH; ASSIMILATION; MODELS; COUPLE; CHILD	Therapeutic Change Process Research (TCPR) connects within-therapeutic change processes to outcomes. The labour intensity of qualitative methods limit their use to small scale studies. Automated text-analyses (e.g. text mining) provide means for analysing large scale text patterns. We aimed to provide an overview of the frequently used qualitative text-based TCPR methods and assess the extent to which these methods are reliable and valid, and have potential for automation. We systematically reviewed PsycINFO, Scopus, and Web of Science to identify articles concerning change processes and text or language. We evaluated the reliability and validity based on replicability, the availability of code books, training data and inter-rater reliability, and evaluated the potential for automation based on the example- and rule-based approach. From 318 articles we identified four often used methods: Innovative Moments Coding Scheme, the Narrative Process Coding Scheme, Assimilation of Problematic Experiences Scale, and Conversation Analysis. The reliability and validity of the first three is sufficient to hold promise for automation. While some text features (content, grammar) lend themselves for automation through a rule-based approach, it should be possible to automate higher order constructs (e.g. schemas) when sufficient annotated data for an example-based approach are available.	[Smink, Wouter; Westerhof, Gerben J.] Univ Twente, Dept Psychol Hlth & Technol, Enschede, Overijssel, Netherlands; [Smink, Wouter; Sools, Anneke M.; Wiegersma, Sytske; Veldkamp, Bernard P.] Univ Twente, Dept Res Methodol Measurement & Data Anal, Enschede, Overijssel, Netherlands; [van der Zwaan, Janneke M.] Netherlands eSci Ctr NWO, Amsterdam, Noord Holland, Netherlands	University of Twente; University of Twente	Smink, W (corresponding author), Univ Twente, Dept Psychol Hlth & Technol, Enschede, Overijssel, Netherlands.; Smink, W (corresponding author), Univ Twente, Dept Res Methodol Measurement & Data Anal, Enschede, Overijssel, Netherlands.	w.a.c.smink@utwente.nl		Veldkamp, Bernard/0000-0003-3543-2164; Westerhof, Gerben/0000-0002-0993-1448	Netherlands eScience Centre (Amsterdam, the Netherlands) [027.015. G04]; Netherlands Organization for Scientific Research (NWO Dutch: Nederlandse organisatie voor Wetenschappelijk Onderzoek)	Netherlands eScience Centre (Amsterdam, the Netherlands)(Netherlands Government); Netherlands Organization for Scientific Research (NWO Dutch: Nederlandse organisatie voor Wetenschappelijk Onderzoek)(Netherlands Organization for Scientific Research (NWO))	The What Works When for Whom project was supported by the Accelerating Scientific Discovery Call grant from the Netherlands eScience Centre (Amsterdam, the Netherlands): 027.015. G04. The eScience centre is funded through the Netherlands Organization for Scientific Research (NWO Dutch: Nederlandse organisatie voor Wetenschappelijk Onderzoek). We received no additional forms of funding, and have no conflict of interests to report.	Abbe A, 2016, INT J METH PSYCH RES, V25, P86, DOI 10.1002/mpr.1481; Adler JM, 2012, J PERS SOC PSYCHOL, V102, P367, DOI 10.1037/a0025289; Althoff Tim, 2016, Trans Assoc Comput Linguist, V4, P463; Amichai-Hamburger Y, 2014, COMPUT HUM BEHAV, V41, P288, DOI 10.1016/j.chb.2014.09.016; Anderson T, 1999, PSYCHOTHER RES, V9, P88, DOI 10.1080/10503309912331332611; Andersson Gerhard, 2009, Cognitive Behaviour Therapy, V38, P196, DOI 10.1080/16506070903318960; Andrews G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013196; Angus L., 1996, NARRATIVE PROC UNPUB; Angus L.E., 2004, HDB NARRATIVE PSYCHO; Angus LynneE., 2011, WORKING NARRATIVE EM; Arntz A, 2012, BEHAV RES THER, V50, P191, DOI 10.1016/j.brat.2011.12.007; Atkins DC, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-49; Atkins DC, 2012, J FAM PSYCHOL, V26, P816, DOI 10.1037/a0029607; Banko M, 2001, 39TH ANNUAL MEETING OF THE ASSOCIATION FOR COMPUTATIONAL LINGUISTICS, PROCEEDINGS OF THE CONFERENCE, P26, DOI 10.3115/1073012.1073017; Barak A, 2008, J TECHNOL HUMAN SERV, V26, P109, DOI 10.1080/15228830802094429; BARKHAM M, 1993, J CONSULT CLIN PSYCH, V61, P667, DOI 10.1037/0022-006X.61.4.667; Basit TN, 2003, EDUC RES-UK, V45, P143, DOI 10.1080/0013188032000133548; BATES M, 1995, P NATL ACAD SCI USA, V92, P9977, DOI 10.1073/pnas.92.22.9977; Bennett K, 2010, J MED INTERNET RES, V12, DOI 10.2196/jmir.1468; Bird S., 2009, NATURAL LANGUAGE PRO; Bishop L, 2009, AUST J SOC ISSUES, V44, P255, DOI 10.1002/j.1839-4655.2009.tb00145.x; Blei DM, 2003, J MACH LEARN RES, V3, P993, DOI 10.1162/jmlr.2003.3.4-5.993; Braakmann D, 2015, PSYCHOTHERAPY RES FD, P39, DOI DOI 10.1007/978-3-7091-1382-0_3; BRZOZOWSKI JA, 1964, J ACM, V11, P481, DOI 10.1145/321239.321249; Campbell LF, 2013, PSYCHOTHERAPY, V50, P98, DOI 10.1037/a0031817; Cariola LA, 2015, INT BODY PSYCHOTHERA, V14, P48; Chung C, 2007, FRONT SOC PSYCHOL, P343; de Graaf R, 2011, VERZUIM DOOR PSYCHIS; Degenhardt L, 2018, LANCET PSYCHIAT, V5, P987, DOI 10.1016/S2215-0366(18)30337-7; Elliott R., 2013, QUALITATIVE RES METH, P69; Elliott R, 2010, PSYCHOTHER RES, V20, P123, DOI 10.1080/10503300903470743; Feldman R., 2007, TEXT MINING HDB ADV; Gallo C, 2015, ADM POLICY MENT HLTH, V42, P574, DOI 10.1007/s10488-014-0538-4; Garfield S. L., 2006, THERAPIES MODERN POP; Gelo O.C.G., 2015, PSYCHOTHER RES, P247, DOI DOI 10.1007/978-3-7091-1382-0_13; Gelo OCG, 2012, RES PSYCHOTHER-PSYCH, V15, P45, DOI 10.7411/RP.2012.005; Goncalves M. M., 2010, YIS YB IDIOGRAPHIC S, V2, P107; Goncalves MM, 2011, PSYCHOTHER RES, V21, P1, DOI 10.1080/10503307.2010.534510; Greenberg LS, 2007, PSYCHOTHER RES, V17, P15, DOI 10.1080/10503300600720390; Halfon S, 2017, PSYCHOANAL PSYCHOL, V34, P35, DOI 10.1037/pap0000081; He Q., 2013, TEXT MINING IRT PSYC, P156; HILL CE, 1993, J COUNS PSYCHOL, V40, P3, DOI 10.1037/0022-0167.40.1.3; Hoogendoorn M, 2017, IEEE J BIOMED HEALTH, V21, P1449, DOI 10.1109/JBHI.2016.2601123; Howes C, 2014, P WORKSH COMP LING C, V27, P7; Imel ZE, 2015, PSYCHOTHERAPY, V52, P19, DOI 10.1037/a0036841; Johnson M., 2009, P EACL 2009 WORKSH I, P3; Jurafsky D, 2014, SPEECH LANGUAGE PROC, P9; Jurafsky D, 2014, SPEECH LANGUAGE PROC, P988; Kazdin AE, 2003, J CHILD PSYCHOL PSYC, V44, P1116, DOI 10.1111/1469-7610.00195; Kent DM, 2007, JAMA-J AM MED ASSOC, V298, P1209, DOI 10.1001/jama.298.10.1209; Lambert M. J., 1994, HDB PSYCHOTHERAPY BE, P143; Lamers SMA, 2015, J GERONTOL B-PSYCHOL, V70, P24, DOI 10.1093/geronb/gbu030; Liberman M, 2002, EMOTIONAL PROSODY SP; Manning C.D., 1999, SIGMOD REC, DOI DOI 10.1145/601858.601867; Martinez A, 2015, WIRES COMPUT STAT, V7, P258, DOI 10.1002/wics.1353; McNaughton Robert, 1960, IRE T ELECT COMPUT, V9, P39, DOI [10.1109/TEC.1960.5221603, DOI 10.1109/TEC.1960.5221603]; Mergenthaler E, 1996, J CONSULT CLIN PSYCH, V64, P1306, DOI 10.1037/0022-006X.64.6.1306; Murphy S.M., 2015, P 2 WORKSH COMP LING, P80, DOI [10.3115/v1/W15-1210, DOI 10.3115/V1/W15-1210]; Mu┬rtl K., 2015, PSYCHOTHERAPY RES FD, P381, DOI [10.1007/978-3-7091-1382-2_20, DOI 10.1007/978-3-7091-1382-0_20]; Mykowiecka A, 2009, J BIOMED INFORM, V42, P923, DOI 10.1016/j.jbi.2009.07.007; Nock MK, 2003, CLIN PSYCHOL-SCI PR, V10, P1, DOI 10.1093/clipsy/10.1.1; Norcross JC, 2011, J CLIN PSYCHOL, V67, P127, DOI 10.1002/jclp.20764; Oh H, 2005, J MED INTERNET RES, V7; Owen J, 2013, PSYCHOTHERAPY, V50, P496, DOI 10.1037/a0034617; Pennebaker J. W., 2015, DEV PSYCHOMETRIC PRO, DOI DOI 10.15781/T29G6Z; Pennebaker JW, 2003, ANNU REV PSYCHOL, V54, P547, DOI 10.1146/annurev.psych.54.101601.145041; Perakyla A., 2013, HDB CONVERSATION ANA, P551, DOI DOI 10.1002/9781118325001.CH27; Pfafflin F, 2005, SEX ABUSE-J RES TR, V17, P141, DOI 10.1007/s11194-005-4601-2; Salvatore S, 2012, PSYCHOTHER RES, V22, P256, DOI 10.1080/10503307.2011.647930; SHAPIRO DA, 1995, PSYCHOTHER RES, V5, P1, DOI 10.1080/10503309512331331106; Smaling A., 2003, INT J QUAL METHODS, V2, P52, DOI 10.1177/160940690300200105; Smink WAC, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.01186; Snow R., 2008, P C EMP METH NAT LAN, P254, DOI DOI 10.3115/1613715.1613751; Sofaer HR, 2019, METHODS ECOL EVOL, V10, P565, DOI 10.1111/2041-210X.13140; Sools AM, TEXT MINING RE UNPUB; STILES WB, 1990, PSYCHOTHER, V27, P411, DOI 10.1037/0033-3204.27.3.411; STILES WB, 1991, PSYCHOTHER, V28, P195, DOI 10.1037/0033-3204.28.2.195; Stivers T, 2015, RES LANG SOC INTERAC, V48, P1, DOI 10.1080/08351813.2015.993837; Street RL, 2009, PATIENT EDUC COUNS, V74, P295, DOI 10.1016/j.pec.2008.11.015; Tanana M, 2015, PROC CLPSYCH, P71; Tasca GA, 2015, PSYCHOTHERAPY, V52, P1, DOI 10.1037/a0038252; Voutilainen L, 2011, PSYCHOTHER RES, V21, P348, DOI 10.1080/10503307.2011.573509; Wallerstein RS, 2001, PSYCHOANAL PSYCHOL, V18, P243; Wynn R, 2006, J PRAGMATICS, V38, P1385, DOI 10.1016/j.pragma.2005.09.008; Xiao B, 2016, INTERSPEECH, P908, DOI 10.21437/Interspeech.2016-1560	85	4	4	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2019	14	12							e0225703	10.1371/journal.pone.0225703	http://dx.doi.org/10.1371/journal.pone.0225703			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP0JY	31805093	gold, Green Published, Green Submitted			2023-01-03	WOS:000534009700047
J	DeFilipp, Z; Bloom, PP; Soto, MT; Mansour, MK; Sater, MRA; Huntley, MH; Turbett, S; Chung, RT; Chen, YB; Hohmann, EL				DeFilipp, Zachariah; Bloom, Patricia P.; Soto, Mariam Torres; Mansour, Michael K.; Sater, Mohamad R. A.; Huntley, Miriam H.; Turbett, Sarah; Chung, Raymond T.; Chen, Yi-Bin; Hohmann, Elizabeth L.			Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLOSTRIDIUM-DIFFICILE INFECTION; EPIDEMIOLOGY; VIRULENCE; GENOTYPE	Fecal microbiota transplantation (FMT) is an emerging therapy for recurrent or refractory Clostridioides difficile infection and is being actively investigated for other conditions. We describe two patients in whom extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli bacteremia occurred after they had undergone FMT in two independent clinical trials; both cases were linked to the same stool donor by means of genomic sequencing. One of the patients died. Enhanced donor screening to limit the transmission of microorganisms that could lead to adverse infectious events and continued vigilance to define the benefits and risks of FMT across different patient populations are warranted.	[DeFilipp, Zachariah; Chen, Yi-Bin] Harvard Med Sch, Massachusetts Gen Hosp, Blood & Marrow Transplant Program, Boston, MA 02115 USA; [Bloom, Patricia P.; Chung, Raymond T.] Harvard Med Sch, Massachusetts Gen Hosp, Liver Ctr, Div Gastroenterol, Boston, MA 02115 USA; [Soto, Mariam Torres; Mansour, Michael K.; Turbett, Sarah; Hohmann, Elizabeth L.] Harvard Med Sch, Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02115 USA; [Sater, Mohamad R. A.; Huntley, Miriam H.] Day Zero Diagnost, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Hohmann, EL (corresponding author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St,Jackson 518, Boston, MA 02114 USA.	ehohmann@mgh.harvard.edu	DeFilipp, Zack/R-6083-2019	Bloom, Patricia/0000-0003-3188-7188; Torres Soto, Mariam/0000-0003-3606-2935; Sater, Mohamad/0000-0003-1912-0590	American College of Gastroenterology	American College of Gastroenterology(General Electric)	Supported by a grant from American College of Gastroenterology (to Dr. Bloom).	Baxter M, 2015, CLIN INFECT DIS, V61, P140, DOI 10.1093/cid/civ247; Beceiro A, 2013, CLIN MICROBIOL REV, V26, P185, DOI 10.1128/CMR.00059-12; Cammarota G, 2017, GUT, V66, P569, DOI 10.1136/gutjnl-2016-313017; Clinical and Laboratory Standards Institute, 2019, M100 CLSI S; De Leon LM, 2013, CLIN GASTROENTEROL H, V11, P1036, DOI 10.1016/j.cgh.2013.04.045; DeFilipp Zachariah, 2019, Biol Blood Marrow Transplant, V25, pe17, DOI 10.1016/j.bbmt.2018.10.022; DeFilipp Z, 2018, BLOOD ADV, V2, P745, DOI 10.1182/bloodadvances.2018017731; Deschamps C, 2009, MICROBIOL-SGM, V155, P1656, DOI 10.1099/mic.0.023234-0; FDA, 2019, IMP SAF AL REG US FE; Gordon NC, 2017, J CLIN MICROBIOL, V55, P2188, DOI 10.1128/JCM.00363-17; Grad YH, 2012, P NATL ACAD SCI USA, V109, P3065, DOI 10.1073/pnas.1121491109; Gupta A, 2018, JAMA-J AM MED ASSOC, V320, P1031, DOI 10.1001/jama.2018.12194; Kassam Z, 2013, AM J GASTROENTEROL, V108, P500, DOI 10.1038/ajg.2013.59; Krajicek E, 2019, CLIN GASTROENTEROL H, V17, P345, DOI 10.1016/j.cgh.2018.09.029; Lavigne JP, 2006, CLIN MICROBIOL INFEC, V12, P1199, DOI 10.1111/j.1469-0691.2006.01536.x; McDonald LC, 2018, CLIN INFECT DIS, V66, pE1, DOI [10.1093/cid/cix1085, 10.1093/cid/ciy149]; Millan B, 2016, CLIN INFECT DIS, V62, P1479, DOI 10.1093/cid/ciw185; Mullish BH, 2018, GUT, V67, P1920, DOI [10.1016/j.jhin.2018.07.037, 10.1136/gutjnl-2018-316818]; Peacock SJ, 2018, MICROBIOL-SGM, V164, P1213, DOI 10.1099/mic.0.000700; Quera R, 2014, J CROHNS COLITIS, V8, P252, DOI 10.1016/j.crohns.2013.10.002; Schurch AC, 2018, CLIN MICROBIOL INFEC, V24, P350, DOI 10.1016/j.cmi.2017.12.016; Shogbesan O, 2018, CAN J GASTROENTEROL, V2018, DOI 10.1155/2018/1394379; Solari PR, 2014, CLIN INFECT DIS, V59, DOI 10.1093/cid/ciu278; Trubiano JA, 2013, EUR J GASTROEN HEPAT, V25, P255, DOI 10.1097/MEG.0b013e32835b2da9; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Wiest R, 2014, J HEPATOL, V60, P197, DOI 10.1016/j.jhep.2013.07.044; Youngster I, 2014, JAMA-J AM MED ASSOC, V312, P1772, DOI 10.1001/jama.2014.13875	27	469	483	10	74	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 21	2019	381	21					2043	2050		10.1056/NEJMoa1910437	http://dx.doi.org/10.1056/NEJMoa1910437			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ6NB	31665575	Bronze			2023-01-03	WOS:000505218800008
J	Carnevale, C; Manni, G; Roberti, G; Micera, A; Bruno, L; Cacciamani, A; Altafini, R; Quaranta, L; Agnifili, L; Tanga, L; Riva, I; Oddone, F				Carnevale, Carmela; Manni, Gianluca; Roberti, Gloria; Micera, Alessandra; Bruno, Luca; Cacciamani, Andrea; Altafini, Romeo; Quaranta, Luciano; Agnifili, Luca; Tanga, Lucia; Riva, Ivano; Oddone, Francesco			Human vitreous concentrations of citicoline following topical application of citicoline 2% ophthalmic solution	PLOS ONE			English	Article							NEUROPROTECTIVE ROLE; CORNEAL THICKNESS; EYE DROPS; PENETRATION; GLAUCOMA; PRECURSOR; DOPAMINE; DISEASE	Purpose To evaluate the presence and concentration of citicoline and its metabolites (choline, cytidine and uridine) in the vitreous body in human eyes after topical application of an ophthalmic solution of citicoline 2%, in vivo. Methods Twenty-one subjects affected by epiretinal membrane with surgical indication for pars-plana vitrectomy underwent treatment with 1 drop 3 times/day of a solution of citicoline 2%, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride (OMK1, Omikron Italia s.r.l., Rome, Italy) 14 days before surgery and 2 hours prior to surgery. Five additional patients served as controls and received an OMK1 vehicle solution without citicoline. The vitreous samples were taken at the beginning of the pars-plana vitrectomy and analyzed for qualitative/quantitative determination of vitreous concentration of citicoline and its metabolites by means of high performance liquid chromatography. Results The overall mean concentration of citicoline in patients treated with citicoline 2% solution was 406.72 +/- 52.99 mu g/mL, while the mean concentration of choline, cytidine and uridine was 180.88 +/- 41.49 mu g/mL, 44.45 +/- 10.19 mu g/mL and 330.41 +/- 75.8 mu g/mL, respectively. The concentration of citicoline in phakic eyes (n = 13, 366.61 +/- 129.61 mu g/mL) was lower compared to that found in pseudophakic eyes (n = 8, 435.89 +/- 131.42 mu g/mL) and the difference was not statistically significant. The concentration of citicoline in the control eyes was 45.66 +/- 26.36 mu g/mL, while the concentration of choline, cytidine and uridine were 17.21 +/- 9.93 mu g/mL, 6.24 +/- 3.6 mu g/mL and 172.80 +/- 99.76 mu g/mL, respectively. Conclusion Citicoline can reach the human vitreous in high concentration when administered in ophthalmic solution. This evidence contributes to the build-up of the pyramid of the evidences required for determining the role of citicoline administered in ophthalmic formulation in retinal and optic nerve neurodegenerative diseases.	[Carnevale, Carmela; Manni, Gianluca; Roberti, Gloria; Micera, Alessandra; Bruno, Luca; Cacciamani, Andrea; Tanga, Lucia; Riva, Ivano; Oddone, Francesco] IRCCS Fdn Bietti, Rome, Italy; [Manni, Gianluca] Univ Roma Tor Vergata, DSCMT, Rome, Italy; [Altafini, Romeo] Dolo Hosp, Ophthalmol Clin, Venice, Italy; [Quaranta, Luciano] Univ Pavia, IRCCS Fdn Policlin San Matteo, Sect Ophthalmol, Dept Surg & Clin Diagnost & Pediat Sci, Pavia, Italy; [Agnifili, Luca] Univ G dAnnunzio, Dept Med & Aging Sci, Ophthalmol Clin, Chieti, Italy	IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in Oftalmologia; University of Rome Tor Vergata; IRCCS Fondazione San Matteo; University of Pavia; G d'Annunzio University of Chieti-Pescara	Oddone, F (corresponding author), IRCCS Fdn Bietti, Rome, Italy.	odd1fr@gmail.com	Cacciamani, Andrea/AAB-2154-2021; Micera, Alessandra/J-3373-2013; Oddone, Francesco/K-8876-2016; Agnifili, Luca/AAC-6345-2022; Riva, Ivano/B-9860-2019	Cacciamani, Andrea/0000-0003-1793-9842; Oddone, Francesco/0000-0002-2504-0004; Riva, Ivano/0000-0002-7397-2260; quaranta, luciano/0000-0002-5462-1713; manni, gianluca/0000-0002-9006-8556	Fondazione Roma; Italian Ministry of Health; Istituto di Ricerca Neuroftalmologia (I.R.N.) s.r. l., Rome, Italy	Fondazione Roma(Fondazione RomaEuropean Commission); Italian Ministry of Health(Ministry of Health, Italy); Istituto di Ricerca Neuroftalmologia (I.R.N.) s.r. l., Rome, Italy	The research for this paper was supported by Fondazione Roma and the Italian Ministry of Health. This study was also sponsored by Istituto di Ricerca Neuroftalmologia (I.R.N.) s.r. l., Rome, Italy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AGNOLI A, 1982, NEUROPSYCHOBIOLOGY, V8, P289, DOI 10.1159/000117914; Bogdanov P., 2018, INT J MOL SCI, V19; Connolly GP, 1999, TRENDS PHARMACOL SCI, V20, P218, DOI 10.1016/S0165-6147(99)01298-5; Faiq MA, 2019, PROG RETIN EYE RES, V72, DOI 10.1016/j.preteyeres.2019.06.003; Fresina M, 2008, GRAEF ARCH CLIN EXP, V246, P143, DOI 10.1007/s00417-007-0621-6; Gareri P, 2017, J ALZHEIMERS DIS, V56, P557, DOI 10.3233/JAD-160808; Grieb P, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00073; Kaur IP, 2002, DRUG DEV IND PHARM, V28, P353, DOI 10.1081/DDC-120002997; Kent AR, 2001, OPHTHALMOLOGY, V108, P784, DOI 10.1016/S0161-6420(00)00654-0; MARTINET M, 1979, ARCH INT PHARMACOD T, V239, P52; Martinez-de-la-Casa JM, 2012, EYE, V26, P972, DOI 10.1038/eye.2012.74; Matteucci A, 2014, INT J MOL SCI, V15, P6286, DOI 10.3390/ijms15046286; Ottobelli L, 2013, OPHTHALMOLOGICA, V229, P219, DOI 10.1159/000350496; Parisi V, 2008, EUR J NEUROL, V15, P465, DOI 10.1111/j.1468-1331.2008.02099.x; Parisi V, 1999, OPHTHALMOLOGY, V106, P1126, DOI 10.1016/S0161-6420(99)90269-5; Parisi V, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220435; Parisi V, 2015, GRAEF ARCH CLIN EXP, V253, P1327, DOI 10.1007/s00417-015-3044-9; Parisi V, 2008, PROG BRAIN RES, V173, P541, DOI 10.1016/S0079-6123(08)01137-0; Park CH, 2005, EXP EYE RES, V81, P350, DOI 10.1016/j.exer.2005.02.007; Porciatti V, 1998, CURR EYE RES, V17, P141, DOI 10.1076/ceyr.17.2.141.5606; Rejdak R, 2002, OPHTHALMIC RES, V34, P146, DOI 10.1159/000063658; Roberti G, 2015, INT J MOL SCI, V16, P28401, DOI 10.3390/ijms161226099; Roberti G, 2014, INDIAN J OPHTHALMOL, V62, P549, DOI 10.4103/0301-4738.133484; Secades J J, 2016, Rev Neurol, V63, pS1; Secades JJ, 2006, METHOD FIND EXP CLIN, V28, P1; Secades JJ, 2016, J STROKE CEREBROVASC, V25, P1984, DOI 10.1016/j.jstrokecerebrovasdis.2016.04.010; Spierer O, 2015, OPTOMETRY VISION SCI, V92, P1027, DOI 10.1097/OPX.0000000000000692; Takamura Y, 2015, J OCUL PHARMACOL TH, V31, P282, DOI 10.1089/jop.2015.0003; Wang L, 2007, BRAIN RES, V1133, P42, DOI 10.1016/j.brainres.2006.11.048; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256	30	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2019	14	11							e0224982	10.1371/journal.pone.0224982	http://dx.doi.org/10.1371/journal.pone.0224982			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN2HK	31725734	Green Published, gold			2023-01-03	WOS:000532764500038
J	Murimi-Worstell, IB; Ballreich, JM; Seamans, MJ; Alexander, GC				Murimi-Worstell, Irene B.; Ballreich, Jeromie M.; Seamans, Marissa J.; Alexander, G. Caleb			Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs	PLOS ONE			English	Article								Despite the importance of pharmacopeial standards, little is known regarding their effect on drug competition. Such information is of particular relevance given the rising costs of prescription drugs and the focus of policy-makers and other stakeholders on addressing these costs. We examined 982 prescription drugs approved by U.S Food and Drug Administration since 1982 to examine the association between U.S. Pharmacopeia (USP) standards, generic entry and prescription costs. The presence of a USP drug product monograph was not associated with the time to the third generic entrant or with the likelihood of having a generic competitor. However, on average, drugs with USP drug product monographs had approximately fifty percent more generic manufacturers in the U.S. than their counterparts after accounting for factors such as market volume, age, route of administration and vintage. This greater competition was associated with an approximate savings of $6.22 billion in 2016, suggesting that USP drug product monographs may play an important role in promoting pharmaceutical competition and reducing prescription drug costs.	[Murimi-Worstell, Irene B.; Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; [Murimi-Worstell, Irene B.; Ballreich, Jeromie M.; Seamans, Marissa J.; Alexander, G. Caleb] Johns Hopkins Univ, Ctr Drug Safety & Effectiveness, Baltimore, MD 21205 USA; [Ballreich, Jeromie M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [Seamans, Marissa J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA; [Alexander, G. Caleb] Johns Hopkins Med, Div Gen Internal Med, Dept Med, Baltimore, MD 21287 USA; [Murimi-Worstell, Irene B.] Massachusetts Coll Pharm & Hlth Sci, Program Pharmaceut Econ & Policy, Boston, MA 02115 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine	Alexander, GC (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.; Alexander, GC (corresponding author), Johns Hopkins Univ, Ctr Drug Safety & Effectiveness, Baltimore, MD 21205 USA.; Alexander, GC (corresponding author), Johns Hopkins Med, Div Gen Internal Med, Dept Med, Baltimore, MD 21287 USA.	galexan9@jhmi.edu		Ballreich, Jeromie/0000-0003-2564-4577	U.S. Pharmacopeia; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007292] Funding Source: NIH RePORTER	U.S. Pharmacopeia; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was funded by a grant from U.S. Pharmacopeia, who participated in the design and conduct of the study, analysis and interpretation of the data, and review of the final manuscript, although the decision to submit the manuscript for publication was the authors' alone.	ANDERSON L, 1995, SPIRIT VOLUNTARISM L; [Anonymous], 2018, IQVIA I HEALTHCARE I; [Anonymous], 2018, US PHARM NAT FORM US; Association for Accessible Medicines, 2017, GENERIC DRUG ACCESS; Association for Accessible Medicines, CASE COMP 2019 GEN D; Bhattacharyya L, 2004, PHARM RES-DORDR, V21, P1725, DOI 10.1023/B:PHAM.0000045222.01170.4c; Butler Henry N., 2015, FLA L REV, V67, P977; Center for Drug Evaluation and Research US Food and Drug Administration, 2018, GOOD SUBM PRACT GUID; Dave CV, 2017, NEW ENGL J MED, V377, P2597, DOI 10.1056/NEJMc1711899; Derbyshire M., 2016, GENERICS BIOSIMILARS, V5, P45; DiJulio B, 2015, KAISER HLTH TRACKING; Erika Lietzan, 2016, FEDERALIST SOC REV, V17; Federal Trade Commission, 2010, PAY DEL DRUG CO PAYO; Heller W M, 1986, J Parenter Sci Technol, V40, P80; HELLER WM, 1970, J AMER MED ASSOC, V213, P576; Heyward J, 2018, J PHARM SCI; Kesselheim AS, 2016, JAMA-J AM MED ASSOC, V316, P858, DOI 10.1001/jama.2016.11237; Kovtun Y, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.768.768; Morton FS, 2017, ENABLING COMPETITION, V2; Sarpatwari A, 2014, NEW ENGL J MED, V370, P1476, DOI 10.1056/NEJMp1400488; The United States Pharmacopeial Convention, USP FDA WORK TOG PRO; U.S Food and Drug Administration, 2018, NAT DRUH COD DIR; US Food and Drug Administration, 2018, OR BOOK APPR DRUG PR; USP-NF, GEN NOT 4	24	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2019	14	11							e0225109	10.1371/journal.pone.0225109	http://dx.doi.org/10.1371/journal.pone.0225109			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN1MV	31714946	Green Published, gold			2023-01-03	WOS:000532710400030
J	Ota, Y; Kitamura, M; Muta, K; Yamashita, H; Uramatsu, T; Obata, Y; Harada, T; Funakoshi, S; Mukae, H; Nishino, T				Ota, Yuki; Kitamura, Mineaki; Muta, Kumiko; Yamashita, Hiroshi; Uramatsu, Tadashi; Obata, Yoko; Harada, Takashi; Funakoshi, Satoshi; Mukae, Hiroshi; Nishino, Tomoya			Effect of statin on life prognosis in Japanese patients undergoing hemodialysis	PLOS ONE			English	Article							TYPE-2 DIABETES-MELLITUS; C-REACTIVE PROTEIN; DIALYSIS OUTCOMES; PRACTICE PATTERNS; RANDOMIZED-TRIAL; RISK; CHOLESTEROL; ATORVASTATIN; MORTALITY; ROSUVASTATIN	The effect of statin on hemodialysis patients is controversial. Although previous large-scale studies did not clarify its effect in this population, recent studies suggest that statins could be useful in reducing the risk of cardiovascular events and all-cause mortality in specific groups of patients undergoing hemodialysis. The aforementioned large-scale studies included a small percentage of Asians, and few studies have investigated the effects of statins in Asians undergoing hemodialysis. Thus, we investigated the benefits of statins in patients undergoing maintenance hemodialysis at a single center in Japan. We obtained demographic, clinical, and hemodialysis data of all patients who underwent maintenance hemodialysis at the Nagasaki Renal Center between July 2011 and June 2012. Patients were followed-up until June 2018. We studied 339 patients, of which 51 (15.0%) were prescribed pitavastatin. The mean observation period was 4.1 +/- 2.3 years, 43% were women, and the median hemodialysis vintage at baseline was 4.7 years. During the follow-up, 198 patients (58%) died, of which 22 (43%) were prescribed pitavastatin and 176 (61%) were not prescribed any statins. After propensity score matching based on age, sex, dialysis vintage, dialysis time, diabetes mellitus, ischemic heart disease, dry weight, left ventricular ejection fraction, and serum albumin, an intergroup comparison between those who received statins and those who did not (44 patients in each group) showed significant differences in survival rate based on the log-rank test (P<0.05). Although the causes of death did not differ significantly between groups, deaths due to cardiovascular events, infections, and cancer were fewer in the group prescribed statins. Our results suggest that statins may reduce mortality in Japanese patients undergoing maintenance hemodialysis. Although potential residual confounders exist, statins may have an influence on the reduction in the incidence of cardiovascular events, infections, and cancer. Nevertheless, further studies are required to prove this hypothesis.	[Ota, Yuki; Kitamura, Mineaki; Muta, Kumiko; Yamashita, Hiroshi; Uramatsu, Tadashi; Obata, Yoko; Nishino, Tomoya] Nagasaki Univ Hosp, Dept Nephrol, Nagasaki, Japan; [Kitamura, Mineaki] Nagasaki Univ Hosp, Div Blood Purificat, Nagasaki, Japan; [Harada, Takashi; Funakoshi, Satoshi] Nagasaki Renal Ctr, Dept Nephrol, Nagasaki, Japan; [Mukae, Hiroshi] Nagasaki Univ, Dept Resp Med, Grad Sch Biomed Sci, Nagasaki, Japan	Nagasaki University; Nagasaki University; Nagasaki University	Kitamura, M (corresponding author), Nagasaki Univ Hosp, Dept Nephrol, Nagasaki, Japan.; Kitamura, M (corresponding author), Nagasaki Univ Hosp, Div Blood Purificat, Nagasaki, Japan.	minekitamura@nagasaki-u.ac.jp	Kitamura, Mineaki/ABA-1041-2021; Kitamura, Mineaki/ADQ-8686-2022	Kitamura, Mineaki/0000-0002-0003-8645; Kitamura, Mineaki/0000-0002-0003-8645	KAKENHI [19K17747]	KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by a Grant-inAid for Scientific Research (KAKENHI; grant number 19K17747) (recipient: Mineaki Kitamura). This funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akizawa T, 2008, NEPHROL DIAL TRANSPL, V23, P3643, DOI 10.1093/ndt/gfn346; Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; Allen SC, 2017, J PHARMACOL EXP THER, V362, P319, DOI 10.1124/jpet.117.242081; Baigent C, 2000, LANCET, V356, P147, DOI 10.1016/S0140-6736(00)02456-9; Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5; Bauer DC, 2004, ARCH INTERN MED, V164, P146, DOI 10.1001/archinte.164.2.146; Chung CM, 2017, ATHEROSCLEROSIS, V267, P158, DOI 10.1016/j.atherosclerosis.2017.09.018; Cice G, 2003, J AM COLL CARDIOL, V41, P1438, DOI 10.1016/S0735-1097(03)00241-9; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; EGASHIRA K, 1994, CIRCULATION, V89, P2519, DOI 10.1161/01.CIR.89.6.2519; Fellstrom BC, 2009, NEW ENGL J MED, V360, P1395, DOI 10.1056/NEJMoa0810177; Floege J, 2011, NEPHROL DIAL TRANSPL, V26, P1948, DOI 10.1093/ndt/gfq219; Gamboa CM, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004264; Glynn RJ, 2009, NEW ENGL J MED, V360, P1851, DOI 10.1056/NEJMoa0900241; Goodkin DA, 2003, J AM SOC NEPHROL, V14, P3270, DOI 10.1097/01.ASN.0000100127.54107.57; Haag MDM, 2009, J NEUROL NEUROSUR PS, V80, P13, DOI 10.1136/jnnp.2008.150433; Hayashino Y, 2007, DIABETOLOGIA, V50, P1170, DOI 10.1007/s00125-007-0650-z; Hou WY, 2013, EUR HEART J, V34, P1807, DOI 10.1093/eurheartj/eht065; Kitamura M, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1400-4; Krane V, 2016, KIDNEY INT, V89, P1380, DOI 10.1016/j.kint.2015.12.033; LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461; Mazzuchi N, 2000, KIDNEY INT, V58, P2147; Mc Causland FR, 2012, CLIN J AM SOC NEPHRO, V7, P1827, DOI 10.2215/CJN.03880412; Novack V, 2012, CAN MED ASSOC J, V184, pE367, DOI 10.1503/cmaj.111017; Oesterle A, 2017, CIRC RES, V120, P229, DOI 10.1161/CIRCRESAHA.116.308537; Pignatelli P, 2012, CIRCULATION, V126, P92, DOI 10.1161/CIRCULATIONAHA.112.095554; Plenge JK, 2002, CIRCULATION, V106, P1447, DOI 10.1161/01.CIR.0000029743.68247.31; Poynter JN, 2005, NEW ENGL J MED, V352, P2184, DOI 10.1056/NEJMoa043792; Preiss D, 2012, JAMA-J AM MED ASSOC, V308, P804, DOI 10.1001/jama.2012.8439; Robinson BM, 2012, CLIN J AM SOC NEPHRO, V7, P1897, DOI 10.2215/CJN.04940512; Sarnak MJ, 2003, AM J KIDNEY DIS, V41, pS11, DOI 10.1016/S0272-6386(03)00372-X; Verma AA, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.117.003764; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545; Wanner C, 2014, KIDNEY INT, V85, P1303, DOI 10.1038/ki.2014.31; Yagisawa T., 2016, RENAL REPLACE THER, V2, P68, DOI [10.1186/s41100-016-0080-9, DOI 10.1186/S41100-016-0080-9]; Yoshida Tadashi, 2017, Keio Journal of Medicine, V66, P44, DOI 10.2302/kjm.2016-0009-OA; Yusuf S, 2016, NEW ENGL J MED, V374, P2021, DOI 10.1056/NEJMoa1600176; Zissimopoulos JM, 2017, JAMA NEUROL, V74, P225, DOI [10.1001/jamaneurol.2016.3783, 10.1001/ja]	38	7	8	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 22	2019	14	10							e0224111	10.1371/journal.pone.0224111	http://dx.doi.org/10.1371/journal.pone.0224111			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM9ME	31639169	Green Published, gold			2023-01-03	WOS:000532571400030
J	Kuramatsu, JB; Biffi, A; Gerner, ST; Sembill, JA; Sprugel, MI; Leasure, A; Sansing, L; Matouk, C; Falcone, GJ; Endres, M; Haeusler, KG; Sobesky, J; Schurig, J; Zweynert, S; Bauer, M; Vajkoczy, P; Ringleb, PA; Purrucker, J; Rizos, T; Volkmann, J; Mullges, W; Kraft, P; Schubert, AL; Erbguth, F; Nueckel, M; Schellinger, PD; Glahn, J; Knappe, UJ; Fink, GR; Dohmen, C; Stetefeld, H; Fisse, AL; Minnerup, J; Hagemann, G; Rakers, F; Reichmann, H; Schneider, H; Rahmig, J; Ludolph, AC; Stosser, S; Neugebauer, H; Rother, J; Michels, P; Schwarz, M; Reimann, G; Bazner, H; Schwert, H; Classen, J; Michalski, D; Grau, A; Palm, F; Urbanek, C; Wohrle, JC; Alshammari, F; Horn, M; Bahner, D; Witte, OW; Gunther, A; Hamann, GF; Hagen, M; Roeder, SS; Lucking, H; Dorfler, A; Testai, FD; Woo, D; Schwab, S; Sheth, KN; Huttner, HB				Kuramatsu, Joji B.; Biffi, Alessandro; Gerner, Stefan T.; Sembill, Jochen A.; Spruegel, Maximilian I.; Leasure, Audrey; Sansing, Lauren; Matouk, Charles; Falcone, Guido J.; Endres, Matthias; Haeusler, Karl Georg; Sobesky, Jan; Schurig, Johannes; Zweynert, Sarah; Bauer, Miriam; Vajkoczy, Peter; Ringleb, Peter A.; Purrucker, Jan; Rizos, Timolaos; Volkmann, Jens; Muellges, Wolfgang; Kraft, Peter; Schubert, Anna-Lena; Erbguth, Frank; Nueckel, Martin; Schellinger, Peter D.; Glahn, Joerg; Knappe, Ulrich J.; Fink, Gereon R.; Dohmen, Christian; Stetefeld, Henning; Fisse, Anna Lena; Minnerup, Jens; Hagemann, Georg; Rakers, Florian; Reichmann, Heinz; Schneider, Hauke; Rahmig, Jan; Ludolph, Albert Christian; Stoesser, Sebastian; Neugebauer, Hermann; Roether, Joachim; Michels, Peter; Schwarz, Michael; Reimann, Gernot; Baezner, Hansjoerg; Schwert, Henning; Classen, Joseph; Michalski, Dominik; Grau, Armin; Palm, Frederick; Urbanek, Christian; Woehrle, Johannes C.; Alshammari, Fahid; Horn, Markus; Bahner, Dirk; Witte, Otto W.; Guenther, Albrecht; Hamann, Gerhard F.; Hagen, Manuel; Roeder, Sebastian S.; Luecking, Hannes; Doerfler, Arnd; Testai, Fernando D.; Woo, Daniel; Schwab, Stefan; Sheth, Kevin N.; Huttner, Hagen B.			Association of Surgical Hematoma Evacuation vs Conservative Treatment With Functional Outcome in Patients With Cerebellar Intracerebral Hemorrhage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDIVIDUAL PARTICIPANT DATA; MIDDLE CEREBRAL-ARTERY; VITAMIN-K ANTAGONIST; STROKE; METAANALYSIS; DECOMPRESSION; MULTICENTER; GUIDELINES; MANAGEMENT; INFARCTION	IMPORTANCE The association of surgical hematoma evacuation with clinical outcomes in patients with cerebellar intracerebral hemorrhage (ICH) has not been established. OBJECTIVE To determine the association of surgical hematoma evacuation with clinical outcomes in cerebellar ICH. DESIGN, SETTING, AND PARTICIPANTS Individual participant data (IPD) meta-analysis of 4 observational ICH studies incorporating 6580 patients treated at 64 hospitals across the United States and Germany (2006-2015). EXPOSURE Surgical hematoma evacuation vs conservative treatment. MAIN OUTCOMES AND MEASURES The primary outcome was functional disability evaluated by the modified Rankin Scale ([mRS] score range: 0, no functional deficit to 6, death) at 3 months; favorable (mRS, 0-3) vs unfavorable (mRS, 4-6). Secondary outcomes included survival at 3 months and at 12 months. Analyses included propensity score matching and covariate adjustment, and predicted probabilities were used to identify treatment-related cutoff values for cerebellar ICH. RESULTS Among 578 patients with cerebellar ICH, propensity score-matched groups included 152 patients with surgical hematoma evacuation vs 152 patients with conservative treatment (age, 68.9 vs 69.2 years; men, 55.9% vs 51.3%; prior anticoagulation, 60.5% vs 63.8%; and median ICH volume, 20.5 cm(3) vs 18.8 cm(3)). After adjustment, surgical hematoma evacuation vs conservative treatment was not significantly associated with likelihood of better functional disability at 3 months (30.9% vs 35.5%; adjusted odds ratio [AOR], 0.94 [95% CI, 0.81 to 1.09], P = .43; adjusted risk difference [ARD], -3.7% [95% CI, -8.7% to 1.2%]) but was significantly associated with greater probability of survival at 3 months (78.3% vs 61.2%; AOR, 1.25 [95% CI, 1.07 to 1.45], P = .005; ARD, 18.5% [95% CI, 13.8% to 23.2%]) and at 12 months (71.7% vs 57.2%; AOR, 1.21 [95% CI, 1.03 to 1.42], P = .02; ARD, 17.0% [95% CI, 11.5% to 22.6%]). A volume range of 12 to 15 cm(3) was identified; below this level, surgical hematoma evacuation was associated with lower likelihood of favorable functional outcome (volume <= 12 cm(3), 30.6% vs 62.3% [P = .003]; ARD, -34.7% [-38.8% to -30.6%]; P value for interaction, .01), and above, it was associated with greater likelihood of survival (volume >= 15 cm(3), 74.5% vs 45.1% [P < .001]; ARD, 28.2% [95% CI, 24.6% to 31.8%]; P value for interaction, .02). CONCLUSIONS AND RELEVANCE Among patients with cerebellar ICH, surgical hematoma evacuation, compared with conservative treatment, was not associated with improved functional outcome. Given the null primary outcome, investigation is necessary to establish whether there are differing associations based on hematoma volume.	[Kuramatsu, Joji B.; Gerner, Stefan T.; Sembill, Jochen A.; Spruegel, Maximilian I.; Hagen, Manuel; Roeder, Sebastian S.; Schwab, Stefan; Huttner, Hagen B.] Univ Erlangen Nurnberg, Dept Neurol, Schwabachanlage 6, D-91054 Erlangen, Germany; [Biffi, Alessandro] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Biffi, Alessandro] J Philip Kistler Stroke Res Ctr, Hemorrhag Stroke Res Program, Boston, MA USA; [Leasure, Audrey; Sansing, Lauren; Matouk, Charles; Falcone, Guido J.; Sheth, Kevin N.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; [Endres, Matthias; Haeusler, Karl Georg; Sobesky, Jan; Zweynert, Sarah] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany; [Endres, Matthias; Haeusler, Karl Georg; Sobesky, Jan; Schurig, Johannes; Bauer, Miriam] Charite Univ Med Berlin, Ctr Stroke Res Berlin, Berlin, Germany; [Endres, Matthias] German Ctr Cardiovasc Res DZHK, Berlin, Germany; [Endres, Matthias] German Ctr Neurodegenerat Dis DZNE, Partner Site Berlin, Berlin, Germany; [Haeusler, Karl Georg; Volkmann, Jens; Muellges, Wolfgang; Kraft, Peter; Schubert, Anna-Lena; Neugebauer, Hermann] Univ Wurzburg, Dept Neurol, Wurzburg, Germany; [Vajkoczy, Peter] Charite Univ Med Berlin, Dept Neurosurg, Berlin, Germany; [Ringleb, Peter A.; Purrucker, Jan; Rizos, Timolaos] Heidelberg Univ Hosp, Dept Neurol, Heidelberg, Germany; [Rizos, Timolaos] Alfried Krupp Krankenhaus Essen, Dept Neurol, Essen, Germany; [Erbguth, Frank; Nueckel, Martin] Community Hosp Nuremberg, Dept Neurol, Nurnberg, Germany; [Schellinger, Peter D.; Glahn, Joerg] UK RUB, Johannes Wesling Med Ctr, Dept Neurol & Neurogeriatry, Minden, Germany; [Knappe, Ulrich J.] UK RUB, Johannes Wesling Med Ctr Minden, Dept Neurosurg, Minden, Germany; [Fink, Gereon R.; Dohmen, Christian; Stetefeld, Henning] Univ Cologne, Dept Neurol, Cologne, Germany; [Fisse, Anna Lena; Minnerup, Jens] Univ Munster, Dept Neurol, Munster, Germany; [Hagemann, Georg; Rakers, Florian] Community Hosp Helios Klinikum Berlin Buch, Dept Neurol, Berlin, Germany; [Reichmann, Heinz; Schneider, Hauke; Rahmig, Jan] Univ Dresden, Dept Neurol, Dresden, Germany; [Schneider, Hauke] Klinikum Augsburg, Dept Neurol, Augsburg, Germany; [Ludolph, Albert Christian; Stoesser, Sebastian; Neugebauer, Hermann] Univ Ulm, Dept Neurol, Ulm, Germany; [Roether, Joachim; Michels, Peter] Community Hosp Asklepios Klin Hamburg Altona, Dept Neurol, Hamburg, Germany; [Schwarz, Michael; Reimann, Gernot] Community Hosp Klinikum Dortmund, Dept Neurol, Dortmund, Germany; [Baezner, Hansjoerg; Schwert, Henning] Community Hosp Klinikum Stuttgart, Dept Neurol, Stuttgart, Germany; [Classen, Joseph; Michalski, Dominik] Univ Leipzig, Dept Neurol, Leipzig, Germany; [Grau, Armin; Palm, Frederick; Urbanek, Christian] Community Hosp Klinikum Stadt Ludwigshafen Rhein, Dept Neurol, Ludwigshafen, Germany; [Woehrle, Johannes C.; Alshammari, Fahid] Community Hosp Klinikum Koblenz, Dept Neurol, Koblenz, Germany; [Horn, Markus; Bahner, Dirk] Community Hosp Bad Hersfeld, Dept Neurol, Bad Hersfeld, Germany; [Witte, Otto W.; Guenther, Albrecht] Univ Jena, Dept Neurol, Jena, Germany; [Hamann, Gerhard F.] Bezirkskrankenhaus Gunzburg, Dept Neurol & Neurol Rehabil, Gunzburg, Germany; [Luecking, Hannes; Doerfler, Arnd] Univ Erlangen Nurnberg, Dept Neuroradiol, Erlangen, Germany; [Testai, Fernando D.] Univ Illinois, Coll Med, Dept Neurol & Rehabil, Chicago, IL USA; [Woo, Daniel] Univ Cincinnati, Dept Neurol & Rehabil Med, Cincinnati, OH USA	University of Erlangen Nuremberg; Harvard University; Massachusetts General Hospital; Yale University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Centre for Cardiovascular Research; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Wurzburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls University Heidelberg; Alfried Krupp Hospital; Ruhr University Bochum; Ruhr University Bochum; University of Cologne; University of Munster; Helios Kliniken; Technische Universitat Dresden; Klinikum Augsburg; Ulm University; Asklepios Klinik Altona; Klinikum Stuttgart; Leipzig University; Ludwigshafen Hospital; Friedrich Schiller University of Jena; University of Erlangen Nuremberg; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University System of Ohio; University of Cincinnati	Huttner, HB (corresponding author), Univ Erlangen Nurnberg, Dept Neurol, Schwabachanlage 6, D-91054 Erlangen, Germany.	Hagen.Huttner@uk-erlangen.de	Fisse, Anna Lena/Q-7543-2019; Häusler, Karl Georg/AAS-5962-2021; Matouk, Charles/AAF-7694-2019; Volkmann, Jens/AAK-7570-2020; Gerner, Stefan T./ABH-8328-2020; Witte, Otto/P-4127-2018; Neugebauer, Hermann/AAD-8309-2019; Fink, Gereon R./E-1616-2012	Fisse, Anna Lena/0000-0003-0493-8656; Gerner, Stefan T./0000-0001-6020-8290; Witte, Otto/0000-0003-2101-4105; Neugebauer, Hermann/0000-0003-3759-356X; Fink, Gereon R./0000-0002-8230-1856; Kuramatsu, Joji B./0000-0002-7630-7880; Rahmig, Jan/0000-0002-7061-8995; Classen, Joseph/0000-0001-7182-6967; Sembill, Jochen A./0000-0003-0014-3389; Schneider, Hauke/0000-0002-9641-0922; Zweynert, Sarah/0000-0002-1665-2666; Sansing, Lauren/0000-0002-6898-1680; Endres, Matthias/0000-0001-6520-3720; Sobesky, Jan/0000-0001-5459-3655	Johannes and Frieda Marohn Foundation (FWN/Zo-Hutt/2011); ELAN-Fonds [ELAN_12.01.04.1]; Erlangen, Germany; NIH [U01NS069763, R01NS093870, P50NS051343, R01AG26484]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS069763, R01NS093870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG026484] Funding Source: NIH RePORTER	Johannes and Frieda Marohn Foundation (FWN/Zo-Hutt/2011); ELAN-Fonds; Erlangen, Germany; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors' work on this study was supported by the Johannes and Frieda Marohn Foundation (FWN/Zo-Hutt/2011), the ELAN-Fonds (ELAN_12.01.04.1), Erlangen, Germany, and NIH (U01NS069763, R01NS093870, P50NS051343 and R01AG26484).	Apps R, 2005, NAT REV NEUROSCI, V6, P297, DOI 10.1038/nrn1646; Aside LM, 2018, JAMA-J AM MED ASSOC, V319, P2190, DOI 10.1001/jama.2018.5725; Burke DL, 2017, STAT MED, V36, P855, DOI 10.1002/sim.7141; Chevret S, 2015, INTENS CARE MED, V41, P348, DOI 10.1007/s00134-014-3624-x; Da Pian R, 1984, Neurol Res, V6, P145; Datar S, 2014, NEUROL CLIN, V32, P993, DOI 10.1016/j.ncl.2014.07.006; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dolderer S, 2004, EUR NEUROL, V52, P112, DOI 10.1159/000080268; DONAUER E, 1994, ACTA NEUROCHIR, V131, P59, DOI 10.1007/BF01401454; Gerner ST, 2018, ANN NEUROL, V83, P186, DOI 10.1002/ana.25134; Hackenberg KAM, 2017, CLIN NEUROL NEUROSUR, V155, P22, DOI 10.1016/j.clineuro.2017.01.019; Hanley DF, 2017, LANCET, V389, P603, DOI 10.1016/S0140-6736(16)32410-2; Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Inohara T, 2018, JAMA-J AM MED ASSOC, V319, P463, DOI 10.1001/jama.2017.21917; Ioannidis JPA, 2008, J EVAL CLIN PRACT, V14, P951, DOI 10.1111/j.1365-2753.2008.00986.x; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Krishnamurthi RV, 2013, LANCET GLOB HEALTH, V1, pE259, DOI 10.1016/S2214-109X(13)70089-5; Kuramatsu JB, 2018, EUR HEART J, V39, P1709, DOI 10.1093/eurheartj/ehy056; Kuramatsu JB, 2015, JAMA-J AM MED ASSOC, V313, P824, DOI 10.1001/jama.2015.0846; Leisman DE, 2019, CRIT CARE MED, V47, P176, DOI 10.1097/CCM.0000000000003567; Nichols M, 2013, EUR HEART J, V34, P3028, DOI 10.1093/eurheartj/eht356; Qureshi AI, 2016, NEW ENGL J MED, V375, P1033, DOI 10.1056/NEJMoa1603460; Reeves MJ, 2009, STROKE, V40, P569, DOI 10.1161/STROKEAHA.108.519355; Saver JL, 2016, JAMA-J AM MED ASSOC, V316, P1279, DOI 10.1001/jama.2016.13647; Sch_unemann H, GRADE HDB GRADING QU; Sembill JA, 2017, NEUROLOGY, V89, P423, DOI 10.1212/WNL.0000000000004174; Sprugel MI, 2018, STROKE, V49, P2621, DOI 10.1161/STROKEAHA.118.021614; Steiner T, 2014, INT J STROKE, V9, P838, DOI 10.1111/ijs.12369; Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919; Stewart LA, 2015, JAMA-J AM MED ASSOC, V313, P1657, DOI 10.1001/jama.2015.3656; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; VANLOON J, 1993, ACTA NEUROCHIR, V122, P187, DOI 10.1007/BF01405527; Woo D, 2013, STROKE, V44, pE120, DOI 10.1161/STROKEAHA.113.002332; Zhang JJ, 2014, J NEUROL, V261, P324, DOI 10.1007/s00415-013-7198-2	35	53	58	2	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2019	322	14					1392	1403		10.1001/jama.2019.13014	http://dx.doi.org/10.1001/jama.2019.13014			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE1GT	31593272	Bronze, Green Published			2023-01-03	WOS:000490441900021
J	Udagawa, C; Horinouchi, H; Shiraishi, K; Kohno, T; Okusaka, T; Ueno, H; Tamura, K; Ohe, Y; Zembutsu, H				Udagawa, Chihiro; Horinouchi, Hidehito; Shiraishi, Kouya; Kohno, Takashi; Okusaka, Takuji; Ueno, Hideki; Tamura, Kenji; Ohe, Yuichiro; Zembutsu, Hitoshi			Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease	PLOS ONE			English	Article							RHEUMATOID-ARTHRITIS PATIENTS; SURFACTANT PROTEIN-A; INDUCED LIVER-INJURY; JAPANESE PATIENTS; GEMCITABINE; ERLOTINIB; SURVEILLANCE; ASSOCIATION; SAFETY; GLI1	Drug-induced interstitial lung disease (DIILD) is a serious side effect of chemotherapy in cancer patients with an extremely high mortality rate. In this study, to identify genetic variants with greater risk of DIILD, we carried out whole genome sequencing (WGS) of germline DNA samples from 26 patients who developed DIILD, and conducted a case-control association study between these 26 cases and general Japanese population controls registered in the integrative Japanese Genome Variation Database (iJGVD) as a screening study. The associations of 42 single nucleotide variants (SNVs) showing P < 0.0001 were further validated using an independent cohort of 18 DIILD cases as a replication study. A further combined analysis of the screening and replication studies showed a possible association of two SNVs, rs35198919 in intron 1 of the chromosome 22 open reading frame 34 (C22orf34) and rs12625311 in intron 1 of the teashirt zinc finger homeobox 2 (TSHZ2), with DIILD (P-combined = 1.87 x 10(-5) and 5.16 x 10(-5), respectively). Furthermore, in a subgroup analysis of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-induced interstitial lung disease (ILD), we observed seven candidate SNVs that were possibly associated with ILD (P < 0.00001). This is the first study to identify genetic markers for the risk of DIILD using WGS. Collectively, our novel findings indicate that these SNVs may be applicable for predicting the risk of DIILD in patients receiving chemotherapy.	[Udagawa, Chihiro; Zembutsu, Hitoshi] Natl Canc Ctr, Div Genet, Res Inst, Tokyo, Japan; [Horinouchi, Hidehito; Ohe, Yuichiro] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan; [Shiraishi, Kouya; Kohno, Takashi] Natl Canc Ctr, Div Genome Biol, Res Inst, Tokyo, Japan; [Okusaka, Takuji; Ueno, Hideki] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan; [Tamura, Kenji] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo, Japan; [Zembutsu, Hitoshi] Japanese Fdn Canc Res, Res Inst, Project Dev Liquid Biopsy Diag, Tokyo, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Japanese Foundation for Cancer Research	Zembutsu, H (corresponding author), Natl Canc Ctr, Div Genet, Res Inst, Tokyo, Japan.; Zembutsu, H (corresponding author), Japanese Fdn Canc Res, Res Inst, Project Dev Liquid Biopsy Diag, Tokyo, Japan.	hitoshi.zembutsu@jfcr.or.jp		Horinouchi, Hidehito/0000-0001-9090-801X	AstraZeneca	AstraZeneca(AstraZeneca)	This work was supported by AstraZeneca (HZ), https://www.astrazeneca.com/.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277; Ballester B, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.congress-2018.PA4798; Behr ER, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078511; BELLAMY EA, 1985, RADIOLOGY, V156, P155, DOI 10.1148/radiology.156.1.2408293; Brehmer D, 2005, CANCER RES, V65, P379; Cohen MH, 2004, CLIN CANCER RES, V10, P1212, DOI 10.1158/1078-0432.CCR-03-0564; Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379; Fernandez AB, 2008, CHEST, V134, P824, DOI 10.1378/chest.08-0943; Furukawa H, 2015, CLIN MED INSIGHTS-CI, V9, P1, DOI [10.4137/CCRPM.S23283, 10.4137/CCRPRPM.S23283]; Furukawa H, 2013, ANN RHEUM DIS, V72, P153, DOI 10.1136/annrheumdis-2012-201944; Gemma A, 2014, CANCER SCI, V105, P1584, DOI 10.1111/cas.12550; Gurjal A, 1999, LUNG CANCER-J IASLC, V26, P109, DOI 10.1016/S0169-5002(99)00081-1; Hamada T, 2016, RESPIROLOGY, V21, P338, DOI 10.1111/resp.12665; Inaguma S, 2015, ONCOTARGET, V6, P33648, DOI 10.18632/oncotarget.5203; Ishikawa N, 2008, INT J CANCER, V122, P2612, DOI 10.1002/ijc.23411; Johkoh T, 2014, CLIN LUNG CANCER, V15, P448, DOI 10.1016/j.cllc.2014.06.003; Juge PA, 2018, NEW ENGL J MED, V379, P2209, DOI 10.1056/NEJMoa1801562; KAMATA T, 1994, INTERNAL MED, V33, P252, DOI 10.2169/internalmedicine.33.252; Kang IS, 2014, KOREAN J INTERN MED, V29, P746, DOI 10.3904/kjim.2014.29.6.746; Koike T, 2014, MOD RHEUMATOL, V24, P390, DOI 10.3109/14397595.2013.843760; Lee T, 2010, ACTA DERM-VENEREOL, V90, P625, DOI 10.2340/00015555-0977; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lucena MI, 2011, GASTROENTEROLOGY, V141, P338, DOI 10.1053/j.gastro.2011.04.001; Martin M., 2011, EMBNET J, V17, P10, DOI 10.14806/ej.17.1.200; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Minami-Shimmyo Y, 2012, J THORAC ONCOL, V7, P177, DOI 10.1097/JTO.0b013e31823c4c07; Nagasaki M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9018; Nakamura K, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3285-6; Nicoletti P, 2017, GASTROENTEROLOGY, V152, P1078, DOI 10.1053/j.gastro.2016.12.016; Nishimura M, 2016, CANCER CHEMOTH PHARM, V77, P1165, DOI 10.1007/s00280-016-3026-6; Ohnishi H, 2002, AM J RESP CRIT CARE, V165, P378, DOI 10.1164/ajrccm.165.3.2107134; Osawa M, 2015, INT J CLIN ONCOL, V20, P1063, DOI 10.1007/s10147-015-0834-3; Perez-Alvarez R, 2011, SEMIN ARTHRITIS RHEU, V41, P256, DOI 10.1016/j.semarthrit.2010.11.002; Qin H, PULMONOLOGY; Riku M, 2016, ONCOTARGET, V7, P5690, DOI 10.18632/oncotarget.6788; Ripley B, 2016, DECIPHERING DRUG IND; Sawada T, 2009, RHEUMATOLOGY, V48, P1069, DOI 10.1093/rheumatology/kep052; Schwaiblmair Martin, 2012, Open Respir Med J, V6, P63, DOI 10.2174/1874306401206010063; Seibold MA, 2011, NEW ENGL J MED, V364, P1503, DOI 10.1056/NEJMoa1013660; Selman M, 2003, HUM GENET, V113, P542, DOI 10.1007/s00439-003-1015-4; Skeoch S, 2018, J CLIN MED, V7, DOI 10.3390/jcm7100356; Tabara H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026034; Tamura M, 2013, ONCOLOGIST, V18, P454, DOI 10.1634/theoncologist.2012-0248; Udagawa C, 2018, CANCER SCI, V109, P446, DOI 10.1111/cas.13471; Ueta Mayumi, 2016, Taiwan J Ophthalmol, V6, P108, DOI 10.1016/j.tjo.2016.06.001; Wang Y, 2009, AM J HUM GENET, V84, P52, DOI 10.1016/j.ajhg.2008.11.010; Yague Xavier Hernandez, 2005, Clin Transl Oncol, V7, P515, DOI 10.1007/BF02717006; Yamasaki K, 2013, RESP MED, V107, P2088, DOI 10.1016/j.rmed.2013.09.023; Zhang Y, 2003, J BIOL CHEM, V278, P573, DOI 10.1074/jbc.M203094200	49	7	7	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2019	14	10							e0223371	10.1371/journal.pone.0223371	http://dx.doi.org/10.1371/journal.pone.0223371			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM7CZ	31584970	Green Published, gold			2023-01-03	WOS:000532407600023
J	Nikooie, R; Neufeld, KJ; Oh, ES; Wilson, LM; Zhang, A; Robinson, KA; Needham, DM				Nikooie, Roozbeh; Neufeld, Karin J.; Oh, Esther S.; Wilson, Lisa M.; Zhang, Allen; Robinson, Karen A.; Needham, Dale M.			Antipsychotics for Treating Delirium in Hospitalized Adults A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							CRITICALLY-ILL PATIENTS; DOUBLE-BLIND; HALOPERIDOL; EFFICACY; CARE; RISPERIDONE; OLANZAPINE; METAANALYSIS; QUETIAPINE; PLACEBO	Background: Delirium is common in hospitalized patients and is associated with worse outcomes. Antipsychotics are commonly used; however, the associated benefits and harms are unclear. Purpose: To conduct a systematic review evaluating the benefits and harms of antipsychotics to treat delirium in adults. Data Sources: PubMed, Embase, CENTRAL, CINAHL, and Psyc-INFO from inception to July 2019 without language restrictions. Study Selection: Randomized controlled trials (RCTs) of antipsychotic versus placebo or another antipsychotic, and prospective observational studies reporting harms. Data Extraction: One reviewer extracted data and assessed strength of evidence (SOE) for critical outcomes, with confirmation by another reviewer. Risk of bias was assessed independently by 2 reviewers. Data Synthesis: Across 16 RCTs and 10 observational studies of hospitalized adults, there was no difference in sedation status (low and moderate SOE), delirium duration, hospital length of stay (moderate SOE), or mortality between haloperidol and second-generation antipsychotics versus placebo. There was no difference in delirium severity (moderate SOE) and cognitive functioning (low SOE) for haloperidol versus second-generation antipsychotics, with insufficient or no evidence for antipsychotics versus placebo. For direct comparisons of different second-generation antipsychotics, there was no difference in mortality and insufficient or no evidence for multiple other outcomes. There was little evidence demonstrating neurologic harms associated with short-term use of antipsychotics for treating delirium in adult inpatients, but potentially harmful cardiac effects tended to occur more frequently. Limitations: Heterogeneity was present in terms of dose and administration route of antipsychotics, outcomes, and measurement instruments. There was insufficient or no evidence regarding multiple clinically important outcomes. Conclusion: Current evidence does not support routine use of haloperidol or second-generation antipsychotics to treat delirium in adult inpatients. Primary Funding Source: Agency for Healthcare Research and Quality. (PROSPERO: CRD42018109552)	[Nikooie, Roozbeh; Neufeld, Karin J.; Oh, Esther S.; Robinson, Karen A.; Needham, Dale M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Wilson, Lisa M.; Zhang, Allen] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Nikooie, Roozbeh; Needham, Dale M.] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, 1830 East Monument St,Fifth Floor, Baltimore, MD 21287 USA; [Neufeld, Karin J.] Johns Hopkins Bayview Med Ctr, Dept Psychiat, A4 Ctr Suite 457,4940 Eastern Ave, Baltimore, MD 21224 USA; [Oh, Esther S.] Johns Hopkins Univ, Sch Med, Dept Med, Mason F Lord Bldg Ctr Tower,5200 Eastern Ave, Baltimore, MD 21224 USA; [Wilson, Lisa M.; Zhang, Allen] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 North Broadway,Sixth Floor, Baltimore, MD 21205 USA; [Robinson, Karen A.] Johns Hopkins Univ, Sch Med, Dept Med, 1830 East Monument St,Room 8068, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University	Needham, DM (corresponding author), Johns Hopkins Univ, Div Pulm & Crit Care Med, 1830 East Monument St,5th Floor, Baltimore, MD 21205 USA.	LisaWilson@jhmi.edu; dale.needham@jhmi.edu			Agency for Healthcare Research and Quality [PROSPERO: CRD42018109552]	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Agency for Healthcare Research and Quality. (PROSPERO: CRD42018109552)	Agar MR, 2017, JAMA INTERN MED, V177, P34, DOI 10.1001/jamainternmed.2016.7491; [Anonymous], 2014, AHRQ PUBLICATION, V10(12)-EHC063-EF; [Anonymous], 2018, MOB NETW PUBL; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Boettger S, 2015, PALLIAT SUPPORT CARE, V13, P1079, DOI 10.1017/S1478951514001059; Boettger S, 2011, EUR J PSYCHIAT, V25, P59; Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528; Burry L, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011749.pub2; Burry L, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005594.pub3; Charoenporn Veevarin, 2018, Journal of the Medical Association of Thailand, V101, P361; Collet MO, 2018, INTENS CARE MED, V44, P1081, DOI 10.1007/s00134-018-5204-y; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Devlin JW, 2018, CRIT CARE MED, V46, pE825, DOI 10.1097/CCM.0000000000003299; Devlin JW, 2010, CRIT CARE MED, V38, P419, DOI 10.1097/CCM.0b013e3181b9e302; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; European Delirium Association, 2014, BMC Med, V12, P141, DOI 10.1186/s12916-014-0141-2; Fick DM, 2017, J AM GERIATR SOC, V65, P2158, DOI 10.1111/jgs.14942; Fox MA, 2019, J INTENSIVE CARE MED, V34, P172, DOI 10.1177/0885066618788018; Girard TD, 2018, NEW ENGL J MED, V379, P2506, DOI 10.1056/NEJMoa1808217; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Girard TD, 2010, CRIT CARE MED, V38, P428, DOI 10.1097/CCM.0b013e3181c58715; Gross AL, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0552-4; Grover S, 2016, WORLD J PSYCHIATR, V6, P365, DOI 10.5498/wjp.v6.i3.365; Grover S, 2011, J PSYCHOSOM RES, V71, P277, DOI 10.1016/j.jpsychores.2011.01.019; Han CS, 2004, PSYCHOSOMATICS, V45, P297, DOI 10.1016/S0033-3182(04)70170-X; Hardy RJ, 1996, STAT MED, V15, P619, DOI 10.1002/(SICI)1097-0258(19960330)15:6<619::AID-SIM188>3.0.CO;2-A; Hatta K, 2014, INT J GERIATR PSYCH, V29, P253, DOI 10.1002/gps.3999; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Hospital Elder Life Program, 2018, DEL BIBL; Hu H., 2006, CHIN J CLIN REHABIL, V10, P188; Kim JY, 2005, PSYCHIAT CLIN NEUROS, V59, P183, DOI 10.1111/j.1440-1819.2005.01355.x; Kim SW, 2010, HUM PSYCHOPHARM CLIN, V25, P298, DOI 10.1002/hup.1117; Kishi T, 2016, J NEUROL NEUROSUR PS, V87, P767, DOI 10.1136/jnnp-2015-311049; Lee KU, 2005, INT CLIN PSYCHOPHARM, V20, P311, DOI 10.1097/00004850-200511000-00005; Leslie DL, 2008, ARCH INTERN MED, V168, P27, DOI 10.1001/archinternmed.2007.4; Leslie DL, 2011, J AM GERIATR SOC, V59, pS241, DOI 10.1111/j.1532-5415.2011.03671.x; Lin C-J., 2008, J INTERNAL MED TAIWA, V19, P346; Maneeton B, 2013, DRUG DES DEV THER, V7, P657, DOI 10.2147/DDDT.S45575; Marcantonio ER, 2017, NEW ENGL J MED, V377, P1456, DOI 10.1056/NEJMcp1605501; Naksuk N, 2017, EUR HEART J-ACUTE CA, V6, P560, DOI 10.1177/2048872615592232; Network for Investigation of Delirium: Unifying Scientists (NIDUS), 2018, DEL MEAS INF CARDS; Network for Investigation of Delirium: Unifying Scientists (NIDUS), 2018, DEL RES CAT; Network for Investigation of Delirium: Unifying Scientists (NIDUS), 2018, CROSSW DEL SEV MEAS; Neufeld KJ, 2016, J AM GERIATR SOC, V64, P705, DOI 10.1111/jgs.14076; Neufeld KJ, 2019, ANTIPSYCHOTICS FOR T; Oh ES, 2019, ANN INTERN MED, V171, P474, DOI 10.7326/M19-1859; Oh ES, 2017, JAMA-J AM MED ASSOC, V318, P1161, DOI 10.1001/jama.2017.12067; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; Page VJ, 2013, LANCET RESP MED, V1, P515, DOI 10.1016/S2213-2600(13)70166-8; Rover C, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0091-1; Rose L, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016371; Ryan DJ, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-001772; Scottish Intercollegiate Guidelines Network, 2019, SIGN PUBL, V157; Siddiqi N, 2006, AGE AGEING, V35, P350, DOI 10.1093/ageing/afl005; Sipahimalani A, 1998, PSYCHOSOMATICS, V39, P422, DOI 10.1016/S0033-3182(98)71301-5; Skrobik YK, 2004, INTENS CARE MED, V30, P444, DOI 10.1007/s00134-003-2117-0; Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919; Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761; Tahir TA, 2010, J PSYCHOSOM RES, V69, P485, DOI 10.1016/j.jpsychores.2010.05.006; Vasilevskis EE, 2012, BEST PRACT RES-CLIN, V26, P277, DOI 10.1016/j.bpa.2012.07.003; Wu YC, 2019, JAMA PSYCHIAT, V76, P526, DOI 10.1001/jamapsychiatry.2018.4365; Yoon HJ, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-240; Zayed Y, 2019, J CRIT CARE, V50, P280, DOI 10.1016/j.jcrc.2019.01.009; 임현국, 2007, [The Korean Journal of Psychopharmacology, 대한정신약물학회지], V18, P423	66	84	85	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	2019	171	7					485	+		10.7326/M19-1860	http://dx.doi.org/10.7326/M19-1860			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JB4LK	31476770				2023-01-03	WOS:000488527900006
J	Prausnitz, MR; Gomaa, Y; Li, W				Prausnitz, Mark R.; Gomaa, Yasmine; Li, Wei			Microneedle patch drug delivery in the gut	NATURE MEDICINE			English	Editorial Material									[Prausnitz, Mark R.; Gomaa, Yasmine; Li, Wei] Georgia Inst Technol, Sch Chem & Biomol Engn, Atlanta, GA 30332 USA; [Gomaa, Yasmine] Alexandria Univ, Fac Pharm, Dept Pharmaceut, El Khartoum Sq, Alexandria, Egypt	University System of Georgia; Georgia Institute of Technology; Egyptian Knowledge Bank (EKB); Alexandria University	Prausnitz, MR (corresponding author), Georgia Inst Technol, Sch Chem & Biomol Engn, Atlanta, GA 30332 USA.	prausnitz@gatech.edu		Prausnitz, Mark/0000-0002-9076-8448; LI, WEI/0000-0002-9339-7267				Abramson A, 2019, NAT MED, V25, P1512, DOI 10.1038/s41591-019-0598-9; Bhatnagar S, 2017, J CONTROL RELEASE, V260, P164, DOI 10.1016/j.jconrel.2017.05.029; Grover N., 2019, ENDPOINTS NEWS; Homayun B, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11030129; Hou A, 2017, DERMATOL SURG, V43, P321, DOI 10.1097/DSS.0000000000000924; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Liu C, 2018, EXPERT OPIN DRUG DEL, V15, P223, DOI 10.1080/17425247.2017.1395853; Marcum ZA, 2013, JAMA-J AM MED ASSOC, V309, P2105, DOI 10.1001/jama.2013.4638; Prausnitz M. R., 1997, ANNU REV CHEM BIOMOL, V8, P177; Rubin RR, 2009, DIABETES EDUCATOR, V35, P1014, DOI 10.1177/0145721709345773	10	24	25	6	85	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2019	25	10					1471	1472		10.1038/s41591-019-0606-0	http://dx.doi.org/10.1038/s41591-019-0606-0			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	JC3GJ	31591600				2023-01-03	WOS:000489166700012
J	Yamamoto, TN; Kishton, RJ; Restifo, NP				Yamamoto, Tori N.; Kishton, Rigel J.; Restifo, Nicholas P.			Developing neoantigen-targeted T cell-based treatments for solid tumors	NATURE MEDICINE			English	Review							HUMAN COLON-CANCER; METASTATIC MELANOMA; CLASS-I; INFILTRATING LYMPHOCYTES; ACQUIRED-RESISTANCE; CHECKPOINT BLOCKADE; ANTITUMOR IMMUNITY; NORMAL-TISSUES; PD-1 BLOCKADE; GENE-THERAPY	Stimulating an immune response against cancer through adoptive transfer of tumor-targeting lymphocytes has shown great promise in hematological malignancies, but clinical efficacy against many common solid epithelial cancers remains low. Targeting 'neoantigens'-the somatic mutations expressed only by tumor cells-might enable tumor destruction without causing undue damage to vital healthy tissues. Major challenges to targeting neoantigens with T cells include heterogeneity and variability in antigen processing and presentation of targets by tumors, and an incomplete understanding of which T cell qualities are essential for clinically effective therapies. Finally, the prospect of targeting somatic tumor mutations to promote T cell destruction of cancer must contend with the biology that not all tumor-expressed 'neoepitopes' actually generate neoantigens that can be functionally recognized and provoke an effective immune response. In this Review, we discuss the promise, progress and challenges for improving neoantigen-targeted T cell-based immunotherapies for cancer.	[Yamamoto, Tori N.; Kishton, Rigel J.; Restifo, Nicholas P.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Yamamoto, Tori N.; Kishton, Rigel J.; Restifo, Nicholas P.] NCI, Ctr Cell Based Therapy, NIH, Bethesda, MD 20892 USA; [Yamamoto, Tori N.] Univ Penn, Immunol Grad Grp, Philadelphia, PA 19104 USA; [Restifo, Nicholas P.] Lyell Immunopharma, San Francisco, CA 94080 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Pennsylvania	Restifo, NP (corresponding author), NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.; Restifo, NP (corresponding author), NCI, Ctr Cell Based Therapy, NIH, Bethesda, MD 20892 USA.; Restifo, NP (corresponding author), Lyell Immunopharma, San Francisco, CA 94080 USA.	restifon@mail.nih.gov		Yamamoto, Tori/0000-0003-1965-7822; Restifo, Nicholas P./0000-0003-4229-4580	Intramural Research Program of the NCI; Cancer Moonshot Program for the Center for Cell-Based Therapy at the NCI, NIH	Intramural Research Program of the NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Moonshot Program for the Center for Cell-Based Therapy at the NCI, NIH	We thank P.-H. Lee for helpful discussions and E. He for illustration design. This work was supported by the Intramural Research Program of the NCI and the Cancer Moonshot Program for the Center for Cell-Based Therapy at the NCI, NIH.	Ahmadzadeh M, 2009, BLOOD, V114, P1537, DOI 10.1182/blood-2008-12-195792; Ahmed N, 2015, J CLIN ONCOL, V33, P1688, DOI 10.1200/JCO.2014.58.0225; Ali M, 2019, NAT PROTOC, V14, P1926, DOI 10.1038/s41596-019-0170-6; Anagnostou V, 2017, CANCER DISCOV, V7, P264, DOI 10.1158/2159-8290.CD-16-0828; Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937; Azizi E, 2018, CELL, V174, P1293, DOI 10.1016/j.cell.2018.05.060; Bausch-Fluck D, 2018, P NATL ACAD SCI USA, V115, pE10988, DOI 10.1073/pnas.1808790115; Beatty GL, 2018, GASTROENTEROLOGY, V155, P29, DOI 10.1053/j.gastro.2018.03.029; Brown CE, 2016, NEW ENGL J MED, V375, P2561, DOI 10.1056/NEJMoa1610497; Brudno JN, 2018, J CLIN ONCOL, V36, P2267, DOI 10.1200/JCO.2018.77.8084; Buonaguro L, 2011, CLIN VACCINE IMMUNOL, V18, P23, DOI 10.1128/CVI.00286-10; Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625; Cafri G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08304-z; Carreno BM, 2015, SCIENCE, V348, P803, DOI 10.1126/science.aaa3828; Chapuis AG, 2019, NAT MED, V25, P1064, DOI 10.1038/s41591-019-0472-9; Chen HL, 1996, NAT GENET, V13, P210, DOI 10.1038/ng0696-210; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Cohen AD, 2019, J CLIN INVEST, V129, P2210, DOI 10.1172/JCI126397; Crompton JG, 2014, IMMUNOL REV, V257, P264, DOI 10.1111/imr.12135; Drost J, 2018, NAT REV CANCER, V18, P407, DOI 10.1038/s41568-018-0007-6; Dudley ME, 2008, J CLIN ONCOL, V26, P5233, DOI 10.1200/JCO.2008.16.5449; Duhen T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05072-0; Francis JM, 2014, CANCER DISCOV, V4, P956, DOI 10.1158/2159-8290.CD-13-0879; Fry TJ, 2018, NAT MED, V24, P20, DOI 10.1038/nm.4441; Gajewski TF, 2015, SEMIN ONCOL, V42, P663, DOI 10.1053/j.seminoncol.2015.05.011; Gargett T, 2016, MOL THER, V24, P1135, DOI 10.1038/mt.2016.63; Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446; Goff SL, 2019, J IMMUNOTHER, V42, P126, DOI 10.1097/CJI.0000000000000260; Goff SL, 2016, J CLIN ONCOL, V34, P2389, DOI 10.1200/JCO.2016.66.7220; Goff SL, 2010, J IMMUNOTHER, V33, P840, DOI 10.1097/CJI.0b013e3181f05b91; Goodyear O, 2010, BLOOD, V116, P1908, DOI 10.1182/blood-2009-11-249474; Gros A, 2016, NAT MED, V22, P433, DOI 10.1038/nm.4051; Gros A, 2014, J CLIN INVEST, V124, P2246, DOI [10.1172/JC173639, 10.1172/JCI73639]; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Guedan S, 2019, MOL THER-METH CLIN D, V12, P145, DOI 10.1016/j.omtm.2018.12.009; Hinrichs CS, 2011, BLOOD, V117, P808, DOI 10.1182/blood-2010-05-286286; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760; Jaigirdar A, 2016, J IMMUNOTHER, V39, P105, DOI 10.1097/CJI.0000000000000116; Jiang Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.162; Johnson LA, 2009, BLOOD, V114, P535, DOI 10.1182/blood-2009-03-211714; Katt ME, 2016, FRONT BIOENG BIOTECH, V4, DOI 10.3389/fbioe.2016.00012; Kerkar SP, 2016, J IMMUNOTHER, V39, P181, DOI 10.1097/CJI.0000000000000119; Keskin DB, 2019, NATURE, V565, P234, DOI 10.1038/s41586-018-0792-9; Klebanoff CA, 2005, P NATL ACAD SCI USA, V102, P9571, DOI 10.1073/pnas.0503726102; Klebanoff CA, 2016, J CLIN INVEST, V126, P318, DOI 10.1172/JCI81217; Klebanoff CA, 2016, NAT MED, V22, P26, DOI 10.1038/nm.4015; Kochenderfer JN, 2017, MOL THER, V25, P2245, DOI 10.1016/j.ymthe.2017.07.004; Kochenderfer JN, 2010, BLOOD, V116, P4099, DOI 10.1182/blood-2010-04-281931; Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426; Lanitis E, 2014, HUM GENE THER, V25, P730, DOI 10.1089/hum.2014.006; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Liu S, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0629-6; Lohr JG, 2014, NAT BIOTECHNOL, V32, P479, DOI 10.1038/nbt.2892; Lu YC, 2018, MOL THER, V26, P379, DOI 10.1016/j.ymthe.2017.10.018; Maeda T, 2016, CANCER RES, V76, P6839, DOI 10.1158/0008-5472.CAN-16-1149; Malekzadeh P, 2019, J CLIN INVEST, V129, P1109, DOI 10.1172/JCI123791; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Maus MV, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.23; Melero I, 2014, NAT REV CLIN ONCOL, V11, P509, DOI 10.1038/nrclinonc.2014.111; Miller BC, 2019, NAT IMMUNOL, V20, P326, DOI 10.1038/s41590-019-0312-6; Mitra A, 2013, TRENDS BIOTECHNOL, V31, P347, DOI 10.1016/j.tibtech.2013.03.006; Miyagi T, 2003, J GASTROEN HEPATOL, V18, P32, DOI 10.1046/j.1440-1746.2003.02921.x; Morgan RA, 2013, J IMMUNOTHER, V36, P133, DOI 10.1097/CJI.0b013e3182829903; Motz GT, 2014, NAT MED, V20, P607, DOI 10.1038/nm.3541; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065; MUUL LM, 1987, J IMMUNOL, V138, P989; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Nielsen M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000796; O'Rourke DM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaa0984; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Park TS, 2016, J IMMUNOTHER, V39, P1, DOI 10.1097/CJI.0000000000000101; Parkhurst M, 2017, CLIN CANCER RES, V23, P2491, DOI 10.1158/1078-0432.CCR-16-2680; Parkhurst MR, 2019, CANCER DISCOV, V9, P1022, DOI 10.1158/2159-8290.CD-18-1494; Parkhurst MR, 2011, MOL THER, V19, P620, DOI 10.1038/mt.2010.272; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pasetto A, 2016, CANCER IMMUNOL RES, V4, P734, DOI 10.1158/2326-6066.CIR-16-0001; Patel S, 2016, BIOL BLOOD MARROW TR, V22, P536, DOI 10.1016/j.bbmt.2015.12.007; Patel SJ, 2017, NATURE, V548, P537, DOI 10.1038/nature23477; Paulos CM, 2007, J CLIN INVEST, V117, P2197, DOI 10.1172/JCI32205; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Prickett TD, 2016, CANCER IMMUNOL RES, V4, P669, DOI 10.1158/2326-6066.CIR-15-0215; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Reay PA, 2000, J IMMUNOL, V164, P5626, DOI 10.4049/jimmunol.164.11.5626; Restifo NP, 2012, NAT REV IMMUNOL, V12, P269, DOI 10.1038/nri3191; Restifo NP, 1996, J NATL CANCER I, V88, P100, DOI 10.1093/jnci/88.2.100; RIDDELL SR, 1990, J IMMUNOL METHODS, V128, P189, DOI 10.1016/0022-1759(90)90210-M; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robbins PF, 2015, CLIN CANCER RES, V21, P1019, DOI 10.1158/1078-0432.CCR-14-2708; Robbins PF, 2013, NAT MED, V19, P747, DOI 10.1038/nm.3161; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Scanlan MJ, 2002, CANCER RES, V62, P4041; Scheper W, 2019, NAT MED, V25, P89, DOI 10.1038/s41591-018-0266-5; Schmitt TM, 2013, BLOOD, V122, P348, DOI 10.1182/blood-2013-01-478164; Shimizu Y, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00248; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Soiffer R, 1998, P NATL ACAD SCI USA, V95, P13141, DOI 10.1073/pnas.95.22.13141; Srivastava S, 2019, CANCER CELL, V35, P489, DOI 10.1016/j.ccell.2019.02.003; Srivastava S, 2018, J IMMUNOL, V200, P459, DOI 10.4049/jimmunol.1701155; Stevanovic S, 2017, SCIENCE, V356, P200, DOI 10.1126/science.aak9510; Stevanovic S, 2015, J CLIN ONCOL, V33, P1543, DOI 10.1200/JCO.2014.58.9093; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tran E, 2017, NAT IMMUNOL, V18, P255, DOI 10.1038/ni.3682; Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279; Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Verdegaal EME, 2016, NATURE, V536, P91, DOI 10.1038/nature18945; Vigneron Nathalie, 2013, Cancer Immun, V13, P15; Vizcardo R, 2018, CELL REP, V22, P3175, DOI 10.1016/j.celrep.2018.02.087; Vodnala SK, 2019, SCIENCE, V363, P1417, DOI 10.1126/science.aau0135; Wang DY, 2018, JAMA ONCOL, V4, P1721, DOI 10.1001/jamaoncol.2018.3923; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Xu YY, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0066-6; Yamamoto TN, 2019, J CLIN INVEST, V129, P1551, DOI 10.1172/JCI121491; Yossef R, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122467; Zacharakis N, 2018, NAT MED, V24, P724, DOI 10.1038/s41591-018-0040-8; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zhu J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00784-1	127	95	101	3	79	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2019	25	10					1488	1499		10.1038/s41591-019-0596-y	http://dx.doi.org/10.1038/s41591-019-0596-y			12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	JC3GJ	31591590				2023-01-03	WOS:000489166700016
J	Crowley, D; Cullen, W; Lambert, JS; Van Hout, MC				Crowley, Desmond; Cullen, Walter; Lambert, John S.; Van Hout, Marie Claire			Competing priorities and second chances - A qualitative exploration of prisoners' journeys through the Hepatitis C continuum of care	PLOS ONE			English	Article							INJECT DRUGS; VIRAL-HEPATITIS; VIRUS-INFECTION; HIGH-RISK; PEOPLE; ELIMINATION; MORTALITY; PREVALENCE; PREVENTION; DIAGNOSIS	High levels of undiagnosed and untreated HCV infection exist in prison populations globally. Prisons are a key location to identify, treat and prevent HCV infection among people who inject drugs (PWID). Understanding prisoners' lived experiences of the HCV continuum of care informs how HCV care can be effectively delivered to this marginalised and high-risk population. This study aimed to explore Irish prisoners' experience of prison and community-based HCV care. We conducted one-to-one interviews with 25 male prisoners with chronic HCV infection. Data collection and analysis was informed by grounded theory. The mean age of participants and first incarceration was 39.5 and 18.3 years respectively. The mean number of incarcerations was eight. The following themes were identified: medical and social factors influencing engagement (fear of treatment and lack of knowledge, HCV relevance and competing priorities), adverse impact of HCV on health and wellness, positive experience of prison life and health care and the transformative clinical and non-clinical changes associated with HCV treatment and cure. Findings suggest that prison release was associated with multiple stressors including homelessness and drug dependence which quickly eroded the health benefits gained during incarceration. The study generated a substantive theory of the need to increase the importance of HCV care among the routine competing priorities associated with the lives of PWID. HCV infected prisoners often lead complex lives and understanding their journeys through the HCV continuum can inform the development of meaningful HCV care pathways. Many challenges exist to optimising HCV treatment uptake in this group and incarceration is an opportunity to successfully engage HCV infected prisoners who underutilise and are underserved by community-based medical services. Support and linkage to care on release is essential to optimising HCV management.	[Crowley, Desmond] Irish Coll Gen Practitioners, Lincoln Pl, Dublin, Ireland; [Crowley, Desmond; Cullen, Walter; Lambert, John S.] Univ Coll Dublin, Sch Med, Dublin, Ireland; [Lambert, John S.] Mater Misericordiae Univ Hosp, Dept Infect Dis, Dublin, Ireland; [Van Hout, Marie Claire] Liverpool John Moores Univ, Liverpool, Merseyside, England	University College Dublin; Mater Misericordiae University Hospital; University College Dublin; Liverpool John Moores University	Crowley, D (corresponding author), Irish Coll Gen Practitioners, Lincoln Pl, Dublin, Ireland.; Crowley, D (corresponding author), Univ Coll Dublin, Sch Med, Dublin, Ireland.	doctordes@hotmail.com	Fazli, Ghazal/AAE-8320-2022	lambert, john/0000-0001-5404-2415; Cullen, Walter/0000-0003-1838-5052				Aldridge RW, 2018, LANCET, V391, P241, DOI 10.1016/S0140-6736(17)31869-X; Asher AK, 2016, SUBST USE MISUSE, V51, P1218, DOI 10.3109/10826084.2016.1161054; Awenat YF, 2018, HEALTH EXPECT, V21, P100, DOI 10.1111/hex.12590; Bagnall AM, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1584-x; Bartlett SR, 2018, CLIN INFECT DIS, V67, P460, DOI 10.1093/cid/ciy210; Barua S, 2015, ANN INTERN MED, V163, P215, DOI 10.7326/M15-0406; Binswanger IA, 2013, ANN INTERN MED, V159, P592, DOI 10.7326/0003-4819-159-9-201311050-00005; Bukten A, 2017, ADDICTION, V112, P1432, DOI 10.1111/add.13803; Crowley D, 2018, Health Justice, V6, P23, DOI 10.1186/s40352-018-0081-6; Cuadrado A, 2018, AM J GASTROENTEROL, V113, P1639, DOI 10.1038/s41395-018-0157-x; Department of Health, 2017, HEP C SCREEN NCES NA; Dolan K, 2016, LANCET, V388, P1089, DOI 10.1016/S0140-6736(16)30466-4; Dong KR, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5201-7; Drummon A., 2014, STUDY PREVALENCE DRU; European Centre for Disease Prevention and Control (ECDC)/ European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2017, SYST REV ACT CAS FIN, DOI [10.2900/348536, DOI 10.2900/348536]; Glaster B. G., 1967, THEORETICAL SENSITIV; Gountas I, 2017, ADDICTION, V112, P1290, DOI 10.1111/add.13764; Grebely Jason, 2017, Clin Liver Dis (Hoboken), V9, P77, DOI 10.1002/cld.626; Grebely J, 2017, INT J DRUG POLICY, V47, P26, DOI 10.1016/j.drugpo.2017.08.001; Greer AM, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5765-2; Gupta Ekta, 2014, Asian J Transfus Sci, V8, P19, DOI 10.4103/0973-6247.126683; Hajarizadeh B, 2017, J HEPATOL, V66, pS291, DOI 10.1016/S0168-8278(17)30899-1; Harris M, 2016, J VIRAL HEPATITIS, V23, P479, DOI 10.1111/jvh.12513; Harris M, 2018, INT J DRUG POLICY, V60, P24, DOI 10.1016/j.drugpo.2018.07.015; Harris M, 2013, HARM REDUCT J, V10, DOI 10.1186/1477-7517-10-7; Health Service Executive, 2012, NAT HEP C STRAT 2011; Health Service Executive, 2018, NAT HEP C TREATM PRO; Hedrich D, 2012, ADDICTION, V107, P501, DOI 10.1111/j.1360-0443.2011.03676.x; Henderson C, 2017, INT J DRUG POLICY, V50, P111, DOI 10.1016/j.drugpo.2017.08.004; Irish Prison Service, 2017, IR PRIS SERV ANN REP; Jacomet C, 2016, EUR J PUBLIC HEALTH, V26, P122, DOI 10.1093/eurpub/ckv183; Jones C, 2014, MOL BIOL CELL, V25; Khaw FM, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-98; Kreisel U, 2018, PUBLIC HLTH GUIDANCE, DOI [10.2900/619331, DOI 10.2900/619331]; Lafferty L, 2018, J VIRAL HEPATITIS, V25, P1526, DOI 10.1111/jvh.12987; Larney S, 2013, HEPATOLOGY, V58, P1215, DOI 10.1002/hep.26387; Lloyd AR, 2013, CLIN INFECT DIS, V56, P1078, DOI 10.1093/cid/cis1202; Martin NK, 2015, CURR OPIN HIV AIDS, V10, P374, DOI 10.1097/COH.0000000000000179; McDonnell A, 2010, MAZE MINEFIELD GROUN; Midgard H, 2016, J HEPATOL, V65, pS33, DOI 10.1016/j.jhep.2016.07.012; Nickasch B, 2009, J AM ACAD NURSE PRAC, V21, P39, DOI 10.1111/j.1745-7599.2008.00371.x; Nijhawan AE, 2016, AM J MED SCI, V352, P399, DOI 10.1016/j.amjms.2016.05.020; O'Donnell P, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0487-5; Park H, 2019, HEPATOLOGY, V69, P1032, DOI 10.1002/hep.30303; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Public Health England, 2017, HEP C 15 2017 REP; Raphael S, 2012, CRIME INCARCERATION, DOI [10.1093/oxfordhb/9780195393781.013.0021, DOI 10.1093/OXFORDHB/9780195393781.013.0021]; Redman JS, 2018, AM J GASTROENTEROL, V113, P1585, DOI 10.1038/s41395-018-0201-x; Rich ZC, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3671-z; Rumble C, 2015, EUR J PUBLIC HEALTH, V25, P1078, DOI 10.1093/eurpub/ckv133; Stone J, 2017, ADDICTION, V112, P1302, DOI 10.1111/add.13783; Swan D, 2018, EXPERT REV GASTROENT, V12, P303, DOI 10.1080/17474124.2018.1424541; Swan D, 2010, AIDS PATIENT CARE ST, V24, P753, DOI 10.1089/apc.2010.0142; Treloar C, 2014, INT J DRUG POLICY, V25, P865, DOI 10.1016/j.drugpo.2014.01.011; Vescio MF, 2008, J EPIDEMIOL COMMUN H, V62, P305, DOI 10.1136/jech.2006.051599; Westbrook RH, 2014, J HEPATOL, V61, pS58, DOI 10.1016/j.jhep.2014.07.012; World Health Organisation, 2014, PRIS HLTH, P207; World Health Organization, 2017, GLOB HEP REP 2017; Yap L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087564; Zhou K, 2016, LANCET INFECT DIS, V16, P1409, DOI 10.1016/S1473-3099(16)30208-0	60	11	11	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2019	14	9							e0222186	10.1371/journal.pone.0222186	http://dx.doi.org/10.1371/journal.pone.0222186			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM3YZ	31509571	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000532188200038
J	Niederer, D; Mueller, J				Niederer, Daniel; Mueller, Juliane			Sustainability effects of motor control stabilisation exercises on pain and function in chronic nonspecific low back pain patients: A systematic review with meta-analysis and meta-regression	PLOS ONE			English	Review							GENERAL EXERCISES; CONTROLLED-TRIAL; CLINICAL-TRIALS; QUALITY; THERAPY; PHYSIOTHERAPY; DISABILITY	Study design Systematic review with meta-analysis and meta-regression. Background and objectives any control. The subgroups' effects are less conclusive and no clear direction of the sustainability effect at short versus mid versus long-term, of the type of the comparator, or of the dose of the training is given. Low quality studies overestimated the effect of motor control exercises. We systematically reviewed and delineated the existing evidence on sustainability effects of motor control exercises on pain intensity and disability in chronic low back pain patients when compared with an inactive or passive control group or with other exercises. Secondary aims were to reveal whether moderating factors like the time after intervention completion, the study quality, and the training characteristics affect the potential sustainability effects. Methods Relevant scientific databases (Medline, Web of Knowledge, Cochrane) were screened. Eligibility criteria for selecting studies: All RCTs und CTs on chronic (>= 12/13 weeks) nonspecific low back pain, written in English or German and adopting a longitudinal core-specific/stabilizing sensorimotor control exercise intervention with at least one pain intensity and disability outcome assessment at a follow-up (sustainability) timepoint of. 4 weeks after exercise intervention completion. Results and conclusions From the 3,415 studies that were initially retrieved, 10 (2 CTs & 8 RCTs) on N = 1081 patients were included in the review and analyses. Low to moderate quality evidence shows a sustainable positive effect of motor control exercise on pain (SMD = -.46, Z = 2.9, p <.001) and disability (SMD = -.44, Z = 2.5, p <.001) in low back pain patients when compared to	[Niederer, Daniel] Goethe Univ Frankfurt, Inst Sports Sci, Dept Sports Med & Exercise Physiol, Frankfurt, Germany; [Mueller, Juliane] Trier Univ Appl Sci, Dept Comp Sci Therapy Sci Professorship Physiothe, Trier, Germany	Goethe University Frankfurt	Niederer, D (corresponding author), Goethe Univ Frankfurt, Inst Sports Sci, Dept Sports Med & Exercise Physiol, Frankfurt, Germany.	niederer@em.uni-frankfurt.de	Niederer, Daniel/Z-1577-2019	Niederer, Daniel/0000-0002-7690-5418; Mueller, Juliane/0000-0002-4184-5427				Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Bae CR, 2018, J BACK MUSCULOSKELET, V31, P871, DOI 10.3233/BMR-170997; Bell JA, 2009, J OCCUP REHABIL, V19, P8, DOI 10.1007/s10926-009-9164-5; Borghuis J, 2008, SPORTS MED, V38, P893, DOI 10.2165/00007256-200838110-00002; Brown SHM, 2009, J ELECTROMYOGR KINES, V19, P727, DOI 10.1016/j.jelekin.2008.04.009; Choi BKL, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006555.pub2; Critchley DJ, 2007, SPINE, V32, P1474, DOI 10.1097/BRS.0b013e318067dc26; Cuijpers P, 2010, PSYCHOL MED, V40, P211, DOI 10.1017/S0033291709006114; de Morton NA, 2009, AUST J PHYSIOTHER, V55, P129, DOI 10.1016/S0004-9514(09)70043-1; Egan M, 2015, SCHMERZ, V29, P562, DOI 10.1007/s00482-015-0043-z; Ferreira ML, 2007, PAIN, V131, P31, DOI 10.1016/j.pain.2006.12.008; FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q; Giesche F, 2017, SCHMERZ, V31, P115, DOI 10.1007/s00482-016-0178-6; Gomes-Neto M, 2017, PHYS THER SPORT, V23, P136, DOI 10.1016/j.ptsp.2016.08.004; Gutknecht M, 2015, J BODYW MOV THER, V19, P722, DOI 10.1016/j.jbmt.2014.12.003; Hartvigsen J, 2004, OCCUP ENVIRON MED, V61; Hicks GE, 2005, ARCH PHYS MED REHAB, V86, P1753, DOI 10.1016/j.apmr.2005.03.033; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Kofotolis N, 2016, J BACK MUSCULOSKELET, V29, P649, DOI 10.3233/BMR-160665; Lim ECW, 2011, J ORTHOP SPORT PHYS, V41, P70, DOI 10.2519/jospt.2011.3393; Lin I, 2020, BRIT J SPORT MED, V54, P79, DOI 10.1136/bjsports-2018-099878; Macedo LG, 2012, PHYS THER, V92, P363, DOI 10.2522/ptj.20110290; Marshall PWM, 2013, SPINE, V38, pE952, DOI 10.1097/BRS.0b013e318297c1e5; Niederer D, 2018, GERMAN J SPORTS MED, V2018, P262, DOI [10.5960/dzsm.2018.321, DOI 10.5960/DZSM.2018.321]; Niederer D, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1645-1; O'Sullivan PB, 1997, SPINE, V22, P2959, DOI 10.1097/00007632-199712150-00020; Owen PJ, 2020, BRIT J SPORT MED, V54, P1279, DOI 10.1136/bjsports-2019-100886; Rasmussen-Barr E, 2003, MANUAL THER, V8, P233, DOI 10.1016/S1356-689X(03)00053-5; Rasmussen-Barr E, 2009, SPINE, V34, P221, DOI 10.1097/BRS.0b013e318191e7cb; Riemann BL, 2002, J ATHL TRAINING, V37, P71; Saragiotto BT, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012004; Searle A, 2015, CLIN REHABIL, V29, P1155, DOI 10.1177/0269215515570379; Sharan D, 2014, CURR PAIN HEADACHE R, V18, DOI 10.1007/s11916-014-0449-9; Smith BE, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-416; Unsgaard-Tondel M, 2010, PHYS THER, V90, P1426, DOI 10.2522/ptj.20090421; Wang XQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052082	36	19	24	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2020	15	1							e0227423	10.1371/journal.pone.0227423	http://dx.doi.org/10.1371/journal.pone.0227423			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5OV	31940397	gold, Green Published			2023-01-03	WOS:000534368000072
J	Short, TG; Campbell, D; Frampton, C; Chan, MTV; Myles, PS; Corcoran, TB; Sessler, DI; Mills, GH; Cata, JP; Painter, T; Byrne, K; Han, RQ; Chu, MHM; McAllister, DJ; Leslie, K				Short, Timothy G.; Campbell, Douglas; Frampton, Christopher; Chan, Matthew T. V.; Myles, Paul S.; Corcoran, Tomas B.; Sessler, Daniel I.; Mills, Gary H.; Cata, Juan P.; Painter, Thomas; Byrne, Kelly; Han, Ruquan; Chu, Mandy H. M.; McAllister, Davina J.; Leslie, Kate		Australian New Zealand Coll	Anaesthetic depth and complications after major surgery: an international, randomised controlled trial	LANCET			English	Article							LOW BISPECTRAL INDEX; MINIMUM ALVEOLAR CONCENTRATION; LOW BLOOD-PRESSURE; POSTOPERATIVE DELIRIUM; CUMULATIVE DURATION; TRIPLE LOW; MORTALITY; AWARENESS; ASSOCIATION; SURVIVAL	Background An association between increasing anaesthetic depth and decreased postoperative survival has been shown in observational studies; however, evidence from randomised controlled trials is lacking. Our aim was to compare all-cause 1-year mortality in older patients having major surgery and randomly assigned to light or deep general anaesthesia. Methods In an international trial, we recruited patients from 73 centres in seven countries who were aged 60 years and older, with significant comorbidity, having surgery with expected duration of more than 2 h, and an anticipated hospital stay of at least 2 days. We randomly assigned patients who had increased risk of complications after major surgery to receive light general anaesthesia (bispectral index [BIS] target 50) or deep general anaesthesia (BIS target 35). Anaesthetists also nominated an appropriate range for mean arterial pressure for each patient during surgery. Patients were randomly assigned in permuted blocks by region immediately before surgery, with the patient and assessors masked to group allocation. The primary outcome was 1-year all-cause mortality. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12612000632897, and is closed to accrual. Findings Patients were enrolled between Dec 19, 2012, and Dec 12, 2017. Of the 18 026 patients screened as eligible, 6644 were enrolled, randomly assigned to treatment or control, and formed the intention-to-treat population (3316 in the BIS 50 group and 3328 in the BIS 35 group). The median BIS was 47.2 (IQR 43.7 to 50.5) in the BIS 50 group and 38.8 (36.3 to 42.4) in the BIS 35 group. Mean arterial pressure was 3.5 mm Hg (4%) higher (median 84.5 [IQR 78.0 to 91.3] and 81.0 [75.4 to 87.6], respectively) and volatile anaesthetic use was 0.26 minimum alveolar concentration (30%) lower (0.62 [0.52 to 0.73] and 0.88 [0.74 to 1.04], respectively) in the BIS 50 than the BIS 35 group. 1-year mortality was 6.5% (212 patients) in the BIS 50 group and 7.2% (238 patients) in the BIS 35 group (hazard ratio 0.88, 95% CI 0.73 to 1.07, absolute risk reduction 0.8%, 95% CI -0.5 to 2.0). Grade 3 adverse events occurred in 954 (29%) patients in the BIS 50 group and 909 (27%) patients in the BIS 35 group; and grade 4 adverse events in 265 (8%) and 259 (8%) patients, respectively. The most commonly reported adverse events were infections, vascular disorders, cardiac disorders, and neoplasms. Interpretation Among patients at increased risk of complications after major surgery, light general anaesthesia was not associated with lower 1-year mortality than deep general anaesthesia. Our trial defines a broad range of anaesthetic depth over which anaesthesia may be safely delivered when titrating volatile anaesthetic concentrations using a processed electroencephalographic monitor. Copyright (C) 2019 Elsevier Ltd. All rights reserved.	[Short, Timothy G.; Campbell, Douglas; McAllister, Davina J.] Auckland City Hosp, Auckland, New Zealand; [Short, Timothy G.; Campbell, Douglas] Univ Auckland, Auckland, New Zealand; [Frampton, Christopher] Univ Otago, Christchurch, New Zealand; [Chan, Matthew T. V.] Chinese Univ Hong Kong, Hong Kong, Peoples R China; [Myles, Paul S.] Alfred Hosp, Melbourne, Vic, Australia; [Myles, Paul S.; Corcoran, Tomas B.; Leslie, Kate] Monash Univ, Melbourne, Vic, Australia; [Corcoran, Tomas B.] Royal Perth Hosp, Perth, WA, Australia; [Corcoran, Tomas B.] Univ Western Australia, Perth, WA, Australia; [Sessler, Daniel I.] Cleveland Clin, Cleveland, OH 44106 USA; [Mills, Gary H.] Sheffield Teaching Hosp, Sheffield, S Yorkshire, England; [Mills, Gary H.] Univ Sheffield, Sheffield, S Yorkshire, England; [Cata, Juan P.] Univ Texas Houston, Houston, TX USA; [Cata, Juan P.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Painter, Thomas] Royal Adelaide Hosp, Adelaide, SA, Australia; [Painter, Thomas] Univ Adelaide, Adelaide, SA, Australia; [Byrne, Kelly] Waikato Hosp, Waikato, New Zealand; [Han, Ruquan] Beijing Tiantan Hosp, Beijing, Peoples R China; [Han, Ruquan] Capital Med Univ, Beijing, Peoples R China; [Chu, Mandy H. M.] Pamela Youde Nethersole Eastern Hosp, Hong Kong, Peoples R China; [Leslie, Kate] Royal Melbourne Hosp, Melbourne, Vic, Australia; [Leslie, Kate] Univ Melbourne, Melbourne, Vic, Australia	Auckland City Hospital; University of Auckland; University of Otago; Chinese University of Hong Kong; Florey Institute of Neuroscience & Mental Health; Monash University; Royal Perth Hospital; University of Western Australia; University of Western Australia; Cleveland Clinic Foundation; University of Sheffield; University of Sheffield; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; Royal Adelaide Hospital; University of Adelaide; Waikato Hospital; Capital Medical University; Capital Medical University; Pamela Youde Nethersole Eastern Hospital; Royal Melbourne Hospital; University of Melbourne	Short, TG (corresponding author), Auckland City Hosp, Dept Anaesthesia, Auckland 1023, New Zealand.	tims@adhb.govt.nz	Pryor, Kane O/I-8632-2017; Chan, Matthew/J-2884-2013; Myles, Paul/AAU-9524-2020; Painter, Thomas/K-3899-2019	Pryor, Kane O/0000-0002-9212-5526; Chan, Matthew/0000-0002-3574-7855; Myles, Paul/0000-0002-3324-5456; Painter, Thomas/0000-0003-2216-2046; Keane, Helen/0000-0002-6042-306X; AYAD, SABRY/0000-0002-6728-9297; Buggy, Donal/0000-0003-3922-4397; Mills, Gary/0000-0002-3929-2149; Chuan, Alwin/0000-0003-4356-6525; Williams, Wendell/0000-0003-2769-0366; Bates, Samantha Jean/0000-0002-8613-1946; Chu, Mandy/0000-0003-4653-0085; Short, Timothy/0000-0001-9374-1710; Kunst, Gudrun/0000-0002-9789-1334; Jhanji, Shaman/0000-0002-1116-628X	Health Research Council of New Zealand [12-308-Short]; Australian National Health and Medical Research Council [APP1042727]; Research Grants Council of Hong Kong [61513]; National Institute for Health and Research in the UK; National Institutes of Health in the USA [P30 CA 008748]; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Health Research Council of New Zealand(Health Research Council of New Zealand); Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Research Grants Council of Hong Kong(Hong Kong Research Grants Council); National Institute for Health and Research in the UK; National Institutes of Health in the USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by grants from the Health Research Council of New Zealand (12-308-Short), the Australian National Health and Medical Research Council (APP1042727), the Research Grants Council of Hong Kong (number 61513), the National Institute for Health and Research in the UK (portfolio status), and the National Institutes of Health in the USA (P30 CA 008748). We thank Johann van Schalkwyk and Katrina Sharples, all the members of the committees overseeing the trial, and the Australian and New Zealand College of Anaesthetists Clinical Trials Network.	Abdelmalak BB, 2013, BRIT J ANAESTH, V111, P209, DOI 10.1093/bja/aet050; Avidan MS, 2008, NEW ENGL J MED, V358, P1097, DOI 10.1056/NEJMoa0707361; Avidan MS, 2011, NEW ENGL J MED, V365, P591, DOI 10.1056/NEJMoa1100403; BRICE DD, 1970, BRIT J ANAESTH, V42, P535, DOI 10.1093/bja/42.6.535; Brown CH, 2014, ANESTH ANALG, V118, P977, DOI 10.1213/ANE.0000000000000157; Chan MTV, 2013, J NEUROSURG ANESTH, V25, P33, DOI 10.1097/ANA.0b013e3182712fba; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cleeland C. S., 2009, BRIEF PAIN INVENTORY; Devereaux PJ, 2014, NEW ENGL J MED, V370, P1504, DOI 10.1056/NEJMoa1401106; International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, INTR GUID MEDDRA VER; Kertai MD, 2014, ANESTHESIOLOGY, V121, P18, DOI 10.1097/ALN.0000000000000281; Kertai MD, 2011, ANESTHESIOLOGY, V114, P545, DOI 10.1097/ALN.0b013e31820c2b57; Kertai MD, 2010, ANESTHESIOLOGY, V112, P1116, DOI 10.1097/ALN.0b013e3181d5e0a3; Krause SJ, 2003, CLIN J PAIN, V19, P306, DOI 10.1097/00002508-200309000-00004; Leslie K, 2010, ANESTH ANALG, V110, P816, DOI 10.1213/ANE.0b013e3181c3bfb2; Lindholm ML, 2009, ANESTH ANALG, V108, P508, DOI 10.1213/ane.0b013e31818f603c; Monk TG, 2005, ANESTH ANALG, V100, P4, DOI 10.1213/01.ANE.0000147519.82841.5E; Myles PS, 2018, NEW ENGL J MED, V378, P2263, DOI 10.1056/NEJMoa1801601; Myles PS, 2004, LANCET, V363, P1757, DOI 10.1016/S0140-6736(04)16300-9; Punjasawadwong Y, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003843.pub3; Sessler DI, 2012, ANESTHESIOLOGY, V116, P1195, DOI 10.1097/ALN.0b013e31825683dc; Short TG, 2015, ANESTH ANALG, V121, P357, DOI 10.1213/ANE.0000000000000797; Short TG, 2014, ANESTH ANALG, V118, P981, DOI 10.1213/ANE.0000000000000209; Shulman MA, 2015, ANESTHESIOLOGY, V122, P524, DOI 10.1097/ALN.0000000000000586; Sieber FE, 2010, MAYO CLIN PROC, V85, P18, DOI 10.4065/mcp.2009.0469; Stark PA, 2013, ANESTHESIOLOGY, V118, P1332, DOI 10.1097/ALN.0b013e318289b84b; Ustun B., 2010, MEASURING HLTH DISAB; Walsh M, 2013, ANESTHESIOLOGY, V119, P507, DOI 10.1097/ALN.0b013e3182a10e26; Willingham M, 2014, BRIT J ANAESTH, V113, P1001, DOI 10.1093/bja/aeu105; Zorrilla-Vaca A, 2017, CAN J ANESTH, V64, P597, DOI 10.1007/s12630-017-0872-6	30	69	73	2	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	2019	394	10212					1907	1914		10.1016/S0140-6736(19)32315-3	http://dx.doi.org/10.1016/S0140-6736(19)32315-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ3SI	31645286				2023-01-03	WOS:000498868500025
J	Hall, W; Stjepanovic, D; Caulkins, J; Lynskey, M; Leung, J; Campbell, G; Degenhardt, L				Hall, Wayne; Stjepanovic, Daniel; Caulkins, Jonathan; Lynskey, Michael; Leung, Janni; Campbell, Gabrielle; Degenhardt, Louisa			Public health implications of legalising the production and sale of cannabis for medicinal and recreational use	LANCET			English	Article							ADOLESCENT MARIJUANA USE; MEDICAL USE; LAWS; LEGALIZATION; WASHINGTON; POLICY; EPIDEMIOLOGY; AUSTRALIA; OUTCOMES; AMERICA	We assess the current and describe possible future public health impacts of the legalisation of cannabis production, sale, and use in the Americas. First, we describe global patterns of cannabis use and their most probable adverse health effects. Second, we summarise evidence regarding the effectiveness of cannabinoids for medicinal use and describe approaches that have been used to regulate the use of medicinal cannabis and how these approaches might have affected medicinal and recreational use and harms (eg, road crashes). Third, we describe how jurisdictions that have legalised recreational use have regulated production and sale of cannabis. Fourth, we evaluate the effects of cannabis legalisation on cannabis use and harms and on the use of alcohol, tobacco, and other drugs. Fifth, we use alcohol and tobacco policy examples to identify possible long-term public health effects of cannabis legalisation. Finally, we outline policy approaches that could minimise harms to public health arising from the legalisation of a commercial cannabis industry.	[Hall, Wayne; Stjepanovic, Daniel] Univ Queensland, Ctr Youth Subst Abuse Res, Brisbane, Qld 4029, Australia; [Leung, Janni] Univ Queensland, Sch Psychol, Brisbane, Qld, Australia; [Hall, Wayne] Kings Coll London, Natl Addict Ctr, London, England; [Lynskey, Michael] Kings Coll London, Inst Psychiat Psychol & Neurosci, Addict Dept, London, England; [Caulkins, Jonathan] Carnegie Mellon Univ, Heinz Coll, Pittsburgh, PA 15213 USA; [Leung, Janni; Campbell, Gabrielle; Degenhardt, Louisa] Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia	University of Queensland; University of Queensland; University of London; King's College London; University of London; King's College London; Carnegie Mellon University; University of New South Wales Sydney	Hall, W (corresponding author), Univ Queensland, Ctr Youth Subst Abuse Res, Brisbane, Qld 4029, Australia.	w.hall@uq.edu.au	Hall, Wayne D/A-3283-2008; Leung, Janni/H-1003-2012; Stjepanovic, Daniel/B-3658-2009	Hall, Wayne D/0000-0003-1984-0096; Leung, Janni/0000-0001-5816-2959; Stjepanovic, Daniel/0000-0003-4307-423X; Lynskey, Michael/0000-0001-9989-737X	Australian National Drug and Alcohol Research Centre, University of New South Wales Sydney (Sydney, NSW, Australia); Australian Government Department of Health under the Drug and Alcohol Program; University of Queensland development fellowship; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA044170] Funding Source: NIH RePORTER	Australian National Drug and Alcohol Research Centre, University of New South Wales Sydney (Sydney, NSW, Australia); Australian Government Department of Health under the Drug and Alcohol Program; University of Queensland development fellowship; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors would like to thank Sarah Yeates for her assistance in doing literature reviews and preparing the paper for publication, and Beau Kilmer, Rosalie Pacula, and Peter Reuter for commenting on earlier drafts of the paper. The Australian National Drug and Alcohol Research Centre, University of New South Wales Sydney (Sydney, NSW, Australia), provided funding towards the costs of this review. The Centre for Youth Substance Abuse Research, The University of Queensland; and The Australian National Drug and Alcohol Research Centre, University of New South Wales Sydney, are supported by funding by the Australian Government Department of Health under the Drug and Alcohol Program. The views expressed in this publication do not necessarily represent the position of the Australian Government. JL acknowledges funding from The University of Queensland development fellowship.	Ablin J, 2016, SCHMERZ, V30, P3, DOI 10.1007/s00482-015-0083-4; Abuhasira R, 2018, EUR J INTERN MED, V49, P2, DOI 10.1016/j.ejim.2018.01.001; Allsop DJ, 2015, CLIN PHARMACOL THER, V97, P571, DOI 10.1002/cpt.109; [Anonymous], COCHRANE HDB SYSTEMA, DOI 10.1002/9781119536604; Anthony J.C., 2006, CANNABIS DEPENDENCE, DOI DOI 10.1017/CBO9780511544248.006; Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244; Asbridge M, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e536; Aydelotte JD, 2017, AM J PUBLIC HEALTH, V107, P1329, DOI 10.2105/AJPH.2017.303848; Babor T. F., 2010, ALCHOL NO ORDINARY C, DOI DOI 10.1093/ACPROF:OSO/9780199551149.003.002; Bachman J. G, 1997, SMOKING DRINKING DRU; Beirness D, 2017, CANNABIS USE DRIVING; Beirness D, 2017, 3 INT S DRUG IMP DRI; Bhandari S, 2019, INTERN MED J, V49, P649, DOI 10.1111/imj.14164; Black N, LANCET PSYCHIAT; Borges G, 2016, J AFFECT DISORDERS, V195, P63, DOI 10.1016/j.jad.2016.02.007; Budney AJ, 2019, EUR ARCH PSY CLIN N, V269, P73, DOI 10.1007/s00406-018-0976-1; Carvalho AF, 2018, EUROPEAN PSYCHIAT; Caulkins J.P., 2012, MARIJUANA LEGALIZATI, V1st; Caulkins JP, 2017, INT J DRUG POLICY, V42, P50, DOI 10.1016/j.drugpo.2017.01.012; Chan GCK, 2017, DRUG ALCOHOL DEPEN, V178, P32, DOI 10.1016/j.drugalcdep.2017.04.014; Chandra S, 2019, EUR ARCH PSY CLIN N, V269, P5, DOI 10.1007/s00406-019-00983-5; Coffey C, 2016, CAN J PSYCHIAT, V61, P318, DOI 10.1177/0706743716645289; Colorado Department of Public Health and Environment, 2019, MAR COL LAWS YOUTH; Compton R, 2017, MARIJUANA IMPAIRED D; Compton WM, 2018, COMPLEX CONNECTION BETWEEN CANNABIS AND SCHIZOPHRENIA, P9, DOI 10.1016/B978-0-12-804791-0.00002-1; Conboy JR, 2000, FOOD DRUG LAW J, V55, P601; Cox C, 2018, HEALTH POLICY, V122, P205, DOI 10.1016/j.healthpol.2018.01.009; Cruz JM, 2018, DRUG ALCOHOL REV, V37, pS429, DOI 10.1111/dar.12642; Danovitch I, 2012, PSYCHIAT CLIN N AM, V35, P309, DOI 10.1016/j.psc.2012.03.003; Degenhardt L, 2018, LANCET PSYCHIAT, V5, P987, DOI 10.1016/S2215-0366(18)30337-7; Degenhardt L, 2013, LANCET, V382, P1564, DOI 10.1016/S0140-6736(13)61530-5; Deutscher Bundestag, 2017, BUND LASST CANN ARZN; Dilley JA, 2019, JAMA PEDIATR, V173, P192, DOI 10.1001/jamapediatrics.2018.4458; EMCDDA, 2015, PREV ADD BEH; Englund A, 2017, LANCET PSYCHIAT, V4, P643, DOI 10.1016/S2215-0366(17)30075-5; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2013, DRUG TREATM OV NETH; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2017, EUR DRUG REP 2017 TR; Faggiano F, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003020.pub2; Faggiano F., 2014, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858.CD003020.PUB3; Fairman BJ, 2016, DRUG ALCOHOL DEPEN, V159, P72, DOI 10.1016/j.drugalcdep.2015.11.015; Felson J, 2019, SOC SCI RES, V78, P12, DOI 10.1016/j.ssresearch.2018.12.011; Ferri M, 2013, COCHRANE DB SYST REV, V6, DOI DOI 10.1016/j.drugpo.2012.07.008; Field D, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001088; FISCHER B, 2017, AM J PUBLIC HEALTH, V107, pE, DOI DOI 10.2105/AJPH.2017.303818; Foxcroft DR, 2014, PREV SCI, V15, P818, DOI 10.1007/s11121-013-0435-1; Foxcroft DR, UNIVERSAL FAMILY BAS; Freeman TP, 2018, PSYCHOL MED, V48, P2346, DOI 10.1017/S0033291717003877; Gage SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122896; Gakidou E, 2017, LANCET, V390, P1345, DOI 10.1016/S0140-6736(17)32366-8; Garvey T, 2014, STATE LEGALIZATION R; Grucza RA, 2018, INT J DRUG POLICY, V59, P67, DOI 10.1016/j.drugpo.2018.06.016; Gunn JKL, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009986; Hall W., HLTH SOCIAL EFFECTS; Hall W, 2018, ADDICTION, V113, P987, DOI 10.1111/add.14139; Hall WD, 2018, MED USE CANNABIS QUE; Hasin DS, 2018, NEUROPSYCHOPHARMACOL, V43, P195, DOI 10.1038/npp.2017.198; Hasin DS, 2015, LANCET PSYCHIAT, V2, P601, DOI 10.1016/S2215-0366(15)00217-5; Hoch E, 2019, EUR ARCH PSY CLIN N, V269, P87, DOI 10.1007/s00406-019-00984-4; Hornik R, 2008, AM J PUBLIC HEALTH, V98, P2229, DOI 10.2105/AJPH.2007.125849; Horwood LJ, 2010, DRUG ALCOHOL DEPEN, V110, P247, DOI 10.1016/j.drugalcdep.2010.03.008; Hudak J., 2018, URUGUAYS CANNABIS LA; Imtiaz S, 2016, ADDICTION, V111, P653, DOI 10.1111/add.13237; Johnston LD, 2018, DEMOGRAPHIC SUBGROUP; Jouanjus E, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000638; Kelley-Baker T, 2017, 2013 14 NATL ROADSID; Kilmer B, 2017, ANNU REV LAW SOC SCI, V13, P181, DOI 10.1146/annurev-lawsocsci-110615-084851; Kilmer B, 2017, ADDICTION, V112, P1140, DOI 10.1111/add.13824; Klieger SB, 2017, ADDICTION, V112, P2206, DOI 10.1111/add.13910; Kruger H-P, 1995, GRAND RAPIDS EFFECTS; Leung J., 2018, CURR ADDICT REP, V5, P403, DOI DOI 10.1007/S40429-018-0224-9; Marshall J, 2014, ASIA-PAC J-JPN FOCU, V12; McGinty EE, 2017, PREV MED, V99, P80, DOI 10.1016/j.ypmed.2017.01.024; Moore THM, 2007, LANCET, V370, P319, DOI 10.1016/S0140-6736(07)61162-3; Mucke M, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012182.pub2; National Academies of Sciences Engineering and Medicine, 2017, HLTH EFF CANN CANN C; Nourbakhsh M, 2019, J FORENSIC SCI, V64, P270, DOI 10.1111/1556-4029.13819; Pardo B, 2014, INT J DRUG POLICY, V25, P727, DOI 10.1016/j.drugpo.2014.05.010; Peacock A, 2018, ADDICTION, V113, P1905, DOI 10.1111/add.14234; Pollack N, 2018, IM JUST MIDDLE AGED; Queirolo R, 2016, INT J DRUG POLICY, V34, P41, DOI 10.1016/j.drugpo.2016.05.015; Quilter J, 2017, INT J CRIME JUSTICE, V6, P47, DOI 10.5204/ijcjsd.v6i3.416; Ries, 2016, MCGILL J LAW HLTH, V9, P215; Rogeberg O, 2016, ADDICTION, V111, P1348, DOI 10.1111/add.13347; Rolles Stephen, 2009, WAR DRUGS BLUEPRINT; Room R., 2010, CANNABIS POLICY MOVI; Rotermann M, 2018, HEALTH REP, V29, P10; Roxburgh A, 2010, ADDICTION, V105, P1071, DOI 10.1111/j.1360-0443.2010.02903.x; Sarvet AL, 2018, ADDICTION, V113, P1003, DOI 10.1111/add.14136; Schroyer J, 2017, GREAT GLUT GROWERS R; Scott JC, 2018, JAMA PSYCHIAT, V75, P585, DOI 10.1001/jamapsychiatry.2018.0335; Smart R, 2017, ADDICTION, V112, P2167, DOI 10.1111/add.13886; Smith LA, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009464.pub2; Stiby AI, 2015, ADDICTION, V110, P658, DOI 10.1111/add.12827; Stockings E, 2018, J NEUROL NEUROSUR PS, V89, P741, DOI 10.1136/jnnp-2017-317168; Stockings E, 2018, PAIN, V159, P1932, DOI 10.1097/j.pain.0000000000001293; Subritzky T, 2016, INT J DRUG POLICY, V27, P1, DOI 10.1016/j.drugpo.2015.12.001; Terry-McElrath YM, 2018, DRUG ALCOHOL DEPEN, V191, P203, DOI 10.1016/j.drugalcdep.2018.07.002; UNODC, 2018, WORLD DRUG REP 2018; UNODC, 2016, WORLD DRUG REPORT 20; Van Keymeulen E, 2019, CANNABIS LEGAL REGUL; Washington State Liquor and Cannabis Board, 2016, MAR ED KNOW LAW; Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI 10.1001/jama.2015.6358	102	133	137	2	61	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 26	2019	394	10208					1580	1590		10.1016/S0140-6736(19)31789-1	http://dx.doi.org/10.1016/S0140-6736(19)31789-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JI3WL	31657733				2023-01-03	WOS:000493399500028
J	Alghofaili, L; Almubarak, H; Gassem, K; Islam, SS; Coskun, S; Kaya, N; Karakas, B				Alghofaili, Lamyaa; Almubarak, Hannah; Gassem, Khawlah; Islam, Syed S.; Coskun, Serdar; Kaya, Namik; Karakas, Bedri			Cell-free DNA levels of twins and sibling pairs indicate individuality and possible use as a personalized biomarker	PLOS ONE			English	Article							CIRCULATING TUMOR DNA; CANCER-PATIENTS; MATERNAL PLASMA; NUCLEIC-ACIDS; FETAL DNA; HETEROGENEITY; SERUM; TIME; QUANTIFICATION; DIAGNOSIS	Cell-free DNA (cfDNA) in the human blood circulation has been under investigation since its initial observation in 1948. Plasma cfDNA is known to be significantly elevated in diseased people. Due to possible variation in the population, evaluating cfDNA as a non-invasive biomarker at disease onset alone may not be sensitive enough to accurately diagnose diseases, particularly early stage cancers on a personal level. To understand the factors that define the cfDNA levels on the personal level and for better use as a non-invasive biomarker, we isolated cfDNA from the plasma of healthy individuals with varying degrees of genetic and/or environmental similarities (monozygotic twins, dizygotic twins, sibling pairs, and unrelated individuals) as well as from patients with varying stages of breast and ovarian cancer undergoing treatment. Cell-free DNA levels were quantified by a fluorometer (ng/ml) and/or real-time PCR (copies/ml). The associations between individuals with various degrees of genetic and/or environmental similarities and their plasma cfDNA levels were evaluated. The ACE model (A = additive genetic, C = common environment, and E = specific environmental factors) was used to determine the proportion of each factor on the cfDNA levels. We found a high correlation (r = 0.77; p < 0.0001) in plasma cfDNA levels between monozygotic twins (n = 39). However, the correlation was gradually reduced to moderate (r = 0.47; p = 0.016) between dizygotic twins (n = 13) and low correlation (r = 0.28; p = 0.043) between sibling pairs (n = 26). The ACE model analysis showed that the plasma cfDNA level of a given healthy individual is influenced both by genetic and the environmental components in similar proportions (53% and 47%, respectively; A = 53%, C = 22.5%, E = 24.5%). Moreover, while age had no effect, gender significantly influenced the individual's plasma cfDNA level. As expected, cfDNA levels were significantly higher in both breast (n = 26) (p<0.0001) and ovarian (n = 64) (p<0.0001) cancer patients compared to the healthy individuals. Our study demonstrated that both genome and environmental factors modulate the individual's cfDNA level suggesting that its diagnostic sensitivity may be improved only if the person's cfDNA level is known prior to disease presentation.	[Alghofaili, Lamyaa; Almubarak, Hannah; Gassem, Khawlah; Islam, Syed S.; Karakas, Bedri] King Faisal Specialist Hosp & Res Ctr, Dept Mol Oncol, Translat Canc Res Sect, Riyadh, Saudi Arabia; [Alghofaili, Lamyaa] Alfaisal Univ, Med Sch, Riyadh, Saudi Arabia; [Coskun, Serdar] King Faisal Specialist Hosp & Res Ctr, Dept Pathol & Lab Med, Riyadh, Saudi Arabia; [Kaya, Namik] King Faisal Specialist Hosp & Res Ctr, Dept Genet, Riyadh, Saudi Arabia; [Almubarak, Hannah] King Saud Univ, Coll Sci, Dept Biochem, Riyadh, Saudi Arabia	King Faisal Specialist Hospital & Research Center; Alfaisal University; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; King Saud University	Karakas, B (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Mol Oncol, Translat Canc Res Sect, Riyadh, Saudi Arabia.	bedrik@yahoo.com	Islam, Syed/AAS-7468-2021; Islam, Syed/AAV-1215-2021; Coskun, Serdar/I-1470-2018	Gassem, Khawlah/0000-0001-7048-8839; Almubarak, Hannah/0000-0001-5895-9968; Coskun, Serdar/0000-0002-7278-0902	Kingdom of Saudi Arabia National Science, Technology and Innovation Plan (NSTIP) Strategic Technologies in the Kingdom-Awards [10-BIO951-20, 10BIO951-20]	Kingdom of Saudi Arabia National Science, Technology and Innovation Plan (NSTIP) Strategic Technologies in the Kingdom-Awards	This work is supported by the Kingdom of Saudi Arabia National Science, Technology and Innovation Plan (NSTIP) Strategic Technologies in the Kingdom-Awards (10-BIO951-20 and 10BIO951-20) to BK. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Moghrabi N, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0529-5; ANKER P, 1976, CANCER RES, V36, P2832; Boomsma D, 2002, NAT REV GENET, V3, P872, DOI 10.1038/nrg932; Chan KCA, 2013, CLIN CHEM, V59, P211, DOI 10.1373/clinchem.2012.196014; Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789; Gal S, 2004, BRIT J CANCER, V90, P1211, DOI 10.1038/sj.bjc.6601609; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gormally E, 2004, INT J CANCER, V111, P746, DOI 10.1002/ijc.20327; Heitzer E, 2015, CLIN CHEM, V61, P112, DOI 10.1373/clinchem.2014.222679; Ivanov M, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S13-S1; Jahr S, 2001, CANCER RES, V61, P1659; Johnson PJ, 2002, CLIN CHEM, V48, P1186; Kamat AA, 2006, ANN NY ACAD SCI, V1075, P230, DOI 10.1196/annals.1368.031; Karakas B, 2019, ANATOL CLIN J MED SC, V24, P47, DOI [10.21673/anadoluklin.441594, DOI 10.21673/ANADOLUKLIN.441594]; Karakas B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126501; Kleppe M, 2014, NAT MED, V20, P342, DOI 10.1038/nm.3522; Kong A, 2018, SCIENCE, V359, P424, DOI 10.1126/science.aan6877; LEON SA, 1977, CANCER RES, V37, P646; Li Y, 2006, ANN NY ACAD SCI, V1075, P81, DOI 10.1196/annals.1368.010; Lo YMD, 1999, AM J HUM GENET, V64, P218, DOI 10.1086/302205; Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; MANDEL P, 1948, CR SOC BIOL, V142, P241; Mouliere F, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4921; Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065; No JH, 2012, ANTICANCER RES, V32, P3467; Page K, 2006, ANN NY ACAD SCI, V1075, P313, DOI 10.1196/annals.1368.042; Papadopoulou E, 2006, ANN NY ACAD SCI, V1075, P235, DOI 10.1196/annals.1368.032; Rago C, 2007, CANCER RES, V67, P9364, DOI 10.1158/0008-5472.CAN-07-0605; Rubin MA, 2015, NATURE, V520, P290, DOI 10.1038/520290a; Sahin U, 2018, SCIENCE, V359, P1355, DOI 10.1126/science.aar7112; Schmidt B, 2005, CLIN CHEM, V51, P1561, DOI 10.1373/clinchem.2005.051003; Schork NJ, 2015, NATURE, V520, P609, DOI 10.1038/520609a; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; Skvortsova TE, 2006, BRIT J CANCER, V94, P1492, DOI 10.1038/sj.bjc.6603117; SORENSON GD, 1994, CANCER EPIDEM BIOMAR, V3, P67; Sozzi G, 2001, CANCER RES, V61, P4675; STEINMAN CR, 1975, J CLIN INVEST, V56, P512, DOI 10.1172/JCI108118; STEINMAN CR, 1977, AM J MED, V62, P693, DOI 10.1016/0002-9343(77)90872-5; Teo YV, 2019, AGING CELL, V18, DOI 10.1111/acel.12890; van Dongen J, 2012, NAT REV GENET, V13, P640, DOI 10.1038/nrg3243; Xue XY, 2009, CLIN CHIM ACTA, V404, P100, DOI 10.1016/j.cca.2009.02.018; Yoon KA, 2009, J MOL DIAGN, V11, P182, DOI 10.2353/jmoldx.2009.080098; Ziegler A, 2002, CANCER TREAT REV, V28, P255, DOI 10.1016/S0305-7372(02)00077-4	43	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2019	14	10							e0223470	10.1371/journal.pone.0223470	http://dx.doi.org/10.1371/journal.pone.0223470			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM7ZE	31600277	Green Published, gold			2023-01-03	WOS:000532467000070
J	Ganesh, K; Wu, C; O'Rourke, KP; Szeglin, BC; Zheng, YY; Sauve, CEG; Adileh, M; Wasserman, I; Marco, MR; Kim, AS; Shady, M; Sanchez-Vega, F; Karthaus, WR; Won, HH; Choi, SH; Pelossof, R; Barlas, A; Ntiamoah, P; Pappou, E; Elghouayel, A; Strong, JS; Chen, CT; Harris, JW; Weiser, MR; Nash, GM; Guillem, JG; Wei, IH; Kolesnick, RN; Veeraraghavan, H; Ortiz, EJ; Petkovska, I; Cercek, A; Manova-Todorova, KO; Saltz, LB; Lavery, JA; DeMatteo, RP; Massague, J; Paty, PB; Yaeger, R; Chen, X; Patil, S; Clevers, H; Berger, MF; Lowe, SW; Shia, JR; Romesser, PB; Dow, LE; Garcia-Aguilar, J; Sawyers, CL; Smith, JJ				Ganesh, Karuna; Wu, Chao; O'Rourke, Kevin P.; Szeglin, Bryan C.; Zheng, Youyun; Sauve, Charles-Etienne Gabriel; Adileh, Mohammad; Wasserman, Isaac; Marco, Michael R.; Kim, Amanda S.; Shady, Maha; Sanchez-Vega, Francisco; Karthaus, Wouter R.; Won, Helen H.; Choi, Seo-Hyun; Pelossof, Raphael; Barlas, Afsar; Ntiamoah, Peter; Pappou, Emmanouil; Elghouayel, Arthur; Strong, James S.; Chen, Chin-Tung; Harris, Jennifer W.; Weiser, Martin R.; Nash, Garrett M.; Guillem, Jose G.; Wei, Iris H.; Kolesnick, Richard N.; Veeraraghavan, Harini; Ortiz, Eduardo J.; Petkovska, Iva; Cercek, Andrea; Manova-Todorova, Katia O.; Saltz, Leonard B.; Lavery, Jessica A.; DeMatteo, Ronald P.; Massague, Joan; Paty, Philip B.; Yaeger, Rona; Chen, Xi; Patil, Sujata; Clevers, Hans; Berger, Michael F.; Lowe, Scott W.; Shia, Jinru; Romesser, Paul B.; Dow, Lukas E.; Garcia-Aguilar, Julio; Sawyers, Charles L.; Smith, J. Joshua			A rectal cancer organoid platform to study individual responses to chemoradiation	NATURE MEDICINE			English	Article							COLORECTAL-CANCER; PREOPERATIVE CHEMORADIOTHERAPY; POSTOPERATIVE CHEMOTHERAPY; NEOADJUVANT CHEMOTHERAPY; GERMAN CAO/ARO/AIO-04; TRANSPLANTATION; FLUOROURACIL; MULTICENTER; OXALIPLATIN; THERAPY	Rectal cancer (RC) is a challenging disease to treat that requires chemotherapy, radiation and surgery to optimize outcomes for individual patients. No accurate model of RC exists to answer fundamental research questions relevant to patients. We established a biorepository of 65 patient-derived RC organoid cultures (tumoroids) from patients with primary, metastatic or recurrent disease. RC tumoroids retained molecular features of the tumors from which they were derived, and their ex vivo responses to clinically relevant chemotherapy and radiation treatment correlated with the clinical responses noted in individual patients' tumors. Upon engraftment into murine rectal mucosa, human RC tumoroids gave rise to invasive RC followed by metastasis to lung and liver. Importantly, engrafted tumors displayed the heterogenous sensitivity to chemotherapy observed clinically. Thus, the biology and drug sensitivity of RC clinical isolates can be efficiently interrogated using an organoid-based, ex vivo platform coupled with in vivo endoluminal propagation in animals.	[Ganesh, Karuna; Kolesnick, Richard N.] Mem Sloan Kettering Canc Ctr, Mol Pharmacol Program, Sloan Kettering Inst, 1275 York Ave, New York, NY 10021 USA; [Ganesh, Karuna; Cercek, Andrea; Saltz, Leonard B.; Yaeger, Rona] Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, 1275 York Ave, New York, NY 10021 USA; [Wu, Chao; Karthaus, Wouter R.; Sawyers, Charles L.; Smith, J. Joshua] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA; [Wu, Chao; Szeglin, Bryan C.; Sauve, Charles-Etienne Gabriel; Adileh, Mohammad; Wasserman, Isaac; Marco, Michael R.; Sanchez-Vega, Francisco; Choi, Seo-Hyun; Pelossof, Raphael; Pappou, Emmanouil; Elghouayel, Arthur; Strong, James S.; Chen, Chin-Tung; Harris, Jennifer W.; Weiser, Martin R.; Nash, Garrett M.; Guillem, Jose G.; Wei, Iris H.; Paty, Philip B.; Garcia-Aguilar, Julio; Smith, J. Joshua] Mem Sloan Kettering Canc Ctr, Dept Surg, Colorectal Serv, 1275 York Ave, New York, NY 10021 USA; [O'Rourke, Kevin P.; Massague, Joan; Lowe, Scott W.] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA; [O'Rourke, Kevin P.] Rockefeller Univ, Weill Cornell Med, Sloan Kettering Triinst MD PhD Program, 1230 York Ave, New York, NY 10021 USA; [Szeglin, Bryan C.] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Zheng, Youyun; Shady, Maha; Won, Helen H.; Ntiamoah, Peter; Berger, Michael F.; Shia, Jinru] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Zheng, Youyun; Shady, Maha; Won, Helen H.; Berger, Michael F.] Mem Sloan Kettering Canc Ctr, Marie Josee & Henry R Kravis Ctr Mol Oncol, 1275 York Ave, New York, NY 10021 USA; [Kim, Amanda S.; Romesser, Paul B.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA; [Sanchez-Vega, Francisco] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Computat Oncol Serv, New York, NY 10021 USA; [Barlas, Afsar; Manova-Todorova, Katia O.] Mem Sloan Kettering Canc Ctr, Mol Cytol Core Facil, 1275 York Ave, New York, NY 10021 USA; [Veeraraghavan, Harini] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA; [Ortiz, Eduardo J.; Petkovska, Iva] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA; [Lavery, Jessica A.; Patil, Sujata] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; [DeMatteo, Ronald P.] Hosp Univ Penn, Dept Surg, 3400 Spruce St, Philadelphia, PA 19104 USA; [Chen, Xi] Sylvestor Comprehens Canc Ctr, Dept Publ Hlth Sci, Miami, FL USA; [Clevers, Hans] Univ Med Ctr, Royal Netherlands Acad Arts & Sci, Hubrecht Inst, Utrecht, Netherlands; [Shia, Jinru] Mem Sloan Kettering Canc Ctr, Dept Pathol, Gastrointestinal Pathol, 1275 York Ave, New York, NY 10021 USA; [Dow, Lukas E.] Weill Cornell Med, Weill Cornell Grad Sch Med Sci, Dept Med & Biochem, Sandra & Edward Meyer Canc Ctr, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Rockefeller University; Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Pennsylvania Medicine; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; Memorial Sloan Kettering Cancer Center; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar	Sawyers, CL; Smith, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA.; Smith, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, Colorectal Serv, 1275 York Ave, New York, NY 10021 USA.	sawyersc@mskcc.org; smithj5@mskcc.org	Wu, Chao/B-8060-2014; Szeglin, Bryan/G-1494-2015	Wu, Chao/0000-0003-0260-2868; Petkovska, Iva/0000-0002-4373-6494; Karthaus, Wouter R./0000-0002-9234-9044; Kolesnick, Richard/0000-0002-1686-6162; Szeglin, Bryan/0000-0002-7866-7548; Garcia-Aguilar, Julio/0000-0003-2451-0948; Dow, Lukas/0000-0001-7048-1418	MSK Molecular Core Cytology Facility [P30CA008748]; NIH/NCI Cancer Center Support Grant [P30 CA008748]; National Cancer Institute of the National Institutes of Health [R25CA020449]; NIH/NCI [1CA200110-01A1]; MSK Colorectal Cancer Research Center; American Society of Colon and Rectal Surgeons Career Development Award; Joel J. Roslyn Faculty Research Award; American Society of Colon and Rectal Surgeons Limited Project Grant; MSK Department of Surgery Junior Faculty Award; John Wasserman Colon and Rectal Cancer Fund; Colorectal Cancer Alliance; Chris4Life Research Award; Stand Up to Cancer (SU2C) Colorectal Cancer Dream Team Translational Research Grant [SU2C: AACR-DR22-17]; Stand Up to Cancer is a program of the Entertainment Industry Foundation; scientific partner of SU2C; NIH via the National Cancer Institute; Howard Hughes Medical Institute; National Institutes of Health [CA94060, CA12924]; Starr Cancer Consortium [I8-A8-030]; American Cancer Society Postdoctoral Fellowship; AACR Basic Cancer Research Fellowship; Conquer Cancer Foundation of ASCO Young Investigator Award, Shulamit Katzman Endowed Postdoctoral Research Fellowship; SU2C Colorectal Cancer Dream Team Translational Research Grant [SU2C: AACR-DR22-17]; MSKCC Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center; NIH [U54 OD020355-01]; Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the National Institutes of Health [T32GM07739]; Stand Up to Cancer Colorectal Cancer Dream Team Translational Research Grant [SU2C: AACR-DR22-17]; NCI/NIH [CA 181280-01]; Memorial Sloan Kettering Cancer Center Imaging and Radiation Sciences Program; K12 Paul Calebresi Career Development Award for Clinical Oncology [K12 CA184746]; NIH loan repayment program award (LRP); NATIONAL CANCER INSTITUTE [P30CA008748, K12CA184746, P01CA129243, K08CA230213] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [U54OD020355] Funding Source: NIH RePORTER	MSK Molecular Core Cytology Facility; NIH/NCI Cancer Center Support Grant; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MSK Colorectal Cancer Research Center; American Society of Colon and Rectal Surgeons Career Development Award; Joel J. Roslyn Faculty Research Award; American Society of Colon and Rectal Surgeons Limited Project Grant; MSK Department of Surgery Junior Faculty Award; John Wasserman Colon and Rectal Cancer Fund; Colorectal Cancer Alliance; Chris4Life Research Award; Stand Up to Cancer (SU2C) Colorectal Cancer Dream Team Translational Research Grant; Stand Up to Cancer is a program of the Entertainment Industry Foundation; scientific partner of SU2C; NIH via the National Cancer Institute; Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Starr Cancer Consortium; American Cancer Society Postdoctoral Fellowship(American Cancer Society); AACR Basic Cancer Research Fellowship; Conquer Cancer Foundation of ASCO Young Investigator Award, Shulamit Katzman Endowed Postdoctoral Research Fellowship; SU2C Colorectal Cancer Dream Team Translational Research Grant; MSKCC Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the National Institutes of Health; Stand Up to Cancer Colorectal Cancer Dream Team Translational Research Grant; NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Memorial Sloan Kettering Cancer Center Imaging and Radiation Sciences Program; K12 Paul Calebresi Career Development Award for Clinical Oncology; NIH loan repayment program award (LRP)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank our patients for giving consent and thereby allowing us access to their tissues for use in this study. We thank B. Carver for critical review of the manuscript as it developed. We thank A. Jungbluth for initial discussion on tissue fixation and immunostaining of the murine rectal tissues. We thank S. Chandarlapaty for discussions regarding the chemoresistance assays and cetuximab resistance assay. We thank L. Diaz for critical comments as this work developed. We thank N. Kemeny for advice, guidance and encouragement as this project developed. We thank N. Fan, S. Fujisawa, X. Liu, M. Turkekul, E. Chan and the Molecular Cytology Core for expert assistance and critical feedback in the design and execution of tissue embedding, immunostaining and processing of tissues, in addition to microscopy assistance. We thank the MSK Molecular Core Cytology Facility for critical technical assistance in performing tissue sections, immunohistochemical stains, scans and analysis (Institutional Core Grant Number P30CA008748). We thank R. Shah for initial discussions on set-up of the MSKIMPACT experiments. We thank H. Park and L. Lee for assistance with preparation and processing of tumor and tumoroid specimens for IHC and immunofluorescence. We thank P. Watson of Memorial Sloan Kettering for sharing the Ubc-eGFP-Luc vector. We thank M. Gonzalez and R. Andrade for their work curating patient tissue and slides for analyses. We also thank members of the Sawyers laboratory for critical review, lively discussion, and helpful comments on this work as it developed. In addition, we thank R. Beauchamp and J. Goldenring for constructive criticism and comments in the development and presentation of this work. The authors thank J. Novak of Memorial Sloan Kettering for editorial assistance. This work was supported in part by the NIH/NCI Cancer Center Support Grant P30 CA008748. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R25CA020449. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. J.J.S. was supported by NIH/NCI grant 5R01-CA182551-04 and the MSK Colorectal Cancer Research Center. J.J.S. is also supported by the American Society of Colon and Rectal Surgeons Career Development Award, the Joel J. Roslyn Faculty Research Award, the American Society of Colon and Rectal Surgeons Limited Project Grant, the MSK Department of Surgery Junior Faculty Award and the John Wasserman Colon and Rectal Cancer Fund. J.J.S. is also supported by the Colorectal Cancer Alliance and the Chris4Life Research Award. The work was funded in part by a Stand Up to Cancer (SU2C) Colorectal Cancer Dream Team Translational Research Grant (Grant Number: SU2C: AACR-DR22-17) (J.J.S., A.C., L.E.D., K.G.). Stand Up to Cancer is a program of the Entertainment Industry Foundation. Research grants are administered by the American Association of Cancer Research, the scientific partner of SU2C. J.J.S. is partly supported by a loan repayment grant from the NIH via the National Cancer Institute for this work. J.J.S. is also supported in part by funding from the Howard Hughes Medical Institute via C.L.S.P.B.P and M.A. are funded in part by gifts from Corinne Berezuk, Michael Stieber, and Patrick A. Gerschel. C.L.S. is an investigator of the Howard Hughes Medical Institute.; This project was supported by National Institutes of Health grants CA155169, CA193837, CA224079, CA092629, CA160001, CA008748 and Starr Cancer Consortium grant I10-0062. K. G. was supported by National Institutes of Health grants K08-CA230213 and T32-CA009207, and by an American Cancer Society Postdoctoral Fellowship, AACR Basic Cancer Research Fellowship, Conquer Cancer Foundation of ASCO Young Investigator Award, Shulamit Katzman Endowed Postdoctoral Research Fellowship, and a SU2C Colorectal Cancer Dream Team Translational Research Grant (SU2C: AACR-DR22-17). J.M. is supported by National Institutes of Health grants CA94060 and CA12924, and by the MSKCC Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center. S.W.L., L.E.D. and K.P.O. are supported by grants from the NIH (U54 OD020355-01) and by the Starr Cancer Consortium (I8-A8-030). S.W.L. is an investigator of the Howard Hughes Medical Institute. K.P.O. was supported by an F30 Award from the NIH/NCI (1CA200110-01A1) and by a Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the National Institutes of Health under award number T32GM07739 to the Weill CornellRockefeller-Sloan Kettering Tri-Institutional MD-PhD Program. L.E.D. is supported by a Stand Up to Cancer Colorectal Cancer Dream Team Translational Research Grant (Grant Number: SU2C: AACR-DR22-17) and was supported by a K22 Career Development Award from the NCI/NIH (CA 181280-01). P.B.R. is supported by the Memorial Sloan Kettering Cancer Center Imaging and Radiation Sciences Program. P.B.R. is also supported in part by a K12 Paul Calebresi Career Development Award for Clinical Oncology (K12 CA184746) and an NIH loan repayment program award (LRP).	Allegra CJ, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv248; Benson A. B., 2019, NCCN GUIDELINES VERS; Bonneville R, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00073; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cercek A, 2014, J NATL COMPR CANC NE, V12, P513, DOI 10.6004/jnccn.2014.0056; Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011; Ding PR, 2012, ANN SURG, V256, P111, DOI 10.1097/SLA.0b013e31825b3a2b; Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033; Emons G, 2017, MOL CANCER RES, V15, P1481, DOI 10.1158/1541-7786.MCR-17-0205; Fleming M, 2012, J GASTROINTEST ONCOL, V3, P153, DOI 10.3978/j.issn.2078-6891.2012.030; Fujii M, 2016, CELL STEM CELL, V18, P827, DOI 10.1016/j.stem.2016.04.003; Funakoshi K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13402-3; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gock M, 2018, WORLD J GASTROENTERO, V24, P4880, DOI 10.3748/wjg.v24.i43.4880; HEROLD KM, 1988, ONCOGENE, V3, P423; Kleiman LB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082982; Maas M, 2010, LANCET ONCOL, V11, P835, DOI 10.1016/S1470-2045(10)70172-8; Martens MH, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw171; O'Rourke KP, 2017, NAT BIOTECHNOL, V35, P577, DOI 10.1038/nbt.3837; Park IJ, 2012, J CLIN ONCOL, V30, P1770, DOI 10.1200/JCO.2011.39.7901; Renehan AG, 2016, LANCET ONCOL, V17, P174, DOI 10.1016/S1470-2045(15)00467-2; Robinson SM, 2013, BRIT J CANCER, V109, P2396, DOI 10.1038/bjc.2013.604; Rodel C, 2015, LANCET ONCOL, V16, P979, DOI 10.1016/S1470-2045(15)00159-X; Rodel C, 2012, LANCET ONCOL, V13, P679, DOI 10.1016/S1470-2045(12)70187-0; Roerink SF, 2018, NATURE, V556, P457, DOI 10.1038/s41586-018-0024-3; Roper J, 2017, NAT BIOTECHNOL, V35, P569, DOI 10.1038/nbt.3836; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schrag D, 2014, J CLIN ONCOL, V32, P513, DOI 10.1200/JCO.2013.51.7904; Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith J. J., 2015, 2015 GASTR CANC S, V6; Smith JJ, 2019, JAMA ONCOL, V5, DOI 10.1001/jamaoncol.2018.5896; Smith JJ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1632-z; Smith JJ, 2015, J CLIN ONCOL, V33, P1797, DOI 10.1200/JCO.2014.60.1054; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; van der Valk MJM, 2018, LANCET, V391, P2537, DOI 10.1016/S0140-6736(18)31078-X; Viera AJ, 2005, FAM MED, V37, P360; Vlachogiannis G, 2018, SCIENCE, V359, P920, DOI 10.1126/science.aao2774; Walker JA, 2004, GENOMICS, V83, P518, DOI 10.1016/j.ygeno.2003.09.003; Weeber F, 2015, P NATL ACAD SCI USA, V112, P13308, DOI 10.1073/pnas.1516689112; Yarilin D, 2015, SCI REP-UK, V5, DOI 10.1038/srep09534; Ye XY, 2016, MOLECULES, V21, DOI 10.3390/molecules21101347; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333	46	193	199	9	60	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2019	25	10					1607	+		10.1038/s41591-019-0584-2	http://dx.doi.org/10.1038/s41591-019-0584-2			22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	JC3GJ	31591597	Green Accepted			2023-01-03	WOS:000489166700030
J	Estes, SJ; Soliman, AM; Epstein, AJ; Bond, JC; Gordon, K; Missmer, SA				Estes, Stephanie J.; Soliman, Ahmed M.; Epstein, Andrew J.; Bond, Julia C.; Gordon, Keith; Missmer, Stacey A.			National trends in inpatient endometriosis admissions: Patients, procedures and outcomes, 2006-2015	PLOS ONE			English	Article							POSTOPERATIVE COMPLICATIONS; MANAGEMENT; HYSTERECTOMY; SURGERY; HEALTH; CONSENSUS; RESECTION; BURDEN; RATES; WOMEN	Introduction Despite guidance towards minimally invasive, outpatient procedures for endometriosis, many patients nonetheless receive inpatient care. Our objective was to assess trends in patient and hospital characteristics, surgical complications and hospital charges for women with an endometriosis-related inpatient admission in the United States. Methods We conducted a pooled cross-sectional analysis of Healthcare Cost and Utilization Project Nationwide Inpatient Sample data. Visits were stratified into three time-period-defined cohorts (2006-2007, 2010-2011, and 2014 through the first three quarters of 2015). Visits were included if the patient was aged 18-49 years and the primary diagnosis code was for endometriosis (International Classification of Diseases, 9th Revision code 617.xx). We evaluated counts of inpatient admissions and rates of patient and hospital characteristics. Results The number of inpatient admissions with a primary diagnosis code for endometriosis decreased by 72.8% from 2006 to 2015. At the same time, among those admitted for inpatient care for endometriosis, the proportions who had Medicaid insurance and multiple documented comorbidities increased. From 2006 to 2015, mean total hospital charges increased by 75% to $39,662 in 2015 US dollars, although average length of stay increased by <1 day. Conclusions The number of inpatient admissions with a primary diagnosis of endometriosis decreased over the past decade, while surgical complications and associated hospital charges increased. The share of patients with multiple comorbidities increased and an increasing proportion of inpatient endometriosis admissions were covered by Medicaid and occurred at urban teaching hospitals. These findings suggest a demographic shift in patients receiving inpatient care for endometriosis towards more complex, vulnerable patients.	[Estes, Stephanie J.] Penn State Hlth, Dept Obstet & Gynecol, Hershey, PA 17033 USA; [Soliman, Ahmed M.; Gordon, Keith] AbbVie Inc, N Chicago, IL USA; [Epstein, Andrew J.; Bond, Julia C.] Medicus Econ, Philadelphia, PA USA; [Missmer, Stacey A.] Michigan State Univ, Dept Obstet Gynecol & Reprod Biol, Grand Rapids, MI USA; [Missmer, Stacey A.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; AbbVie; Michigan State University; Harvard University; Harvard T.H. Chan School of Public Health	Estes, SJ (corresponding author), Penn State Hlth, Dept Obstet & Gynecol, Hershey, PA 17033 USA.	sestes@pennstatehealth.psu.edu		Bond, Julia/0000-0002-2988-7755	AbbVie, Inc; Good Publication Practice (GPP3)	AbbVie, Inc(AbbVie); Good Publication Practice (GPP3)	The design and financial support for the study were provided by AbbVie, Inc (URL: https://www.abbvie.com/).AS and KG are employees of AbbVie. AE and JB are employees of Medicus Economics, which received a research contract from AbbVie to conduct this research. SE and SM have served as research consultants for AbbVie. AbbVie participated in data analysis, interpretation and review of results, preparation of the manuscript, and decision to publish. The development of this study and manuscript followed the Principles of Good Publication Practice (GPP3) for Company-Sponsored Medical Research.	Abo C, 2018, FERTIL STERIL, V109, P172, DOI 10.1016/j.fertnstert.2017.10.001; Alexander AL, 2019, OBSTET GYNECOL, V133, P6, DOI 10.1097/AOG.0000000000002990; Cohen SL, 2014, JSLS-J SOC LAPAROEND, V18, DOI 10.4293/JSLS.2014.00096; Dunselman GAJ, 2014, HUM REPROD, V29, P400, DOI 10.1093/humrep/det457; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Eskenazi B, 1997, OBSTET GYN CLIN N AM, V24, P235, DOI 10.1016/S0889-8545(05)70302-8; Facchin F, 2017, HUM REPROD, V32, P1855, DOI 10.1093/humrep/dex249; Falcone T, 2018, OBSTET GYNECOL, V131, P557, DOI 10.1097/AOG.0000000000002469; Farquhar CM, 2002, OBSTET GYNECOL, V99, P229, DOI 10.1016/S0029-7844(01)01723-9; Fuldeore MJ, 2017, GYNECOL OBSTET INVES, V82, P453, DOI 10.1159/000452660; Gambone JC, 2002, FERTIL STERIL, V78, P961, DOI 10.1016/S0015-0282(02)04216-4; Gao X, 2006, FERTIL STERIL, V86, P1561, DOI 10.1016/j.fertnstert.2006.06.015; Giudice LC, 2010, NEW ENGL J MED, V362, P2389, DOI 10.1056/NEJMcp1000274; Gordts S, 2017, FERTIL STERIL, V108, P872, DOI 10.1016/j.fertnstert.2017.08.036; Houchens R., 2016, HCUP METHODS SERIES; Houchens RL., 2014, HCUP NIS RELATED REP; Howard BV, 2005, CIRCULATION, V111, P1462, DOI 10.1161/01.CIR.0000159344.21672.FD; Johnson NP, 2017, HUM REPROD, V32, P315, DOI 10.1093/humrep/dew293; Lagana AS, 2017, INT J WOMENS HEALTH, V9, P323, DOI 10.2147/IJWH.S119729; Lagana AS, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/3617179; Lee J, 2014, J MINIM INVAS GYN, V21, P656, DOI 10.1016/j.jmig.2014.01.012; Louis GMB, 2011, FERTIL STERIL, V96, P360, DOI 10.1016/j.fertnstert.2011.05.087; Missmer SA, 2004, AM J EPIDEMIOL, V160, P784, DOI 10.1093/aje/kwh275; Morgan DM, 2018, AM J OBSTET GYNECOL, V218, DOI 10.1016/j.ajog.2017.12.218; National Institute for Health and Care Excellence, 2017, END DIAGN MAN; Nisolle M, 2019, BEST PRACT RES CLIN, DOI 10.1016/j.bpobgyn.2019.01; Practice Comm Amer Soc Reprod Med, 2012, FERTIL STERIL, V98, P591, DOI 10.1016/j.fertnstert.2012.05.031; Raffaelli R, 2018, EUR J OBSTET GYN R B, V231, P214, DOI 10.1016/j.ejogrb.2018.10.057; Rehmer JM, 2019, OBSTET GYNECOL SURV, V74, P232, DOI 10.1097/OGX.0000000000000660; Rizk B, 2014, FACTS VIEWS VIS OBGY, V6, P219; Smorgick N, 2018, SEMIN REPROD MED, V36, P116, DOI 10.1055/s-0038-1676088; Soliman AM, 2017, J WOMENS HEALTH, V26, P644, DOI 10.1089/jwh.2016.6043; Soliman AM, 2017, FERTIL STERIL, V107, P1181, DOI 10.1016/j.fertnstert.2017.03.020; Surrey ES, 2017, ADV THER, V34, P2436, DOI 10.1007/s12325-017-0619-3; Vercellini P, 2018, EXPERT REV PHARM OUT, V18, P1, DOI 10.1080/14737167.2018.1411803; Vitale SG, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/7924021; Walsh CA, 2009, EUR J OBSTET GYN R B, V144, P3, DOI 10.1016/j.ejogrb.2009.01.003; Zondervan KT, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0008-5	38	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2019	14	9							e0222889	10.1371/journal.pone.0222889	http://dx.doi.org/10.1371/journal.pone.0222889			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM5BF	31536593	Green Published, gold, Green Submitted			2023-01-03	WOS:000532262800100
J	Cuzin, L; Cotte, L; Delpierre, C; Allavena, C; Valantin, MA; Rey, D; Delobel, P; Pugliese, P; Raffi, F; Cabie, A				Cuzin, L.; Cotte, L.; Delpierre, C.; Allavena, C.; Valantin, M-A; Rey, D.; Delobel, P.; Pugliese, P.; Raffi, F.; Cabie, A.		Dat AIDS Study Grp	Too fast to stay on track? Shorter time to first anti-retroviral regimen is not associated with better retention in care in the French Dat'AIDS cohort	PLOS ONE			English	Article							VIRAL LOAD; THERAPY; INITIATION; PREDICTORS	Background Rapid antiretroviral therapy (ART) initiation has been proven beneficial for patients and the community. We aimed to analyze recent changes in timing of ART initiation in France and consequences of early start. Methods We selected from a prospective nationwide cohort, on 12/31/2017, patients with HIV-1 infection diagnosed between 01/01/2010 and 12/31/2015. We described time from (1) diagnosis to first specialized medical encounter, (2) from this encounter to ART initiation, (3) from diagnosis to first undetectable HIV viral load (VL). We analyzed the determinants of measured temporal trends. A multivariate logistic regression was performed to assess characteristics related with 1-year retention in care. Results In the 7 245 included patients, median time (1) from HIV diagnosis to first medical encounter was 13 (IQR: 6-32) days, (2) to ART initiation was 27 (IQR: 9-91) days, decreasing from 42 (IQR: 13-272) days in 2010 to 18 (IQR: 7-42) in 2015 (p< 0.0001), (3) to first undetectable VL was 257 (IQR: 151-496) days, decreasing from 378 (IQR: 201-810) days in 2010 to 169 (IQR: 97-281) in 2015. After one year, proportion of patients alive and still in care was significantly lower in those in the lower quartile of time from first encounter to ART (< 9 days) than those in the higher quartile (> 90 days), 79.9% and 85.2%, respectively (p< 0.0001). Conclusions In a country with unrestricted rapid access to ART, keeping recently diagnosed HIV infected patients in care remains challenging. Starting ART rapidly did not seem to be profitable for all and every patient.	[Cuzin, L.; Cabie, A.] Univ Hosp Martinique, Infect & Trop Dis Unit, Fort De France, Martinique, France; [Cuzin, L.; Delpierre, C.] Toulouse III Univ, INSERM UMR1017, Toulouse, France; [Cotte, L.] Hosp Civils Lyon, Infect Dis Unit, Lyon, France; [Allavena, C.; Raffi, F.] Hotel Dieu Univ, Infect Dis Unit, Hosp Nantes, Nantes, France; [Valantin, M-A] Univ Hosp Pitie Salpetriere, Infect Dis Unit, Paris, France; [Rey, D.] Univ Hosp, HIV Infect Care Ctr, Strasbourg, France; [Delobel, P.] Purpan Univ Hosp, Infect & Trop Dis Unit, Toulouse, France; [Delobel, P.] Ctr Physiopathol Toulouse Purpan, INSERM U1043, CNRS, UMR 5282, Toulouse, France; [Pugliese, P.] Univ Hosp Nice, Infect Dis Unit, Nice, France; [Raffi, F.] INSERM, CIC 1413, Nantes, France; [Cabie, A.] INSERM, CIC1424, Fort De France, Martinique, France	CHU Martinique; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU Lyon; Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Strasbourg; CHU de Toulouse; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Cuzin, L (corresponding author), Univ Hosp Martinique, Infect & Trop Dis Unit, Fort De France, Martinique, France.; Cuzin, L (corresponding author), Toulouse III Univ, INSERM UMR1017, Toulouse, France.	lise.cuzin@chu-martinique.fr	Delobel, Pierre/K-3166-2014; Cuzin, Lise/AAF-8812-2020	Delobel, Pierre/0000-0002-2874-3581; Cuzin, Lise/0000-0002-6345-497X; Cabie, Andre/0000-0003-0117-3061; delpierre, cyrille/0000-0002-0831-080X				Cuzin L., 2018, Bulletin Epidemiologique Hebdomadaire, P813; Cuzin L, 2018, HIV MED, V19, P238, DOI 10.1111/hiv.12545; Cuzin L, 2016, EPIDEMIOL INFECT, V144, P2363, DOI 10.1017/S0950268816000625; Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198; Desir FA, 2019, CLIN INFECT DIS, V68, P795, DOI 10.1093/cid/ciy556; Ford N, 2018, AIDS, V32, P17, DOI [10.1097/QAD.0000000000001671, 10.1097/qad.0000000000001671]; Gatey C, 2019, HIV MED, V20, P175, DOI 10.1111/hiv.12697; Giordano TR, 2009, HIV CLIN TRIALS, V10, P299, DOI 10.1310/hct1005-299; Israelski D, 2001, PREV MED, V33, P470, DOI 10.1006/pmed.2001.0917; Koenig SP, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002357; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Molina JM, 2018, LANCET HIV, V5, pE172, DOI 10.1016/S2352-3018(18)30003-1; Morlat P, 2013, EXPERTS RECOMMENDATI; Palar K, 2018, J HIV-AIDS SOC SERV, V17, P163, DOI 10.1080/15381501.2017.1407732; Pilcher CD, 2017, JAIDS-J ACQ IMM DEF, V74, P44, DOI 10.1097/QAI.0000000000001134; Saag MS, 2018, JAMA-J AM MED ASSOC, V320, P379, DOI 10.1001/jama.2018.8431; Scheer S, 2018, CLIN INFECT DIS, V66, P1027, DOI 10.1093/cid/cix940; Stirrup OT, 2018, HIV MED, V19, P184, DOI 10.1111/hiv.12567; Zhao Y, 2019, CLIN INFECT DIS, V68, P43, DOI 10.1093/cid/ciy400; Zhao Y, 2018, CLIN INFECT DIS, V66, P727, DOI 10.1093/cid/cix878; Zolopa AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005575	21	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2019	14	9							e0222067	10.1371/journal.pone.0222067	http://dx.doi.org/10.1371/journal.pone.0222067			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM2ZH	31490985	gold, Green Published, Green Submitted			2023-01-03	WOS:000532119700067
J	Creutzfeldt, CJ; Holloway, RG				Creutzfeldt, Claire J.; Holloway, Robert G.			Treatment Decisions for a Future Self: Ethical Obligations to Guide Truly Informed Choices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								This Viewpoint discusses the reality that most decisions about treatment for incapacitated patients involve surrogate assessments of patients' past values at their baseline health, and it proposes that more ethical and informed decision-making would help surrogates consider the degree to which their loved one might be able to adapt to and value a future health state at what is a higher level of disability.	[Creutzfeldt, Claire J.] Univ Washington, Harborview Med Ctr, 325 9Th Ave, Seattle, WA 98104 USA; [Holloway, Robert G.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; University of Rochester	Creutzfeldt, CJ (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurol, 325 Ninth Ave,POB 359775, Seattle, WA 98115 USA.	clairejc@uw.edu			National Institute of Neurological Disorders and Stroke [K23 NS099421]; National Institutes of Health	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Dr Creutzfeldt receives funding from the National Institute of Neurological Disorders and Stroke (grant K23 NS099421). Dr Holloway receives funding from the National Institutes of Health.	Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI 10.1161/CIR.0000000000000659; Consortium Spinal Cord Med, 2008, J SPINAL CORD MED, V31, P403; Kon AA, 2016, CRIT CARE MED, V44, P188, DOI 10.1097/CCM.0000000000001396; Paladino J, 2019, JAMA-J AM MED ASSOC, V322, P1345, DOI 10.1001/jama.2019.11533; Spatz ES, 2016, JAMA-J AM MED ASSOC, V315, P2063, DOI 10.1001/jama.2016.3070; Sprung CL, 2019, JAMA-J AM MED ASSOC, V322, P1692, DOI 10.1001/jama.2019.14608; Ubel PA, 2005, HEALTH PSYCHOL, V24, pS57, DOI 10.1037/0278-6133.24.4.S57	7	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	2020	323	2					115	116		10.1001/jama.2019.19652	http://dx.doi.org/10.1001/jama.2019.19652			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF6MC	31895421				2023-01-03	WOS:000509352900004
J	Ferrario, A; Dedet, G; Humbert, T; Vogler, S; Suleman, F; Pedersen, HB				Ferrario, Alessandra; Dedet, Guillaume; Humbert, Tifenn; Vogler, Sabine; Suleman, Fatima; Pedersen, Hanne Bak			Strategies to achieve fairer prices for generic and biosimilar medicines	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DRUG MARKETS; PROCUREMENT; COMPETITION; POLICY		[Ferrario, Alessandra] Harvard Med Sch, Dept Populat Med, Boston, MA 02115 USA; [Ferrario, Alessandra] Harvard Pilgrim Healthcare Inst, Boston, MA 02215 USA; [Dedet, Guillaume] Org Econ Cooperat & Dev, Paris, France; [Humbert, Tifenn; Pedersen, Hanne Bak] WHO, Reg Off Europe, Copenhagen, Denmark; [Vogler, Sabine] GOG, Austrian Publ Hlth Inst, WHO Collaborating Ctr Pharmaceut Pricing & Reimbu, Pharmacoecon Dept, Vienna, Austria; [Suleman, Fatima] Univ KwaZulu Natal, Sch Hlth Sci, Discipline Pharmaceut Sci, Durban, South Africa	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Organisation for Economic Co-operation & Development (OECD); World Health Organization; University of Kwazulu Natal	Ferrario, A (corresponding author), Harvard Med Sch, Dept Populat Med, Boston, MA 02115 USA.; Ferrario, A (corresponding author), Harvard Pilgrim Healthcare Inst, Boston, MA 02215 USA.	Alessandra_Ferrario@hphci.harvard.edu	Suleman, Fatima/GQP-0955-2022	Suleman, Fatima/0000-0002-8559-9168; Ferrario, Alessandra/0000-0002-1572-3581				Aalto-Setala V, 2008, EUR J HEALTH ECON, V9, P185, DOI 10.1007/s10198-007-0059-0; Acosta A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005979.pub2; [Anonymous], 2019, BIOS INT PROD; [Anonymous], 2018, BIOS MED MARK AUTH; Azevedo VF, 2019, JCR-J CLIN RHEUMATOL, V25, P91, DOI 10.1097/RHU.0000000000000881; Blackstone EA, 2013, AM HEALTH DRUG BENEF, V6, P469; Carrier M, 2017, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20170601.060360/full/2557165, DOI 10.1377/HBLOG20170601.060360/FULL/2557165]; Casanova-Juanes J, 2018, HEALTH POLICY, V122, P1310, DOI 10.1016/j.healthpol.2018.10.008; Chen CT, 2017, J ONCOL PRACT, V13, P352, DOI 10.1200/JOP.2016.019737; Cohen HP, 2018, DRUGS, V78, P463, DOI 10.1007/s40265-018-0881-y; Colgan S, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008915; Douglass CH, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1162-z; Dunne SS, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0415-3; Elek P, 2017, HEALTH POLICY, V121, P558, DOI 10.1016/j.healthpol.2017.02.015; European Commission, 2009, PHARM SECT INQ FIN R; Ferrario A, 2016, CHALLENGES OPPORTUNI; Guan XD, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022328; Hassali MA, 2014, SAUDI PHARM J, V22, P491, DOI 10.1016/j.jsps.2013.12.017; Johnston A, 2011, BRIT J CLIN PHARMACO, V72, P727, DOI 10.1111/j.1365-2125.2011.03987.x; Jones GH, 2016, BLOOD, V127, P1398, DOI 10.1182/blood-2015-11-680058; Kanavos P, 2008, ECON POLICY, P500; Kaplan WA, 2018, HLTH ACTION INT, P106; Kaplan WA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074399; Moorkens E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190147; Pires A, 2018, DRUGS, V78, P851, DOI 10.1007/s40265-018-0918-2; Seidman G, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2016-000243; 't Hoen EFM, 2018, B WORLD HEALTH ORGAN, V96, P185, DOI 10.2471/BLT.17.199364; Unicef, 2016, SUPPL ANN RE 2015; United Nations, 2018, GOAL 11 MAK CIT INCL; United States Congressional Budget Office, 2010, EFF US GEN DRUGS MED; van Valen M, 2018, LANCET GLOB HEALTH, V6, pE609, DOI 10.1016/S2214-109X(18)30190-6; Vogler S, 2012, MED REIMBURSEMENT PO; Vondeling GT, 2018, APPL HEALTH ECON HEA, V16, P653, DOI 10.1007/s40258-018-0406-6; Wouters OJ, 2017, MILBANK Q, V95, P554, DOI 10.1111/1468-0009.12279	34	18	18	4	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 13	2020	368								l5444	10.1136/bmj.l5444	http://dx.doi.org/10.1136/bmj.l5444			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF9OQ	31932323	hybrid			2023-01-03	WOS:000509572000005
J	Darrah, PA; Zeppa, JJ; Maiello, P; Hackney, JA; Ii, MHW; Hughes, TK; Pokkali, S; Swanson, PA; Grant, NL; Rodgers, MA; Kamath, M; Causgrove, CM; Laddy, DJ; Bonavia, A; Casimiro, D; Lin, PL; Klein, E; White, AG; Scanga, CA; Shalek, AK; Roederer, M; Flynn, JL; Seder, RA				Darrah, Patricia A.; Zeppa, Joseph J.; Maiello, Pauline; Hackney, Joshua A.; Ii, Marc H. Wadsworth; Hughes, Travis K.; Pokkali, Supriya; Swanson, Phillip A., II; Grant, Nicole L.; Rodgers, Mark A.; Kamath, Megha; Causgrove, Chelsea M.; Laddy, Dominick J.; Bonavia, Aurelio; Casimiro, Danilo; Lin, Philana Ling; Klein, Edwin; White, Alexander G.; Scanga, Charles A.; Shalek, Alex K.; Roederer, Mario; Flynn, JoAnne L.; Seder, Robert A.			Prevention of tuberculosis in macaques after intravenous BCG immunization	NATURE			English	Article							T-CELL RESPONSES; MYCOBACTERIUM-TUBERCULOSIS; AIRBORNE TUBERCULOSIS; INFECTION; VACCINATION; PROTECTION; MONKEYS; SUBSET; WALLS; GAMMA	Mycobacterium tuberculosis (Mtb) is the leading cause of death from infection worldwide(1). The only available vaccine, BCG (Bacillus Calmette-Guerin), is given intradermally and has variable efficacy against pulmonary tuberculosis, the major cause of mortality and disease transmission(1,2). Here we show that intravenous administration of BCG profoundly alters the protective outcome of Mtb challenge in non-human primates (Macaca mulatta). Compared with intradermal or aerosol delivery, intravenous immunization induced substantially more antigen-responsive CD4 and CD8 T cell responses in blood, spleen, bronchoalveolar lavage and lung lymph nodes. Moreover, intravenous immunization induced a high frequency of antigen-responsive T cells across all lung parenchymal tissues. Six months after BCG vaccination, macaques were challenged with virulent Mtb. Notably, nine out of ten macaques that received intravenous BCG vaccination were highly protected, with six macaques showing no detectable levels of infection, as determined by positron emission tomography-computed tomography imaging, mycobacterial growth, pathology and granuloma formation. The finding that intravenous BCG prevents or substantially limits Mtb infection in highly susceptible rhesus macaques has important implications for vaccine delivery and clinical development, and provides a model for defining immune correlates and mechanisms of vaccine-elicited protection against tuberculosis.	[Darrah, Patricia A.; Hackney, Joshua A.; Pokkali, Supriya; Swanson, Phillip A., II; Kamath, Megha; Roederer, Mario; Seder, Robert A.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Zeppa, Joseph J.; Maiello, Pauline; Rodgers, Mark A.; Causgrove, Chelsea M.; White, Alexander G.; Scanga, Charles A.; Flynn, JoAnne L.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA; [Ii, Marc H. Wadsworth; Hughes, Travis K.; Shalek, Alex K.] Ragon Inst MGH Harvard & MIT, Cambridge, MA USA; [Ii, Marc H. Wadsworth; Hughes, Travis K.; Shalek, Alex K.] MIT, Dept Chem, Inst Med Engn & Sci IMES, Cambridge, MA 02139 USA; [Ii, Marc H. Wadsworth; Hughes, Travis K.; Shalek, Alex K.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Grant, Nicole L.] Univ Pittsburgh, Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15260 USA; [Laddy, Dominick J.; Bonavia, Aurelio; Casimiro, Danilo] Aeras, Rockville, MD USA; [Lin, Philana Ling] UPMC, Childrens Hosp, Dept Pediat, Univ Pittsburgh, Pittsburgh, PA USA; [Klein, Edwin] Univ Pittsburgh, Sch Med, Div Lab Anim Resources, Pittsburgh, PA USA; [Shalek, Alex K.] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Massachusetts Institute of Technology (MIT)	Seder, RA (corresponding author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	rseder@mail.nih.gov	Scanga, Charles/L-2353-2019; Roederer, Mario/G-1887-2011; Flynn, JoAnne/ABC-7371-2020	Scanga, Charles/0000-0003-3654-5603; Zeppa, Joseph/0000-0003-1136-4793	Intramural Research Program of the VRC, NIAID, NIH; Bill and Melinda Gates Foundation; Searle Scholars Program; Beckman Young Investigator Program; NIH [5U24AI118672, 2RM1HG006193]; Sloan Fellowship in Chemistry	Intramural Research Program of the VRC, NIAID, NIH; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Searle Scholars Program; Beckman Young Investigator Program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sloan Fellowship in Chemistry	This project was funded by the Intramural Research Program of the VRC, NIAID, NIH and by the Bill and Melinda Gates Foundation (through Aeras to J.L.F. and to A.K.S.). A.K.S. was also supported, in part, by the Searle Scholars Program, the Beckman Young Investigator Program, the NIH (5U24AI118672, 2RM1HG006193), and a Sloan Fellowship in Chemistry. We acknowledge the outstanding work of veterinary and research technicians (J. Tomko, B. Stein, C. Ameel, A. Myers, N. Schindler, C. Cochran and C. Bigbee), and imaging personnel (L. J. Frye, J. Borish) at the University of Pittsburgh, as well as attending veterinarian D. Scorpio and animal program coordinators J. P. Todd, A. Taylor and H. Bao at the VRC, and BioQual, Inc. for expert animal care. We thank Flynn, Seder and Roederer laboratory members for discussions, Aeras members M. Fitzpatrick and J. Schaeffer for assistance with BCG, VRC NHP Immunogenicity Core for technical assistance, and VRC Flow Cytometry Core members for support. We are grateful to PARI Pharma GmbH for providing the eFlow nebulizer for use in this study.	ANACKER RL, 1972, Z IMMUNITATSFORSCH, V143, P363; Anderson KG, 2014, NAT PROTOC, V9, P209, DOI 10.1038/nprot.2014.005; BARCLAY W R, 1970, Infection and Immunity, V2, P574; BARCLAY WR, 1973, AM REV RESPIR DIS, V107, P351; Becht E, 2019, NAT BIOTECHNOL, V37, P38, DOI 10.1038/nbt.4314; Booty MG, 2016, SCI REP-UK, V6, DOI 10.1038/srep36720; Chattopadhyay PK, 2006, NAT PROTOC, V1, P1, DOI 10.1038/nprot.2006.1; Chowdhury RR, 2018, NATURE, V560, P644, DOI 10.1038/s41586-018-0439-x; Coleman MT, 2014, INFECT IMMUN, V82, P2400, DOI 10.1128/IAI.01599-13; Cooper AM, 2009, ANNU REV IMMUNOL, V27, P393, DOI 10.1146/annurev.immunol.021908.132703; Corbett AJ, 2014, NATURE, V509, P361, DOI 10.1038/nature13160; Corleis B, 2019, CELL REP, V26, P1409, DOI 10.1016/j.celrep.2019.01.021; Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592; Darrah PA, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0113-9; Dijkman K, 2019, NAT MED, V25, P255, DOI 10.1038/s41591-018-0319-9; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Fitzpatrick M, 2019, TUBERCULOSIS, V114, P47, DOI 10.1016/j.tube.2018.10.013; Gideon HP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004603; Gierahn TM, 2017, NAT METHODS, V14, P395, DOI 10.1038/nmeth.4179; Greene JM, 2017, MUCOSAL IMMUNOL, V10, P802, DOI 10.1038/mi.2016.91; Hansen SG, 2018, NAT MED, V24, P130, DOI 10.1038/nm.4473; Harris RC, 2016, HUM VACC IMMUNOTHER, V12, P2813, DOI 10.1080/21645515.2016.1205769; Joosten SA, 2019, VACCINE, V37, P3022, DOI 10.1016/j.vaccine.2019.04.050; Joosten SA, 2018, J CLIN INVEST, V128, P1837, DOI 10.1172/JCI97508; Kauffman KD, 2018, MUCOSAL IMMUNOL, V11, P462, DOI 10.1038/mi.2017.60; Kaufmann E, 2018, CELL, V172, P176, DOI 10.1016/j.cell.2017.12.031; Kaushal D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9533; Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449; Kleinnijenhuis J, 2014, J INNATE IMMUN, V6, P152, DOI 10.1159/000355628; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lewinsohn DA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01262; Li H, 2018, NAT REV IMMUNOL, V18, P591, DOI 10.1038/s41577-018-0028-0; Lin PL, 2014, NAT MED, V20, P75, DOI 10.1038/nm.3412; Lopez D, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-4167-7; Lu LL, 2016, CELL, V167, P433, DOI 10.1016/j.cell.2016.08.072; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Maiello P, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00505-17; Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790; Martin CJ, 2017, MBIO, V8, DOI 10.1128/mBio.00312-17; Masopust D, 2019, ANNU REV IMMUNOL, V37, P521, DOI 10.1146/annurev-immunol-042617-053214; Moguche AO, 2015, J EXP MED, V212, P715, DOI 10.1084/jem.20141518; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Orr MT, 2015, J INFECT DIS, V212, P495, DOI 10.1093/infdis/jiv055; Phuah J, 2016, INFECT IMMUN, V84, P1301, DOI 10.1128/IAI.00083-16; Qaqish A, 2017, J IMMUNOL, V198, P4753, DOI 10.4049/jimmunol.1602019; RIBI E, 1971, J INFECT DIS, V123, P527, DOI 10.1093/infdis/123.5.527; Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015; Saini D, 2012, TUBERCULOSIS, V92, P160, DOI 10.1016/j.tube.2011.11.007; Sakai S, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005667; Sakai S, 2014, J IMMUNOL, V192, P2965, DOI 10.4049/jimmunol.1400019; Sallin MA, 2018, NAT MICROBIOL, V3, P1198, DOI 10.1038/s41564-018-0231-6; Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192; Sharpe S, 2016, TUBERCULOSIS, V101, P174, DOI 10.1016/j.tube.2016.09.004; Soares AP, 2013, J INFECT DIS, V207, P1084, DOI 10.1093/infdis/jis941; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suliman S, 2016, J IMMUNOL, V197, P1100, DOI 10.4049/jimmunol.1501996; White A. G., 2017, JOVE-J VIS EXP, V127; Wolf FA, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-017-1382-0; World Health Organization, 2018, GLOBAL TUBERCULOSIS	59	210	225	12	58	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 2	2020	577	7788					95	+		10.1038/s41586-019-1817-8	http://dx.doi.org/10.1038/s41586-019-1817-8			32	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA2HC	31894150	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000505617400033
J	Toepfer, S; Bolbrinker, J; Konig, M; Steinhagen-Thiessen, E; Kreutz, R; Demuth, I				Toepfer, Sarah; Bolbrinker, Juliane; Koenig, Maximilian; Steinhagen-Thiessen, Elisabeth; Kreutz, Reinhold; Demuth, Ilja			Potentially inappropriate medication in older participants of the Berlin Aging Study II (BASE-II) - Sex differences and associations with morbidity and medication use	PLOS ONE			English	Article							CONSENSUS PANEL; ELDERLY-PEOPLE; BEERS CRITERIA; ADULTS; PREVALENCE; RISK; LIST	Introduction Multimorbidity in advanced age and the need for drug treatment may lead to polypharmacy, while pharmacokinetic and pharmacodynamic changes may increase the risk of adverse drug events (ADEs). Objective The aim of this study was to determine the proportion of subjects using potentially inappropriate medication (PIM) in a cohort of older and predominantly healthy adults in relation to polypharmacy and morbidity. Methods Cross-sectional data were available from 1,382 study participants (median age 69 years, IQR 67-71, 51.3% females) of the Berlin Aging Study II (BASE-II). PIM was classified according to the EU(7)-PIM and German PRISCUS (representing a subset of the former) list. Polypharmacy was defined as the concomitant use of at least five drugs. A morbidity index (MI) largely based on the Charlson Index was applied to evaluate the morbidity burden. Results Overall, 24.1% of the participants were affected by polypharmacy. On average, men used 2 (IQR 1-4) and women 3 drugs (IQR 1-5). According to PRISCUS and EU(7)-PIM, 5.9% and 22.6% of participants received at least one PIM, while use was significantly more prevalent in females (25.5%) compared to males (19.6%) considering EU(7)-PIM (p = 0.01). In addition, morbidity in males receiving PIM according to EU(7)-PIM was higher (median MI 1, IQR 1-3) compared to males without PIM use (median MI 1, IQR 0-2, p<0.001). Conclusion PIM use occurred more frequently in women than in men, while it was associated with higher morbidity in males. As expected, EU(7)-PIM identifies more subjects as PIM users than the PRISCUS list but further studies are needed to investigate the differential impact of both lists on ADEs and outcome. Key points We found PIM use to be associated with a higher number of regular medications and with increased morbidity. Additionally, we detected a higher prevalence of PIM use in females compared to males, suggesting that women and people needing intensive drug treatment are patient groups, who are particularly affected by PIM use.	[Toepfer, Sarah; Bolbrinker, Juliane; Steinhagen-Thiessen, Elisabeth; Kreutz, Reinhold; Demuth, Ilja] Charite Univ Med Berlin, Berlin, Germany; [Toepfer, Sarah; Bolbrinker, Juliane; Steinhagen-Thiessen, Elisabeth; Kreutz, Reinhold; Demuth, Ilja] Free Univ Berlin, Berlin, Germany; [Toepfer, Sarah; Bolbrinker, Juliane; Steinhagen-Thiessen, Elisabeth; Kreutz, Reinhold; Demuth, Ilja] Humboldt Univ, Berlin, Germany; [Toepfer, Sarah; Steinhagen-Thiessen, Elisabeth; Demuth, Ilja] Berlin Inst Hlth, Lipid Clin Interdisciplinary Metab Ctr, Berlin, Germany; [Bolbrinker, Juliane; Kreutz, Reinhold] Berlin Inst Hlth, Inst Klin Pharmakol & Toxikol, Berlin, Germany; [Koenig, Maximilian] Charite, Med Klin Mit Schwerpunkt Nephrol & Internist Inte, Berlin, Germany; [Demuth, Ilja] Charite Univ Med Berlin, Berlin Inst Hlth Ctr Regenerat Therapies Oder Aus, BCRT Berlin Inst Hlth Ctr Regenerat Therapies, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Demuth, I (corresponding author), Charite Univ Med Berlin, Berlin, Germany.; Demuth, I (corresponding author), Free Univ Berlin, Berlin, Germany.; Demuth, I (corresponding author), Humboldt Univ, Berlin, Germany.; Demuth, I (corresponding author), Berlin Inst Hlth, Lipid Clin Interdisciplinary Metab Ctr, Berlin, Germany.; Demuth, I (corresponding author), Charite Univ Med Berlin, Berlin Inst Hlth Ctr Regenerat Therapies Oder Aus, BCRT Berlin Inst Hlth Ctr Regenerat Therapies, Berlin, Germany.	ilja.demuth@charite.de	Kreutz, Reinhold/AEV-0507-2022; König, Maximilian/AAD-8221-2021; Demuth, Ilja/ABD-5352-2021	König, Maximilian/0000-0003-4873-5519; Demuth, Ilja/0000-0002-4340-2523; Bolbrinker, Juliane/0000-0002-0812-8549	German Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung, BMBF) [16SV5536K, 16SV5537, 16SV5538, 16SV5837, 01UW0808, 01GL1716A, 01GL1716B]; Max Planck Institute for Human Development, Berlin, Germany; German Research Foundation (DFG); Open Access Publication Fund of Charite -Universitatsmedizin Berlin	German Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung, BMBF)(Federal Ministry of Education & Research (BMBF)); Max Planck Institute for Human Development, Berlin, Germany; German Research Foundation (DFG)(German Research Foundation (DFG)); Open Access Publication Fund of Charite -Universitatsmedizin Berlin	The BASE-II research project (Co-PIs are Lars Bertram, Ilja Demuth, Denis Gerstorf, Ulman Lindenberger, Graham Pawelec, Elisabeth Steinhagen-Thiessen, and Gert G. Wagner) is supported by the German Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung, BMBF) under grant numbers #16SV5536K, #16SV5537, #16SV5538, #16SV5837, #01UW0808, 01GL1716A and 01GL1716B. Another source of funding is the Max Planck Institute for Human Development, Berlin, Germany. Additional contributions (e.g., equipment, logistics, personnel) are made from each of the other participating sites. We acknowledge support from the German Research Foundation (DFG) and the Open Access Publication Fund of Charite -Universitatsmedizin Berlin. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham O, 2017, INT J CLIN PHARM-NET, V39, P808, DOI 10.1007/s11096-017-0467-x; Abu Sin M, 2015, GESUND HEITSBERICHTE; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; Bertram L, 2014, INT J EPIDEMIOL, V43, P703, DOI 10.1093/ije/dyt018; Butler M, 2018, ANN INTERN MED, V168, P52, DOI 10.7326/M17-1530; Calderon-Larranaga A, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X659295; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chlebowski RT, 2010, JAMA-J AM MED ASSOC, V304, P1684, DOI 10.1001/jama.2010.1500; Coupland C, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4551; DeKosky ST, 2008, JAMA-J AM MED ASSOC, V300, P2253, DOI 10.1001/jama.2008.683; Endres HG, 2018, BUNDESGESUNDHEITSBLA, V61, P40, DOI [10.1007/s00103-017-2662-2, 10.1007/s00103-017-2654-2]; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72; Gallo P, 2019, EUR J INTERN MED, V65, P51, DOI 10.1016/j.ejim.2019.05.002; Gerstorf D, 2016, GERONTOLOGY, V62, P311, DOI 10.1159/000441495; Hedna K, 2015, EUR J CLIN PHARMACOL, V71, P1525, DOI 10.1007/s00228-015-1950-8; Heser K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202068; Holt S, 2010, DTSCH ARZTEBL INT, V107, P543, DOI 10.3238/arztebl.2010.0543; Kachru N, 2015, DRUG AGING, V32, P379, DOI 10.1007/s40266-015-0257-x; Konig M, 2018, J GERONTOL A-BIOL, V73, P117, DOI 10.1093/gerona/glx074; Konig M, 2017, GERONTOLOGY, V63, P201, DOI 10.1159/000454831; Kristensen RU, 2019, J ALZHEIMERS DIS, V67, P949, DOI 10.3233/JAD-180427; Laroche ML, 2007, EUR J CLIN PHARMACOL, V63, P725, DOI 10.1007/s00228-007-0324-2; Leonard CE, 2018, PHARMACOEPIDEM DR S, V27, P9, DOI 10.1002/pds.4337; Linder R, 2014, DEUT MED WOCHENSCHR, V139, P983, DOI 10.1055/s-0034-1369948; Martinot P, 2018, J AM MED DIR ASSOC, V19, P967, DOI 10.1016/j.jamda.2018.07.008; Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2; McLeod PJ, 1997, CAN MED ASSOC J, V156, P385; Meyer A, 2016, GERONTOLOGY, V62, P330, DOI 10.1159/000430950; Miller GE, 2017, HEALTH SERV RES, V52, P1534, DOI 10.1111/1475-6773.12562; Molokhia M, 2017, BMC FAM PRACT, V18, DOI 10.1186/s12875-017-0642-0; Motter FR, 2018, EUR J CLIN PHARMACOL, V74, P679, DOI 10.1007/s00228-018-2446-0; Nathan DM, 2008, DIABETES CARE, V31, P1473, DOI 10.2337/dc08-0545; Nothelle SK, 2019, INT J PHARM PRACT, V27, P408, DOI 10.1111/ijpp.12541; Novaes PH, 2017, GERIATR GERONTOL INT, V17, P1628, DOI 10.1111/ggi.12944; O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145; Oktora MP, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214240; Pesch B, 2018, NEUROTOXICOLOGY, V64, P68, DOI 10.1016/j.neuro.2017.08.008; Radcliff S, 2015, J AM GERIATR SOC, V63, P2227, DOI 10.1111/jgs.13702; Reich O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105425; Renom-Guiteras A, 2015, EUR J CLIN PHARMACOL, V71, P861, DOI 10.1007/s00228-015-1860-9; Saum KU, 2017, J AM GERIATR SOC, V65, pE27, DOI 10.1111/jgs.14718; Schubert I, 2013, PHARMACOEPIDEM DR S, V22, P719, DOI 10.1002/pds.3429; Schwabe U, 2018, ARZNEIVERORDNUNGS RE; Sonnerstam E, 2017, EUR J CLIN PHARMACOL, V73, P735, DOI 10.1007/s00228-017-2218-2; Tommelein E, 2015, EUR J CLIN PHARMACOL, V71, P1415, DOI 10.1007/s00228-015-1954-4; Trelle S, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7086; Vinkers Christiaan H, 2012, Ned Tijdschr Geneeskd, V155, pA4900; Walker C, 2018, INT J RHEUMATOL, V2018, DOI 10.1155/2018/1302835; Wallerstedt SM, 2015, PHARMACOEPIDEM DR S, V24, P906, DOI 10.1002/pds.3827; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407	51	15	15	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2019	14	12							e0226511	10.1371/journal.pone.0226511	http://dx.doi.org/10.1371/journal.pone.0226511			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KN8JV	31887163	Green Published, gold, Green Submitted			2023-01-03	WOS:000515092200020
J	Mcneil, JB; Hughes, CG; Girard, T; Ware, LB; Ely, EW; Chandrasekhar, R; Han, JH				Mcneil, J. Brennan; Hughes, Christopher G.; Girard, Timothy; Ware, Lorraine B.; Ely, E. Wesley; Chandrasekhar, Rameela; Han, Jin H.			Plasma biomarkers of inflammation, coagulation, and brain injury as predictors of delirium duration in older hospitalized patients	PLOS ONE			English	Article							EMERGENCY-DEPARTMENT PATIENTS; PROGNOSTIC-SIGNIFICANCE; ELDERLY-PATIENTS; RISK-FACTORS; CYTOKINES; BARRIER; DYSFUNCTION; ACTIVATION; INPATIENTS; MORTALITY	Background Delirium's pathophysiology is poorly understood. We sought to determine if plasma biomarkers of inflammation, coagulation, endothelial activation, and blood brain barrier (BBB) injury were associated with emergency department (ED) delirium duration. Methods We enrolled hospitalized patients who were 65 years or older from the ED. Plasma biomarkers of inflammation (interleukin-6 [IL-6], IL-8, soluble tumor necrosis factor receptor I [sTNFRI]), coagulation (Protein C), endothelial activation (plasminogen activating inhibitor-1 [PAI-1]), and BBB injury (S100B) at were measured using blood obtained at enrollment. The dependent variable was ED delirium duration which was determined by the Brief Confusion Assessment Method assessed in the ED and hospitalization. Proportional odds logistic regression analyses were performed adjusted for relevant confounders and allowing for interaction by baseline dementia status. Results A total of 156 patients were enrolled. IL-6 (POR = 1.59, 95%CI: 1.09-2.32) and PAI-1 (POR = 2.96, 95%CI: 1.48 to 6.85) were independently associated with more prominent ED delirium duration in subjects without dementia only. No significant associations between IL-8, Protein C, sTNRFI, and S100B and ED delirium duration were observed. Conclusions Plasma Biomarkers of systemic inflammation and endothelial activation are associated with ED delirium duration in older ED patients without dementia.	[Mcneil, J. Brennan; Ware, Lorraine B.; Ely, E. Wesley] Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, Nashville, TN USA; [Mcneil, J. Brennan; Hughes, Christopher G.; Girard, Timothy; Ware, Lorraine B.; Ely, E. Wesley; Chandrasekhar, Rameela; Han, Jin H.] Vanderbilt Univ, Med Ctr, Crit Illness Brain Dysfunct & Survivorship CIBS C, Nashville, TN 37235 USA; [Hughes, Christopher G.] Vanderbilt Univ, Med Ctr, Div Anesthesiol Crit Care Med, Nashville, TN USA; [Girard, Timothy] Univ Pittsburgh, Sch Med, Clin Res Invest & Syst Modeling Acute Illness CRI, Dept Crit Care Med, Pittsburgh, PA USA; [Ely, E. Wesley; Han, Jin H.] Vet Affairs Geriatr Res Educ & Clin Ctr GRECC, Nashville, TN 37212 USA; [Chandrasekhar, Rameela] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA; [Han, Jin H.] Vanderbilt Univ, Med Ctr, Dept Emergency Med, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Geriatric Research Education & Clinical Center; Vanderbilt University; Vanderbilt University	Han, JH (corresponding author), Vanderbilt Univ, Med Ctr, Crit Illness Brain Dysfunct & Survivorship CIBS C, Nashville, TN 37235 USA.; Han, JH (corresponding author), Vet Affairs Geriatr Res Educ & Clin Ctr GRECC, Nashville, TN 37212 USA.; Han, JH (corresponding author), Vanderbilt Univ, Med Ctr, Dept Emergency Med, Nashville, TN 37235 USA.	Jin.h.han@vanderbilt.edu	Ware, Lorraine/AAJ-9307-2021	Ware, Lorraine/0000-0002-9429-4702; McNeil, Joel/0000-0002-9200-1881	National Institutes of Health [HL111111, AG045085, GM120484, K23AG032355, K12HL109019, R01AG027472, R01AG035117]; National Center for Research Resources [UL1 RR024975-01]; National Center for Advancing Translational Sciences [2 UL1 TR000445-06]; Veteran Affairs MERIT award; Veteran Affairs Geriatric Research, Education, and Clinical Center (GRECC); American Geriatrics Society Jahnigen Career Development Award; NIH [HL103836]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL103836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG035117] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Veteran Affairs MERIT award; Veteran Affairs Geriatric Research, Education, and Clinical Center (GRECC); American Geriatrics Society Jahnigen Career Development Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Dr. Han and this study was funded by the National Institutes of Health under award number K23AG032355. This study was also supported by the National Center for Research Resources, Grant UL1 RR024975-01, and is now at the National Center for Advancing Translational Sciences, Grant 2 UL1 TR000445-06. Dr. Han was also supported by the National Institutes of Health under award number K12HL109019. Dr. Ely was supported in part by the National Institutes of Health under award numbers R01AG027472 and R01AG035117, and a Veteran Affairs MERIT award. Drs. Ely and Han are also supported by the Veteran Affairs Geriatric Research, Education, and Clinical Center (GRECC). Dr. Hughes received support from American Geriatrics Society Jahnigen Career Development Award and the National Institutes of Health (HL111111, AG045085, GM120484). Dr. Ware is supported by NIH HL103836. The content is solely the responsibility of the authors and does not necessarily represent the official views of Vanderbilt University Medical Center, National Institutes of Health, and Veterans Affairs.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Adamis D, 2009, AGE AGEING, V38, P326, DOI 10.1093/ageing/afp014; Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887; Ait-Oufella H, 2010, INTENS CARE MED, V36, P1286, DOI 10.1007/s00134-010-1893-6; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Beloosesky Y, 2007, J GERONTOL A-BIOL, V62, P420, DOI 10.1093/gerona/62.4.420; de Rooij SE, 2007, J PSYCHOSOM RES, V62, P521, DOI 10.1016/j.jpsychores.2006.11.013; Downing JEG, 2000, IMMUNOL TODAY, V21, P281, DOI 10.1016/S0167-5699(00)01635-2; Egberts A, 2015, DEMENT GERIATR COGN, V39, P116, DOI 10.1159/000366410; Elie M, 2000, CAN MED ASSOC J, V163, P977; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; Gavins F, 2007, MICROCIRCULATION, V14, P667, DOI 10.1080/10739680701404903; Girard TD, 2012, INTENS CARE MED, V38, P1965, DOI 10.1007/s00134-012-2678-x; Gonzalez M, 2009, PSYCHOSOMATICS, V50, P234, DOI 10.1176/appi.psy.50.3.234; Han J. H., 2013, ACAD EMERG MED, V20, pS125; Han JH, 2017, J AM GERIATR SOC, V65, P1333, DOI 10.1111/jgs.14824; Han JH, 2016, AM J EMERG MED, V34, P1031, DOI 10.1016/j.ajem.2016.02.069; Han JH, 2010, ANN EMERG MED, V56, P244, DOI 10.1016/j.annemergmed.2010.03.003; Han JH, 2009, ACAD EMERG MED, V16, P193, DOI 10.1111/j.1553-2712.2008.00339.x; Hughes CG, 2018, INTENS CARE MED, V44, P345, DOI 10.1007/s00134-018-5120-1; Hughes CG, 2016, CRIT CARE MED, V44, pE809, DOI 10.1097/CCM.0000000000001739; Hughes CG, 2013, ANESTHESIOLOGY, V118, P631, DOI 10.1097/ALN.0b013e31827bd193; Hustey FM, 2003, ANN EMERG MED, V41, P678, DOI 10.1067/mem.2003.152; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; Inouye SK, 1998, J GEN INTERN MED, V13, P234, DOI 10.1046/j.1525-1497.1998.00073.x; JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X; Kakuma R, 2003, J AM GERIATR SOC, V51, P443, DOI 10.1046/j.1532-5415.2003.51151.x; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEVKOFF SE, 1992, ARCH INTERN MED, V152, P334, DOI 10.1001/archinte.152.2.334; Maldonado JR, 2013, AM J GERIAT PSYCHIAT, V21, P1190, DOI 10.1016/j.jagp.2013.09.005; McCusker J, 2003, J GEN INTERN MED, V18, P696, DOI 10.1046/j.1525-1497.2003.20602.x; Mikhailoyich A, 2015, J AM GERIATR SOC, V63, P843, DOI 10.1111/jgs.13406; Murray SB, 2006, ACAD EMERG MED, V13, P530, DOI 10.1197/j.aem.2005.11.084; OKeeffe S, 1997, J AM GERIATR SOC, V45, P174, DOI 10.1111/j.1532-5415.1997.tb04503.x; Pitkala KH, 2005, DEMENT GERIATR COGN, V19, P158, DOI 10.1159/000082888; Plaschke K, 2010, INTENS CARE MED, V36, P2081, DOI 10.1007/s00134-010-2004-4; POMPEI P, 1995, ARCH INTERN MED, V155, P301, DOI 10.1001/archinte.155.3.301; Ritter C, 2014, CRIT CARE, V18, DOI 10.1186/cc13887; Sakr Y, 2004, CRIT CARE MED, V32, P1825, DOI 10.1097/01.CCM.0000138558.16257.3F; Taccone FS, 2010, CRIT CARE, V14, DOI 10.1186/cc9205; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; van Munster BC, 2008, J AM GERIATR SOC, V56, P1704, DOI 10.1111/j.1532-5415.2008.01851.x; van Munster BC, 2010, BRAIN COGNITION, V74, P18, DOI 10.1016/j.bandc.2010.05.010; van Munster BC, 2010, INT J GERIATR PSYCH, V25, P234, DOI 10.1002/gps.2326; van Munster BC, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-21; Vogel C, 2007, J CELL PHYSIOL, V212, P236, DOI 10.1002/jcp.21022	47	26	28	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2019	14	12							e0226412	10.1371/journal.pone.0226412	http://dx.doi.org/10.1371/journal.pone.0226412			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP3WL	31856187	Green Published, gold			2023-01-03	WOS:000534249400038
J	Yang, JC; Roman-Urrestarazu, A; Brayne, C				Yang, Justin C.; Roman-Urrestarazu, Andres; Brayne, Carol			Differences in receipt of opioid agonist treatment and time to enter treatment for opioid use disorder among specialty addiction programs in the United States, 2014-17	PLOS ONE			English	Article							MEDICATION-ASSISTED TREATMENT; SUBSTANCE-ABUSE TREATMENT; METHADONE-MAINTENANCE; OLDER-ADULTS; BUPRENORPHINE; DETERMINANTS; PHYSICIANS; MORTALITY; BARRIERS; THERAPY	Background Access to adequate treatment for opioid use disorder (OUD) has been a high priority among American policymakers. Elucidation of the sociodemographic and institutional differences associated with the use, or lack thereof, of opioid agonist therapy (OAT) provides greater clarity on who receives OAT. Timely access to care is a further consideration and bears scrutiny as well. Methods We draw upon data from the Treatment Episode Data Set-Admissions (TEDS-A) to analyse the relationship between sociodemographic and institutional characteristics and the receipt of opioid agonist treatments and time waiting to enter treatment. Results Estimates from logistic regression models highlight certain groups which show lower odds of receipt of OAT, including those in precarious housing arrangements, those unemployed or not otherwise in the labor force, and those referred by drug abuse care providers, educational institutions, employers, and the criminal justice system. Groups which showed higher odds of waiting over a week to enter treatment included those who were separated, divorced, or widowed, those working part-time, and those referred by drug abuse care providers, employers, and the criminal justice system. Conclusion Given the efficacy of OAT and the adverse outcomes associated with long waiting times, coordinated effort is needed to understand why these differences persist and how they may be addressed through appropriate policy responses.	[Yang, Justin C.; Roman-Urrestarazu, Andres; Brayne, Carol] Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England; [Yang, Justin C.] UCL, Fac Brain Sci, Div Psychiat, Dept & Epidemiol & Appl Clin Res, London, England; [Roman-Urrestarazu, Andres] Maastricht Univ, Fac Hlth Med & Life Sci, Care & Publ Hlth Res Inst, Dept Int Hlth, Maastricht, Netherlands	University of Cambridge; University of London; University College London; Maastricht University; Maastricht University Medical Centre (MUMC)	Yang, JC (corresponding author), Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England.; Yang, JC (corresponding author), UCL, Fac Brain Sci, Div Psychiat, Dept & Epidemiol & Appl Clin Res, London, England.	jcy25@medschl.cam.ac.uk	Roman-Urrestarazu, Andres/U-9224-2018; Yang, Justin Christopher/H-1780-2018	Roman-Urrestarazu, Andres/0000-0002-2405-9432; Yang, Justin Christopher/0000-0003-2881-4906; Brayne, Carol/0000-0001-5307-663X				[Anonymous], 2013, STAT STAT SOFTW REL; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Bachhuber MA, 2017, MED CARE, V55, P985, DOI 10.1097/MLR.0000000000000803; Bell J, 2020, BIOL PSYCHIAT, V87, P82, DOI 10.1016/j.biopsych.2019.06.020; Blanco C, 2013, DRUG ALCOHOL DEPEN, V131, P143, DOI 10.1016/j.drugalcdep.2012.12.013; Carise D, 1999, J SUBST ABUSE TREAT, V17, P67, DOI 10.1016/S0740-5472(98)00047-6; Chen LY, 2013, J ADDICT MED, V7, P325, DOI 10.1097/ADM.0b013e31829b7afe; Chhatre S, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2538-z; Choi NG, 2014, DRUG ALCOHOL DEPEN, V145, P113, DOI 10.1016/j.drugalcdep.2014.10.004; Degenhardt L, 2014, ADDICTION, V109, P1320, DOI 10.1111/add.12551; Dick AW, 2015, HEALTH AFFAIR, V34, P1028, DOI 10.1377/hlthaff.2014.1205; Fullerton CA, 2014, PSYCHIAT SERV, V65, P146, DOI 10.1176/appi.ps.201300235; Gryczynski J, 2011, J SUBST ABUSE TREAT, V41, P431, DOI 10.1016/j.jsat.2011.06.005; Hileman CO, 2019, CURR HIV-AIDS REP, V16, P381, DOI 10.1007/s11904-019-00463-4; Huhn AS, 2018, DRUG ALCOHOL DEPEN, V193, P142, DOI 10.1016/j.drugalcdep.2018.10.002; Jaffe JH, 2003, DRUG ALCOHOL DEPEN, V70, pS3, DOI 10.1016/S0376-8716(03)00055-3; Jones CM, 2015, AM J PUBLIC HEALTH, V105, pE55, DOI 10.2105/AJPH.2015.302664; Joudrey PJ, 2019, ADDICT SCI CLIN PRAC, V14, DOI 10.1186/s13722-019-0145-5; Kampman K, 2015, J ADDICT MED, V9, P358, DOI 10.1097/ADM.0000000000000166; King NB, 2014, AM J PUBLIC HEALTH, V104, pE32, DOI 10.2105/AJPH.2014.301966; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Krawczyk N, 2017, HEALTH AFFAIR, V36, P2046, DOI 10.1377/hlthaff.2017.0890; Krawczyk N, 2017, DRUG ALCOHOL DEPEN, V178, P512, DOI 10.1016/j.drugalcdep.2017.06.009; Kreek MJ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax9140; Lofwall MR, 2012, DRUG ALCOHOL DEPEN, V126, P379, DOI 10.1016/j.drugalcdep.2012.05.025; Peindl Kathleen S, 2007, J Opioid Manag, V3, P215; Peles E, 2013, J ADDICT MED, V7, P177, DOI 10.1097/ADM.0b013e318287cfc9; Perlman DC, 2018, CURR HIV-AIDS REP, V15, P96, DOI 10.1007/s11904-018-0390-3; Quinn PD, 2017, PAIN, V158, P140, DOI 10.1097/j.pain.0000000000000730; Rivers PA, 2006, AM J HEALTH BEHAV, V30, P451, DOI 10.5993/AJHB.30.5.1; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Santoro TN, 2018, CUREUS, V10, DOI 10.7759/cureus.3733; Sharma A, 2016, SUBST ABUSE REHABIL, V7, P27, DOI 10.2147/SAR.S81602; Short VL, 2018, J SUBST ABUSE TREAT, V89, P67, DOI 10.1016/j.jsat.2018.04.003; Stein BD, 2015, MILBANK Q, V93, P561, DOI 10.1111/1468-0009.12137; Stein BD, 2015, J SUBST ABUSE TREAT, V48, P104, DOI 10.1016/j.jsat.2014.07.010; Substance Abuse and Mental Health Services Administration, 2016, BHSIS SER S, V84; Thomas CP, 2014, PSYCHIAT SERV, V65, P158, DOI 10.1176/appi.ps.201300256; Uchtenhagen A., 2007, WHO GUIDELINES PSYCH; Yang JC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199741	40	9	9	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2019	14	12							e0226349	10.1371/journal.pone.0226349	http://dx.doi.org/10.1371/journal.pone.0226349			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP1HF	31830137	Green Published, gold			2023-01-03	WOS:000534070200071
J	Bauer, BW; Gangadoo, S; Bajagai, YS; Van, TTH; Moore, RJ; Stanley, D				Bauer, Benjamin W.; Gangadoo, Sheeana; Bajagai, Yadav Sharma; Thi Thu Hao Van; Moore, Robert J.; Stanley, Dragana			Oregano powder reduces Streptococcus and increases SCFA concentration in a mixed bacterial culture assay	PLOS ONE			English	Article							ESSENTIAL OILS; ENTEROCOCCUS-FAECIUM; GROWTH-PERFORMANCE; GUT MICROBIOTA; DIETARY SUPPLEMENTATION; EXPERIMENTAL-INFECTION; CECAL MICROFLORA; IMMUNE-RESPONSE; CARVACROL; SALMONELLA	Food borne illnesses have a world-wide economic impact and industries are continuously developing technologies to reduce the spread of disease caused by microorganisms. Antimicrobial growth promoters (AGPs) have been used to decrease microbiological infections in animals and their potential transfer to humans. In recent years there has been a global trend to remove AGPs from animal feed in an attempt to reduce the spread of antimicrobial resistant genes into the human population. Phytobiotics, such as oregano powder, are one of the potential replacements for AGPs due to their well-established antimicrobial components. 16S rRNA gene amplicons were used to determine the effect of oregano powder (1% w/v) on the microbiota of mixed bacterial cell cultures, which were obtained from the ceca of traditionally grown meat chickens (broilers). Oregano powder had a mild effect on the microbial cell cultures increasing Enterococcus faecium, rearranging ratios of members in the genus Lactobacillus and significantly reducing the genus Streptococcus (p = 1.6e-3). Beneficial short chain fatty acids (SCFA), acetic and butyric acid, were also significantly increased in oregano powder supplemented cultures. These results suggest that oregano powder at a concentration of 1% (w/v) may have beneficial influences on mixed microbial communities and SCFA production.	[Bauer, Benjamin W.; Gangadoo, Sheeana; Bajagai, Yadav Sharma; Stanley, Dragana] Cent Queensland Univ, Inst Future Farming Syst, Rockhampton, Qld, Australia; [Thi Thu Hao Van; Moore, Robert J.] RMIT Univ, Sch Sci, Bundoora, Vic, Australia	Central Queensland University; Royal Melbourne Institute of Technology (RMIT)	Stanley, D (corresponding author), Cent Queensland Univ, Inst Future Farming Syst, Rockhampton, Qld, Australia.	D.Stanley@cqu.edu.au	Moore, Robert J/D-8352-2011; Bajagai, Yadav Sharma/AAJ-5088-2021	Moore, Robert J/0000-0002-0776-5861; Bajagai, Yadav Sharma/0000-0002-3043-071X; Gangadoo, Sheeana/0000-0002-7803-8899; Van, Thi Thu Hao/0000-0002-1559-568X; Stanley, Dragana/0000-0001-7019-4726	Poultry CRC	Poultry CRC(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme)	We wish to acknowledge Jason Bell and help he provided in all aspects of High-Performance Computing. We also thank Corine Ting, Vicky Carroll and Charmaine Elder for technical support also heritage chicken breeder Kerrilyn Salmond for providing the samples that were used for this assay's cultures. This study, including scholarship for BB, was funded by Poultry CRC established by Australian Government.	Abdulamir AS, 2009, BMC CANCER, V9, P12, DOI [10.1186/1471-2407-9-12, DOI 10.1186/1471-2407-9-12]; Abdulamir AS, 2010, MOL CANCER, V9, P18, DOI [10.1186/1476-4598-9-18, DOI 10.1186/1476-4598-9-18]; Ahlman H, 2001, ANN ONCOL, V12, pS63, DOI 10.1093/annonc/12.suppl_2.S63; Andreatti RL, 2000, BRAZ J MICROBIOL, V31, P107; Arigesavan K, 2015, BIOCHEM BIOPH RES CO, V461, P314, DOI 10.1016/j.bbrc.2015.04.030; Ashelford KE, 2005, APPL ENVIRON MICROB, V71, P7724, DOI 10.1128/AEM.71.12.7724-7736.2005; Audisio MC, 2000, J FOOD PROTECT, V63, P1333, DOI 10.4315/0362-028X-63.10.1333; Bajpai VK, 2012, FOOD RES INT, V45, P722, DOI 10.1016/j.foodres.2011.04.052; Beh BK, 2017, SCI REP, V7, P2045, DOI [10.1038/s41598-017-01960-5, DOI 10.1038/S41598-017-01960-5]; Benyacoub J, 2003, J NUTR, V133, P1158, DOI 10.1093/jn/133.4.1158; Betancourt L, 2014, POULTRY SCI, V93, P2526, DOI 10.3382/ps.2014-03944; Boleij A, 2011, CLIN INFECT DIS, V53, P870, DOI 10.1093/cid/cir609; Boskabady MH, 2013, EXP BIOL MED, V238, P200, DOI 10.1177/1535370212474604; Brenes A, 2010, ANIM FEED SCI TECH, V158, P1, DOI 10.1016/j.anifeedsci.2010.03.007; Cao GT, 2013, POULTRY SCI, V92, P2949, DOI 10.3382/ps.2013-03366; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Casewell M, 2003, J ANTIMICROB CHEMOTH, V52, P159, DOI 10.1093/jac/dkg313; Crisol-Martinez E, 2017, APPL MICROBIOL BIOT, V101, P4547, DOI 10.1007/s00253-017-8193-9; De Vincenzi M, 2004, FITOTERAPIA, V75, P801, DOI 10.1016/j.fitote.2004.05.002; Deplancke B GHR, 2001, AM J CLIN NUTR, V73, P11; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Didry N, 1994, PHARM ACTA HELV, V69, P4; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Emborg HD, 2001, PREV VET MED, V50, P53, DOI 10.1016/S0167-5877(01)00218-5; Fak F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046837; Floret N, 2010, INFECT CONT HOSP EP, V31, P194, DOI 10.1086/650380; Gandhi M, 2007, INT J FOOD MICROBIOL, V113, P1, DOI 10.1016/j.ijfoodmicro.2006.07.008; Giannenas I, 2003, ARCH ANIM NUTR, V57, P99, DOI 10.1080/0003942031000107299; Gul AS, 2013, ISLETS, V5, P149, DOI 10.4161/isl.25519; Hyldgaard M, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00012; Jensen HH, 2014, CURR OPIN MICROBIOL, V19, P30, DOI 10.1016/j.mib.2014.05.020; JORDENS JZ, 1994, J ANTIMICROB CHEMOTH, V34, P515, DOI 10.1093/jac/34.4.515; Karimi A, 2010, J APPL POULTRY RES, V19, P137, DOI 10.3382/japr.2009-00088; Kers JG, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00235; Lagier JC, 2012, CLIN MICROBIOL INFEC, V18, P1185, DOI 10.1111/1469-0691.12023; LAGOURI V, 1993, Z LEBENSM UNTERS FOR, V197, P20, DOI 10.1007/BF01202694; Lakis Z, 2012, FARMACIA, V60, P857; Leeson S, 2005, POULTRY SCI, V84, P1418, DOI 10.1093/ps/84.9.1418; Legendre P, 2001, OECOLOGIA, V129, P271, DOI 10.1007/s004420100716; Legendre P, 2013, ECOL LETT, V16, P951, DOI 10.1111/ele.12141; Lima MD, 2013, EUR J PHARMACOL, V699, P112, DOI 10.1016/j.ejphar.2012.11.040; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lozupone CA, 2012, NATURE, V489, P220, DOI 10.1038/nature11550; Magi G, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00165; Mathlouthi N, 2012, J ANIM SCI, V90, P813, DOI 10.2527/jas.2010-3646; Million M, 2012, INT J OBESITY, V36, P817, DOI 10.1038/ijo.2011.153; Nicholson JK, 2012, SCIENCE, V336, P1262, DOI 10.1126/science.1223813; Ocana-Fuentes A, 2010, FOOD CHEM TOXICOL, V48, P1568, DOI 10.1016/j.fct.2010.03.026; Onrust L, 2015, FRONT VET SCI, V2, DOI 10.3389/fvets.2015.00075; Peng LY, 2009, J NUTR, V139, P1619, DOI 10.3945/jn.109.104638; Peng QY, 2016, ANIM FEED SCI TECH, V214, P148, DOI 10.1016/j.anifeedsci.2016.02.010; Phillips I, 2004, J ANTIMICROB CHEMOTH, V53, P28, DOI 10.1093/jac/dkg483; Ruben O, 2014, FOOD CHEM, V156, P212, DOI 10.1016/j.foodchem.2014.01.087; Rusniok C, 2010, J BACTERIOL, V192, P2266, DOI 10.1128/JB.01659-09; Ryssel H, 2009, BURNS, V35, P695, DOI 10.1016/j.burns.2008.11.009; Sanchez M, 2014, BRIT J NUTR, V111, P1507, DOI 10.1017/S0007114513003875; Scharek L, 2005, VET IMMUNOL IMMUNOP, V105, P151, DOI 10.1016/j.vetimm.2004.12.022; Seth EC, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00350; Silva FV, 2012, J MED FOOD, V15, P984, DOI 10.1089/jmf.2012.0102; Sivropoulou A, 1996, J AGR FOOD CHEM, V44, P1202, DOI 10.1021/jf950540t; Stanley D, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00187; Stanley D, 2014, APPL MICROBIOL BIOT, V98, P4301, DOI 10.1007/s00253-014-5646-2; Svihus B, 2014, J APPL POULTRY RES, V23, P306, DOI 10.3382/japr.2014-00937; Turnidge J, 2004, J ANTIMICROB CHEMOTH, V53, P26, DOI 10.1093/jac/dkg493; Turnidge J, 1999, USE ANTIBIOTICS FOOD; Ultee A, 2002, APPL ENVIRON MICROB, V68, P1561, DOI 10.1128/AEM.68.4.1561-1568.2002; Ursell LK, 2012, NUTR REV, V70, pS38, DOI 10.1111/j.1753-4887.2012.00493.x; Van Immerseel F, 2009, TRENDS MICROBIOL, V17, P32, DOI 10.1016/j.tim.2008.09.005; Windisch W, 2008, J Anim Sci, V86, pE140; Yin DF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07420-4; Young JF, 2003, POULTRY SCI, V82, P1343, DOI 10.1093/ps/82.8.1343; Zakrzewski M, 2017, BIOINFORMATICS, V33, P782, DOI 10.1093/bioinformatics/btw725; Zhang WH, 2011, BRIT POULTRY SCI, V52, P292, DOI 10.1080/00071668.2011.578121	73	8	10	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2019	14	12							e0216853	10.1371/journal.pone.0216853	http://dx.doi.org/10.1371/journal.pone.0216853			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP0TY	31821320	gold, Green Published, Green Submitted			2023-01-03	WOS:000534035700006
J	Gualandi, R; Masella, C; Viglione, D; Tartaglini, D				Gualandi, Raffaella; Masella, Cristina; Viglione, Daniela; Tartaglini, Daniela			Exploring the hospital patient journey: What does the patient experience?	PLOS ONE			English	Article							KNEE ARTHROPLASTY; CARE EXPERIENCE; HEALTH; HIP	Purpose To understand how different methodologies of qualitative research are able to capture patient experience of the hospital journey. Methods A qualitative study of orthopaedic patients admitted for hip and knee replacement surgery in a 250-bed university hospital was performed. Eight patients were shadowed from the time they entered the hospital to the time of transfer to rehabilitation. Four patients and sixteen professionals, including orthopaedists, head nurses, nurses and administrative staff, were interviewed. Results Through analysis of the data collected four main themes emerged: the information gap; the covering patient-professionals relationship; the effectiveness of family closeness; and the micro-integration of hospital services. The three different standpoints (patient shadowing, health professionals' interviews and patients' interviews) allowed different issues to be captured in the various phases of the journey. Conclusions Hospitals can significantly improve the quality of the service provided by exploring and understanding the individual patient journey. When dealing with a key cross-functional business process, the time-space dynamics of the activities performed have to be considered. Further research in the academic field can explore practical, methodological and ethical challenges more deeply in capturing the whole patient journey experience by using multiple methods and integrated tools.	[Gualandi, Raffaella; Viglione, Daniela; Tartaglini, Daniela] Univ Campus Biomed Roma, Dept Nursing, Rome, Italy; [Masella, Cristina] Politecn Milan, Dept Management Econ & Ind Engn, Milan, Italy	University Campus Bio-Medico - Rome Italy; Polytechnic University of Milan	Gualandi, R (corresponding author), Univ Campus Biomed Roma, Dept Nursing, Rome, Italy.	r.gualandi@unicampus.it	Masella, Cristina/AHA-4620-2022	Gualandi, Raffaella/0000-0001-8602-5249				Agozzino E, 2019, BMC MED ETHICS, V20, DOI 10.1186/s12910-018-0340-z; Altringer B, 2010, J HEALTH SERV RES PO, V15, P174, DOI 10.1258/jhsrp.2009.009064; Andersen-Hollekim TE, 2019, NURS OPEN, V6, P574, DOI 10.1002/nop2.241; Bate P, 2006, QUAL SAF HEALTH CARE, V15, P307, DOI 10.1136/qshc.2005.016527; Beattie M, 2015, SYST REV, V4, DOI 10.1186/s13643-015-0089-0; Ben-Tovim DI, 2008, MED J AUSTRALIA, V188, pS14; Benner P., 1984, NOVICE EXPERT EXCELL, P13; Coulson A., 2009, POINT CARE MEASURES, V23, P1; Czarniawska-Joerges B., 2007, SHADOWING OTHER TECH; Edwards PK, 2017, CURR REV MUSCULOSKE, V10, P356, DOI 10.1007/s12178-017-9417-4; Feng JE, 2018, J MULTIDISCIP HEALTH, V11, P63, DOI 10.2147/JMDH.S140550; Ford RC, 2000, HEALTH CARE MANAGE R, V25, P18, DOI 10.1097/00004010-200010000-00003; Gill R, 2011, QUAL RES ORGAN MANAG, V6, P115, DOI 10.1108/17465641111159116; Gleeson H, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011907; Halvorsrud R, 2016, J SERV THEOR PRACT, V26, P840, DOI 10.1108/JSTP-05-2015-0111; Haraden Carol, 2004, Front Health Serv Manage, V20, P3; Health Foundation, 2013, IMPR PAT FLOW LEARN; Honeyford K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187012; Icks A, 2017, J CLIN EPIDEMIOL, V82, P167, DOI 10.1016/j.jclinepi.2016.10.009; Iedema RA, 2015, BMJ QUAL SAF, V24, P356, DOI 10.1136/bmjqs-2015-004298; Jain R, 2017, J SERV THEOR PRACT, V27, P642, DOI 10.1108/JSTP-03-2015-0064; Kaptain K, 2019, J CLIN NURS, V28, P2214, DOI 10.1111/jocn.14817; Kjellsson G, 2014, J HEALTH ECON, V35, P34, DOI 10.1016/j.jhealeco.2014.01.007; Krol MW, 2015, INT J QUAL HEALTH C, V27, P17, DOI 10.1093/intqhc/mzu090; Laverty S.M., 2003, INT J QUAL METHODS, V2, P21, DOI [DOI 10.1177/160940690300200303, 10.1177/160940690300200303, https://doi.org/10.1177/160940690300200303]; Liberati EG, 2017, BMJ QUAL SAF, V26, P343, DOI 10.1136/bmjqs-2016-005308; Lindseth A, 2004, SCAND J CARING SCI, V18, P145, DOI 10.1111/j.1471-6712.2004.00258.x; Litvak E., 2010, MANAGING PATIENT FLO; Manary MP, 2013, NEW ENGL J MED, V368, P201, DOI 10.1056/NEJMp1211775; Marcus-Aiyeku U, 2015, ORTHOP NURS, V34, P269, DOI 10.1097/NOR.0000000000000177; McDonald S., 2005, QUAL RES, V5, P455, DOI [10.1177/1468794105056923, DOI 10.1177/1468794105056923]; McDonald S, 2014, QUAL RES ORGAN MANAG, V9, P3, DOI 10.1108/QROM-02-2014-1204; PLUTCHIK R, 1988, EMOTIONS PSYCHOPATHO; Samaranayake P, 2016, J HEALTH ORGAN MANAG, V30, P950, DOI 10.1108/JHOM-07-2015-0109; Shaw Joanne, 2014, Nurs Manag (Harrow), V21, P20, DOI 10.7748/nm.21.3.20.s24; Sheard L, 2019, HEALTH EXPECT, V22, P46, DOI 10.1111/hex.12829; Sibley M, 2018, J CLIN NURS, V27, P4239, DOI 10.1111/jocn.14504; Specht K, 2016, J CLIN NURS, V25, P836, DOI 10.1111/jocn.13121; The Beryl Institute Website, DEF PAT EXP; Thorne S E, 2000, Annu Rev Nurs Res, V18, P3; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Trbovich P, 2019, BMJ QUAL SAF, V28, P169, DOI 10.1136/bmjqs-2018-008485; Tsianakas V, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-271; van der Meide H, 2015, MED HEALTH CARE PHIL, V18, P577, DOI 10.1007/s11019-015-9621-1; van der Meide H, 2013, MED HEALTH CARE PHIL, V16, P731, DOI 10.1007/s11019-012-9456-y; Webster CS, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027258; Wolf J.A., 2014, PATIENT EXPERIENCE J, V1, P7, DOI [10.35680/2372-0247.1004, DOI 10.35680/2372-0247.1004]; Yanes AF, 2016, BMJ QUAL SAF, V25, P46, DOI 10.1136/bmjqs-2015-004171; Ziebland S, 2013, UNDERSTANDING USING	49	16	16	4	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2019	14	12							e0224899	10.1371/journal.pone.0224899	http://dx.doi.org/10.1371/journal.pone.0224899			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP0JY	31805061	Green Published, gold			2023-01-03	WOS:000534009700012
J	Chun, YJ; Choi, JW; Hong, MH; Jung, D; Son, H; Cho, EK; Min, YJ; Kim, SW; Park, K; Lee, SS; Kim, S; Kim, HR; Cho, BC				Chun, You Jin; Choi, Jae Woo; Hong, Min Hee; Jung, Dongmin; Son, Hyeonju; Cho, Eun Kyung; Min, Young Joo; Kim, Sang-We; Park, Keunchil; Lee, Sung Sook; Kim, Sangwoo; Kim, Hye Ryun; Cho, Byoung Chul		Korean Lung Canc Consortium	Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing	PLOS ONE			English	Article							CLINICAL INTERPRETATION; TARGETED THERAPY; CANCER; MUTATIONS; VARIANTS; PATHWAYS	The treatment of Lung adenocarcinoma (LUAD) could benefit from the incorporation of precision medicine. This study was to identify cancer-related genetic alterations by next generation sequencing (NGS) in resected LUAD samples from Korean patients and to determine their associations with clinical features. A total of 201 tumors and their matched peripheral blood samples were analyzed using targeted sequencing via the Illumina HiSeq 2500 platform of 242 genes with a median depth of coverage greater than 500X. One hundred ninetytwo tumors were amenable to data analysis. EGFR was the most frequently mutated gene, occurring in 106 (55%) patients, followed by TP53 (n = 67, 35%) and KRAS (n = 11, 6%). EGFR mutations were strongly increased in patients that were female and never-smokers. Smokers had a significantly higher tumor mutational burden (TMB) than never-smokers (average 4.84 non-synonymous mutations/megabase [mt/Mb] vs. 2.84 mt/Mb, p = 0.019). Somatic mutations of APC, CTNNB1, and AMER1 in the WNT signaling pathway were highly associated with shortened disease-free survival (DFS) compared to others (median DFS of 89 vs. 27 months, p = 0.018). Patients with low TMB, annotated as less than 2 mt/Mb, had longer DFS than those with high TMB (p = 0.041). A higher frequency of EGFR mutations and a lower of KRAS mutations were observed in Korean LUAD patients. Profiles of 242 genes mapped in this study were compared with whole exome sequencing genetic profiles generated in The Cancer Genome Atlas Lung Adenocarcinoma. NGS-based diagnostics can provide clinically relevant information such as mutations or TMB from readily available formalin-fixed paraffin-embedded tissue.	[Chun, You Jin; Hong, Min Hee; Kim, Hye Ryun; Cho, Byoung Chul] Yonsei Univ, Yonsei Canc Ctr, Dept Internal Med, Div Med Oncol,Coll Med, Seoul, South Korea; [Choi, Jae Woo; Jung, Dongmin] Yonsei Univ, Severance Biomed Sci Inst, Coll Med, Seoul, South Korea; [Choi, Jae Woo] Yonsei Univ, Dept Pharmacol, Coll Med, Seoul, South Korea; [Son, Hyeonju; Kim, Sangwoo] Yonsei Univ, Coll Med, Brain Korea 21 Plus Project Med Sci, Dept Biomed Syst Informat, Seoul, South Korea; [Cho, Eun Kyung] Gil Med Ctr, Gachon Med Sch, Dept Internal Med, Div Hematol Oncol, Incheon, South Korea; [Min, Young Joo] Univ Ulsan, Ulsan Univ Hosp, Dept Internal Med, Div Hematol & Oncol,Coll Med, Ulsan, South Korea; [Kim, Sang-We] Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea; [Park, Keunchil] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea; [Lee, Sung Sook] Inje Univ, Dept Hematol Oncol, Haeundae Paik Hosp, Busan, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Gachon University; University of Ulsan; Ulsan University Hospital; University of Ulsan; Asan Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Inje University	Kim, HR; Cho, BC (corresponding author), Yonsei Univ, Yonsei Canc Ctr, Dept Internal Med, Div Med Oncol,Coll Med, Seoul, South Korea.; Kim, S (corresponding author), Yonsei Univ, Coll Med, Brain Korea 21 Plus Project Med Sci, Dept Biomed Syst Informat, Seoul, South Korea.	SWKIM@yuhs.ac; nobelg@yuhs.ac; cbc1971@yuhs.ac	Park, Keunchil/ABD-7072-2021; Park, Keunchil/ABD-5852-2021	Park, Keunchil/0000-0002-4846-7449; Choi, Jae Woo/0000-0001-5741-8748; Cho, Byoung Chul/0000-0002-5562-270X; Hong, Min Hee/0000-0003-3490-2195; Kim, Sangwoo/0000-0001-5356-0827	Korean Lung Cancer Consortium (KLCC); Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning [2016R1A2B3016282]	Korean Lung Cancer Consortium (KLCC); Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning	This study was supported in part by Korean Lung Cancer Consortium (KLCC) and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2016R1A2B3016282 to B.C. Cho). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn JW, 2014, GENOME MED, V6, DOI 10.1186/gm535; Bahceci I, 2017, BIOINFORMATICS, V33, P2238, DOI 10.1093/bioinformatics/btx149; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan BA, 2015, TRANSL LUNG CANCER R, V4, P36, DOI 10.3978/j.issn.2218-6751.2014.05.01; Choi YW, 2018, AM J CLIN ONCOL-CANC, V41, P385, DOI 10.1097/COC.0000000000000282; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Consonni D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203539; Costello M, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks1443; Dearden S, 2013, ANN ONCOL, V24, P2371, DOI 10.1093/annonc/mdt205; Devarakonda S, 2018, J CLIN ONCOL, V36, P2995, DOI 10.1200/JCO.2018.78.1963; Douville C, 2013, BIOINFORMATICS, V29, P647, DOI 10.1093/bioinformatics/btt017; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Griffith M, 2017, NAT GENET, V49, P170, DOI 10.1038/ng.3774; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jin ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102685; Joshi N, 2011, SICKLE SLIDING WINDO; LACKNER N, 2018, ARCHAEA, V2018, DOI DOI 10.1101/366856; Lamichhane DK, 2017, YONSEI MED J, V58, P1111, DOI [10.3349/ymj.2017.5, 10.3349/ymj.2017.58.6.1111]; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li SY, 2016, J THORAC ONCOL, V11, P2129, DOI 10.1016/j.jtho.2016.08.142; Lim SM, 2016, ONCOTARGET, V7, P36311, DOI 10.18632/oncotarget.8904; Luo WX, 2018, INT J CANCER, V143, P1696, DOI 10.1002/ijc.31542; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mayakonda A, 2018, GENOME RES, V28, P1747, DOI 10.1101/gr.239244.118; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Narzisi G, 2014, NAT METHODS, V11, P1033, DOI [10.1038/NMETH.3069, 10.1038/nmeth.3069]; Oliveros J.C., 2007, INTERACTIVE TOOL COM; Owada-Ozaki Y, 2018, J THORAC ONCOL, V13, P1217, DOI 10.1016/j.jtho.2018.04.003; Rapp J, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0650-6; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Soo RA, 2012, FUTURE ONCOL, V8, P451, DOI [10.2217/FON.12.25, 10.2217/fon.12.25]; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Talevich E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004873; Tamborero D, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0531-8; Tsimberidou AM, 2015, CANCER CHEMOTH PHARM, V76, P1113, DOI 10.1007/s00280-015-2861-1; Van Allen EM, 2014, NAT MED, V20, P682, DOI 10.1038/nm.3559; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603	40	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 25	2019	14	11							e0224379	10.1371/journal.pone.0224379	http://dx.doi.org/10.1371/journal.pone.0224379			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO8QR	31765373	gold, Green Published			2023-01-03	WOS:000533891000008
J	Liu, ZW; Yu, Y; Fang, L; Hu, M; Zhou, L; Xiao, SY				Liu, Zi-Wei; Yu, Yu; Fang, Liang; Hu, Mi; Zhou, Liang; Xiao, Shui-Yuan			Willingness to receive institutional and community-based eldercare among the rural elderly in China	PLOS ONE			English	Article							PEOPLE	Studies on the willingness to receive institutional eldercare among the rural elderly are scarce. This study aims to explore factors associated with the willingness to receive institutional eldercare and community-based eldercare among the rural elderly. A cross-sectional study was conducted in three rural villages of Changde City, Hunan Province, China. A total of 517 elderly were recruited through multistage sampling from these villages. The dependent variable is the willingness to receive eldercare from family (as reference), institution, and community. The independent variables includes sociodemographic characteristics: having physical disease, depression, anxiety, and daily living activities, and concerns toward home-based, institutional, and community-based care, respectively. Results show that 78.3% of the elderly are willing to receive home-based eldercare, 10.8% institutional eldercare, and 8.5% community-based eldercare. The factors associated with the willingness to receive institutional eldercare are having concerns toward home-based (OR = 4.85, P<0.001) and institutional eldercare (OR = 5.51, P<0.001). The factors associated with community-based care is living alone (OR = 2.18, P = 0.034). Finally, the major concerns toward home-based eldercare are lack of care ability and separation of family members, whereas those toward institutional eldercare are unaffordable services and fear of being abandoned by the children. The major concerns toward community-based eldercare includes affordability and lack of necessary services. In summary, elderly having concerns toward home-based care and having no concerns about institutional care are willing to accept institutional eldercare. Elderly who are living alone is tend to accept community-based care. Unaffordable services and loss of contact with family members are the major concerns of institutional eldercare. Aside from the cost, the lack of necessary care services is also a serious concern of community-based eldercare.	[Liu, Zi-Wei; Fang, Liang; Hu, Mi; Xiao, Shui-Yuan] Cent South Univ, Xiangya Sch Publ Hlth, Dept Social Med & Hlth Management, Changsha, Hunan, Peoples R China; [Liu, Zi-Wei] Cent South Univ, Xiangya Hosp 2, Natl Clin Res Ctr Mental Disorders, Mental Hlth Inst, Changsha, Hunan, Peoples R China; [Liu, Zi-Wei] Natl Technol Inst Mental Disorders, Hunan Key Lab Psychiat & Mental Hlth, Changsha, Hunan, Peoples R China; [Yu, Yu] Cent South Univ, Hosp Evaluat Off, Xiangya Hosp, Changsha, Hunan, Peoples R China; [Zhou, Liang] Guangzhou Med Univ, Guangzhou Huiai Hosp, Affiliated Brain Hosp, Guangzhou, Peoples R China	Central South University; Central South University; Central South University; Guangzhou Medical University	Xiao, SY (corresponding author), Cent South Univ, Xiangya Sch Publ Hlth, Dept Social Med & Hlth Management, Changsha, Hunan, Peoples R China.	xiaosy@csu.edu.cn	ZHOU, LIANG/AAG-7587-2020	ZHOU, LIANG/0000-0003-3207-7419				BJELKEVIG C, 2010, SHANGHAI ARCH PSYCHI, V22, DOI DOI 10.1088/0953-8984/22/30/302002; Chen L, 2016, J AGING SOC POLICY, V28, P292, DOI 10.1080/08959420.2016.1151310; Gong X., 2012, QIU YI WEN YAO, V10, P852; [黄晓玲 Huang Xiaoling], 2017, [中国卫生统计, Chinese Journal of Health Statistics], V34, P729; Keimig R, 2017, J AGING SOC POLICY, V29, P461, DOI 10.1080/08959420.2017.1364082; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Li H, 2017, J AGING SOC POLICY, V29, P182, DOI 10.1080/08959420.2016.1220229; [李振华 Li Zhenhua], 2011, [中国临床心理学杂志, Chinese Journal of Clinical Psychology], V19, P171; Luo MY, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021741; Martikainen P, 2009, GERONTOLOGIST, V49, P34, DOI 10.1093/geront/gnp013; Ministry of Civil Affairs of the People's Republic of China, 2016, 4 SAMPL SURV LIV CON; Ministry of Civil Affairs of the People's Republic of China, 2006, 5 GUARANT GRANT FARM; Mo Y, 2017, J EDUC EVAL HEALTH P, V14, DOI 10.3352/jeehp.2017.14.22; National Bureau of Statistics of the People's Republic of China, 2014, STAT B NAT EC SOC DE; National Health Commission of the People's Repulic of China, 2015, REP FAM DEV CHIN; Peng H., 2007, RES DUALISTIC STRUCT; State Council of the People's Republic of China, 2009, GID STAT COUNC LAUNC; Wild B, 2014, AM J GERIAT PSYCHIAT, V22, P1029, DOI 10.1016/j.jagp.2013.01.076; Xing YA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020225; Zeng Y, 2012, CHINA ECON J, V5, P131, DOI 10.1080/17538963.2013.764677; Zhan Heying J, 2006, J Aging Soc Policy, V18, P85, DOI 10.1300/J031v18n02_06	21	10	10	13	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 22	2019	14	11							e0225314	10.1371/journal.pone.0225314	http://dx.doi.org/10.1371/journal.pone.0225314			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LO8QA	31756228	Green Published, gold			2023-01-03	WOS:000533889300018
J	Jordan, S; Davies, GI; Thayer, DS; Tucker, D; Humphreys, I				Jordan, Sue; Davies, Gareth I.; Thayer, Daniel S.; Tucker, David; Humphreys, Ioan			Antidepressant prescriptions, discontinuation, depression and perinatal outcomes, including breastfeeding: A population cohort analysis	PLOS ONE			English	Article							SEROTONIN-REUPTAKE INHIBITORS; PERSISTENT PULMONARY-HYPERTENSION; LOW-BIRTH-WEIGHT; PRETERM BIRTH; MATERNAL DEPRESSION; PREGNANCY; RISK; EXPOSURE; METAANALYSIS; WOMEN	Objectives To explore associations between exposure to antidepressants, their discontinuation, depression [medicated or unmediated] and preterm birth [< 37 and < 32 weeks], small for gestational age (SGA) [< 10th and < 3rd centiles], breastfeeding [any] at 6-8 weeks. Methods Design: A population-based cohort study. Setting: The Secure Anonymised Information Linkage [SAIL] databank in Wales, linking maternal primary care data with infant outcomes. Participants: 107,573, 105,331, and 38,725 infants born 2000-2010 with information on prematurity, SGA and breastfeeding respectively, after exclusions. Exposures: Maternal antidepressant prescriptions in trimesters 2 or 3, discontinuation after trimester 1, recorded diagnosis of depression [medicated or unmediated] in pregnancy. Methods: Odds ratios for adverse pregnancy outcomes were calculated, adjusted for smoking, parity, socio-economic status, and depression. Results Exclusive formula feeding at 6-8 weeks was associated with prescriptions in trimesters 2 or 3 for any antidepressants (adjusted odds ratio [aOR] 0.81, 95% confidence intervals 0.67-0.98), SSRIs [aOR 0.77, 0.62-0.95], particularly higher doses [aOR 0.45, 0.23-0.86], discontinuation of antidepressants or SSRIs after trimester 1 (aOR 0.70, 0.57-0.83 and 0.66, 0.51-0.87), diagnosis of depression aOR 0.76 [0.70-0.82), particularly if medicated (aOR 0.70, 0.58-0.85), rather than unmedicated (aOR 0.87, 0.82-0.92). Preterm birth at < 37 and < 32 weeks' gestation was associated with diagnosis of depression (aOR 1.27, 1.17-1.38, and 1.33, 1.09-1.62), particularly if medicated (aOR 1.56, 1.23-1.96, and 1.63, 0.94-2.84); birth at < 37 weeks was associated with antidepressants, (aOR 1.24, 1.04-1.49]. SGA < 3rd centile was associated with antidepressants (aOR 1.43, 1.07-1.90), and SSRIs (aOR 1.46, 1.06-2.00], particularly higher doses [aOR 2.10, 1.32-3.34]. All adverse outcomes were associated with socio-economic status and smoking.	[Jordan, Sue; Tucker, David; Humphreys, Ioan] Swansea Univ, Coll Human & Hlth Sci, Swansea, W Glam, Wales; [Davies, Gareth I.; Thayer, Daniel S.] Swansea Univ, Sch Med, Swansea, W Glam, Wales; [Tucker, David] Publ Hlth Wales, Cardiff, Wales	Swansea University; Swansea University	Jordan, S (corresponding author), Swansea Univ, Coll Human & Hlth Sci, Swansea, W Glam, Wales.	s.e.jordan@swansea.ac.uk		Thayer, Dan/0000-0003-1847-4362; Davies, Gareth/0000-0001-9005-1618; jordan, sue/0000-0002-5691-2987	European Union [HEALTH-F5-2011-260598]; UK Research and Innovation funding through an Administrative Data Research Centre grant (2018-2921) [ES/S007393/1]	European Union(European Commission); UK Research and Innovation funding through an Administrative Data Research Centre grant (2018-2921)	This paper was developed from the EUROmediCAT project, and uses the cohort identified in that project. The analyses presented here were completed outside the funded period. Financial support for the EUROmediCAT study was provided by the European Union under the 7th Framework Program [grant agreement HEALTH-F5-2011-260598]. Start date: 1 March 2011. Duration: 48 months. Coordinator Prof. Helen Dolk, University of Ulster. Further information can be found at www.euromedicat.eu The paper is based on data in the all-Wales SAIL databank, which is supported by UK Research and Innovation funding to Swansea University through an Administrative Data Research Centre grant (2018-2921), project reference: ES/S007393/1, Principal Investigator: Professor David Ford.; This study uses anonymised data held in the Secure Anonymised Information Linkage [SAIL] system, which is part of the national e-health records research infrastructure for Wales. We should like to acknowledge all the data providers who make anonymised data available for research. Data held in SAIL databases are anonymised and aggregated and have been obtained with permission of relevant Data Protection Officers, as approved by the National Research Ethics Service, Wales. Under this agreement, disclosure of numbers <5 is not permitted. The project was approved by the SAIL Information Governance Review Panel [IGFRP] on 24th March 2011. Since the project uses only anonymised data, ethical review was deemed unnecessary.	Alwan S, 2016, CNS DRUGS, V30, P499, DOI 10.1007/s40263-016-0338-3; Amick HR, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6019; Angermeyer MC, 2014, SOC SCI MED, V103, P60, DOI 10.1016/j.socscimed.2013.11.014; Bennett HA, 2004, OBSTET GYNECOL, V103, P698, DOI 10.1097/01.AOG.0000116689.75396.5f; Bogen DL, 2010, J CLIN PSYCHIAT, V71, P1069, DOI 10.4088/JCP.09m05383blu; Casson IF, 1997, BRIT MED J, V315, P275, DOI 10.1136/bmj.315.7103.275; Chambers CD, 2006, NEW ENGL J MED, V354, P579, DOI 10.1056/NEJMoa052744; Chambers CD, 1996, NEW ENGL J MED, V335, P1010, DOI 10.1056/NEJM199610033351402; Charlton RA, 2015, BJOG-INT J OBSTET GY, V122, P1010, DOI 10.1111/1471-0528.13143; CHISHOLM J, 1990, BRIT MED J, V300, P1092, DOI 10.1136/bmj.300.6732.1092; Christiaens I, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0353-0; Cohen LS, 2006, JAMA-J AM MED ASSOC, V295, P499, DOI 10.1001/jama.295.5.499; Cooper DL, 2013, J EPIDEMIOL COMMUN H, V67, P821, DOI 10.1136/jech-2012-202303; Cooper WO, 2007, AM J OBSTET GYNECOL, V196, P544, DOI 10.1016/j.ajog.2007.01.033; Daws LC, 2011, PHARMACOL THERAPEUT, V131, P61, DOI 10.1016/j.pharmthera.2011.03.013; De Vera MA, 2012, BRIT J CLIN PHARMACO, V74, P362, DOI 10.1111/j.1365-2125.2012.04196.x; Delpisheh A, 2007, PUBLIC HEALTH, V121, P861, DOI 10.1016/j.puhe.2007.03.015; Eke AC, 2016, BJOG-INT J OBSTET GY, V123, P1900, DOI 10.1111/1471-0528.14144; EUROCAT EUROCAT, 2013, GUID 1 4 EUROCAT CEN; EUROmediCAT. [EMC], 2015, SEL SER REUPT INH SS; Fewell Z, 2007, AM J EPIDEMIOL, V166, P646, DOI 10.1093/aje/kwm165; Ford DV, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-157; Galbally M, 2019, J HUM LACT, V35, P127, DOI 10.1177/0890334418758658; Gavin NI, 2005, OBSTET GYNECOL, V106, P1071, DOI 10.1097/01.AOG.0000183597.31630.db; Gemmel M, 2018, NEUROSCI BIOBEHAV R, V85, P102, DOI 10.1016/j.neubiorev.2017.04.023; Gentile S, 2017, J MATERN-FETAL NEO M, V30, P1189, DOI 10.1080/14767058.2016.1209184; Grigoriadis S, 2013, J CLIN PSYCHIAT, V74, pE321, DOI 10.4088/JCP.12r07968; Grote NK, 2010, ARCH GEN PSYCHIAT, V67, P1012, DOI 10.1001/archgenpsychiatry.2010.111; Handal M, 2016, BJOG-INT J OBSTET GY, V123, P1908, DOI 10.1111/1471-0528.13582; Hannerfors AK, TREATMENT SEROTONIN; Hendrick V, 2003, AM J PSYCHIAT, V160, P993, DOI 10.1176/appi.ajp.160.5.993; Hiemke C, 2000, PHARMACOL THERAPEUT, V85, P11, DOI 10.1016/S0163-7258(99)00048-0; Hilli J, 2009, EUR NEUROPSYCHOPHARM, V19, P363, DOI 10.1016/j.euroneuro.2009.01.006; Huang H, 2014, GEN HOSP PSYCHIAT, V36, P13, DOI 10.1016/j.genhosppsych.2013.08.002; Huybrechts KF, 2015, JAMA-J AM MED ASSOC, V314, P1294, DOI 10.1001/jama.2015.10048; Ibm Corp, 2011, IBM SPSS STAT WIND V; ICH, 1996, ICH HARM TRIP GUID G; Jefferies AL, 2011, PAED CHILD HEALT-CAN, V16, P562, DOI 10.1093/pch/16.9.562; Jordan S, 2005, BJOG-INT J OBSTET GY, V112, P927, DOI 10.1111/j.1471-0528.2005.00548.x; Jordan S, 2009, BJOG-INT J OBSTET GY, V116, P1622, DOI 10.1111/j.1471-0528.2009.02256.x; Jordan S., 2015, ARCH WOMEN MENT HLTH, V18, P269, DOI [10.1007/S00737-014-0488-6, DOI 10.1007/S00737-014-0488-6]; Jordan S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165122; Jordan S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067912; Kaihola H, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00160; Kendall-Tackett K, 2010, J HUM LACT, V26, P187, DOI 10.1177/0890334409342071; Kendrick T, 2005, BRIT J GEN PRACT, V55, P280; Kozuki N, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-S3-S2; Laine K, 2003, ARCH GEN PSYCHIAT, V60, P720, DOI 10.1001/archpsyc.60.7.720; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Leggett C, 2017, J HUM LACT, V33, P701, DOI 10.1177/0890334416678209; Lyons RA, 2009, BMC MED INFORM DECIS, V9, DOI 10.1186/1472-6947-9-3; Malin GL, 2015, BJOG-INT J OBSTET GY, V122, P634, DOI 10.1111/1471-0528.13282; Malm H, 2015, AM J PSYCHIAT, V172, P1224, DOI 10.1176/appi.ajp.2015.14121575; Marshall AM, 2010, J CLIN ENDOCR METAB, V95, P837, DOI 10.1210/jc.2009-1575; Martins ACM, 2014, J CLIN PHARM THER, V39, P609, DOI 10.1111/jcpt.12204; Maschi S, 2008, BJOG-INT J OBSTET GY, V115, P283, DOI 10.1111/j.1471-0528.2007.01518.x; McAndrew F., 2012, INFANT FEEDING SURVE; McIntire DD, 1999, NEW ENGL J MED, V340, P1234, DOI 10.1056/NEJM199904223401603; McManus S, ADULT PSYCHIAT 2009; Merlob P., 2015, DRUGS PREGNANCY, VLactation, P743, DOI [10.1016/B978-0-12-408078-2.00034-2, DOI 10.1016/B978-0-12-408078-2.00034-2]; Miquel-Verges F, 2015, J PERINATOL, V35, P198, DOI 10.1038/jp.2014.180; Mitchell J, 2018, ARCH WOMEN MENT HLTH, V21, P505, DOI 10.1007/s00737-018-0844-z; Molenaar NM, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0752-6; Morrow J, 2006, J NEUROL NEUROSUR PS, V77, P193, DOI 10.1136/jnnp.2005.074203; NCCMH. [National Collaborating Centre for Mental Health] Antenatal and postnatal mental health: Clinical management and service guidance updated edition, 2014, ANT POSTN MENT HLTH; Nikfar S, 2012, DARU, V20, DOI 10.1186/2008-2231-20-75; Olivier JDA, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00073; Pearlstein T, 2015, BEST PRACT RES CL OB, V29, P754, DOI 10.1016/j.bpobgyn.2015.04.004; Purisch SE, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.06.089; Ray S, 2014, BEST PRACT RES CL OB, V28, P71, DOI 10.1016/j.bpobgyn.2013.09.005; Reefhuis J, 2006, NEW ENGL J MED, V354, P2188; Robinson D, 1997, J AM MED INFORM ASSN, V4, P465, DOI 10.1136/jamia.1997.0040465; Ross LE, 2013, JAMA PSYCHIAT, V70, P436, DOI 10.1001/jamapsychiatry.2013.684; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Royston P, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b604; Saha MR, 2015, INT BREASTFEED J, V10, DOI 10.1186/s13006-015-0053-6; Saigal S, 2008, LANCET, V371, P261, DOI 10.1016/S0140-6736(08)60136-1; Salisbury AL, 2009, CLIN PERINATOL, V36, P595, DOI 10.1016/j.clp.2009.06.002; Sillesen M, 2011, EUR J CARDIO-THORAC, V40, P448, DOI 10.1016/j.ejcts.2010.12.011; Sockol LE, 2015, J AFFECT DISORDERS, V177, P7, DOI 10.1016/j.jad.2015.01.052; Statistics Wales Birth Statistics from the National Community Child Health Database [NCCHD], 2013, QUAL REP; 't Jong GW, 2012, REPROD TOXICOL, V34, P293, DOI 10.1016/j.reprotox.2012.04.015; Tak CR, 2017, EUR J CLIN PHARMACOL, V73, P1055, DOI 10.1007/s00228-017-2269-4; Taylor D, 2015, FROM THE CAM TO THE ZAMBEZI: COLONIAL SERVICE AND THE PATH TO THE NEW ZAMBIA, P1; The European Network for Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), EMA950982010; Toh S, 2009, J CLIN PSYCHOPHARM, V29, P555, DOI 10.1097/JCP.0b013e3181bf344c; Toh S, 2009, AM J PSYCHIAT, V166, P320, DOI 10.1176/appi.ajp.2008.08060817; Townsend PP., 1988, HLTH DEPRIVATION INE; Velasquez JC, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00047; Venkatesh KK, 2017, J PERINATOL, V37, P1003, DOI 10.1038/jp.2017.92; Victora CG, 2016, LANCET, V387, P475, DOI 10.1016/S0140-6736(15)01024-7; Viktorin A, 2016, AM J PSYCHIAT, V173, P158, DOI 10.1176/appi.ajp.2015.15010085; Wadhwa PD, 2011, CLIN PERINATOL, V38, P351, DOI 10.1016/j.clp.2011.06.007; Weightman AL, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000964; Willner P, 2013, NEUROSCI BIOBEHAV R, V37, P2331, DOI 10.1016/j.neubiorev.2012.12.007; Yonkers KA, 2009, GEN HOSP PSYCHIAT, V31, P403, DOI [10.1097/AOG.0b013e3181ba0632, 10.1016/j.genhosppsych.2009.04.003]; Zhao XF, 2018, J AFFECT DISORDERS, V241, P563, DOI 10.1016/j.jad.2018.08.061	97	12	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2019	14	11							e0225133	10.1371/journal.pone.0225133	http://dx.doi.org/10.1371/journal.pone.0225133			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LN3EY	31738813	gold, Green Published			2023-01-03	WOS:000532826300036
J	Francois, B; Cariou, A; Clere-Jehl, R; Dequin, PF; Renon-Carron, F; Daix, T; Guitton, C; Deye, N; Legriel, S; Plantefeve, G; Quenot, JP; Desachy, A; Kamel, T; Bedon-Carte, S; Diehl, JL; Chudeau, N; Karam, E; Durand-Zaleski, I; Giraudeau, B; Vignon, P; Le Gouge, A				Francois, B.; Cariou, A.; Clere-Jehl, R.; Dequin, P. -F.; Renon-Carron, F.; Daix, T.; Guitton, C.; Deye, N.; Legriel, S.; Plantefeve, G.; Quenot, J. -P.; Desachy, A.; Kamel, T.; Bedon-Carte, S.; Diehl, J. -L.; Chudeau, N.; Karam, E.; Durand-Zaleski, I.; Giraudeau, B.; Vignon, P.; Le Gouge, A.		CRICS-TRIGGERSEP Network ANTHARTIC	Prevention of Early Ventilator-Associated Pneumonia after Cardiac Arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EARLY-ONSET PNEUMONIA; THERAPEUTIC HYPOTHERMIA; CARDIOPULMONARY-RESUSCITATION; INFECTIOUS COMPLICATIONS; COMATOSE SURVIVORS; CARE; ANTIBIOTICS; MORTALITY; DIAGNOSIS; IMPROVE	Patients treated with targeted temperature management (32 to 34 degrees C) after cardiac arrest are at increased risk for early ventilator-associated pneumonia. In this multicenter trial, intravenous amoxicillin-clavulanate for 48 hours after cardiac arrest resulted in a lower incidence of early ventilator-associated pneumonia than placebo but did not affect ventilator-free days or mortality at day 28. Background Patients who are treated with targeted temperature management after out-of-hospital cardiac arrest with shockable rhythm are at increased risk for ventilator-associated pneumonia. The benefit of preventive short-term antibiotic therapy has not been shown. Methods We conducted a multicenter, double-blind, randomized, placebo-controlled trial involving adult patients (>18 years of age) in intensive care units (ICUs) who were being mechanically ventilated after out-of-hospital cardiac arrest related to initial shockable rhythm and treated with targeted temperature management at 32 to 34 degrees C. Patients with ongoing antibiotic therapy, chronic colonization with multidrug-resistant bacteria, or moribund status were excluded. Either intravenous amoxicillin-clavulanate (at doses of 1 g and 200 mg, respectively) or placebo was administered three times a day for 2 days, starting less than 6 hours after the cardiac arrest. The primary outcome was early ventilator-associated pneumonia (during the first 7 days of hospitalization). An independent adjudication committee determined diagnoses of ventilator-associated pneumonia. Results A total of 198 patients underwent randomization, and 194 were included in the analysis. After adjudication, 60 cases of ventilator-associated pneumonia were confirmed, including 51 of early ventilator-associated pneumonia. The incidence of early ventilator-associated pneumonia was lower with antibiotic prophylaxis than with placebo (19 patients [19%] vs. 32 [34%]; hazard ratio, 0.53; 95% confidence interval, 0.31 to 0.92; P=0.03). No significant differences between the antibiotic group and the control group were observed with respect to the incidence of late ventilator-associated pneumonia (4% and 5%, respectively), the number of ventilator-free days (21 days and 19 days), ICU length of stay (5 days and 8 days if patients were discharged and 7 days and 7 days if patients had died), and mortality at day 28 (41% and 37%). At day 7, no increase in resistant bacteria was identified. Serious adverse events did not differ significantly between the two groups. Conclusions A 2-day course of antibiotic therapy with amoxicillin-clavulanate in patients receiving a 32-to-34 degrees C targeted temperature management strategy after out-of-hospital cardiac arrest with initial shockable rhythm resulted in a lower incidence of early ventilator-associated pneumonia than placebo. No significant between-group differences were observed for other key clinical variables, such as ventilator-free days and mortality at day 28. (Funded by the French Ministry of Health; ANTHARTIC ClinicalTrials.gov number, NCT02186951.)	[Francois, B.; Daix, T.; Vignon, P.] CHU Dupuytren, Reanimat Polyvalente, Limoges, France; [Francois, B.; Daix, T.; Vignon, P.] CHU Dupuytren, INSERM, CIC 1435, Limoges, France; [Renon-Carron, F.] CHU Dupuytren, Pharm Usage Interieur, Unite Essais Clin, Limoges, France; [Francois, B.; Daix, T.; Vignon, P.] Univ Limoges, INSERM, Fac Med, UMR 1092, Limoges, France; [Cariou, A.] Hop Univ Paris Ctr Site Cochin, AP HP, Med Intens & Reanimat, Paris, France; [Cariou, A.] Univ Paris 05, Paris, France; [Deye, N.] CHU Lariboisiere, Reanimat Med, AP HP, Paris, France; [Deye, N.] Univ Paris Diderot, INSERM, UMR S942, Paris, France; [Diehl, J. -L.] Hop Europeen Georges Pompidou, AP HP, Reanimat Med, Paris, France; [Diehl, J. -L.] Univ Paris 05, INSERM, UMR S1140, Paris, France; [Durand-Zaleski, I.] AP HP, Unite Rech Clin Econ Sante Ile France, Paris, France; [Durand-Zaleski, I.] Hop Henri Mondor, Paris, France; [Clere-Jehl, R.] Univ Strasbourg, Hop Univ Strasbourg, Nouvel Hop Civil, Fac Med,Serv Reanimat, Strasbourg, France; [Dequin, P. -F.] CHU Bretonneau, Med Intens Reanimat, Tours, France; [Dequin, P. -F.] CHU Bretonneau, INSERM, U1100, Tours, France; [Giraudeau, B.; Le Gouge, A.] CHU Tours, INSERM, CIC 1415, Tours, France; [Guitton, C.] CHU Nantes, Med Intens & Reanimat, Nantes, France; [Guitton, C.] Univ Nantes, INSERM, Ctr Rech Transplantat & Immunol, UMR 1064, Nantes, France; [Guitton, C.; Chudeau, N.] Ctr Hosp Mans, Reanimat Med Chirurg, Le Mans, France; [Legriel, S.] Ctr Hosp Andre Mignot, Reanimat Med Chirurg, Versailles, France; [Plantefeve, G.] Ctr Hosp Victor Dupouy, Reanimat Polyvalente, Argenteuil, France; [Quenot, J. -P.] Univ Bourgogne, CHU Francois Mitterrand, Med Intens & Reanimat,Lipness Team, Ctr Rech,INSERM Lipides,Nutr,Canc UMR 1231, Dijon, France; [Quenot, J. -P.] Univ Bourgogne, Epidemiol Clin, INSERM, CIC 1432, Dijon, France; [Desachy, A.] Ctr Hosp Angouleme, Reanimat Polyvalente, Angouleme, France; [Kamel, T.] Ctr Hosp Reg Orleans, Med Intens & Reanimat, Orleans, France; [Bedon-Carte, S.] Ctr Hosp Perigueux, Reanimat Polyvalente, Perigueux, France; [Karam, E.] Ctr Hosp, Reanimat Polyvalente, Brive La Gaillarde, France	CHU Limoges; CHU Limoges; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Limoges; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Limoges; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Tours; CHU Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Centre Hospitalier Le Mans; Centre Hospitalier de Versailles; CHU Dijon Bourgogne; Institut Agro; AgroSup Dijon; Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Centre Hospitalier Regional d'Orleans	Francois, B (corresponding author), CHU Dupuytren, Reanimat Polyvalente, Limoges, France.; Francois, B (corresponding author), CHU Dupuytren, INSERM, CIC 1435, Limoges, France.; Francois, B (corresponding author), Univ Limoges, INSERM, Fac Med, UMR 1092, Limoges, France.	b.francois@unilim.fr	Vignon, Philippe/O-8886-2016; Giraudeau, Bruno/L-9003-2015; Jacob, Aude/ABA-6265-2020; Chiche, Jean-Daniel/P-5220-2017; LEGRIEL, Stephane/J-1307-2017; Francois, Bruno/O-8404-2016	Vignon, Philippe/0000-0003-4551-5772; Giraudeau, Bruno/0000-0003-3031-8258; Chiche, Jean-Daniel/0000-0002-6433-6254; QUENOT, Jean-Pierre/0000-0003-2351-682X; LEGRIEL, Stephane/0000-0003-4782-6734; PETUA, Philippe/0000-0002-7993-0723; Francois, Bruno/0000-0002-2531-1652; Vodovar, Dominique/0000-0002-8196-5511; KAMEL, Toufik/0000-0001-6788-2544	Programme Hospitalier de Recherche Clinique National; French Ministry of Health	Programme Hospitalier de Recherche Clinique National; French Ministry of Health	Supported by Programme Hospitalier de Recherche Clinique National 2013, a call for proposal from the French Ministry of Health.	Acquarolo A, 2005, INTENS CARE MED, V31, P510, DOI 10.1007/s00134-005-2585-5; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; [Anonymous], 2010, GUID IND HOSP ACQ BA; Barc MC, 2004, ANTIMICROB AGENTS CH, V48, P1365, DOI 10.1128/AAC.48.4.1365-1368.2004; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Davies KJ, 2013, RESUSCITATION, V84, P616, DOI 10.1016/j.resuscitation.2012.11.004; De La Cochetiere MF, 2005, J CLIN MICROBIOL, V43, P5588, DOI 10.1128/JCM.43.11.5588-5592.2005; Dodek P, 2004, ANN INTERN MED, V141, P305, DOI 10.7326/0003-4819-141-4-200408170-00011; Fergusson D, 2002, BMJ-BRIT MED J, V325, P652, DOI 10.1136/bmj.325.7365.652; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Gagnon DJ, 2015, RESUSCITATION, V92, P154, DOI 10.1016/j.resuscitation.2015.01.035; Gajic O, 2004, RESUSCITATION, V60, P65, DOI 10.1016/j.resuscitation.2003.08.005; Geurts M, 2014, CRIT CARE MED, V42, P231, DOI 10.1097/CCM.0b013e3182a276e8; Hazinski MF, 2015, CIRCULATION, V132, pS2, DOI 10.1161/CIR.0000000000000270; Hellenkamp K, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1191-y; HODGES JL, 1963, ANN MATH STAT, V34, P598, DOI 10.1214/aoms/1177704172; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jakobsson HE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009836; Kakavas S, 2015, J INFECTION, V70, P553, DOI 10.1016/j.jinf.2015.01.012; Kitamura T, 2012, CIRCULATION, V126, P2834, DOI 10.1161/CIRCULATIONAHA.112.109496; Lemiale V, 2013, INTENS CARE MED, V39, P1972, DOI 10.1007/s00134-013-3043-4; Melsen WG, 2013, LANCET INFECT DIS, V13, P665, DOI 10.1016/S1473-3099(13)70081-1; Mongardon N, 2011, CRIT CARE MED, V39, P1359, DOI 10.1097/CCM.0b013e3182120b56; Myat A, 2018, LANCET, V391, P970, DOI 10.1016/S0140-6736(18)30472-0; Nair GB, 2015, INTENS CARE MED, V41, P34, DOI 10.1007/s00134-014-3564-5; Nguile-Makao M, 2010, INTENS CARE MED, V36, P781, DOI 10.1007/s00134-010-1824-6; Nielsen N, 2009, ACTA ANAESTH SCAND, V53, P926, DOI 10.1111/j.1399-6576.2009.02021.x; Pabst D, 2013, RESP CARE, V58, P1514, DOI 10.4187/respcare.02307; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Perbet S, 2011, AM J RESP CRIT CARE, V184, P1048, DOI 10.1164/rccm.201102-0331OC; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; PUGIN J, 1991, AM REV RESPIR DIS, V143, P1121, DOI 10.1164/ajrccm/143.5_Pt_1.1121; Ribaric SF, 2017, RESUSCITATION, V111, P103, DOI 10.1016/j.resuscitation.2016.11.025; Schulgen G, 2005, CONTEMP CLIN TRIALS, V26, P386, DOI 10.1016/j.cct.2005.01.010; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; Sullivan A, 2001, Lancet Infect Dis, V1, P101, DOI 10.1016/S1473-3099(01)00066-4; Torres A, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00582-2017; Torres A, 2014, INTENS CARE MED, V40, P1778, DOI 10.1007/s00134-014-3466-6; Valles J, 2013, CHEST, V143, P1219, DOI 10.1378/chest.12-1361; Zandstra DF, 2011, MINERVA ANESTESIOL, V77, P212	40	50	52	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 7	2019	381	19					1831	1842		10.1056/NEJMoa1812379	http://dx.doi.org/10.1056/NEJMoa1812379			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM5EW	31693806	Bronze			2023-01-03	WOS:000496238300008
J	Huang, YH; Lee, MEY; Lou, YS; Lai, HC; Yu, E; Lu, CEH; Wong, CS; Wu, ZF				Huang, Yi-Hsuan; Lee, Meei-Shyuan; Lou, Yu-Sheng; Lai, Hou-Chuan; Yu, Jyh-Cherng; Lu, Chueng-He; Wong, Chih-Shung; Wu, Zhi-Fu			Propofol-based total intravenous anesthesia did not improve survival compared to desflurane anesthesia in breast cancer surgery	PLOS ONE			English	Article							KILLER-CELL ACTIVITY; PREOPERATIVE CHEMOTHERAPY; TUMOR-METASTASIS; DOWN-REGULATION; RECURRENCE; VOLATILE; OUTCOMES; PATHWAY; SEVOFLURANE; SUPPRESSION	Background Breast cancer is the most common cancer in women and several perioperative factors may account for tumor recurrence and metastasis. The anesthetic agents employed during cancer surgery might play a crucial role in cancer cell survival and patient outcomes. We conducted a retrospective cohort study to investigate the relationship between the type of anesthesia and overall survival in patients who underwent breast cancer surgery performed by one experienced surgeon. Methods All patients who underwent breast cancer surgery by an experienced surgeon between January 2006 and December 2010 were included in this study. Patients were separated into two groups according to the use of desflurane or propofol anesthesia during surgery. Locoregional recurrence and overall survival rates were assessed for the two groups (desflurane or propofol anesthesia). Univariable and multivariable Cox regression models and propensity score matching analyses were used to compare the hazard ratios for death and adjust for potential confounders (age, body mass index, American Society of Anesthesiologists physical status classification, TNM stage, neoadjuvant chemotherapy, Charlson Comorbidity Index, anesthesiologists, and functional status). Results Of the 976 breast cancer patients, 632 patients underwent breast cancer surgery with desflurane anesthesia, while 344 received propofol anesthesia. After propensity scoring, 592 patients remained in the desflurane group and 296 patients in the propofol group. The mortality rate was similar in the desflurane (38 deaths, 4%) and propofol (22 deaths, 4%; p = 0.812) groups in 5-year follow-up. The crude hazard ratio (HR) for all patients was 1.13 (95% confidence interval [CI] 0.67-1.92, p = 0.646). No significant difference in the locoregional recurrence or overall 5-year survival rates were found after breast surgery using desflurane or propofol anesthesia (p = 0.454). Propensity score-matched analyses demonstrated similar outcomes in both groups. Patients who received propofol anesthesia had a higher mortality rate than those who received desflurane anesthesia in the matched groups (7% vs 6%, respectively) without significant difference (p = 0.561). In the propensity score-matched analyses, univariable analysis showed an insignificant finding (HR = 1.23, 95% CI 0.72-2.11, p = 0.449). After adjustment for the time since the earliest included patient, the HR remained insignificant (HR = 1.23, 95% CI 0.70-2.16, p = 0.475). Conclusion In our non-randomized retrospective analysis, neither propofol nor desflurane anesthesia for breast cancer surgery by an experienced surgeon can affect patient prognosis and survival. The influence of propofol anesthesia on breast cancer outcome requires further investigation.	[Huang, Yi-Hsuan; Lai, Hou-Chuan; Lu, Chueng-He; Wu, Zhi-Fu] Triserv Gen Hosp, Dept Anesthesiol, Taipei, Taiwan; [Huang, Yi-Hsuan; Lai, Hou-Chuan; Lu, Chueng-He; Wu, Zhi-Fu] Natl Def Med Ctr, Taipei, Taiwan; [Lee, Meei-Shyuan; Lou, Yu-Sheng] Natl Def Med Ctr, Sch Publ Hlth, Taipei, Taiwan; [Yu, Jyh-Cherng] Triserv Gen Hosp, Natl Def Med Ctr, Dept Surg, Div Gen Surg, Taipei, Taiwan; [Wong, Chih-Shung] Cathay Gen Hosp, Div Anesthesiol, Taipei, Taiwan; [Wu, Zhi-Fu] Chi Mei Med Ctr, Dept Anesthesiol, Tainan, Taiwan	Tri-Service General Hospital; National Defense Medical Center; National Defense Medical Center; National Defense Medical Center; Tri-Service General Hospital; Cathay General Hospital; Chi Mei Hospital	Wu, ZF (corresponding author), Triserv Gen Hosp, Dept Anesthesiol, Taipei, Taiwan.; Wu, ZF (corresponding author), Natl Def Med Ctr, Taipei, Taiwan.; Wu, ZF (corresponding author), Chi Mei Med Ctr, Dept Anesthesiol, Tainan, Taiwan.	aneswu@gmail.com	Wu, Zhi-Fu/ABE-6379-2020	Wu, Zhi-Fu/0000-0001-6376-9085	Tri-Service General Hospital, Taiwan, Republic of China [TSGH-C106-087]	Tri-Service General Hospital, Taiwan, Republic of China	This work was supported by grants from Tri-Service General Hospital (TSGH-C106-087), Taiwan, Republic of China.	AARTS L, 1995, FEBS LETT, V357, P83, DOI 10.1016/0014-5793(94)01337-Z; Alberro JA, 2018, LANCET ONCOL, V19, P27, DOI 10.1016/S1470-2045(17)30777-5; Beck-Schimmer B, 2008, ANN SURG, V248, P909, DOI 10.1097/SLA.0b013e31818f3dda; Benedetto U, 2018, EUR J CARDIO-THORAC, V53, P1112, DOI 10.1093/ejcts/ezy167; Benish M, 2008, ANN SURG ONCOL, V15, P2042, DOI 10.1245/s10434-008-9890-5; Benzonana LL, 2013, ANESTHESIOLOGY, V119, P593, DOI 10.1097/ALN.0b013e31829e47fd; Chang HT, 2017, CLIN ONCOL-UK, V29, P362, DOI 10.1016/j.clon.2017.01.005; Chen CS, 2008, BREAST CANCER RES TR, V110, P349, DOI 10.1007/s10549-007-9715-4; Chen Chun-Han, 2009, Chang Gung Med J, V32, P553; Coffey JC, 2003, LANCET ONCOL, V4, P760, DOI 10.1016/S1470-2045(03)01282-8; Ecimovic P, 2013, ANTICANCER RES, V33, P4255; Enlund M, 2014, UPSALA J MED SCI, V119, P251, DOI 10.3109/03009734.2014.922649; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Goldfarb Y, 2006, Breast Dis, V26, P99; Hashim D, 2016, ANN ONCOL, V27, P926, DOI 10.1093/annonc/mdw027; Heaney A, 2012, BRIT J ANAESTH, V109, pI17, DOI 10.1093/bja/aes421; Heinze G, 2011, EUR HEART J, V32, P1704, DOI 10.1093/eurheartj/ehr031; Hooijmans CR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156152; Huang H, 2014, BRIT J CANCER, V111, P1338, DOI 10.1038/bjc.2014.426; Jaeger MT, 2017, ANESTH ANALG, V125, P147, DOI 10.1213/ANE.0000000000001781; Jaura AI, 2014, BRIT J ANAESTH, V113, P63, DOI 10.1093/bja/aet581; Kim MH, 2017, ONCOTARGET, V8, P90477, DOI 10.18632/oncotarget.21014; Kingsmore D, 2004, BRIT J CANCER, V90, P1920, DOI 10.1038/sj.bjc.6601846; Kushida A, 2007, IMMUNOPHARM IMMUNOT, V29, P477, DOI 10.1080/08923970701675085; Lai HC, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006148; Lee JH, 2016, KOREAN J ANESTHESIOL, V69, P126, DOI 10.4097/kjae.2016.69.2.126; Li Q, 2012, BIOMED PHARMACOTHER, V66, P52, DOI 10.1016/j.biopha.2011.10.006; Li R, 2018, BMC ANESTHESIOL, V18, DOI 10.1186/s12871-018-0543-3; Liu TC, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009805; MARKOVIC SN, 1993, ANESTHESIOLOGY, V78, P700, DOI 10.1097/00000542-199304000-00013; Melamed R, 2005, BRAIN BEHAV IMMUN, V19, P114, DOI 10.1016/j.bbi.2004.07.004; Melamed R, 2003, ANESTH ANALG, V97, P1331, DOI 10.1213/01.ANE.0000082995.44040.07; Meng C, 2017, ONCOL REP, V37, P841, DOI 10.3892/or.2016.5332; MICHELSON S, 1994, J THEOR BIOL, V169, P327, DOI 10.1006/jtbi.1994.1155; Mikeljevic JS, 2003, BRIT J CANCER, V89, P487, DOI 10.1038/sj.bjc.6601148; Oh CS, 2018, ANESTHESIOLOGY, V129, P921, DOI 10.1097/ALN.0000000000002382; Rastogi P, 2008, J CLIN ONCOL, V26, P778, DOI 10.1200/JCO.2007.15.0235; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; SHAPIRO J, 1981, J CLIN INVEST, V68, P678, DOI 10.1172/JCI110303; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Skinner KA, 2003, ANN SURG ONCOL, V10, P606, DOI 10.1245/ASO.2003.06.017; Soltanizadeh S, 2017, J CLIN ANESTH, V42, P19, DOI 10.1016/j.jclinane.2017.08.001; Song J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114440; Tavare AN, 2012, INT J CANCER, V130, P1237, DOI 10.1002/ijc.26448; Tohme S, 2017, CANCER RES, V77, P1548, DOI 10.1158/0008-5472.CAN-16-1536; van der Hage JA, 2001, J CLIN ONCOL, V19, P4224, DOI 10.1200/JCO.2001.19.22.4224; Welden Brett, 2009, AANA J, V77, P287; Wigmore TJ, 2016, ANESTHESIOLOGY, V124, P69, DOI 10.1097/ALN.0000000000000936; Woo JH, 2015, J KOREAN MED SCI, V30, P1503, DOI 10.3346/jkms.2015.30.10.1503; Wu ZF, 2018, ANESTHESIOLOGY, V129, P932, DOI 10.1097/ALN.0000000000002357; Yamaguchi K, 2000, ANN SURG, V232, P58, DOI 10.1097/00000658-200007000-00009; Yoo S, 2019, ANESTHESIOLOGY, V130, P31, DOI 10.1097/ALN.0000000000002491; Yu BX, 2018, CANCER BIOMARK, V21, P513, DOI 10.3233/CBM-170234; Yu XN, 2017, BREAST CANCER-TOKYO, V24, P643, DOI 10.1007/s12282-017-0789-5	54	36	38	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2019	14	11							e0224728	10.1371/journal.pone.0224728	http://dx.doi.org/10.1371/journal.pone.0224728			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN1GV	31697743	gold, Green Published			2023-01-03	WOS:000532694400052
J	Mayburd, AL; Koivogui, M; Baranova, A				Mayburd, Anatoly L.; Koivogui, Mathilda; Baranova, Ancha			Pharmacological signatures of the reduced incidence and the progression of cognitive decline in ageing populations suggest the protective role of beneficial polypharmacy	PLOS ONE			English	Article							II RECEPTOR BLOCKERS; ALZHEIMERS-DISEASE; UNITED-STATES; DOUBLE-BLIND; MOUSE MODEL; DEMENTIA; BIOTIN; RISK; SUPPLEMENTATION; PREVALENCE	Preventive treatments for dementia are warranted. Here we show that utilization of certain combinations of prescription medications and supplements correlates with reduced rates of cognitive decline. More than 1,900 FDA-approved agents and supplements were collapsed into 53 mechanism-based groups and traced in electronic medical records (EMRs) for >50,000 patients. These mechanistic groups were aligned with the data presented in more than 300 clinical trials, then regression model was built to fit the signals from EMRs to clinical trial performance. While EMR signals of each single agents correlated with clinical performance relatively weakly, the signals produced by combinations of active compounds were highly correlated with the clinical trial performance (R = 0.93, p = 3.8 x10<^>-8). Higher ranking pharmacological modalities were traced in patient profiles as their combinations, producing protective complexity estimates reflecting degrees of exposure to beneficial polypharmacy. For each age strata, the higher was the protective complexity score, the lower was the prevalence of dementia, with maximized life-long effects for the highest regression score /diversity compositions. The connection was less strong in individuals already diagnosed with cognitive impairment. Confounder analysis confirmed an independent effect of protective complexity in multivariate context. A sub-cohort with lifelong odds of dementia decreased > 5-folds was identified; this sub-cohort should be studied in further details, including controlled clinical trials. In short, our study systematically explored combinatorial preventive treatment regimens for age-associated multi-morbidity, with an emphasis on neurodegeneration, and provided extensive evidence for their feasibility.	[Mayburd, Anatoly L.; Koivogui, Mathilda] Neurocombinatorix, Alexandria, VA 22303 USA; [Mayburd, Anatoly L.; Baranova, Ancha] George Mason Univ, Sch Syst Biol, Colgan Hall,MSN 3E1 George Mason Univ, Manassas, VA 20110 USA; [Baranova, Ancha] Res Ctr Med Genet, Moscow, Russia	George Mason University; Research Centre for Medical Genetics	Mayburd, AL (corresponding author), Neurocombinatorix, Alexandria, VA 22303 USA.; Mayburd, AL; Baranova, A (corresponding author), George Mason Univ, Sch Syst Biol, Colgan Hall,MSN 3E1 George Mason Univ, Manassas, VA 20110 USA.; Baranova, A (corresponding author), Res Ctr Med Genet, Moscow, Russia.	mail@inventomika.org; abaranov@gmu.edu		Mayburd, Anatoly/0000-0001-6281-0066				Aerts L, 2017, NEUROLOGY, V88, P2225, DOI 10.1212/WNL.0000000000004015; Akbari E, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00256; Anagnostouli M, 1999, ACTA NEUROL SCAND, V99, P387, DOI 10.1111/j.1600-0404.1999.tb07369.x; Andrieu S, 2015, LANCET NEUROL, V14, P926, DOI 10.1016/S1474-4422(15)00153-2; [Anonymous], 2019, UPDATED ALZHEIMERS S; [Anonymous], 2018, US, DOI 10.1136/annrheumdis-2014-206917, Patent No. [9,351,961. 51, 9351961]; [Anonymous], [No title captured]; [Anonymous], 2019, ALZHEIMERS DIS RELAT; [Anonymous], 2019, GLENN ISRAEL DETERMI; [Anonymous], 2019, OFFICE SUPPORT LINES; Appleby BS, 2013, DEMENT GERIATR COGN, V35, P1, DOI 10.1159/000345791; Bohlken J, 2018, J ALZHEIMERS DIS, P1; Bonkowski MS, 2016, NAT REV MOL CELL BIO, V17, P679, DOI 10.1038/nrm.2016.93; Bredesen DE, 2014, AGING-US, V6, P707, DOI 10.18632/aging.100690; Campbell JM, 2018, J ALZHEIMERS DIS, P1, DOI DOI 10.3233/JAD-189007; Carrasco L, 2017, ADV ALZH DIS, V5, P281, DOI 10.3233/978-1-61499-706-281; Cohen SH, 2018, J ALZHEIMERS DIS PAR, V8, DOI 10.4172/2161-0460.1000450; Dregan A, 2015, J ALZHEIMERS DIS, V46, P1039, DOI 10.3233/JAD-150171; Echouffo-Tcheugui JB, 2018, NEUROLOGY, V91, pE1961, DOI 10.1212/WNL.0000000000006549; El-Dessouki AM, 2017, MOL NEUROBIOL, V54, P5074, DOI 10.1007/s12035-016-0051-8; Fahy GM, 1999, AGING CELL, V54; Gibson EM, 2019, CELL, V176, P43, DOI 10.1016/j.cell.2018.10.049; Gold PE, 2014, BRAIN RES BULL, V105, P25, DOI 10.1016/j.brainresbull.2013.12.012; Gomm W, 2016, JAMA NEUROL, V73, P410, DOI 10.1001/jamaneurol.2015.4791; Goya RG, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-1075-y; Grinde B, 2017, IMMUN AGEING, V14, DOI 10.1186/s12979-017-0102-7; Hammond BR, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00254; Hejl A, 2002, J NEUROL NEUROSUR PS, V73, P390, DOI 10.1136/jnnp.73.4.390; Hervas D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179283; Huang YM, 2015, BRIT J OPHTHALMOL, V99, P371, DOI 10.1136/bjophthalmol-2014-305503; Iskra R, 2018, HEALTHY AGEING LONG, V8, P133, DOI 10.1007/978-3-030-03742-0_5; Jacobs V, 2017, EXPERT REV CARDIOVAS, V15, P897, DOI 10.1080/14779072.2017.1411189; Jutley G, 2017, NEURODEGENER DIS MAN, V7, P157, DOI 10.2217/nmt-2017-0004; Kim MY, 2018, J ALZHEIMERS DIS, V63, P635, DOI 10.3233/JAD-170895; Kim SH, 2017, BRIT J PHARMACOL, V174, P4224, DOI 10.1111/bph.14030; Kirkland AE, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060730; Kisler K, 2017, NAT REV NEUROSCI, V18, P419, DOI 10.1038/nrn.2017.48; Kivipelto M, 2018, NATURE REV NEUROLOGY, P1; Kumar A, 2017, BIOMED PHARMACOTHER, V88, P698, DOI 10.1016/j.biopha.2017.01.059; Lages Lucas C, 2017, J Clin Transl Res, V2, P135; Langa KM, 2017, JAMA INTERN MED, V177, P51, DOI 10.1001/jamainternmed.2016.6807; Lee S. Y., 2019, MEDICINE, V98; Lehrer S, 2017, DISCOV MED, V24, P147; Liu CT, 2017, ONCOTARGET, V8, P79680, DOI 10.18632/oncotarget.19094; Lu N, 2016, ANN RHEUM DIS, V75, P547, DOI 10.1136/annrheumdis-2014-206917; Manzo Ciro, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5030082; Mayburd AL, INCREASED LIFESPAN I; McCarney R, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-30; McNamee R, 2005, OCCUP ENVIRON MED, V62, P500, DOI 10.1136/oem.2002.001115; Mehta D, 2017, EXPERT OPIN INV DRUG, V26, P735, DOI 10.1080/13543784.2017.1323868; Mocchegiani E, 2018, HDB IMMUNOSENESCENCE, P1; Mok SA, 2018, NAT STRUCT MOL BIOL, V25, P384, DOI 10.1038/s41594-018-0057-1; Ngandu T, 2015, LANCET, V385, P2255, DOI 10.1016/S0140-6736(15)60461-5; Park JH, 2016, ENVIRON TOXICOL PHAR, V42, P1, DOI 10.1016/j.etap.2015.12.014; Park SK, 2018, DRUG SAFETY, V41, P615, DOI 10.1007/s40264-018-0638-2; Plassman BL, 2007, NEUROEPIDEMIOLOGY, V29, P125, DOI 10.1159/000109998; Pourhoseingholi Mohamad Amin, 2012, Gastroenterol Hepatol Bed Bench, V5, P79; Ren X, 2019, BIOCH BIOPHYSICA ACT; Renzi-Hammond LM, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111246; Riveron-Negrete L, 2017, MINI-REV MED CHEM, V17, P529, DOI 10.2174/1389557516666160923132611; Saavedra JM, 2017, PHARMACOL RES, V125, P91, DOI 10.1016/j.phrs.2017.06.017; Saavedra JM, 2016, CELL MOL NEUROBIOL, V36, P259, DOI 10.1007/s10571-015-0327-y; Sanborn V, 2018, CONT CLIN TRIAL COMM, V12, P192, DOI 10.1016/j.conctc.2018.11.006; Tai JJ, 2018, BRAIN RES, V1678, P64, DOI 10.1016/j.brainres.2017.10.012; Tarleton EK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180067; Tourbah A, 2016, MULT SCLER J, V22, P1719, DOI 10.1177/1352458516667568; van Beers M, 2018, EXPERT REV RESP MED, V12, P1061, DOI 10.1080/17476348.2018.1533405; Walker V, 2019, BIORXIV; Weinstein G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212293; Wroolie T.E., 2017, PERS MED PSYCHIAT, V4-6, P7, DOI [10.1016/j.pmip., DOI 10.1016/J.PMIP]; Zaghrioui M, 2018, SOLID STATE SCI, V79, P1, DOI 10.1016/j.solidstatesciences.2018.03.003; Zhang Q, 2015, BRAIN RES, V1622, P361, DOI 10.1016/j.brainres.2015.07.010; Zhang YL, 2017, NATURE, V548, P52, DOI 10.1038/nature23282	73	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2019	14	11							e0224315	10.1371/journal.pone.0224315	http://dx.doi.org/10.1371/journal.pone.0224315			34	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN1FJ	31693707	gold, Green Published			2023-01-03	WOS:000532690100024
J	Verma, A; Sahay, S				Verma, Archana; Sahay, Seema			Healthcare needs and programmatic gaps in transition from pediatric to adult care of vertically transmitted HIV infected adolescents in India	PLOS ONE			English	Article							MEDICATION ADHERENCE; RESPONSIBILITY	Treatment transition for 'adolescents living with perinatally acquired HIV' (ALPH) from paediatric to adult care is not addressed adequately. This study explores the ALPH's health care needs and programmatic gaps in health systems for the care of ALPH in India. Forty-nine indepth interviews were conducted with purposively selected primary and key stakeholders in India. Thematic analysis utilizing grounded theory was performed in QSR NUD* IST 6. Stakeholders explicitly recognized adolescent HIV to be a critical public health issue which requires a separate mandate in India. It was found that none of the health policies in India focus on adolescent age group; ALPH is therefore even more neglected population. No/partial HIV disclosure to ALPH is the first crisis for retention in care continuum and adherence to the treatment becomes sub-optimal. Unmet needs of transitioning from paediatric to adult care in existing settings was the major gap. Age-specific counselling guidelines and counselling skills among HCPs were found lacking where tailored counseling and capacity building of HCPs was an expectation. Need of holistic approach for adolescents led to consensus on establishing 'adolescent transition clinic' with a strict 'no' for 'standalone Adolescent HIV' clinics. School setting having peer-based counselling provision was recommended. Age disaggregated health data is required to inform the policymakers about adolescents' specific needs for developing interventions. Situational analysis to identify and shape health priorities of adolescents is recommended.	[Verma, Archana; Sahay, Seema] Indian Council Med Res, NARI, Div Social & Behav Res, Pune, Maharashtra, India	Indian Council of Medical Research (ICMR); ICMR - National AIDS Research Institute (NARI)	Sahay, S (corresponding author), Indian Council Med Res, NARI, Div Social & Behav Res, Pune, Maharashtra, India.	ssahay@nariindia.org			Indian Council of Medical Research [5/11/119/2014-SBR]; ICMR-National AIDS Research Institute (ICMR-NARI), Pune; Savitribai Phule Pune University (SPPU)	Indian Council of Medical Research(Indian Council of Medical Research (ICMR)); ICMR-National AIDS Research Institute (ICMR-NARI), Pune; Savitribai Phule Pune University (SPPU)	This is a doctoral study of AV. AV was supported by senior research fellowship from Indian Council of Medical Research for this doctoral work (Ref. 5/11/119/2014-SBR) and pursuing her doctoral work from ICMR-NARI. The fellowship has closed. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We acknowledge Indian Council of Medical Research (ICMR), Delhi for supporting the study. The senior research fellowship was awarded to the first author by ICMR is acknowledged (Ref. 5/11/119/2014-SBR). We sincerely thank our respondents for their participation and valuable insights. We acknowledge the support of ICMR-National AIDS Research Institute (ICMR-NARI), Pune. We thank Director, ICMR-NARI, Pune for supporting the study. We also thank Mr. Girish Rahane and Mr. Mufid Baig for their support in recruitment of participants. This study is part of doctoral work of AV and we sincerely thank Savitribai Phule Pune University (SPPU) for support. We sincerely thank Prof. Prashant Kumar, English Literature, SP College, Dumka for editing the grammatical errors in the manuscript.	Abbott-Chapman J, 2009, SPACE CULT, V12, P419, DOI 10.1177/1206331209348091; Agwu AL, 2013, J PEDIATR INFECT DIS, V2, P215, DOI 10.1093/jpids/pit008; [Anonymous], INT APPR HIV PREV CA; Arnett J., 2004, EMERGING ADULTHOOD W; Bernays S, 2014, LANCET, V383, P1355, DOI 10.1016/S0140-6736(13)62328-4; Bryman A, 1988, QUANTITY QUALITY SOC, DOI 10.4324/9780203410028; Dick B, 2015, J ADOLESCENT HEALTH, V56, P3, DOI 10.1016/j.jadohealth.2014.10.260; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Ferrand RA, 2016, LANCET HIV, V3, pE399, DOI 10.1016/S2352-3018(16)30056-X; Ferrand RA, 2016, TROP MED INT HEALTH, V21, P325, DOI 10.1111/tmi.12656; Ferrand RA, 2010, CLIN INFECT DIS, V51, P844, DOI 10.1086/656361; FISHER M, 1994, ARCH DIS CHILD, V70, P461, DOI 10.1136/adc.70.6.461; Giordano TP, 2005, AIDS CARE, V17, P773, DOI 10.1080/09540120412331336652; Glaster B. G., 1967, THEORETICAL SENSITIV; Govindasamy D, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20182; Hanghoj S, 2014, J ADOLESCENT HEALTH, V54, P121, DOI 10.1016/j.jadohealth.2013.08.009; Hutton A, 2010, J ADV NURS, V66, P1802, DOI 10.1111/j.1365-2648.2010.05333.x; Janssens B, 2007, B WORLD HEALTH ORGAN, V85, P880, DOI 10.2471/BLT.06.036574; Kranzer K, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21737; McQuaid EL, 2003, J PEDIATR PSYCHOL, V28, P323, DOI 10.1093/jpepsy/jsg022; Ministry of Health and Family Welfare UNFPA Team, 2014, STRAT HDB; Ministry of Human Resource Development (MOHRD) National AIDS Control Organisation (NACO) and United Nation Children's Fund (UNICEF), 2005, AD ED NAT FRAM STAT; Mofenson LM, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18650; Morgan DL, 2007, J MIX METHOD RES, V1, P48, DOI 10.1177/2345678906292462; NACO. National AIDS Control Organization (NACO), 2017, ANN REP 2016 17; National AIDS Control Organisation, 2007, NAT AIDS CONTR PROGR; Okonofua F., 2014, AFRICAN J REPROD HLT, V18; Philbin MM, 2014, MED ANTHROPOL, V33, P288, DOI 10.1080/01459740.2013.847436; Rice BD, 2011, SEX TRANSM DIS, V38, P685, DOI 10.1097/OLQ.0b013e318214b92e; Sahay S, 2013, INDIAN J PEDIATR, V80, P814, DOI 10.1007/s12098-013-1025-8; Sohn AH, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18555; Strauss Anselm, 1991, BASICS QUALITATIVE R; The NewYork State Department of Health, 2011, NEWYORK STAT DEP HLT; UNAIDS, 2014, 90 90 90 AMB TREATM; UNICEF, 2016, AD DEM; UNICEF, 2016, AD BRAIN 2 WIND OPP; UNICEF, 2012, PROGR CHILDR REP CAR; UNICEF, 2017, AD YOUNG PEOPL; WHO, 2013, REC PUBL HLTH APPR C; World Health Organization, 2015, STRENGTH INT COLL AD; World Health Organization, 2017, MOR 12 MILL AD DIE E	41	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2019	14	10							e0224490	10.1371/journal.pone.0224490	http://dx.doi.org/10.1371/journal.pone.0224490			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LN0RS	31661535	Green Published, gold			2023-01-03	WOS:000532653400035
J	Coakley, JD; Breen, EP; Moreno-Olivera, A; Al-Harbi, AI; Melo, AM; O'Connell, B; McManus, R; Doherty, DG; Ryan, T				Coakley, John D.; Breen, Eamon P.; Moreno-Olivera, Ana; Al-Harbi, Alhanouf, I; Melo, Ashanty M.; O'Connell, Brian; McManus, Ross; Doherty, Derek G.; Ryan, Thomas			Dysregulated T helper type 1 (Th1) and Th17 responses in elderly hospitalised patients with infection and sepsis	PLOS ONE			English	Article							CYTOKINE PRODUCTION; DR EXPRESSION; SEPTIC SHOCK; CELLS; INTERLEUKIN-17; INFLAMMATION; IMMUNOSUPPRESSION; DIFFERENTIATION; MORTALITY; RECEPTOR	Objective The role of Th1 and Th17 lymphocyte responses in human infection and sepsis of elderly patients has yet to be clarified. Design A prospective observational study of patients with sepsis, infection only and healthy controls. Setting The acute medical wards and intensive care units in a 1000 bed university hospital. Patients 32 patients with sepsis, 20 patients with infection, and 20 healthy controls. Patients and controls were older than 65 years of age. Patients with recognised underlying immune compromise were excluded. Methods Phenotype, differentiation status and cytokine production by T lymphocytes were determined by flow cytometry. Measurements The differentiation states of circulating CD3(+), CD4(+), and CD8(+) T cells were characterised as naive (CD45RA(+), CD197(+)), central memory (CD45RA(-), CD197(+)), effector memory (CD45RA(-), CD197(-)), or terminally differentated (CD45RA(+), CD197-). Expression of IL-12 and IL-23 receptors, and the transcription factors T-bet and ROR.t, was analysed in circulating T lymphocytes. Expression of interferon-. and IL-17A were analysed following stimulation in vitro. Results CD4(+) T cells from patients with infection predominantly expressed effector-memory or terminally differentiated phenotypes but CD4(+) T cells from patients with severe sepsis predominantly expressed naive phenotypes (p< 0.0001). CD4(+) T cells expressing IL-23 receptor were lower in patients with sepsis compared to patients with infection alone (p = 0.007). ROR.t expression by CD4(+) T cells was less frequent in patients with sepsis (p< 0.001), whereas T-bet expressing CD8(+) T cells that do not express ROR.t was lower in the sepsis patients. HLA-DR expression by monocytes was lower in patients with sepsis. In septic patients fewer monocytes expressed IL-23. Conclusion Persistent failure of T cell activation was observed in patients with sepsis. Sepsis was associated with attenuated CD8(+) Th1 and CD4(+) Th17 based lymphocyte response.	[Coakley, John D.; Ryan, Thomas] St James Hosp, Dept Intens Care Med, Dublin, Ireland; [Breen, Eamon P.] St James Hosp, Trinity Translat Med Inst, Dublin, Ireland; [Moreno-Olivera, Ana; Al-Harbi, Alhanouf, I; Melo, Ashanty M.; Doherty, Derek G.] Trinity Translat Med Inst, Dept Immunol, Dublin, Ireland; [O'Connell, Brian] St James Hosp, Dept Clin Microbiol, Dublin, Ireland; [McManus, Ross] Trinity Translat Med Inst, Dept Clin Med & Genet, Dublin, Ireland; [Coakley, John D.] St James Hosp, Intens Care Unit, Jamess St, Dublin 8, Ireland	Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; Trinity College Dublin	Coakley, JD (corresponding author), St James Hosp, Dept Intens Care Med, Dublin, Ireland.; Coakley, JD (corresponding author), St James Hosp, Intens Care Unit, Jamess St, Dublin 8, Ireland.	jcoakley@stjames.ie	ALHARBI, ALHANOUF I./GRJ-4297-2022; McManus, Ross/AAE-9236-2020	Doherty, Derek/0000-0002-4394-658X; Melo, Ashanty/0000-0001-6073-5429; Ryan, Thomas/0000-0002-3556-5592; Coakley, John Davis/0000-0002-3607-6109; McManus, Ross/0000-0002-0529-9617	College of Anaesthesiologists of Ireland	College of Anaesthesiologists of Ireland	This work received funding from The College of Anaesthesiologists of Ireland for this research (www.anaesthesia.ie) to JDC. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; [Anonymous], 2017, NAT CONS POL; Breslow JM, 2011, INFECT IMMUN, V79, P3317, DOI 10.1128/IAI.00069-11; Cauvi DM, 2014, SHOCK, V42, P246, DOI 10.1097/SHK.0000000000000207; Chognard G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089092; Brunialti MKC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037393; Cosmi L, 2008, J EXP MED, V205, P1903, DOI 10.1084/jem.20080397; Damsker JM, 2010, ANN NY ACAD SCI, V1183, P211, DOI 10.1111/j.1749-6632.2009.05133.x; Faivre V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047209; Fleischmann C, 2016, DTSCH ARZTEBL INT, V113, P159, DOI [10.3238/arztebl.2016.0159, 10.3238/arztebl.2016.0660b]; Forel JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050446; Grimaldi D, 2011, INTENS CARE MED, V37, P1438, DOI 10.1007/s00134-011-2306-1; Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552; Hotchkiss RS, 2013, LANCET INFECT DIS, V13, P260, DOI 10.1016/S1473-3099(13)70001-X; Hotchkiss RS, 2005, J IMMUNOL, V174, P5110, DOI 10.4049/jimmunol.174.8.5110; Inoue S, 2013, CRIT CARE MED, V41, P810, DOI 10.1097/CCM.0b013e318274645f; Langrish CL, 2004, IMMUNOL REV, V202, P96, DOI 10.1111/j.0105-2896.2004.00214.x; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Liu BN, 2010, EXP HEMATOL, V38, P877, DOI 10.1016/j.exphem.2010.06.004; Lukaszewicz AC, 2009, CRIT CARE MED, V37, P2746, DOI 10.1097/CCM.0b013e3181ab858a; Maravitsa P, 2016, IMMUNOL LETT, V178, P68, DOI 10.1016/j.imlet.2016.08.002; Mikacenic C, 2016, CRIT CARE MED, V44, P496, DOI 10.1097/CCM.0000000000001409; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Monneret G, 2006, INTENS CARE MED, V32, P1175, DOI 10.1007/s00134-006-0204-8; Naylor K, 2005, J IMMUNOL, V174, P7446, DOI 10.4049/jimmunol.174.11.7446; Nordfjall K, 2005, P NATL ACAD SCI USA, V102, P16374, DOI 10.1073/pnas.0501724102; Paraschos MD, 2015, CYTOKINE, V76, P222, DOI 10.1016/j.cyto.2015.05.021; Puel A, 2011, SCIENCE, V332, P65, DOI 10.1126/science.1200439; Ronit A, 2017, J INTENSIVE CARE MED, V32, P77, DOI 10.1177/0885066615606673; Schmitt V, 2013, EXP GERONTOL, V48, P1379, DOI 10.1016/j.exger.2013.09.003; Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110; Shen H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057746; Venet F, 2004, CRIT CARE MED, V32, P2329, DOI 10.1097/01.CCM.0000145999.42971.4B; Venet F, 2013, CRIT CARE MED, V41, P111, DOI 10.1097/CCM.0b013e3182657948; Venet F, 2012, J IMMUNOL, V189, P5073, DOI 10.4049/jimmunol.1202062; Wynn JL, 2016, P NATL ACAD SCI USA, V113, pE2627, DOI 10.1073/pnas.1515793113; Zhang M, 1999, J IMMUNOL, V162, P2441; Zhao Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep20156; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	39	11	14	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2019	14	10							e0224276	10.1371/journal.pone.0224276	http://dx.doi.org/10.1371/journal.pone.0224276			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN0PK	31658288	gold, Green Published			2023-01-03	WOS:000532647400015
J	Ramamoorthi, R; Gahreman, D; Skinner, T; Moss, S				Ramamoorthi, Ramya; Gahreman, Daniel; Skinner, Timothy; Moss, Simon			The effect of yoga practice on glycemic control and other health parameters in the prediabetic state: A systematic review and meta-analysis	PLOS ONE			English	Review							TYPE-2 DIABETES-MELLITUS; LIFE-STYLE INTERVENTION; METABOLIC SYNDROME; RISK-FACTORS; RESTORATIVE YOGA; PUBLICATION BIAS; LIPID PROFILE; ADULTS; DISEASE; QUALITY	A systematic review and meta-analysis was conducted to investigate the effects of yoga on glycemic control, lipid profiles, body composition and blood pressure in people in the pre-diabetic state. Studies on the effectiveness of yoga on population groups under high risk for diabetes, called prediabetic or suffering from metabolic syndromes were extracted from a thorough search of PubMed, Scopus, Cochrane Library, EBSCO and IndMED databases. Both Randomised Controlled Trial (RCT) and non-RCT studies were included in the systematic review and meta-analysis. Studies published between Jan 2002 and Dec 2018 were included. Studies were considered for evaluation if they investigated a yoga intervention to prevent T2DM, against a control group, while also reporting glycemic control and other health parameters of T2DM management. Summary effect sizes and 95% confidence intervals (CI) were calculated using the Comprehensive Meta-Analysis software in addition to publication bias. Of the 46,500 identified studies, 14 studies with 834 participants of whom were 50% women, were found to be eligible for inclusion in our systematic review. Our quantitative synthesis included 12 randomized control trials and 2 non-randomized control trials, with the follow-up period ranging from 4 to 52 weeks. Compared to controls, yoga intervention improved fasting blood glucose (FBG) [Standard Mean Difference (SMD -0.064 mg/dL (95% CI -0.201 to 0.074)]; low density lipoprotein (LDL) [SMD-0.090 mg/dL (95% CI -0.270 to 0.090)]; triglycerides [SMD -0.148 mg/dL (95% CI -0.285 to -0.012)]; total cholesterol [SMD -0.058 mg/dL (95% CI -0.220 to 0.104)] and systolic blood pressure [SMD -0.058 mm Hg (95% CI -0.168 to 0.053)]. This meta-analysis uncovered clinically improved effects of yoga intervention on glycemic control, lipid profiles and other parameters of T2DM management in prediabetic population. These results suggest that yoga intervention may be considered as a comprehensive and alternative approach to preventing T2DM. Further adequately powered, well designed RCTs are needed to support our findings and investigate the long-term effects of yoga in T2DM patients.	[Ramamoorthi, Ramya; Gahreman, Daniel; Moss, Simon] Charles Darwin Univ, Coll Hlth & Human Sci, Darwin, NT, Australia; [Skinner, Timothy] Univ Copenhagen, Ctr Sundhed & Samfund, Inst Psykol, Copenhagen K, Denmark	Charles Darwin University; University of Copenhagen	Ramamoorthi, R (corresponding author), Charles Darwin Univ, Coll Hlth & Human Sci, Darwin, NT, Australia.	Ramya.Ramamoorthi@cdu.edu.au	; Skinner, Timothy/N-2221-2013	Ramamoorthi, Ramya/0000-0001-8325-1785; Skinner, Timothy/0000-0002-0018-6963				Alexander GK, 2008, FAM COMMUNITY HEALTH, V31, P228, DOI 10.1097/01.FCH.0000324480.40459.20; Aljasir B, 2010, EVID-BASED COMPL ALT, V7, P399, DOI 10.1093/ecam/nen027; BEGG C, 1994, OPERATING CHARACTERI, V50, P1088; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BJORNTORP P, 1999, HYPOTHALAMIC AROUSAL, V16, P373; Black PH, 2003, BRAIN BEHAV IMMUN, V17, P350, DOI 10.1016/S0889-1591(03)00048-5; Bonora E, 2004, DIABETES, V53, P1782, DOI 10.2337/diabetes.53.7.1782; care ADAJD, 2014, DIABETES CARE S1, V37, pS81, DOI DOI 10.2337/DC14-S081; Chandler K., 2001, EMERGING FIELD YOGA; Clark HD, 1999, CONTROL CLIN TRIALS, V20, P448, DOI 10.1016/S0197-2456(99)00026-4; Colberg SR, 2016, DIABETES CARE, V39, P2065, DOI 10.2337/dc16-1728; Collaboration C, 2008, COCHRANE HDB SYSTEMA; Corey SM, 2014, PSYCHONEUROENDOCRINO, V49, P260, DOI 10.1016/j.psyneuen.2014.07.012; Cramer H, 2015, CONTEMP CLIN TRIALS, V41, P269, DOI 10.1016/j.cct.2015.02.005; Cui J, 2017, J DIABETES INVEST, V8, P201, DOI 10.1111/jdi.12548; Damodaran A, 2002, J Assoc Physicians India, V50, P633; Delamater AM, 2001, DIABETES CARE, V24, P1286, DOI 10.2337/diacare.24.7.1286; Des Jarlais DC, 2004, AM J PUBLIC HEALTH, V94, P361, DOI 10.2105/AJPH.94.3.361; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Eun CS, 2017, EFFECTS YOGIC EXERCI; FALCI L, 2016, PEER REVIEWED MULTIP, V13, DOI DOI 10.5888/PCD13.150501; Faulenbach M, 2012, DIABETIC MED, V29, P128, DOI 10.1111/j.1464-5491.2011.03431.x; Garfinkel M, 2000, RHEUM DIS CLIN N AM, V26, P125, DOI 10.1016/S0889-857X(05)70126-5; Gordon L, 2008, ARCH MED SCI, V4, P427; Gordon LA, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-21; Hardie EA, 2015, AUST PSYCHOL, V50, P455, DOI 10.1111/ap.12130; Hardy RJ, 1998, STAT MED, V17, P841, DOI 10.1002/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D; Hegde SV, 2013, COMPLEMENT THER MED, V21, P571, DOI 10.1016/j.ctim.2013.08.013; Heraclides A, 2009, PSYCHOSOCIAL STRESS; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Innes KE, 2016, YOGA ADULTS TYPE 2 D, V2016; Innes KE, 2007, EVID-BASED COMPL ALT, V4, P469, DOI 10.1093/ecam/nel103; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jayawardena R, 2018, BENEFITS YOGA PRACTI; Jyotsna V P, 2014, Indian J Endocrinol Metab, V18, P582, DOI 10.4103/2230-8210.137499; Kanaya AM, 2014, J DIABETES COMPLICAT, V28, P406, DOI 10.1016/j.jdiacomp.2013.12.001; Katula JA, 2017, CONTEMP CLIN TRIALS, V53, P89, DOI 10.1016/j.cct.2016.12.005; Keerthi GS, 2017, J CLIN DIAGN RES, V11, pCC10, DOI 10.7860/JCDR/2017/29307.10633; Kumar S, 2011, BIOPSYCHOSOCIAL EFFE, V11; Kumar V, 2016, COMPLEMENT THER MED, V25, P104, DOI 10.1016/j.ctim.2016.02.001; Kyizom T, 2010, EFFECT PRANAYAMA YOG, V131; Lau C, 2015, EFFECTS 12 WEEK HATH, V10; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Liu XC, 2014, J THORAC DIS, V6, P795, DOI 10.3978/j.issn.2072-1439.2014.06.05; LJUNG T, 2000, ACTIVITY HYPOTHALAMI, V8, P487; McDermott KA, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-212; Medagama AB, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-102; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Mooventhan A, 2017, J BODYW MOV THER, V21, P1028, DOI 10.1016/j.jbmt.2017.01.004; Netam R, 2015, INDIAN J MED RES, V141, P775, DOI 10.4103/0971-5916.160698; O'Dea A, 2015, CAN ONSET TYPE 2 DIA, V2015; Organization WH, DIAB 2018; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; Orwin R. G., 1983, J EDUC STAT, V8, P157, DOI [10.3102/10769986008002157, DOI 10.2307/1164923]; Pandya Dipak P., 1999, Comprehensive Therapy, V25, P283, DOI 10.1007/BF02944271; Popli U, 2014, ALTERN THER HEALTH M, V20, P24; RAMAMOORTHI R, 2019, EFFECTIVENESS YOGA P, V98, DOI DOI 10.1097/MD.0000000000014019; Raub JA, 2002, J ALTERN COMPLEM MED, V8, P797, DOI 10.1089/10755530260511810; Raveendran AV, 2018, ENDOCRINOL METAB, V33, P307, DOI 10.3803/EnM.2018.33.3.307; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; Rothstein HR., 2008, J EXP CRIMINOL, V4, P61, DOI [10.1007/s11292-007-9046-9, DOI 10.1007/S11292-007-9046-9]; Saffari M, 2014, PRIM CARE DIABETES, V8, P275, DOI 10.1016/j.pcd.2014.03.004; Sahay B K, 2002, J Indian Med Assoc, V100, P178; Sanders AB, 2017, EFFECTIVENESS LOW DO; Schellenberg ES, 2013, ANN INTERN MED, V159, P543, DOI 10.7326/0003-4819-159-8-201310150-00007; Schulz KF, 2010, J PHARMACOL PHARMACO, V1, P100, DOI [10.1016/j.jclinepi.2010.02.005, 10.4103/0976-500X.72352, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18]; Shantakumari Nisha, 2013, Indian Heart J, V65, P127, DOI 10.1016/j.ihj.2013.02.010; Singh K, 2017, INT J APP DENT SCI, V3, P91; Singh S, 2008, INDIAN J CLIN BIOCHE, V23, P365, DOI 10.1007/s12291-008-0080-9; Siu PM, 2015, DIABETOL METAB SYNDR, V7, DOI 10.1186/s13098-015-0034-3; Skoro-Kondza L, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-33; Sohl SJ, 2016, YOGA RISK REDUCTION, V2016; Supriya R, 2018, SCAND J MED SCI SPOR, V28, P1130, DOI 10.1111/sms.13029; Thind H, 2017, PREV MED, V105, P116, DOI 10.1016/j.ypmed.2017.08.017; TSIGOS C, 1993, J CLIN ENDOCR METAB, V76, P554, DOI 10.1210/jc.76.3.554; Tyagi A, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-445; Vaishali K, 2012, PHYS OCCUP THER GERI, V30, P22, DOI 10.3109/02703181.2012.656835; Violi F, 2017, AM HEART J, V189, P120, DOI 10.1016/j.ahj.2017.04.005; Waryasz GR, 2010, J AM ACAD NURSE PRAC, V22, P217, DOI 10.1111/j.1745-7599.2010.00490.x; Wolff M, 2013, BMC CARDIOVASC DISOR, V13, DOI 10.1186/1471-2261-13-111; World Health Organization, 2016, GLOB REP DIAB; Yadav R, 2018, COMP EFFICACY 12 WEE; Yang K, 2011, UTILIZATION 3 MONTH, V2011; Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3	86	17	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2019	14	10							e0221067	10.1371/journal.pone.0221067	http://dx.doi.org/10.1371/journal.pone.0221067			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM9KK	31618207	Green Published, gold			2023-01-03	WOS:000532566600002
J	Demaria, O; Cornen, S; Daeron, M; Morel, Y; Medzhitov, R; Vivier, E				Demaria, Olivier; Cornen, Stephanie; Daeron, Marc; Morel, Yannis; Medzhitov, Ruslan; Vivier, Eric			Harnessing innate immunity in cancer therapy	NATURE			English	Review							COLONY-STIMULATING FACTOR; NATURAL-KILLER-CELLS; REGULATORY T-CELLS; CYCLIC GMP-AMP; DENDRITIC CELLS; I INTERFERON; TUMOR-GROWTH; DOSE-ESCALATION; INDOLEAMINE 2,3-DIOXYGENASE; METASTATIC MELANOMA	New therapies that promote antitumour immunity have been recently developed. Most of these immunomodulatory approaches have focused on enhancing T-cell responses, either by targeting inhibitory pathways with immune checkpoint inhibitors, or by targeting activating pathways, as with chimeric antigen receptor T cells or bispecific antibodies. Although these therapies have led to unprecedented successes, only a minority of patients with cancer benefit from these treatments, highlighting the need to identify new cells and molecules that could be exploited in the next generation of immunotherapy. Given the crucial role of innate immune responses in immunity, harnessing these responses opens up new possibilities for long-lasting, multilayered tumour control.	[Demaria, Olivier; Cornen, Stephanie; Morel, Yannis; Vivier, Eric] Innate Pharma, Marseille, France; [Daeron, Marc; Vivier, Eric] Aix Marseille Univ, INSERM, CNRS, Ctr Immunol Marseille Luminy, Marseille, France; [Daeron, Marc] Inst Pasteur, Paris, France; [Medzhitov, Ruslan] Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; [Medzhitov, Ruslan] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA; [Vivier, Eric] Hop La Timone, AP HP, Serv Immunol, Marseille Immunopole, Marseille, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Howard Hughes Medical Institute; Yale University; Yale University; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Vivier, E (corresponding author), Innate Pharma, Marseille, France.; Vivier, E (corresponding author), Aix Marseille Univ, INSERM, CNRS, Ctr Immunol Marseille Luminy, Marseille, France.; Vivier, E (corresponding author), Hop La Timone, AP HP, Serv Immunol, Marseille Immunopole, Marseille, France.	vivier@ciml.univ-mrs.fr	Vivier, Eric/F-8939-2010	Vivier, Eric/0000-0001-7022-8287	European Research Council (ERC) under the European Union [694502]; Agence Nationale de la Recherche [ANR-17-RHUS-0007]; Equipe labellisee 'La Ligue' (Ligue Nationale contre le Cancer); MSDAvenir; Innate Pharma	European Research Council (ERC) under the European Union(European Research Council (ERC)); Agence Nationale de la Recherche(French National Research Agency (ANR)); Equipe labellisee 'La Ligue' (Ligue Nationale contre le Cancer); MSDAvenir; Innate Pharma	The E.V. laboratory at CIML and Assistance-Publique des Hopitaux de Marseille is supported by funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (TILC, grant agreement no. 694502), the Agence Nationale de la Recherche including the PIONEER Project (ANR-17-RHUS-0007), Equipe labellisee 'La Ligue' (Ligue Nationale contre le Cancer), MSDAvenir, Innate Pharma and institutional grants to the CIML (INSERM, CNRS, and Aix-Marseille University) and to Marseille Immunopole.	Ablasser A, 2013, NATURE, V503, P530, DOI 10.1038/nature12640; Ablasser A, 2013, NATURE, V498, P380, DOI 10.1038/nature12306; Abruzzese MP, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0362-2; Advani R, 2018, NEW ENGL J MED, V379, P1711, DOI 10.1056/NEJMoa1807315; Aguilera A, 2008, NAT REV GENET, V9, P204, DOI 10.1038/nrg2268; Ahn J, 2018, CANCER CELL, V33, P862, DOI 10.1016/j.ccell.2018.03.027; Ajona D, 2017, CANCER DISCOV, V7, P694, DOI 10.1158/2159-8290.CD-16-1184; Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; Andrews LP, 2017, IMMUNOL REV, V276, P80, DOI 10.1111/imr.12519; Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; [Anonymous], 2019, J CLIN ONCOL S; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; AUTIO KA, 2019, J CLIN ONCOL, V37; BAIXERAS E, 1992, J EXP MED, V176, P327, DOI 10.1084/jem.176.2.327; Barry KC, 2018, NAT MED, V24, P1178, DOI 10.1038/s41591-018-0085-8; Beatson R, 2016, NAT IMMUNOL, V17, P1273, DOI 10.1038/ni.3552; Beffinger M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.97792; Berntsen A, 2010, J IMMUNOTHER, V33, P425, DOI 10.1097/CJI.0b013e3181cd870f; Bottcher JP, 2018, CELL, V172, P1022, DOI 10.1016/j.cell.2018.01.004; Brown CE, 2019, NAT REV IMMUNOL, V19, P73, DOI 10.1038/s41577-018-0119-y; Broz ML, 2014, CANCER CELL, V26, P638, DOI 10.1016/j.ccell.2014.09.007; Buck MD, 2017, CELL, V169, P570, DOI 10.1016/j.cell.2017.04.004; Burdette DL, 2011, NATURE, V478, P515, DOI 10.1038/nature10429; Cao GS, 2015, J BIOL CHEM, V290, P29964, DOI 10.1074/jbc.M115.674010; Cassier PA, 2015, LANCET ONCOL, V16, P949, DOI 10.1016/S1470-2045(15)00132-1; Cauwels A, 2018, CANCER RES, V78, P463, DOI 10.1158/0008-5472.CAN-17-1980; Cekic C, 2014, CANCER RES, V74, P7250, DOI 10.1158/0008-5472.CAN-13-3583; Chao MP, 2010, CELL, V142, P699, DOI 10.1016/j.cell.2010.07.044; Chauvin JM, 2015, J CLIN INVEST, V125, P2046, DOI 10.1172/JCI80445; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chesney J, 2018, J CLIN ONCOL, V36, P1658, DOI 10.1200/JCO.2017.73.7379; Chiba S, 2012, NAT IMMUNOL, V13, P832, DOI 10.1038/ni.2376; Chung HC, 2018, CELL, V172, P811, DOI 10.1016/j.cell.2017.12.038; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031; Crinier A, 2018, IMMUNITY, V49, P971, DOI 10.1016/j.immuni.2018.09.009; D'Aloia MM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0278-6; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; Dahan R, 2016, CANCER CELL, V29, P820, DOI 10.1016/j.ccell.2016.05.001; Daher M, 2018, CURR OPIN IMMUNOL, V51, P146, DOI 10.1016/j.coi.2018.03.013; Das M, 2017, IMMUNOL REV, V276, P97, DOI 10.1111/imr.12520; Della Chiesa M, 2006, BLOOD, V108, P4118, DOI 10.1182/blood-2006-06-006700; Demaria O, 2015, P NATL ACAD SCI USA, V112, P15408, DOI 10.1073/pnas.1512832112; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158; Dou ZX, 2017, NATURE, V550, P402, DOI 10.1038/nature24050; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Dunn GP, 2005, NAT IMMUNOL, V6, P722, DOI 10.1038/ni1213; Fiorica F, 2018, AM J CLIN ONCOL-CANC, V41, P1101, DOI 10.1097/COC.0000000000000428; Poulin LF, 2010, J EXP MED, V207, P1261, DOI 10.1084/jem.20092618; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Gabrilovich DI, 2017, CANCER IMMUNOL RES, V5, P3, DOI 10.1158/2326-6066.CIR-16-0297; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107; Gao P, 2013, CELL, V153, P1094, DOI 10.1016/j.cell.2013.04.046; Gao YL, 2017, NAT IMMUNOL, V18, P1004, DOI 10.1038/ni.3800; Garg AD, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1386829; Gauthier L, 2019, CELL, V177, P1701, DOI 10.1016/j.cell.2019.04.041; Gerdes CA, 2013, CLIN CANCER RES, V19, P1126, DOI 10.1158/1078-0432.CCR-12-0989; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Gibney GT, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0562-8; Godfrey DI, 2018, IMMUNITY, V48, P453, DOI 10.1016/j.immuni.2018.03.009; Gobel C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.531; Guo BC, 2016, SCI REP-UK, V6, DOI 10.1038/srep36107; Gyori D, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120631; Hammerich L, 2019, NAT MED, V25, P814, DOI 10.1038/s41591-019-0410-x; Harding SM, 2017, NATURE, V548, P466, DOI 10.1038/nature23470; Harizi H, 2002, J IMMUNOL, V168, P2255, DOI 10.4049/jimmunol.168.5.2255; Harrington K., 2018, ANN ONCOL, V29, DOI DOI 10.1093/ANNONC/MDY424.015; Herter S, 2013, MOL CANCER THER, V12, P2031, DOI 10.1158/1535-7163.MCT-12-1182; Hickish T, 2017, LANCET ONCOL, V18, P192, DOI 10.1016/S1470-2045(17)30006-2; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Ho SSW, 2016, IMMUNITY, V44, P1177, DOI 10.1016/j.immuni.2016.04.010; Hollingsworth RE, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0103-y; Holmgaard RB, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1151595; Holmgaard RB, 2015, CELL REP, V13, P412, DOI 10.1016/j.celrep.2015.08.077; Holmgaard RB, 2013, J EXP MED, V210, P1389, DOI 10.1084/jem.20130066; Hong DS, 2014, LANCET ONCOL, V15, P656, DOI 10.1016/S1470-2045(14)70155-X; Houot R, 2009, BLOOD, V113, P3546, DOI 10.1182/blood-2008-07-170274; Huang TH, 2007, J IMMUNOL, V179, P6881, DOI 10.4049/jimmunol.179.10.6881; Huntington ND, 2009, J EXP MED, V206, P25, DOI 10.1084/jem.20082013; Hurwitz ME, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.2623; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Ishizuka JJ, 2019, NATURE, V565, P43, DOI 10.1038/s41586-018-0768-9; Jandus C, 2014, J CLIN INVEST, V124, P1810, DOI 10.1172/JCI65899; Jimenez-Sanchez A, 2017, CELL, V170, P927, DOI 10.1016/j.cell.2017.07.025; Johnston RJ, 2014, CANCER CELL, V26, P923, DOI 10.1016/j.ccell.2014.10.018; Joller N, 2011, J IMMUNOL, V186, P1338, DOI 10.4049/jimmunol.1003081; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Khushalani NI, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.TPS9601; Kouo T, 2015, CANCER IMMUNOL RES, V3, P412, DOI 10.1158/2326-6066.CIR-14-0150; Kuan EL, 2018, NAT IMMUNOL, V19, P366, DOI 10.1038/s41590-018-0066-6; Le Mercier I, 2013, CANCER RES, V73, P4629, DOI 10.1158/0008-5472.CAN-12-3058; Li Y, 2018, CELL STEM CELL, V23, P181, DOI 10.1016/j.stem.2018.06.002; Liu HY, 2019, NAT MED, V25, P95, DOI 10.1038/s41591-018-0302-5; Long GV, 2019, LANCET ONCOL, V20, P1083, DOI 10.1016/S1470-2045(19)30274-8; Luke JJ, 2018, J CLIN ONCOL, V36, P1611, DOI 10.1200/JCO.2017.76.2229; Mach N, 2000, CANCER RES, V60, P3239; Mackenzie KJ, 2017, NATURE, V548, P461, DOI 10.1038/nature23449; Mantovani A, 2019, IMMUNITY, V50, P778, DOI 10.1016/j.immuni.2019.03.012; Mantovani A, 2018, IMMUNOL REV, V281, P57, DOI 10.1111/imr.12614; Marabelle A, 2017, ANN ONCOL, V28, P33, DOI 10.1093/annonc/mdx683; Marabelle A, 2013, J CLIN INVEST, V123, P2447, DOI 10.1172/JCI64859; Marcus A, 2018, IMMUNITY, V49, P754, DOI 10.1016/j.immuni.2018.09.016; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Markiewski MM, 2008, NAT IMMUNOL, V9, P1225, DOI 10.1038/ni.1655; Martinet L, 2010, BIOCHEM PHARMACOL, V80, P838, DOI 10.1016/j.bcp.2010.05.002; Mascanfroni ID, 2013, NAT IMMUNOL, V14, P1054, DOI 10.1038/ni.2695; McPherson A, 2016, NAT GENET, V48, P758, DOI 10.1038/ng.3573; Medler TR, 2018, CANCER CELL, V34, P561, DOI 10.1016/j.ccell.2018.09.003; Medzhitov R, 1999, COLD SPRING HARB SYM, V64, P429, DOI 10.1101/sqb.1999.64.429; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; Middleton MR, 2018, ANN ONCOL, V29; Mitchell TC, 2018, J CLIN ONCOL, V36, P3223, DOI 10.1200/JCO.2018.78.9602; Mittal D, 2014, CANCER RES, V74, P3652, DOI 10.1158/0008-5472.CAN-14-0957; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1038/ni.2131, 10.1031/ni.2131]; Munn DH, 2007, J CLIN INVEST, V117, P1147, DOI 10.1172/JCI31178; Murphy MA, 2012, J PROTEOMICS, V75, P4573, DOI 10.1016/j.jprot.2012.01.021; Nasi ML, 1999, CYTOKINES CELL MOL T, V5, P139; Novitskiy SV, 2012, J LEUKOCYTE BIOL, V92, P641, DOI 10.1189/jlb.1211639; O'Hara M, 2019, AACR 2019; Obeid M, 2007, CELL DEATH DIFFER, V14, P1848, DOI 10.1038/sj.cdd.4402201; Oberg HH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00814; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Okazaki T, 2007, INT IMMUNOL, V19, P813, DOI 10.1093/intimm/dxm057; OVERMAN MJ, 2018, J CLIN ONCOL S, V36; Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X; Papadopoulos KP, 2017, CLIN CANCER RES, V23, P5703, DOI 10.1158/1078-0432.CCR-16-3261; Paz-Ares LG, 2011, J CLIN ONCOL, V29, P3783, DOI 10.1200/JCO.2011.34.8888; Pencheva N, 2014, CELL, V156, P986, DOI 10.1016/j.cell.2014.01.038; Pencheva N, 2012, CELL, V151, P1068, DOI 10.1016/j.cell.2012.10.028; Peranzoni E, 2018, P NATL ACAD SCI USA, V115, pE4041, DOI 10.1073/pnas.1720948115; Perrot I, 2019, CELL REP, V27, P2411, DOI 10.1016/j.celrep.2019.04.091; Pradeu T, 2013, NAT REV IMMUNOL, V13, P764, DOI 10.1038/nri3521; Pulido AD, 2018, CANCER CELL, V33, P60, DOI 10.1016/j.ccell.2017.11.019; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Raulet DH, 2009, NAT REV IMMUNOL, V9, P568, DOI 10.1038/nri2604; Reuschenbach M, 2009, CANCER IMMUNOL IMMUN, V58, P1535, DOI 10.1007/s00262-009-0733-4; Ribas A, 2018, CANCER DISCOV, V8, P1250, DOI 10.1158/2159-8290.CD-18-0280; Ribas A, 2018, CELL, V174, P1031, DOI 10.1016/j.cell.2018.07.035; Ridker PM, 2017, LANCET, V390, P1833, DOI 10.1016/S0140-6736(17)32247-X; Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016; Rios-Doria J, 2015, NEOPLASIA, V17, P661, DOI 10.1016/j.neo.2015.08.004; Rodrigues E, 2018, CANCERS, V10, DOI 10.3390/cancers10060207; Roghanian A, 2015, CANCER CELL, V27, P473, DOI 10.1016/j.ccell.2015.03.005; Rossi EA, 2011, BLOOD, V118, P1877, DOI 10.1182/blood-2011-03-343145; Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015; Ruscetti M, 2018, SCIENCE, V362, P1416, DOI 10.1126/science.aas9090; Saad ED, 2017, NAT REV CLIN ONCOL, V14, P317, DOI 10.1038/nrclinonc.2017.8; Sagiv-Barfi I, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan4488; Salmon H, 2016, IMMUNITY, V44, P924, DOI 10.1016/j.immuni.2016.03.012; Salvagno C, 2019, NAT CELL BIOL, V21, P511, DOI 10.1038/s41556-019-0298-1; Sancho D, 2008, J CLIN INVEST, V118, P2098, DOI 10.1172/JCI34584; Scheper W, 2019, NAT MED, V25, P89, DOI 10.1038/s41591-018-0266-5; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Schmohl JU, 2016, ONCOTARGET, V7, P73830, DOI 10.18632/oncotarget.12073; Schreiber H, 2000, SEMIN CANCER BIOL, V10, P351, DOI 10.1006/scbi.2000.0331; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Sikic BI, 2019, J CLIN ONCOL, V37, P946, DOI 10.1200/JCO.18.02018; Sim GC, 2014, J CLIN INVEST, V124, P99, DOI 10.1172/JCI46266; Siu L, 2018, P AACR ANN M 2018; Sivick KE, 2018, CELL REP, V25, P3074, DOI 10.1016/j.celrep.2018.11.047; Spranger S, 2017, CANCER CELL, V31, P711, DOI 10.1016/j.ccell.2017.04.003; Stanczak MA, 2018, J CLIN INVEST, V128, P4912, DOI 10.1172/JCI120612; Stockert E, 1998, J EXP MED, V187, P1349, DOI 10.1084/jem.187.8.1349; Sun XF, 2010, GASTROENTEROLOGY, V139, P1030, DOI 10.1053/j.gastro.2010.05.007; Swann JB, 2007, J IMMUNOL, V178, P7540, DOI 10.4049/jimmunol.178.12.7540; Tannir NM, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.TPS4595; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Tavazoie MF, 2018, CELL, V172, P825, DOI 10.1016/j.cell.2017.12.026; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; Thomas DA, 2005, CANCER CELL, V8, P369, DOI 10.1016/j.ccr.2005.10.012; Titov A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0918-x; Uchida JJ, 2004, J EXP MED, V199, P1659, DOI 10.1084/jem.20040119; Vadrevu SK, 2014, CANCER RES, V74, P3454, DOI 10.1158/0008-5472.CAN-14-0157; Van Gool F, 2014, BLOOD, V124, P3572, DOI 10.1182/blood-2014-07-587493; van Montfoort N, 2018, CELL, V175, P1744, DOI 10.1016/j.cell.2018.10.028; Vanpouille-Box C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15618; Veillette A, 2018, TRENDS IMMUNOL, V39, P173, DOI 10.1016/j.it.2017.12.005; Viel S, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad1884; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687; Wang J, 2019, NAT MED, V25, P656, DOI 10.1038/s41591-019-0374-x; Wang J, 2019, CELL, V176, P334, DOI 10.1016/j.cell.2018.11.010; Wang L, 2011, J CLIN INVEST, V121, P2371, DOI 10.1172/JCI45559; Wang S, 2016, P NATL ACAD SCI USA, V113, pE7240, DOI 10.1073/pnas.1608555113; Wennerberg E, 2015, CANCER IMMUNOL IMMUN, V64, P225, DOI 10.1007/s00262-014-1629-5; Woo SR, 2014, IMMUNITY, V41, P830, DOI 10.1016/j.immuni.2014.10.017; Wu JX, 2014, ANNU REV IMMUNOL, V32, P461, DOI 10.1146/annurev-immunol-032713-120156; Xu F, 2014, CANCER RES, V74, P3418, DOI 10.1158/0008-5472.CAN-13-2690; Yang XM, 2014, CANCER CELL, V25, P37, DOI 10.1016/j.ccr.2013.12.004; Yu XJ, 2018, CANCER CELL, V33, P664, DOI 10.1016/j.ccell.2018.02.009; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zelenay S, 2015, CELL, V162, P1257, DOI 10.1016/j.cell.2015.08.015; Zhang Q, 2018, NAT IMMUNOL, V19, P723, DOI 10.1038/s41590-018-0132-0; Zhang X, 2013, MOL CELL, V51, P226, DOI 10.1016/j.molcel.2013.05.022; Zhou XM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02821; Zhu Y, 2014, CANCER RES, V74, P5057, DOI 10.1158/0008-5472.CAN-13-3723; Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845	201	300	310	24	313	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	2019	574	7776					45	56		10.1038/s41586-019-1593-5	http://dx.doi.org/10.1038/s41586-019-1593-5			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB8OZ	31578484				2023-01-03	WOS:000488832500028
J	Munoz, R; Hileeto, D; Cruz-Munoz, W; Wood, GA; Xu, P; Man, S; Viloria-Petit, A; Kerbel, RS				Munoz, Raquel; Hileeto, Denise; Cruz-Munoz, William; Wood, Geoffrey A.; Xu, Ping; Man, Shan; Viloria-Petit, Alicia; Kerbel, Robert S.			Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion	PLOS ONE			English	Article							GROWTH-FACTOR RECEPTOR; GENE COPY NUMBER; C-MET; TYROSINE KINASE; ADJUVANT CHEMOTHERAPY; THERAPEUTIC TARGET; PROTEIN EXPRESSION; ANTITUMOR-ACTIVITY; TUMOR-REGRESSION; CELL-LINES	Metronomic chemotherapy using the 5-FU prodrug uracil-tegafur (UFT) and cyclophosphamide (CTX) was previously shown to only modestly delay primary tumor growth, but nevertheless markedly suppressed the development of micro-metastasis in an orthotopic breast cancer xenograft model, using the metastatic variant of the MDA-MB-231 cell line, 231/LM2-4. Furthermore, a remarkable prolongation of survival, with no toxicity, was observed in a model of postsurgical advanced metastatic disease. A question that has remained unanswered is the seemingly selective anti-metastatic mechanisms of action responsible for this treatment. We assessed the in vivo effect of metronomic UFT, CTX or their combination, on vascular density, collagen deposition and c-Met (cell mediators or modulators of tumor cell invasion or dissemination) via histochemistry/immunohistochemistry of primary tumor sections. We also assessed the effect of continuous exposure to low and non-toxic doses of active drug metabolites 5-fluorouracil (5-FU), 4-hydroperoxycyclophosphamide (4-HC) or their combination, on 231/LM2-4 cell invasiveness in vitro. In the in vivo studies, a significant reduction in vascular density and p-Met[Y1003] levels was associated with UFT+CTX treatment. All treatments reduced intratumoral collagen deposition. In the in vitro studies, a significant reduction of collagen IV invasion by all treatments was observed. The 3D structures formed by 231/LM2-4 on Matrigel showed a predominantly Mass phenotype under treated conditions and Stellate phenotype in untreated cultures. Taken together, the results suggest the low-dose metronomic chemotherapy regimens tested can suppress several mediators of tumor invasiveness highlighting a new perspective for the anti-metastatic efficacy of metronomic chemotherapy.	[Munoz, Raquel; Cruz-Munoz, William; Xu, Ping; Man, Shan; Kerbel, Robert S.] Sunnybrook Res Inst, Biol Sci Platform, Toronto, ON, Canada; [Hileeto, Denise] Univ Waterloo, Sch Optometry & Vis Sci, Waterloo, ON, Canada; [Wood, Geoffrey A.] Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON, Canada; [Viloria-Petit, Alicia] Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON, Canada; [Kerbel, Robert S.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Munoz, Raquel] Univ Valladolid, Dept Biochem Physiol & Mol Biol, Valladolid, Spain	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Waterloo; University of Guelph; University of Guelph; University of Toronto; Universidad de Valladolid	Munoz, R; Kerbel, RS (corresponding author), Sunnybrook Res Inst, Biol Sci Platform, Toronto, ON, Canada.	rmunoz@bio.uva.es; robert.kerbel@sri.utoronto.ca	Wood, Geoffrey/ABB-2052-2021	Wood, Geoffrey/0000-0003-1756-8607; Munoz, Raquel/0000-0001-9861-0349	Canadian Institutes of Health Research [364411]; Canadian Breast Cancer Foundation; Ontario Veterinary College Bull Fellowship	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Ontario Veterinary College Bull Fellowship	This work was supported by grants from Canadian Institutes of Health Research grant 364411 and Canadian Breast Cancer Foundation to RSK, and an Ontario Veterinary College Bull Fellowship to AVP and RM.	Allegrini G, 2012, ANGIOGENESIS, V15, P275, DOI 10.1007/s10456-012-9260-6; Andre N, 2017, TRENDS CANCER, V3, P319, DOI 10.1016/j.trecan.2017.03.011; Barrow-McGee R, 2014, INT J BIOCHEM CELL B, V49, P69, DOI 10.1016/j.biocel.2014.01.009; Basaki Yuji, 2001, Angiogenesis, V4, P163, DOI 10.1023/A:1014059528046; Benton G, 2011, INT J CANCER, V128, P1751, DOI 10.1002/ijc.25781; Bertolini F, 2003, CANCER RES, V63, P4342; Bisogno G, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.18_suppl.LBA2; Black PC, 2010, BJU INT, V106, P1799, DOI 10.1111/j.1464-410X.2010.09424.x; Bocci G, 2005, ANN ONCOL, V16, P1243, DOI 10.1093/annonc/mdi240; Bocci G, 2002, CANCER RES, V62, P6938; Browder T, 2000, CANCER RES, V60, P1878; Cazzaniga ME, 2017, INT J BREAST CANCER, V2017, DOI 10.1155/2017/1683060; Cazzaniga ME, 2016, BREAST CANCER RES TR, V160, P501, DOI 10.1007/s10549-016-4009-3; Cazzaniga ME, 2017, CANCER LETT, V400, P252, DOI 10.1016/j.canlet.2016.12.019; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Chen MHS, 2008, MODERN PATHOL, V21, P1183, DOI 10.1038/modpathol.2008.90; Colleoni M, 2002, ANN ONCOL, V13, P73, DOI 10.1093/annonc/mdf013; Colleoni M, 2016, J CLIN ONCOL, V34, P3400, DOI 10.1200/JCO.2015.65.6595; Daenen LG, 2009, MOL CANCER THER, V8, P2872, DOI 10.1158/1535-7163.MCT-09-0583; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Ferrer-Font L, 2017, NMR BIOMED, V30, DOI 10.1002/nbm.3748; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Fujii M, 2008, J CANCER RES CLIN, V134, P1319, DOI 10.1007/s00432-008-0417-z; Gaule PB, 2014, EXPERT OPIN THER TAR, V18, P999, DOI 10.1517/14728222.2014.938050; Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262-006-0225-8; Hackl C, 2013, GUT, V62, P259, DOI 10.1136/gutjnl-2011-301585; Hanahan D, 2000, J CLIN INVEST, V105, P1045, DOI 10.1172/JCI9872; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hashimoto K, 2010, MOL CANCER THER, V9, P996, DOI 10.1158/1535-7163.MCT-09-0960; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Ho-Yen CM, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0547-6; Inoue T, 2004, CANCER SCI, V95, P803, DOI 10.1111/j.1349-7006.2004.tb02185.x; Jedeszko C, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010722; John T, 2009, ONCOGENE, V28, pS14, DOI 10.1038/onc.2009.197; Kang JY, 2003, CANCER RES, V63, P1101; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369; Kermorgant S, 2005, CELL CYCLE, V4, P352, DOI 10.4161/cc.4.3.1519; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Knight JF, 2013, P NATL ACAD SCI USA, V110, pE1301, DOI 10.1073/pnas.1210353110; Kurebayashi J, 1997, CLIN CANCER RES, V3, P653; Liu YY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173693; Lovitt CJ, 2015, J CANCER RES CLIN, V141, P951, DOI 10.1007/s00432-015-1950-1; Mai A, 2014, J CELL SCI, V127, P1938, DOI 10.1242/jcs.140657; Man S, 2002, CANCER RES, V62, P2731; Manni A, 2002, CLIN EXP METASTAS, V19, P95, DOI 10.1023/A:1014536909007; McLean KE, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-50; Montagna E, 2018, BREAST CARE, V13, P177, DOI 10.1159/000487630; Munoz R, 2006, CANCER RES, V66, P3386, DOI 10.1158/0008-5472.CAN-05-4411; Munzone E, 2015, NAT REV CLIN ONCOL, V385, P1843; Nagai N, 2008, MED ONCOL, V25, P214, DOI 10.1007/s12032-007-9023-1; Nakanishi H, 1999, CANCER LETT, V142, P31, DOI 10.1016/S0304-3835(99)00114-7; Noguchi S, 2005, J CLIN ONCOL, V23, P2172, DOI 10.1200/JCO.2005.02.158; Pasini F, 2018, INVEST NEW DRUG, V36, P927, DOI 10.1007/s10637-018-0631-8; Pasquier E, 2010, NAT REV CLIN ONCOL, V7, P455, DOI 10.1038/nrclinonc.2010.82; Patten SG, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-683; Penel N, 2012, CRIT REV ONCOL HEMAT, V82, P40, DOI 10.1016/j.critrevonc.2011.04.009; Ponzo MG, 2010, CELL CYCLE, V9, P1043, DOI 10.4161/cc.9.6.11033; Pozner-Moulis S, 2006, CANCER RES, V66, P7976, DOI 10.1158/0008-5472.CAN-05-4335; Puri N, 2007, CLIN CANCER RES, V13, P2246, DOI 10.1158/1078-0432.CCR-06-0776; Rakha EA, 2009, CLIN CANCER RES, V15, P2302, DOI 10.1158/1078-0432.CCR-08-2132; Saunders NA, 2012, EMBO MOL MED, V4, P675, DOI 10.1002/emmm.201101131; Shaked Y, 2016, CANCER RES, V76, P5983, DOI 10.1158/0008-5472.CAN-16-0136; Simkens LHJ, 2015, LANCET, V385, P1843, DOI 10.1016/S0140-6736(14)62004-3; Tanaka F, 2007, SURG TODAY, V37, P923, DOI 10.1007/s00595-007-3578-5; Uchida J, 2007, ONCOL REP, V18, P313; Ueda H, 2008, ONCOL REP, V19, P1355; Vidi Pierre-Alexandre, 2013, Methods Mol Biol, V945, P193, DOI 10.1007/978-1-62703-125-7_13; Viloria-Petit AM, 2009, P NATL ACAD SCI USA, V106, P14028, DOI 10.1073/pnas.0906796106; Wu JJ, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2597-2; Wu JJ, 2014, CANCER LETT, V353, P272, DOI 10.1016/j.canlet.2014.07.033; Xie YQ, 2014, MOL ENDOCRINOL, V28, P1629, DOI 10.1210/me.2014-1078; Xiong GF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-1; Yonekura K, 1999, CLIN CANCER RES, V5, P2185; Zucali PA, 2008, ANN ONCOL, V19, P1605, DOI 10.1093/annonc/mdn240	76	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2019	14	9							e0222580	10.1371/journal.pone.0222580	http://dx.doi.org/10.1371/journal.pone.0222580			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM5BF	31536574	Green Published, gold, Green Submitted			2023-01-03	WOS:000532262800055
J	Singer, AC; Xu, QY; Keller, VDJ				Singer, Andrew C.; Xu, Qiuying; Keller, Virginie D. J.			Translating antibiotic prescribing into antibiotic resistance in the environment: A hazard characterisation case study	PLOS ONE			English	Article							SEWAGE-TREATMENT PLANTS; WASTE-WATER TREATMENT; ESCHERICHIA-COLI; ANTIMICROBIAL RESISTANCE; EFFLUENT CONCENTRATIONS; HUMAN PHARMACEUTICALS; STEROID ESTROGENS; RISK-ASSESSMENT; CLIMATE-CHANGE; RIVER	The environment receives antibiotics through a combination of direct application (e.g., aquaculture and fruit production), as well as indirect release through pharmaceutical manufacturing, sewage and animal manure. Antibiotic concentrations in many sewage-impacted rivers are thought to be sufficient to select for antibiotic resistance genes. Yet, because antibiotics are nearly always found associated with antibiotic-resistant faecal bacteria in wastewater, it is difficult to distinguish the selective role of effluent antibiotics within a 'sea' of gut-derived resistance genes. Here we examine the potential for macrolide and fluoroquinolone prescribing in England to select for resistance in the River Thames catchment, England. We show that 64% and 74% of the length of the modelled catchment is chronically exposed to putative resistance-selecting concentrations (PNEC) of macrolides and fluoroquinolones, respectively. Under current macrolide usage, 115 km of the modelled River Thames catchment (8% of total length) exceeds the PNEC by 5-fold. Similarly, under current fluoroquinolone usage, 223 km of the modelled River Thames catchment (16% of total length) exceeds the PNEC by 5-fold. Our results reveal that if reduced prescribing was the sole mitigating measure, that macrolide and fluoroquinolone prescribing would need to decline by 77% and 85%, respectively, to limit resistance selection in the catchment. Significant reductions in antibiotic prescribing are feasible, but innovation in sewage-treatment will be necessary for achieving substantially-reduced antibiotic loads and inactivation of DNA-pollution from resistant bacteria. Greater confidence is needed in current risk-based targets for antibiotics, particularly in mixtures, to better inform environmental risk assessments and mitigation.	[Singer, Andrew C.; Xu, Qiuying; Keller, Virginie D. J.] NERC Ctr Ecol & Hydrol, Benson Lane, Wallingford, Oxon, England; [Xu, Qiuying] Royal Holloway Univ London, Environm Diag & Management, Egham, Surrey, England	UK Centre for Ecology & Hydrology (UKCEH); University of London; Royal Holloway University London	Singer, AC (corresponding author), NERC Ctr Ecol & Hydrol, Benson Lane, Wallingford, Oxon, England.	acsi@ceh.ac.uk	Keller, virginie/G-5328-2013; Singer, Andrew/B-3398-2010	Keller, virginie/0000-0003-4489-5363; Singer, Andrew/0000-0003-4705-6063	UKRI [NE/N019687/1]; NERC [NE/M011674/1, NE/M01133X/1, NE/N019687/1] Funding Source: UKRI	UKRI(UK Research & Innovation (UKRI)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	This work received an award from the UKRI-funded Cross Research Council AMR in the Real World, Grant NE/N019687/1 to ACS. The funder played no role in the study design, data collection or analysis.	Amos GCA, 2014, J ANTIMICROB CHEMOTH, V69, P1785, DOI 10.1093/jac/dku079; Amos GCA, 2018, ISME J, V12, P681, DOI 10.1038/s41396-017-0030-8; Amos GCA, 2015, ISME J, V9, P1467, DOI 10.1038/ismej.2014.237; AMR Industry Alliance, 2018, AMR ALL REC PNECS RI; Andersson DI, 2014, NAT REV MICROBIOL, V12, P465, DOI 10.1038/nrmicro3270; Andersson DI, 2012, DRUG RESIST UPDATE, V15, P162, DOI 10.1016/j.drup.2012.03.005; [Anonymous], 2018, ENGLISH SURVEILLANCE; Bai FJ, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02833; Bai YW, 2014, ENVIRON SCI-PROC IMP, V16, P586, DOI 10.1039/c3em00567d; Baker-Austin C, 2006, TRENDS MICROBIOL, V14, P176, DOI 10.1016/j.tim.2006.02.006; Baquero F, 2014, MBIO, V5, DOI 10.1128/mBio.02270-14; Barbosa MO, 2016, WATER RES, V94, P257, DOI 10.1016/j.watres.2016.02.047; Beane SJ, 2016, CHEMOSPHERE, V153, P294, DOI 10.1016/j.chemosphere.2016.03.022; Bengtsson-Palme J, 2016, SCI TOTAL ENVIRON, V572, P697, DOI 10.1016/j.scitotenv.2016.06.228; Bengtsson-Palme J, 2016, ENVIRON INT, V86, P140, DOI 10.1016/j.envint.2015.10.015; Berglund B, 2015, ENVIRON TOXICOL CHEM, V34, P192, DOI 10.1002/etc.2784; Besse JP, 2008, HUM ECOL RISK ASSESS, V14, P665, DOI 10.1080/10807030802235078; Besse JP, 2008, TOXICOL LETT, V176, P104, DOI 10.1016/j.toxlet.2007.10.012; Brochado AR, 2018, NATURE, V559, P259, DOI 10.1038/s41586-018-0278-9; BROGARD JM, 1988, PATHOL BIOL, V36, P719; Burgmann H, 2018, FEMS MICROBIOL ECOL, V94, DOI 10.1093/femsec/fiy101; Carey DE, 2015, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00780; Carvalho RN, 2015, EUR27142 EUR COMM; Chait R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10333; Comber SDW, 2005, CHEM SPEC BIOAVAILAB, V17, P117, DOI 10.3184/095422905782774874; Comber S, 2018, SCI TOTAL ENVIRON, V613, P538, DOI 10.1016/j.scitotenv.2017.09.101; Cormican M, 2017, EFSA J, V15, DOI 10.2903/j.efsa.2017.5017; Cottell JL, 2011, EMERG INFECT DIS, V17, P645, DOI 10.3201/eid1704.101009; Davies SC, 2018, J ANTIMICROB CHEMOTH, V73, P833, DOI 10.1093/jac/dkx535; Davies SC, 2011, ANN REPORT CHIEF MED; Dhanji H, 2011, J ANTIMICROB CHEMOTH, V66, P1005, DOI 10.1093/jac/dkr041; Dhanji H, 2011, J ANTIMICROB CHEMOTH, V66, P512, DOI 10.1093/jac/dkq472; Dhanji H, 2011, J ANTIMICROB CHEMOTH, V66, P297, DOI 10.1093/jac/dkq463; Di Cesare A, 2016, J LIMNOL, V75, P59, DOI 10.4081/jlimnol.2016.1198; Dong PY, 2019, ENVIRON INT, V125, P90, DOI 10.1016/j.envint.2019.01.050; European Commission, 2010, RES STRAT ADDR KNOWL; European Commission, 2017, EUR 1 HLTH ACT PLAN; Finistrella V, 2016, RESISTANCE HEALTHCAR; Furness LE, 2017, ENVIRON RES, V154, P28, DOI 10.1016/j.envres.2016.12.014; Gao LH, 2012, J ENVIRON MONITOR, V14, P1248, DOI 10.1039/c2em10916f; Gillings MR, 2018, CURR POLLUT REP, V4, P49, DOI 10.1007/s40726-018-0076-x; Gobel A, 2007, SCI TOTAL ENVIRON, V372, P361, DOI 10.1016/j.scitotenv.2006.07.039; Gouliouris T, 2019, GENOME RES, V29, P626, DOI 10.1101/gr.232629.117; Government HM, 2019, TACKL ANT RES 2019 2; Gullberg E, 2014, MBIO, V5, DOI 10.1128/mBio.01918-14; Gullberg E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002158; Harris CA, 2011, ENVIRON HEALTH PERSP, V119, P306, DOI 10.1289/ehp.1002555; Hernando-Amado S, 2017, ESSAYS BIOCHEM, V61, P37, DOI 10.1042/EBC20160057; Hu AY, 2017, ENVIRON MICROBIOL, V19, P4993, DOI 10.1111/1462-2920.13942; Hughes D, 2012, CURR OPIN MICROBIOL, V15, P555, DOI 10.1016/j.mib.2012.07.005; International Environmental AMR Forum, 2018, IN ADDR ANT RES ENV; Jakobsson HE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009836; Jang J, 2017, J APPL MICROBIOL, V123, P570, DOI 10.1111/jam.13468; Jia A, 2012, WATER RES, V46, P387, DOI 10.1016/j.watres.2011.10.055; Jobling S, 2006, ENVIRON HEALTH PERSP, V114, P32, DOI 10.1289/ehp.8050; Johnson AC, 2004, ENVIRON SCI TECHNOL, V38, P3649, DOI 10.1021/es035342u; Johnson AC, 2008, J HYDROL, V348, P167, DOI 10.1016/j.jhydrol.2007.09.054; Johnson AC, 2017, ENVIRON POLLUT, V220, P919, DOI 10.1016/j.envpol.2016.10.077; Johnson AC, 2015, SCI TOTAL ENVIRON, V511, P747, DOI 10.1016/j.scitotenv.2014.12.055; Johnson AC, 2013, ENVIRON SCI TECHNOL, V47, P12297, DOI 10.1021/es4030035; Johnson AC, 2009, SCI TOTAL ENVIRON, V407, P4787, DOI 10.1016/j.scitotenv.2009.05.018; Kampf G, 2019, ANTIBIOTICS-BASEL, V8, DOI 10.3390/antibiotics8010013; Karkman A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07992-3; Keller V, 2004, DEV INTEGRATED WATER; Keller VDJ, 2015, ENVIRON POLLUT, V197, P262, DOI 10.1016/j.envpol.2014.11.017; Keller VDJ, 2014, ENVIRON TOXICOL CHEM, V33, P447, DOI 10.1002/etc.2441; Khan S, 2017, ECOTOXICOLOGY, V26, P283, DOI 10.1007/s10646-017-1762-y; Kraupner N, 2018, ENVIRON INT, V116, P255, DOI 10.1016/j.envint.2018.04.029; Kugathas S, 2012, ENVIRON INT, V40, P15, DOI 10.1016/j.envint.2011.11.007; Kummerer K, 2003, CLIN MICROBIOL INFEC, V9, P1203, DOI 10.1111/j.1469-0691.2003.00739.x; Kurenbach B, 2017, MICROBIOL-SGM, V163, P1791, DOI 10.1099/mic.0.000573; Kurenbach B, 2015, MBIO, V6, DOI 10.1128/mBio.00009-15; Lehmann K, 2016, WATER RES, V106, P163, DOI 10.1016/j.watres.2016.09.035; Li RC, 2018, INT J ANTIMICROB AG, V51, P578, DOI 10.1016/j.ijantimicag.2017.11.015; Lienert J, 2007, ENVIRON SCI TECHNOL, V41, P4471, DOI 10.1021/es0627693; Lindberg RH, 2005, ENVIRON SCI TECHNOL, V39, P3421, DOI 10.1021/es048143z; Liu A, 2011, ANTIMICROB AGENTS CH, V55, P1204, DOI 10.1128/AAC.01182-10; Mai CY, 2018, OPEN MED-WARSAW, V13, P509, DOI 10.1515/med-2018-0075; Marti E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078906; McCann CM, 2019, ENVIRON INT, V125, P497, DOI 10.1016/j.envint.2019.01.034; McNulty CAM, 2018, J ANTIMICROB CHEMOTH, V73, P1368, DOI 10.1093/jac/dky007; Mezger A, 2015, J CLIN MICROBIOL, V53, P425, DOI 10.1128/JCM.02434-14; Michael I, 2013, WATER RES, V47, P957, DOI 10.1016/j.watres.2012.11.027; Monteiro SC, 2010, REV ENVIRON CONTAM T, V202, P53, DOI 10.1007/978-1-4419-1157-5_2; Murray AK, 2019, INT J ANTIMICROB AG, V53, P767, DOI 10.1016/j.ijantimicag.2019.03.001; Murray AK, 2018, MBIO, V9, DOI 10.1128/mBio.00969-18; Murray GL, 2017, EMERG INFECT DIS, V23, P809, DOI 10.3201/eid2305.161745; NHS England Contracts and Incentives Team, 2015, QUAL PREM 2015 16 GU; Nightingale CH, 2000, PHARMACOTHERAPY, V20, P245, DOI 10.1592/phco.20.4.245.34880; O'Brien TF, 2002, CLIN INFECT DIS, V34, pS78, DOI 10.1086/340244; Ohlsen K, 2003, ENVIRON MICROBIOL, V5, P711, DOI 10.1046/j.1462-2920.2003.00459.x; Owen R, 2012, NATURE, V485, P441, DOI 10.1038/485441a; Parnanen KMM, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau9124; Paulus GK, 2019, INT J HYG ENVIR HEAL, V222, P635, DOI 10.1016/j.ijheh.2019.01.004; Pouwels KB, 2018, J ANTIMICROB CHEMOTH, V73, P19, DOI 10.1093/jac/dkx502; Pruden A, 2006, ENVIRON SCI TECHNOL, V40, P7445, DOI 10.1021/es060413l; Qiao M, 2018, ENVIRON INT, V110, P160, DOI 10.1016/j.envint.2017.10.016; Radjenovic J, 2009, WATER RES, V43, P831, DOI 10.1016/j.watres.2008.11.043; Runcharoen C, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0397-1; Sabri NA, 2020, J ENVIRON CHEM ENG, V8, DOI 10.1016/j.jece.2018.03.004; Sandegren L, 2014, UPSALA J MED SCI, V119, P103, DOI 10.3109/03009734.2014.904457; Seiler C, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00399; Singer AC, 2007, ENVIRON HEALTH PERSP, V115, P102, DOI 10.1289/ehp.9574; Singer AC, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01728; Singer AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108621; Singer AC, 2011, ENVIRON HEALTH PERSP, V119, P1084, DOI 10.1289/ehp.1002757; Smieszek T, 2018, J ANTIMICROB CHEMOTH, V73, P36, DOI 10.1093/jac/dkx500; Song YZ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16898-x; Sousa JCG, 2018, J HAZARD MATER, V344, P146, DOI 10.1016/j.jhazmat.2017.09.058; Strukova EN, 2016, J ANTIMICROB CHEMOTH, V71, P678, DOI 10.1093/jac/dkv387; Tekin E, 2018, NPJ SYST BIOL APPL, V4, DOI 10.1038/s41540-018-0069-9; The White House, 2015, NAT ACT PLAN COMB AN; Valverde A, 2009, ANTIMICROB AGENTS CH, V53, P5204, DOI 10.1128/AAC.01706-08; Veterinary Medicines Directorate, 2018, UK VET ANT RES SAL S; Vikesland P, 2019, ACCOUNTS CHEM RES, V52, P916, DOI 10.1021/acs.accounts.8b00643; Watkinson AJ, 2007, WATER RES, V41, P4164, DOI 10.1016/j.watres.2007.04.005; Watkinson AJ, 2009, SCI TOTAL ENVIRON, V407, P2711, DOI 10.1016/j.scitotenv.2008.11.059; Weingarten RA, 2018, MBIO, V9, DOI 10.1128/mBio.02011-17; Williams RJ, 2009, ENVIRON TOXICOL CHEM, V28, P220, DOI 10.1897/08-047.1; Yazdankhah SP, 2006, MICROB DRUG RESIST, V12, P83, DOI 10.1089/mdr.2006.12.83; Young AR, 2003, WATER SCI TECHNOL, V48, P119, DOI 10.2166/wst.2003.0554; Zhang QQ, 2015, ENVIRON SCI TECHNOL, V49, P6772, DOI 10.1021/acs.est.5b00729; Zhang Y, 2018, ENVIRON POLLUT, V237, P74, DOI 10.1016/j.envpol.2018.01.032	123	18	18	10	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2019	14	9							e0221568	10.1371/journal.pone.0221568	http://dx.doi.org/10.1371/journal.pone.0221568			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IY3SM	31483803	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000486313000037
J	Colombet, I; Rigal, L; Urtizberea, M; Vinant, P; Rouquette, A				Colombet, Isabelle; Rigal, Laurent; Urtizberea, Miren; Vinant, Pascale; Rouquette, Alexandra			Validity of the French version of the Autonomy Preference Index and its adaptation for patients with advanced cancer	PLOS ONE			English	Article							SHARED DECISION-MAKING; END-OF-LIFE; FIT INDEXES; INTERNATIONAL CONSENSUS; CULTURAL-ADAPTATION; NEAR-DEATH; INFORMATION; CARE; HEALTH; RECOMMENDATIONS	Background While patient-centered care is recommended as a key dimension for quality improvement, in case of serious illness, patients may have different expectations regarding information and participation in medical decision-making. In oncology, anticipation of disease worsening remains difficult, especially when patient's preferences towards prognosis medical information are unclear. Valid tools to explore patients' preferences could help targeting end-of-life discussions, which have been shown to decrease aggressiveness of end-of-life care. Our aim was to establish the validity and reliability of the French version of the Autonomy Preference Index (API) among patients with incurable cancer and in primary care setting. Three supplementary items were specifically developed to evaluate preparedness to anticipate disease deterioration among patients with incurable cancer. Methods The psychometric properties of the API translated into French were assessed among patients consecutively recruited from January to March 2017 in the waiting rooms of 19 general practitioners (N = 391) and in an oncology (N = 187) clinic in Paris. Relationships between the newly-developed items and the API subscale scores were studied. Results A three correlated factors confirmatory model (two factors related to decision-making and a factor related to information-seeking preferences) showed an acceptable fit on the whole sample and no measurement invariance issue was found across settings, age, sex and educational level. Internal consistency and test-retest reliability were acceptable for the information-seeking and decision-making subscales. One of the newly-developed items on patients' ability to anticipate a decision on the use of artificial respiration if a sudden deterioration of their illness occurred was not related to the API subscale scores. Conclusion The French version of the API was found valid and reliable for use in general practice and oncology settings. The additional items on patient preparedness to anticipate disease deterioration can be of interest to ensure that patient values guide all end-of-life clinical decisions.	[Colombet, Isabelle; Urtizberea, Miren] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Colombet, Isabelle; Vinant, Pascale] Cochin Hosp, AP HP, Palliat Med, Paris, France; [Rigal, Laurent; Rouquette, Alexandra] Univ Paris Saclay, UVSQ, Inserm, CESP, Paris, France; [Rigal, Laurent] Univ Paris Saclay, Dept Gen Practice, Le Kremlin Bicetre, France; [Rouquette, Alexandra] Bicetre Hosp, AP HP, Publ Hlth & Epidemiol Dept, Le Kremlin Bicetre, France	UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP	Rouquette, A (corresponding author), Univ Paris Saclay, UVSQ, Inserm, CESP, Paris, France.; Rouquette, A (corresponding author), Bicetre Hosp, AP HP, Publ Hlth & Epidemiol Dept, Le Kremlin Bicetre, France.	alex.rouquette@gmail.com	Rouquette, Alexandra/AGY-2116-2022; Colombet, Isabelle/J-8186-2017	Rouquette, Alexandra/0000-0002-2473-1719; Colombet, Isabelle/0000-0002-8721-1526	Fonds pour les Soins Palliatifs [Convention with Paris Descartes University] [J17P99CONV11]	Fonds pour les Soins Palliatifs [Convention with Paris Descartes University]	This work (IC) was supported by the Fonds pour les Soins Palliatifs [Convention with Paris Descartes University no J17P99CONV11]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to thank all the participants in the study, Lamisse Bouti (MSc) from the Research Center in Epidemiology and Population Health, INSERM U1018 and Paris-Sud University for her work in the data management and exploratory analyses processes, Lotfi Dahmane from the Public Health and Epidemiology Department of Paris-Sud University Hospitals for his help for data collection and regulatory procedures, Marie-Yvonne Guillard from the palliative care team for her help in the identification of patients eligible for the ONCO sample, Pr Francois Goldwasser head of the oncology department of the Cochin Hospital and all the staff members for their help in recruitment in the ONCO sample, and the general practitioners and Aude Benichou from the General Practice Department of the Paris-Sud University for their help in recruitment and data collection in the GP sample.	American Educational Research Association American Psychological Association & National Council on Measurement in Education, 2014, STAND ED PSYCH TEST; Anagnostou D, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015277; Barry MJ, 2012, NEW ENGL J MED, V366, P780, DOI 10.1056/NEJMp1109283; Belanger E, 2011, PALLIATIVE MED, V25, P242, DOI 10.1177/0269216310389348; Bonfils KA, 2015, PSYCHIAT RES, V228, P526, DOI 10.1016/j.psychres.2015.06.004; Brown T. A., 2015, CONFIRMATORY FACTOR, V2nd; Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; Chen FF, 2007, STRUCT EQU MODELING, V14, P464, DOI 10.1080/10705510701301834; Cheung GW, 2002, STRUCT EQU MODELING, V9, P233, DOI 10.1207/S15328007SEM0902_5; CRONBACH LJ, 1955, PSYCHOL BULL, V52, P281, DOI 10.1037/h0040957; Davis MA, 1999, ACAD EMERG MED, V6, P781, DOI 10.1111/j.1553-2712.1999.tb01206.x; De Vet H.C., 2011, MEASUREMENT MED PRAC; El-Jawahri A, 2019, ONCOLOGIST, V24, P247, DOI 10.1634/theoncologist.2018-0317; ENDE J, 1989, J GEN INTERN MED, V4, P23, DOI 10.1007/BF02596485; Epstein J, 2015, J CLIN EPIDEMIOL, V68, P435, DOI 10.1016/j.jclinepi.2014.11.021; Epstein J, 2015, J CLIN EPIDEMIOL, V68, P360, DOI 10.1016/j.jclinepi.2013.07.013; Gaston CM, 2005, SOC SCI MED, V61, P2252, DOI 10.1016/j.socscimed.2005.04.015; Gattellari M, 2002, J CLIN ONCOL, V20, P503, DOI 10.1200/JCO.20.2.503; GIBSON PG, 1995, CHEST, V107, P1003, DOI 10.1378/chest.107.4.1003; Hagerty RG, 2004, J CLIN ONCOL, V22, P1721, DOI 10.1200/JCO.2004.04.095; Hagerty RG, 2005, J CLIN ONCOL, V23, P1278, DOI 10.1200/JCO.2005.11.138; Hill SA, 2006, J MENTAL HLTH, V15, P75, DOI DOI 10.1080/09638230500512250; Hoerger M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-188; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Jenkins V, 2011, J CLIN ONCOL, V29, P61, DOI 10.1200/JCO.2010.30.0814; Kline R.B., 2006, PRINCIPLES PRACTICE, V2nd; KRANTZ DS, 1980, J PERS SOC PSYCHOL, V39, P977, DOI 10.1037/0022-3514.39.5.977; Legare F, 2014, PATIENT EDUC COUNS, V96, P281, DOI 10.1016/j.pec.2014.06.014; Maciejewski PK, 2013, J PAIN SYMPTOM MANAG, V45, P841, DOI 10.1016/j.jpainsymman.2012.04.003; Mack JW, 2012, J CLIN ONCOL, V30, P4387, DOI 10.1200/JCO.2012.43.6055; Marsh HW, 2013, DEV PSYCHOL, V49, P1194, DOI 10.1037/a0026913; Millsap R. E., 2011, STAT APPROACHES MEAS; Mokkink LB, 2018, QUAL LIFE RES, V27, P1171, DOI 10.1007/s11136-017-1765-4; Mokkink LB, 2010, J CLIN EPIDEMIOL, V63, P737, DOI 10.1016/j.jclinepi.2010.02.006; Morandi S, 2017, PSYCHOL ASSESSMENT, V29, P110, DOI 10.1037/pas0000327; Muthen L.K., 2015, MPLUS USERS GUIDE VE, Vseventh; Muthn LK, 2012, MPLUS STAT ANAL LATE; Pennec S, 2012, BMC PALLIAT CARE, V11, DOI 10.1186/1472-684X-11-25; Rietjens JAC, 2017, LANCET ONCOL, V18, pE543, DOI 10.1016/S1470-2045(17)30582-X; Rouquette A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215073; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Simon D, 2010, HEALTH EXPECT, V13, P234, DOI 10.1111/j.1369-7625.2009.00584.x; Solomon R, 2017, PATIENT, V10, P489, DOI 10.1007/s40271-017-0226-z; Spies CD, 2006, ACTA ANAESTH SCAND, V50, P1019, DOI 10.1111/j.1399-6576.2006.01097.x; StataCorp, 2012, STAT STAT SOFTW REL; Stein RA, 2013, J CLIN ONCOL, V31, P3403, DOI 10.1200/JCO.2011.40.8872; Vinant P, 2015, B CANCER, V102, P234, DOI 10.1016/j.bulcan.2015.01.009; Washington KT, 2016, PALLIATIVE MED, V30, P270, DOI 10.1177/0269216315601545; Watkins MW, 2017, CLIN NEUROPSYCHOL, V31, P1113, DOI 10.1080/13854046.2017.1317364; Weeks JC, 2012, NEW ENGL J MED, V367, P1616, DOI 10.1056/NEJMoa1204410; Wild D, 2005, VALUE HEALTH, V8, P94, DOI 10.1111/j.1524-4733.2005.04054.x; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665	52	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2020	15	1							e0227802	10.1371/journal.pone.0227802	http://dx.doi.org/10.1371/journal.pone.0227802			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP5JP	31935263	Green Published, gold			2023-01-03	WOS:000534354100053
J	Desai, RJ; Sarpatwari, A; Gautam, N; Lii, J; Fischer, MA; Gagne, JJ				Desai, Rishi J.; Sarpatwari, Ameet; Gautam, Nileesa; Lii, Joyce; Fischer, Michael A.; Gagne, Joshua J.			Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter								This pharmacoepidemiology study uses claims data to characterize angiotensin receptor blocker (ARB) prescription trends to evaluate whether recalls of ARBs prompted by discovery of potentially carcinogenic impurities shifted utilization of ARBs individually and as a drug class.	[Desai, Rishi J.; Sarpatwari, Ameet; Gautam, Nileesa; Lii, Joyce; Fischer, Michael A.; Gagne, Joshua J.] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Desai, RJ (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, 1620 Tremont St,Ste 3030-R, Boston, MA 02120 USA.	rdesai@bwh.harvard.edu	Desai, Rishi/AAH-8988-2021					[Anonymous], FDA UPD PRESS ANN AN; [Anonymous], 2019, FDA STAT FDAS ONG IN; Byrd JB, 2019, NEW ENGL J MED, V380, P1589, DOI 10.1056/NEJMp1901657; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766	4	4	4	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	2020	323	1					87	89		10.1001/jama.2019.17521	http://dx.doi.org/10.1001/jama.2019.17521			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB9WM	31910271	Green Published, Bronze			2023-01-03	WOS:000506838300020
J	Birkner, B; Rech, J; Stargardt, T				Birkner, Benjamin; Rech, Juergen; Stargardt, Tom			Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis	PLOS ONE			English	Article							ADALIMUMAB PLUS METHOTREXATE; DOUBLE-BLIND; ECONOMIC-EVALUATION; EULAR RECOMMENDATIONS; CONTINGENT VALUATION; PARALLEL-GROUP; PHASE-III; ETANERCEPT; REMISSION; SAFETY	Objective Recent guideline updates have suggested de-escalating DMARDs when patients with rheumatoid arthritis achieve remission or low disease activity. We aim to evaluate whether it is cost-effective to de-escalate the biological form of DMARDs (bDMARDs). Methods Using a Markov model, we performed a cost-utility analysis for RA patients on bDMARD treatment. We compared continuing treatment (standard care) to a tapering approach (i.e., an immediate 50% dose reduction), withdrawal (i.e., an immediate 100% dose reduction) and tapering followed by withdrawal of bDMARDs. The parametrization is based on a comprehensive literature review. Results were computed for 30 years with a cycle length of three months. We applied the payer's perspective for Germany and conducted deterministic and probabilistic sensitivity analyses. Results Tapering or withdrawing bDMARD treatment resulted in ICERs of (sic)526,254 (incr. costs -78,845, incr. QALYs -0.1498) or (sic)216,879 (incr. costs -(sic)121,691, incr. QALYs -0.5611) compared to standard care. Tapering followed by withdrawal resulted in a loss of 0.4354 QALYs and savings of (sic)107,969 per patient, with an ICER of (sic)247,987. Deterministic sensitivity analysis revealed that our results remained largely unaffected by parameter changes. Probabilistic sensitivity analysis suggests that tapering, withdrawal and tapering followed by withdrawal were dominant in 39.8%, 28.2% and 29.0% of 10,000 iterations. Conclusion Our findings suggest that de-escalating bDMARDs in patients with RA may result in high cost savings but also a decrease in quality of life compared to standard care. If decision makers choose to implement de-escalation in daily practice, our results suggest the tapering approach.	[Birkner, Benjamin; Stargardt, Tom] Univ Hamburg, HCHE, Hamburg, Germany; [Rech, Juergen] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Internal Med, Erlangen, Germany; Univ Klinikum Erlangen, Rheumatol & Immunol, Erlangen, Germany	University of Hamburg; University of Erlangen Nuremberg; University of Erlangen Nuremberg	Birkner, B (corresponding author), Univ Hamburg, HCHE, Hamburg, Germany.	benjamin.birkner@uni-hamburg.de		Birkner, Benjamin/0000-0002-4452-4733				Ahlert M, 2016, SOC SCI MED, V150, P40, DOI 10.1016/j.socscimed.2015.11.055; Alamanos Y, 2006, SEMIN ARTHRITIS RHEU, V36, P182, DOI 10.1016/j.semarthrit.2006.08.006; Albrecht K, 2017, Z RHEUMATOL, V76, P50, DOI 10.1007/s00393-016-0156-5; Aletaha D, 2005, CLIN EXP RHEUMATOL, V23, pS100; [Anonymous], 2016, HERC DATABASE MAPPIN; Ara R, 2008, VALUE HEALTH, V11, P1131, DOI 10.1111/j.1524-4733.2008.00352.x; Boger RH, 2016, ARZNEIVERORDNUNGS RE, P369, DOI [10.1007/978-3-662-50351-5_19, DOI 10.1007/978-3-662-50351-5_19]; Briggs A., 2011, DECISION MODELLING H; Carthy T, 1998, J RISK UNCERTAINTY, V17, P187, DOI 10.1023/A:1007782800868; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dougados M, 2014, ANN RHEUM DIS, V73, P803, DOI 10.1136/annrheumdis-2013-204761; Emery P, 2008, LANCET, V372, P375, DOI 10.1016/S0140-6736(08)61000-4; Emery P, 2014, NEW ENGL J MED, V371, P1781, DOI 10.1056/NEJMoa1316133; Fautrel B, 2016, JOINT BONE SPINE, V83, P53, DOI 10.1016/j.jbspin.2015.02.023; Fiehn C, 2018, Z RHEUMATOL, V77, pS35, DOI 10.1007/s00393-018-0481-y; Filipovic-Pierucci A, 2017, ARXIV170203252TAT; Haschka J, 2016, ANN RHEUM DIS, V75, P45, DOI 10.1136/annrheumdis-2014-206439; Hense S, 2016, Z RHEUMATOL, V75, P819, DOI 10.1007/s00393-016-0088-0; Horslev-Petersen K, 2014, ANN RHEUM DIS, V73, P654, DOI 10.1136/annrheumdis-2012-202735; Huscher D, 2015, ANN RHEUM DIS, V74, P738, DOI 10.1136/annrheumdis-2013-204311; Hutubessy Raymond, 2003, Cost Eff Resour Alloc, V1, P8, DOI 10.1186/1478-7547-1-8; Jonsson B, 2008, EUR J HEALTH ECON, V8, pS61, DOI 10.1007/s10198-007-0089-7; Kavanaugh A, 2013, ANN RHEUM DIS, V72, P64, DOI 10.1136/annrheumdis-2011-201247; Keystone EC, 2016, RHEUMATOLOGY, V55, P327, DOI 10.1093/rheumatology/kev338; Kim HY, 2012, INT J RHEUM DIS, V15, P188, DOI 10.1111/j.1756-185X.2011.01680.x; Kobelt G, 2014, VALUE HEALTH, V17, P537, DOI 10.1016/j.jval.2014.04.005; Kremer JM, 2005, ARTHRITIS RHEUM, V52, P2263, DOI 10.1002/art.21201; Kuijper TM, 2015, J RHEUMATOL, V42, P2012, DOI 10.3899/jrheum.141520; Lau CS, 2015, INT J RHEUM DIS, V18, P685, DOI 10.1111/1756-185X.12754; Listing J, 2015, ANN RHEUM DIS, V74, P415, DOI 10.1136/annrheumdis-2013-204021; Lundkvist J, 2008, EUR J HEALTH ECON, V8, pS49, DOI 10.1007/s10198-007-0088-8; Machado DA, 2014, JCR-J CLIN RHEUMATOL, V20, P25, DOI 10.1097/RHU.0000000000000055; Markusse IM, 2014, CLIN RHEUMATOL, V33, P1155, DOI 10.1007/s10067-014-2500-y; Nam JL, 2014, ANN RHEUM DIS, V73, P1027, DOI 10.1136/annrheumdis-2013-204882; Nam JL, 2014, ANN RHEUM DIS, V73, P516, DOI 10.1136/annrheumdis-2013-204577; Neubauer S, 2014, HEALTH ECON REV, V4, DOI 10.1186/s13561-014-0032-4; O'Brien BJ, 1998, MED CARE, V36, P370, DOI 10.1097/00005650-199803000-00013; Rubbert-Roth A, 2010, RHEUMATOLOGY, V49, P1683, DOI 10.1093/rheumatology/keq116; Schett G, 2016, ANN RHEUM DIS, V75, P1428, DOI 10.1136/annrheumdis-2016-209201; Schiff M, 2008, ANN RHEUM DIS, V67, P1096, DOI 10.1136/ard.2007.080002; Schiff M, 2014, ANN RHEUM DIS, V73, P86, DOI 10.1136/annrheumdis-2013-203843; Singh JA, 2016, ARTHRITIS RHEUMATOL, V68, P1, DOI 10.1002/art.39480; Smolen JS, 2016, LANCET, V388, P1984; Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis-2016-210715; Smolen JS, 2014, LANCET, V383, P321, DOI 10.1016/S0140-6736(13)61751-1; Smolen JS, 2013, LANCET, V381, P918, DOI 10.1016/S0140-6736(12)61811-X; Tanaka Y, 2010, ANN RHEUM DIS, V69, P1286, DOI 10.1136/ard.2009.121491; Tanaka Y, 2015, ANN RHEUM DIS, V74, P389, DOI 10.1136/annrheumdis-2013-204016; Tran-Duy A, 2018, ARTHRITIS RHEUMATOL, V70, P1557, DOI 10.1002/art.40546; VANHERWAARDEN N, 2015, BMJ-BRIT MED J, V350, P1389, DOI DOI 10.1136/BMJ.H1389; Vanier A, 2017, VALUE HEALTH, V20, P577, DOI 10.1016/j.jval.2017.01.005; Welsing PMJ, 2006, PHARMACOECONOMICS, V24, P1011, DOI 10.2165/00019053-200624100-00008; Westhovens R, 2006, ARTHRITIS RHEUM-US, V54, P1075, DOI 10.1002/art.21734; Wiens A, 2010, PHARMACOTHERAPY, V30, P339, DOI 10.1592/phco.30.4.339; Yoo DH, 2013, ANN RHEUM DIS, V72, P1613, DOI 10.1136/annrheumdis-2012-203090	55	7	8	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 2	2020	15	1							e0226754	10.1371/journal.pone.0226754	http://dx.doi.org/10.1371/journal.pone.0226754			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP4DA	31895926	Green Published, gold			2023-01-03	WOS:000534267300009
J	Russo, M; Crisafulli, G; Sogari, A; Reilly, NM; Arena, S; Lamba, S; Bartolini, A; Amodio, V; Magri, A; Novara, L; Sarotto, I; Nagel, ZD; Piett, CG; Amatu, A; Sartore-Bianchi, A; Siena, S; Bertotti, A; Trusolino, L; Corigliano, M; Gherardi, M; Lagomarsino, MC; Di Nicolantonio, F; Bardelli, A				Russo, Mariangela; Crisafulli, Giovanni; Sogari, Alberto; Reilly, Nicole M.; Arena, Sabrina; Lamba, Simona; Bartolini, Alice; Amodio, Vito; Magri, Alessandro; Novara, Luca; Sarotto, Ivana; Nagel, Zachary D.; Piett, Cortt G.; Amatu, Alessio; Sartore-Bianchi, Andrea; Siena, Salvatore; Bertotti, Andrea; Trusolino, Livio; Corigliano, Mattia; Gherardi, Marco; Lagomarsino, Marco Cosentino; Di Nicolantonio, Federica; Bardelli, Alberto			Adaptive mutability of colorectal cancers in response to targeted therapies	SCIENCE			English	Article							STRESS-INDUCED MUTAGENESIS; PRONE DNA-POLYMERASES; ANTI-EGFR THERAPY; ACQUIRED-RESISTANCE; DRUG-RESISTANCE; REPAIR; MUTATIONS; BLOCKADE; CELLS; REPLICATION	The emergence of drug resistance limits the efficacy of targeted therapies in human tumors. The prevalent view is that resistance is a fait accompli: when treatment is initiated, cancers already contain drug-resistant mutant cells. Bacteria exposed to antibiotics transiently increase their mutation rates (adaptive mutability), thus improving the likelihood of survival. We investigated whether human colorectal cancer (CRC) cells likewise exploit adaptive mutability to evade therapeutic pressure. We found that epidermal growth factor receptor (EGFR)/BRAF inhibition down-regulates mismatch repair (MMR) and homologous recombination DNA-repair genes and concomitantly up-regulates error-prone polymerases in drug-tolerant (persister) cells. MMR proteins were also down-regulated in patient-derived xenografts and tumor specimens during therapy. EGFR/BRAF inhibition induced DNA damage, increased mutability, and triggered microsatellite instability. Thus, like unicellular organisms, tumor cells evade therapeutic pressures by enhancing mutability.	[Russo, Mariangela; Crisafulli, Giovanni; Sogari, Alberto; Arena, Sabrina; Lamba, Simona; Bartolini, Alice; Amodio, Vito; Magri, Alessandro; Novara, Luca; Sarotto, Ivana; Bertotti, Andrea; Trusolino, Livio; Di Nicolantonio, Federica; Bardelli, Alberto] FPO IRCCS, Candiolo Canc Inst, I-10060 Candiolo, TO, Italy; [Russo, Mariangela; Crisafulli, Giovanni; Sogari, Alberto; Arena, Sabrina; Amodio, Vito; Magri, Alessandro; Bertotti, Andrea; Trusolino, Livio; Di Nicolantonio, Federica; Bardelli, Alberto] Univ Torino, Dept Oncol, I-10060 Candiolo, TO, Italy; [Reilly, Nicole M.] Fdn Piemontese Ric Canc ONLUS, I-10060 Candiolo, TO, Italy; [Nagel, Zachary D.; Piett, Cortt G.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, JBL Ctr Radiat Sci, Boston, MA 02115 USA; [Amatu, Alessio; Sartore-Bianchi, Andrea; Siena, Salvatore] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, I-20162 Milan, Italy; [Amatu, Alessio; Sartore-Bianchi, Andrea; Siena, Salvatore] Univ Milan, Dept Oncol & Hematooncol, I-20133 Milan, Italy; [Corigliano, Mattia; Gherardi, Marco; Lagomarsino, Marco Cosentino] IFOM FIRC Inst Mol Oncol, I-20139 Milan, Italy; [Corigliano, Mattia; Gherardi, Marco; Lagomarsino, Marco Cosentino] Univ Milan, Dept Phys, I-20133 Milan, Italy; [Corigliano, Mattia; Gherardi, Marco; Lagomarsino, Marco Cosentino] INFN, I-20133 Milan, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; Harvard University; Harvard T.H. Chan School of Public Health; University of Milan; IFOM - FIRC Institute of Molecular Oncology; University of Milan; Istituto Nazionale di Fisica Nucleare (INFN)	Russo, M; Bardelli, A (corresponding author), FPO IRCCS, Candiolo Canc Inst, I-10060 Candiolo, TO, Italy.; Russo, M; Bardelli, A (corresponding author), Univ Torino, Dept Oncol, I-10060 Candiolo, TO, Italy.	mariangela.russo@unito.it; alberto.bardelli@unito.it	Arena, Sabrina/H-4985-2012; Sartore-Bianchi, Andrea/AAB-9848-2019; Di Nicolantonio, Federica/A-2503-2011; Reilly, Nicole/AAI-3213-2020; sarotto, ivana/AAB-7797-2020; Sogari, Alberto/GQA-5770-2022; Crisafulli, Giovanni/AAB-6256-2019; Amatu, Alessio/K-2669-2018; Russo, Mariangela/K-1900-2018; BARTOLINI, ALICE/K-2534-2018; BARDELLI, Alberto/J-9721-2018	Arena, Sabrina/0000-0002-1318-2494; Sartore-Bianchi, Andrea/0000-0003-0780-0409; Di Nicolantonio, Federica/0000-0001-9618-2010; Crisafulli, Giovanni/0000-0002-5511-1555; Reilly, Nicole/0000-0002-8059-8422; Trusolino, Livio/0000-0002-6379-3365; Russo, Mariangela/0000-0003-4625-1449; Amodio, Vito/0000-0001-6915-4399; BARTOLINI, ALICE/0000-0003-3492-0772; BARDELLI, Alberto/0000-0003-1647-5070; Lamba, Simona Elena/0000-0003-3207-1594; Corigliano, Mattia/0000-0002-6645-6778; Sogari, Alberto/0000-0003-0612-6109	Fondazione AIRC [21091]; AIRC [9970]; AIRC IG [16788, 21923]; H2020 grant [635342-2, 754923]; Ministero Salute; PhoreMost; NeoPhore	Fondazione AIRC; AIRC(Fondazione AIRC per la ricerca sul cancro); AIRC IG; H2020 grant; Ministero Salute(Ministry of Health, Italy); PhoreMost; NeoPhore	This research was supported by Fondazione AIRC under the 5 per Mille 2018 ID 21091 Program(P.I. A. Bardelli, G.L. S. Siena, G.L. A. Bertotti, G.L. L. Trusolino, G.L. F. Di Nicolantonio); AIRC 2010 Special Program Molecular Clinical Oncology 5 per Mille, Project No. 9970 Extension Program (A. Bardelli); AIRC IG no. 16788 (A. Bardelli); AIRC IG 2018-ID 21923 project (P.I. A. Bardelli); H2020 grant agreement no. 635342-2 MoTriColor (A. Bardelli); Ministero Salute, Ricerca Corrente 2019 RC2019 (A. Bardelli); H2020 grant agreement no. 754923 COLOSSUS (L.T.). A. Bardelli has also received research funding from PhoreMost and NeoPhore.	Bertotti A, 2015, NATURE, V526, P263, DOI 10.1038/nature14969; Bindra RS, 2007, CANCER LETT, V252, P93, DOI 10.1016/j.canlet.2006.12.011; Bjedov I, 2003, SCIENCE, V300, P1404, DOI 10.1126/science.1082240; Cesi G, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0667-y; Chan ED, 2001, AM J RESP CELL MOL, V24, P627, DOI 10.1165/ajrcmb.24.5.4280; Chatterjee N, 2015, P NATL ACAD SCI USA, V112, P3764, DOI 10.1073/pnas.1421917112; Corti G, 2019, CLIN COLORECTAL CANC, V18, P91, DOI 10.1016/j.clcc.2019.02.008; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Fitzgerald DM, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1007995; Fitzgerald DM, 2017, ANNU REV CANC BIOL, V1, P119, DOI 10.1146/annurev-cancerbio-050216-121919; Foster PL, 2007, CRIT REV BIOCHEM MOL, V42, P373, DOI 10.1080/10409230701648494; Foster PL, 2000, BIOESSAYS, V22, P1067, DOI 10.1002/1521-1878(200012)22:12<1067::AID-BIES4>3.0.CO;2-Q; Galhardo RS, 2007, CRIT REV BIOCHEM MOL, V42, P399, DOI 10.1080/10409230701648502; Germano G, 2017, NATURE, V552, P116, DOI 10.1038/nature24673; Gnirke A, 2009, NAT BIOTECHNOL, V27, P182, DOI 10.1038/nbt.1523; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Gutierrez A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2607; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Hata AN, 2016, NAT MED, V22, P262, DOI 10.1038/nm.4040; Heidenreich E, 2007, CRIT REV BIOCHEM MOL, V42, P285, DOI 10.1080/10409230701507773; Isella C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15107; Kennedy SR, 2014, NAT PROTOC, V9, P2586, DOI 10.1038/nprot.2014.170; Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075; Koptyra M, 2006, BLOOD, V108, P319, DOI 10.1182/blood-2005-07-2815; Krutyakov VM, 2006, MOL BIOL+, V40, P3; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li LP, 2008, CANCER RES, V68, P9141, DOI 10.1158/0008-5472.CAN-08-1127; Long HA, 2016, P NATL ACAD SCI USA, V113, pE2498, DOI 10.1073/pnas.1601208113; Luria SE, 1943, GENETICS, V28, P491; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Mateo J, 2019, ANN ONCOL, V30, P1437, DOI 10.1093/annonc/mdz192; McKenzie GJ, 2000, P NATL ACAD SCI USA, V97, P6646, DOI 10.1073/pnas.120161797; McKenzie GJ, 2001, CURR OPIN MICROBIOL, V4, P586, DOI 10.1016/S1369-5274(00)00255-1; Mihaylova VT, 2003, MOL CELL BIOL, V23, P3265, DOI 10.1128/MCB.23.9.3265-3273.2003; Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Nagel ZD, 2014, P NATL ACAD SCI USA, V111, pE1823, DOI 10.1073/pnas.1401182111; Niu BF, 2014, BIOINFORMATICS, V30, P1015, DOI 10.1093/bioinformatics/btt755; Nowsheen S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024148; Oxnard GR, 2016, NAT MED, V22, P232, DOI 10.1038/nm.4058; Panier S, 2014, NAT REV MOL CELL BIO, V15, P7, DOI 10.1038/nrm3719; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Petljak M, 2019, CELL, V176, P1282, DOI 10.1016/j.cell.2019.02.012; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Ponder RG, 2005, MOL CELL, V19, P791, DOI 10.1016/j.molcel.2005.07.025; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Ramirez M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10690; Rattray AJ, 2003, ANNU REV GENET, V37, P31, DOI 10.1146/annurev.genet.37.042203.132748; Rodriguez GP, 2012, P NATL ACAD SCI USA, V109, P6153, DOI 10.1073/pnas.1115361109; Rosche WA, 1999, P NATL ACAD SCI USA, V96, P6862, DOI 10.1073/pnas.96.12.6862; Russo M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04506-z; Sagrista ML, 2002, FREE RADICAL RES, V36, P329, DOI 10.1080/10715760290019354; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Schmitt MW, 2015, NAT METHODS, V12, P423, DOI [10.1038/nmeth.3351, 10.1038/NMETH.3351]; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shen JF, 2018, NAT MED, V24, P556, DOI 10.1038/s41591-018-0012-z; Shor E, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003680; Siravegna G, 2018, CANCER CELL, V34, P148, DOI 10.1016/j.ccell.2018.06.004; Taddei F, 1997, NATURE, V387, P700, DOI 10.1038/42696; Torkelson J, 1997, EMBO J, V16, P3303, DOI 10.1093/emboj/16.11.3303; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq622	61	156	161	3	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 20	2019	366	6472			SI		1473	+		10.1126/science.aav4474	http://dx.doi.org/10.1126/science.aav4474			48	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX6SA	31699882	Bronze, Green Submitted			2023-01-03	WOS:000503861000047
J	[Anonymous]				[Anonymous]			The New Bacchus (Reprinted from JAMA, vol 73, pg 1772, 1919)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint																		1919, JAMA, V73, P1772	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	2019	322	21					2140	2140		10.1001/jama.2018.15627	http://dx.doi.org/10.1001/jama.2018.15627			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ6JE	31794617				2023-01-03	WOS:000505207400044
J	Duan, Y; Llorente, C; Lang, S; Brandl, K; Chu, HK; Jiang, L; White, RC; Clarke, TH; Nguyen, K; Torralba, M; Shao, Y; Liu, JY; Hernandez-Morales, A; Lessor, L; Rahman, IR; Miyamoto, Y; Ly, M; Gao, B; Sun, WZ; Kiesel, R; Hutmacher, F; Lee, S; Ventura-Cots, M; Bosques-Padilla, F; Verna, EC; Abraldes, JG; Brown, RS; Vargas, V; Altamirano, J; Caballeria, J; Shawcross, DL; Ho, SB; Louvet, A; Lucey, MR; Mathurin, P; Garcia-Tsao, G; Bataller, R; Tu, XM; Eckmann, L; van der Donk, WA; Young, R; Lawley, TD; Starkel, P; Pride, D; Fouts, DE; Schnabl, B				Duan, Yi; Llorente, Cristina; Lang, Sonja; Brandl, Katharina; Chu, Huikuan; Jiang, Lu; White, Richard C.; Clarke, Thomas H.; Nguyen, Kevin; Torralba, Manolito; Shao, Yan; Liu, Jinyuan; Hernandez-Morales, Adriana; Lessor, Lauren; Rahman, Imran R.; Miyamoto, Yukiko; Ly, Melissa; Gao, Bei; Sun, Weizhong; Kiesel, Roman; Hutmacher, Felix; Lee, Suhan; Ventura-Cots, Meritxell; Bosques-Padilla, Francisco; Verna, Elizabeth C.; Abraldes, Juan G.; Brown, Robert S., Jr.; Vargas, Victor; Altamirano, Jose; Caballeria, Juan; Shawcross, Debbie L.; Ho, Samuel B.; Louvet, Alexandre; Lucey, Michael R.; Mathurin, Philippe; Garcia-Tsao, Guadalupe; Bataller, Ramon; Tu, Xin M.; Eckmann, Lars; van der Donk, Wilfred A.; Young, Ry; Lawley, Trevor D.; Starkel, Peter; Pride, David; Fouts, Derrick E.; Schnabl, Bernd			Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease	NATURE			English	Article							PROKARYOTIC GENOME ANNOTATION; ENTEROCOCCUS-FAECALIS; CYTOLYSIN; THERAPY; SYSTEM; CLASSIFICATION; IDENTIFICATION; DISORDERS; DIVERSITY; MODEL	Chronic liver disease due to alcohol-use disorder contributes markedly to the global burden of disease and mortality(1-3). Alcoholic hepatitis is a severe and life-threatening form of alcohol-associated liver disease. The gut microbiota promotes ethanol-induced liver disease in mice(4), but little is known about the microbial factors that are responsible for this process. Here we identify cytolysin-a two-subunit exotoxin that is secreted by Enterococcus faecalis(5,6)-as a cause of hepatocyte death and liver injury. Compared with non-alcoholic individuals or patients with alcohol-use disorder, patients with alcoholic hepatitis have increased faecal numbers of E. faecalis. The presence of cytolysin-positive (cytolytic) E. faecalis correlated with the severity of liver disease and with mortality in patients with alcoholic hepatitis. Using humanized mice that were colonized with bacteria from the faeces of patients with alcoholic hepatitis, we investigated the therapeutic effects of bacteriophages that target cytolytic E. faecalis. We found that these bacteriophages decrease cytolysin in the liver and abolish ethanol-induced liver disease in humanized mice. Our findings link cytolytic E. faecalis with more severe clinical outcomes and increased mortality in patients with alcoholic hepatitis. We show that bacteriophages can specifically target cytolytic E. faecalis, which provides a method for precisely editing the intestinal microbiota. A clinical trial with a larger cohort is required to validate the relevance of our findings in humans, and to test whether this therapeutic approach is effective for patients with alcoholic hepatitis.	[Duan, Yi; Llorente, Cristina; Lang, Sonja; Chu, Huikuan; Jiang, Lu; Miyamoto, Yukiko; Gao, Bei; Sun, Weizhong; Kiesel, Roman; Hutmacher, Felix; Lee, Suhan; Ho, Samuel B.; Eckmann, Lars; Pride, David; Schnabl, Bernd] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Duan, Yi; Llorente, Cristina; Jiang, Lu; Ho, Samuel B.; Schnabl, Bernd] VA San Diego Healthcare Syst, Dept Med, San Diego, CA 92161 USA; [Brandl, Katharina] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA; [White, Richard C.; Clarke, Thomas H.; Nguyen, Kevin; Fouts, Derrick E.] J Craig Venter Inst, Rockville, MD USA; [Torralba, Manolito] J Craig Venter Inst, La Jolla, CA USA; [Shao, Yan; Lawley, Trevor D.] Wellcome Sanger Inst, Host Microbiota Interact Lab, Hinxton, England; [Liu, Jinyuan; Tu, Xin M.] Univ Calif San Diego, Dept Family Med & Publ Hlth, Div Biostat & Bioinformat, La Jolla, CA 92093 USA; [Hernandez-Morales, Adriana; Young, Ry] Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; [Lessor, Lauren; Young, Ry] Texas A&M AgriLife Res, Ctr Phage Technol, College Stn, TX USA; [Lessor, Lauren; Young, Ry] Texas A&M Univ, College Stn, TX USA; [Rahman, Imran R.; van der Donk, Wilfred A.] Univ Illinois, Dept Biochem, Urbana, IL USA; [Ly, Melissa; Pride, David] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Ventura-Cots, Meritxell; Bataller, Ramon] Univ Pittsburgh, Med Ctr, Div Gastroenterol Hepatol & Nutr, Dept Med,Pittsburgh Liver Res Ctr, Pittsburgh, PA USA; [Bosques-Padilla, Francisco] Univ Autonoma Nuevo Leon, Hosp Univ, Dept Gastroenterol, Monterrey, Mexico; [Verna, Elizabeth C.] Columbia Univ Coll Phys & Surg, Dept Med, Div Digest & Liver Dis, 630 W 168th St, New York, NY 10032 USA; [Abraldes, Juan G.] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Brown, Robert S., Jr.] Weill Cornell Med Coll, Div Gastroenterol & Hepatol, New York, NY USA; [Vargas, Victor; Altamirano, Jose] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Liver Unit, Barcelona, Spain; [Vargas, Victor; Caballeria, Juan] Ctr Invest Red Enfermedades Hepat & Digest CIBERE, Barcelona, Spain; [Caballeria, Juan] Hosp Clin Barcelona, Liver Unit, Barcelona, Spain; [Shawcross, Debbie L.] Kings Coll London, Sch Infect Dis & Microbial Sci, Dept Inflammat Biol, Liver Sci, London, England; [Louvet, Alexandre; Mathurin, Philippe] Hop Huriez, Serv Malad Lappareil Digestif, Lille, France; [Louvet, Alexandre; Mathurin, Philippe] Hop Huriez, Unite INSERM, Lille, France; [Lucey, Michael R.] Univ Wisconsin, Dept Med, Div Gastroenterol & Hepatol, Sch Med & Publ Hlth, Madison, WI USA; [Garcia-Tsao, Guadalupe] Yale Univ, Sch Med, Sect Digest Dis, New Haven, CT USA; [Garcia-Tsao, Guadalupe] VA Connecticut Healthcare Syst, Sect Digest Dis, West Haven, CT USA; [van der Donk, Wilfred A.] Univ Illinois, Dept Chem, Urbana, IL USA; [van der Donk, Wilfred A.] Univ Illinois, Howard Hughes Med Inst, Urbana, IL USA; [Starkel, Peter] Catholic Univ Louvain, St Luc Univ Hosp, Brussels, Belgium; [Pride, David; Schnabl, Bernd] Univ Calif San Diego, Ctr Innovat Phage Applicat & Therapeut, La Jolla, CA 92093 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego; J. Craig Venter Institute; J. Craig Venter Institute; Wellcome Trust Sanger Institute; University of California System; University of California San Diego; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M AgriLife Research; Texas A&M University System; Texas A&M University College Station; University of Illinois System; University of Illinois Urbana-Champaign; University of California System; University of California San Diego; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Universidad Autonoma de Nuevo Leon; Columbia University; University of Alberta; Cornell University; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; University of Barcelona; Hospital Clinic de Barcelona; University of London; King's College London; Universite de Lille - ISITE; CHU Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; University of Wisconsin System; University of Wisconsin Madison; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; University of Illinois System; University of Illinois Urbana-Champaign; Howard Hughes Medical Institute; University of Illinois System; University of Illinois Urbana-Champaign; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of California System; University of California San Diego	Schnabl, B (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.; Schnabl, B (corresponding author), VA San Diego Healthcare Syst, Dept Med, San Diego, CA 92161 USA.; Schnabl, B (corresponding author), Univ Calif San Diego, Ctr Innovat Phage Applicat & Therapeut, La Jolla, CA 92093 USA.		Lucey, Michael/AAR-4571-2020; Shawcross, Debbie Lindsay/H-9669-2012; Llorente, Cristina/AAV-2623-2021; Garcia-Tsao, Guadalupe/ABF-7374-2020; Vargas, Victor/AAD-3303-2020; van der Donk, Wilfred/K-2961-2015; Shao, Yan/AAE-8637-2019; Rahman, Imran/L-3133-2018; Vargas Blasco, Victor Manuel/C-9711-2018	Shawcross, Debbie Lindsay/0000-0001-6133-4619; Llorente, Cristina/0000-0001-8135-9186; van der Donk, Wilfred/0000-0002-5467-7071; Shao, Yan/0000-0002-8662-0504; Hernandez Morales, Adriana Carolina/0000-0003-1259-3854; Gao, Bei/0000-0002-3321-2339; Bosques, Francisco/0000-0002-9795-7209; Bataller, Ramon/0000-0002-1119-7799; Miyamoto, Yukiko/0000-0001-5650-699X; Rahman, Imran/0000-0001-9195-0164; Young, Ry/0000-0001-8001-2914; Gonzalez-Abraldes, Juan/0000-0003-3421-937X; Vargas Blasco, Victor Manuel/0000-0002-7190-6948	DFG fellowship [LA 4286/1-1]; AASLD Pinnacle Research Award in Liver Disease; Southern California Research Center for Alcoholic Liver and Pancreatic Disease (ALPD) and Cirrhosis [P50 AA011999]; Wellcome Trust [WT098051]; National Institute of General Medical Sciences (NIGMS)-NIH Chemistry-Biology Interface Training Grant [T32-GM070421]; Biocodex Microbiota Foundation Grant; NIH [R01 AA24726, U01 AA026939, U01AA021908]; Biomedical Laboratory Research & Development Service of the VA Office of Research and Development [BX004594];  [P30 DK120515]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989, P30DK120531, P30DK120515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM070421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA024726, P50AA011999, U01AA026939, R01AA020703, U01AA021908] Funding Source: NIH RePORTER; Veterans Affairs [I01BX004594] Funding Source: NIH RePORTER	DFG fellowship(German Research Foundation (DFG)); AASLD Pinnacle Research Award in Liver Disease; Southern California Research Center for Alcoholic Liver and Pancreatic Disease (ALPD) and Cirrhosis; Wellcome Trust(Wellcome TrustEuropean Commission); National Institute of General Medical Sciences (NIGMS)-NIH Chemistry-Biology Interface Training Grant; Biocodex Microbiota Foundation Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Biomedical Laboratory Research & Development Service of the VA Office of Research and Development; ; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Veterans Affairs(US Department of Veterans Affairs)	S. Lang was supported by a DFG fellowship (LA 4286/1-1), C.L. was supported by an AASLD Pinnacle Research Award in Liver Disease and a pilot project award from Southern California Research Center for Alcoholic Liver and Pancreatic Disease (ALPD) and Cirrhosis (P50 AA011999), Y.S. was supported by a Wellcome Trust PhD studentship and I.R.R. was supported by National Institute of General Medical Sciences (NIGMS)-NIH Chemistry-Biology Interface Training Grant (T32-GM070421). This study was supported in part by a Biocodex Microbiota Foundation Grant, NIH grants R01 AA24726, U01 AA026939, by Award Number BX004594 from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development (to B.S.), the Wellcome Trust (WT098051) (to T.D.L.), NIH grant U01AA021908 (to R.B.) and services provided by P30 DK120515 and P50 AA011999.	Ball SA, 1997, J ABNORM PSYCHOL, V106, P545, DOI 10.1037/0021-843X.106.4.545; Bertola A, 2013, NAT PROTOC, V8, P627, DOI 10.1038/nprot.2013.032; Brandl K, 2018, J HEPATOL, V69, P396, DOI 10.1016/j.jhep.2018.03.031; Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107; Chatterjee A, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00085-19; Chen LH, 2005, NUCLEIC ACIDS RES, V33, pD325, DOI 10.1093/nar/gki008; Chen P, 2015, GASTROENTEROLOGY, V148, P203, DOI 10.1053/j.gastro.2014.09.014; Chu Chen, 2015, BMC GENOMICS, V16, DOI [DOI 10.1186/S12864-015-1781-0, 10.1186/s12864-015-1676-0]; Clarke TH, 2018, BIOINFORMATICS, V34, P3032, DOI 10.1093/bioinformatics/bty300; Cox CR, 2005, CURR PROTEIN PEPT SC, V6, P77, DOI 10.2174/1389203053027557; Dalmasso M, 2014, TRENDS MICROBIOL, V22, P399, DOI 10.1016/j.tim.2014.02.010; Dedrick RM, 2019, NAT MED, V25, P730, DOI 10.1038/s41591-019-0437-z; Dominguez M, 2008, AM J GASTROENTEROL, V103, P2747, DOI 10.1111/j.1572-0241.2008.02104.x; Fish R, 2018, METHODS MOL BIOL, V1693, P159, DOI 10.1007/978-1-4939-7395-8_14; Fouts DE, 2006, NUCLEIC ACIDS RES, V34, P5839, DOI 10.1093/nar/gkl732; Gao B, 2019, DIGEST DIS SCI, V64, P1878, DOI 10.1007/s10620-019-05638-y; Gill JJ, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-542; GILMORE MS, 1994, J BACTERIOL, V176, P7335, DOI 10.1128/JB.176.23.7335-7344.1994; Gorski A, 2017, FUTURE MICROBIOL, V12, P905, DOI 10.2217/fmb-2017-0049; Haas BJ, 2011, GENOME RES, V21, P494, DOI 10.1101/gr.112730.110; Haas W, 2002, NATURE, V415, P84, DOI 10.1038/415084a; Haft DH, 2018, NUCLEIC ACIDS RES, V46, pD851, DOI 10.1093/nar/gkx1068; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; IKE Y, 1990, J BACTERIOL, V172, P155, DOI 10.1128/JB.172.1.155-163.1990; Iwaisako K, 2012, P NATL ACAD SCI USA, V109, pE1369, DOI 10.1073/pnas.1202464109; Jia BF, 2017, NUCLEIC ACIDS RES, V45, pD566, DOI 10.1093/nar/gkw1004; Khawaldeh A, 2011, J MED MICROBIOL, V60, P1697, DOI 10.1099/jmm.0.029744-0; Krieg L, 2011, BLOOD, V118, P6418, DOI 10.1182/blood-2011-04-350082; Lang S, 2019, HEPATOLOGY, DOI [10.1002/hep.30832, 10.1002/hep.30832/suppinfo]; Lee BP, 2019, JAMA INTERN MED, V179, P340, DOI 10.1001/jamainternmed.2018.6536; Letunic I, 2016, NUCLEIC ACIDS RES, V44, pW242, DOI 10.1093/nar/gkw290; Llopis M, 2016, GUT, V65, P830, DOI 10.1136/gutjnl-2015-310585; Llorente C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00796-x; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; MADDREY WC, 1978, GASTROENTEROLOGY, V75, P193; MARCUK LM, 1971, B WORLD HEALTH ORGAN, V45, P77; Mathurin P, 2012, J HEPATOL, V56, pS39, DOI 10.1016/S0168-8278(12)60005-1; Ogilvie LA, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00918; Ondov BD, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0997-x; Page AJ, 2016, MICROB GENOMICS, V2, DOI 10.1099/mgen.0.000083; Paradis E, 2019, BIOINFORMATICS, V35, P526, DOI 10.1093/bioinformatics/bty633; POINDEXTER JS, 1964, BACTERIOL REV, V28, P231, DOI 10.1128/MMBR.28.3.231-295.1964; Rehm J, 2014, ALCOHOL CLIN EXP RES, V38, P1068, DOI 10.1111/acer.12331; Ryu H, 2013, APPL ENVIRON MICROB, V79, P196, DOI 10.1128/AEM.02802-12; Sarker SA, 2016, EBIOMEDICINE, V4, P124, DOI 10.1016/j.ebiom.2015.12.023; Schooley RT, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00954-17; Seemann T, 2014, BIOINFORMATICS, V30, P2068, DOI 10.1093/bioinformatics/btu153; Shin J, 2016, SCI REP-UK, V6, DOI 10.1038/srep29681; Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033; Tang WX, 2019, J IND MICROBIOL BIOT, V46, P537, DOI 10.1007/s10295-018-2110-9; Tang WX, 2013, NAT CHEM BIOL, V9, P157, DOI [10.1038/NCHEMBIO.1162, 10.1038/nchembio.1162]; Tatusova T, 2016, NUCLEIC ACIDS RES, V44, P6614, DOI 10.1093/nar/gkw569; Thursz MR, 2015, NEW ENGL J MED, V372, P1619, DOI 10.1056/NEJMoa1412278; Ujmajuridze A, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01832; VALENTINE RC, 1968, BIOCHEMISTRY-US, V7, P2143, DOI 10.1021/bi00846a017; Van Tyne D, 2013, TOXINS, V5, P895, DOI 10.3390/toxins5050895; Walker BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112963; Wick RR, 2017, MICROB GENOMICS, V3, DOI 10.1099/mgen.0.000132; Wick RR, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005595	59	285	302	36	291	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 21	2019	575	7783					505	+		10.1038/s41586-019-1742-x	http://dx.doi.org/10.1038/s41586-019-1742-x			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ2WX	31723265	Green Submitted, Green Accepted			2023-01-03	WOS:000498812200052
J	Wandrag, L; Brett, SJ; Frost, GS; Bountziouka, V; Hickson, M				Wandrag, Liesl; Brett, Stephen J.; Frost, Gary S.; Bountziouka, Vasiliki; Hickson, Mary			Exploration of muscle loss and metabolic state during prolonged critical illness: Implications for intervention?	PLOS ONE			English	Article							SKELETAL-MUSCLE; PROTEIN-TURNOVER; EXERCISE; SUPPORT	Background Muscle wasting in the critically ill is up to 2% per day and delays patient recovery and rehabilitation. It is linked to inflammation, organ failure and severity of illness. The aims of this study were to understand the relationship between muscle depth loss, and nutritional and inflammatory markers during prolonged critical illness. Secondly, to identify when during critical illness catabolism might decrease, such that targeted nutritional strategies may logically be initiated. Methods This study was conducted in adult intensive care units in two large teaching hospitals. Patients anticipated to be ventilated for > 48 hours were included. Serum C-reactive protein (mg/L), urinary urea (mmol/24h), 3-methylhistidine (mu mol/24h) and nitrogen balance (g/24h) were measured on days 1, 3, 7 and 14 of the study. Muscle depth (cm) on ultrasound were measured on the same days over the bicep (bicep and brachialis muscle), forearm (flexor compartment of muscle) and thigh (rectus femoris and vastus intermedius). Results Seventy-eight critically ill patients were included with mean age of 59 years (SD: 16) and median Intensive care unit (ICU) length of stay of 10 days (IQR: 6-16). Starting muscle depth, 8.5cm (SD: 3.2) to end muscle depth, 6.8cm (SD: 2.2) were on average significantly different over 14 days, with mean difference -1.67cm (95%CI: -2.3 to -1cm), p<0.0001. Protein breakdown and inflammation continued over 14 days of the study. Conclusion Our patients demonstrated a continuous muscle depth loss and negative nitrogen balance over the 14 days of the study. Catabolism remained dominant throughout the study period. No obvious 'nutritional tipping point" to identify anabolism or recovery could be identified in our cohort. Our ICU patient cohort is one with a moderately prolonged stay. This group showed little consistency in data, reflecting the individuality of both disease and response. The data are consistent with a conclusion that a time based assumption of a tipping point does not exist.	[Wandrag, Liesl; Frost, Gary S.; Hickson, Mary] Imperial Coll London, Dept Metab Digest & Reprod, Sect Nutr Res, London, England; [Wandrag, Liesl] Guys & St Thomas NHS Fdn Trust, Dept Nutr & Dietet, London, England; [Wandrag, Liesl] Guys & St Thomas NHS Fdn Trust, Dept Crit Care, London, England; [Brett, Stephen J.] Imperial Coll Healthcare NHS Trust, Ctr Peri Operat Med & Crit Care Res, London, England; [Bountziouka, Vasiliki] UCL, Inst Child Hlth, Populat Policy & Practice Programme, Stat Support Serv, London, England; [Hickson, Mary] Univ Plymouth, Inst Hlth & Community, Plymouth, Devon, England	Imperial College London; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; Imperial College London; University of London; University College London; University of Plymouth	Wandrag, L (corresponding author), Imperial Coll London, Dept Metab Digest & Reprod, Sect Nutr Res, London, England.; Wandrag, L (corresponding author), Guys & St Thomas NHS Fdn Trust, Dept Nutr & Dietet, London, England.; Wandrag, L (corresponding author), Guys & St Thomas NHS Fdn Trust, Dept Crit Care, London, England.	l.wandrag@imperial.ac.uk	; Bountziouka, Vasiliki/I-6297-2018	Wandrag, Liesl/0000-0003-4577-8775; Bountziouka, Vasiliki/0000-0003-2522-1582; Frost, Gary/0000-0003-0529-6325	Department of Health via the National Institute of Health Research; National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London	Department of Health via the National Institute of Health Research; National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London	The authors acknowledge support from the Department of Health via the National Institute of Health Research who supported this work through the provision of a Clinical Doctoral Research Fellowship for LW, https://www.nihr.ac.uk. The research was further supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.	Arabi YM, 2017, INTENS CARE MED, V43, P1239, DOI 10.1007/s00134-017-4711-6; Bear DE, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1810-2; BIOLO G, 1995, AM J PHYSIOL-ENDOC M, V268, pE514; Cermak NM, 2012, AM J CLIN NUTR, V96, P1454, DOI 10.3945/ajcn.112.037556; Chan KS., 2018, CRIT CARE MED; Chinkes DL, 2005, CURR OPIN CLIN NUTR, V8, P534, DOI 10.1097/01.mco.0000170754.25372.37; Churchward-Venne TA, 2013, AMINO ACIDS; Connolly B, 2015, CRIT CARE MED, V43, P897, DOI 10.1097/CCM.0000000000000821; Dickerson RN, 2005, NUTRITION, V21, P332, DOI 10.1016/j.nut.2004.07.005; Fraipont V, 2013, JPEN-PARENTER ENTER, V37, P705, DOI 10.1177/0148607113505868; Frankenfield D, 2004, JPEN-PARENTER ENTER, V28, P259, DOI 10.1177/0148607104028004259; Frost RA, 2005, CURR OPIN CLIN NUTR, V8, P255, DOI 10.1097/01.mco.0000165003.16578.2d; Gamrin-Gripenberg L, 2018, CRIT CARE, V22, DOI 10.1186/s13054-017-1932-6; Harvey SE, 2014, NEW ENGL J MED, V371, P1673, DOI 10.1056/NEJMoa1409860; Hasselgren PO, 2010, CURR OPIN CLIN NUTR, V13, P423, DOI 10.1097/MCO.0b013e32833a5107; Hasselgren PO, 2000, WORLD J SURG, V24, P1452, DOI 10.1007/s002680010262; Herridge MS, 2011, CRIT CARE, V15, DOI 10.1186/cc10362; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Heyland DK, 2010, JPEN-PARENTER ENTER, V34, P675, DOI 10.1177/0148607110364843; Hooper, 2009, CALCULATIONS LAB SCI; Iwashyna TJ, 2016, LANCET RESP MED, V4, P566, DOI 10.1016/S2213-2600(16)30098-4; Klaude M, 2007, CLIN SCI, V112, P499, DOI 10.1042/CS20060265; Liebau F, 2015, AM J CLIN NUTR, V101, P549, DOI 10.3945/ajcn.114.091934; Looijaard WGPM, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1563-3; McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI [10.1177/0148607115621863, 10.1097/CCM.0000000000001525]; NICE 2, 2009, REH CRIT ILLN CG83; Preiser JC, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0737-8; Puthucheary ZA, 2013, JAMA-J AM MED ASSOC, V310, P1591, DOI 10.1001/jama.2013.278481; Reid CL, 2004, CLIN NUTR, V23, P273, DOI 10.1016/S0261-5614(03)00129-8; Singer P, 2019, CLIN NUTR, V38, P48, DOI 10.1016/j.clnu.2018.08.037; Sluyter JD, 2013, INT J BEHAV NUTR PHY, V10, DOI 10.1186/1479-5868-10-115; The Parenteral & Enteral Nutrition Group of the British Dietetic Association, 2011, POCK GUID CLIN NUTR; Wandrag L, 2011, J HUM NUTR DIET; Wandrag L, 2017, REDOX BIOL, V13, P60, DOI 10.1016/j.redox.2017.05.004; Weijs PJM, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0701-z; Winkelman Chris, 2004, AACN Clin Issues, V15, P74	36	16	16	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2019	14	11							e0224565	10.1371/journal.pone.0224565	http://dx.doi.org/10.1371/journal.pone.0224565			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN2HK	31725748	Green Published, Green Submitted, gold			2023-01-03	WOS:000532764500019
J	Farooqui, HH; Mehta, A; Selvaraj, S				Farooqui, Habib Hasan; Mehta, Aashna; Selvaraj, Sakthivel			Outpatient antibiotic prescription rate and pattern in the private sector in India: Evidence from medical audit data	PLOS ONE			English	Article							RESPIRATORY-TRACT INFECTIONS; PRIMARY-CARE; PRESCRIBING PRACTICES; COST BURDEN; LOW-INCOME; NEW-DELHI; RESISTANCE; PRACTITIONERS; SURVEILLANCE; EXPENDITURES	The key objective of this research was to generate new evidence on outpatient antibiotic prescription rate and patterns in the private sector in India. We used 12-month period (May 2013 to April 2014) medical audit dataset from IQVIA (formerly IMS Health). We coded the diagnosis provided in the medical audit data to International Statistical Classification of Diseases and Related Health Problems (ICD-10) and the prescribed antibiotics for the diagnosis to Anatomic Therapeutic Chemical (ATC) classification of World Health Organization (ATC index-2016). We calculated and reported antibiotic prescription rate per 1,000 persons per year, by age groups, antibiotic class and disease conditions. Our main findings are-approximately 519 million antibiotic prescriptions were dispensed in the private sector, which translates into 412 prescriptions per 1,000 persons per year. Majority of the antibiotic prescriptions were dispensed for acute upper respiratory infections (J06) (20.4%); unspecified acute lower respiratory infection (J22) (12.8%); disorders of urinary system (N39) (6.0%); cough (R05) (4.7%); and acute nasopharyngitis (J00) (4.6%) and highest antibiotic prescription rates were observed in the age group 0-4 years. To conclude our study reports first ever country level estimates of antibiotic prescription by antibiotic classes, age groups, and ICD-10 mapped disease conditions.	[Farooqui, Habib Hasan] Publ Hlth Fdn India, Indian Inst Publ Hlth Delhi, Gurugram, Haryana, India; [Mehta, Aashna; Selvaraj, Sakthivel] Publ Hlth Fdn India, Hlth Econ Financing & Policy, Gurugram, Haryana, India	Public Health Foundation of India; Public Health Foundation of India	Farooqui, HH (corresponding author), Publ Hlth Fdn India, Indian Inst Publ Hlth Delhi, Gurugram, Haryana, India.	drhabibhasan@gmail.com	Farooqui, Habib/AAD-8818-2021; Mehta, Aashna/GQA-8753-2022; Selvaraj, Sakthivel/ABD-5873-2021	Farooqui, Habib/0000-0002-3081-2929; Mehta, Aashna/0000-0003-4099-9915; 	Department of Science and Technology's Public Health Research Grant	Department of Science and Technology's Public Health Research Grant	Habib Hasan Farooqui is supported by Department of Science and Technology's Public Health Research Grant to the Public Health Foundation of India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alsan M, 2015, LANCET INFECT DIS, V15, P1203, DOI 10.1016/S1473-3099(15)00149-8; Ashworth M, 2004, J PUBLIC HEALTH-UK, V26, P268, DOI 10.1093/pubmed/fdh160; Bassani DG, 2010, LANCET, V376, P1853, DOI 10.1016/S0140-6736(10)61461-4; Bert F, 2017, EUR J PUBLIC HEALTH, V27, P506, DOI 10.1093/eurpub/ckw209; Bianco A, 2018, INFECT DRUG RESIST, V11, P2199, DOI 10.2147/IDR.S170349; Chandy SJ, 2014, J INFECT DEV COUNTR, V8, P1096, DOI 10.3855/jidc.4745; Chandy SJ, 2013, J ANTIMICROB CHEMOTH, V68, P229, DOI 10.1093/jac/dks355; Clavenna A, 2011, ARCH DIS CHILD, V96, P590, DOI 10.1136/adc.2010.183541; Durkin MJ, 2018, INFECT CONT HOSP EP, V39, P584, DOI 10.1017/ice.2018.26; Farooqui HH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204805; Gandra S, 2016, INT J INFECT DIS, V50, P75, DOI 10.1016/j.ijid.2016.08.002; GOI, 2006, POP PROJ IND STAT 20; Gopalakrishnan S, 2013, INDIAN J PHARMACOL, V45, P252, DOI 10.4103/0253-7613.111931; Hersh AL, 2013, PEDIATRICS, V132, P1146, DOI 10.1542/peds.2013-3260; Holloway KA, 2017, BMJ-BRIT MED J, V358, P9, DOI 10.1136/bmj.j2291; Holstiege J, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-174; Huang N, 2005, PEDIATRICS, V116, P826, DOI 10.1542/peds.2004-2800; Klein EY, 2018, P NATL ACAD SCI USA, V115, pE3463, DOI 10.1073/pnas.1717295115; Kotwani A, 2014, TROP MED INT HEALTH, V19, P761, DOI 10.1111/tmi.12327; Kotwani A, 2012, VALUE HEALTH, V15, pS116, DOI 10.1016/j.jval.2011.11.008; Kotwani A, 2010, FAM PRACT, V27, P684, DOI 10.1093/fampra/cmq059; Kourlaba G, 2015, J ANTIMICROB CHEMOTH, V70, P2405, DOI 10.1093/jac/dkv091; Kshirsagar MJ, 1998, B WORLD HEALTH ORGAN, V76, P271; Laxminarayan R, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001974; Laxminarayan R, 2016, LANCET, V387, P168, DOI 10.1016/S0140-6736(15)00474-2; Laxminarayan R, 2013, LANCET INFECT DIS, V13, P1057, DOI 10.1016/S1473-3099(13)70318-9; Mackintosh M, 2016, LANCET, V388, P596, DOI 10.1016/S0140-6736(16)00342-1; Napolitano F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084177; NCDC, 2016, NAT TREATM GUID ANT; Pathak D, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-32; Phadke AR, 1996, NATL MED J INDIA, V9, P60; Reddy KS, 2011, HIGH LEVEL EXPERT GR; Sakthivel Selvaraj, 2009, Economic and Political Weekly, V44, P55; Sharma M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142317; Shet A, 2015, ANTIMICROB RESIST IN, V4, DOI 10.1186/s13756-015-0098-8; Suda KJ, 2014, ANTIMICROB AGENTS CH, V58, P2763, DOI 10.1128/AAC.02239-13; Van Boeckel TP, 2014, LANCET INFECT DIS, V14, P742, DOI 10.1016/S1473-3099(14)70780-7; Walia K, 2016, INDIAN J MED MICROBI, V34, P413, DOI 10.4103/0255-0857.195378; Wattal Chand, 2010, J Assoc Physicians India, V58 Suppl, P32; WHOCC, 2015, WHO COLL CTR DRUG ST; World Health Organization, INT STAT CLASS DIS R; 2017, ROUT STUD GLOB INF, V11, P1	42	24	24	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2019	14	11							e0224848	10.1371/journal.pone.0224848	http://dx.doi.org/10.1371/journal.pone.0224848			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN1QS	31721809	gold, Green Published			2023-01-03	WOS:000532720700033
J	Kopetz, S; Grothey, A; Yaeger, R; Van Cutsem, E; Desai, J; Yoshino, T; Wasan, H; Ciardiello, F; Loupakis, F; Hong, YS; Steeghs, N; Guren, TK; Arkenau, HT; Garcia-Alfonso, P; Pfeiffer, P; Orlov, S; Lonardi, S; Elez, E; Kim, TW; Schellens, JHM; Guo, C; Krishnan, A; Dekervel, J; Morris, V; Ferrandiz, AC; Tarpgaard, LS; Braun, M; Gollerkeri, A; Keir, C; Maharry, K; Pickard, M; Christy-Bittel, J; Anderson, L; Sandor, V; Tabernero, J				Kopetz, S.; Grothey, A.; Yaeger, R.; Van Cutsem, E.; Desai, J.; Yoshino, T.; Wasan, H.; Ciardiello, F.; Loupakis, F.; Hong, Y. S.; Steeghs, N.; Guren, T. K.; Arkenau, H. -T.; Garcia-Alfonso, P.; Pfeiffer, P.; Orlov, S.; Lonardi, S.; Elez, E.; Kim, T. -W.; Schellens, J. H. M.; Guo, C.; Krishnan, A.; Dekervel, J.; Morris, V.; Calvo Ferrandiz, A.; Tarpgaard, L. S.; Braun, M.; Gollerkeri, A.; Keir, C.; Maharry, K.; Pickard, M.; Christy-Bittel, J.; Anderson, L.; Sandor, V.; Tabernero, J.			Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROGRESSION-FREE SURVIVAL; ACQUIRED-RESISTANCE; COLON-CANCER; INHIBITION; VEMURAFENIB; DABRAFENIB; TRAMETINIB; IRINOTECAN; MUTATIONS; THERAPY	Colorectal cancers with BRAF mutations have an aggressive natural history and are often resistant to therapy. A treatment regimen that combined BRAF inhibition, MET inhibition, and blocking of EGFR signaling resulted in a response rate of 26% and a median overall survival of 9 months. Background Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. Inhibition of BRAF alone has limited activity because of pathway reactivation through epidermal growth factor receptor signaling. Methods In this open-label, phase 3 trial, we enrolled 665 patients with BRAF V600E-mutated metastatic colorectal cancer who had had disease progression after one or two previous regimens. Patients were randomly assigned in a 1:1:1 ratio to receive encorafenib, binimetinib, and cetuximab (triplet-therapy group); encorafenib and cetuximab (doublet-therapy group); or the investigators' choice of either cetuximab and irinotecan or cetuximab and FOLFIRI (folinic acid, fluorouracil, and irinotecan) (control group). The primary end points were overall survival and objective response rate in the triplet-therapy group as compared with the control group. A secondary end point was overall survival in the doublet-therapy group as compared with the control group. We report here the results of a prespecified interim analysis. Results The median overall survival was 9.0 months in the triplet-therapy group and 5.4 months in the control group (hazard ratio for death, 0.52; 95% confidence interval [CI], 0.39 to 0.70; P<0.001). The confirmed response rate was 26% (95% CI, 18 to 35) in the triplet-therapy group and 2% (95% CI, 0 to 7) in the control group (P<0.001). The median overall survival in the doublet-therapy group was 8.4 months (hazard ratio for death vs. control, 0.60; 95% CI, 0.45 to 0.79; P<0.001). Adverse events of grade 3 or higher occurred in 58% of patients in the triplet-therapy group, in 50% in the doublet-therapy group, and in 61% in the control group. Conclusions A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with the BRAF V600E mutation. (Funded by Array BioPharma and others; BEACON CRC ClinicalTrials.gov number, NCT02928224; EudraCT number, 2015-005805-35.)	[Kopetz, S.; Morris, V.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Grothey, A.] OneOncology, West Canc Ctr & Res Inst, Germantown, TN USA; [Yaeger, R.; Krishnan, A.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Van Cutsem, E.; Dekervel, J.] Univ Hosp Gasthuisberg, Leuven, Belgium; [Van Cutsem, E.; Dekervel, J.] Univ Leuven, Leuven, Belgium; [Desai, J.; Guo, C.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Yoshino, T.] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan; [Wasan, H.] Imperial Coll London, Hammersmith Hosp, Div Canc, London, England; [Arkenau, H. -T.] Sarah Cannon Res Inst, London, England; [Arkenau, H. -T.] UCL, Canc Inst, London, England; [Braun, M.] Christie NHS Fdn Trust, Natl Inst Hlth Res, Manchester Biomed Res Ctr, Manchester, Lancs, England; [Ciardiello, F.] Univ Campania Luigi Vanvitelli, Naples, Italy; [Loupakis, F.; Lonardi, S.] IRCCS, Ist Oncol Veneto, Padua, Italy; [Hong, Y. S.; Kim, T. -W.] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea; [Steeghs, N.; Schellens, J. H. M.] Netherlands Canc Inst, Amsterdam, Netherlands; [Guren, T. K.] Oslo Univ Hosp, Oslo, Norway; [Garcia-Alfonso, P.; Calvo Ferrandiz, A.] Hosp Gregorio Maranon, Madrid, Spain; [Elez, E.; Tabernero, J.] UVic, IOB Quiron, Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain; [Pfeiffer, P.; Tarpgaard, L. S.] Odense Univ Hosp, Odense, Denmark; [Orlov, S.] Pavlov First St Petersburg State Med Univ, St Petersburg, Russia; [Gollerkeri, A.; Keir, C.; Maharry, K.; Pickard, M.; Christy-Bittel, J.; Anderson, L.; Sandor, V.] Array BioPharma, Boulder, CO USA	University of Texas System; UTMD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; KU Leuven; University Hospital Leuven; KU Leuven; Peter Maccallum Cancer Center; National Cancer Center - Japan; Imperial College London; University of London; University College London; Christie NHS Foundation Trust; University of Manchester; Universita della Campania Vanvitelli; IRCCS Istituto Oncologico Veneto (IOV); University of Ulsan; Netherlands Cancer Institute; University of Oslo; General University Gregorio Maranon Hospital; Hospital Universitari Vall d'Hebron; Universitat de Vic - Universitat Central de Catalunya (UVic-UCC); Vall d'Hebron Institut d'Oncologia (VHIO); University of Southern Denmark; Odense University Hospital; Pavlov First Saint Petersburg State Medical University; Pfizer; Array BioPharma	Tabernero, J (corresponding author), Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Passeig Vall dHebron 119-129, Barcelona 08035, Spain.	jtabernero@vhio.net	Desai, Jayesh/AAV-1237-2021; Orlov, Sergey/AAC-8379-2022; Tabernero, Josep/AAG-5026-2019; Élez, Elena/AAH-2945-2019; Kopetz, Scott/AAC-1387-2019; Steeghs, Neeltje/GQH-3468-2022; Van+Cutsem, Eric/ABE-1762-2021; Lonardi, Sara/F-4228-2014; Loupakis, Fotios/I-7243-2012; Dekervel, Jeroen/A-3582-2019	Tabernero, Josep/0000-0002-2495-8139; Kopetz, Scott/0000-0001-9647-3416; Lonardi, Sara/0000-0002-7593-8138; Loupakis, Fotios/0000-0001-9651-0395; Tarpgaard, Line/0000-0001-8505-2544; Wasan, Harpreet/0000-0002-6268-2030; Desai, Jayesh/0000-0003-4246-9344; Dekervel, Jeroen/0000-0001-7208-3480; Krishnan, Asha/0000-0002-3410-4436; Pfeiffer, Per/0000-0002-2925-0586; Elez, Elena/0000-0002-4653-6324	Array BioPharma	Array BioPharma(Pfizer)	Funded by Array BioPharma and others	Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518; Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; Barras D, 2017, CLIN CANCER RES, V23, P104, DOI 10.1158/1078-0432.CCR-16-0140; Bylsma LC, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.4_suppl.681; Chibaudel B, 2011, J CLIN ONCOL, V29, P4199, DOI 10.1200/JCO.2011.35.5867; Clarke CN, 2015, J GASTROINTEST ONCOL, V6, P660, DOI 10.3978/j.issn.2078-6891.2015.077; Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226; Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Delord JP, 2017, CLIN CANCER RES, V23, P5339, DOI 10.1158/1078-0432.CCR-16-2923; Department of Health and Human Services, 2009, COMM TERM CRIT ADV E; Dummer R, 2018, LANCET ONCOL, V19, P1315, DOI 10.1016/S1470-2045(18)30497-2; Dummer R, 2018, LANCET ONCOL, V19, P603, DOI 10.1016/S1470-2045(18)30142-6; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050; Kopetz S, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3505; Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497; Loupakis F, 2009, BRIT J CANCER, V101, P715, DOI 10.1038/sj.bjc.6605177; Loupakis F, 2014, NEW ENGL J MED, V371, P1609, DOI 10.1056/NEJMoa1403108; Mao ML, 2013, CLIN CANCER RES, V19, P657, DOI 10.1158/1078-0432.CCR-11-1446; Morris V, 2014, CLIN COLORECTAL CANC, V13, P164, DOI 10.1016/j.clcc.2014.06.001; Peeters M, 2014, ANN ONCOL, V25, P107, DOI 10.1093/annonc/mdt523; Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Sorbye H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131046; Tabernero J, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3544; Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086; Van Cutsem E, 2019, J CLIN ONCOL, V37, P1460, DOI 10.1200/JCO.18.02459; Wiens BL, 2005, J BIOPHARM STAT, V15, P929, DOI 10.1080/10543400500265660; Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004; Yaeger R, 2017, CANCER RES, V77, P6513, DOI 10.1158/0008-5472.CAN-17-0768; Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779	36	563	569	3	54	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	2019	381	17					1632	1643		10.1056/NEJMoa1908075	http://dx.doi.org/10.1056/NEJMoa1908075			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK2QT	31566309	Green Published, Bronze			2023-01-03	WOS:000494692200007
J	Gilissen, J; Pivodic, L; Wendrich-van Dael, A; Gastmans, C; Vander Stichele, R; Van Humbeeck, L; Deliens, L; Van den Block, L				Gilissen, Joni; Pivodic, Lara; Wendrich-van Dael, Annelien; Gastmans, Chris; Vander Stichele, Robert; Van Humbeeck, Liesbeth; Deliens, Luc; Van den Block, Lieve			Implementing advance care planning in routine nursing home care: The development of the theory-based ACP plus program	PLOS ONE			English	Article							OF-LIFE OUTCOMES; RESIDENTS; INTERVENTIONS; FEASIBILITY; DEFINITION; DEMENTIA; PILOT	Background While various initiatives have been taken to improve advance care planning in nursing homes, it is difficult to find enough details about interventions to allow comparison, replication and translation into practice. Objectives We report on the development and description of the ACP+ program, a multi-component theory-based program that aims to implement advance care planning into routine nursing home care. We aimed to 1) specify how intervention components can be delivered; 2) evaluate the feasibility and acceptability of the program; 3) describe the final program in a standardized manner. Design To develop and model the intervention, we applied multiple study methods including a literature review, expert discussions and individual and group interviews with nursing home staff and management. We recruited participants through convenience sampling. Setting and participants Management and staff (n = 17) from five nursing homes in Flanders (Belgium), a multidisciplinary expert group and a palliative care nurse-trainer. Methods The work was carried out by means of 1) operationalization of key intervention components identified as part of a previously developed theory on how advance care planning is expected to lead to its desired outcomes in nursing homes into specific activities and materials, through expert discussions and review of existing advance care planning programs; 2) evaluation of feasibility and acceptability of the program through interviews with nursing home management and staff and expert revisions; and 3) standardized description of the final program according to the TIDieR checklist. During step 2, we used thematic analysis. Results The original program with nine key components was expanded to include ten intervention components, 22 activities and 17 materials to support delivery into routine nursing home care. The final ACP+ program includes ongoing training and coaching, management engagement, different roles and responsibilities in organizing advance care planning, conversations, documentation and information transfer, integration of advance care planning into multidisciplinary meetings, auditing, and tailoring to the specific setting. These components are to be implemented stepwise throughout an intervention period. The program involves the entire nursing home workforce. The support of an external trainer decreases as nursing home staff become more autonomous in organizing advance care planning. Conclusions The multicomponent ACP+ program involves residents, family, and the different groups of people working in the nursing home. It is deemed feasible and acceptable by nursing home staff and management. The findings presented in this paper, alongside results of the subsequent randomized controlled cluster trial, can facilitate comparison, replicability and translation of the intervention into practice.	[Gilissen, Joni; Pivodic, Lara; Wendrich-van Dael, Annelien; Deliens, Luc; Van den Block, Lieve] Vrije Univ Brussel VUB, End Of Life Care Res Grp, Brussels, Belgium; [Gilissen, Joni; Pivodic, Lara; Wendrich-van Dael, Annelien; Deliens, Luc; Van den Block, Lieve] Univ Ghent, Brussels, Belgium; [Gastmans, Chris] Katholieke Univ Leuven KUL, Ctr Biomed Eth & Law, Brussels, Belgium; [Vander Stichele, Robert] Univ Ghent, Dept Pharmacol, Ghent, Belgium; [Van Humbeeck, Liesbeth] Ghent Univ Hosp, Dept Geriatr Med, Ghent, Belgium; [Deliens, Luc] Univ Ghent, Dept Publ Hlth & Primary Care, Ghent, Belgium; [Van den Block, Lieve] Vrije Univ Brussel VUB, Dept Family Med & Chron Care, Brussels, Belgium; [Van den Block, Lieve] Vrije Univ Brussel VUB, Dept Clin Sci, Brussels, Belgium	Vrije Universiteit Brussel; Ghent University; KU Leuven; Ghent University; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Vrije Universiteit Brussel; Vrije Universiteit Brussel	Gilissen, J (corresponding author), Vrije Univ Brussel VUB, End Of Life Care Res Grp, Brussels, Belgium.; Gilissen, J (corresponding author), Univ Ghent, Brussels, Belgium.	joni.gilissen@vub.be	Stichele, Robert Vander/K-7203-2015; Gastmans, Chris/GWZ-3728-2022; Pivodic, Lara/C-8588-2014; Van den Block, Lieve/D-1247-2011	Stichele, Robert Vander/0000-0001-9118-9651; Pivodic, Lara/0000-0002-8825-3699; Van den Block, Lieve/0000-0002-7770-348X; Gilissen, Joni/0000-0002-5388-495X; Wendrich-van Dael, Annelien/0000-0002-6891-9086	Research Foundation Flanders (FWO) [56955 -G011214N]; Interdisciplinary Network for Dementia Using Current Technology (INDUCT) EU H2020-MSCA-ITN-2015 [676265]; Wetenschappelijk Fonds Willy Gepts (WFWG), UMCOM	Research Foundation Flanders (FWO)(FWO); Interdisciplinary Network for Dementia Using Current Technology (INDUCT) EU H2020-MSCA-ITN-2015; Wetenschappelijk Fonds Willy Gepts (WFWG), UMCOM	This work was supported by: Research Foundation Flanders (FWO), under grant nr 56955 -G011214N (www.fwo.be) & Interdisciplinary Network for Dementia Using Current Technology (INDUCT) EU H2020-MSCA-ITN-2015 under grant number 676265 (https://ec.europa.eu/programmes/horizon2020/en) to LVDB; and by Wetenschappelijk Fonds Willy Gepts (WFWG), UMCOM, no grant nr or website (contact:Aude.Bonehill@uzbrussel.be) to JG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aasmul I, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0713-7; Abbott JH, 2014, J ORTHOP SPORT PHYS, V44, P555, DOI 10.2519/jospt.2014.0110; Ajzen I, 1985, ACTION CONTROL, P11, DOI [10.1007/978-3-642-69746-3_2, DOI 10.1007/978-3-642-69746-3_2]; Ampe S, 2015, J ADV NURS, V71, P1156, DOI 10.1111/jan.12601; Andreasen P, 2022, BMJ SUPPORT PALLIAT, V12, pE393, DOI 10.1136/bmjspcare-2018-001743; Baker R, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005470.pub3; Bleijenberg N, 2018, INT J NURS STUD, V79, P86, DOI 10.1016/j.ijnurstu.2017.12.001; Caplan GA, 2006, AGE AGEING, V35, P581, DOI 10.1093/ageing/afl063; Chan HYL, 2010, J CLIN NURS, V19, P3073, DOI 10.1111/j.1365-2702.2010.03353.x; Cornally N, 2015, BMC PALLIAT CARE, V14, DOI 10.1186/s12904-015-0051-x; Craig P, 2008, MED RES FRAMEWORKS G; Daaleman TP, 2009, J AM MED DIR ASSOC, V10, P243, DOI 10.1016/j.jamda.2008.10.015; De Gendt C, 2010, EUR J PUBLIC HEALTH, V20, P189, DOI 10.1093/eurpub/ckp121; Deliens L, 2009, ADV CARE PLANNING OV; Dixon J, 2018, J PAIN SYMPTOM MANAG, V55, P132, DOI 10.1016/j.jpainsymman.2017.04.009; Froggatt K, 2016, PACE WORK PACKAGE 1; Gilissen J, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0723-5; Gilissen J, 2016, INT J NURS STUD, V93, DOI [10.1016/j.ijnurstu.2017.12.001, DOI 10.1016/J.IJNURSTU.2017.12.001]; Gilissen J, 2017, INT J NURS STUD, V66, P47, DOI 10.1016/j.ijnurstu.2016.12.003; Goodman C, 2017, CARE HOME READINESS; Hanson LC, 2005, J PALLIAT MED, V8, P1207, DOI 10.1089/jpm.2005.8.1207; Harrison KL, 2016, JAMA INTERN MED, V176, P1872, DOI 10.1001/jamainternmed.2016.6751; Hoddinott Pat, 2015, Pilot Feasibility Stud, V1, P36; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Houben CHM, 2014, J AM MED DIR ASSOC, V15, P477, DOI 10.1016/j.jamda.2014.01.008; in der Schmitten J, 2014, DTSCH ARZTEBL INT, V111, P50, DOI 10.3238/arztebl.2014.0050; Korfage IJ, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0087-z; Levy C, 2008, J PALLIAT MED, V11, P217, DOI 10.1089/jpm.2007.0147; Li S, 2018, J AM MED DIR ASSOC, V19, P333, DOI 10.1016/j.jamda.2017.09.021; Livingston G, 2013, INT PSYCHOGERIATRICS; Martin RS, 2016, J AM MED DIR ASSOC, V17, P284, DOI 10.1016/j.jamda.2015.12.017; Meller A., 2009, DEMENTIA, V8, P391, DOI DOI 10.1177/1471301209104981; Molloy W, 2000, JAMA, V283; Moore G., 2012, PROCESS EVALUATION C; Moore GF, 2017, SSM-POPUL HLTH, V3, P132, DOI 10.1016/j.ssmph.2016.12.005; Morrison RS, 2005, J AM GERIATR SOC, V53, P290, DOI 10.1111/j.1532-5415.2005.53116.x; Nys H, 2015, ETHISCHE PERSPECTIVE; Overbeek A, 2018, J AM GERIATR SOC, V66, P1089, DOI 10.1111/jgs.15333; Piers R, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0332-2; Pivodic L, 2018, PALLIATIVE MED, V32, P1584, DOI 10.1177/0269216318800610; Powell BJ, 2017, J BEHAV HEALTH SER R, V44, P177, DOI 10.1007/s11414-015-9475-6; Ramsbottom K., 2014, INT J PALLIATIVE CAR, V2014, DOI [DOI 10.1155/2014/358457, 10.1155/2014/358457]; Ribbe MW, 1997, AGE AGEING, V26, P3, DOI 10.1093/ageing/26.suppl_2.3; Rietjens JAC, 2017, LANCET ONCOL, V18, pE543, DOI 10.1016/S1470-2045(17)30582-X; Royal College of Physicians of London, 2009, NUMB 12 ADV CAR PLAN; Schickedanz AD, 2009, J AM GERIATR SOC, V57, P31, DOI 10.1111/j.1532-5415.2008.02093.x; Schmitten JID, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-14; Sekhon M, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2031-8; Smets T, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0297-1; Sudore RL, 2018, J PAIN SYMPTOM MANAG, V55, P245, DOI 10.1016/j.jpainsymman.2017.08.025; Sudore RL, 2017, J PAIN SYMPTOM MANAG, V53, P821, DOI 10.1016/j.jpainsymman.2016.12.331; Van den Block L, 2015, PUBLIC HLTH PERSPECT; Van Mechelen W., 2014, VROEGTIJDIGE ZORGPLA; Vanderstichelen S, 2019, HEALTH SOC CARE COMM, V27, P459, DOI 10.1111/hsc.12666; Vandervoort A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091130; Vandervoort A, 2014, J PAIN SYMPTOM MANAG, V47, P245, DOI 10.1016/j.jpainsymman.2013.03.009; Walczak A, 2016, PATIENT EDUC COUNS, V99, P3, DOI 10.1016/j.pec.2015.08.017; Whitehead AL, 2014, CONTEMP CLIN TRIALS, V38, P130, DOI 10.1016/j.cct.2014.04.001; World Health Organization, 2015, AG HLTH	59	9	10	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2019	14	10							e0223586	10.1371/journal.pone.0223586	http://dx.doi.org/10.1371/journal.pone.0223586			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM9KP	31622389	Green Published, gold			2023-01-03	WOS:000532567300033
J	Kays, JK; Milgrom, DP; Butler, JR; Liang, TW; Valsangkar, NP; Wojcik, B; Frye, CC; Maluccio, MA; Kubal, CA; Koniaris, LG				Kays, Joshua K.; Milgrom, Daniel P.; Butler, James R.; Liang, Tiffany W.; Valsangkar, Nakul P.; Wojcik, Brandon; Frye, C. Corbin; Maluccio, Mary A.; Kubal, Chandrashekhar A.; Koniaris, Leonidas G.			Specialized care improves outcomes for patients with cirrhosis who require general surgical operations	PLOS ONE			English	Article							HOSPITAL VOLUME; ABDOMINAL OPERATIONS; NONHEPATIC SURGERY; UNITED-STATES; RISK-FACTORS; MORTALITY; MORBIDITY	Background General surgical operations on patients with cirrhosis have historically been associated with high morbidity and mortality rates. This study examines a contemporary series of patients with cirrhosis undergoing general surgical procedures. Methods A retrospective evaluation of 358 cirrhotic patients undergoing general surgical operations at a single institution between 2004-2015 was performed. Thirty- and 90-day mortality along with complications and subsequent transplantation rates were examined. Results 358 cirrhotic patients were identified. The majority were Child-Turcotte-Pugh class (CTP) A (55.9%) followed by class B (32.4%) and class C (11.7%). Mean MELD score differed significantly between the groups (8.7 vs. 12.1 vs. 20.1; p<0.001). The most common operations were herniorrhaphy (29.9%), cholecystectomy (19.3%), and liver resection (14.5%). The majority of cases were performed semi-electively (68.4%), however, within the CTP C patients most cases were performed emergently (73.8%). Thirty and 90-day mortality for all patients were 5% and 6%, respectively. Mortality rates increased from CTP A to CTP C (30 day: 3.0% vs. 5.2% vs. 14.3%; p = 0.01; 90 day: 4.5% vs. 6.9% vs. 16.7%; p = 0.016). Additionally, 30-day mortality (12.8% vs. 2.3%; p<0.001), 90 day mortality (16.0% vs. 3.4%; p<0.001) were higher for emergent compared to elective cases. A total of 13 (3.6%) patients underwent transplantation <= 90 days from surgery. No elective cases resulted in an urgent transplantation. Conclusion Performing general surgical operations on cirrhotic patients carries a significant morbidity and mortality. This contemporary series from a specialized liver center demonstrates improved outcomes compared to historical series. These data strongly support early referral of cirrhotic patients needing general surgical operation to centers with liver expertise to minimize morbidity and mortality.	[Kays, Joshua K.; Milgrom, Daniel P.; Butler, James R.; Liang, Tiffany W.; Valsangkar, Nakul P.; Wojcik, Brandon; Frye, C. Corbin; Maluccio, Mary A.; Kubal, Chandrashekhar A.; Koniaris, Leonidas G.] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington	Koniaris, LG (corresponding author), Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA.	lkoniari@lu.edu	Kubal, Chandrashekhar/AAX-4744-2021	Kays, Joshua/0000-0003-4260-9386; Frye, Christian/0000-0002-4323-0696				Alsfasser G, 2012, SURGERY, V152, pS50, DOI 10.1016/j.surg.2012.05.011; Andraus W, 2015, BMC SURG, V15, DOI 10.1186/s12893-015-0052-y; [Anonymous], 2017, BMI HLTH WEIGHT; Birkmeyer JD, 2001, SURGERY, V130, P415, DOI 10.1067/msy.2001.117139; Cheung MC, 2010, CANCER-AM CANCER SOC, V116, P723, DOI 10.1002/cncr.24758; Child CG, 1964, LIVER PORTAL HYPERTE, P50; de Goede B, 2012, BEST PRACT RES CL GA, V26, P47, DOI 10.1016/j.bpg.2012.01.010; del Olmo JA, 2003, WORLD J SURG, V27, P647, DOI 10.1007/s00268-003-6794-1; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; DOBERNECK RC, 1983, AM J SURG, V146, P306, DOI 10.1016/0002-9610(83)90402-6; Finks JF, 2011, NEW ENGL J MED, V364, P2128, DOI 10.1056/NEJMsa1010705; GARRISON RN, 1984, ANN SURG, V199, P648, DOI 10.1097/00000658-198406000-00003; Ghaferi AA, 2011, MED CARE, V49, P1076, DOI 10.1097/MLR.0b013e3182329b97; Gutierrez JC, 2007, ANN SURG, V245, P952, DOI 10.1097/01.sla.0000250438.04393.a8; Joseph B, 2009, J AM COLL SURGEONS, V208, P520, DOI 10.1016/j.jamcollsurg.2009.01.019; Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172; Kays JK, 2018, JCSM CLIN REPORTS, V3; Mansour A, 1997, SURGERY, V122, P730, DOI 10.1016/S0039-6060(97)90080-5; Markar SR, 2012, J GASTROINTEST SURG, V16, P1055, DOI 10.1007/s11605-011-1731-3; Neeff H, 2011, J GASTROINTEST SURG, V15, P1, DOI 10.1007/s11605-010-1366-9; Nguyen NT, 2004, ANN SURG, V240, P586, DOI 10.1097/01.sla.0000140752.74893.24; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; Scaglione S, 2015, J CLIN GASTROENTEROL, V49, P690, DOI 10.1097/MCG.0000000000000208; Schell MT, 2008, HPB SURG, DOI 10.1155/2008/825940; Yang R, 2010, CANCER-AM CANCER SOC, V116, P2437, DOI 10.1002/cncr.24986; Younossi ZM, 2011, CLIN GASTROENTEROL H, V9, P524, DOI 10.1016/j.cgh.2011.03.020; Zielsdorf SM, 2015, AM SURGEON, V81, P755; Ziser A, 1999, ANESTHESIOLOGY, V90, P42, DOI 10.1097/00000542-199901000-00008	28	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2019	14	10							e0223454	10.1371/journal.pone.0223454	http://dx.doi.org/10.1371/journal.pone.0223454			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM9KK	31618218	gold, Green Published			2023-01-03	WOS:000532566600030
J	Kaissis, G; Ziegelmayer, S; Lohofer, F; Steiger, K; Algul, H; Muckenhuber, A; Yen, HY; Rummeny, E; Friess, H; Schmid, R; Weichert, W; Siveke, JT; Braren, R				Kaissis, Georgios; Ziegelmayer, Sebastian; Lohoefer, Fabian; Steiger, Katja; Alguel, Hana; Muckenhuber, Alexander; Yen, Hsi-Yu; Rummeny, Ernst; Friess, Helmut; Schmid, Roland; Weichert, Wilko; Siveke, Jens T.; Braren, Rickmer			A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy	PLOS ONE			English	Article							CANCER; RADIOMICS	Purpose Development of a supervised machine-learning model capable of predicting clinically relevant molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) from diffusionweighted-imaging-derived radiomic features. Methods The retrospective observational study assessed 55 surgical PDAC patients. Molecular subtypes were defined by immunohistochemical staining of KRT81. Tumors were manually segmented and 1606 radiomic features were extracted with PyRadiomics. A gradientboosted-tree algorithm was trained on 70% of the patients (N = 28) and tested on 30% (N = 17) to predict KRT81+ vs. KRT81- tumor subtypes. A gradient-boosted survival regression model was fit to the disease-free and overall survival data. Chemotherapy response and survival were assessed stratified by subtype and radiomic signature. Radiomic feature importance was ranked. Results The mean +/- STDEV sensitivity, specificity and ROC-AUC were 0.90 +/- 0.07, 0.92 +/- 0.11, and 0.93 +/- 0.07, respectively. The mean +/- STDEV concordance indices between the disease-free and overall survival predicted by the model based on the radiomic parameters and actual patient survival were 0.76 +/- 0.05 and 0.71 +/- 0.06, respectively. Patients with a KRT81+ subtype experienced significantly diminished median overall survival compared to KRT81-patients (7.0 vs. 22.6 months, HR 4.03, log-rank-test P = < 0.001) and a significantly improved response to gemcitabine-based chemotherapy over FOLFIRINOX (10.14 vs. 3.8 months median overall survival, HR 2.33, P = 0.037) compared to KRT81- patients, who responded significantly better to FOLFIRINOX over gemcitabine-based treatment (30.8 vs. 13.4 months median overall survival, HR 2.41, P = 0.027). Entropy was ranked as the most important radiomic feature. Conclusions The machine-learning based analysis of radiomic features enables the prediction of sub-types of PDAC, which are highly relevant for disease-free and overall patient survival and response to chemotherapy.	[Kaissis, Georgios; Ziegelmayer, Sebastian; Lohoefer, Fabian; Rummeny, Ernst; Braren, Rickmer] Tech Univ Munich, Sch Med, Dept Diagnost & Intervent Radiol, Munich, Germany; [Steiger, Katja; Muckenhuber, Alexander; Yen, Hsi-Yu; Weichert, Wilko] Tech Univ Munich, Sch Med, Dept Pathol, Munich, Germany; [Alguel, Hana; Schmid, Roland] Tech Univ Munich, Sch Med, Dept Internal Med 2, Munich, Germany; [Friess, Helmut] Tech Univ Munich, Sch Med, Dept Surg, Munich, Germany; [Siveke, Jens T.] Univ Hosp Essen, Div Solid Tumor Translat Oncol, West German Canc Ctr, Essen, Germany; [Siveke, Jens T.] German Canc Consortium DKTK, Heidelberg, Germany; [Siveke, Jens T.] German Canc Res Ctr, Heidelberg, Germany	Technical University of Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Braren, R (corresponding author), Tech Univ Munich, Sch Med, Dept Diagnost & Intervent Radiol, Munich, Germany.	rbraren@tum.de	Braren, Rickmer/U-3254-2018; Siveke, Jens/AAQ-6170-2021	Braren, Rickmer/0000-0001-6039-6957; Siveke, Jens/0000-0002-8772-4778	German Research Foundation (DFG) within the SFB-Initiative 824 (collaborative research center), "Imaging for Selection, Monitoring and Individualization of Cancer Therapies" [SFB824]	German Research Foundation (DFG) within the SFB-Initiative 824 (collaborative research center), "Imaging for Selection, Monitoring and Individualization of Cancer Therapies"(German Research Foundation (DFG))	This work was supported by funding of the German Research Foundation (DFG) within the SFB-Initiative 824 (collaborative research center), "Imaging for Selection, Monitoring and Individualization of Cancer Therapies" to RB (SFB824, project C6) and WW (project Z2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aung KL, 2018, CLIN CANCER RES, V24, P1344, DOI 10.1158/1078-0432.CCR-17-2994; Bach M, 2019, EUR CONGR RADIOL; Bailey DL, 2018, MOL IMAGING BIOL, V20, P4, DOI 10.1007/s11307-017-1123-5; Caramella C, 2018, MED PHYS, V45, P1529, DOI 10.1002/mp.12809; Chen TQ, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P785, DOI 10.1145/2939672.2939785; Collisson EA, 2019, NAT REV GASTRO HEPAT, V16, P207, DOI 10.1038/s41575-019-0109-y; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Coroller TP, 2015, RADIOTHER ONCOL, V114, P345, DOI 10.1016/j.radonc.2015.02.015; EILAGHI A, 2017, BMC MED IMAGING, V17, DOI DOI 10.1186/S12880-016-0171-7; Hanania AN, 2016, ONCOTARGET, V7, P85776, DOI 10.18632/oncotarget.11769; Heid I, 2017, CLIN CANCER RES, V23, P1461, DOI 10.1158/1078-0432.CCR-15-2432; Kaissis G, 2019, BIORXIV; Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728; Khalvati F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41728-7; Kumar V, 2012, MAGN RESON IMAGING, V30, P1234, DOI 10.1016/j.mri.2012.06.010; Lao JW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10649-8; Muckenhuber A, 2018, CLIN CANCER RES, V24, P351, DOI 10.1158/1078-0432.CCR-17-2180; Mueller S, 2018, NATURE, V554, P62, DOI 10.1038/nature25459; Ojala M, 2009, IEEE DATA MINING, P908, DOI 10.1109/ICDM.2009.108; Polsterl Sebastian, 2016, F1000Res, V5, P2676, DOI 10.12688/f1000research.8231.2; Puleo F, 2018, GASTROENTEROLOGY, V155, P1999, DOI 10.1053/j.gastro.2018.08.033; PyRadiomics, FEAT DOC; Trajkovic-Arsic M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16826-z; Traverso A, 2018, INT J RAD ONCOL; van Griethuysen JJM, 2017, CANCER RES, V77, pE104, DOI 10.1158/0008-5472.CAN-17-0339; Verma V, 2017, J NATL CANC I; Von Hoff DD, 2013, J CLIN ONCOL, V31, DOI 10.1200/jco.2013.31.4_suppl.lba148; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Zhao BS, 2016, SCI REP-UK, V6, DOI 10.1038/srep23428; Zwanenburg A, 2016, CORR	31	33	34	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2019	14	10							e0218642	10.1371/journal.pone.0218642	http://dx.doi.org/10.1371/journal.pone.0218642			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM6VM	31577805	Green Published, Green Submitted, gold			2023-01-03	WOS:000532388000003
J	Yan, ZM; Zhang, JQ; Long, H; Sun, XM; Li, DJ; Tang, T; Li, XA; Hui, W				Yan, Zhumin; Zhang, Jingqiao; Long, Hai; Sun, Xueming; Li, Dingjie; Tang, Tian; Li, X. Allen; Hui, Wu			Correlation of CT texture changes with treatment response during radiation therapy for esophageal cancer: An exploratory study	PLOS ONE			English	Article							NECK-CANCER; RADIOTHERAPY; HEAD; IMAGES	Purpose To analyze the change of CT texture features of esophageal squamous cell carcinoma (ESC) during RT delivery and to correlate these changes with the RT responses and survival. Methods A total of 61 ESC patients received radical RT were screened. Weekly CTs (4-6 sets for each patient) were acquired during RT. The tumors, normal esophageal mucosa tissue (NEC) of 5 cm and the spinal cord in the relevant area were delineated. CT texture features were extracted with a home-made tool. The changes of these features were analyzed by t-test. The correlations of the changes of features with RT responses and with patient survival were investigated by Pearson analysis. Results The average changes were increased by 0.00072 +/- 0.00197 for coarseness, by 0.14 +/- 0.40 for entropy, and by 2.34 +/- 3.56 for strength. In addition, the average changes were reduced by 8.88 +/- 15.71cc for volume and by 0.07 +/- 0.11 for busyness. The changes of the coarseness, strength, STD and entropy in ESC were different for the good and poor response groups. The survival rate of the patients was significantly correlated with the change of coarseness and strength (P = 0.0027 and P = 0.0001). Conclusions During RT, changes of CT texture features of ESC, e.g., coarseness, strength, STD, entropy and volume are correlated with radiation response and survival rate. With more clinical data and robust research, CT features, e.g., coarseness and strength, can be selected as outstanding imaging biomarkers for prediction of RT prognosis of ESC.	[Yan, Zhumin; Long, Hai; Sun, Xueming; Li, Dingjie; Tang, Tian; Hui, Wu] Zhengzhou Univ, Dept Radiat Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China; [Zhang, Jingqiao] New York Proton Ctr, Dept Radiat Oncol, New York, NY USA; [Li, X. Allen] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA	Zhengzhou University; Medical College of Wisconsin	Hui, W (corresponding author), Zhengzhou Univ, Dept Radiat Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China.	wuhui7008@126.com						Cao Y, 2008, INT J RADIAT ONCOL, V72, P1287, DOI 10.1016/j.ijrobp.2008.08.024; Chen XJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178961; Chia-Chin L, 2018, MEDICINE, V97, DOI [10.1097/MD, DOI 10.1097/MD]; Cook GJR, 2013, J NUCL MED, V54, P19, DOI 10.2967/jnumed.112.107375; Diot Q, 2012, INT J RADIAT ONCOL, V84, P1024, DOI 10.1016/j.ijrobp.2011.11.080; Feng M, 2015, INT J RADIAT ONCOL, V91, P1041, DOI 10.1016/j.ijrobp.2014.12.057; Ganeshan B, 2012, CLIN RADIOL, V67, P157, DOI 10.1016/j.crad.2011.08.012; Gillies RJ, 2016, RADIOLOGY, V278, P563, DOI 10.1148/radiol.2015151169; Herfarth KK, 2003, INT J RADIAT ONCOL, V57, P444, DOI 10.1016/S0360-3016(03)00586-8; Lambin P, 2012, EUR J CANCER, V48, P441, DOI 10.1016/j.ejca.2011.11.036; Larue RTHM, 2018, ACTA ONCOL, V57, P1475, DOI 10.1080/0284186X.2018.1486039; Lin SH, 2012, INT J RADIAT ONCOL, V84, P1078, DOI 10.1016/j.ijrobp.2012.02.015; Mayer R, 2015, RADIAT ONCOL INVEST, V6, P281, DOI [10.1002/(SICI)1520-6823(1998)6, DOI 10.1002/(SICI)1520-6823(1998)6]; MIRA JG, 1982, INT J RADIAT ONCOL, V8, P1625, DOI 10.1016/0360-3016(82)90627-7; Paul J, 2017, INT J RADIAT ONCOL, V98, P463, DOI 10.1016/j.ijrobp.2017.02.032; Qiu GQ, 2012, SURG LAPARO ENDO PER, V22, P424, DOI 10.1097/SLE.0b013e31825d393d; Ren W, 2017, ONCOTARGE, V8, DOI [10.18632/oncotarget.22304, DOI 10.18632/ONCOTARGET.22304]; Si Y, 2018, AM J ROENTGENOL, V211, P358, DOI 10.2214/AJR.17.18934; Sylvester R., 1979, WHO HDB REP RES CANC; Tixier F, 2011, J NUCL MED, V52, P369, DOI 10.2967/jnumed.110.082404; Vosmik M, 2010, WORLD J GASTROENTERO, V16, P5555, DOI 10.3748/wjg.v16.i44.5555; Yu H, 2009, IEEE T MED IMAGING, V28, P374, DOI 10.1109/TMI.2008.2004425	22	3	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2019	14	9							e0223140	10.1371/journal.pone.0223140	http://dx.doi.org/10.1371/journal.pone.0223140			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM6FU	31557242	gold, Green Published			2023-01-03	WOS:000532345500080
J	Carrillo, A; Rubio-Aparicio, M; Molinari, G; Enrique, A; Saanchez-Meca, J; Banos, RM				Carrillo, Alba; Rubio-Aparicio, Maria; Molinari, Guadalupe; Enrique, Angel; Sanchez-Meca, Julio; Banos, Rosa M.			Effects of the Best Possible Self intervention: A systematic review and meta-analysis	PLOS ONE			English	Review							EFFECTS META-REGRESSION; NEGATIVE AFFECT; POSITIVE PSYCHOLOGY; INDUCED OPTIMISM; EFFECT SIZE; LIFE; PAIN; VALIDATION; PANAS; SATISFACTION	The Best Possible Self (BPS) exercise promotes a positive view of oneself in the best possible future, after working hard towards it. Since the first work that attempted to examine the benefits of this intervention in 2001, studies on the BPS have grown exponentially and, currently, this is one of the most widely used Positive Psychology Interventions. However, little is yet known about its overall effectiveness in increasing wellbeing outcomes. Thus, the aim of this meta-analysis is to shed light on this question. A systematic literature search was conducted, and 29 studies (in 26 articles) met the inclusion criteria of empirically testing the intervention and comparing it to a control condition. In addition, BPS was compared to gratitude interventions in some of the included studies. A total of 2,909 participants were involved in the analyses. The outcome measures were wellbeing, optimism, depressive symptoms, and positive and negative affect. Results showed that the BPS is an effective intervention to improve wellbeing (d(+) =.325), optimism (d(+) =.334) and positive affect (d(+) =.511) comparing to controls. Small effect sizes were obtained for negative affect and depressive symptoms. Moderator analyses did not show statistically significant results for wellbeing, except for a trend towards significance in the age of the participants (years) and the magnitude of the intervention (total minutes of practice). In addition, the BPS was found to be more beneficial for positive and negative affect than gratitude interventions (d(+) =.326 and d(+) =.485, respectively). These results indicate that the BPS can be considered a valuable Positive Psychology Intervention to improve clients' wellbeing, and it seems that it might be more effective for older participants and with shorter practices (measured as total minutes of practice).	[Carrillo, Alba; Banos, Rosa M.] Univ Valencia, Dept Personal Assessment & Psychol Treatments, Valencia, Spain; [Rubio-Aparicio, Maria] Univ Alicante, Dept Hlth Psychol, Alicante, Spain; [Molinari, Guadalupe] Univ Jaume 1, Dept Basic Clin & Biol Psychol, Castellon de La Plana, Spain; [Molinari, Guadalupe; Banos, Rosa M.] Inst Carlos III, CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Madrid, Spain; [Enrique, Angel] Univ Dublin, Trinity Coll, Sch Psychol, Dublin, Ireland; [Sanchez-Meca, Julio] Univ Murcia, Dept Basic Psychol & Methodol, Murcia, Spain	University of Valencia; Universitat d'Alacant; Universitat Jaume I; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Trinity College Dublin; University of Murcia	Carrillo, A (corresponding author), Univ Valencia, Dept Personal Assessment & Psychol Treatments, Valencia, Spain.	alba.carrillo@uv.es	BAÑOS, ROSA MARIA/C-6077-2011; Rubio-Aparicio, Maria/Z-5592-2019; Sánchez-Meca, Julio/AAA-7807-2019; Carrillo, Alba/B-7513-2019	BAÑOS, ROSA MARIA/0000-0003-0626-7665; Rubio-Aparicio, Maria/0000-0002-2599-4246; Sánchez-Meca, Julio/0000-0002-8412-788X; Carrillo, Alba/0000-0003-3478-2699; Molinari, Guadalupe/0000-0002-1957-9353	Conselleria d'Educacio, Investigacio, Cultura i Esport (Spain) under the grant "INTERSABIAS" [PROMETEO/2018/110]	Conselleria d'Educacio, Investigacio, Cultura i Esport (Spain) under the grant "INTERSABIAS"	This work was supported by the Conselleria d'Educacio ', Investigacio ', Cultura i Esport (Spain) under the grant "INTERSABIAS" (PROMETEO/2018/110) to RMB. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguinis H, 2011, J ORGAN BEHAV, V32, P1033, DOI 10.1002/job.719; Lopez-Lopez JA, 2014, BRIT J MATH STAT PSY, V67, P30, DOI 10.1111/bmsp.12002; Beck A.T., 1996, MANUAL BECK DEPRESSI; Boehm JK, 2011, COGNITION EMOTION, V25, P1263, DOI 10.1080/02699931.2010.541227; Bolier L, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-119; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Boselie JJLM, 2017, J PAIN, V18, P446, DOI 10.1016/j.jpain.2016.12.007; Boselie JJLM, 2016, SCAND J PAIN, V12, P25, DOI 10.1016/j.sjpain.2016.03.001; Boselie JJLM, 2014, PAIN, V155, P334, DOI 10.1016/j.pain.2013.10.014; Cohen J., 2013, STAT POWER ANAL BEHA; Crawford JR, 2004, BRIT J CLIN PSYCHOL, V43, P245, DOI 10.1348/0144665031752934; Davis DE, 2016, J COUNS PSYCHOL, V63, P20, DOI 10.1037/cou0000107; Diener E, 2006, AM PSYCHOL, V61, P305, DOI 10.1037/0003-066X.61.4.305; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Enrique A, 2017, APPL RES QUAL LIFE, P1; Geschwind N, 2015, J PAIN, V16, P258, DOI 10.1016/j.jpain.2014.12.003; Hanssen MM, 2013, PAIN, V154, P53, DOI 10.1016/j.pain.2012.08.006; Hanssen MM, 2014, INVESTIGATING NEGATI; Harrist S, 2007, J RES PERS, V41, P923, DOI 10.1016/j.jrp.2006.09.002; Hedges LV, 2010, RES SYNTH METHODS, V1, P39, DOI 10.1002/jrsm.5; Henrich J, 2010, BEHAV BRAIN SCI, V33, P111, DOI 10.1017/S0140525X10000725; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; King LA, 2001, PERS SOC PSYCHOL B, V27, P798, DOI 10.1177/0146167201277003; Knapp G, 2003, STAT MED, V22, P2693, DOI 10.1002/sim.1482; Laux L, 2013, STATE TRAIT ANGSTDEP; Layous K, 2013, J CROSS CULT PSYCHOL, V44, P1294, DOI 10.1177/0022022113487591; Layous K, 2013, J HAPPINESS STUD, V14, P635, DOI 10.1007/s10902-012-9346-2; Liau AK, 2016, ASIA-PAC EDUC RES, V25, P473, DOI 10.1007/s40299-015-0272-z; LIPSEY MW, 1993, AM PSYCHOL, V48, P1181, DOI 10.1037/0003-066X.48.12.1181; Lopez-Gomez I, 2015, BEHAV PSYCHOL, V23, P529; Loveday PM, 2018, J HAPPINESS STUD, V19, P607, DOI 10.1007/s10902-016-9824-z; Lyubomirsky S, 1999, SOC INDIC RES, V46, P137, DOI 10.1023/A:1006824100041; Lyubomirsky S, 2013, CURR DIR PSYCHOL SCI, V22, P57, DOI 10.1177/0963721412469809; Lyubomirsky S, 2011, EMOTION, V11, P391, DOI 10.1037/a0022575; Maddalena CJ, 2014, QUAL QUANT, V48, P2939, DOI 10.1007/s11135-013-9933-2; Malouff JM, 2017, J POSIT PSYCHOL, V12, P594, DOI 10.1080/17439760.2016.1221122; Manthey L, 2016, J HAPPINESS STUD, V17, P319, DOI 10.1007/s10902-014-9596-2; Meevissen YMC, 2011, J BEHAV THER EXP PSY, V42, P371, DOI 10.1016/j.jbtep.2011.02.012; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Morris SB, 2008, ORGAN RES METHODS, V11, P364, DOI 10.1177/1094428106291059; Nelson SK, 2015, J POSIT PSYCHOL, V10, P463, DOI 10.1080/17439760.2014.983959; Ng WT, 2016, J POSIT PSYCHOL, V11, P51, DOI 10.1080/17439760.2015.1025419; Odou N, 2013, SOC INDIC RES, V110, P111, DOI 10.1007/s11205-011-9919-1; Peters ML, 2016, J POSIT PSYCHOL, V11, P258, DOI 10.1080/17439760.2015.1048816; Peters ML, 2013, TER PSICOL, V31, P93, DOI 10.4067/S0718-48082013000100009; Peters ML, 2010, J POSIT PSYCHOL, V5, P204, DOI 10.1080/17439761003790963; Peterson RA, 2001, J CONSUM RES, V28, P450, DOI 10.1086/323732; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Renner F, 2014, PSYCHIAT RES, V215, P105, DOI 10.1016/j.psychres.2013.10.033; Rubio-Aparicio M, 2018, BEHAV RES METHODS, V50, P2057, DOI 10.3758/s13428-017-0973-8; Rubio-Aparicio M, 2017, BRIT J MATH STAT PSY, V70, P439, DOI 10.1111/bmsp.12092; Sanchez-Meca J, 2013, ANAL CONCORDANCE SCA; Sanchez-Meca J, 2008, PSYCHOL METHODS, V13, P31, DOI 10.1037/1082-989X.13.1.31; Scheier MF, 2006, J BEHAV MED, V29, P291, DOI 10.1007/s10865-005-9044-1; SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063; SELIGMAN MEP, 1979, J ABNORM PSYCHOL, V88, P242, DOI 10.1037/0021-843X.88.3.242; Seligman MEP, 2000, AM PSYCHOL, V55, P5, DOI 10.1037/0003-066X.55.1.5; Seligson JL, 2003, SOC INDIC RES, V61, P121, DOI 10.1023/A:1021326822957; Sheldon K. M., 2006, J POSIT PSYCHOL, P73, DOI [10.1080/17439760500510676, DOI 10.1080/17439760500510676]; Sin NL, 2009, J CLIN PSYCHOL, V65, P467, DOI 10.1002/jclp.20593; Summerfield T., 2015, POSITIVE INTERVENTIO; Tennant R, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-63; Thompson ER, 2007, J CROSS CULT PSYCHOL, V38, P227, DOI 10.1177/0022022106297301; Thompson RB, 2015, J POSIT PSYCHOL, V10, P179, DOI 10.1080/17439760.2014.927908; Troop NA, 2013, PSYCHOL PSYCHOTHER-T, V86, P374, DOI 10.1111/j.2044-8341.2012.02065.x; Van den Noortgate W, 2015, BEHAV RES METHODS, V47, P1274, DOI 10.3758/s13428-014-0527-2; Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0; Viechtbauer W, 2015, PSYCHOL METHODS, V20, P360, DOI 10.1037/met0000023; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Weiss LA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158092; Yogo M, 2008, BRIT J HEALTH PSYCH, V13, P77, DOI 10.1348/135910707X252440	74	25	25	3	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2019	14	9							e0222386	10.1371/journal.pone.0222386	http://dx.doi.org/10.1371/journal.pone.0222386			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM5QI	31545815	Green Published, Green Submitted, gold			2023-01-03	WOS:000532303200015
J	Hung, TW; Huang, JY; Jong, GP				Hung, Tung-Wei; Huang, Jing-Yang; Jong, Gwo-Ping			Long-term outcomes of dialysis in patients with chronic kidney disease and new-onset atrial fibrillation: A population-based cohort study	PLOS ONE			English	Article							STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; RISK-FACTORS; EPIDEMIOLOGY	Background Chronic kidney disease (CKD) is associated with substantial cardiovascular morbidity. Atrial fibrillation (AF) is a prevalent arrhythmia that increases the risk of both stroke and cardiovascular mortality. Information about the mortality risk among patients with advanced CKD and new-onset AF (NAF) in the presence and absence of dialysis is important. However, the association between advanced CKD and NAF in patients with and without dialysis is unclear. Objective To investigate long-term outcomes of the association between advanced CKD and NAF in patients with and without dialysis. Methods We conducted a nested case-control study based on the National Health Insurance Program in Taiwan. Each participant aged 20 years and older who had CKD with dialysis from 2000 to 2013 was assigned to the dialysis group, whereas sex-, age-, CKD duration-, and index date-matched participants without dialysis were randomly selected and assigned to the non-dialysis group. We used the Cox regression model to estimate the hazard ratio (HR) with the 95% confidence interval (CI) for mortality in CKD patients with combined dialysis and NAF. Patients with neither NAF nor dialysis served as the reference group. Results We identified 3,673 dialysis cases and 7,346 Non-dialysis matched controls for enrolment in the study. The crude mortality rates were 3.3 (95% CI: 3.1-3.5), 10.98 (95% CI: 9.3-13.0), 9.2 (95% CI: 8.7-10.0), and 18.0 (95% CI: 15.4-21.2) in the [Non-dialysis, non-NAF], [Nondialysis, NAF], [Dialysis, non-NAF], and [Dialysis, NAF] groups, respectively. After adjustment for age, gender, and co-morbidities, the aHRs were 2.0 (95% CI: 1.7-2.3), 2.7 (95% CI: 2.5-2.9), and 3.5 (95% CI: 2.9-4.1) in the [Non-Dialysis, NAF], [Dialysis, non-NAF], and [Dialysis, NAF] groups compared with the [Non-Dialysis, non-NAF] group, respectively. The Kaplan-Meier survival curves showed the highest mortality risk in the [Dialysis, NAF] group among the study groups. Patients with concurrent peritoneal dialysis and AF had the highest mortality risk: aHR = 4.3 (95% CI: 2.3-8.0). However, there was a relatively lower effect of NAF on mortality in patients on dialysis than in patients who were not. Conclusions Patients with advanced CKD and NAF had a significantly increased risk of mortality. Dialysis is not risky for patients with concurrent CKD and NAF. Dialysis offers a sufficient survival benefit to be considered as a standard treatment, as indicated by the superior physical status of patients on dialysis.	[Hung, Tung-Wei] Chung Shan Med Univ Hosp, Dept Internal Med, Div Nephrol, Taichung, Taiwan; [Hung, Tung-Wei; Jong, Gwo-Ping] Chung Shan Med Univ, Taichung, Taiwan; [Huang, Jing-Yang] Chung Shan Med Univ Hosp, Dept Med Res, Taichung, Taiwan; [Jong, Gwo-Ping] Chung Shan Med Univ Hosp, Dept Internal Med, Div Cardiol, Taichung, Taiwan	Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Chung Shan Medical University Hospital	Jong, GP (corresponding author), Chung Shan Med Univ, Taichung, Taiwan.; Jong, GP (corresponding author), Chung Shan Med Univ Hosp, Dept Internal Med, Div Cardiol, Taichung, Taiwan.	cgp8009@yahoo.com.tw		Jong, Gwo-Ping/0000-0002-7786-5497				Abbott Kevin C, 2003, BMC Nephrol, V4, P1, DOI 10.1186/1471-2369-4-1; Abuhasira R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21229-9; Atar I, 2006, INT J CARDIOL, V106, P47, DOI 10.1016/j.ijcard.2004.12.048; Baber U, 2011, CIRC-ARRHYTHMIA ELEC, V4, P26, DOI 10.1161/CIRCEP.110.957100; Bansal N, 2013, CIRCULATION, V127, P569, DOI 10.1161/CIRCULATIONAHA.112.123992; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; Chou Che-Yi, 2010, Nephrol Dial Transplant, V25, P1225, DOI 10.1093/ndt/gfp589; Chugh SS, 2014, CIRCULATION, V129, P837, DOI 10.1161/CIRCULATIONAHA.113.005119; Das Manisha, 2006, Cardiol Rev, V14, P14, DOI 10.1097/01.crd.0000148162.88296.9f; de Castroviejo EVR, 2006, REV ESP CARDIOL, V59, P779, DOI 10.1016/S1885-5857(07)60043-7; Findlay MD, 2015, STROKE, V46, P2477, DOI 10.1161/STROKEAHA.115.009095; Konigsbrugge O, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169400; Krane V, 2009, CLIN J AM SOC NEPHRO, V4, P394, DOI 10.2215/CJN.02020408; Kulkarni N, 2012, J ATR FIBRILLATION, V5, P448, DOI [10.4022/jafib.448, DOI 10.4022/JAFIB.448]; Liao JN, 2015, KIDNEY INT, V87, P1209, DOI 10.1038/ki.2014.393; Miyasaka Y, 2006, CIRCULATION, V114, P119, DOI 10.1161/CIRCULATIONAHA.105.595140; Rahman F, 2014, NAT REV CARDIOL, V11, P639, DOI 10.1038/nrcardio.2014.118; Shen CH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003933; Soliman EZ, 2010, AM HEART J, V159, P1102, DOI 10.1016/j.ahj.2010.03.027; Winkelmayer WC, 2011, J AM SOC NEPHROL, V22, P349, DOI 10.1681/ASN.2010050459; Wizemann V, 2010, KIDNEY INT, V77, P1098, DOI 10.1038/ki.2009.477; Zebe H, 2000, NEPHROL DIAL TRANSPL, V15, P765, DOI 10.1093/ndt/15.6.765	22	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2019	14	9							e0222656	10.1371/journal.pone.0222656	http://dx.doi.org/10.1371/journal.pone.0222656			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM5BF	31536566	gold, Green Published, Green Submitted			2023-01-03	WOS:000532262800067
J	Pal, H				Pal, Hemraj			In treatment-resistant depression, adding esketamine nasal spray to an oral antidepressant improved symptoms at 28	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								Question In adults with treatment-resistant depression, does adding flexibly dosed esketamine nasal spray to a newly started oral antidepressant reduce symptoms at 28 days? Methods Design: Randomized controlled trial (RCT). ClinicalTrials. gov NCT02418585. Allocation: {Concealed}*.dagger Blinding: Blinded dagger (patients, investigators, center staff, outcome assessors, and data analysts). Follow-up period: 28 days (treatment period). Setting: 39 outpatient referral centers in the Czech Republic, Germany, Poland, Spain, and the USA. Patients: 227 patients 18 to 64 years of age (mean age 46 y, 62% women) who had moderate-to-severe nonpsychotic major depressive disorder and were nonresponsive to an adequate trial (dose, duration, and adherence) of >= 2 oral antidepressants during the current depression episode. Nonresponse was defined as <= 25% improvement to >= 1 oral antidepressant documented retrospectively at the start of the 4-week prerandomization screening period and <= 25% improvement to 1 oral antidepressant used for >= 2 prescreening weeks and assessed prospectively during the 4-week screening period, with a minimum score at weeks 2 and 4. Exclusion criteria included suicidal behavior in the past year; homicidal or active suicidal ideation or intent in the past 6 months; borderline, antisocial, histrionic, or narcissistic personality disorder; current obsessive-compulsive disorder; autism spectrum disorder; intellectual disability; seizures; uncontrolled hypertension; or moderate or severe substance use disorder in the past 6 months. Intervention: Esketamine nasal spray, 56 or 84 mg twice/wk, plus a daily, investigator-selected, oral antidepressant (escitalopram, sertraline, duloxetine, or venlafaxine extended-release) not previously associated with nonresponse in the current depression episode (n = 116) or placebo nasal spray plus an oral antidepressant (n = 111). Outcomes: Primary outcome was the Montgomery-Asberg Depression Rating Scale score. Secondary outcomes included onset of clinical response by day 2 with maintenance of response to day 28 Patient follow-up: 87% completed the 28-day treatment period; 98% received >= 1 study drug dose and were included in the analyses. Main results 54% of patients received duloxetine as the oral antidepressant, 17% escitalopram, 14% sertraline, and 14% venlafaxine extended-release. The main results are in the Table. Conclusion In treatment-resistant depression, adding esketamine nasal spray to a new oral antidepressant improved symptoms at 28 days.	[Pal, Hemraj] Essex Partnership Univ Fdn Trust, Colchester, Essex, England		Pal, H (corresponding author), Essex Partnership Univ Fdn Trust, Colchester, Essex, England.							Schatzberg AF, 2019, AM J PSYCHIAT, V176, P422, DOI 10.1176/appi.ajp.2019.19040423; Swainson J, 2019, EXPERT REV NEUROTHER, DOI 10.1080/14737175.2019.1640604	2	1	1	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 17	2019	171	6					JC33	JC33		10.7326/ACPJ201909170-033	http://dx.doi.org/10.7326/ACPJ201909170-033			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IY0RW	31525767				2023-01-03	WOS:000486101400009
J	Fekad, GA; Omigbodun, AO; Roberts, OA; Yalew, AW				Fekad, Gedefaw Abeje; Omigbodun, Akinyinka O.; Roberts, Olumuyiwa A.; Yalew, Alemayehu Worku			Determinants of change in long-acting or permanent contraceptives use in Ethiopia; A multivariate decomposition analysis of data from the Ethiopian demographic and health survey	PLOS ONE			English	Article							DEMAND; WOMEN	Background There has been an increase in the uptake of long-acting or permanent contraceptive methods (LAPMs) in Ethiopia. Identifying the factors associated with this change is important for designing interventions that will further accelerate the uptake. This study was done to identify components of, and factors associated with, changes in the use of LAPMs in Ethiopia. Methods Information about 16,336 married or in-union reproductive-age women were extracted from the 2005 and 2016 Ethiopian Demographic and Health Surveys (EDHS). Normalized weighting was used to compensate for disproportionate sampling and non-response in the survey. The two data sets were merged and analyzed using multivariate decomposition analysis. Result From 2005 to 2016, the use of LAPMs increased by 12.0 percentage points. Changes in the characteristics of women (compositional factors) were responsible for nearly 7.0% of the observed difference. Most of the change (92.0%) was attributable to differences in the effects of characteristics. Age, working status, woman's occupation, concordance on the desired number of children between women and their partners, and a visit by health workers in the 12 months before the survey were all significantly associated with the change. Conclusion The contribution of variation in the survey population structure was not significant for the observed change. The change in the use of LAPMs was mainly due to behavioral changes among older, educated and working women, and women visited by health workers.	[Fekad, Gedefaw Abeje] Univ Ibadan, Pan African Univ, Inst Life & Earth Sci Including Hlth & Agr, Ibadan, Nigeria; [Fekad, Gedefaw Abeje] Bahir Dar Univ, Sch Publ Hlth, Coll Med & Hlth Sci, Bahir Dar, Ethiopia; [Omigbodun, Akinyinka O.; Roberts, Olumuyiwa A.] Univ Ibadan, Univ Coll Hosp, Coll Med, Dept Obstet & Gynecol, Ibadan, Nigeria; [Yalew, Alemayehu Worku] Addis Ababa Univ, Coll Hlth Sci, Sch Publ Hlth, Addis Ababa, Ethiopia	University of Ibadan; Bahir Dar University; University of Ibadan; University College Hospital, Ibadan; Addis Ababa University	Fekad, GA (corresponding author), Univ Ibadan, Pan African Univ, Inst Life & Earth Sci Including Hlth & Agr, Ibadan, Nigeria.; Fekad, GA (corresponding author), Bahir Dar Univ, Sch Publ Hlth, Coll Med & Hlth Sci, Bahir Dar, Ethiopia.	abejegedefaw@gmail.com	Abeje, Gedefaw/AAL-1098-2021	Fekadu, Gedefaw Abeje/0000-0002-9912-8332; Omigbodun, Akinyinka/0000-0002-6377-9299				Acharya DR, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-15; Adedini SA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217574; Agha N, 2018, PAKISTAN J WOMENS ST, V25; Ameyaw EK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220970; [Anonymous], 2015, TRENDS CONTR US WORL; Bearak J, 2018, LANCET GLOB HEALTH, V6, pE380, DOI 10.1016/S2214-109X(18)30029-9; BLINDER AS, 1973, J HUM RESOUR, V8, P436, DOI 10.2307/144855; Bosomprah S, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/s12884-014-0415-x; Bulto G, 2018, GYNECOL OBSTET, V8, P2161; Bulto GA, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-46; Castro Martin T, 1994, Popul Bull UN, P81; Central Statistical Agency (CSA) and ORC Macro, 2005, ETH DEM HLTH SURV 20; Central Statistical Agency (CSA) [Ethiopia] and ICF, 2011, ETH DEM HLTH SURV AD; CSA ICF, 2016, ETH DEM HLTH SURV; Edoka I, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0661-4; Fruhauf T, 2018, HEALTH POLICY PLANN, V33, P828, DOI 10.1093/heapol/czy058; Hancock NL, 2015, TEMPORAL TRENDS PRED, V2015; Hayter M, 2016, PRIM HEALTH CARE RES, V17, P287, DOI 10.1017/S1463423615000432; Hubacher D, 2017, AM J OBSTET GYNECOL, V216, P101, DOI 10.1016/j.ajog.2016.08.033; Joshi R, 2015, INT J GYNECOL OBSTET, V131, pS60, DOI 10.1016/j.ijgo.2015.04.024; Mekonnen G, 2014, PAN AFR MED J, V18, DOI 10.11604/pamj.2014.18.98.3421; Mesfin YM, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0194-0; Meskele M, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-109; Minstry of Health Ethiopia, 2016, COST IMPL PLAN FAM P; Oaxaca R., 1973, INT ECON REV, V14, P693, DOI 10.2307/2525981; Olson DJ, 2013, STUD FAMILY PLANN, V44, P445, DOI 10.1111/j.1728-4465.2013.00369.x; Ontiri S, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16091543; Powers DA, 2011, STATA J, V11, P556, DOI 10.1177/1536867X1101100404; Radulovic O, 2006, FACTA U, V13, P58; Rutayisire PC, 2014, INT J POPULATION RES, V2014; Stoddard A, 2011, DRUGS, V71, P969, DOI 10.2165/11591290-000000000-00000; Melka AS, 2015, PAN AFR MED J, V21, DOI 10.11604/pamj.2015.21.246.5835; Tsakos G, 2017, J EPIDEMIOL COMMUN H, V71, P1203, DOI 10.1136/jech-2017-209696; Tsui AO, 2017, POPUL DEV REV, V43, P166, DOI 10.1111/padr.12051; Umar AS, 2017, AFR HEALTH SCI, V17, P391, DOI 10.4314/ahs.v17i2.13; USAID, 2012, 3 SUCC SUBS AFR FAM; Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855; Worku AG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116525; Yalew Saleamlak Adbaru, 2015, BMC Res Notes, V8, P29, DOI 10.1186/s13104-015-0974-6; Zenebe CB, 2017, BMC WOMENS HEALTH, V17, DOI 10.1186/s12905-017-0432-9	40	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2020	15	1							e0227218	10.1371/journal.pone.0227218	http://dx.doi.org/10.1371/journal.pone.0227218			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP5JP	31935224	gold, Green Published			2023-01-03	WOS:000534354100015
J	Carayon, P; Cassel, C; Dzau, VJ				Carayon, Pascale; Cassel, Christine; Dzau, Victor J.			Improving the System to Support Clinician Well-being and Provide Better Patient Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Carayon, Pascale] Univ Wisconsin, Coll Engn, Wisconsin Inst Healthcare Syst Engn, Madison, WI USA; [Cassel, Christine] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Dzau, Victor J.] Natl Acad Med, Washington, DC USA	University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Francisco; National Academies of Sciences, Engineering & Medicine	Carayon, P (corresponding author), Univ Wisconsin, Engn Ctr Bldg,1550 Engn Dr, Madison, WI 53715 USA.	pcarayon@wisc.edu						Bodenheimer T, 2014, ANN FAM MED, V12, P573, DOI 10.1370/afm.1713; Institute of Medicine, 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Institute of Medicine, 2000, ERR IS HUMAN BUILDIN; Johnson-Coyle Leah, 2016, Can J Crit Care Nurs, V27, P27; Maslach C., 1986, MASLACH BURNOUT INVE; National Academies of Sciences Engineering and Medicine; National Academy of Medicine, 2019, TAK ACT CLIN BURN SY; National Academy of Medicine, VAL REL SURV INSTR M	7	24	24	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	2019	322	22					2165	2166		10.1001/jama.2019.17406	http://dx.doi.org/10.1001/jama.2019.17406			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ6JI	31644783				2023-01-03	WOS:000505207800005
J	ter Meulen, KJ; Dekker, MJE; Pasch, A; Broers, NJH; van der Sande, FM; van der Net, JB; Konings, CJAM; Gsponer, IM; Bachtler, MDN; Gauly, A; Canaud, B; Kooman, JP				ter Meulen, Karlien J.; Dekker, Marijke J. E.; Pasch, Andreas; Broers, Natascha J. H.; van der Sande, Frank M.; van der Net, Jeroen B.; Konings, Constantijn J. A. M.; Gsponer, Isabelle M.; Bachtler, Matthias D. N.; Gauly, Adelheid; Canaud, Bernard; Kooman, Jeroen P.			Citric-acid dialysate improves the calcification propensity of hemodialysis patients: A multicenter prospective randomized cross-over trial	PLOS ONE			English	Article							PATIENTS RECEIVING HEMODIALYSIS; STAGE RENAL-DISEASE; ALL-CAUSE MORTALITY; MAINTENANCE HEMODIALYSIS; CALCIUM CONCENTRATIONS; CITRATE DIALYSATE; STIFFNESS; OUTCOMES; BALANCE	Introduction The concentration of dialysate calcium (dCa) has been suggested to affect vascular calcification, but evidence is scarce. Calcification propensity reflects the intrinsic capacity of serum to prevent calcium and phosphate to precipitate. The use of citric-acid dialysate may have a beneficial effect on the calcification propensity due to the chelating effect on calcium and magnesium. The aim of this study was to compare the intradialytic and short-term effects of haemodialysis with either standard acetic-acid dialysate with dCa1.50 (A1.5) or dCa1.25 (A1.25), as well as citric-acid dialysate with dCa1.50 (C1.5) in bicarbonate dialysis on the calcification propensity of serum. Methods Chronic stable hemodialysis patients were included. This multicenter randomized cross-over study consisted out of a baseline week (A1.5), followed by the randomized sequence of A1.25 or C1.5 for one week after which the alternate treatment was provided after a washout week with A1.5. Calcification propensity of serum was assessed by time-resolved nephelometry where the T50 reflects the transition time between formation of primary and secondary calciprotein particles. Results Eighteen patients (median age 70 years) completed the study. Intradialytic change in T50 was increased with C1.5 (121 [90-152]min) compared to A1.25 (83 [43-108]min, p<0.001) and A1.5 (66 [18-102]min, p<0.001). During the treatment week, predialysis T-50 increased significantly from the first to the third session with C1.5 (271 [234-291] to 280 [262-339]min, p = 0.002) and with A1.25 (274 [213-308] to 307 [256-337]min, p<0.001), but not with A1.5 (284 [235-346] to 300 [247-335]min, p = 0.33). Conclusion Calcification propensity, as measured by the change in T50, improved significantly during treatment in C1.5 compared to A1.25 and A1.5. Long-term studies are needed to investigate the effects of different dialysate compositions concentrations on vascular calcification and bone mineral disorders.	[ter Meulen, Karlien J.; Dekker, Marijke J. E.; Broers, Natascha J. H.; van der Sande, Frank M.; van der Net, Jeroen B.; Kooman, Jeroen P.] Maastricht Univ, Dept Internal Med, Div Nephrol, Med Ctr, Maastricht, Netherlands; [ter Meulen, Karlien J.; Dekker, Marijke J. E.; Konings, Constantijn J. A. M.] Catharina Hosp, Dept Internal Med, Div Nephrol, Eindhoven, Netherlands; [Pasch, Andreas; Gsponer, Isabelle M.; Bachtler, Matthias D. N.] Calciscon AG, Nidau, Switzerland; [Gauly, Adelheid; Canaud, Bernard] Fresenius Med Care, Bad Homburg, Germany	Maastricht University; Catharina Hospital	ter Meulen, KJ (corresponding author), Maastricht Univ, Dept Internal Med, Div Nephrol, Med Ctr, Maastricht, Netherlands.; ter Meulen, KJ (corresponding author), Catharina Hosp, Dept Internal Med, Div Nephrol, Eindhoven, Netherlands.	karlien.ter.meulen@mumc.nl	Gauly, Adelheid/X-7273-2019	ter Meulen, Karlien/0000-0001-7035-6326	Fresenius Medical Care	Fresenius Medical Care	FS and JK received a grant of Fresenius Medical Care. With this they have set up this trial with BC, MD and KM. There was no grant number attached. Fresenius MC (BC and AG) had no role in data collection and analysis or decision to publish, but indeed had a contribution in interpretation of the data.	Basile C, 2012, AM J KIDNEY DIS, V59, P92, DOI 10.1053/j.ajkd.2011.08.033; Bressendorff I, 2018, CLIN J AM SOC NEPHRO, V13, P1373, DOI 10.2215/CJN.13921217; Brunelli SM, 2015, AM J KIDNEY DIS, V66, P655, DOI 10.1053/j.ajkd.2015.03.038; Dahle DO, 2016, AM J TRANSPLANT, V16, P204, DOI 10.1111/ajt.13443; Dekker M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151508; Gabutti L, 2009, BMC NEPHROL, V10, DOI 10.1186/1471-2369-10-7; Gotch F, 2007, BLOOD PURIFICAT, V25, P139, DOI 10.1159/000096891; Gotch FA, 2010, KIDNEY INT, V78, P343, DOI 10.1038/ki.2010.157; Grundstrom G, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-216; He ZX, 2016, BLOOD PURIFICAT, V42, P337, DOI 10.1159/000450747; Heiss A, 2007, BIOINTERPHASES, V2, P16, DOI 10.1116/1.2714924; Jean G, 2013, NEPHROL THER, V9, P103, DOI 10.1016/j.nephro.2012.08.003; Kim HW, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001694; Kossmann RJ, 2009, CLIN J AM SOC NEPHRO, V4, P1459, DOI 10.2215/CJN.02590409; Kyriazis J, 2007, NEPHRON CLIN PRACT, V106, pC34, DOI 10.1159/000101482; London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414; Lorenz G, 2018, NEPHROL DIAL TRANSPL, V33, P2043, DOI 10.1093/ndt/gfy134; Maduell F, 2012, NEFROLOGIA, V32, P579, DOI 10.3265/Nefrologia.pre2012.May.11391; Markus Ketteler GAB, 2017, KIDNEY INT, V7, DOI [10.1016/j.kisu.2017.04.001, DOI 10.1016/J.KISU.2017.04.001]; McCullough PA, 2004, J NEPHROL, V17, P205; Nunez MM, 2015, BLOOD PURIFICAT, V39, P181, DOI 10.1159/000371569; Ok E, 2016, J AM SOC NEPHROL, V27, P2475, DOI 10.1681/ASN.2015030268; Pasch A, 2017, CLIN J AM SOC NEPHRO, V12, P315, DOI 10.2215/CJN.04720416; Pasch A, 2012, J AM SOC NEPHROL, V23, P1744, DOI 10.1681/ASN.2012030240; PAYNE RB, 1973, BMJ-BRIT MED J, V4, P643, DOI 10.1136/bmj.4.5893.643; Pirklbauer M, 2016, EUR J CLIN INVEST, V46, P976, DOI 10.1111/eci.12680; Pun PH, 2011, KIDNEY INT, V79, P218, DOI 10.1038/ki.2010.315; Rocha AD, 2014, HEMODIAL INT, V18, P467, DOI 10.1111/hdi.12113; Schmitz M, 2016, NEPHROL DIAL TRANSPL, V31, P1327, DOI 10.1093/ndt/gfv347; Smith ER, 2014, J AM SOC NEPHROL, V25, P339, DOI 10.1681/ASN.2013060635; van der Sande FM, 1998, AM J KIDNEY DIS, V32, P125, DOI 10.1053/ajkd.1998.v32.pm9669433; Wellek S, 2012, DTSCH ARZTEBL INT, V109, P276, DOI 10.3238/arztebl.2012.0276; Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523-1755.2005.00185.x	33	11	11	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2019	14	12							e0225824	10.1371/journal.pone.0225824	http://dx.doi.org/10.1371/journal.pone.0225824			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP0JY	31805104	Green Published, gold, Green Submitted			2023-01-03	WOS:000534009700062
J	Pollack, CE; Blackford, AL; Du, S; Deluca, S; Thornton, RLJ; Herring, B				Pollack, Craig Evan; Blackford, Amanda L.; Du, Shawn; Deluca, Stefanie; Thornton, Rachel L. J.; Herring, Bradley			Association of Receipt of a Housing Voucher With Subsequent Hospital Utilization and Spending	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEIGHBORHOODS; CHILDREN; HEALTH	IMPORTANCE Although neighborhoods are thought to be an important health determinant, evidence for the relationship between neighborhood poverty and health care use is limited, as prior studies have largely used observational data without an experimental design. OBJECTIVE To examine whether housing policies that reduce exposure to high-poverty neighborhoods were associated with differences in long-term hospital use among adults and children. DESIGN, SETTING, AND PARTICIPANTS Exploratory analysis of the Moving to Opportunity for Fair Housing Demonstration Program, a randomized social experiment conducted in 5 US cities. From 1994 to 1998, 4604 families in public housing were randomized to 1 of 3 groups: a control condition, a traditional Section 8 voucher toward rental costs in the private market, or a voucher that could only be used in low-poverty neighborhoods. Participants were linked to all-payer hospital discharge data (1995 through 2014 or 2015) and Medicaid data (1999 through 2009). The final follow-up date ranged from 11 to 21 years after randomization. EXPOSURES Receipt of a traditional or low-poverty voucher vs control group. MAIN OUTCOMES AND MEASURES Rates of hospitalizations and hospital days, and hospital spending. RESULTS Among 4602 eligible individuals randomized as adults, 4072 (88.5%) were linked to health data (mean age, 33 years [SD, 9.0 years]; 98% female; median follow-up, 11 years). There were no significant differences in primary outcomes among adults randomized to receive a voucher compared with the control group (unadjusted hospitalization rate, 14.0 vs 14.7 per 100 person-years, adjusted incidence rate ratio [IRR], 0.95 [95% CI, 0.84-1.08; P = .45]; hospital days, 62.8 vs 67.0 per 100 person-years; IRR, 0.93 [95% CI, 0.77-1.13; P = .46]; yearly spending, $2075 vs $1977; adjusted difference, -$129 [95% CI, -$497 to $239; P = .49]). Among 11 290 eligible individuals randomized as children, 9118 (80.8%) were linked to health data (mean age, 8 years [SD, 4.6 years]; 49% female; median follow-up, 11 years). Receipt of a housing voucher during childhood was significantly associated with lower hospitalization rates (6.3 vs 7.3 per 100 person-years; IRR, 0.85 [95% CI, 0.73-0.99; P = .03]) and yearly inpatient spending ($633 vs $785; adjusted difference, -$143 [95% CI, -$256 to -$31; P = .01]) and no significant difference in hospital days (25.7 vs 28.8 per 100 person-years; IRR, 0.92 [95% CI, 0.77-1.11; P = .41]). CONCLUSIONS AND RELEVANCE In this exploratory analysis of a randomized housing voucher intervention, adults who received a housing voucher did not experience significant differences in hospital use or spending. Receipt of a voucher during childhood was significantly associated with lower rates of hospitalization and less inpatient spending during long-term follow-up.	[Pollack, Craig Evan; Herring, Bradley] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Hampton House 403,624 N Broadway St, Baltimore, MD 21287 USA; [Pollack, Craig Evan] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA; [Pollack, Craig Evan] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Blackford, Amanda L.] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD USA; [Du, Shawn] Anal Grp, New York, NY USA; [Deluca, Stefanie] Johns Hopkins Univ, Dept Sociol, Baltimore, MD 21218 USA; [Thornton, Rachel L. J.] Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD USA; [Thornton, Rachel L. J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Analysis Group Inc.; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Pollack, CE (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Hampton House 403,624 N Broadway St, Baltimore, MD 21287 USA.	cpollac2@jhmi.edu		Du, Shawn/0000-0003-2896-7873; Herring, Bradley/0000-0001-6845-1412	HUD [RP13MD004]; Robert Wood Johnson Foundation [73373]; Hopkins Population Research Center from the National Institute of Child Health and Human Development [R24HD042854]; Johns Hopkins Division of General Internal Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD042854] Funding Source: NIH RePORTER	HUD; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); Hopkins Population Research Center from the National Institute of Child Health and Human Development; Johns Hopkins Division of General Internal Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This study was supported by grants from HUD (grant RP13MD004), the Robert Wood Johnson Foundation (grant 73373), the Hopkins Population Research Center (through grant R24HD042854 from the National Institute of Child Health and Human Development), and the Johns Hopkins Division of General Internal Medicine.	Agency for Healthcare Research and Quality, 2016, US APPR PRIC IND AN; [Anonymous], 2018, HEALTHC COST REP INF; Bell JF, 2008, AM J PREV MED, V35, P547, DOI 10.1016/j.amepre.2008.07.006; Byrd V.L., 2012, ASSESSING USABILITY; Chetty R, 2016, AM ECON REV, V106, P855, DOI 10.1257/aer.20150572; Clampet-Lundquist S, 2011, AM J SOCIOL, V116, P1154, DOI 10.1086/657352; Deb P., 2017, HLTH ECONOMETRICS US, V1st ed; Gibson M, 2011, HEALTH PLACE, V17, P175, DOI 10.1016/j.healthplace.2010.09.011; JCHS, 2019, STAT NAT HOUS; Kessler RC, 2014, JAMA-J AM MED ASSOC, V311, P937, DOI 10.1001/jama.2014.607; Kling JR, 2007, ECONOMETRICA, V75, P83, DOI 10.1111/j.1468-0262.2007.00733.x; Ludwig J, 2012, SCIENCE, V337, P1505, DOI 10.1126/science.1224648; Ludwig J, 2011, NEW ENGL J MED, V365, P1509, DOI 10.1056/NEJMsa1103216; Morello-Frosch R, 2006, ENVIRON HEALTH PERSP, V114, P1150, DOI 10.1289/ehp.8930; Morland K, 2002, AM J PREV MED, V22, P23, DOI 10.1016/S0749-3797(01)00403-2; National Bureau of Economic Research, HEALTHC COST REP INF; Nguyen QC, 2017, HOUS POLICY DEBATE, V27, P419, DOI 10.1080/10511482.2016.1245210; Pearlin LI, 2005, J HEALTH SOC BEHAV, V46, P205, DOI 10.1177/002214650504600206; Rice D, 2019, HOUSE BILL INCLUDES; Ross CE, 2001, J HEALTH SOC BEHAV, V42, P258, DOI 10.2307/3090214; Roux AVD, 2010, ANN NY ACAD SCI, V1186, P125, DOI 10.1111/j.1749-6632.2009.05333.x; Rudolph KE, 2018, EPIDEMIOLOGY, V29, P590, DOI 10.1097/EDE.0000000000000832; Rudolph KE, 2018, EPIDEMIOLOGY, V29, P199, DOI 10.1097/EDE.0000000000000774; SANBONMATSU LISA, 2011, MOVING OPPORTUNITY F; Taubman SL, 2014, SCIENCE, V343, P263, DOI 10.1126/science.1246183; Taylor Lauren, 2018, HOUSING HLTH OVERVIE, DOI [10.1377/hpb20180313.396577, DOI 10.1377/HPB20180313.396577]; US Department of Housing and Urban Development Office of Policy Development and Research, 2018, HLTH PICT HUD ASS CH; US Department of Housing and Urban Development Picture of subsidized households, 2018, PICT SUBS HOUS; Waitzman NJ, 1998, AM J PUBLIC HEALTH, V88, P973, DOI 10.2105/AJPH.88.6.973; Waitzman NJ, 1998, AM J PUBLIC HEALTH, V88, P1122	30	16	16	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	2019	322	21					2115	2124		10.1001/jama.2019.17432	http://dx.doi.org/10.1001/jama.2019.17432			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JZ6JE	31794624	Green Published, Bronze			2023-01-03	WOS:000505207400032
J	Pich, O; Muinos, F; Lolkema, MP; Steeghs, N; Gonzalez-Perez, A; Lopez-Bigas, N				Pich, Oriol; Muinos, Ferran; Lolkema, Martijn Paul; Steeghs, Neeltje; Gonzalez-Perez, Abel; Lopez-Bigas, Nuria			The mutational footprints of cancer therapies	NATURE GENETICS			English	Article							SECONDARY MALIGNANCIES; DNA-REPAIR; PEDIATRIC CANCER; READ ALIGNMENT; SIGNATURES; SURVIVORS; CHEMOTHERAPY; MECHANISMS; CHILDHOOD; RADIATION	Some cancer therapies damage DNA and cause mutations in both cancerous and healthy cells. Therapy-induced mutations may underlie some of the long-term and late side effects of treatments, such as mental disabilities, organ toxicity and secondary neoplasms. Nevertheless, the burden of mutation contributed by different chemotherapies has not been explored. Here we identify the mutational signatures or footprints of six widely used anticancer therapies across more than 3,500 metastatic tumors originating from different organs. These include previously known and new mutational signatures generated by platinum-based drugs as well as a previously unknown signature of nucleoside metabolic inhibitors. Exploiting these mutational footprints, we estimate the contribution of different treatments to the mutation burden of tumors and their risk of contributing coding and potential driver mutations in the genome. The mutational footprints identified here allow for precise assessment of the mutational risk of different cancer therapies to understand their long-term side effects.	[Pich, Oriol; Muinos, Ferran; Gonzalez-Perez, Abel; Lopez-Bigas, Nuria] Barcelona Inst Sci & Technol, Inst Res Biomed Barcelona, Barcelona, Spain; [Lolkema, Martijn Paul] Erasmus Univ, Erasmus Med Ctr, Dept Med Oncol, Med Ctr,Canc Inst, Rotterdam, Netherlands; [Steeghs, Neeltje] Netherlands Canc Inst, Amsterdam, Netherlands; [Gonzalez-Perez, Abel; Lopez-Bigas, Nuria] Univ Pompeu Fabra, Res Program Biomed Informat, Barcelona, Spain; [Lopez-Bigas, Nuria] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Netherlands Cancer Institute; Pompeu Fabra University; ICREA	Lopez-Bigas, N (corresponding author), Barcelona Inst Sci & Technol, Inst Res Biomed Barcelona, Barcelona, Spain.; Lopez-Bigas, N (corresponding author), Univ Pompeu Fabra, Res Program Biomed Informat, Barcelona, Spain.; Lopez-Bigas, N (corresponding author), Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain.	nuria.lopez@irbbarcelona.org	Steeghs, Neeltje/GQH-3468-2022; Lolkema, M.P./AAE-2906-2019; Lopez-Bigas, Nuria/F-6193-2011; Pich, Oriol/M-6865-2015	Lolkema, M.P./0000-0003-0466-2928; Lopez-Bigas, Nuria/0000-0003-4925-8988; Muinos, Ferran/0000-0002-4651-4168; Gonzalez-Perez, Abel/0000-0002-8582-4660; Pich, Oriol/0000-0002-1956-1882	European Research Council [682398]; ERDF/Spanish Ministry of Science, Innovation and Universities-Spanish State Research Agency/DamReMap Project [RTI2018-094095-B-I00]; Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness [SEV-2015-0500]; Centres de Recerca de Catalunya (Generalitat de Catalunya); BIST PhD fellowship - Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia; Barcelona Institute of Science and Technology; Ramon y Cajal [RYC-2013-14554]	European Research Council(European Research Council (ERC)European Commission); ERDF/Spanish Ministry of Science, Innovation and Universities-Spanish State Research Agency/DamReMap Project; Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness; Centres de Recerca de Catalunya (Generalitat de Catalunya); BIST PhD fellowship - Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia; Barcelona Institute of Science and Technology; Ramon y Cajal(Spanish Government)	N.L-B. acknowledges funding from the European Research Council (consolidator grant no. 682398) and ERDF/Spanish Ministry of Science, Innovation and Universities-Spanish State Research Agency/DamReMap Project (grant no. RTI2018-094095-B-I00). The Institute for Research in Biomedicine Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award (SEV-2015-0500) from the Spanish Ministry of Economy and Competitiveness and is supported by Centres de Recerca de Catalunya (Generalitat de Catalunya). O.P. is the recipient of a BIST PhD fellowship supported by the Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia and the Barcelona Institute of Science and Technology. A.G-P. is supported by a Ramon y Cajal contract (grant no. RYC-2013-14554). We acknowledge S. Gonzalez for guidance in the analysis of mutations timing and J. Deu-Pons for help with the reimplementation of SigProfiler in the Julia programming language. This publication and the underlying study have been made possible partly on the basis of the data that the Hartwig Medical Foundation has made available to the study. In particular, we acknowledge N. Steeghs (Netherlands Cancer Institute-Antoni van Leeuwenhoekziekenhuis), M. Lolkema (Erasmus University Medical Center), E. Witteveen (UMC Utrecht), H. Bloemendal (Meander Medisch Centrum), H. Verheul (VU University Medical Center Amsterdam), and L. V. Beerepoot (Elisabeth Tweesteden Ziekenhuis), whose institutions contributed more than 5% of the samples in the adult metastatic dataset used in the analyses. Data from the Childhood Solid Tumor Network has also been used in the paper.	Ahles TA, 2007, NAT REV CANCER, V7, P192, DOI 10.1038/nrc2073; Alexandrov L., 2018, PREPRINT, DOI [10.1101/322859322859, DOI 10.1101/322859322859]; Alexandrov LB, 2016, SCIENCE, V354, P618, DOI 10.1126/science.aag0299; Alexandrov LB, 2015, NAT GENET, V47, P1402, DOI 10.1038/ng.3441; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008; Behjati S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12605; Bezanson J, 2017, SIAM REV, V59, P65, DOI 10.1137/141000671; BOFFETTA P, 1994, ACTA ONCOL, V33, P591, DOI 10.3109/02841869409121767; Boot A, 2018, GENOME RES, V28, P654, DOI 10.1101/gr.230219.117; Brady SW, 2019, MOL CANCER RES, V17, P895, DOI 10.1158/1541-7786.MCR-18-0620; Choi DK, 2014, INT J CANCER, V135, P1764, DOI 10.1002/ijc.28991; Dracham CB, 2018, RADIAT ONCOL J, V36, P85, DOI 10.3857/roj.2018.00290; Florea Ana-Maria, 2011, Cancers (Basel), V3, P1351, DOI 10.3390/cancers3011351; Gerstung M., 2018, BIORXIV, DOI [10.1101/161562, DOI 10.1101/161562]; Hanawalt PC, 2008, NAT REV MOL CELL BIO, V9, P958, DOI 10.1038/nrm2549; Haradhvala NJ, 2016, CELL, V164, P538, DOI 10.1016/j.cell.2015.12.050; Helleday T, 2014, NAT REV GENET, V15, P585, DOI 10.1038/nrg3729; Iyer NS, 2015, BLOOD, V126, P346, DOI 10.1182/blood-2015-02-627414; Kasar S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9866; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kim J, 2016, NAT GENET, V48, P600, DOI 10.1038/ng.3557; Kopp LM, 2012, AM J MED, V125, P636, DOI 10.1016/j.amjmed.2012.01.013; Kucab JE, 2019, CELL, V177, P821, DOI 10.1016/j.cell.2019.03.001; Lange SS, 2011, NAT REV CANCER, V11, P96, DOI 10.1038/nrc2998; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lee-Six H, 2018, BIORXIV, DOI [10.1101/416800, DOI 10.1101/416800]; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lipshultz SE, 2013, NAT REV CLIN ONCOL, V10, P697, DOI 10.1038/nrclinonc.2013.195; Liu D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02320-7; Martincorena I, 2015, SCIENCE, V349, P1483, DOI 10.1126/science.aab4082; Morganella S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11383; Nik-Zainal S, 2015, MUTAGENESIS, V30, P763, DOI 10.1093/mutage/gev073; Pich O, 2018, CELL, V175, P1074, DOI 10.1016/j.cell.2018.10.004; Poon SL, 2014, GENOME MED, V6, DOI 10.1186/gm541; Priestley P., 2019, PAN CANC WHOLE GENOM, DOI [10.1101/415133, DOI 10.1101/415133]; Ritt JF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002564; Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4; Segovia R, 2017, P NATL ACAD SCI USA, V114, P2663, DOI 10.1073/pnas.1618555114; Sondka Z, 2018, NAT REV CANCER, V18, P696, DOI 10.1038/s41568-018-0060-1; Stone JB, 2016, NAT REV CLIN ONCOL, V13, P92, DOI 10.1038/nrclinonc.2015.152; Szikriszt B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0963-7; Tomkova M, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1509-y; van der Plas E, 2015, J CAN ACAD CHILD ADO, V24, P25; Wang JG, 2016, NAT GENET, V48, P768, DOI 10.1038/ng.3590; Wyatt MD, 2009, CELL MOL LIFE SCI, V66, P788, DOI 10.1007/s00018-008-8557-5; Xu J, 2017, NATURE, V551, P653, DOI 10.1038/nature24658; Zagar TM, 2016, NAT REV CLIN ONCOL, V13, P172, DOI 10.1038/nrclinonc.2015.171	48	106	111	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2019	51	12					1732	+		10.1038/s41588-019-0525-5	http://dx.doi.org/10.1038/s41588-019-0525-5			24	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	JR5XD	31740835	Green Submitted, Green Accepted			2023-01-03	WOS:000499696700010
J	Konig, M; Sander, A; Demuth, I; Diekmann, D; Steinhagen-Thiessen, E				Koenig, Maximilian; Sander, Andre; Demuth, Ilja; Diekmann, Daniel; Steinhagen-Thiessen, Elisabeth			Knowledge-based best of breed approach for automated detection of clinical events based on German free text digital hospital discharge letters	PLOS ONE			English	Article							PUMP INHIBITOR USE; OLDER-ADULTS; SYSTEM; EXTRACTION	Objectives The secondary use of medical data contained in electronic medical records, such as hospital discharge letters, is a valuable resource for the improvement of clinical care (e.g. in terms of medication safety) or for research purposes. However, the automated processing and analysis of medical free text still poses a huge challenge to available natural language processing (NLP) systems. The aim of this study was to implement a knowledge-based best of breed approach, combining a terminology server with integrated ontology, a NLP pipeline and a rules engine. Methods We tested the performance of this approach in a use case. The clinical event of interest was the particular drug-disease interaction "proton-pump inhibitor [PPI] use and osteoporosis". Cases were to be identified based on free text digital discharge letters as source of information. Automated detection was validated against a gold standard. Results Precision of recognition of osteoporosis was 94.19%, and recall was 97.45%. PPIs were detected with 100% precision and 97.97% recall. The F-score for the detection of the given drug-disease-interaction was 96,13%. Conclusion We could show that our approach of combining a NLP pipeline, a terminology server, and a rules engine for the purpose of automated detection of clinical events such as drug-disease interactions from free text digital hospital discharge letters was effective. There is huge potential for the implementation in clinical and research contexts, as this approach enables analyses of very high numbers of medical free text documents within a short time period.	[Koenig, Maximilian; Demuth, Ilja; Steinhagen-Thiessen, Elisabeth] Charite Univ Med Berlin, Berlin, Germany; [Koenig, Maximilian; Demuth, Ilja; Steinhagen-Thiessen, Elisabeth] Free Univ Berlin, Berlin, Germany; [Koenig, Maximilian; Demuth, Ilja; Steinhagen-Thiessen, Elisabeth] Humboldt Univ, Berlin, Germany; [Koenig, Maximilian; Demuth, Ilja; Steinhagen-Thiessen, Elisabeth] Berlin Inst Hlth, Lipid Clin, Interdisciplinary Metab Ctr, Berlin, Germany; [Koenig, Maximilian] Berlin Inst Hlth, Dept Nephrol & Internal Intens Care Med Berlin, Berlin, Germany; [Sander, Andre; Diekmann, Daniel] ID Informat & Dokumentat Gesundheitswesen GmbH, Berlin, Germany; [Demuth, Ilja] Charite Univ Med Berlin, BCRT Berlin Inst Hlth, Ctr Regenerat Therapies, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Berlin Institute of Health; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Konig, M (corresponding author), Charite Univ Med Berlin, Berlin, Germany.; Konig, M (corresponding author), Free Univ Berlin, Berlin, Germany.; Konig, M (corresponding author), Humboldt Univ, Berlin, Germany.; Konig, M (corresponding author), Berlin Inst Hlth, Lipid Clin, Interdisciplinary Metab Ctr, Berlin, Germany.; Konig, M (corresponding author), Berlin Inst Hlth, Dept Nephrol & Internal Intens Care Med Berlin, Berlin, Germany.	koenig.maximilian@charite.de	König, Maximilian/AAD-8221-2021; Demuth, Ilja/ABD-5352-2021	König, Maximilian/0000-0003-4873-5519; Demuth, Ilja/0000-0002-4340-2523	German Federal Ministry of education and Research [BMBF] [16SV5536K, 16SV5537, 16SV5538, 16SV5837, 01UW0808]; Max Planck Society, Munich, Germany; ID Information und Dokumentation im Gesundheitswesen GmbH Co KGaA	German Federal Ministry of education and Research [BMBF](Federal Ministry of Education & Research (BMBF)); Max Planck Society, Munich, Germany(Max Planck Society); ID Information und Dokumentation im Gesundheitswesen GmbH Co KGaA	BASE-II was funded by the German Federal Ministry of education and Research [BMBF (grant numbers 16SV5536K, 16SV5537, 16SV5538, 16SV5837, and 01UW0808) and the Max Planck Society, Munich, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. ID Information und Dokumentation im Gesundheitswesen GmbH & Co KGaA provided funding in the form of salaries for authors [MK], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The other authors did not receive any funding. The authors were licensed to use the software ID LOGIK (R) without charge.	Amancio DR, CONCENTRIC NETWORK S; Ammenwerth E, 2014, DTSCH ARZTEBL INT, V111, P1195; Bache R, 2013, J AM MED INFORM ASSN, V20, pE327, DOI 10.1136/amiajnl-2013-001858; Bertram L, 2014, INT J EPIDEMIOL, V43, P703, DOI 10.1093/ije/dyt018; Cui Licong, 2012, AMIA Annu Symp Proc, V2012, P1191; Davis K, 2012, BMC MED INFORM DECIS, V12, DOI 10.1186/1472-6947-12-37; Ferrisa A., 2015, MEDINFO 2015 EHEALTH; George CJ, 2008, AM J GERIATR PHARMAC, V6, P249, DOI 10.1016/j.amjopharm.2008.12.001; Gerstorf D, 2016, GERONTOLOGY, V62, P311, DOI 10.1159/000441495; Hahn U, 2018, STUD HEALTH TECHNOL, V247, P26, DOI 10.3233/978-1-61499-852-5-26; Hazlehurst B, 2005, J AM MED INFORM ASSN, V12, P517, DOI 10.1197/jamia.M1771; Huynh T, 2016, P 26 INT C COMP LING, P877; Iqbal E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187121; Iqbal E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134208; Jungmann F, 2019, RADIOLOGE, V59, P828, DOI 10.1007/s00117-019-0555-0; Kayaalp Mehmet, 2017, AMIA Annu Symp Proc, V2017, P1044; Khalili H, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e372; Kolditz T, 2019, STUD HEALTH TECHNOL, V264, P203, DOI 10.3233/SHTI190212; Liu SY, 2016, COMPUT MATH METHOD M, V2016, DOI 10.1155/2016/6918381; Lopprich M, 2016, METHOD INFORM MED, V55, P373, DOI 10.3414/ME15-02-0019; Lohr C., 2018, LREC; Maes ML, 2017, THER ADV DRUG SAF, V8, P273, DOI 10.1177/2042098617715381; Melton CB, 2005, J AM MED INFORM ASSN, V12, P448, DOI 10.1197/jamia.M1794; Meystre S M, 2008, Yearb Med Inform, P128; Mossner J, 2016, DTSCH ARZTEBL INT, V113, P477, DOI 10.3238/arztebl.2016.0477; Othman F, 2016, PHARMACOEPIDEM DR S, V25, P1079, DOI 10.1002/pds.4043; PRYOR TA, 1993, INT J CLIN MONIT COM, V10, P215, DOI 10.1007/BF01133012; Radcliff S, 2015, J AM GERIATR SOC, V63, P2227, DOI 10.1111/jgs.13702; Rea S, 2012, J BIOMED INFORM, V45, P763, DOI 10.1016/j.jbi.2012.01.009; Richter-Pechanski Phillip, 2018, Stud Health Technol Inform, V253, P165; Riedl Bill, 2010, AMIA Annu Symp Proc, V2010, P677; Sander A, 2019, J BIOMED SEMANT, V10, DOI 10.1186/s13326-019-0199-z; Savova GK, 2010, J AM MED INFORM ASSN, V17, P507, DOI 10.1136/jamia.2009.001560; Sheikh-Taha M, 2017, BMC CARDIOVASC DISOR, V17, DOI 10.1186/s12872-017-0623-1; Tang BZ, 2013, J AM MED INFORM ASSN, V20, P828, DOI 10.1136/amiajnl-2013-001635; Toepfer M, 2015, BMC MED INFORM DECIS, V15, DOI 10.1186/s12911-015-0215-x; Trick WE, 2003, INFECT CONT HOSP EP, V24, P950, DOI 10.1086/502165; WINGERT F, 1987, METHOD INFORM MED, V26, P93; WINGERT F, 1986, METHOD INFORM MED, V25, P22; Yang L, TOPICAL WORD EMBEDDI; Yu H, 2002, AMIA 2002 SYMPOSIUM, PROCEEDINGS, P919	41	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2019	14	11							e0224916	10.1371/journal.pone.0224916	http://dx.doi.org/10.1371/journal.pone.0224916			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LO8SS	31774830	Green Published, gold, Green Submitted			2023-01-03	WOS:000533896400020
J	Yang, M; Zhang, XJ; Liu, JL				Yang, Ming; Zhang, Xuejun; Liu, Jinlong			Prognostic value of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy: A systematic review and meta-analysis	PLOS ONE			English	Review							ARTERIAL INFUSION CHEMOTHERAPY; ALPHA-FETOPROTEIN; CHEMOEMBOLIZATION; PREDICTORS; INVASION; CRITERIA; THERAPY	Background Serum des-gamma-carboxy prothrombin (DCP) is a hepatocellular carcinoma (HCC) tumor marker that can be used to assess patient prognosis. Since the value of DCP in predicting the prognosis of hepatocellular carcinoma patients treated with transarterial chemotherapy remains controversial, we performed a meta-analysis of previous clinical studies. Methods A systematic literature search was performed using PubMed, the MEDLINE database, EMBASE, and the Cochrane Library in accordance with the PRISMA guidelines. The hazard ratio (HR) with 95% confidence interval (CI) was used to estimate the effect size. Results Six respective cohort studies including a total of 943 cases were identified. The pooled results showed that low DCP was associated with a favorable overall survival (OS)(HR 0.653, 95% CI 0.444-0.960), and DCP response was associated with increased OS (HR 0.387,95% CI 0.215-0.697) and progression-free survival (PFS) (HR 0.42,95% CI 0.23-0.74) in HCC patients treated with transarterial chemotherapy. Conclusions DCP values in HCC patients undergoing hepatic arterial chemotherapy seem to be associated with OS and PFS. Thus, monitoring DCP values and observing the DCP response should be part of the management of patients undergoing transarterial chemotherapy.	[Yang, Ming; Zhang, Xuejun; Liu, Jinlong] Chengde Med Univ, Affiliated Hosp, Dept Hepatobiliary Surg, Chengde, Hebei, Peoples R China	Chengde Medical University	Liu, JL (corresponding author), Chengde Med Univ, Affiliated Hosp, Dept Hepatobiliary Surg, Chengde, Hebei, Peoples R China.	liujl800813@163.com			"Hebei Province Master Student Innovation Funding Project" in Hebei Province, China [CXZZSS2019137]	"Hebei Province Master Student Innovation Funding Project" in Hebei Province, China	This research is a "Hebei Province Master Student Innovation Funding Project" in Hebei Province, China, and we were supported by the fund CXZZSS2019137.	Ebied OM, 2003, CANCER-AM CANCER SOC, V97, P1042, DOI 10.1002/cncr.11111; European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, 2019, J Hepatol, V70, P817, DOI 10.1016/j.jhep.2019.01.020; Fujiyama S, 2002, ONCOLOGY-BASEL, V62, P57, DOI 10.1159/000048277; Hagiwara S, 2006, J GASTROENTEROL, V41, P1214, DOI 10.1007/s00535-006-1950-7; Herber S, 2008, CARDIOVASC INTER RAD, V31, P768, DOI 10.1007/s00270-007-9270-8; Hisamitsu Miyaaki, 2007, J GASTROENTEROL, V42, P962, DOI [10.1007/s00535-007-2117-x, DOI 10.1007/S00535-007-2117-X]; Kang Lee Yong, 2013, BMC CANCER, V13; Kim HS, 2009, J CLIN GASTROENTEROL, V43, P482, DOI 10.1097/MCG.0b013e318182015a; Kimura H, 2017, HEPATOL INT, V11, P105, DOI 10.1007/s12072-016-9771-0; Lai Q, 2013, LIVER TRANSPLANT, V19, P1108, DOI 10.1002/lt.23706; Lee MH, 2012, J GASTROEN HEPATOL, V27, P313, DOI 10.1111/j.1440-1746.2011.06867.x; Lee YH, 2014, J CLIN GASTROENTEROL, V48, P734, DOI 10.1097/MCG.0b013e3182a8a254; Levasicc N, 2018, J CLIN EXPT ONCOLOGY, V7; LIEBMAN HA, 1984, NEW ENGL J MED, V310, P1427, DOI 10.1056/NEJM198405313102204; Lok AS, 2010, GASTROENTEROLOGY, V138, P493, DOI 10.1053/j.gastro.2009.10.031; Miyaki D, 2013, J GASTROEN HEPATOL, V28, P1834, DOI 10.1111/jgh.12311; Nishikawa H, 2014, ONCOL REP, V31, P65, DOI 10.3892/or.2013.2845; Okuda H, 2010, J GASTROEN HEPATOL, V16, P1290; Park WH, 2012, J VASC INTERV RADIOL, V23, P927, DOI 10.1016/j.jvir.2012.04.021; Saeki I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126649; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; Stewart LA, 2015, JAMA-J AM MED ASSOC, V313, P1657, DOI 10.1001/jama.2015.3656; SUEHIRO T, 1995, SURGERY, V117, P682, DOI 10.1016/S0039-6060(95)80013-1; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Toyoda H, 2012, CANCER SCI, V103, P921, DOI 10.1111/j.1349-7006.2012.02232.x; Ueshima K, 2010, ONCOLOGY-BASEL, V78, P148, DOI 10.1159/000315244; Vora SR, 2009, ONCOLOGIST, V14, P717, DOI 10.1634/theoncologist.2009-0038; Yamasaki T, 2012, HEPATOL RES, V42, P340, DOI 10.1111/j.1872-034X.2011.00938.x; Yu RT, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3609-6	29	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2019	14	11							e0225170	10.1371/journal.pone.0225170	http://dx.doi.org/10.1371/journal.pone.0225170			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW5DY	31730646	Green Published, gold			2023-01-03	WOS:000521186500001
J	Vahidy, FS; Bambhroliya, AB; Meeks, JR; Rahman, O; Ely, EW; Slooter, AJC; Tyson, JE; Miller, CC; McCullough, LD; Savitz, SI; Khan, B				Vahidy, Farhaan S.; Bambhroliya, Arvind B.; Meeks, Jennifer R.; Rahman, Omar; Ely, E. Wesley; Slooter, Arjen J. C.; Tyson, Jon E.; Miller, Charles C.; McCullough, Louise D.; Savitz, Sean, I; Khan, Babar			In-hospital outcomes and 30-day readmission rates among ischemic and hemorrhagic stroke patients with delirium	PLOS ONE			English	Article							TERM COGNITIVE IMPAIRMENT; COMORBIDITY MEASURES; INSTITUTIONALIZATION; DECLINE; CLAIMS; CARE	Objective Delirium is associated with poor outcomes among critically ill patients. However, it is not well characterized among patients with ischemic or hemorrhagic stroke (IS and HS). We provide the population-level frequency of in-hospital delirium and assess its association with in-hospital outcomes and with 30-day readmission among IS and HS patients. Methods We analyzed Nationwide in-hospital and readmission data for years 2010-2015 and identified stroke patients using ICD-9 codes. Delirium was identified using validated algorithms. Outcomes were in-hospital mortality, length of stay, unfavorable discharge disposition, and 30-day readmission. We used survey design logistic regression methods to provide national estimates of proportions and 95% confidence intervals (CI) for delirium, and odds ratios (OR) for association between delirium and poor outcomes. Results We identified 3,107,437 stroke discharges of whom 7.45% were coded to have delirium. This proportion significantly increased between 2010 (6.3%) and 2015 (8.7%) (aOR, 95% CI: 1.04, 1.03-1.05). Delirium proportion was higher among HS patients (ICH: 10.0%, SAH: 9.8%) as compared to IS patients (7.0%). Delirious stroke patients had higher in-hospital mortality (12.3% vs. 7.8%), longer in-hospital stay (11.6 days vs. 7.3 days) and a significantly greater adjusted risk of 30-day-readmission (16.7%) as compared to those without delirium (12.2%) (aRR, 95% CI: 1.13, 1.11-1.15). Upon readmission, patients with delirium at initial admission continued to have a longer length of stay (7.7 days vs. 6.6 days) and a higher in-hospital mortality (9.3% vs. 6.4%). Conclusion Delirium identified through claims data in stroke patients is independently associated with poor in-hospital outcomes both at index admission and readmission. Identification and management of delirium among stroke patients provides an opportunity to improve outcomes.	[Vahidy, Farhaan S.; Bambhroliya, Arvind B.; Meeks, Jennifer R.; McCullough, Louise D.; Savitz, Sean, I] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Inst Stroke & Cerebrovasc Dis, Houston, TX 77030 USA; [Vahidy, Farhaan S.; Bambhroliya, Arvind B.; Meeks, Jennifer R.; McCullough, Louise D.; Savitz, Sean, I] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Neurol, Houston, TX 77030 USA; [Rahman, Omar; Khan, Babar] Indiana Univ Sch Med, Div Pulm Crit Care, Indianapolis, IN 46202 USA; [Ely, E. Wesley] Vanderbilt Univ, Med Ctr, Dept Med, Crit Illness Brain Dysfunct Survivorship CIBS Ctr, Nashville, TN USA; [Ely, E. Wesley] Tennessee Valley Vet Affairs Geriatr Res Educ Cli, Nashville, TN USA; [Slooter, Arjen J. C.] Univ Utrecht, Univ Med Ctr Utrecht, Dept Intens Care Med, Utrecht, Netherlands; [Slooter, Arjen J. C.] Univ Utrecht, Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Utrecht, Netherlands; [Tyson, Jon E.; Miller, Charles C.] Univ Texas Hlth Sci Ctr Houston, Ctr Clin Res & Evidence Based Med, McGovern Med Sch, Houston, TX 77030 USA; [Khan, Babar] Indiana Univ, Ctr Hlth Innovat & Implementat Sci, Regenstrief Inst Inc, Ctr Aging Res, Indianapolis, IN 46204 USA; [Khan, Babar] Indiana Clin & Translat Sci Inst, Indianapolis, IN USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Indiana University System; Indiana University Bloomington; Vanderbilt University; Geriatric Research Education & Clinical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Texas System; University of Texas Health Science Center Houston; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc	Vahidy, FS (corresponding author), Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Inst Stroke & Cerebrovasc Dis, Houston, TX 77030 USA.; Vahidy, FS (corresponding author), Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Neurol, Houston, TX 77030 USA.	Farhaan.Vahidy@uth.tmc.edu		Bambhroliya, Arvind/0000-0002-2584-2517	National Center for Advancing Translational Sciences (NCATS) [UL1 TR000371]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000371] Funding Source: NIH RePORTER	National Center for Advancing Translational Sciences (NCATS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We acknowledge the infrastructural support provided by the Biostatistics/Epidemiology/Research Design (BERD) component of the Center for Clinical and Translational Sciences (CCTS) for this project. CCTS is mainly funded by a grant (UL1 TR000371) from the National Center for Advancing Translational Sciences (NCATS), awarded to University	Association A.P., 2013, DIAGNOSTIC STAT MANU; Brummel NE, 2017, AM J CRIT CARE, V26, P447, DOI 10.4037/ajcc2017263; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Fong TG, 2009, NAT REV NEUROL, V5, P210, DOI 10.1038/nrneurol.2009.24; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Jackson JC, 2004, NEUROPSYCHOL REV, V14, P87, DOI 10.1023/B:NERV.0000028080.39602.17; Khan BA, 2015, AM J NURS, V115, P24, DOI 10.1097/01.NAJ.0000461807.42226.3e; Khan BA, 2012, J HOSP MED, V7, P580, DOI 10.1002/jhm.1949; Kim DH, 2017, PHARMACOEPIDEM DR S, V26, P945, DOI 10.1002/pds.4226; Krogseth M, 2014, J PSYCHOSOM RES, V76, P68, DOI 10.1016/j.jpsychores.2013.10.006; Lee CC, 2016, AURIS NASUS LARYNX, V43, P322, DOI 10.1016/j.anl.2015.10.004; Lin SM, 2004, CRIT CARE MED, V32, P2254, DOI 10.1097/01.CCM.0000145587.16421.BB; Marra A, 2017, CRIT CARE CLIN, V33, P225, DOI 10.1016/j.ccc.2016.12.005; McCoy TH, 2016, PSYCHOSOMATICS, V57, P480, DOI 10.1016/j.psym.2016.06.001; Menendez ME, 2015, SPINE, V40, P809, DOI 10.1097/BRS.0000000000000892; Milbrandt EB, 2004, CRIT CARE MED, V32, P955, DOI 10.1097/01.CCM.0000119429.16055.92; Naidech AM, 2013, AM J RESP CRIT CARE, V188, P1331, DOI 10.1164/rccm.201307-1256OC; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Patel MB, 2018, CRIT CARE MED, V46, P1832, DOI 10.1097/CCM.0000000000003349; Wei LA, 2008, J AM GERIATR SOC, V56, P823, DOI 10.1111/j.1532-5415.2008.01674.x	20	5	5	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2019	14	11							e0225204	10.1371/journal.pone.0225204	http://dx.doi.org/10.1371/journal.pone.0225204			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LN2HK	31725810	Green Published, gold			2023-01-03	WOS:000532764500068
J	Singh, B; Saqib, M; Chakraborty, A; Bhaskar, S				Singh, Bindu; Saqib, Mohd; Chakraborty, Anush; Bhaskar, Sangeeta			Lipoarabinomannan from Mycobacterium indicus pranii shows immunostimulatory activity and induces autophagy in macrophages	PLOS ONE			English	Article							TUBERCULOSIS LIPOARABINOMANNAN; IMMUNE EVASION; INNATE; INDUCTION; LIPIDS; TARGET; ROLES	Mycobacterium indicus pranii (MIP) known for its immunotherapeutic potential against leprosy and tuberculosis is undergoing various clinical trials and also simultaneously being studied in animal models to get insight into the mechanistic details contributing to its protective efficacy as a vaccine candidate. Studies have shown potential immunomodulatory properties of MIP, the most significant being the ability to induce strong Th1 type of response, enhanced expression of pro-inflammatory cytokines, activation of APCs and lymphocytes, elicitation of M.tb specific poly-functional T cells. All of these form crucial components of host-immune response during M.tb infection. Also, MIP was found to be potent inducer of autophagy in macrophages which resulted in enhanced clearance of M.tb from MIP and M.tb co-infected cells. Hence, we further examined the component/s of MIP responsible for autophagy induction. Interestingly, we found that MIP lipids and DNA were able to induce autophagy but not the protein fraction. LAM being one of the crucial components of mycobacterial cell-wall lipids and possessing the ability of immunomodulation; we isolated LAM from MIP and did a comparative study with M.tb-LAM. Stimulation with MIP-LAM resulted in significantly high secretion of pro-inflammatory cytokines and displayed high autophagy inducing potential in macrophages as compared to M.tb-LAM. Treatment with MIP-LAM enhanced the co-localization of M.tb within the phago-lysosomes and increased the clearance of M.tb from the infected macrophages. This study describes LAM to be a crucial component of MIP which has significant contribution to its immunotherapeutic efficacy against TB.	[Singh, Bindu; Saqib, Mohd; Chakraborty, Anush; Bhaskar, Sangeeta] Natl Inst Immunol, Prod Dev Cell 1, New Delhi, India; [Singh, Bindu] Texas Biomed Res Inst, San Antonio, TX USA; [Saqib, Mohd] Albany Med Ctr, Albany, NY USA	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Texas Biomedical Research Institute; Albany Medical College	Bhaskar, S (corresponding author), Natl Inst Immunol, Prod Dev Cell 1, New Delhi, India.	sangeeta@nii.ac.in	Singh, Bindu/GXG-7548-2022; SAQIB, MOHD/AAH-9193-2021	Singh, Bindu/0000-0003-2974-1737; SAQIB, MOHD/0000-0002-3800-0490	Core Research Grant of the National Institute of Immunology	Core Research Grant of the National Institute of Immunology	This work was supported by the Core Research Grant of the National Institute of Immunology.	ADAMS LB, 1993, INFECT IMMUN, V61, P4173, DOI 10.1128/IAI.61.10.4173-4181.1993; Bah A, 2016, FRONT CELL INFECT MI, V6, DOI [10.3389/fcimb.2076.00053, 10.3389/fcimb.2016.00053]; BARNES PF, 1992, J IMMUNOL, V149, P541; Behar SM, 2011, MUCOSAL IMMUNOL, V4, P279, DOI 10.1038/mi.2011.3; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; Dahl KE, 1996, INFECT IMMUN, V64, P399, DOI 10.1128/IAI.64.2.399-405.1996; Dall'Armi C, 2013, CURR BIOL, V23, pR33, DOI 10.1016/j.cub.2012.10.041; Deretic V, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a018481; Flynn JL, 2003, CURR OPIN IMMUNOL, V15, P450, DOI 10.1016/S0952-7915(03)00075-X; Goletti D, 2013, CYTOKINE GROWTH F R, V24, P335, DOI 10.1016/j.cytogfr.2013.01.002; Gupta A, 2012, IMMUNOBIOLOGY, V217, P363, DOI 10.1016/j.imbio.2011.07.008; Harding CV, 2010, NAT REV MICROBIOL, V8, P296, DOI 10.1038/nrmicro2321; Hmama Z, 2004, J CELL SCI, V117, P2131, DOI 10.1242/jcs.01072; Hmama Z, 2015, IMMUNOL REV, V264, P220, DOI 10.1111/imr.12268; Janssens S, 2003, CLIN MICROBIOL REV, V16, P637, DOI 10.1128/CMR.16.4.637-646.2003; Knaevelsrud H, 2012, BBA-MOL CELL BIOL L, V1821, P1133, DOI 10.1016/j.bbalip.2012.01.001; Koul A, 2004, NAT REV MICROBIOL, V2, P189, DOI 10.1038/nrmicro840; Kumar P, 2016, PHYS REV APPL, V6; Lerner TR, 2015, CELL MICROBIOL, V17, P1277, DOI 10.1111/cmi.12480; Levine B, 2007, NAT REV IMMUNOL, V7, P767, DOI 10.1038/nri2161; Maiti D, 2001, J BIOL CHEM, V276, P329, DOI 10.1074/jbc.M002650200; Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08; Nigou J, 2003, BIOCHIMIE, V85, P153, DOI 10.1016/S0300-9084(03)00048-8; Nigou J, 2008, AM SOC MICROBIOLOGY, P75, DOI [10.1128/9781555815783.ch6, DOI 10.1128/9781555815783.CH6]; Padhi A, 2017, MYCOBACTERIUM TUBERC, DOI [10.1101/230698, DOI 10.1101/230698]; Pitarque S, 2008, TUBERCULOSIS, V88, P560, DOI 10.1016/j.tube.2008.04.002; Saqib M, 2019, INT IMMUNOPHARMACOL, V70, P408, DOI 10.1016/j.intimp.2019.02.049; Schlesinger LS, 2017, HDB TUBERCULOSIS, DOI [10.1002/9783527611614.ch18, DOI 10.1002/9783527611614.CH18]; Shin DM, 2010, CELL MICROBIOL, V12, P1648, DOI 10.1111/j.1462-5822.2010.01497.x; Shui WQ, 2011, J PROTEOME RES, V10, P339, DOI 10.1021/pr100688h; Singh B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189606; Strohmeier GR, 1999, MICROBES INFECT, V1, P709, DOI 10.1016/S1286-4579(99)80072-0; Vergne I, 2004, ANNU REV CELL DEV BI, V20, P367, DOI 10.1146/annurev.cellbio.20.010403.114015; Vergne I, 2015, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00187; Welin A, 2008, INFECT IMMUN, V76, P2882, DOI 10.1128/IAI.01549-07; Zhai W, MOL SCI IMMUNE ESCAP, DOI [10.3390/ijms20020340, DOI 10.3390/IJMS20020340]; Zullo AJ, 2012, J BIOL CHEM, V287, P12668, DOI 10.1074/jbc.M111.320135	37	3	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2019	14	10							e0224239	10.1371/journal.pone.0224239	http://dx.doi.org/10.1371/journal.pone.0224239			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN0JK	31648257	Green Published, gold			2023-01-03	WOS:000532631800069
J	Borges, U; Laborde, S; Raab, M				Borges, Uirassu; Laborde, Sylvain; Raab, Markus			Influence of transcutaneous vagus nerve stimulation on cardiac vagal activity: Not different from sham stimulation and no effect of stimulation intensity	PLOS ONE			English	Article							HEART-RATE-VARIABILITY; ELECTRICAL-STIMULATION; NOREPINEPHRINE; SENSITIVITY; EXTINCTION; CORTEX; EAR	The present study investigated the effects of transcutaneous vagus nerve stimulation on cardiac vagal activity, the activity of the vagus nerve regulating cardiac functioning. We applied stimulation on the left cymba conchae and tested the effects of different stimulation intensities on a vagally-mediated heart rate variability parameter (i.e., the root mean square of successive differences) as well as on subjective ratings of strength of perceived stimulation intensity and unpleasantness due to the stimulation. Three experiments (within-subject designs, M = 61 healthy participants each) were carried out: In Experiment 1, to choose one fixed stimulation intensity for the subsequent studies, we compared three preset stimulation intensities (i.e., 0.5, 1.0 and 1.5 mA) with each other. In Experiment 2, we compared the set stimulation method with the free stimulation method, in which the participants were instructed to freely choose an intensity. In Experiment 3, to control for placebo effects, we compared both methods (i.e., set stimulation vs. free stimulation) with their respective sham stimulations. In the three experiments, an increase of cardiac vagal activity was found from resting to the stimulation phases. However, this increase in cardiac vagal activity was not dependent on stimulation intensity (Experiment 1), the method used to stimulate (i.e., set vs. free; Experiment 2), or whether stimulation was active or sham (Experiment 3). This pattern of results was solidly supported by Bayesian estimations. On the subjective level, higher stimulation intensities were perceived as significantly stronger and a stronger stimulation was generally also perceived as more unpleasant. The results suggest that cardiac vagal activity may be similarly influenced by afferent vagal stimuli triggered by active and sham stimulation with different stimulation intensities. Potential explanations for these findings and its implications for future research with tVNS are discussed.	[Borges, Uirassu; Laborde, Sylvain; Raab, Markus] German Sport Univ Cologne, Cologne, Germany; [Laborde, Sylvain] Normandie Univ, Caen, France; [Raab, Markus] London South Bank Univ, London, England	German Sport University Cologne; London South Bank University	Borges, U (corresponding author), German Sport Univ Cologne, Cologne, Germany.	u.borges@dshs-koeln.de	Borges, Uirassu/AAQ-2849-2020; Laborde, Sylvain/A-6087-2012	Laborde, Sylvain/0000-0003-4842-6548; Borges, Uirassu/0000-0002-1032-0580				Aihara M, 2007, PSYCHIAT RES-NEUROIM, V155, P245, DOI 10.1016/j.pscychresns.2006.11.002; Albusoda A, 2018, LANCET GASTROENTEROL, V3, P13, DOI 10.1016/S2468-1253(17)30364-3; Antonino D, 2017, NONINVASIVE VAGUS NE, P1; Badran BW, 2018, BRAIN STIMUL, V11, P492, DOI 10.1016/j.brs.2017.12.009; Badran BW, 2018, BRAIN STIMUL, V11, P699, DOI 10.1016/j.brs.2018.04.004; BERNTSON GG, 1993, PSYCHOPHYSIOLOGY, V30, P183, DOI 10.1111/j.1469-8986.1993.tb01731.x; Berntson GG, RESP SINUS ARRHYTHMI, DOI [10.1016/j.nlm.2019.04.006, DOI 10.1016/J.NLM.2019.04.006]; Beste C, 2016, BRAIN STIMUL, V9, P811, DOI 10.1016/j.brs.2016.07.004; Burger AM, 2019, NEUROBIOL LEARN MEM, V161, P192, DOI 10.1016/j.nlm.2019.04.006; Burger AM, 2019, BIOL PSYCHOL, V142, P80, DOI 10.1016/j.biopsycho.2019.01.014; Burger AM, 2017, BEHAV RES THER, V97, P64, DOI 10.1016/j.brat.2017.07.005; Burger AM, 2016, NEUROBIOL LEARN MEM, V132, P49, DOI 10.1016/j.nlm.2016.05.007; Busch V, 2013, BRAIN STIMUL, V6, P202, DOI 10.1016/j.brs.2012.04.006; Camm AJ, 1996, EUR HEART J, V17, P354; Clancy JA, 2014, BRAIN STIMUL, V7, P871, DOI 10.1016/j.brs.2014.07.031; Clark KB, 1999, ENHANCED RECOGNITION, V2; Colzato LS, 2018, NEUROPSYCHOLOGIA, V111, P72, DOI 10.1016/j.neuropsychologia.2018.01.003; Colzato LS, 2017, THEORY DRIVEN APPROA, P115, DOI DOI 10.1007/978-3-319-57505-6_9; De Couck M, 2017, AUTON NEUROSCI-BASIC, V203, P88, DOI 10.1016/j.autneu.2016.11.003; Dietrich S, 2008, BIOMED TECH, V53, P104, DOI 10.1515/BMT.2008.022; Doheny ER, 2008, IEEE ENG MED BIO, P5684, DOI 10.1109/IEMBS.2008.4650504; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fischer R, 2018, COGN AFFECT BEHAV NE, V18, P680, DOI 10.3758/s13415-018-0596-2; FOOTE SL, 1983, PHYSIOL REV, V63, P844, DOI 10.1152/physrev.1983.63.3.844; Frangos E, 2015, BRAIN STIMUL, V8, P624, DOI 10.1016/j.brs.2014.11.018; Heathers JAJ, 2012, EXP PHYSIOL, V97, P556, DOI 10.1113/expphysiol.2011.063867; Joshi S, 2016, NEURON, V89, P221, DOI 10.1016/j.neuron.2015.11.028; Keller T, 2009, SKIN PROPERTIES INFL, P492; Kemp J, 2014, CLIN NEUROPHYSIOL, V125, P602, DOI 10.1016/j.clinph.2013.08.020; Keute M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47961-4; Kraus T, 2013, BRAIN STIMUL, V6, P798, DOI 10.1016/j.brs.2013.01.011; Kreuzer Peter M, 2012, Front Psychiatry, V3, P70, DOI 10.3389/fpsyt.2012.00070; Laborde S, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00213; LARKIN WD, 1986, IEEE T BIO-MED ENG, V33, P495, DOI 10.1109/TBME.1986.325736; Lehrer PM, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00756; Liu WW, 2008, EUR J APPL PHYSIOL, V103, P361, DOI 10.1007/s00421-008-0718-6; Loerwald KW, 2018, BRAIN STIMUL, V11, P271, DOI 10.1016/j.brs.2017.11.007; Murray AR, 2016, AUTON NEUROSCI-BASIC, V199, P48, DOI 10.1016/j.autneu.2016.06.004; Nemeroff CB, 2006, VNS THERAPY TREATMEN, P1345; Peltola MA, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00148; Peuker ET, 2002, CLIN ANAT, V15, P35, DOI 10.1002/ca.1089; Quintana Daniel S, 2014, Front Psychol, V5, P805, DOI 10.3389/fpsyg.2014.00805; Rangon CM, 2018, CLIN NEUROPHYSIOL, V129, P2501, DOI 10.1016/j.clinph.2018.08.027; Redgrave J, 2018, BRAIN STIMUL, V11, P1225, DOI 10.1016/j.brs.2018.08.010; Roosevelt RW, 2006, BRAIN RES, V1119, P124, DOI 10.1016/j.brainres.2006.08.048; Sellaro R, 2014, TRANSCUTANEOUS VAGUS, P2126; Steenbergen L, 2015, EUR NEUROPSYCHOPHARM, V25, P773, DOI 10.1016/j.euroneuro.2015.03.015; Thayer JF, 2009, HEART RATE VARIABILI, P141; Thayer JF, 2009, NEUROSCI BIOBEHAV R, V33, P81, DOI 10.1016/j.neubiorev.2008.08.004; Van Leusden Jelle W R, 2015, Front Psychol, V6, P102, DOI 10.3389/fpsyg.2015.00102; Ventura-Bort C, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00202; Wagenmakers EJ, 2007, PSYCHON B REV, V14, P779, DOI 10.3758/BF03194105; Warren CM, 2019, BRAIN STIMUL, V12, P635, DOI 10.1016/j.brs.2018.12.224; Wetzels R, 2011, PERSPECT PSYCHOL SCI, V6, P291, DOI 10.1177/1745691611406923; Yakunina N, 2016, OPTIMIZATION TRANSCU; Yakunina N, 2017, NEUROMODULATION, V20, P290, DOI 10.1111/ner.12541; Yerkes RM, 1908, J COMP NEUROL PSYCHO, V18, P459, DOI 10.1002/cne.920180503	57	36	36	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2019	14	10							e0223848	10.1371/journal.pone.0223848	http://dx.doi.org/10.1371/journal.pone.0223848			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM8DE	31603939	Green Published, gold			2023-01-03	WOS:000532477400037
J	van IJzendoorn, M; van den Born, J; Hijmans, R; Bodde, R; Buter, H; Dam, W; Kingma, P; Maes, G; van der Veen, T; Zijlstra, W; Dijkstra, B; Navis, G; Boerma, C				van IJzendoorn, Marjolein; van den Born, Jacob; Hijmans, Ryanne; Bodde, Rianne; Buter, Hanneke; Dam, Wendy; Kingma, Peter; Maes, Gwendolyn; van der Veen, Tsjitske; Zijlstra, Wierd; Dijkstra, Baukje; Navis, Gerjan; Boerma, Christiaan			An observational study on intracutaneous sodium storage in intensive care patients and controls	PLOS ONE			English	Article							OSMOTICALLY INACTIVE NA+; MONOCYTE CHEMOATTRACTANT; TISSUE SODIUM; SKIN; MOBILIZATION; DEFINITIONS; MACROPHAGES; BALANCE; SEPSIS; GROWTH	The development of ICU-acquired sodium disturbances is not fully understood. Alterations in non-osmotic skin sodium storage, hypothetically inflammation-driven, could play a role. To investigate this in critically ill patients we conducted a patient-control study with skin punch biopsies in patients with sepsis (n = 15), after coronary artery bypass grafting (CABG, n = 15) and undergoing total hip arthroplasty (THA-controls, n = 15) respectively, together representing a range in severity of systemic inflammation. Biopsies were taken within 24 hours (sepsis) and within 2 hours (CABG) after ICU-admission, and prior to arthroplasty. Biopsies were analysed for sodium content. In addition immunostainings and quantitative real time PCR were performed. The primary aim of this study was to detect possible differences in amounts of cutaneous sodium. The secondary aims were to quantify inflammation and lymphangiogenesis with concomitant markers. The highest amounts of both water and sodium were found in patients with sepsis, with slightly lower values after CABG and the lowest amounts in THA-controls. Correlation between water and sodium was 0.5 (p<0.01). In skin biopsies in all groups comparable amounts of macrophages, T-cells and lymph vessels were found. In all groups comparable expression of inflammation markers were found. However, higher mRNA transcript expression levels of markers of lymphangiogenesis were found in patients with sepsis and after CABG. The conjoint accumulation of water and sodium points towards oedema formation. However, the correlation coefficient of 0.5 leaves room for alternative explanations, including non-osmotic sodium storage. No signs of dermal inflammation were found, but upregulation of markers of lymphangiogenesis could indicate future lymphangiogenesis.	[van IJzendoorn, Marjolein; Buter, Hanneke; Kingma, Peter; Maes, Gwendolyn; van der Veen, Tsjitske; Boerma, Christiaan] Med Ctr Leeuwarden, Intens Care, Friesland, Netherlands; [van IJzendoorn, Marjolein; van den Born, Jacob; Hijmans, Ryanne; Bodde, Rianne; Dam, Wendy; Navis, Gerjan] Univ Med Ctr Groningen, Dept Internal Med Nephrol, Groningen, Netherlands; [Zijlstra, Wierd; Dijkstra, Baukje] Med Ctr Leeuwarden, Dept Orthopaed Surg, Friesland, Netherlands	Medical Center Leeuwarden; University of Groningen; Medical Center Leeuwarden	van IJzendoorn, M (corresponding author), Med Ctr Leeuwarden, Intens Care, Friesland, Netherlands.; van IJzendoorn, M (corresponding author), Univ Med Ctr Groningen, Dept Internal Med Nephrol, Groningen, Netherlands.	vanijzendoorn@kpnmail.nl	Zijlstra, Wierd/AFM-2737-2022; Zijlstra, Wierd/ABB-9018-2020		Stichting Intensive Care Onderzoek Friesland	Stichting Intensive Care Onderzoek Friesland	Funding for laboratory fees concerning analysis of the biopsies (measurements of sodium and nitrogen, immunostainings and qRT-PCR) was provided by a local hospital fund (Stichting Intensive Care Onderzoek Friesland). Funders did not play any role in the study design, data collection and analysis, decision to publish or preparation of the manuscript and in this way no conflict of interest applies.	Bihari S, 2013, CRIT CARE RESUSC, V15, P294; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; Celie JWAM, 2007, AM J PATHOL, V170, P1865, DOI 10.2353/ajpath.2007.070061; Crescenzi R, 2018, OBESITY, V26, P310, DOI 10.1002/oby.22090; Day J R S, 2005, Int J Surg, V3, P129, DOI 10.1016/j.ijsu.2005.04.002; Fu JX, 2008, J CLIN INVEST, V118, P3725, DOI 10.1172/JCI36077; GARNETT ES, 1968, CLIN SCI, V35, P93; Hijmans RS, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1815-5; Hijmans RS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178940; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Kerjaschki D, 2005, J CLIN INVEST, V115, P2316, DOI 10.1172/JCI26354; Kopp C, 2013, HYPERTENSION, V61, P635, DOI 10.1161/HYPERTENSIONAHA.111.00566; Lindner G, 2013, J CRIT CARE, V28, P214, DOI 10.1016/j.jcrc.2012.11.017; Linz P, 2015, NMR BIOMED, V28, P54, DOI 10.1002/nbm.3224; Machnik A, 2009, NAT MED, V15, P545, DOI 10.1038/nm.1960; Mouta Carla, 2003, Lymphat Res Biol, V1, P201, DOI 10.1089/153968503768330247; Padtberg JH, 1910, ARCH EXP PATHOL PHAR, V63, P60, DOI 10.1007/BF01840852; Reitsma S, 2007, PFLUG ARCH EUR J PHY, V454, P345, DOI 10.1007/s00424-007-0212-8; Schafflhuber M, 2007, AM J PHYSIOL-RENAL, V292, pF1490, DOI 10.1152/ajprenal.00300.2006; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Titze J, 2005, AM J PHYSIOL-RENAL, V289, pF793, DOI 10.1152/ajprenal.00096.2005; Titze J, 2004, AM J PHYSIOL-HEART C, V287, pH203, DOI 10.1152/ajpheart.01237.2003; Titze J, 2003, AM J PHYSIOL-RENAL, V285, pF1108, DOI 10.1152/ajprenal.00200.2003; Titze J, 2002, AM J KIDNEY DIS, V40, P508, DOI 10.1053/ajkd.2002.34908; Titze J, 2002, AM J PHYSIOL-RENAL, V283, pF134, DOI 10.1152/ajprenal.00323.2001; Titze J, 2009, SEMIN DIALYSIS, V22, P253, DOI 10.1111/j.1525-139X.2009.00569.x; van IJzendoorn MCO, 2016, CRIT CARE RES PRACT, V2016, DOI 10.1155/2016/9571583; Wahlgren V, 1909, ARCH EXP PATHOL PHAR, V61, P97, DOI 10.1007/BF01841955	30	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2019	14	10							e0223100	10.1371/journal.pone.0223100	http://dx.doi.org/10.1371/journal.pone.0223100			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM6ZN	31581250	gold, Green Published			2023-01-03	WOS:000532398600029
J	Jeon, SM; Park, S; Rhie, SJ; Kwon, JW				Jeon, Soo-Min; Park, Susan; Rhie, Sandy Jeong; Kwon, Jin-Won			Prescribing patterns of polypharmacy in Korean pediatric patients	PLOS ONE			English	Article							DRUG-DRUG INTERACTIONS; ACUTE GASTROENTERITIS; CHILDREN; PREVALENCE; ASSOCIATION; MANAGEMENT; EVENTS; TRENDS; RISK	Background Several studies have examined the risk and health outcomes related to polypharmacy among the elderly. However, information regarding polypharmacy among pediatric patients is lacking. Objective The aim of this study was to investigate the prevalence of polypharmacy and its related factors among the pediatric population of South Korea. Methods We used national claim data from the Health Insurance Review and Assessment Service-Pediatric Patients Sample (HIRA-PPS) in Korea originating from 2012 through 2016. Polypharmacy was defined as a daily average of two or more drugs used yearly. Complex chronic conditions (CCCs) were examined to evaluate concomitant chronic diseases in pediatric patients. Age-specific contraindications and potential drug-drug interactions were assessed according to criteria established by the Korea Institute of Drug Safety & Risk Management (KIDS). Descriptive statistics and logistic regression were conducted to analyze the status of polypharmacy and its associated risk factors in pediatric patients. Results The 5-year prevalence of pediatric polypharmacy in pediatric patients was 3.7%. The prevalence of polypharmacy was much higher in younger pediatric patients: 9.5% for patients between the ages of 1-7 years, 0.9% for ages 6-11 years, and 1.1% for ages 12-19 years. Pediatric patients with CCCs, Medical Aid benefits, or a hospital admission history had a significantly higher prevalence of polypharmacy when compared to their counterparts without those conditions. The most commonly prescribed drugs were respiratory agents (29%) followed by anti-allergic drugs (18.7%), central nervous system agents (15.9%), antibiotics (10.1%), and gastrointestinal drugs (7.7%). There was a positive correlation between the daily average number of inappropriate prescriptions and the degree of polypharmacy, especially in pediatric patients between the ages of 1-7 years. Contraindications and potential drug-drug interactions occurred in 11.0% and 10.1% of patients exposed to polypharmacy, respectively. Conclusions One in ten pediatric patients under the age of 7 years was prescribed two or more concurrent drugs on average per day. Furthermore, pediatric patients exposed to polypharmacy showed an increased risk of inappropriate drug use. The implementation of a medication review system that considers pediatric patient polypharmacy exposure would reduce inappropriate drug use and prevent unwanted adverse outcomes.	[Jeon, Soo-Min; Park, Susan; Kwon, Jin-Won] Kyungpook Natl Univ, Coll Pharm, Daegu, South Korea; [Jeon, Soo-Min; Park, Susan; Kwon, Jin-Won] Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Daegu, South Korea; [Rhie, Sandy Jeong] Ewha Womans Univ, Coll Pharm, Seoul, South Korea; [Rhie, Sandy Jeong] Ewha Womans Univ, Div Life & Pharmaceut Sci, Seoul, South Korea	Kyungpook National University; Kyungpook National University; Ewha Womans University; Ewha Womans University	Kwon, JW (corresponding author), Kyungpook Natl Univ, Coll Pharm, Daegu, South Korea.; Kwon, JW (corresponding author), Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Daegu, South Korea.	jwkwon@knu.ac.kr		Park, Susan/0000-0002-7082-8554; Rhie, Jeong Yeon/0000-0003-2554-3370	National Research Foundation of Korea (NRF) - Korean government (MSIP) [NRF-2018R1D1A1B07043416]	National Research Foundation of Korea (NRF) - Korean government (MSIP)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (NRF-2018R1D1A1B07043416). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bakaki PM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208047; Bourgeois FT, 2010, PHARMACOEPIDEM DR S, V19, P901, DOI 10.1002/pds.1984; Burns KH, 2010, PEDIATRICS, V126, P638, DOI 10.1542/peds.2009-1658; Burt J, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1078-7; Bushardt RL, 2008, CLIN INTERV AGING, V3, P383, DOI 10.2147/CIA.S2468; Comer JS, 2010, J AM ACAD CHILD PSY, V49, P1001, DOI 10.1016/j.jaac.2010.07.007; Cox ER, 2008, PEDIATRICS, V122, pE1053, DOI 10.1542/peds.2008-0214; Diaz-Caneja CM, 2014, INT J NEUROPSYCHOPH, V17, P1063, DOI 10.1017/S1461145712001265; Doan J, 2013, ANN PHARMACOTHER, V47, P324, DOI 10.1345/aph.1R621; Feinstein JA, 2015, PHARMACOEPIDEM DR S, V24, P1049, DOI 10.1002/pds.3843; Feudtner C, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-199; Feudtner C, 2012, ARCH PEDIAT ADOL MED, V166, P9, DOI 10.1001/archpediatrics.2011.161; Frazier Susan C, 2005, J Gerontol Nurs, V31, P4; Fried TR, 2014, J AM GERIATR SOC, V62, P2261, DOI 10.1111/jgs.13153; Gu Qiuping, 2010, NCHS Data Brief, P1; Guarino A, 2008, J PEDIATR GASTR NUTR, V46, P619, DOI 10.1097/MPG.0b013e31816e219e; Hilt RJ, 2014, J CHILD ADOL PSYCHOP, V24, P83, DOI 10.1089/cap.2013.0036; Juurlink DN, 2003, JAMA-J AM MED ASSOC, V289, P1652, DOI 10.1001/jama.289.13.1652; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; Kim L, 2014, EPIDEMIOL HEALTH, V36, DOI 10.4178/epih/e2014008; Lai SW, 2012, GERIATR GERONTOL INT, V12, P491, DOI 10.1111/j.1447-0594.2011.00800.x; Maher RL, 2014, EXPERT OPIN DRUG SAF, V13, P57, DOI 10.1517/14740338.2013.827660; Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2; Morden NE, 2012, ARCH PEDIAT ADOL MED, V166, P91, DOI 10.1001/archpediatrics.2011.162; Nazarian LF, 1996, PEDIATRICS, V97, P424; OECD, 2017, HLTH GLANC 2017 OECD; Park HY, 2017, DRUG SAFETY, V40, P1109, DOI 10.1007/s40264-017-0559-5; Park HY, 2016, INT J CLIN PHARM TH, V54, P369, DOI 10.5414/CP202484; Principi N, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1772-z; Rui P., 2016, NATL AMBULATORY MED; Sharma S, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1512-4; Tamma PD, 2017, JAMA INTERN MED, V177, P1308, DOI 10.1001/jamainternmed.2017.1938; Tchoe B, 2010, INT J ENV RES PUB HE, V7, P3235, DOI 10.3390/ijerph7083235; Toteja N, 2014, INT J NEUROPSYCHOPH, V17, P1095, DOI 10.1017/S1461145712001320	34	3	3	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2019	14	10							e0222781	10.1371/journal.pone.0222781	http://dx.doi.org/10.1371/journal.pone.0222781			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KL8VK	31574095	gold, Green Submitted, Green Published			2023-01-03	WOS:000513696100001
J	Gering, C; Koivisto, JT; Parraga, J; Leppiniemi, J; Vuornos, K; Hytonen, VP; Miettinen, S; Kellomaki, M				Gering, Christine; Koivisto, Janne T.; Parraga, Jenny; Leppiniemi, Jenni; Vuornos, Kaisa; Hytonen, Vesa P.; Miettinen, Susanna; Kellomaki, Minna			Design of modular gellan gum hydrogel functionalized with avidin and biotinylated adhesive ligands for cell culture applications	PLOS ONE			English	Article							MESENCHYMAL STEM-CELLS; OSTEOGENIC DIFFERENTIATION; EXTRACELLULAR-MATRIX; ALGINATE HYDROGELS; BINDING; GROWTH; ELASTICITY; GELATION	This article proposes the coupling of the recombinant protein avidin to the polysaccharide gellan gum to create a modular hydrogel substrate for 3D cell culture and tissue engineering. Avidin is capable of binding biotin, and thus biotinylated compounds can be tethered to the polymer network to improve cell response. The avidin is successfully conjugated to gellan gum and remains functional as shown with fluorescence titration and electrophoresis (SDS-PAGE). Self-standing hydrogels were formed using bioamines and calcium chloride, yielding long-term stability and adequate stiffness for 3D cell culture, as confirmed with compression testing. Human fibroblasts were successfully cultured within the hydrogel treated with biotinylated RGD or biotinylated fibronectin. Moreover, human bone marrow stromal cells were cultured with hydrogel treated with biotinylated RGD over 3 weeks. We demonstrate a modular and inexpensive hydrogel scaffold for cell encapsulation that can be equipped with any desired biotinylated cell ligand to accommodate a wide range of cell types.	[Gering, Christine; Koivisto, Janne T.; Parraga, Jenny; Leppiniemi, Jenni; Vuornos, Kaisa; Hytonen, Vesa P.; Miettinen, Susanna; Kellomaki, Minna] Tampere Univ, BioMediTech, Fac Med & Hlth Technol, Tampere, Finland; [Vuornos, Kaisa; Miettinen, Susanna] Tampere Univ Hosp, Res Dev & Innovat Ctr, Tampere, Finland; [Hytonen, Vesa P.] Fimlab Labs, Tampere, Finland	Tampere University; Tampere University; Tampere University Hospital	Gering, C (corresponding author), Tampere Univ, BioMediTech, Fac Med & Hlth Technol, Tampere, Finland.	christine.gering@tuni.fi	Hytonen, Vesa P./E-8855-2013; Gering, Christine/AAD-9217-2019; Koivisto, Janne Tapio/P-7057-2019; Kellomaki, Minna/G-6190-2010	Hytonen, Vesa P./0000-0002-9357-1480; Gering, Christine/0000-0002-0476-2622; Koivisto, Janne Tapio/0000-0002-7904-4780; Leppiniemi, Jenni/0000-0002-7225-1648; Kellomaki, Minna/0000-0003-4321-1820; Miettinen, Susanna/0000-0002-0647-9556; Vuornos, Kaisa/0000-0003-4731-3314	Innovation Funding Agency 'Business Finland'; Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital; Academy of Finland [290506]	Innovation Funding Agency 'Business Finland'; Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital; Academy of Finland(Academy of Finland)	The project was funded from several sources: the Innovation Funding Agency 'Business Finland' (formerly TEKES) as the Human Spare Parts program (MK, CG, JK, JP), by the Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital (KV, SM), by Academy of Finland project 290506	Agard NJ, 2004, J AM CHEM SOC, V126, P15046, DOI 10.1021/ja044996f; Anjum F, 2016, BIOMATERIALS, V87, P104, DOI 10.1016/j.biomaterials.2016.01.050; Berrier AL, 2007, J CELL PHYSIOL, V213, P565, DOI 10.1002/jcp.21237; Blache U, 2016, ADV HEALTHC MATER, V5, P489, DOI 10.1002/adhm.201500795; Bondalapati S, 2014, MACROMOL RAPID COMM, V35, P1754, DOI 10.1002/marc.201400354; Broguiere N, 2018, ADV MATER, V30, DOI 10.1002/adma.201801621; da Silva LP, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201700686; De France KJ, 2017, CHEM MATER, V29, P4609, DOI 10.1021/acs.chemmater.7b00531; De Silva DA, 2013, J APPL POLYM SCI, V130, P3374, DOI 10.1002/app.39583; Desai RM, 2015, BIOMATERIALS, V50, P30, DOI 10.1016/j.biomaterials.2015.01.048; Doner LW, 1997, CARBOHYD POLYM, V32, P245, DOI 10.1016/S0144-8617(96)00168-3; Doube M, 2010, BONE, V47, P1076, DOI 10.1016/j.bone.2010.08.023; Douglas TEL, 2014, J TISSUE ENG REGEN M, V8, P906, DOI 10.1002/term.1616; Drury JL, 2003, BIOMATERIALS, V24, P4337, DOI 10.1016/S0142-9612(03)00340-5; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Ferris CJ, 2015, J MATER CHEM B, V3, P1106, DOI 10.1039/c4tb01727g; Frantz C, 2010, J CELL SCI, V123, P4195, DOI 10.1242/jcs.023820; Gebraad A, 2018, FEBS J, V285, P2337, DOI 10.1111/febs.14485; Gering C, 2017, EMBEC NBC 2017, P811; He XZ, 2008, LANGMUIR, V24, P12508, DOI 10.1021/la802447v; Hermanson GT, 2013, BIOCONJUGATE TECHNIQUES, 3RD EDITION, P259, DOI 10.1016/B978-0-12-382239-0.00004-2; Hobzova R, 2011, E-POLYMERS, V11, P474, DOI [10.1515/epoly.2011.11.1.474, DOI 10.1515/EPOLY.2011.11.1.474]; Hughes CS, 2010, PROTEOMICS, V10, P1886, DOI 10.1002/pmic.200900758; Hytonen VP, 2005, J BIOL CHEM, V280, P10228, DOI 10.1074/jbc.M414196200; Justice BA, 2009, DRUG DISCOV TODAY, V14, P102, DOI 10.1016/j.drudis.2008.11.006; Kirchmajer DM, 2014, CARBOHYD RES, V388, P125, DOI 10.1016/j.carres.2014.02.018; Koivisto JT, 2017, BIOMED MATER, V12, DOI 10.1088/1748-605X/aa62b0; Kojima N, 2006, BIOMATERIALS, V27, P4904, DOI 10.1016/j.biomaterials.2006.05.026; Kraehenbuehl TP, 2009, BIOMATERIALS, V30, P4318, DOI 10.1016/j.biomaterials.2009.04.057; Laitinen OH, 2007, TRENDS BIOTECHNOL, V25, P269, DOI 10.1016/j.tibtech.2007.04.001; Langer R, 2004, NATURE, V428, P487, DOI 10.1038/nature02388; Lee JW, 2017, COLLOID SURFACE B, V155, P229, DOI 10.1016/j.colsurfb.2017.04.014; Leppiniemi J, 2017, ACS APPL MATER INTER, V9, P21959, DOI 10.1021/acsami.7b02756; Levental I, 2007, SOFT MATTER, V3, P299, DOI 10.1039/b610522j; Li S, 2005, ANNU REV BIOMED ENG, V7, P105, DOI 10.1146/annurev.bioeng.7.060804.100340; Li Z, 2009, TISSUE ENG PT A, V15, P1729, DOI 10.1089/ten.tea.2008.0247; Lin SJ, 2006, BIOMATERIALS, V27, P1462, DOI 10.1016/j.biomaterials.2005.08.031; Mackova H, 2016, MACROMOL BIOSCI, V16, P1621, DOI 10.1002/mabi.201600159; McKee C, 2017, COLLOID SURFACE B, V159, P62, DOI 10.1016/j.colsurfb.2017.07.051; Morris ER, 2012, FOOD HYDROCOLLOID, V28, P373, DOI 10.1016/j.foodhyd.2012.01.004; Oliveira MB, 2016, ACTA BIOMATER, V41, P119, DOI 10.1016/j.actbio.2016.05.033; Osmalek T, 2014, INT J PHARMACEUT, V466, P328, DOI 10.1016/j.ijpharm.2014.03.038; Oyen ML, 2014, INT MATER REV, V59, P44, DOI 10.1179/1743280413Y.0000000022; Pacelli S, 2016, EUR POLYM J, V77, P114, DOI 10.1016/j.eurpolymj.2016.02.007; Ray S, 2015, LANGMUIR, V31, P1921, DOI 10.1021/la503213f; Rosano C, 1999, BIOMOL ENG, V16, P5, DOI 10.1016/S1050-3862(99)00047-9; Silva NA, 2012, BIOMATERIALS, V33, P6345, DOI 10.1016/j.biomaterials.2012.05.050; Silva-Correia J, 2013, ADV HEALTHC MATER, V2, P568, DOI 10.1002/adhm.201200256; Storm C, 2005, NATURE, V435, P191, DOI 10.1038/nature03521; Tallawi M, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0254; Tibbitt MW, 2009, BIOTECHNOL BIOENG, V103, P655, DOI 10.1002/bit.22361; Tsaryk R, 2017, J TISSUE ENG REGEN M, V11, P637, DOI 10.1002/term.1959; VROMAN L, 1980, BLOOD, V55, P156; Walters NJ, 2015, ACTA BIOMATER, V11, P3, DOI 10.1016/j.actbio.2014.09.038; Wylie RG, 2011, NAT MATER, V10, P799, DOI [10.1038/NMAT3101, 10.1038/nmat3101]; ZHANG SG, 1993, P NATL ACAD SCI USA, V90, P3334, DOI 10.1073/pnas.90.8.3334	56	5	5	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2019	14	8							e0221931	10.1371/journal.pone.0221931	http://dx.doi.org/10.1371/journal.pone.0221931			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW6BO	31469884	Green Published, Green Submitted, gold			2023-01-03	WOS:000485062200039
J	Olfson, M; Zhang, V; Schoenbaum, M; King, M				Olfson, Mark; Zhang, Victoria (Shu); Schoenbaum, Michael; King, Marissa			Trends in Buprenorphine Treatment in the United States, 2009-2018	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Olfson, Mark] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY USA; [Zhang, Victoria (Shu); King, Marissa] Yale Univ, Sch Management, New Haven, CT USA; [Schoenbaum, Michael] NIMH, Bethesda, MD 20892 USA	Columbia University; Yale University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Olfson, M (corresponding author), Columbia Univ, New York State Psychiat Inst, Dept Psychiat, Irving Med Ctr, 1051 Riverside Dr, New York, NY 10032 USA.	mark.olfson@nyspi.columbia.edu	Schoenbaum, Michael/GRR-3988-2022; Olfson, Mark/AAA-8547-2021		NIDA [R01 DA044981]	NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))	This work is supported by NIDA grant R01 DA044981 to Dr King.	Gaither JR, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.6558; National Quality Forum, 2017, BEH HLTH 2016 2017 F; Roberts AW, 2018, PSYCHIAT SERV, V69, P832, DOI 10.1176/appi.ps.201700315; Saha TD, 2016, J CLIN PSYCHIAT, V77, P772, DOI 10.4088/JCP.15m10386; Substance Abuse and Mental Health Services Administration, REP DET TABL 2017 NA; Wen HF, 2019, HEALTH AFFAIR, V38, P24, DOI 10.1377/hlthaff.2018.05145	6	59	59	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	2020	323	3					276	277		10.1001/jama.2019.18913	http://dx.doi.org/10.1001/jama.2019.18913			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF6MK	31961408	Bronze, Green Published			2023-01-03	WOS:000509353700024
J	Altekruse, SF; Cosgrove, CM; Altekruse, WC; Jenkins, RA; Blanco, C				Altekruse, Sean F.; Cosgrove, Candace M.; Altekruse, William C.; Jenkins, Richard A.; Blanco, Carlos			Socioeconomic risk factors for fatal opioid overdoses in the United States: Findings from the Mortality Disparities in American Communities Study (MDAC)	PLOS ONE			English	Article							DRUG POISONING MORTALITY; ALCOHOL-USE DISORDER; LIFE EXPECTANCY; FAMILY COHESION; SUBSTANCE USE; HEALTH; US; DEATH; ADULTS; SEVERITY	Background Understanding relationships between individual-level demographic, socioeconomic status (SES) and U.S. opioid fatalities can inform interventions in response to this crisis. Methods The Mortality Disparities in American Community Study (MDAC) links nearly 4 million 2008 American Community Survey responses to the 2008-2015 National Death Index. Univariate and multivariable models were used to estimate opioid overdose fatality hazard ratios (HR) and 95% confidence intervals (CI). Results Opioid overdose was an overrepresented cause of death among people 10 to 59 years of age. In multivariable analysis, compared to Hispanics, Whites and American Indians/Alaska Natives had elevated risk (HR = 2.52, CI:2.21-2.88) and (HR = 1.88, CI:1.35-2.62), respectively. Compared to women, men were at-risk (HR = 1.61, CI:1.50-1.72). People who were disabled were at higher risk than those who were not (HR = 2.80, CI:2.59-3.03). Risk was higher among widowed than married (HR = 2.44, CI:2.03-2.95) and unemployed than employed individuals (HR = 2.46, CI:2.17-2.79). Compared to adults with graduate degrees, those with high school only were at-risk (HR = 2.48, CI:2.00-3.06). Citizens were more likely than noncitizens to die from this cause (HR = 4.62, CI:3.48-6.14). Compared to people who owned homes with mortgages, those who rented had higher HRs (HR = 1.36, CI:1.25-1.48). Non-rural residents had higher risk than rural residents (HR = 1.46, CI:1.34, 1.59). Compared to respective referent groups, people without health insurance (HR = 1.30, CI:1.20-1.41) and people who were incarcerated were more likely to die from opioid overdoses (HR = 2.70, CI:1.91-3.81). Compared to people living in households at least five-times above the poverty line, people who lived in poverty were more likely to die from this cause (HR = 1.36, CI:1.20-1.54). Compared to people living in West North Central states, HRs were highest among those in South Atlantic (HR = 1.29, CI:1.11, 1.50) and Mountain states (HR = 1.58, CI:1.33, 1.88). Discussion Opioid fatality was associated with indicators of low SES. The findings may help to target prevention, treatment and rehabilitation efforts to vulnerable groups.	[Altekruse, Sean F.] NHLBI, Div Cardiovasc Sci, NIH, Bldg 10, Bethesda, MD 20892 USA; [Cosgrove, Candace M.] US Bur Census, Ctr Adm Records Res & Applicat, Suitland, MD USA; [Altekruse, William C.] NIMH, Div Translat Res, NIH, Bethesda, MD 20892 USA; [Jenkins, Richard A.; Blanco, Carlos] NIDA, Div Epidemiol Serv & Prevent Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Altekruse, SF (corresponding author), NHLBI, Div Cardiovasc Sci, NIH, Bldg 10, Bethesda, MD 20892 USA.	altekrusesf@mail.nih.gov			National Heart, Lung, and Blood Institute; National Institute on Aging; Census Bureau	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Census Bureau	The authors received no specific funding for this work. MDAC is funded by National Heart, Lung, and Blood Institute and National Institute on Aging agreements with the Census Bureau. The National Center for Health Statistics performed the National Death Index match and the Center for Medicare and Medicaid Services performed the CMS match.; MDAC is funded by National Heart, Lung, and Blood Institute and National Institute on Aging agreements with the Census Bureau.	Abrecht CR, 2017, ANESTH ANALG, V125, P1761, DOI 10.1213/ANE.0000000000002499; [Anonymous], INT CLASS DIS; [Anonymous], 2018, BMJ-BRIT MED J, V362, pk3210; Arias E, 2010, AM J PUBLIC HEALTH, V100, pS171, DOI 10.2105/AJPH.2008.135863; Bachhuber MA, 2014, JAMA INTERN MED, V174, P1668, DOI 10.1001/jamainternmed.2014.4005; Binswanger IA, 2016, ADDICTION, V111, P499, DOI 10.1111/add.13200; Blanco C, 2019, LANCET, V393, P1760, DOI 10.1016/S0140-6736(18)33078-2; Bohnert ASB, 2019, NEW ENGL J MED, V380, P71, DOI 10.1056/NEJMra1802148; Bozinoff N, 2018, J ADDICT MED, V12, P19, DOI 10.1097/ADM.0000000000000355; Brinkley-Rubinstein L, 2018, DRUG ALCOHOL DEPEN, V185, P189, DOI 10.1016/j.drugalcdep.2017.12.014; Caetano R, 2017, AM J DRUG ALCOHOL AB, V43, P87, DOI 10.1080/00952990.2016.1225073; Caetano R, 2016, ALCOHOL CLIN EXP RES, V40, P806, DOI 10.1111/acer.13020; Cano MA, 2018, SUBST USE MISUSE, V53, P668, DOI 10.1080/10826084.2017.1356333; Census Bureau, CENS REG DIV US; Centers for Disease Control and Prevention, CDC ACT 2018 RESP OP; Centers for Disease Control and Prevention, NAT DEATH IND; COX DR, 1972, J R STAT SOC B, V34, P187; Dasgupta N, 2018, AM J PUBLIC HEALTH, V108, P182, DOI 10.2105/AJPH.2017.304187; Day BF, 2019, DRUG ALCOHOL DEPEN, V204, DOI 10.1016/j.drugalcdep.2019.06.020; Dowell D, 2019, NEW ENGL J MED, V380, P2285, DOI 10.1056/NEJMp1904190; Dowell D, 2017, JAMA-J AM MED ASSOC, V318, P1065, DOI 10.1001/jama.2017.9308; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI [10.1001/jama.2016.1464, 10.15585/mmwr.rr7103a1]; Economic Innovation Group, ESC VEL EL COMM AR P; Ellaway A, 1998, HEALTH PLACE, V4, P141, DOI 10.1016/S1353-8292(98)00006-9; Hagan J, 2020, PREV MED, V130, DOI 10.1016/j.ypmed.2019.105897; Han B, 2017, ANN INTERN MED, V167, P293, DOI 10.7326/M17-0865; Hedegaard H., 2019, URBAN RURAL DIFFEREN; Hedegaard H, 2017, NCHS DATA BRIEF, V273, p1 ; Hedegaard Holly, 2020, NCHS Data Brief, P1; Hollingsworth A, 2017, J HEALTH ECON, V56, P222, DOI 10.1016/j.jhealeco.2017.07.009; Imtiaz S, 2018, DRUG ALCOHOL REV, V37, pS263, DOI 10.1111/dar.12616; Johnson EM, 2013, J GEN INTERN MED, V28, P522, DOI 10.1007/s11606-012-2225-z; Kiang MV, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0040; Kroelinger CD, 2019, MMWR-MORBID MORTAL W, V68, P777, DOI 10.15585/mmwr.mm6836a1; Kroenke K, 2019, PAIN MED, V20, P724, DOI 10.1093/pm/pny307; Lanier WA, 2012, PAIN MED, V13, P1580, DOI 10.1111/j.1526-4637.2012.01518.x; Linton SL, 2017, SOC SCI MED, V185, P81, DOI 10.1016/j.socscimed.2017.04.055; Lo CC, 2016, INT J PUBLIC HEALTH, V61, P91, DOI 10.1007/s00038-015-0695-6; Martins SS, 2015, AM J PUBLIC HEALTH, V105, P2373, DOI 10.2105/AJPH.2015.302843a; Martins SS, 2015, SOC PSYCH PSYCH EPID, V50, P713, DOI 10.1007/s00127-014-0980-3; Masters RK, 2018, INT J EPIDEMIOL, V47, P81, DOI 10.1093/ije/dyx127; McLean K, 2016, INT J DRUG POLICY, V29, P19, DOI 10.1016/j.drugpo.2016.01.009; Meara ER, 2008, HEALTH AFFAIR, V27, P350, DOI 10.1377/hlthaff.27.2.350; Miranda PY, 2017, PREV MED, V100, P3, DOI 10.1016/j.ypmed.2017.03.006; Monnat SM, 2018, AM J PREV MED, V54, P611, DOI 10.1016/j.amepre.2018.01.040; Muennig PA, 2018, AM J PUBLIC HEALTH, V108, P1626, DOI 10.2105/AJPH.2018.304585; National Academies of Science Engineering and Medicine, 2019, MED OP US DIS SAV LI; Orgera K., KEY FACTS UNINSURED; Paulozzi LJ, 2008, PHARMACOEPIDEM DR S, V17, P997, DOI 10.1002/pds.1626; Pear VA, 2019, DRUG ALCOHOL DEPEN, V195, P66, DOI 10.1016/j.drugalcdep.2018.11.024; Pitt AL, 2018, AM J PUBLIC HEALTH, V108, P1394, DOI 10.2105/AJPH.2018.304590; Preuss CV., 2019, STATPEARLS; Ratcliffe M, 2018, DEFINING RURAL US CE; Rigg KK, 2015, INT J DRUG POLICY, V26, P484, DOI 10.1016/j.drugpo.2014.10.001; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Ruhm CJ, 2017, AM J PREV MED, V53, P745, DOI 10.1016/j.amepre.2017.06.009; Sanchez-Salas A, 2017, INT CONF ENG DES, P21; Schepis TS, 2018, DRUG ALCOHOL DEPEN, V189, P172, DOI 10.1016/j.drugalcdep.2018.05.017; Sehdev AES, 2001, ARCH INTERN MED, V161, P277, DOI 10.1001/archinte.161.2.277; Smith DE, 2017, J PSYCHOACTIVE DRUGS, V49, P95, DOI 10.1080/02791072.2017.1295334; Stoicea N, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015425; U.S. Census Bureau, MORT DISP AM COMM MD; United States Census Bureau, AM COMMUNITY SURVEY; Wagner KD, 2010, INT J DRUG POLICY, V21, P186, DOI 10.1016/j.drugpo.2009.01.003; Willison C, 2017, HEALTH POLICY, V121, P1113, DOI 10.1016/j.healthpol.2017.08.002; Woolf SH, 2019, JAMA-J AM MED ASSOC, V322, P1996, DOI 10.1001/jama.2019.16932	66	74	75	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2020	15	1							e0227966	10.1371/journal.pone.0227966	http://dx.doi.org/10.1371/journal.pone.0227966			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KL0SC	31951640	gold, Green Published			2023-01-03	WOS:000513141900001
J	Chen, GL; Kamat, PK; Ahmad, AS; Dore, S				Chen, Gangling; Kamat, Pradip Kumar; Ahmad, Abdullah Shafique; Dore, Sylvain			Distinctive effect of anesthetics on the effect of limb remote ischemic postconditioning following ischemic stroke	PLOS ONE			English	Article							FOCAL CEREBRAL-ISCHEMIA; IN-VITRO MODEL; BRAIN-INJURY; REPERFUSION INJURY; ARTERY OCCLUSION; KETAMINE; PROTECTION; RECEPTOR; NEUROPROTECTION; SEVOFLURANE	Limb remote ischemic postconditioning (LRIP) has been reported as an effective method to reduce the induced experimental stroke damage after ischemic reperfusion (IR) injury. Studies suggest that anesthetics used during induction of ischemic stroke can reduce IR injury, which could affect the actual mechanisms of neuroprotection by LRIP. This study focuses on the comparative effects of anesthetics such as isoflurane and ketamine-xylazine on ischemic injury when used during LRIP. Adult C57BL/6 mice were anesthetized by isoflurane or halothane, and transient middle cerebral artery occlusion (MCAO) was induced through insertion of the filament. Under isoflurane or ketamine-xylazine anesthesia, LRIP was performed after 90 min of reperfusion by carrying out three cycles of 5 min ischemia/5 min reperfusion of the bilateral hind limbs for one session per day for a total of 3 days. Results showed that the use of different anesthetics-isoflurane or ketamine-xylazine-during LRIP had no effects on body weight. However, LRIP was able to improve neurological function as observed by the neurological deficit score in ischemic mice. Interestingly, the neurological deficit in the group where ketamine-xylazine was used was better than the group where isoflurane was used during LRIP. Furthermore, the LRIP was able to prolong the period of the ischemic mice on the rotarod and this effect was more significant in the groups where ketamine-xylazine was used during LRIP. Moreover, LRIP significantly attenuated the infarction volume; however, this effect was independent of the anesthetic used during LRIP. From these results, we conclude that ischemic mice that were subjected to LRIP under ketamine-xylazine anesthesia had better neurological deficit outcomes after stroke.	[Chen, Gangling; Kamat, Pradip Kumar; Ahmad, Abdullah Shafique; Dore, Sylvain] Univ Florida, Dept Anesthesiol, Ctr Translat Res Neurodegenerat Dis, McKnight Brain Inst, Gainesville, FL 32611 USA; [Chen, Gangling] China Pharmaceut Univ, Sch Tradit Chinese Pharm, Dept Pharmacol Chinese Mat Med, Nanjing, Peoples R China; [Dore, Sylvain] Univ Florida, Dept Neurol, Gainesville, FL 32611 USA; [Dore, Sylvain] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Dore, Sylvain] Univ Florida, Dept Pharmaceut, Gainesville, FL 32611 USA; [Dore, Sylvain] Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; China Pharmaceutical University; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Dore, S (corresponding author), Univ Florida, Dept Anesthesiol, Ctr Translat Res Neurodegenerat Dis, McKnight Brain Inst, Gainesville, FL 32611 USA.; Dore, S (corresponding author), Univ Florida, Dept Neurol, Gainesville, FL 32611 USA.; Dore, S (corresponding author), Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA.; Dore, S (corresponding author), Univ Florida, Dept Pharmaceut, Gainesville, FL 32611 USA.; Dore, S (corresponding author), Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA.	sdore@ufl.edu	Dore, Sylvain/AAG-1470-2020	Dore, Sylvain/0000-0003-3771-5109	McKnight Brain Research Institute, Brain and Spinal Cord Injury Research Trust Fund; National Natural Science Foundation of China [81503284]	McKnight Brain Research Institute, Brain and Spinal Cord Injury Research Trust Fund; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by a grant from the McKnight Brain Research Institute, Brain and Spinal Cord Injury Research Trust Fund (SD, ASA), and the National Natural Science Foundation of China (No. 81503284, GC). The funder had no role in study design, data collection and analyses, decision to publish, or preparation of the manuscript.; This work was supported by a grant from the McKnight Brain Research Institute, Brain and Spinal Cord Injury Research Trust Fund (SD, ASA), and the National Natural Science Foundation of China (No. 81503284, GC). The funder had no role in study design, data collection and analyses, decision to publish, or preparation of the manuscript.	Ahmad AS, 2014, NEUROSCIENCE, V279, P260, DOI 10.1016/j.neuroscience.2014.08.050; Ahmad AS, 2008, NEUROTOX RES, V14, P343, DOI 10.1007/BF03033858; Ahmad M, 2006, EUR J NEUROSCI, V23, P35, DOI 10.1111/j.1460-9568.2005.04540.x; Andreka G, 2007, HEART, V93, P749, DOI 10.1136/hrt.2006.114504; Baumert JH, 2009, J CARDIOTHOR VASC AN, V23, P614, DOI 10.1053/j.jvca.2009.01.028; Chen GL, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17121971; Chen GL, 2014, INDIAN J EXP BIOL, V52, P597; Cruz FF, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1645-x; Dirnagl U, 2009, BRIT J PHARMACOL, V157, P1154, DOI 10.1111/j.1476-5381.2009.00211.x; do Vale EM, 2016, BASIC CLIN PHARMACOL, V119, P562, DOI 10.1111/bcpt.12637; Frankowski JC, 2015, SCI REP-UK, V5, DOI 10.1038/srep17956; Glushakov AV, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-132; Guler L, 2014, ADV CLIN EXP MED, V23, P683, DOI 10.17219/acem/37214; Kapinya KJ, 2002, NEUROREPORT, V13, P1431, DOI 10.1097/00001756-200208070-00017; Khatibi NH, 2011, ANESTH ANALG, V113, P343, DOI 10.1213/ANE.0b013e31821f9524; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Leclerc JL, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0182-2; Lee HT, 2006, AM J PHYSIOL-RENAL, V291, pF67, DOI 10.1152/ajprenal.00412.2005; Lee JJ, 2008, ANESTHESIOLOGY, V108, P1055, DOI 10.1097/ALN.0b013e3181730257; Li J, 2016, INT J IMMUNOPATH PH, V29, P300, DOI 10.1177/0394632016638346; Liang JW, 2018, DRUG DES DEV THER, V12, P845, DOI 10.2147/DDDT.S160046; Liman S, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/380403; Liu J, 2016, AM J TRANSL RES, V8, P2597; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Mathews KS, 2001, NEUROCHEM INT, V38, P367, DOI 10.1016/S0197-0186(00)00125-X; Pi ZB, 2018, MOL MED REP, V17, P6497, DOI 10.3892/mmr.2018.8642; Qi ZF, 2012, CNS NEUROSCI THER, V18, P965, DOI 10.1111/cns.12016; Ramagiri S, 2017, BRAIN RES, V1669, P44, DOI 10.1016/j.brainres.2017.05.016; Redel A, 2009, EXP BIOL MED, V234, P1186, DOI 10.3181/0902-RM-58; Ren CC, 2009, BRAIN RES, V1288, P88, DOI 10.1016/j.brainres.2009.07.029; RIDENOUR TR, 1991, BRAIN RES, V565, P116, DOI 10.1016/0006-8993(91)91742-J; Sakai H, 2007, ANESTHESIOLOGY, V106, P92, DOI 10.1097/00000542-200701000-00017; Schlattmann P, 2010, J CEREBR BLOOD F MET, V30, P1558, DOI 10.1038/jcbfm.2010.95; Sehmidt R, 2007, ANN SURG, V245, P931, DOI 10.1097/01.sla.0000256891.45790.4d; Sloan RC, 2011, J AM ASSOC LAB ANIM, V50, P349; Sunyer B, 2007, BEHAV BRAIN RES, V181, P64, DOI 10.1016/j.bbr.2007.03.025; Toner CC, 2002, BRAIN RES, V958, P390, DOI 10.1016/S0006-8993(02)03696-X; Tsubota H, 2010, EUR J VASC ENDOVASC, V40, P804, DOI 10.1016/j.ejvs.2010.08.014; WAHL F, 1992, STROKE, V23, P267, DOI 10.1161/01.STR.23.2.267; Xiao F, 2012, NEURAL REGEN RES, V7, P833, DOI 10.3969/j.issn.1673-5374.2012.11.006; Xiong LZ, 2003, ANESTH ANALG, V96, P233, DOI 10.1097/00000539-200301000-00047; Xu DJ, 2017, MOL BRAIN, V10, DOI 10.1186/s13041-017-0323-x; Xue QS, 2004, ACTA PHARMACOL SIN, V25, P115; Zeynalov E, 2009, NEUROBIOL DIS, V35, P264, DOI 10.1016/j.nbd.2009.05.010; ZHANG L, 2017, J IMMUNOTHER CANC S2, V5; Zheng SQ, 2004, MOL PHARMACOL, V65, P1172, DOI 10.1124/mol.65.5.1172	46	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2020	15	1							e0227624	10.1371/journal.pone.0227624	http://dx.doi.org/10.1371/journal.pone.0227624			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5PQ	31945776	Green Published, gold			2023-01-03	WOS:000534370100047
J	O'Keefe, RA; Bhola, NE; Lee, DS; Johnson, DE; Grandis, JR				O'Keefe, Rachel A.; Bhola, Neil E.; Lee, David S.; Johnson, Daniel E.; Grandis, Jennifer R.			Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMA; PLUS CETUXIMAB; HEAD; CANCER; MUTATIONS; STAT3; INHIBITION; CHEMOTHERAPY; RECURRENCE; ACTIVATION	The epidermal growth factor receptor inhibitor cetuximab is the only oncogene-targeted agent that has been FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC). Currently, there are no biomarkers used in the clinic to predict which HNSCC tumors will respond to cetuximab, and even in tumors that regress with treatment, acquired resistance occurs in the majority of cases. Though a number of mechanisms of acquired resistance to cetuximab have been identified in preclinical studies, no therapies targeting these resistance pathways have yet been effectively translated into the clinic. To address this unmet need, we examined the role of the cytokine interleukin 6 (IL-6) in acquired cetuximab resistance in preclinical models of HNSCC. We found that IL-6 secretion was increased in PE/CA-PJ49 cells that had acquired resistance to cetuximab compared to the parental cells from which they were derived. However, addition of exogenous IL-6 to parental cells did not promote cetuximab resistance, and inhibition of the IL-6 pathway did not restore cetuximab sensitivity in the cetuximab-resistant cells. Further examination of the IL-6 pathway revealed that expression of IL6R, which encodes a component of the IL-6 receptor, was decreased in cetuximab-resistant cells compared to parental cells, and that treatment of the cetuximab-resistant cells with exogenous IL-6 did not induce phosphorylation of signal transducer and activator of transcription 3, suggesting that the IL-6 pathway was functionally impaired in the cetuximab-resistant cells. These findings demonstrate that, even if IL-6 is increased in the context of cetuximab resistance, it is not necessarily required for maintenance of the resistant phenotype, and that targeting the IL-6 pathway may not restore sensitivity to cetuximab in cetuximab-refractory HNSCC.	[O'Keefe, Rachel A.; Bhola, Neil E.; Lee, David S.; Johnson, Daniel E.; Grandis, Jennifer R.] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Grandis, JR (corresponding author), Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA.	jennifer.grandis@ucsf.edu		Lee, David/0000-0001-7286-325X	National Institutes of Health [R35 CA231998, R01 DE024728, F31 DE026951]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by National Institutes of Health grants R35 CA231998 (JRG), R01 DE024728 (DEJ), and F31 DE026951 (RAO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Avci AB, 2018, BIODRUGS, V32, P531, DOI 10.1007/s40259-018-0320-3; Beck TN, 2016, MOL CANCER THER, V15, P2486, DOI 10.1158/1535-7163.MCT-16-0243; Behren A, 2010, INT J ONCOL, V36, P849, DOI 10.3892/ijo_00000562; Blakely CM, 2015, CELL REP, V11, P98, DOI 10.1016/j.celrep.2015.03.012; Boeckx C, 2014, CANCER LETT, V354, P365, DOI 10.1016/j.canlet.2014.08.039; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Braig F, 2015, ONCOTARGET, V7; Bui N, 2018, MOL CANCER THER, V17, P1585, DOI 10.1158/1535-7163.MCT-17-0937; Cassell A, 2012, NEOPLASIA, V14, P1005, DOI 10.1593/neo.121212; Cassell A, 2010, EXPERT OPIN INV DRUG, V19, P709, DOI 10.1517/13543781003769844; Cerami E., 2012, CBIO CANC GENOMICS P; Chen CC, 2010, INT J RADIAT ONCOL, V76, P1214, DOI 10.1016/j.ijrobp.2009.09.059; Chen LF, 2010, CLIN CANCER RES, V16, P2489, DOI 10.1158/1078-0432.CCR-09-2318; Cheung LWT, 2011, CANCER DISCOV, V1, P170, DOI 10.1158/2159-8290.CD-11-0039; De S, 2018, CANCER RES, V78, P2396, DOI 10.1158/0008-5472.CAN-17-1920; Duffy SA, 2008, CANCER-AM CANCER SOC, V113, P750, DOI 10.1002/cncr.23615; Fisher DT, 2014, SEMIN IMMUNOL, V26, P38, DOI 10.1016/j.smim.2014.01.008; Fletcher EVM, 2013, MOL CANCER RES, V11, P1574, DOI 10.1158/1541-7786.MCR-13-0187; Gao J, 2016, ONCOL REP, V35, P3265, DOI 10.3892/or.2016.4765; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gasparian AV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002530; Hsu HC, 2016, ONCOTARGET, V7, P22257, DOI 10.18632/oncotarget.8076; Johnston PA, 2015, ASSAY DRUG DEV TECHN, V13, P356, DOI 10.1089/adt.2015.663; Johnston PA, 2011, MOL INTERV, V11, P18, DOI 10.1124/mi.11.1.4; Kennedy J, 2019, GENET MED, V21, P850, DOI 10.1038/s41436-018-0259-2; Kim HS, 2017, ONCOTARGET, V8, P100339, DOI 10.18632/oncotarget.22225; Kline CN, 2017, NEURO-ONCOLOGY, V19, P699, DOI 10.1093/neuonc/now254; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Leonard B, 2018, CANCER RES, V78, P4331, DOI 10.1158/0008-5472.CAN-18-0459; Li H, 2014, MOL CANCER RES, V12, P571, DOI 10.1158/1541-7786.MCR-13-0396; Licitra L, 2011, ANN ONCOL, V22, P1078, DOI 10.1093/annonc/mdq588; Licitra L, 2013, EUR J CANCER, V49, P1161, DOI 10.1016/j.ejca.2012.11.018; Loupakis F, 2009, BRIT J CANCER, V101, P715, DOI 10.1038/sj.bjc.6605177; Luedke E, 2012, SURGERY, V152, P431, DOI 10.1016/j.surg.2012.05.035; Lv DG, 2017, CANCER RES, V77, P6190, DOI 10.1158/0008-5472.CAN-17-1388; Mehra Ranee, 2008, Clin Adv Hematol Oncol, V6, P742; Mihara M, 2012, CLIN SCI, V122, P143, DOI 10.1042/CS20110340; Pan C, 2019, CANC HEAD NECK, V4, P1; Pollock NI, 2015, CLIN CANCER RES, V21, P526, DOI 10.1158/1078-0432.CCR-14-1432; Rampias T, 2014, CLIN CANCER RES, V20, P2933, DOI 10.1158/1078-0432.CCR-13-2721; Rebucci M, 2011, INT J ONCOL, V38, P189, DOI 10.3892/ijo_00000838; Sen M, 2012, CLIN CANCER RES, V18, P4986, DOI 10.1158/1078-0432.CCR-12-0792; Sriuranpong V, 2003, CANCER RES, V63, P2948; Stabile LP, 2017, ORAL ONCOL, V69, P38, DOI 10.1016/j.oraloncology.2017.03.011; Stanam A, 2015, MOL ONCOL; Stein-O'Brien G, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0545-2; Tanaka T, 2014, CANCER IMMUNOL RES, V2, P288, DOI 10.1158/2326-6066.CIR-14-0022; Verboogen DRJ, 2019, J MOL CELL BIOL, V11, P144, DOI 10.1093/jmcb/mjy038; Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656; Wang Z., 2014, JNCI-J NATL CANCER I, V106, P1; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734	53	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2020	15	1							e0227261	10.1371/journal.pone.0227261	http://dx.doi.org/10.1371/journal.pone.0227261			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5DK	31914141	gold, Green Published, Green Submitted			2023-01-03	WOS:000534337700034
J	Hsu, CC; Huang, CC; Chang, YC; Chen, JS; Tsai, WC; Wang, KY				Hsu, Chu-Chun; Huang, Chiu-Ching; Chang, Yue-Cune; Chen, Jin-Shuen; Tsai, Wen-Chen; Wang, Kwua-Yun			A comparison of quality of life between patients treated with different dialysis modalities in Taiwan	PLOS ONE			English	Article							PERITONEAL-DIALYSIS; HEMODIALYSIS	Purpose This study compared the quality of life (QOL) of hemodialysis (HD) and peritoneal dialysis (PD) patients in Taiwan. Methods This cross-sectional study recruited end-stage renal disease patients from 34 Taiwanese hospitals or clinics. Patient characteristics, diagnoses, and laboratory data were extracted from charts. The Chinese version of the Quality of Life Index-Dialysis version (QLI-D) was used. Multiple linear regression analysis showed the effects of dialysis modality on QOL. P< 0.05 indicated statistical significance. Results In total, 600 HD and 387 PD patients were included. The mean health and functioning, social and economic, psychological/spiritual, and family subscale scores and total QOL scores were significantly lower in HD patients than PD patients. After adjusting for region, hospital level, age, education level, marital status, and Karnofsky Performance Scale, the total QOL was 2.81 points higher for PD patients than for HD patients visiting medical centers (p < 0.001). The total QOL was 2.53 points lower in PD patients than in HD patients for those visiting clinics. Conclusion Compared to HD patients, PD patients had better QOL in Taiwanese medical centers. The current survey improves our understanding of the QOL of patients undergoing different dialysis modalities in Taiwan.	[Hsu, Chu-Chun] Triserv Gen Hosp, Dept Nursing, Taipei, Taiwan; [Hsu, Chu-Chun; Wang, Kwua-Yun] Natl Def Med Ctr, Sch Nursing, Taipei, Taiwan; [Huang, Chiu-Ching] China Med Univ & Hosp, Dept Internal Med, Div Nephrol, Taichung, Taiwan; [Huang, Chiu-Ching] China Med Univ & Hosp, Kidney Inst, Taichung, Taiwan; [Huang, Chiu-Ching] China Med Univ, Coll Med, Taichung, Taiwan; [Chang, Yue-Cune] Tamkang Univ, Dept Math, New Taipei, Taiwan; [Chen, Jin-Shuen] Triserv Gen Hosp, Div Nephrol, Dept Internal Med, Taipei, Taiwan; [Chen, Jin-Shuen] Natl Def Med Ctr, Taipei, Taiwan; [Tsai, Wen-Chen] China Med Univ, Dept Hlth Serv Adm, Taichung, Taiwan; [Wang, Kwua-Yun] Taipei Vet Gen Hosp, Dept Nursing, Taipei, Taiwan	Tri-Service General Hospital; National Defense Medical Center; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Tamkang University; Tri-Service General Hospital; National Defense Medical Center; China Medical University Taiwan; Taipei Veterans General Hospital	Wang, KY (corresponding author), Natl Def Med Ctr, Sch Nursing, Taipei, Taiwan.; Wang, KY (corresponding author), Taipei Vet Gen Hosp, Dept Nursing, Taipei, Taiwan.	w6688@mail.ndmctsgh.edu.tw	; Tsai, Wen-Chen/O-3095-2015	Chang, Yue-Cune/0000-0002-0224-1268; Hsu, Chu-Chun/0000-0002-4988-9774; Tsai, Wen-Chen/0000-0002-9684-0789	Health Promotion Administration, Ministry of Health and Welfare [DOH100-HP-1104]	Health Promotion Administration, Ministry of Health and Welfare	This study was supported by Health Promotion Administration, Ministry of Health and Welfare (DOH100-HP-1104). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ayoub AM, 2013, J FAM COMMUNITY MED, V20, P106, DOI 10.4103/2230-8229.114772; Diaz-Buxo JA, 2000, AM J KIDNEY DIS, V35, P293, DOI 10.1016/S0272-6386(00)70339-8; FERRANS CE, 1985, ADV NURS SCI, V8, P15, DOI 10.1097/00012272-198510000-00005; Griva K, 2014, QUAL LIFE RES, V23, P57, DOI 10.1007/s11136-013-0431-8; Huang CC, 2008, PERITON DIALYSIS INT, V28, pS15; Jankowska-Polanska B, 2017, EUR J PUBLIC HEALTH, V27, P262, DOI 10.1093/eurpub/ckw193; Karnofsky DA, 1949, CLIN EVALUATION CHEM, P191; Korevaar JC, 2003, KIDNEY INT, V64, P2222, DOI 10.1046/j.1523-1755.2003.00321.x; Kring Daria L, 2009, Nephrol Nurs J, V36, P15; Little J, 2001, AM J KIDNEY DIS, V37, P981, DOI 10.1016/S0272-6386(05)80014-9; Mau LW, 2008, KAOHSIUNG J MED SCI, V24, P453, DOI 10.1016/S1607-551X(09)70002-6; Noshad H, 2009, SINGAP MED J, V50, P185; Oren B, 2013, INT J NURS PRACT, V19, P547, DOI 10.1111/ijn.12098; Peng YS, 2011, QUAL LIFE RES, V20, P399, DOI 10.1007/s11136-010-9755-9; Fructuoso MR, 2011, NEFROLOGIA, V31, P91, DOI 10.3265/Nefrologia.pre2010.Jul.10483; US Renal Data System, 2011, USRDS 2010 ANN DAT R; Wasserfallen JB, 2004, NEPHROL DIAL TRANSPL, V19, P1594, DOI 10.1093/ndt/gfh175; Weinhandl ED, 2010, J AM SOC NEPHROL, V21, P499, DOI 10.1681/ASN.2009060635; Wu AW, 2004, J AM SOC NEPHROL, V15, P743, DOI 10.1097/01.ASN.0000113315.81448.CA	19	11	11	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2020	15	1							e0227297	10.1371/journal.pone.0227297	http://dx.doi.org/10.1371/journal.pone.0227297			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP4ZR	31907493	Green Published, gold			2023-01-03	WOS:000534327700020
J	Geiger, F; Rudiger, D; Zahler, S; Engelke, H				Geiger, Florian; Ruediger, Daniel; Zahler, Stefan; Engelke, Hanna			Fiber stiffness, pore size and adhesion control migratory phenotype of MDA-MB-231 cells in collagen gels	PLOS ONE			English	Article							MODES; IMAGE; CONTRACTILITY; MECHANICS; INVASION; RESPOND	Cancer cell migration is influenced by cellular phenotype and behavior as well as by the mechanical and chemical properties of the environment. Furthermore, many cancer cells show plasticity of their phenotype and adapt it to the properties of the environment. Here, we study the influence of fiber stiffness, confinement, and adhesion properties on cancer cell migration in porous collagen gels. Collagen gels with soft fibers abrogate migration and promote a round, non-invasive phenotype. Stiffer collagen fibers are inherently more adhesive and lead to the existence of an adhesive phenotype and in general confined migration due to adhesion. Addition of TGF-beta lowers adhesion, eliminates the adhesive phenotype and increases the amount of highly motile amoeboid phenotypes. Highest migration speeds and longest displacements are achieved in stiff collagen fibers in pores of about cell size by amoeboid phenotypes. This elucidates the influence of the mechanical properties of collagen gels on phenotype and subsequently migration and shows that stiff fibers, cell sized pores, and low adhesion, are optimal conditions for an amoeboid phenotype and efficient migration.	[Geiger, Florian; Engelke, Hanna] Ludwig Maximilians Univ Munchen, Dept Chem, Munich, Germany; [Geiger, Florian; Engelke, Hanna] Ludwig Maximilians Univ Munchen, Ctr NanoSci, Munich, Germany; [Ruediger, Daniel; Zahler, Stefan] Ludwig Maximilians Univ Munchen, Dept Pharm, Munich, Germany	University of Munich; University of Munich; University of Munich	Engelke, H (corresponding author), Ludwig Maximilians Univ Munchen, Dept Chem, Munich, Germany.; Engelke, H (corresponding author), Ludwig Maximilians Univ Munchen, Ctr NanoSci, Munich, Germany.	hanna.engelke@cup.uni-muenchen.de		Engelke, Hanna/0000-0001-9529-9436	Deutsche Forschungsgemeinschaft [SFB1032]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors gratefully acknowledge funding from the Deutsche Forschungsgemeinschaft (SFB1032, project B08 to SZ and B11 to HE).	Anguiano M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171417; Bergert M, 2012, P NATL ACAD SCI USA, V109, P14434, DOI 10.1073/pnas.1207968109; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Broda E, 2018, ADV BIOSYST, V2, DOI 10.1002/adbi.201800083; Burov S, 2013, P NATL ACAD SCI USA, V110, P19689, DOI 10.1073/pnas.1319473110; Caswell PT, 2018, TRENDS CELL BIOL, V28, P823, DOI 10.1016/j.tcb.2018.06.003; Charras G, 2014, NAT REV MOL CELL BIO, V15, P813, DOI 10.1038/nrm3897; Condor M, 2019, BIOPHYS J, V116, P1305, DOI 10.1016/j.bpj.2019.02.029; Dietrich M, 2018, SOFT MATTER, V14, P2816, DOI 10.1039/c8sm00018b; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Doube M, 2010, BONE, V47, P1076, DOI 10.1016/j.bone.2010.08.023; Doyle AD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9720; Harley BAC, 2008, BIOPHYS J, V95, P4013, DOI 10.1529/biophysj.107.122598; Hawkins RJ, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.058103; Holle AW, 2019, NANO LETT, V19, P2280, DOI 10.1021/acs.nanolett.8b04720; Kick K, 2016, ARTERIOSCL THROM VAS, V36, P2346, DOI 10.1161/ATVBAHA.116.307870; Lammermann T, 2008, NATURE, V453, P51, DOI 10.1038/nature06887; Lammermann T, 2009, CURR OPIN CELL BIOL, V21, P636, DOI 10.1016/j.ceb.2009.05.003; Lampi MC, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao0475; Licup AJ, 2015, P NATL ACAD SCI USA, V112, P9573, DOI 10.1073/pnas.1504258112; Liu YJ, 2015, CELL, V160, P659, DOI 10.1016/j.cell.2015.01.007; Malawista SE, 2000, CELL MOTIL CYTOSKEL, V46, P183, DOI 10.1002/1097-0169(200007)46:3<183::AID-CM3>3.3.CO;2-U; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Poincloux R, 2011, P NATL ACAD SCI USA, V108, P1943, DOI 10.1073/pnas.1010396108; Provenzano PP, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-38; Renkawitz J, 2009, NAT CELL BIOL, V11, P1438, DOI 10.1038/ncb1992; Ruprecht V, 2017, J CELL SCI, V130, P51, DOI 10.1242/jcs.196162; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Sauer F, 2019, SOFT MATTER, V15, P3055, DOI 10.1039/c8sm02264j; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Talkenberger K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09300-3; Tozluoglu M, 2013, NAT CELL BIOL, V15, P751, DOI 10.1038/ncb2775; Vader D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005902; Wisdom KM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06641-z; Wolf K, PHYS LIMITS CELL MIG; Wolf K, 2009, SEMIN CELL DEV BIOL, V20, P931, DOI 10.1016/j.semcdb.2009.08.005; Wu PH, 2018, ANNU REV BIOPHYS, V47, P549, DOI 10.1146/annurev-biophys-070816-033854; Wu PH, 2014, P NATL ACAD SCI USA, V111, P3949, DOI 10.1073/pnas.1318967111	40	12	13	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2019	14	11							e0225215	10.1371/journal.pone.0225215	http://dx.doi.org/10.1371/journal.pone.0225215			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN1QS	31721794	Green Published, gold			2023-01-03	WOS:000532720700045
J	Dubois, J; Bill, AS; Pasquier, J; Keberle, S; Burnand, B; Rodondi, PY				Dubois, Julie; Bill, Anne-Sylvie; Pasquier, Jerome; Keberle, Silva; Burnand, Bernard; Rodondi, Pierre-Yves			Characteristics of complementary medicine therapists in Switzerland: A cross-sectional study	PLOS ONE			English	Article							WESTERN HERBAL MEDICINE; ACUPUNCTURE; PRACTITIONERS; STATE; NATUROPATHY; AUSTRALIA; WORKFORCE; PROFILE	Objective More than 27,000 complementary medicine (CM) therapists are registered in Switzerland, but limited data are available on their occupational profile and role in the healthcare system. Herein we aimed to gain a better understanding of the professional profile of non-physician licensed therapists, focusing on acupuncture, osteopathy, and European naturopathy. Design This cross-sectional study was based on an online anonymous survey conducted from March to June 2017. Setting and participants All 1549 non-physician registered osteopaths, acupuncturists, and naturopaths in the French-speaking part of Switzerland were asked to complete the survey. Main outcome measures We measured the therapists' demographics, training and practice characteristics, and workload. Results A total of 426 therapists returned the questionnaire (response rate: 27.5%). The mean age of the respondents was 46.0 years (SD 11.6) and most were women (67.8%). CM represented the main professional activity for a majority of therapists (82.8%), most of whom were independent (86.3%). The length and number of consultations per month varied across professions. Multivariate analysis showed that acupuncturists and naturopaths performed significantly fewer consults per month than osteopaths did. However, consultation length was significantly longer for acupuncturists and naturopaths than for osteopaths. Acupuncturists (71.6%) and naturopaths (64.4%) were significantly more favorable than osteopaths (27.7%) to have consultation costs covered by basic health insurance. Professional profiles differed between osteopaths, on the one hand, and naturopaths and acupuncturists, on the other, mainly regarding workload, treatment duration, and main reasons to consult. Conclusions This first study to investigate a variety of therapist profiles in Switzerland provides useful information about their activities and role within the Swiss healthcare system. Although all three professions are encompassed under the same umbrella term (CM), our study showed that they have specific work cultures and areas of intervention in the healthcare system.	[Dubois, Julie; Bill, Anne-Sylvie; Pasquier, Jerome; Burnand, Bernard; Rodondi, Pierre-Yves] Univ Lausanne, Ctr Primary Care & Publ Hlth Unisante, Lausanne, Switzerland; [Dubois, Julie; Bill, Anne-Sylvie; Rodondi, Pierre-Yves] Univ Fribourg, Inst Family Med, Fribourg, Switzerland; [Keberle, Silva] Empir Med Register, Basel, Switzerland	University of Lausanne; University of Fribourg	Dubois, J (corresponding author), Univ Lausanne, Ctr Primary Care & Publ Hlth Unisante, Lausanne, Switzerland.; Dubois, J (corresponding author), Univ Fribourg, Inst Family Med, Fribourg, Switzerland.	Julie.dubois@unisante.ch	Rodondi, Pierre-Yves/AAU-3708-2020	Rodondi, Pierre-Yves/0000-0003-2007-2995; Pasquier, Jerome/0000-0002-5554-2988; Dubois, Julie/0000-0001-9241-0231; Burnand, Bernard/0000-0002-5678-6044				Adams J, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3158-y; Bustins GA, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2190-0; Baer HA, 2006, SOC SCI MED, V63, P1771, DOI 10.1016/j.socscimed.2006.04.021; Bensoussan A, 2004, COMPLEMENT THER MED, V12, P17, DOI 10.1016/j.ctim.2004.01.001; Burke SR, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-227; Chen L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1284; Cherkin Daniel C, 2002, J Am Board Fam Pract, V15, P378; Cherkin Daniel C, 2002, J Am Board Fam Pract, V15, P463; Clarke TC, 2015, NATL HLTH STAT REPOR, P1; Cottingham P, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0616-5; Eardley S, 2012, FORSCH KOMPLEMENTMED, V19, P18, DOI 10.1159/000342708; Fawkes CA, 2014, MANUAL THER, V19, P125, DOI 10.1016/j.math.2013.09.001; Floden L, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0659-7; Goetz K, 2017, EUR J INTEGR MED, V11, P41, DOI 10.1016/j.eujim.2017.04.001; Hopton AK, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000456; Hostettler S, 2018, B MED SUISSES, V99, P408; Humphreys BK, 2010, J MANIP PHYSIOL THER, V33, P519, DOI 10.1016/j.jmpt.2010.08.003; Klein SD, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0141985, 10.1371/journal.pone.0144676]; KPMG, 2011, KPMG DAT SURV DO OST; Lin V, 2009, RISK MANAG HEALTHC P, V2, P21, DOI 10.2147/RMHP.S4652; Lorenc A, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020222; Moore A, 2016, J ALTERN COMPLEM MED, V22, P515, DOI 10.1089/acm.2015.0260; Morin C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106259; Myers SP, 2019, J ALTERN COMPLEM MED, V25, P141, DOI 10.1089/acm.2018.0340; Oberg Erica, 2015, ALTERNATIVE INTEGR M, V24, P192, DOI [10.4172/2327-5162.1000192, DOI 10.4172/2327-5162.1000192]; Orrock P, 2009, INT J OSTEOPATH MED, V12, P14, DOI 10.1016/j.ijosm.2008.04.002; Orrock PJ, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-129; Robinson N, 2012, J ETHNOPHARMACOL, V140, P604, DOI 10.1016/j.jep.2012.01.052; Schwarz Ilke, 2007, Chiropr Osteopat, V15, P6, DOI 10.1186/1746-1340-15-6; Sherman KJ, 2005, ANN FAM MED, V3, P151, DOI 10.1370/afm.248; Steel A, 2018, J ALTERN COMPLEM MED, V24, P385, DOI 10.1089/acm.2017.0206; Steel A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35508-y; van Dun PLS, 2016, INT J OSTEOPATH MED, V20, P3, DOI 10.1016/j.ijosm.2016.01.003; Vaucher P, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023770; Vickers AJ, 2014, JAMA-J AM MED ASSOC, V311, P955, DOI 10.1001/jama.2013.285478; von Ammon K, 2012, FORSCH KOMPLEMENTMED, V19, P37, DOI 10.1159/000343129; Wardle J, 2011, AUST J RURAL HEALTH, V19, P197, DOI 10.1111/j.1440-1584.2011.01200.x; Wardle Jonathan L, 2015, Int J Ther Massage Bodywork, V8, P2	38	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2019	14	10							e0224098	10.1371/journal.pone.0224098	http://dx.doi.org/10.1371/journal.pone.0224098			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM9XB	31644559	Green Published, gold			2023-01-03	WOS:000532599700044
J	Ghazy, NA; Suzuki, T				Ghazy, Noureldin A.; Suzuki, Takeshi			Oral delivery of water-soluble compounds to the phytoseiid mite Neoseiulus californicus (Acari: Phytoseiidae)	PLOS ONE			English	Article							2-SPOTTED SPIDER-MITES; BIOLOGICAL-CONTROL; LIFE-STYLES	Phytoseiids are predatory mites that prey on other mites and small arthropods, and several species are used in commercial agriculture for biological control of pests. To optimize phytoseiid mites' use in biocontrol, an efficient method for oral delivery of test compounds is required to assess their sensitivities to pesticides, RNAi for gene functional analysis and artificial diets. Here we developed four methods for oral delivery of a solution of xenobiotics to different life stages of the commercially available generalist predatory mite Neoseiulus californicus: (i) soaking mites in the solution, or allowing them to feed on (ii) spider mites soaked in the solution, (iii) a solution droplet, or (iv) solution-saturated filter paper. As measured by ingestion of a tracer dye, the droplet-based feeding system was most efficient; the dye was observed in the alimentary canal of > 90% test mites of all life stages, with no mortality. The droplet-based feeding system was also effective for the commercially available specialist predatory mite Phytoseiulus persimilis, with > 80% delivery efficiency. This study paves the way for development of methods for high-throughput RNAi and for toxicological or nutritional assays in phytoseiid mites.	[Ghazy, Noureldin A.; Suzuki, Takeshi] Tokyo Univ Agr & Technol, Grad Sch Bioapplicat & Syst Engn, Koganei, Tokyo, Japan; [Ghazy, Noureldin A.] Mansoura Univ, Fac Agr, Agr Zool Dept, Mansoura, Egypt; [Ghazy, Noureldin A.] Japan Soc Promot Sci, Chiyoda Ku, Tokyo, Japan	Tokyo University of Agriculture & Technology; Egyptian Knowledge Bank (EKB); Mansoura University; Japan Society for the Promotion of Science	Ghazy, NA; Suzuki, T (corresponding author), Tokyo Univ Agr & Technol, Grad Sch Bioapplicat & Syst Engn, Koganei, Tokyo, Japan.; Ghazy, NA (corresponding author), Mansoura Univ, Fac Agr, Agr Zool Dept, Mansoura, Egypt.; Ghazy, NA (corresponding author), Japan Soc Promot Sci, Chiyoda Ku, Tokyo, Japan.	noureldinghazy@mans.edu.eg; tszk@cc.tuat.ac.jp	Suzuki, Takeshi/F-7548-2012; Ghazy, Noureldin Abuelfadl Noureldin/G-8649-2017	Suzuki, Takeshi/0000-0002-7930-1425; Ghazy, Noureldin Abuelfadl Noureldin/0000-0001-5911-086X	JSPS KAKENHI [16K18661, 18H02203]; JSPS Invitational Fellowships for Research in Japan	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); JSPS Invitational Fellowships for Research in Japan	This study was supported by JSPS KAKENHI Grant Numbers 16K18661 and 18H02203 to TS. NAG was supported by JSPS Invitational Fellowships for Research in Japan. https://www.jsps.go.jp/english/.	[Anonymous], R LANG ENV STAT COMP; Castagnoli Marisa, 2003, Redia, V86, P153; Chittenden AR, 2001, J ETHOL, V19, P55, DOI 10.1007/s101640170018; Fraulo AB, 2007, EXP APPL ACAROL, V43, P109, DOI 10.1007/s10493-007-9109-7; Gerson U, 2007, PEST MANAG SCI, V63, P658, DOI 10.1002/ps.1380; HAMLEN RA, 1981, ENVIRON ENTOMOL, V10, P524, DOI 10.1093/ee/10.4.524; Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55; Kola VSR, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00119; McMurtry JA, 1997, ANNU REV ENTOMOL, V42, P291, DOI 10.1146/annurev.ento.42.1.291; Mcmurtry JA, 2013, SYST APPL ACAROL-UK, V18, P297, DOI 10.11158/saa.18.4.1; Ozawa R, 2012, MOL ECOL, V21, P5624, DOI 10.1111/mec.12052; Rhodes EM, 2006, J ECON ENTOMOL, V99, P1291, DOI 10.1603/0022-0493-99.4.1291; Sabelis M.W., 1985, P35; Sun D, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00608; Suzuki T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190025; van Lenteren JC, 2012, BIOCONTROL, V57, P1, DOI 10.1007/s10526-011-9395-1; Wu K, 2014, EXP APPL ACAROL, V63, P171, DOI 10.1007/s10493-014-9772-4; Yu N, 2013, INSECT SCI, V20, P4, DOI 10.1111/j.1744-7917.2012.01534.x	18	1	1	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2019	14	10							e0223929	10.1371/journal.pone.0223929	http://dx.doi.org/10.1371/journal.pone.0223929			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM9KK	31618257	Green Published, gold			2023-01-03	WOS:000532566600058
J	Gorodeski, EZ; Magnelli-Reyes, C; Moennich, LA; Grimaldi, A; Rickard, J				Gorodeski, Eiran Z.; Magnelli-Reyes, Christina; Moennich, Laurie Ann; Grimaldi, Adam; Rickard, John			Cardiac resynchronization therapy-heart failure (CRT-HF) clinic: A novel model of care	PLOS ONE			English	Article							TASK-FORCE; MINI-COG; GUIDELINES; MANAGEMENT; EXERCISE; DEMENTIA; SOCIETY	Background Post-implant care of patients with heart failure (HF) undergoing cardiac resynchronization therapy (CRT) is not addressed in current HF or CRT guidelines and is often fragmented with poor communication between specialties. We sought to develop a new model of postCRT care which could be implemented in busy clinical settings. Methods and results We designed a novel, multidisciplinary approach to standardizing post CRT care. All patients receiving a CRT device at the Cleveland Clinic between March 2017 and August 2018 were invited to be seen in the clinic 6 months post implant. A one-time collaborative visit encompassing cardiac imaging, heart failure, and electrophysiology care was performed. We recorded the operational feasibility of the clinic in terms of patient throughput as well as patient characteristics, interventions, and new diagnoses made. Between September 2017 and February 2019, 150 patients were seen in the clinic. Of these, 125 patients had their index CRT implanted for standard indications and were included in the current analysis. Approximately 45 minutes were dedicated for each patient visit. Interventions in care were made in 95% of patients, with CRT non-responders offered a higher number of interventions as compared to responders (median 3 versus 2 interventions). Types of interventions were device-related (26% of population), medication-related (74%), and referral for alternate medical services (80%). Conclusions Multidisciplinary post-implant care of patients with HF receiving CRT devices, regardless of CRT response status, is feasible and results in frequent medical interventions.	[Gorodeski, Eiran Z.] Cleveland Clin, Dept Cardiovasc Med, Sect Heart Failure & Cardiac Transplantat, Heart & Vasc Inst, Cleveland, OH 44106 USA; [Magnelli-Reyes, Christina; Grimaldi, Adam; Rickard, John] Cleveland Clin, Dept Cardiovasc Med, Sect Cardiac Pacing & Electrophysiol, Heart & Vasc Inst, Cleveland, OH 44106 USA; [Moennich, Laurie Ann] Cleveland Clin, Heart & Vasc Inst, Heart & Vasc Res, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Rickard, J (corresponding author), Cleveland Clin, Dept Cardiovasc Med, Sect Cardiac Pacing & Electrophysiol, Heart & Vasc Inst, Cleveland, OH 44106 USA.	rickardj2@ccf.org		Moennich, Laurie Ann/0000-0002-1070-340X	Abbott	Abbott(Abbott Laboratories)	EZG and JR have received unrestricted research grant funding from Abbott to support the CRT-HF clinic research infrastructure.	Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Altman RK, 2012, EUR HEART J, V33, P2181, DOI 10.1093/eurheartj/ehs107; Arslan S, 2007, TEX HEART I J, V34, P166; Borson S, 2003, J AM GERIATR SOC, V51, P1451, DOI 10.1046/j.1532-5415.2003.51465.x; Borson S, 2000, INT J GERIATR PSYCH, V15, P1021, DOI 10.1002/1099-1166(200011)15:11<1021::AID-GPS234>3.0.CO;2-6; Brignole M, 2013, EUR HEART J, V34, P2281, DOI 10.1093/eurheartj/eht150; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; Drey M, 2011, GERONTOLOGY, V57, P11, DOI 10.1159/000313433; Kubala Maciej, 2017, JACC Clin Electrophysiol, V3, P1523, DOI 10.1016/j.jacep.2017.06.012; Maass AH, 2018, EUROPACE, V20, pE1, DOI 10.1093/europace/euw445; Maass AH, 2009, J CARDIOVASC ELECTR, V20, P773, DOI 10.1111/j.1540-8167.2008.01422.x; Mentz RJ, 2018, J AM COLL CARDIOL, V72, P41, DOI 10.1016/j.jacc.2018.04.038; Moss AJ, 2009, NEW ENGL J MED, V361, P1329, DOI 10.1056/NEJMoa0906431; Mullens W, 2009, J AM COLL CARDIOL, V53, P765, DOI 10.1016/j.jacc.2008.11.024; Parkash R, 2013, CAN J CARDIOL, V29, P1346, DOI 10.1016/j.cjca.2013.09.009; Patwala AY, 2009, J AM COLL CARDIOL, V53, P2332, DOI 10.1016/j.jacc.2009.02.063; Rickard J, 2010, HEART RHYTHM, V7, P885, DOI 10.1016/j.hrthm.2010.04.005; Tang ASL, 2010, NEW ENGL J MED, V363, P2385, DOI 10.1056/NEJMoa1009540; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019	19	12	12	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2019	14	9							e0222610	10.1371/journal.pone.0222610	http://dx.doi.org/10.1371/journal.pone.0222610			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM5BF	31536565	Green Published, gold, Green Submitted			2023-01-03	WOS:000532262800063
J	Cheng, MT; Shih, FY; Tsai, CL; Tsai, HB; Tsai, DFC; Fang, CC				Cheng, Ming-Tai; Shih, Fuh-Yuan; Tsai, Chu-Lin; Tsai, Hung-Bin; Tsai, Daniel Fu-Chang; Fang, Cheng-Chung			Impact of major illnesses and geographic regions on do-not-resuscitate rate and its potential cost savings in Taiwan	PLOS ONE			English	Article							END-OF-LIFE; PALLIATIVE MEDICINE; CARE; HEALTH; CANCER; DECISION; DNR	Background/Purpose Do-not-resuscitate (DNR) is a legal order that demonstrates a patient's will to avoid further suffering from advanced treatment at the end of life. The concept of palliative care is increasingly accepted, but the impacts of different major illnesses, geographic regions, and health expenses on DNR rates remain unclear. Methods This study utilized the two-million National Health Insurance (NHI) Research Database to examine the percentage of DNR rates among all deaths in hospitals from 2001 to 2011. DNR in the study was defined as no resuscitation before death in hospitals. Death records were extracted from the database and correlated with healthcare information. Descriptive statistics were compiled to examine the relationships between DNR rates and variables including major illnesses, geographic regions, and NHI spending. Results A total of 126,390 death records were extracted from the database for analysis. Among cancer-related deaths, pancreatic cancer patients had the highest DNR rate (86.99%) and esophageal cancer patients had the lowest DNR rate (71.62%). The higher DNR rate among cancer-only patients (79.53%) decreased with concomitant dialysis (66.07%) or ventilator use (57.85%). The lower DNR rates in patients with either chronic dialysis (51.27%) or ventilator use (59.10%) increased when patients experienced these two conditions concomitantly (61.31%). Although DNR rates have consistently increased over time across all regions of Taiwan, a persistent disparity was noted between the East and the South (76.89% vs. 70.78% in 2011, p < 0.01). After adjusting for potential confounders, DNR patients had significantly lower NHI spending one year prior to death ($67,553), compared with non-DNR patients. Conclusion Our study found that DNR rates varied across cancer types and decreased in cancer patients with concomitant chronic dialysis or ventilator use. Disparities in DNR rates were evident across geographic regions in Taiwan. A wider adoption of the DNR policy may achieve substantial savings in health expenses and improve patients' quality of life.	[Cheng, Ming-Tai; Shih, Fuh-Yuan; Tsai, Chu-Lin; Fang, Cheng-Chung] Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan; [Tsai, Hung-Bin] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan; [Tsai, Daniel Fu-Chang] Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan; [Tsai, Daniel Fu-Chang] Natl Taiwan Univ, Coll Med, Grad Inst Med Educ & Bioeth, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Fang, CC (corresponding author), Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan.	conrad@ntu.edu.tw		TSAI, CHU-LIN/0000-0003-4639-1513; SHIH, FUH-YUAN/0000-0002-7755-0110; FANG, CHENG-CHUNG/0000-0001-5386-6674; CHENG, MING-TAI/0000-0003-2781-340X	Mrs. Hsiu-Chin Lee Kidney Research Fund; Department of Medical Research in National Taiwan University Hospital	Mrs. Hsiu-Chin Lee Kidney Research Fund; Department of Medical Research in National Taiwan University Hospital	This study was supported by grants from the Mrs. Hsiu-Chin Lee Kidney Research Fund, andin part by the Department of Medical Research in National Taiwan University Hospital.; This study was supported by grants from the Mrs. Hsiu-Chin Lee Kidney Research Fund and in part by the Department of Medical Research in National Taiwan University Hospital.	Ahmad Akhwand S, 2016, Sultan Qaboos Univ Med J, V16, pe27, DOI 10.18295/squmj.2016.16.01.006; Celso BG, 2010, AM J HOSP PALLIAT ME, V27, P398, DOI 10.1177/1049909110363806; Cheng MT, 2016, INTENS CARE MED, V42, P1816, DOI 10.1007/s00134-016-4509-y; Ganz FD, 2006, J MED ETHICS, V32, P196, DOI 10.1136/jme.2005.012542; Juang I.-F., 2015, JTCCT, V24, P1; Keam B, 2008, JPN J CLIN ONCOL, V38, P381, DOI 10.1093/jjco/hyn031; Kizawa Y, 2013, AM J HOSP PALLIAT ME, V30, P664, DOI 10.1177/1049909112462860; Levin Tomer T, 2008, Palliat Support Care, V6, P341, DOI 10.1017/S1478951508000540; Middlewood S, 2001, J PAIN SYMPTOM MANAG, V22, P1035, DOI 10.1016/S0885-3924(01)00362-1; Morrison RS, 2008, ARCH INTERN MED, V168, P1783, DOI 10.1001/archinte.168.16.1783; Mun E., 2016, PERM J, V20, P56, DOI DOI 10.7812/TPP/16-036; Oh DY, 2006, SUPPORT CARE CANCER, V14, P103, DOI 10.1007/s00520-005-0885-5; Phua J, 2011, J PALLIAT MED, V14, P1296, DOI 10.1089/jpm.2011.0215; Pinderhughes ST, 2018, J PALLIAT MED, V21, P1272, DOI 10.1089/jpm.2017.0375; Wen CP, 2008, ANN INTERN MED, V148, P258, DOI 10.7326/0003-4819-148-4-200802190-00004; Zhang BH, 2009, ARCH INTERN MED, V169, P480, DOI 10.1001/archinternmed.2008.587	16	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2019	14	9							e0222320	10.1371/journal.pone.0222320	http://dx.doi.org/10.1371/journal.pone.0222320			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM4IG	31513648	Green Submitted, gold, Green Published			2023-01-03	WOS:000532212700053
J	Tornbom, K; Lundalv, J; Palstam, A; Sunnerhagen, KS				Tornbom, Karin; Lundalv, Jorgen; Palstam, Annie; Sunnerhagen, Katharina S.			"My life after stroke through a camera lens" - A photovoice study on participation in Sweden	PLOS ONE			English	Article							EXPERIENCE; NEEDS; UNDERSTAND; SURVIVORS; BODY	Background An increasing number of people with stroke live in their communities, yet the understanding of how their reintegration into society can best be facilitated is incomplete. If needs are not sufficiently met and difficulties overcome, it may result in limited participation and decreased life satisfaction for this group. We aimed to understand life after stroke through the lens of participants' cameras, and hence their views and experiences guided this study. Methods By the means of photovoice, an action research method, this study was conducted in a collaborative format with six women and five men after stroke. Participants photographed in everyday life for up to four weeks and then met to discuss all images in a focus group setting. Subsequently, participants gave feedback on the method and discussed the upcoming photography exhibition. All photos and the three focus group discussions were analyzed using a thematic analysis with an inductive approach. Results In the focus group discussions, life after stroke were conceptualized through five main themes: a driving force to participate in society; managing everyday life through inventiveness and persistent training; insufficient healthcare and rehabilitation in the long-term perspective; finding meaningful relationships and activities in daily life. Participants' voices are made clear through selected photos, which aim to present each theme and make results easier to understand. Conclusions Participants found new ways to approach everyday life situations and had thereby regained a sense of control in life. However, it was evident that psychological processes towards adaptation were hindered by depression and that some individuals felt alone in an ongoing struggle. Additionally, available interventions a long time after stroke were not flexible enough to address all participants' needs.	[Tornbom, Karin; Palstam, Annie; Sunnerhagen, Katharina S.] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Res Grp Rehabil Med,Sect Clin Neurosci, Gothenburg, Sweden; [Tornbom, Karin; Sunnerhagen, Katharina S.] Univ Gothenburg, Ctr Person Centred Care GPCC, Gothenburg, Sweden; [Lundalv, Jorgen] Univ Gothenburg, Dept Social Work, Gothenburg, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg	Tornbom, K (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Res Grp Rehabil Med,Sect Clin Neurosci, Gothenburg, Sweden.; Tornbom, K (corresponding author), Univ Gothenburg, Ctr Person Centred Care GPCC, Gothenburg, Sweden.	karin.tornbom@neuro.gu.se	Sunnerhagen, Katharina Stibrant/AAE-2405-2020	Sunnerhagen, Katharina Stibrant/0000-0002-5940-4400; Lundalv, Jorgen/0000-0003-0552-886X				Arntzen C, 2015, DISABIL REHABIL, V37, P1626, DOI 10.3109/09638288.2014.972590; Balakrishnan R, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14030293; Baum F, 2006, J EPIDEMIOL COMMUN H, V60, P854, DOI 10.1136/jech.2004.028662; Boger EJ, 2015, INT J NURS STUD, V52, P175, DOI 10.1016/j.ijnurstu.2014.05.006; Bonita R, 2004, LANCET NEUROL, V3, P391, DOI 10.1016/S1474-4422(04)00800-2; Booth T, 2003, DISABIL SOC, V18, P431, DOI 10.1080/0968759032000080986; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Brown K, 2010, APHASIOLOGY, V24, P1267, DOI 10.1080/02687031003755429; Cordova D, 2015, ETHNIC HEALTH, V20, P66, DOI 10.1080/13557858.2014.890173; Dassah E, 2017, QUAL HEALTH RES, V27, P1412, DOI 10.1177/1049732316687731; El Tawil S, 2017, CLIN MED, V17, P161, DOI 10.7861/clinmedicine.17-2-161; Ellis-Hill C, 2009, DISABIL REHABIL, V31, P61, DOI 10.1080/09638280701775289; Erikson A, 2016, J REHABIL MED, V48, P847, DOI 10.2340/16501977-2161; Erikson A, 2010, J REHABIL MED, V42, P831, DOI 10.2340/16501977-0608; Fitzpatrick AL, 2012, HEALTH PROMOT PRACT, V13, P48, DOI 10.1177/1524839910364381; Foster-Fishman P, 2005, AM J COMMUN PSYCHOL, V36, P275, DOI 10.1007/s10464-005-8626-y; Gallacher K, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001473; Gleeson K., 2021, HDB VISUAL METHODS P, P535; HOLE E, 2014, THESCIENTIFICWORLDJO, DOI DOI 10.1155/2014/349151; Krishnan S, 2017, AM J PHYS MED REHAB, V96, P487, DOI 10.1097/PHM.0000000000000717; Langemar P., 2008, KVALITATIV FORSKNING; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Mairami FF, 2020, DISABIL REHABIL, V42, P102, DOI 10.1080/09638288.2018.1493544; Maratos M, 2016, QUAL HEALTH RES, V26, P1055, DOI 10.1177/1049732316648114; Mash B., 2014, AFR J PRIM HEALTH CA, V6, P1; McKevitt C, 2011, STROKE, V42, P1398, DOI 10.1161/STROKEAHA.110.598839; Murray CD, 2004, DISABIL REHABIL, V26, P808, DOI 10.1080/09638280410001696746; Pallesen H, 2014, DISABIL REHABIL, V36, P232, DOI 10.3109/09638288.2013.788217; Pearce G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141803; Riksstroke, 2017, QUAL SWED STROK CAR; Sadler E, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-011631; Salter K, 2008, J REHABIL MED, V40, P595, DOI 10.2340/16501977-0238; Sutton-Brown CA, 2014, PHOTOGR CULT, V7, P169, DOI 10.2752/175145214X13999922103165; Tellier M, 2009, TOP STROKE REHABIL, V16, P454, DOI 10.1310/tsr1606-454; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Tornbom K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213447; Wang C, 1997, HEALTH EDUC BEHAV, V24, P369, DOI 10.1177/109019819702400309; Wang CC, 1999, J WOMENS HEALTH, V8, P185, DOI 10.1089/jwh.1999.8.185; Welfare TNBoHa, 2014, SWEDISH DISABILITY P; White JH, 2012, ANN FAM MED, V10, P435, DOI 10.1370/afm.1374; Woodman P, 2014, DISABIL REHABIL, V36, P2031, DOI 10.3109/09638288.2014.887796	41	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2019	14	9							e0222099	10.1371/journal.pone.0222099	http://dx.doi.org/10.1371/journal.pone.0222099			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM3YZ	31509564	Green Published, gold, Green Submitted			2023-01-03	WOS:000532188200033
J	Patel, SR; Lieber, CM				Patel, Shaun R.; Lieber, Charles M.			Precision electronic medicine in the brain	NATURE BIOTECHNOLOGY			English	Article							MESH ELECTRONICS; NEXT-GENERATION; SPATIAL MAP; STIMULATION; MECHANISMS; DEVICES; VISION; TISSUE; PROBES; MODEL	Periodically throughout history developments from adjacent fields of science and technology reach a tipping point where together they produce unparalleled advances, such as the Allen Brain Atlas and the Human Genome Project. Today, research focused at the interface between the nervous system and electronics is not only leading to advances in fundamental neuroscience, but also unlocking the potential of implants capable of cellular-level therapeutic targeting. Ultimately, these personalized electronic therapies will provide new treatment modalities for neurodegenerative and neuropsychiatric illness; powerful control of prosthetics for restorative function in degenerative diseases, trauma and amputation; and even augmentation of human cognition. Overall, we believe that emerging advances in tissue-like electronics will enable minimally invasive devices capable of establishing a stable long-term cellular neural interface and providing long-term treatment for chronic neurological conditions.	[Patel, Shaun R.] Harvard Med Sch, McCance Ctr Brain Hlth, Genet & Aging Res Unit, Dept Neurol,Massachusetts Gen Hosp, Boston, MA 02115 USA; [Lieber, Charles M.] Harvard Univ, Dept Chem & Chem Biol, Ctr Brain Sci, Cambridge, MA 02138 USA; [Lieber, Charles M.] Harvard Univ, John A Paulson Sch Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard University	Patel, SR (corresponding author), Harvard Med Sch, McCance Ctr Brain Hlth, Genet & Aging Res Unit, Dept Neurol,Massachusetts Gen Hosp, Boston, MA 02115 USA.; Lieber, CM (corresponding author), Harvard Univ, Dept Chem & Chem Biol, Ctr Brain Sci, Cambridge, MA 02138 USA.; Lieber, CM (corresponding author), Harvard Univ, John A Paulson Sch Engn & Appl Sci, Cambridge, MA 02138 USA.	shaun.patel@mgh.harvard.edu; cml@cmliris.harvard.edu			Cure Alzheimer's Fund; Henry and Allison McCance Center; Air Force Office of Scientific Research [FA9550-14-1-0136]; National Institutes of Health Director's Pioneer Award [1DP1EB025835-01]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [DP1EB025835] Funding Source: NIH RePORTER	Cure Alzheimer's Fund; Henry and Allison McCance Center; Air Force Office of Scientific Research(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); National Institutes of Health Director's Pioneer Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	S.R.P. is supported by the Cure Alzheimer's Fund and the Henry and Allison McCance Center. C.M.L. acknowledges support of this work by the Air Force Office of Scientific Research (FA9550-14-1-0136) and a National Institutes of Health Director's Pioneer Award (1DP1EB025835-01).	Aflalo T, 2015, SCIENCE, V348, P906, DOI 10.1126/science.aaa5417; Alonso F, 2016, BRAIN SCI, V6, DOI 10.3390/brainsci6030039; Bergey GK, 2015, NEUROLOGY, V84, P810, DOI 10.1212/WNL.0000000000001280; Bjune CK, 2015, IEEE ENG MED BIO, P7825, DOI 10.1109/EMBC.2015.7320206; Boulanger-Weill J, 2017, CURR BIOL, V27, P1707, DOI 10.1016/j.cub.2017.05.029; Buhlmann J, 2011, Front Neuroeng, V4, P15, DOI 10.3389/fneng.2011.00015; Cagnan H, 2019, NAT BIOTECHNOL, V37, P1024, DOI 10.1038/s41587-019-0244-6; Calabresi P, 2014, NAT NEUROSCI, V17, P1022, DOI 10.1038/nn.3743; Chen R, 2017, NAT REV MATER, V2, DOI 10.1038/natrevmats.2016.93; Choi SH, 2018, SCIENCE, V361, P991, DOI 10.1126/science.aan8821; Cicchetti F, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00139; Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711; Ezzyat Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02753-0; Fattahi P, 2014, ADV MATER, V26, P1846, DOI 10.1002/adma.201304496; Fisher B, 2018, STEREOT FUNCT NEUROS, V96, P151, DOI 10.1159/000488684; Frank JA, 2019, NAT BIOTECHNOL, V37, P1013, DOI 10.1038/s41587-019-0198-8; Fu TM, 2017, P NATL ACAD SCI USA, V114, pE10046, DOI 10.1073/pnas.1717695114; Fu TM, 2016, NAT METHODS, V13, P875, DOI 10.1038/nmeth.3969; Gao N, 2015, NANO LETT, V15, P2143, DOI 10.1021/acs.nanolett.5b00133; Garcia JA, 2012, CMES-COMP MODEL ENG, V87, P411; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Ghane-Motlagh B., 2013, MAT SCI APPL, V4, P483, DOI DOI 10.4236/MSA.2013.48059; Gilja V, 2015, NAT MED, V21, P1142, DOI 10.1038/nm.3953; Guo L, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00599; Hadjinicolaou AE, 2015, CLIN EXP OPTOM, V98, P395, DOI 10.1111/cxo.12342; Hafting T, 2005, NATURE, V436, P801, DOI 10.1038/nature03721; Hamilton L, 2015, IEEE ENG MED BIO, P7831, DOI 10.1109/EMBC.2015.7320207; Heelan C, 2018, Annu Int Conf IEEE Eng Med Biol Soc, V2018, P1070, DOI 10.1109/EMBC.2018.8512415; Helmers AK, 2018, NEUROMODULATION, V21, P593, DOI 10.1111/ner.12720; Herrington TM, 2016, J NEUROPHYSIOL, V115, P19, DOI 10.1152/jn.00281.2015; Hochberg LR, 2012, NATURE, V485, P372, DOI 10.1038/nature11076; Hong G., 2019, NAT REV NEUROSCI, V19, P199; Hong GS, 2018, SCIENCE, V360, P1447, DOI 10.1126/science.aas9160; Hong GS, 2018, CURR OPIN NEUROBIOL, V50, P33, DOI 10.1016/j.conb.2017.11.007; Hong GS, 2018, BIOCHEMISTRY-US, V57, P3995, DOI 10.1021/acs.biochem.8b00122; Hong GS, 2015, NANO LETT, V15, P6979, DOI 10.1021/acs.nanolett.5b02987; HUBEL DH, 1959, J PHYSIOL-LONDON, V148, P574, DOI 10.1113/jphysiol.1959.sp006308; Jun JJ, 2017, NATURE, V551, P232, DOI 10.1038/nature24636; Kandel E.R., 2013, PRINCIPLES NEURAL SC, Vfifth; Kasthuri N, 2015, CELL, V162, P648, DOI 10.1016/j.cell.2015.06.054; Kellaway Peter, 1946, BULL HISTORY MED, V20, P112; Kook G, 2016, MICROMACHINES-BASEL, V7, DOI 10.3390/mi7100179; Kringelbach ML, 2007, NAT REV NEUROSCI, V8, P623, DOI 10.1038/nrn2196; Lacour SP, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.63; Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453; Lewis PM, 2015, BRAIN RES, V1595, P51, DOI 10.1016/j.brainres.2014.11.020; Little S, 2016, J NEUROL NEUROSUR PS, V87, P717, DOI 10.1136/jnnp-2015-310972; Lo MC, 2017, INT REV PSYCHIATR, V29, P191, DOI 10.1080/09540261.2017.1282438; Maling N, 2018, J NEUROPHYSIOL, V120, P1932, DOI 10.1152/jn.00067.2018; Mann A, 2018, BRAIN STIMUL, V11, P435, DOI 10.1016/j.brs.2017.11.012; McIntyre CC, 2015, BRAIN STIMUL, V8, P21, DOI 10.1016/j.brs.2014.07.039; Miocinovic S, 2013, JAMA NEUROL, V70, P163, DOI 10.1001/2013.jamaneurol.45; Miranda RA, 2015, J NEUROSCI METH, V244, P52, DOI 10.1016/j.jneumeth.2014.07.019; Molina R, 2018, J NEUROSURG, V129, P308, DOI 10.3171/2017.6.JNS17626; Moore-Kochlacs C., 2014, BMC NEUROSCI, V15, P122; Neely RM, 2018, CURR OPIN NEUROBIOL, V50, P64, DOI 10.1016/j.conb.2017.12.010; Normann RA, 2016, J NEURAL ENG, V13, DOI 10.1088/1741-2560/13/6/061003; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; Parastarfeizabadi M, 2017, J NEUROENG REHABIL, V14, DOI 10.1186/s12984-017-0295-1; Park K, 2018, STEREOT FUNCT NEUROS, V96, P65, DOI 10.1159/000486686; Patil AC, 2016, MED BIOL ENG COMPUT, V54, P23, DOI 10.1007/s11517-015-1430-4; Patolsky F, 2006, SCIENCE, V313, P1100, DOI 10.1126/science.1128640; Polikov VS, 2005, J NEUROSCI METH, V148, P1, DOI 10.1016/j.jneumeth.2005.08.015; Qing Q, 2014, NAT NANOTECHNOL, V9, P142, DOI [10.1038/nnano.2013.273, 10.1038/NNANO.2013.273]; Raducanu BC, 2017, SENSORS-BASEL, V17, DOI 10.3390/s17102388; Ramirez-Zamora A, 2018, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00734; Reardon S, 2016, NATURE, V537, P597, DOI 10.1038/nature.2016.20658; Rosin B, 2011, NEURON, V72, P370, DOI 10.1016/j.neuron.2011.08.023; Saxena T, 2015, NAT MATER, V14, P1190, DOI 10.1038/nmat4454; Shenoy KV, 2014, NEURON, V84, P665, DOI 10.1016/j.neuron.2014.08.038; Shute JB, 2016, NEUROIMAGE-CLIN, V12, P165, DOI 10.1016/j.nicl.2016.06.015; Spitzer NC, 2006, NATURE, V444, P707, DOI 10.1038/nature05300; Starr PA, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00619; Stringer C, 2019, SCIENCE, V364, P255, DOI 10.1126/science.aav7893; Sun FT, 2014, NEUROTHERAPEUTICS, V11, P553, DOI 10.1007/s13311-014-0280-3; Swann NC, 2018, J NEURAL ENG, V15, DOI 10.1088/1741-2552/aabc9b; Teplitzky BA, 2016, FRONT COMPUT NEUROSC, V10, DOI 10.3389/fncom.2016.00058; Terem I, 2018, MAGN RESON MED, V80, P2549, DOI 10.1002/mrm.27236; Tian BZ, 2010, SCIENCE, V329, P830, DOI 10.1126/science.1192033; Tyler WJ, 2012, NAT REV NEUROSCI, V13, P867, DOI 10.1038/nrn3383; van Dijk KJ, 2015, J NEURAL ENG, V12, DOI 10.1088/1741-2560/12/4/046003; Wang SSH, 2008, J NEUROSCI, V28, P4047, DOI 10.1523/JNEUROSCI.5559-05.2008; Wellman SM, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201701269; Wheeler JJ, 2015, IEEE ENG MED BIO, P7837, DOI 10.1109/EMBC.2015.7320208; Yang X, 2019, NAT MATER, V18, P510, DOI 10.1038/s41563-019-0292-9; Zeng Fan-Gang, 2008, IEEE Rev Biomed Eng, V1, P115, DOI 10.1109/RBME.2008.2008250; Zhou T, 2017, P NATL ACAD SCI USA, V114, P5894, DOI 10.1073/pnas.1705509114	87	28	28	2	54	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2019	37	9					1007	1012		10.1038/s41587-019-0234-8	http://dx.doi.org/10.1038/s41587-019-0234-8			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	JB4MP	31477925	Green Accepted			2023-01-03	WOS:000488532200015
J	Slamon, DJ; Neven, P; Chia, S; Fasching, PA; De Laurentiis, M; Im, SA; Petrakova, K; Bianchi, GV; Esteva, FJ; Martin, M; Nusch, A; Sonke, GS; De la Cruz-Merino, L; Beck, JT; Pivot, X; Sondhi, M; Wang, YB; Chakravartty, A; Rodriguez-Lorenc, K; Taran, T; Jerusalem, G				Slamon, Dennis J.; Neven, Patrick; Chia, Stephen; Fasching, Peter A.; De Laurentiis, Michelino; Im, Seock-Ah; Petrakova, Katarina; Bianchi, Giulia V.; Esteva, Francisco J.; Martin, Miguel; Nusch, Arnd; Sonke, Gabe S.; De la Cruz-Merino, Luis; Beck, J. Thaddeus; Pivot, Xavier; Sondhi, Manu; Wang, Yingbo; Chakravartty, Arunava; Rodriguez-Lorenc, Karen; Taran, Tetiana; Jerusalem, Guy			Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SCREENING TRIAL; DEATH VERIFICATION; LUNG; CT; NODULES; MORTALITY; PARTICIPANTS; PROBABILITY; POPULATION; MANAGEMENT	BACKGROUND In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than fulvestrant alone in postmenopausal patients with hormone-receptor positive, human epidermal growth factor receptor 2 (HER2) negative advanced breast cancer. Here we report the results of a protocol-specified second interim analysis of overall survival. METHODS Patients were randomly assigned in a 2;1 ratio to receive either ribociclib or placebo in addition to fulvestrant as first-line or second-line treatment. Survival was evaluated by means of a stratified log-rank test and summarized with the use of Kaplan Meier methods. RES U ITS This analysis was based on 275 deaths: 167 among 484 patients (34.5%) receiving ribociclib and 108 among 242 (44.6 /o) receiving placebo. Ribociclib plus fulvestrant showed a significant overall survival benefit over placebo plus fulvestrant. The estimated overall survival at 42 months was 57.8% (95% confidence interval [CI], 52.0 to 63.2) in the ribociclib group and 45.9% (95% CI, 36.9 to 54.5) in the placebo group, for a 28 /0 difference in the relative risk of death (hazard ratio, 0.72; 95% Cl, 0.57 to 0.92; P=0.00455). The benefit was consistent across most subgroups. In a descriptive update, median progression-free survival among patients receiving first-line treatment was 33.6 months (95% CI, 27.1 to 41.3) in the ribociclib group and 19.2 months (95% Cl, 14.9 to 23.6) in the placebo group. No new safety signals were observed. CONCLUSIONS Ribociclib plus fulvestrant showed a significant overall survival benefit over placebo plus fulvestrant in patients with hormone-receptor positive, HER2-negative advanced breast cancer. (Funded by Novartis; MONALEESA-3 ClinicalTrials.gov number, NCT02422615.)	[Slamon, Dennis J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Neven, Patrick] Univ Ziekenhuis Leuven, Multidisciplinary Breast Ctr, Leuven, Belgium; [Jerusalem, Guy] Ctr Hosp Univ Liege, Liege, Belgium; [Jerusalem, Guy] Univ Liege, Liege, Belgium; [Chia, Stephen] British Columbia Canc Agcy, Vancouver, BC, Canada; [Fasching, Peter A.] Friedrich Alexander Univ Erlangen Nuremberg, Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen European Metropolita, Erlangen, Germany; [Fasching, Peter A.] Friedrich Alexander Univ Erlangen Nuremberg, Dept Gynecol & Obstet, Erlangen, Germany; [De Laurentiis, Michelino] Ist Natl Tumori Fdn G Pascale, Naples, Italy; [Bianchi, Giulia V.] Fdn IRCCS Ist Natl Tumori, Milan, Italy; [Im, Seock-Ah] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Canc Res Inst, Seoul, South Korea; [Petrakova, Katarina] Masaryk Mem Canc Inst, Brno, Czech Republic; [Esteva, Francisco J.] New York Univ Langone Hlth, New York, NY USA; [Martin, Miguel] Univ Complutense, Grp Espanol Invest Canc Mama, Ctr Invest Biomed Red Canc, Inst Invest Saniraria Gregorio Maranon, Madrid, Spain; [De la Cruz-Merino, Luis] Univ Seville, Dept Med, Hosp Univ Virgen Macarena, Seville, Spain; [Sonke, Gabe S.] Netherlands Canc Inst, Borstkanker Onderzoek Groep Study Ctr, Amsterdam, Netherlands; [Beck, J. Thaddeus] Highlands Oncol Grp, Fayetteville, AR USA; [Pivot, Xavier] Inst Reg Canc, Strasbourg, France; [Sondhi, Manu; Chakravartty, Arunava; Rodriguez-Lorenc, Karen] Novartis Pharmaceut, E Hanover, NJ USA; [Wang, Yingbo; Taran, Tetiana] Novartis Pharmaceut, Basel, Switzerland	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; KU Leuven; University Hospital Leuven; University of Liege; University of Liege; British Columbia Cancer Agency; University of Erlangen Nuremberg; University of Erlangen Nuremberg; Fondazione IRCCS Istituto Nazionale Tumori Milan; Seoul National University (SNU); Seoul National University Hospital; Masaryk Memorial Cancer Institute; New York University; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Complutense University of Madrid; Hospital Universitario Virgen Macarena; University of Sevilla; Netherlands Cancer Institute; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Novartis; Novartis	Slamon, DJ (corresponding author), Univ Calif Los Angeles, TORL, 2825 Santa Monica Blvd,Suite 200, Santa Monica, CA 90404 USA.	dslamon@mednet.ucla.edu	de la Cruz-Merino, Luis/K-8633-2017; De Laurentiis, Michelino/AAC-6321-2022; Fasching, Peter A/ABH-9912-2020; Martin, Miguel/AAJ-9242-2020; BIANCHI, GIULIA VALERIA/C-4553-2017	de la Cruz-Merino, Luis/0000-0002-5333-0535; De Laurentiis, Michelino/0000-0001-9009-1572; Fasching, Peter A/0000-0003-4885-8471; Martin, Miguel/0000-0001-9237-3231; Esteva, Francisco J./0000-0003-2437-3920; BIANCHI, GIULIA VALERIA/0000-0003-3630-4527	Novartis	Novartis(Novartis)	Supported by Novartis.	Aberle DR, 2019, J THORAC ONCOL, V14, P1732, DOI 10.1016/j.jtho.2019.05.044; Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873; [Anonymous], 2019, JMIR PUBLIC HLTH SUR, V4, pe53, DOI 10.2196/publichealth.9932; [Anonymous], 2019, TOB DAT STAT; Becker N, 2020, INT J CANCER, V146, P1503, DOI 10.1002/ijc.32486; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; de Koning HJ, 2014, ANN INTERN MED, V160, P311, DOI 10.7326/M13-2316; Expert Panel on Neurologic Imaging, 2017, J AM COLL RADIOL, V14, pS550; Fritz A, 2000, INT CLASSIFICATION D; Health Council WBO Committee, 2000, POP SCREEN ACT CT SC; Heijnsdijk EAM, 2019, CANCER MED-US, V8, P6127, DOI 10.1002/cam4.2476; Horeweg N, 2012, LUNG CANCER, V77, P522, DOI 10.1016/j.lungcan.2012.04.018; Horeweg N, 2013, EUR RESPIR J, V42, P1659, DOI 10.1183/09031936.00197712; Humphrey LL, 2013, ANN INTERN MED, V159, P411, DOI 10.7326/0003-4819-159-6-201309170-00690; Leon ME, 2015, CANCER EPIDEMIOL, V39, pS20, DOI 10.1016/j.canep.2015.06.001; Oudkerk M, 2017, LANCET ONCOL, V18, pE754, DOI [10.1016/S1470-2045(17)30861-6, 10.1016/s1470-2045(17)30861-6]; Patz EF, 2016, LANCET ONCOL, V17, P590, DOI 10.1016/S1470-2045(15)00621-X; Patz EF, 2014, JAMA INTERN MED, V174, P269, DOI 10.1001/jamainternmed.2013.12738; Pinsky PF, 2013, CANCER-AM CANCER SOC, V119, P593, DOI 10.1002/cncr.27774; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; ten Haaf K, 2015, J EPIDEMIOL COMMUN H, V69, P1035, DOI 10.1136/jech-2014-204079; ten Haaf K, 2015, CANCER EPIDEM BIOMAR, V24, P154, DOI 10.1158/1055-9965.EPI-14-0745; van der Aalst CM, 2016, LANCET RESP MED, V4, P749, DOI 10.; van der Aalst CM, 2010, THORAX, V65, P600, DOI 10.1136/thx.2009.133751; van Iersel CA, 2007, INT J CANCER, V120, P868, DOI 10.1002/ijc.22134; van Klaveren RJ, 2002, LUNG CANCER, V38, P243, DOI 10.1016/S0169-5002(02)00222-2; van Klaveren RJ, 2009, NEW ENGL J MED, V361, P2221, DOI 10.1056/NEJMoa0906085; Walter JE, 2019, THORAX, V74, P247, DOI 10.1136/thoraxjnl-2018-212152; Walter JE, 2018, LUNG CANCER, V125, P103, DOI 10.1016/j.lungcan.2018.05.007; Walter JE, 2016, LANCET ONCOL, V17, P907, DOI 10.1016/S1470-2045(16)30069-9; Xie X, 2013, BRIT J RADIOL, V86, DOI 10.1259/bjr.20130160; Xie XQ, 2013, EUR RADIOL, V23, P139, DOI 10.1007/s00330-012-2570-7; Xu DM, 2006, LUNG CANCER, V54, P177, DOI 10.1016/j.lungcan.2006.08.006; Yousaf-Khan AU, 2017, LUNG CANCER, V111, P131, DOI 10.1016/j.lungcan.2017.07.018; Yousaf-Khan AU, 2018, CANC STAGE SHIFT TRE; Yousaf-Khan U, 2017, THORAX, V72, P48, DOI 10.1136/thoraxjnl-2016-208655; Yousaf-Khan U, 2015, J THORAC ONCOL, V10, P747, DOI 10.1097/JTO.0000000000000488	37	293	302	6	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 6	2020	382	6					514	524		10.1056/NEJMoa1911149	http://dx.doi.org/10.1056/NEJMoa1911149			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ3ZG	31826360	Bronze			2023-01-03	WOS:000511997100006
J	Sorolla, A; Wang, E; Golden, E; Duffy, C; Henriques, ST; Redfern, AD; Blancafort, P				Sorolla, Anabel; Wang, Edina; Golden, Emily; Duffy, Ciara; Henriques, Sonia T.; Redfern, Andrew D.; Blancafort, Pilar			Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics	ONCOGENE			English	Review							CELL-PENETRATING PEPTIDES; VIVO HALF-LIFE; TRANSCRIPTION-FACTOR; IN-VIVO; BREAST-CANCER; HOX GENES; LUNG-CANCER; MYC; INHIBITION; PROTEINS	In molecular cancer therapeutics only 10% of known cancer gene products are targetable with current pharmacological agents. Major oncogenic drivers, such as MYC and KRAS proteins are frequently highly overexpressed or mutated in multiple human malignancies. However, despite their key role in oncogenesis, these proteins are hard to target with traditional small molecule drugs due to their large, featureless protein interfaces and lack of deep pockets. In addition, they are inaccessible to large biologicals, which are unable to cross cell membranes. Designer interference peptides (iPeps) represent emerging pharmacological agents created to block selective interactions between protein partners that are difficult to target with conventional small molecule chemicals or with large biologicals. iPeps have demonstrated successful inhibition of multiple oncogenic drivers with some now entering clinical settings. However, the clinical translation of iPeps has been hampered by certain intrinsic limitations including intracellular localization, targeting tissue specificity and pharmacological potency. Herein, we outline recent advances for the selective inhibition of major cancer oncoproteins via iPep approaches and discuss the development of multimodal peptides to overcome limitations of the first generations of iPeps. Since many protein-protein interfaces are cell-type specific, this approach opens the door to novel programmable, precision medicine tools in cancer research and treatment for selective manipulation and reprogramming of the cancer cell oncoproteome.	[Sorolla, Anabel; Wang, Edina; Golden, Emily; Duffy, Ciara; Blancafort, Pilar] Univ Western Australia, QEII Med Ctr, Harry Perkins Inst Med Res, Nedlands, WA 6009, Australia; [Sorolla, Anabel; Wang, Edina; Golden, Emily; Duffy, Ciara; Blancafort, Pilar] Univ Western Australia, Ctr Med Res, Nedlands, WA 6009, Australia; [Henriques, Sonia T.] Queensland Univ Technol, Translat Res Inst, Inst Hlth & Biomed Innovat, Sch Biomed Sci,Fac Hlth, Brisbane, Qld 4102, Australia; [Redfern, Andrew D.] Univ Western Australia, Sch Med, Crawley, WA 6009, Australia	Harry Perkins Institute of Medical Research; University of Western Australia; University of Western Australia; Queensland University of Technology (QUT); University of Western Australia	Sorolla, A; Blancafort, P (corresponding author), Univ Western Australia, QEII Med Ctr, Harry Perkins Inst Med Res, Nedlands, WA 6009, Australia.; Sorolla, A; Blancafort, P (corresponding author), Univ Western Australia, Ctr Med Res, Nedlands, WA 6009, Australia.	anabel.sorollabardaji@perkins.uwa.edu.au; pilar.blancafort@uwa.edu.au	Redfern, Andrew/ABA-4597-2020; Troeira Henriques, Sonia/J-3500-2016	Troeira Henriques, Sonia/0000-0001-9564-9651; Blancafort, Pilar/0000-0002-3881-7396; Sorolla, Anabel/0000-0001-8238-8763; Golden, Emily/0000-0001-6386-201X; Wang, Edina/0000-0002-9652-3513; Redfern, Andrew/0000-0001-6728-8713	Australian Research Council (ARC) [FT130101767]; Cancer Council of Western Australia (CCWA) Research Fellowship; National Health and Medical Research Council (NHMRC) [APP1069308, APP1147528, APP1165208]; NBCF [PF-15-001]; Raine Medical Research Foundation; Australian Government Research Training Program (RTP) Scholarship; Cancer Council of Western Australia PhD Top-Up Scholarship; ARC [FT150100398]; NHMRC [APP1084965]; Australian Government; CCWA [APP1083745, APP1147435]	Australian Research Council (ARC)(Australian Research Council); Cancer Council of Western Australia (CCWA) Research Fellowship; National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NBCF; Raine Medical Research Foundation; Australian Government Research Training Program (RTP) Scholarship(Australian GovernmentDepartment of Industry, Innovation and Science); Cancer Council of Western Australia PhD Top-Up Scholarship; ARC(Australian Research Council); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Australian Government(Australian GovernmentCGIAR); CCWA(Cancer Council Western Australia)	This work was supported by the following grants awarded to PB: the Australian Research Council (ARC) Future Fellowship FT130101767, the Cancer Council of Western Australia (CCWA) Research Fellowship and CCWA project grants APP1083745 and APP1147435, and National Health and Medical Research Council (NHMRC) grants APP1069308, APP1147528, and APP1165208. AS acknowledges the postdoctoral fellowship from the NBCF, PF-15-001 and the research funds from the Raine Medical Research Foundation. CD acknowledges the Australian Government Research Training Program (RTP) Scholarship and the Cancer Council of Western Australia PhD Top-Up Scholarship. STH acknowledges ARC Future Fellowship FT150100398 and NHMRC project grant APP1084965. The Translational Research Institute is supported by a grant from the Australian Government. The authors would like to acknowledge Dr. Kade Roberts for critical reading and review of the paper.	Alharbi RA, 2013, LEUKEMIA, V27, P1000, DOI 10.1038/leu.2012.356; Alvarez-Fischer D, 2011, NAT NEUROSCI, V14, P1260, DOI 10.1038/nn.2916; Annibali D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5632; Avramis VI, 2002, BLOOD, V99, P1986, DOI 10.1182/blood.V99.6.1986; Bale SS, 2010, ACS NANO, V4, P1493, DOI 10.1021/nn901586e; Beaulieu ME, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aar5012; Beltran AS, 2014, ONCOGENE, V33, P4767, DOI 10.1038/onc.2013.422; Benayed R, 2005, AM J HUM GENET, V77, P851, DOI 10.1086/497705; Bernal F, 2010, CANCER CELL, V18, P411, DOI 10.1016/j.ccr.2010.10.024; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bhatlekar S, 2018, J CELL PHYSIOL, V233, P727, DOI 10.1002/jcp.25981; Bidwell GL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055104; Bidwell GL, 2005, MOL CANCER THER, V4, P1076, DOI 10.1158/1535-7163.MCT-04-0253; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blundell TL, 2000, BIOL CHEM, V381, P955, DOI 10.1515/BC.2000.117; BOS JL, 1989, CANCER RES, V49, P4682; Brown RV, 2011, J BIOL CHEM, V286, P41018, DOI 10.1074/jbc.M111.274720; Bruno BJ, 2013, THER DELIV, V4, P1443, DOI [10.4155/TDE.13.104, 10.4155/tde.13.104]; Buckton LK, 2018, ORG LETT, V20, P506, DOI 10.1021/acs.orglett.7b03363; Caruso C, 2019, CANCER DISCOV, V9, P988, DOI 10.1158/2159-8290.CD-NB2019-073; Carvajal LA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao3003; Chang YS, 2013, P NATL ACAD SCI USA, V110, pE3445, DOI 10.1073/pnas.1303002110; Clark RJ, 2005, P NATL ACAD SCI USA, V102, P13767, DOI 10.1073/pnas.0504613102; Craik DJ, 2013, CHEM BIOL DRUG DES, V81, P136, DOI 10.1111/cbdd.12055; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; dos Santos MTMA, 2011, NEURAL DEV, V6, DOI 10.1186/1749-8104-6-23; Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275; Farkhani SM, 2014, PEPTIDES, V57, P78, DOI 10.1016/j.peptides.2014.04.015; Fukazawa T, 2010, ANTICANCER RES, V30, P4193; Gandhi Neha S, 2018, Oncotarget, V9, P22383, DOI 10.18632/oncotarget.25025; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; Giorello L, 1998, CANCER RES, V58, P3654; GREEN M, 1989, CELL, V58, P215, DOI 10.1016/0092-8674(89)90417-0; Gu Z, 2011, CHEM SOC REV, V40, P3638, DOI 10.1039/c0cs00227e; Han G, 2012, ONCOL RES, V20, P149, DOI 10.3727/096504012X13522227232237; Hao XY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138911; Harbour JW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1341, DOI 10.1001/archopht.120.10.1341; Hoffmann K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30790-2; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006; Kater AP, 2019, J CLIN ONCOL, V37, P269, DOI 10.1200/JCO.18.01580; Khan I, 2019, ONCOGENE, V38, P2984, DOI 10.1038/s41388-018-0636-y; Kretzmann JA, 2019, CHEM SCI, V10, P7718, DOI 10.1039/c9sc01432b; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Leshchiner ES, 2015, P NATL ACAD SCI USA, V112, P1761, DOI 10.1073/pnas.1413185112; Li L, 2016, J CONTROL RELEASE, V232, P62, DOI 10.1016/j.jconrel.2016.04.021; Li ZG, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.187; Liu M, 2010, P NATL ACAD SCI USA, V107, P14321, DOI 10.1073/pnas.1008930107; Liu Y, 2011, ANGEW CHEM INT EDIT, V50, P3058, DOI 10.1002/anie.201005740; Luo M, 2017, NAT NANOTECHNOL, V12, P648, DOI [10.1038/NNANO.2017.52, 10.1038/nnano.2017.52]; Marier JF, 2008, J CLIN PHARMACOL, V48, P1289, DOI 10.1177/0091270008320605; Mas-Moruno C, 2010, ANTI-CANCER AGENT ME, V10, P753, DOI 10.2174/187152010794728639; Mathur D, 2016, SCI REP, V6; Morgan R, 2007, CANCER RES, V67, P5806, DOI 10.1158/0008-5472.CAN-06-4231; Morgan R, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-5215; Morgan R, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2106-7; Morgan R, 2014, BMC UROL, V14, DOI 10.1186/1471-2490-14-17; Morgan R, 2012, BREAST CANCER RES TR, V136, P389, DOI 10.1007/s10549-012-2259-2; Morgan R, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-89; Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116; Mundargi RC, 2008, J CONTROL RELEASE, V125, P193, DOI 10.1016/j.jconrel.2007.09.013; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; Oliva R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27231-5; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pandha H, 2012, BJU INT, V110, pE287, DOI 10.1111/j.1464-410X.2012.11208.x; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; Patel S, 2014, ACS NANO, V8, P8959, DOI 10.1021/nn501589f; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Penchala SC, 2015, NAT CHEM BIOL, V11, P793, DOI [10.1038/NCHEMBIO.1907, 10.1038/nchembio.1907]; Plowright L, 2009, BRIT J CANCER, V100, P470, DOI 10.1038/sj.bjc.6604857; Schellenberger V, 2009, NAT BIOTECHNOL, V27, P1186, DOI 10.1038/nbt.1588; Shears L, 2008, J UROLOGY, V180, P2196, DOI 10.1016/j.juro.2008.07.018; SHEINESS D, 1978, J VIROL, V28, P600, DOI 10.1128/JVI.28.2.600-610.1978; Shen LL, 2015, P NATL ACAD SCI USA, V112, P5425, DOI 10.1073/pnas.1501555112; Sodir NM, 2011, GENE DEV, V25, P907, DOI 10.1101/gad.2038411; Sorolla A, 2016, NANOSCALE, V8, P9343, DOI 10.1039/c5nr08331a; Sorolla A, 2019, NANOMED-NANOTECHNOL, V20, DOI 10.1016/j.nano.2019.04.006; Sorolla A, 2012, MOL ONCOL, V6, P530, DOI 10.1016/j.molonc.2012.06.006; Soucek L, 2004, CELL DEATH DIFFER, V11, P1038, DOI 10.1038/sj.cdd.4401443; Soucek L, 2002, CANCER RES, V62, P3507; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Spencer-Smith R, 2017, NAT CHEM BIOL, V13, P62, DOI [10.1038/NCHEMBIO.2231, 10.1038/nchembio.2231]; Tang R, 2013, ACS NANO, V7, P6667, DOI 10.1021/nn402753y; Trinh TB, 2016, ACS COMB SCI, V18, P75, DOI 10.1021/acscombsci.5b00164; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Verdine GL, 2007, CLIN CANCER RES, V13, P7264, DOI 10.1158/1078-0432.CCR-07-2184; Vogler M, 2009, BLOOD, V113, P4403, DOI 10.1182/blood-2008-08-173310; Wang E, 2019, ONCOGENE, V38, P140, DOI 10.1038/s41388-018-0421-y; Wang S, 2013, CLIN CANCER RES, V19, P128, DOI 10.1158/1078-0432.CCR-12-2654; Warren CFA, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1407-6; Wells JA, 2007, NATURE, V450, P1001, DOI 10.1038/nature06526; Wu XH, 2013, MEDCHEMCOMM, V4, P378, DOI 10.1039/c2md20329d	100	41	41	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1167	1184		10.1038/s41388-019-1056-3	http://dx.doi.org/10.1038/s41388-019-1056-3			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31636382	Green Published, hybrid			2023-01-03	WOS:000526714600001
J	Edward, A; Hoffmann, L; Manase, F; Matsushita, K; Pariyo, GW; Brady, TM; Appel, LJ				Edward, Anbrasi; Hoffmann, Lisa; Manase, Frank; Matsushita, Kunihiro; Pariyo, George William; Brady, Tammy M.; Appel, Lawrence J.			An exploratory study on the quality of patient screening and counseling for hypertension management in Tanzania	PLOS ONE			English	Article								Background The global burden of hypertension, currently estimated at 1 billion, is a leading Non-Communicable Disease (NCD) in Sub Saharan Africa. In Tanzania, the reported prevalence of hypertension is 25%. Inherent limitations of the healthcare system to control hypertension include inadequate provider knowledge, system capacity, medication access, and patient awareness, all of which hinder effective screening and disease management. To assess the quality of hypertension screening and patient counseling, we conducted a study in an ambulatory setting in Tanzania. Methods Observations of patient screening were conducted on 69 adult patients during routine outpatient care and screening camps. In addition, 33 healthcare providers participated in a prepost knowledge assessment after observing instructional training videos. Results Patient observations indicated that blood pressure (BP) measurement was explained to 65% of patients, and 77% of the measurements were made with mercury sphygmomanometers. For several aspects of BP measurement, nurses performed better than doctors: patient's arm supported on a flat surface (doctors, 58% vs nurses 67%, p<0.05), and patient's back was supported (doctors, 50% vs nurses 88%, p<0.01). Among those diagnosed with hypertension, 7% were prescribed medications, 14% were advised on reduced salt during cooking, 29% on reduced salt consumption, 21% on reduced consumption of sodium rich foods, 21% on reducing caloric intake, 21% on increasing physical activity, and 43% were informed about follow up appointments. Provider knowledge assessments showed critical gaps in consequences of hypertension, 1st line medicines, and awareness of guidelines at baseline. Following the instructional videos there were improvements in some aspects: diagnostic criteria for hypertension (pre 45% vs post 91%, p<0.001) and counseling for controlling hypertension (pre 30% vs post 58%, p<0.01). Conclusion Enhancing knowledge and performance competencies of health providers at the primary care level is a critical prerequisite for effective hypertension management in low resource settings.	[Edward, Anbrasi; Pariyo, George William] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; [Hoffmann, Lisa] WHO, Patient Safety & Risk Management Unit, Geneva, Switzerland; [Manase, Frank] Community Ctr Prevent Med, Dar Es Salaam, Tanzania; [Matsushita, Kunihiro] Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Sch Med, Dept Epidemiol, Div Cardiol, Baltimore, MD USA; [Brady, Tammy M.] Johns Hopkins Sch Med, Div Pediat Nephrol, Baltimore, MD USA; [Appel, Lawrence J.] Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Sch Med, Dept Epidemiol, Baltimore, MD USA; [Appel, Lawrence J.] Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Sch Med, Dept Int Hlth, Baltimore, MD USA; [Appel, Lawrence J.] Johns Hopkins Sch Nursing, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; World Health Organization; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Medicine; Johns Hopkins University	Edward, A (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.	aedward1@jhu.edu	Appel, Larry/GLT-2608-2022; Matsushita, Kunihiro/AAJ-5817-2020	Matsushita, Kunihiro/0000-0002-7179-718X	Johns Hopkins Bloomberg School of Public Health; Resolve to Save Lives - Bloomberg Philanthropies; Bill and Melinda Gates Foundation; Gates Philanthropy Partners; Chan Zuckerberg Foundation [69577]; MPH travel award; Resolve to Save Lives project at Johns Hopkins	Johns Hopkins Bloomberg School of Public Health(Johns Hopkins University); Resolve to Save Lives - Bloomberg Philanthropies; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Gates Philanthropy Partners; Chan Zuckerberg Foundation; MPH travel award; Resolve to Save Lives project at Johns Hopkins	The study was conducted with support from an MPH travel award from the Johns Hopkins Bloomberg School of Public Health. Partial financial support for the video testing component was provided by Resolve to Save Lives, which is funded by Bloomberg Philanthropies, the Bill and Melinda Gates Foundation, and Gates Philanthropy Partners, funded with support from the Chan Zuckerberg Foundation; Grant #69577. LH was funded by the MPH travel award, and AE, KM, LA, GP and TB were partially funded by the Resolve to Save Lives project at Johns Hopkins. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Diagnostic Corporation, TAK BLOOD PRESS; [Anonymous], 2015, CARD DIS CVDS; Bintabara D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192942; Galson SW, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018829; Hendriks ME, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032638; Mbuya FE, 2014, TANZAN J HLTH RES, V16, P98, DOI [10.4314/thrb.v16i2.5, DOI 10.4314/THRB.V16I2.5]; Mosha NR, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1321279; Peck R, 2014, LANCET GLOB HEALTH, V2, pE285, DOI 10.1016/S2214-109X(14)70033-6; Peck RN, 2013, J HYPERTENS, V31, P1806, DOI 10.1097/HJH.0b013e328362bad7; United Republic of Tanzania Ministry of Health and Social Welfare, 2008, NAT NONC DIS STRAT; World Health Organization, 2018, NONC DIS NCD COUNTR; World Health Organization, 2009, GLOB HLTH RISKS MORT, P16; World Health Organization, 2018, GLOB HLTH OBS GHO DA; World Health Organization, 2018, GLOB HTLH OBS GHO DA	14	5	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2020	15	1							e0227439	10.1371/journal.pone.0227439	http://dx.doi.org/10.1371/journal.pone.0227439			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5PQ	31945075	Green Published, gold			2023-01-03	WOS:000534370100039
J	Shi, HC; Sun, Y; He, M; Yang, X; Hamada, M; Fukunaga, T; Zhang, XP; Chang, CS				Shi, Hangchuan; Sun, Yin; He, Miao; Yang, Xiong; Hamada, Michiaki; Fukunaga, Tsukasa; Zhang, Xiaoping; Chang, Chawnshang			Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; TRANS-RETINOIC ACID; ACUTE PROMYELOCYTIC LEUKEMIA; IN-VITRO; GENE-EXPRESSION; TUMOR-CELLS; CANCER; METFORMIN; THERAPY; RESISTANCE	Renal cell carcinoma (RCC) is one of the most lethal urological tumors. Using sunitinib to improve the survival has become the first-line therapy for metastatic RCC patients. However, the occurrence of sunitinib resistance in the clinical application has curtailed its efficacy. Here we found TR4 nuclear receptor might alter the sunitinib resistance to RCC via altering the TR4/lncTASR/AXL signaling. Mechanism dissection revealed that TR4 could modulate lncTASR (ENST00000600671.1) expression via transcriptional regulation, which might then increase AXL protein expression via enhancing the stability of AXL mRNA to increase the sunitinib resistance in RCC. Human clinical surveys also linked the expression of TR4, lncTASR, and AXL to the RCC survival, and results from multiple RCC cell lines revealed that targeting this newly identified TR4-mediated signaling with small molecules, including tretinoin, metformin, or TR4-shRNAs, all led to increase the sunitinib sensitivity to better suppress the RCC progression, and our preclinical study using the in vivo mouse model further proved tretinoin had a better synergistic effect to increase sunitinib sensitivity to suppress RCC progression. Future successful clinical trials may help in the development of a novel therapy to better suppress the RCC progression.	[Shi, Hangchuan; Yang, Xiong; Zhang, Xiaoping] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Urol, Wuhan 430022, Peoples R China; [Shi, Hangchuan; Sun, Yin; He, Miao; Yang, Xiong; Chang, Chawnshang] Univ Rochester, Wilmot Canc Inst, Radiat Oncol, Med Ctr, Rochester, NY 14642 USA; [Hamada, Michiaki; Fukunaga, Tsukasa] Waseda Univ, Fac Sci & Engn, Tokyo 1698555, Japan; [Chang, Chawnshang] China Med Univ Hosp, Sex Hormone Res Ctr, Taichung 404, Taiwan; [Chang, Chawnshang] China Med Univ Hosp, Dept Urol, Taichung 404, Taiwan; [Hamada, Michiaki] Natl Inst Adv Ind Sci & Technol, Computat Bio Big Data Open Innovat Lab CBBD OIL, Tokyo 1698555, Japan	Huazhong University of Science & Technology; University of Rochester; Waseda University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; National Institute of Advanced Industrial Science & Technology (AIST)	Zhang, XP (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Urol, Wuhan 430022, Peoples R China.; Chang, CS (corresponding author), Univ Rochester, Wilmot Canc Inst, Radiat Oncol, Med Ctr, Rochester, NY 14642 USA.; Chang, CS (corresponding author), China Med Univ Hosp, Sex Hormone Res Ctr, Taichung 404, Taiwan.; Chang, CS (corresponding author), China Med Univ Hosp, Dept Urol, Taichung 404, Taiwan.	xzhang@hust.edu.cn; chang@urmc.rochester.edu	Shi, Hangchuan/GWV-5076-2022; Shi, Hangchuan/J-2637-2014; Hamada, Michiaki/L-9371-2018	Chang, Chawnshang/0000-0001-8510-3516; Shi, Hangchuan/0000-0001-6269-742X; Hamada, Michiaki/0000-0001-9466-1034	NIH [CA156700]; George Whipple Professorship Endowment; Taiwan Department of Health Clinical Trial and Research Center of Excellence [MOHW104-TDU-B-212-113002]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); George Whipple Professorship Endowment; Taiwan Department of Health Clinical Trial and Research Center of Excellence	We thank Karen Wolf for help with manuscript preparation. This work was supported by NIH grant (CA156700), George Whipple Professorship Endowment and Taiwan Department of Health Clinical Trial and Research Center of Excellence (MOHW104-TDU-B-212-113002) to China Medical University, Taichung, Taiwan). Computations were partially performed on the NIG supercomputer at ROIS National Institute of Genetics.	Adelaiye-Ogala R, 2018, CANCER RES, V78, P2886, DOI 10.1158/0008-5472.CAN-17-3386; Bai J, 2018, ONCOGENE, V37, P5901, DOI 10.1038/s41388-018-0269-1; Baldewijns MML, 2008, BBA-REV CANCER, V1785, P133, DOI 10.1016/j.bbcan.2007.12.002; Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719; Busch J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-295; Chae YK, 2016, ONCOTARGET, V7, P40767, DOI 10.18632/oncotarget.8194; Chandel NS, 2016, CELL METAB, V23, P569, DOI 10.1016/j.cmet.2016.03.010; Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796; Chen XY, 2014, CLIN CANCER RES, V20, P2617, DOI 10.1158/1078-0432.CCR-13-3224; Choueiri TK, 2018, EUR J CANCER, V94, P115, DOI 10.1016/j.ejca.2018.02.012; Coppin C, 2011, BJU INT, V108, P1556, DOI 10.1111/j.1464-410X.2011.10629.x; Ding XF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0281-1; Ellis L, 2012, MOL CANCER THER, V11, P383, DOI 10.1158/1535-7163.MCT-11-0748; Faivre S, 2007, NAT REV DRUG DISCOV, V6, P734, DOI 10.1038/nrd2380; Froushani SMA, 2014, IRAN J BASIC MED SCI, V17, P632; Fukunaga T, 2017, BIOINFORMATICS, V33, P2666, DOI 10.1093/bioinformatics/btx287; Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Huang D, 2010, CANCER RES, V70, P1053, DOI 10.1158/0008-5472.CAN-09-3722; Jin RA, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0287-5; Jing YK, 2001, BLOOD, V97, P264, DOI 10.1182/blood.V97.1.264; Joosten SC, 2015, BBA-REV CANCER, V1855, P1, DOI 10.1016/j.bbcan.2014.11.002; Kasznicki J, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.06.01; Kim E, 2011, DIABETES, V60, P1493, DOI 10.2337/db10-0393; Kordes S, 2015, LANCET ONCOL, V16, P839, DOI 10.1016/S1470-2045(15)00027-3; Li B, 2015, EUR J PHARMACOL, V749, P107, DOI 10.1016/j.ejphar.2015.01.009; Liu J, 2013, UROL ONCOL-SEMIN ORI, V31, P264, DOI 10.1016/j.urolonc.2011.01.003; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Liu QL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.417; Liu S, 2014, ENDOCR-RELAT CANCER, V21, pR279, DOI 10.1530/ERC-13-0529; Liu XZ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.197; Lorenzen JM, 2016, NAT REV NEPHROL, V12, P360, DOI 10.1038/nrneph.2016.51; Lou N, 2017, UROL ONCOL-SEMIN ORI, V35, DOI 10.1016/j.urolonc.2016.07.012; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Mei D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182835; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Pawlyk AC, 2014, DIABETES, V63, P2590, DOI 10.2337/db13-1367; Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004; Rho JK, 2014, CANCER RES, V74, P253, DOI 10.1158/0008-5472.CAN-13-1103; Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2; Schodel J, 2016, EUR UROL, V69, P646, DOI 10.1016/j.eururo.2015.08.007; Seo GY, 2017, CELL IMMUNOL, V322, P49, DOI 10.1016/j.cellimm.2017.10.001; Shalita A, 1996, J AM ACAD DERMATOL, V34, P482, DOI 10.1016/S0190-9622(96)90443-0; Shen JL, 2016, ONCOTARGET, V7, P32088, DOI 10.18632/oncotarget.8525; Shojaei F, 2010, CANCER RES, V70, P10090, DOI 10.1158/0008-5472.CAN-10-0489; Staehler M, 2005, CURR DRUG TARGETS, V6, P835, DOI 10.2174/138945005774574498; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tannir NM, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0566-9; Terai G, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-015-2307-5; van der Mijn JC, 2016, INT J CANCER, V138, P3002, DOI 10.1002/ijc.30022; Wang MC, 2018, INT J CANCER, V143, P100, DOI 10.1002/ijc.31289; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Weiss RH, 2018, SEMIN NEPHROL, V38, P175, DOI 10.1016/j.semnephrol.2018.01.006; Wheaton WW, 2014, ELIFE, V3, DOI 10.7554/eLife.02242; Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027; Yu SC, 2015, PROSTATE, V75, P1632, DOI 10.1002/pros.23044; Zhai W, 2017, CELL DEATH DIFFER, V24, P1502, DOI 10.1038/cdd.2017.74; Zhou L, 2016, ONCOGENE, V35, P2687, DOI 10.1038/onc.2015.343; Zhou XE, 2011, J BIOL CHEM, V286, P2877, DOI 10.1074/jbc.M110.168740	59	13	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					530	545		10.1038/s41388-019-0962-8	http://dx.doi.org/10.1038/s41388-019-0962-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31501521	hybrid, Green Published			2023-01-03	WOS:000509718300004
J	Hegedus, O; Juriga, D; Sipos, E; Voniatis, C; Juhasz, A; Idrissi, A; Zrinyi, M; Varga, G; Jedlovszky-Hajdu, A; Nagy, KS				Hegedus, Orsolya; Juriga, David; Sipos, Evelin; Voniatis, Constantinos; Juhasz, Akos; Idrissi, Abdenaccer; Zrinyi, Miklos; Varga, Gabor; Jedlovszky-Hajdu, Angela; Nagy, Krisztina S.			Free thiol groups on poly(aspartamide) based hydrogels facilitate tooth-derived progenitor cell proliferation and differentiation	PLOS ONE			English	Article							MESENCHYMAL STEM-CELLS; DRUG-DELIVERY; DENTAL ORIGIN; ACID); ADHESION; SCAFFOLDS; BIOLOGY; REDOX; CONSTRUCTION; BIOMATERIALS	Cell-based tissue reconstruction is an important field of regenerative medicine. Stem and progenitor cells derived from tooth-associated tissues have strong regeneration potential. However, their in vivo application requires the development of novel scaffolds that will provide a suitable three-dimensional (3D) environment allowing not only the survival of the cells but eliciting their proliferation and differentiation. Our aim was to study the viability and differentiation capacity of periodontal ligament cells (PDLCs) cultured on recently developed bio-compatible and biodegradable poly(aspartamide) (PASP)-based hydrogels. Viability and behavior of PDLCs were investigated on PASP-based hydrogels possessing different chemical, physical and mechanical properties. Based on our previous results, the effect of thiol group density in the polymer matrix on cell viability, morphology and differentiation ability is in the focus of our article. The chemical composition and 3D structures of the hydrogels were determined by FT Raman spectroscopy and Scanning Electron Microscopy. Morphology of the cells was examined by phase contrast microscopy. To visualize cell growth and migration patterns through the hydrogels, two-photon microscopy were utilized. Cell viability analysis was performed according to a standardized protocol using WST-1 reagent. PDLCs were able to attach and grow on PASP-based hydrogels. An increase in gel stiffness enhanced adhesion and proliferation of the cells. However, the highest population of viable cells was observed on the PASP gels containing free thiol groups. The presence of thiol groups does not only enhance viability but also facilitates the osteogenic direction of the differentiating cells. These cell-gel structures seem to be highly promising for cell-based tissue reconstruction purposes in the field of regenerative medicine.	[Hegedus, Orsolya; Varga, Gabor; Nagy, Krisztina S.] Semmelweis Univ, Dept Oral Biol, Budapest, Hungary; [Juriga, David; Sipos, Evelin; Voniatis, Constantinos; Juhasz, Akos; Zrinyi, Miklos; Jedlovszky-Hajdu, Angela] Semmelweis Univ, Dept Biophys & Radiat Biol, Lab Nanochem, Budapest, Hungary; [Juhasz, Akos; Idrissi, Abdenaccer] Univ Lille, Fac Sci & Technol, Villeneuve Dascq, France	Semmelweis University; Semmelweis University; Universite de Lille - ISITE; Universite de Lille	Varga, G (corresponding author), Semmelweis Univ, Dept Oral Biol, Budapest, Hungary.; Jedlovszky-Hajdu, A (corresponding author), Semmelweis Univ, Dept Biophys & Radiat Biol, Lab Nanochem, Budapest, Hungary.	varga.gabor@dent.semmelweis-univ.hu; hajdu.angela@med.semmelweis-univ.hu	juriga, david/AAC-1568-2021; Jedlovszky-Hajdu, Angela/O-6723-2017	Varga, Gabor/0000-0002-5506-8198; Juriga, David/0000-0003-2655-5584; Jedlovszky-Hajdu, Angela/0000-0003-2720-783X	Hungarian Human Resources Development Operational Program [EFOP-3.6.2-16-2017-00006]; National Science Research Fundamentals [OTKA K 115259]; National Research, Development and Innovation Office - NKFIH [FK 124147]; Higher Education Excellence Program of the Hungarian Ministry of Human Capacities; Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences; new national excellence program of the Ministry of Human Capacities [UNKP-19-4-SE-04]	Hungarian Human Resources Development Operational Program; National Science Research Fundamentals; National Research, Development and Innovation Office - NKFIH; Higher Education Excellence Program of the Hungarian Ministry of Human Capacities; Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences(Hungarian Academy of Sciences); new national excellence program of the Ministry of Human Capacities	This work was funded by the Hungarian Human Resources Development Operational Program (EFOP-3.6.2-16-2017-00006), the National Science Research Fundamentals (OTKA K 115259), National Research, Development and Innovation Office - NKFIH FK 124147, and by the Higher Education Excellence Program of the Hungarian Ministry of Human Capacities to Semmelweis University, Therapy Research Module. This project was also supported by the Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences and by the UNKP-19-4-SE-04 new national excellence program of the Ministry of Human Capacities.	Altunbas A, 2012, TOP CURR CHEM, V310, P135, DOI 10.1007/128_2011_206; Bae IH, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/878930; Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19-3-180; Cen SD, 2016, ARCH ORAL BIOL, V68, P1, DOI 10.1016/j.archoralbio.2016.03.009; Chang HY, 2014, J PHYS CHEM C, V118, P14464, DOI 10.1021/jp504662c; Croisier F, 2013, EUR POLYM J, V49, P780, DOI 10.1016/j.eurpolymj.2012.12.009; de Wert G, 2003, HUM REPROD, V18, P672, DOI 10.1093/humrep/DEG143; Diniz IMA, 2015, J MATER SCI-MATER M, V26, DOI 10.1007/s10856-015-5493-4; Dong RJ, 2015, BIOMATER SCI-UK, V3, P937, DOI 10.1039/c4bm00448e; Drury JL, 2003, BIOMATERIALS, V24, P4337, DOI 10.1016/S0142-9612(03)00340-5; El-Sherbiny Ibrahim M, 2013, Glob Cardiol Sci Pract, V2013, P316, DOI 10.5339/gcsp.2013.38; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Foldes A, 2016, CURR NEUROPHARMACOL, V14, P914, DOI 10.2174/1570159X14666160121115210; Galli C, 2016, BIOMED MATER, V11, DOI 10.1088/1748-6041/11/1/015004; Ghosal K, 2014, EUR POLYM J, V60, P58, DOI 10.1016/j.eurpolymj.2014.08.006; Gong C, 2017, J BIOMED MATER RES A, V105, P1000, DOI 10.1002/jbm.a.35931; Gyarmati B, 2013, MACROMOL BIOSCI, V13, P633, DOI 10.1002/mabi.201200420; Hasan A, 2018, ACS BIOMATER SCI ENG, V4, P3224, DOI 10.1021/acsbiomaterials.8b00795; Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004; Hu BH, 2009, BIOMACROMOLECULES, V10, P2194, DOI 10.1021/bm900366e; Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867; Jiang Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117982; Juriga D, 2016, ACS APPL MATER INTER, V8, P23463, DOI 10.1021/acsami.6b06489; Kadar K, 2009, J PHYSIOL PHARMACOL, V60, P167; Khatiwala CB, 2006, AM J PHYSIOL-CELL PH, V290, pC1640, DOI 10.1152/ajpcell.00455.2005; Kim HY, 2017, J TISSUE ENG REGEN M, V11, P44, DOI 10.1002/term.1856; Lima DS, 2018, J MOL LIQ, V262, P29, DOI 10.1016/j.molliq.2018.04.002; Lu CC, 2014, J BIOMED MATER RES A, V102, P628, DOI 10.1002/jbm.a.34725; Matsusaki M, 2007, BIOMATERIALS, V28, P2729, DOI 10.1016/j.biomaterials.2007.02.015; Molnar K, 2017, MACROMOL RAPID COMM, V38, DOI 10.1002/marc.201700147; Mun EA, 2016, INT J PHARMACEUT, V512, P32, DOI 10.1016/j.ijpharm.2016.08.026; Nagy K, 2018, INTERV MED APPL SCI, V10, P162, DOI 10.1556/1646.10.2018.21; Nemeth C, 2017, ACTA BIOMATER, V49, P486, DOI 10.1016/j.actbio.2016.11.065; Nezhad-Mokhtari P, 2019, EUR POLYM J, V117, P64, DOI 10.1016/j.eurpolymj.2019.05.004; Park SH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06911-8; Poole LB, 2015, FREE RADICAL BIO MED, V80, P148, DOI 10.1016/j.freeradbiomed.2014.11.013; Sarraf C, 2005, CELL PROLIFERAT, V38, P343, DOI 10.1111/j.1365-2184.2005.00360.x; Sattari S, 2018, J MOL LIQ, V258, P18, DOI 10.1016/j.molliq.2018.02.116; Sawicki LA, 2014, BIOMATER SCI-UK, V2, P1612, DOI 10.1039/c4bm00187g; Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140-6736(04)16627-0; Shafei AE, 2017, J GENE MED, V19, DOI 10.1002/jgm.2995; Shoichet MS, 2010, MACROMOLECULES, V43, P581, DOI 10.1021/ma901530r; Siangsanoh C, 2018, J MOL LIQ, V256, P90, DOI 10.1016/j.molliq.2018.02.026; Stenzel MH, 2013, ACS MACRO LETT, V2, P14, DOI 10.1021/mz3005814; Stephan MT, 2011, NANO TODAY, V6, P309, DOI 10.1016/j.nantod.2011.04.001; Studenovska H, 2010, J TISSUE ENG REGEN M, V4, P454, DOI 10.1002/term.256; Su J, 2018, GELS-BASEL, V4, DOI 10.3390/gels4030072; Svobodova J, 2017, J TISSUE ENG REGEN M, V11, P831, DOI 10.1002/term.1982; Szilagyi BA, 2018, REACT FUNCT POLYM, V133, P21, DOI 10.1016/j.reactfunctpolym.2018.09.015; Tang RL, 2014, J TISSUE ENG REGEN M, V8, P226, DOI 10.1002/term.1516; Tibbitt MW, 2009, BIOTECHNOL BIOENG, V103, P655, DOI 10.1002/bit.22361; Wang HB, 2000, AM J PHYSIOL-CELL PH, V279, pC1345, DOI 10.1152/ajpcell.2000.279.5.C1345; Webber MJ, 2010, J INTERN MED, V267, P71, DOI 10.1111/j.1365-2796.2009.02184.x; Xu Q, 2017, J TISSUE ENG REGEN M, V11, P627, DOI 10.1002/term.1953; Yu J, 2011, NAT CHEM BIOL, V7, P588, DOI [10.1038/NCHEMBIO.630, 10.1038/nchembio.630]; Zhou Y, 2008, J PERIODONTOL, V79, P525, DOI [10.1902/jop.2008.070373, 10.1902/jop.2008.070373 ]	56	8	8	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2019	14	12							e0226363	10.1371/journal.pone.0226363	http://dx.doi.org/10.1371/journal.pone.0226363			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP3WL	31856233	Green Submitted, Green Published, gold, Green Accepted			2023-01-03	WOS:000534249400034
J	Joyner, MJ; Paneth, N				Joyner, Michael J.; Paneth, Nigel			Cardiovascular Disease Prevention at a Crossroads: Precision Medicine or Polypill?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Joyner, Michael J.] Mayo Clin, Dept Anesthesiol & Perioperat Med, Rochester, MN 55905 USA; [Paneth, Nigel] Michigan State Univ, Coll Human Med, Dept Epidemiol, E Lansing, MI 48824 USA; [Paneth, Nigel] Michigan State Univ, Coll Human Med, Dept Biostat, E Lansing, MI 48824 USA; [Paneth, Nigel] Michigan State Univ, Coll Human Med, Dept Pediat, E Lansing, MI 48824 USA; [Paneth, Nigel] Michigan State Univ, Coll Human Med, Dept Human Dev, E Lansing, MI 48824 USA	Mayo Clinic; Michigan State University; Michigan State University College of Human Medicine; Michigan State University; Michigan State University College of Human Medicine; Michigan State University; Michigan State University College of Human Medicine; Michigan State University; Michigan State University College of Human Medicine	Joyner, MJ (corresponding author), Mayo Clin, Dept Anesthesiol & Perioperat Med, Rochester, MN 55905 USA.	joyner.michael@mayo.edu						Adams J, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1001990, 10.1371/journal.pmed.1002045]; Jarvis MC, 2017, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD009868.pub3; Joseph P, 2018, AM HEART J, V206, P72, DOI 10.1016/j.ahj.2018.07.012; Jowett S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182625; Joyner MJ, 2018, ASS COMBINED GENETIC; Munoz D, 2019, NEW ENGL J MED, V381, P1114, DOI 10.1056/NEJMoa1815359; Sosa-Liprandi A, 2019, GLOB HEART, V14, P3, DOI 10.1016/j.gheart.2018.10.001	7	5	5	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	2019	322	23					2281	2282		10.1001/jama.2019.19026	http://dx.doi.org/10.1001/jama.2019.19026			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ6JR	31764938				2023-01-03	WOS:000505208800011
J	Maiti, P; Plemmons, A; Dunbar, GL				Maiti, Panchanan; Plemmons, Alexandra; Dunbar, Gary L.			Combination treatment of berberine and solid lipid curcumin particles increased cell death and inhibited PI3K/Akt/mTOR pathway of human cultured glioblastoma cells more effectively than did individual treatments	PLOS ONE			English	Article							CANCER CELLS; DNA-DAMAGE; INDUCE APOPTOSIS; DIETARY CURCUMIN; COMET ASSAY; MOUSE MODEL; STEM-CELLS; TEMOZOLOMIDE; ROS; PROLIFERATION	The treatment of glioblastoma is challenging for the clinician, due to its chemotherapeutic resistance. Recent findings suggest that targeting glioblastoma using anti-cancer natural polyphenols is a promising strategy. In this context, curcumin and berberine have been shown to have potent anti-cancer and anti-inflammatory effects against several malignancies. Due to the poor solubility and limited bioavailability, these compounds have limited efficacy for treating cancer. However, use of a formulation of curcumin with higher bioavailability or combining it with berberine as a co-treatment may be proving to be more efficacious against cancer. Recently, we demonstrated that solid lipid curcumin particles (SLCPs) provided more bioavailability and anti-cancer effects in cultured glioblastoma cells than did natural curcumin. Interestingly, a combination of curcumin and berberine has proven to be more effective in inhibiting growth and proliferation of cancer in the liver, breast, lung, bone and blood. However, the effect of combining these drugs for treating glioblastoma, especially with respect to its effect on activating the PI3K/Akt/mTOR pathways has not been studied. Therefore, we decided to assess the co-treatment effects of these drugs on two different glioblastoma cell lines (U-87MG and U-251MG) and neuroblastoma cell lines (SH-SY5Y) derived from human tissue. In this study, we compared single and combination (1:5) treatment of SLCP (20 mu M) and berberine (100 mu M) on measures of cell viability, cell death markers, levels of c-Myc and p53, along with biomarkers of the PI3K/Akt/mTOR pathways after 24-48 h of incubation. We found that co-treatment of SLCP and berberine produced more glioblastoma cell death, more DNA fragmentation, and significantly decreased ATP levels and reduced mitochondrial membrane potential than did single treatments in both glioblastoma cells lines. In addition, we observed that co-treatment inhibited the PI3K/Akt/mTOR pathway more efficiently than their single treatments. Our study suggests that combination treatments of SLCP and berberine may be a promising strategy to reduce or prevent glioblastoma growth in comparison to individual treatments using either compound.	[Maiti, Panchanan; Plemmons, Alexandra; Dunbar, Gary L.] Cent Michigan Univ, Field Neurosci Inst, Lab Restorat Neurol, Mt Pleasant, MI 48859 USA; [Maiti, Panchanan; Dunbar, Gary L.] Cent Michigan Univ, Program Neurosci, Mt Pleasant, MI 48859 USA; [Maiti, Panchanan; Dunbar, Gary L.] Cent Michigan Univ, Dept Psychol, Mt Pleasant, MI 48859 USA; [Maiti, Panchanan; Dunbar, Gary L.] Ascens St Marys Hosp, Field Neurosci Inst, Saginaw, MI 48601 USA; [Maiti, Panchanan] Saginaw Valley State Univ, Dept Biol, Saginaw, MI 48710 USA	Central Michigan University; Central Michigan University; Central Michigan University	Maiti, P; Dunbar, GL (corresponding author), Cent Michigan Univ, Field Neurosci Inst, Lab Restorat Neurol, Mt Pleasant, MI 48859 USA.; Maiti, P; Dunbar, GL (corresponding author), Cent Michigan Univ, Program Neurosci, Mt Pleasant, MI 48859 USA.; Maiti, P; Dunbar, GL (corresponding author), Cent Michigan Univ, Dept Psychol, Mt Pleasant, MI 48859 USA.; Maiti, P; Dunbar, GL (corresponding author), Ascens St Marys Hosp, Field Neurosci Inst, Saginaw, MI 48601 USA.; Maiti, P (corresponding author), Saginaw Valley State Univ, Dept Biol, Saginaw, MI 48710 USA.	maiti1p@cmich.edu; dunba1g@cmich.edu			Field Neurosciences Institute of Ascension Health; John G. Kulhavi Professorship at Central Michigan University	Field Neurosciences Institute of Ascension Health; John G. Kulhavi Professorship at Central Michigan University	This research work was supported by Field Neurosciences Institute of Ascension Health and generous donations from Clif and Diane Rafter, Stan Fawcett, and Robert Schellhas, the Neuroscience Program and the John G. Kulhavi Professorship at Central Michigan University. We thank Verdure Science (Noblesville, IN) for donating Solid lipid curcumin particle for this study.	Agnarelli A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28952-3; Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r; Aristotle L, 2004, ANTICANCER RES, V24, P987; Azqueta A, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00288; Balakrishna A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/354614; Chamberlain MC, 2010, EXPERT REV NEUROTHER, V10, P1537, DOI [10.1586/ern.10.32, 10.1586/ERN.10.32]; Cox KHM, 2015, J PSYCHOPHARMACOL, V29, P642, DOI 10.1177/0269881114552744; Dai W, 2019, MED SCI MONITOR, V25, P730, DOI 10.12659/MSM.912082; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Desai V, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9363040; Dhandapani KM, 2007, J NEUROCHEM, V102, P522, DOI 10.1111/j.1471-4159.2007.04633.x; DiSilvestro RA, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-79; Dobbin ZC, 2013, INT J MOL SCI, V14, P8213, DOI 10.3390/ijms14048213; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Freudlsperger C, 2008, ANTICANCER RES, V28, P209; Gersey ZC, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3058-2; Godugu C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089919; Guerra AR, 2018, J AGR FOOD CHEM, V66, P10663, DOI 10.1021/acs.jafc.8b04104; Gupta SC, 2011, NAT PROD REP, V28, P1937, DOI 10.1039/c1np00051a; Jiapaer S, 2018, NEUROL MED-CHIR, V58, P405, DOI 10.2176/nmc.ra.2018-0141; Jin F, 2019, PHARM BIOL, V56, P665, DOI 10.1080/13880209.2018.1548627; Jin P, 2015, ANTI-CANCER AGENT ME, V15, P511, DOI 10.2174/1871520614666141226124110; Kaposi-Novak P, 2009, CANCER RES, V69, P2775, DOI 10.1158/0008-5472.CAN-08-3357; Kasibhatla Shailaja, 2006, CSH Protoc, V2006, DOI 10.1101/pdb.prot4495; Klinger NV, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9324085; Koronyo Y, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93621; Kunwar A, 2008, BBA-GEN SUBJECTS, V1780, P673, DOI 10.1016/j.bbagen.2007.11.016; Kuo CL, 2011, INT J ONCOL, V39, P319, DOI 10.3892/ijo.2011.1057; Laws ER, 2003, J NEUROSURG, V99, P467, DOI 10.3171/jns.2003.99.3.0467; Lee SY, 2016, GENES DIS, V3, P198, DOI 10.1016/j.gendis.2016.04.007; Li J, 2018, ONCOL LETT, V15, P7409, DOI 10.3892/ol.2018.8249; Liu Q, 2015, MOL CANCER THER, V14, P355, DOI 10.1158/1535-7163.MCT-14-0634; Lu W, 2015, MOL MED REP, V11, P3920, DOI 10.3892/mmr.2014.3139; Luthra PM, 2016, EUR J MED CHEM, V109, P23, DOI 10.1016/j.ejmech.2015.11.049; Ma QL, 2013, J BIOL CHEM, V288, P4056, DOI 10.1074/jbc.M112.393751; Maiti P, 2016, HISTOCHEMISTRY CELL; Maiti P, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020399; Maiti Panchanan, 2017, Int J Alzheimers Dis, V2017, P4164872, DOI 10.1155/2017/4164872; Maiti P, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061637; Maiti P, 2018, BMC NEUROSCI, V19, DOI 10.1186/s12868-018-0406-3; Maiti P, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9656719; Maiti P, 2016, HISTOCHEM CELL BIOL, V146, P609, DOI 10.1007/s00418-016-1464-1; Maiti P, 2011, BIOCHEM J, V433, P323, DOI 10.1042/BJ20101391; Maiti P, 2010, J NEUROCHEM, V113, P1252, DOI 10.1111/j.1471-4159.2010.06692.x; McCubrey James A., 2018, Advances in Biological Regulation, V67, P190, DOI 10.1016/j.jbior.2017.09.012; Mirimanoff RO, 2006, J CLIN ONCOL, V24, P2563, DOI 10.1200/JCO.2005.04.5963; Mrugala MM, 2008, NAT CLIN PRACT ONCOL, V5, P476, DOI 10.1038/ncponc1155; Nahar PP, 2015, J MED FOOD, V18, P786, DOI 10.1089/jmf.2014.0053; Nandhakumar S, 2011, J PHARMACOL PHARMACO, V2, P107, DOI 10.4103/0976-500X.81903; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Prasad S., 2011, HERBAL MED BIOMOLECU; Rastogi RP, 2010, BIOCHEM BIOPH RES CO, V397, P603, DOI 10.1016/j.bbrc.2010.06.006; Ravindran J, 2009, AAPS J, V11, P495, DOI 10.1208/s12248-009-9128-x; Rivlin Noa, 2011, Genes Cancer, V2, P466, DOI 10.1177/1947601911408889; Roychaudhuri R, 2015, ACS CHEM NEUROSCI, V6, P1941, DOI 10.1021/acschemneuro.5b00180; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Sawai H, 2011, BIOCHEM BIOPH RES CO, V411, P569, DOI 10.1016/j.bbrc.2011.06.186; Shishodia S, 2005, BIOCHEM PHARMACOL, V70, P700, DOI 10.1016/j.bcp.2005.04.043; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Sivandzade F, 2019, BIO-PROTOCOL, V9, DOI 10.21769/BioProtoc.3128; Sordillo LA, 2015, ANTICANCER RES, V35, P6373; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Syng-ai C, 2004, MOL CANCER THER, V3, P1101; Tong L, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00364; Vengoji Raghupathy, 2018, Oncotarget, V9, P22194, DOI 10.18632/oncotarget.25175; Wang JW, 2016, ONCOTARGET, V7, P66944, DOI 10.18632/oncotarget.11396; Wang K, 2016, SCI REP-UK, V6, DOI 10.1038/srep26064; Wang YH, 2017, INT J NANOMED, V12, P1369, DOI 10.2147/IJN.S124276; Weissenberger J, 2010, CLIN CANCER RES, V16, P5781, DOI 10.1158/1078-0432.CCR-10-0446; Yin HT, 2014, ONCOL REP, V32, P1610, DOI 10.3892/or.2014.3342	70	30	33	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2019	14	12							e0225660	10.1371/journal.pone.0225660	http://dx.doi.org/10.1371/journal.pone.0225660			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP3RM	31841506	gold, Green Published			2023-01-03	WOS:000534236300013
J	Kamau, M; Mirie, W; Kimani, S; Mugoya, I				Kamau, Mary; Mirie, Waithira; Kimani, Samuel; Mugoya, Isaac			Effect of community based health education on knowledge and attitude towards iron and folic acid supplementation among pregnant women in Kiambu County, Kenya: A quasi experimental study	PLOS ONE			English	Article							SERVICES; MOTHERS; INDIA	Introduction Iron and Folic Acid Supplementation (IFAS) services are currently provided free of charge to pregnant women in Kenya during antenatal care (ANC) but compliance remains low. Poor awareness is an important factor contributing to low utilization of IFAS. Inadequate counselling is one of the key factors associated with poor awareness on IFAS. Community based health education is a promising diversification strategy for IFAS health education to curb this problem. Objectives To determine effect of community based IFAS health education, utilizing CHVs, on IFAS knowledge, levels of counselling on various IFAS topics and attitude towards IFAS among pregnant women in Kiambu County. Methodology A Pretest-Posttest Quasi-Experimental study design, consisting of intervention and control group, was applied among 340 pregnant women 18-49 years, in five health facilities, selected using two stage sampling in Lari Sub-County, Kiambu County, Kenya. Community health volunteers provided IFAS health education with weekly supplements and follow-ups to pregnant women in intervention group, while control group received the same from health care providers. Baseline and endline data were collected during ANC and compared. Quantitative data was analyzed using STATA version 14. Analysis of effect of intervention was done using Difference-In-Difference approach. Results There was an effect difference in maternal IFAS knowledge of 13%, with intervention group levels increasing most by 35 percentage points. The odds of being knowledgeable were 3 times more at endline than baseline. There was significant (p<0.001) change in proportion with positive attitude towards IFAS: the odds of having positive attitude at endline was 9 times that of baseline (OR = 9.2:95%CI 3.1, 27.2). Conclusion Implementation of community based health education improved maternal knowledge, positive attitude and proportion of pregnant women counselled on IFAS, better improvement being recorded in intervention group. Hence, there is need to integrate community based approach with antenatal IFAS distribution to improve supplementation.	[Kamau, Mary; Mirie, Waithira; Kimani, Samuel] Univ Nairobi, Sch Nursing Sci, Nairobi, Kenya; [Mugoya, Isaac] John Snow Inc, Nairobi, Kenya	University of Nairobi	Kamau, M (corresponding author), Univ Nairobi, Sch Nursing Sci, Nairobi, Kenya.	kwanjira@uonbi.ac.ke	Kamau, Mary/ABF-7607-2020	Kamau, Mary/0000-0002-4167-3549; kimani, Samuel/0000-0003-1537-6804	Consortium for Advanced Research Training in Africa (CARTA); Carnegie Corporation of New York [B 8606.R02]; Sida [54100029]; DELTAS Africa Initiative [107768/Z/15/Z]; African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA); New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust (UK) [107768/Z/15/Z]; UK government	Consortium for Advanced Research Training in Africa (CARTA); Carnegie Corporation of New York; Sida; DELTAS Africa Initiative; African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA); New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust (UK)(Wellcome Trust); UK government	This research was supported by the Consortium for Advanced Research Training in Africa (CARTA). CARTA is jointly led by the African Population and Health Research Center and the University of the Witwatersrand and funded by the Carnegie Corporation of New York (Grant No--B 8606.R02), Sida (Grant No:54100029), the DELTAS Africa Initiative (Grant No: 107768/Z/15/Z). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (UK) (Grant No: 107768/Z/15/Z) and the UK government, "The statements made and views expressed are solely the responsibility of the fellow. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in form of research materials to carry out the study. The funder (CARTA) did not provide support in the form of salaries for authors and John Snow Inc. had no role to play in this study.	Abdullahi Hala, 2014, BMC Res Notes, V7, P498, DOI 10.1186/1756-0500-7-498; Aguayo VM, 2005, PUBLIC HEALTH NUTR, V8, P33, DOI 10.1079/PHN2004664; Al-Akhfash AA, 2013, SAUDI MED J, V34, P1173; Al-Hossani H., 2010, Eastern Mediterranean Health Journal, V16, P402; Alam A, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1697-2; Bilimale A, 2010, AUSTRALAS MED J, V3, P281, DOI 10.4066/AMJ.2010.291; Bin Nisar Y, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-305; Birhanu Z, 2018, MATERN CHILD NUTR, V14, DOI 10.1111/mcn.12424; Bruce Martha L, 2002, Ment Health Serv Res, V4, P205, DOI 10.1023/A:1020912531637; Demidenko E, 2008, STAT MED, V27, P36, DOI 10.1002/sim.2980; Galloway R, 1994, SOC SCI MED, P39, DOI [10.1016/0277-9536(94)90164-3, DOI 10.1016/0277-9536(94)90164-3]; Gebreamlak B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169415; Gebremariam AD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210086; Gebremedhin S, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-607; Getachew M, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1716-2; Ilmas T., 2018, THESIS; Kamau M, 2018, AAS OPEN RES, V1; Kamau MW, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5437-2; Klassen TP, 2000, FUTURE CHILD, V10, P83, DOI 10.2307/1602826; Kothari CR, 2014, REMETHODOLOGY METH, V3rd ed; Lee JH, 2007, ADDICT BEHAV, V32, P187, DOI 10.1016/j.addbeh.2006.03.030; Liu N, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-45; Mahmoud A-HAW, 2007, IRON DEFICIENCY ANEM; Maina-Gathigi L, 2013, MATERN CHILD HLTH J, V17, P1236, DOI 10.1007/s10995-012-1120-x; Matiri E, 2017, IMPROVING IRON FOLIC; MCHIP, 2014, COMM BAS DISTR ROUT; MCSP. MCSP Nutrition Brief, 2017, COMM BAS DISTR IR FO; Muro Grace S., 1999, Food and Nutrition Bulletin, V20, P435; Nadia H., 2018, IOSR J NURS HLTH SCI, V7, P49; Nairobi, 2012, ACC RED IR DEF AN PR; Nairobi, 2013, NAT POL GUID COMB IR; Nairobi, 2012, IFAS DIAL GUID HLTH; Nairobi, 2013, NAT IR FOL AC SUPPL; NISAR N, 2014, PLOS ONE, V9, DOI DOI 10.1371/JOURNAL.PONE.0112446; Nuno L, 2008, ADEQUACY PRENATAL CA, V24, P1151; Owusu-Darko I, 2014, APPL GEN ESTIMATING, P3359; Pal PP, 2013, INT J PREVENTIVE MED, V4, P1213; Pouchieu C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070733; Rai S., 2013, COMPLIANCE ITS DETER; Sadore AA, 2015, J ENVIRON PUBLIC HEA, V2015, DOI 10.1155/2015/781973; Saprii L, 2015, HUM RESOUR HEALTH, V13, DOI 10.1186/s12960-015-0094-3; Seck BC, 2008, PUBLIC HEALTH NUTR, V11, P596, DOI 10.1017/S1368980007000924; Shivalli S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137735; Taye B, 2015, PAN AFR MED J, V20, DOI [10.11604/pamj.2015.20.43.4894, 10.11604/pamj.2015.20.276.4243]; Tenaw Z., 2018, INT J NURS MIDWIFERY, V10, P81, DOI DOI 10.5897/IJNM2017.0289; Titaley CR, 2014, ASIA PAC J CLIN NUTR, V23, P91, DOI 10.6133/apjcn.2014.23.1.18; Wang M., 2014, ADV STAT, V1, P1, DOI [10.1155/2014/303728, DOI 10.1155/2014/303728]; Wendt A, 2014, FASEB J S, P28; WHO, 2017, NUTR AN TOOLS EFF PR; Wiradnyani LAA, 2016, PUBLIC HEALTH NUTR, V19, P2818, DOI 10.1017/S1368980016001002; World Health Organization, 2012, GUID DAIL IR FOL AC; Yekta Z, 2008, J RES HEALTH SCI, V8, P39; Zafar M, 2014, BMC PUBLIC HEALTH, V14, DOI [10.1186/1471-2393-14-344, 10.1186/1471-2458-14-437]	53	5	5	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 25	2019	14	11							e0224361	10.1371/journal.pone.0224361	http://dx.doi.org/10.1371/journal.pone.0224361			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LO8QR	31765422	gold, Green Published			2023-01-03	WOS:000533891000007
J	D'Abramo, A; Lepore, L; Iannetta, M; Tekle, SG; Corpolongo, A; Scorzolini, L; Bevilacqua, N; Mariano, A; Giancola, ML; Vulcano, A; Maritti, M; Agresta, A; Antonini, M; D'Alessandro, U; Nicastri, E				D'Abramo, Alessandra; Lepore, Luciana; Iannetta, Marco; Tekle, Saba Gebremeskel; Corpolongo, Angela; Scorzolini, Laura; Bevilacqua, Nazario; Mariano, Andrea; Giancola, Maria Letizia; Vulcano, Antonella; Maritti, Micaela; Agresta, Alessandro; Antonini, Mario; D'Alessandro, Umberto; Nicastri, Emanuele		Spallanzani Grp Malaria Study	Imported severe malaria and risk factors for intensive care: A single-centre retrospective analysis	PLOS ONE			English	Article							SEVERE FALCIPARUM-MALARIA; SCORE; ARTESUNATE; MORTALITY; QUININE; SEPSIS	Objectives This study aims to identify the risk factors for intensive care (IC) in severe malaria patients admitted to the "Lazzaro Spallanzani" National Institute for Infectious Diseases, Rome, Italy. Methods All patients with confirmed severe malaria and hospitalized between 2007 and 2015 were included in the analysis and stratified into two groups: those requiring IC and those who did not. Five prognostic malaria scores were estimated; clinical severity at IC unit admission was assessed using the Sequential Organ Failure Assessment and the quick-Sequential Organ Failure Assessment scores. Univariate and multivariate analysis were performed to assess factors independently associated to IC. Results A total of 98 severe malaria patients were included; 10 of them required IC. There were no deaths or sequelae. Patients requiring IC had higher severity scores. At the multivariate analysis, only the number of World Health Organization criteria and the aspartate aminotransferase value were independently associated with the need of IC. Conclusions An early and accurate assessment of the severity score is essential for the management of severe malaria patients.	[D'Abramo, Alessandra; Lepore, Luciana; Iannetta, Marco; Tekle, Saba Gebremeskel; Corpolongo, Angela; Scorzolini, Laura; Bevilacqua, Nazario; Mariano, Andrea; Giancola, Maria Letizia; Vulcano, Antonella; Maritti, Micaela; Agresta, Alessandro; Antonini, Mario; Nicastri, Emanuele] IRCCS Lazzaro Spallanzani, Natl Inst Infect Dis, Rome, Italy; [D'Alessandro, Umberto] London Sch Hyg & Trop Med, MRC Unit Gambia, Atlantic Blvd, Fajara, Gambia	IRCCS Lazzaro Spallanzani; University of London; London School of Hygiene & Tropical Medicine	Iannetta, M (corresponding author), IRCCS Lazzaro Spallanzani, Natl Inst Infect Dis, Rome, Italy.	marco.iannetta@inmi.it	Scorzolini, Laura/AAC-7427-2022; MARITTI, MICAELA/AHD-4512-2022; Iannetta, Marco/B-5596-2017; Iannetta, Marco/M-4619-2019; D'Abramo, Alessandra/AAA-3054-2019; Scognamiglio, Paola/B-4754-2017; Di Caro, Antonino/K-6854-2016	MARITTI, MICAELA/0000-0003-0606-6353; Iannetta, Marco/0000-0002-6938-8627; Iannetta, Marco/0000-0002-6938-8627; D'Abramo, Alessandra/0000-0002-5160-9743; Scognamiglio, Paola/0000-0002-7938-6457; Di Caro, Antonino/0000-0001-6027-3009; Lepore, Luciana/0000-0002-7965-8168; Giancola, Maria Letizia/0000-0003-2481-6621	Ricerca Corrente and Ricerca finalizzata WFR [PE-2013-02357936]; Italian Ministry of Health	Ricerca Corrente and Ricerca finalizzata WFR; Italian Ministry of Health(Ministry of Health, Italy)	This study was supported by Ricerca Corrente and Ricerca finalizzata WFR PE-2013-02357936 funded by the Italian Ministry of Health to EN.	Arama C, 2015, ACTA TROP, V146, P152, DOI 10.1016/j.actatropica.2015.03.023; Bruneel F., 2018, MED MAL INFECT; Bruneel F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013236; Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1; European Centre for Disease Prevention and Control, 2014, ANN EP REP 2014 EM V; Faiz MA, 2005, LANCET, V366, P717; GREENBERG AE, 1990, ANN INTERN MED, V113, P326, DOI 10.7326/0003-4819-113-4-326; Hanson J, 2010, CLIN INFECT DIS, V50, P679, DOI 10.1086/649928; Kain KC, 1998, CLIN INFECT DIS, V27, P142, DOI 10.1086/514616; Marks M, 2014, BRIT J ANAESTH, V113, P910, DOI 10.1093/bja/aeu157; Mishra SK, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-24; Mohapatra Biranchi Narayan, 2014, J Assoc Physicians India, V62, P14; Mohapatra M K, 2009, J Assoc Physicians India, V57, P119; SABATINELLI G, 1994, T ROY SOC TROP MED H, V88, P314, DOI 10.1016/0035-9203(94)90097-3; Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288; Tatem AJ, 2017, LANCET INFECT DIS, V17, P98, DOI 10.1016/S1473-3099(16)30326-7; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; WHO, 2015, WORLD MAL REP 2015; 2010, WORLD MAL REP 2010, P1	19	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2019	14	11							e0225135	10.1371/journal.pone.0225135	http://dx.doi.org/10.1371/journal.pone.0225135			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN2HK	31725774	Green Accepted, Green Published, gold			2023-01-03	WOS:000532764500059
J	Nigwekar, SU; Pai, AB; Mueller, B; Dean, MC; Costello, G; Sherman, CR				Nigwekar, Sagar U.; Pai, Amy Barton; Mueller, Bruce; Dean, Michael C.; Costello, Gabrielle; Sherman, Craig R.			Impact of hemodialysis on the concentrations of sodium and potassium during infusion of sodium thiosulfate using an In Vitro hemodialysis model	PLOS ONE			English	Article							CALCIPHYLAXIS; BLOOD	Introduction The purpose of this study was to evaluate the impact of hemodialysis on the concentrations of sodium and potassium in the blood when a 25 g dose of sodium thiosulfate injection is infused over 60 minutes in combination with hemodialysis. Methods Sodium thiosulfate (25 g) was prepared by diluting 100 mL of 250 mg/mL Sodium Thiosulfate Injection with 800 mL of 5% dextrose. This was added to the circulating blood surrogate solution at a rate of 15 mL/minute using an infusion pump of an in vitro model of dialysis machine. Serial samples were collected before the administration of the sodium thiosulfate solution, after 15 minutes, 30 minutes, and 60 minutes of infusion from pre-and post-dialyzer ports in both the dialysate circuit and the extracorporeal circuit. Findings The concentration of sodium thiosulfate in pre-dialyzer and post-dialyzer samples of the circulating blood surrogate solution peaked at 30 minutes and 15 minutes, respectively and then remained relatively unchanged during the remainder of the infusion. Mean sodium concentrations (mEq/L) in the circulating blood surrogate solution collected after exposure to a dialyzer were 103.2 +/- 12.2, 114.2 +/- 18.8, 117.2 +/- 7.5, 93.5 +/- 5.9 at 0, 15, 30, and 60 minutes, respectively (p = 0.248). Mean potassium concentrations (mEq/L) in the circulating blood surrogate solution collected after exposure to a dialyzer were 1.4 +/- 0.3, 1.6 +/- 0.3, 1.5 +/- 0.1, 1.2 +/- 0.1 at 0, 15, 30, and 60 minutes, respectively (p = 0.365). Sodium and potassium concentrations in dialysate increased marginally after exposure to the dialyzer. Discussion Our study demonstrates that neither potassium nor sodium accumulated in circulating blood surrogate solution when a dose of sodium thiosulfate was infused in conjunction with hemodialysis.	[Nigwekar, Sagar U.] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA; [Pai, Amy Barton; Mueller, Bruce; Dean, Michael C.; Costello, Gabrielle] Univ Michigan, Coll Pharm, 428 Church St, Ann Arbor, MI 48109 USA; [Sherman, Craig R.] Hope Pharmaceut, Scottsdale, AZ 85260 USA	Harvard University; Massachusetts General Hospital; University of Michigan System; University of Michigan	Sherman, CR (corresponding author), Hope Pharmaceut, Scottsdale, AZ 85260 USA.	sherman@hopepharm.com	Dean, Michael C/G-8172-2012	Dean, Michael C/0000-0003-2234-0631; Dean, Michael/0000-0002-4753-2114	Hope Pharmaceuticals	Hope Pharmaceuticals	This work was funded by the Hope Pharmaceuticals. The funder provided support in the form of salaries for author CRS. CRS played a role in study design, data collection and analysis, decision to publish, and preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Cicone JS, 2004, AM J KIDNEY DIS, V43, P1104, DOI 10.1053/j.ajkd.2004.03.018; Gharibian KN, 2018, J NUCL CARDIOL, V25, P234, DOI 10.1007/s12350-016-0667-0; Hundemer GL, 2016, AM J KIDNEY DIS, V68, P499, DOI 10.1053/j.ajkd.2016.02.040; Kales SN, 2004, NEW ENGL J MED, V350, P800, DOI 10.1056/NEJMra030370; MICHAEL JM, 1975, TRANSFUSION, V15, P144; Morocco AP, 2005, CRIT CARE CLIN, V21, P691, DOI 10.1016/j.ccc.2005.06.002; Nigwekar SU, 2018, NEW ENGL J MED, V378, P1704, DOI 10.1056/NEJMra1505292; Nigwekar SU, 2013, CLIN J AM SOC NEPHRO, V8, P1162, DOI 10.2215/CJN.09880912; Noureddine L, 2011, CLIN NEPHROL, V75, P485, DOI 10.5414/CNP75485; Pani A, 2014, SEMIN DIALYSIS, V27, P571, DOI 10.1111/sdi.12272; Peng T, 2018, NEPHROLOGY, V23, P669, DOI 10.1111/nep.13081; Singh RP, 2011, CLIN J AM SOC NEPHRO, V6, P1155, DOI 10.2215/CJN.09671010; Tanhehco YC, 2012, SEMIN DIALYSIS, V25, P539, DOI 10.1111/j.1525-139X.2012.01089.x; Zitt E, 2013, NEPHROL DIAL TRANSPL, V28, P1232, DOI 10.1093/ndt/gfs548	14	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2019	14	11							e0224767	10.1371/journal.pone.0224767	http://dx.doi.org/10.1371/journal.pone.0224767			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN1QS	31721800	Green Submitted, gold, Green Published			2023-01-03	WOS:000532720700029
J	Perl, AE; Martinelli, G; Cortes, JE; Neubauer, A; Berman, E; Paolini, S; Montesinos, P; Baer, MR; Larson, RA; Ustun, C; Fabbiano, F; Erba, HP; Di Stasi, A; Stuart, R; Olin, R; Kasner, M; Ciceri, F; Chou, WC; Podoltsev, N; Recher, C; Yokoyama, H; Hosono, N; Yoon, SS; Lee, JH; Pardee, T; Fathi, AT; Liu, C; Hasabou, N; Liu, X; Bahceci, E; Levis, MJ				Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Ustun, C.; Fabbiano, F.; Erba, H. P.; Di Stasi, A.; Stuart, R.; Olin, R.; Kasner, M.; Ciceri, F.; Chou, W-C; Podoltsev, N.; Recher, C.; Yokoyama, H.; Hosono, N.; Yoon, S-S; Lee, J-H; Pardee, T.; Fathi, A. T.; Liu, C.; Hasabou, N.; Liu, X.; Bahceci, E.; Levis, M. J.			Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; D835 MUTATIONS; FLT3 GENE; INHIBITION; ACTIVATION; MULTICENTER; CYTARABINE; RESISTANCE; SORAFENIB	BACKGROUND Patients with relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to salvage chemotherapy. Gilteritinib is an oral, potent, selective FLT3 inhibitor with single-agent activity in relapsed or refractory FLT3-mutated AML. METHODS In a phase 3 trial, we randomly assigned adults with relapsed or refractory FLT3-mutated AML in a 2:1 ratio to receive either gilteritinib (at a dose of 120 mg per day) or salvage chemotherapy. The two primary end points were overall survival and the percentage of patients who had complete remission with full or partial hematologic recovery. Secondary end points included event-free survival (freedom from treatment failure [i.e., relapse or lack of remission] or death) and the percentage of patients who had complete remission. RESULTS Of 371 eligible patients, 247 were randomly assigned to the gilteritinib group and 124 to the salvage chemotherapy group. The median overall survival in the gilteritinib group was significantly longer than that in the chemotherapy group (9.3 months vs. 5.6 months; hazard ratio for death, 0.64; 95% confidence interval [CI], 0.49 to 0.83; P<0.001). The median event-free survival was 2.8 months in the gilteritinib group and 0.7 months in the chemotherapy group (hazard ratio for treatment failure or death, 0.79; 95% CI, 0.58 to 1.09). The percentage of patients who had complete remission with full or partial hematologic recovery was 34.0% in the gilteritinib group and 15.3% in the chemotherapy group (risk difference, 18.6 percentage points; 95% CI, 9.8 to 27.4); the percentages with complete remission were 21.1% and 10.5%, respectively (risk difference, 10.6 percentage points; 95% CI, 2.8 to 18.4). In an analysis that was adjusted for therapy duration, adverse events of grade 3 or higher and serious adverse events occurred less frequently in the gilteritinib group than in the chemotherapy group; the most common adverse events of grade 3 or higher in the gilteritinib group were febrile neutropenia (45.9%), anemia (40.7%), and thrombocytopenia (22.8%). CONCLUSIONS Gilteritinib resulted in significantly longer survival and higher percentages of patients with remission than salvage chemotherapy among patients with relapsed or refractory FLT3-mutated AML.	[Kasner, M.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Kasner, M.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA; [Martinelli, G.] Ist Ricovero Cura Carattere Sci IRCCS, Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy; [Paolini, S.] Bologna Univ, Med Sch, L&A Seragnoli Inst Hematol Bologna, Bologna, Italy; [Fabbiano, F.] Osped Riuniti Villa Sofia Cervello, Palermo, Italy; [Ciceri, F.] IRCCS San Raffaele Sci Inst, Milan, Italy; [Cortes, J. E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Neubauer, A.] Univ Klinikum Giessen & Marburg, Marburg, Germany; [Berman, E.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Montesinos, P.] Hosp Univ & Politecn La Fe, Valencia, Spain; [Montesinos, P.] Inst Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain; [Baer, M. R.] Univ Maryland, Greenbaum Comprehens Canc Ctr, Baltimore, MD 21201 USA; [Levis, M. J.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; [Larson, R. A.] Univ Chicago, Chicago, IL 60637 USA; [Liu, C.; Hasabou, N.; Liu, X.; Bahceci, E.] Astellas Pharma, Northbrook, IL USA; [Ustun, C.] Univ Minnesota, Minneapolis, MN USA; [Erba, H. P.; Di Stasi, A.] Univ Alabama Birmingham, Birmingham, AL USA; [Stuart, R.] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Olin, R.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Chou, W-C] Natl Taiwan Univ, Taipei, Taiwan; [Podoltsev, N.] Yale Univ, Sch Med, New Haven, CT USA; [Recher, C.] Univ Toulouse III Paul Sabatier, Inst Univ Canc Toulouse Oncopole, CHU Toulouse, Toulouse, France; [Yokoyama, H.] Natl Hosp Org, Sendai Med Ctr, Sendai, Miyagi, Japan; [Hosono, N.] Univ Fukui, Fukui, Japan; [Yoon, S-S] Seoul Natl Univ, Seoul, South Korea; [Lee, J-H] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea; [Pardee, T.] Wake Forest Baptist Med Ctr, Winston Salem, NC USA; [Fathi, A. T.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA	University of Pennsylvania; Pennsylvania Medicine; Jefferson University; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Meldola (IRST); University of Bologna; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Texas System; UTMD Anderson Cancer Center; University Hospital of Giessen & Marburg; Memorial Sloan Kettering Cancer Center; Hospital Universitari i Politecnic La Fe; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine; University of Chicago; Astellas Pharmaceuticals; University of Minnesota System; University of Minnesota Twin Cities; University of Alabama System; University of Alabama Birmingham; Medical University of South Carolina; University of California System; University of California San Francisco; National Taiwan University; Yale University; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Fukui; Seoul National University (SNU); University of Ulsan; Asan Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Harvard University; Harvard Medical School; Massachusetts General Hospital	Perl, AE (corresponding author), Perelman Ctr AdV Med, 12 South,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	alexander.perl@uphs.upenn.edu	Yoon, Sung-Soo/J-2773-2012; Olin, Rebecca/AAD-6629-2020; ustun, celalettin/AEM-2670-2022; 寿行, 横山/AAF-7015-2019; Martinelli, Giovanni/AAK-9211-2020; ustun, celalettin/AAF-7448-2020	Martinelli, Giovanni/0000-0002-1025-4210; Lee, Je-Hwan/0000-0002-7060-1675; Pardee, Timothy/0000-0002-1186-6948; Yokoyama, Hisayuki/0000-0001-7658-0687; PAOLINI, Stefania/0000-0002-5645-0364; Montesinos, Pau/0000-0002-3275-5593; Cortes, Jorge/0000-0002-8636-1071; CHOU, WEN-CHIEN/0000-0003-2967-698X	Astellas Pharma	Astellas Pharma(Astellas Pharmaceuticals)	Supported by Astellas Pharma.	Borthakur G, 2011, HAEMATOL-HEMATOL J, V96, P62, DOI 10.3324/haematol.2010.030452; Cella D, 2012, VALUE HEALTH, V15, P1051, DOI 10.1016/j.jval.2012.08.2210; Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036; Chevallier P, 2011, LEUKEMIA, V25, P939, DOI 10.1038/leu.2011.25; Cortes J, 2018, LANCET ONCOL, V19, P889, DOI 10.1016/S1470-2045(18)30240-7; Cortes JE, 2019, LANCET ONCOL, V20, P984, DOI 10.1016/S1470-2045(19)30150-0; Megias-Vericat JE, 2018, ANN HEMATOL, V97, P1115, DOI 10.1007/s00277-018-3304-y; Fischer T, 2010, J CLIN ONCOL, V28, P4339, DOI 10.1200/JCO.2010.28.9678; Galanis A, 2015, HAEMATOLOGICA, V100, pE77, DOI 10.3324/haematol.2014.117028; Galanis A, 2014, BLOOD, V123, P94, DOI 10.1182/blood-2013-10-529313; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Jackson G, 2001, BRIT J HAEMATOL, V112, P127, DOI 10.1046/j.1365-2141.2001.02551.x; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; Lee LY, 2017, BLOOD, V129, P257, DOI 10.1182/blood-2016-10-745133; Levis M, 2011, BLOOD, V117, P3294, DOI 10.1182/blood-2010-08-301796; Litzow MR, 2010, BRIT J HAEMATOL, V148, P217, DOI 10.1111/j.1365-2141.2009.07917.x; Man CH, 2012, BLOOD, V119, P5133, DOI 10.1182/blood-2011-06-363960; McMahon CM, 2019, CANCER DISCOV, V9, P1050, DOI 10.1158/2159-8290.CD-18-1453; Mori M, 2017, INVEST NEW DRUG, V35, P556, DOI 10.1007/s10637-017-0470-z; Murphy KM, 2003, J MOL DIAGN, V5, P96, DOI 10.1016/S1525-1578(10)60458-8; Nakao M, 1996, LEUKEMIA, V10, P1911; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Park IK, 2013, BLOOD, V121, P2064, DOI 10.1182/blood-2012-07-444018; Perl AE, 2017, LANCET ONCOL, V18, P1061, DOI 10.1016/S1470-2045(17)30416-3; Ravandi F, 2015, LANCET ONCOL, V16, P1025, DOI 10.1016/S1470-2045(15)00201-6; Ravandi F, 2010, LEUKEMIA RES, V34, P752, DOI 10.1016/j.leukres.2009.10.001; Roboz GJ, 2014, J CLIN ONCOL, V32, P1919, DOI 10.1200/JCO.2013.52.8562; SMALL D, 1994, P NATL ACAD SCI USA, V91, P459, DOI 10.1073/pnas.91.2.459; Smith BD, 2004, BLOOD, V103, P3669, DOI 10.1182/blood-2003-11-3775; Smith CC, 2015, LEUKEMIA, V29, P2390, DOI 10.1038/leu.2015.165; Smith CC, 2012, NATURE, V485, P260, DOI 10.1038/nature11016; Stone RM, 2017, NEW ENGL J MED, V377, P454, DOI 10.1056/NEJMoa1614359; Wattad M, 2017, LEUKEMIA, V31, P1306, DOI 10.1038/leu.2017.23; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434	34	486	494	1	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 31	2019	381	18					1728	1740		10.1056/NEJMoa1902688	http://dx.doi.org/10.1056/NEJMoa1902688			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ3JI	31665578	Green Published, Bronze			2023-01-03	WOS:000498845000008
J	Sunder, S; Grammatico-Guillon, L; Lemaignen, A; Lacasse, M; Gaborit, C; Boutoille, D; Tattevin, P; Denes, E; Guimard, T; Dupont, M; Fauchier, L; Bernard, L				Sunder, S.; Grammatico-Guillon, L.; Lemaignen, A.; Lacasse, M.; Gaborit, C.; Boutoille, D.; Tattevin, P.; Denes, E.; Guimard, T.; Dupont, M.; Fauchier, L.; Bernard, L.			Incidence, characteristics, and mortality of infective endocarditis in France in 2011	PLOS ONE			English	Article							INTERNATIONAL COLLABORATION; STAPHYLOCOCCUS-AUREUS; TEMPORAL TRENDS; POPULATION; EPIDEMIOLOGY; PREVENTION; GUIDELINES; DIAGNOSIS; ETIOLOGY; SURGERY	Objectives We assessed the determinants of mortality in infective endocarditis (IE), using the national hospital discharge databases (HDD) in 2011. Methods IE stays were extracted from the national HDD, with a definition based on IE-related diagnosis codes. This definition has been assessed according to Duke criteria by checking a sample of medical charts of IE giving a predictive positive value of 86.1% (95% confidence interval (CI): 82.7% - 89.5%). The impact of heart valve surgery on survival has been studied if performed during the initial stay, and over the year of follow-up. Risk factors of in-hospital mortality were identified using logistic regression model for the initial stay and Cox Timedependent model for the 1-year mortality. Results The analysis included 6,235 patients. The annual incidence of definite IEs was 63 cases/million residents. Staphylococci and Streptococci were the most common bacteria (44% and 45%, respectively). A valvular surgery was performed in 20% of cases, but substantial variations existed between hospitals. The in-hospital mortality was 21% (ranging 12% to 27% according to the region of patients), associated with age> 70, chronic liver disease, renal failure, S. aureus, P. aeruginosa or candida infection and strokes whereas valvular surgery, a native valve IE or intraveinous drug use (right heart IE) were significantly protective for an initial death. The same factors were associated with the one-year mortality, except for valvular surgery which was associated with a 1.4-fold higher risk of death during the year post IE. Conclusion We reported a high IE incidence rate. Valvular surgery was considerably less frequent in this study than in the previous published data (near 50%) whereas mortality was similar. Surgery was associated with higher survival if undergone within the initial stay. There were significant regional differences in frequency of surgery but it did not impact mortality.	[Sunder, S.] CH Niort, Serv Malad Infect & Trop, Niort, France; [Grammatico-Guillon, L.; Bernard, L.] CHRU Tours, EpiDcliC, Unite Epidemiol Donnees Clin, Tours, France; [Grammatico-Guillon, L.; Gaborit, C.] Univ Tours, Unite Inserm 1259, Tours, France; [Lemaignen, A.; Lacasse, M.; Bernard, L.] CHRU Tours, Serv Med Interne & Malad Infect, Tours, France; [Boutoille, D.] CHU Nantes, Serv Malad Infect & Trop, Nantes, France; [Tattevin, P.] CHU Rennes, Serv Malad Infect & Reanimat Med, Rennes, France; [Denes, E.] CHU Limoges, Serv Malad Infect & Trop, Limoges, France; [Guimard, T.] CH Roche Yon Serv, Serv Malad Infect, La Roche Sur Yon, France; [Dupont, M.] CH St Malo, Serv Malad Resp & Infect, St Malo, France; [Fauchier, L.] Univ Tours, Equipe Accueil EA 1275, Tours, France; [Fauchier, L.] CHRU Tours, Serv Cardiol, Tours, France	CHU Tours; Universite de Tours; CHU Tours; Nantes Universite; CHU de Nantes; CHU Rennes; CHU Limoges; CHD Vendee; Universite de Tours; CHU Tours	Grammatico-Guillon, L (corresponding author), CHRU Tours, EpiDcliC, Unite Epidemiol Donnees Clin, Tours, France.; Grammatico-Guillon, L (corresponding author), Univ Tours, Unite Inserm 1259, Tours, France.	leslie.guillon@univ-tours.fr	fauchier, laurent/HDN-2353-2022; Fauchier, Laurent/AAE-6366-2021; Lemaignen, Adrien/L-5921-2018; DENES, Eric/ABI-2443-2020	Fauchier, Laurent/0000-0002-9267-1658; Lemaignen, Adrien/0000-0001-5974-5689; DENES, Eric/0000-0001-5321-3171; Grammatico-Guillon, Leslie/0000-0001-7934-8912				Akha AAS, 2018, J IMMUNOL METHODS, V463, P21, DOI 10.1016/j.jim.2018.08.005; Cresti A, 2017, CARDIOVASC DIAGN THE, V7, P27, DOI 10.21037/cdt.2016.08.09; Cuervo G, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy183; Dayer MJ, 2015, LANCET, V385, P1219, DOI 10.1016/S0140-6736(14)62007-9; DeSimone DC, 2015, MAYO CLIN PROC, V90, P874, DOI 10.1016/j.mayocp.2015.04.019; Duval X, 2012, J AM COLL CARDIOL, V59, P1968, DOI 10.1016/j.jacc.2012.02.029; Dzupova O, 2012, SCAND J INFECT DIS, V44, P250, DOI 10.3109/00365548.2011.632643; Fedeli U, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-48; Forestier E, 2016, CLIN INTERV AGING, V11, P1199, DOI 10.2147/CIA.S101902; Gavazzi G, 2002, LANCET INFECT DIS, V2, P659, DOI 10.1016/S1473-3099(02)00437-1; Grammatico L, 2008, EPIDEMIOL INFECT, V136, P653, DOI 10.1017/S0950268807008850; Grammatico-Guillon L, 2012, J HOSP INFECT, V82, P40, DOI 10.1016/j.jhin.2012.04.025; Grammatico-Guillon L, 2014, INFECT CONT HOSP EP, V35, P646, DOI 10.1086/676423; Habib G, 2015, EUR HEART J, V36, P3075, DOI [10.5603/KP.2015.0227, 10.1093/eurheartj/ehv319]; Habib G, 2009, EUR HEART J, V30, P2369, DOI 10.1093/eurheartj/ehp285; Hoen B, 2013, NEW ENGL J MED, V368, P1425, DOI 10.1056/NEJMcp1206782; Iversen K, 2019, NEW ENGL J MED, V380, P415, DOI 10.1056/NEJMoa1808312; Kang DH, 2015, HEART, V101, P1786, DOI 10.1136/heartjnl-2015-307878; Keller K, 2017, AM J CARDIOL, V119, P317, DOI 10.1016/j.amjcard.2016.09.035; Miro JM, 2005, CLIN INFECT DIS, V41, P507, DOI 10.1086/431979; Murdoch DR, 2009, ARCH INTERN MED, V169, P463, DOI 10.1001/archinternmed.2008.603; N'Guyen Y, 2017, ANN MED, V49, P117, DOI 10.1080/07853890.2016.1235282; Olmos C, 2017, J AM COLL CARDIOL, V70, P2795, DOI 10.1016/j.jacc.2017.10.005; Ostergaard L, 2018, EUR J CARDIO-THORAC, V54, P860, DOI 10.1093/ejcts/ezy156; Pant S, 2015, J AM COLL CARDIOL, V65, P2070, DOI 10.1016/j.jacc.2015.03.518; Pazdernik M, 2016, BIOMED PAP, V160, P298, DOI 10.5507/bp.2015.062; Rhee C, 2014, NEW ENGL J MED, V370, P1673, DOI 10.1056/NEJMp1400276; Selton-Suty C, 2012, CLIN INFECT DIS, V54, P1230, DOI 10.1093/cid/cis199; Slipczuk L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082665; Sunder S, 2015, INFECT DIS-NOR, V47, P80, DOI 10.3109/00365548.2014.968608; Sy RW, 2010, EUR HEART J, V31, P1890, DOI 10.1093/eurheartj/ehq110; Ursi MP, 2019, DRUG AGING, V36, P115, DOI 10.1007/s40266-018-0614-7; Walls G, 2014, NEW ZEAL MED J, V127, P38; Yombi JC, 2017, ACTA CLIN BELG, V72, P417, DOI 10.1080/17843286.2017.1309341; Yoshikawa TT, 1997, J INFECT DIS, V176, P1053, DOI 10.1086/516547	35	23	23	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 25	2019	14	10							e0223857	10.1371/journal.pone.0223857	http://dx.doi.org/10.1371/journal.pone.0223857			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN0LX	31652280	Green Published, gold			2023-01-03	WOS:000532638300012
J	Solomon, SD; McMurray, JJV; Anand, IS; Ge, J; Lam, CSP; Maggioni, AP; Martinez, F; Packer, M; Pfeffer, MA; Pieske, B; Redfield, MM; Rouleau, JL; van Veldhuisen, DJ; Zannad, F; Zile, MR; Desai, AS; Claggett, B; Jhund, PS; Boytsov, SA; Comin-Colet, J; Cleland, J; Dungen, HD; Goncalvesova, E; Katova, T; Kerr Saraiva, JF; Lelonek, M; Merkely, B; Senni, M; Shah, SJ; Zhou, J; Rizkala, AR; Gong, J; Shi, VC; Lefkowitz, MP				Solomon, S. D.; McMurray, J. J. V.; Anand, I. S.; Ge, J.; Lam, C. S. P.; Maggioni, A. P.; Martinez, F.; Packer, M.; Pfeffer, M. A.; Pieske, B.; Redfield, M. M.; Rouleau, J. L.; van Veldhuisen, D. J.; Zannad, F.; Zile, M. R.; Desai, A. S.; Claggett, B.; Jhund, P. S.; Boytsov, S. A.; Comin-Colet, J.; Cleland, J.; Dungen, H. -D.; Goncalvesova, E.; Katova, T.; Kerr Saraiva, J. F.; Lelonek, M.; Merkely, B.; Senni, M.; Shah, S. J.; Zhou, J.; Rizkala, A. R.; Gong, J.; Shi, V. C.; Lefkowitz, M. P.		PARAGON-HF Investigators Comm	Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMPAIRED SYSTOLIC FUNCTION; MIDDLE CHILD; MIDRANGE; SPIRONOLACTONE	Background The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor-neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear. Methods We randomly assigned 4822 patients with New York Heart Association (NYHA) class II to IV heart failure, ejection fraction of 45% or higher, elevated level of natriuretic peptides, and structural heart disease to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg twice daily). The primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes. Primary outcome components, secondary outcomes (including NYHA class change, worsening renal function, and change in Kansas City Cardiomyopathy Questionnaire [KCCQ] clinical summary score [scale, 0 to 100, with higher scores indicating fewer symptoms and physical limitations]), and safety were also assessed. Results There were 894 primary events in 526 patients in the sacubitril-valsartan group and 1009 primary events in 557 patients in the valsartan group (rate ratio, 0.87; 95% confidence interval [CI], 0.75 to 1.01; P=0.06). The incidence of death from cardiovascular causes was 8.5% in the sacubitril-valsartan group and 8.9% in the valsartan group (hazard ratio, 0.95; 95% CI, 0.79 to 1.16); there were 690 and 797 total hospitalizations for heart failure, respectively (rate ratio, 0.85; 95% CI, 0.72 to 1.00). NYHA class improved in 15.0% of the patients in the sacubitril-valsartan group and in 12.6% of those in the valsartan group (odds ratio, 1.45; 95% CI, 1.13 to 1.86); renal function worsened in 1.4% and 2.7%, respectively (hazard ratio, 0.50; 95% CI, 0.33 to 0.77). The mean change in the KCCQ clinical summary score at 8 months was 1.0 point (95% CI, 0.0 to 2.1) higher in the sacubitril-valsartan group. Patients in the sacubitril-valsartan group had a higher incidence of hypotension and angioedema and a lower incidence of hyperkalemia. Among 12 prespecified subgroups, there was suggestion of heterogeneity with possible benefit with sacubitril-valsartan in patients with lower ejection fraction and in women. Conclusions Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart failure and an ejection fraction of 45% or higher. (Funded by Novartis; PARAGON-HF ClinicalTrials.gov number, NCT01920711.)	[Solomon, S. D.; Pfeffer, M. A.; Desai, A. S.; Claggett, B.] Harvard Med Sch, Brigham & Womens Hosp, Cardiovasc Div, Boston, MA 02115 USA; [McMurray, J. J. V.; Jhund, P. S.] Univ Glasgow, British Heart Fdn, Cardiovasc Res Ctr, 126 Univ Pl, Glasgow G12 8TA, Lanark, Scotland; [Cleland, J.] Univ Glasgow, Inst Hlth & Wellbeing, Robertson Ctr Biostat & Clin Trials, Glasgow, Lanark, Scotland; [Cleland, J.] Imperial Coll, Royal Brompton & Harefield Hosp, Natl Heart & Lung Inst, London, England; [Anand, I. S.] Univ Minnesota, Minneapolis, MN USA; [Redfield, M. M.] Mayo Clin, Rochester, MN USA; [Ge, J.] Fudan Univ, Zhongshan Hosp, Shanghai Inst Cardiovasc Dis, Shanghai, Peoples R China; [Zhou, J.] Fudan Univ, Zhongshan Hosp, Dept Cardiol, Shanghai, Peoples R China; [Lam, C. S. P.] Natl Heart Ctr Singapore, Singapore, Singapore; [Lam, C. S. P.] Duke Natl Univ Singapore, Singapore, Singapore; [Maggioni, A. P.] Natl Assoc Hosp, Cardiologists Res Ctr, Florence, Italy; [Senni, M.] Hosp Papa Giovanni XXIII, Cardiovasc Dept, Cardiol Div, Bergamo, Italy; [Martinez, F.] Natl Univ Cordoba, Cordoba, Argentina; [Packer, M.] Baylor Univ, Med Ctr, Dallas, TX USA; [Pieske, B.] German Ctr Cardiovasc Res Partner Site Berlin, Dept Internal Med & Cardiol, Berlin, Germany; [Dungen, H. -D.] Charite, Dept Cardiol, Campus Virchow Klinikum, Berlin, Germany; [Rouleau, J. L.] Univ Montreal, Inst Cardiol Montreal, Montreal, PQ, Canada; [Rouleau, J. L.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands; [Zannad, F.] INSERM, Ctr Invest Clin 1433, Nancy, France; [Zannad, F.] Univ Lorraine, CHRU Nancy, Nancy, France; [Zile, M. R.] Med Univ South Carolina, Charleston, SC 29425 USA; [Zile, M. R.] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA; [Boytsov, S. A.] Minist Hlth Russian Federat, Natl Res Ctr Cardiol, Moscow, Russia; [Comin-Colet, J.] Univ Barcelona, Bellvitge Univ Hosp, Dept Cardiol, Community Heart Failure Program, Barcelona, Spain; [Comin-Colet, J.] Univ Barcelona, Bellvitge Inst Biomed Res, Barcelona, Spain; [Goncalvesova, E.] Natl Cardiovasc Inst, Dept Heart Failure Transplantat, Bratislava, Slovakia; [Katova, T.] Natl Cardiol Hosp, Clin Cardiol, Sofia, Bulgaria; [Kerr Saraiva, J. F.] Pontificia Univ Catolica Campinas, Fac Med, Disciplina Cardiol, Sao Paulo, Brazil; [Lelonek, M.] Med Univ Lodz, Dept Noninvas Cardiol, Lodz, Poland; [Merkely, B.] Semmelweis Univ, Heart & Vasc Ctr, Budapest, Hungary; [Shah, S. J.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Cardiol, Chicago, IL 60611 USA; [Rizkala, A. R.; Gong, J.; Shi, V. C.; Lefkowitz, M. P.] Novartis Pharmaceut, E Hanover, NJ USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Glasgow; University of Glasgow; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Royal Brompton Hospital; University of Minnesota System; University of Minnesota Twin Cities; Mayo Clinic; Fudan University; Fudan University; National Heart Centre Singapore; National University of Singapore; ASST Papa Giovanni XXIII; National University of Cordoba; Baylor University; Baylor University Medical Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Universite de Montreal; Institut de Cardiologie de Montreal; University of Groningen; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Nancy; Universite de Lorraine; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Ministry of Health of the Russian Federation; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Medical University Sofia; Pontificia Universidade Catolica de Campinas; Medical University Lodz; Semmelweis University; Northwestern University; Feinberg School of Medicine; Novartis	McMurray, JJV (corresponding author), Univ Glasgow, British Heart Fdn, Cardiovasc Res Ctr, 126 Univ Pl, Glasgow G12 8TA, Lanark, Scotland.; Solomon, SD (corresponding author), Brigham & Womens Hosp, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA.	ssolomon@bwh.harvard.edu; john.mcmurray@glasgow.ac.uk	Khromtsova, Oksana M./F-4530-2018; Cleland, John G./AAZ-4185-2020; Espinosa, Luis Manzano/AAB-1702-2020; Urina-Triana, Miguel A/H-2605-2016; Jhund, Pardeep/GLS-9508-2022; Pfister, Otmar/AAB-4752-2022; Beyer-Westendorf, Jan/K-7569-2019; Rafalskiy, Vladimir V/G-3172-2013; Boytsov, Sergey A/M-4486-2014; Bayes-Genis, Antonio/AAV-9422-2021; Maggioni, Aldo Pietro/AAL-5334-2020; Lam, Carolyn SP/ABD-6810-2021; Desai, Akshay/ABE-7250-2020; Comin-Colet, Josep/AAM-3000-2021; Carluccio, Erberto/AAA-4426-2019; Shah, Sanjiv J./AFQ-9480-2022; Zaruba, Marc-Michael/AAI-8571-2020; Pieske, Burkert/M-8089-2016	Khromtsova, Oksana M./0000-0003-0763-0542; Cleland, John G./0000-0002-1471-7016; Espinosa, Luis Manzano/0000-0002-0472-1820; Urina-Triana, Miguel A/0000-0001-6003-4622; Jhund, Pardeep/0000-0003-4306-5317; Beyer-Westendorf, Jan/0000-0002-6983-9993; Rafalskiy, Vladimir V/0000-0002-2503-9580; Boytsov, Sergey A/0000-0001-6998-8406; Bayes-Genis, Antonio/0000-0002-3044-197X; Maggioni, Aldo Pietro/0000-0003-2764-6779; Lam, Carolyn SP/0000-0003-1903-0018; Comin-Colet, Josep/0000-0001-8780-720X; Zaruba, Marc-Michael/0000-0003-1074-5463; Hove, Jens/0000-0002-5600-5623; Lelonek, Malgorzata/0000-0003-0756-5541; GALINIER, Michel/0000-0003-1735-3390; Car, Sinisa/0000-0001-6439-123X; jourdain, patrick/0000-0002-5202-6902; Yehya, Amin/0000-0001-5947-4778; gosse, philippe/0000-0002-5840-7749; Kober, Lars/0000-0002-6635-1466; mcmurray, john/0000-0002-6317-3975; Shah, Sanjiv/0000-0002-5655-8201; Vazir, Ali/0000-0002-6706-7862; Foley, Paul/0000-0002-4856-832X; Pieske, Burkert/0000-0002-6466-5306; Giamouzis, Grigorios/0000-0002-7406-5427; Howes, Laurence/0000-0002-1507-8260; Girerd, Nicolas/0000-0002-3278-2057; Zile, Michael/0000-0001-7076-221X; Merkely, Bela/0000-0001-6514-0723; Hollingdal, Malene/0000-0002-5891-0723; Kostis, William/0000-0002-0543-9798; Westermann, Dirk/0000-0002-7542-1956	Novartis	Novartis(Novartis)	Funded by Novartis	Abdul-Rahim AH, 2018, EUR J HEART FAIL, V20, P1139, DOI 10.1002/ejhf.1160; Cleland JGF, 2006, EUR HEART J, V27, P2338, DOI 10.1093/eurheartj/ehl250; Cleland JGF, 2018, EUR HEART J, V39, P26, DOI 10.1093/eurheartj/ehx564; Cowling BJ, 2006, J ROY STAT SOC C-APP, V55, P31, DOI 10.1111/j.1467-9876.2005.00529.x; Green CP, 2000, J AM COLL CARDIOL, V35, P1245, DOI 10.1016/S0735-1097(00)00531-3; Kraigher-Krainer E, 2014, J AM COLL CARDIOL, V63, P447, DOI 10.1016/j.jacc.2013.09.052; Lam CSP, 2017, CIRCULATION, V135, P1279, DOI 10.1161/CIRCULATIONAHA.117.027324; Lam CSP, 2014, EUR J HEART FAIL, V16, P1049, DOI 10.1002/ejhf.159; Lin DY, 2000, J ROY STAT SOC B, V62, P711, DOI 10.1111/1467-9868.00259; Lund LH, 2018, EUR J HEART FAIL, V20, P1230, DOI 10.1002/ejhf.1149; Massie BM, 2008, NEW ENGL J MED, V359, P2456, DOI 10.1056/NEJMoa0805450; McMurray JJV, 2014, NEW ENGL J MED, V371, P993, DOI 10.1056/NEJMoa1409077; Mohammed SF, 2015, CIRCULATION, V131, P550, DOI 10.1161/CIRCULATIONAHA.114.009625; Mohammed SF, 2014, JACC-HEART FAIL, V2, P113, DOI 10.1016/j.jchf.2013.11.004; Pitt B, 2014, NEW ENGL J MED, V370, P1383, DOI 10.1056/NEJMoa1313731; Redfield MM, 2017, NEW ENGL J MED, V376, P897, DOI 10.1056/NEJMc1615918; Shah AM, 2015, CIRCULATION, V132, P402, DOI 10.1161/CIRCULATIONAHA.115.015884; Shah SJ, 2015, CIRCULATION, V131, P269, DOI 10.1161/CIRCULATIONAHA.114.010637; Solomon SD, 2017, JACC-HEART FAIL, V5, P471, DOI 10.1016/j.jchf.2017.04.013; Solomon SD, 2016, EUR HEART J, V37, P455, DOI 10.1093/eurheartj/ehv464; Solomon SD, 2012, LANCET, V380, P1387, DOI 10.1016/S0140-6736(12)61227-6; Yusuf S, 2003, LANCET, V362, P777, DOI 10.1016/S0140-6736(03)14285-7; Zile MR, 2004, NEW ENGL J MED, V350, P1953, DOI 10.1056/NEJMoa032566	23	911	948	16	88	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	2019	381	17					1609	1620		10.1056/NEJMoa1908655	http://dx.doi.org/10.1056/NEJMoa1908655			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK2QT	31475794	Bronze, Green Published, Green Accepted			2023-01-03	WOS:000494692200005
J	Ward, PJ; Rock, PJ; Slavova, S; Young, AM; Bunn, TL; Kavuluru, R				Ward, Patrick J.; Rock, Peter J.; Slavova, Svetla; Young, April M.; Bunn, Terry L.; Kavuluru, Ramakanth			Enhancing timeliness of drug overdose mortality surveillance: A machine learning approach	PLOS ONE			English	Article							DEATH CERTIFICATES; CLASSIFICATION; MODELS	Background Timely data is key to effective public health responses to epidemics. Drug overdose deaths are identified in surveillance systems through ICD-10 codes present on death certificates. ICD-10 coding takes time, but free-text information is available on death certificates prior to ICD-10 coding. The objective of this study was to develop a machine learning method to classify free-text death certificates as drug overdoses to provide faster drug overdose mortality surveillance. Methods Using 2017-2018 Kentucky death certificate data, free-text fields were tokenized and features were created from these tokens using natural language processing (NLP). Word, bigram, and trigram features were created as well as features indicating the part-of-speech of each word. These features were then used to train machine learning classifiers on 2017 data. The resulting models were tested on 2018 Kentucky data and compared to a simple rule-based classification approach. Documented code for this method is available for reuse and extensions: https://github.com/pjward5656/dcnlp. Results The top scoring machine learning model achieved 0.96 positive predictive value (PPV) and 0.98 sensitivity for an F-score of 0.97 in identification of fatal drug overdoses on test data. This machine learning model achieved significantly higher performance for sensitivity (p<0.001) than the rule-based approach. Additional feature engineering may improve the model's prediction. This model can be deployed on death certificates as soon as the free-text is available, eliminating the time needed to code the death certificates. Conclusion Machine learning using natural language processing is a relatively new approach in the context of surveillance of health conditions. This method presents an accessible application of machine learning that improves the timeliness of drug overdose mortality surveillance. As such, it can be employed to inform public health responses to the drug overdose epidemic in near-real time as opposed to several weeks following events.	[Ward, Patrick J.; Rock, Peter J.; Slavova, Svetla; Bunn, Terry L.] Univ Kentucky, Coll Publ Hlth, Kentucky Injury Prevent & Res Ctr, Lexington, KY 40506 USA; [Ward, Patrick J.; Rock, Peter J.; Young, April M.] Univ Kentucky, Coll Publ Hlth, Dept Epidemiol, Lexington, KY 40506 USA; [Slavova, Svetla] Univ Kentucky, Coll Publ Hlth, Dept Biostat, Lexington, KY USA; [Young, April M.] Univ Kentucky, Coll Med, Ctr Drug & Alcohol Res, Lexington, KY USA; [Bunn, Terry L.] Univ Kentucky, Coll Publ Hlth, Dept Prevent Med & Environm Hlth, Lexington, KY USA; [Kavuluru, Ramakanth] Univ Kentucky, Coll Engn, Dept Comp Sci, Lexington, KY USA; [Kavuluru, Ramakanth] Univ Kentucky, Coll Med, Dept Internal Med, Div Biomed Informat, Lexington, KY USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Ward, PJ (corresponding author), Univ Kentucky, Coll Publ Hlth, Kentucky Injury Prevent & Res Ctr, Lexington, KY 40506 USA.; Ward, PJ (corresponding author), Univ Kentucky, Coll Publ Hlth, Dept Epidemiol, Lexington, KY 40506 USA.	patrickjward@uky.edu	Young, April/I-9518-2012	Young, April/0000-0003-3969-3249	Centers for Disease Control and Prevention [5 NU17CE002732-04-00, 6 NU17CE924880-03-04]; National Institute on Drug Abuse; CDC; SAMHSA; Appalachian Regional Commission (ARC) [UG3 DA044798]; NATIONAL INSTITUTE ON DRUG ABUSE [UG3DA044798] Funding Source: NIH RePORTER	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); CDC(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); SAMHSA; Appalachian Regional Commission (ARC); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This paper was supported by Cooperative Agreement Numbers 5 NU17CE002732-04-00 and 6 NU17CE924880-03-04, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services. Support for manuscript preparation was also provided by the National Institute on Drug Abuse, CDC, SAMHSA, and the Appalachian Regional Commission (ARC) (UG3 DA044798; PIs: Young and Cooper). The manuscript's content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, CDC, SAMHSA, or ARC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This paper was supported by Cooperative Agreement Numbers 5 NU17CE002732-04-00 and 6 NU17CE924880-03-04, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services. Support for manuscript preparation was also provided by the National Institute on Drug Abuse, CDC, SAMHSA, and the Appalachian Regional Commission (ARC) (UG3 DA044798; PIs: Young and Cooper). The manuscript's content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, CDC, SAMHSA, or ARC. Data used in this study is from the Kentucky Death Certificate Database, Kentucky Office of Vital Statistics, Cabinet for Health and Family Services. The data used in this study was solely for the development of the methods discussed, and are not intended to be used as state-wide estimates for calculating official mortality statistics.	[Anonymous], 2012, INJ SURV WORKGR 7 CO; Association of State and Territorial Health Officials, 2018, STAK M REP FEB 23; Butt L, 2013, AUSTRALAS MED J, V6, P292, DOI 10.4066/AMJ.2013.1654; Centers for Disease Control and Prevention, 2018, ENH STAT OP OV SURV; Centers for Disease Control (CDC), 1989, MMWR Morb Mortal Wkly Rep, V38, P1; Concheiro M, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01210; Demner-Fushman D, 2009, J BIOMED INFORM, V42, P760, DOI 10.1016/j.jbi.2009.08.007; Duarte F, 2017, DEEP LEARNING METHOD; Duarte F, 2018, J BIOMED INFORM, V80, P64, DOI 10.1016/j.jbi.2018.02.011; Gerace E, 2018, CURR PHARM BIOTECHNO, V19, P113, DOI 10.2174/1389201019666180405162734; Honnibal M., 2017, SPACY 2 NATURAL LANG; Hsu C.-W., 2010, PRACTICAL GUIDE SUPP; Kavuluru R, 2013, AMIA SUMMITS TRANSLA, V112; Kim JH, 2009, COMPUT STAT DATA AN, V53, P3735, DOI 10.1016/j.csda.2009.04.009; Koopman B, 2015, INT J MED INFORM, V84, P956, DOI 10.1016/j.ijmedinf.2015.08.004; Koopman B, 2015, BMC MED INFORM DECIS, V15, DOI 10.1186/s12911-015-0174-2; Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05; National Center for Health Statistics, 2003, US STAND CERT DEATH; National Center for Health Statistics, 2019, RED DEATH CERT LIT T; National Center for Health Statistics, 2017, INSTR CLASS UND CAUS; National Center for Health Statistics, 2003, MED EX COR HDB DEATH; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Osborne JD, 2016, J AM MED INFORM ASSN, V23, P1077, DOI 10.1093/jamia/ocw006; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Riedl Bill, 2010, AMIA Annu Symp Proc, V2010, P677; Rios A, 2018, P 2018 C EMP METH NA; Rios A, 2017, J BIOMED INFORM, V75, pS85, DOI 10.1016/j.jbi.2017.05.008; Ruiz L, 2018, J FORENSIC SCI, V63, P1138, DOI 10.1111/1556-4029.13689; Simpson M.S., 2012, MINING TEXT DATA, P465, DOI 10.1007/978-1-4614-3223-4_14; Sokolova M, 2006, LECT NOTES COMPUT SC, V4304, P1015; Spencer M.R., 2017, TIMELINESS DEATH CER; Trinidad James P, 2016, Natl Vital Stat Rep, V65, P1; Warner M, 2013, ACAD FORENSIC PATHOL, V3, P231, DOI [DOI 10.23907/2013.029, 10.23907/2013.029]; Warner M, 2018, AM J PUBLIC HEALTH, V108, P1587, DOI 10.2105/AJPH.2018.304781; WHO, 2011, INT STAT CLASS DIS R; Williams Karl E, 2017, Acad Forensic Pathol, V7, P60, DOI 10.23907/2017.007; Witten I.H., 2000, DATA MINING PRACTICA; World Health Organization, 2019, INT CLASS DIS	38	10	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2019	14	10							e0223318	10.1371/journal.pone.0223318	http://dx.doi.org/10.1371/journal.pone.0223318			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM9KK	31618226	Green Published, gold			2023-01-03	WOS:000532566600024
J	Huang, LC; Tung, HJ; Lin, PC				Huang, Li-Chun; Tung, Ho-Jui; Lin, Pei-Chao			Associations among knowledge, attitudes, and practices toward palliative care consultation service in healthcare staffs: A cross-sectional study	PLOS ONE			English	Article							HOSPICE SHARED-CARE; NURSES KNOWLEDGE; PERCEPTIONS; DEATH; TEAMS	Background The palliative care consultation service (PCCS) of the National Health Insurance payments has been promoted in Taiwan since 2011, although few studies have been conducted on healthcare staffs' knowledge, attitudes, and practices regarding PCCS in Taiwan; consequently, the main objective of this study was to explore any correlations regarding the above by cross-sectional design using convenience sampling. Methods A total of 210 healthcare staff members were enrolled from a regional hospital from June 1, 2018, to September 30, 2018. Questionnaire items on the Palliative Care Consultation Service Inventory (KAP-PCCSI) were used to measure healthcare staff's knowledge, attitudes, and practices of PCCS. The collected data were analyzed by using descriptive statistics, independent samples t-test, Pearson's correlation coefficient analysis, and multiple linear regression analysis. Results The results revealed that the mean scores for knowledge of and attitudes of KAP-PCCSI were 58.7 +/- 8.9 (perfect score: 75) and 42.7 +/- 4.7 (perfect score: 50) respectively, while the mean score for practices of KAP-PCCSI was 36.3 +/- 8.1 (perfect score: 50); moreover, the healthcare staff's knowledge and attitudes were positively correlated with their practices (p < 0.01). The results also showed that knowledge, attitudes, experience of having a family member(s) or friend(s) passing away, and being a medical personnel constituted the major predictors of practices (p < 0.001). These factors explained 43.2% of the overall variance for practices of KAP-PCCSI. Conclusions The findings can help healthcare staff understand factors influencing practices of KAP-PCCSI and can serve as a reference for the development of strategies for palliative care education and training while improving the care quality of patients undergoing such palliative care with terminal life considerations in the hospitals, thereby fulfilling the goal of achieving holistic care.	[Huang, Li-Chun] Kaohsiung Armed Forces Gen Hosp, Dept Nursing, Zuoying Branch, Kaohsiung, Taiwan; [Huang, Li-Chun; Tung, Ho-Jui] Asia Univ, Dept Healthcare Adm, Taichung, Taiwan; [Tung, Ho-Jui] Georgia Southern Univ, Jiann Ping Hsu Coll Publ Hlth, Dept Hlth Policy & Community Hlth, Statesboro, GA USA; [Lin, Pei-Chao] Kaohsiung Med Univ, Coll Nursing, Sch Nursing, Kaohsiung, Taiwan; [Lin, Pei-Chao] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan	Asia University Taiwan; University System of Georgia; Georgia Southern University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Lin, PC (corresponding author), Kaohsiung Med Univ, Coll Nursing, Sch Nursing, Kaohsiung, Taiwan.; Lin, PC (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan.	payjau@gmail.com		Lin, Pei-Chao/0000-0002-1495-2550	Zuoying Branch of Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan	Zuoying Branch of Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan	This work was supported by Zuoying Branch of Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan.	Abudari G, 2014, INT J PALLIAT NURS, V20, P435, DOI 10.12968/ijpn.2014.20.9.435; Anderson WG, 2017, AM J CRIT CARE, V26, P361, DOI 10.4037/ajcc2017336; Boyd D, 2011, ONCOL NURS FORUM, V38, P379, DOI 10.1188/11.ONF.E229-E239; Brinkman-Stoppelenburg A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201191; Brody AA, 2010, J PALLIAT MED, V13, P541, DOI 10.1089/jpm.2009.0300; Chand Pushkar, 2013, Perm J, V17, P53, DOI 10.7812/TPP/12-092; de Meritens AB, 2017, J ONCOL PRACT, V13, pE703, DOI 10.1200/JOP.2017.021048; El-Jawahri Areej, 2011, J Support Oncol, V9, P87; Enguidanos S, 2014, PALLIATIVE MED, V28, P42, DOI 10.1177/0269216313491620; Enguidanos S, 2009, J PALLIAT MED, V12, P1137, DOI 10.1089/jpm.2009.0131; Firn J, 2016, PALLIATIVE MED, V30, P240, DOI 10.1177/0269216315615483; Fromme EK, 2006, J PALLIAT MED, V9, P903, DOI 10.1089/jpm.2006.9.903; Huang KS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171365; Huijer HA, 2009, INT J PALLIAT NURS, V15, P346, DOI 10.12968/ijpn.2009.15.7.43425; Iranmanesh S, 2014, PALLIAT SUPPORT CARE, V12, P203, DOI 10.1017/S1478951512001058; Kassa H, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-6; Kim S, 2014, EUR J CARDIOVASC NUR, V13, P124, DOI 10.1177/1474515113519521; Lange M, 2008, ONCOL NURS FORUM, V35, P955, DOI 10.1188/08.ONF.955-959; Lin WY, 2014, SUPPORT CARE CANCER, V22, P1907, DOI 10.1007/s00520-014-2168-5; Liu OY, 2017, AM J HOSP PALLIAT ME, V34, P47, DOI 10.1177/1049909115610077; May P, 2014, J PALLIAT MED, V17, P1054, DOI 10.1089/jpm.2013.0594; McDarby M, 2018, AM J HOSP PALLIAT CA; Ministry of Health and Welfare, 2018, 2017 STAT CAUS DEATH; Morrison RS, 2011, HEALTH AFFAIR, V30, P454, DOI 10.1377/hlthaff.2010.0929; Nelson Craig, 2011, Perm J, V15, P48; Pan HH, 2017, BMC PALLIAT CARE, V16, DOI 10.1186/s12904-017-0228-6; Park KS, 2014, INT NURS REV, V61, P563, DOI 10.1111/inr.12135; Prem V, 2012, INDIAN J PALLIAT CAR, V18, P122, DOI 10.4103/0973-1075.100832; Smith TJ, 2012, ANN ONCOL, V23, P70, DOI 10.1093/annonc/mds092; White KR, 2011, ONCOL NURS FORUM, V38, P711, DOI 10.1188/11.ONF.711-717; World Health Organization, 2019, WHO DEF PALL CAR; World Health Organization, 2019, PLANN IMPL PALL CAR; Wu LF, 2016, SUPPORT CARE CANCER, V24, P53, DOI 10.1007/s00520-015-2741-6; Yang CH, 2013, KAOHSIUNG J MED SCI, V29, P444, DOI 10.1016/j.kjms.2012.12.005	34	1	1	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2019	14	10							e0223754	10.1371/journal.pone.0223754	http://dx.doi.org/10.1371/journal.pone.0223754			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM8DE	31603946	Green Published, gold			2023-01-03	WOS:000532477400029
J	Yehl, K; Lemire, S; Yang, AC; Ando, H; Mimee, M; Torres, MDT; de la Fuente-Nunez, C; Lu, TK				Yehl, Kevin; Lemire, Sebastien; Yang, Andrew C.; Ando, Hiroki; Mimee, Mark; Torres, Marcelo Der Torossian; de la Fuente-Nunez, Cesar; Lu, Timothy K.			Engineering Phage Host-Range and Suppressing Bacterial Resistance through Phage Tail Fiber Mutagenesis	CELL			English	Article							ESCHERICHIA-COLI; BACTERIOPHAGE; PROTEIN; ANTIBODIES; EVOLUTION; THERAPY; REGIONS; CAPSULE; DOMAIN; GENES	The rapid emergence of antibiotic-resistant infections is prompting increased interest in phage-based antimicrobials. However, acquisition of resistance by bacteria is a major issue in the successful development of phage therapies. Through natural evolution and structural modeling, we identified host-range-determining regions (HRDRs) in the T3 phage tail fiber protein and developed a high-throughput strategy to genetically engineer these regions through site-directed mutagenesis. Inspired by antibody specificity engineering, this approach generates deep functional diversity while minimizing disruptions to the overall tail fiber structure, resulting in synthetic "phagebodies." We showed that mutating HRDRs yields phagebodies with altered host-ranges, and select phagebodies enable long-term suppression of bacterial growth in vitro, by preventing resistance appearance, and are functional in vivo using a murine model. We anticipate that this approach may facilitate the creation of next-generation antimicrobials that slow resistance development and could be extended to other viral scaffolds for a broad range of applications.	[Yehl, Kevin; Lemire, Sebastien; Yang, Andrew C.; Ando, Hiroki; Mimee, Mark; Torres, Marcelo Der Torossian; de la Fuente-Nunez, Cesar; Lu, Timothy K.] MIT, Synthet Biol Grp, Synthet Biol Ctr, Ctr Microbiome Informat & Therapeut, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Yehl, Kevin; Lemire, Sebastien; Ando, Hiroki; Mimee, Mark; Torres, Marcelo Der Torossian; de la Fuente-Nunez, Cesar; Lu, Timothy K.] MIT, Elect Res Lab, Cambridge, MA 02139 USA; [Lu, Timothy K.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA; [Lu, Timothy K.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Lu, Timothy K.] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Lu, Timothy K.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Yang, Andrew C.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Lemire, Sebastien] Armata Pharmaceut, Marina Del Rey, CA 90292 USA; [Ando, Hiroki] Gifu Univ, Grad Sch Med, Dept Microbiol, Gifu 5011194, Japan; [Mimee, Mark] Univ Chicago, Dept Microbiol, Chicago, IL 60637 USA; [Mimee, Mark] Univ Chicago, Pritzker Sch Mol Engn, Chicago, IL 60637 USA; [Torres, Marcelo Der Torossian; de la Fuente-Nunez, Cesar] Univ Penn, Perelman Sch Med, Dept Psychiat, Machine Biol Grp, Philadelphia, PA 19104 USA; [Torres, Marcelo Der Torossian; de la Fuente-Nunez, Cesar] Univ Penn, Perelman Sch Med, Dept Microbiol, Machine Biol Grp, Philadelphia, PA 19104 USA; [Torres, Marcelo Der Torossian; de la Fuente-Nunez, Cesar] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Stanford University; Gifu University; University of Chicago; University of Chicago; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Lu, TK (corresponding author), MIT, Synthet Biol Grp, Synthet Biol Ctr, Ctr Microbiome Informat & Therapeut, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Lu, TK (corresponding author), MIT, Elect Res Lab, Cambridge, MA 02139 USA.; Lu, TK (corresponding author), MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.; Lu, TK (corresponding author), Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA.; Lu, TK (corresponding author), MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Lu, TK (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.	timlu@mit.edu	de la Fuente, Cesar/ABE-2369-2021	de la Fuente, Cesar/0000-0002-2005-5629; /0000-0002-3083-2671	Defense Threat Reduction Agency [HDTRA1-14-1-0007]; NIH [1DP2OD008435, 1P50GM098792, 1R01EB017755]; US Army Research Laboratory/Army Research Office via the Institute for Soldier Nanotechnologies [W911NF-13-D-0001]; Japan Society for the Promotion of Science; Naito Foundation; Koch Institute Support (core) grant from the National Cancer Institute [P30-CA14051]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R33AI121669, R21AI121669] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM098792] Funding Source: NIH RePORTER	Defense Threat Reduction Agency(United States Department of DefenseDefense Threat Reduction Agency); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Army Research Laboratory/Army Research Office via the Institute for Soldier Nanotechnologies; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Naito Foundation(Naito Memorial Foundation); Koch Institute Support (core) grant from the National Cancer Institute; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to thank Robert Citorik and Fahim Farzadfard for continued constructive discussions throughout this project. Bacteriophage T3 was a kind gift from Ian Molineux, University of Texas, Austin. This work was supported by grants from the Defense Threat Reduction Agency (HDTRA1-14-1-0007), the NIH (1DP2OD008435, 1P50GM098792, 1R01EB017755), and the US Army Research Laboratory/Army Research Office via the Institute for Soldier Nanotechnologies under contract number W911NF-13-D-0001. C.d.l.F.-N. holds a Presidential Professorship at the University of Pennsylvania. H.A. was supported by fellowships from the Japan Society for the Promotion of Science and the Naito Foundation. This work was supported in part by the Koch Institute Support (core) grant P30-CA14051 from the National Cancer Institute.	Alam KK, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.4; Ando H, 2015, CELL SYST, V1, P187, DOI 10.1016/j.cels.2015.08.013; Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Beck A, 2010, NAT REV IMMUNOL, V10, P345, DOI 10.1038/nri2747; BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378-1119(92)90627-2; Bikard D, 2014, NAT BIOTECHNOL, V32, P1146, DOI 10.1038/nbt.3043; Chen MM, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00147; Chen ZY, 2014, J CLIN INVEST, V124, P3391, DOI 10.1172/JCI72517; Citorik RJ, 2014, NAT BIOTECHNOL, V32, P1141, DOI 10.1038/nbt.3011; Cooper CJ, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01209; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Datta S, 2006, GENE, V379, P109, DOI 10.1016/j.gene.2006.04.018; Dedrick RM, 2019, NAT MED, V25, P730, DOI 10.1038/s41591-019-0437-z; Devlin AS, 2016, CELL HOST MICROBE, V20, P709, DOI 10.1016/j.chom.2016.10.021; Ducancel F, 2012, MABS-AUSTIN, V4, P445, DOI 10.4161/mabs.20776; Farzadfard F, 2014, SCIENCE, V346, P825, DOI 10.1126/science.1256272; Foltz IN, 2013, CIRCULATION, V127, P2222, DOI 10.1161/CIRCULATIONAHA.113.002033; Garcia-Doval C, 2012, P NATL ACAD SCI USA, V109, P9390, DOI 10.1073/pnas.1119719109; Gebhart D, 2017, VIROLOGY, V507, P263, DOI 10.1016/j.virol.2017.02.025; Gladstone EG, 2012, J BIOL ENG, V6, DOI 10.1186/1754-1611-6-13; Harris LJ, 1997, BIOCHEMISTRY-US, V36, P1581, DOI 10.1021/bi962514+; Hawkins SA, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-97; Heilpern AJ, 2003, J BACTERIOL, V185, P1037, DOI 10.1128/JB.185.3.1037-1044.2003; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; Hsu CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070092; Kim MS, 2015, APPL ENVIRON MICROB, V81, P900, DOI 10.1128/AEM.02606-14; Kutateladze M, 2010, TRENDS BIOTECHNOL, V28, P591, DOI 10.1016/j.tibtech.2010.08.001; Kutter E, 2010, CURR PHARM BIOTECHNO, V11, P69, DOI 10.2174/138920110790725401; Kutter EM, 2015, FUTURE MICROBIOL, V10, P685, DOI [10.2217/fmb.15.28, 10.2217/FMB.15.28]; Labrie SJ, 2010, NAT REV MICROBIOL, V8, P317, DOI 10.1038/nrmicro2315; LEBOURGEOIS P, 1992, GENE, V111, P109, DOI 10.1016/0378-1119(92)90610-2; Leiman PG, 2007, J MOL BIOL, V371, P836, DOI 10.1016/j.jmb.2007.05.083; Lin TY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030954; Lin TL, 2014, J INFECT DIS, V210, P1734, DOI 10.1093/infdis/jiu332; Lu TK, 2007, P NATL ACAD SCI USA, V104, P11197, DOI 10.1073/pnas.0704624104; Lu TK, 2009, P NATL ACAD SCI USA, V106, P4629, DOI 10.1073/pnas.0800442106; Maynard ND, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001017; Miedzybrodzki R, 2012, ADV VIRUS RES, V83, P73, DOI 10.1016/B978-0-12-394438-2.00003-7; MONTAG D, 1987, J MOL BIOL, V196, P165, DOI 10.1016/0022-2836(87)90519-5; Nguyen AH, 2012, EVOLUTION, V66, P363, DOI 10.1111/j.1558-5646.2011.01433.x; Pawluk A, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.85, 10.1038/nmicrobiol.2016.85]; Pickard D, 2008, J BACTERIOL, V190, P2580, DOI 10.1128/JB.01654-07; Pouillot F, 2010, BIOSECUR BIOTERROR, V8, P155, DOI 10.1089/bsp.2009.0057; Qimron U, 2006, P NATL ACAD SCI USA, V103, P19039, DOI 10.1073/pnas.0609428103; Ross A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01352; Scholl D, 2009, ANTIMICROB AGENTS CH, V53, P3074, DOI 10.1128/AAC.01660-08; Schooley RT, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00954-17; Shen TCD, 2015, J CLIN INVEST, V125, P2841, DOI 10.1172/JCI79214; Silva JB, 2016, FEMS MICROBIOL LETT, V363, DOI 10.1093/femsle/fnw002; Tetart F, 1996, J MOL BIOL, V258, P726, DOI 10.1006/jmbi.1996.0281; Torres MDT, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0224-2; Trojet SN, 2011, GENOME BIOL EVOL, V3, P674, DOI 10.1093/gbe/evr059; Yoichi M, 2005, J BIOTECHNOL, V115, P101, DOI 10.1016/j.jbiotec.2004.08.003; Yosef I, 2017, MOL CELL, V66, P721, DOI 10.1016/j.molcel.2017.04.025; Yu PF, 2016, APPL ENVIRON MICROB, V82, P808, DOI 10.1128/AEM.02382-15	55	111	115	16	131	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	2019	179	2					459	+		10.1016/j.cell.2019.09.015	http://dx.doi.org/10.1016/j.cell.2019.09.015			20	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JB7WL	31585083	Green Accepted, Green Submitted, Bronze			2023-01-03	WOS:000488775900015
J	Lubick, N; Jarhult, J				Lubick, Naomi; Jarhult, Josef			Resistance in the wild	NATURE			English	Editorial Material									[Jarhult, Josef] Uppsala Univ, Uppsala, Sweden	Uppsala University			Jarhult, Josef D./ABE-8149-2020	Jarhult, Josef D./0000-0002-7075-1059				Gillman A, 2015, APPL ENVIRON MICROB, V81, P2378, DOI 10.1128/AEM.04034-14; Jarhult JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024742; Takanami R., 2010, Journal of Water and Environment Technology, V8, P363, DOI 10.2965/jwet.2010.363	3	0	0	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 19	2019	573	7774					S53	S53		10.1038/d41586-019-02752-9	http://dx.doi.org/10.1038/d41586-019-02752-9			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IY8MD	31534254				2023-01-03	WOS:000486647800005
J	Nave, AH; Rackoll, T; Grittner, U; Blasing, H; Gorsler, A; Nabavi, DG; Audebert, HJ; Klostermann, F; Muller-Werdan, U; Steinhagen-Thiessen, E; Meisel, A; Endres, M; Hesse, S; Ebinger, M; Floel, A				Nave, Alexander H.; Rackoll, Torsten; Grittner, Ulrike; Blaesing, Holger; Gorsler, Anna; Nabavi, Darius G.; Audebert, Heinrich J.; Klostermann, Fabian; Mueller-Werdan, Ursula; Steinhagen-Thiessen, Elisabeth; Meisel, Andreas; Endres, Matthias; Hesse, Stefan; Ebinger, Martin; Floeel, Agnes			Physical Fitness Training in Patients with Subacute Stroke (PHYS-STROKE): multicentre, randomised controlled, endpoint blinded trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE PROFESSIONALS; REHABILITATION; RECOVERY; INTENSITY; EXERCISE; SURVIVORS; EFFICACY; OUTCOMES; THERAPY; WALKING	OBJECTIVE To determine the safety and efficacy of aerobic exercise on activities of daily living in the subacute phase after stroke. DESIGN Multicentre, randomised controlled, endpoint blinded trial. SETTING Seven inpatient rehabilitation sites in Germany (2013-17). PARTICIPANTS 200 adults with subacute stroke (days 5-45 after stroke) with a median National Institutes of Health stroke scale (NIHSS, range 0-42 points, higher values indicating more severe strokes) score of 8 (interquartile range 5-12) were randomly assigned (1: 1) to aerobic physical fitness training (n=105) or relaxation sessions (n=95, control group) in addition to standard care. INTERVENTION Participants received either aerobic, bodyweight supported, treadmill based physical fitness training or relaxation sessions, each for 25 minutes, five times weekly for four weeks, in addition to standard rehabilitation therapy. Investigators and endpoint assessors were masked to treatment assignment. MAIN OUTCOME MEASURES The primary outcomes were change in maximal walking speed (m/s) in the 10 m walking test and change in Barthel index scores (range 0-100 points, higher scores indicating less disability) three months after stroke compared with baseline. Safety outcomes were recurrent cardiovascular events, including stroke, hospital readmissions, and death within three months after stroke. Efficacy was tested with analysis of covariance for each primary outcome in the full analysis set. Multiple imputation was used to account for missing values. RESULTS Compared with relaxation, aerobic physical fitness training did not result in a significantly higher mean change in maximal walking speed (adjusted treatment effect 0.1 m/s (95% confidence interval 0.0 to 0.2 m/s), P=0.23) or mean change in Barthel index score (0 (-5 to 5), P=0.99) at three months after stroke. A higher rate of serious adverse events was observed in the aerobic group compared with relaxation group (incidence rate ratio 1.81, 95% confidence interval 0.97 to 3.36). CONCLUSIONS Among moderately to severely affected adults with subacute stroke, aerobic bodyweight supported, treadmill based physical fitness training was not superior to relaxation sessions for maximal walking speed and Barthel index score but did suggest higher rates of adverse events. These results do not appear to support the use of aerobic bodyweight supported fitness training in people with subacute stroke to improve activities of daily living or maximal walking speed and should be considered in future guidelines.	[Nave, Alexander H.; Rackoll, Torsten; Audebert, Heinrich J.; Meisel, Andreas; Endres, Matthias; Ebinger, Martin; Floeel, Agnes] Charite Univ Med Berlin, Ctr Stroke Res Berlin, Berlin, Germany; [Nave, Alexander H.; Audebert, Heinrich J.; Klostermann, Fabian; Meisel, Andreas; Endres, Matthias] Charite Univ Med Berlin, Klin & Hsch Ambulanz Neurol, Berlin, Germany; [Nave, Alexander H.; Endres, Matthias] German Ctr Cardiovasc Res, Partner Site Berlin, Berlin, Germany; [Nave, Alexander H.; Grittner, Ulrike; Endres, Matthias] Berlin Inst Hlth, Berlin, Germany; [Rackoll, Torsten; Gorsler, Anna] Kliniken Beelitz, Beelitz, Germany; [Grittner, Ulrike] Charite Univ Med Berlin, Inst Biometry & Clin Epidemiol, Berlin, Germany; [Blaesing, Holger] Median Klin Grunheide, Grunheide, Germany; [Nabavi, Darius G.] Vivantes Klinikum Neukolln, Klin Neurol, Berlin, Germany; [Mueller-Werdan, Ursula; Steinhagen-Thiessen, Elisabeth] Evangel Geriatriezentrum Berlin, Berlin, Germany; [Meisel, Andreas; Endres, Matthias] Charite Univ Med Berlin, NeuroCure Clin Res Ctr, Berlin, Germany; [Endres, Matthias] German Ctr Neurodegenerat Dis, Partner Site Berlin, Berlin, Germany; [Hesse, Stefan; Ebinger, Martin] Med Pk Berlin Humboldtmuhle, Berlin, Germany; [Floeel, Agnes] Univ Med Greifswald, Dept Neurol, Ferdinand Sauerbruch Str, D-17475 Greifswald, Germany; [Floeel, Agnes] German Ctr Neurodegenerat Dis, Partner Site, Rostock, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Centre for Cardiovascular Research; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; VIivantes Klinikum Neukolln; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Greifswald Medical School; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE)	Floel, A (corresponding author), Charite Univ Med Berlin, Ctr Stroke Res Berlin, Berlin, Germany.; Floel, A (corresponding author), Univ Med Greifswald, Dept Neurol, Ferdinand Sauerbruch Str, D-17475 Greifswald, Germany.; Floel, A (corresponding author), German Ctr Neurodegenerat Dis, Partner Site, Rostock, Germany.	agnes.floeel@med.uni-greifswald.de	; Grittner, Ulrike/I-2026-2019	Meisel, Andreas/0000-0001-7233-5342; Endres, Matthias/0000-0001-6520-3720; Rackoll, Torsten/0000-0003-2170-5803; Grittner, Ulrike/0000-0003-2595-0224; Audebert, Heinrich J./0000-0002-4785-0366	German Ministry for Health and Education through Center for Stroke Research Berlin grant [01EO0801, G.2.15]	German Ministry for Health and Education through Center for Stroke Research Berlin grant	This trial was supported by the German Ministry for Health and Education (01EO0801) through Center for Stroke Research Berlin grant G.2.15. The funder had no role in study design; data collection, analysis, or interpretation; or writing manuscript. AHN, AF, TR, MEb, and UG had full access to all the data in the study and the corresponding author had final responsibility for the decision to submit for publication.	Adams HP, 1999, NEUROLOGY, V53, P126, DOI 10.1212/WNL.53.1.126; [Anonymous], R LANG ENV STAT COMP; Bernhardt J, 2017, INT J STROKE, V12, P444, DOI 10.1177/1747493017711816; Bernhardt J, 2017, CURR OPIN NEUROL, V30, P48, DOI 10.1097/WCO.0000000000000404; Bernhardt J, 2015, LANCET, V386, P46, DOI 10.1016/S0140-6736(15)60690-0; Biernaskie J, 2004, J NEUROSCI, V24, P1245, DOI 10.1523/JNEUROSCI.3834-03.2004; Billinger SA, 2014, STROKE, V45, P2532, DOI 10.1161/STR.0000000000000022; Bushnell C, 2015, CIRC-CARDIOVASC QUAL, V8, pS163, DOI 10.1161/CIRCOUTCOMES.115.002098; Catanese L, 2017, CIRC RES, V120, P541, DOI 10.1161/CIRCRESAHA.116.309278; Collen F M, 1991, Int Disabil Stud, V13, P50; Crichton SL, 2016, J NEUROL NEUROSUR PS, V87, P1091, DOI 10.1136/jnnp-2016-313361; da Cunha IT, 2002, ARCH PHYS MED REHAB, V83, P1258, DOI 10.1053/apmr.2002.34267; Duncan P, 2003, STROKE, V34, P2173, DOI 10.1161/01.STR.0000083699.95351.F2; Duncan PW, 2011, NEW ENGL J MED, V364, P2026, DOI 10.1056/NEJMoa1010790; Eich HJ, 2004, CLIN REHABIL, V18, P640, DOI 10.1191/0269215504cr779oa; English C, 2015, INT J STROKE, V10, P594, DOI 10.1111/ijs.12470; Feigin VL, 2017, CIRC RES, V120, P439, DOI 10.1161/CIRCRESAHA.116.308413; Floel A, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-45; Globas C, 2012, NEUROREHAB NEURAL RE, V26, P85, DOI 10.1177/1545968311418675; IBM, REL 2016 IBM SPSS ST; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Loudon K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2147; MAHONEY F I, 1965, Md State Med J, V14, P61; Medical University of Graz, RAND; Mehrholz J, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002840.pub4; Nave AH, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-197; Pohl M, 2007, CLIN REHABIL, V21, P17, DOI 10.1177/0269215506071281; Saunders DH, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003316.pub6; StataCorp, 2015, STAT STAT SOFTW REL; Strommen AM, 2016, INT J REHABIL RES, V39, P145, DOI 10.1097/MRR.0000000000000158; Tyson SF, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0588-2; van Buuren S, 2011, J STAT SOFTW, V45, P1; van de Port IGL, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2672; Wang Z, 2014, J STROKE CEREBROVASC, V23, pE187, DOI 10.1016/j.jstrokecerebrovasdis.2013.09.021; Winstein CJ, 2016, STROKE, V47, pE98, DOI 10.1161/STR.0000000000000098; Winters C, 2017, NEUROREHAB NEURAL RE, V31, P334, DOI 10.1177/1545968316680492; Wolfe CDA, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001033; Wood SN, 2004, J AM STAT ASSOC, V99, P673, DOI 10.1198/016214504000000980	39	27	29	2	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 18	2019	366								l5101	10.1136/bmj.l5101	http://dx.doi.org/10.1136/bmj.l5101			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA3VZ	31533934	Green Published, hybrid			2023-01-03	WOS:000487759000002
J	Fulton, BD; Proudman, DG; Sample, HA; Gelfand, JM; Chiu, CY; DeRisi, JL; Wilson, MR				Fulton, Brent D.; Proudman, David G.; Sample, Hannah A.; Gelfand, Jeffrey M.; Chiu, Charles Y.; DeRisi, Joseph L.; Wilson, Michael R.			Exploratory analysis of the potential for advanced diagnostic testing to reduce healthcare expenditures of patients hospitalized with meningitis or encephalitis	PLOS ONE			English	Article							UNITED-STATES; MANAGEMENT; PREDICTORS; CHILDREN; BURDEN	Objective To estimate healthcare expenditures that could be impacted by advanced diagnostic testing for patients hospitalized with meningitis or encephalitis Methods Patients hospitalized with meningitis (N = 23,933) or encephalitis (N = 7,858) in the U.S. were identified in the 2010-2014 Truven Health MarketScan Commercial Claims and Encounters Database using ICD-9-CM diagnostic codes. The database included an average of 40.8 million commercially insured enrollees under age 65 per year. Clinical, demographic and healthcare utilization criteria were used to identify patient subgroups early in their episode who were at risk to have high inpatient expenditures. Healthcare expenditures of patients within each subgroup were bifurcated: those expenditures that remained five days after the patient could be classified into the subgroup versus those that had occurred previously. Results The hospitalization episode rate per 100,000 enrollee-years for meningitis was 13.0 (95% CI: 12.9-13.2) and for encephalitis was 4.3 (95% CI: 4.2-4.4), with mean inpatient expenditures of $36,891 (SD = $92,636) and $60,181 (SD = $130,276), respectively. If advanced diagnostic testing had been administered on the day that a patient could be classified into a subgroup, then a test with a five-day turnaround time could impact the following mean inpatient expenditures that remained by subgroup for patients with meningitis or encephalitis, respectively: had a neurosurgical procedure ($83,337 and $56,020), had an ICU stay ($34,221 and $46,051), had HIV-1 infection or a previous organ transplant ($37,702 and $62,222), were age <1 year ($35,371 and $52,812), or had a hospital length of stay >2 days ($18,325 and $30,244). Discussion Inpatient expenditures for patients hospitalized with meningitis or encephalitis were substantial and varied widely. Patient subgroups who had high healthcare expenditures could be identified early in their stay, raising the potential for advanced diagnostic testing to lower these expenditures.	[Fulton, Brent D.; Proudman, David G.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; [Sample, Hannah A.; DeRisi, Joseph L.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; [Gelfand, Jeffrey M.; Wilson, Michael R.] Univ Calif San Francisco, Dept Neurol, Weill Inst Neurosci, San Francisco, CA 94143 USA; [Chiu, Charles Y.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Chiu, Charles Y.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Chiu, Charles Y.] UCSF Abbott Viral Diagnost & Discovery Ctr, San Francisco, CA USA; [DeRisi, Joseph L.] Chan Zuckerberg Biohub, San Francisco, CA USA	University of California System; University of California Berkeley; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Fulton, BD (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.	fultonb@berkeley.edu		Sample, Hannah/0000-0002-5398-3907; Wilson, Michael/0000-0002-8705-5084; Fulton, Brent/0000-0002-8305-4711	UCSF Center for Next-Gen Precision Diagnostics - Sandler Foundation; William K. Bowes, Jr. Foundation; Charles and Helen Schwab Foundation; Chan Zuckerberg Biohub; Mentored Clinical Scientist Development award from the National Institute of Neurological Disorders and Stroke [K08NS096117]	UCSF Center for Next-Gen Precision Diagnostics - Sandler Foundation; William K. Bowes, Jr. Foundation; Charles and Helen Schwab Foundation; Chan Zuckerberg Biohub; Mentored Clinical Scientist Development award from the National Institute of Neurological Disorders and Stroke	This study was supported by UCSF Center for Next-Gen Precision Diagnostics, https://nextgendiagnostics.ucsf.edu/, which is supported by the Sandler Foundation, https://www.sandlerfoundation.org/(BDF, DGP, HAS, JMG, CYC and MRW) the William K. Bowes, Jr. Foundation, https://www.wkbowesjrfoundation.org/(BDF, DGP, HAS, JMG, CYC, JLD and MRW), and the Charles and Helen Schwab Foundation, http://www.schwabfoundation.org/(CYC).Additional support was from the Chan Zuckerberg Biohub, https://www.czbiohub.org/(JLD) and a Mentored Clinical Scientist Development award K08NS096117 from the National Institute of Neurological Disorders and Stroke, https://www.ninds.nih.gov/(MRW).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bai G, 2015, HEALTH AFFAIR, V34, P922, DOI 10.1377/hlthaff.2014.1414; Bai G, 2015, HEALTH AFFAIR, V34, P64, DOI 10.1377/hlthaff.2014.1072; Beernink T M J, 2016, Pract Neurol, V16, P136, DOI 10.1136/practneurol-2015-001166; Britton PN, 2015, INTERN MED J, V45, P563, DOI 10.1111/imj.12749; Chiu CY, 2017, EMERG INFECT DIS, V23, P1694, DOI 10.3201/eid2310.161986; Fremond ML, 2015, J PEDIAT INF DIS SOC, V4, pE53, DOI 10.1093/jpids/piv040; George BP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104169; GRENINGER A, 2015, GENOME MED, V7, P1; Greninger AL, 2018, EXPERT REV MOL DIAGN, V18, P605, DOI 10.1080/14737159.2018.1487292; Hasbun R, 2017, CLIN INFECT DIS, V65, P359, DOI 10.1093/cid/cix319; Hong DK, 2018, DIAGN MICR INFEC DIS, V92, P210, DOI 10.1016/j.diagmicrobio.2018.06.009; Jouan Y, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1046-y; Kaiser Family Foundation, 2017, 2017 EMPL HLTH BEN S; KENNEDY CR, 1987, ARCH DIS CHILD, V62, P1156, DOI 10.1136/adc.62.11.1156; Khetsuriani N, 2002, CLIN INFECT DIS, V35, P175, DOI 10.1086/341301; Maeda J, 2017, ANAL PRIVATE SECTOR; Messacar K, 2016, DIAGN MICR INFEC DIS, V86, P118, DOI 10.1016/j.diagmicrobio.2016.05.020; Mongkolrattanothai K, 2017, J PEDIATR INFECT DIS, V6, P393, DOI 10.1093/jpids/piw066; Murkey JA, 2017, OPEN FORUM INFECT DI, P1; Naccache SN, 2015, CLIN INFECT DIS, V60, P919, DOI 10.1093/cid/ciu912; Nigrovic LE, 2013, PEDIATRICS, V131, P670, DOI 10.1542/peds.2012-3077; Schlaberg R, 2017, ARCH PATHOL LAB MED, V141, P776, DOI 10.5858/arpa.2016-0539-RA; Simner PJ, 2018, CLIN INFECT DIS, V66, P778, DOI 10.1093/cid/cix881; Takhar SS, 2012, ACAD EMERG MED, V19, P632, DOI 10.1111/j.1553-2712.2012.01377.x; Thakur KT, 2013, NEUROLOGY, V81, P793, DOI 10.1212/WNL.0b013e3182a2cc6d; Truven Health Analytics, 2017, TRUV HLTH MARKETSCAN; Vora NM, 2014, NEUROLOGY, V82, P443, DOI 10.1212/WNL.0000000000000086; Wilson MR, 2019, NEW ENGL J MED, V380, P2327, DOI 10.1056/NEJMoa1803396; Wilson M, 2016, JAMA NEUROL, V73, P1389, DOI 10.1001/jamaneurol.2016.3617; Wilson MR, 2015, ANN NEUROL, V78, P722, DOI 10.1002/ana.24499; Wilson MR, 2014, NEW ENGL J MED, V370, P2408, DOI 10.1056/NEJMoa1401268; Wilson MR, 2018, JAMA NEUROL, pE1	32	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2020	15	1							e0226895	10.1371/journal.pone.0226895	http://dx.doi.org/10.1371/journal.pone.0226895			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5OV	31940319	Green Published, gold			2023-01-03	WOS:000534368000048
J	Orchard, JW				Orchard, John W.			Is there a place for intra-articular corticosteroid injections in the treatment of knee osteoarthritis?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PAIN; TRIAL		[Orchard, John W.] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia	University of Sydney	Orchard, JW (corresponding author), Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia.	john.orchard@sydney.edu.au	Orchard, John W/AAY-7216-2020	Orchard, John W/0000-0003-3530-1711				Abbott JH, 2019, OSTEOARTHR CARTILAGE, V27, P424, DOI 10.1016/j.joca.2018.12.004; Cancienne JM, 2016, ARTHROSCOPY, V32, P90, DOI 10.1016/j.arthro.2015.09.003; Cancienne JM, 2015, J ARTHROPLASTY, V30, P1879, DOI 10.1016/j.arth.2015.05.027; Fransen M, 2015, COCHRANE DB SYST REV, V1; Gregori D, 2018, JAMA-J AM MED ASSOC, V320, P2564, DOI 10.1001/jama.2018.19319; Juni P, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005328.pub3; Kompel AJ, 2019, RADIOLOGY, V293, P656, DOI 10.1148/radiol.2019190341; Liu SH, 2018, J RHEUMATOL, V45, P1316, DOI 10.3899/jrheum.171385; McAlindon TE, 2017, JAMA-J AM MED ASSOC, V317, P1967, DOI 10.1001/jama.2017.5283; National Institute for Health and Care Excellence, 2019, MAN OST; Pabinger C, 2015, OSTEOARTHR CARTILAGE, V23, P1664, DOI 10.1016/j.joca.2015.05.008; Raynauld JP, 2003, ARTHRITIS RHEUM, V48, P370, DOI 10.1002/art.10777; Skou ST, 2015, NEW ENGL J MED, V373, P1597, DOI 10.1056/NEJMoa1505467; The Royal Australian College of General Practitioners, 2018, GUIDELINE MANAGEMENT; Thorlund JB, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2747; van Middelkoop M, 2016, OSTEOARTHR CARTILAGE, V24, P1143, DOI 10.1016/j.joca.2016.01.983; Zeng C, 2019, OSTEOARTHR CARTILAGE, V27, P855, DOI 10.1016/j.joca.2019.01.007	17	12	12	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 15	2020	368								l6923	10.1136/bmj.l6923	http://dx.doi.org/10.1136/bmj.l6923			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF9PC	31941647				2023-01-03	WOS:000509573400004
J	Tian, YH; Liu, H; Wu, YQ; Si, YQ; Song, J; Cao, YY; Li, M; Wu, Y; Wang, XW; Chen, LB; Wei, C; Gao, P; Hu, YH				Tian, Yaohua; Liu, Hui; Wu, Yiqun; Si, Yaqin; Song, Jing; Cao, Yaying; Li, Man; Wu, Yao; Wang, Xiaowen; Chen, Libo; Wei, Chen; Gao, Pei; Hu, Yonghua			Association between ambient fine particulate pollution and hospital admissions for cause specific cardiovascular disease: time series study in 184 major Chinese cities	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MATTER AIR-POLLUTION; SHORT-TERM EXPOSURE; DAILY MORTALITY; EXHAUST INHALATION; HEMORRHAGIC STROKE; ISCHEMIC-STROKE; GLOBAL BURDEN; PM2.5; RISK; PARTICLES	OBJECTIVE To estimate the risks of daily hospital admissions for cause specific major cardiovascular diseases associated with short term exposure to ambient fine particulate matter (aerodynamic diameter <= 2.5 mu m; PM 2.5) pollution in China. DESIGN National time series study. SETTING 184 major cities in China. POPULATION 8 834 533 hospital admissions for cardiovascular causes in 184 Chinese cities recorded by the national database of Urban Employee Basic Medical Insurance from 1 January 2014 to 31 December 2017. MAIN OUTCOME MEASURES Daily counts of city specific hospital admissions for primary diagnoses of ischaemic heart disease, heart failure, heart rhythm disturbances, ischaemic stroke, and haemorrhagic stroke among different demographic groups were used to estimate the associations between PM2.5 and morbidity. An overdispersed generalised additive model was used to estimate city specific associations between PM(2.)5 and cardiovascular admissions, and random effects meta-analysis used to combine the city specific estimates. RESULTS Over the study period, a mean of 47 hospital admissions per day (standard deviation 74) occurred for cardiovascular disease, 26 (53) for ischaemic heart disease, one (five) for heart failure, two (four) for heart rhythm disturbances, 14 (28) for ischaemic stroke, and two (four) for haemorrhagic stroke. At the national average level, an increase of 10 mu g/m(3) in PM2.5 was associated with a 0.26% (95% confidence interval 0.17% to 0.35%) increase in hospital admissions on the same day for cardiovascular disease, 0.31% (0.22% to 0.40%) for ischaemic heart disease, 0.27% (0.04% to 0.51%) for heart failure, 0.29% (0.12% to 0.46%) for heart rhythm disturbances, and 0.29% (0.18% to 0.40%) for ischaemic stroke, but not with haemorrhagic stroke (-0.02% (-0.23% to 0.19%)). The national average association of PM2.5 with cardiovascular disease was slightly non-linear, with a sharp slope at PM2.5 levels below 50 mu g/m(3), a moderate slope at 50-250 mu g/m(3), and a plateau at concentrations higher than 250 mu g/m(3). Compared with days with PM2.5 up to 15 mu g/m(3), days with PM2.5 of 15-25, 25-35, 35-75, and 75 mu g/m(3) or more were significantly associated with increases in cardiovascular admissions of 1.1% (0 to 2.2%), 1.9% (0.6% to 3.2%), 2.6% (1.3% to 3.9%), and 3.8% (2.1% to 5.5%), respectively.According to projections, achieving the Chinese grade 2 (35 mu g/m3), Chinese grade 1 (15 mu g/m(3)), and World Health Organization (10 mu g/m(3)) regulatory limits for annual mean PM2.5 concentrations would reduce the annual number of admissions for cardiovascular disease in China. Assuming causality, which should be done with caution, this reduction would translate into an estimated 36 448 (95% confidence interval 24 441 to 48 471), 85 270 (57 129 to 113 494), and 97 516 (65 320 to 129 820), respectively. CONCLUSIONS These data suggest that in China, short term exposure to PM2.5 is associated with increased hospital admissions for all major cardiovascular diseases except for haemorrhagic stroke, even for exposure levels not exceeding the current regulatory limits.	[Tian, Yaohua] Huazhong Univ Sci & Technol, Sch Publ Hlth, Dept Maternal & Child Hlth, Tongji Med Coll, Wuhan, Peoples R China; [Tian, Yaohua] Huazhong Univ Sci & Technol, Minist Educ, Key Lab Environm & Hlth, Wuhan, Peoples R China; [Tian, Yaohua] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, State Key Lab Environm Hlth Incubating, Wuhan, Peoples R China; [Tian, Yaohua; Liu, Hui; Wu, Yiqun; Si, Yaqin; Song, Jing; Cao, Yaying; Li, Man; Wu, Yao; Wang, Xiaowen; Gao, Pei; Hu, Yonghua] Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 38 Xueyuan Rd, Beijing 100191, Peoples R China; [Liu, Hui; Hu, Yonghua] Peking Univ, Med Informat Ctr, Beijing, Peoples R China; [Si, Yaqin; Chen, Libo; Wei, Chen] Beijing HealthCom Data Technol, Beijing, Peoples R China; [Gao, Pei] Peking Univ, Key Lab Mol Cardiovasc, Minist Educ, Beijing, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Peking University; Peking University; Peking University	Hu, YH (corresponding author), Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 38 Xueyuan Rd, Beijing 100191, Peoples R China.; Hu, YH (corresponding author), Peking Univ, Med Informat Ctr, Beijing, Peoples R China.	yhhu@bjmu.edu.cn	WU, YAO/GYJ-3813-2022; WEI, CHENYI/HIR-5672-2022	WU, YAO/0000-0002-8105-0522; Tian, Yaohua/0000-0002-9853-6991; Song, Jing/0000-0002-0987-3284; Wu, Yiqun/0000-0002-5554-1678	National Natural Science Foundation of China [81872695, 91846112, 81573226]; National Thousand Talents Programme for Distinguished Young Scholars, China [QNQR201501]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Thousand Talents Programme for Distinguished Young Scholars, China	This study was supported by the National Natural Science Foundation of China (grant 81872695, 91846112, and 81573226) and the National Thousand Talents Programme for Distinguished Young Scholars, China (QNQR201501). The funders were not involved in the research and preparation of the article, including study design; collection, analysis, and interpretation of data; writing of the article; or in the decision to submit it for publication.	Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; Amsalu E, 2019, ENVIRON HEALTH-GLOB, V18, DOI 10.1186/s12940-019-0506-2; Atkinson RW, 2014, THORAX, V69, P660, DOI 10.1136/thoraxjnl-2013-204492; Bell ML, 2009, AM J RESP CRIT CARE, V179, P1115, DOI 10.1164/rccm.200808-1240OC; Bell ML, 2008, AM J EPIDEMIOL, V168, P1301, DOI 10.1093/aje/kwn252; Bhaskaran K, 2013, INT J EPIDEMIOL, V42, P1187, DOI 10.1093/ije/dyt092; Bhaskaran K, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5531; Brauer M, 2016, ENVIRON SCI TECHNOL, V50, P79, DOI 10.1021/acs.est.5b03709; Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1; Burgan O, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-26; Chen RJ, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4306; Chen RC, 2017, AM J RESP CRIT CARE, V196, P700, DOI [10.1164/rccm.201609-1862OC, 10.1164/rccm.201612-2427OC, 10.1164/rccm.201609-1862oc]; Cohen AJ, 2017, LANCET, V389, P1907, DOI [10.1016/s0140-6736(17)30505-6, 10.1016/S0140-6736(17)30505-6]; Costa AF, 2017, ENVIRON HEALTH PERSP, V125, P349, DOI 10.1289/EHP98; Di Q, 2017, JAMA-J AM MED ASSOC, V318, P2446, DOI 10.1001/jama.2017.17923; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Dominici F, 2002, AM J EPIDEMIOL, V156, P193, DOI 10.1093/aje/kwf062; Goldman GT, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-61; Hay SI, 2017, LANCET, V390, P1260, DOI 10.1016/S0140-6736(17)32130-X; Huang J, 2018, LANCET PLANET HEALTH, V2, pE313, DOI 10.1016/S2542-5196(18)30141-4; Lanzinger S, 2016, AM J RESP CRIT CARE, V194, P1233, DOI 10.1164/rccm.201510-2042OC; Lisabeth LD, 2008, ANN NEUROL, V64, P53, DOI 10.1002/ana.21403; Liu C, 2019, NEW ENGL J MED, V381, P705, DOI 10.1056/NEJMoa1817364; Liu H, 2018, EPIDEMIOLOGY, V29, P649, DOI [10.1097/ede.0000000000000869, 10.1097/EDE.0000000000000869]; Liu H, 2017, STROKE, V48, P2052, DOI 10.1161/STROKEAHA.116.016482; Lu F, 2015, ENVIRON RES, V136, P196, DOI 10.1016/j.envres.2014.06.029; Lucking AJ, 2011, CIRCULATION, V123, P1721, DOI 10.1161/CIRCULATIONAHA.110.987263; Lucking AJ, 2008, EUR HEART J, V29, P3043, DOI 10.1093/eurheartj/ehn464; Macdonald RW, 2005, SCI TOTAL ENVIRON, V342, P5, DOI 10.1016/j.scitotenv.2004.12.059; Maheswaran R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158556; Moghadamnia MT, 2017, PEERJ, V5, DOI 10.7717/peerj.3574; Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9; Newell K, 2017, LANCET PLANET HEALTH, V1, pE368, DOI 10.1016/S2542-5196(17)30166-3; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; Peng RD, 2008, JAMA-J AM MED ASSOC, V299, P2172, DOI 10.1001/jama.299.18.2172; Peng RD, 2009, ENVIRON HEALTH PERSP, V117, P957, DOI 10.1289/ehp.0800185; Phung D, 2016, SCI TOTAL ENVIRON, V550, P1084, DOI 10.1016/j.scitotenv.2016.01.154; Pope CA, 2006, J AIR WASTE MANAGE, V56, P709, DOI 10.1080/10473289.2006.10464545; Sade MY, 2015, STROKE, V46, P3348, DOI 10.1161/STROKEAHA.115.010992; Samoli E, 2005, ENVIRON HEALTH PERSP, V113, P88, DOI 10.1289/ehp.7387; Shah ASV, 2015, BMJ-BRIT MED J, V350, DOI [10.1136/bmj.h1295, 10.1136/bmj.i4851]; Shang Y, 2013, ENVIRON INT, V54, P100, DOI 10.1016/j.envint.2013.01.010; Shi LH, 2016, ENVIRON HEALTH PERSP, V124, P46, DOI 10.1289/ehp.1409111; Thurston GD, 2016, ENVIRON HEALTH PERSP, V124, P785, DOI 10.1289/ehp.1509777; Tian YH, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002738; Villeneuve PJ, 2006, EUR J EPIDEMIOL, V21, P689, DOI 10.1007/s10654-006-9050-9; Wang MH, 2019, LANCET RESP MED, V7, P35, DOI [10.1016/s2213-2600(18)30432-6, 10.1016/S2213-2600(18)30432-6]; Wang WD, 2019, SCI TOTAL ENVIRON, V695, DOI 10.1016/j.scitotenv.2019.133780; Wellenius GA, 2005, STROKE, V36, P2549, DOI 10.1161/01.STR.0000189687.78760.47; Wellenius GA, 2012, ARCH INTERN MED, V172, P229, DOI 10.1001/archinternmed.2011.732; Yang F, 2011, ATMOS CHEM PHYS, V11, P5207, DOI 10.5194/acp-11-5207-2011; Yin P, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j667; Yip WCM, 2012, LANCET, V379, P833, DOI 10.1016/S0140-6736(11)61880-1; Zhao BT, 2016, J INTEGR ENVIRON SCI, V13, P85, DOI 10.1080/1943815X.2016.1150301	54	86	92	7	47	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 30	2019	367								l6572	10.1136/bmj.l6572	http://dx.doi.org/10.1136/bmj.l6572			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB7RR	31888884	Green Published, hybrid			2023-01-03	WOS:000506688300003
J	Poeschel, V; Held, G; Ziepert, M; Witzens-Harig, M; Holte, H; Thurner, L; Borchmann, P; Viardot, A; Soekler, M; Keller, U; Schmidt, C; Truemper, L; Mahlberg, R; Marks, R; Hoeffkes, HG; Metzner, B; Dierlamm, J; Frickhofen, N; Haenel, M; Neubauer, A; Kneba, M; Merli, F; Tucci, A; Brown, PD; Federico, M; Lengfelder, E; di Rocco, A; Trappe, R; Rosenwald, A; Berdel, C; Maisenhoelder, M; Shpilberg, O; Amam, J; Christofyllakis, K; Hartmann, F; Murawski, N; Stilgenbauer, S; Nickelsen, M; Wulf, G; Glass, B; Schmitz, N; Altmann, B; Loeffler, M; Pfreundschuh, M				Poeschel, Viola; Held, Gerhard; Ziepert, Marita; Witzens-Harig, Mathias; Holte, Harald; Thurner, Lorenz; Borchmann, Peter; Viardot, Andreas; Soekler, Martin; Keller, Ulrich; Schmidt, Christian; Truemper, Lorenz; Mahlberg, Rolf; Marks, Reinhard; Hoeffkes, Heinz-Gert; Metzner, Bernd; Dierlamm, Judith; Frickhofen, Norbert; Haenel, Mathias; Neubauer, Andreas; Kneba, Michael; Merli, Francesco; Tucci, Alessandra; Brown, Peter de Nully; Federico, Massimo; Lengfelder, Eva; di Rocco, Alice; Trappe, Ralf; Rosenwald, Andreas; Berdel, Christian; Maisenhoelder, Martin; Shpilberg, Ofer; Amam, Josif; Christofyllakis, Konstantinos; Hartmann, Frank; Murawski, Niels; Stilgenbauer, Stephan; Nickelsen, Maike; Wulf, Gerald; Glass, Bertram; Schmitz, Norbert; Altmann, Bettina; Loeffler, Markus; Pfreundschuh, Michael		FLYER Trial Investigators; German Lymphoma Alliance	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial	LANCET			English	Article							NON-HODGKIN-LYMPHOMA; ELDERLY-PATIENTS; R-CHOP; RESPONSE CRITERIA; PLUS RITUXIMAB; YOUNG-PATIENTS; RADIOTHERAPY; SURVIVAL; THERAPY	Background Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin lymphoma. In the FLYER trial, we assessed whether four cycles of CHOP plus six applications of rituximab are non-inferior to six cycles of R-CHOP in a population of patients with B-cell non-Hodgkin lymphoma with favourable prognosis. Methods This two-arm, open-label, international, multicentre, prospective, randomised phase 3 non-inferiority trial was done at 138 clinical sites in Denmark, Israel, Italy, Norway, and Germany. We enrolled patients aged 18-60 years, with stage I-II disease, normal serum lactate dehydrogenase concentration, ECOG performance status 0-1, and without bulky disease (maximal tumour diameter <7.5 cm). Randomisation was computer-based and done centrally in a 1:1 ratio using the Pocock minimisation algorithm after stratification for centres, stage (I vs II), and extralymphatic sites (no vs yes). Patients were assigned to receive either six cycles of R-CHOP or four cycles of R-CHOP plus two doses of rituximab. CHOP comprised cyclophosphamide (750 mg/m(2)), doxorubicin (50 mg/m(2)), and vincristine (1.4 mg/m(2), with a maximum total dose of 2 mg), all administered intravenously on day 1, plus oral prednisone or prednisolone at the discretion of the investigator (100 mg) administered on days 1-5. Rituximab was given at a dose of 375 mg/m(2) of body surface area. Cycles were repeated every 21 days. No radiotherapy was planned except for testicular lymphoma treatment. The primary endpoint was progression-free survival after 3 years. The primary analysis was done in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of assigned treatment. A non-inferiority margin of -5.5% was chosen. The trial, which is completed, was prospectively registered at ClinicalTrials.gov, NCT00278421. Findings Between Dec 2, 2005, and Oct 7, 2016, 592 patients were enrolled, of whom 295 patients were randomly assigned to receive six cycles of R-CHOP and 297 were assigned to receive four cycles of R-CHOP plus two doses of rituximab. Four patients in the four-cycles group withdrew informed consent before the start of treatment, so 588 patients were included in the intention-to-treat analysis. After a median follow-up of 66 months (IQR 42-100), 3-year progression-free survival of patients who had four cycles of R-CHOP plus two doses of rituximab was 96% (95% CI 94-99), which was 3% better (lower limit of the one-sided 95% CI for the difference was 0%) than six cycles of R-CHOP, demonstrating the non-inferiority of the four-cycles regimen. 294 haematological and 1036 non-haematological adverse events were documented in the four-cycles group compared with 426 haematological and 1280 non-haematological adverse events in the six-cycles group. Two patients, both in the six-cycles group, died during study therapy. Interpretation In young patients with aggressive B-cell non-Hodgkin lymphoma and favourable prognosis, four cycles of R-CHOP is non-inferior to six cycles of R-CHOP, with relevant reduction of toxic effects. Thus, chemotherapy can be reduced without compromising outcomes in this population. Copyright (C) 2019 Elsevier Ltd. All rights reserved.	[Poeschel, Viola; Thurner, Lorenz; Amam, Josif; Christofyllakis, Konstantinos; Hartmann, Frank; Murawski, Niels; Stilgenbauer, Stephan; Pfreundschuh, Michael] Saarland Univ, Med Sch, Dept Internal Med Oncol Hematol Clin Immunol & Rh, Homburg, Germany; [Held, Gerhard] Westpfalz Klinikum, Dept Internal Med 1, D-67655 Kaiserslautern, Germany; [Ziepert, Marita; Altmann, Bettina; Loeffler, Markus] Univ Leipzig, Inst Med Informat Stat & Epidemiol, Leipzig, Germany; [Witzens-Harig, Mathias] Heidelberg Univ, Dept Internal Med 5, Heidelberg, Germany; [Holte, Harald] Oslo Univ Hosp, Dept Oncol, Oslo, Norway; [Borchmann, Peter] Univ Hosp Cologne, Dept Hematol & Oncol, Cologne, Germany; [Viardot, Andreas] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany; [Soekler, Martin] Univ Hosp Tuebingen, Dept Internal Med 2, Tubingen, Germany; [Keller, Ulrich] Tech Univ Munich, Klinikum Rechts Isar, Dept Internal Med 3, Munich, Germany; [Schmidt, Christian] Univ Hosp, Dept Med 3, Munich, Germany; [Truemper, Lorenz; Wulf, Gerald] Georg August Univ Goettingen, Dept Hematol & Oncol, Gottingen, Germany; [Mahlberg, Rolf] Klinikum Mutterhaus Borromaerinnen, Dept Internal Med 1, Trier, Germany; [Marks, Reinhard] Univ Med Ctr, Dept Hematol & Oncol, Freiburg, Germany; [Hoeffkes, Heinz-Gert] Klinikum Fulda Tumorklin, Fulda, Germany; [Metzner, Bernd] Klinikum Oldenburg, Dept Hematol & Oncol, Oldenburg, Germany; [Dierlamm, Judith] Univ Hosp Eppendorf, Dept Internal Med 2, Hamburg, Germany; [Frickhofen, Norbert] Dr Horst Schmidt Kliniken Wiesbaden, Dept Internal Med 3, Wiesbaden, Germany; [Haenel, Mathias] Kuchwald Hosp Chemnitz, Dept Internal Med 3, Chemnitz, Germany; [Neubauer, Andreas] Univ Hosp Marburg, Dept Hematol Oncol & Immunol, Marburg, Germany; [Kneba, Michael] City Hosp Kiel, Dept Internal Med 2, Kiel, Germany; [Merli, Francesco] Ist Ricovero & Cura Carattere Sci Reggio Emilia, Hematol Azienda Unita Sanitarie Locali, Reggio Emilia, Italy; [Tucci, Alessandra] Hematol Azienda Socio Sanitana Terr Spedali Civil, Brescia, Italy; [Brown, Peter de Nully] Rigshosp, Dept Hematol, Copenhagen, Denmark; [Federico, Massimo] Univ Modena & Reggio Emilia, Dipartimento Chirurg Med Odontoiatr & Sci Morfol, Modena, Italy; [Lengfelder, Eva] Univ Hosp Mannheim, Dept Internal Med 3, Mannheim, Germany; [di Rocco, Alice] Sapienza Univ Rome, Dept Translat & Precis Med, Rome, Italy; [Trappe, Ralf] Evangelisches Diakonie Krankenhaus, Dept Internal Med 2, Bremen, Germany; [Rosenwald, Andreas] Univ Wurzburg, Inst Pathol, Wurzburg, Germany; [Rosenwald, Andreas] Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Berdel, Christian] Saarland Univ, Dept Radiooncol, Med Sch, Homburg, Germany; [Maisenhoelder, Martin] Univ Hosp North Norway, Dept Oncol, Tromso, Norway; [Shpilberg, Ofer] Rabin Med Ctr, Beilinson Hosp, Dept Hematol, Petah Tiqwa, Israel; [Nickelsen, Maike; Glass, Bertram; Schmitz, Norbert] Asklepios Klin St Georg, Dept Hematol Oncol & Stem Cell Transplantat, Hamburg, Germany	Universitatsklinikum des Saarlandes; Westpfalz-Klinikum GmbH; Leipzig University; Ruprecht Karls University Heidelberg; University of Oslo; University of Cologne; Ulm University; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Technical University of Munich; University of Munich; University of Munich; University of Gottingen; University of Freiburg; Klinikum Fulda; Klinikum Oldenburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University Hospital of Giessen & Marburg; Rigshospitalet; University of Copenhagen; Universita di Modena e Reggio Emilia; Ruprecht Karls University Heidelberg; Sapienza University Rome; University of Wurzburg; University of Wurzburg; Universitatsklinikum des Saarlandes; UiT The Arctic University of Tromso; University Hospital of North Norway; Rabin Medical Center; Tel Aviv University; Asklepios Klinik St. Georg	Held, G (corresponding author), Westpfalz Klinikum, Dept Internal Med 1, D-67655 Kaiserslautern, Germany.; Poeschel, V (corresponding author), Saarland Univ, Med Sch, Dept Internal Med 1, D-66421 Homburg, Germany.	viola.poeschel@uks.eu; gheld@westpfalz-klinikum.de	Metzner, Bernd/AAM-4054-2021; Trappe, Ralf Ulrich/W-5801-2019; Christofyllakis, Konstantinos/AAN-2597-2020; Italiana Linfomi, Fondazione/AAW-6910-2021; Stilgenbauer, Stephan/ABE-6609-2020; Holte, Harald/AAO-5647-2020; Keller, Ulrich/L-1763-2016; Tucci, Alessandra/K-7818-2016	Metzner, Bernd/0000-0002-1496-1377; Trappe, Ralf Ulrich/0000-0001-7565-7160; Italiana Linfomi, Fondazione/0000-0002-5918-8824; Brown, Peter de Nully/0000-0002-6522-4086; Keller, Ulrich/0000-0002-8485-1958; Tucci, Alessandra/0000-0003-3052-7463; Christofyllakis, Konstantinos/0000-0002-0308-388X	Deutsche Krebshilfe	Deutsche Krebshilfe(Deutsche Krebshilfe)	Deutsche Krebshilfe.	Bartlett NL, 2019, J CLIN ONCOL, V37, P1790, DOI 10.1200/JCO.18.01994; Boehme V, 2009, BLOOD, V113, P3896, DOI 10.1182/blood-2008-10-182253; Burggraaff CN, 2019, EUR J NUCL MED MOL I, V46, P65, DOI 10.1007/s00259-018-4103-3; Casasnovas RO, 2011, BLOOD, V118, P37, DOI 10.1182/blood-2010-12-327767; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Copie-Bergman C, 2015, BLOOD, V126, P2466, DOI 10.1182/blood-2015-05-647602; Davies A, 2019, LANCET ONCOL, V20, P649, DOI 10.1016/S1470-2045(18)30935-5; Duhrsen U, 2018, J CLIN ONCOL, V36, P2024, DOI 10.1200/JCO.2017.76.8093; Jaeger U, 2015, HAEMATOLOGICA, V100, P955, DOI 10.3324/haematol.2015.125344; Lamy T, 2018, BLOOD, V131, P174, DOI 10.1182/blood-2017-07-793984; Luminari S, 2018, J CLIN ONCOL, V36, P689, DOI 10.1200/JCO.2017.74.1652; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; Maurer MJ, 2014, J CLIN ONCOL, V32, P1066, DOI 10.1200/JCO.2013.51.5866; Persky DO, 2008, J CLIN ONCOL, V26, P2258, DOI 10.1200/JCO.2007.13.6929; Pfreundschuh M, 2008, LANCET ONCOL, V9, P435, DOI 10.1016/S1470-2045(08)70078-0; Pfreundschuh M, 2008, LANCET ONCOL, V9, P105, DOI 10.1016/S1470-2045(08)70002-0; Pfreundschuh M, 2017, BLOOD, V130; Pfreundschuh M, 2014, J CLIN ONCOL, V32, P4127, DOI 10.1200/JCO.2013.54.6861; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; Piantadosi S, 1983, CLIN TRIALS, P213; Rosenwald A, 2003, J EXP MED, V198, P851, DOI 10.1084/jem.20031074; ROTHMANN MD, 2012, CH CRC BIOSTAT SER, P1; Schmitz N, 2016, J CLIN ONCOL, V34, P3150, DOI 10.1200/JCO.2015.65.6520; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; Vitolo U, 2017, J CLIN ONCOL, V35, P3529, DOI 10.1200/JCO.2017.73.3402; Vitolo U, 2011, J CLIN ONCOL, V29, P2766, DOI 10.1200/JCO.2010.31.4187; Wunderlich A, 2003, ANN ONCOL, V14, P881, DOI 10.1093/annonc/mdg249; Younes A, 2019, J CLIN ONCOL, V37, P1285, DOI 10.1200/JCO.18.02403; Ziepert M, 2010, J CLIN ONCOL, V28, P2373, DOI 10.1200/JCO.2009.26.2493	32	98	101	3	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	2019	394	10216					2271	2281						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX5QC	31868632	Green Published			2023-01-03	WOS:000503788300030
J	Quan, V; Toro-Silva, S; Sriruttan, C; Chetty, V; Chihota, V; Candfield, S; Vassall, A; Grant, AD; Govender, NP				Quan, Vanessa; Toro-Silva, Sandra; Sriruttan, Charlotte; Chetty, Verushka; Chihota, Violet; Candfield, Sophie; Vassall, Anna; Grant, Alison D.; Govender, Nelesh P.		GERMS SA	Pathways to care and outcomes among hospitalised HIV-seropositive persons with cryptococcal meningitis in South Africa	PLOS ONE			English	Article							HEALTH	Introduction Cryptococcus causes 15% of AIDS-related deaths and in South Africa, with its high HIV burden, is the dominant cause of adult meningitis. Cryptococcal meningitis (CM) mortality is high, partly because patients enter care with advanced HIV disease and because of failure of integrated care following CM diagnosis. We evaluated pathways to hospital care, missed opportunities for HIV testing and initiation of care. Methods We performed a cross-sectional study at five public-sector urban hospitals. We enrolled adults admitted with a first or recurrent episode of cryptococcal meningitis. Study nurses conducted interviews, supplemented by a prospective review of medical charts and laboratory records. Results From May to October 2015, 102 participants were enrolled; median age was 40 years (interquartile range [IQR] 33.9-46.7) and 56 (55%) were male. In the six weeks prior to admission, 2/102 participants were asymptomatic, 72/100 participants sought care at a public-sector facility, 16/100 paid for private health care. The median time from seeking care to admission was 4 days (IQR, 0-27 days). Of 94 HIV-seropositive participants, only 62 (66%) knew their status and 41/62 (66%) had ever taken antiretroviral treatment. Among 13 participants with a known previous CM episode, none were taking fluconazole maintenance therapy. In-hospital management was mostly amphotericin B; in-hospital mortality was high (28/92, 30%). Sixty-four participants were discharged, 92% (59/64) on maintenance fluconazole, 4% (3/64) not on fluconazole and 3% (2/64) unknown. Twelve weeks post-discharge, 31/64 (48%) participants were lost to follow up. By 12 weeks post discharge 7/33 (21%) had died. Interviewed patients were asked if they were still on fluconazole, 11% (2/18) were not. Conclusions Among hospitalised participants with CM, there were many missed opportunities for HIV care and linkage to ART prior to admission. Universal reflex CrAg screening may prompt earlier diagnosis of cryptococcal meningitis but there is a wider problem of timely linkage to care for HIV-seropositive people.	[Quan, Vanessa] Natl Inst Communicable Dis, GERMS SA, Div Publ Hlth Surveillance & Response, Johannesburg, South Africa; [Toro-Silva, Sandra; Candfield, Sophie; Vassall, Anna; Grant, Alison D.] London Sch Hyg & Trop Med, TB Ctr, London, England; [Sriruttan, Charlotte; Chetty, Verushka; Govender, Nelesh P.] Natl Inst Communicable Dis, Ctr Healthcare Associated Infect Antimicrobial Re, Natl Hlth Lab Serv, Johannesburg, South Africa; [Sriruttan, Charlotte] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Johannesburg, South Africa; [Chihota, Violet] Aurum Inst, Johannesburg, South Africa; [Chihota, Violet; Grant, Alison D.] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa; [Grant, Alison D.] Cent & North West NHS Fdn Trust, Mortimer Market Ctr, London, England; [Grant, Alison D.] Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Africa Hlth Res Inst, Durban, South Africa	National Institute for Communicable Diseases (NICD); University of London; London School of Hygiene & Tropical Medicine; National Health Laboratory Service; National Institute for Communicable Diseases (NICD); University of Witwatersrand; University of Witwatersrand; Africa Health Research Institute; University of Kwazulu Natal	Quan, V (corresponding author), Natl Inst Communicable Dis, GERMS SA, Div Publ Hlth Surveillance & Response, Johannesburg, South Africa.	vanessaq@nicd.ac.za	Candfield, Sophie/ABD-7413-2021; Chihota, Violet/DWH-9372-2022; Govender, Nelesh/ABI-6429-2020	Chihota, Violet/0000-0003-1444-9266; Candfield, Sophie/0000-0002-6543-7276; Govender, Nelesh/0000-0001-7869-9462	National Institute for Communicable Diseases; National Institute Of Allergy And Infectious Diseases of the National Institutes of Health [R01AI118511]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI118511] Funding Source: NIH RePORTER	National Institute for Communicable Diseases; National Institute Of Allergy And Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded by the National Institute for Communicable Diseases (www.nicd.ac.za).N.P.G.was partly supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health (www.niaid.nih.gov) under Award Number R01AI118511. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Adeyemi B, 2014, J INT AIDS SOC, V17, P88, DOI 10.7448/IAS.17.4.19623; [Anonymous], 2018, PRIM HEALTHC STAND T, V6; [Anonymous], 2015, ANN REP; [Anonymous], 2016, ANN REP; Barnighausen T, 2010, AIDS, V24, P2741, DOI 10.1097/QAD.0b013e3283408735; Britz E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163036; Cichowitz C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189820; Comulada WS, 2019, PREV SCI, V20, P126, DOI 10.1007/s11121-018-0950-1; Daftary A, 2007, AIDS CARE, V19, P572, DOI 10.1080/09540120701203931; De Lima YV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0049140; Drain PK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055305; Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243; Govender NP, 2018, SAMJ S AFR MED J, V108, P534, DOI [10.7196/samj.2018.v108i7.13094, 10.7196/SAMJ.2018.v108i7.13094]; Govender NP, 2019, INT C AIDS STIS AFR; Haber N, 2017, LANCET HIV, V4, pE223, DOI 10.1016/S2352-3018(16)30224-7; Harling G, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-80; Iwuji CC, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002107; Jarvis JN, 2010, AIDS, V24, P612, DOI 10.1097/QAD.0b013e32833547f7; Lessells RJ, 2011, SAMJ S AFR MED J, V101, P251, DOI 10.7196/SAMJ.4378; Meiring S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004865; Molloy SF, 2018, NEW ENGL J MED, V378, P1004, DOI 10.1056/NEJMoa1710922; Moore HA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215454; Namutebi AMN, 2013, AFR HEALTH SCI, V13, P977, DOI 10.4314/ahs.v13i4.17; National Department of Health SA, 2017, S AFR NAT STRAT PLAN; National Department of Health SA, 2010, CLIN GUID MAN HIV AI; National Department of Health SA, 2015, NAT CONS GUID PREV M; Osungbade KO, 2011, J PREGNANCY, V2011, DOI 10.1155/2011/481095; Pai N, 2018, 22 INT AIDS C 23 27, P1105; Park BJ, 2011, INT J STD AIDS, V22, P199, DOI 10.1258/ijsa.2010.010235; Rajasingham R, 2017, LANCET INFECT DIS, V17, P873, DOI [10.1016/s1473-3099(17)30243-8, 10.1016/S1473-3099(17)30243-8]; Ritchwood TD, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6402-4; Saavedra A, 2017, PAN AFR MED J, V27, DOI 10.11604/pamj.2017.27.48.8917; Steele SJ, 2018, C RETR OPP INF CROI, P418; Tariq S, 2018, AIDS CARE, V30, P32, DOI 10.1080/09540121.2017.1349277; Ulett KB, 2009, AIDS PATIENT CARE ST, V23, P41, DOI 10.1089/apc.2008.0132; Vallabhaneni S, 2016, JAIDS-J ACQ IMM DEF, V72, pE37, DOI 10.1097/QAI.0000000000000976; World Health Organization, 2018, GUID DIAGN PREV MAN; Yu DB, 2008, GLOBALIZATION HEALTH, V4, DOI 10.1186/1744-8603-4-8	38	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2019	14	12							e0225742	10.1371/journal.pone.0225742	http://dx.doi.org/10.1371/journal.pone.0225742			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP1HF	31830060	Green Published, gold, Green Accepted			2023-01-03	WOS:000534070200025
J	Samuels, EA; Warren, OU; Davis, CS; Christopher, PP				Samuels, Elizabeth A.; Warren, Otis U.; Davis, Corey S.; Christopher, Paul P.			Will Emergency Holds Reduce Opioid Overdose Deaths?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Samuels, Elizabeth A.; Warren, Otis U.] Brown Univ, Warren Alpert Med Sch, Dept Emergency Med, Providence, RI 02912 USA; [Christopher, Paul P.] Brown Univ, Warren Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI 02912 USA; [Davis, Corey S.] Network Publ Hlth Law, Los Angeles, CA USA	Brown University; Brown University	Samuels, EA (corresponding author), Brown Univ, Warren Alpert Med Sch, Dept Emergency Med, Providence, RI 02912 USA.		Samuels, Elizabeth/AAC-9987-2020	Samuels, Elizabeth/0000-0003-2414-110X; Davis, Corey/0000-0002-6278-5013				Hedman LC, 2016, PSYCHIAT SERV, V67, P529, DOI 10.1176/appi.ps.201500205; Leshner AI, 2019, JAMA-J AM MED ASSOC, V321, P2071, DOI 10.1001/jama.2019.5523; Olfson M, 2018, DRUG ALCOHOL DEPEN, V190, P112, DOI 10.1016/j.drugalcdep.2018.06.004; Weiner SG, 2019, ANN EMERG MED; Werb D, 2016, INT J DRUG POLICY, V28, P1, DOI 10.1016/j.drugpo.2015.12.005	5	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 7	2019	381	19					1795	1797		10.1056/NEJMp1907692	http://dx.doi.org/10.1056/NEJMp1907692			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JM5EW	31618535				2023-01-03	WOS:000496238300003
J	Luo, J; Kulldorff, M; Sarpatwari, A; Pawar, A; Kesselheim, AS				Luo, Jing; Kulldorff, Martin; Sarpatwari, Ameet; Pawar, Ajinkya; Kesselheim, Aaron S.			Variation in Prescription Drug Prices by Retail Pharmacy Type A National Cross-sectional Study	ANNALS OF INTERNAL MEDICINE			English	Article							GEOGRAPHIC-VARIATION; REGIONAL-VARIATION; COST; PREVALENCE; COVERAGE; GROWTH; COHORT	Background: Cash prices for prescription drugs vary widely in the United States. Objective: To describe cash price variation by retail pharmacy type for 10 generic and 6 brand-name drugs throughout the United States and stratified by ZIP code. Design: Cross-sectional study. Setting: Drug pricing data from GoodRx, an online tool for comparing drug prices, representing more than 60 000 U.S. pharmacies (fall 2015). Measurements: Cash prices for a 1-month supply of generic and brand-name drugs were ascertained. Stratified by ZIP code, relative cash prices for groups of generic and brand-name drugs were estimated for big box, grocery-based, small chain, and independent pharmacies compared with a reference group of large chain pharmacies. Results: Across 16 325 ZIP codes, 68 353 unique pharmacy stores contributed cash prices. When stratified by 5-digit ZIP code, the relative cash prices for generic drugs at big box, grocery-based, small chain, and independent pharmacies compared with those at large chain pharmacies were 0.52 (95% CI, 0.51 to 0.53), 0.82 (CI, 0.81 to 0.83), 1.51 (CI, 1.45 to 1.56), and 1.61 (CI, 1.58 to 1.64), respectively. The relative cash prices for brandname drugs were 0.97 (CI, 0.96 to 0.97), 1.00 (CI, 0.99 to 1.00), 1.06 (CI, 1.05 to 1.08), and 1.03 (CI, 1.02 to 1.04), respectively. Limitation: Results may not reflect current drug prices and do not account for point-of-sale discounts or price matching that may be offered by smaller pharmacies. Conclusion: Compared with large chains, independent pharmacies and small chains had the highest cash prices for generic drugs and big box pharmacies the lowest. Relative differences in cash prices for brand-name drugs were modest across types of retail pharmacies.	[Luo, Jing; Kulldorff, Martin; Sarpatwari, Ameet; Pawar, Ajinkya; Kesselheim, Aaron S.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law PORTAL, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA	Harvard University; Brigham & Women's Hospital	Luo, J (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law PORTAL, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	jluo1@bwh.harvard.edu	Pawar, Ajinkya/AAW-4051-2020	Pawar, Ajinkya/0000-0002-8585-9505	Arnold Ventures; Engelberg Foundation; Harvard-MIT Center for Regulatory Science	Arnold Ventures; Engelberg Foundation; Harvard-MIT Center for Regulatory Science	By Arnold Ventures. The work of Drs. Kesselheim and Sarpatwari is also supported by the Engelberg Foundation and the Harvard-MIT Center for Regulatory Science.	Aitken M, 2016, HEALTH AFFAIR, V35, P1595, DOI 10.1377/hlthaff.2015.1636; Arora S, 2017, AM J MANAG CARE, V23, P410; Baicker K, 2013, NEW ENGL J MED, V368, P1713, DOI 10.1056/NEJMsa1212321; Chhatwal J, 2015, ANN INTERN MED, V162, P397, DOI 10.7326/M14-1336; Cox ER, 2003, PEDIATRICS, V111, P237, DOI 10.1542/peds.111.2.237; Donohue JM, 2012, NEW ENGL J MED, V366, P530, DOI 10.1056/NEJMsa1104816; Fendrick AM, 2001, AM J MANAG CARE, V7, P861; Frank RG, 2001, HEALTH AFFAIR, V20, P115, DOI 10.1377/hlthaff.20.2.115; Gellad WF, 2013, ANN INTERN MED, V159, P105, DOI 10.7326/0003-4819-159-2-201307160-00664; Hauptman PJ, 2017, JAMA INTERN MED, V177, P126, DOI 10.1001/jamainternmed.2016.6955; Huskamp HA, 2003, NEW ENGL J MED, V349, P2224, DOI 10.1056/NEJMsa030954; IMS Institute for Healthcare Informatics, 2014, MED USE SHIFTING COS; JPMorgan Chase, 2018, REW CAT FAQS; Kesselheim AS, 2016, JAMA-J AM MED ASSOC, V316, P858, DOI 10.1001/jama.2016.11237; Kesselheim AS, 2015, AM J PUBLIC HEALTH, V105, pE17, DOI 10.2105/AJPH.2014.302240; Kullgren JT, 2017, AM J MANAG CARE, V23, P444; Martin AB, 2016, HEALTH AFFAIR, V35, P150, DOI 10.1377/hlthaff.2015.1194; Mathew R, 2019, REAL PRICE MEDICATIO; Nass SJ, 2017, MAK MED AFF NAT IMP; Orstein C, 2017, PROPUBLICA; Pauly NJ, 2015, J MANAG CARE SPEC PH, V21, P1162, DOI 10.18553/jmcp.2015.21.12.1162; Robinson JC, 2017, NEW ENGL J MED, V377, P658, DOI 10.1056/NEJMsa1700087; Schumock GT, 2017, AM J HEALTH-SYST PH, V74, P1158, DOI 10.2146/ajhp170164; Spooner JJ, 2008, J MANAGE CARE PHARM, V14, P878, DOI 10.18553/jmcp.2008.14.9.878; Tungol A, 2012, J MANAGE CARE PHARM, V18, P690, DOI 10.18553/jmcp.2012.18.9.690; Zhang YT, 2012, NEW ENGL J MED, V367, P1724, DOI 10.1056/NEJMsa1203980; Zhang YT, 2010, NEW ENGL J MED, V363, P405, DOI 10.1056/NEJMp1004872	27	17	17	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 5	2019	171	9					605	+		10.7326/M18-1138	http://dx.doi.org/10.7326/M18-1138			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK6WN	31569218				2023-01-03	WOS:000494983000004
J	Lopez-Cedrun, JL; Otero-Rico, A; Vazquez-Mahia, I; Seoane, J; Garcia-Caballero, L; Seoane-Romero, JM; Varela-Centelles, P				Luis Lopez-Cedrun, Jose; Otero-Rico, Ana; Vazquez-Mahia, Ines; Seoane, Juan; Garcia-Caballero, Lucia; Manuel Seoane-Romero, Juan; Varela-Centelles, Pablo			Association between hospital interval and survival in patients with oral cancer: A waiting time paradox	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMA; DIAGNOSTIC DELAY; TREATMENT INITIATION; GLOBAL EPIDEMIOLOGY; ADVANCED-STAGE; NECK-CANCER; HEAD; IMPACT; MORTALITY; COMMON	Background In early diagnosis studies on symptomatic cancer, survival was the most recommended outcome. The magnitude and impact of the patient interval and primary care interval is wellknown in oral cancer; however, the hospital interval and its influence on surviving this neoplasia are not well known. Aims To quantify the interval between the first contact with the specialist and the start of treatment for patients with oral cancer and to evaluate whether there was a link between this interval and disease survival. Methods We designed a hospital-based study that included 228 patients diagnosed with oral/oropharyngeal squamous cell carcinoma between 1998 and 2008 at A Coruna University Hospital (Spain) who were followed up until 2016. The data were extracted retrospectively from hospital medical charts. The study interval was defined in the context of the "pathways to treatment" model as the interval from the first specialist visit (start point) to the start of treatment (end point). We calculated the total interval (from first symptom to treatment) to evaluate the relative length of the hospital interval, and we considered the variables age, sex, location, comorbidity and tumour classification stage. Survival time was defined as the interval from the first treatment to death or censoring. Results The median hospital interval was 20 days, with an interquartile range of 15-29.1 days. The most relevant prognostic variable was the tumour stage (III-IV: Exp. beta = 2.8, p = 0.001). The hospital interval was part of the multivariate model, and its association with mortality showed a V-shaped association, where patients with short hospital intervals (3-18 days) and those with long hospital intervals (26-55 days) had significantly higher mortality than those with medium hospital intervals (19-25 days). Conclusion The hospital interval represents a relevant interval for the patient's path towards treatment, has prognostic implications and is subject to a severity bias (waiting time paradox) that should be avoided.	[Luis Lopez-Cedrun, Jose; Otero-Rico, Ana; Vazquez-Mahia, Ines] A Coruna Univ Hosp CHUAC, Serv Oral & Maxillofacial Surg, Galician Hlth Serv, La Coruna, Spain; [Seoane, Juan; Garcia-Caballero, Lucia] Univ Santiago de Compostela, Sch Med & Dent, Dept Surg & Med Surg Special, Santiago De Compostela, A Coruna, Spain; [Manuel Seoane-Romero, Juan] Univ Oviedo, Sch Med & Hlth Sci, Dept Surg & Med Surg Special, Oviedo, Spain; [Varela-Centelles, Pablo] Galician Hlth Serv, Praza Ferrol Hlth Ctr, EOXI Lugo Cervo & Monforte Lemos, Lugo, Spain	Complejo Hospitalario Universitario A Coruna; Universidade de Santiago de Compostela; University of Oviedo; Hospital Universitario Lucus Augusti-Lugo	Seoane-Romero, JM (corresponding author), Univ Oviedo, Sch Med & Hlth Sci, Dept Surg & Med Surg Special, Oviedo, Spain.	jseoaner@hotmail.com		Seoane, Juan/0000-0002-1370-9524	2013-2016 Spanish National RD Programme [PI14/01446]; ISCIII-General Subdirectorate for Evaluation and Promotion of Research (ISCIII-Subdireccion General de Evaluacion y Fomento de la Investigacion); European Regional Development Fund (ERDF)	2013-2016 Spanish National RD Programme; ISCIII-General Subdirectorate for Evaluation and Promotion of Research (ISCIII-Subdireccion General de Evaluacion y Fomento de la Investigacion); European Regional Development Fund (ERDF)(European Commission)	This study was supported by the research project PI14/01446 of the 2013-2016 Spanish National R&D Programme and was cofunded by the ISCIII-General Subdirectorate for Evaluation and Promotion of Research (ISCIII-Subdireccion General de Evaluacion y Fomento de la Investigacion) and the European Regional Development Fund (ERDF). This award was received by JLL-C, JS and PV-C. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscrip	Abdo Evandro Neves, 2007, Med Oral Patol Oral Cir Bucal, V12, pE469; Aggarwal A, 2015, BRIT J NEUROSURG, V29, P520, DOI 10.3109/02688697.2015.1012050; Allgar VL, 2005, BRIT J CANCER, V92, P1959, DOI 10.1038/sj.bjc.6602587; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen MM, 2018, OTOLARYNG HEAD NECK, V158, P1051, DOI 10.1177/0194599817751679; CHIOU SJ, 2016, MEDICINE, V95, P5632; Coxon D, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3476-0; Fujiwara RJT, 2017, HEAD NECK-J SCI SPEC, V39, P639, DOI 10.1002/hed.24608; Gao W, 2009, J ORAL MAXIL SURG, V67, P1015, DOI 10.1016/j.joms.2008.12.022; Gomez I, 2009, EUR J ORAL SCI, V117, P541, DOI 10.1111/j.1600-0722.2009.00672.x; Goy J, 2009, LARYNGOSCOPE, V119, P889, DOI 10.1002/lary.20185; Gupta B, 2016, ONCOLOGY-BASEL, V91, P13, DOI 10.1159/000446117; Kyriacou DN, 2016, JAMA-J AM MED ASSOC, V316, P1818, DOI 10.1001/jama.2016.16435; Liao CT, 2017, EUR J CANCER, V72, P226, DOI 10.1016/j.ejca.2016.11.010; Lyratzopoulos G, 2013, BRIT J CANCER, V108, P686, DOI 10.1038/bjc.2013.1; Morelatto RA, 2007, J ORAL PATHOL MED, V36, P405, DOI 10.1111/j.1600-0714.2007.00547.x; Murphy CT, 2016, J CLIN ONCOL, V34, P169, DOI 10.1200/JCO.2015.61.5906; Neal RD, 2015, BRIT J CANCER, V112, pS92, DOI 10.1038/bjc.2015.48; Olesen F, 2009, BRIT J CANCER, V101, pS5, DOI 10.1038/sj.bjc.6605383; Polesel J, 2017, ORAL ONCOL, V67, P175, DOI 10.1016/j.oraloncology.2017.02.009; SCULLY C, 1986, BRIT MED J, V293, P599, DOI 10.1136/bmj.293.6547.599; Seoane J, 2018, ORAL DIS, V24, P112, DOI 10.1111/odi.12754; Seoane J, 2012, CLIN OTOLARYNGOL, V37, P99, DOI 10.1111/j.1749-4486.2012.02464.x; Seoane J, 2016, HEAD NECK-J SCI SPEC, V38, pE2182, DOI 10.1002/hed.24050; Seoane J, 2010, HEAD NECK-J SCI SPEC, V32, P1377, DOI 10.1002/hed.21338; Silverman S, 2010, J CANCER EDUC, V25, P279, DOI 10.1007/s13187-010-0045-6; Symonds RP, 2002, BMJ-BRIT MED J, P325; Torring ML, 2013, EUR J CANCER, V49, P2187, DOI 10.1016/j.ejca.2013.01.025; Torring ML, 2012, J CLIN EPIDEMIOL, V65, P669, DOI 10.1016/j.jclinepi.2011.12.006; Tsai WC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175148; van der Waal I, 2011, MED ORAL PATOL ORAL, V16, pE300, DOI 10.4317/medoral.16.e300; van Huizen LS, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3637-1; Varela-Centelles P, 2018, CLIN OTOLARYNGOL, V43, P164, DOI 10.1111/coa.12919; Varela-Centelles P, 2017, INT J ORAL MAX SURG, V46, P1, DOI 10.1016/j.ijom.2016.09.017; Warnakulasuriya S, 2010, ORAL ONCOL, V46, P407, DOI 10.1016/j.oraloncology.2010.02.015; Warnakulasuriya S, 2009, ORAL ONCOL, V45, P309, DOI 10.1016/j.oraloncology.2008.06.002; Weller D, 2012, BRIT J CANCER, V106, P1262, DOI 10.1038/bjc.2012.68; WILLIAMS RG, 1981, ANN ROY COLL SURG, V63, P423	38	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 25	2019	14	10							e0224067	10.1371/journal.pone.0224067	http://dx.doi.org/10.1371/journal.pone.0224067			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN0LX	31652279	Green Published, gold			2023-01-03	WOS:000532638300014
J	Kimura, Y; Fukuda, H; Hayakawa, K; Ide, S; Ota, M; Saito, S; Ishikane, M; Kusama, Y; Matsunaga, N; Ohmagari, N				Kimura, Yuki; Fukuda, Haruhisa; Hayakawa, Kayoko; Ide, Satoshi; Ota, Masayuki; Saito, Sho; Ishikane, Masahiro; Kusama, Yoshiki; Matsunaga, Nobuaki; Ohmagari, Norio			Longitudinal trends of and factors associated with inappropriate antibiotic prescribing for non-bacterial acute respiratory tract infection in Japan: A retrospective claims database study, 2012-2017	PLOS ONE			English	Article							PRESCRIPTIONS; CARE; ADULTS	Background Inappropriate antibiotic prescribing is a cause of antimicrobial resistance. Acute Respiratory Tract Infections (ARTI) are common diseases for those antibiotics are most likely prescribed in outpatient setting. Objectives To clarify factors associated with antibiotic prescribing for non-bacterial acute respiratory tract infections (NB-ARTI) and identify targets for reducing inappropriate prescribing for NBARTI in Japan. Methods We conducted a retrospective, observational study using longitudinal claims data between April 2012 and June 2017. We assessed the rate of and factors associated with inappropriate antibiotic prescribing in outpatient settings for all NB-ARTI consultations included in the database. Results The mean monthly antibiotic prescribing rate per 100 NB-ARTI consultations during the study period was 31.65. The monthly antibiotic prescribing rate per 100 NB-ARTI consultations decreased by 19.2% from April 2012 to June 2017. Adolescents (13-18 years) and adults of working age (19-29 and 30-39 years) were more likely prescribed antibiotics compared with elderly patients. 60 years (aOR: 1.493 [95%CI: 1.482-1.503], 1.585 [95%CI: 1.575-1.595], and 1.507 [95%CI: 1.498-1.516], respectively). Outpatient clinics registered as internal medicine or ear, nose, and throat specialty were more likely to prescribe antibiotics than those of paediatric specialty or other specialties. Among health facility type, clinics without beds (aOR 2.123 [95%CI: 2.113-2.133]) and clinics with beds (aOR: 1.752 [95%CI: 1.7371-1.767]) prescribed significantly more antibiotics for NB-ARTI than outpatient departments inside general hospitals. Conclusions Inappropriate antibiotic prescribing for NB-ARTI is common in Japan. Although the antibiotic prescribing rate has decreased, further interventions are required to promote antimicrobial stewardship (ASP). Education and awareness for adults and promotion of ASP among physicians in clinics without beds are key drivers to reduce inappropriate antibiotic prescribing in Japan.	[Kimura, Yuki; Fukuda, Haruhisa; Hayakawa, Kayoko; Ishikane, Masahiro; Kusama, Yoshiki; Matsunaga, Nobuaki; Ohmagari, Norio] Natl Ctr Global Hlth & Med, AMR Clin Reference Ctr, Tokyo, Japan; [Fukuda, Haruhisa] Kyushu Univ, Dept Hlth Care Adm & Management, Grad Sch Med Sci, Fukuoka, Japan; [Hayakawa, Kayoko; Ide, Satoshi; Ota, Masayuki; Saito, Sho; Ishikane, Masahiro; Ohmagari, Norio] Natl Ctr Global Hlth & Med, Dis Control & Prevent Ctr, Tokyo, Japan	National Center for Global Health & Medicine - Japan; Kyushu University; National Center for Global Health & Medicine - Japan	Kimura, Y (corresponding author), Natl Ctr Global Hlth & Med, AMR Clin Reference Ctr, Tokyo, Japan.	ykimura@hosp.ncgm.go.jp	Hayakawa, Kayoko/GNW-2394-2022; Ohmagari, Norio/GLN-5290-2022; Ishikane, Masahiro/ABA-9878-2020	Ohmagari, Norio/0000-0002-4622-8970; Ide, Satoshi/0000-0001-8254-3700; Kimura, Yuki/0000-0001-5808-1905; Ishikane, Masahirio/0000-0002-4719-651X; Kusama, Yoshiki/0000-0002-7072-2338	Ministry of Health, Labour and Welfare research grant of Japan [H29-H30-shinkougyousei-shitei-005]	Ministry of Health, Labour and Welfare research grant of Japan(Ministry of Health, Labour and Welfare, Japan)	This study was supported by a Ministry of Health, Labour and Welfare research grant of Japan (H29-H30-shinkougyousei-shitei-005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204878; Bert F, 2017, EUR J PUBLIC HEALTH, V27, P506, DOI 10.1093/eurpub/ckw209; Bianco A, 2018, INFECT DRUG RESIST, V11, P2199, DOI 10.2147/IDR.S170349; Bou-Antoun S, 2018, J ANTIMICROB CHEMOTH, V73, P2883, DOI 10.1093/jac/dky237; Davis M, 2017, ANTIBIOTICS, V6, P1; Dekker ARJ, 2015, FAM PRACT, V32, P401, DOI 10.1093/fampra/cmv019; Denny KJ, 2018, J ANTIMICROB CHEMOTH, P1, DOI [10.1093/jac/dkx349, DOI 10.1093/JAC/DKX349]; Di Giuseppe G, 2013, PLOS ONE, V8, P1, DOI [DOI 10.1371/annotation/753c6a63-2aea-4cb8-b38c-28db972d60df, DOI 10.1371/J0URNAL.P0NE.0084177]; Fleming-Dutra KE, 2016, JAMA-J AM MED ASSOC, V315, P1864, DOI 10.1001/jama.2016.4151; Fletcher-Lartey S, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012244; Havers FP, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0243; Higashi T, 2009, INTERNAL MED, V48, P1369, DOI 10.2169/internalmedicine.48.1893; Kamata K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207017; King LM, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k3047; Lindberg BH, 2017, SCAND J PRIM HEALTH, V35, P178, DOI 10.1080/02813432.2017.1333301; Minitry of Health Labour and Welfare, 2017, HDB HLTH WELF STAT, V2017; Miyawaki A, 2017, SOC SCI MED, V191, P89, DOI 10.1016/j.socscimed.2017.09.001; Muraki Y, 2016, J GLOB ANTIMICROB RE, V7, P19, DOI 10.1016/j.jgar.2016.07.002; Nakahama C, 2017, JAPANESE J CHEMOTHER, V66, P185; O'Connor R, 2018, IRISH J MED SCI, V187, P969, DOI 10.1007/s11845-018-1774-5; Schwartz Kevin L, 2018, CMAJ Open, V6, pE445, DOI 10.9778/cmajo.20180017; Shapiro DJ, 2014, J ANTIMICROB CHEMOTH, V69, P234, DOI 10.1093/jac/dkt301; Silverman M, 2017, ANN INTERN MED, V166, P765, DOI 10.7326/M16-1131; Takahashi Y, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1796; Teratani Y, 2019, FAM PRACT, V36, P402, DOI 10.1093/fampra/cmy094; The Government of Japan, 2016, VETFUTURES ACTION PL; The Government of Japan Ministry of Health Labour and Welfare, 2017, MAN ANT STEW; Tsutsui A, 2018, J INFECT CHEMOTHER, V24, P414, DOI 10.1016/j.jiac.2018.01.003; WHO, 2018, HLTH SYST TRANSIT, P1; World Health Organization, 2018, WHO REP SURV ANT CON; Yoshida S, 2018, J PUBLIC HEALTH-UK, V40, P397, DOI 10.1093/pubmed/fdx045; Zucco R, 2018, INT J MED INFORM, V111, P131, DOI 10.1016/j.ijmedinf.2017.12.005	32	21	21	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2019	14	10							e0223835	10.1371/journal.pone.0223835	http://dx.doi.org/10.1371/journal.pone.0223835			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM9KK	31618258	Green Published, gold			2023-01-03	WOS:000532566600054
J	Zeggini, E; Gloyn, AL; Barton, AC; Wain, LV				Zeggini, Eleftheria; Gloyn, Anna L.; Barton, Anne C.; Wain, Louise V.			Translational genomics and precision medicine: Moving from the lab to the clinic	SCIENCE			English	Review							ASSOCIATION; RISK; GENETICS	Translational genomics aims to improve human health by building on discoveries made through genetics research and applying them in the clinical setting. This progress has been made possible by technological advances in genomics and analytics and by the digital revolution. Such advances should enable the development of prognostic markers, tailored interventions, and the design of prophylactic preventive approaches. We are at the cusp of predicting disease risk for some disorders by means of polygenic risk scores integrated with classical epidemiological risk factors. This should lead to better risk stratification and clinical decision-making. A deeper understanding of the link between genome-wide sequence and association with well-characterized phenotypes will empower the development of biomarkers to aid diagnosis, inform disease progression trajectories. and allow better targeting of treatments to those patients most likely to respond.	[Zeggini, Eleftheria] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Translat Genom, Neuherberg, Germany; [Gloyn, Anna L.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England; [Gloyn, Anna L.] Univ Oxford, Wellcome Ctr Human Genet, Oxford, England; [Gloyn, Anna L.] Churchill Hosp, Oxford NIHR Biomed Res Ctr, Oxford, England; [Barton, Anne C.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Ctr Musculoskeletal Res, Versus Arthrit Ctr Genet & Genom, Manchester, Lancs, England; [Barton, Anne C.] Manchester Univ NHS Fdn Trust, NIHR Manchester Biomed Res Ctr, Manchester, Lancs, England; [Wain, Louise V.] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England; [Wain, Louise V.] Glenfield Hosp, Leicester Resp Biomed Res Ctr, Natl Inst Hlth Res, Leicester, Leics, England	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Manchester; University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital	Zeggini, E (corresponding author), German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Translat Genom, Neuherberg, Germany.	eftheria.zeggini@helmholtz-muenchen.de	; Barton, Anne/N-2053-2014	Gloyn, Anna/0000-0003-1205-1844; Wain, Louise/0000-0003-4951-1867; Barton, Anne/0000-0003-3316-2527; Zeggini, Eleftheria/0000-0003-4238-659X	Wellcome Trust [095101, 200837, 106130, 203141]; Medical Research Council [MR/L020149/1]; European Union; U.S. National Institutes of Health [U01-DK105535, U01-DK085545]; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC); NIHR Manchester Biomedical Research Centre; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK105535] Funding Source: NIH RePORTER	Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union(European Commission); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)(National Institute for Health Research (NIHR)); NIHR Manchester Biomedical Research Centre(National Institute for Health Research (NIHR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	A.L.G is a Wellcome Trust Senior Fellow in Basic Biomedical Science. A.L.G. is funded by the Wellcome Trust (095101, 200837, 106130, 203141), the Medical Research Council (MR/L020149/1), the European Union Horizon 2020 Programme (T2D Systems), the U.S. National Institutes of Health (U01-DK105535; U01-DK085545), and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS the NIHR or the Department of Health. A.C.B. is an NIHR Senior Investigator and is supported by the NIHR Manchester Biomedical Research Centre. L.V.W. holds a GSK/British Lung Foundation Chair in Respiratory Research.	Bentley AR, 2019, NAT GENET, V51, P636, DOI 10.1038/s41588-019-0378-y; Bluett J, 2015, RHEUMATOLOGY, V54, P494, DOI 10.1093/rheumatology/keu358; Clancy JP, 2012, AM J RESP CRIT CARE, V186, P593, DOI 10.1164/rccm.201204-0785PP; Clayton DG, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000540; Corbin LJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03109-y; Dand N., 2018, J ALLERGY CLIN IMMUN; Dawed AY, 2019, DIABETES CARE, V42, P1027, DOI 10.2337/dc18-2182; Dewey FE, 2017, NEW ENGL J MED, V377, P211, DOI 10.1056/NEJMoa1612790; Dudbridge F, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003348; Elliott LT, 2018, NATURE, V562, P210, DOI 10.1038/s41586-018-0571-7; Evangelou E, 2018, NAT GENET, V50, P1412, DOI 10.1038/s41588-018-0205-x; Feigl B, 2011, CURR MED RES OPIN, V27, P1745, DOI 10.1185/03007995.2011.603301; Gamazon ER, 2018, NAT GENET, V50, P956, DOI 10.1038/s41588-018-0154-4; Giri A, 2019, NAT GENET, V51, P51, DOI 10.1038/s41588-018-0303-9; Glicksberg BS, 2018, HUM MOL GENET, V27, pR56, DOI 10.1093/hmg/ddy114; Gurdasani D, 2015, NATURE, V517, P327, DOI 10.1038/nature13997; Heesterbeek TJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43144-3; Jorgensen AL, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1308-7; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Khera AV, 2019, CELL, V177, P587, DOI 10.1016/j.cell.2019.03.028; Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z; King E. A., 2019, BIORXIV; Kotowski IK, 2006, AM J HUM GENET, V78, P410, DOI 10.1086/500615; Kullo IJ, 2017, NEW ENGL J MED, V376, P1192, DOI 10.1056/NEJMc1700362; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; Laslett LJ, 2012, J AM COLL CARDIOL, V60, pS1, DOI 10.1016/j.jacc.2012.11.002; Mahajan A, 2018, NAT GENET, V50, P1505, DOI 10.1038/s41588-018-0241-6; Martin AR, 2019, NAT GENET, V51, P584, DOI 10.1038/s41588-019-0379-x; Massey J, 2018, PHARMACOGENOMICS J, V18, P657, DOI 10.1038/s41397-018-0040-6; Moltke I, 2014, NATURE, V512, P190, DOI 10.1038/nature13425; Nelson MR, 2015, NAT GENET, V47, P856, DOI 10.1038/ng.3314; Njolstad PR, 2019, NAT GENET, V51, P924, DOI 10.1038/s41588-019-0391-1; Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168; Rose G., 1992, STRATEGY PREVENTIVE; Rozenblatt-Rosen O, 2017, NATURE, V550, P451, DOI 10.1038/550451a; Rutten-Jacobs LC, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4168; Schork NJ, 2015, NATURE, V520, P609, DOI 10.1038/520609a; Seibold MA, 2011, NEW ENGL J MED, V364, P1503, DOI 10.1056/NEJMoa1013660; Shrine N, 2019, NAT GENET, V51, P481, DOI 10.1038/s41588-018-0321-7; Sparks JA, 2018, ARTHRIT CARE RES, V70, P823, DOI 10.1002/acr.23411; Stunnenberg HG, 2016, CELL, V167, P1145, DOI 10.1016/j.cell.2016.11.007; Styrkarsdottir U, 2017, NAT GENET, V49, P801, DOI 10.1038/ng.3816; Tachmazidou I, 2019, NAT GENET, V51, P230, DOI 10.1038/s41588-018-0327-1; Udler M. S., 2019, ENDOCR REV; Viatte S, 2015, JAMA-J AM MED ASSOC, V313, P1645, DOI 10.1001/jama.2015.3435; Warwick A, 2018, EYE, V32, P849, DOI 10.1038/eye.2017.245; Wheeler E, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002383; Zeggini E, 2016, DIABETOLOGIA, V59, P938, DOI 10.1007/s00125-016-3926-3; Zhou KX, 2016, NAT GENET, V48, P1055, DOI 10.1038/ng.3632	50	64	66	7	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 27	2019	365	6460					1409	1413		10.1126/science.aax4588	http://dx.doi.org/10.1126/science.aax4588			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB8QM	31604268	Green Submitted			2023-01-03	WOS:000488838600039
J	Huang, J; Lan, XW; Wang, T; Lu, HL; Cao, MR; Yan, S; Cui, Y; Jia, DX; Cai, L; Xing, Y				Huang, Jian; Lan, Xiuwen; Wang, Ting; Lu, Hailing; Cao, Mengru; Yan, Shi; Cui, Yue; Jia, Dexin; Cai, Li; Xing, Ying			Targeting the IL-1 beta/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC	ONCOGENE			English	Article							CELL LUNG-CANCER; DOMAIN 1 PROMOTES; III BETA-TUBULIN; BINDING PROTEIN; FOCAL ADHESIONS; STRESS FIBERS; KAPPA-B; INHIBITORS; SENSITIVITY; MICROTUBULES	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) significantly prolong the survival time of non-small-cell lung cancer (NSCLC) patients with EGFR-activating mutations, but resistance develops universally. Activation of the phosphatidyl inositol-3 kinase (PI3K)/AKT signaling pathway and phenotypic alterations in epithelial-mesenchymal transition (EMT) are both mechanisms of acquired resistance to EGFR-TKIs. However, the mechanisms underlying this resistance remain unclear. In this study, EHD1 depletion significantly increased NSCLC cell sensitivity to EGFR-TKI, which was accompanied by EMT reversal. Microarray analysis showed that the PTEN/PI3K/AKT signaling pathway is a crucial pathway regulated by EHD1. Moreover, a PTEN inhibitor abolished EHD1 shRNA regulation of EGFR-TKI sensitivity, EMT, and cancer progression. Mass spectrometry showed that TUBB3 is a novel EHD1-interacting protein. EHD1 modulated microtubule stability by interacting with TUBB3. Furthermore, TUBB3 depletion significantly attenuated EHD1-induced EGFR-TKI resistance and EMT. Bioinformatics analysis revealed that EHD1 is significantly associated with the gene set, "Cellular Response to Interleukin-1 beta (IL-1 beta)". As expected, treatment with IL-1 beta led to increased expression of EHD1, activation of PTEN/PI3K/AKT signaling, and induction of EMT in NSCLC cells. In patient specimens, EHD1 was highly expressed in EGFR-TKI-refractory specimens. EHD1 was positively associated with TUBB3 and IL-1R1 but negatively associated with PTEN. In addition, targeting the IL-1 beta/EHD1/TUBB3 axis mitigated cancer progression by inhibiting cell proliferation and metastasis and promoting apoptosis. Our study demonstrates the involvement of the IL-1 beta/EHD1/TUBB3 axis in EGFR-TKI resistance and provides a potential therapeutic approach for treating patients with NSCLC that has acquired EGFR-TKI resistance.	[Huang, Jian; Wang, Ting; Lu, Hailing; Cao, Mengru; Yan, Shi; Cui, Yue; Jia, Dexin; Cai, Li; Xing, Ying] Harbin Med Univ, Dept Med Oncol 4, Canc Hosp, 150 Haping Rd, Harbin 150040, Peoples R China; [Lan, Xiuwen] Harbin Med Univ, Dept Crit Care Med, Canc Hosp, 150 Haping Rd, Harbin 150040, Peoples R China	Harbin Medical University; Harbin Medical University	Cai, L; Xing, Y (corresponding author), Harbin Med Univ, Dept Med Oncol 4, Canc Hosp, 150 Haping Rd, Harbin 150040, Peoples R China.	caili@ems.hrbmu.edu.cn; xingying0618@163.com	cao, mengmeng/HJB-1637-2022	Huang, Jian/0000-0002-2409-0878	Certificate of China Postdoctoral Science Foundation [2015M581477, 2017M621307]; Hei Long Jiang Postdoctoral Foundation [LBH-Z15145, LBH-Z17182]; Natural Science and Technology Foundation of Heilongjiang Province [LC2016037]; Fundamental Research Funds for the Provincial Universities; Hai Yan Youth Fund from Harbin Medical University Cancer Hospital [JJQN2018-11, JJQN2018-02, BJQN2019-07]; Top-Notch Youth Fund from Harbin Medical University Cancer Hospital [JJQN2018-11, JJQN2018-02, BJQN2019-07]; NSFC [81772474, 81572276, 81803023, 81602717]	Certificate of China Postdoctoral Science Foundation; Hei Long Jiang Postdoctoral Foundation; Natural Science and Technology Foundation of Heilongjiang Province; Fundamental Research Funds for the Provincial Universities; Hai Yan Youth Fund from Harbin Medical University Cancer Hospital; Top-Notch Youth Fund from Harbin Medical University Cancer Hospital; NSFC(National Natural Science Foundation of China (NSFC))	This study was supported in part by grants from the Certificate of China Postdoctoral Science Foundation Grant (2015M581477, 2017M621307), the Hei Long Jiang Postdoctoral Foundation (LBH-Z15145, LBH-Z17182), the Natural Science and Technology Foundation of Heilongjiang Province (LC2016037), the Fundamental Research Funds for the Provincial Universities, the Hai Yan Youth Fund and Top-Notch Youth Fund from Harbin Medical University Cancer Hospital (JJQN2018-11, JJQN2018-02 and BJQN2019-07), and the NSFC (Grant Nos. 81772474, 81572276, 81803023 and 81602717).	Amann J, 2005, CANCER RES, V65, P226; Apte RN, 2006, EUR J CANCER, V42, P751, DOI 10.1016/j.ejca.2006.01.010; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burke SJ, 2015, AM J PHYSIOL-ENDOC M, V309, pE715, DOI 10.1152/ajpendo.00153.2015; Chan JK, 2014, GYNECOL ONCOL, V133, P568, DOI 10.1016/j.ygyno.2014.03.564; Daumke O, 2007, NATURE, V449, P923, DOI 10.1038/nature06173; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Du JT, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1553-x; Duran GE, 2017, BRIT J CANCER, V116, P1318, DOI 10.1038/bjc.2017.102; Edgar KA, 2010, CANCER RES, V70, P1164, DOI 10.1158/0008-5472.CAN-09-2525; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Etienne-Manneville S, 2004, TRAFFIC, V5, P470, DOI 10.1111/j.1600-0854.2004.00196.x; Fernando RI, 2016, ONCOTARGET, V7, P42031, DOI 10.18632/oncotarget.9662; Franco-Barraza J, 2010, ARCH MED RES, V41, P170, DOI 10.1016/j.arcmed.2010.04.010; Gan PP, 2007, CANCER RES, V67, P9356, DOI 10.1158/0008-5472.CAN-07-0509; Gelfo V, 2018, CANCERS, V10, DOI 10.3390/cancers10100355; George M, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-3; Hehnly H, 2014, DEV CELL, V28, P497, DOI 10.1016/j.devcel.2014.01.014; Hinsch A, 2017, HUM PATHOL, V61, P210, DOI 10.1016/j.humpath.2016.11.005; Hyman DM, 2015, CANCER CHEMOTH PHARM, V75, P747, DOI 10.1007/s00280-015-2693-z; Jackman D, 2010, J CLIN ONCOL, V28, P357, DOI 10.1200/JCO.2009.24.7049; Jacobsen K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00450-6; Jean A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172358; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948; Kavallaris M, 2010, NAT REV CANCER, V10, P194, DOI 10.1038/nrc2803; Kim SM, 2012, MOL CANCER THER, V11, P2254, DOI 10.1158/1535-7163.MCT-12-0311; Kim SB, 2017, LANCET ONCOL, V18, P1360, DOI 10.1016/S1470-2045(17)30450-3; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Lebok P, 2016, ONCOL LETT, V11, P1987, DOI 10.3892/ol.2016.4206; Lee DH, 2017, PHARMACOL THERAPEUT, V174, P1, DOI 10.1016/j.pharmthera.2017.02.001; Li YJ, 2005, WORLD J GASTROENTERO, V11, P2117, DOI 10.3748/wjg.v11.i14.2117; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; Liu Y, 2018, ONCOL LETT, V16, P4263, DOI 10.3892/ol.2018.9200; LUDUENA RF, 1993, MOL BIOL CELL, V4, P445, DOI 10.1091/mbc.4.5.445; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Mantovani A, 2018, IMMUNOL REV, V281, P57, DOI 10.1111/imr.12614; Mariani M, 2012, CLIN CANCER RES, V18, P2964, DOI 10.1158/1078-0432.CCR-11-2318; McCarroll JA, 2015, CANCER RES, V75, P415, DOI 10.1158/0008-5472.CAN-14-2740; Meng QW, 2017, ONCOTARGET, V8, P22433, DOI 10.18632/oncotarget.11220; Nakaya Y, 2008, NAT CELL BIOL, V10, P765, DOI 10.1038/ncb1739; Nickoloff BJ, 2005, J INVEST DERMATOL, V124, pX, DOI 10.1111/j.0022-202X.2005.23724.x; Ono M, 2004, MOL CANCER THER, V3, P465; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Parker AL, 2016, CARCINOGENESIS, V37, P787, DOI 10.1093/carcin/bgw058; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Powell S, 2014, ONCOL LETT, V7, P405, DOI 10.3892/ol.2013.1734; Reiman T, 2012, ANN ONCOL, V23, P86, DOI 10.1093/annonc/mdr033; Reinecke JB, 2015, TRAFFIC, V16, P48, DOI 10.1111/tra.12234; Riihimaki M, 2014, LUNG CANCER, V86, P78, DOI 10.1016/j.lungcan.2014.07.020; SATIR P, 1990, CANCER INVEST, V8, P685, DOI 10.3109/07357909009018945; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sobierajska K, 2016, BBA-MOL CELL RES, V1863, P2221, DOI 10.1016/j.bbamcr.2016.05.008; Solinas G, 2010, CANCER METAST REV, V29, P243, DOI 10.1007/s10555-010-9227-2; Soucheray M, 2015, CANCER RES, V75, P4372, DOI 10.1158/0008-5472.CAN-15-0377; Steel JL, 2018, PSYCHOSOM MED, V80, P483, DOI 10.1097/PSY.0000000000000579; Suda K, 2018, MOL CANCER THER, V17, P2257, DOI 10.1158/1535-7163.MCT-17-1279; Sullivan I, 2016, THER ADV RESPIR DIS, V10, P549, DOI 10.1177/1753465816670498; Sun XO, 2011, CELL CYCLE, V10, P3929, DOI 10.4161/cc.10.22.18106; Tong DD, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317691010; Walczak CE, 2010, NAT REV MOL CELL BIO, V11, P91, DOI 10.1038/nrm2832; Wang DY, 2015, INFLAMMATION, V38, P2235, DOI 10.1007/s10753-015-0206-1; Wang XF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0208-z; Weng CH, 2019, ONCOGENE, V38, P455, DOI 10.1038/s41388-018-0454-2; Yao Z, 2010, P NATL ACAD SCI USA, V107, P15535, DOI 10.1073/pnas.1009472107; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245	68	17	19	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1739	1755		10.1038/s41388-019-1099-5	http://dx.doi.org/10.1038/s41388-019-1099-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740781				2023-01-03	WOS:000514923000009
J	Kang, DH; Park, SJ; Lee, SA; Lee, S; Kim, DH; Kim, HK; Yun, SC; Hong, GR; Song, JM; Chung, CH; Song, JK; Lee, JW; Park, SW				Kang, Duk-Hyun; Park, Sung-Ji; Lee, Seung-Ah; Lee, Sahmin; Kim, Dae-Hee; Kim, Hyung-Kwan; Yun, Sung-Cheol; Hong, Geu-Ru; Song, Jong-Min; Chung, Cheol-Hyun; Song, Jae-Kwan; Lee, Jae-Won; Park, Seung-Woo			Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VALVULAR HEART-DISEASE; VALVE-REPLACEMENT; TASK-FORCE; TRANSCATHETER; MANAGEMENT; ASSOCIATION; GUIDELINES; SOCIETY	Background The timing and indications for surgical intervention in asymptomatic patients with severe aortic stenosis remain controversial. Methods In a multicenter trial, we randomly assigned 145 asymptomatic patients with very severe aortic stenosis (defined as an aortic-valve area of <= 0.75 cm(2) with either an aortic jet velocity of >= 4.5 m per second or a mean transaortic gradient of >= 50 mm Hg) to early surgery or to conservative care according to the recommendations of current guidelines. The primary end point was a composite of death during or within 30 days after surgery (often called operative mortality) or death from cardiovascular causes during the entire follow-up period. The major secondary end point was death from any cause during follow-up. Results In the early-surgery group, 69 of 73 patients (95%) underwent surgery within 2 months after randomization, and there was no operative mortality. In an intention-to-treat analysis, a primary end-point event occurred in 1 patient in the early-surgery group (1%) and in 11 of 72 patients in the conservative-care group (15%) (hazard ratio, 0.09; 95% confidence interval [CI], 0.01 to 0.67; P=0.003). Death from any cause occurred in 5 patients in the early-surgery group (7%) and in 15 patients in the conservative-care group (21%) (hazard ratio, 0.33; 95% CI, 0.12 to 0.90). In the conservative-care group, the cumulative incidence of sudden death was 4% at 4 years and 14% at 8 years. Conclusions Among asymptomatic patients with very severe aortic stenosis, the incidence of the composite of operative mortality or death from cardiovascular causes during the follow-up period was significantly lower among those who underwent early aortic-valve replacement surgery than among those who received conservative care. (Funded by the Korean Institute of Medicine; RECOVERY ClinicalTrials.gov number, NCT01161732.)	[Kang, Duk-Hyun; Lee, Seung-Ah; Lee, Sahmin; Kim, Dae-Hee; Song, Jong-Min; Song, Jae-Kwan] Univ Ulsan, Coll Med, Div Cardiol, Asan Med Ctr, 388-1 Poongnap Dong, Seoul, South Korea; [Chung, Cheol-Hyun; Lee, Jae-Won] Univ Ulsan, Coll Med, Dept Cardiothorac Surg, Asan Med Ctr, Seoul, South Korea; [Yun, Sung-Cheol] Univ Ulsan, Coll Med, Dept Biostat, Asan Med Ctr, Seoul, South Korea; [Park, Sung-Ji; Park, Seung-Woo] Sungkyunkwan Univ, Samsung Med Ctr, Div Cardiol, Sch Med, Seoul, South Korea; [Hong, Geu-Ru] Severance Hosp, Div Cardiol, Seoul, South Korea; [Kim, Hyung-Kwan] Seoul Natl Univ Hosp, Cardiovasc Ctr, Seoul, South Korea	University of Ulsan; Asan Medical Center; University of Ulsan; University of Ulsan; Sungkyunkwan University (SKKU); Samsung Medical Center; Yonsei University; Yonsei University Health System; Seoul National University (SNU); Seoul National University Hospital	Kang, DH (corresponding author), Univ Ulsan, Coll Med, Div Cardiol, Asan Med Ctr, 388-1 Poongnap Dong, Seoul, South Korea.; Park, SW (corresponding author), Sungkyunkwan Univ, Samsung Med Ctr, Heart Vasc Stroke Inst, Sch Med, 81 Irwon Ro, Seoul, South Korea.	dhkang@amc.seoul.kr; s.woo.park@samsung.com		Kim, Hyung-Kwan/0000-0001-7950-2131; Hong, Geu-Ru/0000-0003-4981-3304; Kim, Dae-Hee/0000-0002-8275-4871	Korean Institute of Medicine	Korean Institute of Medicine	Supported by the Korean Institute of Medicine.	Adams DH, 2014, NEW ENGL J MED, V370, P1790, DOI 10.1056/NEJMoa1400590; Baumgartner H, 2017, EUR HEART J, V38, P2739, DOI 10.1093/eurheartj/ehx391; Bhattacharyya S, 2012, EUR HEART J, V33, P2377, DOI 10.1093/eurheartj/ehs190; Bonow RO, 1998, CIRCULATION, V98, P1949, DOI 10.1161/01.CIR.98.18.1949; Bonow RO, 2006, CIRCULATION, V114, pE84, DOI 10.1161/CIRCULATIONAHA.106.176857; Brennan JM, 2012, CIRCULATION, V126, P1621, DOI 10.1161/CIRCULATIONAHA.112.091371; Carabello BA, 2012, CIRCULATION, V126, P112, DOI 10.1161/CIRCULATIONAHA.111.079350; Genereux P, 2016, J AM COLL CARDIOL, V67, P2263, DOI 10.1016/j.jacc.2016.02.057; Harold JG, 2014, J AM COLL CARDIOL, V63, pE57, DOI 10.1016/j.jacc.2014.02.536; Kang DH, 2010, CIRCULATION, V121, P1502, DOI 10.1161/CIRCULATIONAHA.109.909903; Leon MB, 2010, NEW ENGL J MED, V363, P1597, DOI 10.1056/NEJMoa1008232; Mack MJ, 2019, NEW ENGL J MED, V380, P1695, DOI 10.1056/NEJMoa1814052; OH JK, 1988, J AM COLL CARDIOL, V11, P1227, DOI 10.1016/0735-1097(88)90286-0; Pellikka PA, 2005, CIRCULATION, V111, P3290, DOI 10.1161/CIRCULATIONAHA.104.495903; Popma JJ, 2019, NEW ENGL J MED, V380, P1706, DOI 10.1056/NEJMoa1816885; Rosenhek R, 2000, NEW ENGL J MED, V343, P611, DOI 10.1056/NEJM200008313430903; Shah PK, 2012, CIRCULATION, V126, P118, DOI 10.1161/CIRCULATIONAHA.111.079368; Smith CR, 2011, NEW ENGL J MED, V364, P2187, DOI 10.1056/NEJMoa1103510; Taniguchi T, 2015, J AM COLL CARDIOL, V66, P2827, DOI 10.1016/j.jacc.2015.10.001	19	184	187	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 9	2020	382	2					111	119		10.1056/NEJMoa1912846	http://dx.doi.org/10.1056/NEJMoa1912846			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB6CS	31733181	Bronze			2023-01-03	WOS:000506581500009
J	Nakashima, T; Noguchi, T; Tahara, Y; Nishimura, K; Yasuda, S; Onozuka, D; Iwami, T; Yonemoto, N; Nagao, K; Nonogi, H; Ikeda, T; Sato, N; Tsutsui, H				Nakashima, Takahiro; Noguchi, Teruo; Tahara, Yoshio; Nishimura, Kunihiro; Yasuda, Satoshi; Onozuka, Daisuke; Iwami, Taku; Yonemoto, Naohiro; Nagao, Ken; Nonogi, Hiroshi; Ikeda, Takanori; Sato, Naoki; Tsutsui, Hiroyuki		Japanese Circulation Soc Resuscita	Public-access defibrillation and neurological outcomes in patients with out-of-hospital cardiac arrest in Japan: a population-based cohort study	LANCET			English	Article							AMERICAN-HEART-ASSOCIATION; BYSTANDER CARDIOPULMONARY-RESUSCITATION; INTERNATIONAL LIAISON COMMITTEE; PERMEABILITY TRANSITION PORE; HEALTH-CARE PROFESSIONALS; EUROPEAN-RESUSCITATION; STROKE-FOUNDATION; TASK-FORCE; SURVIVAL; STATEMENT	Background More than 80% of public-access defibrillation attempts do not result in sustained return of spontaneous circulation in patients who have had an out-of-hospital cardiac arrest (OHCA) and a shockable heart rhythm before arrival of emergency medical service (EMS) personnel. Neurological and survival outcomes in such patients have not been evaluated. We aimed to assess the neurological status and survival outcomes in such patients. Methods This is a retropective analysis of a cohort study from a prospective, nationwide, population-based registry of 1 299 784 patients who had an OHCA event between Jan 1, 2005, and Dec 31, 2015 in Japan. The primary outcome was favourable neurological outcome (Cerebral Performance Category of 1 or 2) at 30 days after the OHCA and the secondary outcome was survival at 30 days following the OHCA. This study is registered with the University Hospital Medical Information Network Clinical Trials Registry, UMIN000009918. Findings We identified 28 019 patients with bystander-witnessed OHCA and shockable heart rhythm who had received CPR from a bystander. Of these, 2242 (8.0%) patients did not achieve return of spontaneous circulation with CPR plus public-access defibrillation, and 25 087 (89.5%) patients did not achieve return of spontaneous circulation with CPR alone before EMS arrival. The proportion of patients with a favourable neurological outcome was significantly higher in those who received public-access defibrillation than those who did not (845 [37.7%] vs 5676 [22.6%]; adjusted odds ratio [OR] after propensity score-matching, 1.45 [95% CI 1.24-1.69], p<0.0001). The proportion of patients who survived at 30 days after the OHCA was also significantly higher in those who received public-access defibrillation than those who did not (987 [44.0%] vs 7976 [31.8%]; adjusted OR after propensity score-matching, 1.31 [95% CI 1.13-1.52], p<0.0001). Interpretation Our findings support the benefits of public-access defibrillation and greater accessibility and availability of automated external defibrillators in the community. Copyright (C) 2019 Elsevier Ltd. All rights reserved.	[Nakashima, Takahiro; Noguchi, Teruo; Tahara, Yoshio; Nishimura, Kunihiro; Yasuda, Satoshi; Onozuka, Daisuke] Natl Cerebral & Cardiovasc Ctr, Dept Cardiovasc Med, Suita, Osaka 5648565, Japan; [Onozuka, Daisuke] Kyushu Univ, Dept Hlth Commun, Grad Sch Med Sci, Fukuoka, Fukuoka, Japan; [Iwami, Taku] Kyoto Univ Hlth Serv, Kyoto, Japan; [Yonemoto, Naohiro] Kyoto Univ, Dept Biostat, Sch Publ Hlth, Kyoto, Japan; [Nagao, Ken] Nihon Univ Hosp, Cardiovasc Ctr, Tokyo, Japan; [Nonogi, Hiroshi] Shizuoka Prefectural Gen Hosp, Intens Care Ctr, Shizuoka, Japan; [Ikeda, Takanori] Toho Univ, Dept Cardiovasc Med, Fac Med, Tokyo, Japan; [Sato, Naoki] Nippon Med Sch, Musashi Kosugi Hosp, Cardiol & Intens Care Unit, Kawasaki, Kanagawa, Japan; [Tsutsui, Hiroyuki] Kyushu Univ, Dept Cardiovasc Med, Fukuoka, Fukuoka, Japan	National Cerebral & Cardiovascular Center - Japan; Kyushu University; Kyoto University; Kyoto University; Nihon University; Shizuoka General Hospital; Toho University; Nippon Medical School; Kyushu University	Tahara, Y (corresponding author), Natl Cerebral & Cardiovasc Ctr, Dept Cardiovasc Med, Suita, Osaka 5648565, Japan.	tahara@nm.go.jp	IWAMI, Taku/HCH-0599-2022; Nakashima, Takahiro/AFV-5953-2022; Onozuka, Daisuke/F-5067-2014	IWAMI, Taku/0000-0002-4150-7065; Nakashima, Takahiro/0000-0001-6369-6154; Onozuka, Daisuke/0000-0001-9596-9188				Assaly R, 2012, EUR J PHARMACOL, V675, P6, DOI 10.1016/j.ejphar.2011.11.036; Becker LB, 2011, CIRCULATION, V124, P2158, DOI 10.1161/CIR.0b013e3182340239; Berdowski J, 2010, CIRCULATION, V122, P1101, DOI 10.1161/CIRCULATIONAHA.110.958173; Brooks B, 2015, HEART, V101, P967, DOI 10.1136/heartjnl-2015-307624; Claesson A, 2017, AM J EMERG MED, V35, P1043, DOI 10.1016/j.ajem.2017.02.030; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Eilevstjonn J, 2007, RESUSCITATION, V75, P60, DOI 10.1016/j.resuscitation.2007.02.014; Hansen CM, 2015, JAMA-J AM MED ASSOC, V314, P255, DOI 10.1001/jama.2015.7938; Hasegawa M, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0112-4; Hasselqvist-Ax I, 2015, NEW ENGL J MED, V372, P2307, DOI 10.1056/NEJMoa1405796; Izawa J, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l430; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Kastrup A, 1999, J NEUROL SCI, V166, P91, DOI 10.1016/S0022-510X(99)00121-5; Kitamura T, 2016, NEW ENGL J MED, V375, P1649, DOI 10.1056/NEJMsa1600011; Kitamura T, 2012, CIRCULATION, V126, P2834, DOI 10.1161/CIRCULATIONAHA.112.109496; Kitamura T, 2010, NEW ENGL J MED, V362, P994, DOI 10.1056/NEJMoa0906644; Kronick SL, 2015, CIRCULATION, V132, pS397, DOI 10.1161/CIR.0000000000000258; Kuramoto N, 2008, RESUSCITATION, V79, P475, DOI 10.1016/j.resuscitation.2008.07.005; Nagao K, 2016, CIRCULATION, V133, P1386, DOI 10.1161/CIRCULATIONAHA.115.018788; Nagao K, 2013, CIRC J, V77, P2742, DOI 10.1253/circj.CJ-13-0457; Perkins GD, 2015, CIRCULATION, V132, P1286, DOI 10.1161/CIR.0000000000000144; Shanmuganathan S, 2005, AM J PHYSIOL-HEART C, V289, pH237, DOI 10.1152/ajpheart.01192.2004; Song KJ, 2014, RESUSCITATION, V85, P34, DOI 10.1016/j.resuscitation.2013.06.004; Williamson LJ, 2005, EMERG MED J, V22, P140, DOI 10.1136/emj.2004.016444; Wissenberg M, 2013, JAMA-J AM MED ASSOC, V310, P1377, DOI 10.1001/jama.2013.278483; Yukawa T, 2017, SCAND J TRAUMA RESUS, V25, DOI 10.1186/s13049-017-0440-7	26	20	20	1	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	2019	394	10216					2255	2262		10.1016/S0140-6736(19)32488-2	http://dx.doi.org/10.1016/S0140-6736(19)32488-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX5QC	31862250				2023-01-03	WOS:000503788300028
J	Ndung'u, T; McCune, JM; Deeks, SG				Ndung'u, Thumbi; McCune, Joseph M.; Deeks, Steven G.			Why and where an HIV cure is needed and how it might be achieved	NATURE			English	Review							CD4(+) T-CELLS; LATENT RESERVOIR; ANTIRETROVIRAL THERAPY; PLASMA VIREMIA; INTACT HIV-1; REPLICATION; PERSISTENCE; VACCINATION; INFECTION; TRANSPLANTATION	Despite considerable global investment, only 60% of people who live with HIV currently receive antiretroviral therapy. The sustainability of current programmes remains unknown and key incidence rates are declining only modestly. Given the complexities and expenses associated with lifelong medication, developing an effective curative intervention is now a global priority. Here we review why and where a cure is needed, and how it might be achieved. We argue for expanding these efforts from resource-rich regions to sub-Saharan Africa and elsewhere: for any intervention to have an effect, region-specific biological, therapeutic and implementation issues must be addressed.	[Ndung'u, Thumbi] Africa Hlth Res Inst, Durban, South Africa; [Ndung'u, Thumbi] Univ KwaZulu Natal, HIV Pathogenesis Programme, Doris Duke Med Res Inst, Durban, South Africa; [Ndung'u, Thumbi] Max Planck Inst Infect Biol, Berlin, Germany; [McCune, Joseph M.] Bill & Melinda Gates Fdn, HIV Frontiers, Global Hlth Innovat Technol Solut, Seattle, WA USA; [Deeks, Steven G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	Africa Health Research Institute; University of Kwazulu Natal; Max Planck Society; Bill & Melinda Gates Foundation; University of California System; University of California San Francisco	Deeks, SG (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.	Steven.Deeks@ucsf.edu		Deeks, Steven/0000-0001-6371-747X	Bill & Melinda Gates Foundation; Gilead Sciences [00406]; International AIDS Vaccine Initiative (IAVI) [UKZNRSA1001]; NIAID [R37AI067073, K24 AI069994]; South African Department of Science and Technology through the National Research Foundation; sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative [DEL-15-006]; New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust [107752/Z/15/Z]; UK government; amfAR Institute for HIV Cure Research [amfAR 109301]; Delaney AIDS Research Enterprise (DARE) [A127966]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI069994, R37AI067073] Funding Source: NIH RePORTER	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Gilead Sciences(Gilead Sciences); International AIDS Vaccine Initiative (IAVI); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); South African Department of Science and Technology through the National Research Foundation; sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative; New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust(Wellcome TrustEuropean Commission); UK government; amfAR Institute for HIV Cure Research; Delaney AIDS Research Enterprise (DARE); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	T.N. is supported in part by grants from the Bill & Melinda Gates Foundation, Gilead Sciences (grant no. 00406), the International AIDS Vaccine Initiative (IAVI) (UKZNRSA1001), the NIAID (R37AI067073) and the South African Department of Science and Technology through the National Research Foundation. T.N. is also partially supported through the sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative (grant no. DEL-15-006). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS) Alliance for Accelerating Excellence in Science in Africa (AESA) and is supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (grant no. 107752/Z/15/Z) and the UK government. J.M.M. is an employee of the Bill & Melinda Gates Foundation. S.G.D. is supported by the amfAR Institute for HIV Cure Research (amfAR 109301), the Delaney AIDS Research Enterprise (DARE; A127966), and the NIAID (K24 AI069994). We thank W. Greene for assistance with Fig. 1. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust, the UK government, the Bill & Melinda Gates Foundation or amfAR.	Ananworanich J, 2015, LANCET HIV, V2, pE410, DOI 10.1016/S2352-3018(15)00186-1; Anthony-Gonda K, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav5685; Archin NM, 2012, NATURE, V487, P482, DOI 10.1038/nature11286; Ayouba A, 2019, NEW ENGL J MED, V381, P816, DOI 10.1056/NEJMoa1904340; Banga R, 2016, NAT MED, V22, P754, DOI 10.1038/nm.4113; Barr E. L., 2019, J VIRUS ERADICATION; Battivelli E, 2018, ELIFE, V7, DOI 10.7554/eLife.34655; Beacroft L, 2019, GLOB HEALTH RES POL, V4, DOI 10.1186/s41256-019-0107-1; Borducchi EN, 2018, NATURE, V563, P360, DOI 10.1038/s41586-018-0600-6; Borducchi EN, 2016, NATURE, V540, P284, DOI 10.1038/nature20583; Bruner KM, 2019, NATURE, V566, P120, DOI 10.1038/s41586-019-0898-8; Casazza JP, 2013, J INFECT DIS, V207, P1829, DOI 10.1093/infdis/jit098; Chew GM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005349; Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972; Chu CE, 2015, AIDS RES HUM RETROV, V31, P78, DOI [10.1089/aid.2014.0200, 10.1089/AID.2014.0200]; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Cohn LB, 2018, NAT MED, V24, P604, DOI 10.1038/s41591-018-0017-7; Cohn LB, 2015, CELL, V160, P420, DOI 10.1016/j.cell.2015.01.020; Colby DJ, 2018, NAT MED, V24, P923, DOI 10.1038/s41591-018-0026-6; Conway JM, 2015, P NATL ACAD SCI USA, V112, P5467, DOI 10.1073/pnas.1419162112; Cuadros DF, 2019, AIDS, V33, P305, DOI [10.1097/qad.0000000000002052, 10.1097/QAD.0000000000002052]; Dash PK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10366-y; Davenport MP, 2019, NAT REV IMMUNOL, V19, P45, DOI 10.1038/s41577-018-0085-4; Deeks SG, 2002, MOL THER, V5, P788, DOI 10.1006/mthe.2002.0611; Deeks SG, 2016, NAT MED, V22, P839, DOI 10.1038/nm.4108; Deng K, 2015, NATURE, V517, P381, DOI 10.1038/nature14053; Descours B, 2017, NATURE, V543, P564, DOI 10.1038/nature21710; Dong KL, 2018, LANCET HIV, V5, pE35, DOI 10.1016/S2352-3018(17)30146-7; Einkauf KB, 2019, J CLIN INVEST, V129, P988, DOI 10.1172/JCI124291; Eisinger RW, 2019, JAMA-J AM MED ASSOC, V321, P451, DOI 10.1001/jama.2018.21167; Elliott JH, 2015, LANCET HIV, V2, pE520, DOI 10.1016/S2352-3018(15)00226-X; Elliott JH, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004473; Estes JD, 2017, NAT MED, V23, P1271, DOI 10.1038/nm.4411; Fidler S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13287-2; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Fletcher CV, 2014, P NATL ACAD SCI USA, V111, P2307, DOI 10.1073/pnas.1318249111; Frange P, 2016, LANCET HIV, V3, pE49, DOI 10.1016/S2352-3018(15)00232-5; Frank TD, 2019, LANCET HIV, V6, pE831, DOI 10.1016/S2352-3018(19)30196-1; Fromentin R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08798-7; Fromentin R, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005761; Gaiha GD, 2019, SCIENCE, V364, P480, DOI 10.1126/science.aav5095; Gay CL, 2017, J INFECT DIS, V215, P1725, DOI 10.1093/infdis/jix191; Gelpi A, 2015, SEX TRANSM INFECT, V91, P70, DOI 10.1136/sextrans-2014-051781; Gupta RK, 2019, NATURE, V568, P244, DOI 10.1038/s41586-019-1027-4; Hansen SG, 2016, SCIENCE, V351, P714, DOI 10.1126/science.aac9475; Hansen SG, 2013, NATURE, V502, P100, DOI 10.1038/nature12519; Haworth KG, 2017, CYTOTHERAPY, V19, P1325, DOI 10.1016/j.jcyt.2017.05.013; Henrich TJ, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002417; Henrich TJ, 2014, ANN INTERN MED, V161, P319, DOI 10.7326/M14-1027; Hersperger AR, 2011, BLOOD, V117, P3799, DOI 10.1182/blood-2010-12-322727; Hessell AJ, 2016, NAT MED, V22, P362, DOI 10.1038/nm.4063; Hiener B, 2017, CELL REP, V21, P813, DOI 10.1016/j.celrep.2017.09.081; Hill AL, 2014, P NATL ACAD SCI USA, V111, P13475, DOI 10.1073/pnas.1406663111; Ho YC, 2013, CELL, V155, P540, DOI 10.1016/j.cell.2013.09.020; Hogan LE, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006856; Holt N, 2010, NAT BIOTECHNOL, V28, P839, DOI 10.1038/nbt.1663; Hosmane NN, 2017, J EXP MED, V214, P959, DOI 10.1084/jem.20170193; Huang SH, 2018, J CLIN INVEST, V128, P876, DOI [10.1172/JCI97555, 10.1172/jci97555]; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Julg B, 2019, LANCET HIV, V6, pE259, DOI 10.1016/S2352-3018(19)30052-9; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Katz IT, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.3.18640; Kearney MF, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004010; Keating SM, 2017, J INFECT DIS, V216, P72, DOI 10.1093/infdis/jix225; Kessing CF, 2017, CELL REP, V21, P600, DOI 10.1016/j.celrep.2017.09.080; Khoury G, 2016, AIDS, V30, P1511, DOI 10.1097/QAD.0000000000001029; Kityo C, 2018, J CLIN INVEST, V128, P2763, DOI 10.1172/JCI97377; Kordelas L, 2014, NEW ENGL J MED, V371, P880, DOI 10.1056/NEJMc1405805; Kuo HH, 2018, IMMUNITY, V48, P1183, DOI 10.1016/j.immuni.2018.04.004; Laird GM, 2015, J CLIN INVEST, V125, P1901, DOI 10.1172/JCI80142; Leal L, 2017, EXPERT REV VACCINES, V16, P587, DOI 10.1080/14760584.2017.1322513; Lee GQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10659-2; Lee GQ, 2017, J CLIN INVEST, V127, P2689, DOI 10.1172/JCI93289; Leibman RS, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006613; Lelievre JD, 2019, J INFECT DIS, V220, pS5, DOI 10.1093/infdis/jiz012; Leth S, 2016, LANCET HIV, V3, pE463, DOI 10.1016/S2352-3018(16)30055-8; Lim SY, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4521; Macedo AB, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122673; Maldarelli F, 2014, SCIENCE, V345, P179, DOI 10.1126/science.1254194; Martinez-Navio JM, 2019, IMMUNITY, V50, P567, DOI 10.1016/j.immuni.2019.02.005; McGary CS, 2017, IMMUNITY, V47, P776, DOI 10.1016/j.immuni.2017.09.018; Mendoza P, 2018, NATURE, V561, P479, DOI 10.1038/s41586-018-0531-2; Migueles SA, 2009, J VIROL, V83, P11876, DOI 10.1128/JVI.01153-09; Mousseau G, 2015, MBIO, V6, DOI 10.1128/mBio.00465-15; Moyo S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204840; Namazi G, 2018, J INFECT DIS, V218, P1954, DOI 10.1093/infdis/jiy479; Ndhlovu ZM, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau0528; Ndhlovu ZM, 2015, IMMUNITY, V43, P591, DOI 10.1016/j.immuni.2015.08.012; Nishimura Y, 2017, NATURE, V543, P559, DOI 10.1038/nature21435; Okoye AA, 2018, NAT MED, V24, P1430, DOI 10.1038/s41591-018-0130-7; Paltiel AD, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx081; Pardons M, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007619; Peretz Y, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002840; Persaud D, 2013, NEW ENGL J MED, V369, P1828, DOI 10.1056/NEJMoa1302976; Peterson CW, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006956; Petrovas C, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag2285; Phillips AN, 2016, J INFECT DIS, V214, P73, DOI 10.1093/infdis/jiw120; Pinzone MR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08431-7; Priddy FH, 2019, LANCET HIV, V6, pE230, DOI 10.1016/S2352-3018(19)30003-7; Rasmussen TA, 2014, LANCET HIV, V1, pE13, DOI 10.1016/S2352-3018(14)70014-1; Rochat MA, 2017, J VIROL, V91, DOI 10.1128/JVI.02084-16; Rodger AJ, 2019, LANCET, V393, P2428, DOI 10.1016/S0140-6736(19)30418-0; Rossouw T, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21521; Rothenberger MK, 2015, P NATL ACAD SCI USA, V112, pE1126, DOI 10.1073/pnas.1414926112; Rueda S, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011453; Saez-Cirion A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003211; Santangelo PJ, 2015, NAT METHODS, V12, P427, DOI [10.1038/NMETH.3320, 10.1038/nmeth.3320]; Scully EP, 2019, J INFECT DIS, V219, P1084, DOI 10.1093/infdis/jiy617; Shan L, 2012, IMMUNITY, V36, P491, DOI 10.1016/j.immuni.2012.01.014; Sneller MC, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan8848; Sogaard OS, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005142; Sung JAM, 2015, J CLIN INVEST, V125, P4077, DOI 10.1172/JCI82314; Takata H, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag1809; Tauriainen J, 2017, SCI REP-UK, V7, DOI 10.1038/srep40354; UNAIDS, 2019, GLOBAL HIV AIDS STAT; UNAIDS, 2016, FAST TRACK UPD INV N; Venter WDF, 2019, NEW ENGL J MED, V381, P803, DOI 10.1056/NEJMoa1902824; Vibholm L, 2017, CLIN INFECT DIS, V64, P1686, DOI 10.1093/cid/cix201; Violari A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08311-0; Wacleche VS, 2016, RETROVIROLOGY, V13, DOI 10.1186/s12977-016-0293-6; Wagner TA, 2014, SCIENCE, V345, P570, DOI 10.1126/science.1256304; Wang G, 2016, CELL REP, V17, P2819, DOI 10.1016/j.celrep.2016.11.057; Wang Z, 2018, P NATL ACAD SCI USA, V115, pE2575, DOI 10.1073/pnas.1720665115; Wang ZX, 2017, INT J DISTRIB SENS N, V13, DOI 10.1177/1550147717726309; Webb GM, 2018, BLOOD ADV, V2, P76, DOI 10.1182/bloodadvances.2017012971; Wiegand A, 2017, P NATL ACAD SCI USA, V114, pE3659, DOI 10.1073/pnas.1617961114; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Xu L, 2017, SCIENCE, V358, P85, DOI 10.1126/science.aan8630; Yin H, 2017, NAT REV DRUG DISCOV, V16, P387, DOI 10.1038/nrd.2016.280; Yukl SA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aap9927; Yukl SA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003347	131	56	56	2	41	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 19	2019	576	7787					397	405		10.1038/s41586-019-1841-8	http://dx.doi.org/10.1038/s41586-019-1841-8			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY8LS	31853080	Green Accepted			2023-01-03	WOS:000504660500088
J	Meerholz, EW; Spears, R; Epstude, K				Meerholz, Ernst Willem; Spears, Russell; Epstude, Kai			Having pity on our victims to save ourselves: Compassion reduces self-critical emotions and self-blame about past harmful behavior among those who highly identify with their past self	PLOS ONE			English	Article							GROUP-BASED GUILT; VISUAL PERSPECTIVE; ASSOCIATION; IMAGERY; TIME; LIFE	Previous research has shown that people often separate the present self from past selves. Applying knowledge gained from intergroup research to the interpersonal domain, we argue that the degree to which people identify with their past self (self-identification) influences their reaction when recalling a past event during which they harmed another person. Because they feel close to their past self, we expected this to be threatening for high selfidentifiers, and expected them to be motivated to avoid self-critical emotions and blame. Using four meta-analyses, conducted on a set of seven experimental studies, we investigated four ways in which high self-identifiers can distance themselves from the event: by feeling compassion, by taking a third-person rather than first-person perspective, by emphasizing ways in which their present self is different to their past self, and by disidentifying with the past self altogether. We found the strongest interaction effects for compassion: whereas a compassion manipulation increased self-critical emotions and self-blame about the past event for low self-identifiers, it decreased them for high self-identifiers. We argue that this occurs because the other-focused nature of compassion allows high self-identifiers subtly to shift the focus away from their harmful behavior. Our concept of past self-identification had stronger effects than a measure of self-continuity beliefs. It also correlated only moderately with the latter, suggesting they are distinct concepts. Our findings suggest that, ironically, the most effective way to protect the self against reminders of an undesirable past, may be to have compassion for our victims.	[Meerholz, Ernst Willem; Spears, Russell; Epstude, Kai] Univ Groningen, Dept Social Psychol, Groningen, Netherlands	University of Groningen	Meerholz, EW (corresponding author), Univ Groningen, Dept Social Psychol, Groningen, Netherlands.	e.w.meerholz@rug.nl	Spears, Russell/E-8279-2014	Spears, Russell/0000-0001-5244-0575				BATSON CD, 1988, J PERS SOC PSYCHOL, V55, P52, DOI 10.1037/0022-3514.55.1.52; Batson CD, 1997, J PERS SOC PSYCHOL, V72, P105, DOI 10.1037/0022-3514.72.1.105; Baumeister R.F., 1998, HDB, V1, P680; Branscombe Nyla, 2004, COLLECTIVE GUILT INT; Doosje B, 1998, J PERS SOC PSYCHOL, V75, P872, DOI 10.1037/0022-3514.75.4.872; Ellemers N, 2002, ANNU REV PSYCHOL, V53, P161, DOI 10.1146/annurev.psych.53.100901.135228; Fabrigar LR, 2016, J EXP SOC PSYCHOL, V66, P68, DOI 10.1016/j.jesp.2015.07.009; Fergusson PA, 1993, WRITING TRAUMATIC EV; Francis G, 2014, PSYCHON B REV, V21, P1180, DOI 10.3758/s13423-014-0601-x; Hanko K, 2010, EUR J SOC PSYCHOL, V40, P160, DOI 10.1002/ejsp.625; Hayes A. F., 2013, MEDIATION MODERATION; Higgins ET, 1996, J PERS SOC PSYCHOL, V71, P1062, DOI 10.1037/0022-3514.71.6.1062; Iyer A, 2003, PERS SOC PSYCHOL B, V29, P117, DOI 10.1177/0146167202238377; Iyer A, 2007, PERS SOC PSYCHOL B, V33, P572, DOI 10.1177/0146167206297402; James William, 1950, PRINCIPLES PSYCHOL, VOne; Johnson B. T., 1993, DSTAT 1 10 SOFTWARE; Kotlewska I, 2015, BIOL PSYCHOL, V110, P201, DOI 10.1016/j.biopsycho.2015.07.015; Kross E, 2017, ADV EXP SOC PSYCHOL, V55, P81, DOI 10.1016/bs.aesp.2016.10.002; Kross E, 2014, J PERS SOC PSYCHOL, V106, P304, DOI 10.1037/a0035173; Kuppens T, 2015, PERS SOC PSYCHOL B, V41, P1260, DOI 10.1177/0146167215594122; Lakens D, 2017, SOC PSYCHOL PERS SCI, V8, P875, DOI 10.1177/1948550617693058; Lazarus R. S., 1991, EMOTION ADAPTATION; Leach CW, 2008, J PERS SOC PSYCHOL, V95, P144, DOI 10.1037/0022-3514.95.1.144; Libby LK, 2011, J PERS SOC PSYCHOL, V101, P1157, DOI 10.1037/a0026105; Libby LK, 2011, ADV EXP SOC PSYCHOL, V44, P185, DOI 10.1016/B978-0-12-385522-0.00004-4; Libby LK, 2002, J PERS SOC PSYCHOL, V82, P167, DOI 10.1037//0022-3514.82.2.167; McGarty C, 2005, BRIT J SOC PSYCHOL, V44, P659, DOI 10.1348/014466604X18974; Meerholz EW, 2018, OTHER SIDE COMPASSIO; NIGRO G, 1983, COGNITIVE PSYCHOL, V15, P467, DOI 10.1016/0010-0285(83)90016-6; ROSS M, 1989, PSYCHOL REV, V96, P341, DOI 10.1037/0033-295X.96.2.341; Sani F, 2008, EUR J SOC PSYCHOL, V38, P365, DOI 10.1002/ejsp.461; Schimmack U, 2012, PSYCHOL METHODS, V17, P551, DOI 10.1037/a0029487; Thomas EF, 2009, BRIT J SOC PSYCHOL, V48, P115, DOI 10.1348/014466608X313774; Thomas James, 2012, BMC Res Notes, V5, P571, DOI 10.1186/1756-0500-5-571; Trivers R., 2011, FOLLY FOOLS LOGIC DE; Tuk MA, 2015, J EXP PSYCHOL GEN, V144, P639, DOI 10.1037/xge0000065; Wallace-Hadrill SMA, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01715; Wilson AE, 2003, MEMORY, V11, P137, DOI 10.1080/741938210; Zebel S, 2009, GROUP PROCESS INTERG, V12, P61, DOI 10.1177/1368430208098777; Zhang C, 2015, ACTA PSYCHOL, V157, P101, DOI 10.1016/j.actpsy.2015.02.011	40	0	0	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2019	14	12							e0223945	10.1371/journal.pone.0223945	http://dx.doi.org/10.1371/journal.pone.0223945			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP1HF	31830055	Green Published, gold			2023-01-03	WOS:000534070200009
J	Souliotis, K; Golna, C; Kani, C; Nikolaidi, S; Boumpas, D				Souliotis, Kyriakos; Golna, Christina; Kani, Chara; Nikolaidi, Sofia; Boumpas, Dimitrios			Real world, big data cost of pharmaceutical treatment for rheumatoid arthritis in Greece	PLOS ONE			English	Article							TREATED PATIENT; IMPACT	Introduction Rheumatoid Arthritis (RA) is a highly prevalent autoimmune disease associated with joint inflammation and destruction. Treatment for RA, especially with biologic agents (biologics), improves patient functionality and quality of life and averts costly complications or disease progression. Cost of RA pharmaceutical treatment has rarely been reported on the basis of real-world, big data. This study reports on the real-world, big data RA pharmaceutical treatment cost in Greece. Methods The Business Intelligence database of the National Organization for Healthcare Services Provision (EOPYY) was used to identify and provide analytics on patients on treatment for RA. EOPYY is responsible for funding healthcare and pharmaceutical care services for approximately 95% of the population in the country. ICD-10 codes were applied to identify patients with RA and at least one reimbursed prescription between 1 June 2014 and 31 May 2015. Results 35,873 unique patients were recorded as undergoing treatment for RA. Total reimbursed treatment cost for the study period was (sic)81,206,363.70, of which (sic)52,732,142.18 (64.94%) was for treatment with biologics. Of that cost, (sic)39,724,489.71 (48.32%) accounted for treatment with anti-TNFs and/or methotrexate/corticosteroids. Conclusion Real world, big data analysis confirms that the major driver of RA pharmaceutical cost is, as expected, the cost of treatment with biologics. It is critical to be able to match this cost to the treatment outcome it produces to ensure an optimal, no-waste, evidence-based allocation of healthcare resources to need.	[Souliotis, Kyriakos] Univ Peloponnese, Fac Social & Polit Sci, Corinth, Greece; [Souliotis, Kyriakos; Nikolaidi, Sofia] Hlth Policy Inst, Athens, Greece; [Golna, Christina] Innowth Ltd, Larnax, Cyprus; [Kani, Chara] Natl Org Healthcare Serv Provis EOPYY, Med Div, Athens, Greece; [Boumpas, Dimitrios] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Athens, Greece	University of Peloponnese; National & Kapodistrian University of Athens; University Hospital Attikon	Souliotis, K (corresponding author), Univ Peloponnese, Fac Social & Polit Sci, Corinth, Greece.; Souliotis, K (corresponding author), Hlth Policy Inst, Athens, Greece.	info@ksouliotis.gr	SOULIOTIS, KYRIAKOS/AAM-3164-2021	SOULIOTIS, KYRIAKOS/0000-0003-1624-9444				Andrianakos A, 2006, RHEUMATOLOGY, V45, P1549, DOI 10.1093/rheumatology/kel140; Benucci M, 2016, CLINICOECONOMIC OUTC, V8, P33, DOI 10.2147/CEOR.S91006; Bonafede MMK, 2012, ADV THER, V29, P234, DOI 10.1007/s12325-012-0007-y; Borman P, 2007, CLIN RHEUMATOL, V26, P330, DOI 10.1007/s10067-006-0298-y; Chevreul K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097077; Gulacsi L, 2015, EXPERT REV CLIN IMMU, V11, pS43, DOI 10.1586/1744666X.2015.1090313; Huscher D, 2006, ANN RHEUM DIS, V65, P1175, DOI 10.1136/ard.2005.046367; Kanavos P, 2017, POLIT SCI ENVIRON, P359; Kobelt, 2009, REPORT PREPARED EURO; Kobelt G, 2008, EUR J HEALTH ECON, V8, pS95, DOI 10.1007/s10198-007-0091-0; Li X, 2006, MED CARE, V44, P304, DOI 10.1097/01.mlr.0000204257.25875.04; Ozminkowski RJ, 2006, J OCCUP ENVIRON MED, V48, P135, DOI 10.1097/01.jom.0000194161.12923.52; Schabert VF, 2013, J MANAGE CARE PHARM, V19, P621, DOI 10.18553/jmcp.2013.19.8.621; Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140-6736(10)60826-4; Sfikakis P, 2015, ANN RHEUM DIS, V74, P790, DOI 10.1136/annrheumdis-2015-eular.4854; Singh JA, 2009, CAN MED ASSOC J, V181, P787, DOI 10.1503/cmaj.091391; Smolen JS, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2019-000900; Souliotis K, 2016, J MED ECON, V19, P1021, DOI 10.1080/13696998.2016.1192547; Souliotis K, 2014, RHEUMATOL INT, V34, P25, DOI 10.1007/s00296-013-2866-1; Weissmann G, 2006, BULL HOSP JT DIS, V64, P12	20	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2019	14	12							e0226287	10.1371/journal.pone.0226287	http://dx.doi.org/10.1371/journal.pone.0226287			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP1HF	31830144	Green Published, gold			2023-01-03	WOS:000534070200065
J	Dunne, J; Rebay-Salisbury, K; Salisbury, RB; Frisch, A; Walton-Doyle, C; Evershed, RP				Dunne, J.; Rebay-Salisbury, K.; Salisbury, R. B.; Frisch, A.; Walton-Doyle, C.; Evershed, R. P.			Milk of ruminants in ceramic baby bottles from prehistoric child graves	NATURE			English	Article							INFANT	The study of childhood diet, including breastfeeding and weaning, has important implications for our understanding of infant mortality and fertility in past societies(1). Stable isotope analyses of nitrogen from bone collagen and dentine samples of infants have provided information on the timing of weaning(2); however, little is known about which foods were consumed by infants in prehistory. The earliest known clay vessels that were possibly used for feeding infants appear in Neolithic Europe, and become more common throughout the Bronze and Iron Ages. However, these vesselswhich include a spout through which liquid could be poured-have also been suggested to be feeding vessels for the sick or infirm(3,4). Here we report evidence for the foods that were contained in such vessels, based on analyses of the lipid `fingerprints' and the compound-specific delta C-13 and Delta C-13 values of the major fatty acids of residues from three small, spouted vessels that were found in Bronze and Iron Age graves of infants in Bavaria. The results suggest that the vessels were used to feed infants with milk products derived from ruminants. This evidence of the foodstuffs that were used to either feed or wean prehistoric infants confirms the importance of milk from domesticated animals for these early communities, and provides information on the infant-feeding behaviours that were practised by prehistoric human groups.	[Dunne, J.; Walton-Doyle, C.; Evershed, R. P.] Univ Bristol, Sch Chem, Organ Geochem Unit, Bristol, Avon, England; [Rebay-Salisbury, K.; Salisbury, R. B.] Austrian Acad Sci, Inst Oriental & European Archaeol, Vienna, Austria; [Frisch, A.] Museen Stadt Regensburg, Abt Archaol, Regensburg, Germany	University of Bristol; Austrian Academy of Sciences	Dunne, J; Evershed, RP (corresponding author), Univ Bristol, Sch Chem, Organ Geochem Unit, Bristol, Avon, England.	julie.dunne@bristol.ac.uk; r.p.evershed@bristol.ac.uk	Salisbury, Roderick B./B-8957-2013	Salisbury, Roderick B./0000-0003-3773-5337; Walton-Doyle, Caitlin/0000-0001-7123-3336; Rebay-Salisbury, Katharina/0000-0003-0126-8693	European Research Council (ERC) under the EU Horizon 2020 research and innovation programme [676828]; NERC; Leverhulme Trust [RPG-2016-115]; NERC [lsmsf010001] Funding Source: UKRI	European Research Council (ERC) under the EU Horizon 2020 research and innovation programme(European Research Council (ERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Leverhulme Trust(Leverhulme Trust); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	Background research and travel for this study was funded as part of the framework of the project 'The value of mothers to society: responses to motherhood and child rearing practices in prehistoric Europe' which received funding from the European Research Council (ERC) under the EU Horizon 2020 research and innovation programme (676828). We thank the NERC for partial funding of the National Environmental Isotope Facility (NEIF; Bristol laboratory). J.D. thanks The Leverhulme Trust (RPG-2016-115) for funding and I. Bull and A. Kuhl for technical help. We thank H. Grant of the NEIF (Lancaster laboratory) for stable isotopic characterization of reference standards and derivatizing agents. G. Almstadter, S. Gairhos, K. Gromer, A. Kern, D. Kern, D. Pany-Kucera, K. Wiltschke-Schrotta and M. Berner provided practical support for sampling.	Augstein M., 2015, BEITRAG ANAL MIKRORE, V262; Bocquet-Appel JP, 2011, SCIENCE, V333, P560, DOI 10.1126/science.1208880; Correa-Ascencio M, 2014, ANAL METHODS-UK, V6, P1330, DOI 10.1039/c3ay41678j; Dudd SN, 1998, SCIENCE, V282, P1478, DOI 10.1126/science.282.5393.1478; Dunne J, 2012, NATURE, V486, P390, DOI 10.1038/nature11186; Evershed RP, 2002, ACCOUNTS CHEM RES, V35, P660, DOI 10.1021/ar000200f; Fildes V.A., 1986, BREASTS BOTTLES BABI; Fontecha J, 2005, INT DAIRY J, V15, P1217, DOI 10.1016/j.idairyj.2004.11.013; Fulminante F., 2015, CHILDHOOD, V8, P24, DOI DOI 10.1179/1758571615Z.00000000026; GURR MI, 1981, J DAIRY RES, V48, P519, DOI 10.1017/S0022029900022020; Halcrow SE, 2018, BREASTFEEDING: NEW ANTHROPOLOGICAL APPROACHES, P155; Howcroft R, 2012, ANTHROPOZOOLOGICA, V47, P31, DOI 10.5252/az2012n2a3; Humphrey LT, 2010, SEMIN CELL DEV BIOL, V21, P453, DOI 10.1016/j.semcdb.2009.11.003; Jay M., 2009, CHILDHOOD, V2, P163, DOI [DOI 10.1179/CIP.2009.2.1.163, 10.1179/cip.2009.2.1.163]; Knott C, 2001, FOUND HUM B, P429; Kramer MS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003517.pub2; Mays S., 2017, CHILDHOOD, V10, P38, DOI [10.1080/17585716.2017.1301066, DOI 10.1080/17585716.2017.1301066]; Meller H. E, 2011, BRONZERAUSCH SPATNEO, V4; Rebay-Salisbury Katharina, 2017, MITTEILUNGEN ANTHR G, V147, P13; Robinson SM, 2015, J DEV ORIG HLTH DIS, V6, P384, DOI 10.1017/S2040174415001257; Rohrig K-H, 1994, HALLSTATTZEITLICHE G; Sellen DW, 2007, ANNU REV NUTR, V27, P123, DOI 10.1146/annurev.nutr.25.050304.092557; Sellen DW, 2001, HUM NATURE-INT BIOS, V12, P47, DOI 10.1007/s12110-001-1013-y; SHEPPARD JJ, 1984, CHILD DEV, V55, P831, DOI 10.2307/1130134; Wirth S., AUGSBURGER BEITRAGE, V1	25	30	32	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 10	2019	574	7777					246	+		10.1038/s41586-019-1572-x	http://dx.doi.org/10.1038/s41586-019-1572-x			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JD2DB	31554964	Green Submitted			2023-01-03	WOS:000489784200047
J	Ma, TL; Hu, TH; Hung, CH; Wang, JH; Lu, SN; Chen, CH				Ma, Te-Ling; Hu, Tsung-Hui; Hung, Chao-Hung; Wang, Jing-Houng; Lu, Sheng-Nan; Chen, Chien-Hung			Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment	PLOS ONE			English	Article							SURFACE-ANTIGEN; GUIDELINES; THERAPY	Background This study investigated the incidence and predictors of retreatment after discontinuation of either entecavir (ETV) or tenofovir disoproxil fumarate (TDF) treatment in Taiwan. Methods A total of 535 non-cirrhotic chronic hepatitis B (CHB) patients undergoing either ETV (n = 358) or TDF (n = 177) treatment were enrolled. Patients were followed for at least 12 months after stopping ETV or TDF treatment. Most patients (86.3%) fulfilled the retreatment criteria of Taiwan's National Health Plan. Results The 5-year cumulative rates of clinical relapse and retreatment were 52.1% and 47%, respectively, in 160 hepatitis B e antigen (HBeAg)-positive patients, and were 62% and 54.8%, respectively, in 375 HBeAg-negative patients. The median duration from the end of treatment until clinical relapse and retreatment was 40 and 57 weeks, respectively, for all patients. Multivariate Cox regression analysis revealed that discontinuing TDF treatment, old age, male gender, and higher baseline HBsAg levels were independent factors of retreatment in HBeAg-positive patients; old age, HBV genotype B, and higher baseline and end-of-treatment HBsAg levels were independent factors in HBeAg-negative patients. A total of 18.8% of retreated patients satisfied the retreatment criteria of hepatic decompensation according to Taiwan's National Health Plan. Of the 64 patients who had clinical relapse without retreatment, 17 achieved sustained virological remission and 26 did not experience clinical relapse until their last visit after clinical relapse. Four patients developed HBsAg loss. Conclusions The 5-year retreatment rate was about 50% in HBeAg-positive and HBeAg-negative patients. Discontinuing TDF treatment was an independent factor of retreatment in HBeAg-positive patients.	[Ma, Te-Ling; Hu, Tsung-Hui; Hung, Chao-Hung; Wang, Jing-Houng; Lu, Sheng-Nan; Chen, Chien-Hung] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung, Taiwan; [Ma, Te-Ling; Hu, Tsung-Hui; Hung, Chao-Hung; Wang, Jing-Houng; Lu, Sheng-Nan; Chen, Chien-Hung] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan	Chang Gung Memorial Hospital; Chang Gung University	Chen, CH (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung, Taiwan.	e580306@ms31.hinet.net			Ministry of Science and Technology [NMRPG8G6102]; Chang Gung Memorial Hospital, Taiwan	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Chang Gung Memorial Hospital, Taiwan(Chang Gung Memorial Hospital)	This study was financially supported by grants NMRPG8G6102 from the Ministry of Science and Technology and CMRPG8F from the Chang Gung Memorial Hospital, Taiwan.	Chen CH, 2018, CLIN MICROBIOL INFEC, V24, P997, DOI 10.1016/j.cmi.2017.12.013; Chen CH, 2018, J VIRAL HEPATITIS, V25, P590, DOI 10.1111/jvh.12851; Chen CH, 2015, CLIN GASTROENTEROL H, V13, P1984, DOI 10.1016/j.cgh.2015.06.002; European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021; Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; Jeng WJ, 2018, HEPATOLOGY, V68, P425, DOI 10.1002/hep.29640; Jeng WJ, 2016, CLIN GASTROENTEROL H, V14, P1813, DOI 10.1016/j.cgh.2016.07.002; Jeng WJ, 2013, HEPATOLOGY, V58, P1888, DOI 10.1002/hep.26549; Kuo MT, 2019, ALIMENT PHARM THER, V49, P218, DOI 10.1111/apt.15053; Lee CM, 2003, SCAND J GASTROENTERO, V38, P95, DOI 10.1080/00365520310000500; Liaw YF, 2018, GASTROENTEROLOGY, V154, P2280, DOI 10.1053/j.gastro.2018.03.066; Liaw YF, 2012, HEPATOL INT, V6, P531, DOI 10.1007/s12072-012-9365-4; Liaw YF, 2009, LANCET, V373, P582, DOI 10.1016/S0140-6736(09)60207-5; Papatheodoridis GV, 2018, ANTIVIR THER, V23, P677, DOI 10.3851/IMP3256; Papatheodoridis GV, 2018, HEPATOLOGY, V68, P415, DOI 10.1002/hep.29497; Sarin SK, 2016, HEPATOL INT, V10, P1, DOI 10.1007/s12072-015-9675-4; Su TH, 2018, J INFECT DIS, V217, P1193, DOI 10.1093/infdis/jix690; Terrault NA, 2016, HEPATOLOGY, V63, P261, DOI 10.1002/hep.28156; Weinbaum Cindy M., 2008, Morbidity and Mortality Weekly Report, V57, P1, DOI 10.1002/hep.22882; Xu WX, 2018, CAN J GASTROENTEROL, V2019, DOI 10.1155/2018/1817680	20	13	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2019	14	10							e0222221	10.1371/journal.pone.0222221	http://dx.doi.org/10.1371/journal.pone.0222221			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM7CZ	31584951	gold, Green Published			2023-01-03	WOS:000532407600006
J	Gotts, JE; Jordt, SE; McConnell, R; Tarran, R				Gotts, Jeffrey E.; Jordt, Sven-Eric; McConnell, Rob; Tarran, Robert			What are the respiratory effects of e-cigarettes?	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TOBACCO PRODUCT USE; OBSTRUCTIVE PULMONARY-DISEASE; NICOTINE ENHANCES EXPRESSION; ELECTRONIC VAPOR PRODUCT; RECEPTOR SUBUNIT GENES; HIGH-SCHOOL-STUDENTS; UNITED-STATES; PROPYLENE-GLYCOL; ACETYLCHOLINE-RECEPTOR; ALVEOLAR MACROPHAGES	Electronic cigarettes (e-cigarettes) are alternative, non-combustible tobacco products that generate an inhalable aerosol containing nicotine, flavors, propylene glycol, and vegetable glycerin. Vaping is now a multibillion dollar industry that appeals to current smokers, former smokers, and young people who have never smoked. E-cigarettes reached the market without either extensive preclinical toxicology testing or long term safety trials that would be required of conventional therapeutics or medical devices. Their effectiveness as a smoking cessation intervention, their impact at a population level, and whether they are less harmful than combustible tobacco products are highly controversial. Here, we review the evidence on the effects of e-cigarettes on respiratory health. Studies show measurable adverse biologic effects on organ and cellular health in humans, in animals, and in vitro. The effects of e-cigarettes have similarities to and important differences from those of cigarettes. Decades of chronic smoking are needed for development of lung diseases such as lung cancer or chronic obstructive pulmonary disease, so the population effects of e-cigarette use may not be apparent until the middle of this century. We conclude that current knowledge of these effects is insufficient to determine whether the respiratory health effects of e-cigarette are less than those of combustible tobacco products.	[Gotts, Jeffrey E.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Jordt, Sven-Eric] Duke Univ, Dept Anesthesiol, Durham, NC USA; [Jordt, Sven-Eric] Yale Sch Med, Dept Psychiat, Yale Ctr Study Tobacco Prod & Addict, New Haven, CT USA; [McConnell, Rob] Univ Southern Calif, Dept Prevent Med, Los Angeles, CA 90089 USA; [Tarran, Robert] Univ N Carolina, Marsico Lung Inst, Chapel Hill, NC 27599 USA; [Tarran, Robert] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC 27599 USA	University of California System; University of California San Francisco; Duke University; Yale University; University of Southern California; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Tarran, R (corresponding author), Univ N Carolina, Marsico Lung Inst, Chapel Hill, NC 27599 USA.; Tarran, R (corresponding author), Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC 27599 USA.	robert_tarran@med.unc.edu	Jordt, Sven-Eric/ABE-6517-2020	Jordt, Sven-Eric/0000-0001-6171-5622	NIH/FDA [HL120100, P50CA180905]; NIH/NHLBI [R01 HL135642, U54DA036151, R01ES029435]; NHLBI [U54 HL147127]; NIH/NICHD [R21HD084812]; NIH; FDA Center for Tobacco Products (CTP); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R21HD084812] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA180905] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL135642, U54HL147127, P50HL120100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES029435, P30ES007048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [U54DA036151] Funding Source: NIH RePORTER	NIH/FDA; NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FDA Center for Tobacco Products (CTP)(United States Department of Health & Human Services); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was funded by NIH/FDA HL120100 and NIH/NHLBI R01 HL135642 (RT), U54DA036151 and R01ES029435 (SEJ), NHLBI U54 HL147127 (JG), and NIH/FDA P50CA180905 and NIH/NICHD R21HD084812 (RM). Research reported in this publication was in part supported by NIH and the FDA Center for Tobacco Products (CTP). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Food and Drug Administration.	Agius AM, 1998, CLIN OTOLARYNGOL, V23, P227; Agustin Michael, 2018, Case Rep Pulmonol, V2018, P9724530, DOI 10.1155/2018/9724530; Ahluwalia IB, 2018, MMWR-MORBID MORTAL W, V67, P1072, DOI 10.15585/mmwr.mm6738a7; Ahmad S, 2019, AM J PHYSIOL-LUNG C, V316, pL94, DOI 10.1152/ajplung.00564.2017; Alexander LEC, 2018, AM J PHYSIOL-REG I, V314, pR834, DOI 10.1152/ajpregu.00270.2017; Allen JG, 2016, ENVIRON HEALTH PERSP, V124, P733, DOI 10.1289/ehp.1510185; Anderson WH, 2015, AM J RESP CRIT CARE, V192, P182, DOI 10.1164/rccm.201412-2230OC; Antunes MA, 2011, AN ACAD BRAS CIENC, V83, P1385, DOI 10.1590/S0001-37652011005000039; Armstrong LW, 1996, AM J RESP CRIT CARE, V154, P1520, DOI 10.1164/ajrccm.154.5.8912774; Aurora P, 2011, AM J RESP CRIT CARE, V183, P752, DOI 10.1164/rccm.200911-1646OC; Babic M, 2019, EUR J CLIN INVEST, V49, DOI 10.1111/eci.13077; Bals R, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01151-2018; Barrington-Trimis JL, 2018, NICOTINE TOB RES, V20, P271, DOI 10.1093/ntr/ntx069; Behar RZ, 2016, TOB CONTROL, V25, pii94, DOI 10.1136/tobaccocontrol-2016-053224; Bein K, 2011, MOL NUTR FOOD RES, V55, P1342, DOI 10.1002/mnfr.201100279; Bessac BF, 2008, PHYSIOLOGY, V23, P360, DOI 10.1152/physiol.00026.2008; Blake DA, 1996, CURR EYE RES, V15, P263, DOI 10.3109/02713689609007620; Borrelli B, 2019, NEW ENGL J MED, V380, P678, DOI 10.1056/NEJMe1816406; Boulay ME, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0518-9; Bullen C, 2013, LANCET, V382, P1629, DOI 10.1016/S0140-6736(13)61842-5; Caceres AI, 2009, P NATL ACAD SCI USA, V106, P9099, DOI 10.1073/pnas.0900591106; Caponnetto P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066317; Caporaso N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004653; Carson JL, 2017, INHAL TOXICOL, V29, P137, DOI 10.1080/08958378.2017.1318985; Carter Thomas, 2017, Clin Pract Cases Emerg Med, V1, P212, DOI 10.5811/cpcem.2017.3.33171; Centers for Disease Control and Prevention, 2019, SEV PULM DIS ASS EL; Centers for Disease Control and Prevention, 2019, OUTBR LUNG INJ ASS E; Centers for Disease Control and Prevention, 2014, SMOK CESS REP SURG G; Chadi N, 2019, SUBST ABUS, V40, P7, DOI 10.1080/08897077.2019.1580241; Chaumont M, 2019, AM J PHYSIOL-LUNG C, V316, pL705, DOI 10.1152/ajplung.00492.2018; Chaumont M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28723-0; Cho JH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151022; Choi K, 2016, AM J PREV MED, V51, P446, DOI 10.1016/j.amepre.2016.03.010; Chung S, 2019, AM J RESP CRIT CARE, V200, P1134, DOI 10.1164/rccm.201811-2087OC; Churg A, 2008, AM J PHYSIOL-LUNG C, V294, pL612, DOI 10.1152/ajplung.00390.2007; Cibella F, 2016, CLIN SCI, V130, P1929, DOI 10.1042/CS20160268; Clapp PW, 2019, AM J PHYSIOL-LUNG C, V316, pL470, DOI 10.1152/ajplung.00304.2018; Clapp PW, 2017, AM J PHYSIOL-LUNG C, V313, pL278, DOI 10.1152/ajplung.00452.2016; Clunes LA, 2012, FASEB J, V26, P533, DOI 10.1096/fj.11-192377; Conti-Fine BM, 2000, EUR J PHARMACOL, V393, P279, DOI 10.1016/S0014-2999(00)00036-4; Cooper EC, 1989, GUIDANCE IND; Coxson HO, 2014, AM J RESP CRIT CARE, V190, P135, DOI 10.1164/rccm.201402-0256PP; Cravo AS, 2016, REGUL TOXICOL PHARM, V81, pS1, DOI 10.1016/j.yrtph.2016.10.003; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; Cullen KA, 2018, MMWR-MORBID MORTAL W, V67, P1276, DOI 10.15585/mmwr.mm6745a5; Cummings KM, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009944; D'Ruiz CD, 2017, REGUL TOXICOL PHARM, V87, P36, DOI 10.1016/j.yrtph.2017.05.002; DALHAMN T, 1970, ARCH ENVIRON HEALTH, V21, P633, DOI 10.1080/00039896.1970.10667307; Dalton P, 2018, INHAL TOXICOL, V30, P124, DOI 10.1080/08958378.2018.1470207; Dicpinigaitis PV, 2016, CHEST, V149, P161, DOI 10.1378/chest.15-0817; Douglas CE, 2018, CA-CANCER J CLIN, V68, P240, DOI 10.3322/caac.21455; Eaton DL, 2018, PUBLIC HLTH CONSEQUE; Egleton RD, 2008, TRENDS PHARMACOL SCI, V29, P151, DOI 10.1016/j.tips.2007.12.006; Einarsson GG, 2016, THORAX, V71, P795, DOI 10.1136/thoraxjnl-2015-207235; Erythropel HC, 2019, NICOTINE TOB RES, V21, P1248, DOI 10.1093/ntr/nty192; European Public Health Association, 2018, FACTS FICT E CIGS; Ferkol TW, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00278-2018; Ferrari M, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0106-z; Flouris AD, 2013, INHAL TOXICOL, V25, P91, DOI 10.3109/08958378.2012.758197; Flower M, 2017, RESPIROL CASE REP, V5, DOI 10.1002/rcr2.230; Fodor AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045001; Galstyan E, 2019, EVAL HEALTH PROF, V42, P118, DOI 10.1177/0163278718812976; Garcia-Arcos I, 2016, THORAX, V71, P1119, DOI 10.1136/thoraxjnl-2015-208039; Gentzke AS, 2019, MMWR-MORBID MORTAL W, V68, P157, DOI 10.15585/mmwr.mm6806e1; Gerloff Janice, 2017, Appl In Vitro Toxicol, V3, P28, DOI 10.1089/aivt.2016.0030; Ghosh A, 2018, AM J RESP CRIT CARE, V198, P67, DOI 10.1164/rccm.201710-2033OC; Ghosh A, 2015, CELL MOL LIFE SCI, V72, P3637, DOI 10.1007/s00018-015-1946-7; Glantz SA, 2018, ANNU REV PUBL HEALTH, V39, P215, DOI 10.1146/annurev-publhealth-040617-013757; Glynos C, 2018, AM J PHYSIOL-LUNG C, V315, pL662, DOI 10.1152/ajplung.00389.2017; Gomes JP, 2018, PHARMACOL RES, V128, P101, DOI 10.1016/j.phrs.2017.10.005; Gottlieb MA, 2019, CHILDREN-BASEL, V6, DOI 10.3390/children6030040; Gotts JE, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1585; Hajek P, 2019, NEW ENGL J MED, V380, P629, DOI 10.1056/NEJMoa1808779; Hammond D, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l5445; HARRIS JO, 1975, AM REV RESPIR DIS, V111, P579; Haswell LE, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00852-y; Haussmann HJ, 2012, CHEM RES TOXICOL, V25, P794, DOI 10.1021/tx200536w; Hedman L, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0789; Higham A, 2018, INT J CHRONIC OBSTR, V13, P989, DOI 10.2147/COPD.S157728; Higham A, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0368-x; Holden VK, 2016, CURR OPIN PULM MED, V22, P158, DOI 10.1097/MCP.0000000000000250; Hsu G, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.8550; Hua M, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2324; Huang JD, 2019, TOB CONTROL, V28, P146, DOI 10.1136/tobaccocontrol-2018-054382; Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885; Hwang JH, 2016, J MOL MED, V94, P667, DOI 10.1007/s00109-016-1378-3; Itoh M, 2018, RESPIROL CASE REP, V6, DOI 10.1002/rcr2.282; Jackler RK, 2019, TOB CONTROL, V28, P623, DOI 10.1136/tobaccocontrol-2018-054796; Jensen RP, 2015, NEW ENGL J MED, V372, P392, DOI 10.1056/NEJMc1413069; Kalkhoran S, 2016, LANCET RESP MED, V4, P116, DOI 10.1016/S2213-2600(15)00521-4; Kalkhoran S, 2015, JAMA INTERN MED, V175, P1671, DOI 10.1001/jamainternmed.2015.4209; KAMINSKI EJ, 1968, ARCH ENVIRON HEALTH, V16, P188, DOI 10.1080/00039896.1968.10665042; Kesimer M, 2017, NEW ENGL J MED, V377, P911, DOI 10.1056/NEJMoa1701632; Khan MS, 2018, CLIN RESPIR J, V12, P1295, DOI 10.1111/crj.12775; Khosravi M, 2018, AM J PHYSIOL-LUNG C, V315, pL467, DOI 10.1152/ajplung.00137.2018; King BA, 2018, JAMA-J AM MED ASSOC, V320, P1379, DOI 10.1001/jama.2018.10488; Klager S, 2017, ENVIRON SCI TECHNOL, V51, P10806, DOI 10.1021/acs.est.7b02205; Kozlowski LT, 2008, TOB CONTROL, V17, pI6, DOI 10.1136/tc.2007.020602; Kreda SM, 2001, AM J RESP CELL MOL, V24, P224, DOI 10.1165/ajrcmb.24.3.4367; Kulik MC, 2018, AM J PREV MED, V54, P603, DOI 10.1016/j.amepre.2017.12.017; Lam DCL, 2007, CANCER RES, V67, P4638, DOI 10.1158/0008-5472.CAN-06-4628; Lappas AS, 2018, RESPIROLOGY, V23, P291, DOI 10.1111/resp.13180; Larcombe AN, 2019, LANCET RESP MED, V7, P985, DOI 10.1016/S2213-2600(19)30189-4; Larcombe AN, 2017, AM J PHYSIOL-LUNG C, V313, pL67, DOI 10.1152/ajplung.00203.2016; Law SM, 2017, J INFLAMM-LOND, V14, DOI 10.1186/s12950-017-0176-1; Layden JE, 2020, NEW ENGL J MED, V382, P903, DOI 10.1056/NEJMoa1911614; Lee HW, 2018, P NATL ACAD SCI USA, V115, pE1560, DOI 10.1073/pnas.1718185115; Lee KM, 2018, INHAL TOXICOL, V30, P553, DOI 10.1080/08958378.2019.1576807; Leone FT, 2018, AM J RESP CRIT CARE, V198, pE90, DOI 10.1164/rccm.201808-1443ST; Lim HB, 2014, TOX RESEARCH, V30, P13, DOI 10.5487/TR.2014.30.1.013; Lin VY, 2019, AM J RESP CELL MOL, V61, P162, DOI 10.1165/rcmb.2017-0432OC; Livingston CJ, 2019, AM J PREV MED, V56, P167, DOI 10.1016/j.amepre.2018.09.010; Lorenz E, 1943, CANCER RES, V3, P123; Macklin KD, 1998, J PHARMACOL EXP THER, V287, P435; Madeira A, 2015, CELL MOL LIFE SCI, V72, P759, DOI 10.1007/s00018-014-1773-2; Malerba M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/271918; Maouche K, 2013, P NATL ACAD SCI USA, V110, P4099, DOI 10.1073/pnas.1216939110; Marini S, 2014, TOXICOL APPL PHARM, V278, P9, DOI 10.1016/j.taap.2014.04.004; Martin EM, 2016, AM J PHYSIOL-LUNG C, V311, pL135, DOI 10.1152/ajplung.00170.2016; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331; Maus ADJ, 1998, MOL PHARMACOL, V54, P779, DOI 10.1124/mol.54.5.779; McConnell R, 2017, AM J RESP CRIT CARE, V195, P1043, DOI 10.1164/rccm.201604-0804OC; McNeill A, 2015, E CIGARETTES AN EVID; Meo SA, 2018, AM J MENS HEALTH, V13, DOI 10.1177/1557988318806073; Miech R, 2019, NEW ENGL J MED, V380, P192, DOI 10.1056/NEJMc1814130; Miyashita L, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01592-2017; Moazed F, 2016, THORAX, V71, P1130, DOI 10.1136/thoraxjnl-2015-207886; Moazed F, 2014, CLIN CHEST MED, V35, P625, DOI 10.1016/j.ccm.2014.08.003; MORSHED KM, 1994, FUND APPL TOXICOL, V23, P38, DOI 10.1006/faat.1994.1076; Moses E, 2017, TOXICOL SCI, V155, P248, DOI 10.1093/toxsci/kfw198; MULEY T, 1994, CLIN INVESTIGATOR, V72, P269; Muthumalage T, 2018, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.01130; Niedermirtl F, 2018, MOL PAIN, V14, DOI 10.1177/1744806918811699; Ochsner A, 1999, Ochsner J, V1, P109; Paleari L, 2008, CELL PROLIFERAT, V41, P936, DOI 10.1111/j.1365-2184.2008.00566.x; Park HR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37913-9; Patel W, 2019, CELL MOL LIFE SCI, V76, P977, DOI 10.1007/s00018-018-2989-3; Patrick ME, 2016, DRUG ALCOHOL REV, V35, P586, DOI 10.1111/dar.12372; Pearson JL, 2020, NICOTINE TOB RES, V22, P848, DOI 10.1093/ntr/nty223; PETTERSSON B, 1982, TOXICOLOGY, V23, P41; Phillips B, 2017, FOOD CHEM TOXICOL, V109, P315, DOI 10.1016/j.fct.2017.09.001; Pisinger C, 2019, PREV MED, V119, P124, DOI 10.1016/j.ypmed.2018.12.011; Pocivavsek L, 2011, BIOPHYS J, V101, P118, DOI 10.1016/j.bpj.2011.05.036; Polosa R, 2016, DISCOV MED, V21, P99; Proctor RN, 2012, TOB CONTROL, V21, P87, DOI 10.1136/tobaccocontrol-2011-050338; Rasmussen JE, 2014, J BIOL CHEM, V289, P7671, DOI 10.1074/jbc.M113.545137; Rayner RE, 2019, AM J PHYSIOL-LUNG C, V317, pL295, DOI 10.1152/ajplung.00096.2019; Reid KM, 2018, MMWR-MORBID MORTAL W, V67, P599, DOI 10.15585/mmwr.mm6721a2; Reidel B, 2018, AM J RESP CRIT CARE, V197, P492, DOI 10.1164/rccm.201708-1590OC; Reinikovaite V, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01661-2017; Royal College of Physicians, 2016, NIC SMOK TOB HARM RE; Saccone NL, 2009, CANCER RES, V69, P6848, DOI 10.1158/0008-5472.CAN-09-0786; Salamanca JC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25907-6; Samburova V, 2018, TOXICS, V6, DOI 10.3390/toxics6030046; Sassano MF, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2003904; Schweitzer KS, 2015, AM J PHYSIOL-LUNG C, V309, pL175, DOI 10.1152/ajplung.00411.2014; Schweitzer RJ, 2017, PREV MED, V105, P226, DOI 10.1016/j.ypmed.2017.09.023; Scott A, 2018, THORAX, V73, P1161, DOI 10.1136/thoraxjnl-2018-211663; Shapiro SD, 2003, AM J PATHOL, V163, P2329, DOI 10.1016/S0002-9440(10)63589-4; Shivalingappa PC, 2016, ANTIOXID REDOX SIGN, V24, P186, DOI 10.1089/ars.2015.6367; Sleiman M, 2016, ENVIRON SCI TECHNOL, V50, P9644, DOI 10.1021/acs.est.6b01741; Sohal SS, 2010, RESPIROLOGY, V15, P930, DOI 10.1111/j.1440-1843.2010.01808.x; Sommerfeld CG, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2016-3927; Spitz Margaret R, 2008, J Natl Cancer Inst, V100, P1552, DOI 10.1093/jnci/djn363; Staudt MR, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0778-z; Stick SM, 2009, J PEDIATR-US, V155, P623, DOI 10.1016/j.jpeds.2009.05.005; Sussan TE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116861; TAKAHASHI H, 1993, AM REV RESPIR DIS, V147, P1562, DOI 10.1164/ajrccm/147.6_Pt_1.1562; Thota D, 2014, J EMERG MED, V47, P15, DOI 10.1016/j.jemermed.2013.09.034; TSUNODA S, 1974, RESP PHYSIOL, V22, P285, DOI 10.1016/0034-5687(74)90078-4; US Department of Health Education and Welfare, 1964, PUBLIC HLTH SERVICE, V1103; Vardavas CI, 2012, CHEST, V141, P1400, DOI 10.1378/chest.11-2443; Veldheer S, 2019, ADDICT BEHAV, V91, P95, DOI 10.1016/j.addbeh.2018.10.041; Verkman AS, 2012, ANNU REV MED, V63, P303, DOI 10.1146/annurev-med-043010-193843; Visser WF, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16091525; Viswam Darsana, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2018-224350; Walele T, 2018, REGUL TOXICOL PHARM, V92, P226, DOI 10.1016/j.yrtph.2017.12.010; Walley SC, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-2741; Wang JB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198681; Wang MP, 2016, JAMA PEDIATR, V170, P89, DOI [10.1001/jamapediatrics.2015.3024, 10.1001/jamapediatric]; Wang TW, 2018, MMWR-MORBID MORTAL W, V67, P1225, DOI 10.15585/mmwr.mm6744a2; Warner KE, 2019, NICOTINE TOB RES, V21, P41, DOI 10.1093/ntr/nty062; Webster MJ, 2018, CURR TOP MEMBR, V81, P293, DOI 10.1016/bs.ctm.2018.08.004; WEITZ JI, 1987, ANN INTERN MED, V107, P680, DOI 10.7326/0003-4819-107-5-680; Werley MS, 2016, INHAL TOXICOL, V28, P22, DOI 10.3109/08958378.2015.1130758; Wieslander G, 2001, OCCUP ENVIRON MED, V58, P649, DOI 10.1136/oem.58.10.649; Wills TA, 2019, DRUG ALCOHOL DEPEN, V194, P363, DOI 10.1016/j.drugalcdep.2018.10.004; Woodruff PG, 2016, NEW ENGL J MED, V374, P1811, DOI 10.1056/NEJMoa1505971; WYNDER EL, 1953, CANCER RES, V13, P855; Yaucher NE, 2003, PHARMACOTHERAPY, V23, P1094, DOI 10.1592/phco.23.10.1094.32762; Zia S, 1997, RES COMMUN MOL PATH, V97, P243	192	215	219	13	63	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 30	2019	366								l5275	10.1136/bmj.l5275	http://dx.doi.org/10.1136/bmj.l5275			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JD1YS	31570493	hybrid, Green Published			2023-01-03	WOS:000489772900001
J	Fuente-Soro, L; Iniesta, C; Lopez-Varela, E; Cuna, M; Guilaze, R; Maixenchs, M; Bernardo, EL; Augusto, O; Gonzalez, R; Couto, A; Munguambe, K; Naniche, D				Fuente-Soro, Laura; Iniesta, Carlos; Lopez-Varela, Elisa; Cuna, Mauro; Guilaze, Rui; Maixenchs, Maria; Luis Bernardo, Edson; Augusto, Orvalho; Gonzalez, Raquel; Couto, Aleny; Munguambe, Khatia; Naniche, Denise			Tipping the balance towards long-term retention in the HIV care cascade: A mixed methods study in southern Mozambique	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; FOLLOW-UP; BARRIERS; FACILITATORS; LINKAGE; PATIENT; INITIATION; CONTINUUM; TANZANIA; SERVICES	Background The implementation of quality HIV control programs is crucial for the achievement of the UNAIDS 90-90-90 targets and to motivate people living with HIV (PLWHIV) to link and remain in HIV-care. The aim of this mixed method cross-sectional study was to estimate the linkage and long-term retention in care of PLWHIV and to identify factors potentially interfering along the HIV-care continuum in southern Mozambique. Methods A home-based semi-structured interview was conducted in 2015 to explore barriers and facilitators to the HIV-care cascade among individuals that had been newly HIV-diagnosed in community testing campaigns in 2010 or 2012. Linkage and long-term retention were estimated retrospectively through client self-reports and clinical records. Cohen's Kappa coefficient was calculated to measure the agreement between participant self-reported and documented cascade outcomes. Results Among the 112 interviewed participants, 24 (21.4%) did not disclose their HIV-positive serostatus to the interviewer. While 84 (75.0%) self-reported having enrolled in care, only 69 (61.6%) reported still being in-care 3-5 years after diagnosis of which 17.4% reported having disengaged and re-engaged. An important factor affecting optimal continuum in HIV-care was the impact of the fear-based authoritarian relationship between the health system and the patient that could act as both driver and barrier. Conclusion Special attention should be given to quantify and understand repeated cycles of patient disengagement and re-engagement in HIV-care. Strategies to improve the relationship between the health system and patients are still needed in order to optimally engage PLWHIV for long-term periods.	[Fuente-Soro, Laura; Lopez-Varela, Elisa; Cuna, Mauro; Guilaze, Rui; Maixenchs, Maria; Luis Bernardo, Edson; Augusto, Orvalho; Munguambe, Khatia; Naniche, Denise] CISM, Maputo, Mozambique; [Fuente-Soro, Laura; Lopez-Varela, Elisa; Maixenchs, Maria; Gonzalez, Raquel; Naniche, Denise] Univ Barcelona, Hosp Clin, ISGlobal, Barcelona, Spain; [Iniesta, Carlos] Inst Salud Carlos III, Ctr Nacl Epidemiol, Madrid, Spain; [Luis Bernardo, Edson] Direccao Dist SaUde, Manhica, Maputo, Mozambique; [Couto, Aleny] Minist Hlth, Natl STI HIV AIDS Program, Maputo, Mozambique; [Munguambe, Khatia] Eduardo Mondlane Univ, Fac Med, Maputo, Mozambique	Centro de Investigacao em Saude de Manhica; ISGlobal; University of Barcelona; Hospital Clinic de Barcelona; Instituto de Salud Carlos III; Centro Nacional de Epidemiologia (CNE); Eduardo Mondlane University	Fuente-Soro, L (corresponding author), CISM, Maputo, Mozambique.; Fuente-Soro, L (corresponding author), Univ Barcelona, Hosp Clin, ISGlobal, Barcelona, Spain.	laura.delafuente@isglobal.org	varela, elisa lopez/ABE-4092-2020; Gonzalez, Raquel/J-3604-2017; Augusto, Orvalho/J-8767-2019; Naniche, Denise/S-1814-2018	varela, elisa lopez/0000-0002-6725-5687; Gonzalez, Raquel/0000-0001-5487-801X; Augusto, Orvalho/0000-0002-0005-3968; Naniche, Denise/0000-0002-4495-6325; Fuente-Soro, Laura/0000-0002-8580-5857; Maixenchs, Maria/0000-0002-5782-8197; Iniesta, Carlos/0000-0002-0928-2679	Government of Mozambique; Spanish Agency for International Development (AECID)	Government of Mozambique; Spanish Agency for International Development (AECID)	The authors gratefully acknowledge the Ministry of Health of Mozambique, our research team, collaborators, Fundacao Ariel Glaser, and especially all communities and participants involved. Also, we want acknowledge Elisabeth Salvo and Clara Pons for their contributions and the study interviewers Vitorina Felipe Cossa, Ines Lui ' s Macamo and Lui ' sa Antonieta Macumbe. ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya. CISM is supported by the Government of Mozambique and the Spanish Agency for International Development (AECID).	Abdalla SM, 2019, NURS ETHICS, V26, P2239, DOI 10.1177/0969733018787224; Agaba Patricia A, 2018, J AIDS Clin Res, V9, DOI 10.4172/2155-6113.1000756; [Anonymous], 2016, REP MOC CONS NAC COM; Arnold EM, 2008, AIDS CARE, V20, P80, DOI 10.1080/09540120701449138; Ayieko J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202990; Bassett IV, 2017, JAIDS-J ACQ IMM DEF, V74, P432, DOI [10.1097/QAI.0000000000001277, 10.1097/qai.0000000000001277]; Bezabhe WM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097353; Bogart LM, 2013, AIDS CARE, V25, P843, DOI 10.1080/09540121.2012.729808; Boulle A, 2016, HIV CASE BASED SURVE; Camlin CS, 2017, J INT AIDS SOC, V20, DOI 10.1002/jia2.25023; Chi BH, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001111; da Silva M, 2015, AIDS BEHAV, V19, P666, DOI 10.1007/s10461-014-0874-0; De Schacht C, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1240; Decroo T, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016800; Eshun-Wilson I, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210408; Fuente-Soro L, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25095; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Gonzalez R., HIGH HIV PREVALENCE, DOI [10.1111/j.1468-1293.2012.01018.x, DOI 10.1111/J.1468-1293.2012.01018.X]; Gonzalez R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132053; Govindasamy D, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19032; Govindasamy D, 2012, AIDS, V26, P2059, DOI 10.1097/QAD.0b013e3283578b9b; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hartung C., 2010, OPEN DATA KIT TOOLS; HIarlaithe MO, 2014, AIDS BEHAV, V18, pS516, DOI 10.1007/s10461-014-0756-5; Hladik W, 2016, INT J STD AIDS, V27, P5, DOI 10.1177/0956462415581728; Holtzman CW, 2015, AIDS CARE, V27, P817, DOI 10.1080/09540121.2015.1009362; Inguane CA, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.5.20846; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2017, END AIDS PROGR 90 90; Kabudula CW, 2014, POPUL HEALTH METR, V12, DOI 10.1186/s12963-014-0023-z; Kagoya HR, 2013, AFR J PRIM HEALTH CA, V5, DOI 10.4102/phcfm.v5i1.491; Kiwanuka G, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3450-9; Knight LC, 2015, AIDS CARE, V27, P1162, DOI 10.1080/09540121.2015.1035633; Kruk ME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160764; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Layer EH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104961; Lifson Alan R, 2013, J Int Assoc Provid AIDS Care, V12, P32, DOI 10.1177/1545109712456428; Lopez-Varela E, 2018, JAIDS-J ACQ IMM DEF, V78, P527, DOI [10.1097/qai.0000000000001720, 10.1097/QAI.0000000000001720]; Maixenchs M, 2015, POST ART SYMPTOMS WE, DOI [10.1371/journal.pone.0137336, DOI 10.1371/JOURNAL.PONE.0137336]; Marty L, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25100; Masa R, 2017, AJAR-AFR J AIDS RES, V16, P91, DOI 10.2989/16085906.2017.1308386; Miller CM, 2010, TROP MED INT HEALTH, V15, P48, DOI 10.1111/j.1365-3156.2010.02514.x; Nhacolo AQ, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-291; Nhassengo P, 2018, BARRIERS FACILITATOR, DOI [10.1371/journal.pone.0205919, DOI 10.1371/JOURNAL.PONE.0205919]; Pecoraro A, 2014, AIDS CARE, V26, P1249, DOI 10.1080/09540121.2014.897910; Phelps BR, 2013, AIDS, V27, pS207, DOI 10.1097/QAD.0000000000000095; Pons-Duran C, 2016, TROP MED INT HEALTH, V21, P1513, DOI 10.1111/tmi.12789; Sacoor C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0184249; Sacoor C, 2013, INT J EPIDEMIOL, V42, P1309, DOI 10.1093/ije/dyt148; Sando D, 2014, JAIDS-J ACQ IMM DEF, V67, pS228, DOI 10.1097/QAI.0000000000000378; SEEMAN M, 1964, AM SOCIOL REV, V29, P770, DOI 10.2307/2091442; Shabalala FS, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25120; Tabatabai J, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.24795; Tomori C, 2014, AIDS CARE, V26, P907, DOI 10.1080/09540121.2013.861574; Topp SM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193641; UNAIDS, 2018, MILES GO CLOS GAPS B; UNAIDS, 2014, 90 90 90 AMB TREATM; Zanolini A, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002636	57	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 27	2019	14	9							e0222028	10.1371/journal.pone.0222028	http://dx.doi.org/10.1371/journal.pone.0222028			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LM6IT	31560689	gold, Green Published			2023-01-03	WOS:000532353700006
J	Gouyon, B; Martin-Mons, S; Iacobelli, S; Razafimahefa, H; Kermorvant-Duchemin, E; Brat, R; Caeymaex, L; Couringa, Y; Alexandre, C; Lafon, C; Ramful, D; Bonsante, F; Binson, G; Flamein, F; Moussy-Durandy, A; Di Maio, M; Mazeiras, G; Girard, O; Desbruyeres, C; Mourdie, J; Escourrou, G; Flechelles, O; Abasse, S; Rosenthal, JM; Pages, AS; Dorsi, M; Karaoui, L; ElGellab, A; Dantec, FL; Yangui, MA; Norbert, K; Kugbe, Y; Lorrain, S; Pignolet, A; Garnier, EM; Lapillonne, A; Mitanchez, D; Jacqz-Aigrain, E; Gouyon, JB				Gouyon, Beatrice; Martin-Mons, Severine; Iacobelli, Silvia; Razafimahefa, Hasinirina; Kermorvant-Duchemin, Elsa; Brat, Roselyne; Caeymaex, Laurence; Couringa, Yvan; Alexandre, Ceneric; Lafon, Catherine; Ramful, Duksha; Bonsante, Francesco; Binson, Guillaume; Flamein, Florence; Moussy-Durandy, Amelie; Di Maio, Massimo; Mazeiras, Gael; Girard, Olivier; Desbruyeres, Cecile; Mourdie, Julien; Escourrou, Guillaume; Flechelles, Olivier; Abasse, Soumeth; Rosenthal, Jean-Marc; Pages, Anne-Sophie; Dorsi, Marine; Karaoui, Leila; ElGellab, Abdellah; Dantec, Florence Le Bail; Yangui, Mohamed-Amine; Norbert, Karine; Kugbe, Yaovi; Lorrain, Simon; Pignolet, Anaelle; Garnier, Elodie Marie; Lapillonne, Alexandre; Mitanchez, Delphine; Jacqz-Aigrain, Evelyne; Gouyon, Jean-Bernard			Characteristics of prescription in 29 Level 3 Neonatal Wards over a 2-year period (2017-2018). An inventory for future research	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; OFF-LABEL USE; MEDICATION ERRORS; DRUG UTILIZATION; INFANTS; SAFETY	Objectives The primary objective of this study is to determine the current level of patient medication exposure in Level 3 Neonatal Wards (L3NW). The secondary objective is to evaluate in the first month of life the rate of medication prescription not cited in the Summary of Product Characteristics (SmPC). A database containing all the medication prescriptions is collected as part of a prescription benchmarking program in the L3NW. Material and methods The research is a two-year observational cohort study (2017-2018) with retrospective analysis of medications prescribed in 29 French L3NW. Seventeen L3NW are present since the beginning of the study and 12 have been progressively included. All neonatal units used the same computerized system of prescription, and all prescription data were completely de-identified within each hospital before being stored in a common data warehouse. Results The study population includes 27,382 newborns. Two hundred and sixty-one different medications (International Nonproprietary Names, INN) were prescribed. Twelve INN (including paracetamol) were prescribed for at least 10% of patients, 55 for less than 10% but at least 1% and 194 to less than 1%. The lowest gestational ages (GA) were exposed to the greatest number of medications (18.0 below 28 weeks of gestation (WG) to 4.1 above 36 WG) (p<0.0001). In addition, 69.2% of the 351 different combinations of an medication INN and a route of administration have no indication for the first month of life according to the French SmPC. Ninety-five percent of premature infants with GA less than 32 weeks received at least one medication not cited in SmPC. Conclusion Neonates remain therapeutic orphans. The consequences of polypharmacy in L3NW should be quickly assessed, especially in the most immature infants.	[Gouyon, Beatrice; Martin-Mons, Severine; Iacobelli, Silvia; Bonsante, Francesco; Lorrain, Simon; Pignolet, Anaelle; Garnier, Elodie Marie; Gouyon, Jean-Bernard] Ctr Hosp Univ La Reunion Site Sud, Ctr Etud Perinatales Ocean Indien EA 7388, St Pierre, Reunion, France; [Razafimahefa, Hasinirina] Ctr Hosp Sud Francilien, Corbeil Essonnes, France; [Kermorvant-Duchemin, Elsa; Lapillonne, Alexandre] Hop Necker Enfants Malad, Paris, France; [Brat, Roselyne] Ctr Hosp Reg Orleans, Orleans, France; [Caeymaex, Laurence] Ctr Hosp Intercommunal Creteil, Creteil, France; [Couringa, Yvan] Ctr Hosp Andree Rosemon, Guyane Francaise, France; [Alexandre, Ceneric] CHU Caen, Caen, France; [Lafon, Catherine] Ctr Hosp Arras, Arras, France; [Ramful, Duksha] Ctr Hosp Univ La Reunion Site Nord, St Denis, Reunion, France; [Binson, Guillaume] CHU Poitiers, Poitiers, France; [Flamein, Florence] CHU Lille, Lille, France; [Moussy-Durandy, Amelie] Ctr Hosp Intercommunal Poissy St Germain Laye, Poissy, France; [Di Maio, Massimo] CHU Nimes, Nimes, France; [Mazeiras, Gael] Ctr Hosp Cote Basque, Bayonne, France; [Girard, Olivier] Ctr Hosp St Denis, St Denis, Reunion, France; [Desbruyeres, Cecile] Ctr Hosp Metropole Savoie, Chambery, France; [Mourdie, Julien] Grp Hosp Havre, Hop Jacques Monod, Montivilliers, France; [Escourrou, Guillaume] Ctr Hosp Intercommunal Andre Gregoire, Montreuil, France; [Flechelles, Olivier] Ctr Hosp Univ Fort de France, Fort De France, Martinique, France; [Abasse, Soumeth] Ctr Hosp Mayotte, Mamoudzou, Mayotte, France; [Rosenthal, Jean-Marc] CHU Pointe a Pitre, Pointe A Pitre, Guadeloupe, France; [Pages, Anne-Sophie] Ctr Hosp Publ Cotentin, Cherbourg En Cotentin, France; [Dorsi, Marine] Ctr Hosp Terr Gaston Bourret, Dumbea, Nouvelle Caledo, France; [Karaoui, Leila] Grand Hop Est Francilien, Meaux, France; [ElGellab, Abdellah] Ctr Hosp Lens, Lens, France; [Dantec, Florence Le Bail] Ctr Hosp St Brieuc, St Brieuc, France; [Yangui, Mohamed-Amine] Hop Rene Dubos, Pontoise, France; [Norbert, Karine] Ctr Hosp Pau, Pau, France; [Kugbe, Yaovi] Ctr Hosp Ouest Guyanais Franck Joly, St Laurent Du Maroni, Guyane Francais, France; [Mitanchez, Delphine] Hop Armand Trousseau, Paris, France; [Jacqz-Aigrain, Evelyne] Hop Robert Debre, Paris, France	CHU Reunion; Centre Hospitalier Sud Francilien; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre Hospitalier Regional d'Orleans; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; CHU de Caen NORMANDIE; Universite de Caen Normandie; CHU Reunion; CHU Poitiers; Universite de Poitiers; Universite de Lille - ISITE; CHU Lille; Universite de Montpellier; CHU de Nimes; CHU Martinique; CHU Guadeloupe; Centre Hospitalier Rene Dubos, Pontoise; Centre Hospitalier de Pau; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	Gouyon, JB (corresponding author), Ctr Hosp Univ La Reunion Site Sud, Ctr Etud Perinatales Ocean Indien EA 7388, St Pierre, Reunion, France.	jean-bernard.gouyon@chu-reunion.fr	Binson, Guillaume/AAQ-3038-2020; Jacqz-Aigrain, Evelyne/AAW-7089-2021; caeymaex, laurence/ABF-1423-2020; ABASSE, Soumeth/ABD-6071-2020	Jacqz-Aigrain, Evelyne/0000-0002-4285-7067; caeymaex, laurence/0000-0003-3822-5136; ABASSE, Soumeth/0000-0003-2806-0999; Garnier, Elodie/0000-0003-2682-4369; Razafimahefa, Hasinirina/0000-0001-9183-3523	European research program FEDER [2014-34018]	European research program FEDER	This study is part of a European research program FEDER number 2014-34018 (https://ec.europa.eu/regional_policy/en/funding/erdf/) about benchmark of prescription in NICUs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allegaert K, 2019, EXPERT REV CLIN PHAR, V12, P343, DOI 10.1080/17512433.2019.1580569; Ancel PY, 2015, JAMA PEDIATR, V169, P230, DOI 10.1001/jamapediatrics.2014.3351; Cantey JB, 2018, J PEDIATR-US, V203, P62, DOI 10.1016/j.jpeds.2018.07.036; Cantey JB, 2016, LANCET INFECT DIS, V16, P1178, DOI 10.1016/S1473-3099(16)30205-5; Clark RH, 2006, PEDIATRICS, V117, P1979, DOI 10.1542/peds.2005-1707; Dai DW, 2016, PEDIATR CRIT CARE ME, V17, pE218, DOI 10.1097/PCC.0000000000000684; de Souza AS, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0551-8; Fabiano V, 2012, EXPERT OPIN DRUG SAF, V11, P95, DOI 10.1517/14740338.2011.584531; Flint RB, 2018, BRIT J CLIN PHARMACO, V84, P1313, DOI 10.1111/bcp.13563; Girardi A, 2017, ITAL J PEDIATR, V43, DOI 10.1186/s13052-017-0354-z; Gouyon B, 2017, J CLIN PHARM THER, V42, P64, DOI 10.1111/jcpt.12474; Horri J, 2014, J CLIN PHARM THER, V39, P637, DOI 10.1111/jcpt.12194; Hsieh EM, 2014, AM J PERINAT, V31, P811, DOI 10.1055/s-0033-1361933; Jain S, 2014, INDIAN PEDIATR, V51, P644, DOI 10.1007/s13312-014-0468-y; Kieran EA, 2014, ACTA PAEDIATR, V103, pE139, DOI 10.1111/apa.12541; Krzyzaniak N, 2016, J CLIN PHARM THER, V41, P612, DOI 10.1111/jcpt.12440; Krzyzaniak N, 2016, THER ADV DRUG SAF, V7, P102, DOI 10.1177/2042098616642231; Ku LC, 2017, PEDIATR CARDIOL, V38, P155, DOI 10.1007/s00246-016-1496-2; Laforgia N, 2014, PEDIATR INT, V56, P57, DOI 10.1111/ped.12190; Laughon MM, 2014, JAMA PEDIATR, V168, P130, DOI 10.1001/jamapediatrics.2013.4208; Lee JL, 2013, INT J CLIN PHARM-NET, V35, P1025, DOI 10.1007/s11096-013-9846-0; Costa HTMD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204427; Neubert A, 2010, EUR J CLIN PHARMACOL, V66, P87, DOI 10.1007/s00228-009-0722-8; Nir-Neuman H, 2018, ADV THER, V35, P1122, DOI 10.1007/s12325-018-0732-y; Nuytten A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170234; Porta A, 2012, J ANTIMICROB CHEMOTH, V67, P1278, DOI 10.1093/jac/dks021; Puopolo KM, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-0925; Quantin C, 2014, J GYNECOL OBST BIO R, V43, P680, DOI 10.1016/j.jgyn.2013.09.004; Rosli R, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00027; Sweet DG, 2019, NEONATOLOGY, V115, P432, DOI 10.1159/000499361; Taketomo CKH J. H., 2016, LEXICOMP; Zimmerman KO, 2017, J PEDIATR-US, V180, P99, DOI 10.1016/j.jpeds.2016.07.001	32	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2019	14	9							e0222667	10.1371/journal.pone.0222667	http://dx.doi.org/10.1371/journal.pone.0222667			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU6QQ	31536560	Green Published, Green Submitted, gold			2023-01-03	WOS:000501799400001
J	Harel, M; Ortenberg, R; Varanasi, SK; Mangalhara, KC; Mardamshina, M; Markovits, E; Baruch, EN; Tripple, V; Arama-Chayoth, M; Greenberg, E; Shenoy, A; Ayasun, R; Knafo, N; Xu, SH; Anafi, L; Yanovich-Arad, G; Barnabas, GD; Ashkenazi, S; Besser, MJ; Schachter, J; Bosenberg, M; Shadel, GS; Barshack, I; Kaech, SM; Markel, G; Geiger, T				Harel, Michal; Ortenberg, Rona; Varanasi, Siva Karthik; Mangalhara, Kailash Chandra; Mardamshina, Mariya; Markovits, Ettai; Baruch, Erez N.; Tripple, Victoria; Arama-Chayoth, May; Greenberg, Eyal; Shenoy, Anjana; Ayasun, Ruveyda; Knafo, Naama; Xu, Shihao; Anafi, Liat; Yanovich-Arad, Gali; Barnabas, Georgina D.; Ashkenazi, Shira; Besser, Michal J.; Schachter, Jacob; Bosenberg, Marcus; Shadel, Gerald S.; Barshack, Iris; Kaech, Susan M.; Markel, Gal; Geiger, Tamar			Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence	CELL			English	Article							MHC CLASS-I; TUMOR-INFILTRATING LYMPHOCYTES; METASTATIC MELANOMA; SOMATIC MUTATIONS; ADOPTIVE TRANSFER; CD4+T CELLS; IFN-GAMMA; PHASE-II; CHECKPOINT; MICROENVIRONMENT	Immunotherapy has revolutionized cancer treatment, yet most patients do not respond. Here, we investigated mechanisms of response by profiling the proteome of clinical samples from advanced stage melanoma patients undergoing either tumor infiltrating lymphocyte (TIL)-based or anti- programmed death 1 (PD1) immunotherapy. Using high-resolution mass spectrometry, we quantified over 10,300 proteins in total and similar to 4,500 proteins across most samples in each dataset. Statistical analyses revealed higher oxidative phosphorylation and lipid metabolism in responders than in non-responders in both treatments. To elucidate the effects of the metabolic state on the immune response, we examined melanoma cells upon metabolic perturbations or CRISPR-Cas9 knockouts. These experiments indicated lipid metabolism as a regulatory mechanism that increases melanoma immunogenicity by elevating antigen presentation, thereby increasing sensitivity to T cell mediated killing both in vitro and in vivo. Altogether, our proteomic analyses revealed association between the melanoma metabolic state and the response to immunotherapy, which can be the basis for future improvement of therapeutic response.	[Harel, Michal; Mardamshina, Mariya; Arama-Chayoth, May; Shenoy, Anjana; Knafo, Naama; Yanovich-Arad, Gali; Barnabas, Georgina D.; Geiger, Tamar] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-6997801 Tel Aviv, Israel; [Ortenberg, Rona; Markovits, Ettai; Baruch, Erez N.; Greenberg, Eyal; Ashkenazi, Shira; Besser, Michal J.; Schachter, Jacob; Markel, Gal] Sheba Med Ctr, Ella Lemelbaum Inst Immunooncol, IL-5265601 Tel Hashomer, Israel; [Ortenberg, Rona; Markovits, Ettai; Baruch, Erez N.; Ashkenazi, Shira; Besser, Michal J.; Markel, Gal] Tel Aviv Univ, Sackler Sch Med, Dept Clin Immunol & Microbiol, IL-6997801 Tel Aviv, Israel; [Varanasi, Siva Karthik; Tripple, Victoria; Ayasun, Ruveyda; Xu, Shihao; Kaech, Susan M.] Salk Inst Biol Studies, NOMIS Ctr Immunobiol & Microbial Pathogenesis, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA; [Mangalhara, Kailash Chandra; Shadel, Gerald S.] Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA; [Anafi, Liat; Barshack, Iris] Sheba Med Ctr, Inst Pathol, IL-5265601 Tel Hashomer, Israel; [Schachter, Jacob; Barshack, Iris] Tel Aviv Univ, Sackler Sch Med, IL-6997801 Tel Aviv, Israel; [Bosenberg, Marcus] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Bosenberg, Marcus] Yale Comprehens Canc Ctr, New Haven, CT 06510 USA; [Bosenberg, Marcus] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA	Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Salk Institute; Salk Institute; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Yale University; Yale University; Yale University	Geiger, T (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-6997801 Tel Aviv, Israel.; Markel, G (corresponding author), Sheba Med Ctr, Ella Lemelbaum Inst Immunooncol, IL-5265601 Tel Hashomer, Israel.; Markel, G (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Clin Immunol & Microbiol, IL-6997801 Tel Aviv, Israel.	markel@post.tau.ac.il; geiger@tauex.tau.ac.il		Arad, Gali/0000-0003-1415-5997; Mardamshina, Mariya/0000-0003-0066-0861; Baruch, Erez Nissim/0000-0001-6001-6598; Geiger, Tamar/0000-0002-9526-197X	Melanoma Research Alliance Saban Family Team Science Award; Kamin grant of the Israel Innovation Authority; Samueli Foundation Grant for Integrative Immuno-Oncology; NIH [R01 CA216102]; Salkexcellerators Postdoctoral fellowship; NOMIS Center Postdoctoral Foundation; National Cancer Center; NATIONAL CANCER INSTITUTE [P01CA128814] Funding Source: NIH RePORTER	Melanoma Research Alliance Saban Family Team Science Award; Kamin grant of the Israel Innovation Authority; Samueli Foundation Grant for Integrative Immuno-Oncology; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Salkexcellerators Postdoctoral fellowship; NOMIS Center Postdoctoral Foundation; National Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Prof. Juergen Cox, Dr. Livnat Jerby-Arnon, and Dr. Yael Elbaz-Alon for fruitful discussions and Dr. Keren Yizhak for her assistance in computational analyses. We thank Diana Nemichenitzer for technical assistance in sample preparation. We thank the Lemelbaum family for the generous continuous support. This work was funded by the Melanoma Research Alliance Saban Family Team Science Award and Kamin grant of the Israel Innovation Authority to G.M. and T.G., Samueli Foundation Grant for Integrative Immuno-Oncology to G.M., NIH R01 CA216102 to G.S.S. and S.M.K., the Salkexcellerators Postdoctoral fellowship to K.C.M., and NOMIS Center Postdoctoral Foundation and the National Cancer Center to S.K.V.	Ahmed D, 2017, CANCER LETT, V409, P20, DOI 10.1016/j.canlet.2017.08.037; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Ardiani A, 2014, CANCER RES, V74, P1945, DOI 10.1158/0008-5472.CAN-13-2045; Auslander N, 2018, NAT MED, V24, P1545, DOI 10.1038/s41591-018-0157-9; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Besser MJ, 2013, CLIN CANCER RES, V19, P4792, DOI 10.1158/1078-0432.CCR-13-0380; Besser MJ, 2010, CLIN CANCER RES, V16, P2646, DOI 10.1158/1078-0432.CCR-10-0041; Brand A, 2016, CELL METAB, V24, P657, DOI 10.1016/j.cmet.2016.08.011; Buck MD, 2017, CELL, V169, P570, DOI 10.1016/j.cell.2017.04.004; Cascone T, 2018, CELL METAB, V27, P977, DOI 10.1016/j.cmet.2018.02.024; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Charni S, 2010, J IMMUNOL, V185, P3498, DOI 10.4049/jimmunol.1001250; Charni S, 2009, J IMMUNOL, V182, P3398, DOI 10.4049/jimmunol.0803006; Conforti F, 2018, LANCET ONCOL, V19, P737, DOI 10.1016/S1470-2045(18)30261-4; Cox J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S16-S12; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Dudley ME, 2005, J CLIN ONCOL, V23, P2346, DOI 10.1200/JCO.2005.00.240; Geiger T, 2010, NAT METHODS, V7, P383, DOI 10.1038/nmeth.1446; Gibney GT, 2016, LANCET ONCOL, V17, pE542, DOI 10.1016/S1470-2045(16)30406-5; Goto Y, 2010, J INVEST DERMATOL, V130, P221, DOI 10.1038/jid.2009.195; Herber DL, 2010, NAT MED, V16, P880, DOI 10.1038/nm.2172; Ho PC, 2017, CURR OPIN IMMUNOL, V46, P38, DOI 10.1016/j.coi.2017.04.003; Ho PC, 2015, CELL, V162, P1217, DOI 10.1016/j.cell.2015.08.012; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Hunder NN, 2008, NEW ENGL J MED, V358, P2698, DOI 10.1056/NEJMoa0800251; Jerby-Arnon L, 2018, CELL, V175, P984, DOI 10.1016/j.cell.2018.09.006; Johnson DB, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10582; Jongsma MLM, 2017, MOL IMMUNOL, V17, P30598; Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426; Lauss M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01460-0; Li HJ, 2019, CELL, V176, P775, DOI 10.1016/j.cell.2018.11.043; Liebermeister W, 2014, P NATL ACAD SCI USA, V111, P8488, DOI 10.1073/pnas.1314810111; Lim S, 2017, CANCER RES, V77, P1245, DOI 10.1158/0008-5472.CAN-16-1647; Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270; Meeth K, 2016, PIGM CELL MELANOMA R, V29, P590, DOI 10.1111/pcmr.12498; Meissner TB, 2010, P NATL ACAD SCI USA, V107, P13794, DOI 10.1073/pnas.1008684107; Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003; Mills EL, 2016, CELL, V167, P457, DOI 10.1016/j.cell.2016.08.064; Montoya M, 1999, J IMMUNOL, V163, P1914; Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084; Pan YD, 2017, NATURE, V543, P252, DOI 10.1038/nature21379; Patsoukis N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7692; Pearce Erika L, 2013, Science, V342, P1242454, DOI 10.1126/science.1242454; Perry CJ, 2018, J EXP MED, V215, P877, DOI 10.1084/jem.20171435; Pitroda SP, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-68; Pitt JM, 2016, IMMUNITY, V44, P1255, DOI 10.1016/j.immuni.2016.06.001; Radvanyi LG, 2012, CLIN CANCER RES, V18, P6758, DOI 10.1158/1078-0432.CCR-12-1177; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; Rudolph JD, 2019, J PROTEOME RES, V18, P2052, DOI 10.1021/acs.jproteome.8b00927; Sade-Feldman M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01062-w; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Scharping NE, 2016, IMMUNITY, V45, P374, DOI [10.1016/j.immuni.2016.08.009, 10.1016/j.immuni.2016.07.009]; Scheltema RA, 2014, MOL CELL PROTEOMICS, V13, P3698, DOI 10.1074/mcp.M114.043489; Seliger B, 2014, J IMMUNOTOXICOL, V11, P308, DOI 10.3109/1547691X.2013.875084; Sethumadhavan S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187314; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Singer M, 2016, CELL, V166, P1500, DOI 10.1016/j.cell.2016.08.052; Sisler JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144444; Sumimoto H, 2006, J EXP MED, V203, P1651, DOI 10.1084/jem.20051848; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Vogel C, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.59; Wang J, 2017, PIGM CELL MELANOMA R, V30, P428, DOI 10.1111/pcmr.12591; Wang J, 2017, MOL CELL PROTEOMICS, V16, P121, DOI 10.1074/mcp.M116.060301; Weide B, 2016, CLIN CANCER RES, V22, P5487, DOI 10.1158/1078-0432.CCR-16-0127; Wellenstein MD, 2018, IMMUNITY, V48, P399, DOI 10.1016/j.immuni.2018.03.004; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Yanovich G, 2018, CANCER RES, V78, P6001, DOI 10.1158/0008-5472.CAN-18-1079; York AG, 2015, CELL, V163, P1716, DOI 10.1016/j.cell.2015.11.045; Zhang Y, 2017, CANCER CELL, V32, P377, DOI 10.1016/j.ccell.2017.08.004; Zhou F, 2009, INT REV IMMUNOL, V28, P239, DOI 10.1080/08830180902978120; Zikich D, 2016, IMMUNOTHERAPY-UK, V8, P35, DOI 10.2217/imt.15.99	84	120	122	2	70	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	2019	179	1					236	+		10.1016/j.cell.2019.08.012	http://dx.doi.org/10.1016/j.cell.2019.08.012			33	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	IY8BG	31495571	Bronze, Green Accepted			2023-01-03	WOS:000486618500026
J	Tong, TYN; Appleby, PN; Bradbury, KE; Perez-Cornago, A; Travis, RC; Clarke, R; Key, TJ				Tong, Tammy Y. N.; Appleby, Paul N.; Bradbury, Kathryn E.; Perez-Cornago, Aurora; Travis, Ruth C.; Clarke, Robert; Key, Timothy J.			Risks of ischaemic heart disease and stroke in meat eaters, fish eaters, and vegetarians over 18 years of follow-up: results from the prospective EPIC-Oxford study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIETARY ASSESSMENT METHODS; CROSS-SECTIONAL ANALYSIS; WEIGHED RECORDS; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; PLASMA-CONCENTRATIONS; SERUM CONCENTRATIONS; HEMORRHAGIC STROKE; CHOLESTEROL LEVELS; ADVENTIST HEALTH	OBJECTIVE To examine the associations of vegetarianism with risks of ischaemic heart disease and stroke. DESIGN Prospective cohort study. SETTING The EPIC-Oxford study, a cohort in the United Kingdom with a large proportion of non-meat eaters, recruited across the country between 1993 and 2001. PARTICIPANTS 48 188 participants with no history of ischaemic heart disease, stroke, or angina (or cardiovascular disease) were classified into three distinct diet groups: meat eaters (participants who consumed meat, regardless of whether they consumed fish, dairy, or eggs; n=24 428), fish eaters (consumed fish but no meat; n=7506), and vegetarians including vegans (n=16 254), based on dietary information collected at baseline, and subsequently around 2010 (n=28 364). MAIN OUTCOME MEASURES Incident cases of ischaemic heart disease and stroke (including ischaemic and haemorrhagic types) identified through record linkage until 2016. RESULTS Over 18.1 years of follow-up, 2820 cases of ischaemic heart disease and 1072 cases of total stroke (519 ischaemic stroke and 300 haemorrhagic stroke) were recorded. After adjusting for sociodemographic and lifestyle confounders, fish eaters and vegetarians had 13% (hazard ratio 0.87, 95% confidence interval 0.77 to 0.99) and 22% (0.78, 0.70 to 0.87) lower rates of ischaemic heart disease than meat eaters, respectively (P<0.001 for heterogeneity). This difference was equivalent to 10 fewer cases of ischaemic heart disease (95% confidence interval 6.7 to 13.1 fewer) in vegetarians than in meat eaters per 1000 population over 10 years. The associations for ischaemic heart disease were partly attenuated after adjustment for self reported high blood cholesterol, high blood pressure, diabetes, and body mass index (hazard ratio 0.90, 95% confidence interval 0.81 to 1.00 in vegetarians with all adjustments). By contrast, vegetarians had 20% higher rates of total stroke (hazard ratio 1.20, 95% confidence interval 1.02 to 1.40) than meat eaters, equivalent to three more cases of total stroke (95% confidence interval 0.8 to 5.4 more) per 1000 population over 10 years, mostly due to a higher rate of haemorrhagic stroke. The associations for stroke did not attenuate after further adjustment of disease risk factors. CONCLUSIONS In this prospective cohort in the UK, fish eaters and vegetarians had lower rates of ischaemic heart disease than meat eaters, although vegetarians had higher rates of haemorrhagic and total stroke.	[Tong, Tammy Y. N.; Appleby, Paul N.; Bradbury, Kathryn E.; Perez-Cornago, Aurora; Travis, Ruth C.; Key, Timothy J.] Univ Oxford, Nuffield Dept Populat Hlth, Canc Epidemiol Unit, Richard Doll Bldg, Oxford OX3 7LF, England; [Clarke, Robert] Univ Oxford, Big Data Inst, Nuffield Dept Populat Hlth, Clin Trial Serv Unit, Oxford, England; [Clarke, Robert] Univ Oxford, Big Data Inst, Nuffield Dept Populat Hlth, Epidemiol Studies Unit, Oxford, England	University of Oxford; University of Oxford; University of Oxford	Tong, TYN (corresponding author), Univ Oxford, Nuffield Dept Populat Hlth, Canc Epidemiol Unit, Richard Doll Bldg, Oxford OX3 7LF, England.	tammy.tong@ndph.ox.ac.uk	Bradbury, Kathryn/I-2132-2019; Tong, Tammy YN/I-8770-2019; Perez-Cornago, Aurora/C-1097-2016	Bradbury, Kathryn/0000-0003-3345-7333; Tong, Tammy YN/0000-0002-0284-8959; Perez-Cornago, Aurora/0000-0002-5652-356X	UK Medical Research Council [MR/M012190/1]; Wellcome Trust Our Planet Our Health (Livestock, Environment, and People) [LEAP 205212/Z/16/Z]; Girdlers' New Zealand Health Research Council Fellowship; MRC [G0700474, MR/K02700X/1, MR/M012190/1, G9900923] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust Our Planet Our Health (Livestock, Environment, and People); Girdlers' New Zealand Health Research Council Fellowship; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The work is supported by the UK Medical Research Council MR/M012190/1 and Wellcome Trust Our Planet Our Health (Livestock, Environment, and People, LEAP 205212/Z/16/Z). KEB is supported by the Girdlers' New Zealand Health Research Council Fellowship.	Afshin A, 2014, AM J CLIN NUTR, V100, P278, DOI 10.3945/ajcn.113.076901; Amarenco P, 2006, NEW ENGL J MED, V355, P549; [Anonymous], 2015, CIRCULATION, DOI DOI 10.1161/CIR.0000000000000207; Appleby PN, 2016, P NUTR SOC, V75, P287, DOI 10.1017/S0029665115004334; Appleby PN, 2016, AM J CLIN NUTR, V103, P218, DOI 10.3945/ajcn.115.119461; Appleby PN, 1999, AM J CLIN NUTR, V70, p525S, DOI 10.1093/ajcn/70.3.525s; Appleby PN, 2002, PUBLIC HEALTH NUTR, V5, P645, DOI 10.1079/PHN2002332; Aune D, 2017, INT J EPIDEMIOL, V46, P1029, DOI 10.1093/ije/dyw319; Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5; Bates B, 2014, NATIONAL DIET AND NU; Bingham SA, 1997, INT J EPIDEMIOL, V26, pS137, DOI 10.1093/ije/26.suppl_1.S137; BINGHAM SA, 1994, BRIT J NUTR, V72, P619, DOI 10.1079/BJN19940064; BINGHAM SA, 1995, BRIT J NUTR, V73, P531, DOI 10.1079/BJN19950057; Bradbury KE, 2014, EUR J CLIN NUTR, V68, P178, DOI 10.1038/ejcn.2013.248; Chang-Claude J, 2005, CANCER EPIDEM BIOMAR, V14, P963, DOI 10.1158/1055-9965.EPI-04-0696; Chiu YF, 2015, BRIT J NUTR, V114, P1313, DOI 10.1017/S0007114515002937; Collins R, 2016, LANCET, V388, P2532, DOI 10.1016/S0140-6736(16)31357-5; Crowe FL, 2012, EUR J CLIN NUTR, V66, P950, DOI 10.1038/ejcn.2012.51; Crowe FL, 2013, AM J CLIN NUTR, V97, P597, DOI 10.3945/ajcn.112.044073; Crowe FL, 2011, PUBLIC HEALTH NUTR, V14, P340, DOI 10.1017/S1368980010002454; Davey GK, 2003, PUBLIC HEALTH NUTR, V6, P259, DOI 10.1079/PHN2002430; Di Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993, DOI 10.1001/jama.2009.1619; Dinu M, 2017, CRIT REV FOOD SCI, V57, P3640, DOI 10.1080/10408398.2016.1138447; DONG H, 2015, PLOS ONE, V10, DOI DOI 10.1371/JOURNAL.PONE.0137533; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; Ference BA, 2012, J AM COLL CARDIOL, V60, P2631, DOI 10.1016/j.jacc.2012.09.017; Forouzanfar MH, 2015, LANCET, V386, P2287, DOI 10.1016/S0140-6736(15)00128-2; Gilsing AMJ, 2010, EUR J CLIN NUTR, V64, P933, DOI 10.1038/ejcn.2010.142; Hindy G, 2018, STROKE, V49, P820, DOI 10.1161/STROKEAHA.117.019653; Holland B, 1991, MCCANCE AND WIDDOWSO; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; Iso H, 2001, CIRCULATION, V103, P856, DOI 10.1161/01.CIR.103.6.856; Key TJ, 1999, AM J CLIN NUTR, V70, p516S, DOI 10.1093/ajcn/70.3.516s; Kinjo Y, 1999, J Epidemiol, V9, P268; Lacey B, 2018, LANCET GLOB HEALTH, V6, pE641, DOI 10.1016/s2214-109x(18)30217-1; Leahy E, 2010, ESRI WORKING PAPER 3; Lewington S, 2007, LANCET, V370, P1829, DOI 10.1016/S0140-6736(07)61778-4; Masset G, 2009, J NUTR, V139, P1541, DOI 10.3945/jn.109.104398; McGreevy C, 2011, ANN INTERN MED, V155, P820, DOI 10.7326/0003-4819-155-12-201112200-00004; Ministry of Agriculture Fisheries and Food, 1993, FOOD PORTION SIZES; Orlich MJ, 2013, JAMA INTERN MED, V173, P1230, DOI 10.1001/jamainternmed.2013.6473; Rosell MS, 2005, AM J CLIN NUTR, V82, P327, DOI 10.1093/ajcn/82.2.327; Sacks FM, 2017, CIRCULATION, V136, pE1, DOI 10.1161/CIR.0000000000000510; Sauvaget C, 2004, STROKE, V35, P1531, DOI 10.1161/01.STR.0000130426.52064.09; Sauvaget C, 2003, INT J EPIDEMIOL, V32, P536, DOI 10.1093/ije/dyg151; Schmidt JA, 2016, EUR J CLIN NUTR, V70, P306, DOI 10.1038/ejcn.2015.144; Sinha S, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-74; Sobiecki JG, 2016, NUTR RES, V36, P464, DOI 10.1016/j.nutres.2015.12.016; Spencer EA, 2002, PUBLIC HEALTH NUTR, V5, P561, DOI 10.1079/PHN2001322; Sun LL, 2019, NAT MED, V25, P569, DOI 10.1038/s41591-019-0366-x; TAKEYA Y, 1984, STROKE, V15, P15, DOI 10.1161/01.STR.15.1.15; The Vegan Society, 2016, FIND OUT HOW MANY VE; THOROGOOD M, 1987, BMJ-BRIT MED J, V295, P351, DOI 10.1136/bmj.295.6594.351; Tong TYN, 2018, AM J CLIN NUTR, V107, P909, DOI 10.1093/ajcn/nqy042; Tong TYN, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018245; Tonstad S, 2013, NUTR METAB CARDIOVAS, V23, P292, DOI 10.1016/j.numecd.2011.07.004; Townsend P., 1979, POVERTY IN THE UNITE; Wang X, 2013, STROKE, V44, P1833, DOI 10.1161/STROKEAHA.113.001326; Wareham NJ, 2003, PUBLIC HEALTH NUTR, V6, P407, DOI 10.1079/PHN2002439; Wilson NG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080277; Wright FL, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-161; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460	62	60	61	3	34	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 4	2019	366								l4897	10.1136/bmj.l4897	http://dx.doi.org/10.1136/bmj.l4897			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IX1FO	31484644	Green Published, hybrid			2023-01-03	WOS:000485437600002
